<SUBMISSION>
<ACCESSION-NUMBER>0000950134-08-006517
<TYPE>S-1
<PUBLIC-DOCUMENT-COUNT>44
<FILING-DATE>20080414
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>FLUIDIGM CORP
<CIK>0001162194
<IRS-NUMBER>000000000
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>S-1
<ACT>33
<FILE-NUMBER>333-150227
<FILM-NUMBER>08753554
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>7100 SHORELINE CT
<CITY>SOUTH SAN FRANCISCO
<STATE>CA
<ZIP>94080
<PHONE>6502666000
</BUSINESS-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>f39432orsv1.htm
<DESCRIPTION>FORM S-1
<TEXT>
<HTML>
<HEAD>
<TITLE>sv1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 94%; margin-left: 3%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>As filed with the Securities and Exchange Commission on
    April&#160;14, 2008</B>
</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Registration
    <FONT style="white-space: nowrap">No.&#160;333-&#160;&#160;&#160;&#160;&#160;&#160;</FONT></B>
</DIV>

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 2pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=0 -->

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=0 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 14pt">UNITED STATES SECURITIES AND
    EXCHANGE COMMISSION</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">Washington,&#160;D.C.
    20549</FONT></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 18pt"><FONT style="white-space: nowrap">Form&#160;S-1</FONT></FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">REGISTRATION
    STATEMENT</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">UNDER</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">THE SECURITIES ACT OF
    1933</FONT></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 24pt">FLUIDIGM CORPORATION</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">(Exact name of Registrant as
    specified in its charter)</FONT></I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="34%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="32%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="32%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom">
<TD nowrap align="center" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Delaware</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <B>3826</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <B>77-0513190</B>
</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">
    <I><FONT style="font-size: 8pt">(State or other jurisdiction
    of<BR>
    incorporation or organization)</FONT></I>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <I><FONT style="font-size: 8pt">(Primary Standard Industrial<BR>
    Classification Code Number)<BR>
    </FONT></I>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <I><FONT style="font-size: 8pt">(I.R.S. Employer<BR>
    Identification Number)</FONT></I><FONT style="font-size: 8pt">
    </FONT>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>



<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>7000 Shoreline Court, Suite 100</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>South San&#160;Francisco, CA 94080</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>(650) 266-6000</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">(Address, including zip code,
    and telephone number,<BR>
    including area code, of Registrant&#146;s principal executive
    offices)</FONT></I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Gajus V. Worthington</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>President and Chief Executive Officer</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>7000 Shoreline Court, Suite&#160;100</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>South San&#160;Francisco, CA 94080</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="white-space: nowrap">(650)&#160;266-6000</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">(Name, address, including zip
    code, and telephone number,<BR>
    including area code, of agent for service)</FONT></I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Copies to:</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="34%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="32%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="32%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom">
<TD align="center" valign="top">
    <B>David J. Segre<BR>
    Robert F. Kornegay<BR>
    Asaf H. Kharal<BR>
    Wilson Sonsini Goodrich &#038; Rosati P.C.<BR>
    650 Page&#160;Mill Road<BR>
    Palo Alto, CA 94304<BR>
    Telephone:
    <FONT style="white-space: nowrap">(650)&#160;493-9300</FONT><BR>
    Telecopy:
    <FONT style="white-space: nowrap">(650)&#160;493-6811</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <B>William M. Smith<BR>
    Vice President, Legal Affairs<BR>
    and General Counsel<BR>
    7000 Shoreline Court, Suite 100<BR>
    South San&#160;Francisco, CA 94080<BR>
    Telephone: (650) 266-6000<BR>
    Telecopy: (650) 871-7152</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <B>Charles K. Ruck<BR>
    B. Shayne Kennedy<BR>
    Latham &#038; Watkins LLP<BR>
    650 Town Center Drive,
    20<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>&#160;Floor<BR>
    Costa Mesa, CA 92626<BR>
    Telephone: (714) 540-1235<BR>
    Telecopy: (714) 755-8290</B>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Approximate date of commencement of proposed sale to the
    public:</B>&#160;&#160;As soon as practicable after the
    effective date of this Registration Statement.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If any of the securities being registered on this Form are to be
    offered on a delayed or continuous basis pursuant to
    Rule&#160;415 under the Securities Act, as amended, check the
    following
    box.&#160;&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If this Form is filed to register additional securities for an
    offering pursuant to Rule&#160;462(b) under the Securities Act,
    please check the following box and list the Securities Act
    registration statement number of the earlier effective
    registration statement for the same
    offering.&#160;&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;<FONT style="word-spacing: 60pt; white-space: nowrap; font-size: 1pt"><U>&#173;
    &#173;</U></FONT><!-- callerid=128 iwidth=540 length=60 -->
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If this Form is a post-effective amendment filed pursuant to
    Rule&#160;462(c) under the Securities Act, check the following
    box and list the Securities Act registration statement number of
    the earlier effective registration statement for the same
    offering.&#160;&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;<FONT style="word-spacing: 60pt; white-space: nowrap; font-size: 1pt"><U>&#173;
    &#173;</U></FONT><!-- callerid=128 iwidth=540 length=60 -->
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If this Form is a post-effective amendment filed pursuant to
    Rule&#160;462(d) under the Securities Act, check the following
    box and list the Securities Act registration statement number of
    the earlier effective registration statement for the same
    offering.&#160;&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;<FONT style="word-spacing: 60pt; white-space: nowrap; font-size: 1pt"><U>&#173;
    &#173;</U></FONT><!-- callerid=128 iwidth=540 length=60 -->
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Indicate by check mark whether the registrant is a large
    accelerated filer, an accelerated filer, a non-accelerated
    filer, or a smaller reporting company. See the definitions of
    &#147;large accelerated filer,&#148; &#147;accelerated
    filer&#148; and &#147;smaller reporting company&#148; in Ruler
    <FONT style="white-space: nowrap">12b-2</FONT> of the
    Exchange Act. (Check one):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="24%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="22%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="24%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="24%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom">
<TD align="center" valign="top">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Large accelerated
    filer&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Accelerated
    filer&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Non-accelerated
    filer&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    Smaller reporting
    company&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="5" align="center" valign="top">
    (Do not check if a smaller reporting company)
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CALCULATION
    OF REGISTRATION FEE</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="44%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutterright -->
    <TD width="26%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="26%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom" style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt; border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-top: 3px double #000000">
    <B>Proposed Maximum<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt; border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-top: 3px double #000000">
    <B>Amount of<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 9pt">Title of Each Class of<BR>
    </FONT></B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 9pt">Aggregate<BR>
    </FONT></B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 9pt">Registration<BR>
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    <B>Securities to be Registered</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Offering
    Price<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Fee<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP></B>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top" style="border-top: 1px solid #000000">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Common Stock $0.001&#160;par value per share
</DIV>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt; border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-top: 1px solid #000000">
    $86,250,000
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt; border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-top: 1px solid #000000">
    $3,389.63
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom" style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="border-top: 3px double #000000">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    (1)&#160;
</TD>
    <TD align="left">    Estimated solely for the purpose of computing the amount of the
    registration fee pursuant to Rule&#160;457(o) under the
    Securities Act. Includes $11,250,000 of shares that the
    underwriters have the option to purchase to cover
    over-allotments, if any.
</TD>
</TR>





<TR valign="top" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    (2)&#160;
</TD>
    <TD align="left">    Calculated pursuant to Rule&#160;457(o) under the Securities Act
    based on an estimate of the proposed maximum offering price.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>The Registrant hereby amends this Registration Statement on
    such date or dates as may be necessary to delay its effective
    date until the Registrant shall file a further amendment that
    specifically states that this Registration Statement shall
    thereafter become effective in accordance with Section&#160;8(a)
    of the Securities Act of 1933, as amended, or until the
    Registration Statement shall become effective on such date as
    the Securities and Exchange Commission, acting pursuant to such
    Section&#160;8(a), may determine.</B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=0 -->

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 2pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=0 -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 94%; margin-left: 3%"><!-- BEGIN PAGE WIDTH -->

<TABLE style="color: #FF0000" width="100%" border="1" cellpadding="5"><TR><TD style=text-align:justify>
<FONT style="font-size: 9pt; font-family: Arial, Helvetica; color: #F93F26">The
information in this preliminary prospectus is not complete and
may be changed. We may not sell these securities until the
registration statement filed with the Securities and Exchange
Commission is declared effective. This preliminary prospectus is
not an offer to sell these securities and is not soliciting an
offer to buy these securities in any state where the offer or
sale is not permitted.<BR>
</FONT>
</TD></TR></TABLE>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 89%; margin-left: 5%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 12pt; color: #F93F26">PROSPECTUS
    (Subject to Completion)</FONT></I>
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 11pt; color: #F93F26">Issued April
    14, 2008</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 18pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Shares</FONT></I>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="f39432orf3943216.gif" alt="(FLUIDIGM LOGO)"><FONT style="font-size: 18pt">
    </FONT>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 12pt">COMMON STOCK</FONT></I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Fluidigm Corporation is
    offering&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of its common stock. This is our initial public offering, and no
    public market currently exists for our shares. We anticipate
    that the initial public offering price will be between
    $&#160;&#160;&#160;&#160;&#160; and
    $&#160;&#160;&#160;&#160;&#160; per share.</I></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We intend to apply to list our common stock on the NASDAQ
    Global Market under the symbol &#147;FLDM.&#148;</I></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 12pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Investing in our common stock involves risks. See
    &#147;Risk Factors&#148; beginning on page&#160;8.</I></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>PRICE
    <FONT style="font-size: 12pt">$&#160;&#160;&#160;&#160;&#160;</FONT>
    A SHARE</I>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="64%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><I>Underwriting<BR>
    </I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><I>Proceeds to<BR>
    </I></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><I>Price to<BR>
    </I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><I>Discounts and<BR>
    </I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><I>Fluidigm<BR>
    </I></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><I>Public</I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><I>Commissions</I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><I>Corporation</I></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Per Share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><I>$</I></B>&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><I>$</I></B>&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><I>$</I></B>&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><I>$</I></B>
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><I>$</I></B>
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><I>$</I></B>
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have granted the underwriters the right to purchase up to an
    additional&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock to cover over-allotments.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Securities and Exchange Commission and state securities
    regulators have not approved or disapproved these securities or
    determined if this prospectus is truthful or complete. Any
    representation to the contrary is a criminal offense.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Morgan Stanley&#160;&#038; Co. Incorporated expects to deliver
    the shares to purchasers
    on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    2008.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 18pt; font-variant: SMALL-CAPS">MORGAN
    STANLEY</FONT></I>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 18pt; font-variant: SMALL-CAPS">UBS
    INVESTMENT BANK</FONT></I>
</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 18pt; font-variant: SMALL-CAPS">LEERINK
    SWANN</FONT></I>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    2008
    </FONT>
</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="f39432orf3943218.gif" alt="(GRAPHIC)">
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 89%; margin-left: 5%"><!-- BEGIN PAGE WIDTH -->
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV align="left">
<!-- TOC -->
</DIV>

<DIV align="left">
<A name="tocpage"></A>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">TABLE OF
    CONTENTS</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>



<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="89%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="4%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Page</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#101'>Prospectus Summary</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#102'>Risk Factors</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#103'>Special Note Regarding Forward-Looking
    Statements</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#104'>Use of Proceeds</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#105'>Dividend Policy</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#106'>Capitalization</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#107'>Dilution</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#108'>Selected Consolidated Financial Data</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#109'>Management&#146;s Discussion and Analysis of
    Financial Condition and Results of Operations</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#110'>Business</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#111'>Management</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    69
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#112'>Certain Relationships and Related Party
    Transactions</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    95
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#113'>Principal Stockholders</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    98
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#114'>Description of Capital Stock</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#115'>Shares Eligible For Future Sale</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    105
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#120'>Material U.S. Federal Income and Estate Tax
    Consequences to Non-U.S. Holders</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    107
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#121'>Underwriters</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    110
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#116'>Legal Matters</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    114
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#117'>Experts</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    114
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#118'>Where You Can Find Additional Information</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    114
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#119'>Index to Consolidated Financial Statements</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-1
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv3w1.htm">EXHIBIT 3.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv3w3.htm">EXHIBIT 3.3</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv4w2.htm">EXHIBIT 4.2</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv4w3.htm">EXHIBIT 4.3</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv4w4.htm">EXHIBIT 4.4</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv4w4a.htm">EXHIBIT 4.4A</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv4w4b.htm">EXHIBIT 4.4B</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv4w5.htm">EXHIBIT 4.5</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv4w5a.htm">EXHIBIT 4.5A</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv10w1.htm">EXHIBIT 10.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv10w2.htm">EXHIBIT 10.2</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv10w2a.htm">EXHIBIT 10.2A</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv10w4.htm">EXHIBIT 10.4</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv10w4a.htm">EXHIBIT 10.4A</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv10w5.htm">EXHIBIT 10.5</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv10w5a.htm">EXHIBIT 10.5A</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv10w6.htm">EXHIBIT 10.6</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv10w7.htm">EXHIBIT 10.7</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv10w8.htm">EXHIBIT 10.8</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv10w8a.htm">EXHIBIT 10.8A</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv10w9.htm">EXHIBIT 10.9</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv10w9a.htm">EXHIBIT 10.9A</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv10w10.htm">EXHIBIT 10.10</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv10w10a.htm">EXHIBIT 10.10A</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv10w11.htm">EXHIBIT 10.11</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv10w12.htm">EXHIBIT 10.12</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv10w14.htm">EXHIBIT 10.14</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv10w15.htm">EXHIBIT 10.15</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv10w15a.htm">EXHIBIT 10.15A</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv10w16.htm">EXHIBIT 10.16</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv10w17.htm">EXHIBIT 10.17</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv21w1.htm">EXHIBIT 21.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432orexv23w1.htm">EXHIBIT 23.1</A></FONT></TD></TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left">
<!-- /TOC -->
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 21%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=455 length=96 -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    You should rely only on the information contained in this
    prospectus and in any free writing prospectus prepared by or on
    behalf of us. We have not, and the underwriters have not,
    authorized anyone to provide you with information different
    from, or in addition to, that contained in this prospectus or
    any related free writing prospectus. This prospectus is an offer
    to sell only the shares offered hereby but only under
    circumstances and in jurisdictions where it is lawful to do so.
    The information contained in this prospectus is current only as
    of its date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Through and
    including,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    2008 (the 25th&#160;day after the date of this prospectus), all
    dealers effecting transactions in these securities, whether or
    not participating in this offering, may be required to deliver a
    prospectus. This is in addition to a dealer&#146;s obligation to
    deliver a prospectus when acting as an underwriter and with
    respect to an unsold allotment or subscription</B>.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For investors outside the United States: Neither we nor any of
    the underwriters have done anything that would permit this
    offering or possession or distribution of this prospectus in any
    jurisdiction where action for that purpose is required, other
    than the United States. You are required to inform yourselves
    about and to observe any restrictions relating to this offering
    and the distribution of this prospectus.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    i
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<A name='101'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PROSPECTUS
    SUMMARY</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>This summary highlights information contained in greater
    detail elsewhere in this prospectus. This summary may not
    contain all the information that you should consider before
    investing our common stock. You should read the entire
    prospectus carefully, including &#147;Risk Factors&#148;
    beginning on page&#160;8 and our consolidated financial
    statements and related notes included elsewhere in this
    prospectus, before making an investment decision. Unless
    otherwise indicated, the terms &#147;Fluidigm,&#148;
    &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to
    Fluidigm Corporation.</I>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Overview</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We develop, manufacture and market proprietary Integrated
    Fluidic Circuit systems that significantly improve productivity
    in life science research. Our Integrated Fluidic Circuits, or
    IFCs, integrate a diverse set of critical liquid handling
    functions on a nanoliter scale. Our IFCs can meter, combine,
    diffuse, fold, mix, separate or pump nanoliter volumes of fluids
    with precise control and reproducibility, many thousands of
    times&#160;&#151; all in parallel on a single chip. This
    technology enables our customers to perform thousands of
    sophisticated biochemical measurements on samples smaller than
    the content of a single cell, with minute volumes of reagents,
    in half the area of a credit card. We achieved this
    &#147;integrated circuit for biology&#148; by miniaturizing and
    integrating liquid handling components on a single
    microfabricated device. Through innovations in material science
    and manufacturing, our IFC architectures are highly flexible,
    and can be designed to support a wide range of applications and
    assay types. Our IFC systems, consisting of instrumentation,
    software and single-use IFCs, increase throughput, decrease
    costs and enhance sensitivity compared to conventional
    laboratory systems.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have commercialized IFC systems for a wide range of life
    science applications, including our BioMark system for gene
    expression analysis, genotyping and digital PCR, and our Topaz
    system for protein crystallization. Researchers and clinicians
    have successfully employed our products to help achieve
    breakthroughs in a variety of fields, including genetic
    variation, cellular function and structural biology. These
    include using our IFC systems to help detect life-threatening
    mutations in patients&#146; cancer cells, discover indicators of
    susceptibility to cancer, manage some of the world&#146;s most
    valuable fisheries, analyze the genetic composition of
    individual stem cells, identify fetal chromosomal abnormalities,
    analyze the infectiousness of the avian flu virus and assess the
    quality of agricultural seed products. We believe that the broad
    applicability of our IFC technology will lead to the development
    of IFC systems for a wide variety of additional markets and
    applications, including molecular diagnostics.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We attribute our success and continued growth prospects to the
    following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Disruptive and Enabling Technology.</I>&#160;&#160;We believe
    our IFC systems overcome many of the limitations of conventional
    methods of laboratory research by integrating on a single device
    a multitude of diverse microfluidic components, such as
    channels, valves, reaction chambers, pumps and mixers, to
    perform thousands of experiments at one time and in nanoliter
    volumes. In addition, we believe our IFC architectures assist
    users in addressing problems that would be difficult or
    impractical to solve using conventional life science tools.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Market Validation of Technology through Multiple Marketed
    Products.</I>&#160;&#160;We have sold our Topaz and BioMark IFCs
    to over 100 customers. These customers include many leading
    biotechnology and pharmaceutical companies, academic
    institutions and life science laboratories worldwide, such as
    MedImmune, Merck &#038; Co., Myriad Genetics, the National
    Cancer Institute and Vertex Pharmaceuticals.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Readily Adoptable Products.</I>&#160;&#160;Our IFC systems
    are compatible with a variety of widely-used chemistries, such
    as TaqMan for real time quantitative PCR, and typically
    accommodate users&#146; existing assays without requiring
    significant modifications and re-validation. Additionally, the
    reliability and accuracy of the data produced by our systems has
    proven comparable to or better than conventional microwell
    plates for large-scale experimentation. Our IFCs are designed to
    be compatible with standard, existing equipment for liquid
    dispensing and consumables handling.
</TD>
</TR>

</TABLE>
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Broad Application In the Life Science
    Market.</I>&#160;&#160;We believe that our IFC technology is
    broadly applicable to biotechnology automation and could be
    further developed for a wide variety of additional applications,
    including molecular diagnostics. To date, researchers have
    successfully used IFCs in such diverse fields as immunoassays,
    high throughput drug screening, chemical synthesis,
    pharmacogenomics, systems biology, synthetic biology and
    cellular assays.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Large and Growing Target Markets.</I>&#160;&#160;Our IFC
    systems are designed for various applications in the life
    science market, with particular emphasis currently on genomic
    analysis instruments and supplies. Gene expression and
    genotyping together comprise a market of approximately
    $4.9&#160;billion, with 8% annual growth expected through 2010,
    according to Strategic Directions International. The digital PCR
    market is currently an emerging market, but we believe it has
    the potential to grow significantly as new applications are
    developed.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Strong Research and Development Capabilities and Intellectual
    Property Position.</I>&#160;&#160;We have and will continue to
    invest substantially in research and development to increase the
    density and throughput of our IFCs, thereby enabling scalability
    and greater efficiency. We have developed an extensive portfolio
    of intellectual property, including more than 80&#160;issued
    U.S.&#160;patents and 240&#160;patent applications pending
    worldwide either owned by or licensed to us.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Efficient Singapore-Based Manufacturing and Process
    Development.</I>&#160;&#160;We established our manufacturing
    facility in Singapore to take advantage of the skilled
    workforce, supplier and partner network, lower operating costs
    and government support available there. Our IFC manufacturing
    process includes photolithography and fabrication technologies
    that are very similar to those used in the fabrication of
    semiconductor chips. As a result, we are able to hire from a
    pool of skilled manpower and access and collaborate with a broad
    network of suppliers and partners for our manufacturing
    operations created by the existing semiconductor industry in
    Singapore.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    Target Markets</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The life science industry is currently facing challenges similar
    to those faced by the information technology industry when
    computational power was constrained by the inherent limitations
    of the vacuum tube. Life science research efforts, ranging from
    large-scale initiatives, such as the Human Genome Project, to
    more traditional academic and commercial research projects, are
    continuing to reveal the complex biological and chemical
    processes that are fundamental to living organisms. Developing
    and applying this knowledge increasingly requires performing
    experimentation on a scale and with a precision that can be
    achieved only through automation. However, the most common forms
    of life science automation rely on cumbersome robotic systems
    that are slow, expensive and labor intensive and, we believe,
    fundamentally constrain life science research. In much the same
    way that integrated circuits overcame the limitations of early
    computers by placing an increasing number of transistors on a
    single silicon chip, our IFCs are designed to overcome many of
    the limitations of conventional laboratory systems by
    integrating an increasing number of fluidic components on a
    single microfabricated IFC.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFCs are designed to meet the needs of researchers and
    clinicians performing large-scale experimentation in the areas
    of genomics, including gene expression, genotyping and digital
    PCR, protein crystallization and, potentially, molecular
    diagnostics. Genomic analysis is useful in a broad range of
    medical, scientific and commercial applications. Protein
    crystallization is a fundamental step in structural biology and
    is widely used to understand and analyze disease pathways and
    the effects of pharmaceutical agents. Molecular diagnostic tests
    are used in clinical practice to diagnose, classify or monitor a
    disease, often by using forms of genomic analysis.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To achieve and exploit advances in genomics, proteomics and
    molecular diagnostics, research and clinical laboratories need
    robust systems that deliver increased throughput and simpler
    workflows at decreased costs. Researchers performing large-scale
    experimentation using conventional laboratory systems, such as
    microwell-based systems, face many limitations including complex
    workflow, limited throughput, labor intensive operations, large
    sample requirements and high running costs. Alternative high
    throughput approaches, such as microarrays, pre-formatted
    arrays, bead arrays and mass spectrometry analysis face one or
    more limitations such as limited flexibility, poor data quality,
    complex and slow workflows or high running costs.
</DIV>
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">The
    Fluidigm Solution</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFC systems are designed to overcome many of the limitations
    of conventional methods by enabling researchers and clinicians
    to rapidly perform a large number of experiments at one time and
    in nanoliter volumes, significantly increasing throughput,
    reducing reagent costs, conserving patient samples and reducing
    workflow complexity. We commercially introduced our Topaz IFCs
    in the first quarter of 2003, our BioMark 48.48 IFC in the
    fourth quarter of 2006 and we expect to commercialize our
    BioMark 96.96&#160;IFCs in the second half of 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The advantages of our IFC systems over existing microwell-based
    systems include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Reduced Complexity.</I>&#160;&#160;Loading our IFC requires
    orders of magnitude fewer pipetting steps than
    384&#160;microwell plates for the same experiment, which reduces
    the time, cost and potential for error.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Improved Throughput.</I>&#160;&#160;A single IFC based on our
    96.96&#160;format can conduct 9,216&#160;real time quantitative
    PCR or other assays, or 24&#160;times the assays that can be
    conducted on a single 384&#160;microwell plate. The improved
    throughput reduces the time and cost associated with complex
    experiments and expands the number and range of experiments that
    may be conducted.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Nanoliter Precision.</I>&#160;&#160;Our IFC systems allow
    users to dispense samples and reagents in volumes which are
    automatically combined and mixed in nanoliter and sub-nanoliter
    volumes. In addition to cost and workflow benefits, this
    capability makes it practical for users to conduct certain high
    sensitivity, low volume techniques, such as digital PCR and
    single cell analysis.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Reduced Reagent and Sample Requirements.</I>&#160;&#160;Our
    systems operate on nanoliter volumes of reagents and samples.
    Each assay conducted on our systems requires a total of
    10&#160;nanoliters or less of reagents and samples, which is
    between 0.5% and 1.0% of the amount required by conventional
    microwell systems.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Decreased Capital Cost.</I>&#160;&#160;A single BioMark
    system has the same throughput as the combined throughput of
    multiple conventional systems. As a result, for high volume
    users, the cost of purchasing one BioMark system can be much
    lower than the cost of purchasing the number of competing
    systems and associated robotic equipment required to provide the
    same throughput, even though our BioMark system may cost more on
    a per unit basis.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Compatibility with Existing
    Infrastructure.</I>&#160;&#160;Our IFCs incorporate plastic
    input frames that are the same size as standard microwell plates
    and are designed to work with the most commonly used laboratory
    systems, including existing robotic pipetting systems, bar code
    readers, plate handling systems and other equipment. Our IFCs
    are also designed to work with standard real time quantitative
    PCR techniques and TaqMan chemistries.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our systems and technology also have advantages over other high
    throughput methods for large-scale experimentation. Unlike many
    microarrays, pre-formatted arrays and bead arrays, our systems
    offer a range of flexibility that allow researchers to
    dynamically specify and refine their assay panels during the
    course of a study. Conventional microwell plates are routinely
    used to measure gene expression levels over a broad range
    whereas microarrays, pre-formatted arrays, bead arrays and mass
    spectrometer analysis generally do not. These other methods can
    also be very expensive for certain types of large-scale
    experimentation. For validation studies, which typically require
    the analysis of thousands or tens of thousands of samples, the
    high per unit cost of microarrays and bead arrays often make
    them uneconomical. Similarly, the high initial setup costs for
    mass spectrometry analysis generally make it economical only for
    very large-scale studies.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">The
    Fluidigm Strategy</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We intend to become a global leader in providing life science
    automation systems. Our business strategy consists of the
    following elements:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Establish our IFC technology as the leading solution for a broad
    range of life science applications;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Continue to increase the throughput and efficiency of our IFCs;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Expand recurring IFC revenue stream through product innovation
    and system sales;
</TD>
</TR>

</TABLE>
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Provide superior customer service;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Enhance IFC manufacturing efficiency; and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Continue to develop our technology and intellectual property
    position.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Risks
    Affecting Us</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our business is subject to numerous risks, as more fully
    described in the section entitled &#147;Risk Factors&#148;
    immediately following this prospectus summary, including the
    following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We have incurred significant losses since our inception, had an
    accumulated deficit of $133.8&#160;million as of
    December&#160;29, 2007 and expect to incur losses for the
    foreseeable future.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    If our products fail to achieve and sustain market acceptance,
    our revenue will be adversely affected.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Our sales cycle for the BioMark and Topaz systems is lengthy and
    unpredictable, which makes it difficult for us to forecast
    revenue and could cause significant quarterly fluctuations in
    revenue and other operating results.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We receive a substantial portion of our revenues from a limited
    number of customers and other entities, and the loss of, or a
    significant reduction in, orders or grants from one or more of
    our major customers or grantors would adversely affect our
    operations and financial condition.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The life science industry is highly competitive and subject to
    rapid technological change, and we may not be able to
    successfully compete.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We have limited experience in producing our products, and we may
    experience development or manufacturing problems or delays that
    could limit the growth of our revenue or increase our losses.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We are dependent on single source suppliers for some of the
    components and materials used in our systems, and the loss of
    any of these suppliers could harm our business.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Our ability to protect our intellectual property and proprietary
    technology through patents and other means is uncertain, and we
    are dependent on certain licensed-in technology. In addition,
    future third-party claims of intellectual property infringement
    could adversely affect our operations and financial condition.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Corporate
    History and Information</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We were incorporated in California in May 1999 as Mycometrix
    Corporation, changed our name to Fluidigm Corporation in April
    2001 and reincorporated in Delaware in July 2007. Our principal
    executive offices are located at 7000 Shoreline Court,
    Suite&#160;100, South San&#160;Francisco, CA 94080. Our
    telephone number is
    <FONT style="white-space: nowrap">(650)&#160;266-6000.</FONT>
    Our website address is www.fluidigm.com. Information contained
    on our website is not incorporated by reference into this
    prospectus, and should not be considered to be part of this
    prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    &#147;Fluidigm,&#148; the Fluidigm logo, &#147;Topaz,&#148;
    &#147;BioMark,&#148; &#147;AutoInspeX,&#148; &#147;MSL&#148; and
    &#147;NanoFlex&#148; are trademanrks or registered trademarks of
    Fluidigm. Other service marks, trademarks and trade names
    referred to in this prospectus are the property of their
    respective owners.
</DIV>
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">THE
    OFFERING</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="36%"></TD>
    <TD width="1%"></TD>
    <TD width="63%"></TD>
</TR>

<TR>
    <TD valign="top">
    Common stock offered by us</TD>
    <TD></TD>
    <TD valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    shares</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    Common stock to be outstanding after this offering</TD>
    <TD></TD>
    <TD valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    shares</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    Use of proceeds</TD>
    <TD></TD>
    <TD valign="bottom">
    We intend to use the net proceeds from this offering to expand
    our sales force, support the commercialization of our products,
    continue research and development, expand our facilities and
    manufacturing operations and for working capital and other
    general corporate purposes. We may also use a portion of the net
    proceeds to acquire other businesses, products or technologies.
    However, we do not have agreements or commitments for any
    specific acquisitions at this time. See &#147;Use of
    Proceeds.&#148;</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    Proposed NASDAQ Global Market symbol</TD>
    <TD></TD>
    <TD valign="bottom">
    FLDM</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The number of shares of our common stock to be outstanding
    following this offering is based on 66,572,205&#160;shares of
    our common stock outstanding as of December&#160;29, 2007, but
    excludes:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    7,467,230&#160;shares of common stock issuable upon exercise of
    options outstanding as of December&#160;29, 2007 at a weighted
    average exercise price of $0.79 per share;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    698,720&#160;shares of common stock issuable upon the exercise
    of warrants outstanding as of December&#160;29, 2007 at a
    weighted average exercise price of $2.71 per share, after
    conversion from preferred stock;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    1,197,154&#160;shares of common stock reserved for future
    issuance under our stock-based compensation plans,
    including&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock reserved for issuance under our 2008 Equity
    Incentive Plan, which will become effective on the date of this
    prospectus, and any future increase in shares reserved for
    issuance under such plan;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    33,334&#160;shares of common stock that were legally issued and
    outstanding but were not included in stockholders&#146; deficit
    as of December&#160;29, 2007 pursuant to accounting principles
    generally accepted in the United States, as these shares were
    subject to a right of repurchase by us.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless otherwise indicated, this prospectus reflects and assumes
    the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a&#160;&#160;-for-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    reverse split of our outstanding common stock and convertible
    preferred stock, to be effected prior to the completion of this
    offering;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the conversion of all outstanding shares of our convertible
    preferred stock into an aggregate of 56,670,894&#160;shares of
    common stock upon the closing of this offering;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the filing of our amended and restated certificate of
    incorporation immediately prior to the effectiveness of this
    offering;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the automatic conversion of principal and accrued interest on a
    convertible promissory note held by Biomedical Sciences
    Fund&#160;Pte. Ltd. into 1,466,210&#160;shares of our common
    stock upon closing of this offering; and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    no exercise by the underwriters of their over-allotment option.
</TD>
</TR>

</TABLE>
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SUMMARY
    CONSOLIDATED FINANCIAL DATA</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have derived the summary consolidated statement of operations
    data for the years ended December&#160;31, 2005,
    December&#160;31, 2006 and December&#160;29, 2007 and the
    consolidated balance sheet data as of December&#160;29, 2007
    from our audited consolidated financial statements included
    elsewhere in this prospectus. Our historical results are not
    necessarily indicative of the results that may be expected in
    the future. The following summary consolidated financial data
    should be read in conjunction with &#147;Management&#146;s
    Discussion and Analysis of Financial Condition and Results of
    Operations&#148; and our consolidated financial statements and
    related notes, included elsewhere in this prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="64%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom" style="font-size: 1pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom">
    <B>(in thousands, except per share amounts)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Consolidated Statement of Operations Data:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Revenue:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Product revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,076
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,959
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,451
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Collaboration revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,568
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,376
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    460
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Grant revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,063
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,364
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Total revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,674
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,398
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,275
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cost and expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Cost of product revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,764
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,773
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,514
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Research and development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,449
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,589
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,389
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Selling, general and administrative
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,955
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,699
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,898
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Total costs and expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,168
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,061
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,801
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Loss from operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,494
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21,663
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,526
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (898
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,261
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,790
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,140
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Other income (expense), net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (194
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (170
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Loss before provision for income taxes and cumulative effect of
    change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,022
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,346
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Provision for income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (105
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Loss before cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,022
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    637
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16,385
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Net loss per share of common stock, basic and
    diluted<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.82
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.53
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Shares used in computing net loss per share of common stock,
    basic and
    diluted<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,316
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Pro forma net loss per share of common stock, basic and
    diluted<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Shares used in computing net loss per share of common stock,
    basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Please see Note&#160;2 to our
    audited consolidated financial statements for an explanation of
    the method used to calculate basic and diluted net loss per
    share and pro forma net loss per share.
    </FONT></TD>
</TR>

</TABLE>
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="63%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As of December&#160;29, 2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Pro Forma<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Actual</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Pro
    Forma<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As
    Adjusted<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Consolidated Balance Sheet Data:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cash and cash equivalents and available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    40,363
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Working capital
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,754
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54,776
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total long-term debt and convertible promissory notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,359
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Convertible preferred stock warrant liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    468
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Convertible preferred stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    162,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total stockholders&#146; equity (deficit)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (130,331
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The pro forma balance sheet data in
    the table above reflects (1)&#160;the automatic conversion
    principal and accrued interest of a convertible promissory note
    held by BioMedical Sciences Fund Pte. Ltd. into
    1,466,210&#160;shares of our common stock upon closing of this
    offering, (2)&#160;the conversion of all outstanding shares of
    convertible preferred stock into common stock and (3)&#160;the
    reclassification of the convertible preferred stock warrant
    liabilities to additional
    <FONT style="white-space: nowrap">paid-in-capital,</FONT>
    each effective upon the closing of this offering.
    </FONT></TD>
</TR>
    <FONT style="font-size: 8pt">
    </FONT>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The pro forma as adjusted balance
    sheet data in the table above also reflects the sale
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of our common stock in this offering and the application of the
    net proceeds at an initial public offering price of
    $&#160;&#160;&#160;&#160;&#160; per share, the midpoint of the
    range set forth on the cover page of this prospectus, after
    deducting estimated underwriting discounts and commissions and
    estimated offering expenses payable by us.
    </FONT></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">A $1.00 increase (decrease) in the
    assumed initial public offering price of
    $&#160;&#160;&#160;&#160;&#160; per share, the midpoint of the
    range set forth on the cover page of this prospectus, would
    increase (decrease) each of cash, cash equivalents and
    available-for-sale securities, working capital, total assets and
    total stockholders&#146; equity by
    $&#160;&#160;&#160;&#160;&#160;&#160;million, assuming that the
    number of shares offered by us, as set forth on the cover page
    of this prospectus, remains the same, and after deducting
    estimated underwriting discounts and commissions payable by us.
    Each increase of 1.0&#160;million shares in the number of shares
    offered by us would increase each of cash, cash equivalents,
    available-for-sale securities, working capital, total assets and
    total stockholders&#146; equity by approximately
    $&#160;&#160;&#160;&#160;&#160;&#160;million. Similarly, each
    decrease of 1.0&#160;million shares in the number of shares
    offered by us would decrease each of cash, cash equivalents,
    available-for-sale securities, working capital, total assets and
    total stockholders&#146; equity by approximately
    $&#160;&#160;&#160;&#160;&#160;&#160;million. The pro forma as
    adjusted information discussed above is illustrative only and
    will adjust based on the actual public offering price and other
    terms of this offering determined at pricing.
    </FONT></TD>
</TR>

</TABLE>
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='102'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">RISK
    FACTORS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Investing in our common stock involves a high degree of risk.
    You should consider carefully the risks and uncertainties
    described below, together with all of the other information in
    this prospectus, including our consolidated financial statements
    and related notes, before deciding whether to purchase shares of
    our common stock. If any of the following risks is realized, our
    business, financial condition, results of operations and
    prospects could be materially and adversely affected. In that
    event, the price of our common stock could decline and you could
    lose part or all of your investment.</I>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Risks
    Related to our Business and Strategy</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We have incurred losses since inception, and we expect to
    continue to incur substantial losses for the foreseeable
    future.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have a limited operating history and have incurred
    significant losses in each fiscal year since our inception,
    including net losses of $16.4&#160;million, $23.6&#160;million
    and $25.5&#160;million during 2005, 2006 and 2007. As of
    December&#160;29, 2007, we had an accumulated deficit of
    $133.8&#160;million. These losses have resulted principally from
    costs incurred in our research and development programs and from
    our selling, general and administrative expenses. We expect to
    continue to incur operating and net losses and negative cash
    flow from operations, which may increase, for the foreseeable
    future due in part to anticipated increases in expenses for
    research and product development and expansion of our sales and
    marketing capabilities. Additionally, following this offering,
    we expect that our selling, general and administrative expenses
    will increase due to the additional operational and reporting
    costs associated with being a public company. We anticipate that
    our business will generate operating losses until we
    successfully implement our commercial development strategy and
    generate significant additional revenues to support our level of
    operating expenses. Because of the numerous risks and
    uncertainties associated with our commercialization efforts and
    future product development, we are unable to predict when we
    will become profitable, and we may never become profitable. Even
    if we do achieve profitability, we may not be able to sustain or
    increase our profitability.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>If our products fail to achieve and sustain sufficient
    market acceptance, our revenue will be adversely
    affected.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our success depends, in part, on our ability to develop and
    market products that are recognized and accepted as reliable,
    enabling and cost effective. Most of our potential customers
    already use expensive research systems in their laboratories and
    may be reluctant to replace those systems. Market acceptance of
    our instrument systems will depend on many factors, including
    our ability to convince potential customers that our systems are
    an attractive alternative to existing technologies. Compared to
    other technologies, our Integrated Fluidic Circuit, or IFC,
    technology is new and unproven, and most potential customers
    have limited knowledge of, or experience with, our products.
    Prior to adopting our technology, potential customers generally
    need to devote significant effort to testing and validating our
    systems and benchmarking them against their current systems and
    performance requirements. Any failure of our systems to meet
    these customer benchmarks could result in customers choosing to
    retain their existing systems or to purchase systems other than
    ours.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, many customers intend to publish the results of
    their experiments in scientific and medical journals. Therefore,
    it is important that our systems be perceived as accurate and
    reliable by the scientific and medical research community as a
    whole. Many factors influence the perception of a system
    including its use by leading research groups and the publication
    of their results in well regarded journals. A significant part
    of our sales and marketing efforts have been directed at
    convincing industry leaders of the advantages of our systems and
    encouraging such leaders to publish or present the results of
    their evaluation of our system. If we are unable to induce
    leading researchers to use our system or if such researchers are
    unable to achieve and publish or present significant
    experimental results using our system, acceptance and adoption
    of our systems will be slowed.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our sales cycle is lengthy and unpredictable, which makes
    it difficult for us to forecast revenue and could cause
    significant quarterly fluctuations in revenue and other
    operating results.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The sales cycles for our instrument systems is lengthy, which
    makes it difficult for us to accurately forecast revenues in a
    given period, and may cause revenue and operating results to
    vary significantly from period to period.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    8
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Due in part to the high up-front cost associated with our
    systems, potential customers for our instrument systems
    typically need to commit significant time and resources to
    evaluate our technology and their decision to purchase our
    instruments may be further limited by budgetary constraints and
    several layers of internal review and approval, which are beyond
    our control. Even after initial approval by appropriate decision
    makers, the negotiation and documentation processes for a
    purchase can be lengthy. As a result of these factors, our sales
    cycle has varied widely and, in certain instances has been
    longer than 12&#160;months. The complexity and variability of
    our sales cycle has made it difficult for us to accurately
    project quarterly revenues, and we have frequently failed to
    meet our internal quarterly projections. Moreover, we do not
    recognize revenue on sales of our systems until the system has
    been delivered to the customer and, in many instances, installed
    and our other revenue recognition criteria have been met. This
    further complicates our ability to project quarterly revenue as
    we may have entered into a sale agreement with a customer for a
    system but cannot predict when that customer will take delivery
    of the system and when we will be able to recognize the revenue.
    We expect that our sales will continue to fluctuate on a
    quarterly basis and that our financial results for some periods
    may be below those projected by securities analysts. Such
    fluctuations could have a material adverse effect on our
    business and on the price of our common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our sales efforts require significant time and effort and
    could hinder our ability to increase sales.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Before purchasing one of our systems, customers typically
    require input from one or more scientific evaluators as well as
    a review by personnel with finance or operational expertise. As
    a result, during our sales effort, we must identify all persons
    involved in the purchasing decision and devote a sufficient
    amount of time to presenting our systems to those individuals.
    The newness and complexity of our products often requires us to
    spend substantial time and effort assisting potential customers
    in evaluating our instruments including providing demonstrations
    and benchmarking our products against other available
    technologies. This process can be costly and time consuming. We
    expect that our sales process will become less burdensome as our
    products become more widely known and used. However, if this
    change does not occur, we will not be able to expand our sales
    effort as quickly as anticipated and our sales will be adversely
    affected.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our future success is dependent upon our ability to expand
    our customer base and introduce new applications.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our customer base is primarily composed of pharmaceutical and
    biotechnology companies, academic institutions and life science
    laboratories that perform large-scale experimentation for life
    science research purposes. Our success will depend in part upon
    our ability to increase our market share amongst these
    customers, attract life science research customers who do not
    currently perform large-scale experimentation, attract customers
    outside the life science research market and market new
    applications to existing and new customers as we develop such
    applications. Attracting new customers and introducing new
    applications requires substantial time and expense. For example,
    it may be difficult to identify, engage and market to customers
    who do not currently perform large-scale experimentation or are
    unfamiliar with our current applications. In addition, certain
    new applications that we are considering developing are not
    practical to perform with conventional techniques. Any failure
    to expand our existing customer base or launch new applications
    would adversely affect our ability to increase our revenues.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our inability to develop new systems and enhance the
    capabilities of our IFC systems to keep pace with rapidly
    changing technology and customer requirements could adversely
    affect our business.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our success depends on our ability to develop new applications
    for our IFC technology in existing and new markets, while
    improving the performance and cost effectiveness of our systems.
    New technologies, techniques or products could emerge that might
    offer better combinations of price and performance than our
    current or future product lines and systems. Existing markets
    for our products, including gene expression analysis,
    genotyping, digital polymerase chain reaction, or PCR, and
    proteomics, as well as potential markets for our products such
    as molecular diagnostics, are characterized by rapid
    technological change and innovation. It is critical to our
    success for us to anticipate changes in technology and customer
    requirements and to successfully introduce new, enhanced and
    competitive technology to meet our customers&#146; and
    prospective customers&#146; needs on a timely basis. While we
    have planned substantial improvements to the BioMark system,
    including enhancing the capabilities of our IFCs, we may not be
    able to successfully implement these improvements. Even if we
    successfully implement some or all of these planned
    improvements, we could incur substantial development costs in
    doing so. We may not have adequate resources available to
    develop new technologies or be able to successfully introduce
    new applications of,
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    9
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    or enhancements to, our systems. We cannot guarantee that we
    will be able to maintain technological advantages over emerging
    technologies in the future. If we fail to keep pace with
    emerging technologies, demand for our systems will not grow and
    may decline, and our business, revenue, financial condition and
    operating results could suffer materially.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We have limited resources for marketing, selling and
    distributing our products and we may not be able to develop a
    direct sales and marketing force or distribution capabilities
    that can meet our customers&#146; needs.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have limited marketing, sales and distribution resources and
    capabilities. We sell our products primarily through our own
    sales force and through distributors in certain territories. Our
    first product line, the Topaz system for protein
    crystallization, was introduced for commercial sale in 2002. Our
    BioMark system was introduced for commercial sale in 2006.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our future sales will depend in large part on our ability to
    develop and expand our direct sales force and to increase the
    scope of our marketing efforts. Our products are technically
    complex and used for highly specialized applications. As a
    result, we believe it is necessary to develop a direct sales
    force that includes people with specific scientific backgrounds
    and expertise and a marketing group with technical
    sophistication. Competition for such employees is intense. We
    may not be able to attract and retain personnel or be able to
    build an efficient and effective sales and marketing force,
    which could negatively impact sales of our products, and reduce
    our revenues and profitability.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, we may seek to enlist one or more parties to assist
    with sales, distribution and customer support globally or in
    certain regions of the world. If we do seek to enter into such
    arrangements, we may not be successful in attracting desirable
    sales and distribution partners, or we may not be able to enter
    into such arrangements on favorable terms. If our sales and
    marketing efforts, or those of any third-party sales and
    distribution partners, are not successful, our technologies and
    products may not gain market acceptance, which would materially
    impact our business operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>The life science industry is highly competitive and
    subject to rapid technological change, and we may not be able to
    successfully compete.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The markets for our products are characterized by rapidly
    changing technology, evolving industry standards, changes in
    customer needs, emerging competition, new product introductions
    and strong price competition. We compete with both established
    and development stage life science companies that design,
    manufacture and market instruments for gene expression analysis,
    genotyping, other nucleic acid detection and additional
    applications using well established laboratory techniques, as
    well as newer technologies such as bead encoded arrays,
    microfluidics, nanotechnology, next-generation DNA sequencing
    and inkjet and photolithographic arrays. Most of our current
    competitors have significantly greater name recognition, greater
    financial and human resources, broader product lines and product
    packages, larger sales forces, large existing installed bases,
    substantial intellectual property portfolios and greater
    experience in research and development, manufacturing and
    marketing than we do. For example, companies such as Affymetrix,
    Applied Biosystems, BioTrove, Illumina, Roche Diagnostics and
    Sequenom have products that compete in certain segments of the
    market in which we sell our BioMark system.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Competitors may be able to respond more quickly and effectively
    than we can to new or changing opportunities, technologies,
    standards or customer requirements. In light of these
    advantages, even if our technology is more effective than the
    product or service offerings of our competitors, current or
    potential customers might accept competitive products and
    services in lieu of purchasing our technology. We anticipate
    that we will face increased competition in the future as
    existing companies and competitors develop new or improved
    products and as new companies enter the market with new
    technologies. We may not be able to compete effectively against
    these organizations. Increased competition is likely to result
    in pricing pressures, which could harm our sales, profitability
    or market share. Our failure to compete effectively could
    materially and adversely affect our business, financial
    condition and results of operations.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    10
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We receive a substantial portion of our revenue from a
    limited number of customers and other entities, and the loss of,
    or a significant reduction in, orders or grants from one or more
    of our major customers or grantors would adversely affect our
    operations and financial condition.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We receive a substantial portion of our revenue from a limited
    number of customers and grantors. We received an aggregate of
    approximately 36%, 44% and 37% of our total revenue from our top
    three customers in 2005, 2006 and 2007. Grant revenue from the
    Singapore Economic Development Board, or EDB, represented 14%
    and 24% of our total revenue in 2006 and 2007. We anticipate
    that we will continue to be dependent on a limited number of
    customers and grantors for a significant portion of our revenue
    in the near future and in some cases the portion of our revenue
    attributable to certain customers or grantors may increase in
    the future. However, we may not be able to maintain or increase
    sales to our top customers or grants from our top grantors for a
    variety of reasons, including the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our agreements with our customers and grantors do not require
    them to purchase a minimum quantity of our products or make a
    minimum amount of grants in any year;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our customers can stop using our products with limited notice to
    us and suffer little or no payment penalty;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our grants are subject to the achievement of milestones that we
    may not meet;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    many of our customers have pre-existing or concurrent
    relationships with our current or potential competitors that may
    affect the customers&#146; decisions to purchase our products.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the past, we have relied in significant part on our strategic
    relationships with customers that are technology leaders in our
    target markets. We intend to pursue the expansion of such
    relationships and the formation of new strategic relationships
    but we cannot assure you that we will be able to do so. These
    relationships often require us to develop new products that may
    involve significant technological challenges. Our customers
    frequently place considerable pressure on us to meet their tight
    development schedules. Our grantors frequently condition their
    present and future grants on our compliance with certain
    development, hiring and local investment milestones.
    Accordingly, we may have to devote a substantial amount of our
    resources to our strategic relationships, which could detract
    from or delay our completion of other important development
    projects. Delays in development could impair our relationships
    with our strategic customers and grantors and negatively impact
    sales of the products under development or future grant
    activity. The loss of a key customer or grantor, a reduction in
    sales to any key customer, a reduction in grants from a key
    grantor, or our inability to attract new significant customers
    could seriously impact our revenue and materially and adversely
    affect our results of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our business depends on research and development spending
    levels of pharmaceutical and biotechnology companies and
    academic, clinical and governmental research institutions and
    any reduction in such spending could limit our ability to sell
    our products.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We expect that our revenue in the foreseeable future will be
    derived primarily from sales of instruments and IFCs to academic
    institutions, biotechnology and pharmaceutical companies and
    life science laboratories worldwide. Our success will depend
    upon their demand for and use of our products. Accordingly, the
    spending policies of these customers could have a significant
    effect on the demand for our technology. These policies may be
    based on a wide variety of factors, including the resources
    available to make purchases, the spending priorities among
    various types of equipment, policies regarding spending during
    recessionary periods and changes in the political climate. In
    addition, academic, governmental and other research institutions
    that fund research and development activities may be subject to
    stringent budgetary constraints that could result in spending
    reductions, reduced allocations or budget cutbacks, which could
    jeopardize the ability of these customers to purchase our
    system. Our operating results may fluctuate substantially due to
    reductions and delays in research and development expenditures
    by these customers. For example, reductions in capital
    expenditures by these customers may result in lower than
    expected system sales and, similarly, reductions in operating
    expenditures by these customers could result in lower than
    expected sales of IFCs. These reductions and delays may result
    from factors that are not within our control, such as:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    changes in economic conditions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    changes in government programs that provide funding to research
    institutions and companies;
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    11
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    changes in the regulatory environment affecting life science
    companies and life science research;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    market-driven pressures on companies to consolidate operations
    and reduce costs;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    mergers and acquisitions in the life science industry;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    other factors affecting research and development spending.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Any decrease in our customers&#146; budgets or expenditures or
    in the size, scope or frequency of capital or operating
    expenditures as a result of the foregoing or other factors could
    materially adversely affect our operations or financial
    condition.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>If we cannot provide quality technical support, we could
    lose customers and our operating results could suffer.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The placement of our products at new customer sites, the
    introduction of our technology into our customers&#146; existing
    systems and ongoing customer support can be complex.
    Accordingly, we need highly trained technical support personnel.
    Hiring technical support personnel is very competitive in our
    industry due to the limited number of people available with the
    necessary biochemistry background and ability to understand our
    systems at a technical level. We are currently expanding our
    technical support staff and will need to increase it further to
    support expected new customers as well as the expanding needs of
    existing customers. If we are unable to attract, train or retain
    the number of highly qualified technical services personnel that
    our business needs, our business and prospects will suffer.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>To use our products, customers typically need to purchase
    specialized reagents. Any interruption in the availability of
    these reagents for use in our products could limit our ability
    to market our products.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our products must be used in conjunction with one or more
    reagents designed to produce or facilitate the particular
    biological or chemical reaction desired by the user. Many of
    these reagents are highly specialized and available to the user
    only from a single supplier or a limited number of suppliers.
    Our customers typically purchase these reagents directly from
    the suppliers and we have no control over the supply of those
    materials. In addition, our products are designed to work with
    these reagents as they are currently formulated. We have no
    control of the formulation of these reagents and the performance
    of our products might be adversely affected if the formulation
    of these reagents was changed. If one or more of these reagents
    were to become unavailable or were reformulated, our ability to
    market and sell our products could be materially and adversely
    affected.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, the use of a reagent for a particular process may
    be covered by one or more patents relating to the reagent
    itself, the use of the reagent for the particular process, the
    performance of that process or the equipment required to perform
    the process. Typically, reagent suppliers, who are either the
    patent holders or their authorized licensees, sell the reagents
    along with a license or covenant not to sue with respect to such
    patents. The license accompanying the sale of a reagent often
    purports to restrict the purposes for which the reagent may be
    used. If a patent holder or authorized licensee were to assert
    against us or our customers that the license or covenant
    relating to a reagent precluded its use with our systems, our
    ability to sell and market our products could be materially and
    adversely affected. For example, the current applications of our
    BioMark system involve real-time polymerase chain reaction, or
    PCR, reactions. The primary producers of reagents for PCR
    reactions are Applied Biosystems and Roche Diagnostics, who are
    our direct competitors, and their licensees. These PCR reagents
    are sold pursuant to limited licenses or covenants with respect
    to patents held by these companies. We do not have any
    contractual relationship with Roche Molecular Diagnostics or
    Applied Biosystems regarding these PCR reagents, and we cannot
    assure you that these reagents will continue to be available to
    our customers for use with our systems, or that these patent
    holders will not seek to enforce their patents against us, our
    customers, or suppliers.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    12
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We are dependent on single source suppliers for some of
    the components and materials used in our systems, and the loss
    of any of these suppliers could harm our business.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We rely on single source suppliers for certain components and
    materials used in our systems. Of these single source suppliers,
    the loss of any of the following would require significant time
    and effort to locate and qualify an alternative source of supply:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    An essential component of our BioMark system is a specialized
    thermal cycler that is available from a limited number of
    suppliers. We purchase this thermal cycler from one supplier,
    Eppendorf North America, which customizes it to our
    specifications pursuant to a supply agreement.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Our IFCs are fabricated using a specialized polymer that is
    available from a limited number of sources. In the past we have
    encountered quality issues that have reduced our manufacturing
    yield or required the use of additional manufacturing processes.
    We do not have a long term contract with our current sole
    supplier.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The plastic carriers that hold the core components of our IFCs
    need to be produced to specifications and tolerances that few
    manufacturers are able to meet. We have experienced quality
    issues in the past and, as a result, have recently switched
    suppliers. We do not have a long term contract with either of
    our current sole suppliers for particular carriers.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The reader for our BioMark system requires specialized high
    resolution camera lenses that are available from a limited
    number of sources. We do not have a long term contract with our
    current sole supplier.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our reliance on these suppliers also subjects us to other risks
    that could harm our business, including the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we may be subject to increased component costs;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we are not a major customer of many of our suppliers, and these
    suppliers may therefore give other customers&#146; needs higher
    priority than ours;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we may not be able to obtain adequate supply in a timely manner
    or on commercially reasonable terms;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our suppliers may make errors in manufacturing components that
    could negatively affect the efficacy of our systems or cause
    delays in shipment of our systems;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our suppliers may encounter financial hardships unrelated to our
    demand for components, which could inhibit their ability to
    fulfill our orders and meet our requirements.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have in the past experienced supply problems with some of our
    suppliers, such as manufacturing errors, and may again
    experience problems in the future. We may not be able to quickly
    establish additional or replacement suppliers, particularly for
    our single source components. Any interruption or delay in the
    supply of components or materials, or our inability to obtain
    components or materials from alternate sources at acceptable
    prices in a timely manner, could impair our ability to meet the
    demand of our customers and cause them to cancel orders or
    switch to competitive products.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We have limited experience in producing our products, and
    we may experience development or manufacturing problems or
    delays that could limit the growth of our revenue or increase
    our losses.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have limited experience manufacturing and assembling our
    products in commercial quantities and we may encounter
    unforeseen situations that would result in delays or shortfalls.
    In addition, our production processes and assembly methods may
    have to change to accommodate any significant future expansion
    of our manufacturing capacity. If we are unable to keep up with
    demand for our products, our revenue could be impaired, market
    acceptance for our products could be adversely affected and our
    customers might instead purchase our competitors&#146; products.
    Our inability to successfully manufacture our products would
    have a material adverse effect on our operating results.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We first produced the IFCs used in our current Topaz system in
    June 2002 at our facility in South San&#160;Francisco. We have
    since moved our commercial production of IFCs to our facility in
    Singapore, which first produced commercial IFCs for our Topaz
    systems in October 2006 and first produced commercial IFCs for
    our BioMark
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    13
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    system in December 2007. We do not expect to commercialize our
    96.96 BioMark IFCs until the second half of 2008. Production of
    the elastomeric block that is at the core of our IFCs is a
    complex process requiring advanced clean rooms, sophisticated
    equipment and strict adherence to procedures. Any contamination
    of the clean room, equipment malfunction or failure to strictly
    follow procedures can significantly reduce our yield in one or
    more batches. Such a drop in yield can greatly increase our cost
    to manufacture our IFCs or, in more severe cases, require us to
    halt the manufacture of IFCs until the problem is resolved.
    Identifying and resolving the cause of a drop in yield can
    require substantial time and resources. We have had significant
    yield problems in the past and cannot assure you that these
    types of yield issues will not occur again. Sustained yield
    problems would have a material adverse affect on our business,
    financial condition and results of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, developing an IFC for a new application typically
    requires developing a specific production process for that type
    of IFC. While all of our IFCs are produced using the same basic
    processes, significant variations are required to ensure
    adequate yield of any particular type of IFC. Developing such a
    process can be very time consuming, and any unexpected
    difficulty in doing so can delay the introduction of a product.
    For example, in the second quarter of 2006, our ability to
    conduct demonstrations for potential customers for our BioMark
    system was impaired because we were unable to produce sufficient
    quantities of that IFC. Though these production problems were
    resolved, the delay in conducting customer demonstrations
    resulted in the loss and delay of orders from potential
    customers. We cannot assure you that we will not face similar
    difficulties in developing new processes in the future.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>If we are unable to recruit and retain key executives and
    scientists, we may be unable to achieve our goals.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our performance is substantially dependent on the performance of
    our senior management and key scientific and technical
    personnel, particularly Gajus V. Worthington, our President and
    Chief Executive Officer. We do not maintain fixed term
    employment contracts with any of our employees. The loss of the
    services of any member of our senior management or our
    scientific or technical staff might significantly delay or
    prevent the development of our products or achievement of other
    business objectives by diverting management&#146;s attention to
    transition matters and identification of suitable replacements,
    if any, and could have a material adverse effect on our
    business. We do not maintain significant key man life insurance
    on any of our employees.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, our research and product development efforts could
    be delayed or curtailed if we are unable to attract, train and
    retain highly skilled employees, particularly, senior scientists
    and engineers. To expand our research and product development
    efforts we need additional people skilled in areas such as
    molecular and cellular biology, assay development and
    manufacturing. Competition for these people is intense. Because
    of the complex and technical nature of our system and the
    dynamic market in which we compete, any failure to attract and
    retain a sufficient number of qualified employees could
    materially harm our ability to develop and commercialize our
    technology.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We may be unable to manage our anticipated growth
    effectively.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The rapid growth of our business has placed a significant strain
    on our managerial, operational and financial resources and
    systems. We have increased the number of our employees from 78
    at December&#160;31, 2005 to 131 at December&#160;29, 2007. In
    addition, since October 2006 we have commenced manufacturing
    operations in Singapore and opened sales offices in Europe and
    Japan. To execute our anticipated growth successfully, we must
    continue to attract and retain qualified personnel and manage
    and train them effectively. We must also upgrade our internal
    business processes and capabilities to create the scalability
    that a growing business demands.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe our primary commercial manufacturing facility located
    in Singapore is sufficient to meet our short-term manufacturing
    needs. However, the current lease for our manufacturing facility
    in Singapore expires in October&#160;2008. In order to meet the
    long-term demand for our IFC systems, we believe that we will
    need to add to our existing manufacturing space in Singapore or
    move all of our manufacturing facilities to a new location in
    Singapore. Such a move will involve significant expense in
    connection with the establishment of new clean rooms, the
    movement and installation of key manufacturing equipment and
    modifications to our manufacturing process and we cannot assure
    you that such a move would not delay or otherwise adversely
    affect our manufacturing activities.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    14
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Further, our anticipated growth will place additional strain on
    our suppliers and manufacturing facilities, resulting in an
    increased need for us to carefully monitor quality assurance.
    Any failure by us to manage our growth effectively could have an
    adverse effect on our ability to achieve our development and
    commercialization goals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our research and product development efforts may not
    result in commercially viable products within the timeline
    anticipated, if at all.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our business is dependent on the improvement of our existing
    products, our development of new products to serve existing
    markets and our development of new products to create new
    markets and applications that were previously not practical with
    existing systems. We intend to devote significant personnel and
    financial resources to research and development activities
    designed to advance the capabilities of our IFC technology. Our
    IFC technology is new and complex and the behavior of fluids and
    surrounding compounds in a nanoscale environment is difficult to
    predict in advance. Though we have developed design rules for
    the implementation of our IFC technology, these are frequently
    revised to reflect new insights we have gained about the
    technology. In addition, we have discovered that biological or
    chemical reactions sometimes behave differently when implemented
    on IFCs rather than in a standard laboratory environment. As a
    result, significant research and development efforts may be
    required to transfer even well-understood reactions to our
    technology. In the past, product development projects have been
    significantly delayed when we encountered unanticipated
    difficulties in implementing a process on our IFCs. We may have
    similar delays in the future, and we may not obtain any benefits
    from our research and development activities. Any delay or
    failure by us to develop new products or enhance existing
    products would have a substantial adverse effect on our business
    and results of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our products, although not currently regulated, could in
    the future be subject to regulation by the U.S. Food and Drug
    Administration or other regulatory agencies.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our products are currently labeled and sold for research
    purposes only and are not subject to U.S.&#160;Food and Drug
    Administration, or FDA, clearance or approval. However, in the
    future, certain of our products or related applications could be
    subject to the FDA&#146;s regulation, the FDA&#146;s regulatory
    jurisdiction could be expanded to include our products, or both.
    For example, if we wished to label and market our products for
    use in performing clinical diagnostics, FDA clearance or
    approval would be required. Even where a product is exempted
    from FDA clearance or approval, the FDA may impose restrictions
    on how and to whom we can market and sell our products.
    Obtaining FDA approval can be expensive and uncertain, generally
    takes several years to obtain and requires detailed and
    comprehensive scientific and clinical data. Notwithstanding the
    expense, these efforts may never result in FDA approval or
    clearance. Even if we were to obtain regulatory approval or
    clearance, it may not be for the uses we believe are important
    or commercially attractive. As a result, these regulations and
    restrictions could materially and adversely affect our business,
    financial condition and results of operations. Similar laws and
    regulations are also in effect in many foreign countries that
    could affect our ability to market certain products. The number
    and scope of these requirements are increasing. We may not be
    able to obtain regulatory approvals in such countries or may
    incur significant costs in obtaining or maintaining our foreign
    regulatory approvals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our future capital needs are uncertain and we may need to
    raise additional funds in the future.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that the net proceeds from this offering, together
    with our existing cash and cash equivalents, available for sale
    securities balances and cash receipts generated from sales of
    our products, will be sufficient to meet our anticipated cash
    requirements for at least the next 18&#160;months. However, we
    may need to raise substantial additional capital to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    expand the commercialization of our products;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    fund our operations;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    continue our research and development;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    defend, in litigation or otherwise, any claims that we infringe
    third-party patents or violate other intellectual property
    rights;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    commercialize new products;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    acquire companies and in-license products or intellectual
    property.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    15
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our future funding requirements will depend on many factors,
    including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    market acceptance of our products;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the cost of our research and development activities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the cost of filing and prosecuting patent applications;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the cost of defending, in litigation or otherwise, any claims
    that we infringe third-party patents or violate other
    intellectual property rights;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the cost and timing of regulatory clearances or approvals, if
    any;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the cost and timing of establishing additional sales, marketing
    and distribution capabilities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the cost and timing of establishing additional technical support
    capabilities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the effect of competing technological and market
    developments;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the extent to which we acquire or invest in businesses, products
    and technologies, although we currently have no commitments or
    agreements relating to any of these types of transactions.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>If we require additional funds in the future, such funds
    may not be available on acceptable terms, or at all.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We may require additional funds in the future and we may not be
    able to obtain such funds on acceptable terms, or at all. If we
    raise additional funds by issuing equity securities, our
    stockholders may experience dilution. Debt financing, if
    available, may involve covenants restricting our operations or
    our ability to incur additional debt. Any debt or additional
    equity financing that we raise may contain terms that are not
    favorable to us or our stockholders. If we raise additional
    funds through collaboration and licensing arrangements with
    third parties, it may be necessary to relinquish some rights to
    our technologies or our products, or grant licenses on terms
    that are not favorable to us. If we are unable to raise adequate
    funds, we may have to liquidate some or all of our assets, or
    delay, reduce the scope of or eliminate some or all of our
    development programs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If we do not have, or are not able to obtain, sufficient funds,
    we may have to delay development or commercialization of our
    products or license to third parties the rights to commercialize
    products or technologies that we would otherwise seek to
    commercialize. We also may have to reduce marketing, customer
    support or other resources devoted to our products or cease
    operations. Any of these factors could harm our operating
    results.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our products could have unknown defects or errors, which
    may give rise to claims against us and adversely affect market
    adoption of our systems.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFC systems utilize novel and complex technology applied on
    a nanoliter scale and such systems may develop or contain
    undetected defects or errors. We cannot assure you that material
    performance problems, defects or errors will not arise, and as
    we increase the density and integration of our IFCs, these risks
    may increase. While we do not provide express warranties that
    our IFCs will meet performance expectations or be free from
    defects, we have done so in the past, and expect to in the
    future in response to customer concerns in order to preserve
    customer relationships and help foster continued adoption and
    use of our systems. We typically do provide warranties relating
    to other parts of our IFC systems. The costs incurred in
    correcting any defects or errors may be substantial and could
    adversely affect our operating margins.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In manufacturing our products, we depend upon third parties for
    the supply of various components. Many of these components
    require a significant degree of technical expertise to produce.
    If our suppliers fail to produce components to specification, or
    if the suppliers, or we, use defective materials or workmanship
    in the manufacturing process, the reliability and performance of
    our products will be compromised.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If our products contain defects, we may experience:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a failure to achieve market acceptance or expansion of our
    product sales;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    loss of customer orders and delay in order fulfillment;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    damage to our brand reputation;
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    16
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    increased cost of our warranty program due to product repair or
    replacement;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    product recalls or replacements;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    inability to attract new customers;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    diversion of resources from our manufacturing and research and
    development departments into our service department;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    legal claims against us, including product liability claims,
    which could be costly and time consuming to defend and result in
    substantial damages.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The occurrence of any one or more of the foregoing could
    negatively affect our business, financial condition and results
    of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We sell our systems internationally and are subject to
    various risks relating to such international activities which
    could adversely affect our international sales and operating
    performance.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the years ended December&#160;31, 2006 and December&#160;29,
    2007, approximately 39% and 52% of our total revenue was
    attributable to sales in areas outside of North America. We
    believe that a significant percentage of our future revenue will
    come from international sales as we expand our overseas
    operations and develop opportunities in additional international
    areas. Our international business may be adversely affected by
    changing economic, political and regulatory conditions in
    foreign countries. Because the majority of our sales are
    currently denominated in U.S.&#160;dollars, if the value of the
    U.S.&#160;dollar increases relative to foreign currencies, our
    products could become more costly to the international consumer
    and therefore less competitive in international markets, which
    could affect our financial performance. In addition, if the
    value of the U.S.&#160;dollar decreases relative to the
    Singapore dollar, it would become more costly in
    U.S.&#160;dollars for us to manufacture our products in
    Singapore. Furthermore, fluctuations in exchange rates could
    reduce our revenue and affect demand for our products. Engaging
    in international business inherently involves a number of other
    difficulties and risks, including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    required compliance with existing and changing foreign
    regulatory requirements and laws;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    export or import restrictions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    laws and business practices favoring local companies;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    longer payment cycles and difficulties in enforcing agreements
    and collecting receivables through certain foreign legal systems;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    political and economic instability;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    potentially adverse tax consequences, tariffs, customs charges,
    bureaucratic requirements and other trade barriers;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    difficulties and costs of staffing and managing foreign
    operations;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    difficulties protecting or procuring intellectual property
    rights.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If one or more of these risks occurs, it could require us to
    dedicate significant resources to remedy, and if we are
    unsuccessful in finding a solution, our financial results will
    suffer.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We use hazardous chemicals and biological materials in our
    business. Any claims relating to improper handling, storage or
    disposal of these materials could be time consuming and
    costly.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our research and development and manufacturing processes involve
    the controlled use of hazardous materials, including flammables,
    toxics, corrosives and biologics. Our operations produce
    hazardous biological and chemical waste products. We cannot
    eliminate the risk of accidental contamination or discharge and
    any resultant injury from these materials. In addition, our IFC
    systems involve the use of pressurized systems and may involve
    the use of hazardous materials, which could result in injury. We
    may be sued for any injury or contamination that results from
    our use or the use by third parties of these materials. We do
    not currently maintain separate environmental liability
    coverage. Federal, state and local laws and regulations govern
    the use, manufacture, storage, handling and disposal
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    17
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    of hazardous materials. Compliance with environmental laws and
    regulations may be expensive, and current or future
    environmental regulations may impair our research, development
    and production efforts.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>If our facilities become inoperable, we will be unable to
    continue manufacturing our products and as a result, our
    business will be harmed until we are able to secure a new
    facility.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We manufacture and assemble our IFCs for commercial sale at our
    facility in Singapore and assemble our instrument platforms at
    our facilities in Singapore and South San&#160;Francisco,
    California. No other manufacturing or assembly facilities are
    currently available to us. Our facilities and the equipment we
    use to manufacture our products would be costly to replace and
    could require substantial lead time to repair or replace. The
    facilities may be harmed or rendered inoperable by natural or
    man-made disasters, including earthquakes, flooding and power
    outages, which may render it difficult or impossible for us to
    perform our research, development and manufacturing for some
    period of time. The inability to perform our research,
    development and manufacturing activities, combined with our
    limited inventory of reserve raw materials and manufactured
    supplies, may result in the loss of customers or harm our
    reputation, and we may be unable to reestablish relationships
    with those customers in the future. Although we possess
    insurance for damage to our property and the disruption of our
    business, this insurance may not be sufficient to cover all of
    our potential losses and may not continue to be available to us
    on acceptable terms, or at all.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>If we fail to maintain effective internal control over
    financial reporting in the future, the accuracy and timing of
    our financial reporting may be adversely affected.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In connection with the audit of our consolidated financial
    statements for the years ended December&#160;31, 2005 and 2006
    we, together with our independent registered public accounting
    firm identified material weaknesses in our internal control over
    financial reporting.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The material weaknesses related to our financial statement close
    process, revenue recognition and accrual processes and inventory
    costing, cost of sales, purchases cut-off and stock-based
    compensation. These material weaknesses resulted in the
    recording of numerous audit adjustments over the two year period
    ending December&#160;31, 2006. Since the date of our independent
    registered public accounting firm&#146;s reports on our
    consolidated financial statements for the years ended
    December&#160;31, 2005 and 2006 and through the date of this
    prospectus, we have taken steps intended to remediate these
    material weaknesses, primarily through the hiring of additional
    accounting and finance personnel with technical accounting and
    financial reporting experience. In addition, we have implemented
    procedures and controls in the financial statement close process
    designed to improve the accuracy and timeliness in financial
    accounting and reporting.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In April 2008, following the audit of our consolidated financial
    statements for 2007, we reviewed our internal control over
    financial reporting and concluded that we had certain
    significant deficiencies. A significant deficiency is defined as
    a deficiency, or combination of deficiencies, in internal
    control over financial reporting that is less severe than a
    material weakness, yet important enough to merit attention by
    those responsible for oversight of a company&#146;s financial
    reporting. The significant deficiencies identified by us related
    to our controls for the consolidation and elimination entries
    relating to intercompany transfer pricing and elimination of
    intercompany profits embedded in deferred costs of our Japanese
    subsidiary and our controls for applying SFAS&#160;123R to
    option grants with non-standard vesting terms and validation of
    stock compensation expenses calculated by our option tracking
    software.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We do not know the specific time frame that we will require to
    remediate the significant deficiencies identified. In addition,
    we expect to incur some incremental costs associated with this
    remediation. If we fail to enhance our internal control over
    financial reporting to meet the demands that will be placed upon
    us as a public company, including the requirements of the
    Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley Act, we may be
    unable to report our financial results accurately and prevent
    fraud. While we expect to remediate the significant
    deficiencies, we cannot assure you that we will be able to do so
    in a timely manner, which could impair our ability to accurately
    and timely report our financial position, results of operations
    or cash flows.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     No material weaknesses in internal control over financial
    reporting were identified in our April 2008 review. However, our
    management and independent registered public accounting firm did
    not perform an evaluation of our internal control over financial
    reporting during any period in accordance with the provisions of
    Section&#160;404 of the
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    18
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Sarbanes-Oxley Act. Had we and our independent registered public
    accounting firm performed an evaluation of our internal control
    over financial reporting in accordance with the provisions of
    Section&#160;404 of the Sarbanes-Oxley Act, additional control
    deficiencies may have been identified by management or our
    independent registered public accounting firm.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We will incur significant increased costs as a result of
    operating as a public company, and our management will be
    required to devote substantial time to new compliance
    initiatives.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have never operated as a public company. As a public company,
    we will incur significant legal, accounting and other expenses
    that we did not incur as a private company. In addition, the
    Sarbanes-Oxley Act, as well as new rules subsequently
    implemented by the Securities and Exchange Commission and the
    NASDAQ Global Market, have imposed various new requirements on
    public companies, including requiring changes in corporate
    governance practices. Our management and other personnel will
    need to devote a substantial amount of time to these new
    compliance initiatives. Moreover, these rules and regulations
    will increase our legal and financial compliance costs and will
    make some activities more time-consuming and costly. For
    example, we expect these new rules and regulations to make it
    more difficult and more expensive for us to obtain director and
    officer liability insurance and we may be required to incur
    substantial costs to maintain the same or similar coverage.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, the Sarbanes-Oxley Act requires, among other
    things, that we maintain effective internal control over
    financial reporting and disclosure controls and procedures. In
    particular, commencing in 2009, we must perform system and
    process evaluation and testing of our internal control over
    financial reporting to allow management to report on the
    effectiveness of our internal control over financial reporting,
    as required by Section&#160;404 of the Sarbanes-Oxley Act. Our
    testing, or the subsequent testing by our independent registered
    public accounting firm, may reveal deficiencies in our internal
    control over financial reporting that are deemed to be material
    weaknesses. Our compliance with Section&#160;404 will require
    that we incur substantial accounting expense and expend
    significant management time on compliance-related issues. We
    currently do not have an internal audit group and we will
    evaluate the need to hire additional accounting and financial
    staff with appropriate public company experience and technical
    accounting knowledge. Moreover, if we are not able to comply
    with the requirements of Section&#160;404 in a timely manner, or
    if we or our independent registered public accounting firm
    identifies deficiencies in our internal control over financial
    reporting that are deemed to be material weaknesses, the market
    price of our stock could decline and we could be subject to
    sanctions or investigations by the NASDAQ Global Market, the
    Securities and Exchange Commission or other regulatory
    authorities, which would require additional financial and
    management resources.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Some of our programs are partially supported by government
    grants, which may be reduced, withdrawn, delayed or
    reclaimed.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have received and may continue to receive funds under
    research and economic development programs funded by the
    governments of Singapore and the United States. Funding by these
    governments may be significantly reduced or eliminated in the
    future for a number of reasons. For example, some
    U.S.&#160;programs are subject to a yearly appropriations
    process in Congress. Similarly, our grants from the Singapore
    government are part of an official policy to develop a life
    science industry in Singapore; that policy could change or the
    role of grants in it could be reduced or eliminated at any time.
    In addition, we may not receive funds under existing or future
    grants because of budgeting constraints of the agency
    administering the program. A restriction on the government
    funding available to us would reduce the resources that we would
    be able to devote to existing and future research and
    development efforts. Such a reduction could delay the
    introduction of new products and hurt our competitive position.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our agreements with the government of Singapore provide that
    grants extended to us in the past and future grants are subject
    to our operation of increasing levels of research, development
    and manufacturing in Singapore, including the use of local
    service providers, the hiring of personnel in Singapore, the
    incurrence of research and development expenses in Singapore,
    our receipt of new investment in our company and our achievement
    of certain milestones relating to the development of our
    products. These agreements further provide the government with
    the right to demand repayment of past grants in the event that
    it concludes that we have not met our obligations under the
    applicable agreements.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    19
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our ability to use net operating losses to offset future
    taxable income may be subject to certain limitations.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, under Section&#160;382 of the Internal Revenue Code,
    a corporation that undergoes an &#147;ownership change&#148; is
    subject to limitations on its ability to utilize its pre-change
    net operating losses or NOLs to offset future taxable income.
    Our existing NOLs may be subject to limitations arising from
    previous ownership changes, and if we undergo an ownership
    change in connection with or after this offering, our ability to
    utilize NOLs could be further limited by Section&#160;382 of the
    Internal Revenue Code. Future changes in our stock ownership,
    some of which are outside of our control, could result in an
    ownership change under Section&#160;382 of the Internal Revenue
    Code. We may not be able to utilize a material portion of the
    NOLs reflected on our balance sheet and for this reason, we have
    fully reserved against the value of our NOLs on our balance
    sheet.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Risks
    Related to Intellectual Property</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our ability to protect our intellectual property and
    proprietary technology through patents and other means is
    uncertain.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our commercial success may depend in part on our ability to
    protect our intellectual property and proprietary technologies.
    We rely on patent protection, where appropriate and available,
    as well as a combination of copyright, trade secret and
    trademark laws, and nondisclosure, confidentiality and other
    contractual restrictions to protect our proprietary technology.
    However, these legal means afford only limited protection and
    may not adequately protect our rights or permit us to gain or
    keep any competitive advantage. Our pending U.S.&#160;and
    foreign patent applications may not issue as patents or may not
    issue in a form that will be advantageous to us. Any patents we
    have obtained or do obtain may be subject to re-examination,
    reissue, opposition or other administrative proceeding, or may
    be challenged in litigation, and such challenges could result in
    a determination that the patent is invalid or unenforceable. In
    addition, competitors may be able to design alternative methods
    or devices that avoid infringement of our patents. To the extent
    our intellectual property, including licensed intellectual
    property, offers inadequate protection, or is found to be
    invalid or unenforceable, we are exposed to a greater risk of
    direct competition. If our intellectual property does not
    provide adequate protection against our competitors&#146;
    products, our competitive position could be adversely affected,
    as could our business. Both the patent application process and
    the process of managing patent disputes can be time consuming
    and expensive. Furthermore, the laws of some foreign countries
    may not protect our intellectual property rights to the same
    extent as do the laws of the United States.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The patent positions of life sciences companies can be highly
    uncertain and involve complex legal and factual questions for
    which important legal principles remain unresolved. No
    consistent policy regarding the breadth of claims allowed in
    such companies&#146; patents has emerged to date in the United
    States. The laws of some
    <FONT style="white-space: nowrap">non-U.S.&#160;countries</FONT>
    do not protect intellectual property rights to the same extent
    as the laws of the United States, and many companies have
    encountered significant problems in protecting and defending
    such rights in foreign jurisdictions. The legal systems of
    certain countries, particularly certain developing countries, do
    not favor the enforcement of patents and other intellectual
    property protection, particularly those relating to
    biotechnology, which could make it difficult for us to stop the
    infringement of our patents. Proceedings to enforce our patent
    rights in foreign jurisdictions could result in substantial cost
    and divert our efforts and attention from other aspects of our
    business. Changes in either the patent laws or in
    interpretations of patent laws in the United States or other
    countries may diminish the value of our intellectual property.
    We cannot predict the breadth of claims that may be allowed or
    enforced in our patents or in third-party patents. For example:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We might not have been the first to make the inventions covered
    by each of our pending patent applications.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We might not have been the first to file patent applications for
    these inventions.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Others may independently develop similar or alternative products
    and technologies or duplicate any of our products and
    technologies.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    It is possible that none of our pending patent applications will
    result in issued patents, and even if they issue as patents,
    they may not provide a basis for commercially viable products,
    or may not provide us with any competitive advantages, or may be
    challenged and invalidated by third parties.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We may not develop additional proprietary products and
    technologies that are patentable.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    20
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The patents of others may have an adverse effect on our business.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We apply for patents covering our products and technologies and
    uses thereof, as we deem appropriate. However, we may fail to
    apply for patents on important products and technologies in a
    timely fashion or at all.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition to pursuing patents on our technology, we take steps
    to protect our intellectual property and proprietary technology
    by entering into confidentiality agreements and intellectual
    property assignment agreements with our employees, consultants,
    corporate partners and, when needed, our advisors. Such
    agreements may not be enforceable or may not provide meaningful
    protection for our trade secrets or other proprietary
    information in the event of unauthorized use or disclosure or
    other breaches of the agreements, and we may not be able to
    prevent such unauthorized disclosure. Monitoring unauthorized
    disclosure is difficult, and we do not know whether the steps we
    have taken to prevent such disclosure are, or will be, adequate.
    If we were to enforce a claim that a third party had illegally
    obtained and was using our trade secrets, it would be expensive
    and time consuming, and the outcome would be unpredictable. In
    addition, courts outside the United States may be less willing
    to protect trade secrets.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We depend on certain technologies that are licensed to us.
    We do not control these technologies and any loss of our rights
    to them could prevent us from selling our products.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We rely on licenses in order to be able to use various
    proprietary technologies that are material to our business,
    including our core integrated fluidic circuit and multi-layer
    soft lithography technologies. We do not own the patents that
    underlie these licenses. Our rights to use these technologies
    and employ the inventions claimed in the licensed patents are
    subject to the negotiation of, continuation of and compliance
    with the terms of those licenses. In some cases, we do not
    control the prosecution, maintenance, or filing of the patents
    to which we hold licenses, or the enforcement of these patents
    against third parties. Some of our patents and patent
    applications were either acquired from another company who
    acquired those patents and patent applications from yet another
    company, or are licensed from a third party. Thus, these patents
    and patent applications are not written by us or our attorneys,
    and we did not have control over the drafting and prosecution.
    The former patent owners and our licensors might not have given
    the same attention to the drafting and prosecution of these
    patents and applications as we would have if we had been the
    owners of the patents and applications and had control over the
    drafting and prosecution. We cannot be certain that drafting
    <FONT style="white-space: nowrap">and/or</FONT>
    prosecution of the licensed patents and patent applications by
    the licensors have been or will be conducted in compliance with
    applicable laws and regulations or will result in valid and
    enforceable patents and other intellectual property rights.
    Enforcement of our licensed patents or defense or any claims
    asserting the invalidity of these patents is often subject to
    the control or cooperation of our licensors. Certain of our
    licenses contain provisions that allow the licensor to terminate
    the license upon specific conditions. Our rights under the
    licenses are subject to our continued compliance with the terms
    of the license, including the payment of royalties due under the
    license. Because of the complexity of our products and the
    patents we have licensed, determining the scope of the license
    and related royalty obligation can be difficult and can lead to
    disputes between us and the licensor. An unfavorable resolution
    of such a dispute could lead to an increase in the royalties
    payable pursuant to the license. If a licensor believed we were
    not paying the royalties due under the license or were otherwise
    not in compliance with the terms of the license, the licensor
    might attempt to revoke the license. If such an attempt were
    successful, we might be barred from producing and selling some
    or all of our products. In addition, certain of the patents we
    have licensed relate to technology that was developed with
    U.S.&#160;government grants. Federal regulations impose certain
    domestic manufacturing requirements with respect to some of our
    products embodying these patents. We are in the process of
    assisting our licensors who received such government grants in
    considering the applicability of such regulations or seeking
    waivers from these regulations. If such waivers are required and
    are not obtained, and the federal government chooses to enforce
    these regulations, our sales and manufacturing could be
    materially disrupted, such licenses to us could be made
    non-exclusive or terminated.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We may be involved in lawsuits to protect or enforce our
    patents and proprietary rights and to determine the scope,
    coverage and validity of others&#146; proprietary rights.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Litigation may be necessary to enforce our patent and
    proprietary rights
    <FONT style="white-space: nowrap">and/or</FONT> to
    determine the scope, coverage and validity of others&#146;
    proprietary rights. Litigation on these matters has been
    prevalent in our industry and we expect that this will continue.
    To determine the priority of inventions, we may have to initiate
    and participate in interference and re-examination proceedings
    declared by the U.S.&#160;Patent and Trademark Office that could
    result in
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    21
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    substantial legal fees and could substantially affect the scope
    of our patent protection. Also, our intellectual property may be
    subject to significant administrative and litigation proceedings
    such as invalidity, unenforceability and opposition proceedings
    against our patents. The outcome of any litigation or
    interference proceeding might not be favorable to us, and we
    might not be able to obtain licenses to technology that we
    require. Even if such licenses are obtainable, they may not be
    available at a reasonable cost. In addition, if we resort to
    legal proceedings to enforce our intellectual property rights or
    to determine the validity, scope and coverage of the
    intellectual property or other proprietary rights of others, the
    proceedings could be burdensome and expensive, even if we were
    to prevail. Any litigation that may be necessary in the future
    could result in substantial costs and diversion of resources and
    could have a material adverse effect on our business, operating
    results or financial condition.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Litigation, other proceedings or third party claims of
    intellectual property infringement could require us to spend
    significant time and money and could prevent us from selling our
    products or services or impact our stock price.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our commercial success may depend in part on our
    non-infringement of the patents or proprietary rights of third
    parties. Third parties have asserted and may assert in the
    future that we are employing their proprietary technology
    without authorization. Competitors may assert that our products
    infringe their intellectual property rights as part of a
    business strategy to impede our successful entry into those
    markets. For example, numerous significant intellectual property
    issues have been litigated between existing and new participants
    in the PCR market, including litigation initiated by Applied
    Biosystems, Inc., one of our competitors. In addition, our
    competitors and others may have patents or may in the future
    obtain patents and claim that use of our products infringes
    these patents. We could incur substantial costs and divert the
    attention of our management and technical personnel in defending
    against any of these claims. Parties making claims against us
    may be able to obtain injunctive or other relief, which could
    block our ability to develop, commercialize and sell products,
    and could result in the award of substantial damages against us.
    In the event of a successful claim of infringement against us,
    we may be required to pay damages and obtain one or more
    licenses from third parties, or be prohibited from selling
    certain products. We may not be able to obtain these licenses at
    a reasonable cost, if at all. We could therefore incur
    substantial costs related to royalty payments for licenses
    obtained from third parties, which could negatively affect our
    gross margins. In addition, we could encounter delays in product
    introductions while we attempt to develop alternative methods or
    products to avoid infringing third-party patents or proprietary
    rights. Defense of any lawsuit or failure to obtain any of these
    licenses on favorable terms could prevent us from
    commercializing products, and the prohibition of sale of any of
    our products could materially affect our ability to grow and
    gain market acceptance for our products.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Furthermore, because of the substantial amount of discovery
    required in connection with intellectual property litigation,
    there is a risk that some of our confidential information could
    be compromised by disclosure during this type of litigation. In
    addition, during the course of this kind of litigation, there
    could be public announcements of the results of hearings,
    motions or other interim proceedings or developments. If
    securities analysts or investors perceive these results to be
    negative, it could have a substantial adverse effect on the
    price of our common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We may be subject to damages resulting from claims that we
    or our employees have wrongfully used or disclosed alleged trade
    secrets of our employees&#146; former employers.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Many of our employees were previously employed at universities
    or other life science companies, including our competitors or
    potential competitors. Although no claims against us are
    currently pending, we may be subject to claims that these
    employees or we have inadvertently or otherwise used or
    disclosed trade secrets or other proprietary information of
    their former employers. Litigation may be necessary to defend
    against these claims. If we fail in defending such claims, in
    addition to paying monetary damages, we may lose valuable
    intellectual property rights or personnel. A loss of key
    research personnel or their work product could hamper or prevent
    our ability to commercialize certain potential products, which
    could severely harm our business. Even if we are successful in
    defending against these claims, litigation could result in
    substantial costs and be a distraction to management.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    22
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Risks
    Related to Our Common Stock and this Offering</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We expect that our stock price will fluctuate
    significantly, and you may not be able to resell your shares at
    or above the initial public offering price.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to this offering, there has been no public market for
    shares of our common stock. We cannot predict the extent to
    which investor interest in our company will lead to the
    development of an active trading market on the NASDAQ Global
    Market or otherwise or how liquid that market might become. If
    an active trading market does not develop, you may have
    difficulty selling any of our shares of common stock that you
    buy. We and the underwriters will determine the initial public
    offering price of our common stock through negotiation. This
    price will not necessarily reflect the price at which investors
    in the market will be willing to buy and sell our shares
    following this offering. In addition, the trading price of our
    common stock following this offering may be highly volatile and
    could be subject to wide fluctuations in response to various
    factors, some of which are beyond our control. These factors
    include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    actual or anticipated quarterly variation in our results of
    operations or the results of our competitors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    announcements by us or our competitors of new commercial
    products, significant contracts, commercial relationships or
    capital commitments;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    issuance of new or changed securities analysts&#146; reports or
    recommendations for our stock;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    developments or disputes concerning our intellectual property or
    other proprietary rights;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    commencement of, or our involvement in, litigation;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    market conditions in the life science sector;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any major change in our Board or management;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    general economic conditions and slow or negative growth of our
    markets.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The trading market for our common stock will rely in part on the
    research and reports that equity research analysts publish about
    us and our business. We do not control these analysts or the
    content and opinions included in their reports. Securities
    analysts may elect not to provide research coverage of our
    common stock after the completion of this offering, and such
    lack of research coverage may adversely affect the market price
    of our common stock. The price of our stock could decline if one
    or more equity research analysts downgrade our stock or if those
    analysts issue other unfavorable commentary or cease publishing
    reports about us or our business. If one or more equity research
    analysts ceases coverage of our company, we could lose
    visibility in the market, which in turn could cause our stock
    price to decline.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Purchasers in this offering will experience immediate and
    substantial dilution in the book value of their
    investment.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The initial public offering price of our common stock is
    substantially higher than the net tangible book value per share
    of our common stock immediately after this offering. Therefore,
    if you purchase our common stock in this offering, you will
    incur an immediate dilution of $&#160;&#160;&#160;&#160;&#160;
    in net tangible book value per share from the price you paid,
    based on an assumed initial public offering price of
    $&#160;&#160;&#160;&#160;&#160; per share, the mid-point of the
    range set forth on the cover page of this prospectus. In
    addition, new investors who purchase shares in this offering
    will contribute approximately&#160;&#160;&#160;&#160;&#160;% of
    the total amount of equity capital raised by us through the date
    of this offering, but will only own
    approximately&#160;&#160;&#160;&#160;&#160;% of the outstanding
    share capital and approximately&#160;&#160;&#160;&#160;&#160;%
    of the voting rights. The exercise of outstanding options and
    warrants will result in further dilution. For a further
    description of the dilution that you will experience immediately
    after this offering, see &#147;Dilution.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Future sales of shares by existing stockholders could
    cause our stock price to decline.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If our existing stockholders sell, or indicate an intention to
    sell, substantial amounts of our common stock in the public
    market after the
    <FONT style="white-space: nowrap">lock-up</FONT> and
    other legal restrictions on resale discussed in this prospectus
    lapse, the trading price of our common stock could decline.
    Based on shares outstanding as of December&#160;29, 2007, upon
    completion of this offering, we will have outstanding a total
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock, assuming no exercise of the
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    23
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    underwriters&#146; over-allotment option. Of these shares, only
    the&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock sold in this offering by us will be freely
    tradable, without restriction, in the public market immediately
    after the offering. Each of our directors and officers, and
    certain of our stockholders, have entered into
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements with the underwriters that restrict their ability to
    sell or transfer their shares. The
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements pertaining to this offering will expire 180&#160;days
    from the date of this prospectus, although they may be extended
    for up to an additional 34&#160;days under certain
    circumstances. Our underwriters, however, may, in their sole
    discretion, permit our officers, directors and other current
    stockholders who are subject to the contractual
    <FONT style="white-space: nowrap">lock-up</FONT> to
    sell shares prior to the expiration of the
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements. After the
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements expire, based on shares outstanding as of
    December&#160;29, 2007, up to an
    additional&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock will be eligible for sale in the public
    market,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    of which are held by directors, executive officers and other
    affiliates and will be subject to volume limitations under
    Rule&#160;144 under the Securities Act and various vesting
    agreements. In
    addition,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock that are subject to outstanding options as of
    December&#160;29, 2007 will become eligible for sale in the
    public market to the extent permitted by the provisions of
    various vesting agreements, the
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements and Rules&#160;144 and 701 under the Securities Act.
    If these additional shares are sold, or if it is perceived that
    they will be sold, in the public market, the trading price of
    our common stock could decline.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our directors and executive officers will continue to have
    substantial control over us after this offering and could limit
    your ability to influence the outcome of key transactions,
    including changes of control.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our executive officers, directors and their affiliates will
    beneficially own or control
    approximately&#160;&#160;&#160;&#160;&#160;% of the outstanding
    shares of our common stock, following the completion of this
    offering. Accordingly, these executive officers, directors and
    their affiliates, acting as a group, will have substantial
    influence over the outcome of corporate actions requiring
    stockholder approval, including the election of directors, any
    merger, consolidation or sale of all or substantially all of our
    assets or any other significant corporate transactions. These
    stockholders may also delay or prevent a change of control of
    us, even if such a change of control would benefit our other
    stockholders. The significant concentration of stock ownership
    may adversely affect the trading price of our common stock due
    to investors&#146; perception that conflicts of interest may
    exist or arise.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Anti-takeover provisions in our charter documents and
    under Delaware law could make an acquisition of us, which may be
    beneficial to our stockholders, more difficult and may prevent
    attempts by our stockholders to replace or remove our current
    management and limit the market price of our common
    stock.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Provisions in our certificate of incorporation and bylaws, as
    amended and restated upon the closing of this offering, may have
    the effect of delaying or preventing a change of control or
    changes in our management. Our amended and restated certificate
    of incorporation and amended and restated bylaws to become
    effective upon completion of this offering include provisions
    that:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    authorize our Board of Directors to issue, without further
    action by the stockholders, up to 20,000,000&#160;shares of
    undesignated preferred stock;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    require that any action to be taken by our stockholders be
    effected at a duly called annual or special meeting and not by
    written consent;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    specify that special meetings of our stockholders can be called
    only by our Board of Directors, the Chairman of the Board, the
    Chief Executive Officer or the President;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    establish an advance notice procedure for stockholder approvals
    to be brought before an annual meeting of our stockholders,
    including proposed nominations of persons for election to our
    Board of Directors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    establish that our Board of Directors is divided into three
    classes, Class&#160;I, Class&#160;II and Class&#160;III, with
    each class serving staggered terms;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    provide that our directors may be removed only for cause;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    provide that vacancies on our Board of Directors may be filled
    only by a majority of directors then in office, even though less
    than a quorum;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    specify that no stockholder is permitted to cumulate votes at
    any election of directors;&#160;and
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    24
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    require a super-majority of votes to amend certain of the
    above-mentioned provisions.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    These provisions may frustrate or prevent any attempts by our
    stockholders to replace or remove our current management by
    making it more difficult for stockholders to replace members of
    our Board of Directors, which is responsible for appointing the
    members of our management. In addition, because we are
    incorporated in Delaware, we are governed by the provisions of
    Section&#160;203 of the Delaware General Corporation Law, which
    limits the ability of stockholders owning in excess of 15% of
    our outstanding voting stock to merge or combine with us.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We have broad discretion in the use of the net proceeds
    from this offering and may not use them effectively.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We will have broad discretion in the application of the net
    proceeds from this offering and could spend the proceeds in ways
    that do not improve our results of operations or enhance the
    value of our common stock. Our failure to apply these funds
    effectively could have a material adverse effect on our
    business, delay the development of our product candidates and
    cause the price of our common stock to decline.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We have never paid dividends on our capital stock, and we
    do not anticipate paying any cash dividends in the foreseeable
    future.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have paid no cash dividends on any of our classes of capital
    stock to date, have contractual restrictions against paying cash
    dividends and currently intend to retain our future earnings to
    fund the development and growth of our business. As a result,
    capital appreciation, if any, of our common stock will be your
    sole source of gain for the foreseeable future.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    25
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='103'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SPECIAL
    NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This prospectus includes forward-looking statements that relate
    to future events or our future financial performance and involve
    known and unknown risks, uncertainties and other factors that
    may cause our actual results, levels of activity, performance or
    achievements to differ materially from any future results,
    levels of activity, performance or achievements expressed or
    implied by these forward-looking statements. Words such as, but
    not limited to, &#147;believe,&#148; &#147;expect,&#148;
    &#147;anticipate,&#148; &#147;estimate,&#148;
    &#147;intend,&#148; &#147;plan,&#148; &#147;targets,&#148;
    &#147;likely,&#148; &#147;will,&#148; &#147;would,&#148;
    &#147;could,&#148; and similar expressions or phrases, or the
    negative of those expressions or phrases identify
    forward-looking statements. Although we believe that we have a
    reasonable basis for each forward-looking statement contained in
    this prospectus, we caution you that these statements are based
    on our projections of the future that are subject to known and
    unknown risks and uncertainties and other factors that may cause
    our actual results, level of activity, performance or
    achievements expressed or implied by these forward-looking
    statements, to differ. The sections in this prospectus entitled
    &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and
    Analysis of Financial Condition and Results of Operations&#148;
    and &#147;Business,&#148; as well as other sections in this
    prospectus, discuss some of the factors that could contribute to
    these differences.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Other unknown or unpredictable factors also could harm our
    results. Consequently, actual results or developments
    anticipated by us may not be realized or, even if substantially
    realized, may not have the expected consequences to, or effects
    on, us. Given these uncertainties, prospective investors are
    cautioned not to place undue reliance on such forward-looking
    statements. Except as required by law, we undertake no
    obligation to update or revise publicly any of the
    forward-looking statements after the date of this prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This prospectus contains market data that we obtained from
    industry sources. These sources do not guarantee the accuracy or
    completeness of the information. Although we believe that the
    industry sources are reliable, we have not independently
    verified the information. The market data include projections
    that are based on a number of projections. While we believe
    these assumptions to be reasonable and sound as of the date of
    this prospectus, if these assumptions turn out to be incorrect,
    actual results may differ from the projections based on these
    assumptions.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    26
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='104'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">USE OF
    PROCEEDS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We estimate that the net proceeds from the sale
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of our common stock that we are selling in this offering will be
    $&#160;&#160;&#160;&#160;&#160;&#160;million, based on an
    assumed initial public offering price of
    $&#160;&#160;&#160;&#160;&#160; per share, the midpoint of the
    range set forth on the cover page of this prospectus, after
    deducting estimated underwriting discounts and commissions and
    estimated offering expenses. A $1.00 increase (decrease) in the
    assumed initial public offering price of
    $&#160;&#160;&#160;&#160;&#160; per share would increase
    (decrease) the net proceeds to us by
    $&#160;&#160;&#160;&#160;&#160;&#160;million, after deducting
    estimated underwriting discounts and commissions and estimated
    offering expenses, assuming that the number of shares offered by
    us, as set forth on the cover page of this prospectus, remains
    the same. We may also increase or decrease the number of shares
    we are offering. An increase of 1.0&#160;million shares in the
    number of shares offered by us would increase the net proceeds
    to us by $&#160;&#160;&#160;&#160;&#160;&#160;million.
    Similarly, a decrease of 1.0&#160;million shares in the number
    of shares offered by us would decrease the net proceeds to us by
    $&#160;&#160;&#160;&#160;&#160;&#160;million. If the
    underwriters&#146; over-allotment option is exercised in full,
    we estimate that we will receive net proceeds of
    $&#160;&#160;&#160;&#160;&#160;&#160;million.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Of the net proceeds that we will receive from this offering, we
    expect to use approximately:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    $&#160;&#160;&#160;&#160;&#160;&#160;million for sales and
    marketing initiatives, including significantly expanding our
    sales force, to support the ongoing commercialization of our
    products;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    $&#160;&#160;&#160;&#160;&#160; for research and product
    development activities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    $&#160;&#160;&#160;&#160;&#160;&#160;million to expand our
    facilities and manufacturing operations;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the balance for working capital and other general corporate
    purposes.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We may also use a portion of our net proceeds to acquire and
    invest in complementary products, technologies or businesses;
    however, we currently have no agreements or commitments to
    complete any such transaction and are not involved in
    negotiations to do so. Pending these uses, we intend to invest
    our net proceeds from this offering primarily in
    investment-grade, interest-bearing instruments.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of the date of this prospectus, we cannot specify with
    certainty all of the particular uses for the net proceeds to be
    received upon the completion of this offering. The amount and
    timing of our expenditures will depend on several factors,
    including cash flows from our operations and the anticipated
    growth of our business. Accordingly, our management will have
    broad discretion in the application of the net proceeds and
    investors will be relying on the judgment of our management
    regarding the application of the proceeds from this offering. We
    reserve the right to change the use of these proceeds as a
    result of certain contingencies such as the results of our
    commercialization efforts, competitive developments,
    opportunities to acquire products, technologies or businesses
    and other factors.
</DIV>
<A name='105'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">DIVIDEND
    POLICY</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have never declared or paid any cash dividends on our capital
    stock. We currently intend to retain all future earnings for the
    operation and expansion of our business and, therefore, we do
    not anticipate declaring or paying cash dividends in the
    foreseeable future. The payment of dividends will be at the
    discretion of our Board of Directors and will depend on our
    results of operations, capital requirements, financial
    condition, prospects, contractual arrangements, any limitations
    on payment of dividends present in our current and future debt
    agreements, and other factors that our Board of Directors may
    deem relevant. In addition, we are subject to several covenants
    under our debt arrangements that place restrictions on our
    ability to pay dividends.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    27
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='106'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CAPITALIZATION</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth our capitalization as of
    December&#160;29, 2007:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    on an actual basis;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    on a pro forma basis to give effect to (1)&#160;the automatic
    conversion of principal and accrued interest on a convertible
    promissory note held by BioMedical Sciences Fund Pte. Ltd. into
    1,466,210&#160;shares of our common stock upon closing of this
    offering, (2) the conversion of all outstanding shares of
    convertible preferred stock into common stock and (3)&#160;the
    reclassification of the convertible preferred stock warrant
    liabilities to additional
    <FONT style="white-space: nowrap">paid-in-capital,</FONT>
    each effective upon the closing of this offering;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    on a pro forma as adjusted basis to also give effect to the pro
    forma conversions and reclassifications described above and the
    sale
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of our common stock in this offering and the application of the
    net proceeds at the assumed initial public offering price of
    $&#160;&#160;&#160;&#160;&#160; per share, the midpoint of the
    range set forth on the cover page of this prospectus, after
    deducting estimated underwriting discounts and commissions and
    estimated offering expenses payable by us.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    You should read this table together with &#147;Management&#146;s
    Discussion and Analysis of Financial Condition and Results of
    Operations&#148; and our consolidated financial statements and
    related notes included elsewhere in this prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="66%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As of December&#160;29, 2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Pro Forma<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Actual</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Pro Forma</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>as
    Adjusted<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom">
    <B>(in thousands, except per share amounts)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Long-term debt
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9,362
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Convertible promissory notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,997
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Convertible preferred stock warrant liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    468
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Convertible preferred stock issuable in series, $0.001&#160;par
    value: 61,798&#160;shares authorized, 56,671&#160;shares issued
    and outstanding (actual); no shares authorized, issued or
    outstanding (pro forma and pro forma as adjusted)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    162,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Stockholders&#146; equity (deficit):
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Common stock, $0.001&#160;par value: 87,386&#160;shares
    authorized, 9,901&#160;shares issued and outstanding (actual);
    87,386&#160;shares
    authorized,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    issued and outstanding (pro
    forma);&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    authorized,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    issued and outstanding (pro forma as adjusted)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Preferred stock, $0.001 par value: no shares authorized, no
    shares issued
    (actual);&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    authorized, no shares issued (pro forma and pro forma as
    adjusted)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Additional paid-in
    capital<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,592
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accumulated other comprehensive loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (135
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accumulated deficit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (133,798
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total stockholders&#146; equity
    (deficit)<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (130,331
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total
    capitalization<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    46,578
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">A $1.00 increase (decrease) in the
    assumed initial public offering price of
    $&#160;&#160;&#160;&#160;&#160; per share, the midpoint of the
    range set forth on the cover page of this prospectus, would
    increase (decrease) each of additional paid-in capital, total
    stockholders&#146; equity and total capitalization by
    $&#160;&#160;&#160;&#160;&#160;&#160;million, assuming that the
    number of shares offered by us, as set forth on the cover page
    of this prospectus, remains the same, and after deducting
    estimated underwriting discounts and commissions payable by us.
    Each increase of 1.0&#160;million shares in the number of shares
    offered by us, together with a $1.00 increase in the assumed
    offering price of $&#160;&#160;&#160;&#160;&#160; per share,
    would increase additional paid-in capital, total
    stockholders&#146; equity and total capitalization by
    approximately $&#160;&#160;&#160;&#160;&#160;&#160;million.
    Similarly, each decrease of 1.0&#160;million shares in the
    number of
    </FONT></TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    28
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">shares offered by us, together with
    a $1.00 decrease in the assumed offering price of
    $&#160;&#160;&#160;&#160;&#160; per share, would decrease
    additional paid-in capital, total stockholders&#146; equity and
    total capitalization by approximately
    $&#160;&#160;&#160;&#160;&#160;&#160;million. The pro forma as
    adjusted information discussed above is illustrative only and
    will adjust based on the actual public offering price and terms
    of this offering determined at pricing.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The table above excludes the following shares:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    7,467,230&#160;shares of common stock issuable upon exercise of
    options outstanding as of December&#160;29, 2007 at a weighted
    average exercise price of $0.79&#160;per share;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    698,720&#160;shares of common stock issuable upon the exercise
    of warrants outstanding as of December&#160;29, 2007 at a
    weighted average exercise price of $2.71 per share, after
    conversion from preferred stock;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    1,197,154&#160;shares of common stock reserved for future
    issuance under our stock-based compensation plans,
    including&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock reserved for issuance under our 2008 Equity
    Incentive Plan, and any future increase in shares reserved for
    issuance under such plan, each of which will become effective on
    the date of this prospectus;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    33,334&#160;shares of common stock that were legally issued and
    outstanding but were not included in stockholders&#146; deficit
    as of December&#160;29, 2007 pursuant to accounting principles
    generally accepted in the United States, as these shares were
    subject to a right of repurchase by us.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    29
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='107'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">DILUTION</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If you invest in our common stock, your interest will be diluted
    to the extent of the difference between the initial public
    offering price per share of our common stock and the pro forma
    as adjusted net tangible book value per share of our common
    stock immediately after this offering. Net tangible book value
    dilution per share to new investors represents the difference
    between the amount per share paid by purchasers of shares of
    common stock in this offering and the pro forma as adjusted net
    tangible book value per share of common stock immediately after
    completion of this offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net tangible book value per share is determined by dividing our
    total tangible assets less our total liabilities by the number
    of shares of common stock outstanding. Our historical net
    tangible book value (deficit) as of December&#160;29, 2007, was
    $(32.1)&#160;million, or $(0.48) per share. Our pro forma net
    tangible book value as of December&#160;29, 2007 was
    $&#160;&#160;&#160;&#160;&#160;&#160;million, or
    $&#160;&#160;&#160;&#160;&#160; per share, based on the total
    number of shares of our common stock outstanding as of
    December&#160;29, 2007, after giving effect to (1)&#160;the
    conversion of an outstanding convertible promissory note into
    1,466,210&#160;shares of common stock, (2)&#160;the conversion
    of all outstanding shares of our convertible preferred stock
    into common stock and (3)&#160;the reclassification of the
    convertible preferred stock warrant liabilities to additional
    <FONT style="white-space: nowrap">paid-in-capital,</FONT>
    each effective upon the closing of this offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After giving effect to our sale
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock in this offering at an assumed initial public
    offering price of $&#160;&#160;&#160;&#160;&#160; per share, the
    midpoint of the range set forth on the cover page of this
    prospectus, and after deducting the estimated underwriting
    discounts and commissions and estimated offering expenses, our
    pro forma as adjusted net tangible book value as of
    December&#160;29, 2007 would have been
    $&#160;&#160;&#160;&#160;&#160;&#160;million, or
    $&#160;&#160;&#160;&#160;&#160; per share. This represents an
    immediate increase in net tangible book value of
    $&#160;&#160;&#160;&#160;&#160; per share to existing
    stockholders and an immediate dilution in net tangible book
    value of $&#160;&#160;&#160;&#160;&#160; per share to purchasers
    of common stock in this offering, as illustrated in the
    following table:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="88%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Assumed initial public offering price per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Historical net tangible book value per share as of
    December&#160;29, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Pro forma as adjusted net tangible book value per share as of
    December&#160;29, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Increase in pro forma as adjusted net tangible book value per
    share attributable to new investors
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pro forma as adjusted net tangible book value per share after
    this offering
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pro forma dilution per share to new investors in this offering
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each $1.00 increase (decrease) in the assumed public offering
    price of $&#160;&#160;&#160;&#160;&#160; per share, the
    mid-point of the range set forth on the cover of this
    prospectus, would increase (decrease) our pro forma as adjusted
    net tangible book value by approximately
    $&#160;&#160;&#160;&#160;&#160;&#160;million, or approximately
    $&#160;&#160;&#160;&#160;&#160; per share, and the pro forma
    dilution per share to investors in this offering by
    approximately $&#160;&#160;&#160;&#160;&#160; per share,
    assuming that the number of shares offered by us, as set forth
    on the cover page of this prospectus, remains the same and after
    deducting estimated underwriting discounts and commissions. We
    may also increase or decrease the number of shares we are
    offering. An increase of 1.0&#160;million shares in the number
    of shares offered by us, together with a $1.00 increase in the
    assumed offering price of $&#160;&#160;&#160;&#160;&#160; per
    share, would result in a pro forma as adjusted net tangible book
    value of approximately
    $&#160;&#160;&#160;&#160;&#160;&#160;million, or
    $&#160;&#160;&#160;&#160;&#160; per share, and the pro forma
    dilution per share to investors in this offering would be
    $&#160;&#160;&#160;&#160;&#160; per share. Similarly, a decrease
    of 1.0&#160;million shares in the number of shares offered by
    us, together with a $1.00 decrease in the assumed public
    offering price of $&#160;&#160;&#160;&#160;&#160; per share,
    would result in an pro forma as adjusted net tangible book value
    of approximately $&#160;&#160;&#160;&#160;&#160;&#160;million,
    or $&#160;&#160;&#160;&#160;&#160; per share, and the pro forma
    dilution per share to investors in this offering would be
    $&#160;&#160;&#160;&#160;&#160; per share. The pro forma as
    adjusted information discussed above is illustrative only and
    will adjust based on the actual public offering price and other
    terms of this offering determined at pricing.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If the underwriters&#146; over-allotment option is exercised in
    full, the pro forma as adjusted net tangible book value per
    share after this offering would be
    $&#160;&#160;&#160;&#160;&#160; per share, the increase in pro
    forma as adjusted net tangible book value per share to existing
    stockholders would be $&#160;&#160;&#160;&#160;&#160; per share
    and the dilution to new investors purchasing shares in this
    offering would be $&#160;&#160;&#160;&#160;&#160; per share.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    30
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table presents on a pro forma as adjusted basis as
    of December&#160;29, 2007, after giving effect to the automatic
    conversion of all outstanding shares of convertible preferred
    stock into common stock, the differences between the existing
    stockholders and the purchasers of shares in this offering with
    respect to the number of shares purchased from us, the total
    consideration paid and the average price paid per share, and
    before deducting estimated underwriting discounts and
    commissions and estimated offering expenses payable by us (in
    thousands, except per share amounts and percentages):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="48%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares Purchased</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Total Consideration</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Average Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Number</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Percent</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Amount</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Percent</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Per Share</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Existing stockholders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    New investors
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Totals
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Each $1.00 increase (decrease) in
    the assumed initial public offering price of
    $&#160;&#160;&#160;&#160;&#160; per share would increase
    (decrease) the total consideration paid to us by new investors
    and total consideration paid to us by all stockholder by
    $&#160;&#160;&#160;&#160;&#160;&#160;million, assuming that the
    number of shares offered by us, as set forth on the cover page
    of this prospectus, remains the same, and after deducting
    estimated underwriting discounts and commissions payable by us.
    An increase of 1.0&#160;million shares in the number of shares
    offered by us would increase the total consideration paid to us
    by new investors and total consideration paid to us by all
    stockholder by $&#160;&#160;&#160;&#160;&#160;&#160;million.
    Similarly, a decrease of 1.0&#160;million shares in the number
    of shares offered by us would decrease the total consideration
    paid to us by new investors and total consideration paid to us
    by all stockholder by
    $&#160;&#160;&#160;&#160;&#160;&#160;million.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If the underwriters exercise their over-allotment option in
    full, our existing stockholders would
    own&#160;&#160;&#160;&#160;&#160;% and our new investors would
    own&#160;&#160;&#160;&#160;&#160;% of the total number of shares
    of our common stock outstanding after this offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The table above excludes the following shares:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    7,467,230&#160;shares of common stock issuable upon exercise of
    options outstanding as of December&#160;29, 2007 at a weighted
    average exercise price of $0.79 per share;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    698,720&#160;shares of common stock issuable upon the exercise
    of warrants outstanding as of December&#160;29, 2007 at a
    weighted average exercise price of $2.71 per share;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    1,197,154&#160;shares of common stock reserved for future
    issuance under our stock-based compensation plans,
    including&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock reserved for issuance under our 2008 Equity
    Incentive Plan,
    and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock reserved for issuance under our 2008 Employee
    Stock Purchase Plan, each of which will become effective on the
    date of this prospectus;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    33,334&#160;shares of common stock that were legally issued and
    outstanding but were not included in stockholders&#146; deficit
    as of December&#160;29, 2007 pursuant to accounting principles
    generally accepted in the United States, as these shares were
    subject to a right of repurchase by us.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Assuming the exercise in full of the outstanding options and
    warrants, pro forma net tangible book value before this offering
    at December&#160;29, 2007 would be
    $&#160;&#160;&#160;&#160;&#160; per share, and after giving
    effect to the sale of shares in this offering, there would be
    immediate dilution of $&#160;&#160;&#160;&#160;&#160; per share
    to new investors in this offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Effective upon the closing of this offering, an aggregate
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of our common stock will be reserved for future issuance under
    our benefit plans. To the extent that any of these options or
    warrants are exercised, new options are issued under our benefit
    plans or we issue additional shares of common stock in the
    future, there will be further dilution to investors
    participating in this offering.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    31
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='108'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SELECTED
    CONSOLIDATED FINANCIAL DATA</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following selected consolidated financial data should be
    read in conjunction with &#147;Management&#146;s Discussion and
    Analysis of Financial Condition and Results of Operations&#148;
    and our consolidated financial statements and related notes
    included elsewhere in this prospectus. We have derived the
    selected consolidated statement of operations data for the years
    ended December&#160;31, 2005, December&#160;31, 2006 and
    December&#160;29, 2007 and the selected consolidated balance
    sheet data as of December&#160;31, 2006 and December&#160;29,
    2007 from our audited consolidated financial statements included
    elsewhere in this prospectus. We have derived the selected
    consolidated statement of operations data for the years ended
    December&#160;31, 2003 and 2004 and the selected consolidated
    balance sheet data as of December&#160;31, 2003, 2004 and 2005
    from our audited consolidated financial statements not included
    in this prospectus. Our historical results are not necessarily
    indicative of the results to be expected for any future period.
</DIV>

<DIV style="margin-top: 2pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="45%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2003</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2004</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom">
    <B>(in thousands, except per share amounts)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Consolidated Statement of Operations Data:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Revenue:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Product revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,133
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,603
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,076
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,959
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,451
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Collaboration revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    366
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,568
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,376
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    460
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Grant revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,063
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,364
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Total revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,133
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,039
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,674
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,398
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,275
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Costs and expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Cost of product revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,918
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,362
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,764
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,773
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,514
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Research and development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,218
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,608
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,449
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,589
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,389
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Selling, general and administrative
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,263
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,690
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,955
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,699
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,898
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Total costs and expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,399
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,660
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,168
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,061
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,801
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 32pt">
    Loss from operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,266
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,621
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,494
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21,663
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,526
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (305
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (508
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (898
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,261
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,790
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    267
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    291
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,140
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Other income (expense), net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (194
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (170
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Loss before provision for income taxes and cumulative of change
    in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,304
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,838
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,022
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,346
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Provision for income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (105
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Loss before cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,304
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,838
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,022
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    673
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (17,304
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16,838
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16,385
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net loss per share of common stock, basic and
    diluted<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.23
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.98
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.82
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.53
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Shares used in computing net loss per share of common stock,
    basic and
    diluted<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,775
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,505
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,316
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Please see Note&#160;2 to our
    audited consolidated financial statements for an explanation of
    the method used to calculate basic and diluted net loss per
    share.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="45%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As of</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2003</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2004</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Consolidated Balance Sheet Data:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Cash and cash equivalents and
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    28,874
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    12,520
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    19,659
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    25,518
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    40,363
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Working capital
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,590
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,610
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,764
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,964
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,754
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,908
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,493
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54,776
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total long-term debt and convertible promissory notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,261
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,111
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,910
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,359
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Convertible preferred stock warrant liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    814
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    223
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    468
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Convertible preferred stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    75,072
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,596
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,966
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    112,295
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    162,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total stockholder&#146;s deficit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (49,812
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (65,471
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (83,154
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (106,172
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (130,331
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    32
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='109'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">MANAGEMENT&#146;S
    DISCUSSION AND ANALYSIS OF<BR>
    FINANCIAL CONDITION AND RESULTS OF OPERATIONS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>The following discussion and analysis of the financial
    condition and results of our operations should be read in
    conjunction with the consolidated financial statements and
    related notes included elsewhere in this prospectus. This
    discussion contains forward-looking statements that involve
    risks and uncertainties. Our actual results could differ
    materially from those discussed below. Factors that could cause
    or contribute to such differences include, but are not limited
    to, those identified below, and those discussed in the section
    titled &#147;Risk Factors&#148; included elsewhere in this
    prospectus.</I>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Overview</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We develop, manufacture and market proprietary Integrated
    Fluidic Circuit systems that significantly improve the
    productivity of life science research. Our Integrated Fluidic
    Circuits, or IFCs, enable the simultaneous performance of
    thousands of biochemical measurements in extremely minute
    volumes. We created this &#147;integrated circuit for
    biology&#148; by achieving unprecedented miniaturization,
    integration and automation of sophisticated liquid handling
    processes on a single microfabricated device. Our IFC systems,
    consisting of instrumentation, software and single-use IFCs,
    increase throughput, decrease costs and enhance sensitivity
    compared to conventional laboratory systems. We have sold our
    IFCs to over 100 customers, including many leading biotechnology
    and pharmaceutical companies, academic institutions, and life
    science laboratories worldwide.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have commercialized IFC systems for a wide range of life
    science applications, including our BioMark system for gene
    expression analysis, genotyping and digital PCR, and our Topaz
    system for protein crystallization. Researchers and clinicians
    have successfully employed our products to help achieve
    breakthroughs in the fields of genetic variation, cellular
    function and structural biology. We believe that the broad
    applicability of our IFC technology will lead to the development
    of IFC systems for a wide variety of additional markets and
    applications, including molecular diagnostics.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We were founded in 1999. In the first quarter of 2003, we
    introduced our first product line, the Topaz system for protein
    crystallization based on our first generation Topaz IFC. In
    subsequent years, we enhanced the capability of the Topaz system
    by introducing IFCs with increased throughput. Prior to 2007,
    Topaz system products accounted for substantially all of our
    product revenue. In the fourth quarter of 2006, we announced the
    commercial availability of our BioMark system. We currently sell
    two types of single-use IFCs for use with the BioMark system,
    the Dynamic Array for gene expression and genotyping and the
    Digital Array for digital PCR.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have incurred significant losses in each year since our
    inception, including net losses of $16.4&#160;million,
    $23.6&#160;million and $25.5&#160;million in 2005, 2006 and
    2007. As of December&#160;29, 2007, we had an accumulated
    deficit of $133.8&#160;million. We sell our IFC systems around
    the world. For 2007, customers in North America accounted for
    approximately 54% of our product revenue while European and
    Asian customers accounted for 17% and 29%. We distribute our
    systems through our direct field sales and support organizations
    located in North America, Europe and Asia and through
    distributors or sales agents in several European countries. Our
    manufacturing operations are located in Singapore and South
    San&#160;Francisco. Our facility in Singapore fabricates all of
    our IFCs for commercial sale and some IFCs for our own research
    and development purposes and assembles certain elements of our
    BioMark and Topaz instrumentation. Our South San&#160;Francisco
    facility also assembles certain elements of our BioMark and
    Topaz instrumentation and fabricates IFCs for our own research
    and development purposes.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Since 2002, we have received significant revenue from research
    and development agreements and government grants. The most
    significant of these arrangements has been with entities
    associated with the government of Singapore that have helped
    support our establishment of manufacturing facilities in
    Singapore and research and development activities. Our
    agreements with the government of Singapore provide for
    reimbursement of eligible research and development expenses
    relating to our BioMark instruments and IFCs. Together these
    agreements provide for funding through 2011. In addition, we
    have entered into other collaboration and license arrangements
    that generally provide us with up-front and periodic milestone
    fees or fees based on
    <FONT style="white-space: nowrap">agreed-upon</FONT>
    rates for time incurred by our research staff.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    33
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Fiscal
    Year Presentation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During the year ended December&#160;29, 2007, we adopted a 52 or
    53&#160;week year convention for our fiscal years and,
    therefore, our 2007 fiscal year ended on December&#160;29, 2007
    and future fiscal years will end on the last Saturday in
    December of each year. Prior to the adoption of this method, we
    reported our fiscal years on a calendar basis. The fiscal years
    discussed in this management&#146;s discussion and analysis of
    financial condition and results of operations ended on
    December&#160;31, 2005, December&#160;31, 2006 and
    December&#160;29, 2007.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Critical
    Accounting Policies, Significant Judgments and
    Estimates</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our consolidated financial statements and the related notes
    included elsewhere in this prospectus are prepared in accordance
    with accounting principles generally accepted in the United
    States. The preparation of these consolidated financial
    statements requires us to make estimates and assumptions that
    affect the reported amounts of assets, liabilities, revenues,
    costs and expenses and related disclosures. We base our
    estimates on historical experience and on various other
    assumptions that we believe to be reasonable under the
    circumstances. Changes in the accounting estimates are
    reasonably likely to occur from period to period. Accordingly,
    actual results could differ significantly from the estimates
    made by our management. We evaluate our estimates and
    assumptions on an ongoing basis. To the extent that there are
    material differences between these estimates and actual results,
    our future financial statement presentation, financial
    condition, results of operations and cash flows will be affected.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that the following critical accounting policies
    involve a greater degree of judgment and complexity than our
    other accounting policies. Accordingly, these are the policies
    we believe are the most critical to understanding and evaluating
    our consolidated financial condition and results of operations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Revenue
    Recognition</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We generate revenue from sales of our products and services,
    collaboration agreements and government grants. Our products
    consist of single-use IFCs, various instruments and software
    related to our BioMark and Topaz systems. Our services include
    system installation, training and customer support services. We
    also have entered into a number of research and development
    contracts and have received government grants to conduct
    research and development activities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We record revenue in accordance with the guidelines established
    by the Securities and Exchange Commission, or SEC, Staff
    Accounting Bulletin&#160;No.&#160;104, <I>Revenue
    Recognition</I>, or SAB&#160;104. In addition, we have concluded
    that software included with certain of our instruments is
    essential to their functionality. We apply AICPA Statement of
    Position
    <FONT style="white-space: nowrap">97-2,</FONT>
    <I>Software Revenue Recognition</I>, or
    <FONT style="white-space: nowrap">SOP&#160;97-2.</FONT>
    If the arrangement includes IFCs, we use the separation criteria
    in EITF Issue
    <FONT style="white-space: nowrap">No.&#160;00-21,</FONT>
    <I>Revenue Arrangements with Multiple Deliverables, </I>to
    separate revenues related to IFCs, which are non-software
    related deliverables, from software related deliverables.
    Revenue is recognized when all of the following criteria are
    met: persuasive evidence of an arrangement exists, delivery has
    occurred or services rendered, the price to the buyer is fixed
    or determinable and collectibility is reasonably assured. The
    evaluation of these revenue recognition criteria requires
    significant management judgment. For instance, we use judgment
    to assess items such as collectibility based on factors such as
    the customer&#146;s creditworthiness and past collection
    history, if applicable. If we determine that collection of a
    payment is not reasonably assured, revenue recognition is
    deferred until the time collection becomes reasonably assured,
    which is generally upon receipt of payment. We also use judgment
    to assess whether a price is fixed or determinable by reviewing
    contractual terms and conditions related to payment terms and
    sales price adjustments, if any.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2007, no right of return existed for our products. In prior
    years, if an agreement included a right of return, the related
    revenue was deferred until the right had lapsed. Historically,
    we have not experienced any significant returns of our products.
    Also, accruals are provided for estimated warranty expenses at
    the time that the associated revenue is recognized. We use
    judgment to estimate these accruals and if we were to experience
    an increase in warranty claims, or if costs of servicing our
    products under warranty were greater than our estimates, our
    gross margins could be adversely affected in future periods.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Some of our sales contracts, which include items such as our
    BioMark instrument systems or our Topaz readers, involve the
    delivery or performance of multiple products and services within
    contractually binding arrangements.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    34
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Significant contract interpretation is sometimes required to
    determine the appropriate accounting, including whether the
    deliverables specified in a multiple element arrangement should
    be treated as separate units of accounting for revenue
    recognition purposes, and if so, how the price should be
    allocated among the elements, when to recognize revenue for each
    element, and the period over which revenue should be recognized.
    We use judgment to evaluate whether a delivered item has value
    on a stand-alone basis prior to delivery of the remaining items
    by determining whether we have made separate sales of such items
    or whether the undelivered items are essential to the
    functionality of the delivered items. Further, we use judgment
    to evaluate whether there is vendor-specific objective evidence,
    or VSOE, of fair value of the undelivered items, determined by
    reference to stand-alone sales of such items. We recognize
    revenue for delivered elements only when we determine that the
    fair values of undelivered elements are known. For a multiple
    element arrangement that includes both IFCs and instruments we
    separate these elements into separate units of accounting as we
    consider these elements to have standalone value to the
    customer. We recognize revenue for the IFCs under SAB&#160;104
    and the instruments under SAB&#160;104 or
    <FONT style="white-space: nowrap">SOP&#160;97-2,</FONT>
    as applicable. If the fair value of any undelivered item related
    to instruments and software included in a multiple element
    arrangement cannot be objectively determined, revenue will be
    deferred until all items are delivered, or until fair value can
    objectively be determined for any remaining undelivered items.
    However, if the only such undelivered element is post-contract
    customer support services, such as maintenance agreements, the
    entire revenue is recognized ratably over the service period.
    Recognition of revenue from these arrangements generally begins
    upon installation of the instruments as installation is deemed
    essential to the functionality of the instruments. The
    corresponding costs of products sold related to multiple element
    arrangements are also deferred and amortized over the same
    period.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our deferred revenue balance increased by $1.6&#160;million
    during 2007. This increase is primarily due to the increase in
    sales of our BioMark instrument systems, all of which included
    maintenance agreements. We expect this trend to continue, and
    therefore, our deferred revenue balance will continue to
    increase until we are able to establish VSOE of the fair value
    of the post-contract customer support. We expect to establish
    VSOE for post-contract customer support as we enter into renewal
    agreements for maintenance with our customers upon the
    expiration of the initial agreements; however, we are not able
    to estimate when that will occur.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Changes in judgments and estimates regarding application of
    these revenue recognition guidelines as well as changes in facts
    and circumstances including the establishment of VSOE of fair
    value could result in a change in the timing or amount of
    revenue recognized in future periods.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Revenue from the sales of our products that is not part of a
    multiple element arrangement is recognized when no significant
    obligations remain undelivered and collection of the receivables
    is reasonably assured, which is generally upon shipment of the
    product and transfer of title to the customer.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have entered into collaboration research and development
    arrangements that generally provide us with up-front and
    periodic milestone fees or fees based on
    <FONT style="white-space: nowrap">agreed-upon</FONT>
    rates for time incurred by our research staff. Revenue is
    recognized either ratably over the term of the agreement or as
    time is incurred on the project. Revenue from government grants
    is for reimbursement of research and development expenses and
    recognized in the period related costs are incurred, provided
    that the conditions under which the government grants were
    awarded have been substantially met.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Stock-Based
    Compensation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to January&#160;1, 2006, we accounted for our stock
    options granted to employees using the intrinsic value method
    prescribed by Accounting Principles Board Opinion No.&#160;25,
    <I>Accounting for Stock Issued to Employees</I>, or APB 25, and
    related interpretations as permitted by Statement of Financial
    Accounting Standards, or SFAS&#160;No.&#160;123, <I>Accounting
    for Stock-Based Compensation</I>, or SFAS&#160;123, and
    SFAS&#160;No.&#160;148, <I>Accounting for Stock-Based
    Compensation&#160;&#151; Transaction and Disclosure</I>, or
    SFAS&#160;148. Accordingly, any compensation cost relating to
    stock options was recorded on the date of the grant in
    stockholders&#146; equity as deferred compensation and was
    thereafter amortized to expense over the vesting period of the
    grant, which was generally four years. We amortized deferred
    stock-based compensation using the multiple option method as
    prescribed by FASB Interpretation No.&#160;28, <I>Accounting for
    Stock Appreciation Rights and Other Variable Stock Option or
    Award Plans</I>, or FIN&#160;28, over the option vesting period
    using an accelerated amortization schedule.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    35
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Effective January&#160;1, 2006, we adopted the fair value
    recognition provisions of SFAS&#160;No.&#160;123 (revised 2004),
    <I>Share-Based Payment</I>, or SFAS&#160;123(R), which requires
    companies to measure the cost of employee services received in
    exchange for an award of equity instruments, including stock
    options, based on the grant date fair value of the award. The
    fair value is estimated using Black-Scholes option-pricing
    model. The resulting cost is recognized over the period during
    which an employee is required to provide service in exchange for
    the award, usually the vesting period.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We adopted SFAS&#160;123(R) using the prospective-transition
    method as all prior grants were measured using the minimum value
    method for the pro forma disclosures previously required by
    SFAS&#160;123. The prospective-transition method requires us to
    continue to apply APB 25 in future periods to equity awards
    outstanding at the date of our adoption of SFAS&#160;123(R) on
    January&#160;1, 2006. Under the prospective-transition method,
    any compensation costs that will be recognized from
    January&#160;1, 2006 will include only: (a)&#160;compensation
    cost for all stock-based awards granted prior to, but not yet
    vested as of, December&#160;31, 2005, based on the intrinsic
    value method in accordance with the provisions of ABP 25; and
    (b)&#160;compensation cost for all stock-based awards granted or
    modified subsequent to December&#160;31, 2005, net of estimated
    forfeitures, based on the grant date fair value estimated in
    accordance with the provisions of SFAS&#160;123(R). We amortize
    the fair value of stock-based compensation under
    SFAS&#160;123(R) on a straight-line basis. In accordance with
    the prospective-transition method as prescribed under
    SFAS&#160;123(R), results for prior periods are not restated.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We account for stock options issued to nonemployees in
    accordance with the provisions of SFAS 123(R) and EITF Issue No.
    96-18, <I>Accounting for Equity Instruments That Are Issued to
    Other Than Employees for Acquiring, or in Conjunction with
    Selling, Goods or Services,</I> or EITF
    <FONT style="white-space: nowrap">96-18.</FONT> In
    accordance with SFAS 123(R) and EITF
    <FONT style="white-space: nowrap">96-18,</FONT> stock
    options issued to nonemployees are accounted for at their
    estimated fair value determined using the Black-Scholes
    option-pricing model. The fair value of the options granted to
    nonemployees is remeasured as they vest, and the resulting
    increase in value, if any, is recognized as expense during the
    period the related services are rendered.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We use the Black-Scholes option-pricing model to calculate the
    fair value of our options on the grant date. This model requires
    inputs such as expected term, expected volatility and risk-free
    interest rate. Further, the forfeiture rate also affects the
    amount of aggregate compensation. These inputs are subjective
    and generally require significant judgment.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our expected volatility is derived from the historical
    volatilities of several unrelated public companies within the
    life science industry because we have little information on the
    volatility of the price of our common stock since we have no
    trading history. When making the selections of our industry peer
    companies to be used in the volatility calculation, we also
    considered the stage of development, size and financial leverage
    of potential comparable companies. Our historical volatility is
    weighted based on certain qualitative factors and combined to
    produce a single volatility factor. The risk-free interest rate
    is based on the U.S.&#160;Treasury yield in effect at the time
    of grant for zero coupon U.S.&#160;Treasury notes with
    maturities approximately equal to each grant&#146;s expected
    life. Given our limited history to accurately estimate the
    expected lives for the various employee groups, we used the
    &#145;simplified&#146; method as provided by Staff Accounting
    Bulletin&#160;No.&#160;107, <I>Share Based Payment</I>. The
    &#145;simplified&#146; method is calculated as the average of
    the
    <FONT style="white-space: nowrap">time-to-vesting</FONT>
    and the contractual life of the options.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Beginning on January&#160;1, 2006 upon the adoption of
    SFAS&#160;123(R), the fair value of each new option awarded was
    estimated on the grant date for the periods below using the
    Black-Scholes option-pricing model with the following
    weighted-average assumptions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="75%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="10%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="10%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006 Grants</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007 Grants</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected volatility
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    72.8%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    63.0%
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected life
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    6.1&#160;years
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    6.0&#160;years
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Risk-free interest rate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4.8%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4.4%
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dividend yield
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If in the future we determine that another method is more
    reasonable, or if another method for calculating these input
    assumptions is prescribed by authoritative guidance, and,
    therefore, should be used to estimate expected volatility or
    expected life, the fair value calculated for our stock options
    could change significantly. Higher
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    36
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    volatility and longer expected lives result in an increase to
    stock-based compensation expense determined at the date of
    grant. Stock-based compensation expense affects our cost of
    revenue; sales and marketing expense; research and development
    expense; and general and administrative expense.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We estimate our forfeiture rate based on an analysis of our
    actual forfeitures and will continue to evaluate the
    appropriateness of the forfeiture rate based on actual
    forfeiture experience, analysis of employee turnover behavior
    and other factors. Quarterly changes in the estimated forfeiture
    rate can have a significant effect on reported stock-based
    compensation expense, as the cumulative effect of adjusting the
    rate for all expense amortization is recognized in the period
    the forfeiture estimate is changed. If a revised forfeiture rate
    is higher than the previously estimated forfeiture rate, an
    adjustment is made that will result in a decrease to the
    stock-based compensation expense recognized in the consolidated
    financial statements. If a revised forfeiture rate is lower than
    the previously estimated forfeiture rate, an adjustment is made
    that will result in an increase to the stock-based compensation
    expense recognized in the consolidated financial statements. The
    effect of forfeiture adjustments during 2006 and 2007 was
    insignificant. We will continue to use judgment in evaluating
    the expected term, volatility and forfeiture rate related to our
    own stock-based compensation on a prospective basis and
    incorporating these factors into the Black-Scholes
    option-pricing model.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Also required for the fair value calculation of the options is
    the fair value of the underlying common stock. We have
    historically granted stock options with exercise prices no less
    than the fair market value of our common stock as determined at
    the date of grant by our Board of Directors, with input from
    management. The following table summarizes, by grant date, the
    number of stock options granted since January&#160;1, 2007 and
    the associated per share exercise price, which equaled the fair
    value of our common stock for each of these grants.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="74%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>and Fair Value<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Per Share of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Grant Date</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Granted</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Common Stock</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    May&#160;8, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,613,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    September&#160;20, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    December&#160;28, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    328,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Given the absence of an active market for our common stock prior
    to this offering, our Board of Directors determined the fair
    value of our common stock for our grants of stock options. Our
    Board of Directors determined the estimated fair value of our
    common stock based in part on an analysis of relevant metrics,
    including the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the prices of our convertible preferred stock sold to outside
    investors in arms-length transactions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the rights, preferences and privileges of our convertible
    preferred stock relative to those of our common stock;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the rights of freestanding warrants and other similar
    instruments related to shares that are redeemable;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our operating and financial performance;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the hiring of key personnel;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the introduction of new products;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our stage of development;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the fact that the option grants involve illiquid securities in a
    private company;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the risks inherent in the development and expansion of our
    products and services;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the likelihood of achieving a liquidity event, such as an
    initial public offering or sale of our company given prevailing
    market conditions.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During 2007, our Board of Directors performed three
    contemporaneous valuations of our common stock to coincide with
    our three stock option grants during the year.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    37
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The valuations were prepared using the market approach and the
    income approach to estimate our aggregate enterprise value at
    each valuation date. The market approach measures the value of a
    company through the analysis of recent sales of comparable
    companies. Consideration is given to the financial condition and
    operating performance of the company being valued relative to
    those of publicly traded companies operating in the same or
    similar lines of business. When choosing the comparable
    companies to be used for the market approach, we focused on
    companies in the life science industry. Some of the specific
    criteria used to select comparable companies within this
    industry include the business description, business size,
    projected growth, financial condition and historical earnings.
    The income approach measures the value of a company as the
    present value of its future economic benefits by applying an
    appropriate risk-adjusted discount rate to expected cash flows,
    based on forecasted revenue and costs. We prepared a financial
    forecast for each valuation report to be used in the computation
    of the enterprise value for both the market approach and the
    income approach. The financial forecasts took into account our
    past experience and future expectations. The risks associated
    with achieving these forecasts were assessed in selecting the
    appropriate discount rate. There is inherent uncertainty in
    these estimates.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In assessing the fair value of our common stock, our Board of
    Directors applied an equal weighting to the value indications
    presented by the income approach and market approach. In order
    to arrive at the estimated fair value of our common stock, the
    indicated enterprise value of our company calculated at each
    valuation date was allocated to the shares of convertible
    preferred stock and the warrants to purchase these shares, and
    shares of common stock and the options to purchase these shares
    using an option-pricing methodology. The option-pricing method
    treats common stock and preferred stock as call options on the
    total equity value of a company, with exercise prices based on
    the value thresholds at which the allocation among the various
    holders of a company&#146;s securities changes. Under this
    method, the common stock has value only if the funds available
    for distribution to stockholders exceed the value of the
    liquidation preference at the time of a liquidity event, such as
    a strategic sale, merger or initial public offering, assuming
    the enterprise has funds available to make a liquidation
    preference meaningful and collectable by the holders of
    preferred stock. The common stock is modeled as a call option on
    the underlying equity value at a predetermined exercise price.
    In the model, the exercise price is based on a comparison with
    the total equity value rather than, as in the case of a regular
    call option, a comparison with a per share stock price. Thus,
    common stock is considered to be a call option with a claim on
    the enterprise at an exercise price equal to the remaining value
    immediately after the preferred stock is liquidated. The
    option-pricing method uses the Black-Scholes option-pricing
    model to price the call options. This model defines the
    securities&#146; fair values as functions of the current fair
    value of a company and uses assumptions such as the anticipated
    timing of a potential liquidity event and the estimated
    volatility of the equity securities. The anticipated timing of a
    liquidity event utilized in these valuations was based on
    then-current plans and estimates of our Board of Directors and
    management regarding a liquidity event. Estimates of the
    volatility of our stock were based on available information on
    the volatility of capital stock of comparable publicly traded
    companies. This approach is consistent with the methods outlined
    in the AICPA Practice Guide, <I>Valuation of
    Privately-Held-Company Equity Securities Issued as
    Compensation</I>. Also, we considered the fact that our
    stockholders cannot freely trade our common stock in the public
    markets. Therefore, the estimated fair value of our common stock
    at each grant date reflected a non-marketability discount.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There is inherent uncertainty in these estimates and if we had
    made different assumptions than those described above, the
    amount of our stock-based compensation expense, net loss and net
    loss per share amounts could have been significantly different.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors performed a contemporaneous valuation in
    order to determine the fair value of our common stock for the
    grant of options on May&#160;8, 2007 which indicated a fair
    value of $1.36 per share for our common stock. Our Board of
    Directors performed a second contemporaneous valuation in order
    to update the determination of the fair value of our common
    stock for the grant of options on September&#160;20, 2007 which
    indicated a fair value of $1.38 per share for our common stock.
    The increase in the fair value between the contemporaneous
    valuation performed for the grant of options on May&#160;8, 2007
    and the date of this contemporaneous valuation was minimal,
    however, it relates mostly to a slight decrease in the
    non-marketability discount rate and the time to a liquidity
    event. Our Board of Directors performed another contemporaneous
    valuation in order to update the determination of the fair value
    of our common stock for the grant of options on
    December&#160;28, 2007 which indicated a fair value of $2.40 per
    share for our common stock. The increase in the fair value
    between the contemporaneous valuation performed for the grant of
    options on September&#160;20, 2007 and the date of the most
    recent
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    38
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    contemporaneous valuation relates mostly to the decrease in the
    non-marketability discount rate, the risk-adjusted discount and
    the time to a liquidity event.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We recorded stock-based compensation of $5,000,
    $0.1&#160;million and $0.7&#160;million during 2005, 2006 and
    2007. Included in these amounts was employee stock-based
    compensation of $0, $145,000 and $526,000, and nonemployee
    stock-based compensation of $5,000, $59,000 and $182,000 during
    2005, 2006 and 2007. In future periods, stock-based compensation
    expense is expected to increase as a result of our existing
    unrecognized stock-based compensation and as we issue additional
    stock-based awards to continue to attract and retain employees
    and nonemployee directors. Additionally, SFAS&#160;123(R)
    requires that we recognize compensation expense only for the
    portion of stock options that are expected to vest. If the
    actual rate of forfeitures differs from that estimated by
    management, we may be required to record adjustments to
    stock-based compensation expense in future periods. As of
    December&#160;29, 2007, we had $1.7&#160;million of unrecognized
    stock-based compensation costs related to stock options granted
    under our 1999 Stock Option Plan, which is expected to be
    recognized over an average period of 2.9&#160;years.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Accounting
    for Income Taxes</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Significant management judgment is required in determining our
    provision for income taxes, our deferred tax assets and
    liabilities and any valuation allowance recorded against our net
    deferred tax assets. We have recorded a full valuation allowance
    on our net deferred tax assets as of December&#160;31, 2006 and
    December&#160;29, 2007 due to uncertainties related to our
    ability to utilize our deferred tax assets in the foreseeable
    future. These deferred tax assets primarily consist of certain
    net operating loss carryforwards and research and development
    tax credits.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We adopted FASB Interpretation No.&#160;48, <I>Accounting for
    Uncertainties in Income Taxes&#160;&#151; an interpretation of
    FASB Statement No.&#160;109</I>, or FIN&#160;48, effective
    January&#160;1, 2007. FIN&#160;48 requires us to recognize the
    financial statement effects of a tax position when it is more
    likely than not, based on the technical merits, that the
    position will be sustained upon examination. Upon adoption, the
    Company recorded a charge of $75,000 as a cumulative effect of a
    change in accounting principle in the accumulated deficit during
    2007.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Inventory
    Valuation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We record adjustments to inventory for potentially excess,
    obsolete or impaired goods in order to state inventory at net
    realizable value. The business environment in which we operate
    is subject to rapid changes in technology and customer demand.
    We regularly review inventory for excess and obsolete products
    and components, taking into account product life cycle and
    development plans, product expiration and quality issues,
    historical experience and our current inventory levels. If
    actual market conditions are less favorable than anticipated,
    additional inventory adjustments could be required.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Warrants
    to Purchase Convertible Preferred Stock</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We account for freestanding warrants related to shares that are
    redeemable in accordance with FASB Staff Position
    <FONT style="white-space: nowrap">No.&#160;150-5,</FONT>
    <I>Issuer&#146;s Accounting Under FASB Statement No.&#160;150
    for Freestanding Warrants and Other Similar Instruments on
    Shares&#160;That Are Redeemable</I>, or
    <FONT style="white-space: nowrap">FSP&#160;150-5,</FONT>
    an interpretation of SFAS&#160;No.&#160;150, <I>Accounting for
    Certain Financial Instruments with Characteristics of Both
    Liabilities and Equity</I>. Under
    <FONT style="white-space: nowrap">FSP&#160;150-5,</FONT>
    freestanding warrants to purchase shares of our convertible
    preferred stock are classified as liabilities on the
    consolidated balance sheets at fair value because the warrants
    may conditionally obligate us to transfer assets at some point
    in the future. The warrants are subject to remeasurement at each
    balance sheet date, and any change in fair value will be
    recognized as a component of other income (expense), net in the
    consolidated statements of operations. We estimated the fair
    value of these warrants at the respective balance sheet dates
    using the Black-Scholes option-pricing model. A number of our
    assumptions used in the
    <FONT style="white-space: nowrap">Black-Scholes</FONT>
    <FONT style="white-space: nowrap">option-pricing</FONT>
    model, especially the market value and the expected volatility,
    are highly judgmental and could differ materially in the future.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We will continue to record adjustments to the fair value of the
    warrants until they are exercised, expire or, upon the closing
    of this offering, become warrants to purchase shares of our
    common stock, wherein the warrants will no longer be subject to
    <FONT style="white-space: nowrap">FSP&#160;150-5.</FONT>
    At that time, the then-current aggregate fair value of these
    warrants will be
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    39
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    reclassified from current liabilities to additional paid-in
    capital, a component of stockholders&#146; equity, and we will
    cease to record any related periodic fair value adjustments.
    Upon the closing of this offering, the preferred stock warrants
    will be converted into common stock warrants with the same
    exercise prices and expiration dates.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Results
    of Operations</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Revenue</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table presents our revenue by source for each
    period presented (in thousands).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="74%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Revenue:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Product revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,076
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,959
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,451
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Collaboration revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,568
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,376
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    460
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Grant revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,063
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,364
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Total revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,674
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,398
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,275
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We generate revenue from sales of our products, collaboration
    agreements and government grants. Our products consist of
    single-use IFCs, various instruments, software and service
    related to our BioMark and Topaz systems. We also have entered
    into a number of research and development contracts and have
    received government grants to conduct research and development
    activities.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Total
    Revenue</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our total revenue for 2007 increased by $0.9&#160;million, or
    14%, compared to 2006, and our 2006 revenue decreased by
    $1.3&#160;million, or 17%, compared to 2005. Total revenue from
    our top five customers comprised 50% of revenue in 2005, 47% of
    revenue in 2006 and 47% of revenue in 2007. We expect this
    percentage to decrease over time as we continue to grow our
    business and expand into new markets.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As we expand our business through Europe and Asia, we expect our
    sales from outside of North America to increase as a percentage
    of our revenue. The following table presents our revenue by
    geography based on the billing address of our customers for each
    period presented (in thousands).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    North America
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,185
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,932
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    61%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,526
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Europe
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    545
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    189
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    735
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Asia
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,944
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,277
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,014
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,674
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,398
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,275
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Product
    Revenue</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We derive product revenue from sales to leading academic
    institutions, biotechnology and pharmaceutical companies and
    life science laboratories worldwide. These sales are generally
    made through direct sales personnel to customers in North
    America, Asia and most of Europe and through distributors in
    parts of Europe and Asia.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Product revenue for 2007 increased by $0.4&#160;million, or 12%,
    compared to 2006. The increase relates mostly to the increase in
    sales of our BioMark instrument systems, and related IFCs, which
    were introduced in late 2006, as we sold 14 BioMark instrument
    systems during 2007 compared to three BioMark instrument systems
    during 2006. This increase of $1.2&#160;million in revenue
    recognized for BioMark instrument systems and IFCs, however, was
    mostly offset by a decrease in the revenue related to Topaz IFC
    sales, which were $1.1&#160;million. The unit sales of our Topaz
    systems remained constant as we sold 10 Topaz systems during
    both 2006 and 2007. In addition, our deferred revenue balance
    increased from $1.8&#160;million at December&#160;31, 2006 to
    $3.4&#160;million at December&#160;29, 2007 as we sold more
    BioMark instrument systems as part of multiple element
    arrangements for which we did not have VSOE on post-contract
    support. We recognized $1.0&#160;million of the deferred revenue
    balance at December&#160;31, 2006 during
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    40
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    2007. We expect the current portion of our deferred revenue
    balance as of December&#160;29, 2007 in the amount of
    $2.6&#160;million will be recognized as revenue during 2008.
    Product revenue for 2006 decreased by $2.1&#160;million, or 35%,
    when compared to 2005. The decrease was primarily due to a
    decrease in the sales of our Topaz systems as we sold 10 Topaz
    systems during 2006 compared to 16 Topaz systems during 2005;
    however, sales of our Topaz IFCs remained relatively consistent
    with 2005.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The increase in sales of our BioMark instrument systems in 2007
    and the concurrent decrease in sales of our Topaz systems
    reflect the refocusing of our product development and sales and
    marketing efforts, beginning in 2005, to focus on the larger
    markets served by our BioMark instrument systems. Since then, we
    have reduced new Topaz product introductions. We will continue
    to manufacture and sell our Topaz systems and IFCs and we expect
    unit sales of Topaz systems and IFCs in 2008 and future periods
    to be consistent with or slightly lower than the 2006 and 2007
    levels. We expect unit sales of our BioMark instrument systems
    and IFCs to increase in 2008.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Collaboration
    Revenue</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We receive payments from third parties under research and
    development contracts. Fixed-fee research and development
    contracts generally provide us with up-front and periodic
    milestone-based fees. Variable-fee research and development
    contracts generally provide us with fees based on an
    <FONT style="white-space: nowrap">agreed-upon</FONT>
    rate for time incurred by our research staff.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Collaboration revenue for 2007 decreased by $0.9&#160;million,
    or 67%, compared to 2006. This decrease was primarily due to the
    completion of one of our collaboration agreements during 2006
    that accounted for $1.0&#160;million of our 2006 collaboration
    revenue. Collaboration revenue for 2006 decreased by
    $0.2&#160;million, or 12%, compared to 2005. The decrease was
    primarily due to the termination of one of our collaboration
    agreements in December 2005. We expect collaboration revenue to
    continue to decrease as we complete our current collaboration
    agreements, most of which are likely to terminate during 2008.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Grant
    Revenue</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We receive payments in the form of grants from certain
    government entities. Government grants are agreements that
    generally provide us reimbursement for specified research and
    development activities over a contractually defined period.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Grant revenue for 2007 increased by $1.3&#160;million, or 122%,
    when compared to 2006 and our grant revenue for 2006 increased
    by $1.0&#160;million when compared to 2005. These increases were
    primarily due to the addition of a grant from the National
    Institutes of Health, or NIH, which was awarded in June 2006,
    and Singapore research grants, which were awarded in January
    2006 and February 2007. We recognized revenue from the 2006
    Singapore research grant in the amount of $0.9&#160;million
    during 2006 and $1.1&#160;million during 2007. In addition, we
    recognized revenue in the amount of $0.6&#160;million during
    2007 from the 2007 Singapore research grant. Also, we recognized
    revenue from the NIH grant in the amount of $0.2&#160;million
    during 2006 and $0.6&#160;million during 2007. Although the NIH
    grant is scheduled to terminate in June 2008, we expect grant
    revenue from the Singapore research grants to increase in 2008
    and remain at such levels through 2011, therefore, we expect our
    total grant revenue in 2008 through 2011 to be consistent with
    2007 levels.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our agreements with the government of Singapore provide that
    grants extended to us in the past and future grants are subject
    to our operation of increasing levels of research, development
    and manufacturing in Singapore, including the use of local
    service providers, the hiring of personnel in Singapore, the
    incurrence of research and development expenses in Singapore,
    our receipt of new investment in our company and our achievement
    of certain milestones relating to the development of our
    products. These agreements further provide the government with
    the right to demand repayment of past grants in the event that
    it concludes that we have not met our obligations under the
    applicable agreements. We have confirmed that we have satisfied
    all conditions applicable to funds received from grants as of
    December&#160;29, 2007.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    41
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Cost of
    Product Revenue and Gross Margin</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table presents our cost of revenue and gross
    margin for each period presented (in thousands).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="74%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cost of product revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,764
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,773
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,514
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Gross margin
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cost of product revenue includes manufacturing costs incurred in
    the production process, including component materials, assembly
    labor and overhead, testing, installation, warranty, packaging
    and delivery costs. In addition, cost of product revenue
    includes royalty expenses for licensed technologies included in
    our products, provisions for warranties and stock-based
    compensation expense. Costs related to collaboration and
    government grant revenue are included in research and
    development expense. Cost of product revenue for 2007 increased
    $0.7&#160;million, or 27%, compared to 2006, primarily driven by
    higher instrument sales, start-up costs for our new Singapore
    manufacturing facility and underutilized capacity as we
    transitioned manufacturing from the U.S. to Singapore.
    Additionally we wrote-off obsolete raw materials in 2007 in the
    amount of $0.2&#160;million, which decreased our gross margin by
    5&#160;percentage points. Cost of product revenue for 2006
    decreased by $2.0&#160;million, or 42%, when compared to 2005,
    primarily driven by a decrease in sales of our Topaz instruments
    during 2006. We expect our unit costs to decline in future
    periods as a result of our ongoing efforts to automate our
    manufacturing processes and expected increases in production
    volumes and yields. However, improvement in unit costs may be
    offset by increasing price competition, which could cause our
    gross margins to fluctuate from
    <FONT style="white-space: nowrap">year-to-year</FONT>
    and
    <FONT style="white-space: nowrap">quarter-to-quarter.</FONT>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Operating
    Expenses</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table presents our operating expenses for each
    period presented (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="71%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Operating expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Research and development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    11,449
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    15,589
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    14,389
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Selling, general and administrative
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,955
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,699
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,898
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Total operating expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    19,404
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    25,288
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    27,287
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Research
    and Development</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Research and development expense is the largest component of our
    operating expenses and consists primarily of personnel costs,
    independent contractor costs, prototype expenses and other
    allocated facilities and information technology expenses. We
    have made substantial investments in research and development
    since our inception. Our research and development efforts have
    focused primarily on the tasks required to optimize our
    technologies and to support commercialization of the products
    and services derived from these technologies. Research and
    development expense decreased in 2007 by $1.2&#160;million, or
    8%, compared to 2006, primarily due to decreased research and
    development license costs of $0.3&#160;million, decreased supply
    costs of $0.3&#160;million due to more efficient development
    activities and decreased compensation costs of
    $0.2&#160;million. Research and development expense for 2006
    increased by $4.1&#160;million, or 36%, compared to 2005,
    primarily due to increased compensation costs of
    $2.1&#160;million, of which $0.1&#160;million was related to the
    adoption of SFAS&#160;123(R) during 2006, $0.7&#160;million
    attributable to increased contractor expenses, $0.6&#160;million
    in increased licenses and royalties, and $0.3&#160;million
    attributable to increased supply expenses. We believe that our
    continued investment in research and development is essential to
    a long-term competitive position and expect these expenses,
    including stock-based compensation, to increase in future
    periods.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Selling,
    General and Administrative</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Selling, general and administrative expense consists primarily
    of personnel costs for our sales and marketing, business
    development, finance, legal, human resources and general
    management, as well as professional services, such as legal and
    accounting services. Selling, general and administrative expense
    for 2007 increased by
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    42
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    $3.2&#160;million, or 33%, primarily due to increased
    compensation costs of $1.7&#160;million, including a
    $0.5&#160;million increase in stock-based compensation over
    2006, an increase of $1.4&#160;million in spending primarily for
    accounting and legal services, $0.3&#160;million resulting from
    increased advertising and promotions, and $0.2&#160;million
    attributable to increased supplies for customer demonstrations.
    However, this increase was partially offset by a decrease of
    $0.4&#160;million due to fewer patent filings. Selling, general
    administrative expense for 2006 increased by $1.7&#160;million,
    or 22%, compared to 2005, primarily due to increased
    compensation costs of $1.1&#160;million, $0.4&#160;million due
    to the filing of additional patents, $0.1&#160;million from
    increased advertising and promotions, and $0.1&#160;million
    attributable to increased supplies for customer demonstrations.
    We expect selling, general and administrative expense, including
    stock-based compensation, to significantly increase in 2008 and
    future periods as we continue to grow our sales, technical
    support, marketing and administrative headcount, support
    increased product sales, broaden our customer base and incur
    additional costs to support the growth in our business.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Interest
    Income and Expense</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We receive interest income from our cash and cash equivalents
    and our
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    security balances held with certain financial institutions.
    Conversely, we incur interest expense from our long-term debt
    and convertible promissory notes and the amortization of our
    debt discounts related to these items. The following table
    presents our interest income and expense for each period
    presented (in thousands).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="73%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    565
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,140
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (898
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,261
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,790
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Interest income for 2007 increased by $0.6&#160;million compared
    to 2006. The increase in interest income was due to higher cash
    and available-for-sale securities balances during 2007 as
    compared to 2006. Interest income for 2006 increased by
    $0.2&#160;million compared to 2005. The increase in interest
    income was also primarily due to higher cash and
    available-for-sale securities balances during 2006 as compared
    to 2005. We expect interest income to increase as we invest a
    portion of the net proceeds from this offering in
    available-for-sale securities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Interest expense for 2007 increased by $0.5&#160;million
    compared to 2006. The increase was primarily due to higher debt
    balances during 2007 as compared to 2006 primarily due to the
    $5.0&#160;million convertible promissory note issued in March
    2007. Interest expense for 2006 increased by $1.4&#160;million
    compared to 2005. The increase was primarily due to higher debt
    balances from the $13.0&#160;million Loan and Security agreement
    that was fully drawn by December 2005. We expect interest
    expense to increase if we draw on the $10.0&#160;million credit
    line which is available up to July&#160;1, 2008.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Cumulative
    Effect of Change in Accounting Principle</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon adoption of
    <FONT style="white-space: nowrap">FSP&#160;150-5</FONT>
    on July&#160;1, 2005, we reclassified the fair value of warrants
    to purchase shares of our convertible preferred stock from
    stockholders&#146; equity to liabilities and recorded a
    cumulative effect of a change in accounting principle in the
    amount of $0.6&#160;million during 2005 in the statement of
    operations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Liquidity
    and Capital Resources</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Sources
    of Liquidity</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To date, we have principally funded our operations through
    issuances of convertible preferred stock, which has provided us
    with aggregate net proceeds of $162.1&#160;million since our
    inception. As of December&#160;29, 2007, we had
    $34.1&#160;million of cash and cash equivalents and
    $6.3&#160;million of
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities. As of December&#160;29, 2007, our working capital
    was $38.8&#160;million, and we had an accumulated deficit of
    $133.8&#160;million.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    From December 2003 through December 2007, we entered into
    multiple Convertible Note Purchase Agreements with Biomedical
    Sciences Investment Fund&#160;Pte. Ltd., or Biomedical Sciences,
    an investment arm of the Singapore Economic Development Board,
    or EDB, pursuant to which we issued convertible notes and
    received proceeds in the amount of $20.0&#160;million. Principal
    and interest on the notes is convertible into our Series&#160;E
    convertible preferred stock at the lender&#146;s election, at
    any time, and automatically convert upon the achievement of
    certain milestones or upon the completion of an initial public
    offering in which the convertible preferred stock has
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    43
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    converted into common stock. Through December&#160;29, 2007,
    $15.0&#160;million of these notes had been converted to shares
    of our Series&#160;E convertible preferred stock. As of
    December&#160;29, 2007, the outstanding principal and accrued
    interest balance for the Convertible Note Purchase Agreements
    with Biomedical Sciences was $5.0&#160;million, net of
    unamortized debt discounts of $0.3&#160;million.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In March 2005, we entered into a loan and security agreement
    with a lender under which we borrowed $13.0&#160;million to be
    used for general corporate purposes. We are currently making
    equal monthly payments of $0.3&#160;million towards the loan
    which is to be paid off on February&#160;1, 2010. The loan is
    subject to prepayment penalties if paid off prior to 2010. As of
    December&#160;29, 2007, the outstanding principal and accrued
    interest balance for this loan and security agreement was
    $8.0&#160;million, net of unamortized debt discounts of $31,000.
    In February 2008, this loan and security agreement was amended
    to provide us with an additional credit line in the amount of
    $10.0&#160;million that we can draw upon until July&#160;1, 2008
    for general corporate purposes. Amounts drawn down under this
    additional line of credit plus accrued interest will be repaid
    in installments through June 2011 and outstanding amounts accrue
    interest at the rate of 11.5% per year.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In November 2002, we entered into a master security agreement
    with a lender under which we borrowed $3.6&#160;million to be
    used for purchases of capital equipment, software and tenant
    improvements. As of December&#160;29, 2007, the outstanding
    principal and accrued interest balance for this master security
    agreement was $1.1&#160;million. The outstanding principal and
    accrued interest balance for this loan was paid in February
    2008. Upon full payment of the debt in February 2008, restricted
    cash in the amount of $0.5&#160;million was released by the
    lender.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each of the security and note agreements above contain
    covenants, however, no financial covenants exist related to
    these agreements. As of December&#160;29, 2007, we were in
    compliance with or had obtained waivers for all of the covenants
    related to these agreements.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Net
    Cash Used in Operating Activities</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We derive cash flows from operations primarily from cash
    collected from the sale of our products and related services,
    collaboration agreements and grants from certain government
    entities. Our cash flows from operating activities are also
    significantly influenced by our use of cash for operating
    expenses to support the growth of our business. We have
    historically experienced negative cash flows from operating
    activities as we have expanded our business and built our
    infrastructure domestically and internationally and we expect
    this trend to continue for the foreseeable future as our
    business grows and we continue to expand into new markets.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash used by operating activities was $21.8&#160;million
    during 2007. Net cash used by operating activities primarily
    consisted of a net loss of $25.5&#160;million, which was
    partially offset by non-cash expense items such as depreciation
    and amortization of our property and equipment in the amount of
    $1.6&#160;million, amortization of our debt discounts in the
    amount of $0.5&#160;million, stock-based compensation in the
    amount of $0.7&#160;million, and changes in our working capital
    accounts in the amount of $0.5&#160;million.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash used by operating activities was $22.3&#160;million
    during 2006. Net cash used by operating activities primarily
    consisted of a net loss of $23.6&#160;million and changes in our
    working capital accounts in the amount of $1.2&#160;million. The
    cash used by operating activities for these items was partially
    offset by non-cash expense items such as depreciation and
    amortization of our property and equipment in the amount of
    $1.4&#160;million, amortization of our debt discounts in the
    amount of $0.1&#160;million, stock-based compensation in the
    amount of $0.1&#160;million, and the issuance of convertible
    preferred stock under a license agreement in the amount of
    $0.6&#160;million.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash used by operating activities was $14.3&#160;million
    during 2005. Net cash used by operating activities primarily
    consisted of a net loss of $16.4&#160;million. The cash used by
    operating activities was partially offset by non-cash expense
    items such as depreciation and amortization of our property and
    equipment in the amount of $1.3&#160;million and increases in
    our working capital accounts in the amount of $1.4&#160;million.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Net
    Cash Used in Investing Activities</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Historically, our primary investing activities have consisted of
    capital expenditures for laboratory, manufacturing and computer
    equipment and software to support our expanding infrastructure
    and work force; restricted cash related to leased space and
    lending agreements; and purchases, sales and maturities of our
    <FONT style="white-space: nowrap">available-for-sale</FONT>
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    44
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    securities. We expect to continue to expand our manufacturing
    capability, primarily in Singapore, and expect to incur
    additional costs for capital expenditures related to these
    efforts in 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We used $6.7&#160;million of cash in investing activities during
    2007, primarily for purchases of
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities in the amount of $6.3&#160;million and
    $1.0&#160;million for capital expenditures related to purchases
    of equipment, including $0.4&#160;million for our Singapore
    manufacturing facility, partially offset by maturities of
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities in the amount of $0.5&#160;million.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We used $2.9&#160;million of cash in investing activities during
    2006, primarily for capital expenditures in the amount of
    $2.9&#160;million related to purchases of equipment, including
    $1.3&#160;million for our Singapore manufacturing facility.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During 2005, investing activities provided cash of
    $6.8&#160;million. This cash was generated primarily from sales
    and maturities of
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities in the amount of $8.9&#160;million, partially offset
    by purchases of
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities in the amount of $0.5&#160;million and capital
    expenditures in the amount of $1.7&#160;million. Our capital
    expenditures during 2005 consisted of $1.0&#160;million related
    to purchases of manufacturing equipment for our Singapore
    facility, which began operations during the year.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Net
    Cash Provided by Financing Activities</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Historically, we have principally funded our operations through
    issuances of convertible preferred stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During 2007, we generated $37.6&#160;million of cash from
    financing activities primarily due to $35.9&#160;million of net
    proceeds from sales of our Series&#160;E convertible preferred
    stock and $5.0&#160;million of proceeds from the issuance of
    convertible promissory notes, partially offset by repayments of
    our long-term debt in the amount of $3.5&#160;million. During
    2006, we generated approximately $31.1&#160;million of cash from
    financing activities primarily due to $22.0&#160;million of net
    proceeds from sales of our Series&#160;E convertible preferred
    stock and $13.0&#160;million of proceeds from the issuance of
    convertible promissory notes, partially offset by repayments of
    our long-term debt in the amount of $4.0&#160;million. During
    2005, we generated approximately $23.0&#160;million of cash from
    financing activities, primarily due to $10.0&#160;million of net
    proceeds from sales of our Series&#160;D convertible preferred
    stock and $14.7&#160;million of net proceeds from the issuance
    of long-term debt, partially offset by repayments of our
    long-term debt in the amount of $1.7&#160;million.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Capital
    Resources</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe our existing cash and cash equivalents,
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities, amounts available under current credit lines and the
    net proceeds from this offering, will be sufficient to meet our
    working capital and capital expenditure needs for at least the
    next 18&#160;months. However, we may need to raise substantial
    additional capital to expand the commercialization of our
    products, fund our operations, continue our research and
    development, defend, in litigation or otherwise, any claims that
    we infringe third-party patents or violate other intellectual
    property rights, commercialize new products and acquire
    companies and in-license products or intellectual property. Our
    future funding requirements will depend on many factors,
    including market acceptance of our products, the cost of our
    research and development activities, the cost of filing and
    prosecuting patent applications, the cost of defending, in
    litigation or otherwise, any claims that we infringe third-party
    patents or violate other intellectual property rights, the cost
    and timing of regulatory clearances or approvals, if any, the
    cost and timing of establishing additional sales, marketing and
    distribution capabilities, the cost and timing of establishing
    additional technical support capabilities, the effect of
    competing technological and market developments, and the extent
    to which we acquire or invest in businesses, products and
    technologies, although we currently have no commitments or
    agreements relating to any of these types of transactions. We
    currently expect to use the proceeds from this offering to
    expand our sales force, to support the ongoing commercialization
    of our products, for research and product development
    activities, to expand our facilities and manufacturing
    operations, and for working capital and other general corporate
    purposes. As of the date of this prospectus, we cannot predict
    with certainty all of the particular uses for the proceeds from
    this offering or the amounts that we will actually spend on the
    uses set forth above.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We may require additional funds in the future and we may not be
    able to obtain such funds on acceptable terms, or at all. If we
    raise additional funds by issuing equity securities, our
    stockholders may experience dilution. Debt
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    45
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    financing, if available, may involve covenants restricting our
    operations or our ability to incur additional debt. Any debt or
    additional equity financing that we raise may contain terms that
    are not favorable to us or our stockholders. If we raise
    additional funds through collaboration and licensing
    arrangements with third parties, it may be necessary to
    relinquish some rights to our technologies or our products, or
    grant licenses on terms that are not favorable to us. If we are
    unable to raise adequate funds, we may have to liquidate some or
    all of our assets, or delay, reduce the scope of or eliminate
    some or all of our development programs. If we do not have, or
    are not able to obtain, sufficient funds, we may have to delay
    development or commercialization of our products or license to
    third parties the rights to commercialize products or
    technologies that we would otherwise seek to commercialize. We
    also may have to reduce marketing, customer support or other
    resources devoted to our products or cease operations. Any of
    these factors could harm our operating results.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Off-Balance
    Sheet Arrangements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Since our inception, we have not had any off-balance sheet
    arrangements as defined in Item&#160;303(a)(4) of the Securities
    and Exchange Commission&#146;s
    <FONT style="white-space: nowrap">Regulation&#160;S-K.</FONT>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Contractual
    Obligations and Commitments</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following summarizes our contractual obligations as of
    December&#160;29, 2007 (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="47%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Payments Due by Period</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Less Than<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Total</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>1&#160;Year</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>1-3&#160;Years</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>3-5&#160;Years</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Thereafter</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Operating lease obligations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,459
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,436
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,782
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    241
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Long-term debt
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,908
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,478
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Convertible promissory notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,278
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,278
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Purchase obligations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    435
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    580
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    21,660
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,349
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    15,070
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    241
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our operating lease obligations relate to leases for our current
    headquarters and leases for office space for our foreign
    subsidiaries. Principal and interest on our convertible
    promissory notes are convertible into shares of our
    Series&#160;E convertible preferred stock at the lender&#146;s
    election, at any time, or upon our election upon the achievement
    of certain milestones or automatically upon the completion of
    this offering. Purchase obligations consist of contractual and
    legally binding commitments to purchase goods. We have entered
    into several patent license agreements in which we are obligated
    to pay annual license maintenance fees, non-refundable license
    issuance fees and royalties as a percentage of sales for the
    sale or sublicense of products using the licensed technology.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On March&#160;7, 2003 we entered into a Master Closing Agreement
    with Oculus Pharmaceuticals, Inc. and the UAB Research
    Foundation, or UAB, related to certain intellectual property and
    technology rights licensed by us from UAB. Pursuant to the
    agreement, we are obligated to issue UAB shares of our common
    stock with a value equal to $1,500,000 upon the achievement of a
    certain milestone and based upon the fair market value of our
    common stock at the time the milestone is achieved. We currently
    do not anticipate achieving this milestone in the foreseeable
    future and do not anticipate issuing these shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    License Agreements: We have entered into several license and
    patent agreements. Under these agreements, we are obligated to
    pay annual license maintenance fees, nonrefundable license
    issuance fees, and royalties as a percentage of net sales for
    the sale or sublicense of products using the licensed
    technology. Under our current agreements, we are required to pay
    aggregate annual fees of $315,000 in 2008 and $270,000 per year
    thereafter if we maintain the licenses from 2012 to 2027. For a
    more detailed description of our license agreements, see
    note&#160;3 to the consolidated financial statements.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Recent
    Accounting Pronouncements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In September 2006, the FASB issued SFAS&#160;No.&#160;157,
    <I>Fair Value Measurement</I>, or SFAS&#160;157, which defines
    and establishes a framework for measuring the fair value of
    assets and liabilities when required or permitted by other
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    46
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    standards within generally accepted accounting principles in the
    United States but does not require any new fair value
    measurements. SFAS&#160;157 also expands disclosures about fair
    value measurements. SFAS&#160;157 is effective for all financial
    statements issued for fiscal years beginning after
    November&#160;15, 2007. However, in February 2008 the FASB
    issued FSP
    <FONT style="white-space: nowrap">No.&#160;157-2,</FONT>
    or
    <FONT style="white-space: nowrap">FSP&#160;157-2</FONT>
    which delays the effective date of SFAS&#160;157 in accordance
    with the provisions in
    <FONT style="white-space: nowrap">FSP&#160;157-2</FONT>
    as of January&#160;1, 2008. The adoption of SFAS&#160;157 is not
    expected to have a significant impact on our consolidated
    financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In February 2007, the FASB issued SFAS&#160;No.&#160;159, <I>The
    Fair Value Option for Financial Assets and Financial
    Liabilities</I>, or SFAS&#160;159, including an amendment of
    SFAS&#160;No.&#160;115, <I>Accounting for Certain Investments in
    Debt and Equity Securities</I>, which allows an entity to choose
    to measure certain financial instruments and liabilities at fair
    value. Subsequent measurements for the financial instruments and
    liabilities an entity elects to measure at fair value will be
    recognized in earnings. SFAS&#160;159 also establishes
    additional disclosure requirements. SFAS&#160;159 is effective
    for fiscal years beginning after November&#160;15, 2007. We
    adopted SFAS&#160;159 as of January&#160;1, 2008 but chose not
    to measure the financial instruments and liabilities permitted
    by the standard at fair value. Therefore, the adoption of
    SFAS&#160;159 is not expected to have a significant impact on
    our consolidated financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In December 2007, the FASB ratified EITF Issue
    <FONT style="white-space: nowrap">No.&#160;07-1,</FONT>
    <I>Accounting for Collaborative Agreements</I>, or
    <FONT style="white-space: nowrap">EITF&#160;07-1,</FONT>
    which addresses the accounting for participants in collaborative
    agreements, defined as contractual arrangements that involve a
    joint operating activity, that are conducted without the
    creation of a separate legal entity.
    <FONT style="white-space: nowrap">EITF&#160;07-1</FONT>
    requires participants in a collaborative agreement to make
    separate disclosures for each period a statement of operations
    is presented regarding the nature and purpose of the agreement,
    the rights and obligations under the agreement, the accounting
    policy for the agreement, and the classification of and amounts
    arising from the agreement between participants. These
    arrangements involve two or more parties who are both active
    participants in the activity and that are exposed to significant
    risks and rewards dependent on the commercial success of the
    activity.
    <FONT style="white-space: nowrap">EITF&#160;07-1</FONT>
    provides that a company should report the effects of adoption as
    a change in accounting principle through retrospective
    application to all periods and requires specific additional
    disclosures.
    <FONT style="white-space: nowrap">EITF&#160;07-1</FONT>
    is effective for interim and annual reporting periods beginning
    after December&#160;15, 2008. We are currently assessing the
    impact the adoption of
    <FONT style="white-space: nowrap">EITF&#160;07-1</FONT>
    will have on our consolidated financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In June 2007, the FASB ratified EITF Issue
    <FONT style="white-space: nowrap">No.&#160;07-3,</FONT>
    <I>Accounting for Nonrefundable Advance Payments for Goods or
    Services to Be Used in Future Research and Development
    Activities</I>, or
    <FONT style="white-space: nowrap">EITF&#160;07-3.</FONT>
    <FONT style="white-space: nowrap">EITF&#160;07-3</FONT>
    provides clarification surrounding the accounting for
    nonrefundable research and development advance payments, whereby
    such payments should be recorded as an asset when the advance
    payment is made and recognized as an expense when the research
    and development activities are performed.
    <FONT style="white-space: nowrap">EITF&#160;07-3</FONT>
    is effective for interim and annual reporting periods beginning
    after December&#160;15, 2007. We do not expect the adoption of
    <FONT style="white-space: nowrap">EITF&#160;07-3</FONT>
    to have a significant our consolidated financial statements.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Quantitative
    and Qualitative Disclosures about Market Risk</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Market risk represents the risk of loss that may impact our
    financial position due to adverse changes in financial market
    prices and rates. Our market risk exposure is primarily a result
    of fluctuations in foreign currency exchange rates and interest
    rates. We do not hold or issue financial instruments for trading
    purposes.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Foreign
    Currency Exchange Risk</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As we expand internationally our results of operations and cash
    flows will become increasingly subject to fluctuations due to
    changes in foreign currency exchange rates. Our revenue is
    generally denominated in the local currency of the contracting
    party. Historically, the substantial majority of our revenue has
    been denominated in U.S.&#160;dollars. Our expenses are
    generally denominated in the currencies in which our operations
    are located, which is primarily in the United States, with a
    portion of expenses incurred in Singapore where our other
    manufacturing facility is located. Our results of operations and
    cash flows are, therefore, subject to fluctuations due to
    changes in foreign currency exchange rates. Fluctuations in
    currency exchange rates could harm our business in the future.
    However, the effect of a 10% adverse change in exchange rates on
    foreign denominated receivables and payables as of
    December&#160;31, 2006 and December&#160;29, 2007 would not have
    been material. To date, we have not entered into any foreign
    currency hedging contracts although we may do so in the future.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    47
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Interest
    Rate Sensitivity</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We had cash and cash equivalents of $25.0&#160;million and
    $34.1&#160;million as of December&#160;31, 2006 and
    December&#160;29, 2007 and
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities of $0.5&#160;million and $6.3&#160;million as of
    December&#160;31, 2006 and December&#160;29, 2007. These amounts
    were held primarily in cash on deposit with banks, money market
    funds, commercial paper, corporate notes or notes from
    government-sponsored agencies, which are short-term. Cash and
    cash equivalents and
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities are held for working capital purposes and restricted
    cash amounts are held as letters of credit for collateral for a
    security agreement with a lender and for our facility lease
    agreements. Due to the short-term nature of these investments,
    we believe that we do not have any material exposure to changes
    in the fair value of our investment portfolio as a result of
    changes in interest rates. Declines in interest rates, however,
    will reduce future investment income. If overall interest rates
    had decreased by 10% during 2007, our interest income would not
    have been materially affected.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    At December&#160;31, 2006 and December&#160;29, 2007, the
    principal amount of our long-term debt outstanding was
    $12.8&#160;million and $9.4&#160;million and the principal
    amount of our convertible promissory notes outstanding was
    $13.1&#160;million and $5.0&#160;million. The interest rates on
    our long-term debt and convertible promissory notes are largely
    fixed, however, a small portion of our long-term debt
    outstanding has interest rates that are variable and adjust
    periodically based on the prime rate. If overall interest rates
    had increased by 10% during 2007, our interest expense would not
    have been materially affected.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Fair
    Value of Financial Instruments</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We do not have material exposure to market risk with respect to
    investments as our investments consist primarily of highly
    liquid securities that approximate their fair values due to
    their short period of time to maturity. We do not use derivative
    financial instruments for speculative or trading purposes,
    however, we may adopt specific hedging strategies in the future.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Controls
    and Procedures</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2008, in connection with the audit of our
    consolidated financial statements for 2005 and 2006, we
    determined that we had material weaknesses relating to our
    financial statement close and accrual process and revenue
    recognition and inventory costing, cost of sales, purchases
    cut-off and stock-based compensation. A material weakness is
    defined as a deficiency, or combination of deficiencies, in
    internal control over financial reporting, such that there is a
    reasonable possibility that a material misstatement of the
    company&#146;s annual or interim financial statements will not
    be prevented or detected on a timely basis by the company&#146;s
    internal controls. These material weaknesses were as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we did not have a sufficient number of personnel in the
    accounting and finance department with sufficient proficiency
    and technical accounting expertise;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we did not have effective controls in place or designed to
    evaluate the accounting implications of our business
    transactions during 2005 and 2006 and to determine if such
    matters had been properly accounted for in a timely
    manner;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we had not designed or maintained effective operating controls
    over the financial statement close and reporting process in
    order to ensure the accurate and timely preparation of our
    financial statements in accordance with generally accepted
    accounting principles.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    These material weaknesses resulted in the recording of numerous
    audit adjustments for 2005 and 2006. We have taken steps
    intended to remediate these material weaknesses through:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the hiring of additional accounting and finance personnel with
    technical accounting and financial reporting experience,
    including Vikram Jog, our new Chief Financial Officer, who
    joined us in February 2008;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the engagement of a consulting firm to provide further
    accounting expertise to complement the skills of our existing
    team;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the engagement of an accounting firm to advise us on local and
    international tax planning and compliance;
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    48
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the hiring of an experienced finance manager for Fluidigm
    Singapore Pte. Ltd., who is expected to start in May 2008;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    increased scheduled communication and coordination among our
    finance teams in the United States and our foreign subsidiaries;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    enhanced coordination among, and training of, accounting, sales,
    technical support and legal personnel on transactional issues;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    enhancements to our financial statement close process and
    financial close calendar to help enable processes and procedures
    to be completed on a timely basis;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    installation of common accounting software and systems in our
    U.S. and Singapore offices.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In April 2008, following the audit of our consolidated financial
    statements for 2007, we reviewed our internal control over
    financial reporting and concluded that we had certain
    significant deficiencies, none of which were determined to be
    material weaknesses. A significant deficiency is defined as a
    deficiency, or combination of deficiencies, in internal control
    over financial reporting that is less severe than a material
    weakness, yet important enough to merit attention by those
    responsible for oversight of a company&#146;s financial
    reporting. These significant deficiencies were as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we did not have sufficient controls in place to review
    consolidation and elimination entries relating to intercompany
    transfer pricing to detect and eliminate intercompany profits
    embedded in deferred costs of our Japanese subsidiary;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we did not have effective controls in place designed to apply
    SFAS&#160;123R to option grants with a variety of vesting terms
    and to validate stock compensation expenses calculated by our
    option tracking software.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We do not know the specific time frame needed to remediate the
    significant deficiencies identified. In addition, we expect to
    incur some incremental costs associated with this remediation.
    If we fail to enhance our internal control over financial
    reporting to meet the demands that will be placed upon us as a
    public company, including the requirements of the Sarbanes-Oxley
    Act, we may be unable to report our financial results
    accurately. The actions we plan to take are subject to continued
    management review supported by confirmation and testing, as well
    as audit committee oversight. While we expect to remediate these
    significant deficiencies, we cannot assure you that we will be
    able to do so in a timely manner, which could impair our ability
    to report our financial position, results of operations or cash
    flows accurately and timely.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    49
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='110'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">BUSINESS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Overview</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We develop, manufacture and market proprietary Integrated
    Fluidic Circuit systems that significantly improve productivity
    in life science research. Our Integrated Fluidic Circuits, or
    IFCs, integrate a diverse set of critical liquid handling
    functions on a nanoliter scale. Our IFCs can meter, combine,
    diffuse, fold, mix, separate or pump nanoliter volumes of
    fluids, with precise control and reproducibility, many thousands
    of times&#160;&#151; all in parallel on a single chip. This
    technology enables our customers to perform thousands of
    sophisticated biochemical measurements on samples smaller than
    the content of a single cell, with minute volumes of reagents,
    in half the area of a credit card. We achieved this
    &#147;integrated circuit for biology&#148; by miniaturizing and
    integrating liquid handling components on a single
    microfabricated device. Through innovations in material science
    and manufacturing, our IFC architectures are highly flexible,
    and can be designed to support a wide range of applications and
    assay types. Our IFC systems, consisting of instrumentation,
    software and single-use IFCs, increase throughput, decrease
    costs and enhance sensitivity compared to conventional
    laboratory systems. We have sold our IFCs to over 100 customers,
    including many leading biotechnology and pharmaceutical
    companies, academic institutions and life science laboratories
    worldwide.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have commercialized IFC systems for a wide range of life
    science applications, including our BioMark system for gene
    expression analysis, genotyping and digital PCR, and our Topaz
    system for protein crystallization. Researchers and clinicians
    have successfully employed our products to help achieve
    breakthroughs in a variety of fields, including genetic
    variation, cellular function and structural biology. These
    include using our IFC systems to help detect life-threatening
    mutations in patients&#146; cancer cells, discover indicators of
    susceptibility to cancer, manage some of the world&#146;s most
    valuable fisheries, analyze the genetic composition of
    individual stem cells, identify fetal chromosomal abnormalities,
    analyze the infectiousness of the avian flu virus and assess the
    quality of agricultural seed products. We believe that the broad
    applicability of our IFC technology will lead to the development
    of IFC systems for a wide variety of additional markets and
    applications, including molecular diagnostics.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="f39432orf3943217.gif" alt="(IFC FIGURE)">
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Schematic of our 96.96 Dynamic Array IFC including an
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    enlarged section showing four of the IFC&#146;s 9,216 test
    chambers.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The life science industry is currently facing challenges similar
    to those faced by the information technology industry when
    computational power was constrained by the inherent limitations
    of the vacuum tube. Life science research efforts, ranging from
    large-scale initiatives, such as the Human Genome Project, to
    more traditional academic and commercial research projects, are
    continuing to reveal the complex biological and chemical
    processes that are fundamental to living organisms. Automated,
    high-precision and large-scale experimentation is increasingly
    necessary to develop and apply this knowledge. However, the most
    common forms of life science automation rely on cumbersome
    robotic systems that are slow, expensive and labor-intensive
    and, we believe,
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    50
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    fundamentally constrain the pace and productivity of life
    science research. In much the same way that integrated circuits
    overcame the limitations of early computers by placing an
    increasing number of transistors on a single silicon chip, our
    IFCs overcome many of the limitations of conventional laboratory
    systems by integrating an increasing number of fluidic
    components on a single microfabricated IFC.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that much of analytical biology and chemistry can be
    performed more efficiently and more economically in nanoliter,
    or one billionth of a liter, volumes than in conventional
    microliter volume platforms. Moreover, we believe that these
    advantages can be further enhanced through high levels of
    integration. Our IFC systems overcome many of the limitations of
    conventional methods by integrating on a single device the
    ability to perform thousands of experiments at one time and in
    nanoliter volumes. Our IFCs consist of an elastomeric, or
    rubber-like, core bonded to a specialized hard plastic input
    frame. The input frame is compatible with standard laboratory
    workflow equipment and facilitates loading the IFC with samples
    and reagents. Each IFC contains an extensive network of
    microfluidic components, such as valves, channels, pumps, mixers
    and other components that deliver samples and reagents to
    thousands of nanoliter chambers across the IFC where individual
    tests can be performed. This high level of nanofluidic
    integration significantly reduces the time and complexity of
    large-scale experimentation and the volume of costly reagents
    and scarce patient samples required. In addition, our IFC
    systems enable users to address problems that would be difficult
    or impractical to solve using conventional life science tools.
    We believe that our ongoing research efforts to increase the
    density and degree of miniaturization of our IFCs will result in
    further such benefits to our customers.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    Target Markets</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Biotechnology and pharmaceutical companies, academic
    institutions and life science laboratories collectively spent
    approximately $35&#160;billion in 2007 for analytical and life
    science instruments, according to Strategic Directions
    International, or SDI. Growth in the life science equipment and
    supplies industry has been driven in part by increased demand
    for tools that allow researchers to discover how fundamental
    functional elements of biology such as nucleic acids, proteins,
    carbohydrates and cells interact within living organisms. This
    research often entails analyzing or identifying numerous such
    elements across large sample populations. Conducting and
    commercializing this research requires equipment that reliably
    performs experimentation with precision, on a large scale and at
    an affordable cost. The need for equipment with these
    capabilities is particularly evident in the areas of genomics,
    proteomics and molecular diagnostics, which comprise our initial
    target markets.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Genomics</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Genomics is the analysis of nucleic acids, including DNA and
    RNA, the fundamental building blocks of life. The entire DNA
    content of an organism is known as its genome and is commonly
    organized into functional units known as genes. Analysis of
    variations in genomes, genes and gene activity in and between
    organisms can provide tremendous insight into its health and
    functioning. The worldwide demand for genomic analysis
    instruments and supplies was approximately $4.9&#160;billion in
    2005, according to SDI. Of this total, SDI estimated that 56%,
    or about $2.7&#160;billion, was spent on gene expression
    analysis, and 20%, or about $1.0&#160;billion, was spent on
    genotyping. In a 2006 report, SDI projected that the markets for
    gene expression analysis and genotyping would grow approximately
    8% per year from 2005 to 2010.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Gene expression and genotyping today are studied through a
    combination of various technology platforms that characterize
    gene function and genetic variation. Gene expression and
    genotyping are commonly performed using a technique known as
    polymerase chain reaction, or PCR, and often with a chemistry
    known as TaqMan. The PCR method is used to replicate a strand of
    DNA or RNA into millions of copies to facilitate detection in a
    sample. Real time quantitative PCR, or real time qPCR, is a more
    advanced form of PCR that makes it possible to identify the
    number of copies of DNA present in a sample at a certain time.
    According to Frost and Sullivan, the U.S.&#160;market for real
    time qPCR was approximately $741&#160;million in 2007, growing
    at approximately 11% per year from 2005 to 2012. Based on our
    estimates, we believe the global market for real time qPCR was
    approximately $1.7&#160;billion in 2007. Gene expression,
    genotyping and digital PCR are three powerful forms of genomic
    analysis.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Gene Expression Analysis.</I>&#160;&#160;One of the ways
    genes control cellular activity is through a process known as
    gene expression, when a cell transcribes a section of a
    gene&#146;s DNA to create another nucleic acid sequence,
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    51
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>
</TD>
    <TD align="left">
    known as messenger RNA. This messenger RNA may then be
    translated by the cell into a protein. Messenger RNA can be
    detected and quantified by performing real time qPCR tests, or
    assays. Gene expression analysis typically entails determining
    which genes are active by measuring messenger RNA levels in a
    blood or tissue sample. These results can be correlated with
    disease activity and clinical outcomes. As multiple genes are
    involved in most biological processes, gene expression analysis
    usually requires assaying the expression levels of many genes
    simultaneously across many samples. We estimate that
    approximately 80% of the market for real time qPCR involves gene
    expression analysis.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Genotyping.</I>&#160;&#160;Genotyping involves the analysis
    of variations across individual genomes. These variations often
    take the form of single nucleotide changes, known as single
    nucleotide polymorphisms, or SNPs, that can determine the
    characteristics or health of the individual. In SNP genotyping
    studies, the DNA sequences of a group of individuals are
    analyzed to determine patterns of SNPs. Statistical analysis is
    then performed to determine whether a SNP or group of SNPs can
    be associated with a particular characteristic, such as
    propensity for a disease. We estimate that approximately 20% of
    the market for real time qPCR involves genotyping analysis. We
    believe this percentage share of the real time qPCR market is
    growing based on technological innovations allowing increasing
    amounts of genetic content to be analyzed more quickly and cost
    effectively.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Digital PCR.</I>&#160;&#160;Digital PCR is a technique that
    allows researchers to detect nucleic acid sequences that are
    present in a patient sample in concentrations that are too low
    to be detected by conventional methods. Digital PCR typically
    relies on standard PCR techniques, but increases their
    sensitivity by dividing a sample into hundreds or thousands of
    smaller samples and performing a PCR assay on each such sample.
    The ability to actually count the presence or absence of
    amplification in this assay format provides quantitative
    measurement capabilities. Digital PCR has the potential to
    enable early detection of diseases and other conditions, thereby
    improving prospects for effective treatment. In addition, this
    technique enhances the precision of single molecule assays and
    copy number variation. While the digital PCR market is currently
    nascent, we believe it has the potential to grow significantly
    as researchers learn how to apply this technique to a broader
    range of research applications and associated diseases.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Proteomics</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Proteomics is the study of the function and structure of
    proteins. Proteins are produced by all living organisms and
    directly affect cellular function, the overall health of an
    organism and, in the case of pathogens, how the organism
    interacts with its host. Developing drugs to treat a disease
    often involves identifying molecules that are able to interfere
    with the activity of a particular protein in the pathway for
    that disease. One approach to finding such molecules is to first
    determine the structure of the protein and then look for
    molecules that bind to the structure and interfere with the
    activity of the protein. A technique known as protein
    crystallization is typically used to determine protein
    structures. Crystallizing a protein can be a time-consuming and
    labor-intensive process because different proteins will
    crystallize in the presence of different reagents and under
    different conditions. As samples of particular proteins are
    often scarce and expensive, researchers usually conduct only a
    limited number of experiments, none of which might provide a
    crystallized protein.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Molecular
    Diagnostics</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Molecular diagnostic tests are used in clinical practice to
    diagnose, classify or monitor a disease; determine a
    patient&#146;s susceptibility to a disease; or monitor a
    patient&#146;s response to therapy by detecting one or more
    biomarkers, such as nucleic acids or proteins, in a blood,
    tissue or other type of patient sample. The advancement of
    molecular diagnostics is being driven by researchers performing
    large-scale experiments analyzing the prevalence of SNPs,
    variations in gene expression levels and patterns of protein
    production. SNPs, gene expression levels and proteins often
    directly cause or control diseases. Molecular diagnostic tests
    based on measuring these biomarkers have the potential to be
    much more accurate, discriminating and robust than conventional
    diagnostics. According to Frost and Sullivan, the
    U.S.&#160;market for molecular diagnostics was estimated at
    $2.0&#160;billion in 2007, growing at a compound annual growth
    rate of 17% from 2005 to 2012.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    52
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">The
    Limitations of Existing Laboratory Systems</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Scientists increasingly seek to identify and measure a large
    number of characteristics across large populations. The most
    common existing methods of large-scale experimentation require a
    workflow that is complex, labor-intensive and expensive. In this
    workflow, biological samples and chemical compounds, usually in
    solution, are generally dispensed or pipetted into standard
    microwell plates, which usually consist of 96 or 384&#160;wells
    each in a standardized format. The plates may then be moved to
    another station where reagents can be applied to the sample or
    compound to create a single assay in each microwell. The
    microwell plates may be moved again to attain ideal reaction
    temperatures or other conditions. The plates are then generally
    moved into a reader to detect the results of the experiment in
    each well. This process of dispensing materials and conveying
    the plates may include robotically performed steps but generally
    also requires a significant manual labor component. To
    accomplish these steps on a large scale typically requires the
    use of large laboratories equipped with many types of equipment,
    robotics, conveyor systems and personnel.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Conventional microwell plate workflows have a number of
    characteristics that inherently limit their effectiveness as
    tools for large scale experimentation:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Complex Workflow.</I>&#160;&#160;Pipetting stations may have
    to perform hundreds of thousands of pipetting steps using
    hundreds of microwell plates in order to conduct a single set of
    experiments. These microwell plates must typically be moved
    among several work stations to complete and measure the results
    of each assay. Maintaining and overseeing complex workflows
    involving large numbers of microwell plates requires ongoing
    attention from trained technicians.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Limited Throughput.</I>&#160;&#160;Due to the large number of
    pipetting steps, microwell plates and process steps involved in
    a conventional microwell workflow, these systems are often
    unable to perform large-scale experiments in a timely and
    cost-effective manner.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Limited Low Volume Capabilities.</I>&#160;&#160;Conventional
    systems are typically unable to dispense samples and reagents in
    quantities small enough to conduct certain high sensitivity, low
    volume techniques, such as digital PCR.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Large Sample Requirements and Significant Running
    Costs.</I>&#160;&#160;Biological samples are often available in
    only very small quantities. As a result, the sample amount that
    needs to be placed in each well often limits the number of
    experiments that can be performed. In addition, reagents can be
    expensive to purchase or produce, and consuming them in
    microliter or larger quantities results in significant and
    sometimes prohibitive costs.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>High Capital Cost.</I>&#160;&#160;Because of the limited
    throughput of conventional systems, multiple pipetting stations,
    plate handlers and readers may be required to meet the demands
    of large-scale experimentation, resulting in high capital
    equipment costs.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Other methods of large-scale experimentation, including
    microarrays, pre-formatted arrays, bead arrays and mass
    spectrometer analysis, have been developed to address some of
    the limitations of conventional microwell plate systems.
    However, each of these high throughput methods has one or more
    limitations that reduce its utility for large-scale
    experimentation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Microarrays, pre-formatted arrays and bead arrays all lack
    flexibility because researchers must specify the assays they
    wish to perform at the time the products are ordered. This in
    turn limits researchers&#146; ability to refine their assay
    panel during the course of a study. In addition, if researchers
    wish to use assay panels other than a manufacturer&#146;s
    standard panels, it may take weeks for a customized product to
    be produced, and the cost may be significant. Furthermore, it is
    often difficult or impossible to convert existing validated
    assays for use with these technologies or with mass spectrometry
    analysis.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The quality of the data produced by microarrays, pre-formatted
    arrays and mass spectrometer analysis is insufficient for
    certain research activities. For genotyping studies, data
    quality is typically measured by a call rate, which is the
    percentage of time that a method provides a reading with respect
    to a particular SNP. Both pre-formatted arrays and mass
    spectrometer analysis generally have call rates lower than
    conventional microwell plate systems. For gene expression
    studies, it is often important to measure expression levels over
    a broad dynamic range to capture all or most of the variation
    typically found among subjects. None of microarrays,
    pre-formatted arrays,
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    53
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    bead arrays or mass spectrometer analysis routinely measure gene
    expression levels over as broad and dynamic a range as
    conventional microwell plates.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The workflow for bead arrays and mass spectrometer analysis is
    complex, time consuming and expensive. For example, standard
    protocols often require multiple complex operations to be
    performed over several days by skilled technicians.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    These methods can also be very expensive for certain types of
    large-scale experimentation. For example, a single microarray or
    bead array is capable of analyzing thousands of genes from a
    single sample and these devices have been successfully used for
    surveying the genome to discover basic patterns of gene
    expression and genotyping. These surveys or &#147;association
    studies&#148; are commonly performed on tens or hundreds of
    samples and are intended to identify a subset of genes for
    further study. However, for validation studies, which typically
    require the analysis of thousands or tens of thousands of
    samples, the high per sample cost of microarrays and bead arrays
    often make them uneconomical. Similarly, the high initial setup
    costs for mass spectrometry analysis generally make it
    economical only for very large-scale studies.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A number of companies have attempted to develop more universal
    <FONT style="white-space: nowrap">&#147;lab-on-a-chip&#148;</FONT>
    solutions which could perform large numbers of complex
    biochemical operations on a single device. These chips typically
    incorporate a variety of micron-level features, such as channels
    and wells, but lack robust methods of fluid control such as
    valves. As a result, the products have been unable to support
    the complex fluidic manipulation required by large-scale
    experimentation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The limitations of existing technologies become even more acute
    when clinicians attempt to translate scientific research into
    molecular diagnostics. Given the commercial nature of their
    operations, clinical laboratories need systems that can test
    large numbers of patient samples at low cost and with minimal
    labor requirements. Moreover, many of the most promising
    research studies rely on measuring each sample across tens or
    even hundreds of SNPs, gene expression levels or protein
    concentrations to diagnose or classify a disease. We believe
    that using standard microwell plate technology to make multiple
    measurements on a large number of samples is often too complex
    and expensive for most clinical laboratories. As a result, the
    molecular diagnostic tests adopted by clinical laboratories have
    generally been relatively simple or have required specialized
    machines to perform. Diagnostic approaches that require
    measuring large numbers of SNPs, gene expression levels or
    protein concentrations are generally not available or are
    available only from a diagnostic laboratory that specializes in
    the particular test.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To achieve and exploit breakthroughs in genomics, proteomics and
    molecular diagnostics, research and clinical laboratories need
    robust systems that deliver increased throughput and simpler
    workflows with decreased costs.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">The
    Fluidigm Solution</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFC systems are designed to overcome many of the limitations
    of conventional methods by empowering researchers and clinicians
    to rapidly perform a large number of experiments at one time and
    in nanoliter volumes, significantly increasing throughput,
    reducing costs associated with reagents and patient samples and
    reducing the time and number of steps involved. Our IFCs deliver
    these advantages through integration of sophisticated nanoliter
    fluid handling in an easy-to-use format. We believe the
    advantages of our IFC systems can be applied to a wide variety
    of applications across many fields using standard chemistries.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For each application, we provide a complete IFC system
    consisting of specially designed single-use IFCs,
    instrumentation, software and support services. Our IFC systems
    are designed to be easily incorporated into our customers&#146;
    laboratory environments and analysis workflow. For example, our
    IFCs are the same size and shape as standard 384 microwell
    plates, which facilitate the loading and handling of our IFCs by
    standard laboratory equipment. Each IFC includes an elastomeric,
    or rubber-like, core that contains an extensive network of
    microfluidic components, such as valves, channels, pumps, mixers
    and other components that deliver samples and reagents to
    thousands of nanoliter volume chambers where individual assays
    can be performed. In much the same way that semiconductor
    technology has enabled tremendous computational power to be
    placed onto a single silicon chip, the integration of large
    numbers of miniaturized components on our IFCs enables
    sophisticated fluid handling at high throughput and low cost.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    54
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our BioMark 48.48 Dynamic Array IFC allows users to individually
    assay 48 samples against 48 primer-probe sets, generating 2,304
    separate real time qPCR reactions on a single device. In
    December 2007, we completed the development of a prototype 96.96
    Dynamic Array IFC, which is configured to run 96 samples against
    96 primer-probe sets, generating 9,216 separate reactions. We
    expect that our 96.96 Dynamic Array will be commercially
    available in the second half of 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table compares the performance of one conventional
    384 microwell plate to that of one of our 48.48 Dynamic Array
    IFCs and one of our 96.96 Dynamic Array IFCs for a genotyping
    study involving 1,000 samples and 96 SNPs:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="55%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="13%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="13%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="13%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Fluidigm 48.48<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Fluidigm 96.96<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>384 Microwell<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Dynamic Array<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Dynamic Array<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Plate (5 &#181;l/well)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>IFC</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>IFC</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Runs for Study
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    250
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    42
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    11
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total reaction volume
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    480 ml
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    20 ml
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    10 ml
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pipetting Steps
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    192,000
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4,032
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    2,112
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The advantages of our IFC systems over existing microwell-based
    systems include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Reduced Complexity.</I>&#160;&#160;Loading our IFC requires
    orders of magnitude fewer pipetting steps than
    384&#160;microwell plates for the same experiment, which reduces
    the time, cost and potential for error.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Improved Throughput.</I>&#160;&#160;A single IFC based on our
    96.96 format can conduct 9,216 real time qPCR or other assays,
    or 24 times more assays than a single 384 microwell plate. The
    improved throughput reduces the time and cost associated with
    complex experiments and expands the number and range of
    experiments that may be conducted.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Nanoliter Precision.</I>&#160;&#160;Our IFC systems allow
    users to dispense samples and reagents in microliter volumes
    which are automatically combined and mixed in nanoliter and
    sub-nanoliter volumes. In addition to cost and workflow
    benefits, this capability makes it practical for users to
    conduct certain high sensitivity, low volume techniques, such as
    digital PCR and single cell analysis.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Reduced Sample and Reagent
    Requirements.</I>&#160;&#160;Obtaining patient samples for
    assays can also be costly, and in many cases the amount of those
    samples is finite. Our systems typically require between 0.5%
    and 1.0% of the amount of sample and reagent per reaction as
    conventional systems, allowing scarce samples and costly
    reagents to be conserved or tested more extensively.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Decreased Capital Cost.</I>&#160;&#160;A single BioMark
    system has the same throughput as the combined throughput of
    multiple conventional systems. As a result, for high volume
    users, the cost of purchasing one BioMark system can be much
    lower than the cost of purchasing the number of competing
    systems and associated robotic equipment required to provide the
    same throughput, even though our BioMark system may cost more on
    a per unit basis.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Compatibility with Existing
    Infrastructure.</I>&#160;&#160;Our IFCs incorporate plastic
    input frames that are the same size as standard microwell plates
    and are designed to work with the most commonly used laboratory
    systems, including existing robotic pipetting systems, bar code
    readers, plate handling systems and other equipment. Our IFCs
    are also designed to work with standard real time qPCR
    techniques and TaqMan chemistries. As a result, we believe users
    are able to quickly introduce our systems into their
    laboratories and achieve results equal to or better than they
    were obtaining with conventional systems.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFC systems also have significant advantages over other
    high-throughput approaches. For example, our BioMark system can
    detect gene expression levels over a much broader dynamic range
    than microarrays, pre-formatted arrays, bead arrays or mass
    spectrometry analysis. For genotyping, our BioMark system has a
    call rate equal to or better than conventional microwell-based
    systems. Also, our IFC systems provide researchers with needed
    flexibility in assay selection and study design. Unlike
    microarrays, bead arrays and pre-formatted arrays, our IFCs are
    not limited to detecting certain predetermined genetic markers.
    Instead, users can perform experiments with our IFCs using
    assays from their existing libraries, purchased from a wide
    variety of commercial sources or
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    55
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    developed in their own laboratories. Finally, the efficient
    workflow of our IFC systems enables users to complete an IFC run
    in less than three hours.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFC systems address the needs of researchers and clinicians
    who perform large-scale experimentation in the areas of
    genomics, proteomics and molecular diagnostics. In particular,
    for validation studies or projects of a similar scale, our IFC
    systems substantially reduce cost, simplify workflow and
    increase throughput as compared to conventional microwell plate
    systems. Nevertheless, researchers and clinicians may be slow to
    adopt our IFC systems as they are based on technology that,
    compared to conventional technology, is new and not yet
    well-established in the industry. Moreover, many of the existing
    laboratories have already made substantial capital investments
    in their existing systems and may be hesitant to abandon that
    investment. While we believe our systems provide significant
    cost-savings, the initial price of our systems and the price of
    our IFCs is higher than conventional systems and standard
    384&#160;microwell plates. Our IFC systems are less well suited
    for smaller scale research initiatives where complexity and
    workflow issues may be less pressing and conventional systems
    may be more economical. In addition, for very large-scale
    association or survey projects, researchers may choose to use
    microarrays because of the ability of those products to measure
    thousands of genetic markers with a single device. As life
    science research continues to evolve and is commercialized, we
    believe that there will be increasing demand for life science
    automation solutions that enable experimentation on the scale
    supported by our IFC systems.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Applications</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFC technology has the potential to be applied to a vast
    range of research and commercial applications. We have
    commercialized IFC systems for life science research
    applications such as gene expression analysis, genotyping,
    digital PCR and protein crystallization. We believe that these
    applications are relevant to markets beyond life science
    research, such as the development of molecular diagnostics, and
    that IFC systems can be developed for numerous other life
    science applications. We and our academic collaborators have
    developed non-commercial IFCs for a wide variety of applications
    in the areas of genomics, proteomics, cellular biology and
    synthetic chemistry. As illustrated by the examples below,
    researchers have been able to utilize the advantages of our IFC
    systems in their laboratories to achieve significant research
    successes.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Current
    Commercial Applications</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Gene Expression Analysis.</I>&#160;&#160;Researchers may
    conduct gene expression studies to measure the activity of tens
    or hundreds of genes across hundreds or thousands of
    individuals. For these validation studies, it is often important
    to know the expression level of a gene, not merely whether the
    gene is &#147;on&#148; or &#147;off,&#148; as often either high
    or low activity level is associated with a particular
    characteristic or disease state. Our IFC systems have been used
    to deliver high throughput and precise measurements in gene
    expression analysis applications. For example, researchers at
    Myriad Genetics have identified panels of genes that could be
    used to predict cancer progression or select treatment options.
    However, the cost and complexity of high-throughput real time
    qPCR using conventional microwell plates significantly limited
    researchers&#146; ability to perform the appropriate assays. In
    response, Myriad Genetics adopted our BioMark system which,
    together with our Dynamic Array IFCs, has allowed them to
    significantly reduce their pipetting workload, and therefore
    pursue research projects that may have been prohibitively
    cumbersome without our system.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Genotyping.</I>&#160;&#160;Researchers performing genotyping
    studies may begin by surveying the genomes of relatively few
    individuals looking for tens of thousands or even hundreds of
    thousands of SNPs. Analysis of these studies will often reveal
    that a relatively small number of SNPs appear to be correlated
    with the characteristic of interest. In order to validate this
    analysis, researchers may conduct additional studies involving
    hundreds or even thousands of individuals focused on tens or
    hundreds of SNPs. For example, the National Cancer
    Institute&#146;s Core Genotyping Facility, or the CGF,
    collaborates with researchers at other government research
    centers and academic institutions with the goal of developing
    screens to identify individuals susceptible to particular forms
    of cancer and guiding the development of targeted therapeutics.
    One of the CGF&#146;s primary responsibilities in these
    collaborations is conducting the large-scale experiments
    necessary to accurately interrogate hundreds of SNPs on many
    patient samples. In a typical association study, the CGF runs 30
    to 300 assays on 1,000 to 10,000&#160;patient samples. Such
    large-scale studies are difficult and expensive to perform with
    conventional microwell plate technology. Using our
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    56
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    BioMark system, the CGF continues to perform the same assays
    previously developed in its existing library of over 5,000
    assays.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Genotyping analysis is also used in situations where research
    has already identified particular genetic profiles of interest
    and there is a need to test a group of subjects to determine
    which profile they fit. For example, the Alaska Department of
    Fish and Game uses our BioMark system to perform genotyping
    analysis to determine the region of origin of salmon caught in
    commercial or sport fisheries. By analyzing a large number of
    salmon, the department can gain an understanding of the effects
    that fisheries have on populations of salmon and thereby manage
    the resource more effectively. The department has developed
    panels for three species which range from 40 to 60 SNPs, and
    their throughput approaches 100,000 samples per year.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Digital PCR.</I>&#160;&#160;The widespread use of genetic
    testing in high-risk pregnancies has created strong interest in
    rapid and accurate molecular diagnostics for certain common
    chromosomal abnormalities. However, conventional methods have
    limitations related to speed, precision and the risks associated
    with sampling a significant amount of material from the fetus
    during an invasive procedure such as amniocentesis or chorionic
    villi sampling. Digital PCR has been identified as a technique
    for highly sensitive and precise nucleic acid measurement, but
    performing it with conventional laboratory equipment is so
    cumbersome that it has not been widely adopted. In an article
    published by Analytical Chemistry in August 2007, researchers at
    the laboratory of Professor Stephen Quake, our
    <FONT style="white-space: nowrap">co-founder,</FONT>
    at Stanford University demonstrated that digital PCR can be used
    for accurate measurement of trisomy&#160;21, or Down syndrome.
    Using our Digital Array IFC and DNA from human cell lines,
    Dr.&#160;Quake&#146;s laboratory was able to precisely measure
    the number of copies of a DNA sequence from this chromosome and
    at the same time measure the number of copies of a DNA sequence
    from another chromosome whose copy number does not vary. For
    trisomy 21, the ratio of these markers is significantly higher
    than normal. Similar work in pre-natal genetic testing is being
    pursued using our IFCs by other customers at leading academic
    institutions. We believe that with further clinical validation
    and development, such research could be developed into a
    diagnostic test that would require significantly less material
    from the fetus and deliver and answer much more rapidly than
    current methods. We also believe that digital PCR will enable
    such diagnostics to ultimately be used in a non-invasive
    fashion, thus further reducing risk to the fetus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Similarly, cancer researchers who have identified a particular
    mutation in chronic myeloid leukemia cells that render those
    cells resistant to the drug Gleevec. Gleevec is typically used
    as the initial treatment for this type of leukemia and is often
    able to put the disease into remission for months or years.
    However, a significant proportion of these leukemia patients
    eventually develop mutated leukemia cells that are resistant to
    Gleevec. These mutated cells are initially very scarce and
    undetectable using conventional systems, but they eventually
    multiply and cause the patient to become symptomatic again.
    Researchers at the Fred Hutchinson Cancer Research Center have
    used our Digital Array IFC in their laboratory to test patient
    samples and have been able to detect these mutated cells earlier
    than with conventional techniques. With additional validation
    and demonstration of clinical relevance, we believe a test based
    on digital PCR could be a useful tool for monitoring patients
    who are diagnosed with chronic myeloid leukemia.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Protein Crystallization.</I>&#160;&#160;In order to determine
    how a particular protein interacts with other components of a
    disease pathway, researchers often attempt to determine its
    structure using protein crystallization. Because most proteins
    will crystallize only under very specific conditions, protein
    crystallization involves performing numerous assays to determine
    the conditions under which the protein can be crystallized. As
    described in the April&#160;21, 2006 issue of <I>Science</I>,
    the Scripps Research Institute in La&#160;Jolla, California used
    our Topaz system to understand how the H5N1 Avian Flu virus
    infects humans. The lab had a very small sample of the protein
    that the virus uses to attach itself to cells. With the Topaz
    system, they were able to quickly screen a few microliters of
    the sample across a wide variety of different conditions and
    determine the optimum conditions for protein crystallization.
    With this information, they then created a larger crystal using
    standard crystallization techniques. Analysis of the structure
    of the crystallized protein revealed why the current form of the
    H5N1 virus is less infectious among humans than other flu
    viruses.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    57
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Potential
    Future Applications</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Molecular Diagnostics.</I>&#160;&#160;Life science research
    is revealing an increasing number of diseases and conditions
    that can be diagnosed, evaluated and monitored by measuring
    panels of gene expression levels, SNPs, proteins or other
    biomarkers. Validating these research findings and translating
    them into clinically available tests often requires life science
    automation systems that are able to efficiently measure multiple
    biomarkers in a large number of patient samples. Our existing
    IFC systems are able to measure certain nucleic acid biomarkers
    that are commonly used in these tests, and we expect that we
    will be able to develop IFC systems to measure other relevant
    biomarkers. As described above, researchers have used our IFC
    systems to detect clinically relevant biomarkers, such as drug
    resistant leukemia cells and fetal chromosomal abnormalities. We
    believe that the high throughput, flexibility and simplified
    workflow of our IFC systems could make them an attractive
    solution for validating and commercializing a wide range of
    molecular diagnostic tests being developed by researchers. In
    addition, we believe that our IFC systems&#146; ability to
    measure gene expression levels across a broad range and to
    detect nucleic acid sequences present in very low concentrations
    will support the development and commercialization of molecular
    diagnostic tests that would not be practical with conventional
    systems. Our IFC systems have not been cleared or approved by
    the U.S.&#160;Food and Drug Administration, or FDA, for use in
    any molecular diagnostic tests and we cannot currently market
    them for the purpose of performing molecular diagnostic tests.
    We do not have any current plans to develop products that are
    regulated by the FDA.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Other Applications.</I>&#160;&#160;We believe that the
    inherent design flexibility of our core technology allows us to
    build IFC systems that can provide significant benefits in a
    wide range of fields and industries. For example, the
    architecture of our Dynamic Array is flexible and supports the
    development of IFCs that create matrixed combinations of a
    variable number of samples versus a variable number of reagents.
    In addition, our IFC technology utilizes a variety of
    microfluidic components, such as pumps, mixers and separation
    columns, that allow the implementation of sophisticated
    biochemical processes on our IFCs. While we have not commenced
    commercial development of IFC systems for these fields, we have
    developed IFCs for internal research purposes in such diverse
    fields as:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    immunoassays, which can measure levels of protein expression and
    other molecules in a highly-parallel, multiplexed format;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    high-throughput drug screening, including the analysis of
    molecules that inhibit protein-protein and protein-nucleic acid
    interactions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    chemical synthesis, including production of radio-labeled sugars
    which in combination with advanced medical imaging can help
    diagnose and monitor cancer;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    pharmacogenomics, an emerging field that analyzes how variations
    in human genomes affect the performance and toxicity of
    therapeutic agents;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    systems biology, an effort to understand the collective behavior
    of genes as they collaborate in networks;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    synthetic biology, an emerging field aimed at engineering
    biological systems to build novel biological functions, systems
    and perhaps organisms; and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    cellular assays, including stem cells and regenerative medicine,
    where our IFCs have been used to isolate, cultivate and analyze
    single cells.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, there have been a variety of publications by
    independent researchers demonstrating the use of multi-layer
    soft lithography, or MSL, for applications such as immunoassays
    based on surface-plasma resonance, cell culturing, and
    complementary DNA library synthesis from single cells.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Strategy</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We intend to become a global leader in providing automated
    bio-analytical research and molecular diagnostic systems. Our
    business strategy consists of the following elements:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Establish our IFC Technology as the Leading Solution for a
    Broad Range of Life Science Applications.</I>&#160;&#160;Our
    initial sales and marketing efforts have been focused on
    establishing our IFC systems as leading solutions
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    58
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    for high throughput life science research applications. We
    intend to leverage the market awareness and acceptance created
    by our initial product offerings to market new products and
    applications to life science researchers and to sell new and
    existing applications to customers in other markets, such as
    molecular diagnostics and applied genomics.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Continue to Increase the Throughput and Efficiency of Our
    IFCs.</I>&#160;&#160;A primary focus of our research and
    development efforts is the development of IFCs with increased
    component density and, therefore, the ability to conduct an
    increased number of experiments on a single IFC. Increasing
    density provides value to our customers by increasing
    throughput, enhancing efficiency, reducing labor costs and
    reducing reagent and sample volumes. We expect that these
    increased capacity IFCs will allow us to deliver additional
    capabilities and cost savings, and further improve our
    competitive position.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Expand Recurring IFC Revenue Stream Through Product
    Innovation and System Sales.</I>&#160;&#160;We intend to drive
    revenue growth by increasing the number of installed IFC
    systems, improving the cost per test of our IFCs and developing
    IFCs and systems for additional applications.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Provide Superior Customer Service.</I>&#160;&#160;We have a
    global sales force and support organization that offers
    technical solutions and customer support through direct
    relationships with our current and potential customers. Through
    the direct connection with our customers, we are able to better
    understand their needs and apprise them of new product offerings
    and technological advances in our current IFC systems, related
    instrumentation and software, while maintaining a consistent
    marketing message and high level of customer service.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Enhance IFC Manufacturing Efficiency.</I>&#160;&#160;We
    intend to enhance our manufacturing efficiency through
    improvements in our existing processes, development of new IFC
    designs and implementation of new manufacturing methods in order
    to improve our manufacturing yields and reduce our manufacturing
    costs. We believe that these improvements will enable us to
    deliver additional value to our customers and to maintain or
    enhance our advantages over competing systems.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Continue to Develop our Technology and Intellectual Property
    Position.</I>&#160;&#160;Our products are based on a set of
    related proprietary technologies that we have either developed
    internally or licensed from third parties. We intend to continue
    making significant investments in research and development to
    further expand and deepen our technological base. At the same
    time, we intend to maintain and strengthen our intellectual
    property position through the continued filing and prosecution
    of patents in the United States and internationally and through
    the in-licensing of third party intellectual property as
    appropriate.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Products</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We currently market two IFC systems, the BioMark system for real
    time qPCR and the Topaz system for protein crystallization. Each
    system consists of single-use IFCs, loaders that control the
    IFCs, readers that detect reactions on the IFCs and software for
    analyzing, annotating and archiving the data produced by the
    readers.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    BioMark System for Real Time qPCR</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The BioMark system allows users to perform gene expression
    analysis, genotyping and digital PCR using standard TaqMan
    chemistry.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">BioMark
    Dynamic Array IFCs</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our BioMark 48.48 Dynamic Array IFC is based on matrix
    architecture that allows users to individually assay 48 samples
    against 48 primer-probe sets, generating 2,304 real time qPCR
    reactions on a single device. One version of this IFC is
    optimized to perform gene expression analysis and another is
    optimized for genotyping, each assay in volumes of
    10&#160;nanoliters or less.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We commercially introduced our Dynamic Arrays in the fourth
    quarter of 2006 and, as of March&#160;29, 2008, 23 customers
    have purchased Dynamic Array IFCs for use in applications, such
    as SNP association follow-up studies and single stem-cell gene
    expression profiling. In December 2007, we completed the
    development of a prototype 96.96 Dynamic Array IFC, which is
    configured to run 96 samples against 96 primer-probe sets,
    generating 9,216
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    59
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    reactions. We expect to release evaluation prototypes of this
    IFC to customers in the second half of 2008 and expect that it
    will be commercially available in the second half of 2008.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">BioMark
    Digital Array IFCs</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The BioMark 12.765 Digital Array IFC is based on partitioning
    architecture that allows users to divide 12&#160;separate
    samples into 765 smaller samples and perform a real time qPCR
    assay against each sample in less than 10&#160;nanoliter
    volumes. This IFC can be used for digital PCR and to precisely
    quantify the amount of a particular nucleic acid sequence
    present in a sample. We have been selling Digital Array IFCs
    since March 2007 and, as of March&#160;29, 2008, 14 customers
    have purchased Digital Array IFCs for use in applications, such
    as characterizing unculturable bacteria and cancer detection.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">BioMark
    Instrumentation and Software</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our NanoFlex IFC Controller for the BioMark system fully
    automates the setup of IFCs for real time qPCR-based experiments
    and includes software for implementing and tracking experiments.
    The instrumentation for our BioMark system controls the real
    time qPCR process and detects the fluorescent signals generated
    using a white light source, emission and excitation filters,
    precision lenses, a licensed thermal cycler and a digital
    camera. We also offer various software packages that provide
    data analysis following data collection. Our analysis software
    shows data as color-coded maps of every position on the IFC, as
    amplification curves and as numeric tabular data.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    Topaz System for Protein Crystallization</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Topaz system allows users to screen protein samples against
    a set of reagents in order to determine the optimum conditions
    for crystallizing a protein. The Topaz system includes IFCs
    similar to our Dynamic Array architecture that have been
    optimized for highly efficient protein crystallization screening.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Topaz
    Screening IFCs and Reagents</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our 1.96, 4.96 and 8.96 Screening IFCs for our Topaz system
    allow users to test 96 different reagents or reagent
    concentrations against one, four or eight different protein
    samples. We estimate that our screening IFCs require only
    1%&#160;the amount of sample used in standard microwell plate
    technologies, which is important because protein samples are
    often extremely scarce or difficult to prepare. The 4.96 and
    8.96 IFCs provide greater fluid handling efficiency by enabling
    the parallel processing of different samples containing a
    particular protein or different constructs of the same protein
    on a single IFC. This parallel processing saves pipetting steps
    and allows the user to determine the best sample or construct to
    use when scaling up production of a protein to generate
    diffraction-quality crystals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We also re-sell third party reagents that we have tested with
    our Topaz system. Though our customers may purchase or make
    their own reagents for use with our system, we recommend that
    they use reagents that we have validated.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We commercially introduced our Topaz systems in the first
    quarter of 2003 and, as of March&#160;29, 2008, 75 customers
    have purchased Topaz IFCs for use in applications such as
    functional studies and structure-based drug design.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Topaz
    Instrumentation and Software</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The NanoFlex IFC controller for the Topaz system fully automates
    the setup of diffusion-based protein crystallization experiments
    and includes software for tracking experiments.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Topaz AutoInspeX II workstation automates the scanning of
    Topaz IFCs and the identification of reaction chambers where
    crystallization has occurred. The AutoInspeX II incorporates
    high-end optical performance and a full suite of software for
    analyzing and archiving crystallization results. The
    sophisticated instrumentation and software included in our Topaz
    system enables users to automatically image and accurately score
    crystals as small as 10 microns by 20 microns.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    60
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Sales and
    Marketing</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We distribute our systems through our direct field sales and
    support organizations located in North America, Europe and Asia
    and through distributors or sales agents in several European
    countries. Our global sales force is able to apprise our current
    and potential customers of new product offerings and
    technological advances in our current IFC systems, related
    instrumentation and software to help drive revenue growth. As
    our primary point of contact in the marketplace, our sales force
    ensures a consistent marketing message and high level of
    customer service, while enhancing our understanding of customer
    needs. As of December&#160;29, 2007, we had 24 people employed
    in sales, sales support and marketing, including 9 sales
    representatives.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our sales and marketing efforts are targeted at laboratory
    directors and principal investigators at leading companies and
    institutions who need reliable, high throughput life science
    automation solutions to conduct large-scale experimentation. We
    seek to increase awareness of our products among our target
    customers through participation in tradeshows and academic
    conferences including sponsoring scientific lectures by
    prominent users of our systems. Because our systems are
    relatively new and require a capital investment, the sales
    process typically involves numerous interactions and
    demonstrations with multiple people within an organization. In
    addition, potential customers will often wish to conduct
    in-depth evaluations of the system including running identical
    sets of samples and reagents on both our system and competing
    systems. As a result of these factors and the budget cycles of
    our customers, our sales cycle, the time from initial contact
    with a customer to our receipt of a purchase order, can often be
    12&#160;months or longer.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Customers</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have sold our BioMark and Topaz systems to a wide variety of
    biotechnology and pharmaceutical companies and to academic,
    governmental and clinical research institutions. As of
    March&#160;29, 2008, 75 of our Topaz systems have been installed
    at customer sites and 20 of our BioMark systems have been
    installed at customer sites. The following is a list of our
    representative customers in each of the listed markets.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="36%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="19%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="40%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Customer</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Market</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Application</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    MedImmune
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Gene Expression
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Pharmaceutical drug development&#160;&#151; real time qPCR for
    gene expression profiling in research and clinical trials
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Myriad Genetics
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Gene Expression
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Cancer and diagnostics research&#160;&#151; real time qPCR for
    differential gene expression in cancer studies
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Merck &#038; Co.
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Gene Expression
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Gene expression profiling for pharmaceutical drug development
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Alaska Department of Fish and Game
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Genotyping
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Government wild-life resource management&#160;&#151; SNP
    genotyping for identification of salmon species
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    National Cancer Institute
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Genotyping
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Academic basic research; clinical diagnostics
    research&#160;&#151; genotyping for cancer research
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Chinese University of Hong Kong
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Digital PCR
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Academic basic research; clinical diagnostics
    research&#160;&#151; digital PCR for early cancer detection
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Vertex Pharmaceuticals
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Protein crystallization
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Pharmaceutical drug discovery
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Revenue Concentration.</I>&#160;&#160;We receive a
    substantial portion of our revenue from a limited number of
    customers and grantors. For the year ended December&#160;29,
    2007, the Singapore Economic Development Board, or EDB,
    accounted for 24% of our total revenue. For the year ended
    December&#160;31, 2006, CTI Molecular Imaging accounted for 16%
    of our total revenue, Kikotech Co., Ltd. accounted for 14% of
    our total revenue and EDB accounted for 14% of our total
    revenue. For the year ended December&#160;31, 2005, Kikotech
    accounted for 16% of our total revenue and a collaboration
    agreement accounted for 14% of our total revenue. We anticipate
    that we will continue to be
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    61
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    dependent on a limited number of customers and grantors for a
    significant portion of our revenue in the near future. The loss
    of any of these customers could have a material adverse effect
    on our results of operations and cash flows.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Competition</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We compete with both established and development stage life
    science companies that design, manufacture and market
    instruments for gene expression analysis, genotyping, other
    nucleic acid detection and additional applications using
    established laboratory techniques. For example, companies such
    as Affymetrix, Applied Biosystems, BioTrove, Illumina, Roche
    Diagnostics and Sequenom have products for gene expression
    <FONT style="white-space: nowrap">and/or</FONT>
    genotyping that compete in certain segments of the market in
    which we sell our BioMark system. In addition, a number of other
    companies and academic groups are in the process of developing
    novel technologies for genetic analysis, many of which have also
    received grants from the National Human Genome Research
    Institute, a branch of the National Institutes of Health.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The high-throughput life science platforms industry is highly
    competitive and expected to grow more competitive with the
    increasing knowledge gained from molecular biology
    experimentation. Many of our competitors are either
    publicly-traded or are divisions of publicly-traded companies
    and enjoy several competitive advantages over us, including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    significantly greater name recognition;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    greater financial and human resources;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    broader product lines and product packages;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    larger sales forces;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    larger and more geographically dispersed customer support
    organization;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    substantial intellectual property portfolios;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    established customer bases and relationships;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    greater experience in research and development, manufacturing
    and marketing.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that the principal competitive factors in our markets
    include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    cost of capital equipment and supplies;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    ease of use;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    accuracy and reproducibility of results;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    compatibility with existing laboratory processes.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In order to successfully compete with existing products and
    future technologies, we will need to demonstrate to potential
    customers that the cost savings and performance of our
    technologies and products, as well as our customer support
    capabilities, are superior to those of our competitors.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Technology</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our products are based on a tiered set of related proprietary
    technologies that we have either developed internally or
    licensed from third parties.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Multi-Layer
    Soft Lithography</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFCs are manufactured using a technology known as
    multi-layer soft lithography, or MSL. With MSL, we are able to
    use standard semiconductor manufacturing techniques, along with
    certain proprietary processes, to create complex integrated
    microfluidic devices.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Using MSL technology, we are able to create valves, chambers,
    channels and other fluidic components on our IFCs at high
    density. We combine these components in complex arrangements
    that allow nanoliter quantities of
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    62
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    fluids to be precisely directed to specific positions within the
    IFC. Unlike most prior microfluidic technologies, our IFCs do
    not rely on electricity, magnetism or similar approaches to
    control fluid movement. Rather, our IFCs control fluid flow with
    valves. The most important components on our IFCs are our
    NanoFlex valves, which are created by the intersection of two
    channels. When the valve is open, fluid is able to flow through
    the lower channel. When the upper or &#147;control&#148; channel
    is pressurized, the material separating the two channels is
    deflected into the lower channel, closing the valve and stopping
    fluid flow. If pressure is removed from the control channel, the
    channels return to their original form, and the valve is again
    open. The elastomeric properties of IFC cores allow our NanoFlex
    valves to form a reliable seal and cycle through millions of
    openings and closings.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The elastomer we currently use for our commercial products is a
    form of silicone rubber known as polydimethylsiloxane, or PDMS,
    but we have researched other materials with different properties
    for specific purposes. PDMS is transparent, which allows fluid
    movement to be easily monitored with a variety of existing
    optical technologies, such as bright field or phase contrast
    microscopy. In addition, the gas permeability of PDMS allows the
    reliable metering of fluids with near picoliter precision by
    eliminating the bubble problems encountered by most other
    microfluidic technologies. In essence, we are able to pump
    fluids into closed reaction chambers at sufficient pressure to
    drive any air out of the chamber directly through the chamber
    walls. PDMS also supports an environment that is favorable to
    maintaining cell cultures.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have developed commercial manufacturing processes to
    fabricate valves, channels and chambers with dimensions in the
    10 to 100 micron range, at high density and with high
    reliability. For research purposes, we have created devices with
    both substantially smaller and larger features. Though our
    manufacturing is based on standard semiconductor manufacturing
    technologies and techniques, we have also developed novel
    processes for mold fabrication that enable mass production of
    high density IFCs with nanoliter volume features.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Integrated
    Fluidic Circuits</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFCs incorporate several different types of technology that
    together enable us to use MSL to rapidly design and deploy new
    microfluidic applications.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Microfluidic Components.</I>&#160;&#160;The first level of
    our IFC technology is a library of components that perform basic
    microfluidic functions. We have proven designs for numerous
    elements, such as pumps, mixers, separation columns, control
    logic and reaction chambers. These are readily integrated to
    create circuits capable of performing a wide range of
    biochemical reactions. Even when it is necessary to integrate
    multiple elements to perform a particularly complex reaction,
    the area taken up on a circuit for a single reaction is small
    compared to a typical overall circuit size of three centimeters
    by three centimeters. As a result, we are routinely able to
    develop IFCs that perform thousands of reactions per square
    centimeter.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Architectures.</I>&#160;&#160;The second level of our IFC
    technology comprises the architectures we have designed to
    exploit our ability to conduct thousands of reactions on a
    single IFC. The first of these is the Dynamic Array, a matrix
    architecture that allows multiple different samples and multiple
    different reagents to be loaded onto a single IFC and then
    combined so that there is an isolated reaction between each
    sample and each reagent. The primary advantage of this
    architecture is that each sample and reagent has to be pipetted
    only once per IFC rather than once per reaction, as is the case
    with plate-based technologies. For example, a single 48.48
    Dynamic Array IFC can perform a total of 2,304 unique reactions
    between 48 samples and 48 reagents with only 96 pipetting steps.
    With conventional microwell plate-based technologies, the same
    experiment would require about 4,608 pipetting steps and at
    least six conventional microwell plates. Our Digital Array
    architecture provides similar benefits with respect to pipetting
    steps and fluid handling. The Digital Array architecture allows
    a sample to be split into hundreds or thousands of smaller
    samples. Separate reactions can then be conducted on each of the
    smaller samples.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Interface and Handling Frames.</I>&#160;&#160;The third level
    of our IFC technology involves the interaction of our IFCs with
    the actual laboratory environment. The elastomeric blocks at the
    center of our IFCs sit in specially designed frames that are
    able to deliver samples and reagents to the block. These frames
    are the same size as standard 384&#160;microwell plates and have
    sample and reagent input ports laid out in a standard
    384&#160;microwell plate format. As a result, our IFCs can be
    loaded with standard laboratory pipetting robots and can be used
    with standard plate handling equipment.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    63
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Technological Advances.</I>&#160;&#160;In the second quarter
    of 2002, we sold the first prototype of our 1.48 IFC for our
    Topaz system, which featured 22 valves capable of 2.5 assays per
    square centimeter. In the second quarter of 2006, we introduced
    our 12.765&#160;Digital Array IFC, with over 1,000 valves
    capable of more than 1,000 assays per square centimeter, a
    46-fold increase in valve density and a 400-fold increase in
    assay capability. The chart below illustrates the timing of a
    number of our technological advances. We expect to ship the
    first prototype of our 96.96&#160;Dynamic Array IFC in the
    second half of 2008, which will again increase the number of
    valves and assays per square centimeter relative to the
    48.48&#160;Dynamic Array. In the semiconductor industry,
    Moore&#146;s Law describes the principle that the shrinking of
    features has allowed for a doubling of transistors on a chip
    approximately every 18&#160;months. Based on manufacturing
    processes borrowed from those in the semiconductor industry,
    Fluidigm has similarly achieved exponential gains in the density
    and productivity of our IFCs.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="f39432orf3943222.gif" alt="(BAR GRAPH)">
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Software
    and Instrumentation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have developed instrumentation technology to load samples and
    reagents on to the IFC and to control and monitor reactions
    within our IFCs. Our NanoFlex controller consists of commercial
    pneumatic components and both custom and commercial electronics.
    It uses precise control of multiple pressures to independently
    move fluid through up to four IFCs simultaneously and can be
    configured for use with either our BioMark or Topaz systems. Our
    Topaz Auto-InspeX II workstation consists of a commercial
    microscope, illumination source, stage and camera system in a
    single package. Our BioMark system consists of a commercial
    thermal cycler packaged with a sophisticated fluorescence
    detection system. All of these instruments are designed to be
    easily introduced into standard automated lab environments.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have developed specialized software packages to manage and
    analyze the unusually large amounts of data produced by our
    systems. Our BioMark gene expression analysis software
    automatically identifies individual real time qPCR reactions
    from fluorescent images and generates amplification threshold
    crossing values allowing researchers to readily perform complete
    normalized comparative gene expression analysis across large
    numbers of samples and assays. Similarly, the BioMark genotyping
    analysis software automatically clusters fluorescent intensities
    from individual genotype reactions and makes genotype calls
    across individual and multiple IFC runs. Our Topaz system
    software incorporates sophisticated image processing and
    analysis functionality that enables the automatic detection and
    classification of protein crystals. Most of our software
    development uses Microsoft.NET tools to facilitate interaction
    with typical laboratory information management systems.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Manufacturing</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our manufacturing operations are located in Singapore and South
    San&#160;Francisco. Our Singapore facility fabricates all of our
    IFCs for commercial sale. IFCs for research and development
    purposes are fabricated at both
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    64
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    locations. We manufacture instrument systems at both locations,
    with certain instruments assembled in Singapore and others in
    South San&#160;Francisco.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Singapore facility commenced operations in October 2005 and
    established full process capability for its first product, the
    Topaz Screening IFC, in June 2006 and for its first Dynamic
    Array, the 48.48 Dynamic Array in October 2006. Our Singapore
    facility has been producing components for our Topaz system
    since October 2006 and components for our BioMark system since
    December 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We established our manufacturing facility in Singapore to take
    advantage of the skilled workforce, supplier and partner
    network, lower operating costs and government support available
    there. Our IFC manufacturing process includes photolithography
    and fabrication technologies that are very similar to those used
    in the fabrication of semiconductor chips. As a result, we are
    able to hire from a pool of skilled manpower created by the
    existing semiconductor industry in Singapore. Similarly, the
    Singapore semiconductor industry has created a broad network of
    potential suppliers and partners for our manufacturing
    operations. We are able to locally source a large proportion of
    the raw materials required in our processes and have been able
    to collaborate with local engineering companies to develop
    enabling technologies for IFC fabrication. We have made
    significant improvements in yields through process improvements
    at our Singapore facility and IFC production increased
    three-fold in 2007 compared to 2006.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our manufacturing operations in Singapore have been supported by
    grants from the Singapore Economic Development Board which
    provide partial reimbursement of qualifying costs arising from
    research and development projects relating to our manufacturing
    process. Our arrangements with the Singapore Economic
    Development Board require us to maintain a significant and
    increasing manufacturing and research and development presence
    in Singapore.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our South San&#160;Francisco facility began producing Topaz
    systems in 2002. In 2005, our South San Francisco facility began
    assembling instrumentation for our BioMark system.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We expect that our existing manufacturing capacity for
    instrumentation and IFCs is sufficient to meet our needs for at
    least the next two years. However, we are considering developing
    additional capacity in order to ensure that all or most of our
    products are produced by at least two different facilities. We
    believe that having dual sources for our products would help
    mitigate the potential impact of a production disruption at any
    one of our facilities and that such redundancy may be required
    by our customers in the future. We have not determined the
    timing or location of any additional manufacturing capacity.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We rely on a limited number of suppliers for certain components
    and materials used in our systems. While we are in the process
    of qualifying additional sources of supply, we cannot predict
    how long that qualification process will last. If we were to
    lose one or more of our limited source suppliers, it would take
    significant time and effort to qualify alternative suppliers.
    Key components in our products that are supplied by sole or
    limited source suppliers include a thermal cycler customized to
    our specifications, a specialized polymer from which our IFC
    cores are fabricated, the plastic carrier that holds the IFC
    core in certain of our products and the specialized high
    resolution camera lenses used in the reader for our BioMark
    system. We are neither a major customer of our suppliers, nor do
    we have long term supply contracts with most of these suppliers.
    These suppliers may therefore give other customers&#146; needs
    higher priority than ours, and we may not be able to obtain
    adequate supply in a timely manner or on commercially reasonable
    terms.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Research
    and Development</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have assembled experienced research and development teams at
    our South San&#160;Francisco and Singapore locations with the
    scientific, engineering, software and process talent that we
    believe is required to grow our business.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">New
    Product and Application Development</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The largest component of our current research and development
    effort is in the areas of new product and new application
    development. In particular, we are focused on extending and
    supporting the BioMark and Topaz product lines by developing new
    DNA-based applications, improving the introduction of these
    products into existing workflows of our customers and increasing
    the functionality of the products. For example, the addition of
    multi-
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    65
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    color analysis allows Digital Array users to analyze as many as
    36,720 real time qPCR assays in parallel on a single Digital
    Array.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are also developing new product lines that leverage our
    investment in our Dynamic Array and Digital Array architectures.
    As an example, we have demonstrated Dynamic Array formats that
    can implement over 1,000 immunoassays in parallel. We also
    invest in extending the reach of existing chip designs through
    new chemistries. From time to time, we collaborate with other
    life science companies, universities and government labs on the
    development of prototype IFCs for particular purposes.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Process
    Development</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The second component of our research and development effort is
    process development. We frequently develop new manufacturing
    processes and test methods to support new IFC designs, drive
    down manufacturing cost and increase manufacturing throughput.
    We also invest in manufacturing automation, process changes and
    design modifications in order to improve yield and lower costs
    on existing IFCs.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">New
    Technology Development</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have active research and development efforts to increase the
    density of components on our IFCs and to lower the materials
    cost of our current production methods. We are evaluating new
    materials that can increase the functionality of existing
    products and that would allow our IFCs to be used for a wider
    variety of biological and chemical reactions. Over the longer
    term, we are seeking ways to transfer functionality from
    instrumentation to IFCs to support development of field-based
    and point-of-care applications.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our research and development expenses were $11.4&#160;million,
    $15.6&#160;million and $14.4&#160;million in 2005, 2006 and
    2007. As of December&#160;29, 2007, 68 of our employees were
    engaged in research and development activities.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Scientific
    Advisory Board</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We maintain a scientific advisory board consisting of members
    with experience and expertise in the field of microfluidic
    systems and their application, who provide us with consulting
    services. On March&#160;29, 2008, our scientific advisory board
    consisted of the following members:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Stephen Quake, Ph.D.</I> is a co-founder of Fluidigm and the
    chair of our scientific advisory board. He is a co-chair of the
    bioengineering department at Stanford University and an
    investigator of the Howard Hughes Medical Institute.
    Dr.&#160;Quake received a B.S. in Physics and a M.S. in
    Mathematics from Stanford University and a Ph.D. in Physics from
    Oxford University.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Frances Hamilton Arnold, Ph.D.</I> is the Dick and Barbara
    Dickinson Professor of chemical engineering and biochemistry at
    the California Institute of Technology. She is a member of the
    National Academy of Engineering and a fellow at the American
    Institute for Medical and Biological Engineering.
    Dr.&#160;Arnold received a B.S. in Mechanical and Aerospace
    Engineering from Princeton University and a Ph.D. in Chemical
    Engineering from the University of California, Berkeley.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>James M. Berger, Ph.D.</I> is a Professor of Biochemistry and
    Molecular Biology at the University of California, Berkeley and
    a member of the Physical Biosciences Division, Lawrence Berkeley
    National Laboratory. Dr.&#160;Berger received a B.S. in
    Biochemistry from the University of Utah and a Ph.D. in
    Biochemistry from Harvard University.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Frank McCormick, Ph.D.</I> is the David A. Wood Distinguished
    Professor of Tumor Biology and the E. Dixon Heise Distinguished
    Professor in Oncology at the University of California,
    San&#160;Francisco, or UCSF. He is also the director of
    UCSF&#146;s Comprehensive Cancer Center. He is a member of the
    Institute of Medicine and a fellow of The Royal Society.
    Dr.&#160;McCormick received a B.Sc. in Biochemistry from the
    University of Birmingham and a Ph.D. in Biochemistry from the
    University of Cambridge.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Howard M. Shapiro,&#160;M.D.</I> is a lecturer on Pathology
    at Harvard Medical School, a visiting scientist at the
    Rosenstiel Basic Medical Sciences Research Center at Brandeis
    University and a research associate in
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    66
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Medicine and Pathology at Beth Israel Hospital. Dr.&#160;Shapiro
    received a B.A. from Harvard College and an M.D. from New York
    University School of Medicine.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Richard N. Zare,&#160;Ph.D.</I> is the Marguerite Blake
    Wilbur Professor of Natural Science and chair of the chemistry
    department at Stanford University. He is a member of the
    National Academy of Sciences, the American Academy of Arts and
    Sciences and the recipient of the National Medal of Science.
    Dr.&#160;Zare received a B.S. in Chemistry and Physics and a
    Ph.D. in Chemical Physics from Harvard University.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Intellectual
    Property Strategy and Position</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Fluidigm&#146;s core technology originated at the California
    Institute of Technology, or Caltech, in the laboratory of
    Professor Stephen Quake, who is a co-founder of Fluidigm.
    Dr.&#160;Quake, his students and their collaborators pioneered
    the application of multilayer soft lithography in the field of
    microfluidics. In particular, Dr.&#160;Quake&#146;s laboratory
    developed technologies that enabled the production of
    specialized valves and pumps capable of controlling fluid flow
    at nanoliter volumes. In a series of transactions, we
    exclusively licensed from Caltech the relevant patent filings
    relating to these developments.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our patent strategy is to seek broad patent protection on new
    developments in microfluidic technology and then later file
    patent applications covering new implementations of the
    technology and new microfluidic circuit architectures utilizing
    the technology. As these technologies are implemented and
    tested, we file new patent applications covering scientific
    methodology enabled by our technology. Additionally, where
    appropriate, we file new patent applications covering
    instrumentation and software that are used in conjunction with
    our IFCs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition to our in-licensed patent portfolio from Caltech, we
    have also taken co-exclusive licenses to patents and patent
    applications owned by Harvard University, a non-exclusive,
    field-limited license to patents and patent applications
    controlled by Gyros AB and additional patent licenses from other
    academic institutions and companies.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of March&#160;29, 2008, we own or have licensed 81 issued US
    patents and 62 issued international patents.  There are
    240&#160;pending patent applications, including 116 in the
    United States, 118 international applications and 6 applications
    filed under the Patent Cooperation Treaty. The issued patents we
    have licensed from Caltech expire between 2019 and 2024, and the
    issued patents owned by us expire between 2018 and 2025.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The patent positions of companies like ours are generally
    uncertain and involve complex legal and factual questions. Our
    patents may not enable us to obtain or keep any competitive
    advantage. Our pending U.S.&#160;and foreign patent applications
    may not issue as patents or may not issue in a form that will be
    advantageous to us. Any patents we have obtained or do obtain
    may be challenged by re-examination, opposition or other
    administrative proceeding, or may be challenged in litigation,
    and such challenges could result in a determination that the
    patent is invalid. In addition, competitors may be able to
    design alternative methods or devices that avoid infringement of
    our patents. To the extent our intellectual property protection
    offers inadequate protection, or is found to be invalid, we are
    exposed to a greater risk of direct competition. If our
    intellectual property does not provide adequate protection
    against our competitors&#146; products, our competitive position
    could be adversely affected, as could our business. Both the
    patent application process and the process of managing patent
    disputes can be time consuming and expensive. Furthermore, the
    laws of some foreign countries may not protect our intellectual
    property rights to the same extent as do the laws of the United
    States.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition to pursuing patents on our technology, we have taken
    steps to protect our intellectual property and proprietary
    technology by entering into confidentiality agreements and
    intellectual property assignment agreements with our employees,
    consultants, corporate partners and, when needed, our advisors.
    Such agreements may not be enforceable or may not provide
    meaningful protection for our trade secrets or other proprietary
    information in the event of unauthorized use or disclosure or
    other breaches of the agreements, and we may not be able to
    prevent such unauthorized disclosure. Monitoring unauthorized
    disclosure is difficult, and we do not know whether the steps we
    have taken to prevent such disclosure are, or will be, adequate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our commercial success may depend in part on our
    non-infringement of the patents or proprietary rights of third
    parties. Third parties have asserted and may assert in the
    future that we are employing their proprietary technology
    without authorization. Competitors may assert that our products
    infringe their intellectual property
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    67
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    rights as part of a business strategy to impede our successful
    entry into those markets. In addition, our competitors and
    others may have patents or may in the future obtain patents and
    claim that use of our products infringes these patents. We could
    incur substantial costs and divert the attention of our
    management and technical personnel in defending against any of
    these claims. Parties making claims against us may be able to
    obtain injunctive or other relief, which could block our ability
    to develop, commercialize and sell products, and could result in
    the award of substantial damages against us. In the event of a
    successful claim of infringement against us, we may be required
    to pay damages and obtain one or more licenses from third
    parties, or be prohibited from selling certain products. We may
    not be able to obtain these licenses at a reasonable cost, if at
    all.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Employees</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;29, 2007, we had 131&#160;employees, of
    which 68 work in research and development, 18 work in general
    and administrative, 21 work in manufacturing and 24 work in
    sales and marketing. None of our employees are represented by a
    labor union or are the subject of a collective bargaining
    agreement.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Property</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We lease approximately 35,000&#160;square feet of office and
    laboratory space at our headquarters in South
    San&#160;Francisco, California under leases and subleases that
    expire in March 2011, and 13,000&#160;square feet of
    manufacturing and office space at our facility in Singapore
    under a lease that expires in September 2008. In addition, we
    lease office space in Tokyo and Osaka, Japan. We are in
    negotiations to extend and expand our lease relating to our
    Singapore facility and we believe that our existing office,
    laboratory and manufacturing space, together with additional
    space and facilities available on commercially reasonable terms,
    will be sufficient to meet our needs for at least the next two
    years.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Legal
    Proceedings</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are not engaged in any material legal proceedings.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    68
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='111'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">MANAGEMENT</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Executive
    Officers and Directors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our executive officers and directors, and their ages and
    positions as of March&#160;29, 2008, are as set forth below:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="42%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="51%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Age</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Position</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Gajus V. Worthington
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    38
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    President, Chief Executive Officer and Director
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Vikram Jog
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    51
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Chief Financial Officer
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Robert C. Jones
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    53
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Executive Vice President, Research and Development
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    William M. Smith
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    57
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Vice President, Legal Affairs and General Counsel, Secretary
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mai Chan (Grace) Yow
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    49
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Vice President, Worldwide Manufacturing and Managing Director of
    Fluidigm Singapore Pte. Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Samuel
    Colella<SUP style="font-size: 85%; vertical-align: text-top">(2),(3)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    68
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Michael W. Hunkapiller,
    Ph.D<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    59
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Elaine V. Jones,
    Ph.D.<SUP style="font-size: 85%; vertical-align: text-top">(1),(3)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    53
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Kenneth
    Nussbacher<SUP style="font-size: 85%; vertical-align: text-top">(1),(2)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    55
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    John A.
    Young<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    75
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Member of the Audit Committee
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Member of the Compensation Committee
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Member of the Nominating and
    Governance Committee
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Executive
    Officers</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Gajus V. Worthington </I>is a Co-Founder of Fluidigm
    Corporation and has served as our President and Chief Executive
    Officer and a Director since our inception in June 1999. From
    May 1994 to April 1999, Mr.&#160;Worthington held various staff
    and management positions at Actel Corporation, a public
    semiconductor corporation. Mr.&#160;Worthington received a B.S.
    in Physics and an M.S. in Electrical Engineering from Stanford
    University.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Vikram Jog </I>has served as our Chief Financial Officer
    since February 2008. From April 2005 to February 2008,
    Mr.&#160;Jog served as Chief Financial Officer for XDx, Inc., a
    molecular diagnostics company. From March 2003 to April 2005,
    Mr.&#160;Jog was a Vice President of Applera Corporation and
    Vice President of Finance for its related businesses, Celera
    Genomics and Celera Diagnostics. From April 2001 to March 2003,
    Mr.&#160;Jog was Vice President of Finance for Celera
    Diagnostics and Corporate Controller of Applera Corporation.
    Mr.&#160;Jog holds a Bachelor of Commerce degree from Delhi
    University and an M.B.A. from Temple University. Mr.&#160;Jog is
    a member of the American Institute of Certified Public
    Accountants.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Robert C. Jones </I>has served as our Executive Vice
    President, Research and Development since August 2005. From
    August 1984 to July 2005, Mr.&#160;Jones held various managerial
    and research and development positions at Applied Biosystems, a
    laboratory equipment and supplies manufacturer that is a
    division of Applera Corporation, including: Senior Vice
    President Research and Development from April 2001 to August
    2005, Vice President and General Manager Informatics Division
    from 1998 to 2001&#160;and Vice President PCR Business Unit from
    1994 to 1998. Mr.&#160;Jones received a BSEE and an MSEE in
    Computer Engineering from the University of Washington.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>William M. Smith </I>has served as our Vice President, Legal
    Affairs and General Counsel as well as our Secretary since May
    2000 and served as a Director from May 2000 to April 2008.
    Mr.&#160;Smith served as a partner at the law firm of Townsend
    and Townsend and Crew, LLP from 1985 through April 2008.
    Mr.&#160;Smith received a J.D. and an M.P.A. from the University
    of Southern California and a B.A. in Biology from the University
    of California, San&#160;Diego.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Mai Chan (Grace) Yow </I>has served as our Vice President,
    Worldwide Manufacturing, and Managing Director, Fluidigm
    Singapore Pte. Ltd., our Singapore subsidiary, since March 2006.
    From June 2005 to March 2006,
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    69
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Ms.&#160;Yow served as General Manager of Fluidigm Singapore
    Pte. Ltd. From August 2004 to May 2005, Ms.&#160;Yow served as
    Vice President Engineering (Asia) for Kulicke and Soffa, a
    public semiconductor equipment manufacturer. From March 1991 to
    July 2004, Ms.&#160;Yow served as Director, Assembly Operations,
    Plant Facilities and EHS, for National Semiconductor Singapore,
    a semiconductor fabrication subsidiary of National Semiconductor
    Corporation. Ms.&#160;Yow received a BE in Electronic
    Engineering from Curtin University, a Certificate in Management
    Studies from the Singapore Institute of Management and a Diploma
    in Electrical Engineering from Singapore Polytechnic.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Board of
    Directors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Samuel Colella </I>has served as a member of our Board of
    Directors since July 2000. Mr.&#160;Colella is a managing
    director of Versant Ventures, a healthcare venture capital firm
    he co-founded in 1999, and has been a general partner of
    Institutional Venture Partners since 1984. Mr.&#160;Colella is a
    member of the Board of Directors of Alexza Pharmaceuticals,
    Inc., Genomic Health, Inc. and Jazz Pharmaceuticals, Inc.
    Mr.&#160;Colella received a B.S. in business and engineering
    from the University of Pittsburgh and an M.B.A. from Stanford
    University.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Michael Hunkapiller, Ph.D. </I>has served as a member of our
    Board of Directors since August 2005. He has been a Partner at
    Alloy Ventures, a venture capital firm, since February 2004.
    From July 1983 to August 2004, he served in various managerial
    and research and development positions at Applied Biosystems,
    most recently as President, from March 1997 to August 2004. He
    received a B.S. in Chemistry from Oklahoma Baptist University
    and a Ph.D. in Chemical Biology from Caltech.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Elaine V. Jones,&#160;Ph.D.</I> has been a member of our
    Board of Directors since October 2001. Since August 2003, she
    has been a general partner of EuclidSR Associates, L.P., which
    is the general partner of EuclidSR Partners, L.P., a venture
    capital fund that focuses on life sciences and information
    technology companies. Dr.&#160;Jones was an investment manager
    from June 1999 to September 2001, and was a Vice President from
    September 2001 to August 2003, for S.R. One, Limited, a venture
    capital subsidiary of SmithKline Beecham. Dr.&#160;Jones is a
    graduate of Juniata College and received a Ph.D. in Microbiology
    from the University of Pittsburgh.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Kenneth J. Nussbacher </I>has been a member of our Board of
    Directors since July 2003. He has been an Affymetrix fellow
    since 2000. From 1995 to 2000, Mr.&#160;Nussbacher was Executive
    Vice President of Affymetrix, Inc., a biotechnology company,
    and, from 1995 to 1997, he was also Chief Financial Officer of
    Affymetrix. Prior to joining Affymetrix, Mr.&#160;Nussbacher was
    Executive Vice President for business and legal affairs of
    Affymax Research Institute. He received a B.S. from Cooper Union
    and a J.D. from Duke University. Mr.&#160;Nussbacher is also a
    member of the Board of Directors of Symyx Technologies, Inc., a
    research and development solutions provider, and Xenoport, a
    biopharmaceutical company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Gajus V. Worthington </I>is a Co-Founder of Fluidigm
    Corporation and has served as our President and Chief Executive
    Officer and a Director since our inception in June 1999.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>John A. Young </I>has been a member of our Board of Directors
    since March 2001. Mr.&#160;Young retired as President and Chief
    Executive Officer of Hewlett-Packard Company, a diversified
    electronics manufacturer, in October 1992, where he had served
    as President and Chief Executive Officer since 1978.
    Mr.&#160;Young received a B.S. in Electrical Engineering from
    Oregon State University and an M.B.A. from Stanford University.
    Mr.&#160;Young serves as a director of Affymetrix, Inc.,
    Vermillion, Inc., a molecular diagnostics company, Perlegen
    Sciences, Inc., a drug development company, and Nanosys, Inc., a
    nanotechnology company.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Board
    Composition</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors is currently composed of six members,
    five of whom are independent within the meaning of the
    independent director guidelines of the NASDAQ Stock Market LLC.
    Immediately prior to this offering, our Board of Directors will
    be divided into three staggered classes of directors. At each
    annual meeting of stockholders, a class of directors will be
    elected for a three-year term to succeed the same class whose
    terms are then expiring. The terms of the directors will expire
    upon the election and qualification of successor directors at
    the Annual Meeting of Stockholders to be held during the years
    2009 for the Class&#160;I directors, 2010 for the Class&#160;II
    directors and 2011 for the Class&#160;III directors.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    70
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Our Class&#160;I directors will
    be&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Our Class&#160;II directors will
    be&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Our Class&#160;III directors will
    be&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our amended and restated certificate of incorporation and bylaws
    provide that the number of our directors, which is currently six
    members, shall be fixed from time to time by a resolution of the
    majority of our Board of Directors. Each officer serves at the
    discretion of the Board of Directors and holds office until his
    successor is duly elected and qualified or until his or her
    earlier resignation or removal. There are no family
    relationships among any of our directors or executive officers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The division of our Board of Directors into three classes with
    staggered three-year terms may delay or prevent a change of our
    management or a change of control. See &#147;Description of
    Capital Stock&#160;&#151; Anti-Takeover Effects of Delaware Law
    and Our Certificate of Incorporation and Bylaws&#148; for a
    discussion of other anti-takeover provisions found in our
    certificate of incorporation.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Board
    Committees</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board has an audit committee, a compensation committee and a
    nominating and governance committee, each of which has the
    composition and the responsibilities described below.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Audit Committee.</I>&#160;&#160;Our audit committee oversees
    our corporate accounting and financial reporting process and
    assists the Board in monitoring our financial systems and our
    legal and regulatory compliance. Our audit committee will also:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    oversee the work of our independent auditors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    approve the hiring, discharging and compensation of our
    independent auditors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    approve engagements of the independent auditors to render any
    audit or permissible non-audit services;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    review the qualifications and independence of the independent
    auditors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    monitor the rotation of partners of the independent auditors on
    our engagement team as required by law;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    review our financial statements and review our critical
    accounting policies and estimates;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    review the adequacy and effectiveness of our internal
    controls;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    review and discuss with management and the independent auditors
    the results of our annual audit, our quarterly financial
    statements, and our publicly filed reports.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The members of our audit committee are Elaine Jones and Kenneth
    Nussbacher. Mr. Nussbacher is our acting audit committee
    chairman. We are currently conducting a search for an additional
    audit committee member who we expect to serve as chairman and as
    financial expert under the rules of the Securities and Exchange
    Commission, or SEC, implementing Section&#160;407 of the
    Sarbanes Oxley Act of 2002. We expect that, prior to the
    completion of this offering, that the composition of our audit
    committee will meet the requirements for independence under the
    current requirements of the NASDAQ Stock Market LLC and SEC
    rules and regulations. We believe that the functioning of our
    audit committee complies with the applicable requirements of the
    NASDAQ Stock Market LLC and SEC rules and regulations. We intend
    to comply with future requirements to the extent they become
    applicable to us.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Compensation Committee.</I>&#160;&#160;Our compensation
    committee oversees our corporate compensation programs. The
    compensation committee will also:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    review and recommend policy relating to compensation and
    benefits of our officers and employees;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    review and approve corporate goals and objectives relevant to
    compensation of our Chief Executive Officer and other senior
    officers;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    evaluate the performance of our officers in light of established
    goals and objectives;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    recommend compensation of our officers based on its
    evaluations;&#160;and
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    71
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    administer the issuance of stock options and other awards under
    our stock plans;
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The members of our compensation committee are Samuel Colella,
    Michael Hunkapiller and Kenneth Nussbacher. Mr.&#160;Colella is
    the chairman of our compensation committee. Our Board of
    Directors has determined that each member of our compensation
    committee is independent within the meaning of the independent
    director guidelines of the NASDAQ Stock Market LLC. We believe
    that the composition of our compensation committee meets the
    requirements for independence under, and the functioning of our
    compensation committee complies with, any applicable
    requirements of the NASDAQ Stock Market LLC and SEC rules and
    regulations. We intend to comply with future requirements to the
    extent they become applicable to us.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Nominating and Governance Committee.</I>&#160;&#160;Our
    nominating and governance committee oversees and assists our
    Board of Directors in reviewing and recommending nominees for
    election as directors. The nominating and governance committee
    will also:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    evaluate and make recommendations regarding the organization and
    governance of the Board and its committees;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    assess the performance of members of the Board and make
    recommendations regarding committee and chair assignments;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    recommend desired qualifications for Board membership and
    conduct searches for potential Board members;&#160;and
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    review and make recommendations with regard to our corporate
    governance guidelines.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The members of our nominating and governance committee are
    Elaine Jones, John Young and Samuel Colella. Ms.&#160;Jones is
    the chairman of our nominating and governance committee. Our
    Board of Directors has determined that each member of our
    compensation committee is independent within the meaning of the
    independent director guidelines of the NASDAQ Stock Market LLC.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors may from time to time establish other
    committees.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Director
    Compensation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth information concerning
    compensation paid or accrued for services rendered to us by
    members of our Board of Directors for the fiscal year ended
    December&#160;29, 2007. The table excludes Mr.&#160;Worthington
    and Mr.&#160;Smith, who are Named Executive Officers and did not
    receive any compensation from us in their roles as directors in
    the fiscal year ended December&#160;29, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="44%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Non-Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Fees Earned<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Stock<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Incentive Plan<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>All Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>or Paid in<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Cash&#160;($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Bruce Burrows
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Samuel D. Colella
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Hingge Hsu
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Michael Hunkapiller
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Elaine V. Jones
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    S. Edward Torres
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Kenneth J.
    Nussbacher<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    42,498
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    40,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    82,498
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    John A. Young
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Amounts represent the aggregate
    compensation expense recognized by us for financial statement
    reporting purposes in fiscal 2007 related to grants of stock
    options in 2007, calculated in accordance with Financial
    Accounting Standards Board Statement of Financial Accounting
    Standards No.&#160;123 (Revised 2004) (&#147;SFAS
    No.&#160;123(R)&#148;) without regard to estimated forfeitures.
    See Note&#160;2 of Notes to Consolidated Financial Statements
    for a discussion of valuation assumptions made in determining
    the grant date fair value and compensation expense of our stock
    options.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Mr.&#160;Nussbacher was granted an
    option to purchase 100,000 shares of common stock on
    December&#160;28, 2007 at an exercise price of $2.40 and was
    paid fees of $40,000 for services rendered pursuant to a
    consulting agreement with us.
    </FONT></TD>
</TR>



<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Our shares of common stock were not
    publicly traded during the 2007 fiscal year; our Board of
    Directors in good faith determined the fair market value on the
    date of grant.
    </FONT></TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    72
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    None of our non-employee directors held any stock awards during
    our fiscal year ended December&#160;29, 2007. The aggregate
    number of shares subject to stock options outstanding at
    December&#160;29, 2007 for each director is as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="69%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="14%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="14%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Aggregate Number of Stock Options<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Outstanding as of December&#160;29, 2007&#160;(#)</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Bruce Burrows
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Samuel D. Colella
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Hingge Hsu
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Michael Hunkapiller
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Elaine V. Jones
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Kenneth J. Nussbacher
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    200,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    S. Edward Torres
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    John A. Young
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our directors do not currently receive any cash compensation for
    their services as members of our Board of Directors or any
    committee of our Board of Directors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon consummation of our initial public offering, non-employee
    directors will receive an annual retainer of $20,000. The
    chairman of the audit committee will be paid an additional
    annual retainer of $15,000. The chairman of the compensation
    committee will be paid an additional annual retainer of $10,000.
    The chairman of the nominating and governance committee will be
    paid an additional annual retainer of $5,000.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our outside director equity compensation policy was adopted by
    our Board of Directors on January&#160;29, 2008 and will become
    effective immediately upon the completion of this offering. The
    policy is intended to formalize the granting of equity
    compensation to our non-employee directors under the 2008 Equity
    Incentive Plan. Non-employee directors may receive all types of
    awards under the 2008 Equity Incentive Plan, except for
    incentive stock options, including discretionary awards not
    covered by the policy. The policy provides for automatic and
    nondiscretionary grants of nonstatutory stock options subject to
    the terms and conditions of the policy and the 2008 Equity
    Incentive Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the policy, each non-employee director, who first becomes
    a non-employee director following the effective date of the
    first registration statement filed by us and declared effective
    with respect to any class of our securities, will be
    automatically granted a stock option to purchase
    40,000&#160;shares of our common stock on the date such person
    first becomes a non-employee director. A director who is an
    employee and who ceases to be an employee, but who remains a
    director will not receive such an initial award.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, each non-employee director will be automatically
    granted an annual stock option to purchase 10,000&#160;shares of
    our common stock on the date of each annual meeting beginning on
    the date of the first annual meeting that is held at least
    six&#160;months after such non-employee director received his or
    her initial award. In connection with the closing of this
    initial public offering, each non-employee director serving on
    our Board at the time of this offering will be automatically
    granted an option to purchase 10,000&#160;shares of our common
    stock at the price per share at which such common stock is sold
    in this offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The exercise price of all stock options granted pursuant to the
    policy will be equal to the fair market value of our common
    stock on the date of grant. The term of all stock options will
    be 10&#160;years. Subject to the adjustment provisions of the
    2008 Equity Incentive Plan, initial awards will vest as to 25%
    of the shares subject to such awards each anniversary of the
    date of grant, provided such non-employee director continues to
    serve as a director through each such date. Subject to the
    adjustment provisions of the 2008 Equity Incentive Plan, the
    annual awards, including such awards granted in connection with
    this offering, will vest monthly over a twelve month period
    following the date of grant, provided such non-employee director
    continues to serve as a director through such date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The administrator of the 2008 Equity Incentive Plan in its
    discretion may change or otherwise revise the terms of awards
    granted under the outside director equity compensation policy.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the event of a &#147;change in control,&#148; as defined in
    our 2008 Equity Incentive Plan, with respect to awards granted
    under the 2008 Equity Incentive Plan to non-employee directors,
    the participant non-employee director will
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    73
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    fully vest in and have the right to exercise awards as to all
    shares underlying such awards and all restrictions on awards
    will lapse, and all performance goals or other vesting criteria
    will be deemed achieved at 100% of target level and all other
    terms and conditions met.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Code of
    Business Conduct and Ethics</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to the completion of this offering, we expect to adopt a
    code of business conduct and ethics that is applicable to all of
    our employees, officers and directors.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Compensation
    Committee Interlocks and Insider Participation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    None of the members of our compensation committee is an officer
    or employee of our company. None of our executive officers
    currently serves, or in the past year has served, as a member of
    the Board of Directors or compensation committee of any entity
    that has one or more executive officers serving on our Board of
    Directors or compensation committee.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Executive
    Compensation</FONT></B>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Compensation
    Discussion and Analysis</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Overview</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We seek to have a compensation program that supports a team
    ethic among our management, fairly rewards executives for
    corporate performance and provides incentives for executives to
    meet or exceed our short and long term goals. The primary
    components of our compensation program are base salary, an
    annual incentive bonus plan, option awards and change of control
    arrangements. In addition, we provide our executive officers a
    variety of benefits that are available generally to all salaried
    employees. The compensation committee of our Board of Directors
    is responsible for evaluating the compensation of our executive
    officers and making recommendations to the Board of Directors.
    The independent members of the Board of Directors have final
    approval authority with respect to executive compensation.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Objectives
    and Principles of Our Executive Compensation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The primary goal of our executive compensation program is to
    ensure that we hire and retain talented and experienced
    executives that are motivated toward achieving or exceeding our
    short-term and long-term corporate goals. As a starting point,
    we believe that it is critical that our executive officers work
    together as a team and look beyond departmental lines to achieve
    overall corporate goals rather than focusing on individual
    departmental objectives. Our compensation philosophy is team
    oriented and our success dependent on what our management team
    can accomplish together. Therefore, we seek to provide the
    executive officers listed in the Summary Compensation table
    below, or our &#147;named executive officers,&#148; with
    comparable levels of base salary, bonuses and equity awards that
    are based largely on overall company performance.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For our fiscal year 2007, our named executive officers were
    Gajus Worthington, President and Chief Executive Officer,
    Richard DeLateur, our former Chief Financial Officer, Michael
    Lucero, our former Executive Vice President, Sales and
    Marketing, William Smith, Vice President, Legal Affairs and
    General Counsel, Robert Jones, our Executive Vice President,
    Research and Development, Grace Yow, Vice President, Worldwide
    Manufacturing and Managing Director, Fluidigm Singapore and
    Robert Jones, Executive Vice President, Research and
    Development. Mr.&#160;DeLateur resigned as our Chief Financial
    Officer effective February&#160;29, 2008 and Mr.&#160;Lucero
    resigned as our Executive Vice President, Sales and Marketing on
    March&#160;14, 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    While the compensation level of Mr.&#160;Worthington, our Chief
    Executive Officer, is marginally higher than our other executive
    officers, his compensation has historically been based on our
    team-based compensation philosophy rather than on CEO
    compensation levels reported in market surveys of other
    companies in the life science industry.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We strongly believe that executive compensation should be
    directly linked to our performance. Our compensation program is
    designed so that a significant portion of the potential
    compensation of all of our executive
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    74
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    officers is contingent on the achievement of our business
    objectives. In rewarding performance, we seek to reward both
    short and long term performance. We expect our executive
    leadership to manage our company so that we achieve our annual
    goals while at the same time positioning us to achieve our
    longer term strategic objectives. Short term elements of
    compensation include annual salary reviews, stock option awards
    and incentive bonuses that are tied closely to achieving our
    corporate and, to a lesser extent, on achieving individual
    performance objectives. Long term elements have historically
    been limited to stock options with multi-year vesting designed
    to retain executives and align their long term interests with
    those of our stockholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that hiring and retaining well performing executives
    is important to our ongoing success. While we review generally
    available surveys on executive compensation to confirm that our
    compensation decisions do not result in compensation levels that
    are dramatically different from other companies in our industry,
    the compensation committee has not in the past attempted to
    benchmark our executive compensation against any particular
    indices or salary surveys. While occasional review of market
    surveys is considered helpful, the compensation committee has
    historically placed substantially greater weight on internal
    considerations than on position-specific pay differences found
    in the market.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Except as described below, neither the Board of Directors nor
    the compensation committee has adopted any formal or informal
    policies or guidelines for allocating compensation between cash
    and non-cash compensation, among different forms of non-cash
    compensation or with respect to long and short term performance.
    The determination of the Board of Directors or compensation
    committee as to the appropriate use and weight of each component
    of executive compensation is subjective, based on their view of
    the relative importance of each component in meeting our overall
    objectives and factors relevant to the individual executive.
    Historically, our Board of Directors has focused significantly
    on the affordability of our compensation arrangements. As a
    result, when weighting forms of compensation, the Board of
    Directors and the compensation committee have historically
    placed greater emphasis on non-cash equity incentive
    compensation together with base salary. We did not pay any
    material cash bonuses until 2007, when the Board of Directors
    determined that our business was of sufficient maturity to
    permit us to establish a cash bonus plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As a publicly held company, we expect to periodically engage the
    services of a compensation consultant to assist us in further
    aligning our compensation philosophy with our corporate
    objectives. In particular, in order to attract and retain key
    executives, we may be required to modify individual executive
    compensation levels to remain competitive in the market for such
    positions.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Compensation
    Process and Compensation Committee</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For 2007 and January 2008, the compensation committee consisted
    of Messrs.&#160;Colella and Nussbacher and Ms.&#160;Jones. Since
    January&#160;29, 2008, the compensation committee has consisted
    of Messrs.&#160;Colella, Nussbacher and Hunkapiller, each of
    whom is an independent director under the rules of the NASDAQ
    Stock Market LLC and a &#147;non-employee director&#148; for
    purposes of
    <FONT style="white-space: nowrap">Rule&#160;16b-3</FONT>
    under the Securities Exchange Act of 1934, as amended.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The compensation committee makes recommendations to the Board
    regarding compensation structure, goals and individual
    compensation levels, which recommendations are considered for
    approval by the independent members of the Board. The
    compensation committee makes its compensation recommendations
    based on input from Mr.&#160;Worthington, our Chief Executive
    Officer, the judgment of its members based on their tenure and
    experience in our industry, and, starting with compensation
    levels for 2007, the advice of Compensia, Inc., an independent
    compensation consultant hired by the compensation committee in
    April 2007. The compensation committee has the responsibility of
    formulating, evaluating and recommending to the Board of
    Directors the compensation of our executive officers.
    Historically, our annual compensation review process has been
    initiated by Mr.&#160;Worthington who performs a review of the
    performance of each executive officer in the prior year and
    formulates proposals regarding the elements of compensation,
    corporate and individual goals and compensation levels for our
    executive officers, other than himself.
    Mr.&#160;Worthington&#146;s proposals for compensation
    structure, goals and individual compensation levels are
    typically based on discussions with and directions from members
    of the compensation committee. Mr.&#160;Worthington does not
    prepare proposals or advise the compensation committee on his
    own compensation.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    75
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Compensation levels and mix for Mr.&#160;Worthington, our Chief
    Executive Officer, are recommended by the compensation committee
    based on the committee&#146;s assessment of our overall
    corporate performance and Mr.&#160;Worthington&#146;s
    contribution to that performance. Mr.&#160;Worthington does not
    participate in compensation committee or Board deliberations
    regarding his own compensation. As with other members of our
    executive team, the compensation committee determines
    Mr.&#160;Worthington&#146;s compensation based on our
    achievement of corporate objectives and compensation levels of
    other members of our executive team, rather than attempting to
    tie Mr.&#160;Worthington&#146;s compensation to a specific
    percentile of CEO compensation reported in market compensation
    surveys.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subject to any limitations or guidelines that may be adopted by
    the Board of Directors in the future, the compensation committee
    does have the authority to approve the grant of stock options or
    stock purchase rights to individuals eligible for such grants,
    including officers and directors. The compensation committee met
    three times during 2007 and we expect that it will meet at least
    quarterly during 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The compensation committee has the authority under its charter
    to engage the services of outside advisors, experts and others
    for assistance. In April 2007, the compensation committee
    engaged Compensia, Inc., an outside consulting firm, to advise
    it on developing a principles based executive compensation
    strategy to help transition us from a privately held to a
    publicly held company and on matters relating to our equity
    compensation plans as a whole. The consulting firm reviewed our
    proposed 2007 compensation philosophy and compensation levels
    and provided general advice and comments, but did not prepare a
    formal report or recommend specific compensation levels. In
    2008, we expect the compensation committee will engage an
    outside consulting firm to review more broadly our compensation
    practices and provide specific recommendations on executive
    compensation levels.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After setting compensation levels for our executive officers for
    2007, but before making its recommendations to the Board, the
    compensation committee reviewed the 2006 Radford Biotechnology
    Survey by Aon Consulting and the 2006 Executive Compensation
    Survey for pre-IPO life science companies by Top Five Data
    Services, Inc. to confirm that the proposed mix and levels of
    compensation for our executive officers was not outside of the
    ranges reported for senior executive officers in general. The
    compensation committee did not benchmark or tie compensation
    levels for our executive officers to any particular compensation
    level provided by the companies included in these surveys.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Corporate
    and Individual Performance Goals</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>2007 Corporate Goals.</I>&#160;&#160;Our corporate and
    individual performance goals for each year are formulated by the
    Board of Directors with input from the compensation committee
    and our Chief Executive Officer. For 2007, two corporate goals
    were established. The first related to our selling a certain
    number of IFC systems and reaching certain revenue targets,
    whether through system sales or collaboration agreements. The
    second goal related to our equity fund raising activity. The
    compensation committee believed attaining these goals would take
    a high level of executive performance and that such goals would
    be very challenging given the initial lack of market awareness
    of our products in 2007. The committee did not assign weights to
    these goals, except to treat them as equally important.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    76
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>2007 Individual Goals.</I>&#160;&#160;Individual goals for
    2007 were as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="48%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Named Executive Officer</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>2007 Individual Goals</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    Gajus Worthington, Chief Executive Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Achieving target levels of sales of our IFC systems and
    achieving target revenues, whether through system sales or
    collaboration agreements.
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Raising target levels of equity financing.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Richard DeLateur, former Chief Financial Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Preparing our finance organization for an initial public
    offering and public company status.
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    Michael Lucero, former Executive Vice President,
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Launching our BioMark product and developing a
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt; z-index: 1; position: relative">
    Sales and Marketing
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    strategy for new market penetration.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    William Smith, Vice President, Legal Affairs and
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Maintaining and advancing our intellectual property
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    General Counsel
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
     position with respect to existing and new products.
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    Robert Jones, Executive Vice President, Research
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Deliver commercial genotyping applications, digital
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt; z-index: 1; position: relative">
    and Development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    array applications and finish feasibility phase of additional
    products.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Grace Yow, Vice President, Worldwide
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Achieving specified IFC manufacturing yields and
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Manufacturing and Managing Director of
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    output levels.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Fluidigm Singapore
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>2008 Corporate Goals.</I>&#160;&#160;For 2008, the Board,
    with the participation of the compensation committee and members
    of management, reassessed our corporate goals in light of the
    maturation of our business and commercialization of our
    products. Following this reassessment, the Board approved
    corporate goals that include achieving specified levels of
    product sales and product gross margins, completing an initial
    public offering and keeping expenses and cash outlays within the
    budget approved by the Board of Directors. The Board believes
    that the goals are attainable with a very high level of
    executive performance. The target sales level represents
    significant growth from 2007 levels and will be achieved only if
    we are able to increase market awareness of our products and
    expand our customer base. The targeted gross margin will require
    significant contributions from both our manufacturing and
    research and development groups. Given the uncertainty in global
    financial markets, our ability to complete an initial public
    offering was also uncertain at the time these corporate goals
    were established. Achieving our overall corporate goals while
    staying within our proposed budget will require strong fiscal
    discipline.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    77
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>2008 Individual Goals.</I>&#160;&#160;The goals for our
    individual executives in 2008 are as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="48%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Named Executive Officer</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008 Individual Goals</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    Gajus Worthington, Chief Executive Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Achieving specified levels of product sales and product gross
    margins, completing an initial public offering and keeping
    expenses and cash outlays within the budget approved by the
    Board of Directors.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Vikram Jog, Chief Financial Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Ensuring accurate revenue recognition during each quarter,
    closing our books in an accurate and timely manner, completing
    our 2005, 2006 and 2007 audits and ensuring compliance with
    applicable financial and disclosure regulations of the
    Securities and Exchange Commission.
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    William Smith, Vice President, Legal Affairs and
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Maintaining our intellectual property position and
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt; z-index: 1; position: relative">
    General Counsel
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    supporting our initial public offering.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Robert Jones, Executive Vice President, Research
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Completing market-ready 96.96 BioMark IFC, loaders
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    and Development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    and readers for 96.96 and certain future applications.
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    Grace Yow, Vice President, Worldwide
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Achieving overall IFC yields sufficient to achieve our
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt; z-index: 1; position: relative">
    Manufacturing and Managing Director of
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
     gross margin goals, achieving specified yields on our
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt; z-index: 1; position: relative">
    Fluidigm Singapore
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    new 96.96 Dynamic Array IFC, maintaining or improving 2007
    quality levels for our IFC systems and ensuring on-time
    manufacture and delivery of IFCs and IFC systems.
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Elements
    of Executive Compensation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our executive compensation program consists of four main
    elements: base salary, an annual incentive bonus plan, option
    awards and change of control arrangements. The following is a
    discussion of each element.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Base Salary.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to 2007, the Board and the compensation committee
    established base salaries based on a number of factors including
    the scope of responsibility of each individual and a desire to
    encourage a team ethic. In 2007, the compensation committee and
    the Board concluded that our company and its stockholders would
    be better served by placing greater emphasis on creating a team
    ethic among our executive officers and that a team ethic would
    be better supported if all executive officers received
    approximately the same salary. Therefore, in May 2007, the
    compensation committee recommended and the Board approved a
    raise in the base annual salaries of Richard DeLateur, Michael
    Lucero, William Smith and Robert Jones to $265,000 effective
    February&#160;1, 2007, which represented a 29% increase for
    Mr.&#160;DeLateur, a 2.5% increase for Mr.&#160;Lucero, a 16%
    increase for Mr.&#160;Smith and a 17% increase for
    Mr.&#160;Jones, based on their salaries for 2006. This salary
    increase was based upon the compensation committee&#146;s
    assessment of the life science industry in the
    San&#160;Francisco Bay Area gathered from the active involvement
    of committee members as investors in such industry and the
    committee&#146;s conclusion that competition for executives in
    our industry was increasing. Ms.&#160;Yow&#146;s salary was set
    at S$307,224, or US$200,000 using the exchange rate at the time
    such salary was set, to reflect the lower cost of living in
    Singapore where she is based. In December 2007, the compensation
    committee reviewed Mr.&#160;Worthington&#146;s performance and
    determined that an increase in salary was justified based on his
    partial achievement of revenue goals for 2007, his full
    achievement of his fundraising goals for 2007 and the
    committee&#146;s assessment of market conditions as described
    above. It recommended increasing Mr.&#160;Worthington&#146;s
    base salary by 5% to $270,400 effective retroactively as of
    February&#160;15, 2007 and this increase was approved by the
    Board and accepted by Mr.&#160;Worthington.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2008, the compensation committee reviewed 2008 base
    salaries in light of general market conditions in the
    San&#160;Francisco Bay Area life science industry. The
    compensation committee concluded that competition for executive
    talent remained strong as a result of the solid economic
    performance of the industry and the region overall, the
    continued high level of investment by venture capital firms in
    new and existing life science
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    78
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    companies and the specialized skills and experiences required to
    manage life science companies. The compensation committee&#146;s
    assessment of general market conditions in the life science
    industry, and the life science industry in the
    San&#160;Francisco Bay Area in particular, was based on the
    experience of the committee members who were and are actively
    involved in venture capital investing in such industry and area.
    The compensation committee did not rely on any formal
    compensation survey data in making its assessment. The
    compensation committee therefore recommended and the Board
    approved a 4.0% raise for all executive officers other than
    Messrs.&#160;DeLateur and Lucero, who were expected to be
    leaving our company in early 2008. This 4.0% raise was applied
    to Ms.&#160;Yow&#146;s salary in Singapore dollars, resulting in
    an increase of S$12,289. As a result, the 2008 base salary for
    Mr.&#160;Smith was increased to $275,600, the 2008 base salary
    for Ms.&#160;Yow was increased to S$319,513, or US$232,002 on
    the date of the increase, and the 2008 salary for
    Mr.&#160;Worthington was increased to $283,920. These salary
    increases became effective on February&#160;1, 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2008, we entered into an offer letter with Vikram
    Jog, our Chief Financial Officer that provides for him to
    receive a base salary of $278,000 per year and a signing bonus
    of $20,000. The Board approved this departure from our standard
    base salary and bonus practice for executive officers based on
    several factors, including his unique qualifications, the need
    to induce him to leave his existing employment, his base salary
    at his previous employer and our need to fill the position as
    soon as possible.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Incentive Bonus Plan.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For 2007, the compensation committee and the Board established a
    bonus structure for all named executive officers that provided
    for performance bonuses of up to 35% of base salary. 80% of the
    performance bonus was payable based upon our reaching our
    corporate goals described above, with each corporate goal
    receiving equal weighting and the remaining 20% payable to each
    executive based on the executive&#146;s attainment of his or her
    individual performance goals described above. Payment of
    performance bonuses was allocated among corporate and individual
    goals in this manner in recognition of our compensation
    philosophy in which the compensation committee sought to
    incentivize executive officers to look beyond their individual
    departmental goals and work with other executive officers to
    achieve our overall corporate goals. The compensation committee
    and Board concluded that the corporate goals portion of the
    bonus would not be payable if the goals were less than 80%
    attained, based on the average percentage completion of all such
    goals, and would be paid in full if the goals were 100%
    attained. The compensation committee retained discretion to
    determine the portion of the bonus that would be paid if the
    corporate goals were achieved at a level between 80% and 100%.
    The compensation committee also retained the discretion to
    change the bonus structure and the bonus payment amounts as it
    considered appropriate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2008, the compensation committee concluded that the
    first 2007 corporate goal described above had been partially met
    and the second 2007 corporate goal had been fully met, but that
    taken together the 80% threshold had not been attained. As a
    result, no 2007 bonuses were paid to our executive officers with
    respect to achievement of corporate goals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The compensation committee also considered the achievement of
    2007 individual performance goals in January 2008 and concluded
    that Mr.&#160;Smith had achieved his goals by maintaining and
    advancing our intellectual property position with respect to
    existing and new products. The Board awarded Mr.&#160;Smith 100%
    of his individual performance bonus of $18,550. The compensation
    committee concluded that Mr.&#160;Jones achieved his 2007
    individual goals of delivering a commercial genotyping
    application and digital array applications and awarded him his
    maximum individual performance bonus of $18,550. The
    compensation committee concluded that Ms.&#160;Yow had achieved
    her 2007 individual goals by achieving specified IFC
    manufacturing yields and output levels in 2007 and the Board
    awarded Ms.&#160;Yow 100% of her individual performance bonus of
    $14,000. The compensation committee concluded that
    Mr.&#160;Worthington had partially achieved his 2007 individual
    performance goals of achieving target levels of IFC system sales
    and revenue and the Board awarded Mr.&#160;Worthington a partial
    bonus of $14,175. No other individual performance bonuses were
    awarded to our named executive officers for 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For 2008, the compensation committee and Board of Directors have
    approved the same bonus structure and potential bonus
    percentages as for 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In making recommendations regarding and approving compensation
    with respect to 2007, the compensation committee and the Board
    have not exercised their discretion to either award compensation
    absent attainment of
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    79
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    relevant performance goals or to reduce the size of an award or
    payout following the attainment of relevant performance goals.
    We intend for the bonus plan to provide a significant portion of
    an executive&#146;s potential compensation. It is designed to
    help ensure that executives are focused on our near-term
    performance and on working together to achieve key corporate
    objectives. We expect that corporate and individual goals will
    be reviewed each year and adjusted to reflect changes in our
    stage of development, competitive position and corporate
    objectives.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Option Awards.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We grant options to new executives upon the commencement of
    their employment and on an annual basis make additional grants
    to existing executives based on our overall corporate
    performance, individual performance and the executives&#146;
    existing option grants and equity holdings. We believe that
    option awards are an effective means of aligning the interests
    of executives and stockholders, rewarding executives for our
    achieving success over the long term and providing executives an
    incentive to remain with us. Most option grants to our named
    executive officers provide the holder with the right to exercise
    options and purchase shares prior to vesting, subject to our
    right to repurchase unvested shares pursuant to the terms of our
    restricted stock purchase agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2007, the compensation committee redesigned our option
    granting policy in light of the shift in our compensation
    philosophy toward team-based compensation. The compensation
    committee concluded that the number of shares that vest each
    year for each executive should be relatively consistent and
    should be comparable to the number of shares that vest for other
    executives. The committee determined that each executive should
    vest in approximately 70,000&#160;shares per year over a four
    year period. For each executive, the exact number of shares that
    vest in any year would be subject to adjustment either upward or
    downward by up to 35,000&#160;shares based on the
    executive&#146;s performance relative to the corporate goals and
    his or her individual performance goals. The compensation
    committee&#146;s selection of 70,000&#160;shares as the target
    number of shares to vest annually for each executive officer was
    based on the committee&#146;s determination that such number of
    shares would provide meaningful compensation to our executive
    officers. The committee did not rely on compensation surveys or
    other third party sources in arriving at the 70,000 annual
    vesting target. In addition to this annual vesting target and
    the possible adjustment of actual vesting amounts by up to
    35,000, the compensation committee retained the authority to
    approve additional option grants to executive officers who
    demonstrated exceptional performance in a given year.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As a result of our adoption of this new approach to equity
    compensation, our grants in 2007 were primarily intended to
    regularize each executive&#146;s vesting schedules to
    approximately 70,000 per year. As a result, certain executives
    received option grants where shares were immediately vested
    while others received grants where the vesting occurs largely
    three or four years from the grant of the date. The number of
    shares vesting for each such officer in 2007 were
    68,332&#160;shares for Mr.&#160;Worthington, 187,499&#160;shares
    for Mr.&#160;DeLateur, 104,083&#160;shares for Mr.&#160;Lucero,
    68,750 for Mr.&#160;Smith, 91,667 for Mr.&#160;Jones and 97,500
    for Ms.&#160;Yow, excluding for Mr.&#160;Smith and Ms.&#160;Yow
    the discretionary option shares described below. Variations in
    the number of shares vested in 2007 for these officers was the
    result of vesting under options granted prior to 2007 rather
    than intentional variation in 2007 grants on the part of the
    compensation committee. In the future, once the vesting of
    existing options are normalized at approximately
    70,000&#160;shares per year, we intend for executives to receive
    additional grants that vest only in the fourth year following
    the date of their grant. We also expect to reconsider the target
    share amount each year and may in the future consider granting
    restricted stock as a form of equity compensation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As discussed above, the compensation committee retains the
    discretion to grant additional options to executive officers as
    a reward for exceptional performance. In addition, the committee
    may decide to grant options that vest upon the achievement of
    certain performance goals. Finally, the committee is exploring
    the desirability of other forms of equity based compensation
    including restricted stock grants.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2008, the Board approved amendments to our 1999 Stock
    Option Plan to permit the use of performance based vesting in
    connection with equity grants under the plan. The amendment
    provided the Board and compensation committee with the ability
    to grant options or other equity awards under the plan that vest
    upon the achievement of specified milestones or goals. These
    amendments were made to enhance the ability of the Board and
    compensation committee to closely align equity compensation with
    the achievement of corporate or individual goals.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    80
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors adopted our 2008 Equity Incentive Plan in
    January 2008 and we expect our stockholders will approve it
    prior to the completion of this offering. Subject to stockholder
    approval, the 2008 Equity Incentive Plan is effective upon its
    adoption by our Board of Directors, but is not expected to be
    utilized until after the completion of this offering. Our 2008
    Equity Incentive Plan provides for the grant of incentive stock
    options, within the meaning of Section&#160;422 of the Internal
    Revenue Code, to our employees and any parent and subsidiary
    corporations&#146; employees, and for the grant of nonstatutory
    stock options, restricted stock, restricted stock units, stock
    appreciation rights, performance units and performance shares to
    our employees, directors and consultants and our parent and
    subsidiary corporations&#146; employees and consultants. Our
    Board and compensation committee are evaluating the costs and
    benefits of the various forms of equity compensation issuable
    under the 2008 plan and may elect to use restricted stock,
    restricted stock units, stock appreciation rights, performance
    units and performance shares in the future to further align the
    interests of our management and stockholders and to manage the
    financial statement impact of such forms of equity compensation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2008, the compensation committee participated in the
    negotiation of a compensation package for Vikram Jog, our Chief
    Financial Officer, in which the compensation committee agreed to
    grant Mr.&#160;Jog compensation that exceeded our standard
    compensation package for the named executive officers. As
    indicated above, the compensation committee approved this
    package based on Mr.&#160;Jog&#146;s unique qualifications, our
    need to fill this position and the need to induce Mr.&#160;Jog
    to leave his then current employer. In February 2008, the
    compensation committee approved the grant of the following
    options to Mr.&#160;Jog in February 2008 under our 1999 Stock
    Option Plan:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=01 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=01 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=01 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="27%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="27%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="27%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="2" nowrap align="left" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B>Accelerated Vesting if<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="2" nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Shares</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Standard Vesting</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Milestones Met</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Performance Milestones</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    500,000
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    25% on first anniversary<BR>
    of the vesting commencement date, and 1/48 per month thereafter
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    n/a
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    n/a
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    50,000&#160;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    100% on December&#160;31, 2011
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    100% upon achievement<BR>
    of Milestones prior to December 31, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    (1) Revenue recognition - no material changes upon quarterly
    reviews and annual audit;<BR>
    (2) Accurate and timely closing of books and reporting
    (timeliness as required by investors and SEC);<BR>
    (3) SEC and Sarbanes-Oxley compliance, as needed; and<BR>
    (4) Produce audited financial statements for 2005, 2006 and 2007
    (and the first quarter of 2008, if necessary) to enable the
    filing of a Form S-1 registration statement.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    50,000&#160;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    25% on first anniversary<BR>
    of the vesting  commencement date and 1/48 per month thereafter
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    100% upon achievement<BR>
    of Milestones prior to December 31, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    (1) Achievement of target revenues;<BR>
    (2) Achievement of target margins for 2008;<BR>
    (3) Completion of an initial public offering in 2008; and<BR>
    (4) Compliance with 2008 budget for expenses and cash outflows.
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    81
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In light of these grants to Mr.&#160;Jog and our team-based
    compensation philosophy, the compensation committee expects to
    consider and grant additional performance-based options to our
    other named executive officers that are similar to the two
    50,000&#160;share grants made to Mr.&#160;Jog, with one such
    grant subject to accelerated vesting upon achievement of
    individual performance goals and one such grant subject to
    accelerated vesting based on achievement of corporate goals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Employment and Severance Agreements.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In February 2008, we entered into Employment and Severance
    Agreements with each of our named executive officers that
    provide for specified payments and benefits if the
    officer&#146;s employment is terminated without cause, or if the
    officer&#146;s employment is terminated without cause or for
    good reason within 12&#160;months following a change of control.
    The terms of these agreements are described under
    &#147;Potential Payments Upon Termination or Change of
    Control.&#148; We adopted these arrangements because we
    recognize that we will from time to time consider the
    possibility of an acquisition by another company or other change
    of control transaction and that such consideration can be a
    distraction to our executive officers and can cause such
    officers to consider alternative employment opportunities.
    Accordingly, the Board concluded that it is in the best
    interests of our company and its stockholders to provide
    executives with certain severance benefits upon termination of
    employment without cause or for good reason following a change
    of control. Our Board determined to provide such executives with
    certain severance benefits upon their termination of employment
    without cause outside of the change of control context in order
    to provide executives with enhanced financial security and
    incentive to remain with our company. In addition, we believe
    that providing for acceleration of options if an officer is
    terminated following a change of control transaction aligns the
    executive officer&#146;s interest more closely with those of
    other stockholders when evaluating the transaction rather than
    putting the officer at risk of losing the benefits of those
    equity incentives.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, all outstanding options granted to our employees
    will become fully vested upon a change of control if the options
    are not assumed by the acquiring company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In connection with the departure of Mr.&#160;Lucero, our former
    Vice President of Sales and Marketing, on March&#160;22, 2008,
    we entered into a Settlement Agreement and General Release of
    Claims with Mr.&#160;Lucero that provided for mutual releases of
    us and Mr.&#160;Lucero, our continued payment of
    Mr.&#160;Lucero&#146;s salary and health insurance premiums
    through July 2008 and payment of an additional $90,000 to
    Mr.&#160;Lucero. The amount and timing of payments to
    Mr.&#160;Lucero under this agreement were the result of
    negotiations between us and Mr.&#160;Lucero, with the
    involvement of the compensation committee. The compensation
    committee concluded that this agreement was in the best
    interests of our company in reaching an amicable separation with
    Mr.&#160;Lucero.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In connection with Mr.&#160;DeLateur&#146;s resignation, we
    entered into a consulting agreement dated February&#160;29,
    2008. Under the consulting agreement, we agreed to pay
    Mr.&#160;DeLateur $200 per hour for performing various
    consulting services, provided that Mr.&#160;DeLateur work no
    more than five hours per week without our written authorization.
    We entered into this arrangement to ensure that
    Mr.&#160;DeLateur would be available as needed to ensure an
    orderly transition to our new Chief Financial Officer,
    Mr.&#160;Jog.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Other Benefits.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Executive officers are eligible to participate in all of our
    employee benefit plans, such as medical, dental, vision, group
    life, disability, and accidental death and dismemberment
    insurance and our 401(k) plan, in each case on the same basis as
    other employees, subject to applicable law. We also provide
    vacation and other paid holidays to all employees, including our
    executive officers, which we believe are comparable to those
    provided at peer companies.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">CEO
    Loan and Stock Repurchase</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On January&#160;20, 2004, we entered into an Employee Loan
    Agreement, Secured Promissory Note and Stock Pledge Agreement
    with Mr.&#160;Worthington pursuant to which we loaned
    Mr.&#160;Worthington $250,000 at an interest rate of 3.52% per
    annum. The loan was secured by the pledge of 833,334&#160;shares
    of our common stock held by Mr.&#160;Worthington. On
    April&#160;10, 2008, Mr.&#160;Worthington repaid the loan in
    full in accordance with Section&#160;2.2(d) of the note by
    exchanging shares of our common stock held by
    Mr.&#160;Worthington to us at the fair market value of such
    stock, which was determined by the Board of Directors to be
    $3.19 per share. The note and Mr.&#160;Worthington&#146;s loan
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    82
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    were repaid in full and cancelled in exchange for
    90,913&#160;shares of our common stock which
    Mr.&#160;Worthington transferred to us pursuant to the terms of
    a repurchase agreement dated April&#160;10, 2008. This loan
    repayment and share cancellation transaction were approved by
    the [compensation committee] based on its determination that we
    received full and fair consideration for the cancellation of the
    loan and that the cancellation of the loan was in the best
    interests of our company and its stockholders.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Accounting
    and Tax Considerations</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Section 162(m) of the Internal Revenue Code of 1986, as amended,
    or the Code, places a limit of $1,000,000 on the amount of
    compensation that we may deduct as a business expense in any
    year with respect to our Chief Executive Officer and certain of
    our highly paid executive officers. We can, however, preserve
    the deductibility of certain performance-based compensation in
    excess of $1,000,000 if the conditions of Code
    Section&#160;162(m) are met. Under applicable tax guidance for
    newly-public companies, the deduction limitation generally will
    not apply to compensation paid pursuant to any plan or agreement
    that existed before the company became publicly held. In
    addition, compensation provided by newly-public companies
    through the first stockholder meeting to elect directors after
    the close of the third calendar year following the year in which
    the initial public offering occurs, or earlier upon the
    occurrence of certain events (e.g., a material modification of
    the plan or agreement under which the compensation is granted),
    will not be included in for purposes of the Code
    Section&#160;162(m) limit provided the arrangement is adequately
    described in this prospectus. Accordingly, we believe that
    deductibility of all income recognized by executives pursuant to
    equity compensation granted by us prior to this offering, as
    well as any equity compensation granted by us under the 2008
    Equity Incentive Plan following this offering through the
    expiration of the reliance period, will not be limited by Code
    Section&#160;162(m). While the compensation committee cannot
    predict how the deductibility limit may impact our compensation
    program in future years, the compensation committee intends to
    maintain an approach to executive compensation that strongly
    links pay to performance. While the compensation committee has
    not adopted a formal policy regarding tax deductibility of
    compensation paid to our executive officers, the compensation
    committee intends to consider tax deductibility under
    Section&#160;162(m) as a factor in compensation decisions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Code Section 409A imposes additional taxes on certain
    non-qualified deferred compensation arrangements that do not
    comply with its requirements. These requirements regulate an
    individual&#146;s election to defer compensation and the
    individual&#146;s selection of the timing and form of
    distribution of the deferred compensation. Code
    Section&#160;409A generally also provides that distributions of
    deferred compensation only can be made on or following the
    occurrence of certain events (i.e., the individual&#146;s
    separation from service, a predetermined date, a change in
    control, or the individual&#146;s death or disability). For
    certain executives, Code Section&#160;409A requires that such
    individual&#146;s distribution commence no earlier than six
    (6)&#160;months after such officer&#146;s separation from
    service. We have and will continue to endeavor to structure our
    compensation arrangements to comply with Code Section&#160;409A
    so as to avoid the adverse tax consequences associated therewith.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    83
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Summary
    Compensation Table</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table presents information concerning the total
    compensation of our Chief Executive Officer, Chief Financial
    Officer and three other most highly compensated officers during
    the last fiscal year (the &#147;Named Executive Officers&#148;)
    for services rendered to us in all capacities for the fiscal
    year ended December&#160;29, 2007:
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Summary
    Compensation Table</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="49%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Non-Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Incentive Plan<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Salary<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name and Principal Position</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)<SUP style="font-size: 85%; vertical-align: text-top">(4)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    Gajus V. Worthington
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    283,357
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    16,227
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    14,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    313,489
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt; z-index: 1; position: relative">
    President and Chief<BR>
    Executive Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Richard A.
    DeLateur<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    241,375
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    75,409
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    312,900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    Former Chief Financial Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    Michael Y.
    Lucero<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    264,517
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    14,605
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    286,142
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt; z-index: 1; position: relative">
    Former Executive Vice President,<BR>
    Sales and Marketing
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    William M. Smith
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    261,983
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    19,223
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    18,550
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    310,121
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    Vice President, Legal<BR>
    Affairs and General<BR>
    Counsel
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    Robert C. Jones
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    247,502
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    18,550
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,263
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    270,315
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt; z-index: 1; position: relative">
    Executive Vice President<BR>
    Research and Development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Grace Yow
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    204,214
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    73,630
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    14,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    293,278
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    Vice President, Worldwide<BR>
    Manufacturing and Managing Director of Fluidigm Singapore
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Amounts represent the aggregate
    expense recognized for financial statement reporting purposes
    for fiscal 2007 calculated in accordance with
    SFAS&#160;No.&#160;123(R) without regard for estimated
    forfeitures. See Note&#160;2 of Notes to Consolidated Financial
    Statements for a discussion of assumptions made in determining
    the grant date fair value and compensation expense of our stock
    options.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Mr.&#160;DeLateur resigned
    effective February&#160;29, 2008. From August&#160;16, 2007 to
    December&#160;31, 2007, Mr.&#160;DeLateur worked for us on a
    <FONT style="white-space: nowrap">part-time</FONT>
    basis. Currently Mr.&#160;DeLateur serves as a consultant. See
    &#147;Employment Agreements and Offer Letters.&#148;
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Mr.&#160;Lucero resigned effective
    March&#160;22, 2008. See &#147;Employment and Severance
    Agreements.&#147;
    </FONT></TD>
</TR>



<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(4)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The amounts in this column
    represent total
    <FONT style="white-space: nowrap">performance-based</FONT>
    bonuses earned for service rendered during fiscal 2007 under our
    incentive bonus plan. Under our incentive bonus plan, each
    executive was eligible to receive a cash bonus of up to 35% of
    his or her base salary based on achievement of certain corporate
    goals and certain individual performance goals. Please see
    &#147;Incentive Bonus Plan&#148; under &#147;Compensation
    Discussion and Analysis&#148; above for additional information
    regarding our fiscal 2007 cash bonuses.
    </FONT></TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    84
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Grants
    of Plan-Based Awards</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table presents information concerning grants of
    plan-based awards to each of the Named Executive Officers during
    the fiscal year ended December&#160;29, 2007.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Grants of
    Plan-Based Awards</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="43%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="8%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Estimated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>All Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Payouts Under<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards:<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Non-Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Grant Date<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Incentive Plan<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise or<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Fair Value of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Base Price of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Stock and<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Maximum<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Grant Date</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(#)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($/Sh)<SUP style="font-size: 85%; vertical-align: text-top">(8)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Awards<SUP style="font-size: 85%; vertical-align: text-top">(7)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    Gajus V. Worthington
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    5/8/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    155,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    131,533
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4/24/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    99,225
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Richard DeLateur
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    5/8/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    140,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    115,668
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4/24/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    92,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    Michael Y. Lucero
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    5/8/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    21,753
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4/24/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    92,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    William M. Smith
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    5/8/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    118,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(4)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    101,114
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4/24/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    92,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    Grace Yow
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    5/8/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    199,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(5)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    165,250
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4/24/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Robert C. Jones
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    5/8/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    80,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(6)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    69,288
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4/24/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    92,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">10,000 of the shares subject to
    this grant were vested as of the grant date, 20,000&#160;shares
    vested on February&#160;1, 2008, 65,000&#160;shares vest on
    February&#160;1, 2009, and 70,000&#160;shares vest on
    February&#160;1, 2010.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">70,000 of the shares subject to
    this grant were vested as of the grant date and
    70,000&#160;shares vest on February&#160;1, 2010.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">All of the shares subject to this
    grant vest on February&#160;1, 2010.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(4)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">10,000 of the shares subject to
    this grant vested on February&#160;1, 2008, 38,000&#160;shares
    vest on February&#160;1, 2009, and 70,000&#160;shares vest on
    February&#160;1, 2010.
    </FONT></TD>
</TR>



<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(5)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">50,000 of the shares subject to
    this grant were vested as of the grant date, 50,000&#160;shares
    vested on February&#160;1, 2008, 40,000&#160;shares vest on
    February&#160;1, 2009, and 49,000&#160;shares vest on
    February&#160;1, 2010.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(6)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">10,000 of the shares subject to
    this grant vest on February&#160;1, 2009 and 70,000&#160;shares
    vest on February&#160;1, 2010.
    </FONT></TD>
</TR>



<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(7)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Amounts represent the aggregate
    expense recognized for financial statement reporting purposes
    for fiscal 2007 calculated in accordance with
    SFAS&#160;No.&#160;123(R) without regard for estimated
    forfeitures. See Note&#160;2 of Notes to Consolidated Financial
    Statements for a discussion of assumptions made in determining
    the grant date fair value and compensation expense of our stock
    options.
    </FONT></TD>
</TR>



<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(8)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Our shares of common stock were not
    publicly traded during the 2007 fiscal year; our board of
    directors in good faith determined the fair market value on the
    date of grant.
    </FONT></TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    85
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Outstanding
    Equity Awards at Fiscal Year-End</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table presents certain information concerning
    equity awards held by the Named Executive Officers at the end of
    the fiscal year ended December&#160;29, 2007. None of the named
    executive officers held any stock award at the end of the fiscal
    year ended December&#160;29, 2007.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Outstanding
    Equity Awards at Fiscal Year-End</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="54%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="14" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Option Awards</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unexercised<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unexercised<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options (#)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options (#)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Expiration<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Exercisable<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Unexercisable</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Price&#160;($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Date</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Gajus V. Worthington
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    200,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
     0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.56
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    01/17/2015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    155,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    05/08/2017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Richard DeLateur
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    95,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(4)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    235,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(6)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.56
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12/20/2015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    140,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(5)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    05/08/2017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Michael Y. Lucero
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(7)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12/04/2011
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    180,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(8)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    04/18/2014
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(9)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    07/15/2013
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    150,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(10)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.56
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    01/17/2015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(11)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.83
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    08/14/2016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(12)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    05/08/2017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    William M. Smith
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(13)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12/04/2011
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    175,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(14)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    07/15/2013
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(15)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    04/18/2014
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(16)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.56
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    01/17/2015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(17)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.83
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    08/14/2016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    118,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(18)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.83
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    05/08/2017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Grace Yow
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    150,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(19)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.56
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    08/03/2015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(20)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.83
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    09/27/2006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    199,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(21)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    05/08/2017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Robert C. Jones
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    400,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(22)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.56
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    08/03/2015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    80,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(23)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    05/08/2017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Unless otherwise noted, all option
    grants may be exercised pursuant to a restricted stock purchase
    agreement prior to vesting; any shares purchased prior to
    vesting are subject to a right of repurchase in our favor in the
    event the individual ceases to provide services for any reason
    which lapses in accordance with the vesting schedule of the
    option.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    January&#160;18, 2005 and vest over 4&#160;years. 20% of the
    shares subject to the stock option vest one year after grant.
    1.667% of the shares vest at the end of each monthly period
    during the subsequent year and 2.5% of the shares vest at the
    end of each monthly period thereafter.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">10,000 of the shares subject to
    this grant were vested as of May&#160;8, 2007, the grant date,
    20,000&#160;shares vested on February&#160;1, 2008,
    65,000&#160;shares vest on February&#160;1, 2009, and 70,000
    vest on February&#160;1, 2010.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(4)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    December&#160;21, 2005 and vest over 4&#160;years. 25% of the
    shares vest one year after grant and 2.083% of the shares vest
    at the end of each monthly period thereafter.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(5)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">70,000 of the shares subject to
    this grant were vested as of May&#160;8, 2007, the grant date,
    and 70,000&#160;shares vest on February&#160;1, 2010.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(6)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">This option may not be exercised
    prior to vesting, as set forth in footnote (1).
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(7)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    December&#160;4, 2001 and vest over 4&#160;years. 25% of the
    shares vest one year after grant and 2.083% of the shares vest
    at the end of each monthly period thereafter.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(8)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    April&#160;19, 2004 and vest over 4&#160;years at the rate of
    2.083% of the shares per month.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(9)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    July&#160;16, 2003 and vest over 4&#160;years at the rate of
    2.083% of the shares per month.
    </FONT></TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    86
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(10)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    January&#160;18, 2005 and vest over 4&#160;years. 20% of the
    shares subject to the stock option vest one year after grant.
    1.667% of the shares vest at the end of each monthly period
    during the subsequent year and 2.5% of the shares vest at the
    end of each monthly period thereafter.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(11)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    August&#160;15, 2006 vest over 4&#160;years. 1.67% of the shares
    vest each month for the first two years and 2.5% of the shares
    vest each month in the final two years.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(12)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    May&#160;8, 2007. All of the shares subject to this grant vest
    on February&#160;1, 2010.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(13)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    December&#160;4, 2001 and vest over 4&#160;years at the rate of
    2.083% of the shares per month.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(14)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    July&#160;16, 2003 and vest over 4&#160;years at the rate of
    2.083% of the shares per month.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(15)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    April&#160;19, 2004 and vest over 4&#160;years at the rate of
    2.083% of the shares per month.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(16)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    January&#160;18, 2005 and vest over 4&#160;years. 20% of the
    shares subject to the stock option vest one year after grant.
    1.667% of the shares vest at the end of each monthly period
    during the subsequent year and 2.5% of the shares vest at the
    end of each monthly period thereafter.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(17)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    August&#160;15, 2006 vest over 4&#160;years. 1.67% of the shares
    vest each month for the first two years and 2.5% of the shares
    vest each month in the final two years.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(18)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    May&#160;8, 2007. 10,000 of the shares subject to this grant
    vested on February&#160;1, 2008, 38,000&#160;shares vest on
    February&#160;1, 2009, and 70,000&#160;shares vest on
    February&#160;1, 2010.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(19)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    August&#160;3, 2005 and vest over 4&#160;years. 25% of the
    shares vest one year after grant and 2.083% of the shares vest
    at the end of each monthly period thereafter.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(20)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    September&#160;27, 2006. These stock options vest over
    4&#160;years in monthly increments. During the first two years,
    1.67% of the shares vest each month and during the final two
    years, 2.5% of the shares vest each month.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(21)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">50,000 of the shares subject to
    this grant were vested as of May&#160;8, 2007, the grant date,
    50,000&#160;shares vested on February&#160;1, 2008,
    40,000&#160;shares vest on February&#160;1, 2009, and
    49,000&#160;shares vest on February&#160;1, 2010.
    </FONT></TD>
</TR>




<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(22)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">This option was granted on
    August&#160;3, 2005 and vests over 4&#160;years. Twenty-five
    percent of the shares vest one year after grant and 2.083% of
    the shares vest each month thereafter.
    </FONT></TD>
</TR>



<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(23)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    May&#160;8, 2007. 10,000 of the shares subject to this grant
    vest on February&#160;1, 2009, and 70,000&#160;shares subject to
    this grant vest on February&#160;1, 2010.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Employment
    Agreements and Offer Letters</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Richard A DeLateur.</I>&#160;&#160;We entered into a
    consulting agreement dated February&#160;29, 2008 with Richard
    A. DeLateur, our former Chief Financial Officer. Under the
    consulting agreement, we agreed to pay Mr.&#160;DeLateur $200
    per hour for performing various consulting services, provided
    that Mr.&#160;DeLateur shall work no more than five hours per
    week without our written authorization. The consulting agreement
    will remain in force until the earlier of: (i)&#160;the
    completion of the services; (ii)&#160;the termination of the
    agreement; or (iii)&#160;the expiration of the agreement on
    May&#160;17, 2008, unless otherwise agreed in writing by both
    parties.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Michael Y. Lucero.</I>&#160;&#160;We entered into to a
    Settlement Agreement and General Release of Claims on
    March&#160;22, 2008 with Michael Y. Lucero, our former Executive
    Vice President of Sales and Marketing. Under the settlement
    agreement, we agreed, in exchange for a general release of all
    claims and other customary terms and conditions, (i)&#160;to pay
    Mr.&#160;Lucero on each pay day through July&#160;15, 2008 an
    amount equal to what he would have received on that pay day
    based on an annual base salary of $265,000 and (ii)&#160;to
    reimburse Mr.&#160;Lucero for costs of coverage under the
    Consolidated Omnibus Budget Reconciliation Act of 1985, or
    COBRA, that are incurred during April, May, June and July of
    2008, in an amount no greater than the amount we contributed on
    Mr.&#160;Lucero&#146;s behalf for February 2008. We also agreed
    to make a one time payment to Mr.&#160;Lucero of $90,000.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Vikram Jog.</I>&#160;&#160;We are a party to an offer letter
    dated January&#160;29, 2008, with Vikram Jog, our Chief
    Financial Officer. Under the offer letter, we employ
    Mr.&#160;Jog on an at-will basis for no specified term and
    agreed to pay Mr.&#160;Jog an annual base salary of $278,000,
    which continues to be his base salary. We also agreed to pay
    Mr.&#160;Jog a signing bonus of $20,000 pursuant to his offer
    letter. Pursuant to the offer letter, we granted Mr.&#160;Jog an
    initial options to purchase a total of 600,000&#160;shares of
    our common stock.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Potential
    Payments Upon Termination or Change of Control</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In February 2008, we entered into employment and severance
    agreements with Gajus V. Worthington, William M. Smith, Mai Chan
    (Grace) Yow, Robert C. Jones and Vikram Jog, which require us to
    make payments if the named executive officer&#146;s employment
    with us is terminated in certain circumstances.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    87
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to our employment and severance agreements with our
    named executive officers, a &#147;change of control&#148; is
    defined as the occurrence of the following events:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any &#147;person,&#148; as such term is used in
    Sections&#160;13(d) and 14(d) of the Securities Exchange Act of
    1934, as amended, is or becomes the &#147;beneficial
    owner,&#148; as such term is defined in
    <FONT style="white-space: nowrap">Rule&#160;13d-3</FONT>
    under said Act, directly or indirectly, of our securities
    representing 50% or more of the total voting power represented
    by our then outstanding voting securities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a change in the composition of our Board occurring within a
    two-year period, as a result of which fewer than a majority of
    our directors are &#147;incumbent directors,&#148; which term is
    defined as either (i)&#160;our directors as of the execution
    date of the relevant agreement or (ii)&#160;directors who are
    elected, or nominated for election, to our Board with the
    affirmative votes of at least a majority of the incumbent
    directors at the time of such election or nomination (but will
    not include an individual whose election or nomination is in
    connection with an actual or threatened proxy contest relating
    to the election of our directors);
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the date of the consummation of our merger or consolidation with
    any other corporation that has been approved by the our
    stockholders, other than a merger or consolidation that would
    result in our voting securities outstanding immediately prior
    thereto continuing to represent (either by remaining outstanding
    or by being converted into voting securities of the surviving
    entity) more than 50% of the total voting power represented by
    our voting securities or such surviving entity outstanding
    immediately after such merger or consolidation, or our
    stockholders approve a plan of our complete liquidation;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the date of the consummation of the sale or disposition by us of
    all or substantially all of our assets.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to our employment and severance agreements with our
    named executive officers, &#147;cause&#148; is defined as:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an act of dishonesty in connection with a named executive
    officer&#146;s responsibilities as an employee;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a conviction of, or plea of <I>nolo contendere </I>to, a felony
    or any crime involving fraud, embezzlement or any other act of
    moral turpitude;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    gross misconduct;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an unauthorized use or disclosure of any of our proprietary
    information or of any other party to whom he or she owes an
    obligation of nondisclosure as a result of his or her
    relationship with us;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a willful breach of any obligations under any written agreement
    or covenant with us;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a named executive officer&#146;s continued failure to perform
    his or her employment duties after he or she has received a
    written demand of performance from us and has failed to cure
    such non-performance to our satisfaction within 10 business days
    after receiving such notice.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to our employment and severance agreements with Gajus
    V. Worthington, William M. Smith, Robert C. Jones and Vikram
    Jog, &#147;good reason&#148; means the occurrence of one or more
    of the following events effected without the named executive
    officer&#146;s prior consent, provided that he or she terminates
    his or her employment within one year thereafter:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the assignment to the named executive officer of any duties or a
    reduction of the named executive officer&#146;s duties, either
    of which significantly reduces his or her responsibilities;
    provided that the continuance of his or her responsibilities at
    the subsidiary or divisional level following a change of
    control, rather than at the parent, combined or surviving
    company level following such change of control shall not be
    deemed &#147;good reason&#148; within the meaning of this clause;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a material reduction of the named executive officer&#146;s base
    salary;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the relocation of the named executive officer to a facility or a
    location greater than 50&#160;miles from his or her present
    location;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a material breach by us of any material provision of the
    employment and severance agreement.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    88
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    However, no act or omission by us shall constitute &#147;good
    reason&#148; if we fully cure that act or omission within
    30&#160;days of receiving notice of receiving notice from the
    named executive officer.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to our employment and severance agreement with Mai Chan
    (Grace) Yow, &#147;good reason&#148; means the occurrence of one
    or more of the following events effected without her consent,
    provided that she terminates her employment within one year
    thereafter:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the assignment to Ms.&#160;Yow of any duties or a reduction of
    her duties, either of which significantly reduces her
    responsibilities; provided that the continuance of her
    responsibilities at the subsidiary or divisional level following
    a change of control, rather than at the parent, combined or
    surviving company level following such change of control shall
    not be deemed &#147;good reason&#148; within the meaning of this
    clause;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a material reduction of Ms.&#160;Yow&#146;s base salary;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the relocation of Ms.&#160;Yow to a facility or a location
    outside the country of Singapore;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a material breach by us of any material provision of the
    employment and severance agreement.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    However, no act or omission by us shall constitute &#147;good
    reason&#148; if we fully cure that act or omission within
    30&#160;days of receiving notice of receiving notice from the
    named executive officer.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The employment and severance agreements provide that in the
    event the named executive officer&#146;s employment is
    terminated by us or our successor without &#147;cause&#148;
    prior to a &#147;change of control&#148; or after 12&#160;months
    following a &#147;change of control&#148; and the named
    executive officer executes a standard release of claims with us,
    the named executive officer is entitled to receive, in addition
    to such officer&#146;s salary payable through the date of
    termination of employment and any other benefits earned and owed
    through the date of termination, the following cash payments:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an amount, payable in accordance with our customary payroll
    practices, equal to six&#160;months of the named executive
    officer&#146;s base salary in effect immediately prior to the
    time of termination;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reimbursement of costs and expenses incurred by the executive
    officer and his or her eligible dependents for coverage under
    group health plans, policies or arrangements sponsored by us for
    a period of up to six&#160;months, provided that such coverage
    is timely elected under COBRA or similar applicable state
    statute.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The employment and severance agreements further provide that in
    the event the named executive officer&#146;s employment is
    terminated by (i)&#160;us or our successor without
    &#147;cause&#148; and within 12&#160;months following a
    &#147;change of control&#148; or (ii)&#160;by the executive
    officer for &#147;good reason&#148; and within 12&#160;months
    following a &#147;change of control&#148;, and in each case the
    named executive officer executes a standard release of claims
    with us, the executive officer is entitled to receive, in
    addition to such officer&#146;s salary payable through the date
    of termination of employment and any other benefits earned and
    owed through the date of termination, the following cash
    payments and benefits:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an amount, payable in a lump sum, equal to the greater of
    (i)&#160;six&#160;months of the named executive officer&#146;s
    base salary in effect immediately prior to the change in control
    or (ii)&#160;six&#160;months of the named executive&#146;s
    officer&#146;s base salary in effect immediately prior to the
    time of termination;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    all outstanding unvested stock options, equity appreciation
    rights or similar equity awards then held by the named executive
    officer as of the date of termination will immediately vest and
    become exercisable as to all shares underlying such options;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any shares of restricted stock, restricted stock units and
    similar equity awards then held by the named executive officer
    will immediately vest and any of our rights of repurchase or
    reacquisition with respect to such shares will lapse as to all
    shares;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reimbursement of costs and expenses incurred by the executive
    officer and his or her eligible dependents for coverage under
    group health plans, policies or arrangements sponsored by us for
    a period of up to six months, provided that such coverage is
    timely elected under COBRA or similar applicable state statute.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table describes the payments and benefits that
    each of our named executive officers would be entitled to
    receive pursuant to the employment and severance agreements,
    assuming that each of the following
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    89
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    triggers occurred in December&#160;29, 2007: their employment
    was terminated without &#147;cause&#148; prior to or after
    12&#160;months following a &#147;change of control&#148; and
    (ii) their employment was terminated without &#147;cause&#148;
    or for &#147;good reason&#148; within 12&#160;months following a
    &#147;change of control&#148;.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="43%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Employment Terminated without Cause Prior<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B>Employment Terminated within 12 Months<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>to or After 12 Months Following Change of
    Control<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Following Change of
    Control<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Severance<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Health Care<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Severance<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Health Care<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Payments<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Benefits<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Acceleration<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Payments<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Benefits<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name and Principal Position</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)<SUP style="font-size: 85%; vertical-align: text-top">(4)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)<SUP style="font-size: 85%; vertical-align: text-top">(5)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    Gajus V. Worthington
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    135,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9,213
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    135,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9,213
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt; z-index: 1; position: relative">
    President and Chief Executive Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    William M. Smith
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    132,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8,056
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    132,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8,056
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    Vice President, Legal Affairs and General Counsel
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    Mai Chan (Grace) Yow
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    100,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    525
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(6)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    100,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    525
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(6)</SUP>
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt; z-index: 1; position: relative">
    Vice President, Worldwide Manufacturing and Managing Director of
    Fluidigm Singapore
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Robert C. Jones
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    132,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9,213
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    132,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9,213
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    Executive Vice President, Research and Development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt; z-index: 1; position: relative">
    Vikram Jog
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    139,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10,142
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    139,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10,142
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt; z-index: 1; position: relative">
    Chief Financial Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The change of control severance
    agreements we entered into with our named executive officers do
    not provide for equity acceleration in connection with a
    termination other than a termination without cause that occurs
    prior to or within 12&#160;months following a change of control.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Includes involuntary termination
    other than for cause, death or disability, and voluntary
    termination for good reason.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The amounts shown in this column
    are equal to 6&#160;months of the named executive officer&#146;s
    base salary as of December&#160;29, 2007.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(4)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The amounts shown in this column
    are equal to the spread value between (i)&#160;the unvested
    portion of all outstanding stock options, equity appreciation
    rights or similar equity awards held by the named executive
    officer on December&#160;29, 2007 and (ii)&#160;the initial
    public offering price of our common stock, which we have assumed
    to be the midpoint of the price range set forth on the cover
    page of this prospectus.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(5)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The amounts shown in this column
    are equal to the cost of covering the named executive officer
    and his or her eligible dependents coverage under our benefit
    plans for a period of six months, assuming that such coverage is
    timely elected under COBRA.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(6)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Amount shown has been converted
    from Singapore dollars to U.S. dollars based on the interbank
    exchange rate for December&#160;29, 2007 of 1&#160;Singapore
    dollar = 0.6909 U.S. dollars.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition to the benefits described above, our 2008 Equity
    Incentive Plan and 1999 Stock Option Plan provide for the
    acceleration of vesting of awards in certain circumstances in
    connection with or following a change of control of our company.
    See &#147;Employee Benefit Plans&#148; below.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Employee
    Benefit Plans</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">2008
    Equity Incentive Plan.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors adopted our 2008 Equity Incentive Plan on
    January&#160;29, 2008 and we expect our stockholders will
    approve it prior to the completion of this offer. Subject to
    stockholder approval, the 2008 Equity Incentive Plan is
    effective upon its adoption by our Board of Directors, but is
    not expected to be utilized until after the completion of this
    offering. Our 2008 Equity Incentive Plan provides for the grant
    of incentive stock options, within the meaning of
    Section&#160;422 of the Internal Revenue Code, to our employees
    and any parent and subsidiary corporations&#146; employees, and
    for the grant of nonstatutory stock options, restricted stock,
    restricted stock units, stock appreciation rights, performance
    units and performance shares to our employees, directors and
    consultants and our parent and subsidiary corporations&#146;
    employees and consultants.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A total
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of our common stock are reserved for issuance pursuant to the
    2008 Equity Incentive Plan, of which no options were issued and
    outstanding. In addition, the shares reserved for issuance under
    our 2008 Equity Incentive Plan will also include (a)&#160;those
    shares reserved but unissued under the 1999 Stock Option Plan as
    of the effective date of the first registration statement filed
    by us and declared effective with respect to any
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    90
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    class of our securities and (b)&#160;shares returned to the 1999
    Stock Option Plan as the result of expiration or termination of
    options (provided that the maximum number of shares that may be
    added to the 2008 Equity Incentive Plan pursuant to (a)&#160;and
    (b)&#160;is&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares).
    The number of shares available for issuance under the 2008
    Equity Incentive Plan will also include an annual increase on
    the first day of each fiscal year beginning
    in&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    equal to the lesser of:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    4% of the outstanding shares of common stock as of the last day
    of our immediately preceding fiscal year;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    such other amount as our Board of Directors may determine.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors or a committee appointed by our Board
    administers our 2008 Equity Incentive Plan. Our compensation
    committee will administer our 2008 Equity Incentive Plan after
    the completion of the offering. In the case of options intended
    to qualify as &#147;performance-based compensation&#148; within
    the meaning of Section&#160;162(m) of the Internal Revenue Code,
    the committee will consist of two or more &#147;outside
    directors&#148; within the meaning of Section&#160;162(m).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subject to the provisions of our 2008 Equity Incentive Plan, the
    administrator has the power to determine the terms of the
    awards, including the exercise price, the number of shares
    subject to each such award, the exercisability of the awards and
    the form of consideration, if any, payable upon exercise. The
    administrator also has the authority to amend existing awards to
    reduce their exercise price, to allow participants the
    opportunity to transfer outstanding awards to a financial
    institution or other person or entity selected by the
    administrator and to institute an exchange program by which
    outstanding awards may be surrendered in exchange for awards
    with a higher or lower exercise price.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The exercise price of options granted under our 2008 Equity
    Incentive Plan must at least be equal to the fair market value
    of our common stock on the date of grant. The term of an
    incentive stock option may not exceed 10&#160;years, except that
    with respect to any participant who owns 10% of the voting power
    of all classes of our outstanding stock, the term must not
    exceed 5&#160;years and the exercise price must equal at least
    110% of the fair market value on the grant date. Subject to the
    provisions of our 2008 Equity Incentive Plan, the administrator
    determines the term of all other options.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After the termination of service of an employee, director or
    consultant, he or she may exercise his or her option for the
    period of time stated in his or her option agreement. Generally,
    if termination is due to death or disability, the option will
    remain exercisable for 12&#160;months. In all other cases, the
    option will generally remain exercisable for three months
    following the termination of service. However, in no event may
    an option be exercised later than the expiration of its term.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Stock appreciation rights may be granted under our 2008 Equity
    Incentive Plan. Stock appreciation rights allow the recipient to
    receive the appreciation in the fair market value of our common
    stock between the exercise date and the date of grant. Subject
    to the provisions of our 2008 Equity Incentive Plan, the
    administrator determines the terms of stock appreciation rights,
    including when such rights become exercisable and whether to pay
    any increased appreciation in cash or with shares of our common
    stock, or a combination thereof, except that the per share
    exercise price for the shares to be issued pursuant to the
    exercise of a stock appreciation right will be no less than 100%
    of the fair market value per share on the date of grant.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Restricted stock may be granted under our 2008 Equity Incentive
    Plan. Restricted stock awards are grants of shares of our common
    stock that vest in accordance with terms and conditions
    established by the administrator. The administrator will
    determine the number of shares of restricted stock granted to
    any employee, director or consultant. The administrator may
    impose whatever conditions to vesting it determines to be
    appropriate (for example, the administrator may set restrictions
    based on the achievement of specific performance goals or
    continued service to us); provided, however, that the
    administrator, in its sole discretion, may accelerate the time
    at which any restrictions will lapse or be removed. Shares of
    restricted stock that do not vest are subject to our right of
    repurchase or forfeiture.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Restricted stock units may be granted under our 2008 Equity
    Incentive Plan. Restricted stock units are bookkeeping entries
    representing an amount equal to the fair market value of one
    share of our common stock. The
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    91
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    administrator determines the terms and conditions of restricted
    stock units including the vesting criteria (which may include
    accomplishing specified performance criteria or continued
    service to us) and the form and timing of payment.
    Notwithstanding the foregoing, the administrator, in its sole
    discretion may accelerate the time at which any restrictions
    will lapse or be removed.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Performance units and performance shares may be granted under
    our 2008 Equity Incentive Plan. Performance units and
    performance shares are awards that will result in a payment to a
    participant only if performance goals established by the
    administrator are achieved or the awards otherwise vest. The
    administrator will establish organizational or individual
    performance goals in its discretion, which, depending on the
    extent to which they are met, will determine the number
    <FONT style="white-space: nowrap">and/or</FONT> the
    value of performance units and performance shares to be paid out
    to participants. After the grant of a performance unit or
    performance share, the administrator, in its sole discretion,
    may reduce or waive any performance objectives or other vesting
    provisions for such performance units or performance shares.
    Performance units shall have an initial dollar value established
    by the administrator prior to the grant date. Performance shares
    shall have an initial value equal to the fair market value of
    our common stock on the grant date. The administrator, in its
    sole discretion, may pay earned performance units or performance
    shares in the form of cash, in shares or in some combination
    thereof.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our 2008 Equity Incentive Plan provides that all non-employee
    directors will be eligible to receive all types of awards
    (except for incentive stock options) under the 2008 Equity
    Incentive Plan. Please see the description of our Outside
    Director Equity Compensation Policy below.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless the administrator provides otherwise, our 2008 Equity
    Incentive Plan generally does not allow for the transfer of
    awards and only the recipient of an award may exercise an award
    during his or her lifetime.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our 2008 Equity Incentive Plan provides that in the event of a
    merger or &#147;change in control,&#148; as defined in the 2008
    Equity Incentive Plan, each outstanding award will be treated as
    the administrator determines, including that the successor
    corporation or its parent or subsidiary will assume or
    substitute an equivalent award for each outstanding award. The
    administrator is not required to treat all awards similarly. If
    there is no assumption or substitution of outstanding awards,
    the awards will fully vest, all restrictions will lapse, all
    performance goals or other vesting criteria will be deemed
    achieved at 100% of target levels and the awards will become
    fully exercisable. The administrator will provide notice to the
    recipient that he or she has the right to exercise the option
    and stock appreciation right as to all of the shares subject to
    the award, all restrictions on restricted stock will lapse, and
    all performance goals or other vesting requirements
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">1999
    Stock Option Plan, as amended</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our 1999 Stock Option Plan was adopted by our Board of Directors
    and approved by our stockholders on May&#160;12, 1999. Our 1999
    Stock Option Plan was most recently amended on January&#160;29,
    2008. Our 1999 Stock Option Plan provides for the grant of
    incentive stock options, within the meaning of Section&#160;422
    of the Internal Revenue Code, to our employees and any parent
    and subsidiary corporations&#146; employees, and for the grant
    of nonstatutory stock options to our employees, directors and
    consultants and our parent and subsidiary corporations&#146;
    employees and consultants. Our Board of Directors has decided
    not to grant any additional options under our 1999 Stock Option
    Plan following the completion of this offering. However, our
    1999 Stock Option Plan will continue to govern the terms and
    conditions of the outstanding stock options previously granted
    thereunder.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subject to the provisions of our 1999 Stock Option Plan, the
    maximum aggregate number of shares which may be subject to
    option and sold under our 1999 Stock Option Plan is
    12,800,000&#160;shares. As of December&#160;29, 2007, options to
    purchase 7,467,230&#160;shares of our common stock were
    outstanding and 1,197,154&#160;shares were available for future
    grant under the 1999 Stock Option Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our compensation committee appointed by our Board of Directors
    currently administers our 1999 Stock Option Plan. Under our 1999
    Stock Option Plan, the administrator has the power to determine
    the terms of the stock options, including the employees,
    directors and consultants who will receive stock options, the
    number of shares subject to each stock option, the vesting
    schedule, any vesting acceleration, and the exercisability of
    stock options. The administrator also has the authority to
    initiate an option exchange program whereby stock options are
    exchanged for stock options with a lower exercise price. The
    administrator may also reduce the exercise price of any
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    92
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    option to the then current fair market value if the fair market
    value of our common stock has declined since the date the option
    was granted.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The exercise price of options granted under our 1999 Stock
    Option Plan must at least be equal to the fair market value of
    our common stock on the date of grant. The term of an incentive
    stock option may not exceed 10&#160;years, except that with
    respect to any optionee who owns 10% of the voting power of all
    classes of our outstanding stock as of the grant date, the term
    must not exceed 5&#160;years and the exercise price must equal
    at least 110% of the fair market value on the grant date.
    Subject to the provisions of our 1999 Stock Option Plan, the
    administrator determines the terms of all other options in its
    discretion.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After the termination of service of an employee, director or
    consultant, he or she may exercise his or her option for the
    period of time stated in his or her option agreement. Generally,
    if termination is due to death or disability, the option will
    remain exercisable for 12&#160;months. In all other cases, the
    option will generally remain exercisable for three months
    following the termination of service. In some cases, options
    issued to consultants pursuant to our 1999 Stock Option Plan
    provide that they may be exercised at anytime prior to the
    expiration of the ten year term of the option. However, in no
    event may an option be exercised later than the expiration of
    its term.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless the administrator provides otherwise, our 1999 Stock
    Option Plan generally does not allow for the transfer of awards
    and only the recipient of an award may exercise an award during
    his or her lifetime.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our 1999 Stock Option Plan provides that in the event of a
    merger of our company or a sale of substantially all of our
    assets, each outstanding stock option will be assumed or an
    equivalent option or right substituted by the successor
    corporation. If there is no assumption or substitution of
    outstanding options (or portions thereof), the options (or
    portions thereof) will fully vest and become fully exercisable.
    In such case, the administrator will provide notice to the
    optionee that he or she has the right to exercise the option as
    to all of the shares subject to the option for a period of at
    least 15&#160;days. The option will terminate upon the
    expiration of the period of time the administrator provides in
    the notice.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors has the authority to amend, suspend or
    terminate the 1999 Stock Option Plan provided such action does
    not impair the rights of any optionee without his or her written
    consent.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Retirement
    Plans</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>401(k) Plan.</I>&#160;&#160;We maintain a tax-qualified
    retirement plan that provides eligible employees with an
    opportunity to save for retirement on a tax advantaged basis.
    Eligible employees are able to participate in the 401(k) plan as
    of the first&#160;day of the month on or following the date they
    begin employment and participants are able to defer up to 60% of
    their eligible compensation subject to applicable annual
    Internal Revenue Code limits. All participants&#146; interests
    in their deferrals are 100% vested when contributed. [The 401(k)
    plan permits us to make matching contributions and profit
    sharing contributions to eligible participants, although we have
    not made any such contributions to date.] Pre-tax contributions
    are allocated to each participant&#146;s individual account and
    are then invested in selected investment alternatives according
    to the participants&#146; directions. The 401(k) plan is
    intended to qualify under Sections&#160;401(a) and 501(a) of the
    Internal Revenue Code. As a tax-qualified retirement plan,
    contributions to the 401(k) plan and earnings on those
    contributions are not taxable to the employees until distributed
    from the 401(k) plan and all contributions are deductible by us
    when made.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Limitation
    on Liability and Indemnification Matters</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our amended and restated certificate of incorporation and bylaws
    that will become effective upon the completion of this offering
    contain provisions that limit the personal liability of our
    directors for monetary damages to the fullest extent permitted
    by Delaware law. Consequently, our directors will not be
    personally liable to us or our stockholders for monetary damages
    for any breach of fiduciary duties as directors, except
    liability for:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Any breach of the director&#146;s duty of loyalty to us or our
    stockholders;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Any act or omission not in good faith or that involves
    intentional misconduct or a knowing violation of law;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Unlawful payments of dividends or unlawful stock repurchases or
    redemptions as provided in Section&#160;174 of the Delaware
    General Corporation Law;&#160;or
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    93
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Any transaction from which the director derived an improper
    personal benefit.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our amended and restated certificate of incorporation that will
    become effective upon the completion of this offering, provides
    that we indemnify our directors to the fullest extent permitted
    by Delaware law. In addition, our amended and restated bylaws,
    that will become effective upon the completion of this offering,
    provides that we indemnify our directors and officers to the
    fullest extent permitted by Delaware law. Our amended and
    restated bylaws, that will become effective upon the completion
    of this offering, also provide that we shall advance expenses
    incurred by a director or officer in advance of the final
    disposition of any action or proceeding, and permit us to secure
    insurance on behalf of any officer, director, employee or other
    agent for any liability arising out of his or her actions in
    that capacity, regardless of whether we would otherwise be
    permitted to indemnify him or her under the provisions of
    Delaware law. We have entered and expect to continue to enter
    into agreements to indemnify our directors, executive officers
    and other employees as determined by the Board of Directors.
    With certain exceptions, these agreements provide for
    indemnification for related expenses including, among others,
    attorneys&#146; fees, judgments, fines and settlement amounts
    incurred by any of these individuals in any action or
    proceeding. We believe that these bylaw provisions and
    indemnification agreements are necessary to attract and retain
    qualified persons as directors and officers. We also maintain
    directors&#146; and officers&#146; liability insurance.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The limitation of liability and indemnification provisions in
    our amended and restated certificate of incorporation and
    bylaws, that will become effective upon the completion of this
    offering, may discourage stockholders from bringing a lawsuit
    against our directors for breach of their fiduciary duty of
    care. They may also reduce the likelihood of derivative
    litigation against our directors and officers, even though an
    action, if successful, might benefit us and other stockholders.
    Further, a stockholder&#146;s investment may be adversely
    affected to the extent that we pay the costs of settlement and
    damage awards against directors and officers. At present, there
    is no pending litigation or proceeding involving any of our
    directors, officers or employees for which indemnification is
    sought, and we are not aware of any threatened litigation that
    may result in claims for indemnification.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    94
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='112'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CERTAIN
    RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition to the director and executive compensation
    arrangements discussed above in &#147;Management&#148;, we have
    been a party to the following transactions since January&#160;1,
    2005, in which the amount involved exceeded or will exceed
    $120,000 and in which any director, executive officer or holder
    of more than 5% of any class of our voting stock, or any member
    of the immediate family of or entities affiliated with any of
    them, had or will have a material interest.
</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Sales of
    Series&#160;E Preferred Stock</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In June 2006, December 2006, March 2007, October 2007 and
    December 2007, we sold an aggregate of 14,810,444&#160;shares of
    our Series&#160;E Preferred stock at a price of $4.00 per share
    for aggregate consideration of $59,241,776. In connection with
    these sales, we granted the purchasers certain registration
    rights with respect to their securities. See &#147;Description
    of Capital Stock&#160;&#151; Registration Rights.&#148; The
    purchasers of the Series&#160;E Preferred stock included, among
    others, the following 5% stockholders and directors and their
    affiliates:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="76%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Series E<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Aggregate<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Preferred<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Purchase<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Purchasers</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Stock</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Price</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>5% Stockholders:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Entities affiliated with Versant
    Ventures<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    250,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Entities affiliated with EuclidSR
    Partners<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    211,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    847,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Entities affiliated with Alloy
    Ventures<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    161,250
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    645,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Entities affiliated with Lehman Brothers Holdings,
    Inc.<SUP style="font-size: 85%; vertical-align: text-top">(4)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    159,749
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    638,996
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Lilly
    Ventures<SUP style="font-size: 85%; vertical-align: text-top">(5)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    89,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    359,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Bruce
    Burrows<SUP style="font-size: 85%; vertical-align: text-top">(6)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    394,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,579,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,267,249
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,068,996
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 5,000&#160;shares
    purchased by Versant Affiliates
    <FONT style="white-space: nowrap">Fund&#160;1-A,</FONT>
    L.P., 10,500&#160;shares purchased by Versant Affiliates
    <FONT style="white-space: nowrap">Fund&#160;1-B,</FONT>
    L.P., 4,500&#160;shares purchased by Versant Side Fund&#160;I,
    L.P. and 230,000&#160;shares purchased by Versant Venture
    Capital&#160;I, L.P. Sam Colella, an affiliate of Versant
    Ventures, is a member of our Board of Directors.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 105,875&#160;shares
    purchased EuclidSR Biotechnology Partners, L.P. and
    105,875&#160;shares purchased by EuclidSR Partners, L.P. Elaine
    Jones, an affiliate of Euclid SR Partners, is a member of our
    Board of Directors.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 2,120&#160;shares
    purchased by Alloy Partners 2002, L.P., 78,505&#160;shares
    purchased by Alloy Ventures 2002, L.P. and 80,625&#160;shares
    purchased by Alloy Ventures 2005, L.P. Michael Hunkapiller, an
    affiliate of Alloy Ventures, is a member of our Board of
    Directors.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(4)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 39,937&#160;shares
    purchased by Lehman Brothers Healthcare Venture Capital L.P.,
    8,932&#160;shares purchased by Lehman Brothers Offshore
    Partnership Account 2000/2001, L.P., 76,440&#160;shares
    purchased by Lehman Brothers P.A., LLC, and 34,440 purchased by
    Lehman Brothers Partnership Account 2001/2001, L.P. Hingge Hsu,
    an affiliate of Lehman Brothers Holdings, Inc., served as a
    member of our Board of Directors at the time of the financing.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(5)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Ed Torres, an affiliate of Lilly
    Ventures, served as a member of our Board of Directors at the
    time of the financing.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(6)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Bruce Burrows served as member of
    our Board of Directors at the time of the financing.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Transactions
    with the Singapore Economic Development Board</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In December 2003, we entered into a convertible note purchase
    agreement with Biomedical Sciences Investment Fund&#160;Pte Ltd,
    or BSIF, an investment arm of the Singapore Economic Development
    Board. Under the terms of the agreement, BSIF was obligated to
    purchase up to two convertible promissory notes with an
    aggregate principal amount of $5&#160;million. The principal and
    interest on these notes was convertible into our Series&#160;D
    Preferred Stock at a price of $2.80 per share at any time at the
    option of BSIF and automatically upon our attaining certain
    milestones. The first note, with a principal amount of
    $2&#160;million, was sold concurrently with the execution of the
    agreement, and the second note was to be sold, at our option,
    after the conversion of the first note. In December 2004, we and
    BSIF entered into an amendment of this agreement which provided
    that under certain conditions the second note could be sold in
    two tranches of $1.5&#160;million each. These conditions were
    not met. The first note was
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    95
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    converted into stock in December 2005. The second note was sold
    in June 2006 and was converted into stock in June 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In August 2006, we entered into a second convertible note
    purchase agreement with BSIF pursuant to which BSIF was
    obligated, at our option, to purchase up to three convertible
    promissory notes each with a principal amount of $5&#160;million
    upon the occurrence of certain events. The principal and
    interest on these notes was convertible into our Series&#160;E
    Preferred Stock at a price of $3.60 per share at any time at the
    option of BSIF and automatically upon our attaining certain
    milestones. In November 2006, the terms of the second and third
    notes were amended to change conditions under which they would
    automatically convert. We sold the first note in August 2006 and
    it was converted into stock in March 2007. We sold the second
    note in November 2006 and it was converted into stock in March
    2007. The third note was sold in April 2007 and will
    automatically convert upon the closing of this offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In October 2005, our Singapore subsidiary received a grant in
    the amount of approximately S$10&#160;million (approximately
    US$6.5&#160;million at current exchange rates) from the
    Singapore Economic Development Board. The grant provides for
    reimbursement of certain qualifying expenses incurred by the
    subsidiary between August 2005 and December 2010. Receipt of
    funds under the grant is conditioned upon our subsidiary
    conducting certain research and development activities and
    achieving certain levels of employment in Singapore during that
    period.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In February 2007, our Singapore subsidiary received an
    additional grant in the amount of approximately
    S$3.7&#160;million (approximately US$2.4&#160;million at current
    exchange rates) from the Singapore Economic Development Board.
    The grant provides for reimbursement of certain qualifying
    expenses incurred by the subsidiary between June 2006 and May
    2011. Receipt of funds under the grant is conditioned upon our
    subsidiary conducting certain research, development and
    manufacturing activities and achieving certain levels of
    employment in Singapore during that period and our raising a
    certain amount of additional capital by December 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    BSIF is the owner of more than 5% of our outstanding Preferred
    Stock.
</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Loan to
    Gajus Worthington</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On January&#160;20, 2004, we entered into an Employee Loan
    Agreement, Secured Promissory Note and Stock Pledge Agreement
    with Mr.&#160;Worthington pursuant to which we loaned
    Mr.&#160;Worthington $250,000 at an interest rate of 3.52% per
    annum and the principal and interest were not due and payable
    until 7&#160;years after the date of the loan or upon the
    earlier occurrence of certain events. The loan was secured by
    the pledge of 833,334&#160;shares of our common stock held by
    Mr.&#160;Worthington and was otherwise non-recourse. On
    April&#160;10, 2008, Mr.&#160;Worthington repaid the loan in
    full in accordance with Section&#160;2.2(d) of the note by
    selling shares of our common stock held by Mr.&#160;Worthington
    to us at the fair market value of such stock on the date of such
    sale, which was determined by the Board of Directors to be $3.19
    per share. The note and Mr.&#160;Worthington&#146;s loan were
    repaid in full and cancelled in exchange for 90,913&#160;shares
    of our common stock which Mr.&#160;Worthington transferred to us
    pursuant to the terms of a repurchase agreement dated
    April&#160;10, 2008. This loan repayment and share cancellation
    transaction were approved by the compensation committee based on
    its determination that we received full and fair consideration
    for the cancellation of the loan and that the cancellation of
    the loan was in the best interests of our company and its
    stockholders.
</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Consulting
    Agreement with Stephen Quake</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In May 2006, we entered into an agreement with Stephen Quake
    pursuant to which it has agreed to pay Dr.&#160;Quake $8,333 per
    month for providing various consulting services to Fluidigm
    including serving on our Scientific Advisory Board. The
    agreement has a term of 10&#160;years and is terminable by
    Fluidigm only for cause. At approximately the same time, we
    repurchased from Dr.&#160;Quake 123,974&#160;shares of our
    Common Stock for aggregate consideration of $69,425.
    Dr.&#160;Quake served as a director of Fluidigm from its
    inception until December 2005 and, at the time of these
    transactions, was the holder of more than 5% of our outstanding
    Common Stock.
</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Engagement
    of Townsend and Townsend and Crew LLP</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Since before 2005, the law firm of Townsend and Townsend and
    Crew LLP, or Townsend, has served as our primary outside patent
    counsel. William Smith, our Vice President, Legal Affairs and
    General Counsel as well as our Secretary since May 2000 and a
    director from May 2000 until April&#160;7, 2008, was a partner
    at Townsend from
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    96
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    1985 to April&#160;7, 2008. We incurred legal fees and expenses
    with Townsend of $901,312, $861,920, $624,208 in 2005, 2006 and
    2007 respectively.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Registration
    Rights Agreement</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Holders of our preferred stock and our co-founders are entitled
    to certain registration rights with respect to the common stock
    issued or issuable upon conversion of the preferred stock. See
    &#147;Registration Rights&#148; under &#147;Description of
    Capital Stock&#148; below for additional information.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Stock
    Option Grants</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Certain stock option grants to our directors and executive
    officers and related option grant policies are described above
    in this prospectus under the caption &#147;Management.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Employment
    Arrangements and Indemnification Agreements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have entered into employment arrangements with certain of our
    executive officers. See &#147;Management&#160;&#151; Employment
    Agreements and Offer Letters&#148; above.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have also entered into indemnification agreements with each
    of our directors and executive officers. The indemnification
    agreements and our certificate of incorporation and bylaws
    require us to indemnify our directors and executive officers to
    the fullest extent permitted by Delaware law. See
    &#147;Management&#160;&#151; Limitations on Liability and
    Indemnification Matters&#148; above.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Related
    Party Transaction Policy</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We expect to adopt a related party transactions policy in April
    2008. Pursuant to this policy, the audit committee will be
    required to review and approve all related party transactions
    for which such approval is required by applicable law or the
    rules of the NASDAQ Stock Market LLC. Material transactions must
    be presented to the full Board of Directors for review and
    approval.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    97
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='113'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PRINCIPAL
    STOCKHOLDERS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth certain information with respect
    to the beneficial ownership of our common stock at
    December&#160;29, 2007, as adjusted to reflect the sale of
    common stock offered by us in this offering, for:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    each person who we know beneficially owns more than five percent
    of our common stock;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    each of our directors;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    each of our named executive officers;&#160;and
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    all of our directors and executive officers as a group.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have determined beneficial ownership in accordance with SEC
    rules. Except as indicated by the footnotes below, we believe,
    based on the information furnished to us, that the persons and
    entities named in the table below have sole voting and
    investment power with respect to all shares of common stock that
    they beneficially own, subject to applicable community property
    laws.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Applicable percentage ownership is based on
    66,572,205&#160;shares of common stock outstanding at
    December&#160;29, 2007. For purposes of the table below, we have
    assumed
    that&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock will be outstanding upon completion of this
    offering, based upon an assumed initial public offering price of
    $&#160;&#160;&#160;&#160;&#160; per share. In computing the
    number of shares of common stock beneficially owned by a person
    and the percentage ownership of that person, we deemed to be
    outstanding all shares of common stock subject to options,
    warrants or other convertible securities held by that person or
    entity that are currently exercisable or exercisable within
    60&#160;days of December&#160;29, 2007. We did not deem these
    shares outstanding, however, for the purpose of computing the
    percentage ownership of any other person. Beneficial ownership
    representing less than one percent is denoted with an
    &#147;*.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless otherwise indicated, the address of each beneficial owner
    listed in the table below is
    <FONT style="white-space: nowrap">c/o&#160;Fluidigm</FONT>
    Corporation, 7000 Shoreline Court, Suite&#160;100, South
    San&#160;Francisco, California 94080.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="58%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Beneficial Ownership<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Beneficial Ownership<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Prior to the Offering</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>After the Offering</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name of Beneficial Owner</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Percentage</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Percentage</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>5% Stockholders:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Entities affiliated with Alloy
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,732,679
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.60
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Entities affiliated with EuclidSR
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,898,996
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.35
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Entities affiliated with EDB
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,989,496
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13.49
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Entities affiliated with Fidelity
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(4)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,250,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.38
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Entities affiliated with Interwest
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(5)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,776,885
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.67
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Entities affiliated with Lehman
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(6)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,693,907
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.54
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    SMALLCAP World Fund,
    Inc.<SUP style="font-size: 85%; vertical-align: text-top">(8)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,378,695
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.57
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Entities affiliated with Versant
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(9)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,879,980
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.83
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Directors and Named Executive Officers:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Gajus V.
    Worthington<SUP style="font-size: 85%; vertical-align: text-top">(10)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,787,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.16
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Richard
    DeLateur<SUP style="font-size: 85%; vertical-align: text-top">(11)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    394,583
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
    *
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Hingge
    Hsu<SUP style="font-size: 85%; vertical-align: text-top">(6)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,693,907
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.54
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Robert C.
    Jones<SUP style="font-size: 85%; vertical-align: text-top">(12)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    480,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
    *
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Michael Y.
    Lucero<SUP style="font-size: 85%; vertical-align: text-top">(13)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    825,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.22
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    William M.
    Smith<SUP style="font-size: 85%; vertical-align: text-top">(14)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    877,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.31
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    S. Edward
    Torres<SUP style="font-size: 85%; vertical-align: text-top">(7)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,077,715
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.12
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Mai Chan (Grace)
    Yow<SUP style="font-size: 85%; vertical-align: text-top">(15)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    264,166
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
    *
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Samuel
    Colella<SUP style="font-size: 85%; vertical-align: text-top">(9)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,879,980
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.83
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Michael
    Hunkapiller<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,732,679
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.60
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Elaine V.
    Jones<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,898,996
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.35
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Kenneth
    Nussbacher<SUP style="font-size: 85%; vertical-align: text-top">(16)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    131,250
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
    *
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    John
    Young<SUP style="font-size: 85%; vertical-align: text-top">(17)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Bruce
    Burrows<SUP style="font-size: 85%; vertical-align: text-top">(18)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,647,339
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.47
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    All directors and executive officers as a group
    (14&#160;persons)<SUP style="font-size: 85%; vertical-align: text-top">(20)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29,689,615
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42.69
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">(footnotes appear on following
    page)</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(*)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Less than one percent.
    </FONT></TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    98
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 1,866,340&#160;shares
    held of record by Alloy Ventures 2005, L.P.,
    1817,272&#160;shares held of record by Alloy Ventures 2002,
    L.P., and 49,067&#160;shares held of record by Alloy Partners
    2002, L.P. Michael Hunkapiller, a member of our Board of
    Directors is a Managing Member of Alloy Ventures 2005, LLC, the
    General Partner of Alloy Ventures 2005, L.P. Alloy Ventures
    2002, LLC is the General Partner of Alloy Ventures 2002, L.P.
    and Alloy Partners 2002, L.P. The Managing Members of Alloy
    Ventures 2002, LLC are Craig C. Taylor, John F. Shoch, Douglas
    E. Kelly, Daniel I. Rubin and Tony Di Bona. Each of the Managing
    Members of Alloy Ventures 2002, LLC is also a Managing Member of
    Alloy Ventures 2005, LLC. Each Managing Member disclaims
    beneficial ownership of the shares except to extent of their
    pecuniary interest therein. The address of the entities
    affiliated with Alloy Ventures is 400 Hamilton Avenue, Fourth
    Floor, Palo Alto, CA 94301.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 2,449,498&#160;shares
    held of record by EuclidSR Partners, L.P. and
    2,449,498&#160;shares held of record by EuclidSR Biotechnology
    Partners, L.P. Elaine V. Jones, a member of our Board of
    Directors shares voting and investment power with Graham D.S.
    Anderson, Raymond J. Whitaker, Milton J. Pappas and Stephen K.
    Reidy, each of whom are General Partners of EuclidSR Associates,
    L.P., the General Partner of EuclidSR Partners and EuclidSR
    Biotechnology Associates, L.P., the General Partner of EuclidSR
    Biotechnology Partners. Each General Partner of EuclidSR
    Associates, L.P. and EuclidSR Biotechnology Associates, L.P.
    disclaims beneficial ownership of the shares except to the
    extent of their pecuniary interest therein. The address of the
    entities affiliated with EuclidSR Associates, L.P. and EuclidSR
    Biotechnology Associates, L.P. is 45 Rockefeller Plaza, Suite
    3240, New York, NY 10111.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 6,729,828&#160;shares
    held of record by Biomedical Sciences Fund Pte. Ltd., which
    includes 1,484,474&#160;shares issued upon conversion of a
    convertible promissory note, and 775,194&#160;shares held of
    record by Singapore Bio-Innovations Pte. Ltd. EDB Investments
    Pte. Ltd. (&#147;EDB Investments&#148;), the parent entity of
    Biomedical Sciences Investment Fund Pte. Ltd. and Singapore
    Bio-Innovations Pte. Ltd., and the Economic Development Board of
    Singapore (&#147;EDB&#148;), the ultimate parent entity of EDB
    Investments, may be deemed to have voting and dispositive power
    over the shares owned beneficially and of record by Biomedical
    Sciences Investment Fund&#160;Pte. Ltd. and Singapore
    Bio-Innovations Pte. Ltd. The address associated with entities
    affiliated with EDB is 20 Biopolis Way, #09-01 Centros,
    Singapore 138668.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(4)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 481,170&#160;shares
    held of record by Fidelity Contrafund: Fidelity new Advisor New
    Insights Fund, 4,389,865&#160;shares held of record by Fidelity
    Contrafund: Fidelity Contrafund and 1,378,965&#160;shares held
    of record by Variable Insurance Products Fund&#160;II:
    Contrafund Portfolio. Each of these entities is a registered
    investment fund (the &#147;Fund&#148;) advised by Fidelity
    Management&#160;&#038; Research Company (&#147;FMR Co.&#148;), a
    registered investment adviser under the Investment Advisers Act
    of 1940, as amended. The address of FMR Co., a wholly-owned
    subsidiary of FMR Corp. and an investment adviser registered
    under Section&#160;203 of the Investment Advisers Act of 1940 is
    82&#160;Devonshire Street, Boston Massachusetts 02109. Edward C.
    Johnson 3d, FMR Corp., through its control of FMR Co., and the
    Fund each has sole power to dispose of the securities owned by
    the Fund. Neither FMR Corp. nor Edward C. Johnson 3d, Chairman
    of FMR Corp., has sole power to vote or direct the voting of the
    shares owned directly by the Fund, which power resides with the
    Fund&#146;s Board of Trustees. The Fund is an affiliate of a
    broker-dealer. The Fund purchased the securities in the ordinary
    course of business and, at the time of the purchase of the
    securities to be resold, the Fund did not have any agreements or
    understandings, directly or indirectly, with any person to
    distribute the securities. The Fund does not intend to sell,
    transfer, assign, pledge or hypothecate or otherwise enter into
    any hedging, short sale, derivative, put or call transaction
    that would result in the effective economic disposition of the
    securities through an affiliated broker-dealer.
    </FONT></TD>
</TR>



<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(5)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 172,602&#160;shares
    held of record by InterWest Investors VII, L.P. and
    3,604,283&#160;shares held of record by InterWest Partners VII,
    L.P. InterWest Management Partners VII, L.L.C. has sole voting
    and investment control over the shares owned by InterWest
    Partners VII, L.P. and InterWest Investors VII, L.P. Harvey B.
    Cash, Philip T. Gianos, W. Scott Hedrick, W. Stephen Holmes,
    Gilbert H. Kliman, Thomas L. Rosch and Arnold L. Oronsky each
    Managing Directors of InterWest Management Partners VII, LLC
    have shared voting and investment control over the shares owned
    by InterWest Partners VII, L.P. and InterWest Investors VII,
    L.P. Stephen C. Bowsher, Alan W. Crites, Rodney A. Ferguson and
    Karen A. Wilson are Members of InterWest Management Partners
    VII, L.L.C. All Managing Directors and Members disclaim
    beneficial ownership of the shares owned by InterWest Partners
    VII, LP and InterWest Investor VII, LP except to the extent of
    their pro rata partnership interests in such shares. The address
    of the entities affiliated with InterWest is 2710 Sand Hill
    Road, Second Floor, Menlo Park, CA 94025.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(6)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 923,476&#160;shares
    held of record by Lehman Brothers Healthcare Venture Capital,
    L.P., 206,536&#160;shares held of record by Lehman Brothers
    Offshore Partnership Account 2000/2001, L.P.,
    1,767,535&#160;shares held of record by Lehman Brothers P.A.,
    LLC and 796,360&#160;shares held of record by Lehman Brothers
    Partnership Account 2000/2001, L.P. Hingge Hsu, a former member
    of our Board of Directors, was formerly employed by Lehman
    Brothers Inc., and now serves as a consultant of Lehman Brothers
    Inc. In each of the limited partnerships referenced above,
    Lehman Brothers Inc. controls the general partner of the fund.
    In the limited liability company, Lehman Brothers controls the
    manager of that fund. In all instances, the general partner or
    the manager has voting and dispositive control of the shares
    held by that particular fund, and thus may be attributed to
    Lehman Brothers. In all four funds listed above, Lehman Brothers
    Holdings Inc. ultimately controls the manager and the general
    partners of the funds. Employees of Lehman Brothers Inc., a
    subsidiary of Lehman Brothers Holdings Inc. manages each of the
    funds. No one person controls Lehman Brothers Holdings Inc. The
    address of the entities affiliated with Lehman Brothers is 399
    Park Avenue,
    11<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>
    Floor, New York, NY 10022. (Calling Lehman to get further
    clarification for the footnote)
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(7)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 2,077,715&#160;shares
    held of record by Lilly Bio Ventures, Eli Lilly and Company. S.
    Edward Torres, was a member of our Board of Directors serves as
    Managing Director of Lilly Bio Ventures. The Executive Director
    of New Ventures, Eli Lilly and Company or the Senior Vice
    President of Corporate Strategy and Business Development. Eli
    Lilly and Company has the authority to vote and dispose of the
    shares held by Lilly Bio Ventures, Eli Lilly and Company. The
    address for Lilly Bio Ventures, Eli Lilly and Company is Lilly
    Corporate Center, Indianapolis, IN 46285.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(8)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 4,378,695&#160;shares
    held of record by SMALLCAP World Fund, Inc
    (&#147;SMALLCAP&#148;). SMALLCAP is an investment company
    registered under the Investment Company Act of 1940. Capital
    Research and Management Company, or CRMC, an investment adviser
    registered under the Investment Advisers Act of 1940, is the
    investment adviser to SMALLCAP. In that capacity, CRMC may be
    deemed to be the beneficial owner of the shares held by
    SMALLCAP. CRMC, however, disclaims such beneficial ownership.
    The address of the SMALLCAP is The Capital Group Companies, 333,
    South Hope Street, Los Angeles, California 90071.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(9)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 5,378,019&#160;shares
    held of record by Versant Venture Capital&#160;I, L.P.,
    98,662&#160;shares held of record by Versant Affiliates
    <FONT style="white-space: nowrap">Fund&#160;I-A,</FONT>
    L.P., 291,146&#160;shares held of record by Versant Affiliates
    <FONT style="white-space: nowrap">Fund&#160;I-B,</FONT>
    L.P. and 112,153&#160;shares held of record by Versant Side
    Fund&#160;I, L.P. Voting and investment power over the shares
    directly held by Versant Venture Capital&#160;I, L.P., Versant
    Affiliates
    <FONT style="white-space: nowrap">Fund&#160;I-A,</FONT>
    L.P., Versant Affiliates
    <FONT style="white-space: nowrap">Fund&#160;I-B,</FONT>
    L.P., and Versant Side Fund&#160;I, L.P. is held by Versant
    Ventures&#160;I, LLC, their sole General Partner. Samuel D.
    Colella, a member of our Board of Directors is a Managing Member
    of Versant Ventures&#160;I, LLC but he disclaims beneficial
    ownership of these shares,
    </FONT></TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    99
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">except to the extent of his
    pecuniary interest in such shares. The individual Managing
    Members of Versant Ventures&#160;I, LLC are Brian G. Atwood,
    Samuel D. Colella, Ross A. Jaffe, William J. Link, Barbara N.
    Lubash, Donald B. Milder, and Rebecca B. Robertson, all of whom
    share voting and dispositive control. Each respective individual
    General Partner disclaims beneficial ownership of these shares,
    except to the extent of their pecuniary interest in such shares.
    The address of the entities affiliated with Versant Ventures is
    3000 Sand Hill Road, Building Four, Suite&#160;210, Menlo Park,
    CA 94025.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(10)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 2,432,000&#160;shares
    held of record by Gajus Worthington and Jami A. Worthington as
    TTEES of the Worthington Family Trust dtd 3-6-07 and options to
    purchase 355,000&#160;shares of Common Stock that are
    exercisable within 60&#160;days of December&#160;29, 2007,
    164,999&#160;shares of which are vested as of February&#160;27,
    2008.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(11)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 140,000&#160;shares
    held of record by Richard A. DeLateur and options to purchase
    254,583&#160;shares of Common Stock that are exercisable within
    60&#160;days of December&#160;29, 2007, 184,582 of which are
    vested as of February&#160;27, 2008.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(12)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of options to purchase
    480,000&#160;shares of Common Stock that are exercisable within
    60&#160;days of December&#160;29, 2007, 249,999 of which are
    vested as of February&#160;27, 2008.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(13)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of options to purchase
    825,000&#160;shares of Common Stock that are exercisable within
    60&#160;days of December&#160;29, 2007, 716,750 of which are
    vested as of February&#160;27, 2008.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(14)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 300,000&#160;shares
    held of record by William M. Smith and options to purchase
    577,000&#160;shares of Common Stock that are exercisable within
    60&#160;days of December&#160;29, 2007, 381,500 of which are
    vested as of February&#160;27, 2008.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(15)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of options to purchase
    264,166&#160;shares of Common Stock that are exercisable within
    60&#160;days of December&#160;29, 2007, 214,166 of which are
    vested as of February&#160;27, 2008.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(16)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of options to purchase
    131,250&#160;shares of Common Stock that are exercisable within
    60&#160;days of December&#160;29, 2007, all of which are vested
    as of February&#160;27, 2008
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(17)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Mr.&#160;Young disclaims beneficial
    ownership of 270,000&#160;shares as all of the shares were
    subsequently transferred to his children, Diana Young, Gregory
    Young and John Peter Young. As of February&#160;27, 2008
    29,167&#160;shares of Common Stock are subject to a right of
    repurchase at cost. The right of repurchase lapses at a rate of
    approximately 2,083&#160;shares of Common Stock per month.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(18)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 3,597,339&#160;shares
    held of record and options to purchase 50,000&#160;shares of
    Common Stock that are exercisable within 60&#160;days of
    December&#160;29, 2007, all of which are vested.
    </FONT></TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    100
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='114'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">DESCRIPTION
    OF CAPITAL STOCK</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">General</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following is a summary of the rights of our common stock and
    preferred stock and of certain provisions of our restated
    certificate of incorporation and bylaws, as they will be in
    effect upon the completion of this offering. For more detailed
    information, please see our restated certificate of
    incorporation and bylaws, which are filed as exhibits to the
    registration statement of which this prospectus is part.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Immediately following the completion of this offering, our
    authorized capital stock will consist of
    320,000,000&#160;shares, all with a par value of $0.001 per
    share, of which:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    300,000,000&#160;shares are designated as common stock;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    20,000,000&#160;shares are designated as preferred stock.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;29, 2007, we had outstanding
    66,572,205&#160;shares of common stock held of record by 247
    stockholders, assuming the automatic conversion of all
    outstanding shares of our preferred stock into
    56,670,894&#160;shares of common stock. In addition, as of
    December&#160;29, 2007, 7,467,230&#160;shares of our common
    stock were subject to outstanding options and
    698,720&#160;shares of our capital stock were subject to
    outstanding warrants, neither of which will expire upon the
    completion of this offering. For more information on our
    capitalization see &#147;Capitalization&#148; above.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Common
    Stock</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The holders of our common stock are entitled to one vote per
    share on all matters to be voted on by our stockholders. Subject
    to preferences that may be applicable to any outstanding shares
    of preferred stock, holders of common stock are entitled to
    receive ratably such dividends as may be declared by our Board
    of Directors out of funds legally available for that purpose. In
    the event of our liquidation, dissolution or winding up, the
    holders of common stock are entitled to share ratably in all
    assets remaining after the payment of liabilities, subject to
    the prior distribution rights of preferred stock then
    outstanding. Holders of common stock have no preemptive,
    conversion or subscription rights. There are no redemption or
    sinking fund provisions applicable to the common stock.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Preferred
    Stock</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Immediately after the completion of this offering, no shares of
    preferred stock will be outstanding (assuming the automatic
    conversion of all outstanding shares of our preferred stock into
    56,670,894&#160;shares of common stock immediately prior to the
    completion of this offering). Though we currently have no plans
    to issue any shares of preferred stock, upon the closing of this
    offering and the filing of our restated certificate of
    incorporation, our Board of Directors will have the authority,
    without further action by our stockholders, to designate and
    issue up to 20,000,000&#160;shares of preferred stock in one or
    more series. Our Board of Directors may also designate the
    rights, preferences and privileges of the holders of each such
    series of preferred stock, any or all of which may be greater
    than or senior to those granted to the holders of common stock.
    Though the actual effect of any such issuance on the rights of
    the holders of common stock will not be known until our Board of
    Directors determines the specific rights of the holders of
    preferred stock, the potential effects of such an issuance
    include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    diluting the voting power of the holders of common stock;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reducing the likelihood that holders of common stock will
    receive dividend payments;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reducing the likelihood that holders of common stock will
    receive payments in the event of our liquidation, dissolution,
    or winding up;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    delaying, deterring or preventing a
    <FONT style="white-space: nowrap">change-in-control</FONT>
    or other corporate takeover.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Warrants</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;29, 2007, we had outstanding warrants to
    purchase an aggregate of 698,720&#160;shares of our preferred
    stock, all of which will be converted into warrants to purchase
    an equal number of shares of our common
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    101
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    stock at exercise prices ranging from $1.78 per share to $2.80
    per share. These warrants will expire at various times between
    May 2008 and March 2012. In the event of a distribution of
    dividends, a stock split, a reorganization, a reclassification,
    a consolidation, or a similar event, each warrant provides for
    adjustment of the exercise price and the number of shares
    issuable upon exercise.
</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Potential
    Issuance of Common Stock</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On March&#160;7, 2003, we entered into a Master Closing
    Agreement with Oculus Pharmaceuticals, Inc. and The UAB Research
    Foundation, or UAB, related to certain intellectual property and
    technology rights licensed by us from UAB. Pursuant to the
    agreement, we are obligated to issue UAB shares of our common
    stock with a value equal to approximately $1,500,000 upon the
    achievement of a certain milestone and based upon the fair
    market value of our common stock at the time the milestone is
    achieved. We currently do not anticipate achieving this
    milestone in the foreseeable future and do not anticipate
    issuing these shares.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Registration
    Rights</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;29, 2007, the holders of an aggregate of
    58,854,088&#160;shares of our common stock, which includes
    56,670,894&#160;shares of common stock issued on conversion of
    outstanding preferred stock, 698,720&#160;shares of common stock
    issuable upon the exercise of warrants and conversion of
    preferred stock underlying such warrants and
    1,466,210&#160;shares of common stock issuable upon the
    conversion of convertible promissory notes and the shares of
    preferred stock underlying such notes, are entitled to the
    following rights with respect to the registration of such shares
    for public resale under the Securities Act, pursuant to an
    investor rights agreement by and among us and certain of our
    stockholders. In addition, the holders of an additional
    4,858,878&#160;shares of common stock are also entitled to the
    rights described below, in the section titled &#147;Piggyback
    Registration Rights.&#148; We refer to these shares collectively
    as &#147;registrable securities.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The registration of shares of common stock as a result of the
    following rights being exercised would enable the holders to
    trade these shares without restriction under the Securities Act
    when the applicable registration statement is declared
    effective. Ordinarily, we will be required to pay all expenses,
    other than underwriting discounts and commissions, related to
    any registration effected pursuant to the exercise of these
    registration rights.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The registration rights terminate upon the earlier of five years
    after completion of this offering, or, with respect to the
    registration rights of an individual holder, when the holder of
    one percent or less of our outstanding common stock can sell all
    of such holder&#146;s registrable securities in any three-month
    period without registration, in compliance with Rule&#160;144 of
    the Securities Act or another similar exemption.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Demand
    Registration Rights</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If at any time after this offering the holders of at least a
    majority of the registrable securities request in writing that
    we effect a registration that has a reasonably anticipated
    aggregate price to the public in excess of $20,000,000, we may
    be required to register their shares. At most, we are obligated
    to effect two registrations for the holders of registrable
    securities in response to these demand registration rights.
    Depending on certain conditions, however, we may defer such
    registration for up to 90&#160;days. If the holders requesting
    registration intend to distribute their shares by means of an
    underwriting, the managing underwriter of such offering will
    have the right to limit the number of shares to be underwritten
    for reasons related to the marketing of the shares.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Piggyback
    Registration Rights</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If at any time after this offering we propose to register any
    shares of our common stock under the Securities Act, subject to
    certain exceptions, the holders of registrable securities will
    be entitled to notice of the registration and to include their
    shares of registrable securities in the registration. If our
    proposed registration involves an underwriting, the managing
    underwriter of such offering will have the right to limit the
    number of shares to be underwritten for reasons related to the
    marketing of the shares.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    102
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times"><FONT style="white-space: nowrap">Form&#160;S-3</FONT>
    Registration Rights</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If at any time after we become entitled under the Securities Act
    to register our shares on
    <FONT style="white-space: nowrap">Form&#160;S-3</FONT>
    a holder of registrable securities requests in writing that we
    register their shares for public resale on
    <FONT style="white-space: nowrap">Form&#160;S-3</FONT>
    and the reasonably anticipated price to the public of the
    offering exceeds $2,000,000, we will be required to use our best
    efforts to effect such registration; provided, however, that if
    such registration would be seriously detrimental to us or our
    stockholders, we may defer the registration for up to
    90&#160;days.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Voting
    Rights</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the provisions of our amended and restated certificate of
    incorporation to become effective upon completion of this
    offering, holders of our common stock are entitled to one vote
    for each share of common stock held by such holder on any matter
    submitted to a vote at a meeting of stockholders. In addition,
    our amended and restated certificate of incorporation provides
    that certain corporate actions require the approval of our
    stockholders. These actions, and the vote required, are as
    follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the removal of a director requires the vote of a majority of the
    voting power of our issued and outstanding capital stock
    entitled to vote in the election of directors;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the amendment of provisions of our amended and restated
    certificate of incorporation relating to blank check preferred
    stock, the classification of our directors, the removal of
    directors, the filling of vacancies on our Board of Directors,
    cumulative voting, annual and special meetings of our
    stockholders and the amendment of certain provisions of our
    restated certificate of incorporation require the vote of 66
    2/3% of our then outstanding voting securities.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Anti
    Takeover Effects of Delaware Law and Our Certificate of
    Incorporation and Bylaws</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Certain provisions of Delaware law and our restated certificate
    of incorporation and bylaws that will become effective upon
    completion of this offering contain provisions that could have
    the effect of delaying, deferring or discouraging another party
    from acquiring control of us. These provisions, which are
    summarized below, are expected to discourage certain types of
    coercive takeover practices and inadequate takeover bids. These
    provisions are also designed in part to encourage anyone seeking
    to acquire control of us to first negotiate with our Board of
    Directors. We believe that the advantages gained by protecting
    our ability to negotiate with any unsolicited and potentially
    unfriendly acquirer outweigh the disadvantages of discouraging
    such proposals, including those priced above the then-current
    market value of our common stock, because, among other reasons,
    the negotiation of such proposals could improve their terms.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Certificate
    of Incorporation and Bylaws</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our amended and restated certificate of incorporation and bylaws
    to become effective upon completion of this offering include
    provisions that:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    authorize our Board of Directors to issue, without further
    action by the stockholders, up to 20,000,000&#160;shares of
    undesignated preferred stock;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    require that any action to be taken by our stockholders be
    effected at a duly called annual or special meeting and not by
    written consent;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    specify that special meetings of our stockholders can be called
    only by our Board of Directors, the Chairman of the Board, the
    Chief Executive Officer or the President;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    establish an advance notice procedure for stockholder approvals
    to be brought before an annual meeting of our stockholders,
    including proposed nominations of persons for election to our
    Board of Directors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    provide that directors may be removed only for cause;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    provide that vacancies on our Board of Directors may be filled
    only by a majority of directors then in office, even though less
    than a quorum;
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    103
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    establish that our Board of Directors is divided into three
    classes, Class&#160;I, Class&#160;II, and Class&#160;III, with
    each class serving staggered terms;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    specify that no stockholder is permitted to cumulate votes at
    any election of the Board of Directors;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    require a super-majority of votes to amend certain of the
    above-mentioned provisions.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Delaware
    Anti-Takeover Statute</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are subject to the provisions of Section&#160;203 of the
    Delaware General Corporation Law regulating corporate takeovers.
    In general, Section&#160;203 prohibits a publicly-held Delaware
    corporation from engaging, under certain circumstances, in a
    business combination with an interested stockholder for a period
    of three years following the date the person became an
    interested stockholder unless:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    prior to the date of the transaction, the Board of Directors of
    the corporation approved either the business combination or the
    transaction which resulted in the stockholder becoming an
    interested stockholder;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    upon completion of the transaction that resulted in the
    stockholder becoming an interested stockholder, the interested
    stockholder owned at least 85% of the voting stock of the
    corporation outstanding at the time the transaction commenced,
    excluding for purposes of determining the voting stock
    outstanding, but not for determining the outstanding voting
    stock owned by the interested stockholder, (1)&#160;shares owned
    by persons who are directors and also officers, and
    (2)&#160;shares owned by employee stock plans in which employee
    participants do not have the right to determine confidentially
    whether shares held subject to the plan will be tendered in a
    tender or exchange offer;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    at or subsequent to the date of the transaction, the business
    combination is approved by the Board of Directors of the
    corporation and authorized at an annual or special meeting of
    stockholders, and not by written consent, by the affirmative
    vote of at least
    66<FONT style="vertical-align: text-top; font-size: 70%;">2</FONT>/<FONT style="font-size: 70%;">3</FONT>%
    of the outstanding voting stock which is not owned by the
    interested stockholder.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Generally, a business combination includes a merger, asset or
    stock sale, or other transaction resulting in a financial
    benefit to the interested stockholder. An interested stockholder
    is a person who, together with affiliates and associates, owns
    or, within three years prior to the determination of interested
    stockholder status, did own 15% or more of a corporation&#146;s
    outstanding voting stock. We expect the existence of this
    provision to have an anti-takeover effect with respect to
    transactions our Board of Directors does not approve in advance.
    We also anticipate that Section&#160;203&#160;may discourage
    business combinations or other attempts that might result in a
    premium over the market price for the shares of common stock
    held by our stockholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The provisions of Delaware law and our restated certificate of
    incorporation and bylaws to become effective upon completion of
    this offering could have the effect of discouraging others from
    attempting hostile takeovers and, as a consequence, they may
    also inhibit temporary fluctuations in the market price of our
    common stock that often result from actual or rumored hostile
    takeover attempts. These provisions may also have the effect of
    preventing changes in our management. It is possible that these
    provisions could make it more difficult to accomplish
    transactions that stockholders may otherwise deem to be in their
    best interests.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Transfer
    Agent and Registrar</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The transfer agent and registrar for our common stock is
    Computershare Trust Company, N.A. The transfer agent&#146;s
    address
    is&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    and its telephone number
    is&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Nasdaq
    Global Market Listing</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We expect to apply to have our common stock listed on the Nasdaq
    Global Market under the symbol &#147;FLDM.&#148;
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    104
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='115'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SHARES
    ELIGIBLE FOR FUTURE SALE</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Before this offering, there has not been a public market for
    shares of our common stock. Future sales of substantial amounts
    of shares of our common stock, including shares issued upon the
    exercise of outstanding options, in the public market after this
    offering, or the possibility of these sales occurring, could
    cause the prevailing market price for our common stock to fall
    or impair our ability to raise equity capital in the future.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon the completion of this offering, a total
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock will be outstanding, assuming that there are no
    exercises of options or warrants after December&#160;29, 2007.
    Of these shares,
    all&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock sold in this offering by us, plus any shares
    sold upon exercise of the underwriters&#146; over-allotment
    option, will be freely tradable in the public market without
    restriction or further registration under the Securities Act,
    unless these shares are held by &#147;affiliates,&#148; as that
    term is defined in Rule&#160;144 under the Securities Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The remaining 66,572,205&#160;shares of common stock will be
    &#147;restricted securities,&#148; as that term is defined in
    Rule&#160;144 under the Securities Act. These restricted
    securities are eligible for public sale only if they are
    registered under the Securities Act or if they qualify for an
    exemption from registration under Rules&#160;144 or 701 under
    the Securities Act, which are summarized below.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subject to the lock up agreements described below and the
    provisions of Rules&#160;144 and 701 under the Securities Act,
    these restricted securities will be available for sale in the
    public market as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="88%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Date</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    On the date of this prospectus
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Between 90 and 180&#160;days after the date of this prospectus
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    At various times beginning more than 180&#160;days after the
    date of this prospectus
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    66,617,499
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, of the 7,467,230&#160;shares of our common stock
    that were subject to stock options outstanding as of
    December&#160;29, 2007, options to purchase
    4,307,131&#160;shares of common stock were vested as of
    December&#160;29, 2007 and will be eligible for sale
    180&#160;days following the effective date of this offering.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Rule&#160;144</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, under Rule&#160;144 as currently in effect, once we
    have been subject to public company reporting requirements for
    at least 90&#160;days, a person who is not deemed to have been
    one of our affiliates for purposes of the Securities Act at any
    time during the 90&#160;days preceding a sale and who has
    beneficially owned the shares proposed to be sold for at least
    six months, including the holding period of any prior owner
    other than our affiliates, is entitled to sell those shares
    without complying with the manner of sale, volume limitation or
    notice provisions of Rule&#160;144, subject to compliance with
    the public information requirements of Rule&#160;144. If such a
    person has beneficially owned the shares proposed to be sold for
    at least one year, including the holding period of any prior
    owner other than our affiliates, then that person is entitled to
    sell those shares without complying with any of the requirements
    of Rule&#160;144.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, under Rule&#160;144, as currently in effect, our
    affiliates or persons selling shares on behalf of our affiliates
    are entitled to sell upon expiration of the
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements described above, within any three-month period
    beginning 90&#160;days after the date of this prospectus, a
    number of shares that does not exceed the greater of:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    1% of the number of shares of common stock then outstanding,
    which will equal
    approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    immediately after this offering;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the average weekly trading volume of the common stock during the
    four calendar weeks preceding the filing of a notice on
    Form&#160;144 with respect to that sale.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Sales under Rule&#160;144 by our affiliates or persons selling
    shares on behalf of our affiliates are also subject to certain
    manner of sale provisions and notice requirements and to the
    availability of current public information about us.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    105
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Rule&#160;701</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, under Rule&#160;701 as currently in effect, any of
    our employees, consultants or advisors who purchase shares from
    us in connection with a compensatory stock or option plan or
    other written agreement in a transaction before the effective
    date of this offering that was completed in reliance on
    Rule&#160;701 and complied with the requirements of
    Rule&#160;701 will, subject to the lock up restrictions
    described below, be eligible to resell such shares 90&#160;days
    after the effective date of this offering in reliance on
    Rule&#160;144, but without compliance with certain restrictions,
    including the holding period, contained in Rule&#160;144.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Lock Up
    Agreements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We and all of our directors and officers, as well as the other
    holders of substantially all shares of common stock outstanding
    immediately prior to this offering, have agreed that, without
    the prior written consent of Morgan Stanley&#160;&#038; Co.
    Incorporated on behalf of the underwriters, we and they will
    not, during the period ending 180&#160;days after the date of
    this prospectus:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    offer, pledge, sell, contract to sell, sell any option or
    contract to purchase, purchase any option or contract to sell,
    grant any option, right or warrant to purchase, lend or
    otherwise transfer or dispose of, directly or indirectly, any
    shares of our common stock or any securities convertible into or
    exercisable or exchangeable for shares of our common stock;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    enter into any swap or other arrangement that transfers to
    another, in whole or in part, any of the economic consequences
    of ownership of our common stock,
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    whether any transaction described above is to be settled by
    delivery of shares of our common stock or such other securities,
    in cash or otherwise. This agreement is subject to certain
    exceptions, and is also subject to extension for up to an
    additional days, as set forth in &#147;Underwriters.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Registration
    Rights</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon completion of this offering, the holders of
    63,712,966&#160;shares of common stock or their transferees will
    be entitled to various rights with respect to the registration
    of these shares under the Securities Act. Registration of these
    shares under the Securities Act would result in these shares
    becoming fully tradable without restriction under the Securities
    Act immediately upon the effectiveness of the registration,
    except for shares purchased by affiliates. See &#147;Description
    of Capital Stock&#160;&#151; Registration Rights&#148; for
    additional information.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Registration
    Statements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We intend to file a registration statement on
    <FONT style="white-space: nowrap">Form&#160;S-8</FONT>
    under the Securities Act covering all of the shares of common
    stock subject to options outstanding or reserved for issuance
    under our stock plans. We expect to file this registration
    statement as soon as practicable after this offering. In
    addition, we intend to file a registration statement on
    <FONT style="white-space: nowrap">Form&#160;S-8</FONT>
    under the Securities Act for the resale of shares of common
    stock issued upon the exercise of options that were not granted
    under Rule&#160;701. We expect to file this registration
    statement as soon as practicable after this offering. However,
    none of the shares registered on
    <FONT style="white-space: nowrap">Form&#160;S-8</FONT>
    will be eligible for resale until the expiration of the lock up
    agreements to which they are subject.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    106
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='120'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">MATERIAL
    U. S. FEDERAL INCOME AND ESTATE TAX<BR>
    CONSEQUENCES TO NON-U. S. HOLDERS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following is a general discussion of certain material United
    States federal income and estate tax considerations with respect
    to the acquisition, ownership and disposition of shares of our
    common stock applicable to
    <FONT style="white-space: nowrap">non-U.S.&#160;holders.</FONT>
    In general, a
    <FONT style="white-space: nowrap">&#147;non-U.S.&#160;holder&#148;</FONT>
    is any holder other than:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an individual who is a citizen or resident of the United States
    for United States federal income tax purposes;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a corporation (or other entity treated as a corporation for
    United States federal income tax purposes) created or organized
    in or under the laws of the United States, any state thereof or
    the District of Columbia;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an estate, the income of which is includible in gross income for
    United States federal income tax purposes regardless of its
    source;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a trust if (a)&#160;a court within the United States is able to
    exercise primary supervision over the administration of the
    trust and one or more United States persons have the authority
    to control all substantial decisions of the trust or (b)&#160;it
    has a valid election in effect under applicable Treasury
    regulations to be treated as a United&#160;States person.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This discussion is based on current provisions of the Internal
    Revenue Code, final, temporary or proposed Treasury regulations
    promulgated thereunder, judicial opinions, published positions
    of the Internal Revenue Service and all other applicable
    authorities, all of which are subject to change (possibly with
    retroactive effect). We assume in this discussion that a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    holds shares of our common stock as a capital asset (generally
    property held for investment).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This discussion does not address all aspects of United States
    federal income and estate taxation that may be important to a
    particular
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    in light of that
    <FONT style="white-space: nowrap">non-U.S.&#160;holder&#146;s</FONT>
    individual circumstances, nor does it address any aspects of
    United States state or local taxes or
    <FONT style="white-space: nowrap">non-U.S.&#160;taxes.</FONT>
    This discussion also does not consider any specific facts or
    circumstances that may apply to a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    subject to special treatment under the United&#160;States
    federal income tax laws, including, without limitation:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    banks, insurance companies or other financial institutions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    partnerships or other pass-through entities or persons that hold
    shares of our common stock through such entities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    tax-exempt organizations;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    tax-qualified retirement plans;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    dealers in securities or currencies;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    traders in securities that elect to use a mark-to-market method
    of accounting for their securities holdings;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    United States expatriates;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    persons that will hold common stock as a position in a hedging
    transaction, &#147;straddle&#148; or &#147;conversion
    transaction&#148; for tax purposes.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Accordingly, we urge prospective investors to consult with their
    own tax advisors regarding the United States federal, state and
    local income and
    <FONT style="white-space: nowrap">non-U.S.&#160;income</FONT>
    and other tax considerations of acquiring, holding and disposing
    of shares of our common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If a partnership or other pass-through entity holds shares of
    our common stock, the tax treatment of a partner in such
    partnership or an owner of such other pass-through entity will
    generally depend upon the status of such partner or other owner
    and the activities of such partnership or other entity. Any
    partnership or other pass-through entity that holds shares of
    our common stock or any partner in such partnership or owner of
    such other entity should consult its own tax advisors.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    107
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Dividends</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If we make cash or other property distributions on our common
    stock, such distributions will constitute dividends for United
    States federal income tax purposes to the extent paid from our
    current or accumulated earnings and profits, as determined under
    United States federal income tax principles. To the extent those
    distributions exceed both our current and our accumulated
    earnings and profits, such excess will constitute a return of
    capital and will first reduce the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder&#146;s</FONT>
    adjusted tax basis in our common stock, but not below zero. Any
    remaining excess will be treated as gain from the sale or other
    disposition of shares of our common stock (as described under
    &#147;&#151;&#160;Gain on Sale or Other Disposition of Common
    Stock&#148; below).
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, dividends we pay, if any, to a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    will be subject to United States withholding tax at a rate of
    30% of the gross amount. The withholding tax might not apply or
    might apply at a reduced rate under the terms of an applicable
    income tax treaty between the United States and the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder&#146;s</FONT>
    country of residence. A
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    must demonstrate its entitlement to treaty benefits by
    certifying, among other things, its nonresident status. A
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    generally can meet this certification requirement by providing
    an Internal Revenue Service
    <FONT style="white-space: nowrap">Form&#160;W-8BEN</FONT>
    or appropriate substitute form to us or our paying agent. Also,
    special rules apply if the dividends are effectively connected
    with a trade or business carried on by the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    within the United States and, if a treaty applies, are
    attributable to a permanent establishment of the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    within the United States. Dividends effectively connected with
    this United States trade or business, and, if a treaty applies,
    attributable to such a permanent establishment of a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder,</FONT>
    generally will not be subject to United States withholding tax
    if the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    files certain forms, including Internal Revenue Service
    <FONT style="white-space: nowrap">Form&#160;W-8ECI</FONT>
    (or any successor form), with the payor of the dividend, and
    generally will be subject to United States federal income tax on
    a net income basis, in the same manner as if the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    were a resident of the United States. A
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    that is a corporation may be subject to an additional
    &#147;branch profits tax&#148; at a rate of 30% (or a reduced
    rate as may be specified by an applicable income tax treaty) on
    the repatriation from the United States of its &#147;effectively
    connected earnings and profits,&#148; subject to certain
    adjustments. A
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    of shares of our common stock eligible for a reduced rate of
    United States withholding tax pursuant to an income tax treaty
    may obtain a refund of any excess amounts withheld by timely
    filing an appropriate claim for refund with the Internal Revenue
    Service.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Gain on
    Sale or Other Disposition of Common Stock</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    will not be subject to United States federal income tax on any
    gain realized upon the sale or other disposition of the
    holder&#146;s shares of our common stock unless:
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the gain is effectively connected with a trade or business
    carried on by the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    within the United&#160;States and, if required by an applicable
    income tax treaty as a condition to subjecting a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    to United States income tax on a net basis, the gain is
    attributable to a permanent establishment of the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    maintained in the United States, in which case a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    will be subject to United States federal income tax on any gain
    realized upon the sale or other disposition on a net income
    basis, in the same manner as if the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    were a resident of the United States. Furthermore, the branch
    profits tax discussed above may also apply if the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    is a corporation;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    is an individual and is present in the United States for
    183&#160;days or more in the taxable year of disposition and
    certain other tests are met, in which case a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    will be subject to a flat 30% tax on any gain realized upon the
    sale or other disposition, which tax may be offset by United
    States source capital losses (even though the individual is not
    considered a resident of the United States);&#160;or
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we are or have been a United States real property holding
    corporation (a USRPHC) for United States federal income tax
    purposes at any time within the shorter of the five-year period
    preceding the disposition and the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder&#146;s</FONT>
    holding period. We do not believe that we are or have been a
    USRPHC, and we do not anticipate becoming a USRPHC. If we have
    been in the past or were to become a USRPHC at any time during
    this period, generally gains realized upon a disposition of
    shares of our common stock by a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    that did not directly or indirectly own more than 5% of our
    common stock during this period would not be subject to United
    States federal income tax, provided that our common stock is
    &#147;regularly traded on an established securities market&#148;
    (within the meaning of Section&#160;897(c)(3) of the Internal
    Revenue Code). Our common stock will be treated as regularly
    traded on an established securities market during any period in
    which it is listed on a registered national securities exchange
    or any over-the-counter market.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    108
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">United
    States Federal Estate Tax</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Shares of our common stock that are owned or treated as owned by
    an individual who is not a citizen or resident (as defined for
    United States federal estate tax purposes) of the United States
    at the time of death will be includible in the individual&#146;s
    gross estate for United States federal estate tax purposes,
    unless an applicable estate tax treaty provides otherwise, and
    therefore may be subject to United States federal estate tax.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Backup
    Withholding, Information Reporting and Other Reporting
    Requirements</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Generally, we must report annually to the Internal Revenue
    Service and to each
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    the amount of dividends paid to, and the tax withheld with
    respect to, each
    <FONT style="white-space: nowrap">non-U.S.&#160;holder.</FONT>
    These reporting requirements apply regardless of whether
    withholding was reduced or eliminated by an applicable tax
    treaty. Copies of this information also may be made available
    under the provisions of a specific treaty or agreement with the
    tax authorities in the country in which the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    resides or is established.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    United States backup withholding tax is imposed (at a current
    rate of 28%) on certain payments to persons that fail to furnish
    the information required under the United States information
    reporting requirements. A
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    of shares of our common stock will be subject to this backup
    withholding tax on dividends we pay unless the holder certifies,
    under penalties of perjury, among other things, its status as a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    (and we or our paying agent do not have actual knowledge or
    reason to know the holder is a United States person) or
    otherwise establishes an exemption.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the Treasury regulations, the payment of proceeds from the
    disposition of shares of our common stock by a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    made to or through a United States office of a broker generally
    will be subject to information reporting and backup withholding
    unless the beneficial owner certifies, under penalties of
    perjury, among other things, its status as a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    (and we or our paying agent do not have actual knowledge or
    reason to know the holder is a United States person) or
    otherwise establishes an exemption. The payment of proceeds from
    the disposition of shares of our common stock by a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    made to or through a
    <FONT style="white-space: nowrap">non-U.S.&#160;office</FONT>
    of a broker generally will not be subject to backup withholding
    and information reporting, except as noted below. In the case of
    proceeds from a disposition of shares of our common stock by a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    made to or through a
    <FONT style="white-space: nowrap">non-U.S.&#160;office</FONT>
    of a broker that is:
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a United States person;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a &#147;controlled foreign corporation&#148; for United States
    federal income tax purposes;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a foreign person 50% or more of whose gross income from certain
    periods is effectively connected with a United States trade or
    business;&#160;or
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a foreign partnership if at any time during its tax year
    (a)&#160;one or more of its partners are United States persons
    who, in the aggregate, hold more than 50% of the income or
    capital interests of the partnership or (b)&#160;the foreign
    partnership is engaged in a United States trade or business;
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    information reporting (but not backup withholding) will apply
    unless the broker has documentary evidence in its files that the
    owner is a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    and certain other conditions are satisfied, or the beneficial
    owner otherwise establishes an exemption (and the broker has no
    actual knowledge or reason to know to the contrary).
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Backup withholding is not an additional tax. Any amounts
    withheld under the backup withholding rules from a payment to a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    may generally be refunded or credited against the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder&#146;s</FONT>
    United States federal income tax liability, if any, provided
    that the required information is furnished to the Internal
    Revenue Service in a timely manner.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    THE FOREGOING DISCUSSION OF CERTAIN MATERIAL UNITED STATES
    FEDERAL INCOME TAX CONSIDERATIONS IS FOR GENERAL INFORMATION
    ONLY AND IS NOT TAX ADVICE. ACCORDINGLY, EACH PROSPECTIVE HOLDER
    OF SHARES OF OUR COMMON STOCK SHOULD CONSULT HIS, HER OR ITS OWN
    TAX ADVISOR WITH RESPECT TO THE UNITED STATES FEDERAL, STATE AND
    LOCAL TAX CONSEQUENCES AND
    <FONT style="white-space: nowrap">NON-U.S.&#160;TAX</FONT>
    CONSEQUENCES OF THE ACQUISITION, OWNERSHIP AND DISPOSITION OF
    OUR COMMON STOCK.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    109
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='121'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">UNDERWRITERS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the terms and subject to the conditions contained in an
    underwriting agreement dated the date of this prospectus, the
    underwriters named below, for whom Morgan Stanley&#160;&#038;
    Co. Incorporated is acting as the representative, have severally
    agreed to purchase, and we have agreed to sell to them,
    severally, the number of shares indicated in the table below:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="90%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Morgan Stanley&#160;&#038; Co. Incorporated
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    UBS Securities LLC
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Leerink Swann LLC
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The underwriters are offering the shares of common stock subject
    to their acceptance of the shares from us and subject to prior
    sale. The underwriting agreement provides that the obligations
    of the several underwriters to pay for and accept delivery of
    the shares of common stock offered by this prospectus are
    subject to the approval of certain legal matters by their
    counsel and to certain other conditions. The underwriters are
    obligated to take and pay for all of the shares of common stock
    offered by this prospectus if any such shares are taken.
    However, the underwriters are not required to take or pay for
    the shares covered by the underwriters&#146; over-allotment
    option described below.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The underwriters initially propose to offer part of the shares
    of common stock directly to the public at the offering price
    listed on the cover page of this prospectus and part to certain
    dealers at a price that represents a concession not in excess of
    $&#160;&#160;  per share under the public offering price. After
    the initial offering of the shares of common stock, the offering
    price and other selling terms may from time to time be varied by
    the representative.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have granted to the underwriters an option, exercisable for
    30&#160;days from the date of this prospectus, to purchase up to
    an aggregate
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;additional
    shares of common stock at the public offering price set forth on
    the cover page of this prospectus, less underwriting discounts
    and commissions. The underwriters may exercise this option
    solely for the purpose of covering over-allotments, if any, made
    in connection with the offering of the shares of common stock
    offered by this prospectus. To the extent the option is
    exercised, each underwriter will become obligated, subject to
    certain conditions, to purchase approximately the same
    percentage of the additional shares of common stock as the
    number listed next to the underwriter&#146;s name in the
    preceding table bears to the total number of shares of common
    stock listed next to the names of all underwriters in the
    preceding table.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table shows the per share and total public
    offering price, underwriting discounts and commissions and
    proceeds before expenses to us. These amounts are shown assuming
    both no exercise and full exercise of the underwriters&#146;
    option to purchase up to an
    additional&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    of common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="65%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Per Share</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>No exercise</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Full Exercise</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Public offering price
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Underwriting discounts and commissions
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Proceeds, before expenses, to us
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The estimated offering expenses payable by us, exclusive of the
    underwriting discounts and commissions are approximately
    $&#160;&#160;&#160;&#160;&#160; .
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The underwriters have informed us that they do not intend sales
    to discretionary accounts to exceed five percent of the total
    number of shares of common stock offered by them.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We intend to apply to have the common stock listed on the NASDAQ
    Global Market under the symbol &#147;FLDM.&#148;
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    110
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We and all directors, officers and substantially all of our
    other security holders have agreed that, without the prior
    written consent of Morgan Stanley&#160;&#038; Co. Incorporated
    on behalf of the underwriters, we and they will not, during the
    period ending 180&#160;days after the date of this prospectus:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    offer, pledge, sell, contract to sell, sell any option or
    contract to purchase, purchase any option or contract to sell,
    grant any option, right or warrant to purchase, lend, or
    otherwise transfer or dispose of directly or indirectly, any
    shares of common stock or any securities convertible into or
    exercisable or exchangeable for common stock;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    enter into any swap or other arrangement that transfers to
    another, in whole or in part, any of the economic consequences
    of ownership of the common stock; or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    in our case only, file or cause to be filed a registration
    statement, including any amendments with respect to the
    registration statement of any shares of common stock or
    securities convertible, exercisable or exchangeable into our
    common stock or any other securities of the company (other than
    any registration statement on
    <FONT style="white-space: nowrap">Form&#160;S-8),</FONT>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    whether any such transaction described above is to be settled by
    delivery of common stock or such other securities, in cash or
    otherwise. In addition, each such person agrees that, without
    the prior written consent of Morgan Stanley&#160;&#038; Co.
    Incorporated on behalf of the underwriters, they will not,
    during the period ending 180&#160;days after the date of this
    prospectus, make any demand for, or exercise any right with
    respect to, the registration of any shares of common stock or
    any security convertible into or exercisable or exchangeable for
    common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subject to certain restrictions, the restrictions described in
    the immediately preceding paragraph do not apply to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the sale of shares to the underwriters;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    transactions relating to shares of common stock or other
    securities acquired in open market transactions after the
    completion of this offering, provided that no filing under
    Section&#160;16(a) of the Securities Exchange Act of 1934, as
    amended, shall be required or shall be voluntarily made in
    connection with subsequent sales of common stock or other
    securities acquired in such open market transactions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the exercise of any options to acquire common stock or
    conversion of any convertible security into common stock;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    transfers of shares of common stock or any security convertible
    into common stock as a bona fide gift;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    distributions of shares of common stock or any security
    convertible into common stock to limited partners, members or
    stockholders of the undersigned;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    transfers of shares of common stock or any security convertible
    into common stock by will or intestacy to the undersigned&#146;s
    immediate family or to a trust, the beneficiaries of which are
    members of the transferor&#146;s immediate family;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the establishment of a trading plan pursuant to
    <FONT style="white-space: nowrap">Rule&#160;10b5-1</FONT>
    under the Exchange Act for the transfer of shares of common
    stock, provided that such plan does not provide for the transfer
    of common stock during the restricted period.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The <FONT style="white-space: nowrap">180-day</FONT>
    restricted period described in the preceding paragraph will be
    extended if:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    during the last 17&#160;days of the
    <FONT style="white-space: nowrap">180-day</FONT>
    restricted period, we issue a release regarding earnings or
    regarding material news or events relating to us;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    prior to the expiration of the
    <FONT style="white-space: nowrap">180-day</FONT>
    restricted period, we announce that we will release earnings
    results during the
    <FONT style="white-space: nowrap">16-day</FONT>
    period beginning on the last day of the
    <FONT style="white-space: nowrap">180-day</FONT>
    period,
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    in which case, the restrictions described in the preceding
    paragraph will continue to apply until the expiration of the
    <FONT style="white-space: nowrap">18-day</FONT>
    period beginning on the issuance of the earnings release or the
    occurrence of the material news or material event, unless such
    extension is waived, in writing, by Morgan Stanley&#160;&#038;
    Co. Incorporated on behalf of the underwriters.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    111
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In order to facilitate the offering of the common stock, the
    underwriters may engage in transactions that stabilize, maintain
    or otherwise affect the price of the common stock. Specifically,
    the underwriters may sell more shares than they are obligated to
    purchase under the underwriting agreement, creating a short
    position. A short sale is covered if the short position is no
    greater than the number of shares available for purchase by the
    underwriters under the over-allotment option. The underwriters
    can close out a covered short sale by exercising the
    over-allotment option or purchasing shares in the open market.
    In determining the source of shares to close out a covered short
    sale, the underwriters will consider, among other things, the
    open market price of shares compared to the price available
    under the over-allotment option. The underwriters may also sell
    shares in excess of the over-allotment option, creating a naked
    short position. The underwriters must close out any naked short
    position by purchasing shares in the open market. A naked short
    position is more likely to be created if the underwriters are
    concerned that there may be downward pressure on the price of
    the common stock in the open market after pricing that could
    adversely affect investors who purchase in the offering. As an
    additional means of facilitating the offering, the underwriters
    may bid for, and purchase, shares of common stock in the open
    market. Finally, the underwriting syndicate may reclaim selling
    concessions allowed to an underwriter or a dealer for
    distributing the common stock in the offering, if the syndicate
    repurchases previously distributed common stock to cover
    syndicate short positions or to stabilize the price of the
    common stock. These activities may raise or maintain the market
    price of the common stock above independent market levels or
    prevent or retard a decline in the market price of the common
    stock. The underwriters are not required to engage in these
    activities, and may end any of these activities at any time.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We and the underwriters have agreed to indemnify each other
    against certain liabilities, including liabilities under the
    Securities Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A prospectus in electronic format may be made available on
    websites maintained by one or more underwriters participating in
    this offering. Other than the prospectus in electronic format,
    the information on the underwriters&#146; websites is not part
    of this prospectus. The underwriters may agree to allocate a
    number of shares of common stock to underwriters for sale to
    their online brokerage account holders. Internet distributions
    will be allocated by Morgan Stanley&#160;&#038; Co. Incorporated
    to underwriters that may make Internet distributions on the same
    basis as other allocations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">European
    Economic Area</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In relation to each Member State of the European Economic Area
    which has implemented the Prospectus Directive, each underwriter
    has represented and agreed that with effect from and including
    the date on which the Prospectus Directive is implemented in
    that Member State it has not made and will not make an offer of
    the common stock to the public in that Member State, except that
    it may, with effect from and including such date, make an offer
    of the common stock to the public in that Member State:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    at any time to legal entities which are authorized or regulated
    to operate in the financial markets or, if not so authorized or
    regulated, whose corporate purpose is solely to invest in
    securities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    at any time to any legal entity which has two or more of
    (1)&#160;an average of at least 250&#160;employees during the
    last financial year; (2)&#160;a total balance sheet of more than
    &#128;43,000,000 and (3)&#160;an annual net turnover of more
    than &#128;50,000,000, as shown in its last annual or
    consolidated accounts;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    at any time in any other circumstances which do not require the
    publication by us of a prospectus pursuant to Article&#160;3 of
    the Prospectus Directive.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For the purposes of the above, the expression an &#147;offer of
    the common stock to the public&#148; in relation to any shares
    of common stock in any Member State means the communication in
    any form and by any means of sufficient information on the terms
    of the offer and the common stock to be offered so as to enable
    an investor to decide to purchase or subscribe shares of common
    stock, as the same may be varied in that Member State by any
    measure implementing the Prospectus Directive in that Member
    State and the expression Prospectus Directive means Directive
    2003/71/EC and includes any relevant implementing measure in
    that Member State.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    112
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">United
    Kingdom</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each underwriter has represented and agreed that it has only
    communicated or caused to be communicated and will only
    communicate or cause to be communicated an invitation or
    inducement to engage in investment activity (within the meaning
    of Section&#160;21 of the Financial Services and Markets Act
    2000)&#160;in connection with the issue or sale of shares of
    common stock in circumstances in which Section&#160;21(1) of
    such Act does not apply to us and it has complied and will
    comply with all applicable provisions of such Act with respect
    to anything done by it in relation to any shares of common stock
    in, from or otherwise involving the United Kingdom.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Other
    Relationships</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Morgan Stanley&#160;&#038; Co. Incorporated has provided, and
    the underwriters may in the future provide, investment banking
    services to us for which they would receive customary
    compensation. In addition, as described under &#147;Certain
    Relationships and Related Party Transactions,&#148; in October
    2007 we sold shares of our Series&#160;E Preferred Stock in a
    private placement transaction. Leerink Swann LLC acted as the
    placement agent for this offering and entities affiliated with
    Leerink Swann LLC purchased shares of Series&#160;E Preferred
    Stock in connection with such offering.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Pricing
    of the Offering</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to this offering, there has been no public market for our
    common stock. The initial public offering price will be
    determined by negotiations between us and the underwriters.
    Among the factors to be considered in determining the initial
    public offering price are:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our future prospects and those of our industry in general;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our sales, earnings and certain other financial and operating
    information in recent periods;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the price-earnings ratios, price-sales ratios and market prices
    of securities and certain financial and operating information of
    companies engaged in activities similar to ours.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    An active trading market for the shares may not develop. It is
    also possible that after the offering the shares will not trade
    in the public market at or above the initial public offering
    price.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    113
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='116'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">LEGAL
    MATTERS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The validity of the shares of common stock offered hereby will
    be passed upon for us by Wilson Sonsini Goodrich&#160;&#038;
    Rosati, Professional Corporation, Palo Alto, California.
    Latham&#160;&#038; Watkins LLP, Costa Mesa, California is acting
    as counsel to the underwriters. Members of Wilson Sonsini
    Goodrich &#038; Rosati, Professional Corporation and investment
    funds associated with that firm hold 160,956 shares of our
    common stock.
</DIV>
<A name='117'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">EXPERTS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Ernst &#038; Young LLP, independent registered public accounting
    firm, has audited our consolidated financial statements at
    December&#160;31, 2006 and December&#160;29, 2007, and for each
    of the three years in the period ended December&#160;29, 2007,
    as set forth in their report. We have included our consolidated
    financial statements in the prospectus and elsewhere in the
    registration statement in reliance on Ernst &#038; Young
    LLP&#146;s report, given on their authority as experts in
    accounting and auditing.
</DIV>
<A name='118'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">WHERE YOU
    CAN FIND ADDITIONAL INFORMATION</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have filed with the SEC a registration statement on
    <FONT style="white-space: nowrap">Form&#160;S-1</FONT>
    under the Securities Act with respect to the shares of common
    stock offered hereby. This prospectus, which constitutes a part
    of the registration statement, does not contain all of the
    information set forth in the registration statement or the
    exhibits and schedules filed therewith. For further information
    about us and the common stock offered hereby, we refer you to
    the registration statement and the exhibits and schedules filed
    thereto. Statements contained in this prospectus regarding the
    contents of any contract or any other document that is filed as
    an exhibit to the registration statement are not necessarily
    complete, and each such statement is qualified in all respects
    by reference to the full text of such contract or other document
    filed as an exhibit to the registration statement. Upon
    completion of this offering, we will be required to file
    periodic reports, proxy statements, and other information with
    the SEC pursuant to the Securities Exchange Act of 1934. You may
    read and copy this information at the Public Reference Room of
    the SEC, 100 F. Street, N.E., Room&#160;1580,
    Washington,&#160;D.C. 20549. You may obtain information on the
    operation of the public reference rooms by calling the SEC at
    <FONT style="white-space: nowrap">1-800-SEC-0330.</FONT>
    The SEC also maintains an Internet website that contains
    reports, proxy statements and other information about issuers,
    like us, that file electronically with the SEC. The address of
    that site is www.sec.gov.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We intend to provide our stockholders with annual reports
    containing financial statements that have been audited by an
    independent registered public accounting firm, and to file with
    the SEC quarterly reports containing unaudited financial data
    for the first three quarters of each year.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    114
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='119'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">INDEX TO
    CONSOLIDATED FINANCIAL STATEMENTS</FONT></B>
</DIV>
</A>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>
<DIV align="left">
<!-- TOC -->
</DIV>

<DIV align="left">
<A name="tocpage"></A>
</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="95%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Page</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#300'>Report of Independent Registered Public
    Accounting Firm</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-2
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#301'>Consolidated Balance Sheets</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-3
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#302'>Consolidated Statements of Operations</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-4
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#303'>Consolidated Statements of Convertible Preferred
    Stock and Stockholders&#146; Equity (Deficit)</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-5
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#304'>Consolidated Statements of Cash Flows</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-6
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#305'>Notes to Consolidated Financial Statements</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-7
</TD>
<TD>&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left">
<!-- /TOC -->
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='300'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Report of
    Independent Registered Public Accounting Firm</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Board of Directors and Stockholders<BR>
    Fluidigm Corporation
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have audited the accompanying consolidated balance sheets of
    Fluidigm Corporation as of December&#160;31, 2006 and
    December&#160;29, 2007, and the related consolidated statements
    of operations, convertible preferred stock and
    stockholders&#146; equity (deficit), and cash flows for each of
    the three fiscal years in the period ended December&#160;29,
    2007. These financial statements are the responsibility of the
    Company&#146;s management. Our responsibility is to express an
    opinion on these financial statements based on our audits.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We conducted our audits in accordance with the standards of the
    Public Company Accounting Oversight Board (United States). Those
    standards require that we plan and perform the audit to obtain
    reasonable assurance about whether the financial statements are
    free of material misstatement. We were not engaged to perform an
    audit of the Company&#146;s internal control over financial
    reporting. Our audits included consideration of internal control
    over financial reporting as a basis for designing audit
    procedures that are appropriate in the circumstances, but not
    for the purpose of expressing an opinion on the effectiveness of
    the Company&#146;s internal control over financial reporting.
    Accordingly, we express no such opinion. An audit also includes
    examining, on a test basis, evidence supporting the amounts and
    disclosures in the financial statements, assessing the
    accounting principles used and significant estimates made by
    management, and evaluating the overall financial statement
    presentation. We believe that our audits provide a reasonable
    basis for our opinion.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In our opinion, the financial statements referred to above
    present fairly, in all material respects, the consolidated
    financial position of Fluidigm Corporation at December&#160;31,
    2006 and December&#160;29, 2007, and the consolidated results of
    its operations and its cash flows for each of the three fiscal
    years in the period ended December&#160;29, 2007, in conformity
    with U.S.&#160;generally accepted accounting principles.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As discussed in Note&#160;2 to the consolidated financial
    statements, Fluidigm Corporation changed its method of
    accounting for preferred stock warrants as of July&#160;1, 2005,
    its method of accounting for stock-based compensation as of
    January&#160;1, 2006, and its method of accounting for uncertain
    tax positions as of January&#160;1, 2007.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Ernst&#160;&#038;
    Young LLP</DIV>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Palo Alto, California
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    April 12, 2008
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='301'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Consolidated
    Balance Sheets</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(in
    thousands, except per share amounts)</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="75%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD colspan="9" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Assets</B>
</DIV>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Current assets:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Cash and cash equivalents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    25,018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    34,077
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,286
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Accounts receivable (net of allowances $3 in 2006 and $0 in 2007)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,765
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Inventories
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,038
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,498
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Prepaid expenses and other current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    768
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,068
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Restricted cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Total current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31,089
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,329
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Restricted cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    381
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Property and equipment, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,068
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,378
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Other assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    436
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    688
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    36,493
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    54,776
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="9">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="9" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Liabilities, Convertible Preferred Stock and
    Stockholders&#146; Equity (Deficit)</B>
</DIV>
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Current liabilities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Accounts payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,188
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,725
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Accrued compensation and related benefits
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    397
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    898
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Other accrued liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    856
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    998
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Deferred revenue, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,652
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Long-term debt, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,476
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,834
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Convertible preferred stock warrant liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    223
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    468
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Total current liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,575
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Deferred revenue, net of current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    786
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    762
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Long-term debt, net of current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,362
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,528
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Convertible promissory notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,072
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,997
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Other liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    163
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,370
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,025
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Commitments and contingencies (Note&#160;6)&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Convertible preferred stock issuable in series, $0.001&#160;par
    value: 52,438 and 61,798&#160;shares authorized, 43,284 and
    56,671&#160;shares issued and outstanding as of
    December&#160;31, 2006 and December&#160;29, 2007, respectively;
    aggregate liquidation preference of $165,169 as of
    December&#160;29, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    112,295
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    162,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Stockholders&#146; equity (deficit):
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Common stock, $0.001&#160;par value: 77,857 and
    87,386&#160;shares authorized, 9,498 and 9,901&#160;shares
    issued and outstanding as of December&#160;31, 2006 and
    December&#160;29, 2007, respectively
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Additional paid-in capital
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,108
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,592
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Accumulated other comprehensive loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (135
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Accumulated deficit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (108,272
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (133,798
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total stockholders&#146; equity (deficit)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (106,172
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (130,331
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total liabilities, convertible preferred stock and
    stockholders&#146; equity (deficit)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    36,493
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    54,776
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See accompanying notes.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='302'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Consolidated
    Statements of Operations</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(in
    thousands, except per share amounts)</FONT></B>
</DIV>
</A>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="62%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Revenue:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Product revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,076
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,959
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,451
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Collaboration revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,568
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,376
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    460
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Grant revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,063
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,364
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,674
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,398
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,275
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Costs and expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Cost of product revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,764
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,773
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,514
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Research and development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,449
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,589
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,389
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Selling, general and administrative
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,955
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,699
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,898
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total costs and expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,168
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,061
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,801
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Loss from operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,494
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21,663
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,526
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (898
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,261
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,790
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,140
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Other income (expense), net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (194
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (170
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Loss before provision for income taxes and cumulative effect of
    change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,022
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,346
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Provision for income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (105
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Loss before cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,022
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    637
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16,385
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss per share of common stock before cumulative effect of
    change in accounting principle, basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.89
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.53
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cumulative effect of change in accounting principle, basic and
    diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.07
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss per share of common stock, basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.82
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.53
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Shares used in computing net loss per share of common stock,
    basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,316
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See accompanying notes.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 100%; margin-left: 0%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<A name='303'>
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Consolidated
    Statements of Convertible Preferred Stock and Stockholders&#146;
    Equity (Deficit)</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(in
    thousands, except per share amounts)</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 6pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="57%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=09 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=09 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=09 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=09 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Accumulated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Convertible<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Additional<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Preferred Stock</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Common Stock</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Paid-In<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Comprehensive<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Accumulated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Stockholders&#146;<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Amount</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Amount</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Capital</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Income (Loss)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Deficit</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Deficit</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -6pt; margin-left: 6pt">
    Balance as of January&#160;1, 2005
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32,845
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    76,596
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,929
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,870
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (68,334
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (65,471
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 20pt">
    Issuance of common stock upon exercise of stock options for cash
    and for vesting of stock options that were exercised early
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    170
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 20pt">
    Issuance of Series&#160;D convertible preferred stock for cash
    at $2.80 per share, net of issuance costs of $11
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,589
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,042
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 20pt">
    Issuance of common stock for services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    80
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 20pt">
    Stock-based compensation expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 20pt">
    Issuance of convertible preferred stock warrants in connection
    with financing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 20pt">
    Issuance of Series&#160;D convertible preferred stock upon
    conversion of promissory note at $2.80 per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    833
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,328
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 20pt">
    Reclassification of convertible preferred stock warrants to
    liabilities upon adoption of FSP
    <FONT style="white-space: nowrap">150-5</FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,473
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,473
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 20pt">
    Comprehensive loss:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -6pt; margin-left: 26pt">
    Foreign currency translation adjustment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -6pt; margin-left: 26pt">
    Unrealized gain on available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -6pt; margin-left: 26pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,385
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,385
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 20pt">
    Total comprehensive loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,349
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -6pt; margin-left: 6pt">
    Balance as of December&#160;31, 2005
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,267
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,966
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,179
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,536
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (84,719
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (83,154
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 20pt">
    Issuance of common stock upon exercise of stock options for cash
    and for vesting of stock options that were exercised early
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    443
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    190
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    190
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 20pt">
    Repurchase of common stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (124
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (69
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (69
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 20pt">
    Issuance of Series&#160;D convertible preferred stock at $2.80
    per share upon exercise of warrants
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    268
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    729
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 20pt">
    Issuance of Series&#160;E convertible preferred stock for cash
    at $4.00 per share, net of issuance costs of $133
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,535
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,003
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 20pt">
    Issuance of Series&#160;D convertible preferred stock at $2.80
    per share under license agreement, net of issuance costs of $3
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    214
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    597
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 20pt">
    Stock-based compensation expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    145
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    145
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 20pt">
    Beneficial conversion feature for convertible promissory notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    306
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    306
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 20pt">
    Comprehensive loss:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -6pt; margin-left: 26pt">
    Foreign currency translation adjustment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (36
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (36
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -6pt; margin-left: 26pt">
    Unrealized loss on available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -6pt; margin-left: 26pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 20pt">
    Total comprehensive loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,590
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -6pt; margin-left: 6pt">
    Balance as of December&#160;31, 2006
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,284
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    112,295
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,498
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,108
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (108,272
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (106,172
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 13pt">
    Cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (75
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (75
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 13pt">
    Issuance of common stock upon exercise of stock options for cash
    and for vesting of stock options that were exercised early
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    297
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    146
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    147
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 13pt">
    Issuance of Series&#160;E convertible preferred stock for cash
    at $4.00 per share, net of issuance costs of $1,189
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,276
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    35,911
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 13pt">
    Issuance of common stock for services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    106
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    145
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    145
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 13pt">
    Stock-based compensation expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    708
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    708
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 13pt">
    Issuance of Series&#160;D convertible preferred stock upon
    conversion of promissory note at $2.80 per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,157
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,240
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 13pt">
    Issuance of Series&#160;E convertible preferred stock upon
    conversion of promissory notes at $3.60 per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,954
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,636
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 13pt">
    Beneficial conversion feature for convertible promissory notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    485
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    485
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 13pt">
    Comprehensive loss:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 20pt">
    Foreign currency translation adjustment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (107
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (107
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 20pt">
    Unrealized loss on available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 20pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 13pt">
    Total comprehensive loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,569
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -6pt; margin-left: 6pt">
    Balance as of December&#160;29, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    162,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,901
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,592
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (135
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (133,798
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (130,331
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See accompanying notes.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 100%; margin-left: 0%"><!-- BEGIN PAGE WIDTH -->
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<A name='304'>
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Consolidated
    Statements of Cash Flows</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(in
    thousands)</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="63%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Operating activities</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16,385
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Adjustments to reconcile net loss to net cash used in operating
    activities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Depreciation and amortization
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,309
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,379
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,643
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Stock-based compensation expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    145
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    708
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Adjustment to fair value of convertible preferred stock warrants
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (72
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    138
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    245
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Loss on retirement of property and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    111
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Amortization of debt discount
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    80
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    495
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Issuance of common stock for services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    145
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Issuance of convertible preferred stock under license agreement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    597
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (637
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (75
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Changes in assets and liabilities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Accounts receivable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (287
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (400
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (135
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Inventories
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    152
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (955
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,460
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Prepaid expenses and other assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (75
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (78
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,552
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Accounts payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    773
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (575
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,537
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Deferred revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,202
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    533
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,618
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Other liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (320
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    272
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,503
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Net cash used in operating activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,292
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (22,306
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21,759
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Investing activities</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Purchases of available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (500
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,990
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,273
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Maturities of available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,249
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,987
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    487
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Sales of available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,650
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Restricted cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    95
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Purchase of property and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,656
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,932
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (973
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Net cash provided by (used in) investing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,838
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,943
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,740
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Financing activities</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Proceeds from long-term debt
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,651
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Repayment of long-term debt
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,745
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,000
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,503
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Proceeds from exercise of stock options
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    190
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    147
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Proceeds from issuance of convertible preferred stock, net of
    issuance costs
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,042
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,003
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    35,911
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Proceeds from issuance of convertible promissory notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Repurchase of common stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (69
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Net cash provided by financing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,994
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31,124
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,555
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Effect of exchange rate changes on cash and cash equivalents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (19
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Net increase in cash and cash equivalents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,538
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,856
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,059
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Cash and cash equivalents as of beginning of year
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,624
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,162
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Cash and cash equivalents as of end of year
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    19,162
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    25,018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    34,077
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Supplemental disclosures of cash flow information</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Cash paid for interest
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    589
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,826
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,523
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Conversion of convertible promissory notes into convertible
    preferred stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,328
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    13,876
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Cashless net exercise of convertible preferred stock warrants
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    729
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Issuance of warrants in connection with long-term debt
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    744
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Issuance of convertible preferred stock under license agreement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    597
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See accompanying notes.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>
<A name='305'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial Statements</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">1.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Description
    of Business</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Fluidigm Corporation (the Company) was incorporated in the state
    of California on May&#160;19, 1999, to commercialize
    microfluidic technology initially developed at the California
    Institute of Technology (Caltech). In July 2007, the Company was
    reincorporated in Delaware. The Company&#146;s headquarters are
    located in South San&#160;Francisco, California.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company develops, manufactures and markets proprietary
    Integrated Fluidic Circuit systems that significantly improve
    the productivity of life science research. The Company&#146;s
    Integrated Fluidic Circuits, or IFCs, enable the simultaneous
    performance of thousands of biochemical measurements in
    extremely minute volumes. The Company created this
    &#147;integrated circuit for biology&#148; by achieving
    unprecedented miniaturization, integration and automation of
    sophisticated liquid handling processes on a single
    microfabricated device. The Company&#146;s customers include
    many leading biotechnology and pharmaceutical companies,
    academic institutions, and life science laboratories worldwide.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For the year ended December&#160;29, 2007, the Company incurred
    a net loss of approximately $25.5&#160;million and used
    approximately $21.8&#160;million of cash in operating
    activities. As of December&#160;29, 2007, the Company had an
    accumulated deficit of approximately $133.8&#160;million and
    cash, cash equivalents and available-for-sale securities of
    approximately $40.4&#160;million. The Company expects to incur
    significant expenses to fund operations to develop new products
    and to support existing product sales. Failure to generate
    sufficient revenues, achieve planned gross margins, control
    operating costs, or to raise sufficient additional funds may
    require the Company to modify, delay, or abandon some of its
    future expansion or expenditures, which could have a material
    adverse effect on the Company&#146;s business, operating
    results, financial condition, and ability to achieve its
    intended business objectives.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">2.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Summary
    of Significant Accounting Policies</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Basis of
    Presentation and Consolidation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The consolidated financial statements of the Company have been
    prepared in conformity with U.S.&#160;generally accepted
    accounting principles and include the accounts of the Company
    and its wholly owned subsidiaries. The Company has wholly owned
    subsidiaries in Singapore, the Netherlands, Japan, and France.
    All subsidiaries, except for Singapore, use their local currency
    as their functional currency. The Singapore subsidiary uses the
    U.S.&#160;dollar as its functional currency. All intercompany
    transactions and balances have been eliminated in consolidation.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Fiscal
    Year</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During 2007, the Company adopted a 52 or 53&#160;week year
    convention for its fiscal years and, therefore, fiscal years for
    2007 and future years will end on the last Saturday in December
    of each respective year. Prior to 2007, the Company used a
    calendar year. The fiscal years presented in these consolidated
    financial statements ended on December&#160;31, 2005,
    December&#160;31, 2006 and December&#160;29, 2007.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Use of
    Estimates</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The preparation of consolidated financial statements requires
    management to make estimates and assumptions that affect the
    amounts reported in the consolidated financial statements and
    accompanying notes. The Company regularly assesses these
    estimates which affect the fair value of undelivered elements
    for revenue recognition purposes, the valuation of accounts
    receivable, the valuation of inventories, accrued liabilities,
    the fair value of the Company&#146;s convertible preferred stock
    and common stock, warrants, stock-based compensation, beneficial
    conversion features, and valuation allowances associated with
    deferred tax assets. The Company bases its estimates on
    historical experience and on various other assumptions believed
    to be reasonable, the results of which form the basis for making
    judgments about the carrying values of assets and liabilities.
    Actual results could differ materially from these estimates.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Foreign
    Currency</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Assets and liabilities of
    <FONT style="white-space: nowrap">non-U.S.&#160;subsidiaries</FONT>
    that use the local currency as their functional currency are
    translated into U.S.&#160;dollars at exchange rates in effect at
    the balance sheet date, with the resulting translation
    adjustments recorded to a separate component of accumulated
    other comprehensive income (loss) within stockholders&#146;
    equity. Income and expense accounts are translated at average
    exchange rates during the year. Foreign currency transaction
    gains and losses for
    <FONT style="white-space: nowrap">non-U.S.&#160;subsidiaries</FONT>
    that use the U.S.&#160;dollar as their functional currency are
    recognized in other income (expense), net. The Company had net
    foreign currency transaction losses of $27,000 and $70,000
    during 2005 and 2006, respectively, and a net foreign currency
    transaction gain of $72,000 during 2007.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Cash and
    Cash Equivalents</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company considers all highly liquid financial instruments
    with maturities at the time of purchase of three months or less
    to be cash equivalents. Cash and cash equivalents consist of
    cash on deposit with banks, money market funds, commercial
    paper, corporate notes, and notes from government-sponsored
    agencies.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Available-for-Sale
    Securities</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Available-for-sale securities are comprised of corporate notes
    and notes from government-sponsored agencies. Investments
    classified as &#147;available-for-sale&#148; and are recorded at
    estimated fair value, as determined by quoted market rates, on
    the consolidated balance sheets with any unrealized gains and
    losses reported in stockholders&#146; equity as a component of
    accumulated other comprehensive income (loss). Realized gains
    and losses and declines in the fair value of available-for-sale
    securities below their cost that are deemed to be &#147;other
    than temporary&#148; are reflected in interest income. No
    &#147;other than temporary&#148; unrealized losses have been
    incurred to date and realized gains and losses were immaterial
    during the years presented. The cost of securities sold is based
    on the specific-identification method.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Restricted
    Cash</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company had restricted cash balances of $900,000 and
    $881,000 as of December&#160;31, 2006 and December&#160;29,
    2007, respectively. Included in current restricted cash is a
    $500,000 amount that collateralizes a letter of credit that the
    Company maintains under the terms of a master security agreement
    with a lender (see Note&#160;5). The Company also had
    non-current restricted cash amounts that collateralize the
    Company&#146;s standby letters of credit issued under operating
    lease agreements for office facilities that it currently
    occupies.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Fair
    Value of Financial Instruments</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;31, 2006 and December&#160;29, 2007, the
    respective carrying values of the Company&#146;s financial
    instruments, including accounts receivable, restricted cash, and
    accounts payable, approximated their fair values due to their
    short period of time to maturity or repayment. Based on
    borrowing rates currently available to the Company for loans
    with similar terms, the carrying value of long-term debt and
    convertible promissory notes approximated their fair values.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Accounts
    Receivable</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Trade accounts receivable are recorded at net invoice value. The
    Company considers receivables past due based on the contractual
    payment terms. The Company reviews its exposure to accounts
    receivable and reserves specific amounts if collectibility is no
    longer reasonably assured based on historical experience and
    specific customer collection issues. The Company reevaluates
    such reserves on a regular basis and adjusts its reserves as
    needed. Write-offs of accounts receivable were insignificant
    during 2005, 2006 and 2007.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-8
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Concentrations
    of Credit Risk</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Financial instruments that potentially subject the Company to
    credit risk consist of cash, cash equivalents,
    available-for-sale securities, and accounts receivable. The
    Company maintains cash, cash equivalents, and available-for-sale
    securities with major financial institutions. The Company&#146;s
    cash, cash equivalents, and available-for-sale securities
    consist of deposits held with banks, commercial paper, money
    market funds, and other highly liquid investments that, at
    times, exceed federally insured limits. The Company performs
    periodic evaluations of its investments and the relative credit
    standing of these financial institutions and limits the amount
    of credit exposure with any one institution.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company does not require collateral to support credit sales.
    To reduce credit risk, the Company performs periodic credit
    evaluations of its customers. The Company has had no credit
    losses to date. Customers with revenues of 10% or greater of
    total revenues for 2005, 2006 and 2007 are as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="82%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="9" nowrap align="center" valign="bottom">
    <B>Percentage of<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="9" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Total Revenue</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B>Customers:</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    A
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    24%
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    B
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    *
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    C
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    *
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    * </TD>
    <TD></TD>
    <TD valign="bottom">
    Represents less than 10% of total revenues.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s products include components that are
    currently available from a single source or a limited number of
    sources. The Company believes that other vendors would be able
    to provide similar components; however, the qualification of
    such vendors may require
    <FONT style="white-space: nowrap">start-up</FONT>
    time. In order to mitigate any adverse impacts from a disruption
    of supply, the Company attempts to maintain an adequate supply
    of critical limited-sourced components.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Inventories</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Inventories are stated at the lower of cost (which approximates
    actual cost on a
    <FONT style="white-space: nowrap">first-in,</FONT>
    first-out method) or market. Inventories include raw materials,
    <FONT style="white-space: nowrap">work-in-process,</FONT>
    and finished goods that may be used in the research and
    development process, and such items are expensed when they are
    designated for use in research and development. Provisions for
    slow moving, excess, and obsolete inventories are recorded based
    on product life cycle, development plans, product expiration,
    and quality issues.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Property
    and Equipment</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Property and equipment, including leasehold improvements, are
    stated at cost less accumulated depreciation, which is
    calculated using the straight-line method over the estimated
    useful lives of the assets, which range from three to five
    years. Leasehold improvements are amortized using the
    straight-line method over the estimated useful lives of the
    assets or the remaining term of the lease, whichever is shorter.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In accordance with SFAS&#160;No.&#160;144, <I>Accounting for the
    Impairment or Disposal of Long-Lived Assets</I>, if indicators
    of impairment exist, the Company assesses the recoverability of
    the affected long-lived assets by determining whether the
    carrying value of such assets can be recovered through
    undiscounted future operating cash flows. If impairment is
    indicated, the Company measures the future discounted cash flows
    associated with the use of the asset and adjusts the value of
    the asset accordingly. While the Company&#146;s current and
    historical operating and cash flow losses are indicators of
    impairment, the Company believes the future cash flows to be
    received from the long-lived assets recorded as of
    December&#160;29, 2007 will exceed the assets&#146; carrying
    value, and, accordingly, the Company has not recognized any
    impairment losses through December&#160;29, 2007.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-9
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Reserve
    for Product Warranties</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company generally provides a one-year warranty on
    instruments. The Company reviews its exposure to estimated
    warranty expenses associated with instrument sales and
    establishes an accrual based on historical product failure rates
    and actual warranty costs incurred. This expense is recorded as
    a component of cost of product revenue in the consolidated
    statements of operations. Warranty accruals and expenses were
    immaterial for all periods presented.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Revenue
    Recognition</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company generates revenue from sales of its products and
    services. The Company&#146;s products consist of single-use
    IFCs, various instruments, software, and reagents. The
    Company&#146;s services include instrument installation,
    training, and customer support services. The Company has also
    entered into a number of research and development agreements and
    received government grants to conduct research and development
    activities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company records revenue in accordance with the guidelines
    established by the Securities and Exchange Commission (SEC)
    Staff Accounting Bulletin&#160;No.&#160;104, <I>Revenue
    Recognition </I>(SAB&#160;104). In addition, the Company has
    concluded that pursuant to AICPA Statement of Position
    <FONT style="white-space: nowrap">97-2,</FONT>
    <I>Software Revenue Recognition
    </I><FONT style="white-space: nowrap">(SOP&#160;97-2),</FONT>
    software included with certain of its instruments is more than
    incidental to their functionality. Accordingly, the Company
    applies
    <FONT style="white-space: nowrap">SOP&#160;97-2</FONT>
    to sales of such instruments and related deliverables. Revenue
    is recognized when all of the following criteria are met:
    persuasive evidence of an arrangement exists, delivery has
    occurred or services rendered, the seller&#146;s price to the
    buyer is fixed or determinable, and collectibility is reasonably
    assured.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Product
    Revenue</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company sells instruments in arrangements that may include
    related installation and training, customer support services and
    software and may also include single-use IFCs. If the
    arrangement includes IFCs, the Company uses the separation
    criteria in EITF Issue
    <FONT style="white-space: nowrap">No.&#160;00-21,</FONT>
    <I>Revenue Arrangements with Multiple Deliverables</I>, to
    separate revenues related to IFCs, which are non-software
    related deliverables, from software related deliverables. IFC
    revenue is recognized upon delivery. Revenue from software
    related deliverables is recognized in accordance with
    <FONT style="white-space: nowrap">SOP&#160;97-2</FONT>
    and related pronouncements. Under
    <FONT style="white-space: nowrap">SOP&#160;97-2,</FONT>
    the Company recognizes revenue for delivered elements only when
    it determines that undelivered elements are not essential to the
    functionality of the delivered elements and the vendor-specific
    objective evidence (VSOE) of fair values of undelivered elements
    are known. Installation is deemed essential to the functionality
    of certain instruments; for those instruments recognition of
    revenue begins after installation has been completed. Fair value
    of undelivered elements is established by reference to VSOE
    which is based on stand-alone sales of such elements. If any
    undelivered element does not have VSOE of fair value, revenue is
    deferred until all of such elements are delivered, or until VSOE
    of fair value can objectively be determined for any remaining
    undelivered elements. However, if the only undelivered element
    is post-contract customer support services, such as those
    included in the Company&#146;s maintenance agreements, revenue
    on the software related deliverables is recognized ratably over
    the service period. When revenues are deferred, the
    corresponding costs of products sold are also deferred in other
    assets in the consolidated financial statements and recognized
    over the same period. If VSOE of fair value exists for all
    undelivered elements, but does not exist for the delivered
    elements in the arrangement, revenue is allocated to the
    undelivered elements based on their VSOE of fair values, with
    the residual amount allocated to the delivered elements and
    recognized upon their delivery.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During 2005, 2006 and 2007, the Company did not have VSOE of
    fair value for software support services. Therefore, revenue and
    the corresponding costs of software-related deliverables is
    deferred and recognized over the customer support period ranging
    from one to three years. All revenue from these arrangements has
    been classified as product revenue in the statements of
    operations, as the amount attributed to services was immaterial.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-10
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2007, no right of return existed for the Company&#146;s
    products. In prior years, if there was a right of return, the
    entire revenue from the arrangement was deferred until the right
    had lapsed. The Company has not experienced any significant
    returns of its products. Accruals are provided for anticipated
    warranty expenses at the time the associated revenue is
    recognized. Amounts received in advance of when revenue
    recognition criteria are met are recorded as deferred revenue on
    the consolidated balance sheets.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company sells its products to third-party resellers located
    in certain international markets. From time to time, these
    arrangements may be subject to contingencies such as completion
    of the instrument delivery to or installation at the end
    customer. The Company recognizes revenue on sales of products to
    the resellers if all revenue recognition criteria have been met
    and any contingency provisions related to the sale have been
    satisfied.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Collaboration
    Revenue</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company has entered into agreements with third parties,
    including government entities, to provide research and
    development services. Fixed-fee research and development
    agreements generally provide the Company with up-front and
    periodic milestone fees. Variable-fee research and development
    agreements generally provide the Company with fees based upon
    <FONT style="white-space: nowrap">agreed-upon</FONT>
    rates for time incurred by research staff. Under
    <FONT style="white-space: nowrap">EITF&#160;00-21,</FONT>
    the Company evaluates whether these arrangements contain
    multiple units of accounting by evaluating whether delivered
    elements have value on a stand-alone basis and whether there is
    objective and reliable evidence of fair value of the undelivered
    items. During 2005, 2006 and 2007, the Company concluded that
    these arrangements consisted of a single unit of accounting,
    namely, research and development services. Accordingly, the
    Company recognizes the fees under these arrangements over the
    period the Company performs these services. Costs associated
    with the research and development agreements are included in
    research and development expense.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Grant
    Revenue</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Government grants provide the Company with cost reimbursement
    for certain types of research and development activities
    performed over a contractually defined period. Revenue from
    government grants is recognized during the period during which
    the related costs are incurred, provided that the conditions
    under which the government grants were provided have been met
    and the Company has only perfunctory obligations outstanding.
    Amounts received in advance of when revenue recognition criteria
    are met are recorded as deferred revenue on the consolidated
    balance sheets. Costs associated with the grants are included in
    research and development expense.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Shipping
    and Handling Costs</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Shipping and handling costs incurred for product shipments are
    included within cost of product revenue in the consolidated
    statements of operations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Research
    and Development</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company expenses research and development expenditures in
    the period incurred. Research and development expense consists
    of personnel costs, independent contractor costs, prototype
    expenses, and allocated facilities and information technology
    expenses. These costs include direct and research-related
    overhead expenses.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Advertising
    Costs</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company expenses advertising costs as incurred. The Company
    incurred advertising costs of $237,000, $324,000 and $701,000
    during 2005, 2006 and 2007, respectively.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Income
    Taxes</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company uses the liability method to account for income
    taxes, whereby deferred income taxes reflect the impact of
    temporary differences for items recognized for financial
    reporting purposes over different periods than
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-11
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    for income tax purposes. Valuation allowances are provided when
    the expected realization of deferred tax assets does not meet a
    &#147;more likely than not&#148; criterion.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company adopted Financial Accounting Standards Board (FASB)
    Interpretation No.&#160;48, <I>Accounting for Uncertainties in
    Income Taxes&#160;&#151; an interpretation of FASB Statement
    No.&#160;109 </I>(FIN&#160;48), effective January&#160;1, 2007.
    FIN&#160;48 requires that the Company recognize the financial
    statement effects of a tax position when it is more likely than
    not, based on the technical merits, that the position will be
    sustained upon examination. Upon adoption, the Company recorded
    a charge of $75,000 as a cumulative effect of a change in
    accounting principle in the accumulated deficit during 2007.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Stock-Based
    Compensation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to January&#160;1, 2006, the Company accounted for its
    employee stock option plans using the intrinsic value method
    prescribed by Accounting Principles Board Opinion No.&#160;25,
    <I>Accounting for Stock Issued to Employees </I>(APB 25), which
    required the Company to recognize the difference between the
    exercise price of an employee option and the fair value of the
    underlying common stock as of the grant date. The resulting
    stock-based compensation expense, if any, was recorded on the
    date of the grant in stockholders&#146; equity as deferred
    compensation and amortized to expense over the vesting period of
    the grant, which was generally four years.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In December 2004, the FASB issued SFAS&#160;No.&#160;123
    (revised 2004), <I>Share-Based Payment </I>(SFAS&#160;123(R)),
    that addresses the accounting for stock-based payment
    transactions in which a company receives services in exchange
    for equity instruments, including stock options. The Company
    adopted SFAS&#160;123(R) beginning January&#160;1, 2006 using
    the prospective-transition method, as options granted prior to
    January&#160;1, 2006 were measured using the minimum value
    method for the pro forma disclosures previously required by
    SFAS&#160;No.&#160;123, <I>Accounting for Stock-Based
    Compensation </I>(SFAS&#160;123). Under the
    prospective-transition method, the Company continues to apply
    APB 25 to employee equity awards outstanding at the date of the
    Company&#146;s adoption of SFAS&#160;123(R). Any compensation
    costs recognized from January&#160;1, 2006 onward consists of:
    (a)&#160;compensation cost for all stock-based awards granted
    prior to, but not vested as of, December&#160;31, 2005 based on
    the intrinsic value determined in accordance with the provisions
    of APB 25; and (b)&#160;compensation cost for all stock-based
    awards granted or modified subsequent to December&#160;31, 2005,
    net of estimated forfeitures, based on the grant date fair value
    estimated in accordance with the provisions of SFAS&#160;123(R).
    The Company recognizes stock-based compensation expense on a
    straight-line basis over the vesting period of the respective
    grants. In accordance with the prospective-transition method,
    results for prior periods have not been restated.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company applies SFAS&#160;123(R) and EITF Issue
    <FONT style="white-space: nowrap">No.&#160;96-18,</FONT>
    <I>Accounting for Equity Instruments That Are Issued to Other
    Than Employees for Acquiring, or in Conjunction with Selling,
    Goods or Services
    </I><FONT style="white-space: nowrap">(EITF&#160;96-18),</FONT>
    to options and other stock-based awards issued to nonemployees.
    In accordance with SFAS&#160;123(R) and
    <FONT style="white-space: nowrap">EITF&#160;96-18,</FONT>
    the Company uses the Black-Scholes option-pricing model to
    measure the fair value of the options at the measurement dates.
    The nonemployee options are subject to periodic reevaluation
    over their vesting terms.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Comprehensive
    Loss</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Comprehensive loss is comprised of net loss and other
    comprehensive income (loss). Other comprehensive income (loss)
    includes unrealized holding gains and losses on the
    Company&#146;s available-for-sale securities and foreign
    currency translation adjustments. Total comprehensive loss for
    all periods presented has been disclosed in the consolidated
    statements of convertible preferred stock and stockholders&#146;
    equity (deficit).
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-12
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Accumulated other comprehensive income (loss) consists of the
    following (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="59%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Unrealized loss on available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (12
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Foreign currency translation adjustment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (123
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (17
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (135
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Convertible
    Preferred Stock Warrants</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Freestanding warrants related to shares that may be redeemable
    are accounted for in accordance with FASB Staff Position (FSP)
    <FONT style="white-space: nowrap">No.&#160;150-5,</FONT>
    <I>Issuer&#146;s Accounting Under FASB Statement No.&#160;150
    for Freestanding Warrants and Other Similar Instruments on
    Shares That Are Redeemable
    </I><FONT style="white-space: nowrap">(FSP&#160;150-5),</FONT>
    an interpretation of SFAS&#160;No.&#160;150, <I>Accounting for
    Certain Financial Instruments with Characteristics of Both
    Liabilities and Equity</I>. Under
    <FONT style="white-space: nowrap">FSP&#160;150-5,</FONT>
    freestanding warrants to purchase the Company&#146;s convertible
    preferred stock are classified as liabilities on the
    consolidated balance sheets and carried at fair value because
    the warrants may conditionally obligate the Company to transfer
    assets at some point in the future. The warrants are subject to
    remeasurement at each balance sheet date, and any change in fair
    value is recognized as a component of other income (expense),
    net in the consolidated statements of operations. The Company
    will continue to adjust the liability for changes in fair value
    until the earlier of the exercise or expiration of the warrants,
    the completion of a deemed liquidation event, conversion of
    preferred stock into common stock, or until the convertible
    preferred stockholders can no longer trigger a deemed
    liquidation event. At that time, the convertible preferred stock
    warrant liabilities will be reclassified to convertible
    preferred stock or additional paid-in capital.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="white-space: nowrap">FSP&#160;150-5</FONT>
    is effective for all periods beginning after June&#160;30, 2005,
    and accordingly, it was adopted by the Company on July&#160;1,
    2005. Upon adoption, the Company reclassified the fair value of
    its warrants to purchase shares of its convertible preferred
    stock as of the adoption date from additional paid-in capital to
    liabilities and recorded a gain of $637,000 as the cumulative
    effect of a change in an accounting principle in the
    consolidated statement of operations during 2005.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Net Loss
    per Share of Common Stock</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s basic net loss per share of common stock is
    calculated by dividing the net loss by the weighted-average
    number of shares of common stock outstanding for the period. The
    weighted-average number of shares of common stock excludes those
    shares subject to repurchase related to stock options that were
    exercised prior to vesting as they are not deemed to be issued
    for accounting purposes until they vest. The diluted net loss
    per share of common stock is computed by dividing the net loss
    by the weighted-average number of common stock equivalents
    outstanding for the period determined using the treasury-stock
    method. For purposes of this calculation, convertible preferred
    stock, options to purchase common stock, common stock subject to
    repurchase, warrants to purchase convertible preferred stock,
    and shares of convertible preferred stock subject to conversion
    of the Company&#146;s convertible promissory notes are
    considered to be common stock equivalents but have been excluded
    from the calculation of diluted net loss per share of common
    stock as their effect is anti-dilutive.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-13
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth the computation of net loss per
    share of common stock (in thousands, except per share amounts):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="68%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Historical</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Numerator:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Loss before cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (17,022
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    23,553
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    25,451
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    637
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16,385
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Denominator:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Shares used in computing net loss per share of common stock,
    basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,316
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss per share of common stock, basic and diluted:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss per share of common stock before cumulative effect of
    change in accounting principle, basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.89
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.53
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cumulative effect of change in accounting principle, basic and
    diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.07
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss per share of common stock, basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.82
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.53
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2.63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following outstanding shares of common stock equivalents
    were excluded from the computation of diluted net loss per share
    of common stock for the periods presented because including them
    would have been anti-dilutive.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="74%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Convertible preferred stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,267
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,284
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Options to purchase common stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,094
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,050
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,467
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Common stock subject to repurchase
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    65
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Warrants to purchase convertible preferred stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,211
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    704
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    699
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Convertible promissory notes convertible into shares of
    convertible preferred stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,952
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,466
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Recent
    Accounting Pronouncements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In September 2006, the FASB issued SFAS&#160;No.&#160;157,
    <I>Fair Value Measurement </I>(SFAS&#160;157), which establishes
    a framework for measuring the fair value of assets and
    liabilities when required or permitted by other standards within
    generally accepted accounting principles in the United States
    but does not require any new fair value measurements.
    SFAS&#160;157 also expands disclosures about fair value
    measurements. SFAS&#160;157 is effective for all financial
    statements issued for fiscal years beginning after
    November&#160;15, 2007. However, in February 2008 the FASB
    issued FSP
    <FONT style="white-space: nowrap">No.&#160;157-2</FONT>
    <FONT style="white-space: nowrap">(FSP&#160;157-2)</FONT>
    which allows companies to delay the effective date of
    SFAS&#160;157 for all nonfinancial assets and liabilities,
    except those that are recognized or disclosed at fair value in
    the financial statements on a recurring basis, until fiscal
    years beginning after November&#160;15, 2008. Generally, the
    provisions of this statement should be applied prospectively as
    of the beginning of the fiscal year in which this statement is
    initially applied. The Company adopted SFAS&#160;157 in
    accordance with the provisions in
    <FONT style="white-space: nowrap">FSP&#160;157-2</FONT>
    as of December&#160;30, 2007. The adoption of SFAS&#160;157 is
    not expected to have a significant impact on the Company&#146;s
    consolidated financial statements.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-14
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In February 2007, the FASB issued SFAS&#160;No.&#160;159, <I>The
    Fair Value Option for Financial Assets and Financial Liabilities
    </I>(SFAS&#160;159), including an amendment of
    SFAS&#160;No.&#160;115, A<I>ccounting for Certain Investments in
    Debt and Equity Securities</I>, which allows an entity to choose
    to measure certain financial instruments and liabilities at fair
    value. Subsequent measurements for the financial instruments and
    liabilities an entity elects to measure at fair value will be
    recognized in earnings. SFAS&#160;159 also establishes
    additional disclosure requirements. SFAS&#160;159 is effective
    for fiscal years beginning after November&#160;15, 2007. The
    Company adopted SFAS&#160;159 as of January&#160;1, 2008 but
    chose not to measure the financial instruments and liabilities
    permitted by the standard at fair value. Therefore, the adoption
    of SFAS&#160;159 is not expected to have a significant impact on
    the Company&#146;s consolidated financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In December 2007, the FASB ratified EITF Issue
    <FONT style="white-space: nowrap">No.&#160;07-1,</FONT>
    <I>Accounting for Collaborative Agreements
    </I><FONT style="white-space: nowrap">(EITF&#160;07-1),</FONT>
    which addresses the accounting for participants in collaborative
    agreements, defined as contractual arrangements that involve a
    joint operating activity, that are conducted without the
    creation of a separate legal entity.
    <FONT style="white-space: nowrap">EITF&#160;07-1</FONT>
    requires participants in a collaborative agreement to make
    separate disclosures for each period a statement of operations
    is presented regarding the nature and purpose of the agreement,
    the rights and obligations under the agreement, the accounting
    policy for the agreement, and the classification of and amounts
    arising from the agreement between participants. These
    arrangements involve two or more parties who are both active
    participants in the activity and are exposed to significant
    risks and rewards dependent on the commercial success of the
    activity.
    <FONT style="white-space: nowrap">EITF&#160;07-1</FONT>
    provides that a company should report the effects of adoption as
    a change in accounting principle through retrospective
    application to all periods and requires specific additional
    disclosures.
    <FONT style="white-space: nowrap">EITF&#160;07-1</FONT>
    is effective for interim and annual reporting periods beginning
    after December&#160;15, 2008. The Company is currently assessing
    the impact of the adoption of
    <FONT style="white-space: nowrap">EITF&#160;07-1</FONT>
    on the Company&#146;s consolidated financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In June 2007, the FASB ratified EITF Issue
    <FONT style="white-space: nowrap">No.&#160;07-3,</FONT>
    <I>Accounting for Nonrefundable Advance Payments for Goods or
    Services to Be Used in Future Research and Development
    Activities
    </I><FONT style="white-space: nowrap">(EITF&#160;07-3).</FONT>
    <FONT style="white-space: nowrap">EITF&#160;07-3</FONT>
    provides clarification surrounding the accounting for
    nonrefundable research and development advance payments, whereby
    such payments should be recorded as an asset when the advance
    payment is made and recognized as an expense when the research
    and development activities are performed.
    <FONT style="white-space: nowrap">EITF&#160;07-3</FONT>
    is effective for interim and annual reporting periods beginning
    after December&#160;15, 2007. The Company is currently assessing
    the impact of the adoption of
    <FONT style="white-space: nowrap">EITF&#160;07-3</FONT>
    on the Company&#146;s consolidated financial statements.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">3.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">License,
    Development, Collaboration and Grant Agreements</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">License
    Agreements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In March 2003, the Company entered into a license agreement to
    obtain an exclusive worldwide license for certain technology
    regarding nanovolume crystallization arrays. The Company may, in
    its sole discretion, cancel the license agreement with a
    <FONT style="white-space: nowrap">30-day</FONT>
    notice; otherwise, the license terminates at the end of the life
    of the last patent to expire. Under the terms of the agreement,
    the Company is obligated to issue up to $2,100,000 of shares of
    the Company&#146;s common or convertible preferred stock if the
    Company achieves certain milestones. As a result of achieving
    one of these milestones during 2006, the Company issued
    214,285&#160;shares of Series&#160;D convertible preferred stock
    at $2.80 per share for an aggregate value of $597,000, net of
    issuance costs. During 2003, the Company also entered into a
    separate research sponsorship agreement under which the Company
    agreed to pay a total of $900,000 over 5&#160;years in 20
    quarterly installments of $45,000 to sponsor certain research.
    As of December&#160;29, 2007, $855,000 of this amount had been
    paid and the remaining amount of $45,000 was paid during the
    first quarter of 2008, upon which the agreement terminated.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In December 2003, the Company entered into a license agreement
    to obtain a nonexclusive worldwide license for certain
    technology regarding submicroliter protein crystallization. The
    Company may, in its sole discretion, cancel the agreement with a
    <FONT style="white-space: nowrap">30-day</FONT>
    notice; otherwise, the license terminates at the end of the life
    of the last licensed patent to expire. Pursuant to the
    agreement, the Company made four payments for annual
    nonrefundable license fees, each in the amount of $250,000,
    beginning in January 2004 with subsequent payments made in
    January 2005,
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-15
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    2006 and 2007. Also pursuant to the agreement, the Company began
    making quarterly payments in the amount of $25,000 starting in
    the first quarter of 2007. These quarterly payments, which are
    scheduled to continue until the agreement is terminated, could
    increase in future periods if the Company meets certain sales
    volumes. The annual nonrefundable license fee payments were
    recorded as expense during the year in which they were paid.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Development
    Agreements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In June 2004, the Company entered into a development agreement
    to evaluate two application areas of interest. Under the
    agreement, the Company performed research and development
    services, manufactured prototypes, and licensed certain
    nonexclusive rights. In addition, the Company issued a fully
    vested warrant to purchase 507,407&#160;shares of Series&#160;D
    convertible preferred stock at $2.80 per share (see
    Note&#160;8). As consideration, the Company received payments
    totaling $1,500,000 during 2004 and 2005. The Company determined
    that the license, research and development services, and
    prototypes should be accounted for as a combined unit of
    accounting and recognized the revenues ratably over the
    <FONT style="white-space: nowrap">12-month</FONT>
    project period. The fair value of the warrant issued was
    estimated to be $750,000, as determined using the Black-Scholes
    option-pricing model, and was recognized as a reduction to the
    collaboration revenue. The Company recognized collaboration
    revenue of $366,000 and $384,000 related to this agreement
    during 2004 and 2005, respectively. The agreement terminated
    during 2005.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In June 2005, the Company entered into another development
    agreement to develop another application area of interest. Under
    the agreement, the Company performed research and development
    services and manufactured prototype instruments. The agreement
    provided for payments to the Company in the amount of $942,000,
    to be paid in installments over the
    <FONT style="white-space: nowrap">30-month</FONT>
    life of the agreement. The Company determined that the research
    and development services and the manufacturing of prototype
    instruments should be accounted for as a combined unit of
    accounting and revenue was therefore recognized ratably over the
    estimated project period. The Company recognized revenue of
    $94,000, $377,000 and $377,000 related to this agreement during
    2005, 2006 and 2007, respectively. The agreement terminated
    during the first quarter of 2008.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Collaboration
    Agreement</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2005, the Company entered into a collaborative
    agreement to develop and commercialize radiopharmaceutical
    manufacturing products for use in the positron emission
    tomography field. As consideration, the Company received an
    up-front fee of $1,000,000, which the Company deferred and
    recognized over the obligation period of approximately two
    years, with $458,000 and $542,000 recognized as revenue during
    2005 and 2006, respectively. Also, the Company recognized
    additional revenue of $635,000 and $500,000 during 2005 and
    2006, respectively, related to payments for research and
    development activities under the agreement based on
    <FONT style="white-space: nowrap">agreed-upon</FONT>
    rates for time incurred by the research staff. The agreement
    terminated on December&#160;31, 2006.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Grants</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">National
    Institutes of Health</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In June 2006, the Company was awarded a government grant from
    the National Institutes of Health (NIH) in the amount of
    $1,048,000 to be earned over a two-year period. Under the grant,
    the Company performs research and development activities to
    design a diffraction capable Topaz screening chip. The agreement
    provides for quarterly reimbursement of the eligible research
    and development expenses, including salaries, equipment,
    scientific consumables, and certain third-party costs. The grant
    revenue is recognized as the related services are performed and
    costs associated with this grant are reported as research and
    development expense in the period incurred. The Company
    recognized revenue of $184,000 and $606,000 during 2006 and
    2007, respectively, under this grant. This agreement terminates
    in June 2008.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-16
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Singapore
    Economic Development Board</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company has entered into two research and development grant
    agreements with the Singapore Economic Development Board (EDB)
    for the reimbursement of eligible research and development
    expenses relating to IFCs and BioMark instruments. Under the EDB
    grants, the Company is to perform research and development
    activities and establish a research facility in Singapore. For
    both agreements, eligible costs include salaries, equipment,
    scientific consumables, and certain third-party costs.
    Reimbursement for these costs under the grants is subject to the
    satisfaction of certain conditions by the Company, including
    completion of the development center within a specified
    timeline, spending specified amounts on the project, the
    completion of other development milestones, and the maintenance
    of specified levels of employment. Subject to
    <FONT style="white-space: nowrap">agreed-upon</FONT>
    audit rights by the EDB, eligible costs are reimbursed upon
    application of the submitted claims. The first grant agreement
    with the EDB was executed during 2006 and provided for the
    reimbursement of eligible research and development expenses, as
    submitted by the Company on a quarterly basis, up to an amount
    of 9,926,000 Singapore dollars (approximately $6,900,000 in
    U.S.&#160;dollars) over a five-year period beginning in January
    2006. The second grant agreement with the EDB was executed
    during 2007 and provided for the reimbursement of eligible
    research and development expenses, as submitted by the Company
    on a quarterly basis, up to an amount of 3,715,000 Singapore
    dollars (approximately $2,600,000 in U.S.&#160;dollars) through
    May 2011.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company recognized revenue of $879,000 and $1,758,000
    related to the EDB grants during 2006 and 2007, respectively. As
    of December&#160;31, 2006 and December&#160;29, 2007, the
    Company had deferred revenue of $720,000 and $635,000,
    respectively, related to equipment reimbursements for the EDB
    grant, which is being recognized ratably over the estimated
    useful life of the equipment of four years.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-17
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">4.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Balance
    Sheet Data</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Cash
    Equivalents and Available-for-Sale Securities</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following are summaries of cash equivalents and
    available-for-sale securities (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="57%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Amortized<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unrealized<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unrealized<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Estimated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Cost</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Gain</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Loss</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Fair Value</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    As of December&#160;31, 2006:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Money market funds
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    95
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    95
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Commercial paper
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,997
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,999
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Corporate notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    503
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,595
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,594
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Reported as:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Cash equivalents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,094
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,594
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    As of December&#160;29, 2007:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Money market funds
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,787
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,787
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Commercial paper
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,287
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,287
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Corporate notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,002
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,999
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Notes from government-sponsored agencies
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,207
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,198
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    36,283
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (17
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    36,271
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Reported as:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Cash equivalents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    29,985
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,286
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    36,271
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;31, 2006 and December&#160;29, 2007, the
    contractual maturities of the Company&#146;s available-for-sale
    securities were less than one year.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Inventories</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Inventories consist of the following (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="73%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Raw materials
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    803
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,551
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="white-space: nowrap">Work-in-process</FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    291
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Finished goods and demonstration units
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,224
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,656
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,038
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,498
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-18
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Property
    and Equipment</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Property and equipment consists of the following (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="73%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Computer equipment and software
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,285
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,328
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Lab and manufacturing equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,707
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,207
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Leasehold improvements
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    577
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    582
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Office furniture and fixtures
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    347
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    372
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,916
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,489
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Less accumulated depreciation and amortization
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,885
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,177
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="white-space: nowrap">Construction-in-progress</FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    66
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Property and equipment, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,068
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,378
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Depreciation and amortization expense was $1,309,000, $1,379,000
    and $1,643,000 for 2005, 2006 and 2007, respectively. During
    2005, 2006 and 2007, the Company recognized a loss on retirement
    of property and equipment of $0, $111,000 and $20,000,
    respectively.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">5.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Long-Term
    Debt</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In November 2002, the Company entered into a master security
    agreement with a lender. Per the terms of the agreement, the
    Company could draw up to $4,000,000 for purchases of capital
    equipment, software, and tenant improvements. A second master
    security agreement entered into in March 2004 increased the
    amount of the allowable draw for the Company to $11,000,000. The
    draw down period expired on December&#160;31, 2005, at which
    time the Company had drawn down $3,584,000 under the agreement.
    The loan, which was secured by the underlying equipment and a
    letter of credit, carried an interest rate between 8.0% and
    10.5% per annum, and each draw under the agreement was to be
    repaid in 42 varying monthly installments, which was originally
    scheduled to end on July&#160;1, 2009. In connection with the
    execution of the second agreement in 2004, the Company issued a
    warrant to purchase 37,500&#160;shares of Series&#160;D
    convertible preferred stock at $2.80 per share (see
    Note&#160;8)&#160;which was recorded on the consolidated balance
    sheet at fair value of $90,000 as a debt discount that was
    amortized to interest expense over two years. As of
    December&#160;31, 2006 and December&#160;29, 2007, the
    outstanding principal balance of this loan was $2,267,000 and
    $1,130,000, respectively. In February 2008, prior to the due
    date, the Company paid off the outstanding principal and accrued
    interest balance and paid a prepayment fee in the amount of
    $41,000 to the lender. Accordingly, the entire outstanding
    principal balance for this loan as of December&#160;29, 2007 was
    classified as a current liability on the consolidated balance
    sheet. Upon full payment of this debt, restricted cash in the
    amount of $500,000 was released by the lender and thus has been
    classified as a current asset as of December&#160;29, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In March 2005, the Company entered into a loan and security
    agreement with another lender. Under this agreement the Company
    borrowed $13,000,000 during 2005 for general corporate purposes.
    This loan is secured by the Company&#146;s assets except for
    intellectual property; however, the security interest does
    include proceeds from sales of the intellectual property. The
    loan was originally scheduled to be repaid by 2009; however, the
    agreement was amended in August 2006 to extend the final
    repayment date to February&#160;1, 2010. The agreement carried a
    variable interest rate of prime plus 2.5% through March 2006.
    Thereafter, the agreement carried a fixed interest rate of 10.0%
    through July 2006 and a fixed interest rate of 9.75% following
    the amendment to the agreement in August 2006. In August 2006,
    the Company began making monthly payments in the amount of
    $310,000 for principal and interest under the agreement. The
    agreement also requires payment of fees in March 2009 in the
    amount of $1,612,500. The fees are accreted as interest expense
    over the term of the loan. The agreement restricts the
    Company&#146;s ability to pay dividends. The Company is subject
    to a prepayment fee in the amount of 1% of the
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-19
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    outstanding principal amount being prepaid if paid during 2008
    or 2009. In connection with the execution of this loan and
    security agreement, the Company issued a warrant to purchase
    185,714&#160;shares of Series&#160;D convertible preferred stock
    at $2.80 per share (see Note&#160;8)&#160;which was recorded on
    the consolidated balance sheet at fair value of $54,000 as a
    debt discount. In connection with the final draw down of this
    loan, the Company issued another warrant to purchase
    185,714&#160;shares of Series&#160;D convertible preferred stock
    at $2.80 per share (see Note&#160;8)&#160;which was recorded on
    the consolidated balance sheet at fair value of $50,000 as a
    debt discount. The debt discounts are amortized to interest
    expense over the life of the agreement. As of December&#160;31,
    2006 and December&#160;29, 2007, the outstanding principal
    balance of this loan was $10,570,000 and $8,232,000,
    respectively, net of the unamortized debt discounts of $58,000
    and $31,000, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The amortization of the debt discounts for the Company&#146;s
    long-term debt agreements was recorded as interest expense in
    the consolidated statements of operations in the amounts of
    $9,000, $37,000 and $27,000 during 2005, 2006 and 2007,
    respectively. As of December&#160;29, 2007, the Company was
    either in compliance with all loan covenants or had obtained
    waivers from the respective lenders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table does not include principal payments for the
    master security agreement with a principal balance of $1,130,000
    as of December&#160;29, 2007 that was paid off in February 2008.
    The scheduled principal payments of the Company&#146;s other
    long-term debt, net of the debt discounts, are as follows (in
    thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="92%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Years:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,724
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,929
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    609
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total principal payments due in future periods
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,262
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Less: debt discounts
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (31
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8,231
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">6.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Commitments
    and Contingencies</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Operating
    Leases</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company leases its headquarters in South San&#160;Francisco,
    California, under multiple noncancelable lease agreements that
    expire in February 2011. These agreements include renewal
    options which provide the Company with the ability to extend the
    lease terms for an additional three years. The Company also
    leases office and manufacturing space under noncancelable leases
    in Singapore that expire in September 2008. The Company&#146;s
    other operating leases are for office space in the Netherlands,
    Japan, and France and are on a month-to-month basis. As of
    December&#160;29, 2007, future minimum lease payments under
    noncancelable operating leases were as follows (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="92%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Years:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,436
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,374
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,408
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2011
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    241
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total minimum payments
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,459
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-20
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s lease payments are recognized as an expense
    on a straight-line basis over the life of the lease. Rental
    expense under operating leases for 2005, 2006 and 2007 totaled
    $1,468,000, $1,494,000 and $1,574,000, respectively.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Contingencies</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company is party to various claims arising in the ordinary
    course of business. These claims relate to intellectual property
    rights and employment matters. While there is no assurance that
    an adverse determination of any of such matters will not occur,
    management does not believe, based upon information known to it,
    that a potential resolution of any of these matters will have a
    material adverse effect upon the Company&#146;s financial
    position, results of operations, or cash flows.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Indemnifications</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    From time to time, the Company has entered into indemnification
    provisions under certain of its agreements with other companies
    in the ordinary course of business, typically with business
    partners, customers, and suppliers. Pursuant to these
    agreements, the Company may indemnify, hold harmless, and agree
    to reimburse the indemnified parties on a case by case basis for
    losses suffered or incurred by the indemnified parties in
    connection with any patent or other intellectual property
    infringement claim by any third-party with respect to its
    products. The term of these indemnification provisions is
    generally perpetual from the time of the execution of the
    agreement. The maximum potential amount of future payments the
    Company could be required to make under these indemnification
    provisions is typically not limited to a specific amount. In
    addition, the Company has entered into indemnification
    agreements with its officers and directors. The Company has not
    incurred material costs to defend lawsuits or settle claims
    related to these indemnification provisions. As of
    December&#160;29, 2007, the Company had not accrued a liability
    for these indemnification provisions because the likelihood of
    incurring a payment obligation was remote.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">7.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Convertible
    Promissory Notes</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In December 2003, the Company entered into a convertible note
    purchase agreement with the Biomedical Sciences Investment
    Fund&#160;Pte. Ltd. (Biomedical Sciences), an investment arm of
    the EDB. Under this agreement Biomedical Sciences agreed to
    provide a $2,000,000 credit facility to be used for general
    corporate purposes. In December 2003, the Company issued a
    $2,000,000 convertible promissory note to Biomedical Sciences.
    The note, which was unsecured, carried an interest rate of 8%
    per year. Per the agreement, principal and interest were
    convertible into the Company&#146;s Series&#160;D convertible
    preferred stock at $2.80 per share at the lender&#146;s
    election, at any time, or upon the election of the Company upon
    the achievement of certain milestones by the Company. In June
    2005, the agreement was amended to allow the Company to issue
    additional convertible promissory notes in the amount of
    $3,000,000 if the Company achieved certain milestones. In
    December 2005, upon the successful completion of specified
    milestones, the $2,000,000 convertible promissory note and
    interest of $331,000 converted into 832,635&#160;shares of
    Series&#160;D convertible preferred stock at $2.80 per share as
    settlement of the outstanding balance on the date of the
    conversion. In June 2006, the Company issued a $3,000,000
    convertible promissory note, which was also unsecured, that
    carried an interest rate of 8% per year. Principal and interest
    are also convertible into the Company&#146;s Series&#160;D
    convertible preferred stock at $2.80 per share at the
    lender&#146;s election, at any time, or upon the election of the
    Company upon the achievement of certain milestones by the
    Company or upon the completion of an initial public offering in
    which the convertible preferred stock has converted into common
    stock. As of December&#160;31, 2006, the outstanding principal
    and accrued interest balance for the convertible promissory note
    was $3,128,000. In July 2007, upon the successful completion of
    specified milestones, the principal balance in the amount of
    $3,000,000 for the convertible promissory note and accrued
    interest of $240,000 converted into 1,157,142&#160;shares of
    Series&#160;D convertible preferred stock at $2.80 per share.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-21
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In August 2006, the Company entered into another convertible
    note purchase agreement with Biomedical Sciences. Under this
    agreement, Biomedical Sciences agreed to provide a $15,000,000
    credit facility, to be issued in three separate $5,000,000
    tranches, and to be used for general corporate purposes. The
    Company issued two $5,000,000 convertible promissory notes
    against equal amounts of borrowings under this facility, each
    unsecured and carrying an interest rate of 8% per year, in
    August and November 2006. In March 2007, Biomedical Sciences
    exercised the conversion provision of the convertible note
    purchase agreement and the Company issued 2,954,337&#160;shares
    of Series&#160;E convertible preferred stock at $3.60 per share
    as settlement of the outstanding principal and accrued interest
    balance on the date of the conversion in the amount of
    $10,636,000. Upon conversion of these convertible promissory
    notes, the Company issued the third and final $5,000,000
    convertible promissory note against an equal amount of borrowing
    under this facility with an interest rate of 8% per year in
    April 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The outstanding principal and accrued interest under the credit
    facility are convertible into the Company&#146;s Series&#160;E
    convertible preferred stock at $3.60 per share at the
    lender&#146;s election, at any time, or upon the election of the
    Company either: (i)&#160;upon the achievement of certain
    milestones by the Company or (ii)&#160;upon the completion of an
    initial public offering in which the convertible preferred stock
    has converted into common stock. In order for the Company to be
    able to elect conversion of the remaining convertible promissory
    note outstanding upon achievement of certain milestones, the
    milestones are required to be achieved by April&#160;30, 2008.
    If the milestones are not met, the principal and interest are
    due two years from the date of borrowing. The conversion feature
    embedded in the convertible note purchase agreements does not
    allow net settlement; accordingly, it does not represent a
    derivative within the scope of SFAS&#160;No.&#160;133,
    <I>Accounting for Derivative Instruments and Hedging
    Activities</I>.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For the convertible note purchase agreements in which the
    repayment either was or can be in the form of Series&#160;E
    convertible preferred stock, the conversion price of $3.60 per
    share was a discount to the estimated fair values of $3.71 and
    $4.00 per share for the Series&#160;E convertible preferred
    stock at the times of the borrowings. The intrinsic value of the
    embedded beneficial conversion option associated with each
    borrowing of convertible promissory notes under the arrangement
    is measured as the difference between the conversion price and
    the fair value of Series&#160;E convertible preferred stock on
    the commitment date and the resulting debt discount is being
    amortized to interest expense over the two year contractual term
    of the debt. Upon conversion of the notes to convertible
    preferred stock, any remaining unamortized debt discount is
    immediately recognized as interest expense.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During 2006 and 2007, the Company recognized debt discounts of
    $306,000 and $485,000, respectively, related to the beneficial
    conversion feature of the notes. Amortization of the debt
    discounts for the convertible note purchase agreements was
    recorded as interest expense in the consolidated statements of
    operations in the amount of $43,000 and $468,000 during 2006 and
    2007, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;31, 2006 and December&#160;29, 2007, the
    outstanding principal and accrued interest balance for the
    convertible note purchase agreements with Biomedical Sciences
    was $9,944,000 and $4,997,000, respectively, net of the
    unamortized debt discounts of $263,000 and $280,000,
    respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s ability to pay the amounts that may arise
    under the convertible promissory notes is limited by a
    Subordination Agreement between Biomedical Sciences and one of
    the Company&#146;s current lenders in which the Company entered
    into a loan and security agreement with in March 2005 (see
    Note&#160;5).
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-22
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">8.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Convertible
    Preferred Stock Warrant Liabilities</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company issued warrants to purchase 1,211,203&#160;shares of
    the Company&#146;s convertible preferred stock at various times
    between 2001 and 2005. The Company did not issue any warrants to
    purchase convertible preferred stock during 2006 or 2007. The
    convertible preferred stock warrants are generally exercisable
    immediately and can only be exercised for cash or net share
    settled. Changes in the fair value of the underlying stock do
    not affect the settlement amounts of the warrants, therefore,
    the maximum amount of shares to be issued upon the settlement of
    these warrants is noted in the table below. As of
    December&#160;29, 2007, the following warrants were issued and
    outstanding:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="21%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="14%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="14%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="29%">&nbsp;</TD>	<!-- colindex=06 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Warrant to Purchase<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Reason for<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Convertible<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Issue Date</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Grant</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Preferred Stock</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>per Share</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Expiration</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    May 2001
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series C
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    41,284
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.58
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) May 14, 2008
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    March 2002
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series C
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    17,500
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.58
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) March 27, 2012
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    November 2002
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series C
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    31,008
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.58
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) December 16, 2012
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    September 2003
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Collaboration agreement
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series C
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    200,000
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.58
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    December 31, 2007
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    March 2004
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series D
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    37,500
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.80
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) March 18, 2012
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    March 2005
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series D
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    185,714
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.80
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) March 29, 2012
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    December 2005
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series D
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    185,714
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.80
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) March 29, 2012
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    698,720
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following is a summary of the warrants to purchase
    convertible preferred stock outstanding and their fair values as
    of December&#160;31, 2006 and December&#160;29, 2007:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="45%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B>Outstanding<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares as of</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Fair Value as of</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B>Warrants to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Purchase</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Series&#160;C
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    294,868
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    289,792
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    29,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    61,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Series&#160;D
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    408,928
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    408,928
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    194,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    407,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    703,796
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    698,720
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    223,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    468,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During 2007, warrants to purchase 5,076&#160;shares of
    Series&#160;C convertible preferred stock expired. Upon
    expiration, the related warrant liability was eliminated and
    reflected as other income (expense), net. During 2006, warrants,
    issued in connection with a collaboration agreement (see
    Note&#160;3), to purchase 507,407&#160;shares of the
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-23
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Series&#160;D convertible preferred stock were exercised
    utilizing a cashless exercise option that allowed the holder to
    receive 267,857&#160;shares of convertible preferred stock. The
    fair value of the warrants and the shares of convertible
    preferred stock issued upon the cashless exercise was $729,000
    on the exercise date, calculated as the fair value of the shares
    of convertible preferred stock issued. Subsequent to the
    Company&#146;s year end on December&#160;29, 2007, warrants to
    purchase 200,000&#160;shares of the Company&#146;s Series&#160;C
    convertible preferred stock expired unexercised on
    December&#160;31, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The fair values of the outstanding convertible preferred stock
    warrants were measured using the Black-Scholes option-pricing
    model with the following weighted-average assumptions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="73%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="11%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="11%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected volatility
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    63.6%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    49.7%
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected life (equals the remaining contractual term)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    3.7 years
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    2.8 years
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Risk-free interest rate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4.8%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    3.2%
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dividend yield
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A decrease in fair value of the convertible preferred stock
    warrant liabilities in the amount of $72,000 during 2005, and
    increases in fair value in the amounts of $138,000 and $245,000
    during 2006 and 2007, respectively, were recognized as other
    income (expense), net in the consolidated statements of
    operations. Upon adoption of
    <FONT style="white-space: nowrap">FSP&#160;150-5</FONT>
    on July&#160;1, 2005, the Company recorded a gain of $637,000 as
    a cumulative effect of a change in accounting principle in the
    consolidated statement of operations during 2005.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">9.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Convertible
    Preferred Stock</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;31, 2006 and December&#160;29, 2007,
    convertible preferred stock was comprised of the following (in
    thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="33%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31, 2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="14" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;29, 2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Aggregate<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Issued and<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Issued and<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Liquidation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Designated</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Outstanding</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Net Proceeds</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Designated</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Outstanding</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Net Proceeds</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Value</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Series&#160;A
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,727
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,727
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,989
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,727
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,727
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,989
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Series&#160;B
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,461
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,461
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,479
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,461
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,461
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,479
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Series&#160;C
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,365
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,030
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,365
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,030
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,221
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Series&#160;D
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,196
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33,794
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,353
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,034
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,388
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Series&#160;E
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,535
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,003
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,110
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,765
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68,550
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    71,060
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,438
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,284
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    112,295
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    61,798
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    162,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    165,169
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s convertible preferred stock had been
    classified as temporary equity on the consolidated balance sheet
    instead of in stockholders&#146; equity (deficit) in accordance
    with EITF Abstracts Topic
    <FONT style="white-space: nowrap">No.&#160;D-98,</FONT>
    <I>Classification and Measurement of Redeemable Securities</I>.
    Upon certain change in control events that are outside of the
    control of the Company, including liquidation, sale or transfer
    of control of the Company, holders of the convertible preferred
    stock can cause its redemption. Accordingly, these shares are
    considered contingently redeemable. The Company has not adjusted
    the carrying values of the convertible preferred stock to their
    redemption values since it is uncertain whether or when a
    redemption event will occur. Subsequent adjustments
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-24
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    to increase the carrying values to the redemption values would
    be made if it becomes probable that such redemption will occur.
    The significant rights, privileges, and preferences of the
    convertible preferred stock are as follows:
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Conversion</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each share of convertible preferred stock is convertible, at any
    time at the option of the holder, into common stock based upon a
    conversion rate of one share of common stock for each share of
    convertible preferred stock regardless of the series.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Conversion is automatic upon: (i)&#160;the closing of an
    underwritten initial public offering of the Company&#146;s
    common stock at an offering price of not less that $5.69 per
    share (appropriately adjusted for any stock splits, stock
    dividends, recapitalization, or similar events) and with
    aggregate gross proceeds of not less than $25,000,000,
    (ii)&#160;the closing of an underwritten initial public offering
    of the Company&#146;s common stock at an offering price of less
    than $5.69 per share (appropriately adjusted for any stock
    splits, stock dividends, recapitalization, or similar events) or
    with aggregate gross proceeds of less than $25,000,000 and
    written consent of the holders of two-thirds of all shares of
    convertible preferred stock voting together for such automatic
    conversion, or (iii)&#160;the written consent of the holders of
    two-thirds of all shares of convertible preferred stock voting
    together, except that the written consent of the holders of
    greater than two-thirds of all shares of Series&#160;E
    convertible preferred stock voting separately is required for
    Series&#160;E convertible preferred stock to convert if such
    conversion is not in connection with the closing of an
    underwritten initial public offering of the Company&#146;s
    common stock.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Dividends</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Holders of Series&#160;A, B, C, D, and E convertible preferred
    stock are entitled to noncumulative dividends of $0.11, $0.18,
    $0.26, $0.30, and $0.43 per share, respectively, if and when
    declared by the Board of Directors (adjusted for any stock
    splits, stock dividends, recapitalization, or similar events)
    and subject to the preferences described below. Holders of
    Series&#160;D and E convertible preferred stock shall be
    entitled to receive dividends, when and if declared, in
    preference and priority to any declaration or payment of
    dividends to holders of Series&#160;A, B, or C convertible
    preferred stock or common stock, other than for dividends
    payable in only common stock. Payments of any dividends to the
    holders of Series&#160;D and E convertible preferred stock shall
    be on a pro rata, pari passu basis in proportion to the entitled
    dividend rates for these respective series, as applicable.
    Holders of Series&#160;C convertible preferred stock shall be
    entitled to receive dividends, when and if declared, in
    preference and priority to any declaration or payment of
    dividends to holders of Series&#160;A and B convertible
    preferred stock or common stock, other than for dividends
    payable in only common stock. Holders of Series&#160;A and B
    convertible preferred stock shall be entitled to receive
    dividends, when and if declared, in preference and priority to
    any declaration or payment of dividends to holders of common
    stock, other than for dividends payable in only common stock.
    Payments of any dividends to the holders of Series&#160;A and B
    convertible preferred stock shall be on a pro rata, pari passu
    basis in proportion to the entitled dividend rates for these
    respective series, as applicable. No dividends have been
    declared or paid through December&#160;29, 2007.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Liquidation
    Preferences</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the event of a liquidation, dissolution, or winding up of the
    Company, holders of Series&#160;E convertible preferred stock
    shall be entitled to receive a liquidation preference of $4.00
    per share, together with any declared but unpaid dividends,
    prior to any payment or distribution to holders of Series A, B,
    C, or D convertible preferred stock or common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After payment to the holders of Series&#160;E convertible
    preferred stock, holders of Series&#160;D convertible preferred
    stock shall be entitled to receive a liquidation preference of
    $2.80 per share, together with any declared but unpaid
    dividends, prior to any payment or distribution to holders of
    Series A, B, or C convertible preferred stock or common stock.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-25
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After payment to the holders of Series&#160;D convertible
    preferred stock, holders of Series&#160;C convertible preferred
    stock shall be entitled to receive a liquidation preference of
    $2.58 per share, together with any declared but unpaid
    dividends, prior to any payment or distribution to holders of
    Series A or B convertible preferred stock or common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After payment to the holders of Series&#160;C convertible
    preferred stock, holders of Series&#160;B convertible preferred
    stock shall be entitled to receive a liquidation preference of
    $1.78 per share, together with any declared but unpaid
    dividends, prior to any payment or distribution to holders of
    Series&#160;A convertible preferred stock or common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After payment to the holders of Series&#160;B convertible
    preferred stock, holders of Series&#160;A convertible preferred
    stock shall be entitled to receive a liquidation preference of
    $1.10 per share, together with any declared but unpaid
    dividends, prior to any payment or distribution to holders of
    common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After the payment to the holders of convertible preferred stock
    or their respective liquidation preferences, the entire
    remaining assets of the Company shall be distributed on a pro
    rata basis to the holders of common stock. A change of control
    or a sale, transfer, or lease of all or substantially all of the
    assets of the Company is considered to be a liquidation event.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Voting
    Rights</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Holders of convertible preferred stock are entitled to the
    number of votes they would have upon conversion of their
    convertible preferred stock into common stock on the applicable
    record date. So long as 2,000,000&#160;shares of Series&#160;D
    convertible preferred stock remain outstanding, the holders of
    Series&#160;D convertible preferred stock are entitled to elect
    two members to the Company&#146;s Board of Directors, and so
    long as 2,000,000&#160;shares of Series&#160;C convertible
    preferred stock remain outstanding, the holders of Series&#160;C
    convertible preferred stock are entitled to elect three members
    to the Board of Directors. The holders of Series&#160;A, B, and
    E convertible preferred stock and the holders of common stock,
    voting together as a single class, are entitled to elect any
    additional members to the Board of Directors.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">10.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Stock
    Option Activity</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">1999
    Stock Option Plan</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On May&#160;12, 1999, the Board of Directors adopted the 1999
    Stock Option Plan (the Stock Plan) under which incentive stock
    options and nonstatutory stock options may be granted to
    employees, officers, and directors of, or consultants to, the
    Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Options granted under the Stock Plan expire no later than ten
    years from the date of grant. The exercise price of each
    incentive stock option granted to an employee shall be at least
    110% of the fair market value of the underlying common stock on
    the date of grant if, on the grant date, the employee owns stock
    representing more than 10% of the voting power of all classes of
    the Company&#146;s capital stock; otherwise, the exercise price
    shall be at least 100% of the fair market value of the
    underlying common stock on the date of grant. The exercise price
    for each nonstatutory stock option granted to a service provider
    shall be at least 110% of the fair market value of the
    underlying common stock on the date of grant if, on the grant
    date, the service provider owns stock representing more than 10%
    of the voting power of all classes of the Company&#146;s capital
    stock; otherwise, the exercise price shall be at least 85% of
    the fair market value of the underlying common stock on the date
    of grant. The fair market value of the underlying common stock
    shall be determined by the Board of Directors until such time as
    the Company&#146;s common stock is listed on any established
    stock exchange or national market system. Options may be granted
    with different vesting terms from time to time, but the vesting
    terms may not exceed five years from the date of grant.
    Generally, outstanding options are immediately exercisable and
    vest at a rate of 25% on the first anniversary of the option
    grant date and
    <FONT style="vertical-align: text-top; font-size: 70%;">1</FONT>/<FONT style="font-size: 70%;">48</FONT>
    of the total grant each month thereafter.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-26
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;29, 2007, the Stock Plan is the
    Company&#146;s only stock-based compensation plan and a total of
    12,800,000&#160;shares of common stock have been authorized for
    issuance under the Stock Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Activity under the Stock Plan is as follows (in thousands,
    except per share amounts):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="59%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Outstanding Options</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted-Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Available for<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise Price per<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Grant</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Share</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance as of January&#160;1, 2005
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,183
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,858
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.37
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Additional shares authorized
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Options granted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,559
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,559
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.56
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Options exercised
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (170
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.31
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Options canceled
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    153
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (153
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.47
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance as of December&#160;31, 2005
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,277
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,094
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.45
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Options granted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,216
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,216
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.83
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Options exercised
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (443
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.41
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Options canceled
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    817
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (817
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.52
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance as of December&#160;31, 2006
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    878
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,050
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.52
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Additional shares authorized
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Options granted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,042
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,042
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.53
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Options exercised
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (264
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.49
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Options canceled
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    361
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (361
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.66
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance as of December&#160;29, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,197
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,467
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.79
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Options exercised during 2005, 2006 and 2007 exclude options
    that are exercised prior to vesting. These shares generally vest
    over a four-year period. Unvested shares, which amount to 65,000
    and 33,334 as of December&#160;31, 2006 and December&#160;29,
    2007, respectively, are subject to a repurchase option held by
    the Company at the original exercise price and are not deemed to
    be issued for accounting purposes until those shares vest.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Effective January&#160;1, 2006, the Company adopted the
    provisions of SFAS&#160;123(R). The fair value of each new
    option awarded was estimated on the grant date using the
    Black-Scholes option-pricing model using the following
    weighted-average assumptions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="79%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="8%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="8%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected volatility
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    72.8%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    63.0%
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected life
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    6.1&#160;years
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    6.0&#160;years
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Risk-free interest rate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4.8%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4.4%
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dividend yield
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Weighted-average fair value of options granted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    $0.55
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    $0.92
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Expected volatility is derived from historical volatilities of
    several unrelated public companies within the biomedical
    instrument and system industry. Each company&#146;s historical
    volatility is weighted based on certain qualitative factors and
    combined to produce a single volatility factor used by the
    Company. The risk-free interest rate is based on the
    U.S.&#160;Treasury yield curve in effect at the time of grant
    for zero coupon U.S.&#160;Treasury notes with maturities
    approximately equal to the option&#146;s expected life. Given
    the limited history to accurately estimate expected lives of
    options granted to the various employee groups, the Company used
    the &#147;simplified&#148; method as provided by the
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-27
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    SEC Staff Accounting Bulletin&#160;No.&#160;107, <I>Share Based
    Payment </I>(SAB&#160;107). The &#147;simplified&#148; method is
    calculated as the average of the time-to-vesting and the
    contractual life of the options. The Company estimates its
    forfeiture rate based on an analysis of its actual forfeitures
    and will continue to evaluate the adequacy of the forfeiture
    rate based on actual forfeiture experience, analysis of employee
    turnover behavior, and other factors. The impact from a
    forfeiture rate adjustment will be recognized in full in the
    period of adjustment, and if the actual number of future
    forfeitures differs from that estimated by the Company, the
    Company may be required to record adjustments to stock-based
    compensation expense in future periods. Adjustments to the
    forfeiture rates have not had a significant impact on any of the
    periods presented. Each of these inputs is subjective and
    generally requires significant judgment to determine.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The absence of an active market for the Company&#146;s common
    stock required the Company&#146;s Board of Directors, with input
    from management, to estimate the fair value of the common stock
    for purposes of granting options and for determining stock-based
    compensation expense for the periods presented. In response to
    these requirements, the Company&#146;s Board of Directors
    estimated the fair value of the common stock at each meeting at
    which options were granted based on factors such as the price of
    the most recent convertible preferred stock sales to investors,
    the preferences held by the convertible preferred stock classes
    in favor of common stock, the valuations of comparable
    companies, the hiring of key personnel, the status of the
    Company&#146;s development and sales efforts, revenue growth and
    additional objective, and subjective factors relating to the
    Company&#146;s business. The Company has historically granted
    stock options at not less than the fair value of the underlying
    common stock as determined at the time of grant by the
    Company&#146;s Board of Directors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Information regarding the Company&#146;s stock option grants,
    including the grant date; the number of stock options issued
    with each grant; and the exercise price, which equals the grant
    date fair value of the underlying common stock for each grant of
    stock options during 2007, is summarized as follows (in
    thousands, except per share amounts):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="75%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>and Fair Value<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>per Share of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Grant Date</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Granted</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Common Stock</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    May&#160;8, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,613
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    September&#160;20, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    December&#160;28, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    328
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-28
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Additional information regarding the Company&#146;s stock
    options outstanding and exercisable as of December&#160;29, 2007
    is summarized in the following table:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="61%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Options Outstanding</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Exercisable<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted-<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Remaining<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Contractual<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Subject<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Exercise Price</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>of Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Life</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>to Options</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in years)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    $0.15
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    0.30
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,719
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,651
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    0.40
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    342
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    342
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    0.56
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,296
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,057
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    0.83
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,025
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    912
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    1.36
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,587
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,240
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    1.38
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    97
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2.40
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    328
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    217
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,467
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,539
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Certain options under the Stock
    Plan may be exercised prior to vesting but are subject to
    repurchase at the original exercise price in the event the
    optionees&#146; employment is terminated.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Options exercisable as of December&#160;29, 2007 had a
    weighted-average remaining contractual life of 7.4&#160;years, a
    weighted-average exercise price per share of $0.74, and an
    aggregate intrinsic value of $3,662,000.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Options outstanding that have vested and are expected to vest as
    of December&#160;29, 2007 are summarized as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="40%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted-Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted-Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Remaining<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Aggregate<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Contractual<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Intrinsic<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>per Share</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Life</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Value<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in years)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Vested
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,307
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.52
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8,097
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected to vest
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,049
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.16
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,781
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total vested and expected to vest
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,356
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.79
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    11,878
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The aggregate intrinsic value was
    calculated as the difference between the exercise price of the
    underlying options and the fair value of the Company&#146;s
    common stock in the amount of $2.40 per share as of
    December&#160;29, 2007.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The total intrinsic value of options exercised during 2006 and
    2007 was $167,000 and $259,000, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There were no stock-based compensation tax benefits during 2005,
    2006 or 2007. Capitalized stock-based compensation costs were
    insignificant during 2005, 2006 and 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company recognized stock-based compensation expense of
    $5,000, $145,000 and $708,000 during 2005, 2006 and 2007.
    Included in these amounts was employee stock-based compensation
    expense of zero, $86,000 and $526,000 and nonemployee
    stock-based compensation expense of $5,000, $59,000 and $182,000
    during 2005, 2006 and 2007, respectively. As of
    December&#160;29, 2007, there was $1,698,000 of total
    unrecognized compensation
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-29
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    costs related to stock-based compensation arrangements granted
    under the Stock Plan, which is expected to be recognized over an
    average period of 2.9&#160;years.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Stock
    Options Granted to Nonemployees</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company accounts for options granted to nonemployees under
    the fair value method in accordance with SFAS&#160;123(R) and
    <FONT style="white-space: nowrap">EITF&#160;96-18.</FONT>
    The fair value of these options was estimated using the
    Black-Scholes option-pricing model with the following
    assumptions for 2005, 2006 and 2007: risk-free interest rates of
    4.1% to 5.0%, dividend yield of 0%, expected volatility of 63.0%
    to 82.9%, and an expected life of the options equal to the
    remaining contractual terms of one to ten years. In accordance
    with
    <FONT style="white-space: nowrap">EITF&#160;96-18,</FONT>
    options granted to nonemployees are remeasured at each
    accounting period-end until the award is vested.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company granted options to nonemployees to purchase 17,050,
    88,250 and 116,000&#160;shares of common stock during 2005, 2006
    and 2007, respectively. As of December&#160;29, 2007, there were
    52,184&#160;shares subject to unvested options held by
    nonemployees with a weighted-average exercise price of $1.63 and
    an average remaining vesting period of 2.7&#160;years.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">11.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Shares
    Reserved for Issuance</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;29, 2007, the Company has reserved shares of
    common stock for future issuance as follows (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="92%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Options outstanding
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,467
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Options available for grant
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,197
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Conversion of outstanding convertible preferred stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Conversion of convertible preferred stock upon exercise of
    warrants
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    699
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    66,034
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The above table does not include shares of common stock reserved
    for potential conversions of the convertible promissory notes
    (see Note&#160;7)&#160;into shares of convertible preferred
    stock. The outstanding principal and accrued interest related to
    the convertible promissory notes as of December&#160;29, 2007 in
    the amount of $5,278,000 is potentially convertible into
    1,466,210&#160;shares of Series&#160;E convertible preferred
    stock.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">12.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Income
    Taxes</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s net loss before the provision for income
    taxes is as follows (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="68%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Domestic
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (15,181
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (21,816
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (23,372
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    International
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,737
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,079
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss before provision for income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16,385
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-30
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Significant components of the Company&#146;s provision for
    income taxes are as follows (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="74%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Current:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Federal
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    State
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Foreign
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    105
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total current provision
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    105
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Federal
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    State
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Foreign
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total deferred provision
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total provision for income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    105
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Reconciliation of the benefits for income taxes at the statutory
    rate to the provision for income taxes is as follows:
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="80%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Tax benefit at federal statutory rate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    State income taxes (net of federal benefit)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Foreign
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Change in valuation allowance
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (34.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (34.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (31.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Effective tax rate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.4
</TD>
<TD nowrap align="left" valign="bottom">
    )%
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Significant components of the Company&#146;s deferred tax assets
    and liabilities are as follows (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="73%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax assets:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Reserves and accruals
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    485
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    866
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Depreciation and amortization
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,685
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    478
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Tax credit carryforwards
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,450
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,936
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Net operating loss carryforwards
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,467
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total deferred tax assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,177
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,747
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Valuation allowance
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (43,177
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (52,747
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net deferred tax assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Recognition of deferred tax assets is appropriate when
    realization of these assets is more likely than not. The Company
    has incurred losses since its inception; accordingly, the net
    deferred tax assets have been fully offset by a valuation
    allowance. The valuation allowance increased by $5,954,000,
    $8,534,000 and $9,570,000 during 2005, 2006 and 2007,
    respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;29, 2007, the Company had net operating loss
    carryforwards for federal income tax purposes of $121,531,000
    which expire in the years 2019 through 2026 and federal research
    and development tax credits of $2,749,000 which expire in the
    years 2008 through 2016. As of December&#160;29, 2007, the
    Company had net operating
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-31
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    loss carryforwards for state income tax purposes of $119,340,000
    which expire in the years 2012 through 2016 and state research
    and development tax credits of $2,722,000 which do not expire.
    As of December&#160;29, 2007, the Company had foreign net
    operating loss carryforwards of $4,768,000. A significant
    portion of the foreign net operating losses relate to activity
    in Singapore that has an indefinite carryforward period.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Utilization of the net operating loss carryforwards and credits
    may be subject to a substantial annual limitation due to the
    ownership change limitations provided by the Internal Revenue
    Code of 1986, as amended, and similar state provisions. The
    annual limitation may result in the expiration of net operating
    losses and credits before utilization. If an ownership change
    has occurred at different dates or in addition to the dates
    preliminarily identified, the utilization of net operation loss
    and credit carryforwards could be significantly reduced.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company has not provided for U.S. federal and state income
    taxes on all of the non U.S. subsidiaries&#146; undistributed
    earnings as of December&#160;29, 2007, because such earnings are
    intended to be indefinitely reinvested under APB&#160;23. Upon
    distribution of those earnings in the form of dividends or
    otherwise, the Company would be subject to applicable U.S.
    federal and state income taxes.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Uncertain
    Tax Positions</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Effective January&#160;1, 2007, the Company adopted the
    provisions of FIN&#160;48. As a result, the Company recorded a
    liability for net unrecognized tax benefits of $75,000, and
    recognized a cumulative effect of a change in accounting
    principle that resulted in a charge to the accumulated deficit.
    The liability for unrecognized tax benefits is classified as
    non-current.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The aggregate changes in the balance of the Company&#146;s gross
    unrecognized tax benefits during 2007 were as follows (in
    thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="92%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    January&#160;1, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,157
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Increases in balances related to tax provisions taken during
    current periods
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    765
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    December&#160;29, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,922
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Accrued interest and penalties related to unrecognized tax
    benefits are classified as income tax expense and were
    immaterial. As of December&#160;29, 2007, unrecognized tax
    benefits of $162,000, if recognized, would affect the
    Company&#146;s effective tax rate. The remaining unrecognized
    tax benefits were netted against deferred tax assets with a full
    valuation allowance, and if recognized, would not affect the
    Company&#146;s effective tax rate. The Company does not
    anticipate that the amount of existing unrecognized tax benefits
    will significantly increase or decrease within the next
    12&#160;months. The Company files income tax returns in the
    United States, various states and certain foreign jurisdictions.
    The tax years 1999 through 2007 remain open in most
    jurisdictions.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">13.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Employee
    Benefit Plans</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company sponsors a 401(k) plan that stipulates that eligible
    employees can elect to contribute to the plan, subject to
    certain limitations, up to the lesser of 60% of eligible
    compensation or the maximum amount allowed by the IRS on a
    pretax basis annually. The Company has not made contributions to
    this plan since its inception.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">14.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Related-Party
    Transaction</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2004, the Company loaned an officer of the Company
    $250,000 in connection with the purchase of a new home, which is
    secured by 833,334&#160;shares of the Company&#146;s common
    stock held by the officer. The loan carried an interest rate of
    3.52% per annum. The outstanding balance of this loan, including
    accrued interest, was $277,000 and $287,000 as of
    December&#160;31, 2006 and December&#160;29, 2007, respectively.
    On April&#160;10, 2008, the
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-32
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    principal amount of this note and all accrued interest was
    settled with shares held by the officer at fair value of the
    common stock, which was determined by the Board of Directors to
    be $3.19 per share.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Dr.&#160;Stephen Quake, who is a professor of bioengineering at
    Stanford University, is one of the Company&#146;s founding
    stockholders and as such held 2,326,000&#160;shares of common
    stock as of December&#160;29, 2007. In June 2006, the Company
    repurchased 124,000&#160;shares of the Company&#146;s common
    stock held by Dr.&#160;Quake for $0.56 per share.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Dr.&#160;Quake also serves as a consultant to the Company and is
    a member of the Company&#146;s Scientific Advisory Board. The
    Company paid consulting fees of $45,000, $97,000 and $67,000 to
    Dr.&#160;Quake during 2005, 2006 and 2007, respectively, and
    accrued amounts payable to Dr.&#160;Quake related to these
    payments were $0 and $33,000 as of December&#160;31, 2006 and
    December&#160;29, 2007, respectively. The Company recognized
    $205,000, $241,000 and $15,000 in revenue related to products
    and services sold to Stanford University during 2005, 2006 and
    2007, respectively, and had accounts receivable balances related
    to these sales of $0 and $11,000 as of December&#160;31, 2006
    and December&#160;29, 2007, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s general counsel is also a member of a law
    firm whose services are utilized by the Company. Amounts paid to
    the law firm for services and direct patent fees were $880,000,
    $960,000 and $576,000 for 2005, 2006 and 2007, respectively, and
    accrued amounts payable to the law firm were $174,000 and
    $257,000 as of December&#160;31, 2006 and December&#160;29,
    2007, respectively.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">15.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Information
    about Geographic Areas</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    SFAS&#160;No.&#160;131, <I>Disclosures about Segments of an
    Enterprise and Related Information</I>, establishes standards
    for reporting information about operating segments. Operating
    segments are defined as components of an enterprise about which
    separate financial information is available that is evaluated
    regularly by a company&#146;s chief operating decision maker, or
    decision making group, in deciding how to allocate resources and
    in assessing performance. The chief operating decision maker for
    the Company is the Chief Executive Officer. The Chief Executive
    Officer reviews financial information presented on a
    consolidated basis, accompanied by information about revenue by
    geographic region, for purposes of allocating resources and
    evaluating financial performance. The Company has one business
    activity and there are no segment managers who are held
    accountable for operations, operating results or plans for
    levels or components below the consolidated unit level.
    Accordingly, the Company has determined that it has a single
    reporting segment and operating unit structure which is the
    development, manufacturing and commercialization of IFCs and
    complementary laboratory instruments.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Revenue by geography is based on the billing address of the
    customer. The following tables set forth revenue and long-lived
    assets by geographic area (in thousands):
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Revenue</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="74%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    North America
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,185
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,932
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,526
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Europe
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    545
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    189
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    735
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Asia
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,944
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,277
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,014
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,674
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,398
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,275
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-33
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Long-lived
    Assets</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="73%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    North America
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,158
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,626
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    All other
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,910
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,751
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,068
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,378
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">16.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Subsequent
    Events</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In February 2008, the Company amended a loan and security
    agreement with one of its current lenders that was originally
    executed in March 2005 and allowed the Company to borrow
    $13,000,000 during 2005. The agreement was amended to provide
    the Company with an additional credit line in the amount of
    $10,000,000 that the Company can draw upon until July&#160;1,
    2008 for general corporate purposes. In connection with the
    amendment of this loan and security agreement, the Company
    issued a warrant to purchase 100,000&#160;shares of
    Series&#160;E convertible preferred stock at $4.00 per share. As
    of the date of these financial statements, the Company had not
    utilized any of this facility. If the Company does borrow from
    this credit line, the borrowing will bear interest at 11.5% per
    annum and will be repaid in installments through June 2011. In
    addition, the Company could be required to issue additional
    warrants to purchase up to 200,000&#160;shares of Series&#160;E
    convertible preferred stock depending on the amounts of draws on
    the facility, if any.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In April 2008, the Company&#146;s Board of Directors approved
    the filing of a registration statement with the Securities and
    Exchange Commission for an initial public offering of the
    Company&#146;s common stock.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-34
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="f39432orf3943219.gif" alt="(DYNAMIC ARRAY SCHEMATIC GRAPHIC)">
</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="f39432orf3943220.gif" alt="(CIRCUITS &#38; SYSTEMS GRAPHIC)">
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="f39432orf3943216.gif" alt="(FLUIDIGM LOGO)">
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PART&#160;II<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">INFORMATION
    NOT REQUIRED IN PROSPECTUS</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;13.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Other
    Expenses of Issuance and Distribution.</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth all expenses to be paid by the
    registrant, other than estimated underwriting discounts and
    commissions, in connection with this offering. All amounts shown
    are estimates except for the SEC registration fee, the NASD
    filing fee and the Nasdaq Global Market listing fee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="92%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    SEC registration fee
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,390
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    NASD filing fee
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,125
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Nasdaq Global Market listing fee
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Printing and engraving
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Legal fees and expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accounting fees and expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Blue sky fees and expenses (including legal fees)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Transfer agent and registrar fees
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Miscellaneous
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    *&#160;</TD>
    <TD></TD>
    <TD valign="bottom">
    To be provided by amendment.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;14.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Indemnification
    of Directors and Officers.</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Section&#160;145 of the Delaware General Corporation Law
    authorizes a corporation&#146;s board of directors to grant, and
    authorizes a court to award, indemnity to officers, directors
    and other corporate agents.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As permitted by Section&#160;102(b)(7) of the Delaware General
    Corporation Law, the registrant&#146;s certificate of
    incorporation includes provisions that eliminate the personal
    liability of its directors and officers for monetary damages for
    breach of their fiduciary duty as directors and officers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, as permitted by Section&#160;145 of the Delaware
    General Corporation Law, the bylaws of the registrant provide
    that:
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The registrant shall indemnify its directors and officers for
    serving the registrant in those capacities or for serving other
    business enterprises at the registrant&#146;s request, to the
    fullest extent permitted by Delaware law. Delaware law provides
    that a corporation may indemnify such person if such person
    acted in good faith and in a manner such person reasonably
    believed to be in or not opposed to the best interests of the
    registrant and, with respect to any criminal proceeding, had no
    reasonable cause to believe such person&#146;s conduct was
    unlawful.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The registrant may, in its discretion, indemnify employees and
    agents in those circumstances where indemnification is not
    required by law.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The registrant is required to advance expenses, as incurred, to
    its directors and officers in connection with defending a
    proceeding, except that such director or officer shall undertake
    to repay such advances if it is ultimately determined that such
    person is not entitled to indemnification.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The registrant will not be obligated pursuant to the bylaws to
    indemnify a person with respect to proceedings initiated by that
    person, except with respect to proceedings authorized by the
    registrant&#146;s Board of Directors or brought to enforce a
    right to indemnification.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The rights conferred in the bylaws are not exclusive, and the
    registrant is authorized to enter into indemnification
    agreements with its directors, officers, employees and agents
    and to obtain insurance to indemnify such persons.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The registrant may not retroactively amend the bylaw provisions
    to reduce its indemnification obligations to directors,
    officers, employees and agents.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The registrant&#146;s policy is to enter into separate
    indemnification agreements with each of its directors and
    officers that provide the maximum indemnity allowed to directors
    and executive officers by Section&#160;145 of the Delaware
    General Corporation Law and also provides for certain additional
    procedural protections. The registrant also maintains directors
    and officers insurance to insure such persons against certain
    liabilities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    These indemnification provisions and the indemnification
    agreements entered into between the registrant and its officers
    and directors may be sufficiently broad to permit
    indemnification of the registrant&#146;s officers and directors
    for liabilities (including reimbursement of expenses incurred)
    arising under the Securities Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The underwriting agreement filed as Exhibit&#160;1.1 to this
    registration statement provides for indemnification by the
    underwriters of the registrant and its officers and directors
    for certain liabilities arising under the Securities Act and
    otherwise.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;15.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Recent
    Sales of Unregistered Securities.</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the three years prior to the filing of this registration
    statement, the registrant has issued the following unregistered
    securities:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;From March 2005 through July&#160;17, 2007, Fluidigm
    Corporation, a California corporation, issued and sold an
    aggregate of 470,965&#160;shares of its common stock upon the
    exercise of options issued to certain employees, directors and
    consultants under the registrant&#146;s 1999 Stock Option Plan,
    as amended, at exercise prices ranging from $0.30 to $0.83, for
    aggregate consideration of $188,442. From July&#160;18, 2007
    through April&#160;11, 2008, the registrant issued and sold an
    aggregate of 250,720&#160;shares of its common stock upon the
    exercise of options issued to certain employees, directors and
    consultants under the registrant&#146;s 1999 Stock Plan, as
    amended, at exercise prices ranging from $0.30 to $1.36 per
    share, for aggregate consideration of $123,346.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;From March 2005 through July&#160;17, 2007, Fluidigm
    Corporation, a California corporation, granted to certain of its
    employees, directors and consultants under the registrant&#146;s
    1999 Stock Option Plan, as amended, options to purchase an
    aggregate of 4,753,044&#160;shares of its common stock at
    exercise prices ranging from $0.30 to $1.36 per share. From
    September&#160;20, 2007 through April&#160;11, 2008, the
    registrant granted to certain of its employees, directors and
    consultants under the registrant&#146;s 1999 Stock Option Plan,
    as amended, options to purchase an aggregate of
    552,200&#160;shares of the registrant&#146;s common stock at
    exercise prices ranging from $1.38 to $2.40 per share.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (c)&#160;In March 2005, Fluidigm Corporation, a California
    corporation, pursuant to a loan and security agreement, issued
    and sold a warrant to purchase 371,428&#160;shares of its
    Series&#160;D Preferred Stock to one accredited investor at an
    exercise price of $2.80 per share. In connection with the
    registrant&#146;s reincorporation into the State of Delaware on
    July&#160;18, 2007, the warrant was converted into a warrant to
    purchase an equal number of shares of the registrant&#146;s
    Series&#160;D Preferred Stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (d)&#160;In November 2005, Fluidigm Corporation, a California
    corporation, issued and sold 70,000&#160;shares of its common
    stock to one accredited investor at an issuance price of $0.56
    per share for aggregate monetary consideration of $39,200, which
    amount was deemed paid by the transfer of certain rights granted
    to registrant pursuant to the terms of a licensing agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (e)&#160;In December 2005, Fluidigm Corporation, a California
    corporation, issued 832,635&#160;shares of its Series&#160;D
    Preferred Stock to one accredited investor in connection with
    the conversion of a convertible promissory note at a conversion
    price per share of $2.80.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (f)&#160;In June 2006, Fluidigm Corporation, a California
    corporation, issued to one accredited investor a convertible
    promissory notes in an aggregate principal amount of $3,000,000
    convertible into shares of its Series&#160;D Preferred Stock. In
    July 2007, the notes were converted into 1,157,142&#160;shares
    of Series&#160;D Preferred Stock at a conversion price per share
    of $2.80.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (g)&#160;In June 2006, Fluidigm Corporation, a California
    corporation, issued 214,285&#160;shares of its Series&#160;D
    Preferred Stock to one accredited investor at an issuance price
    of $2.80 per share, for aggregate monetary consideration of
    $599,998, which amount was deemed paid by the transfer of
    certain rights granted to registrant pursuant to the terms of a
    licensing agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (h)&#160;In June 2006, Fluidigm Corporation, a California
    corporation, issued 267,858&#160;shares of its Series&#160;D
    Preferred Stock to one accredited investor in connection with
    the exercise of a warrant to purchase shares of its
    Series&#160;D Preferred Stock at an exercise price per share of
    $2.80.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (i)&#160;From August 2006 through April 2007, Fluidigm
    Corporation, a California corporation, issued three convertible
    promissory notes to one accredited investor in an aggregate
    principal amount of $15,000,000, all of which were convertible
    into shares of its Series&#160;E Preferred Stock. In March 2007,
    two of the notes were converted into an aggregate of
    2,954,337&#160;shares of the Series&#160;E Preferred Stock of
    Fluidigm Corporation, a California corporation. In connection
    with the registrant&#146;s reincorporation into the State of
    Delaware on July&#160;18, 2007, the remaining outstanding
    convertible promissory note was made convertible into shares of
    the registrant&#146;s Series&#160;E Preferred Stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (j)&#160;In March 2007, Fluidigm Corporation, a California
    corporation, issued 100,000&#160;shares of its common stock to
    one accredited investor at an issuance price of $0.83 per share,
    for aggregate monetary consideration of $83,000, which amount
    was deemed paid by the transfer of certain rights granted to
    registrant pursuant to the terms of a licensing agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (k)&#160;In connection with the registrant&#146;s
    reincorporation into the State of Delaware on July&#160;18,
    2007, the registrant issued an aggregate of
    9,695,998&#160;shares of common stock to a total of 128
    stockholders in exchange for the outstanding shares of common
    stock Fluidigm Corporation, a California corporation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (l)&#160;In connection with the registrant&#146;s
    reincorporation into the State of Delaware on July&#160;18,
    2007, the registrant issued an aggregate of
    2,727,273&#160;shares of the registrant&#146;s Series&#160;A
    Preferred Stock to a total of 41 investors in exchange for the
    outstanding shares of Series&#160;A Preferred Stock of Fluidigm
    Corporation, a California corporation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (m)&#160;In connection with the registrant&#146;s
    reincorporation into the State of Delaware on July&#160;18,
    2007, the registrant issued an aggregate of
    6,460,675&#160;shares of the registrant&#146;s Series&#160;B
    Preferred Stock to a total of 35 investors in exchange for the
    outstanding shares of Series&#160;B Preferred Stock of Fluidigm
    Corporation, a California corporation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (n)&#160;In connection with the registrant&#146;s
    reincorporation into the State of Delaware on July&#160;18,
    2007, the registrant issued an aggregate of
    16,364,832&#160;shares of the registrant&#146;s Series&#160;C
    Preferred Stock to a total of 62 investors in exchange for the
    outstanding shares of Series&#160;C Preferred Stock of Fluidigm
    Corporation, a California corporation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (o)&#160;In connection with the registrant&#146;s
    reincorporation into the State of Delaware on July&#160;18,
    2007, the registrant issued an aggregate of
    12,196,191&#160;shares of the registrant&#146;s Series&#160;D
    Preferred Stock to a total of 52 investors in exchange for the
    outstanding shares of Series&#160;D Preferred Stock of Fluidigm
    Corporation, a California corporation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (p)&#160;In connection with the registrant&#146;s
    reincorporation into the State of Delaware on July&#160;18,
    2007, the registrant issued an aggregate of
    8,969,836&#160;shares of the registrant&#146;s Series&#160;E
    Preferred Stock to a total of 35 investors in exchange for the
    outstanding shares of Series&#160;E Preferred Stock of Fluidigm
    Corporation, a California corporation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (q)&#160;From October 2007 through December 2007, the registrant
    issued and sold an aggregate of 8,794,945&#160;shares of
    Series&#160;E Preferred Stock to a total of seven investors at
    $4.00 per share, for aggregate proceeds of $35,179,780.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (r)&#160;In December 2007, the registrant issued
    6,000&#160;shares of its common stock to one accredited investor
    at an issuance price of $1.36 per share for aggregate monetary
    consideration of $8,160, which amount was deemed paid by the
    transfer of certain rights granted to registrant pursuant to the
    terms of a licensing agreement.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (s)&#160;In February 2008, the registrant issued a warrant to
    purchase 100,000&#160;shares of the registrant&#146;s
    Series&#160;E Preferred Stock to one accredited investor at an
    exercise price of $4.00 per share.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (t)&#160;In February 2008, the registrant granted to one of its
    executive officers under the registrant&#146;s 1999 Stock Option
    Plan, as amended, options to purchase an aggregate of
    600,000&#160;shares of the registrant&#146;s common stock at an
    exercise price of $2.40 per share.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    None of the foregoing transactions involved any underwriters,
    underwriting discounts or commissions, or any public offering,
    and the registrant believes that each transaction was exempt
    from the registration requirements of the Securities Act in
    reliance on the following exemptions:
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    with respect to the transactions described in paragraphs
    (a)&#160;and (b), Rule&#160;701 promulgated under the Securities
    Act as transactions pursuant to a compensatory benefit plan
    approved by the registrant&#146;s Board of Directors;&#160;and
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    with respect to the transactions described in paragraphs
    (c)&#160;through (t), Section&#160;4(2) of the Securities Act,
    or Rule&#160;506 of Regulation&#160;D promulgated thereunder, as
    a transaction by an issuer not involving a public offering. Each
    recipient of the securities in this transaction represented his
    or her intention to acquire the securities for investment only
    and not with a view to, or for resale in connection with, any
    distribution thereof, and appropriate legends were affixed to
    the share certificates issued in each such transaction. In each
    case, the recipient received adequate information about the
    registrant or had adequate access, through his or her
    relationship with the registrant, to information about the
    registrant.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;16.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Exhibits
    and Financial Statement Schedules.</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;<I>Exhibits.</I>&#160;&#160;The following exhibits are
    included herein or incorporated herein by reference:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=01 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=01 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>	<!-- colindex=01 type=align1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="85%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Exhibit Number</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Description</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    1
</TD>
<TD nowrap align="left" valign="top">
    .1*
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Underwriting Agreement.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Certificate of Incorporation of the Registrant, as currently in
    effect.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .2*
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Restated Certificate of Incorporation of the Registrant,
    to be in effect upon the completion of this offering.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .3
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Bylaws of the Registrant.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .4*
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Amended and Restated Bylaws of the Registrant, to be in
    effect upon completion of this offering.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .1*
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Specimen Common Stock Certificate of the Registrant.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .2
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Series&#160;E Preferred Stock Purchase Agreement dated
    June&#160;13, 2006 through October&#160;26, 2007 between the
    Registrant and the Purchasers set forth therein, as amended.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .3
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Eighth Amended and Restated Investor Rights Agreement between
    the Registrant and certain holders of the Registrant&#146;s
    common stock named therein, including amendments No.&#160;1 and
    No.&#160;2.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .4&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Loan and Security Agreement No.&#160;4561 between the Registrant
    and Lighthouse Capital Partners&#160;V, L.P. dated
    March&#160;29, 2005, including amendments Nos. 1 through 4.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .4A
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Preferred Stock Purchase Warrant issued to Lighthouse Capital
    Partners&#160;V, L.P. effective March&#160;29, 2005.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .4B
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Negative Pledge Agreement by and between the Registrant and
    Lighthouse Capital Partners&#160;V, L.P. dated March&#160;29,
    2005.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .5
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Convertible Note Purchase Agreement by and between Biomedical
    Sciences Investment Fund&#160;Pte. Ltd. and the Registrant dated
    August&#160;7, 2006.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .5A&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Convertible Promissory Note issued to Biomedical Sciences
    Investment Fund&#160;Pte. Ltd. dated April&#160;19, 2007, as
    amended.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    5
</TD>
<TD nowrap align="left" valign="top">
    .1*
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Opinion of Wilson Sonsini Goodrich&#160;&#038; Rosati,
    Professional Corporation.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Indemnification Agreement between the Registrant and its
    directors and officers.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .2
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    1999 Stock Plan of the Registrant, as amended.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .2A
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Forms of agreements under the 1999 Stock Plan.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .3*
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    2008 Equity Incentive Plan.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .3A*
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Forms of agreements under the 2008 Equity Incentive Plan.
</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=01 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=01 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>	<!-- colindex=01 type=align1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="85%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Exhibit Number</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Description</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .4&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Second Amended and Restated License Agreement by and between
    California Institute of Technology and the Registrant effective
    as of May&#160;1, 2004.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .4A&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    First Addendum, effective as of March&#160;29, 2007, to Second
    Amended and Restated License Agreement by and between California
    Institute of Technology and the Registrant effective as of
    May&#160;1, 2004.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .5&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Co-Exclusive License Agreement between President and Fellows of
    Harvard College and the Registrant effective as of
    October&#160;15, 2000.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .5A&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    First Amendment to Co-Exclusive License Agreement between
    President and Fellows of Harvard College and the Registrant
    effective as of October&#160;15, 2000.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .6&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Co-Exclusive License Agreement between President and Fellows of
    Harvard College and the Registrant effective as of
    October&#160;15, 2000.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .7&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Co-Exclusive License Agreement between President and Fellows of
    Harvard College and the Registrant effective as of
    October&#160;15, 2000.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .8&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Patent License Agreement by and between Gyros AB and the
    Registrant dated January&#160;9, 2003.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .8A&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amendment No.&#160;1 dated January&#160;9, 2005 to Patent
    License Agreement by and between Gyros AB and the Registrant
    dated January&#160;9, 2003.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .9&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Master Closing Agreement by and between UAB Research Foundation,
    Oculus Pharmaceuticals, Inc. and the Registrant dated
    March&#160;7, 2003.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .9A&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    License Agreement by and between UAB Research Foundation and the
    Registrant dated March&#160;7, 2003.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .10&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amended and Restated Letter Agreement Regarding Application for
    Incentives Under the Research Incentive Scheme for Companies
    (RISC) dated March&#160;27, 2008 (originally dated
    October&#160;7, 2005), by and between Singapore Economic
    Development Board and Fluidigm Singapore Pte. Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .10A&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Supplement Dated January&#160;11, 2006 to Letter Agreement
    Relating to Application for Incentives under the Research
    Incentive Scheme for Companies (RISC), dated October&#160;7,
    2005 between Singapore Economic Development Board and Fluidigm
    Singapore Pte. Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .11&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amended and Restated Letter Agreement Regarding Application for
    Incentives Under the Research Incentive Scheme for Companies
    (RISC) dated March&#160;27, 2008 (originally dated
    February&#160;12, 2007), by and between Singapore Economic
    Development Board and Fluidigm Singapore Pte. Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .12&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Distribution Agreement by and between Eppendorf AG and the
    Registrant effective as of April&#160;1, 2005.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .13*
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Employment and Severance Agreement between the
    Registrant and each of its executive officers.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .14
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consulting Agreement by and between the Registrant and Richard
    DeLateur dated February&#160;29, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .15
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Employee Loan Agreement with Gajus Worthington dated
    January&#160;20, 2004.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .15A
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Stock Repurchase Agreement between the Registrant and Gajus V.
    Worthington dated April&#160;10, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .16
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Offer Letter to Vikram Jog dated January&#160;29, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .17
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Settlement Agreement and General Release of all Claims by and
    between Michael Ybarra Lucero and the Registrant dated
    March&#160;20, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    21
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    List of subsidiaries of Registrant.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    23
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Independent Registered Public Accounting Firm.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    23
</TD>
<TD nowrap align="left" valign="top">
    .2*
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Wilson Sonsini Goodrich&#160;&#038; Rosati,
    Professional Corporation (included in Exhibit&#160;5.1).
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    24
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Power of Attorney (see
    <FONT style="white-space: nowrap">page&#160;II-7</FONT>
    to this registration statement on
    <FONT style="white-space: nowrap">Form&#160;S-1).</FONT>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">*
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">To be filed by amendment.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">&#134;
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Confidential treatment has been
    requested with respect to certain portions of this exhibit.
    Omitted portions have been filed separately with the Securities
    and Exchange Commission.
    </FONT></TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    II-5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;<I>Financial Statement Schedules.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All schedules have been omitted because the information required
    to be presented in them is not applicable or is shown in the
    consolidated financial statements or related notes.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;17.&#160;&#160;<I>Undertakings.</I></FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The undersigned registrant hereby undertakes to provide to the
    underwriters at the closing specified in the underwriting
    agreement certificates in such denominations and registered in
    such names as required by the underwriters to permit prompt
    delivery to each purchaser.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Insofar as indemnification for liabilities arising under the
    Securities Act of 1933&#160;may be permitted to directors,
    officers and controlling persons of the registrant pursuant to
    the foregoing provisions, or otherwise, the registrant has been
    advised that in the opinion of the Securities and Exchange
    Commission such indemnification is against public policy as
    expressed in the Act and is, therefore, unenforceable. In the
    event that a claim for indemnification against such liabilities
    (other than the payment by the registrant of expenses incurred
    or paid by a director, officer or controlling person of the
    registrant in the successful defense of any action, suit or
    proceeding) is asserted by such director, officer or controlling
    person in connection with the securities being registered, the
    registrant will, unless in the opinion of its counsel the matter
    has been settled by controlling precedent, submit to a court of
    appropriate jurisdiction the question whether such
    indemnification by it is against public policy as expressed in
    the Act and will be governed by the final adjudication of such
    issue.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The undersigned registrant hereby undertakes that:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (1)&#160;For purposes of determining any liability under the
    Securities Act of 1933, the information omitted from the form of
    prospectus filed as part of this registration statement in
    reliance upon Rule&#160;430A and contained in a form of
    prospectus filed by the registrant pursuant to
    Rule&#160;424(b)(1) or (4)&#160;or 497(h) under the Securities
    Act shall be deemed to be part of this registration statement as
    of the time it was declared effective.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (2)&#160;For the purpose of determining any liability under the
    Securities Act of 1933, each post effective amendment that
    contains a form of prospectus shall be deemed to be a new
    registration statement relating to the securities offered
    therein, and the offering of such securities at that time shall
    be deemed to be the initial bona fide offering thereof.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SIGNATURES</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the requirements of the Securities Act of 1933, the
    Registrant has duly caused this registration statement to be
    signed on its behalf by the undersigned, thereunto duly
    authorized, in the City of Fremont, State of California, on the
    14th day of April 2008.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>FLUIDIGM CORPORATION</B>
</DIV>

<DIV style="margin-top: 36pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="4%"></TD>
    <TD width="47%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="center">
    <DIV style="display:inline; text-align:center; width:90%">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Gajus
    V. Worthington</FONT></DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 53%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV align="center" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Gajus V. Worthington
</DIV>

<DIV align="center" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>President and Chief Executive Officer</I>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">POWER OF
    ATTORNEY</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose
    signature appears below hereby constitutes and appoints Gajus V.
    Worthington and Vikram Jog, and each of them, as his true and
    lawful attorney in fact and agent with full power of
    substitution, for him in any and all capacities, to sign any and
    all amendments to this registration statement (including post
    effective amendments or any abbreviated registration statement
    and any amendments thereto filed pursuant to Rule&#160;462(b)
    increasing the number of securities for which registration is
    sought), and to file the same, with all exhibits thereto and
    other documents in connection therewith, with the Securities and
    Exchange Commission, granting unto said attorney in fact and
    agent full power and authority to do and perform each and every
    act and thing requisite and necessary to be done in connection
    therewith, as fully for all intents and purposes as he might or
    could do in person, hereby ratifying and confirming all that
    said attorney in fact and agent, or his substitute, may lawfully
    do or cause to be done by virtue hereof.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the requirements of the Securities Act of 1933, this
    registration statement has been signed by the following persons
    in the capacities indicated on the 14th day of April 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="3%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="37%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="40%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="13%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Signature</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Title</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Date</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 12pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:center; width:90%">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Gajus
    V. Worthington</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=184 length=0 -->Gajus
    V. Worthington
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    President, Chief Executive Officer and Director (Principal
    Executive Officer)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    April&#160;14, 2008
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:center; width:90%">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Vikram
    Jog</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=184 length=0 -->Vikram
    Jog
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    Chief Financial Officer (Principal Accounting and Financial
    Officer)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    April&#160;14, 2008
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:center; width:90%">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Samuel
    Colella</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=184 length=0 -->Samuel
    Colella
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    April&#160;14, 2008
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:center; width:90%">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Michael
    W. Hunkapiller</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=184 length=0 -->Michael
    W. Hunkapiller
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    April&#160;14, 2008
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:center; width:90%">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Elaine
    V. Jones</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=184 length=0 -->Elaine
    V. Jones
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    April&#160;14, 2008
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:center; width:90%">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Kenneth
    Nussbacher</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=184 length=0 -->Kenneth
    Nussbacher
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    April&#160;14, 2008
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:center; width:90%">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">John
    A. Young</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=184 length=0 -->John
    A. Young
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    April&#160;14, 2008
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">EXHIBIT&#160;INDEX</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=01 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=01 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>	<!-- colindex=01 type=align1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="85%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Exhibit Number</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Description</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    1
</TD>
<TD nowrap align="left" valign="top">
    .1*
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Underwriting Agreement.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Certificate of Incorporation of the Registrant, as currently in
    effect.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .2*
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Restated Certificate of Incorporation of the Registrant,
    to be in effect upon the completion of this offering.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .3
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Bylaws of the Registrant.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .4*
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Amended and Restated Bylaws of the Registrant, to be in
    effect upon completion of this offering.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .1*
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Specimen Common Stock Certificate of the Registrant.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .2
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Series&#160;E Preferred Stock Purchase Agreement dated
    June&#160;13, 2006 through October&#160;26, 2007 between the
    Registrant and the Purchasers set forth therein, as amended.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .3
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Eighth Amended and Restated Investor Rights Agreement between
    the Registrant and certain holders of the Registrant&#146;s
    common stock named therein, including amendments No.&#160;1 and
    No.&#160;2.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .4&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Loan and Security Agreement No.&#160;4561 between the Registrant
    and Lighthouse Capital Partners&#160;V, L.P. dated
    March&#160;29, 2005, including amendments Nos. 1 through 4.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .4A
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Preferred Stock Purchase Warrant issued to Lighthouse Capital
    Partners&#160;V, L.P. effective March&#160;29, 2005.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .4B
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Negative Pledge Agreement by and between the Registrant and
    Lighthouse Capital Partners&#160;V, L.P. dated March&#160;29,
    2005.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .5
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Convertible Note Purchase Agreement by and between Biomedical
    Sciences Investment Fund&#160;Pte. Ltd. and the Registrant dated
    August&#160;7, 2006.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .5A&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Convertible Promissory Note issued to Biomedical Sciences
    Investment Fund&#160;Pte. Ltd. dated April&#160;19, 2007, as
    amended.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    5
</TD>
<TD nowrap align="left" valign="top">
    .1*
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Opinion of Wilson Sonsini Goodrich&#160;&#038; Rosati,
    Professional Corporation.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Indemnification Agreement between the Registrant and its
    directors and officers.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .2
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    1999 Stock Plan of the Registrant, as amended.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .2A
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Forms of agreements under the 1999 Stock Plan.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .3*
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    2008 Equity Incentive Plan.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .3A*
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Forms of agreements under the 2008 Equity Incentive Plan.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .4&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Second Amended and Restated License Agreement by and between
    California Institute of Technology and the Registrant effective
    as of May&#160;1, 2004.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .4A&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    First Addendum, effective as of March&#160;29, 2007, to Second
    Amended and Restated License Agreement by and between California
    Institute of Technology and the Registrant effective as of
    May&#160;1, 2004.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .5&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Co-Exclusive License Agreement between President and Fellows of
    Harvard College and the Registrant effective as of
    October&#160;15, 2000.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .5A&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    First Amendment to Co-Exclusive License Agreement between
    President and Fellows of Harvard College and the Registrant
    effective as of October&#160;15, 2000.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .6&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Co-Exclusive License Agreement between President and Fellows of
    Harvard College and the Registrant effective as of
    October&#160;15, 2000.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .7&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Co-Exclusive License Agreement between President and Fellows of
    Harvard College and the Registrant effective as of
    October&#160;15, 2000.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .8&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Patent License Agreement by and between Gyros AB and the
    Registrant dated January&#160;9, 2003.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .8A&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amendment No.&#160;1 dated January&#160;9, 2005 to Patent
    License Agreement by and between Gyros AB and the Registrant
    dated January&#160;9, 2003.
</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=01 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=01 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>	<!-- colindex=01 type=align1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="85%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Exhibit Number</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Description</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .9&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Master Closing Agreement by and between UAB Research Foundation,
    Oculus Pharmaceuticals, Inc. and the Registrant dated
    March&#160;7, 2003.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .9A&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    License Agreement by and between UAB Research Foundation and the
    Registrant dated March&#160;7, 2003.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .10&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amended and Restated Letter Agreement Regarding Application for
    Incentives Under the Research Incentive Scheme for Companies
    (RISC) dated March&#160;27, 2008 (originally dated
    October&#160;7, 2005), by and between Singapore Economic
    Development Board and Fluidigm Singapore Pte. Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .10A&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Supplement Dated January&#160;11, 2006 to Letter Agreement
    Relating to Application for Incentives under the Research
    Incentive Scheme for Companies (RISC), dated October&#160;7,
    2005 between Singapore Economic Development Board and Fluidigm
    Singapore Pte. Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .11&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amended and Restated Letter Agreement Regarding Application for
    Incentives Under the Research Incentive Scheme for Companies
    (RISC) dated March&#160;27, 2008 (originally dated
    February&#160;12, 2007), by and between Singapore Economic
    Development Board and Fluidigm Singapore Pte. Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .12&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Distribution Agreement by and between Eppendorf AG and the
    Registrant effective as of April&#160;1, 2005.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .13*
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Employment and Severance Agreement between the
    Registrant and each of its executive officers.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .14
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consulting Agreement by and between the Registrant and Richard
    DeLateur dated February&#160;29, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .15
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Employee Loan Agreement with Gajus Worthington dated
    January&#160;20, 2004.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .15A
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Stock Repurchase Agreement between the Registrant and Gajus V.
    Worthington dated April&#160;10, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .16
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Offer Letter to Vikram Jog dated January&#160;29, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .17
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Settlement Agreement and General Release of all Claims by and
    between Michael Ybarra Lucero and the Registrant dated
    March&#160;20, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    21
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    List of subsidiaries of Registrant.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    23
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Independent Registered Public Accounting Firm.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    23
</TD>
<TD nowrap align="left" valign="top">
    .2*
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Wilson Sonsini Goodrich&#160;&#038; Rosati,
    Professional Corporation (included in Exhibit&#160;5.1).
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    24
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Power of Attorney (see
    <FONT style="white-space: nowrap">page&#160;II-7</FONT>
    to this registration statement on
    <FONT style="white-space: nowrap">Form&#160;S-1).</FONT>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">*
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">To be filed by amendment.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">&#134;
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Confidential treatment has been
    requested with respect to certain portions of this exhibit.
    Omitted portions have been filed separately with the Securities
    and Exchange Commission.
    </FONT></TD>
</TR>

</TABLE>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>f39432orexv3w1.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv3w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;3.1</B>
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">State of Delaware<BR>
Secretary of State<BR>
Divisions of Corporations<BR>
Delivered 07:02 PM 07/16/2007<BR>
Filed 05:02 PM 07/16/2007<BR>
SRV 070818529 &#151; 4292717 File
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMENDED AND RESTATED</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>CERTIFICATE OF INCORPORATION OF</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>FLUIDIGM CORPORATION</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fluidigm Corporation, a corporation organized and existing under the laws of the State of
Delaware (the &#147;Corporation&#148;), certifies that:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A.&nbsp;The name of the Corporation is Fluidigm Corporation. The Corporation&#146;s original
Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on
March&nbsp;29, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B.&nbsp;This Amended and Restated Certificate of Incorporation was duly adopted in accordance with
Sections&nbsp;242 and 245 of the General Corporation Law of the State of Delaware, and restates,
integrates and further amends the provisions of the Corporation&#146;s Certificate of Incorporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C.&nbsp;The text of the Certificate of Incorporation is amended and restated to read as set forth
in EXHIBIT A attached hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, Fluidigm Corporation has caused this Amended and Restated Certificate of
Incorporation to be signed by Gajus V. Worthington, a duly authorized officer of the Corporation,
on July&nbsp;16, 2007.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">                                                   /s/ Gajus V. Worthington
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Gajus V. Worthington&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">President &#038; Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="right" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT A</B></U>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt">ARTICLE I
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The name of this corporation is Fluidigm Corporation.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE II
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The purpose of the Corporation is to engage in any lawful act or activity for which a
corporation may be organized under the General Corporation Law of Delaware.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE III
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The address of the Corporation&#146;s registered office in the State of Delaware is Corporation
Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware, 19801. The name of its
registered agent at such address is The Corporation Trust Company.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE IV
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The total number of shares of stock that the Corporation shall have authority to issue is
130,295,092, $0.001 par value, consisting of 77,857,144 shares of Common Stock, $0.001 par value
per share (&#147;Common&#148;) and 52,437,948 shares of Preferred Stock, $0.001 par value per share
(&#147;Preferred&#148;). The Preferred shall be divided into series. The first series shall consist of
2,727,273 shares and shall be designated Series&nbsp;A Preferred Stock (&#147;Series&nbsp;A Preferred Stock&#148;).
The second series shall consist of 6,460,675 shares and shall be designated Series&nbsp;B Preferred
Stock (&#147;Series&nbsp;B Preferred Stock&#148;). The third series shall consist of 17,000,000 shares and shall
be designated Series&nbsp;C Preferred Stock (&#147;Series&nbsp;C Preferred Stock&#148;). The fourth series shall
consist of 15,500,000 shares and shall be designated Series&nbsp;D Preferred Stock (&#147;Series&nbsp;D Preferred
Stock&#148;). The fifth series shall consist of 10,750,000 shares and shall be designated Series&nbsp;E
Preferred Stock (&#147;Series&nbsp;E Preferred Stock&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The terms and provisions of the Common Stock and Preferred Stock are as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Definitions</U>. For purposes of this Article&nbsp;IV, the following definitions shall
apply:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) &#147;<U>Conversion Price</U>&#148; shall mean $1.10 per share for the Series&nbsp;A Preferred Stock,
$1.78 per share for the Series&nbsp;B Preferred Stock, $2.58 per share for the Series&nbsp;C Preferred Stock,
$2.80 per share for the Series&nbsp;D Preferred Stock, and $4.00 for the Series&nbsp;E Preferred Stock (each
subject to adjustment from time to time as set forth elsewhere herein).
</DIV>


<P align="right" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) &#147;<U>Convertible Securities</U>&#148; shall mean any evidences of indebtedness, shares or other
securities (other than shares of Common Stock) convertible into or exchangeable for Common Stock.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) &#147;<U>Corporation</U>&#148; shall mean Fluidigm Corporation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) &#147;<U>Dividend Rate</U>&#148; shall mean an annual rate of $0.11 per share for the Series&nbsp;A
Preferred Stock, an annual rate of $0.18 for the Series&nbsp;B Preferred Stock, an annual rate of $0.26
per share for the Series&nbsp;C Preferred Stock, an annual rate of $0.30 per share for the Series&nbsp;D
Preferred Stock, and an annual rate of $0.43 per share for the Series&nbsp;E Preferred Stock (each
subject to adjustment from time to time as set forth elsewhere herein).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) &#147;<U>Liquidation Preference</U>&#148; shall mean $1.10 per share for the Series&nbsp;A Preferred
Stock, $1.78 per share for the Series&nbsp;B Preferred Stock, $2.58 per share for the Series&nbsp;C Preferred
Stock, $2.80 per share for the Series&nbsp;D Preferred Stock, and $4.00 per share for the Series&nbsp;E
Preferred Stock (each subject to adjustment from time to time as set forth elsewhere herein).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) &#147;<U>Options</U>&#148; shall mean rights, options or warrants to subscribe for, purchase or
otherwise acquire Common Stock or Convertible Securities.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) &#147;<U>Original Issue Price</U>&#148; shall mean $1.10 per share for the Series&nbsp;A Preferred
Stock, $1.78 for the Series&nbsp;B Preferred Stock, $2.58 per share for the Series&nbsp;C Preferred Stock,
$2.80 per share for the Series&nbsp;D Preferred Stock, and $4.00 per share for the Series&nbsp;E Preferred
Stock (each subject to adjustment from time to time as set forth elsewhere herein).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) &#147;<U>Preferred Stock</U>&#148; shall mean the Series&nbsp;A Preferred Stock, the Series&nbsp;B Preferred
Stock, the Series&nbsp;C Preferred Stock, the Series&nbsp;D Preferred Stock, and the Series&nbsp;E Preferred
Stock.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Dividends</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Series&nbsp;D and Series&nbsp;E Preferred Stock</U>. The holders of outstanding shares of
Series&nbsp;D Preferred Stock and the holders of outstanding shares of Series&nbsp;E Preferred Stock shall be
entitled to receive dividends, when and as declared by the Board of Directors, out of any assets at
the time legally available therefor, at the Dividend Rates specified for such shares of Preferred
Stock, payable in preference and priority to any declaration or payment of any distribution on
Series&nbsp;A Preferred Stock, Series&nbsp;B Preferred Stock, Series&nbsp;C Preferred Stock or Common Stock
(collectively, the &#147;<B>Junior Stock</B>&#148;) of the Corporation other than a dividend payable solely in
Common Stock. No distributions shall be made with respect to the Junior Stock during any fiscal
year of the Corporation, other than dividends on the Common Stock payable solely in Common Stock,
until all dividends at the applicable Dividend Rate on the Series&nbsp;E Preferred Stock and Series&nbsp;D
Preferred Stock have been declared and paid or set apart for payment to the holders of Series&nbsp;E
Preferred Stock and the holders of Series&nbsp;D Preferred Stock. Payment of any dividends to the
holders of the Series&nbsp;E Preferred Stock and the Series&nbsp;D Preferred Stock shall be on a <U>pro</U>
<U>rata</U>, pari passu basis in proportion to the Dividend Rates for the Series&nbsp;E Preferred Stock
and Series&nbsp;D Preferred Stock, as applicable. The right to receive dividends on shares of Series&nbsp;E
Preferred Stock and Series&nbsp;D Preferred Stock shall not be cumulative, and no right to such
dividends shall accrue to holders of Series&nbsp;E Preferred Stock and Series&nbsp;D Preferred Stock by
reason of the fact that dividends on said shares are not declared or paid in any year.
</DIV>


<P align="right" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Series&nbsp;C Preferred Stock</U>. The holders of outstanding shares of Series&nbsp;C Preferred
Stock shall be entitled to receive dividends, when and as declared by the Board of Directors, out
of any assets at the time legally available therefor, at the Dividend Rate specified for such
shares of Preferred Stock payable in preference and priority to any declaration or payment of any
distribution on Series&nbsp;A Preferred Stock, Series&nbsp;B Preferred Stock or Common Stock of the
Corporation other than a dividend payable solely in Common Stock. No distributions shall be made
with respect to the Series&nbsp;A Preferred Stock, Series&nbsp;B Preferred Stock or Common Stock during any
fiscal year of the Corporation, other than dividends on the Common Stock payable solely in Common
Stock, until all dividends at the applicable Dividend Rate on the Series&nbsp;C Preferred Stock have
been declared and paid or set apart for payment to the holders of Series&nbsp;C Preferred Stock. The
right to receive dividends on shares of Series&nbsp;C Preferred Stock shall not be cumulative, and no
right to such dividends shall accrue to holders of Series&nbsp;C Preferred Stock by reason of the fact
that dividends on said shares are not declared or paid in any year.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Series&nbsp;A Preferred Stock and Series&nbsp;B Preferred Stock</U>. The holders of outstanding
shares of Series&nbsp;A Preferred Stock and the holders of outstanding shares of Series&nbsp;B Preferred
Stock shall be entitled to receive dividends, when and as declared by the Board of Directors, out
of any assets at the time legally available therefor, at the Dividend Rate specified for such
shares of Preferred Stock payable in preference and priority to any declaration or payment of any
distribution on Common Stock of the Corporation other than a dividend payable solely in Common
Stock. No distributions shall be made with respect to the Common Stock, other than dividends
payable solely in Common Stock, until all dividends at the applicable Dividend Rate on the
Preferred Stock have been declared and paid or set apart for payment to the Preferred Stock
holders. Payment of any dividends to the holders of the Series&nbsp;A Preferred Stock and Series&nbsp;B
Preferred Stock shall be on a <U>pro</U> <U>rata</U>, pari passu basis in proportion to the
Dividend Rates for the Series&nbsp;A Preferred Stock and Series&nbsp;B Preferred Stock, as applicable. The
right to receive dividends on shares of Series&nbsp;A Preferred Stock and Series&nbsp;B Preferred Stock shall
not be cumulative, and no right to such dividends shall accrue to holders of Series&nbsp;A Preferred
Stock or Series&nbsp;B Preferred Stock by reason of the fact that dividends on said shares are not
declared or paid in any year.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Distribution</U>. For purposes of this Section&nbsp;2, unless the context otherwise
requires, a &#147;<B>distribution</B>&#148; shall mean the transfer of cash or other property without consideration
whether by way of dividend or otherwise, payable other than in Common Stock, or the purchase or
redemption of shares of the Corporation other than (i)&nbsp;repurchase of shares of Common Stock issued
to or held by employees, consultants, officers and directors of the Corporation or its subsidiaries
upon termination of their employment or services pursuant to agreements providing for the right of
said repurchase and at the original purchase price paid by such employees, consultants, officers
and directors; and (ii)&nbsp;repurchase of Common Stock issued to or held by employees, officers,
directors or consultants of the Corporation or its subsidiaries pursuant to rights of first refusal
contained in agreements providing for such rights, provided that such repurchase is unanimously
approved by the Board of Directors; and (iii)&nbsp;any other repurchase or redemption of capital stock
of the corporation unanimously approved by the Board of Directors and approved by the holders of
the majority of the Common Stock and the holders of more than two-thirds (<FONT style="font-size: 70%"><SUP>2</SUP></FONT>/<FONT style="font-size: 60%">3</FONT>) of the outstanding
shares of the Preferred Stock, voting as separate classes.
</DIV>


<P align="right" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Common Stock</U>. Dividends may be paid on the Common Stock as and when declared by
the Board of Directors, subject to the prior dividend rights of the Preferred Stock and Section&nbsp;6
below.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U>Non-Cash Distributions</U>. Whenever a distribution provided for in this Section&nbsp;2
shall be payable in property other than cash, the value of such distribution shall be deemed to be
the fair market value of such property as determined in good faith by the Board of Directors.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <U>Consent to Certain Repurchases</U>. If Sections&nbsp;502 and 503 of the California
Corporations Code are determined to apply to the Corporation, as authorized by Section&nbsp;402.5(c) of
the California Corporations Code, Sections&nbsp;502 and 503 of the California Corporations Code shall
not apply with respect to payments made by the Corporation in connection with (i)&nbsp;repurchase of
shares of Common Stock issued to or held by employees, consultants, officers and directors of the
Corporation or its subsidiaries upon termination of their employment or services pursuant to
agreements providing for the right of said repurchase and at the original purchase price paid by
such employees, consultants, officers and directors, and (ii)&nbsp;repurchase of Common Stock issued to
or held by employees, officers, directors and consultants of the Corporation or its subsidiaries
pursuant to rights of first refusal contained in agreements providing for such rights, provided
that such repurchase is unanimously approved by the Board of Directors, and (iii)&nbsp;any other
repurchase or redemption of Common Stock unanimously approved by the Board of Directors and
approved by the holders of more than two-thirds (2/3) of the outstanding shares of Preferred Stock
voting together as a single class.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Liquidation Rights</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of any liquidation, dissolution or winding up of the Corporation, either
voluntary or involuntary, distribution of the assets of the Corporation legally available for
distribution to the Corporation&#146;s stockholders shall be made in the following manner:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Series&nbsp;E Liquidation Preference</U>. The holders of the Series&nbsp;E Preferred Stock
shall be entitled to receive, prior and in preference to any distribution of any of the assets of
the Corporation to the holders of the Common Stock, the Series&nbsp;A Preferred Stock, the Series&nbsp;B
Preferred Stock, the Series&nbsp;C Preferred Stock, or the Series&nbsp;D Preferred Stock, by reason of their
ownership of such stock, an amount per share for each share of Series&nbsp;E Preferred Stock held by
them equal to the sum of (i)&nbsp;the Liquidation Preference for such shares and (ii)&nbsp;all declared and
unpaid dividends on such share of Series&nbsp;E Preferred Stock. If the assets of the Corporation
legally available for distribution to the holders of the Series&nbsp;E Preferred Stock are insufficient
to permit the payment to such holders of the full amounts specified in this Section&nbsp;3(a), then the
entire assets of the Corporation legally available for distribution shall be distributed with equal
priority and <U>pro</U> <U>rata</U> among the holders of the Series&nbsp;E Preferred Stock in
proportion to the full amounts they would otherwise be entitled to receive pursuant to this Section
3(a).
</DIV>


<P align="right" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Series&nbsp;D Liquidation Preference</U>. After payment to the holders of Series&nbsp;E
Preferred Stock of the full amounts specified in Section 3(a) above, the holders of the Series&nbsp;D
Preferred Stock shall be entitled to receive, prior and in preference to any distribution of any of
the assets of the Corporation to the holders of the Common Stock, the Series&nbsp;A Preferred Stock, the
Series&nbsp;B Preferred Stock or the Series&nbsp;C Preferred Stock by reason of their ownership of such
stock, an amount per share for each share of Series&nbsp;D Preferred Stock held by them equal to the sum
of (i)&nbsp;the Liquidation Preference for such shares and (ii)&nbsp;all declared and unpaid dividends on
such share of Series&nbsp;D Preferred Stock. If the remaining assets of the Corporation legally
available for distribution to the holders of Series&nbsp;D Preferred Stock are insufficient to permit
the payment to such holders of the full amounts specified in this Section&nbsp;3(b), then the entire
remaining assets of the Corporation legally available for distribution shall be distributed with
equal priority and <U>pro</U> <U>rata</U> among the holders of the Series&nbsp;D Preferred Stock in
proportion to the full amounts they would otherwise be entitled to receive pursuant to this Section
3(b).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Series&nbsp;C Liquidation Preference</U>. After payment to the holders of Series&nbsp;E
Preferred Stock and to the holders of Series&nbsp;D Preferred Stock of the full amounts specified in
Sections 3(a) and 3(b) above, the holders of the Series&nbsp;C Preferred Stock shall be entitled to
receive, prior and in preference to any distribution of any of the assets of the Corporation to the
holders of the Common Stock, the Series&nbsp;A Preferred Stock or the Series&nbsp;B Preferred Stock by reason
of their ownership of such stock, an amount per share for each share of Series&nbsp;C Preferred Stock
held by them equal to the sum of (i)&nbsp;the Liquidation Preference for such shares and (ii)&nbsp;all
declared and unpaid dividends on such share of Series&nbsp;C Preferred Stock. If the remaining assets
of the Corporation legally available for distribution to the holders of the Series&nbsp;C Preferred
Stock are insufficient to permit the payment to such holders of the full amounts specified in this
Section&nbsp;3(c), then the entire remaining assets of the Corporation legally available for
distribution shall be distributed with equal priority and <U>pro</U> <U>rata</U> among the
holders of the Series&nbsp;C Preferred Stock in proportion to the full amounts they would otherwise be
entitled to receive pursuant to this Section&nbsp;3(c).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Series&nbsp;B Liquidation Preference</U>. After the payment to the holders of Series&nbsp;E
Preferred Stock, the holders of Series&nbsp;D Preferred Stock, and the holders of Series&nbsp;C Preferred
Stock of the full amounts specified in Sections&nbsp;3(a), 3(b), and 3(c) above, the holders of the
Series&nbsp;B Preferred Stock shall be entitled to receive, prior and in preference to any distribution
of any of the remaining assets of the Corporation to the holders of the Common Stock or Series&nbsp;A
Preferred Stock by reason of their ownership of such stock, an amount per share for each share of
Series&nbsp;B Preferred Stock held by them equal to the sum of (i)&nbsp;the Liquidation Preference for such
shares and (ii)&nbsp;all declared and unpaid dividends on such share of Series&nbsp;B Preferred Stock. If
the remaining assets of the Corporation legally available for distribution to the holders of the
Series&nbsp;B Preferred Stock are insufficient to permit the payment to such holders of the full amounts
specified in this Section&nbsp;3(d), then the entire remaining assets of the Corporation legally
available for distribution shall be distributed with equal priority and <U>pro</U> <U>rata</U>
among the holders of the Series&nbsp;B Preferred Stock in proportion to the full amounts they would
otherwise be entitled to receive pursuant to this Section&nbsp;3(d).
</DIV>


<P align="right" style="font-size: 10pt"><!-- Folio -->-5-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Series&nbsp;A Liquidation Preference</U>. After the payment to the holders of Series&nbsp;E
Preferred Stock, the holders of Series&nbsp;D Preferred Stock, the holders of Series&nbsp;C Preferred Stock,
and the holders of Series&nbsp;B Preferred Stock of the full amounts specified in Sections&nbsp;3(a), 3(b),
3(c) and 3(d) above, the holders of the Series&nbsp;A Preferred Stock shall be entitled to receive,
prior and in preference to any distribution of any of the remaining assets of the Corporation to
the holders of the Common Stock by reason of their ownership of such stock, an amount per share for
each share of Series&nbsp;A Preferred Stock held by them equal to the sum of (i)&nbsp;the Liquidation
Preference for such shares and (ii)&nbsp;all declared and unpaid dividends on such share of Series&nbsp;A
Preferred Stock. If the remaining assets of the Corporation legally available for distribution to
the holders of the Series&nbsp;A Preferred Stock are insufficient to permit the payment to such holders
of the full amounts specified in this Section&nbsp;3(e), then the entire remaining assets of the
Corporation legally available for distribution shall be distributed with equal priority and
<U>pro</U> <U>rata</U> among the holders of the Series&nbsp;A Preferred Stock in proportion to the
full amounts they would otherwise be entitled to receive pursuant to this Section&nbsp;3(e).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U>Remaining Assets</U>. After the payment to the holders of Preferred Stock of the full
amounts specified in Sections&nbsp;3(a), 3(b), 3(c), 3(d) and 3(e) above, the entire remaining assets of
the Corporation legally available for distribution shall be distributed <U>pro</U> <U>rata</U> to
holders of the Common Stock of the Corporation in proportion to the number of shares of Common
Stock held by them.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <U>Shares Not Treated as Both Preferred Stock and Common Stock in Any Distribution</U>.
Shares of Preferred Stock shall not be entitled to be converted into shares of Common Stock in
order to participate in any distribution, or series of distributions, as shares of Common Stock,
without first foregoing participation in the distribution, or series of distributions, as shares of
Preferred Stock.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <U>Reorganization</U>. For purposes of this Section&nbsp;3, a liquidation, dissolution or
winding up of the Corporation shall be deemed to be occasioned by, or to include, (i)&nbsp;the
acquisition of the Corporation by another entity by means of any transaction or series of related
transactions (including, without limitation, any stock acquisition, reorganization, merger or
consolidation but excluding any merger effected exclusively for the purpose of changing the
domicile of the Corporation) other than a transaction or series of transactions in which the
holders of the voting securities of the Corporation outstanding immediately prior to such
transaction or series of transactions continue to retain (either by such voting securities
remaining outstanding or by such voting securities being converted into voting securities of the
surviving entity), as a result of shares in the Corporation held by such holders prior to such
transaction, at least fifty percent (50%) of the total voting power represented by the voting
securities of the Corporation or such surviving entity outstanding immediately after such
transaction or series of transactions; or (ii)&nbsp;a sale, transfer, lease or other conveyance of all
or substantially all of the assets of the Corporation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <U>Valuation of Non-Cash Consideration</U>. If any assets of the Corporation distributed
to stockholders in connection with any liquidation, dissolution, or winding up of the Corporation
are other than cash, then the value of such assets shall be their fair market value as determined
in good faith by the Board of Directors, <U>except that</U> any securities to be distributed to
stockholders in a liquidation, dissolution, or winding up of the Corporation shall be valued as
follows:
</DIV>


<P align="right" style="font-size: 10pt"><!-- Folio -->-6-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;If the securities are then traded on a national securities exchange or the Nasdaq Stock
Market System (or a similar national quotation system), then the value of the securities shall be
deemed to be to the average of the closing prices of the securities on such exchange or system over
the ten (10)&nbsp;trading day period ending five (5)&nbsp;trading days prior to the distribution;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;if the securities are actively traded over-the-counter, then the value of the securities
shall be deemed to be the average of the closing bid prices of the securities over the ten (10)
trading day period ending five (5)&nbsp;trading days prior to the distribution; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;if there is no active public market for the securities, then the value of the securities
shall be deemed to be the fair market value thereof as determined in good faith by the Board of
Directors which determination shall include consideration of the illiquidity of the securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of a merger or other acquisition of the Corporation by another entity, the
distribution date shall be deemed to the date such transaction closes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For the purposes of this Section&nbsp;3(i), &#147;<B>trading day</B>&#148; shall mean any day on which the exchange
or system on which the securities to be distributed are traded is open, and &#147;closing prices&#148; or
&#147;closing bid prices&#148; shall be deemed to be: (i)&nbsp;for securities traded primarily on the New York
Stock Exchange, the American Stock Exchange or Nasdaq, the last reported trade price or sale price,
as the case may be, at 4:00 p.m., New York time, on that day and (ii)&nbsp;for securities listed or
traded on other exchanges, markets and systems, the market price as of the end of the &#147;regular
hours&#148; trading period that is generally accepted as such for such exchange, market or system. If,
after the date hereof, the benchmark times generally accepted in the securities industry for
determining the market price of a stock as of a given trading day shall change from those set forth
above, the fair market value shall be determined as of such other generally accepted benchmark
times.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Conversion</U>. The holders of the Preferred Stock shall have conversion rights as
follows (the &#147;<B>Conversion Rights</B>&#148;):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Right to Convert</U>. Subject to Section&nbsp;4(c), each share of Preferred Stock shall be
convertible, at the option of the holder thereof, at any time after the date of issuance of such
share at the office of the Corporation or any transfer agent for the Preferred Stock, into that
number of fully-paid, nonassessable shares of Common Stock determined by dividing the Original
Issue Price for the relevant series by the Conversion Price for such series. (The number of shares
of Common Stock into which each share of Preferred Stock of a series may be converted is
hereinafter referred to as the &#147;<B>Conversion Rate</B>&#148; for each such series.) Upon any decrease or
increase in the Conversion Price for any series of Preferred Stock, as described in this Section&nbsp;4,
the Conversion Rate for such series shall be appropriately increased or decreased.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Automatic Conversion</U>. Each share of Preferred Stock shall automatically be
converted into fully-paid, non-assessable shares of Common Stock at the then effective Conversion
Rate for such share (i)&nbsp;immediately prior to the closing of a firm commitment underwritten initial
public offering on Form S-1 (or successor form) filed under the Securities Act of 1933, as amended
(the &#147;<B>Securities Act</B>&#148;), covering the offer and sale of the Corporation&#146;s Common Stock, provided
</DIV>


<P align="right" style="font-size: 10pt"><!-- Folio -->-7-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">that the offering price per share is not less than $5.69 (as adjusted for subdivisions and
combinations of the Common Stock and changes in the Common Stock as set forth in Sections 4(e) and
4(g)) and the aggregate gross proceeds to the Corporation are not less than $25,000,000, or (ii)
upon the receipt by the Corporation of a written consent or request for such conversion from the
holders of two-thirds of the shares of Preferred Stock then outstanding, or, if later, the
effective date for conversion specified in such requests (each of the events referred to in (i)&nbsp;and
(ii)&nbsp;being hereinafter referred to as an &#147;<B>Automatic Conversion Event</B>&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Mechanics of Conversion</U>. No fractional shares of Common Stock shall be issued
upon conversion of Preferred Stock. In lieu of any fractional shares to which the holder would
otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied by the then
fair market value of a share of Common Stock as determined by the Board of Directors. For such
purpose, all shares of Preferred Stock held by each holder of Preferred Stock shall be aggregated,
and any resulting fractional share of Common Stock shall be paid in cash. Before any holder of
Preferred Stock shall be entitled to convert the same into full shares of Common Stock, and to
receive certificates therefor, he shall either surrender the certificate or certificates therefor,
duly endorsed, at the office of the Corporation or of any transfer agent for the Preferred Stock,
or notify the Corporation or its transfer agent that such certificate or certificates have been
lost, stolen or destroyed and execute an agreement satisfactory to the Corporation to indemnify the
Corporation from any loss incurred by it in connection with such certificate or certificates, and
shall give written notice to the Corporation at such office that he elects to convert the same;
<U>provided</U>,<U> however</U>, that on the date of an Automatic Conversion Event, the
outstanding shares of Preferred Stock shall be converted automatically without any further action
by the holders of such shares and whether or not the certificates representing such shares are
surrendered to the Corporation or its transfer agent; <U>provided further</U>, however, that the
Corporation shall not be obligated to issue certificates evidencing the shares of Common Stock
issuable upon such Automatic Conversion Event unless either the certificates evidencing such shares
of Preferred Stock are delivered to the Corporation or its transfer agent as provided above, or the
holder notifies the Corporation or its transfer agent that such certificates have been lost, stolen
or destroyed and executes an agreement satisfactory to the Corporation to indemnify the Corporation
from any loss incurred by it in connection with such certificates. On the date of the occurrence
of an Automatic Conversion Event, each holder of record of shares of Preferred Stock shall be
deemed to be the holder of record of the Common Stock issuable upon such conversion,
notwithstanding that the certificates representing such shares of Preferred Stock shall not have
been surrendered at the office of the Corporation, that notice from the Corporation shall not have
been received by any holder of record of shares of Preferred Stock, or that the certificates
evidencing such shares of Common Stock shall not then be actually delivered to such holder.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Corporation shall, as soon as practicable after such delivery, or after such agreement and
indemnification, issue and deliver at such office to such holder of Preferred Stock, a certificate
or certificates for the number of shares of Common Stock to which he shall be entitled as aforesaid
and a check payable to the holder in the amount of any cash amounts payable as the result of a
conversion into fractional shares of Common Stock, plus any declared and unpaid dividends on the
converted Preferred Stock. Such conversion shall be deemed to have been made immediately prior to
the close of business on the date of such surrender of the shares of Preferred Stock to be
converted, and the person or persons entitled to receive the shares of Common Stock issuable upon
such conversion shall be treated for all purposes as the record holder or holders of such shares of
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-8-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Common Stock on such date; <U>provided</U>, <U>however</U>, that if the conversion is in
connection with an underwritten offer of securities registered pursuant to the Securities Act the
conversion may, at the option of any holder tendering Preferred Stock for conversion, be
conditioned upon the closing of the sale of securities pursuant to such offering, in which event
the person(s) entitled to receive the Common Stock issuable upon such conversion of the Preferred
Stock shall not be deemed to have converted such Preferred Stock until immediately prior to the
closing of the sale of such securities.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Adjustments to Conversion Price for Diluting Issues</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;<U>Special Definition</U>. For purposes of this Section&nbsp;4(d), &#147;<B>Additional Shares of
Common</B>&#148; shall mean all shares of Common Stock issued (or, pursuant to Section&nbsp;4(d)(iii), deemed to
be issued) by the Corporation after the filing of this Certificate of Incorporation, other than:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;&#091;omitted&#093;;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;shares of Common Stock issued or issuable to officers, directors and employees of, or
consultants and other service providers to, the Corporation pursuant to stock grants, option plans,
purchase plans or other employee stock incentive programs or arrangements approved by the Board of
Directors or upon exercise of options or warrants granted to such parties pursuant to any such
plan, program or arrangement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;shares of Common Stock issued upon the exercise or conversion of Options or Convertible
Securities outstanding as of the date of the filing of this Certificate of Incorporation;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;shares of Common Stock issued or issuable as a dividend or distribution on Preferred Stock
or pursuant to any event for which adjustment is made pursuant to Section&nbsp;4(e), 4(f) or 4(g)
hereof;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)&nbsp;shares of Common Stock issued in a registered public offering under the Securities Act
pursuant to which all outstanding shares of Preferred Stock are automatically converted into Common
Stock pursuant to an Automatic Conversion Event;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6)&nbsp;shares of Common Stock issued or issuable pursuant to the acquisition of another
corporation by the Corporation by merger, purchase of substantially all of the assets or other
reorganization or to a joint venture agreement, provided, that such issuances are unanimously
approved by the Board of Directors;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(7)&nbsp;shares of Common Stock issued or issuable to banks, equipment lessors or other financial
institutions pursuant to a commercial leasing or debt financing transaction approved by the Board
of Directors;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(8)&nbsp;shares of Common Stock issued or issuable in connection with sponsored research,
collaboration, technology license, development, OEM, marketing or other similar agreements, or
strategic partnerships or relationships, if the issuance is approved by the Board of Directors; and
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-9-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(9)&nbsp;shares of Common Stock issued or issuable upon conversion of convertible promissory notes
issued or issuable to Biomedical Sciences Investment Fund Pte Ltd. or its affiliates (&#147;BMSIF&#148;)
pursuant to that certain Convertible Note Purchase Agreement, dated as of August&nbsp;7, 2006, between
the Company and BMSIF, as amended by the Letter Agreement dated November&nbsp;15, 2006 (as amended, the
&#147;Note Purchase Agreement&#148;) (as such Note Purchase Agreement may be further amended from time to
time after the date hereof) or upon any failure of the milestones to be satisfied under such
convertible promissory notes; and shares of Common Stock issued or issuable upon conversion of up
to $3&nbsp;million in aggregate principal amount (plus interest) of convertible promissory notes
originally issued or issuable to BMSIF pursuant to that certain Convertible Note Purchase
Agreement, dated as of December&nbsp;18, 2003, between the Company and BMSIF.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;<U>No Adjustment of Conversion Price</U>. No adjustment in the Conversion Price of a
particular series of Preferred Stock shall be made in respect of the issuance of Additional Shares
of Common unless the consideration per share (as determined pursuant to Section&nbsp;4(d)(vii)) for an
Additional Share of Common issued or deemed to be issued by the Corporation is less than the
Conversion Price in effect on the date of, and immediately prior to such issue, for such series of
Preferred Stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;<U>Deemed Issue of Additional Shares of Common</U>. In the event the Corporation at
any time or from time to time after the date of the filing of this Certificate of Incorporation
shall issue any Options or Convertible Securities or shall fix a record date for the determination
of holders of any class of securities entitled to receive any such Options or Convertible
Securities, then the maximum number of shares (as set forth in the instrument relating thereto
without regard to any provisions contained therein for a subsequent adjustment of such number) of
Common Stock issuable upon the exercise of such Options or, in the case of Convertible Securities,
the conversion or exchange of such Convertible Securities or, in the case of Options for
Convertible Securities, the exercise of such Options and the conversion or exchange of the
underlying securities, shall be deemed to have been issued as of the time of such issue or, in case
such a record date shall have been fixed, as of the close of business on such record date, provided
that in any such case in which shares are deemed to be issued:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;no further adjustment in the Conversion Price of the Preferred Stock shall be made upon
the subsequent issue of Convertible Securities or shares of Common Stock in connection with the
exercise of such Options or conversion or exchange of such Convertible Securities pursuant to the
terms of such Options or Convertible Securities;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;if no adjustment in the Conversion Price of the Preferred Stock was made upon the original
issue of (or upon the occurrence of a record date with respect to) such Options or Convertible
Securities and such Options or Convertible Securities are revised to provide, or by their terms
provide, with the passage of time or otherwise, for any increase or decrease in the consideration
payable to the Corporation, or any increase or decrease in the number of shares of Common Stock
issuable, upon the exercise, conversion or exchange thereof, then such Options or Convertible
Securities as so revised (and the Additional Shares of Common subject thereto) shall be deemed to
have been issued effective upon such increase or decrease becoming effective;
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-10-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;if such Options or Convertible Securities are revised to provide, or by their terms
provide, with the passage of time or otherwise, for any increase or decrease in the consideration
payable to the Corporation, or any increase or decrease in the number of shares of Common Stock
issuable, upon the exercise, conversion or exchange thereof, the Conversion Price of the Preferred
Stock computed upon the original issue thereof (or upon the occurrence of a record date with
respect thereto), and any subsequent adjustments based thereon, shall, upon any such increase or
decrease becoming effective, be recomputed to reflect such increase or decrease insofar as it
affects such Options or the rights of conversion or exchange under such Convertible Securities;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;no readjustment pursuant to clause (3)&nbsp;above shall have the effect of increasing the
Conversion Price of the Preferred Stock to an amount which exceeds the lower of (i)&nbsp;the Conversion
Price of the Preferred Stock on the original adjustment date, or (ii)&nbsp;the Conversion Price of the
Preferred Stock that would have resulted from any issuance of Additional Shares of Common between
the original adjustment date and such readjustment date;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)&nbsp;upon the expiration of any such Options or any rights of conversion or exchange under such
Convertible Securities which shall not have been exercised, the Conversion Price computed upon the
original issue thereof (or upon the occurrence of a record date with respect thereto) and any
subsequent adjustments based thereon shall, upon such expiration, be recomputed as if:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)&nbsp;in the case of Convertible Securities or Options for Common Stock, the only Additional
Shares of Common issued were the shares of Common Stock, if any, actually issued upon the exercise
of such Options or the conversion or exchange of such Convertible Securities and the consideration
received therefor was the consideration actually received by the Corporation for the issue of such
exercised Options plus the consideration actually received by the Corporation upon such exercise or
for the issue of all such Convertible Securities which were actually converted or exchanged, plus
the additional consideration, if any, actually received by the Corporation upon such conversion or
exchange, and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)&nbsp;in the case of Options for Convertible Securities, only the Convertible Securities, if
any, actually issued upon the exercise thereof were issued at the time of issue of such Options,
and the consideration received by the Corporation for the Additional Shares of Common deemed to
have been then issued was the consideration actually received by the Corporation for the issue of
such exercised Options, plus the consideration deemed to have been received by the Corporation
(determined pursuant to Section&nbsp;4(d)(vii)) upon the issue of the Convertible Securities with
respect to which such Options were actually exercised; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6)&nbsp;if such record date shall have been fixed and such Options or Convertible Securities are
not issued on the date fixed therefor, the adjustment previously made in the Conversion Price which
became effective on such record date shall be canceled as of the close of business on such record
date, and thereafter the Conversion Price shall be adjusted pursuant to this Section&nbsp;4(d)(iii) as
of the actual date of their issuance.
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-11-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;<U>Adjustment of Conversion Price of Series&nbsp;E Preferred Stock Upon Issuance of
Additional Shares of Common</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;For so long as the Conversion Price of the Series&nbsp;E Preferred Stock is greater than $2.58
(as adjusted for subdivisions and combinations of the Common Stock and changes in the Common Stock
as set forth in Sections 4(e) and 4(g)) (the &#147;<B>Series&nbsp;D/E Ratchet Amount</B>&#148;), in the event this
Corporation shall issue Additional Shares of Common (including Additional Shares of Common deemed
to be issued pursuant to Section&nbsp;4(d)(iii)) for a consideration per share less than the applicable
Conversion Price of the Series&nbsp;E Preferred Stock in effect on the date of and immediately prior to
such issue, but for a consideration per share equal to or greater than the Series&nbsp;D/E Ratchet
Amount, then the Conversion Price of the Series&nbsp;E Preferred Stock shall be reduced concurrently
with such issue to a price (calculated to the nearest cent) equal to the per share price of the
Additional Shares of Common.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;In the event this Corporation shall issue Additional Shares of Common (including
Additional Shares of Common deemed to be issued pursuant to Section&nbsp;4(d)(iii)) without
consideration or for a consideration per share less than the Series&nbsp;D/E Ratchet Amount, then the
Conversion Price of the Series&nbsp;E Preferred Stock immediately prior to such issue shall be deemed to
be equal to the Series&nbsp;D/E Ratchet Amount (the &#147;<B>Series&nbsp;E Adjusted Conversion Price</B>&#148;), and such
Series&nbsp;E Adjusted Conversion Price shall be further reduced, concurrently with such issue, to a
price (calculated to the nearest cent) determined by multiplying such Series&nbsp;E Adjusted Conversion
Price by a fraction, the numerator of which shall be the number of shares of Common Stock
outstanding immediately prior to such issue plus the number of shares of Common Stock which the
aggregate consideration received by the Corporation for the total number of Additional Shares of
Common so issued would purchase at such Adjusted Conversion Price, and the denominator of which
shall be the number of shares of Common Stock outstanding immediately prior to such issue plus the
number of such Additional Shares of Common so issued. For the purposes of this Section
4(d)(iv)(2), all shares of Common Stock issuable upon exercise of outstanding Options or the
conversion of outstanding Convertible Securities and shares of Preferred Stock, and all Additional
Shares of Common deemed issued pursuant to Section&nbsp;4(d)(iii) hereof, shall be deemed to be
outstanding. Section&nbsp;4(d)(iv)(3) shall govern adjustments to the Conversion Price of the Series&nbsp;E
Preferred Stock after the first adjustment to the Conversion Price of the Series&nbsp;E Preferred Stock
pursuant to this Section&nbsp;4(d)(iv)(2).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;After any adjustment to the Conversion Price of the Series&nbsp;E Preferred Stock pursuant to
Section&nbsp;4(d)(iv)(2), in the event this Corporation shall issue Additional Shares of Common
(including Additional Shares of Common deemed to be issued pursuant to Section&nbsp;4(d)(iii)) without
consideration or for a consideration per share less than Conversion Price of the Series&nbsp;E Preferred
Stock in effect on the date of and immediately prior to such issue, then, the Conversion Price of
the Series&nbsp;E Preferred Stock shall be reduced concurrently with such issue, to a price (calculated
to the nearest cent) determined by multiplying such Conversion Price by a fraction, the numerator
of which shall be the number of shares of Common Stock outstanding immediately prior to such issue
plus the number of shares of Common Stock which the aggregate consideration received by the
Corporation for the total number of Additional Shares of Common so issued would purchase at such
Conversion Price, and the denominator of which shall be the number of shares of Common Stock
outstanding immediately prior to such issue plus the number of such Additional Shares of Common so
issued. For the purposes of this Section&nbsp;4(d)(iv)(3), all shares of Common
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-12-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Stock issuable upon exercise of outstanding Options or the conversion of outstanding
Convertible Securities and shares of Preferred Stock, and all Additional Shares of Common deemed
issued pursuant to Section&nbsp;4(d)(iii) hereof, shall be deemed to be outstanding.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;<U>Adjustment of Conversion Price of Series&nbsp;D Preferred Stock Upon Issuance of Additional
Shares of Common</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;For so long as the Conversion Price of the Series&nbsp;D Preferred Stock is greater than the
Series&nbsp;D/E Ratchet Amount, in the event this Corporation shall issue Additional Shares of Common
(including Additional Shares of Common deemed to be issued pursuant to Section&nbsp;4(d)(iii)) for a
consideration per share less than the applicable Conversion Price of the Series&nbsp;D Preferred Stock
in effect on the date of and immediately prior to such issue, but for a consideration per share
equal to or greater than the Series&nbsp;D/E Ratchet Amount, then the Conversion Price of the Series&nbsp;D
Preferred Stock shall be reduced concurrently with such issue to a price (calculated to the nearest
cent) equal to the per share price of the Additional Shares of Common.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;In the event this Corporation shall issue Additional Shares of Common (including
Additional Shares of Common deemed to be issued pursuant to Section&nbsp;4(d)(iii)) without
consideration or for a consideration per share less than the Series&nbsp;D/E Ratchet Amount, then the
Conversion Price of the Series&nbsp;D Preferred Stock immediately prior to such issue shall be deemed to
be equal to the Series&nbsp;D/E Ratchet Amount (the &#147;<B>Series&nbsp;D Adjusted Conversion Price</B>&#148;), and such
Series&nbsp;D Adjusted Conversion Price shall be further reduced, concurrently with such issue, to a
price (calculated to the nearest cent) determined by multiplying such Series&nbsp;D Adjusted Conversion
Price by a fraction, the numerator of which shall be the number of shares of Common Stock
outstanding immediately prior to such issue plus the number of shares of Common Stock which the
aggregate consideration received by the Corporation for the total number of Additional Shares of
Common so issued would purchase at such Series&nbsp;D Adjusted Conversion Price, and the denominator of
which shall be the number of shares of Common Stock outstanding immediately prior to such issue
plus the number of such Additional Shares of Common so issued. For the purposes of this Section
4(d)(v)(2), all shares of Common Stock issuable upon exercise of outstanding Options or the
conversion of outstanding Convertible Securities and shares of Preferred Stock, and all Additional
Shares of Common deemed issued pursuant to Section&nbsp;4(d)(iii) hereof, shall be deemed to be
outstanding. Section&nbsp;4(d)(v)(3) shall govern adjustments to the Conversion Price of the Series&nbsp;D
Preferred Stock after the first adjustment to the Conversion Price of the Series&nbsp;D Preferred Stock
pursuant to this Section&nbsp;4(d)(v)(2).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;After any adjustment to the Conversion Price of the Series&nbsp;D Preferred Stock pursuant to
Section&nbsp;4(d)(v)(2), in the event this Corporation shall issue Additional Shares of Common
(including Additional Shares of Common deemed to be issued pursuant to Section&nbsp;4(d)(iii)) without
consideration or for a consideration per share less than Conversion Price of the Series&nbsp;D Preferred
Stock in effect on the date of and immediately prior to such issue, then, the Conversion Price of
the Series&nbsp;D Preferred Stock shall be reduced concurrently with such issue, to a price (calculated
to the nearest cent) determined by multiplying such Conversion Price by a fraction, the numerator
of which shall be the number of shares of Common Stock outstanding immediately prior to such issue
plus the number of shares of Common Stock which the aggregate consideration received by the
Corporation for the total number of Additional Shares of Common so issued would purchase at such
Conversion Price, and the denominator of which shall be the number of shares of
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-13-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Common Stock outstanding immediately prior to such issue plus the number of such Additional
Shares of Common so issued. For the purposes of this Section&nbsp;4(d)(v)(3), all shares of Common
Stock issuable upon exercise of outstanding Options or the conversion of outstanding Convertible
Securities and shares of Preferred Stock, and all Additional Shares of Common deemed issued
pursuant to Section&nbsp;4(d)(iii) hereof, shall be deemed to be outstanding.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)&nbsp;<U>Adjustment of Conversion Price of Series&nbsp;A, B and C Preferred Stock</U>. In the
event this Corporation shall issue Additional Shares of Common (including Additional Shares of
Common deemed to be issued pursuant to Section&nbsp;4(d)(iii)) without consideration or for a
consideration per share less than the applicable Conversion Price of the Series&nbsp;A Preferred Stock,
Series&nbsp;B Preferred Stock or Series&nbsp;C Preferred Stock in effect on the date of and immediately prior
to such issue, then, the Conversion Price of the Series&nbsp;A Preferred Stock, Series&nbsp;B Preferred Stock
or Series&nbsp;C Preferred Stock (if affected) shall be reduced, concurrently with such issue, to a
price (calculated to the nearest cent) determined by multiplying such Conversion Price by a
fraction, the numerator of which shall be the number of shares of Common Stock outstanding
immediately prior to such issue plus the number of shares of Common Stock which the aggregate
consideration received by the Corporation for the total number of Additional Shares of Common so
issued would purchase at such Conversion Price, and the denominator of which shall be the number of
shares of Common Stock outstanding immediately prior to such issue plus the number of such
Additional Shares of Common so issued. For the purposes of this Section&nbsp;4(d)(vi), all shares of
Common Stock issuable upon exercise of outstanding Options or the conversion of outstanding
Convertible Securities and shares of Preferred Stock, and all Additional Shares of Common deemed
issued pursuant to Section&nbsp;4(d)(iii) hereof, shall be deemed to be outstanding.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)&nbsp;<U>Determination of Consideration</U>. For purposes of this Section&nbsp;4(d), the
consideration received by the Corporation for the issue (or deemed issue) of any Additional Shares
of Common shall be computed as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;<U>Cash and Property</U>. Such consideration shall:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)&nbsp;insofar as it consists of cash, be computed at the aggregate amount of cash received by
the Corporation before deducting reasonable discounts, commissions or other expenses allowed, paid
or incurred by the Corporation for any underwriting or otherwise in connection with such issue (or
deemed issue);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)&nbsp;insofar as it consists of property other than cash, be computed at the fair market value
thereof at the time of such issue, as determined in good faith by the Board of Directors; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)&nbsp;in the event Additional Shares of Common are issued together with other shares or
securities or other assets of the Corporation for consideration which covers both, be the
proportion of such consideration so received, computed as provided in clauses (A)&nbsp;and (B)&nbsp;above, as
reasonably determined in good faith by the Board of Directors.
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-14-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;<U>Options and Convertible Securities</U>. The consideration per share received by the
Corporation for Additional Shares of Common deemed to have been issued pursuant to Section
4(d)(iii) shall be determined by dividing
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(X)&nbsp;the total amount, if any, received or receivable by the Corporation as consideration for
the issue of such Options or Convertible Securities, plus the minimum aggregate amount of
additional consideration (as set forth in the instruments relating thereto, without regard to any
provision contained therein for a subsequent adjustment of such consideration) payable to the
Corporation upon the exercise of such Options or the conversion or exchange of such Convertible
Securities, or in the case of Options for Convertible Securities, the exercise of such Options for
Convertible Securities and the conversion or exchange of such Convertible Securities by
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Y)&nbsp;the maximum number of shares of Common Stock (as set forth in the instruments relating
thereto, without regard to any provision contained therein for a subsequent adjustment of such
number) issuable upon the exercise of such Options or the conversion or exchange of such
Convertible Securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Adjustments for Subdivisions or Combinations of Common Stock</U>. In the event the
outstanding shares of Common Stock shall be subdivided (by stock split, by payment of a stock
dividend or otherwise), into a greater number of shares of Common Stock, the Conversion Price of
each series of Preferred Stock in effect immediately prior to such subdivision shall, concurrently
with the effectiveness of such subdivision, be proportionately decreased. In the event the
outstanding shares of Common Stock shall be combined (by reclassification or otherwise) into a
lesser number of shares of Common Stock, the Conversion Prices in effect immediately prior to such
combination shall, concurrently with the effectiveness of such combination, be proportionately
increased.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U>Adjustments for Subdivisions or Combinations of Preferred Stock</U>. In the event the
outstanding shares of Preferred Stock or a series of Preferred Stock shall be subdivided (by stock
split, by payment of a stock dividend or otherwise), into a greater number of shares of Preferred
Stock, the Dividend Rate, Original Issue Price and Liquidation Preference of the affected series of
Preferred Stock in effect immediately prior to such subdivision shall, concurrently with the
effectiveness of such subdivision, be proportionately decreased. In the event the outstanding
shares of Preferred Stock or a series of Preferred Stock shall be combined (by reclassification or
otherwise) into a lesser number of shares of Preferred Stock, the Dividend Rate, Original Issue
Price and Liquidation Preference of the affected series of Preferred Stock in effect immediately
prior to such combination shall, concurrently with the effectiveness of such combination, be
proportionately increased.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <U>Adjustments for Reclassification, Exchange and Substitution</U>. Subject to Section&nbsp;3
above (&#147;<B>Liquidation Rights</B>&#148;), if the Common Stock issuable upon conversion of the Preferred Stock
shall be changed into the same or a different number of shares of any other class or classes of
stock, whether by capital reorganization, reclassification or otherwise (other than a subdivision
or combination of shares provided for above), then, in any such event, in lieu of the number of
shares of Common Stock which the holders would otherwise have been entitled to receive, each holder
of such Preferred Stock shall have the right thereafter to convert such shares of
</DIV>


<P align="right" style="font-size: 10pt"><!-- Folio -->-15-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Preferred Stock into a
number of shares of such other class or classes of stock which a holder of the number of
shares of Common Stock deliverable upon conversion of such series of Preferred Stock immediately
before that change would have been entitled to receive in such reorganization or reclassification,
all subject to further adjustment as provided herein with respect to such other shares.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <U>No Impairment</U>. The Corporation will not through any reorganization, transfer of
assets, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or
seek to avoid the observance or performance of any of the terms to be observed or performed
hereunder by the Corporation but will at all times in good faith assist in the carrying out of all
the provisions of this Section&nbsp;4 and in the taking of all such action as may be necessary or
appropriate in order to protect the Conversion Rights of the holders of Preferred Stock against
impairment. Notwithstanding the foregoing, nothing in this Section 4(h) shall prohibit the
Corporation from amending its Certificate of Incorporation with the requisite consent of its
stockholders and the board of directors.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <U>Certificate as to Adjustments</U>. Upon the occurrence of each adjustment or
readjustment of the Conversion Price pursuant to this Section&nbsp;4, the Corporation at its expense
shall promptly compute such adjustment or readjustment in accordance with the terms hereof and
furnish to each holder of Preferred Stock a certificate setting forth such adjustment or
readjustment and showing in detail the facts upon which such adjustment or readjustment is based.
The Corporation shall, upon the written request at any time of any holder of Preferred Stock,
furnish or cause to be furnished to such holder a like certificate setting forth (i)&nbsp;such
adjustments and readjustments, (ii)&nbsp;the Conversion Price at the time in effect and (iii)&nbsp;the number
of shares of Common Stock and the amount, if any, of other property which at the time would be
received upon the conversion of Preferred Stock.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) <U>Notices of Record Date</U>. In the event that this Corporation shall propose at any
time:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;to declare any dividend or distribution upon its Common Stock, whether in cash, property,
stock or other securities, whether or not a regular cash dividend and whether or not out of
earnings or earned surplus;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;to effect any reclassification or recapitalization of its Common Stock outstanding
involving a change in the Common Stock; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;to voluntarily liquidate or dissolve or to enter into any transaction deemed to be a
liquidation, dissolution or winding up of the corporation pursuant to Section&nbsp;3(h);
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">then, in connection with each such event, this Corporation shall send to the holders of the
Preferred Stock at least 14&nbsp;days&#146; prior written notice of the date on which a record shall be taken
for such dividend or distribution (and specifying the date on which the holders of Common Stock
shall be entitled thereto) or for determining rights to vote in respect of the matters referred to
in (ii)&nbsp;and (iii)&nbsp;above.
</DIV>


<P align="right" style="font-size: 10pt"><!-- Folio -->-16-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each such written notice shall be given by first class mail, postage prepaid, addressed to the
holders of Preferred Stock at the address for each such holder as shown on the books of this
Corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The right of the holders of the Preferred Stock to notice hereunder may be waived by the
holders of more than two-thirds (<FONT style="font-size: 70%"><SUP>2</SUP></FONT>/<FONT style="font-size: 60%">3</FONT>) of the outstanding shares of the Preferred Stock voting
together as a single class.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) <U>Reservation of Stock Issuable Upon Conversion</U>. The Corporation shall at all times
reserve and keep available out of its authorized but unissued shares of Common Stock solely for the
purpose of effecting the conversion of the shares of the Preferred Stock, such number of its shares
of Common Stock as shall from time to time be sufficient to effect the conversion of all then
outstanding shares of the Preferred Stock; and if at any time the number of authorized but unissued
shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding
shares of the Preferred Stock, the Corporation will take such corporate action as may, in the
opinion of its counsel, be necessary to increase its authorized but unissued shares of Common Stock
to such number of shares as shall be sufficient for such purpose.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) <U>Waiver of Adjustment of Conversion Price</U>. Notwithstanding anything herein to the
contrary, any downward adjustment of the Conversion Price of any series of Preferred Stock may be
waived by the consent or vote of the holders of more than two-thirds (
<FONT style="font-size: 70%"><SUP>2</SUP></FONT>/<FONT style="font-size: 60%">3</FONT>
) of the outstanding shares
of such series. Any such waiver shall bind all future holders of shares of such series of
Preferred Stock.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Voting</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Restricted Class&nbsp;Voting</U>. Except as otherwise expressly provided herein or as
required by law, the holders of Preferred Stock and the holders of Common Stock shall vote together
and not as separate classes.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>No Series&nbsp;Voting</U>. Other than as provided herein or required by law, there shall
be no series voting.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Preferred Stock</U>. Each holder of Preferred Stock shall be entitled to the number
of votes equal to the number of shares of Common Stock into which the shares of Preferred Stock
held by such holder could be converted as of the record date. The holders of shares of the
Preferred Stock shall be entitled to vote on all matters on which the Common Stock shall be
entitled to vote. Holders of Preferred Stock shall be entitled to notice of any stockholders&#146;
meeting in accordance with the Bylaws of the Corporation. Fractional votes shall not, however, be
permitted and any fractional voting rights resulting from the above formula (after aggregating all
shares into which shares of Preferred Stock held by each holder could be converted), shall be
disregarded.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Common Stock</U>. Each holder of shares of Common Stock shall be entitled to one vote
for each share thereof held.
</DIV>


<P align="right" style="font-size: 10pt"><!-- Folio -->-17-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Adjustment in Authorized Common Stock</U>. The number of authorized shares of Common
Stock may be increased or decreased (but not below the number of shares of Common Stock then
outstanding) by an affirmative vote of the holders of a majority of the outstanding Common Stock
and Preferred Stock, voting together as a single class.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U>Election of Directors</U>. So long as at least 2,000,000 shares of Series&nbsp;D Preferred
Stock (as adjusted for stock splits, subdivisions, combinations or stock dividends with respect to
such shares) remain outstanding, the holders of the Series&nbsp;D Preferred Stock, voting as a separate
class, shall be entitled to elect two (2)&nbsp;members of the Corporation&#146;s Board of Directors at each
meeting or pursuant to each consent of the Corporation&#146;s stockholders for the election of
directors. So long as at least 2,000,000 shares of Series&nbsp;C Preferred Stock (as adjusted for stock
splits, subdivisions, combinations or stock dividends with respect to such shares) remain
outstanding, the holders of Series&nbsp;C Preferred Stock, voting as a separate class, shall be entitled
to elect three (3)&nbsp;members of the Corporation&#146;s Board of Directors at each meeting or pursuant to
each consent of the Corporation&#146;s stockholders for the election of directors. Any additional
members of the Corporation&#146;s Board of Directors shall be elected by the holders of Common Stock,
Series&nbsp;A Preferred Stock, Series&nbsp;B Preferred Stock, and Series&nbsp;E Preferred Stock, voting together
as a single class.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Amendments and Changes Requiring Approval of Preferred Stock</U>. As long as any of
the Preferred Stock shall be issued and outstanding, the Corporation shall not, without first
obtaining the approval (by vote or written consent as provided by law) of the holders of at least
two-thirds (<FONT style="font-size: 70%"><SUP>2</SUP></FONT>/<FONT style="font-size: 60%">3</FONT>) of the outstanding shares of the Preferred Stock voting together as a single class:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;amend, alter or repeal any provision of the Certificate of Incorporation or By-laws of the
Corporation if such action would adversely alter the rights, preferences, privileges or powers of,
or restrictions provided for the benefit of the Preferred Stock or any series thereof;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;enter into any transaction or series of related transactions deemed to be a liquidation,
dissolution or winding up of the Corporation pursuant to Section 3(h) above;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;voluntarily liquidate or dissolve;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;declare or pay any distribution (as defined in Section 2(d) except for distributions upon
a liquidation or dissolution) with respect to the Common Stock of the Corporation;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;permit any subsidiary of the Corporation to sell securities to a third party (other than
directors&#146; qualifying shares in the case of subsidiaries outside the United States);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;increase or decrease (other than for decreases resulting from conversion of the Preferred
Stock) the authorized number of shares of Preferred Stock;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;authorize or create (by reclassification or otherwise) any new class or series of capital
stock having rights, preferences or privileges with respect to dividends, liquidation, redemption,
conversion or other rights senior to or on a parity with any series of Preferred Stock or with
respect to voting senior to any series of Preferred Stock;
</DIV>


<P align="right" style="font-size: 10pt"><!-- Folio -->-18-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;increase or decrease the authorized number of directors of the Corporation; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;amend this Section&nbsp;6.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Amendments and Changes Requiring the Approval of the Series&nbsp;E Preferred Stock</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;As long as any of the Series&nbsp;E Preferred Stock shall be issued and outstanding, the
Corporation shall not, without first obtaining the approval (by vote or written consent as provided
by law) of the holders of at least 60% of the outstanding shares of the Series&nbsp;E Preferred Stock:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;amend, alter or repeal any provision of the Certificate of Incorporation of the
Corporation if such action would adversely alter the rights, preferences, privileges or powers of,
or restrictions provided for the benefit of the Series&nbsp;E Preferred Stock in a manner different from
any other series of Preferred Stock; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;amend this Section&nbsp;7(a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;As long as any of the Series&nbsp;E Preferred Stock shall be issued and outstanding, the
Corporation shall not, without first obtaining the approval (by vote or written consent as provided
by law) of the holders of at least a majority of the outstanding shares of the Series&nbsp;E Preferred
Stock:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;declare or pay any distribution (as defined in Section 2(d) except for distributions upon
a liquidation or dissolution) with respect to the Common Stock or Preferred Stock of the
Corporation; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;amend this Section&nbsp;7(b).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;As long as any of the Series&nbsp;E Preferred Stock shall be issued and outstanding, the
Corporation shall not, without first obtaining the approval (by vote or written consent as provided
by law) of the holders of at least 66 2/3% of the outstanding shares of the Series&nbsp;D Preferred
Stock and Series&nbsp;E Preferred Stock voting together as a single class on an as converted to Common
Stock basis:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;increase or decrease (other than for decreases resulting from conversion of the Preferred
Stock) the authorized number of shares of Series&nbsp;E Preferred Stock;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;authorize or create (by reclassification or otherwise) any new class or series of capital
stock having rights, preferences or privileges with respect to dividends, payments upon liquidation
or other rights senior to or on a parity with the Series&nbsp;E Preferred Stock or with respect to
voting senior to the Series&nbsp;E Preferred Stock; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;amend this Section&nbsp;7(c).
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-19-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Amendments and Changes Requiring the Approval of the Series&nbsp;D Preferred Stock</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;As long as any of the Series&nbsp;D Preferred Stock shall be issued and outstanding, the
Corporation shall not, without first obtaining the approval (by vote or written consent as provided
by law) of the holders of at least 60% of the outstanding shares of the Series&nbsp;D Preferred Stock:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;amend, alter or repeal any provision of the Certificate of Incorporation of the
Corporation if such action would adversely alter the rights, preferences, privileges or powers of,
or restrictions provided for the benefit of the Series&nbsp;D Preferred Stock in a manner different from
any other series of Preferred Stock; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;amend this Section&nbsp;8(a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;As long as any of the Series&nbsp;D Preferred Stock shall be issued and outstanding, the
Corporation shall not, without first obtaining the approval (by vote or written consent as provided
by law) of the holders of at least a majority of the outstanding shares of the Series&nbsp;D Preferred
Stock:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;increase or decrease (other than for decreases resulting from conversion of the Preferred
Stock) the authorized number of shares of Series&nbsp;D Preferred Stock;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;authorize or create (by reclassification or otherwise) any new class or series of capital
stock having rights, preferences or privileges with respect to dividends, payments upon liquidation
or other rights senior to or on a parity with the Series&nbsp;D Preferred Stock or with respect to
voting senior to the Series&nbsp;D Preferred Stock;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;declare or pay any distribution (as defined in Section 2(d) except for distributions
upon a liquidation or dissolution) with respect to the Common Stock or Preferred Stock of the
Corporation;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;increase the authorized number of directors of the Corporation above eleven (11); or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;amend this Section&nbsp;8(b).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>Amendments and Changes Requiring the Approval of the Series&nbsp;C Preferred Stock</U>. As
long as any of the Series&nbsp;C Preferred Stock shall be issued and outstanding, the Corporation shall
not, without first obtaining the approval (by vote or written consent as provided by law) of the
holders of at least two-thirds (<FONT style="font-size: 70%"><SUP>2</SUP></FONT>/<FONT style="font-size: 60%">3</FONT>) of the outstanding shares of the Series&nbsp;C Preferred Stock:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;amend, alter or repeal any provision of the Certificate of Incorporation of the
Corporation if such action would adversely alter the rights, preferences, privileges or powers of,
or restrictions provided for the benefit of the Series&nbsp;C Preferred Stock in a manner different from
any other series of Preferred Stock;
</DIV>


<P align="right" style="font-size: 10pt"><!-- Folio -->-20-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;increase or decrease (other than for decreases resulting from conversion of the Preferred
Stock) the authorized number of shares of Series&nbsp;C Preferred Stock;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;authorize or create (by reclassification or otherwise) any new class or series of capital
stock having rights, preferences or privileges with respect to dividends, payments upon liquidation
or other rights senior to or on a parity with the Series&nbsp;C Preferred Stock or with respect to
voting senior to the Series&nbsp;C Preferred Stock;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;declare or pay any distribution (as defined in Section 2(d) except for distributions upon
a liquidation or dissolution) with respect to the Common Stock or Preferred Stock of the
Corporation;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;increase the authorized number of directors of the Corporation above eleven (11); or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;amend this Section&nbsp;9.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U>Amendments and Changes Requiring the Approval of the Series&nbsp;B Preferred Stock</U>. As
long as any of the Series&nbsp;B Preferred Stock shall be issued and outstanding, the Corporation shall
not, without first obtaining the approval (by vote or written consent as provided by law) of the
holders of at least two-thirds of the outstanding shares of the Series&nbsp;B Preferred Stock:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;amend, alter or repeal any provision of the Certificate of Incorporation of the
Corporation if such action would adversely alter the rights, preferences, privileges or powers of,
or restrictions provided for the benefit of the Series&nbsp;B Preferred Stock in a manner different from
any other series of Preferred Stock;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;increase or decrease (other than for decreases resulting from conversion of the Preferred
Stock) the authorized number of shares of Series&nbsp;B Preferred Stock; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;amend this Section&nbsp;10.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<U>Status of Converted Stock.</U> In the event any shares of Preferred Stock shall be
converted pursuant to Article&nbsp;4 hereof, then the shares so converted shall be cancelled and shall
not be issuable by the Corporation. The Certificate of Incorporation shall be appropriately
amended to effect the corresponding reduction in the Corporation&#146;s authorized capital stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;<U>Notices</U>. Any notice required by the provisions of this Article&nbsp;IV to be given to
the holders of Preferred Stock shall be deemed given if deposited in the United States mail,
postage prepaid, and addressed to each holder of record at such holder&#146;s address appearing on the
books of the Corporation.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE V
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Corporation reserves the right to amend, alter, change, or repeal any provision contained
in this Certificate of Incorporation, in the manner now or hereafter prescribed by statute, and all
rights conferred upon the stockholders herein are granted subject to this right.
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-21-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE VI
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Corporation is to have perpetual existence.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE VII
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Elections of directors need not be by written ballot unless a stockholder demands election by
written ballot at the meeting and before voting begins or unless the Bylaws of the Corporation
shall so provide.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE VIII
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise set forth herein, the number of directors which constitute the Board of
Directors of the Corporation shall be designated in the Bylaws of the Corporation .
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE IX
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In furtherance and not in limitation of the powers conferred by statute, the Board of
Directors is expressly authorized to make, alter, amend or repeal the Bylaws of the Corporation.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE X
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Limitation of Directors&#146; Liability</U>. To the fullest extent permitted by the General
Corporation Law of the State of Delaware as the same exists or as may hereafter be amended, a
director of the Corporation shall not be personally liable to the Corporation or its stockholders
for monetary damages for breach of fiduciary duty as a director.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Indemnification</U>. The Corporation may indemnify to the fullest extent permitted by
law any person made or threatened to be made a party to an action or proceeding, whether criminal,
civil, administrative or investigative, by reason of the fact that such person or his or her
testator or intestate is or was a director, officer or employee of the Corporation, or any
predecessor of the Corporation, or serves or served at any other enterprise as a director, officer
or employee at the request of the Corporation or any predecessor to the Corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;Amendments. Neither any amendment nor repeal of this Article&nbsp;VII, nor the adoption of any
provision of the Corporation&#146;s Certificate of Incorporation inconsistent with this Article&nbsp;VII,
shall eliminate or reduce the effect of this Article&nbsp;VII, in respect of any matter occurring, or
any action or proceeding accruing or arising or that, but for this Article&nbsp;VII, would accrue or
arise, prior to such amendment, repeal, or adoption of an inconsistent provision.
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-22-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE XI
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Meetings of the stockholders may be held within or without the State of Delaware, as the
Bylaws may provide. The books of the Corporation may be kept (subject to any provision contained
in the statutes) outside of the State of Delaware at such place or places as may be designated from
time to time by the Board of Directors or in the Bylaws of the Corporation.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">***
</DIV>



<P align="right" style="font-size: 10pt"><!-- Folio -->-23-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="right" style="font-size: 10pt; margin-top: 12pt">State of Delaware<BR>
Secretary of State<BR>
Divisions of Corporations<BR>
Delivered 09:37 AM 10/10/2007<BR>
Filed 09:30 AM 10/10/2007<BR>
SRV 071099475 &#151; 4292717 File
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CERTIFICATE OF AMENDMENT</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>OF FLUIDIGM CORPORATION</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fluidigm Corporation, a corporation organized and existing under the laws of the State of
Delaware (the &#147;<U>Corporation</U>&#148;), hereby certifies as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A.&nbsp;The name of the corporation is Fluidigm Corporation. The original Certificate of
Incorporation of the Corporation was filed with the Secretary of State of the State of Delaware
on March&nbsp;29, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B.&nbsp;This Certificate of Amendment to Amended and Restated Certificate of Incorporation was
duly adopted in accordance with Sections&nbsp;228 and 242 of the General Corporation Law of the State
of Delaware by the Board of Directors and the stockholders of the Corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C.&nbsp;Pursuant to Section&nbsp;242 of the General Corporation Law of the State of Delaware, this
Certificate of Amendment to Amended and Restated Certificate of Incorporation amends the
provisions of this Corporation&#146;s Amended and Restated Certificate of Incorporation as set forth
herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D.&nbsp;The first paragraph of Article&nbsp;IV of the Amended and Restated Certificate of
Incorporation is hereby amended to read in its entirety as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;The total number of shares of stock that the Corporation shall have authority to issue is
143,193,229, $0.001 par value, consisting of 85,232,144 shares of Common Stock, $0.001 par value
per share (&#147;Common&#148;) and 57,961,085 shares of Preferred Stock, $0.001 par value per share
(&#147;Preferred&#148;). The Preferred shall be divided into series. The first series shall consist of
2,727,273 shares and shall be designated Series&nbsp;A Preferred Stock (&#147;Series&nbsp;A Preferred Stock&#148;).
The second series shall consist of 6,460,675 shares and shall be designated Series&nbsp;B Preferred
Stock (&#147;Series&nbsp;B Preferred Stock&#148;). The third series shall consist of 16,854,624 shares and shall
be designated Series&nbsp;C Preferred Stock (&#147;Series&nbsp;C Preferred Stock&#148;). The fourth series shall
consist of 13,962,261 shares and shall be designated Series&nbsp;D Preferred Stock (&#147;Series&nbsp;D Preferred
Stock&#148;). The fifth series shall consist of 17,956,252 shares and shall be designated Series&nbsp;E
Preferred Stock (&#147;Series&nbsp;E Preferred Stock&#148;).&#148;
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;E.&nbsp;Subsection (b)&nbsp;of Section&nbsp;4 of Article&nbsp;IV of the Amended and Restated Certificate of
Incorporation is hereby amended to read in its entirety as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;(b) <U>Automatic Conversion</U>. Each share of Preferred Stock shall automatically be
converted into fully-paid, non-assessable shares of Common Stock at the then effective Conversion
Rate for such share (i)&nbsp;immediately prior to the closing of a firm commitment underwritten initial
public offering on Form&nbsp;S 1 (or successor form) filed under the Securities Act of 1933, as amended
(the &#147;Securities Act&#148;), covering the offer and sale of the Corporation&#146;s Common Stock, provided
that the offering price per share is not less than $5.69 (as adjusted for subdivisions and
combinations of the Common Stock and changes in the Common Stock as set forth in Sections 4(e) and
4(g)) and the aggregate gross proceeds to the Corporation are not less than $25,000,000, or (ii)
upon the receipt by the Corporation of a written consent or request for such conversion from the
holders of two-thirds of the shares of Preferred Stock then outstanding, or, if later, the
effective date for conversion specified in such requests (each of the events referred to in (i)&nbsp;and
(ii)&nbsp;being hereinafter referred to as an &#147;Automatic Conversion Event&#148;). <U>Notwithstanding the
foregoing, the Series&nbsp;E Preferred Stock shall not be subject to an Automatic Conversion Event
unless either (x)&nbsp;such Automatic Conversion Event is approved by the written consent of holders of
more than two-thirds of the shares of Series&nbsp;E Preferred Stock then outstanding, or (y)&nbsp;such
Automatic Conversion Event is the closing of a firm commitment underwritten initial public offering
on Form S-1 (or successor form) filed under the Securities Act and the requirements of Section
4(b)(i) or 4(b)(ii) are met</U>.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;F.&nbsp;The last paragraph of Subsection (j)&nbsp;of Section&nbsp;4 of Article&nbsp;IV of the Amended and Restated
Certificate of Incorporation is hereby amended to read in its entirety as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;The right of the holders of the Preferred Stock to notice hereunder may be waived by the
holders of more than two-thirds (<FONT style="font-size: 70%"><SUP>2</SUP></FONT>/<FONT style="font-size: 60%">3</FONT>) of the outstanding shares of the Preferred Stock voting
together as a single class. <U>Notwithstanding the foregoing, no waiver of notice under this
Section 4(j) shall constitute a waiver of notice with respect to the Series&nbsp;E Preferred Stock
unless such waiver shall have been approved by the written consent of holders of more than
two-thirds (<FONT style="font-size: 70%"><SUP>2</SUP></FONT>/<FONT style="font-size: 60%">3</FONT>) of the shares of Series&nbsp;E Preferred Stock then outstanding</U>.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;G.&nbsp;Subsection (a)&nbsp;of Section&nbsp;6 of Article&nbsp;IV of the Amended and Restated Certificate of
Incorporation is hereby amended to read in its entirety as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;(a) amend, alter or repeal any provision of the Certificate of Incorporation or By-laws of
the Corporation (including pursuant to a merger) if such action would adversely alter the rights,
preferences, privileges or powers of, or restrictions provided for the benefit of the Preferred
Stock or any series thereof;&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;H.&nbsp;Subsection (g)&nbsp;of Section&nbsp;6 of Article&nbsp;IV of the Amended and Restated Certificate of
Incorporation is hereby amended to read in its entirety as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;(g) authorize or create (by reclassification, merger or otherwise) any new class or series of
capital stock having rights, preferences or privileges with respect to dividends, liquidation,
redemption, conversion or other rights senior to or on a parity with any series of Preferred Stock
or with respect to voting senior to any series of Preferred Stock;&#148;
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I.&nbsp;Subsection (a)(i) of Section&nbsp;7 of Article&nbsp;IV of the Amended and Restated Certificate of
Incorporation is hereby amended to read in its entirety as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;(i) amend, alter or repeal any provision of the Certificate of Incorporation of the
Corporation (including pursuant to a merger) if such action would adversely alter the rights,
preferences, privileges or powers of, or restrictions provided for the benefit of the Series&nbsp;E
Preferred Stock in a manner different from any other series of Preferred Stock; or&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;J.&nbsp;Subsection (c)(ii) of Section&nbsp;7 of Article&nbsp;IV of the Amended and Restated Certificate of
Incorporation is hereby amended to read in its entirety as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;(ii) authorize or create (by reclassification, merger or otherwise) any new class or series
of capital stock having rights, preferences or privileges with respect to dividends, payments upon
liquidation or other rights senior to or on a parity with the Series&nbsp;E Preferred Stock or with
respect to voting senior to the Series&nbsp;E Preferred Stock; or&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, Fluidigm Corporation has caused this Certificate of Amendment to Amended
and Restated Certificate of Incorporation to be signed by Gajus V. Worthington, a duly authorized
officer of the Corporation, on October&nbsp;9, 2007.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">                                                   /s/ Gajus Worthington
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Gajus V. Worthington&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">President &#038; Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="right" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">State of Delaware<BR>
Secretary of State<BR>
Divisions of Corporations<BR>
Delivered 09:08 AM 10/26/2007<BR>
Filed 08:56 AM 10/26/2007<BR>
SRV 071157559 &#151; 4292717 File
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CERTIFICATE OF AMENDMENT</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>OF FLUIDIGM CORPORATION</B>

</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fluidigm Corporation, a corporation organized and existing under the laws of the State of
Delaware (the &#147;<U>Corporation</U>&#148;), hereby certifies as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A.&nbsp;The name of the corporation is Fluidigm Corporation. The original Certificate of
Incorporation of the Corporation was filed with the Secretary of State of the State of Delaware
on March&nbsp;29, 2007. An Amended and Restated Certificate of Incorporation was filed with the
Secretary of State of the State of Delaware on July&nbsp;16, 2007, and a Certificate of Amendment to
Amended and Restated Certificate of Incorporation was filed with the Secretary of State of the
State of Delaware on October&nbsp;10, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B.&nbsp;This Certificate of Amendment to Amended and Restated Certificate of Incorporation was
duly adopted in accordance with Sections&nbsp;228 and 242 of the General Corporation Law of the State
of Delaware by the Board of Directors and the stockholders of the Corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C.&nbsp;Pursuant to Section&nbsp;242 of the General Corporation Law of the State of Delaware, this
Certificate of Amendment to Amended and Restated Certificate of Incorporation amends the
provisions of this Corporation&#146;s Amended and Restated Certificate of Incorporation as set forth
herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D.&nbsp;The first paragraph of Article&nbsp;IV of the Amended and Restated Certificate of
Incorporation is hereby amended to read in its entirety as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;The total number of shares of stock that the Corporation shall have authority to issue is
147,500,619, $0.001 par value, consisting of 87,385,839 shares of Common Stock, $0.001 par value
per share (&#147;Common&#148;) and 60,114,780 shares of Preferred Stock, $0.001 par value per share
(&#147;Preferred&#148;). The Preferred shall be divided into series. The first series shall consist of
2,727,273 shares and shall be designated Series&nbsp;A Preferred Stock (&#147;Series&nbsp;A Preferred Stock&#148;).
The second series shall consist of 6,460,675 shares and shall be designated Series&nbsp;B Preferred
Stock (&#147;Series&nbsp;B Preferred Stock&#148;). The third series shall consist of 16,854,624 shares and shall
be designated Series&nbsp;C Preferred Stock (&#147;Series&nbsp;C Preferred Stock&#148;). The fourth series shall
consist of 13,962,261 shares and shall be designated Series&nbsp;D Preferred Stock (&#147;Series&nbsp;D Preferred
Stock&#148;). The fifth series shall consist of 20,109,947 shares and shall be designated Series&nbsp;E
Preferred Stock (&#147;Series&nbsp;E Preferred Stock&#148;).&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, Fluidigm Corporation has caused this Certificate of Amendment to Amended
and Restated Certificate of Incorporation to be signed by Gajus V. Worthington, a duly authorized
officer of the Corporation, on October&nbsp;24, 2007.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">                                                   /s/ Gajus V. Worthington
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Gajus V. Worthington&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">President &#038; Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="right" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.3
<SEQUENCE>3
<FILENAME>f39432orexv3w3.htm
<DESCRIPTION>EXHIBIT 3.3
<TEXT>
<HTML>
<HEAD>
<TITLE>exv3w3</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;3.3</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>BYLAWS OF</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>FLUIDIGM CORPORATION</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">(a Delaware corporation)

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>As Adopted by the Sole Incorporator on March&nbsp;29, 2007<BR>
As Ratified by the Sole Director on April&nbsp;30, 2007</B>

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><b>Page</b></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">ARTICLE I &#151; MEETINGS OF STOCKHOLDERS</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">1.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Place of Meetings</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">1.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Annual Meeting</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">1.3
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Special Meeting</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">1.4
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Notice of Stockholders&#146; Meetings</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">1.5
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Quorum</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">1.6
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Adjourned Meeting; Notice</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">1.7
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Conduct of Business</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">1.8
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Voting</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">1.9
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Stockholder Action by Written Consent Without a Meeting</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">1.10
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Record Date for Stockholder Notice; Voting; Giving Consents</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">1.11
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Proxies</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">1.12
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>List of Stockholders Entitled to Vote</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">ARTICLE II &#151; DIRECTORS</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Powers</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Number of Directors</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2.3
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Election, Qualification and Term of Office of Directors</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">6</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2.4
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Resignation and Vacancies</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">6</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2.5
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Place of Meetings; Meetings by Telephone</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">7</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2.6
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Conduct of Business</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">7</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2.7
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Regular Meetings</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">7</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2.8
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Special Meetings; Notice</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">7</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2.9
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Quorum; Voting</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2.10
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Board Action by Written Consent Without a Meeting</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2.11
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Fees and Compensation of Directors</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2.12
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Removal of Directors</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">ARTICLE III &#151; COMMITTEES</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">9</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">3.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Committees of Directors</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">9</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">3.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Committee Minutes</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">9</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">3.3
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Meetings and Actions of Committees</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">9</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">3.4
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Subcommittees</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">10</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">ARTICLE IV &#151; OFFICERS</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">10</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Officers</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">10</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Appointment of Officers</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">10</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.3
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Subordinate Officers</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">10</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.4
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Removal and Resignation of Officers</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">10</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.5
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Vacancies in Offices</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">10</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS<BR>
(Continued)</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><b>Page</b></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.6
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Representation of Shares of Other Corporations</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">10</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.7
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Authority and Duties of Officers</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">11</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">ARTICLE V &#151; INDEMNIFICATION</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">11</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">5.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Indemnification of Directors and Officers in Third Party Proceedings</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">11</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">5.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Indemnification of Directors and Officers in Actions by or in the Right
of the Company </I></B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">11</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">5.3
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Successful Defense</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">5.4
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Indemnification of Others</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">5.5
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Advanced Payment of Expenses</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">5.6
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Limitation on Indemnification and Advancement of Expenses</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">5.7
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Determination; Claim</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">5.8
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Non-Exclusivity of Rights</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">5.9
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Insurance</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">5.10
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Survival</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">5.11
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Effect of Repeal or Modification</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">5.12
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Certain Definitions</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">ARTICLE VI &#151; STOCK</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">6.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Stock Certificates; Partly Paid Shares</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">6.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Special Designation on Certificates</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">6.3
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Lost Certificates</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">6.4
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Dividends</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">6.5
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Stock Transfer Agreements</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">6.6
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Registered Stockholders</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">6.7
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Transfers</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">ARTICLE VII &#151; MANNER OF GIVING NOTICE AND WAIVER</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">7.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Notice of Stockholder Meetings</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">7.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Notice by Electronic Transmission</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">7.3
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Notice to Stockholders Sharing an Address</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">16</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">7.4
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Notice to Person with Whom Communication is Unlawful</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">17</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">7.5
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Waiver of Notice</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">17</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">ARTICLE VIII &#151; GENERAL MATTERS</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">17</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">8.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Fiscal Year</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">17</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">8.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Seal</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">17</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">8.3
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Annual Report</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">17</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">8.4
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><I>Construction; Definitions</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">18</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">ARTICLE IX &#151; AMENDMENTS</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">18</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="right" style="font-size: 10pt"><!-- Folio -->-ii-<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>BYLAWS</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>ARTICLE I &#151; MEETINGS OF STOCKHOLDERS</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 <B><I>Place of Meetings</I></B>. Meetings of stockholders of Fluidigm Corporation (the &#147;<B>Company</B>&#148;) shall be held at any
place, within or outside the State of Delaware, determined by the Company&#146;s board of directors (the
&#147;<B>Board</B>&#148;). The Board may, in its sole discretion, determine that a meeting of stockholders shall not
be held at any place, but may instead be held solely by means of remote communication as authorized
by Section&nbsp;211(a)(2) of the Delaware General Corporation Law (the &#147;<B>DGCL</B>&#148;). In the absence of any
such designation or determination, stockholders&#146; meetings shall be held at the Company&#146;s principal
executive office.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2 <B><I>Annual Meeting</I></B>. An annual meeting of stockholders shall be held for the election of directors at such date
and time as may be designated by resolution of the Board from time to time. Any other proper
business may be transacted at the annual meeting. The Company shall not be required to hold an
annual meeting of stockholders, <I>provided </I>that (i)&nbsp;the stockholders are permitted to act by written
consent under the Company&#146;s certificate of incorporation and these bylaws, (ii)&nbsp;the stockholders
take action by written consent to elect directors and (iii)&nbsp;the stockholders unanimously consent to
such action or, if such consent is less than unanimous, all of the directorships to which directors
could be elected at an annual meeting held at the effective time of such action are vacant and are
filled by such action.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3 <B><I>Special Meeting</I></B>. A special meeting of the stockholders may be called at any time by the Board, Chairperson
of the Board, Chief Executive Officer or President (in the absence of a Chief Executive Officer) or
by one or more stockholders holding shares in the aggregate entitled to cast not less than 10% of
the votes at that meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any person(s) other than the Board calls a special meeting, the request shall:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;be in writing;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;specify the time of such meeting and the general nature of the business proposed to be
transacted; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;be delivered personally or sent by registered mail or by facsimile transmission to the
Chairperson of the Board, the Chief Executive Officer, the President (in the absence of a Chief
Executive Officer) or the Secretary of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The officer(s) receiving the request shall cause notice to be promptly given to the
stockholders entitled to vote at such meeting, in accordance with these bylaws, that a meeting will
be held at the time requested by the person or persons calling the meeting. No business may be
transacted at such special meeting other than the business specified in such notice to
stockholders. Nothing contained in this paragraph of this <B>section 1.3 </B>shall be construed as
limiting, fixing, or affecting the time when a meeting of stockholders called by action of the
Board may be held.
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-1-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.4 <B><I>Notice of Stockholders&#146; Meetings</I></B>. Whenever stockholders are required or permitted to take any action at a meeting, a written
notice of the meeting shall be given which shall state the place, if any, date and hour of the
meeting, the means of remote communication, if any, by which stockholders and proxy holders may be
deemed to be present in person and vote at such meeting, and, in the case of a special meeting, the
purpose or purposes for which the meeting is called. Except as otherwise provided in the DGCL, the
certificate of incorporation or these bylaws, the written notice of any meeting of stockholders
shall be given not less than 10 nor more than 60&nbsp;days before the date of the meeting to each
stockholder entitled to vote at such meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.5 <B><I>Quorum</I></B>. Except as otherwise provided by law, the certificate of incorporation or these bylaws, at
each meeting of stockholders the presence in person or by proxy of the holders of shares of stock
having a majority of the votes which could be cast by the holders of all outstanding shares of
stock entitled to vote at the meeting shall be necessary and sufficient to constitute a quorum. If,
however, such quorum is not present or represented at any meeting of the stockholders, then either
(i)&nbsp;the chairperson of the meeting, or (ii)&nbsp;the stockholders entitled to vote at the meeting,
present in person or represented by proxy, shall have the power to adjourn the meeting from time to
time, in the manner provided in <B>section 1.6</B>, until a quorum is present or represented.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.6 <B><I>Adjourned Meeting; Notice</I></B>. Any meeting of stockholders, annual or special, may adjourn from time to time to reconvene
at the same or some other place, and notice need not be given of the adjourned meeting if the time,
place, if any, thereof, and the means of remote communications, if any, by which stockholders and
proxy holders may be deemed to be present in person and vote at such adjourned meeting are
announced at the meeting at which the adjournment is taken. At the adjourned meeting, the Company
may transact any business which might have been transacted at the original meeting. If the
adjournment is for more than 30&nbsp;days, or if after the adjournment a new record date is fixed for
the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of
record entitled to vote at the meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.7 <B><I>Conduct of Business</I></B>. Meetings of stockholders shall be presided over by the Chairperson of the Board, if any, or
in his or her absence by the Vice Chairperson of the Board, if any, or in the absence of the
foregoing persons by the Chief Executive Officer, or in the absence of the foregoing persons by the
President, or in the absence of the foregoing persons by a Vice President, or in the absence of the foregoing
persons by a chairperson designated by the Board, or in the absence of such designation by a
chairperson chosen at the meeting. The Secretary shall act as secretary of the meeting, but in his
or her absence the chairperson of the meeting may appoint any person to act as secretary of the
meeting. The chairperson of any meeting of stockholders shall determine the order of business and
the procedure at the meeting, including such regulation of the manner of voting and the conduct of
business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.8 <B><I>Voting</I></B>. The stockholders entitled to vote at any meeting of stockholders shall be determined in
accordance with the provisions of <B>section 1.10 </B>of these bylaws, subject to Section&nbsp;217 (relating to
voting rights of fiduciaries, pledgors and joint owners of stock) and Section&nbsp;218 (relating to
voting trusts and other voting agreements) of the DGCL.
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as may be otherwise provided in the certificate of incorporation, each stockholder
entitled to vote at any meeting of stockholders shall be entitled to one vote for each share of
capital stock held by such stockholder which has voting power upon the matter in question. Voting
at meetings of stockholders need not be by written ballot and, unless otherwise required by law,
need not be conducted by inspectors of election unless so determined by the holders of shares of
stock having a majority of the votes which could be cast by the holders of all outstanding shares
of stock entitled to vote thereon which are present in person or by proxy at such meeting. If
authorized by the Board, such requirement of a written ballot shall be satisfied by a ballot
submitted by electronic transmission (as defined in <B>section 7.2 </B>of these bylaws), <I>provided </I>that any
such electronic transmission must either set forth or be submitted with information from which it
can be determined that the electronic transmission was authorized by the stockholder or proxy
holder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise required by law, the certificate of incorporation or these bylaws, in all
matters other than the election of directors, the affirmative vote of a majority of the voting
power of the shares present in person or represented by proxy at the meeting and entitled to vote
on the subject matter shall be the act of the stockholders. Except as otherwise required by law,
the certificate of incorporation or these bylaws, directors shall be elected by a plurality of the
voting power of the shares present in person or represented by proxy at the meeting and entitled to
vote on the election of directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.9 <B><I>Stockholder Action by Written Consent Without a Meeting</I></B>. Unless otherwise provided in the certificate of incorporation, any action required by the
DGCL to be taken at any annual or special meeting of stockholders of a corporation, or any action
which may be taken at any annual or special meeting of such stockholders, may be taken without a
meeting, without prior notice, and without a vote, if a consent or consents in writing, setting
forth the action so taken, shall be signed by the holders of outstanding stock having not less than
the minimum number of votes that would be necessary to authorize or take such action at a meeting
at which all shares entitled to vote thereon were present and voted.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An electronic transmission (as defined in <B>section 7.2</B>) consenting to an action to be taken and
transmitted by a stockholder or proxy holder, or by a person or persons authorized to act for a
stockholder or proxy holder, shall be deemed to be written, signed and dated for purposes of
this section, <I>provided </I>that any such electronic transmission sets forth or is delivered with
information from which the Company can determine (i)&nbsp;that the electronic transmission was
transmitted by the stockholder or proxy holder or by a person or persons authorized to act for the
stockholder or proxy holder and (ii)&nbsp;the date on which such stockholder or proxy holder or
authorized person or persons transmitted such electronic transmission.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event that the Board shall have instructed the officers of the Company to solicit the
vote or written consent of the stockholders of the Company, an electronic transmission of a
stockholder written consent given pursuant to such solicitation may be delivered to the Secretary
or the President of the Company or to a person designated by the Secretary or the President. The
Secretary or the President of the Company or a designee of the Secretary or the President shall
cause any such written consent by electronic transmission to be reproduced in paper form and
inserted into the corporate records.
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prompt notice of the taking of the corporate action without a meeting by less than unanimous
written consent shall be given to those stockholders who have not consented in writing and who, if
the action had been taken at a meeting, would have been entitled to notice of the meeting if the
record date for such meeting had been the date that written consents signed by a sufficient number
of holders to take the action were delivered to the Company as provided in Section&nbsp;228 of the DGCL.
In the event that the action which is consented to is such as would have required the filing of a
certificate under any provision of the DGCL, if such action had been voted on by stockholders at a
meeting thereof, the certificate filed under such provision shall state, in lieu of any statement
required by such provision concerning any vote of stockholders, that written consent has been given
in accordance with Section&nbsp;228 of the DGCL.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.10 <B><I>Record Date for Stockholder Notice; Voting; Giving Consents</I></B>. In order that the Company may determine the stockholders entitled to notice of or to vote
at any meeting of stockholders or any adjournment thereof, or entitled to express consent to
corporate action in writing without a meeting, or entitled to receive payment of any dividend or
other distribution or allotment of any rights, or entitled to exercise any rights in respect of any
change, conversion or exchange of stock or for the purpose of any other lawful action, the Board
may fix a record date, which record date shall not precede the date upon which the resolution
fixing the record date is adopted by the Board and which record date:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;in the case of determination of stockholders entitled to notice of or to vote at any
meeting of stockholders or adjournment thereof, shall, unless otherwise required by law, not be
more than sixty nor less than ten days before the date of such meeting;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;in the case of determination of stockholders entitled to express consent to corporate
action in writing without a meeting, shall not be more than ten days after the date upon which the
resolution fixing the record date is adopted by the Board; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;in the case of determination of stockholders for any other action, shall not be more
than 60&nbsp;days prior to such other action.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If no record date is fixed by the Board:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;the record date for determining stockholders entitled to notice of or to vote at a meeting
of stockholders shall be at the close of business on the day next preceding the day on which notice
is given, or, if notice is waived, at the close of business on the day next preceding the day on
which the meeting is held;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;the record date for determining stockholders entitled to express consent to corporate
action in writing without a meeting when no prior action of the Board is required by law, shall be
the first date on which a signed written consent setting forth the action taken or proposed to be
taken is delivered to the Company in accordance with applicable law, or, if prior action by the
Board is required by law, shall be at the close of business on the day on which the Board adopts
the resolution taking such prior action; and
</DIV>


<P align="right" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;the record date for determining stockholders for any other purpose shall be at the close
of business on the day on which the Board adopts the resolution relating thereto.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A determination of stockholders of record entitled to notice of or to vote at a meeting of
stockholders shall apply to any adjournment of the meeting, <I>provided </I>that the Board may fix a new
record date for the adjourned meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.11 <B><I>Proxies</I></B>. Each stockholder entitled to vote at a meeting of stockholders or to express consent or
dissent to corporate action in writing without a meeting may authorize another person or persons to
act for such stockholder by proxy authorized by an instrument in writing or by a transmission
permitted by law filed in accordance with the procedure established for the meeting, but no such
proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a
longer period. The revocability of a proxy that states on its face that it is irrevocable shall be
governed by the provisions of Section&nbsp;212 of the DGCL.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.12 <B><I>List of Stockholders Entitled to Vote</I></B>. The officer who has charge of the stock ledger of the Company shall prepare and make, at
least ten days before every meeting of stockholders, a complete list of the stockholders entitled
to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder
and the number of shares registered in the name of each stockholder. The Company shall not be
required to include electronic mail addresses or other electronic contact information on such list.
Such list shall be open to the examination of any stockholder, for any purpose germane to the
meeting for a period of at least ten days prior to the meeting: (i)&nbsp;on a reasonably accessible
electronic network, <I>provided </I>that the information required to gain access to such list is provided
with the notice of the meeting, or (ii)&nbsp;during ordinary business hours, at the Company&#146;s principal
place of business. In the event that the Company determines to make the list available on an
electronic network, the Company may take reasonable steps to ensure that such information is
available only to stockholders of the Company. If the meeting is to be held at a place, then the
list shall be produced and kept at the time and place of the meeting during the
whole time thereof, and may be inspected by any stockholder who is present. If the meeting is
to be held solely by means of remote communication, then the list shall also be open to the
examination of any stockholder during the whole time of the meeting on a reasonably accessible
electronic network, and the information required to access such list shall be provided with the
notice of the meeting.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE II &#151; DIRECTORS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 <B><I>Powers</I></B>. The business and affairs of the Company shall be managed by or under the direction of the
Board, except as may be otherwise provided in the DGCL or the certificate of incorporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 <B><I>Number of Directors</I></B>. The number of directors of the Company shall be not less than seven (7)&nbsp;nor more than
thirteen (13). The exact number of directors shall be twelve (12)&nbsp;until changed, within the limits
specified above, by a bylaw amending this Section&nbsp;2.2, duly adopted by the Board or by the
stockholders. The indefinite number of directors may be changed, or a definite number may be fixed
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-5-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">without provision for an indefinite number, by a duly adopted amendment to the certificate of
incorporation or by an amendment to this bylaw duly adopted by the vote or written consent of
holders of a majority of the outstanding shares entitled to vote; provided, however, that an
amendment reducing the fixed number or the minimum number of directors to a number less than seven
(7)&nbsp;cannot be adopted if the votes cast against its adoption at a meeting, or the shares not
consenting in the case of an action by written consent, are equal to more than sixteen and
two-thirds percent (16-2/3%) of the outstanding shares entitled to vote thereon. No amendment may
change the stated maximum number of authorized directors to a number greater than two (2)&nbsp;times the
stated minimum number of directors minus one (1).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No reduction of the authorized number of directors shall have the effect of removing any
director before that director&#146;s term of office expires.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3 <B><I>Election, Qualification and Term of Office of Directors</I></B>. Except as provided in <B>section 2.4 </B>of these bylaws, and subject to <B>sections 1.2 </B>and <B>1.9 </B>of
these bylaws, directors shall be elected at each annual meeting of stockholders. Directors need not
be stockholders unless so required by the certificate of incorporation or these bylaws. The
certificate of incorporation or these bylaws may prescribe other qualifications for directors. Each
director shall hold office until such director&#146;s successor is elected and qualified or until such
director&#146;s earlier death, resignation or removal.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4 <B><I>Resignation and Vacancies</I></B>. Any director may resign at any time upon notice given in writing or by electronic
transmission to the Company. A resignation is effective when the resignation is delivered unless
the resignation specifies a later effective date or an effective date determined upon the happening
of an event or events. A resignation which is conditioned upon the director failing to receive a
specified vote for reelection as a director may provide that it is irrevocable. Unless otherwise provided in the certificate of
incorporation or these bylaws, when one or more directors resign from the Board, effective at a
future date, a majority of the directors then in office, including those who have so resigned,
shall have power to fill such vacancy or vacancies, the vote thereon to take effect when such
resignation or resignations shall become effective.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise provided in the certificate of incorporation or these bylaws:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;Vacancies and newly created directorships resulting from any increase in the authorized
number of directors elected by all of the stockholders having the right to vote as a single class
may be filled by a majority of the directors then in office, although less than a quorum, or by a
sole remaining director.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;Whenever the holders of any class or classes of stock or series thereof are entitled to
elect one or more directors by the provisions of the certificate of incorporation, vacancies and
newly created directorships of such class or classes or series may be filled by a majority of the
directors elected by such class or classes or series thereof then in office, or by a sole remaining
director so elected.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If at any time, by reason of death or resignation or other cause, the Company should have no
directors in office, then any officer or any stockholder or an executor, administrator, trustee or
guardian of a stockholder, or other fiduciary entrusted with like responsibility for the person or
estate of a
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-6-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">stockholder, may call a special meeting of stockholders in accordance with the
provisions of the certificate of incorporation or these bylaws, or may apply to the Court of
Chancery for a decree summarily ordering an election as provided in Section&nbsp;211 of the DGCL.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If, at the time of filling any vacancy or any newly created directorship, the directors then
in office constitute less than a majority of the whole Board (as constituted immediately prior to
any such increase), the Court of Chancery may, upon application of any stockholder or stockholders
holding at least 10% of the voting stock at the time outstanding having the right to vote for such
directors, summarily order an election to be held to fill any such vacancies or newly created
directorships, or to replace the directors chosen by the directors then in office as aforesaid,
which election shall be governed by the provisions of Section&nbsp;211 of the DGCL as far as applicable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A director elected to fill a vacancy shall be elected for the unexpired term of his or her
predecessor in office and until such director&#146;s successor is elected and qualified, or until such
director&#146;s earlier death, resignation or removal.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5 <B><I>Place of Meetings; Meetings by Telephone</I></B>. The Board may hold meetings, both regular and special, either within or outside the State
of Delaware.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise restricted by the certificate of incorporation or these bylaws, members of
the Board, or any committee designated by the Board, may participate in a meeting of the Board, or
any committee, by means of conference telephone or other communications equipment by means of which
all persons participating in the meeting can hear each other, and such participation in a
meeting shall constitute presence in person at the meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.6 <B><I>Conduct of Business</I></B>. Meetings of the Board shall be presided over by the Chairperson of the Board, if any, or in
his or her absence by the Vice Chairperson of the Board, if any, or in the absence of the foregoing
persons by a chairperson designated by the Board, or in the absence of such designation by a
chairperson chosen at the meeting. The Secretary shall act as secretary of the meeting, but in his
or her absence the chairperson of the meeting may appoint any person to act as secretary of the
meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.7 <B><I>Regular Meetings</I></B>. Regular meetings of the Board may be held without notice at such time and at such place as
shall from time to time be determined by the Board.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.8 <B><I>Special Meetings; Notice</I></B>. Special meetings of the Board for any purpose or purposes may be called at any time by the
Chairperson of the Board, the Chief Executive Officer, the President, the Secretary or any two
directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notice of the time and place of special meetings shall be:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;delivered personally by hand, by courier or by telephone;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;sent by United States first-class mail, postage prepaid;
</DIV>
<P align="right" style="font-size: 10pt"><!-- Folio -->-7-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (iii)&nbsp;sent by facsimile; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;sent by electronic mail,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">directed to each director at that director&#146;s address, telephone number, facsimile number or
electronic mail address, as the case may be, as shown on the Company&#146;s records.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the notice is (i)&nbsp;delivered personally by hand, by courier or by telephone, (ii)&nbsp;sent by
facsimile or (iii)&nbsp;sent by electronic mail, it shall be delivered or sent at least 24 hours before
the time of the holding of the meeting. If the notice is sent by United States mail, it shall be
deposited in the United States mail at least four days before the time of the holding of the
meeting. Any oral notice may be communicated to the director. The notice need not specify the place
of the meeting (if the meeting is to be held at the Company&#146;s principal executive office) nor the
purpose of the meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.9 <B><I>Quorum; Voting</I></B>. At all meetings of the Board, a majority of the total authorized number of directors shall
constitute a quorum for the transaction of business. If a quorum is not present at any meeting of
the Board, then the directors present thereat may adjourn the meeting from time to time, without
notice other than announcement at the meeting, until a quorum is present. A meeting at which a quorum is
initially present may continue to transact business notwithstanding the withdrawal of directors, if
any action taken is approved by at least a majority of the required quorum for that meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The vote of a majority of the directors present at any meeting at which a quorum is present
shall be the act of the Board, except as may be otherwise specifically provided by statute, the
certificate of incorporation or these bylaws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the certificate of incorporation provides that one or more directors shall have more or
less than one vote per director on any matter, every reference in these bylaws to a majority or
other proportion of the directors shall refer to a majority or other proportion of the votes of the
directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.10 <B><I>Board Action by Written Consent Without a Meeting</I></B>. Unless otherwise restricted by the certificate of incorporation or these bylaws, any action
required or permitted to be taken at any meeting of the Board, or of any committee thereof, may be
taken without a meeting if all members of the Board or committee, as the case may be, consent
thereto in writing or by electronic transmission and the writing or writings or electronic
transmission or transmissions are filed with the minutes of proceedings of the Board or committee.
Such filing shall be in paper form if the minutes are maintained in paper form and shall be in
electronic form if the minutes are maintained in electronic form.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.11 <B><I>Fees and Compensation of Directors</I></B>. Unless otherwise restricted by the certificate of incorporation or these bylaws, the Board
shall have the authority to fix the compensation of directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.12 <B><I>Removal of Directors</I></B>. Unless otherwise restricted by statute, the certificate of incorporation or these bylaws,
any director or the entire Board may be removed, with or without cause, by the holders of a
majority of the shares then entitled to vote at an election of directors.
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-8-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No reduction of the authorized number of directors shall have the effect of removing any
director prior to the expiration of such director&#146;s term of office.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE III &#151; COMMITTEES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 <B><I>Committees of Directors</I></B>. The Board may designate one or more committees, each committee to consist of one or more of
the directors of the Company. The Board may designate one or more directors as alternate members of
any committee, who may replace any absent or disqualified member at any meeting of the committee.
In the absence or disqualification of a member of a committee, the member or members thereof
present at any meeting and not disqualified from voting, whether or not such member or members
constitute a quorum, may unanimously appoint another member of the Board to act at the meeting in
the place of any such absent or disqualified member. Any such committee, to the extent provided in the
resolution of the Board or in these bylaws, shall have and may exercise all the powers and
authority of the Board in the management of the business and affairs of the Company, and may
authorize the seal of the Company to be affixed to all papers that may require it; but no such
committee shall have the power or authority to (i)&nbsp;approve or adopt, or recommend to the
stockholders, any action or matter (other than the election or removal of directors) expressly
required by the DGCL to be submitted to stockholders for approval, or (ii)&nbsp;adopt, amend or repeal
any bylaw of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 <B><I>Committee Minutes</I></B>. Each committee shall keep regular minutes of its meetings and report the same to the Board
when required.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3 <B><I>Meetings and Actions of Committees</I></B>. Meetings and actions of committees shall be governed by, and held and taken in accordance
with, the provisions of:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <B>section 2.5 </B>(Place of Meetings; Meetings by Telephone);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) <B>section 2.7 </B>(Regular Meetings);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) <B>section 2.8 </B>(Special Meetings; Notice);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) <B>section 2.9 </B>(Quorum; Voting);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) <B>section 2.10 </B>(Board Action by Written Consent Without a Meeting); and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) <B>section 7.5 </B>(Waiver of Notice)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">with such changes in the context of those bylaws as are necessary to substitute the committee and
its members for the Board and its members. <I>However</I>:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;the time of regular meetings of committees may be determined either by resolution of the
Board or by resolution of the committee;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;special meetings of committees may also be called by resolution of the Board; and
</DIV>


<P align="right" style="font-size: 10pt"><!-- Folio -->-9-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;notice of special meetings of committees shall also be given to all alternate members,
who shall have the right to attend all meetings of the committee. The Board may adopt rules for the
government of any committee not inconsistent with the provisions of these bylaws.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4 <B><I>Subcommittees</I></B>. Unless otherwise provided in the certificate of incorporation, these bylaws or the
resolutions of the Board designating the committee, a committee may create one or more
subcommittees, each subcommittee to consist of one or more members of the committee, and delegate to a
subcommittee any or all of the powers and authority of the committee.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE IV &#151; OFFICERS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 <B><I>Officers</I></B>. The officers of the Company shall be a President and a Secretary. The Company may also
have, at the discretion of the Board, a Chairperson of the Board, a Vice Chairperson of the Board,
a Chief Executive Officer, one or more Vice Presidents, a Chief Financial Officer, a Treasurer, one
or more Assistant Treasurers, one or more Assistant Secretaries, and any such other officers as may
be appointed in accordance with the provisions of these bylaws. Any number of offices may be held
by the same person.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 <B><I>Appointment of Officers</I></B>. The Board shall appoint the officers of the Company, except such officers as may be
appointed in accordance with the provisions of <B>section 4.3 </B>of these bylaws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3 <B><I>Subordinate Officers</I></B>. The Board may appoint, or empower the Chief Executive Officer or, in the absence of a Chief
Executive Officer, the President, to appoint, such other officers and agents as the business of the
Company may require. Each of such officers and agents shall hold office for such period, have such
authority, and perform such duties as are provided in these bylaws or as the Board may from time to
time determine.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4 <B><I>Removal and Resignation of Officers</I></B>. Any officer may be removed, either with or without cause, by an affirmative vote of the
majority of the Board at any regular or special meeting of the Board or, except in the case of an
officer chosen by the Board, by any officer upon whom such power of removal may be conferred by the
Board.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any officer may resign at any time by giving written notice to the Company. Any resignation
shall take effect at the date of the receipt of that notice or at any later time specified in that
notice. Unless otherwise specified in the notice of resignation, the acceptance of the resignation
shall not be necessary to make it effective. Any resignation is without prejudice to the rights, if
any, of the Company under any contract to which the officer is a party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.5 <B><I>Vacancies in Offices</I></B>. Any vacancy occurring in any office of the Company shall be filled by the Board or as
provided in <B>section 4.3</B>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.6 <B><I>Representation of Shares of Other Corporations</I></B>. Unless otherwise directed by the Board, the President or any other person authorized by the
Board or the President is authorized to vote, represent and exercise on behalf of the Company all
rights incident to any and all shares of any other
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-10-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">corporation or corporations standing in the name of the Company. The authority granted herein may be exercised either by such person directly or by
any other person authorized to do so by proxy or power of attorney duly executed by such person
having the authority.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.7 <B><I>Authority and Duties of Officers</I></B>. Except as otherwise provided in these bylaws, the officers of the Company shall have such
powers and duties in the management of the Company as may be designated from time to time by the
Board and, to the extent not so provided, as generally pertain to their respective offices, subject
to the control of the Board.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE V &#151; INDEMNIFICATION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 <B><I>Indemnification of Directors and Officers in Third Party Proceedings</I></B>. Subject to the other provisions of this <B>Article&nbsp;V</B>, the Company shall indemnify, to the
fullest extent permitted by the DGCL, as now or hereinafter in effect, any person who was or is a
party or is threatened to be made a party to any threatened, pending or completed action, suit or
proceeding, whether civil, criminal, administrative or investigative (a &#147;<B>Proceeding</B>&#148;) (other than
an action by or in the right of the Company) by reason of the fact that such person is or was a
director or officer of the Company, or is or was a director or officer of the Company serving at
the request of the Company as a director, officer, employee or agent of another corporation,
partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#146;
fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such
person in connection with such Proceeding if such person acted in good faith and in a manner such
person reasonably believed to be in or not opposed to the best interests of the Company, and, with
respect to any criminal action or proceeding, had no reasonable cause to believe such person&#146;s
conduct was unlawful. The termination of any Proceeding by judgment, order, settlement, conviction,
or upon a plea of <I>nolo contendere </I>or its equivalent, shall not, of itself, create a presumption
that the person did not act in good faith and in a manner which such person reasonably believed to
be in or not opposed to the best interests of the Company, and, with respect to any criminal action
or proceeding, had reasonable cause to believe that such person&#146;s conduct was unlawful.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2 <B><I>Indemnification of Directors and Officers in Actions by or in the Right of the Company</I></B>. Subject to the other provisions of this <B>Article&nbsp;V</B>, the Company shall indemnify, to the
fullest extent permitted by the DGCL, as now or hereinafter in effect, any person who was or is a
party or is threatened to be made a party to any threatened, pending or completed action or suit by
or in the right of the Company to procure a judgment in its favor by reason of the fact that such
person is or was a director or officer of the Company, or is or was a director or officer of the
Company serving at the request of the Company as a director, officer, employee or agent of another
corporation, partnership, joint venture, trust or other enterprise against expenses (including
attorneys&#146; fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit if such person
acted in good faith and in a manner such person reasonably believed to be in or not opposed to the
best interests of the Company; except that no indemnification shall be made in respect of any
claim, issue or matter as to which such person shall have been adjudged to be liable to the Company
unless and only to the extent that the Court of Chancery or the court in which such action or suit
was brought shall determine upon application that, despite the adjudication of liability but in
view of all the circumstances of the case, such
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-11-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3 <B><I>Successful Defense</I></B>. To the extent that a present or former director or officer of the Company has been
successful on the merits or otherwise in defense of any action, suit or proceeding described in
<B>section 5.1 </B>or <B>section 5.2</B>, or in defense of any claim, issue or matter therein, such person shall
be indemnified against expenses (including attorneys&#146; fees) actually and reasonably incurred by
such person in connection therewith.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4 <B><I>Indemnification of Others</I></B>. Subject to the other provisions of this <B>Article&nbsp;V</B>, the Company shall have power to
indemnify its employees and agents to the extent not prohibited by the DGCL or other applicable
law. The Board shall have the power to delegate to such person or persons the determination of
whether employees or agents shall be indemnified.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.5 <B><I>Advanced Payment of Expenses</I></B>. Expenses (including attorneys&#146; fees) incurred by an officer or director of the Company in
defending any Proceeding shall be paid by the Company in advance of the final disposition of such
Proceeding upon receipt of an undertaking by or on behalf of the person to repay such amounts if it
shall ultimately be determined that the person is not entitled to be indemnified under this <B>Article
V </B>or the DGCL. Such expenses (including attorneys&#146; fees) incurred by former directors and officers
or other employees and agents may be so paid upon such terms and conditions, if any, as the Company
deems appropriate.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.6 <B><I>Limitation on Indemnification and Advancement of Expenses</I></B>. Subject to the requirements in <B>section 5.3 </B>and the DGCL, the Company shall not be required
to provide indemnification or, with respect to clauses (i), (iii)&nbsp;and (iv)&nbsp;below, advance expenses
to any person pursuant to this <B>Article&nbsp;V</B>:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;in connection with any Proceeding (or part thereof) initiated by such person except (i)&nbsp;as
otherwise required by law, (ii)&nbsp;in specific cases if the Proceeding was authorized by the Board, or
(iii)&nbsp;as is required to be made under <B>section 5.7</B>;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;in connection with any Proceeding (or part thereof) against such person providing for an
accounting or disgorgement of profits pursuant to the provisions of Section 16(b) of the Securities
Exchange Act of 1934, as amended, or similar provisions of any federal, state or local
statutory law or common law;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;for amounts for which payment has actually been made to or on behalf of such person
under any statute, insurance policy or indemnity provision, except with respect to any excess
beyond the amount paid; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;if prohibited by applicable law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.7 <B><I>Determination; Claim</I></B>. If a claim for indemnification or advancement of expenses under this <B>Article&nbsp;V </B>is not paid
in full within 60&nbsp;days after a written claim therefor has been received by the Company, the
claimant may file suit to recover the unpaid amount of such claim and, if successful in
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-12-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">whole or in part, shall be entitled to be paid the expense of prosecuting such claim. In any such suit, the
Company shall have the burden of proving that the claimant was not entitled to the requested
indemnification or advancement of expenses under applicable law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.8 <B><I>Non-Exclusivity of Rights</I></B>. The indemnification and advancement of expenses provided by, or granted pursuant to, this
<B>Article&nbsp;V </B>shall not be deemed exclusive of any other rights to which those seeking indemnification
or advancement of expenses may be entitled under the certificate of incorporation or any statute,
bylaw, agreement, vote of stockholders or disinterested directors or otherwise, both as to action
in such person&#146;s official capacity and as to action in another capacity while holding such office.
The Company is specifically authorized to enter into individual contracts with any or all of its
directors, officers, employees or agents respecting indemnification and advancement of expenses, to
the fullest extent not prohibited by the DGCL or other applicable law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.9 <B><I>Insurance</I></B>. The Company may purchase and maintain insurance on behalf of any person who is or was a
director, officer, employee or agent of the Company, or is or was serving at the request of the
Company as a director, officer, employee or agent of another corporation, partnership, joint
venture, trust or other enterprise against any liability asserted against such person and incurred
by such person in any such capacity, or arising out of such person&#146;s status as such, whether or not
the Company would have the power to indemnify such person against such liability under the
provisions of the DGCL.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.10 <B><I>Survival</I></B>. The rights to indemnification and advancement of expenses conferred by this <B>Article&nbsp;V </B>shall
continue as to a person who has ceased to be a director, officer, employee or agent and shall inure
to the benefit of the heirs, executors and administrators of such a person.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.11 <B><I>Effect of Repeal or Modification</I></B>. Any repeal or modification of this <B>Article&nbsp;V </B>shall not adversely affect any right or
protection hereunder of any person in respect of any act or omission occurring prior to the time of
such repeal or modification.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.12 <B><I>Certain Definitions</I></B>. For purposes of this <B>Article&nbsp;V</B>, references to the &#147;<B>Company</B>&#148; shall include, in addition to
the resulting corporation, any constituent corporation (including any constituent of a constituent)
absorbed in a consolidation or merger which, if its separate existence had continued, would have
had power and authority to indemnify its directors, officers, employees or agents, so that any
person who is or was a director, officer, employee or agent of such constituent corporation, or is
or was serving at the request of such constituent corporation as a director, officer, employee or
agent of another corporation, partnership, joint venture, trust or other enterprise, shall stand in
the same position under the provisions of this <B>Article&nbsp;V </B>with respect to the resulting or surviving
corporation as such person would have with respect to such constituent corporation if its separate
existence had continued. For purposes of this <B>Article&nbsp;V</B>, references to &#147;<B>other enterprises</B>&#148; shall
include employee benefit plans; references to &#147;<B>fines</B>&#148; shall include any excise taxes assessed on a
person with respect to an employee benefit plan; and references to &#147;<B>serving at the request of the
Company</B>&#148; shall include any service as a director, officer, employee or agent of the Company which
imposes duties on, or involves services by, such director, officer, employee or agent with respect
to an employee benefit plan, its participants or beneficiaries; and a person who acted in good
faith and in a manner such person reasonably believed to be in the interest of
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-13-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner &#147;<B>not opposed to
the best interests of the Company</B>&#148; as referred to in this <B>Article&nbsp;V</B>.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VI &#151; STOCK</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1 <B><I>Stock Certificates; Partly Paid Shares</I></B>. The shares of the Company shall be represented by certificates, <I>provided </I>that the Board may
provide by resolution or resolutions that some or all of any or all classes or series of its stock
shall be uncertificated shares. Any such resolution shall not apply to shares represented by a
certificate until such certificate is surrendered to the Company. Every holder of stock represented
by certificates shall be entitled to have a certificate signed by, or in the name of the Company by
the Chairperson of the Board or Vice-Chairperson of the Board, or the President or a
Vice-President, and by the Treasurer or an Assistant Treasurer, or the Secretary or an Assistant
Secretary of the Company representing the number of shares registered in certificate form. Any or
all of the signatures on the certificate may be a facsimile. In case any officer, transfer agent or
registrar who has signed or whose facsimile signature has been placed upon a certificate has ceased
to be such officer, transfer agent or registrar before such certificate is issued, it may be issued
by the Company with the same effect as if such person were such officer, transfer agent or
registrar at the date of issue. The Company shall not have power to issue a certificate in bearer
form.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company may issue the whole or any part of its shares as partly paid and subject to call
for the remainder of the consideration to be paid therefor. Upon the face or back of each stock
certificate issued to represent any such partly paid shares, or upon the books and records of the Company
in the case of uncertificated partly paid shares, the total amount of the consideration to be paid
therefor and the amount paid thereon shall be stated. Upon the declaration of any dividend on fully
paid shares, the Company shall declare a dividend upon partly paid shares of the same class, but
only upon the basis of the percentage of the consideration actually paid thereon.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2 <B><I>Special Designation on Certificates</I></B>. If the Company is authorized to issue more than one class of stock or more than one series
of any class, then the powers, the designations, the preferences, and the relative, participating,
optional or other special rights of each class of stock or series thereof and the qualifications,
limitations or restrictions of such preferences and/or rights shall be set forth in full or
summarized on the face or back of the certificate that the Company shall issue to represent such
class or series of stock; <I>provided </I>that, except as otherwise provided in Section&nbsp;202 of the DGCL,
in lieu of the foregoing requirements there may be set forth on the face or back of the certificate
that the Company shall issue to represent such class or series of stock a statement that the
Company will furnish without charge to each stockholder who so requests the powers, the
designations, the preferences, and the relative, participating, optional or other special rights of
each class of stock or series thereof and the qualifications, limitations or restrictions of such
preferences and/or rights.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3 <B><I>Lost Certificates</I></B>. Except as provided in this <B>section 6.3</B>, no new certificates for shares shall be issued to
replace a previously issued certificate unless the latter is surrendered to the Company and
cancelled at the same time. The Company may issue a new certificate of stock or uncertificated
shares in the place of any certificate theretofore issued by it, alleged to have been lost, stolen
or
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-14-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">destroyed, and the Company may require the owner of the lost, stolen or destroyed certificate, or such owner&#146;s legal representative, to give the Company a bond sufficient to indemnify it against
any claim that may be made against it on account of the alleged loss, theft or destruction of any
such certificate or the issuance of such new certificate or uncertificated shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4 <B><I>Dividends</I></B>. The Board, subject to any restrictions contained in the certificate of incorporation or
applicable law, may declare and pay dividends upon the shares of the Company&#146;s capital stock.
Dividends may be paid in cash, in property, or in shares of the Company&#146;s capital stock, subject to
the provisions of the certificate of incorporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board may set apart out of any of the funds of the Company available for dividends a
reserve or reserves for any proper purpose and may abolish any such reserve.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.5 <B><I>Stock Transfer Agreements</I></B>. The Company shall have power to enter into and perform any agreement with any number of
stockholders of any one or more classes of stock of the Company to restrict the transfer of shares
of stock of the Company of any one or more classes owned by such stockholders in any manner not
prohibited by the DGCL.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.6 <B><I>Registered Stockholders</I></B>. The Company:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;shall be entitled to recognize the exclusive right of a person registered on its books as
the owner of shares to receive dividends and to vote as such owner;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;shall be entitled to hold liable for calls and assessments the person registered on its
books as the owner of shares; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;shall not be bound to recognize any equitable or other claim to or interest in such
share or shares on the part of another person, whether or not it shall have express or other notice
thereof, except as otherwise provided by the laws of Delaware.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.7 <B><I>Transfers</I></B>. Transfers of record of shares of stock of the Company shall be made only upon its books by
the holders thereof, in person or by an attorney duly authorized, and upon the surrender of a
certificate or certificates for a like number of shares, properly endorsed.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VII &#151; MANNER OF GIVING NOTICE AND WAIVER</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1 <B><I>Notice of Stockholder Meetings</I></B>. Notice of any meeting of stockholders, if mailed, is given when deposited in the United
States mail, postage prepaid, directed to the stockholder at such stockholder&#146;s address as it
appears on the Company&#146;s records. An affidavit of the Secretary or an Assistant Secretary of the
Company or of the transfer agent or other agent of the Company that the notice has been given
shall, in the absence of fraud, be <I>prima facie </I>evidence of the facts stated therein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2 <B><I>Notice by Electronic Transmission</I></B>. Without limiting the manner by which notice otherwise may be given effectively to
stockholders pursuant to the DGCL, the certificate of
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-15-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">incorporation or these bylaws, any notice to stockholders given by the Company under any provision of the DGCL, the certificate of incorporation
or these bylaws shall be effective if given by a form of electronic transmission consented to by
the stockholder to whom the notice is given. Any such consent shall be revocable by the stockholder
by written notice to the Company. Any such consent shall be deemed revoked if:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;the Company is unable to deliver by electronic transmission two consecutive notices given
by the Company in accordance with such consent; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;such inability becomes known to the Secretary or an Assistant Secretary of the Company or
to the transfer agent, or other person responsible for the giving of notice.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">However, the inadvertent failure to treat such inability as a revocation shall not invalidate any
meeting or other action.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any notice given pursuant to the preceding paragraph shall be deemed given:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;if by facsimile telecommunication, when directed to a number at which the stockholder has
consented to receive notice;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;if by electronic mail, when directed to an electronic mail address at which the
stockholder has consented to receive notice;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;if by a posting on an electronic network together with separate notice to the
stockholder of such specific posting, upon the later of (A)&nbsp;such posting and (B)&nbsp;the giving of such
separate notice; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;if by any other form of electronic transmission, when directed to the stockholder.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An affidavit of the Secretary or an Assistant Secretary or of the transfer agent or other
agent of the Company that the notice has been given by a form of electronic transmission shall, in
the absence of fraud, be <I>prima facie </I>evidence of the facts stated therein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An &#147;<B>electronic transmission</B>&#148; means any form of communication, not directly involving the
physical transmission of paper, that creates a record that may be retained, retrieved, and reviewed
by a recipient thereof, and that may be directly reproduced in paper form by such a recipient
through an automated process.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notice by a form of electronic transmission shall not apply to Sections&nbsp;164, 296, 311, 312 or
324 of the DGCL.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3 <B><I>Notice to Stockholders Sharing an Address</I></B>. Except as otherwise prohibited under the DGCL, without limiting the manner by which notice
otherwise may be given effectively to stockholders, any notice to stockholders given by the Company
under the provisions of the DGCL, the certificate of incorporation or these bylaws shall be
effective if given by a single written notice to stockholders who
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-16-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">share an address if consented to by the stockholders at that address to whom such notice is given. Any such consent shall be
revocable by the stockholder by written notice to the Company. Any stockholder who fails to object
in writing to the Company, within 60&nbsp;days of having been given written notice by the Company of its
intention to send the single notice, shall be deemed to have consented to receiving such single
written notice.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.4 <B><I>Notice to Person with Whom Communication is Unlawful</I></B>. Whenever notice is required to be given, under the DGCL, the certificate of incorporation
or these bylaws, to any person with whom communication is unlawful, the giving of such notice to
such person shall not be required and there shall be no duty to apply to any governmental authority
or agency for a license or permit to give such notice to such person. Any action or meeting which
shall be taken or held without notice to any such person with whom communication is unlawful shall
have the same force and effect as if such notice had been duly given. In the event that the action
taken by the Company is such as to require the filing of a certificate under the DGCL, the
certificate shall state, if such is the fact and if notice is required, that notice was given to
all persons entitled to receive notice except such persons with whom communication is unlawful.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.5 <B><I>Waiver of Notice</I></B>. Whenever notice is required to be given under any provision of the DGCL, the certificate of
incorporation or these bylaws, a written waiver, signed by the person entitled to notice, or a
waiver by electronic transmission by the person entitled to notice, whether before or after the
time of the event for which notice is to be given, shall be deemed equivalent to notice. Attendance
of a person at a meeting shall constitute a waiver of notice of such meeting, except when the
person attends a meeting for the express purpose of objecting at the beginning of the meeting, to
the transaction of any business because the meeting is not lawfully called or convened. Neither the
business to be transacted at, nor the purpose of, any regular or special meeting of the
stockholders need be specified in any written waiver of notice or any waiver by electronic
transmission unless so required by the certificate of incorporation or these bylaws.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VIII &#151; GENERAL MATTERS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.1 <B><I>Fiscal Year</I></B>. The fiscal year of the Company shall be fixed by resolution of the Board and may be changed
by the Board.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.2 <B><I>Seal</I></B>. The Company may adopt a corporate seal, which shall be in such form as may be approved from
time to time by the Board. The Company may use the corporate seal by causing it or a facsimile
thereof to be impressed or affixed or in any other manner reproduced.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.3 <B><I>Annual Report</I></B>. The Company shall cause an annual report to be sent to the stockholders of the Company to
the extent required by applicable law. If and so long as there are fewer than 100 holders of record
of the Company&#146;s shares, the requirement of sending an annual report to the stockholders of the
Company is expressly waived (to the extent permitted under applicable law).
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-17-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.4 <B><I>Construction; Definitions</I></B>. Unless the context requires otherwise, the general provisions, rules of construction, and
definitions in the DGCL shall govern the construction of these bylaws. Without limiting the
generality of this provision, the singular number includes the plural, the plural number includes
the singular, and the term &#147;person&#148; includes both a corporation and a natural person.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE IX &#151; AMENDMENTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These bylaws may be adopted, amended or repealed by the stockholders entitled to vote.
However, the Company may, in its certificate of incorporation, confer the power to adopt, amend or
repeal bylaws upon the directors. The fact that such power has been so conferred upon the directors
shall not divest the stockholders of the power, nor limit their power to adopt, amend or repeal
bylaws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A bylaw amendment adopted by stockholders which specifies the votes that shall be necessary
for the election of directors shall not be further amended or repealed by the Board.
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-18-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FLUIDIGM CORPORATION</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>CERTIFICATE OF ADOPTION OF BYLAWS</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned hereby certifies that he or she is the duly elected, qualified and acting
Secretary of Fluidigm Corporation, a Delaware corporation (the &#147;<B>Company</B>&#148;), and that the foregoing
bylaws, comprising eighteen (18)&nbsp;pages, were adopted as the bylaws of the Company on March&nbsp;29,
2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned has executed this certificate as of April&nbsp;30, 2007.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Richard A. DeLateur
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="center">(<I>signature</I>)&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">Richard A. DeLateur
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="center">(<I>print name</I>)&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">Secretary
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="center">(<I>title</I>)&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
</TABLE>

<P align="right" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FLUIDIGM CORPORATION</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>CERTIFICATE OF AMENDMENT OF BYLAWS</B>

</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned hereby certifies that he or she is the duly elected, qualified, and acting
Secretary or Assistant Secretary of Fluidigm Corporation, a Delaware corporation (the &#147;<B>Company</B>&#148;),
and that the foregoing bylaws, were amended and restated on <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> by the
Company&#146;s board of directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned has executed this certificate as of <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">

&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="center">(<I>signature</I>)&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="center">(<I>print name</I>)&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="center">(<I>title</I>)&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>4
<FILENAME>f39432orexv4w2.htm
<DESCRIPTION>EXHIBIT 4.2
<TEXT>
<HTML>
<HEAD>
<TITLE>exv4w2</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;4.2</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FLUIDIGM CORPORATION</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>SERIES E PREFERRED STOCK PURCHASE AGREEMENT</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>First Closing: June&nbsp;13, 2006<BR>
Second Closing: December&nbsp;22, 2006<BR>
Third Closing: March&nbsp;30, 2007<BR>
Fourth Extended Closing: October&nbsp;10, 2007<BR>
Fifth Extended Closing: October&nbsp;26, 2007<BR>
Sixth Extended Closing: December&nbsp;31, 2007</B>

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Page</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>1.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Purchase and Sale of Preferred Stock</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Authorization of the Shares</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Purchase and Sale of the Shares</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Closing Date</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Delivery</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>2.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Representations and Warranties of the Company</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Organization, Good Standing and Qualification</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Corporate Power</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Subsidiaries</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Capitalization</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Authorization</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Valid Issuance of Preferred and Common Stock</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Governmental Consents</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.8</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Litigation</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.9</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Employees</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.10</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Patents and Other Intangible Assets</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.11</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Compliance with Other Instruments</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.12</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Permits</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.13</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Environmental and Safety Laws</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.14</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title to Property and Assets</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.15</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Agreements; Action</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.16</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Financial Statements</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.17</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Changes</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.18</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Brokers or Finders</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.19</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Qualified Small Business Stock</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.20</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Employee Benefit Plans</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.21</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tax Matters</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.22</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Insurance</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.23</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Corporate Documents</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.24</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Disclosure</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.25</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Offering</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.26</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Returns and Complaints</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>3.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Representations and Warranties of the Purchasers</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Experience</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Investment</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Rule&nbsp;144</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Legends</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">No Public Market</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Access to Data</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-i-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS<BR>
(continued)</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Page</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Authorization</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.8</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Accredited Investor</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.9</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Public Solicitation</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.10</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tax Advisors</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.11</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Purchaser Counsel</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.12</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Brokers or Finders</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.13</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Non-United States Persons</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>4.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Conditions of Purchaser&#146;s Obligations at Closing</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Representations and Warranties</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Performance</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Compliance Certificate</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Blue Sky</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Opinion of Company Counsel</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Investor Rights Agreement</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Restated Articles</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.8</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Corporate Proceedings; Waivers and Consents</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>5.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Conditions of the Company&#146;s Obligations at Closing</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Representations and Warranties</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Payment of Purchase Price</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Blue Sky</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Investor Rights Agreements</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Restated Articles</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Proceedings and Documents</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>6.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Miscellaneous</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Governing Law; Jurisdiction</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Indemnification</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Survival</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Successors and Assigns</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Entire Agreement; Amendment</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Notices, Etc</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Delays or Omissions</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.8</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">California Corporate Securities Law</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.9</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Finder&#146;s Fee</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.10</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Expenses</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.11</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Waiver of Conflict</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.12</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Severability</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.13</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Counterparts; Facsimile</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.14</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Titles and Subtitles</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-ii-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS<BR>
(continued)</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Page</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.15</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Exculpation Among Purchasers</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.16</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Like Treatment of Holders</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.17</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Jury Trial</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" align="left"><B>EXHIBITS</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" align="left">Exhibit&nbsp;A</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Schedule of Purchasers</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" align="left">Exhibit&nbsp;B</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Amended and Restated Articles of Incorporation</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" align="left">Exhibit&nbsp;C</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Schedule of Exceptions</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" align="left">Exhibit&nbsp;D</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Eighth Amended and Restated Investor Rights Agreement</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" align="left">Exhibit&nbsp;E</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Legal Opinion</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-iii-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>SERIES E PREFERRED STOCK PURCHASE AGREEMENT</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIS SERIES E PREFERRED STOCK PURCHASE AGREEMENT is made as of June&nbsp;13, 2006, by and among
Fluidigm Corporation, a California corporation (the &#147;<B>Company</B>&#148;), and the purchasers listed on the
Schedule of Purchasers attached hereto as <U>EXHIBIT A</U> (the &#147;<B>Schedule of Purchasers</B>&#148;). The
persons or entities listed thereon are hereinafter referred to collectively as the &#147;<B>Purchasers</B>&#148; and
individually as a &#147;<B>Purchaser</B>.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THE PARTIES HEREBY AGREE AS FOLLOWS:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Purchase and Sale of Preferred Stock</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 <U>Authorization of the Shares</U>. The Company will on or before the Closing
(as defined below) authorize the sale and issuance pursuant to this Agreement of up
to 5,000,000 shares (the &#147;<B>Shares</B>&#148;) of its Series&nbsp;E Preferred Stock (the &#147;<B>Series&nbsp;E
Preferred</B>&#148;), having the rights, preferences and privileges as set forth in the
Amended and Restated Articles of Incorporation attached hereto as <U>EXHIBIT B</U>
(the &#147;<B>Restated Articles</B>&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2 <U>Purchase and Sale of the Shares</U>. Subject to the terms and conditions
hereof and in reliance upon the representations, warranties and agreements contained
herein, the Company will issue and sell to each Purchaser, severally and not jointly,
and each Purchaser will purchase from the Company, severally and not jointly, at the
Closing, the number of Shares set forth opposite the Purchaser&#146;s name on the Schedule
of Purchasers, at a purchase price of Four Dollars ($4.00) per Share. The Company
shall be entitled to sell any unpurchased Shares to any Purchaser or to a person who
is not a Purchaser and to amend the Schedule of Purchasers to include the information
relating to such sales, and such purchasers shall be considered &#147;Purchasers&#148; and
parties to this Agreement; provided that (i)&nbsp;such sales are made pursuant to this
Agreement or an agreement identical to this one except for the Closing Date and
exhibits, and (ii)&nbsp;such sales are completed within 120&nbsp;days of the Initial Closing
(as defined below). The Company&#146;s agreement with each Purchaser is a separate
agreement, and the sale of the Shares to each Purchaser is a separate sale.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3 <U>Closing Date</U>. The first closing of the purchase and sale of the Shares
hereunder (the &#147;<B>Initial Closing</B>&#148;) shall be held at the offices of Wilson Sonsini
Goodrich &#038; Rosati, 650 Page Mill Road, Palo Alto, California 94304 on June&nbsp;13, 2006
(the &#147;<B>Closing Date</B>&#148;) or such other date as the Company and a majority-in-interest of
the Purchasers may agree. Subject to Section&nbsp;1.2 above, subsequent closings under
this Agreement may be held from time to time after the Initial Closing at such time
and place as the Company and the relevant Purchasers agree (&#147;<B>Subsequent Closings</B>&#148;).
For the purposes of this Agreement, the term &#147;<B>Closing</B>&#148; and &#147;<B>Closing Date</B>&#148; unless
otherwise indicated, refers to the closing or date of closing
of the purchase and sale of the Shares with respect to a particular Purchaser or
group of Purchasers, whether such closing occurs at the Initial Closing or at a
Subsequent Closing.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.4 <U>Delivery</U>. At Closing, the Company shall deliver to each Purchaser a
certificate, in such denomination and registered in Purchaser&#146;s name as set forth on
the Schedule of Purchasers, representing the number of Shares which Purchaser is
purchasing from the Company
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">against delivery to the Company of a check or wire
transfer payable to the order of the Company in the amount of the purchase price of
the Shares to be purchased by such Purchaser.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Representations and Warranties of the Company</U>. The Company hereby represents
and warrants to Purchaser that, except as set forth in the Schedule of Exceptions attached
hereto as <U>EXHIBIT C</U> (the &#147;<B>Schedule of Exceptions</B>&#148;), which has been delivered to each
Purchaser prior to Purchaser&#146;s execution hereof, each of the representations, warranties and
statements contained in this Section&nbsp;2 is true and correct as of the date of this Agreement and
will be true and correct on and as of the Closing Date. For all purposes of this Agreement,
the statements contained in the Schedule of Exceptions shall also be deemed to be
representations and warranties made and given by Company under this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 <U>Organization, Good Standing and Qualification</U>. The Company is a
corporation duly organized, validly existing and in good standing under the laws of
the State of California and has all requisite corporate power and authority to carry
on its business as currently conducted. The Company is duly qualified to transact
business and is in good standing in each jurisdiction in which the failure to so
qualify, individually or in the aggregate, would have a material adverse effect on
its business (as now conducted), properties, or financial condition.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 <U>Corporate Power</U>. The Company will have at the Closing all requisite
legal and corporate power and authority to (i)&nbsp;execute and deliver this Agreement;
(ii)&nbsp;sell and issue the Shares hereunder; (iii)&nbsp;issue the Common Stock issuable upon
conversion of the Shares (the &#147;<B>Conversion Shares</B>&#148;); and (iv)&nbsp;carry out and perform
its obligations under the terms of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3 <U>Subsidiaries</U>. The Company does not presently own or control, directly or
indirectly, any interest in any other corporation, association, or other business
entity.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4 <U>Capitalization</U>. The authorized capital stock of the Company consists, or
immediately prior to the Initial Closing will consist, of 77,857,144 shares of Common
Stock (&#147;<B>Common Stock</B>&#148;), of which 9,274,356 shares are issued and outstanding
immediately prior to the Initial Closing and 51,687,948 shares of Preferred Stock
(&#147;<B>Preferred Stock</B>&#148;), 2,727,273 of which are designated Series&nbsp;A Preferred Stock of
which 2,727,273 are outstanding immediately prior to the Initial Closing; 6,460,675
of which are designated Series&nbsp;B Preferred Stock of which 6,460,675 are outstanding
immediately prior to the Initial Closing; 17,000,000 of which are designated Series&nbsp;C
Preferred Stock, 16,364,832 of which are issued and outstanding immediately prior to
the Initial Closing; and 15,500,000 of which are designated Series&nbsp;D Preferred Stock,
11,714,048 of which are issued and outstanding immediately prior to the Initial
Closing; and 10,000,000 of which are designated Series&nbsp;E Preferred Stock, none of
which will be outstanding immediately prior to the Initial Closing. All such issued
and outstanding shares have been duly authorized and validly issued in compliance
with applicable laws, and are fully paid and nonassessable.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has reserved: (i)&nbsp;5,000,000 shares of Series&nbsp;E Preferred for issuance hereunder
and 5,000,000 shares of Common Stock for issuance upon conversion of such shares of Series&nbsp;E
Preferred; (ii)&nbsp;11,714,048 shares of Common Stock for issuance upon conversion of the outstanding
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">shares of Series&nbsp;D Preferred; (iii)&nbsp;916,335 shares of Series&nbsp;D Preferred for issuance upon exercise
of outstanding warrants and 916,335 shares of Common Stock for issuance upon conversion of such
Series&nbsp;D Preferred; (iv)&nbsp;16,364,832 shares of Common Stock for issuance upon conversion of the
outstanding shares of Series&nbsp;C Preferred Stock; (v)&nbsp;294,868 shares of Series&nbsp;C Preferred Stock for
issuance upon exercise of outstanding warrants and 294,868 shares of Common Stock for issuance upon
conversion of such Series&nbsp;C Preferred Stock; (vi)&nbsp;6,460,675 shares of Common Stock for issuance
upon conversion of the outstanding Series&nbsp;B Preferred Stock; (vii)&nbsp;2,727,273 shares of Common Stock
for issuance upon conversion of the outstanding Series&nbsp;A Preferred Stock; and (viii)&nbsp;an aggregate
of 10,800,000 shares of Common Stock for issuance to employees and consultants of the Company
pursuant to the Company&#146;s 1999 Stock Option Plan, pursuant to which options to purchase 5,597,763
shares are granted and outstanding and 1,554,643 shares are available for future grant. Other than
with respect to the shares reserved for issuance in the preceding sentence, or as set forth in the
Ancillary Agreements (as defined below), there are no outstanding rights, options, warrants,
conversion rights, preemptive rights, rights of first refusal or similar rights for the purchase or
acquisition from the Company of any securities of the Company. There are no outstanding
obligations of the Company to repurchase or redeem any of its securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as contemplated in the Investor Rights Agreement (as defined below), the Company has
not granted or agreed to grant any registration rights, including piggyback rights, to any person
or entity. Except as contemplated in the Second Amended and Restated Voting Agreement dated as of
August&nbsp;16, 2005, the Company is not a party or subject to any agreement or understanding, and to
the Company&#146;s knowledge, there is no agreement or understanding between any person or entities,
which relates to the voting or the giving of written consents with respect to any security of the
Company or by a director of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5 <U>Authorization</U>. All corporate action on the part of the Company, its
officers, directors and shareholders necessary for the authorization, execution and
delivery of this Agreement, the Eighth Amended and Restated Investor Rights Agreement
in the form attached hereto as <U>EXHIBIT D</U> (the &#147;<B>Investor Rights Agreement</B>&#148;),
the performance of all obligations of the Company under this Agreement and the
Investor Rights Agreement (other than those registration obligations contained in
Section&nbsp;1 of the Investor Rights Agreement), and any other agreements to which the
Company is a party, the execution and delivery of which is a contemplated hereby (the
&#147;<B>Ancillary
Agreements</B>&#148;) and the authorization, issuance (or reservation for issuance), sale and
delivery of the Shares and the Conversion Shares has been taken or will be taken
prior to the Closing. This Agreement and the Investor Rights Agreement constitute
valid and legally binding obligations of the Company, enforceable against the Company
in accordance with their respective terms, subject to: (i)&nbsp;judicial principles
limiting the availability of specific performance, injunctive relief, and other
equitable remedies; (ii)&nbsp;bankruptcy, insolvency, reorganization, moratorium or other
similar laws now or hereafter in effect generally relating to or affecting creditors&#146;
rights; and (iii)&nbsp;limitations on the enforceability of the indemnification provisions
of the Investor Rights Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.6 <U>Valid Issuance of Preferred and Common Stock</U>. The Shares that are being purchased by the Purchasers hereunder, when issued, sold and
delivered in accordance with the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">terms of this Agreement for the consideration expressed herein,
will be duly and validly issued, fully paid, and nonassessable, and will be free of restrictions on
transfer other than restrictions on transfer under this Agreement and the Investor Rights Agreement
and under applicable state and federal securities laws. The Conversion Shares have been duly and
validly reserved for issuance, and, upon issuance in accordance with the terms of the Restated
Articles, will be duly and validly issued, fully paid, and nonassessable and will be free of
restrictions on transfer other than restrictions on transfer under this Agreement and the Investor
Rights Agreement and under applicable state and federal securities laws. The Conversion Shares may
be issued without any registration or qualification under state and federal securities laws as such
laws are currently in effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.7 <U>Governmental Consents</U>. No consent, approval, order or authorization of,
or registration, qualification, designation, declaration or filing with, any federal,
state or local governmental authority on the part of the Company is required in
connection with the offer, sale or issuance of the Shares or the Conversion Shares or
the consummation of any other transaction contemplated hereby, except for (a)&nbsp;the
filing of the Restated Articles with the Secretary of State of the State of
California prior to the Closing and (b)&nbsp;filings required pursuant to applicable
federal and state securities laws and blue sky laws, which filings, the Company
covenants to complete within the required statutory period.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.8 <U>Litigation</U>. There is no action, suit, proceeding or investigation
pending or, to the Company&#146;s knowledge, currently threatened against the Company
before any court, administrative agency or other governmental body which questions
the validity of this Agreement or the Investor Rights Agreement or the right of the
Company to enter into any of them, or to consummate the transactions contemplated
hereby or thereby, or which could result, either individually or in the aggregate, in
any material adverse change in the condition (financial or otherwise), business,
property, assets or liabilities of the Company, nor is the Company aware that there
is any basis for the foregoing. The Company is not a party or subject to, and none
of its assets is bound
by, the provisions of any order, writ, injunction, judgment or decree of any court or
government agency or instrumentality. There is no action, suit, proceeding or
investigation by or involving the Company currently pending or that the Company
intends to initiate.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.9 <U>Employees</U>. Each employee of the Company has executed a proprietary
information and invention assignment agreement substantially in the form or forms
made available to the Purchasers. To the Company&#146;s knowledge, no officer or key
employee is in violation of any prior employee contract or proprietary information
agreement. No employees of the Company are represented by any labor union or covered
by any collective bargaining agreement. There is no pending or, to the Company&#146;s
knowledge, threatened labor dispute involving the Company and any group of its
employees. The Company is not aware that any officer or key employee intends to
terminate his or her employment with the Company within the six months after Closing.
The Company does not have a present intention to terminate the employment of any
officer or key employee. Each officer and key employee is devoting 100% of his or
her business time to the conduct of the business of the Company. The Company is not
aware that any officer or key employee intends to work less than full time during the
six months after Closing. Subject to general
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">principles related to wrongful
termination of employees, the employment of each officer and employee of the Company
is terminable at will.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.10 <U>Patents and Other Intangible Assets</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Company owns, or is licensed or otherwise has the legally enforceable right to use,
all copyrights, domain names, maskworks, applications for the issuance or registration of any of
the foregoing, trade secrets, confidential or proprietary know-how, data and information, ideas,
inventions, designs, developments, algorithms, processes, schematics, techniques, computer
programs, applications and other software, works of authorship, creative effort and, to the
Company&#146;s knowledge after such investigation as the Company deemed reasonable, patents, patent
applications, trademarks (including service marks and design marks) and applications therefor,
tradenames (all of the foregoing generically, &#147;<B>Intellectual Property Rights</B>&#148;) utilized in, or
necessary for, its business as now conducted (collectively, the &#147;<B>Company Intellectual Property</B>&#148;)
without infringing upon the right of any person, corporation or other entity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Section&nbsp;2.10 of the Schedule of Exceptions lists (i)&nbsp;all patents and patent applications
and all registered and unregistered trademarks, trade names, copyrights and maskworks and
registered domain names included in the Company Intellectual Property, including the jurisdictions
in which each such intellectual property right has been issued or registered or in which any
application for such issuance or registration has been filed, (ii)&nbsp;all licenses, sublicenses,
collaborations and other agreements (or options for any of the foregoing) to which the Company is a
party and pursuant to which any person, corporation or other entity is authorized to use any of the
Company Intellectual Property, and (iii)&nbsp;all licenses, sublicenses, collaborations and other
agreements (or options for any of the foregoing) to which the Company is a party and pursuant
to which the Company is authorized to use any Intellectual Property Right of any third party (other
than standard licenses for commercially available software). Each of the agreements in (ii)&nbsp;and
(iii)&nbsp;above remain in full force and effect and, to the Company&#146;s knowledge, no party to any such
agreement is in material breach or default under such agreement, and the Company is not aware of
any act or failure to act by a party which would constitute a material breach or default under any
such agreement, give rise to a right of the licensor to terminate any such agreement or otherwise
result in termination of, or suspension or loss of exclusive rights under, any such agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) To the Company&#146;s knowledge, the Company has not infringed or misappropriated any
Intellectual Property Right of any other person, corporation or other entity. The Company has not
received any communication or otherwise received any information alleging any such conduct by the
Company or asserting a claim by any third party to the ownership of, or right to use, any of the
Company Intellectual Property, and the Company does not know of any basis for any such claim. The
Company is not aware of any action, suit, proceeding or investigation pending or currently
threatened against the Company (or any third party owner or licensor of rights to the Company of
any of the Company Intellectual Property) which would have a material impact on the Company&#146;s
ownership of or exclusive or co-exclusive rights to use, the Company Intellectual Property.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-5-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The Company is not aware that any of its employees is obligated under any agreement, or
subject to any judgment, decree or order of any court or administrative agency, that would
materially interfere with his or her ability to fully and freely perform their duties to the
Company or that would conflict with the Company&#146;s business. To the Company&#146;s knowledge, neither
the filing of the Restated Articles nor the execution and delivery of this Agreement or the
Investor Rights Agreement, nor the carrying on of the Company&#146;s business by the employees of the
Company, will conflict with or result in a material breach of the terms, conditions, or provisions
of, or constitute a default under, any agreement under which any such employee is now obligated.
The Company does not utilize, and will not be required to utilize, any invention, development or
work of authorship of any of its employees (or persons it currently intends to hire) made prior to
their employment by the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;Except as described in Schedule&nbsp;2.10, (i)&nbsp;the Company is not obligated, or under any
liability whatsoever to make any payments by way of royalties, fees or otherwise, to any owner or
licensor of, or other claimant to, any Company Intellectual Property, and (ii)&nbsp;the Company is not a
party to any agreement concerning the Company Intellectual Property or any other Intellectual
Property Right used or to be used by the Company in its business as conducted. No founder,
director, officer or employee of the Company, or, to the Company&#146;s knowledge, no shareholder of the
Company has any interest in the Company Intellectual Property.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Except with respect to any rights granted under the agreements described in Schedule&nbsp;2.10,
the Company owns exclusively all rights arising from or associated with the research and
development efforts of the Company, its founders, employees and independent contractors relating to
the Company&#146;s business as now conducted, and all such rights form part of
the Company Intellectual Property. The Company has secured valid written assignments from all
employees and independent contractors who contributed to the creation or development of any of the
Company Intellectual Property of the rights to such contributions that the Company does not already
own by operation of law. The Company has not received notice of any claim being asserted by any
current or former employee, independent contractor or other third party to the ownership, of or
right to use, any of the Company Intellectual Property, or challenging or questioning the validity
of any of the Company Intellectual Property, and the Company is not aware of any basis for any such
claim.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;The Company has taken reasonable steps to protect and preserve the confidentiality of all
material trade secrets included in Company Intellectual Property not otherwise protected by patents
or copyright (&#147;<B>Confidential Information</B>&#148;). All disclosure of Confidential Information to a third
party has been pursuant to the terms of a written confidentiality or non-disclosure agreement
between the Company and such third party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) The Company hereby represents and warrants that the data, written and oral reports and
other representations and information that the Company provided to its investors (or their counsel)
pertaining to the Company Intellectual Property, when taken as a whole, were truthful and, to the
Company&#146;s knowledge, accurate in all material respects, and there was no omission therefrom which
made such information misleading, or incomplete in any material way<B>.</B>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-6-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.11 <U>Compliance with Other Instruments</U>. The Company is not in violation or default of any provision of its Articles of
Incorporation or Bylaws, each as amended and in effect on and as of the Closing. The Company is
not in violation or default of any material provision of any instrument, mortgage, deed of trust,
loan, contract, commitment, judgment, decree, order or obligation to which it is a party or by
which it or any of its properties or assets are bound or, to the best of its knowledge, of any
provision of any federal, state or local statute, rule or governmental regulation. The execution,
delivery and performance of and compliance with this Agreement and the Investor Rights Agreement,
and the issuance and sale of the Shares, will not result in any such violation, be in conflict with
or constitute, with or without the passage of time or giving of notice, a default under any such
provision, license, indenture, instrument, mortgage, deed of trust, loan, contract, commitment,
judgment, decree, order or obligation; or require any consent or waiver under any such provision,
license, indenture, instrument, mortgage, deed of trust, loan, contract, commitment, judgment,
decree, order or obligation (other than any consents or waivers that have been obtained); or result
in the creation of any mortgage, pledge, lien, encumbrance or charge upon any of the properties or
assets of the Company pursuant to any such provision, license, indenture, instrument, mortgage,
deed of trust, loan, contract, commitment, judgment, decree, order or obligation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.12 <U>Permits</U>. The Company has all franchises, permits, licenses, and any
similar authority necessary for the conduct of its business as now being conducted by
it. The Company is not in default in any material respect under any of such
franchises, permits, licenses, or other similar authority.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.13 <U>Environmental and Safety Laws</U>. To its knowledge, the Company is not in violation of any applicable statute, law, or regulation
relating to the environment or occupational health and safety, and to its knowledge, no material
expenditures by the Company are or will be required in order to comply with any such existing
statute, law, or regulation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.14 <U>Title to Property and Assets</U>. The Company has good and marketable title
to all of its properties and assets free and clear of all pledges, mortgages, liens
security interests, charges and encumbrances, except liens for current taxes and
assessments not yet due and possible minor liens and encumbrances which do not, in
any case, individually or in the aggregate, materially detract from the value of the
property subject thereto or materially impair the ownership or use of said property
or assets, or the operations of the Company. With respect to the property and assets
it leases, the Company is in compliance with such leases and, to the best of its
knowledge, holds a valid leasehold interest free of all liens, claims or
encumbrances. The Company&#146;s properties and assets are in good condition and repair
in all material respects.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.15 <U>Agreements; Action</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Except for agreements contemplated by this Agreement, there are no agreements,
understandings or proposed transactions between the Company and any of its officers, directors,
affiliates, or any affiliate thereof other than standard option grants and stock purchase
agreements entered into prior to the date of this Agreement.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-7-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;There are no agreements, understandings, instruments, contracts, proposed transactions,
judgments, orders, writs or decrees to which the Company is a party or by which it is bound that
may involve (i)&nbsp;obligations (contingent or otherwise) of, or payments by the Company in excess of,
$100,000, other than in the ordinary course of business, (ii)&nbsp;the license of any patent, copyright,
trade secret or other proprietary right to or from the Company other than standard commercial
software licenses, (iii)&nbsp;provisions restricting or adversely affecting the development, manufacture
or distribution of the Company&#146;s products or services, or (iv)&nbsp;indemnification by the Company with
respect to infringements of proprietary rights other than indemnifications entered into in the
ordinary course of business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;For the purposes of subsection (b)&nbsp;above, all indebtedness, liabilities, agreements,
understandings, instruments, contracts and proposed transactions involving the same person or
entity (including persons or entities the Company has reason to believe are affiliated therewith)
shall be aggregated for the purpose of meeting the individual minimum dollar amounts of such
subsection.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The Company is not a party to and is not bound by any contract, agreement or instrument,
or subject to any restriction under its Restated Articles or its Bylaws that adversely affects its
business as now conducted, its properties or its financial condition.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;The Company is not a guarantor or indemnitor of any indebtedness of any other person or
entity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;The Company has not engaged in the past three months in any discussion (i)&nbsp;with any
representative of any entity or entities regarding the merger of the Company with or into any such
entity or entities or any affiliate thereof, (ii)&nbsp;with any representative of any entity or any
individual regarding the sale, conveyance or disposition of all or substantially all of the assets
of the Company or a transaction or series of related transactions in which more than fifty percent
(50%) of the voting power of the Company would be disposed of, or (iii)&nbsp;regarding any other form of
liquidation, dissolution or winding up of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.16 <U>Financial Statements</U>. The Company has made available to each Purchaser
its unaudited balance sheet dated as of December&nbsp;31, 2005 and the unaudited statement
of operations for the fiscal year then ended, its unaudited balance sheet as of March
31, 2006, and its unaudited statement of operations and cash flow statement covering
the three month period then ended (collectively, the &#147;<B>Financial Statements</B>&#148;). The
Financial Statements are complete and correct in all material respects and have been
prepared in accordance with generally accepted accounting principles applied on a
consistent basis throughout the periods indicated. The Financial Statements
accurately set out and describe the financial condition and operating results of the
Company as of the date, and during the periods, indicated therein. Except as set
forth in the Financial Statements, the Company has no material liabilities,
contingent or otherwise, other than (i)&nbsp;liabilities incurred in the ordinary course
of business subsequent to March&nbsp;31, 2006 and (ii)&nbsp;obligations under contracts and
commitments incurred in the ordinary course of business and not required under
generally accepted accounting principles to be reflected in the Financial Statements,
which, in both cases, individually or in the aggregate are not material to the
financial condition or operating results of the Company.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-8-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.17 <U>Changes</U>. Since March&nbsp;31 2006:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;the Company has not (i)&nbsp;declared or paid any dividends or authorized or made any
distribution upon or with respect to any class or series of its capital stock, (ii)&nbsp;incurred any
indebtedness for money borrowed or any other liabilities outside the ordinary course of its
business individually in excess of $100,000 or, in the case of indebtedness and/or liabilities
individually less than $100,000, in excess of $200,000 in the aggregate, (iii)&nbsp;made any loans or
advances to any person, other than ordinary advances for reimbursable businesses expenses,
(iv)&nbsp;sold, exchanged, assigned, transferred, licensed or otherwise disposed of any of its assets or
rights (including Company Intellectual Property), other than the sale of its inventory in the
ordinary course of business, (v)&nbsp;waived or compromised a valuable right or a material debt owed to
it, (vi)&nbsp;materially changed any compensation arrangement or agreement with any employee, officer,
director or shareholder, or (vii)&nbsp;arranged or committed to do any of the things described in this
subsection (a); and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;there has not been (i)&nbsp;a loss of, or a material order cancellation by, any major customer
of the Company, (ii)&nbsp;any damage, destruction or loss, whether or not covered by insurance,
materially and adversely affecting the business, properties, or financial condition of the Company,
(iii)&nbsp;any change in the assets, liabilities, financial condition or operating results of the
Company from that reflected in the Financial Statements, except changes in the ordinary course of
business that have not been, in the aggregate, materially adverse, (iv)&nbsp;any resignation or
termination of any officer or key employee of the Company, and the Company is not aware of the
impending resignation or termination of employment of any such officer, or (v)&nbsp;to the best of the
Company&#146;s knowledge, any other event or condition of any character that would materially and
adversely affect the business, properties, or financial condition of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.18 <U>Brokers or Finders</U>. The Company has not agreed to incur, directly or
indirectly, any liability for brokerage or finders&#146; fees, agents&#146; commissions or
other similar charges in connection with this Agreement or any of the transactions
contemplated hereby.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.19 <U>Qualified Small Business Stock</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;As of and immediately following the Closing, the Shares will meet each of the requirements
for qualification as &#147;qualified small business stock&#148; set forth in Section 1202(c) of the Internal
Revenue Code of 1986, as amended (the &#147;<B>Code</B>&#148;), including without limitation the following: (i)&nbsp;the
Company will be a domestic C corporation, (ii)&nbsp;the Company will not have made any purchases of its
own stock described in Code Section&nbsp;1202(c)(3)(B) during the one-year period preceding the Closing,
and (iii)&nbsp;the Company&#146;s (and any predecessor&#146;s) aggregate gross assets, as defined by Code Section
1202(d)(2), at no time from the date of incorporation of the Company and through the Closing have
exceeded or will exceed $50&nbsp;million, taking into account the assets of any corporations required to
be aggregated with the Company in accordance with Code Section&nbsp;1202(d)(3).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;As of the Closing, at least 80% (by value) of the assets of the Company are used by it in
the active conduct of one or more qualified trades or businesses, as defined by Code
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-9-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Section
1202(e)(3), and the Company is an eligible corporation, as defined by Code Section&nbsp;1202(e)(4).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.20 <U>Employee Benefit Plans</U>. The Company does not have any Employee Benefit
Plan as defined in the Employee Retirement Income Security Act of 1974 other than the
Company&#146;s 401(k) Plan. The Company is in material compliance with the terms of the
Company&#146;s 401(k) Plan and has not received notice of any material increase in the
costs of such plans.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.21 <U>Tax Matters</U>. The Company has filed all tax returns and reports as
required by law. These returns and reports are true and correct in all material
respects. The Company has paid all taxes and other assessments due. The Company has
not elected
pursuant to the Code, to be treated as a Subchapter S corporation or a collapsible
corporation pursuant to Section 1362(a) or Section 341(f) of the Code, nor has it
made any other elections pursuant to the Code (other than elections that relate
solely to methods of accounting, depreciation or amortization) that would have a
material effect on the business, properties or condition (financial or otherwise) of
the Company. None of the Company&#146;s tax returns have ever been audited by any
governmental authorities. The Company has withheld or collected from each payment
made to its employees the amount of all taxes (including without limitation, federal
income taxes, Federal Insurance Contribution Act taxes and Federal Unemployment Tax
Act taxes) required to be withheld or collected therefrom, and has paid the same to
the proper tax receiving officers or authorized depositories.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.22 <U>Insurance</U>. The Company has in full force and effect fire and casualty
insurance policies, with extended coverage, sufficient in amount (subject to
reasonable deductibles) to allow it to replace any of its properties that might be
damaged or destroyed. The Company has obtained term life insurance payable to the
Company on the lives of Stephen Quake and Gajus Worthington in the amount of
$500,000. The Company has in full force and effect directors and officers liability
insurance, covering all of its directors, with aggregate coverage in the amount of
$2,000,000.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.23 <U>Corporate Documents</U>. The Restated Articles and Bylaws of the Company
are in the form made available to the Purchasers. The copy of the minute books of
the Company made available to the Purchasers&#146; counsel contains true and correct
minutes of all meetings of directors (including any committees thereof) and
shareholders and all actions by written consent taken without a meeting by the
directors and shareholders since December&nbsp;18, 2003.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.24 <U>Disclosure</U>. The Company has fully provided each Purchaser with all the
information which such Purchaser has requested in connection with the purchase of the
Shares hereunder, as well as all information which the Company in its judgment
believes is reasonably necessary to enable such Purchaser to make a decision as to
whether to invest in the Company. Neither this Agreement with the Exhibits hereto,
nor any other statements, certificates or documents made or delivered in connection
herewith or therewith, contains any untrue statement of a material fact or omits to
state a material fact necessary to make the statements herein or therein not
misleading in light of the circumstances under which they were made. The financial
projections made available to the Purchasers (the &#147;<B>Projections</B>&#148;) were prepared in
good faith and based upon assumptions that the Company believes are reasonable, and
represent the Company&#146;s good faith
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-10-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">estimate of its future plans and results; provided
however that the Company does not represent or warrant that it will achieve any of
the Projections.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.25 <U>Offering</U>. Subject in part to the truth and accuracy of each Purchaser&#146;s representations set forth in
this Agreement, the offer, sale and issuance of the Shares as contemplated by this Agreement is
exempt from the registration requirements of the Securities Act of 1933, as amended (the
&#147;<B>Securities Act</B>&#148;), and from the registration or qualification requirements of applicable state
securities laws or blue sky laws, and neither the Company nor any authorized agent acting on its
behalf will take any action hereafter that would cause the loss of such exemption.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.26 <U>Returns and Complaints</U>. The Company has not received customer
complaints concerning alleged defects in the design of its products that, if true,
would have, individually or in the aggregate, a material adverse effect on its
business, properties, or financial condition.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Representations and Warranties of the Purchasers</U>. Each Purchaser, individually
and not jointly, hereby represents and warrants as of the Closing Date that:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 <U>Experience</U>. Such Purchaser is experienced in evaluating start-up
companies such as the Company, is able to evaluate and represent its own interests in
transactions such as the one contemplated by this Agreement, has such knowledge and
experience in financial and business matters such that Purchaser is capable of
evaluating the merits and risks of Purchaser&#146;s prospective investment in the Company,
and has the ability to bear the economic risks of its investment.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 <U>Investment</U>. Such Purchaser is acquiring the Shares, and the Conversion
Shares, for investment for such Purchaser&#146;s own account and not with the view to, or
for resale in connection with, any distribution thereof. Such Purchaser understands
that the Shares, and the Conversion Shares have not been registered under the
Securities Act by reason of a specific exemption from the registration provisions of
the Securities Act which depends upon, among other things, the bona fide nature of
the investment intent as expressed herein. Such Purchaser further represents that it
does not have any contract, undertaking, agreement or arrangement with any person to
sell, transfer or grant participation to any third person with respect to any of the
Shares, or the Conversion Shares, other than a transfer not involving a change of
beneficial ownership. Such Purchaser understands and acknowledges that the offering
of the Shares pursuant to this Agreement will not be registered under the Securities
Act on the ground that the sale provided for in this Agreement is exempt from the
registration requirements of the Securities Act.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3 <U>Rule&nbsp;144</U>. Such Purchaser acknowledges that the Shares and the Conversion
Shares must be held indefinitely unless subsequently registered under the Securities
Act or an exemption from such registration is available. Such Purchaser is aware of
the provisions of Rule&nbsp;144 promulgated under the Securities Act which permit limited
resale of shares purchased in a private placement subject to the satisfaction of
certain conditions. Such Purchaser covenants that, in the absence of an effective
registration statement covering the stock in question, such Purchaser will sell,
transfer, or otherwise dispose of the Shares or the Conversion Shares only in a
manner consistent
with applicable securities laws and such Purchaser&#146;s representations and covenants
set forth in this Section&nbsp;3. In connection therewith, such Purchaser acknowledges
that the Company
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-11-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">will make a notation on its stock books regarding the restrictions
on transfers set forth in this Section&nbsp;3 and will transfer securities on the books of
the Company only to the extent not inconsistent therewith.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4 <U>Legends</U>. Purchaser understands and acknowledges that the certificate
evidencing its Shares and the Conversion Shares will be imprinted with legends in the
form set forth in Section&nbsp;1.3 of the Investor Rights Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.5 <U>No Public Market</U>. Such Purchaser understands that no public market now
exists for any of the securities issued by the Company, and that the Company has made
no assurances that a public market will ever exist for the Shares or the Conversion
Shares.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.6 <U>Access to Data</U>. Such Purchaser has received and reviewed information
about the Company and has had an opportunity to discuss the Company&#146;s business,
management and financial affairs with its management and to review the Company&#146;s
facilities. The foregoing, however, does not limit or modify the representations and
warranties of the Company in Section&nbsp;2 of this Agreement or the right of the
Purchasers to rely thereon.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.7 <U>Authorization</U>. This Agreement when executed and delivered by such
Purchaser will constitute a valid and legally binding obligation of the Purchaser,
enforceable against the Purchaser in accordance with its terms, subject to:
(i)&nbsp;judicial principles respecting election of remedies or limiting the availability
of specific performance, injunctive relief, and other equitable remedies;
(ii)&nbsp;bankruptcy, insolvency, reorganization, moratorium or other similar laws now or
hereafter in effect generally relating to or affecting creditors&#146; rights; and
(iii)&nbsp;limitations on the enforceability of the indemnification provisions of the
Investor Rights Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.8 <U>Accredited Investor</U>. Such Purchaser acknowledges that it is an
&#147;accredited investor&#148; as defined in Rule&nbsp;501 of Regulation&nbsp;D as promulgated by the
Securities and Exchange Commission under the Securities Act and shall submit to the
Company such further assurances of such status as may be reasonably requested by the
Company. The principal address of such Purchaser is as set forth on the Schedule of
Purchasers.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.9 <U>Public Solicitation</U>. Purchaser knows of no public solicitation or
advertisement of an offer in connection with the proposed issuance and sale of the
Shares.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.10 <U>Tax Advisors</U>. Purchaser has reviewed with Purchaser&#146;s own tax advisors
the federal, state and local tax consequences of this investment, where applicable,
and the transactions contemplated by this Agreement. Each Purchaser is relying
solely on
such advisors and not on any statements or representations of the Company or any of
its agents and understands that each Purchaser (and not the Company) shall be
responsible for the Purchaser&#146;s own tax liability that may arise as a result of this
investment or the transactions contemplated by this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.11 <U>Purchaser Counsel</U>. Purchaser acknowledges that it has had the
opportunity to review this Agreement, the exhibits and the schedules attached hereto
and the transactions contemplated by this Agreement with Purchaser&#146;s own legal
counsel. Each Purchaser is relying
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-12-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">solely on such counsel and not on any statements
or representations of the Company or any of its agents for legal advice with respect
to this investment or the transactions contemplated by this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.12 <U>Brokers or Finders</U>. The Company has not incurred and will not incur,
directly or indirectly, as a result of any action taken by such Purchaser, any
liability for brokerage or finders&#146; fees or agents&#146; commissions or any similar
changes in connection with this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.13 <U>Non-United States Persons</U>. If Purchaser is not a United States person, such Purchaser hereby represents that such
Purchaser is satisfied as to the full observance of the laws of such Purchaser&#146;s jurisdiction in
connection with any invitation to subscribe for the Shares and the Conversion Shares or any use of
this Agreement, the Investor Rights Agreement and the Voting Agreement, including (i)&nbsp;the legal
requirements within such Purchaser&#146;s jurisdiction for the purchase of Shares and the Conversion
Shares, (ii)&nbsp;any foreign exchange restrictions applicable to such purchase, (iii)&nbsp;any governmental
or other consents that may need to be obtained and (iv)&nbsp;the income tax and other tax consequences,
if any, that may be relevant to the purchase, holding, redemption, sale or transfer of such
securities. Such Purchaser&#146;s subscription and payment for, and such Purchaser&#146;s continued
beneficial ownership of, the Shares and the Conversion Shares will not violate any applicable
securities or other laws of such Purchaser&#146;s jurisdiction.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Conditions of Purchaser&#146;s Obligations at Closing</U>. The obligations of each
Purchaser under this Agreement are subject to the fulfillment on or before the Closing of each
of the following conditions, the waiver of which shall not be effective against any Purchaser
who does not consent in writing thereto:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 <U>Representations and Warranties</U>. The representations and warranties of
the Company contained in Section&nbsp;2 shall be true on and as of the Closing with the
same effect as though such representations and warranties had been made on and as of
the date of the Closing.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 <U>Performance</U>. The Company shall have performed and complied with all
agreements, obligations and conditions contained in this Agreement that are required
to be performed or complied with by it on or before the Closing.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3 <U>Compliance Certificate</U>. The President of the Company shall deliver to
each Purchaser at the Closing a certificate stating that the conditions specified in
Sections&nbsp;4.1 and 4.2 have been fulfilled and stating that as of the Closing there
shall have been no adverse change in the business, affairs, operations, properties,
assets or condition of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4 <U>Blue Sky</U>. The Company shall have obtained all necessary permits and
qualifications, if any, or secured an exemption therefrom, required by any state or
country prior to the offer and sale of the Shares.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.5 <U>Opinion of Company Counsel</U>. Each Purchaser in the Initial Closing shall
have received from Wilson Sonsini Goodrich &#038; Rosati, Professional Corporation,
counsel for the Company, an opinion, dated as of the Initial Closing, in the form
attached hereto as <U>EXHIBIT E</U>.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-13-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.6 <U>Investor Rights Agreement</U>. The Company and each Purchaser shall have
entered into the Investor Rights Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.7 <U>Restated Articles</U>. The Restated Articles shall have been accepted for
filing by the California Secretary of State and shall be in full force and effect as
of the Closing Date.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.8 <U>Corporate Proceedings; Waivers and Consents</U>. All corporate and other
proceedings to be taken and all waivers, consents and permits necessary or
appropriate for the consummation of the transactions contemplated by this Agreement
will have been taken or obtained.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Conditions of the Company&#146;s Obligations at Closing</U>. The obligations of the
Company to each Purchaser under this Agreement are subject to the fulfillment on or before the
Closing of each of the following conditions by that Purchaser:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 <U>Representations and Warranties</U>. The representations and warranties of
the Purchasers contained in Section&nbsp;3 shall be true on and as of the Closing with the
same effect as though such representations and warranties had been made on and as of
the Closing.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2 <U>Payment of Purchase Price</U>. Each Purchaser shall have delivered the
purchase price against delivery of the Shares as set forth in Section&nbsp;1.4 by the
Company to such Purchaser.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3 <U>Blue Sky</U>. The Company shall have obtained all necessary permits and
qualifications, if any, or secured an exemption therefrom, required by any state or
country for the offer and sale of the Shares.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4 <U>Investor Rights Agreements</U>. The Company and each Purchaser shall have
entered into the Investor Rights Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.5 <U>Restated Articles </U>. The Restated Articles shall have been accepted for
filing by the California Secretary of State and shall be in full force and effect as
of the Closing Date.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.6 <U>Proceedings and Documents</U>. All corporate and other proceedings in
connection with the transactions contemplated at the Closing hereby, and all
documents and instruments incident to these transactions, shall be reasonably
satisfactory in substance to the Company and its counsel.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Miscellaneous</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1 <U>Governing Law; Jurisdiction</U>. This Agreement and all acts and
transactions pursuant hereto and the rights and obligations of the parties hereto
shall be governed in all respects by the laws of the State of California, without
regard to any provisions thereof relating to conflicts of laws among different
jurisdictions. The parties hereto agree to submit to the exclusive jurisdiction of
the federal and state courts of San Mateo County, California with respect to the
breach or interpretation of this Agreement or the enforcement of any and all rights,
duties, liabilities, obligations, powers, and other relations between the parties
arising under this Agreement.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-14-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2 <U>Indemnification</U>. The Company shall indemnify, defend and hold each
Purchaser harmless against all liability, loss or damage (collectively, &#147;<B>Losses</B>&#148; and
individually, a &#147;<B>Loss</B>&#148;) arising from any litigation, proceeding or dispute arising
from such Purchaser&#146;s status as a shareholder of the Company other than Losses
arising from such Purchaser&#146;s gross negligence or willful misconduct, provided that
such indemnification shall apply only to litigation, proceedings or disputes arising
prior to the Company&#146;s Initial Public Offering (as defined in the Investor Rights
Agreement) and the Company&#146;s obligation to indemnify any Purchaser shall be limited
in amount to the amount paid by such Purchaser for the purchase of such Purchaser&#146;s
Shares as set forth on <U>EXHIBIT A</U>. The foregoing indemnity is not intended to
supercede or replace the indemnification obligations of the parties set forth in
Section&nbsp;1.10 of the Investor Rights Agreement nor shall it be construed to limit any
other rights and remedies of the Purchasers under this Agreement or any other
indemnification to which such Purchaser may be entitled under any other agreement of
the Company. The foregoing indemnification rights are transferable only to
Affiliates (as defined in the Investor Rights Agreement) of a Purchaser.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3 <U>Survival</U>. The representations, warranties, covenants and agreements made
herein shall survive any investigation made by any Purchaser or the Company and the
Closing of the transactions contemplated hereby; provided, however, that such
representations and warranties are only made as of the date of such execution and
delivery and as of such Closing.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4 <U>Successors and Assigns</U>. Except as otherwise provided herein, the
provisions hereof shall inure to the benefit of, and be binding upon, the successors,
assigns, heirs, executors and administrators of the parties hereto; provided,
however, that the rights of a Purchaser to purchase Shares at the Closing shall not
be assignable without the consent of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.5 <U>Entire Agreement; Amendment</U>. This Agreement and the other documents
delivered pursuant hereto constitute the full and entire understanding and agreement
among the parties with regard to the subjects hereof and thereof relating to the
purchase of the Shares. Neither this Agreement nor any term hereof may be amended,
waived, discharged or terminated other than by a written instrument signed by the
Company and the holder or holders of greater than fifty percent (50%) of the
then-outstanding Shares or the Conversion Shares. Notwithstanding the foregoing, any
additional purchaser pursuant to Section&nbsp;1.2 may become a party to this Agreement by
executing and delivering an additional counterpart signature page to this Agreement
and such purchaser shall be deemed a Purchaser hereunder. The parties agree that the
Schedule of Purchasers attached hereto as <U>Exhibit&nbsp;A</U> shall be updated
automatically without any formal amendment to reflect the addition of any such
additional Purchaser. Any amendment or waiver effected in accordance with this
Section&nbsp;6.5 shall be binding upon the Purchasers and each transferee of the Shares
(or the Common Stock issuable upon conversion thereof), each future holder of all
such securities, and the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.6 <U>Notices, Etc</U>. All notices and other communications required or permitted
hereunder, shall be in writing and shall be personally delivered, sent by facsimile,
mailed by registered or certified mail, postage prepaid, return receipt requested, or
delivered by a nationally recognized overnight courier, addressed (a)&nbsp;if to a
Purchaser, at such Purchaser&#146;s address or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-15-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">facsimile number set forth on the Schedule
of Purchasers, or at such other address or facsimile number as such Purchaser shall
have furnished to the Company in writing, or (b)&nbsp;if to the Company, at its address or
facsimile number set forth on the signature page to this Agreement addressed to the
attention of the Corporate Secretary, or at such other address or facsimile number as
the Company shall have furnished to the Purchasers. Any such notice or communication
shall be deemed to have been received (A)&nbsp;in the case of personal delivery or
delivery by telecopier, on the date of such delivery, (B)&nbsp;in the case of a commercial
overnight courier, on the next business day after the date when sent and (C)&nbsp;in the
case of mailing, on the fifth business day following that on which the piece of mail
containing such communication is posted.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.7 <U>Delays or Omissions</U>. No delay or omission to exercise any right, power
or remedy accruing to any holder of any Shares upon any breach or default of the
Company under this Agreement shall impair any such right, power or remedy of such
holder, nor shall it be construed to be a waiver of any such breach or default, or an
acquiescence therein, or of or in any similar breach or default thereafter occurring;
nor shall any waiver of any single breach or default be deemed a waiver of any other
breach or default theretofore or thereafter occurring. Any waiver, permit, consent
or approval of any kind or character on the part of any holder of any breach or
default under this Agreement, or any waiver on the part of any holder of any
provisions or conditions of this Agreement, must be in writing and shall be effective
only to the extent specifically set forth in such writing or as provided in this
Agreement. All remedies, either under this Agreement or by law or otherwise afforded
to any holder, shall be cumulative and not alternative.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.8 <U>California Corporate Securities Law</U>. THE SALE OF THE SECURITIES WHICH
ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER OF
CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF SUCH SECURITIES OR THE
PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION THEREFOR PRIOR TO SUCH
QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SECURITIES IS EXEMPT FROM THE
QUALIFICATION BY SECTION 25100, 25102, OR 25105 OF THE CALIFORNIA CORPORATIONS CODE.
THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE EXPRESSLY CONDITIONED UPON SUCH
QUALIFICATION BEING OBTAINED, UNLESS THE SALE IS SO EXEMPT.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.9 <U>Finder&#146;s Fee</U>. The Company and each Purchaser shall each indemnify and
hold the other harmless from any liability for any commission or compensation in the
nature of a finder&#146;s fee (including the costs, expenses and legal fees of defending
against such liability) for which the Company or the Purchasers, or any of their
respective partners, employees, or representatives, as the case may be, is
responsible.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.10 <U>Expenses</U>. The Company and each Purchaser shall bear its own expenses
and legal fees incurred on its behalf with respect to this Agreement and the
transactions contemplated hereby.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.11 <U>Waiver of Conflict</U>. Each of the Purchasers and the Company acknowledges
that Wilson Sonsini Goodrich &#038; Rosati, Professional Corporation (&#147;<B>WSGR</B>&#148;) may have
represented and may currently represent Purchasers. In the course of such
representation, WSGR may have
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-16-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">come into possession of confidential information
relating to such Purchasers. Each of the Purchasers and the Company acknowledges
that WSGR is representing only the Company in this transaction. Pursuant to Rule
3-310 of the Rules of Professional Conduct promulgated by the State Bar of
California, an attorney must avoid representations in which the attorney has or had a
relationship with another party interested in the representation without the informed
written consent of all parties affected. By executing this Agreement, each of the
Purchasers
and the Company hereby waives any actual or potential conflict of interest that may
arise in this financing as a result of WSGR&#146;s representation of such persons or
entities, WSGR&#146;s possession of such confidential information and the participation by
WSGR&#146;s affiliate in the financing. Each of the Purchasers and the Company represents
that it has had the opportunity to consult with independent counsel concerning the
giving of this waiver.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.12 <U>Severability</U>. In the event that any provision of this Agreement becomes
or is declared by a court of competent jurisdiction to be illegal, unenforceable or
void, this Agreement shall continue in full force and effect without said provision;
provided that no such severability shall be effective if it materially changes the
economic benefit of this Agreement to any party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.13 <U>Counterparts; Facsimile</U>. This Agreement may be executed in any number
of counterparts, each of which may be executed by less than all Purchasers, each of
which shall be enforceable against the parties actually executing such counterparts,
and all of which together shall constitute one instrument. This Agreement may be
executed by facsimile signature.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.14 <U>Titles and Subtitles</U>. The titles and subtitles used in this Agreement
are used for convenience only and are not to be considered in construing or
interpreting this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.15 <U>Exculpation Among Purchasers</U>. Each Purchaser acknowledges that it is
not relying upon any person, firm or corporation (including without limitation any
other Purchaser), other than the Company and its officers and directors (acting in
their capacity as representatives of the Company), in deciding to invest and in
making its investment in the Company. Each Purchaser agrees that no other Purchaser
nor the respective controlling persons, officers, directors, partners, agents or
employees of any other Purchaser shall be liable to such Purchaser for any losses
incurred by such Purchaser in connection with its investment in the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.16 <U>Like Treatment of Holders</U>. The Company shall not directly or indirectly
pay or cause to be paid any consideration, whether by way of interest, fee, payment
for the redemption or exchange of Preferred Stock, or otherwise to any holder of
Preferred Stock for or as inducement to, any consent, waiver or amendment of any term
or provision of the Preferred Stock, this Agreement or the Investor Rights Agreement
unless equivalent consideration is offered on equivalent terms and conditions to all
Purchasers of Preferred Stock under this Agreement bound by such consent, waiver or
amendment.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.17 <U>Jury Trial</U>. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO
THE FULLEST EXTENT PERMITTED BY LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL
PROCEEDING (WHETHER
SOUNDING IN CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATED TO THIS AGREEMENT.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-17-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>FLUIDIGM CORPORATION</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Gajus Worthington
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Gajus Worthington&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">President and Chief Executive Officer<br><br>
7100 Shoreline Court<br>
South San Francisco, CA 94080<br>
FAX: (650) 871-7195&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;FLUIDIGM CORPORATION SERIES E PREFERRED STOCK PURCHASE AGREEMENT&#093;</I></B>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="46%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>PURCHASER:</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>AllianceBernstein L.P.</B></FONT></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Adam Spilka</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Adam Spilka</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SVP, Counsel, Secretary</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;FLUIDIGM CORPORATION SERIES E PREFERRED STOCK PURCHASE AGREEMENT&#093;</I></B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXHIBIT A</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>SCHEDULE OF PURCHASERS</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="23%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="13%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Name and Address</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Shares of Series E</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Purchase Price</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>AllianceBernstein L.P.</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,250,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">5,000,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>TOTALS</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>1,250,000</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>$</B></TD>
    <TD align="right"><B>5,000,000.00</B></TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FLUIDIGM CORPORATION</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>AMENDMENT NO. 1 TO<BR>
SERIES E PREFERRED STOCK PURCHASE AGREEMENT</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Amendment No.&nbsp;1 (the &#147;<B>Amendment</B>&#148;) to that certain Series&nbsp;E Preferred Stock Purchase
Agreement, dated as of June&nbsp;13, 2006 (the &#147;<B>Purchase Agreement</B>&#148;), is made and entered into effective
as of December&nbsp;22, 2006 (the &#147;<B>Effective Date</B>&#148;) by and among Fluidigm Corporation, a California
corporation (the &#147;<B>Company</B>&#148;), and the Purchasers named therein. Capitalized terms used in this
Amendment that are not otherwise defined herein shall have the respective meanings assigned to them
in the Purchase Agreement.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>RECITALS</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS</B>, the Company previously sold and issued an aggregate of 1,250,000 shares of Series&nbsp;E
Preferred Stock of the Company (the &#147;<B>Series&nbsp;E Preferred</B>&#148;) pursuant to the terms of the Purchase
Agreement at the Initial Closing held on June&nbsp;13, 2006;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS</B>, the Company and the Purchaser now desire to amend the terms of the Purchase Agreement
to provide that the Company may sell and issue additional shares of Series&nbsp;E Preferred pursuant to
the Purchase Agreement, at one or more additional Subsequent Closings, provided that any such
additional Subsequent Closings shall take place no later than March&nbsp;31, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS</B>, pursuant to Section&nbsp;6.5 of the Purchase Agreement, the terms of the Purchase
Agreement may be amended upon the written consent of the Company and the holder or holders of
greater than fifty percent (50%) of the outstanding Shares or the Conversion Shares; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS</B>, the Purchaser who has signed below holds greater than fifty percent (50%) of the
outstanding Shares purchased under the Purchase Agreement as of the Effective Date and consents to
the changes as set forth in this Amendment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>NOW, THEREFORE, </B>in consideration of the foregoing, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto
mutually agree as follows:
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>AGREEMENT</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Amendment to Section&nbsp;1.1</U>. Section&nbsp;1.1 (Authorization of the Shares) of the
Purchase Agreement is hereby amended and restated in its entirety as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;1.1 <U>Authorization of the Shares</U>. The Company will on or
before the Closing (as defined below) authorize the sale and issuance
pursuant to this Agreement of up to 6,318,333 shares (the &#147;<B>Shares</B>&#148;) of its
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 1 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">Series&nbsp;E Preferred Stock (the &#147;<B>Series&nbsp;E Preferred</B>&#148;), having the rights,
preferences and privileges as set forth in the Amended and Restated Articles
of Incorporation attached hereto as <U>EXHIBIT B</U> (the &#147;<B>Restated
Articles</B>&#148;).&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Amendment to Section&nbsp;1.2</U>. Section&nbsp;1.2 (Purchase and Sale of the Shares) of the
Purchase Agreement is hereby amended and restated in its entirety as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;1.2 <U>Purchase and Sale of the Shares</U>. Subject to the terms and
conditions hereof and in reliance upon the representations, warranties and
agreements contained herein, the Company will issue and sell to each
Purchaser, severally and not jointly, and each Purchaser will purchase from
the Company, severally and not jointly, at the Closing, the number of Shares
set forth opposite the Purchaser&#146;s name on the Schedule of Purchasers, at a
purchase price of Four Dollars ($4.00) per Share. The Company shall be
entitled to sell any unpurchased Shares to any Purchaser or to a person who
is not a Purchaser and to amend the Schedule of Purchasers to include the
information relating to such sales, and such purchasers shall be considered
&#147;Purchasers&#148; and parties to this Agreement; provided that (i)&nbsp;such sales are
made pursuant to this Agreement or an agreement identical to this one except
for the Closing Date and exhibits, and (ii)&nbsp;such sales are completed on or
prior to March&nbsp;31, 2007. The Company&#146;s agreement with each Purchaser is a
separate agreement, and the sale of the Shares to each Purchaser is a
separate sale.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Governing Law</U>. This Amendment shall be governed in all respects by the laws of the
State of California, without regard to any provisions thereof relating to conflicts of laws among
different jurisdictions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Purchase Agreement</U>. Wherever necessary, all other terms of the Purchase Agreement
are hereby amended to be consistent with the terms of this Amendment. Except as specifically set
forth herein, the Purchase Agreement shall remain in full force and effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Counterparts; Facsimile</U>. This Amendment may be executed in any number of
counterparts, each of which shall be an original, and all of which together shall constitute one
instrument. Executed signatures transmitted via facsimile will be accepted and considered duly
executed.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Effect of Execution of Amendment by Certain Purchaser</U>. This Amendment, when
executed and delivered by the Company and a Purchaser purchasing shares of Series&nbsp;E Preferred at a
Subsequent Closing held on or after the date hereof, shall also constitute and shall be deemed a
counterpart signature page to the Purchase Agreement. Consequently, each undersigned Purchaser
purchasing shares of Series&nbsp;E Preferred at a Subsequent Closing held on or after the date hereof
acknowledges and agrees that he, she or it is bound by the terms and
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 2 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">conditions contained in the Purchase Agreement, as amended by this Amendment, with respect to
the purchase of such shares.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;</B><B><I>Remainder of page intentionally left blank</I></B><B>&#093;</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->- 3 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment No.&nbsp;1 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left"><B>COMPANY:</B></TD>
    <TD colspan="3" align="left"><B>FLUIDIGM CORPORATION</B><BR>
a California corporation<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Gajus Worthington
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Gajus Worthington,&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">President and Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature Page to Amendment No.&nbsp;1 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">





<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment No.&nbsp;1 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PURCHASER:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="14%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Cross Creek Capital, L.P.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Cross Creek Capital GP, L.P.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its Sole General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Cross Creek Capital, LLC</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its Sole General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Wasatch Advisors, Inc. <br>
Its Sole Member</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Karey Barker
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Karey Barker</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="14%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Cross Creek Capital Employees&#146; Fund, L.P.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Cross Creek Capital GP, L.P.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its Sole General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Cross Creek Capital, LLC</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its Sole General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Wasatch Advisors, Inc.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its Sole Member</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Karey Barker
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Karey Barker</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature Page to Amendment No.&nbsp;1 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment No.&nbsp;1 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PURCHASER:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="18%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>WASATCH FUNDS, INC.</B><BR>
Wasatch Small Cap Growth Fund</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Wasatch Advisors, Inc.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Investment Adviser</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Dan Thurber
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name: Dan Thurber
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature Page to Amendment No.&nbsp;1 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment No.&nbsp;1 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PURCHASER:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>SMALLCAP World Fund, Inc.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>By:</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><FONT style="white-space: nowrap">Capital Research and Management Company,</FONT></B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>its, investment adviser</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Michael Downer
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Michael Downer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature Page to Amendment No.&nbsp;1 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment No.&nbsp;1 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PURCHASER:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>AllianceBernstein Venture Fund I, L.P.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>By:</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>AllianceBernstein ESG Venture Management, L.P.,
its general partner</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>By:</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>AllianceBernstein Global Derivatives Corporation,
its general partner</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ James D. Kiggen
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">James D. Kiggen</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Senior Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature Page to Amendment No.&nbsp;1 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment No.&nbsp;1 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PURCHASER:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-variant: SMALL-CAPS"><b>Versant</B></FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-variant: SMALL-CAPS"><b>Affiliates Fund 1-A, L.P.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-variant: SMALL-CAPS"><b>Versant</B></FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-variant: SMALL-CAPS"><b>Affiliates Fund 1-B, L.P.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-variant: SMALL-CAPS"><b>Versant</B></FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-variant: SMALL-CAPS"><b>Side Fund I, L.P.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-variant: SMALL-CAPS"><b>Versant</B></FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-variant: SMALL-CAPS"><b>Venture Capital I, L.P.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Versant Ventures I, LLC</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Samuel D. Colella
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Samuel D. Colella</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Managing Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature Page to Amendment No.&nbsp;1 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment No.&nbsp;1 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PURCHASER:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Lehman Brothers Healthcare Venture Capital L.P.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Lehman Brothers HealthCare Venture Capital Associates L.P.,</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">LB I Group Inc., its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Michael Odrich
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Michael Odrich</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Senior Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Lehman Brothers P.A. LLC</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Michael Odrich
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Michael Odrich</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Senior Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Lehman Brothers Partnership Account <BR>
2000/2001, L.P.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">LB I Group Inc., its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Michael Odrich
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Michael Odrich</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Senior Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Lehman Brothers Offshore Partnership Account 2000/2001, L.P.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">LB I Offshore Partners Group Ltd., its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Michael Odrich
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Michael Odrich</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Senior Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature Page to Amendment No.&nbsp;1 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment No.&nbsp;1 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PURCHASER:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>EuclidSR Partners, L.P.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">EuclidSR Associates, L.P.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Elaine V. Jones
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Elaine V. Jones</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>EuclidSR Biotechnology Partners, L.P</B></FONT><B>.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">EuclidSR Biotechnology Associates, L.P.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Elaine V. Jones
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Elaine V. Jones</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature Page to Amendment No.&nbsp;1 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment No.&nbsp;1 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PURCHASER:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Iinterwest Partners VII, L.P.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">InterWest Management Partners VII, LLC</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Michael Sweeney
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Michael Sweeney</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">As agent for the general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Interwest Investors VII, L.P.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">InterWest Management Partners VII, LLC</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Michael Sweeney
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Michael Sweeney</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">As agent for the general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature Page to Amendment No.&nbsp;1 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment No.&nbsp;1 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PURCHASER:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Lilly Bioventures, Eli Lilly &#038; Company</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Thomas W. Grein
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Thomas W. Grein</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vice President and Treasurer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature Page to Amendment No.&nbsp;1 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment No.&nbsp;1 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PURCHASER:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Alloy Ventures 2005, L.P.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Alloy Ventures 2005, LLC</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Tony DiBona
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Toni DiBona</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Managing Member of Alloy Ventures
2005 LLC</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Alloy Ventures 2002, L.P.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Alloy Partners 2002, L.P.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Alloy Ventures 2002, LLC</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Tony DiBona
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tony DiBona</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Managing Member of Alloy
Ventures
2002, LLC, the general partner of Alloy
Partners 2002, L.P. and Alloy Ventures
2002, L.P.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature Page to Amendment No.&nbsp;1 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment No.&nbsp;1 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PURCHASER:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>SightLine Healthcare Fund III, L.P.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Kenneth E. Higgins
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Kenneth E. Higgins</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Managing Director of Sightline
Partners
LLC, general partner of its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature Page to Amendment No.&nbsp;1 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment No.&nbsp;1 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PURCHASER:</B>
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Bruce Burrow
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Bruce Burrows</B></FONT>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature Page to Amendment No.&nbsp;1 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment No.&nbsp;1 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the 30<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> day of March, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PURCHASER:</B>
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ John M. Harland
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><FONT style="font-variant: SMALL-CAPS"><B>John M. Harland</B></FONT>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature Page to Amendment No.&nbsp;1 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment No.&nbsp;1 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the 30<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> day of March, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>PURCHASER:</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Ferguson/Egan Family Trust dated 6/28/99</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:<BR>
Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Rodney A. Ferguson
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Rodney A. Ferguson
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Trustee</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature Page to Amendment No.&nbsp;1 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment No.&nbsp;1 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the 30<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> day of March, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>PURCHASER:</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Health Care Administration Company</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gary L. Bowers
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Gary L. Bowers</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature Page to Amendment No.&nbsp;1 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment No.&nbsp;1 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the 30<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> day of March, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>PURCHASER:</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>The Condon Family Trust</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Thomas J. Condon
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Thomas J. Condon</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Trustee</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature Page to Amendment No.&nbsp;1 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment No.&nbsp;1 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the 30<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> day of March, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>PURCHASER:</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>In-Q-Tel, Inc.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Scott G. Yancey
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Scott G. Yancey</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Executive Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>In-Q-Tel Employee Fund, LLC</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Scott G. Yancey</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Scott G. Yancey</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">EVP of In-Q-Tel, Inc., the manager of the
fund</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature Page to Amendment No.&nbsp;1 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment No.&nbsp;1 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the 30<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> day of March, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>PURCHASER:</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>The V Foundation for Cancer Research</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:<BR>
Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Nicholas Valvano
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Nicholas Valvano
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature Page to Amendment No.&nbsp;1 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment No.&nbsp;1 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the 30<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> day of March, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>PURCHASER:</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Fredrick H. Stern
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
<FONT style="font-variant: SMALL-CAPS"><B>Fredrick H. Stern</B></FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature Page to Amendment No.&nbsp;1 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment No.&nbsp;1 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the 30<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> day of March, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PURCHASER:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Alfred J. Mandel
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
<FONT style="font-variant: SMALL-CAPS"><B>Alfred J. Mandel</B></FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature Page to Amendment No.&nbsp;1 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment No.&nbsp;1 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the 30<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> day of March, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>PURCHASER:</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Pauline E. van Ysendoorn
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
<FONT style="font-variant: SMALL-CAPS"><B>Pauline E. van Ysendoorn</B></FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature Page to Amendment No.&nbsp;1 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment No.&nbsp;1 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the 30<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> day of March, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>PURCHASER:</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Rhett E. Brown
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-variant: SMALL-CAPS"><B>Rhett E. Brown</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature Page to Amendment No.&nbsp;1 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment No.&nbsp;1 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the 30<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> day of March, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>PURCHASER:</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="44%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>SMALLCAP World Fund, Inc.</B></FONT></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>By:</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Capital Research and Management Company,
its investment adviser</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Timothy D. Amour</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Timothy D. Armour</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature Page to Amendment No.&nbsp;1 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXHIBIT A<BR>
SCHEDULE OF PURCHASERS<BR>
SERIES E PREFERED STOCK FINANCING<BR>
DECEMBER 22, 2006</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Shares of Series E</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Name</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Preferred Stock</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Purchase Price</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:0px; text-indent:-0px"><B>CLIPPERBAY &#038; CO.</B><BR>
SMALLCAP World Fund, Inc.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,875,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">7,500,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:0px; text-indent:-0px"><B>PACO c/o 80-16-200-1037662</B><BR>
Cross Creek Capital, L.P.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">569,074</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">2,276,296.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:0px; text-indent:-0px"><B>PACO c/o 80-16-200-1037670</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55,926</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">223,704.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:0px; text-indent:-0px"><B>CLEARMOON &#038; CO.</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">625,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">2,500,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:0px; text-indent:-0px"><B>ALLIANCEBERNSTEIN VENTURE FUND I, L.P.</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">62,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">250,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:0px; text-indent:-0px"><B>ALLOY VENTURES 2005, L.P.</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">80,625</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">322,500.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:0px; text-indent:-0px"><B>ALLOY VENTURES 2002, L.P.</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">78,505</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">314,020.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:0px; text-indent:-0px"><B>ALLOY PARTNERS 2002, L.P.</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,120</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">8,480.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:0px; text-indent:-0px"><B>INTERWEST INVESTORS VII, L.P.</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,285</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">9,140.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:0px; text-indent:-0px"><B>INTERWEST PARTNERS VII, L.P.</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">47,715</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">190,860.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:0px; text-indent:-0px"><B>EUCLIDSR BIOTECHNOLOGY PARTNERS, L.P.</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">105,875</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">423,500.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:0px; text-indent:-0px"><B>EUCLIDSR PARTNERS, L.P.</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">105,875</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">423,500.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:0px; text-indent:-0px"><B>VERSANT AFFLIATES FUND 1-A, L.P.</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">20,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:0px; text-indent:-0px"><B>VERSANT AFFLIATES FUND 1-B, L.P.</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">42,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXHIBIT A<BR>
SCHEDULE OF PURCHASERS<BR>
SERIES E PREFERED STOCK FINANCING<BR>
DECEMBER 22, 2006</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Shares of Series E</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Name</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Preferred Stock</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Purchase Price</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>VERSANT SIDE FUND I, L.P.</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">18,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>VERSANT VENTURE CAPITAL I, L.P.</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">230,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">920,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>LILLY BIO VENTURES, ELI LILLY AND COMPANY</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">89,750</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">359,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>SIGHTLINE HEALTHCARE FUND III, L.P.</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">120,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>BRUCE BURROWS</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">144,750</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">579,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>LEHMAN BROTHERS HEALTHCARE VENTURE CAPITAL, L.P.</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">39,937</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">159,748.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>LEHMAN BROTHERS OFFSHORE PARTNERSHIP ACCOUNT 2000/2001, L.P.</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,932</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">35,728.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>LEHMAN BROTHERS P.A., LLC</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">76,440</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">305,760.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>LEHMAN BROTHERS PARTNERSHIP ACCOUNT 2000/2001, L.P.</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">34,440</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">137,760.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>TOTALS</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,284,749</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">17,138,996.00</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXHIBIT A<BR>
SCHEDULE OF PURCHASERS<BR>
SERIES E PREFERED STOCK FINANCING<BR>
MARCH 30, 2007</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Shares of Series E</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Name</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Preferred Stock</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Purchase Price</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>JOHN M. HARLAND</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">20,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>FERGUSON/EGAN FAMILY TRUST DATED 6/28/99</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">60,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>HEALTH CARE ADMINISTRATION COMPANY</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">100,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>THE CONDON FAMILY TRUST</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">50,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>IN-Q-TEL, INC.</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,125</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">40,500.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>IN-Q-TEL EMPLOYEE FUND, LLC</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,375</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">13,500.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>THE V FOUNDATION FOR CANCER RESEARCH</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,250</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">25,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>FREDRICK H. STERN</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">150,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>ALFRED J. MANDEL</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">4,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>PAULINE E. </B><FONT style="font-variant: SMALL-CAPS"><B>van YSENDOORN</B></FONT> </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">10,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>RHETT E. BROWN</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">50,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>CLIPPERBAY &#038; CO.</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">350,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">1,400,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>TOTALS</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>480,750</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>$</B></TD>
    <TD align="right"><B>1,923,000.00</B></TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FLUIDIGM CORPORATION</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>AMENDMENT NO. 2 TO<BR>
SERIES E PREFERRED STOCK PURCHASE AGREEMENT</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Amendment No.&nbsp;2 (the &#147;<B>Amendment</B>&#148;) to that certain Series&nbsp;E Preferred Stock Purchase
Agreement, dated as of June&nbsp;13, 2006, as amended December&nbsp;22, 2006, by and among Fluidigm
Corporation, a California corporation (&#147;<B>Fluidigm California</B>&#148;) and the Purchasers named therein (the
&#147;<B>Purchase Agreement</B>&#148;), is made and entered into effective as of October&nbsp;10, 2007 (the &#147;<B>Effective
Date</B>&#148;) by and among Fluidigm Corporation, a Delaware corporation (the &#147;<B>Company</B>&#148;), and the
Purchasers named herein. Capitalized terms used in this Amendment that are not otherwise defined
herein shall have the respective meanings assigned to them in the Purchase Agreement.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>RECITALS</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS</B>, Fluidigm California previously sold and issued an aggregate of 1,250,000 shares of
Series&nbsp;E Preferred Stock (the &#147;<B>Series&nbsp;E Preferred</B>&#148;) pursuant to the terms of the Purchase Agreement
at the Initial Closing held on June&nbsp;13, 2006 and an additional 6,015,499 shares of Series&nbsp;E
Preferred at Subsequent Closings held on December&nbsp;22, 2006 and March&nbsp;30, 2007;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS</B>, on July&nbsp;18, 2007, Fluidigm California was merged with and into the Company, with the
Company being the surviving corporation such that the Company succeeded to all of Fluidigm
California&#146;s rights and obligations under the Purchase Agreement and all outstanding shares of
Series&nbsp;E Preferred of Fluidigm California were exchanged on a one for one basis for shares of
Series&nbsp;E Preferred of the Company;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS, </B>the Company and the Purchasers now desire to amend the terms of the Purchase
Agreement to provide that the Company may sell and issue up to 7,375,000 additional shares of
Series&nbsp;E Preferred (the &#147;<B>Additional Shares</B>&#148;) pursuant to the Purchase Agreement, at one or more
additional Subsequent Closings, provided that any such additional Subsequent Closings shall take
place no later than December&nbsp;31, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS</B>, pursuant to Section&nbsp;6.5 of the Purchase Agreement, the terms of the Purchase
Agreement may be amended upon the written consent of the Company and the holder or holders of
greater than fifty percent (50%) of the outstanding Shares or the Conversion Shares;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS</B>, the Purchasers who have signed below hold greater than fifty percent (50%) of the
outstanding Shares purchased under the Purchase Agreement as of the Effective Date and consent to
the changes as set forth in this Amendment;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS</B>, in connection with the execution of this Amendment, the Company is amending the
Amended and Restated Certificate of Incorporation of the Company to increase the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">number of
authorized shares of capital stock of the Company to facilitate the sale of the Additional Shares.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>NOW, THEREFORE, </B>in consideration of the foregoing, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto
mutually agree as follows:
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>AGREEMENT</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Amendment to Section&nbsp;1.1</U>. Section&nbsp;1.1 (Authorization of the Shares) of the
Purchase Agreement is hereby amended and restated in its entirety as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;1.1 <U>Authorization of the Shares</U>. The Company will on or
before the Closing (as defined below) authorize the sale and issuance
pursuant to this Agreement of up to 17,956,252 shares (the &#147;<B>Shares</B>&#148;) of its
Series&nbsp;E Preferred Stock (the &#147;<B>Series&nbsp;E Preferred</B>&#148;), having the rights,
preferences and privileges as set forth in the Amended and Restated
Certificate of Incorporation, as amended by Amendment No.&nbsp;1 to Amended and
Restated Certificate of Incorporation and Amendment No.&nbsp;2 to Amended and
Restated Certificate of Incorporation, as attached hereto as <U>EXHIBITS
B-1</U> AND <U>B-2</U>, respectively (together for purposes of this
Agreement, the &#147;<B>Restated Certificate</B>&#148;).&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Amendment to Section&nbsp;1.2</U>. Section&nbsp;1.2 (Purchase and Sale of the Shares) of the
Purchase Agreement is hereby amended and restated in its entirety as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;1.2 <U>Purchase and Sale of the Shares</U>. Subject to the terms and
conditions hereof and in reliance upon the representations, warranties and
agreements contained herein, the Company will issue and sell to each
Purchaser, severally and not jointly, and each Purchaser will purchase from
the Company, severally and not jointly, at the applicable Closing, the
number of Shares set forth opposite the Purchaser&#146;s name on the Schedule of
Purchasers, at a purchase price of Four Dollars ($4.00) per Share. The
Company shall be entitled to sell any unpurchased Shares to any Purchaser or
to a person who is not a Purchaser and to amend the Schedule of Purchasers
to include the information relating to such sales, and such purchasers shall
be considered &#147;Purchasers&#148; and parties to this Agreement; provided that (i)
such sales are made pursuant to this Agreement or an agreement identical to
this one except for the Closing Date and exhibits, and (ii)&nbsp;such sales are
completed on or prior to December&nbsp;31, 2007. The Company&#146;s agreement with
each Purchaser is a separate agreement, and the sale of the Shares to each
Purchaser is a separate sale.&#148;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Amendment to Section&nbsp;2</U>. Section&nbsp;2 (Representations and Warranties of the Company)
of the Purchase Agreement is hereby amended to add the following sentence to the end of the
paragraph which reads in its entirety as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;At each Subsequent Closing, the Company shall provide an updated
Schedule of Exceptions and <U>EXHIBIT C</U> shall be concurrently amended
and restated for purposes of such Subsequent Closing.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Amendment to Section&nbsp;2.4</U>. Solely in connection with the sale of Additional Shares
pursuant to this Amendment, Section&nbsp;2.4 (Capitalization) of the Purchase Agreement is hereby
amended and restated in its entirety as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;The authorized capital stock of the Company consists, or immediately
prior to the Closing will consist, of 85,232,144 shares of Common Stock
(&#147;<B>Common Stock</B>&#148;), of which 9,760,848 shares are issued and outstanding
immediately prior to the Closing and 57,961,085 shares of Preferred Stock
(&#147;<B>Preferred Stock</B>&#148;), 2,727,273 of which are designated Series&nbsp;A Preferred
Stock of which 2,727,273 are outstanding immediately prior to the Closing;
6,460,675 of which are designated Series&nbsp;B Preferred Stock of which
6,460,675 are outstanding immediately prior to the Closing; 16,854,624 of
which are designated Series&nbsp;C Preferred Stock, 16,364,832 of which are
issued and outstanding immediately prior to the Closing; and 13,962,261 of
which are designated Series&nbsp;D Preferred Stock, 13,353,333 of which are
issued and outstanding immediately prior to the Closing; and 17,956,252 of
which are designated Series&nbsp;E Preferred Stock, 8,969,836 of which are issued
and outstanding immediately prior to the Closing. All such issued and
outstanding shares have been duly authorized and validly issued in
compliance with applicable laws, and are fully paid and nonassessable.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has reserved: (i)&nbsp;17,956,252 shares of Series&nbsp;E Preferred
for issuance hereunder and 17,956,252 shares of Common Stock for issuance
upon conversion of such shares of Series&nbsp;E Preferred; (ii)&nbsp;13,353,333
shares of Common Stock for issuance upon conversion of the outstanding
shares of Series&nbsp;D Preferred; (iii)&nbsp;408,928 shares of Series&nbsp;D Preferred for
issuance upon exercise of outstanding warrants and 408,928 shares of Common
Stock for issuance upon conversion of such Series&nbsp;D Preferred; (iv)
16,364,832 shares of Common Stock for issuance upon conversion of the
outstanding shares of Series&nbsp;C Preferred Stock; (v)&nbsp;289,792shares of Series
C Preferred Stock for issuance upon exercise of outstanding warrants and
289,792 shares of Common Stock for issuance upon conversion of such Series&nbsp;C
Preferred Stock; (vi)&nbsp;6,460,675 shares of Common Stock for issuance upon
conversion of the outstanding Series&nbsp;B Preferred Stock; (vii)&nbsp;2,727,273
shares of Common Stock for issuance upon conversion of the outstanding
Series&nbsp;A Preferred Stock; and (viii)&nbsp;an aggregate of 12,800,000 shares of
Common Stock for issuance to
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">employees and consultants of the Company
pursuant to the Company&#146;s 1999 Stock Option Plan, pursuant to which options
to purchase 7,247,691 shares are granted and outstanding and 1,518,223
shares are available for future grant. As of the date hereof and after
giving effect to the purchase of Shares hereunder, each share of each series
of the Company&#146;s Preferred Stock is convertible into one share of the
Company&#146;s Common Stock. Other than with respect to the shares reserved for
issuance in this paragraph, or as set forth in the Ancillary Agreements (as
defined below), there are no outstanding rights, options, warrants,
conversion rights, preemptive rights, rights of first refusal or similar
rights for the purchase or acquisition from the Company of any securities of
the Company. There are no outstanding obligations of the Company to
repurchase or redeem any of its securities.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Amendment to Section&nbsp;2.16</U>. Solely in connection with the sale of Additional Shares
pursuant to this Amendment, Section&nbsp;2.16 (Financial Statements) of the Purchase Agreement is hereby
amended and restated in its entirety as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;The Company has made available to each Purchaser its audited balance
sheet dated as of December&nbsp;31, 2004. The Company has also made available to
each Purchaser unaudited balance sheets dated December&nbsp;31, 2005 and December
31, 2006 and the unaudited statements of operations for the fiscal years
then ended (collectively, the &#147;<B>Financial Statements</B>&#148;). The Financial
Statements are complete and correct in all material respects and have been
prepared in accordance with generally accepted accounting principles applied
on a consistent basis throughout the periods indicated. The Financial
Statements accurately set out and describe the financial condition and
operating results of the Company as of the date, and during the periods,
indicated therein. Except as set forth in the Financial Statements, the
Company has no material liabilities, contingent or otherwise, other than (i)
liabilities incurred in the ordinary course of business subsequent to
December&nbsp;31, 2006 and (ii)&nbsp;obligations under contracts and commitments
incurred in the ordinary course of business and not required under generally
accepted accounting principles to be reflected in the Financial Statements,
which, in both cases, individually or in the aggregate are not material to
the financial condition or operating results of the Company.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Deletion of Sections&nbsp;6.9 and 6.11</U>. Solely in connection with the sale of
Additional Shares pursuant to this Amendment, the Purchase Agreement is hereby amended to delete
Section&nbsp;6.9 (Finder&#146;s Fee) and Section&nbsp;6.11 (Waiver of Conflict), each in its entirety.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Amendment to Section&nbsp;6.10</U>. Solely in connection with the sale of Additional Shares
pursuant to this Amendment, Section&nbsp;6.10 of the Purchase Agreement is hereby amended and restated
in its entirety to read as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;6.10 <U>Expenses</U>. The Company and each Purchaser shall bear its
own expenses and legal fees incurred on its behalf with respect to this
Agreement and the transactions contemplated hereby, <I>provided, however</I>, that
if a Closing is effected, the Company shall reimburse the reasonable
documented fees of one counsel for the Purchasers, such amount not to exceed
$25,000, by wire transfer at such Closing.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Addition of Section&nbsp;6.17</U>. The Purchase Agreement is hereby amended to add the
following Section&nbsp;6.17 which reads in its entirety as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;6.17 <U>Reincorporation</U>. Each Purchaser hereunder acknowledges
that the Company completed a reincorporation into the State of Delaware on
July&nbsp;18, 2007 and each Purchaser hereby consents to the assignment of this
Agreement to Fluidigm Corporation, a Delaware corporation effective as of
July&nbsp;18, 2007.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>Restated Certificate</U>. All references in the Purchase Agreement to the term
&#147;Restated Articles&#148; are hereby deleted and replaced with the term &#147;Restated Certificate.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U>Governing Law</U>. This Amendment shall be governed in all respects by the laws of
the State of California, without regard to any provisions thereof relating to conflicts of laws
among different jurisdictions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<U>Purchase Agreement</U>. Wherever necessary, all other terms of the Purchase Agreement
are hereby amended to be consistent with the terms of this Amendment. Except as specifically set
forth herein, the Purchase Agreement shall remain in full force and effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;<U>Counterparts; Facsimile</U>. This Amendment may be executed in any number of
counterparts, each of which shall be an original, and all of which together shall constitute one
instrument. Executed signatures transmitted via facsimile will be accepted and considered duly
executed.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;<U>Effect of Execution of Amendment by Certain Purchasers</U>. This Amendment, when
executed and delivered by the Company and a Purchaser purchasing shares of Series&nbsp;E Preferred at a
Subsequent Closing held on or after the date hereof, shall also constitute and shall be deemed a
counterpart signature page to the Purchase Agreement. Consequently, each undersigned Purchaser
purchasing shares of Series&nbsp;E Preferred at a Subsequent Closing held on or after the date hereof
acknowledges and agrees that he, she or it is bound by the terms and conditions contained in the
Purchase Agreement, as amended by this Amendment, with respect to the purchase of such shares.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;</B><B><I>Remainder of page intentionally left blank</I></B><B>&#093;</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-5-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment No.&nbsp;2
to Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>COMPANY:</B>

</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>FLUIDIGM CORPORATION</B><BR>
a Delaware corporation<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Gajus Worthington
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Gajus Worthington,&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">President and Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature Page to Amendment No.&nbsp;2 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;2 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PURCHASERS:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fidelity Contrafund: </B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fidelity Advisor New Insights Fund</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gary Ryan
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Gary Ryan</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Assistant Treasurer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><FONT style="white-space: nowrap"><B>Fidelity Contrafund: Fidelity Contrafund</B></FONT></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gary Ryan</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Gary Ryan</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Assistant Treasurer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Variable Insurance Products Fund II:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Contrafund Portfolio</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gary Ryan</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Gary Ryan</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Assistant Treasurer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;</B><B><I>Signature Page to Amendment No.&nbsp;2 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement</I></B><B>&#093;</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;2 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PURCHASERS:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Leerink Swann Holdings, LLC</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Jeffrey A. Leerink
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Jeffrey A. Leerink</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Leerink Swann Holdings, LLC </B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Co-Investment Fund, LLC</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Donald D. Notman, Jr.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Donald D. Notman, Jr.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Managing Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;</B><B><I>Signature Page to Amendment No.&nbsp;2 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement</I></B><B>&#093;</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;2 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><B>PURCHASERS:</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Cross Creek Capital, L.P.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Cross Creek Capital GP, L.P.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its Sole General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Cross Creek Capital, LLC</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its Sole General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Wasatch Advisors, Inc.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its Sole Member</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Karey Barker
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Karey Barker</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><FONT style="white-space: nowrap"><B>Cross Creek Capital Employees&#146; Fund, L.P.</B></FONT></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Cross Creek Capital GP, L.P.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its Sole General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Cross Creek Capital, LLC</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its Sole General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Wasatch Advisors, Inc.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its Sole Member</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Karey Barker
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Karey Barker</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;</B><B><I>Signature Page to Amendment No.&nbsp;2 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement</I></B><B>&#093;</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;2 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>PURCHASERS:</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"> <B>Wasatch Funds, Inc.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Wasatch Advisors, Inc.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its Sole Member</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Dan Thurber
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Dan Thurber</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;</B><B><I>Signature Page to Amendment No.&nbsp;2 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement</I></B><B>&#093;</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;2 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>PURCHASERS:</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>SMALLCAP World Fund, Inc.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>By:</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="white-space: nowrap"><B>Capital Research and Management Company,</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>its, investment adviser</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Michael Downer
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Michael Downer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;</B><B><I>Signature Page to Amendment No.&nbsp;2 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement</I></B><B>&#093;</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;2 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>PURCHASERS:</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><FONT style="white-space: nowrap"><B>AllianceBernstein Venture Fund I, L.P.</B></FONT></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>By:</B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top"><B>AllianceBernstein ESG Venture <BR>
Management, L.P., its general partner</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>By:</B>
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top"><B>AllianceBernstein Global
Derivatives <BR>
Corporation, its general partner</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ James D. Kiggen
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">James D. Kiggen</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Senior Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;</B><B><I>Signature Page to Amendment No.&nbsp;2 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement</I></B><B>&#093;</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;2 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>PURCHASERS:</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Versant Affiliates Fund 1-A, L.P.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Versant Affiliates Fund1-B, L.P.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Versant Side Fund I, L.P.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Versant Venture Capital I, L.P.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Versant Ventures I, LLC</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Samuel D. Colella
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Samuel D. Colella</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Managing Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;</B><B><I>Signature Page to Amendment No.&nbsp;2 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement</I></B><B>&#093;</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;2 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>PURCHASERS:</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD colspan="3"  nowrap valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Lehman
Brothers Healthcare Venture Capital <br>L.P.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">Lehman Brothers HealthCare Venture Capital</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Associates L.P.,</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">LB I Group Inc., its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:<BR>
Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Steven Berkenfeld
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Steven Berkenfeld
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Senior Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" nowrap valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Lehman Brothers P.A. LLC</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Steven Berkenfeld</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Steven Berkenfeld</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Senior Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" nowrap valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Lehman Brothers Partnership Account 2000/2001,<BR>
L.P.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">LB I Group Inc., its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Steven Berkenfeld</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Steven Berkenfeld</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Senior Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD colspan="3" nowrap valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Lehman
Brothers Offshore Partnership Account</B><br><b>2000/2001, L.P.</b></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">LB I Offshore Partners Group Ltd., its General</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Steven Berkenfeld</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Steven Berkenfeld</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Senior Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;</B><B><I>Signature Page to Amendment No.&nbsp;2 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement</I></B><B>&#093;</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;2 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>PURCHASERS:</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" nowrap><FONT style="font-variant: SMALL-CAPS"><B>EuclidSR Partners, L.P.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>EuclidSR Associates, L.P.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Elaine V. Jones
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Elaine V. Jones</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"> General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" nowrap><FONT style="font-variant: SMALL-CAPS"><B>EuclidSR Biotechnology Partners, L.P.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">EuclidSR Biotechnology Associates, L.P.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Elaine V. Jones</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Elaine V. Jones</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"> General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;</B><B><I>Signature Page to Amendment No.&nbsp;2 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement</I></B><B>&#093;</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;2 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>PURCHASERS:</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><FONT style="white-space: nowrap"><B>Interwest Partners VII, L.P.</B></FONT></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>InterWest Management Partners VII,
LLC</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Michael Sweeney
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Michael Sweeney</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">As agent for the general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" nowrap><FONT style="font-variant: SMALL-CAPS"><B>Interwest Investors VII, L.P.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">InterWest Management Partners VII,
LLC</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Michael Sweeney</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Michael Sweeney</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">As agent for the general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;</B><B><I>Signature Page to Amendment No.&nbsp;2 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement</I></B><B>&#093;</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;2 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>PURCHASERS:</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><FONT style="white-space: nowrap"><B>Lilly Bioventures, Eli Lilly &#038; Company</B></FONT></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Darren J. Carroll
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Darren J. Carroll</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Executive Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;</B><B><I>Signature Page to Amendment No.&nbsp;2 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement</I></B><B>&#093;</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;2 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>PURCHASERS:</B>

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;</B><B><I>Signature Page to Amendment No.&nbsp;2 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement</I></B><B>&#093;</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;2 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>PURCHASERS:</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Bruce Burrows
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
<FONT style="font-variant: SMALL-CAPS"><B>Bruce Burrows</B></FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;</B><B><I>Signature Page to Amendment No.&nbsp;2 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement</I></B><B>&#093;</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;2 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>PURCHASERS:</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" nowrap><FONT style="font-variant: SMALL-CAPS"><B>Biomedical Sciences Investment Fund Pte Ltd</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Chu Swee Yeok
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chu Swee Yeok</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" nowrap><FONT style="font-variant: SMALL-CAPS"><B>Singapore Bio-Innovations Pte Ltd</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Sim Sze Kuan</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Sim Sze Kuan</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;</B><B><I>Signature Page to Amendment No.&nbsp;2 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement</I></B><B>&#093;</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;2 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>PURCHASERS:</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Invus, L.P.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Invus Advisors LLC</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">General Partner of Invus LP</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Aflalo Guimaraes
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Aflalo Guimaraes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Managing Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;</B><B><I>Signature Page to Amendment No.&nbsp;2 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement</I></B><B>&#093;</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXHIBIT A<BR>
SCHEDULE OF PURCHASERS<BR>
SERIES E PREFERED STOCK FINANCING<BR>
OCTOBER 10, 2007</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Shares of Series&nbsp;E</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Name</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Preferred Stock</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Purchase Price</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>FIDELITY CONTRAFUND:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>FIDELITY ADVISOR NEW INSIGHTS FUND</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">481,170</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,924,679.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>FIDELITY CONTRAFUND: FIDELITY CONTRAFUND</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,389,865</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">17,559,461.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>VARIABLE INSURANCE PRODUCTS FUND II:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>CONTRAFUND PORTFOLIO</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,378,965</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">5,515,860.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>LEERICK SWANN HOLDINGS, LLC</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">62,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">250,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>LEERICK SWANN CO-INVESTMENT FUND, LLC</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">78,750</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">315,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>TOTALS</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>6,391,250</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left"><B>$</B></TD>
    <TD align="right"><B>25,565,000.00</B></TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FLUIDIGM CORPORATION</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>AMENDMENT NO.&nbsp;3 TO<BR>
SERIES&nbsp;E PREFERRED STOCK PURCHASE AGREEMENT</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Amendment No.&nbsp;3 (the &#147;<B>Amendment</B>&#148;) to that certain Series&nbsp;E Preferred Stock Purchase
Agreement, dated as of June&nbsp;13, 2006, as amended December&nbsp;22, 2006 and further amended October&nbsp;10,
2007, by and among Fluidigm Corporation, a California corporation (&#147;<B>Fluidigm California</B>&#148;) and the
Purchasers named therein (the &#147;<B>Purchase Agreement</B>&#148;), is made and entered into effective as of
October&nbsp;26, 2007 (the &#147;<B>Effective Date</B>&#148;) by and among Fluidigm Corporation, a Delaware corporation
(the &#147;<B>Company</B>&#148;), and the Purchasers named herein. Capitalized terms used in this Amendment that
are not otherwise defined herein shall have the respective meanings assigned to them in the
Purchase Agreement.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>RECITALS</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS</B>, Fluidigm California previously sold and issued an aggregate of 1,250,000 shares of
Series&nbsp;E Preferred Stock (the &#147;<B>Series&nbsp;E Preferred</B>&#148;) pursuant to the terms of the Purchase Agreement
at the Initial Closing held on June&nbsp;13, 2006, an additional 4,284,749 shares of Series&nbsp;E Preferred
at a Subsequent Closing held on December&nbsp;22, 2006, an additional 480,750 shares of Series&nbsp;E
Preferred at a Subsequent Closing held on March&nbsp;30, 2007, and an additional 6,391,250 shares of
Series&nbsp;E Preferred at a Subsequent Closing held on October&nbsp;10, 2007;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS</B>, on July&nbsp;18, 2007, Fluidigm California was merged with and into the Company, with the
Company being the surviving corporation such that the Company succeeded to all of Fluidigm
California&#146;s rights and obligations under the Purchase Agreement and all outstanding shares of
Series&nbsp;E Preferred of Fluidigm California were exchanged on a one for one basis for shares of
Series&nbsp;E Preferred of the Company;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS, </B>the Company and the Purchasers now desire to amend the terms of the Purchase
Agreement to provide that the Company may sell and issue up to 2,153,695 additional shares of
Series&nbsp;E Preferred (the &#147;<B>Additional Shares</B>&#148;) pursuant to the Purchase Agreement, at one or more
additional Subsequent Closings, provided that any such additional Subsequent Closings shall take
place no later than December&nbsp;31, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS</B>, pursuant to Section&nbsp;6.5 of the Purchase Agreement, the terms of the Purchase
Agreement may be amended upon the written consent of the Company and the holder or holders of
greater than fifty percent (50%) of the outstanding Shares or the Conversion Shares;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS</B>, the Purchasers who have signed below hold greater than fifty percent (50%) of the
outstanding Shares purchased under the Purchase Agreement as of the Effective Date and consent to
the changes as set forth in this Amendment;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS</B>, in connection with the execution of this Amendment, the Company is amending the
Amended and Restated Certificate of Incorporation of the Company to increase the number of
authorized shares of capital stock of the Company to facilitate the sale of the Additional Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>NOW, THEREFORE, </B>in consideration of the foregoing, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto
mutually agree as follows:
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>AGREEMENT</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Amendment to Section&nbsp;1.1</U>. Section&nbsp;1.1 (Authorization of the Shares) of the
Purchase Agreement is hereby amended and restated in its entirety as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;1.1 <U>Authorization of the Shares</U>. The Company will on or
before the Closing (as defined below) authorize the sale and issuance
pursuant to this Agreement of up to 18,498,531 shares (the &#147;<B>Shares</B>&#148;) of its
Series&nbsp;E Preferred Stock (the &#147;<B>Series&nbsp;E Preferred</B>&#148;), having the rights,
preferences and privileges as set forth in the Amended and Restated
Certificate of Incorporation, as amended by a Certificate of Amendment to
Amended and Restated Certificate of Incorporation dated October&nbsp;10,&nbsp;2007 and
a Certificate of Amendment to Amended and Restated Certificate of
Incorporation dated October&nbsp;26, 2007, as attached hereto as <U>EXHIBITS
B-1</U> AND <U>B-2</U>, respectively (together for purposes of this
Agreement, the &#147;<B>Restated Certificate</B>&#148;).&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Amendment to Section&nbsp;2.4</U>. Solely in connection with the sale of Additional Shares
pursuant to this Amendment, Section&nbsp;2.4 (Capitalization) of the Purchase Agreement is hereby
amended and restated in its entirety as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;The authorized capital stock of the Company consists, or immediately
prior to the Closing will consist, of 87,385,839 shares of Common Stock
(&#147;<B>Common Stock</B>&#148;), of which 9,760,848 shares are issued and outstanding
immediately prior to the Closing and 60,114,780 shares of Preferred Stock
(&#147;<B>Preferred Stock</B>&#148;), 2,727,273 of which are designated Series&nbsp;A Preferred
Stock of which 2,727,273 are outstanding immediately prior to the Closing;
6,460,675 of which are designated Series&nbsp;B Preferred Stock of which
6,460,675 are outstanding immediately prior to the Closing; 16,854,624 of
which are designated Series&nbsp;C Preferred Stock, 16,364,832 of which are
issued and outstanding immediately prior to the Closing; and 13,962,261 of
which are designated Series&nbsp;D Preferred Stock, 13,353,333 of which are
issued and outstanding immediately prior to the Closing; and 20,109,947 of
which are designated Series&nbsp;E Preferred Stock, 15,361,086 of which are
issued and outstanding immediately prior to the Closing. All such issued
and outstanding shares have been duly
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 2 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">authorized and validly issued in compliance with applicable laws, and
are fully paid and nonassessable.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has reserved: (i)&nbsp;18,498,531 shares of Series&nbsp;E Preferred
for issuance hereunder and 20,109,947 shares of Common Stock for issuance
upon conversion of all shares of Series&nbsp;E Preferred; (ii)&nbsp; 13,353,333 shares
of Common Stock for issuance upon conversion of the outstanding shares of
Series&nbsp;D Preferred; (iii)&nbsp;408,928 shares of Series&nbsp;D Preferred for issuance
upon exercise of outstanding warrants and 408,928 shares of Common Stock for
issuance upon conversion of such Series&nbsp;D Preferred; (iv)&nbsp;16,364,832 shares
of Common Stock for issuance upon conversion of the outstanding shares of
Series&nbsp;C Preferred Stock; (v)&nbsp;289,792 shares of Series&nbsp;C Preferred Stock for
issuance upon exercise of outstanding warrants and 289,792 shares of Common
Stock for issuance upon conversion of such Series&nbsp;C Preferred Stock;
(vi)&nbsp;6,460,675 shares of Common Stock for issuance upon conversion of the
outstanding Series&nbsp;B Preferred Stock; (vii)&nbsp;2,727,273 shares of Common Stock
for issuance upon conversion of the outstanding Series&nbsp;A Preferred Stock;
and (viii)&nbsp;an aggregate of 12,800,000 shares of Common Stock for issuance to
employees and consultants of the Company pursuant to the Company&#146;s 1999
Stock Option Plan, pursuant to which options to purchase 7,247,691 shares
are granted and outstanding and 1,518,223 shares are available for future
grant. As of the date hereof and after giving effect to the purchase of
Shares hereunder, each share of each series of the Company&#146;s Preferred Stock
is convertible into one share of the Company&#146;s Common Stock. Other than
with respect to the shares reserved for issuance in this paragraph, or as
set forth in the Ancillary Agreements (as defined below), there are no
outstanding rights, options, warrants, conversion rights, preemptive rights,
rights of first refusal or similar rights for the purchase or acquisition
from the Company of any securities of the Company. There are no outstanding
obligations of the Company to repurchase or redeem any of its securities.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Amendment to Section&nbsp;2.16</U>. Solely in connection with the sale of Additional Shares
pursuant to this Amendment, Section&nbsp;2.16 (Financial Statements) of the Purchase Agreement is hereby
amended and restated in its entirety as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;The Company has made available to each Purchaser its audited balance
sheet dated as of December&nbsp;31, 2004. The Company has also made available to
each Purchaser unaudited balance sheets dated December&nbsp;31, 2005 and December
31, 2006 and the unaudited statements of operations for the fiscal years
then ended (collectively, the &#147;<B>Financial Statements</B>&#148;). The Financial
Statements are complete and correct in all material respects and have been
prepared in accordance with generally
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 3 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">accepted accounting principles applied on a consistent basis throughout
the periods indicated. The Financial Statements accurately set out and
describe the financial condition and operating results of the Company as of
the date, and during the periods, indicated therein. Except as set forth in
the Financial Statements, the Company has no material liabilities,
contingent or otherwise, other than (i)&nbsp;liabilities incurred in the ordinary
course of business subsequent to December&nbsp;31, 2006 and (ii)&nbsp;obligations
under contracts and commitments incurred in the ordinary course of business
and not required under generally accepted accounting principles to be
reflected in the Financial Statements, which, in both cases, individually or
in the aggregate are not material to the financial condition or operating
results of the Company.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Governing Law</U>. This Amendment shall be governed in all respects by the laws of the
State of California, without regard to any provisions thereof relating to conflicts of laws among
different jurisdictions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Purchase Agreement</U>. Wherever necessary, all other terms of the Purchase Agreement
are hereby amended to be consistent with the terms of this Amendment. Except as specifically set
forth herein, the Purchase Agreement shall remain in full force and effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Counterparts; Facsimile</U>. This Amendment may be executed in any number of
counterparts, each of which shall be an original, and all of which together shall constitute one
instrument. Executed signatures transmitted via facsimile will be accepted and considered duly
executed.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Effect of Execution of Amendment by Certain Purchasers</U>. This Amendment, when
executed and delivered by the Company and a Purchaser purchasing shares of Series&nbsp;E Preferred at a
Subsequent Closing held on or after the date hereof, shall also constitute and shall be deemed a
counterpart signature page to the Purchase Agreement. Consequently, each undersigned Purchaser
purchasing shares of Series&nbsp;E Preferred at a Subsequent Closing held on or after the date hereof
acknowledges and agrees that he, she or it is bound by the terms and conditions contained in the
Purchase Agreement, as amended by this Amendment, with respect to the purchase of such shares.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;</B><B><I>Remainder of page intentionally left blank</I></B><B>&#093;</B>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->- 4 -<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;3
to Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><B>COMPANY:</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>FLUIDIGM CORPORATION</B></FONT></TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left">a Delaware corporation</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gajus Worthington</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Gajus Worthington,</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President and Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature
Page to Amendment No.&nbsp;3 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;3 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PURCHASERS:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fidelity Contrafund: </B></FONT></TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fidelity Advisor New Insights Fund</B></FONT></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Peter Lydecker
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Peter Lydecker</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Assistant Treasurer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fidelity Contrafund: Fidelity Contrafund</B></FONT></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Peter Lydecker</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Peter Lydecker</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Assistant Treasurer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Variable Insurance Products Fund II:</B></FONT></TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Contrafund Portfolio</B></FONT></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Peter Lydecker</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Peter Lydecker</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Assistant Treasurer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature
Page to Amendment No.&nbsp;3 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;3 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PURCHASERS:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Leerink Swann Holdings, LLC</B></FONT></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Jeffrey Leerink</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Jeffrey Leerink</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chairman</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Leerink Swann Holdings, LLC </B></FONT></TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Co-Investment Fund, LLC</B></FONT></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Donald D. Notman, Jr.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Donald D. Notman, Jr.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Managing Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature
Page to Amendment No.&nbsp;3 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;3 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><B>PURCHASERS</B><FONT style="font-variant: SMALL-CAPS"><B>:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Cross Creek Capital, L.P.</B></FONT></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Cross Creek Capital GP, L.P.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its Sole General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Cross Creek Capital, LLC</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its Sole General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Wasatch Advisors, Inc.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its Sole Member</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Karey Barker</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Karey Barker</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Cross Creek Capital Employees&#146; Fund, L.P.</B></FONT></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Cross Creek Capital GP, L.P.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its Sole General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Cross Creek Capital, LLC<BR>
Its Sole General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Wasatch Advisors, Inc.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its Sole Member</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Karey Barker</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Karey Barker</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature
Page to Amendment No.&nbsp;3 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;3 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PURCHASERS:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><B>W</B><FONT style="font-variant: SMALL-CAPS"><B>asatch Funds, Inc.</B></FONT></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Wasatch Advisors, Inc.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its Sole Member</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Venice Edwards
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Venice Edwards</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Secretary</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature
Page to Amendment No.&nbsp;3 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;3 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PURCHASERS:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>SMALLCAP World Fund, Inc.</B></FONT></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>By:</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Capital Research and Management Company,</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>its, investment adviser</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Paul Haaga
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Paul Haaga</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature
Page to Amendment No.&nbsp;3 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;3 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PURCHASERS:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>AllianceBernstein Venture Fund I, L.P.</B></FONT></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>By:</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>AllianceBernstein ESG Venture</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Management, L.P., its general partner</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>By:</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>AllianceBernstein Global Derivatives</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Corporation, its general partner</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ James D. Kiggen
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">James D. Kiggen</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Senior Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature
Page to Amendment No.&nbsp;3 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;3 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PURCHASERS:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Versant Affiliates Fund 1-A, L.P.</B></FONT></TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Versant Affiliates Fund1-B, L.P.</B></FONT></TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Versant Side Fund I, L.P.</B></FONT></TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Versant Venture Capital I, L.P.</B></FONT></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Versant Ventures I, LLC</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Samuel D. Colella
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Samuel D. Colella</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Managing Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature
Page to Amendment No.&nbsp;3 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;3 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PURCHASERS:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Lehman Brothers Healthcare Venture Capital</B></font></TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><B>L.P.</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Lehman Brothers HealthCare Venture Capital</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Associates L.P.,</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">LB I Group Inc., its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:<BR>
Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Ashvin Rao
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Ashvin Rao
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Lehman Brothers P.A. LLC</B></FONT></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Deborah Nordell</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Deborah Nordell</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Lehman Brothers Partnership Account 2000/2001,</B></font></TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><B>L.P.</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">LB I Group Inc., its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Ashvin Rao</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Ashvin Rao</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Lehman Brothers Offshore Partnership Account</B></font></TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><B>2000/2001, L.P.</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">LB I Offshore Partners Group Ltd., its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Ashvin Rao</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Ashvin Rao</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature
Page to Amendment No.&nbsp;3 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;3 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PURCHASERS:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>EuclidSR Partners, L.P.</B></FONT></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">EuclidSR Associates, L.P.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">its
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Elaine V. Jones
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Elaine V. Jones</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>EuclidSR Biotechnology Partners, L.P.</B></FONT></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">EuclidSR Biotechnology Associates, L.P.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Elaine V. Jones</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Elaine V. Jones</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature
Page to Amendment No.&nbsp;3 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;3 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PURCHASERS:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Interwest Partners VII, L.P.</B></FONT></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">InterWest Management Partners VII, LLC</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Michael Sweeney
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Michael Sweeney</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">As agent for the general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Interwest Investors VII, L.P.</B></FONT></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">InterWest Management Partners VII, LLC</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Michael Sweeney</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Michael Sweeney</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">As agent for the general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature
Page to Amendment No.&nbsp;3 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;3 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PURCHASERS:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Lilly Bioventures, Eli Lilly &#038; Company</B></FONT></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Darren J. Carroll
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Darren J. Carroll</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Executive Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature
Page to Amendment No.&nbsp;3 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;3 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PURCHASERS:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Alloy Ventures 2005, L.P.</B></FONT></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Alloy Ventures 2005, LLC</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Tony DiBona</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Toni DiBona</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Managing Member of Alloy Ventures</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2005 LLC</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Alloy Ventures 2002, L.P.</B></FONT></TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Alloy Partners 2002, L.P.</B></FONT></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Alloy Ventures 2002, LLC</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">its General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Tony DiBona</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tony DiBona</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Managing Member of Alloy Ventures</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2002, LLC, the general partner of Alloy</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Partners 2002, L.P. and Alloy Ventures</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2002, L.P.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature
Page to Amendment No.&nbsp;3 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;3 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PURCHASERS:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Bruce Burrows
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
<FONT style="font-variant: SMALL-CAPS"><B>Bruce Burrows</B></FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature
Page to Amendment No.&nbsp;3 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;3 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PURCHASERS:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>SightLine Healthcare Fund III, L.P.</B></FONT></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Maureen Harder
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Maureen Harder</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Managing Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature
Page to Amendment No.&nbsp;3 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;3 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PURCHASERS:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Biomedical Sciences Investment Fund Pte Ltd</B></FONT></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Chu Swee Yeok
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chu Swee Yeok</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Singapore Bio-Innovations Pte Ltd</B></FONT></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Sim Sze Kuan</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Sim Sze Kuan</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature
Page to Amendment No.&nbsp;3 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;3 to
Series&nbsp;E Preferred Stock Purchase Agreement as of the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PURCHASERS:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Invus, L.P.</B></FONT></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Invus Advisors LLC</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">General Partner of Invus LP</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Aflalo Guimaraes
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Aflalo Guimaraes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Managing Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature
Page to Amendment No.&nbsp;3 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXHIBIT A<BR>
SCHEDULE OF PURCHASERS<BR>
SERIES E PREFERRED STOCK FINANCING &#150; SECOND EXTENDED CLOSING<BR>
OCTOBER 26, 2007</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Shares of Series&nbsp;E</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Name</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Preferred Stock</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Purchase Price</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>CLIPPERBAY &#038; CO.</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">SMALLCAP World Fund, Inc.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,153,695</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">8,614,780.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>TOTALS</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>2,153,695</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>$</B></TD>
    <TD align="right"><B>8,614,780.00</B></TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;3
to Series&nbsp;E Preferred Stock Purchase Agreement as of the 31<SUP style="font-size: 85%; vertical-align: text-top">st</SUP> day of December, 2007.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><B>COMPANY:</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>FLUIDIGM CORPORATION</B></FONT></TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left">a Delaware corporation</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gajus Worthington
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Gajus Worthington,
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President and Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature
Page to Amendment No.&nbsp;3 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment&nbsp;No.&nbsp;3
to Series&nbsp;E Preferred Stock Purchase Agreement as of the 31<SUP style="font-size: 85%; vertical-align: text-top">st </SUP>day of December, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PURCHASER:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Bruce Burrows
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
<B>Bruce Burrows</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Signature
Page to Amendment No.&nbsp;3 to Fluidigm Corporation Series&nbsp;E Preferred Stock Purchase Agreement&#093;</I></B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXHIBIT A<BR>
SCHEDULE OF PURCHASER<BR>
SERIES E PREFERRED STOCK FINANCING &#150; THIRD EXTENDED CLOSING<BR>
DECEMBER 31, 2007</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Shares of Series&nbsp;E</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Name</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Preferred Stock</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Purchase Price</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>BRUCE BURROWS</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">250,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">1,000,000.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>TOTALS</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>250,000</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>$</B></TD>
    <TD align="right"><B>1,000,000.00</B></TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>5
<FILENAME>f39432orexv4w3.htm
<DESCRIPTION>EXHIBIT 4.3
<TEXT>
<HTML>
<HEAD>
<TITLE>exv4w3</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt"><B>Exhibit 4.3</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FLUIDIGM CORPORATION</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>EIGHTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>June&nbsp;13, 2006</B>

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="79%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Page</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="5" align="left">SECTION 1 Restrictions on Transferability; Registration Rights</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Certain Definitions</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Restrictions</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Restrictive Legend</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Notice of Proposed Transfers</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Requested Registration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Company Registration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Registration on Form S-3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.8</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Expenses of Registration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.9</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Registration Procedures</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.10</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Indemnification</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.11</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Information by Holder</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.12</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Reports Under Securities Exchange Act of 1934</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.13</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Transfer of Registration Rights</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.14</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Standoff Agreement</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.15</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">No Right to Delay Registration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.16</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Termination of Rights</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.17</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Limitations on Subsequent Registration Rights</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">SECTION 2 Affirmative Covenants of the Company</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Delivery of Financial Statements</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Additional Information Rights</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Confidentiality</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Visitation Rights</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Stock Option Vesting</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Insurance</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Proprietary Information Agreements</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.8</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Invention Assignments</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.9</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Key-Man Life Insurance</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.10</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Compliance with Laws</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.11</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Termination of Covenants</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">SECTION 3 Right of First Offer For Company Securities</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Right of First Offer</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Sale of Securities by Company</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Offer Amount</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Financing</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Termination of Right of First Offer</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">SECTION 4 Right of First Offer with Respect to Founder Shares</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Notice of Sales</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-i-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS<BR>(continued)</B>
</DIV>


<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="79%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Page</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Purchase Right</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Sale of Securities by Founder</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Termination and Transfer</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Prohibited Transfer</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">SECTION 5 Right of Co-Sale</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Notice of Sales</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Participation Right</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Sale of Securities by Founder</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Termination and Transfer</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Prohibited Transfers</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">SECTION 6 Miscellaneous</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Governing Law; Jurisdiction</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Successors and Assigns</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Notices, Etc</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Delays or Omissions</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Third Parties</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Severability</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Amendment and Waiver</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.8</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Rights of Holders</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.9</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Counterparts</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.10</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Titles and Subtitles</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.11</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Amendment and Restatement of Prior Agreement</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.12</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Waiver of Right of First Offer</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.13</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Aggregation of Stock</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.14</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Jury Trial</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->-ii-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EIGHTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIS EIGHTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the &#147;<B>Agreement</B>&#148;) is entered into
as of June&nbsp;13, 2006 by and among Fluidigm Corporation, a California corporation (the &#147;<B>Company</B>&#148;),
the persons set forth on <U>EXHIBIT A</U> hereto (the &#147;<B>New Investors</B>&#148;), the persons set forth on
the Schedule of Founders attached hereto as <U>EXHIBIT B</U> (the &#147;<B>Founders</B>&#148;), and the persons set
forth on <U>EXHIBIT C</U> hereto (the &#147;<B>Prior Investors</B>&#148;). The Prior Investors and the New
Investors are referred to herein collectively as the &#147;<B>Investors</B>.&#148;
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>RECITALS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Company and the New Investors have entered into a Series&nbsp;E Preferred Stock
Purchase Agreement of even date herewith (the &#147;<B>Purchase Agreement</B>&#148;) pursuant to which the Company
shall sell, and the New Investors shall acquire, shares of the Company&#146;s Series&nbsp;E Preferred Stock;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Company has granted certain registration rights and other rights to the Founders
and the Prior Investors pursuant to that certain Seventh Amended and Restated Investor Rights
Agreement dated August&nbsp;16, 2005 (the &#147;<B>Prior Agreement</B>&#148;); and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, as an inducement to the New Investors to purchase shares of the Company&#146;s Series&nbsp;E
Preferred Stock pursuant to the Purchase Agreement, the Company, the Prior Investors and the
Founders desire to amend and restate the Prior Agreement to allow the New Investors to become a
party to this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the mutual promises and covenants hereinafter set forth,
the parties agree as follows:
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">SECTION 1
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Restrictions on Transferability; Registration Rights</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 <U>Certain Definitions</U>. As used in this Agreement, the following terms shall have
the following meanings:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Affiliate</B>&#148; shall have the meaning set forth in Rule&nbsp;405 of the Securities Act;
<U>provided</U> <U>that</U> for AllianceBernstein L.P. and its permitted transferees, the
definition of &#147;Affiliate&#148; shall also include (i)&nbsp;any general partner, officer or director of such
person, (ii)&nbsp;any private equity or venture capital fund now or hereafter existing (a &#147;<B>Fund</B>&#148;) for
which such person or an Affiliate of such person is a general partner or management company, and
(iii)&nbsp;if such person is a Fund, any other Fund that is directly or indirectly controlled by or
under common control with one or more general partners of such person, or that shares the same
management company with such person or an Affiliated management company.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Commission</B>&#148; shall mean the Securities and Exchange Commission or any other federal agency at
the time administering the Securities Act.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Eligible Securities</B>&#148; shall mean (i)&nbsp;the Series&nbsp;A Preferred Stock issued pursuant to the
Series&nbsp;A Preferred Stock Purchase Agreement dated December&nbsp;1, 1999; (ii)&nbsp;the Series&nbsp;B Preferred
Stock issued pursuant to the Series&nbsp;B Preferred Stock Purchase Agreement dated July&nbsp;5, 2000; (iii)
the Series&nbsp;C Preferred Stock issued pursuant to the Series&nbsp;C Preferred Stock Purchase Agreement
dated October&nbsp;23, 2001; (iv)&nbsp;the Series&nbsp;C Preferred Stock issued pursuant to the Series&nbsp;C Preferred
Stock Purchase Agreement dated November&nbsp;1, 2002; (v)&nbsp;the Series&nbsp;C Preferred Stock issued pursuant
to the Series&nbsp;C Preferred Stock and Warrant Purchase Agreement dated September&nbsp;22, 2003; (vi)&nbsp;the
Series&nbsp;D Preferred Stock issued pursuant to the Series&nbsp;D Preferred Stock Purchase Agreement dated
December&nbsp;18, 2003; (vii)&nbsp;the Series&nbsp;D Preferred Stock issued pursuant to the Series&nbsp;D Preferred
Stock Purchase Agreement dated August&nbsp;16, 2005; (viii)&nbsp;the Series&nbsp;D Preferred Stock issued upon
conversion of convertible promissory note(s) issued pursuant to the Convertible Promissory Note
Purchase Agreement (the &#147;<B>CNPA</B>&#148;) dated December&nbsp;18, 2003, as amended by Amendment No.&nbsp;1 to
Convertible Note Purchase Agreement dated December&nbsp;17, 2004, between the Company and Biomedical
Sciences Investment Fund Pte Ltd (the &#147;<B>BMSIF</B>&#148;); (ix)&nbsp;the Series&nbsp;D Preferred Stock issued upon
conversion of convertible promissory note(s) issued in connection with the Convertible Note
Agreement (the &#147;<B>CNA</B>&#148;) dated December&nbsp;18, 2003, between the Company and Invus, L.P. (the &#147;<B>Invus</B>&#148;);
(x)&nbsp;the Series&nbsp;E Preferred Stock issued pursuant to the Purchase Agreement; (xi)&nbsp;all Securities
acquired by any Investor pursuant to the rights of first offer described in Sections&nbsp;3 or 4 of this
Agreement; and (xii)&nbsp;any Securities issued with respect to the foregoing upon any stock split,
stock dividend, recapitalization, or similar event or upon any exercise or conversion, as
applicable.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Exchange Act</B>&#148; shall mean the Securities Exchange Act of 1934, as amended, or any similar
federal statute, and the rules and regulations of the Commission thereunder, all as the same shall
be in effect at the time.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Founders Shares</B>&#148; shall mean the shares of Common Stock of the Company issued to the Founders
as of the date of this Agreement or at any time in the future.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Holder</B>&#148; shall mean (i)&nbsp;any Investor and any person to whom registration rights under this
Agreement have been transferred in accordance with Section&nbsp;1.13 hereof, (ii)&nbsp;for the purposes of
Section&nbsp;1.6 (and other portions of this Section&nbsp;1, to the extent they relate to rights of
registration under Section&nbsp;1.6), any Founder or holder of Other Shares and (iii)&nbsp;for the purposes
of Sections&nbsp;1.5, 1.6 and 1.7 (and other portions of this Section&nbsp;1, to the extent they relate to
rights of registration under Sections&nbsp;1.5, 1.6 and 1.7), Warrantholders.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Initial Public Offering</B>&#148; shall mean the first sale of Securities of the Company pursuant to
an effective registration statement under the Securities Act.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Initiating Holders</B>&#148; shall mean Holders who in the aggregate hold a majority of the
Registrable Securities then held by Holders assuming conversion or exercise, as applicable, of all
Eligible Securities.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Lighthouse Preferred Warrant</B>&#148; shall mean the Preferred Stock Purchase Warrant dated March&nbsp;29,
2005, pursuant to which Lighthouse Capital Partners V, L.P. (&#147;<B>Lighthouse</B>&#148;) may purchase shares of
the Company&#146;s authorized Series&nbsp;D Preferred Stock.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Other Shares</B>&#148; shall mean the shares of Common Stock of the Company issued pursuant to the
Common Stock Purchase Agreements dated July&nbsp;17, 2001 and February&nbsp;2005 by and between the Company
and President and Fellows of Harvard College.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Permitted Transferee</B>&#148; shall mean (i)&nbsp;any general partner or retired general partner of any
Holder which is a partnership; (ii)&nbsp;any family member of a Holder or trust for the benefit of any
individual Holder; (iii)&nbsp;any Investor; (iv)&nbsp;an Affiliate of an Investor; or (v)&nbsp;any transferee who
acquires at least 40,000 shares of Eligible Securities.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The terms &#147;<B>register</B>,&#148; &#147;<B>registered</B>&#148; and &#147;<B>registration</B>&#148; refer to a registration effected by
preparing and filing a registration statement in compliance with the Securities Act, and the
declaration or ordering of the effectiveness of such registration statement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Registration Expenses</B>&#148; shall mean all expenses incurred by the Company in complying with
Sections&nbsp;1.5, 1.6 and 1.7 hereof, including, without limitation, all registration, qualification,
stock exchange and filing fees, printing expenses, escrow fees, fees and disbursements of counsel
for the Company and accountants and other persons retained by or for the Company (including the
fees of one counsel for the Holders, not to exceed $25,000), blue sky fees and expenses, accounting
fees and the expense of any special audits incident to or required by any such registration (but
excluding the compensation of regular employees of the Company which shall be paid in any event by
the Company).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Registrable Securities</B>&#148; means (i)&nbsp;any shares of Common Stock which are Eligible Securities,
(ii)&nbsp;any shares of Common Stock issuable upon the exercise or conversion, as applicable, of
Eligible Securities, (iii)&nbsp;for the purposes of Section&nbsp;1.6 (and other portions of this Section&nbsp;1,
to the extent they relate to rights of registration under Section&nbsp;1.6) any shares of Common Stock
which are Founder Shares or Other Shares, and (iv)&nbsp;for the purposes of Sections&nbsp;1.5, 1.6 and 1.7
(and other portions of this Section&nbsp;1, to the extent they relate to rights of registration under
Sections&nbsp;1.5, 1.6 and 1.7) any shares of Common Stock which are Warrant Shares; <U>provided</U>,
<U>however</U>, that shares of Common Stock shall be treated as Registrable Securities only if and
so long as they have not been (A)&nbsp;sold to or through a broker or dealer or underwriter in a public
distribution or a public securities transaction, (B)&nbsp;sold in a transaction exempt from the
registration and prospectus delivery requirements of the Securities Act under Section&nbsp;4(1) thereof
so that all transfer restrictions and restrictive legends with respect thereto are removed upon the
consummation of such sale or (C)&nbsp;sold in a transaction in which the rights granted under this
Section&nbsp;1 are not assigned in accordance with this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Restricted Securities</B>&#148; shall mean the securities of the Company required to bear the legends
set forth in Section&nbsp;1.3 hereof.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Securities</B>&#148; shall mean shares of, or securities convertible into or exercisable for any
shares of, any class of capital stock of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Securities Act</B>&#148; shall mean the Securities Act of 1933, as amended, or any similar federal
statute and the rules and regulations of the Commission thereunder, all as the same shall be in
effect at the time.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Selling Expenses</B>&#148; shall mean all underwriting discounts and selling commissions and
applicable to the securities registered by the Holders and any fees and disbursements of counsel
for the Holders not included in the definition of Registration Expenses.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Voting Agreement</B>&#148; shall mean the Second Amended and Restated Voting Agreement dated August
16, 2005 among the Company and certain stockholders of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Warrant Shares</B>&#148; shall mean the shares of Common Stock of the Company issued or issuable upon
conversion of the (i)&nbsp;Series&nbsp;C Preferred Stock issued or issuable upon exercise or conversion of
(A)&nbsp;the warrant to purchase up to 17,500 shares of Series&nbsp;C Preferred Stock issued to TBCC Funding
Trust II (&#147;<B>TBCC</B>&#148;) pursuant to the Master Loan and Security Agreement dated March&nbsp;27, 2002 by and
between the Company and Transamerica Technology Finance Corporation; (B)&nbsp;the warrant to purchase
up to 31,008 shares of Series&nbsp;C Preferred Stock issued to General Electric Capital Corporation (&#147;<B>GE
Capital</B>&#148;) in connection with the Master Security Agreement dated as of November&nbsp;8, 2002, as amended
(the &#147;<B>Master Security Agreement</B>&#148;) by and between the Company and GE Capital; (C)&nbsp;the warrants to
purchase an aggregate of up to 90,000 shares of Series&nbsp;C Preferred Stock issued to Glaxo Group
Limited (&#147;<B>GGL</B>&#148;) in connection with the Development Collaboration and License Agreement dated
September&nbsp;22, 2003 (the &#147;<B>License Agreement</B>&#148;); and (D)&nbsp;the warrants to purchase an aggregate of up
to 110,000 shares of Series&nbsp;C Preferred Stock issued to SmithKline Beecham Corporation (&#147;<B>SBC</B>&#148;) in
connection with the License Agreement; and (ii)&nbsp;the Series&nbsp;D Preferred Stock issued or issuable
upon exercise or conversion of (A)&nbsp;the warrant to purchase up to 37,500 shares of Series&nbsp;D
Preferred Stock dated March&nbsp;18, 2004 and issued to GE Capital in connection with extensions of
credit to the Company; (B)&nbsp;the warrant to purchase up to 380,556 shares of Series&nbsp;D Preferred Stock
dated June&nbsp;30, 2004 and issued to In-Q-Tel, Inc. (&#147;<B>In-Q-Tel</B>&#148;); (C)&nbsp;the Lighthouse Preferred
Warrant; and (D)&nbsp;the warrant to purchase up to 126,851 shares of Series&nbsp;D Preferred Stock dated
June&nbsp;30, 2004 and issued to In-Q-Tel Employee Fund, LLC (&#147;<B>Employee Fund</B>&#148;) . GGL, SBC, TBCC, GE
Capital, In-Q-Tel, Employee Fund, and Lighthouse are collectively referred to herein as
&#147;<B>Warrantholders</B>.&#148;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Worthington Shares</B>&#148; shall mean the Founder Shares issued to Gajus Worthington.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2 <U>Restrictions</U>. No Restricted Securities shall be sold, assigned, transferred or
pledged except upon the conditions specified in this Agreement. Each Holder will cause any
proposed purchaser, assignee, transferee or pledgee of its Restricted Securities to agree in
writing to
take and hold such securities subject to the provisions and upon the conditions specified in
this Agreement, including, without limitation, Section&nbsp;1.14, except where such Restricted
Securities would cease to be Restricted Securities in connection with such proposed purchase,
assignment, transfer or pledge.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3 <U>Restrictive Legend</U>. Each certificate representing Registrable Securities shall
(unless otherwise permitted by the provisions of Section&nbsp;1.4 below) be stamped or otherwise
imprinted with a legend in the following form (in addition to any legend required under applicable
state securities laws):
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&#147;THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
&#147;SECURITIES ACT&#148;). SUCH SHARES MAY NOT BE SOLD, TRANSFERRED OR PLEDGED IN THE
ABSENCE OF SUCH REGISTRATION OR UNLESS THE COMPANY RECEIVES AN OPINION OF COUNSEL
(WHICH MAY BE COUNSEL FOR THE COMPANY), OR OTHER EVIDENCE, REASONABLY ACCEPTABLE TO
IT STATING THAT SUCH SALE OR TRANSFER IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS
DELIVERY REQUIREMENTS OF THE SECURITIES ACT.&#148;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&#147;THE SHARES REPRESENTED BY THIS CERTIFICATE MAY BE TRANSFERRED ONLY IN ACCORDANCE
WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE SHAREHOLDER, A COPY OF
WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.&#148;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&#147;THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A MARKET STAND-OFF
AGREEMENT IN THE EVENT OF A PUBLIC OFFERING, A COPY OF WHICH IS ON FILE WITH THE
SECRETARY OF THE COMPANY.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Holder consents to the Company making a notation on its records and giving instructions
to any transfer agent of the Restricted Securities in order to implement the restrictions on
transfer established in this Section&nbsp;1.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.4 <U>Notice of Proposed Transfers</U>. Each Holder of each certificate representing
Restricted Securities, by acceptance thereof, agrees to comply in all respects with the
restrictions on transfer contained in Sections&nbsp;1.2, 1.3, 1.4 and 1.14 of this Agreement. Solely
for purposes of the foregoing sentence and for the sake of clarification, the term &#147;Holder&#148; shall
also include and the term &#147;Restricted Securities&#148; shall also apply to any Founder, holder of Other
Shares or Warrantholders. Prior to any proposed sale, assignment, transfer or pledge of any
Restricted Securities (other than any transfer not involving a change in beneficial ownership),
unless there is in effect a registration statement under the Securities Act covering the proposed
transfer, the Holder thereof shall give written notice to the Company of such Holder&#146;s intention to
effect such transfer, sale, assignment or
pledge. Each such notice shall describe the manner and circumstances of the proposed
transfer, sale, assignment or pledge in sufficient detail, and shall be accompanied at such
Holder&#146;s expense by either (i)&nbsp;a written opinion of legal counsel who shall, and whose legal
opinion shall be, reasonably satisfactory to the Company, addressed to the Company, to the effect
that the proposed transfer of the Restricted Securities may be effected without registration under
the Securities Act and applicable state securities laws, or (ii)&nbsp;a &#147;no action&#148; letter from the
Commission
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-5-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">to the effect that the transfer of such securities without registration will not result
in a recommendation by the staff of the Commission that action be taken with respect thereto, or
(iii)&nbsp;any other evidence reasonably satisfactory to counsel to the Company, whereupon the Holder of
such Restricted Securities shall be entitled to transfer such Restricted Securities in accordance
with the terms of the notice delivered by the Holder to the Company; <U>provided</U>,
<U>however</U>, that no such legal opinion, &#147;no action&#148; letter or other evidence shall be required
with respect to a transfer to an Affiliate. Each certificate evidencing the Restricted Securities
transferred as above provided shall bear, except if such transfer is made pursuant to Rule&nbsp;144, the
appropriate restrictive legend set forth in Section&nbsp;1.3 above, except that such certificate shall
not bear such restrictive legend if, in the opinion of counsel for such Holder and reasonably
acceptable to the Company, such legend is not required in order to establish compliance with any
provisions of the Securities Act or this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.5 <U>Requested Registration</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<U>Request for Registration</U>. In case the Company shall receive from Initiating
Holders a written request that the Company effect any registration with respect to a public
offering of at least 50% of the Registrable Securities, the reasonably anticipated aggregate price
to the public of which, net of underwriting discounts and commissions, would exceed $20,000,000,
the Company will:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;promptly give written notice of the proposed registration to all other Holders; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;use its best efforts to effect as soon as practicable such registration (including,
without limitation, the execution of an undertaking to file post-effective amendments, appropriate
qualification under applicable blue sky or other state securities laws and appropriate compliance
with applicable regulations issued under the Securities Act and any other governmental requirements
or regulations) as may be so requested and as would permit or facilitate the sale and distribution
of all or such portion of such Registrable Securities as are specified in such request, together
with all or such portion of the Registrable Securities of any Holder or Holders joining in such
request as are specified in a written request received by the Company within 15&nbsp;days after receipt
of the written notice from the Company; <U>provided</U>, <U>however</U>, that the Company shall
not be obligated to take any action to effect any such registration pursuant to this Section&nbsp;1.5:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;Prior to six months following the closing of the Company&#146;s Initial Public Offering;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;During the period starting with the date 60&nbsp;days prior to the Company&#146;s estimated date of
filing of, and ending on the date three months immediately following the effective date of, any
registration statement (other than a registration of Securities in a Rule&nbsp;145 transaction or with
respect to an employee benefit plan) pertaining to Securities of the Company (subject to Section
1.6(a) hereof), provided that the Company is actively employing in good faith all reasonable
efforts to cause such registration statement to be filed and become effective and that the Company
provides the Initiating Holders written notice of its intent to file such
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-6-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">registration statement
within 30&nbsp;days of receiving the request for registration from the Initiating Holders and provided
further, however, that the Company may not utilize this right more than once in any 12-month
period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;After the Company has effected two registrations pursuant to this Section&nbsp;1.5; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;If the Company shall furnish to such Holders a certificate, signed by the President of the
Company, stating that in the good faith judgment of the Board of Directors it would be seriously
detrimental to the Company or its shareholders for a registration statement to be filed in the near
future, in which case the Company&#146;s obligation to use its best efforts to register under this
Section&nbsp;1.5 shall be deferred for a period not to exceed 90&nbsp;days from the date of receipt of
written request from the Initiating Holders; provided, however, that the Company may not utilize
this right more than once in any 12-month period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<U>Underwriting</U>. If the Initiating Holders intend to distribute the Registrable
Securities covered by their request by means of an underwriting, they shall so advise the Company
as part of their request made under Section&nbsp;1.5(a), and the Company shall so advise the Holders as
part of the notice given pursuant to Section&nbsp;1.5(a)(i). The right of any Holder to registration
pursuant to Section&nbsp;1.5 shall be conditioned upon such Holder&#146;s participation in the underwriting
arrangements required by this Section&nbsp;1.5 and the inclusion of such Holder&#146;s Registrable Securities
in the underwriting, to the extent requested and provided herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company shall (together with all Holders proposing to distribute their securities through
such underwriting) enter into an underwriting agreement in customary form with the managing
underwriter selected for such underwriting by the Company and a majority of the Holders.
Notwithstanding any other provision of this Section&nbsp;1.5, if the managing underwriter advises the
Company in writing that marketing factors require a limitation of the number of shares to be
underwritten, then the Company shall so advise all Holders of Registrable Securities who indicated
their intent to participate in the registration in a timely manner, and the number of shares of
Registrable Securities that may be included in the registration and underwriting shall be allocated
among such Holders in proportion, as nearly as practicable, to the respective number of Registrable
Securities held by such Holders at the time of filing the registration statement, <U>provided</U>,
<U>however</U>, that the number of shares of Registrable Securities to be included in such
underwriting shall not be reduced unless all Worthington Shares, all Other Shares and all other
Securities that are not Registrable Securities (other than Securities to be sold for the account of
the Company) are first
entirely excluded from the underwriting. No Registrable Securities excluded from the
underwriting by reason of the underwriter&#146;s marketing limitation shall be included in such
registration. To facilitate the allocation of shares in accordance with the above provisions, the
Company or the underwriters may round the number of shares allocated to any Holder to the nearest
100 shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any Holder of Registrable Securities disapproves of the terms of the underwriting, such
person may elect to withdraw therefrom by written notice to the Company, the managing underwriter
and the Initiating Holders. The Registrable Securities so withdrawn shall also be withdrawn from
registration.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-7-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.6 <U>Company Registration</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<U>Notice of Registration</U>. If at any time or from time to time, the Company shall
determine to register any Common Stock, either for its own account or the account of a security
holder or holders other than (i)&nbsp;a registration relating to employee benefit plans, (ii)&nbsp;a
registration relating to the offer and sale of debt securities, (iii)&nbsp;a registration relating to a
Commission Rule&nbsp;145 transaction, or (iv)&nbsp;a registration pursuant to Sections&nbsp;1.5 or 1.7 hereof, the
Company will:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;promptly give to each Holder written notice thereof; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;include in such registration (and any related qualification under blue sky laws or other
compliance), and in any underwriting involved therein, all the Registrable Securities specified in
a written request or requests made within 15&nbsp;days after receipt of such written notice from the
Company by any Holder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<U>Underwriting</U>. If the registration of which the Company gives notice is for a
registered public offering involving an underwriting, the Company shall so advise the Holders in a
written notice given pursuant to this Section&nbsp;1.6. In such event, the right of any Holder to
registration pursuant to this Section&nbsp;1.6 shall be conditioned upon such Holder&#146;s participation in
such underwriting and the inclusion of Registrable Securities in the underwriting to the extent
provided herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All Holders proposing to distribute their securities through such underwriting shall (together
with the Company and the other holders distributing their securities through such underwriting)
enter into an underwriting agreement in customary form with the managing underwriter selected for
such underwriting by the Company. Notwithstanding any other provision of this Section&nbsp;1.6, if the
managing underwriter advises the Company in writing that marketing factors require a limitation of
the number of shares to be underwritten, then the Company shall so advise all Holders of
Registrable Securities and the number of shares of Registrable Securities that may be included in
the registration and underwriting shall be allocated among all Holders thereof in proportion, as
nearly as practicable, to the respective number of Registrable Securities held by such Holders at
the time of filing the registration statement; <U>provided</U>, <U>however</U>, that, no
Registrable Securities shall be excluded until all Worthington Shares, all Other Shares and all
other Securities that are not Registrable Securities
(other than Securities to be sold for the account of the Company) are first excluded, and
<U>provided</U> <U>further</U>, that, except in the case of the Company&#146;s Initial Public Offering
(where Registrable Securities may be excluded entirely), the number of Registrable Securities
included in such underwriting shall not be reduced below 25% of the total number of shares in the
underwriting. No Registrable Securities excluded from the underwriting by reason of the
underwriter&#146;s marketing limitation shall be included in such registration. To facilitate the
allocation of shares in accordance with the above provisions, the Company or the underwriters may
round the number of shares allocated to any Holder to the nearest 100 shares. The Company may
include shares of Common Stock held by shareholders other than Holders in a registration statement
pursuant to this Section&nbsp;1.6 to the extent that the amount of Registrable Securities otherwise
includible in such registration statement would not thereby be diminished.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-8-<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any Holder or other holder disapproves of the terms of any such underwriting, he or she may
elect to withdraw therefrom by written notice to the Company and the managing underwriter. The
Registrable Securities so withdrawn shall also be withdrawn from such registration and, in the case
of the Company&#146;s Initial Public Offering, shall be subject to Section&nbsp;1.14.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;<U>Right to Terminate Registration</U>. The Company shall have the right to terminate or
withdraw any registration initiated by it under this Section&nbsp;1.6 prior to the effectiveness of such
registration, whether or not any Holder has elected to include securities in such registration.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.7 <U>Registration on Form&nbsp;S-3</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;If any Holder or Holders request that the Company file a registration statement on Form
S-3 (or any successor form to Form S-3) for a public offering of Registrable Securities, the
reasonably anticipated aggregate price to the public of which, net of underwriting discounts and
commissions, would exceed $2,000,000, and the Company is then entitled to use Form S-3 under
applicable Commission rules to register the Registrable Securities for such an offering, the
Company will:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;promptly give written notice of the proposed registration to all other Holders; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;use its best efforts to effect as soon as practicable such registration (including,
without limitation, the execution of an undertaking to file post-effective amendments, appropriate
qualification under applicable blue sky or other state securities laws and appropriate compliance
with applicable regulations issued under the Securities Act and any other governmental requirements
or regulations) as may be so requested and as would permit or facilitate the sale and distribution
of all or such portion of such Registrable Securities as are specified in such request, together
with all or such portion of the Registrable Securities of any Holder or Holders joining in such
request as are specified in a written request received by the Company within 15&nbsp;days after receipt
of the written notice from the Company; <U>provided</U>, <U>however</U>, that the Company shall
not be obligated to take any action to effect any such registration pursuant to this Section&nbsp;1.7:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;if the Company, within ten (10)&nbsp;days of the receipt of the request for registration
pursuant to this Section&nbsp;1.7, gives notice of its bona fide intention to effect the filing of a
registration statement with the Commission within ninety (90)&nbsp;days of receipt of such request
(other than with respect to a registration statement relating to a Rule&nbsp;145 transaction or an
employee benefit plan or any other registration which is not appropriate for the registration of
Registrable Securities);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;during the period starting with the date sixty (60)&nbsp;days prior to the Company&#146;s estimated
date of filing of, and ending on the date three months immediately following, the effective date of
any registration statement pertaining to Securities of the Company (other than with respect to a
registration statement relating to a Rule&nbsp;145 transaction or an employee benefit plan), provided
that the Company is actively employing in good faith all reasonable efforts to cause such
registration statement to be filed and become effective; or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-9-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;if the Company shall furnish to such Holder or Holders a certificate signed by the
President of the Company stating that in the good faith judgment of the Board of Directors it would
be seriously detrimental to the Company or its shareholders for registration statements to be filed
in the near future, then the Company&#146;s obligation to use its best efforts to file a registration
statement shall be deferred for a period not to exceed 90&nbsp;days from the receipt of the request to
file such registration by such Holder or Holders; <U>provided</U> <U>further</U>, however, that
the Company may not utilize the rights provided for in subsections (1)&nbsp;and (2)&nbsp;above and this
subsection (3)&nbsp;more than once in total in any twelve month period. For the avoidance of doubt, if
the Company utilizes any of the rights provided for in subsections (1), (2)&nbsp;and (3), it shall not
have the right to utilize the same right again; nor shall it have the right to utilize any of the
other rights provided in subsections (1), (2)&nbsp;and (3)&nbsp;for twelve months.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<U>Underwriting</U>. If the Holders requesting registration intend to distribute the
Registrable Securities covered by their request by means of an underwriting, they shall so advise
the Company as part of their request made under Section&nbsp;1.7(a), and the Company shall so advise the
Holders as part of the notice given pursuant to Section&nbsp;1.7(a)(i). The substantive provisions of
Section&nbsp;1.5(b) shall otherwise apply to such registration.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.8 <U>Expenses of Registration</U>. All Registration Expenses incurred in connection with
any registration pursuant to Sections&nbsp;1.5, 1.6 and 1.7 shall be borne by the Company. If a
registration proceeding is begun upon the request of Holders pursuant to Section&nbsp;1.5 or 1.7, but
such request is subsequently withdrawn at the request of the Holders, then the Holders of
Registrable Securities to have been registered may either: (i)&nbsp;bear all Registration Expenses of
such proceeding, pro rata on the basis of the number of shares to have been registered, in which
case the Company shall be deemed not to have effected a registration pursuant to Section&nbsp;1.5(a) or
1.7(a) of this Agreement as applicable; <U>provided</U>, <U>however</U>, that the Company, and
not the Holders, shall be required to pay for the Registration Expenses if the Holders learn of a
materially adverse change in the condition, business, or prospects of the Company from that known
to the Holders at the time of their request and have withdrawn the request promptly following
discovery of such material adverse
change; or (ii)&nbsp;if the registration is being effected pursuant to Section&nbsp;1.5, require the
Company to bear all Registration Expenses of such proceeding, in which case the Company shall be
deemed to have effected a registration pursuant to Section&nbsp;1.5(a). Unless otherwise stated, all
other Selling Expenses relating to securities registered on behalf of the Holders shall be borne by
the Holders of the registered securities included in such registration pro rata on the basis of the
number of shares so registered, <U>provided</U> <U>that</U> to the extent a Holder elects to
retain its own counsel (an &#147;<B>Additional Counsel</B>&#148;) separate from the counsel for all the Holders
permitted pursuant to the definition of &#147;Registration Expenses&#148; under Section&nbsp;1.1, then such Holder
shall exclusively bear the costs of such Additional Counsel.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.9 <U>Registration Procedures</U>. In the case of each registration, qualification or
compliance effected by the Company pursuant to this Section&nbsp;1, the Company will keep each Holder
advised in writing as to the initiation of each registration, qualification and compliance and as
to the completion thereof. At its expense the Company will, as expeditiously as reasonably
possible:
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-10-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Prepare and file with the Commission a registration statement with respect to such
Registrable Securities and use its best efforts to cause such registration statement to become
effective, and, upon the request of the Holders of a majority of the Registrable Securities
registered thereunder, keep such registration statement effective for a period of up to one hundred
twenty (120)&nbsp;days or until the distribution described in the registration statement has been
completed; <U>provided</U>, <U>however</U>, that such 120-day period shall be extended for a
period of time equal to the period the Holder refrains from selling any securities included in such
registration at the request of an underwriter of Common Stock (or other securities) of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Prepare and file with the Commission, in consultation with the Holders, such amendments
and supplements to such registration statement and the prospectus used in connection with such
registration statement as may be necessary to comply with the provisions of the Securities Act with
respect to the disposition of all securities covered by such registration statement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Furnish to the Holders participating in such registration and to the underwriters of the
securities being registered such reasonable number of copies of the registration statement,
preliminary prospectus, final prospectus and such other documents as such underwriters may
reasonably request in order to facilitate the public offering of such securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Use its best efforts to register and qualify the securities covered by such registration
statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably
requested by the Holders; provided that the Company shall not be required in connection therewith
or as a condition thereto to qualify to do business or to file a general consent to service of
process in any such states or jurisdictions, unless the Company is already subject to service in
such jurisdiction and except as may be required by the Securities Act.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;In the event of any underwritten public offering, enter into and perform its obligations
under an underwriting agreement, in usual and customary form, with the managing
underwriter of such offering. Each Holder participating in such underwriting shall also enter
into and perform its obligations under such an agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Notify each Holder of Registrable Securities covered by such registration statement at any
time when a prospectus relating thereto is required to be delivered under the Securities Act of the
happening of any event as a result of which the prospectus included in such registration statement,
as then in effect, includes an untrue statement of a material fact or omits to state a material
fact required to be stated therein or necessary to make the statements therein not misleading or
incomplete in light of the circumstances then existing, and at the request of any such Holder,
prepare and furnish to such Holder a reasonable number of copies of a supplement to or an amendment
of such prospectus as may be necessary so that, as thereafter delivered to the purchasers of such
shares, such prospectus shall not include an untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary to make the statements therein not
misleading or incomplete in the light of the circumstances then existing.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-11-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;Cause all such Registrable Securities registered pursuant hereunder to be listed on each
securities exchange, or quoted in a U.S. automated inter-dealer quotation system, as the case may
be, on which similar securities issued by the Company are then listed or quoted.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;Provide a transfer agent and registrar for all Registrable Securities registered pursuant
hereunder and a CUSIP number for all such Registrable Securities, in each case not later than the
effective date of such registration.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;In the event of any underwritten public offering, cooperate with the selling Holders, the
underwriters participating in the offering and their counsel in any due diligence investigation
reasonably requested by the selling Holders or the underwriters in connection therewith, and
participate, to the extent reasonably requested by the managing underwriter for the offering or the
selling Holder, in efforts to sell the Registrable Securities under the offering (including,
without limitation, participating in &#147;roadshow&#148; meetings with prospective investors) that would be
customary for underwritten primary offerings of a comparable amount of equity securities by the
Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.10 <U>Indemnification</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Company will indemnify and defend each Holder, each of its officers and directors and
partners, and each person controlling such Holder within the meaning of Section&nbsp;15 of the
Securities Act, with respect to which registration, qualification or compliance is being effected
pursuant to this Section&nbsp;1, and each underwriter, if any, and each person who controls any
underwriter within the meaning of Section&nbsp;15 of the Securities Act, against all expenses, claims,
losses, damages or liabilities (or actions in respect thereof), including any of the foregoing
incurred in settlement of any litigation, commenced or threatened, arising out of or based on any
untrue statement (or alleged untrue statement) of a material fact contained in any registration
statement, prospectus, preliminary prospectus, offering circular or other document, or any
amendment or supplement thereto, incident to any such registration, qualification or compliance, or
based on any
omission (or alleged omission) to state therein a material fact required to be stated therein
or necessary to make the statements therein, in light of the circumstances in which they were made,
not misleading, or any violation or any alleged violation by the Company of the Securities Act or
the Exchange Act or any state securities law, or any rule or regulation promulgated thereunder,
applicable to the Company in connection with any such registration, qualification or compliance,
and the Company will reimburse each such Holder, each of its officers and directors, and each
person controlling such Holder, each such underwriter and each person who controls any such
underwriter, for any legal and any other expenses reasonably incurred in connection with
investigating, preparing or defending any such claim, loss, damage, liability or action, as such
expenses are incurred, provided that the Company will not be liable in any such case to the extent
that any such claim, loss, damage, liability or expense arises out of or is based on any untrue
statement or omission or alleged untrue statement or omission, made in reliance upon and in
conformity with written information furnished to the Company by an instrument duly executed by such
Holder, controlling person or underwriter and stated to be specifically for use therein.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-12-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each Holder will, if Registrable Securities held by such Holder are included in the
securities as to which such registration, qualification or compliance is being effected, indemnify
the Company, each of its directors and officers, each underwriter, if any, of the Company&#146;s
securities covered by such a registration statement, each person who controls the Company or such
underwriter within the meaning of Section&nbsp;15 of the Securities Act, and each other such Holder,
each of its officers and directors and each person controlling such Holder within the meaning of
Section&nbsp;15 of the Securities Act, against all claims, losses, damages and liabilities (or actions
in respect thereof) arising out of or based on any untrue statement (or alleged untrue statement)
of a material fact contained in any such registration statement, prospectus, offering circular or
other document, or any omission (or alleged omission) to state therein a material fact required to
be stated therein or necessary to make the statements therein not misleading, and will reimburse
the Company, such Holders, such directors, officers, persons, underwriters or control persons for
any legal or any other expenses reasonably incurred in connection with investigating or defending
any such claim, loss, damage, liability or action, as such expenses are incurred, in each case to
the extent, but only if and to the extent, that such untrue statement (or alleged untrue statement)
or omission (or alleged omission) is made in such registration statement, prospectus, offering
circular or other document in reliance upon and in conformity with written information furnished to
the Company by an instrument duly executed by such Holder and stated to be specifically for use
therein; <U>provided</U>, <U>however</U>, that the liability of any Holder shall be limited to
the net proceeds received by such Holder from the sale of Securities pursuant to such registration.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Each party entitled to indemnification under this Section&nbsp;1.10 (the &#147;<B>Indemnified Party</B>&#148;)
shall give notice to the party required to provide indemnification (the &#147;<B>Indemnifying Party</B>&#148;)
promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may
be sought, and shall permit the Indemnifying Party to assume the defense of any such claim or any
litigation resulting therefrom, provided that counsel for the Indemnifying Party, who shall conduct
the defense of such claim or litigation, shall be approved by the Indemnified Party (whose approval
shall not unreasonably be withheld), and the Indemnified Party
may participate in such defense at such party&#146;s expense; <U>provided</U>, <U>however</U>,
that an Indemnified Party (together with all other Indemnified Parties which may be represented
without conflict by one counsel) shall have the right to retain one separate counsel, with the fees
and expenses to be paid by the Indemnifying Party, if representation of such Indemnified Party by
the counsel retained by the Indemnifying Party would be inappropriate due to actual or potential
differing interests between such Indemnified Party and any other party represented by such counsel
in such proceeding. The failure of any Indemnified Party to give notice as provided herein shall
not relieve the Indemnifying Party of its obligations under this Section&nbsp;1 unless, and only to the
extent that, the failure to give such notice is materially prejudicial to an Indemnifying Party&#146;s
ability to defend such action. No Indemnifying Party, in the defense of any such claim or
litigation, shall, except with the consent of each Indemnified Party, consent to entry of any
judgment or enter into any settlement which does not include as an unconditional term thereof the
giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in
respect to such claim or litigation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;If the indemnification provided for in this Section&nbsp;1.10 is held by a court of competent
jurisdiction to be unavailable to an Indemnified Party with respect to any loss,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-13-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">liability, claim,
damage, or expense referred to therein, then the Indemnifying Party, in lieu of indemnifying such
Indemnified Party hereunder, shall contribute to the amount paid or payable by such Indemnified
Party as a result of such loss, liability, claim, damage, or expense in such proportion as is
appropriate to reflect the relative fault of the Indemnifying Party on the one hand and of the
Indemnified Party on the other in connection with the statements or omissions that resulted in such
loss, liability, claim, damage, or expense as well as any other relevant equitable considerations
(except to the extent that contribution is not permitted under Section 11(f) of the Securities
Act); <U>provided</U>, <U>however</U>, that, no Holder will be required to pay any amount under
this subsection 1.10(d) in excess of the net proceeds from the sale of all Registrable Securities
offered and sold by such Holder pursuant to such registration statement. The relative fault of the
Indemnifying Party and of the Indemnified Party shall be determined by reference to, among other
things, whether the untrue or alleged untrue statement of a material fact or the omission to state
a material fact relates to information supplied by the Indemnifying Party or by the Indemnified
Party and the parties&#146; relative intent, knowledge, access to information, and opportunity to
correct or prevent such statement or omission.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;Notwithstanding the foregoing, to the extent that the provisions on indemnification and
contribution contained in the underwriting agreement entered into in connection with the
underwritten public offering are in conflict with the foregoing provisions, the provisions in the
underwriting agreement shall control with respect to the rights and obligations of each of the
parties to such underwriting agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;The obligations of the Company and Holders under this Section&nbsp;1.10 shall survive the
completion of any offering of Registrable Securities in a registration statement under this Section
1, and otherwise.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.11 <U>Information by Holder</U>. The Holder or Holders of Registrable Securities included
in any registration shall furnish to the Company such information regarding such Holder or Holders,
the Securities held by them and the distribution proposed by such Holder or Holders as the Company
may reasonably request in writing and as shall be required in connection with any registration
referred to in this Section&nbsp;1.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.12 <U>Reports Under Securities Exchange Act of 1934</U>. With a view to making available
to the Holders the benefits of Rule&nbsp;144 promulgated under the Securities Act and any other rule or
regulation of the Commission that may at any time permit a Holder to sell securities of the Company
to the public without registration or pursuant to a registration on Form S-3, the Company agrees to
use its best efforts to:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;make and keep public information available, as those terms are understood and defined in
Rule&nbsp;144 under the Securities Act, at all times after the effective date that the Company becomes
subject to the reporting requirements of the Securities Act or the Exchange Act;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-14-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;file with the Commission in a timely manner all reports and other documents required of
the Company under the Securities Act and the Exchange Act (at any time after it has become subject
to such reporting requirements);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;register its Common Stock under Section&nbsp;12 of the Exchange Act at such time as it is
required to do so pursuant to the Exchange Act; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith
upon request (i)&nbsp;a written statement by the Company as to its compliance with the reporting
requirements of Rule&nbsp;144 (at any time after ninety (90)&nbsp;days after the effective date of the first
registration statement filed by the Company), the Securities Act and the Exchange Act (at any time
after it has become subject to such reporting requirements), or that it qualifies as a registrant
whose securities may be resold pursuant to Form S-3 (at any time after it so qualifies), (ii)&nbsp;a
copy of the most recent annual or quarterly report of the Company and such other reports and
documents so filed by the Company, and (iii)&nbsp;such other information in the possession of or
reasonably obtainable by the Company as may be reasonably requested in availing any Holder of any
rule or regulation of the Commission which permits the selling of any such securities without
registration or pursuant to such form.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.13 <U>Transfer of Registration Rights</U>. The rights to cause the Company to register
Registrable Securities granted to the Investors under Sections&nbsp;1.5, 1.6 and 1.7 may be assigned to
a transferee or assignee in connection with any transfer or assignment of Eligible Securities by an
Investor; provided that (a)&nbsp;such transfer may otherwise be effected in accordance with applicable
securities laws, (b)&nbsp;notice of such assignment is given to the Company, (c)&nbsp;such transferee is a
Permitted Transferee and (d)&nbsp;such transferee or assignee agrees to be bound by and subject to the
terms and conditions of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.14 <U>Standoff Agreement</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Each Holder agrees in connection with the first sale of the Company&#146;s Common Stock in a
firm commitment underwritten public offering pursuant to an effective registration statement under
the Securities Act, upon notice by the Company or the underwriters managing such public offering,
not to sell, make any short sale of, loan, pledge (or otherwise encumber or hypothecate), grant any
option for the purchase of, or otherwise directly or indirectly dispose of any Securities (other
than those included in the registration) without the prior written consent of the Company and such
managing underwriters for such period of time as the Board of Directors establishes pursuant to its
good faith negotiations with such managing underwriters; provided, however that:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;such agreement shall not exceed one hundred eighty (180)&nbsp;days;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;such agreement shall not apply to transfers to an Affiliate, provided that such Affiliate
agrees to be bound by the terms of such agreement, to the same extent as if such transferee were
the original party thereunder;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-15-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;a Holder shall not be subject to such agreement unless (A)&nbsp;all executive officers and
directors of the Company, (B), all shareholders of the Company holding more than 1% of the
Company&#146;s outstanding capital stock; and (C)&nbsp;all other Holders and holders of other registration
rights, are subject to or obligated to enter into similar agreements; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;if and when any person identified in clause (iii)&nbsp;is released, in whole or in part, from
such agreement (whether or not such release is contemplated at the time of the offering) or if any
such agreement is terminated, the Holder shall be concurrently released on a pro rata basis based
on the number of shares held by such person and the Holder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each Holder agrees that prior to the Initial Public Offering it will not transfer
securities of the Company unless each transferee agrees in writing to be bound by all of the
provisions of this Section&nbsp;1.14; provided that this Section&nbsp;1.14(b) shall not apply to transfers
pursuant to a registration statement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Each Holder hereby consents to the placement of stop transfer orders with the Company&#146;s
transfer agent in order to enforce the foregoing provision and agrees to execute a market standoff
agreement with said underwriters in customary form consistent with the provisions of this Section
1.14.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.15 <U>No Right to Delay Registration</U>. No holder shall restrain, enjoin, or otherwise
delay any registration hereunder, notwithstanding any controversy that might arise with respect to
the interpretation or implementation of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.16 <U>Termination of Rights</U>. No Holder shall be entitled to exercise any right
provided for in this Section&nbsp;1 after the earlier of (i)&nbsp;five (5)&nbsp;years following the consummation
of the Initial Public Offering, and (ii)&nbsp;that date following the Initial Public Offering upon which
each Holder holds less than 1% of the then issued and outstanding shares of capital stock of the
Company and all such shares may be sold under Section&nbsp;5 of the Securities Act whether pursuant to
Rule&nbsp;144 or another applicable exemption during any 90&nbsp;day period. All other provisions hereof
relating to registration rights shall continue to be effective despite any termination of such
registration rights pursuant to this section.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.17 <U>Limitations on Subsequent Registration Rights</U>. From and after the date of this
Agreement, the Company shall not enter into any agreement granting any holder or prospective holder
of any securities of the Company registration rights with respect to such securities unless (i)
such new registration rights, are subordinate to the registration rights granted Holders hereunder
and include similar market stand-off obligations or (ii)&nbsp;such new registration rights are approved
by the Holders of 50% of the Registrable Securities then held by Holders (assuming exercise or
conversion of all outstanding Eligible Securities); <U>provided</U>, <U>however</U>, that
Warrantholders may enter into this Agreement by executing and delivering a counterpart signature
page to this Agreement.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">SECTION 2
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>Affirmative Covenants of the Company</U>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-16-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company hereby covenants and agrees as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 <U>Delivery of Financial Statements</U>. The Company will furnish to each Investor who
holds at least 40,000 shares of Eligible Securities (as adjusted for stock splits and
combinations):
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;as soon as reasonably practicable, an income statement for such fiscal year, a balance
sheet of the Company and statement of shareholder&#146;s equity as of the end of such year, and a cash
flow statement for such year, such year-end financial reports to be in reasonable detail, prepared
in accordance with generally accepted accounting principles (&#147;<B>GAAP</B>&#148;), and audited and certified by
independent public accountants of nationally recognized standing selected by the Company; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;as soon as practicable, but in any event within forty-five (45)&nbsp;days after the end of each
of the first three (3)&nbsp;quarters of each fiscal year of the Company, an unaudited income statement,
cash flow statement for such fiscal quarter and an unaudited balance sheet as of the end of such
fiscal quarter.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 <U>Additional Information Rights</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<U>Budget and Operating Plan</U>. The Company will furnish to each Investor who holds at
least 750,000 shares of Eligible Securities (as adjusted for stock splits and
combinations) as soon as practicable upon approval or adoption by the Company&#146;s Board of
Directors, and in any event within 15&nbsp;days prior to the start of a fiscal year, the Company&#146;s
budget and operating plan for such fiscal year.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<U>Other Information</U>. The Company will furnish to each Investor who holds at least
750,000 shares of Eligible Securities (as adjusted for stock splits and combinations) such other
information relating to the financial condition, business, prospects or corporate affairs of the
Company as such Investor may from time to time request; <U>provided</U>, <U>however</U>, that the
Company shall not be obligated under this subsection (b)&nbsp;or any other subsection of Section&nbsp;2.2 to
provide information which it deems in good faith to be a trade secret or similar confidential
information.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;<U>Inspection</U>. The Company shall permit each Investor who holds at least 750,000
shares of Eligible Securities (as adjusted for stock splits and combinations), at such Investor&#146;s
expense, to visit and inspect the Company&#146;s properties, to examine its books of account and records
and to discuss the Company&#146;s affairs, finances and accounts with its officers, all at such
reasonable times and during normal working hours as may be requested by such Investor;
<U>provided</U>, <U>however</U>, that the Company shall not be obligated under this subsection
(c)&nbsp;or any other subsection of Section&nbsp;2.2 to provide access to information which it deems in good
faith to be a trade secret or similar confidential information.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;<U>Monthly Financial Statements</U>. The Company will furnish to each Investor who holds
at least 750,000 shares of Eligible Securities (as adjusted for stock splits and combinations),
upon the request of such Investors, within thirty (30)&nbsp;days of the end of each month,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-17-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">an unaudited
income statement and cash flow statement and unaudited balance sheet for and as of the end of such
month, in reasonable detail.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3 <U>Confidentiality</U>. Each Investor agrees to use commercially reasonable efforts to
maintain the confidentiality of information obtained pursuant to this Section&nbsp;2, provided that such
obligation shall not apply to (i)&nbsp;information previously in possession or independently developed
by Investor, (ii)&nbsp;information publicly available other than as a result of breach of this provision
(iii)&nbsp;information required to be disclosed by statute, regulation or court or administrative order.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4 <U>Visitation Rights</U>. One representative chosen collectively by LB I Group Inc.,
Lehman Brothers P.A. LLC, Lehman Brothers Partnership Account 2000/2001, L.P. and Lehman Brothers
Offshore Partnership Account 2000/2001, L.P. (collectively, &#147;<B>Lehman</B>&#148;), one representative chosen
collectively by EuclidSR Partners, L.P. and EuclidSR Biotechnology Partners, L.P. (collectively,
&#147;<B>EuclidSR</B>&#148;), one representative chosen by Piper Jaffray Healthcare Fund III, L.P. (&#147;<B>Piper
Jaffray</B>&#148;), one representative chosen by GE Capital Equity Investments, Inc. (&#147;<B>GE Capital</B>&#148;), one
representative chosen collectively by Interwest Investors VII, L. P. and Interwest Partners VII,
L.P. (collectively, &#147;<B>Interwest</B>&#148;), one representative chosen by AllianceBernstein L.P. (&#147;<B>Alliance</B>&#148;),
and one representative chosen by BMSIF shall have the right to attend all meetings of the Board of
Directors, including meetings of any committee of the Board and including the right to participate
in any telephonic board meetings, so long as such Investor holds at least 750,000 shares
of Eligible Securities (as adjusted for stock splits and combinations and the like). Said
representative(s) shall be provided with notice of the meetings in the same manner at the same time
as the members of the Board of Directors and shall be provided with any materials distributed to
the Board of Directors in connection with board meetings. The foregoing visitation rights may be
limited by the Board of Directors if (i), upon the advice of counsel, the Board of Directors
determines that exclusion is required by third party confidentiality agreements, (ii)&nbsp;the Board is
discussing engaging Investor or an affiliate of Investor as a financial advisor or underwriter; or
(iii)&nbsp;the Board is discussing a material transaction with an entity in which Investor or a private
equity fund affiliated with Investor is a 5% or greater shareholder, or (iv)&nbsp;the Board determines
in good faith upon advice of counsel that limitations are required to maintain attorney-client
privilege.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5 <U>Stock Option Vesting</U>. Unless otherwise decided by the Board of Directors, all
option grants to employees shall vest over a four-year period with 25% of the shares subject to
each option vesting a year after commencement of employment and the remainder of the shares vesting
in equal amounts on a monthly basis thereafter.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.6 <U>Insurance</U>. The Company shall, subject to the approval of the Board of Directors,
maintain such fire, casualty and general liability insurance with coverages and in amounts as shall
be determined by the Board of Directors. The Company agrees to maintain in full force and effect
directors and officers liability insurance with coverage in the aggregate amount of amount of $2
million covering all of its directors. The Company will maintain coverage for the Series&nbsp;C
Directors (as defined in the Voting Agreement) and the Series&nbsp;D Directors (as defined in the Voting
Agreement) under such directors and officers liability insurance at all times commencing upon the
Closing (as defined in the Purchase Agreement).
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-18-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.7 <U>Proprietary Information Agreements</U>. Unless otherwise determined by the Board of
Directors, all future employees and consultants of the Company shall be required to execute and
deliver a proprietary information and invention assignment agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.8 <U>Invention Assignments</U>. The Company agrees to use commercially reasonable efforts
to obtain from each of the individual contributing inventors for each invention that forms any part
of any patent or patent application owned by or licensed to the Company, executed invention
assignments in favor of the Company or the appropriate third party licensor, as the case may be.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.9 <U>Key-Man Life Insurance</U>. The Company shall obtain and maintain key-man life
insurance in such amount as is determined by the Company&#146;s Board of Directors, on Gajus
Worthington. Such policy shall name the Company as loss payee and shall not be cancelable by the
Company without prior unanimous approval of the Board of Directors.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.10 <U>Compliance with Laws</U>. The Company shall use its best efforts to comply with the
requirements of all applicable laws, rules, regulations and orders of any governmental authority,
where noncompliance would have a material adverse effect on the Company&#146;s business and financial
condition.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.11 <U>Termination of Covenants</U>. The covenants set forth in Section&nbsp;2 shall terminate
on, and be of no further force or effect after, the closing of the Company&#146;s Initial Public
Offering. The rights granted pursuant to this Section&nbsp;2 are not transferable other than to
Affiliates of Holders.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">SECTION 3
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>Right of First Offer For Company Securities</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 <U>Right of First Offer</U>. Subject to the terms and conditions specified in this
Section&nbsp;3, the Company hereby grants to each Investor a right of first offer with respect to future
sales by the Company of its Securities. An Investor shall be entitled to apportion the right of
first offer hereby granted among itself and its partners and Affiliates in such proportions as it
deems appropriate.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each time the Company proposes to offer any Securities in a Financing (as defined below), the
Company shall first make an offering of such Securities to each Investor in accordance with the
following provisions:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Company shall deliver a notice (&#147;<B>Notice</B>&#148;) to each Investor stating (i)&nbsp;its intention
to offer such Securities for sale, (ii)&nbsp;the number of such Securities to be offered (the &#147;<B>Offered
Securities</B>&#148;), (iii)&nbsp;the price, if any, for which it proposes to offer such Securities, (iv)&nbsp;the
terms of such offer and (v)&nbsp;the Offer Amount (as defined below).
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-19-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Within fifteen (15)&nbsp;calendar days after receipt of the Notice, each Investor may elect to
purchase, at the price and on the terms specified in the Notice, such Securities in an amount up to
the Offer Amount by providing the Company with written notice of its election.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;An election by an Investor pursuant to Section&nbsp;3.1(b) to purchase Offered Securities shall
not be considered a binding commitment on the Investor unless and until the Company receives
binding commitments to purchase on the terms and conditions contained in the Notice substantially
all of the Offered Securities which the Investors have not elected to purchase.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing, the Company and each of the Investors acknowledge and agree
that Lighthouse shall have the opportunity to invest not less than $250,000 in connection with the
first Financing completed after the date of this Agreement that involves the sale and issuance by
the Company of shares of the Company&#146;s convertible preferred stock with aggregate gross proceeds to
the Company of at least $3&nbsp;million. In the event that Lighthouse&#146;s right to purchase Offered
Securities as otherwise set forth in this Section&nbsp;3.1 would not permit such $250,000 investment,
then each of the Investors agrees that its respective right to purchase Offered Securities pursuant
to this Section&nbsp;3.1 may be cut-back (proportionately with all other Investors based on the number
of shares of Eligible Securities held by the Investors) in such amounts as may be necessary to
permit the exercise of Lighthouse&#146;s rights as set forth herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 <U>Sale of Securities by Company</U>. Within 60&nbsp;days of the expiration of the period
described in Section&nbsp;3.1(b), any Offered Securities which the Investors have not elected to
purchase may be sold by the Company to any person or persons at a price not less than, and upon
terms no more favorable to the offeree than, those specified in the Notice. If the Company does
not complete the sale of all such Offered Securities within said 60-day period, the rights of the
Investors with respect to any such unsold Offered Securities shall be deemed to be revived.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3 <U>Offer Amount</U>. The &#147;<B>Offer Amount</B>&#148; shall equal that percentage of the Offered
Securities equal to the number of shares of Eligible Securities held by an Investor which are
Registrable Securities divided by the total number of outstanding shares of Common Stock of the
Company. For the purposes of the foregoing calculations, all outstanding options and warrants
shall be deemed to be exercised and all Preferred Stock shall be deemed to have been converted into
Common Stock at the prevailing conversion rate.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4 <U>Financing</U>. &#147;<B>Financing</B>&#148; shall mean an offering or series of related offerings of
Securities by the Company for purposes of raising working capital in a minimum amount of $250,000.
Financing shall not include (i)&nbsp;the issuance or sale of shares of Common Stock or options to
purchase Common stock to employees, officers, directors or consultants for the primary purpose of
soliciting or retaining their services in such amount as shall have been approved by the Board of
Directors, (ii)&nbsp;the issuance or sale of Securities to leasing entities or financial institutions in
connection with commercial leasing or borrowing transactions approved by the Board of Directors,
(iii)&nbsp;the issuance or sale of Securities to third party providers of goods or services in
connection with transactions approved by the Board of Directors; (iv)&nbsp;the sale of Securities in a
registered public offering, (v)&nbsp;any issuances of Securities in connection with any stock split,
stock dividend or recapitalization by the Company, (vi)&nbsp;the issuance of Securities at a price (on
an as converted to
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-20-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Common Stock basis) below the original issue price of the Company&#146;s Series&nbsp;E
Preferred Stock (as adjusted for stock splits, recapitalizations and like events) in connection
with sponsored research, collaboration, technology license, development, OEM, marketing or other
similar agreements or any joint venture or strategic alliance, if such issuance is approved
unanimously by the Board of Directors, <U>provided</U> <U>that</U> the issuance of the Company&#146;s
Series&nbsp;E Preferred Stock to BMSIF or any Affiliate thereof or any related entity to the Singapore
Economic Development Board pursuant to Section&nbsp;3.4(xii) below at a price below the original issue
price of the Company&#146;s Series&nbsp;E Preferred Stock (as adjusted for stock splits, recapitalizations
and like events) shall also not be a Financing hereunder, (vii)&nbsp;the issuance of Securities at a
price (on an as converted to Common Stock basis) at or above the original issue price of the
Company&#146;s Series&nbsp;E Preferred Stock (as adjusted for stock splits, recapitalizations and like
events) in connection with sponsored research, collaboration, technology license, development, OEM,
marketing or other similar agreements or any joint venture or strategic alliance, if such issuance
is approved by the Board of Directors, (viii)&nbsp;the issuance of Securities at a price (on an as
converted to Common Stock basis) below the original issue price of the Company&#146;s Series&nbsp;E Preferred
Stock (as adjusted for stock splits, recapitalizations and like events) in connection with the
acquisition of another corporation by the Company by merger, consolidation, or purchase of all or
substantially all of the assets or shares of such corporation unanimously approved by the Board of
Directors, (ix)&nbsp;the issuance of Securities at a price (on an as
converted to Common Stock basis) at or above the original issue price of the Company&#146;s Series
E Preferred Stock (as adjusted for stock splits, recapitalizations and like events) in connection
with the acquisition of another corporation by the Company by merger, consolidation, or purchase of
all or substantially all of the assets or shares of such corporation approved by the Board of
Directors; (x)&nbsp;shares of Series&nbsp;E Preferred Stock issued pursuant to the terms of the Purchase
Agreement; (xi)&nbsp;interest-bearing convertible promissory notes in the aggregate principal amount of
$8&nbsp;million issued or issuable pursuant to the CNPA and/or the CNA and any Securities issued on
conversion thereof; and (xii)&nbsp;additional interest-bearing convertible promissory notes to be issued
after the date hereof in the aggregate principal amount of up to $15&nbsp;million to BMSIF or any
Affiliate thereof or any related entity to the Singapore Economic Development Board, and any
Securities issued on conversion thereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.5 <U>Termination of Right of First Offer</U>. The right of first offer contained in this
section shall not apply to and shall terminate upon the closing of an Initial Public Offering. The
right of first offer granted under this Section&nbsp;3 is transferable to transferees of at least
750,000 shares of Registrable Securities (as adjusted for stock splits, combinations and the like)
or to Affiliates.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-21-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center" style="font-size: 10pt; margin-top: 18pt">SECTION 4
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>Right of First Offer with Respect to Founder Shares</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 <U>Notice of Sales</U>. Should a Founder (a &#147;<B>Seller</B>&#148;) propose to accept one or more bona
fide offers (collectively, the &#147;<B>Purchase Offer</B>&#148;) from any persons (&#147;<B>Purchasers</B>&#148;) to purchase
Founders Shares from such Seller (other than as set forth 4.2(d) hereof), then such Seller shall,
promptly after exercise or termination of any rights of first refusal held by the Company, deliver
a notice (the &#147;<B>Notice</B>&#148;) to the Company and all Investors holding more than 750,000 shares of
Eligible Securities (&#147;<B>Eligible Investors</B>&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 <U>Purchase Right</U>. Each Eligible Investor shall have the right, exercisable upon
written notice to such Seller within ten (10)&nbsp;business days after receipt of the Notice, to
purchase Founders Shares on the terms and conditions specified in the Purchase Offer. To the
extent an Eligible Investor exercises its right to purchase such shares in accordance with the
terms and conditions set forth below, the number of shares of stock which such Seller may sell to
the Purchasers pursuant to the Purchase Offer shall be correspondingly reduced. The purchase right
of each Eligible Investor shall be subject to the following terms and conditions:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<U>Calculation of Shares</U>. Each Eligible Investor may purchase all or any part of
that number of Founder Shares equal to the number obtained by multiplying (i)&nbsp;the aggregate number
of Founders Shares covered by the Purchase Offer by (ii)&nbsp;a fraction, the numerator of which is the
number of shares of Common Stock of the Company at the time owned by such Eligible Investor and the
denominator of which is the number of shares of Common Stock of the Company then outstanding. For
the purposes of the foregoing calculations, all outstanding options and
warrants shall be deemed to be exercised and all Preferred Stock shall be deemed to have been
converted into Common Stock at the prevailing conversion rate.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<U>Delivery of Consideration</U>. Each Eligible Investor may effect its purchase right
by promptly delivering to such Seller a written notice and a check or wire transfer equal to the
purchase price specified in the Purchase Offer for the number of shares the Eligible Investor
desires to purchase pursuant to this Section&nbsp;4.2.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;<U>Certificate</U>. Within ten (10)&nbsp;business days of receipt of Eligible Investor&#146;s
funds pursuant to Section&nbsp;4.2(c), Seller shall deliver to such Eligible Investor a certificate or
certificates representing the shares of Founder Shares purchased by such Eligible Investor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;<U>Permitted Transactions</U>. The participation rights in this Section&nbsp;4 shall not
pertain or apply to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;Any transfer to a revocable grantor trust with respect to which the Founder and members of
his family are the sole beneficiaries;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;Any repurchase of Founders Shares by the Company;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-22-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;Any exercise by the Company of a right or remedy under the terms of any loan, security
or stock pledge agreement where the Founders Shares serve as security for a loan made by the
Company;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;Any transfer to any ancestors or descendants or spouse of a Founder or to a trustee for
their benefit or to a custodian for the benefit of a Founders&#146; issue; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;Any bona fide gift;
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">provided, however, that such Founder shall inform the Eligible Investors of such transfer or gift
(other than a transfer pursuant to clause (ii)&nbsp;or (iii)) prior to effecting it and the transferee
or donee (if other than the Company) shall furnish the Company and the Eligible Investors with a
written agreement to be bound by and comply with all applicable provisions of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3 <U>Sale of Securities by Founder</U>. Within 60&nbsp;days of the expiration of the period
described in the first paragraph of Section&nbsp;4.2, any Founders Shares covered by the Purchase Offer
which the Eligible Investors have not elected to purchase may be sold by the Seller to the
Purchasers on the terms and conditions of the Purchase Offer. If the Seller does not complete the
sale of all Founders Shares covered by the Purchase Offer within such period, the rights of the
Eligible Investors with respect to any such unsold Founders Shares shall be deemed to be revived.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4 <U>Termination and Transfer</U>. The restrictions imposed and rights granted by this
Section&nbsp;4 shall not apply to and shall terminate immediately prior to the closing of the Company&#146;s
Initial Public Offering. Securities received pursuant to any stock dividend, stock split,
recapitalization, or exercise of a conversion right shall be subject to this Section&nbsp;4 to the
same extent as the shares of the Company with respect to which they were issued. The right of
first offer granted under this Section&nbsp;4 is transferable to transferees of at least 750,000 shares
of Registrable Securities (as adjusted for stock splits, combinations and the like) or to
Affiliates.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.5 <U>Prohibited Transfer</U>. Any attempt by a Founder to transfer Founders Shares in
violation of Section&nbsp;4 hereof shall be void and the Company agrees it will not effect such a
transfer nor will it treat any alleged transferee(s) as the holder of such shares, without the
written consent of two-thirds (2/3) in interest of the Eligible Investors.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">SECTION 5
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>Right of Co-Sale</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 <U>Notice of Sales</U>. Should a Founder (a &#147;<B>Seller</B>&#148;) propose to accept one or more bona
fide offers (collectively, the &#147;<B>Purchase Offer</B>&#148;) from any persons (&#147;<B>Purchasers</B>&#148;) to purchase
Founders Shares from such Seller (other than as set forth 5.2(d)), then such Seller shall, promptly
after exercise or termination of any rights of first refusal held by the Company or the Eligible
Investors, deliver a notice (the &#147;<B>Notice</B>&#148;) to the Company and all Eligible Investors describing the
terms and conditions of the Purchase Offer.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-23-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2 <U>Participation Right</U>. Each Eligible Investor shall have the right, exercisable
upon written notice to such Seller within fifteen (15)&nbsp;business days after receipt of the Notice,
to participate in such Seller&#146;s sale of stock pursuant to the specified terms and conditions of
such Purchase Offer. To the extent an Eligible Investor exercises such right of participation in
accordance with the terms and conditions set forth below, the number of shares of stock which such
Seller may sell pursuant to such Purchase Offer shall be correspondingly reduced. The right of
participation of each Eligible Investor shall be subject to the following terms and conditions:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<U>Calculation of Shares</U>. Each Eligible Investor may sell all or any part of that
number of shares of Common Stock of the Company equal to the number obtained by multiplying (i)&nbsp;the
aggregate number of Founders Shares covered by the Purchase Offer by (ii)&nbsp;a fraction, the numerator
of which is the number of shares of Common Stock of the Company at the time owned by such Eligible
Investor and the denominator of which is the number of shares of Common Stock of the Company then
outstanding. For the purposes of the foregoing calculations, all outstanding options and warrants
shall be deemed to be exercised and all Preferred Stock shall be deemed to have been converted into
Common Stock at the prevailing conversion rate.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<U>Delivery of Certificates</U>. Each Eligible Investor may effect its participation in
the sale by delivering to such Seller for transfer to the Purchaser(s) one or more certificates,
properly endorsed for transfer, which represent at least the number of shares of Common Stock which
such Eligible Investor elects to sell pursuant to this Section&nbsp;5.2.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;<U>Transfer</U>. The stock certificate or certificates which the Eligible Investor
delivers to such Seller pursuant to Section&nbsp;5.2 shall be delivered by the Seller to the
Purchaser(s) in consummation of the sale of the Securities pursuant to the terms and conditions
specified in the Notice, and such Seller shall promptly thereafter remit to such Eligible Investor
that portion of the sale proceeds to which such Eligible Investor is entitled by reason of its
participation in such sale.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;<U>Permitted Transactions</U>. The participation rights in this Section&nbsp;5 shall not
pertain or apply to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;Any transfer to a revocable grantor trust with respect to which the Seller and members of
his family are the sole beneficiaries;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;Any repurchase of Founders Shares by the Company;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;Any exercise by the Company of a right or remedy under the terms of any loan, security
or stock pledge agreement where the Founders Shares serve as security for a loan made by the
Company;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;Any transfer to any ancestors or descendants or spouse of a Founder or to a trustee for
their benefit or to a custodian for the benefit of a Founders&#146; issue; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) Any bona fide gift;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-24-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">provided, however, that such Founder shall inform the Eligible Investors of such transfer or gift
(other than a transfer pursuant to clause (ii)&nbsp;or (iii)) prior to effecting it and the transferee
or donee (if other than the Company) shall furnish the Company and the Eligible Investors with a
written agreement to be bound by and comply with all applicable provisions of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3 <U>Sale of Securities by Founder</U>. Within 45&nbsp;days of the expiration of the period
described in the first paragraph of Section&nbsp;5.2, any Founders Shares covered by the Purchase Offer
which the Eligible Investors have not elected to purchase may be sold by the Seller to the
Purchasers on the terms and conditions of the Purchase Offer. If the Seller does not complete the
sale of all Founders Shares covered by the Purchase Offer within such period, the rights of the
Eligible Investors with respect to any such unsold Founders Shares shall be deemed to be revived.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4 <U>Termination and Transfer</U>. The restrictions imposed and rights granted by this
Section&nbsp;5 shall not apply to and shall terminate immediately prior to the closing of the Company&#146;s
Initial Public Offering. Securities received pursuant to any stock dividend, stock split,
recapitalization, or exercise of a conversion right shall be subject to this Section&nbsp;5 to the same
extent as the shares of the Company with respect to which they were issued. The co-sale right
granted under this Section&nbsp;5 is transferable to transferees of at least 750,000 shares of
Registrable Securities (as adjusted for stock splits, combinations and the like) or to Affiliates.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.5 <U>Prohibited Transfers</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;In the event any Founder should sell any Founders Shares in contravention of the co-sale
rights of the Investors under Section&nbsp;5 (a &#147;<B>Prohibited Transfer</B>&#148;), the Investors, in addition to
such other remedies as may be available at law, in equity or hereunder, shall have the put option
provided below, and the Founder shall be bound by the applicable provisions of such option.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;In the event of a Prohibited Transfer, each Eligible Investor shall have the right to sell
to the Founder the type and number of shares of Common Stock equal to the number of shares that
such Eligible Investor would have been entitled to transfer to the third-party transferee(s) under
Section&nbsp;5.2 hereof had the Prohibited Transfer been effected pursuant to and in compliance with the
terms thereof. Such sale shall be made on the following terms and conditions:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;The price per share at which the shares are to be sold to the Founder shall be equal to
the price per share paid by the third-party transferee(s) to the Founder in the Prohibited
Transfer. Such price per share shall be paid to the Eligible Investor in cash if the Founder
received cash for his shares. If the Founder did not receive cash but received other property
instead, the price per share to be paid to the Eligible Investor shall be paid (A)&nbsp;in the form of
the property received by the Founder for his shares, or (B)&nbsp;in cash equal to the fair market value
of the property received by such Founder as determined in good faith by the Company&#146;s Board of
Directors, at the option of the Eligible Investor. The Founder shall also reimburse each Eligible
Investor for any and all fees and expense, including legal fees and expenses, incurred pursuant to
the exercise or the attempted exercise of the Eligible Investor&#146;s rights under Section&nbsp;5.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-25-<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;Within thirty (30)&nbsp;days after the later of the dates on which the Eligible Investor (A)
received notice of the Prohibited Transfer or (B)&nbsp;otherwise became aware of the Prohibited
Transfer, each Eligible Investor shall, if exercising the option created hereby, deliver to the
Founder the certificate or certificates representing shares to be sold, each certificate to be
properly endorsed for transfer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;The Founder shall, upon receipt of the certificate or certificates for the shares to be
sold by an Eligible Investor pursuant to this Section&nbsp;5, pay the aggregate purchase price therefor
and the amount of reimbursable fees and expenses, as specified in subparagraph 5.5(b)(i), in cash
or by other means acceptable to the Eligible Investor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Notwithstanding the foregoing, any attempt by a Founder to transfer Founders Shares in
violation of Section&nbsp;5 hereof shall be void and the Company agrees it will not effect such a
transfer nor will it treat any alleged transferee(s) as the holder of such shares, without the
written consent of two-thirds (2/3) in interest of the Eligible Investors.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">SECTION 6
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>Miscellaneous</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1 <U>Governing Law; Jurisdiction</U>. This Agreement shall be construed in accordance
with, and governed in all respects by, the laws of the State of California, as applied to
agreements entered into, and to be performed entirely in such state, between residents of such
state.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The parties hereto agree to submit to the jurisdiction of the federal and state courts of San
Mateo County, California with respect to the breach or interpretation of this Agreement or the
enforcement of any and all rights, duties, liabilities, obligations, powers, and other relations
between the parties arising under this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2 <U>Successors and Assigns</U>. Except as otherwise provided herein, the provisions
hereof shall inure to the benefit of, and be binding upon, the successors, assigns, heirs,
executors and administrators of the parties hereto.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3 <U>Notices, Etc</U>. All notices and other communications required or permitted
hereunder, shall be in writing and shall be sent by facsimile personally delivered, mailed by
registered or certified mail, postage prepaid, return receipt requested, or otherwise delivered by
a nationally-recognized overnight courier, addressed (a)&nbsp;if to an Investor, at Investor&#146;s facsimile
number or address as set forth in the records of the Company or (b)&nbsp;if to any other holder of any
Eligible Securities, at such address as such holder shall have furnished the Company in writing,
or, until any such holder so furnishes an address to the Company, then to and at the address of the
last holder of such Eligible Securities who has so furnished an address or facsimile number to the
Company, or (c)&nbsp;if to a Founder, at such Founder&#146;s facsimile number or address set forth on
<U>EXHIBIT B</U> hereto, or a such other address as such Founder shall have furnished to the
Company in writing, or (d)&nbsp;if to the Company, at its facsimile number or address set forth on the
signature page hereto addressed to the attention of the Corporate Secretary, or at such other
address as the Company
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-26-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">shall have furnished to the Investors. Any such notice or communication
shall be deemed to have been received (A)&nbsp;in the case of personal delivery, on the date of such
delivery, (B)&nbsp;in the case of a nationally-recognized overnight courier, on the next business day
after the date when sent, (C)&nbsp;in the case of mailing, on the third business day following that on
which the piece of mail containing such communication is posted and (D)&nbsp;in the case of delivery via
facsimile, one (1)&nbsp;business day after the date of transmission provided that said transmission is
confirmed telephonically on the date of transmission.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4 <U>Delays or Omissions</U>. No delay or omission to exercise any right, power or remedy
accruing to any holder of any Eligible Securities upon any breach or default of the Company under
this Agreement shall impair any such right, power or remedy of such holder, nor shall it be
construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any
similar breach or default thereafter occurring; nor shall any waiver of any single breach or
default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any
waiver, permit, consent or approval of any kind or character on the part of any holder of any
breach or default under this Agreement, or any waiver on the part of any holder of any provisions
or conditions of this Agreement, must be in writing and shall be effective only to the extent
specifically set forth in such writing or as provided in this Agreement. All remedies, either under this Agreement or
by law or otherwise afforded to any holder, shall be cumulative and not alternative.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.5 <U>Third Parties</U>. Nothing in this Agreement, express or implied, is intended to
confer upon any party, other than the parties hereto, and their respective successors and assigns,
any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as
expressly provided herein.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.6 <U>Severability</U>. If one or more provisions of this Agreement are held to be
unenforceable under applicable law, portions of such provisions, or such provisions in their
entirety, to the extent necessary, shall be severed from this Agreement, and the balance of this
Agreement shall be enforceable in accordance with its terms.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.7 <U>Amendment and Waiver</U>. Any provision of this Agreement may be amended or waived
with the written consent of the Company and the Holders of at least two-thirds of the outstanding
shares of the Registrable Securities then held by Holders (assuming the exercise or conversion of
all outstanding Eligible Securities); <U>provided</U>, <U>however</U>, (i)&nbsp;that in the event such
amendment or waiver adversely affects the rights and/or obligations of the Founders under this
Agreement in a different manner than the other Holders, such amendment or waiver shall also require
written consent of the Founders holding a majority of the then outstanding Founders Shares, (ii)
that in the event such amendment or waiver adversely affects the rights and/or obligations of
Lehman, EuclidSR, Piper Jaffray, GE Capital, Interwest, Alliance, and BMSIF under Section&nbsp;2.4 of
this Agreement, such amendment or waiver shall not be effective as to Lehman, EuclidSR, Piper
Jaffray, GE Capital, Interwest or BMSIF, as the case may be, without the written consent of such
party, and (iii)&nbsp;that in the event such amendment or waiver adversely affects the rights and/or
obligations of Warrantholders under this Agreement in a different manner than the other Holders,
such amendment or waiver shall also require the written consent of Warrantholders holding a
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-27-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">majority of the then outstanding Warrant Shares. Notwithstanding the foregoing, any purchaser of
Series&nbsp;E Preferred Stock pursuant to the Purchase Agreement may become a party to this Agreement by
executing and delivering an additional counterpart signature page to this Agreement and such
purchaser shall be deemed a Holder and an Investor hereunder. The parties agree that <U>Exhibit
A</U> shall be updated automatically without any formal amendment to reflect the addition of any
such additional party. Any amendment or waiver effected in accordance with this paragraph shall be
binding upon each Holder, the Founders, the holder of the Other Shares, Warrantholders and the
Company. In addition, the Company may waive performance of any obligation owing to it, as to some
or all of the Holders, or agree to accept alternatives to such performance, without obtaining the
consent of any other Holder. In the event that an underwriting agreement is entered into between
the Company and any Holder, and such underwriting agreement contains terms differing from this
Agreement, as to any such Holder the terms of such underwriting agreement shall govern.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.8 <U>Rights of Holders</U>. Each Holder shall have the absolute right to exercise or
refrain from exercising any right or rights that such holder may have by reason of this Agreement,
including, without limitation, the right to consent to the waiver or modification of any obligation
under this Agreement, and such holder shall not incur any liability to any other holder of any
Securities as a result of exercising or refraining from exercising any such right or rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.9 <U>Counterparts</U>. This Agreement may be executed in any number of counterparts, each
of which shall be enforceable against the parties actually executing such counterparts, and all of
which together shall constitute one instrument.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.10 <U>Titles and Subtitles</U>. The titles of the paragraphs and subparagraphs of this
Agreement are for convenience of reference only and are not to be considered in construing this
Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.11 <U>Amendment and Restatement of Prior Agreement</U>. The undersigned Prior Investors
who in the aggregate hold at least two-thirds of the outstanding Registrable Securities (as defined
in the Prior Agreement) and the undersigned Founders hereby amend and restate the Prior Agreement
pursuant to Section&nbsp;6.7 thereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.12 <U>Waiver of Right of First Offer</U>. The undersigned Prior Investors who in the
aggregate hold at least two-thirds of the outstanding Registrable Securities (as defined in the
Prior Agreement) hereby waive on behalf of all Prior Investors any rights of participation or
notice under Section&nbsp;3 of this Agreement and the Prior Agreement with respect to the securities
sold pursuant to the Purchase Agreement. By its execution below, Lighthouse waives any right of
participation or notice under Section&nbsp;3 of this Agreement and Section&nbsp;3 of the Prior Agreement with
respect to securities sold under the Purchase Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.13 <U>Aggregation of Stock</U>. All shares of Eligible Securities held or acquired by
Affiliated entities or persons shall be aggregated together for the purpose of determining the
availability of any rights under this Agreement.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-28-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.14 <U>Jury Trial</U>. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST
EXTENT PERMITTED BY LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING (WHETHER
SOUNDING IN CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATED TO THIS AGREEMENT.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Remainder
of Page Left Blank Intentionally&#093;</I></B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-29-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FLUIDIGM CORPORATION<BR>
AMENDMENT NO. 1 TO<BR>
EIGHTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIS AMENDMENT NO. 1 (this &#147;<B>Amendment</B>&#148;) to that certain Eighth Amended and Restated Investor
Rights Agreement, dated as of June&nbsp;13, 2006 (the &#147;<B>Rights Agreement</B>&#148;), by and among Fluidigm
Corporation, a California corporation (the &#147;<B>Company</B>&#148;), and the Investors and Founders named therein
is entered into this 22nd day of December, 2006 by and among the Company and the undersigned,
collectively the Holders of at least two-thirds of the outstanding shares of the Registrable
Securities then held by Holders (assuming the exercise or conversion of all outstanding Eligible
Securities). Capitalized terms not defined herein have the meanings set forth in the Rights
Agreement.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">RECITALS
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A.&nbsp;It is contemplated that the Company will sell and issue additional shares of the Company&#146;s
Series&nbsp;E Preferred Stock (&#147;<B>Series&nbsp;E Preferred Stock</B>&#148;) pursuant to that certain Series&nbsp;E Preferred
Stock Purchase Agreement, dated as of June&nbsp;13, 2006 (the &#147;<B>Purchase Agreement</B>&#148;), by and among the
Company and the Purchasers named therein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B.&nbsp;In connection with the sale of additional shares of Series&nbsp;E Preferred Stock, the Company
and the Investors desire to (i)&nbsp;provide that the standoff agreement in Section&nbsp;1.14 of the Rights
Agreement shall not apply to securities of the Company purchased by certain Holders in the Initial
Public Offering or in the public market for the Company&#146;s securities following the Initial Public
Offering, and (ii)&nbsp;grant visitation rights pursuant to Section&nbsp;2.4 of the Rights Agreement
collectively to Cross Creek Capital, L.P., Cross Creek Capital Employees&#146; Fund, L.P. and Wasatch
Small Cap Growth.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C.&nbsp;The Company and the undersigned Holders of at least two-thirds of the outstanding shares of
the Registrable Securities then held by Holders (assuming the exercise or conversion of all
outstanding Eligible Securities) have agreed to amend the Rights Agreement to provide for the
foregoing changes to the standoff agreement in Section&nbsp;1.14 and the visitation rights in Section
2.4.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">AGREEMENT
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, all of the parties
hereto mutually agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 7 <U>Amendment to Section&nbsp;1.14</U>. Section&nbsp;1.14 (Standoff Agreement) of the Rights
Agreement is hereby amended and restated in its entirety as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;1.14 <U>Standoff Agreement</U>.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Each Holder agrees in connection with the first sale of the Company&#146;s
Common Stock in a firm commitment underwritten public offering pursuant to an
effective registration statement under the Securities Act, upon notice by the
Company or the underwriters managing such public offering, not to sell, make any
short sale of, loan, pledge (or otherwise encumber or hypothecate), grant any option
for the purchase of, or otherwise directly or indirectly dispose of any Securities
(other than those included in the registration) without the prior written consent of
the Company and such managing underwriters for such period of time as the Board of
Directors establishes pursuant to its good faith negotiations with such managing
underwriters; provided, however that:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) such agreement shall not exceed one hundred eighty (180)&nbsp;days;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) such agreement shall not apply to transfers to an Affiliate, provided that
such Affiliate agrees to be bound by the terms of such agreement, to the same extent
as if such transferee were the original party thereunder;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) such agreement shall not apply to securities of the Company purchased by
AllianceBernstein Venture Fund I, L.P., SmallCap World Fund, Inc., Cross Creek
Capital, L.P., Cross Creek Capital Employees&#146; Fund, L.P. or Wasatch Small Cap Growth
or their respective Affiliates in the Initial Public Offering or in the public
market for the Company&#146;s securities following the Initial Public Offering;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) a Holder shall not be subject to such agreement unless (A)&nbsp;all executive
officers and directors of the Company, (B), all shareholders of the Company holding
more than 1% of the Company&#146;s outstanding capital stock; and (C)&nbsp;all other Holders
and holders of other registration rights, are subject to or obligated to enter into
similar agreements; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) if and when any person identified in clause (iv)&nbsp;is released, in whole or
in part, from such agreement (whether or not such release is contemplated at the
time of the offering) or if any such agreement is terminated, the Holder shall be
concurrently released on a pro rata basis based on the number of shares held by such
person and the Holder.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Each Holder agrees that prior to the Initial Public Offering it will not
transfer securities of the Company unless each transferee agrees in writing to be
bound by all of the provisions of this Section&nbsp;1.14; provided that this Section
1.14(b) shall not apply to transfers pursuant to a registration statement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Each Holder hereby consents to the placement of stop transfer orders with
the Company&#146;s transfer agent in order to enforce the foregoing provision and agrees
to execute a market standoff agreement with said
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">underwriters in customary form consistent with the provisions of this Section&nbsp;1.14.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 8 <U>Amendment to Section&nbsp;2.4</U>. Section&nbsp;2.4 (Visitation Rights) of the Rights
Agreement is hereby amended and restated in its entirety as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;2.4 <U>Visitation Rights</U>. One representative chosen collectively by LB I Group
Inc., Lehman Brothers P.A. LLC, Lehman Brothers Partnership Account 2000/2001, L.P. and
Lehman Brothers Offshore Partnership Account 2000/2001, L.P. (collectively, &#147;<B>Lehman</B>&#148;), one
representative chosen collectively by EuclidSR Partners, L.P. and EuclidSR Biotechnology
Partners, L.P. (collectively, &#147;<B>EuclidSR</B>&#148;), one representative chosen by Piper Jaffray
Healthcare Fund III, L.P. (&#147;<B>Piper Jaffray</B>&#148;), one representative chosen by GE Capital Equity
Investments, Inc. (&#147;<B>GE Capital</B>&#148;), one representative chosen collectively by Interwest
Investors VII, L. P. and Interwest Partners VII, L.P. (collectively, &#147;<B>Interwest</B>&#148;), one
representative chosen by AllianceBernstein Venture Fund I, L.P. (&#147;<B>Alliance</B>&#148;), one
representative chosen collectively by Cross Creek Capital, L.P., Cross Creek Capital
Employees&#146; Fund, L.P. and Wasatch Small Cap Growth (collectively, &#147;<B>Wasatch</B>&#148;), and one
representative chosen by BMSIF shall have the right to attend all meetings of the Board of
Directors, including meetings of any committee of the Board and including the right to
participate in any telephonic board meetings, so long as such Investor holds at least
750,000 shares of Eligible Securities (as adjusted for stock splits and combinations and the
like). Said representative(s) shall be provided with notice of the meetings in the same
manner at the same time as the members of the Board of Directors and shall be provided with
any materials distributed to the Board of Directors in connection with board meetings. The
foregoing visitation rights may be limited by the Board of Directors if (i), upon the advice
of counsel, the Board of Directors determines that exclusion is required by third party
confidentiality agreements, (ii)&nbsp;the Board is discussing engaging Investor or an affiliate
of Investor as a financial advisor or underwriter; or (iii)&nbsp;the Board is discussing a
material transaction with an entity in which Investor or a private equity fund affiliated
with Investor is a 5% or greater shareholder, or (iv)&nbsp;the Board determines in good faith
upon advice of counsel that limitations are required to maintain attorney-client privilege.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 9 <U>Amendment to Section&nbsp;6.7</U>. Section&nbsp;6.7 (Amendment and Waiver) of the Rights
Agreement is hereby amended and restated in its entirety as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;6.7 <U>Amendment and Waiver</U>. Any provision of this Agreement may be amended
or waived with the written consent of the Company and the Holders of at least
two-thirds of the outstanding shares of the Registrable Securities then held by
Holders (assuming the exercise or conversion of all outstanding Eligible
Securities); <U>provided</U>, <U>however</U>, (i)&nbsp;that in the event such amendment
or waiver adversely affects the rights and/or obligations of the Founders under this
Agreement in a different manner than the other Holders, such amendment or waiver
shall also require written consent of the Founders holding a majority of the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">then outstanding Founders Shares, (ii)&nbsp;that in the event such amendment or waiver
adversely affects the rights and/or obligations of Lehman, EuclidSR, Piper Jaffray,
GE Capital, Interwest, Alliance, Wasatch or BMSIF under Section&nbsp;2.4 of this
Agreement, such amendment or waiver shall not be effective as to Lehman, EuclidSR,
Piper Jaffray, GE Capital, Interwest, Alliance, Wasatch or BMSIF, as the case may
be, without the written consent of such party, and (iii)&nbsp;that in the event such
amendment or waiver adversely affects the rights and/or obligations of
Warrantholders under this Agreement in a different manner than the other Holders,
such amendment or waiver shall also require the written consent of Warrantholders
holding a majority of the then outstanding Warrant Shares. Notwithstanding the
foregoing, any purchaser of Series&nbsp;E Preferred Stock pursuant to the Purchase
Agreement may become a party to this Agreement by executing and delivering an
additional counterpart signature page to this Agreement and such purchaser shall be
deemed a Holder and an Investor hereunder. The parties agree that <U>Exhibit&nbsp;A</U>
shall be updated automatically without any formal amendment to reflect the addition
of any such additional party. Any amendment or waiver effected in accordance with
this paragraph shall be binding upon each Holder, the Founders, the holder of the
Other Shares, Warrantholders and the Company. In addition, the Company may waive
performance of any obligation owing to it, as to some or all of the Holders, or
agree to accept alternatives to such performance, without obtaining the consent of
any other Holder. In the event that an underwriting agreement is entered into
between the Company and any Holder, and such underwriting agreement contains terms
differing from this Agreement, as to any such Holder the terms of such underwriting
agreement shall govern.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 10 <U>Governing Law</U>. This Amendment shall be construed in accordance with, and
governed in all respects by, the laws of the State of California, as applied to agreements entered
into, and to be performed entirely in such state, between residents of such state.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 11 <U>Counterparts</U>. This Amendment may be executed in any number of
counterparts, each of which shall be enforceable against the parties actually executing such
counterparts, and all of which together shall constitute one instrument.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;</B><B><I>Remainder of Page Intentionally Blank</I></B><B>&#093;</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FLUIDIGM CORPORATION</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMENDMENT NO. 2 TO<BR>
EIGHTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIS AMENDMENT NO. 2 (this &#147;<B>Amendment</B>&#148;) to that certain Eighth Amended and Restated Investor
Rights Agreement, dated as of June&nbsp;13, 2006, as amended December&nbsp;22, 2006 (the &#147;<B>Rights Agreement</B>&#148;),
by and among Fluidigm Corporation, a California corporation (&#147;<B>Fluidigm California</B>&#148;), and the
Investors and Founders named therein is entered into effective as of October&nbsp;10, 2007 by and among
Fluidigm Corporation, a Delaware corporation (the &#147;<B>Company</B>&#148;), the undersigned Investors, and the
undersigned Holders, collectively the Holders of at least two-thirds of the outstanding shares of
the Registrable Securities held by Holders (assuming the exercise or conversion of all outstanding
Eligible Securities). Capitalized terms not defined herein have the meanings set forth in the
Rights Agreement.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>RECITALS</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS</B>, on July&nbsp;18, 2007, Fluidigm California was merged with and into the Company, with the
Company being the surviving corporation such that the Company succeeded to all of Fluidigm
California&#146;s rights and obligations under the Rights Agreement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS</B>, it is contemplated that the Company will sell and issue additional shares of the
Company&#146;s Series&nbsp;E Preferred Stock (&#147;<B>Series&nbsp;E Preferred Stock</B>&#148;) pursuant to that certain Series&nbsp;E
Preferred Stock Purchase Agreement, dated as of June&nbsp;13, 2006, as amended December&nbsp;22, 2006 and
further amended on the date hereof (the &#147;<B>Purchase Agreement</B>&#148;), by and among the Company and the
Purchasers named therein;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS</B>, in connection with the sale of additional shares of Series&nbsp;E Preferred Stock, the
Company and the Holders desire to amend the Rights Agreement to include the additional shares of
Series&nbsp;E Preferred Stock to be issued pursuant to the Purchase Agreement and make certain other
changes as set forth herein; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS</B>, pursuant to Section&nbsp;6.7 of the Rights Agreement, the Rights Agreement may be amended
with the written consent of the Company and Holders of at least two-thirds of the outstanding
shares of the Registrable Securities then held by Holders (assuming the exercise or conversion of
all outstanding Eligible Securities) and the Company and the undersigned Holders have agreed to
amend the Rights Agreement to provide for the foregoing changes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>NOW, THEREFORE</B>, in consideration of the foregoing, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, all of the parties
hereto mutually agree as follows:
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>AGREEMENT</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 12 <U>Amendment to Recital</U>. The first Recital of the Rights Agreement is hereby
amended and restated in its entirety as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&#147;WHEREAS, the Company and the New Investors have entered into a Series&nbsp;E Preferred Stock
Purchase Agreement of even date herewith, as amended from time to time (such agreement, as
amended from time to time, the &#147;<B>Purchase Agreement</B>&#148;), pursuant to which the Company shall
sell, and the New Investors shall acquire, shares of the Company&#146;s Series&nbsp;E Preferred
Stock;&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 13 <U>Amendment to Section&nbsp;1.14</U>. Subsection (a)(i) of Section&nbsp;1.14 (Standoff
Agreement) of the Rights Agreement is hereby amended and restated in its entirety as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&#147;(i) such agreement shall not exceed one hundred and eighty (180)&nbsp;days (or such greater
period, not to exceed 17&nbsp;days, as may be requested by the Company or an underwriter to
accommodate regulatory restrictions on (i)&nbsp;the publication or other distribution of research
reports and (ii)&nbsp;analyst recommendations and opinions, including, but not limited to, the
restrictions contained in NASD Rule&nbsp;2711(f)(4) or NYSE Rule&nbsp;472(f)(4), or any successor
provisions or amendments thereto);&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 14 <U>Deletion of Section&nbsp;1.15</U>. The Rights Agreement is hereby amended to delete
Section&nbsp;1.15 (No Right to Delay Registration) in its entirety.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 15 <U>Amendment to Section&nbsp;2.4</U>. Section&nbsp;2.4 (Visitation Rights) of the Rights
Agreement is hereby amended and restated in its entirety as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;2.4 <U>Visitation Rights</U>. One representative chosen collectively by LB I Group
Inc., Lehman Brothers P.A. LLC, Lehman Brothers Partnership Account 2000/2001, L.P. and
Lehman Brothers Offshore Partnership Account 2000/2001, L.P. (collectively, &#147;<B>Lehman</B>&#148;), one
representative chosen collectively by EuclidSR Partners, L.P. and EuclidSR Biotechnology
Partners, L.P. (collectively, &#147;<B>EuclidSR</B>&#148;), one representative chosen by Piper Jaffray
Healthcare Fund III, L.P. (&#147;<B>Piper Jaffray</B>&#148;), one representative chosen by GE Capital Equity
Investments, Inc. (&#147;<B>GE Capital</B>&#148;), one representative chosen collectively by Interwest
Investors VII, L. P. and Interwest Partners VII, L.P. (collectively, &#147;<B>Interwest</B>&#148;), one
representative chosen by AllianceBernstein Venture Fund I, L.P. (&#147;<B>Alliance</B>&#148;), one
representative chosen collectively by Cross Creek Capital, L.P., Cross Creek Capital
Employees&#146; Fund, L.P. and Wasatch Small Cap Growth (collectively, &#147;<B>Wasatch</B>&#148;), one
representative chosen by BMSIF, and one representative chosen collectively by the holders of
a majority of the Shares purchased under Amendment No.&nbsp;2 to the Purchase Agreement
(collectively, the &#147;<B>October&nbsp;2007 Representative</B>&#148;) shall have the right to attend all
meetings of the Board of Directors, including meetings of any committee of the Board and
including the right to participate in any telephonic board meetings, so long as such
Investor or the October&nbsp;2007 Representative holds at least
750,000 shares of Eligible Securities (as adjusted for stock
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">splits and combinations and the like). Said representative(s) shall be provided with
notice of the meetings in the same manner at the same time as the members of the Board of
Directors and shall be provided with any materials distributed to the Board of Directors in
connection with board meetings. The foregoing visitation rights may be limited by the Board
of Directors if (i), upon the advice of counsel, the Board of Directors determines that
exclusion is required by third party confidentiality agreements, (ii)&nbsp;the Board is
discussing engaging Investor or an affiliate of Investor as a financial advisor or
underwriter; or (iii)&nbsp;the Board is discussing a material transaction with an entity in which
Investor or a private equity fund affiliated with Investor is a 5% or greater shareholder,
or (iv)&nbsp;the Board determines in good faith upon advice of counsel that limitations are
required to maintain attorney-client privilege.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 16 <U>Amendment to Section&nbsp;6.7</U>. Section&nbsp;6.7 (Amendment and Waiver) of the Rights
Agreement is hereby amended and restated in its entirety as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;6.7 <U>Amendment and Waiver</U>. Any provision of this Agreement may be amended or
waived with the written consent of the Company and the Holders of at least two-thirds of the
outstanding shares of the Registrable Securities then held by Holders (assuming the exercise
or conversion of all outstanding Eligible Securities); <U>provided</U>, <U>however</U>,
(i)&nbsp;that in the event such amendment or waiver adversely affects the rights and/or
obligations of the Founders under this Agreement in a different manner than the other
Holders, such amendment or waiver shall also require written consent of the Founders holding
a majority of the then outstanding Founders Shares, (ii)&nbsp;that in the event such amendment or
waiver adversely affects the rights and/or obligations of Lehman, EuclidSR, Piper Jaffray,
GE Capital, Interwest, Alliance, Wasatch, BMSIF or the October&nbsp;2007 Representative under
Section&nbsp;2.4 of this Agreement, such amendment or waiver shall not be effective as to Lehman,
EuclidSR, Piper Jaffray, GE Capital, Interwest, Alliance, Wasatch, BMSIF or the October&nbsp;2007
Representative, as the case may be, without the written consent of such party, and (iii)
that in the event such amendment or waiver adversely affects the rights and/or obligations
of Warrantholders under this Agreement in a different manner than the other Holders, such
amendment or waiver shall also require the written consent of Warrantholders holding a
majority of the then outstanding Warrant Shares. Notwithstanding the foregoing, any
purchaser of Series&nbsp;E Preferred Stock pursuant to the Purchase Agreement may become a party
to this Agreement by executing and delivering an additional counterpart signature page to
this Agreement and such purchaser shall be deemed a Holder and an Investor hereunder. The
parties agree that <U>Exhibit&nbsp;A</U> shall be updated automatically without any formal
amendment to reflect the addition of any such additional party. Any amendment or waiver
effected in accordance with this paragraph shall be binding upon each Holder, the Founders,
the holder of the Other Shares, Warrantholders and the Company. In addition, the Company
may waive performance of any obligation owing to it, as to some or all of the Holders, or
agree to accept alternatives to such performance, without obtaining the
consent of any other Holder. In the event that an underwriting agreement is entered
into between the Company and any Holder, and such underwriting agreement contains terms
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">differing from this Agreement, as to any such Holder the terms of such underwriting
agreement shall govern.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 17 <U>Addition of Section&nbsp;6.15</U>. The Rights Agreement is hereby amended to add
the following Section&nbsp;6.15 which reads in its entirety as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;6.15 <U>Reincorporation</U>. Each Investor and Founder acknowledges that the Company
completed a reincorporation into the State of Delaware on July&nbsp;18, 2007 and each Investor
and Founder hereby consents to the assignment of this Agreement to Fluidigm Corporation, a
Delaware corporation, effective as of July&nbsp;18, 2007.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 18 <U>Governing Law</U>. This Amendment shall be construed in accordance with, and
governed in all respects by, the laws of the State of California, as applied to agreements entered
into, and to be performed entirely in such state, between residents of such state.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 19 <U>Rights Agreement</U>. Wherever necessary, all other terms of the Rights
Agreement are hereby amended to be consistent with the terms of this Amendment. Except as
specifically set forth herein, the Rights Agreement shall remain in full force and effect
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 20 <U>Counterparts</U>. This Amendment may be executed in any number of
counterparts, each of which shall be enforceable against the parties actually executing such
counterparts, and all of which together shall constitute one instrument.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 21 <U>Effect of Execution of Amendment by Investor</U>. This Amendment, when
executed and delivered by the Company and an Investor purchasing shares of Series&nbsp;E Preferred
pursuant to the Purchase Agreement as contemplated in the Recitals, shall also constitute and shall
be deemed a counterpart signature page to the Rights Agreement. Consequently, each undersigned
Investor purchasing shares of Series&nbsp;E Preferred acknowledges and agrees that he, she or it is
bound by the terms and conditions contained in the Rights Agreement, as amended by this Amendment.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;</B><B><I>Remainder of Page Intentionally Blank</I></B><B>&#093;</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>FOUNDERS</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Gajus V. Worthington
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Stephen R. Quake
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>INVESTORS</B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Alejandro Berenstein, M.D.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Alfred J. Mandel
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Allan Johnson
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Allen May, Trustee, Intervivos Trust Dated 5/14/91
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">AllianceBernstein Venture Fund I, L.P.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Alloy Partners 2002, L.P.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Alloy Ventures 2002, L.P.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Alloy Ventures 2005, L.P.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Analiza, Inc.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Athersys, Inc.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Beveren Company
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Biomedical Sciences Investment Fund Pte Ltd
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Bradford S. Goodwin and Cathy W. Goodwin As Trustees of the Goodwin Family Trust U/A/D 7/30/97
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Bradford W. Baer
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Bruce Burrows
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Burr &#038; Forman LLP
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Burwen Family Trust U/D/T Dated 9/30/88
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Charles C. Moore
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Charles R. Engles
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Clark-Boyd Family Trust
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Cross Creek Capital Employees&#146; Fund, L.P.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Cross Creek Capital, L.P.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">David S. Frampton and Gaja Roberta Frampton, as Trustees of the Frampton Family Trust Dtd 4/25/03
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Dwayne Hardy
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Edward R. LeMoure
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Erick Vanderburg
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Erik T. Engelson, Trustee of the Elisabeth North Kuechler Engelson Trust UTA dated January&nbsp;17, 2001
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Erik T. Engelson, Trustee of the Erik T. Engelson Trust UTD dated March&nbsp;29, 2000
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">EuclidSR Biotechnology Partners, L.P.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">EuclidSR Partners, L.P.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Ferguson/Egan Family Trust Dated 6/28/99
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Fidelity Contrafund: Fidelity Advisor New Insights Fund
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Fidelity Contrafund: Fidelity Contrafund
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Finnegan, Henderson, Farabow, Garrett &#038; Dunner, LLP
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Frances H. Arnold
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Fred St. Goar
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Fredrick Stern
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Gary R. Bang
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GE Capital Equity Investments, Inc.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">General Electric Capital Corporation
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">George S. Taylor
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Glaxo Group Limited
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Health Care Administration Company
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Heath Lukatch
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Henry P. Massey, Jr. TTEE Massey Family Trust U/A DTD 7/06/88
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Herbert L. Heyneker
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Howard R. Engelson
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Howard R. Engelson and Mariam T. Engelson, Ttees Engelson Fam Tr UA DTD 5/26/94
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In-Q-Tel Employee Fund, LLC
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In-Q-Tel, Inc.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Interwest Investors VII, L.P.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Interwest Partners VII, L.P.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Invus, L.P.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">J.F. Shea Co., Inc. As Nominee 1999-114
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Jacaranda Partners
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">James H. Eberwine
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">James W. Larrick, M.D.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">John E. Strobeck, Ph.D., M.D.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">John East
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">John M. Harland
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Jonathan S. Hoot and Andrea T. Hoot, Trustees of the Hoot Family Revocable Trust DTD 3/16/99
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Joseph M. Jacobson
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Kenneth A. Clark
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Kiley Revocable Trust
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Kristin T. McClanahan Trust
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Leerink Swann Co-Investment Fund, LLC
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Leerink Swann Holdings, LLC
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Lehman Brothers Healthcare Venture Capital L.P.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Lehman Brothers Offshore Partnership Account 2000/2001, L.P.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Lehman Brothers P.A. LLC
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Lehman Brothers Partnership Account 2000/2001, L.P.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Leo J. Parry, Jr. and Roberta J. Parry TTEES Parry Family Revocable Trust DTD 01/22/97
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Lighthouse Capital Partners V, L.P.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Lilly Bio Ventures, Eli Lilly and Company
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Markwell Partners
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Matthew Collier
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Matthew Frank
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Michael H. McKay
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Michael J. Reardon Trust Agreement dated June&nbsp;5, 1996
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Needle &#038; Rosenberg PC
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Newman Family Investment Partnership
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Oculus Pharmaceuticals, Inc.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pamela East
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pat and Betsy Collins Revocable Trust
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Patrick Tenney
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Paul Machle
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pauline van Ysendoorn
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Peter B. Dervan
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Peter S. Heinecke
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Rhett E. Brown
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Robert D. McCulloch and Kathleen M. McCulloch, Trustee, or their successor(s)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Robert F. Kornegay, Jr. Revocable Trust u/d/t dated May&nbsp;27, 2004, Robert F. Kornegay, Jr., Trustee
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Security Trust Co., Custodian FBO Frank Ruderman IRA/RO
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">SightLine Healthcare Fund III, L.P.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Singapore Bio-Innovations Pte Ltd.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">SMALLCAP World Fund, Inc.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">SmithKline Beecham Corporation
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Stanley D. Hayden, and his successor(s), as the Trustee of the Stanley D. Hayden Family Trust
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Stephen J. Weiss
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Stephen J. Weiss and Ursula G. Weiss, Trustees of the Weiss Family 1996 Trust
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Stephen L. Parry
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Technogen Liquidating Trust
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Condon Family Trust
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Heckmann Family Trust
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The UAB Research Foundation
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The V Foundation for Cancer Research
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Thomas J. Parry
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Thomas L. Barton
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Tim L. Traff Trust
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Timothy P. Lynch
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">TTC Fund I, LLC
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Variable Insurance Products Fund II: Contrafund Portfolio
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Versant Affiliates Fund 1-A, L.P.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Versant Affiliates Fund 1-B, L.P.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Versant Side Fund I, L.P.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Versant Venture Capital I, L.P.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Wasatch Funds, Inc.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">William L. Caton III, M.D.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">William L. Traff Trust
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">William S. Brown and Barbara G. Brown, or their successors, as Trustees of the Brown FRT DTD
3/10/99
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">WS Investment Company 2000B
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">WS Investment Company 99B
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">WS Investment Company, LLC (2001D)
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>6
<FILENAME>f39432orexv4w4.htm
<DESCRIPTION>EXHIBIT 4.4
<TEXT>
<HTML>
<HEAD>
<TITLE>exv4w4</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#091;***&#093; Indicates
text has been omitted from this Exhibit pursuant to a confidential treatment
request and has been filed separately with the Securities and Exchange Commission.
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;4.4</B></DIV>



<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Loan
and Security Agreements</B></FONT></DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>This
Loan and Security Agreement</B> </FONT><B>No.&nbsp;4561</B> (this <I>&#147;Agreement&#148;) </I>is entered into as of March
29, 2005, by and between
<FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital
Partners</B></FONT> <B>V, L.P.</B> <I>(&#147;Lender&#148;) </I>and
<FONT style="font-variant: SMALL-CAPS"><B>Fluidigm
Corporation</B></FONT>, a California corporation <I>(&#147;Borrower&#148; </I>or sometimes referred to herein as <I>&#147;Debtor&#148;)</I>
and sets forth the terms and conditions upon which Lender will lend and Borrower will repay money.
In consideration of the mutual covenants herein contained, the parties agree as follows:</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>1.</B> <FONT style="font-variant: SMALL-CAPS"><B>Definitions and Construction</B></FONT></DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><B>1.1 Definitions.</B> Initially capitalized terms used and not otherwise defined herein are
defined in the California Uniform Commercial Code <I>(&#147;UCC&#148;).</I></DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;ACH&#148; </I>means the Automated Clearing House electronic funds transfer system.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Advance&#148; </I>means a Loan advanced by Lender to Borrower hereunder.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Basic Rate&#148; </I>means a variable <I>per annum </I>rate of interest equal to the Index plus the Interest
Margin which shall be subject to adjustment as provided in the Loan Agreement and/or the Note. On
and after the Loan Commencement Date the Basic Rate shall be fixed and not subject to any further
adjustments.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Borrower&#146;s Books&#148; </I>means all of Borrower&#146;s books and records, including records concerning
Collateral, Borrower&#146;s assets, liabilities, business operations or financial condition, on any
media, and the equipment containing such information.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Change
of Management or Board Composition&#148; </I>means that <B>(i)</B>&nbsp;Borrower&#146;s senior management shall not
include Gajus Worthington; <B>(ii)</B>&nbsp;Versant Ventures shall cease to have a representative (currently
Samuel Colella) serving on Borrower&#146;s Board of Directors; or<B>(iii)</B> Lehman Brothers shall cease to
have a representative (currently Hingge Hsu) serving on Borrower&#146;s Board of Directors;.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Collateral&#148; </I>means: <B>(i)</B>&nbsp;all property listed on <I><B>Exhibit&nbsp;A</B> </I>attached hereto; and <B>(ii)</B>&nbsp;all products
and proceeds of the foregoing, including proceeds of insurance and proceeds of proceeds, <I>provided
that, </I>notwithstanding anything to the contrary contained in this Agreement, the term Collateral
shall not include (a)&nbsp;any property that is subject to a Lien that is otherwise permitted pursuant
to subsection (v)&nbsp;of the definition of &#145;Permitted Liens&#148; and Lender agrees to execute any
instruments or documents necessary to evidence the intent of the foregoing; (b)&nbsp;more than 65% of
the issued and outstanding voting securities of any Subsidiary of Borrower that is not
incorporated or organized in the United States; or (c)&nbsp;any of the Company&#146;s Intellectual Property
(as defined below).</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Commitment&#148; </I>means
$13,000,000.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Commitment Fee&#148; </I>means $10,000.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Commitment Termination Date&#148; </I>means the earliest to occur of <B>(i)</B>&nbsp;the earlier to occur of (a)&nbsp;June
1, 2005, if Borrower has not borrowed at least $2,000,000 by such date; (b)&nbsp;September&nbsp;1, 2005, if
Borrower has not borrowed an additional $3,000,000 by such date or (c)&nbsp;December&nbsp;1, 2005; <B>(ii)</B>&nbsp;any
Default or Event of Default that has not been cured by Borrower or waived in writing by Lender, or
<B>(iii)</B>&nbsp;Change of Management or Board Composition (unless Lender has waived this condition in
writing).</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Control Agreement&#148; </I>means an agreement substantially in the form <I>of <B>Exhibit&nbsp;I</B> </I>or otherwise
reasonably acceptable to Lender.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Default&#148; </I>means any event that with the passing of time or the
giving of notice or both would become an Event of Default.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Default Rate&#148; </I>means the lesser of
5% per annum above the otherwise applicable rate or the highest rate permitted by applicable
law.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Disclosure Schedule&#148; </I>means the Disclosure Schedule, dated as of the date hereof, and delivered to
Lender in connection with the execution and delivery of this Agreement.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Event of Default&#148; </I>is defined in <B>Section&nbsp;8.</B></DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Funding Date&#148; </I>means any date on which an Advance is made to or on account of Borrower hereunder.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Indebtedness&#148; </I>means <B>(i)</B>&nbsp;all indebtedness for borrowed money or the deferred purchase of property
or services, <B>(ii)</B>&nbsp;all obligations evidenced by notes, bonds, debentures or similar instruments,
<B>(iii)</B>&nbsp;all capital lease obligations, and <B>(iv)</B> all contingent obligations, consisting of guaranties
of Indebtedness of other persons and obligations of reimbursement with respect to letters of
credit.</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio --></DIV></DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">


<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Incumbency Certificate&#148; </I>means the document in the form <I>of <B>Exhibit&nbsp;E.</B></I></DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Index&#148; </I>means the prevailing variable Prime Rate of annual interest as quoted from time to time in
the western edition of the Wall Street Journal.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Intellectual Property&#148; </I>means, collectively, all rights, priorities and privileges of the Borrower
relating to intellectual property, in any medium, of any kind or nature whatsoever, now or
hereafter owned or acquired or received by Borrower, or in which Borrower now holds or hereafter
acquires or receives any right or interest, whether arising under United States, multinational or
foreign laws or otherwise, including, without limitation, any and all property of the Borrower
that is subject to, listed in or otherwise described in the Negative Pledge Agreement dated March
29, 2005 between Borrower and Lender, and shall include, in any event, all copyrights, copyright
licenses, patents, patent licenses, trademarks, trademark licenses, trade secrets, internet domain
names (including any right related to the registration thereof), proprietary or confidential
information, mask works, sources object or other programming codes, inventions (whether or not
patented or patentable), technical information, procedures, designs, knowledge, know-how,
software, data base, data, skill, expertise, recipe, experience, process, models, drawings,
materials or records. Notwithstanding the foregoing, Intellectual Property as defined above does
not include proceeds or other revenue consisting of accounts, accounts receivable, royalties,
licensing fees, or payment intangibles, obtained or owed from or on account of the licensing or
other exploitation or disposition of Intellectual Property, and all of which are included as
Collateral in the security interest granted by Borrower to Lender.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Interest Margin&#148; </I>means 2.5% per annum.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Lender&#146;s Expenses&#148; </I>means all reasonable costs or expenses (including reasonable attorneys&#146; fees
and expenses) incurred in connection with the preparation, negotiation, modification,
administration, or enforcement of the Loan or Loan Documents, or the exercise or preservation of
any rights or remedies by Lender, whether or not suit is brought. Lender will apply deposits
(including the Commitment Fee) received by Lender, if any, towards Lender&#146;s Expenses.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Lien&#148; </I>means any lien, security interest, pledge, bailment, lease, mortgage, hypothecation,
conditional sales and title retention agreement, charge, claim, or other encumbrance.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Liquidation Event&#148; </I>means any of: <B>(i)</B>&nbsp;a merger of Borrower with another entity, other than a
merger whereby the shareholders of Borrower immediately prior to such merger own at least 50% of
the outstanding voting securities of Borrower immediately after such merger; <B>(ii)</B>&nbsp;the sale (in one
or a series of related transactions) of all or substantially all of Borrower&#146;s assets; or <B>(iii)</B>
any transaction (or series of related transactions) whereby the shareholders of Borrower
immediately prior to such transaction(s) own less than 50% of the outstanding voting securities of
Borrower immediately after such transaction(s).</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Loan&#148; </I>means all of the Advances, however evidenced, and all other amounts due or to
become due hereunder.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Loan
Commencement Date&#148; </I>means March&nbsp;1, 2006.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Loan Documents&#148; </I>means, collectively, this Agreement, the Warrant, the Notes, the Financing
Statement and Security Agreement in the form attached as <I><B>Exhibit&nbsp;A</B> </I>and all other documents,
instruments and agreements entered into between Borrower and Lender in connection with the Loan,
all as amended or extended from time to time.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Negative Pledge Agreement&#148; </I>means an agreement, dated as of the date hereof, in the form <I>of <B>Exhibit
H.</B></I></DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Note&#148; </I>means each Secured Promissory Note in the form <I>of <B>Exhibit&nbsp;B,</B> </I>delivered in connection with
each Advance.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Notice
of Borrowing&#148; </I>means the form attached as <I><B>Exhibit D.</B></I></DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Obligations&#148; </I>means all Loans, debt, principal, interest, fees, charges, Lender&#146;s Expenses and
other amounts, obligations, covenants, and duties owing by Borrower to Lender of any kind or
description (whether pursuant to the Loan Documents or otherwise (with the exception of the
Warrant), and whether or not for the payment of money), whether direct or indirect, absolute or
contingent, due or to become due, now existing or hereafter arising, and including any of the same
obtained by Lender by assignment or otherwise, and all amounts Borrower is required to pay or
reimburse by the Loan Documents, by law, or otherwise.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Permitted Indebtedness&#148; </I>means: <B>(i)</B>&nbsp;the Loan; <B>(ii)</B>&nbsp;unsecured trade debt incurred in the ordinary
course of Borrower&#146;s business; <B>(iii)</B>&nbsp;Indebtedness secured by clause <B>(ii)</B>&nbsp;and <B>(v)</B>&nbsp;of Permitted
Liens; <B>(iv)</B>&nbsp;Subordinated Indebtedness; <B>(v)</B>&nbsp;Indebtedness existing as of the date hereof and listed
on the Disclosure Schedule; <B>(vi)</B>&nbsp;Indebtedness arising from the endorsement of negotiable
instruments for deposits or
collections or similar transactions in the ordinary course of business; <B>(vii)</B>&nbsp;other Indebtedness
consisting of letters of credit and</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio --></DIV></DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">





<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">reimbursement obligations in an amount not to exceed $250,000; <B>(viii)</B>&nbsp;Indebtedness of (A)&nbsp;Borrower
to any Subsidiary that is unsecured, (B)&nbsp;one Subsidiary to another Subsidiary, or (C)&nbsp;any
Subsidiary to Borrower in an amount not to exceed $4,500,000 in the aggregate; <B>(ix)</B>&nbsp;other
Indebtedness in an outstanding principal amount not to exceed $150,000 in the aggregate; and <B>(x)</B>
Indebtedness incurred in connection with the extension, renewal or refinancing of any Indebtedness
of the type described in clauses (i)&nbsp;through (ix)&nbsp;above, provided that the principal amount of such
Indebtedness does not increase other than any reasonable premium in connection therewith.
Notwithstanding the foregoing, the restrictions on Indebtedness for Subordinated Indebtedness and
referenced in clause (v)&nbsp;of the definition of Permitted Liens shall cease at the effective date of
a public offering of Borrower&#146;s capital stock which results in proceeds of at least $25,000,000.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Permitted Liens&#148; </I>means: <B>(i)</B>&nbsp;Liens in favor of Lender; <B>(ii)</B>&nbsp;Liens disclosed in the Disclosure
Schedule; <B>(iii)</B>&nbsp;Liens for taxes, fees, assessments or other governmental charges or levies not
delinquent or being contested in good faith by appropriate proceedings, that do not jeopardize
Lender&#146;s interest in any Collateral; <B>(iv)</B>&nbsp;Liens to secure payment of worker&#146;s compensation,
employment insurance, old age pensions or other social security obligations of Borrower on which
Borrower is current and are in the ordinary course of its business; provided none of the same
diminish or impair Lender&#146;s rights and remedies respecting the Collateral; and <B>(v)</B>&nbsp;Liens upon or
in any equipment (including any accessions, attachments, replacements, improvements or proceeds
thereto) acquired or held by Borrower to secure the purchase price of such equipment or
Indebtedness incurred solely for the purposes of financing such equipment, provided that the
aggregate outstanding principal amount of all such financing shall not exceed $5,000,000, <B>(vi)</B>
license or sublicenses of Intellectual Property granted in the ordinary course of business; <B>(vii)</B>
banker&#146;s Liens, rights of setoff and similar Liens incurred on deposit and securities accounts in
the ordinary course of business; <B>(viii)</B>&nbsp;Liens arising from judgments in circumstances not
constituting and Event of Default; <B>(ix)</B>&nbsp;Liens in favor of customs and revenue authorities arising
as a matter of law to secure payments of customs duties in connections with the importation of
goods; <B>(x)</B>&nbsp;Liens on insurance proceeds in favor of insurance companies granted solely as security
for financed premiums; <B>(xi)</B>&nbsp;carriers&#146;, warehousemen&#146;s, mechanics&#146;, landlords&#146;, materialmen&#146;s,
repairmen&#146;s or other similar Liens arising in the ordinary course of business which are not
delinquent or remain payable without penalty or which are being contested in good faith and by
appropriate proceedings; <B>(xii)</B>&nbsp;Liens with respect to cash collateral to secure Indebtedness
otherwise permitted pursuant to clause (vii)&nbsp;of the definition of Permitted Indebtedness; and
<B>(xiii)</B>&nbsp;Liens incurred in connection with the extension, renewal or refinancing of the Indebtedness
secured by Liens of the type described in clauses (i)&nbsp;through (xi)&nbsp;above, provided that any
extension, renewal, or replacement Lien shall be limited to the collateral securing the existing
Lien and the principal amount of such Indebtedness does not increase other than any reasonable
premium in connection therewith.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Regulated Substance&#148; </I>means any substance, material or waste the use, generation, handling,
storage, treatment or disposal of which is regulated by any local or state government authority,
including any of the same designated by any authority as hazardous, genetic, cloning, fetal, or
embryonic.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Responsible Officer&#148; </I>means each person as authorized by the board of directors of Borrower as set
forth on the Incumbency Certificate.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Subordinated Indebtedness&#148; </I>means Indebtedness of Borrower to Singapore EDB and Invus Group that
is subordinated in both security and right of payment to the Obligations on terms and conditions
reasonably satisfactory to Lender in an amount not to exceed $6,000,000.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Subsidiary&#148; </I>shall mean any entity of which a majority of the outstanding equity interests
entitled to vote for the election of directors is owned by Borrower.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Term&#148; </I>means the period from and after the date hereof until the full, final and indefeasible
payment and performance of all Obligations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Warrant&#148; </I>means the Warrant, dated as of the date hereof, in favor of Lender and its affiliates to
purchase securities of Borrower substantially in the form <I>of <B>Exhibit&nbsp;C.</B></I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>1.2 Interpretation.</B> References to &#147;Articles,&#148; &#147;Sections,&#148; &#147;Exhibits,&#148; and &#147;Schedules&#148; are to
articles, sections, exhibits and schedules herein and hereto unless otherwise indicated. &#147;Hereof,&#148;
&#147;herein&#148; and &#147;hereunder&#148; refer to this Agreement as a whole. &#147;Including&#148; is not limiting. All
accounting and financial computations shall be computed in accordance with generally accepted
accounting principles consistently applied <I>(&#147;GAAP&#148;). </I>&#147;Or&#148; is not necessarily exclusive. All
interest computation interest shall be based on a 360-day year and actual days elapsed.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>2. The Loans</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>2.1
Commitment. </B>Subject to the terms hereof, Lender will make Advances to Borrower up to the principal amount of the Commitment,
before the Commitment Termination Date. Notwithstanding anything in the Loan Documents to the contrary, Lender&#146;s obligation to make any Advances or to lend the undisbursed portion of the Commitment shall terminate on the Commitment Termination Date. Repaid principal of the Advances may not be re-borrowed.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">

<DIV style="font-size: 10pt; margin-top: 6pt"><B>2.2 The Advances. </B>A Note setting forth the specific terms of repayment will evidence each
Advance. No Advance will be made for
less than $1,000,000, unless less than $1,000,000 remains available under the Commitment for
borrowing. Absence of a Note evidencing
any portion of the Loan shall not impair Borrower&#146;s obligation to repay it to Lender.
</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><B>2.3
Terms of Payment, Repayment.</B>
</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;Repayment. </B>Borrower shall repay the principal and pay interest on each Advance on the
terms set forth in the applicable Note. Amounts not paid when due hereunder or under the Note shall bear interest
at the Default Rate. If a court of competent jurisdiction determines that Lender has received payments that, if interest, would
exceed the maximum lawfully permitted, Lender will instead apply such money to fees and expenses and then to early prepayment of
principal (provided that notwithstanding anything contained in any Loan Document, any such prepayment shall not trigger any
Prepayment Fees).
</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;ACH.</B> All payments due to Lender must be, at Lender&#146;s option, paid to Lender in cash or
through ACH. Borrower
shall execute and deliver the ACH Authorization Form substantially in the form of <B><I>Exhibit&nbsp;G.</I></B>
Lender shall provide Borrower an
invoice for any Obligations that are to be transferred by ACH at least 10&nbsp;days in advance of
the date of any ACH funds transfer with
respect to Obligations which have become due and payable and are to be transferred by ACH.
If the ACH payment arrangement is
terminated for any reason, Borrower shall make all payments due to Lender at Lender&#146;s
address specified in <B>Section&nbsp;11.</B>
</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;Default Rate. </B>While an Event of Default has occurred and is continuing, interest on the
Loan shall be increased to
the Default Rate. Lender&#146;s failure to charge or accrue interest at the Default Rate during
the existence of a Default shall not be deemed
a waiver by Lender of its right or claim thereto.
</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;Date. </B>Whenever any payment due under the Loan Documents is due on a day other than a
business day, such
payment shall be made on the next succeeding business day, and such extension of time shall
be included in the computation of interest or fees, as the case may be.
</DIV>
<DIV style="font-size: 10pt; margin-top: 6pt"><B>2.4 Fees.</B> Borrower shall pay to Lender the following:
</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;Commitment Fee. </B>The Commitment Fee, which has been previously paid by Borrower,
and shall be applied by Lender to Lender&#146;s Expenses and other Obligations;
</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;Late Fee. </B>On demand, a late charge on any sums due hereunder that are not paid when due,
in an amount equal to 2%
of the past due amount, payable on demand.
</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;Lender&#146;s Expenses. </B>The payment of all Lender&#146;s Expenses, which may become due to Lender
by Borrower
hereunder shall be payable by Borrower as set forth in <B>Section 2.3(b).</B> Lender&#146;s Expenses not
paid when due shall bear interest as
principal at the Default Rate.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>3.</B> <FONT style="font-variant: SMALL-CAPS"><B>Conditions of Advances; Procedure for Requesting Advances</B></FONT>
</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><B>3.1 Conditions Precedent to any and all Advances. </B>The obligation of Lender to make any Advances is
subject to each and
every of the following conditions precedent in form and substance satisfactory to Lender in its
sole discretion: <B>(i)</B>&nbsp;this Agreement, a
Note evidencing the Advance, the Warrant, and all other UCC financing statements, and other
documents required or as specified herein
have been duly authorized, executed and delivered; <B>(ii)</B>&nbsp;no Default or Event of Default has
occurred and is continuing; <B>(iii)</B>&nbsp;delivery of a
Notice of Borrowing with respect to the proposed Advance; <B>(iv)</B>&nbsp;Lender&#146;s security interests in the
Collateral are valid and first priority,
except for Permitted Liens; and <B>(v)</B>&nbsp;all such other items as Lender may reasonably deem necessary
or appropriate have been delivered or
satisfied. The extension of an Advance prior to the receipt by Lender of any of the foregoing
shall not constitute a waiver by Lender of
Borrower&#146;s obligation to deliver such item.
</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><B>3.2 Procedure for Making Advances. </B>For any Advance, Borrower shall provide Lender an irrevocable
Notice of Borrowing at
least 7 business days prior to the desired Funding Date and Lender shall only be required to make
Advances hereunder based upon
written requests which comply with the terms and exhibits of this Loan Agreement (as the same may
be amended from time to time),
and which are submitted and signed by a Responsible Officer. Borrower shall execute and deliver to
Lender a Note and such other
documents and instruments as Lender may reasonably require for each Advance made.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>4.</B> <FONT style="font-variant: SMALL-CAPS"><B>Creation of Security Interest</B></FONT>
</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><B>4.1
Grant of Security Interest. </B>Borrower grants to Lender a valid, first priority,
continuing security interest in all present and future Collateral in order to secure prompt,
full, faithful and timely payment and performance of all Obligations.
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">





<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>4.2 Inspections. </B>Lender shall have the right upon reasonable prior notice to inspect Borrower&#146;s
Books, including computer files,
and to make copies, and to test, inspect and appraise the Collateral, in order to verify any matter
relating to Borrower or the Collateral.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>4.3 Authorization to File Financing Statements. </B>Borrower irrevocably authorizes Lender at any time
and from time to time to
file in any jurisdiction any financing statements and amendments that: <B>(i)</B>&nbsp;name Collateral as
collateral thereunder, regardless of
whether any particular Collateral falls within the scope of the UCC; <B>(ii)</B>&nbsp;contain any other
information required by the UCC for
sufficiency or filing office acceptance, including organization identification numbers; and <B>(iii)</B>
contain such language as Lender
determines helpful in protecting or preserving rights against third parties. Borrower ratifies any
such filings made prior to the date
hereof.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>5.</B> <FONT style="font-variant: SMALL-CAPS"><B>Representations and Warranties</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Except as set forth on the Disclosure Schedule, Borrower represents and warrants as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5.1 Due Organization and Qualification. </B>Borrower is a corporation duly formed, existing and in good
standing under the laws
of its state of incorporation and qualified and licensed to do business in, and is in good standing
in, any state in which the conduct of its
business or its ownership of property requires that it be so qualified or in which the Collateral
is located, except to the extent that such
non-compliance would not reasonably be expected to result in an adverse effect on Borrower&#146;s
business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5.2 Authority. </B>Borrower has all corporate power and authority, and has taken all actions, and has
obtained all third party
consents necessary to execute, deliver, and perform the Loan Documents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5.3 Disclosure Schedule. </B>All information on the Disclosure Schedule is true, correct and complete.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5.4 Authorization; Enforceability. </B>The execution and delivery hereof, the granting of the security
interest in the Collateral, the
incurring of the Obligations, the execution and delivery of all Loan Documents and the consummation
of the transactions herein and
therein contemplated have been duly authorized by all necessary action by Borrower. The Loan
Documents constitute legal, valid and
binding obligations of Borrower, enforceable in accordance with their terms, except as
enforceability may be limited by bankruptcy or
similar laws relating to enforcement of creditors&#146; rights generally.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5.5 Name and Location. </B>Borrower has not done business under any name other than that specified on
the signature page hereof.
The chief executive office, principal place of business, and the place where Borrower maintains its
records concerning the Collateral
is set forth in <B>Section&nbsp;11. </B>The Collateral is presently located at the address(es) set forth in
<B>Section&nbsp;11 </B>and on the Disclosure Schedule
or any other location that Borrower has provided Lender with written notice thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5.6 Litigation. </B>All actions or proceedings pending by or against Borrower that could reasonably
be expected to result in a
material adverse effect on Borrower&#146;s business before any court or administrative agency are set
forth on the Disclosure Schedule.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5.7 Financial Statements. </B>All financial statements delivered by Borrower to Lender present fairly
in all material respects
Borrower&#146;s financial condition for the periods indicated. All statements respecting Collateral that
have been or may hereafter be
delivered by Borrower to Lender are true, complete and correct in all material respects for the periods indicated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5.8 Solvency. </B>Borrower is solvent and able to pay its debts (including trade debts) as they come due.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5.9 Taxes. </B>Borrower has filed and will file all required tax returns, and has paid and will pay all
taxes it owes other than where
the failure to comply would not reasonably be expected to have a material adverse effect on
Borrower.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5.10 Rights; Title to Assets. </B>To Borrower&#146;s knowledge, Borrower possesses, owns, or has the right
to use all necessary assets,
rights, trademarks, trade names, copyrights, patents, patent rights, franchises and licenses which
are required to conduct of its business
as now operated, except where the failure to possess or own could not reasonably be expected to
have a material adverse effect on
Borrower&#146;s business. Borrower has good title to its assets, free and clear of any Liens, except for
Permitted Liens.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5.11 Full Disclosure. </B>No written representation, warranty or other statement made by Borrower in
any Loan Document, certificate
or statement furnished to Lender contains any untrue statement of a material fact or omits to state
a material fact necessary in order to
make the statements contained in such certificates or statements not misleading (it being
recognized by Lender that projections and
estimates as to future events are not to be viewed as facts and the actual results during the
period or periods covered by any such
projections and estimates may differ from projected or estimated results).
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">





<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.12 Regulated Substances. </B>Borrower complies and will comply with all laws respecting Regulated
Substances, except where the
failure to comply could not reasonably be expected to have an adverse effect on Borrower&#146;s
business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.13
Reaffirmation. </B>Each Notice of Borrowing will constitute <B>(i)</B>&nbsp;a warranty and representation in
favor of Lender that there does
not exist any Default and <B>(ii)</B>&nbsp;subject to any amended Disclosure Schedule delivered to Lender or
any other written disclosure required
to be sent to Lender pursuant to the terms hereof, a reaffirmation as of the date thereof of all of
the representations and warranties
contained in this Agreement and the Loan Documents.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>6.</B> <FONT style="font-variant: SMALL-CAPS"><B>Affirmative Covenants</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">So long as any Obligations (other than inchoate indemnity obligations) remain outstanding,
Borrower covenants and agrees that it shall do all of the following:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>6.1 Good Standing and Compliance. </B>Borrower shall maintain all governmental licenses, rights and
agreements necessary for its
operations or business and comply in all respects with all statutes, laws, ordinances and
government rules and regulations to which it is
subject except where the failure to comply would not reasonably be expected to result in a material
adverse effect on Borrower.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>6.2 Financial Statements, Reports, Certificates. </B>Borrower shall deliver to Lender: <B>(i)</B>&nbsp;as soon as
prepared, and no later than 30
days after the end of each calendar month, a balance sheet, income statement and cash flow
statement covering Borrower&#146;s operations
during such period; <B>(ii)</B>&nbsp;as soon as prepared, but no later than 90&nbsp;days after the end of the fiscal
year, or such other timeframe formally
approved by Borrower&#146;s audit committee, audited financial statements prepared in accordance with
GAAP, together with an opinion
that such financial statements fairly present Borrower&#146;s financial condition by an independent
public accounting firm reasonably
acceptable to Lender; <B>(iii) </B>immediately upon notice thereof, a report of any legal or
administrative action pending or threatened in
writing against Borrower which is likely to result in liability to Borrower in excess of $100,000
(provided that Borrower shall not be
required to report notices of possibly relevant third party patents, or proposals or demands to
license intellectual property); and
<B>(iv)</B>&nbsp;such other financial information as Lender may reasonably request from time to time. Financial
statements delivered pursuant to
subsections <B>(i)</B>&nbsp;and <B>(ii)</B>&nbsp;above shall be accompanied by a certificate signed by a Responsible
Officer (each an <I>&#147;Officer&#146;s Certificate&#148;) </I>in
the form <B><I>of Exhibit&nbsp;F.</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>6.3 Notice of Defaults. </B>Upon any Default or Event of Default, an Officer&#146;s Certificate setting
forth the facts relating to or giving
rise thereto, and the Borrower&#146;s proposed action with respect thereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>6.4
Use; Maintenance. </B>Borrower, at its expense, shall <B>(i)</B>&nbsp;maintain the tangible Collateral in good condition, reasonable wear
and tear excepted, and will comply in all material respects with all laws, rules and regulations
regarding use and operation of the
tangible Collateral and <B>(ii)</B>&nbsp;repair or replace any lost or damaged Collateral except to the extent
that Borrower in its good faith
judgment deems it to be in its best interest not to repair or replace such lost or damaged
Collateral, so long as applied to a purchase or
acquisition useful to Borrower&#146;s business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>6.5 Insurance. </B>Borrower, at its own expense, shall maintain insurance in amounts and coverages reasonably satisfactory to
Lender. Each insurance shall: <B>(i)</B>&nbsp;name Lender loss payee or additional insured, as appropriate,
<B>(ii)</B>&nbsp;provide for insurer&#146;s waiver of its
right of subrogation against Lender and Borrower, <B>(iii)</B>&nbsp;provide that such insurance shall not be
invalidated by any action of, or breach
of warranty by, Borrower and waive set-off, counterclaim or offset against Lender, <B>(iv)</B>&nbsp;be primary
without a right of contribution of
Lender&#146;s insurance, if any, or any obligation on the part of Lender to pay premiums of Borrower,
and <B>(v)</B>&nbsp;require the insurer to give
Lender at least 30&nbsp;days prior written notice of cancellation. Borrower shall furnish all
certificates of insurance required by Lender.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>6.6 Loss Proceeds. </B>So long as no Event of Default has occurred and is continuing, any proceeds of
insurance on or
condemnation of Collateral shall, at Borrower&#146;s election and so long as Lender&#146;s security interest
in such proceeds remains first
priority, be used either to repair or replace such Collateral or otherwise applied to the purchase
or acquisition of property useful to
Borrower&#146;s business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>6.7 Further Assurances. </B>At any time and from time to time, Borrower shall execute and deliver such further instruments and
take such further action as Lender may reasonably request to effect the intent and purposes hereof,
to perfect and continue perfected
and of first priority Lender&#146;s security interests in the Collateral, and to effect and maintain ACH
payment arrangements.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>7.</B> <FONT style="font-variant: SMALL-CAPS"><B>Negative Covenants</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">So long as any Obligations (other than inchoate indemnity obligations) remain outstanding, Borrower
will not do any of the following:
</DIV>






<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<div style="border: 1px solid black; padding: 11px">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>7.1 Location of Collateral. </B>Change its chief executive office or principal place of business or
remove, except in the ordinary course of Borrower&#146;s business, the Collateral or Borrower&#146;s Books
from the premises listed in <B>Section&nbsp;11 </B>and the Disclosure Schedule (or otherwise provided to Lender
in writing pursuant to this <B>Section 7.1</B>) without giving 30&nbsp;days prior written notice to Lender.
Borrower&#146;s practice of delivering and maintaining inventory at a customer&#146;s location pending
testing, validation and/or acceptance of such inventory by such customer shall be deemed to be in
the &#147;ordinary course of business&#148; for purposes of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>7.2 Extraordinary Transactions. </B>Enter into any transaction not in the ordinary course of
Borrower&#146;s business, including the sale, lease, license or other disposition of its assets, other
than <B>(i)</B>&nbsp;sales of inventory in the ordinary course of
Borrower&#146;s business; and <b>(ii)</b>&nbsp;licenses of
intellectual property assets entered into in the ordinary course of business (provided that
licensing arrangements involving universities, governmental agencies, research institutions and
corporate partners shall be deemed in the &#147;ordinary course of business&#148;). The parties hereto
agree (a)&nbsp;strategic partnerships, strategic collaborations, sponsored research collaborations and
development transactions, (b)&nbsp;transactions otherwise permitted in this <B>Article 7,</B> and (c)
transactions for fair value involving the sale or exclusive licensing of Intellectual Property,
that is outside the scope of Borrower&#146;s business in the biotechnology field, that is not being
commercialized or monetized by the Borrower; in each case, shall be deemed to be in the &#147;ordinary
course of business&#148; for purposes of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>7.3 Restructure. </B>Make any material change in Borrower&#146;s corporate structure or business other than
the business of the type conducted by Borrower as of the date of this Agreement or any business
reasonably related or incidental thereto; or suspend operation of Borrower&#146;s business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>7.4 Liens. </B>Create, incur, assume or suffer to exist any Lien of any kind with respect to any of its
property, whether now owned or hereafter acquired, except for Permitted Liens.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>7.5 Indebtedness. </B>Create, incur, assume or suffer to exist any Indebtedness, other than Permitted
Indebtedness or cause or suffer any Subsidiary to create, incur, assume or suffer to exist any
Indebtedness, other than Permitted Indebtedness.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>7.6 Distributions. </B>Pay any dividends or distributions, or redeem or purchase, any capital stock,
except for <b>(i)</b>&nbsp;repurchases of capital stock from employees, consultants or directors, under
incentive stock option plans, restricted stock purchase agreements, repurchase agreements or other
similar agreements approved by the Borrower&#146;s Board of Directors
and <b>(ii)</b>&nbsp;dividends payable solely
in capital stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>7.7 Transactions with Affiliates. </B>Directly or indirectly enter into any transaction with any
affiliate which is on terms less favorable to Borrower than would be obtained in an arm&#146;s length
transaction with a non-affiliated entity; <I>provided, </I>any such transaction shall not be a breach of
this Section&nbsp;7.7 if <b>(i)</b>&nbsp;approved by a disinterested majority of the Borrower&#146;s Board of Directors,
or <b>(ii)</b>&nbsp;such transaction involves sales, licensing or other transfers of property between Borrower
and its Subsidiaries, or between Subsidiaries if the consideration for such sale or transfer is not
less than cost (or the fair market value of such property, if lower),
or <b>(iii)</b>&nbsp;such transaction
involves intercompany loans that are otherwise permitted by <B>Section&nbsp;7.5.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>7.8
Compliance. </B><b>(i)</b>&nbsp;Become regulated as an &#147;investment company&#148; under the Investment Company Act of
1940 or extend credit to purchase or carry margin stock; <b>(ii)</b>&nbsp;fail to meet the minimum funding
requirements of ERISA; <B>(iii) </B>permit a Reportable Event or Prohibited Transaction, as defined in
ERISA, to occur; <b>(iv)</b>&nbsp;fail to comply with the Federal
Fair Labor Standards Act; or <b>(v)</b>&nbsp;violate any
other material law or material regulation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>7.9 UCC Effectiveness. </B>Change its name, jurisdiction of organization, or take any other action
that could render Lender&#146;s financing statements misleading under the Code, without giving Lender 30
days advance written notice.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>7.10 Deposit and Securities Accounts. </B>Maintain any deposit accounts or accounts holding securities
owned by Borrower except accounts in which Lender has obtained a perfected first priority security
interest with the exception of <b>(i)</b>&nbsp;account number &#091;***&#093; with Silicon Valley Bank or a
successor account with Wells Fargo Bank securing a letter of credit in favor of Borrower&#146;s landlord
in an amount not to exceed $250,000 in principal amount; <b>(ii)</b>&nbsp;account number &#091;***&#093; with
Comerica Bank or a successor account with Wells Fargo Bank securing a letter of credit in favor of
a lender providing equipment financing to Borrower in an amount not to exceed $500,000 in principal
amount; or <b>(iii)</b>&nbsp;account number &#091;***&#093; with Wells Fargo Bank securing a letter of credit in favor
of Borrower&#146;s landlord in an amount not to exceed $137,527 in
principal amount; or <b>(iv)</b>&nbsp;any other
accounts at Silicon Valley Bank or Comerica Bank (other than those specified in clause (i)&nbsp;or (ii)
of this <B>Section&nbsp;7.10, </B>provided that such accounts are closed and such funds are move to deposit or
securities accounts in which Lender has a perfect first priority security interest, on or before
June&nbsp;30, 2005.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>8. </B><FONT style="font-variant: SMALL-CAPS"><B>Events of Default</B></FONT>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

</div>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<div style="border: 1px solid black; padding: 11px">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Any one or more of the following shall constitute an Event of Default by Borrower hereunder:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>8.1
Payment. </B>Borrower fails to pay when due and payable in accordance with the Loan Documents any
portion of the Obligations, or cancels an ACH payment or transfer Lender has initiated in
conformity with the terms hereof <I>provided, however,</I> that an Event of Default shall not occur on
account of a failure to pay due solely to an administrative or operational error if Borrower had
the funds to make the payment when due and makes the payment the business day following Borrower&#146;s
knowledge of such failure to pay.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>8.2 Certain Covenant Defaults. </B>Borrower fails to perform any obligation under <B>Section&nbsp;6.5 </B>or <B>6.6,</B>
or violates any of the covenants contained in <B>Section&nbsp;7.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>8.3 Other Covenant Defaults. </B>Borrower fails or neglects to perform, keep, or observe any other
term, provision, condition, covenant, or agreement contained in this Agreement, in any of the other
Loan Documents, or in any other present or future agreement between Borrower and Lender and has
failed to cure such failure within 30&nbsp;days after its occurrence.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>8.4 Attachment. </B>Any material portion of Borrower&#146;s assets is attached, seized, subjected to a
government levy, lien, writ or distress warrant, or comes into the possession of any trustee or
receiver and the same is not returned, removed, waived, stayed, discharged or rescinded within 15
days.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>8.5 Other Agreements. </B>There is a default in any agreement to which Borrower is a party resulting in
a right by a third party, whether or not exercised, to accelerate the maturity of any Indebtedness,
in an amount greater than $ 100,000.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>8.6 Judgments. </B>One or more judgments for an aggregate of at least $100,000 is rendered against
Borrower and remains unsatisfied and unstayed for more than 30&nbsp;days.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>8.7 Injunction. </B>Borrower is enjoined, restrained, or in any way prevented by court order from
continuing to conduct any material part of its business affairs, or if a judgment or other claim
becomes a Lien upon any material portion of Borrower&#146;s assets.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>8.8 Misrepresentation. </B>Any representation, statement, or report made to Lender by Borrower was
false or misleading when made in any material respect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>8.9 Enforceability. </B>Lender&#146;s ability to enforce its rights against Borrower or any Collateral is
impaired in any material respect, or Borrower asserts that any Loan Document is not a legal, valid
and binding obligation of Borrower enforceable in accordance with its terms.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>8.10 Involuntary Bankruptcy. </B>An involuntary bankruptcy case remains undismissed or unstayed for 60
days or, if earlier, an order granting the relief sought is entered.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>8.11 Voluntary Bankruptcy or Insolvency. </B>Borrower commences a voluntary case under applicable
bankruptcy or insolvency law, consents to the entry of an order for relief in an involuntary case
under any such law, or consents or is subject to the appointment of or taking possession by a
receiver, liquidator, assignee, trustee, custodian or other similar official of Borrower or any
substantial part of its property, or makes an assignment for the benefit of creditors, or fails
generally or admits in writing to its inability to pay its debts as they become due, or takes any
corporate action in furtherance of any of the foregoing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>8.12 Merger without Assumption. </B>Borrower or all or substantially all of Borrower&#146;s assets are
acquired by or merged into any other business entity where more than 50% of Borrower&#146;s voting power
is transferred by existing shareholders of Borrower, and such acquirer or resulting entity either:
<b>(i)</b>&nbsp;does not pay off the Obligations at the closing of
the acquisition, merger or sale; or <b>(ii)</b>
does not provide an unconditional, unlimited guaranty of the Obligations in form and substance
satisfactory to Lender and is of a credit quality unacceptable to Lender.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>8.13
Liquidation Event. </B>Borrower consummates a Liquidation Event where the acquirer or resulting
entity either: <b>(i)</b>&nbsp;does not pay off the Obligations at the closing of the acquisition, merger or
sale; or <b>(ii)</b>&nbsp;does not provide an unconditional, unlimited guaranty of the Obligations in form and
substance satisfactory to Lender and is of a credit quality unacceptable to Lender.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>8.14 General Electric Capital Corporation Indebtedness. </B>The outstanding principal balance of
Borrower owed to General Electric Capital Corporation in connection with any equipment financing
shall be greater than $2,500,000 at any time after December&nbsp;31, 2006.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>9. </B><FONT style="font-variant: SMALL-CAPS"><B>Lender&#146;s Rights and Remedies</B></FONT>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

</div>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<div style="border: 1px solid black; padding: 11px">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>9.1 Rights and Remedies. </B>Upon the occurrence and continuance of any Event of Default, Lender
may, at its election, without notice of election and without demand, do any one or more of the
following, all of which are authorized by Borrower: <b>(i)</b>&nbsp;accelerate and declare the Loan and all
Obligations immediately due and payable; <b>(ii)</B>&nbsp;make such payments and do such acts as Lender
considers necessary or reasonable to protect its security interest in the Collateral, with such
amounts becoming Obligations bearing interest at the Default Rate;
<b>(iii)</b>&nbsp;exercise any and all other
rights and remedies available under the UCC or otherwise; <b>(iv)</b>&nbsp;require Borrower to assemble the
Collateral at such places as Lender may designate; <b>(v)</b>&nbsp;enter premises where any Collateral is
located, take, maintain possession of, or render unusable the
Collateral or any part of it; <b>(vi)</b>
without notice to Borrower, set off and recoup against any portion of
the Obligations; <b>(vii)</b>&nbsp;ship,
reclaim, recover, store, finish, maintain, repair, prepare for sale, advertise for sale, and sell
the Collateral, in connection with which Borrower hereby grants Lender a license to use without
charge Borrower&#146;s premises, labels, name, trademarks, and other property necessary to complete,
advertise, and sell any Collateral; and <b>(viii)</b>&nbsp;sell the Collateral at one or more public or private
sales.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>9.2 Power of Attorney in Respect of the Collateral. </B>Borrower hereby irrevocably appoints Lender
(which appointment is coupled with an interest) its true and lawful attorney in fact with full
power of substitution, for it and in its name to, during the
existence of an Event of Default: <b>(i)</b>
ask, demand, collect, receive, sue for, compound and give acquittance for any and all Collateral
with full power to settle, adjust or compromise any claim, <b>(ii)</b>&nbsp;receive payment of and endorse the
name of Borrower on any items of Collateral, <b>(iii)</b>&nbsp;make all demands, consents and waivers, or take
any other action with respect to, the Collateral, <b>(iv)</b>&nbsp;file any claim or take any other action, in
Lender&#146;s or Borrower&#146;s name, which Lender may reasonably deem appropriate to protect its rights in
the Collateral, or <b>(v)</b>&nbsp;otherwise act with respect to the Collateral as though Lender were its
outright owner.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>9.3 Charges. </B>If Borrower fails to pay any amounts required hereunder to be paid by Borrower to any
third party, Lender may at its option pay any part thereof and any amounts so paid including
Lender&#146;s Expenses incurred shall become Obligations, immediately due and payable, bearing interest
at the Default Rate, and secured by the Collateral. Any such payments by Lender shall not
constitute an agreement to make similar payments or a waiver of any Event of Default.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>9.4 Remedies Cumulative. </B>Lender&#146;s rights and remedies under the Loan Documents and all other
agreements with Borrower shall be cumulative. Lender shall have all other rights and remedies as
provided under the UCC, by law, or in equity. No exercise by Lender of one right or remedy shall be
deemed an election, and no waiver by Lender of any Event of Default shall be deemed a continuing
waiver. No delay by Lender shall constitute a waiver, election, or acquiescence.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>9.5 Application of Collateral Proceeds. </B>Lender will apply proceeds of sale, to the extent
actually received in cash, in the manner and order it determines in its sole discretion, and as
prescribed by applicable law.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>10. </B><FONT style="font-variant: SMALL-CAPS"><B>Waivers; Indemnification</B></FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>10.1 Waivers. </B>Without limiting the generality of the other waivers made by Borrower herein, to the
maximum extent permitted under applicable law, Borrower hereby irrevocably waives all of the
following: <b>(i)</b>&nbsp;any right to assert <I>against Lender </I>as a defense, counterclaim, set-off or
crossclaim, any defense (legal or equitable), set-off, counterclaim, crossclaim and/or other claim
(a)&nbsp;which Borrower may now or at any time hereafter have against any party liable to Lender in any
way or manner, or (b)&nbsp;arising directly or indirectly from the present or future lack of perfection,
sufficiency, validity and/or enforceability of any Loan Document, or
any security interest; <b>(ii)</b>
notice of presentment, dishonor, notice of intent to accelerate, protest, default, nonpayment,
maturity; <b>(iii)</b>&nbsp;the benefit of all marshalling,
valuation, appraisal and exemption laws; <b>(iv)</b>&nbsp;the
right, if any, to require Lender to (a)&nbsp;proceed against any person liable for any of the
Obligations as a condition to or before proceeding hereunder; or (b)&nbsp;foreclose upon, sell or
otherwise realize upon or collect or apply any other property, real or personal, securing any of
the Obligations, as a condition to, or before proceeding hereunder;
<b>(v)</b>&nbsp;any demand for possession
before the commencement of any suit or action to recover possession
of Collateral; and <b>(vi)</b>&nbsp;any
requirement that Lender retain possession and not dispose of Collateral until after trial or final
judgment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>10.2 Lender&#146;s Liability for Collateral. </B>Lender shall not in any way or manner be liable or
responsible for: <b>(i)</b>&nbsp;the safekeeping of any Collateral (except to the extent mandated by the UCC);
<b>(ii)</b>&nbsp;any loss or damage thereto occurring or arising in
any manner or fashion from any cause; <b>(iii)</b>
any diminution in the value thereof; or <b>(iv)</b>&nbsp;any act or default of any carrier, warehouseman,
bailee, forwarding agency, or other person or entity whomsoever. All risk of loss, damage or
destruction of the Collateral shall be borne by Borrower. Lender will have no responsibility for
taking any steps to preserve rights against any parties respecting any Collateral. Lender&#146;s powers
hereunder are conferred solely to protect its interest in the Collateral and do not impose any duty
to exercise any such powers. None of Lender or any of its officers, directors, employees, agents or
counsel will be liable for any action lawfully taken or omitted to be taken hereunder or in
connection herewith (excepting gross negligence or willful misconduct), nor under any circumstances
have any liability to Borrower for lost profits or other special, indirect, punitive, or
consequential damages. Lender retains any documents delivered by Borrower only for its purposes and
for such period as Lender, at its sole discretion, may determine necessary, after which time Lender
may destroy such records without notice to or consent from Borrower.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

</div>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<div style="border: 1px solid black; padding: 11px">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>10.3 Indemnification. </B>Borrower shall, on an after tax basis, defend, indemnify, and
hold Lender and each of its officers, directors, employees, counsel, partners, agents and
attorneys-in-fact (each, an <I>&#147;Indemnified Person&#148;) </I>harmless from and against any and all
liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, charges,
expenses or disbursements (including Lender&#146;s Expenses and reasonable attorney&#146;s fees and the
allocated cost of in-house counsel) of any kind or nature whatsoever with respect to the execution,
delivery, enforcement, performance and administration of this Agreement and any other Loan
Documents, or the transactions contemplated hereby and thereby, with respect to noncompliance with
laws or regulations respecting Regulated Substances, government secrecy or technology export, or
any Lien not created by Lender or right of another against any Collateral, even if the Collateral
is foreclosed upon or sold pursuant hereto, and with respect to any investigation, litigation or
proceeding before any agency, court or other governmental authority relating to this Agreement or
the Advances or the use of the proceeds thereof, whether or not any Indemnified Person is a party
thereto (all the foregoing, collectively, the <I>&#147;Indemnified Liabilities&#148;); provided, </I>that Borrower
shall have no obligation hereunder to any Indemnified Person with respect to Indemnified
Liabilities arising from the gross negligence or willful misconduct of such Indemnified Person. The
obligations in this Section shall survive the Term. At the election of any Indemnified Person,
Borrower shall defend such Indemnified Person using legal counsel satisfactory to such Indemnified
Person, at the sole cost and expense of Borrower. All amounts owing under this Section shall be
paid within 30&nbsp;days after written demand.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>11. </B><FONT style="font-variant: SMALL-CAPS"><B>Notices</B></FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All notices shall be in writing and personally delivered or sent by certified mail, postage
prepaid, return receipt requested, or by confirmed facsimile, at the respective addresses set
forth below:
</DIV>
<DIV align="left">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="96%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">If to Borrower:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">If to Lender:</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Fluidigm Corporation
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Lighthouse Capital Partners V, LP</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">7100 Shoreline Court
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">500 Drake&#146;s Landing Road</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">South San Francisco, California 94080
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Greenbrae, California 94904</TD>
</TR>
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Attention:
General Counsel,</div>
<DIV style="margin-left:60px; text-indent:-0px">Director of
Finance</div>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention: Contract Administrator</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">FAX: (650)871-7152
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">FAX: (415)925-3387</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>12. </B><FONT style="font-variant: SMALL-CAPS"><B>General Provisions</B></FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>12.1 Successors and Assigns. </B>This Agreement shall bind and inure to the benefit of the parties&#146;
respective successors and permitted assigns. Borrower may not assign any rights hereunder without
Lender&#146;s prior written consent, which consent may be granted or withheld in Lender&#146;s sole
discretion. Lender shall have the right without the consent of or notice to Borrower to sell,
transfer, negotiate, or grant participations in all or any part of any Loan Document, <I>provided </I>that
Lender shall not sell, transfer, negotiate, or grant participations in all or any part of any Loan
Document to any competitor of Borrower.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>12.2 Time of Essence. </B>Time is of the essence for the performance of all Obligations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>12.3 Severability of Provisions. </B>Each provision hereof shall be severable from every other
provision in determining its legal enforceability.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>12.4 Entire Agreement. </B>This Agreement and each of the other Loan Documents dated as of the date
hereof, taken together, constitute and contain the entire agreement between Borrower and Lender
with respect to their subject matter and supersede any and all prior agreements, negotiations,
correspondence, understandings and communications between the parties, whether written or oral.
This Agreement is the result of negotiations between and has been reviewed by the Borrower and
Lender as of the date hereof and their respective counsel; <I>accordingly, </I>this Agreement shall be
deemed to be the product of the parties hereto, and no ambiguity shall be construed in favor of or
against Borrower or Lender. This Agreement may only be modified with the written consent of Lender.
Any waiver or consent with respect to any provision of the Loan Documents shall be effective only
in the specific instance and for the specific purpose for which it was given. No notice to or
demand on Borrower in any one case shall entitle Borrower to any other or further notice or demand
in similar or other circumstances.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>12.5 Reliance by Lender. </B>All covenants, agreements, representations and warranties made herein
by Borrower shall, notwithstanding any investigation by Lender, be deemed to be material to and to
have been relied upon by Lender.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>12.6 No Set-Offs by Borrower. </B>All sums payable by Borrower pursuant to this Agreement or any of the
other Loan Documents shall be payable without notice or demand and shall be payable in United
States Dollars without set-off or reduction of any manner whatsoever.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

</div>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<div style="border: 1px solid black; padding: 11px">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>12.7 Counterparts</B>. This Agreement may be executed in any number of counterparts, each
of which shall be deemed to be an original, and all of which, when taken together, shall constitute
one and the same original instrument.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>12.8 Survival. </B>All covenants, representations and warranties made in this Agreement shall continue
in full force and effect so long as any Obligations (other than inchoate indemnity obligations)
remain outstanding.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><b>12.9 No
Original Issue Discount.</b> Borrower and Lender acknowledge and agree that the Warrant is part
of an investment unit within the meaning of Section&nbsp;1273(c)(2) of the Internal Revenue Code, which
includes the Loan. Borrower and Lender further agree as between them, that the fair market value of
the Warrant is $100 and that, pursuant to Treas. Reg. &#167; 1.1273-2(h), $100 of the issue price of the
investment unit will be allocable to the Warrant and the balance shall be allocable to the Loans.
Borrower and Lender agree to prepare their federal income tax returns in a manner consistent with
the foregoing and, pursuant to Treas. Reg. &#167; 1.1273, the original issue discount on the Loan shall
be considered to be zero.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>12.10 Relationship of Parties. </B>The relationship between Borrower and Lender is, and at all times
shall remain, solely that of a borrower and lender. Lender is not a partner or joint venturer of
Borrower; nor shall Lender under any circumstances be deemed to be in a relationship of confidence
or trust or have a fiduciary relationship with Borrower or any of its affiliates, or to owe any
fiduciary duty to Borrower or any of its affiliates. Lender does not undertake or assume any
responsibility or duty to Borrower or any of its affiliates to select, review, inspect, supervise,
pass judgment upon or otherwise inform any of them of any matter in connection with its or their
property, the Loans, any Collateral or the operations of Borrower or any of its affiliates.
Borrower and each of its affiliates shall rely entirely on their own judgment with respect to such
matters, and any review, inspection, supervision, exercise of judgment or supply of information
undertaken or assumed by Lender in connection with such matters is solely for the protection of
Lender and neither Borrower nor any affiliate is entitled to rely thereon.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>12.11
Choice of Law and Venue; Jury
Trial Waiver.<FONT style="font-variant: SMALL-CAPS"> This Agreement shall be governed by and construed in
accordance with, the internal laws of the State of California,
without regard to principles of conflicts of law. Each of Borrower
and Lender hereby submits to the exclusive jurisdiction of the State
and Federal courts located in the City and County of San Francisco,
State of California. Borrower and lender hereby waive their
respective rights to a jury trial of any claim or cause of action
based upon or arising out of any of the Loan Documents or any of the
transactions contemplated therein, including contract claims, tort
claims, breach of duty claims, and all other common law or statutory
claims. Each party further waives any right to consolidate any action
in which a jury trial has been waived with any other action in which
a jury trial cannot be or has not been waived.</FONT></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>12.12 Termination. </B>Upon the full, faithful and indefeasible payment and performance of all
Obligations(other than inchoate indemnity obligations) and the termination of any commitment to
extend credit under this Agreement, the security interest granted herein and under the other Loan
Documents shall terminate and this Agreement and the other Loan Documents (other than the Warrant)
shall terminate, except for any inchoate indemnity obligations under
<b>Section&nbsp;10.3</b> of this
Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>In
Witness Whereof, </B></font>the parties hereto have executed this Agreement as of the date first above written.
</DIV>
<DIV align="left">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="95%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm
Corporation</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital Partners </B></FONT><B>V, L.P.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>

<TD nowrap align="left" valign="top"><FONT style="font-variant: SMALL-CAPS"><B>Lighthouse
Management Partners </B></FONT><B>V, L.L.C.,</B> <BR>
its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gajus Worthington
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Thomas Conneely
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Name:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"> Gajus Worthington</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Thomas Conneely</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top">PRESIDENT &#38; CEO</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">
Exhibit A&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Collateral Description<BR>
Exhibit&nbsp;B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form of Note<BR>
Exhibit&nbsp;C&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form of Preferred Stock Warrant<BR>
Exhibit&nbsp;D&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form of Notice of Borrowing<BR>
Exhibit&nbsp;E&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form of Incumbency Certificate<BR>
Exhibit&nbsp;F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form of Officers Certificate<BR>
Exhibit&nbsp;G&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ACH Authorization<BR>
Exhibit&nbsp;H&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form of Negative Pledge Agreement<BR>
Exhibit&nbsp;I&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Control Agreement

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>



</div>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="width: 99%; border: 1px solid black; padding: 11px">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Exhibit </B></FONT><b>A</b></div>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Collateral</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This FINANCING STATEMENT and SECURITY AGREEMENT covers all of Debtor&#146;s interests in all of the
following types or items of property described on this <B>Exhibit&nbsp;A </B>(collectively, the <I>&#147;Collateral&#148;),</I>
wherever located and whether now owned or hereafter acquired, and Debtor hereby grants Secured
Party a security interest therein as collateral for the payment and performance of all present and
future indebtedness, liabilities, guarantees and obligations of Debtor to Secured Party, howsoever
arising. Debtor agrees that said security interest may be enforced by Secured Party in accordance
with the terms of all security and other agreements between Secured Party and Debtor, the
California Uniform Commercial Code, or both, and that this document shall be fully effective as a
security agreement, even if there is no other security or other agreement between Secured Party or
Debtor:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All assets of the Debtor; all personal property of Debtor;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All &#147;accounts&#148;, &#147;general intangibles&#148;, &#147;chattel paper&#148;, &#147;contract rights&#148;, &#147;documents&#148;,
&#147;instruments&#148;, &#147;deposit accounts&#148;, &#147;inventory&#148;, &#147;farm products&#148;, &#147;fixtures&#148; and &#147;equipment&#148;, as
such terms are defined in Division 9 of the California Uniform Commercial Code in effect on the
date hereof;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All general intangibles of every kind, including without limitation, federal, state and local tax
refunds and claims of all kinds; all rights as a licensee or any kind; all customer lists,
telephone numbers, and purchase orders, and all rights to purchase, lease sell, or otherwise
acquire or deal with real or personal property and all rights relating thereto;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All returned and repossessed goods and all rights as a seller of goods; all collateral securing
any of the foregoing; all deposit accounts, special and general, whether on deposit with Secured
Party or others;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All life and other insurance policies, claims in contract, tort or otherwise, and all judgments now
or hereafter arising therefrom;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All right, title and interest of Debtor, and all of Debtor&#146;s rights, remedies, security and liens,
in, to and in respect of all accounts and other collateral, including, without limitation, rights
of stoppage in transit, replevin, repossession and reclamation and other rights and remedies of an
unpaid vendor, lienor or secured party, and all guarantees and other contracts of suretyship with
respect to any accounts and other collateral, and all deposits and other security for any accounts
and other collateral, and all credit and other insurance;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All notes, drafts, letters of credit, contract rights, and things in action; all drawings,
specifications, blueprints and catalogs; and all raw materials, work in process, materials used or
consumed in Debtor&#146;s business, goods, finished goods, returned goods and all other goods and
inventory of whatsoever land or nature, any and all wrapping, packaging, advertising and shipping
materials, and all documents relating thereto, and all labels and other devices, names and marks
affixed or to be affixed thereto for purposes of selling or identifying the same or the seller or
manufacturer thereof;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All inventory wherever located; all present and future claims against any supplier of any of the
foregoing, including claims for defective goods or overpayments to or undershipments by suppliers;
all proceeds arising from the lease or rental of any of the foregoing;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All equipment and fixtures, including without limitation all machinery, machine tools, motors,
controls, parts, vehicles, workstations, tools, dies, jigs, furniture, furnishings and fixtures;
and all attachments, accessories, accessions and property now or hereafter affixed to or used in
connection with any of the foregoing, and all substitutions and replacements for any of the
foregoing; all warranty and other claims against any vendor or lessor of any of the foregoing;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All investment property;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All books, records, ledger cards, computer data and programs and other property and general
intangibles at any time evidencing or relating to any or all of the foregoing; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All cash and non-cash products and proceeds of any of the foregoing, in whatever form, including
proceeds in the form of inventory, equipment or any other form of personal property, including
proceeds of proceeds and proceeds of insurance, and all claims by Debtor against third parties for
loss or damage to, or destruction of, or otherwise relating to, any or all of the foregoing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">NOTICE &#151; PURSUANT TO AN AGREEMENT BETWEEN DEBTOR AND SECURED PARTY, DEBTOR HAS AGREED NOT TO
FURTHER ENCUMBER THE COLLATERAL DESCRIBED HEREIN (EXCEPT AS EXPRESSLY PERMITTED PURSUANT TO SUCH
AGREEMENT), THE FURTHER ENCUMBERING OF WHICH MAY CONSTITUTE THE TORTIOUS INTERFERENCE
</DIV>
<DIV align="center" style="font-size: 10pt; margin-top: 6pt">1</div>
</div>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="width: 99%; border: 1px solid black; padding: 11px">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">WITH SECURED PARTY&#146;S RIGHTS BY SUCH ENCUMBRANCER. IN THE EVENT THAT ANY ENTITY IS GRANTED A
SECURITY INTEREST IN DEBTOR&#146;S ACCOUNTS, CHATTEL PAPER, GENERAL INTANGIBLES OR OTHER ASSETS CONTRARY
TO THE ABOVE, THE SECURED PARTY ASSERTS A CLAIM TO ANY PROCEEDS THEREOF RECEIVED BY SUCH ENTITY.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Notwithstanding any of the foregoing, this Financing Statement and Security Agreement does not
cover any of Debtor&#146;s interests in, and the Collateral shall not under any circumstance include,
and no security interest is granted in, (i)&nbsp;any property that is subject to a Lien that is
otherwise permitted pursuant to subsection (v)&nbsp;of the definition of &#147;Permitted Liens&#148; as defined
in that certain Loan and Security Agreement, dated as of March&nbsp;29, 2005, by and between Secured
Party and Debtor, and Secured Party agrees to execute any instruments or documents necessary to
evidence the intent of the foregoing, (ii)&nbsp;more than 65% of the issued and outstanding voting
securities of any subsidiary of Debtor that is not incorporated or organized in the United States,
or (iii)&nbsp;Debtor&#146;s Intellectual Property, including, without limitation, any and all property of
the Debtor that is subject to, listed in or otherwise described in the Negative Pledge Agreement
dated March&nbsp;29, 2005 between the Secured Party and the Debtor. <I>&#147;Intellectual Property&#148; </I>means,
collectively, all rights, priorities and privileges of the Debtor relating to intellectual
property, in any medium, of any kind or nature whatsoever, now or hereafter owned or acquired or
received by Debtor, or in which Debtor now holds or hereafter acquires or receives any right or
interest, whether arising under United States, multinational or foreign laws or otherwise, and
shall include, in any event, all copyrights, copyright licenses, patents, patent licenses,
trademarks, trademark licenses, trade secrets, internet domain names (including any right related
to the registration thereof), proprietary or confidential information, mask works, sources object
or other programming codes, inventions (whether or not patented or patentable), technical
information, procedures, designs, knowledge, know-how, software, data base, data, skill,
expertise, recipe, experience, process, models, drawings, materials or records. Notwithstanding
the foregoing, Intellectual Property as defined above does not include proceeds or other revenue
consisting of accounts, accounts receivable, royalties, licensing fees, or payment intangibles
obtained or owed from or on account of the licensing or other exploitation or disposition of
Intellectual Property, none of which are excluded, and all of which are included as collateral in
the security interest granted by Debtor to Secured Party.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD colspan="3" valign="top" align="left"><B>&#147;<FONT style="font-variant: SMALL-CAPS">Debtor</font>&#148;</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD colspan="3" valign="bottom" align="left"><FONT style="font-variant: SMALL-CAPS"><B>&#147;Secured
Party&#148;</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation, </B></FONT>a California corporation</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="left" valign="bottom"><FONT style="font-variant: SMALL-CAPS"><b>Lighthouse Capital Partners V, L.P.</b></font></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-variant: SMALL-CAPS"><B>By:</B></font>
</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="bottom"><FONT style="font-variant: SMALL-CAPS"><B>Lighthouse
Management Partners V, L.L.C.,</B></font><br>
its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Name:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">By:</TD>
    <TD>&nbsp;</TD>

<TD align="right" valign="bottom"><DIV style="font-size: 1px; border-bottom: 1px solid #000000">&nbsp;</DIV></td>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">Name:</TD>
    <TD>&nbsp;</TD>
<TD align="right" valign="bottom"><DIV style="font-size: 1px; border-bottom: 1px solid #000000">&nbsp;</DIV></td>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>

<TD align="right" valign="top"><DIV style="font-size: 1px; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

</div>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV style="width: 99%; border: 1px solid black; padding: 11px">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Exhibit </B></FONT><b>B</b>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#091;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&#093;

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Secured Promissory Note</B></FONT>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This
<FONT style="font-variant: SMALL-CAPS">Secured Promissory Note
</FONT>(this <I>&#147;Note&#148;) </I>is made
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,
200<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>,
by <FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation
(</B>&#147;</FONT><I>Borrower&#148;) </I>in favor
of <FONT style="font-variant: SMALL-CAPS"><B>Lighthouse
</B><B>Capital Partners</b></FONT> <B>V, L.P. </B>(collectively with its assigns, <I>&#147;Lender&#148;).</I>
Initially capitalized terms used and not otherwise defined herein are defined in that certain Loan
and Security Agreement No.&nbsp;4561 between Borrower and Lender
dated March&nbsp;29, 2005 (the <I>&#147;Loan
Agreement&#148;).</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS">For Value Received, </FONT>Borrower promises to pay in lawful money of the United States, to the
order of Lender, at 500 Drake&#146;s Landing Road, Greenbrae, California 94904, or such other place as
Lender may from time to time designate <I>(&#147;Lender&#146;s Office&#148;), </I>the principal
 sum of $<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> (the &#147;Advance&#148;), including interest on the unpaid balance and all other amounts due or to
become due hereunder according to the terms hereof and of the Loan Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Basic Rate&#148; </I>means a variable <I>per annum </I>rate of interest equal to the Index plus the Interest
Margin which shall be subject to adjustment as provided herein. On and after the Loan Commencement
Date the Basic Rate shall be fixed and not subject to any further adjustments.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Final Payment&#148; </I>means 9% of the Advance.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Index&#148; </I>means the prevailing variable Prime Rate of annual interest as quoted from time to time in
the western edition of the Wall Street Journal.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Interest
Margin&#148; </I>means 2.5% per annum.</div>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Loan
Commencement Date&#148; </I>means March&nbsp;1, 2006.</div>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Maturity Date&#148; </I>means the last day of the Repayment Period, or if earlier, the date of prepayment
under the Note.</div>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Payment Date&#148; </I>means the first day of each calendar month.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Prepayment
Fee&#148; </I>means (i)&nbsp;if prepaid in the calendar year 2006, 3% of the outstanding principal
amount being prepaid; (ii)&nbsp;if prepaid in the calendar year 2007, 2% of the outstanding principal
amount being prepaid; and (iii)&nbsp;if prepaid in the calendar year 2008 or 2009, 1% of the
outstanding principal amount being prepaid.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Repayment Period&#148; </I>means the period beginning on the Loan Commencement Date and continuing for 36
calendar months.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>1. Repayment. </B>Borrower shall pay principal and interest due hereunder from the Funding Date, until
this Note is paid in full, on
each Payment Date pursuant to the terms of the Loan Agreement and this Note. Prior to the Loan
Commencement Date, Borrower
shall pay to Lender, monthly in advance on each Payment Date, interest calculated using the Basic
Rate prevailing on the first business
day of such calendar month. Beginning on the Loan Commencement Date and on each Payment Date
thereafter during the Repayment
Period, Borrower shall make equal installments of principal and interest in advance, calculated at
the Basic Rate. On the Maturity
Date, Borrower shall pay, in addition to all unpaid principal and interest outstanding hereunder,
the Final Payment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>2. Interest. </B>Interest not paid when due will, to the maximum extent permitted under applicable law,
become part of principal, at
Lender&#146;s option, and thereafter bear like interest as principal. Interest shall be computed on the
basis of a 360&nbsp;day year. All
Obligations not paid when due shall bear interest at the Default Rate unless waived in writing by
Lender. All amounts paid hereunder
will be applied to the Obligations in Lender&#146;s discretion and as provided in the Loan Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>3.
Voluntary Prepayment. </B>Borrower may prepay the Note if and only if
Borrower pays to Lender <b>(i)</b>
the outstanding principal
amount of this Note and any unpaid accrued interest
<b>(ii)</b>&nbsp;the Final Payment, <b>(iv)</b>&nbsp;the Prepayment
Fee, and <b>(v)</b>&nbsp;all other sums, if any, that
shall have become due and payable hereunder with respect to this Note.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>4. Collateral. </B>This Note is secured by the Collateral.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

</div>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV style="width: 99%; border: 1px solid black; padding: 11px">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5. Waivers. </B>Borrower, and all guarantors and endorsers of this Note, regardless of the time, order or
place of signing, hereby
waive notice, demand, presentment, protest, and notices of every kind, presentment for the purpose
of accelerating maturity, diligence
in collection to the fullest extent permitted by law.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt"><B>6.
Choice of Law; Venue. <FONT style="font-variant: SMALL-CAPS">This
Note shall be governed by, and construed in accordance with the
internal</font></B>
<FONT style="font-variant: SMALL-CAPS"><B>laws of the State of
California, without regard to principles of conflicts of law. Each of
Borrower and Lender hereby submits to the exclusive jurisdiction of
the State and Federal courts
located in the City and County of San Francisco, State of California.
Borrower and Lender each
hereby waive their respective rights to a jury trial of any claim or cause of action based upon or
arising out of this Note. Each party further waives any right to consolidate any action in which a
jury trial has been waived with any other action in which a jury trial cannot be or has not been
waived.</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>7.
Miscellaneous. </B> The Note <FONT style="font-variant: SMALL-CAPS">
may be modified only by </FONT>
<FONT style="font-variant: SMALL-CAPS">a writing signed by Borrower and
Lender. </FONT>Each provision hereof is severable from every other provision hereof and of the Loan Agreement when determining its
legal enforceability. Sections and
subsections are titled for convenience, and not for construction. &#147;Hereof,&#148; &#147;herein,&#148; &#147;hereunder,&#148;
and similar words refer to this Note
in its entirety. &#147;Or&#148; is not necessarily&#146; exclusive. &#147;Including&#148; is not limiting. The terms and
conditions hereof inure to the benefit of
and are binding upon the parties&#146; respective permitted successors and assigns. This Note is subject
to all the terms and conditions of
the Loan Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS">In Witness Whereof</FONT>, Borrower has caused this Note to be executed by a duly authorized
officer as of the day and year first above written.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="38%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV></td>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV></td>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV></td>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

</div>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV style="width: 99%; border: 1px solid black; padding: 11px">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Exhibit
</B></FONT><b>C</b></div>
<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Warrants</B></FONT>
</DIV>



<P align="center" style="font-size: 10pt; margin-top: 18pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

</div>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">NEITHER THIS WARRANT NOR THE SHARES OF CAPITAL STOCK ISSUABLE UPON EXERCISE HEREOF HAVE BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
<I>&#147;1933 ACT&#148;), </I>OR ANY APPLICABLE STATE
SECURITIES LAWS. SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED UNLESS SUCH SALE OR TRANSFER IS IN
ACCORDANCE WITH THE REGISTRATION REQUIREMENTS OF SUCH ACT AND APPLICABLE LAWS OR THE COMPANY HAS
RECEIVED AN OPINION OF COUNSEL, REASONABLY ACCEPTABLE TO THE COMPANY, TO THE EFFECT THAT SUCH SALE
OR TRANSFER IS EXEMPT FROM THE REGISTRATION REQUIREMENTS OF SUCH ACT AND APPLICABLE LAWS.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">PREFERRED STOCK PURCHASE WARRANT
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="55%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Warrant No.<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">Number of Shares: initially, 185,714</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">Series&nbsp;D Preferred Stock</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">subject to increase as set forth below</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><b>Fluidigm
Corporation</b></FONT>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Effective
as of March&nbsp;29, 2005

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Void after March&nbsp;29, 2012

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.&nbsp;Issuance</B>.
This Preferred Stock Purchase Warrant (the <I>&#147;Warrant&#148;)
</I>is issued to <FONT style="font-variant: SMALL-CAPS"><b>Lighthouse
Capital Partners </b></FONT><b>V, L.P.</b> by <FONT style="font-variant: SMALL-CAPS">
<b>Fluidigm Corporation,</b> </FONT>a California corporation
(hereinafter with its successors
called the <I>&#147;Company&#148;).</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.&nbsp;Purchase Price; Number of Shares.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>The registered holder of this Warrant (the <I>&#147;Holder&#148;), </I>commencing on the date hereof, is
entitled upon surrender of this Warrant with the subscription form annexed hereto duly executed, at the
principal office of the Company, to purchase from the Company, at a price per share of $2.80 (the <I>&#147;Purchase
Price&#148;), </I>185,714 fully
paid and nonassessable shares of the Company&#146;s Series&nbsp;D Preferred Stock, (the <I>&#147;Exercise
Quantity&#148;), </I>$0.001 par
value (the <I>&#147;Preferred Stock&#148;).</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>On the Commitment Termination Date, the Exercise Quantity shall automatically be increased
by
such additional number of shares (rounded to the nearest whole share) of Series&nbsp;D Preferred
Stock, if any, as is equal
to the amount determined by dividing (A)&nbsp;4% of the Aggregate Advances under the Loan
Agreement, if any, by (B)
the Purchase Price
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In addition to other terms which may be defined herein, the following terms, as used in this
Warrant, shall have the following meanings:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>(i)</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#147;Aggregate Advances&#148; means the aggregate original dollar amount of all
Advances made under the Loan Agreement, whether such Advances are outstanding or
prepaid, at the time of any scheduled adjustment to the Exercise Quantity.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>(ii)</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#147;Loan Agreement&#148; means that certain Loan and Security Agreement No.&nbsp;4561 dated
March&nbsp;29, 2005 between the Company and Lighthouse Capital Partners V, L.P..</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Any capitalized term not defined herein shall have the meaning as set forth in the Loan Agreement.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->1.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Until such time as this Warrant is exercised in full or expires, the Purchase Price and the
securities issuable upon exercise of this Warrant are subject to adjustment as hereinafter
provided. The person or persons in whose name or names any certificate representing shares of
Preferred Stock is issued hereunder shall be deemed to have become the holder of record of the
shares represented thereby as at the close of business on the date this Warrant is exercised with
respect to such shares, whether or not the transfer books of the Company shall be closed.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.&nbsp;</B><b>Payment
of Purchase Price.</b> The Purchase Price may be paid (i)&nbsp;in cash or by check, (ii)&nbsp;by
the
surrender by the Holder to the Company of any promissory notes or other obligations issued by
the Company, with
all such notes and obligations so surrendered being credited against the Purchase Price in an
amount equal to the
principal amount thereof plus accrued interest to the date of surrender, or (iii)&nbsp;by any
combination of the foregoing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>4</B>.&nbsp;<b>Net
Issue Election.</b> The Holder may elect to receive, without the payment by the Holder of
any
additional consideration, shares of Preferred Stock equal to the value of this Warrant or any
portion hereof by the
surrender of this Warrant or such portion to the Company, with the net issue election notice
annexed hereto duly
executed, at the principal office of the Company. Thereupon, the Company shall issue to the
Holder such number of
fully paid and nonassessable shares of Preferred Stock as is computed using the following
formula:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><I>X</I><SUB style="font-size: 85%; vertical-align: text-bottom"><I>=</I></SUB>
</TD>

    <TD colspan="2" align="center" valign="top"><I>Y(A-B)</I>
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
A<I></I>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="83%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">where:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">X =
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">the number of shares of Preferred Stock to be issued to the
Holder pursuant to this <b>Section&nbsp;4.</b></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Y =
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">the number of shares of Preferred Stock covered by this
Warrant in respect of which the net issue election is made
pursuant to this <b>Section&nbsp;4.</b></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">A =
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">the Fair Market Value (defined below) of one share of
Preferred Stock, as determined at the time the net issue
election is made pursuant to this <b>Section&nbsp;4.</b></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">B =
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">the Purchase Price in effect under this Warrant at the time
the net issue election is made pursuant to this <b>Section&nbsp;4.</b></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;Fair <I>Market Value&#148; </I>of a share of Preferred Stock (or fully paid and nonassessable shares of
the Company&#146;s common stock, $0.001 par value (the <I>&#147;Common Stock&#148;) </I>if the Preferred Stock has been
automatically converted into Common Stock) as of the date that the net issue election is made (the
<I>&#147;Determination Date&#148;) </I>shall mean:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i) </B>If the net issue election is made in connection with and contingent upon the closing of the
sale of the Company&#146;s Common Stock to the public in a public offering pursuant to a Registration
Statement under the Securities Act of 1933, as amended (a <I>&#147;Public Offering&#148;), </I>and if the Company&#146;s
Registration Statement relating to such Public Offering <I>(&#147;Registration Statement&#148;) </I>has been
declared effective by the Securities and Exchange Commission, then the initial &#147;Price to Public&#148;
specified in the final prospectus with respect to such offering multiplied by the number of shares
of Common Stock into which each share of Preferred Stock is then convertible.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ii) </B>
If the net issue election is not made in connection with and
contingent upon a Public Offering, then as follows:</div>


<!-- link3 " (ii)&nbsp;If the net issue election is not made in connection with and contingent upon a Public Offering, then as follows:" -->

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>If traded on a securities exchange or the Nasdaq National Market, the fair
market value of the Common Stock shall be deemed to be the average of the closing or last reported
sale prices of the Common Stock on such exchange or market over the five day period ending five
trading days prior to the Determination Date, and the fair market value of the Preferred Stock
shall be deemed to be such fair market value of the Common Stock multiplied by the number of
shares of Common Stock into which each share of Preferred Stock is then convertible;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>If otherwise traded in an over-the-counter market, the fair market value
of the
Common Stock shall be deemed to be the average of the closing ask prices of the Common Stock over
the five day period ending five trading days prior to the Determination Date, and the fair market
value of the Preferred Stock shall be deemed to be such fair market value of the Common Stock
multiplied by the number of shares of Common Stock into which each share of Preferred Stock is then
convertible; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>If
there is no public market for the Common Stock, then fair market value shall
be determined in good faith by the Company&#146;s Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.&nbsp;Partial Exercise. </B>This Warrant may be exercised in part, and the Holder shall be entitled
to
receive a new warrant, which shall be dated as of the date of this Warrant, covering the
number of shares in respect
of which this Warrant shall not have been exercised.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>6.&nbsp;Fractional Shares. </B>In no event shall any fractional share of Preferred Stock be issued upon
any
exercise of this Warrant. If, upon exercise of this Warrant in its entirety, the Holder would,
except as provided in
this <B>Section&nbsp;6, </B>be entitled to receive a fractional share of Preferred Stock, then the Company
shall issue the next
higher number of full shares of Preferred Stock, issuing a full share with respect to such
fractional share.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>7.&nbsp;Expiration Date; Automatic Exercise. </B>This Warrant shall expire at the close of
business on
March&nbsp;29, 2012, and shall be void thereafter (the <I>&#147;Expiration Date&#148;). </I>Notwithstanding the
term of this Warrant
fixed pursuant to this <B>Section 7,</B> and provided Holder has received advance written notice of
at least twenty (20)
days and has not earlier exercised this Warrant, and provided this Warrant has not been
assumed by the successor
entity (or parent thereof), upon the consummation of a Merger (as defined below), this Warrant
shall automatically
be exercised pursuant to <B>Section&nbsp;4 </B>hereof, without any action by Holder. <I>&#147;Merger&#148; </I>means: (i)
a sale of all or
substantially all of the Company&#146;s assets to an Unaffiliated Entity (as defined below), or
(ii)&nbsp;the merger,
consolidation or acquisition of the Company with, into or by an Unaffiliated Entity (other
than a merger or
consolidation for the principle purpose of changing the domicile of the Company or a bona fide
round of preferred
stock equity financing), that results in the Company&#146;s shareholders immediately prior to such
merger, consolidation,
or acquisition holding, immediately thereafter, less than a majority of the outstanding
voting securities of the
successor corporation or its parent. <I>&#147;Unaffiliated Entity&#148; </I>means any entity that is owned or
controlled by parties
who own less than twenty percent (20%) of the combined voting power of the voting securities
of the Company
immediately prior to such merger or sale of assets, consolidation or acquisition.
Notwithstanding the foregoing, in
the event that any outstanding warrants to purchase equity securities of the Company (it being
acknowledged and
agreed that options to acquire common stock issued to officers, directors, employees and
consultants shall not be
deemed &#147;warrants&#148;) are assumed by the successor entity of a Merger (or parent thereof), this
Warrant shall also be
similarly assumed and the automatic exercise provision in this <B>Section 7</B> shall have no effect.
The Company agrees
to give the Holder written notice promptly after it has entered into a definitive agreement
relating to any proposed
Merger and written notice of termination of any definitive agreement relating to any proposed
Merger.
Notwithstanding anything to the contrary in this Warrant, (i)&nbsp;the Holder may expressly make
any voluntary exercise
of this Warrant contingent on, and effective immediately prior to, the consummation of such
Merger and (ii)&nbsp;any
automatic exercise of this Warrant in connection with a Merger shall be conditioned on
consummation of such
Merger and shall be effective immediately prior thereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>8.&nbsp;Reserved Shares; Valid Issuance. </B>The Company covenants that it will at all times from and
after
the date hereof reserve and keep available such number of its authorized shares of Preferred
Stock and Common
Stock free from all preemptive or similar rights therein, as will be sufficient to permit,
respectively, the exercise of
this Warrant in full and the conversion into shares of Common Stock of all shares of Preferred
Stock receivable
upon such exercise. The Company further covenants that such shares as may be issued pursuant
to such exercise
and/or conversion will, upon issuance, be duly and validly issued, fully paid and
nonassessable and free from all
taxes, liens and charges with respect to the issuance thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.&nbsp;Stock Splits and Dividends. </B>If after the date hereof the Company shall subdivide the
Preferred
Stock, by split-up or otherwise, or combine the Preferred Stock, or issue additional shares of
Preferred Stock in
payment of a stock dividend on the Preferred Stock, the number of shares of Preferred Stock
issuable on the exercise
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of this Warrant shall forthwith be proportionately increased in the case of a subdivision or stock
dividend, or proportionately decreased in the case of a combination, and the Purchase Price shall
forthwith be proportionately decreased in the case of a subdivision or stock dividend, or
proportionately increased in the case of a combination.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>10.&nbsp;Adjustments for Diluting Issuances. </B>The antidilution rights applicable to the Series&nbsp;D
Preferred
Stock of the Company are set forth in the Amended and Restated Articles of Incorporation, as
amended from time to
time (the <I>&#147;Articles&#148;), </I>a true and complete copy in its current form which has been made
available to Holder. Such
rights shall not be restated, amended or modified in any manner which affects the Holder
differently than the holders
of outstanding Series&nbsp;D Preferred Stock without such Holder&#146;s prior written consent. The
Company shall provide
the Holder hereof with any restatement, amendment or modification to the Articles promptly
after the same has been
made.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>11.&nbsp;Mergers and Reclassifications. (a) </B>Except as set forth in <B>Section 7,</B> If after the
date hereof the Company shall enter into any Reorganization (as hereinafter defined), then, as a
condition of such Reorganization, lawful provisions shall be made, and duly executed documents
evidencing the same from the Company or its successor shall be delivered to the Holder, so that
the Holder shall thereafter have the right to purchase, at a total price not to exceed that
payable upon the exercise of this Warrant in full, the kind and amount of shares of stock and
other securities and property receivable upon such Reorganization by a holder of the number of
shares of Preferred Stock which might have been purchased by the Holder immediately prior to such
Reorganization, and in any such case appropriate provisions shall be made with respect to the
rights and interest of the Holder to the end that the provisions hereof (including without
limitation, provisions for the adjustment of the Purchase Price and the number of shares issuable
hereunder and the provisions relating to the net issue election) shall thereafter be applicable in
relation to any shares of stock or other securities and property thereafter deliverable upon
exercise hereof. For the purposes of this <B>Section&nbsp;11, </B>the term <I>&#147;Reorganization&#148; </I>shall include
without limitation any reclassification, capital reorganization or change of the Preferred Stock
(other than as a result of a subdivision, combination or stock dividend provided for in <B>Section&nbsp;9</B>
hereof), or any consolidation of the Company with, or merger of the Company into, another
corporation or other business organization (other than a merger in which the Company is the
surviving corporation and which does not result in any reclassification or change of the
outstanding Preferred Stock), or any sale or conveyance to another corporation or other business
organization of all or substantially all of the assets of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b) </B>Notwithstanding any other provision of this Warrant, in the event of an automatic
conversion of the Company&#146;s outstanding Series&nbsp;D Preferred Stock into Common Stock in accordance
with the Company&#146;s Articles, as in effect from time to time, this Warrant shall thereafter
represent the right to acquire for the aggregate Purchase Price (as then in effect) the number of
shares of Common Stock into which the number of shares of Preferred Stock issuable upon exercise
of this Warrant would have then been convertible.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>12.&nbsp;Certificate of Adjustment. </B>Whenever the Purchase Price is adjusted, as herein provided,
the
Company shall promptly deliver to the Holder a certificate of the Company&#146;s chief financial
officer (or other
appropriate officer) setting forth the Purchase Price after such adjustment and setting forth
a brief statement of the
facts requiring such adjustment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>13.&nbsp;Notices of Record Date, Etc. </B>In the event of:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a) </B>any taking by the Company of a record of the holders of any class of securities for the
purpose of determining the holders thereof who are entitled to receive any dividend or other
distribution, or any right
to subscribe for, purchase, sell or otherwise acquire or dispose of any shares of stock of any
class or any other
securities or property, or to receive any other right;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b) </B>any reclassification of the capital stock of the Company, capital reorganization of the
Company, consolidation or merger involving the Company, or sale or conveyance of all or
substantially all of its
assets; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c) </B>any voluntary or involuntary dissolution, liquidation or winding-up of the
Company;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->4.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">then in each such event the Company will provide or cause to be provided to the Holder a written
notice thereof. Such notice shall be provided at least twenty (20)&nbsp;business days prior to the date
specified in such notice on which any such action is to be taken.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.&nbsp;Representations, Warranties and Covenants. </B>This Warrant is issued and delivered by the
Company and accepted by each Holder on the basis of the following representations, warranties
and covenants made
by the Company:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a) </B>The Company has all necessary corporate power and authority to issue, execute and
deliver this Warrant and to perform its obligations hereunder. This Warrant has been duly
authorized issued,
executed and delivered by the Company and is the valid and binding obligation of the Company,
enforceable in
accordance with its terms, except as enforceability may be limited by bankruptcy or similar
laws relating to the
enforcement of creditors&#146; rights generally.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b) </B>The shares of Preferred Stock issuable upon the exercise of this Warrant have been duly
authorized and reserved for issuance by the Company and, when issued in accordance with the
terms hereof, will be
validly issued, fully paid and nonassessable.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)
</B>The issuance, execution and delivery of this Warrant do not, and the issuance of the shares of Preferred Stock upon the exercise of this Warrant in accordance with the terms
hereof will not, (i)&nbsp;violate
or contravene the Company&#146;s Articles or by-laws, or any law, statute, regulation, rule,
judgment or order applicable
to the Company, (ii)&nbsp;violate, contravene or result in a breach or default under any contract,
agreement or instrument
to which the Company is a party or by which the Company or any of its assets are bound or
(iii)&nbsp;require the consent
or approval of or the filing of any notice or registration with any person or entity (other
than such notices or filings
as may be required under applicable securities laws).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d) </B>As long as this Warrant is, or any shares of Preferred Stock issued upon exercise of this
Warrant or any shares of Common Stock issued upon conversion of such shares of Preferred Stock
are, issued and
outstanding, the Company will provide to the Holder the financial and other information
described in that certain
Loan and Security Agreement No.&nbsp;4561 between the Company and Lighthouse Capital Partners
V, L.P. dated as of
March&nbsp;29, 2005.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e) </B>As of the date hereof, the authorized capital stock of the Company consists of (i)
65,500,000 shares of Common Stock, of which 8,909,357 shares are issued and outstanding and
185,714 shares are
reserved for issuance upon the exercise of this Warrant with respect to Common Stock and the
conversion of the
Preferred Stock into Common Stock if this Warrant is exercised with respect to Preferred
Stock, (ii)&nbsp;2,727,273
shares of Series&nbsp;A Preferred Stock, of which 2,727,273 are issued and outstanding shares,
(iii)&nbsp;6,460,675 shares of
Series&nbsp;B Preferred Stock, of which 6,460,675 are issued and outstanding shares, (iv)
20,551,163 shares of Series&nbsp;C
Preferred Stock, of which 16,364,832 are issued and outstanding shares, and (v)&nbsp;13,887,716
shares of Series&nbsp;D
Preferred Stock, of which 7,292,127 are issued and outstanding shares. Company has delivered
a capitalization
table to Holder summarizing the capitalization of the Company. At the request of Holder, not
more than once per
calendar quarter, the Company will provide Holder with a current capitalization table
indicating changes, if any, to
the number of outstanding shares of common stock and preferred stock.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>15.&nbsp;Registration Rights. </B>The Company grants to the Holder all the rights of a &#147;Holder&#148; &#091;and
an
&#147;Investor&#148;&#093; under the Company&#146;s Amended and Restated Investors&#146; Rights Agreement dated as of
December&nbsp;18,
2003 (the <I>&#147;Rights Agreement&#148;), </I>including, without limitation, the registration rights
contained therein, and agrees to
amend the Rights Agreement so that (i)&nbsp;the shares of Common Stock issuable upon conversion of
the shares of
Preferred Stock issuable upon exercise of this Warrant shall be <I>&#147;Registrable Securities,&#148; </I>and
(ii)&nbsp;the Holder shall be
a &#147;Holder&#148; &#091;and an &#147;Investor"&#093; for all purposes of such Rights Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>16.&nbsp;Amendment. </B>The terms of this Warrant may be amended, modified or waived only with the
written consent of the Holder and the Company.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->5.<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>17.&nbsp;Representations and Covenants of the Holder. </B>This Warrant has been entered into by the
Company in reliance upon the following representations and covenants of the Holder, which by its
execution hereof the Holder hereby confirms:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;Investment Purpose. </B>The right to acquire Preferred Stock or the Preferred Stock
issuable upon exercise of the Holder&#146;s rights contained herein will be acquired for investment and
not with a view to the sale or distribution of any part thereof, and the Holder has no present
intention of selling or engaging in any public distribution of the same except pursuant to a
registration or exemption.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;Accredited Investor. </B>Holder is an &#147;accredited investor&#148; within the meaning of Rule&nbsp;501 of
Regulation&nbsp;D, promulgated under the 1933 Act as presently in effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;Private Issue. </B>The Holder understands (i)&nbsp;that neither the issuance of this Warrant nor
the issuance of any shares of the Company&#146;s capital stock issuable upon exercise of the Holder&#146;s
rights contained herein has been registered under the 1933 Act or qualified under applicable state
securities laws on the ground that the issuances contemplated by this Warrant will be exempt from
the registration and qualifications requirements thereof, and (ii)&nbsp;that the Company&#146;s reliance on
such exemption is predicated on the representations of the Holderset forth in this <B>Section&nbsp;17.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;Financial Risk. </B>The Holder has such knowledge and experience in financial and business
matters as to be capable of evaluating the merits and risks of its investment and has the ability
to bear the economic risks of its investment.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>18.&nbsp;Notices, Transfers, Etc.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a) </B>Any notice or written communication required or permitted to be given to the Holder may be
given by certified mail or delivered to the Holder at the address most recently provided by the
Holder to the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b) </B>Subject to compliance with applicable federal and state securities laws, this Warrant may
be transferred by the Holder with respect to any or all of the shares purchasable hereunder. Upon
surrender of this Warrant to the Company, together with the assignment notice annexed hereto duly
executed, for transfer of this Warrant as an entirety by the Holder, the Company shall issue a new
warrant of the same denomination to the assignee. Upon surrender of this Warrant to the Company,
together with the assignment hereof properly endorsed, by the Holder for transfer with respect to a
portion of the shares of Preferred Stock purchasable hereunder, the Company shall issue a new
warrant to the assignee, in such denomination as shall be requested by the Holder hereof, and shall
issue to such Holder a new warrant covering the number of shares in respect of which this Warrant
shall not have been transferred.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c) </B>In case this Warrant shall be mutilated, lost, stolen or destroyed, the Company shall
issue a new warrant of like tenor and denomination and deliver the same (i)&nbsp;in exchange and
substitution for and upon surrender and cancellation of any mutilated Warrant, or (ii)&nbsp;in lieu of
any Warrant lost, stolen or destroyed, upon receipt of an affidavit of the Holder or other evidence
reasonably satisfactory to the Company of the loss, theft or destruction of such Warrant.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>19.&nbsp;No Impairment. </B>The Company will not, by amendment of its Articles or through any
reclassification, capital reorganization, consolidation, merger, sale or conveyance of assets,
dissolution, liquidation, issue or sale of securities or any other voluntary action, avoid or seek
to avoid the observance of performance of any of the terms of this Warrant, but will at all times
in good faith assist in the carrying out of all such terms and in the taking of all such action as
may be necessary or appropriate in order to protect the rights of the Holder. In no event shall any
reclassification, capital reorganization, consolidation, merger, sale or conveyance of assets,
dissolution, liquidation, issue or sale of securities or any other transaction be deemed an
&#147;impairment&#148; for purposes of this Section&nbsp;18 if the shares of the Company&#146;s capital stock issuable
upon exercise of this Warrant are affected thereby in the same manner as outstanding shares of such
capital stock.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>20.&nbsp;Governing Law. </B>The provisions and terms of this Warrant shall be governed by and construed
in accordance with the internal laws of the State of California without giving effect to its
principles regarding conflicts of laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>21.&nbsp;Successors and Assigns. </B>This Warrant shall be binding upon the Company&#146;s successors and
assigns and shall inure to the benefit of the Holder&#146;s successors, legal representatives and
permitted assigns.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>22.&nbsp;Business Days. </B>If the last or appointed day for the taking of any action required or the
expiration of any rights granted herein shall be a Saturday or Sunday or a legal holiday in
California, then such action may be taken or right may be exercised on the next succeeding day
which is not a Saturday or Sunday or such a legal holiday.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>23.&nbsp;Value. </B>The Company and the Holder agree that the value of this Warrant on the date of
grant is $100.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->7.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Subscription</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="61%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">To:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The undersigned hereby subscribes for <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> shares of Preferred Stock covered by this Warrant. The
certificate(s) for such shares shall be issued in the name of the undersigned or as otherwise
indicated below:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="38%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="61%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Signature
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name for Registration
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Mailing Address
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->1.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Net Issue Election Notice</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">To:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The undersigned hereby elects under <B>Section&nbsp;4 </B>to surrender the right to purchase shares of
Preferred Stock pursuant to this Warrant. The certificate(s) for such shares issuable upon such
net issue election shall be issued in the name of the undersigned or as otherwise indicated below:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="38%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="61%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Signature
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name for Registration
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Mailing Address
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->1.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Assignment</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">For value received <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> hereby sells, assigns and transfers unto
</DIV>

<DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: rule%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>

<DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: rule%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>


<DIV align="left" style="font-size: 10pt">&#091;Please print or typewrite name and address of Assignee&#093;</DIV>


<DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: rule%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>


<DIV align="left" style="font-size: 10pt">the within Warrant, and does hereby irrevocably constitute and appoint
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
its attorney to transfer the within Warrant on the books of the within named Company with full
power of substitution on the premises.</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="34%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="61%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dated:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Signature</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Name for Registration</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">In the Presence of:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->1.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Exhibit </B></FONT><B>A</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Amended and Restated Articles of Incorporation</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>See attached pages.</B>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->1.<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Exhibit&nbsp;d</B></FONT>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Notice of Borrowing</B></FONT>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, ________
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Lighthouse
Capital Partners V, L.P.<BR>
500 Drake&#146;s Landing Road<BR>
Greenbrae, CA 94904-3011

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Ladies and Gentlemen:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reference
is made to the Loan and Security Agreement No.&nbsp;4561 dated as of March&nbsp;29, 2005 (as
it has been and may be amended from time to time, the <I>&#147;Loan Agreement,&#148; </I>initially capitalized
terms used herein as defined therein), between <FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital </B><B>Partners </B></FONT><B>V, L.P. </B>and
<FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation </B></FONT>(the <I>&#147;Company&#148;)</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned is the President and CEO of the Company, and hereby irrevocably requests an
Advance under the Loan Agreement, and in that connection certifies as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;The amount of the proposed Advance is $<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>. The business day of the proposed Advance is <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;The
Loan Commencement Date for this Advance shall be March&nbsp;1, 2006.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;As of this date, no Event of Default, or event which with notice or the passage of time
would constitute an Event of Default, has occurred and is continuing, or will result from the
making of the proposed Advance, and the representations and warranties of the Company contained in
<B>Section&nbsp;5</B> of the Loan Agreement are true and correct in all material respects.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;No event that could reasonably be expected to have a material adverse effect on the
ability of Borrower to fulfill its obligations under the Loan Agreement has occurred since the
date of the most recent financial statements, submitted to you by the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company agrees to notify you promptly before the funding of the Advance if any of the
matters to which I have certified above shall not be true and correct
on the Funding Date.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="14%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Very truly yours,</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Exhibit&nbsp;e</B></FONT>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Incumbency Certificate</B></FONT>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned, William Smith, hereby certifies that:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>1.</B> He/She is the duly elected and acting General Counsel and Vice
President of Legal Affairs of
<FONT style="font-variant: SMALL-CAPS"><B>Fluidigm
Corporation</B></font>, a California
corporation (the <I>&#147;Company&#148;).</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>2.</B> That on the date hereof, each person listed below holds the office in the Company indicated
opposite his or her name and that the signature appearing thereon is the genuine signature of each
such person:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">NAME</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">OFFICE</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">SIGNATURE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Gajus Worthington
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President and CEO</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</div>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">William Smith
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">General Counsel and Vice <BR>
President of Legal Affairs</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="middle"><DIV style="font-size: 1pt; border-bottom: 1px solid #000000">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>3.</B>
Attached hereto as <B><I>Exhibit A</I></B> is a true and correct copy of the Articles of Incorporation of the
Company, as amended, as in effect as of the date hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>4.</B> Attached hereto as <B><I>Exhibit&nbsp;B </I></B>is a true and correct copy of the Bylaws of the Company, as
amended, as in effect as of the date hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5.</B> Attached hereto as <B><I>Exhibit&nbsp;C </I></B>is a copy of the resolutions of the Board of Directors of the
Company authorizing and approving the Company&#146;s execution, delivery and performance of a loan
facility with Lighthouse Capital Partners V, L.P.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the undersigned has executed this Incumbency Certificate on March
29, 2005.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="14%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>

</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
William Smith
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
    <TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">General Counsel and Vice President of Legal Affairs</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I, the President and CEO of the Company, do hereby certify that William Smith is the duly
qualified, elected and acting General Counsel and Vice President of Legal Affairs of the Company
and that the above signature is his or her genuine signature.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the undersigned has executed and delivered this Officer&#146;s Certificate on
March&nbsp;29, 2005.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="14%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>

</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
Gajus Worthington
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="top"><!-- Blank Space -->
 <TD>&nbsp;</TD></TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President and CEO</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">1</div>

</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Exhibit&nbsp;f</B></FONT>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Officer&#146;s Certificate</B></FONT>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned, to induce <FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital Partners</B></FONT><B> V, L.P. </B><I>(&#147;Lender&#148;), </I>to extend or
continue financial accommodations to <FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT>, a California corporation (the
<I>&#147;Borrower&#148;) </I>pursuant to the terms of that certain
Loan and Security Agreement dated March&nbsp;29, 2005
(the <I>&#147;Loan Agreement&#148;), </I>hereby certifies that on the date hereof:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>1.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>I am the duly elected and acting <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> of Borrower.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>2.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>I am a Responsible Officer as that term is defined in the Loan Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>3.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The information submitted herewith complies with <B>Sections
</B><B>5.7</B> and <B>6.2 </B>of the Loan
Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>4.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The financial statements delivered herewith fairly present the financial condition of
Borrower</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>5.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Borrower is currently able to meet its obligations as they come due.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>6.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>I understand that Lender is relying upon the truthfulness, accuracy and
completeness hereof in connection with the Loan Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>7.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>I will advise you if it comes to my attention that, as of the date hereof, the
information submitted herewith was not in fact true, correct and complete.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the undersigned has executed this Officer&#146;s Certificate on <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="14%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>


</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">1</div>
</div>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<P>
<div style="width: 100%; border: 1px solid black; padding: 11px">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Exhibit&nbsp;g</B></FONT>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Authorization for Automatic Payment</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The
undersigned <FONT style="font-variant: SMALL-CAPS"><B>Fluidigm
Corporation </B></font><I>(&#147;Borrower&#148;) </I>authorizes
<FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital Partners
</B></font><B>V, L.P.</B>
and any and all affiliated funds (collectively, <I>&#147;Lender&#148;) </I>and the bank / financial institution
(<I>&#147;Bank&#148;) </I>named below to initiate variable debit and/or credit entries to Borrower&#146;s deposit,
checking or savings accounts as designated below and to cause funds transfers to an account of
Lender as payment of any and all amounts due under the Loan and Security Agreement between
Borrower and Lender dated March <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2005 (the <I>&#147;Loan Agreement&#148;).</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>1.</B> Lender is hereby authorized to initiate
variable debit and/or credit transactions and
resulting funds transfers in Borrower&#146;s designated accounts with respect to amounts calculated
by Lender to be due and owing to Lender by Borrower periodically under the Loan Agreement.
Borrower consents to all such debit and/or credit transactions and resulting funds transfers and
hereby authorizes Lender to take all such actions as may be required by Bank with respect to
such transactions. Borrower acknowledges and agrees that such credit and/or debit entries may be
made in amounts due under the Loan Agreement in order to cause timely payments as required by
the terms of the Loan Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>2.</B> Borrower hereby authorizes Lender to
release to Bank all information concerning Borrower that
may be necessary or desirable for Bank to investigate or recover any erroneous funds transfers
that may occur.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>3.</B> Borrower acknowledges and agrees that
all such debit and/or credit transactions and funds
transfers are intended to be made through an Automated Clearing House system and in compliance
with the NACHA Rules and in compliance with Bank&#146;s security procedures.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>4.</B> Borrower represents and warrants that the account information set forth below is accurate and
complete and that each of the account(s) set forth below is a business account maintained in
Borrower&#146;s name and for Borrower&#146;s account.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Consent shall be effective as of March&nbsp;29, 2005 and shall remain in effect until the Loan
Agreement has been terminated. Any cancellation by Borrower of this consent shall (i)&nbsp;be made in
writing and (ii)&nbsp;delivered to Bank and Lender in such time as to afford Bank and Lender a
reasonable opportunity to act on said cancellation.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="92%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Wells Fargo Bank
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
(Name of Borrower&#146;s Bank)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="23%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;420 Montgomery St.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">San Francisco
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CA
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">94104&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(Address of Bank)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(City)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(State)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(Zip Code)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="71%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Bank Routing Number
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#091;***&#093;
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(between these symbols &#147; </I>/:&#148; &#147;:/&#148; <I>on bottom left of check)</I>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Account Number:<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#091;***&#093;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(checking /deposit /savings)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><I>(circle one)</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Copy of a voided check is attached to this form</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">Borrower Name:</TD>
    <TD>&nbsp;</TD>

<TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm
Corporation</B></font></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Borrower Address:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><U>7100 Shoreline
Court</U></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><U>South San Francisco.
CA 94080</U></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Authorized by:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date authorized:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Internal ACH Authorizations from Lender:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Approved by:<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date: <u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>
</DIV>








<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->

</div>
</div>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Exhibit&nbsp;h</B></FONT>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Negative Pledge Agreement</B></FONT>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant: SMALL-CAPS"><B>This Negative Pledge Agreement </B></FONT>is made as of March&nbsp;29, 2005, by and between
<FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation </B></FONT><I>(&#147;Borrower&#148;) </I>and <FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital Partners </B></FONT><B>V, L.P.</B>
<I>(&#147;Lender&#148;)</I><I>.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In consideration of the Loan and Security Agreement between the parties of proximate date herewith
(the <I>&#147;Loan Agreement&#148;), </I>Borrower agrees as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Except as otherwise permitted in the Loan Agreement, Borrower shall not sell, transfer, assign,
mortgage, pledge, lease, grant a security interest in, or encumber any of Borrower&#146;s owned
intellectual property, including, without limitation, the following:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>(a)</B>&nbsp;Any and all copyright rights, copyright applications, copyright registration and like
protection in each work or authorship and derivative work thereof, whether published or
unpublished and whether or not the same also constitutes a trade secret, now or hereafter
existing, created, acquired or held (collectively, the <I>&#147;Copyrights&#148;);</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>(b)</B>&nbsp;Any and all trade secrets, and any and all intellectual property rights in computer software
and computer software products now or hereafter existing, created, acquired or held;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>(c)</B>&nbsp;Any and all design rights which may be available to Borrower now or hereafter existing,
created, acquired or held;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>(d)</B>&nbsp;All patents, patent applications and like protections, including, without limitation,
improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part
of the same, including, without limitation, the patents and patent applications (collectively, the
<I>&#147;Patents&#148;);</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>(e)</B>&nbsp;Any trademark and servicemark rights, whether registered or not, applications to register and
registrations of the same and like protections, and the entire goodwill of the business of
Borrower connected with and symbolized by such trademarks (collectively, the <I>&#147;Trademarks&#148;);</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>(f)</B>&nbsp;Any and all claims for damages by way of past, present and future infringements of any of the
rights included above, with the right, but not the obligation, to sue for an collect such damages
for said use or infringement of the intellectual property rights identified above;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>(g)</B>&nbsp;Any and all licenses or other rights to use any of the Copyrights, Patents or Trademarks and
all license fees and royalties arising from such use to the extent permitted by such license or
rights
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>(h)</B>&nbsp;Any and all amendments, extensions, renewals and extensions of any of the Copyrights,
Patents or Trademarks; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>(i)</B>&nbsp;Any and all proceeds and products of the foregoing, including, without limitation, all payments
under insurance or any indemnity or warranty payable in respect of
any of the foregoing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">It shall be an Event of Default under the Loan Agreement if there is a breach of any term of this
Negative Pledge Agreement. Borrower agrees to properly execute all documents reasonably required
by Lender in order to fulfill the intent and purposes hereof.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital Partners </B></FONT><B>V, L.P.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="middle" style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left">By: <FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Management Partners </B></FONT><B>V, L.L.C</B>., its</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" colspan="3" valign="top"> general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Name:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV></DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Exhibit&nbsp;I</B></FONT>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Control Agreement</B></FONT>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">&#091;In form and substance acceptable to Lender in its reasonable discretion&#093;

</DIV>
<DIV align="Center" style="font-size: 10pt; margin-top: 34pt">&nbsp;</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>
</DIV>


<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="f39432ore3943201.gif" alt="(WELLS FARGO LOGO)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>RESTRICTED ACCOUNT AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>(ACCOUNT RESTRICTED AFTER INSTRUCTIONS &#151; Standing Wire Transfers)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This <B>Restricted Account Agreement</B> (the &#147;Agreement&#148;), dated as of the date specified at the end of
this Agreement, is entered into among <B>Fluidigm Corporation </B>(&#147;Company&#148;), <B>Lighthouse Capital Partners
V, L.P. </B>(&#147;Secured Party&#148;) and the Wells Fargo Bank identified in the signature block at the end of
this Agreement (&#147;Bank&#148;), and sets forth the rights of Secured Party and the obligations of Bank
with respect to the deposit account(s) of Company at Bank identified at the end of this Agreement
as the &#147;Restricted Account(s)&#148;. As used in this Agreement, the term &#147;Restricted Account&#148; refers,
individually and collectively, to each such deposit account.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>1.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Secured Party&#146;s Interest in Restricted Account. </B>Secured Party represents that it is either
(i)&nbsp;a lender who has extended credit to Company and has been granted a security interest in
the Restricted Account or (ii)&nbsp;such a lender and the agent for a group of such lenders (the
&#147;Lenders&#148;). Company hereby confirms, and Bank hereby acknowledges, the security interest
granted by Company to Secured Party in all of Company&#146;s right, title and interest in and to
the Restricted Account and all sums now or hereafter on deposit in or payable or withdrawable
from the Restricted Account (the &#147;Account Funds&#148;). Except as specifically provided otherwise
in this Agreement, Company has given Secured Party complete control over the Account Funds. Secured
Party hereby appoints Bank as agent for Secured Party only for the purpose of perfecting
the security interest of Secured Party in the Account Funds while they are in the
Restricted Account. Company and Secured Party would like to use the Restricted Account
Service of Bank described in this Agreement (the &#147;Service&#148;) to further the arrangements
between Secured Party and Company regarding the Restricted Account and the Account Funds.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>2.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Access to Restricted Account. </B>Secured Party agrees that Company will be allowed access to the
Account Funds until Bank receives written instructions from Secured Party directing that
Company no longer have access to any Account Funds (the &#147;Instructions&#148;). Company agrees that
the Account Funds should be paid to Secured Party after Bank receives the Instructions, and
hereby irrevocably authorizes Bank to comply with the Instructions even if Company objects in
any way to the Instructions. Company further agrees that after Bank receives the Instructions,
Company will not have access to any Account Funds.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>3.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Balance Reports. </B>Bank agrees, at the telephone request of Secured Party on any Business Day
(a day on which Bank is open to conduct its regular banking business, other than a Saturday,
Sunday or public holiday), to make available to Secured Party a report (&#147;Balance Report&#148;)
showing the opening available balance in the Restricted Account as of the beginning of such
Business Day, either on-line or by facsimile transmission, at Bank&#146;s option. Company expressly
consents to this transmission of information. Secured Party and Company understand and agree
that the opening available balance in the Restricted Account at the beginning of any Business
Day will be determined after deducting from the Restricted Account the face amount of all
Returned Items (as defined in Section&nbsp;8 of this Agreement).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>4.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Transfers to Secured Party. </B>Bank agrees that on each Business Day after it receives the
Instructions it will transfer to the Secured Party&#146;s account specified at the end of this
Agreement</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><I>Restricted Account Agreement<BR>
(Revised 09/21/01)</I>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><i>Page 1</i></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>with the bank specified at the end of this Agreement (the &#147;Secured Party Account&#148;) the full
amount of the opening available balance in the Restricted Account at the beginning of such
Business Day. Bank will use the Fedwire system to make each funds transfer unless for any
reason the Fedwire system is unavailable, in which case Bank will determine the funds
transfer system to be used in making each funds transfer and the means by which each
transfer will be made. Bank, Secured Party and Company each agree that Bank will comply with
instructions given to Bank by Secured Party directing disposition of funds in the Restricted
Account without further consent by Company, subject otherwise to the terms of this Agreement
and Bank&#146;s standard policies, procedures and documentation in effect from time to time
governing the type of disposition requested. Company authorizes all such transfers. Except
as otherwise required by law, Bank will not agree with any third party to comply with
instructions for disposition of funds in the Restricted Account originated by such third
party.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>5.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Delays in Making Funds Transfers. </B>Secured Party and Company understand that a funds transfer
may be delayed or not made if (a)&nbsp;the transfer would cause Bank to exceed any limitation on
its intra-day net funds position established in accordance with Federal Reserve or other
regulatory guidelines or to violate any other Federal Reserve or other regulatory risk control
program, or (b)&nbsp;the funds transfer would otherwise cause Bank to violate any applicable law or
regulation. If a funds transfer cannot be made or will be delayed, Bank will notify Secured
Party by telephone.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>6.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Reliance on Identifying Numbers. </B>If Secured Party indicates a name and an identifying number
for the bank of the person or entity to receive funds transfers out of the Restricted Account,
Secured Party and Company understand and agree that Bank may rely on the number Secured Party
indicates even if that number identifies a bank different from the bank Secured Party named.
If Secured Party indicates a name and an account number for the person or
entity to receive funds transfers out of the Restricted Account, Secured Party and Company
understand and agree that Bank may rely on the account number Secured Party indicates
even if that account number is not the account number for the person or entity who is to
receive the transfers.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>7.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Reporting Errors in Transfers. </B>If Secured Party or Company learns of any error in a funds
transfer or any unauthorized funds transfer, then the party learning of such error or
unauthorized transfer (the &#147;Informed Party&#148;) must notify Bank as soon as possible by telephone
at (800)&nbsp;AT- WELLS (which is a recorded line), and provide written confirmation to Bank of
such telephonic notice within two Business Days at the address given for Bank on the signature
page of this Agreement. In no case may such notice to Bank by an Informed Party be made more
than fourteen (14)&nbsp;calendar days after such Informed Party learns of the erroneous or
unauthorized transfer. If a funds transfer is made in error and Bank suffers a loss because an
Informed Party breached its agreement to notify Bank of such error within the time limits
specified in this Section&nbsp;7, then such Informed Party shall reimburse Bank for the loss
promptly upon demand by Bank; provided, however, that in the event both Secured Party and
Company breach this notification requirement, Secured Party shall not be obligated to
reimburse Bank for the loss unless Company fails to satisfy Bank&#146;s demand for reimbursement
within fifteen (15)&nbsp;calendar days after demand is made on Company.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>8.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Returned Item&nbsp;Amounts. </B>Secured Party and Company understand and agree that the face amount
(&#147;Returned Item&nbsp;Amount&#148;) of each Returned Item will be paid by Bank debiting the Restricted
Account, without prior notice to Secured Party or Company. As used in this Agreement, the term
&#147;Returned Item&#148; means (i)&nbsp;any item deposited to the Restricted Account and returned unpaid,
whether for insufficient funds or for any other reason, and without regard to the timeliness
of such return or the occurrence or timeliness of any drawee&#146;s
notice of non-payment; (ii)&nbsp;any
item subject to a claim against Bank of breach of transfer or presentment warranty under the
Uniform Commercial Code, as adopted in the applicable state; (iii)&nbsp;any automated clearing
house (&#147;ACH&#148;) entry credited to the Restricted Account and returned unpaid</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><I>Restricted Account Agreement<BR>
(Revised 09/21/01)</I>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><i>Page 2</i></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B></B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>or subject to an adjustment entry under applicable clearing house rules, whether for
insufficient funds or for any other reason, and without regard to the timeliness of such
return or adjustment; (iv)&nbsp;any credit to the Restricted Account from a merchant card
transaction, against which a contractual demand for chargeback has been made; and (v)&nbsp;any
credit to the Restricted Account made in error. Company agrees to pay all Returned Item
Amounts immediately on demand, without setoff or counterclaim, to the extent there are not
sufficient funds in the Restricted Account to cover the Returned Item&nbsp;Amounts on the day
they are to be debited from the Restricted Account. Secured Party agrees to pay all Returned
Item&nbsp;Amounts within thirty (30)&nbsp;calendar days after demand, without setoff or counterclaim,
to the extent the Returned Item&nbsp;Amounts are not paid in full by Company within fifteen (15)
calendar days after demand on Company by Bank, and to the extent Secured Party received
proceeds from the corresponding Returned Items.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>9.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Bank Fees. </B>Company agrees to pay all Bank&#146;s fees and charges for the maintenance and
administration of the Restricted Account and for the treasury management and other account
services provided with respect to the Restricted Account (collectively &#147;Bank Fees&#148;),
including, but not limited to, the fees for (a)&nbsp;the Balance Reports provided on the Restricted
Account, (b)&nbsp;the wire transfer services received with respect to the Restricted Account, (c)
Returned Items, (d)&nbsp;funds advanced to cover overdrafts in the Restricted Account (but without
Bank being in any way obligated to make any such advances), and (e)&nbsp;duplicate bank statements
on the Restricted Account. Before Bank receives the Instructions, the Bank Fees will be paid
by Bank debiting the Restricted Account, and after Bank receives the Instructions the Bank
fees will be paid by Bank debiting one or more of the demand deposit operating accounts of
Company at Bank specified at the end of this Agreement (the &#147;Operating Accounts&#148;). All such
debits will be made on the Business Day that the Bank Fees are due without notice to Secured
Party or Company. If there are not sufficient funds in the Restricted Account, or after Bank
receives the Instructions, the Operating Accounts, to cover fully the Bank Fees on the Business Day they
are debited from the Restricted Account or the Operating Accounts, or if no Operating
Accounts are indicated at the end of this Agreement, such shortfall or the amount of
such Bank Fees will be paid by Company sending Bank a check in the amount of such
shortfall or such Bank Fees, without setoff or counterclaim, within fifteen (15)
calendar days after demand of Bank. After Bank receives the Instructions, Secured Party
agrees to pay the Bank Fees within thirty (30)&nbsp;calendar days after demand, without
setoff or counterclaim, to the extent such Bank Fees are not paid in full by Company by
check within fifteen (15)&nbsp;calendar days after demand on Company by Bank. Bank may, in
its discretion, change the Bank Fees upon thirty (30)&nbsp;calendar days prior written notice
to Company and Secured Party.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>10.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Account Documentation. </B>Secured Party and Company agree that, except as specifically provided
in this Agreement, the Restricted Account will be subject to, and Bank&#146;s operation of the
Restricted Account will be in accordance with, the terms and provisions of Bank&#146;s deposit
account agreement governing the Restricted Account (&#147;Account
Agreement&#148;), a copy of which
Company and Secured Party acknowledge having received.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>11.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Bank Statements. </B>After Bank receives the Instructions, Bank will, if so indicated on the
signature page of this Agreement, send to Secured Party by United States mail, at the address
indicated for Secured Party after its signature to this Agreement, duplicate copies of all
bank statements on the Restricted Account which are sent to Company. Company and/or Secured
Party will have thirty (30)&nbsp;calendar days after receipt of a bank statement to notify Bank of
an error in such statement. Bank&#146;s liability for such errors is limited as provided in the
&#147;Limitation of Liability&#148; section of this Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>12.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Partial Subordination of Bank&#146;s Rights. </B>Bank hereby subordinates to the security interest of
Secured Party in the Restricted Account (i)&nbsp;any security interest which Bank may have or
acquire in the Restricted Account, and (ii)&nbsp;any right which Bank may have or acquire to set
off or otherwise apply any Account Funds against the payment of any indebtedness from time to
time</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><I>Restricted Account Agreement<BR>
(Revised 09/21/01)</I>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><i>Page 3</i></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B></B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>owing to Bank from Company, except for debits to the Restricted Account permitted under this
Agreement for the payment of Returned Item&nbsp;Amounts or Bank Fees.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>13.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Bankruptcy Notice; Effect of Filing. </B>If Bank at any time receives notice of the commencement
of a bankruptcy case or other insolvency or liquidation proceeding by or against Company (a
&#147;Bankruptcy Notice&#148;), Bank will continue to comply with its obligations under this Agreement,
except to the extent that any action required of Bank under this Agreement is prohibited under
applicable bankruptcy laws or regulations or is stayed pursuant to the automatic stay imposed
under the United States Bankruptcy Code or by order of any court or agency. With respect to
any obligation of Secured Party hereunder which requires prior demand upon Company, the
commencement of a bankruptcy case or other insolvency or liquidation proceeding by or against
Company shall automatically eliminate the necessity of such demand
upon Company by Bank, and
shall immediately entitle Bank to make demand on Secured Party with the same effect as if
demand had been made upon Company and the time for Company&#146;s performance had expired.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>14.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Legal Process, Legal Notices and Court Orders. </B>Bank will comply with any legal process, legal
notice or court order it receives if Bank determines in its sole discretion that the legal
process, legal notice or court order is legally binding on it.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>15.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Indemnification for Following Instructions. </B>Secured Party and Company each agree that,
notwithstanding any other provision of this Agreement, except to the extent caused by Bank&#146;s
gross negligence or willful misconduct Bank will not be liable to Secured Party or Company for
any losses, liabilities, damages, claims (including, but not limited to, third party claims),
demands, obligations, actions, suits, judgments, penalties, costs or expenses, including, but
not limited to, attorneys&#146; fees, (collectively, &#147;Losses and Liabilities&#148;) suffered or incurred
by Secured Party or Company as a result of or in connection with, (a)&nbsp;Bank complying with any
binding legal process, legal notice or court order referred to in Section&nbsp;14 of this
Agreement, (b)&nbsp;Bank following any instruction or request of Secured Party, or (c)&nbsp;Bank
complying with its obligations under this Agreement. Further, Company, and to the extent
not paid by Company within fifteen (15)&nbsp;calendar days after demand, Secured Party, will
indemnify Bank against any Losses and Liabilities Bank may suffer or incur as a result of
or in connection with any of the circumstances referred to in clauses (a)&nbsp;through (c)&nbsp;of
the preceding sentence.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>16.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>No Representations or Warranties of Bank. </B>Bank agrees to perform its obligations under this
Agreement in a manner consistent with the quality provided when Bank performs similar services
for its own account. However, Bank will not be responsible for the errors, acts or omissions
of others, such as communications carriers, correspondents or clearinghouses through which
Bank may perform its obligations under this Agreement or receive or transmit information in
performing its obligations under this Agreement. Secured Party and Company also understand
that Bank will not be responsible for any loss, liability or delay caused by wars, failures in
communications networks, labor disputes, legal constraints, fires, power surges or failures,
earthquakes, civil disturbances or other events beyond Bank&#146;s control. <B>BANK MAKES NO EXPRESS
OR IMPLIED REPRESENTATIONS OR WARRANTIES WITH RESPECT TO THE SERVICE OTHER THAN THOSE
EXPRESSLY SET FORTH IN THIS AGREEMENT.</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>17.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Limitation of Liability. </B>In the event that Secured Party, Company or Bank suffers or incurs
any Losses and Liabilities as a result of, or in connection with, its or any other party&#146;s
performance or failure to perform its obligations under this Agreement, the affected parties
shall negotiate in good faith in an effort to reach a mutually satisfactory allocation of such
Losses and Liabilities, it being understood that Bank will not be responsible for any Losses
and Liabilities due to any cause other than its own negligence or breach of this Agreement, in
which case its liability to Secured Party and Company shall, unless otherwise provided by any
law which cannot be</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><I>Restricted Account Agreement<BR>
(Revised 09/21/01)</I>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><i>Page 4</i></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>varied by contract, be limited to direct money damages in an amount not to exceed ten (10)
times all the Bank Fees charged or incurred during the calendar month immediately preceding
the calendar month in which such Losses and Liabilities occurred (or, if no Bank Fees were
charged or incurred in the preceding month, the Bank Fees charged or incurred in the month
in which the Losses and Liabilities occurred). Company will indemnify Bank against all
Losses and Liabilities suffered or incurred by Bank as a result of third party claims;
provided, however, that to the extent such Losses and Liabilities are directly caused by
Bank&#146;s negligence or breach of this Agreement such indemnity will only apply to those Losses
and Liabilities which exceed the liability limitation specified in the preceding sentence.
The limitation of Bank&#146;s liability and the indemnification by Company set out above will not
be applicable to the extent any Losses and Liabilities of any party to this Agreement are
directly caused by Bank&#146;s gross negligence or willful misconduct. <B>IN NO EVENT WILL BANK BE
LIABLE FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT OR PUNITIVE DAMAGES, WHETHER ANY
CLAIM IS BASED ON CONTRACT OR TORT, WHETHER THE LIKELIHOOD OF SUCH DAMAGES WAS KNOWN TO BANK
AND REGARDLESS OF THE FORM OF THE CLAIM OR ACTION, INCLUDING, BUT NOT LIMITED TO, ANY CLAIM
OR ACTION ALLEGING GROSS NEGLIGENCE, WILLFUL MISCONDUCT, FAILURE TO EXERCISE REASONABLE CARE
OR FAILURE TO ACT IN GOOD FAITH. </B>Any action against Bank by Company or Secured Party under
or related to this Agreement must be brought within twelve months after the cause of action
accrues.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>18.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Termination. </B>This Agreement and the Service may be terminated by Secured Party or Bank at any
time by either of them giving thirty (30)&nbsp;calendar days prior written notice of such
termination to the other two parties to this Agreement at their contact addresses specified
after their signatures to this Agreement; provided, however, that this Agreement and the
Service may
be terminated immediately upon written notice from Bank to Company and Secured Party
should Secured Party fail to make any payment when due to Bank from Secured Party under
the terms of this Agreement. Secured Party and Company agree that the Restricted Account
may be closed by Bank as provided in the Account Agreement. Company&#146;s and Secured
Party&#146;s obligation to report errors in funds transfers and bank statements and to pay
the Bank Fees, as well as the indemnifications made, and the limitations on the
liability of Bank accepted, by Company and Secured Party under this Agreement will
continue after the termination of this Agreement and/or the closure of the Restricted
Account with respect to all the circumstances to which they are applicable existing or
occurring before such termination or closure, and any liability of any party to this
Agreement, as determined under the provisions of this Agreement, with respect to acts or
omissions of such party prior to such termination or closure will also survive such
termination or closure. Upon any termination of this Agreement and the Service or
closure of the Restricted Account all collected and available balances in the Restricted
Account on the date of such termination or closure will be transferred to Secured Party
as requested by Secured Party in writing to Bank.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>19.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Modifications, Amendments, and Waivers. </B>This Agreement may not be modified or amended, or any
provision thereof waived, except in a writing signed by all the parties to this Agreement;
provided, however, that the Bank Fees may be changed after thirty (30)&nbsp;calendar days prior
written notice to Company and Secured Party.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>20.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Notices. </B>All notices from one party to another shall be in writing, or be made by a telecommunications
device capable of creating a written record, shall be delivered to Company,
Secured Party and/or Bank at their contact addresses specified after their signatures to this
Agreement, or any other address of any party notified to the other parties in writing, and
shall be effective upon receipt. Any notice sent by one party to this Agreement to another
party shall also be sent to the third party to this Agreement. Bank is authorized by Company
and Secured Party to act on any instructions or notices received by Bank if (a)&nbsp;such
instructions or notices</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><I>Restricted Account Agreement<BR>
(Revised 09/21/01)</I>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><i>Page 5</i></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>purport to be made in the name of Secured Party, (b)&nbsp;Bank reasonably believes that they are
so made, and (c)&nbsp;they do not conflict with the terms of this Agreement as such terms may be
amended from time to time, unless such conflicting instructions or notices are supported by
a court order.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>21.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Successors and Assigns. </B>Neither Company nor Secured Party may assign or transfer its rights
or obligations under this Agreement to any person or entity without the prior written consent
of Bank, which consent will not be unreasonably withheld. Bank may not assign its rights or
obligations under this Agreement to any person or entity without the prior written consent of
Secured Party, which consent will not be unreasonably withheld; provided, however, that no
such consent will be required if the assignee is a bank affiliate of Bank.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>22.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Governing Law. </B>Company and Secured Party understand that Bank&#146;s provision of the Service
under this Agreement is subject to federal laws and regulations. To the extent that such
federal laws and regulations are not applicable this Agreement shall be governed by and be
construed in accordance with the laws of the state in which the office of Bank that maintains
the Restricted Account is located, without regard to conflict of laws principles.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>23.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Severability. </B>To the extent that this Agreement or the Service to be provided under this
Agreement are inconsistent with, or prohibited or unenforceable under, any applicable law or
regulation, they will be deemed ineffective only to the extent of such prohibition or
unenforceability and be deemed modified and applied in a manner consistent with such law or
regulation. Any provision of this Agreement which is deemed unenforceable or invalid in any
jurisdiction shall not affect the enforceability or validity of the remaining provisions of
this Agreement or the same provision in any other jurisdiction.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>24.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Usury. </B>It is never the intention of Bank to violate any applicable usury or interest rate
laws. Bank does not agree to, or intend to contract for, charge, collect, take, reserve or
receive (collectively, &#147;charge or collect&#148;) any amount in the nature of interest or in the
nature of a fee, penalty or other charge which would in any way or event cause Bank to charge
or collect more than the maximum Bank would be permitted to charge or collect by any
applicable federal or state law. Any such excess interest or unauthorized fee shall,
notwithstanding anything stated to the contrary in this Agreement, be applied first to reduce
the amount owed, if any, and then any excess amounts will be refunded.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>25.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Counterparts. </B>This Agreement may be executed in any number of counterparts each of which
shall be an original with the same effect as if the signatures thereto and hereto were upon
the same instrument.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>26.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Entire Agreement. </B>This Agreement, together with the Account Agreement, contains the entire
and only agreement among all the parties to this Agreement and between Bank and Company, and
Bank and Secured Party, with respect to (a)&nbsp;the Service, (b)&nbsp;the interest of Secured Party and
the Lenders in the Account Funds and the Restricted Account, and (c)&nbsp;Bank&#146;s obligations to
Secured Party and the Lenders in connection with the Account Funds and the Restricted Account.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Agreement has been signed by the duly authorized officers or representatives of Company,
Secured Party and Bank on the date specified below.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><I>Restricted Account Agreement<BR>
(Revised 09/21/01)</I>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><i>Page 6</i></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">






<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Date:
March&nbsp;29, 2005</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="34%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Restricted Account Number(s):</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD nowrap align="left" valign="top"><B>&#091;***&#093;</B></TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Operating Account Number(s):</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD nowrap align="right" valign="top"><B>&#091;***&#093;</B></TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Secured Party Account Number:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="left" valign="top"><B>&#091;***&#093;</B></TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Bank of Secured Party Account:</B>
</DIV></TD>
    <TD>&nbsp;</TD>

<TD nowrap colspan="3" align="left" valign="top"><DIV style="margin-left:125px; text-indent:90px"><B>Comerica
Bank</B></div>
</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Secured Party is to be sent duplicate Bank Statements.</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="54%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="34%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>&#091;Company&#093; FLUIDIGM CORPORATION</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>&#091;Secured Party&#093; LIGHTHOUSE CAPITAL</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>PARTNERS V, L.P.</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>BY: LIGHTHOUSE MANAGEMENT</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>PARTNERS V, L.L.C. ITS GENERAL</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>PARTNER</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>

    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>

    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Name: <B>Gajus Worthington</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Name: <B>Thomas Conneely</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Title: <B>CEO</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Title: <B>Vice President</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>Address For All Notices:</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>Address For All Notices:</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<tr><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>Fluidigm Corporation</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>Lighthouse Capital Partners V, L.P.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>Attn: James Neesen</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>500 Drakes Landing Road</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>7100 Shoreline Court</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>Greenbrae, CA 94904</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>Attn: Contracts Administration</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>WELLS FARGO BANK
</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>, N.A.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Name: <B>Scott M. Van Gorder</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" valign="top" align="left">Title: <B>Vice President, Senior Relationship Manager</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>Address For All Notices:</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<tr><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>420 Montgomery
Street,
9</B><SUP style="font-size: 85%; vertical-align: text-top"><B>th</b></SUP>
<b>Floor</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>MAC A0101-096</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>San Francisco, CA 94108</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><I>Restricted Account Agreement<BR>
(Revised 09/21/01)</I>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><i>Page 7</i></TD>
</TR>
</table>
<P align="right" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>


</div>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">March&nbsp;29,
2005
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Morgan Stanley &#038; Co. Incorporated </B>(the &#147;Broker&#148;)<BR>
555 California Street 14<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Floor<BR>
San Francisco, CA 94104

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Re: <U><B>Notice of Pledge and Security</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Gentlemen:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Please be advised that the undersigned, Fluidigm Corporation (&#147;Pledgor&#148;), has pledged a security
interest in Account No.&nbsp;&#091;***&#093; (the &#147;Account&#148;) held by Broker, as securities intermediary,
and in all of the securities, proceeds, cash or other assets now or hereafter held in the Account
(collectively, the &#147;Collateral&#148;), to Lighthouse Capital Partners V, L.P. (&#147;Pledgee&#148;) pursuant to
the terms and provisions of a certain Loan and Security Agreement (the &#147;Agreement&#148;), dated March
29, 2005.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Broker,
Pledgor and Pledgee, by signing this letter, hereby agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">a) The
Account shall be retitled &#147;Fluidigm Corporation &#151; Pledgor/
Lighthouse Capital &#150; Pledgee&#148;;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">b) Pledgee has a security interest in the Collateral and is authorized to instruct the Broker
with regard to the Account without further consent needed by Pledgor;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">c) Broker is hereby notified of Pledgee&#146;s security interest, and agrees to comply with all
instructions and entitlement orders of Pledgee with regard to the Account. Broker shall
not comply with instructions and entitlement orders with respect to the Collateral or the
Account that are originated by the Pledgor except as described in Paragraph&nbsp;D below.
Broker is also hereby authorized and agrees to send duplicate copies of any and all
statements and confirmations, as well as any other appropriate correspondence, relating to
the Account directly to the Pledgee at the address indicated below, or to such other
address as Pledgee may designate in writing. This pledge will remain in full force and
effect until Pledgee notifies Broker in writing to the contrary;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">d) Pledgee hereby instructs Broker that until further instruction in writing from an
Authorized Officer of Pledgee (as defined below) that Pledgee is assuming exclusive
control over the Account (&#147;Notice of Exclusive Control&#148;), the Broker shall comply with
directions of Pledgor with respect to any transactions, including withdrawals, in the
Account. Notwithstanding anything contained herein, upon receipt of a Notice of
Exclusive Control (it being understood that Broker shall have no duty or obligation
whatsoever to investigate or determine whether the Notice of Exclusive Control was
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">rightfully or legally issued), Broker shall only follow the directions and instructions of
Pledgee with regard to the Account. In that case, if Pledgee so requests, Broker will proceed to
liquidate the assets of the Account in accordance with Pledgee&#146;s instructions and to deliver the
proceeds to Pledgee.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this Agreement, &#147;Authorized Officer of Pledgee&#148; shall refer to any one of
the following individuals: Richard Stubblefield and Thomas Conneely. If Pledgee finds it
necessary to designate a replacement for any of the designated Authorized Officers of Pledgee,
written notice of replacement shall be given to Broker, which notice shall be signed by the
President, an Executive Vice President, a Senior Vice President, or such other officer of Pledgee
as Broker may approve. However, Broker shall be entitled to rely on any notice it receives from
someone whom it reasonably believes is an Authorized Officer of Pledgee;
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">e) Broker shall have no obligation to monitor the Account for any purpose in connection
with the pledge granted hereunder. The Pledgee accepts and acknowledges full
responsibility for reviewing daily confirmations and monthly statements to ensure that it
is adequately secured;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">f) Pledgor and Pledgee hereby agree to indemnify and hold harmless Broker, its affiliates,
officers, and employees from and against any and all claims, causes of actions, liabilities,
lawsuits, demands, and/or damages, including, without limitation, any and all court costs and
reasonable attorney&#146;s fees, that might result by reason of the actions of Broker under this
Agreement. Broker shall not be responsible for any losses, claims, damages, liabilities and
expenses incurred by Pledgor or Pledgee, except to the extent that such losses, claims,
damages, liabilities or expenses arise out of the bad faith, gross negligence, or criminal
acts or omissions on the part of Broker;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">g) Broker may terminate this Agreement at any time by canceling the Account and
transferring all funds and securities in the Account to Pledgee;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">h) As of the date hereof, the Collateral has not been paid to or withdrawn by the Pledgor; Broker
is not in receipt of any notice of withdrawal or redemption with regard to the Collateral or
notice not to renew the Account, and Broker has not given any notice that the Account will not be
renewed or extended, as the case may be;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">i) Broker&#146;s records indicate that the value of the Collateral, as of the date hereof, is
approximately &#091;***&#093;.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">j) Broker subordinates any right of offset Broker may now or hereafter have against the
Collateral for any indebtedness now or hereafter owing to Broker by the Pledgors to the security
interest of Pledgee; <U>provided that</U> Broker shall continue to have a first perfected
security interest in the Collateral with respect to any charges incurred in connection with the
operation of the Account, including, but not limited to, fees, commissions and any costs related
to unsettled securities transactions.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">k) This Agreement shall be governed by the law of the State of New York, excluding its conflict of
law rules. The parties hereby agree that (i)&nbsp;the &#147;securities intermediary&#146;s jurisdiction&#148; with
respect to the Account and the Collateral is New York and (ii)&nbsp;the parties shall not agree with any
other person that such securities intermediary&#146;s jurisdiction is any jurisdiction other than New
York.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="13%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Very truly yours,
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>FLUIDIGM CORPORATION</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="1" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By: &nbsp;&nbsp;&nbsp;James Neeson</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Controller</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Read and Agreed to:<BR>
<B>MORGAN STANLEY &#038; CO. INCORPORATED</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="67%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>LIGHTHOUSE CAPITAL PARTNERS V, L.P.</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="95%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>By:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Lighthouse Management Partners V, L.L.C.</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>its general partner</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="62%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name: Thomas Conneely
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title: Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Address: 500 Drakes Landing Road</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><div style="margin-left: 26%">Greenbrae, CA 94904</div></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SUBORDINATION AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This SUBORDINATION AGREEMENT (this &#147;Agreement&#148;), dated as of March&nbsp;29, 2005, is between, on
the one hand, each undersigned holder (each a &#147;Holder&#148; and collectively the &#147;Holders&#148;) of
Convertible Promissory Notes issued pursuant to those certain Convertible Note Purchase Agreement
dated December&nbsp;18, 2003, as amended from time to time (each a &#147;Note&#148; and collectively the &#147;Notes&#148;)
issued by <FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation,</B> </FONT>a California corporation (&#147;Company&#148;), and, on the other
hand, <FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital
Partners</B> </FONT><B>V, L.P.,</B> a Delaware limited partnership (&#147;LCP&#148;), lender
under that certain Loan and Security Agreement No.&nbsp;4561, dated March&nbsp;29, 2005 (the &#147;Loan
Agreement&#148;) with Company (all obligations of payment and performance due or to become due pursuant
to the Obligations or the Loan Documents as those terms are defined therein, as the same may be
amended from time to time, are the &#147;LCP Obligations&#148;), with reference to the following:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, in order to induce LCP to enter into the Loan Agreement, the Holders agree to enter
into this Agreement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the mutual promises herein contained, the parties
hereby agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Subordination</U>. Each Holder agrees that it shall not receive any payment of any
amounts on account of the Notes until the LCP Obligations have been paid and performed in
full.
Regardless of (i)&nbsp;any agreement of any Holder or LCP with Company, (ii)&nbsp;the time, place,
manner or order of attachment, perfection, or the filing of UCC-1 filings or other documents,
or
(iii)&nbsp;the giving or failure to give notice, each Holder does hereby subordinate payment by
Company on its Notes to the full and final payment to LCP of the LCP Obligations. Each Holder
agrees that all payments and the proceeds received by Holders on account of the Notes shall be
held by them in trust for LCP for the payment of the LCP Obligations, and turned over to LCP
in
kind upon receipt of notice from LCP that Company has failed to pay LCP any of the LCP Obligations. Holders hereby agree they have no security interest in any property of the Company.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Notwithstanding anything in this Agreement, (i)&nbsp;in the event the Convertible Note, dated as of
December&nbsp;18, 2003 (the &#147;Initial EDB Note&#148;), issued by Company to Biomedical Sciences Investment Fund
Pte Ltd (&#147;BMSIF&#148;) has not been converted according to the terms set forth in Section&nbsp;2 of such
Initial EDB Note by the Payment Date (as defined in such Initial EDB Note), BMSIF may receive
payment by the Company in an amount not to exceed 50% of the principal amount outstanding under
such Initial EDB Note, and (ii)&nbsp;each Holder may convert any Note into capital stock of the Company
and accept cash in lieu of fractional shares in connection with any such conversion. Upon
conversion of any Note into capital stock of the Company and acceptance of cash in lieu of
fractional shares in connection with any such conversion, this Agreement shall terminate with
respect to such Note and any proceeds received by a Holder in connection with the conversion of
such Note.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Bankruptcy</U>. (Subject to paragraph (1)&nbsp;above), Each Holder agrees that upon any
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">distribution of assets or readjustment of indebtedness of Company, whether by liquidation,
bankruptcy, assignment for the benefit of creditors, or otherwise, LCP shall receive payment in
full on the LCP Obligations before Holder receives payment of any amounts due under the Notes and
Holders shall pay over to LCP any amounts so received by them related to the Notes until the LCP
Obligations are paid in full. In furtherance thereof, each Holder authorizes LCP to make and vote
(without LCP being obligated to make or vote) any and all proofs of claim respecting the Notes in
any such proceeding and to receive and collect all dividends or other payments thereupon; provided
that LCP will pay over to Holders a pro rata distribution of amounts received by it in excess of
that necessary for the full and final satisfaction of the LCP Obligations. Holders agree to execute
such instruments of assignment and other documents as may be necessary to enforce such claims and
collect such dividends or to otherwise carry out the intent and purpose hereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Representations</U>. Each party hereto warrants and represents to the others
that it has full power and authority to enter hereinto and to perform all obligations hereunder,
that this Agreement is valid, binding and enforceable in accordance with its terms and that
execution and performance hereof does not violate any agreement with any other person or entity.
Each Holder represents and warrants that it (i)&nbsp;is the owner of the Notes, free and clear of the
claims of any others, (ii)&nbsp;has not heretofore subordinated or assigned the Notes or its interest
therein to any entity, (iii)&nbsp;will not transfer any Notes to any entity other than one which agrees
to be bound hereby, and (iv)&nbsp;waives any rights to claim that the enforceability of this Agreement
may be affected by any subsequent modification, release, extension,
or change in LCP obligations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>No Third Party Beneficiaries.</U> Company has no rights hereunder. This
Agreement is made only for the benefit of Holders and LCP and their successors and assigns, and may
not be relied upon by any other third party, including Company or any successor thereto or any
judgment lien creditor thereof. Nothing herein shall constitute a commitment or agreement by either
of LCP or Holder to provide funds to Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Miscellaneous</U>. This Agreement: (i)&nbsp;may only be amended by a writing signed by
LCP and the affected Holder; (ii)&nbsp;contains the entire agreement between Holders and LCP with
respect to its subject matter, and all prior negotiations, documents and discussions are
superseded
hereby; (iii)&nbsp;shall be governed by the laws of the state of California; (iv)&nbsp;may be executed
in
counterparts delivered by telefacsimile, all of which, when taken together, shall constitute
one
and the same original document; and (v)&nbsp;may be attached to a Form UCC-1 and filed in the
public records of any jurisdiction; and (vi)&nbsp;shall terminate upon the full, final and
indefeasible
payment and performance by Company to LCP of all LCP Obligations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Waiver of Jury Trial.</U> TO THE FULLEST EXTENT PERMITTED BY LAW,
EACH OF THE PARTIES HERETO WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY
JURY IN RESPECT OF LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF,
UNDER OR IN CONNECTION WITH THIS AGREEMENT. EACH PARTY FURTHER
WAIVES ANY RIGHT TO CONSOLIDATE ANY ACTION IN WHICH A JURY TRIAL HAS
BEEN WAIVED WITH ANY OTHER ACTION IN WHICH A JURY TRIAL CANNOT BE
OR HAS NOT BEEN WAIVED.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B><FONT style="font-variant: SMALL-CAPS">Lighthouse
Capital Partners </FONT>V, L.P.</B><BR>
a Delaware limited partnership

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">by:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Lighthouse Management Partners V, L.L.C.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">by:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Thomas Conneely</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Thomas Conneely</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">500 Drakes Landing Road</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Greenbrae, CA 94904</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: Contracts Administration</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: (415)&nbsp;464-5900</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: (415)&nbsp;925-3387</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">HOLDERS:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Biomedical
Sciences Investment Fund </b><b>Ptd </b></FONT>
<FONT style="font-variant: SMALL-CAPS"><B>Ltd</B></FONT>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By: <BR>
Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Lily Chan
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Director
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">20 Biopolis Way</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">#09-01 Centros</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Singapore 138668</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: Lily Chan, PhD</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: 65-6395-7700</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 65-6395-7796</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B><FONT style="font-variant: SMALL-CAPS">Invus,
L.P.</font></B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Invus Advisors, LLC
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;Its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom" style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD >&nbsp;</TD>
    <TD align="left" valign="bottom" style="border-bottom: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">135 East 57<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Street</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">New York, NY 10022</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: Phillipe J. Amouyal</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: (212)&nbsp;371-1717</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: (212)&nbsp;371-1829</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Company hereby acknowledges and consents to the Agreement, promises to take all such action as may
be necessary to fulfill its essential intent and purpose, agrees that failure to do so shall be an
Event of Default under the LCP Obligations, and acknowledges that in the transactions referenced
herein it has been advised to seek, and has selected, counsel of its own choosing, namely Wilson,
Sonsini, Goodrich &#038; Rosati of Palo Alto, California.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm
Corporation</B></FONT>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="67%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"  style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Its</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Signature page to Fluidigm Corporation<BR>
Subordination Agreement
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Fluidigm Confidential</B>

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">HOLDERS:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Biomedical
Sciences Investment Fund Ptd Ltd</B></font>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">20 Biopolis Way</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">#09-01 Centros</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Singapore 138668</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: General Manager</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: 65-6395-7700</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 65-6395-7796</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Invus,
L.P.</B></font>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Invus Advisors, LLC
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;Its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By: <BR>
Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Aflalo Guimaraes
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Managing Director
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">135 East
57<SUP style="font-size: 85%; vertical-align: text-top">th</sup> Street</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">New York, NY 10022</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: Phillipe J. Amouyal</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: (212)&nbsp;371- 1717</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: (212) 371-1829</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Company hereby acknowledges and consents to the Agreement, promises to take all such action as may
be necessary to fulfill its essential intent and purpose, agrees that failure to do so shall be an
Event of Default under the LCP Obligations, and acknowledges that in the transactions referenced
herein it has been advised to seek, and has selected, counsel of its own choosing, namely Wilson,
Sonsini, Goodrich &#038; Rosati of Palo Alto, California.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm
Corporation</B></font>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="67%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By</DIV></TD>
    <TD >&nbsp;</TD>

<TD align="left" valign="top" style="border-bottom:1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Its</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">HOLDERS:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B><FONT style="font-variant: SMALL-CAPS">Biomedical
Sciences Investment Fund Ptd</FONT>
<FONT style="font-variant: SMALL-CAPS">Ltd</FONT></B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top" style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"  style="border-bottom: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">20 Biopolis Way</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">#09-01 Centros</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Singapore 138668</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: General Manager</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: 65-6395-7700</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 65-6395-7796</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Invus,
L.P.</B></font>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Invus Advisors, LLC
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"  style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"  style="border-bottom: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">135 East 57<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Street</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">New York, NY 10022</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: Phillipe J. Amouyal</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: (212)&nbsp;371-1717</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: (212)&nbsp;371-1829</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Company hereby acknowledges and consents to the Agreement, promises to take all such action as may
be necessary to fulfill its essential intent and purpose, agrees that failure to do so shall be an
Event of Default under the LCP Obligations, and acknowledges that in the transactions referenced
herein it has been advised to seek, and has selected, counsel of its own choosing, namely Wilson,
Sonsini, Goodrich &#038; Rosati of Palo Alto, California.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B><FONT style="font-variant: SMALL-CAPS">
Fluidigm Corporation</FONT></B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gajus Worthington
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Its
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President &#38; CEO</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMENDMENT NO. 01 (&#147;<I>Amendment</I>&#148;)<BR>
TO LOAN AND SECURITY AGREEMENT NO. 4561</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt">Entered into as of August&nbsp;4, 2006 by and between<BR>
<FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital Partners </B></FONT><B>V, L.P. </B><I>(&#147;Lender&#148;) </I>and <FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation </B></FONT><I>(&#147;Borrower&#148;).</I>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>RECITALS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, Borrower and Lender have previously entered into that certain Loan and Security
Agreement No.&nbsp;4561 dated as of March&nbsp;29, 2005 (the <I>&#147;Loan and Security Agreement&#148;; </I>all initially
capitalized terms not otherwise defined herein shall have the meanings given to such terms in
the Loan and Security Agreement), together with the other agreements and instruments entered
into in connection therewith (collectively, the <I>&#147;Loan Documents&#148;); </I>and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, Borrower and Lender each have agreed to amend the Loan Documents subject to
Borrower&#146;s performance of the terms and conditions hereof; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, as of August&nbsp;31, 2006, Borrower and Lender mutually agree that the outstanding
principal balance of the Loans is $11,093,832.04;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the foregoing and the mutual covenants herein
contained, the parties hereby agree to modify the Loan Documents by entering into this Amendment
and Borrower agrees to perform such other covenants and conditions as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>A) Loan and Security Agreement</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;<U>Definitions</U> &#151; The definition <I>of &#147;Subordinated Indebtedness&#148;, </I>shall be amended and
restated to read as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%"><I>&#147;Subordinated Indebtedness&#148; </I>means Indebtedness of Borrower to Singapore EDB (including
its investment fund BioMedical Sciences Investment Fund Ptd Ltd) and Invus Group that is
subordinated in both security and right of payment to the Obligations on terms and
conditions reasonably satisfactory to Lender in an amount not to exceed $8,000,000.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>B) Secured Term Promissory Note</B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">(i) <U>Definitions</U> &#151; The following definitions shall be added to the Notes, and to the
extent these terms are already defined in the Loan Documents, they shall be deleted in their
entirety and replaced with the following:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>&#147;Final Payment&#148; </I>means 11.25% of the Advance.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>&#147;Basic Rate&#148; </I>means a variable <I>per annum </I>rate of interest equal to the Index plus the
Interest Margin which shall be subject to adjustment as provided herein. On and after March&nbsp;1,
2006 through and including August&nbsp;31, 2006, the Basic Rate shall be fixed at 10.00%. On and
after September&nbsp;1, 2006, the Basic Rate shall be fixed at 9.75%.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>&#147;Repayment
Period&#148; </I>means the period beginning on the Loan Commencement Date and continuing
for 48 calendar months.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>C) Additional Terms and Conditions</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->1.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Repayment.</U> Notwithstanding anything contained in any Note issued in connection
with the Loan and Security Agreement, Section&nbsp;1 of each such Note shall be superseded by the following payment
terms: for and on account of all of the Notes, from March&nbsp;1, 2006 through and including August&nbsp;31,
2006, Borrower will pay Lender $416,006.71 per month. On and after September&nbsp;1, 2006 through February&nbsp;28,
2010, Borrower shall pay Lender $310,305.95 per month. In addition to all other amounts due or to
become due hereunder, the Final Payment is due on the earliest to occur of the Maturity Date or March
1, 2009.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Restructure Fee.</U> In addition to all other amounts due or to become due
hereunder, on the earliest to occur of (i)&nbsp;the Maturity Date; (ii)&nbsp;the date of prepayment of all of the Notes, or (ii)&nbsp;March&nbsp;1,
2009, Borrower shall pay to Lender a restructure fee in the amount of $150,000, in cash.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Expenses.</U> Borrower shall pay reasonable fees and expenses incurred by
Lender&#146;s legal counsel in connection with the preparation and negotiation of documentation related to this Amendment.
Such restructure expenses are due and payable when billed.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>D)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acknowledgments; Representations and Warranties.</B> Borrower warrants and represents to
Lender, as a material inducement to Lender&#146;s entering hereinto, as follows:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>No Further Funding Obligations.</U> Lender has no obligations to make further Advances to
Borrower.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>No Waivers.</U> Lender has made no separate oral or written waiver of any existing
or future Default or Event of Default by Borrower under any Loan
Document.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>No Set-Off.</U> Borrower has no claims or rights of set-off against Lender of any
kind under any Loan Document or otherwise. Borrower has no defenses to payments of any amounts owed to Lender as
the same become due and payable.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Representations and Warranties of Borrower.</U> The representations and warranties contained in the Loan Agreement are true and complete in all material respects as of the date hereof, except with
respect to any such representation or warranty which speak only as of a specific date prior to the date
hereof. Borrower warrants and represents that no Events of Default have occurred. Borrower warrants and
represents that it has not reached any settlement with any other creditor of Borrower that has not been
disclosed in writing to Lender.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>E.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Release.</B> Borrower for itself and for its agents, partners, stockholders, employees and
affiliates and its or their successors and assigns hereby (a)&nbsp;agrees to waive, release and further
discharge Lender and its officers, directors, stockholders, partners, successors, assigns, agents
and employees of and from any and all manner of claims arising in connection with the Loan
Documents for damages at law or in equity with respect to any matter occurring prior to the date
hereof which Borrower or such other releasing party may have had, and (b)&nbsp;waives California Civil
Code Section&nbsp;1542, which reads: &#147;A general release does not extend to claims which the creditor
does not know or suspect to exist in his favor at the time of executing the release, which if
known by him must have materially affected his settlement with the debtor.&#148; Each provision of this
release shall be severable from every other provision when determining its legal enforceability.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->2.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">





<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Except as amended hereby, the Loan Documents remain unmodified and unchanged and ratified by
Borrower as though fully set forth herein. In the event of any contradiction between any term
of this Amendment with any other Loan Document, the terms under this Amendment shall control
Lender and Borrower have executed this Amendment as of the date first written above.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Borrower:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Lender:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital Partners</B> </FONT><B>V, L.P.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Management</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top"><B><FONT style="font-variant: SMALL-CAPS">Partners
</FONT>V, L.L.C.,</B> its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gajus Worthington
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Thomas Conneely
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Name:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Gajus Worthington
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Thomas Conneely</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CEO
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->3.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMENDMENT NO. 02 <I>(&#147;Amendment&#148;)</I><BR>
TO LOAN AND SECURITY AGREEMENT NO. 4561</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt">Entered
into as of November&nbsp;16, 2006 by and between<BR>
<FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital Partners </B></FONT><B>V, L.P. </B><I>(&#147;Lender&#148;) </I>and <FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation </B></FONT><I>(&#147;Borrower&#148;).</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Without limiting or amending any other provisions of the Agreement, as amended, Lender and Borrower
agree to the following:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Section&nbsp;1.1</B> of the Agreement, the definition of <I>&#147;Subordinated Indebtedness&#148;, </I>shall be amended and
restated to read as follows:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%"><I>&#147;Subordinated Indebtedness&#148; </I>means Indebtedness of Borrower to Singapore EDB (including its
investment fund BioMedical Sciences Investment Fund Ptd Ltd) and Invus Group that is
subordinated in both security and right of payment to the Obligations on terms and
conditions reasonably satisfactory to Lender in an amount not to exceed $13,000,000.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All capitalized terms not otherwise defined herein shall have the meanings given to such terms in
the Agreement.</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Borrower:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Lender:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 6pt"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital Partners </B></FONT><B>V, L.P.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Management</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top"><FONT style="font-variant: SMALL-CAPS"><B>Partners</B>
</FONT><B>V, L.L.C.,</B> its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Rich Delateur
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Darren Haggerty
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Name:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Rich Delateur
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Darren Haggerty</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chief Financial Officer
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director of Portfolio Analysis</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->1.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B>AMENDMENT NO. 03</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt">Dated August&nbsp;8, 2007
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt">TO
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt">that certain Loan and Security Agreement No.&nbsp;4561<BR>
dated as of March&nbsp;29, 2005, as amended <I>(&#147;Agreement&#148;), </I>by and between<BR>
<FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital Partners </B></FONT><B>V, L.P. </B><I>(&#147;Lender&#148;) </I>and<BR>
<FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT>, a Delaware corporation (formerly a California corporation) <I>(&#147;Borrower&#148;).</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(All capitalized terms not otherwise defined herein shall have the meanings given to such terms in
the Agreement.)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Without limiting or amending any other provisions of the Loan Documents, Lender and Borrower
agree to the following:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">Effective
March&nbsp;29, 2007, Borrower&#146;s state of incorporation has reincorporated from the State
of California to the State of Delaware.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Except as amended hereby, the Loan Documents remains unmodified and unchanged.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>BORROWER:</b></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>LENDER:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B><FONT style="font-variant: SMALL-CAPS">Lighthouse Capital Partners </FONT>V, L.P.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Management</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top"><B><FONT style="font-variant: SMALL-CAPS">Partners </FONT>V, L.L.C.,</B> its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gajus Worthington
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Tom Conneely
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Name:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Gajus Worthington
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tom Conneely</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President &#38; CEO
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"> Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>ORIGINAL</B>
</DIV>

<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMENDMENT NO. 04</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Dated February&nbsp;15, 2008

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">TO

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">that certain Loan and Security Agreement No.&nbsp;4561<BR>
dated as of March&nbsp;29, 2005, as amended <I>(&#147;Agreement&#148;), </I>by and between<BR>
<FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital Partners
V, L.P.</B></FONT> <I>(&#147;Lender&#148;) </I>and<BR>
<FONT style="font-variant: SMALL-CAPS"><B>Fluidigm
Corporation</B></FONT><I> (&#147;Borrower&#148;).</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant: SMALL-CAPS"><B>this Amendment No.</B></FONT><B> 04 </B><I>(&#147;Amendment 04&#148;) </I>to that certain Loan and Security Agreement
No.&nbsp;4561 dated March&nbsp;29, 2005 (as amended to date, the <I>&#147;Agreement) </I>is entered into as of February
15, 2008, by and between
<FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital Partners V, L.P.</B></FONT> <I>(&#147;Lender&#148;) </I>and <FONT style="font-variant: SMALL-CAPS"><B>Fluidigm
Corporation</B></FONT>, a Delaware corporation
<I>(&#147;Borrower&#148;)</i>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, Borrower and Lender have previously entered into and amended the Agreement; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, Borrower has requested Lender provide an additional term loan financing, which
Lender has agreed to provide subject to the terms of this Amendment 04.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the foregoing and the mutual covenants herein contained,
the parties hereby agree to modify the Agreement and to perform such other covenants and conditions
as follows:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(All capitalized terms not otherwise defined herein shall have the meanings given to such terms in
the Agreement.)
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>I. Section&nbsp;1.1</B>, the following definitions shall be added to the Agreement:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Change
of Management or Board Composition &#148; </I>means that <B>(i) </B>Borrower&#146;s senior management shall not
include Gajus Worthington; <B>(ii) </B>Versant Ventures or any of its affiliated funds shall cease to
have a representative (currently Samuel Colella) serving on Borrower&#146;s Board of Directors; or
<B>(iii) </B>Alloy Ventures or any of its affiliated funds shall cease to have a representative
(currently Mike Hunkapiller) serving on Borrower&#146;s Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Commitment One&#148; </I>means the Commitment as that term is used in the Agreement prior to the
effect of this Amendment 04.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Commitment Two&#148; </I>means $10,000,000.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Commitment Two Warrant&#148; </I>mean the Warrant in favor of Lender to purchase securities of Borrower,
substantially in the form <I>of <B>Exhibit&nbsp;C-2</B></I> attached to this Amendment 04 and issued in conjunction
with Commitment Two.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>II. Section&nbsp;1.1</B>, the following definitions of the Agreement shall be deleted in its entirety and
replaced with the following:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Basic Rate&#148; </I>(i)&nbsp;under Commitment One, as defined in the Notes, as amended pursuant to Amendment
No.&nbsp;01, and (ii)&nbsp;under Commitment Two, as defined in the Notes for Advances under Commitment Two.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Commitment&#148; </I>means Commitment One and Commitment Two.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Commitment Fee&#148; </I>means $10,000 under Commitment One and $10,000 under Commitment Two.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Commitment Termination Date&#148; </I>has occurred for Commitment One, and for Commitment Two it means the
earliest to occur of <B>(i) </B>July&nbsp;1, 2008; <B>(ii) </B>any Default or Event of Default, or <B>(iii) </B>Change of
Management or Board Composition (unless Lender has waived this condition in writing).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Disclosure Schedule&#148; </I>means the Disclosure Schedule delivered to Lender in connection with the
execution and delivery of Amendment No.&nbsp;04 to this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Loan Commencement Date&#148; </I>means <B>(i) </B>for Advances under Commitment One, as defined in the Notes, as
amended pursuant to Amendment No.&nbsp;01, and <B>(ii) </B>for Advances under Commitment Two, as defined in
the Notes for Advances under Commitment Two.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>


</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Note&#148; </I>means (i)&nbsp;in connection with Advances under Commitment One, Secured Promissory Notes in the
form <I>of </I><B><I>Exhibit&nbsp;B</I></B><I>, </I>and (ii)&nbsp;in connection with Advances under Commitment Two, Secured Promissory
Notes in the form <I>of </I><B><I>Exhibits B-2 </I></B>to Amendment 04.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Notice of Borrowing&#148; </I>means (i)&nbsp;in connection with Advances under Commitment One, the form
attached as <B><I>Exhibit&nbsp;D, </I></B>and (ii)&nbsp;in connection with Advances under Commitment Two in the form of
<B><I>Exhibit&nbsp;D-2 </I></B>attached to Amendment 04.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Warrant&#148; </I>means (i)&nbsp;all Warrants issued by Borrower to Lender prior to the date of Amendment 04,
and (ii)&nbsp;the Commitment Two Warrant.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>III. </B><B>Section&nbsp;6.2 </B>&#151; Section&nbsp;6.2 of the Agreement shall be amended deleted in its entirety and
replaced with the following:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>6.2
Financial Statements, Reports, Certificates. </B>Borrower shall deliver to Lender: <B>(i)</B>&nbsp;as soon as
prepared, and no later than 30&nbsp;days after the end of each calendar quarter, a balance sheet,
income statement and cash flow statement covering Borrower&#146;s operations for each of the three
months during such period, provided for each calendar month ending after the calendar quarter
ending on September&nbsp;30, 2008, Borrower shall deliver to Lender as soon as prepared, and no later
than 30&nbsp;days after the end of each calendar month, a balance sheet, income statement and cash flow
statement covering Borrower&#146;s operations during such period; <B>(ii) </B>as soon as prepared, but no
later than 90&nbsp;days after the end of the fiscal year, or such other timeframe formally approved by
Borrower&#146;s audit committee, audited financial statements prepared in accordance with GAAP,
together with an opinion that such financial statements fairly present Borrower&#146;s financial
condition by an independent public accounting firm reasonably acceptable to Lender; <B>(iii)</B>
immediately upon notice thereof, a report of any legal or administrative action pending or
threatened in writing against Borrower which is likely to result in liability to Borrower in
excess of $100,000 (provided that Borrower shall not be required to report notices of possibly
relevant third party patents, or proposals or demands to license intellectual property); and <B>(iv)</B>
such other financial information as Lender may reasonably request from time to time. Financial
statements delivered pursuant to subsections <B>(i) </B>and <B>(ii) </B>above shall be accompanied by a
certificate signed by a Responsible Officer (each an <I>&#147;Officer&#146;s Certificate&#148;) </I>in the form <I>of<B>
Exhibit&nbsp;F.</B></I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>IV. Section&nbsp;3 &#151; Conditions of Advances; Procedure for requesting Advances; </B>the following new
<B>Sections&nbsp;3.2 and 3.3 </B>shall be added:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>3.2 Procedure for Making Advances. </B>For any Advance, Borrower shall provide Lender an irrevocable
Notice of Borrowing at least 15 business days prior to the desired Funding Date and Lender shall
only be required to make Advances hereunder based upon written requests which comply with the
terms and exhibits of this Loan Agreement (as the same may be amended from time to time), and
which are submitted and signed by a Responsible Officer. Borrower shall execute and deliver to
Lender a Note and such other documents and instruments as Lender may reasonably require for each
Advance made.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>3.3. Conditions Precedent to Initial Advance under Commitment Two. </B>The obligation of Lender to
make the Initial Advance under Commitment Two is subject the satisfaction of each of the following
conditions:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>This Amendment 04 duly executed by Borrower.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>The Commitment Two Warrant to be issued to Lender duly executed by
Borrower.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>Delivery to Ledner of an officer&#146;s certificate of Borrower with copies of
the following documents
attached: <B>(i) </B>the certificate of incorporation and by-laws or other organizational documents of
Borrower certified by Borrower as being in full force and effect as of the date of Amendment 04,
<B>(ii) </B>incumbency and representative signatures, and <B>(iii) </B>resolutions authorizing the execution and
delivery of Amendment 04 and each of the other Loan Documents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>Delivery to Lender of a good standing certificate from Borrower&#146;s state of
incorporation or formation
and the state in which Borrower&#146;s principal place of business is located, together with
certificates of the applicable governmental authorities stating that Borrower is in compliance with
the franchise tax laws of each such state, each dated as of a recent date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;</B>Borrower has obtained all necessary consents of shareholders, members, and
other third parties with
respect to the execution, delivery and performance of the Agreement, Amendment 04, the Commitment
Two Warrant, and the other Loan Documents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(f)&nbsp;</B>Borrower shall have satisfied all the conditions set forth in <B>Section&nbsp;3.1
and 3.2 </B>of the Agreement.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>3.4 Reaffirmation </B>Subject to the Disclosure Schedule attached hereto as Schedule&nbsp;1, Borrower
reaffirms the representations and warranties made to Lender in the Agreement as of the date hereof
as though fully set forth herein.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>


</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>3.5 Existing Notes </B>Notes for Advances under Commitment Two are not affected by
Amendment No.&nbsp;01 and Notes for Advances under Commitment One remain subject to Amendment No.
01
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>V. Further Terms and Conditions of this Amendment 04.</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Representations and Warranties of Borrower</U>. Borrower warrants and
represents, as a significant material inducement to
Lender to enter hereinto, that: (i)&nbsp;no Events of Default have occurred and are
continuing that have not been disclosed to
Lender by Borrower in writing; (ii)&nbsp;it is not and has no reason to believe it may be
named as a party to any judicial or administrative proceeding, litigation or
arbitration, and has not received any written communication from any person or entity
(whether
private or governmental) threatening or indicating the same, except
to the extent that
any such written communication could not
reasonably be expected to result in a material adverse effect on Borrower&#146;s business;
and (iii)&nbsp;it is in full compliance with Section
7.10 of the Loan and Security Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>No Control.</U> Borrower warrants and represents, as a significant material
inducement to Lender to enter hereinto, that none of
Lender nor any affiliate, officer, director, employee, agent, or attorney of Lender,
have at any time, from Borrower&#146;s date of
formation through to the date hereof, (i)&nbsp;exercised management or other control over the
Borrower, (ii)&nbsp;exercised undue influence
over Borrower or any of its officers, employees or directors, (iii)&nbsp;made any
representation or warranty, express or implied, to any
party on behalf of Borrower, (iv)&nbsp;entered into any joint venture, agency relationship,
employment relationship, or partnership with
Borrower, (v)&nbsp;directed or instructed Borrower on the manner, method, amount, or identity
of payee of any payment made to any
creditor of Borrower, and further, Borrower warrants and represents that by entering
hereinto with Lender has not, are not and will
not have engaged in any of the foregoing.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Integration Clause.</U> This Agreement represents and documents the entirety
of the agreement and understanding of the parties
hereto with respect to its subject matter. All prior understandings, whether oral or
written, other than the Loan Documents,
are hereby merged hereinto. <B>NEITHER THE LOAN AND SECURITY AGREEMENT NOR THIS AGREEMENT
MAY BE MODIFIED EXCEPT BY A WRITING SIGNED BY LENDER AND BORROWER. </B>Each provision hereof
shall be severable from every other provision when determining its legal enforceability
such that Lender&#146;s rights and
remedies under this Agreement and the Loan Documents may be enforced to the maximum
extent permitted under applicable
law. This Agreement shall be binding upon, and inure to the benefit of, each party&#146;s
respective permitted successors and
assigns. This Agreement may be executed in counterpart originals, all of which, when
taken together, shall constitute one
and the same original document. No provision of any other document between Lender and
Borrower shall limit the
effectiveness hereof or the rights and remedies of Lender against Borrower. In the
event of any contradiction or
inconsistency among the terms and conditions of this Agreement or any Loan Document, the
interpretation most favorable to
the interests of Lender shall prevail.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Except as amended hereby, the Agreement remains unmodified and unchanged.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="38%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="38%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>BORROWER:</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>LENDER:</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>FLUIDIGM CORPORATION</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>LIGHTHOUSE CAPITAL PARTNERS V, L.P.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gajus Worthington
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" colspan="3" nowrap><B>LIGHTHOUSE MANAGEMENT PARTNERS V, L.L.C.,</B></TD>


</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Name:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Gajus Worthington</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">its general partner&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President and CEO</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Thomas Conneely
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Thomas Conneely</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>


</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">





<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Exhibit&nbsp;B-2 </B></FONT><BR>
<FONT style="font-variant: SMALL-CAPS"><B>(Commitment Two)</B></FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>&#091;</B><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><B>&#093;</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Secured Promissory Note</B></FONT>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This
<FONT style="font-variant: SMALL-CAPS">Secured Promissory
Note</FONT> (this <I>&#147;Note&#148;) </I>is
made <u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u> , 2008, by <FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B>
</FONT><I>(&#147;Borrower&#148;) </I>in favor of <FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital Partners </B></FONT><B>V, L.P.</B> (collectively with its assigns, <I>&#147;Lender&#148;). </I>Initially
capitalized terms used and not otherwise defined herein are defined in that certain Loan and
Security Agreement No.&nbsp;4561 between Borrower and Lender dated
March&nbsp;29, 2005, as amended (the <I>&#147;Loan
Agreement&#148;).</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS">For
Value Received, </FONT>Borrower promises to pay in lawful money of the United States, to the
order of Lender, at 500 Drake&#146;s Landing Road, Greenbrae, California 94904, or such other place as
Lender may from time to time designate (&#147;<I>Lender&#146;s Office&#148;), </I>the principal
sum of
$<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>
(the <I>&#147;Advance&#148;), </I>including interest on the unpaid balance and all other amounts due or to
become due hereunder according to the terms hereof and of the Loan Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Basic Rate&#148; </I>means a fixed per <I>annum </I>rate of interest equal 8.5%.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Final Payment&#148; </I>means 6.5% of the Advance.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Loan Commencement Date&#148; </I>means January&nbsp;1,2009.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Maturity Date&#148; </I>means the last day of the Repayment Period, or if earlier, the date of prepayment
under the Note.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Payment Date&#148; </I>means the first day of each calendar month.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Prepayment Fee&#148; </I>means (i)&nbsp;if prepaid in the calendar years 2008 or 2009, 3% of the outstanding
principal amount being prepaid; (ii)&nbsp;if prepaid in the calendar year 2010, 2% of the outstanding
principal amount being prepaid; and (iii)&nbsp;if prepaid in the calendar year 2011 or thereafter, 1%
of the outstanding principal amount being prepaid.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Repayment Period&#148; </I>means the period beginning on the Loan Commencement Date and continuing for 30
calendar months.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>1. Repayment. </B>Borrower shall pay principal and interest due hereunder from the Funding Date, until
this Note is paid in full,
on each Payment Date pursuant to the terms of the Loan Agreement and this Note. Borrower shall
pay to Lender, monthly in
advance on each Payment Date, interest calculated using the Basic Rate. Beginning on the Loan
Commencement Date and on each
Payment Date thereafter during the Repayment Period, Borrower shall make equal installments of
principal and interest in advance,
calculated at the Basic Rate. On the Maturity Date, Borrower shall pay, in addition to all unpaid
principal and interest outstanding
hereunder, the Final Payment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>2.
Interest. </B>Interest not paid when due will, to the maximum extent permitted under applicable law,
become part of principal,
at Lender&#146;s option, and thereafter bear like interest as principal. Interest shall be computed on
the basis of a 360&nbsp;day year. All
Obligations not paid when due shall bear interest at the Default Rate unless waived in writing by
Lender. All amounts paid hereunder
will be applied to the Obligations in Lender&#146;s discretion and as provided in the Loan Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>3. Voluntary Prepayment. </B>Borrower may prepay the Note if and only if Borrower pays to Lender <B>(i</B>)
the outstanding principal
amount of this Note and any unpaid accrued interest <B>(ii)</B>&nbsp;the Final Payment, <B>(iv)</B>&nbsp;the Prepayment
Fee, and <B>(v)</B>&nbsp;all other sums, if any, that
shall have become due and payable hereunder with respect to this Note.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>4. Collateral. </B>This Note is secured by the Collateral.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5. Waivers. </B>Borrower, and all guarantors and endorsers of this Note, regardless of the time, order
or place of signing, hereby
waive notice, demand, presentment, protest, and notices of every kind, presentment for the purpose
of accelerating maturity, diligence
in collection to the fullest extent permitted by law.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt"><B>6. Choice of Law; Venue. </B><FONT style="font-variant: SMALL-CAPS"><B>This Note shall be governed by, and construed in accordance with the
internal
laws of the State of California, without regard to principles of conflicts of law. Each of
Borrower and
Lender hereby submits to the exclusive jurisdiction of the State and Federal courts located in
the City and</B></FONT>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>


</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>County of San Francisco, State of California. Borrower and Lender each hereby waive their
respective rights to a jury trial of any claim or cause of action based upon or arising out of this
Note. Each party further waives any right to consolidate any action in which a jury trial has been
waived with any other action in which a jury trial cannot be or has not been waived.</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>7. Miscellaneous. </B><FONT style="font-variant: SMALL-CAPS">This Note may be modified only by a</font> <FONT style="font-variant: SMALL-CAPS">writing signed by Borrower and
Lender. </FONT>Each provision
hereof is severable from every other provision hereof and of the Loan Agreement when determining
its legal enforceability. Sections and subsections are titled for convenience, and not for
construction. &#147;Hereof,&#148; &#147;herein,&#148; &#147;hereunder,&#148; and similar words refer to this Note in its
entirety. &#147;Or&#148; is not necessarily exclusive. &#147;Including&#148; is not limiting. The terms and conditions
hereof inure to the benefit of and are binding upon the parties&#146; respective permitted successors
and assigns. This Note is subject to all the terms and conditions of the Loan Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS">In Witness Whereof, </FONT>Borrower has caused this Note to be executed by a duly authorized
officer as of the day and year first above written.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>


</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4A
<SEQUENCE>7
<FILENAME>f39432orexv4w4a.htm
<DESCRIPTION>EXHIBIT 4.4A
<TEXT>
<HTML>
<HEAD>
<TITLE>exv4w4a</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;4.4A</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">NEITHER THIS WARRANT NOR THE SHARES OF CAPITAL STOCK ISSUABLE UPON EXERCISE HEREOF HAVE BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
<I>&#147;1933 ACT&#148;), </I>OR ANY APPLICABLE STATE
SECURITIES LAWS. SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED UNLESS SUCH SALE OR TRANSFER IS IN
ACCORDANCE WITH THE REGISTRATION REQUIREMENTS OF SUCH ACT AND APPLICABLE LAWS OR THE COMPANY HAS
RECEIVED AN OPINION OF COUNSEL, REASONABLY ACCEPTABLE TO THE COMPANY, TO THE EFFECT THAT SUCH SALE
OR TRANSFER IS EXEMPT FROM THE REGISTRATION REQUIREMENTS OF SUCH ACT AND APPLICABLE LAWS.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">PREFERRED STOCK PURCHASE WARRANT
</DIV>

<DIV align="center" STYLE="MARGIN-TOP: 12PT">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top">Warrant No.<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">Number of Shares: initially, 185,714<BR>
Series&nbsp;D Preferred Stock<BR>
subject to increase as set forth below</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Effective
as of March&nbsp;29, 2005
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Void after March&nbsp;29, 2012

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.&nbsp;Issuance. </B>This Preferred Stock Purchase Warrant (the <I>&#147;Warrant&#148;) </I>is issued to
<FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital Partners</B></FONT><B> V, L.P. </B>by <FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT>, a California corporation
(hereinafter with its successors
called the <I>&#147;Company&#148;).</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.&nbsp;Purchase Price; Number of Shares.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>The registered holder of this Warrant (the <I>&#147;Holder&#148;), </I>commencing on the date hereof, is
entitled
upon surrender of this Warrant with the subscription form annexed hereto duly executed, at the
principal office of
the Company, to purchase from the Company, at a price per share of $2.80 (the <I>&#147;Purchase
Price&#148;), </I>185,714 fully
paid and nonassessable shares of the Company&#146;s Series&nbsp;D Preferred Stock, (the <I>&#147;Exercise
Quantity&#148;), </I>$0.001 par
value (the <I>&#147;Preferred Stock&#148;).</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>On the Commitment Termination Date, the Exercise Quantity shall automatically be increased
by
such additional number of shares (rounded to the nearest whole share) of Series&nbsp;D Preferred
Stock, if any, as is equal
to the amount determined by dividing (A)&nbsp;4% of the Aggregate Advances under the Loan
Agreement, if any, by (B)
the Purchase Price
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In addition to other terms which may be defined herein, the following terms, as used in this
Warrant, shall have the following meanings:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>(i)</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#147;Aggregate Advances&#148; means the aggregate original dollar amount of all Advances made
under
the Loan Agreement, whether such Advances are outstanding or prepaid, at the time of
any scheduled adjustment to the Exercise Quantity.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>(ii)</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#147;Loan Agreement&#148; means that certain Loan and Security Agreement No.
4561 dated March&nbsp;29, 2005 between the Company and Lighthouse Capital Partners V, L.P..</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Any capitalized term not defined herein shall have the meaning as set forth in the Loan Agreement.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --> 1.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Until such time as this Warrant is exercised in full or expires, the Purchase Price and the
securities issuable upon exercise of this Warrant are subject to adjustment as hereinafter
provided. The person or persons in whose name or names any certificate representing shares of
Preferred Stock is issued hereunder shall be deemed to have become the holder of record of the
shares represented thereby as at the close of business on the date this Warrant is exercised with
respect to such shares, whether or not the transfer books of the Company shall be closed.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.&nbsp;Payment of Purchase Price. </B>The Purchase Price may be paid (i)&nbsp;in cash or by check, (ii)&nbsp;by
the
surrender by the Holder to the Company of any promissory notes or other obligations issued by
the Company, with
all such notes and obligations so surrendered being credited against the Purchase Price in an
amount equal to the
principal amount thereof plus accrued interest to the date of surrender, or (iii)&nbsp;by any
combination of the foregoing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>4.&nbsp;Net Issue Election. </B>The Holder may elect to receive, without the payment by the Holder of
any
additional consideration, shares of Preferred Stock equal to the value of this Warrant or any
portion hereof by the
surrender of this Warrant or such portion to the Company, with the net issue election notice
annexed hereto duly
executed, at the principal office of the Company. Thereupon, the Company shall issue to the
Holder such number of
fully paid and nonassessable shares of Preferred Stock as is computed using the following
formula:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="44%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">X
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Y<I>(A-B)</I>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 3px double #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">A</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="80%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">where:&nbsp;&nbsp;&nbsp;X =
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">the number of shares of Preferred Stock to be issued to the Holder
pursuant to this <B>Section&nbsp;4.</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">Y =
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">the number of shares of Preferred Stock covered by
this Warrant in respect of which the net issue election is made pursuant to
this <B>Section&nbsp;4.</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">A =
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">the Fair Market Value (defined below) of one share of
Preferred Stock, as determined at the time the net issue election is made
pursuant to this <B>Section&nbsp;4.</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">B =
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">the Purchase Price in effect under this Warrant at the
time the net issue election is made pursuant to this <B>Section&nbsp;4.</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>&#147;Fair Market Value&#148; </I>of a share of Preferred Stock (or fully paid and nonassessable shares of
the Company&#146;s common stock, $0.001 par value (the <I>&#147;Common Stock&#148;) </I>if the Preferred Stock has been
automatically converted into Common Stock) as of the date that the net issue election is made (the
<I>&#147;Determination Date&#148;) </I>shall mean:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i) </B>If the net issue election is made in connection with and contingent upon the closing of the
sale of the Company&#146;s Common Stock to the public in a public offering pursuant to a Registration
Statement under the Securities Act of 1933, as amended (a <I>&#147;Public Offering&#148;), </I>and if the Company&#146;s
Registration Statement relating to such Public Offering <I>(&#147;Registration Statement&#148;) </I>has been
declared effective by the Securities and Exchange Commission, then the initial &#147;Price to Public&#148;
specified in the final prospectus with respect to such offering multiplied by the number of shares
of Common Stock into which each share of Preferred Stock is then convertible.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ii) </B>If the net issue election is not made in connection with and contingent upon a Public
Offering, then as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>If traded on a securities exchange or the Nasdaq National Market, the fair
market value of the Common Stock shall be deemed to be the average of the closing or last reported
sale prices of the Common Stock on such exchange or market over the five day period ending five
trading days prior to the Determination Date, and the fair market value of the Preferred Stock
shall be deemed to be such fair market value of the Common Stock multiplied by the number of
shares of Common Stock into which each share of Preferred Stock is then convertible;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --> 2.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>If otherwise traded in an over-the-counter market, the fair
market value of the
Common Stock shall be deemed to be the average of the closing ask prices of the Common Stock over
the five day period ending five trading days prior to the Determination Date, and the fair market
value of the Preferred Stock shall be deemed to be such fair market value of the Common Stock
multiplied by the number of shares of Common Stock into which each share of Preferred Stock is then
convertible; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>If there is no public market for the Common Stock, then fair market value shall
be determined in good faith by the Company&#146;s Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.&nbsp;Partial Exercise. </B>This Warrant may be exercised in part, and the Holder shall be entitled
to
receive a new warrant, which shall be dated as of the date of this Warrant, covering the
number of shares in respect
of which this Warrant shall not have been exercised.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>6.&nbsp;Fractional Shares. </B>In no event shall any fractional share of Preferred Stock be issued
upon any
exercise of this Warrant. If, upon exercise of this Warrant in its entirety, the Holder
would, except as provided in
this <B>Section&nbsp;6, </B>be entitled to receive a fractional share of Preferred Stock, then the Company
shall issue the next
higher number of full shares of Preferred Stock, issuing a full share with respect to such
fractional share.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>7.&nbsp;Expiration Date; Automatic Exercise. </B>This Warrant shall expire at the close of
business on
March&nbsp;29, 2012, and shall be void thereafter (the <I>&#147;Expiration Date&#148;). </I>Notwithstanding the
term of this Warrant
fixed pursuant to this <B>Section 7,</B> and provided Holder has received advance written notice of
at least twenty (20)
days and has not earlier exercised this Warrant, and provided this Warrant has not been
assumed by the successor
entity (or parent thereof), upon the consummation of a Merger (as defined below), this Warrant
shall automatically
be exercised pursuant to <B>Section&nbsp;4 </B>hereof, without any action by Holder. <I>&#147;Merger&#148; </I>means: (i)
a sale of all or
substantially all of the Company&#146;s assets to an Unaffiliated Entity (as defined below), or
(ii)&nbsp;the merger,
consolidation or acquisition of the Company with, into or by an Unaffiliated Entity (other
than a merger or
consolidation for the principle purpose of changing the domicile of the Company or a bona fide
round of preferred
stock equity financing), that results in the Company&#146;s shareholders immediately prior to such
merger, consolidation,
or acquisition holding, immediately thereafter, less than a majority of the outstanding
voting securities of the
successor corporation or its parent. <I>&#147;Unaffiliated Entity&#148; </I>means any entity that is owned or
controlled by parties
who own less than twenty percent (20%) of the combined voting power of the voting securities
of the Company
immediately prior to such merger or sale of assets, consolidation or acquisition.
Notwithstanding the foregoing, in
the event that any outstanding warrants to purchase equity securities of the Company (it being
acknowledged and
agreed that options to acquire common stock issued to officers, directors, employees and
consultants shall not be
deemed &#147;warrants&#148;) are assumed by the successor entity of a Merger (or parent thereof), this
Warrant shall also be
similarly assumed and the automatic exercise provision in this <B>Section 7</B> shall have no effect.
The Company agrees
to give the Holder written notice promptly after it has entered into a definitive agreement
relating to any proposed
Merger and written notice of termination of any definitive agreement relating to any proposed
Merger.
Notwithstanding anything to the contrary in this Warrant, (i)&nbsp;the Holder may expressly make
any voluntary exercise
of this Warrant contingent on, and effective immediately prior to, the consummation of such
Merger and (ii)&nbsp;any
automatic exercise of this Warrant in connection with a Merger shall be conditioned on
consummation of such
Merger and shall be effective immediately prior thereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>8.&nbsp;Reserved Shares; Valid Issuance. </B>The Company covenants that it will at all times from and
after
the date hereof reserve and keep available such number of its authorized shares of Preferred
Stock and Common
Stock free from all preemptive or similar rights therein, as will be sufficient to permit,
respectively, the exercise of
this Warrant in full and the conversion into shares of Common Stock of all shares of Preferred
Stock receivable
upon such exercise. The Company further covenants that such shares as may be issued pursuant
to such exercise
and/or conversion will, upon issuance, be duly and validly issued, fully paid and
nonassessable and free from all
taxes, liens and charges with respect to the issuance thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.&nbsp;Stock Splits and Dividends. </B>If after the date hereof the Company shall subdivide the
Preferred
Stock, by split-up or otherwise, or combine the Preferred Stock, or issue additional shares of
Preferred Stock in
payment of a stock dividend on the Preferred Stock, the number of shares of Preferred Stock
issuable on the exercise
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --> 3.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of this Warrant shall forthwith be proportionately increased in the case of a subdivision or
stock dividend, or proportionately decreased in the case of a combination, and the Purchase Price
shall forthwith be proportionately decreased in the case of a subdivision or stock dividend, or
proportionately increased in the case of a combination.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>10.&nbsp;Adjustments for Diluting Issuances. </B>The antidilution rights applicable to the Series&nbsp;D
Preferred Stock of the Company are set forth in the Amended and Restated Articles of
Incorporation, as amended from time to time (the <I>&#147;Articles&#148;), </I>a true and complete copy in its
current form which has been made available to Holder. Such rights shall not be restated, amended
or modified in any manner which affects the Holder differently than the holders of outstanding
Series&nbsp;D Preferred Stock without such Holder&#146;s prior written consent. The Company shall provide
the Holder hereof with any restatement, amendment or modification to the Articles promptly after
the same has been made.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>11.
Mergers and Reclassifications. (a) </B>Except as set forth in <B>Section&nbsp;7,</B> If after the
date hereof the Company shall enter into any Reorganization (as hereinafter defined), then, as a
condition of such Reorganization, lawful provisions shall be made, and duly executed documents
evidencing the same from the Company or its successor shall be delivered to the Holder, so that
the Holder shall thereafter have the right to purchase, at a total price not to exceed that
payable upon the exercise of this Warrant in full, the kind and amount of shares of stock and
other securities and property receivable upon such Reorganization by a holder of the number of
shares of Preferred Stock which might have been purchased by the Holder immediately prior to such
Reorganization, and in any such case appropriate provisions shall be made with respect to the
rights and interest of the Holder to the end that the provisions hereof (including without
limitation, provisions for the adjustment of the Purchase Price and the number of shares issuable
hereunder and the provisions relating to the net issue election) shall thereafter be applicable in
relation to any shares of stock or other securities and property thereafter deliverable upon
exercise hereof. For the purposes of this <B>Section&nbsp;11, </B>the term <I>&#147;Reorganization&#148; </I>shall include
without limitation any reclassification, capital reorganization or change of the Preferred Stock
(other than as a result of a subdivision, combination or stock dividend provided for in <B>Section&nbsp;9</B>
hereof), or any consolidation of the Company with, or merger of the Company into, another
corporation or other business organization (other than a merger in which the Company is the
surviving corporation and which does not result in any reclassification or change of the
outstanding Preferred Stock), or any sale or conveyance to another corporation or other business
organization of all or substantially all of the assets of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b) </B>Notwithstanding any other provision of this Warrant, in the event of an automatic
conversion of the Company&#146;s outstanding Series&nbsp;D Preferred Stock into Common Stock in accordance
with the Company&#146;s Articles, as in effect from time to time, this Warrant shall thereafter
represent the right to acquire for the aggregate Purchase Price (as then in effect) the number of
shares of Common Stock into which the number of shares of Preferred Stock issuable upon exercise
of this Warrant would have then been convertible.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>12.&nbsp;Certificate of Adjustment. </B>Whenever the Purchase Price is adjusted, as herein provided,
the
Company shall promptly deliver to the Holder a certificate of the Company&#146;s chief financial
officer (or other
appropriate officer) setting forth the Purchase Price after such adjustment and setting forth
a brief statement of the
facts requiring such adjustment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>13.&nbsp;Notices of Record Date, Etc. </B>In the event of:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a) </B>any taking by the Company of a record of the holders of any class of securities for the
purpose of determining the holders thereof who are entitled to receive any dividend or other
distribution, or any right
to subscribe for, purchase, sell or otherwise acquire or dispose of any shares of stock of any
class or any other
securities or property, or to receive any other right;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b) </B>any reclassification of the capital stock of the Company, capital reorganization of the
Company, consolidation or merger involving the Company, or sale or conveyance of all or
substantially all of its
assets; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c) </B>any voluntary or involuntary dissolution, liquidation or winding-up of the
Company;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --> 4.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">then in each such event the Company will provide or cause to be provided to the Holder a
written notice thereof. Such notice shall be provided at least twenty (20)&nbsp;business days prior to
the date specified in such notice on which any such action is to be taken.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.&nbsp;Representations, Warranties and Covenants. </B>This Warrant is issued and delivered by the
Company and accepted by each Holder on the basis of the following representations, warranties
and covenants made
by the Company:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a) </B>The Company has all necessary corporate power and authority to issue, execute and
deliver this Warrant and to perform its obligations hereunder. This Warrant has been duly
authorized issued,
executed and delivered by the Company and is the valid and binding obligation of the Company,
enforceable in
accordance with its terms, except as enforceability may be limited by bankruptcy or similar
laws relating to the
enforcement of creditors&#146; rights generally.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b) </B>The shares of Preferred Stock issuable upon the exercise of this Warrant have been duly
authorized and reserved for issuance by the Company and, when issued in accordance with the
terms hereof, will be
validly issued, fully paid and nonassessable.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c) </B>The issuance, execution and delivery of this Warrant do not, and the issuance of the
 shares of Preferred Stock upon the exercise of this Warrant in accordance with the terms
hereof will not, (i)&nbsp;violate
or contravene the Company&#146;s Articles or by-laws, or any law, statute, regulation, rule,
judgment or order applicable
to the Company, (ii)&nbsp;violate, contravene or result in a breach or default under any contract,
agreement or instrument
to which the Company is a party or by which the Company or any of its assets are bound or
(iii)&nbsp;require the consent
or approval of or the filing of any notice or registration with any person or entity (other
than such notices or filings
as may be required under applicable securities laws).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d) </B>As long as this Warrant is, or any shares of Preferred Stock issued upon exercise of this
Warrant or any shares of Common Stock issued upon conversion of such shares of Preferred Stock
are, issued and
outstanding, the Company will provide to the Holder the financial and other information
described in that certain
Loan and Security Agreement No.&nbsp;4561 between the Company and Lighthouse Capital Partners V,
L.P. dated as of
March&nbsp;29, 2005.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e) </B>As of the date hereof, the authorized capital stock of the Company consists of (i)
65,500,000 shares of Common Stock, of which 8,909,357 shares are issued and outstanding and
185,714 shares are
reserved for issuance upon the exercise of this Warrant with respect to Common Stock and the
conversion of the
Preferred Stock into Common Stock if this Warrant is exercised with respect to Preferred
Stock, (ii)&nbsp;2,727,273
shares of Series&nbsp;A Preferred Stock, of which 2,727,273 are issued and outstanding shares,
(iii)&nbsp;6,460,675 shares of
Series&nbsp;B Preferred Stock, of which 6,460,675 are issued and outstanding shares, (iv)
20,551,163 shares of Series&nbsp;C
Preferred Stock, of which 16,364,832 are issued and outstanding shares, and (v)&nbsp;13,887,716
shares of Series&nbsp;D
Preferred Stock, of which 7,292,127 are issued and outstanding shares. Company has delivered
a capitalization
table to Holder summarizing the capitalization of the Company. At the request of Holder, not
more than once per
calendar quarter, the Company will provide Holder with a current capitalization table
indicating changes, if any, to
the number of outstanding shares of common stock and preferred stock.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>15.&nbsp;Registration Rights. </B>The Company grants to the Holder all the rights of a &#147;Holder&#148; &#091;and
an &#147;Investor&#148; under the Company&#146;s Amended and
Restated Investors&#146; Rights Agreement dated as of
December&nbsp;18,
2003 (the <I>&#147;Rights Agreement&#148;), </I>including, without limitation, the registration rights
contained therein, and agrees to
amend the Rights Agreement so that (i)&nbsp;the shares of Common Stock issuable upon conversion of
the shares of
Preferred Stock issuable upon exercise of this Warrant shall be <I>&#147;Registrable Securities&#148; </I>and
(ii)&nbsp;the Holder shall be
a &#147;Holder&#148; &#091;and an &#147;Investor&#148; for all purposes of such Rights Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>16.&nbsp;Amendment. </B>The terms of this Warrant may be amended, modified or waived only with the
written consent of the Holder and the Company.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --> 5.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>17.&nbsp;Representations and Covenants of the Holder. </B>This Warrant has been entered into
by the
Company in reliance upon the following representations and covenants of the Holder, which by
its execution hereof
the Holder hereby confirms:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;Investment Purpose. </B>The right to acquire Preferred Stock or the Preferred Stock
issuable upon exercise of the Holder&#146;s rights contained herein will be acquired for investment
and not with a view to
the sale or distribution of any part thereof, and the Holder has no present intention of
selling or engaging in any
public distribution of the same except pursuant to a registration or exemption.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;Accredited Investor. </B>Holder is an &#147;accredited investor&#148; within the meaning of Rule&nbsp;501
of Regulation&nbsp;D, promulgated under the 1933 Act as presently in effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;Private Issue. </B>The Holder understands (i)&nbsp;that neither the issuance of this Warrant nor
the issuance of any shares of the Company&#146;s capital stock issuable upon exercise of the
Holder&#146;s rights contained
herein has been registered under the 1933 Act or qualified under applicable state securities
laws on the ground that
the issuances contemplated by this Warrant will be exempt from the registration and
qualifications requirements
thereof, and (ii)&nbsp;that the Company&#146;s reliance on such exemption is predicated on the
representations of the Holderset
forth in this <B>Section&nbsp;17.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;Financial Risk. </B>The Holder has such knowledge and experience in financial and
business matters as to be capable of evaluating the merits and risks of its investment and has
the ability to bear the
economic risks of its investment.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>18.&nbsp;Notices, Transfers, Etc.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a) </B>Any notice or written communication required or permitted to be given to the Holder may
be given by certified mail or delivered to the Holder at the address most recently provided by
the Holder to the
Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b) </B>Subject to compliance with applicable federal and state securities laws, this Warrant may
be transferred by the Holder with respect to any or all of the shares purchasable hereunder.
Upon surrender of this
Warrant to the Company, together with the assignment notice annexed hereto duly executed, for
transfer of this
Warrant as an entirety by the Holder, the Company shall issue a new warrant of the same
denomination to the
assignee. Upon surrender of this Warrant to the Company, together with the assignment hereof
properly endorsed,
by the Holder for transfer with respect to a portion of the shares of Preferred Stock
purchasable hereunder, the
Company shall issue a new warrant to the assignee, in such denomination as shall be requested
by the Holder hereof,
and shall issue to such Holder a new warrant covering the number of shares in respect of which
this Warrant shall
not have been transferred.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c) </B>In case this Warrant shall be mutilated, lost, stolen or destroyed, the Company shall
issue
a new warrant of like tenor and denomination and deliver the same (i)&nbsp;in exchange and
substitution for and upon
surrender and cancellation of any mutilated Warrant, or (ii)&nbsp;in lieu of any Warrant lost,
stolen or destroyed, upon
receipt of an affidavit of the Holder or other evidence reasonably satisfactory to the Company
of the loss, theft or
destruction of such Warrant
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>19.&nbsp;No Impairment. </B>The Company will not, by amendment of its Articles or through any
reclassification, capital reorganization, consolidation, merger, sale or conveyance of assets,
dissolution, liquidation,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the
observance of performance of any
of the terms of this Warrant, but will at all times in good faith assist in the carrying out
of all such terms and in the
taking of all such action as may be necessary or appropriate in order to protect the rights of
the Holder. In no event
shall any reclassification, capital reorganization, consolidation, merger, sale or conveyance
of assets, dissolution,
liquidation, issue or sale of securities or any other transaction be deemed an &#147;impairment&#148;
for purposes of this
Section&nbsp;18 if the shares of the Company&#146;s capital stock issuable upon exercise of this Warrant
are affected thereby in
the same manner as outstanding shares of such capital stock.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --> 6.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>20. Governing Law. </B>The provisions and terms of this Warrant shall be governed by and
construed in accordance with the internal laws of the State of California without giving effect to its
principles regarding conflicts
of laws.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>21. Successors and Assigns. </B>This Warrant shall be binding upon the Company&#146;s successors and
assigns and shall inure to the benefit of the Holder&#146;s successors, legal representatives and
permitted assigns.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>22. Business Days. </B>If the last or appointed day for the taking of any action required or the
expiration
of any rights granted herein shall be a Saturday or Sunday or a legal holiday in California,
then such action may be
taken or right may be exercised on the next succeeding day which is not a Saturday or Sunday
or such a legal
holiday.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>23. Value. </B>The Company and the Holder agree that the value of this Warrant on the date of
grant is
$100.
</DIV>





<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gajus Worthington</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"> Gajus Worthington</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President &#38; CEO</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --> 7.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Subscription</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">To:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The
undersigned hereby subscribes for
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>  shares of Preferred Stock covered by this Warrant. The
certificate(s) for such shares shall be issued in the name of the undersigned or as otherwise
indicated below:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Name for Registration</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Mailing Address</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --> 1.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Net Issue Election Notice</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top">To: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">Date: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The undersigned hereby elects under <B>Section&nbsp;4 </B>to surrender the right to purchase shares of
Preferred Stock pursuant to this Warrant. The certificate(s) for such shares issuable upon such net
issue election shall be issued in the name of the undersigned or as otherwise indicated below:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Name for Registration</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Mailing Address</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --> 1.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Assignment</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">For value received <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> hereby sells, assigns and transfers unto</div>


<DIV align="right">
<DIV style="width: 33%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
</DIV>
</div>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
&#091;Please print or typewrite name and address of Assignee&#093;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the within
Warrant, and does hereby irrevocably constitute and appoint
<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>
its attorney to transfer the within Warrant on the books of the within named Company with full
power of substitution on the premises.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dated:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Name for Registration</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">In the Presence of:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
    <TR><TD>&nbsp;</TD></TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --> 1.<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4B
<SEQUENCE>8
<FILENAME>f39432orexv4w4b.htm
<DESCRIPTION>EXHIBIT 4.4B
<TEXT>
<HTML>
<HEAD>
<TITLE>exv4w4b</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;4.4B</B>
</DIV>




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Negative
Pledge Agreement</B></FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant: SMALL-CAPS"><B>This
Negative Pledge Agreement</B></FONT> is made as of March&nbsp;29, 2005, by and between
<FONT style="font-variant: SMALL-CAPS"><B>Fluidigm</B></FONT> <FONT style="font-variant: SMALL-CAPS"><B>Corporation</B></FONT> <I>(&#147;Borrower&#148;) </I>and <FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital Partners</B></FONT><B> V, L.P. </B><I>(&#147;Lender&#148;).</I>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In consideration of the Loan and Security Agreement between the parties of proximate date herewith
(the <I>&#147;Loan Agreement&#148;), </I>Borrower agrees as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Except as otherwise permitted in the Loan Agreement, Borrower shall not sell, transfer, assign,
mortgage, pledge, lease, grant a security interest in, or encumber any of Borrower&#146;s owned
intellectual property, including, without limitation, the following:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>(a) </B>Any and all copyright rights, copyright applications, copyright registration and like
protection in each work or
authorship and derivative work thereof, whether published or unpublished and whether or not the
same also constitutes a
trade secret, now or hereafter existing, created, acquired or held (collectively, the
<I>&#147;Copyrights&#148;);</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>(b) </B>Any and all trade secrets, and any and all intellectual property rights in computer software
and computer
software products now or hereafter existing, created, acquired or held;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>(c) </B>Any and all design rights which may be available to Borrower now or hereafter existing,
created, acquired or
held;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>(d) </B>All patents, patent applications and like protections, including, without limitation,
improvements, divisions,
continuations, renewals, reissues, extensions and continuations-in-part of the same, including,
without limitation, the
patents and patent applications (collectively, the <I>&#147;Patents&#148;);</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>(e) </B>Any trademark and servicemark rights, whether registered or not, applications to register and
registrations of the same and like protections, and the entire goodwill of the business of Borrower connected with
and symbolized by
such trademarks (collectively, the <I>&#147;Trademarks&#148;);</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>(f) </B>Any and all claims for damages by way of past, present and future infringements of any of the
rights included
above, with the right, but not the obligation, to sue for an collect such damages for said use or
infringement of the
intellectual property rights identified above;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>(g) </B>Any and all licenses or other rights to use any of the Copyrights, Patents or Trademarks and
all license fees and
royalties arising from such use to the extent permitted by such license or rights
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>(h) </B>Any and all amendments, extensions, renewals and extensions of any of the Copyrights, Patents
or Trademarks; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>(i) </B>Any and all proceeds and products of the foregoing, including, without limitation, all
payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">It shall be an Event of Default under the Loan Agreement if there is a breach of any term of this
Negative Pledge Agreement. Borrower agrees to properly execute all documents reasonably required
by Lender in order to fulfill the intent and purposes hereof.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital Partners</B></FONT><b> V, L.P.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gajus Worthington
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" colspan="3"  valign="top">By:&nbsp; <FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Management Partners</B></FONT><b> V</B>,
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" colspan="3"><B>L.L.C.</B>, its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Name:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Gajus Worthington</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Thomas Conneely</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President &#38; CEO</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Thomas Conneely</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 0px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">





<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><IMG src="f39432ore3943202.gif" alt="(FLUIDIGM LOGO)">

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">March&nbsp;29,
2005

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Lighthouse Capital Partners V,
L.P.<BR>
 500 Drakes Landing Road<BR>
Greenbrae, CA 94904

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Re: <U>Management Rights </u>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Ladies and Gentlemen:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This letter will confirm our agreement that pursuant to and effective as of the
date hereof Fluidigm Corporation (the <B>&#147;Company&#148;) </B>shall grant Lighthouse Capital
Partners V, L.P. (the <B>&#147;Investor&#148;) </B>the following contractual management rights, in
addition to any rights to non-public financial information, inspection rights, and
other rights specifically provided to Investor under that certain Loan and Security
Agreement of even date herewith (the &#147;Loan Agreement&#148;):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;If Investor is not represented on Company&#146;s Board of Directors, Investor shall be
entitled to consult with and advise management of the Company on significant business
issues,
including management&#146;s proposed annual operating plans, and management will meet with
Investor regularly during each year at the Company&#146;s facilities at mutually agreeable
times for
such consultation and advice and to review progress in achieving said plans.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;Investor may examine the books and records of the Company and inspect its
facilities
and may request information at reasonable times and intervals concerning the general
status of
the Company&#146;s financial condition and operations, provided that access to highly
confidential
proprietary information and facilities need not be provided.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;If Investor is not represented on the Company&#146;s Board of Directors, the Company
shall, concurrently with delivery to the Board of Directors, give a representative of
Investor
copies of all notices, minutes, consents and other material that the Company provides
to its
directors, except that the representative may be excluded from access to any material
or meeting
or portion thereof if the Board of Directors determines in good faith, upon advice of
counsel, that
such exclusion is reasonably necessary to preserve the attorney-client privilege, to
protect highly
confidential proprietary information, or for other similar reasons. Upon reasonable
notice and at
a scheduled meeting of the Board or such other time, if any, as the Board may
determine in its
sole discretion, such representative may address the Board with respect to Investor&#146;s
concerns
regarding significant business issues facing the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investor agrees that any confidential information provided to or learned by it
in connection with it rights under this letter shall be subject to the
confidentiality provisions set forth in that certain Investor&#146;s Rights Agreement
dated December&nbsp;18, 2003.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Fluidigm Corporation</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">7100
Shoreline Court, South San Francisco, California 94080 tel: 650.266.6000 fax: 650.871.7152 www.fluidigm.com

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The rights described herein shall terminate and be of no further force or effect upon (a)&nbsp;such time
as both (i)&nbsp;the Loan Agreement has been terminated following the repayment by the Company of all
amounts owed to Investor under the Loan Agreement and (ii)&nbsp;neither the Investor nor any of its
affiliates holds any shares of the Company&#146;s capital stock or warrants to purchase shares of the
Company&#146;s capital stock; (b)&nbsp;the consummation of the sale of the Company&#146;s securities pursuant to a
registration statement filed by the Company under the Securities Act of 1933, as amended, in
connection with the firm commitment underwritten offering of its securities to the general public
or (c)&nbsp;the consummation of a merger or consolidation of the Company that is effected (i)&nbsp;for
independent business reasons unrelated to extinguishing such rights and (ii)&nbsp;for purposes other the
(A)&nbsp;the reincorporation of the Company in a different state or (B)&nbsp;the formation of a holding
company that will be owned exclusively by the Company&#146;s stockholders and will hold all of the
outstanding shares of capital stock of the Company&#146;s successor. The confidentiality obligations
referenced here will survive any such termination.<BR>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Very truly yours,</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Agreed and Accepted:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>FLUIDIGM CORPORATION</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>LIGHTHOUSE CAPITAL PARTNERS V, L.P.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BY:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Lighthouse Management Partners V,</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">L.L.C., its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gajus Worthington</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Thomas Conneely</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Name:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Gajus Worthington
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Thomas Conneely</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 0px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President &#38; CEO
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 0px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Fluidigm Corporation</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt">7100 Shoreline Court, South San Francisco, California 94080 tel: 650.266.6000 fax: 650.871.7152 www.fluidigm.com
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>9
<FILENAME>f39432orexv4w5.htm
<DESCRIPTION>EXHIBIT 4.5
<TEXT>
<HTML>
<HEAD>
<TITLE>exv4w5</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;4.5</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CONVERTIBLE NOTE PURCHASE AGREEMENT</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">(US$15 Million Credit Facility)

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>August&nbsp;7, 2006</B>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="84%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD nowrap align="center" colspan="2"><B>Page</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR style="font-size: 1pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD nowrap align="center" colspan="2"  style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>


<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>1.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">The First Note</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Authorization; Purchaser&#146;s Obligation to Purchase</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">First Note Procedure</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Closing of First Note Purchase</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Effect of Change in Series E Preferred Stock</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>2.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Representations and Warranties of the Company</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Organization, Good Standing and Qualification</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Corporate Power</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Subsidiaries</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Capitalization</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Authorization</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Valid Issuance of Note and Conversion Shares</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Governmental Consents</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.8</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Litigation</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.9</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Employees</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.10</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Patents and Other Intangible Assets</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.11</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Compliance with Other Instruments</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">7</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.12</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Permits</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.13</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Environmental and Safety Laws</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.14</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title to Property and Assets</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.15</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Agreements; Action</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.16</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Financial Statements</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">9</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.17</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Changes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">9</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.18</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Brokers or Finders</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">10</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.19</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Employee Benefit Plans</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">10</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.20</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tax Matters</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">10</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.21</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Insurance</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">10</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.22</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Corporate Documents</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">11</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.23</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Disclosure</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">11</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.24</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Offering</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">11</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.25</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Returns and Complaints</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">11</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>3.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Representations and Warranties of the Purchasers</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">11</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Experience</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">11</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Investment</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">11</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Rule&nbsp;144</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">No Public Market</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Access to Data</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Authorization</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Accredited Investor</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-i-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">TABLE OF CONTENTS<br>(Continued)
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="84%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Page</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR style="font-size: 1pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>

        <TD>&nbsp;</TD>
<TD nowrap align="center" colspan="2"  style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>


<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.8</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Public Solicitation</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.9</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tax Advisors</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.10</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Purchaser Counsel</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.11</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Brokers or Finders</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.12</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Non-United States Persons</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>4.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Covenants of the Company</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Subsidiary Business Plan</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Subsidiary Board of Directors</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Affirmative Covenants</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Preservation of Existence</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Payment of Taxes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Compliance with Laws</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Maintenance of Properties</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.8</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Government Authority</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.9</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Opinion of Company Counsel</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>5.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Covenants of the Purchaser</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Transfers</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Additional Convertible Promissory Notes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>6.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Termination</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">17</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>7.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Miscellaneous</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">17</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Governing Law</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">17</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">California Corporate Securities Law</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">17</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Survival</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">17</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Successors and Assigns</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">18</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Entire Agreement; Amendment</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">18</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Notices, etc.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">18</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Counterparts; Facsimile</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.8</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Severability</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.9</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Expenses</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.10</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Titles and Subtitles</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.11</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Jury Trial</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.12</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Jurisdiction; Venue</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.13</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Currency</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-ii-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="4%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="94%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">EXHIBITS</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">A
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Convertible Promissory Note (First Note)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">B
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Convertible Promissory Note (Second Note)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">C
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Convertible Promissory Note (Third Note)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">D
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Compliance Certificate</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">E
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Investment Representation Statement</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">F
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Legal Opinion</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->-iii-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Fluidigm Corporation</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>CONVERTIBLE NOTE PURCHASE AGREEMENT</B><BR>
(US$15 Million Credit Facility)

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This <B>Convertible Note Purchase Agreement </B>(the &#147;<B>Agreement</B>&#148;) is made as of August&nbsp;7,&nbsp;2006, by
and between Fluidigm Corporation, a California corporation (the &#147;<B>Company</B>&#148;), and Biomedical Sciences
Investment Fund Pte Ltd (&#147;<B>Purchaser</B>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Purchaser has agreed to purchase, pursuant to the terms of this Agreement and
upon the election of the Company, up to US$15,000,000 in aggregate principal of Convertible
Promissory Notes of the Company;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Purchaser has agreed that the Company may elect to sell to the Purchaser within
the time periods set forth herein, and the Purchaser has agreed to purchase should the Company so
elect, a Convertible Promissory Note in the principal amount of US$5,000,000 in substantially the
form attached hereto as <U>Exhibit&nbsp;A</U> (the &#147;<B>First Note</B>&#148;), the principal and interest on which
are convertible into shares of Series&nbsp;E Preferred Stock of the Company upon the happening of
certain events described in the First Note;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, provided that the First Note has converted (as set forth in the First Note), the
Purchaser has agreed that the Company may elect to sell to the Purchaser within the time periods
set forth herein, and Purchaser has agreed to purchase should the Company so elect, a second
Convertible Promissory Note of the Company in the principal amount of US$5,000,000, in
substantially the form attached hereto as <U>Exhibit&nbsp;B</U> (the &#147;<B>Second Note</B>&#148;), the principal and
interest on which are convertible into shares of Series&nbsp;E Preferred Stock of the Company upon the
happening of certain events as described in the Second Note; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, provided that the Second Note has converted (as set forth in the Second Note), the
Purchaser has agreed that the Company may elect to sell to the Purchaser within the time periods
set forth herein, and Purchaser has agreed to purchase should the Company so elect, a third
Convertible Promissory Note of the Company in the principal amount of US$5,000,000, in
substantially the form attached hereto as <U>Exhibit&nbsp;C</U> (the &#147;<B>Third Note</B>,&#148; and together with
the First Note and the Second Note, an &#147;<B>Additional Note</B>&#148; or the &#147;<B>Additional Notes</B>&#148;), the principal
and interest on which are convertible into shares of Series&nbsp;E Preferred Stock of the Company upon
the happening of certain events as described in the Third Note.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, the parties hereby agree as follows:
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>The First Note</U>.&nbsp;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 <U>Authorization; Purchaser&#146;s Obligation to Purchase</U>.&nbsp; The Purchaser shall, at the
Company&#146;s election and in accordance with the procedures set forth in this Section&nbsp;1, purchase the
First Note. Such election shall indicate that the Company has authorized the sale and issuance of
the First Note in the principal amount of US$5,000,000, convertible (i)&nbsp;at the election of the
Purchaser, (ii)&nbsp;upon the achievement of certain Milestones (as set forth in the First Note), or
(iii)&nbsp;as otherwise as set forth in the First Note into shares of Series&nbsp;E Preferred Stock of the
Company at a conversion price of US$3.60 per share. Shares of Series&nbsp;E Preferred Stock together
with any other securities which may be issued upon conversion of any of the Additional Notes are
referred to herein as the &#147;<B>Note Shares</B>.&#148; The Additional Notes, the Note Shares and securities of
the Company issued or issuable upon conversion thereof are referred to herein as the &#147;<B>Securities</B>.&#148;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2 <U>First Note Procedure</U>.&nbsp; Subject to Section&nbsp;1.1, the Company may exercise its option to
require the Purchaser to purchase the First Note at any time on or before September&nbsp;30, 2006 by
giving Purchaser written notice thereof (the &#147;<B>First Note Election Notice</B>&#148;). The First Note
Election Notice shall state that the Company has elected to require the Purchaser to purchase the
First Note and shall indicate the date, time, and location of the closing of the purchase and sale
of the First Note (the &#147;<B>First Note Closing</B>&#148;), which shall occur no sooner than 14&nbsp;days or later
than 25&nbsp;days after the date of the First Note Election Notice.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3 <U>Closing of First Note Purchase</U>.&nbsp; At the First Note Closing, the Company shall deliver
to the Purchaser the First Note and a duly executed Compliance Certificate in the form attached
hereto as <U>Exhibit&nbsp;D</U> (the &#147;<B>Compliance Certificate</B>&#148;). At the First Note Closing, the
Purchaser shall deliver to the Company (i)&nbsp;the aggregate principal amount of the First Note
totalling US$5,000,000 by check or wire transfer and (ii)&nbsp;the Investment Representation Statement,
duly executed by Purchaser, in the form attached hereto as <U>Exhibit&nbsp;E</U> (the &#147;<B>Investment
Representation Statement</B>&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.4 <U>Effect of Change in Series&nbsp;E Preferred Stock</U>.&nbsp; The form of the First Note will be
modified upon the happening of certain events as set forth in Section&nbsp;5.2(d).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Representations and Warranties of the Company</U>.&nbsp; Except as set forth in the Schedule of
Exceptions dated of even date hereof and separately delivered to Purchaser contemporaneously with
the execution and delivery of this Agreement (the
&#147;<B>Schedule of Exceptions</B>&#148;), the Company represents and warrants to Purchaser as of the date
hereof as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 <U>Organization, Good Standing and Qualification</U>.&nbsp; The Company is a corporation duly
organized, validly existing and in good standing under the laws of the State of California and has
all requisite corporate power and authority to carry on its business as currently conducted. The
Company is duly qualified to transact business and is in good standing in each jurisdiction in
which the failure to so qualify, individually or in the aggregate, would have a material adverse
effect on its business (as now conducted), properties, or financial condition.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 <U>Corporate Power</U>.&nbsp; The Company has all requisite legal and corporate power and
authority to execute and deliver this Agreement and to carry out and perform its obligations under
the terms of this Agreement. Subject to the corporate authorization of and election to sell and
issue any of the Additional Notes hereunder, the Company will have all requisite legal and
corporate power and authority to (i)&nbsp;sell and issue the Additional Notes hereunder and (ii)&nbsp;issue
the Series&nbsp;E Preferred Stock initially issuable upon conversion of any of the Additional Notes.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3 <U>Subsidiaries</U>.&nbsp; The Company does not presently own or control, directly or indirectly,
any interest in any other corporation, association, or other business entity.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4 <U>Capitalization</U>.&nbsp; The authorized capital stock of the Company consists of 77,857,144
shares of Common Stock (&#147;<B>Common Stock</B>&#148;), of which 9,422,895 shares are issued and outstanding and
51,687,948 shares of Preferred Stock (&#147;<B>Preferred Stock</B>&#148;), 2,727,273 of which are designated
Series&nbsp;A Preferred Stock of which 2,727,273 are outstanding, 6,460,675 of which are designated
Series&nbsp;B Preferred Stock of which 6,460,675 are outstanding, 17,000,000 of which are designated
Series&nbsp;C Preferred Stock, 16,364,832 of which are issued and outstanding, 15,500,000 of which are
designated Series&nbsp;D Preferred Stock, 12,196,191 of which are issued and outstanding, and 10,000,000
of which are designated Series&nbsp;E Preferred Stock, 1,250,000 of which are issued and outstanding.
All such issued and outstanding shares have been duly authorized and validly issued in compliance
with applicable laws, and are fully paid and nonassessable.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the sale and issuance of any Additional Notes, the Company will have
reserved 4,166,667 shares of Series&nbsp;E Preferred Stock for issuance upon conversion of such
Additional Note (the &#147;<B>Conversion Shares</B>&#148;) and 4,166,667 shares of Common Stock for issuance upon
conversion of such Conversion Shares. As of the date of this Agreement, the Company has reserved:
(i)&nbsp;10,000,000 shares of Common Stock for issuance upon conversion of the outstanding shares of
Series&nbsp;E Preferred Stock; (ii)&nbsp;12,196,191 shares of Common Stock for issuance upon
conversion of the outstanding shares of Series&nbsp;D Preferred Stock; (iii)&nbsp;408,928 shares of
Series&nbsp;D Preferred Stock for issuance upon exercise of outstanding warrants and 408,928 shares of
Common Stock for issuance upon conversion of such Series&nbsp;D Preferred Stock; (iv)&nbsp;16,364,832 shares
of Common Stock for issuance upon conversion of the outstanding shares of Series&nbsp;C Preferred Stock;
(v)&nbsp;294,868 shares of Series&nbsp;C Preferred Stock for issuance upon exercise of outstanding warrants
and 294,868 shares of Common Stock for issuance upon conversion of such Series&nbsp;C Preferred Stock;
(vi)&nbsp;6,460,675 shares of Common Stock for issuance upon conversion of the outstanding Series&nbsp;B
Preferred Stock; (vii)&nbsp;2,727,273 shares of Common Stock for issuance upon conversion of the
outstanding Series&nbsp;A Preferred Stock; and (viii)&nbsp;an aggregate of 10,800,000 shares of Common Stock
for issuance to employees and consultants of the Company pursuant to the Company&#146;s 1999 Stock Plan,
pursuant to which options to purchase 5,276,828 shares are granted and outstanding and 1,727,039
shares are available for future grant. Other than with respect to the shares reserved for issuance
in the preceding sentence, or as set forth in this Agreement, the Investor Rights Agreement (as
defined below) or the Voting Agreement (as defined below), there are no outstanding rights,
options, warrants, conversion rights, preemptive rights, rights of first refusal or similar rights
for the purchase or acquisition from the Company of any securities of the Company. There are no
outstanding obligations of the Company to repurchase or redeem any of its securities.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as contemplated in the Eighth Amended and Restated Investor Rights Agreement dated
June&nbsp;13, 2006 (the &#147;<B>Investor Rights Agreement</B>&#148;), the Company has not granted or agreed to grant any
registration rights, including piggyback rights, to any person or entity. Except as contemplated
in the Second Amended and Restated Voting Agreement dated August&nbsp;16, 2005 (the &#147;<B>Voting Agreement</B>&#148;),
the Company is not a party or subject to any agreement or understanding, and to the Company&#146;s
knowledge, there is no agreement or understanding between any person or entities, which relates to
the voting or the giving of written consents with respect to any security of the Company or by a
director of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5 <U>Authorization</U>.&nbsp; All corporate action on the part of the Company, its officers,
directors and shareholders necessary for the authorization, execution and delivery of this
Agreement, the performance of all obligations of the Company under this Agreement has been taken,
subject to corporate authorization of any election to require the Purchasers to purchase Additional
Notes pursuant to this Agreement. This Agreement constitutes a valid and legally binding
obligation of the Company, enforceable in accordance with its terms, subject to: (i)&nbsp;judicial
principles limiting the availability of specific performance, injunctive relief, and other
equitable remedies; and (ii)&nbsp;bankruptcy, insolvency, reorganization, moratorium or other similar
laws now or hereafter in effect generally relating to or affecting creditors&#146; rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.6 <U>Valid Issuance of Note and Conversion Shares</U>.&nbsp; Any Additional Note that is purchased
by the Purchaser hereunder, when issued, sold and delivered in accordance with the terms of this
Agreement, will be free of restrictions on transfer other than restrictions on transfer under this
Agreement, such Additional Note, and the Investor
Rights Agreement and under applicable state and federal securities laws as in effect on the
date of issuance of such Additional Note. Any Conversion Shares (and the shares of Common Stock
issuable upon conversion thereof) will have been duly and validly reserved for issuance, and, upon
issuance in accordance with the terms of the applicable Additional Note and the Amended and
Restated Articles of Incorporation of the Company as amended through the date of issuance of such
Additional Note (the &#147;<B>Restated Articles</B>&#148;), will be duly and validly issued, fully paid, and
nonassessable and will be free of restrictions on transfer other than restrictions on transfer
under this Agreement, the terms of the applicable Additional Note, and the Investor Rights
Agreement and under applicable state and federal securities laws as in effect on the date of
issuance of such Additional Note. The Conversion Shares (and the shares of Common Stock issuable
upon conversion thereof) may be issued without any registration or qualification under state and
federal securities laws as such laws are in effect as of the date of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.7 <U>Governmental Consents</U>.&nbsp; As of the date of this Agreement, no consent, approval, order
or authorization of, or registration, qualification, designation, declaration or filing with, any
federal, state or local governmental authority on the part of the Company would be required in
connection with the offer, sale or issuance of any of the Additional Notes or the Conversion Shares
(and the shares of Common Stock issuable upon conversion thereof) or the consummation of any other
transaction contemplated hereby, except in connection with the sale and issuance of Additional
Notes for filings that may be required pursuant to applicable federal and state securities laws and
blue sky laws, which filings, the Company covenants to complete within the required statutory
period.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.8 <U>Litigation</U>.&nbsp; There is no action, suit, proceeding or investigation pending or, to the
Company&#146;s knowledge, currently threatened against the Company before any court, administrative
agency or other governmental body which questions the validity of this Agreement or the Investor
Rights Agreement or the right of the Company to enter into any of them, or to consummate the
transactions contemplated hereby or thereby, or which could result, either individually or in the
aggregate, in any material adverse change in the condition (financial or otherwise), business,
property, assets or liabilities of the Company, nor is the Company aware that there is any basis
for the foregoing. The Company is not a party or subject to, and none of its assets is bound by,
the provisions of any order, writ, injunction, judgment or decree of any court or government agency
or instrumentality. There is no action, suit, proceeding or investigation by or involving the
Company currently pending or that the Company intends to initiate.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.9 <U>Employees</U>.&nbsp; Each employee of the Company has executed a proprietary information and
invention assignment agreement substantially in the form or forms made available to the Purchaser.
To the Company&#146;s knowledge, no officer or key employee is in violation of any prior employee
contract or proprietary information agreement. No employees of the Company are represented by any
labor union or covered by any collective bargaining agreement. There is no pending or, to the
Company&#146;s
knowledge, threatened labor dispute involving the Company and any group of its employees. The
Company is not aware that any officer or key employee intends to terminate his or her employment
with the Company within the six months after the date of this Agreement. The Company does not have
a present intention to terminate the employment of any officer or key employee. Each officer and
key employee is devoting 100% of his or her business time to the conduct of the business of the
Company. The Company is not aware that any officer or key employee intends to work less than full
time during the six months after the date of this Agreement. Subject to general principles related
to wrongful termination of employees, the employment of each officer and employee of the Company is
terminable at will.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.10 <U>Patents and Other Intangible Assets</U>.&nbsp;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Company owns, or is licensed or otherwise has the legally enforceable right to use,
all copyrights, domain names, maskworks, applications for the issuance or registration of any of
the foregoing, trade secrets, confidential or proprietary know-how, data and information, ideas,
inventions, designs, developments, algorithms, processes, schematics, techniques, computer
programs, applications and other software, works of authorship, creative effort and, to the
Company&#146;s knowledge after such investigation as the Company deemed reasonable, patents, patent
applications, trademarks (including service marks and design marks) and applications therefor,
tradenames (all of the foregoing generically, &#147;<B>Intellectual Property Rights</B>&#148;) utilized in, or
necessary for, its business as now conducted (collectively, the &#147;<B>Company Intellectual Property</B>&#148;)
without infringing upon the right of any person, corporation or other entity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Section&nbsp;2.10 of the Schedule of Exceptions lists (i)&nbsp;all patents and patent applications
and all registered and unregistered trademarks, trade names, copyrights and maskworks and
registered domain names included in the Company Intellectual Property, including the jurisdictions
in which each such intellectual property right has been issued or registered or in
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-5-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">which any
application for such issuance or registration has been filed, (ii)&nbsp;all licenses, sublicenses,
collaborations and other agreements (or options for any of the foregoing) to which the Company is a
party and pursuant to which any person, corporation or other entity is authorized to use any of the
Company Intellectual Property, and (iii)&nbsp;all licenses, sublicenses, collaborations and other
agreements (or options for any of the foregoing) to which the Company is a party and pursuant to
which the Company is authorized to use any Intellectual Property Right of any third party (other
than standard licenses for commercially available software). Each of the agreements in (ii)&nbsp;and
(iii)&nbsp;above remain in full force and effect and, to the Company&#146;s knowledge, no party to any such
agreement is in material breach or default under such agreement, and the Company is not aware of
any act or failure to act by a party which would constitute a material breach or default under any
such agreement, give rise to a right of the licensor to terminate any such agreement or otherwise
result in termination of, or suspension or loss of exclusive rights under, any such agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;To the Company&#146;s knowledge, the Company has not infringed or misappropriated any
Intellectual Property Right of any other person, corporation or other entity. The Company has not
received any communication or otherwise received any information alleging any
such conduct by the Company or asserting a claim by any third party to the ownership of, or
right to use, any of the Company Intellectual Property, and the Company does not know of any basis
for any such claim. The Company is not aware of any action, suit, proceeding or investigation
pending or currently threatened against the Company (or any third party owner or licensor of rights
to the Company of any of the Company Intellectual Property) which would have a material impact on
the Company&#146;s ownership of or exclusive or co-exclusive rights to use, the Company Intellectual
Property.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The Company is not aware that any of its employees is obligated under any agreement, or
subject to any judgment, decree or order of any court or administrative agency, that would
materially interfere with his or her ability to fully and freely perform their duties to the
Company or that would conflict with the Company&#146;s business. To the Company&#146;s knowledge, neither
the execution and delivery of this Agreement nor the issuance of any of the Additional Notes nor
the carrying on of the Company&#146;s business by the employees of the Company, will conflict with or
result in a material breach of the terms, conditions, or provisions of, or constitute a default
under, any agreement under which any such employee is now obligated. The Company does not utilize,
and will not be required to utilize, any invention, development or work of authorship of any of its
employees (or persons it currently intends to hire) made prior to their employment by the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;Except as described in Schedule&nbsp;2.10, (i)&nbsp;the Company is not obligated, or under any
liability whatsoever to make any payments by way of royalties, fees or otherwise, to any owner or
licensor of, or other claimant to, any Company Intellectual Property, and (ii)&nbsp;the Company is not a
party to any agreement concerning the Company Intellectual Property or any other Intellectual
Property Right used or to be used by the Company in its business as conducted. No founder,
director, officer or employee of the Company, or, to the Company&#146;s knowledge, no shareholder of the
Company has any interest in the Company Intellectual Property.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-6-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Except with respect to any rights granted under the agreements described in Schedule&nbsp;2.10,
the Company owns exclusively all rights arising from or associated with the research and
development efforts of the Company, its founders, employees and independent contractors relating to
the Company&#146;s business as now conducted, and all such rights form part of the Company Intellectual
Property. The Company has secured valid written assignments from all employees and independent
contractors who contributed to the creation or development of any of the Company Intellectual
Property of the rights to such contributions that the Company does not already own by operation of
law. The Company has not received notice of any claim being asserted by any current or former
employee, independent contractor or other third party to the ownership, of or right to use, any of
the Company Intellectual Property, or challenging or questioning the validity of any of the Company
Intellectual Property, and the Company is not aware of any basis for any such claim.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;The Company has taken reasonable steps to protect and preserve the confidentiality of all
material trade secrets included in Company Intellectual Property not otherwise protected by patents
or copyright (&#147;<B>Confidential Information</B>&#148;). All disclosure of Confidential Information to a third
party has been pursuant to the terms of a written confidentiality or non-disclosure agreement
between the Company and such third party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;The Company hereby represents and warrants that the data, written and oral reports and
other representations and information that the Company provided to its investors (or their counsel)
pertaining to the Company Intellectual Property, when taken as a whole, were truthful and, to the
Company&#146;s knowledge, accurate in all material respects, and there was no omission therefrom which
made such information misleading, or incomplete in any material way.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.11 <U>Compliance with Other Instruments</U>.&nbsp; The Company is not in violation or default of any
provision of its Articles of Incorporation or Bylaws, each as amended and in effect on and as of
the date hereof. The Company is not in violation or default of any material provision of any
instrument, mortgage, deed of trust, loan, contract, commitment, judgment, decree, order or
obligation to which it is a party or by which it or any of its properties or assets are bound or,
to the best of its knowledge, of any provision of any federal, state or local statute, rule or
governmental regulation. The execution, delivery and performance of and compliance with this
Agreement, the Investor Rights Agreement and the Voting Agreement and the issuance and sale of the
Additional Notes, will not result in any such violation, be in conflict with or constitute, with or
without the passage of time or giving of notice, a default under any such provision, license,
indenture, instrument, mortgage, deed of trust, loan, contract, commitment, judgment, decree, order
or obligation; or require any consent or waiver under any such provision, license, indenture,
instrument, mortgage, deed of trust, loan, contract, commitment, judgment, decree, order or
obligation (other than any consents or waivers that have been obtained); or result in the creation
of any mortgage, pledge, lien, encumbrance or charge upon any of the properties or assets of the
Company pursuant to any such provision, license, indenture, instrument, mortgage, deed of trust,
loan, contract, commitment, judgment, decree, order or obligation.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->-7-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.12 <U>Permits</U>.&nbsp; The Company has all franchises, permits, licenses, and any similar authority
necessary for the conduct of its business as now being conducted by it. The Company is not in
default in any material respect under any of such franchises, permits, licenses, or other similar
authority.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.13 <U>Environmental and Safety Laws</U>.&nbsp; To its knowledge, the Company is not in violation of
any applicable statute, law, or regulation relating to the environment or occupational health and
safety, and to its knowledge, no material expenditures by the Company are or will be required in
order to comply with any such existing statute, law, or regulation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.14 <U>Title to Property and Assets</U>.&nbsp; The Company has good and marketable title to all of its
properties and assets free and clear of all pledges, mortgages, liens, security interests, charges
and encumbrances, except liens for current taxes and assessments not yet due and possible minor
liens and encumbrances which do not,
in any case, individually or in the aggregate, materially detract from the value of the
property subject thereto or materially impair the ownership or use of said property or assets, or
the operations of the Company. With respect to the property and assets it leases, the Company is
in compliance with such leases and, to the best of its knowledge, holds a valid leasehold interest
free of all liens, claims or encumbrances. The Company&#146;s properties and assets are in good
condition and repair in all material respects.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.15 <U>Agreements; Action</U>.&nbsp;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Except for agreements contemplated by this Agreement, there are no agreements,
understandings or proposed transactions between the Company and any of its officers, directors,
affiliates, or any affiliate thereof other than standard option grants and stock purchase
agreements entered into prior to the date of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;There are no agreements, understandings, instruments, contracts, proposed transactions,
judgments, orders, writs or decrees to which the Company is a party or by which it is bound that
may involve (i)&nbsp;obligations (contingent or otherwise) of, or payments by the Company in excess of,
US$100,000, other than in the ordinary course of business, (ii)&nbsp;the license of any patent,
copyright, trade secret or other proprietary right to or from the Company other than standard
commercial software licenses, (iii)&nbsp;provisions restricting or adversely affecting the development,
manufacture or distribution of the Company&#146;s products or services, or (iv)&nbsp;indemnification by the
Company with respect to infringements of proprietary rights other than indemnifications entered
into in the ordinary course of business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;For the purposes of subsection&nbsp;(b) above, all indebtedness, liabilities, agreements,
understandings, instruments, contracts and proposed transactions involving the same person or
entity (including persons or entities the Company has reason to believe are affiliated therewith)
shall be aggregated for the purpose of meeting the individual minimum dollar amounts of such
subsection.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-8-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The Company is not a party to and is not bound by any contract, agreement or instrument,
or subject to any restriction under its Restated Articles or its Bylaws that adversely affects its
business as now conducted, its properties or its financial condition.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;The Company is not a guarantor or indemnitor of any indebtedness of any other person or
entity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;The Company has not engaged in the past three months in any discussion (i)&nbsp;with any
representative of any entity or entities regarding the merger of the Company with or into any such
entity or entities or any affiliate thereof, (ii)&nbsp;with any representative of any entity or any
individual regarding the sale, conveyance or disposition of all or substantially all of the assets
of the Company or a transaction or series of related transactions in which more than fifty
percent (50%) of the voting power of the Company would be disposed of, or (iii)&nbsp;regarding any
other form of liquidation, dissolution or winding up of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.16 <U>Financial Statements</U>.&nbsp; The Company has fully provided the Purchaser with all the
information that the Purchaser has requested for deciding whether to enter into this Agreement and
to acquire the Additional Notes. The Company has made available to Purchaser its audited balance
sheets dated as of December&nbsp;31, 2005 and the audited statement of operations for the fiscal year
then ended, its unaudited balance sheets as of March&nbsp;31, 2006, and its unaudited statement of
operations and cash flow statement covering the three month period then ended (collectively, the
&#147;<B>Financial Statements</B>&#148;). The Financial Statements are complete and correct in all material
respects and have been prepared in accordance with generally accepted accounting principles applied
on a consistent basis throughout the periods indicated. The Financial Statements accurately set
out and describe the financial condition and operating results of the Company as of the date, and
during the periods, indicated therein. Except as set forth in the Financial Statements, the
Company has no material liabilities, contingent or otherwise, other than (i)&nbsp;liabilities incurred
in the ordinary course of business subsequent to March&nbsp;31, 2006 and (ii)&nbsp;obligations under
contracts and commitments incurred in the ordinary course of business and not required under
generally accepted accounting principles to be reflected in the Financial Statements, which, in
both cases, individually or in the aggregate are not material to the financial condition or
operating results of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.17 <U>Changes</U>.&nbsp; Since March&nbsp;31, 2006:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;the Company has not (i)&nbsp;declared or paid any dividends or authorized or made any
distribution upon or with respect to any class or series of its capital stock, (ii)&nbsp;incurred any
indebtedness for money borrowed or any other liabilities outside the ordinary course of its
business individually in excess of US$100,000 or, in the case of indebtedness and/or liabilities
individually less than US$100,000, in excess of US$200,000 in the aggregate, (iii)&nbsp;made any loans
or advances to any person, other than ordinary advances for reimbursable businesses expenses,
(iv)&nbsp;sold, exchanged, assigned, transferred, licensed or otherwise disposed of any of its assets or
rights (including Company Intellectual Property), other than the sale of its inventory in the
ordinary course of business, (v)&nbsp;waived or compromised a valuable right or a material debt owed to
it, (vi)&nbsp;materially changed any compensation arrangement or agreement with any employee, officer,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-9-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">director or shareholder, or (vii)&nbsp;arranged or committed to do any of the things described in this
subsection&nbsp;(a); and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;there has not been (i)&nbsp;a loss of, or a material order cancellation by, any major customer
of the Company, (ii)&nbsp;any damage, destruction or loss, whether or not covered by insurance,
materially and adversely affecting the business, properties, or financial condition of the Company,
(iii)&nbsp;any change in the assets, liabilities, financial condition or operating results of the
Company from that reflected in the Financial Statements, except changes in the ordinary course of
business that have not been, in the aggregate, materially adverse, (iv)&nbsp;any resignation or
termination
of any officer or key employee of the Company, and the Company is not aware of the impending
resignation or termination of employment of any such officer, or (v)&nbsp;to the best of the Company&#146;s
knowledge, any other event or condition of any character that would materially and adversely affect
the business, properties, or financial condition of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.18 <U>Brokers or Finders</U>.&nbsp; The Company has not agreed to incur, directly or indirectly, any
liability for brokerage or finders&#146; fees, agents&#146; commissions or other similar charges in
connection with this Agreement or any of the transactions contemplated hereby.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.19 <U>Employee Benefit Plans</U>.&nbsp; The Company does not have any Employee Benefit Plan as
defined in the Employee Retirement Income Security Act of 1974 other than the Company&#146;s 401(k)
Plan. The Company is in material compliance with the terms of the Company&#146;s 401(k) Plan and has
not received notice of any material increase in the costs of such plans.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.20 <U>Tax Matters</U>.&nbsp; The Company has filed all tax returns and reports as required by law.
These returns and reports are true and correct in all material respects. The Company has paid all
taxes and other assessments due. The Company has not elected pursuant to the Code, to be treated
as a Subchapter S corporation or a collapsible corporation pursuant to Section&nbsp;1362(a) or
Section&nbsp;341(f) of the Code, nor has it made any other elections pursuant to the Code (other than
elections that relate solely to methods of accounting, depreciation or amortization) that would
have a material effect on the business, properties or condition (financial or otherwise) of the
Company. None of the Company&#146;s tax returns have ever been audited by any governmental authorities.
The Company has withheld or collected from each payment made to its employees the amount of all
taxes (including without limitation, federal income taxes, Federal Insurance Contribution Act taxes
and Federal Unemployment Tax Act taxes) required to be withheld or collected therefrom, and has
paid the same to the proper tax receiving officers or authorized depositories.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.21 <U>Insurance</U>.&nbsp; The Company has in full force and effect fire and casualty insurance
policies, with extended coverage, sufficient in amount (subject to reasonable deductibles) to allow
it to replace any of its properties that might be damaged or destroyed. The Company has obtained
term life insurance payable to the Company on the lives of Stephen Quake and Gajus Worthington in
the amount of US$500,000. The Company has in full force and effect directors and officers
liability insurance, covering its directors, with aggregate coverage in the amount of US$2,000,000.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->-10-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.22 <U>Corporate Documents</U>.&nbsp; The Restated Articles and By-Laws of the Company are in the form made available to the
Purchaser. The copy of the minute books of the Company made available to Purchaser&#146;s counsel
contains true and correct minutes of all meetings of directors (including any committees thereof)
and shareholders and all actions by written consent taken without a meeting by the directors and
shareholders since December&nbsp;18, 2003.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.23 <U>Disclosure</U>.&nbsp; The Company has fully provided Purchaser with all the information which
Purchaser has requested in connection with the purchase of the Additional Notes hereunder, as well
as all information which the Company in its judgment believes is reasonably necessary to enable
Purchaser to make a decision as to whether to enter into this Agreement and to invest in the
Company. Neither this Agreement with the Exhibits hereto, nor any other statements, certificates
or documents made or delivered in connection herewith or therewith, contains any untrue statement
of a material fact or omits to state a material fact necessary to make the statements herein or
therein not misleading in light of the circumstances under which they were made. The financial
projections made available to the Purchaser (the &#147;<B>Projections</B>&#148;) were prepared in good faith and
based upon assumptions that the Company believes are reasonable, and represent the Company&#146;s good
faith estimate of its future plans and results; provided however, that the Company does not
represent or warrant that it will achieve any of the Projections.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.24 <U>Offering</U>.&nbsp; Subject in part to the truth and accuracy of Purchaser&#146;s representations
set forth in this Agreement, the offer, sale and issuance of the Additional Notes as contemplated
by this Agreement would be, if issued as of this date of this Agreement, exempt from the
registration requirements of the Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;), and
neither the Company nor any authorized agent acting on its behalf will take any action hereafter
that would cause the loss of such exemption.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.25 <U>Returns and Complaints</U>.&nbsp; The Company has not received customer complaints concerning
alleged defects in the design of its products that, if true, would have, individually or in the
aggregate, a material adverse effect on its business, properties, or financial condition.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Representations and Warranties of the Purchasers</U>.&nbsp; Purchaser hereby represents,
warrants and agrees as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 <U>Experience</U>.&nbsp; Purchaser is experienced in evaluating start-up companies such as the
Company, is able to evaluate and represent its own interests in transactions such as the one
contemplated by this Agreement, has such knowledge and experience in financial and business matters
such that
Purchaser is capable of evaluating the merits and risks of Purchaser&#146;s investment in the
Company, and has the ability to bear the economic risks of its investment.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 <U>Investment</U>.&nbsp; Purchaser is acquiring and will acquire, the Securities, for investment
for Purchaser&#146;s own account and not with the view to, or for resale in connection with, any
distribution thereof. Purchaser understands that the Securities have not been registered under the
Securities Act by reason of a specific exemption from the registration provisions of the Securities
Act, which depends upon, among other things, the bona fide nature of Purchaser&#146;s investment intent
as expressed herein. Purchaser further represents that it does not have any contract, undertaking,
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-11-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">agreement or arrangement with any person to sell, transfer or grant participation to any third
person with respect to any of the Securities other than a transfer not involving a change of
beneficial ownership. Purchaser understands and acknowledges that the offering of the Securities
pursuant to this Agreement will not be registered under the Securities Act on the ground that the
sale provided for in this Agreement is exempt from the registration requirements of the Securities
Act.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3 <U>Rule&nbsp;144</U>.&nbsp; Purchaser acknowledges that the Securities must be held indefinitely unless
subsequently registered under the Securities Act or an exemption from such registration is
available. Purchaser is aware of the provisions of Rule&nbsp;144 promulgated under the Securities Act,
which permit limited resale of shares purchased in a private placement subject to the satisfaction
of certain conditions. Purchaser covenants that, in the absence of an effective registration
statement covering the securities in question, Purchaser will sell, transfer, or otherwise dispose
of the Securities only in accordance with applicable securities laws and in a manner consistent
with Purchaser&#146;s representations and covenants set forth in this Agreement and the applicable
Additional Note. In connection therewith, Purchaser acknowledges that the Company will make a
notation on its stock books regarding the restrictions on transfer set forth in this Agreement and
the applicable Additional Note and will transfer securities on the books of the Company only to the
extent not inconsistent therewith.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4 <U>No Public Market</U>.&nbsp; Purchaser understands that no public market now exists for any of
the securities issued by the Company, and that the Company has made no assurances that a public
market will ever exist for the Securities.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.5 <U>Access to Data</U>.&nbsp; Purchaser has received and reviewed information about the Company and
has had an opportunity to discuss the Company&#146;s business, management and financial affairs with its
management and to review the Company&#146;s facilities.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.6 <U>Authorization</U>.&nbsp; This Agreement when executed and delivered by the Purchaser will constitute a valid and
legally binding obligation of the Purchaser, enforceable against the Purchaser in accordance with
its terms, subject to: (i)&nbsp;judicial principles respecting election of remedies or limiting the
availability of specific performance, injunctive relief, and other equitable remedies; and
(ii)&nbsp;bankruptcy, insolvency, reorganization, moratorium or other similar laws now or hereafter in
effect generally relating to or affecting creditors&#146; rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.7 <U>Accredited Investor</U>.&nbsp; Purchaser acknowledges that it is an &#147;accredited investor&#148; as
defined in Rule&nbsp;501 of Regulation&nbsp;D as promulgated by the United States Securities and Exchange
Commission (the &#147;<B>Commission</B>&#148;) under the Securities Act and shall submit to the Company such further
assurances of such status as may be reasonably requested by the Company. The principal address of
such Purchaser is as set forth on the signature page hereto.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.8 <U>Public Solicitation</U>.&nbsp; Purchaser knows of no public solicitation or advertisement of an
offer in connection with the proposed issuance and sale of the Securities.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.9 <U>Tax Advisors</U>.&nbsp; Purchaser has reviewed with its own tax advisors the tax consequences
of the purchase of the Securities and the transactions contemplated by this Agreement.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-12-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Purchaser
is relying solely on such advisors and not on any statements or representations of the Company or
any of its agents and understands that Purchaser (and not the Company) shall be responsible for the
Purchaser&#146;s own tax liability that may arise as a result of the Purchase of the Securities or the
transactions contemplated by this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.10 <U>Purchaser Counsel</U>.&nbsp; Purchaser acknowledges that it has had the opportunity to review
this Agreement and the exhibits hereto and the transactions contemplated by this Agreement with its
own legal counsel. Purchaser is relying solely on such counsel and not on any statements or
representations of the Company or any of its agents for legal advice with respect to this
investment or the transactions contemplated by this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.11 <U>Brokers or Finders</U>.&nbsp; The Company has not incurred and will not incur, directly or
indirectly, as a result of any action taken by such Purchaser, any liability for brokerage or
finders&#146; fees or agents&#146; commissions or any similar changes in connection with this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.12 <U>Non-United States Persons</U>.&nbsp; Purchaser hereby represents that Purchaser is satisfied as to the full observance of the
laws of Purchaser&#146;s jurisdiction in connection with any invitation to subscribe for the Securities
and the Additional Notes (and securities issuable upon conversion thereof) or any use of this
Agreement, including (i)&nbsp;the legal requirements within Purchaser&#146;s jurisdiction for the purchase of
the Securities and the Additional Notes (and securities issuable upon conversion thereof), (ii)&nbsp;any
foreign exchange restrictions applicable to such purchase, (iii)&nbsp;any governmental or other consents
that may need to be obtained and (iv)&nbsp;the income tax and other tax consequences, if any, that may
be relevant to the purchase, holding, redemption, sale or transfer of such securities. Purchaser&#146;s
subscription and payment for, and Purchaser&#146;s continued beneficial ownership of, the Securities and
the Additional Notes (and securities issuable on conversion thereof) will not violate any
applicable securities or other laws of Purchaser&#146;s jurisdiction.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Covenants of the Company</U>.&nbsp; The Company hereby covenants and agrees as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 <U>Subsidiary Business Plan</U>.&nbsp; The Company has incorporated a wholly owned (either
directly or indirectly through another subsidiary of the Company) subsidiary of the Company in
Singapore (the &#147;<B>Subsidiary</B>&#148;). Unless prohibited by applicable law, or unless the Company and the
Purchaser otherwise agree in writing, from and after incorporation of the Subsidiary, the Company
shall cause the Subsidiary to use commercially reasonable efforts to conduct, its activities
materially in accordance with the provisions of the business plan as established by the Board of
Directors of the Subsidiary and described to the Purchaser, including the Subsidiary&#146;s plans with
respect to the BioMark II project, as may be modified as set forth in this Section&nbsp;4.1 (the
&#147;<B>Subsidiary Business Plan</B>&#148;); <U>provided</U>, <U>however</U>, that the Company and the Subsidiary
shall have no such obligation in the event the Subsidiary does not receive a grant under the
Singapore Research Incentive Scheme for Companies (&#147;<B>RISC</B>&#148;) and tax incentives from the Economic
Development Board of Singapore (the &#147;<B>EDB</B>&#148;) consistent with the application submitted by the Company
to the EDB. Notwithstanding any provision in this Agreement to the contrary, the Company and
Purchaser agree that the Subsidiary Business Plan may only be modified by the Board of Directors of
the Subsidiary.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->-13-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 <U>Subsidiary Board of Directors</U>.&nbsp; Unless the Purchaser or its affiliates (as such term
is defined under Rule&nbsp;12b-2 promulgated by the Commission under the Securities Exchange Act of
1934, as amended) shall fail to hold 500,000 shares of the Company&#146;s Common Stock (on an as
converted basis), the Company agrees that it will vote the voting securities of the Subsidiary now
or hereafter held by the Company in such a manner as may be necessary to elect a nominee of
Purchaser to the Board of Directors of the Subsidiary (the &#147;<B>Nominee</B>&#148;). The Purchaser may notify
the Company in writing of an intention to remove from the Subsidiary&#146;s Board of Directors any
incumbent Nominee or notify the Company in writing of an intention to select a new Nominee. In
such event the Company shall take reasonable actions necessary to facilitate such removal and
election of the new Nominee to the Board of Directors of the Subsidiary.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3 <U>Affirmative Covenants</U>.&nbsp; So long as any of the Additional Notes (if issued) shall
remain unpaid or unconverted or the Purchaser shall have any obligation to purchase any of the
Additional Notes hereunder, the Company agrees that:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4 <U>Preservation of Existence</U>.&nbsp; It will maintain and preserve, through itself or any
successor to its business, its corporate existence and its rights to transact business and will
maintain and preserve, through itself or any successor to its business, such other rights,
franchises and privileges as it may in good faith determine necessary or desirable in the normal
course of its business and operations and the ownership of its material properties.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.5 <U>Payment of Taxes</U>.&nbsp; It will pay and discharge all taxes, fees, assessments and
governmental charges or levies imposed upon it or upon its properties or assets prior to the date
on which material penalties attach thereto, and all lawful claims for labor, materials and supplies
which, if unpaid, might become a material lien upon any properties or assets of the Company, except
to the extent such taxes, fees, assessments or governmental charges or levies, or such claims, are
being contested in good faith by appropriate proceedings and are adequately reserved against in
accordance with generally accepted accounting principles.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.6 <U>Compliance with Laws</U>.&nbsp; It will comply in all material respects with the requirements
of all applicable laws, rules, regulations and orders of any governmental authority and the terms
of any material indenture, contract or other instrument to which it may be a party or under which
it or its properties may be bound, except to the extent failure to so comply would not have a
material adverse effect on the Company&#146;s business.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.7 <U>Maintenance of Properties</U>.&nbsp; It will use commercially reasonable efforts to maintain
and preserve all of its material properties, as it may in good faith determine to be necessary or
useful in the proper conduct of its business, in good working order and condition in accordance
with the general practice of other corporations of similar character and size, ordinary wear and
tear accepted.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.8 <U>Government Authority</U>.&nbsp; It will use commercially reasonable efforts to obtain and
maintain all authorizations, consents, filings, exemptions, registrations and other governmental
approvals necessary in connection with the execution, delivery and performance of this Agreement,
the consummation of the transactions contemplated hereby or the operation and conduct of its
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-14-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">business and ownership of
its properties, except to the extent such failure to obtain or maintain would not have a
material adverse effect on the Company&#146;s business or financial condition or its ability to deliver
or perform under this Agreement or consummate the transactions contemplated hereby.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.9 <U>Opinion of Company Counsel</U>.&nbsp; Contemporaneously with the execution and delivery of this
Agreement, the Purchaser will receive from Wilson Sonsini Goodrich &#038; Rosati, P.C., counsel for the
Company, an opinion, dated as of the date of this Agreement, in the form attached hereto as
<U>Exhibit&nbsp;F</U> (the &#147;<B>Legal Opinion</B>&#148;), relating to the sale and issuance of the First Note
pursuant to this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Covenants of the Purchaser</U>.&nbsp; The Purchaser hereby covenants and agrees as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 <U>Transfers</U>.&nbsp; Purchaser shall be bound by the restrictions on transfer of the Securities
as set forth in the applicable Additional Note. Any permitted purchaser, assignee, transferee or
pledgee of securities issued on conversion of the applicable Additional Note shall agree in writing
to take and hold such securities subject to and upon the conditions set forth in the this
Agreement, the applicable Additional Note, the Investor Rights Agreement, and the Voting Agreement,
as each may be amended from time to time.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2 <U>Additional Convertible Promissory Notes</U>.&nbsp;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<U>Purchaser&#146;s Obligation to Purchase</U>. In the event that the First Note is converted
as set forth in the First Note, the Purchaser shall, at the Company&#146;s election, purchase the Second
Note in the principal amount of US$5,000,000 (the &#147;<B>Additional Note Principal</B>&#148;) in accordance with
Section&nbsp;5.2(b), and in the event the Second Note is converted as set forth in the Second Note, the
Purchaser shall, at the Company&#146;s election, purchase the Third Note in the principal amount equal
to the Additional Note Principal in accordance with Section&nbsp;5.2(b).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<U>Additional Notes Procedure</U>. Subject to Section&nbsp;5.2(a), the Company may exercise
its option to require the Purchaser to purchase the (i)&nbsp;Second Note at any time within 45&nbsp;days
following the conversion of the First Note and (ii)&nbsp;the Third Note at any time within 45&nbsp;days
following the conversion of the Second Note by giving Purchaser written notice thereof (the
&#147;<B>Election Notice</B>&#148;). The Election Notice shall state that the Company has elected to require the
Purchaser to purchase the Second Note or the Third Note, as the case may require, and shall
indicate the date, time and location of the closing of the purchase and sale of the Second Note or
the Third Note, as the case may require (each, an &#147;<B>Additional Note Closing</B>&#148;), which shall occur no
sooner than 28&nbsp;days or later than 50&nbsp;days after the date of the Election Notice.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;<U>Closing of Subsequent Purchase</U>. At an Additional Note Closing, the Company shall
deliver to the Purchaser the Second Note, or the Third Note, as the case may require, and a duly
executed Compliance Certificate in substantially the form attached hereto as <U>Exhibit&nbsp;D</U>. At
an Additional Note Closing, the Purchaser shall deliver to the Company (i)&nbsp;the Additional Note
Principal by check or wire transfer and (ii)&nbsp;the Investment Representation Statement, duly executed
by Purchaser.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-15-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;<U>Effect of Change in Series&nbsp;E Preferred Stock on Additional Notes</U>. The forms of
any then-unissued Additional Notes attached hereto as <U>Exhibits&nbsp;A, B, and C</U> shall be
modified upon the happening of certain events as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;In the event the Company should at any time prior to the First Note Closing or an
Additional Note Closing split or subdivide the outstanding shares of its Series&nbsp;E Preferred Stock
(or other securities that would be issuable upon conversion of any then-unissued Additional Note)
or issue additional shares of Series&nbsp;E Preferred Stock (or other securities that would be issuable
upon conversion of any then-unissued Additional Note) to the holders thereof as a dividend or make
any other distribution payable in additional shares of Series&nbsp;E Preferred Stock (or other
securities that would be issuable upon conversion of any then-unissued Additional Note) to the
holders thereof without payment of any consideration by such holder for the additional shares of
Series&nbsp;E Preferred Stock (or such other securities), then, as of the date of such dividend,
distribution, split or subdivision, the Conversion Price as set forth in the form of Additional
Note shall be appropriately decreased so that the number of shares of Series&nbsp;E Preferred Stock or
other securities issuable upon conversion of the Additional Note shall be increased in proportion
to such increase of outstanding shares of Series&nbsp;E Preferred Stock or other securities issuable
upon conversion of the Additional Note, as applicable. If the number of shares of Series&nbsp;E
Preferred Stock (or other securities that would be issuable upon conversion of any then-unissued
Additional Note) outstanding at any time prior to the First Note Closing or an Additional Note
Closing is decreased by a combination of the outstanding shares of Series&nbsp;E Preferred Stock (or
such other securities), then, following the record date of such combination, the Conversion Price
set forth in the form of Additional Note shall be appropriately increased so that the number of
shares of Series&nbsp;E Preferred Stock or other securities issuable upon conversion of the Additional
Note shall be decreased in proportion to such decrease in outstanding shares of Series&nbsp;E Preferred
Stock or other securities issuable upon conversion of the Additional Note, as applicable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;In case of any reclassification, capital reorganization, or change in the Series&nbsp;E
Preferred Stock (or other securities that would be issuable upon conversion of any then-unissued
Additional Note) of the Company prior to the First Note Closing or an Additional Note Closing,
including conversion of such shares pursuant to the Company&#146;s Articles of Incorporation then in
effect (other than as a result of a split, subdivision, combination, or stock dividend provided for
in Section&nbsp;5.2(d)(i)), then appropriate adjustment shall be made to the Conversion Price and kind
of securities or other property issuable upon conversion of the form of Additional Note so that the
Additional Note if purchased shall be convertible upon the terms set forth therein as of the date
of such First Note Closing or Additional Note Closing, as applicable, into the kind and amount of
shares of stock and other securities and property receivable in connection
with such reclassification, reorganization, or change by a holder of the same number of shares
of Series&nbsp;E Preferred Stock or other securities as would be issuable on conversion of the
Additional Note as of the First Note Closing or such Additional Note Closing, as the case may
require.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;If at any time prior to the First Note Closing or an Additional Note Closing, as the
case may require, there shall be an acquisition of the Company by merger, consolidation or
otherwise where the Company is not the surviving corporation or as a result of
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-16-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">which all of the
outstanding capital stock of the Company is exchanged for capital stock of another corporation,
then, as a part of such acquisition, the Conversion Price and kind of securities issuable upon
conversion of the form of Additional Note shall be appropriately adjusted so that if such
Additional Note is purchased such Additional Note shall initially be convertible into, the number
of shares of stock or other securities or property of the surviving or successor corporation
resulting from such acquisition (or the corporation the capital stock of which is issued in
exchange for the capital stock of the Company), to which a holder of the securities that would be
issuable upon conversion of such Additional Note would have been entitled in such acquisition if
such Additional Note had been converted immediately before such acquisition.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;<U>Transfer</U>. In the event that the Company issues any of the Additional Notes to the
Purchaser, each issued Additional Note and any securities issued on conversion thereof (including
securities issued on conversion of such securities) shall be subject to Section&nbsp;4.1 of this
Agreement, the Investment Representation Statement and the restrictions on transfer set forth in
such Additional Note.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Termination</U>.&nbsp; This Agreement shall terminate and shall be of no further force or
effect at such time as (i)&nbsp;the Company has paid to Purchaser in cash, by check or by wire transfer
the principal amount and accrued interest owing under all outstanding Additional Notes or all
outstanding Additional Notes have been converted into Note Shares in accordance with their Terms
and (ii)&nbsp;the Company has no further right to require the Purchaser to purchase any Additional Notes
pursuant to this Agreement; <U><I>provided</I></U>, <U><I>however</I></U>, that in the event of the conversion
of any of the Additional Notes, Section&nbsp;12 of each such Additional Note, and Section&nbsp;3, Section&nbsp;5.1
and Section&nbsp;8 hereof shall survive such termination.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Miscellaneous</U>.&nbsp;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1 <U>Governing Law</U>.&nbsp; This Agreement and the Additional Notes (if issued) shall in all
respects be governed by and construed and enforced in accordance with the laws of the State of
California, without reference to the conflicts of law provisions thereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2 <U>California Corporate Securities Law</U>.&nbsp; THE SALE OF THE SECURITIES THAT ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED
WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF SUCH
SECURITIES OR THE PAYMENT AND RECEIPT OF ANY PART OF THE CONSIDERATION THEREFROM PRIOR TO SUCH
REGISTRATION IS UNLAWFUL UNLESS AN EXEMPTION FROM SUCH QUALIFICATION IS AVAILABLE. THE RIGHTS OF
ALL PARTIES TO THIS AGREEMENT ARE EXPRESSLY CONDITIONED UPON REGISTRATION BEING OBTAINED, UNLESS
THE SALE IS SO EXEMPT.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3 <U>Survival</U>.&nbsp; The representations, warranties, covenants and agreements made in this
Agreement shall survive any investigation made by any party hereto and the closing of the
transactions contemplated hereby.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->-17-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.4 <U>Successors and Assigns</U>.&nbsp; Except as otherwise provided herein, the provisions hereof
shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and
administrators of the parties hereto; <I>provided</I>, <I>however</I>, that the covenants and agreements of the
Company set forth in Section&nbsp;4 and the obligation of the Purchaser to purchase the Additional Notes
as set forth in Section&nbsp;1.1 and Section&nbsp;5.2 shall not be assigned or transferred by Purchaser by
operation of law or otherwise without the prior written consent of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.5 <U>Entire Agreement; Amendment</U>.&nbsp; This Agreement (including its exhibits), the Schedule of
Exceptions, the Business Plan, and the Additional Notes constitute the full and entire
understanding and agreement between the parties with regard to the subjects hereof and thereof, and
no party shall be liable or bound to any other party in any manner by any warranties,
representations, or covenants except as specifically set forth herein or therein. Except as
expressly provided herein, neither this Agreement nor any term hereof may be amended, waived,
discharged or terminated other than by a written instrument signed by the party against whom
enforcement of any such amendment, waiver, discharge or termination is sought.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.6 <U>Notices, etc</U>.&nbsp; Any notice, request, other communication, or payment required or
permitted hereunder shall be in writing and shall be deemed to have been duly given upon delivery,
if delivered personally or by facsimile, or by recognized overnight courier service, or five days
after deposit, if deposited in the United States mail for mailing by registered or certified mail,
postage prepaid, and addressed as follows:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="79%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">If to Purchaser:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Biomedical Sciences Investment Fund Pte Ltd</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">20 Biopolis Way</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">#09-01 Centros</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Singapore 138668</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention: Chu Swee Yeok</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel:&nbsp;&nbsp;65-6336-2288</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax:&nbsp;&nbsp;65-6334-8478</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">If to the Company:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fluidigm Corporation</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7100 Shoreline Court</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">South San Francisco, California  94080</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention:  Chief Executive Officer</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel:&nbsp;&nbsp;(650) 266-6000</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax:&nbsp;&nbsp;(650) 871-7195</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">with a copy to:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Wilson Sonsini Goodrich &#038; Rosati, P.C.</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">650 Page Mill Road</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Palo Alto, California  94304-1050</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention:  Ken Clark and Robert Kornegay</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel:&nbsp;&nbsp;(650) 493-9300</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax:&nbsp;&nbsp;(650) 493-6811</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-18-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of the above addressees may change its address or facsimile number for purposes of this
paragraph by giving to the other addressee notice of such new address in conformity with this
paragraph.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.7 <U>Counterparts; Facsimile</U>.&nbsp; This Agreement may be executed in counterparts, each of
which shall be enforceable against the party or parties actually executing such counterparts, and
all of which together shall constitute one instrument. This Agreement may be executed by facsimile
signature.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.8 <U>Severability</U>.&nbsp; In the event that any provision of this Agreement becomes or is
declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement
shall continue in full force and effect without said provision.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.9 <U>Expenses</U>.&nbsp; Except as set forth in the Purchase Agreement, each party shall pay all
costs and expenses that it incurs with respect to the negotiation, execution and delivery and
performance of this Agreement. If any action at law or in equity is necessary to enforce or
interpret the terms of this Agreement, or any of the Additional Notes, the prevailing party shall
be entitled to reasonable
attorney&#146;s fees, costs and necessary distributions in addition to any other relief to which
such party may be entitled.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.10 <U>Titles and Subtitles</U>.&nbsp; The titles and subtitles used in this Agreement are used for
convenience only and are not considered in construing or interpreting this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.11 <U>Jury Trial</U>.&nbsp; EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST
EXTENT PERMITTED BY LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING (WHETHER
SOUNDING IN CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATED TO THIS AGREEMENT.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.12 <U>Jurisdiction; Venue</U>.&nbsp; The parties hereto agree to submit to the jurisdiction of and
venue in the federal and state courts of San Mateo County, California with respect to the breach or
interpretation of this Agreement or the enforcement of any and all rights, duties, liabilities,
obligations, powers, and other relations between the parties arising under this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.13 <U>Currency</U>.&nbsp; Any reference to &#147;dollars&#148; or &#147;$&#148; in this Agreement shall refer to the
lawful currency of the United States of America.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Remainder of Page Intentionally Left Blank; Signature Page to Follow&#093;</I></B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-19-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have caused this Convertible Note Purchase Agreement to be
duly executed and delivered by their proper and duly authorized officers as of the date and year
first written above.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="38%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>COMPANY:</B><BR>
<BR style="font-size:10pt">

<FONT style="font-variant: SMALL-CAPS"><B>Fluidigm
Corporation</B></FONT><br><BR style="font-size: 10pt">
</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Gajus V. Worthington
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Gajus&nbsp;V. Worthington&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="38%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>PURCHASER</B>:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Biomedical Sciences Investment Fund Pte Ltd</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Chu Swee Yeok
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">Print Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chu Swee Yeok
<DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="36%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director
<DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><b>[SIGNATURE PAGE TO CONVERTIBLE NOTE PURCHASE AGREEMENT]</b>


</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5A
<SEQUENCE>10
<FILENAME>f39432orexv4w5a.htm
<DESCRIPTION>EXHIBIT 4.5A
<TEXT>
<HTML>
<HEAD>
<TITLE>exv4w5a</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#091;***&#093; Indicates
text has been omitted from this Exhibit pursuant to a confidential treatment
request and has been filed separately with the Securities and Exchange Commission.
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;4.5A</B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%"><B>THIS NOTE AND THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT
AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
&#147;SECURITIES ACT&#148;). SUCH SECURITIES MAY NOT BE SOLD, TRANSFERRED OR PLEDGED IN THE
ABSENCE OF SUCH REGISTRATION OR UNLESS THE COMPANY RECEIVES AN OPINION OF COUNSEL
(WHICH MAY BE COUNSEL FOR THE COMPANY), OR OTHER EVIDENCE, REASONABLY ACCEPTABLE TO
IT STATING THAT SUCH SALE OR TRANSFER IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS
DELIVERY REQUIREMENTS OF THE SECURITIES ACT. THIS NOTE MAY ONLY BE TRANSFERRED UPON
THE TERMS AND CONDITIONS CONTAINED IN THE NOTE AND IN AN AGREEMENT BETWEEN HOLDER
AND THE COMPANY</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT><BR>
a California corporation
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">CONVERTIBLE PROMISSORY NOTE

</DIV>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">NOTE NUMBER&nbsp;E-3 (REVISED)
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">US$5,000,000
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">April&nbsp;19, 2007</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">South San Francisco, California</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Principal and Interest</U>. <FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT> (the &#147;<U>Company</U>&#148;), a
California corporation, for value received, hereby promises to pay to the order of Biomedical
Sciences Investment Fund Pte Ltd (the &#147;<U>Holder</U>&#148;) in lawful money of the United States of
America, the principal amount of Five Million Dollars (US$5,000,000), or such lesser amount as
shall equal the outstanding principal amount hereof, together with interest from the date of this
Note on the unpaid principal balance at a rate equal to 8.00% per annum, computed on the basis of
the actual number of days elapsed and a year of 365&nbsp;days, compounded annually.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Convertible Promissory Note (&#147;<U>Note</U>&#148;) is the third Note issued pursuant to that
certain Convertible Note Purchase Agreement dated August&nbsp;7, 2006 (as amended, modified or
supplemented, the &#147;<U>Note Purchase Agreement</U>&#148;) between the Company and the Holder. Unless
defined herein, capitalized terms shall have the same meanings ascribed to them in the Note
Purchase Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless converted in accordance with Section&nbsp;3, this Note shall become due and payable as to
both accrued interest and principal on the Payment Date (as defined in Section&nbsp;3). This Note may
be prepaid by Company at any time, in accordance with the terms of Section&nbsp;2 of this Note. Upon
payment in full of all principal and interest payable hereunder (including upon any conversion),
this Note shall be surrendered to the Company for cancellation. All payments hereon shall be
applied first to accrued interest and second to the reduction of principal.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Prepayment of Note</U>. Upon five days prior written notice to Holder (the
&#147;<U>Prepayment Notice</U>&#148;), the Company may prepay this Note in whole or in part; provided that
any such prepayment will be applied first to the payment of expenses due under this Note, second to
interest accrued on this Note and third, if the amount of prepayment exceeds the amount of all such
expenses and accrued interest, to the payment of principal of this Note. In the event that the
Holder desires to avoid prepayment of the Note by the Company, the Holder must within five days of
its receipt of the Prepayment Notice deliver to the Company the Conversion Notice pursuant to
Section&nbsp;3(c)(iii) electing to convert this Note, in which case this Note will not be prepaid as
provided in the Prepayment Notice and will instead be converted into shares of Series&nbsp;E Preferred
Stock of the Company in accordance with Section&nbsp;3 of this Note.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Conversion</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Conversion Events</U>. Upon the earlier to occur of (i)&nbsp;an Initial Public Offering
(as defined below) or (ii)&nbsp;satisfaction of each of the Milestones pursuant to Section&nbsp;3(b)(iv)
below (either, a &#147;<U>Conversion Event</U>&#148;), all of the then outstanding principal and accrued
interest owing under this Note shall convert into that number of shares of Series&nbsp;E Preferred Stock
of the Company determined by dividing (i)&nbsp;the aggregate principal and accrued interest owing under
this Note as of the date of such Conversion Event by (ii)&nbsp;the Conversion Price (as defined below).
Notwithstanding the foregoing, by complying with Section&nbsp;3(c)(iii) hereof, the Holder may at any
time earlier elect to convert this Note into that number of shares of Series&nbsp;E Preferred Stock
determined by dividing (i)&nbsp;the aggregate principal and accrued interest owing under this Note as of
the date of the Conversion Notice (as defined in Section&nbsp;3(c)(iii)) by (ii)&nbsp;the Conversion Price
(as defined below).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Definitions</U>. For purposes of this Note, the following terms shall have the
following meanings:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;The term &#147;<U>Change of Control Transaction</U>&#148; shall mean (i)&nbsp;the acquisition of the
Company by another entity by means of any transaction or series of related transactions (including,
without limitation, any stock acquisition, reorganization, merger or consolidation but excluding
any merger effected exclusively for the purpose of changing the domicile of the Corporation) other
than a transaction or series of transactions in which the holders of the voting securities of the
Company outstanding immediately prior to such transaction or series of transactions continue to
retain (either by such voting securities remaining outstanding or by such voting securities being
converted into voting securities of the surviving entity), as a result of shares in the Company
held by such holders prior to such transaction, at least fifty percent (50%) of the total voting
power represented by the voting securities of the Company or such surviving entity outstanding
immediately after such transaction or series of transactions; or (ii)&nbsp;a sale, transfer, lease or
other conveyance of all or substantially all of the assets of the Corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;The term &#147;<U>Conversion Price</U>&#148; shall mean US$3.60, subject to adjustment as set
forth in Section&nbsp;5 below.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;The term &#147;<U>Initial Public Offering</U>&#148; shall mean the first sale of securities of
the Company pursuant to an effective registration statement under the Securities Act of 1933 (the
&#147;<U>Securities Act</U>&#148;) after or in connection with which the outstanding shares of Preferred
Stock of the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Company have been converted into Common Stock pursuant to the Company&#146;s then existing Articles
of Incorporation or otherwise.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;Unless otherwise agreed in writing between the Company and the Holder, the term
&#147;<U>Milestones</U>&#148; shall mean satisfaction of the following on or before April&nbsp;30, 2008:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;The
Company will have released &#091;***&#093; to &#091;***&#093;, as
demonstrated by a &#091;***&#093; approval form duly signed-off. The approval is typically
characterized by having completed &#091;***&#093;, including &#091;***&#093; and &#091;***&#093; of
suitable &#091;***&#093;;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;The
approved &#091;***&#093; (or a subsequent &#091;***&#093; thereof) will be &#091;***&#093;
generally &#091;***&#093; to &#091;***&#093;, as demonstrated by a Company &#091;***&#093;;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;The Subsidiary will also have &#091;***&#093; and &#091;***&#093;
them &#091;***&#093; to at &#091;***&#093;;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;The Subsidiary will have at least &#091;***&#093; the &#091;***&#093; of &#091;***&#093; to achieve &#091;***&#093; in the First Note and the &#091;***&#093;
 in the Second Note; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)&nbsp;The Company will be &#091;***&#093; the &#091;***&#093; through the Subsidiary in
Singapore, and the Company&#146;s then-current &#091;***&#093; and &#091;***&#093; will provide for the
&#091;***&#093; of the &#091;***&#093; through the Subsidiary in
Singapore; &#091;***&#093; if the Holder provides the Company with a &#091;***&#093; pursuant to Section
3(c)(ii) below, then the Company shall have 30&nbsp;days following the Company&#146;s receipt of the
&#091;***&#093; to &#091;***&#093; any &#091;***&#093; to &#091;***&#093; identified by the Holder in the &#091;***&#093;.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;The term &#147;<U>Payment Date</U>&#148; shall mean April&nbsp;19, 2009 or such later date as may be
mutually agreed in writing by Holder and the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Conversion Procedure</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;<U>Conversion in Connection with Initial Public Offering</U>. Upon the occurrence of an
Initial Public Offering as set forth in Section&nbsp;3(a), this Note shall convert automatically without
further action on the part of the Holder hereof. Written notice shall be delivered to Holder at
the address last shown on the records of Company for Holder or given by Holder to Company for the
purpose of notice notifying Holder of the conversion effected or to be effected, specifying the
Conversion Price, the date on which such conversion occurred or is expected to occur and calling
upon such Holder to surrender to Company, in the manner and at the place designated, the Note.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;<U>Conversion in Connection with Satisfaction of Milestones</U>. If the Company
reasonably believes that it has satisfied all of the Milestones, it may send written notice thereof
(the &#147;<U>Milestone Completion Notice</U>&#148;) to the Holder (at the address last shown on the records
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of the Company for the Holder or given by Holder to Company for the purpose of notice)
specifying the Conversion Price, the date on which the Company reasonably believes all of the
Milestones were satisfied (the &#147;<U>Notified Milestone Completion Date</U>&#148;), together with a duly
executed compliance certificate dated as of the Notified Milestone Completion Date substantially in
the form attached hereto as <U>Exhibit&nbsp;A</U> (the &#147;<U>Compliance Certificate</U>&#148;), and calling
upon Holder to surrender to the Company the Note. In the event that the Holder reasonably believes
that any of (i)&nbsp;the Milestones have not been satisfied or (ii)&nbsp;the representations and warranties
made in the Compliance Certificate are inaccurate in any material respect, the Holder may provide
written notice (the &#147;<U>Milestone Response Notice</U>&#148;) to the Company of such disagreement and/or
inaccuracy within 30&nbsp;days of its receipt of the Milestone Completion Notice. The Milestone
Response Notice shall specify in reasonable detail the reasons for such disagreement and/or basis
for belief that any of the representations and warranties made in the Compliance Certificate are
inaccurate and shall be accompanied by reasonably available support documentation evidencing the
basis for such disagreement or belief. If the Holder shall fail to provide the Milestone Response
Notice within such time period, the Milestones shall be deemed satisfied as of the Notified
Milestone Completion Date and this Note shall be automatically converted as set forth in
Section&nbsp;3(a). If the Holder shall have timely provided the Milestone Response Notice, the Company
and the Holder shall in good faith attempt to resolve their disagreement as to the satisfaction of
the Milestones and/or the accuracy of the representations and warranties in the Compliance
Certificate. If the Company and Holder are unable to resolve their disagreement within the
Milestones Cure Period, the Company may pay to the Holder the principal and interest owing under
this Note as of the Notified Milestone Completion Date (in which case the Note shall be cancelled
and surrendered) or may pursue any other remedy that may be available to it under applicable law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;<U>Elective Conversion</U>. If the Holder wishes to voluntarily convert this Note as
set forth in Section&nbsp;3(a) hereof prior to a Conversion Event, the Holder shall surrender this Note
to the Company and provide the Company with a written notice (the &#147;<U>Conversion Notice</U>&#148;) to
that effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;<U>Certificate; Time of Conversion</U>. Upon conversion of this Note, the Holder shall
promptly surrender this Note, duly endorsed, at the principal office of Company. At its expense,
the Company shall, as soon as practicable thereafter, issue and deliver to such Holder at such
principal office a certificate or certificates for the number of shares to which Holder shall be
entitled upon such conversion (bearing such legends as are required by this Note and the Note
Purchase Agreement and applicable state and federal securities laws in the opinion of counsel to
Company), together with any other securities and property to which Holder is entitled upon such
conversion under the terms of this Note, including a check payable to Holder for any cash amounts
payable as described in Section&nbsp;3(d). Any such conversion of this Note shall be deemed to have
been made immediately prior to the Conversion Event as described in Section&nbsp;3(a) (or in the case of
delivery of the Conversion Notice as set forth in Section&nbsp;3(c)(iii), upon the Company&#146;s receipt of
such Conversion Notice); <U>provided</U>, <U>however</U>, the Holder shall not be deemed a record
holder of such shares or a purchaser of such shares until the Holder has delivered the Note for
conversion. On and after such date, the Holder shall be treated as a purchaser of such shares
under the Note Purchase Agreement and shall be bound by the applicable terms of this Note and Note
Purchase Agreement.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Fractional Shares</U>. No fractional shares will be issued upon any conversion of
this Note. In lieu of any fractional share to which the Holder would otherwise be entitled, the
Company will pay to the Holder in cash that amount of the unconverted principal and interest
balance of this Note.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Reservation of Shares</U>. The Company will at all times reserve and keep available
out of its authorized but unissued shares or shares held in treasury, sufficient shares of Series&nbsp;E
Preferred Stock or other securities to permit the full conversion of the outstanding principal and
interest of this Note pursuant to the terms of this Note. In the event the Company shall have
insufficient shares of Series&nbsp;E Preferred Stock or other securities to permit the full conversion
of the outstanding principal and accrued interest of this Note pursuant to the terms hereof, the
Company hereby covenants and agrees that the Company shall use its commercially reasonable efforts
to seek board and shareholder approval of an amendment to the Company&#146;s Articles of Incorporation
in order to authorize an increase in the number of authorized shares of Series&nbsp;E Preferred Stock or
other securities of the Company in a sufficient amount so that the aggregate number of shares of
Series&nbsp;E Preferred Stock or other securities issuable upon conversion of this Note will then be
authorized and available for issuance.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Change of Control Transaction</U>. The Company shall provide the Holder with 15&nbsp;days
written notice of the closing of a Change of Control Transaction, specifying in reasonable detail
the terms of such Change of Control Transaction. If the Holder shall not have voluntarily elected
to convert this Note as set forth in Section&nbsp;3(c)(iii) within such 15&nbsp;day period, the Company may
prepay the entire principal amount and interest owing under this Note as of the date of such
prepayment. The Holder shall thereafter promptly return the Note to the Company for cancellation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Change in Series&nbsp;E Preferred Stock</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Split, Subdivision or Combination of Series&nbsp;E Preferred Stock</U>. In the event the
Company should at any time or from time to time after the date of issuance hereof split or
subdivide the outstanding shares of its Series&nbsp;E Preferred Stock (or other securities issuable upon
conversion of this Note) or issue additional shares of Series&nbsp;E Preferred Stock (or other
securities issuable upon conversion of this Note) to the holders thereof as a dividend or make any
other distribution payable in additional shares of Series&nbsp;E Preferred Stock (or other securities
issuable upon conversion of this Note) to the holders thereof without payment of any consideration
by such holder for the additional shares of Series&nbsp;E Preferred Stock (or such other securities),
then, as of the date of such dividend, distribution, split or subdivision, the Conversion Price of
this Note shall be appropriately decreased so that the number of shares of Series&nbsp;E Preferred Stock
or other securities issuable upon conversion of this Note shall be increased in proportion to such
increase of outstanding shares of Series&nbsp;E Preferred Stock or other securities issuable upon
conversion of this Note, as applicable. If the number of shares of Series&nbsp;E Preferred Stock (or
other securities issuable upon conversion of this Note) outstanding at any time after the date
hereof is decreased by a combination of the outstanding shares of Series&nbsp;E Preferred Stock (or
other securities issuable upon conversion of this Note), then, following the record date of such
combination, the Conversion Price for this Note shall be appropriately increased so that the number
of shares of Series&nbsp;E Preferred Stock or other securities issuable on conversion hereof shall be
decreased in proportion to such
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">decrease in outstanding shares of Series&nbsp;E Preferred Stock or other securities issuable upon
conversion of this Note, as applicable.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Reclassification etc</U>. In case of any reclassification, capital reorganization, or
change in the Series&nbsp;E Preferred Stock (or other securities issuable upon conversion of this Note)
of the Company, including conversion of such shares pursuant to the Company&#146;s Articles of
Incorporation then in effect (other than as a result of a split, subdivision, combination, or stock
dividend provided for in Section&nbsp;5(a) above), then appropriate adjustment shall be made to the
Conversion Price and kind of securities or other property issuable upon conversion of this Note so
that this Note shall be convertible upon the terms set forth herein into the kind and amount of
shares of stock and other securities and property receivable in connection with such
reclassification, reorganization, or change by a holder of the same number of shares of Series&nbsp;E
Preferred Stock or other securities as are issuable on conversion of this Note.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Merger or Consolidation</U>. Other than a Change of Control Transaction in connection
with which this Note has been converted or prepaid, if at any time there shall be an acquisition of
the Company by merger, consolidation or otherwise where the Company is not the surviving
corporation or as a result of which all of the outstanding capital stock of the Company is
exchanged for capital stock of another corporation, then, as a part of such acquisition, the
Conversion Price and kind of securities issuable upon conversion hereof shall be appropriately
adjusted so that the Holder shall receive upon conversion of this Note, the number of shares of
stock or other securities or property of the surviving or successor corporation resulting from such
acquisition (or the corporation the capital stock of which is issued in exchange for the capital
stock of the Company), to which a holder of the securities issuable upon conversion of this Note
would have been entitled in such acquisition if this Note had been converted immediately before
such acquisition.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Payment Due Date</U>. If not previously converted into shares of Series&nbsp;E Preferred
Stock pursuant to Section&nbsp;3 hereof and if not sooner prepaid by the Company pursuant to Section&nbsp;2
hereof or accelerated and declared due and owing by the Holder pursuant to Section&nbsp;7 hereof, the
principal amount and any accrued interest due thereon then outstanding under this Note will become
due and payable on the Payment Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Default</U>. The Company shall be deemed to be in default under this Note in the event
(i)&nbsp;the Company shall fail to materially perform any covenant or agreement of the Company contained
in Section&nbsp;4 of the Note Purchase Agreement for a period of 30&nbsp;days after written notice of such
failure from Holder; (ii)&nbsp;the Company shall have failed to make payment of principal or interest
due on the Note when such principal and interest becomes due; or (iii)&nbsp;the Company shall commence,
whether voluntarily or involuntarily a case or other proceeding seeking liquidation, reorganization
or other relief with respect to itself or its debts under any bankruptcy, insolvency or other
similar law now or hereafter in effect or consent to any such relief or to the appointment of or
taking possession of its property by any official in an involuntary case or other proceeding
commenced against it. In the case of an event of default, the Holder may, by written notice to the
Company, declare the unpaid principal amount of this Note, all interest accrued and unpaid hereon,
and all other amounts payable hereunder to be immediately due and payable, without presentment,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">demand, protest, or further notice of any kind, as well as enforce all other rights and
remedies available to the Holder under applicable law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Notices</U>. Any notice, request, other communication, or payment required or
permitted hereunder shall be in writing and shall be deemed to have been duly given upon delivery,
if delivered personally by facsimile, or by recognized overnight courier service, or five days
after deposit, if deposited in the United States mail for mailing by registered or certified mail,
postage prepaid, and addressed as follows:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="76%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">If to Holder:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Biomedical Sciences Investment Fund Pte Ltd</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">20 Biopolis Way</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">#09-01 Centros</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Singapore 138668</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention: Chu Swee Yeok</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel:  65-6336-2288</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax:  65-6334-8478</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">If to the Company:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fluidigm Corporation</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7100 Shoreline Court</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">South San Francisco, California  94080</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention:  Chief Executive Officer</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel:  (650) 266-6000</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: (650) 871-7195</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">with a copy to:</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Wilson Sonsini Goodrich&nbsp;&#038; Rosati, P.C.</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">650 Page Mill Road</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Palo Alto, California  94304-1050</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention:  Ken Clark and Robert Kornegay</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: (650) 493-9300</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: (650) 493-6811</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of the above addressees may change its address or facsimile number for purposes of this
paragraph by giving to the other addressee notice of such new address in conformity with this
paragraph.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>Amendments</U>. This Note may be amended and any provision hereof waived with the
consent of the Company and the Holder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U>No Rights as Shareholder</U>. Nothing in this Note shall be construed as conferring
upon the Holder or any other person the right to vote or to consent or to receive notice as a
shareholder in respect of meetings of shareholders for the election of directors of the Company or
any other matters or any rights whatsoever as a shareholder of the Company until, and only to the
extent that, this Note shall have been converted.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<U>Successors and Assigns</U>. Subject to the restrictions on transfer described in
Section&nbsp;12 and in the Note Purchase Agreement, the rights and obligations of the Company and
Investor shall be binding upon and benefit the successors, assigns, heirs, administrators and
transferees of the parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;<U>Transfer of Note and Securities Issuable on Conversion Hereof</U>. Prior to the
conversion of this Note, this Note (or the underlying securities issuable upon conversion hereof)
may not be sold, assigned, transferred, pledged or otherwise disposed of by the Holder, in whole or
in part, without the prior written consent of the Company. With respect to any sale, assignment,
transfer, pledge or other disposition of the securities into which this Note may be converted after
conversion of this Note, the Holder may only transfer such securities pursuant to, and on the
conditions set forth in that certain Eighth Amended and Restated Investor Rights Agreement dated
June&nbsp;13, 2006 between the Company and certain investors in the Company (including Holder), as may
be amended from time to time (the &#147;<U>Rights Agreement</U>&#148;). The Holder shall cause any proposed
purchaser, assignee, transferee or pledgee of such securities to agree in writing to take and hold
such securities subject to and upon the conditions specified in this Note, the Note Purchase
Agreement, and the Rights Agreement, including, without limitation, Sections&nbsp;1.2, 1.3, 1.4, and
1.14 of the Rights Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;<U>Highest Lawful Rate</U>. Anything herein to the contrary notwithstanding, if during
any period for which interest is computed hereunder, the amount of interest computed on the basis
provided for in this Note, together will all fees, charges, and other payments or rights which are
treated as interest under applicable law, as provided for herein or in any other document executed
in connection herewith, would exceed the amount of such interest computed on the basis of the
Highest Lawful Rate, the Company shall not be obligated to pay, and the Holder shall not be
entitled to charge, collect, receive, reserve, or take, interest in excess of the Highest Lawful
Rate, and during any such period the interest payable hereunder shall be computed on the basis of
the Highest Lawful Rate. As used herein, &#147;<U>Highest Lawful Rate</U>&#148; means the maximum
non-usurious rate of interest, as in effect from time to time, which may be charged, contracted
for, reserved, received, or collected by the Holder in connection with this Note under applicable
law. In accordance with this section, any amounts received in excess of the Highest Lawful Rate
shall be applied towards the prepayment of principal then outstanding.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.&nbsp;<U>Miscellaneous</U>. The Company agrees to pay on demand all of the losses, costs, and
expenses (including, without limitation, attorneys&#146; fees and disbursements) which the Holder incurs
in connection with enforcement of this Note, or the protection or preservation of the Holder&#146;s
rights under this Note, whether by judicial proceeding or otherwise. Such costs and expenses
include, without limitation, those incurred in connection with any workout or refinancing, or any
bankruptcy, insolvency, liquidation, or similar proceedings. The Company hereby waives
presentment, demand for performance, notice of non-performance, protest, notice of protest, and
notice of dishonor. No delay on the part of the Holder in exercising any right hereunder shall
operate as a waiver of such right or any other right. This Note is being delivered in and shall be
construed in accordance with the laws of the State of California without regard to the conflicts of
law provisions thereof. Any reference to &#147;dollars&#148; or &#147;$&#148; in this Note shall refer to the lawful
money of the United States of America.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the Company has caused this Convertible Promissory Note to be executed by
its officer thereunto duly authorized as of the date first above written.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="21%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">Dated: April&nbsp;19, 2007</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">a California corporation</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gajus V. Worthington
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Gajus Worthington
<DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chief Executive Officer
<DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Acknowledged and Agreed:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Holder</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Biomedical Sciences Investment Fund Pte Ltd</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Chu Swee Yeok
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chu Swee Yeok
<DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director
<DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>11
<FILENAME>f39432orexv10w1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FLUIDIGM CORPORATION</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>INDEMNIFICATION AGREEMENT</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Indemnification Agreement (&#147;<B>Agreement</B>&#148;) is made as of <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 20<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>, by and between
Fluidigm Corporation, a Delaware corporation (the &#147;<B>Company</B>&#148;), and <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> (&#147;<B>Indemnitee</B>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>WHEREAS</I></B>, the Company and Indemnitee recognize the significant cost of directors&#146; and officers&#146;
liability insurance and the general reductions in the coverage of such insurance;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>WHEREAS</I></B>, the Company and Indemnitee further recognize the substantial increase in corporate
litigation in general, subjecting officers and directors to expensive litigation risks at the same
time as the coverage of liability insurance has been severely limited; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>WHEREAS</I></B>, the Company desires to attract and retain the services of highly qualified
individuals, such as Indemnitee, to serve as officers and directors of the Company and to indemnify
its officers and directors so as to provide them with the maximum protection permitted by law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>NOW, THEREFORE</I></B>, in consideration for Indemnitee&#146;s services as an officer or director of the
Company, the Company and Indemnitee hereby agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<B><i>Indemnification</i></B>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<i>Third Party Proceedings</I>. The Company shall indemnify Indemnitee if Indemnitee was or is a
party or is threatened to be made a party to any threatened, pending or completed action, suit,
proceeding or any alternative dispute resolution mechanism, whether civil, criminal, administrative
or investigative (other than an action by or in the right of the Company) by reason of the fact
that Indemnitee is or was a director, officer, employee or agent of the Company, or any subsidiary
of the Company, or by reason of the fact that Indemnitee is or was serving at the request of the
Company as a director, officer, employee or agent of another corporation, partnership, joint
venture, trust or other enterprise, against expenses (including attorneys&#146; fees), judgments, fines
and amounts paid in settlement (if such settlement is approved in advance by the Company, which
approval shall not be unreasonably withheld) actually and reasonably incurred by Indemnitee in
connection with such action, suit or proceeding if Indemnitee acted in good faith and in a manner
Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, and,
with respect to any criminal action or proceeding, had no reasonable cause to believe Indemnitee&#146;s
conduct was unlawful. The termination of any action, suit or proceeding by judgment, order,
settlement, conviction, or upon a plea of <I>nolo contendere </I>or its equivalent, shall not, of itself,
create a presumption that Indemnitee did not act in good faith and in a manner which Indemnitee
reasonably believed to be in or not opposed to the best interests of the Company, and, with respect
to any criminal action or proceeding, had reasonable cause to believe that Indemnitee&#146;s conduct was
unlawful.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<I>Proceedings By or in the Right of the Company</I>. The Company shall indemnify Indemnitee if
Indemnitee was or is a party or is threatened to be made a party to any threatened,
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">pending or completed action or suit by or in the right of the Company or any subsidiary of the
Company to procure a judgment in its favor by reason of the fact that Indemnitee is or was a
director, officer, employee or agent of the Company, or any subsidiary of the Company, or by reason
of the fact that Indemnitee is or was serving at the request of the Company as a director, officer,
employee or agent of another corporation, partnership, joint venture, trust or other enterprise,
against expenses (including attorneys&#146; fees) and, to the fullest extent permitted by law, amounts
paid in settlement actually and reasonably incurred by Indemnitee in connection with the defense or
settlement of such action or suit if Indemnitee acted in good faith and in a manner Indemnitee
reasonably believed to be in or not opposed to the best interests of the Company, except that no
indemnification shall be made in respect of any claim, issue or matter as to which Indemnitee shall
have been adjudged to be liable to the Company unless and only to the extent that the Court of
Chancery of the State of Delaware or the court in which such action or suit was brought shall
determine upon application that, despite the adjudication of liability but in view of all the
circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnity for such
expenses which the Court of Chancery of the State of Delaware or such other court shall deem
proper.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;<I>Mandatory Payment of Expenses</I>. To the extent that Indemnitee has been successful on the
merits or otherwise in defense of any action, suit or proceeding referred to in Subsections&nbsp;(a) and
(b)&nbsp;of this Section&nbsp;1, or in defense of any claim, issue or matter therein, Indemnitee shall be
indemnified against expenses (including attorneys&#146; fees) actually and reasonably incurred by
Indemnitee in connection therewith.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<B><I>Expenses; Indemnification Procedure</I></B>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<I>Advancement of Expenses</I>. The Company shall advance all expenses actually and reasonably
incurred by Indemnitee in connection with the investigation, defense, settlement or appeal of any
civil or criminal action, suit or proceeding referenced in Section&nbsp;1(a) or 1(b) hereof (but not
amounts actually paid in settlement of any such action, suit or proceeding). Indemnitee hereby
undertakes to repay such amounts advanced only if, and to the extent that, it shall ultimately be
determined that Indemnitee is not entitled to be indemnified by the Company as authorized hereby.
The advances to be made hereunder shall be paid by the Company to Indemnitee within thirty&nbsp;(30)
days following delivery of a written request therefor by Indemnitee to the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<I>Notice/Cooperation by Indemnitee</I>. Indemnitee shall, as a condition precedent to his right
to be indemnified under this Agreement, give the Company notice in writing as soon as practicable
of any claim made against Indemnitee for which indemnification will or could be sought under this
Agreement. Notice to the Company shall be directed to the President of the Company at the address
shown on the signature page of this Agreement (or such other address as the Company shall designate
in writing to Indemnitee). Notice shall be deemed received three business days after the date
postmarked if sent by domestic certified or registered mail, properly addressed; otherwise notice
shall be deemed received when such notice shall actually be received by the Company. In addition,
Indemnitee shall give the Company such information and cooperation as it may reasonably require and
as shall be within Indemnitee&#146;s power.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->- 2 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;<I>Procedure</I>. Any indemnification and advances provided for in Section&nbsp;1 and this Section&nbsp;2
shall be made no later than thirty (30)&nbsp;days after receipt of the written request of Indemnitee. If
a claim under this Agreement, under any statute, or under any provision of the Company&#146;s
Certificate of Incorporation or Bylaws providing for indemnification, is not paid in full by the
Company within thirty (30)&nbsp;days after a written request for payment thereof has first been received
by the Company, Indemnitee may, but need not, at any time thereafter bring an action against the
Company to recover the unpaid amount of the claim and, subject to Section&nbsp;12 of this Agreement,
Indemnitee shall also be entitled to be paid for the reasonable expenses (including reasonable
attorneys&#146; fees) of bringing such action. It shall be a defense to any such action (other than an
action brought to enforce a claim for expenses incurred in connection with any action, suit or
proceeding in advance of its final disposition) that Indemnitee has not met the standards of
conduct which make it permissible under applicable law for the Company to indemnify Indemnitee for
the amount claimed. However, Indemnitee shall be entitled to receive interim payments of expenses
pursuant to Subsection&nbsp;2(a) unless and until such defense may be finally adjudicated by court order
or judgment from which no further right of appeal exists. It is the parties&#146; intention that if the
Company contests Indemnitee&#146;s right to indemnification, the question of Indemnitee&#146;s right to
indemnification shall be for the court to decide, and neither the failure of the Company (including
its Board of Directors, any committee or subgroup of the Board of Directors, independent legal
counsel, or its stockholders) to have made a determination that indemnification of Indemnitee is
proper in the circumstances because Indemnitee has met the applicable standard of conduct required
by applicable law, nor an actual determination by the Company (including its Board of Directors,
any committee or subgroup of the Board of Directors, independent legal counsel, or its
stockholders) that Indemnitee has not met such applicable standard of conduct, shall create a
presumption that Indemnitee has or has not met the applicable standard of conduct.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;<I>Notice to Insurers</I>. If, at the time of the receipt of a notice of a claim pursuant to
Section&nbsp;2(b) hereof, the Company has director and officer liability insurance in effect, the
Company shall give prompt notice of the commencement of such proceeding to the insurers in
accordance with the procedures set forth in the respective policies. The Company shall thereafter
take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee,
all amounts payable as a result of such proceeding in accordance with the terms of such policies.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;<I>Selection of Counsel</I>. In the event the Company shall be obligated under Section&nbsp;2(a)
hereof to pay the expenses of any proceeding against Indemnitee, the Company, if appropriate, shall
be entitled to assume the defense of such proceeding, with counsel approved by Indemnitee, which
approval shall not be unreasonably withheld, upon the delivery to Indemnitee of written notice of
its election to do so. After delivery of such notice, approval of such counsel by Indemnitee and
the retention of such counsel by the Company, the Company will not be liable to Indemnitee under
this Agreement for any fees of counsel subsequently incurred by Indemnitee with respect to the same
proceeding; <I>provided </I>that Indemnitee shall have the right to employ Indemnitee&#146;s counsel in any
such proceeding at Indemnitee&#146;s expense; and <I>provided further </I>that if (i)&nbsp;the Company has expressly
authorized (and continues to authorize) the employment of counsel by Indemnitee at the Company&#146;s
expense, (ii)&nbsp;the use of counsel chosen by the Company to represent Indemnitee would present such
counsel with a conflict of interest, or (iii)&nbsp;the Company shall not, in fact, have employed counsel
reasonably satisfactory to Indemnitee within a reasonable time after notice of the institution of
such
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 3 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">proceeding, Indemnitee shall have the right to employ counsel at the expense of the Company in
accordance herewith.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<B><I>Additional Indemnification Rights; Nonexclusivity</I></B>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<I>Scope</I>. Notwithstanding any other provision of this Agreement, the Company hereby agrees to
indemnify the Indemnitee to the fullest extent permitted by law, notwithstanding that such
indemnification is not specifically authorized by the other provisions of this Agreement, the
Company&#146;s Certificate of Incorporation, the Company&#146;s Bylaws or by statute. In the event of any
change, after the date of this Agreement, in any applicable law, statute, or rule which expands the
right of a Delaware corporation to indemnify a member of its board of directors or an officer, such
changes shall be, <I>ipso facto</I>, within the purview of Indemnitee&#146;s rights and Company&#146;s obligations,
under this Agreement. In the event of any change in any applicable law, statute or rule which
narrows the right of a Delaware corporation to indemnify a member of its board of directors or an
officer, such changes, to the extent not otherwise required by such law, statute or rule to be
applied to this Agreement shall have no effect on this Agreement or the parties&#146; rights and
obligations hereunder.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<I>Nonexclusivity. </I>The indemnification provided by this Agreement shall not be deemed
exclusive of any rights to which Indemnitee may be entitled under the Company&#146;s Certificate of
Incorporation, its Bylaws, any agreement, any vote of stockholders or disinterested Directors, the
General Corporation Law of the State of Delaware, or otherwise, both as to action in Indemnitee&#146;s
official capacity and as to action in another capacity while holding such office. The
indemnification provided under this Agreement shall continue as to Indemnitee for any action taken
or not taken while serving in an indemnified capacity even though he may have ceased to serve in
such capacity at the time of any action, suit or other covered proceeding.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<B><I>Partial Indemnification</I></B>. If Indemnitee is entitled under any provision of this Agreement to
indemnification by the Company for some or a portion of the expenses, judgments, fines or penalties
actually or reasonably incurred by him in the investigation, defense, appeal or settlement of any
civil or criminal action, suit or proceeding, but not, however, for the total amount thereof, the
Company shall nevertheless indemnify Indemnitee for the portion of such expenses, judgments, fines
or penalties to which Indemnitee is entitled.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<B><I>Mutual Acknowledgement</I></B>. Both the Company and Indemnitee acknowledge that in certain
instances, Federal law or applicable public policy may prohibit the Company from indemnifying its
directors and officers under this Agreement or otherwise. Indemnitee understands and acknowledges
that the Company has undertaken or may be required in the future to undertake with the Securities
and Exchange Commission to submit the question of indemnification to a court in certain
circumstances for a determination of the Company&#146;s right under public policy to indemnify
Indemnitee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<B><I>Officer and Director Liability Insurance</I></B>. The Company shall, from time to time, make the
good faith determination whether or not it is practicable for the Company to obtain and maintain a
policy or policies of insurance with reputable insurance companies providing the officers and
directors of the Company with coverage for losses from wrongful acts, or to ensure the Company&#146;s
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 4 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">performance of its indemnification obligations under this Agreement. Among other
considerations, the Company will weigh the costs of obtaining such insurance coverage against the
protection afforded by such coverage. In all policies of director and officer liability insurance,
Indemnitee shall be named as an insured in such a manner as to provide Indemnitee the same rights
and benefits as are accorded to the most favorably insured of the Company&#146;s directors, if
Indemnitee is a director; or of the Company&#146;s officers, if Indemnitee is not a director of the
Company but is an officer. Notwithstanding the foregoing, the Company shall have no obligation to
obtain or maintain such insurance if the Company determines in good faith that such insurance is
not reasonably available, if the premium costs for such insurance are disproportionate to the
amount of coverage provided, if the coverage provided by such insurance is limited by exclusions so
as to provide an insufficient benefit, or if Indemnitee is covered by similar insurance maintained
by a subsidiary or parent of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<B><I>Severability</I></B>. Nothing in this Agreement is intended to require or shall be construed as
requiring the Company to do or fail to do any act in violation of applicable law. The Company&#146;s
inability, pursuant to court order, to perform its obligations under this Agreement shall not
constitute a breach of this Agreement. The provisions of this Agreement shall be severable as
provided in this Section&nbsp;7. If this Agreement or any portion hereof shall be invalidated on any
ground by any court of competent jurisdiction, then the Company shall nevertheless indemnify
Indemnitee to the full extent permitted by any applicable portion of this Agreement that shall not
have been invalidated, and the balance of this Agreement not so invalidated shall be enforceable in
accordance with its terms.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<B><I>Exceptions</I></B>. Any other provision herein to the contrary notwithstanding, the Company shall
not be obligated pursuant to the terms of this Agreement:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<I>Claims Initiated by Indemnitee</I>. To indemnify or advance expenses to Indemnitee with
respect to proceedings or claims initiated or brought voluntarily by Indemnitee and not by way of
defense, except with respect to proceedings brought to establish or enforce a right to
indemnification under this Agreement or any other statute or law or otherwise as required under
Section&nbsp;145 of the Delaware General Corporation Law, but such indemnification or advancement of
expenses may be provided by the Company in specific cases if the Board of Directors has approved
the initiation or bringing of such suit; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<I>Lack of Good Faith</I>. To indemnify Indemnitee for any expenses incurred by the Indemnitee
with respect to any proceeding instituted by Indemnitee to enforce or interpret this Agreement, if
a court of competent jurisdiction determines that each of the material assertions made by the
Indemnitee in such proceeding was not made in good faith or was frivolous; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;<I>Insured Claims</I>. To indemnify Indemnitee for expenses or liabilities of any type whatsoever
(including, but not limited to, judgments, fines, ERISA excise taxes or penalties, and amounts paid
in settlement) which have been paid directly to Indemnitee by an insurance carrier under a policy
of officers&#146; and directors&#146; liability insurance maintained by the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;<I>Claims Under Section&nbsp;16(b)</I>. To indemnify Indemnitee for expenses and the payment of
profits arising from the purchase and sale by Indemnitee of securities in violation of
Section&nbsp;16(b) of the Securities Exchange Act of 1934, as amended, or any similar successor statute.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->- 5 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<B><I>Construction of Certain Phrases</I></B>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;For purposes of this Agreement, references to the &#147;Company&#148; shall include, in addition to
the resulting corporation, any constituent corporation (including any constituent of a constituent)
absorbed in a consolidation or merger which, if its separate existence had continued, would have
had power and authority to indemnify its directors, officers, and employees or agents, so that if
Indemnitee is or was a director, officer, employee or agent of such constituent corporation, or is
or was serving at the request of such constituent corporation as a director, officer, employee or
agent of another corporation, partnership, joint venture, trust or other enterprise, Indemnitee
shall stand in the same position under the provisions of this Agreement with respect to the
resulting or surviving corporation as Indemnitee would have with respect to such constituent
corporation if its separate existence had continued.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;For purposes of this Agreement, references to &#147;other enterprises&#148; shall include employee
benefit plans; references to &#147;fines&#148; shall include any excise taxes assessed on Indemnitee with
respect to an employee benefit plan; and references to &#147;serving at the request of the Company&#148;
shall include any service as a director, officer, employee or agent of the Company which imposes
duties on, or involves services by, such director, officer, employee or agent with respect to an
employee benefit plan, its participants, or beneficiaries; and if Indemnitee acted in good faith
and in a manner Indemnitee reasonably believed to be in the interest of the participants and
beneficiaries of an employee benefit plan, Indemnitee shall be deemed to have acted in a manner
&#147;not opposed to the best interests of the Company&#148; as referred to in this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<B><I>Counterparts</I></B>. This Agreement may be executed in one or more counterparts, each of which
shall constitute an original.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<B><I>Successors and Assigns</I></B>. This Agreement shall be binding upon the Company and its
successors and assigns, and shall inure to the benefit of Indemnitee and Indemnitee&#146;s estate,
heirs, legal representatives and assigns.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;<B><I>Attorneys&#146; Fees. </I></B>In the event that any action is instituted by Indemnitee under this
Agreement to enforce or interpret any of the terms hereof, Indemnitee shall be entitled to be paid
all court costs and expenses, including attorneys&#146; fees, actually and reasonably incurred by
Indemnitee with respect to such action, unless as a part of such action, the court of competent
jurisdiction determines that each of the material assertions made by Indemnitee as a basis for such
action were not made in good faith or were frivolous. In the event of an action instituted by or in
the name of the Company under this Agreement or to enforce or interpret any of the terms of this
Agreement, Indemnitee shall be entitled to be paid all court costs and expenses, including
attorneys&#146; fees, actually and reasonably incurred by Indemnitee in defense of such action
(including with respect to Indemnitee&#146;s counterclaims and cross-claims made in such action), unless
as a part of such action the court determines that each of Indemnitee&#146;s material defenses to such
action were made in bad faith or were frivolous.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;<B><I>Notice</I></B>. All notices, requests, demands and other communications under this Agreement shall
be in writing and shall be deemed duly given (i)&nbsp;if delivered by hand and receipted for by the
party addressee, on the date of such receipt, or (ii)&nbsp;if mailed by domestic certified or registered
mail
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 6 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">with postage prepaid, on the third business day after the date postmarked. Addresses for
notice to either party are as shown on the signature page of this Agreement, or as subsequently
modified by written notice.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.&nbsp;<B><I>Consent to Jurisdiction</I></B>. The Company and Indemnitee each hereby irrevocably consent to the
jurisdiction of the courts of the State of Delaware for all purposes in connection with any action
or proceeding which arises out of or relates to this Agreement and agree that any action instituted
under this Agreement shall be brought only in the state courts of the State of Delaware.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.&nbsp;<B><I>Choice of Law</I></B>. This Agreement shall be governed by and its provisions construed in
accordance with the laws of the State of Delaware, as applied to contracts between Delaware
residents entered into and to be performed entirely within Delaware without regard to the conflict
of law principles thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.&nbsp;<B><I>Period of Limitations</I></B>. No legal action shall be brought and no cause of action shall be
asserted by or in the right of the Company against Indemnitee, Indemnitee&#146;s estate, spouse, heirs,
executors or personal or legal representatives after the expiration of two years from the date of
accrual of such cause of action, and any claim or cause of action of the Company shall be
extinguished and deemed released unless asserted by the timely filing of a legal action within such
two-year period; <I>provided, however</I>, that if any shorter period of limitations is otherwise
applicable to any such cause of action, such shorter period shall govern.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17.&nbsp;<B><I>Subrogation</I></B>. In the event of payment under this Agreement, the Company shall be subrogated
to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all
documents required and shall do all acts that may be necessary to secure such rights and to enable
the Company effectively to bring suit to enforce such rights.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.&nbsp;<B><I>Amendment and Termination</I></B>. No amendment, modification, termination or cancellation of this
Agreement shall be effective unless it is in writing signed by both the parties hereto. No waiver
of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any
other provisions hereof (whether or not similar) nor shall such waiver constitute a continuing
waiver.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.&nbsp;<B><I>Integration and Entire Agreement</I></B>. This Agreement sets forth the entire understanding
between the parties hereto and supersedes and merges all previous written and oral negotiations,
commitments, understandings and agreements relating to the subject matter hereof between the
parties hereto.
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">(<I>signature page follows</I>)

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 7 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above
written.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="38%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="13%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>FLUIDIGM CORPORATION</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><I>Signature of Authorized Signatory</I></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><I>Print Name</I></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><I>Title</I></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7000 Shoreline Court, Suite&nbsp;100</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">South San Francisco, CA 94080</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>AGREED TO AND ACCEPTED:</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>INDEMNITEE:</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><I>Signature</I></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><I>Print Name</I></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><I>Title</I></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Address:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>12
<FILENAME>f39432orexv10w2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w2</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.2</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FLUIDIGM CORPORATION</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>1999 STOCK OPTION PLAN<BR>
(as amended April&nbsp;24, 2007, January&nbsp;29, 2008)</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Purposes&nbsp;of&nbsp;the&nbsp;Plan</U>. The purposes of this Stock Option Plan are to attract and
retain the best available personnel for positions of substantial responsibility, to provide
additional incentive to Employees, Directors and Consultants and to promote the success of the
Company&#146;s business. Options granted under the Plan may be Incentive Stock Options or Nonstatutory
Stock Options, as determined by the Administrator at the time of grant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Definitions</U>. As used herein, the following definitions shall apply:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) &#147;<U>Administrator</U>&#148; means the Board or any of its Committees as shall be administering
the Plan in accordance with Section&nbsp;4 hereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) &#147;<U>Applicable Laws</U>&#148; means the requirements relating to the administration of stock
option plans under U.S. state corporate laws, U.S. federal and state securities laws, the Code, any
stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable
laws of any other country or jurisdiction where Options are granted under the Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) &#147;<U>Board</U>&#148; means the Board of Directors of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) &#147;<U>Code</U>&#148; means the Internal Revenue Code of 1986, as amended.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) &#147;<U>Committee</U>&#148; means a committee of Directors appointed by the Board in accordance
with Section&nbsp;4 hereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) &#147;<U>Common Stock</U>&#148; means the Common Stock of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) &#147;<U>Company</U>&#148; means Fluidigm Corporation, a Delaware corporation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) &#147;<U>Consultant</U>&#148; means any person who is engaged by the Company or any Parent or
Subsidiary to render consulting or advisory services to such entity.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) &#147;<U>Director</U>&#148; means a member of the Board of Directors of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) &#147;<U>Disability</U>&#148; means total and permanent disability as defined in Section&nbsp;22(e)(3)
of the Code.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) &#147;<U>Employee</U>&#148; means any person, including Officers and Directors, employed by the
Company or any Parent or Subsidiary of the Company. A Service Provider shall not cease to be an
Employee in the case of (i)&nbsp;any leave of absence approved by the Company or (ii)&nbsp;transfers between
locations of the Company or between the Company, its Parent, any Subsidiary, or any successor. For
purposes of Incentive Stock Options, no such leave may exceed three (3)&nbsp;months, unless reemployment
upon expiration of such leave is guaranteed by statute or contract. If
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">reemployment upon expiration of a leave of absence approved by the Company is not so
guaranteed, then six (6)&nbsp;months following the first day of such leave any Incentive Stock Option
held by the Optionee shall cease to be treated as an Incentive Stock Option and shall be treated
for tax purposes as a Nonstatutory Stock Option. Neither service as a Director nor payment of a
director&#146;s fee by the Company shall be sufficient to constitute &#147;employment&#148; by the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) &#147;<U>Exchange Act</U>&#148; means the Securities Exchange Act of 1934, as amended.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) &#147;<U>Fair Market Value</U>&#148; means, as of any date, the value of Common Stock determined as
follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;If the Common Stock is listed on any established stock exchange or a national market
system, including without limitation the Nasdaq National Market or The Nasdaq SmallCap Market of
The Nasdaq Stock Market, its Fair Market Value shall be the closing sales price for such stock (or
the closing bid, if no sales were reported) as quoted on such exchange or system for the last
market trading day prior to the time of determination, as reported in <I>The Wall Street Journal </I>or
such other source as the Administrator deems reliable;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;If the Common Stock is regularly quoted by a recognized securities dealer but selling
prices are not reported, its Fair Market Value shall be the mean between the high bid and low asked
prices for the Common Stock on the last market trading day prior to the day of determination; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;In the absence of an established market for the Common Stock, the Fair Market Value
thereof shall be determined in good faith by the Administrator.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n) &#147;<U>Incentive Stock Option</U>&#148; means an Option intended to qualify as an incentive stock
option within the meaning of Section&nbsp;422 of the Code.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o) &#147;<U>Nonstatutory Stock Option</U>&#148; means an Option not intended to qualify as an
Incentive Stock Option.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p) &#147;<U>Officer</U>&#148; means a person who is an officer of the Company within the meaning of
Section&nbsp;16 of the Exchange Act and the rules and regulations promulgated thereunder.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q) &#147;<U>Option</U>&#148; means a stock option granted pursuant to the Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(r) &#147;<U>Option Agreement</U>&#148; means a written or electronic agreement between the Company and
an Optionee evidencing the terms and conditions of an individual Option grant. The Option
Agreement is subject to the terms and conditions of the Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(s) &#147;<U>Option Exchange Program</U>&#148; means a program whereby outstanding Options are
exchanged for Options with a lower exercise price.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(t) &#147;<U>Optioned&nbsp;Stock</U>&#148; means the Common Stock subject to an Option.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(u) &#147;<U>Optionee</U>&#148; means the holder of an outstanding Option granted under the Plan.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) &#147;<U>Parent</U>&#148; means a &#147;parent corporation,&#148; whether now or hereafter existing, as
defined in Section&nbsp;424(e) of the Code.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(w) &#147;<U>Plan</U>&#148; means this 1999 Stock Option Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) &#147;<U>Service Provider</U>&#148; means an Employee, Director or Consultant.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(y) &#147;<U>Share</U>&#148; means a share of the Common Stock, as adjusted in accordance with Section
11 below.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(z) &#147;<U>Subsidiary</U>&#148; means a &#147;subsidiary corporation,&#148; whether now or hereafter existing,
as defined in Section&nbsp;424(f) of the Code.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Stock&nbsp;Subject&nbsp;to&nbsp;the&nbsp;Plan</U>. Subject to the provisions of Section&nbsp;11 of the Plan,
the maximum aggregate number of Shares which may be subject to option and sold under the Plan is
12,800,000 Shares. The Shares may be authorized but unissued, or reacquired Common Stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If an Option expires or becomes unexercisable without having been exercised in full, or is
surrendered pursuant to an Option Exchange Program, the unpurchased Shares which were subject
thereto shall become available for future grant or sale under the Plan (unless the Plan has
terminated). However, Shares that have actually been issued under the Plan, upon exercise of an
Option, shall not be returned to the Plan and shall not become available for future distribution
under the Plan, except that if Shares are repurchased by the Company at their original purchase
price, such Shares shall become available for future grant under the Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Administration&nbsp;of&nbsp;the&nbsp;Plan</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Administrator</U>. The Plan shall be administered by the Board or a Committee
appointed by the Board, which Committee shall be constituted to comply with Applicable Laws.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Powers&nbsp;of&nbsp;the&nbsp;Administrator</U>. Subject to the provisions of the Plan and, in the
case of a Committee, the specific duties delegated by the Board to such Committee, and subject to
the approval of any relevant authorities, the Administrator shall have the authority in its
discretion:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;to determine the Fair Market Value;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;to select the Service Providers to whom Options may from time to time be granted
hereunder;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;to determine the number of Shares to be covered by each such award granted hereunder;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;to approve forms of agreement for use under the Plan;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;to determine the terms and conditions, of any Option granted hereunder. Such terms and
conditions include, but are not limited to, the exercise price, the time or times when Options may
be exercised (which may be based on performance criteria), any vesting
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">acceleration or waiver of
forfeiture restrictions, and any restriction or limitation regarding any Option or the Common Stock
relating thereto, based in each case on such factors as the Administrator, in its sole discretion,
shall determine;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)&nbsp;to determine whether and under what circumstances an Option may be settled in cash under
subsection 9(e) instead of Common Stock;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)&nbsp;to reduce the exercise price of any Option to the then current Fair Market Value if the
Fair Market Value of the Common Stock covered by such Option has declined since the date the Option
was granted;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii)&nbsp;to initiate an Option Exchange Program;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix)&nbsp;to prescribe, amend and rescind rules and regulations relating to the Plan, including
rules and regulations relating to sub-plans established for the purpose of qualifying for preferred
tax treatment under foreign tax laws;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x)&nbsp;to allow Optionees to satisfy withholding tax obligations by electing to have the Company
withhold from the Shares to be issued upon exercise of an Option that number of Shares having a
Fair Market Value equal to the amount required to be withheld. The Fair Market Value of the Shares
to be withheld shall be determined on the date that the amount of tax to be withheld is to be
determined. All elections by Optionees to have Shares withheld for this purpose shall be made in
such form and under such conditions as the Administrator may deem necessary or advisable; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xi)&nbsp;to construe and interpret the terms of the Plan and awards granted pursuant to the Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Effect&nbsp;of&nbsp;Administrator&#146;s Decision</U>. All decisions, determinations and
interpretations of the Administrator shall be final and binding on all Optionees.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Eligibility</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Nonstatutory Stock Options may be granted to Service Providers. Incentive Stock Options
may be granted only to Employees.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each Option shall be designated in the Option Agreement as either an Incentive Stock
Option or a Nonstatutory Stock Option. However, notwithstanding such designation, to the extent
that the aggregate Fair Market Value of the Shares with respect to which Incentive Stock Options
are exercisable for the first time by the Optionee during any calendar year (under all plans of the
Company and any Parent or Subsidiary) exceeds $100,000, such Options shall be treated as
Nonstatutory Stock Options. For purposes of this Section&nbsp;5(b), Incentive Stock Options
shall be taken into account in the order in which they were granted. The Fair Market Value of
the Shares shall be determined as of the time the Option with respect to such Shares is granted.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Neither the Plan nor any Option shall confer upon any Optionee any right with respect to
continuing the Optionee&#146;s relationship as a Service Provider with the Company, nor shall it
interfere in any way with his or her right or the Company&#146;s right to terminate such relationship at
any time, with or without cause.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Term&nbsp;of&nbsp;Plan</U>. The Plan shall become effective upon its adoption by the Board. It
shall continue in effect for a term of ten (10)&nbsp;years unless sooner terminated under Section&nbsp;13 of
the Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Term of Option</U>. The term of each Option shall be stated in the Option Agreement;
provided, however, that the term shall be no more than ten&nbsp;(10) years from the date of grant
thereof. In the case of an Incentive Stock Option granted to an Optionee who, at the time the
Option is granted, owns stock representing more than ten percent (10%) of the voting power of all
classes of stock of the Company or any Parent or Subsidiary, the term of the Option shall be five
(5)&nbsp;years from the date of grant or such shorter term as may be provided in the Option Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Option Exercise Price and Consideration</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The per share exercise price for the Shares to be issued upon exercise of an Option shall
be such price as is determined by the Administrator, but shall be subject to the following:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;In the case of an Incentive Stock Option
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;granted to an Employee who, at the time of grant of such Option, owns stock representing
more than ten percent (10%) of the voting power of all classes of stock of the Company or any
Parent or Subsidiary, the exercise price shall be no less than 110% of the Fair Market Value per
Share on the date of grant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;granted to any other Employee, the per Share exercise price shall be no less than 100% of
the Fair Market Value per Share on the date of grant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;In the case of a Nonstatutory Stock Option, the per Share exercise price shall be no less
than 100% of the Fair Market Value per Share on the date of grant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;Notwithstanding the foregoing, Options may be granted with a per Share exercise price
other than as required above pursuant to a transaction described in, and in a manner consistent
with, Section 424(a) of the Code.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The consideration to be paid for the Shares to be issued upon exercise of an Option,
including the method of payment, shall be determined by the Administrator (and, in the case of an
Incentive Stock Option, shall be determined at the time of grant). Such consideration may consist
of (1)&nbsp;cash, (2)&nbsp;check, (3)&nbsp;promissory note, (4)&nbsp;other Shares, provided such Shares have a Fair
Market Value on the date of surrender equal to the aggregate exercise price of the Shares as
to which such Option shall be exercised and provided further that accepting such Shares will not
result in adverse accounting consequences to the Company, as determined by the Administrator in its
sole
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-5-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">discretion, (5)&nbsp;consideration received by the Company under a cashless exercise program
implemented by the Company in connection with the Plan, or (6)&nbsp;such other consideration and method
of payment for the issuance of Shares to the extent permitted by Applicable Laws, (7)&nbsp;any
combination of the foregoing methods of payment. In making its determination as to the type of
consideration to accept, the Administrator shall consider if acceptance of such consideration may
be reasonably expected to benefit the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>Exercise&nbsp;of&nbsp;Option</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Procedure&nbsp;for&nbsp;Exercise; Rights as a Stockholder</U>. Any Option granted hereunder
shall be exercisable according to the terms hereof at such times and under such conditions as
determined by the Administrator and set forth in the Option Agreement. Unless the Administrator
provides otherwise, vesting of Options granted shall be tolled during any unpaid leave of absence.
An Option may not be exercised for a fraction of a Share.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An Option shall be deemed exercised when the Company receives: (i)&nbsp;written or electronic
notice of exercise (in accordance with the Option Agreement) from the person entitled to exercise
the Option, and (ii)&nbsp;full payment for the Shares with respect to which the Option is exercised.
Full payment may consist of any consideration and method of payment authorized by the Administrator
and permitted by the Option Agreement and the Plan. Shares issued upon exercise of an Option shall
be issued in the name of the Optionee or, if requested by the Optionee, in the name of the Optionee
and his or her spouse. Until the Shares are issued (as evidenced by the appropriate entry on the
books of the Company or of a duly authorized transfer agent of the Company), no right to vote or
receive dividends or any other rights as a stockholder shall exist with respect to the Shares,
notwithstanding the exercise of the Option. The Company shall issue (or cause to be issued) such
Shares promptly after the Option is exercised. No adjustment will be made for a dividend or other
right for which the record date is prior to the date the Shares are issued, except as provided in
Section&nbsp;11 of the Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exercise of an Option in any manner shall result in a decrease in the number of Shares
thereafter available, both for purposes of the Plan and for sale under the Option, by the number of
Shares as to which the Option is exercised.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Termination&nbsp;of Relationship as a Service Provider</U>. If an Optionee ceases to be a
Service Provider, such Optionee may exercise his or her Option within such period of time as is
specified in the Option Agreement (of at least thirty (30)&nbsp;days) to the extent that the Option is
vested on the date of termination (but in no event later than the expiration of the term of the
Option as set forth in the Option Agreement). In the absence of a specified time in the Option
Agreement, the Option shall remain exercisable for three (3)&nbsp;months following the Optionee&#146;s
termination. If, on the date of termination, the Optionee is not vested as to his or her entire
Option, the Shares covered by the unvested portion of the Option shall revert to the Plan. If,
after termination, the Optionee does
not exercise his or her Option within the time specified by the Administrator, the Option
shall terminate, and the Shares covered by such Option shall revert to the Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Disability of Optionee</U>. If an Optionee ceases to be a Service Provider as a
result of the Optionee&#146;s Disability, the Optionee may exercise his or her Option within such period
of
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-6-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">time as is specified in the Option Agreement (of at least six (6)&nbsp;months) to the extent the
Option is vested on the date of termination (but in no event later than the expiration of the term
of such Option as set forth in the Option Agreement). In the absence of a specified time in the
Option Agreement, the Option shall remain exercisable for twelve (12)&nbsp;months following the
Optionee&#146;s termination. If, on the date of termination, the Optionee is not vested as to his or
her entire Option, the Shares covered by the unvested portion of the Option shall revert to the
Plan. If, after termination, the Optionee does not exercise his or her Option within the time
specified herein, the Option shall terminate, and the Shares covered by such Option shall revert to
the Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Death&nbsp;of&nbsp;Optionee</U>. If an Optionee dies while a Service Provider, the Option may
be exercised within such period of time as is specified in the Option Agreement (of at least six
(6)&nbsp;months) to the extent that the Option is vested on the date of death (but in no event later
than the expiration of the term of such Option as set forth in the Option Agreement) by the
Optionee&#146;s estate or by a person who acquires the right to exercise the Option by bequest or
inheritance. In the absence of a specified time in the Option Agreement, the Option shall remain
exercisable for twelve (12)&nbsp;months following the Optionee&#146;s termination. If, at the time of death,
the Optionee is not vested as to the entire Option, the Shares covered by the unvested portion of
the Option shall immediately revert to the Plan. If the Option is not so exercised within the time
specified herein, the Option shall terminate, and the Shares covered by such Option shall revert to
the Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Buyout Provisions</U>. The Administrator may at any time offer to buy out for a
payment in cash or Shares, an Option previously granted, based on such terms and conditions as the
Administrator shall establish and communicate to the Optionee at the time that such offer is made.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U>Non-Transferability&nbsp;of&nbsp;Options</U>. The Options may not be sold, pledged, assigned,
hypothecated, transferred, or disposed of in any manner other than by will or by the laws of
descent or distribution and may be exercised, during the lifetime of the Optionee, only by the
Optionee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<U>Adjustments&nbsp;Upon&nbsp;Changes&nbsp;in&nbsp;Capitalization, Merger or Asset Sale</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Changes in Capitalization</U>. Subject to any required action by the stockholders of
the Company, the number of shares of Common Stock covered by each outstanding Option, and the
number of shares of Common Stock which have been authorized for issuance under the Plan but as to
which no Options have yet been granted or which have been returned to the Plan upon cancellation or
expiration of an Option, as well as the price per share of Common Stock covered by each such
outstanding Option, shall be proportionately adjusted for any increase or decrease in the number of
issued shares of Common Stock resulting from a stock split, reverse stock split, stock dividend,
combination or reclassification of the Common Stock, or any other increase or decrease in the
number of issued shares of Common Stock effected without receipt of consideration by the Company or
other change in the corporate structure of the Company affecting the Shares that the
Administrator determines is necessary to prevent diminution or enlargement of benefits or
potential benefits intended to be made available under the Plan. The conversion of any convertible
securities of the Company shall not be deemed to have been &#147;effected without receipt of
consideration.&#148; Such adjustment shall be made by the Board, whose determination in that respect
shall be final, binding and conclusive. Except as expressly provided herein, no issuance by the
Company of shares of stock of any class, or securities convertible into shares of stock of any
class, shall affect, and no
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-7-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">adjustment by reason thereof shall be made with respect to, the number
or price of shares of Common Stock subject to an Option.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Dissolution or Liquidation</U>. In the event of the proposed dissolution or
liquidation of the Company, the Administrator shall notify each Optionee as soon as practicable
prior to the effective date of such proposed transaction. The Administrator in its discretion may
provide for an Optionee to have the right to exercise his or her Option until fifteen (15)&nbsp;days
prior to such transaction as to all of the Optioned Stock covered thereby, including Shares as to
which the Option would not otherwise be exercisable. In addition, the Administrator may provide
that any Company repurchase option applicable to any Shares purchased upon exercise of an Option
shall lapse as to all such Shares, provided the proposed dissolution or liquidation takes place at
the time and in the manner contemplated. To the extent it has not been previously exercised, an
Option will terminate immediately prior to the consummation of such proposed action.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Merger or Asset Sale</U>. In the event of a merger of the Company with or into
another corporation, or the sale of substantially all of the assets of the Company, each
outstanding Option shall be assumed or an equivalent option or right substituted by the successor
corporation or a Parent or Subsidiary of the successor corporation. In the event that the
successor corporation refuses to assume or substitute for an Option (or portion thereof), the
Optionee shall fully vest in and have the right to exercise the Option (or portion thereof) that is
not assumed or substituted for as to all of the Optioned Stock, including Shares as to which it
would not otherwise be vested or exercisable. If an Option is not assumed or substituted for in
the event of a merger or sale of assets, the Administrator shall notify the Optionee in writing or
electronically that the Option shall be fully exercisable for a period of fifteen (15)&nbsp;days from
the date of such notice, and the Option shall terminate upon the expiration of such period. For
the purposes of this paragraph, the Option shall be considered assumed if, following the merger or
sale of assets, the option or right confers the right to purchase or receive, for each Share
subject to the Option immediately prior to the merger or sale of assets, the consideration (whether
stock, cash, or other securities or property) received in the merger or sale of assets by holders
of Common Stock for each Share held on the effective date of the transaction (and if holders were
offered a choice of consideration, the type of consideration chosen by the holders of a majority of
the outstanding Shares); provided, however, that if such consideration received in the merger or
sale of assets is not solely common stock of the successor corporation or its Parent, the
Administrator may, with the consent of the successor corporation, provide for the consideration to
be received upon the exercise of the Option, for each Share subject to the Option, to be solely
common stock of the successor corporation or its Parent equal in fair market value to the per share
consideration received by holders of Common Stock in the merger or sale of assets.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;<U>Time&nbsp;of&nbsp;Granting&nbsp;Options</U>. The date of grant of an Option shall, for all purposes,
be the date on which the Administrator makes the determination granting such Option, or such other
date as is determined by the Administrator. Notice of the determination shall be given to
each Service Provider to whom an Option is so granted within a reasonable time after the date of
such grant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;<U>Amendment&nbsp;and&nbsp;Termination&nbsp;of&nbsp;the&nbsp;Plan</U>.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-8-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Amendment and Termination</U>. The Board may at any time amend, alter, suspend or
terminate the Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Stockholder Approval</U>. The Board shall obtain stockholder approval of any Plan
amendment to the extent necessary and desirable to comply with Applicable Laws.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Effect&nbsp;of&nbsp;Amendment&nbsp;or&nbsp;Termination</U>. No amendment, alteration, suspension or
termination of the Plan shall impair the rights of any Optionee, unless mutually agreed otherwise
between the Optionee and the Administrator, which agreement must be in writing and signed by the
Optionee and the Company. Termination of the Plan shall not affect the Administrator&#146;s ability to
exercise the powers granted to it hereunder with respect to Options granted under the Plan prior to
the date of such termination.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.&nbsp;<U>Conditions&nbsp;Upon&nbsp;Issuance&nbsp;of&nbsp;Shares</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Legal Compliance</U>. Shares shall not be issued pursuant to the exercise of an
Option unless the exercise of such Option and the issuance and delivery of such Shares shall
comply with Applicable Laws and shall be further subject to the approval of counsel for the Company
with respect to such compliance.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Investment Representations</U>. As a condition to the exercise of an Option, the
Administrator may require the person exercising such Option to represent and warrant at the time of
any such exercise that the Shares are being purchased only for investment and without any present
intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a
representation is required.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.&nbsp;<U>Inability to Obtain Authority</U>. The inability of the Company to obtain authority
from any regulatory body having jurisdiction, which authority is deemed by the Company&#146;s counsel to
be necessary to the lawful issuance and sale of any Shares hereunder, shall relieve the Company of
any liability in respect of the failure to issue or sell such Shares as to which such requisite
authority shall not have been obtained.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.&nbsp;<U>Reservation&nbsp;of&nbsp;Shares</U>. The Company, during the term of this Plan, shall at all
times reserve and keep available such number of Shares as shall be sufficient to satisfy the
requirements of the Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17.&nbsp;<U>Stockholder Approval</U>. The Plan shall be subject to approval by the stockholders of the
Company within twelve (12)&nbsp;months after the date the Plan is adopted. Such stockholder approval
shall be obtained in the degree and manner required under Applicable Laws.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-9-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>APPENDIX A</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>FLUIDIGM
CORPORATION</B></div>
<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><b>1999 STOCK OPTION PLAN</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Additional Terms and Conditions for Options received by Employees Resident in the
Netherlands</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The additional terms and conditions detailed below are to be read in conjunction with the Plan
and the Option Agreement relating to Options granted to Employees resident in the Netherlands. Any
terms and provisions not specifically defined below for Employees subject to the laws of the
Netherlands will have the same meaning as defined in the Plan and the applicable Option Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Definitions</U>. Notwithstanding the provisions of the Plan, the following definitions
shall apply for Options granted to Employees resident in the Netherlands.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Acknowledgement Date</U>. &#147;Acknowledgement Date&#148; means the date upon which an Option
Agreement is signed and returned to the Company (or the Employee&#146;s employer if so designated by the
Company) by the Employee.<U> </U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Employee</U>. &#147;Employee&#148; means any person permanently employed by the Company or any
Parent or Subsidiary of the Company based upon such factors as are deemed appropriate by the
Administrator in its discretion, subject to any requirements and provisions of the applicable Dutch
laws, including the provisions of the Dutch Civil Code (<I>Burgerlijk Wetboek</I>). The term &#147;Employee&#148;,
however, shall not include an individual who, either by himself or through his Relative or through
a corporate entity, holds, directly or indirectly, 5% or more of the equity of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Relative</U>. &#147;Relative&#148; means immediate relative, namely one&#146;s spouse, parent,
parent of spouse, brother, sister, brother of spouse, sister of spouse or child of the person or
spouse.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Eligibility</U>. Notwithstanding the provisions of the Plan, Options granted to
residents of the Netherlands may only be granted to Employees who, either by themselves or through
a corporate entity or through his Relative, do not hold, directly or indirectly, 5% or more of the
equity of the Company. Consultants resident in the Netherlands shall not be eligible to receive
Options.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Options may be granted to Employees in accordance with the terms of the Plan and this Appendix
A to the Plan as the Administrator deems appropriate. In determining which Employees may be
granted Options, the Administrator will take into account whether will
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">provide additional incentive to Employees and whether such Options will promote the success of
the Company&#146;s business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Dutch Taxes</U>. Notwithstanding the provisions of the Plan and pursuant to
Section&nbsp;4(b)(ix) of this Plan, the following shall apply for residents in the Netherlands
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;All tax and social security consequences and obligations regarding any other compulsory
payments arising from the grant, possesion or exercise of any Options, from the payment for, or the
subsequent possesion or disposition of or from any other event or act of the Company (or the
Employee&#146;s employer) or the Employee hereunder, shall be borne solely by the Employee, and the
Employee shall indemnify the Company (or the Employee&#146;s employer) and hold it harmless against and
from any and all liability for any such tax or social security payment, or interest or penalty
thereon, including without limitation, liabilities relating to the necessity to withhold, or to
have withheld, any such tax or social security payment from any payment made to the Employee.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Company (or the Employee&#146;s employer) is at any time entitled to withhold from wages
payable to the Employee any tax and social security amounts due with respect to the grant or
exercise of any Options.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;On the Acknowledgement Date, the Employee may deliver to the Company a signed written
notice in accordance with Article&nbsp;10(a)(3) of the Dutch Wage Tax Act 1964 (<I>Wet op de Loonbelasting
1964</I>) (hereafter: the &#147;Written Notice&#148;) with respect to the Options. The Written Notice will
indicate that Dutch withholding tax will be due upon exercise of the Options. If no such Written
Notice has been received by the Company on the Acknowledgement Date, any withholding tax will
automatically be due upon vesting of the Options.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company shall immediately send the Written Notice to the competent Dutch tax authorities.
Notwithstanding the provisions under Section&nbsp;9 of the Plan, if a Written Notice has been received
by the Company on the Acknowledgement Date, the Options granted under Appendix&nbsp;A will not be
exercisable until the competent Dutch tax authorities has received the Written Notice.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Merger or Asset Sale</U>. Notwithstanding the provisions of Section&nbsp;11(c), if the successor
corporation (or any parent or subsidiary thereof) intends to assume or substitute each outstanding
Option in a merger of the Company with or into another corporation, or the sale of substantially
all of the assets of the Company and the rules and regulations governing Options granted to
Employees in the Netherlands (the &#147;Netherlands Options&#148;) do not permit assumption or substitution
of the Netherlands Options in the same manner as other Options, then the Administrator, in its
discretion, may provide for the termination of the Netherlands Options upon the consummation of the
transaction or provide for the assumption or substitution of the Netherlands Options in a different
manner than the assumption or substitution of other Options.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>APPENDIX B</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>FLUIDIGM CORPORATION</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>1999 STOCK OPTION PLAN<BR>
(Added April&nbsp;24, 2007)</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Additional Terms and Conditions for Options received by Employees Resident in France</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The additional terms and conditions detailed below are to be read in conjunction with the Plan
and the Option Agreement relating to Options granted to Employees resident in France. Any terms
and provisions not specifically defined below for Employees subject to the laws of France will have
the same meaning as defined in the Plan and the applicable Option Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to promote compliance of the Plan with the principles set out by the French tax
authorities in their regulations 4 N 2431 dated August&nbsp;30, 1997, in furtherance of Article&nbsp;80 bis
III of the French Code G&#233;n&#233;ral des Imp&#244;ts, any Option granted under the Plan to residents of France
will be subject to the conditions stated below.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a matter of principle, any provision included in the Plan, the Option Agreement or any
other document evidencing the terms and conditions of an Option that would contravene any
substantive principle set out in Articles L.225-177 to L.225-186 of the French Code de Commerce
shall not be applicable to Optionees who are residents of France.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Definitions</U>. Notwithstanding the provisions of the Plan, the following definitions
shall apply for Options granted to Employees resident in France.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Applicable Laws</U>. &#147;Applicable Laws&#148; means the legal requirements relating to the
administration of stock option plans under U.S. state corporate laws, U.S. federal and state
securities laws, the Code, any stock exchange or quotation system on which the Common Stock is
listed or quoted and French corporate, securities, labor and tax laws.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Employee</U>. &#147;Employee&#148; means (i)&nbsp;any person employed by the Company or a branch of
the Company or a Subsidiary in a salaried position within the meaning Applicable Laws, who does not
own more than ten percent (10%) of the voting power of all classes of stock of the Company, or any
Parent or Subsidiary, and who is a resident of the Republic of France or (ii)&nbsp;any person employed
by the Company or a branch of the Company or a Subsidiary who is a resident of the Republic of
France for tax purposes or who performs his or her duties in France and is subject to French income
social security contributions on his or her remuneration.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Fair Market Value</U>. &#147;Fair Market Value&#148; means, as of any date, the dollar value of
Common Stock determined as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) If the Common Stock is listed on any established stock exchange or a national market
system, including without limitation the Nasdaq Global Market or the Nasdaq
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Global Select Market of the Nasdaq Stock Market, its Fair Market Value will be the average
quotation price for the last twenty (20)&nbsp;days preceding the date of determination for such Common
Stock (or the average closing bid for such twenty (20)&nbsp;day period, if no sales were reported) as
quoted on such exchange or system and reported in <I>The Wall Street Journal </I>or such other source as
the Administrator deems reliable;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;If the Common Stock is quoted on the Nasdaq Stock market (but not on the Nasdaq Global
Market or Nasdaq Global Select Market thereof) or regularly quoted by a recognized securities
dealer but selling prices are not reported, its Fair Market Value will be the mean between the high
bid and low asked prices for the Common Stock for the last twenty (20)&nbsp;days preceding the date of
determination; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;In the absence of an established market for the Common Stock, the Fair Market Value
thereof will be determined in good faith by the Administrator.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Subsidiary</U>. &#147;Subsidiary&#148; means any participating subsidiary of the Company
located in the Republic of France and that falls within the definition of &#147;subsidiary&#148; within the
meaning of Section&nbsp;L. 225-180 paragraph 1 of the French commercial code.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Termination</U>. &#147;Termination&#148; means if the Optionee is an Employee, the last day of
any statutory or contractual notice period whether worked or not (provided, only the employer, and
not the Optionee, may decide whether the Optionee works during the notice period) and irrespective
of whether the termination of the employment agreement is due to resignation or dismissal of the
Employee for any reason whatsoever; if the Optionee is a corporate officer as defined in Section&nbsp;2
of this Appendix&nbsp;B, Termination means the date on which he or she effectively leaves his or her
position as a corporate officer for any reason whatsoever.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Eligibility</U>. Options granted pursuant to this Appendix&nbsp;B may be granted only to
Employees, the <I>Pr&#233;sident du conseil d&#146;administration, </I>the <I>membres du directoire, </I>the <I>Directeur
g&#233;n&#233;ral</I>, the directeurs g&#233;n&#233;raux d&#233;l&#233;gu&#233;s, the <I>G&#233;rant </I>of a company with capital divided by shares;
provided, however, that the <I>administrateurs </I>and the <I>membres du conseil de surveillance </I>who are also
Employees of the Subsidiary in accordance with a valid employment agreement pursuant to Applicable
Laws may be granted Options hereunder. For the purpose of this Appendix&nbsp;B, when applicable, the
rules set forth for an Employee will be applicable to the aforementioned corporate officers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Stock Subject to the Plan</U>. The total number of Options outstanding which may be
exercised for newly issued Shares may at no time exceed that number equal to one-third
(1/3<SUP style="font-size: 85%; vertical-align: text-top">rd</SUP>) of the Company&#146;s voting stock, whether preferred stock of the Company or Common
Stock. If any Optioned Stock is to consist of reacquired Shares, such Optioned Stock must be
purchased by the Company, in the limit of ten percent (10%) of its share capital, prior to the date
of the grant of the corresponding new Option and must be reserved and set aside for such purposes.
In addition, the new Option must be granted within one (1)&nbsp;year of the acquisition of the Shares
underlying such new Option.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Limitations Upon Granting of Options</U>.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Declaration of Dividend; Capital Increase</U>. To the extent applicable to the
Company, Options cannot be granted during the twenty (20)&nbsp;trading days from (i)&nbsp;the date the Common
Stock is trading on an ex-dividend basis or (ii)&nbsp;a capital increase.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Non-Public Information</U>. To the extent applicable to the Company, the Company will
not grant Options during the closed periods required under Section&nbsp;L 225-177 of the French
Commercial Code. As a result, notwithstanding any other provision of the Plan, Options cannot be
granted:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;during the ten (10)&nbsp;trading days preceding and following the date on which the
consolidated accounts, or, if unavailable, the annual accounts, are made public;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;during the period between the date on which the Company&#146;s governing bodies (i.e., the
Board) become aware of information which, if made public, could have a material impact on the price
of the Shares, and the date ten (10)&nbsp;trading days after such information is made public.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Right to Employment</U>. Neither the Plan nor any Option will confer upon any
Optionee any right with respect to continuing the Optionee&#146;s employment relationship with the
Company or any Subsidiary.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Exercise Price</U>. The exercise price for the Shares to be issued pursuant to
exercise of an Option will be determined by the Administrator upon the date of grant of the Option
and stated in the Option Agreement, but in no event will be less than the higher of (i)&nbsp;eighty
percent (80%) of (A)&nbsp;the Fair Market Value on the date the Option is granted, or (B)&nbsp;if applicable,
the average purchase price paid by the Company for such Shares, or (ii)&nbsp;the exercise price as
determined under Section&nbsp;8(a) of the Plan. The exercise price cannot be modified while an Option
is outstanding, except as required by Applicable Laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Term of Option</U>. The term of each Option will be as stated in the Option Agreement;
provided, however, that the maximum term of an Option will not exceed ten (10)&nbsp;years from the date
of grant of the Option.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Exercise of Option; Restriction on Sale</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Except as otherwise explicitly set forth in the Option Agreement, Options granted
hereunder may be not be exercised within one (1)&nbsp;year of the date the Option is granted (the
&#147;Initial Exercise Date&#148;) whether or not the Option has vested prior to such time; provided,
however, that the Initial Exercise Date will be automatically adjusted to conform with any changes
under Applicable Laws so that the length of time from the date of grant to the Initial Exercise
Date when added to the length of time in which Shares may not be disposed of after the Initial
Exercise Date as provided in Section&nbsp;7(b) below, will allow for favorable tax and social security
treatment under Applicable Laws. Thereafter, Options may be exercised to the extent they have
vested.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">An Option will be deemed exercised when the Company receives: (i)&nbsp;written or electronic notice of
exercise (in accordance with the Option Agreement) from the person entitled to exercise the Option,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">and (ii)&nbsp;full payment for the Shares with respect to which the Option is exercised together with
any applicable withholding taxes and social security contributions. Full payment may consist of
any consideration and method of payment authorized by the Administrator and permitted by the Option
Agreement and the Plan. Until the Shares are issued (as evidenced by the appropriate entry on the
books of the Company or of a duly authorized transfer agent of the Company), no right to vote or
receive dividends or any other rights as a stockholder will exist with respect to the Shares,
notwithstanding the exercise of the Option. The Company will issue (or cause to be issued) such
Shares promptly after the Option is exercised. No adjustment will be made for a dividend or other
right for which the record date is prior to the date the Shares are issued, except as provided in
Section&nbsp;11 of the Plan and to the extent permitted by Applicable Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Shares subject to an Option may not be transferred, assigned or hypothecated in any
manner otherwise than by will or by the laws of descent or distribution before the date three (3)
years from the Initial Exercise Date, except for any events provided for in Article&nbsp;91 ter of
Annex&nbsp;II to the French tax code; provided, however, that the duration of this restriction on sale
will be automatically adjusted to conform with any changes to the holding period required for
favorable tax and social security treatment under Applicable Laws to the extent permitted under
Applicable Laws.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Termination&nbsp;of&nbsp;Employment Relationship</U>. Upon Termination of an Optionee&#146;s status
as an Employee (other than upon the Optionee&#146;s death or Disability), the Optionee may exercise his
or her Option within such period of time as specified in the Option Agreement, and only to the
extent that the Optionee was entitled to exercise it at the date of Termination (but in no event
later than the expiration of the term of such Option as set forth in the Option Agreement). If, at
the date of Termination, the Optionee is not entitled to exercise his or her entire Option, the
Shares covered by the unexercisable portion of the Option will revert to the Plan. If, after
Termination, the Optionee does not exercise his or her Option within the time specified by the
Administrator, the Option will terminate, and the Shares covered by such Option will revert to the
Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Disability of Optionee</U>. Upon Termination of an Optionee&#146;s status as an Employee
terminates as a result of the Optionee&#146;s Disability, the Optionee may exercise his or her Option at
any time within such period of time as specified in the Option Agreement, but only to the extent
that the Optionee was entitled to exercise it at the date of such Termination (but in no event
later than the expiration of the term of such Option as set forth in the Option Agreement). If, at
the date of Termination, the Optionee is not entitled to exercise his or her entire Option, the
Shares covered by the unexercisable portion of the Option will revert to the Plan. If, after
Termination, the Optionee does not exercise his or her Option within the time specified herein, the
Option will terminate, and the Shares covered by such Option will revert to the Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Death&nbsp;of&nbsp;Optionee</U>. In the event of the death of an Optionee while an Employee,
the Option may be exercised at any time within six (6)&nbsp;months following the date of death by the
Optionee&#146;s estate or by a person who acquired the right to exercise the Option by bequest or
inheritance, but only to the extent that the Optionee was entitled to exercise the Option at the
date of death. If, at the time of death, the Optionee was not entitled to exercise his or her entire
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Option, the Shares covered by the unexercisable portion of the Option will revert to the Plan. If,
after death, the Optionee&#146;s estate or a person who acquired the right to exercise the Option by
bequest or inheritance does not exercise the Option within the time specified herein, the Option
will terminate, and the Shares covered by such Option will immediately revert to the Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Non-Transferability&nbsp;of&nbsp;Options</U>. An Option may not be sold, pledged, assigned,
hypothecated, transferred, or disposed of in any manner other than by will or by the laws of
descent or distribution and may be exercised, during the lifetime of the Optionee, only by the
Optionee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>Changes in Capitalization</U>. If any adjustment provided for in Section&nbsp;11(a) of the
Plan to the exercise price and the number of shares of Common Stock covered by outstanding Options
would violate Applicable Laws in such a way to jeopardize the favorable tax and social security
treatment of this Plan together with this Appendix&nbsp;B and the Options granted thereunder, then no
such adjustment will be made prior to the exercise of any such outstanding Option.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U>Information Statements to Optionees</U>. The Company or its Subsidiary, as required
under Applicable Laws, will provide to each Optionee, with copies to the appropriate governmental
entities, such statements of information as required by the Applicable Laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<U>Reporting to the Stockholders&#146; Meeting</U>. The Subsidiary of the Company, if
required under Applicable Laws, will provide its stockholders with an annual report with respect to
Options granted and/or exercised by its Employees in the financial year.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-5-<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2A
<SEQUENCE>13
<FILENAME>f39432orexv10w2a.htm
<DESCRIPTION>EXHIBIT 10.2A
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w2a</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.2A</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FLUIDIGM CORPORATION<BR>
1999 STOCK OPTION PLAN<BR>
STOCK OPTION AGREEMENT</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Unless otherwise defined herein, the terms defined in the 1999 Stock Option Plan shall have the
same defined meanings in this Stock Option Agreement (the &#147;Option Agreement&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>I. NOTICE OF STOCK OPTION GRANT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Name<BR>
Address</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">You have been granted an option to purchase Common Stock of the Company, subject to the terms and
conditions of the Plan and this Option Agreement, as follows:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="58%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Date of Grant</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top" align="left">&nbsp;</TD>
    <TD valign="top" align="right">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Grant Number:</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top" align="left">&nbsp;</TD>
    <TD valign="top" align="right">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Vesting Commencement Date</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top" align="left">&nbsp;</TD>
    <TD valign="top" align="right">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Exercise Price per Share</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top" align="left">&nbsp;</TD>
    <TD valign="top" align="right">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Total Number of Shares Granted</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top" align="left">&nbsp;</TD>
    <TD valign="top" align="right">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Total Exercise Price</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top" align="left">&nbsp;</TD>
    <TD valign="top" align="right">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Type of Option:</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> Incentive Stock Option</DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top" align="left">&nbsp;</TD>
    <TD valign="top" align="right">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top" align="left">&nbsp;</TD>
    <TD valign="top" align="right">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> Nonstatutory Stock Option</DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top" align="left">&nbsp;</TD>
    <TD valign="top" align="right">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Term/Expiration Date:</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:30px; text-indent:-15px"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U>Exercise and Vesting Schedule:</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Option shall be exercisable in whole or in part, and shall vest according to the following
vesting schedule:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>&#091;Vesting Schedule language&#093;</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>Termination Period:</U>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Option may be exercised, to the extent it is then vested, for three months after Optionee
ceases to be a Service Provider. Upon death or Disability of the Optionee, this Option may be
exercised, to the extent it is then vested, for one year after Optionee ceases to be Service
Provider. In no event shall this Option be exercised later than the Term/Expiration Date as
provided above.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>II. AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Grant of Option</U>. The Administrator of the Company hereby grants to the Optionee
named in the Notice of Grant (the &#147;Optionee&#148;), an option (the &#147;Option&#148;) to purchase the number of
Shares set forth in the Notice of Grant, at the exercise price per Share set forth in the Notice of
Grant (the &#147;Exercise Price&#148;), and subject to the terms and conditions of the Plan, which is
incorporated herein by reference. Subject to Section 13(c) of the Plan, in the event of a conflict
between the terms and conditions of the Plan and this Option Agreement, the terms and conditions of
the Plan shall prevail.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If designated in the Notice of Grant as an Incentive Stock Option (&#147;ISO&#148;), this Option is
intended to qualify as an Incentive Stock Option as defined in Section&nbsp;422 of the Code.
Nevertheless, to the extent that it exceeds the $100,000 rule of Code Section&nbsp;422(d), this Option
shall be treated as a Nonstatutory Stock Option (&#147;NSO&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Exercise of Option</U>. This Option shall be exercisable during its term in accordance
with the provisions of Section&nbsp;9 of the Plan as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Right to Exercise</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;Subject to subsections 2(a)(ii) and 2(a)(iii) below, this Option shall be exercisable
cumulatively according to the vesting schedule set forth in the Notice of Grant. Alternatively, at
the election of the Optionee, this Option may be exercised in whole or in part at any time as to
Shares which have not yet vested. Vested Shares shall not be subject to the Company&#146;s repurchase
right (as set forth in the Restricted Stock Purchase Agreement, attached hereto as
<U>Exhibit&nbsp;C-1</U>).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;As a condition to exercising this Option for unvested Shares, the Optionee shall execute
the Restricted Stock Purchase Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;This Option may not be exercised for a fraction of a Share.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Method of Exercise</U>. This Option shall be exercisable by delivery of an exercise
notice in the form attached as <U>Exhibit&nbsp;A</U> (the &#147;Exercise Notice&#148;) which shall state the
election to exercise the Option, the number of Shares with respect to which the Option is being
exercised, and such other representations and agreements as may be required by the Company. The
Exercise Notice shall be accompanied by payment of the aggregate Exercise Price as to all Exercised
Shares. This Option shall be deemed to be exercised upon receipt by the Company of such fully
executed Exercise Notice accompanied by the aggregate Exercise Price.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Shares shall be issued pursuant to the exercise of an Option unless such issuance and such
exercise complies with Applicable Laws. Assuming such compliance, for income tax purposes the
Shares shall be considered transferred to the Optionee on the date on which the Option is exercised
with respect to such Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Optionee&#146;s Representations</U>. In the event the Shares have not been registered under
the Securities Act of 1933, as amended, at the time this Option is exercised, the Optionee shall,
if
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">required by the Company, concurrently with the exercise of all or any portion of this Option,
deliver to the Company his or her Investment Representation Statement in the form attached hereto
as <U>Exhibit&nbsp;B</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Lock-Up Period</U>. Optionee hereby agrees that, if so requested by the Company or any
representative of the underwriters (the &#147;Managing Underwriter&#148;) in connection with any registration
of the offering of any securities of the Company under the Securities Act, Optionee shall not sell
or otherwise transfer any Shares or other securities of the Company during the 180-day period (or
such other period as may be requested in writing by the Managing Underwriter and agreed to in
writing by the Company) (the &#147;Market Standoff Period&#148;) following the effective date of a
registration statement of the Company filed under the Securities Act. The Company may impose
stop-transfer instructions with respect to securities subject to the foregoing restrictions until
the end of such Market Standoff Period and Optionee agrees to enter into a market stand-off
agreement in customary form consistent with this section with the managing underwriter.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Method of Payment</U>. Payment of the aggregate Exercise Price shall be by any of the
following, or a combination thereof, at the election of the Optionee:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;cash;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;check;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;consideration received by the Company under a formal cashless exercise program adopted by
the Company in connection with the Plan; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;surrender of other Shares which, (i)&nbsp;in the case of Shares acquired upon exercise of an
option, have been owned by the Optionee for more than six (6)&nbsp;months on the date of surrender, and
(ii)&nbsp;have a Fair Market Value on the date of surrender equal to the aggregate Exercise Price of the
Exercised Shares.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Restrictions on Exercise</U>. This Option may not be exercised until such time as the
Plan has been approved by the stockholders of the Company, or if the issuance of such Shares upon
such exercise or the method of payment of consideration for such shares would constitute a
violation of any Applicable Law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Non-Transferability of Option</U>. This Option may not be transferred in any manner
otherwise than by will or by the laws of descent or distribution and may be exercised during the
lifetime of Optionee only by Optionee. The terms of the Plan and this Option Agreement shall be
binding upon the executors, administrators, heirs, successors and assigns of the Optionee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Term of Option</U>. This Option may be exercised only within the term set out in the
Notice of Grant, and may be exercised during such term only in accordance with the Plan and the
terms of this Option.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>Tax Consequences</U>. Set forth below is a brief summary as of the date of this Option
of some of the federal tax consequences of exercise of this Option and disposition of the Shares.
THIS SUMMARY IS NECESSARILY INCOMPLETE, AND THE TAX LAWS AND REGULATIONS
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">ARE SUBJECT TO CHANGE. THE OPTIONEE SHOULD CONSULT A TAX ADVISER BEFORE EXERCISING THIS
OPTION OR DISPOSING OF THE SHARES.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Exercise of NSO</U>. There may be a regular federal income tax liability upon the
exercise of an NSO. The Optionee will be treated as having received compensation income (taxable
at ordinary income tax rates) equal to the excess, if any, of the Fair Market Value of the
Exercised Shares on the date of exercise over the Exercise Price. If Optionee is an Employee or a
former Employee, the Company will be required to withhold from Optionee&#146;s compensation or collect
from Optionee and pay to the applicable taxing authorities an amount in cash equal to a percentage
of this compensation income at the time of exercise, and may refuse to honor the exercise and
refuse to deliver Shares if such withholding amounts are not delivered at the time of exercise.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Exercise of ISO</U>. If this Option qualifies as an ISO, there will be no regular
federal income tax liability upon the exercise of the Option, although the excess, if any, of the
Fair Market Value of the Exercised Shares on the date of exercise over the Exercise Price will be
treated as an adjustment to the alternative minimum tax for federal tax purposes and may subject
the Optionee to the alternative minimum tax in the year of exercise.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Exercise of ISO Following Disability</U>. If the Optionee ceases to be an Employee as
a result of a disability that is not a total and permanent disability as defined in
Section&nbsp;22(e)(3) of the Code, to the extent permitted on the date of termination, the Optionee must
exercise an ISO within three months of such termination for the ISO to be qualified as an ISO.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Disposition of Shares</U>. In the case of an NSO, if Shares are held for at least one
year, any gain realized on disposition of the Shares will be treated as long-term capital gain for
federal income tax purposes. In the case of an ISO, if Shares transferred pursuant to the Option
are held for at least one year after exercise and at least two years after the Date of Grant, any
gain realized on disposition of the Shares will also be treated as long-term capital gain for
federal income tax purposes. If Shares purchased under an ISO are disposed of within one year
after exercise or two years after the Date of Grant, any gain realized on such disposition will be
treated as compensation income (taxable at ordinary income rates) to the extent of the difference
between the Exercise Price of the Exercised Shares and the lesser of (i)&nbsp;the Fair Market Value of
the Exercised Shares on the date of exercise, or (ii)&nbsp;the sale price of the Exercised Shares.
Different rules may apply if the Shares are subject to a substantial risk of forfeiture (within the
meaning of Section&nbsp;83 of the Code) at the time of purchase. Any additional gain will be taxed as
capital gain, short-term depending on the period that the ISO Shares were held.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Notice of Disqualifying Disposition of ISO Shares</U>. If the Option granted to
Optionee herein is an ISO, and if Optionee sells or otherwise disposes of any of the Shares
acquired pursuant to the ISO on or before the later of (i)&nbsp;the date two years after the Date of
Grant, or (ii)&nbsp;the date one year after the date of exercise, the Optionee shall immediately notify
the Company in writing of such disposition. Optionee agrees that Optionee may be subject to income
tax withholding by the Company on the compensation income recognized by the Optionee.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U>Section&nbsp;83(b) Election for Unvested Shares Purchased Pursuant to Options</U>. With
respect to the exercise of an Option for unvested Shares, an election (the &#147;Election&#148;) may be filed
by the Optionee with the Internal Revenue Service, <U>within 30&nbsp;days</U> of the purchase of the
Shares, electing pursuant to Section 83(b) of the Code to be taxed currently on any difference
between the
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">purchase price of the Shares and their Fair Market Value on the date of purchase. In the case
of an NSO, this will result in a recognition of taxable income to the Optionee on the date of
exercise, measured by the excess, if any, of the Fair Market Value of the Exercised Shares, at the
time the Option is exercised over the purchase price for the Exercised Shares. Absent such an
election, taxable income will be measured and recognized by Optionee at the time or times on which
the Company&#146;s Repurchase Option lapses. In the case of an ISO, such an election will result in a
recognition of income to the Optionee for alternative minimum tax purposes on the date of exercise,
measured by the excess, if any, of the Fair Market Value of the Exercised Shares, at the time the
Option is exercised, over the purchase price for the Exercised Shares. Absent such an election,
alternative minimum taxable income will be measured and recognized by Optionee at the time or times
on which the Company&#146;s Repurchase Option lapses. Optionee is strongly encouraged to seek the
advice of his or her own tax consultants in connection with the purchase of the Shares and the
advisability of filing of the Election under Section 83(b) of the Code. A form of Election under
Section 83(b) is attached hereto as <U>Exhibit&nbsp;C-5</U> for reference.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;OPTIONEE ACKNOWLEDGES THAT IT IS OPTIONEE&#146;S SOLE RESPONSIBILITY AND NOT THE COMPANY&#146;S TO FILE
TIMELY THE ELECTION UNDER SECTION 83(b), EVEN IF OPTIONEE REQUESTS THE COMPANY OR ITS
REPRESENTATIVE TO MAKE THIS FILING ON OPTIONEE&#146;S BEHALF.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U>Entire Agreement; Governing Law</U>. The Plan is incorporated herein by reference.
The Plan and this Option Agreement constitute the entire agreement of the parties with respect to
the subject matter hereof and supersede in their entirety all prior undertakings and agreements of
the Company and Optionee with respect to the subject matter hereof, and may not be modified
adversely to the Optionee&#146;s interest except by means of a writing signed by the Company and
Optionee. This Option Agreement is governed by the internal substantive laws but not the choice of
law rules of the State of California.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<U>No Guarantee of Continued Service</U>. OPTIONEE ACKNOWLEDGES AND AGREES THAT THE
VESTING OF SHARES PURSUANT TO THE VESTING SCHEDULE HEREOF IS EARNED ONLY BY CONTINUING AS A SERVICE
PROVIDER AT THE WILL OF THE COMPANY (NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS OPTION
OR ACQUIRING SHARES HEREUNDER). OPTIONEE FURTHER ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT, THE
TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN
EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE VESTING PERIOD,
FOR ANY PERIOD, OR AT ALL, AND SHALL NOT INTERFERE IN ANY WAY WITH OPTIONEE&#146;S RIGHT OR THE
COMPANY&#146;S RIGHT TO TERMINATE OPTIONEE&#146;S RELATIONSHIP AS A SERVICE PROVIDER AT ANY TIME, WITH OR
WITHOUT CAUSE.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Optionee acknowledges receipt of a copy of the Plan and represents that he or she is familiar
with the terms and provisions thereof, and hereby accepts this Option subject to all of the terms
and provisions thereof. Optionee has reviewed the Plan and this Option in their entirety, has had
an opportunity to obtain the advice of counsel prior to executing this Option and fully understands
all provisions of the Option. Optionee hereby agrees to accept as binding, conclusive and final
all decisions or interpretations of the Administrator upon any questions arising under the Plan or
this
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Option. Optionee further agrees to notify the Company upon any change in the residence
address indicated below.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">OPTIONEE:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">FLUIDIGM CORPORATION</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
&#091;Name&#093;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Residence Address:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-5-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT A</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>1999 STOCK OPTION PLAN<BR>
EXERCISE NOTICE</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Fluidigm Corporation<BR>
Attn: President<BR>
7000 Shoreline Court<BR>
Suite&nbsp;100<BR>
South San Francisco, CA 94080

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Exercise of Option</U>. Effective as of today, <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, the undersigned,
&#091;Name&#093; (&#147;Optionee&#148;) hereby elects to exercise Optionee&#146;s option (the &#147;Option&#148;) to purchase
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
shares of the Common Stock (the &#147;Shares&#148;) of Fluidigm Corporation (the &#147;Company&#148;) under
and pursuant to the 1999 Stock Option Plan (the &#147;Plan&#148;) and the Stock Option Agreement dated &#091;Grant
Date&#093; (the &#147;Option Agreement&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Delivery of Payment</U>. Purchaser herewith delivers to the Company the full purchase
price of the Shares, as set forth in the Option Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Representations of Optionee</U>. Optionee acknowledges that Optionee has received,
read and understood the Plan and the Option Agreement and agrees to abide by and be bound by their
terms and conditions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Rights as Stockholder</U>. Until the issuance of the Shares (as evidenced by the
appropriate entry on the books of the Company or of a duly authorized transfer agent of the
Company), no right to vote or receive dividends or any other rights as a stockholder shall exist
with respect to the optioned stock, notwithstanding the exercise of the Option. The Shares shall
be issued to the Optionee as soon as practicable after the Option is exercised. No adjustment
shall be made for a dividend or other right for which the record date is prior to the date of
issuance except as provided in Section&nbsp;11 of the Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Company&#146;s Right of First Refusal</U>. Before any Shares held by Optionee or any
transferee (either being sometimes referred to herein as the &#147;Holder&#148;) may be sold or otherwise
transferred (including transfer by gift or operation of law), the Company or its assignee(s) shall
have a right of first refusal to purchase the Shares on the terms and conditions set forth in this
Section (the &#147;Right of First Refusal&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Notice of Proposed Transfer</U>. The Holder of the Shares shall deliver to the
Company a written notice (the &#147;Notice&#148;) stating: (i)&nbsp;the Holder&#146;s bona fide intention to sell or
otherwise transfer such Shares; (ii)&nbsp;the name of each proposed purchaser or other transferee
(&#147;Proposed Transferee&#148;); (iii)&nbsp;the number of Shares to be transferred to each Proposed Transferee;
and (iv)&nbsp;the bona fide cash price or other consideration for which the Holder proposes to transfer
the Shares (the &#147;Offered Price&#148;), and the Holder shall offer the Shares at the Offered Price to the
Company or its assignee(s).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Exercise of Right of First Refusal</U>. At any time within thirty (30)&nbsp;days after
receipt of the Notice, the Company and/or its assignee(s) may, by giving written notice to the
Holder,
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">elect to purchase all, but not less than all, of the Shares proposed to be transferred to any
one or more of the Proposed Transferees, at the purchase price determined in accordance with
subsection (c)&nbsp;below.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Purchase Price</U>. The purchase price (&#147;Purchase Price&#148;) for the Shares purchased by
the Company or its assignee(s) under this Section shall be the Offered Price. If the Offered Price
includes consideration other than cash, the cash equivalent value of the non-cash consideration
shall be determined by the Board of Directors of the Company in good faith.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Payment</U>. Payment of the Purchase Price shall be made, at the option of the
Company or its assignee(s), in cash (by check), by cancellation of all or a portion of any
outstanding indebtedness of the Holder to the Company (or, in the case of repurchase by an
assignee, to the assignee), or by any combination thereof within 30&nbsp;days after receipt of the
Notice or in the manner and at the times set forth in the Notice.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Holder&#146;s Right to Transfer</U>. If all of the Shares proposed in the Notice to be
transferred to a given Proposed Transferee are not purchased by the Company and/or its assignee(s)
as provided in this Section, then the Holder may sell or otherwise transfer such Shares to that
Proposed Transferee at the Offered Price or at a higher price, provided that such sale or other
transfer is consummated within 120&nbsp;days after the date of the Notice, that any such sale or other
transfer is effected in accordance with any applicable securities laws and that the Proposed
Transferee agrees in writing that the provisions of this Section shall continue to apply to the
Shares in the hands of such Proposed Transferee. If the Shares described in the Notice are not
transferred to the Proposed Transferee within such period, a new Notice shall be given to the
Company, and the Company and/or its assignees shall again be offered the Right of First Refusal
before any Shares held by the Holder may be sold or otherwise transferred.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U>Exception for Certain Family Transfers</U>. Anything to the contrary contained in
this Section notwithstanding, the transfer of any or all of the Shares during the Optionee&#146;s
lifetime or on the Optionee&#146;s death by will or intestacy to the Optionee&#146;s immediate family or a
trust for the benefit of the Optionee&#146;s immediate family shall be exempt from the provisions of
this Section. &#147;Immediate Family&#148; as used herein shall mean spouse, lineal descendant or
antecedent, father, mother, brother or sister. In such case, the transferee or other recipient
shall receive and hold the Shares so transferred subject to the provisions of this Section, and
there shall be no further transfer of such Shares except in accordance with the terms of this
Section.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <U>Termination of Right of First Refusal</U>. The Right of First Refusal shall terminate
as to any Shares upon the first sale of Common Stock of the Company to the general public pursuant
to a registration statement filed with and declared effective by the Securities and Exchange
Commission under the Securities Act of 1933, as amended.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Tax Consultation</U>. Optionee understands that Optionee may suffer adverse tax
consequences as a result of Optionee&#146;s purchase or disposition of the Shares. Optionee represents
that Optionee has consulted with any tax consultants Optionee deems advisable in connection with
the purchase or disposition of the Shares and that Optionee is not relying on the Company for any
tax advice.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Restrictive Legends and Stop-Transfer Orders</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Legends</U>. Optionee understands and agrees that the Company shall cause the legends
set forth below or legends substantially equivalent thereto, to be placed upon any certificate(s)
evidencing ownership of the Shares together with any other legends that may be required by the
Company or by state or federal securities laws:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933 (THE &#147;ACT&#148;) AND MAY NOT BE OFFERED, SOLD OR
OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL
REGISTERED UNDER THE ACT OR, IN THE OPINION OF COMPANY COUNSEL
SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR
TRANSFER, PLEDGE OR HYPOTHECATION IS IN COMPLIANCE THEREWITH.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN
RESTRICTIONS ON TRANSFER AND RIGHT OF FIRST REFUSAL OPTIONS HELD BY
THE ISSUER OR ITS ASSIGNEE(S) AS SET FORTH IN THE EXERCISE NOTICE
BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY OF
WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER. SUCH
TRANSFER RESTRICTIONS AND RIGHT OF FIRST REFUSAL ARE BINDING ON
TRANSFEREES OF THESE SHARES.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Stop-Transfer Notices</U>. Optionee agrees that, in order to ensure compliance with
the restrictions referred to herein, the Company may issue appropriate &#147;stop transfer&#148; instructions
to its transfer agent, if any, and that, if the Company transfers its own securities, it may make
appropriate notations to the same effect in its own records.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Refusal to Transfer</U>. The Company shall not be required (i)&nbsp;to transfer on its
books any Shares that have been sold or otherwise transferred in violation of any of the provisions
of this Exercise Notice or (ii)&nbsp;to treat as owner of such Shares or to accord the right to vote or
pay dividends to any purchaser or other transferee to whom such Shares shall have been so
transferred.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Successors and Assigns</U>. The Company may assign any of its rights under this
Exercise Notice to single or multiple assignees, and the terms and conditions of this Exercise
Notice shall inure to the benefit of the successors and assigns of the Company. Subject to the
restrictions on transfer herein set forth, the terms and conditions of this Exercise Notice shall
be binding upon Optionee and his or her heirs, executors, administrators, successors and assigns.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>Interpretation</U>. Any dispute regarding the interpretation of this Exercise Notice
shall be submitted by Optionee or by the Company forthwith to the Administrator which shall review
such dispute at its next regular meeting. The resolution of such a dispute by the Administrator
shall be final and binding on all parties.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U>Governing Law; Severability</U>. This Exercise Notice is governed by the internal
substantive laws, but not the choice of law rules, of the State of California.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<U>Entire Agreement</U>. The Plan and Option Agreement are incorporated herein by
reference. This Exercise Notice, the Plan, the Restricted Stock Purchase Agreement, the Option
Agreement and the Investment Representation Statement constitute the entire agreement of the
parties with respect to the subject matter hereof and supersede in their entirety all prior
undertakings and agreements of the Company and Optionee with respect to the subject matter hereof,
and may not be modified adversely to the Optionee&#146;s interest except by means of a writing signed by
the Company and Optionee.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="28%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">Submitted by:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left">Accepted by:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">OPTIONEE:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left">FLUIDIGM CORPORATION</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#091;Name&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Address:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Date Received:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT B</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>INVESTMENT REPRESENTATION STATEMENT</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="87%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">OPTIONEE
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;NAME&#093;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">COMPANY
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">FLUIDIGM CORPORATION</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">SECURITY
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">COMMON STOCK</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">AMOUNT
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">DATE
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the purchase of the above-listed Securities, the undersigned Optionee
represents to the Company the following:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;Optionee is aware of the Company&#146;s business affairs and financial condition and has
acquired sufficient information about the Company to reach an informed and knowledgeable decision
to acquire the Securities. Optionee is acquiring these Securities for investment for Optionee&#146;s
own account only and not with a view to, or for resale in connection with, any &#147;distribution&#148;
thereof within the meaning of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Optionee acknowledges and understands that the Securities constitute &#147;restricted
securities&#148; under the Securities Act and have not been registered under the Securities Act in
reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the
bona fide nature of Optionee&#146;s investment intent as expressed herein. In this connection, Optionee
understands that, in the view of the Securities and Exchange Commission, the statutory basis for
such exemption may be unavailable if Optionee&#146;s representation was predicated solely upon a present
intention to hold these Securities for the minimum capital gains period specified under tax
statutes, for a deferred sale, for or until an increase or decrease in the market price of the
Securities, or for a period of one year or any other fixed period in the future. Optionee further
understands that the Securities must be held indefinitely unless they are subsequently registered
under the Securities Act or an exemption from such registration is available. Optionee further
acknowledges and understands that the Company is under no obligation to register the Securities.
Optionee understands that the certificate evidencing the Securities will be imprinted with a legend
which prohibits the transfer of the Securities unless they are registered or such registration is
not required in the opinion of counsel satisfactory to the Company, and with any other legend
required under applicable state securities laws.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Optionee is familiar with the provisions of Rule&nbsp;701 and Rule&nbsp;144, each promulgated under
the Securities Act, which, in substance, permit limited public resale of &#147;restricted securities&#148;
acquired, directly or indirectly from the issuer thereof, in a non-public offering subject to the
satisfaction of certain conditions. Rule&nbsp;701 provides that if the issuer qualifies under Rule&nbsp;701
at the time of the grant of the Option to the Optionee, the exercise will be exempt from
registration under the Securities Act. In the event the Company becomes subject to the reporting
requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, ninety (90)&nbsp;days
thereafter (or such longer period as any market stand-off agreement may require) the Securities
exempt under Rule&nbsp;701 may be resold, subject to the satisfaction of certain of the conditions
specified by Rule&nbsp;144, including: (1)&nbsp;the resale being made through a broker in an unsolicited
&#147;broker&#146;s transaction&#148; or in transactions
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">directly with a market maker (as said term is defined under the Securities Exchange Act of
1934); and, in the case of an affiliate, (2)&nbsp;the availability of certain public information about
the Company, (3)&nbsp;the amount of Securities being sold during any three month period not exceeding
the limitations specified in Rule&nbsp;144(e), and (4)&nbsp;the timely filing of a Form&nbsp;144, if applicable.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event that the Company does not qualify under Rule&nbsp;701 at the time of grant of the
Option, then the Securities may be resold in certain limited circumstances subject to the
provisions of Rule&nbsp;144, which requires the resale to occur not less than one year after the later
of the date the Securities were sold by the Company or the date the Securities were sold by an
affiliate of the Company, within the meaning of Rule&nbsp;144; and, in the case of acquisition of the
Securities by an affiliate, or by a non-affiliate who subsequently holds the Securities less than
two years, the satisfaction of the conditions set forth in sections (1), (2), (3)&nbsp;and (4)&nbsp;of the
paragraph immediately above.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Optionee further understands that in the event all of the applicable requirements of
Rule&nbsp;701 or 144 are not satisfied, registration under the Securities Act, compliance with
Regulation&nbsp;A, or some other registration exemption will be required; and that, notwithstanding the
fact that Rules&nbsp;144 and 701 are not exclusive, the Staff of the Securities and Exchange Commission
has expressed its opinion that persons proposing to sell private placement securities other than in
a registered offering and otherwise than pursuant to Rules&nbsp;144 or 701 will have a substantial
burden of proof in establishing that an exemption from registration is available for such offers or
sales, and that such persons and their respective brokers who participate in such transactions do
so at their own risk. Optionee understands that no assurances can be given that any such other
registration exemption will be available in such event.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Signature of Optionee:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;Name&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT C-1</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>FLUIDIGM CORPORATION</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>1999 STOCK OPTION PLAN<BR>
RESTRICTED STOCK PURCHASE AGREEMENT</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIS AGREEMENT is made between (the &#147;Purchaser&#148;) and Fluidigm Corporation (the &#147;Company&#148;) as
of <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise defined herein, the terms defined in the 1999 Stock Option Plan shall have
the same defined meanings in this Agreement.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>RECITALS</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A.&nbsp;Pursuant to the exercise of the option granted to Purchaser under the Plan and pursuant to
the Option Agreement dated &#091;Grant Date&#093; by and between the Company and Purchaser with respect to
such grant (the &#147;Option&#148;), which Plan and Option Agreement are hereby incorporated by reference,
Purchaser has elected to purchase
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> shares of Common Stock, of which <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
shares have not become vested
under the vesting schedule set forth in the Option Agreement (&#147;Unvested Shares&#148;). The Unvested
Shares and the shares subject to the Option Agreement which have become vested are sometimes
collectively referred to herein as the &#147;Shares&#148;.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B.&nbsp;As required by the Option Agreement, as a condition to Purchaser&#146;s election to exercise the
option, Purchaser must execute this Agreement, which sets forth the rights and obligations of the
parties with respect to Shares acquired upon exercise of the Option.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Repurchase Option</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;If Purchaser&#146;s status as a Service Provider is terminated for any reason, including for
cause, death, and Disability, the Company shall have the right and option to purchase from
Purchaser, or Purchaser&#146;s personal representative, as the case may be, all of the Purchaser&#146;s
Unvested Shares as of the date of such termination at the price paid by the Purchaser for such
Shares (the &#147;Repurchase Option&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Upon the occurrence of such termination, the Company may exercise its Repurchase Option by
delivering personally or by registered mail, to Purchaser (or his transferee or legal
representative, as the case may be), within ninety (90)&nbsp;days of the termination, a notice in
writing indicating the Company&#146;s intention to exercise the Repurchase Option and setting forth a
date for closing not later than thirty (30)&nbsp;days from the mailing of such notice. The closing
shall take place at the Company&#146;s office. At the closing, the holder of the certificates for the
Unvested Shares being transferred shall deliver the stock certificate or certificates evidencing
the Unvested Shares, and the Company shall deliver the purchase price therefor.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;At its option, the Company may elect to make payment for the Unvested Shares to a bank
selected by the Company. The Company shall avail itself of this option by a notice in writing to
Purchaser stating the name and address of the bank, date of closing, and waiving the closing at the
Company&#146;s office.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;If the Company does not elect to exercise the Repurchase Option conferred above by giving
the requisite notice within ninety (90)&nbsp;days following the termination, the Repurchase Option shall
terminate.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;The Repurchase Option shall terminate in accordance with the vesting schedule contained in
Optionee&#146;s Option Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Transferability of the Shares; Escrow</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Purchaser hereby authorizes and directs the Secretary of the Company, or such other person
designated by the Company, to transfer the Unvested Shares as to which the Repurchase Option has
been exercised from Purchaser to the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;To insure the availability for delivery of Purchaser&#146;s Unvested Shares upon repurchase by
the Company pursuant to the Repurchase Option under Section&nbsp;1, Purchaser hereby appoints the
Secretary, or any other person designated by the Company as escrow agent, as its attorney-in-fact
to sell, assign and transfer unto the Company, such Unvested Shares, if any, repurchased by the
Company pursuant to the Repurchase Option and shall, upon execution of this Agreement, deliver and
deposit with the Secretary of the Company, or such other person designated by the Company, the
share certificates representing the Unvested Shares, together with the stock assignment duly
endorsed in blank, attached hereto as <U>Exhibit&nbsp;C-2</U>. The Unvested Shares and stock
assignment shall be held by the secretary in escrow, pursuant to the Joint Escrow Instructions of
the Company and Purchaser attached as <U>Exhibit&nbsp;C-3</U> hereto, until the Company exercises its
Repurchase Option, until such Unvested Shares are vested, or until such time as this Agreement no
longer is in effect. As a further condition to the Company&#146;s obligations under this Agreement, the
spouse of the Purchaser, if any, shall execute and deliver to the Company the Consent of Spouse
attached hereto as <U>Exhibit&nbsp;C-4</U>. Upon vesting of the Unvested Shares, the escrow agent
shall promptly deliver to the Purchaser the certificate or certificates representing such Shares in
the escrow agent&#146;s possession belonging to the Purchaser, and the escrow agent shall be discharged
of all further obligations hereunder; provided, however, that the escrow agent shall nevertheless
retain such certificate or certificates as escrow agent if so required pursuant to other
restrictions imposed pursuant to this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The Company, or its designee, shall not be liable for any act it may do or omit to do with
respect to holding the Shares in escrow and while acting in good faith and in the exercise of its
judgment.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Transfer or sale of the Shares is subject to restrictions on transfer imposed by any
applicable state and federal securities laws. Any transferee shall hold such Shares subject to all
the provisions hereof and the Exercise Notice executed by the Purchaser with respect to any
Unvested Shares purchased by Purchaser and shall acknowledge the same by signing a copy of this
Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Ownership, Voting Rights, Duties</U>. This Agreement shall not affect in any way the
ownership, voting rights or other rights or duties of Purchaser, except as specifically provided
herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Legends</U>. The share certificate evidencing the Shares issued hereunder shall be
endorsed with the following legend (in addition to any legend required under applicable federal and
state securities laws):
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN
RESTRICTIONS UPON TRANSFER AND RIGHTS OF REPURCHASE AS SET FORTH IN AN
AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON
FILE WITH THE SECRETARY OF THE COMPANY.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Adjustment for Stock Split</U>. All references to the number of Shares and the
purchase price of the Shares in this Agreement shall be appropriately adjusted to reflect any stock
split, stock dividend or other change in the Shares which may be made by the Company pursuant to
Section&nbsp;11 of the Plan after the date of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Notices</U>. Notices required hereunder shall be given in person or by registered mail
to the address of Purchaser shown on the records of the Company, and to the Company at their
respective principal executive offices.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Survival of Terms</U>. This Agreement shall apply to and bind Purchaser and the
Company and their respective permitted assignees and transferees, heirs, legatees, executors,
administrators and legal successors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Section&nbsp;83(b) Election</U>. Purchaser hereby acknowledges that he or she has been
informed that, with respect to the exercise of an Option for Unvested Shares, an election (the
&#147;Election&#148;) may be filed by the Purchaser with the Internal Revenue Service, <U>within 30&nbsp;days</U>
of the purchase of the exercised Shares, electing pursuant to Section 83(b) of the Code to be taxed
currently on any difference between the purchase price of the exercised Shares and their Fair
Market Value on the date of purchase. In the case of a Nonstatutory Stock Option, this will result
in a recognition of taxable income to the Purchaser on the date of exercise, measured by the
excess, if any, of the Fair Market Value of the exercised Shares, at the time the Option is
exercised over the purchase price for the exercised Shares. Absent such an Election, taxable
income will be measured and recognized by Purchaser at the time or times on which the Company&#146;s
Repurchase Option lapses. In the case of an Incentive Stock Option, such an Election will result
in a recognition of income to the Purchaser for alternative minimum tax purposes on the date of
exercise, measured by the excess, if any, of the Fair Market Value of the exercised Shares, at the
time the option is exercised, over the purchase price for the exercised Shares. Absent such an
Election, alternative minimum taxable income will be measured and recognized by Purchaser at the
time or times on which the Company&#146;s Repurchase Option lapses. Purchaser is strongly encouraged to
seek the advice of his or her own tax consultants in connection with the purchase of the Shares and
the advisability of filing of the Election under Section 83(b) of the Code. A form of Election
under Section 83(b) is attached hereto as <U>Exhibit&nbsp;C-5</U> for reference.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PURCHASER ACKNOWLEDGES THAT IT IS PURCHASER&#146;S SOLE RESPONSIBILITY AND NOT THE COMPANY&#146;S TO
FILE TIMELY THE ELECTION UNDER SECTION 83(b) OF THE CODE, EVEN IF PURCHASER REQUESTS THE COMPANY OR
ITS REPRESENTATIVE TO MAKE THIS FILING ON PURCHASER&#146;S BEHALF.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>Representations</U>. Purchaser has reviewed with his own tax advisors the federal,
state, local and foreign tax consequences of this investment and the transactions contemplated by
this Agreement. Purchaser is relying solely on such advisors and not on any statements or
representations
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of the Company or any of its agents. Purchaser understands that he (and not the Company)
shall be responsible for his own tax liability that may arise as a result of this investment or the
transactions contemplated by this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U>Governing Law</U>. This Agreement shall be governed by the internal substantive laws,
but not the choice of law rules, of the State of California.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchaser represents that he has read this Agreement and is familiar with its terms and
provisions. Purchaser hereby agrees to accept as binding, conclusive and final all decisions or
interpretations of the Board upon any questions arising under this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, this Agreement is deemed made as of the date first set forth above.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">OPTIONEE:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">FLUIDIGM CORPORATION</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#091;Name&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Residence Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dated:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT C-2 </B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">ASSIGNMENT SEPARATE FROM CERTIFICATE

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FOR VALUE RECEIVED I, &#091;Name&#093;, hereby sell, assign and transfer unto <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> (<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>) shares of the Common Stock of Fluidigm Corporation standing in my
name of the books of said corporation represented by Certificate No. <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> herewith and do hereby
irrevocably constitute and appoint <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> to transfer the said stock on the books of the
within named corporation with full power of substitution in the premises.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Stock Assignment may be used only in accordance with the Restricted Stock Purchase
Agreement between Fluidigm Corporation and the undersigned dated <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dated: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Signature:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
&#091;Name&#093;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>INSTRUCTIONS: Please do not fill in any blanks other than the signature line. The purpose of this
assignment is to enable the Company to exercise its &#147;repurchase option,&#148; as set forth in the
Agreement, without requiring additional signatures on the part of the Purchaser.</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT C-3 </B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>JOINT ESCROW INSTRUCTIONS</U>

</DIV>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Wilson Sonsini Goodrich &#038; Rosati<BR>
Attn: Robert F. Kornegay<BR>
650 Page Mill Road<BR>
Palo Alto, CA 94304

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Ladies and Gentlemen:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As Escrow Agent for both Fluidigm Corporation (the &#147;Company&#148;), and the undersigned purchaser
of stock of the Company (the &#147;Purchaser&#148;), you are hereby authorized and directed to hold the
documents delivered to you pursuant to the terms of that certain Restricted Stock Purchase
Agreement (&#147;Agreement&#148;) between the Company and the undersigned, in accordance with the following
instructions:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;In the event the Company and/or any assignee of the Company (referred to collectively for
convenience herein as the &#147;Company&#148;) exercises the Company&#146;s repurchase option set forth in the
Agreement, the Company shall give to Purchaser and you a written notice specifying the number of
shares of stock to be purchased, the purchase price, and the time for a closing hereunder at the
principal office of the Company. Purchaser and the Company hereby irrevocably authorize and direct
you to close the transaction contemplated by such notice in accordance with the terms of said
notice.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;At the closing, you are directed (a)&nbsp;to date the stock assignments necessary for the
transfer in question, (b)&nbsp;to fill in the number of shares being transferred, and (c)&nbsp;to deliver the
stock assignments, together with the certificate evidencing the shares of stock to be transferred,
to the Company or its assignee, against the simultaneous delivery to you of the purchase price (by
cash, a check, or some combination thereof) for the number of shares of stock being purchased
pursuant to the exercise of the Company&#146;s repurchase option.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;Purchaser irrevocably authorizes the Company to deposit with you any certificates
evidencing shares of stock to be held by you hereunder and any additions and substitutions to said
shares as defined in the Agreement. Purchaser does hereby irrevocably constitute and appoint you
as Purchaser&#146;s attorney-in-fact and agent for the term of this escrow to execute with respect to
such securities all documents necessary or appropriate to make such securities negotiable and to
complete any transaction herein contemplated, including but not limited to the filing with any
applicable state blue sky authority of any required applications for consent to, or notice of
transfer of, the securities. Subject to the provisions of this paragraph 3, Purchaser shall
exercise all rights and privileges of a stockholder of the Company while the stock is held by you.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;Upon written request of the Purchaser, but no more than once per calendar year, unless the
Company&#146;s repurchase option has been exercised, you will deliver to Purchaser a certificate or
certificates representing so many shares of stock as are not then subject to the Company&#146;s
repurchase option. Within 120&nbsp;days after cessation of Purchaser&#146;s continuous employment by or
services to the Company, or any parent or subsidiary of the Company, you will deliver to Purchaser
a certificate or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">certificates representing the aggregate number of shares held or issued pursuant to the
Agreement and not purchased by the Company or its assignees pursuant to exercise of the Company&#146;s
repurchase option.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;If at the time of termination of this escrow you should have in your possession any
documents, securities, or other property belonging to Purchaser, you shall deliver all of the same
to Purchaser and shall be discharged of all further obligations hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;Your duties hereunder may be altered, amended, modified or revoked only by a writing signed
by all of the parties hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;You shall be obligated only for the performance of such duties as are specifically set
forth herein and may rely and shall be protected in relying or refraining from acting on any
instrument reasonably believed by you to be genuine and to have been signed or presented by the
proper party or parties. You shall not be personally liable for any act you may do or omit to do
hereunder as Escrow Agent or as attorney-in-fact for Purchaser while acting in good faith, and any
act done or omitted by you pursuant to the advice of your own attorneys shall be conclusive
evidence of such good faith.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;You are hereby expressly authorized to disregard any and all warnings given by any of the
parties hereto or by any other person or corporation, excepting only orders or process of courts of
law and are hereby expressly authorized to comply with and obey orders, judgments or decrees of any
court. In case you obey or comply with any such order, judgment or decree, you shall not be liable
to any of the parties hereto or to any other person, firm or corporation by reason of such
compliance, notwithstanding any such order, judgment or decree being subsequently reversed,
modified, annulled, set aside, vacated or found to have been entered without jurisdiction.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;You shall not be liable in any respect on account of the identity, authorities or rights of
the parties executing or delivering or purporting to execute or deliver the Agreement or any
documents or papers deposited or called for hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;You shall not be liable for the outlawing of any rights under the Statute of Limitations
with respect to these Joint Escrow Instructions or any documents deposited with you.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;You shall be entitled to employ such legal counsel and other experts as you may deem
necessary properly to advise you in connection with your obligations hereunder, may rely upon the
advice of such counsel, and may pay such counsel reasonable compensation therefor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;Your responsibilities as Escrow Agent hereunder shall terminate if you shall cease to be
an officer or agent of the Company or if you shall resign by written notice to each party. In the
event of any such termination, the Company shall appoint a successor Escrow Agent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;If you reasonably require other or further instruments in connection with these Joint
Escrow Instructions or obligations in respect hereto, the necessary parties hereto shall join in
furnishing such instruments.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.&nbsp;It is understood and agreed that should any dispute arise with respect to the delivery
and/or ownership or right of possession of the securities held by you hereunder, you are authorized
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">and directed to retain in your possession without liability to anyone all or any part of said
securities until such disputes shall have been settled either by mutual written agreement of the
parties concerned or by a final order, decree or judgment of a court of competent jurisdiction
after the time for appeal has expired and no appeal has been perfected, but you shall be under no
duty whatsoever to institute or defend any such proceedings.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.&nbsp;Any notice required or permitted hereunder shall be given in writing and shall be deemed
effectively given upon personal delivery or upon deposit in the United States Post Office, by
registered or certified mail with postage and fees prepaid, addressed to each of the other parties
thereunto entitled at the following addresses or at such other addresses as a party may designate
by ten days&#146; advance written notice to each of the other parties hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.&nbsp;By signing these Joint Escrow Instructions, you become a party hereto only for the purpose
of said Joint Escrow Instructions; you do not become a party to the Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17.&nbsp;This instrument shall be binding upon and inure to the benefit of the parties hereto, and
their respective successors and permitted assigns.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.&nbsp;These Joint Escrow Instructions shall be governed by the internal substantive laws, but
not the choice of law rules, of the State of California.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">PURCHASER:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">FLUIDIGM CORPORATION</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
&#091;Name&#093;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">ESCROW AGENT<BR>
Wilson Sonsini Goodrich &#038; Rosati, PC</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Robert F. Kornegay
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dated: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT C-4</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>CONSENT OF SPOUSE</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I, <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, spouse of &#091;Name&#093;, have read
 and approve the foregoing Restricted
Stock Purchase Agreement (the &#147;Agreement&#148;). In consideration of granting of the right to my spouse
to purchase shares of Fluidigm Corporation, as set forth in the Agreement, I hereby appoint my
spouse as my attorney-in-fact in respect to the exercise of any rights under the Agreement and
agree to be bound by the provisions of the Agreement insofar as I may have any rights in said
Agreement or any shares issued pursuant thereto under the community property laws or similar laws
relating to marital property in effect in the state of our residence as of the date of the signing
of the foregoing Agreement.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dated: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Signature:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT C-5</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>ELECTION UNDER SECTION 83(b)</U><BR>
<U>OF THE INTERNAL REVENUE CODE OF 1986</U>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The undersigned taxpayer hereby elects, pursuant to Sections&nbsp;55 and 83(b) of the Internal Revenue
Code of 1986, as amended, to include in taxpayer&#146;s gross income or alternative minimum taxable
income, as the case may be, for the current taxable year the amount of any compensation taxable to
taxpayer in connection with taxpayer&#146;s receipt of the property described below:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The name, address, taxpayer identification number and taxable year of the undersigned are as
follows:</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">NAME:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TAXPAYER:&nbsp;&#091;Name&#093;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SPOUSE:</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ADDRESS:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">IDENTIFICATION NO.:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TAXPAYER:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SPOUSE:</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TAXABLE YEAR:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The property with respect to which the election is made is described as follows: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
shares (the &#147;Shares&#148;) of the Common Stock of Fluidigm Corporation (the &#147;Company&#148;).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The date on which the property was transferred is: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The property is subject to the following restrictions:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Shares may not be transferred and are subject to forfeiture under the terms of an
agreement between the taxpayer and the Company. These restrictions lapse upon the
satisfaction of certain conditions contained in such agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The fair market value at the time of transfer, determined without regard to any restriction
other than a restriction which by its terms will never lapse, of such property is:<BR>
$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The amount (if any) paid for such property is:<BR>
$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The undersigned has submitted a copy of this statement to the person for whom the services were
performed in connection with the undersigned&#146;s receipt of the above-described property. The
transferee of such property is the person performing the services in connection with the transfer
of said property.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>The undersigned understands that the foregoing election may not be revoked except with the
consent of the Commissioner</U>.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="14%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dated: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
&#091;Name&#093;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">The undersigned spouse of taxpayer joins in this election.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dated: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Spouse of &#091;Name&#093;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FLUIDIGM CORPORATION<BR>
1999 STOCK OPTION PLAN<BR>
STOCK OPTION AGREEMENT<BR>
(NSO for Consultants)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Unless otherwise defined herein, the terms defined in the 1999 Stock Option Plan shall have the
same defined meanings in this Stock Option Agreement (the &#147;Option Agreement&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>I. NOTICE OF STOCK OPTION GRANT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Name<BR>
Address

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">You have been granted an option to purchase Common Stock of the Company, subject to the terms and
conditions of the Plan and this Option Agreement, as follows:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Date of Grant</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top" align="left">&nbsp;</TD>
    <TD valign="top" align="right">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Grant Number</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top" align="left">&nbsp;</TD>
    <TD valign="top" align="right">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Vesting Commencement Date</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top" align="left">&nbsp;</TD>
    <TD valign="top" align="right">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Exercise Price per Share</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:30px; text-indent:-15px">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top" align="left">&nbsp;</TD>
    <TD valign="top" align="right">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Total Number of Shares Granted</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top" align="left">&nbsp;</TD>
    <TD valign="top" align="right">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Total Exercise Price</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top" align="left">&nbsp;</TD>
    <TD valign="top" align="right">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Type of Option:</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Incentive Stock Option</DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top" align="left">&nbsp;</TD>
    <TD valign="top" align="right">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top" align="left">&nbsp;</TD>
    <TD valign="top" align="right">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;X&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nonstatutory Stock Option</DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top" align="left">&nbsp;</TD>
    <TD valign="top" align="right">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Term/Expiration Date:</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:30px; text-indent:-15px"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U>Exercise and Vesting Schedule:</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Option shall be exercisable in whole or in part, and shall vest according to the following
vesting schedule:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">&#091;Vesting Schedule&#093;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>Termination Period</U>:

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Option may be exercised in whole or in part, to the extent it is then vested, at any time
prior to the Expiration Date set forth above. This Option may not be exercised with respect to
unvested shares.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>II. AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Grant of Option</U>. The Administrator of the Company hereby grants to the Optionee
named in the Notice of Grant (the &#147;Optionee&#148;), an option (the &#147;Option&#148;) to purchase the number of
Shares set forth in the Notice of Grant, at the exercise price per Share set forth in the Notice of
Grant (the &#147;Exercise Price&#148;), and subject to the terms and conditions of the Plan, which is
incorporated herein by reference. Subject to Section 13(c) of the Plan, in the event of a conflict
between the terms and conditions of the Plan and this Option Agreement, the terms and conditions of
the Plan shall prevail.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If designated in the Notice of Grant as an Incentive Stock Option (&#147;ISO&#148;), this Option is
intended to qualify as an Incentive Stock Option as defined in Section&nbsp;422 of the Code.
Nevertheless, to the extent that it exceeds the $100,000 rule of Code Section&nbsp;422(d), this Option
shall be treated as a Nonstatutory Stock Option (&#147;NSO&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Exercise of Option</U>. This Option shall be exercisable during its term in accordance
with the provisions of Section&nbsp;9 of the Plan as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Right to Exercise</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;Subject to subsections 2(a)(ii) below, this Option shall be exercisable cumulatively
according to the vesting schedule set forth in the Notice of Grant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;This Option may not be exercised for a fraction of a Share.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Method of Exercise</U>. This Option shall be exercisable by delivery of an exercise
notice in the form attached as <U>Exhibit&nbsp;A</U> (the &#147;Exercise Notice&#148;) which shall state the
election to exercise the Option, the number of Shares with respect to which the Option is being
exercised, and such other representations and agreements as may be required by the Company. The
Exercise Notice shall be accompanied by payment of the aggregate Exercise Price as to all Exercised
Shares. This Option shall be deemed to be exercised upon receipt by the Company of such fully
executed Exercise Notice accompanied by the aggregate Exercise Price.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Shares shall be issued pursuant to the exercise of an Option unless such issuance and such
exercise complies with Applicable Laws. Assuming such compliance, for income tax purposes the
Shares shall be considered transferred to the Optionee on the date on which the Option is exercised
with respect to such Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Optionee&#146;s Representations</U>. In the event the Shares have not been registered under
the Securities Act of 1933, as amended, at the time this Option is exercised, the Optionee shall,
if required by the Company, concurrently with the exercise of all or any portion of this Option,
deliver to the Company his or her Investment Representation Statement in the form attached hereto
as <U>Exhibit&nbsp;B</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Lock-Up Period</U>. Optionee hereby agrees that, if so requested by the Company or any
representative of the underwriters (the &#147;Managing Underwriter&#148;) in connection with any registration
of the offering of any securities of the Company under the Securities Act, Optionee shall not sell
or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">otherwise transfer any Shares or other securities of the Company during the 180-day period (or
such other period as may be requested in writing by the Managing Underwriter and agreed to in
writing by the Company) (the &#147;Market Standoff Period&#148;) following the effective date of a
registration statement of the Company filed under the Securities Act. The Company may impose
stop-transfer instructions with respect to securities subject to the foregoing restrictions until
the end of such Market Standoff Period and Optionee agrees to enter into a market stand-off
agreement in customary form consistent with this section with the managing underwriter.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Method of Payment</U>. Payment of the aggregate Exercise Price shall be by any of the
following, or a combination thereof, at the election of the Optionee:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;cash;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;check;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;consideration received by the Company under a formal cashless exercise program adopted by
the Company in connection with the Plan; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;surrender of other Shares which, (i)&nbsp;in the case of Shares acquired upon exercise of an
option, have been owned by the Optionee for more than six (6)&nbsp;months on the date of surrender, and
(ii)&nbsp;have a Fair Market Value on the date of surrender equal to the aggregate Exercise Price of the
Exercised Shares.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Restrictions on Exercise</U>. This Option may not be exercised until such time as the
Plan has been approved by the stockholders of the Company, or if the issuance of such Shares upon
such exercise or the method of payment of consideration for such shares would constitute a
violation of any Applicable Law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Non-Transferability of Option</U>. This Option may not be transferred in any manner
otherwise than by will or by the laws of descent or distribution and may be exercised during the
lifetime of Optionee only by Optionee. The terms of the Plan and this Option Agreement shall be
binding upon the executors, administrators, heirs, successors and assigns of the Optionee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Term of Option</U>. This Option may be exercised only within the term set out in the
Notice of Grant, and may be exercised during such term only in accordance with the Plan and the
terms of this Option.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>Tax Consequences</U>. Set forth below is a brief summary as of the date of this Option
of some of the federal tax consequences of exercise of this Option and disposition of the Shares.
THIS SUMMARY IS NECESSARILY INCOMPLETE, AND THE TAX LAWS AND REGULATIONS ARE SUBJECT TO CHANGE.
THE OPTIONEE SHOULD CONSULT A TAX ADVISER BEFORE EXERCISING THIS OPTION OR DISPOSING OF THE SHARES.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There may be a regular federal income tax liability upon the exercise of an NSO. The Optionee
will be treated as having received compensation income (taxable at ordinary income tax rates) equal
to the excess, if any, of the Fair Market Value of the Exercised Shares on the date of exercise
over the Exercise Price. If Optionee is an Employee or a former Employee, the Company will be
required to withhold from Optionee&#146;s compensation or collect from Optionee and pay to the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">applicable taxing authorities an amount in cash equal to a percentage of this compensation
income at the time of exercise, and may refuse to honor the exercise and refuse to deliver Shares
if such withholding amounts are not delivered at the time of exercise.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U>Entire Agreement; Governing Law</U>. The Plan is incorporated herein by reference.
The Plan and this Option Agreement constitute the entire agreement of the parties with respect to
the subject matter hereof and supersede in their entirety all prior undertakings and agreements of
the Company and Optionee with respect to the subject matter hereof, and may not be modified
adversely to the Optionee&#146;s interest except by means of a writing signed by the Company and
Optionee. This Option Agreement is governed by the internal substantive laws but not the choice of
law rules of the State of California.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<U>No Guarantee of Continued Service</U>. OPTIONEE ACKNOWLEDGES AND AGREES THAT THE
VESTING OF SHARES PURSUANT TO THE VESTING SCHEDULE HEREOF IS EARNED ONLY BY CONTINUING AS A SERVICE
PROVIDER AT THE WILL OF THE COMPANY (NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS OPTION
OR ACQUIRING SHARES HEREUNDER). OPTIONEE FURTHER ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT, THE
TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN
EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE VESTING PERIOD,
FOR ANY PERIOD, OR AT ALL, AND SHALL NOT INTERFERE IN ANY WAY WITH OPTIONEE&#146;S RIGHT OR THE
COMPANY&#146;S RIGHT TO TERMINATE OPTIONEE&#146;S RELATIONSHIP AS A SERVICE PROVIDER AT ANY TIME, WITH OR
WITHOUT CAUSE.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Optionee acknowledges receipt of a copy of the Plan and represents that he or she is familiar
with the terms and provisions thereof, and hereby accepts this Option subject to all of the terms
and provisions thereof. Optionee has reviewed the Plan and this Option in their entirety, has had
an opportunity to obtain the advice of counsel prior to executing this Option and fully understands
all provisions of the Option. Optionee hereby agrees to accept as binding, conclusive and final
all decisions or interpretations of the Administrator upon any questions arising under the Plan or
this Option. Optionee further agrees to notify the Company upon any change in the residence
address indicated below.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">OPTIONEE:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">FLUIDIGM CORPORATION</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
&#091;Name&#093;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Residence Address:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT A</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>1999 STOCK OPTION PLAN<BR>
EXERCISE NOTICE</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Fluidigm Corporation<BR>
Attn: President<BR>
7000 Shoreline Court<BR>
Suite&nbsp;100<BR>
South San Francisco, CA 94080

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Exercise of Option</U>. Effective as of today, <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, the undersigned
(&#147;Optionee&#148;) hereby elects to exercise Optionee&#146;s option (the &#147;Option&#148;) to purchase <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
shares of the Common Stock (the &#147;Shares&#148;) of Fluidigm Corporation (the &#147;Company&#148;) under and
pursuant to the 1999 Stock Option Plan (the &#147;Plan&#148;) and the Stock Option Agreement dated &#091;Grant
Date&#093; (the &#147;Option Agreement&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Delivery of Payment</U>. Purchaser herewith delivers to the Company the full purchase
price of the Shares, as set forth in the Option Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Representations of Optionee</U>. Optionee acknowledges that Optionee has received,
read and understood the Plan and the Option Agreement and agrees to abide by and be bound by their
terms and conditions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Rights as Stockholder</U>. Until the issuance of the Shares (as evidenced by the
appropriate entry on the books of the Company or of a duly authorized transfer agent of the
Company), no right to vote or receive dividends or any other rights as a stockholder shall exist
with respect to the optioned stock, notwithstanding the exercise of the Option. The Shares shall
be issued to the Optionee as soon as practicable after the Option is exercised. No adjustment
shall be made for a dividend or other right for which the record date is prior to the date of
issuance except as provided in Section&nbsp;11 of the Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Company&#146;s Right of First Refusal</U>. Before any Shares held by Optionee or any
transferee (either being sometimes referred to herein as the &#147;Holder&#148;) may be sold or otherwise
transferred (including transfer by gift or operation of law), the Company or its assignee(s) shall
have a right of first refusal to purchase the Shares on the terms and conditions set forth in this
Section (the &#147;Right of First Refusal&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Notice of Proposed Transfer</U>. The Holder of the Shares shall deliver to the
Company a written notice (the &#147;Notice&#148;) stating: (i)&nbsp;the Holder&#146;s bona fide intention to sell or
otherwise transfer such Shares; (ii)&nbsp;the name of each proposed purchaser or other transferee
(&#147;Proposed Transferee&#148;); (iii)&nbsp;the number of Shares to be transferred to each Proposed Transferee;
and (iv)&nbsp;the bona fide cash price or other consideration for which the Holder proposes to transfer
the Shares (the &#147;Offered Price&#148;), and the Holder shall offer the Shares at the Offered Price to the
Company or its assignee(s).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Exercise of Right of First Refusal</U>. At any time within thirty (30)&nbsp;days after
receipt of the Notice, the Company and/or its assignee(s) may, by giving written notice to the
Holder,
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">elect to purchase all, but not less than all, of the Shares proposed to be transferred to any
one or more of the Proposed Transferees, at the purchase price determined in accordance with
subsection (c)&nbsp;below.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Purchase Price</U>. The purchase price (&#147;Purchase Price&#148;) for the Shares purchased by
the Company or its assignee(s) under this Section shall be the Offered Price. If the Offered Price
includes consideration other than cash, the cash equivalent value of the non-cash consideration
shall be determined by the Board of Directors of the Company in good faith.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Payment</U>. Payment of the Purchase Price shall be made, at the option of the
Company or its assignee(s), in cash (by check), by cancellation of all or a portion of any
outstanding indebtedness of the Holder to the Company (or, in the case of repurchase by an
assignee, to the assignee), or by any combination thereof within 30&nbsp;days after receipt of the
Notice or in the manner and at the times set forth in the Notice.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Holder&#146;s Right to Transfer</U>. If all of the Shares proposed in the Notice to be
transferred to a given Proposed Transferee are not purchased by the Company and/or its assignee(s)
as provided in this Section, then the Holder may sell or otherwise transfer such Shares to that
Proposed Transferee at the Offered Price or at a higher price, provided that such sale or other
transfer is consummated within 120&nbsp;days after the date of the Notice, that any such sale or other
transfer is effected in accordance with any applicable securities laws and that the Proposed
Transferee agrees in writing that the provisions of this Section shall continue to apply to the
Shares in the hands of such Proposed Transferee. If the Shares described in the Notice are not
transferred to the Proposed Transferee within such period, a new Notice shall be given to the
Company, and the Company and/or its assignees shall again be offered the Right of First Refusal
before any Shares held by the Holder may be sold or otherwise transferred.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U>Exception for Certain Family Transfers</U>. Anything to the contrary contained in
this Section notwithstanding, the transfer of any or all of the Shares during the Optionee&#146;s
lifetime or on the Optionee&#146;s death by will or intestacy to the Optionee&#146;s immediate family or a
trust for the benefit of the Optionee&#146;s immediate family shall be exempt from the provisions of
this Section. &#147;Immediate Family&#148; as used herein shall mean spouse, lineal descendant or
antecedent, father, mother, brother or sister. In such case, the transferee or other recipient
shall receive and hold the Shares so transferred subject to the provisions of this Section, and
there shall be no further transfer of such Shares except in accordance with the terms of this
Section.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <U>Termination of Right of First Refusal</U>. The Right of First Refusal shall terminate
as to any Shares upon the first sale of Common Stock of the Company to the general public pursuant
to a registration statement filed with and declared effective by the Securities and Exchange
Commission under the Securities Act of 1933, as amended.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Tax Consultation</U>. Optionee understands that Optionee may suffer adverse tax
consequences as a result of Optionee&#146;s purchase or disposition of the Shares. Optionee represents
that Optionee has consulted with any tax consultants Optionee deems advisable in connection with
the purchase or disposition of the Shares and that Optionee is not relying on the Company for any
tax advice.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Restrictive Legends and Stop-Transfer Orders</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<U>Legends</U>. Optionee understands and agrees that the Company shall cause the legends
set forth below or legends substantially equivalent thereto, to be placed upon any certificate(s)
evidencing ownership of the Shares together with any other legends that may be required by the
Company or by state or federal securities laws:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933 (THE &#147;ACT&#148;) AND MAY NOT BE OFFERED, SOLD OR
OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL
REGISTERED UNDER THE ACT OR, IN THE OPINION OF COMPANY COUNSEL
SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR
TRANSFER, PLEDGE OR HYPOTHECATION IS IN COMPLIANCE THEREWITH.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN
RESTRICTIONS ON TRANSFER AND RIGHT OF FIRST REFUSAL OPTIONS HELD BY
THE ISSUER OR ITS ASSIGNEE(S) AS SET FORTH IN THE EXERCISE NOTICE
BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY OF
WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER. SUCH
TRANSFER RESTRICTIONS AND RIGHT OF FIRST REFUSAL ARE BINDING ON
TRANSFEREES OF THESE SHARES.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Stop-Transfer Notices</U>. Optionee agrees that, in order to ensure compliance with
the restrictions referred to herein, the Company may issue appropriate &#147;stop transfer&#148; instructions
to its transfer agent, if any, and that, if the Company transfers its own securities, it may make
appropriate notations to the same effect in its own records.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Refusal to Transfer</U>. The Company shall not be required (i)&nbsp;to transfer on its
books any Shares that have been sold or otherwise transferred in violation of any of the provisions
of this Exercise Notice or (ii)&nbsp;to treat as owner of such Shares or to accord the right to vote or
pay dividends to any purchaser or other transferee to whom such Shares shall have been so
transferred.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Successors and Assigns</U>. The Company may assign any of its rights under this
Exercise Notice to single or multiple assignees, and the terms and conditions of this Exercise
Notice shall inure to the benefit of the successors and assigns of the Company. Subject to the
restrictions on transfer herein set forth, the terms and conditions of this Exercise Notice shall
be binding upon Optionee and his or her heirs, executors, administrators, successors and assigns.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>Interpretation</U>. Any dispute regarding the interpretation of this Exercise Notice
shall be submitted by Optionee or by the Company forthwith to the Administrator which shall review
such dispute at its next regular meeting. The resolution of such a dispute by the Administrator
shall be final and binding on all parties.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U>Governing Law; Severability</U>. This Exercise Notice is governed by the internal
substantive laws, but not the choice of law rules, of the State of California.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<U>Entire Agreement</U>. The Plan and Option Agreement are incorporated herein by
reference. This Exercise Notice, the Plan, the Restricted Stock Purchase Agreement, the Option
Agreement and the Investment Representation Statement constitute the entire agreement of the
parties with respect to the subject matter hereof and supersede in their entirety all prior
undertakings and agreements of the Company and Optionee with respect to the subject matter hereof,
and may not be modified adversely to the Optionee&#146;s interest except by means of a writing signed by
the Company and Optionee.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="28%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">Submitted by:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left">Accepted by:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">OPTIONEE:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left">FLUIDIGM CORPORATION</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#091;Name&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Address:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Date Received:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT B</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>INVESTMENT REPRESENTATION STATEMENT</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="87%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">OPTIONEE
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;NAME&#093;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">COMPANY
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">FLUIDIGM CORPORATION</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">SECURITY
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">COMMON STOCK</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">AMOUNT
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">DATE
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the purchase of the above-listed Securities, the undersigned Optionee
represents to the Company the following:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Optionee is aware of the Company&#146;s business affairs and financial condition and has
acquired sufficient information about the Company to reach an informed and knowledgeable decision
to acquire the Securities. Optionee is acquiring these Securities for investment for Optionee&#146;s
own account only and not with a view to, or for resale in connection with, any &#147;distribution&#148;
thereof within the meaning of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Optionee acknowledges and understands that the Securities constitute &#147;restricted
securities&#148; under the Securities Act and have not been registered under the Securities Act in
reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the
bona fide nature of Optionee&#146;s investment intent as expressed herein. In this connection, Optionee
understands that, in the view of the Securities and Exchange Commission, the statutory basis for
such exemption may be unavailable if Optionee&#146;s representation was predicated solely upon a present
intention to hold these Securities for the minimum capital gains period specified under tax
statutes, for a deferred sale, for or until an increase or decrease in the market price of the
Securities, or for a period of one year or any other fixed period in the future. Optionee further
understands that the Securities must be held indefinitely unless they are subsequently registered
under the Securities Act or an exemption from such registration is available. Optionee further
acknowledges and understands that the Company is under no obligation to register the Securities.
Optionee understands that the certificate evidencing the Securities will be imprinted with a legend
which prohibits the transfer of the Securities unless they are registered or such registration is
not required in the opinion of counsel satisfactory to the Company, and with any other legend
required under applicable state securities laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Optionee is familiar with the provisions of Rule&nbsp;701 and Rule&nbsp;144, each promulgated under
the Securities Act, which, in substance, permit limited public resale of &#147;restricted securities&#148;
acquired, directly or indirectly from the issuer thereof, in a non-public offering subject to the
satisfaction of certain conditions. Rule&nbsp;701 provides that if the issuer qualifies under Rule&nbsp;701
at the time of the grant of the Option to the Optionee, the exercise will be exempt from
registration under the Securities Act. In the event the Company becomes subject to the reporting
requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, ninety (90)&nbsp;days
thereafter (or such longer period as any market stand-off agreement may require) the Securities
exempt under Rule&nbsp;701
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">may be resold, subject to the satisfaction of certain of the conditions specified by Rule&nbsp;144,
including: (1)&nbsp;the resale being made through a broker in an unsolicited &#147;broker&#146;s transaction&#148; or
in transactions directly with a market maker (as said term is defined under the Securities Exchange
Act of 1934); and, in the case of an affiliate, (2)&nbsp;the availability of certain public information
about the Company, (3)&nbsp;the amount of Securities being sold during any three month period not
exceeding the limitations specified in Rule&nbsp;144(e), and (4)&nbsp;the timely filing of a Form&nbsp;144, if
applicable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event that the Company does not qualify under Rule&nbsp;701 at the time of grant of the
Option, then the Securities may be resold in certain limited circumstances subject to the
provisions of Rule&nbsp;144, which requires the resale to occur not less than one year after the later
of the date the Securities were sold by the Company or the date the Securities were sold by an
affiliate of the Company, within the meaning of Rule&nbsp;144; and, in the case of acquisition of the
Securities by an affiliate, or by a non-affiliate who subsequently holds the Securities less than
two years, the satisfaction of the conditions set forth in sections (1), (2), (3)&nbsp;and (4)&nbsp;of the
paragraph immediately above.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Optionee further understands that in the event all of the applicable requirements of
Rule&nbsp;701 or 144 are not satisfied, registration under the Securities Act, compliance with
Regulation&nbsp;A, or some other registration exemption will be required; and that, notwithstanding the
fact that Rules&nbsp;144 and 701 are not exclusive, the Staff of the Securities and Exchange Commission
has expressed its opinion that persons proposing to sell private placement securities other than in
a registered offering and otherwise than pursuant to Rules&nbsp;144 or 701 will have a substantial
burden of proof in establishing that an exemption from registration is available for such offers or
sales, and that such persons and their respective brokers who participate in such transactions do
so at their own risk. Optionee understands that no assurances can be given that any such other
registration exemption will be available in such event.
</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Signature of Optionee:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;Name&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FLUIDIGM CORPORATION</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>1999 STOCK OPTION PLAN</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>INTERNATIONAL STOCK OPTION AGREEMENT</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise defined herein, the terms defined in the 1999 Stock Option Plan (or the
applicable appendix thereunder) shall have the same defined meanings in this Stock Option Agreement
(the &#147;Option Agreement&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>I. NOTICE OF STOCK OPTION GRANT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Name<BR>
Address

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You have been granted an option to purchase Common Stock of the Company, subject to the terms
and conditions of the Plan (and the applicable appendix thereunder, if any) and this Option
Agreement, as follows:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date of Grant</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Grant Number:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vesting Commencement Date</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Exercise Price per Share
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">U.S.$</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Total Number of Shares Granted</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Total Exercise Price
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">U.S.$</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Type of Option:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Incentive Stock Option</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">X
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Nonstatutory Stock Option</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Term/Expiration Date:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise and Vesting Schedule</U>:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Option shall be exercisable in whole or in part, and shall vest according to the
following vesting schedule:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#091;Vesting Schedule&#093;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination Period</U>:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Option may be exercised, to the extent it is then vested, for three months after Optionee
ceases to be a Service Provider. Upon death or Disability of the Optionee, this Option may be
exercised, to the extent it is then vested, for one year after Optionee ceases to be Service
Provider. In no event shall this Option be exercised later than the Term/Expiration Date as
provided above.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>II. AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Grant of Option</U>. The Administrator of the Company hereby grants to the Optionee
named in the Notice of Grant (the &#147;Optionee&#148;), an option (the &#147;Option&#148;) to purchase the number of
Shares set forth in the Notice of Grant, at the exercise price per Share set forth in the Notice of
Grant (the &#147;Exercise Price&#148;), and subject to the terms and conditions of the Plan, which is
incorporated herein by reference. Subject to Section 13(c) of the Plan, in the event of a conflict
between the terms and conditions of the Plan (including any applicable appendix thereunder) and
this Option Agreement, the terms and conditions of the Plan (including any applicable appendix
thereunder) shall prevail.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If designated in the Notice of Grant as an Incentive Stock Option (&#147;ISO&#148;), this Option is
intended to qualify as an Incentive Stock Option as defined in Section&nbsp;422 of the Code.
Nevertheless, to the extent that it exceeds the $100,000 rule of Code Section&nbsp;422(d), this Option
shall be treated as a Nonstatutory Stock Option (&#147;NSO&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Exercise of Option</U>. This Option shall be exercisable during its term in accordance
with the provisions of Section&nbsp;9 of the Plan as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Right to Exercise</U>. This Option shall be exercisable during its term in accordance
with the Vesting Schedule set out in the Notice of Grant and with the applicable provisions of the
Plan and this Option Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Method of Exercise</U>. This Option shall be exercisable by delivery of an exercise
notice in the form attached as <U>Exhibit&nbsp;A</U> (the &#147;Exercise Notice&#148;) which shall state the
election to exercise the Option, the number of Shares with respect to which the Option is being
exercised, and such other representations and agreements as may be required by the Company. The
Exercise Notice shall be accompanied by payment of the aggregate Exercise Price as to all Exercised
Shares. This Option shall be deemed to be exercised upon receipt by the Company of such fully
executed Exercise Notice accompanied by the aggregate Exercise Price.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Shares shall be issued pursuant to the exercise of an Option unless such issuance and such
exercise complies with Applicable Laws. Assuming such compliance, for income tax purposes the
Shares shall be considered transferred to the Optionee on the date on which the Option is exercised
with respect to such Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Optionee&#146;s Representations</U>. In the event the Shares have not been registered under
the Securities Act of 1933, as amended, at the time this Option is exercised, the Optionee shall,
if required by the Company, concurrently with the exercise of all or any portion of this Option,
deliver
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">to the Company his or her Investment Representation Statement in the form attached hereto as
<U>Exhibit&nbsp;B</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Lock-Up Period</U>. Optionee hereby agrees that, if so requested by the Company or any
representative of the underwriters (the &#147;Managing Underwriter&#148;) in connection with any registration
of the offering of any securities of the Company under the Securities Act, Optionee shall not sell
or otherwise transfer any Shares or other securities of the Company during the 180-day period (or
such other period as may be requested in writing by the Managing Underwriter and agreed to in
writing by the Company) (the &#147;Market Standoff Period&#148;) following the effective date of a
registration statement of the Company filed under the Securities Act. The Company may impose
stop-transfer instructions with respect to securities subject to the foregoing restrictions until
the end of such Market Standoff Period and Optionee agrees to enter into a market stand-off
agreement in customary form consistent with this section with the managing underwriter.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Method of Payment</U>. Payment of the aggregate Exercise Price shall be by any of the
following, or a combination thereof, at the election of the Optionee:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;cash;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;check;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;consideration received by the Company under a formal cashless exercise program adopted by
the Company in connection with the Plan; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;surrender of other Shares, provided that Shares acquired from the Company (i)&nbsp;have been
owned by the Optionee and not subject to a substantial risk of forfeiture for more than six (6)
months on the date of surrender, and (ii)&nbsp;have a Fair Market Value on the date of surrender equal
to the aggregate Exercise Price of the Exercised Shares.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Restrictions on Exercise</U>. This Option may not be exercised until such time as the
Plan has been approved by the stockholders of the Company, or if the issuance of such Shares upon
such exercise or the method of payment of consideration for such shares would constitute a
violation of any Applicable Law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Non-Transferability of Option</U>. This Option may not be transferred in any manner
otherwise than by will or by the laws of descent or distribution and may be exercised during the
lifetime of Optionee only by Optionee. The terms of the Plan and this Option Agreement shall be
binding upon the executors, administrators, heirs, successors and assigns of the Optionee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Term of Option</U>. This Option may be exercised only within the term set out in the
Notice of Grant, and may be exercised during such term only in accordance with the Plan and the
terms of this Option.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>Tax Obligations</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Withholding</U>. Optionee agrees to make appropriate arrangements with the Company
(or the Parent or Subsidiary employing or retaining Optionee) for the satisfaction of all Federal,
state, local and foreign income and employment tax withholding requirements as well as
</DIV>
<P align="right" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">social security charges applicable to the vesting of the Option, the exercise of the Option or
the disposition of any Shares acquired upon exercise. In this regard, Optionee authorizes the
Company (and/or the Parent or Subsidiary employing or retaining Optionee) to withhold all
applicable taxes legally payable by Optionee from the Optionee&#146;s wages or other cash compensation
paid to Optionee by the Company (and/or the Parent or Subsidiary employing or retaining Optionee)
or from proceeds from the sale of Shares acquired upon exercise of the Option in an amount
sufficient to cover such tax obligations. Optionee acknowledges and agrees that the Company may
refuse to honor the exercise and refuse to deliver Shares if such withholding amounts are not
delivered at the time of exercise.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Tax Consultation</U>. Optionee understands that he or she may suffer adverse tax
consequences as a result of Optionee&#146;s purchase or disposition of the Shares. Optionee represents
that he or she will consult with any tax advisors Optionee deems appropriate in connection with the
purchase or disposition of the Shares and that Optionee is not relying on the Company for any tax
advice.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U>Acknowledgements</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Optionee acknowledges receipt of a copy of the Plan (including any applicable appendixes
thereunder) and represents that he or she is familiar with the terms and provisions thereof, and
hereby accepts this Option subject to all of the terms and provisions thereof. Optionee has
reviewed the Plan (including any applicable appendixes thereunder) and this Option Agreement in
their entirety, has had an opportunity to obtain the advice of counsel prior to executing this
Option and fully understands all provisions of the Option. Optionee hereby agrees to accept as
binding, conclusive and final all decisions or interpretations of the Administrator upon any
questions arising under the Plan or this Option. Optionee further agrees to notify the Company
upon any change in the residence address indicated below.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Company (and not Optionee&#146;s employer) is granting the Option. The Company will
administer the Plan from outside Optionee&#146;s country of residence and that United States of America
law will govern all Options granted under the Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;That benefits and rights provided under the Plan are wholly discretionary and, although
provided by the Company, do not constitute regular or periodic payments. The benefits and rights
provided under the Plan are not to be considered part of Optionee&#146; s salary or compensation for
purposes of calculating any severance, resignation, redundancy or other end of service payments,
vacation, bonuses, long-term service awards, indemnification, pension or retirement benefits, or
any other payments, benefits or rights of any kind. Optionee waives any and all rights to
compensation or damages as a result of the termination of employment with the Company for any
reason whatsoever insofar as those rights result or may result from:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;the loss or diminution in value of such rights under the Plan, or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;Optionee ceases to have any rights under, or ceases to be entitled to any rights under
the Plan as a result of such termination.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The grant of the Option, and any future grant of Options under the Plan is entirely
voluntary, and at the complete discretion of the Company. Neither the grant of the Option
</DIV>
<P align="right" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">nor any future grant of an Option by the Company will be deemed to create any obligation to
grant any further Options, whether or not such a reservation is explicitly stated at the time of
such a grant. The Company has the right, at any time to amend, suspend or terminate the Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;The Plan will not be deemed to constitute, and will not be construed by Optionee to
constitute, part of the terms and conditions of employment, and that the Company will not incur any
liability of any kind to Optionee as a result of any change or amendment, or any cancellation, of
the Plan at any time.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Participation in the Plan will not be deemed to constitute, and will not be deemed by
Optionee to constitute, an employment or labor relationship of any kind with the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;By entering into this Option Agreement, and as a condition of the grant of the Option,
Optionee consents to the collection, use, and transfer of personal data as described in this
subsection to the full extent permitted by and in full compliance with Applicable Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;Optionee understands that the Company and its Subsidiaries hold certain personal
information about the Optionee, including, but not limited to, name, home address and telephone
number, date of birth, social insurance number, salary, nationality, job title, any Shares or
directorships held in the Company, details of all Options or other entitlement to Shares awarded,
canceled, exercised, vested, unvested, or outstanding in Optionee&#146;s favor, for the purpose of
managing and administering the Plan (&#147;Data&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;Optionee further understands that the Company and/or its Subsidiaries will transfer Data
among themselves as necessary for the purposes of implementation, administration, and management of
Optionee&#146;s participation in the Plan, and that the Company and/or its Subsidiary may each further
transfer Data to any third parties assisting the Company in the implementation, administration, and
management of the Plan (&#147;Data Recipients&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;Optionee understands that these Data Recipients may be located in Optionee&#146;s country of
residence or elsewhere, such as the United States. Optionee authorizes the Data Recipients to
receive, possess, use, retain, and transfer Data in electronic or other form, for the purposes of
implementing, administering, and managing Optionee&#146;s participation in the Plan, including any
transfer of such Data, as may be required for the administration of the Plan and/or the subsequent
holding of Shares on Optionee&#146; s behalf, to a broker or third party with whom the Shares acquired
on exercise may be deposited.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;Optionee understands that Optionee may, at any time, review the Data, request that any
necessary amendments be made to it, or withdraw Optionee&#146;s consent herein in writing by contacting
the Company. Optionee further understands that withdrawing consent may affect Optionee&#146;s ability
to participate in the Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;Optionee has received the terms and conditions of this Option Agreement and any other
related communications, and Optionee consents to having received these documents in English.
</DIV>


<P align="right" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<U>Entire Agreement; Governing Law</U>. The Plan is incorporated herein by reference.
The Plan and this Option Agreement constitute the entire agreement of the parties with respect to
the subject matter hereof and supersede in their entirety all prior undertakings and agreements of
the Company and Optionee with respect to the subject matter hereof, and may not be modified
adversely to the Optionee&#146;s interest except by means of a writing signed by the Company and
Optionee. This Option Agreement is governed by the internal substantive laws but not the choice of
law rules of the State of California.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;<U>No Guarantee of Continued Service</U>. OPTIONEE ACKNOWLEDGES AND AGREES THAT THE
VESTING OF SHARES PURSUANT TO THE VESTING SCHEDULE HEREOF IS EARNED ONLY BY CONTINUING AS A SERVICE
PROVIDER AT THE WILL OF THE COMPANY (NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS OPTION
OR ACQUIRING SHARES HEREUNDER). OPTIONEE FURTHER ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT, THE
TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN
EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE VESTING PERIOD,
FOR ANY PERIOD, OR AT ALL, AND SHALL NOT INTERFERE IN ANY WAY WITH OPTIONEE&#146;S RIGHT OR THE
COMPANY&#146;S RIGHT TO TERMINATE OPTIONEE&#146;S RELATIONSHIP AS A SERVICE PROVIDER AT ANY TIME, WITH OR
WITHOUT CAUSE.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Optionee acknowledges receipt of a copy of the Plan and represents that he or she is familiar
with the terms and provisions thereof, and hereby accepts this Option subject to all of the terms
and provisions thereof. Optionee has reviewed the Plan and this Option in their entirety, has had
an opportunity to obtain the advice of counsel prior to executing this Option and fully understands
all provisions of the Option. Optionee hereby agrees to accept as binding, conclusive and final
all decisions or interpretations of the Administrator upon any questions arising under the Plan or
this Option. Optionee further agrees to notify the Company upon any change in the residence
address indicated below.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">OPTIONEE:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">FLUIDIGM CORPORATION</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
&#091;Name&#093;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Residence Address:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>


<P align="RIGHT" style="font-size: 10pt"><!-- Folio -->-5-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT A</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>1999 STOCK OPTION PLAN</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>EXERCISE NOTICE</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Fluidigm Corporation<BR>
Attn: President<BR>
7000 Shoreline Court<BR>
Suite&nbsp;100<BR>
South San Francisco, CA 94080

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Exercise of Option</U>. Effective as of today, <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, the undersigned
(&#147;Optionee&#148;) hereby elects to exercise Optionee&#146;s option (the &#147;Option&#148;) to purchase <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
shares of the Common Stock (the &#147;Shares&#148;) of Fluidigm Corporation (the &#147;Company&#148;) under and
pursuant to the 1999 Stock Option Plan, including any applicable appendixes thereunder
(collectively, the &#147;Plan&#148;), and the Stock Option Agreement dated &#091;Grant Date&#093; (the &#147;Option
Agreement&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Delivery of Payment</U>. Optionee herewith delivers to the Company the full purchase
price of the Shares, as set forth in the Option Agreement, and any and all withholding taxes due in
connection with the exercise of the Option.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Representations of Optionee</U>. Optionee acknowledges that Optionee has received,
read and understood the Plan and the Option Agreement and agrees to abide by and be bound by their
terms and conditions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Rights as Stockholder</U>. Until the issuance of the Shares (as evidenced by the
appropriate entry on the books of the Company or of a duly authorized transfer agent of the
Company), no right to vote or receive dividends or any other rights as a stockholder shall exist
with respect to the optioned stock, notwithstanding the exercise of the Option. The Shares shall
be issued to the Optionee as soon as practicable after the Option is exercised. No adjustment
shall be made for a dividend or other right for which the record date is prior to the date of
issuance except as provided in Section&nbsp;11 of the Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Company&#146;s Right of First Refusal</U>. Before any Shares held by Optionee or any
transferee (either being sometimes referred to herein as the &#147;Holder&#148;) may be sold or otherwise
transferred (including transfer by gift or operation of law), the Company or its assignee(s) shall
have a right of first refusal to purchase the Shares on the terms and conditions set forth in this
Section (the &#147;Right of First Refusal&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Notice of Proposed Transfer</U>. The Holder of the Shares shall deliver to the
Company a written notice (the &#147;Notice&#148;) stating: (i)&nbsp;the Holder&#146;s bona fide intention to sell or
otherwise transfer such Shares; (ii)&nbsp;the name of each proposed purchaser or other transferee
(&#147;Proposed Transferee&#148;); (iii)&nbsp;the number of Shares to be transferred to each Proposed Transferee;
and (iv)&nbsp;the bona fide cash price or other consideration for which the Holder proposes to transfer
the Shares (the &#147;Offered Price&#148;), and the Holder shall offer the Shares at the Offered Price to the
Company or its assignee(s).
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Exercise of Right of First Refusal</U>. At any time within thirty (30)&nbsp;days after
receipt of the Notice, the Company and/or its assignee(s) may, by giving written notice to the
Holder, elect to purchase all, but not less than all, of the Shares proposed to be transferred to
any one or more of the Proposed Transferees, at the purchase price determined in accordance with
subsection (c)&nbsp;below.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Purchase Price</U>. The purchase price (&#147;Purchase Price&#148;) for the Shares purchased by
the Company or its assignee(s) under this Section shall be the Offered Price. If the Offered Price
includes consideration other than cash, the cash equivalent value of the non-cash consideration
shall be determined by the Board of Directors of the Company in good faith.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Payment</U>. Payment of the Purchase Price shall be made, at the option of the
Company or its assignee(s), in cash (by check), by cancellation of all or a portion of any
outstanding indebtedness of the Holder to the Company (or, in the case of repurchase by an
assignee, to the assignee), or by any combination thereof within 30&nbsp;days after receipt of the
Notice or in the manner and at the times set forth in the Notice.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Holder&#146;s Right to Transfer</U>. If all of the Shares proposed in the Notice to be
transferred to a given Proposed Transferee are not purchased by the Company and/or its assignee(s)
as provided in this Section, then the Holder may sell or otherwise transfer such Shares to that
Proposed Transferee at the Offered Price or at a higher price, provided that such sale or other
transfer is consummated within 120&nbsp;days after the date of the Notice, that any such sale or other
transfer is effected in accordance with any applicable securities laws and that the Proposed
Transferee agrees in writing that the provisions of this Section shall continue to apply to the
Shares in the hands of such Proposed Transferee. If the Shares described in the Notice are not
transferred to the Proposed Transferee within such period, a new Notice shall be given to the
Company, and the Company and/or its assignees shall again be offered the Right of First Refusal
before any Shares held by the Holder may be sold or otherwise transferred.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U>Exception for Certain Family Transfers</U>. Anything to the contrary contained in
this Section notwithstanding, the transfer of any or all of the Shares during the Optionee&#146;s
lifetime or on the Optionee&#146;s death by will or intestacy to the Optionee&#146;s immediate family or a
trust for the benefit of the Optionee&#146;s immediate family shall be exempt from the provisions of
this Section. &#147;Immediate Family&#148; as used herein shall mean spouse, lineal descendant or
antecedent, father, mother, brother or sister. In such case, the transferee or other recipient
shall receive and hold the Shares so transferred subject to the provisions of this Section, and
there shall be no further transfer of such Shares except in accordance with the terms of this
Section.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <U>Termination of Right of First Refusal</U>. The Right of First Refusal shall terminate
as to any Shares upon the first sale of Common Stock of the Company to the general public pursuant
to a registration statement filed with and declared effective by the Securities and Exchange
Commission under the Securities Act of 1933, as amended.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;<U>Tax Consultation</U>. Optionee understands that Optionee may suffer adverse tax
consequences as a result of Optionee&#146;s purchase or disposition of the Shares. Optionee represents
that Optionee has consulted with any tax consultants Optionee deems advisable in connection with
the purchase or disposition of the Shares and that Optionee is not relying on the Company for any
tax advice.
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Restrictive Legends and Stop-Transfer Orders</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Legends</U>. Optionee understands and agrees that the Company shall cause the legends
set forth below or legends substantially equivalent thereto, to be placed upon any certificate(s)
evidencing ownership of the Shares together with any other legends that may be required by the
Company or by state or federal securities laws:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933 (THE &#147;ACT&#148;) AND MAY NOT BE OFFERED, SOLD OR
OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL
REGISTERED UNDER THE ACT OR, IN THE OPINION OF COMPANY COUNSEL
SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR
TRANSFER, PLEDGE OR HYPOTHECATION IS IN COMPLIANCE THEREWITH.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN
RESTRICTIONS ON TRANSFER AND RIGHT OF FIRST REFUSAL OPTIONS HELD BY
THE ISSUER OR ITS ASSIGNEE(S) AS SET FORTH IN THE EXERCISE NOTICE
BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY OF
WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER. SUCH
TRANSFER RESTRICTIONS AND RIGHT OF FIRST REFUSAL ARE BINDING ON
TRANSFEREES OF THESE SHARES.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS
ON TRANSFER FOR A PERIOD NOT TO EXCEED 180 DAYS FOLLOWING THE
EFFECTIVE DATE OF UNDERWRITTEN PUBLIC OFFERING OF THE COMPANY&#146;S
SECURITIES AND MAY NOT BE SOLD OR OTHERWISE DISPOSED OF BY THE HOLDER
WITHOUT THE CONSENT OF THE COMPANY OR THE MANAGING UNDERWRITER.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Stop-Transfer Notices</U>. Optionee agrees that, in order to ensure compliance with
the restrictions referred to herein, the Company may issue appropriate &#147;stop transfer&#148; instructions
to its transfer agent, if any, and that, if the Company transfers its own securities, it may make
appropriate notations to the same effect in its own records.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Refusal to Transfer</U>. The Company shall not be required (i)&nbsp;to transfer on its
books any Shares that have been sold or otherwise transferred in violation of any of the provisions
of this Exercise Notice or (ii)&nbsp;to treat as owner of such Shares or to accord the right to vote or
pay dividends to any purchaser or other transferee to whom such Shares shall have been so
transferred.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Successors and Assigns</U>. The Company may assign any of its rights under this
Exercise Notice to single or multiple assignees, and the terms and conditions of this Exercise
Notice
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">shall inure to the benefit of the successors and assigns of the Company. Subject to the
restrictions on transfer herein set forth, the terms and conditions of this Exercise Notice shall
be binding upon Optionee and his or her heirs, executors, administrators, successors and assigns.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Interpretation</U>. Any dispute regarding the interpretation of this Exercise Notice
shall be submitted by Optionee or by the Company forthwith to the Administrator which shall review
such dispute at its next regular meeting. The resolution of such a dispute by the Administrator
shall be final and binding on all parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>Governing Law; Severability</U>. This Exercise Notice is governed by the internal
substantive laws, but not the choice of law rules, of the State of California.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U>Entire Agreement</U>. The Plan and Option Agreement are incorporated herein by
reference. This Exercise Notice, the Plan, the Restricted Stock Purchase Agreement, the Option
Agreement and the Investment Representation Statement constitute the entire agreement of the
parties with respect to the subject matter hereof and supersede in their entirety all prior
undertakings and agreements of the Company and Optionee with respect to the subject matter hereof,
and may not be modified adversely to the Optionee&#146;s interest except by means of a writing signed by
the Company and Optionee.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="28%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">Submitted by:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left">Accepted by:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">OPTIONEE:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left">FLUIDIGM CORPORATION</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#091;Name&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><U>Address</U>:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Date Received:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="right" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT B</B></U>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>INVESTMENT REPRESENTATION STATEMENT</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="70%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">OPTIONEE &nbsp;&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;NAME&#093;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">COMPANY&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">FLUIDIGM CORPORATION</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">SECURITY&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">COMMON STOCK</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">AMOUNT&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">DATE
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In connection with the purchase of the above-listed Securities, the undersigned Optionee represents
to the Company the following:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Optionee is aware of the Company&#146;s business affairs and financial condition and has
acquired sufficient information about the Company to reach an informed and knowledgeable decision
to acquire the Securities. Optionee is acquiring these Securities for investment for Optionee&#146;s
own account only and not with a view to, or for resale in connection with, any &#147;distribution&#148;
thereof within the meaning of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Optionee acknowledges and understands that the Securities constitute &#147;restricted
securities&#148; under the Securities Act and have not been registered under the Securities Act in
reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the
bona fide nature of Optionee&#146;s investment intent as expressed herein. In this connection, Optionee
understands that, in the view of the Securities and Exchange Commission, the statutory basis for
such exemption may be unavailable if Optionee&#146;s representation was predicated solely upon a present
intention to hold these Securities for the minimum capital gains period specified under tax
statutes, for a deferred sale, for or until an increase or decrease in the market price of the
Securities, or for a period of one year or any other fixed period in the future. Optionee further
understands that the Securities must be held indefinitely unless they are subsequently registered
under the Securities Act or an exemption from such registration is available. Optionee further
acknowledges and understands that the Company is under no obligation to register the Securities.
Optionee understands that the certificate evidencing the Securities will be imprinted with a legend
which prohibits the transfer of the Securities unless they are registered or such registration is
not required in the opinion of counsel satisfactory to the Company, and with any other legend
required under applicable state securities laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Optionee is familiar with the provisions of Rule&nbsp;701 and Rule&nbsp;144, each promulgated under
the Securities Act, which, in substance, permit limited public resale of &#147;restricted securities&#148;
acquired, directly or indirectly from the issuer thereof, in a non-public offering subject to the
satisfaction of certain conditions. Rule&nbsp;701 provides that if the issuer qualifies under Rule&nbsp;701
at the time of the grant of the Option to the Optionee, the exercise will be exempt from
registration under the Securities Act. In the event the Company becomes subject to the reporting
requirements of Section&nbsp;13 or 15(d)&nbsp;of the Securities Exchange Act of 1934, ninety (90)&nbsp;days
thereafter (or such longer period as any market stand-off agreement may require) the Securities
exempt under Rule&nbsp;701
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">may be resold, subject to the satisfaction of certain of the conditions specified by Rule&nbsp;144,
including: (1)&nbsp;the resale being made through a broker in an unsolicited &#147;broker&#146;s transaction&#148; or
in transactions directly with&nbsp;a market maker (as said term is defined under the Securities Exchange
Act of 1934); and, in the case of an affiliate, (2)&nbsp;the availability of certain public information
about the Company, (3)&nbsp;the amount of Securities being sold during any three month period not
exceeding the limitations specified in Rule&nbsp;144(e), and (4)&nbsp;the timely filing of a Form&nbsp;144, if
applicable.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event that the Company does not qualify under Rule&nbsp;701 at the time of grant of the
Option, then the Securities may be resold in certain limited circumstances subject to the
provisions of Rule&nbsp;144, which requires&nbsp;the resale to occur not less than one year after the later
of the date the Securities were sold by the Company or the date the Securities were sold by an
affiliate of the Company, within the meaning of Rule&nbsp;144; and, in the case of acquisition of the
Securities by an affiliate, or by a non-affiliate who subsequently holds the Securities less than
two years, the satisfaction of the conditions set forth in sections (1), (2), (3)&nbsp;and (4)&nbsp;of the
paragraph immediately above.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Optionee further understands that in the event all of the applicable requirements of
Rule&nbsp;701 or 144 are not satisfied, registration under the Securities Act, compliance with
Regulation&nbsp;A, or some other registration exemption will be required; and that, notwithstanding the
fact that Rules&nbsp;144 and 701 are not exclusive, the Staff of the Securities and Exchange Commission
has expressed its opinion that persons proposing to sell private placement securities other than in
a registered offering and otherwise than pursuant to Rules&nbsp;144 or 701 will have a substantial
burden of proof in establishing that an exemption from registration is available for such offers or
sales, and that such persons and their respective brokers who participate in such transactions do
so at their own risk. Optionee understands that no assurances can be given that any such other
registration exemption will be available in such event.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Signature of Optionee:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;Name&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="right" style="font-size: 10pt"><!-- Folio -->- 2 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FLUIDIGM CORPORATION</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B>1999 STOCK OPTION PLAN</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B>FRENCH STOCK OPTION AGREEMENT</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Unless otherwise defined herein, the terms defined in the 1999 Stock Option Plan (or the applicable
appendix thereunder) shall have the same defined meanings in this Stock Option Agreement (the
&#147;Option Agreement&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>I. NOTICE OF STOCK OPTION GRANT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Name<BR>
Address

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">You have been granted an option to purchase Common Stock of the Company, subject to the terms and
conditions of the Plan (and the applicable appendix thereunder, if any) and this Option Agreement,
as follows:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"></TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date of Grant</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"></TD><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"></TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Vesting Commencement Date</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"></TD><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"></TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Exercise Price per Share
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">$&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"></TD><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"></TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Total Number of Shares Granted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"></TD><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"></TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Total Exercise Price
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">U.S.$&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"></TD><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"></TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Type of Option:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> Incentive Stock Option&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"></TD><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"></TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">X &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nonstatutory Stock Option</TD>
</TR>

<tr style="font-size: 6pt">
    <TD>&nbsp;</TD>
</tr>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"></TD><!-- Blank Space -->

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Term/Expiration
Date:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<tr>
    <TD>&nbsp;</TD>
</tr>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise and Vesting Schedule:</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Option shall be exercisable in whole or in part, and shall vest according to the
following vesting schedule:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&#091;Twenty-five percent (25%) of the Shares subject to the Option shall vest twelve months after
the Vesting Commencement Date, and 1/48 of the Shares subject to the Option shall vest each month
thereafter on the same day of the month as the Vesting Commencement Date (and if there is no
corresponding date, the last day of the month), subject to Optionee continuing to be a Service
Provider through such dates; </B><U><B>provided</B></U><B>, </B><U><B>however</B></U><B>, the Option granted hereunder may
not be exercised before one (1)&nbsp;year following the date the Option is granted (&#147;</B><U><B>Initial
Exercise Date</B></U><B>&#148;) whether or not the Option has vested prior to such time.&#093;</B>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Restriction on Sale</U>:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>The Shares may not be transferred, assigned or hypothecated in any manner otherwise than by
will or by the laws of descent or distribution before the date three (3)&nbsp;years after the Initial
Exercise Date (the &#147;Holding Period&#148;), except upon the occurrence of an event provided for by
Article&nbsp;91 ter of Annex II to the French Tax Code.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Optionee shall be obligated to have Shares held pursuant to an escrow arrangement established
by the Company, in order to insure compliance with the Holding Period and so that the Company may
sufficiently track the Shares acquired upon exercise of the Option and the Company shall be given
sufficient access to any account Optionee may have with respect to any such Shares so that the
Company may correctly provide any required reports to the French taxing authorities as required by
Applicable Laws. Optionee hereby authorizes and directs the Company to hold all Shares exercised
subject to this Option under the Escrow Provisions attached hereto as <U>Exhibit&nbsp;B</U>, for the
duration of the Holding Period or until such time as this Agreement is no longer in effect.
Optionee hereby appoints the Secretary, or any other person designated by the Company as escrow
agent and shall, upon execution of this Agreement, deliver and deposit with the Secretary of the
Company, or such other person designated by the Company, the share certificates representing the
Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company, or its designee, shall not be liable for any act it may do or omit with respect
to holding the Shares in escrow and while acting in good faith and in the exercise of its judgment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination Period:</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Option will be exercisable for three (3)&nbsp;months after Optionee ceases to be a Service
Provider, unless such termination is due to Optionee&#146;s death or Disability, in which case this
Option will be exercisable for one (1)&nbsp;year after Optionee ceases to be Service Provider in the
event of Optionee&#146;s Disability and six (6)&nbsp;months after Optionee ceases to be a Service Provider in
the event of Optionee&#146;s death. Notwithstanding the foregoing, in no event may this Option be
exercised after the Term/Expiration Date as provided above.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>II. AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Grant of Option</U>. The Administrator of the Company hereby grants to the Optionee
named in the Notice of Grant (the &#147;Optionee&#148;), an option (the &#147;Option&#148;) to purchase the number of
Shares set forth in the Notice of Grant, at the exercise price per Share set forth in the Notice of
Grant (the &#147;Exercise Price&#148;), and subject to the terms and conditions of the Plan, which is
incorporated herein by reference. Subject to Section&nbsp;13(c)&nbsp;of the Plan, in the event of a conflict
between the terms and conditions of the Plan (including any applicable appendix thereunder) and
this Option Agreement, the terms and conditions of the Plan (including any applicable appendix
thereunder) shall prevail.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If designated in the Notice of Grant as an Incentive Stock Option (&#147;ISO&#148;), this Option is
intended to qualify as an Incentive Stock Option as defined in Section&nbsp;422 of the Code.
Nevertheless, to the extent that it exceeds the $100,000 rule of Code Section&nbsp;422(d), this Option
shall be treated as a Nonstatutory Stock Option (&#147;NSO&#148;).
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Exercise of Option</U>. This Option shall be exercisable during its term in accordance
with the provisions of Section&nbsp;9 of the Plan as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Right to Exercise</U>. This Option shall be exercisable during its term in accordance
with the Vesting Schedule set out in the Notice of Grant and with the applicable provisions of the
Plan and this Option Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Method of Exercise</U>. This Option shall be exercisable by delivery of an exercise
notice to the Company, in the form attached as <U>Exhibit&nbsp;A</U> (the &#147;Exercise Notice&#148;) or in a
manner and pursuant to such procedures as the Administrator may determine, which shall state the
election to exercise the Option, the number of Shares with respect to which the Option is being
exercised (the &#147;Exercised Shares&#148;), and such other representations and agreements as may be
required by the Company and/or the Subsidiary pursuant to the provisions of the Plan (including
Appendix&nbsp;B). Until the issuance of the Shares (as evidenced by the appropriate entry on the books
of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive
dividends or any other rights as a stockholder shall exist with respect to the Optioned Stock,
notwithstanding the exercise of the Option. No adjustment shall be made for a dividend or other
right for which the record date is prior to the date of issuance of the Shares, except as provided
in Appendix&nbsp;B of the Plan. The Exercise Notice shall be signed by Optionee and shall be delivered
in person or by certified mail to the Secretary of the Subsidiary or such other person as the
Company may designate. The Exercise Notice shall be accompanied by payment of the aggregate
Exercise Price as to all Exercised Shares and all applicable tax withholdings. This Option shall
be deemed to be exercised upon receipt by the Subsidiary of such fully executed Exercise Notice
accompanied by the aggregate Exercise Price and payment of all applicable tax withholdings.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Shares shall be issued pursuant to the exercise of an Option unless such issuance and such
exercise complies with Applicable Laws. Assuming such compliance, for income tax purposes the
Shares shall be considered transferred to the Optionee on the date on which the Option is exercised
with respect to such Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Optionee&#146;s Representations</U>. In the event the Shares have not been registered under
the Securities Act of 1933, as amended, at the time this Option is exercised, the Optionee shall,
if required by the Company, concurrently with the exercise of all or any portion of this Option,
deliver to the Company his or her Investment Representation Statement in the form attached hereto
as <U>Exhibit&nbsp;C</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Lock-Up Period</U>. Optionee hereby agrees that, if so requested by the Company or any
representative of the underwriters (the &#147;Managing Underwriter&#148;) in connection with any registration
of the offering of any securities of the Company under the Securities Act, Optionee shall not sell
or otherwise transfer any Shares or other securities of the Company during the 180-day period (or
such other period as may be requested in writing by the Managing Underwriter and agreed to in
writing by the Company) (the &#147;Market Standoff Period&#148;) following the effective date of a
registration statement of the Company filed under the Securities Act. The Company may impose
stop-transfer instructions with respect to securities subject to the foregoing restrictions until
the end of such Market Standoff Period and Optionee agrees to enter into a market stand-off
agreement in customary form consistent with this section with the managing underwriter.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Method of Payment</U>. Payment of the aggregate Exercise Price shall be by any of the
following, or a combination thereof, at the election of the Optionee:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;cash or check (denominated in U.S. Dollars);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;wire transfer (denominated in U.S. Dollars); or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;consideration received by the Company under a formal cashless exercise program adopted by
the Company in connection with the Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Restrictions on Exercise</U>. This Option may not be exercised until such time as the
Plan has been approved by the stockholders of the Company, or if the issuance of such Shares upon
such exercise or the method of payment of consideration for such shares would constitute a
violation of any Applicable Law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Non-Transferability of Option</U>. This Option may not be transferred in any manner
otherwise than by will or by the laws of descent or distribution and may be exercised during the
lifetime of Optionee only by Optionee. The terms of the Plan and this Option Agreement shall be
binding upon the executors, administrators, heirs, successors and assigns of the Optionee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Term of Option</U>. This Option may be exercised only within the term set out in the
Notice of Grant, and may be exercised during such term only in accordance with the Plan and the
terms of this Option.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>Withholding and Responsibility for Tax Related Items</U>. Optionee hereby acknowledges
and agrees that the ultimate liability for any and all tax, social insurance and payroll tax
withholding (&#147;Tax-Related Items&#148;) is and remains, to the extent provided for by law, his or her
responsibility and liability and that his or her employer, the Company and its Subsidiaries (a)
make no representations or undertakings regarding the treatment of any Tax-Related Items in
connection with any aspect of the Option grant, including the grant, vesting or exercise of the
Option and the subsequent sale of Shares acquired pursuant to such exercise; and (b)&nbsp;do not commit
to structure the terms of the grant or any aspect of the Option to reduce or eliminate his or her
liability for Tax-Related Items.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Optionee agrees that prior to exercise of the Option or sale of the Share(s) acquired thereunder,
he or she shall pay or make adequate arrangements satisfactory to the Company and/or his or her
employer, as applicable, to satisfy all withholding obligations of the Company and/or his or her
employer. Optionee acknowledges and agrees that the Company may refuse to honor the exercise of
the Option and refuse to deliver Shares if such withholding amounts are not delivered at the time
of exercise or related sale. In this regard, Optionee authorizes the Company and/or his or her
employer (be it through the intermediary of the Broker or otherwise) to withhold all applicable
Tax-Related Items legally payable by him or her from his or her wages or other cash compensation
paid to him or her by the Company and/or his or her employer, or from proceeds of sale.
Alternatively, or in addition, Optionee agrees and acknowledges that the Company may sell or
arrange for the sale of Shares that Optionee is due to acquire with respect to the Option to meet
the minimum withholding obligation for Tax Related Items. Any estimated withholding which is not
required in satisfaction of any Tax Related Items shall be repaid to Optionee by the Company or his
or her employer, as applicable. Finally, Optionee agrees that he or she shall pay to the Company
or his or her employer, as
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">applicable, any amount of any Tax Related Items that the Company and/or his or her employer may be
required to withhold as a result of his or her participation in the Plan or his or her exercise of
the Option or sale of Shares acquired thereunder that cannot be satisfied by the means previously
described. In the event that the Options under the Plan are subsequently disqualified for purposes
of French tax law, Optionee agrees to submit immediately the amount of any income tax withholding
and/or Optionee&#146;s social security contributions due by means of check, cash or credit transfer. In
addition, Optionee grants the Company or his/her employer the right to require the Broker to
withhold sufficient amounts from the sale proceeds to meet the Tax Related Items withholding
obligations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Optionee&#146;s employer or the Company may withhold Shares owed to Optionee at the time of exercise in
order to meet the tax and/or social insurance charges that might be due on behalf of Optionee at
the time of sale of the underlying Shares. Upon sale of the underlying Shares, Optionee
authorizes his/her employer or the Company to withhold, or request the Broker to withhold, from the
proceeds to be paid to Optionee the amount necessary to satisfy the Tax Related Items due on behalf
of Optionee at the time of exercise of the Option and/or sale of the Shares acquired thereunder.
If such amounts are due and are not withheld, Optionee shall agree to submit the amount due to the
Company, his or her employer or the appropriate tax authorities by check, cash or credit transfer
upon request.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Optionee also agrees that in the hypothesis he/she breaches any obligation set forth in the Plan,
or this Option Agreement, the damages that shall be suffered by his/her employer and/or the Company
shall be no less than the amount of the taxes and social security contributions (employer&#146;s and
Employee&#146;s part) applicable to the related Options or Shares acquired thereunder, which minimum
amount shall therefore be withheld by his/her employer, the Company or the Broker as damages,
notwithstanding any further action from his/her employer and or the Company against Optionee.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U>Acknowledgements</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Optionee acknowledges receipt of a copy of the Plan (including any applicable appendixes
thereunder) and represents that he or she is familiar with the terms and provisions thereof, and
hereby accepts this Option subject to all of the terms and provisions thereof. Optionee has
reviewed the Plan (including any applicable appendixes thereunder) and this Option Agreement in
their entirety, has had an opportunity to obtain the advice of counsel prior to executing this
Option and fully understands all provisions of the Option. Optionee hereby agrees to accept as
binding, conclusive and final all decisions or interpretations of the Administrator upon any
questions arising under the Plan (including any applicable appendixes thereunder) or this Option.
Optionee further agrees to notify the Company upon any change in the residence address indicated
below.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Company (and not Optionee&#146;s employer) is granting the Option. The Company will
administer the Plan from outside Optionee&#146;s country of residence and that United States of America
law will govern all Options granted under the Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;That benefits and rights provided under the Plan are wholly discretionary and, although
provided by the Company, do not constitute regular or periodic payments. The benefits and rights
provided under the Plan are not to be considered part of Optionee&#146;s salary or compensation for
purposes of calculating any severance, resignation, redundancy or other end of service payments,
vacation, bonuses, long-term service awards, indemnification, pension or retirement benefits, or
any other payments, benefits or rights of any kind. Optionee waives any and all rights to
compensation or
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">damages as a result of the termination of employment with the Company for any reason
whatsoever insofar as those rights result or may result from:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;the loss or diminution in value of such rights under the Plan, or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;Optionee ceases to have any rights under, or ceases to be entitled to any rights under
the Plan as a result of such termination.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The grant of the Option, and any future grant of Options under the Plan is entirely
voluntary, and at the complete discretion of the Company. Neither the grant of the Option nor any
future grant of an Option by the Company will be deemed to create any obligation to grant any
further Options, whether or not such a reservation is explicitly stated at the time of such a
grant. The Company has the right, at any time to amend, suspend or terminate the Plan (including
any applicable appendixes thereunder).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;The Plan will not be deemed to constitute, and will not be construed by Optionee to
constitute, part of the terms and conditions of employment, and that the Company will not incur any
liability of any kind to Optionee as a result of any change or amendment, or any cancellation, of
the Plan at any time.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Participation in the Plan will not be deemed to constitute, and will not be deemed by
Optionee to constitute, an employment or labor relationship of any kind with the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;By entering into this Option Agreement, and as a condition of the grant of the Option,
Optionee consents to the collection, use, and transfer of personal data as described in this
subsection to the full extent permitted by and in full compliance with Applicable Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;Optionee understands that the Company and its Subsidiaries hold certain personal
information about the Optionee, including, but not limited to, name, home address and telephone
number, date of birth, social insurance number, salary, nationality, job title, any Shares or
directorships held in the Company, details of all Options or other entitlement to Shares awarded,
canceled, exercised, vested, unvested, or outstanding in Optionee&#146;s favor, for the purpose of
managing and administering the Plan (&#147;Data&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;Optionee further understands that the Company and/or its Subsidiaries will transfer Data
among themselves as necessary for the purposes of implementation, administration, and management of
Optionee&#146;s participation in the Plan, and that the Company and/or its Subsidiary may each further
transfer Data to any third parties assisting the Company in the implementation, administration, and
management of the Plan (&#147;Data Recipients&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;Optionee understands that these Data Recipients may be located in Optionee&#146;s country of
residence or elsewhere, such as the United States. Optionee authorizes the Data Recipients to
receive, possess, use, retain, and transfer Data in electronic or other form, for the purposes of
implementing, administering, and managing Optionee&#146;s participation in the Plan, including any
transfer of such Data, as may be required for the administration of the Plan and/or the subsequent
holding of Shares on Optionee&#146;s behalf, to a broker or third party with whom the Shares acquired on
exercise may be deposited.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-5-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;Optionee understands that Optionee may, at any time, review the Data, request that any
necessary amendments be made to it, or withdraw Optionee&#146;s consent herein in writing by contacting
the Company. Optionee further understands that withdrawing consent may affect Optionee&#146;s ability
to participate in the Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;Optionee has received the terms and conditions of this Option Agreement and any other
related communications, and Optionee consents to having received these documents in English.
<U><B>Je reconnais express&#233;ment par les pr&#233;sentes, que je comprends et parle parfaitement la langue
anglaise, que j&#146;ai eu le temps n&#233;cessaire pour enti&#232;rement lire et parfaitement comprendre le
pr&#233;sent contrat ainsi que l&#146;ensemble des documents et annexes s&#146;y aff&#233;rant et que j&#146;ai eu
l&#146;opportunit&#233; de m&#146;en entretenir avec les conseils de mon choix.</B></U> (<I>I represent that I perfectly
speak and understand English language, that I had enough time to review and understand this
agreement as all the related documents and appendix and that I had the opportunity to obtain advice
from the counsels of my choice).</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<U>Entire Agreement; Governing Law</U>. The Plan is incorporated herein by reference.
The Plan and this Option Agreement constitute the entire agreement of the parties with respect to
the subject matter hereof and supersede in their entirety all prior undertakings and agreements of
the Company and Optionee with respect to the subject matter hereof, and may not be modified
adversely to the Optionee&#146;s interest except by means of a writing signed by the Company and
Optionee. This Option Agreement is governed by the internal substantive laws but not the choice of
law rules of the State of California.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;<U>No Guarantee of Continued Service</U>. OPTIONEE ACKNOWLEDGES AND AGREES THAT THE
VESTING OF SHARES PURSUANT TO THE VESTING SCHEDULE HEREOF IS EARNED ONLY BY CONTINUING AS A SERVICE
PROVIDER AT THE WILL OF THE COMPANY OR THE PARENT OR SUBSIDIARY OF THE COMPANY EMPLOYING OR
RETAINING OPTIONEE (NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS OPTION OR ACQUIRING
SHARES HEREUNDER). OPTIONEE FURTHER ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT, THE TRANSACTIONS
CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR
IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE VESTING PERIOD, FOR ANY
PERIOD, OR AT ALL, AND SHALL NOT INTERFERE IN ANY WAY WITH OPTIONEE&#146;S RIGHT OR THE RIGHT OF THE
COMPANY (OR THE PARENT OR SUBSIDIARY OF THE COMPANY EMPLOYING OR RETAINING OPTIONEE) TO TERMINATE
OPTIONEE&#146;S RELATIONSHIP AS A SERVICE PROVIDER AT ANY TIME, WITH OR WITHOUT CAUSE.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><I>&#091;Signature Page Follows&#093;</I>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-6-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Optionee acknowledges receipt of a copy of the Plan (including Appendix&nbsp;B attached thereto)
and represents that he or she is familiar with the terms and provisions thereof, and hereby accepts
this Option subject to all of the terms and provisions thereof. Optionee has reviewed the Plan and
this Option in their entirety, has had an opportunity to obtain the advice of counsel prior to
executing this Option and fully understands all provisions of the Option. Optionee hereby agrees
to accept as binding, conclusive and final all decisions or interpretations of the Administrator
upon any questions arising under the Plan or this Option. Optionee further agrees to notify the
Company upon any change in the residence address indicated below.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">OPTIONEE:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">FLUIDIGM CORPORATION</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#091;Name&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Residence Address:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT A</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>1999 STOCK OPTION PLAN<BR>
EXERCISE NOTICE</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Fluidigm Corporation<BR>
Attn: President<BR>
7000 Shoreline Court<BR>
Suite&nbsp;100<BR>
South San Francisco, CA 94080

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Exercise of Option</U>. Effective as of today, <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, <U>&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</U>, the undersigned
(&#147;Optionee&#148;) hereby elects to exercise Optionee&#146;s option (the &#147;Option&#148;) to purchase <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
shares of the Common Stock (the &#147;Shares&#148;) of Fluidigm Corporation (the &#147;Company&#148;) under and
pursuant to the 1999 Stock Option Plan, including any applicable appendixes thereunder
(collectively, the &#147;Plan&#148;), and the Stock Option Agreement dated &#091;Grant Date&#093;
(the&nbsp;&#147;Option&nbsp;Agreement&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Delivery of Payment</U>. Optionee herewith delivers to the Company the full purchase
price of the Shares, as set forth in the Option Agreement. Should any tax or social contribution
be due by the Company (or Optionee&#146;s employer) due to the exercise of the Option or the disposition
of the Shares, Optionee hereby agrees that the corresponding amount may be withheld on the proceeds
due to Optionee from any sale of the Shares by the broker previously selected by the Company to be
used by Optionee and such amount shall be directly paid to the Company so that the Company may pay
the relevant taxing authorities any amounts due.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Representations of Optionee</U>. Optionee acknowledges that Optionee has received,
read and understood the Plan and the Option Agreement and agrees to abide by and be bound by their
terms and conditions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Rights as Stockholder</U>. Until the issuance of the Shares (as evidenced by the
appropriate entry on the books of the Company or of a duly authorized transfer agent of the
Company), no right to vote or receive dividends or any other rights as a stockholder shall exist
with respect to the optioned stock, notwithstanding the exercise of the Option. The Shares shall
be issued to the Optionee as soon as practicable after the Option is exercised. No adjustment
shall be made for a dividend or other right for which the record date is prior to the date of
issuance except as provided in Section&nbsp;11 of the Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Company&#146;s Right of First Refusal</U>. Before any Shares held by Optionee or any
transferee (either being sometimes referred to herein as the &#147;Holder&#148;) may be sold or otherwise
transferred (including transfer by gift or operation of law), the Company or its assignee(s) shall
have a right of first refusal to purchase the Shares on the terms and conditions set forth in this
Section&nbsp;(the &#147;Right of First Refusal&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Notice of Proposed Transfer</U>. The Holder of the Shares shall deliver to the
Company a written notice (the &#147;Notice&#148;) stating: (i)&nbsp;the Holder&#146;s bona fide intention to sell or
otherwise transfer such Shares; (ii)&nbsp;the name of each proposed purchaser or other transferee
(&#147;Proposed Transferee&#148;); (iii)&nbsp;the number of Shares to be transferred to each Proposed Transferee;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">and (iv)&nbsp;the bona fide cash price or other consideration for which the Holder proposes to
transfer the Shares (the &#147;Offered Price&#148;), and the Holder shall offer the Shares at the Offered
Price to the Company or its assignee(s).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Exercise of Right of First Refusal</U>. At any time within thirty (30)&nbsp;days after
receipt of the Notice, the Company and/or its assignee(s) may, by giving written notice to the
Holder, elect to purchase all, but not less than all, of the Shares proposed to be transferred to
any one or more of the Proposed Transferees, at the purchase price determined in accordance with
subsection&nbsp;(c)&nbsp;below.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Purchase Price</U>. The purchase price (&#147;Purchase Price&#148;) for the Shares purchased by
the Company or its assignee(s) under this Section&nbsp;shall be the Offered Price. If the Offered Price
includes consideration other than cash, the cash equivalent value of the non-cash consideration
shall be determined by the Board of Directors of the Company in good faith.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Payment</U>. Payment of the Purchase Price shall be made, at the option of the
Company or its assignee(s), in cash (by check), by cancellation of all or a portion of any
outstanding indebtedness of the Holder to the Company (or, in the case of repurchase by an
assignee, to the assignee), or by any combination thereof within 30&nbsp;days after receipt of the
Notice or in the manner and at the times set forth in the Notice.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Holder&#146;s Right to Transfer</U>. If all of the Shares proposed in the Notice to be
transferred to a given Proposed Transferee are not purchased by the Company and/or its assignee(s)
as provided in this Section, then the Holder may sell or otherwise transfer such Shares to that
Proposed Transferee at the Offered Price or at a higher price, provided that such sale or other
transfer is consummated within 120&nbsp;days after the date of the Notice, that any such sale or other
transfer is effected in accordance with any applicable securities laws and that the Proposed
Transferee agrees in writing that the provisions of this Section&nbsp;shall continue to apply to the
Shares in the hands of such Proposed Transferee. If the Shares described in the Notice are not
transferred to the Proposed Transferee within such period, a new Notice shall be given to the
Company, and the Company and/or its assignees shall again be offered the Right of First Refusal
before any Shares held by the Holder may be sold or otherwise transferred.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U>Exception for Certain Family Transfers</U>. Anything to the contrary contained in
this Section&nbsp;notwithstanding, the transfer of any or all of the Shares during the Optionee&#146;s
lifetime or on the Optionee&#146;s death by will or intestacy to the Optionee&#146;s immediate family or a
trust for the benefit of the Optionee&#146;s immediate family shall be exempt from the provisions of
this Section. &#147;Immediate Family&#148; as used herein shall mean spouse, lineal descendant or
antecedent, father, mother, brother or sister. In such case, the transferee or other recipient
shall receive and hold the Shares so transferred subject to the provisions of this Section, and
there shall be no further transfer of such Shares except in accordance with the terms of this
Section.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <U>Termination of Right of First Refusal</U>. The Right of First Refusal shall terminate
as to any Shares upon the first sale of Common Stock of the Company to the general public pursuant
to a registration statement filed with and declared effective by the Securities and Exchange
Commission under the Securities Act of 1933, as amended.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Tax Consultation</U>. Optionee understands that Optionee may suffer adverse tax
consequences as a result of Optionee&#146;s purchase or disposition of the Shares. Optionee represents
that Optionee has consulted with any tax consultants Optionee deems advisable in connection with
the purchase or disposition of the Shares and that Optionee is not relying on the Company for any
tax advice.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Restrictive Legends and Stop-Transfer Orders</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Legends</U>. Optionee understands and agrees that the Company shall cause the legends
set forth below or legends substantially equivalent thereto, to be placed upon any certificate(s)
evidencing ownership of the Shares together with any other legends that may be required by the
Company or by state or federal securities laws:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933 (THE &#147;ACT&#148;) AND MAY NOT BE OFFERED, SOLD OR
OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL
REGISTERED UNDER THE ACT OR, IN THE OPINION OF COMPANY COUNSEL
SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR
TRANSFER, PLEDGE OR HYPOTHECATION IS IN COMPLIANCE THEREWITH.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN
RESTRICTIONS ON TRANSFER AND RIGHT OF FIRST REFUSAL OPTIONS HELD BY
THE ISSUER OR ITS ASSIGNEE(S) AS SET FORTH IN THE EXERCISE NOTICE
BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY OF
WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER. SUCH
TRANSFER RESTRICTIONS AND RIGHT OF FIRST REFUSAL ARE BINDING ON
TRANSFEREES OF THESE SHARES.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">THE SHARES REPRESENTED BY THIS CERTIFICATE MAY NOT BE TRANSFERRED,
ASSIGNED OR HYPOTHECATED IN ANY MANNER OTHER THAN BY WILL OR BY THE
LAWS OF DESCENT OR DISTRIBUTION BEFORE THE DATE THREE (3)&nbsp;YEARS AFTER
THE INITIAL EXERCISE DATE, AS SUCH TERM IS DEFINED IN THE STOCK OPTION
AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES,
A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER.
SUCH TRANSFER RESTRICTIONS ARE BINDING ON TRANSFEREES OF THESE
SHARES.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS
ON TRANSFER FOR A PERIOD NOT TO EXCEED 180 DAYS FOLLOWING THE
EFFECTIVE DATE OF UNDERWRITTEN PUBLIC OFFERING OF THE
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 30px; text-indent: -0px">COMPANY&#146;S SECURITIES AND MAY NOT BE SOLD OR OTHERWISE DISPOSED OF BY
THE HOLDER WITHOUT THE CONSENT OF THE COMPANY OR THE MANAGING
UNDERWRITER.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Stop-Transfer Notices</U>. Optionee agrees that, in order to ensure compliance with
the restrictions referred to herein, the Company may issue appropriate &#147;stop transfer&#148; instructions
to its transfer agent, if any, and that, if the Company transfers its own securities, it may make
appropriate notations to&nbsp;the same effect in its own records.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Refusal to Transfer</U>. The Company shall not be required (i)&nbsp;to transfer on its
books any Shares that have been sold or otherwise transferred in violation of any of the provisions
of this Exercise Notice or (ii)&nbsp;to treat as owner of such Shares or to accord the right to vote or
pay dividends to any purchaser or other transferee to whom such Shares shall have been so
transferred.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Successors and Assigns</U>. The Company may assign any of its rights under this
Exercise Notice to single or multiple assignees, and the terms and conditions of this Exercise
Notice shall inure to the benefit of the successors and assigns of the Company. Subject to the
restrictions on transfer herein set forth, the terms and conditions of this Exercise Notice shall
be binding upon Optionee and his or her heirs, executors, administrators, successors and assigns.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>Interpretation</U>. Any dispute regarding the interpretation of this Exercise Notice
shall be submitted by Optionee or by the Company forthwith to the Administrator which shall review
such dispute at its next regular meeting. The resolution of such a dispute by the Administrator
shall be final and binding on all parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U>Governing Law; Severability</U>. This Exercise Notice is governed by the internal
substantive laws, but not the choice of law rules, of the State of California.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<U>Entire Agreement</U>. The Plan and Option Agreement are incorporated herein by
reference. This Exercise Notice, the Plan, the Restricted Stock Purchase Agreement, the Option
Agreement and the Investment Representation Statement constitute the entire agreement of the
parties with respect to the subject matter hereof and supersede in their entirety all prior
undertakings and agreements of the Company and Optionee with respect to the subject matter hereof,
and may not be modified adversely to the Optionee&#146;s interest except by means of a writing signed by
the Company and Optionee.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U><B>Je reconnais express&#233;ment par les pr&#233;sentes, que je comprends et parle parfaitement la
langue anglaise, que j&#146;ai eu le temps n&#233;cessaire pour enti&#232;rement lire et parfaitement comprendre
le pr&#233;sent contrat ainsi que l&#146;ensemble des documents et annexes s&#146;y aff&#233;rant et que j&#146;ai eu
l&#146;opportunit&#233; de m&#146;en entretenir avec les conseils de mon choix.</B></U> (<I>I represent that I perfectly
speak and understand English language, that I had enough time to review and understand this
agreement as all the related documents and appendix and that I had the opportunity to obtain advice
from the counsels of my choice).</I>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">Submitted by:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left">Accepted by:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">OPTIONEE:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left">FLUIDIGM CORPORATION</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#091;Name&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Address:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Date Received:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT B</B></U>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B>FLUIDIGM CORPORATION</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B>1999 STOCK OPTION PLAN</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>ESCROW PROVISIONS &#150; FRENCH EMPLOYEES</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<U>Option</U>. As set forth in the Notice of Grant, you have been granted the Option
under the Plan. The Shares acquired upon exercise of the Option shall be held by the Company under
these Escrow Provisions in an account in your name.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<U>Legal and Equitable Title</U>. Legal and equitable title to the Option and any cash
or securities acquired pursuant thereto, shall remain with you at all times, notwithstanding that
such items may be held by the Company pursuant to these Escrow Instructions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;<U>Exercise of Option</U>. You may instruct the Company to exercise the Option on your
behalf at such time or times as permitted by the Notice of Grant, the Stock Option Agreement and
the Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;<U>Proceeds of Exercise</U>. Shares acquired upon exercise of the Option shall be
retained in this Escrow until the date three (3)&nbsp;years from the Initial Exercise Date (the &#147;Holding
Period&#148;); provided, however, that the duration of this restriction on sale shall be automatically
adjusted to conform with any changes to the holding period required for favorable tax and social
security treatment under Applicable Laws, as defined in the Plan. Upon the expiration of the
Holding Period, you may elect to keep the Shares in your account under these Escrow Provisions or
have them distributed to you as soon as administratively feasible. You may elect to keep any
proceeds from any sale of such Shares, made following the expiration of the Holding Period, in your
account under these Escrow Provisions or to have them distributed to you within ten (10)&nbsp;business
days of the sale, pursuant to such channels as the Company reasonably determines appropriate.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;<U>Powers of Company</U>. The Company may take any and all actions, and is hereby
granted such powers and discretion, as may appear necessary or proper to comply with the Applicable
Laws and to effectuate and carry out the terms and purposes of this Escrow, including, but not
limited to, the power to exercise the Option and hold or dispose of the proceeds of such exercise
in accordance with the terms of these Escrow Provisions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;<U>Limitation of Liability</U>. The Company shall not be liable for any damage caused by
the exercise of its discretion as authorized by these Escrow Provisions for any reason, except
gross negligence or willful misconduct. The Company shall not be liable for honest mistakes of
judgment or for losses or liabilities due to such honest mistakes of judgment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;<U>Costs and Expenses of this Escrow</U>. All costs and expenses of these Escrow
Provisions shall be borne by the Company.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;<U>Governing Law</U>. This Escrow shall be administered in the State of California, and
its validity, construction and all rights hereunder, shall be governed by the laws of the State of
California; provided, however, that all matters affecting the title, ownership and transferability
of any security, whether created or held hereunder, shall be governed by all applicable federal,
state, or foreign securities laws.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">OPTIONEE
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">FLUIDIGM CORPORATION
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Print Name
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Residence Address</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT C</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>INVESTMENT REPRESENTATION STATEMENT</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="70%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">OPTIONEE &nbsp;&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;NAME&#093;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">COMPANY&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">FLUIDIGM CORPORATION</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">SECURITY&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">COMMON STOCK</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">AMOUNT&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">DATE
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the purchase of the above-listed Securities, the undersigned Optionee
represents to the Company the following:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Optionee is aware of the Company&#146;s business affairs and financial condition and has
acquired sufficient information about the Company to reach an informed and knowledgeable decision
to acquire the Securities. Optionee is acquiring these Securities for investment for Optionee&#146;s
own account only and not with a view to, or for resale in connection with, any &#147;distribution&#148;
thereof within the meaning of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Optionee acknowledges and understands that the Securities constitute &#147;restricted
securities&#148; under the Securities Act and have not been registered under the Securities Act in
reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the
bona fide nature of Optionee&#146;s investment intent as expressed herein. In this connection, Optionee
understands that, in the view of the Securities and Exchange Commission, the statutory basis for
such exemption may be unavailable if Optionee&#146;s representation was predicated solely upon a present
intention to hold these Securities for the minimum capital gains period specified under tax
statutes, for a deferred sale, for or until an increase or decrease in the market price of the
Securities, or for a period of one year or any other fixed period in the future. Optionee further
understands that the Securities must be held indefinitely unless they are subsequently registered
under the Securities Act or an exemption from such registration is available. Optionee further
acknowledges and understands that the Company is under no obligation to register the Securities.
Optionee understands that the certificate evidencing the Securities will be imprinted with a legend
which prohibits the transfer of the Securities unless they are registered or such registration is
not required in the opinion of counsel satisfactory to the Company, and with any other legend
required under applicable state securities laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Optionee is familiar with the provisions of Rule&nbsp;701 and Rule&nbsp;144, each promulgated under
the Securities Act, which, in substance, permit limited public resale of &#147;restricted securities&#148;
acquired, directly or indirectly from the issuer thereof, in a non-public offering subject to the
satisfaction of certain conditions. Rule&nbsp;701 provides that if the issuer qualifies under Rule&nbsp;701
at the time of the grant of the Option to the Optionee, the exercise will be exempt from
registration under the Securities Act. In the event the Company becomes subject to the reporting
requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, ninety (90)&nbsp;days
thereafter (or such longer period as any market stand-off agreement may require) the Securities
exempt under Rule&nbsp;701 may be resold, subject to the satisfaction of certain of the conditions
specified by Rule&nbsp;144, including:
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(1)&nbsp;the resale being made through a broker in an unsolicited &#147;broker&#146;s transaction&#148; or in
transactions directly with a market maker (as said term is defined under the Securities Exchange
Act of 1934); and, in the case of an affiliate, (2)&nbsp;the availability of certain public information
about the Company, (3)&nbsp;the amount of Securities being sold during any three month period not
exceeding the limitations specified in Rule&nbsp;144(e), and (4)&nbsp;the timely filing of a Form&nbsp;144, if
applicable.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event that the Company does not qualify under Rule&nbsp;701 at the time of grant of the
Option, then the Securities may be resold in certain limited circumstances subject to the
provisions of Rule&nbsp;144, which requires the resale to occur not less than one year after the later
of the date the Securities were sold by the Company or the date the Securities were sold by an
affiliate of the Company, within the meaning of Rule&nbsp;144; and, in the case of acquisition of the
Securities by an affiliate, or by a non-affiliate who subsequently holds the Securities less than
two years, the satisfaction of the conditions set forth in sections&nbsp;(1), (2), (3)&nbsp;and (4)&nbsp;of the
paragraph immediately above.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Optionee further understands that in the event all of the applicable requirements of
Rule&nbsp;701 or 144 are not satisfied, registration under the Securities Act, compliance with
Regulation&nbsp;A, or some other registration exemption will be required; and that, notwithstanding the
fact that Rules&nbsp;144 and 701 are not exclusive, the Staff of the Securities and Exchange Commission
has expressed its opinion that persons proposing to sell private placement securities other than in
a registered offering and otherwise than pursuant to Rules&nbsp;144 or 701 will have a substantial
burden of proof in establishing that an exemption from registration is available for such offers or
sales, and that such persons and their respective brokers who participate in such transactions do
so at their own risk. Optionee understands that no assurances can be given that any such other
registration exemption will be available in such event.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Signature of Optionee:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;Name&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>14
<FILENAME>f39432orexv10w4.htm
<DESCRIPTION>EXHIBIT 10.4
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w4</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#091;***&#093; Indicates
text has been omitted from this Exhibit pursuant to a confidential treatment
request and has been filed separately with the Securities and Exchange Commission.
</DIV>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.4</B>
</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="65%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>2020.LICI.001.B</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>California Institute of Technology</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SECOND AMENDED AND RESTATED LICENSE AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><FONT style="font-variant: SMALL-CAPS">This</font> SECOND AMENDED AND RESTATED LICENSE AGREEMENT</B>
(&#147;Agreement&#148;), effective May&nbsp;1, 2000 (the &#147;Effective Date&#148;) with a second restatement
date as of May&nbsp;1, 2004 (the &#147;Second Restatement Date&#148;), between <FONT style="font-variant: SMALL-CAPS"><B>California Institute
Of Technology</B>, </FONT>1200 East California Boulevard, Pasadena, California 91125
(&#147;Caltech&#148;) and <FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B>,</FONT> 7100 Shoreline Court, South San Francisco,
California 94080 (formerly Mycometrix Corporation) (&#147;Licensee&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant: SMALL-CAPS"><B>Whereas</B></FONT>, Caltech has been engaged in basic research in the field of microfluidics;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant: SMALL-CAPS"><B>Whereas</B></FONT>, that research led to the United States patents, patent applications and
other inventions listed in Exhibit&nbsp;A, which are owned, solely or jointly, by Caltech;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant: SMALL-CAPS"><B>Whereas</B>, </FONT>Licensee is desirous of obtaining, and Caltech wishes to grant to
Licensee, an exclusive license (or the maximum rights Caltech can grant) to the Licensed
Patents (as defined in Section&nbsp;1.5) and Improvements thereof in the Field (as defined in
Sections&nbsp;1.4 and 1.3, respectively) and an exclusive license to the Technology (as
defined in Section&nbsp;1.9);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant: SMALL-CAPS"><B>Whereas</B>, </FONT>the Caltech and Licensee have entered into a prior License
Agreement made as of May&nbsp;1, 2000, and an Amended and Restated License Agreement made as
of June&nbsp;1, 2002, which the parties now wish to further amend and restate as set forth
herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant: SMALL-CAPS"><B>Now, Therefore</B></FONT>, the parties agree as follows:
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 1</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>DEFINITIONS</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 <B>
 &#147;Affiliate&#148; </B>shall mean, with respect to Licensee, any entity which controls, is
controlled by or is under common control with Licensee. An entity shall be regarded as in control
of another entity for purposes of this definition if it owns or
controls fifty percent (50%) or
more of the shares of the subject entity entitled to vote in the election of directors (or, in the
case of an entity that is not a corporation, for the election of the corresponding managing
authority). &#147;Affiliate&#148; shall mean, with respect to Caltech, any research entity which is operated
or managed as a facility under Caltech.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2  <B>
&#147;Deductible Expenses&#148; </B>means (i)&nbsp;all trade, cash and quantity credits, discounts, refunds
or government rebates; (ii)&nbsp;amounts for claims, allowances or credits for returns, retroactive
price reductions, or chargebacks; (iii)&nbsp;packaging, handling fees and prepaid freight, sales taxes,
duties and other governmental charges (including value added tax); and (iv)&nbsp;provisions for
uncollectible accounts determined in accordance with reasonable accounting practices, consistently
applied to all products of the selling party. For the removal of doubt, Net Sales shall not
include sales by Licensee to its Affiliates for resale, provided that if Licensee sells a Licensed
Product to an Affiliate for resale, Net Sales shall include the amounts invoiced by such Affiliate
to third parties on the resale of such Licensed Product. In the event that Licensee grants a
sublicense hereunder, and receives payments based upon the Sublicensee&#146;s sales of Licensed
Products, Licensee may upon notice to Caltech modify this definition of &#147;Net Sales&#148; for purposes
of calculating royalties payable to Caltech on such Sublicensee&#146;s sales to be the same as the
definition of &#147;Net Sales&#148; on which such royalties to Licensee are calculated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3  <B>
&#147;Field&#148; </B>means &#091;***&#093; </DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->- 2 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">[***]
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.4 <B>&#147;Improvements&#148; </B>shall mean all Caltech rights (whether or not Caltech has sole or joint
rights) in any improvement or invention conceived and reduced to practice or otherwise developed
in or arising from research in the Field as conducted by
Dr.&nbsp;Stephen Quake, researchers of the Quake laboratory, or in
collaboration with members of the Frances Arnold or Axel Scherer
laboratories, whether invented solely by Caltech researchers or
jointly with (i)&nbsp;Licensee or (ii)&nbsp;other researchers without
an obligation of assignment to Caltech.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.5 <B>&#147;Licensed Patents&#148; </B>means the patent applications listed in Exhibit&nbsp;A hereto; any patents
issuing on such patent applications, all divisionals, continuations, continuations-in-part,
patents of addition, substitutions, registrations, reissues, reexaminations or extensions of any
kind with respect to any of the existing patents and any foreign counterparts of such patent
applications and patents, and Improvements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.6 <B>&#147;Licensed Product&#148; </B>means products covered by a Valid Claim of a Licensed Patent in the
country in which such product is sold or products in which the Technology is utilized.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.7 <B>&#147;Net Sales&#148; </B>means the total amount invoiced to third parties on sales of Licensed
Products for which royalties are due under Article&nbsp;4 below, less, to the extent allocable to such
invoiced amounts, Deductible Expenses.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.8 <B>&#147;Sublicensee&#148; </B>shall mean any non-Affiliate third party to whom Licensee has granted the
right under the Licensed Patents and Technology to manufacture and sell Licensed Products, with
respect to Licensed Products made and sold by such third party.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 3 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.9 <B>&#147;Technology&#148; </B>means all proprietary information, know-how, procedures, methods, prototypes,
designs, technical data, reports, and data owned by Caltech that are
necessary or useful in the development of products in the Field covered by any issued patent or
pending patent application within the Licensed Patents, and which relate to such products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.10 <B>&#147;Valid Claim&#148; </B>means a claim of an issued and unexpired patent or a claim of a pending
patent application within the Licensed Patents which has not been held unpatentable, invalid or
unenforceable by a court or other government agency of competent jurisdiction and
has not been admitted to be invalid or unenforceable through reissue, re-examination, disclaimer
or otherwise; provided, however, that if the holding of such court or agency is later reversed by
a court or agency with overriding authority, the claim shall be reinstated as a Valid Claim with
respect to Net Sales made after the date of such reversal. Notwithstanding the foregoing
provisions of this Section&nbsp;1.10, if a claim of a pending patent application within the Licensed
Patents has not issued as a claim of an issued patent within the Licensed Patents, within five (5)
years after the filing date from which such claim takes priority, such pending claim shall not be
a Valid Claim for purposes of this Agreement.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 2</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>PATENT LICENSE GRANT</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 Caltech hereby grants to Licensee an exclusive, royalty-bearing, worldwide license, with
the right to grant and authorize sublicenses, under the Licensed Patents and Technology to make,
have made, use, import, offer for sale and sell Licensed Products, practice any method or
procedure and otherwise exploit the Licensed Patents and Technology.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 These licenses are subject to: (a)&nbsp;the reservation of Caltech&#146;s right to make, have made,
and use Licensed Products for noncommercial educational and research purposes, but not for sale or
other distribution to third parties; and (b)&nbsp;the rights of the U.S. Government under Title 35,
United States Code, Section&nbsp;200 et seq., including but not limited to the grant to the U.S.
government of a nonexclusive, nontransferrable, irrevocable, paid-up license to practice or have
practiced any invention conceived or first actually reduced to practice in the performance of work
for or on behalf of the U.S. Government throughout the world. These licenses are not
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 4 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">transferable by Licensee except as provided in Section&nbsp;16.4, but Licensee shall have the right to
grant non-exclusive or exclusive sublicenses hereunder, provided that:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;License shall include all its sublicensing income in Licensee&#146;s reports to
Caltech, as provided in Section&nbsp;9.2, and Licensee shall pay royalties thereon to Caltech
pursuant
to Section&nbsp;4.2 and 4.4;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Licensee shall furnish Caltech within thirty (30)&nbsp;days of the execution thereof, a true
and complete copy of each sublicense and any changes or additions thereto;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;License may grant sublicenses of no greater scope than the license granted under Section
2.1; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each sublicense granted by Licensee shall include provisions similar in all material
respects to those of Articles 6, 12, 15, 16 and Section&nbsp;2.2.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 3</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><b>IMPROVEMENTS</b>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 The parties acknowledge that Exhibit&nbsp;A includes all Improvements disclosed by Caltech to
Licensee between May&nbsp;1, 2000 and the Second Restatement Date, and elected by Licensee as of the
Second Restatement Date. Caltech shall notify Licensee in writing of Improvements made after the
Second Restatement Date and during the term of the Agreement. Upon receipt of an invention
disclosure constituting an Improvement, Licensee can elect to add such Improvement and any related
patent filings to Exhibit&nbsp;A hereof to be within the Licensed
Patents. Thereafter, Licensee shall
be responsible for patent prosecution and costs associated with such elected Improvement in
accordance with Article&nbsp;11 herein, as well as to issue additional stock pursuant to Section&nbsp;5.3.
No less than at each anniversary of the Second Restatement Date, Exhibit&nbsp;A shall be updated by the
parties to reflect the inclusion of all Improvements so elected, as well as updates on all
Licensed Patents.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->- 5 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 4</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>ROYALTIES</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 With respect to Licensed Products manufactured or sold by Licensee in a country in which
such manufacture or sale is covered by a Valid Claim of a Licensed Patent, Licensee agrees to pay
Caltech &#091;***&#093; of Net Sales of such Licensed Products wherein the Licensed
Products are instruments or apparatus directly used for the reading and/or analysis of data from
other Licensed Products, including microfluidic chips that are
Licensed Products, and &#091;***&#093; of Net Sales of Licensed Products by Licensee for all such other Licensed Products,
including microfluidic chips that are Licensed Products, Royalties due under this Section&nbsp;4.1 shall
be payable on a country-by-country and Licensed Product-by-Licensed Product basis until the
expiration of the last-to-expire issued Valid Claim covering such Licensed Product in such country.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 With respect to Licensed Products manufactured or sold by Sublicensees in a country in
which such manufacture or sale is covered by a Valid Claim of a Licensed Patent, Licensee agrees to
pay Caltech &#091;***&#093; of the revenues received by Licensee from Sublicensees&#146; Net Sales
of such Licensed Products wherein the Licensed Products are instruments or apparatus directly used
for the reading and/or analysis of data from other Licensed Products, including microfluidic chips
that are Licensed Products, and &#091;***&#093; of the revenues received by Licensee from
Sublicensees&#146; Net Sales of Licensed Products for all such other Licensed Products, including
microfluidic chips that are Licensed Products. Royalties due under this Section&nbsp;4.2 shall be
payable on a country-by-country and Licensed Product-by-Licensed Product basis until the expiration
of the last-to-expire issued Valid Claim covering such Licensed Product in such country.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3 With respect to Licensed Products manufactured or sold by Licensee in a country in which
such manufacture or sale is not covered by Valid Claim of a Licensed Patent but the Technology is
utilized, Licensee agrees to pay Caltech &#091;***&#093; of Net
Sales of such Licensed Products by Licensee, wherein the Licensed Products are instruments or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 6 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">apparatus directly used for the reading and/or analysis of data from other Licensed Products,
including microfluidic chips that are Licensed Products, and &#091;***&#093; of Net
Sales of Licensed Products by Licensee for all such other Licensed Products, including microfluidic
chips that are Licensed Products. Royalties due under this Section&nbsp;4.3 shall be payable on a
country-by-country and Licensed Product-by-Licensed Product basis for a period of &#091;***&#093;&nbsp;years
from the Effective Date or the issuance of a U.S. patent that covers the Licensed Product,
whichever first occurs.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4 With respect to Licensed Products manufactured or sold by Sublicensees in a country in
which such manufacture or sale is not covered by a Valid Claim of a Licensed Patent but the
Technology is utilized, Licensee agrees to pay Caltech &#091;***&#093; of the revenues received
by Licensee from Sublicensees&#146; Net Sales of such Licensed Products wherein the Licensed Products
are instruments or apparatus directly used for the reading and/or analysis of data from other
Licensed Products, including microfluidic chips that are Licensed Products, and &#091;***&#093; of the revenues received by Licensee from
Sublicensees&#146; Net Sales of
Licensed Products for all such other Licensed Products, including microfluidic chips that are
Licensed Products. Royalties due under this Section&nbsp;4.4 shall be payable on a country-by-country
and Licensed Product-by-Licensed Product basis for a period of
&#091;***&#093; years from the Effective
Date or the issuance of a U.S. patent that covers the Licensed Product, whichever first occurs.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.5 Notwithstanding the above, it is understood and agreed that Caltech shall not be entitled
to any share of amounts received by Licensee for equity, debt, pilot studies, to support research
or development activities to be undertaken by Licensee, research and development or other
performance based milestones, the achievement by Licensee or Sublicensee of specified milestones
or benchmarks relating to the development of Licensed Products, the license or sublicense of any
intellectual property other than the Licensed Patents, reimbursement for patent or other expenses,
or with respect to products other than Licensed Products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.6 In the event that a Licensed Product is sold in combination with one or more other
products or other items that are not Licensed Products, Net Sales for such combination products
will be reasonably calculated on a country-by-country and Licensed Product-by-Licensed
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 7 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Product basis by Licensee by multiplying the Net Sales of that combination by a fraction equal to
the relative value of the combination attributable to the Licensed Product, in relation to the
relative value of the combination, as reasonably determined by Licensee in good faith. In addition,
in the event that a Licensed Product is not sold in combination with one or more other products or
other items that are not Licensed Products, but instead comprises multiple components, some of
which would constitute a Licensed Product if sold separately (each, a
&#147;Licensed Component&#148;), and
the others would not constitute a Licensed Product if sold separately, then Net Sales for such
Licensed Product will be calculated by multiplying the Net Sales of such Licensed Product by the
fraction A/B, where A is the gross selling price of the Licensed Component sold separately and B is
the gross selling price of such Licensed Product. If no such separate sales are made by Licensee,
its Affiliate or Sublicensee, Net Sales for such Licensed Product shall be calculated by
multiplying Net Sales of such Licensed Product by the fraction C/(C&#043;D), where C is the fully
allocated cost of the Licensed Component and D is the fully allocated cost of the other components.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.7 Commencing on January&nbsp;1, 2004, and continuing for each anniversary thereof during the term
of this Agreement, if Licensee has not paid, during the preceding calendar year, a minimum of &#091;***&#093; in royalties under Sections&nbsp;4.1, 4.2, 4.3, and 4.4, Licensee agrees
to pay, on or before March 1 of that calendar year, an additional royalty for the prior calendar
year equal to the difference between &#091;***&#093; and any lower amount paid
under Sections&nbsp;4.1, 4.2, 4.3, and 4.4 for the prior calendar year.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.8 In the event Licensee or Sublicensee becomes obligated to pay amounts to a third party
with respect to a Licensed Product for patent rights of a third party, Licensee may deduct
&#091;***&#093; of the amounts owing to such third party (prior to reductions) from the
amount owing to Caltech for such Licensed Product; provided, however, the amounts otherwise due to
Caltech shall not be so reduced by more than &#091;***&#093;.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.9 For the purpose of determining royalties payable under this Agreement, any royalties or
other revenues Licensee receives from Sublicensees in currencies other than U.S. dollars and any
Net Sales denominated in currencies other than U.S. dollars shall be converted
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 8 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">into U.S. dollars according to Licensee&#146;s reasonable standard internal conversion procedures,
including Licensee&#146;s standard internal rates and conversion schedule.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.10 No more than one royalty payment shall be due with respect to a sale of a particular
Licensed Product. No multiple royalties shall be payable because any Licensed Product, or its
manufacture, sale or use is covered by more than one Valid Claim in a given country. No royalty
shall be payable under this Article&nbsp;4 with respect to Licensed Products distributed for use in
research and/or development or as promotional samples or otherwise distributed without charge to
third parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.11 Any sublicenses granted by Licensee, including, without limitation, any nonexclusive
sublicenses, shall remain in effect in the event this license terminates pursuant to Article&nbsp;12;
provided, the financial obligations of each Sublicensee to Caltech shall be limited to the amounts
Licensee shall be obligated to pay Caltech for the activities of such Sublicensee pursuant to this
Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.12 Royalties due under this Article&nbsp;4 shall be payable on a country-by-country and Licensed
Product-by-Licensed Product basis until the expiration of the last-to-expire issued Valid Claim
covering such Licensed Product in such country, if the manufacture or sale of such Licensed Product
was at the time of the first commercial sale in such country covered
by a Valid Claim. Otherwise,
royalties due under this Article&nbsp;4 shall be payable on a country-by-country and Licensed
Product-by-Licensed Product basis until &#091;***&#093; whichever first occurs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.13 Notwithstanding the provisions of this Article&nbsp;4, no royalty shall be payable to Caltech
with respect to any sales of Licensed Products to the U.S. Government on sales made solely to
permit the U.S. Government to practice or have practiced or have practiced or sue on its behalf
any invention or process covered by the Licensed Patents.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 5</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>LICENSEE EQUITY INTEREST</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 In accordance with the License Agreement of May&nbsp;1, 2000, Licensee issued to Caltech, in
consideration of Licensee&#146;s receipt of the intangible property rights granted under
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->- 9 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">that License Agreement (which rights are carried forward herein), &#091;***&#093; shares of common stock of Licensee, pursuant to the terms of a reasonable and customary
stock issuance agreement. Further, it is acknowledged that, as partial consideration for entering
into the first Amended and Restated License Agreement of June&nbsp;1, 2002, with the reformation of the
initial License Agreement of May&nbsp;1, 2000 and the associated restatements and amendments (including,
but not limited to, an updated Exhibit&nbsp;A), Licensee issued to Caltech &#091;***&#093; shares of common stock of Licensee.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2 Caltech agrees that, in the event of any underwritten or public offering of
securities of Licensee or a Affiliate, Caltech shall comply with and agree to any reasonable
restriction on the transfer of equity interest, or any part thereof, imposed by an underwriter, and
shall perform all acts and sign all necessary documents required with respect thereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3 If Licensee wishes at its sole discretion to license hereunder any Improvements
disclosed by Caltech to Licensee during a twelve (12)&nbsp;month period beginning with June&nbsp;1,
2003,
and for each anniversary thereafter (each twelve month period will be referred to as an
&#147;Improvement Period&#148;), Licensee shall notify Caltech in
writing accordingly within thirty (30)&nbsp;days after the end of
each Improvement Period. For the first two (2)&nbsp;Improvement Periods,
Licensee agrees to issue to Caltech, in consideration of Licensee&#146;s election to receive
additional
intangible property rights to all Improvements disclosed to Licensee during an Improvement
Period, &#091;***&#093; shares of common stock of Licensee, pursuant to the terms of a
reasonable and customary stock issuance agreement. Thereafter, Licensee is hereby granted an
option by Caltech that Licensee can exercise during the final year of
the first two (2)&nbsp;Improvement Period on an annual basis on the same terms
and conditions. The consideration of this option was partially paid by the &#091;***&#093; shares granted by Licensee to Caltech as referenced in Section&nbsp;5.1 of this Agreement. Further,
it
is acknowledged that pursuant to the initial License Agreement of May
1, 2000 and the first
Amended and Restated License Agreement of June&nbsp;1, 2002, Licensee elected to receive
additional intangible property rights to Improvements disclosed to Licensee by Caltech during
May&nbsp;1, 2000 through May&nbsp;31, 2003, in consideration of the issuance to Caltech by Licensee of
&#091;***&#093; shares of common stock of Licensee (which represents the &#091;***&#093;
share grant under Section&nbsp;5.1 above and &#091;***&#093; shares pursuant to the
parties&#146;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->- 10 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Letter
Agreement dated June&nbsp;19, 2003, paragraph #3), receipt of which
shares Caltech hereby acknowledges.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 6</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>DUE DILIGENCE</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1 Licensee agrees to use commercially reasonable efforts to introduce commercial Licensed
Product(s) as soon as practical, consistent with sound and reasonable business practices and
judgments. Licensee shall be deemed to have satisfied its obligations under this Section if
Licensee has an ongoing and active research program or marketing program, as appropriate, directed
toward production and use of one or more Licensed Products. Any efforts of Licensee&#146;s Sublicensees
shall be considered efforts of Licensee for the sole purpose of determining Licensee&#146;s compliance
with its obligation under this Section.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2 After the first year from the Effective Date, Caltech shall have the right, no more often
than once each year, to require Licensee to report to Caltech in
writing on its progress in
introducing commercial Licensed Product(s) in the United States.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3 If Licensee is not fulfilling its obligations under Section&nbsp;6.1 with respect to the Field
and Caltech so notifies Licensee in writing, Caltech and Licensee shall negotiate in good faith
any additional efforts to be taken by Licensee. If the parties do not reach agreement within
ninety (90)&nbsp;days, the parties shall submit the issue to arbitration as provided in Article&nbsp;14 to
determine whether any additional efforts shall be required of Licensee. If subsequent to the
conclusion of such arbitration proceedings Licensee then fails to make any required efforts, and
does not remedy that failure within sixty (60)&nbsp;days after further written notice to Licensee,
Caltech may convert the license granted in Section&nbsp;2.1 to a nonexclusive license in any part of
the Field in which Licensee is not fulfilling its obligations under Section&nbsp;6.1, and the royalties
payable under this Agreement shall be reduced by [***] for Licensed Products
in the Field sold under such a nonexclusive license.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->- 11 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 7</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><b>INFRINGEMENT BY THIRD PARTY</b>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1 Both Caltech and
Licensee agree to notify the other in writing should either party become
aware of infringement of the Licensed Patents. Licensee, upon notice to Caltech, shall have the
sole right to initiate an action against the infringer at Licensee&#146;s expense, either in Licensee&#146;s
name or in Caltech&#146;s name if so required by law, Licensee shall have sole control of the action.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2 If Licensee,
its Affiliate or Sublicensee, distributor or other customer is sued by a
third party charging infringement of patent rights that dominate a claim of the Licensed Patents
or that cover the development, manufacture, use, distribution or sale of a Licensed Product,
Licensee will promptly notify Caltech. As between the parties to this Agreement, Licensee shall
have sole control of the defense in any such action(s).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3 If a declaratory
judgment action alleging invalidity unenforceability or
noninfringement of any of the Licensed Patents is brought against Licensee and/or Caltech,
Licensee may elect to have sole control of the action, and if
Licensee so elects it shall bear all the costs of the action. Licensee also may elect to undertake
and have sole control of the defense
of any interference, opposition or similar action with respect to the Licensed Patents providing
it bears all the costs of such action.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.4
In the event Licensee institutes a legal action pursuant to Section&nbsp;7.1, within thirty
(30)&nbsp;days after receipt of notice of Licensee&#146;s intent to institute such legal action,
Caltech shall
have the right to jointly prosecute such action and to fund up to
one-half (&#189;) the costs of
such
action. Caltech shall fully cooperate with and supply all assistance reasonably requested by
Licensee, including by using commercially reasonable efforts to have its employees testify
when
requested and to make available relevant records, papers, information, samples, specimens,
and
the like. Licensee shall bear the reasonable expenses incurred by Caltech in providing such
assistance and cooperation as is requested pursuant to this Section&nbsp;7.4. Licensee shall keep
Caltech reasonably informed of the progress of the legal action, and Caltech shall be
entitled to
be represented by counsel in connection with such legal action at its own expense. Licensee&#146;s
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->- 12 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">reasonable and customary expenses for such action (including attorneys&#146; fees and expert fees) shall
be fully creditable against royalties owed to Caltech hereunder, provided that in no one year shall
such expenses to be credited against more than [***] of royalty payments to Caltech.
Any remaining expenses may be carried over and credited against royalties owed in future years.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.5 Licensee shall have the light to settle any claims, but only upon terms and conditions
that are reasonably acceptable to Caltech. Should Licensee elect to abandon such an action other
than pursuant to a settlement with the alleged infringer that is reasonably acceptable to Caltech,
Licensee shall give timely notice to Caltech who, if it so desires, may continue the action;
provided, however, that the sharing of expenses and any recovery in such suit shall be as agreed
upon between the parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.6 Any amounts paid to Licensee by third parties as the result of an action pursuant to this
Article&nbsp;7 (such as in satisfaction of a judgment or pursuant to a settlement) shall first be
applied to reimbursement of the unreimbursed expenses (including attorneys&#146; fees and expert fees)
incurred by Licensee and then to the payment to Caltech of any royalties against which were
credited expenses of the action in accordance with Section&nbsp;7.4. Any remainder shall be divided
between the parties as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;To the extent the amount recovered reflects lost profits, Licensee shall retain the
remainder, less the amount of any royalties that would have been due Caltech on sales of Licensed
Product lost by Licensee as a result of the infringement had Licensee made such sales, provided
that (i)&nbsp;Licensee shall in any event retain at least [***] of the remainder; and (ii)
Caltech shall receive an amount equal to the royalties it would have received if such sales had
been made by Licensee, provided such amount shall in no event exceed [***] of the
remainder; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;To the extent the amount recovered does not reflect lost profits, such amount shall be
shared by Caltech and Licensee pro rata according to the respective percentages of costs borne by
each in such action; provided, however, that in no event shall Caltech receive less than
twenty-five percent (25%) of such amount.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->- 13 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 8</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>BENEFITS OF LITIGATION,</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>EXPIRATION OR ABANDONMENT</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.1 In a case where one or more patents or particular claims thereof within the
Licensed Patents expire, or are abandoned, or are declared invalid or unenforceable or
otherwise
construed by a court of last resort or by a lower court from whose decree no appeal is taken,
or
certiorari is not granted within the period allowed therefor, then the effect thereof
hereunder shall
be:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;that such patents or particular claims shall, as of the date of expiration or abandonment
or final decision as the case may be, cease to be included within the Licensed Patents for the
purpose of this Agreement;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;that such construction so placed upon the Licensed Patents by the court shall be followed
from and after the date of entry of the decision, and royalties shall
thereafter be payable by
Licensee only in accordance with such construction; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;In the event that Licensee challenges the validity of Licensed Patents, Licensee may not
cease paying royalties as of the date validity of the claims in issue are challenged, but rather
may cease paying royalties as to those claims only after a final adjudication of invalidity of
those claims.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.2 In the event that any of the contingencies provided for in Section&nbsp;8.1 occurs,
Caltech agrees to renegotiate in good faith with Licensee a reasonable royalty rate under the
remaining Licensed Patents which are unexpired and in effect and under which Licensee desires to
retain a License.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 9</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>RECORDS, REPORTS AND PAYMENTS</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.1 Licensee shall keep records and books of account in respect of all Licensed Products made
and sold by Licensee or its Affiliates under this Agreement and of royalties or other revenues
Licensee receives from Sublicensees other than Licensee&#146;s Affiliates for the sale
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->- 14 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of Licensed Products. Caltech shall have the right at its own cost, during Licensee&#146;s business
hours, no more often than annually, to have an independent certified public accounting firm of
nationally recognized standing to examine such records and books. Licensee shall keep the same for
at least three (3)&nbsp;years after it pays Caltech the royalties due for such Licensed Products and
require Licensee&#146;s Affiliates to do the same. The accounting firm shall disclose to Caltech only
whether or not the reports are correct and the amount of any
discrepancies. Caltech shall, and
shall cause its accounting firm to, not disclose to any third party any confidential information
learned through an examination of such records and books.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.2 Following
the first commercial sale of a Licensed Product, on or before the last day of
each February, May, August and November for so long as royalties are payable under this Agreement,
Licensee shall render to Caltech a report in writing, setting forth Net Sales and the number of
units of Licensed Products sold during the preceding calendar quarter by Licensee and its
Affiliates, and the royalties or other revenues received by Licensee from Net Sales of Licensed
Products made by Licensee&#146;s Sublicensees other than Affiliates during the preceding calendar
quarter. Each such report shall also set forth an explanation of the calculation of the royalties
payable hereunder and be accompanied by payment of the royalties shown by said report to be due
Caltech. Notwithstanding foregoing, if (i)&nbsp;Caltech materially
breaches this Agreement, (ii)&nbsp;Licensee gives Caltech written
notice of the breach, and (iii)&nbsp;Caltech has not cured the breach
by the time a payment is due under this Section, then Licensee may
make the required payment into an interest bearing escrow account to
be released when the breach is cured, less any damages that may be
payable to License by virtue or Caltech&#146;s breach. Royalty
reports which are not challenged by Caltech or amended by Licensee
within thirty-six (36) months after receipt by Caltech shall be
conclusively presumed correct and not subject to challenge, audit, or
amendment.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 10</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>CONFIDENTIALITY</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.1 Except
as provided herein, each party shall maintain in confidence, and shall not use
for any purpose or disclose to any third party, information disclosed by the other party in
writing and marked &#147;Confidential&#148; or that is disclosed orally and confirmed in writing as
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->- 15 -<!-- /Folio -->
</DIV>


<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">confidential within forty-five (45)&nbsp;days following such disclosure (collectively, &#147;Confidential
Information&#148;). Confidential Information shall not include any information that is; (i)&nbsp;already
known to the receiving party at the time of disclosure hereunder, (ii)&nbsp;now or hereafter becomes
publicly known other than through acts or omissions of the receiving party, (iii)&nbsp;disclosed to the
receiving party by a third party under no obligation of confidentiality to the disclosing party,
(iv)&nbsp;disclosed as required by securities or other applicable laws or pursuant to legal requirement,
or (v)&nbsp;disclosed to actual or prospective investors or corporate partners, or to a party&#146;s
accountants, attorneys, and other professional advisors. All reports provided to Caltech by
Licensee pursuant to this Agreement shall be treated as confidential information of Licensee,
pursuant to this Section&nbsp;10.1. The terms of this Agreement shall be treated as confidential
information of Licensee, pursuant to this Section&nbsp;10.1.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.2 Notwithstanding the provisions of Section&nbsp;10.1 above, Licensee may use or disclose
confidential information comprising the Licensed Patents and Technology to the extent necessary to
exercise its rights hereunder (including commercialization and/or sublicensing of the Licensed
Patents and Technology) or fulfill its obligations and/or duties hereunder and in filing for,
prosecuting or maintaining any proprietary rights, prosecuting or defending litigation, complying
with applicable governmental regulations and/or submitting information to tax or other
governmental authorities.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 11</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>PATENT PROSECUTION AND PATENT COSTS</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.1 Licensee shall have the right to apply for, prosecute and maintain during the term of
this Agreement, the Licensed Patents. Caltech shall provide Licensee with timely disclosures
regarding Improvements and potential Improvements. The application filings, prosecution,
maintenance and payment of all fees and expenses, including legal fees, relating to such Licensed
Patents shall be the responsibility of Licensee, provided that Licensee shall pay for all
reasonable fees and expenses, including reasonable legal fees, incurred in such application
filings, prosecution and maintenance. Caltech shall provide Licensee with all information
necessary or useful for the filing and prosecution of such Licensed Patents and shall cooperate
fully with Licensee so that Licensee may establish and maintain such rights. Patent attorneys
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->- 16 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">chosen by Licensee shall handle all patent filings and prosecutions, on behalf of Caltech,
provided, however, Caltech shall be entitled to review and comment upon and approve all actions
undertaken in the prosecution of all patents and applications. Caltech shall provide any comments
or approvals hereunder promptly.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.2 In the event Licensee declines to apply for, prosecute or maintain any Licensed Patents,
Caltech shall have the right to pursue the same at Caltech&#146;s expense and Licensee shall have no
rights under Caltech&#146;s interest therein. If Licensee decides not to apply for, prosecute or
maintain any Licensed Patents, Licensee shall give sufficient and timely notice to Caltech so as to
permit Caltech to apply for, prosecute and maintain such Licensed
Patents. In such event, Licensee
shall provide Caltech with all information necessary or useful for the filing and prosecution of
such Licensed Patents and shall cooperate fully with Caltech so that Caltech may establish and
maintain such rights.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.3 Licensee shall reimburse Caltech for all reasonable out-of-pocket expenses incurred by
Caltech for the filing for, prosecution and maintenance of the Licensed Patents Rights. Such
expenses shall be reimbursed following receipt by Licensee from Caltech of (i)&nbsp;an invoice covering
such fees (including copies of invoices for legal fees describing the legal services performed in
reasonable detail) and (ii)&nbsp;reasonably satisfactory evidence that such fees were paid. Initially,
payments shall be made in six (6)&nbsp;equal quarterly installments due within ten days after the end
of the first six (6)&nbsp;full calendar quarters, effective twenty-four (24)&nbsp;months from the Effective
Date of this Agreement. Subsequent payments under this Section&nbsp;11.3 shall be made to Caltech
within sixty (60)&nbsp;days following receipt by Licensee from Caltech of (i)&nbsp;an invoice covering such
fees (including copies of invoices for legal fees describing the legal services performed in
reasonable detail) and (ii)&nbsp;reasonably satisfactory evidence that such fees were paid. If Licensee
elects to no longer pay the expenses of a patent or patent application within the Licensed Patents
in any country, Licensee shall notify Caltech not less than thirty (30)&nbsp;days prior to such action.
In the event that Licensee elects not to pay such expenses the license granted to Licensee
hereunder shall terminate. [***] of patent expenses paid by Licensee in
conjunction with foreign patent costs shall be creditable against earned royalties due Caltech in
the respective territory covered by the patent or patents that are foreign filed.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->- 17 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 12</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>TERMINATION</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.1 The term of this Agreement shall commence upon the Effective Date and shall terminate on
a country-by-country and Licensed Product by Licensed Product basis upon the expiration of the last
to expire Licensed Patent in such country. Caltech shall have the right to terminate this
Agreement, subsequent to and subject to the outcome of arbitration proceedings pursuant to Article
14, prior to the date it would otherwise expire pursuant to this Section&nbsp;12.1 if Licensee fails to
make any payment due hereunder and Licensee continues to fail to make the payment, either to
Caltech directly or by placing any disputed amount into an interest bearing escrow account to be
released when the dispute is resolved, for a period of sixty (60)&nbsp;days after receiving written
notice from Caltech specifying Licensee&#146;s failure. If this Agreement expires pursuant to the first
sentence of this Section&nbsp;12.1, Licensee shall retain a nonexclusive, perpetual, royalty-free,
worldwide license, with the right to sublicense, under the Licensed Patents and Technology, to
research, develop, make, use, sell, offer for sale and import Licensed Products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.2 If either party materially breaches this Agreement, the other party may elect to give the
bleaching party written notice describing the alleged breach. If the breaching party has not cured
such breach within sixty (60)&nbsp;days after receipt of such notice, the notifying party will be
entitled, in addition to any other rights it may have under this Agreement, to terminate this
Agreement effective immediately; provided, however, that if either party receives notification from
the other of a material breach and if the party alleged to be in default notifies the other party
in writing within thirty (30)&nbsp;days of receipt of such default notice that it disputes the asserted
default, the matter will be submitted to arbitration as provided in
Article&nbsp;14 of this Agreement.
In such event, the nonbreaching party shall not have the right to terminate this Agreement until it
has been determined in such arbitration proceeding that the other party materially breached this
Agreement, and the breaching party fails to cure such breach within ninety (90)&nbsp;days after the
conclusion of such arbitration proceeding.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.3 Licensee shall have the right to terminate this Agreement either in its entirety or as to
any jurisdiction or any part of the Licensed Patents or Technology upon thirty (30)&nbsp;days
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 18 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">written notice. If Licensee does so, it shall submit all required reports and make all required
payments in accordance with Section&nbsp;9.2
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.4 In the event of any termination or expiration of the term of this Agreement, Licensee
shall have the right to use or sell Licensed Products on hand on the date of such termination or
expiration and to complete Licensed Products in the process of manufacture at the time of such
termination or expiration and use or sell the same, provided that Licensee shall submit the
applicable royalty report described in Section&nbsp;9.2, along with the royalty payments required above
in accordance with Section&nbsp;4.1 for sale of such Licensed Products, provided that the Licensed
Products are still covered by a Valid Claim following such termination or expiration.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.5 Termination of this Agreement for any reason shall not release any party hereto from any
liability which, at the time of such termination, has already accrued to the other party or which
is attributable to a period prior to such termination, nor preclude either party from pursuing any
rights and remedies it may have hereunder or at law or in equity which accrued or are based upon
any event occurring prior to such termination.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.6 Section&nbsp;5.2 and Articles 10, 12, 14, and 16 of this Agreement shall survive
termination of this Agreement for any reason.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.7 If Licensee is acquired by or merges into a third party (i.e., Licensee is not a
surviving company in the merger), then Caltech may terminate its
obligations to disclose and grant licenses to Improvements by
providing notice to Licensee of that termination.  The
remainder of the Agreement and the licenses granted hereunder
(including prior licenses granted to Improvements) continues.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 13</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>WARRANTIES AND NEGATION OF</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>WARRANTIES, IMPLIED LICENSES AND AGENCY</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.1 Caltech represents and warrants that (i)&nbsp;it owns all right, title and interest in and to
the Licensed Patents and Technology, (ii)&nbsp;it has the right to enter into this Agreement, (iii)&nbsp;it
has not granted and will not grant during the term of this Agreement rights in or to any Licensed
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 19 -<!-- /Folio -->
</DIV>


<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Patents or Technology that are inconsistent with the rights granted to Licensee herein, (iv)&nbsp;to
Caltech&#146;s knowledge, there are no claims of third parties that would call into question the rights
of Caltech to grant to Licensee the rights contemplated hereunder; (v)&nbsp;to Caltech&#146;s knowledge,
practice of the Licensed Patents will not infringe intellectual property rights of third parties;
(vi)&nbsp;except for the Licensed Patents, as of the effective date of the Agreement, to Caltech&#146;s
belief and knowledge, Caltech does not own or control any patents or patent applications that would
dominate any practice of the Licensed Patents or Technology, and (vii)&nbsp;there are no threatened or
pending actions, suits, investigations, claims, or proceedings in any way relating to the Licensed
Patents or Technology.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.2 Nothing in this Agreement shall be construed as:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;a representation or warranty of Caltech as to the validity or scope of
Licensed Patents or any claim thereof; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;an obligation to bring or prosecute actions or suits against third parties for
infringement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;conferring by implication, estoppel or otherwise, any license or rights under any
existing patents of Caltech other than Licensed Patents, regardless of whether such other patents
are dominant or subordinate to Licensed Patents. Notwithstanding the foregoing, and to the extent
legally permissible, Caltech hereby grants Licensee a right of first refusal as to such dominant
or subordinate patents, providing that a Caltech faculty member does not wish to personally
commercialize the technology embodied in such patents.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.3 CALTECH MAKES NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE, AND ASSUMES NO RESPONSIBILITIES WHATEVER WITH RESPECT TO THE USE, SALE, OR
OTHER DISPOSITION BY LICENSEE OF LICENSED PRODUCT(S).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.4 Caltech shall indemnify, defend and hold harmless Licensee from and against any and all
losses, damages, costs and expenses (including attorneys&#146; fees) arising out of a material breach
by Caltech of its representations and warranties (&#147;Claims&#148;), provided that (i)&nbsp;Caltech is notified
promptly of any Claims, (ii)&nbsp;Licensee has the sole right to control and defend or settle
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 20 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">any litigation within the scope of this indemnity, and (iii)&nbsp;all indemnified parties cooperate to
the extent necessary in the defense of any Claims.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 14</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>ARBITRATION</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.1 Any dispute under this Agreement which is not settled by mutual consent shall be finally
settled by binding arbitration, conducted in accordance with the Commercial Arbitration Rules of
the American Arbitration Association by one (1)&nbsp;independent, neutral arbitrator appointed in
accordance with said rules. The arbitration shall be held in San Francisco, California. The
arbitrators shall determine what discovery shall be permitted, consistent with the goal of
limiting the cost and time that the parties must expend for discovery; provided the arbitrators
shall permit such discovery as they deem necessary to permit an equitable resolution of the
dispute. Any written evidence originally in a language other than English shall be submitted in
English translation accompanied by the original or a true copy thereof. Except as otherwise
expressly provided in this Agreement, the costs of the arbitration, including administrative and
arbitrator(s)&#146; fees, shall be shared equally by the parties and each party shall bear its own
costs and attorneys&#146; and witness&#146; fees incurred in
connection with the arbitration. A disputed
performance or suspended performances pending the resolution of the arbitration must be completed
within a reasonable time period following the final decision of the arbitrator(s). Any arbitration
subject to this Article shall be completed within one (1)&nbsp;year from the filing of notice of a
request for such arbitration. The arbitration proceedings and the decision shall not be made
public without the joint consent of the parties and each party shall maintain the confidentiality
of such proceedings and decision unless otherwise permitted by the other party. Any decision which
requires a monetary payment shall require such payment to be payable in United States dollars,
free of any tax or other deduction. The parties agree that the decision shall be the sole,
exclusive and binding remedy between them regarding any and all disputes, controversies, claims
and counterclaims presented to the arbitrators. Any award may be entered in a court of competent
jurisdiction for a judicial recognition of the decision and an order of enforcement.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 21 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 15</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>PRODUCT LIABILITY</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.1 Licensee agrees that Caltech shall have no liability to Licensee or to any purchasers or
users of Licensed Products made or sold by Licensee for any claims, demands, losses, costs, or
damages suffered by Licensee, or purchasers or users of such Licensed Products, or any other party,
which may result from personal injury, death, or property damage related to the manufacture, use,
or sale of such Licensed Products (&#147;Product Claims&#148;). Licensee agrees to defend, indemnify, and
hold harmless Caltech, its trustees, officers, agents, and employees from any such Product Claims,
provided that (i)&nbsp;Licensee is notified promptly of any Product Claims, (ii)&nbsp;Licensee has the sole
right to control and defend or settle any litigation within the scope of this indemnity, (iii)&nbsp;all
indemnified parties cooperate in the defense of any Product Claims, and (iv)&nbsp;the Product Claims do
not involve or relate to a material breach by Caltech of its representations and warranties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.2 At such time as Licensee begins to sell or distribute Licensed Products (other than for
the purpose of obtaining regulatory approvals), Licensee shall at its sole expense, procure and
maintain policies of comprehensive general liability insurance in amounts not less than [***] in annual aggregate and naming those
indemnified under Section&nbsp;15.1 as
additional insureds. Such comprehensive general liability insurance shall provide (i)&nbsp;product
liability coverage and (ii)&nbsp;broad form contractual liability coverage for Licensee&#146;s
indemnification under Section&nbsp;15.1. In the event the aforesaid product liability coverage does not
provide for occurrence liability, Licensee shall maintain such comprehensive general liability
insurance for a reasonable period of not less than five (5)&nbsp;years after it has ceased commercial
distribution or use of any Licensed Product.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.3 Licensee shall provide Caltech with written evidence of Such insurance upon request of
Caltech. Licensee shall provide Caltech with notice at least fifteen (15)&nbsp;days prior to any
cancellation, non-renewal or material change in such insurance, to the extent Licensee
receives advance notice of such matters from its insurer. If Licensee does not obtain replacement
insurance providing comparable coverage within ninety (90) days following the date of such
cancellation, non-renewal or material change, Caltech shall have the right to terminate this
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->- 22 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Agreement effective at the end of such ninety (90)&nbsp;day period without any additional waiting
period; provided that if Licensee uses reasonable efforts but is unable to obtain the required
insurance at commercially reasonable rates, Caltech shall not have the right to terminate this
Agreement, and Caltech instead shall cooperate with Licensee to either grant a waiver of Licensee&#146;s
obligations under this Article or assist Licensee in identifying a carrier to provide such
insurance or in developing a program for self-insurance or other alternative measures.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 16</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>MISCELLANEOUS</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.1 Licensee agrees that it shall not use the name of Caltech, or California Institute of
Technology, in any advertising or publicity material, or make any form of representation or
statement which would constitute an express or implied endorsement by Caltech of any Licensed
Product, and that it shall not authorize others to do so, without first having obtained written
approval from Caltech, except as may be required by governmental law, rule or regulation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.2 Licensee agrees to mark the appropriate U.S. patent number or numbers on all Licensed
Products made or sold in the United States in accordance with all applicable governmental laws,
rules and regulations, and to require its Sublicensees to do the same.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.3 This Agreement sets forth the complete agreement of the parties concerning the subject
matter hereof. No claimed oral agreement in respect thereto shall be considered as any part
hereof. No waiver of or change in any of the terms hereof subsequent to the execution hereof
claimed to have been made by any representative of either party shall have any force or effect
unless in writing, signed by duly authorized representatives of the parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.4 This Agreement shall be binding upon and inure to the benefit of any successor or
assignee of Caltech. This Agreement is not assignable by Licensee without the prior written
consent of Caltech, except that Licensee may assign this Agreement without the prior written
consent of Caltech, to any Affiliate, or in connection with the sale or transfer of all or
substantially all the assets of Licensee relating to the Licensed Products or services utilizing
the methods within the Licensed Patents. Any permitted assignee shall succeed to all of the rights
and obligations of Licensee under this Agreement.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 23 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.5 This Agreement is subject in all respects to the laws and regulations of the United
States of America, including the Export Administration Act of 1979, as amended, and any regulations
thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.6 This Agreement shall be deemed to have been entered into in California and shall be
construed and enforced in accordance with California law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.7 Any notice or communication required or permitted to be given or made under this
Agreement shall be addressed as follows:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="87%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Caltech:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Office of Technology Transfer</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">California Institute of Technology</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1200 East California Boulevard (MC 210-85)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Pasadena, CA 91125</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax No.: (626) 356-2486</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Licensee:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fluidigm Corporation</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7100 Shoreline Court</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">South San Francisco, CA 94080</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: President</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax No: (650)&nbsp;871-7195</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Phone: (650) 266-6000</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Either party may notify the other in writing of a change of address or fax number, in which event
any subsequent communication relative to this Agreement shall be sent to the last said notified
address or number, provided, however, that the parties shall deliver
all material notices under
this Agreement by registered mail or overnight delivery service. All notices and communications
relating to this Agreement shall be deemed to have been given when received.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.8 Nothing in this Agreement will impair Licensee&#146;s right to independently acquire,
license, develop for itself, or have others develop for it, intellectual property and technology
performing similar functions as the Licensed Patents and Technology or to market and distribute
products other than Licensed Products based on such other intellectual property and technology.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.9 NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL,
OR INDIRECT DAMAGES ARISING OUT OF THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 24 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.10 The relationship of Licensee and Caltech established by this Agreement is that of
independent contractors, Nothing in this Agreement shall be construed to create any other
relationship between Licensee and Caltech. Neither party shall have any right, power or
authority to assume, create or incur any expense, liability or obligation, express or implied,
on behalf of the other.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.11 Licensee agrees that a Licensed Product which embodies a patented invention or
is produced through the use thereof for sale in the United States shall be manufactured
substantially in the United States to the extent required by 35 U.S.C. Section&nbsp;204.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.12 Neither party shall lose any rights hereunder or be liable to the other party for
damages or losses (except for payment obligations) on account of failure of performance by the
defaulting party if the failure is occasioned by war, strike, fire, Act of God, earthquake, flood,
lockout, embargo, governmental acts or orders or restrictions, failure of suppliers, or any other
reason where failure to perform is beyond reasonable control and not caused by the negligence or
intentional conduct or misconduct of the nonperforming party, and such party has exerted all
reasonable efforts to avoid or remedy such force majeure; provided, however, that in no event
shall a party be required to settle any labor dispute or disturbance.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.13 In the event that any provisions of this Agreement are determined to be invalid or
unenforceable by a court of competent jurisdiction, the remainder of the Agreement shall remain in
full force and effect without said provision. The parties shall in good faith negotiate a
substitute clause for any provision declared invalid or unenforceable, which shall most nearly
approximate the intent of the parties in entering this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.14 This Agreement may be executed in two or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one
and the same instrument.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.15 The headings of the several Sections are inserted for convenience of reference only and
are not intended to be a part of or to affect the meaning or interpretation of this Agreement.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 25 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.16 Whenever provision is made in this Agreement for either party to secure the consent or
approval of the other, that consent or approval shall not unreasonably be withheld or delayed, and
whenever in this Agreement provisions are made for one party to object to or disapprove a matter,
such objection or disapproval shall not unreasonably be exercised.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant: SMALL-CAPS"><B>In Witness Whereof</B></FONT>, the parties have caused this Agreement to be executed:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>CALIFORNIA INSTITUTE OF TECHNOLOGY</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">(Caltech)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date: 4/29/04
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:

</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Lawrence Gilbert
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<tr><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:

</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Lawrence Gilbert
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR>
<td>&nbsp;</td>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Senior Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Office of Technology Transfer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Date: April&nbsp;28, 2004</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>FLUIDIGM CORPORATION</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">(Licensee)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gajus
Worthington<div style="font-size: 1pt; border-bottom: 1px solid #000000">&nbsp;</div>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<tr><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
Gajus Worthington
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<tr><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President and CEO</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->- 26 -<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Exhibit&nbsp;A</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B>Licensed Patents</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top">Date: April&nbsp;22, 2004
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><B>Confidential</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">[***]
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-27-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Exhibit&nbsp;A</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B>Licensed Patents</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">[***]
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-28-<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Exhibit&nbsp;A</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B>Licensed Patents</B>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 6pt">&#091;***&#093;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-29-<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Exhibit&nbsp;A</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Licensed Patents</B>

</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt">&#091;***&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-30-<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="CENTER" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Exhibit&nbsp;A</B>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Licensed Patents</B>

</DIV>
<DIV align="center" style="font-size: 10pt; margin-top: 6pt">&#091;***&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-31- <!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Exhibit&nbsp;A</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Licensed Patents</B>

</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt">&#091;***&#093;
</DIV>




<P align="center" style="font-size: 10pt">-32-<!-- Folio --><!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Exhibit&nbsp;A</B>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B>Licensed Patents</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt">&#091;***&#093;
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->-33-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Exhibit&nbsp;A</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B>Licensed Patents</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-34-<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Exhibit&nbsp;A</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Licensed Patents</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->- 35 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Exhibit&nbsp;A</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Licensed Patents</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->- 36 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Exhibit&nbsp;A</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Licensed Patents</B>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->- 37 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Exhibit&nbsp;A</B></DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Licensed Patents</B></DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->- 38 -<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Exhibit&nbsp;A</B></DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Licensed Patents</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->- 39 -<!-- /Folio --></DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Exhibit&nbsp;A</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B>Licensed Patents</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->- 40 -<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Exhibit&nbsp;A</B>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Licensed Patents</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 41 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Exhibit&nbsp;A</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Licensed Patents</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->- 42 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Exhibit&nbsp;A</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B>Licensed Patents</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-43-<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Exhibit&nbsp;A</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Licensed Patents</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>

<P align="center" style="font-size: 10pt">-44-<!-- Folio --><!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4A
<SEQUENCE>15
<FILENAME>f39432orexv10w4a.htm
<DESCRIPTION>EXHIBIT 10.4A
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w4a</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#091;***&#093; Indicates
text has been omitted from this Exhibit pursuant to a confidential treatment
request and has been filed separately with the Securities and Exchange Commission.
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.4A</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="60%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>2020.LICI.001.C</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>California Institute of Technology</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ADDENDUM TO<BR>
SECOND AMENDED AND RESTATED LICENSE AGREEMENT
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIS ADDENDUM TO SECOND AMENDED AND RESTATED LICENSE AGREEMENT (this &#147;Addendum&#148;) dated as
of March&nbsp;29, 2007 (the &#147;Addendum Date&#148;), is entered into between CALIFORNIA INSTITUTE OF
TECHNOLOGY (&#147;Caltech&#148;), having an address at 1200 East California Boulevard, Pasadena,
California 91125, and FLUIDIGM CORPORATION (&#147;Licensee&#148;), having a principal place of business
at 7100 Shoreline Court, South San Francisco, California 94080, with respect to the following
facts:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A. The parties entered into the Second Amended and Restated License
Agreement (the &#147;Agreement&#148;) effective May&nbsp;1, 2000, with a second restatement date as
of May&nbsp;1, 2004. All terms used, but not defined herein, shall have the respective
meanings set forth in the Agreement.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B.&nbsp;On the terms and conditions of this Addendum, the parties desire to clarify
and modify certain provisions to the Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants
set forth below, the parties agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">1. <U>Licensed Patents and Improvements</U>.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 The Agreement is amended by deleting Exhibit&nbsp;A to the Agreement and
by replacing it with Exhibit&nbsp;A to this Addendum.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2 Caltech represents that it has disclosed to Licensee all Improvements
arising prior to the Addendum Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3 The parties acknowledge that Exhibit&nbsp;A to this Addendum includes (a)&nbsp;all
Improvements disclosed by Caltech to Licensee prior to the Addendum Date, and elected
by Licensee to be included in the scope of the license grant by Caltech to Licensee under
the Agreement, and (b)&nbsp;all updates on all Licensed Patents as of the Addendum Date.
Caltech confirms that Licensee has taken all action on its part that is necessary for all
subject matter included in Exhibit&nbsp;A to this Addendum to be included in the scope of the
license grant by Caltech to Licensee under the Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">2. <U>Licensee Equity Interest and Improvement Periods</U>.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 Notwithstanding anything to the contrary in Article&nbsp;5 of the Agreement, the
Improvement Periods shall be those periods from June&nbsp;1, 2003 through May&nbsp;31, 2004, from June
1, 2004 through May&nbsp;31, 2005, from &#091;***&#093;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 Notwithstanding anything to the contrary in Article&nbsp;5 of the Agreement, (a)&nbsp;Licensee
shall issue to Caltech &#091;***&#093; &#091;***&#093; shares of common stock of Licensee, pursuant
to the terms of a reasonable and customary stock issuance agreement, and (b)&nbsp;the parties
acknowledge that the issuance of such shares (in addition to the shares issued by Licensee to
Caltech prior to the Second Restatement Date) shall be in full satisfaction of Licensee&#146;s
obligations to issue shares or otherwise make payments to Caltech pursuant to the Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">3. <U>Royalty Reports</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The parties acknowledge (a)&nbsp;that the royalty reports received by Caltech under Section&nbsp;9.2 of
the Agreement prior to the Addendum Date are presumed correct and not subject to challenge, audit
or amendment, and (b)&nbsp;that the format of, and the methodology used by Licensee in preparing, the
royalty reports under Section&nbsp;9.2 of the Agreement are mutually acceptable and in compliance with
the terms and conditions of the Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">4.&nbsp;<U>Patent Costs</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary in Article&nbsp;11 of the Agreement, Licensee shall have
no obligation to reimburse Caltech for any costs or expenses incurred by Caltech in connection with
the Licensed Patents that have not been reimbursed by Licensee prior to the Addendum Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">5. <U>Further Assurances</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each party shall take such further actions, and execute such further documents and
instruments, as reasonably requested by the other party to effectuate the grant of licenses and
rights from Caltech to Licensee under the Agreement and otherwise to enable Licensee to enjoy the
full benefit thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">6. <U>Miscellaneous</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1 This Addendum shall be effective for all purposes as of the Addendum
Date. Except as otherwise expressly modified by this Addendum, the Agreement shall
remain in full force and effect in accordance with its terms.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2 This Addendum shall be governed by, interpreted and construed in
accordance with the laws of the State of California, without regard to conflicts of law
principles.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3 This Addendum may be executed in counterparts, each of which shall be
deemed to be an original and together shall be deemed to be one and the same document.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have caused this Addendum to be duly executed and delivered
effective as of the Addendum Date.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">California Institute of Technology<br></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>/s/ Lawrence Gilbert</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">(Signature)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="center">Lawrence Gilbert</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">(Printed Name)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">SR DR Tech Transfer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">(Title)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">FLUIDIGM CORPORATION</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>/s/ Gajus V. Worthington</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">(Signature)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="center">Gajus V. Worthington<BR></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">(Printed Name)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="center">CEO<BR></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">(Title)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">EXHIBIT A

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">&#091;TO BE ATTACHED&#093;

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Appendix&nbsp;1.7 Fluidigm Patent Family<BR>
US Cases
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">[ * * * ]</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Page 1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Appendix&nbsp;1.7 Fluidigm Patent Family<BR>
US Cases
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->Page 2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Appendix&nbsp;1.7 Fluidigm Patent Family<BR>
US Cases
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->Page 3<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Appendix&nbsp;1.7 Fluidigm Patent Family<BR>
US Cases
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->Page 4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Appendix&nbsp;1.7 Fluidigm Patent Family<BR>
US Cases
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Page 5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Appendix&nbsp;1.7 Fluidigm Patent Family<BR>
US Cases
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Page 6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Appendix&nbsp;1.7 Fluidigm Patent Family<BR>
US Cases
</DIV>





<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[***]</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Page 7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Appendix&nbsp;1.7 Fluidigm Patent Family<BR>
US Cases
</DIV>





<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[***]</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->Page 8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Appendix&nbsp;1.7 Fluidigm Patent Family</DIV>
<DIV align="center" style="font-size: 10pt; margin-top: 0pt">US Cases
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[***]</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Page 9<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Appendix&nbsp;1.7 Fluidigm Patent Family<BR>
US Cases
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[***]</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Page 10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Appendix&nbsp;1.7 Fluidigm Patent Family<BR>
US Cases
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[***]</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->Page 11<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Appendix&nbsp;1.7 Fluidigm Patent Family<BR>
International Cases
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[***]</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --> Page 1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Appendix&nbsp;1.7 Fluidigm Patent Family<BR>
International Cases
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[***]</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --> Page 2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Appendix&nbsp;1.7 Fluidigm Patent Family<BR>
International Cases
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[***]</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --> Page 3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Appendix&nbsp;1.7 Fluidigm Patent Family<BR>
International Cases
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[***]</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio --> Page 4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Appendix&nbsp;1.7 Fluidigm Patent Family<BR>
International Cases
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[***]</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio --> Page 5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Appendix&nbsp;1.7 Fluidigm Patent Family<BR>
International Cases
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[***]</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio --> Page 6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Appendix&nbsp;1.7 Fluidigm Patent Family<BR>
International Cases
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[***]</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --> Page 7<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 6pt">Appendix&nbsp;1.7
Fluidigm Patent
Family <BR>
International Cases
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Page 8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 6pt">Appendix&nbsp;1.7 Fluidigm
Patent Family<BR>

International Cases</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[***]</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->Page 9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Appendix&nbsp;1.7 Fluidigm Patent Family<BR>
International Cases
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[***]</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Page 10<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>16
<FILENAME>f39432orexv10w5.htm
<DESCRIPTION>EXHIBIT 10.5
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w5</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#091;***&#093; Indicates
text has been omitted from this Exhibit pursuant to a confidential treatment
request and has been filed separately with the Securities and Exchange Commission.
</DIV>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.5</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>4060.LICI.010 Harvard</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS">Co-Exclusive License Agreement</FONT>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><I>Between</I>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>President and Fellows of Harvard College</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">And

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Mycometrix Corporation</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Effective as of October&nbsp;15, 2000

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Re: Harvard Case #&#091;***&#093;

</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">In consideration of the mutual promises and covenants set forth below, the parties
hereto agree as follows:
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Article </FONT>I<BR>
<FONT style="font-variant: SMALL-CAPS">Definitions</FONT>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">As used in this Agreement, the following terms shall have the following meanings:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>ACADEMIC RESEARCH PURPOSES: use of PATENT RIGHTS for academic research
or other not-for-profit scholarly purposes which are undertaken at a non-profit or
governmental institution that does not use the PATENT RIGHTS in the production or
manufacture of products for sale or the performance of services for a fee.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>AFFILIATE: any entity which controls, is controlled by, or is under common control with
a party by ownership or control of at least fifty percent (50%) of the voting stock or other
ownership. Unless otherwise specified, the term LICENSEE includes AFFILIATES.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>FIELD : use of PATENT RIGHTS to develop, manufacture, use, offer for sale, sell, or
import components and products in FIELD I and/or FIELD II:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>FIELD I: &#091;***&#093;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>FIELD II: &#091;***&#093;</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD: President and Fellows of Harvard College, a nonprofit Massachusetts
educational corporation having offices at the Office for Technology and Trademark
Licensing, Holyoke Center, Suite&nbsp;727, 1350 Massachusetts Avenue, Cambridge,
Massachusetts 02138.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSED PROCESSES: the processes covered by at least one VALID CLAIM included
within the PATENT RIGHTS.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSED PRODUCTS: products covered by at least one VALID CLAIM included
within the PATENT RIGHTS or products made or services provided in accordance with or
by means of LICENSED PROCESSES.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE: Mycometrix Corporation, a corporation organized under the laws of California
having its principal offices at 213 East Grand Avenue, South San Francisco, CA 94080.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>NET SERVICE INCOME: SERVICE INCOME less LICENSEE&#146;s actual direct and
indirect cost for research, development and/or services provided.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.9</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>NET SALES: the amount actually received for sales, leases, or other transfers of
LICENSED PRODUCTS, less:</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">(i)&nbsp;customary trade, quantity or cash discounts and
non-affiliated brokers&#146; or agents&#146; commissions actually allowed and taken;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">(ii)&nbsp;amounts repaid or credited by reason of rejection or return;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">(iii)&nbsp;to the extent separately stated on purchase orders, invoices, or other
documents of sale, taxes levied on and/or other governmental charges made as to
production, sale, transportation, delivery or use and paid by or on behalf of
LICENSEE; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">(iv)&nbsp;reasonable charges for delivery or transportation provided by third parties
and cost of insurance in transit, if separately stated.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>NET SALES also includes the fair market value of any non-cash consideration received by
LICENSEE for the sale, lease, or transfer of LICENSED PRODUCTS.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If a LICENSED PRODUCT is sold as a combination product containing the LICENSED PRODUCT and
one or more other components, NET SALES shall be calculated by multiplying the gross amount
invoiced for the sale of the combination product by the fraction A/A&#043;B where A is the average
gross selling price of the LICENSED PRODUCT sold separately by LICENSEE and B is the average
gross selling price of such other components of the combination products sold separately by
LICENSEE during the relevant royalty payment period.</TD>
</TR>


</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event that LICENSEE grants a sublicensee hereunder, and receives payments based
upon SUBLICENSEE&#146;s sales of LICENSED PRODUCTS, LICENSEE may upon approval from HARVARD (which
shall not be unreasonably withheld) modify the definition of NET SALES for the purposes of
calculating royalties payable to HARVARD on such SUBLICENSEE&#146;s sales to be the same as the
definition of NET SALES on which such royalties to LICENSEE are calculated.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.10</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>SERVICE INCOME: the total financial consideration received by LICENSEE for
commercial services performed on a fee-for-service basis using the LICENSED
PRODUCTS or LICENSED PROCESSES by LICENSEE under a contract with a third
party, where such services are based primarily on the use of fully functional LICENSED
PRODUCTS or LICENSED PROCESSES (as applicable) for their intended commercial
use (such as, for example, where LICENSEE performs commercial-scale genotyping
services for a pharmaceutical company on a fee-for-service basis using fully developed
microfluidics chips comprising LICENSED PRODUCTS). SERVICE INCOME shall not
include amounts received in connection with research and/or development of LICENSED
PRODUCTS or LICENSED PROCESSES themselves.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.11</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>PATENT RIGHTS: The applications and patents as listed in Appendix&nbsp;A of this
Agreement, the allowed claims of such applications, the inventions described and claimed
therein, and any divisions or continuations of the applications and patents as listed in
Appendix&nbsp;A, and specific claims of any continuations-in-part of such applications to the
extent the specific claims are directed to subject matter described in the applications and
patents listed in Appendix&nbsp;A in a manner sufficient to support such specific claims under
35 U.S.C., patents issuing thereon or reissues thereof, and any and all foreign patents and
patent applications corresponding thereto, all to the extent owned or controlled by
HARVARD.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.12</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>SUBLICENSE INCOME: the amount paid to LICENSEE by a third party (other than an
AFFILIATE of LICENSEE) (a)&nbsp;for the sublicening of PATENT RIGHTS to a third party
as well as (b)&nbsp;for the related licensing of LICENSEE&#146;s own patent rights or know-how or
LICENSEE&#146;s in-licensed non-HARVARD technologies, including but not limited to (i)
license fees, (ii)&nbsp;milestone payments, (iii)&nbsp;royalties, (iv)&nbsp;the fair market value in cash of
any non-cash consideration for such sublicense, and (v)&nbsp;in the event that LICENSEE receives
any payment for equity in consideration for the grant of sublicense rights that included a
premium over the fair market value of such equity, the amount of such premium.
LICENSEE shall be responsible for determining such fair market value with reasonable
business judgment.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.13</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>SUBLICENSEE: any non-AFFILIATE granted a sublicense of any of the rights
HARVARD has granted to LICENSEE under Section&nbsp;3.1.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.14</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>TERRITORY: Worldwide.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.15</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>VALID CLAIM: either (i)&nbsp;a claim of an issued patent that has not been held
unenforceable or invalid by an agency or a court of competent jurisdiction in any</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>unappealable or unappealed decision or (ii)&nbsp;a claim of a published, pending patent
application, which claim is substantially identical to a corresponding claim in a subsequently
issued patent having priority to the patent application.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.16</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The terms &#147;Public Law 96-517&#148; and &#147;Public Law 98-620&#148; include all amendments to those
statutes.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.17</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The terms &#147;sold&#148; and &#147;sell&#148; include, without limitation, leases and other transfers and
similar transactions.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Article </FONT>II<BR>
<FONT style="font-variant: SMALL-CAPS">Representations</FONT>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD is owner by assignment from [***], in the foreign patent applications corresponding thereto, and in the
inventions described and claimed therein.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD has authority to issue licenses under PATENT RIGHTS.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD is committed to the policy that ideas or creative works produced at
HARVARD should be used for the greatest possible public benefit, and believes that
every reasonable incentive should be provided for the prompt introduction of such ideas
into public use, all in a manner consistent with the public interest.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE is prepared and intends to diligently develop the invention and to bring
products to market which are subject to this Agreement, specifically including one or
more products in the FIELD selected from a [***].</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE is desirous of obtaining a co-exclusive license in the FIELD and in the
TERRITORY in order to practice the PATENT RIGHTS in the United States and in
certain foreign countries, and to manufacture, use and sell in the commercial market the
products made in accordance therewith, and HARVARD is desirous of granting such a
license to LICENSEE in accordance with the terms of this Agreement.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Article</FONT> III<BR>
<FONT style="font-variant: SMALL-CAPS">Grant of Rights</FONT>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD hereby grants to LICENSEE and LICENSEE accepts, subject to the terms and
conditions hereof, in the TERRITORY a co-exclusive commercial license under PATENT RIGHTS in
FIELD I and in FIELD II to make and have made, to use and have used, to sell</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>and have sold, and to offer for sale and have offered for sale the LICENSED PRODUCTS,
and to practice the LICENSED PROCESSES, for the life of the PATENT RIGHTS. HARVARD will grant
no more than two commercial licenses in FIELD I at any time and will grant no more than two
commercial licenses in FIELD II at any time and HARVARD will not grant other licenses in the
FIELD except as required by HARVARD&#146;s obligations in Section&nbsp;3.2(a) or as permitted Section
3.2(b). Such co-exclusive license shall include the right to grant sublicenses under the
following circumstances: (i)&nbsp;LICENSEE can demonstrate that it has added significant value to
the PATENT RIGHTS to be sublicensed, and that such a sublicense also contains a substantial
and essentially simultaneous license of LICENSEE owned intellectual property, or (ii)
LICENSEE grants a sublicense under other HARVARD patent rights licensed exclusively to
LICENSEE which are dominated by PATENT RIGHTS, and such sublicense under PATENT RIGHTS is
necessary to practice such other HARVARD patent rights.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The granting and exercise of this license is subject to the following conditions:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD&#146;s &#147;Statement of Policy in Regard to Inventions, Patents and Copyrights,&#148;
dated August&nbsp;10, 1998, Public Law 96-517, Public Law 98-620. In addition, this
Agreement is subject to HARVARD&#146;s obligations under agreements with other
sponsors of research, provided that such obligations are not in conflict with the rights
granted hereunder. Any right granted in this Agreement greater than that permitted
under Public Law 96-517, or Public Law 98-620, shall be subject to modification as
may be required to conform to the provisions of those statutes.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD reserves the right to make and use, and grant to others non-exclusive
licenses to make and use solely for ACADEMIC RESEARCH PURPOSES the
subject matter described and claimed in PATENT RIGHTS.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall use commercially reasonable efforts to effect introduction of the
LICENSED PRODUCTS into the commercial market as soon as practicable,
consistent with sound and reasonable business practice and judgment; thereafter, until
the expiration of this Agreement, LICENSEE shall endeavor to keep LICENSED
PRODUCTS reasonably available to the public.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>At any time after three years from the effective date of this Agreement and as
HARVARD&#146;s sole remedy for such non-performance, HARVARD may increase the
license maintenance royalty under Section&nbsp;4.4 to [***] dollars
each in FIELD I and in FIELD II in year 2004 and [***] dollars
each in FIELD I and in FIELD II per year each year beginning in 2005, if in
HARVARD&#146;s reasonable judgment, the Progress Reports furnished by LICENSEE do
not demonstrate that LICENSEE has satisfied at least one of the following conditions,
which non-performance is not cured within ninety (90)&nbsp;days following the written
notification of such by HARVARD to LICENSEE:</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>has put the licensed subject matter into commercial use in
at least one of the countries hereby licensed, directly or through a sublicense,
and is keeping the licensed subject matter reasonably available to the public; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>is engaged in research, development, manufacturing, marketing or
sublicensing activity appropriate to achieving 3.2(d)(i).</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In all sublicenses granted by LICENSEE hereunder, LICENSEE shall include a
requirement that the SUBLICENSEE use commercially reasonable efforts to bring
the subject matter of the sublicense into commercial use. LICENSEE shall further
provide in such sublicenses that such sublicenses are subject and subordinate to the
terms and conditions of this Agreement, except: (i)&nbsp;the SUBLICENSEE may not
further sublicense; and (ii)&nbsp;the rate of royalty on NET SALES paid by the
SUBLICENSEE to the LICENSEE. Copies of the relevant provisions of all
sublicense agreements shall be provided promptly to HARVARD. HARVARD agrees
to maintain any information contained in such provisions in confidence, except as
otherwise required by law, however, HARVARD may include in its usual reports
annual amounts of royalties paid.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(f)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>A license in any other field of use in addition to the FIELD shall be the
subject of a
separate agreement and shall require LICENSEE&#146;s submission of evidence,
satisfactory to HARVARD, demonstrating LICENSEE&#146;s willingness and ability to
develop and commercialize in such other field of use the kinds of products or
processes likely to be encompassed in such other fields.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(g)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To the extent that federal funds are used to support research leading to a
patent or patent application in the PATENT RIGHTS, LICENSEE shall cause any LICENSED
PRODUCT produced for sale by LICENSEE or SUBLICENSEES in the United States to be
manufactured substantially in the United States during the period of exclusivity of
this license in the United States.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All rights reserved to the United States Government and others under Public Law 96-517,
and Public Law 98-620, shall remain and shall in no way be affected by this Agreement.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Article </FONT>IV<BR>
<FONT style="font-variant: SMALL-CAPS">Royalties</FONT>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall pay to HARVARD a non-refundable license royalty fee in the sum of
[***] payable within thirty (30)&nbsp;days of the execution date of
this Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>(a)&nbsp;In consideration of the right and license granted herein, LICENSEE shall pay to
HARVARD during the term of this Agreement a royalty of [***] on NET
SALES of LICENSED PRODUCTS sold by LICENSEE.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">(b)&nbsp;In the event that a single LICENSED PRODUCT or LICENSED PROCESS is
covered by HARVARD intellectual property in addition to PATENT RIGHTS, which is
licensed to LICENSEE under other agreements as of the date of this Agreement, then the
total royalty payment due HARVARD under all such agreements including this
Agreement shall be [***] of NET SALES. LICENSEE shall notify
HARVARD of the identity of each license agreement that includes patent rights covering
the product or process, and HARVARD shall distribute the royalties evenly among such
agreements.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">(c)&nbsp;As consideration for the rights granted hereunder, LICENSEE shall pay to
HARVARD during the term of this Agreement a royalty in the form of stock of
LICENSEE as follows:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall issue to HARVARD [***] shares of the Common Stock of LICENSEE (&#147;Shares&#148;) pursuant to the terms of a
mutually acceptable Stock Subscription Agreement, provided, however, that HARVARD shall
be subject to and enter into appropriate agreements and related documents as required of
other stockholders of LICENSEE.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD represents and warrants to LICENSEE that:</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 10%">(1)&nbsp;HARVARD is acquiring the Shares for its own account for
investment and not with a view to, or for sale in connection with
any distribution thereof, nor with any present intention of
distributing or selling the same; and HARVARD has no present or
contemplated agreement, undertaking, arrangement, obligation,
indebtedness or commitment providing for the disposition thereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 10%">(2)&nbsp;HARVARD has full power and authority to enter into and to
perform this Agreement in accordance with its terms.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 10%">(3)&nbsp;HARVARD has sufficient knowledge and experience in
investing in companies similar to LICENSEE so as to be able to
evaluate the risks and merits of its investment in LICENSEE and is
able financially to bear the risks thereof.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Each certificate representing the Shares shall bear a legend
substantially in the following form:</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#147;The shares represented by this certificate have not been registered under the
Securities Act of 1933 or any state securities law and they may not be sold or otherwise
transferred by any person, including a pledgee, unless (1)&nbsp;either (a)&nbsp;a registration
statement with respect to such shares shall be effective under the Securities Act of
1933, as amended, or (b)&nbsp;the Corporation shall have received an opinion of counsel
satisfactory to the Corporation that an exemption from registration under such Act is
then available, and (2)&nbsp;there shall have been compliance with all applicable securities
laws.&#148;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#147;The shares represented by this certificate are subject to a mutually agree-upon Stock
Purchase and Right of First Refusal Agreement with this Corporation, a copy of which
Stock Purchase and Right of First Refusal Agreement is available for inspection at the
offices of the Corporation or may be made available upon request.&#148;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The foregoing legend shall be removed from the certificates representing any Shares, at
the request of the holder thereof, at such time as they become eligible for resale
pursuant to the Securities Act of 1933, as amended.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If at any time prior to the time the Shares are eligible for resale pursuant to an
exemption from registration under the Securities Act of 1933, as amended, LICENSEE
proposes to register any of its Common Stock, under the Securities Act of 1933, except at
LICENSEE&#146;s initial public offering or any offering pursuant to Forms S-4 or S-8, LICENSEE
shall offer HARVARD the opportunity to have its Shares registered under the registration
statement to be filed at such time. HARVARD will be offered the right to register its
Shares under the same terms, conditions and restrictions as other shareholders with
piggyback registration rights and the inclusion of any Shares in such registration
statement shall be subject to the approval of the underwriters of such offering</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iv)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD&#146;s ownership rights to Shares shall not be affected should the license
pursuant to this Agreement be converted to a nonexclusive one.</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">(d)&nbsp;In the case
of sublicenses, LICENSEE shall also pay to HARVARD a royalty of [***] of
SUBLICENSE INCOME. If compensation for such a sublicense of PATENT RIGHTS is bundled with
compensation received for the sublicensing of the other HARVARD patent rights licensed to LICENSEE
under other agreements as of the date of this Agreement, LICENSEE
shall pay HARVARD only [***] of the total compensation received no matter how many license agreements from HARVARD
are involved. In such a case, LICENSEE shall notify HARVARD of the identity of each license
agreement involved and HARVARD shall distribute its [***] of
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">compensation equally among those license agreements, including this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">(e)&nbsp;LICENSEE
shall pay HARVARD [***] of NET SERVICE INCOME. If SERVICE
INCOME is bundled with service income under another license to LICENSEE as of the date of
this Agreement, LICENSEE shall pay a royalty of [***] of NET SERVICE INCOME
received from each and every third party (&#147;Third Party&#148;) to which services are provided.
LICENSEE shall notify HARVARD of the identity of each license agreement involved in the
services and HARVARD shall distribute its [***] of compensation equally among
those license agreements, including this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">(f)&nbsp;If other co-exclusive licenses in the same FIELD and TERRITORY are granted after the
date this Agreement is executed, the above financial compensation shall not exceed the
financial compensation to be paid by other licensees in the same FIELD and TERRITORY during
the term of the co-exclusive license provided LICENSEE accepts any less favorable terms
included in such other license.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">If stock is part of the financial compensation to be paid by other licensees in the same
FIELD and TERITORY, the fair market value of the stock shall be the same as the price per
share which other investors paid in the last round of financing unless the stock is publicly
traded.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>On sales between LICENSEE and its AFFILIATES for resale or incorporation into
products, the royalty shall be paid on the NET SALES of the AFFILIATE. On sales
between LICENSEE and sublicensees for resale, the royalty shall be paid on the
SUBLICENSE INCOME.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>No later than January 1 of each calendar year indicated below, LICENSEE shall pay to
HARVARD the following non-refundable license maintenance royalty and/or advance on
royalties. Such payments shall be credited against running royalties due for that calendar
year and Royalty Reports shall reflect such a credit. Such payments shall not be credited
against milestone payments (if any) nor against royalties due for any subsequent calendar
year nor against such payments due under any other agreements with HARVARD.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" colspan="3">FIELD I</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" colspan="3">FIELD II</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">January&nbsp;1, 2002</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD align="right">[***]</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD align="right">[***]</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">January&nbsp;1, 2003</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD align="right">[***]</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD align="right">[***]</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">January&nbsp;1, 2004</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD align="right">[***]</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD align="right">[***]</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">each year thereafter</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD align="right">[***]</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD align="right">[***]</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Article </FONT>V<BR>
<FONT style="font-variant: SMALL-CAPS">Reporting</FONT>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Prior to signing this Agreement, LICENSEE has provided to HARVARD a written business plan
under which LICENSEE intends to bring the subject matter of the licenses</TD>
</TR>


</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>granted hereunder into commercial use upon execution of this Agreement. Such plan
includes proposed marketing efforts.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>No later than sixty (60)&nbsp;days after June&nbsp;30 of each calendar year, LICENSEE shall provide
to HARVARD a written annual Progress Report describing progress on research and
development, regulatory approvals, manufacturing, sublicensing, marketing and sales
during the most recent twelve (12)&nbsp;month period ending June&nbsp;30 and plans for the
forthcoming year. If multiple technologies are covered by the license granted hereunder,
the Progress Report shall provide the information set forth above for each technology. If
progress differs from that anticipated in the plan required under Section&nbsp;5.1, LICENSEE
shall explain the reasons for the difference and propose a modified
plan for HARVARD&#146;s
review. LICENSEE shall also provide any reasonable additional data HARVARD
requires to evaluate LICENSEE&#146;s performance.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall report to HARVARD the date of first sale of LICENSED PRODUCTS
(or results of LICENSED PROCESSES) in each country within thirty
(30)&nbsp;days of occurrence.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><div style="margin-left: 15px; text-indent: -15px">(a)&nbsp;LICENSEE shall submit to HARVARD within sixty (60)&nbsp;days after each calendar
half year ending June&nbsp;30 and December&nbsp;31, a Royalty Report setting forth for such half
year at least the following information:</div></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the number of LICENSED PRODUCTS sold by LICENSEE in each country;<BR></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>total billings and amounts actually received for such LICENSED PRODUCTS;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>an accounting for all LICENSED PROCESSES used or sold;<BR></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iv)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>deductions applicable to determine the NET SALES thereof;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(v)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the amount of SERVICE INCOME received by LICENSEE and an accounting
of all deductions to yield NET SERVICE INCOME;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(vi)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the amount of SUBLICENSE INCOME received by LICENSEE; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(vii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the amount of royalty due thereon, or, if no royalties are due to
HARVARD for any reporting period, the statement that no royalties are due.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Such report shall be certified as correct by an officer of LICENSEE and shall include a
detailed listing of all deductions from royalties.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall pay to HARVARD with each such Royalty Report the amount of
royalty due with respect to such half year. If multiple technologies are covered by the
license granted hereunder, LICENSEE shall specify which PATENT RIGHTS are utilized for
each LICENSED PRODUCT and LICENSED PROCESS included in the Royalty Report.</TD>
</TR>


</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All payments due hereunder shall be deemed received when funds are credited to
HARVARD&#146;s bank account and shall be payable by check or wire transfer in United
States dollars. Conversion of foreign currency to U.S. dollars shall be made at the
conversion rate existing in the United States (as reported in the New York Times or
the Wall Street Journal) on the last working day of each royalty period. No transfer,
exchange, collection or other charges shall be deducted from such payments.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All such reports shall be maintained in confidence by HARVARD except as required
by law; however, HARVARD may include in its usual reports annual
amounts of royalties paid.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Late payments shall be subject to a charge of one and one-half percent (1.5%) per
month, or $250, whichever is greater.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event of acquisition, merger, change of corporate name or change in make-up,
organization, or identity, LICENSEE shall notify HARVARD in writing
within thirty (30)&nbsp;days of such event.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If by law, regulation or fiscal policy of a particular country, conversion into United States
dollars or transfer of funds of a convertible currency to the United States is restricted or
forbidden, LICENSEE shall give HARVARD prompt notice in writing and shall pay the
royalty and other amounts due through such means or methods as are lawful in such
country as HARVARD may reasonably designate. Failing the designation by HARVARD
of such lawful means or methods within thirty (30)&nbsp;days after such notice is given to
HARVARD, LICENSEE shall deposit such royalty or other payment in local currency to
the credit of HARVARD in a recognized banking institution designated by HARVARD,
or if none is designated by HARVARD within the thirty (30)&nbsp;day period described above,
in a recognized banking institution selected by LICENSEE and identified in a written
notice to HARVARD by LICENSEE, and such deposit shall fulfill all obligations of
LICENSEE to HARVARD with respect to such royalties. When in any country in which
the law or regulations prohibit both the transmittal and deposit of royalties on sales in
such
country, royalty payments shall be suspended for as long as such prohibition is in effect,
and as soon as such prohibition ceases to be in effect, all royalties which LICENSEE
would have been under obligation to transmit or deposit, but for the prohibition, shall be
deposited or transmitted promptly to the extent allowable.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Article </FONT>VI<BR>
<FONT style="font-variant: SMALL-CAPS">Record Keeping</FONT>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">6.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall keep, and shall require its SUBLICENSEES to keep, accurate records (together
with supporting documentation) of LICENSED PRODUCTS made, used or sold under this Agreement,
and SERVICE INCOME and SUBLICENSE INCOME received by LICENSEE under this Agreement,
appropriate to determine the amount of royalties due to HARVARD hereunder. Such records shall
be retained for three (3)&nbsp;years following the end of the reporting period to which they
relate. For such three year period, they shall be</TD>
</TR>


</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>available during normal business hours upon reasonable advance notice for examination
by a certified public accountant selected by HARVARD, and reasonably acceptable to LICENSEE,
for the sole purpose of verifying reports and payments hereunder. In conducting examinations
pursuant to this Section&nbsp;6.1, HARVARD&#146;s accountant shall have access to all records which
HARVARD reasonably believes to be relevant to the calculation of royalties under Article&nbsp;IV.
HARVARD agrees to maintain any information contained in such records in confidence, except
as otherwise required by law and except information in regarding the amount of royalties
due.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">6.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD&#146;s accountant shall not disclose to HARVARD any information other than
information relating to the accuracy of reports and payments made hereunder.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">6.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Such examination by HARVARD&#146;s accountant shall be at
HARVARD&#146;s expense, except
that if such examination shows an underreporting or underpayment in excess of five
percent (5%) for any twelve (12)&nbsp;month period, then LICENSEE shall pay the cost of such
examination as well as any additional sum that would have been payable to HARVARD
had the LICENSEE reported correctly, plus interest on said sum at the rate of one and one-half percent (1.5%) per month.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Article </FONT>VII<BR>
<FONT style="font-variant: SMALL-CAPS">Domestic and Foreign Patent Filing and Maintenance</FONT>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon execution of this Agreement, LICENSEE shall reimburse HARVARD for fifty
percent (50%) of all reasonable expenses HARVARD has incurred for the preparation,
filing, prosecution, maintenance and counseling with respect to PATENT RIGHTS. Such
expenses total [***] as of October&nbsp;1, 2000. Thereafter, LICENSEE shall reimburse
HARVARD for fifty percent (50%) of all such future reasonable expenses prior to the
termination of this Agreement upon receipt of invoices from HARVARD.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD shall be responsible for the preparation, filing, prosecution and maintenance
of any and all patent applications and patents included in PATENT RIGHTS.
HARVARD will instruct counsel to directly notify HARVARD and LICENSEE and
provide them copies of any official communications from the United States and foreign
patent offices relating to said prosecution, and to provide LICENSEE with advance draft
copies of all relevant communications to the various patent offices, so that LICENSEE
may be informed and apprised of the continuing prosecution of patent applications in
PATENT RIGHTS. LICENSEE shall have reasonable opportunities to participate in
decision making on all key decisions affecting filing, prosecution and maintenance of
patents and patent applications in PATENT RIGHTS. HARVARD will use reasonable
efforts to incorporate LICENSEE&#146;s reasonable suggestions regarding said prosecution.
HARVARD shall use all reasonable efforts to amend any patent application to include
claims reasonably requested by LICENSEE to protect LICENSED PRODUCTS.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD and LICENSEE shall cooperate fully in the preparation, filing, prosecution
and maintenance of PATENT RIGHTS and of all patents and patent
applications licensed to LICENSEE hereunder, executing all papers and instruments or requiring members of</TD>
</TR>


</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD to execute such papers and instruments so as to enable HARVARD to apply
for, to prosecute and to maintain patent applications and patents in
HARVARD&#146;s name in any
country. Each party shall provide to the other prompt notice as to all matters which come to
its attention and which may affect the preparation, filing, prosecution or maintenance of
any such patent applications or patents.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE may elect to surrender its PATENT RIGHTS in any country upon sixty (60)
days written notice to HARVARD. Such notice shall not relieve LICENSEE from
responsibility to reimburse HARVARD for patent-related expenses incurred prior to the
expiration of the (60)&nbsp;day notice period.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If HARVARD elects not to prosecute or maintain any of the patents or patent applications
relating to PATENT RIGHTS or any portion thereof in any country, LICENSEE shall be
given sufficient notice of HARVARD&#146;s decision so that LICENSEE may request that
HARVARD continue prosecuting or maintaining such patents or patent applications, at
LICENSEE&#146;s expense. If HARVARD elects not to prosecute or maintain such patents or
patent applications after such request by LICENSEE, then LICENSEE shall have the
right, but not the obligation, at its own expense to prosecute and maintain such patents and
patent applications or portion thereof in such country and in
HARVARD&#146;s name. If
LICENSEE assumes 100% of the costs to file, prosecute, and maintain certain patents and
patent applications relating to the PATENT RIGHTS pursuant to this Section&nbsp;7.5, and, if
HARVARD licenses the PATENT RIGHTS to one or more co-exclusive licensees
designated in Section&nbsp;3.1 after such time, then HARVARD will credit LICENSEE with
the costs LICENSEE has paid in excess of 50% if one other licensee, due for the
preparation, filing, prosecution and maintenance of patents and patent applications relating
to PATENT RIGHTS pursuant to Section&nbsp;7.1 above.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If LICENSEE can demonstrate that it is not being adequately informed or apprised of the
continuing prosecution of patents or patent applications in PATENT RIGHTS, or that it is
not being provided with reasonable opportunities to participate in decision making or that
its interests are not being adequately protected, LICENSEE shall be entitled to engage, at
LICENSEE&#146;s expense, independent patent counsel to review and evaluate patent
prosecution and filing of patents and patent applications included in PATENT RIGHTS.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Article </FONT>VIII<BR>
<FONT style="font-variant: SMALL-CAPS">Infringement</FONT>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>With respect to any PATENT RIGHTS that are licensed to LICENSEE pursuant to this Agreement,
LICENSEE shall have the right to prosecute in its own name and at its own expense any
infringement of such patent. HARVARD agrees to notify LICENSEE promptly of each infringement
of such patents of which HARVARD, as applicable, is or becomes aware. Before LICENSEE
commences an action with respect to any infringement of such patents, LICENSEE shall give
careful consideration to the views of HARVARD and to potential effects on the public interest
in making its decision whether or not to sue.</TD>
</TR>


</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE acknowledges that other co-exclusive licensees of PATENT RIGHTS designated
in Section&nbsp;3.1 shall have rights identical to LICENSEE to prosecute infringers and that co-exclusive licensees will be bound by the identical terms of this Section&nbsp;8.2. In any
prosecution instigated by LICENSEE and in which HARVARD, as necessary, is also named
plaintiff as owner of the PATENT RIGHTS, LICENSEE must notify other co-exclusive
licensees of the existence of such legal action and allow other co-exclusive licensees to join
as a plaintiff upon co-exclusive licensees&#146; request. In addition, in the event other co-exclusive licensees instigate an infringement prosecution, LICENSEE hereby consents to
being joined as a plaintiff in such suit solely for the purpose of procuring standing to bring
the action and at the sole expense of the instigating co-exclusive licensee. To the extent that
LICENSEE desires to participate in any strategic decisions affecting the prosecution of the
action brought by other co-exclusive licensees, LICENSEE acknowledges that it and co-exclusive licensees will necessarily have to reach a mutual agreement concerning litigation
expenses and strategy. In no event shall HARVARD incur any liability or expense in
connection with any action of co-exclusive licensees, joint or otherwise.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During any such litigation, HARVARD will agree to not license any defendant or accused
infringer of the PATENT RIGHTS in the litigation, without
LICENSEE&#146;s prior written consent.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">8.3</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If LICENSEE elects to commence an action as described above, HARVARD may, to
the extent permitted by law, elect to join as parties in that action. Regardless of
whether HARVARD elects to join as parties, HARVARD shall cooperate fully with LICENSEE
in connection with any such action.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD agrees to join as a party in any action if required by law to do so in
order
to bring an action under the PATENT RIGHTS.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall reimburse HARVARD for any costs incurs with
LICENSEE&#146;s
approval, including reasonable attorneys&#146; fees, as part of an
action brought by LICENSEE, irrespective of whether HARVARD becomes a co-plaintiff.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If LICENSEE elects to commence an action as described above, LICENSEE may deduct
from its royalty payments to HARVARD with respect to the patent(s) subject to suit an
amount not exceeding fifty percent (50%) of LICENSEE&#146;s expenses and costs of such
action, including reasonable attorneys&#146; fees; provided, however, that such reduction shall
not exceed fifty percent (50%) of the total royalty due to HARVARD with respect to the
patent(s) subject to suit for each calendar year. If such fifty percent (50%) of
LICENSEE&#146;s expenses and costs exceeds the amount of royalties deducted by LICENSEE
for any calendar year, LICENSEE may to that extent reduce the royalties due to
HARVARD from LICENSEE in succeeding calendar years, but never by more than fifty
percent (50%) of the total royalty due in any one year with respect to the patent(s) subject
to suit.</TD>
</TR>


</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>No settlement, consent judgment or other voluntary final disposition of the suit may be
entered into without the prior written consent of HARVARD which
consent shall not be unreasonably withheld.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Recoveries or reimbursements from actions commenced by LICENSEE pursuant to this
Article shall first be applied to reimburse LICENSEE, HARVARD for litigation costs not
paid from royalties and then to reimburse HARVARD for royalties deducted by
LICENSEE pursuant to Section&nbsp;8.4. Any remaining recoveries or reimbursements shall
be shared as follows:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If the amount is lost profits or lost royalties, LICENSEE shall receive an amount
equal to the damages the court determines LICENSEE has suffered as a result of the
infringement less the amount of any royalties that would have been due HARVARD on sales
of LICENSED PRODUCTS lost by LICENSEE as a result of the infringement had LICENSEE made
such sales, and HARVARD shall receive an amount equal to the royalties it would have
received if such sales had been made by LICENSEE, and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>As to awards other than lost profits or lost royalties, fifty percent (50%)
to LICENSEE and fifty percent (50%) to HARVARD.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If two or more co-exclusive licensees undertake the suit, the provision of this
Section&nbsp;8.6 will be modified to take into account each co-exclusive licensee&#146;s expenses
and lost profits.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If LICENSEE elects not to exercise its right to prosecute an infringement of the PATENT
RIGHTS pursuant to this Article, HARVARD may do so at its own expense, controlling
such action and retaining all recoveries therefrom. LICENSEE shall cooperate fully with
HARVARD in connection with any such action.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If a declaratory judgment action is brought naming LICENSEE as a defendant and
alleging invalidity of any of the PATENT RIGHTS, HARVARD may elect to take over
the sole defense of the action at its own expense. LICENSEE shall cooperate fully with
HARVARD in connection with any such action. HARVARD shall consult with
LICENSEE regarding such defense.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Article </FONT>IX<BR>
<FONT style="font-variant: SMALL-CAPS">Termination of Agreement</FONT>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">9.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Agreement, unless terminated as provided herein, shall remain in effect until the last
patent or patent application in PATENT RIGHTS has expired or been abandoned.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">9.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD may terminate this Agreement as follows:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If LICENSEE does not make a payment due hereunder and fails to cure such
non-payment (including the payment of interest in accordance with Section&nbsp;5.4(e)) within</TD>
</TR>


</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>thirty (30)&nbsp;days after the date of notice in writing of such non-payment by
HARVARD.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If LICENSEE defaults in its obligations under Sections&nbsp;10.3(c) and 10.3(d) to
procure and maintain insurance.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If LICENSEE shall become insolvent, shall make an assignment for the benefit of
creditors, or shall have a petition in bankruptcy filed for or against it. Such
termination shall be effective immediately upon HARVARD giving written notice to
LICENSEE.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If an examination by HARVARD&#146;s accountant pursuant to Article&nbsp;V shows an
underreporting or underpayment by LICENSEE in excess of twenty percent (20%)
for any twelve (12)&nbsp;month period, provided that such underreporting or underpayment
is not determined to be inadvertent or the result of an honest mistake.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If LICENSEE is convicted of a felony relating to the manufacture, use, or sale of
LICENSED PRODUCTS.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(f)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Except as provided in Subsections (a), (b), and (c)&nbsp;above, if LICENSEE defaults
in
the performance of any material obligations under this Agreement and the default has
not been remedied within forty-five (45)&nbsp;days after the date of notice in writing of
such default by HARVARD.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">9.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall provide, in all sublicenses granted by it under this Agreement, that
LICENSEE&#146;s interest in such sublicenses shall at HARVARD&#146;s option terminate or be assigned to
HARVARD upon termination of this Agreement; however, LICENSEE shall have the option to
nominate one of its sublicensees as a substitute for LICENSEE. The proposed substitute must
(i)&nbsp;have a net worth of at least equivalent to the net worth LICENSEE had as of the date of
this Agreement and (ii)&nbsp;have available resources and sufficient scientific, business and other
expertise comparable to LICENSEE in order to satisfy its obligations under this Agreement. At
least sixty (60)&nbsp;days prior to termination of this Agreement, LICENSEE shall provide HARVARD
with written notice of LICENSEE&#146;s nominee together with documentation sufficient to
demonstrate the requirements set forth in subparagraphs (i)&nbsp;and
(ii)&nbsp;above for HARVARD&#146;s approval, which shall not be unreasonably withheld. HARVARD shall notify LICENSEE in writing
of its decision prior to termination of this Agreement. If HARVARD
approves LICENSEE&#146;s
nominee, LICENSEE shall assign this Agreement to its nominee and its nominee shall accept the
assignment no later than thirty (30)&nbsp;days after the termination date of this Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event that HARVARD disapproved LICENSEE&#146;s first nominee, prior to the termination date
of this Agreement, LICENSEE shall have the option to nominate one of its other sublicensees
for HARVARD&#146;s approval which shall not be unreasonably withheld.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">9.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE may terminate this Agreement by giving ninety (90)&nbsp;days advance written
notice of termination to HARVARD. Upon termination, LICENSEE shall submit a final
Royalty Report to HARVARD and any royalty payments and unreimbursed patent
expenses invoiced by HARVARD shall become immediately payable.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">9.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Sections&nbsp;6.1, 6.2, 6.3, 7.1, 9.4, 9.5, 10.2, 10.3, 10.4, and 10.7 of this Agreement shall
survive termination.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Article </FONT>X<BR>
<FONT style="font-variant: SMALL-CAPS">General</FONT>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD does not warrant the validity of the PATENT RIGHTS licensed hereunder
and make no representations whatsoever with regard to the scope of the licensed
PATENT RIGHTS or that such PATENT RIGHTS may be exploited by LICENSEE, an
AFFILIATE, or SUBLICENSEE without infringing other patents, provided, however,
HARVARD represents that it has no knowledge of any facts or circumstances as of the
execution date of this Agreement that would render any of the PATENT RIGHTS invalid
or unenforceable. HARVARD represents and warrants, to the best of its knowledge, that
HARVARD owns all right, title and interest in and to the PATENT RIGHTS.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD EXPRESSLY DISCLAIMS ANY AND ALL IMPLIED WARRANTIES
AND MAKES NO EXPRESS OR IMPLIED WARRANTIES OF
MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF THE
PATENT RIGHTS OR INFORMATION SUPPLIED BY HARVARD, LICENSED
PROCESSES OR LICENSED PRODUCTS CONTEMPLATED BY THIS
AGREEMENT.</TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.3</TD>
    <TD width="1%" nowrap>&nbsp;(a)&nbsp;</TD>
    <TD>LICENSEE shall indemnify, defend and hold harmless HARVARD and its current or
former directors, governing board members, trustees, officers, faculty, medical and
professional staff, employees, students, and agents and their respective successors, heirs
and assigns (collectively, the &#147;INDEMNITEES&#148;), from and against any claim, liability, cost,
expense, damage, deficiency, loss or obligation of any kind or nature (including, without
limitation, reasonable attorney&#146;s fees and other costs and expenses of litigation)
(collectively, &#147;Claims&#148;), based upon, arising out of, or otherwise relating to this
Agreement, including without limitation any cause of action relating to product liability
concerning any product, process, or service made, used or sold pursuant to any right or
license granted under this Agreement, provided, however, that such indemnification shall not
apply to any liability, damage, loss, or expense to the extent directly attributable to the
negligent activities, reckless misconduct or intentional misconduct of Indemnitees.</TD>
</TR>
<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">(b)</TD>
    <TD>Each Indemnitee that intends to claim indemnification under Section&nbsp;10.3(a)
shall promptly notify LICENSEE of any claim or action in respect of which the
Indemnitee intends to claim such indemnification, and LICENSEE shall assume the defense
thereof with counsel mutually satisfactory to LICENSEE and HARVARD. The failure to
deliver notice to LICENSEE within a reasonable time after the</TD>
</TR>



</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>commencement of any such claim or action, if materially prejudicial to its ability to
defend such action, shall relieve LICENSEE of any liability to the Indemnitee under Section
10.3(a) with respect to such action, but the omission so to deliver notice to LICENSEE will
not relieve it of any liability that it may have to any Indemnitee otherwise than under
Section&nbsp;10.3(a). HARVARD and any other Indemnitee, and their respective employees and agents,
shall cooperate fully with LICENSEE and its legal representatives in the investigation of any
claim or action covered by the indemnification under Section&nbsp;10.3(a).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Beginning at the time any such product, process or service is being commercially
distributed or sold (other than for the purpose of obtaining regulatory approvals) by
LICENSEE or by a SUBLICENSEE, AFFILIATE or agent of LICENSEE,
LICENSEE shall, at its sole cost and expense, procure and maintain commercial
general liability insurance in amounts not less than $2,000,000 per incident and
$2,000,000 annual aggregate and naming the Indemnitees as additional insureds.
During clinical trials of any such product, process or service, LICENSEE shall, at its
sole cost and expense, procure and maintain commercial general liability insurance in
such equal or lesser amount as HARVARD shall require, naming the Indemnitees as
additional insureds. Such commercial general liability insurance shall provide: (i)
product liability coverage; and (ii)&nbsp;broad form contractual liability coverage for
LICENSEE&#146;s indemnification under this Agreement. If LICENSEE elects to self-insure all or part of the limits described above (including deductibles or retentions
which are in excess of $250,000 annual aggregate) such self-insurance program must
be acceptable to HARVARD and the Risk Management Foundation of the Harvard
Medical Institutions, Inc. in their sole discretion. The minimum amounts of insurance
coverage required shall not be construed to create a limit of
LICENSEE&#146;s liability
with respect to its indemnification under this Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall provide HARVARD with written evidence of such insurance upon
request of HARVARD. LICENSEE shall provide HARVARD with written notice at
least fifteen (15)&nbsp;days prior to the cancellation, non-renewal or material change in
such insurance; if LICENSEE does not obtain replacement insurance providing
comparable coverage within such fifteen (15)&nbsp;day period, HARVARD shall have the
right to terminate this Agreement effective at the end of such fifteen (15)&nbsp;day period
without notice or any additional waiting periods.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall maintain such commercial general liability insurance beyond the
expiration or termination of this Agreement during: (i)&nbsp;the period that any product,
process, or service, relating to, or developed pursuant to, this Agreement is being
commercially distributed or sold by LICENSEE or by a SUBLICENSEE,
AFFILIATE or agent of LICENSEE; and (ii)&nbsp;a reasonable period after the period
referred to in Subsection (e)(i) above which in no event shall be less than fifteen (15)
years.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall not use HARVARD&#146;s name or insignia, or any adaptation of them,
or
the name of any of HARVARD&#146;s inventors in any advertising,
promotional or sales literature without the prior written approval of HARVARD.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Without the prior written approval of HARVARD in each instance, neither this Agreement
nor the rights granted hereunder shall be transferred or assigned in whole or in part by
LICENSEE to any person whether voluntarily or involuntarily, by operation of law or
otherwise, except that each of LICENSEE and its AFFILIATES may assign this
Agreement in connection with a merger, consolidation or sale or transfer of all or
substantially all of its assets. This Agreement shall be binding upon the respective
successors, legal representatives and assignees of HARVARD and LICENSEE.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The interpretation and application of the provisions of this Agreement shall be governed
by the laws of the Commonwealth of Massachusetts.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall comply with all applicable laws and regulations. In particular, it is
understood and acknowledged that the transfer of certain commodities and technical data
is subject to United States laws and regulations controlling the export of such commodities
and technical data, including all Export Administration Regulations of the United States
Department of Commerce. These laws and regulations among other things, prohibit or
require a license for the export of certain types of technical data to certain specified
countries. LICENSEE hereby agrees and gives written assurance that it will comply with
all United States laws and regulations controlling the export of commodities and technical
data, that it will be solely responsible for any violation of such by LICENSEE or its
AFFILIATES or SUBLICENSEES, and that it will defend and hold HARVARD,
CHILDREN, and MIT harmless in the event of any legal action of any nature occasioned
by such violation.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE agrees: (i)&nbsp;to obtain all regulatory approvals required for the manufacture and
sale of LICENSED PRODUCTS and LICENSED PROCESSES; and (ii)&nbsp;to utilize
appropriate patent marking on such LICENSED PRODUCTS. LICENSEE also agrees to
register or record this Agreement as is required by law or regulation in any country where
the license is in effect.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.9</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any notices to be given hereunder shall be sufficient if signed by the party (or party&#146;s
attorney) giving same and either: (i)&nbsp;delivered in person; (ii)&nbsp;mailed certified mail
return
receipt requested; or (iii)&nbsp;faxed to other party if the sender has evidence of successful
transmission and if the sender promptly sends the original by ordinary mail, in any event
to the following addresses:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If to LICENSEE:<br>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mycometrix Corporation<br>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;213 E. Grand Ave.<br>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;South San Francisco, CA 94080<br>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Attention:<br>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fax: (650)-</TD>
</TR>


</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->19<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If to HARVARD:<br>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Office for Technology and Trademark Licensing<br>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Harvard University<br>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holyoke Center, Suite&nbsp;727<br>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1350 Massachusetts Avenue<br>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cambridge, MA 02138<br>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fax: (617) 495-9568</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>By such notice either party may change their address for future notices.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Notices delivered in person shall be deemed given on the date delivered. Notices sent by
fax shall be deemed given on the date faxed. Notices mailed shall be deemed given on the
date postmarked on the envelope.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.10</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Should a court of competent jurisdiction later hold any provision of this Agreement to be
invalid, illegal, or unenforceable, and such holding is not reversed on appeal, it shall be
considered severed from this Agreement. All other provisions, rights and obligations shall
continue without regard to the severed provision, provided that the remaining provisions
of this Agreement are in accordance with the intention of the parties.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.11</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event of any controversy or claim arising out of or relating to any provision of
this
Agreement or the breach thereof, the parties shall try to settle such conflict amicably
between themselves. Subject to the limitation stated in the final sentence of this Section
10.11, any such conflict which the parties are unable to resolve promptly shall be settled
through arbitration conducted in accordance with the rules of the American Arbitration
Association. The demand for arbitration shall be filed within a reasonable time after the
controversy or claim has arisen, and in no event after the date upon which institution of
legal proceedings based on such controversy or claim would be barred by the applicable
statute of limitation. Such arbitration shall be held in Boston, Massachusetts. The award
through arbitration shall be final and binding. Either party may enter any such award in a
court having jurisdiction or may make application to such court for judicial acceptance of
the award and an order of enforcement, as the case may be. Notwithstanding the
foregoing, either party may, without recourse to arbitration, assert against the other
party a
third-party claim or cross-claim in any action brought by a third party, to which the
subject matter of this Agreement may be relevant.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.12</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Agreement constitutes the entire understanding between the parties and neither party
shall be obligated by any condition or representation other than
those expressly stated herein or as may be subsequently agreed to by the parties hereto in writing.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;The remainder of this page is intentionally blank.&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->20<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
duly authorized representatives.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-variant: SMALL-CAPS">President And Fellows</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT style="font-variant: SMALL-CAPS">Mycometrix Corporation</FONT></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-variant: SMALL-CAPS"> of Harvard College</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Joyce Brinton
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/s/ Gajus Worthington</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="center" valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">Joyce Brinton, Director</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">Office for Technology and
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">President</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">Trademark Licensing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">12/20/00
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">12/21/00</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="center" valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Date</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->21<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Appendix
A </FONT>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The following comprise PATENT RIGHTS:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">[***]
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->22<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5A
<SEQUENCE>17
<FILENAME>f39432orexv10w5a.htm
<DESCRIPTION>EXHIBIT 10.5A
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w5a</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#091;***&#093; Indicates
text has been omitted from this Exhibit pursuant to a confidential treatment
request and has been filed separately with the Securities and Exchange Commission.
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.5A</B></DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>First Amendment</B></DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>To</B></DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Co-Exclusive License Agreement</B></DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B><I>Between</I></B></DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>PRESIDENT AND FELLOWS OF HARVARD COLLEGE</B></DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>And</B></DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>MYCOMETRIX CORPORATION (now Fluidigm Corporation)</B></DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Re: Harvard Case #&#091;***&#093;</B></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This is the first amendment to a co-exclusive license agreement effective October 15, 2000, by and
between the President and Fellows of Harvard College, with offices at 1350 Massachusetts Avenue,
Suite&nbsp;727, Cambridge, MA 02138 (&#147;Harvard&#148;) and Mycometrix Corporation, a California Corporation,
with offices at 213 East Grand Avenue, South San Francisco, CA 94080 (&#147;Licensee&#148;).</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">WHEREAS, Licensee has changed its name to Fluidigm Corporation, and moved to a new address at 7100
Shoreline Court, South San Francisco, California 94080; and</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">WHEREAS, both parties desire to clarify the definition of NET SALES and to make various minor
changes to the Agreement.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">NOW THEREFORE, Harvard and Licensee agree as follows:</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Change Paragraph&nbsp;1.5 to:</TD>
</TR>

</TABLE></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">LICENSED PROCESSES: the processes claimed, in whole or in part, by at least one
VALID CLAIM included within PATENT RIGHTS.</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><I>2.</I></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Change Paragraph&nbsp;1.6 to:</TD>
</TR>

</TABLE></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">LICENSED PRODUCTS: the products which are claimed, or the use of which is claimed,
by at least one VALID CLAIM included within</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">PATENT RIGHTS or products made or services provided in accordance with or by means of
LICENSED PROCESSES.</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Change Paragraph&nbsp;1.7 to:</TD>
</TR>

</TABLE></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">LICENSEE: Fluidigm Corporation, a corporation organized under the laws of California,
having its principal offices at 7100 Shoreline Court, South San Francisco, California
94080.</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Change the second full paragraph of Paragraph&nbsp;1.9 to:</TD>
</TR>

</TABLE></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">In the event that a LICENSED PRODUCT is sold or leased as a combination product containing
the LICENSED PRODUCT and one or more other components, NET SALES shall be calculated by
multiplying the gross amount invoiced for the sale of the combination product by the
fraction A/A&#043;B, where A is the average gross selling price of the LICENSED PRODUCT sold
separately by LICENSEE, and B is the average gross selling price of such other components
of the combination products sold separately by LICENSEE during the relevant royalty payment
period. In the event a substantial number of such separate sales were not made during the
relevant royalty period, then NET SALES shall be reasonably allocated by LICENSEE between
such LICENSED PRODUCT and such other components of the combination based on their relative
importance or value. If LICENSEE does so allocate, LICENSEE shall promptly deliver to
HARVARD a written report providing a detailed explanation of how LICENSEE determined said
relative importance or value. In the event that HARVARD disagrees with the determination
made by LICENSEE of said allocation of importance or value, HARVARD shall so notify
LICENSEE in writing, and a representative of LICENSEE and a representative of HARVARD shall
meet in order to discuss and resolve such disagreement. If such disagreement cannot be
resolved within sixty (60)&nbsp;days, such disagreement shall be subject to resolution in
accordance with Section&nbsp;10.11.</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Add the following sentence to the end of Paragraph&nbsp;1.10:</TD>
</TR>

</TABLE></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">In addition, SERVICE INCOME shall be subject to the following deductions:</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>customary trade, quantity or cash discounts and
non-affiliated broker&#146;s or agents&#146; commissions actually allowed and taken;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>amounts repaid or credited by reason of rejection; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to the extent separately stated on purchase orders, invoices, or
other documents of sale, taxes levied on and/or other governmental</TD>
</TR>


</TABLE></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>charges made as to performance, production, sale or use and paid by or on behalf
of LICENSE.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Change Paragraph&nbsp;1.15 to:</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">VALID CLAIM: either (i)&nbsp;a claim of an issued patent that has not been held unenforceable or
invalid by an agency or a court of competent jurisdiction in any unappealable or unappealed
decision or (ii)&nbsp;a claim of a pending patent application that has not been abandoned or
finally rejected without the possibility of appeal or refiling and that has been pending
for less than six (6)&nbsp;years from the earlier of a) the first priority date of such patent
application or b) the effective date of this Agreement.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Change Paragraph&nbsp;3.2(c) to:</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">LICENSEE shall use commercially reasonable efforts to effect introduction of the
LICENSED PRODUCTS into the commercial market as soon as practicable, consistent with
sound and reasonable business practice and judgment; thereafter, until the expiration
of this Agreement, LICENSEE shall endeavor to keep LICENSED PRODUCTS reasonably
available to the public, in each case consistent with industry practices for similar
companies and similar products.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Replace the last two sentences of Paragraph&nbsp;3.2(e) with:</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">&#147;Copies of all sublicense agreements shall be promptly provided to HARVARD. If a
sublicense agreement is part of a larger agreement (i.e., one that includes a business
relationship in addition to a sublicense agreement), LICENSEE need only send the part of
said larger agreement that is the sublicense agreement. HARVARD agrees to maintain any
information contained in such sublicensing agreements in confidence, except as otherwise
required by law, however, HARVARD may include in its usual reports annual amounts of
royalties paid.&#148;
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In Paragraph&nbsp;5.3 delete &#147;in each country&#148;, so LICENSEE needs to report the date of first
sale in the first country to have a sale, but LICENSEE still needs to report the date of
first sale for each LICENSED PRODUCT.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Replace Paragraph&nbsp;6.2 with:</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">&#147;HARVARD&#146;s accountant shall not disclose to HARVARD any information other than
whether the reports are correct or not, the reasons for any incorrectness and the amount
of any discrepancies.&#148;
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">11.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Add new Paragraph&nbsp;6.4:</TD>
</TR>
<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#147;Such examination by HARVARD&#146;s accountant shall take place not more than once in
each calendar year.&#148;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap>12.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Change Paragraph&nbsp;9.2(d) to:</TD>
</TR>

</TABLE></DIV>


<DIV style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;If
an examination by HARVARD&#146;s accountant pursuant to Article&nbsp;V shows an
underreporting or underpayment by LICENSEE in excess of twenty (20%) percent for any twelve
(12)&nbsp;month period and HARVARD&#146;s accountant determines said underreporting or underpayment
was not inadvertent or not the result of an honest mistake on
LICENSEE&#146;s part. In that
event, LICENSEE may promptly request HARVARD to have its accountant&#146;s findings reviewed by
another independent certified public accounting firm of nationally recognized standing
reasonably acceptable to LICENSEE, the total cost of which will be
invoiced to LICENSEE and paid within thirty (30)&nbsp;days. If said review indicates said
underreporting or underpayment by LICENSEE was inadvertent or the result of an honest
mistake then HARVARD will not terminate this Agreement.</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap>13.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In Paragraph&nbsp;10.9, change lines 6-11
to:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If to LICENSEE:</TD>
</TR>

</TABLE></DIV>
<DIV style="font-size: 10pt; margin-left: 6%; margin-top: 6pt">Fluidigm Corporation<BR>
7100 Shoreline Court<BR>South San Francisco, CA 94080<BR>
Attention: General Counsel<BR>
Fax: 650-871-7195</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">In all
other respects the co-exclusive License Agreement, effective October&nbsp;15, 2000, shall remain
the same. This amendment shall become effective upon both parties signing below, and have an
effective date of January&nbsp;1, 2005.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">IN WITNESS WHEREOF, the parties hereto have caused this second amendment to be executed by their
duly authorized representatives.</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><B>PRESIDENT AND FELLOWS</B></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top"><B>FLUIDIGM</B></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><B>OF HARVARD COLLEGE:</B></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top"><B>CORPORATION:</B></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">/s/ Joyce Brinton</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top">/s/ Gajus Worthington</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Joyce Brinton</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Director</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Printed:
</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Gajus Worthington</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Office for Technology and</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Trademark Licensing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">President &#38; CEO</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date: 12/22/04</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">12/23/04</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE></DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio --></DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>18
<FILENAME>f39432orexv10w6.htm
<DESCRIPTION>EXHIBIT 10.6
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w6</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">[***]
Indicates text has been omitted from this Exhibit pursuant to a
confidential treatment request and has been filed separately with the
Securities and Exchange Commission.</DIV>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.6
</B></DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>4060.LICI.006 Harvard</B></DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Co-Exclusive License Agreement</FONT></DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><I>Between</I></DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">President and Fellows of Harvard College</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">And</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Mycometrix Corporation</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Effective as of October&nbsp;15, 2000</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Re:
Harvard Case [***]</DIV>



<DIV style="font-size: 10pt; margin-top: 6pt; margin-left: 3%">In consideration of the mutual promises and covenants set forth below, the parties hereto
agree as follows:</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Article </FONT>I<BR>
<FONT style="font-variant: SMALL-CAPS">Definitions</FONT></DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>As used in this Agreement, the following terms shall have the following meanings:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>ACADEMIC RESEARCH PURPOSES: use of PATENT RIGHTS for academic research or other
not-for-profit scholarly purposes which are undertaken at a non-profit or governmental
institution that does not use the PATENT RIGHTS in the production or manufacture of products
for sale or the performance of services for a fee.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>AFFILIATE: any entity which controls, is controlled by, or is under common control with a
party by ownership or control of at least fifty percent (50%) of the voting stock or other
ownership. Unless otherwise specified, the term LICENSEE includes AFFILIATES.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>FIELD: use of PATENT RIGHTS to develop, manufacture, use, offer for sale, sell, or import
components and products in FIELD I and/or FIELD II:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>FIELD I:
[***]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>FIELD II:
[***]<BR></TD>
</TR>

</TABLE></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD: President and Fellows of Harvard College, a nonprofit Massachusetts educational
corporation having offices at the Office for Technology and Trademark Licensing, Holyoke
Center, Suite&nbsp;727, 1350 Massachusetts Avenue, Cambridge, Massachusetts 02138.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSED PROCESSES: the processes covered by at least one VALID CLAIM included within the
PATENT RIGHTS.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSED PRODUCTS: products covered by at least one VALID CLAIM included within the PATENT
RIGHTS or products made or services provided in accordance with or by means of LICENSED
PROCESSES.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE: Mycometrix Corporation, a corporation organized under the laws of Califonia having
its principal offices at 213 East Grand Avenue, South San Francisco, CA 94080.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>NET SERVICE INCOME: SERVICE INCOME less LICENSEE&#146;s actual direct and indirect cost for
research, development and/or services provided.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.9</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>NET SALES: the amount actually received for sales, leases, or other transfers of LICENSED
PRODUCTS, less:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>customary trade, quantity or cash discounts and
non-affiliated brokers&#146; or agents&#146; commissions actually allowed and taken;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>amounts repaid or credited by reason of rejection or return;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to the extent separately stated on purchase orders, invoices, or other
documents of sale, taxes levied on and/or other governmental charges made as to
production, sale, transportation, delivery or use and paid by or on behalf of
LICENSEE; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">(iv)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>reasonable charges for delivery or transportation provided by third parties
and cost of insurance in transit, if separately stated.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>NET SALES also includes the fair market value of any non-cash consideration received by
LICENSEE for the sale, lease, or transfer of LICENSED PRODUCTS.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If a LICENSED PRODUCT is sold as a combination product containing the LICENSED PRODUCT and
one or more other components, NET SALES shall be calculated by multiplying the gross amount
invoiced for the sale of the combination product by the fraction A/A&#043;B where A is the average
gross selling price of the LICENSED PRODUCT sold separately by LICENSEE and B is the average
gross selling price of such other components of the combination products sold separately by
LICENSEE during the relevant royalty payment period.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event that LICENSEE grants a sublicensee hereunder, and receives payments based upon
SUBLICENSEE&#146;s sales of LICENSED PRODUCTS, LICENSEE may upon approval from HARVARD (which
shall not be unreasonably withheld) modify the definition of NET SALES for the purposes of
calculating royalties payable to HARVARD on such SUBLICENSEE&#146;s sales to be the same as the
definition of NET SALES on which such royalties to LICENSEE are calculated.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>1.10</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>SERVICE INCOME: the total financial consideration received by LICENSEE for commercial
services performed on a fee-for-service basis using the LICENSED PRODUCTS or LICENSED
PROCESSES by LICENSEE under a contract with a third party, where such services are based
primarily on the use of fully functional LICENSED PRODUCTS or LICENSED PROCESSES (as
applicable) for their intended commercial use (such as, for example, where LICENSEE performs
commercial-scale genotyping services for a pharmaceutical company on a fee-for-service basis
using fully developed microfluidics chips comprising LICENSED PRODUCTS). SERVICE INCOME shall
not include amounts received in connection with research and/or development of LICENSED
PRODUCTS or LICENSED PROCESSES themselves.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>1.11</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>PATENT RIGHTS: The applications and patents as listed in Appendix&nbsp;A of this Agreement, the
allowed claims of such applications, the inventions described and claimed therein, and any
divisions or continuations of the applications and patents as listed in Appendix&nbsp;A, and
specific claims of any continuations-in-part of such applications to the extent the specific
claims are directed to subject matter described in the applications and patents listed in
Appendix&nbsp;A in a manner sufficient to support such specific claims under 35 U.S.C., patents
issuing thereon or reissues thereof, and any and all foreign patents and patent applications
corresponding thereto, all to the extent owned or controlled by HARVARD.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>1.12</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>SUBLICENSE INCOME: the amount paid to LICENSEE by a third party (other than an AFFILIATE of
LICENSEE) (a)&nbsp;for the sublicening of PATENT RIGHTS to a third party as well as (b)&nbsp;for the
related licensing of LICENSEE&#146;s own patent rights or know-how or
LICENSEE&#146;s in-licensed
non-HARVARD technologies, including but not limited to (i)&nbsp;license fees, (ii)&nbsp;milestone
payments, (iii)&nbsp;royalties, (iv)&nbsp;the fair market value in cash of any non-cash consideration
for such sublicense, and (v)&nbsp;in the event that LICENSEE receives any payment for equity in
consideration for the grant of sublicense rights that included a premium over the fair market
value of such equity, the amount of such premium. LICENSEE shall be responsible for
determining such fair market value with reasonable business judgment.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>1.13</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>SUBLICENSEE: any non-AFFILIATE granted a sublicense of any of the rights HARVARD has granted
to LICENSEE under Section&nbsp;3.1.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>1.14</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>TERRITORY: Worldwide.</TD>
</TR>



</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>1.15</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>VALID CLAIM: either (i)&nbsp;a claim of an issued patent that has not been held
unenforceable or invalid by an agency or a court of competent jurisdiction in any
unappealable or unappealed decision or (ii)&nbsp;a claim of a published, pending patent
application, which claim is substantially identical to a corresponding claim in a subsequently
issued patent having priority to the patent application.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>1.16</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The terms &#147;Public Law 96-517&#148; and &#147;Public Law 98-620&#148; include all amendments to those statutes.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>1.17</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The terms &#147;sold&#148; and &#147;sell&#148; include, without limitation, leases and other transfers and similar transactions.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Article </FONT>II<BR>
<FONT style="font-variant: SMALL-CAPS">Representations</FONT>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD is owner by assignment from [***], in the US and foreign patent applications
corresponding thereto, and in the inventions described and claimed therein. Inventorship
will be finalized in the near future.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD has authority to issue licenses under PATENT RIGHTS.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD is committed to the policy that ideas or creative works produced at HARVARD should
be used for the greatest possible public benefit, and believes that every reasonable
incentive should be provided for the prompt introduction of such ideas into public use, all
in a manner consistent with the public interest.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE is prepared and intends to diligently develop the invention and to bring products
to market which are subject to this Agreement, specifically including one or more products in
the FIELD selected from a [***].</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE is desirous of obtaining a co-exclusive license in the FIELD and in the TERRITORY
in order to practice the PATENT RIGHTS in the United States and in certain foreign countries,
and to manufacture, use and sell in the commercial market the products made in accordance
therewith, and HARVARD is desirous of granting such a license to LICENSEE in accordance with
the terms of this Agreement.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Article</FONT>&nbsp;III<BR>
<FONT style="font-variant: SMALL-CAPS">Grant of Rights</FONT>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD hereby grants to LICENSEE and LICENSEE accepts, subject to the terms and conditions
hereof, in the TERRITORY a co-exclusive commercial license under PATENT</TD>
</TR>


</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>RIGHTS in FIELD I and in FIELD II to make and have made, to use and have used, to sell and
have sold, and to offer for sale and have offered for sale the LICENSED PRODUCTS, and to
practice the LICENSED PROCESSES, for the life of the PATENT RIGHTS. HARVARD will grant no
more than two commercial licenses in FIELD I at any time and will grant no more than two
commercial licenses in FIELD II at any time and HARVARD will not grant other licenses in the
FIELD except as required by HARVARD&#146;s obligations in Section&nbsp;3.2(a) or as permitted Section
3.2(b). Such co-exclusive license shall include the right to grant sublicenses under the
following circumstances: (i)&nbsp;LICENSEE can demonstrate that it has added significant value to
the PATENT RIGHTS to be sublicensed, and that such a sublicense also contains a substantial
and essentially simultaneous license of LICENSEE owned intellectual property, or (ii)
LICENSEE grants a sublicense under other HARVARD patent rights licensed exclusively to
LICENSEE which are dominated by PATENT RIGHTS, and such sublicense under PATENT RIGHTS is
necessary to practice such other HARVARD patent rights.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The granting and exercise of this license is subject to the following conditions:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD&#146;s &#147;Statement of Policy in Regard to Inventions, Patents and Copyrights,&#148;
dated August&nbsp;10, 1998, Public Law 96-517, Public Law 98-620. In addition, this Agreement
is subject to HARVARD&#146;s obligations under agreements with other sponsors of research,
provided that such obligations are not in conflict with the rights granted hereunder.
Any right granted in this Agreement greater than that permitted under Public Law 96-517,
or Public Law 98-620, shall be subject to modification as may be required to conform to
the provisions of those statutes.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD reserves the right to make and use, and grant to others non-exclusive
licenses to make and use solely for ACADEMIC RESEARCH PURPOSES the subject matter
described and claimed in PATENT RIGHTS.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall use commercially reasonable efforts to effect introduction of the
LICENSED PRODUCTS into the commercial market as soon as practicable, consistent with
sound and reasonable business practice and judgment; thereafter, until the expiration
of this Agreement, LICENSEE shall endeavor to keep LICENSED PRODUCTS reasonably
available to the public.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>At any time after three years from the effective date of this Agreement and as
HARVARD&#146;s sole remedy for such non-performance, HARVARD may increase the license
maintenance royalty under Section&nbsp;4.4 to [***] ($[***]) dollars each in
FIELD I and in FIELD II in year 2004 and [***] ($[***]) dollars each in FIELD
I and FIELD II per year each year beginning in 2005, if in
HARVARD&#146;s reasonable
judgment, the Progress Reports furnished by LICENSEE do not demonstrate that LICENSEE
has satisfied at least one of the following conditions, which non-performance is not
cured within ninety (90)&nbsp;days following the written notification of such by HARVARD to
LICENSEE:</TD>
</TR>



</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 18pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>has put the licensed subject matter into commercial use in at least one of
the countries hereby licensed, directly or through a sublicense, and is keeping
the licensed subject matter reasonably available to the public; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>is engaged in research, development, manufacturing, marketing or
sublicensing activity appropriate to achieving 3.2(d)(i).</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In all sublicenses granted by LICENSEE hereunder, LICENSEE shall include a
requirement that the SUBLICENSEE use commercially reasonable efforts to bring the
subject matter of the sublicense into commercial use. LICENSEE shall further provide in
such sublicenses that such sublicenses are subject and subordinate to the terms and
conditions of this Agreement, except: (i)&nbsp;the SUBLICENSEE may not further sublicense;
and (ii)&nbsp;the rate of royalty on NET SALES paid by the SUBLICENSEE to the LICENSEE.
Copies of the relevant provisions of all sublicense agreements shall be provided
promptly to HARVARD. HARVARD agrees to maintain any information contained in such
provisions in confidence, except as otherwise required by law, however, HARVARD may
include in its usual reports annual amounts of royalties paid.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(f)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>A license in any other field of use in addition to the FIELD shall be the
subject of a separate agreement and shall require LICENSEE&#146;s submission of evidence,
satisfactory to HARVARD, demonstrating LICENSEE&#146;s willingness and ability to develop
and commercialize in such other field of use the kinds of products or processes likely
to be encompassed in such other fields.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(g)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To the extent that federal funds are used to support research leading to a
patent or patent application in the PATENT RIGHTS, LICENSEE shall cause any LICENSED
PRODUCT produced for sale by LICENSEE or SUBLICENSEES in the United States to be
manufactured substantially in the United States during the period of exclusivity of
this license in the United States.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All rights reserved to the United States Government and others under Public Law 96-517, and
Public Law 98-620, shall remain and shall in no way be affected by this Agreement.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Article </FONT>IV<BR>
<FONT style="font-variant: SMALL-CAPS">Royalties</FONT>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall pay to HARVARD a non-refundable license
royalty fee in the sum of [***] dollars ($[***]) payable within thirty (30)&nbsp;days of the execution date of this
Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>(a)&nbsp;In consideration of the right and license granted herein, LICENSEE shall pay to HARVARD
during the term of this Agreement a royalty of [***] percent ([***]) on NET SALES of LICENSED
PRODUCTS sold by LICENSEE.</TD>
</TR>



</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>(b)&nbsp;In the event that a single LICENSED PRODUCT or LICENSED PROCESS is covered by HARVARD
intellectual property in addition to PATENT RIGHTS, which is licensed to LICENSEE under other
agreements as of the date of this Agreement, then the total royalty payment due HARVARD under all
such agreements including this Agreement shall be [***] percent ([***]) of NET SALES. LICENSEE shall
notify HARVARD of the identity of each license agreement that includes patent rights covering the
product or process, and HARVARD shall distribute the royalties evenly among such agreements.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>(c)&nbsp;As consideration for the rights granted hereunder, LICENSEE shall pay to
HARVARD during the term of this Agreement a royalty in the form of stock of LICENSEE as follows:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap>(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall issue to HARVARD [***] shares of the Common Stock of LICENSEE (&#147;Shares&#148;) pursuant to the terms of a
mutually acceptable Stock Subscription Agreement, provided, however, that HARVARD shall
be subject to and enter into appropriate agreements and related documents as required of
other stockholders of LICENSEE.</TD>
</TR>

</TABLE>
</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">(ii)&nbsp;HARVARD represents and warrants to LICENSEE that:
</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">(1)&nbsp;HARVARD is acquiring the Shares for its own account for investment and not
with a view to, or for sale in connection with any distribution thereof, nor with
any present intention of distributing or selling the same; and HARVARD has no
present or contemplated agreement, undertaking, arrangement, obligation,
indebtedness or commitment providing for the disposition thereof.
</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">(2)&nbsp;HARVARD has full power and authority to enter into and to perform this
Agreement in accordance with its terms.
</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">(3)&nbsp;HARVARD has sufficient knowledge and experience in investing in companies
similar to LICENSEE so as to be able to evaluate the risks and merits of its
investment in LICENSEE and is able financially to bear the risks thereof.
</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">(iii)&nbsp;Each certificate representing the Shares shall bear a legend
substantially in the following form:
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">&#147;The shares represented by this certificate have not been registered under the Securities
Act of 1933 or any state securities law and they may not be sold or otherwise transferred
by any person, including a pledgee, unless (1)&nbsp;either (a)&nbsp;a registration statement with
respect to such shares shall be effective under the Securities Act of 1933, as amended,
or (b)&nbsp;the Corporation shall have received an opinion of counsel satisfactory to the
Corporation that an exemption from registration under such Act is then available, and (2)
there shall have been compliance with all applicable securities laws.&#148;</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">&#147;The shares represented by this certificate are subject to a mutually agree-upon Stock
Purchase and Right of First Refusal Agreement with this Corporation, a copy of which
Stock Purchase and Right of First Refusal Agreement is available for inspection at the
offices of the Corporation or may be made available upon request.&#148;</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">The foregoing legend shall be removed from the certificates representing any Shares, at
the request of the holder thereof, at such time as they become eligible for resale
pursuant to the Securities Act of 1933, as amended.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">If at any time prior to the time the Shares are eligible for resale pursuant to an
exemption from registration under the Securities Act of 1933, as amended, LICENSEE
proposes to register any of its Common Stock, under the Securities Act of 1933, except at
LICENSEE&#146;s initial public offering or any offering pursuant to Forms S-4 or S-8, LICENSEE
shall offer HARVARD the opportunity to have its Shares registered under the registration
statement to be filed at such time. HARVARD will be offered the right to register its
Shares under the same terms, conditions and restrictions as other shareholders with
piggyback registration rights and the inclusion of any Shares in such registration
statement shall be subject to the approval of the underwriters of such offering</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">(iv)&nbsp;HARVARD&#146;s ownership rights to Shares shall not be affected should the license
pursuant to this Agreement be converted to a non-exclusive one.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt; margin-left: 3%">(d)&nbsp;In the case of sublicenses, LICENSEE shall also pay to HARVARD a royalty of [***] of
SUBLICENSE INCOME. If compensation for such a sublicense of PATENT RIGHTS is bundled with
compensation received for the sublicensing of the other HARVARD patent rights licensed to LICENSEE
under other agreements as of the date of this Agreement, LICENSEE
shall pay HARVARD only [***] of the total compensation received no matter how many license agreements from HARVARD
are involved. In such a case, LICENSEE shall notify HARVARD of the identity of each license
agreement involved and HARVARD shall distribute its [***] of</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="font-size: 10pt; margin-top: 6pt; margin-left: 3%">compensation equally among those license agreements, including this Agreement.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt; margin-left: 3%">(e)&nbsp;LICENSEE shall pay HARVARD [***] of NET SERVICE INCOME. If SERVICE INCOME
is bundled with service income under another license to LICENSEE as of the date of this
Agreement, LICENSEE shall pay a royalty of [***] of NET SERVICE INCOME
received from each and every third party (&#147;Third Party&#148;) to which services are provided.
LICENSEE shall notify HARVARD of the identity of each license agreement involved in the
services and HARVARD shall distribute its [***] of compensation equally among
those license agreements, including this Agreement.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt; margin-left: 3%">(f)&nbsp;If other co-exclusive licenses in the same FIELD and TERRITORY are granted after the
date this Agreement is executed, the above financial compensation shall not exceed the
financial compensation to be paid by other licensees in the same FIELD and TERRITORY during
the term of the co-exclusive license provided LICENSEE accepts any less favorable terms
included in such other license.</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt; margin-left: 3%">If stock is part of the financial compensation to be paid by other licensees in the same
FIELD and TERITORY, the fair market value of the stock shall be the same as the price per
share which other investors paid in the last round of financing unless the stock is publicly
traded.</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>On sales between LICENSEE and its AFFILIATES for resale or incorporation into
products, the royalty shall be paid on the NET SALES of the AFFILIATE. On sales
between LICENSEE and sublicensees for resale, the royalty shall be paid on the
SUBLICENSE INCOME.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>4.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>No later than January 1 of each calendar year indicated below, LICENSEE shall pay to
HARVARD the following non-refundable license maintenance royalty and/or advance on
royalties. Such payments shall be credited against running royalties due for that calendar
year and Royalty Reports shall reflect such a credit. Such payments shall not be credited
against milestone payments (if any) nor against royalties due for any subsequent calendar
year nor against such payments due under any other agreements with HARVARD.</TD>
</TR>

</TABLE></DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">FIELD I</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">FIELD II</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">January&nbsp;1, 2002</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD align="right">[***]</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD align="right">[***]</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD><DIV style="margin-left:15px; text-indent:-15px">January&nbsp;1, 2003</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD align="right">[***]</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD align="right">[***]</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">

<TD><DIV style="margin-left:15px; text-indent:-15px">January&nbsp;1, 2004</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD align="right">[***]</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD align="right">[***]</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">each year thereafter</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD align="right">[***]</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD align="right">[***]</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE></DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Article </FONT>V<BR>
<FONT style="font-variant: SMALL-CAPS">Reporting</FONT></DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>5.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Prior to signing this Agreement, LICENSEE has provided to HARVARD a written business plan
under which LICENSEE intends to bring the subject matter of the licenses</TD>
</TR>


</TABLE></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD colspan="3">granted hereunder into commercial use upon execution of this Agreement. Such plan includes
proposed marketing efforts.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD nowrap>5.2&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">No later than sixty (60)&nbsp;days after June&nbsp;30 of each calendar year, LICENSEE shall provide to
HARVARD a written annual Progress Report describing progress on research and development,
regulatory approvals, manufacturing, sublicensing, marketing and sales during the most recent
twelve (12)&nbsp;month period ending June&nbsp;30 and plans for the forthcoming year. If multiple
technologies are covered by the license granted hereunder, the Progress Report shall provide
the information set forth above for each technology. If progress differs from that anticipated
in the plan required under Section&nbsp;5.1, LICENSEE shall explain the reasons for the difference
and propose a modified plan for HARVARD&#146;s review. LICENSEE shall also provide any reasonable
additional data HARVARD requires to evaluate LICENSEE&#146;s performance.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD>5.3</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">LICENSEE shall report to HARVARD the date of first sale of LICENSED PRODUCTS (or results of
LICENSED PROCESSES) in each country within thirty (30)&nbsp;days of occurrence.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD>5.4</TD>
    <TD>&nbsp;</TD>
    <TD>(a)</TD>
    <TD colspan="2">LICENSEE shall submit to HARVARD within sixty (60)&nbsp;days after each calendar
half year ending June&nbsp;30 and December&nbsp;31, a Royalty Report setting forth for such half
year at least the following information:</TD>
</TR>

<TR valign="bottom" style="font-size:6pt">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(i)</TD>
    <TD>the number of LICENSED PRODUCTS sold by LICENSEE in each country;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(ii)</TD>
    <TD>total billings and amounts actually received for such LICENSED PRODUCTS;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(iii)</TD>
    <TD>an accounting for all LICENSED PROCESSES used or sold;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(iv)</TD>
    <TD>deductions applicable to determine the NET SALES thereof;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
   <TD>(v)</TD>
    <TD>the amount of SERVICE INCOME received by LICENSEE and an accounting
of all deductions to yield NET SERVICE INCOME;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
   <TD>(vi)</TD>
    <TD>the amount of SUBLICENSE INCOME received by LICENSEE; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
   <TD nowrap>(vii)&nbsp;</TD>
    <TD>the amount of royalty due thereon, or, if no royalties are due to
HARVARD for any reporting period, the statement that no royalties are due.</TD>
</TR>
<TR valign="bottom" style="font-size:6pt">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">Such report shall be certified as correct by an officer of LICENSEE and shall include a
detailed listing of all deductions from royalties.</TD>
</TR>
<TR valign="bottom" style="font-size:6pt">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(b)</TD>
    <TD colspan="2">LICENSEE shall pay to HARVARD with each such Royalty Report the amount of
royalty due with respect to such half year. If multiple technologies are covered by the
license granted hereunder, LICENSEE shall specify which PATENT RIGHTS are utilized for
each LICENSED PRODUCT and LICENSED PROCESS included in the Royalty Report.</TD>
</TR>

</TABLE></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All payments due hereunder shall be deemed received when funds are credited to
HARVARD&#146;s bank account and shall be payable by check or wire transfer in United States
dollars. Conversion of foreign currency to U.S. dollars shall be made at the conversion
rate existing in the United States (as reported in the New York Times or the Wall
Street Journal) on the last working day of each royalty period. No transfer, exchange,
collection or other charges shall be deducted from such payments.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All such reports shall be maintained in confidence by HARVARD except as required
by law; however, HARVARD may include in its usual reports annual amounts of royalties
paid.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Late payments shall be subject to a charge of one and one-half percent (1.5%)
per month, or $250, whichever is greater.</TD>
</TR>

</TABLE></DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event of acquisition, merger, change of corporate name or change in make-up,
organization, or identity, LICENSEE shall notify HARVARD in writing within thirty
(30)&nbsp;days of such event.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If by law, regulation or fiscal policy of a particular country, conversion into United
States
dollars or transfer of funds of a convertible currency to the United States is restricted or
forbidden, LICENSEE shall give HARVARD prompt notice in writing and shall pay the
royalty and other amounts due through such means or methods as are lawful in such
country as HARVARD may reasonably designate. Failing the designation by HARVARD
of such lawful means or methods within thirty (30)&nbsp;days after such notice is given to
HARVARD, LICENSEE shall deposit such royalty or other payment in local currency to
the credit of HARVARD in a recognized banking institution designated by HARVARD,
or if none is designated by HARVARD within the thirty (30)&nbsp;day period described above,
in a recognized banking institution selected by LICENSEE and identified in a written
notice to HARVARD by LICENSEE, and such deposit shall fulfill all obligations of
LICENSEE to HARVARD with respect to such royalties. When in any country in which
the law or regulations prohibit both the transmittal and deposit of royalties on sales in
such
country, royalty payments shall be suspended for as long as such prohibition is in effect,
and as soon as such prohibition ceases to be in effect, all royalties which LICENSEE
would have been under obligation to transmit or deposit, but for the prohibition, shall be
deposited or transmitted promptly to the extent allowable.</TD>
</TR>

</TABLE></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Article </FONT>VI<BR>
<FONT style="font-variant: SMALL-CAPS">Record Keeping</FONT></DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">6.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall keep, and shall require its SUBLICENSEES to keep, accurate records (together
with supporting documentation) of LICENSED PRODUCTS made, used or sold under this Agreement,
and SERVICE INCOME and SUBLICENSE INCOME received by LICENSEE under this Agreement,
appropriate to determine the amount of royalties due to HARVARD hereunder. Such records shall
be retained for three (3)&nbsp;years following the end of the reporting period to which they
relate. For such three year period, they shall be</TD>
</TR>

</TABLE></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>available during normal business hours upon reasonable advance notice for examination by a
certified public accountant selected by HARVARD, and reasonably acceptable to LICENSEE, for
the sole purpose of verifying reports and payments hereunder. In conducting examinations
pursuant to this Section&nbsp;6.1, HARVARD&#146;s accountant shall have access to all records which
HARVARD reasonably believes to be relevant to the calculation of royalties under Article&nbsp;IV.
HARVARD agrees to maintain any information contained in such records in confidence, except
as otherwise required by law and except information in regarding the amount of royalties
due.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>6.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD&#146;s accountant shall not disclose to HARVARD any information other than information
relating to the accuracy of reports and payments made hereunder.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>6.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Such examination by HARVARD&#146;s accountant shall be at
HARVARD&#146;s expense, except that if such
examination shows an underreporting or underpayment in excess of five percent (5%) for any
twelve (12)&nbsp;month period, then LICENSEE shall pay the cost of such examination as well as any
additional sum that would have been payable to HARVARD had the LICENSEE reported correctly,
plus interest on said sum at the rate of one and one-half percent (1.5%) per month.</TD>
</TR>

</TABLE></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Article </FONT>VII<BR>
<FONT style="font-variant: SMALL-CAPS">Domestic and Foreign Patent Filing and Maintenance</FONT></DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>7.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon execution of this Agreement, LICENSEE shall reimburse HARVARD for fifty percent (50%)
of all reasonable expenses HARVARD has incurred for the preparation, filing, prosecution,
maintenance and counseling with respect to PATENT RIGHTS. Such
expenses total [ *  *  * ] as
of October&nbsp;1, 2000. Thereafter, LICENSEE shall reimburse HARVARD for [ *  *  * ]  of
all such future reasonable expenses prior to termination of this Agreement upon receipt of
invoices from HARVARD.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>7.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD shall be responsible for the preparation, filing, prosecution and maintenance of any
and all patent applications and patents included in PATENT RIGHTS. HARVARD will instruct
counsel to directly notify HARVARD and LICENSEE and provide them copies of any official
communications from the United States and foreign patent offices relating to said prosecution,
and to provide LICENSEE with advance draft copies of all relevant communications to the
various patent offices, so that LICENSEE may be informed and apprised of the continuing
prosecution of patent applications in PATENT RIGHTS. LICENSEE shall have reasonable
opportunities to participate in decision making on all key decisions affecting filing,
prosecution and maintenance of patents and patent applications in PATENT RIGHTS. HARVARD will
use reasonable efforts to incorporate LICENSEE&#146;s reasonable suggestions regarding said
prosecution. HARVARD shall use all reasonable efforts to amend any patent application to
include claims reasonably requested by LICENSEE to protect LICENSED PRODUCTS.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>7.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD and LICENSEE shall cooperate fully in the preparation, filing, prosecution and
maintenance of PATENT RIGHTS and of all patents and patent applications licensed to LICENSEE
hereunder, executing all papers and instruments or requiring members of</TD>
</TR>

</TABLE></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD to execute such papers and instruments so as to enable HARVARD to apply for, to
prosecute and to maintain patent applications and patents in
HARVARD&#146;s name in any country.
Each party shall provide to the other prompt notice as to all matters which come to its
attention and which may affect the preparation, filing, prosecution or maintenance of any
such patent applications or patents.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE may elect to surrender its PATENT RIGHTS in any country upon sixty (60)&nbsp;days
written notice to HARVARD. Such notice shall not relieve LICENSEE from responsibility to
reimburse HARVARD for patent-related expenses incurred prior to the expiration of the (60)
day notice period.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If HARVARD elects not to prosecute or maintain any of the patents or patent applications
relating to PATENT RIGHTS or any portion thereof in any country, LICENSEE shall be given
sufficient notice of HARVARD&#146;s decision so that LICENSEE may request that HARVARD continue
prosecuting or maintaining such patents or patent applications, at
LICENSEE&#146;s expense. If
HARVARD elects not to prosecute or maintain such patents or patent applications after such
request by LICENSEE, then LICENSEE shall have the right, but not the obligation, at its own
expense to prosecute and maintain such patents and patent applications or portion thereof in
such country and in HARVARD&#146;s name. If LICENSEE assumes 100% of the costs to file, prosecute,
and maintain certain patents and patent applications relating to the PATENT RIGHTS pursuant to
this Section&nbsp;7.5, and, if HARVARD licenses the PATENT RIGHTS to one or more co-exclusive
licensees designated in Section&nbsp;3.1 after such time, then HARVARD will credit LICENSEE with
the costs LICENSEE has paid in excess of [ *  *  * ] if one other licensee, due for the preparation,
filing, prosecution and maintenance of patents and patent applications relating to PATENT
RIGHTS pursuant to Section&nbsp;7.1 above.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If LICENSEE can demonstrate that it is not being adequately informed or apprised of the
continuing prosecution of patents or patent applications in PATENT RIGHTS, or that it is not
being provided with reasonable opportunities to participate in decision making or that its
interests are not being adequately protected, LICENSEE shall be entitled to engage, at
LICENSEE&#146;s expense, independent patent counsel to review and evaluate patent prosecution and
filing of patents and patent applications included in PATENT RIGHTS.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Article </FONT>VIII<BR>
<FONT style="font-variant: SMALL-CAPS">Infringement</FONT>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>With respect to any PATENT RIGHTS that are licensed to LICENSEE pursuant to this Agreement,
LICENSEE shall have the right to prosecute in its own name and at its own expense any
infringement of such patent. HARVARD agrees to notify LICENSEE promptly of each infringement
of such patents of which HARVARD, as applicable, is or becomes aware. Before LICENSEE
commences an action with respect to any infringement of such patents, LICENSEE shall give
careful consideration to the views of HARVARD and to potential effects on the public interest
in making its decision whether or not to sue.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE acknowledges that other co-exclusive licensees of PATENT RIGHTS designated
in Section&nbsp;3.1 shall have rights identical to LICENSEE to prosecute infringers and that co-
exclusive licensees will be bound by the identical terms of this Section&nbsp;8.2. In any
prosecution instigated by LICENSEE and in which HARVARD, as necessary, is also named
plaintiff as owner of the PATENT RIGHTS, LICENSEE must notify other co-exclusive
licensees of the existence of such legal action and allow other co-exclusive licensees to join
as a plaintiff upon co-exclusive licensees&#146; request. In addition, in the event other co-
exclusive licensees instigate an infringement prosecution, LICENSEE hereby consents to
being joined as a plaintiff in such suit solely for the purpose of procuring standing to bring
the action and at the sole expense of the instigating co-exclusive licensee. To the extent that
LICENSEE desires to participate in any strategic decisions affecting the prosecution of the
action brought by other co-exclusive licensees, LICENSEE acknowledges that it and co-
exclusive licensees will necessarily have to reach a mutual agreement concerning litigation
expenses and strategy. In no event shall HARVARD incur any liability or expense in
connection with any action of co-exclusive licensees, joint or otherwise.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During any such litigation, HARVARD will agree to not license any defendant or accused
infringer of the PATENT RIGHTS in the litigation, without LICENSEE&#146;s prior written consent.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="95%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">8.3
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(a)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">If LICENSEE elects to commence an action as described above, HARVARD may, to
the extent permitted by law, elect to join as parties in that action. Regardless of
whether HARVARD elects to join as parties, HARVARD shall cooperate fully with LICENSEE
in connection with any such action.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(b)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">HARVARD agrees to join as a party in any action if required by law to do so in
order to bring an action under the PATENT RIGHTS.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(c)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">LICENSEE shall reimburse HARVARD for any costs incurs with LICENSEE&#146;s approval,
including reasonable attorneys&#146; fees, as part of an action brought by LICENSEE,
irrespective of whether HARVARD becomes a co-plaintiff.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If LICENSEE elects to commence an action as described above, LICENSEE may deduct
from its royalty payments to HARVARD with respect to the patent(s) subject to suit an
amount not exceeding [ *  *  * ] of LICENSEE&#146;s expenses and costs of such
action, including reasonable attorneys&#146; fees; provided, however, that such reduction shall
not exceed [ *  *  * ] of the total royalty due to HARVARD with respect to the
patent(s) subject to suit for each calendar year. If such [ *  *  * ] of
LICENSEE&#146;s expenses and costs exceeds the amount of royalties deducted by LICENSEE
for any calendar year, LICENSEE may to that extent reduce the royalties due to
HARVARD from LICENSEE in succeeding calendar years, but never by more than [ *  *  * ] of
the total royalty due in any one year with respect to the patent(s) subject
to suit.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>No settlement, consent judgment or other voluntary final disposition of the suit may be
entered into without the prior written consent of HARVARD which consent shall not be
unreasonably withheld.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Recoveries or reimbursements from actions commenced by LICENSEE pursuant to this Article
shall first be applied to reimburse LICENSEE, HARVARD for litigation costs not paid from
royalties and then to reimburse HARVARD for royalties deducted by LICENSEE pursuant to Section
8.4. Any remaining recoveries or reimbursements shall be shared as follows:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If the amount is lost profits or lost royalties, LICENSEE shall receive an
amount equal to the damages the court determines LICENSEE has suffered as a result of
the infringement less the amount of any royalties that would have been due HARVARD on
sales of LICENSED PRODUCTS lost by LICENSEE as a result of the infringement had
LICENSEE made such sales, and HARVARD shall receive an amount equal to the royalties it
would have received if such sales had been made by LICENSEE, and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>As to awards other than lost profits or lost royalties, [ *  *  * ]
to LICENSEE and fifty percent (50%) to HARVARD.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If two or more co-exclusive licensees undertake the suit, the provision of this
Section&nbsp;8.6 will be modified to take into account each co-exclusive licensee&#146;s expenses
and lost profits.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If LICENSEE elects not to exercise its right to prosecute an infringement of the PATENT
RIGHTS pursuant to this Article, HARVARD may do so at its own expense, controlling
such action and retaining all recoveries therefrom. LICENSEE shall cooperate fully with
HARVARD in connection with any such action.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If a declaratory judgment action is brought naming LICENSEE as a defendant and
alleging invalidity of any of the PATENT RIGHTS, HARVARD may elect to take over
the sole defense of the action at its own expense. LICENSEE shall cooperate fully with
HARVARD in connection with any such action. HARVARD shall consult with
LICENSEE regarding such defense.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Article </FONT>IX<BR>
<FONT style="font-variant: SMALL-CAPS">Termination of Agreement</FONT>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">9.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Agreement, unless terminated as provided herein, shall remain in effect until the last
patent or patent application in PATENT RIGHTS has expired or been abandoned.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">9.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD may terminate this Agreement as follows:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If LICENSEE does not make a payment due hereunder and fails to cure such
non-payment (including the payment of interest in accordance with Section&nbsp;5.4(e)) within</TD>
</TR>


</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>thirty (30)&nbsp;days after the date of notice in writing of such non-payment by HARVARD.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If LICENSEE defaults in its obligations under Sections&nbsp;10.3(c) and 10.3(d) to
procure and maintain insurance.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If LICENSEE shall become insolvent, shall make an assignment for the benefit of
creditors, or shall have a petition in bankruptcy filed for or against it. Such
termination shall be effective immediately upon HARVARD giving written notice to
LICENSEE.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If an examination by HARVARD&#146;s accountant pursuant to Article&nbsp;V shows an
underreporting or underpayment by LICENSEE in excess of twenty percent (20%) for any
twelve (12)&nbsp;month period, provided that such underreporting or underpayment is not
determined to be inadvertent or the result of an honest mistake.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If LICENSEE is convicted of a felony relating to the manufacture, use, or sale
of LICENSED PRODUCTS.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(f)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Except as provided in Subsections (a), (b), and (c)&nbsp;above, if LICENSEE defaults
in the performance of any material obligations under this Agreement and the default has
not been remedied within forty-five (45)&nbsp;days after the date of notice in writing of
such default by HARVARD.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">9.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall provide, in all sublicenses granted by it under this Agreement, that
LICENSEE&#146;s interest in such sublicenses shall at HARVARD&#146;s option terminate or be assigned to
HARVARD upon termination of this Agreement; however, LICENSEE shall have the option to
nominate one of its sublicensees as a substitute for LICENSEE. The proposed substitute must
(i)&nbsp;have a net worth of at least equivalent to the net worth LICENSEE had as of the date of
this Agreement and (ii)&nbsp;have available resources and sufficient scientific, business and other
expertise comparable to LICENSEE in order to satisfy its obligations under this Agreement. At
least sixty (60)&nbsp;days prior to termination of this Agreement, LICENSEE shall provide HARVARD
with written notice of LICENSEE&#146;s nominee together with documentation sufficient to
demonstrate the requirements set forth in subparagraphs (i)&nbsp;and (ii)&nbsp;above for HARVARD&#146;s
approval, which shall not be unreasonably withheld. HARVARD shall notify LICENSEE in writing
of its decision prior to termination of this Agreement. If HARVARD approves LICENSEE&#146;s
nominee, LICENSEE shall assign this Agreement to its nominee and its nominee shall accept the
assignment no later than thirty (30)&nbsp;days after the termination date of this Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event that HARVARD disapproved LICENSEE&#146;s first nominee, prior to the termination date
of this Agreement, LICENSEE shall have the option to nominate one of its other sublicensees
for HARVARD&#146;s approval which shall not be unreasonably withheld.<BR></TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">9.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE may terminate this Agreement by giving ninety (90)&nbsp;days advance written notice
of termination to HARVARD. Upon termination, LICENSEE shall submit a final Royalty Report to
HARVARD and any royalty payments and unreimbursed patent expenses invoiced by HARVARD shall
become immediately payable.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">9.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Sections&nbsp;6.1, 6.2, 6.3, 7.1, 9.4, 9.5, 10.2, 10.3, 10.4, and 10.7 of this Agreement shall
survive termination.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Article </FONT>X<BR>
<FONT style="font-variant: SMALL-CAPS">General</FONT>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD does not warrant the validity of the PATENT RIGHTS licensed hereunder and make no
representations whatsoever with regard to the scope of the licensed PATENT RIGHTS or that such
PATENT RIGHTS may be exploited by LICENSEE, an AFFILIATE, or SUBLICENSEE without infringing
other patents, provided, however, HARVARD represents that it has no knowledge of any facts or
circumstances as of the execution date of this Agreement that would render any of the PATENT
RIGHTS invalid or unenforceable. HARVARD represents and warrants, to the best of its
knowledge, that HARVARD owns all right, title and interest in and to the PATENT RIGHTS.</TD>
</TR>



<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD EXPRESSLY DISCLAIMS ANY AND ALL IMPLIED WARRANTIES AND MAKES NO EXPRESS OR IMPLIED
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF THE PATENT RIGHTS OR
INFORMATION SUPPLIED BY HARVARD, LICENSED PROCESSES OR LICENSED PRODUCTS CONTEMPLATED BY THIS
AGREEMENT.</TD>
</TR>
</TABLE>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" nowrap align="left">10.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">(a)</TD>
    <TD>LICENSEE shall indemnify, defend and hold harmless HARVARD and its current or
former directors, governing board members, trustees, officers, faculty, medical and
professional staff, employees, students, and agents and their respective successors, heirs
and assigns (collectively, the &#147;INDEMNITEES&#148;), from and against any claim, liability, cost,
expense, damage, deficiency, loss or obligation of any kind or nature (including, without
limitation, reasonable attorney&#146;s fees and other costs and expenses of litigation)
(collectively, &#147;Claims&#148;), based upon, arising out of, or otherwise relating to this
Agreement, including without limitation any cause of action relating to product liability
concerning any product, process, or service made, used or sold pursuant to any right or
license granted under this Agreement, provided, however, that such indemnification shall not
apply to any liability, damage, loss, or expense to the extent directly attributable to the
negligent activities, reckless misconduct or intentional misconduct of Indemnitees.</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="3%">(b)</TD>
    <TD>Each Indemnitee that intends to claim indemnification under Section&nbsp;10.3(a)
shall promptly notify LICENSEE of any claim or action in respect of which the
Indemnitee intends to claim such indemnification, and LICENSEE shall assume the defense
thereof with counsel mutually satisfactory to LICENSEE and HARVARD. The failure to
deliver notice to LICENSEE within a reasonable time after the</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>commencement of any such claim or action, if materially prejudicial to its ability to defend
such action, shall relieve LICENSEE of any liability to the Indemnitee under Section&nbsp;10.3(a)
with respect to such action, but the omission so to deliver notice to LICENSEE will not
relieve it of any liability that it may have to any Indemnitee otherwise than under Section
10.3(a). HARVARD and any other Indemnitee, and their respective employees and agents, shall
cooperate fully with LICENSEE and its legal representatives in the investigation of any claim
or action covered by the indemnification under Section&nbsp;10.3(a).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Beginning at the time any such product, process or service is being commercially distributed
or sold (other than for the purpose of obtaining regulatory approvals) by LICENSEE or by a
SUBLICENSEE, AFFILIATE or agent of LICENSEE, LICENSEE shall, at its sole cost and expense,
procure and maintain commercial general liability insurance in amounts not less than
[ *  *  * ] per incident and [ *  *  * ] annual aggregate and naming the Indemnitees as
additional insureds. During clinical trials of any such product, process or service, LICENSEE
shall, at its sole cost and expense, procure and maintain commercial general liability
insurance in such equal or lesser amount as HARVARD shall require, naming the Indemnitees as
additional insureds. Such commercial general liability insurance shall provide: (i)&nbsp;product
liability coverage; and (ii)&nbsp;broad form contractual liability coverage for LICENSEE&#146;s
indemnification under this Agreement. If LICENSEE elects to self-insure all or part of the
limits described above (including deductibles or retentions which are in excess of [ *  *  * ]
annual aggregate) such self-insurance program must be acceptable to HARVARD and the Risk
Management Foundation of the Harvard Medical Institutions, Inc. in their sole discretion. The
minimum amounts of insurance coverage required shall not be construed to create a limit of
LICENSEE&#146;s liability with respect to its indemnification under this Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall provide HARVARD with written evidence of such insurance upon request of
HARVARD. LICENSEE shall provide HARVARD with written notice at least fifteen (15)&nbsp;days prior
to the cancellation, non-renewal or material change in such insurance; if LICENSEE does not
obtain replacement insurance providing comparable coverage within such fifteen (15)&nbsp;day
period, HARVARD shall have the right to terminate this Agreement effective at the end of such
fifteen (15)&nbsp;day period without notice or any additional waiting periods.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall maintain such commercial general liability insurance beyond the expiration or
termination of this Agreement during: (i)&nbsp;the period that any product, process, or service,
relating to, or developed pursuant to, this Agreement is being commercially distributed or
sold by LICENSEE or by a SUBLICENSEE, AFFILIATE or agent of LICENSEE; and (ii)&nbsp;a reasonable
period after the period referred to in Subsection (e)(i) above which in no event shall be
less than fifteen (15)&nbsp;years.</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall not use HARVARD&#146;s name or insignia, or any adaptation of them, or the
name of any of HARVARD&#146;s inventors in any advertising, promotional or sales literature
without the prior written approval of HARVARD.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Without the prior written approval of HARVARD in each instance, neither this Agreement nor
the rights granted hereunder shall be transferred or assigned in whole or in part by LICENSEE
to any person whether voluntarily or involuntarily, by operation of law or otherwise, except
that each of LICENSEE and its AFFILIATES may assign this Agreement in connection with a
merger, consolidation or sale or transfer of all or substantially all of its assets. This
Agreement shall be binding upon the respective successors, legal representatives and assignees
of HARVARD and LICENSEE.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The interpretation and application of the provisions of this Agreement shall be governed by
the laws of the Commonwealth of Massachusetts.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall comply with all applicable laws and regulations. In particular, it is
understood and acknowledged that the transfer of certain commodities and technical data is
subject to United States laws and regulations controlling the export of such commodities and
technical data, including all Export Administration Regulations of the United States
Department of Commerce. These laws and regulations among other things, prohibit or require a
license for the export of certain types of technical data to certain specified countries.
LICENSEE hereby agrees and gives written assurance that it will comply with all United States
laws and regulations controlling the export of commodities and technical data, that it will
be solely responsible for any violation of such by LICENSEE or its AFFILIATES or
SUBLICENSEES, and that it will defend and hold HARVARD, CHILDREN, and MIT harmless in the
event of any legal action of any nature occasioned by such violation.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE agrees: (i)&nbsp;to obtain all regulatory approvals required for the manufacture and
sale of LICENSED PRODUCTS and LICENSED PROCESSES; and (ii)&nbsp;to utilize appropriate patent
marking on such LICENSED PRODUCTS. LICENSEE also agrees to register or record this Agreement
as is required by law or regulation in any country where the license is in effect.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.9</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any notices to be given hereunder shall be sufficient if signed by the party (or party&#146;s
attorney) giving same and either: (i)&nbsp;delivered in person; (ii)&nbsp;mailed certified mail return
receipt requested; or (iii)&nbsp;faxed to other party if the sender has evidence of successful
transmission and if the sender promptly sends the original by ordinary mail, in any event to
the following addresses:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If to LICENSEE:</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 0pt">Mycometrix Corporation<BR>
213 E. Grand Ave.<BR>
South San Francisco, CA 94080<BR>
Attention:<BR>
Fax: (650)-
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->19<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
<TD width="4%">&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD colspan="2">If to HARVARD:</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
    <TD>Office for Technology and Trademark Licensing<BR>
Harvard University<BR>
Holyoke Center, Suite&nbsp;727<BR>
1350 Massachusetts Avenue<BR>
Cambridge, MA 02138<BR>
Fax: (617) 495-9568</TD>
</TR>
<TR valign="bottom" style="font-size:6pt">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD colspan="2">By such notice either party may change their address for future notices.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">Notices delivered in person shall be deemed given on the date delivered. Notices sent by fax
shall be deemed given on the date faxed. Notices mailed shall be deemed given on the date
postmarked on the envelope.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
<TD></TD>
<TD>&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD nowrap>10.10</TD>
    <TD>&nbsp;</TD>
<TD colspan="2">Should a court of competent jurisdiction later hold any provision of this Agreement to be
invalid, illegal, or unenforceable, and such holding is not reversed on appeal, it shall be
considered severed from this Agreement. All other provisions, rights and obligations shall
continue without regard to the severed provision, provided that the remaining provisions of
this Agreement are in accordance with the intention of the parties.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD nowrap>10.11</TD>
    <TD>&nbsp;</TD>
<TD colspan="2">In the event of any controversy or claim arising out of or relating to any provision of this
Agreement or the breach thereof, the parties shall try to settle such conflict amicably
between themselves. Subject to the limitation stated in the final sentence of this Section
10.11, any such conflict which the parties are unable to resolve promptly shall be settled
through arbitration conducted in accordance with the rules of the American Arbitration
Association. The demand for arbitration shall be filed within a reasonable time after the
controversy or claim has arisen, and in no event after the date upon which institution of
legal proceedings based on such controversy or claim would be barred by the applicable statute
of limitation. Such arbitration shall be held in Boston, Massachusetts. The award through
arbitration shall be final and binding. Either party may enter any such award in a court
having jurisdiction or may make application to such court for judicial acceptance of the award
and an order of enforcement, as the case may be. Notwithstanding the foregoing, either party
may, without recourse to arbitration, assert against the other party a third-party claim or
cross-claim in any action brought by a third party, to which the subject matter of this
Agreement may be relevant.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
<TD></TD>
<TD>&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD nowrap>10.12</TD>
    <TD>&nbsp;</TD>
<TD colspan="2">This Agreement constitutes the entire understanding between the parties and neither party
shall be obligated by any condition or representation other than those expressly stated
herein or as may be subsequently agreed to by the parties hereto in writing.</TD>
</TR>

</TABLE></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;The remainder of this page is intentionally blank.&#093;</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->20<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="font-size: 10pt; margin-top: 6pt">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their duly
authorized representatives.</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top" align="center"><FONT style="font-variant: SMALL-CAPS">President And Fellows</FONT></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top" align="center"><FONT style="font-variant: SMALL-CAPS">Mycometrix Corporation</FONT></TD>
</TR>
<TR valign="bottom">
    <TD valign="top" align="center"><FONT style="font-variant: SMALL-CAPS">of Harvard College</FONT></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top" align="center">/s/ Joyce Brinton</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top" align="center">/s/ Gajus Worthington</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top" align="center">Joyce Brinton, Director</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top" align="center">Office for Technology and</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top" align="center">President</TD>
</TR>
<TR valign="bottom">
    <TD valign="top" align="center">Trademark Licensing</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top" align="center">12/7/00</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top" align="center">12/10/00</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top" align="center">Date</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top" align="center">Date</TD>
</TR>
<!-- End Table Body -->
</TABLE></DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->21<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS">Appendix A</FONT></DIV>
<DIV style="font-size: 10pt; margin-top: 6pt">The following comprise PATENT RIGHTS:</DIV>


<DIV style="font-size: 10pt; margin-top: 12pt"><U>[ *  *  * ]</U></DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">[ *  *  * ]</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->22<!-- /Folio --></DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>19
<FILENAME>f39432orexv10w7.htm
<DESCRIPTION>EXHIBIT 10.7
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w7</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#091;***&#093; Indicates
text has been omitted from this Exhibit pursuant to a confidential treatment
request and has been filed separately with the Securities and Exchange Commission.
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.7</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>4060.LICI.008 Harvard</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS">Co-Exclusive License Agreement</FONT>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><I>Between</I>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">President and Fellows of Harvard College

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">And

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Mycometrix Corporation

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Effective as of October&nbsp;15, 2000<BR>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Re: Harvard Case #&#091;***&#093;
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&nbsp;&nbsp;In consideration of the mutual promises and covenants set forth below, the parties
hereto agree as follows:</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Article I</FONT><BR>
<FONT style="font-variant: SMALL-CAPS">Definitions</FONT>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>As used in this Agreement, the following terms shall have the following meanings:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>ACADEMIC RESEARCH PURPOSES: use of PATENT RIGHTS for academic research or other
not-for-profit scholarly purposes which are undertaken at a non-profit or governmental
institution that does not use the PATENT RIGHTS in the production or manufacture of
products for sale or the performance of services for a fee.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>AFFILIATE: any entity which controls, is controlled by, or is under common control
with a party by ownership or control of at least fifty percent (50%) of the voting
stock or other ownership. Unless otherwise specified, the term LICENSEE includes
AFFILIATES.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>FIELD: use of PATENT RIGHTS to develop, manufacture, use, offer for sale, sell, or
import components and products in FIELD I and/or FIELD II:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>FIELD I: &#091;***&#093;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>FIELD II: &#091;***&#093;</TD>
</TR>
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD: President and Fellows of Harvard College, a nonprofit Massachusetts
educational corporation having offices at the Office for Technology and Trademark
Licensing, Holyoke Center, Suite&nbsp;727, 1350 Massachusetts Avenue, Cambridge,
Massachusetts 02138.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSED PROCESSES: the processes covered by at least one VALID CLAIM included
within the PATENT RIGHTS.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSED PRODUCTS: products covered by at least one VALID CLAIM included
within the PATENT RIGHTS or products made or services provided in accordance with or
by means of LICENSED PROCESSES.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE: Mycometrix Corporation, a corporation organized under the laws of
Califonia having its principal offices at 213 East Grand Avenue, South San Francisco,
CA 94080.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>NET SERVICE INCOME: SERVICE INCOME less LICENSEE&#146;S actual direct and
indirect cost for research, development and/or services provided.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.9</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>NET SALES: the amount actually received for sales, leases, or other transfers
of LICENSED PRODUCTS, less:</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">(i)&nbsp;customary trade, quantity or cash discounts and non-affiliated brokers&#146; or
agents&#146; commissions actually allowed and taken;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">(ii)&nbsp;amounts repaid or credited by reason of rejection or return;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 77px; text-indent: -28px">(iii)&nbsp;&nbsp;to the extent separately stated on purchase orders, invoices, or other
documents of sale, taxes levied on and/or other governmental charges made as
to production, sale, transportation, delivery or use and paid by or on behalf
of LICENSEE; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">(iv)&nbsp;reasonable charges for delivery or transportation provided by third
parties and cost of insurance in transit, if separately stated.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>NET SALES also includes the fair market value of any non-cash consideration received by
LICENSEE for the sale, lease, or transfer of LICENSED PRODUCTS.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If a LICENSED PRODUCT is sold as a combination product containing the LICENSED PRODUCT and one or
more other components, NET SALES shall be calculated by multiplying the gross amount invoiced for
the sale of the combination product by the fraction A/A&#043;B where A is the average gross selling
price of the LICENSED PRODUCT sold separately by LICENSEE and B is the average gross selling price
of such other components of the combination products sold separately by LICENSEE during the
relevant royalty payment period.</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event that LICENSEE grants a sublicensee hereunder, and receives payments based upon
SUBLICENSEE&#146;s sales of LICENSED PRODUCTS, LICENSEE may upon approval from HARVARD (which
shall not be unreasonably withheld) modify the definition of NET SALES for the purposes of
calculating royalties payable to HARVARD on such SUBLICENSEE&#146;s sales to be the same as the
definition of NET SALES on which such royalties to LICENSEE are calculated.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.10</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>SERVICE INCOME: the total financial consideration received by LICENSEE for commercial
services performed on a fee-for-service basis using the LICENSED PRODUCTS or LICENSED
PROCESSES by LICENSEE under a contract with a third party, where such services are based
primarily on the use of fully functional LICENSED PRODUCTS or LICENSED PROCESSES (as
applicable) for their intended commercial use (such as, for example, where LICENSEE performs
commercial-scale genotyping services for a pharmaceutical company on a fee-for-service basis
using fully developed microfluidics chips comprising LICENSED PRODUCTS). SERVICE INCOME shall
not include amounts received in connection with research and/or development of LICENSED
PRODUCTS or LICENSED PROCESSES themselves.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.11</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>PATENT RIGHTS: The applications and patents filed on the basis of the disclosure attached in
Appendix&nbsp;A of this Agreement, the allowed claims of such applications, the inventions
described and claimed therein, and any divisions or continuations of the applications and
patents, and specific claims of any continuations-in-part of such applications to the extent
the specific claims are directed to subject matter described in the applications and patents
in a manner sufficient to support such specific claims under 35 U.S.C., patents issuing
thereon or reissues thereof, and any and all foreign patents and patent applications
corresponding thereto, all to the extent owned or controlled by HARVARD.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.12</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>SUBLICENSE INCOME: the amount paid to LICENSEE by a third party (other than an AFFILIATE of
LICENSEE) (a)&nbsp;for the sublicening of PATENT RIGHTS to a third party as well as (b)&nbsp;for the
related licensing of LICENSEE&#146;s own patent rights or know-how or LICENSEE&#146;s in-licensed
non-HARVARD technologies, including but not limited to (i)&nbsp;license fees, (ii)&nbsp;milestone
payments, (iii)&nbsp;royalties, (iv)&nbsp;the fair market value in cash of any non-cash consideration
for such sublicense, and (v)&nbsp;in the event that LICENSEE receives any payment for equity in
consideration for the grant of sublicense rights that included a premium over the fair market
value of such equity, the amount of such premium. LICENSEE shall be responsible for
determining such fair market value with reasonable business judgment.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.13</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>SUBLICENSEE: any non-AFFILIATE granted a sublicense of any of the rights HARVARD has granted
to LICENSEE under Section&nbsp;3.1.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.14</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>TERRITORY: Worldwide.</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.15</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>VALID CLAIM: either (i)&nbsp;a claim of an issued patent that has not been held unenforceable or
invalid by an agency or a court of competent jurisdiction in any unappealable or unappealed
decision or (ii)&nbsp;a claim of a published, pending patent application, which claim is
substantially identical to a corresponding claim in a subsequently issued patent having priority
to the patent application.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.16</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The terms &#147;Public Law 96-517&#148; and &#147;Public Law 98-620&#148; include all amendments to those
statutes.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.17</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The terms &#147;sold&#148; and &#147;sell&#148; include, without limitation, leases and other transfers and
similar transactions.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Article </FONT>II<BR>
<FONT style="font-variant: SMALL-CAPS">Representations</FONT>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD is or will be owner by assignment from &#091;***&#093; in the US and foreign patent applications
corresponding thereto, and in the inventions described and claimed therein. Inventorship will
be finalized at the time of the US utility filing or in the near future when it is necessary.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD has authority to issue licenses under PATENT RIGHTS.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD is committed to the policy that ideas or creative works produced at HARVARD should
be used for the greatest possible public benefit, and believes that every reasonable
incentive should be provided for the prompt introduction of such ideas into public use, all
in a manner consistent with the public interest.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE is prepared and intends to diligently develop the invention and to bring products
to market which are subject to this Agreement, specifically including one or more products in
the FIELD selected from a &#091;***&#093;.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE is desirous of obtaining a co-exclusive license in the FIELD and in the TERRITORY
in order to practice the PATENT RIGHTS in the United States and in certain foreign countries,
and to manufacture, use and sell in the commercial market the products made in accordance
therewith, and HARVARD is desirous of granting such a license to LICENSEE in accordance with
the terms of this Agreement.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Article </FONT>III<BR>
<FONT style="font-variant: SMALL-CAPS">Grant of Rights</FONT>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD hereby grants to LICENSEE and LICENSEE accepts, subject to the terms and conditions
hereof, in the TERRITORY a co-exclusive commercial license under PATENT</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>RIGHTS in FIELD I and in FIELD II to make and have made, to use and have used, to sell and
have sold, and to offer for sale and have offered for sale the LICENSED PRODUCTS, and to
practice the LICENSED PROCESSES, for the life of the PATENT RIGHTS. HARVARD will grant no
more than two commercial licenses in FIELD I at any time and will grant no more than two
commercial licenses in FIELD II at any time and HARVARD will not grant other licenses in the
FIELD except as required by HARVARD&#146;s obligations in Section&nbsp;3.2(a) or as permitted Section
3.2(b). Such co-exclusive license shall include the right to grant sublicenses under the
following circumstances: (i)&nbsp;LICENSEE can demonstrate that it has added significant value to
the PATENT RIGHTS to be sublicensed, and that such a sublicense also contains a substantial
and essentially simultaneous license of LICENSEE owned intellectual property, or (ii)
LICENSEE grants a sublicense under other HARVARD patent rights licensed exclusively to
LICENSEE which are dominated by PATENT RIGHTS, and such sublicense under PATENT RIGHTS is
necessary to practice such other HARVARD patent rights.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The granting and exercise of this license is subject to the following conditions:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD&#146;s &#147;Statement of Policy in Regard to Inventions, Patents and Copyrights,&#148;
dated August&nbsp;10, 1998, Public Law 96-517, Public Law 98-620. In addition, this Agreement
is subject to HARVARD&#146;s obligations under agreements with other sponsors of research,
provided that such obligations are not in conflict with the rights granted hereunder.
Any right granted in this Agreement greater than that permitted under Public Law 96-517,
or Public Law 98-620, shall be subject to modification as may be required to conform to
the provisions of those statutes.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD reserves the right to make and use, and grant to others non-exclusive
licenses to make and use solely for ACADEMIC RESEARCH PURPOSES the subject matter
described and claimed in PATENT RIGHTS.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall use commercially reasonable efforts to effect introduction of the
LICENSED PRODUCTS into the commercial market as soon as practicable, consistent with
sound and reasonable business practice and judgment; thereafter, until the expiration
of this Agreement, LICENSEE shall endeavor to keep LICENSED PRODUCTS reasonably
available to the public.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>At any time after three years from the effective date of this Agreement and as
HARVARD&#146;s sole remedy for such non-performance, HARVARD may increase the license
maintenance royalty under Section&nbsp;4.4 to &#091;***&#093; dollars each in
FIELD I and in FIELD II in year 2004 and &#091;***&#093; dollars each in FIELD
I and in FIELD II per year each year beginning in 2005, if in HARVARD&#146;s reasonable
judgment, the Progress Reports furnished by LICENSEE do not demonstrate that LICENSEE
has satisfied at least one of the following conditions, which non-performance is not
cured within ninety (90)&nbsp;days following the written notification of such by HARVARD to
LICENSEE:</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>has put the licensed subject matter into commercial use in at least one of
the countries hereby licensed, directly or through a sublicense, and is keeping
the licensed subject matter reasonably available to the public; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>is engaged in research, development, manufacturing, marketing or
sublicensing activity appropriate to achieving 3.2(d)(i).</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In all sublicenses granted by LICENSEE hereunder, LICENSEE shall include a
requirement that the SUBLICENSEE use commercially reasonable efforts to bring the
subject matter of the sublicense into commercial use. LICENSEE shall further provide in
such sublicenses that such sublicenses are subject and subordinate to the terms and
conditions of this Agreement, except: (i)&nbsp;the SUBLICENSEE may not further sublicense;
and (ii)&nbsp;the rate of royalty on NET SALES paid by the SUBLICENSEE to the LICENSEE.
Copies of the relevant provisions of all sublicense agreements shall be provided
promptly to HARVARD. HARVARD agrees to maintain any information contained in such
provisions in confidence, except as otherwise required by law, however, HARVARD may
include in its usual reports annual amounts of royalties paid.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(f)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>A license in any other field of use in addition to the FIELD shall be the
subject of a separate agreement and shall require LICENSEE&#146;s submission of evidence,
satisfactory to HARVARD, demonstrating LICENSEE&#146;s willingness and ability to develop
and commercialize in such other field of use the kinds of products or processes likely
to be encompassed in such other fields.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(g)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To the extent that federal funds are used to support research leading to a
patent or patent application in the PATENT RIGHTS, LICENSEE shall cause any LICENSED
PRODUCT produced for sale by LICENSEE or SUBLICENSEES in the United States to be
manufactured substantially in the United States during the period of exclusivity of
this license in the United States.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All rights reserved to the United States Government and others under Public Law 96-517, and
Public Law 98-620, shall remain and shall in no way be affected by this Agreement.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Article </FONT>IV<BR>
<FONT style="font-variant: SMALL-CAPS">Royalties</FONT>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall pay to HARVARD a non-refundable license royalty fee in the sum of &#091;***&#093; payable
within thirty (30)&nbsp;days of the execution date of this
Agreement.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>(a)&nbsp;In consideration of the right and license granted herein, LICENSEE shall pay to HARVARD
during the term of this Agreement a royalty of &#091;***&#093; on NET SALES of LICENSED
PRODUCTS sold by LICENSEE.</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">(b)&nbsp;In the event that a single LICENSED PRODUCT or LICENSED PROCESS is covered by HARVARD
intellectual property in addition to PATENT RIGHTS, which is licensed to LICENSEE under other
agreements as of the date of this Agreement, then the total royalty payment due HARVARD under all
such agreements including this Agreement shall be &#091;***&#093; of NET SALES. LICENSEE shall
notify HARVARD of the identity of each license agreement that includes patent rights covering the
product or process, and HARVARD shall distribute the royalties evenly among such agreements.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">(c)&nbsp;As consideration for the rights granted hereunder, LICENSEE shall pay to HARVARD during the
term of this Agreement a royalty in the form of stock of LICENSEE as follows:</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap>(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall issue to HARVARD &#091;***&#093; shares of the Common Stock of LICENSEE (&#147;Shares&#148;) pursuant to the terms of a mutually
acceptable Stock Subscription Agreement, provided, however, that HARVARD shall be subject
to and enter into appropriate agreements and related documents as required of other
stockholders of LICENSEE.</TD>
</TR>
</TABLE></DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent" align="right">(ii)&nbsp;&nbsp;</TD>
    <TD width="3%" nowrap>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD represents and warrants to LICENSEE that:</TD>
</TR>
<TR style="margin-top: 6pt">
    <TD>&nbsp;</TD>
</TR>


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>(1)&nbsp;HARVARD is acquiring the Shares for its own account for investment and not
with a view to, or for sale in connection with any distribution thereof, nor with
any present intention of distributing or selling the same; and HARVARD has no
present or contemplated agreement, undertaking, arrangement, obligation,
indebtedness or commitment providing for the disposition thereof.
</TD>
<TR style="margin-top: 6pt">
    <TD>&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>(2)&nbsp;HARVARD has full power and authority to enter into and to perform this
Agreement in accordance with its terms.</TD>
<TR style="margin-top: 6pt">
    <TD>&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>(3)&nbsp;HARVARD has sufficient knowledge and experience in investing in companies
similar to LICENSEE so as to be able to evaluate the risks and merits of its
investment in LICENSEE and is able financially to bear the risks thereof.</TD>
<TR style="margin-top: 6pt">
    <TD>&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="10%" style="background: transparent" align="right">(iii)&nbsp;&nbsp;</TD>
    <TD width="3%" nowrap>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Each certificate representing the Shares shall bear a legend
substantially in the following form:</TD>
</TR>
</TABLE></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#147;The shares represented by this certificate have not been registered under the Securities
Act of 1933 or any state securities law and they may not be sold or otherwise transferred
by any person, including a pledgee, unless (1)&nbsp;either (a)&nbsp;a registration statement with
respect to such shares shall be effective under the Securities Act of 1933, as amended,
or (b)&nbsp;the Corporation shall have received an opinion of counsel satisfactory to the
Corporation that an exemption from registration under such Act is then available, and (2)
there shall have been compliance with all applicable securities laws.&#148;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#147;The shares represented by this certificate are subject to a mutually agree-upon Stock
Purchase and Right of First Refusal Agreement with this Corporation, a copy of which
Stock Purchase and Right of First Refusal Agreement is available for inspection at the
offices of the Corporation or may be made available upon request.&#148;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The foregoing legend shall be removed from the certificates representing any Shares, at
the request of the holder thereof, at such time as they become eligible for resale
pursuant to the Securities Act of 1933, as amended.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If at any time prior to the time the Shares are eligible for resale pursuant to an
exemption from registration under the Securities Act of 1933, as amended, LICENSEE
proposes to register any of its Common Stock, under the Securities Act of 1933, except at
LICENSEE&#146;s initial public offering or any offering pursuant to Forms S-4 or S-8, LICENSEE
shall offer HARVARD the opportunity to have its Shares registered under the registration
statement to be filed at such time. HARVARD will be offered the right to register its
Shares under the same terms, conditions and restrictions as other shareholders with
piggyback registration rights and the inclusion of any Shares in such registration
statement shall be subject to the approval of the underwriters of such offering</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD colspan="3">(iv)&nbsp;&nbsp;HARVARD&#146;s ownership rights to Shares shall not be affected should the license
pursuant to this Agreement be converted to a nonexclusive one.</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">(d)&nbsp;In the case of sublicenses, LICENSEE
shall also pay to HARVARD a royalty of &#091;***&#093; of
SUBLICENSE INCOME. If compensation for such a sublicense of PATENT RIGHTS is bundled with
compensation received for the sublicensing of the other HARVARD patent rights licensed to LICENSEE
under other agreements as of the date of this Agreement, LICENSEE shall pay HARVARD only &#091;***&#093; of
the total compensation received no matter how many license agreements from HARVARD
are involved. In such a case, LICENSEE shall notify HARVARD of the identity of each license
agreement involved and HARVARD shall distribute its &#091;***&#093; of
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">compensation equally among those license agreements, including this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">(e)&nbsp;LICENSEE shall pay HARVARD &#091;***&#093; of NET SERVICE INCOME. If SERVICE INCOME
is bundled with service income under another license to LICENSEE as of the date of this
Agreement, LICENSEE shall pay a royalty of &#091;***&#093; of NET SERVICE INCOME
received from each and every third party (&#147;Third Party&#148;) to which services are provided.
LICENSEE shall notify HARVARD of the identity of each license agreement involved in the
services and HARVARD shall distribute its &#091;***&#093; of compensation equally among
those license agreements, including this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">(f)&nbsp;If other co-exclusive licenses in the same FIELD and TERRITORY are granted after the
date this Agreement is executed, the above financial compensation shall not exceed the
financial compensation to be paid by other licensees in the same FIELD and TERRITORY during
the term of the co-exclusive license provided LICENSEE accepts any less favorable terms
included in such other license.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">If stock is part of the financial compensation to be paid by other licensees in the same
FIELD and TERITORY, the fair market value of the stock shall be the same as the price per
share which other investors paid in the last round of financing unless the stock is publicly
traded.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>On sales between LICENSEE and its AFFILIATES for resale or incorporation into products, the
royalty shall be paid on the NET SALES of the AFFILIATE. On sales between LICENSEE and
sublicensees for resale, the royalty shall be paid on the SUBLICENSE INCOME.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>No later than January 1 of each calendar year indicated below, LICENSEE shall pay to HARVARD
the following non-refundable license maintenance royalty and/or advance on royalties. Such
payments shall be credited against running royalties due for that calendar year and Royalty
Reports shall reflect such a credit. Such payments shall not be credited against milestone
payments (if any) nor against royalties due for any subsequent calendar year nor against such
payments due under any other agreements with HARVARD.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" colspan="2">FIELD I</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" colspan="2">FIELD II</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">

<TD><DIV style="margin-left:15px; text-indent:-15px">January&nbsp;1, 2002</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left"></TD>
    <TD align="center">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="center">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD><DIV style="margin-left:15px; text-indent:-15px">January&nbsp;1, 2003</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="center">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="center">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">

<TD><DIV style="margin-left:15px; text-indent:-15px">January&nbsp;1, 2004</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="center">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="center">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">each year thereafter</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="center">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD align="center">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Article </FONT>V<BR>
<FONT style="font-variant: SMALL-CAPS">Reporting</FONT>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Prior to signing this Agreement, LICENSEE has provided to HARVARD a written business plan
under which LICENSEE intends to bring the subject matter of the licenses</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>granted hereunder into commercial use upon execution of this Agreement. Such plan includes
proposed marketing efforts.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>No later than sixty (60)&nbsp;days after June&nbsp;30 of each calendar year, LICENSEE shall provide to
HARVARD a written annual Progress Report describing progress on research and development,
regulatory approvals, manufacturing, sublicensing, marketing and sales during the most recent
twelve (12)&nbsp;month period ending June&nbsp;30 and plans for the forthcoming year. If multiple
technologies are covered by the license granted hereunder, the Progress Report shall provide
the information set forth above for each technology. If progress differs from that anticipated
in the plan required under Section&nbsp;5.1, LICENSEE shall explain the reasons for the difference
and propose a modified plan for HARVARD&#146;s review. LICENSEE shall also provide any reasonable
additional data HARVARD requires to evaluate LICENSEE&#146;s performance.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall report to HARVARD the date of first sale of LICENSED PRODUCTS (or results of
LICENSED PROCESSES) in each country within thirty (30)&nbsp;days of occurrence.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="margin-left:30px; text-indent:-30px">(a)&nbsp;&nbsp;&nbsp;&nbsp; LICENSEE shall submit to HARVARD within sixty (60)&nbsp;days after each calendar
half year ending June&nbsp;30 and December&nbsp;31, a Royalty Report setting forth for such half
year at least the following information:</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the number of LICENSED PRODUCTS sold by LICENSEE in each country;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>total billings and amounts actually received for such LICENSED PRODUCTS;</TD>
</TR>
<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>an accounting for all LICENSED PROCESSES used or sold;
</TD>
</TR>
<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iv)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>
deductions applicable to determine the NET SALES thereof;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(v)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the amount of SERVICE INCOME received by LICENSEE and an accounting
of all deductions to yield NET SERVICE INCOME;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(vi)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the amount of SUBLICENSE INCOME received by LICENSEE; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(vii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the amount of royalty due thereon, or, if no royalties are due to
HARVARD for any reporting period, the statement that no royalties are due.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Such report shall be certified as correct by an officer of LICENSEE and shall include a
detailed listing of all deductions from royalties.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall pay to HARVARD with each such Royalty Report the amount of
royalty due with respect to such half year. If multiple technologies are covered by the
license granted hereunder, LICENSEE shall specify which PATENT RIGHTS are utilized for
each LICENSED PRODUCT and LICENSED PROCESS included in the Royalty Report.</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All payments due hereunder shall be deemed received when funds are credited to
HARVARD&#146;s bank account and shall be payable by check or wire transfer in United States
dollars. Conversion of foreign currency to U.S. dollars shall be made at the conversion
rate existing in the United States (as reported in the New York Times or the Wall
Street Journal) on the last working day of each royalty period. No transfer, exchange,
collection or other charges shall be deducted from such payments.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All such reports shall be maintained in confidence by HARVARD except as required
by law; however, HARVARD may include in its usual reports annual amounts of royalties
paid.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Late payments shall be subject to a charge of one and one-half percent (1.5%)
per month, or $250, whichever is greater.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event of acquisition, merger, change of corporate name or change in make-up,
organization, or identity, LICENSEE shall notify HARVARD in writing within thirty (30)
days of such event.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If by law, regulation or fiscal policy of a particular country, conversion into United
States dollars or transfer of funds of a convertible currency to the United States is
restricted or forbidden, LICENSEE shall give HARVARD prompt notice in writing and shall pay
the royalty and other amounts due through such means or methods as are lawful in such country
as HARVARD may reasonably designate. Failing the designation by HARVARD of such lawful means
or methods within thirty (30)&nbsp;days after such notice is given to HARVARD, LICENSEE shall
deposit such royalty or other payment in local currency to the credit of HARVARD in a
recognized banking institution designated by HARVARD, or if none is designated by HARVARD
within the thirty (30)&nbsp;day period described above, in a recognized banking institution
selected by LICENSEE and identified in a written notice to HARVARD by LICENSEE, and such
deposit shall fulfill all obligations of LICENSEE to HARVARD with respect to such royalties.
When in any country in which the law or regulations prohibit both the transmittal and deposit
of royalties on sales in such country, royalty payments shall be suspended for as long as
such prohibition is in effect, and as soon as such prohibition ceases to be in effect, all
royalties which LICENSEE would have been under obligation to transmit or deposit, but for the
prohibition, shall be deposited or transmitted promptly to the extent allowable.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Article </FONT>VI<BR>
<FONT style="font-variant: SMALL-CAPS">Record Keeping</FONT>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">6.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall keep, and shall require its SUBLICENSEES to keep, accurate records (together
with supporting documentation) of LICENSED PRODUCTS made, used or sold under this Agreement,
and SERVICE INCOME and SUBLICENSE INCOME received by LICENSEE under this Agreement,
appropriate to determine the amount of royalties due to HARVARD hereunder. Such records shall
be retained for three (3)&nbsp;years following the end of the reporting period to which they
relate. For such three year period, they shall be</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>available during normal business hours upon reasonable advance notice for examination by a
certified public accountant selected by HARVARD, and reasonably acceptable to LICENSEE, for
the sole purpose of verifying reports and payments hereunder. In conducting examinations
pursuant to this Section&nbsp;6.1, HARVARD&#146;s accountant shall have access to all records which
HARVARD reasonably believes to be relevant to the calculation of royalties under Article&nbsp;IV.
HARVARD agrees to maintain any information contained in such records in confidence, except
as otherwise required by law and except information in regarding the amount of royalties
due.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">6.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD&#146;s accountant shall not disclose to HARVARD any information other than information
relating to the accuracy of reports and payments made hereunder.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">6.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Such examination by HARVARD&#146;s accountant shall be at
HARVARD&#146;s expense, except that if such
examination shows an underreporting or underpayment in excess of five percent (5%) for any
twelve (12)&nbsp;month period, then LICENSEE shall pay the cost of such examination as well as any
additional sum that would have been payable to HARVARD had the LICENSEE reported correctly,
plus interest on said sum at the rate of one and one-half percent (1.5%) per month.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Article </FONT>VII<BR>
<FONT style="font-variant: SMALL-CAPS">Domestic and Foreign Patent Filing and Maintenance</FONT>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon execution of this Agreement, LICENSEE shall reimburse HARVARD for fifty percent (50%)
of all reasonable expenses HARVARD has incurred for the preparation, filing, prosecution,
maintenance and counseling with respect to PATENT RIGHTS. Such expenses total &#091;***&#093; as of
October&nbsp;1, 2000. Thereafter, LICENSEE shall reimburse HARVARD for fifty percent (50%) of all
such future reasonable expenses prior to the termination of this Agreement upon receipt of
invoices from HARVARD.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD shall be responsible for the preparation, filing, prosecution and maintenance of any
and all patent applications and patents included in PATENT RIGHTS. HARVARD will instruct
counsel to directly notify HARVARD and LICENSEE and provide them copies of any official
communications from the United States and foreign patent offices relating to said prosecution,
and to provide LICENSEE with advance draft copies of all relevant communications to the
various patent offices, so that LICENSEE may be informed and apprised of the continuing
prosecution of patent applications in PATENT RIGHTS. LICENSEE shall have reasonable
opportunities to participate in decision making on all key decisions affecting filing,
prosecution and maintenance of patents and patent applications in PATENT RIGHTS. HARVARD will
use reasonable efforts to incorporate LICENSEE&#146;s reasonable suggestions regarding said
prosecution. HARVARD shall use all reasonable efforts to amend any patent application to
include claims reasonably requested by LICENSEE to protect LICENSED PRODUCTS.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD and LICENSEE shall cooperate fully in the preparation, filing, prosecution and
maintenance of PATENT RIGHTS and of all patents and patent applications licensed to LICENSEE
hereunder, executing all papers and instruments or requiring members of</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD to execute such papers and instruments so as to enable HARVARD to apply for, to
prosecute and to maintain patent applications and patents in
HARVARD&#146;s name in any country.
Each party shall provide to the other prompt notice as to all matters which come to its
attention and which may affect the preparation, filing, prosecution or maintenance of any
such patent applications or patents.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE may elect to surrender its PATENT RIGHTS in any country upon sixty (60)&nbsp;days
written notice to HARVARD. Such notice shall not relieve LICENSEE from responsibility to
reimburse HARVARD for patent-related expenses incurred prior to the expiration of the (60)
day notice period.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If HARVARD elects not to prosecute or maintain any of the patents or patent applications
relating to PATENT RIGHTS or any portion thereof in any country, LICENSEE shall be given
sufficient notice of HARVARD&#146;s decision so that LICENSEE may request that HARVARD continue
prosecuting or maintaining such patents or patent applications, at
LICENSEE&#146;s expense. If
HARVARD elects not to prosecute or maintain such patents or patent applications after such
request by LICENSEE, then LICENSEE shall have the right, but not the obligation, at its own
expense to prosecute and maintain such patents and patent applications or portion thereof in
such country and in HARVARD&#146;s name. If LICENSEE assumes 100% of the costs to file, prosecute,
and maintain certain patents and patent applications relating to the PATENT RIGHTS pursuant to
this Section&nbsp;7.5, and, if HARVARD licenses the PATENT RIGHTS to one or more co-exclusive
licensees designated in Section&nbsp;3.1 after such time, then HARVARD will credit LICENSEE with
the costs LICENSEE has paid in excess of 50% if one other licensee, due for the preparation,
filing, prosecution and maintenance of patents and patent applications relating to PATENT
RIGHTS pursuant to Section&nbsp;7.1 above.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If LICENSEE can demonstrate that it is not being adequately informed or apprised of the
continuing prosecution of patents or patent applications in PATENT RIGHTS, or that it is not
being provided with reasonable opportunities to participate in decision making or that its
interests are not being adequately protected, LICENSEE shall be entitled to engage, at
LICENSEE&#146;s expense, independent patent counsel to review and evaluate patent prosecution and
filing of patents and patent applications included in PATENT RIGHTS.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Article </FONT>VIII<BR>
<FONT style="font-variant: SMALL-CAPS">Infringement</FONT>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>With respect to any PATENT RIGHTS that are licensed to LICENSEE pursuant to this Agreement,
LICENSEE shall have the right to prosecute in its own name and at its own expense any
infringement of such patent. HARVARD agrees to notify LICENSEE promptly of each infringement
of such patents of which HARVARD, as applicable, is or becomes aware. Before LICENSEE
commences an action with respect to any infringement of such patents, LICENSEE shall give
careful consideration to the views of HARVARD and to potential effects on the public interest
in making its decision whether or not to sue.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE acknowledges that other co-exclusive licensees of PATENT RIGHTS designated in
Section&nbsp;3.1 shall have rights identical to LICENSEE to prosecute infringers and that
co-exclusive licensees will be bound by the identical terms of this Section&nbsp;8.2. In any
prosecution instigated by LICENSEE and in which HARVARD, as necessary, is also named
plaintiff as owner of the PATENT RIGHTS, LICENSEE must notify other co-exclusive licensees
of the existence of such legal action and allow other co-exclusive licensees to join as a
plaintiff upon co-exclusive licensees&#146; request. In addition, in the event other co-exclusive
licensees instigate an infringement prosecution, LICENSEE hereby consents to being joined as
a plaintiff in such suit solely for the purpose of procuring standing to bring the action and
at the sole expense of the instigating co-exclusive licensee. To the extent that LICENSEE
desires to participate in any strategic decisions affecting the prosecution of the action
brought by other co-exclusive licensees, LICENSEE acknowledges that it and co-exclusive
licensees will necessarily have to reach a mutual agreement concerning litigation expenses
and strategy. In no event shall HARVARD incur any liability or expense in connection with any
action of co-exclusive licensees, joint or otherwise.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During any such litigation, HARVARD will agree to not license any defendant or accused
infringer of the PATENT RIGHTS in the litigation, without LICENSEE&#146;S prior written consent.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="margin-left:30px; text-indent:-30px">(a)&nbsp;&nbsp;&nbsp;&nbsp; If LICENSEE elects to commence an action as described above, HARVARD may, to
the extent permitted by law, elect to join as parties in that action. Regardless of
whether HARVARD elects to join as parties, HARVARD shall cooperate fully with LICENSEE
in connection with any such action.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD agrees to join as a party in any action if required by law to do so in
order to bring an action under the PATENT RIGHTS.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall reimburse HARVARD for any costs incurs with
LICENSEE&#146;s approval,
including reasonable attorneys&#146; fees, as part of an action brought by LICENSEE,
irrespective of whether HARVARD becomes a co-plaintiff.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If LICENSEE elects to commence an action as described above, LICENSEE may deduct from its
royalty payments to HARVARD with respect to the patent(s) subject to suit an amount not
exceeding fifty percent (50%) of LICENSEE&#146;s expenses and costs of such action, including
reasonable attorneys&#146; fees; provided, however, that such reduction shall not exceed fifty
percent (50%) of the total royalty due to HARVARD with respect to the patent(s) subject to
suit for each calendar year. If such fifty percent (50%) of
LICENSEE&#146;s expenses and costs
exceeds the amount of royalties deducted by LICENSEE for any calendar year, LICENSEE may to
that extent reduce the royalties due to HARVARD from LICENSEE in succeeding calendar years,
but never by more than fifty percent (50%) of the total royalty due in any one year with
respect to the patent(s) subject to suit.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>No settlement, consent judgment or other voluntary final disposition of the suit may be
entered into without the prior written consent of HARVARD which consent shall not be
unreasonably withheld.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Recoveries or reimbursements from actions commenced by LICENSEE pursuant to this Article
shall first be applied to reimburse LICENSEE, HARVARD for litigation costs not paid from
royalties and then to reimburse HARVARD for royalties deducted by LICENSEE pursuant to Section
8.4. Any remaining recoveries or reimbursements shall be shared as follows:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If the amount is lost profits or lost royalties, LICENSEE shall receive an
amount equal to the damages the court determines LICENSEE has suffered as a result of
the infringement less the amount of any royalties that would have been due HARVARD on
sales of LICENSED PRODUCTS lost by LICENSEE as a result of the infringement had
LICENSEE made such sales, and HARVARD shall receive an amount equal to the royalties it
would have received if such sales had been made by LICENSEE, and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>As to awards other than lost profits or lost royalties, fifty percent (50%) to
LICENSEE and fifty percent (50%) to HARVARD.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If two or more co-exclusive licensees undertake the suit, the provision of this
Section&nbsp;8.6 will be modified to take into account each co-exclusive licensee&#146;s expenses
and lost profits.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If LICENSEE elects not to exercise its right to prosecute an infringement of the PATENT
RIGHTS pursuant to this Article, HARVARD may do so at its own expense, controlling such
action and retaining all recoveries therefrom. LICENSEE shall cooperate fully with HARVARD in
connection with any such action.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If a declaratory judgment action is brought naming LICENSEE as a defendant and alleging
invalidity of any of the PATENT RIGHTS, HARVARD may elect to take over the sole defense of
the action at its own expense. LICENSEE shall cooperate fully with HARVARD in connection with
any such action. HARVARD shall consult with LICENSEE regarding such defense.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Article </FONT>IX<BR>
<FONT style="font-variant: SMALL-CAPS">Termination of Agreement</FONT>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">9.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Agreement, unless terminated as provided herein, shall remain in effect until the last
patent or patent application in PATENT RIGHTS has expired or been abandoned.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">9.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD may terminate this Agreement as follows:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If LICENSEE does not make a payment due hereunder and fails to cure such
non-payment (including the payment of interest in accordance with Section&nbsp;5.4(e)) within</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>thirty (30)&nbsp;days after the date of notice in writing of such non-payment by HARVARD.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If LICENSEE defaults in its obligations under Sections&nbsp;10.3(c) and 10.3(d) to
procure and maintain insurance.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If LICENSEE shall become insolvent, shall make an assignment for the benefit of
creditors, or shall have a petition in bankruptcy filed for or against it. Such
termination shall be effective immediately upon HARVARD giving written notice to
LICENSEE.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If an examination by HARVARD&#146;s accountant pursuant to Article&nbsp;V shows an
underreporting or underpayment by LICENSEE in excess of twenty percent (20%) for any
twelve (12)&nbsp;month period, provided that such underreporting or underpayment is not
determined to be inadvertent or the result of an honest mistake.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If LICENSEE is convicted of a felony relating to the manufacture, use, or sale
of LICENSED PRODUCTS.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(f)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Except as provided in Subsections (a), (b), and (c)&nbsp;above, if LICENSEE defaults
in the performance of any material obligations under this Agreement and the default has
not been remedied within forty-five (45)&nbsp;days after the date of notice in writing of
such default by HARVARD.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">9.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall provide, in all sublicenses granted by it under this Agreement, that
LICENSEE&#146;s interest in such sublicenses shall at HARVARD&#146;s option terminate or be assigned to
HARVARD upon termination of this Agreement; however, LICENSEE shall have the option to
nominate one of its sublicensees as a substitute for LICENSEE. The proposed substitute must
(i)&nbsp;have a net worth of at least equivalent to the net worth LICENSEE had as of the date of
this Agreement and (ii)&nbsp;have available resources and sufficient scientific, business and other
expertise comparable to LICENSEE in order to satisfy its obligations under this Agreement. At
least sixty (60)&nbsp;days prior to termination of this Agreement, LICENSEE shall provide HARVARD
with written notice of LICENSEE&#146;s nominee together with documentation sufficient to
demonstrate the requirements set forth in subparagraphs (i)&nbsp;and
(ii)&nbsp;above for HARVARD&#146;s
approval, which shall not be unreasonably withheld. HARVARD shall notify LICENSEE in writing
of its decision prior to termination of this Agreement. If HARVARD
approves LICENSEE&#146;s
nominee, LICENSEE shall assign this Agreement to its nominee and its nominee shall accept the
assignment no later than thirty (30)&nbsp;days after the termination date of this Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event that HARVARD disapproved LICENSEE&#146;s first nominee, prior to the termination date
of this Agreement, LICENSEE shall have the option to nominate one of its other sublicensees
for HARVARD&#146;s approval which shall not be unreasonably withheld.</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">9.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE may terminate this Agreement by giving ninety (90)&nbsp;days advance written notice
of termination to HARVARD. Upon termination, LICENSEE shall submit a final Royalty Report to
HARVARD and any royalty payments and unreimbursed patent expenses invoiced by HARVARD shall
become immediately payable.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">9.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Sections&nbsp;6.1, 6.2, 6.3, 7.1, 9.4, 9.5, 10.2, 10.3, 10.4, and 10.7 of this Agreement shall
survive termination.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Article </FONT>X<BR>
<FONT style="font-variant: SMALL-CAPS">General</FONT>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD does not warrant the validity of the PATENT RIGHTS licensed hereunder and make no
representations whatsoever with regard to the scope of the licensed PATENT RIGHTS or that
such PATENT RIGHTS may be exploited by LICENSEE, an AFFILIATE, or SUBLICENSEE without
infringing other patents, provided, however, HARVARD represents that it has no knowledge of
any facts or circumstances as of the execution date of this Agreement that would render any
of the PATENT RIGHTS invalid or unenforceable. HARVARD represents and warrants, to the best
of its knowledge, that HARVARD will own all right, title and interest in and to the PATENT
RIGHTS.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>HARVARD EXPRESSLY DISCLAIMS ANY AND ALL IMPLIED WARRANTIES AND MAKES NO EXPRESS OR IMPLIED
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF THE PATENT RIGHTS OR
INFORMATION SUPPLIED BY HARVARD, LICENSED PROCESSES OR LICENSED PRODUCTS CONTEMPLATED BY THIS
AGREEMENT.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="margin-left:30px; text-indent:-30px">(a)&nbsp;&nbsp;&nbsp;&nbsp; LICENSEE shall indemnify, defend and hold harmless HARVARD and its current or
former directors, governing board members, trustees, officers, faculty, medical and
professional staff, employees, students, and agents and their respective successors, heirs
and assigns (collectively, the &#147;INDEMNITEES&#148;), from and against any claim, liability, cost,
expense, damage, deficiency, loss or obligation of any kind or nature (including, without
limitation, reasonable attorney&#146;s fees and other costs and expenses of litigation)
(collectively, &#147;Claims&#148;), based upon, arising out of, or otherwise relating to this
Agreement, including without limitation any cause of action relating to product liability
concerning any product, process, or service made, used or sold pursuant to any right or
license granted under this Agreement, provided, however, that such indemnification shall not
apply to any liability, damage, loss, or expense to the extent directly attributable to the
negligent activities, reckless misconduct or intentional misconduct of Indemnitees.</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Each Indemnitee that intends to claim indemnification under Section&nbsp;10.3(a)
shall promptly notify LICENSEE of any claim or action in respect of which the
Indemnitee intends to claim such indemnification, and LICENSEE shall assume the defense
thereof with counsel mutually satisfactory to LICENSEE and HARVARD. The failure to
deliver notice to LICENSEE within a reasonable time after the commencement of any such
claim or action, if materially prejudicial to its ability to</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>defend such action, shall relieve LICENSEE of any liability to the Indemnitee under
Section&nbsp;10.3(a) with respect to such action, but the omission so to deliver notice to
LICENSEE will not relieve it of any liability that it may have to any Indemnitee
otherwise than under Section&nbsp;10.3(a). HARVARD and any other Indemnitee, and their
respective employees and agents, shall cooperate fully with LICENSEE and its legal
representatives in the investigation of any claim or action covered by the
indemnification under Section&nbsp;10.3(a).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Beginning at the time any such product, process or service is being commercially
distributed or sold (other than for the purpose of obtaining regulatory approvals) by
LICENSEE or by a SUBLICENSEE, AFFILIATE or agent of LICENSEE, LICENSEE shall, at its
sole cost and expense, procure and maintain commercial general liability insurance in
amounts not less than $2,000,000 per incident and $2,000,000 annual aggregate and naming
the Indemnitees as additional insureds. During clinical trials of any such product,
process or service, LICENSEE shall, at its sole cost and expense, procure and maintain
commercial general liability insurance in such equal or lesser amount as HARVARD shall
require, naming the Indemnitees as additional insureds. Such commercial general
liability insurance shall provide: (i)&nbsp;product liability coverage; and (ii)&nbsp;broad form
contractual liability coverage for LICENSEE&#146;s indemnification under this Agreement. If
LICENSEE elects to self-insure all or part of the limits described above (including
deductibles or retentions which are in excess of $250,000 annual aggregate) such
self-insurance program must be acceptable to HARVARD and the Risk Management Foundation
of the Harvard Medical Institutions, Inc. in their sole discretion. The minimum amounts
of insurance coverage required shall not be construed to create a
limit of LICENSEE&#146;s
liability with respect to its indemnification under this Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall provide HARVARD with written evidence of such insurance upon
request of HARVARD. LICENSEE shall provide HARVARD with written notice at least fifteen
(15)&nbsp;days prior to the cancellation, non-renewal or material change in such insurance;
if LICENSEE does not obtain replacement insurance providing comparable coverage within
such fifteen (15)&nbsp;day period, HARVARD shall have the right to terminate this Agreement
effective at the end of such fifteen (15)&nbsp;day period without notice or any additional
waiting periods.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall maintain such commercial general liability insurance beyond the
expiration or termination of this Agreement during: (i)&nbsp;the period that any product,
process, or service, relating to, or developed pursuant to, this Agreement is being
commercially distributed or sold by LICENSEE or by a SUBLICENSEE, AFFILIATE or agent of
LICENSEE; and (ii)&nbsp;a reasonable period after the period referred to in Subsection
(e)(i) above which in no event shall be less than fifteen (15)&nbsp;years.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall not use HARVARD&#146;s name or insignia, or any adaptation of them, or the name of
any of HARVARD&#146;s inventors in any advertising, promotional or sales literature without the
prior written approval of HARVARD.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Without the prior written approval of HARVARD in each instance, neither this Agreement
nor the rights granted hereunder shall be transferred or assigned in whole or in part by
LICENSEE to any person whether voluntarily or involuntarily, by operation of law or
otherwise, except that each of LICENSEE and its AFFILIATES may assign this Agreement in
connection with a merger, consolidation or sale or transfer of all or substantially all of
its assets. This Agreement shall be binding upon the respective successors, legal
representatives and assignees of HARVARD and LICENSEE.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The interpretation and application of the provisions of this Agreement shall be governed by
the laws of the Commonwealth of Massachusetts.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE shall comply with all applicable laws and regulations. In particular, it is
understood and acknowledged that the transfer of certain commodities and technical data is
subject to United States laws and regulations controlling the export of such commodities and
technical data, including all Export Administration Regulations of the United States
Department of Commerce. These laws and regulations among other things, prohibit or require a
license for the export of certain types of technical data to certain specified countries.
LICENSEE hereby agrees and gives written assurance that it will comply with all United States
laws and regulations controlling the export of commodities and technical data, that it will
be solely responsible for any violation of such by LICENSEE or its AFFILIATES or
SUBLICENSEES, and that it will defend and hold HARVARD, CHILDREN, and MIT harmless in the
event of any legal action of any nature occasioned by such violation.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>LICENSEE agrees: (i)&nbsp;to obtain all regulatory approvals required for the manufacture and
sale of LICENSED PRODUCTS and LICENSED PROCESSES; and (ii)&nbsp;to utilize appropriate patent
marking on such LICENSED PRODUCTS. LICENSEE also agrees to register or record this Agreement
as is required by law or regulation in any country where the license is in effect.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.9</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any notices to be given hereunder shall be sufficient if signed by the party (or party&#146;s
attorney) giving same and either: (i)&nbsp;delivered in person; (ii)&nbsp;mailed certified mail return
receipt requested; or (iii)&nbsp;faxed to other party if the sender has evidence of successful
transmission and if the sender promptly sends the original by ordinary mail, in any event to
the following addresses:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If to LICENSEE:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 0pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Mycometrix Corporation<BR>
213 E. Grand Ave.<BR>
South San Francisco, CA 94080<BR>
Attention:<BR>
Fax: (650)-</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->19<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If to HARVARD:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 0pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Office for Technology and Trademark Licensing</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 0pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Harvard University<BR> Holyoke
Center, Suite&nbsp;727<BR> 1350
Massachusetts Avenue<BR>
Cambridge, MA 02138<BR> Fax:
(617)&nbsp;495-9568</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>By such notice either party may change their address for future notices.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Notices delivered in person shall be deemed given on the date delivered. Notices sent by fax
shall be deemed given on the date faxed. Notices mailed shall be deemed given on the date
postmarked on the envelope.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.10</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Should a court of competent jurisdiction later hold any provision of this Agreement
to  be invalid, illegal, or unenforceable, and such holding is not reversed on appeal, it shall be
considered severed from this Agreement. All other provisions, rights and obligations shall
continue without regard to the severed provision, provided that the remaining provisions of
this Agreement are in accordance with the intention of the parties.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.11</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event of any controversy or claim arising out of or relating to any provision of this
Agreement or the breach thereof, the parties shall try to settle such conflict amicably
between themselves. Subject to the limitation stated in the final sentence of this Section
10.11, any such conflict which the parties are unable to resolve promptly shall be settled
through arbitration conducted in accordance with the rules of the American Arbitration
Association. The demand for arbitration shall be filed within a reasonable time after the
controversy or claim has arisen, and in no event after the date upon which institution of
legal proceedings based on such controversy or claim would be barred by the applicable statute
of limitation. Such arbitration shall be held in Boston, Massachusetts. The award through
arbitration shall be final and binding. Either party may enter any such award in a court
having jurisdiction or may make application to such court for judicial acceptance of the award
and an order of enforcement, as the case may be. Notwithstanding the foregoing, either party
may, without recourse to arbitration, assert against the other party a third-party claim or
cross-claim in any action brought by a third party, to which the subject matter of this
Agreement may be relevant.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.12</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Agreement constitutes the entire understanding between the parties and neither party
shall be obligated by any condition or representation other than those expressly stated
herein or as may be subsequently agreed to by the parties hereto in writing.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;The remainder of this page is intentionally blank.&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->20<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their duly
authorized representatives.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-variant: SMALL-CAPS">
President And Fellows<br>
of Harvard College</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD align="center" valign="top"><FONT style="font-variant: SMALL-CAPS"><br>Mycometrix Corporation</FONT></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Joyce Brinton
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">/s/ Gajus Worthington</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="center" valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">Joyce Brinton, Director<br>
Office for Technology and <br>
Trademark Licensing
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">President</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->

<TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom"><!-- Blank Space -->

<TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">12/7/00&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">12/18/00&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="center" valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Date</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->21<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">Appendix </FONT>A
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">The following comprise PATENT RIGHTS:
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->22<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>20
<FILENAME>f39432orexv10w8.htm
<DESCRIPTION>EXHIBIT 10.8
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w8</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#091;***&#093; Indicates
text has been omitted from this Exhibit pursuant to a confidential treatment
request and has been filed separately with the Securities and Exchange Commission.
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><b>Exhibit&nbsp;10.8</b>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%"></TD>
    <TD width="5%"></TD>
    <TD width="30%"></TD>
    <TD width="5%"></TD>
    <TD width="30%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>PATENT LICENSE AGREEMENT</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">3950.LICI.001 Gyros AB</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Agreement, effective as of January&nbsp;9, 2003, is made by and between <B>GYROS AB </B>having its
principal office at Uppsala Science Park, SE-751 83 Uppsala, Sweden, a corporation organized and
existing under the laws of Sweden (hereinafter referred to as
<B>&#147;Licensor&#148;),</B> and<b> FLUIDIGM Corporation</b>
having its principal office at 7100 Shoreline Court, South San Francisco, CA 94080, a corporation
organized and existing under the laws of the state of California, U.S.A (hereinafter referred to as
the <B>&#147;Licensee&#148;).</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>RECITALS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>WHEREAS, </B>the Licensor is the holder of intellectual property pertaining to, and possesses a special
expertise in the field of fluidic microsystems.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>WHEREAS, </B>the Licensor is active in the field of microfluidics and microfluidic applications,
primarily within the Life Sciences and Diagnostics.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>WHEREAS, </B>the Licensor is the owner of certain patents and patent applications pertaining to
microfluidics and microfluidic applications.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>WHEREAS, </B>Licensor is willing to grant Licensee a royalty-bearing non-exclusive licence to such
patents on the terms and conditions given below.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>NOW, THEREFORE, </B>in consideration of the promises and the faithful performance of the covenants
herein contained IT IS AGREED;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ARTICLE 1 DEFINITIONS</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>&#147;Affiliate&#148; </B>shall mean any corporation, partnership, or other business entity
controlled by, or controlling, or under common control with any party or signatory to this
Agreement, with &#147;control&#148; meaning direct or indirect beneficial ownership of more than fifty
percent (50%) of the voting power, or of the interest in the income of such corporation,
partnership or other entity, or having the power to appoint the majority of its directors or
otherwise having the power to direct its business activities.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 34px; text-indent: -34px">1.2&nbsp;&nbsp;&nbsp;&nbsp; <B>&#147;Competitor of Licensor&#148; </B>shall mean a company in the business of making and selling
compact disc-like structures in which fluids are moved by centrifugal force.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">1.3 <B>&#147;Net Sales&#148; </B>shall mean the gross selling price charged by Licensee for Products
manufactured or sold by the Licensee in a country in which the Product is covered by a Patent
(i.e., a country in which, but for the license granted herein, the Product would infringe a valid,
enforceable, unexpired claim of a Patent) less:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>allowances for damaged and returned goods;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>discounts actually credited to customers or commissions paid to third parties in amounts
customary in the trade;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>custom duties, forwarding insurance premiums, sales, excise, and other taxes actually paid by
the Licensee or otherwise included in the gross selling price with respect to the sale of Products;</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">A Product shall be considered sold hereunder in accordance with extant GAAP accounting procedures
and guidelines.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">If the Products are sold in combination with, or as a component of, other products not licensed
hereunder, Net Sales for purposes of determining royalty hereunder shall be calculated by
multiplying the Net Sales from the combined product by the fraction
A/B, where A is the invoice price of the Products sold separately and B is the invoice price of the
combined product. If the Products are not sold separately, the Net Sales for purposes of
calculating royalties hereunder shall be reasonably determined by agreement of Licensor and the
Licensee promptly after such combination products are sold by Licensee. The parties agree to use
good faith in negotiating the appropriate adjustment to Net Sales of any combined product within
thirty (30)&nbsp;days after the Licensee notifies Licensor of sales of a combination product. The Net
Sales of any Products sold by the Licensee to any Affiliate of the Licensee or any other person or
organization enjoying a special course of dealing with the Licensee, shall be determined by
reference to the Net Sales which would be applicable under this Article&nbsp;1.2 in an arm&#146;s length sale
of such Products by the Licensee to a third party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">1.4 <B>&#147;Patents&#148; </B>shall mean the patents listed in Exhibit&nbsp;A, attached hereto, together with
any other corresponding patents/ patent applications in any country owned or controlled by the
Licensor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">1.5 <B>&#147;Covered Products&#148; </B>shall mean all products now or hereafter manufactured, assembled, used
or sold by or on behalf of the Licensee or its Affiliates and which are covered by any of the
Patents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">It is hereby acknowledged that any and all products consisting of compact discs (&#147;CD&#146;s&#148;) and
CD-like structures where a centrifugal force is utilized to move the liquids within the CD are
explicitly excluded from this definition.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.6</TD>
       <TD><B>&#147;Option Field of Use&#148; </B>means each of (i)&nbsp;&#091;***&#093; and (ii)&nbsp;&#091;***&#093;.</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>&#147;Licensed Fields of Use&#148; </B>means &#091;***&#093; and each Option Field of Use for which
Licensee exercises the option as set forth in Section&nbsp;5.2 below.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>&#147;Product&#148; </B>means each Covered Product useful, used, or for use in a Licensed Field of Use.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ARTICLE 2 GRANT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">2.1 Upon the terms and subject to the conditions of this Agreement, Licensor hereby grants
to the Licensee and its Affiliates, and the Licensee and its Affiliates accept from Licensor, a
restricted, perpetual, irrevocable (except as set forth in
Section&nbsp;9.1), non-exclusive,
non-transferable (except as set forth in Section&nbsp;7.4), royalty-bearing license under the Patents
for the term hereof solely to make, have made, import, use, offer for sale, and sell Products. No
other license is granted to the Licensee expressly, impliedly or by estoppel, except as explicitly
set forth in Section&nbsp;5.2 below.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Licensee expressly acknowledges and agrees that the Licensee shall have no right to sublicense,
assign, or otherwise transfer any or all of the license granted to it under the Patents, except as
set forth in Section&nbsp;9.1, provided that Licensee can sublicense Patents to a third party other than
a Competitor of Licensor (as defined in Section&nbsp;7.4) in conjunction with a license from Licensee to
make and sell any of Licensee&#146;s Products. Licensor reserves the right to practice the Patents
itself, and to sublicense, assign or otherwise transfer the Patents to others for any purposes
whatsoever, provided that such transfer or assignment shall be subject to the licenses granted to
Licensee in this Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Licensor hereby irrevocably releases Licensee and its Affiliates, and each of their
subcontract manufactures and direct and indirect customers, of and from all claims of infringement
of Patents, known or unknown, which claims have been made or might have
been made at any time, with respect to any apparatus made, used, imported, offered for sale, or
sold, or any method or process practiced, before the effective date of this Agreement, which
apparatus, method, or process would have been licensed had it been made, used, imported, offered
for sale, or sold, or practiced after effective date of this Agreement. A corresponding release
will be deemed made in relation to each of the Option Fields of Use when and if exercised under
Section&nbsp;5.2 below.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ARTICLE 3 PATENT MARKING</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Beginning two (2)&nbsp;years after the effective date of this Agreement, Licensee shall display or cause
to be displayed proper patent notices on the documentation, inserts, packages or containers of all
Products which shall indicate that the Product is sold or manufactured under a patent license from
Licensor. The Licensee shall provide Licensor for its review prior to use,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">representative samples containing such patent notices and the parties agree to use good faith in
determining the requirements for and adequacy of such notices under the controlling patent laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ARTICLE 4 RESTRICTIONS ON PUBLICATION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Upon the signing of this Agreement and upon exercise of any of the Option Fields of Use under 5.2,
both parties shall be entitled to make public &#151; through a press
release or otherwise - that Licensee
has taken a license to the Patents from the Licensor. Such press-release or similar shall be in a
form reasonably acceptable to the other party and shall not disclose any of the financial terms
agreed in this Agreement. Within thirty (30)&nbsp;days of the effective date of this Agreement, Licensee
will publish on its corporate website that it has taken a license from Licensor under the Patents.
Under all other circumstances, neither party shall use the other&#146;s name nor any variation thereof,
nor any emblem, logo, trademark or variation thereof, nor the name of any employee in any press
releases, advertising, promotional or sales literature, or in any securities reports required by
the Securities and Exchange Commission, without the prior written consent of the other party in
each case; provided however, that both parties (a)&nbsp;may refer to publications by employees of the
other party in the scientific literature, (b)&nbsp;may only state that a non-exclusive, royalty-bearing
patent license from Licensor to Licensee has been granted (excluding financial terms) and (c)&nbsp;may
make such disclosures as required by law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ARTICLE 5 ROYALTIES AND PAYMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">5.1 In consideration of the rights granted by Licensor to the Licensee under this Agreement, the
Licensee agrees to pay to Licensor:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>a non-refundable sum of &#091;***&#093; payable on March&nbsp;31,
2003 (&#147;Annual Payment Date&#148;). The foregoing payment includes full payment for all sales by the
Licensee of Products before the effective date of this Agreement;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>a sum of &#091;***&#093; payable on each anniversary of the
Annual Payment Date during the term of this Agreement; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>a royalty of &#091;***&#093; of the Net Sales of all Products sold by the Licensee during the
term of this Agreement. Sums paid under Subsections 5.1 (a)&nbsp;and (b)&nbsp;above, and Section&nbsp;5.2 below,
shall be fully creditable against such royalties, regardless of the year in which such royalties
accrue.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">5.2 At any time(s) during the first twelve (12)&nbsp;months of the term of this Agreement, Licensee
shall be entitled, at its option, to add one or both Option Fields of Use to the
Licensed Field of Use under this Agreement, and upon each such exercise, each such Option Field of
Use shall become a Licensed Field of Use under this Agreement. If Licensee has not, during the
first
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">twelve (12)&nbsp;month period of the term of this Agreement, added both Option Fields of Use to the
Licensed Field of Use, then during the second twelve (12)&nbsp;month period of the term of this
Agreement, Licensee shall be entitled, at its option, to add one Option Field of Use to the
Licensed Field of Use under this Agreement. Each such exercise of this option by Licensee shall be
by written notice to Licensor, referencing this Agreement and specifying the Option Field(s) of Use
to be added. Within thirty (30)&nbsp;days after such exercise, Licensee shall pay an additional
&#091;***&#093; license fee for the first added Option Field of Use, and an additional &#091;***&#093;
license fee for the second added Option Field of Use. For the avoidance of doubt, during the first
twelve (12)&nbsp;month period of the term of this Agreement, Licensee may exercise this option for one
or both Option Fields of Use and on one or two occasions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">5.3 Within thirty (30)&nbsp;days of the end of each calendar quarter the Licensee shall pay to Licensor
the royalty having accrued on the Products sold during such calendar quarter to the extent the
royalty exceeds the credited sums paid by Licensee. Such payments shall be made in US Dollars by
wire transfer, at the Licensee&#146;s cost, to such bank as shall be notified by Licensor. Payments of
royalties accrued on sales in other currencies than US Dollars shall be made in US Dollars at the
rate of exchange quoted by a first class commercial bank in the Licensee&#146;s country on the last day
of the relevant calendar quarter.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">5.4 If the Licensee fails to make the payments as provided for herein, such amounts shall bear
interest from and after the due date at the rate of &#091;***&#093; above the one month LIBOR
for the currency of payment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">5.5 Withholding or other taxes assessed on Licensor in connection with the payment of royalties
and other consideration due hereunder and which the Licensee is required by law to deduct and
withhold when making payments, may be deducted from royalty payments hereunder (including without
limitation payments under Sections&nbsp;5.1(a), 5.1(b), and 5.2) and shall be paid by the Licensee to
the competent authority on behalf of Licensor. The originals of the official government receipt for
such taxes paid by the Licensee on Licensor&#146;s behalf, shall so indicate such fact and shall be sent
by the Licensee to Licensor not later than fifteen (15)&nbsp;working days after the date of payment,
indicating net payment of royalties to which such taxes relate, and in accordance with the
instructions given by Licensor. The sums so paid by the Licensee shall be credited by Licensor in
partial discharge of the Licensee&#146;s obligation for gross royalties as provided for herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ARTICLE 6 RECORDS, AUDITS AND REPORTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">6.1 The Licensee agrees to maintain accurate, complete and up to date records, until five (5)
years after a royalty payment has been made, in sufficient detail to enable the royalties payable
by the Licensee to be determined. Licensor shall have the right, at its own expense and during
regular business hours, at any time upon sixty (60)&nbsp;days prior written notice to Licensee, during
the term of this Agreement and for one (1)&nbsp;year thereafter, to have such records examined, in its
own discretion, by an independent auditor of its own choice, provided such auditor is bound by
confidentiality in writing to Licensee and reasonably acceptable to the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Licensee. The auditor shall not disclose the contents of the examination to any other entity and
shall use the information only to verify proper reporting and payment of royalties under this
Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">6.2 Once Licensee&#146;s royalty obligations have exceeded the sums paid under Subsections 5.1(a)&nbsp;and
(b)&nbsp;above or in the event of a completed initial public offering of Licensee&#146;s common stock, then
Licensee agrees to deliver to Licensor within forty-five (45)&nbsp;days of the end of each subsequent
calendar quarter a confidential written report, in a format to be agreed by the parties and made an
exhibit to this Agreement, of all Products sold by it during such quarter in sufficient detail to
permit a calculation of the royalties due thereon. Licensor shall not disclose the contents of the
report to any other entity and shall use the information only to verify proper reporting and
payment of royalties under this Agreement. Such report shall include, but not be limited to,
information of the total quantities of Products sold and the Net Sales thereof on a country by
country basis, and the amount of royalties due.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ARTICLE 7 TERM AND TERMINATION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">7.1 Unless otherwise terminated as provided for in this Agreement, the license shall run to the
end of the life of the last to expire of the Patents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">7.2 The Licensee shall have the right to terminate this Agreement and surrender the license
granted hereunder at any time by giving thirty (30)&nbsp;days&#146; written notice to Licensor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">7.3 If Licensor or the Licensee is in default in the performance of any of its respective
obligations under this Agreement, including the failure by the Licensee to make any of the payments
provided for at the times specified herein, and such default is not cured within ninety (90)&nbsp;days
after the aggrieved party has given to the other a written notice specifying the nature of the
default, the aggrieved party shall have the right to terminate this Agreement by giving written
notice of termination to the other, subject to the remainder of this section. Upon the giving of
such notice this Agreement shall terminate; provided, however, that if there is a dispute as to the
alleged default (including as to whether there is a default, or whether it has been cured), the
aggrieved party alleging the default shall not be entitled to terminate unless and until a further
notice of termination after (i)&nbsp;an agreed dispute resolution entity has determined that there was a
default, as specified in the aggrieved party&#146;s notice of default, that was not cured within the
applicable cure period and (ii)&nbsp;the defaulting party does not cure the default within thirty (30)
days after such determination.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">7.4 If during the term of this Agreement, Licensee effects a Competitor Assignment (as defined in
Section&nbsp;9.1), or a change of control over Licensee takes place meaning that fifty percent (50%) or
more of the shares in Licensee come under common control of a third party Competitor of Licensor or
Affiliates of such Competitor of Licensor, or if Licensee and/or certain of its shareholders enter
into an arrangement of a similar effect, Licensor shall be entitled to terminate this Agreement on
sixty (60)&nbsp;days prior written notice to Licensee. Upon such termination by Licensor, Licensor shall
promptly refund to Licensee (or its successor) a
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">pro rata (on a day for day basis) the annual payment made by Licensee for that year
under Section&nbsp;5.1(a), 5.1(b), or 5.2, as applicable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">7.5 If during the term of this Agreement, the Licensee becomes bankrupt or insolvent, or if the
business of Licensor or the Licensee is placed in the hands of a receiver or trustee, whether by
voluntary act or otherwise, this Agreement shall immediately and automatically terminate.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">7.6 The following rights and obligations shall survive any termination to the degree necessary to
permit their complete fulfilment or discharge:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Licensee&#146;s obligation to supply a final report on each impacted Product in accordance
with Section&nbsp;6.2 above with respect to the terminated license;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Licensor&#146;s right to receive or recover and the Licensee&#146;s obligation to pay royalties,
including minimum royalties, if any, accrued or accruable for payment at the time of any
termination;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Licensee&#146;s obligation to maintain records and to allow Licensor to audit such records
as provided for herein.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ARTICLE 8 RESTRICTED WARRANTY AND INDEMNITY</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">8.1 The Licensor represents and warrants that it has full authority to enter into this
Agreement, that it has not granted, and will not grant, any rights or licenses that would conflict
with the rights and licenses granted in this Agreement, that it is not aware of any third party
claims with respect to any Patent, and that it has no knowledge of any third party rights that
would affect its ability to grant the license hereunder. Licensor further represents and warrants
that the Patents are the only patent filings owned or controlled by Licensor or its Affiliates, or
which Licensor or its Affiliates otherwise have the right to enforce, license or sublicense, which
pertain to microfluidics based on multilayer soft lithography or its uses. However, the Licensor
makes no representation or warranty, express or implied, as to the validity of the Patents nor to
the merchantability or satisfactory quality of the Products that are or may be sold by the
Licensee. Licensor does not assume any liability for any infringement or alleged infringement of
any patent or other rights of third parties due to the Licensee&#146;s activities under the license set
forth herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">8.2 The Licensee shall assume full responsibility for its use of the Patents and shall defend
Licensor and its officers, directors, agents, and employees (&#147;Indemnified Parties&#148;) against any
claims or actions arising out of this Agreement by reason of death, personal injury, illness or
property damage, or any other injury or damage arising out of the use by the Licensee of the
Patents or the preparation of, use or sale of Products, including but not limited to, use or
reliance upon such Products by the Licensee&#146;s customers, and Licensee shall indemnify the
Indemnified Parties against all liability, costs, damages, and expenses awarded against the
Indemnified Parties with respect to such claims or actions.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ARTICLE 9 MISCELLANEOUS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">9.1 <U>Assignment.</U> This Agreement is personal to the Licensee who shall not have any right
to assign or transfer the Agreement, in whole or in part, or the license granted hereunder, without
the prior written consent of Licensor, which shall not be unreasonably withheld; provided, however,
that Licensee may transfer or assign its rights and obligations under this Agreement to a successor
to all or substantially all of Licensee&#146;s Product business relating to one or more Licensed Fields
of Use, whether
by sale, merger or otherwise, provided further that that Licensee shall not have the right to
transfer or assign this Agreement to a Competitor of Licensor (&#147;Competitor Assignment&#148;) without the
prior written consent of Licensor . Notwithstanding the foregoing, Licensor shall have the right to
assign or transfer this Agreement, in whole or in part, to any Affiliate.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">9.2 <U>Entire Agreement.</U> This Agreement constitutes the entire agreement between the
parties as to the subject matter hereof, and all prior negotiations, representations, agreements
and understandings are merged into, extinguished by and completely expressed by it. This Agreement
may be modified or amended only by a writing executed by authorized officers of each of the
parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">9.3 <U>Waiver.</U> The waiver by either Licensor or the Licensee of any right or failure to
perform or of any breach by the other shall not be deemed as a waiver of any other right hereunder
or of any other breach or failure by the other, whether of a similar nature or otherwise.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">9.4 <U>Notices.</U> Any notice or other communication relating to this Agreement shall be sent
registered mail or overnight express prepaid or telefax/telecopier to the address of the party to
be served therewith which is shown below and shall be deemed to have been given upon the date the
notice or communication was sent:
</DIV>
<DIV align="right">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="98%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">If to Licensor:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Gyros AB</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Att: Maris Hartmanis</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President &#038; CEO</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Uppsala Science Park</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">S-751 83 Uppsala, Sweden</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#091;***&#093;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">with a copy to:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">rambe legal consultants
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Att: Lars J. Rambe, LL.M</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Telefax &#043;46-8-6508835</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">If to the Licensee:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Fluidigm Corporation</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Att: Gajus Worthington</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President &#038; CEO</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7100 Shoreline Court</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">South San Francisco</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CA 94080</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Telefax: (650)&nbsp;871-7152</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">with a copy to:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fluidigm General Counsel
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Att: William M. Smith</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Telefax: (650)&nbsp;871-7195</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Such addresses may be changed by notice so given.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">9.5 <U>Severability.</U> If any provision of this Agreement is held to be unenforceable for any
reason, it shall be adjusted rather than voided, if possible, in order to achieve the intent of the
parties to the extent possible. In any event, all other provisions of this Agreement shall be
deemed valid and enforceable to the full extent possible consistent with the intent of the parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">9.6 <U>Governing Law.</U> This Agreement and its effects shall be subject to and shall be
construed and enforced in accordance with the laws of the state of New York, U.S.A.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">9.7 <U>Disputes.</U> Any dispute in connection with this Agreement shall be first elevated to
each party&#146;s respective President for a period of thirty (30)&nbsp;days prior to giving a notice of
default under section 9.3 above, who shall convene a face-to-face meeting prior to pursuing any
legal courses of action.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>IN WITNESS WHEREOF, </B>the parties hereto have caused their respective duly authorized representatives
to execute this Agreement the day and year first above written.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>Gyros AB</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>Fluidigm Corporation</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Maris Hartmanis
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gajus Worthington</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Maris Hartmanis
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Gajus Worthington</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ (ILLEGIBLE)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Exhibit&nbsp;A</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Patent family:</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>&#091;***&#093;</B></DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8A
<SEQUENCE>21
<FILENAME>f39432orexv10w8a.htm
<DESCRIPTION>EXHIBIT 10.8A
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w8a</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#091;***&#093; Indicates
text has been omitted from this Exhibit pursuant to a confidential treatment
request and has been filed separately with the Securities and Exchange Commission.
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.8A</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">AMENDMENT NO. 1 TO<BR>
PATENT LICENSE AGREEMENT
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Amendment No.&nbsp;1 (the &#147;Amendment&#148;) to the parties&#146; January&nbsp;9, 2003 Patent License Agreement is
entered into as of the date of the latter signature below by and between <B>GYROS AB</B> having its
principal office at Uppsala Science Park, SE-751 83 Uppsala, Sweden, a corporation organized and
existing under the laws of Sweden (hereinafter referred to as
<B>&#147;Licensor&#148;)</B>, and <B>FLUIDIGM Corporation</B>
having its principal office at 7100 Shoreline Court, South San Francisco, CA 94080, a corporation
organized and existing under the laws of the state of California, U.S.A (hereinafter referred to as
the <B>&#147;Licensee&#148;).</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">RECITALS
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A.&nbsp;The parties have entered into a January&nbsp;9, 2003 Patent License Agreement (the
&#147;Agreement&#148;); and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B.&nbsp;The parties desire to amend the Agreement to include an additional Option Field of Use,
and to extend Licensee&#146;s time period for exercising the remaining, unexercised Option Fields of
Use, on the terms and conditions set forth herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, the parties agree that the Agreement is amended as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;In order to add &#147;protein analysis&#148; as an additional Option Field of Use, Section&nbsp;1.6 of the
Agreement is amended to read in its entirety as follows:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&#147;1.6 <B>&#145;Option Field of Use&#146; </B>means each of (i)&nbsp;&#091;***&#093; (ii)&nbsp;&#091;***&#093; and (iii)
&#091;***&#093;&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">It is acknowledged that Licensee has previously exercised its option in accordance with Section&nbsp;5.2
of the Agreement for the Option Field of Use &#147;nucleic acid analysis,&#148; and made the required payment
with respect thereto, and that therefore &#147;nucleic acid analysis&#148; is already a Licensed Field of
Use.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;Section&nbsp;5.1(b)
of the Agreement is amended by adding the following at the end: &#147;, in
consideration of the rights granted to Licensee pursuant to Amendment No.&nbsp;1 to this Agreement, on
or before February&nbsp;9, 2005 Licensee shall pay to Licensee an additional, one time license fee of
&#091;***&#093; and&#148;.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;With
respect to the remaining two Option Fields of Use (i.e. cell assays, and protein
analysis), Section&nbsp;5.2 of the Agreement is amended to read in its entirety as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;5.2
At any time(s) until and including January&nbsp;9, 2007 (Pacific
Standard Time), Licensee shall be
entitled, at its option, to add one or both of the remaining, unexercised Option Fields of Use to
the Licensed Field of Use under this Agreement, and upon each such exercise, each such Option Field
of Use shall become a Licensed Field of Use under this Agreement. Each such exercise of this option
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->Page 1 of 2<!-- /Folio -->
</DIV>


<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">by Licensee shall be by written notice to Licensor, referencing this Agreement and specifying the
Option Field(s) of Use to be added. Within thirty (30)&nbsp;days after each such exercise, Licensee
shall pay an additional &#091;***&#093; license fee for
each added Option Field of Use. For the avoidance of doubt, until and including January&nbsp;9, 2007
(Pacific Standard Time), Licensee may exercise this option for one or both of the remaining,
unexercised Option Fields of Use and on one or two occasions.&#148;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;All payments designated to be made in Swedish kronor shall be made by Licensee in Swedish
kronor by wire transfer to a Licensor account designated by Licensor, including all necessary
information, in writing to Licensee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;Except as expressly provided in this Amendment, the Agreement shall remain unmodified and in
full force and effect. In the event of any inconsistency or conflict, the provisions of this
Amendment shall control and govern over the provisions of the Agreement. The Agreement, as amended
herein, shall constitute a single, integrated contract.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>Gyros AB</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>Fluidigm Corporation</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Rolf Ehmstrom
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gajus Worthington</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<tr>
    <TD>&nbsp;</TD>
</tr>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Print Name: Rolf Ehmstrom</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Print Name: Gajus Worthington</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>


<TR>
<TD STYLE="FONT-SIZE: 10PT">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Title: CEO (acting)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Title: CEO</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>


<TR>
<TD STYLE="FONT-SIZE: 10PT">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Date: 2005-01-09</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Date: 01/04/05</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->Page 2 of 2<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>22
<FILENAME>f39432orexv10w9.htm
<DESCRIPTION>EXHIBIT 10.9
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w9</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#091;***&#093; Indicates
text has been omitted from this Exhibit pursuant to a confidential treatment
request and has been filed separately with the Securities and Exchange Commission.
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><b>Exhibit&nbsp;10.9</b>
</DIV>

<div style="border-bottom: 3px double #000000">&nbsp;</div>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">MASTER CLOSING AGREEMENT
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">By and Among
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">FLUIDIGM CORPORATION,<BR>
a California corporation,
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">OCULUS PHARMACEUTICALS, INC.,<BR>
a Delaware corporation,
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">and
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">THE UAB RESEARCH FOUNDATION
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">dated
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">March&nbsp;7, 2003
</DIV>

<div style="border-bottom: 3px double #000000">&nbsp;</div>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">TABLE OF CONTENTS
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="63%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">Page</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE I DEFINITIONS</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">1</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Affiliate&#148;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">1</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Ancillary Documents&#148;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Assigned Rights&#148;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Cash Consideration&#148;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Closing&#148;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Closing Cash Consideration&#148;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Closing Date&#148;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.8</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Encumbrances&#148;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.9</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Fluidigm Series C Preferred Stock&#148;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.10</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;License Agreement&#148;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.11</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;New License Agreement&#148;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.12</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Sponsored Research Agreement&#148;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.13</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Technology&#148;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.14</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Transfer Taxes&#148;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE II TRANSFER OF ASSIGNED RIGHTS AND LICENSE OF TECHNOLOGY</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Transfer of Rights and License of Technology</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Excluded Assets and Liabilities</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Payment</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Taxes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Assigned Rights</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Unassignable Rights</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE III THE CLOSING</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Closing</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Termination of License Agreement</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Agreements Between Fluidigm and UABRF</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Other Documents</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE IV REPRESENTATIONS AND WARRANTIES OF OCULUS</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Organization</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Authorization</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">No Conflicts; Consents</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title to Assigned Rights</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">6</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">No Assignment</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">6</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Litigation and Claims</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">6</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Distribution Agreement</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">6</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE V REPRESENTATIONS AND WARRANTIES OF FLUIDIGM</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">7</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Organization</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">7</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Authorization</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">7</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">No Conflicts; Consents</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">7</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Litigation and Claims</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->i<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt">TABLE OF CONTENTS<br> (continued)
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="64%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">Page</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Securities Laws Exemptions</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE VI REPRESENTATIONS AND WARRANTIES OF UABRF</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Authorization</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">No conflicts; Consents</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title to Technology</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">9</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Litigation and Claims</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">9</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Distribution Agreement</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">9</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Investment Representations</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">10</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Restrictions</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">10</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.8</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Restrictive Legend</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">10</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.9</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Notice of Proposed Transfers</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">11</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.10</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Standoff Agreement</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">11</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE VII COVENANTS OF OCULUS</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Conduct of Business</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Access to Information</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Regulatory Approvals</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Satisfaction of Conditions Precedent</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE VIII COVENANTS OF UABRF</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">8.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Conduct of Business</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">8.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Access to Information</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">8.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Regulatory Approvals</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">8.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Satisfaction of Conditions Precedent</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE IX COVENANTS OF FLUIDIGM</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Regulatory Approvals</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Satisfaction of Conditions Precedent</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE X MUTUAL COVENANTS</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">10.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Confidentiality</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">10.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Publicity</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">10.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Governmental Filings</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE XI CONDITIONS TO CLOSING</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">11.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Conditions to Each Party&#146;s Obligations</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">11.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Conditions to Obligations of  Oculus and UABRF</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">16</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">11.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Conditions to Obligations of Fluidigm</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">16</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE XII POST-CLOSING MATTERS</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">17</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">12.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Additional Payments by Fluidigm</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">17</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">12.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Settlement of Lawsuit</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">18</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->ii<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">TABLE OF CONTENTS<BR>
(continued)
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="64%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">Page</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE XIII TERMINATION OF AGREEMENT</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">18</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">13.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Termination by Fluidigm</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">18</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">13.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Termination by UABRF</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">18</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">13.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mutual Consent</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">18</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">13.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Effect of Termination</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE XIV SURVIVAL OF REPRESENTATIONS AND WARRANTIES</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">14.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Survival of Representations and Warranties</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE XV GENERAL</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Governing Law</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Assignment; Binding upon Successors and Assigns</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Severability</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Entire Agreement</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">20</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Counterparts</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">20</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Expenses</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">20</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Other Remedies</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">20</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.8</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Amendment</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">20</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.9</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Waiver</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">20</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.10</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Informal  Resolution</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">21</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.11</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mediation</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">21</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.12</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Notices</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">21</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.13</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Construction and Interpretation of Agreement</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">22</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.14</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">No Joint Venture</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">22</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.15</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Absence of Third Party Beneficiary Rights</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">22</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.16</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Further Assurances</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">23</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->iii<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>EXHIBITS AND SCHEDULES</U>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="87%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">

<TD nowrap align="center" style="border-bottom: 0px solid #000000"><u>Exhibit</u></TD>
    <TD>&nbsp;</TD>

<TD nowrap align="left" style="border-bottom: 0px solid #000000"><u>Description</u></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">A
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Amended and Restated Articles of Incorporation of Fluidigm</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">B
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of New License Agreement</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">C
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Sponsored Research Agreement</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">D
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Description of Technology</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 8pt">

<TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><u>Schedule</u>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><u>Description</u></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.6
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Pending Litigation</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->iv<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">MASTER CLOSING AGREEMENT
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIS
MASTER CLOSING AGREEMENT is entered into as of March&nbsp;7, 2003 by and among FLUIDIGM
CORPORATION, a California corporation (<u>&#147;Fluidigm&#148;</u>), OCULUS PHARMACEUTICALS, INC., a Delaware
corporation (<u>&#147;Oculus&#148;</u>), and THE UAB RESEARCH FOUNDATION (<U>&#147;UABRF&#148;</U>).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>RECITALS</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A.&nbsp;Oculus and UABRF have entered into a license agreement dated September&nbsp;21,
2001 (together with all amendments and modifications thereto, the &#147;<U>License Agreement</U>&#148;)
under which Oculus was granted an exclusive license to practice the intellectual property and
technology relating to nanovolume crystallization arrays described in Schedule&nbsp;A to the
License Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B.&nbsp;The parties hereto have entered into a binding letter agreement dated
December&nbsp;19, 2002 (the &#147;<U>Letter Agreement</U>&#148;) under which Oculus and UABRF have agreed to
terminate the License Agreement, UABRF has agreed to grant to Fluidigm an exclusive license
to practice the intellectual property and technology relating to nanovolume crystallization
arrays covered by the License Agreement, and Fluidigm and UABRF have agreed to enter into a
sponsored research agreement. In exchange for the rights to be acquired by Fluidigm as
contemplated by the Letter Agreement, Fluidigm has paid cash in the amount of &#091;***&#093;
pursuant to the Letter Agreement and has agreed to the payment of additional cash and
securities as specified in the Letter Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C.&nbsp;The parties desire to enter into this Agreement to set out additional terms and
conditions related to the closing of the transactions, and the payments to be made by
Fluidigm, contemplated by the Letter Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the representations, warranties and agreements herein
contained, the parties agree as follows:
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE I
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>DEFINITIONS</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As used in this Agreement, the following terms shall have the meanings set forth or
referenced below:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 &#147;<U>Affiliate</U>&#148; of any specified person shall mean any other person directly or
indirectly controlling or controlled by or under direct or indirect common control with such
specified person. For purposes of this definition, &#147;control&#148; when used with respect to any
specified person means the power to direct or cause the direction of the management and policies of
such person, directly or indirectly, whether through the ownership of voting securities, by
contract or otherwise; and the terms &#147;controlling&#148; and &#147;controlled&#148; have meanings correlative to
the foregoing.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-1-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2 &#147;<U>Ancillary Documents</U>&#148; shall mean all documents or agreements required by this
Agreement to be executed or delivered by any party hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3 &#147;<U>Assigned Rights</U>&#148; shall mean any intellectual property rights owned by Oculus that
pertain in any way to the Technology, including without limitation any Inventions (as such term is
defined in Section&nbsp;11 of the License Agreement) and any other patent rights and other intellectual
property rights therein owned by Oculus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.4 &#147;<U>Cash Consideration</U>&#148; shall mean the sum of cash in the amount of &#091;***&#093; paid in
accordance with the Letter Agreement and the Closing Cash Consolidation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.5 <U>&#147;Closing</U>&#148; shall mean the closing of the transactions contemplated by this
Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.6 <U>&#147;Closing Cash Consideration</U>&#148; shall mean cash in the amount of &#091;***&#093;.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.7
&#147;<U>Closing Date</U>&#148; shall mean March&nbsp;7, 2003, or such other date to which the parties
shall mutually agree in writing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.8 <U>&#147;Encumbrances</U>&#148; shall mean restrictions on or conditions to transfer or assignment,
claims, liabilities, licenses, immunities from lawsuits to third parties, liens, pledges, mortgages
or security interests of any kind, whether accrued, absolute, contingent, or otherwise.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.9 <U>&#147;Fluidigm Series&nbsp;C Preferred Stock</U>&#148; shall mean the Series&nbsp;C Preferred Stock of
Fluidigm having the rights, preferences and privileges set forth in Fluidigm&#146;s Articles of
Incorporation attached hereto as <U>Exhibit&nbsp;A</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.10 &#147;<U>License Agreement</U>&#148; shall mean the license agreement between Oculus and
UABRF as described in Recital A.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.11 &#147;<U>New License Agreement</U>&#148; shall mean the license agreement between Fluidigm and
UABRF in the form of <U>Exhibit&nbsp;B</U> attached hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.12 &#147;<U>Sponsored Research Agreement</U>&#148; shall mean the sponsored research agreement
between Fluidigm and UABRF in the form of <U>Exhibit&nbsp;C</U> attached hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.13 &#147;<U>Technology</U>&#148; shall mean all intellectual property and other rights relating
to nanovolume crystallization arrays described in <U>Exhibit&nbsp;D</U> attached hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.14
&#147;<U>Transfer Taxes</U>&#148; shall mean all sales taxes, use taxes, conveyance taxes,
transfer taxes, filing fees, recording fees, reporting fees and other similar duties, taxes and
fees, if any, imposed upon, or resulting from, the transfer of the Assigned Rights hereunder,
except federal, state or local income or similar taxes based upon or measured by revenue, income,
profit or gain from the transfer of the Assigned Rights or the operation of Oculus&#146; business prior
to the Closing or by any increase in the value of any of the Assigned Rights through the Closing
Date.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE II
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>TRANSFER OF ASSIGNED RIGHTS AND LICENSE OF TECHNOLOGY</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1
<U>Transfer of Rights and License of Technology.</U> Oculus and UABRF have mutually
terminated the License Agreement as of January&nbsp;30, 2003 and Oculus has surrendered all rights under
the License Agreement to UABRF. Subject to and upon the terms and conditions of this Agreement,
effective as of the Closing, Fluidigm and UABRF will enter into the New License Agreement. It is
the intent of the parties that all intellectual property rights subject to the License Agreement as
of November&nbsp;27, 2002 shall be transferred and/or assigned to Fluidigm, and that all such rights
owned by UABRF shall be licensed to Fluidigm under the New License Agreement, subject to the
reservation by UABRF of certain rights as set forth in the License Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 <U>Excluded Assets and Liabilities</U>. Notwithstanding the provisions of Section&nbsp;2.1,

(a)&nbsp;Fluidigm and Oculus expressly acknowledge and agree that Oculus shall not sell, transfer,
assign, convey or deliver to Fluidigm, and Fluidigm shall not purchase, acquire or accept from
Oculus, any right, title or interest of Oculus in or to any other property or assets of Oculus, and

(b)&nbsp;Fluidigm does not assume, and Oculus does not transfer or assign, any liabilities or
obligations, whether presently fixed and determined, contingent or otherwise, of Oculus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3 <U>Payment</U>. In
consideration of the execution of the New License Agreement and the
transfer of the rights thereunder, Fluidigm will deliver to UABRF the Closing Cash Consideration
and [&nbsp;*&nbsp;*&nbsp;*&nbsp;] shares of Fluidigm Series&nbsp;C
Preferred Stock valued at 2.58 per share, the price at
which Fluidigm sold and issued shares of its Series&nbsp;C Preferred Stock to other investors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4 <U>Taxes</U>. Fluidigm and Oculus shall each pay (or reimburse the other for) one-half of
all Transfer Taxes, whether imposed by law on Fluidigm and Oculus or otherwise.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5 <U>Assigned Rights</U>. Oculus hereby sells, assigns and transfers to Fluidigm
all Assigned Rights, free and clear of all Encumbrances (except to the extent that the
settlement agreement pertaining to the Lawsuit (as such term is defined in Section&nbsp;6.3) may
include an immunity from lawsuits for conduct arising prior to the date of the settlement
agreement).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.6 <U>Unassignable Rights</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Notwithstanding any provision of this Agreement or any of the Ancillary Documents, but
subject to Section&nbsp;11.3(c), to the extent that any of the Assigned Rights are not assignable or
otherwise transferable to Fluidigm, or if such assignment or transfer would constitute a breach
thereof or a violation of any applicable law, then neither this Agreement nor such Ancillary
Documents shall constitute an assignment or transfer (or an attempted assignment or transfer)
thereof until such consent, approval or waiver of such party or parties has been duly obtained.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;If any consent required to transfer the Assigned Rights to Fluidigm has not been obtained
as of the Closing Date and Fluidigm nevertheless determines to proceed with the
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Closing, Oculus and UABRF shall, at their own expense, continue to cooperate with Fluidigm and use
commercially reasonable efforts to obtain such consent after the Closing.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;If any Assigned Right is not transferred to Fluidigm at the Closing pursuant to this
Agreement, Oculus and Fluidigm shall cooperate with each other in any reasonable arrangement
designed to provide for Fluidigm all of the benefits of such Assigned Rights. At Fluidigm&#146;s
request, Oculus shall take all reasonable actions requested by Fluidigm to enforce for the benefit
of Fluidigm any and all rights of Oculus with respect to any such Assigned Right that is not
otherwise transferred pursuant to the provisions of this Agreement. Oculus agrees to hold in trust
for, and remit promptly to, Fluidigm all future collections or payments received by Oculus in
respect of all such Assigned Rights (net of all costs and expenses incurred by Oculus in respect
thereto); <U>provided,</u> <u>however,</U> that nothing herein shall create or provide any rights or
benefits in or to third parties.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;If any intellectual property rights that are described in the New License Agreement cannot
be licensed to Fluidigm by UABRF under the New License Agreement without the consent of any third
party or without resulting in a breach or default of any agreement affecting such rights, UABRF
covenants and agrees that it shall not sue or otherwise take any legal action to restrict or
prevent Fluidigm and Fluidigm&#146;s permitted assignees and sublicensees from practicing such
intellectual property rights as purported to be granted under the terms of the New License
Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;If, subsequent to the Closing, a claim brought by any party challenging any of the
transactions contemplated hereby results in any ruling or order which has the result of frustrating
in a material way the transfer of any of the Assigned Rights hereunder to Fluidigm or the grant of
rights to Fluidigm under the New License Agreement or Fluidigm&#146;s use thereof as provided herein,
Oculus and UABRF shall cooperate with Fluidigm in any reasonable arrangement designed to give
Fluidigm, as nearly as practicable, the same economic benefits as if such transfer or license, as
the case may be, had been consummated in accordance with the provisions hereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Nothing in this Section&nbsp;2.6 shall be deemed to modify in any respect any of the
representations or warranties of Oculus and UABRF set forth herein or the conditions to Fluidigm&#146;s
obligations contained in this Agreement, be deemed a waiver by Fluidigm of its right to have
received on or before the Closing Date an effective assignment of all of the Assigned Rights or be
deemed to constitute an agreement to exclude any assets from the Assigned Rights.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE III
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>THE CLOSING</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 <U>The Closing</U>. The Closing shall take place at the offices of Gray Cary Ware &#038;
Freidenrich <FONT style="font-variant: SMALL-CAPS">llp, </FONT>400 Hamilton Avenue, Palo Alto, California, at 11:00&nbsp;a.m., Pacific Time,
on the Closing Date, or at such other time and place as Oculus, Fluidigm and UABRF may agree.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 <U>Termination of License Agreement</U>. On or before the Closing, Oculus and UABRF
shall deliver to Fluidigm an agreement and acknowledgment that the License
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Agreement has been terminated and such other agreements and instruments as may be necessary or
appropriate to evidence the return by Oculus to UABRF of all rights under the License Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3
<U>Agreements Between Fluidigm and UABRF</U>. At the Closing, Fluidigm and UABRF shall execute and deliver the New License Agreement and the
Sponsored Research Agreement.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4 <U>Other Documents</U>. Each party shall deliver to the other at the Closing such other
documents, certificates, schedules, agreements and instruments required by this Agreement to
be delivered at such time.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE IV
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>REPRESENTATIONS AND WARRANTIES OF OCULUS </U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Oculus hereby represents and warrants to Fluidigm as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 <U>Organization</U>. Oculus is a corporation duly incorporated, validly existing and in
good standing under the laws of the State of Delaware and has all requisite corporate power to
own, lease and operate its properties and to conduct its business as it is currently being
conducted. Oculus is duly qualified or licensed to do business as a foreign corporation in
each jurisdiction in which the failure to be so qualified or licensed would have a material adverse
effect on Oculus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 <u> Authorization</u>. This Agreement and all of the Ancillary Documents to which
Oculus is or will be a party have been, or upon their execution and delivery hereunder will have
been, duly and validly executed and delivered by Oculus and constitute, or will constitute, valid
and binding agreements of Oculus, enforceable against Oculus in accordance with their respective
terms, except as enforceability may be limited by bankruptcy, insolvency, reorganization,
moratorium or similar laws affecting creditors&#146; rights generally or by principles of public policy
or general equitable principles or the exercise of judicial discretion in accordance with such
principles. Oculus has the requisite corporate power and authority to execute and deliver this
Agreement and the Ancillary Documents to which Oculus is or will be a party and, at the time of the
Closing, will have the requisite corporate power and authority to carry out the transactions
contemplated by this Agreement and the Ancillary Documents. The execution, delivery and performance
by Oculus of this Agreement and the Ancillary Documents have been duly and validly approved and
authorized by the Board of Directors and shareholders of Oculus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3 <U>No Conflicts; Consents</U>. The execution and delivery by Oculus of this Agreement
and the Ancillary Documents to which Oculus is or will be a party do not, and the consummation
of the transactions contemplated hereby and thereby and compliance by Oculus with the
provisions hereof and thereof will not, contravene, conflict with, result in a breach of,
constitute a default (with or without notice or lapse of time, or both) under or violation of, or result
in the creation of any Encumbrance pursuant to, (i)&nbsp;any provision of the Certificate of Incorporation
or Bylaws of Oculus, (ii)&nbsp;any judgment, order, decree, rule, law or regulation of any court or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-5-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">governmental authority, foreign or domestic, applicable to Oculus or to any of the Assigned Rights,
except where any such contravention, conflict, breach or default could not reasonably be expected
to have a material adverse effect on Fluidigm&#146;s ownership of the Assigned Rights, or (iii)&nbsp;any
provision of any material agreement, instrument or understanding to which Oculus is a party or by
which Oculus is bound or any of the Assigned Rights are affected, except where any such
contravention, conflict, breach or default could not reasonably be expected to have a material
adverse effect on Fluidigm&#146;s ownership of the Assigned Rights, nor will such actions give to any
other person or entity any interests or rights of any kind, including rights of termination,
acceleration or cancellation, in or with respect to any of the Assigned Rights, or result in the
creation of any Encumbrance on any of the Assigned Rights. No consent, approval, order or
authorization of, or registration, declaration or filing with, any third party or any governmental
authority is required to be obtained on the part of Oculus to permit the consummation of the
transactions contemplated by this Agreement or the Ancillary Documents.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4 <U>Title to Assigned Rights</U>. Oculus has good and marketable title to all of the
Assigned Rights. All of the Assigned Rights are free and clear of any Encumbrances (except to the
extent that the settlement agreement pertaining to the Lawsuit (as such term is defined in Section
6.3) may include an immunity from lawsuits for conduct arising prior to the date of the settlement
agreement). At the Closing, Oculus will sell, convey, assign, transfer and deliver to Fluidigm
good, valid and marketable title and all right and interest in and to all of the Assigned Rights,
free and clear of any Encumbrances.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.5 <U>No Assignment</U>. Oculus has not sublicensed or otherwise transferred any material
rights under the License Agreement to any third party. As of
December&nbsp;19, 2002, the License
Agreement was in full force and effect in accordance with its terms. Prior to the termination of
the License Agreement, no provisions of the License Agreement had been waived in any
material respect. <U>Exhibit&nbsp;D</U> lists all of the patent filings subject to the License
Agreement. To the knowledge of Oculus, UABRF is the owner of the patent rights within the
technology and inventions subject to the License Agreement and has not granted a license to such
technology and inventions to any person or entity other than Oculus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.6 <U>Litigation and Claims</U>. Except as set forth on Schedule&nbsp;4.6 attached hereto, there
are no claims, actions, suits, proceedings arbitrations or investigations in progress or pending
(or, to the knowledge of Oculus, threatened) before any court, tribunal or governmental agency
against Oculus that relate to any of the Assigned Rights. Oculus is not a party to any judgment,
decree, order or arbitration award (or agreement entered into in any administrative, judicial or
arbitration proceeding with any governmental authority) with respect to any of the Assigned Rights.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.7 <U>Distribution Agreement</U>. Oculus has entered into a mutually acceptable
agreement with UABRF regarding the distribution of any and all consideration to be paid by
Fluidigm in connection with the transactions contemplated by this Agreement.
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->-6-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE V
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>REPRESENTATIONS AND WARRANTIES OF FLUIDIGM </U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fluidigm hereby represents and warrants to Oculus and UABRF as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 <U>Organization</U>. Fluidigm is a corporation duly organized, validly existing and
in good standing under the laws of the State of California and has all requisite corporate power to
own, lease and operate its properties, to conduct its business as it is currently being conducted.
Fluidigm is duly qualified or licensed to do business as a foreign corporation in each jurisdiction
in which the failure to be so qualified or licensed would have a material adverse effect on
Fluidigm.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2
<U>Authorization</U>. This Agreement and all of the Ancillary Documents to which Fluidigm
is or will be a party have been, or upon their execution and delivery hereunder will have been,
duly and validly executed by Fluidigm and constitute, or will constitute, valid and binding
agreements of Fluidigm, enforceable against Fluidigm in accordance with their respective terms,
except as enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or
similar laws affecting creditors&#146; rights generally or by principles of public policy or general
equitable principles or the exercise of judicial discretion in accordance with such principles.
Fluidigm has the requisite corporate power and authority to execute and deliver this Agreement and
the Ancillary Documents to which Fluidigm is or will be a party and, at the time of the Closing,
will have the requisite corporate power and authority to sell, issue and deliver the Securities
pursuant to this Agreement and to carry out the other transactions contemplated by this Agreement
and the Ancillary Documents. The execution, delivery and performance by Fluidigm of this Agreement
and the Ancillary Documents have been duly and validly approved and authorized by Fluidigm&#146;s Board
of Directors and by all requisite action of Fluidigm&#146;s stockholders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3
<U>No Conflicts; Consents</U>. The execution and delivery by Fluidigm of this Agreement
and the Ancillary Documents to which Fluidigm is or will be a party do not, and the consummation of
the transactions contemplated hereby and thereby and compliance by Fluidigm with the provisions
hereof and thereof will not, contravene, conflict with, result in a breach of, constitute a default
(with or without notice or lapse of time, or both) under or violation of, or result in the creation
of any Encumbrance pursuant to, (i)&nbsp;any provision of the Articles of Incorporation or Bylaws of
Fluidigm, (ii)&nbsp;any judgment, order, decree, rule, law or regulation of any court or governmental
authority, foreign or domestic, applicable to Fluidigm except where such any such contravention,
conflict, breach or default could not reasonably be expected to have a material adverse effect on
the consummation of the transactions contemplated hereby, or
(iii)&nbsp;any provision of any agreement, instrument or understanding to which Fluidigm is a party or
by which Fluidigm is bound, except where such any such contravention, conflict, breach or default
could not reasonably be expected to have a material adverse effect on the consummation of the
transactions contemplated hereby. No consent, approval, order or authorization of, or registration,
declaration or filing with, any third party or any governmental authority is required to be
obtained on the part of Fluidigm to permit the consummation of the transactions contemplated by
this Agreement or the Ancillary Documents.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-7-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4 <U>Litigation and Claims</U>. There are no claims, actions, suits, proceedings,
arbitrations or investigations in progress or pending (or, to Fluidigm&#146;s knowledge, threatened,
other than potential claims relating to the Interfering Patent (as such term is defined in Section
12.1(a) below), including, but not limited to, a possible interference) before any court, tribunal
or governmental agency, against or relating to Fluidigm, which, if determined adversely to
Fluidigm, would be likely to have a material adverse effect upon Fluidigm&#146;s financial condition or
materially impair its ability to carry out and perform its obligations hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.5 <U>Securities Laws Exemptions</U>. Based in part on the representations of UABRF
contained in Section&nbsp;6.5, the issuance of the Securities pursuant to the terms of this Agreement
will be exempt from the registration requirements of the Securities Act and the regulations
thereunder, and the registration, permit or qualification requirements of any applicable state
securities laws.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE VI
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>REPRESENTATIONS AND WARRANTIES OF UABRF</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the best knowledge of the UABRF Director and Dr.&nbsp;Larry DeLucas, UABRF hereby represents to
Fluidigm as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1 <U>Authorization</U>. This Agreement and the Ancillary Documents to which UABRF is
or will be a party have been, or upon their execution and delivery hereunder will have been, duly
and validly executed and delivered by UABRF and constitute, or will constitute, valid and binding
agreements of UABRF, enforceable against UABRF in accordance with their respective terms, except as
enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws
affecting creditors&#146; rights generally or by principles of public policy or general equitable
principles or the exercise of judicial discretion in accordance with such principles. UABRF has
full power and authority to execute and deliver this Agreement and the Ancillary Documents to which
UABRF is or will be a party and, at the time of the Closing, will have all requisite power and
authority to carry out the transactions contemplated by this Agreement and the Ancillary Documents.
All university, foundation and other internal approvals necessary for UABRF to consummate the
transactions contemplated by this Agreement and the Ancillary Documents to which UABRF is or will
be a party have been obtained.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2 <U>No Conflicts; Consents</U>. The execution and delivery by UABRF of this Agreement
and the Ancillary Documents to which UABRF is or will be a party do not, and the consummation of
the transactions contemplated hereby and thereby and compliance by UABRF with the provisions hereof
and thereof will not, contravene, conflict with, result in a breach of, constitute a default (with
or without notice or lapse of time, or both) under or violation of, or result in the creation of
any Encumbrance pursuant to, (i)&nbsp;any provision of the charter documents of UABRF, (ii)&nbsp;any
judgment, order, decree, rule, law or regulation of any court or governmental authority, foreign or
domestic, applicable to UABRF or to the Technology, except where any such contravention, conflict,
breach or default could not reasonably be expected to have a material adverse effect on Fluidigm&#146;s
rights under the New License Agreement or the consummation of the transactions contemplated hereby,
or (iii)&nbsp;any provision of any agreement, instrument or understanding to which UABRF is a party or
by which UABRF is bound or any of
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-8-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the Technology is affected, except where such any such contravention, conflict, breach or default
could not reasonably be expected to have a material adverse effect on Fluidigm&#146;s rights under the
New License Agreement or the consummation of the transactions contemplated hereby, nor will such
actions give to any other person or entity any interests or rights of any kind, including rights
of termination, acceleration or cancellation, in or with respect to any of the Technology, or
result in the creation of any Encumbrance on any of the Technology. No consent, approval, order or
authorization of, or registration, declaration or filing with, any third party or any governmental
authority is required to be obtained on the part of the UABRF to permit the consummation of the
transactions contemplated by this Agreement or the Ancillary Documents.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3 <U>Title to Technology</U>. UABRF is the sole owner of the technology, inventions and
patent rights in the Technology and subject to the License Agreement and has not granted a
license to such technology, inventions and patent rights to any person or entity other than
Oculus. The License Agreement has been mutually terminated by UABRF and Oculus and
neither Oculus nor any other party has any rights thereunder. UABRF has the right to grant an
exclusive license to the technology, inventions, patent rights and other rights under the New
License Agreement to Fluidigm, free and clear of any Encumbrances of any nature whatsoever,
subject to those liens, encumbrances or restrictions which may arise as a result of the
settlement of the litigation between Oculus and Syrrx, Inc. (&#147;<U>Syrrx</U>&#148;) described in Schedule&nbsp;4.6
(the &#147;<U>Lawsuit</U>&#148;), provided that Syrrx shall have no rights that may be exercised after the
Closing to practice the technology, inventions, patent rights and
other rights subject to the New License Agreement, and the potential infringement by Diversified Scientific, Inc. of the Licensed IP
Rights (as such term is defined in the New License Agreement) described in Section&nbsp;2.2.3 of
the New License Agreement. <U>Exhibit&nbsp;D</U> lists all of the patent filings subject to the
License Agreement. UABRF is not aware of any third-party challenges to the ownership, validity or
entitlement to priority date of any of the patent filings subject to the License Agreement or
the New License Agreement, except for the Lawsuit between Oculus and Syrrx and the settlement
agreement related to said Lawsuit provided to Fluidigm pursuant to Section&nbsp;7.2 of this
Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4 <U>Litigation and Claims</U>. Except as set forth on Schedule&nbsp;4.6 attached hereto, there
are no claims, actions, suits, proceedings, arbitrations or investigations in progress or
pending (or, to the knowledge of UABRF, threatened) before any court, tribunal or governmental agency<BR>
against UABRF that relate to any of the Technology. UABRF is not a party to any judgment,
decree, order or arbitration award (or agreement entered into in any administrative, judicial
or arbitration proceeding with any governmental authority) with respect to any of the Technology,
except to the extent that UABRF may be deemed to be a party thereto as a result of UABRF&#146;s
status as a shareholder of Oculus and having a member on the Board of Directors of Oculus as
well as the status of Dr.&nbsp;Larry DeLucas as a member of the Board of Directors of Oculus and a
shareholder of Oculus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.5 <u>Distribution Agreement.</u> UABRF has entered into a mutually acceptable
agreement with Oculus regarding the distribution of any and all consideration to be paid
by Fluidigm in connection with the transactions contemplated by this Agreement.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-9-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.6 <U>Investment Representations</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;UABRF is acquiring the shares of Fluidigm capital stock to be issued
hereunder (the &#147;<U>Securities</U>&#148;) for investment and not with the view to the public resale
or distribution thereof, and UABRF has no present intention of selling, granting any
participation in, or otherwise distributing the Securities, other than in accordance with the terms of a
Termination Agreement dated as of &#95;&#95;&#95;&#95;, 2003 between UABRF and Oculus.
UABRF understands that the Securities have not been registered under the Securities Act by reason
of a specific exemption thereunder, which depends upon, among other things, the bona fide nature of
UABRF&#146;s investment intent as expressed herein.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;UABRF acknowledges that the Securities must be held indefinitely unless they are
subsequently registered under the Securities Act or Fluidigm receives an opinion of counsel
satisfactory to Fluidigm that such registration is not required. UABRF is aware of the provisions
of Rule&nbsp;144 promulgated under the Securities Act which permit limited resale of stock purchased in
a private placement subject to the satisfaction of certain conditions.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;UABRF understands that no public market now exists for the Securities and that there can
be no assurance that a public market will ever exist for the Securities.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;UABRF is an &#147;accredited investor&#148; as defined in the Securities Act, and has such knowledge
and experience in financial and business matters that it is capable of evaluating the merits and
risks of the investment in the Securities.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;UABRF has been given the opportunity to obtain any information or documents related to,
and ask questions and receive answers about Fluidigm and its business, prospects and risks which
UABRF deems necessary, to evaluate the merits and risks related to UABRF&#146;s investment in the
Securities and to verify the information UABRF received.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;UABRF&#146;s financial condition is such that it can afford to bear the economic risk of
holding the Securities for an indefinite period of time, and it has adequate means of providing for
its current needs and contingencies and to suffer a complete loss of its investment in such
Securities.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.7 <U>Restrictions</U>. No Securities shall be sold, assigned, transferred or pledged except
upon the conditions specified in this Agreement. UABRF will cause any proposed purchaser, assignee,
transferee or pledgee of the Securities to agree in writing to take and hold such securities
subject to the provisions and upon the conditions specified in this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.8 <U>Restrictive Legend</U>. Each certificate representing the Securities shall (unless
otherwise permitted by the provisions of Section&nbsp;6.9 below) be stamped or otherwise imprinted with
a legend in the following form (in addition to any legend required under applicable state
securities laws):
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&#147;THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED
FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE &#147;SECURITIES ACT&#148;). SUCH
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-10-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">SECURITIES MAY NOT BE SOLD, TRANSFERRED OR PLEDGED IN THE ABSENCE
OF SUCH REGISTRATION OR UNLESS THE COMPANY RECEIVES AN OPINION OF
COUNSEL (WHICH MAY BE COUNSEL FOR THE COMPANY) OR OTHER EVIDENCE
REASONABLY ACCEPTABLE TO IT STATING THAT SUCH SALE OR TRANSFER IS
EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS
OF THE SECURITIES ACT.&#148;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&#147;THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A MARKET
STAND-OFF AGREEMENT IN THE EVENT OF A PUBLIC OFFERING, A COPY OF WHICH
IS ON FILE WITH THE SECRETARY OF THE COMPANY.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;UABRF consents to Fluidigm making a notation on its records and giving instructions to any
transfer agent of the Securities in order to implement the restrictions on transfer established in
Sections&nbsp;6.7 through 6.10 of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.9 <U>Notice of Proposed Transfers</U>. UABRF and any transferee of any certificate
representing the Securities, by acceptance thereof, agrees to comply in all respects with the
restrictions on transfer contained in Sections&nbsp;6.7 through 6.10 of this Agreement. Prior to any
proposed sale, assignment, transfer or pledge of any Securities (other than any transfer not
involving a change in beneficial ownership), unless there is in effect a registration statement
under the Securities Act covering the proposed transfer, the holder thereof shall give written
notice to Fluidigm of such holder&#146;s intention to effect such transfer, sale, assignment or pledge.
Each such notice shall describe the manner and circumstances of the
proposed transfer, sale, assignment or pledge in sufficient detail, and shall be accompanied at such holder&#146;s expense by
either (i)&nbsp;a written opinion of legal counsel who shall, and whose legal opinion shall be,
reasonably satisfactory to Fluidigm, addressed to Fluidigm, to the effect that the proposed
transfer of the Securities may be effected without registration under the Securities Act, or (ii)&nbsp;a
&#147;no action&#148; letter from the Securities and Exchange Commission (the &#147;Commission&#148;) to the effect
that the transfer of such Securities without registration will not result in a recommendation by
the staff of the Commission that action be taken with respect thereto, or (iii)&nbsp;any other evidence
reasonably satisfactory to counsel to Fluidigm, whereupon the holder of such Securities shall be
entitled to transfer such Securities in accordance with the terms of the notice delivered by the
holder to Fluidigm; provided, however, that no such legal opinion, &#147;no action&#148; letter or other
evidence shall be required with respect to a transfer to an affiliate of the holder. Each
certificate evidencing the Securities transferred as above provided shall bear, except if such
transfer is made pursuant to Rule&nbsp;144, the appropriate restrictive legend set forth in Section&nbsp;6.8
above, except that such certificate shall not bear such restrictive legend if, in the opinion of
counsel for such holder and Fluidigm, such legend is not required in order to establish compliance
with any provisions of the Securities Act or this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.10 <U>Standoff Agreement</U>. UABRF agrees in connection with Fluidigm&#146;s initial sale of
securities pursuant to an effective registration statement, upon notice by Fluidigm or the
underwriters managing such offering, not to sell, make any short sale of, loan, pledge (or
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-11-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">otherwise encumber or hypothecate), grant any option for the purchase of, or otherwise directly or
indirectly dispose of any Securities (other than those included in the registration) without the
prior written consent of Fluidigm and such managing underwriters for such period of time as
Fluidigm&#146;s Board of Directors establishes pursuant to its good faith negotiations with such
managing underwriters; provided, however that:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;such agreement shall not exceed one hundred eighty (180)&nbsp;days;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;such agreement shall not apply to transfers to an affiliate, provided that such
affiliate agrees to be bound by the terms of such agreement, to the same extent as if such
transferee were the original party thereunder;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;UABRF shall not be subject to such agreement unless (A)&nbsp;all executive officers and
directors of Fluidigm, (B)&nbsp;all shareholders of Fluidigm holding more than 1% of Fluidigm&#146;s
outstanding capital stock and (C)&nbsp;all holders of registration rights, are subject to or obligated
to enter into similar agreements; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;if and when any person identified in clause (iii)&nbsp;is released, in whole or in part,
from such agreement (whether or not such release is contemplated at the time of the offering) or if
any such agreement is terminated, UABRF shall be concurrently released on a pro rata basis based on
the number of Securities held by such person and UABRF.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;UABRF agrees that prior to the initial public offering it will not transfer
securities of Fluidigm unless each transferee agrees in writing to be bound by all of the
provisions of this Section&nbsp;6.10, provided that this Section&nbsp;6.10 shall not apply to transfers
pursuant to a registration statement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;UABRF hereby consents to the placement of stop transfer orders with Fluidigm&#146;s transfer agent
in order to enforce the foregoing provision and agrees to execute a market standoff agreement with
said underwriters in customary form consistent with the provisions of this Section&nbsp;6.10.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE VII
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>COVENANTS OF OCULUS</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1 <U>Conduct of Business</U>. During the period from the date of this Agreement to the
Closing, Oculus will conduct its business in the ordinary course consistent with past
practices. During the period from the date of this Agreement to the Closing, Oculus will not
without the prior written consent of Fluidigm:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;encumber or permit to be encumbered any of the Technology or Assigned Rights;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;dispose of any of the Technology or Assigned Rights;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;waive or release any right or claim relating to any Technology or Assigned Rights; or
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-12-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;agree to do any of the things described in the preceding clauses of this Section&nbsp;7.1.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Fluidigm agrees that the foregoing restrictions will not prevent Oculus from entering into a
settlement agreement with Syrrx to settle the Lawsuit, provided that such settlement does not
involve the sale, transfer or assignment of the Technology or the Assigned Rights, or any rights in
any of the foregoing, or result in the creation of any Encumbrance on the Technology, the Assigned
Rights, or any rights in any of the foregoing.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2 <U>Access to Information</U>. Until the earlier of the termination of this Agreement or
the Closing, Oculus will allow Fluidigm and its agents reasonable access upon reasonable notice and
during normal working hours to its files, books, records, and offices relating to the Technology
and Assigned Rights, except where prohibited by contract or protected by privilege. In furtherance
of the above, Fluidigm and its counsel and advisors shall have reasonable access during normal
business hours to pertinent contracts of Oculus, including an unsigned final version of the
settlement agreement between Oculus and Syrrx related to the Lawsuit, and drafts of such settlement
agreement (to the extent it is permissible under applicable confidentiality terms and with the
understanding that Oculus may be required to obtain the return or destruction by Fluidigm of the
final version and drafts of such settlement agreement prior to its execution), as well as all
scientific notebooks, invention records and other documents related to the conception and reduction
to practice and prosecution of the patent filings listed on
<U>Exhibit&nbsp;D</U>, including, without
limitation, all patent searches, patent file wrappers, legal and scientific investigations and
research related to the Technology, the License Agreement and the New License Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3 <U>Regulatory Approvals</U>. Prior to the Closing, Oculus will execute and file, or join
in the execution and filing of, any application or other document that may be reasonably necessary
in order to obtain the authorization, approval or consent of any governmental entity that may be
required in connection with the consummation of the transactions contemplated by this Agreement.
Oculus will use commercially reasonable efforts to obtain all such authorizations, approvals and
consents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.4
<U>Satisfaction of Conditions Precedent</U>. Oculus will use commercially reasonable
efforts to satisfy or cause to be satisfied all the conditions precedent to the Closing hereunder,
and to cause the transactions contemplated hereby to be consummated, and, without limiting the
generality of the foregoing, to obtain all consents and authorizations of third parties and to make
all filings with, and give all notices to, third parties which may be necessary or reasonably
required on its part in order to effect the transactions contemplated hereby.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE VIII
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>COVENANTS OF UABRF</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.1 <U>Conduct of Business</U>. During the period from the date of this Agreement to
the Closing, UABRF will not without the prior written consent of Fluidigm:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;encumber or permit to be encumbered any of the Technology;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-13-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;dispose
of any of the Technology;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;waive or release any right or claim relating to any Technology; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;agree to do any of the things described in the preceding clauses of this
Section&nbsp;8.1.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Fluidigm agrees that the foregoing restrictions will not prevent UABRF from consenting to a
settlement agreement between Oculus and Syrrx to settle the Lawsuit, provided that such
settlement does not involve the sale, transfer or assignment of the Technology or the
Assigned Rights, or any rights in any of the foregoing, or result in the creation of any
Encumbrance on the Technology, the Assigned Rights, or any rights in any of the foregoing.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.2 <U>Access to Information</U>. Until the earlier of the termination of this
Agreement or the Closing, UABRF will allow Fluidigm and its agents reasonable access upon
reasonable notice and during normal working hours to its files, books, records, and offices
relating to the Technology and Assigned Rights, except where prohibited by contract or
protected by privilege. In furtherance of the above, Fluidigm and its counsel and advisors
shall have reasonable access during normal business hours to pertinent scientific notebooks,
invention records and other documents related to the conception and reduction to practice
and prosecution of the patent filings listed on <U>Exhibit&nbsp;D,</U> including, without
limitation, all patent searches, patent file wrappers, legal and scientific investigations
and research related to the Technology, the License Agreement and the New License Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.3 <U>Regulatory Approvals</U>. Prior to the Closing, UABRF will execute and file, or
join in the execution and filing of, any application or other document that may be
reasonably necessary in order to obtain the authorization, approval or consent of any governmental entity
that may be required in connection with the consummation of the transactions contemplated by
this Agreement. UABRF will use commercially reasonable efforts to obtain all such
authorizations, approvals and consents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.4 <U>Satisfaction of Conditions Precedent</U>. UABRF will use commercially
reasonable efforts to satisfy or cause to be satisfied all the conditions precedent to the Closing
hereunder, and to cause the transactions contemplated hereby to be consummated, and, without
limiting the generality of the foregoing, to obtain all consents and authorizations of third parties
and to make all filings with, and give all notices to, third parties which may be necessary or
reasonably required on its part in order to effect the transactions contemplated hereby.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt">ARTICLE IX
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><U>COVENANTS OF FLUIDIGM</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.1 <U>Regulatory Approvals</U>. Prior to the Closing, Fluidigm will execute and
file, or join in the execution and filing of, any application or other document that may be
reasonably necessary in order to obtain the authorization, approval or consent of any
governmental entity that may be required in connection with the consummation of the
transactions contemplated by this Agreement. Fluidigm will use its commercially reasonable
efforts to obtain all such authorizations, approvals and consents.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-14-<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.2 <U>Satisfaction of Conditions Precedent.</U> Fluidigm will use commercially reasonable
efforts to satisfy or cause to be satisfied all the conditions precedent to the Closing hereunder,
and to cause the transactions contemplated hereby to be consummated, and, without limiting the
generality of the foregoing, to obtain all consents and authorizations of third parties and to make
all filings with, and give all notices to, third parties which may be necessary or reasonably
required on its part in order to effect the transaction contemplated hereby.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE X
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>MUTUAL COVENANTS</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.1 <U>Confidentiality.</U> The parties acknowledge that the Confidential Disclosure
Agreement dated as of October&nbsp;8, 2002 between Fluidigm and Oculus and the Confidential Disclosure
Agreement dated December&nbsp;19, 2002 between Fluidigm, Oculus and UABRF are binding upon the parties
hereto and in full force and effect, except to the extent that the provisions hereof supersede
provisions to similar effect contained in the Confidential Disclosure Agreements. The terms of the
Confidential Disclosure Agreements (exclusive of such superseded provisions) are incorporated in
this Agreement by this reference.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.2 <U>Publicity.</U> Except as may otherwise be required by law, none of the parties hereto
shall make or cause to be made any public announcements in respect of this Agreement or the
transactions contemplated herein or otherwise communicate with any news media without the prior
written consent of the other party, provided, however, that following the Closing Fluidigm may
issue a press release to announce the closing of the transactions contemplated hereby and the
execution and delivery of the New License Agreement and Sponsored Research Agreement with UABRF
provided that such press release shall not be issued prior to the execution by Syrrx
of a settlement agreement with Oculus to settle the litigation described in Schedule&nbsp;4.6 but in any
event the press release may be issued no later than 30&nbsp;days from the execution date of the New
License Agreement. Except for the press release issued by Fluidigm, none of the parties hereto will
make any public disclosure prior to the Closing or with respect to the Closing unless all parties
agree on the text and timing of such public disclosure, except as required by law. Nothing
contained in this Section shall prevent any party at any time from furnishing any information
pursuant to the requirements of any governmental entity; <U>provided,</U> <U>however,</U> that
if such party is required to furnish such information, it will provide a copy to the other parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.3 <U>Governmental Filings.</U> As promptly as practicable after the execution of this
Agreement, each party shall make any and all governmental filings required with respect to the
transactions contemplated in this Agreement and the Ancillary Documents.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE XI
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>CONDITIONS TO CLOSING</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.1 <U>Conditions to Each Party&#146;s Obligations.</U> The respective obligations of each party
to effect the transactions to be performed by such party at the Closing are subject to the
satisfaction at or prior to the Closing of the following conditions any of which may be waived in
writing by each party:
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-15-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;No order shall have been entered, and not vacated, by a court or administrative agency
of competent jurisdiction, in any action or proceeding which enjoins, restrains or prohibits the
sale of the Assigned Rights, the grant of rights under the New License Agreement or the
consummation of any other transaction contemplated hereby.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;All permits, authorizations, approvals and orders required to be obtained under all
applicable statutes, codes, ordinances, rules and regulations in connection with the transactions
contemplated hereby shall have been obtained and shall be in full force and effect at the Closing
Date.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;There shall be no litigation pending or threatened by any regulatory body or private
party in which (i)&nbsp;an injunction is or may be sought against the transactions contemplated hereby,
or (ii)&nbsp;relief is or may be sought against any party hereto as a result of this Agreement and in
which, in the good faith judgment of the Board of Directors of either Fluidigm, Oculus or UABRF
(relying on the advice of their respective legal counsel), such regulatory body or private party
has the probability of prevailing and such relief would have a material adverse affect upon such
party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.2 <U>Conditions to Obligations of Oculus and UABRF.</U> The obligations of Oculus and UABRF
to effect the transactions to be performed by Oculus and UABRF at the Closing are subject to the
satisfaction at or prior to the Closing of the following additional conditions any of which may be
waived in writing by Oculus and UABRF:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;All of the representations and warranties of Fluidigm set forth in Article&nbsp;V hereof
shall be true in all material respects on and as of the Closing Date with the same force and effect
as if they had been made at the Closing, except for changes contemplated by this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;All of the terms, covenants and conditions of this Agreement to be complied with and
performed by Fluidigm at or prior to the Closing shall have been duly complied with and performed
in all material respects.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.3 <U>Conditions to Obligations of Fluidigm.</U> The obligations of Fluidigm to effect the
transactions to be performed by it at the Closing are subject to the satisfaction at or prior to
the Closing of the following additional conditions any of which may be waived in writing by
Fluidigm:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;All of the representations and warranties of Oculus and UABRF set forth in Articles IV
and VI hereof shall be true in all material respects on and as of the Closing Date with the same
force and effect as if they had been made at the Closing, except for changes contemplated by this
Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;All of the terms, covenants and conditions of this Agreement to be complied with and
performed by Oculus and UABRF at or prior to the Closing shall have been duly complied with and
performed in all material respects.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;All required consents from third parties required to allow the consummation of the sale
of the Assigned Rights, the grant of rights under the New License
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-16-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="font-size: 10pt; margin-top: 6pt">Agreement and the other transactions contemplated hereby shall have been obtained and delivered to
Fluidigm.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Fluidigm shall have received an opinion from the attorney(s) prosecuting the patent
filings listed on <U>Exhibit&nbsp;D</U>, in form and substance reasonably acceptable to Fluidigm, as to
the following matters: (i)&nbsp;assignments of the inventions covered by the patent filings to UABRF
have been properly filed with the United States Patent and Trademark Office (&#147;USPTO&#148;), (ii)&nbsp;UABRF
is named as the sole owner of the inventions covered by the patent filings listed on <U>Exhibit
D</U>, (iii)&nbsp;a declaration of interference was timely requested with at least one of the pending
U.S. patent applications listed on <U>Exhibit&nbsp;D</U> and U.S. Patent No.&nbsp;6,296,673 with the USPTO
in accordance with U.S.C. Section&nbsp;135, (iv)&nbsp;none of the patents listed on <U>Exhibit&nbsp;D</U> have
been held to be permanently revoked, unenforceable or invalid by a decision of a court or other
governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed
for appeal, and none of the patents listed on <U>Exhibit&nbsp;D</U> have been admitted to be invalid or
unenforceable through reissue or disclaimer or otherwise, and (v)&nbsp;the patent applications listed on
<U>Exhibit&nbsp;D</U> were filed in good faith and have not been abandoned or finally disallowed
without the possibility of appeal or refiling of such application.</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE XII</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>POST-CLOSING MATTERS</U></DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.1 <U>Additional Payments by Fluidigm.</U> In addition to the consideration delivered by
Fluidigm at the Closing, Fluidigm will pay the following amounts to UABRF upon the achievement of
the following milestones:</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)
<U>Milestone 1</U>. Milestone 1 shall be satisfied [***]. Within
[***]&nbsp;days after [***], Fluidigm will issue shares of its stock having a
value of [***] (based on the fair value of the stock at the time Milestone 1 is achieved),
subject to compliance with applicable securities laws.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)
<U>Milestone 2.</U> Milestone 2 shall be satisfied [***].
Within [***]&nbsp;days after [***], Fluidigm will issue shares of its stock having a value of [***]
(based on the fair value at the time Milestone 2 is achieved), subject to compliance with
applicable securities laws. In addition, (i)&nbsp;[***]</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-17-<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">[***]</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Stock to
be Issued.</U> If Fluidigm is a private company at the time a milestone is
achieved, upon achievement of a milestone Fluidigm will issue shares of the series of Fluidigm
Preferred Stock that was issued in Fluidigm&#146;s most recent financing and the shares will be valued
at the price at which the shares were sold in such financing. If Fluidigm is a public company at
the time a milestone is achieved, upon achievement of a milestone Fluidigm will issue shares of
Fluidigm Common Stock and the shares will be valued at the average closing price of Fluidigm&#146;s
Common Stock over the five trading days preceding the achievement of the milestone.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.2
<U>Settlement of Lawsuit</U>. If the Lawsuit has not been settled or dismissed as of the
Closing Date:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Oculus agrees that Fluidigm and its counsel and advisors shall have reasonable access
during normal business hours to the final version of the settlement agreement between Oculus and
Syrrx related to the Lawsuit, and drafts of such settlement agreement (to the extent permissible
under applicable confidentiality terms), in the manner contemplated by Section&nbsp;7.2 of this
Agreement, until the Lawsuit is settled or dismissed.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Oculus and UABRF agree that if a settlement agreement related to the Lawsuit is entered
into after the Closing Date, the settlement will not involve the sale, transfer or assignment of
the Technology or the Assigned Rights, or any rights in any of the foregoing, or result in the
creation of any Encumbrance on the Technology, the Assigned Rights, or any rights in any of the
foregoing.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE XIII
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>TERMINATION OF AGREEMENT</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.1 <U>Termination by Fluidigm.</U> This Agreement may be terminated at any time before the
Closing by action of the Board of Directors of Fluidigm upon written notice to Oculus and UABRF,
specifying the basis for such termination, if (i)&nbsp;Oculus or UABRF shall have breached in any
material respect any of their covenants or agreements contained in this Agreement, or (ii)&nbsp;any
representation or warranty of Oculus or UABRF contained in this Agreement shall have been
materially inaccurate.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.2 <U>Termination by UABRF.</U> This Agreement may be terminated at any time before the
Closing by action of the Board of Directors or other governing body of UABRF upon written notice to
Fluidigm, specifying the basis for such termination, if (i)&nbsp;Fluidigm shall have breached in any
material respect any of its covenants or agreements contained in this Agreement, or (ii)&nbsp;any
representation or warranty of Fluidigm contained in this Agreement shall have been materially
inaccurate.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.3 <U>Mutual Consent.</U> This Agreement may be terminated at any time before the Closing,
by the mutual written consent of Fluidigm, Oculus and UABRF.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-18-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.4
<U>Effect of Termination</U>. Upon any termination of this Agreement, all parties hereto
shall be relieved of all further obligations under this Agreement, except for the provisions of
Section&nbsp;2.5 regarding the assignment by Oculus to Fluidigm of Assigned Rights, together with all
patent rights and all other intellectual property rights therein, Section&nbsp;15.6 regarding the
payment of certain expenses and Section&nbsp;10.1 regarding the continuing obligations of the parties
under the Confidential Disclosure Agreements.</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE XIV</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>SURVIVAL OF REPRESENTATIONS AND WARRANTIES</U></DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.1 <U>Survival of Representations and Warranties</U>. The representations and warranties set forth
in this Agreement shall survive the Closing for a period equal to the greater of 12&nbsp;months after
the Closing Date or the date on which both Milestones specified in Section&nbsp;12.1 have been achieved.
After the expiration of such period, such representations and warranties shall expire and be of no
further force and effect.</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE XV</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>GENERAL</U></DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.1
<U>Governing Law</U>. It is the intention of the parties hereto that the internal laws of
the State of California (irrespective of its choice of law principles) shall govern the validity of
this Agreement, the construction of its terms, and the interpretation and enforcement of the rights
and duties of the parties hereto; provided, however, that any disputes involving UABRF shall be
governed by the internal laws of the State of Alabama (irrespective of its choice of law principles
and any disputes involving UABRF shall be resolved Birmingham, Alabama in accordance with the
provisions of Section&nbsp;15.11 and UABRF shall have the right to raise all of the defenses available
to the University of Alabama at Birmingham.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.2
<U>Assignment; Binding upon Successors and Assigns</U>. None of the parties hereto may
assign any of its rights or obligations hereunder (whether by operation of law or otherwise)
without the prior written consent of the other party; provided, however, that any party may assign
its rights and obligations under covenants and agreements to be performed after the Closing in
connection with the sale of all or substantially all of such party&#146;s business. This Agreement will
be binding upon and inure to the benefit of the parties hereto and their respective permitted
successors and assigns.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.3
<U>Severability</U>. If any provision of this Agreement, or the application thereof,
becomes or is declared by a court of competent jurisdiction to be illegal, void or unenforceable,
the remainder of this Agreement will continue in full force and effect and the application of such
provision to other persons or circumstances shall be interpreted so as best to reasonably effect
the intent of the parties hereto. The parties further agree to replace such illegal, void or
unenforceable provision of this Agreement with a valid and enforceable provision which will
achieve, to the extent possible, the economic, business and other purposes of the illegal, void or
unenforceable provision.</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-19-<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.4 <U>Entire Agreement.</U> This Agreement (including the Exhibits and Schedules hereto) the
Ancillary Agreements, the documents and instruments and other agreements among the parties hereto
referenced herein and therein, and the exhibits thereto, constitute the entire understanding and
agreement of the parties hereto with respect to the subject matter hereof and thereof and supersede
all prior and contemporaneous agreements or understandings, inducements or conditions, express or
implied, written or oral, between the parties with respect hereto and thereto including, without
limitation, the Letter Agreement. To the extent that any provision of this Agreement conflicts with
any provision of the New License Agreement or the Sponsored Research Agreement between Fluidigm and
UABRF, the applicable provision of the New License Agreement or the Sponsored Research Agreement,
as the case may be, shall control and supersede the applicable provision of this Agreement.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.5 <U>Counterparts.</U> This Agreement may be executed in any number of counterparts, each of
which shall constitute an original and all of which together shall constitute one and the same
instrument.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.6 <U>Expenses.</U></DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The parties shall each pay their own legal, accounting and financial advisory fees and
other out-of-pocket expenses incurred incident to the negotiation, preparation and carrying out of
this Agreement and the transactions herein contemplated, whether or not the transactions
contemplated hereby are consummated.</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each party shall indemnify the other against, and agrees to hold the other harmless from,
all liabilities and expenses (including reasonable attorneys&#146; fees) in connection with
any claim by any person for compensation as a broker, finder or in any similar capacity, by
reason of services allegedly rendered to the indemnifying party in connection with the
transactions contemplated hereby.</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.7 <U>Other Remedies.</U> Except as otherwise provided herein, any and all remedies herein
expressly conferred upon a party shall be deemed cumulative with and not exclusive of any other
remedy conferred hereby or by law on such party, and the exercise of any one remedy shall not
preclude the exercise of any other.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.8 <U>Amendment.</U> Any term or provision of this Agreement may be amended by a written
instrument signed by Fluidigm, Oculus and UABRF; provided that any term or provision that pertains
only to UABRF and Fluidigm may be amended by a written instrument signed by UABRF and Fluidigm.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.9 <U>Waiver.</U> Any party hereto may, by written notice to the other party: (i)&nbsp;waive any
of the conditions to its obligations hereunder or extend the time for the performance of any of the
obligations or actions of another party; (ii)&nbsp;waive any inaccuracies in the representations of
another party contained in this Agreement or in any documents delivered pursuant to this Agreement;
(iii)&nbsp;waive compliance with any of the covenants of the other contained in this Agreement; or (iv)
waive or modify performance of any of the obligations of another party. Except as specifically
contemplated by this Agreement, no action taken pursuant to this Agreement, including without
limitation any investigation by or on behalf of any party, shall be</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-20-<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="font-size: 10pt; margin-top: 6pt">deemed to constitute a waiver by the party taking such action of compliance with any
representation, warranty, condition or agreement contained herein. Waiver of the breach of any one
or more provisions of this Agreement shall not be deemed or construed to be a waiver of other
breaches or subsequent breaches of the same provisions.</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.10
<U>Informal Resolution</U>. In the event of any controversy or claim arising under this
Agreement, officers or comparable officials of UABRF, Oculus and Fluidigm shall promptly meet and
attempt in good faith to reach a resolution of such controversy or claim.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.11
<U>Mediation</U>. Any controversy or claim between any of the parties hereto arising out
of or relating to this Agreement that is not resolved by the parties within thirty (30)&nbsp;days after
delivery of notice of such controversy or claim, upon written notice of either Fluidigm, Oculus or
UABRF, shall be submitted for resolution by mediation in accordance with commercial mediation
guidelines. Any mediation proceeding shall be conducted in the County of Cook, City of Chicago, in
the State of Illinois. The mediation shall be concluded within a ninety (90)&nbsp;day period after
notice.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.12
<U>Notices</U>. All notices and other communications hereunder will be in writing and will
be deemed given (i)&nbsp;upon receipt if delivered personally (or if mailed by registered or certified
mail), (ii)&nbsp;the next business day after dispatch if sent by overnight delivery
service, (iii)&nbsp;upon dispatch if transmitted by facsimile (and confirmed by a copy delivered in
accordance with clause (i)&nbsp;or (ii)), properly addressed to the parties at the following addresses:</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="80%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Fluidigm:
</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Fluidigm Corporation</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">7100 Shoreline Court</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">South San Francisco, CA 94080</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Attention:&nbsp;&nbsp;President</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Facsimile No.: (650)&nbsp;871-7192</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">with a copy to:
</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Fluidigm Corporation</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">7100 Shoreline Court</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">South San Francisco, CA 94080</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Attention: General Counsel</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Facsimile No.: (650)&nbsp;871-7195</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Oculus:
</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Oculus Pharmaceuticals, Inc.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">1601 12th Avenue South</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Birmingham, AL 35205</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Attention: B.J. Lehman</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Facsimile No: (216)&nbsp;361-9495</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">and</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Oculus Pharmaceuticals, Inc.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">3201 Carnegie Avenue</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Cleveland, OH 44115</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Attention: B.J. Lehman</TD>
</TR>


<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Facsimile No.: (216) 361-9495</TD>
</TR>


<!-- End Table Body -->
</TABLE></DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-21-<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="80%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">UABRF:
</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">The UAB Research Foundation</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">1120G Administration Building</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">701 20th Street South</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Birmingham, AL 35294-0111</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Attention: Director</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Facsimile No.: (205)&nbsp;975-5560</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any party may change its address for such communications by giving notice thereof to the other
party in conformity with this Section.
</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.13 <U>Construction and Interpretation of Agreement.</U>
</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;This Agreement has been negotiated by the parties hereto and their respective attorneys,
and the language hereof shall not be construed for or against any party.
</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The titles and headings herein are for reference purposes only and shall not in any
manner limit the construction of this Agreement, which shall be considered as a
whole.
</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Any reference to a &#147;material adverse effect&#148; with respect to any entity or group of
entities means a material adverse effect on the business, assets (including intangible assets),
financial condition, properties, liabilities, results of operations or prospects of such entity.
</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Any reference to a party&#146;s &#147;knowledge means such party&#146;s actual
knowledge after reasonable inquiry of its directors, officers and other management level employees
that have responsibility for the referenced matters.
</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;When reference is made to a Section or Article, such reference shall be to a Section or
Article of the Agreement, unless otherwise indicated.
</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.14 <U>No Joint Venture.</U> Nothing contained in this Agreement shall be deemed or construed
as creating a joint venture or partnership between any of the parties hereto. No party is by virtue
of this Agreement authorized as an agent, employee or legal representative of any other party. No
party shall have the power to control the activities and operations of any other and their status
is, and at all times, will continue to be, that of independent contractors with respect to each
other. No party shall have any power or authority to bind or commit any other. No party shall hold
itself out as having any authority or relationship in contravention of this Section.
</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.15 <U>Absence of Third Party Beneficiary Rights.</U> No provisions of this Agreement are
intended, nor shall be interpreted, to provide or create any third party beneficiary rights or any
other rights of any kind in any client, customer, affiliate, shareholder, partner of any party
hereto or any other person or entity unless specifically provided otherwise herein, and, except as
so provided, all provisions hereof shall be personal solely between the parties to this Agreement.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-22-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.16 <U>Further Assurances.</U> In connection with this Agreement and the transactions
contemplated hereby, each party shall execute and deliver any additional documents and instruments
and perform any additional acts that may be reasonably necessary or appropriate to effectuate and
perform the provisions of this Agreement and such transactions and the intention of the parties.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;REMAINDER OF PAGE INTENTIONALLY LEFT BLANK&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-23-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first set forth
above.</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top">FLUIDIGM CORPORATION</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">/s/ Gajus Worthington</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>



<tr>
    <TD>&nbsp;</TD>
</tr>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" valign="top">Title:</TD>
    <TD>President &#038; CEO</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top" colspan="3">OCULUS PHARMACEUTICALS, INC.</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">By:
</TD>

    <TD>&nbsp;</TD>
    <TD valign="top">/s/ (ILLEGIBLE)</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<tr>
    <TD>&nbsp;</TD>
</tr>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" valign="top">Title:</TD>
    <TD>President &#038; CEO</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top">THE UAB RESEARCH FOUNDATION</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">/s/ (ILLEGIBLE)</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<tr>
    <TD>&nbsp;</TD>
</tr>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" valign="top">Title:</TD>
    <TD>Director</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE></DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">Acknowledged and agreed to</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">this March&nbsp;7, 2003.</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">/s/ Dr.&nbsp;Larry DeLucas
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Dr. Larry DeLucas</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE></DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-24-<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>SCHEDULE 4.6</U>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt">[***]</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>EXHIBIT A</U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Amended and Restated<BR>
Articles of Incorporation of Fluidigm

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>EXHIBIT B</U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Form of New License Agreement

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>EXHIBIT C</U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Form of Sponsored Research Agreement

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>EXHIBIT D </U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>PATENTS AND PATENT APPLICATIONS</B>

</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[***]
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9A
<SEQUENCE>23
<FILENAME>f39432orexv10w9a.htm
<DESCRIPTION>EXHIBIT 10.9A
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w9a</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#091;***&#093; Indicates
text has been omitted from this Exhibit pursuant to a confidential treatment
request and has been filed separately with the Securities and Exchange Commission.
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><b>Exhibit&nbsp;10.9A</b>
</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="70%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>8805. LICI.001</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>UAB Research Foundation</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>LICENSE AGREEMENT</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIS LICENSE AGREEMENT (this &#147;Agreement&#148;) dated as of March&nbsp;7, 2003 (the &#147;Effective Date&#148;), is
entered into between The UAB Research Foundation, an Alabama not for profit organization (&#147;UABRF&#148;),
having a place of business at 1120G Administration Building, 704 20th Street, Birmingham, Alabama
35294, and Fluidigm Corporation, a California corporation (&#147;Fluidigm&#148;), having a place of business
at 7100 Shoreline Court, South San Francisco, California 94080.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, UABRF owns or has rights in certain technology regarding nanovolume crystallization
arrays.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, UABRF and Oculus Pharmaceuticals, Inc. (&#147;Oculus&#148;) have entered into that certain
License Agreement dated as of September&nbsp;21, 2001 (&#147;Oculus Agreement&#148;) pursuant to which UABRF has
granted to Oculus an exclusive license to the Oculus Agreement Technology (as defined below), on
the terms and conditions of the Oculus Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS,
UABRF and Oculus have terminated the Oculus Agreement effective as of January&nbsp;30,
2003.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, UABRF has licensed to Diversified Scientific, Inc. (&#147;DSI&#148;) rights in certain other
technology, which certain technology is identified in the attached <U>Exhibit&nbsp;A</U> (&#147;UABRF/DSI
Technology&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, DSI is performing certain research pursuant to one or more grants, existing as of
December&nbsp;19, 2002, between UAB (as defined below) and DSI under Defense Small Business Innovation
Research Program.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, Fluidigm desires to obtain an exclusive worldwide license under the Licensed IP
Rights (as defined below), on the terms and conditions of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants
herein contained, the parties agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;DEFINITIONS
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 &#147;<U>Affiliate</U>&#148; shall mean, with respect to any Person, any other Person which
directly or indirectly controls, is controlled by, or is under common control with, such Person. A
Person shall be regarded as in control of another Person if it owns, or directly or indirectly
controls, at least forty percent (40%) of the voting stock or other ownership interest of the other
Person, or if it directly or indirectly possesses the power to direct or cause the direction of the
management and policies of the other Person by any means whatsoever.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2 &#147;<U>Confidential Information</U>&#148; shall mean, with respect to a party, all information of
any kind whatsoever, and all tangible and intangible embodiments thereof of any
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">kind whatsoever, which is disclosed by such party to the other party and is marked, identified as
or otherwise acknowledged to be confidential at the time of disclosure to the other party.
Notwithstanding the foregoing, Confidential Information of a party shall not include information
which the other party can establish by written documentation (a)&nbsp;to have been publicly known prior
to disclosure of such information by the disclosing party to the other party, (b)&nbsp;to have become
publicly known, without fault on the part of the other party, subsequent to disclosure of such
information by the disclosing party to the other party, (c)&nbsp;to have been received by the other
party at any time from a source, other than the disclosing party, rightfully having possession of
and the right to disclose such information, (d)&nbsp;to have been otherwise known by the other party
prior to disclosure of such information by the disclosing party to the other party, or (e)&nbsp;to have
been independently developed by employees or agents of the other party without access to or use of
such information disclosed by the disclosing party to the other party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3 &#147;<U>Fluidigm Series&nbsp;C Preferred Stock</U>&#148; shall have the meaning set forth in Section
1.9 of the Master Closing Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.4 &#147;<U>Licensed IP Rights</U>&#148; shall mean, collectively, the Licensed Patent Rights and the
Licensed Know-How Rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.5 &#147;<U>Licensed Know-How Rights</U>&#148; shall mean all trade secret and other know-how rights
in all information and data disclosed on or before the Effective Date that (i)&nbsp;is not generally
known (including, but not limited to, information and data regarding formulae, procedures,
protocols, techniques and results of experimentation and testing), (ii)&nbsp;is developed by Dr.&nbsp;Larry
DeLucas in his capacity as a UAB faculty member or by UAB personnel under the scientific direction
and scientific supervision of Dr.&nbsp;Larry DeLucas, and (iii)&nbsp;is necessary or useful for Fluidigm to
research, develop, make, use, sell or seek regulatory approval to market a composition, or to
practice any method or process, at any time (a)&nbsp;comprising the Oculus Agreement Technology or (b)
claimed or covered by in any issued patent or pending patent application within the Licensed Patent
Rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.6 &#147;<U>Licensed Patent Rights</U>&#148; shall mean (a)&nbsp;those certain patent applications and
patents listed on <U>Exhibit&nbsp;B</U> hereto; (b)&nbsp;all patent applications heretofore or hereafter
filed or having legal force in any country which claim any Oculus Agreement Technology; (c)&nbsp;all
patents that have issued or in the future issue from the patent applications described in clauses
(a)&nbsp;and (b)&nbsp;of this Section&nbsp;1.6, including utility, model and design patents and certificates of
invention; and (d)&nbsp;all divisionals, continuations, continuations-in-part, reissues, renewals,
extensions or additions to any such patent applications and patents.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.7 &#147;<U>Master Closing Agreement</U>&#148; shall mean a Master Closing Agreement between
Fluidigm, UABRF and Oculus of even date hereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.8 &#147;<U>NanoScreen Patent Rights</U>&#148; shall mean (a)&nbsp;those certain patent applications and
patents listed on <U>Exhibit&nbsp;B</U> hereto; (b)&nbsp;all patents that have issued or in the future issue
from any such patent applications, including utility, model and design patents and certificates of
invention; and (c)&nbsp;all divisionals, continuations, continuations-in-part, reissues, renewals,
extensions or additions to any such patent applications and patents.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --> - 2 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.9 &#147;<U>Oculus Agreement Technology</U>&#148; shall mean collectively, the technology, processes,
inventions, trade secrets, know-how and other proprietary property described in <U>Exhibit&nbsp;C</U>
hereto.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.10 &#147;<U>Person</U>&#148; shall mean an individual, corporation, partnership, limited liability
company, trust, business trust, association, joint stock company, joint venture, pool, syndicate,
sole proprietorship, unincorporated organization, governmental authority or any other form of
entity not specifically listed herein.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.11 <U>&#147;Third Party</U>&#148; shall mean any Person other than UABRF, Fluidigm and their
respective Affiliates.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.12 &#147;<U>UAB</U>&#148; shall mean the University of Alabama at Birmingham.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.13 &#147;<U>UABRF/DSI
License Agreements</U>&#148; shall mean, collectively,
&#091;***&#093;.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.14 &#147;<U>UAB Related Entities</U>&#148; shall mean and include UAB, UABRF, University Hospital,
The University of Alabama Health Services Foundation (&#147;UAHSF&#148;), Southern Research Institute and all
other entities within the UAB Medical Center, which are under the control of the Board of Trustees
of The University of Alabama or are associated with said Board of Trustees through an affiliation
agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;REPRESENTATIONS AND WARRANTIES
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 <U>Mutual Representations and Warranties</U> Each party hereby represents and warrants to
the other party as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1.1 <U>Corporate Existence</U>. Such party is a corporation duly organized, validly
existing and in good standing under the laws of the state in which it is incorporated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1.2 <U>Authorization and Enforcement of Obligations</U>. Such party (a)&nbsp;has the corporate
power and authority and the legal right to enter into this Agreement and to perform its obligations
hereunder, and (b)&nbsp;has taken all necessary corporate action on its part to authorize the execution
and delivery of this Agreement and the performance of its obligations hereunder. This Agreement has
been duly executed and delivered on behalf of such party, and constitutes a legal, valid, binding
obligation, enforceable against such party in accordance with its terms.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1.3 <U>No Consents</U>. All necessary consents, approvals and authorizations of all
governmental authorities and other Persons required to be obtained by such party in connection with
this Agreement have been obtained.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1.4 <U>No Conflict</U>. The execution and delivery of this Agreement and the performance of
such party&#146;s obligations hereunder (a)&nbsp;do not conflict with or violate any
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --> - 3 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">requirement of applicable laws or regulations, and (b)&nbsp;do not conflict with, or constitute a
default under, any contractual obligation of it.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 <U>UABRF Representations and Warranties</U>. UABRF represents and warrants to
Fluidigm as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2.1
<U>Ownership</U>. UABRF is the sole owner of the Licensed IP Rights (other than those
listed under Item&nbsp;No.&nbsp;3 of <U>Exhibit&nbsp;B</U>), and as of the Effective Date has no knowledge of any
Third Party having any license or other interest in such Licensed IP Rights. UABRF shall use its
commercially reasonable efforts to provide Fluidigm with (a)&nbsp;evidence of UABRF&#146;s sole ownership of
those Licensed IP Rights listed under Item&nbsp;No.&nbsp;3 of <U>Exhibit&nbsp;B</U>, and (b)&nbsp;a letter from DSI to
Fluidigm stating that DSI has no license or other interest in NanoScreen Patent Rights except to
the extent necessary for DSI to perform its research obligations pursuant to the SBIR Grants (as
defined below).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2.2 <U>No Injunction</U>. No action, suit or proceeding before any court or government body
is instituted (or is pending) by any government authority or any other Person to restrain or
prohibit this Agreement or the consummation of the transactions contemplated hereby. No preliminary
or permanent injunction or other order issued by any federal or state court of competent
jurisdiction preventing this Agreement or the consummation of the transactions contemplated hereby
is in effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2.3 <U>No Infringement</U>. As of the Effective Date, UABRF and Dr.&nbsp;Larry DeLucas (a)&nbsp;are
not aware of any Third Party patent, patent application or other intellectual property rights that
would be infringed by practicing any process or method or by making, using or selling any
composition which is claimed or disclosed in the Licensed Patent Rights or which constitutes
Licensed Know-How Rights; (b)&nbsp;are not aware of any infringement or misappropriation by a Third
Party of the Licensed IP Rights; and (c)&nbsp;are not aware of any license or other right granted to DSI
or any other Third Party under the NanoScreen Patent Rights. Provided however, UABRF has disclosed
to Fluidigm the potential infringement by DSI of the Licensed IP Rights to the extent necessary for
DSI to perform its research obligations pursuant to one or more grants (the &#147;SBIR Grants&#148;),
existing as of December&nbsp;19, 2002, between UAB and DSI under the Defense Small Business Innovation
Research (SBIR)&nbsp;Program, with the understanding that neither DSI nor any other third party would
have the right to commercialize any results of such SBIR grants that would infringe the Licensed IP
Rights without first obtaining a license from Fluidigm under the Licensed IP Rights. Not later than
ten (10)&nbsp;days following the Effective Date, UABRF shall provide Fluidigm with copies of all
documents and instruments relating to such SBIR Grants.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;LICENSE GRANT
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 <U>Licensed IP Rights</U>. UABRF hereby grants to Fluidigm an exclusive, perpetual,
irrevocable, royalty-free, worldwide license (including the right to grant sublicenses) under the
Licensed IP Rights. The license grant under the Licensed IP Rights (other than the NanoScreen
Patent Rights) is subject to the licenses previously and expressly granted by UABRF to DSI pursuant
to the UABRF/DSI License Agreements regarding the UABRF/DSI Technology only to the extent necessary
for DSI to exercise its license rights under the
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --> - 4 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">UABRF/DSI Technology granted thereunder. The license grant under the NanoScreen Patent Rights is
not subject to any previously granted licenses other than those certain rights which may have been
granted to DSI to the extent necessary for DSI to perform its research obligations pursuant to the
SBIR Grants. To the extent any of the rights, title and interest in and to the Licensed IP Rights
can be neither assigned nor licensed by UABRF to Fluidigm without (a)&nbsp;the consent of, or (b)
breach by UABRF of any agreement with, any Third Party, UABRF hereby irrevocably waives and agrees
never to assert such non-assignable and non-licensable rights, title and interest against Fluidigm
or any of Fluidigm&#146;s successors in interest to such non-assignable and non-licensable rights
during the term of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 <U>Sublicenses</U>. Fluidigm shall not sublicense the Licensed IP Rights prior to the
first (1st) anniversary of the Effective Date except in connection with settlement of any action or
claim relating to the technology that is the subject of the Licensed IP Rights. Fluidigm shall give
UABRF prompt written notice of each sublicense under this Agreement. Each sublicense shall be
subject to the terms and conditions of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3 <U>Availability of the Licensed IP Rights</U>. UABRF shall provide Fluidigm with all
information available to UABRF regarding the Licensed IP Rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4 <U>Reservation of Rights</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4.1 <U>Research Use</U>. UABRF hereby retains the right to, and this Agreement shall not
limit UABRF&#146;s ability to, utilize the Licensed IP Rights for internal research, academic and
educational purposes at UAB, UAB Related Entities and academic institution collaborators of UAB,
for patient care at UAB and UAB Related Entities, and/or for the performance of services for
for-profit or not-for-profit institutions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4.2 <U>Obligations to U.S. Government</U>. UABRF agrees that during the term of this
Agreement UABRF shall not use the Licensed IP Rights in any manner except for internal research,
academic and educational purposes at UAB, UAB Related Entities and academic institution
collaborators of UAB, for patient care at UAB and UAB Related Entities, and/or for the performance
of services for for-profit or not-for-profit institutions as provided in Section&nbsp;3.4.1 above and as
may be necessary or appropriate to fulfill the obligations of UABRF or UAB under the National
Institutes of Health (&#147;NIH&#148;) grant used to fund the research resulting in the development of
certain portion of the Licensed IP Rights. In determining the actions required under such grant,
UABRF shall consult with Fluidigm and keep Fluidigm informed, but UABRF shall have the ultimate
right to determine the necessary and appropriate actions relative thereto. UABRF&#146;s rights to the
Licensed IP Rights for use in fulfilling UAB&#146;s obligations under
the NIH grant shall only relate to
those portions of the Licensed IP Rights funded by such NIH grant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.5 <U>Non-Assertion Covenant</U>. To the extent the research activities of DSI
conducted in accordance with the SBIR Grants infringe the rights granted to Fluidigm under this
Section&nbsp;3, Fluidigm agrees not to assert such rights against DSI. Fluidigm agrees not to assert
against DSI such rights only to the extent expressly stated herein. No license or other right by
Fluidigm in favor of DSI shall be created hereunder by implication, estoppel or otherwise.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --> - 5 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;LICENSE ISSUE FEE
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Within thirty (30)&nbsp;days after the Effective Date Fluidigm shall (a)&nbsp;pay UABRF the sum in cash
of [***] and (b)&nbsp;issue to UABRF such number of Fluidigm Series&nbsp;C
Preferred Stock as provided in Section&nbsp;2.3 of the Master Closing Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;RESEARCH AND DEVELOPMENT OBLIGATIONS
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 <U>Research and Development Efforts</U>. Fluidigm shall use commercially reasonable
efforts to research, develop and commercialize the Licensed IP Rights as Fluidigm determines
commercially feasible. Appendix&nbsp;1 of the Sponsored Research Agreement sets forth the components of
Fluidigm&#146;s Topaz System which Fluidigm plans to release commercially.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2 <U>Records</U>. Fluidigm shall maintain records, in sufficient detail and in good
scientific manner, which shall reflect all work done and results achieved in the performance of its
research and development regarding the Licensed IP Rights (including all data in the form required
under all applicable laws and regulations).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3 <U>Reports</U>. Within ninety (90)&nbsp;days following the end of each calendar year during
the term of this Agreement, Fluidigm shall prepare and deliver to UABRF a written summary report
which shall describe the research and development of the Licensed IP Rights during such year.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;CONFIDENTIALITY
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1 <U>Confidential Information</U>. During the term of this Agreement, and for a period of
five (5)&nbsp;years following the expiration or earlier termination hereof, each party shall maintain in
confidence all Confidential Information disclosed by the other party, and shall not use, disclose
or grant the use of the Confidential Information except on a need-to-know basis to those directors,
officers, employees, consultants, clinical investigators, contractors, (sub)licensees, distributors
or permitted assignees, to the extent such disclosure is reasonably necessary in connection with
such party&#146;s activities as expressly authorized by this Agreement. To the extent that disclosure is
authorized by this Agreement, prior to disclosure, each party hereto shall obtain agreement of any
such person or entity to hold in confidence and not make use of the Confidential Information for
any purpose other than those permitted by this Agreement. Each party shall notify the other
promptly upon discovery of any unauthorized use or disclosure of the other party&#146;s Confidential
Information.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2 <U>Terms of this Agreement</U>. Except as otherwise provided in Section&nbsp;6.1 or 6.3,
neither party shall disclose any terms or conditions of this Agreement to any third party without
the prior consent of the other party. Notwithstanding the foregoing, prior to execution of this
Agreement, the parties have agreed upon the substance of information that can be used to describe
the terms of this transaction, and each party may disclose such information, as modified by mutual
agreement from time to time, without the other party&#146;s consent.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3 <U>Permitted Disclosures</U>. The confidentiality obligations contained in this Section&nbsp;6
shall not apply to the extent that the receiving party (the &#147;Recipient&#148;) is required (a)&nbsp;to
disclose information by law, order or regulation of a governmental agency or a court of
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio --> - 6 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">competent jurisdiction, or (b)&nbsp;to disclose information to any governmental agency for purposes of
obtaining approval to test or market a product, provided in either case that the Recipient shall
provide written notice thereof to the other party and sufficient opportunity to object to any such
disclosure or to request confidential treatment thereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;PATENTS
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1 <U>Prosecution and Maintenance</U>. Fluidigm shall be responsible for and shall
control, at its sole cost, the preparation, filing, prosecution, defense (including without
limitation prosecution, defense and settlement of any interference or opposition) and maintenance
of the Licensed Patent Rights. Fluidigm shall give UABRF an opportunity to review and comment on
the text of each patent application within the Licensed Patent Rights before filing, and shall
provide UABRF with a copy of such patent application as filed, together with notice of its filing
date and serial number. UABRF shall cooperate with Fluidigm, execute all lawful papers and
instruments and make all rightful oaths and declarations as may be necessary in the preparation,
prosecution and maintenance of the Licensed Patent Rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Enforcement</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2.1 Each party shall notify the other party of any infringement known to such party of any
Licensed Patent Rights and shall provide the other party with the available evidence, if any, of
such infringement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2.2 Fluidigm, at its sole expense, shall have the right to determine the appropriate course
of action to enforce the Licensed Patent Rights or otherwise abate the infringement thereof, to
take (or refrain from taking) appropriate action to enforce the Licensed Patent Rights, to control
any litigation or other enforcement action and to enter into, or permit, the settlement of any such
litigation or other enforcement action with respect to the Licensed Patent Rights, and shall
consider, in good faith, the interests of UABRF in so doing. UABRF shall cooperate with Fluidigm in
the execution of any action to enforce the Licensed Patent Rights. Fluidigm shall retain all monies
recovered upon the final judgment or settlement of any such suit to enforce the Licensed Patent
Rights.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;TERMINATION
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.1 <U>Expiration</U>. Subject to the provisions of Section&nbsp;8.2 below, this Agreement
shall expire on the expiration of the last to expire of the Licensed Patent Rights. Upon
expiration of this Agreement under this Section&nbsp;8.1, Fluidigm shall have a paid-up,
exclusive, worldwide license under the Licensed Know-How Rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.2 <U>Termination by Fluidigm</U>. Fluidigm may terminate this Agreement, in its sole
discretion, upon thirty (30)&nbsp;days prior written notice to UABRF. Upon termination of this Agreement
by Fluidigm under this Section&nbsp;8.2, Fluidigm shall have a paid-up, non-exclusive, worldwide license
under the Licensed Know-How Rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Effect of Expiration or Termination</U>. Expiration or termination of this Agreement
shall not relieve the parties of any obligation accruing prior to such expiration or termination,
and the provisions of Sections&nbsp;6, 7 and 9 shall survive the expiration or termination
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --> - 7 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of this Agreement. Except as the parties otherwise agree in writing, termination of this
Agreement shall not affect the Master Closing Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;INDEMNIFICATION
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.1 <U>Indemnification</U>. Fluidigm shall defend, indemnify and hold the UABRF harmless from
all losses, liabilities, damages and expenses (including reasonable attorneys&#146; fees and costs)
resulting from any claims, demands, actions and other proceedings by any Third Party to the extent
resulting from Fluidigm&#146;s use of the Licensed IP Rights under this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.2 <U>Procedure</U>. UABRF promptly shall notify Fluidigm of any claim, demand, action or
other proceeding for which UABRF intends to claim indemnification. Fluidigm shall have the right to
participate in, and to the extent Fluidigm so desires jointly with any other indemnitor similarly
noticed, to assume the defense thereof with counsel selected by Fluidigm; provided, however, that
UABRF shall have the right to retain its own counsel, with the fees and expenses to be paid by
UABRF, if representation of UABRF by the counsel retained by Fluidigm would be inappropriate due to
actual or potential differing interests between UABRF and any other party represented by such
counsel in such proceedings. The indemnity obligations under this Section&nbsp;9 shall not apply to
amounts paid in settlement of any claim, demand, action or other proceeding if such settlement is
effected without the prior express written consent of Fluidigm, which consent shall not be
unreasonably withheld or delayed. The failure to deliver notice to Fluidigm within a reasonable
time after notice of any such claim or demand, or the commencement of any such action or other
proceeding, if prejudicial to its ability to defend such claim, demand, action or other proceeding,
shall relieve such Indemnitor of any liability to UABRF under this Section&nbsp;9 with respect thereto,
but the omission so to deliver notice to Fluidigm shall not relieve it of any liability that it may
have to UABRF other than under this Section&nbsp;9. Fluidigm may not settle or otherwise consent to an
adverse judgment in any such claim, demand, action or other proceeding, that diminishes the rights
or interests of UABRF without the prior express written consent of UABRF, which consent shall not
be unreasonably withheld or delayed. UABRF, its employees and agents, shall reasonably cooperate
with Fluidigm and its legal representatives in the investigation of any claim, demand, action or
other proceeding covered by this Section&nbsp;9.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.3 <U>Insurance</U>. Fluidigm shall maintain insurance with respect to the research,
development and commercialization of products by Fluidigm pursuant to this Agreement in such
amount as Fluidigm customarily maintains with respect to the research, development and
commercialization of its similar products. Fluidigm shall maintain such insurance for so long as
it continues to research, develop or commercialize any products pursuant to this Agreement, and
thereafter for so long as Fluidigm customarily maintains insurance covering the research,
development or commercialization of its similar products.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;MISCELLANEOUS
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.1 <U>Notices</U>. Any consent, notice or report required or permitted to be given or
made under this Agreement by one of the parties to the other shall be in writing and addressed to
such other party at its address indicated below, or to such other address as the addressee shall
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --> - 8 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">have last furnished in writing to the addressor, and shall be effective upon receipt by the
addressee.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="80%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">If to UABRF:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">UAB Research Foundation</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1120G Administration Building</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">704 20th Street</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Birmingham, Alabama 35294</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention: Director</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">If to Fluidigm:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fluidigm Corporation</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7100 Shoreline Court</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">South San Francisco, California 94080</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention: President</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">with a copy to:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fluidigm Corporation</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7100 Shoreline Court</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">South San Francisco, California 94080</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention: General Counsel</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.2 <U>Assignment</U>. Except as otherwise expressly provided under this Agreement neither
this Agreement nor any right or obligation hereunder may be assigned or otherwise transferred
(whether voluntarily, by operation of law or otherwise), without the prior express written consent
of the other party; provided, however, that either party may, without such consent, assign this
Agreement and its rights and obligations hereunder in connection with the transfer or sale of all
or substantially all of its business, or in the event of its merger, consolidation, change in
control or similar transaction. Any permitted assignee shall assume all obligations of its assignor
under this Agreement. Any purported assignment or transfer in violation of this Section&nbsp;10.2 shall
be void.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.3 <U>Applicable Law</U>. This Agreement shall be governed by and construed in accordance
with the laws of the State of Alabama, without regard to the conflicts of law principles thereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.4 <U>Entire Agreement</U>. This Agreement and the Master Closing Agreement (together with
the Ancillary Agreements, as defined in the Master Closing Agreement) contain the entire
understanding of the parties with respect to the subject matter hereof. All express or implied
representations, agreements and understandings, either oral or written, heretofore made are
expressly superseded by this Agreement and the Master Closing Agreement. To the extent that any
provision of this Agreement conflicts with any provision of the Sponsored Research Agreement
between the parties of even date hereof (&#147;Sponsored Research Agreement&#148;), the applicable provision
of this Agreement shall control and supersede the applicable provision of the Sponsored Research
Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.5 <U>Independent Contractors</U>. Each party hereby acknowledges that the parties shall be
independent contractors and that the relationship between the parties shall not constitute a
partnership, joint venture or agency. Neither party shall have the authority to make any
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio --> - 9 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">statements, representations or commitments of any kind, or to take any action, which shall be
binding on the other party, without the prior consent of the other party to do so.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.6 <U>Waiver</U>. The waiver by a party of any right hereunder, or of any failure to
perform or breach by the other party hereunder, shall not be deemed a waiver of any other right
hereunder or of any other breach or failure by the other party hereunder whether of a similar
nature or otherwise.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.7 <U>Force Majeure</U>. Neither party shall be held liable or responsible to the other
party nor be deemed to have defaulted under or breached this Agreement for failure or delay in
fulfilling or performing any term of this Agreement to the extent, and for so long as, such failure
or delay is caused by or results from causes beyond the reasonable control of the affected party
including but not limited to fire, floods, embargoes, war, acts of war (whether war be declared or
not), insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, acts
of God or acts, omissions or delays in acting by any governmental authority or the other party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.8 <U>Counterparts</U>. This Agreement may be executed in two or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and the same
instrument.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="14%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">UAB RESEARCH FOUNDATION</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ (ILLEGIBLE)
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<tr>
    <TD>&nbsp;</TD>
</tr>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">FLUIDIGM CORPORATION</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gajus Worthington
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<tr>
    <TD>&nbsp;</TD>
</tr>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President &#38; CEO</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Acknowledged and agreed to</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">this March&nbsp;7, 2003.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<tr><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Dr.&nbsp;Larry DeLucas
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Dr.&nbsp;Larry DeLucas
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --> - 10 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">EXHIBIT A
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>UABRF/DSI TECHNOLOGY</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#091;***&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --> - 11 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">EXHIBIT B
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>PATENT RIGHTS</U>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#091;***&#093;</TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#091;***&#093;</TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#091;***&#093;</TD>
</TR>
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --> - 12 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" style="background: transparent">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#091;***&#093;</TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#091;***&#093;</TD>
</TR>
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --> - 13 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">EXHIBIT C
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>OCULUS AGREEMENT TECHNOLOGY</U>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#091;***&#093;</TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#091;***&#093;</TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Copies of all documentation describing the foregoing, in particular, drawings, operations
manuals.</TD>
</TR>
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --> - 14 - <!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>24
<FILENAME>f39432orexv10w10.htm
<DESCRIPTION>EXHIBIT 10.10
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w10</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#091;***&#093; Indicates
text has been omitted from this Exhibit pursuant to a confidential treatment
request and has been filed separately with the Securities and Exchange Commission.
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.10</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">COY-15-RISC/F269-1<BR>
S05/1-25730208
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">27 March&nbsp;2008

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Ms Grace Yow<BR>
General Manager<BR>
Fluidigm Singapore Pte Ltd<BR>
Block 1026, #07-3532<BR>
Tai Seng Avenue<BR>
Singapore 534413

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Dear Ms Grace Yow,

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>APPLICATION FOR INCENTIVES UNDER THE RESEARCH INCENTIVE SCHEME FOR COMPANIES (RISC)</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This is with reference to your application of 15 June&nbsp;2005 and subsequent revisions for
incentives under the Research Incentive Scheme for Companies. This letter amends, restates and
replaces our original letter agreement dated 7 October&nbsp;2005 (the &#147;Prior Letter&#148;), provided that the
Supplement to the Prior Letter dated 11 January&nbsp;2006 (the &#147;Supplement&#148;) shall remain in full force
and effect and all references in the Supplement to the Prior Letter or LOF shall be considered
references to this amended and restated letter.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">2 We are pleased to inform you that the Economic Development Board (hereinafter called &#147;EDB&#148;) has
agreed to provide a grant not exceeding S$9,926,000 in total to Fluidigm Singapore Pte Ltd
(hereinafter called &#147;the Company&#148;) under the RISC for your project on the development of the
Fluidigm R&#038;D centre (hereinafter called the &#147;Development Project&#148;), as described in your
application. This grant shall be subject to the following conditions:
</DIV>


<DIV style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&nbsp;</B></TD>
    <TD width="1%"><B>&nbsp;</B></TD>
    <TD><B>Project Implementation</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall implement the Development Project as indicated in the Company&#146;s
application dated 15 June&nbsp;2005 and subsequent revisions.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Development Project shall meet the project milestones, deliverables and headcount
commitment as shown in <U>Annex 1</U>.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall carry out the entire Development Project in Singapore unless
otherwise stated.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall employ at least &#091;***&#093; Research Scientists and Engineers in Singapore by 31
December&nbsp;2007.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall employ at least &#091;***&#093; Research Scientists and Engineers in Singapore by 31
December&nbsp;2009.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(f)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall incur annual R&#038;D spending of at least &#091;***&#093; by 31 December&nbsp;2008
and at least &#091;***&#093; by 31 December&nbsp;2010.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(g)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall be the legal and economic owner of all intellectual property (IP)&nbsp;arising
from this project.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(h)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall engage a Singapore-based IP or legal firm(s) to file, draft and manage
all patent applications arising from this project.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall manufacture all products developed from this RISC project in Singapore
for the lifetime of the products.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&nbsp;</B></TD>
    <TD width="1%"><B>&nbsp;</B></TD>
    <TD><B>Supported Period</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(j)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Only expenses incurred during the qualifying period, which shall be from 1 August&nbsp;2005 to
31 July&nbsp;2010, will be supported.</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&nbsp;</B></TD>
    <TD width="1%"><B>&nbsp;</B></TD>
    <TD><B>Grant Support</B></TD>
</TR>
<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(k)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All manpower, equipment, materials &#038; software, professional services and intellectual
property rights supported under this RISC grant shall be used exclusively for the Development
Project and shall follow the administrative guidelines laid out in Annex 2.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(l)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall not sell, lease, dispose or otherwise transfer the equipment &#038; software
supported under this RISC grant to another party during the execution of the Development
Project without first obtaining the written approval of EDB, which if so granted, shall be on
such terms as EDB deems fit. The Company shall at all times maintain proper records with
respect to the assets acquired through the grant.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(m)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall not seek or receive funds from any other incentives offered by other
agencies of the Government of Singapore for funding of this Development Project.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(n)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All grant monies received shall be used solely for the implementation of this Development
project.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&nbsp;</B></TD>
    <TD width="1%"><B>&nbsp;</B></TD>
    <TD><B>Project Management &#038; Co-ordination</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(o)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall appoint a person (hereinafter called the &#147;Principal Investigator&#148;) to
lead the Development Project. The Principal Investigator shall be responsible for the
proper management, co-ordination and progress of the Development Project, the management of
grants disbursed and all other matters pertaining to the Development Project, including the
preparation of claims, submission of audited statements and progress reports.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(p)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Principal Investigator shall be deemed as an agent of the Company throughout the
Development Project and EDB shall at all times have access to the Principal Investigator
with regards to all matters pertaining to the Development Project.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(q)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall inform EDB in writing of any change in the Principal Investigator.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&nbsp;</B></TD>
    <TD width="1%"><B>&nbsp;</B></TD>
    <TD><B>Other Conditions</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(r)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall permit EDB officers to inspect the premises where the development
work is carried out, the Company&#146;s accounts on the development expenditures and the records
on the progress of the Development Project.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(s)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall be required to provide, through responses to surveys or any other
such studies carried out by EDB, relevant information on the Development Project, as and
when requested by EDB.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(t)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If required by EDB, the Company shall submit a report comparing its projections in the
application form with the actual realised figures. The template for this report and the
timeline for submission will be provided by EDB.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">3 In the event the Project is aborted, the Company is to inform EDB in writing immediately.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">4 EDB reserves the right to recover from the Company the total amount of grant released to the
Company for any breach of condition under which the RISC grant was approved.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">5 The Company shall keep the terms and conditions of this RISC grant confidential.
Such information shall not be released to any external party, the public or the press unless prior
written consent from EDB is given.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">6 EDB reserves the right to change the terms and conditions of this offer from time to time as may
be specified and deemed necessary by EDB.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">7 If you are prepared to accept this amended and restated offer of a grant under the conditions
stipulated above, please sign below and return it to EDB within <U>1&nbsp;month</U> from the date of this
letter, <B>failing which this offer shall be deemed to have lapsed</B>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">8 If you have any queries, please contact Ih-Ming CHAN at 6395 7794. For queries on claims, please
call the EDAS hotline at 6832 6416. We wish you every success in this project.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Yours sincerely
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">DR BEH SWAN GIN<BR>
DIRECTOR<BR>
BIOMEDICAL SCIENCES CLUSTER

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Enclosures:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Annex 1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Project Milestones and Deliverables

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Annex 2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Administrative Guidelines

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Accepted and Agreed
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">FLUIDIGM CORPORATION

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><BR>
Name:<BR>
Title:

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Annex 1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PROJECT MILESTONES AND DELIVERABLES</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall employ at least &#091;***&#093; Research Scientists and Engineers in Singapore by 31
December&nbsp;2007.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall employ at least &#091;***&#093; Research Scientists and Engineers in Singapore by 31
December&nbsp;2009.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall incur annual R&#038;D spending of at least &#091;***&#093; by 31 December&nbsp;2008 and
at least &#091;***&#093; by 31 December&nbsp;2010.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall be the legal and economic owner of all intellectual property (IP)&nbsp;arising
from this project. The economic benefits resulting from the exploitation of the IP arising from
this project shall accrue to the Company.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall engage a Singapore-based IP or legal firm(s) to file, draft and manage all
patent applications arising from this project.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(f)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall manufacture all products developed from this RISC project in Singapore for
the lifetime of the products.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(g)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall fulfil the following project milestones as indicated below:</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="70%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="29%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Milestones</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Date of Completion</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>TOPAZ Screening Chip</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>


<TR valign="bottom">
    <TD align="left" colspan="1" valign="top">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" colspan="1" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" colspan="1" valign="top">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" colspan="1" valign="top">&#091;***&#093;</TD>
</TR>


<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>TOPAZ Next Generation Screening Chip</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD align="left" colspan="1" valign="top">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" colspan="1" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" colspan="1" valign="top">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" colspan="1" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" colspan="1" valign="top">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" colspan="1" valign="top">&#091;***&#093;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>TOPAZ Diffraction Chip</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" colspan="1" valign="top">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" colspan="1" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" colspan="1" valign="top">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" colspan="1" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" colspan="1" valign="top">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" colspan="1" valign="top">&#091;***&#093;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="70%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="29%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Milestones</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Date of Completion</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Dynamic Array IFCs</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:30px; text-indent:-15px"><B>&nbsp;</B>&#091;***&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:30px; text-indent:-15px"><B>&nbsp;</B>&#091;***&#093;</DIV></TD>


    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:30px; text-indent:-15px"><B>&nbsp;</B>&#091;***&#093;&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Next Generation IFCs (Immunoassays, PET Synthesis, DID, Pathogen Detection)</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:30px; text-indent:-15px">&#091;***&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Annex 2</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ADMINISTRATIVE GUIDELINES</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The grant shall cover &#091;***&#093; of the actual qualifying manpower costs and &#091;***&#093; of the actual
qualifying costs for equipment, materials &#038; software, professional services and intellectual
property rights incurred by the Company on the Development Project during the qualifying
period. In the event where qualifying cost items are not used exclusively for the Development
Project, the qualifying costs items shall be suitably pro-rated. The qualifying cost items are
listed below, but shall be subject to a total maximum grant of S$9,926,000. Virement from one
qualifying cost item to another will not be considered and the grant shall not cover GST
payments.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Category</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2" style="border-bottom: 1px solid #000000"><B>Approved Grant (S$)</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Manpower</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Equipment, Materials and Software</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Professional services</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="5" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="5" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:0px; text-indent:-0px">Total Approved Grant<BR>
(Rounded down to nearest thousand dollars)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">9,926,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="5" align="left" style="border-top: 3px double #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The qualifying cost for equipment (less its residual value, if any) is pro-rated based on the
number of months the equipment is used for the project (this refers to the date of delivery to
the end of qualifying period) over the approved useful life of equipment.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The qualifying cost of equipment is based on the actual expenses, residual value, number of
months that the equipment is used for the project and approved useful life of equipment.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The qualifying cost for intellectual property rights (IPR)&nbsp;is pro-rated based on the
project duration over the approved useful life of IPR.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The qualifying cost of IPR is based on the cost of acquiring IPR, project duration and the
approved useful life of IPR.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Disbursements shall be made on a reimbursement basis upon application by the Company at
quarterly intervals. Claims must be submitted using the prescribed forms and shall be
certified by the Company&#146;s Chief Financial Officer and the Principal Investigator. The amount
disbursed shall be based on the actual
qualifying cost item incurred by the Company on the Development Project during the
qualifying period.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The grant will be disbursed as follows:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Disbursements of up to a cumulative total &#091;***&#093; of the approved grant amount shall be
made upon application by the Company.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The remaining &#091;***&#093; of the grant may be released upon application by the Company on
completion of the Development Project.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>For all claims (except for the final claim), the first &#091;***&#093; of the amount claimed will be
disbursed to the Company upon receipt of claim and the remaining &#091;***&#093; will be disbursed upon
the completion of checks.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The final claim must be submitted within 6&nbsp;months with complete documentation from the end of
the qualifying period (31 July&nbsp;2010), failing which any claim will be disqualified.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">6.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>For total approved grant exceeding S$100,000, all claims must be externally audited. The
audited statement of accounts shall be submitted on an annual basis, as well as when the
Development Project is completed or terminated. The Company shall make available to its
auditor this Letter of Offer and its accompanying annexes. The Company shall ensure that the
external auditor forwards a copy of the audited accounts directly to EDB upon completion of
the audit. In the event that the external auditor cannot issue an unqualified report, EDB
shall have direct access to the external auditor to gather details with regard to the audit
findings.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall submit progress reports to EDB at half-yearly intervals. The disbursement
of any grant shall be subject to the Company achieving the project milestones as stated in the
Offer Letter. The final report is to be submitted upon completion of the project.</TD>
</TR>

</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10A
<SEQUENCE>25
<FILENAME>f39432orexv10w10a.htm
<DESCRIPTION>EXHIBIT 10.10A
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w10a</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#091;***&#093; Indicates
text has been omitted from this Exhibit pursuant to a confidential treatment
request and has been filed separately with the Securities and Exchange Commission.
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.10A</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="f39432ore3943217.gif" alt="(EDB SINGAPORE LOGO)">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">11 January&nbsp;2006

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Mr Gajus Worthington<BR>
CEO<BR>
Fluidigm Corporation<BR>
7100 Shoreline Court<BR>
South San Francisco, CA 94080

</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">Re:</TD>
    <TD>&nbsp;</TD>
    <TD>Supplement to Letter Dated 7 October&nbsp;2005 Relating to Application for Incentives under
the Research Incentive Scheme for Companies (RISC)</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Dear Gajus:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reference
is made to the Singapore Economic Development Board&#146;s
(&#147;<B><I>EDB</i></b>&#148;) Letter of Offer dated 07
October&nbsp;2005 (the &#147;<B><I>LOF</I></B>&#148;), executed by EDB and relating to the application by Fluidigm Singapore Pte
Ltd (&#147;<B><I>Fluidigm Singapore</I></B>&#148;) for incentives under the Research Incentive Scheme for Companies
(&#147;<B><I>RISC</I></B>&#148;). Fluidigm Singapore is a subsidiary of Fluidigm Corporation, a California corporation
(&#147;<B><I>Fluidigm Parent</I></B>&#148;). This letter agreement,
referred to as the &#147;<B><I>Supplemental Agreement,</I></B>&#148; is and
shall be construed as supplemental to the LOF and every
clause of the LOF shall continue in full force and effect and be binding on the parties thereto
save as expressly amended and supplemented by this Supplemental
Agreement. For the avoidance of
doubt, except as specifically set forth in this Supplemental Agreement, clause 4 of the LOF shall
apply to any breach of conditions under which the RISC grant was approved. For purposes of this
Supplemental Agreement, a &#147;<B><I>Business Day</I></B>&#148; shall refer to any day that is not a Saturday, Sunday, or
statutory holiday in Singapore. Consistent with the RISC grant, this Supplemental Agreement will be
deemed effective as of 1 August&nbsp;2005.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
EDB, Fluidigm Singapore, and Fluidigm Parent agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;In addition to and based on the milestones and deliverables identified in Paragraph&nbsp;2 and Annex
1 of the LOF, Fluidigm Singapore shall be required throughout the project development period,
commencing from 1 January&nbsp;2006, to furnish to EDB annually, quarterly milestones and deliverables
for the forthcoming year in accordance with the relevant milestones and deliverables identified in
Paragraph&nbsp;2 and Annex 1 of the LOF (the &#147;<B><I>New Milestone List</I></B>&#148;). EDB shall be entitled to accept or
reject such milestones and deliverables in accordance with paragraph 5 below. Fluidigm Singapore
shall deliver the New Milestone List on or before January&nbsp;31 of
each year.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;Fluidigm Singapore shall deliver to EDB on a quarterly basis evidence of the satisfaction of
previously identified objective milestones and deliverables (as set forth in a New Milestone List)
for the entire prior fiscal period of Fluidigm Parent (the &#147;<B><I>Quarterly Update Reports</I></B>&#148;). Quarterly
Update Report submission shall take place no later than the fifth
(5<sup>th</sup>) Business Day after the end
of each fiscal quarter and shall include Fluidigm Singapore&#146;s claims
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="79%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Economic Development Board<br>
250 North Bridge Road, #28-00 Raffles City Tower, Singapore 179101. Tel: 65 6832 6832 Fax: 65 6832 6565
<br>www.sedb.com
</DIV></TD>
    <TD>&nbsp;</TD>

<TD align="center" valign="top"><IMG src="f39432ore3943218.gif" alt="(LOGOS)"></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="f39432ore3943217.gif" alt="(EDB SINGAPORE LOGO)">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Page 2

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">for the entire prior fiscal quarter. The Quarterly Update Reports must be in sufficient detail to
satisfy EDB that the milestones and deliverables identified in the applicable New Milestone List
have been met. Scheduled quarterly update meetings or teleconference calls arranged between Fluidigm
Singapore and EDB to review the progress of the development project will be held in advance of
Quarterly Update Report submission.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;If EDB objects to or otherwise disagrees with the conclusion of Fluidigm Singapore and Fluidigm
Parent that the Quarterly Update Report evidences satisfaction in full of the milestones and
deliverables previously identified in the New Milestone List for the period covered by such
Quarterly Update Report, then EDB shall deliver a written notice to Fluidigm Singapore and Fluidigm
Parent stating its objections or disagreement (&#147;<B><I>Notice of
Objection</I></b>&#148;). In the event that EDB
delivers a Notice of Objection, EDB, Fluidigm Singapore, and Fluidigm Parent will act in good faith
to promptly resolve any such objection or disagreement. Fluidigm Singapore and Fluidigm Parent
shall deliver to EDB a revised Quarterly Update Report which is satisfactory to EDB on or before
the fifteenth (15<sup>th</sup>) calendar day after the end of the fiscal quarter. If EDB is satisfied with the
progress of the milestone completion and project achievements as set out in the Quarterly Update
Reports, EDB will qualify in writing the company&#146;s quarterly claims for that quarter and limit its
right of recovery set forth in paragraph 4 of the LOF to &#091;***&#093; of the qualified claim amount for
that quarterly fiscal period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;EDB, Fluidigm Parent, and Fluidigm Singapore agree that Fluidigm may elect to conduct the audits
contemplated pursuant to paragraph 2, subsection (t)&nbsp;of the LOF on a half-yearly (i.e., every six
months) rather than on an annual basis. In the event that any such audit reveals inaccuracies or
errors that would have resulted in a recovery pursuant to paragraph 4 of the LOF, EDB may effect
such recovery, in all events subject to the &#091;***&#093; limitation set forth in
paragraph 3 above, directly from Fluidigm Singapore or, at EDB&#146;s election, as an off-set against
future reimbursements. EDB will fully qualify in writing the company&#146;s quarterly claim only upon
the company&#146;s subsequent half-yearly submission of externally audited claims for the quarterly
period(s) concerned and satisfactory verification by EDB.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;On
or before the tenth (10<sup>th</sup>) Business Day following delivery of the New Milestone List, EDB
shall deliver written notice (<B><I>&#147;Notice of Objection on
Milestone List</i></b>&#148;) to Fluidigm Singapore and
Fluidigm Parent if EDB objects to or otherwise disagrees with the objective milestones and
deliverables identified in any New Milestone List. In the event that EDB delivers a Notice of
Objection on Milestone List within the prescribed period, EDB, Fluidigm Singapore, and Fluidigm
Parent will act in good faith to promptly resolve any such objection
or disagreement. Fluidigm
Singapore and Fluidigm Parent shall, within ten (10)&nbsp;Business Days of the date of the Notice of
Objection on Milestone List, deliver to EDB a New Milestone List which is satisfactory to EDB.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;in the event of (i)&nbsp;fraud by Fluidigm Singapore or Fluidigm Parent or (ii)&nbsp;any intentional
misrepresentation of a material fact by Fluidigm Singapore or Fluidigm Parent, in either case
relating to Fluidigm Singapore&#146;s performance of the activities contemplated by the development
project, then the limitations set forth in this Supplemental Agreement (including,
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="79%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Economic Development Board<br>
250 North Bridge Road, #28-00 Raffles City Tower, Singapore 179101. Tel: 65 6832 6832 Fax: 65 6832 6565
<br>www.sedb.com
</DIV></TD>
    <TD>&nbsp;</TD>

<TD align="center" valign="top"><IMG src="f39432ore3943218.gif" alt="(LOGOS)"></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="f39432ore3943217.gif" alt="(EDB SINGAPORE LOGO)">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Page 3

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">without limitation, paragraph 3 of this Supplemental Agreement) on EDB&#146;s right of recovery under
paragraph 4 of the LOF shall not apply and EDB reserves the right to full recovery of any disbursed
grant monies.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;Neither the LOF nor this Supplemental Agreement may be amended or modified, nor may any
provision of the LOF or this Supplemental Agreement be waived, except with the written consent of
EDB, Fluidigm Singapore, and Fluidigm Parent or in the case of a waiver, the written consent of the
party giving such waiver. Except to the extent the LOF is supplemented, amended, or superseded
pursuant to this Supplemental Agreement, the LOF shall remain in full force and effect in
accordance with its terms.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Yours Sincerely,
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="37%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Dr Beh Swan Gin<BR>
<DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
Dr Beh Swan Gin <BR>Director
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Biomedical Sciences</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">EDB</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="79%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Economic Development Board<br>
250 North Bridge Road, #28-00 Raffles City Tower, Singapore 179101. Tel: 65 6832 6832 Fax: 65 6832 6565
<br>www.sedb.com
</DIV></TD>
    <TD>&nbsp;</TD>

<TD align="center" valign="top"><IMG src="f39432ore3943218.gif" alt="(LOGOS)"></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="f39432ore3943217.gif" alt="(EDB SINGAPORE LOGO)">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">COY-15-RISC/F269-1<BR>
S05/1-25730208

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Chairman<BR>
Economic Development Board<BR>
250 North Bridge Road<BR>
#28-00 Raffles City Tower<BR>
Singapore 179101

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Attention: DR BEH SWAN GIN

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>ACCEPTANCE OF SUPPLEMENTAL AGREEMENT TO THE LOF DATED 7 OCT 2005 PERTAINING TO RESEARCH INCENTIVE
SCHEME FOR COMPANIES</b>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>I refer to your LOF dated 7 October&nbsp;2005 and the Supplemental Agreement to the LOF
dated 11 January&nbsp;2006.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>I confirm that my company will be undertaking the development project as submitted to
the Board dated 15 June&nbsp;2005 and subsequent revisions and that we accept the award of your grant
not exceeding S$9,926,000 in aggregate, subject to the terms and conditions set out in the LOF
dated 7 October&nbsp;2005 and the above mentioned Supplemental Agreement to the LOF.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>We understand the need for EDB to ensure good governance of public fund and hence
will ensure that all claims for reimbursement of project expenditure are true and correct and all
terms and conditions as set out in the LOF dated 7 October&nbsp;2005 and the above mentioned
Supplemental Agreement are complied with.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="12%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="37%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="44%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gajus Worthington</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mr Gajus Worthington/ CEO Fluidigm Corporation</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Grace Yow</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Ms Grace Yow / General Manager</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Company Stamp
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fluidigm Singapore Pte Ltd</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="79%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Economic Development Board<br>
250 North Bridge Road, #28-00 Raffles City Tower, Singapore 179101. Tel: 65 6832 6832 Fax: 65 6832 6565
<br>www.sedb.com
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><IMG src="f39432ore3943218.gif" alt="(LOGOS)"></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>26
<FILENAME>f39432orexv10w11.htm
<DESCRIPTION>EXHIBIT 10.11
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w11</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#091;***&#093; Indicates
text has been omitted from this Exhibit pursuant to a confidential treatment
request and has been filed separately with the Securities and Exchange Commission.
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.11</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">COY-15-RISC/F269-2<BR>
S06/1-39831633

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">27 March&nbsp;2008

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Ms Grace Yow<BR>
General Manager<BR>
Fluidigm Singapore Pte Ltd<BR>
Block 1026, #07-3532<BR>
Tai Seng Avenue<BR>
Singapore 534413

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Dear Ms Grace Yow,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>APPLICATION FOR INCENTIVES UNDER THE RESEARCH INCENTIVE SCHEME FOR COMPANIES (RISC)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This is with reference to your application of 26 March&nbsp;2006 and subsequent revisions for
incentives under the Research Incentive Scheme for Companies. This letter amends, restates and
replaces our original letter agreement dated 12 February&nbsp;2007 (the &#147;Prior Letter&#148;) and all
references in the Prior Letter shall be considered references to this amended and restated letter.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">2 We are pleased to inform you that the Economic Development Board (hereinafter called &#147;EDB&#148;) has
agreed to provide a grant not exceeding S$3,715,000 in total to Fluidigm Singapore Pte Ltd
(hereinafter called &#147;the Company&#148;) under the RISC for your project on the development of the
Fluidigm Instrumentation R&#038;D Project (hereinafter called the &#147;Development Project&#148;), as described
in your application. This grant shall be subject to the following conditions:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Project Implementation</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall implement the Development Project as follows:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall implement the Development Project as indicated in the Company&#146;s
application dated 26 March&nbsp;2006 and subsequent revisions.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall manufacture all products developed from the Development
Project in Singapore for the lifetime of the products.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall be the legal and economic owner of all intellectual property
(IP)&nbsp;arising from the Development Project.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iv)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall engage a Singapore-based IP or legal firm(s) to file, draft
and manage all patent applications arising from the Development Project.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(v)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall employ at least &#091;***&#093; new Research Scientists and Engineers (RSEs)
in Singapore by 31 May&nbsp;2009 for the Development Project.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(vi)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall employ at least &#091;***&#093; new RSEs in Singapore by 31 May&nbsp;2011 for
the Development Project.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(vii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall incur total annual R&#038;D spending of at least &#091;***&#093; by
31 May&nbsp;2009 for the Development Project.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(viii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall incur total annual R&#038;D spending of at least &#091;***&#093; by
31 May&nbsp;2011 for the Development Project.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ix)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall maintain at least &#091;***&#093; RSEs in total at its R&#038;D Centre in
Singapore until 31 May&nbsp;2013.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(x)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Fluidigm Corporation shall raise a minimum of &#091;***&#093; in new funding
between 1 Jan 2006 and 31 Dec 2008.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(xi)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Development Project shall meet the project milestones and deliverables as
shown in <U>Annex 1</U>.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall carry out the entire Development Project in Singapore unless otherwise
stated.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&nbsp;</B></TD>
    <TD width="1%"><B>&nbsp;</B></TD>
    <TD><B>Supported Period</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>c)</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Only expenses incurred during the qualifying period, which shall be from 1 June&nbsp;2006 to 31
May&nbsp;2011, will be supported.</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&nbsp;</B></TD>
    <TD width="1%"><B>&nbsp;</B></TD>
    <TD><B>Grant Support</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All manpower, equipment, materials &#038; software, professional services and intellectual
property rights supported under this RISC grant shall be used
exclusively for the Development Project and shall follow the administrative guidelines laid
out in Annex 2.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall not sell, lease, dispose or otherwise transfer the equipment &#038; software
supported under this RISC grant to another party during the execution of the Development
Project without first obtaining the written approval of EDB, which if so granted, shall be on
such terms as EDB deems fit. The Company shall at all times maintain proper records with
respect to the assets acquired through the grant.</TD>
</TR>


</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">f)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall not seek or receive funds from any other incentives offered by other
agencies of the Government of Singapore for funding of this Development Project.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">g)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All grant monies received shall be used solely for the implementation of this Development
project.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&nbsp;</B></TD>
    <TD width="1%"><B>&nbsp;</B></TD>
    <TD><B>Project Management &#038; Co-ordination</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">h)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall appoint a person (hereinafter called the &#147;Principal Investigator&#148;) to
lead the Development Project. The Principal Investigator shall be responsible for the proper
management, co-ordination and progress of the Development Project, the management of grants
disbursed and all other matters pertaining to the Development Project, including the
preparation of claims, submission of audited statements and progress reports.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Principal Investigator shall be deemed as an agent of the Company throughout the
Development Project and EDB shall at all times have access to the Principal Investigator with
regards to all matters pertaining to the Development Project.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">j)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall inform EDB in writing of any change in the Principal Investigator.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&nbsp;</B></TD>
    <TD width="1%"><B>&nbsp;</B></TD>
    <TD><B>Other Conditions</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">k)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall permit EDB officers to inspect the premises where the development work
is carried out, the Company&#146;s accounts on the development expenditures and the records on the
progress of the Development Project.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">l)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall be required to provide, through responses to surveys or any other such
studies carried out by EDB, relevant information on the Development Project, as and when
requested by EDB.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">m)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If required by EDB, the Company shall submit a report comparing its projections in the
application form with the actual realised figures. The template for this report and the
timeline for submission will be provided by EDB.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">3 In the event the Project is aborted, the Company is to inform EDB in writing immediately.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">4 EDB reserves the right to recover from the Company the total amount of grant released to the
Company for any breach of condition under which the RISC grant was approved.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">5 The Company shall keep the terms and conditions of this RISC grant confidential.
Such information shall not be released to any external party, the public or the press unless prior
written consent from EDB is given.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">6 EDB reserves the right to change the terms and conditions of this offer from time to time as may
be specified and deemed necessary by EDB.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">7 If you are prepared to accept this amended and restated offer of a grant under the conditions
stipulated above, please sign below and return it to EDB within
<U>1&nbsp;month</U> from the date of this
letter, <B>failing which this offer shall be deemed to have lapsed</B>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">8 If you have any queries, please contact Ih-Ming CHAN at 6395 7794. For queries on claims, please
call the EDAS hotline at 6832 6416. We wish you every success in this project.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Yours sincerely

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">YEOH KEAT CHUAN<BR>
EXECUTIVE DIRECTOR<BR>
BIOMEDICAL SCIENCES CLUSTER

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Enclosures:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Annex 1 Project Milestones and Deliverables

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Annex 2 Administrative Guidelines

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Accepted and Agreed

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">FLUIDIGM CORPORATION

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><u>/s/ Gajus
Worthington&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>
</div>

<DIV align="left" style="font-size: 10pt; margin-top: 1pt">Name:&nbsp;&nbsp;Gajus Worthington<BR>
Title:&nbsp;&nbsp;President &#038; CEO
</div>
<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Annex 1</B>
</DIV>


<DIV align="CENTER" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>PROJECT MILESTONES AND DELIVERABLES</B>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company shall meet the following R&#038;D milestones:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="80%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Milestones</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Completion Date</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>AIX Gen II development</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:30px; text-indent:-15px"><b></b>&#091;***&#093;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="CENTER" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:30px; text-indent:-15px"><b></b>&#091;***&#093;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="CENTER" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>BioMark II Chip Loader development</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:30px; text-indent:-15px"><b></b>&#091;***&#093;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="CENTER" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:30px; text-indent:-15px"><b></b>&#091;***&#093;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="CENTER" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:30px; text-indent:-15px"><b></b>&#091;***&#093;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="CENTER" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><b>BioMark II End Point Reader development</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="CENTER" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="CENTER" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:30px; text-indent:-15px"><b></b>&#091;***&#093;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="CENTER" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:30px; text-indent:-15px"><b></b>&#091;***&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="CENTER" valign="top"></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:30px; text-indent:-15px"><b></b>&#091;***&#093;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="CENTER" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>BioMark Next Generation Instrument Development</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="CENTER" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:30px; text-indent:-15px"><b></b>&#091;***&#093;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="CENTER" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:30px; text-indent:-15px"><b></b>&#091;***&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="CENTER" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:30px; text-indent:-15px"><b></b>&#091;***&#093;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="CENTER" valign="top">&#091;***&#093;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Annex 2</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ADMINISTRATIVE GUIDELINES</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The grant shall cover &#091;***&#093; of the actual qualifying manpower costs and &#091;***&#093; of the actual
qualifying costs for equipment, materials &#038; software, professional services and intellectual
property rights incurred by the Company on the Development Project during the qualifying
period. In the event where qualifying cost items are not used exclusively for the Development
Project, the qualifying costs items shall be suitably pro-rated. The qualifying cost items are
listed below, but shall be subject to a total maximum grant of S$3,715,000. Virement from one
qualifying cost item to another will not be considered and the grant shall not cover GST
payments.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Category</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="3" style="border-bottom: 1px solid #000000"><B>Approved Grant (S$)</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Manpower</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="right">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Equipment, Materials and Software</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="right">&#091;***&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Professional services</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="right">&#091;***&#093;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="5" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Total</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="right">&#091;***&#093;</TD>
</TR>
<TR>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="5" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:0px; text-indent:-0px"><B>Total
Approved Grant</B><BR> (Rounded down to nearest thousand dollars)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="right"><B>3,715,000</B></TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="5" align="left" style="border-top: 3px double #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The qualifying cost for equipment (less its residual value, if any) is pro-rated based on the
number of months the equipment is used for the project (this refers to the date of delivery to the end of qualifying period) over the approved useful life of
equipment.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The qualifying cost of equipment is based on the actual expenses, residual value, number of
months that the equipment is used for the project and approved useful life of equipment.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The qualifying cost for intellectual property rights (IPR)&nbsp;is pro-rated based on the
project duration over the approved useful life of IPR.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The qualifying cost of IPR is based on the cost of acquiring IPR, project duration and the
approved useful life of IPR.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Disbursements shall be made on a reimbursement basis upon application by the Company at
quarterly intervals. Claims must be submitted using the prescribed forms and shall be
certified by the Company&#146;s Chief Financial Officer and the Principal Investigator. The amount
disbursed shall be based on the actual qualifying cost item incurred by the Company on the
Development Project during the qualifying period.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The grant will be disbursed as follows:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Disbursements of up to a cumulative total &#091;***&#093; of the approved grant amount
shall be made upon application by the Company.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The remaining &#091;***&#093; of the grant may be released upon application by the Company
on completion of the Development Project.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>For all claims (except for the final claim), the first &#091;***&#093; of the amount claimed will be
disbursed to the Company upon receipt of claim and the remaining &#091;***&#093; will be disbursed upon
the completion of checks.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The final claim must be submitted within <U>6&nbsp;months</U> with complete documentation from the end of
the qualifying period (31 May&nbsp;2011), failing which any claim will be disqualified.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>For total approved grant exceeding S$100,000, all claims must be externally audited. The
audited statement of accounts shall be submitted on an annual basis, as well as when the
Development Project is completed or terminated. The Company shall make available to its
auditor this Letter of Offer and its accompanying annexes. The Company shall ensure that the
external auditor forwards a copy of the audited accounts directly to EDB upon completion of
the audit. In the event that the external auditor cannot issue an unqualified report, EDB
shall have direct access to the external auditor to gather details with regard to the audit
findings.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company shall submit progress reports to EDB at half-yearly intervals. The disbursement
of any grant shall be subject to the Company achieving the project milestones as stated in the
Offer Letter. The final report is to be submitted upon completion of the project.</TD>
</TR>

</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>27
<FILENAME>f39432orexv10w12.htm
<DESCRIPTION>EXHIBIT 10.12
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w12</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.12</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">[***]&nbsp;&nbsp;&nbsp;Indicates
text has been omitted from this Exhibit pursuant to a confidential
treatment request and has been filed separately with the Securities and Exchange Commission.</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Distribution Agreement</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Agreement, effective as of April&nbsp;1,
2005 (&#147;Effective Date&#148;), is made by and between Fluidigm
Corporation, a corporation of the State of California, having an office at 7100 Shoreline Court,
South San Francisco CA 94080, United States of America (&#147;FC&#148;), and Eppendorf AG, a German
corporation, having its headquarter at Barkhausenweg 1, D-22339 Hamburg, Germany (&#147;EAG&#148;), each
hereinafter referred to as the &#147;Party&#148; or collectively called the &#147;Parties&#148;.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">WHEREAS, FC is specialized in development
and manufacturing of systems with integrated fluidic
circuits for life-science research,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">WHEREAS, EAG is a biotechnology company
with a broad range of applications and products, mainly in
the fields of bio tools, molecular technologies and complementary products,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">WHEREAS, the Parties intend to engage in a
mutually beneficial relationship concerning new FC
applications which include the Eppendorf product Mastercycler personal for thermal control of
microfluidic components;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">NOW, THEREFORE, in consideration of the
premises and the mutual agreements and covenants contained
herein, the Parties hereto hereby agree as follows:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 1</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B> Subject Matter of the Agreement</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The object of this Agreement is the development, manufacture and delivery by EAG to FC of a
special brand version of Eppendorf Mastercycler personal for the exclusive handling of FC
microfluidic chips and licensed for PCR thermocycling practiced in fields of research and
development, quality assurance or control, environmental testing, plant diagnostics,
identity testing (other than parentage testing for humans) and forensics (&#147;PCR Field&#148;) and
hereinafter referred to as &#147;Product&#148; - in accordance with the description of Product
(Enclosure 1). EAG grants FC the right to commercially use, market, import, offer to sell,
sell and/or distribute (including through one or more tiers of sub-distributors) the
&#147;Product&#148; under the EAG label as an &#147;Authorized Thermal Cycler&#148; on a worldwide basis.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The use, marketing, distribution and/or selling of the Product (i)&nbsp;for PCR thermocycling
outside the PCR Field as defined above and/or (ii)&nbsp;for real time PCR thermocycling as
covered by United States Patent No.&nbsp;6,814,934 (the
&#147;Higuchi Patent&#148;) is not authorized
under this Agreement, whereas EAG does not restrict FC to use, market, distribute and sell
the Product in all other fields of use outside the PCR thermocycling. It is the duty of FC
to determine the freedom to operate the Product in such cases and not to infringe third
party patents. The Parties acknowledge that FC acts as a distributor of the Product
(including without limitation [***].</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#167;</b> <b>2</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><b>Up-front payment</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Up-front payment of FC for EAG R&#038;D of the Product is EURO [***] and it is due as
follows:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>EURO [***] already received ([***] USD)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>EURO [***] already received</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>EURO [***] due in July&nbsp;2005 against separate invoice.</TD>
</TR>
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->Page 1 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The up-front payment for R&#038;D further includes
manufacturing of [ *  *  * ]. One of these units will remain in its
final serial execution in EAG&#146;s engineering as a basic reference
unit. One unit will be a life unit in EAG&#146;s R&#38;D used for
measuring, testing, modification evaluation, etc. One licensed unit
will be for FC for acceptance and release of serial production. It
will also serve as a reference unit for Fluidigm.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 3</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B> Execution and Delivery</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Delivery of PRODUCT by EAG will be to a worldwide maximum of three (3)&nbsp;addresses, which
are detailed below.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>1- Fluidigm Corporation<br>
7100 Shoreline Court<br>
South San Francisco, CA 94080</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>United States of America</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>2- Fluidigm KK<br>
Attn: Takeshi Iwabuchi<br>
Ginza TK Building 5F<br>
1-1-7 Shintomi<br>
Chuo-ku, Tokyo 104-0041</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Japan</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>3- Fluidigm Europe, BV<br>
Attn: Anja Wienecke<br>
Flughafenstrasse 52a, Haus C<br>
D-22335 Hamburg</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Germany</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>FC shall order the Product in a purchase order (&#147;Purchase Order&#148;) and EAG shall confirm
each order in writing, by e-mail or fax within 14 calendar days, provided that EAG must
accept all Purchase Orders that fall within FC&#146;s forecast specified in Section&nbsp;6 below.
Each order shall identify the quantity of Products being ordered and the required delivery
date and delivery address. Deliveries shall be within 6&nbsp;weeks after the effective date of
the order (or such longer period as may be specified in FC&#146;s order), unless a later date
was previously agreed by the Parties in writing.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>EAG is permitted to make partial deliveries and no penalty for minimum delivery will be
applied in this case. EAG agrees to notify FC promptly of any factor, occurrence or event
coming to its attention that may impact EAG&#146;s ability to meet any deliveries or other
requirements set forth in this Agreement, particularly that may cause a material delay in
delivery of Products, including any loss or reassignment of key employees, threat of strike
or major equipment failure.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Products manufactured and delivered by EAG will be inspected and tested, as required,
by FC within forty-five (45)&nbsp;days of receipt (the &#147;Acceptance Period&#148;). If during the
Acceptance Period any Products are found to be not new, defective in material or
workmanship and/or fail to meet the specifications set forth in Enclosure 1 below,
Reclaimed Products will be repaired or replaced, as outlined in Section&nbsp;11 hereafter.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->Page 2 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 4</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B> Minimum Quantity and Minimum Delivery Lot</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subject to the terms and conditions of this Agreement, FC shall order, and subject to
timely delivery of conforming units, will buy and take delivery of a total of [ *  *  * ]. The orders
for the following minimum number of Products per calendar year are to be purchased by FC
in good time to allow delivery before the end of the specified calendar year:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[ *  *  * ]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[ *  *  * ]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[ *  *  * ]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[ *  *  * ]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>[ *  *  * ]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Minimum delivery lot per single order is [ *  *  * ]. In the event FC orders
deliveries with fewer than [ *  *  * ] per delivery lot, each such delivery lot will
be regularly invoiced plus a lump sum penalty of [ *  *  * ] per delivery lot.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>EAG&#146;s sole remedy for FC&#146;s failure to meet the minimum purchase requirements as set forth
in this Section&nbsp;4 shall be as follows: Should the ordered number of units be less than [ *  *  * ]
of the above minimum number for each of [ *  *  * ], then EAG shall have the
right to terminate this Agreement on written notice to FC within [ *  *  * ] after the
end of [ *  *  * ].</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 5</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B> Forecast</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>A revolving [ *  *  * ] forecast will be given from FC to EAG. The forecast covers [ *  *  * ] and will be given [ *  *  * ]
before the [ *  *  * ] forecast period
begins. It will be submitted on the appropriate form Enclosure 3 or a similar form.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The forecasted unit orders for the next [ *  *  * ] represent a firm order to be delivered in
that [ *  *  * ]. The corresponding written order is to be enclosed with the forecast.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The figure forecasted for [ *  *  * ], may vary by [ *  *  * ] before used in next regular
forecast as firm order.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The figure forecasted for [ *  *  * ], may vary by [ *  *  * ] before used in next regular
forecast as figure for [ *  *  * ].</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The figure forecasted for the [ *  *  * ], is considered [&nbsp;*&nbsp;*&nbsp;*&nbsp;]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The forecast is used by EAG to control the production of the Product and EAG agrees to
delivery within [ *  *  * ] weeks of receiving FC&#146;s order (or such longer period as may be
specified in FC&#146;s order).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 6</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Conditions of Prices, Packaging and Payment</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The prices are to be understood exclusive of VAT/sales tax, administrative or other fees,
deductions, customs charges, transport and insurance. The prices are including solid
cardboard packing and vary in accordance with the staggered price list (Enclosure 2).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Price conditions: net, for delivery EXW Hamburg (Incoterms 2000).</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="80%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="3" align="left" valign="top">&nbsp;Export packing:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Product in cardboard box on a pallet suitable for
airfreight, transportation by truck or by sea freight in an LCL container.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="3" align="left" valign="top">&nbsp;Payment:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">net in EUROS by check or wire transfer, within 30&nbsp;days from date of invoice.</TD>
</TR>

<TR style="margin-top: 6pt">
    <TD>&nbsp;</TD>
</TR>



<TR valign="top">
    <TD>&nbsp;</TD>
    <TD colspan="5">&nbsp;Place of Delivery: EXW EAG warehouse (Incoterms 2000).</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->Page 3 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 7</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Staggered Prices</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Product price depends on the effectively delivered quantity within a calendar year.
The valid prices are shown in the staggered price list (Enclosure 2).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The first units to be delivered in each calendar year are invoiced at a unit price as per
staggered price list for the number of units to be delivered. Each additional set of units
to be delivered later within the same calendar year will be invoiced at an actual
staggered unit price (&#147;ASUP&#148;) resulting from the staggered price list for the sum of all
units actually delivered in the respective calendar year.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>ASUP will also be applied for all units having been delivered and invoiced earlier in that
calendar year. For this purpose, each invoice for new orders within a calendar year will
be accompanied by a credit note for the difference between previously invoiced prices and
ASUP, if applicable.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 8</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B> Price Adjustment to Cost Situation</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Prices of Staggered Price List can be reviewed and adjusted once annually, beginning as of
January&nbsp;1, 2007. Thereafter, EAG is entitled to change prices if justified by a change in
costs pertaining to the manufacture of the Product. Changes in price must be announced at
least 3&nbsp;months before the price change becomes effective.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Annual changes in price may not exceed the changes contained in the index published by the
German Federal Office of Statistics (GFOS)&nbsp;as part of the specialist series 17, sub-series
II, &#147;Prices and price indices for commercial products (manufacturing prices)&#148; under no.
33205 of the GP systematic &#147;Instrument, apparatus and devices for certain chemical and
physical measuring or examinations&#148;. The index multiplier is the change of the annual mean
value, published each year by the GFOS.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 9</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B> Documentation</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>FC shall be entitled to receive from EAG software files of user documentation in EAG&#146;s
standard form, to enable FC to modify such software for its applications. After return of
modified files to EAG, EAG will ensure that the modified documentation is included with the
Product.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>FC shall also receive software files of technical illustrations, test instructions, parts
lists, etc., which pertain to the Product. The copyright remains with EAG, but is hereby
licensed to FC in accordance with FC&#146;s distribution and other specified rights under this
Agreement. FC shall use the documentation exclusively with respect to this Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any Product supplied will be accompanied by a certificate as shown in Enclosure 4 (which
Enclosure shall be updated from time to time to accurately reflect the then current
situation). Any related marketing material produced by FC needs to show in prominent
position the disclaimer as given in Enclosure 5 (which Enclosure shall be updated from
time to time to accurately reflect the then current situation).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 10</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Modifications</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Applications for modifications to the Product must be made in writing to FC and the
modifications must be authorized in writing by FC. Modifications carried out without prior
written confirmation from FC are not permissible. FC shall not unreasonably withhold
agreement to any reasonable proposal made by EAG for Product modifications.<BR></TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->Page 4 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Should FC make a written request for modifications to the Product, it is in EAG&#146;s
discretion to effect these modifications, provided that EAG shall not unreasonably
withhold agreement to any reasonable proposal made by FC for product modification. All
pre-approved costs related to the modifications requested by FC will be covered by FC. EAG
is not obliged to carry out modifications to Products which have already been manufactured
or delivered.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 11</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B> Warranty</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>EAG warrants to &#091;***&#093;. This includes
&#091;***&#093; under all patent or contract rights controlled by &#091;***&#093;
and/or &#091;***&#093; as defined in &#091;***&#093;. EAG is not aware of any third party patent rights that the sale or use of the Products
may be infringing in view of the licenses granted hereunder.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>EAG represents and warrants &#091;***&#093;.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>EAG shall have discretion as to &#091;***&#093;. This
warranty does not cover &#091;***&#093;.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>FC will report all warranty and replaced service parts via &#091;***&#093; (as specified in Section&nbsp;15
below) reporting to EAG.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Deliveries to EAG of &#091;***&#093; shall be
made at FC expenses. Replacement deliveries &#091;***&#093; shall be made at &#091;***&#093; expense.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 12</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Liability</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>12.1&nbsp;IN NO EVENT WILL EITHER PARTY&#146;S LIABILITY ARISING OUT OF THIS
AGREEMENT EXCEED THE GREATER OF (a)&nbsp;[***] OR
(b)&nbsp;&#091;***&#093;. IN NO EVENT SHALL EITHER PARTY
BE LIABLE FOR ANY SPECIAL, CONSEQUENTIAL, INDIRECT, OR INCIDENTAL
DAMAGES, HOWEVER CAUSED, ON ANY THEORY OF LIABILITY AND WHETHER
OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES, ARISING OUT OF THIS AGREEMENT.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>12.2&nbsp;The limitations of Section&nbsp;12.1, however, shall not apply to (i)&nbsp;[***] (ii)&nbsp;[***] or (iii)&nbsp;[***]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 13</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>No Compete Clause</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>FC shall refrain from manufacturing and/or selling products, in standalone form, of another
make that are identical or similar to the Product. FC shall also abstain in every other
respect from any direct or indirect competition for the Product, for sale in standalone
form, with EAG, including by means of trusts or third parties, legal and commercial
entities or private individuals; this includes any entity that is
controlled by or controls FC including those, which are acquired at a later date or granted a controlling
influence.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->Page 5 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In particular FC shall not, directly or indirectly, act as distributor, dealer, commission
merchant or commercial agent for a third party with regard to identical or similar products
for sale in standalone form. Exceptions require the prior written consent of EAG. FC at the
date hereof, is not preparing and not engaged in the production or distribution of other
similar items to the Products.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Notwithstanding the foregoing in this Section&nbsp;13, in the case of EAG&#146;s sustained inability
to supply for reasons other than Force Majeure, as specified in Section&nbsp;14, both Parties
will co-operate in good faith to resolve the difficulty to both Parties&#146; satisfaction, or
if unable to so resolve the difficulty, to use the documentation and convey rights (only to
the extent EAG is so able) necessary for production to enable FC or third party to make or
have made the Product involved. It is the duty of FC to determine the freedom to operate in
such cases and especially not to infringe ABI&#146;s IP rights.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>EAG agrees not to sell or otherwise provide the Product (or any identical or similar
product that has been specifically adapted to receive FC microfluidic chips) to any person
or entity other than FC, during and two (2)&nbsp;years after the term of this Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 14</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B> Force Majeure</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>No failure or omission by the Parties hereto in the performance of any obligation of this
Agreement shall be deemed a breach of this Agreement or create any liability if the same
shall arise from any cause or causes beyond the control of the Parties, including but not
limited to the following: act of God; acts of omissions of any government; any rules,
regulations or orders issued by any governmental authority or by any officer, department,
agency or instrumentality thereof; fire; storm; flood; earthquake; accident; war;
rebellion; insurrection; riot, strikes and lockouts; and invasion; and provided that such
failure or omission resulting from one of the above causes is cured as soon as practicable
after the occurrence of one or more of the above-mentioned causes.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This applies only if the disabled Party informs the other Party as soon as possible about
the extent and the grounds of the disabling cause or causes.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Should the disabling circumstance(s) last longer than three (3)&nbsp;months, the other Party can
terminate the Agreement without a period of notice and/or proceed in accordance with
Section&nbsp;13 Para. 3.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 15</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Service, Spare Parts</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>FC is responsible for the service of the Products. FC may delegate service responsibility
to its distribution partners. EAG will support service by training of the trainers of FC as
per Section&nbsp;16 below.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>FC will purchase and keep on stock a sufficient number of spare parts to fulfill service
needs. FC agrees to order minimum spare parts value of &#091;***&#093; - per spare parts
shipment.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 16</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B> Training of Service Trainers</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Not later than the date of signature of this Agreement FC shall supply EAG with the names
of up to three key service managers of FC with defined responsibilities for a training as
service trainers. They will each receive a training course by EAG of the technical service
for the Product in a way which enables them to commence service training themselves to service
engineers of FC or to service engineers of international
distribution partners of FC.</TD>
</TR>
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->Page 6 of 34<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>EAG shall provide this training course regarding the Product and regarding reporting
system via &#091;***&#093; for such key service personnel of FC in Hamburg,
Germany. EAG shall bear the cost of training, lodging and lunch within EAG&#146;s facilities.
Other expenses, traveling fees and salary shall be borne by FC. Should a trained key
service person leave FC then FC shall bear all costs for the renewed training of a
successor.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any training which may be requested by FC in addition to the aforesaid provision shall be
at the expense of FC.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 17</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B> Confidentiality - Publicity</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>17.1&nbsp;A Confidential Disclosure Agreement (&#147;CDA&#148;) has been signed by the Parties in Sept.
2004 (Enclosure 6). For purposes of this Agreement, the &#147;Purpose&#148; in the CDA shall include
the performance of obligations and the exercise of rights pursuant to this Agreement.
Additionally terms of this Agreement are confidential as set forth in Section&nbsp;17.3.
Information about this Agreement shall be released only after mutual agreement of the
Parties, except as set forth in Section&nbsp;17.3.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>17.2&nbsp;With respect to FC&#146;s distribution of any written information to third parties,
including but not limited to advertising, brochures, catalogs, promotional and sales
material, and public relations material, EAG shall only have the right to prescribe changes
regarding references to, or descriptions of: Applied Biosystems, PCR, the amplification
patent rights, the amplification system patent rights, the PCR instrument patents, PCR
licenses or authorizations, or this Agreement. FC agrees to comply provided that such
prescriptions are reasonable in nature and documented by EAG as appropriate for accuracy.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>17.3&nbsp;Except as provided in Enclosure 5 and Section17.2, each Party shall, to the extent
reasonably practicable, maintain the confidentiality of the provisions of this Agreement in
accordance with the CDA and shall refrain from disclosing the terms of this Agreement
without prior written consent of the other Party, except (i)&nbsp;to the extent either Party
concludes in good faith that such disclosure is required by any court or other governmental
body or is otherwise required under applicable law or regulation, in which case the other
Party shall be notified in advance; (ii)to legal counsel of the Parties; (iii)&nbsp;in
connection with the requirements of a public offering or securities filing; (iv)&nbsp;in
confidence, to accountants, banks, and financing sources and their advisors; (v)&nbsp;in
confidence, in connection with the enforcement of this Agreement or rights under this
Agreement; or (vi)&nbsp;in confidence, in connection with a merger or acquisition or proposed
merger or acquisition, or the like.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 18</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Compliance and Quality</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>It shall be the duty of each Party to comply fully with all applicable laws, regulations
and ordinances and to obtain and keep in effect licenses, permits and other governmental
approvals (federal, state or local) necessary or appropriate to carry on activities
hereunder.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 19</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Assignment</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Agreement shall not be assigned by either Party except in any assignment or transfer
of all or substantially all of such Party&#146;s business related to this Agreement.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->Page 7 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 20</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Duration of Agreement, Termination of Agreement with Good Reason</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>20.1&nbsp;This Agreement is valid as of Effective Date and will continue for a minimum of five
(5)&nbsp;calendar years after Effective Date provided terms and conditions are met by both
Parties. After five years from Effective Date, this Agreement may be terminated with a
period of written notice of not less than six months.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>20.2&nbsp;The duration of Agreement automatically extends for another calendar year if not
cancelled by FC at least [***] before the end of minimum duration date or at least
[***] before the end of any Agreement extension period. Provided that FC meets or
exceeds unit forecasts, EAG will give FC at least [***] notice of termination before
the end of the minimum duration date or any Agreement extension period.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>20.3&nbsp;Either Party can terminate the Agreement with good reason especially in the event of
the other Party not fulfilling one or more of its material contractual obligations and then
not rectifying this situation within sixty (60)&nbsp;days of receipt of a written warning to
this effect. Timely delivery of conforming Product units shall - amongst others &#150; be deemed
to be a material contractual obligation.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>20.4&nbsp;Each Party may also terminate this Agreement with immediate effect and with no
liability for compensation in the event of the other Party becoming insolvent or filing for
bankruptcy.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>20.5&nbsp;Should EAG terminate the Agreement with the reason of not having received orders for
at least the agreed minimum number minus 25% as of Section&nbsp;4, FC has the right to place,
and EAG shall accept and fulfill, one final order for delivery within the commencing period
of termination.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>20.6&nbsp;FC shall be entitled to terminate this Agreement for its convenience on at least sixty
(60)&nbsp;days prior written notice to EAG, provided that no such termination shall be effective
prior to the second anniversary of the Effective Date.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>20.7&nbsp;At the time of termination of this Agreement, FC will buy all Products still on stock,
provided the stock is resulting from FC&#146;s forecast (Enclosure 3)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>20.8&nbsp;The Parties&#146; rights and obligations pursuant to the following sections shall survive
termination or expiration of this Agreement: Sections&nbsp;1, 11, 12, 17, 18, 19, 21, 22, and
23. FC shall be entitled to distribute all Products purchased from EAG. All payment
obligations of FC under this Agreement shall survive termination or expiration.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 21</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B> Court of Jurisdiction and Applicable Law</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>21.1&nbsp;This Agreement shall be governed by and interpreted in accordance with the laws of the
State of New York, U.S.A. without reference to conflict of laws principles.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>21.2&nbsp;All disputes arising out of this Agreement shall be finally settled by final and
binding arbitration in New York, New York before, and under the then current
commercial arbitration rules of, the International Chamber of Commerce, subject to the
additional limitations set forth herein. The arbitration shall be conducted by a single
arbitrator appointed in accordance with such rules. No discovery (e.g., document
production; depositions) will be permitted. The arbitration shall be conducted in the
English language, and all documentary evidence shall be presented in English;
documentary evidence not originally in English shall be presented both in the original
language and in English translation. The Parties agree that the decision of the arbitrator
shall be final and binding. The arbitration shall take no more than one day, and each Party
shall have a total of up to four (4)&nbsp;hours to present/rebut its case on that day, with the
arbitrator announcing the decision at the end of such presentations/rebuttals. Judgment on
any decision made by the arbitrator may be entered and enforced in any court of competent
jurisdiction. All fees and charges by the International Chamber of Commerce shall be
shared equally by the Parties unless otherwise specified by the arbitrator; each Party
shall be responsible for the payment of all fees and expenses<BR></TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->Page 8 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>connected with the presentation of its respective case, provided that the arbitrator may
in his/her discretion award to the prevailing Party the costs and expenses incurred by the
prevailing Party in connection with the arbitration proceeding. The arbitration shall be
confidential.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 22</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B> Indemnification</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>22.1&nbsp;EAG holds limited license rights under [***].</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>22.2&nbsp;EAG shall defend FC or assist FC at its own discretion in defending FC against any
claim or action, with the exemption of i) claims based on the [***] ii) the [***] and iii) [***] for:
(a)&nbsp;&#091;***&#093; (b)&nbsp;&#091;***&#093; or (c)&nbsp;[***]</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>22.3&nbsp;FC shall reasonably cooperate in EAG&#146;s defense of any such claim or action, and FC
shall not engage in any actions or communications that negatively affect EAGs defense or
settlement of the claim or action. &#091;***&#093;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>22.4&nbsp;(w)&nbsp;FC agrees &#091;***&#093;
(a)&nbsp;&#091;***&#093; (b)&nbsp;&#091;***&#093; or (c)&nbsp;&#091;***&#093;
with respect to the Products.</TD>
</TR>
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) FC shall
pay &#091;***&#093; under (a), (b), or (c)&nbsp;of Section&nbsp;22.2(w) above.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(y) As a
condition of FC&#146;s liability and obligations under this Section&nbsp;22.2, however,
(i)&nbsp;&#091;***&#093; (ii)&nbsp;except as set
forth hereinbelow, FC shall [***]
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->Page 9 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&#091;***&#093;. In
no event shall &#091;***&#093;.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">Notwithstanding
the foregoing, &#091;***&#093;.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(z) Notwithstanding
the foregoing, FC shall have no liability or obligation with
respect to any claim or action resulting from an actual or alleged breach by EAG of the
first paragraph of Section&nbsp;11.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>22.3&nbsp;EAG represents and warrants that &#091;***&#093;.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 23</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B> Final Clauses</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>23.1&nbsp;This Agreement contains the entire and only agreement between the Parties and
supersedes and cancels all prior written and/or oral agreements, undertakings and
negotiations between the Parties with respect to the subject matter hereof.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>23.2&nbsp;No amendments, changes, modifications or alterations of the terms and conditions
of this Agreement shall be binding upon either Party unless in writing and signed by both
Parties. Any waiver of this provision shall be made in each specific case in writing.
Documents transmitted by fax are considered to be in writing.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>23.3&nbsp;Each Party represents and warrants that it has full power and authority to enter into
this Agreement and to take all actions required by this Agreement and that each Party&#146;s
obligations under the Agreement do not conflict with its obligations under any other
agreement to which EAG or FC is a party.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>23.4&nbsp;The headlines are for orientation purposes only and do not form part of the Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>23.5&nbsp;Should any provision of this Agreement be invalid or unenforceable or should the
Agreement contain an omission, the remaining provisions shall be valid. In the place of an
invalid provision, a valid provision is presumed to be agreed upon by the Parties, which
comes economically closest to the one actually agreed upon; the same shall apply in the
case of an omission.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>23.6&nbsp;The Parties shall endeavor to settle amicably any disputes which result from the
execution of this Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><b>&#167; 24</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B> Enclosures</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The enclosures are integral part of the Agreement.<br>
Enclosure 1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Description of Product<br>
Enclosure 2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#091;***&#093;<br>
Enclosure 3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Forecast Form<br>
Enclosure 4 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#091;***&#093;<br>
Enclosure 5 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disclaimer<br>
Enclosure 6 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confidential Disclosure Agreement<br>
Enclosure 7 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#091;***&#093;<br></TD>
</TR>
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->Page 10 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized
representatives.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="12%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="61%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top" nowrap><DIV style="margin-left:0px; text-indent:-0px">South San Francisco, the
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">17 August 2005
<DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Fluidigm Corporation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">President / CEO</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="19%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="78%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Gajus V. Worthington
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Gajus V. Worthington
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="68%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top" nowrap><DIV style="margin-left:0px; text-indent:-0px">Hamburg, the 4 Aug. 2005 <BR>
Eppendorf AG
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
<DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Heinz Gerhard Koehn, Ph. D.
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Heinz Gerhard Koehn, Ph. D.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Michael Schroeder, Ph. D.
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Michael Schroeder, Ph. D.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Board Member, Technology
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Board Member, Marketing and Sales</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->Page 11 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV  align="center" style="font-size: 10pt; margin-top: 6pt"><B>Enclosure
1 </B>Page 1</DIV>
<DIV  align="center" style="font-size: 10pt; margin-top: 6pt"><B>Description
of Product and Specifications</b></DIV>
<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[***]
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->Page 12 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV  align="center" style="font-size: 10pt; margin-top: 6pt"><B>Enclosure 1 </B>Page 2</DIV>
<DIV  align="center" style="font-size: 10pt; margin-top: 6pt">[***]</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Page 13 of 34<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Enclosure 1</B> Page 3</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">[***]</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio --></DIV>





<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Enclosure 1 </B>Page 4</DIV>



<DIV align="Center" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">[***]</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio --></DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Enclosure 1 </B>Page 5</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[***]</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->To page 13: sub-page 3 of 8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Enclosure 1 </B>Page 6</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[***]</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->To page 13: sub-page 4 of 8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Enclosure 1 </B>Page 7</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[***]</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[***]</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->To page 13: sub-page 5 of 8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Enclosure 1 </B>Page 8</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[***]</DIV>
<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[***]</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->To page 13: sub-page 6 of 8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Enclosure 1 </B>Page 9</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->[***]<!-- /Folio -->

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->To page 13:
Sub-page 7 of 8<!-- /Folio -->

</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Enclosure 1 </B>Page 10</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->[***]<!-- /Folio -->

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->To page 13:
Sub-page 8 of 8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure
2</B>
</div>
<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><b>
Staggered price list</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B>Prices per number of products to be delivered within one
Agreement Year</B>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="46%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="26%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">

<TD align="right"><DIV style="margin-left:15px; text-indent:-15px"><I>[***] and more units/a</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>price per unit</I></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>Euro</I></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>[***]</I></TD>
</TR>
<TR valign="bottom">
    <TD align="right"><DIV style="margin-left:15px; text-indent:-15px"><I>[***] and more units/a</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>price per unit</I></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>Euro</I></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>[***]</I></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD align="right"><DIV style="margin-left:15px; text-indent:-15px"><I>[***] and more units/a</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>price per unit</I></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>Euro</I></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>[***]</I></TD>
</TR>
<TR valign="bottom">
    <TD align="right"><DIV style="margin-left:15px; text-indent:-15px"><I>[***] and more units/a</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>price per unit</I></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>Euro</I></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>[***]</I></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD align="right"><DIV style="margin-left:15px; text-indent:-15px"><I>[***] and more units/a</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>price per unit</I></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>Euro</I></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>[***]</I></TD>
</TR>
<TR valign="bottom">
    <TD align="right"><DIV style="margin-left:15px; text-indent:-15px"><I>[***] and more units/a</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>price per unit</I></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>Euro</I></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>[***]</I></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD align="right"><DIV style="margin-left:15px; text-indent:-15px"><I>[***] and more units/a</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>price per unit</I></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>Euro</I></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>[***]</I></TD>
</TR>
<TR valign="bottom">
    <TD align="right"><DIV style="margin-left:15px; text-indent:-15px"><I>[***] and more units/a</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>price per unit</I></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>Euro</I></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>[***]</I></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV style="font-size: 10pt; margin-top: 12pt"><B>License condition of prices:</B>
</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">Prices include the newly reduced up-front-fee-component of PCR license (fixed license portion) as
pre-announced by EAG&#146;s licensor. Possible reductions (or elimination) of this license fee by the
PCR licensor shall result in reductions.
</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">The prices include PCR license, neglecting a price value for a device providing vacuum. Should PCR
license also be requested for a vacuum providing device by the licensor, the requested license has
to be borne by FC and above staggered prices will be revised correspondingly.
</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">The prices include PCR license for the Product calculated on basis of Enclosure 1, (Description of
Product) with the chuck supplied and invoiced to EAG as specified. Should the licensor request
another price value for the chuck for the calculation of the PCR license, the requested license has
to be borne by FC and above staggered prices will be revised accordingly.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->Page 14 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Enclosure 3</B></DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Forecast Form</B></DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Special brand version of Eppendorf Mastercycler personal &#151; Quarterly Forecast</B></DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">Forecast period (12 Months), revolving quarterly:</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&#91;***&#93;</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">Confirmation:</DIV>
<DIV style="font-size: 10pt; margin-top: 6pt">Number of units forecasted above for delivery in 1. Quarter herewith are firmly ordered. The
definitive composition of individual delivery lots and the delivery address for each lot must be
conveyed to EAG with &#091;6&nbsp;weeks&#093; notice.</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">Place / Date: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><B>Fluidigm Corporation</B></DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;<br><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><BR>
(Signature)</DIV>
<DIV style="font-size: 10pt; margin-top: 6pt">Our production planning is controlled by forecast instruments. For this purpose the above forecast
system is used. Please return the completed form before the middle of running quarter, to ensure
punctual delivery for the next quarter.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">The form contains an
overview about the coming &#091;***&#093;. The figures for the &#091;***&#093;.
The figure for the following &#091;***&#093; with the following forecast as indicated.
The figure for the &#091;***&#093;.</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">Eppendorf AG</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Page 15 of 34<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Enclosure 4 </B>Page 1</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><I>Authorization Notice</I></DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">[ * * * ]</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Page 16 of 34<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure 4 </B>Page 2
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>EAG will affix permanently and prominently to each Authorized Thermal Cycler the
designation &#147;Authorized Thermal Cycler&#148;, its Serial Number and a direction to consult
the user&#146;s manual for the license information.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>FC agrees to instruct the ultimate purchaser that transfer of the thermal cycler without
the Serial Number or the Notice shall automatically terminate the authorization granted
by this Agreement and the thermal cycler shall cease to be an Authorized Thermal
Cycler.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->Page 17 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Enclosure 5</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Disclaimer</B>

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B><I>Wording of the Disclaimer</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Practice of the patented polymerase chain reaction (PCR)&nbsp;process requires a license. The
Mastercycler is an Authorized Thermal Cycler and may be used with PCR licenses available from
Applied Biosystems. Its use with Authorized Reagents also provides a limited PCR license in
accordance with the label rights accompanying such reagents.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->Page 18 of 34<!-- /Folio -->
</DIV>


<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure 6</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><I>Confidential Disclosure Agreement</I>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Confidential Disclosure Agreement

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This
Agreement, effective as of 11 August&nbsp;2004 (&#147;Effective Date&#148;), is made by and between Fluidigm
Corporation a corporation of the State of California, having an office at 7100 Shoreline Court,
South San Francisco, CA 94080. United States of America
(&#147;FLUIDIGM&#148;), and Eppendort AG, a German
corporation, having its headquarters at Barkhausenweg 1. D-22339
Hamburg. Germany (&#147;EAG&#148;), each
hereinafter also referred to as the &#147;Party&#148; or collectively
called the &#147;Parties&#148;.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">WHEREAS,
FLUIDIGM is specialised in development and manufacturing of systems
with integrated fluid c
circuits for life-science research with a concentration on protein
structure determination.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">WHEREAS, EAG is a leading biotechnology
 company with a broad range of applications and products,
mainly in the fields of biotools, molecular technologies and
complementary products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">WHEREAS,
the Parties intend to engage in discussions concerning a co-operation for a new FLUIDIGM
application which possibly may include components of the EAG product
Mastercycler ep 18.Aug.04 (&#147;Purpose&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">NOW, THEREFORE, in consideration of the premises and the mutual agreements and covenants contained
herein the Parties hereto hereby agree
 as follows.
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">Confidential information
 (&#147;Information&#147;), as used herein, shall mean any and all
information,
know-how, data and experience in whatever form, be it verbally, in writing, in drawing,
samples, displays, in software, on tapes, hard disks, diskettes or otherwise furnished by
either Party (hereinafter referred to as the &#147;Disclosing
Party&#148;) to the other Party (hereinafter
referred to as the &#147;Receiving Party&#148;) either directly or indirectly and disclosed to the
Receiving Party under this Agreement.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Receiving Party undertakes to keep confidential any and
all information, except</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">a.
Information, which the Receiving Party can establish by competent proof was at the time of
disclosure or became after disclosure, part of the public domain by publication, except by
breach of the undertakings hereunder by the Receiving Party;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">b. Information which
 the Receiving Party can establish by competent proof was in its
possession already at the time of disclosure, and which was not acquired, directly or
indirectly, from the Disclosing Party, and information which the Receiving Party can establish
by competent proof was later received from a third party, provided,
however, that such
information was not obtained by said third party directly or indirectly from the Disclosing
Party;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">c.
Information which the Receiving Party can establish by competent proof was
independently developed by the Receiving Party without use of the Confidential Informal on of
the Disclosing Party; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">d.
Information which was required to be disclosed by law or court or
governmental order;
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Receiving Party undertakes to use any and all information
only for the Purpose agreed
upon in writing with the Disclosing Party, and will not, directly or indirectly, exploit or
otherwise use information for any other purpose, unless and until the Disclosing Party from
case to case explicitly accepts in writing prior to the proposed use of information for such
other purpose.</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Page 19 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Receiving Party undertakes only to disclose Information
to those employees who need to
make use of Information in order to carry out agreed upon work for the Purpose, and guarantees
that every such employee is aware of and will respect the
confidentiality of Information.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Receiving Party agrees that its affiliates will treat Information as if they were
themselves a Party to this Agreement. Affiliate in this Agreement means any and all company or
individual related to the Receiving Party, whether the relationship be that of employment or
ownership or other, including any company or organization owning,
owned by or under common
control with the Receiving Party.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Within thirty (30)&nbsp;days after the Disclosing Party&#146;s request, the Receiving Party shall
return to the Disclosing Party all Information, including all copies
thereof, unless another
agreement covering the use of Information has been made between the
Parties.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Nothing herein and nothing said or written in connection with
the disclosure of Information
constitutes a promise or an undertaking to enter into further
cooperation between the Parties.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Parties further agree that the furnishing of Information
under this Agreement shall
    not constitute any grant or license of any rights now or
hereafter held by the Parties.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">9.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All obligations of the Parties with respect to the confidential information disclosed
under this Agreement shall cease five (5)&nbsp;years from the
Effective Date.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Agreement shall be construed in accordance with and
governed by substantive German law.
The place of jurisdiction is the place of business of the defendant.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">IN WITNESS
WHEREOF, the Parties have caused this Agreement to be executed by
their duly authorized
representatives.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="14%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">FLUIDIGM
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">EAG</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Gajus Worthington
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Dr. Heinz G. Kohn
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Ernst Tennstedt</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Gajus Worthington
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Dr. Heinz G. Kohn
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Ernst Tennstedt
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Chief Executive Officer
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Board Member
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Head of Legal</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Technology
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Department</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Date:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Date: 20.8.2004</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->Page 20 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure 7 </B>(1 of 14)
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>&#091;***&#093;</B>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Pages 21 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure 7 </B>(2 of 14)
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Pages 22 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure 7 </B>(3 of 14)
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->Pages 23 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure 7 </B>(4 of 14)
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->Pages 24 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure 7 </B>(5 of 14)
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Pages 25 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure 7 </B>(6 of 14)
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Pages 26 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure 7 </B>(7 of 14)
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Pages 27 of 34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure 7 </B>(8 of 14)
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->Pages 28 of 34<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure 7 </B>(9 of 14)</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --> Page 29 of 34 <!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure 7 </B>(10 of 14)
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --> Page 30 of 34 <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure 7 </B>(11 of 14)
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --> Page 31 of 34 <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure 7 </B>(12 of 14)
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --> Page 32 of 34 <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure 7 </B>(13 of 14)
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --> Page 33 of 34 <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Enclosure 7 </B>(14 of 14)
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">&#091;***&#093;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --> Page 34 of 34 <!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>28
<FILENAME>f39432orexv10w14.htm
<DESCRIPTION>EXHIBIT 10.14
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w14</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.14</B>
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">2494.CNSLT.001<BR>
DeLateur, Richard
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FLUIDIGM CORPORATION</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>CONSULTING AGREEMENT</B></U>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Consulting Agreement (&#147;Agreement&#148;) is made and entered into as of February&nbsp;29, 2008, by
and between FLUIDIGM CORPORATION, a Delaware Corporation with place of business at 7100 Shoreline
Court, South San Francisco, CA 94080 (the &#147;Company&#148;), and RICHARD DeLATEUR, residing at 1333 Jones
Street, San Francisco, CA 94109 (&#147;Consultant&#148;). The Company desires to retain Consultant as an
independent contractor to perform services for the Company and Consultant is willing to perform
such services, on terms set forth more fully below. Consultant&#146;s specific services are not
currently part of Company&#146;s core business and therefore Company needs to independently contract for
Consultant&#146;s specific skill set, and the Company does not retain the authority to direct the
day-to-day performance of Consultant&#146;s services, but rather is requesting certain tasks to be
accomplished by Consultant based upon Consultant&#146;s specific skill set and expertise.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In consideration of the mutual promises contained herein, the parties agree
as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U><B>SERVICES AND COMPENSATION</B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Services.</U> Consultant agrees to perform for the Company the services described in
<U>Exhibit&nbsp;A</U> attached hereto and incorporated herein (&#147;Services&#148;) and any other such Services
as the Company may prescribe.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Compensation.</U> The Company agrees to pay Consultant as set forth in <U>Exhibit&nbsp;A
</U>attached hereto and incorporated herein
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Equity Incentives.</U> Consultant agrees that he will not receive any stock options or
other equity incentives as compensation for the Services provided hereunder. Consultant further
acknowledges and agrees that as of February&nbsp;29, 2008 (the effective date of this Agreement and the
date Consultant terminated as an employee of the Company), Consultant held options to acquire
610,000 shares of the Company&#146;s Common Stock (the &#147;Option&#148;) under the Company&#146;s 1999 Stock Option
Plan (the &#147;<U>Plan</U>&#148;). Consultant agrees that (i)&nbsp;as of February&nbsp;29, 2008, the Option was vested with
respect to 324,582 shares of Common Stock (the &#147;Vested Shares&#148;); (ii)&nbsp;the Option will immediately
terminate as of February&nbsp;29, 2008 with respect to all shares that are not Vested Shares; and (iii)
Consultant&#146;s right to exercise the Option with respect to Vested Shares will be governed by the
terms of the Plan and the agreement between the Company and Consultant documenting the Option,
which permits the Consultant limited rights to exercise the Option with respect to Vested Shares
after the Consultant has ceased to be a &#147;Service Provider&#148; to the Company (e.g., ninety days from
end of Service Provider period and as otherwise defined in the Plan). Consultant represents and
warrants that he has read the Plan and such option agreement and understands his rights thereunder
with respect to the exercise of Vested Shares. Consultant further represents and warrants that he
has consulted or will consult with such tax and financial advisors as he deems appropriate with
respect to any decision to exercise or not to exercise the Option.
</DIV>
<DIV align="right" style="font-size: 10pt; margin-top: 18pt">2/29/2008</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">









<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U><B>CONFIDENTIALITY</B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Definition</U>. &#147;Confidential Information&#148; means any Company (including its parents,
subsidiaries, or affiliates) proprietary information, technical data, trade secrets or know-how,
including, but not limited to, research, product plans, products, services, customers, customer
lists, markets, software, developments, inventions, processes, formulas, technology, designs,
drawings, engineering, hardware configuration information, marketing, finances or other business
information disclosed by the Company either directly or indirectly in writing, orally or by
drawings or inspection of parts or equipment. Confidential Information does not include information
which is known to Consultant at the time of disclosure to Consultant by the Company as evidenced by
written records of Consultant, has become publicly known and made generally available through no
wrongful act of Consultant, or has been rightfully received by Consultant from a third party who is
authorized to make such disclosure.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Non-Use and Non-Disclosure</U>. Consultant will not, during or subsequent to the term
of this Agreement, use the Company&#146;s Confidential Information for any purpose whatsoever other than
the performance of the Services on behalf of the Company or disclose the Company&#146;s Confidential
Information to any third party. It is understood that said Confidential Information shall remain
the sole property of the Company. Consultant further agrees to take all reasonable precautions to
prevent any unauthorized disclosure of such Confidential Information including, but not limited to,
having each employee of Consultant, if any, with access to any Confidential Information, execute a
nondisclosure agreement containing provisions in the Company&#146;s favor identical to Sections&nbsp;2
(Confidentiality), 3 (Ownership) and 4 (Conflicting Obligations) of this Agreement. Without the
Company&#146;s prior written approval, Consultant will not directly or indirectly disclose to anyone the
existence of this Agreement or the fact that Consultant has this arrangement with the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Former Employer&#146;s Confidential Information</U>. Consultant agrees that Consultant will
not, during the term of this Agreement, improperly use or disclose any proprietary information or
trade secrets of any former or current employer or other person or entity with which Consultant has
an agreement or duty to keep in confidence information acquired by Consultant, if any, and that
Consultant will not bring onto the premises of the Company any unpublished document or proprietary
information belonging to such employer, person or entity unless consented to in writing by such
employer, person or entity. Consultant will indemnify the Company and hold it harmless from and
against all claims, liabilities, damages and expenses, including reasonable attorneys fees and
costs of suit, arising out of or in connection with any violation or claimed violation of a third
party&#146;s rights resulting in whole or in part from the Company&#146;s use of the work product of
Consultant under this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Third Party Confidential Information</U>. Consultant recognizes that the Company has
received and in the future will receive from third parties their confidential or proprietary
information subject to a duty on the Company&#146;s part to maintain the confidentiality of such
information and to use it only for certain limited purposes. Consultant agrees that Consultant owes
the Company and such third parties, during the term of this Agreement and thereafter, a duty to
hold all such confidential or proprietary information in the strictest confidence and not to
disclose it to any person, firm or corporation or to use it except as necessary in carrying out the
Services for the Company consistent with the Company&#146;s agreement with such third party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Return of Materials</U>. Upon the termination of this Agreement, or upon Company&#146;s
earlier request, Consultant will deliver to the Company all of the Company&#146;s property or
Confidential Information that Consultant may have in Consultant&#146;s possession or control. Consultant
agrees to sign and deliver the Termination Certification attached hereto as <U>Exhibit&nbsp;B</U>.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.&nbsp;</B><u><B>OWNERSHIP</B></u>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Assignment</U>. Consultant has attached hereto, as <U>Exhibit&nbsp;C</U>, a list
describing all inventions, original works of authorship, developments, improvements, and trade
secrets, which were made by Consultant prior to the date of this Agreement, which belong to
Consultant and which relate to the business of the Company. If no such list is attached or left
blank, Consultant represents that there are no such inventions. Consultant agrees that all
copyrightable material, notes, records, drawings, designs, inventions, improvements, developments,
discoveries and trade secrets (collectively, &#147;Inventions&#148;) conceived, made or discovered by
Consultant, solely or in collaboration with others, during the period of this Agreement which
relate in any manner to the business of the Company that Consultant may be directed to undertake,
investigate or experiment with, or which Consultant may become associated with in work,
investigation or experimentation in the line of business of Company in performing the Services
hereunder, are the sole property of the Company. Consultant further agrees to assign (or cause to
be assigned) and does hereby assign fully to the Company all Inventions and any copyrights,
patents, mask work rights or other intellectual property rights relating thereto.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Further Assurances</U>. Consultant agrees to assist Company, or its designee, at the
Company&#146;s expense, in every proper way to secure the Company&#146;s rights in the Inventions and any
copyrights, patents, mask work rights or other intellectual property rights relating thereto in any
and all countries, including the disclosure to the Company of all pertinent information and data
with respect thereto, the execution of all applications, specifications, oaths, assignments and all
other instruments which the Company shall deem necessary in order to apply for and obtain such
rights and in order to assign and convey to the Company, its successors, assigns and nominees the
sole and exclusive right, title and interest in and to such Inventions, and any copyrights,
patents, mask work rights or other intellectual property rights relating thereto. Consultant
further agrees that Consultant&#146;s obligation to execute or cause to be executed, when it is in
Consultant&#146;s power to do so, any such instrument or papers shall continue after the termination of
this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Pre-Existing Materials</U>. Consultant agrees that if in the course of performing the
Services, Consultant incorporates into any Invention developed hereunder any invention,
improvement, development, concept, discovery or other proprietary information owned by Consultant
or in which Consultant has an interest, (i)&nbsp;Consultant shall inform Company, in writing before
incorporating such invention, improvement, development, concept, discovery or other proprietary
information into any Invention; and (ii)&nbsp;the Company is hereby granted and shall have a
nonexclusive, royalty-free, perpetual, irrevocable, worldwide license to make, have made, modify,
use and sell such item as part of or in connection with such Invention. Consultant shall not
incorporate any invention, improvement, development, concept, discovery or other proprietary
information owned by any third party into any Invention without Company&#146;s prior written permission.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Attorney in Fact</U>. Consultant agrees that if the Company is unable because of
Consultant&#146;s unavailability, dissolution, mental or physical incapacity, or for any other reason,
to secure Consultant&#146;s signature to apply for or to pursue any application for any United States or
foreign patents or mask work or copyright registrations covering the Inventions assigned to the
Company above, then Consultant hereby irrevocably designates and appoints the Company and its duly
authorized officers and agents as Consultant&#146;s agent and attorney in fact, to act for and in
Consultant&#146;s behalf and stead to execute and file any such applications and to do all other
lawfully permitted acts to further the prosecution and issuance of patents, copyright and mask work
registrations thereon with the same legal force and effect as if executed by Consultant.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. <U><B>CONFLICTING OBLIGATIONS</B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consultant certifies that Consultant has no outstanding agreement or obligation that is
in conflict with any of the provisions of this Agreement, or that would preclude Consultant
from complying with the provisions hereof, and further certifies that Consultant will not
enter into any such conflicting agreement during the term of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U><B>TERM AND TERMINATION</B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Term</U>. This Agreement will commence on the date first written above and
will continue until the earlier of (i)&nbsp;final completion of the Services or (ii)&nbsp;termination as provided
below; provided, however, that the term will expire on May&nbsp;17, 2008 unless agreed otherwise in
writing by both
parties.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Termination</U>. Without limiting any rights which either party to this Agreement may
have by reason of any default by the other party, the Consultant reserves the right to terminate
this Agreement at his convenience by written notice given to the Company, and the Company my
terminate this Agreement for Cause immediately upon written notice to the Consultant. Any
termination by the Consultant shall be effective upon the date not earlier than 30&nbsp;days following
the effective date of such notice as shall be specified in said notice, and any termination by the
Company shall be effective immediately upon delivery of written notice thereof to the Consultant if
personally delivered or forty-eight (48)&nbsp;hours after deposited in the United States mail, postage
pre-aid, registered or certified mail, return receipt requested. For purposes of this Agreement,
&#147;Cause&#148; shall mean (i)&nbsp;Consultant&#146;s repeated failure to perform his duties or responsibilities as a
Consultant as directed or assigned by an officer of the Company; (ii)&nbsp;Consultant&#146;s personally
engaging in knowing and intentional illegal conduct which is seriously injurious to the Company or
its affiliates; (iii)&nbsp;Consultant&#146;s being convicted of a felony, or committing an act of dishonesty
or fraud against, or the misappropriation of property belonging to, the Company or its affiliates;
or (iv)&nbsp;any breach by Consultant of any provision of this Agreement or any other agreement between
Consultant and the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Survival</U>. Upon such termination all rights and duties of the parties toward
each other shall cease except:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;that the Company shall be obliged to pay, within thirty (30)&nbsp;days
of the
effective date of termination, all amounts owing to Consultant for satisfactory Services
completed and accepted by the Company through the termination date and if a work in progress,
Company shall be liable only for the pro rata portion of the completed work, and related
expenses, if any, in accordance with the provisions of Section&nbsp;1 (Services and Compensation)
hereof; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;Sections&nbsp;2 (Confidentiality), 3 (Ownership) and 7 (Independent Contractors) shall
survive termination of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U><B>ASSIGNMENT</B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither this Agreement nor any right hereunder or interest herein may be assigned or
transferred by Consultant without the express written consent of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<u><B>INDEPENDENT CONTRACTOR</B></u>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Independent Contractor Status</U>. It is the express intention of the
parties that Consultant is an independent contractor. Nothing in this Agreement shall in any
way be construed to constitute Consultant as an agent, employee or representative of the
Company, but Consultant shall perform
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the Services hereunder as an independent contractor. Consultant agrees to furnish (or reimburse the
Company for) all tools and materials necessary to accomplish this contract, and shall incur all
expenses associated with performance, except as expressly provided on <U>Exhibit&nbsp;A</U> of this
Agreement. Consultant acknowledges and agrees that Consultant is obligated to report as income all
compensation received by Consultant pursuant to this Agreement, and Consultant agrees to and
acknowledges the obligation to pay all self-employment and other taxes thereon. Consultant further
agrees to indemnify and hold harmless the Company and its directors, officers, and employees from
and against all taxes, losses, damages, liabilities, costs and expenses, including attorney&#146;s fees
and other legal expenses, arising directly or indirectly from (i)&nbsp;any negligent, reckless or
intentionally wrongful act of Consultant or Consultant&#146;s assistants, employees or agents, (ii)&nbsp;a
determination by a court or agency that the Consultant is not an independent contractor, or (iii)
any breach by the Consultant or Consultant&#146;s assistants, employees or agents of any of the
covenants contained in this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Consultation for Others</U>. Consultant is free to perform work as a consultant or
employee for any other entity and/or person <U>provided</U> that such engagement does not create a
conflict of interest with Consultant&#146;s obligations to Company. Specifically, none of Consultant&#146;s
services for any other entity and/or person shall compromise in any way the Company&#146;s &#147;Confidential
Information&#148; as defined in Section&nbsp;2 (Confidentiality). Further, Consultant must, at all times
comply with Section&nbsp;2 (Confidentiality).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Employment of Assistants</U>. Consultant may, at Consultant&#146;s own expense, employ
such assistants as Consultant deems necessary to perform the services required of Consultant by
this Agreement. Consultant assumes full and sole responsibility for the payment of all
compensation and expenses of these assistants and for all federal, state and local income taxes,
unemployment insurance, workers&#146; compensation insurance, disability insurance, Social Security
taxes, and other applicable withholdings.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Time and Places of Providing Services</U>. As long as Consultant delivers acceptable
services to Company in a timely fashion, Consultant shall generally have the discretion to
determine the location and times of rendering services as well as the method of accomplishing
Consultant&#146;s Services.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Records and Reports</U>. Consultant shall keep complete and systematic written
records of all work relating to the performance of Services by Consultant hereunder and shall
submit invoices to Company&#146;s accounts payable for all services rendered monthly.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U>Equipment, Documentation and Specifications</U>. Consultant shall supply all
equipment and instruments required to perform Services under this Agreement, except when such
equipment or supplies are unique to Company in which case Company shall provide Consultant with
such equipment, instruments, documentation and specifications as may reasonably be required by
Consultant for performance by Consultant of duties set forth herein. Such equipment,
instruments, documentation and specifications shall at all times remain the property of Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U><B>NONSOLICITATION</B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consultant agrees that for a period of one (1)&nbsp;year after the termination of this Agreement,
in any county in the United States or equivalent geographical subdivision in which Company does
business, Consultant will not (i)&nbsp;solicit or induce employees of Company to terminate their
employment with Company, or (ii)&nbsp;solicit any identified customers or identified potential customers
of Company to induce such customers or potential customers to cease their relationship with
Company, or any of its affiliated companies.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U><B>BENEFITS</B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consultant acknowledges and agrees and it is the intent of the parties hereto that Consultant
receive no Company-sponsored benefits from the Company either as a Consultant or employee. Such
benefits include, but are not limited to, paid vacation, sick leave, medical insurance, and 401(k)
participation. If Consultant is reclassified by a state or federal agency or court as an employee,
Consultant will become a reclassified employee and will receive no benefits except those mandated
by state or federal law, even if by the terms of the Company&#146;s benefit plans in effect at the time
of such reclassification Consultant would otherwise be eligible for such benefits.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U><B>ARBITRATION AND EQUITABLE RELIEF</B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Disputes</U>. Except as provided in Section 10(d) below, the Company and Consultant
agree that any dispute or controversy arising out of, relating to or in connection with the
interpretation, validity, construction, performance, breach or termination of this Agreement
(&#147;arbitrable claims&#148;) shall be settled by binding arbitration to be held in San Francisco County,
California, in accordance with the Commercial Arbitration Rules, supplemented by the Supplemental
Procedures for Large Complex Disputes, of the American Arbitration Association as then in effect
(the &#147;Rules&#148;). The arbitrator may grant injunctions or other relief in such dispute or controversy.
The decision of the arbitrator shall be final, conclusive and binding on the parties to the
arbitration. Judgment may be entered on the arbitrator&#146;s decision in any court of competent
jurisdiction. This shall <U>not</U> apply to claims arising under Sections&nbsp;2 (Confidentiality) and
3 (Ownership).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Consent to Personal Jurisdiction</U>. The arbitrator(s) shall apply California law to
the merits of any dispute or claim, without reference to conflicts of law rules. Consultant hereby
consents to the personal jurisdiction of the state and federal courts located in California for any
action or proceeding arising from or relating to this Agreement or relating to any arbitration in
which the parties are participants.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;<u>Costs</u>. The Company and Consultant shall each pay one-half of the costs and expenses of
such arbitration, and each shall separately pay its counsel fees and expenses unless otherwise
required by law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Equitable Relief</U>. With the exception of &#147;arbitrable claims,&#148; the parties may apply
to any court of competent jurisdiction for a temporary restraining order, preliminary injunction,
or other interim or conservatory relief, as necessary, without breach of this arbitration agreement
and without abridgment of the powers of the arbitrator.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Acknowledgment</U>. CONSULTANT HAS READ AND UNDERSTANDS SECTION 9, WHICH DISCUSSES
ARBITRATION. CONSULTANT UNDERSTANDS THAT BY SIGNING THIS AGREEMENT, CONSULTANT AGREES TO SUBMIT ANY
CLAIMS ARISING OUT OF, RELATING TO, OR IN CONNECTION WITH THIS AGREEMENT, OR THE INTERPRETATION,
VALIDITY, CONSTRUCTION, PERFORMANCE, BREACH OR TERMINATION THEREOF, TO BINDING ARBITRATION, EXCEPT
AS PROVIDED IN SECTION 10 (d), AND THAT THIS ARBITRATION CLAUSE CONSTITUTES A WAIVER OF
CONSULTANT&#146;S RIGHT TO A JURY TRIAL AND RELATES TO THE RESOLUTION OF ALL DISPUTES RELATING TO ALL
ASPECTS OF THE RELATIONSHIP BETWEEN THE PARTIES.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<U><B>GOVERNING LAW</B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Agreement shall be governed by the internal substantive laws, but not the choice of law
rules, of the State of California. With the exception of &#147;arbitral claims,&#148; the federal courts or
state courts of
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the State of California, County of San Mateo, shall have exclusive jurisdiction to adjudicate any
dispute arising out of this Agreement, and the parties hereto consent to the jurisdiction of said
court and waive any objection to said venue.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;<U><B>ENTIRE AGREEMENT</B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Agreement is the entire agreement of the parties and supersedes any prior agreements
between them, whether written or oral, with respect to the subject matter hereof. No waiver,
alteration, or modification of any of the provisions of this Agreement shall be binding unless in
writing and signed by duly authorized representatives of the parties hereto.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;<U><B>ATTORNEY&#146;S FEES</B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In any court action at law or equity which is brought by one of the parties to enforce or
interpret the provisions of this Agreement, the prevailing party will be entitled to reasonable
attorney&#146;s fees, in addition to any other relief to which that party may be entitled.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.&nbsp;</B><U><B>SEVERABILITY</B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The invalidity or unenforceability of any provision of this Agreement, or any terms thereof,
shall not affect the validity of this Agreement as a whole, which shall at all times remain in full
force and effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>FLUIDIGM</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>PARTY</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gajus Worthington
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Richard DeLateur</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">

    <TD colspan="2" valign="top" align="left">Name:</TD>
<TD  valign="top" align="left"> Gajus Worthington</td>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" valign="top" align="left">Name:</TD>
<TD  valign="top" align="left">  Richard DeLateur</td>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="2" valign="top" align="left">Title: </TD>
<TD valign="top" align="left">CEO</td>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" valign="top" align="left">Title: </TD>
    <TD  valign="top" align="left">Self</td>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Dated: 29 Feb 2008</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Dated: 29 Feb 2008</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Social Security or Tax Payer ID Number:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">XXX-XX-XXXX</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT A</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>SERVICES AND COMPENSATION</B></U>

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Contact</U>. Consultant&#146;s principal Company
contact:<br><br> Name: Gajus Worthington</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Title:&nbsp;&nbsp; CEO</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Services</U>. Consultant will render to the Company the following Services:</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">* Support 2007 audit<BR>
* Assist new CFO<BR>
* Prepare March stock valuation<BR>
* Train Singapore and U.S. Company accounting personnel about cost and inventory
accounting procedures
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">3. <U>Compensation</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Company shall pay Consultant Two Hundred Dollars ($200.00) per hour during the term of
this Agreement upon receipt of Consultant&#146;s invoice for Services rendered. Consultant shall be paid
every two (2)&nbsp;weeks after receipt and approval of statements specified in section 3(c) below.
Consultant will not work more than five (5)&nbsp;hours per week without written authorization from the
Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Company shall reimburse Consultant for all reasonable travel and living expenses
incurred by Consultant in performing Services pursuant to this Agreement, provided Consultant
receives written consent from an authorized agent of the Company prior to incurring such expenses.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Consultant shall submit all statements for the number of hours of service and expenses in
a form prescribed by the Company every two weeks and such statement shall be approved by the
contact person listed above or other designated agent of the Company.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/
Gajus Worthington</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Richard DeLateur</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="1" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Fluidigm Corporation </DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Consultant</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;This page is to be signed ONLY at the termination of the Consulting Agreement&#093;
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><u><B>EXHIBIT B</B></u>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>FLUIDIGM</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>CERTIFICATION OF RETURN OF COMPANY PROPERTY AND INFORMATION</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This is to certify that I do not have in my possession, nor have I failed to return, any devices,
records, software, data, notes, reports, proposals, lists, and sources of customers, lists of
employees, proposals to customers, drafts of proposals, business plans and projections, reports,
job notes, correspondence, specifications, drawings, blueprints, sketches, materials, equipment,
other documents or property, or reproductions of any aforementioned items belonging to Fluidigm,
its subsidiaries, affiliates, successors or assigns (together, the &#147;Company&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">I further certify that I have complied with all terms of the Company&#146;s confidential and proprietary
information provisions in the Consulting Agreement signed by me, including the reporting of any
inventions and original works of authorship (as defined therein) conceived or made by me (solely or
jointly with others) covered by that Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">I further agree that, in compliance with the Consulting Agreement, I will preserve as confidential
all trade secrets, confidential knowledge, data or other proprietary information relating to
products, processes, know-how, designs, formulas, developmental or experimental work, computer
programs, data bases, other original works of authorship, customer lists, business plans, financial
information or other subject matter pertaining to any business of the Company of any of its
customers, consultants or licensees.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="60%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Signature</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><u><B>EXHIBIT C</B></u>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>LIST OF PRIOR INVENTIONS<BR>
AND ORIGINAL WORKS OF AUTHORSHIP</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>IDENTIFYING NUMBER OR</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>TITLE</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>DATE</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>BRIEF DESCRIPTION</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>29
<FILENAME>f39432orexv10w15.htm
<DESCRIPTION>EXHIBIT 10.15
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w15</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.15</B>
</DIV>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EMPLOYEE LOAN AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIS EMPLOYEE LOAN AGREEMENT (the &#147;<U>Agreement</U>&#148;) is entered into as of January&nbsp;20, 2004,
by and between Fluidigm Corporation, a California corporation (the &#147;<U>Lender</U>&#148;), and Gajus V.
Worthington (&#147;<U>Borrower</U>&#148;).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>RECITALS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A.&nbsp;Borrower is employed by the Lender as its Chief Executive Officer and President.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B.&nbsp;The Lender and Borrower desire that the Lender lend to Borrower the sum of Two Hundred
Fifty Thousand Dollars ($250,000.00) for the purposes described in Section&nbsp;1 below.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C.&nbsp;Borrower owns 2,447,000 shares of the Common Stock of the Lender, of which 833,334 shares,
together with the other collateral described in the Stock Pledge Agreement, shall constitute
security for the Loan (as defined below).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, the Lender and Borrower agree as follows:
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;PAYMENT: The Lender will lend to Borrower the amount of Two Hundred Fifty Thousand Dollars
($250,000.00) (the &#147;<U>Loan</U>&#148;), such Loan to be made for the purposes of assisting Borrower to
pay any costs, fees, or expenses (including, without limitation, purchase consideration, broker&#146;s
or agents commissions, mortgage points, closing costs, or similar costs or expenses) associated
with Borrower&#146;s purchase of a principal residence in the San Francisco Bay Area (the
&#147;<U>Property</U>&#148;) and/or any improvements or other modifications made to any Property so
purchased.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;CONDITIONS PRECEDENT: The Lender&#146;s obligation to extend the Loan to Borrower pursuant to
this Agreement is expressly conditioned upon the satisfaction of or waiver by the Lender of all of
the following conditions precedent, each of which is exclusively for the benefit of the Lender:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 Borrower shall have delivered to the Lender each of the following (herein collectively
referred to as &#147;<U>Loan Documents</U>&#148;):
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;One (1)&nbsp;original promissory note in the amount of Two Hundred Fifty Thousand Dollars
($250,000.00) in substantially the same form as <U>Exhibit&nbsp;A</U> attached hereto (the
&#147;<U>Note</U>&#148;), with all uncompleted information fully completed;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;One (1)&nbsp;fully executed, validly acknowledged Stock Pledge Agreement, providing for the
pledge of 833,334 shares of Common Stock of the Lender and certain other collateral as security for
the Note (collectively, the &#147;<U>Pledged Collateral</U>&#148;), in substantially the same form as
<U>Exhibit&nbsp;B</U> attached hereto, with all uncompleted information fully completed (the &#147;<U>Stock
Pledge Agreement</U>&#148;);
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->C-1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Two (2)&nbsp;fully executed Stock Powers and Assignments Separate From Certificate attached as
a part of <U>Exhibit&nbsp;B</U> hereto, with all uncompleted information fully completed, unless
otherwise indicated thereon (the &#147;<U>Stock Power</U>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;All certificates representing the securities that constitute Pledged Collateral as of the
date of the closing of the Loan; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;Two (2)&nbsp;fully executed Spousal Consents, in substantially the same form as
<U>Exhibit&nbsp;C</U> attached hereto, with all uncompleted information fully completed (the
&#147;<U>Spousal Consent</U>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;BORROWER&#146;S REPRESENTATIONS AND WARRANTIES: Borrower hereby makes the following
representations and warranties to the Lender, which representations and warranties shall be true
and correct as of the date hereof and as of the date of the closing of the Loan, and Borrower
acknowledges that the Lender is relying on such representations in making the Loan:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 The Borrower has good and marketable title to the Pledged Collateral free and clear of any
security interests, liens or encumbrances other than (i)&nbsp;joint ownership of the Pledged Collateral
with Borrower&#146;s spouse, and (ii)&nbsp;a right of first refusal and certain repurchase rights in favor of
Lender. All of the shares that constitute Pledged Collateral are fully vested.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 Other than the consent of Borrower&#146;s spouse and the Lender, the consent of no other person
or entity is required to grant the Lender the security interest in the Pledged Collateral.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3 There are no actions, proceedings, claims or disputes pending or, to Borrower&#146;s knowledge,
threatened against or affecting Borrower, the Pledged Collateral, or any other properties of
Borrower.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;BORROWER&#146;S ADDITIONAL OBLIGATIONS: Borrower shall take any and all further actions that may
from time to time be required to ensure that the Stock Pledge Agreement creates a security interest
in favor of the Lender, which shall secure the Note. Borrower shall not sell, hypothecate or
otherwise dispose of any interest in the Pledged Collateral and shall not encumber the Pledged
Collateral or permit any lien to encumber the Pledged Collateral.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;REPAYMENT OF LOAN: Borrower shall pay to the Lender the outstanding principal balance of
the Note, together with all accrued, but unpaid interest thereon, and all other sums due hereunder,
under the Note, the Stock Pledge Agreement or under any other document executed by Borrower in
connection herewith in accordance with the terms and conditions of this Agreement, the Note, the
Stock Pledge Agreement or such other document.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;MATURITY EVENT: The Note shall immediately become due and payable, without notice or
demand, upon the earlier to occur of January&nbsp;20, 2011 or the occurrence of any &#147;Maturity Event&#148; as
defined in the Note.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;INTEREST PAYABLE BY BORROWER: Interest shall accrue on the unpaid principal amounts of the
Note at the rate specified in the Note.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;ENTIRE AGREEMENT: This Agreement, together with the Loan Documents, constitutes the full
and entire understanding and agreement between the parties hereto with regard to the subject matter
hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;NO COVENANT FOR EMPLOYMENT OR ADVANCES: Borrower understands and acknowledges that neither
this Agreement nor any other Loan Document modifies Borrower&#146;s at-will status at the Lender and
does not constitute an employment agreement or a promise by the Lender to continue Borrower&#146;s
employment. Either the Lender or Borrower may terminate such employment relationship at any time,
with or without cause.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;NOTICES: All notices and other communications required or permitted hereunder shall be in
writing and may be given by (a)&nbsp;personal delivery, (b)&nbsp;certified mail, postage prepaid,
return-receipt requested, (c)&nbsp;courier service, fully prepaid for next business day delivery, or (d)
facsimile. Any such notice shall be properly addressed to the address of the parties set forth on
the signature page hereof and shall be deemed to have been given (i)&nbsp;if personally delivered, when
delivered, (ii)&nbsp;if by certified mail, return-receipt requested, when delivered or refused, (iii)&nbsp;if
by courier service, on the next business day following deposit, cost prepaid, with Federal Express
or similar private carrier, or (iv)&nbsp;if by facsimile, instantaneously upon confirmation of receipt
of facsimile. The Lender or Borrower may change their respective addresses by giving notice of the
same in accordance with this paragraph. The term &#147;business day&#148; shall mean a day on which national
banks are open for business in San Francisco, California.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;ASSIGNMENT: Borrower may not assign any of his rights and/or duties under this Agreement
(or any other Loan Document) without the prior written consent of the Lender, which consent may be
withheld in the sole discretion of Lender. All of the rights and/or duties of the Lender under the
Loan Documents, or any of them, shall be freely assignable. Subject to the foregoing, the rights
and obligations of the Borrower and Lender under the Loan Documents shall be binding upon and shall
inure to the benefit of the Borrower and Lender and their respective personal representatives,
successors, heirs, and permitted assigns.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;INCOME TAX CONSEQUENCES: <B>Borrower hereby acknowledges that the Lender has made no
representation or warranty to Borrower concerning the income tax consequences of the loan to
Borrower and Borrower shall be solely responsible for ascertaining and bearing such tax
consequences</B>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;GOVERNING LAW: This Agreement shall be governed in all respects by the laws of the State
of California.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.&nbsp;HEADINGS: The titles and headings of the various paragraphs hereof are intended for means
of reference and are not intended to place any construction on the provisions hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.&nbsp;INVALIDITY: If any provision of this Agreement shall be invalid or unenforceable, the
remaining provisions shall not be affected thereby and every provision hereof shall be valid and
enforceable to the fullest extent permitted by law.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.&nbsp;COUNTERPARTS: This Agreement may be executed in one (1)&nbsp;or more separate counterparts,
each of which, when so executed, shall be deemed to be an original. Such counterparts, together,
shall constitute one and the same instrument.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17.&nbsp;MISCELLANEOUS: Time is of the essence of this Agreement, the Loan Documents, and any other
document executed by Borrower in connection therewith. If any action shall be commenced between the
parties with respect to the Loan, the prevailing party shall be entitled to recover its reasonable
attorneys&#146; fees and expenses from the non-prevailing party or parties. Liability hereunder shall
be joint and several among Borrower and all other persons and entities now or hereafter liable for
all or any part of the Loan. <B>Notwithstanding any provision above to the contrary, the Lender may
waive in writing or by notation initialed hereon any obligation of Borrower provided for herein.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.&nbsp;JURY TRIAL: EACH OF LENDER AND BORROWER TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW
HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY AS TO ANY ISSUE RELATING HERETO IN ANY ACTION,
PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE NOTE OR THE STOCK
PLEDGE AGREEMENT.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first written
above.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><B>BORROWER:</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>THE LENDER:</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">FLUIDIGM CORPORATION</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Gajus V. Worthington
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Gajus V. Worthington
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Erik T. Engelson
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Name: Erik T. Engelson</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Title: Chief Financial Officer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="28%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Address:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address: 7100 Shoreline Court</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>

    <TD colspan="2" align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;South San Francisco, California 94080</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>

    <TD colspan="2" align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Telephone:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Telephone: (650)&nbsp;266-6000</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Facsimile:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Facsimile: (650)&nbsp;871-7152</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15A
<SEQUENCE>30
<FILENAME>f39432orexv10w15a.htm
<DESCRIPTION>EXHIBIT 10.15A
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w15a</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.15A</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FLUIDIGM CORPORATION</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>STOCK REPURCHASE AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This agreement is made this 10<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> day of April&nbsp;2008, between Fluidigm Corporation, a
Delaware corporation (the &#147;Company&#148;) and Gajus V. Worthington (the &#147;Founder&#148;).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>Recitals</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Company and the Founder are parties to that certain Employee Loan Agreement (the
&#147;Loan Agreement&#148;), Secured Promissory Note (the &#147;Note&#148;) and Stock Pledge Agreement (the &#147;Pledge
Agreement&#148; and together, the &#147;Loan Agreements&#148;), each dated January&nbsp;20, 2004, pursuant to which the
Company loaned the Founder $250,000 at an interest rate of 3.52% per annum (the &#147;Loan&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Loan is secured pursuant to the Pledge Agreement by 833,334 shares of the
Company&#146;s common stock;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Founder desires to repay the Loan in connection with the initial public offering
of the Company&#146;s common stock in accordance with Section&nbsp;2.2(d) of the Note by selling 90,913
shares of Company common stock (the &#147;Shares&#148;) held by the Founder to the Company at purchase price
of $3.19 per share (the &#147;Share Price&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Share Price was agreed to pursuant to an independent valuation report received by
the Company and prepared by VRC, with a valuation date of April&nbsp;9, 2008, in which it determined the
fair market value of the Company&#146;s common stock to be $3.19 per share.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Company desires to accept repayment of the Loan by repurchasing the Shares at the
Share Price from the Founder and canceling the Note pursuant to the terms and conditions contained
in this Agreement and the Loan Agreements.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>Agreement</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW THEREFORE, in consideration of the mutual promises made herein, the parties agree as
follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Stock Repurchase</U>. Upon the Closing Date (as defined below), the Company hereby
agrees to repurchase from the Founder, and the Founder hereby agrees to sell to the Company, the
Shares, at the Share Price and for an aggregate repurchase price specified in Section&nbsp;2 below.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From and after the payment of the repurchase price by the Company in the manner set forth in
Section&nbsp;2 below, the Founder&#146;s rights as a stockholder with respect to the Shares, including
without limitation the right to vote or receive cash or stock dividends, shall cease. Upon payment
in full of such repurchase price as specified in Section&nbsp;2 below, the Shares shall be retired and
eliminated from the shares which the Company shall be authorized to issue.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Closing</U>. The closing of the sale and purchase of the Shares (the &#147;Closing&#148;) shall
be on April&nbsp;10, 2008 or on such other date as the parties may agree (the &#147;Closing Date&#148;). At or
before the Closing, the Founder shall deliver the stock certificate representing the Shares, duly
endorsed on the reverse side for transfer to the Company, and the Company shall deliver payment to
the Founder of the aggregate repurchase price of $290,014.38 by canceling and delivering the Note
marked &#147;canceled&#148; in the principal amount of $250,000, plus $40,014.38 as of April&nbsp;10, 2008 in
accrued interest.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Release</U>. In exchange for the repurchase of the Shares described above, the Company
hereby releases you from all obligations under the Loan Agreements. The Company acknowledges that
the Note has been repaid in full and has been canceled.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Founder&#146;s Representations</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1. The Shares are duly authorized, validly issued and are fully paid and non-assessable.
Founder is the sole owner of the Shares, and has good and marketable title to the Shares free and
clear of any security interests, liens or encumbrances other than (i)&nbsp;joint ownership of the Shares
with Founder&#146;s spouse; (ii)&nbsp;a right of first refusal and repurchase rights in favor of the Company
entered into in connection with the purchase of the Shares; and (iii)&nbsp;the Stock Pledge Agreement in
favor of Company&#146;s securing the Note. The Shares are fully vested.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2. Founder represents and warrants that the Founder has had the opportunity to consult with
his own tax, legal and investment advisors regarding the sale of the Shares to the Company.
Founder represents that he is familiar with the Company&#146;s business and financial conditions by
virtue of position with the Company and has the capacity to protect his own interests in connection
with the repurchase of the Shares. Founder acknowledges that the Share Price is fair and equitable
to him. In addition, Founder acknowledges that the Company may effect an initial public offering
or other financing in the future, and such financing may be at a price substantially greater than
the Share Price. Founder acknowledges that this Agreement does not confer upon Founder any right
with respect to continuing as an employee or other service provider of the Company, nor will it
interfere in any way with the Founder&#146;s right or the Company&#146;s right to terminate such relationship
at any time, with or without cause, to the extent permitted by applicable laws. Founder
acknowledges that the Company has no obligation (past, present or future) to issue to Founder any
shares of the Company&#146;s capital stock. Founder agrees that this Agreement represents a negotiated
transaction and that no offering was conducted by the Founder in connection herewith.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>General Provisions</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A. This Agreement shall be governed, construed and enforced in accordance with the laws of the
state of California, except with respect to its choice of law provisions. In the event that any
provision of this Agreement becomes or is declared by a court of competent jurisdiction to be
illegal, unenforceable, or void, this Agreement shall continue in full force and effect without
such provision.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B. This Agreement represents the entire agreement between the parties with respect to the
repurchase of the Shares by the Company from the Founder and supersedes any prior or concurrent
representations or agreements with respect to such repurchase and the repayment of the Note. This
Agreement may only be modified or amended by a writing signed by both parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C. The Company and Founder agree upon the request of either party to execute such further
documents or instruments as may be necessary or desirable to carry out the purposes and intent of
this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D. This Agreement may be executed in any number of counterparts, each of which shall be an
original, but all of which together shall constitute one instrument.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><I>&#091;Signature Page Follows&#093;</I>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed this Agreement as of the first date above.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">"<B>COMPANY</B>&#148;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">"<B>FOUNDER</B>&#148;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>FLUIDIGM CORPORATION</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Vikram Jog
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gajus V. Worthington</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vikram Jog<BR>
Chief Financial Officer
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Gajus V. Worthington</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>31
<FILENAME>f39432orexv10w16.htm
<DESCRIPTION>EXHIBIT 10.16
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w16</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 18pt"><B>Exhibit
10.16</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">
<IMG src="f39432ore3943202.gif" alt="(FLUIDIGM LOGO)">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">January&nbsp;29, 2008

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Vikram Jog<BR>
914 Lundy Lane<BR>
Los Altos, California 94024

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Dear Vikram:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I am pleased to offer you a position with Fluidigm Corporation (the &#147;Company&#148;) as Chief
Financial Officer reporting to me commencing no later than Tuesday, February&nbsp;19, 2008. You will
receive a semi-monthly salary of $11,583.34 (equivalent to an annual salary of $278,000.00) less
deductions required by law, which will be paid in accordance with the Company&#146;s normal payroll
procedures.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, you will receive a $20,000 signing bonus (subject to all applicable federal and
state taxes and to full repayment if you terminate your employment with Fluidigm prior to your
one-year anniversary) with your first payroll.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You will be eligible to participate in the Company&#146;s executive annual bonus program which is
based on achievement of targets or performance criteria as may be specified by the Board. The terms
and conditions of the executive annual program may be amended or varied from time to time at the
sole discretion of the Board. The projected annual bonus for 2008 is estimated to be a maximum of
35% of the employee&#146;s annual base salary, subject to all applicable federal and state taxes,
payable on February&nbsp;13, 2009 and pro-rated on a monthly basis, if less than 12&nbsp;months&#146; service as
of December&nbsp;31<SUP style="font-size: 85%; vertical-align: text-top">st</SUP>, 2008. The primary principle for payout of variable cash bonus is &#147;pay
for performance.&#148; Bonuses for executives will be 35% at 100%o of plan, payable as follows:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>80% of bonus is for meeting corporate goals.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>20% of bonus is for meeting departmental goals.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The bonus will begin to be paid at meeting 80% of plan.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At the next Board meeting, or at the next committee meeting with requisite authorization,
after you become an employee of the Company, the Company will grant you an option to purchase up
to 500,000 shares of the Common Stock of the Company, at an exercise price equal to the fair
market value of the shares at that time. 1/4th of said options will vest and become exercisable
one year after the commencement of your employment with the Company
and an additional 1/48th of
said options will vest and become exercisable at the end of each month after said one year
period. These options will be subject to Board approval and the terms of the Company&#146;s stock
option plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furthermore, at the same board meeting, or at the next committee meeting with requisite
authorization, the Company will grant you additional options to purchase (i)&nbsp;50,000 shares of the
Common Stock of the Company, at an exercise price equal to the fair market value of the shares
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Fluidigm Corporation</B><BR>
7000 Shoreline Court, Suite&nbsp;100, South San Francisco, California 94080 tel: 650.266.6000 fax: 650.871.7152 www.fluidigm.com
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">at that time. These options will vest at the end of 2008 in conjunction with the company
achieving its corporate goals (see Corporate Goals in the attached appendix A), and (ii)&nbsp;50,000
shares of the Common Stock of the Company, at an exercise price equal to the fair market value of
the shares at that time. These options will vest on the earlier of (a)&nbsp;achievement of
departmental goals so long as the goals are achieved in 2008 (see Departmental Goals in the
attached appendix A), or (b)&nbsp;December&nbsp;31, 2011. Pay-out for partial achievement of goals will be
at the discretion of the Compensation Committee. Goals can also be adjusted with approval by the
CEO and the Compensation committee.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You are eligible to receive the Company&#146;s standard benefits package which includes medical,
dental, vision, life and disability insurance benefits. Additional benefits, as the company may
make generally available to its employees from time to time, will be made available to you. You
will be entitled to 4&nbsp;weeks paid vacation each year and such paid holidays as the Company gives
to its employees generally.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You should be aware that your employment with the Company is for no specified period and
constitutes at-will employment. As a result, you are free to resign at any time, for any reason
or for no reason. Similarly, the Company is free to conclude its employment relationship with you
at any time, with or without cause.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your employment contract will also contain certain change of control and termination without
cause provisions, summarized below:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Termination &#147;Without Cause&#148; prior to a change of control
results in: (i)&nbsp;6&nbsp;months severance paid as salary continuation, plus (ii)&nbsp;up
to 6&nbsp;months of reimbursement for COBRA expenses.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Termination &#147;Without Cause&#148; after 12&nbsp;months following a
change of control results in: (i)&nbsp;6&nbsp;months severance paid as salary
continuation, plus (ii)&nbsp;up to 3&nbsp;months of reimbursement for COBRA expenses.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Termination &#147;Without Cause&#148; or for &#147;Good Reason&#148; within 12
months following a change of control results in: (i)&nbsp;6&nbsp;months severance paid
in lump sum, plus (ii)&nbsp;acceleration of all unvested options and restricted
stock, and (iii)&nbsp;up to 6&nbsp;months of reimbursement for COBRA expenses.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If benefits are subject to 280G parachute payment excise
taxes, then the executive will receive the &#147;best of (i)&nbsp;the benefits
delivered in full and subject to the excise tax, or (ii)&nbsp;reduced benefits
such that no excise tax is applied.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the case of (i)&nbsp;death, (ii)&nbsp;disability, (iii)&nbsp;termination
for cause, or (iv)&nbsp;termination that is voluntary and is not for Good Reason
within 12&nbsp;months of a change of control, then the executive gets no
severance, and only salary and other employee benefits that are owing and due
through date of termination of employment.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Fluidigm Corporation</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">7000 Shoreline Court, Suite&nbsp;100, South San Francisco, California 94080 tel: 650.266.6000 fax: 650.871.7152 www.fluidigm.com

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the above, the final language and provisions of change of control clauses of
your employment contract are subject to Board approval.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For purposes of federal immigration law, you will be required to provide to the Company
documentary evidence of your identity and eligibility for employment in the United States. Such
documentation must be provided to us within three (3)&nbsp;business days of your date of hire, or our
employment relationship with you may be terminated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You understand that as a condition of your employment you will be required to sign the
Company&#146;s standard proprietary information agreement which the Company will be providing you with
shortly.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To indicate your acceptance of the Company&#146;s offer, please sign and date this letter in the
space provided below and return/fax it to me at (650)&nbsp;871-7192. This offer expires on Tuesday,
January&nbsp;29, 2008 at midnight. A copy is provided for your records. This letter, along with the
agreement relating to proprietary rights between you and the Company, set forth the terms of your
employment with the Company and supersede any prior representations or agreements, whether written
or oral. This letter may not be modified or amended except by a written agreement, signed by the
Company and by you.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Vikram, we look forward to working with you at Fluidigm Corporation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Sincerely,
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><u>/s/
Gajus Worthington&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Gajus Worthington</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">President and Chief Executive Officer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Fluidigm Corporation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Encl.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">ACCEPTED AND AGREED TO:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">


<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/&nbsp;&nbsp;Vikram
Jog
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1/29/2008&nbsp;</TD>
</TR>

<TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Vikram Jog
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Fluidigm Corporation</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">7000 Shoreline Court, Suite&nbsp;100, South San Francisco, California 94080&nbsp; tel: 650.266.6000&nbsp; fax: 650.871.7152&nbsp; www.fluidigm.com

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">FLUIDIGM CONFIDENTIAL<BR>
Appendix&nbsp;A
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">2008 Fluidigm Corporate goals:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Revenues of $ 18M (&#062;100% year-on-year growth)<BR></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>50%&#043; margins throughout the year</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Conduct IPO in 2008 &#151;$300M&#043; pre-money valuation, raising &#062;$60M<BR></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Meet expense budget/cash burn</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Finance Specific for 2008:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Revenue recognition</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>


    <TD COLSPAN="3">a ) No material changes upon quarterly reviews and annual audit.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Accurate (no material restatements), timely (within 3 to 4&nbsp;weeks of quarter end) closing of
books and reporting (timeliness as required by investors and SEC).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>SEC and SOX compliance, as needed.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Produce audited financial statements for 2005, 2006 and 2007 (and Q1 2008, if necessary) to
enable the filing of Form S-1 registration statement in 1H08 (together with legal).</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Fluidigm Corporation</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">7000
Shoreline Court, Suite&nbsp;100, South San Francisco, California
94080&nbsp; tel: 650.266.6000&nbsp; fax: 650.871.7152&nbsp; www.fluidigm.com

</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FLUIDIGM CORPORATION</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>EMPLOYMENT, CONFIDENTIAL INFORMATION AND<BR>
INVENTION ASSIGNMENT AGREEMENT</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a condition of my employment with FLUIDIGM Corporation, its subsidiaries, affiliates,
successors or assigns (together the &#147;Company&#148;), and in consideration of my employment with the
Company and my receipt of the compensation now and hereafter paid to me by the Company, I agree to
the following:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U><B>At-Will
Employment</B></U>. I understand and acknowledge that my employment with the
Company is for an unspecified duration and constitutes &#147;at-will&#148; employment. I acknowledge that
this employment relationship may be terminated at any time, with or without good cause or for any
or no cause, at the option either of the Company or myself.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U><B>Confidential Information</B></U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U><B>Company Information</B></U>. I agree at all times during the term of my employment and
thereafter, to hold in strictest confidence, and not to use, except for the benefit of the Company,
or to disclose to any person, firm or corporation without written authorization of the Board of
Directors of the Company, any Confidential Information of the Company. I understand that
&#147;Confidential Information&#148; means any Company proprietary information, technical data, trade secrets
or know-how, including, but not limited to, research, product plans, products, services, customer
lists and customers (including, but not limited to, customers of the Company on whom I called or
with whom I became acquainted during the term of my employment), markets, software, developments,
inventions, processes, formulas, technology, designs, drawings, engineering, hardware configuration
information, marketing, finances or other business information disclosed to me by the Company
either directly or indirectly in writing, orally or by drawings or observation of parts or
equipment. I further understand that Confidential Information does not include any of the foregoing
items which has become publicly known and made generally available through no wrongful act of mine
or of others who were under confidentiality obligations as to the item or items involved.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)
<U><b>Former Employer Information</b></U>. I agree that I will not, during my employment with
the Company, improperly use or disclose any proprietary information or trade secrets of any former
or concurrent employer or other person or entity and that I will not bring onto the premises of the
Company any unpublished document or proprietary information belonging to any such employer, person
or entity unless consented to in writing by such employer, person or entity.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U><B>Third Party Information</B></U>. I recognize that the Company has received and in
the future will receive from third parties their confidential or proprietary information subject to
a duty on the Company&#146;s part to maintain the confidentiality of such information and to use it only
for certain limited purposes. I agree to hold all such confidential or proprietary information in
the strictest confidence and not to disclose it to any person, firm or corporation or to use it
except as necessary in carrying out my work for the Company consistent with the Company&#146;s agreement
with such third party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U><B>Inventions</B></U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U><B>Inventions Retained and Licensed</B></U>. I have attached hereto, as <U>Exhibit&nbsp;A</U>, a
list describing all inventions, original works of authorship, developments, improvements, and trade
secrets which were made by me prior to my employment with the Company (collectively referred to as
&#147;Prior inventions&#148;), which belong to me, which relate to the Company&#146;s proposed business, products
or research and development, and which are not assigned to the Company hereunder; or, if no such
list is attached, I represent that there are no such Prior Inventions. If in the course of my
employment with the Company, I incorporate into a Company product, process or machine a Prior
Invention owned by me or in which I have an interest, the Company is hereby granted and shall have
a nonexclusive, royalty-free, irrevocable, perpetual, worldwide license to make, have made, modify,
use and sell such Prior Invention as part of or in connection with such product, process or
machine.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U><B>Assignment of Inventions</B></U>. I agree that I will promptly make full written
disclosure to the Company, will hold in trust for the sole right and benefit of the Company, and
hereby assign to the Company, or its designee, all my right, title, and interest in and to any and
all inventions, original works of authorship, developments, concepts, improvements or trade
secrets, whether or not patentable or registrable under copyright or similar laws, which I may
solely or jointly conceive or develop or reduce to practice, or cause to be conceived or developed
or reduced to practice, during the period of time I am in the employ of the Company (collectively
referred to as &#147;Inventions&#148;), except as provided in Section 3(f) below. I further acknowledge that
all original works of authorship which are made by me (solely or jointly with others) within the
scope of and during the period of my employment with the Company and which are protectible by
copyright are &#147;works made for hire,&#148; as that term is defined in the United States Copyright Act.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U><B>Inventions Assigned to the United States</B></U>. I agree to assign to the United States
government all my right, title, and interest in and to any and all Inventions whenever such full
title is required to be in the United States by a contract between the Company and the United
States or any of its agencies.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U><B>Maintenance of Records</B></U>. I agree to keep and maintain adequate and current written
records of all Inventions made by me (solely or jointly with others) during the term of my
employment with the Company. The records will be in the form of notes, sketches, drawings, and any
other format that may be specified by the Company. The records will be available to and remain the
sole property of the Company at all times.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U><B>Patent and Copyright Registrations</B></U>. I agree to assist the Company, or its
designee, at the Company&#146;s expense, in every proper way to secure the Company&#146;s rights in the
Inventions and any copyrights, patents, mask work rights or other intellectual property rights
relating thereto in any and all countries, including the disclosure to the Company of all pertinent
information and data with respect thereto, the execution of all applications, specifications,
oaths, assignments and all other instruments which the Company shall deem necessary in order to
apply for and obtain such rights and in order to assign and convey to the Company, its successors,
assigns, and nominees the sole and exclusive rights, title and interest in and to such Inventions,
and any copyrights, patents, mask work rights or other intellectual property rights relating
thereto. I further agree that my obligation to execute or cause to be executed, when it is in my
power to do so, any such instrument or papers shall continue after the termination of this
Agreement. If the Company is unable because of my mental or physical incapacity or for any other
reason to secure my signature to apply for or to pursue any application for any United States or
foreign patents or copyright registrations covering Inventions or original works of authorship
assigned to the Company as above, then I hereby irrevocably designate and appoint the Company and
its duly authorized officers and agents as my agent and attorney in fact, to act for and in my
behalf and stead to execute and file any such applications and to do all other lawfully permitted
acts to further the prosecution and issuance of letters patent or copyright registrations thereon
with the same legal force and effect as if executed by me.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U><B>Exception to Assignments</B></U>. I understand that the provisions of this
Agreement requiring assignment of Inventions to the Company do not apply to any invention which
qualifies fully under the provisions of California Labor Code Section&nbsp;2870 (attached hereto as
<U>Exhibit&nbsp;B</U>). I will advise the Company promptly in writing of any inventions that I believe
meet the criteria in California Labor Code Section&nbsp;2870 and not otherwise disclosed on <U>Exhibit
A</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U><B>Conflicting Employment</B></U>. I agree that, during the term of my employment with the
Company, I will not engage in any other employment, occupation, consulting or other business
activity directly related to the business in which the Company is now involved or becomes involved
during the term of my employment, nor will I engage in any other activities that conflict with my
obligations to the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U><B>Returning Company Documents</B></U>. I agree that, at the time of leaving the employ of
the Company, I will deliver to the Company (and will not keep in my possession, recreate or
deliver to anyone else) any and all devices, records, data, notes, reports, proposals, lists,
correspondence, specifications, drawings blueprints, sketches, materials, equipment, other
documents or property, or reproductions of any aforementioned items developed by me pursuant to my
employment with the Company or otherwise belonging to the Company, its successors or assigns. In
the event of the termination of my employment, I agree to sign and deliver the &#145;Termination
Certification&#148; attached hereto as <U>Exhibit&nbsp;C</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U><B>Notification of New Employer</B></U>. In the event that I leave the employ of the Company,
I hereby grant consent to notification by the Company to my new employer about my rights and
obligations under this Agreement.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U><B>Solicitation of Employees</B></U>. I agree that for a period of twelve (12)&nbsp;months
immediately following the termination of my relationship with the Company for any reason, whether
with or without cause, I shall not either directly or indirectly solicit, induce, recruit or
encourage any of the Company&#146;s employees to leave their employment, or take away such employees, or
attempt to solicit, induce, recruit, encourage or take away employees of the Company, either for
myself or for any other person or entity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U><B>Conflict of Interest Guidelines</B></U>. I agree to diligently adhere to the Conflict
of Interest Guidelines attached as <U>Exhibit&nbsp;D</U> hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U><B>Representations</B></U>. I agree to execute any proper oath or verify any proper document
required to carry out the terms of this Agreement. I represent that my performance of all the terms
of this Agreement will not breach any agreement to keep in confidence proprietary information
acquired by me in confidence or in trust prior to my employment by the Company. I have not entered
into, and I agree I will not enter into, any oral or written agreement in conflict herewith.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U><B>Arbitration and Equitable Relief</B></U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)
<U><b>Arbitration</b></U>. Except as provided in Section 10(b) below, I agree that any dispute
or controversy arising out of or relating to any interpretation, construction, performance or
breach of this Agreement, shall be settled by arbitration to be held in Santa Clara County,
California, in accordance with the rules then in effect of the American Arbitration Association.
The arbitrator may grant injunctions or other relief in such dispute or controversy. The decision
of the arbitrator shall be final, conclusive and binding on the parties to the arbitration.
Judgment may be entered on the arbitrator&#146;s decision in any court having jurisdiction. The Company
and I shall each pay one-half of the costs and expenses of such arbitration, and each of us shall
separately pay our counsel fees and expenses.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)
<U><b>Equitable Remedies</b></U>. I agree that it would be impossible or inadequate to measure
and calculate the Company&#146;s damages from any breach of the covenants set forth in Sections&nbsp;2, 3,
and 5 herein. Accordingly, I agree that if I breach any of such Sections, the Company will have
available, in addition to any other right or remedy available, the right to obtain an injunction
from a court of competent jurisdiction restraining such breach or threatened breach and to specific
performance of any such provision of this Agreement. I further agree that no bond or other security
shall be required in obtaining such equitable relief and I hereby consent to the issuance of such
injunction and to the ordering of specific performance.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<U><B>General Provisions</B></U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U><B>Governing Law; Consent to Personal Jurisdiction</B></U>. This Agreement will be
governed by the laws of the State of California, without reference to choice of laws or conflict
of laws principles. I hereby expressly consent to the personal jurisdiction of the state and
federal courts located in California for any lawsuit filed there against me by the Company arising
from or relating to this Agreement.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U><B>Entire Agreement</B></U>. This Agreement sets forth the entire agreement and
understanding between the Company and me relating to the subject matter herein and merges all
prior discussions between us. No modification of or amendment to this Agreement, nor any waiver
of any rights under this agreement, will be effective unless in writing signed by the party to
be charged. Any subsequent change or changes in my duties, salary or compensation will not
affect the validity or scope of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U><B>Severability</B></U>. If one or more of the provisions in this Agreement are deemed
void by law, then the remaining provisions will continue in full force and effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U><B>Successors and Assigns</B></U>. This Agreement will be binding upon my heirs,
executors, administrators and other legal representatives and will be for the benefit of
the Company, its successors, and its assigns.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="38%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">02/25/2008&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top">Signature&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/
Vikram Jog</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name of Employee (typed or
printed)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vikram Jog</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD colspan="3" align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Denise Jimenez</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>


<TR style="font-size: 1px">

<TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>



<TR valign="bottom">
    <TD align="left" valign="top"><DIV style="margin-left:0px; text-indent:-0px">Witness</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="CENTER" style="font-size: 10pt; margin-top: 6pt"><U><B>EXHIBIT A</B></U>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>LIST OF PRIOR INVENTIONS<BR>
AND ORIGINAL WORKS OF AUTHORSHIP</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">Identifying Number</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">

<TD nowrap align="left" style="border-bottom: 1px solid #000000; margin-left:75px; text-indent:75px">Title</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">Date</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">or Brief Description</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>No inventions or improvements
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>Additional Sheets Attached
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="68%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Employee:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD align="left" valign="top" colspan="2"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top" nowrap><DIV style="margin-left:0px; text-indent:-0px">Print Name of Employee:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top" colspan="3"><DIV style="margin-left:0px; text-indent:-0px">Date: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> ,<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT B</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>CALIFORNIA LABOR CODE SECTION 2870<BR>
EMPLOYMENT AGREEMENTS; ASSIGNMENT OF RIGHTS</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;(a) Any provision in an employment agreement which provides that an employee shall
assign, or offer to assign, any of his or her rights in an invention to his or her employer shall
not apply to an invention that the employee developed entirely on his or her own time without using
the employer&#146;s equipment, supplies, facilities, or trade secret information except for those
inventions that either:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;Relate at the time of conception or reduction to practice of the invention to the
employer&#146;s business, or actual or demonstrably anticipated research or development of the employer.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;Result from any work performed by the employee for the employer.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;To the extent a provision in an employment agreement purports to require an
employee to assign an invention otherwise excluded from being required to be assigned under
subdivision (a), the provision is against the public policy of this state and is
unenforceable.&#148;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT C</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>FLUIDIGM CORPORATION</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>TERMINATION CERTIFICATION</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This is to certify that I do not have in my possession, nor have I failed to return, any
devices, records, data, notes, reports, proposals, lists, correspondence, specifications, drawings,
blueprints, sketches, materials, equipment, other documents or property, or reproductions of any
aforementioned items belonging to <B>FLUIDIGM Corporation, </B>its subsidiaries, affiliates, successors or
assigns (together, the &#147;Company&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I further certify that I have complied with all the terms of the Company&#146;s Employment
Confidential Information and Invention Assignment Agreement signed by me, including the reporting
of any inventions and original works of authorship (as defined therein), conceived or made by me
(solely or jointly with others) covered by that agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I further agree that, in compliance with the Employment, Confidential Information and
Invention Assignment Agreement, I will preserve as confidential all trade secrets, confidential
knowledge, data or other proprietary information relating to products, processes, know-how,
designs, formulas, developmental or experimental work, computer programs, data bases, other
original works of authorship, customer lists, business plans, financial information or other
subject matter pertaining to any business of the Company or any of its employees, clients,
consultants or licensees.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I further agree that for twelve (12)&nbsp;months from this date, I will not solicit, induce,
recruit or encourage any of the Company&#146;s employees to leave their employment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Date: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="60%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="39%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(Employee&#146;s Signature)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>


<tr>
    <TD>&nbsp;</TD>
</tr>

<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(Type/Print Employee&#146;s Name)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT D</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>FLUIDIGM CORPORATION</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>CONFLICT OF INTEREST GUIDELINES</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It
is the policy of <b>FLUIDIGM Corporation</b> to conduct its affairs in strict compliance with the
letter and spirit of the law and to adhere to the highest principles of business ethics.
Accordingly, all officers, employees and independent contractors must avoid activities which are in
conflict, or give the appearance of being in conflict, with these principles and with the interests
of the Company. The following are potentially compromising situations which must be avoided. Any
exceptions must be reported to the President and written approval for continuation must be
obtained.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;Revealing confidential information to outsiders or misusing confidential information.
Unauthorized divulging of information is a violation of this policy whether or not for personal
gain and whether or not harm to the Company is intended. (The Employment, Confidential Information
and Invention Assignment Agreement elaborates on this principle and is a binding agreement.)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;Accepting or offering substantial gifts, excessive entertainment, favors or payments which
may be deemed to constitute undue influence or otherwise be improper or embarrassing to the
Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;Participating in civic or professional organizations that might involve divulging
confidential information of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;Initiating or approving personnel actions affecting reward or punishment of employees or
applicants where there is a family relationship or is or appears to be a personal or social
involvement (other than as officers of the Company appointed by the Board of Directors).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;Initiating or approving any form of personal or social harassment of employees.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;Investing or holding outside directorship in suppliers, customers, or competing companies,
including financial speculations, where such investment or directorship might influence in any
manner a decision or course of action of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;Borrowing from or lending to employees, customers or suppliers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;Acquiring real estate of interest to the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;Improperly using or disclosing to the Company any proprietary information or trade secrets
of any former or concurrent employer or other person or entity with whom obligations of
confidentiality exist.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;Unlawfully discussing prices, costs, customers, sales or markets with competing
companies or their employees.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;Making any unlawful agreement with distributors with respect to prices.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;Improperly using or authorizing the use of any inventions which are the subject of patent
claims of any other person or entity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;Engaging in any conduct which is not in the best interest of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each officer, employee and independent contractor must take every necessary action to ensure
compliance with these guidelines and to bring problem areas to the attention of higher management
for review. Violations of this conflict of interest policy may result in discharge without warning.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>32
<FILENAME>f39432orexv10w17.htm
<DESCRIPTION>EXHIBIT 10.17
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w17</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.17</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><IMG src="f39432ore3943202.gif" alt="(FLUIDIGM LOGO)">

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SETTLEMENT AGREEMENT AND GENERAL RELEASE OF ALL CLAIMS</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Settlement Agreement and General Release of All Claims (&#147;Agreement&#148;) is made and entered into
as of March&nbsp;20, 2008, by and between Michael Ybarra Lucero (&#147;Employee&#148;), on the one hand, and
Fluidigm Corporation (&#147;Employer&#148;), on the other hand, for the purpose of settling any and all
claims between them, as more specifically described below, including any and all claims arising
from or in any way related to the Employee&#146;s employment by and cessation of employment with the
Employer, except as noted below.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In consideration of the mutual promises and covenants contained herein, and in consideration of
other good and valuable consideration, the adequacy of which is hereby acknowledged, the Employee
and the Employer (hereinafter sometimes referred to individually as a &#147;Party&#148; or collectively as
the &#147;Parties&#148;), and each of them, covenant and agree as follows:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>1.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Claims Pending and Agreement to Not Pursue Claims.</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Employee represents that the Employee does not have pending against the Employer;
against any of the Employer&#146;s parents, subsidiaries, affiliates, stock option plan, 401(k) or
other retirement plans, directors, owners, shareholders, employees, members of the Employer&#146;s Board
of Directors, attorneys, agents, owners, insurers and/or representatives; or against any of their
predecessors, successors and assigns, and each of them (collectively the &#147;Releasees&#148;), any lawsuit,
grievance, charge, claim, complaint, action, demand and/or petition, including any workers&#146;
compensation claim, in or with any federal, state or local court or administrative agency. The
Employer represents that the Employer does not have pending any lawsuit, charge, claim, complaint,
action, demand and/or petition against the Employee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Employee and Releasees, and each of them, wish to resolve any and all existing
and/or potential lawsuits, grievances, charges, claims, complaints, actions, demands, petitions
and/or disputes between them, including any and all claims through March&nbsp;14, 2008, (the &#147;Date of
Cessation of Employment&#148;), arising from and/or in any way related to the Employee&#146;s employment by
and cessation of employment with the Employer (the &#147;Released Claims&#148;), except as noted herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The Employee agrees that the Employee shall not file or cause to be filed and shall not
prosecute in any manner any lawsuits, grievances, charges, claims, complaints, actions, demands,
petitions and/or disputes, against Releasees, or any of them, at any time hereinafter, with respect
to any of the Released Claims; and that if any agency or court assumes jurisdiction of any such
lawsuit, grievance, charge, claim, complaint, action, demand, petition and/or dispute against
Releasees, or any of them, the Employee shall request that such agency or court dismiss such matter
with prejudice, or if applicable, the Employee shall opt out of any actual or purported class
action, and agrees that, in any event, the Employee shall not accept any remedy obtained through
the efforts of any such agency or court.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Fluidigm Corporation</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">7100 Shoreline Court, South San Francisco, California 94080 tel: 650.266.6000 fax: 650.871.7152 www.fluidigm.com

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>2.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Cessation of Employment, Return of Records and Continuing Obligation Regarding
Confidential and/or Proprietary Information.</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Effective the Date of Cessation of Employment, the Employee&#146;s at-will
employment with the Employer ceased and all benefit coverage also ceased. The Employee acknowledges
and agrees that, after the Date of Cessation of Employment, the Employee shall not have any
authority to represent or bind the Employer and shall not act or convey the impression that
Employee is acting on behalf of the Employer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Employee represents that, no later than the Date of Cessation of Employment, the
Employee returned any and all property of the Employer, including, but not limited to, office keys,
computer hardware and related accessories, software and the original and all copies (including
electronic versions) of all files, including research, strategic, operational, technical, financial
and confidential files, of the Employer and/or of its former, current and/or potential customers,
suppliers, vendors, other independent contractors and/or others doing business with the Employer.
The Employee agrees that the Employee remains bound by the obligation of the Employee to not
reveal, use or disclose any research, strategic, operational, technical, financial and/or other
confidential or proprietary information or trade secrets of the Employer, and/or of its former,
current and/or potential customers, suppliers, vendors, other independent contractors and/or others
doing business with the Employer. The Employee further covenants and agrees that the Employee will
keep confidential any and all customer or client lists of the Employer, mailings and other business
information that the Employee has acquired about the Employer and shall not disclose or reveal any
of such information to any person or entity until, if ever, such information is published and
becomes public knowledge (other than through acts by or on behalf of the Employee), or as required
by legal process in a formal legal proceeding. The Parties further agree that despite the
provisions of Paragraph&nbsp;17 below, only injunctive relief can adequately remedy a violation of this
Paragraph, that the Employer shall be entitled to injunctive relief to prevent any such violation,
and, if successful in pursuing such an action, that the Employer shall be entitled to recover from
the Employee its reasonable attorneys fees and costs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;During the period of March&nbsp;15 to July&nbsp;15, 2008, the Employee shall be available to the
Employer on an &#147;as needed&#148; basis, up to a maximum of five (5)&nbsp;hours per calendar month, shall at
all times comply with any applicable policies and procedures of the Employer, shall comply fully
with Paragraph 9(b) below, and shall conduct himself in a &#147;professional&#146; manner with respect to the
Employer and the Releasees.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>3.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Transition Funds and Tax Liability.</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;No later than the Date of Cessation of Employment, the Employer provided to the Employee
a check, minus applicable taxes and deductions, for all accrued, but unused vacation and for all
unpaid wages for the period up through and including the Date of Cessation of Employment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Assuming no revocation of this Agreement by the Employee, pursuant to Paragraphs 6 and
7 below, and assuming compliance by the Employee with Paragraphs 2(b), 2(c) and 9(d), then the
Employer (i)&nbsp;shall pay the Employee, through July&nbsp;15, 2008, on Fluidigm&#146;s
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Fluidigm Corporation</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">7000 Shoreline Court, Suite&nbsp;100, South San Francisco, California 94080 tel: 650.266.6000 fax: 650.871.7152 www.fluidigm.com

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">normal pay days, a sum, minus applicable taxes and deductions, equal to what the Employee would
have received on that pay day based on an annual salary of Two Hundred Sixty-Five Thousand Dollars
($265,000.00); and (ii)&nbsp;shall reimburse the Employee, based on submitted receipts, for the
Employee&#146;s COBRA costs, for the months of April, May, June and July, 2008, in an amount no greater
than the amount the Employer contributed on behalf of the Employee for February, 2008 (collectively
the &#147;Transition Funds&#148;); provided, however, that the obligation of the Employer to pay the Employee
any of the Transition Funds, as set forth in this Paragraph&nbsp;3(b)(i) and (ii), shall immediately
cease prior to July&nbsp;15, 2008 upon the Employee accepting any employment (self-employment, or as an
employee) and further provided that the Employee is obligated to notify Annie Butler, Sr. Manager,
Human Resources &#038; Administration or person with equivalent title, in writing, within two (2)
business days of accepting any such employment. Employee agrees that if he provides consulting
services under section 2(c), five thousand dollars ($5,000) of the separation payment shall be
considered compensation for any services provided. In addition to the Transition Funds, as
additional consideration for the execution of this Agreement by Employee, the Employer shall pay
Employee an amount equal to $90,000 (after all applicable withholding) (the &#147;Special Bonus&#148;) within
10&nbsp;days of the effective date of this Agreement. Employee is expected, but not required, to use the
Special Bonus to exercise Employee&#146;s existing option to purchase 300,000 shares of Employer&#146;s
Common Stock at $0.30 per share pursuant to option grant number 99-98.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;It is the intent of the Parties that the Transition Funds are not a &#147;deferral of
compensation&#148; and are exempt from adverse taxation under Section&nbsp;409A of the Internal Revenue Code
pursuant to the exception from Section&nbsp;409A provided under Treasury Regulations Sections
1.409A-l(b) (4)&nbsp;and 1.409A-l(b) (9) (iii)&nbsp;and (v). Notwithstanding the foregoing, and
notwithstanding the Employer&#146;s withholding of applicable taxes as provided in Paragraph&nbsp;3(a)&nbsp;and
(b)&nbsp;above, the Employee agrees that, if it is determined that additional federal, state and/or
local taxes are required to be levied against the Employee by any applicable local, state and/or
federal taxing authority with respect to any or all of the sums described above in Paragraph 3(a)
and/or the Transition Funds described above in Paragraphs 3(b), including penalties, interest and
assessments thereon, the Employee agrees to be solely responsible for the taxes, penalties,
interest and assessments and hereby agrees to release and indemnify Releasees, and each of them,
from any and all claims by the Employee and by any local, state or federal governmental agency for
any unpaid taxes, penalties, interest and assessments thereon.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The Employee agrees that, upon payment of the funds set forth in Paragraph&nbsp;3(a), the
Employee will have received all wages, vacation, bonus and other benefits owed to the Employee by
Releasees, or any of them. The Employee further agrees that the funds, as set forth above in
Paragraph&nbsp;3(b), constitute the entire financial consideration provided to the Employee under this
Agreement and the Employee shall not seek any further compensation and/or consideration from
Releasees, or any of them, and/or from any other person and/or entity, for any other claimed
damages, costs or attorneys&#146; fees with respect to the Released Claims.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>4.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>No Admission of Liability.</B></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Agreement affects the settlement of claims, charges and disputes, all of which are denied and
contested. Nothing contained in this Agreement or by compliance with this Agreement shall be
construed as an admission in any manner by the Employee Parties (as defined below) or by
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Fluidigm Corporation</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">7000 Shoreline Court, Suite&nbsp;100, South San Francisco, California 94080 tel: 650.266.6000 fax: 650.871.7152 www.fluidigm.com

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">any of the Releasees of any liability whatsoever. The Releasees and the Employee Parties
specifically deny any wrongdoing or liability for any alleged violation of the rights of the other
or for any alleged violation of any order, law, statute, duty, contract, or public policy.
Releasees and the Employee Parties continue to contest every claim, complaint, charge, grievance,
action, petition and dispute resolved in this Agreement.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>5.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Release of Claims.</B></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Employee, individually and on behalf of the Employee&#146;s predecessors, successors, assigns,
heirs, estates, executors, administrators, agents, representatives and attorneys (collectively, the
&#147;Employee Parties&#148;), and each of them, voluntarily, irrevocably and unconditionally releases,
acquits and forever discharges Releasees, and each of them, from any and all charges, complaints,
claims, promises, agreements, controversies, suits, demands, costs, losses, debts, actions, causes
of action, damages, judgments, obligations, liabilities, and expenses of whatever kind and
character, known or unknown, suspected or unsuspected, including any claims for attorneys&#146; fees and
costs, which the Employee now has, owns, holds or claims to have, own or hold, or may have owned or
held against any of the Releasees regarding events that have occurred through the Date of Execution
in connection with or related to the Employee&#146;s employment by or with cessation of employment with
the Employer, including, without limitation, any and all claims under the Age Discrimination in
Employment Act of 1967, the Americans with Disabilities Act of 1990, the Vietnam Era Veterans&#146;
Readjustment Assistance Act of 1974, the Employee Retirement Income Security Act of 1974, the Civil
Rights Act of 1991, Title VII of the Civil Rights Act of 1964, Sections&nbsp;503 and 504 of the
Rehabilitation Act of 1973, the California Labor Code, the California Government Code, any other
applicable federal, state and/or local statute, ordinance, regulation and/or the common law, and/or
any amendments to any of these federal, state and/or local statutes, ordinances and/or regulations
(the &#147;Released Claims&#148;). The Employee hereby waives any right to assert a claim for any relief
available under these acts, statutes and/or regulations (including, but not limited to, back pay,
attorneys&#146; fees, damages, lost benefits, reinstatement and/or other injunctive relief) the Employee
may otherwise recover based upon any alleged violation(s) of these acts and/or statutes for causes
of action that arose up to the Date of Execution of this Agreement. <I>The Employee understands and
agrees that, notwithstanding any provisions and covenants in this Agreement, specifically in
Paragraphs 5(a) and 5(b), nothing in this Agreement is intended to constitute an unlawful release
and/or waiver of any of the Employee&#146;s ability and/or right to (i)&nbsp;provide truthful testimony if
under subpoena to do so and/or (ii)&nbsp;participate in an investigation and/or proceeding conducted by
the Equal Employment Opportunity Commission (&#147;EEOC&#148;), the California Fair Employment and Housing
Commission (&#147;FEHC&#148;) and/or any other governmental agency. </I>The Employer acknowledges that it has an
ongoing obligation to comply with California Labor Code Section&nbsp;2802, and the Parties acknowledge
that the Employee is not releasing the Employee&#146;s right to indemnification by the Releasees
pursuant to any indemnification insurance maintained by the Employer or pursuant to applicable law.
The Employee further asserts and represents that the Employee is not aware of any facts giving rise
to a basis for the Employee to file, and the Employee has no plans to file, a workers&#146; compensation
claim against the Employer and/or any of its
subsidiaries and/or affiliates and is not aware of any pending claim and/or action that would
require the Employer to defend and/or indemnify the Employee pursuant to California Labor Code
Section&nbsp;2802.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Fluidigm Corporation</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">7000 Shoreline Court, Suite&nbsp;100, South San Francisco, California 94080 tel: 650.266.6000 fax: 650.871.7152 www.fluidigm.com

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>6.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Acknowledgment of Waiver of Claims under ADEA</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Employee specifically understands and acknowledges that the Age
Discrimination in Employment Act of 1967, as amended, (&#147;ADEA&#148;), provides the Employee the right to
bring a claim against the Employer if the Employee believes that the Employee has been
discriminated against on the basis of age. Employee acknowledges that he is waiving and releasing
any rights he may have under the Age Discrimination in Employment Act of 1967 (&#147;ADEA&#148;), and that
this waiver and release is knowing and voluntary. Employee agrees that this waiver and release does
not apply to any rights or claims that may arise under the ADEA after the Effective Date of this
Agreements. Employee acknowledges that the consideration given for this waiver and release is in
addition to anything of value to which Employee was already entitled. Employee further acknowledges
that he has been advised by this writing that: (a)&nbsp;he should consult with an attorney <U>prior</U>
to executing this Agreement; (b)&nbsp;he has twenty-one (21)&nbsp;days within which to consider this
Agreement; (c)&nbsp;he has seven (7)&nbsp;days following his execution of this Agreement to revoke this
Agreement; (d)&nbsp;this Agreement shall not be effective until after the revocation period has expired;
and (e)&nbsp;nothing in this Agreement prevents or precludes Employee from challenging or seeking a
determination in good faith of the validity of this waiver under the ADEA, nor does it impose any
condition precedent, penalties, or costs for doing so, unless specifically authorized by federal
law. In the event Employee signs this Agreement and returns it to the Company in less than the
21-day period identified above Employee hereby acknowledges that he has freely and voluntarily
chosen to waive the time period allotted for considering this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;This Agreement was delivered to the Employee on March&nbsp;20, 2008. The Employee agrees to
deliver or cause to be delivered any such revocation in writing to: Annie Butler, Fluidigm
Corporation, 7000 Shoreline Court, Suite&nbsp;100, So. San Francisco, CA 94080, within seven (7)
calendar days of the Employee&#146;s execution of this Agreement. The Employee further understands and
agrees that any such revocation of this Agreement by the Employee shall render this Agreement
(including the release of the Releasees&#146; Claims in Section&nbsp;5(b)) wholly null and void, except as
set forth below in Paragraph&nbsp;Seven.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>7.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Effect of Revocation.</B></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">If the Employee exercises the Employee&#146;s right to revoke this Agreement, pursuant to Paragraph&nbsp;6
above, the Employee shall be deemed, effective as of the Date of Cessation of Employment, to have
been terminated and the Employee shall not be entitled to any of the Transition Funds described
above in Paragraph 3(b) and to the benefits set forth below in Paragraphs 9 (a), (b)&nbsp;and (c), and
each of them.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>8.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Section&nbsp;1542 Waiver.</B></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">With respect to any alleged claim of the Employee arising under any California statutory provision,
the Employee agrees that all of the Employee&#146;s rights under Section&nbsp;1542 of
the Civil Code of the State of California which are related or in any manner incidental to the
matters encompassed by this Agreement are hereby waived. Section&nbsp;1542 provides as follows:
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Fluidigm Corporation</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">7000 Shoreline Court, Suite&nbsp;100, South San Francisco, California 94080 tel: 650.266.6000 fax: 650.871.7152 www.fluidigm.com

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>&#147;A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST
IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE
MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.&#148;</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>9.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Public Statement.</B></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Employer and the Employee agree that:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;if asked about the outcome, resolution and/or status regarding the Employee&#146;s
relationship with the Employer, the response of the Employee shall be to explain that, effective as
of the Date of Cessation of Employment, the Employee left the employ of the Employer to pursue
other professional and personal interests;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;absent a subpoena/court order, a written release executed by the Employee and/or a
request by a governmental agency, the Employer shall provide any prospective employer of the
Employee with confirmation of the Employee&#146;s dates of employment, the Employee&#146;s last position held
with the Employer and the fact of the cessation of employment as described above in Paragraph&nbsp;9(a);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;if the Employee ever requires employment references from the Employer for any
prospective employer(s), the Employee shall refer the prospective employer(s) only to Annie Butler,
Sr. Manager, Human Resources &#038; Administration or person with equivalent title and to no one else
and Annie Butler or person with equivalent title shall provide the information set forth above in
Paragraph&nbsp;9(b); and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;the Parties agrees that neither shall, orally or in writing, publicly or privately,
post, publish, make or express any comment, view or opinion which criticizes, is adverse to, brings
into disrepute in the eyes of the public, defames, derogates or disparages the other, nor shall the
Party authorize any agent or representative to make or express any such comment, view or opinion.
It is further agreed that providing any of the information as set forth in this Paragraph&nbsp;Nine,
and testifying truthfully in a court of law or duly authorized arbitral forum, shall not be a
violation of Paragraph&nbsp;9(d). Employee agrees that the Company&#146;s obligations under this provision
shall only extend to executives and members of the Board and only for so long as such individuals
remain in service to the Company.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>10.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Confidentiality.</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Employee agrees that the Employee shall keep all of the facts and terms of the settlement
and the terms and conditions of the Transition Funds provided under this Agreement completely
confidential and shall not disclose or allow the disclosure to any person or entity, unless
expressly required by law to do so and except as to the Employee&#146;s spouse or registered domestic
partner, if any) and persons assisting in legal, tax and financial preparation, provided, however,
that any such person or entity shall first agree in writing to be bound by the
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Fluidigm Corporation</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">7000 Shoreline Court, Suite&nbsp;100, South San Francisco, California 94080 tel: 650.266.6000 fax: 650.871.7152 www.fluidigm.com

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">confidentiality terms as set forth in this Paragraph&nbsp;10; that the Employee shall respond to any
inquiry about the Employee&#146;s relationship with the Employer or the cessation of the Employee&#146;s
employment with the Employer in accordance with the terms of Paragraphs 9(a) and 9(b) and 9(c)
above.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Parties agree that a breach by the Employee of any of the provisions as set forth above in
Paragraphs 9 and/or 10(a) would be a material breach of this Agreement. The Parties further agree
that if any of these provisions are breached by the Employee, or any of the persons or entities to
whom the Employee is authorized to disclose the terms of this Agreement, the Employee shall be
obligated to return to the Employer all of the Transition Funds received by the Employee from the
Employer pursuant to Paragraph 3(b) above and the Employee shall also be liable to any Releasee for
any actual damages it suffers as a result of any such breach. The Employee further acknowledges and
agrees that in the event of any threatened and/or actual breach as provided in this Section&nbsp;10(a),
the Employer shall be entitled to directly seek injunctive relief in any court of competent
jurisdiction with respect to any threatened or actual breach of these provisions. The Parties
further agree that this Agreement is fully admissible and enforceable in any judicial or
arbitration proceedings.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>11.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Legal Counsel.</B></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Each Party expressly warrants and agrees that the Party has had the opportunity to be represented
by counsel and that each has been supplied with, has read and has had an opportunity, if the Party
so desired, to discuss the terms of this Agreement with the Party&#146;s own legal counsel. Each Party
further warrants and agrees that the Party fully understands the contents and effect of this
document, approves and voluntarily accepts the terms and provisions of the Agreement with full
knowledge of their significance, agrees to be bound by the Agreement and signs with the express
intention of effecting the extinguishment of any and all claims.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>12.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Entire Agreement.</B></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Agreement incorporates the entire understanding between the Parties and recites the whole
consideration for the promises exchanged herein. It fully supersedes any and all prior agreements
or understandings, written or oral, between the Parties hereto pertaining to the subject matter
hereof with the exception of the Employment, Confidential Information and Invention Assignment
Agreement and the 1999 Stock Option Plan, Stock Option Agreement. The terms of this Agreement are
contractual and not mere recitals.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>13.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Severability.</B></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Should any term, clause or provision of this Agreement be determined by any final decision of any
Court to be wholly or partially illegal or invalid, the validity of the remaining terms, clauses,
and provisions shall not be affected thereby, and said illegal or invalid term, clause or provision
shall be deemed not to be part of this Agreement.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Fluidigm Corporation</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">7000 Shoreline Court, Suite&nbsp;100, South San Francisco, California 94080 tel: 650.266.6000 fax: 650.871.7152 www.fluidigm.com

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>14.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Choice of Law.</B></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Agreement is made and entered into in the State of California and shall in all respects be
interpreted, enforced, construed and governed under the laws of the State of California. Any court
proceeding arising from this Agreement shall be filed in the County of San Mateo, State of
California, except that the Parties agree that this Agreement may be pleaded as a full, final and
complete defense to, and may be used as the basis for, an injunction against, any action, suit or
other proceeding which may be instituted, prosecuted or maintained in any court in breach of this
Agreement.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>15.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Modification.</B></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Agreement may not be amended or modified in any respect whatsoever except by a writing duly
executed by the Parties, and the Parties agree that they shall make no claim(s) at any time that
this Agreement has been orally amended or modified.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>16.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Reliance.</B></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Parties to this Agreement represent and acknowledge that in executing this Agreement, the
Parties, and each of them, do not rely and have not relied upon any representation or statement
made by any other Party to this Agreement with regard to the subject matter, basis or fact of this
Agreement, other than the terms of this Agreement.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>17.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Arbitration.</B></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In the event of any dispute between the Parties arising out of, relating to or in connection with
any of the provisions of this Agreement, any documents executed and delivered pursuant to this
Agreement, or compliance with this Agreement, the Parties hereby agree that any such dispute(s)
shall be submitted to final and binding arbitration in the San Francisco Bay Area, California
before an Arbitrator chosen mutually by the Parties or, absent such agreed choice within two (2)
calendar weeks, from a list provided by the American Arbitration Association and under the
California Employment Dispute Resolution Rules of the American Arbitration Association. The
Arbitrator chosen shall be bound by the express terms of this Agreement except as necessary to
comply with the requirements of applicable case law, such as <I>Armendariz v. Employer Health Psychare
Services, Inc. </I>(2000)&nbsp;24 Cal.4<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> 83 and <I>Nyulassy v. Lockheed Martin Corporation </I>(2004)
04 C.D.O.S. 6770; and shall hear and determine all disputes as presented to him or her as
expeditiously and economically as possible. Any award of the Arbitrator shall be final and binding
and may be confirmed as a final judgment in any Court of competent jurisdiction in California. To
the extent consistent with applicable statutory and case law, the prevailing Party in any action,
proceeding or arbitration shall be entitled to recover not only the amount of any damages,
judgment, award or settlement in favor of said
Party, if any, but also such other damages, costs and expenses as may be actually incurred by said
Party, including Court costs, reasonable attorneys&#146; fees, or expert witness or consultant fees
incurred in connection with such action, proceeding or arbitration.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Fluidigm Corporation</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">7000 Shoreline Court, Suite&nbsp;100, South San Francisco, California 94080 tel: 650.266.6000 fax: 650.871.7152 www.fluidigm.com

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>18.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Authority to Execute.</B></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Each individual signing this Agreement, whether signed individually or on behalf of any person or
entity, warrants and represents that the individual has full authority to so execute this Agreement
on behalf of the Party on whose behalf he or she signs. Each of the Parties separately acknowledges
and represents that this representation and warranty is accurate and is an essential and material
provision of this Agreement and shall survive the execution of this Agreement.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>19.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Voluntariness and Construction as a Whole.</B></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Employee acknowledges and agrees that the Employee is entering into this Agreement knowingly
and voluntarily, that this Agreement is written in a manner understood by the Employee and that the
Employee has been informed that the Employee may want to consider having this Agreement translated
by an interpreter. The Employee further acknowledges and agrees that the language used in this
Agreement shall be deemed to be the language chosen by the Parties to express their mutual intent,
and no rule of strict construction shall be applied against any Party. The language of all parts of
this Agreement shall be construed as a whole, according to fair meaning and not strictly for or
against any Party, no matter which Party drafted the clause, term or provision. The Parties agree
that the drafting and negotiating of this Agreement has been participated in by each of the Parties
and their counsel, and for all purposes this Agreement shall be deemed to have been created by all
Parties.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>20.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Facsimile and Execution in Parts.</B></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Parties agree that facsimile signatures are deemed to be originals and that this Agreement may
be executed in counterparts each of which shall be deemed an original.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>21.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Failure to Enforce.</B></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">A failure by any Party to enforce at any time, or over a period of time, any provision of this
Agreement shall not be construed to be a waiver of such provision or of the right to enforce such
provision or any other provision in this Agreement.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>22.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Headings.</B></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The headings in this Agreement are descriptive only.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>23.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Non-Assignability.</B></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Employee represents and warrants that the Employee has not heretofore assigned, transferred,
conveyed, hypothecated, encumbered or purported to assign, transfer, convey, hypothecate or
encumber to or in favor of any person or entity any claim or any portion thereof or interest herein
released.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Fluidigm Corporation</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">7000 Shoreline Court, Suite&nbsp;100, South San Francisco, California 94080 tel: 650.266.6000 fax: 650.871.7152 www.fluidigm.com

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>24.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Date of Execution.</B></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The date of the Employee&#146;s signature on this Agreement shall be known as the &#147;Date of Execution&#148; of
this Agreement.
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%"><B>PLEASE READ CAREFULLY. THIS AGREEMENT INCLUDES A RELEASE OF CLAIMS KNOWN AND UNKNOWN.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%"><B>Agreement on the date set forth below.</B>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="41%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dated: March&nbsp;22, 2008
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Michael Ybarra Lucero
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Michael Ybarra Lucero</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">FLUIDIGM CORPORATION</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dated: March 20, 2008
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gajus Worthington</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Gajus Worthington, President &#038; CEO</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Fluidigm Corporation</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">7000 Shoreline Court, Suite&nbsp;100, South San Francisco, California 94080 tel: 650.266.6000 fax: 650.871.7152 www.fluidigm.com

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>33
<FILENAME>f39432orexv21w1.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv21w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;21.1</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Subsidiaries of Fluidigm Corporation (Delaware):</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Fluidigm Japan K.K (Japan)<BR>
Fluidigm Singapore Pte. Ltd. (Singapore)<BR>
Fluidigm Europe, BV (Netherlands)

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Subsidiaries
of Fluidigm Europe, BV (Netherlands):</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Fluidigm France SARL (France)

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>34
<FILENAME>f39432orexv23w1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv23w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;23.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Consent of Independent Registered Public Accounting Firm</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We consent to the reference to our firm under the caption &#147;Experts&#148; and to the use of our report
dated April&nbsp;12, 2008 in the Registration Statement (Form S-1) and related Prospectus of Fluidigm
Corporation for the registration of shares of its common stock.
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">     /s/ Ernst &#038; Young LLP
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Palo Alto, California<BR>
April 12, 2008

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>f39432orf3943216.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432orf3943216.gif
M1TE&.#EAG`%>`-4F`(>/ODI7GL/(W]7=[1TMA?'R]WZ8R&ESKM/6YZ6LSSM)
ME>+D[RP[C5IEII:=QDI7G<+'WJFZVGB!MK2ZU]3<['Z8Q]_F\5Y_NF)OK+_,
MXZ"OTG.0P[&[V?7W^X^CS:F[VFF'OI2JT8FAS%-VM?___PX???___P``````
M````````````````````````````````````````````````````````````
M`````````````````````````````````"'Y!`$``"8`+`````"<`5X```;_
M0)-P2"P:C\BD<LEL.I_0J'1*K5JOV*QVBQQYOV"O@4LNF\_HM'K-;J_#\-'8
M3:_;[_B\?K^,A^=\@8*#A(6&='Y@@(>,C8Z/D(.)7XN1EI>8F9I.DV*;GZ"A
MHH:=<J.GJ*FJ9*65JZ^PL;&MLK6VMZ"TN+N\O82ZOL'"PVK`Q,?(R5+&RLW.
MFP@.`-/4U=;7V-41V]S=VQK9UL_CY'H%``PEZNOL[>[O[B3R\_3R$/#MY?K[
M:PX$^``#QJM'\)Y`?@@39BEP0*!#AP0+.E1(L2*4``\S`HQ8SV!`BR!#&I&@
ML>0[CO0\`A3)$J0`DS#9H9RG$E_+FPHQQHPYT]Y$_YQ`R[W<R;-G37A!DSXC
M211F3Q)'WRF=FDQ!4Z=&?^X)-VT!L@1<O5(-=!7KS*CNR`(4@$PG/+9C^90U
M^11M/KEKV^:-NT>@`@&``PL>3+@PX`J($RM&[,'P8+7XX!)S^TXR7SP"`Y1A
MUBB@Y3P"N"9(0]G=9Q.APYV^;"7SYDZNL*3F2IN:9<^!``#4C*9TN].Z\0%@
MO<4U*]A;$C28JV[X$-Q\@L/C?<8W.^``G1/'8IP+YRD"TC%O3@3ZUMVD]Q*1
M_D[[]M8!J6_Y'B7!>';NS>MA[TY^&>OK8"?<>]S%]]HDL4%AWWWKY*?>?NCU
M]J`0_+7C'H%3=#<?<E44\/\/@^0]-R$>%;+C'QD`JB,@/!=B&(6&6M#GA`,@
M-EC>B'>4N,Z)7*18PHKMN5@%C%G(V,1R-9;@8&2Y15C=B#J&**041&)A)!,^
M_NC8EH&))81^H(F6'I-%S(;-:E,R4>455RZ1)1=@!N,CFFG":>!Q"%KQ9G$X
M]C)GG55DF:1`=6EEQ)Y:Q.G+GX!.(>B@&V5U$!*(9J&HGWTVZB:D.Q4ZZ1&5
M%D@F+`A,<(T`!1#!:!H(""!--0X(X.4="PC6H6"S/LFI62C9Q4X2H5X!IIG7
MC-;$`K090:PUQCI1@'(?PL/``0B8L.H0RU9#9Q$(2"`H`0W$NJ6VZX5UQ`02
M6.7_#K@.I+H$`@``J(`$U2K1JKL7[<HK1[ZN`^Q'?(Y*H9-+#&53$5&6P.,1
M!4@0K4,!J/N6$0FW6$0!#H@'XI(3#W&.Q@`18+$0"4@<7ZY"^$.`50?@V\2C
M^K;C*<"@TFSIA`DOK*S-`^.C\WH/SP6D.R,+,4'0#')<V1#^E*2`RR9,`+)#
M!-0[Q`$$P+5``P1`K03,,:\S\TJ4\BPLS@0K83!2"*=M!`(FCS>TA4DTQ*G2
MIIFP0-P945<`DB81X.5+".@40`$!'/`$V&&7,/;!-9.=*-H^.[&V5&U7GH0`
M2#,W-WY(V'WWC9$ET'E&HR$P=4F*"W&`X@$`4,"/$Y2P_WCC&3W.=N20WRRP
M"3E;;G;P2"R8Y.<VCA0SWNTP#H\"QA/E;NS6)BZX"258O2GN$$E:8P#@AR_^
M^.1K_R7ETPDO^1#$OWWZNN&O#F5V.PM$[1#=OD^_B-R;9"SUX&L``TPP.Y25
MK7\!T1T"KV,$,+6O8,-S&P'UIPX"T.MB"7@4\J0TA"PIP'Q"V%M`#D"86<&$
M`0X0B^EB<C_4\(UN)DB7M627O00,T`G.BYD"%ZBB!J+O'3\CPN72DKGT&0%P
M^&B`UXA`HSA5C%L!Z5H2"O!"=AB0?P\A@`,H9I*6E2D@#0BA%B4PF@.8KF@C
M(9\:!4(`-;KQC>2C@!SG2$<Y<O\`CN'#W6D<*,$C#/$NZW%;[4;8A(3]B(L#
M8F)`FH6$/[)#`DK0B!*/L`"-_`4)\MO1$$Q'0@%PL@QKLD*;L->X/?ZP/^KK
M7<^,2(1,KJ-U3$"`$_<W!"2ZXX9+J*(Z?I:1+28A(UX\("OU=H``,C)@FO,.
MAY:@1Q_^[H%JBV`RA>#(=3!@B4B892([V,<B,$5:D60C"(OPJ&,B<IAL"&45
M1MG,(O!QFM%<WRJ!6`31P<.<X?P=\&@I!!\%<9ZWS"<^GH:E*(ZSB/2D@SJI
MP,Y2.K-C[.OF%^6Y3WCJCP!1N!9`8<A-?.!2";I4F$#?$<SM2>N@"$6E0N^D
MS#P%RC/_7'*,U]Z)SLU)<YBR!`@L<3B_;;KN4D.HI$Y'FK>7\5,)T%S#0J<P
MRG]1%#[/E*@0;YI0DBTRHSUE41&B]PZ"(H&*5_UEILAYU"0D50U+7<8R'64V
MJ$)THR9*Y>XB.DU#;HMW2TLI1X4PNX`HP("(BR(SQZJJLB+AK&E(:Q2:*LRY
MBNJM%:UI(ZFJ4K@R,%_Z?&(]V7C!$`*`@B7PI5CUV5BB.0&Q:%`L%!B+5\Q-
M+JKPM"E%'VA7K&:VK!X"T3^!2E:?(E6JH&3IAEQ*A6"Y-:]TE:P?*=N\0`)D
M`K:%;&2#5+_Q>)6HO^&I;\T*7#*H]@FL/51;AW3*YC:!JT1T_^XP#8G&UF97
MKZ`[`GJ)<K@F\+:PVSUL=^VTW]6N50K&)2]LE;O53R6WJJCQ:W21>V#3(N%H
M96DOZ:1;VKW^-K95L,``-LSA#G/X`2`.L8A!C`$/F_C$*.YP>'NKRK,-&,&A
M,Y1E=TF$O@+DBD@(Z0:5I(2_$>4`.#["?3NJU4+VEPD&*,4(GA(!)3OYR0G2
M;HN/6]0&FQ<)(I3Q="LKA)"6((Q.L">#9\QC)2S`E4E,`#:Q>]F"YO<(J)5"
MDDO!Y"?;^;\+=JWO()NPCQ8!P@\Y)XR;"!!\&D',8]ZRA6N,Z`JJ$0"QHO)[
MW5QD)L0Y"G/N1)WOS&DX?$!/XZ4"3?_A@3*&E$307)Y@%+?E8X'L>&2?A8<$
MUNQB"KLWOI8^\A(R/8E-=_K7(Q@`J)\J8#X3TF.Q/C5\-;EL"WGM'*#M8;/+
M3`2XP2-KB24LD:F;:PQ3@=>)\#6P[PR"*P18U!.:;_.F@;68H/K*'D/S.@A@
M1L`XH-T9>36WWH?2U]I:O&]^=URU`&X_B'O<3\Z`N4.=H0D)M2D4%#BS)PHI
M?7M,?Q/H]V,376%<+^'24"AX'`Z.\%)L``OG;K@^<]B\0;88L>J6F\0Y2.C[
M,"!V&A]R/PT+9UTK0>1P('G)$W$!"Z"<X50:434=,IREVV[:.HOY0XJ956XK
MFD$,@&XVM;W_\X!#?0M`#X/0AQX'A1^=V.@F[3<M62^GSURD20!T%ZU5=0=;
M=5<[G3#';YV\;A-8SDH>.]F_<`%A9R'E22>M"6HN$`8PTNU?[W&C0^9+C5Z]
M[T*P99(@^="]`[S2'_=Y$L(.!L$/7@0=V`+B7Y2I!>`[S=5U[.5IS`37@Y8!
MLMMVE:WL<0I%^RH@U#G=O:Y>&%N!]%\P/<(O$`*C#\-5`&A`^*9QUSL4`%T!
M>%@;`:#Q,SS+RU?A/#(TG.(/C_C\)2Z_^LOO?$V=8NVZK<AWW>^++#<OIH)!
M1\CD+USZ.P,!G7--4A!2_"=Z_E<+``@/W7<$FC=Q"3%_!U@+"W`ZGGGG!`]'
M4@7H;1$H)_BP@!<34H96#A"X@:]P@;O7!*H#$'Z&$"-(@JJP=!]D@9/'#B$H
M@OWG@K[@="700@\V@^P`9AGX=SAH"SG%1K%3#0<`?NMP7131@D-X"BSG-+2F
M#T[XA**0@)O'$E5HA:&`A?=Q25IX@URX"PL0A<]3@V.8AHT@``VH$0S066H8
4AYFP`,HA;^S``.'B@7(H!4$``#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>f39432orf3943218.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432orf3943218.gif
M1TE&.#EA^`+>`^8``+/6ZW.'JZVXSMS<W;&QM8J4L20V9]K=Z9QG8R(N5RA(
MA[>.;^?GZ/W^_21">1<H5"E3E6MUCA$A22(X=8R*C9NLRW%N<,;'R3-%>%)H
MDTE3;456C,ZOGY:GN6AZK-7H].KHVTM+4LC+VC5)A04%!N?>W2HJ+S-8F=+.
MGE=MI1@R97"A:A$70SA2BRE:GW20PXZ<PE=D>.?K]@<2*?OY\38_4S-#:J28
ME,S6X.[X_2$G9"0YA=;6U!,B,H1Z?*VFH#$Y:6!85Q1%AA@Q6C5EIVMD7]'.
MSN?>Z$@V4!5">+C`N2E2C*&?KL"]Q(.T@RA":-[HVV)8:R<I<3QCF-;.V#Y0
M>A)9HS\Q,1P5%`<B1C,X=H(Z/O+OZ3A.9,W6S$5=H2F8SN[WZJO`WQLP0P]D
MK"8A(!=$51H843IL;V-=B!@8(3-#C?#O]R="C2UO5UAZ6C4G8`@C4R158**A
MPP6!O"E+<RUYO(^]UVN[YC(I=`LQ/@8Y9A!C2AYBH3@\/QT86R'Y!```````
M+`````#X`MX#``?_@#4/"82%"0^(B8J+C(J&AHF/A8V2E9:7F)F'C)J=EY&>
ME*&#GH^BI9VGFHBHK82JF;"2CJZ0B[6QG+FDJ;J]N+*XMK>CO*^^PL#(N\G-
MSI6LQ;2N#X(2U]C9VMO<W=[?X.'BX^3EYN?HZ>KK[.WN[_#Q\O/T]?;W^/GZ
M^^:$_/\``PH<2+"@P8,($RI<R+#A.'\.(TJ<2+&BQ8L8,VK<2`\BQX\@0XH<
M2;*DR9,`#Z%<R;*ERY<P8\J4IW*FS9LX<^K<R3/E@YY`@PH=2K0HRYI&DRI=
MRK2ITWA(GTJ=2K6JU9U1KVK=RK6K5X=9OXH=2[:LV7-ASZI=R[9MU;1N_^/*
MG4MW)MRZ>//JW5OQ+M^_@`,+ON=WL.'#B!-W*ZRXL>/'>!E#GDRY\E>/EC-K
MWFP5,^?/H$,']2RZM.G31Q.@7LVZ]4?2KF/+GET0-NW;N'/35%T4D>[?P)7:
MENF[\L]]Q[<F1[D\>,+F_7CK+$Z9.C[H(ZT;9;'MC/=LVIT7#%]NN/CS/+%?
M.X-^I7GBZMNS)$^TA_T>+.Q?P[^9?LCXX;PGWX`PC:%!%`@>B."""(;0'X`?
M0?B-@`16N%(-3."@X054X"`"%52(H&$!%KXF78DHNN1'$PTTD$,.+<;X8@-,
M2&B1C;%1F.*.'*W8`!LYL$%#BR\"F0,3/&*D8_\Y.";II#P^PDC#D`T,2>4-
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M"!_\JCC+XOH/A.<.VL3_IS+(<*B++B*[CL`?@].P/0V/C(ZO(I=\Y[X1QB,N
MR-_6JBL[_:+,G,3(49RPLB[?E\U]0`<M]-!!US!'QDC+P`8;&3/-Q!A$ZZ<?
MQ`H#]"]V,-<+8-8G8UVU.BQ'Q+6_$II,,\4U0WOM.:Z:;#.O!^/<[;K,CII<
M#V/4$$(4%O3==P2`!R[XX'[[/?CAB!]N0>*`]ZT!O6N3#+#=]'A;L;_/^?JV
M!)N7MR5(YM93<=G8+AQRW`NG?>>M$`><LMV=SVKVSN.&7G#L,DO`@H$^$"`"
M`Y\&+_SPQ!>?@P@AV#<&U%,SKX'&QKOK,><_X:YULVY_K>O8<8\]<NF3:Q[Y
M_[6^L7QY10B?GWNLT.'8I"(%H]MU^S.S7[;LO,JJ^=;U4JW]ZW!CVW%J$`$"
M0`]&&XN1`A?(P`8J\``U^`8+6*`!!"IP1D2B$=F\9[G_`5!D[5`?YE!7+NY1
M;W69@E78JI<1[=A(A.-+':WN1S[YS>IV[J,A_O2'-;3Y1E4]Q-_I>'9"A_D/
M72^\1A<*<(`<*$U,5(J>%(O7`!%$L'X22`,;AB4\(L&(1$@DH>G2`3\ROA"&
M(+QA_[[7JNXY2XBO>V,8;R<!\SB+7&:;G?VPV,;6Z1%["TEAP-#XL1]&#)#W
M6$2L4G8-`Q'`B1J#H@,G24D&XN"*7ZM@`_74@`+0C_]DQRDC&><VQB+.8Y`=
M'.'VD/A'/B+"`)]C7[(*:<)!`NQLH819*^-GQ&8]S(V5(YO+Y#8N5H+,-RP(
MP=&8MD5)5O*9D[SD-N*@#4TRD)-@=)W+5"G&8=I0=+;<5@]S-4YN;A.)8?N/
M+[NIQCTR9(;$%.<W%UG*7LKRFZMCFSU92)@"O$AC-.!"IZ!)T`9>L@?:H&8V
MK.G`*_62>[:+5CPU0I_9[?);I-A(J@Z91GN>,F<F;.<IM3E'1B+R9/WS8$?7
MR4YO8B,&!QA6B^+EIH+:M$4'-:)"L<'03;:H1EW+GT?M93W(E?*B<*39*CDG
MTI%^,YT3$]\H.YJ]E2*5E:#_+.GWMA;.EA*1?'0CZ?MHF=5K)``&0"J4L6[*
MUIPRE6!12.`U?PH[H2*GI!*=)T85AM3B1+1RN<0&5,G:J%"V)*3\T```<D`E
M(=64K3:5)L]Z$%=H>I(KB/7H29I#FJM^$'MU-2GU0-I'E.*5I2L5;5)5.UJC
M'I6>HC4L:&GW5:6.(0(?B%%-J20CN4)V@9*M7V7GJL!LIO:77MWK:6,X.;VB
M5EG4`9]F=P;#3[;NM+"YE6>G&U6LL><G8S#!)B2PO)^<8;L;!,=.1ZNZY;XU
MNB88@TJ69P(3(/0GZC)B%AZP7N=ZU;K^7>U)6XO%B3*7M<T];AC]P(0W09&F
M-"B2_V.-1>$*6WBM.#"`$;6C`2Y`\<(TZ!.KM"M2O\K1G&]-\?LV*N"8?="%
M2]6>S0++RZ/&SC:937%#V`.$-%@@#4`&<@06EP$;<'>8^?H)=[33W__Y9SDV
M6!S@TC!DOZ7!R,E-,'+-F+,:DO*>-2"`@RW,Q=].$H(3W,8$N:,!WNJ63$,"
MZG6[/#<.PM./A?3R;K@\D"P$)`$6T!C2E@:I'!P@`K$D<&G7=T)"FE+1Q(PN
MBKF1!BX2&F,1"*.C9^G:>8I0JGPF\/[4@T)2T[A[23U.#T+`HMU6>`!-N(`(
M+D#K6MOZUK*>-:UU;6L15$`#-0BVL(<=["CD6@2Z1K:MC?]``5!+FLXZCC:C
M76E@<9*:C]*&;I:=*UU5"G(QB:YQ0/S<XCD_-#E%`!*<(44#&40`H8]&H^44
M*;MG__66HD9C!'IK)0_GX-WG5G!$@VC.Z.+QU-T$E[GXMTY1BE+'Q>F!!H3E
MZC<QH``:.%#&-\[QCF<\01[G>`P"P`0FS&$.)3_YR4M>@"B$W..8S/9X7/AD
MVBU<=-/N=A\?3O,`WQ/;V7@/>DN("'*7>X\/L``-PA`I"#.=`1:`]\-373UN
M+9P1*;7/FKDC`?Z8U)#7ZT8$`DKF'/@@O@\X+PNWOO6JT1O21]_>&3<,8#@^
M.^$D_JKMROCV1]=[/QH0`<>NZ<3_"-@7WO#P43/=3*3IZ;FI^(YVWU,Z=;^K
M%,4"VR@*Q6AB@[?-VVZ?M.45O0VA#QVLI]^>TBD,10:DX;OGJSPPPR[[:]1@
MXR$(`<S#A[K+.?PX:7!UL7YD^%`>XO8:R'W(:W!?0VH>U;.O-ZAC*]OT)IC%
M[AU]HWD/_;"G-/`R?7,8EA:`,43^'"9@T1;)C"ANMN_:+9[ZY.U.GMJ37O3:
MSGY*HR_,_N_=ZD\&?Q"'5S^D-=@G;794>SG6#?E11\3V@!`8@5U0`^;G&U$`
M9S1`:`T@`Z^G?;^G5:AD3.2A`15`:TUP@BC8!&(0`>9'>;)%<P9W#<''>&["
M!@#G,&,0_P,"@(*W)@`"D`92YS6]%X.C$WO:,D(PF$L(1U+Y%WV=)W=/Z&G8
M5QS@AT&Z%09!4G[G!84TIC[!\B,"16:4\C),:$PQEEZ;9F)Q-$[O1W?<!H"_
MDH1S5%'P0X9_AT]BQ88&B(?0(2`*R#72M3LU$`4^P`05X(,IF(B*&&NUQH-S
M$',6\"+&\B[N=H;V)W?NQPU1(`,.Y$3E1WO[(WTX,X/A5X.9%C?V$0%6>$'_
M5H&0=G4$>'4WQTYPV%6-%H.TJ(:KU7EDZ'D@V(;6)P%5Z%LN8H-C`'O2)X+3
M50,L\B*=PGK3<RYUUXLR]G91"()-)7M@1W^81V\'2$)%^'>G5O]YUZA=_`2.
M,)APT#5_G+4EX=B$Y@9TER.($2``.'!`Q'A3!Q`"+3@&D;A6+C(EE8AM/(=P
M?N<JE&4D1>)%,O")=_B*XB@Q^^9%'#,D-M@]J1@\4R(\+*B&!7F-+?6!!^F+
M_><P=CAZL/*.&U1UMIAOF'-OCU:%G>AN"?!=W`=WVO`H[.=XZMA]\58W<!B2
M2BA@2LAW!"=YZZA-T@B2FN6-3-E:2RF*2FF.VF>`*EE')])WNS1BWH<-!"0`
M3?0I6,A8!'5A#;"/Z!*)[(:%+L)T`XF)_->+:>@;E"6)%>:)%2B2DJ=YS3&1
M&KF1%\E4/]$#JMA`G_)N?(E5/IF,J!;_3BFI?]O7?57G1LZVDB&(A$;I5P_I
M=ODEC((W285WC,H8F5A%;^TBEE,2*0AT69=YA\\'EW%9B_A7D#(4A;CH>:B$
MFT<FF?)'F4JI1M3HFT-9E<Y'F;FC0NXX?PJF3WMH>P$0EB["!?'R82!6G4.R
MCRV8=,ZX=`CDEJ<(A8K)FT$IA7095XQUEPV9ER?YBKBY')7&1>=I**?(0H29
MCR\"<*%XB^$IBZU9BV7(F%IFC9LCH#UWB\.9;Z.34,<Q<3Y5C"S('L89H46$
M=:?Y*:DY(T<R7A**H/T9C/>7D@(:B]^(CGK9G-F6F;HX5'+I;'K9GCXDH0$H
ME_X'"I:Y>4JU_X<LD``1$)8@5I;4>9W\>#!J228,&0$V*8JGI9L^.6I=9YX6
MYHDFH)^2N9)FB`WO.2QKU8HI5I^ZM4#_UGR*^3(_6:._V)CZAW4!^GMYJ(L%
M:J"<-VJ=TYD,"IK&:)DE":+P\R@8Y&9,4!/.AXL&:HW6QZ(L68>`ZJ8[AZ8X
M29I)*9[N5YPC.9KGUE7/`GTIJF)JZIHT2J8#5IMWEUZ4=0%.=)[2"6&,1TE6
MLE;[&$J1^&%0Y&X0*I65N8YK6)?Q65-XB6"-(%+!YT59.I_8P*4.)B,W*%6)
MF93V1X>>>I*&JJ)3J:BSF&J_^&D\)7@51R1U*H('V`C%H:=O%B,U0O^@^<E_
M7+BMXCJ@NTI'Z,A7CRE$`%BESNIPM!69XPF5+(FI6J6M9U0^&BJIY0:4\KJ'
M"4`!32.=%69F#^0@0OJCQ6*#L2J<P2F4X1-8E<5)+I*>TP2HW"I=8T>DP\<&
M/O!=^468:L5X7_I6.[64X*-(ZG.H;_J2T/J"<IB9OOF0<KA/1<F7R0%^!XNM
M+`BQZ1@W_?6%;S9\=*4NZ1*,5PFG6GF.5#FIW(I@HC:C3XMWY"B;FNI])!FS
M=/=^<K.Q(VH=QP"GM-J5M0E`838L!DMA1W``#)`T&?.V&7,`&?,!!_`!'X`T
M>2L&&E`<JW=A#OM>>'J5E/>FKI,&,55FPY+_GC`9M5KY5A.Y)V]B@XC72!'`
MB0ST3YG&=05X/;=9KR5YHI!JKR(YNFDJG#;KM8;+2BTHI5T7>.=9LEQ4?LT'
MMF9('E^X?E5"4^`:M4N*-F&JC096.BS+CN,H5OLI?RO;IB@*BSZWNHRZ8>ZE
ML;P8.^W8K.2ZF-H[L<+KF8.G0`$5!G/`..0[.&D`!&_UCZF:0>ZV9`9YDQ^*
MC8*Y:A3`!`5``?A;`/JKOQJ0EZXTAUC'3Q;06Y)[LD&G`11PO_FKP`40`(_#
M=5/*>0#LKQ(0!Q:,9UV[O7XF/M&ZC5,;K15,35/H?$B+"#T0I<H"-1H@!A@4
MGTX$)&<'P81U!1>0_X%NLG1$*F?-Q:0VA+7:ZWL#ZKI->[/@R)LCJ;.@Z+L>
M*KS#*:9*"XR!6K.M,[8?>91Q9Z=MI`'-V*5BP@`^T+KSU()3@PTRG`CJZV`P
MTKZ6JJ1?0QZ=N9Z#,`:XD@#^&[TN";7<$+DSPELGFTO^L#SEQ53R-:FA^U!#
MD*[>8,']Q3K8(,<BVI7559S*J;*/.IP)$%_;$%[U)7$7`[X;J;GUA<+I@%"`
MW'5(0`!;=&E!LC1*\S29;'YXLSP<>J?E6$Z+::Z%;'E1N<8>>L3NNK57F\M5
M^IKTQ[QX"J]M3`J*BLR=:I4VHL7?FX&.!75@O)MP><:XNH$1P+F'VIN[>/_!
MIL1?398-97R@`&S.WJ#'4D*L]Q4WC@R_4LK(X0RP*0L=ZR7+OKQ_NHR9XSHK
M]?QBQY$`:>`#B.,#!FW0-X`#"50L[B(#!'#0$!W1$BW1@7/0@.,#?U,X5?8W
M$3#1!GW1!AT%NURF'LBD1;BFF\FHK_FN*1VQ)&K.P7RF+,W,+CW+)[V9T9"]
MKOMXD_/.X`#-"^U89L?/EZ@-V!Q%VNR^=JQV(QK"BOS46/?4*9L-$'JIGH8N
M*M&>V7"E>\S.[+73-P3%G4FZN6S+'B75S%QO:M>O)::M`'I_W%#"W0/.-B``
MQ).!3[0TP]I;1@(D"CE%@%U%R;,-I,PY4;!%T4/_5ZE4E;J\:8':S]NKK\:;
MF-:[H32M<_,\Q&;K;<N,S)<#$9-\M3>]5,I935M<M)'B`\'KP;>DG3>,U`/I
MF(CP'<J;#5*=7RSKU!:LE,B(DRDZ"+K#>V?`U>M,)/B)M))],)OP?CN%VY^K
M'B*LSRB;+HD@PGRG-=[A'=JH57#!Q%0[E/EE`V+04$("1<]HLA+63`B[0!"$
M4)R[#3TU2>'JE,#<.2KK.KZ8V[U\D';JQ.$)HT[[E)[-0TVLU86<J==-IF^'
M&9.=A*J[AC]]VE4R8697J-6W-JZ]OA&FS6[(#=Q1N_V)(U`=W$$G'57\W_L1
MR\OC,]F@S@5\W+M]7;3)_PTJ'EXJKG7,"5;/ZQV(QRU/S:BPK#S[@;HJS8N6
M*@',^*.FRGJ/Q8K6>:H+=&%6))@3>@UMQK`4=@/I.N/2B*0_/)2(3+;_;:AA
M[K7]')67B*9I;IL.SH3GNIX`7N(&OM^37;9H!,V%DN<;Z0,@_"I'725I_)W\
MN@NY^4.:8'Z*S#F54`.F<*]0*;AY$P(Q$`$);'+Z&P`1$`,A0(%91,`7=-R"
MQ>B?L*'B$FP:,.D!L+_Z2P%#%@7!AL_HLCR%`,BO4.*80%+R=7M10&41`&3`
MQN@]K%!^E0"FONN]G@8Q`&QT;)S#/I7X=`TL4`,4]^0]^R/J398-^DP'&URV
M1/]!4*[A0$6@".I';#RC\HNHLP>V=W>L,/K2O.RO0"S;;J>F7+M]QRRIBI0`
M!D#$:6W'6S[GVD!!K49V,<)T#:#:,C?/K8+-"_26OJ$!,%!R$B_Q,#`':2#'
MQUL^$8!R$R_Q<X!QIM0%'-_Q)=<!,=`#@DH=/9``&E"/!]!,&]/7(L`$4>`'
M`QQA>VK<[[R@(]_Q)Z<![NLZ[#$&?A`":3`']ZB!7LHT."``/E`$+I<@#-(W
M!\T$`:`:X%6_!4#R)L<$S&=64),W$5``3?#RP</T3!`!_8N47<?R$5`!(J`T
M"BD#'L($%D"!\D5C+(_LF%33MC?MT-3D46ZTZZU`5H3_\B5YY8/O8#I<Y(^*
MC2B:M<G[[K\[?<\]F>0*ND:.[HT]^<&[QB.VTH6^0?K.[Y8-UHAZ*[6N9JP6
MD%.BUTQ7X9WMY['+>`[_$Q&0](2V-$S3D!IJ;W7D3WY]]FP@`FFP#5%`MX/&
M3#+P`9\8HFVO`040]Y]2C!LY?A@S\P3PR8<211WISI<K][S/RA^0:32;H](O
M`G1;_9.KWL/"!@QP`#AP`/1?_W++-!^0`P(003\!"#5-.3(Y;&PYAH4'(3T/
M$A(/&@$"!XB).32:-)@'8A$UD0]G#Z4]8QH%(@<REYBO.0<"H)"BD),%`0$%
M$3:VD'&ED,*U-1<-FS0-R\S-_\O*SLS)T=35U3@UCK6_M]#.RIK+3(^UI<2B
MY.;;YNG"ZNS#\/'EY_+SZMSLQ/CXZ^WQ^MKU.\<-W39T`<D9I*>P'L)YO_C9
MB^1O7<2&`1D^2)"@'\"#``F&!)E0)#V*!UF$$$"#2S)P87+X>-31H\5R%2%9
MR`3.F8P(.,=$.)`H69B8,B@D0*B0XB,_!9Z]7'8@S;H>461(HW&4T($(8T(^
M.A>B`(Y"13>Y?,D&&INUF)RQ`5INC(D(B9I!2P36'3Q4!2ZTS2LUV=J6UAKD
M+9I70"A(?@@H#D?C$")&)B3TJ!%!A*L<R,!I"L,UT8$"H<RQ,!%%%2)7+X_&
M3"0"E/^CCA)21=!0HT:77;YRPGMD3#&LXW$3A^:$O+GSN-AZY*08A8WQYLL*
M-"VI4>SVDO4RCOR(<J$]@?*&[UL/'B13C?KRL0\O<#K[[N*9TJ]O7B)!<QQ-
ME)`_\75'8'[Y!-B/!DV$P85+R"S3%@T^C.=>>#=)L!-EH2WSTQG#2"`4*[$A
M%4!FW(58`Q.%3<-#%&.D@Y5UHQT62P!AA80;"PFD(4`KADQ(XTN4>:-)<LS,
M)1U*/5A0R'*;&`+6.KCUV(2$EA&Y"37A=/@*5UQ<0D!J#T0VV2:'<,)(#SW^
MB(F61C%'"!,UL#!&`C7X(`(F,C"05HE<S/95#1Q)`$0!,7#_%D`$4=2PZ'@%
M2E"<<I1&(^=SF+[2``Z-P">,!J`]E]U8!T4*WC[D#>C=1^I!Y)^I`YWZJGXD
MG8>>7PR)Y>E]M.+TZJ_SY<?K>P`I:--#!\9:8'ONZ0I)#PQ6%J9>E=%E4JD8
M^KIA3Q$V\&$\(TZ8#"84A#46K"OR-%4#5,008RTS0AD.(11DQE!';'9F"!<M
MPMGE<LL0EJ2UPC2)B)9\21=?`A8<@\PAS$!HS9M;'=DB:(X5(X!B'<[+0PA^
M^'!!(FENJ<E;AQUIG0P^F&""!DPP$+!U\IX,390YB`#C+72&`(,&,<SA1RID
M8D0J))-6JO323'.*4COO@AK-8J`U_Z!=0<LRZYW6I^;Z-'_O*'MKBN?*FFRJ
M8>LWMGKT/?1??*KV&K9?YXX4=RF%(A@I?+L:?2Q%+(`[QN!C0,O2,]2RX<,8
M@3=;2^/8@K1MM\S\-(]01]3,"1L4^(%2',@2QX0A1(+&0QKO!H-5(46&P\")
M!";00PA,?+`OG-14K1AI>^DNX90A"F6(NEOF$$$/I-04200X$!^GMS@T(4`3
MJX1Z";5=)F-=QD@/DH.#+:TEPP$!,-&6N.L2&>CF#1`011%-/*B)2P]VB$R8
MHCG(12),+-5CO2&80P0B$`!"44`#=8M;TJ3"I4OYCFD07`8V;$&W1TC-4HAK
MP#C<)BN],?\K/1T4#]R`M;4!B4V$P`HA>DH8+!7VK8(M;,_<R.:10A%K5=@Z
MX0EK!0D;$'"`0!P@$YI'&HF%)@Q,B$$,TJ#$)CKQB4^T`6ZV,3EO>`@HZFA2
MYBQEB,Z]S1S!D%0!BM*,O.`@!L``G01B@(ANK<5;2I'(9L:("=ZE;P`7((`>
MC4"S[W6),'OI"[@B@!;06+$!$3"!/#0@@.^E["C,.4T40D#)$%B``$09GO/2
M5)AE-.$Q$HA,(L!G(QF(02O]H@$(>%`"?@'L&0_*P0`(<`SY$8D!`RB!:!"6
MLVP\(`T4F-T<"E`!"YA@#`?D53^*TSI_(:<:_HJFOQH@`E\(2P+_&]CE-+JT
M0;9EC6X'(@\+0<@?N^TG(^3\![%L%<)[Z%!`,03;%],QQ76B4(2L2J=";'A#
M9_&M;UMK5AJ:9QG+R(!?F4"&[J`Q`!PX]*$0C>A##W``')!O*0VI(C-`8SE;
M8,Y^H4F$4LJC-C'^R1EG?$@,#'DS91`"1V6#A`E\8`G2W&]^8<K!!RH0@1CP
MI@8VT(`%*-!(-LB@=QDT7HS8(3SG=:DOI$I``5KQ(#O&,@<"2%2.-#.&&EA@
M3Y=0WP!N8($@]E1Y?MA8)NS8$J[X"4)'RD$3*)"&*$0A`HV$TG4.<[_])8(!
M(J"K7?7T0(#)P"H2J`(3_%"6$,3@1&6Q_V;HW"&!+HC`.&74%,"0U%9,7$]I
M`J,&#H+CN-P\L&K)88*GU.;-#B9KAN,TVZY8R%H8GG,^'(1M27<[0MO*ME7V
M5*&P%K:4<.:P*?UD+0ZW@94#6.I?`7O@(2%()Z=$P@*\<P9'Z>*4H?!$&@$;
MZ='B,01AU(".TVW`Z4BACBBP5+LRP)$H=/`(UC3OJ&J9'R$(D"AR!(X8>1H9
M4KTTI2SB!:3SPB*I0F"$!N#/,&&0P1RB(`$6K$=$:?#,29\Q`!\4MQ;!*&\H
MK[3)_![%K[7IPH>Q*0:]DHRO7='I+`A581$-I8$-F$M8$@"#-$S"#^=U5`0P
MNI'><J0+,!"#"/^6S.0+,+D)33`"".8%R+8>P,E+-@*3MZQE$71YRV!FLI;G
MH`$@].;,2$#"F6N088>"^<LBH`(%_#%%X7XSIO]$IVO]\T_>?E`BRU65V?[F
M+#NS#2(X-#1N^\..`)W-N*_-YSQM$@7GZC6"E"*2U1[C#NQ"EV,=I<B(OIM4
M\9IG",H[;V(&$`/V"L.]"%9,?'>,F]FIU:F*80,!-)`C0)\B`C*++@-UO)`#
M_^NIQ48EC>!"30V8P!$-Z8B=;JPN:<A5`XW[;Y%'?*9I1/=(#"@`KS^2@`"X
MF'3%,PTM(%'<S3CL&R<;\BUXP>NN1J``DEWA1O)F@RZL><TVL(&9TQ#_/Y<*
M3!,EH$`(>A/PA@?\WQ"W`<!#(/'>1&$.8I@>E"^P<8X+@`D+!VK#&5[Q&@!A
M;8JF83SU+-R3B*(F*:KMG^,!<Q>ZUN7[+EMO!=VU8=0\Y3$/5@(,<%M(1UJW
MCZY%I5N$Z4I-!37W\/0AMWNY&Q\[O!CM3WF)$Q5KL)J]2G\OXEX:(T<G@`)'
M0+?V%,,$9QN((X5;R4:K%HZYD,?81H+&\6PA5?NU]1`Y6&S@ZAD,4]0@KWY7
MAI+H)F(_D%A+"J79`7S@AU,8:WF[Q.PKL6J!PBV5)G>:`S1S/.1'C"$-PQQ@
M+C2`:%,-8ZL@<@^#(I0<U[7L%,B5P!EB#PG>_]>"]TT1I>\,<1W53J=4)<1)
M;?GF6Q/.\,X@3+X[_XP1@P2DSBN'5$7P]G-)#Y=KWQ_TW>9C`*(7_;BO;6&M
M/+)TYRU-FE,9%]1)-0:I:]=;!(.$U8V$=>N65-5>AT;G`&M71W8(H0$CPP9A
M`"6`)P#C9EREP"-=IWEU1S#D@'=;L0Q[1PXU(!DI8QV'(`,6H!%#H$8=,5.H
MA#@NL8`%@"(_]P""<":=-#P,X#ZRLQ"UD`8RLR41TA*2)V[/5BB[5V0]4``T
M\PVDMU0B8@-ID`8]50.]IG.VD@!**!^Y<0R]PU*5T3+]U%OCY'@U<S[(L$&]
M\C7@UW/OT5KA%RR0TO]\\.1-!F)]/0=HL+(?,E=]*E=!NN)!SX<?V8(.Y><1
M"%*&<A,W=@,)E?8GZ64-\,>#.#-_3F%_981_$+%_X*48IB9/8I08ZS6`8C<O
MLU8."0!L'/,2II$&"I.&RA<!<S=L&QA&375L>I>*E;4QZW((!\!Z#"%BHA8#
M`_!<^],_@R<0,5AMS]!&,@!R/0!MRH>();!Y#1`&-,,`0\8";%)<8]$18Q``
M*:@7I,=]-69#8H.#"*%&Y?$I`A9=AK06XI5[<\@=QB`N;`4.-X!RW+&&:[-\
M<EB';#A9>NAGT9=\;DA"[#0K*?1".E=2^O0=?:B0U1</@6@2>V.(>2@2&1'_
M`\Y56)2BD96""?,G#/6779/84<1@B:66=5US7DC2#"_B:H]`@*(1,*%($34P
M!PL5/I=0`77R?=W5BHAC=Y$`BWA!:AVC8+=@B]X6@A2F$'$0#&$$"2-RB?-C
M-42&*V`H=@JU*10`!-AHAA6F`3S0,;1'&Q:0`-HV0@G@`=T(7L93$^(8"3`7
M(ED3(L!P#EF0!9\R"%FX#"ZA.,JS6SB83I+2!.+R8)6A#-UD'W;69]\44-1'
M0JZRF(4HF'=8D.>$<Y(97`%I:*O5AO]8#T,W$?Y$B#&'+&>C`7,`9:JIFH(A
MELA@4SP09K(YFR(0`-@X%I*X493X"R;9+3F0B;JE_Y()%0TO\A`P"5*SI@X:
M<%E%\B!&]0$%5B"%UQ2L*&QE9"U/.930!0Y&*0$VL#'TTU:500AIT`_3"9(4
ML)9]]9M*R'U/06(=4W>4=Y8,R0)@Z9H1P@.)I'P946[JB2:EAS;0%X?YL'42
M$`)ZJ8X_*6\/<)XV831>,Y@Y)BWK,@Y/Z3@-:9D$FD(-.9E_Z(7^-*#B]'S\
M>)F>J9ECDV@#:8BFR4ZYT@_&<BQO2(=[`Y@(@2<0UQL9-J'=TA(+J'#]I@%=
MH`%$6J1"V@4V4$F5Y&^W^0`A^6E4%SS>=768B))]*)SI59SP<)P^42_;1D@U
M$XTY@`.LEY`@1A#5B5G>8/\\"]$#&,A`B&000,`BX=E62-$_\E$*C",(H152
M.K8/-@2&0\)`:R).#Z$!OYB!'/,#?J!(R%4@W/A<U8)])DHK;X@L(8"%!J<[
MA,"@V0)._E@+5SD:W"(.#[IHOS);Y`B'_CAI%J(L(\J/(8I;!1EI@<FA#&FB
MEZH?RC,W>?9%!J(.,7JJ@GB/?+BKFK$DTF&-"$I\>N%7/M`#D%-:R[B,K\4P
M(JF;H69Z4\I_55J9$B!5?<H,K&:<6%DY]2(*R'2NQB$`7:!<="D,:9H7:ZI@
M!?.F]M.=9[=6+Y%39V26&T%S#\`F-,4QSA`3!["4`R*HB=<`:P*J[Y`;8:FH
MH/'_`T7C-^00J?`VJ4%'HK$R3E=H/Z$U%U7YD(R6(J,*27'%=NYHC_&T6NW4
ML45G*^!JJ>,76_<T:2AD3M#GLBN:L_E(01-)'^)XK+GJL<4**_64$@BZ'/)H
M"".8?A>V6]@*I;LI:MUZB;]9E9,5KG14#5^WI5@)#4F!(N'*(B!%>Q\).C4J
M#&G0BO7Z$&XZMGIWHS%`!0TP9<MQ5;5!9,^RC'EB"85E5(%WL>G`;3334K$0
M`@;1E.DAL=02,!IDN/>P%-OXG_%6<['*<C'D:NJ*@)1#1@%CFS<$L<HD#(Y7
M1[P#"V087&E8J4"+CS/KA7U(3K-EF2+4JY!ILSL7JA69_Z(7`:K*5:*/RC9%
MV[:BR9G2]W*B.7MU-QJS42&14Q#K]PZY*;G;JG]$0:5;NWSFA5[4$+;M-;8>
MDJXT(1EI"PWM:%L/,:^&M%''`P]SBV!U6PIAM")9$ANT$0`A0(75.C1FX2VE
MFF,YDP8E>PX,VX-'P@B-.T*0FX&<,+FQ9T+:J+'80[(TVYFQFQ!CD*G:-9R*
M0;I`YX7%\28NQ1P:!'2(5IE(*T/G][HM=ZMW%EN:Z9@].\([!,/&BG*%5J-;
M8P!-.K2XNY`8J[--,7MK02,Q-A.1X\/]<5W9BKW<=8'.Q;WBY:#+-#H@W`SB
M^VKOQ8-E:UZ2\6G04``'K*KN&_^Z&WBO=*N!0:E&)F`!.)!C;0$E^^,M!.`#
M%I`&%F`!@:$5)?-'B6#&<"D>"9P_B^N2#0IHB%HQ%E-=`>44%EPQ&)S!+(PK
MX:J[IN#!F54\(HS#&5&,H@O"XZ#"[S1]P\MS,<2[-]S*4JAHF_M;]Z3#SO>.
M+JR&12R:X?0`0/S"JBR[`+4UH`,Z#)(#2;P)LQ$!Q5N:`X%1UPMJW%4+O;D7
M5]Q:)K7%Y&H58AN?9%LN8OQ*&30'G':I%PBW\*LP;$R4<0443:E&F^$#`Z!V
MAI%3;,``1\``3W((*8/"!Z",X?J/AWQ$L?"N`8'%9]#(VA3!D,Q;X3K)A8'!
M//O*I]+_E-YW"^_V;74'4Q)=R_\HH9K##*7L0CH,KSNG6[A,O!R-LQL\PXPF
MD"(JF"VLTI>\T9%,4L>5<RM'TZ2YTD?;SKEQ)5J2S,4[T\/QS%&Z#=/<?X?&
M=^!+G`KKQ=Q<OEN5`"S"@P##/84($&E<KPHC8G.KSLS!SA3-$3W@!TR@%8>)
MS%'R,&T4)`[F;0T@SLNX;>\1T*,QT`Y)#@?]B[A#)Q/\#BOFGY(*T3S+O#U;
M6K4`NCCVIWY#("[7C!*`!%?RT:::AQ<1T6K8F=.WT3HDH+GLJW0]RWGM?0OY
MV._$PV7(9VFSC]FH?HBM(^9WD"J-TJJ*0\7<4@##Q(Y]R^DA_W56=-143#F8
MQ3E!&#95(B)1,`CK`UVL=I82D`;O^TJA:'I,P!4)S0DZ(XIDTQ&L*"=R`57J
MJIUYIQ@%)@'!4"B.@@,M)9[2\!;Y=3)U3`-R%APXG1`QN(!LB=<RE]AAR0D1
MW"'5A8:7^USD_8)PJ#<=T:@FP!$,SA%PX#(O4PD4->$3;E&U40,FX`<-ON$<
MWN$='H/HXQ;6$=(\G5L2#;(V-QR:2UN%W+O&6T^@_-FX6LLPK*(I;KJ-1L0M
M.Q^A2<12BX9&ZZH_[4<]&@ZZ_:([W-MV-))3#`EI4,69E6/U@GLYQVYF:26M
MD#X-,`!1X-S07>1D*U_D0`%OD;CC\O\5YO)!'7$&W;V22>@7L3C>QH/.Y%`H
M"1`#1N`2ZVA+)U.G,4D#1T``:6`"]`F/5X+?F74`[WJ[%M3?M8>8ACL@8Z"6
M@UUZ-VXJG$$!/J`+G!X`FNX#FCY`&6!60)0!3A@!/I#JG;[JK-[JK!X!%/"+
M@YHDUG$UG,N9XX<W+:>\ORQ^OJ41<;F8[>2AN'[KPOZS/INSPZK3^_V[-T<K
MQ6Q3Z]T`1P[*P^#;3#[!VINVB9`4?[EM`>L'!/?H5C0`B&4+7VY%86XND!`#
M.``Q##2>`4XE^,`1@=/F?4IL3(6O"8;.0^!SIA<$,0,EH<(3TLBIA(`#`A0"
MA6,>FBRAB#[_=XH>O-@'N=[=+6/23I..N1PKA41="]\9)#(P\B-O&7.RZ(23
M\H,SBD31"@7U\C`?\S"?=GEQA`;7`!1`3Y0*(,A.0\O.\W5#U.V@('")&U4>
MVC$,]*SB:+?U6T2?'D:?TZY\?:T-RSA[7#]ORQL,LI$<']'.+5O"Q"?=-9VV
MY-H:`:20G55\2(=`R`\/@V9A5.YMU<M@[B>1[M[H+1J--&IUB02,`ZBS'C^'
M4<[KYOK.QE;=[TRA/&/@!VCG8"N()'QR`"(@/;L!A2L_[/<]-7@M^!EQGQ</
M#1EOIO"0EIA+>@8NH/`JRJ_01LR!U9$P.(-$%)\A*L\$C)EG,=0N_XH&SMM`
MBY#.GMGNF?0520^]G^NQ*_0S7LO'W^NR5;/`WOQ6_Y@W#!_%G%#3[F$LO/BZ
M"\5TOUUI3PY/#LXY)F$[&?4BH@$=8#V<%+[E"0_I/M[)6><4$-W9PPD$$`**
M#"!+`0@L8S$".30-.8D-BXML$6,2#Y(2/1&)-(>+F(N/DI()"0]G"381!`.(
M;#F(.$P4%`4W!10!$6D:-C63D0\ZH9&@#[R[#S5-#6&,C(D'7<.>T)X2&CP-
M-(FKUHL$NM'"SQ()`3+*FH<Y$:'1$N#0D<]QDS4"UC1A]V'9-%PYW,_2#Q*,
MB7``$::#"!,J7(CIWB%,;#!QR73$@C!O&/^!_<+H[1_'CP%!KA/YZ5M(7K\\
MEC1),EK*D-[4C20I$^8PE1UQD@1VL:5/CNR>@=+Y<V9&G.R`)O6D042.,`_-
M'?*1`)S'I9\,&*@9R0+43<L:R(BPE%V:`PF7Y1`3@D7`E#4B")`19F*Y<H<&
MI(DT9%*459G,B:4P!MJ8*"*4/3S$A0V;`C7:>>IA(HH8&1$7*5+FJ+`T"9;J
M,0+;Z6*H45%@X%B5PW$#-@(BU#`Q)D$-KE@U]I4TI&:T><CN,G/6<EJU:YLS
M^6LICAS><^F*?O843QAPA>7Z1>98=2"#>@S#BS_8""'414TT2(>YWBA(W])]
M!TNZ\61[[M!>P@?_273EI_H][=0?4/;=5Q16;R$H$U;[9?114%<AA6!33T4%
M7@-4K7/3+L,D``00!KCS@%?DA3566:"AA9!:'U@`25(U1%%`06QP\=5K;#S7
M``\Q\"1,%#D&1IX,`4!24@T%Y#C:08VQ<0`3&@P5E#!C:.!#$ZUEAD@VC'0V
MB20#`28D=)YY,D9<<RFBR)-15L4+A/^]Q-U^P"6370[-H"2G.]18@XU@3&P'
MWSN?C'/7)HXT^"5`''K2FP37@9<)#3GF,(<-^+$3P1'VC%?B7:!N0NEB![$Q
MAR[J("A2,/DYZ(FB/M$'($LV^<A<3_LMQ>J`#[(WW7^+MN>C5<!^":M+_R;-
M]]E5L>KJIH3("G@4KP\V91!8HOD08$<:!F0`$*Q>9$%$V"(B5@1G#%,E#I(N
MF4-L&H2@@2D%(3018T%*M6,,;TV2!F!++B(#8>Q52<^U*V9R`05IA%!##2&$
MD$8!(@1Y7EBB>2E-F(:,B0A9&VLPAPQ/!8G-#7Y0ENJ;LK*D:DFVUJF-6GD6
MFY$&J&"CSR'<O!JLK(8>2FETVS;[P!!(0TH/N<AIP@4B!&#ZX$`'..2I>$NF
M!=X].>"0!BBPHI3?L2+VVVNT1IO]$]@_Z<D?M4K9;&"WGX5[-MG3NBK24EI]
MHY)'=O_]\J_N3*F4M2L*IJU.JLJJK"3CEFNN(_\0"F1,#G:!9R,B!S1!0!-'
M:/(5/@.4("JI^_+FKYB+7#QPF1<-M)K5Y('%!@Y-,,'$YZA,ND]@.W_<PTUA
MBB88.C?5P`1K][S6V,!^F&!"HRZ!#;8$+,`9K#1^T).,J-C4S-ZLT^3\)U@]
M!PAX<T*_1G3;ZR!MW3&2B]:/#9'$P5=?*&UZ]?_8D<H^PB`#R-B-6V?S%;?8
MED"?%>UEND)@<?SS'@>ZYR-A:^#>*%@TC,RJ@XS:F^"2@A1/]&V"><L)M%3X
M-V%HX!@=\]U40!C"=P@E&I$+C&;<]R9A)*``K1&31#*GPWIP@1\Y6!@!@HB7
M!@R@1^[XE_%<1S"_%8K_9`R0R$(8H*2L105;P4/>34##NN.1Y1UCH,`'#%*7
M5*CB`C=X10#F.,=7V/&.=O1!!"P0!0W4P$BF,8G2@F..\&E`*+G"V984@;YN
M[&T,05,,1-YWH(P8XS5%!(]VM!<-J@'PDV#!W!'SL99#6G![J!P<X<8F'56&
MD)7$>%M_Z`-+&N:$/QQ<4`M;&9,%I>V5="N<X4!RPK)=\)C4NV4*._)"@XB&
M/(OCE0UOZ(D<6F@58SE#+--`LBP),'%ID0$!BA`""N`(5$\$AQ0W42&!46!Z
MP>H!DDAV1-1!)'&-Z5(3F@`\P5".>*'!%CO/Z,,.-(`!$PD#"#2CBAS(X*$0
M_Y7!!R#*``9@QJ$49<``1"``)D2@"VZJU2#MI`EL?,"4K\*-"X_SIYD%2B>I
M8M\.$9(H6Q*(49`ZAI8DB0E_#$X"G@3EU?)I#BZ0[`+1H67A+@@W^<R-0+O2
MFU)F:2NU/=6##]KE??3$E:MN"X+#9)0ZBOFK`VIPE<9L93,-\<Q-1+-M$*HJ
MB42UPQ.%HRI5J0$,$H&91=03+**Z:`,.$``-4,:<KKE+.J/(NJ=D8V#3&]0\
ML^08WTDJL(G`00PLX*?D'()R[N"80*'SI@00X*`U"N41L].03&X)5`YM0@1L
M\"+VR$P9AISE2CNKCT6\%(.3D*FYHE)3N/'GDK7+VO\FESH)JFT&5-"-[I+"
MX!ALL$$,7PN(*EWIU9UT][OK,>Y5Q6L@[N+RE3]593"VHLQ<">XHX)T&#!/F
M5EJ)T&__2,!<KWDNQ[%#9*MIS;T24D]$R``'<T@#$![``B2=;U*I.]HWTA"D
M<VP&LDA)0!H(0++1,L3`<XB"?GGK3Y!MS!(="Q@Z/*.I@C3@KXM9Y"4ZI3,N
ML14\U>U:`3106PG7X+3?4PN>B+.3/B$G>+]-ZZN"-F-$$>V]O704_R(%3DPL
M=V6?(<ASI<OEYQR1-4^*0F0&9-Z;GM6^<8O)4R.DY.)0"T'B+3-X?YD;9"93
M)M:38$J3J6>T,C=6B`L5AM#_[!Z6Y9>SKOU8!(,2ER9D47('<:@(8!`!()#P
MAY=`9QI49Q8NW84-[_P'RTAQI0%T,=.:T,0`!$`!_($&NIDPL9DBD&J>EH8=
M-?`!%2RDP\J22B'/);"5$R&`,?.E&/2#[0>(',MU:*`$TEV.B&I2FP!T,6`T
MH*0*RR:3W>2TRPVH@*7/0.ZX?H,@X$XW3Q'!`P+,%BO>'N%]X:=,)8>5@VV6
MLYRS^DN;=E":<(XR#0%^7E0NZY0/8._=5L:X-,/W)R(3P04D/G$16'SB%KFW
MPXN6@!A(W.(@!WD3]F(?4(RA!U6B0!,&,(`C8(8-#V4`[@H0@S_2)QP1N+@(
MC&"$_Y`+(`J%TT#%0Q[RI(J()RQ(@`8H<`K!ED,&!UA8"%XD@310@>@[[[D(
M-NV--%A<ZU_O.5*CT0/]$N`(F8$PI.OG17O<*[-?(U0QF/#QBP]=`%WH\R0T
M0`"L@QP'D.%5`B)P@:N#G.<3OT!V^8T?=]1@#@>(O.0G'WD$1PD.<+">Y@E_
M`!Q0?O(L__P`/D_Y`?``!Q=@@@5"$%+5^9G0P8Q5O_U=;V"FTKC[UOL&=1_[
MQML>K`>23+T9F/"J((NJ4M70"JU:O6]]Z/G09Z^Y:YE,H4#_^A]2^/:6`@0,
M;"`-$8A`+3*0ABJ`B[F@`((-GK_^Z!?-^=%W?HB*8H!Y%?\`!AT@@/Z94(`(
M^+$^D8!]U[<?'F(#[7=]6[$;'!(C%(`#I[9EZI8P];`*3*`.U9$`\`<B"&A6
M'82!`OA\*L5*P'"``J@.705<8I,?-E`%&J`!+-B"+E@%,J@!:<`$/W"#.)B#
MNU-8,PB#+<B",OB"+NB#1$B$0;A@2_4XL!=\TY9\MB<L!^>$9&83W%9>:35&
M3(A5K5)>Y-5F]C4?=U4]LR<M9O9PPC1,YJ8JQ-=L$A)7^W9O&C=5&C=&<$A>
M7/4P#_,L9LA)@:1\;C@VH<`"26<!(L!.F24``K!/BM@$%W`!B\B((G``%?9%
MU]``!!`"U%%[O*=\RY*"<#5]2\C_A:#(#CT@=#-C+IR1#FZXBG!F.*S(AUOE
MA',VBYM(BUY%++98B[G('//GB6[62ON&-_IF4W6VA;$406Z6AN8%.+0R+(A$
M>P(')F5A&ASX>G"54I:3<S)@#WXB`CX0,3XH+T78@E$0`11@!)X%%NG1A<#D
MBS?5('AF2WE627IC.,1'"=8"*OFD,0B'9_,H-^AUA4E8C0;'2S;3(=T%-]RU
M)\)'D,P1@L'"0.SX-@"YBV:&@1X4+ND59]2"-P7)B;*'0A6$*U;T9Q2Y2I(!
M(.R((CRA$;%8('$S%*4X,MMH#SER`.F0/7_(BI1!B*Z!$*L@`E%@*V'%+-OG
MDB*4>UKX_X0&HA^^,0U.T4\O]EG:UH1[YH7<Q3CN"'RQZ)`)R7PO^7!/N54E
M=$`3>3>WV)$025;8:(UQ>)*RR)1OR6<*9&<967M@18>^HI<%R8PNJ574^(7)
M4I%0>$Q#$0)+Y%!NIPH5F#T`09#X*``_&6D-L(ZZV"I$`89ZUH6#LI*/Z8_.
M=@&8=&21Q@8!X)'%HH17>)8GP68LD2KUJ&8A^9%BB&\HV1XFN">^%)"A6!->
MN4&*TIF]!Y(/Y".::4+SMV9VV"'"N%U:24(K<8)-U9FB)GS35)<C:8W](F?A
M,A]2`I:SZ#;L$`(CHPH3\65;AY2?L!MQ4!T)T@.(P4B4*6UE./]><'D?NT(4
MF8DV#B1?%])DKW&:"&>,<?*+<Z-+C'>@M-E=O\F@6(:=7M6@\;6<-'%!&-B@
MSMEPP]><!<="@ZDV/51!CG.,`7>&=)F="[01@=-4_^&)RI(`O8%!6,8J',@.
M;!,.!4`R-4DICE$`H1!5T=">+J$\#24IJU``5&=6^644?PF>/D$V]3&6]@F&
MH.!MIAA*AF`7*P:<*JJ1&KHVOGF"`TJ@5:@18DJ83YHLL+*;$V0W4KJ%Y#44
M`+E\3OB=9BF%K+D+&*E[L(B5:JF=K+D^!4=+P`>+KHE?;Q&F/G.6(VI!+ZJF
MP-5+B@HS(Y&;$A`%!]!DE7@$$6`"'B+_I5TZGCEJ1!/14)K%8@5ZE4H*C(EJ
M+/'H>_>UAN/3G_S))XD12B56&-T9(!RH4O_XF9%ZEZ\9G&\JDJVJGH_:,D6Q
MAJ`YD5/"K-^@A'98H&[#?$H5J0SB*@TGJ^B7G$!JAIJXH-0WAZZDE&CZ,R5T
M=%W8J/$1F*LBH7!(A7."FL$EIP&!8C$$$05T&_V8GPD0!4SP'4-T#HY1;+H:
M%-S*>)-Z2PE+$QY9K>U*I@^`.)D0/*:I*,@*'TXIH6@#F><*5?3&L9#ZL22;
MIN\HLDOY'ARKK&93K0AYH'BSJTP9BGDZG+-ILEZ(9BB;H-'HG68%FHL"C]V9
MFQ\D@@X+M&`)_X9``$2M06`-@`,4$"6UT:4G5QM^`#$4<`$144_GD0C7E0:`
M%(W;62N^YTK_.+0WFYTO:GP$^JU76K%2<;%[EJUS>ZT]VZ5+^*TR>I5..J8R
M^JIC.R=/.K3&=YPIJ[+^F)NAN*QHJYZG1*_)B*S$H+&0>Z(?R2`82I82:XSY
MZ;`?4KGUV98V0Z/C\Y3,"9O$YYMM^ZZHB[:V:3;BD`@(92\"`R_\JA'24P/S
M0G<59@U0X1BJ@)-AZQ^I"[@06E;,ZKIW^ZZU2;S4!Y90:3P6*Z"C&Z6Q=T#*
MZZ9.%4)Y!K''V[R":Z:KZ[>OA+TRRWRJBQ]KF[WD&ZRIZBN)V[[,*_^'T(L3
M.]MLURNLN_B,Y/NPWJ)^YS>S:T.2%)2X:TM#$IFT!FRT&3FIJLM5KBH,_X)J
MJ<5.,L!1KA!^%F`!/G`#?==-!L$T$-$UE89(\8NTK<JWY;NPQGNVN:+"O8J-
M4:6:+G2K<#LS-67`>/NW7"K#*OHS,CRRM>3":WK`Q-NEVMM>VCO#.APGQ!JF
M26RFK2M!-YK"0^S"?5BKLR>A;$F/5Z6WL^BF[8J%`0&".3O`F6(KOWJT#DN-
MV$MHO]K"N$*Y$A`"DEE4^_!V.@.\+65=2E+!YS``LC&L\.C&*MRW5LR?4*S%
M@`B<0<S`TO"V.X3#T4&C*YO(#F*GT#HX:US_J<;[OI(*I3O\O*X:PX$IOJ([
MKP+7I)?<R=-FR<6[*C&IMB\<#5T<KB49E]4#FV%Y+#6ZRXM*.!<:S$VIN"KK
MR:S[HU`JJ39*@&Q#P^#;HB&A7^PB0%M[#S:B0Y2"#5S34#^)'D705<^<OHQ\
MI\!<Q91+N<3<R(,;$PK8;?R3C])%O58EN0W\NJ3<H,'0L(?,08(:N.Z+RAV[
MS\LLMGM;Q8(;S9Y,T&U<FP19HRM)%`JGG^GZL4!ZO[@LJ<K$G.O<*.E;LT)[
ME<XRN-4(N"/=I+MLN&K3N6,;"KFV&C@B0VFA18L!%5Z+&8<@`@40!6/@&4OL
MS'7;SPT\P_HKU`6<_\#]`K0C:K>2H`$4$W)B(`:*R%'O8[@2ZLHE]Z!7?:S4
M5,_L,2#\7$L"_<2]^JHC37NN[+I+_;?=V]4@&H;-_&\=ZET"#*_+9[I&[:5S
MS;B@.U6JBJBZA]&,#+X)^\L/Z<9`7:&E!;`X0#).,V`*41<!U`@+$R4MV=)E
M7:L$.+=R4[-RL\8_>GQ@:@`&6-HD:(!;`3OQL;!!.[\)G:AL6J''S%7J+-N.
M6LJ^=(^RZ2J:_-KX&;^[+;\*ZY&RJEO*3&]02+ISTY&J'+%Z9H(6&9*H*=@X
M6]TP%1<=`-,Z\Q4*,6#WH`H7/`?^YP=ZF-BV>"R>[;Z@G,D1F2HZZ88Z*?_+
M[CBF/YO8,/7)T?V]^8V=TQU??!VQCNN@&*U]=/W;?ENL9TS2&&O0\^J_VZF>
MPG?/O.JNN43<7JB\K\O:66QR9Q(%%$!WW>1IN,57G2<"'N4P/3T\[(S((@VB
ML/K&XMHK26Q3M8V,1PW,CWR0-_[9F\W.-K[2VRO;(7K%#XFQ_\SB>QNO:EVR
M*Y&M+HK1?4V@F-OB],>V*+K718WEZY&\E>N0/!'6TZ&9&IG@W#K*\JK//<[*
MLV+?;UVZ;G(FNAL#$5``<X"(CXB(<U```7`+76!S='N78(W$>8NW/W[EKPQ+
M+\N\<I>]NCFC,-ZV2HW)X<O1U;LM]1W!/113&([_;^A=58W;'[&<RZ?<LH1I
MOL-$SF&=Z)Q>M*]-0G=ES-6YVUL!UEN\R/LMZ;B90:F\VDTI5J2\W].ML9FL
MS*'0TST-"GB8['@H);E150R^MQ;=Z[8-O[P,H=48X+B>PK34N(?[U0>^K$4^
MV+[=Y2BJX?U:S+6]XC/!P@C:Y-3G5)GNVCB>58)*X&%,N`[9[NC.Z6!JDL^.
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M:\0%`L433^/=QM:)W_C&$LJ`*,>CF_-23^1J#"#=R_>P=,`F7/H'C]\@KV:H
M3N%9C]@*[:@MW/GJGJ+%>KKSSM^[VI*%O^)[#Y[57O1:KV1KZ.EK`_B!K^`:
M;?0F:[Z&KKYGNOK3;I'!&<%9WO>DO_;XVQ*]H;@";?&[S4"/<\DNS[>"1\[&
MC__@_L'\J@JZUJL2EHSH!2_CHC_+(`0("0\/$@\)@H:#BH>(BHZ#AX^2BXV-
MAI&/EI.3A9B2GIN)A(^%BIV@E)JAJXZ,J*RP0*JPGJ6IK:^7LY2;H*6NB["0
MNZVZIK:9PYFYPK2CD:?!D,'1QM6"G;C-RI>\@Z5#A!(2N>&20PGFT+J>FL37
ME=C#EJ"SV,C=^=KXT_W+\\JR.?OT#!$Z1*^8;?,&K5JHA),8>?-':9RH9-+R
M2=36J^,GA/40_?IV4=2]B^U(ZJ.XSJ.QDA2/\>/V$1@^8JL,X'R82Z(MA<`^
MDO+V4R$KH_-R(0,9+^C"H\4FTN.9T!ZF>K>2+K,:K]G_1J&XIOK[:FTB6+(<
M`6[MA9!MNZHT5[I-]^"@*K0.Q=)T*DQO1'HA>9I-JS:K*7TI!_LL#)BP6;YR
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MA3F!5V60T&6YH8A7GG<G?:Y)N&4C*JJX7Z$K:J7E?`*]UV-S/Q+)G&[I4>;D
MI$KZ$AMM%SZ99HA_WADI>Z!^U8E.-0;:9$";&EF>G6FU%J%*@WKY7D&.'=(=
M,`G*2J"J`MK&HRJ7;5/F9[""Y]^!.:H%88:UJ-?BFXU&0F`PVUG(G*6E)1+-
MLNW5BIZ1T&$'()9:W@(.CO:1RNAFB="H8)3[R=L;ER5JE\R6Y>I85&:/NKKC
M?X@=XO\0?^D6&?"^R_TR*V\+:TC<M"..>V)`#B,WZF+SC),MH*O.B!:QQ9)Y
M[6QL]LK5F8>%:MBSWCEB$9!C*@*$+"2KE-%L<7*9\J)BYLLD>91MW)[+[-SJ
MZ:`L&V9TB)A$0^.Y?`*[I).<3@UTT-%E^>/*1W=]M,K#1MSJUF%CQ>3#,",\
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MJ'!^>MW4K"0D;IP*1,Y+X`)/MYNOM4MW'\-.-^J6I(7,SV_.R6'4,$45"-JO
M::*K4`R3-D2>F4L:U@-2=MA$OWGY2%6D4Q`%JY<WWA6P5,9[(H*(!K*=><YT
M5=,@S:2RMI39*G)=B6#>YD.UY$S/1Z!1H*]*B#0L186(8>O6"[\'JN`HT%W;
M8TG!I"&0LGCE9.B;UN'R)S@O-E)Q_S(T$1C_<D!$$LR$U9K(MNS&-)+\YF"&
MO*+*-*F_):J))INL'@$CHA@<%2R'64EENF`U0R7.S(?B<R#@:M.-O'CM.:&!
M#R^L-A+YT,]15M10?13Y1A**PY<8:6:33*6+T#GRE,K`IA''5#/1Z+!EV.%A
MIY`Y.-MU:E+D4DJ1%H+%8[2PD6\3E%]R@[LO$48YYZ'E752SBW;,SXQQS-.9
M^FFM.P[O._@CZ"K?Z<A70J)S2ML9/4MD0:<A<H+2B=I0_D0\R$PT<8@SGBMI
M"#T'L5!B4QIB-P_)%46>U#2+.I\X%+<U@&4$3AKMBZ>BF<8%_D^DN%2;QJ0I
M).D4@X+V0_\B+F&J*'*>L9"U[-U"N87',[(P>TX;4MUB2KK)Q70J0A5E;B:Y
MCPOR$7$2BY2]H@>EO5C*C`;+WYR,2E#D[:=+M_O&3%8:Q2"^S'-$M%5+P4FV
M\93R0@+A!ZSVECDWH94U'8QD\XC4V"\VT*>/R>E8*5LKRXY0F;K9E@\!:E#8
M%2VBA)`>UZ`$RR%ETZD3P]5IKPH1_&DE8RA-7=&6."\Q8G"FJ[(>9F3(1Z!T
M!9U5[!94&DK+WB:QI'6-6?C0B;[-#?.BM>1F_$PHMB`*D[/$D^)V^=1*D617
MCU";+!JW6%G/MNLGN!,?N<SB2Q`"%GJ@S9XKVYHPR:F7M95!("/_22O;]@[L
MD@)MX3(;MJ/,]J22>!ML<_?WE#X^DJ;4A"(CV[KA.]TRN77\1Q&1IUTQ'I6H
M6B/6$[MX,>KJ-KO1?2E"[ULC3Q)X<BS9".NH1+[4S9>+87PD'?/+-N(*";<N
MA"U'V<7B9$IVG?2R:$%)]5JL7BI4O^ICKPZH7"]V:#I[-8#W4%8^WN*"R^'C
M<!V?&\./Z3?+C_&F=G#,2:ST1D8[]:AJ8?K#UG5U;C#\\?TJVQ`L[VZ`C84J
M6M/;QO`E"[(/E602H04U%%YXNS2[G'Q1BVA,3QK*'87M6"TIZB\'"(/`:HZ8
MO4(:,[\4BH7@X*B_5#Y[OC)]4Q89G(%\_Q2M^2_.GY6KAG/\L]].D,P+=57I
MXN9K#K=Q./9](&2'W#/A`EK9QOZ<VURM[7A%UE&KW:RH:`U@]X4UF:;6\IS0
MW6RVE)'$D0U<JB?\H3'W>M+8/FN::5S8)%=7H?>Y;JXKS*X.JGNMKN77P8`Z
MM/B!.]E*9!\5V:I4;M'ZDD>:JY!5J\1<%;O','I@NUU78P>'VVSAG34971OH
MAUO5Q%,=+RN#.1T-+I?%S:TW+%:$W9S7U$,553/2Y-DZI#23A`N6EZ+G@N!)
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M?7^3,2I@D>ZV]@>UZ*\=ZF3_[I]!5O-!!8=Y&>1RP+=U._$:GF`7-V)\JU9#
MV.52KP9AW\-M_$9Y^"88\E1EJ&92#653%7@W^2%]Y:9A5X%"D))Q4_3_`+O"
M?+2E2T^#;VED:I$6:<46+G^#&"AH;L?S75CR3YME@J5G>((E1SKA,2Y(@E[S
M<BZT+SQH3#\H@T.E7S5(>C?(3AU81353=!W'@@]X<]>G0UQH7O0V4`#C;Q=&
M'<Q"7B1(6=N@1D+C/O/'.2@X=E45?9=0A_!756V8AXP&?_,FAPEW5GCX(9JV
MAU!4B!S$><+S2]9SB*]3A(%(#[+V))229(#1@L>#<_H4B5Z2'\-3?I2P@Z1'
M/J%H@(YEA7VH"(G""H8R/`9@`SBS"%]H4,A'=M/3B6((@O#D<]L1@-=U=@GX
M@5/X9C]S*B0F/T(X:J=5"1`5BOMC<%?8?)^5_V*+@#,%"&95^'LB1(W:)W((
M48G4J%Z>:&A6HR>6AVZ5Z%^'YBMR)6N3^%L_96S^]U/-J(SS9AR6-F#%1V8I
M%H&/H"*'T(KJ8P,8@`&SR#D#<8N=6(K;UV&ZB#8P)I%$\GUUMFYN&&'Y"([(
MN$KG"(Q1>#H?N7[2&(_MEX.L-VZ!:(XAA'WQ>%D?UWQ\9E=5-X^!XAG,"([%
MY9(G$FN=9X+/^##L6(+UV(UN\W"3:(Y=6#9XJ'B+%X:#T(J#$(L8T#BX48LH
M<8M^%5C&2(:)YUTD>7%GH4_0187+E8)'"3\[Z!,NYH<I5'QA&33^IY*2.(9O
MZ8A9TX0VB8$5:(."=?^4GZ.7M3*4O:2$07F7F*AO$31N:8F`Y<=&@\F%"*.'
MIYA7W2<V\'92&TDQVL=7WF`H,D,.5JD+9>*99C)K3/DI&=B+;FF!*/:05K:3
M;ZAR?!B)0E@TBWB'T+B">;B6,6@T9Y:8F+D1N1D2%E1S7>."GL@FN:F;R>B0
M4Z.)G25"[/=0OMF5'7*([-:/C"!`>DB::/@5RJF=?KB3X2E`+K>,TK><&?6$
M&B%?WPDW.-0('S8,LK!R6BF!A<B4JUE<$"F&^P1CU'&&-:,.=FE^)JF#@6=^
MXU@J0$"!@9F4.HB-P[:;U4B=F0>="RHNAHB=Y^*2IJ4^FPET&WD;Q4EG&)K_
MB[X!C^[WF''7H84C/1O:42Q:/RX*=^O8H@WZ;0`57GR(>E+9#`P(@8W##>B0
MGSTTCTXY54[&#M<IB$S:@R"$-D7T:Q>*G'NH$36J5!6:?2DJ52H:F_H%H7A9
M<G^$B0N#CM,9CF3Z*NG&A.X',B=HEF7*:&$:<7(:?.\#F6V:A<\&4Q#JF%X*
M$H'*0#:Z-&MT''JWIU&)"0<QFT<Z%P]Z"0:*I/Z8IV?7I)TXHWK6GV[WHU1Z
M,J<X0CXZEPT:@LR)1?VXGO6`GA\*AS`H:#?:@32'@:MZ-Q17I_P93*XJI\V)
M:(`IIW8F?VOZ9I`8CN0TJK]*A2,3GV-:FI<9K#&)_T:L&C`&>A"%(J0,>!>H
M\J#R::F?$)3\B&91BIJI>6DE]'1=>)(LE5J+6'A+YG#7P:(>V7GD!:/I.4=T
M9H7VVJ_/=JX(Z!X@DH3UTY?D-XT9QQW(^H_I]R@#NZOT]V(H5I(<9YT,>Y%_
MZ);YVI>L-V%A]%^.2AN%0A<LA2`ZL:S@ZH_3^)":NI<KBXM@0HA@LX6.MR:1
MV8,J*4P(YWL>6J]QF(C+>+-_R8[GNH2P1[0_&:9\YHWL5DV(*)Q6Q'Y!>[%T
MBJN0^91&*[0R6:UKFK-RLWW5N68G&'1S,Y#T$0[=9*.Z\H"FV3ZN<2P36U-#
M5:Z=*K>*BJI).IO&F*0T>?^2M\=PM;JO@"M9@HN:U?:W31AZ2M-)VTE[O'*8
M2OBU]:2DL4J.NNJOEMNE1>=93>6X]BB`&6JX_;>O8NL*9%NV`QE!(TMJ@3BI
M`9>RME)1UA>1^?:C0I<.8@DW(+E\(#:*"^N*T;J-H.BZD9N2(5F*;1FU<!NV
M:FMA6LJVM$HW`7:5[8FU']>-NF*PJ2MZ8ULCOHDM/CI(Y,`\!FAM1LF>G1I'
M8T.^?<MFQ4F^]7IZ[[=&@=HB`NN]#?AO3G&?)`N[YP":=;&M6Z$B.B`<!*DR
MY'IT0^H(JYL=`HE>Z)@9W@H+.N`*:"MQ#"S`]D@7F@N-^#6.BE#!3K'`A@#`
M"5#_P,,Y6E`*P.$P!H""*#P'L`5GN\V+=Q.YN5%I%Q.!#@:ZNX9+6CV<8BL"
MPZPX&5[SP,,@POW[958BD"V*N0GTQ$F;1\"8<S4:(#'<?LL3>$+:3,L3J?Z[
M#.:`*`J,N[S8,[!IP0Q,2TZL;!?\<W75H?<6E5],PCW$B>IPG]U6;9U;GH_:
M1=MJ$$<:M%L7Q`N8(B2[G-?QQU*\M,=KMBV[$8-,*)$*#&"<3"0\D(P,(A-\
ML5SY97E,<H)@*$0,>C=+8F.LPR@2P'PZI<U[HWVLN#@<(RO;G7L4D#?*94-D
M%Q5E`'H<QAKRQVTHP.B*IG+[D&W,@RGXBZH2I+%QHEF6_W\W$CPQ-X^!C+Y]
M2<P+3+0-FVTC>\'B6A=4"Z(>ZJBO*(2HXL*L#!*DO()3F\,":<AR[)B5ZZ+-
MZ*?<S`@]K+TA`9K9.839EFXTV$5W&F/6"*H)N+!J!*+)U[^^#,R[=(-$>+:\
M%0E#D(0P2Y',0:\$RK=K:+:03*F1EW!+*-'2N\]8&I@0=VQ&*\X`Z\\UFS8$
MZXB-U;$P2M$PYL1^&[UV,<8;@Y-F*3]H)FY`*XU<-BZ_Q('\-[IO$0XBS(_1
M&Z]!\:Y6Y\'98M/8QQ^7?`[XN[8*W;NXZQ3'!]&=BVT3G30'O)>N&;?`X[%-
M*:<`O'L!7(7(=GGZM\JEF'^4H/\.VNE/(&3'P=;2(L3(C(#"17Q<_*?/DFQ_
M7B>/R),HDFS";<31:!=J]]P44FEU[K$^(&Q[OG4+,-V`)_RO7FNO-<E/PFE]
M'IV).7G5JE*C"[H)J^L:YC#6$&VJ7!W2:0R@QA#/F5VWT0/97,P6*C`^M!W#
ME90H#ZS/SGS8IJ>H:)I^^R>FHTR]SAVRJ1##B9R+1\@./NV\:N-;`[AB_<##
MR!J5+KW/.5R,=!@A#YC)<PK/,2C2)9RM#6>*=`@)_/NF`[/7+EW=AHQT_]J=
M=-W:QS%H4Z3:<_$Y?1-WN>VD+SDMVLT(Q!O&QON_6[W.RI>IZ_Q\&Z;*WGW1
MS3T(.E#_P3=DC/:]T*J@P^DPXB0>V>K-GK08VUCCC,XHL8?PR_^MR=F=I9^[
M",7]S?*SC7Z*LB:XW_80S]U9)O'<*B@]IS<9#H5PS81J$``]PF3<2W)<E,!R
MG8_,%"D2R!>MP@2H=Z<*NK^;M5V.AH%$:`N])$:7/1LZ.A[N&A4.&Q5,"%DP
M#GL^,Q8A`3V`'H,P!N/PYX7>YV/0`SHS4WJU+!?]3&,0Z1(P!OE1Z(50"L4"
M9I;N&I:N!P^@!Z"N!^JL"*+^`(1NZ9A^Z1(P!"Z<Z3Y2P%*>!7K0YPDP!K5^
MZH5>%_K`ZH$N"7ONZ7'UZ98>J9*.Z=[BA:8NZI&N$H+N+?Z1_]?98Q'%/K[W
MD.ON_0V*OA^VSBNC4`BX+J*-3JFB[NF_(`&R3N[./@1\+NDV6.NH3NBV_L9+
M[L*G?@Q2[C&I^TR#'NGKH"*EH`?CH,ZV69PXH^Z`SN]>O2UC,`2A?NJ,,+Z<
M#`11R>=94/';G@#6SNFM;@@;K^Z!?O%Z]0"RG@6V?E>\OO#U3@B&,@ZB+F;H
M,*D;;T6`W@/+7I3"JYQ9A+U3JL?XRN%WM-/N[8,J92VQ/;MJO,:VS)`)\`2'
M0.EB%FLV4`-2K\Z3+O4UX#%/8``U<`AFP/16C_'D\`1BK_527V^=8"BQJ`$Q
MT`5E#PF3GO5+G_5,G^M5PD%S[PI`4/\#J"+V3V`&-1#U&!_W8@_XZ@,$ISX&
M0)#U!B#V-5#LN631?-_X4A_U6T_HRR/V_[+JE'\9$B#V9F#P+,@X7E\#3T#H
M#U`#;/\A61_IIG\(%?P$5C_Y$F\*"5`#&G#[76"5EN.0D?[WN-_XII_X??_Y
M"6`#%CSY3,\(IG\="_\$77#[QL_ZMB[V8!_`SM_X'A/]?-_TM;_XZ0#[6_\A
M$B_IQ?_\OU_KRF@(LI`%"9`!$1`!70#O3V`#8H\.4F\1?,_J9"^+HP`(0V,/
M!ET:&C8U-6,2#PD)C@:/DP8&-BD>,0D]C0F5D@^1#Q()AEVG!A*DDZRL!@]C
M0T^GB`9/C`G_0#9`JH2"!C65I&-CA555IPG$I$^V9D-F9C4VB0D28T^+BD^>
MBHR$3^%/>IT)LN$UH\-CIAI=B@E9JZ&3CJWWK*'VGJ#[D8_[\`FL%Q"@/TCZ
M].7[)S"A0H0.(QZ4U.J@P8>3ADC,6$FBQX\2:@2H0+)"APH%;+"0$,%DA0`U
MY$FP,3+`F!XM3Y;LH!-&C!YC1I8D>3)EKRQ#8L"X(P:`&#$=(G3IU1(&C*$%
M8MSLH5!"%Z$^5XY*D(8HSY,Z._P,>H?G4)1=>O3H4H`HR0(!M,I=!1#@F!AN
M=9*$H4%"E@PD(S!JY&A(4I(!$JPDY>%.A0@]9M0H(,:NY;@BVW:X_],V@-0Q
M>@9)B+'SI`";6;(`U5!``(#;`F`H)F7O@>.;-2)TN.WT9=P$(P-7(-PCN$G!
M+V/$=*3.3,NFMSL$B*LG`NG=JIX$L*Q!GH:A.FUV<2O:[=V;>KY6(`X`Y=J*
M`/7$$/,!1HT9/6APE5T"*-:<4.Y5\%H\$L2GU%,?U!=`"*J08H!&OG6D"A`!
M.)7!7KE0E,\3+=W6V7:]`(&0)^8H%$-=]*%40P]*+:>!'GK`TL6`&1CV%PQ/
M8:?;(BU9U@$,HY$D0`4QI):395AU,8,$B!UITQB/>(7D'0$8(--?HV$'500U
M\(5?)9#PL^)"D8@XT$*/@,+BFG"^"5%$;_\6=.=''^79FS\87131$"UVQ.>A
MH80T''T`="!E#QT"\($8/<Z011<5?-!!9I$R2E\$:O0`PVT1$O=!!?^I(A)]
M04I:P!A3=OH4<6(4$%<OH^Q'7`!9L#`*'!&4ZFF$F/50`'T??(##I%+.H(%M
MG@)0@`:<C+4B+!Z0BBP.,60Q0Z2O6II0'!%(BBH+Z([Q0H0!S*#9?(R*(64-
MBWH:54RJZ,KHJ[*-$4%3$0H`L!@V5,BB1B$%,#!V'P30@PFCTH>#`"',$!2M
M`$\:0,&]?$6J&+8E6^RQ`#@L$[VWQ>"N!M@Y==NK7;0<;Z.P:K`H5!5`R&]"
M+*K2A0`?"/#?RM#_$H>#31;#R^BD,>FQF:1.`=RH9*L,(4^.A#ZP4@VC5M!%
M;`(EW%14,$3X@@$K&931*&-D@-V2.4NJ,LJ-QL2"OQ&B:O&_)E;`5,IX1RBS
MI#AX(%>DP@)P@``:N)NMB=2J<O%MJ(+]K^`*BK%LMYWT<T^;$-E)$(OT]%.Z
MG!0%JK:=?:(99^@5(>K10+WU-7KLAQHJ^^Q`Q2`<Y1%H`"L+CU,>UPR8`@!#
M9AJ8%D'$TD8000"-BWH;E],'D!>L%G<885:&O"@M]^4"<$<$OI,,`&8R7=-I
M?:F2TKQIZA>0O91J1'I^]J8-_;,2TO*=PI+E-4Z4@SI9>)P83*.]_KFK_WP%
MR$P6$I*%&)@K`5.ZVPMN$P%WC4$#@*%<#+3RKNQ(;R22$H.!0N([[*BE/#W0
MSQV25:!#1,`VC5,%/T:QJI?%`(0=BJ`:0$@R%4;!!-TSH>\B)H88&"9A)LH*
M"#N`@PA^ZS;MND86GO8!E<T@`;Z[@P^IY:\&BK$^)QS9]Z33!=\)8&>E4]$U
MRN?%S-2@A;?1#;4LMJBH2&]ZBDGB&%_4&6NH(@MZB`9J4A,*%CBK*;#IG(J4
M(0&614A*8Q"CO*H5$,<\(`N6+%D-0A""&"C,B_KZR;LBY,50;J<&;>1,#-00
M`NU%H'[9JUX`:/C'/_ZG!\4KV4UF<D::`6@_D_\*'BP)V:T)UD-TL(N=FNSA
M.6@2I""JP\?LYL2FANPNFWL"%.UDI[MO.@02LL$)%C/CKAF4;U>PJL%\-D4"
M`*U,C'<8FCW'<*PFSJ">[6RG!;'(/7?12)606F<]_;"H5_F*A_,1@R:]B"ZY
MN*L+^/2#0=W%@DAU,*`!Q6C0:E#/`$6L`ZGJC4:R`,&"@A2"$DR48<JE*5@9
M1@\D<UA`(]6N=HYA46@PZ.3$4!X)9.:G3O&BN^CF*'8BCTQ34H@@W,9!I_[E
M0^U$P_4*ZJ^J+C5D$8A-5Y-JU1%R:IV-V&('(M0XGT:JK0;-C!X\RDX[0NZ?
M[:R!\'J1BWI@M%$:98'_7!R)5``HU6*C\B=(,S/0]7'5E+!JC@:FAY<,:,`:
MHP#*+N]P*PM-TAKZZ@()>C`<,<R(K_W0R!@>=X<QD."UHSU%#T8;J0K<!%S<
M>UP'7/M:`!T"I#4XX]#J2E>`VM-2[S/ME-YIS#%$[%6PM9@&3JL0-^GIFG$"
M@N?<9*?M?NZZ]!#=.2EANVBRZ9O:I,Y#PIM>1)73G`E1!8#*URZ`LJ!\I+F-
ME/PP3Y"2@&7FTX-Q`42RCX(40+7UPX!)L!*#\O2?M(T0#,8P&5"^S#O*T\,,
M*NHMS>#3I;'"8D#5$%`;S">?`4WEAO\T!)9D9[8'5N<'K#C!4,3&@E#8[90:
M_\131[;SP3Z-6.,`6@.`Z=1;8XAH#`!:P;L.^"86,\@0#$"R"0_88CWP\4#O
M@$0/1DIEKTVRI#[*S^^Y-J!`<5=.#;C%`K`UH),;<D!IFS*0:L!$!G)723=\
M0$?4(`->39L$DI8RX_*SSC&N[9G;V8--:$9AC*J`#;AB5&=5U9FM:$[$;'+G
MDF6F6FL+Q5!#P+W>AO2,P6N*8K\5H0Z$P**]=>I2-4E2-#].I^XB<3OQ6^<$
M1%2,.G9N=HX'X7;RQA':I5TW@9!L;TY33=8,K^O6:Y$[/?-VL`L(?%7',_;&
M243F?"]\(7%(EKXL,^AR\?HLV!\S(+4#'19H4UK+4?_"DNPE#?3)4A?5P=%*
M4-;N7*=OSYB!%6=AK,*;#^,`5"&CQLQ\^DPWR;@4@`)8?(_(F_?0",OO7G5"
M'WI(@8F<-ST+D,]5,=5'DVNZ840"F04'YZE3^8MH!V?'IEM4<CNSH&A&9YFC
M9G):IM;'SG37F[%;W;!FO4HCXK2U!M`ZK`30]6.T&H9>;Q:L("FJ"L)^&;CP
MDB@,\C(CCOX)$@;8(&>![@B@G)'KPF[4";7WG\(:>,=NY8^M8#D2&TQI#$B>
MX<[H-&BN98<\Q(!E#=:4J+:)23O!*Z@CFVZ^&1)=H/3I@/VZP+W!9N;A`-`G
MDA_WQ@9FA9T0[-"$+:B;L<'_RMS$@;SP#%H.[,JIO&F"MNFB_;K<,[YTW?2V
M.,>9#VQOV]OAQ,?NN9T0<1__D^HL&=#5+;Q%O4$.PX&!MR8S`UV)@7OHNEN]
M))6LAGW>-HH-3O:"A_KKG1!:2%O)I3+U?1+(?`9GR+]A'H[B#:]D<E!3?DB3
M<>;3+.BB!QOD:6+1(G$0<L54*B/U0`*G"F?02.RF8S!W:.LS?3P5;W2C5((%
M:'6S826D6+(1*9LR?>HP"OO0'&_G+E/7"$8E`6=@5%L&*V<`%*P5`1DP'ARD
M81X&`-SB+OE7A(-V10!``7RF5EEW5%^'+C4X:)-31U.'$_R1++$72#I$":F1
M*1-F_W:.<`TOR&>%A2Q=1&B&96RA8%%BMH&OI0:+,"7HY%Q!XP=`P3/6T!S'
MLBS21P(Y$0&890\ME@5/D(#TT1:J1'7R%"/ZI!GJ0QQW,"UR84`$V'\P%W.F
M$B')8D7NQ"X8Q27#$3PWMU2/&$4W$AN`(GS7A0\JDDW`AX>2@"&/H!'8=5Z!
MLHJKHQ&$HC;59(N(P@H8@H?MY8KZX'S'9U0PE4'W56=_I1UBM#Q\9H.J-CQ=
MIX$4UT"JE#QW@$I0(RE?&'"F`D_UI@<B6%^65`$:]7&7HG'1Z#[78WI9P3W\
M-UPQM&9?U!N&41G940!G`8CS)7!94('J<('#<W`%%BI&E?]0GK9C'PB#,22"
M>K-4.@<@"IF"DS$(]/`06W1&;54AZD"#L8%?.+ATX>@4F&%/BYB&%D.#*L=S
M(C8E6R1D,,@""4`R/S$9:36%,#@*%A-"GN(!-A403@-)U&@/!_>"Z)(%"7!&
MD6@5/-$X8Q!U[B(/U&%4<7<^T]5E&Q8+F*A<C*$/Q&`#_;0HJ&(LQ))E+`@0
M<N$<GD)465:%&7!&381N!M4%'J`TM%(]UL`"-D!KT8B)YM-`%:=*X!@`<^4R
M^=0%HV@I(E$TD-@X5(EMQ<>+*_()M7AMJ]--=,)\X=69&<)=PBB+:R*:OL@G
MNWA-!5%-X'01QK@[$.%RY[9CRVC_6/54/K,"`]-'>=\7C33);Y,XB?OF%`Y#
M`E]1`&>T/+7YCO4"5Y*3@'L7`R_H3`\P%^R(DP^P9K_I5/PG)8+%`F;@FU$%
M$/F8'78H%\0PE<DH#UGR``1I*8CD9M+'"7*1@#JE*HNB,@TV5\\866BH,EFF
MD/0F.>=$04\`+U[T<?:@`PV"7QAT!G>#@@$`)+>A`<:5/"J)CY]TF-(W`Y]$
M-XVS$BSP-(:E!@_U"(GT=7+(DT#11B5B(E+"5\J@!S8`29G!%V/Q@G)Q<!&E
M&*E!#$<5,1_%&.1V8\7D%&KQEA)@-9/S'YC6>/1E!KIR/FL%`,VB7H\`9<W1
M1B.!'04@_QE4IX%6MF.5MJ(9\`+ULEN-IC5_%7I1Q3:WMA7`*8'2MZ;MHIC&
MU$Y.,UG\2"HF(Z2?\R:]J)GB-7R;B7RYAQ$9TFR"DHJ9N0_39DY_V@J]B(M]
MH5W/IQ"C`)O2,I7(6&@DD)(O]I<#M9N3<3<VV5L#)@&*5E)C!5T!-V-`<5(:
MQ6=R4$Q_LRMZX$P.QXX-IZI8A*H`)1?SR&C0.:$K%B<MI@>/$T&FMH39,F.<
M6B$L8$$XH&-B!9\?-7E`MI:+TE;"*D8?\%%'9:!Q]4ZJY*,2(`EFH@I#0#+6
MBB77L'C6T'U)MY5T18?2,JM\=!LOH&&(Q`BQ@"/WYRT>RF=;!_^#D^".:3@9
MA``KP2I#3A$Y0AJ6-!IEY'8W8]@#!Q<Q8#9@D-)JKZ<."6`#D=4%PC$KK`04
MY!84$<*D_B`!3P"D[E*L4124%S$&9<=H9N"N-9!N@D5?[,07>&50.TL<\;..
MMY%2UK!:8U9L/D=?HU4V\D*<HWAPBV4&\+(I-::*U.8)K8@?@BJ9";&+HLE>
MQ.@0IVD`R1:,>$B:A@IM>/(1IVE-=!LBETH/@]@=`J=TE[-DR1E[Z'9(WD>-
M4Q=WAP52H_H3O<5NX5*8_P1@PK25:"`F3G&K*$65^\>K,N510XMF/P-Q==E'
MKD63KS.>C0)CM&>Z1Y:04Z<!RB(`S<+_A.'*:'/%+D57L`#20\HE6$`QD<(Z
M=#`0%QH[%Q%0,"]+)5!SDG+H.^D@%S?H5AST3_HR@-%W!VC@K\60`1EP$^6#
M4@:E`6=D@`^*:+Z2)5,H6%/W`!L`57KVJ:7UHBN2>/,1+E_I(S@:0X;K<S_7
M6`8B5E7@`?'`3FKP%ZC&"9``%&XF!AJ%:5EB>-("8VA0+T'%9Q=A`^CC5'_;
M`9(AG]&'-.H)!!<,8<DY*9&5N4D;GM?P./V&9AI+7X][P?\UBJN%<7@5*<NS
MM=2T)[SXM:0#7H-:C)/*J)H)?-\63M[F&*/S65X+;I@JMZPS.MQU#Y)@J7=+
M#R-$EC\T/"AJ_S'J8Y&JH)NO5XU3ZD=_1$)?%"D+-%T]!(W15P#_1"/8@32&
MZP>+P`[8T2U<\4G#RANJ<&_HTTN_]'`J)$#0XBA$2$VO`'L5@&XX:;K[`\B:
M044S%@-:RA_]]T$^^4*PXFM8-$(H1%8;IE=\4S(Q\&K.ZT+!,UDY\Z+^L$7>
MLT`_9$I0<1-$A&>S-SF8,5KO%$@SX`<31SUZ6BOQ-'34TT;/Q3U@U*)2A)9+
MBZ*]L!\^\0Y\]S(V=1&D<"QZL[5`L`%4)2WN<!/Y"X.,X8@C%\OC85M!$0/E
M*:(G.0A"ISPAFP]CU40WL1Z[@D%RF";IRAG@HPBLD3(UFH<T]2H&=/\-G$%V
MRP2D-6K";*JR"AL5OB,]TH%@+TF1*R/#.8/0=S1T!UH[DCFHKG`18&M\B"K$
MYU7$M+BHH2F(19Q=UI61AT)>J%FW+$+%=SL30T<JS+)AN[2![01@FA*X^9)"
M+JLU^$I^FN@U>=>-+1,N"=4PC!8LT7MGDZ)@]31:QU)3I+N.3)//?9R)Y2<O
M%]4RY3<IP6M0+'`&V;4)-.7%UQ`*M;LTR=)6Y[$TYG.2(9HI$)BT)-"&VM)J
MRCNMPY*">S,X1`T@6"*>Y(R%IM(NI,78DK)P'QNN[,2R9[E4$2,L9_FWFET?
MS=)].&"&,(!!,F@`N_0!%@"#Q,!N@D-^(QC_GOJ0PG5&E>H[.`T#*TDF,M-'
M"H-F,\/RP#W`'_71`2XT--?P00!9>X!'+V(R*[<:O,1`Q-Z#+$Y1`$@D:%TU
M8R7<QYJ(+"KT:<I`G2V+V-:`'&5=UD2%8)L(<)9V*JZ5VXDC.,,9F=$T$95Y
M>W3"Q)':%VQ;786J)^REMM74W\((Q"T-;2*-*(1BF8)"MVAB":]PJ7TQ$OQH
M<=HQ-(#1`6TU><\3%>BF#LVC>4%IU,*A>3Q1`%<!$W!&&PJR)$?"OC3"CX39
M/3P!$P)R&0!'&Q?N*ZI`$R]!VNLI'!9^XIHW-)MA%3"`XO8S>SNI$"KR%_P8
M2`_E&->0`4>2Y$/N_Q]U&0"N(0#:06R/AA)#7@`DM5I7?B1X8<;A1QM8[I01
M@$2?%N*D41JS9\"S"'U0#C<F$0$:A1,G;N$J3B-(LD=VA.(7[E.`01*=D14Y
M^T'\*`!+,B0;I>-8SA/@H2K"P1P6`QRFU`&0#NEJP3TUQ@J&,:/C8RF-4`41
MBN).J4K(\92.=&R)TCM701K+`54TTN5[SCV28]Y4VN3[8%3!X>F0SB1^\!4U
MSC&M8,%U\120<2-F5]X9@"2!!!0.Q^69<Q<8UVB,0!-'\A_E>PT9;G'\6.,8
M?A*).(F@9"4E*QS9KGD8!Z..D=*8&=*5F9D]K$V]-[:D2>_,)Q#^WB=KHO^V
MC_!9#QXZOWC@,-U[4<P/:&+3\+7@UG!P<!JGB`UEAT21%M6FDI-F.Y8HJ9&=
M0"'4=86SWB!KDPAE)(AE(A^T7SSR)H"6C$#Q/V>C.-+R*B\7>I#R`)<V&''<
M*O]0L4T,%6_Q0J4(B\!.O7+Q(L]1,=3TQA:#J"'R%>5C0&'R6.J1:_-I8T#'
MBH#R1;_Q+9^=-\&[%X_T)5_R2*_R.X8E%7^>C"$Y.5\A6V'R-6"'`26DJ;,2
MNS27;>^C._^;2@><Y0L1AG%4WN"C:(;U.:\,H-04-/:5+8C8BN`'!<7SY1M?
M<N'U2=]."P@)/BI!1,_U";#V3@4B`$OX,DCT82__]B,OSG2_%2#5]:8?];57
MJ!_M;`?..MN$F:LI98WJ$63K&P[O.MQDQ!LQ3IUY_*[@.A`/J2V2\0>600'5
MR""%*_(5]0]E&-.OAM+?_>D4;QFT]`=F7_.0&?64;C8&4A4($.)_8"#:_:DK
M^;TA&Y[/D@GA8]W/N^P-"#."$@\2+(*(B3V)C((L/1*$$HV.$F,2BXDDB80/
M#PF@!@D/F919DY0S$EF*D9B,KH>I/0F&J2RXL9J"D)^%LC.0D0]CI8*;@ZX)
M0**@AEUB'QTU,UG6C,B0P#.Y":*%GV/8CCW;C)"C8P$?8AJ"69^C\:/E,R3(
MW(V=GA*UYHFG"(%ZP`J1_X0A\5"EDM3)5K)]"BF]2L2O(:=_C+*,\31OR!!0
M`^-Q#`E2'DA/H4JJ5,FQI<L''TV&G-<,%$*4)&>^M(G3`!!F-;U]\_724\R5
M)W%^,E"S&5.F()D6G=J2)\Q:67`5K);5FB$6KE99`SN,WUAA#<461`LQUJ-W
MU@*NPH2V8KD>Y7"!!7DI$BZ4!$]Q0XE0;*)';!5FP>N*F,B;WFH58[S34*2X
M8Y75PILI;D,6IXR!Q57*:]B$:LGM'87Y$-G5./F*E07:+:Y@7\/BK9A@<N.-
M7^L-JFB8-L-/MNAR$S@P[+#F>GGIW>?3),$>$0!\"%!C%><>:_W2I=P/ZKS4
MP_]=E>95J%]V`!$6G1*9$MP8VM_E[SL?:5%T:R,!P9HEX(WD#&V("//2)8,-
M-!!F<=6FWB/]@..,7&%=\\X8?4466TRQ&3C*2O-$]4U22%'E$E+R?,*,AX1=
M)9.*('D4RHLUO0C85"RRN%100CW5E`$J\CC4)T,XYUQ[IQ'7F)-/$D4<DR4Z
MR61;)<X$"H?M9=G</C?M:%2+2\Y4IE(V>822*!SV]8`.;X[8I4N2K#37:<UY
MTM>32W9YTG-4RN-1''R.U(PG.I1$)Z"`E?6<,_V4A&=2DXXHBI)GT%<+,1QJ
MIE-['K;5SZ.BV'A2#V/$$(`'74`RQI>6.+-E+SFQ5!'_6$H-TQA(50000`;B
MJ-(3D%LNV6E#\0@XHC^ZKEG2$!M5I:A=D<JC(T>1"/5IDUSN%X\!<*XX2I2=
MV&HJB?4IJBZQYL665)$ALOC3D6&22.-0H4!EWKLO'86B2B]JJY)/4)7$#+PM
M^0N3`3<)U)+#<R+\\)L6'KE32F0BJ28X\<`!QT\M+J-ECA;'XV^+Y\I3IX,M
M>G*B@"Y!EJ6!\\Q,U#(U,53ND7E297`"*7MI5&'3X@RBE^/N:&^M&RUS<,LS
M1Y)RT2:!_*UL-%4G8M%*?8O0$/-NR8MO(`&*5-,>?;2OG9G^7&Y)-4S&2X4N
M/MWNN-4J6AXH(/>F4QP/:.U-_\`AG3SNJT@-=6G@!Y<8K;M??H007R>)[&RV
MRB9E:L%7]\CRH3A3;2N\GC->XT[MJAC3Y`/#G(`-,!=EKXC58?QS9"K90*3$
M-2.I0I@Z!"_/XY"U'.:*.X8+(XQ5`5F5"NJ"]''L*&5NWD<_I5VT*'"<-#5@
ME7O<HD^)QG[334'5I.FR*3K-;^7X6LZ1#MVWY)/5IE<_8OT/J&!`]_"#BO8,
M%CMMN6A$!427%%*4+/-))7!/F%%)/)8YOE5N%#KP">S6]#+V.>M9AHL(+2KW
MD^H!X1,U$)2-UN:Y96QP*07,!&/R1C"@,2QM'QG)$&KH":LY37\:BXKMWK5#
M'KJO;O\(M%0+403#`@)A<LUXE>O0):1IJ>U:'L)9UW`G,"YJ*5\R@9JX3$(L
M*]),8BM1FRA$88,J5(%ZTN*7H9151C`.3'>\.YH<$28G-&XM1+*;W<EN5KN6
M`05_/:H7QA0YNMG5C7,7^R#46!9&EGPJCO*XV[3J5L$ZSD1K2ZDDONXWL!ZM
MJ7&X0]HC>U2P3S8.E%[,9-]60BQ#9;*.XLD2D`K&,V6%DGW3,@#L:`FK)X7N
M1TIDGON6^,67Q>]=RTS<TG1T1*&MDIGC.J(!?10Z;!JJED(3(@/%!+D@25*,
M>5P:2("``3=BX%#E])D=2Z*O"@H%CWRD)-!XQ\^I'$5&Z-S_VCX%VK(N5F66
MT4N3#D=GS7C^B"D!B^0O=9*3V/@$`S;P((\N2!*:86Q?/L0BQGY93FE.=)O5
MV]TQATA,!*HTHLFJVHG0E9)"[DN3J4QEU-SENIOR;)LXE:;@$)FTE+JTDBR"
M94\3F*Z@LO*6)A*EI:BWQ/0Y:(KS=*I3Z-D4!/KR6S-]INA,2<[.1:9X#.6=
MCV[6QBKHCB1!(5T="VDB8>ZN2/\*:#_36:LBG>QX@R2CNA[ZE%J=;DR-'*<I
M!P=3$9TT9"PK'A#:B`%[;A1%)0LE!X>41'J63I=DO&G[K&I)KH;6F9;BK$EU
M>2)29K64+-4G9@GG1=7&$JGPFV4K_W-BVU%&M8&>%6=LQYK3+HHVN&0U[4.1
MR\7=>E*<9FWJ<VEJJR6>,28").XE23?.D0P3:=!$9^+TM1*@X)-&^]SD7M=K
MDU'\,Y_J71HR'=2,L"&U&<>;W5I;)Y/"`BV_Z54)6GO'21]N%R8*R^L!-SNP
M]!46B57Z%B)W*]RGX(^H[",E@TG2R9\L-9D63:`]TX4SP=&U5I-5Z8D9YQ0/
M*PZ5L_7EX(8(NOO%;EZ`7*>,_1O5?$'4L_%:9T:7547AEOB!*^5HV.;;8"72
ME9K1(QA.1EQ<^[JHM5(EJ'Y9*Q/641=AAI,CBF@+6;URM8;>N++(&B=/,FYL
MO7NUXAXO>_]8@%:NG"][:VG5&V;0ADS"P+1=F':X+'\-$*!;`Z<85^A>P[80
MAD2F,.C&3&9+FA@H32E@+RL=S(#=S[GZK-Z0%VNYP5&8HU4#2FQ=]MU/-YFD
M2X'=5DM+3?L"V5:3'36%76:]2HO5A%2FM%&)F6,//WJ;OGXF1R9+3>>I&8:[
M#'764)U03!JP=]0&I#P-=['4QO?`P\(1/<7-YD!2$L%PCO,7]6KN37+;EH*[
M$4,%S)$^@_>;Z@0:1=GWUS2]3TAQE=**2N4E3[>OA2S4:#?AF5=6.H_2\Z1V
M&2U;)6_H>=*!3FJ^62QO/',SEA6OX8DS;LEF$QF!PRRN;!/J21/_&KE6M=SF
MRNV;\&/ONF9.$U#M@NRY4U>7BTI#=4EK],_DUMDH,3MX.?$7QZ)`1N3\+1B;
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MYQ1`@FE1@4?G0U[[=WS\]"QI)3$XE&^6YF,C$W`E92"[13M1EEAGY5%B%0K:
M%EK7YG2,!$:P%G0-=W^()W,^1UW]AU56N&KH9U+7QU+MMX6AUF3,%'`Q9UB<
M<W/*U5S`9%:$XVQCN"ZBQ'?0)5RUEX5A98=TASON-U''E5!E>'J:-8(G(BVM
ME7)'$S3<U$K_M/]\?M9?+N1&;I1`5!%F+49SN\<PI\0PYO=?/)A.)W(4E.A7
M-F)H6D9?;A=33)0E`*9.#T:":;0^X)==%05<J!0SD`$9M39_?8B(T]15)Z=_
MQP@_'_AL#-2!#A*`0#5=MS:%(X5L?:<^!Q<_\.=3I%9:23A;WE95T09,-=9:
M:$ARAH=;NL54QV9_8:A;TCA2-K-YZ(AVR*4[RV>(E8=I'=%FV`2#;M5'4.,O
MSP11A/,B;X5$3-%\X%:*"2-@1X=UAE9F&A9*/#8L1[=(2@A-:$:"879NB.5?
MXC<R-JA"2;>,!;ANR25]^'*0HX2-H_6,FL6,&#9_GA=XH!.,A6=1],7_,B<%
M4@7)>CTID.4X59:(C)`&5RKF.AA&-9P#>E>C=\<D@+^%4MOX,NQ(7"XS4\[R
M2)I'$_^B/HDXAV.):C8)7%/9;4EE/37T7O[X<O'01AM0!>_44;@G:)O%2SBR
M04XC?S9$B@ZYB0)V+H$973*18DEEDP`W29+(D[2T1CX$EM07<6Z)76M35H+X
M(F\V1A]I=*%7>'#)9$>H7:6C6*79<S\GEM/&@8F9FO571^?T64-TALE45?*H
M7P+#FK&'7&/7C+%WA,-8CW`HA!_G?`KGFQHT8G2F2VRIF<SSEH1#'VU%@9@T
M%,73D:XV3`03-@N90ZG(@X;F90,5F+[I:8@W_U=BJ29V1'RE]`FP(V-KU9O=
MIQ/8Q0P,*4$ZMETYV%H]Y9E#R)RR1);$V9.$&#OQ5D88)W@_:92;!TFB&8D!
M"FLOMX>?LW_8IX]KB"[4='%(^5M>@EJF@X[U1V(:6A,OY'K,%)5<I)/#%9::
MY"XC>8[Y5I%_5U!AA6F95AT*4Q68Q`PKF)),F!(Y9&>9AFFR9I!$V)"E^%<[
M6IBM2$`0V$B?)U!56%VJ)I!II4ZRPTL%18X&*%ZO-H]CA$WCJ)L8NIN_AI%(
M-73=F'X#JG$"RERVJ(9FVHZV&:<4&H^P-3/[E84A2(\C")J'2&T7)):.Y%B`
MVD)AIT,$)7)H]F/G,O^+/-611!EH=F9[MR4*(&-CG(I]"^FD)WDZ.G5[>504
M3<**`B&6S,$2S]%*%8%T8TJB(%0I^S0,@]2/XN*6>`@C5V<5A*8WE*(DB+6K
MB@(BU08..TIOS-$UCRB#I#)I:>,G7;:L01>4JH>L_-!7I/HEI]0<6CHTL9DK
MA(`X7Z1'WT"M>:)(2%A8;P."2?.N*,,Q154B2=*NZ>@,XA>C115?8;*JC9*O
MWOIF=H03JR,05Z<S4L(O15=M[J9E0C(O-,AU`&M:98=^1DA%./(B(-,WS-98
MH#I`Q?F#/`(3Q/`$9G"R*/L$8Y!"H&`#*-L;\]`%-1`WA)!!0/,$,YM"!]'_
M2B9[LCE[LGI0+@]@!EW0!1SB/3MD`T_0!2A;`T_0#V/0LV;`)2Y3`S(K`?0#
M)Y9`M$5;M&:@!Z]B;4\D`68@!SA;`WH`#PD`!Y^`LB=;&`<AL]$""C7@MFUR
M"1CY-:!0/V-@MY&2.4,`ME&K`3&@`7&3-![1MT6K`4S+(87AMDU;`RIEMU*Q
M0Y,#N2H[L^XU!#TKLS,[M4'[(X@R!DJ+LH40"D^`LU+KLS-;#$X;N3H[!D/@
MMA\A$'%SN#HW!F!KM83+M&"+@>ZUNB?+M*W+`E%[LM1WLA'$#Z7+NG'S!#>4
M4H'KN9?`,`_T`*GKMIH+!UM;MCFKN9?0MV:KO%-K_[7_LA1M\@2$R[A3.[<P
MT;=$6[A&VRFO&[F;8K<)4`,VH+D(5K=FH+*N8`">>[B;.P9%BP9%J[O98@`H
MRR'?6PMIUK?J6[B&>[0<\3LU\IP.:V-]0X,,=3[6!:Z8%22R]7E"H7/*8@,I
M!Q6(R6X.Z8/>E$=#T`4P<`<54,,V7`$54`#=40,14`%W<`<O4`,LX`E5H,/<
M(0GQ\,-`'``)D`7+T#U`\`(5T`$=`,1B``,!L`%P:P`!$,0Q@#C8<L0Z7,4=
M<`<!4`P)\,4V'`$)0!8;T,0)<`;C4@,94,-B``!Z7`$1H`&;`CD,HP<9H,,=
M$`!=``\/T#TUX`%!+,1/0/\6-@`#.DS$$J`!0-S(=Z#%&6`#C^(->OL_M4##
M00P#&K"JF](%$7#&>@P`=U``:5`+D?`$=WP'>BP&K1P#!$'#.FS#.5P!'O#&
M"<#(=Y`"Y%I$#S#%O-S+%9#&+.#%0%S&5?PK3QLIA:$!-;S#8=P>-<#&05S%
MC:S#&J`'$=#(5GP'`A`#X"'*F;P!?>','5#*OI`J5)S'>QP`,0#+`\/$07S%
MW2P`=Y`!++#-=_#.":'+%:`!8.'%^PS--]P%)'ME,/'%?+RYWZ#0`\W/,-`%
MQCO.R@S$0\P"3_`"F?S,NUP`1LM1V!L#(DW/8K#,?MP>3Y#*=T#/0AS&VPS$
M9VS_SC``!#/P`,+,S]`<`Y'0!07PS!GP'`%0Q=F,$ANPTK4,`V[<T^/\S#DL
M``<]##80`36\RBT=`*6\'_Z66=7Y:?[%I1H\-9XS:!D<&9<YH:*7$BJL+!FK
MI.FV,:LCGGV4;N,"#:NLQQ^@'15`Q&/P'GH<'Y&@`8!-#651`Q6PRG?0!3,@
M1<O0V'WMV%\M`39`V<`B)95,SWT-`^(P!C!@V5R1`1_P`05P'X6PS=JAQS/=
MVFGL+8GR7T,PVMK1#M:PMJ`0`'U]U(]0`[0L!M0P`XA=V:<M!@6@`<5P-1Y1
M'9$0`WT=`/):"S80`)XM!GG\`:!M#3Z<W0"`W8`M#L5=_]G:D=HSL,9ZG,8C
MI"TV0,M^_=>G#0-Z$-D5\-??[=UH_,>)R]NK'`'%@`F,;=_D_=<:@!WD#0`Q
M<`@:X-G<L1<P0.#"D@`9D-TXT-*T_`$5T"J2[3(O<.!^#1\SP-AZ7."LT06U
MG.`LD``=WM?P+08V4,0C908/#A^&<$`2``2VW=?MH`K\O<JGS0XV$.(=,.`8
M;@-JJSY#,,ZN'<39'0&74=T7?M_:,0TUD..K+`"*W>,LC@,1(`C`O<H58`/"
ML`X?8-B6H.1<?=ONT`-:?MHX\`$X4."1W>,V+`"MC<Z$`,)-ZG3/XJC^]:N?
MDD8@*Z361L)L^J$&HYTX0G`?&_^$&?Q]JHA#(RL!-9#'61P#,1`!F1X#)A`,
MA,W*D!WB>=P!"2`LA1`#G@T`&<`8=#OC7JT!7US8?5'E>HSG?Y(`&C#(Z<VX
MBS`&!=#7!5#J/0#=`!``Y2`!7ES+7CVSL`X`,"`9+9$H)+O@T9VVV?KI=^`.
M(1[<PVWBA4VX20W8!;ZJJK;:*[['1`P83]#C!1`#-:`!$=#2XJ`''K#*[=X%
M\([=I:X![OTKF([I!9[B_&WL/>U??`T`[1X!"M_'@C`&0^[LA1L#H\T.XWX5
M74#9>KS=DA$#&9#I#W\'FJ[PI5X#JJ+L?BP(7>#>A0T>"?#K'^`.8('J?PT#
M[O[N'$W_XA;T"1L0`1F0`;_^W?:L\)#]Y0!0\7K@[6(0`]R@#GK<`1W_[_>L
M"J7W!+8=`8>P-Y]`N#]?`3%@M)']'C3_[QT?VK8-U9FN\&&\&@<S!OS^UQ'@
MN:@L!EVN$?R-W%T?]]/0`UT@\:Y=N.*0!>\A]V>O\#7`"B).SVE<#?R-SF!Q
M\%Q?M#%0`$GOZ7L<\I@>`=20!=#-#ICO!WZ@*N<\'U]C>GZE;_H&<+HH2/<9
M1P5#=3YF1*0GA]"V0;4#1TZ:,J,TI!+9KQ*0\J!^#XU@X-$M#I6.X8I="+Y>
MRWILWK;[\&AP#TQ?[)/A\+5>#DEQ".KPUTJ?(#^_RMM/[`2O__GT[-_`']F9
M?@D,-`3U_MU[;`:1O1F?CO#$']RE/@/>?@=^<`]Z7P!_#0@%8RP/#PE`-A@&
MA1(:8@!WCP`:,X4/C6(?'P%C,R0S/1H1G345``"",ZJA$0DS77>079ZJM3UC
M`:<!/94)"0:^78]W&I^UM6,=IS&TL,L]MT-C,:=BCV*48Q+0JQ&GJ:#'-;%W
ML[7.IQ\5-3-C!:>4,PD='P`P["2?/5T1-3T)AH!=DI!%E2-([,3%`C#KEAYA
M`,3$4-,N%X``M(S-R"+AEZ\$8\S`.!6!5\>/"0K&>%2`%HLQ'I;1LM7NG<29
MM5B<M&%`PAAO'SJ,R;=*@SEA]4;18O^5<(8W5+S40'M:H(?&53-*G:K&;(;%
M&+SFG:HPRUB-&)1Z/"V9[RJN;WK:MM-00Z>$!T.&%/JHUY+?O'J'^`+VRP`P
MPPD$?P26U]?>PK[Z%E*,&&_>OP:``('LV.-'0YP1^T)T:/-B@7Y3JU[-&C#?
MUY%9RY;=&*`$B!*A03/!JQU590"8^7FT;H:$;3:&H1F)#=3Q!,S1Y/-C$RRH
M&N\FS2!46T)-F;9L=H@E9I8&7;S>`A!Z59_Q,2@C2WBB[$X$X&!/2O`FI@+P
M"#/X09XKKYQR1T*?'!0<1QUIMIDT0U@4002/['*73Q'4L\XG+/3&#36GF,--
M.[S`\@$QNHW_T=MW%_70T6,)V$`>6+>,H:(JR<"C"@E:!0<*0'K$!,"$NNBA
MTP,LK`(B>ZITJ$H7!M9@3!8:D/,?+]G%<YXL.*TBP9&Q'9=%00>),90X]<5@
M@A\UC%%E1!I0U(-%N^C6FT_P96:`C=F5Y*(AFAE0$%6KO"0A+[HATZ<>NO&V
M78.*//`35WYT0I-:4>KCX8J$@@*-11WXT2BB69ER1P>/=,#.5Z!LZ>,QGH+R
M5`"BVHFC17?$4"FLE:26V&22_?4K:"@9QAA>C"F6&$!XQ1?L9'P!VY=@A@%!
M6+'7$AL?0)XA8D-\H%DVV[BJN892L[%9`MA`Q[7K[KN^V@;1>@$4_U!O`2&P
M\-)3:#Q50:7$L7-7%AF@-ZM)'0%70`PQ%/"(=;S4@-]VA@P!C'?0/0/*2R/=
MT>\W^^BBBL0DY=3ABG=Q5D@/2_HQJQXI_V1-!"N=:*,R8DA9("1^S$!1.\`%
MD(5.A%4[Q!,C,33.>H.,F4``]>Q"@HO')3F#'E`#(("E=R4Z@XRG='"OO0FY
M0Y*+S#(+MAAB%^!V`?&(!0`:.%(8$3O_/$`?)'*8$79=/ATW5=B6ZJ3B/@&K
M,F85%6I@2GE8ZXBI/4.=/.:('1G0V%V2S@"BF29W`5P';L-0KX%IJ7?'VV[G
M-\9>-@#A4](`_@D90195Q<V<84\8P._,D/]@!G!W_/ZV=:"9-D;!6U40`,V6
M5@3RU+>LJ!M5B$(CI!ANW]O*R*8V3)(>3S$SN:KZ5+W[4]R/71(H($8D=@8:
M6)H%L<_.)IE'RGJ$KF,6&Q9GAG49:#4K6+49C$`*<RUN><8SH"&,M[(5+G)9
M4%V60$D"F669RW0A`R`$(<-&.$(0=H$C>#&$#BY1`TFD`P`?P$$,O#.Y+D3N
M(LZH0">>DYT8D``B!S(."Q)@BJT8\7WZZE%7)&`Q@60A8\'I01:@,8:.L>EQ
M&EA)B[*RD*[4X'<1^)T&>O`2!?[J+1^(@!I:"(!UY&T_RW!'4D0'"4M!B6>@
M>,!W-O&ESQC+3:G_4E%U-I(%[)S-.)PC2$7J495'&>)P^UA(.C0QB?1D9Q>$
ML,1QDK,537BR*SFRA^^N\3ZJQ2`6,&!4$?,#&A4]!0:=0%L"MO&F(`K.1`'0
MPY*Z8)%LT"DN+GM>&)42D+Q<BR"?*YR^;``<&!Z@'ELA!BC,-DE/IN(DB)E=
MR8SS@&N-(4@@XX9Z3H$#'&AB%P%J9B?YR+F``&$,3W"8$;\1@TZ8;1.(TD^[
M7"0D&/"B0Q*P"`P]&92$D.P.8X#2B40AD\F!XR0#R<(X!ZH)'8)OGA$I0!>D
M"!\(0HN#K8E/LB;S/VT-1H/BDM9C]J?!;05J6]=J8'QB1YB]7/"FJ5%6__^&
MU<%"!,"%&)UG`(Z30AVL4`)LI)?O`J`!&CYE%FPL7BR$@L@WL2>4&N`(QPQD
MO,<%`&\U2!HSCC0$TW0D2U)$6\<Z`:+554@5PXL(,]2@`7/B`(94[>@O\C*&
M@W9A:A.[RZ1\Y`RI1L2.43).2J@IM"&>9@AFL`C=/%<A;12R3R8YPT>,I!ZJ
M'FDS-D+<-R84QJ]2D4Z\T*SF+L')]9`VC&53)S1SE4^?2$@5!^O!`S3CRF_L
M,%R`1(AB)5"%6&!$C@!X`7`:\LL9A"`3`\4&-'QB@"<X:)8LJT8LJP8V5+S6
M(MB0DT4JX+LP6J=!FRF$2,[V1,TX4#TP6,4MQO\[MH7U0`U^&)TP)]14Q[CS
M`86,0`6L8<2;,!9AX7*7D%[0)$/@2I@!H$`]+PHZ4(D5MW]SY&>.\^#76F=D
M$9#D0,ER"VX=BUCC,I=HRL4_!5XK?ZWIRVG2QAGW+L:,VT():3H#4IQ:D%H.
M_$Q.]?*3"E0`!ATPLG\ZP.0D'SD&0^.<45EXC7A@)4F3*X93YDG5+)!O+#'H
MPBE)LL,Q/(Y&D4Q*>I(6#X)0JR=AE0F#,F8F$H1R*QAA$3J_*$_*]4*!0]!E
M-2+0!<>=PI^*E=`GGF)$Q`K7.%DPT9"XN9A`HR,`A0X`.38JT5QLHA.&L.DM
MMK=#R-B(2INVQ>Z>AA[_Q6IN"$@EQV1C-3+@P.`^B>7F;8+6A2YD1PP]&T/L
M;/1*4#]F&@;:J#8PL0E/W-&(#7D*>TP0@0(0;Z-_,@`&;/P`01_V1[/<&XIJ
M888NKH).\N7&_4ICFR'0[D<-#+1%XOL>5@\)DC=:(SVB>`QH/.9:!;E.#`)0
MQ*"H*'?V9)9`VK7@'UU"2*FPE11[Y`<>%7$K76GK+#B'DN,\Q0/1TQ<B5Y'0
M:E^<$T,$@@Z<=5.]%"LQ!8Q@8_3DWQ3"*'\;-,S^:(XMSRPPQX?@R;9\G.+`
MM%3(0[Z$C0ZW]*8[?2-2/FI2BW$5?0V6$A8W(E6!!DV@]H<=$C65ENW\TRU2
M_[,K=LE<(2_\GCC?H>(S<)7(KH:KH>R&*J5>#%ZR4PT7!E$GZ":!'Y*FW2?E
MF@59B!\EGF.M122^P$`%D*R2O1%&[+83S&/(=FPC[#&@6AUP[_<0#_4H)L)Z
M:=@@RI0*B9\>E*(>+^B$X>S6]TXRHZ^@+3:E%Q&*Q-K%$1^HRM3X+CG@EX?D
M-2L'I9O(EVE<(Y:^F`_._HH,\L2C!S:1_(XJ_W*?O&";-@)43QRJBB^I)WC&
M^"<UZ4:4\N^E,K]8T30]_2_/56,6A)CE;H%PB2P\A<'_\"5"T@%J<!60UB,Z
M$S_@40-;\3[MTDVS%%`E8X"&8SVN-SJ#`('(@AKK4O]T0%89ZN)BU0)2`D08
M@3$M,^9?"F0MBV$:$#1`Q6(:,$)T,;93-Y=!/78)\L<K/,AQ*P=@;-0<=D)&
M^Z(CJJ!%A&,0T*5D228)H)0FJX`.[U-%<>0B8R`8/J$'AA1%TY4Q000*`H4*
MM?`F]U8+0'%-?#$$D28)3N8?3M@-<Q=W+@0Z.Z-\>N`F^W9-`7$Q8_!]$6%D
M33@6=B0)7Z4'=S@-`>`*/:)1A@@?`\<.A=40C`(-2=*'9%8C\*0B2Y,KGC)=
MJD!$\/`)2,@)UY$T_G&*DB`(_Y![OD5IOA!)7*(3G]=(KW!QVI$5>>@/GQ")
MKA9DB:%+U]`S1"4!-E!$(I+_%56&(YC5B?[&8[-$A4-"1?!1`R#Q3?\WB=(S
M:4TB."Q`,EPXA'F230F0`?W0&U,#%+#$(]!5B'=8`QK@`=@V6)Q`B1+03[&D
M&XJ$@,IH1*!DBAI@B'<H"F/$.Q=QC]4C#]!3"W;V#I^F$SK@@CDF&3"&@[]@
M+1D4&)G!@C5%4A%4&8!!&2OV*RUX+2_E/S#8<S26@S3X/T*F&!(Y=)HT-(JC
M+S3I)624,OY52&Q86F"D1Y/3%=G(-!L!<;5R"QF""O8T.@P3`,JP4#B2-+?V
M.V`$'QF@:=^0`3,$"C;1%#VR1<9QE,D5`W+`2X\`2XH5&]XF%"F"=QBFC:#@
MA]^V_S-B($PP\`@?<`_E%Q^W00XT8B/H<'T"U0$1H`$9\`X6U0,%4P^"N91B
M$$3H4``>()5,U4<O,`R2&0`>\`2PN!X>\`+V$@`9@#'`@763PV^16#VA,`P;
MQXI(>98)$`-A5`T!$&:T9%P>@H2:MQU(2%Y=4`-/H7R$8!CXHX9:!&Q09PA_
M2481@W$XXH>K(YD18`/KYD`/L%YM=)D>T":P23Q8R0[J(7E$90AGX(V"*94%
MT`_AV!G?QYN]-F8?T!6E25Z$Z3#K,`VX!@DTDP`=(B0742]2N0'>(3$?D#/G
MX$+P289SN921,%<=YI^$AHOVD`&]R0^9T!Q$!0>K)1@E2?]`K`%`QH(:OV(Q
MUW52'`22#Y)S/]<LAU$T>N(@,253V$*1*DF#+)>&,0<CGQ&![W(&[^(N*%8(
M62`'005#8N`*:J$)0!D@18107U,!]9"D)!`"6S$+8R!B`[4>8X0CLE4/ZI!0
M,#1/%E5%]=`4]@=#NI,>M(=1I'@2B3$?,("DL#)U;9EGO"`CT&0I<F=$Q9,0
MTRD8*P<J9U(+;XI/=0-46P$./V&EK8@41L2EJ0"-%*4)Y>%Z&.5),%`09@:G
M^U@/8P0BPJ<HZ'$2DV)PKED`E-1)D@=\M!B4\=`AAM9U6Z$JSM%-1:,7!+,5
MPOA(Z-`0!/%LH$1\G:1Y;`H066#_G9,$0^N@!X1G1+ZT3>V4`.,I6^D@`,IV
M"(XQ6/,TH!%@`L@08I4J"'Y@BZ<@`'@3AE^J"1%0$.,00^R0)%\&'E(Q9MD:
M1&I@KE=Z>YX&3=%D'>%7&,:4D29H0/&"@\;"+&\V@BH*<]B"&`G$L"%8L`[D
MHCOV0`^T%Q9)D:OQD1K;H48G4@+QD3(ZH^0R='T5F9<YE:WR.UV0)">C`2AK
M`_X9<K[Q.][)D]"9$%9GL]#I>B<+FH@R<&L*#;H$/+;B)M669*0SF_Z@$_XS
M'S&+%3,+-[S@LK.9'M!`M:28%2=+,QN%(QWE%PE06E;6&U0["KUAM`5@9/92
MCK;`#VG;_Q_G:0Z^V;.SN4-52;?>2;?V-;.8-B)?5"\Q<!;/8PZV4+8ZZB;`
M\UN24I@G*[>`*WMCPDLJFT?746TP8&2F$V;I\7XK=AM/JQ^^23:/TE=2V:[+
M<[+=(S"`PGG5)IF?:;:M>YEX`[1C1%0<-+<]6XXX>3$V,'#6AKE]ZRDTY+:`
M^#S^8`)`:YX1T#,L\YFNBVDC(Y7V8Y1B]$_0,+>72SJ#B2A8V[@"QY1.%K=G
M&Q\VA@@%FT(=^!A@RT#+`K%`QT"-!Z,@F$&B06,&8`,T1;$#E$&:H;'^^[\;
MRV(NIW,M5G/J`L#_>T%ZN0TG8RNE1X1I9Q<>$EI-,EU#2')#N/\BA@-)&;PI
M&:QJ^*@-#8R/(($H?54#U(@R=W&QC,"R+M+!Z98B":"<(S+"7I,3F4."`-$;
M=L$(=O(E5C-$*'PXVV'#)UP#W`K"'9S!(_P2-](.O+'$&&PG6,;!E+B-@?,E
MNK4-#W@):8>3VW#!S(B/G*.<[D)R;-(F*!-JHY%>C'`A>7FX7_(HCL'`GK)T
M=D+!=E$:E_!(V1/%/[/$UCM=1\*1>+S$X>D1BG0+**S&MD#!TX3",UP+4M$#
M)A#%X&C%J$ER*L*R^X2/$G?$DYP30XC)(Q+)0WP,3"N<[%:1+FK`PA(L(EB_
M'P&1,<6".F8:/Y>"#XL(#\)SQE)`BL'_$PA<S"";=$!F@S;W%\9\S"S&09\A
M<CS8)-)<>L>1$SQH.""Q#;!RRK#"M-L\S>)<P61D"RDSQ]OX$8,PS1UB"96!
MSO6V;/)G-23G&/-<S=_\)\GC7_",2!V%SD=2-=ELA=JP@_*%S[QRQ>.,T-],
MSUY2T.RL+SX!$/1L.%5#DX4\$`Y-RA5]'*_C';40,]ZQT2&=,B]J&]?L?M&,
MQ6=,S@:MRG<!?[,TSN-,A#GQM>%"TC@LHRG=@WC2T[S2(3K=B>*L+[H1Q/K1
M;X:P3]OGTC1],D7]K$53DOA[OS)8+C>ZAP";AB0J&HCQHANJ+0WT4841*!F9
M&"NF+/>[",W<_]8@RWPX=L!N[=8_*J(.)#@9W*,/B-+MLFP^^AE^[1-]''[M
M`B9US(UAS,5`#%"VRRZV^Q$^:F,B3,:2HE?6JDE@DAD`$=CP`BB;H=>%;87M
MDJ,V9AL2S7&'W=C#>-HW>=G[9-3MI-B?K,WO\L4>S=E:W-?+ML>^(,(Z\<)[
MG5[ZI%?LHKZ.S<`;')Z,A]+;3"QX_<./#7\L&&J/70B:W=>R`=I?XM'6G5[6
MNMW<"-Q:;"/[!,9[#2[N(D59S*8X>M%&72,4^=II5V(ZB-BB^BY4\]-_S4%`
M#%&WO=BZK=?;_!P1*)/4C),CF1E"%W20X=:+05-7;1DX!K&$@;^-Y_^,]=NQ
M`U2^N/R1"A0[<]W6RW((1=.2,!?B(FZ_07;<7<RQ;XR3\0(NU/VCZUMS/MI1
MG%U!JD&B(<LL^QT0H[$(FF2Q+MC'.][=(MO'O?U^/2<;,*DMZ_MOT/S&)A6!
MY_+8/AYJ41[;%S*#.#H;K8QT0([E\\O/"!ZRQGTNDC+1-4>B"XNC9J3DL`SD
M2JY)J'W2.#@0=2RCC$#<])LM/=;F*BCC6/YRMJ'E,]C81IXVEM>A'O77(,K7
M-%[C>:[7<%X:U2)T-*=S;:VBKURB[H1C#_[I05:_,`*Q(GH8@8*"D-&_*([`
M'LOC__/JQ2SHNUQT4;X:0(>C+U7E0$=!%+G_D1:[8H^QH?5[OC6NV9"QX^:K
MV8[NV3(NH\"\6AXUYW8M4C0V[.]+OZ_,N3\7Z4P.+K\>DD,G9.0+D;Y8[/GK
M0.2>-B2Y0#`*S;T.&3(-HD2NYC(^&--]ZN[\[FV<[Y'.<P2K@C'%[BN^[!'$
M;;Z.\/ZUH?I'['%=Y7"NZQ2+&MJ"RX.>[0.1YB`*X57][\D"ZX!A+"59&T#&
MOL4"X?$N[J*.D6;ML"[&;K3^OS<&:`(4&3,/P(-^TMRR00KKO[$,++)NHKO,
MRQVIYF+=\QU)RT'7>.ZEH@4KD=6"RT5?R]9B+2A8&P*A)PX[&355D0!A3!\)
M?P&LUEQ]4H%QL?Z:_[#:GJ,JTT$!Q.2<>V,8R1A<34%:;[!8S_:M#.UT#F@-
MR[!Z,L#)XC_0KK_N:V*=89%O1O@G;F/.KN\*.V,1E))[&+$8;V(K[U_,U_AQ
M?O@FZ;Z"P?:T:O#Y7MKNCNH9FQH>2>(NY\KQF_J=<6+F_D`9Z2WQ2W/&W+ZA
MD>&V+U.Q$R/NRW,PE>&>CO5N7K^(D/,:ZRP:JCD`Q/DY+\#+WN#3XN$&VX$T
M/_8?2D`N&LQ0'\PJ-M9`3AK-XNWP_J$T15*)H0+*KBZW?U)0;MT?&L`;B"Q8
MS^DBZH(U!0A#@@8&0P^$!@D/BX*-AH<&0(2&0Y$)@Y*,@X4/E9P&-@:+0/\V
MA@D)B)</J(F""9*NFY=#F8>9E4"/GI.=B(RWIZS!B8N@0)=`Q[V(G*RZDXZ\
MM(FG-C:GEJNOPMC*V*>"RY30KT#%P,RFVXNHP</$K_"$BMG<Q*N\\8Z#BL*K
M-L=0!625BEVM(>W<M<,WR9BA2.%V29NERQ7#<?=P)8.%D%TD4=P>:3,(;V,D
M2:=(4=SG*"4UA`2I44-)3:!)F9*2U5282F$W3@B9O?S8JM-*ED@]%G(%#AS,
MHTBC.F(4S%2R?M#"=9+*56JZ98@X/D.T#]N\B#&7,NJ9$!7`>:JV$E7EBM2Q
M>]JJAFW%$A6_2LXZZ22%MY&*</Z2@FV5]:35I>3_[!&ZJBCHV:RTGESZZ(IO
MS["PC*8[*QC(85JY@EXR:_9C9<N0U:(N5.[;.Z'&%&F#:WO554R-6A%</5EL
MS&]60_VT/9R@SLKM=CKEO&O0T\\GJ^):&GA[MW?!=#)[8GPRWZU&*5(LZA?2
M2;&4/'D"MRA]+)3=<DJ2J5L[T^&4.&,`!M?$DU`B1`6$X&`#N9/*4VF=M=TQ
M"$T#V"FK=+6/4DR]I.&'+.45X#P7=:4)B$A)F-433V"VR5(LD17?B[(AM)]R
MNXDWBU)P-9*2?OVY,Y].44'6&B\?$5F?(RJ<QLIA6Z6("'G!-413;)3\1LM;
M1:EF`)7%Q`89A+:D5DXZ_U4Z!M8NR"U4FV]O[3AD>9OA1QN)KX12#$!NMG;5
M;@C.TR,QJ%5V$R=@*7F@G<3-A))&/7X#RC5K/@A-3416PB5?$ATTB8&V49AG
M:B=):)TT%1JUX29IHM*BC#&^=&)?-27X7$@GWH;A5OG]R%\\H""(32B$X<G*
MH^JQ)4RI,#W`$6E1FBC:+#W.BF)7[I"$E5C17OLA,V(1Y:)$4L*($:R8`$0A
M9/M!$^6#/B8H'3@-O9IB<#0V0E-5W0)FHS)<$?($0/KFXJR>%LJ'2S_B9=6-
M#4_H"QD&2W'D%W6=RC89P8)%K"F6MGQW)&9NA5*P*0@;+-]PMC#3#SYV,5P3
MP?_R:<,FI-5U1@JE_N0&B2P",=:NPZ`06%DVG-E"(W:"FAL)QTK_8_`VDFXT
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M*YXHR%<-H^-<$,$GP!W)*;#1_\EB;%`%>9BJ*V=9Y0=/*!5VL$*'H8L2"`,G
MN"-I21S9>%=/`@2@EIA'1J6BS?0BV46XG,,FM.DAIKCI)MKPD3)].@HWUNG*
M.EEC)B;+C62FR*-(0A&4P7#CF0+E,J6\;6Z+](8^@SG%Z>PE/'%BXR$&.KL$
MSHF0@HQH0&4RQ+^Q1G@FRU,@[12[Z%$+-(\D9($42C6786R&:7R:@MQ(&$G&
M)(VW!(])4^>38NT'.@"BCP!+"9>=&#,;"DM@,PN8$L<U[4R4@:=&)R@N(`:-
M9:/BY1Z#!B+A\.8_.R7FN>@Q5<%%9:A@!<^P0G&/!6)(@P6IISK?(RIQ4>.G
M<^%)I/\"<JO_]+2@(Z3:;7A9H'GMZJ)M21ZFXE:</.Z,87H"57[TV;#O492+
M.V3GTW`4QM@]E2!B=%\'8:*[N05J.<<Z8["`M@P@8&!JQ4I?`Y.1V%OQYEA:
M\(9=3#JTG%0O6,*\VB4;VYJ?V$4'H]J,G#8VD(:!JVE/DXD;+;'`U.W.'\!5
M)8*6^U:!7)24BH.KLMQAG%@&::C+"%K,]&B2=]B%,BY,JZXL\Z_Q2HI30)2+
M<#:KU:1,18>DK5!]6X+3$<+LIDD\3K,0^=?U^JB\R[H>?<!9UOPPIFW!M`P]
M\IA$BO*$EQNHPET\M"$"!O.R=X4+&%-KMM&]=5)7HB<M*#;_+-2UBS7LL`'Z
M&M5!-MZQO._9ECJL,;M5+I0:ZL(-2N38'QG_YJ#T8FE"\]9!W\PX0N"PB^U^
M6)"@.&*V(1Z*<C2%.9"&5U_O+&"D,AOD08+'(TL>!F!SZ!L'$V>;%JZ0$4'8
M3>9^MQXF0:%"`L0C+//SO,)B8TO%+"NS\&W*&Z/-!?T*YX_N-RKIV9%U\_IH
MJ?C$K_`2XC2U*!QQWO1Y?D16WN)5U^"LD2\Z$N>=8GJA;:1J"+Q,0QJNP35J
M?J-E0<DH`U<3H3Z2RC.,05\BK6N[NQ+GR,4E!HH3.1],""6IT,8*3M[24M7`
M!LG@;-.0PWA:9AOQVG/QS;JL*AP>_U]6'WR,)#K)/3IJ6^QLJAT=+.9L9RP_
MCC<*)H=K3]>?6-K:'J(2$$5E@4",2)O#7W7.3M)+"'/S=\\^L@J"YT&WOL+R
M+AA_<<053.KG+#)0^GV**51DKDH_W'@D6EC(EWE"FQVSR;UU*IH,NK8.]6@[
M*@7*M0V7RY7TED3,_=0J,_<9XD0$'QC8P`9HK?.^>/*X2"[XRPMIZK82ZMFL
MI5!>96N^3^[FV.!B;3/NZLA.]"*#;4ZW]T1M86<HY#?^B!#=@+V9.X7&S7'/
M9L79S8WG4&70G$D+W>Y>MN4@YFL7.<[@N=-WWVWSC&U)7#W5H6F7V*CNM".W
M"UWXWM64$O]"V4D5M=S-G0]JQY@_@JEMR?K8B1<6?KV-16AA`03-J`\F;!.K
M,TQ>RK_B^="QX#U1+T*5G+Z/-+S>]"V#">@`NTSV2QP1N+`2<]74^*F?@M\=
M:[E'IP\?DYL)LS$1+6Z]H6D^^/P'@?"#UM\=[;/#R'4H)T6=6\XOO$"]W161
MT6WM,)D]5Q5_<"(*!Y,33=$YR'=4UF='L%-EN/-(_6%/PB%EHW)SU_4F.S<Z
MB"4*L,-^PS%.!U<0\U0?[:,)[S`(7`)\;D=0J-4@GM1#(D=Q<O(O&80VD;9G
M/V4]H>8:@J(N!4)7<X=3W,00L5,LR,!K='&"[&5R8#5RB$,A*,3_>W)&4![2
M*"UT)!;!1P<X>RTX1#;'&^=0:C0R;[KB:`L!,\]G+-)E6R770W*%$-:`"7N4
M(6@H=`JX>P;R-"%E'B/'AZR!)ZZU(*'T.1\6;GUG0)X!A(J6:FG"/FI6<$L(
M=S>A==ZA39>1?`[R$W+(+/]E,?-&4$TA-.N28H<G+",T#6+U*2.&8(UH=987
M7LBA<EH8:=,R1FN$>PN#>392,<KQ/5"!2VCE#77B,P90!;UT@_Y1=S!510XD
M8EVF((-7'L]W-&>D$1IF;0<H1)\('_LU5'UH=[IQ<E*8=_.UA=/TA;`728-D
M)X&B)&HC(4KT*<&8"T845^@W$<=55$W!_Q2#YWEN6%,7M!\PF!?'\EB9@WXV
MH1$I]5IS@58'"%3#YAHX9WXB>(L(=#K0R(Z=EA8C,SW?YE'5-HT<Z7BT$P__
M96@SP6P3Z6`:,Q0!F7WJ&!9@9RXK:%PP&2E-56RV!(KBYDL/LF#79&2B!QUV
M5I1_EE3`*'*M5#G1$6HVH'37`"$!QF3.L2EJ=&K'XV<QM1Y\B$!&<TPNYY&U
M\D*/YHW-\2<$*23"AR>D(7)3>%7OB'OVIS,[F'R!5T!IA$9\(V]O`Q(Q<7D*
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M8B5AUA=!*/<@6F2B[GD9R$46?^-W]N-+CU>&Z7`;%O.70/,=Z::;.GG_5OLD
M;4Z%1/4@@L.&BY.B',PEE<4F"RJU'\+64VYH>JC1?.FQ;OYW?'Z5=<)P7ESB
M$AM!,,""8*'(<8&T?\UTB@@YC@(*@90FE6I9:1#A&XSF50[E4FC!D,I%HG\C
M-PEZA3E6873:*,JS$'(97!]F39*I=2_X)F="J*H$<2X%JNXCD=$)J@4#+4DR
M@19V/AQ(21!Y)>6C;P:D#%]3"2SV)H3J"YQ&I'B8"96$;KLX.-T#8)J9.`YQ
M"*=%J'B3:G4X-:<9'LHVF%1%A(6F<8KEC/2P7.&B?*G&3LUT=7=W0>]C6A33
M"RY(I5"X;%\T=[CPCP>8'#$3()A`+U`(9]L5_T&VT6VU-%U9)Q_GQ3J2Q&&L
M@*<EV8<T1A?U&7&;E9>`JCKUQ9]A=6E"M7/05UB>92K2&BD<J1Y^)"27,V37
M!JP`RI(!IS4P2E80MZ.#A$!=!;)IX;(<A1]!5JS\6!R9]Y,_.1A11&/GE%(D
MZASREH^<]5$RV9&6@4X!J4OE$`MA43VCYJ2S%(@YB[.^DGEK9)@PBBS1]%*V
M"6^`2%M*E",XVUY5ZU>=08WB*DAYE#A0Q7,?.'<M]3F.=J%(Q(P(:DUU@XGU
MIT3AX2O]*IFYT7JS5:=`:KAX"H/-ABM9I55`=#MBZ(V/E@^O-;&&.R_/*9OO
M1#R'2F`5=HXHB8O?>?]%<A9:=6(Y=/1#PZ5HK!>H\49LA7*I(/N<T%9B@VH@
M(RJR!X6BH!!^MU6W4Z8EV02:V+=H,N.=6<=/.CMO$/59GT27Z$1@I<$[D<6\
M9742JRDNG`6-CO(]-FIHD*=NHO(;:/H=T$LS/.BRC&:CLR%Q&%MO(*&&21AT
ML^5G@/:N\/I1-T&=CK2$(UF=V_:T+T9+.-9$<;HOGXF$QQ5R:B.E)<ER)[0H
M&Z6=S32YL6&Y0U50-@=WBF02?-.0TZ$C)3F-[LMX0/9D![=<8ZJ0T1L1V9>"
M2+A%H81NUC6E(\R@@]HR]BHS%6(,,'HG(JE9R=JTTWMVWU-:F8HVWF$[H'G_
M=GWUM33501BS#K6!1=Z+<VOS5!J1/4RZ4+UH50*91+7@J2Q(@,F%D#WA<G\2
MNV@<$((1E>NVETCH22#FG-&)?J+))A&*AH[#6KWX.96`-4#4?L\UO^26CW!F
MK%$TM_[*R*7B9YQD32YSHJ`G154(L9/[L?T;+4T8L>Q2CAALE^?XI.;5<`;3
MI",LD@G\J'\+)['I0UH:H?::9PRL`@:YI9JBI6ML%D>TA<GB;6@9>'##570E
MIYE%3V?R$`%G></*9?6:2_,U5<C"7CHLF<BDD-%<$O1(/H6R4`:C$N!&0LXF
M<E1L)VYTS.6E+>+VGXV"@J,(Q;`I6RXHB>-+*<&"_ZZ?EK__^:HB&[!FXIV.
M$L6<5C*+]ZY?(@B"'"/&&GWSVU9O>FD_I`W>4S;+YHQS]\@,:K'1FTH796OC
MB-']6[IAY<FF5J@C7<H+=U3141SW:EZ\5EJYF;3AE#VAQU9DB*Y\0H8UI5(0
M&V(:RFWI['(2.\=N*+;X4(/1ADC@PTC@-C_"H\PI.;0"<JL*1\V7Q8XS27%+
MUE0-^XEW6%N)5J?LF"6$U'8,-EW9ZWJ(Y8N;Q6".(V:^^%],/$UR2UP']RC(
M>+`U)C?G*:="K;P>_0L&/'C4%DA-E,6;J,#EI5\_LLCE6%#<9<HU[(,;)EX$
M`QKGY9\$-JRS"\1I^AI,>/\H\R/2(TU,C:%-H2RJ;GVY;.MG$[1/LF%4N(2Q
M&[RY><@LEB0)-`-Q=Q%F"LT:.I$R/OA=N#EAT@&HF+TMH280Q=H/1@.'W88.
M=JU"_R-BC(&G:_>H%.@2Z8D3OKL4,M:Z\\BJKQ=GL)981F8@[;D3#*+)]?!.
MKAR^#20/,3H:`"-CKQK=/IG.2OVQ0>/*B@`$54`L8ZFZ9*H7X]M8(NQ*:62"
M[52![SLT4ZJ2;[3,=+DQL_UBE;G4@-NZ-OTLDY6UXN:!<*>GD2.%*(BSS,+8
MEALXO&*C[=/B'^+?YK5_03=S@ENY>P$C7BMGNN-1>(=0#0<2P3<?/MR&E^)L
M('C_.\XW6/0JNT^SK-X<X+E*71OS*O6=H#+F,9/$4HY5A/I!R:"@82T6X!]7
M=UN+<>O9K.%MQ>$'C0O4O`I615])FP-"5VVW1=@F/$9#FK6IC\\6CW;6#5_)
MFO>$U9$:+-[&C(XV3']G0#F=Y11[MYY4?G<^/OYSLA."G(>#VKAHF+:U+8Y:
MD%QKTU^,8BP%2H>E5UY8#0A:PYYP&BC>-?5[#%J"F)(+(@H\EJD-P26MXSQV
M?OY&/1HN6!&FU`-+28-4N7Q"NK),&YN"LH-P&N\[$Z$J5[VR$BK`#G`89.MI
MD_TP,`KR*CI@RT,4"=UV&'HGX7R)T'I^:$_0;1]^4[!2_WMVE^#!\PKK-]]Y
M4RLV'HB#OG9*[5:9"7AQK'K[?M8+WF(-5,J6I"Z(!.[#$&;)-;#3UE&-HXIT
MTY[;6=K,W:X37,-6F)MR5:@AOC2'AKV8PUV4C5*=Y3;$PCQO(VJ;R<=9,^M:
M,S#!;@R#^7`3>RUURGF]KNN0;=D9I>3J4S+Y.FSK.%T(I;H=V]C*+B1ZA"Z0
M(PBV/%YF+3@]<>M:D1]^?,)H_7;+]1:+T;V2P")C7S(71BJ4N;&P\&Q:(`H&
MH`7G2G_TH2;@AYO(YD=6]/=^N9E*G[IP3TF4A*<`[L5KN)`'W+,D-5;^BI>M
MQ].85,P"BO?ZSH%1SU8RU!>=4/]+0HFN[8/K8$5Q6PLCKK5M-.[+G>I;FW/D
M8!SV#UG021*$25*>:M2=N5ULO(/ST<"&-DV6&,Q,P`%8J:WK'2M2[NA;NT5M
M\R+"%^Y:0;9M*#F6DX6<=><[6P,R.ME2E0N0QQL?'"*A6EKV?>7]#&(`U!YV
MV,`B6%.XB?3M>_YL*#AC`T(Q]+/N++V@M0\("4,&-AA`"0E`-H>)-@:(BHP&
M0`:3C)"5BX\)A#:+D)2(GIN6E::3FXBGDPD/"9Z?C8R*FT"AJY6(JJ:VNX6S
MH8F7D9RWH4/%MKG(Q;B50]#1R,C*EI1#KKVHS+K=WMZYI]&ZO=1`R)7!WMR"
MW..KQ:K_GL>EZ8O8#]29AZC6FMJC1MU:%(D=)P,8;!Q\-.B:M(<0(TJ,6.G)
MDU*1E$W<R%'BLX8&.HJ<*&BAK6.-Q$FS%E+5R5S@*,$L.6F>(%0+4^WJIRM7
MI)#0>@*M]A':QZ('@6"H@D'5NJ!&'28"NM+A$"!:3@Z4:<L3!@.N1KFR"/:!
M@8O$$%E4H4)9,U`_S;5TV^S)5Z.CZEER">2)(VA*#:C`27.2H:`_W=*"^RNL
M(Y?=:AIR59-?JEZ-8,UZ_!:=(D,EYZU*6W,>M5BL'E#^K%`UK5/)7&J&]`E=
M.V%GJ0YR9@HJMF<(SX&,=LG4-T01V^W>.ZXPS6J'@GK+=_RY_\QH&,7B3D<I
MV*#M7+4J[J[YE-9[R!?.B[YKI/N-W&7^<J3[O?W=K:[6O]^Q6_>$Z.!B%6`R
MZ9283LLM@YQ2FA"6U#+,I//,5+),B!PK(*V"G5%`]63#!AEL8%EZ#[5S5&\)
M=FA2*]DPI(@CP9BBVA`781-5+#(-M@PM@"D$3HUO74@6A]V,H1HAPITER!@7
M4J("9*HEPA0_T,7HB2H)N55*29BY@H$AM^!R$XY9QH@9A4$5HDE.;ET%&B?K
M`</>3(E\*8EQRR!)6X./O-A*,>^\A)U#O:$85#A]`;7-;L1=\E1$^:1(E2X-
MA4902;<YU8U!W#'43F+&%$B*>0JBDO]1F)UT!0EM+Z:SBS($1<>*<OS9=Y8R
M72U28ZVV4F45IKR2Q&5>.`5H:$,%CJ,479BRU.0_?W&C58>[O21,6`5Z<\TV
M$A(7TD>W?9A!!DU-Z(I'&@DSYA.[L.A**T!H4,4CL/'%X0-C,`K-$S7TZ5!;
MI!`5D@U5^+AM.`I:M)P@^4Q*:;YGU3`&DXK"9`LZOVP9)"\%RCI*/.:4M!0E
M:PX'5W<H88:ANIS8:<U-Y50[[9C&!`P6(89PUXHXYED+YV.]':1<I^-@=^*@
M@ER\*(2SHHF<L-*8I&)/7'U,Z31[1=F<LY&]>`Z<*!-*9=8FQHGGB_0AVI7`
MUI"'RS0BJ1#_K%%/R$=0M'/W5]0D>8M$Z78-&IT.1+CJXEBV3V,$TL]26>=H
M4MH<\@!TDV(H]M$H?EK%!AM\=4U^$RU-%!#C1N!!!!EHP"Z3$8@!0Q=C8$C<
M839$$$$,"4@`31<9H-X%;2MM4F--0XR1004!//'`KC@]TT4$`=ANNP9,QM"[
M]!YL\(`$8SRA`?31QZ`!57GBNC:/1!YT&D._C1)RPVTOXC[,(3=R-9*C"A5?
MJS9J.5=M>$&-)*ITDMH(;2H]T@G.9'4YHR7*(]\ZBJBB4C$7$4HES8D:W)9S
M)DQ5:#'2,58OWB44F91$+B<9TS\&*"J4!/`EK$";(M25$=!L:V9`_YB7QNY#
M&0[M)W@\B]4/^P81'1F-B'YK3ZHNX</K8*=NLLO'3V9BCIFUC"`P808,@<4Q
M2K2H%(>*SL4D=31FX*4**+L:?$)BED(,00(UJ,`'`$!'.A:@!ED8@P8"X`$\
M,LE($M`=W#)0QQADX9`1F.,=8%<#1*CFD0C$ARLFY@$`P`"/^(H2G3)PASH"
M0``QZ$$7!.!)`'R@`&/H00T"8$H`B(&.'9#8(XLW(UID8STM05;YBC.M``U+
M.`Q*H1;IHI_G-(."@'F3U\#%DD8-JEMO,0PCU.0@8="E',W81C)\."@G/F1I
M=L$@-Q=WE<^=;X@2289W/(2:EG`I%!K!VO^6W%$/=1XHFQI*CR4$PH]YY,5N
MK>*8_(J#Q0FY!W[1`-@0*V(1A_@%BNA$XA",N!R)ZJT<2((B$(\ELZ*XJ3ON
MC,JRDD:E:DBG'^QIXDGTP0N&8(AO/FRIOGQ3SIKDLB-J,P"3Y-@!#3R/CAK(
M0@_&4(,:]&`&0WU"%[K@B3%((!^$M*,99O"$#M#Q#D9E$L&6^H0WJJ4+3YA8
M6,?`2E3.0`]^T:E94F&#/;XR`-2;00TZ60'QQ2`&7>A!#R)@1[S&H``5J,$,
M\M6%*C`57J'"%?FXPB5Z.22>*!V>>+RCE^$LK53QR>RB.*@HI34P11U3K#X%
MA8EC(@N9%24C1,[_<L9D?5."0]G*2MW#EUQ0QQY?BT<V^%$W0'T1FU2CQZEF
M6-/*=BT\W(F395+EB0S-XS!\T<K3>(A2C]*-$<.+8$0ERHDCVLBBH2/?VUYK
MW0SI9HO0J&6#+A8I<<9TM=SA$($49",V"NZ!5_DNP_9EB]Y*9$;?)0U1*P"`
M",R`!#5XI09F,`,-="``8T"J#0H@``%4H``:2$`/LA`#3RZXPU<5[%XK4($[
MW*$#$:@!]V(`@P!DP`,%R"M?S<IB&%!/`K'1JP9>&0,&RU6.!B8!"7P\UU,*
MEL%CR&L/8A"`"HBAPA'XD\;B*SB@4.98,&V(9)DWN"I7T*/;D&)T:AI3__MJ
MB$/7:*_8",4\UQIM:/&L;\7DO%'[UMD`5>@J!#OD1?.>ZCV02\66,#N5_<%0
M8_J#B5G65H\6JJ.C%C2,_`PFB\6$)Z!?6Y;/:B5!&PQO$'X134VRN]U@C<89
MX#7*:H<TB8M4I+\GN@A9"M7070VB$&B9TR\^,^97)ZJ[Y31I3#7JV6E%3KL,
M[0NH?W@61_A%.,$3W"`2<I,$Q!$`L?3#C",\@QA\0`""K4$!`(`\JU8@J`UV
M90?$$`&RGA@`BT1J!&!@.U866*]\%0.!`2#C#P1@J'(,@,2>RB`#2*`'.P9`
MCQE\;0QWH08AB+`&Z+AP'S.X"YT,`),%`(,G!/\2(5\YTJ%EQCQ/\XQ0[NM$
M!!^JT?U]2Q.#H)N>57[K:+5:HUJ&];3Q1K1@WOHPNK3*S6^(-U`[-+O,(\O!
MJ$*P<SRA8!&4;T7^]W)-P()8\DT.Y,R7PD%/43%]RMD8@^NIK=<&5,QYE0F?
MM6N@H0V+51/4Q0B&Q1"^YQ0?`E$&4L#W%.S=`X`/?-\'W_=Q[9WP?#>\XA?/
M>,,CWN^#']?C$]_XRB^>\I*/_.01?WC.=Y[O'J!\WT._><!O/O*?)WSF07_Z
MT:M^]2DPO><=[WK-J][O&T@;)9AD57*_\MY#[G`%_-!M<@MV#`2&</'O\-<[
MM"YZKCSRQ/3:A0Z<\JC_WF;W72/,5X%W/P$SR,*5GY&%A%?\VJ7\,+R[P&"]
M'G6O\%[P8+.J=@QLP/.L+WSK\U][UY,>]J*7>`*X?P&(>IP7>X4'@`@X>J&7
M>ICW>)]'>P4H>?]W>HYG>J2'>H>G@`S(@+(W@)C'@1^H?XC7@"%2!?,B9G$Q
M6G&&$5\G:I]3&";$#<PE*DB":95V#TI3"`7#'M/E'I.P.;B'@D2(@IRS`43(
M.4;(%$Q(A%_RA%`8A5((A458A5;(%$^(A5.XA5)XA5:(A%;X)5[(A&)8A66X
MA%>HA)N#A%^BAILSADY8AF"(@DO!A&KHAD6HA'5(AV=XA$4X`G&XAVL8B%DH
M_X:=4PN.D$?F5F]WP&X1)GRI%`#^U@-#QE?#EVYBT`4@EHD=AE5(I4?04P"O
M5`!']0:6Q&WRAFVBF(GM1R&<\`1Z8'Y']6/D)CTIMGSRAV,2P`(2`&+((SX1
M)@$P80E[B(>"2(=P.(>#B(9G&(=PF(98^(9-&(W/^(R&B(QZF(9N*(ALZ(5E
M>(QF>(7-J(>"2(59Z(3+B(=@V(U;Z(5'J(Q5.(><(WFYEQ$P%UPHT2G]H%PS
M6$(*PA?$@EMQ`@I"5`]U^&BTPA%`80,OE@%0)V<%!&V=4".1DFK1%A46N4;>
M]5U51E[EQ0O?9'4V\!MC\Y&]$2GP\Y$H8V57!EE6MO\2$/4(`)9>,3<YYU!>
MV&%RM*%38V!]`7!@,V!O74`"'28&J50`'Q`!E%A\8B!874!'?C`&G81*?(55
M)$!6KA0]5@4#I7A]/@9_KN1*\L<DA58)L<AC>D6+2FEQZ79O,_!4B)!'$;!N
M=01A0Q4PC%!FXI4:"=(HBJ(P".5E'8D=-U%!J*4O*?D,B0D6:":1$N28-*DA
MBREG)RD-"!68@^D,^6%=%0D8FRD>0&-RMC81%9D,,->9BU,@!,-W(E((?3(7
MUC)?C%5SA^`UVE(-,1$?IED>_L";`%4P>8,!+[8!-R,<D%"',&<7NE)J1`13
MF\5=U7%:NK011'$;7.,?V4+_'6JR7B7D'9XA3)A2.$]C35="0E73'AZ$0HL`
M8,V2:9Y#+6%4#+,&#3V9E$N92``@6)T8B?XV!I5(;O[YE`!`?#%P;DOF2GY`
M`A/';R2@!I)(BC-@`:<485DP6*S44Y9X?(!!%F-PE@J7EC5@?6OI?C.0`)W4
M`4JF!S40`ZDT5#7@8!_0E#V`8Y+#'-6R'C`C.@-$=95"(&&4*YVE#NJR,$/P
M,=HT=L)0"%]16RXU0HMB$\913E*V3X]14Y^3=AZD/Y[1GL:F,M"F,!,!6064
M)97A7AJ$CR]Q+F(&"CC1%\/Y;%)J/ECS$AAU$F`"GFU3=NHT*I4Q4O"4$'GQ
M&)&@_R9ZQFE/,)QE83)=43!)FA"CF9'ZHB-R8U'5(12%*1@*62_X:"'V%!D9
M8S71Y4(H]2<[,S/3,%Q=LP\+`15H"FV9,BO+LA?IH0Q2I`54$3L\)3X1(``?
M``./^&T!*@9B$`,O^DI!-G%-.63<EDA-V9;4TP5R!*'>YJOAET</"G#^9E2Z
M@PK+PV1VI`'A5@$XH'R?J%<9(`8?T`%W5:"!=5<2XP=(V:P]@`GD-&U?$:5M
M<T*=40HB]TXMH2>$<9TNP6?&B:]6LD(B12@P(SFO,&93L5N*\D]?8RJ/<S7?
M@">$@2P"H4"?11&/-:8KY!:HV1R8,%G#:&CUX`DO5@52JO\G9V(JLHH9:U-:
M4A,UX6&=_N0(GV"/UD(>5U>H]U$)5>`!&6!K/M,5@/J$`P*I'R&IJ5:IBQ)G
M&Q%H^II9QW5-DG$ITT"U6UM=)\42_WH>YW!;^KA.E,*SMR$M]!(K8V2OCC6V
M^&``<A2667EDD$@"2_9*>DNN1<E^7YFA)6IO%0`#I/1OQ6=6@825I$B4PLJB
M.%8)JK$!^V9*YR97'8`#[894\YH[8Q`!!#9'KM1N,:"WKU17/<`"FA0JR01,
M/E*R]M4F6%I10ZHG*9&P,CD<M^9.C@6;-P$@5_$7>_J9QLE>5/,ILD)M;@(6
MS8"D!G&Q%B,5L7H/]+0K=3.I$+'_3<40*Y]@$U.;3>PA'EM""P#Q(L*9`N=`
M'NE"GD?;1=]+.5`!MIOB-03T7`JQC[;I:?RA(P:P=R,)11>C"-^II*(!J<$C
M-QP%G>L0I;B11&!K1OE*0FW3)G17+(Z3"I[A*HECJH56<*"SIQUTM@21$"%5
MO!1KH[OV)LB!+]^SKGB%BC60.MPF2M!S.S&<`-M'HC(<5ZK$9!&P5!J@`4=5
M`Q$`Q&_)/1H@/I0X!C'0PS-Z$*K!D+>SKN"GQ$P\5,*02D3%9-$35Z`8`-%C
M5&\I:(DU&IPA-#?$9YRA$4W#$K@BO;JTNVFRI%Y'#@+3%;I[M-^+'EK"2S#D
M-=W4MN-Y_QSXL:7J9!.;8EZ8>KULNK`R!$/"(EWM90_K=6B=X)H8D#W(D+.M
MFB1<5YL3.Y#2(!Y;`Z2)<&NYTG63ME[,^1#Z:P!$VS"QNELE13!+2L#>E1L$
MO"G[VK;]$5UZ"K]-PAH$0DTHL746G"$QN*>U$!+RJT#\-#7?N4!_,[#JXRP:
M&W+3<4ALV7[;7*'M-XM#!<YZ-3&Y0Z)(Q0)(M<WN-Z-/M3T'Q\U?N1HR*0'>
MS&`5FI9'!4=:,0;U[,VSJ,Y&$DW;\B6,J2;QA!L%(<]EVCP#L:2O4":"1HS1
M`AZ,=4P/#01A,259U)N=I5D=TQ(C<YRQ(KP=)!W501CB<='I:_\B^*5U%,08
MGU&J3N*Q8#2>MB#"TI0=7=%5-I`]@SK2G4S'HE5;?APAG>)!/7,-!70IN'%U
M5;/*&_4$1)M>B5"H*B<+2W%33+N7N7Q<;PLZUIM.,G@=S]$M$6+0]E.DGA,C
MODP3]K0)B.$SWW(^5W,J[I2;L:H3-.LQ*`U2W^#.0H7.B;N+N\B+@11(Z(Q4
M[W)PW/,`J-L+!^=4AEW8[L>+$\.+4:(:@63%N_B6C@0V[CR+AW38A[UH:2H!
M#,8">I4`J?3-#(9C41(,T/$)>8I-)`.<ZU,G(UE.LKG'*R3&=.>O'Z4/.0JV
MHM$F#3'!U'`7#.*CQ44,$?PY(+$FFKK_#KB1O?O03#]XP"N!-`R-1<E@7:/*
M"8;SNTLJ:KT)<T#@TW=3FP4)#"TE.8AQI^B!0@Z[.,^`*V!R&'\Z4#B!OW=W
M"D_@=Y-B/J^9O9Q!P"BRM$]+*5%*3",1$\SRG1VT0#2WW+$9S!.>KRQX,>J2
MIYXJ75O;)#^3.22UUUU*L]V@V9H-EX_T5.W<XCC62']M320$28AP<(832.]B
M6ZY`XQ-#,>JTXXF;XW!Y&:EPV(E@Y'_D5)I2I6"3-")<LM!+IKA5MGQ&;>%]
M,IZB%#GC+`51+#6')6GL,Z_0@Y=F#_'%*G.-(VD$RS!8QAETP;\K3%OT@PKI
MX%R!&,SL=L>0_[!">K4%]1^:L1M2G0$W'3;*-;`@OK7+A,$:S,@&TMXHY35&
M6@D8`+0<H;_:X'>NUBB.`,L6#"'0$-9]HVS+9LOL$+!N#&B1T0^Y%+QP8@]:
M_B?$+#EJ!IZ`GBD(W<9P!]=M@\)=<YP@%11M1%(1LI*\BP@Z8#@D5+S/[BXL
M$PF.X2\,RQ>Q?>V0'`_J<DN;4)ZI*Y/=SB8L0MZ@(')K"^69(>5-<2[-U*?0
M;:3:$7:[C1`*`>C6'I'$?IR>,N8[%Y[6$L&T_0OV.F9U3B\$O:G&.UG,,LW_
MOD#>,D\1[H]9E*KP\-8CGAX+`C1]XM1X1[2,QES<N\$9CBP<;$^\_/_6.#MI
M;]%V?8((2Z'I$\'I,$?@>S,_5WVI4/T>@X&_K6;JD!H;NH3G'/&#.?'+=/I8
M:-X3=7*OLL+(*>6]>KU/-QFR,:,59*K+MR#"F($-"#0K5<0_39,`S0X.>'G2
M,#$;^%,A'LQUK1HPU"WO/O(RL-[UC7893.W;O##)FV9-I&6;J1+>)L^^><*V
M`Y0SQ7`75]UH7(>71%,:<<<X;VVR+"U,P5:VC?,TRY3AU9604/,@U;2P7^V"
ME9J;W)$E]V`*/=V:>Q(0@LKP_=[VB(B;W2FDDBPAKS!I?:P(>382P)$H%V'S
M>T,Y#O*<<S.I@R$3.*?J.2H7&D];":R/-"C_&1YS*G7-]4Q$GDC!,7>MTKCO
M]YQ\Y5D*J]/"/F>,CRAXDXY2]J^>4[<Y"RXSVR7EY6L+&K3;[#>-1KJ@!9D.
M"$""@S9`!@:"-C88!@D)BP9#"8*10XB(53:.CQB#AHB4!H6+G9)`G8Z4#PF@
MBS9#JXN&E).%J8H8J).ZE)*M54`)DK*@AX/&N*A#LJ:&0\VGP<,8A:''B+FY
MFD.G&,V1JYZ-PJ#7H`FKFZRSU+[.EH;K0,_T]?;/FX?EE?7ZC8C5/@FS)$R=
MNF>4@"@Z5<T?!@\9SBT,.*M0L4/J]`T2=HW9)DL7,Y:S)HJ:0DV?%F)X<N^>
M/FY/*HGRL.$9*'H`_VV,NY1/D(J60(/24_$2$4NA2).VU$?.(CY'2I]^Q+>O
MD:1UN8)=%*<NVLV"\N)=Y2:.WLE$.A^D\Q1L4J1HM'HZ&BEPG:EQ4(%4V;#A
M4[Q-*@P::UMLKL)X=!'+<N1JHRA;K"!'KD*M4:@G,4VA0J1%D:W'TH9@_LDJ
MF\Y)QYQA^T1MH=]2\*1%SCJ8+<=VNSI9!$CX[^1.M8_=/LWPVN%(Q6`]HHR8
M;:39J;):4U1P8S.G3>,)DO?<<"M-WLDA/F2/O#VP!6O+Q$D+=%NI5PUV]6PR
M8<PG56BR&^4YV'&NDH`4"E2\)?*.1G7-54XSNZ#ESTF*`(.4/X\-M`Q--O]%
M`XLEU&T""4Z911743T09\!,\_(BHHDM_\22?B`8]I=XX\'1RUB:V9529;^X,
M.%`QJOGE&7ITN<7A-5TAY]<Q**YC%3H&[)6)("$.H4)@`R50XH&"V&1#3`!5
MT@M9LW@RER+__"60`1@`<Z,E(0XV4G3$S8.03&VB9:<_897%X6?-*0;<888%
M:@UAN:3Y'"(%M<E?;S*Q9=UC2C[7"YM3$AJ;@@DQ65*E\)Q6Z%_Q.9E*BY3L
MYHP\I\K$CS_GE6K3/A;Z8LPACC[YD7P'L:D;(ZB=E=\&W^%2C6M^<AJ78=I8
M%B23^93SD2AZVF*(9[C8"111"<%J"43(#4;5=K7_T))ABBL.]4Z)Z*:K(K?S
M/'".C%,E%6-\,W*WFE5I"F=6?;J2Z=NH3')C(T_].G<DGX:EHJ1Q6KUSE5Z9
M@OG,E4"]!))&^L`VZZVA/F=390L[.=*G#VP,,J4ZGI:<:#%5RXA9GY!7&$X?
MHD:P)PM-K%4A?W8G;Z(,MEHL;.NPRG)ZT7@'#2$*>7PH1T#C1#19_>)%JV`\
MD<6=N>36LI/-%/IS8JE0,3WF4\N,4D4:&YP6(-H'"4C,DD]\^1"QAV&[WUD#
MJY<1(3,'BV2TH>`[$2H*/<(?M2,^*.910Z20`68FHAC?6:!^[&X_SJCP"4Z?
MJ^AB<C'6BA2O@AVZT\%X_PF\JB\`CV5X6VI#4IVDTTJ:=6&1W9FA<:9"A=!"
M!F!^,<9+6<RF3G#J=/;'<0*=<E6#S94+2X]]>0B)!DR@<=>1):<"9EX"[?AN
M["78Y?#F7C+-/)P`IS5OL$`._ZKM,8-)0P0JRSG$XXES18=^W3!7G]YBB_U9
M2DVK,ESL"K63_X0F/*CAUYZ25S.-T:UWB5.<(C20AA("`SVL(Z"!L,:0Y#TD
M`S([Q+&.)9M1D:<GSJ%:0_`%(%M%K1J1F<BQVO6Q0Z#/)B%*P0:4IQD:)8!H
MZX`>3C*7KA+]Y!+\8%[ID,(N4U0M0!92W8HJD3ME)`8=K`A.[(H308+MQ!+2
M&?_@R=(V$D"IYRHNP]T^R+6LM"E$AD1<2LW0="1A3$\?3+S)3;BAOEXL9H_K
M0B3]$":JQL4&&7:"B[E8"*GL-0D>491&?P88&W)M11I_U!>A;M=`%)ER.W*L
M6BB05ZX".E!?3EGD=CYYJHV@ITD)[$5!#)A!A&22(K"J5SU4^`YYX&(#<`-&
M=R8H(ZY<HF\6L0%$7%,?P/F-CH?[QNBFHXOV]=&9O!"$22RBETI<Z9W<&HP4
MGU`S)6K.8*22XW&R1,_EU0.>_[02(JXHL2TJ)5)[8J)!6P)0+YG$5-?D$;5"
M,8X6[A)QZM,>(UIXE3EFZ3"YX(BS!O2^L-'E@5K"R)G_=(*F87;4B:%:DMS>
M61YZ\H^6^/CC,%252@F:\X%]C(M7L`>@-,9ECL2D%&\2-KN3E?(]Y;H%],Q$
MIHPZ=:*-2`>UI!J<ISWI,+LLT*M44Q3RE657K*2&,@7ZCC%)JC\<,@]-6>3+
MD[%I`S82"RM^^=2O0@T(+'D"1/*&EEUDRZ)+&A,.X\+(:I0S+"IEIIQ`LR-#
M=.$H\+R24;YGE`X^P9XP&T0\P4C12[(G$M-K*$(%ZL&%'M0\R:.B:R<D0T)`
M+XU;6VE[AA,_@G%$2,!AQ;GJ&I92-"Z#V]EE>YZZ#7(1I2<VZI"L7H*C1E*F
M("0JST60HSZ90*8;R$D4CBC:_R?%3))VKS"L9:[F435&L3O?,-C,1''"I^FQ
M6Z$*H_["Q"'8.%6R?YI+3C,)G/Z241P:])1.IPA;"CDC'#IA%!CG!QHR:O=]
M\E,J#9TEVVTE1CCE:Y6LP,(6>LPF:JS9YJ<F*D3'(&N"_XVB25;&%>%6!8?]
M:<Z7E@=/4(2(GM7#$)S:@9`"_RD8X1C38[:5VEY8<;91D1\\0C0]*-L$?C*L
M#!US&QD0IX(Y??PP8_)*/P&!]7Z(K6"G%+774FYF3UCR(M1,G)%H`>E-51Z*
M$3%\U.Y*RLM%W<?QM-8>!!^&M#AUYI[>9U0$L26CL@-J6'<YO%/6F,4TLLTG
MW<&Q:__NT+Z+,M##3L2N5V4F6`0<X$"BULW(GDVS0+@BYO24D]08(K6"Q)0O
M.45!VY'CQO`S"3VC%(`,N`97A=#&;B(\$3(:M;2]9(;L-@G9R"[#)(R[5A6>
M0"+5KBVV2`17AAB1,G\9+(^#8.NP`SK7>);:RDF1<O*JI$5XGXB#=`K;LR]*
M->MX,2!.#%96?IO#G0!\+EC):X)'TJ3!N>)6>QV<GMJ(\/?.YA6@J+<]B$)/
M67[796KEA';$0BUYUUBH4_7XDD+M[]NE>KM`*\G(#0ZM!9:/TTN=1"9$7-YQ
M3>I9EOEN.OV*G5I*HQCL.B13HMK7'R6".:TR9'E&1Q3I5`;_&S/&XJO]B;-L
M#(P[8`?AH;N2"/O%I`H!6"+0X)*,",OPFV2'%E/[I_"Q7%*E[LCQV_7";1Z?
M[65E,X#E8&L;%STUL2D)Y/`(VF%XNV21^K-20QT_6D8BV%8WWME;YN%16[5I
M4,[(H;)JYL/HZA%(=8H10`;U#X3?!9_GM$IQ)#'P##:^'ZU`94"N$S&+=!FA
M!2NQS9>ZFMTA3C@G/7PHHXANF_&NZ1XU#LD8&4`]238LT*L*0WI4?4,'A."?
M(#7N'XC0<Y0#@*;-L^CZ[JL6BU5E5:YR^[4LGT+[)O<T$M!6])$?&)Y_AB>A
M#Z[04K]68\\F/YTR8UMV.*.B*JNQ_Q)#,7D<YRIH(GB70V51L@W!$FK8<1Q2
MMBU.%GZ.YV&7`EA9-%<C:!3&Y&B(<0O'D`ZUA'ZU!%_!!!D5!2T],BF,82SF
M@5Q3]1Y@M"^^IR#NX`B)XB._%AP")()<-RLK1"9LIE0EN!T/`%9$5B2_AR)B
M-6GW1PJ-]'V7]#45Z$L$V`H**'S;53,6]#`$XE@N<U53>"0504&<(AV]%((%
MU6[RLX%W:&O$Y&3RIX:-80/,\7:WXBT7`SHHQEAJ@R".EE'>`4LCD1\I@!(G
M5!EH\D?1@#Q\E"Q]\E)@-837-V#FEQ+)MFT,]7<6,VB5<X$F8AAYI&65=@OB
M$CF<]3Z2-_^"_R1OL*%%>>8N&@<OC.>$Y.5&/.1U8R%6J=8-X-%]!86%Y(!M
M$A,L,?=UFJ%.A9-&#8-/(#->LJ=688B()I):5R4GT9A]_:-'B7(Z5$4>F@(Y
MW&%:ZB5,FN9\;;%/&?1[3<%.DV0F:10;_V8I<A,_Z\B%/K(I85A,TE(:H"=5
ME[(>?@<O#T-TW81#BI)9B7@^8+(XI%`FQ]9:>O9G"J1F#R,I4@$UA-8)+W06
MV,)ZW>,:$09670(63A4@";20+E=-N]8WVD`-O_A/E6<PGQ41FH,,AWA4:S9L
M6_=//A$;/^E:&,,\)M=WNL@\]\9GO!).31<@[3<Z#H1A6>$4.07_<'-S?K)!
M+=F2?V4W#XSF>G#Q6&1G7V=96<LB+AIY;TUHEN3'?1NC4_.R?09S@ZL45:RB
M,C-7(\U5C>8V+UL%$DU2BB2S".,E=R1G2D&WEPPQ9I*V*GOX%1C!)EF3&^N%
M0&!U#U8)3_JRA\NADKCC0ZA$E?7&,2=1'\9U&HP@"I@U$!Q'@$9'70G)1MH"
M:A:"#81($\0Y@/PH<VHE"EE6<R>5'J`@7I:&$?LC%CN50#LF%%$Y/@HA;H#7
M0KU69&7R/1MW+B;R,KKX>,YG'I3W:IH5)S&1E5J)?Q\#<%8!#0OA3#JA0.5"
M2G+(F6AA(Q6'8HL$G0T"G@IR*G<(>:XP_V,O90P$55#G<5)*]B$EASH>:%O_
MH$:,M1BVMR:)(7.5UBFJX:$ZU6?\&(`$,5$_4T$NTU)?82">8!(3\WV,N4J$
MDCBY1SC_8'EK`Y3OI$*UR).Z(#(G)7Z[:`R&U6*J`2;]-"NL@!G"=#N*%88,
M`1DYJ%@F<PJ#19Q-HXFM<9O68B-$EA<UQFDWB9B;9%^]HD[[F9VFF5E;P@^"
M51/]%6L.97!5TY_AEUH1&B[DF9[:A5!/"94\IF2902&CMW3N-7H)L@N9,%DR
MFG_,6:".)CF:!$XP^23?4UP%ED8$U2J=X@A/D`VZ4'$T)J&YZ*E2)))3(YIP
ME"F+HI=9ZCN,DO\;6J$-FF(X#\5<AJ8:52`AG+![Y25%'T8+?IDG_74P:G,6
M:/IG8C,,]=61C.9C]!:1'04Q/,.LTX))I*9^A^@W-U*IB`@GFX5[@["*SJ@7
M&"!VPF0WGU"G:-EJHZ!L,5D2V4*3/61SA,2,,.8G.3@H1!:G`/5N\@(N\_85
M*UARVO&FXQB54OF0Y%FHL]5%4^9.%+M%[Z2"C.0J?&)FU/8=_-)7F69US81@
M=,1.>%%>EG%B6'IBAV8KJU9V0_B9S2$GL)2<M2))2'1K0'F,.W<DS^`1/&57
MR*)76`=R[5J%P@I+?[9W^Q0;N4*+.G>;"G%)*-8GHH@-E/$/'Z(7KX#_-:QD
MB@:X>L"":KYR&SB7H<BT.\=Q2:<YJ^]`B#QC#@BG#^[I8=GTIFK(EK<V5H!5
M)?5`":0V3+DQ$4='GXX:"8(5$<S(;&X:@']$65:[>8Y!%8(&88.0%3R$?&X$
M4E70+G**>TET@>AXLO@H#ML!L33%08SWK?;FGB:'IP*%@E"VL?04H1<3>*-8
M*,@S-@#"%LKJ"TU77;,P37;U&M]778^C(%@2"G&TH1]Z@T#"AMT*,N;:;B72
M%+JJ?0[H4&U!#`M$#X28=3G*4QYB/P%87*%1OCS#3F06*<LYKL@R,<$:$`>3
MH:$!7K6F:*W'KD\+,6IQ;IATCSCX0TY*N+O+_ZA"0DNBEP]`&A0D&C5>:R<*
M!2?'"Q0^>S'&P[5OAG@THD8VH6+$$)/8DI\\21%/"TY>-C29(E0@EJT*IA"A
M2["VF[VM6*J4PR;T@Q4];$&.(*>PEAGK=X+IN26)VI22]["QRW'L)S&EMG3[
MUD9FJ2!S%'.R8$J'MQ.]R4,.&$H>.)IAK%*]`#A\PA,S>6>=:`D/BB*:A;>H
MJ4$`B'7K=5L^+`RNX'3",7%C*K"*);[@*;79ARS+9C^+,6[-57MP6+>X,E^T
M(1[B!5YYQU,<:7WXZG0D,WM]Y0N$-6R;];`,DQ.-W!TR^21C<</WT*ZW0W.X
M!5LVI1I+464!1!]'=_^TE`JPC9O%,8EB#[<==$N(C9!-M<-RB8,C7J>@M%*6
M5-6&&*!^DZ=G^C!XX)9[C>B#-"+$R7$3&'G$)B>Z&?LYHJ,%F?.!1<04/L>`
M^$<@Y2!>J-&V/H./`EAS6DN:?0-!^-I!W&4`\O)B_E`GQ$S!9&$K'85$B1H3
MF65#V,B6`P=>AE4F*,E,?IE`!U0:*9>B9W5^P542AKR<D>RJ2@:M6)<2I?`I
M)_9A:N8<J_<SF['0M/%7J#N$<)+`^W!%-P2U5,(O`1%A#^J+IOEFC!H=^3QE
MF.-./^MWUX>LW9LE<W0B==I"UV2O&S&;K9831I:E$Y008@FV!3/%*YL*E`/_
MI$*\L<DC9!S4)9-;G9[2#T-\GH#XS,!H2*YB6KA).CS&8$Q\FA*X<6S"?G+U
MK4*\P';K0+X0'5IV*.EF3E/:FQ%7#+J3$"HYD68\V/](I63,>:(B3WNQ46^X
MS5@D)R=R&_>88Y1`&]W3M4;8"1+IN](T#:.06!@MK)R[D*`0K).4Q1;DD:0P
M#H["<^V<";Z@RT+2P/<;JV&;2E(;J?.CNNI+"KP`'*+#9QQU/,F).C;+#JJ\
M8&K<'6^,0H/:V8DH#QGR8HXYWN7Q=X`SF8)@VFZ[IC,1$1=!'P"SN:T!<%?:
M4K<$G7L\5;JZ@`5SGHS+$F$=X/!4I_10JC9`&IIR_Z<452(\=BO"*'D"'N%R
M6C9:2+@)FXI_AW`TM9W?@Y<1>-C@)N%AC50]LAO&_"C\`F0&;2498E-.9)+Y
MX%B<EU@\!7LMXB2<A)218(/K\#8ID`;[.0]$,>(9]M'ZJXR[W3U[O.(&H`7B
M?":%*&;<X-OWG!JY)%2FH81\M!D#.$@D`SQ/1!EUDB/L>AL`0YRA":E7][13
MKM+Q_;98@T3;XZ(1XXB+#;^5Y`"H-<V`A0^P<"5JL0JK$"`12WI^=[55>U0]
MZD&O$AO(0Q6V;7_[Q"]L8ISZUY+CF2?`K9P;]2R,I7S,AXWW4]:9(Z?H(^(C
M/GB55L!R29UQG7&EUFVH+O_B&QIT9G(1-CSD,G*?B;@Q2+K$W3SKV(S2!9@(
M@IG096D4!HTQ>JDU!Y<70^0UR<L.HM83FU?`'%,\:>3C&=#I$2B5;SS.)HA/
MY]:P?:NZ7`40:$2%](5)3E/`7)&9Q=2Q<%0?B@`-2B@G]3Z>5'L*+VS`')C3
M][CF(WTICN*FJ_YAQ#%PX&:NX1U"3!&CE:FZID3$B)!4?R<*&A`:*I`RQ(BW
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M`04@`!&P#1OR(T8$)F=CA%,BOL.9/(M`E6PL.@K8K,UB#/';P0(H9!A,#9Y,
M)5FQYL<)'.ST[&[$J0FM2H"UP4(,]%Q/%-+L3CRL'3LBBJTLD47\L.,OX`XF
MDZ(&/K2^.540`30A*LX+[$P."!A`0X0JAH>(B8I#"09`_X^/!@D)0XZ/-AB"
MDT`VES:2A08&3Y&$H9!`HHU#G*@&ID`858*8DHVHK0FMEZF,CJ^/A):=EI21
MC08JNIB=-I^FB-#)HT_"F4"Z&)^OJY:<KZS$"2K?D6,)73$1$1K.!@\)UZ6W
MJ)/%E:B=C,<&F(/]5:IT2D4/$C!-^USM>V;@FB-,52#YPN6+6,)6KQYB:RB(
M$)!9!O&E>D2I7Z]PJ#SV(O<$G"-2!`DA$Y6*9B9'@D`5%/5+I#V,3](%*"``
M1X$8-<:8,H4,IB@5IOIEPD"SYL21SJQ6(I5UTD]<I6()(D@)7\M^'C8(&Q7K
MTS>IF09N<\;,8+-.FBC=&JCJZ_\C;9*DNH*JZ!"IPH@+&TB1051+809UC9QG
MCZ?C)U`-:#F9N+-G0Y5$,0.,TX:T9)^YV="0)D*!"AZJG*T\3<5+E>`^>_;E
M[5CHAP(S;H/T;&W#D*AW]6HD^6'@2C9F07R'#)4VR?EZ%>O';1@O5@1Y>MTE
MB/!:J$-L9R8FF%7>LCPY/;%1#1_/9[J>U.@2H0*.#Q7$8(->6555DG('8F7+
M==!]DLU&;7TGDD0^M>)1)_3@U)%4`Y&TT$C"08A-`K5DV)Y[<ME2%2>;$(-1
M.*^0<])9:[FB8F`8-B0=6<E4!PXI&9%TRQ-/:.`:#!1TT$$`[`PRQ`,/,-6;
M9<-$5%'_3<T]Y!0^'7K%)7*X!!032C4]D99]L:3BXE_-X))55I%PQ$Q?_11H
MBTB6..>>-JF@!YHB1.J&6",IJ$5-1C(:9)),M/$$Y%8U"2II(L9@(LM8=RTE
MJ"DVN,:.!C'$T`5]-QI259!`9#8I8BKRLMP^VG1H"W$GI<?6?/5E1FM&P+A2
MW24@&9=5)IM,%EDPW-4XEB:_T&;/FU2E9]R?Z.%TEJ^,,/K;?*@-P\TD^\40
M0`<B?"!&`!K44`.R-&U3:60:G91G(_Y4E2,N@2DG'%]78;.GL3419PMVI<3;
M'48/K?E6AR-Z(XXG\D9B"!"/Y0D9MLSU%LLLO#UEVRBHYNM8_Q>@!C`4DP5T
ML`X[-4#YI%<%Q3E03MI%8G.:QL)YTEXA3<1GO4'R:Z9:0-:<BCPTJTG+6)$,
M&U&>"0N98$H$6XK99X&NBLAB:N$)&6#?^&(/;1*S11AJB16R*2++6"H7TZFJ
MO=L03]1A9`0Q:*"W!J.2.C8YFPESEGI:)T+GE*`H)\L@7B$>U2-`@K-7K-\Z
MC(V'.@Y4DDW7@"?)KL=@7LFRPP4F7HM_Q2U,-.FA]\1->YI>"7PE$?D(5&F^
M3"*HKJ4L0@<%1#`J-O#D&5.=G`Q(KW9/'N<1[`;,P@U8%R,'F)=U&B-]);,T
M3E',T7+$4T4.BI51L/2(\V'8)WX5(__%&1'IDHTP;X*I-C)1&=\_4@.AM[@%
M*`"3UM&!"JR,'0F`$I0FP1LWE>@>44N>FS!%%I'P2R^<B`N>II09#S3&=LGX
MFMOBE#Q+V<P94RD06+#T$UG-;@C1D<O@Y):(K!7.-H6*D6WBIK&&T:DZ%<-`
MKG0##:U%J!9PZ=S<0B&+#8#*`NO(F][ZYB!D;"8S5[NA8JBTO(4=!"0#*\@,
MMR*(1ZTB3>Y`1D$`LQ`X]65R-$/5+O11,-3AC"2B8,2!9I836T4%/;^Q"[Q,
MQY,=GJH19[%!.C*P,A\P001,H`#>NC`B#%IL0A:9%V[``Q9QQ$PGY=".18KU
M.6*8,B?%JH?_,11R21-UDCU=U,>SK+><+)D*9.GA5O5\4Y$=]4Q_**E,`FJ@
M@:&\)G@'A('*0A6##&@@@?#0RU?H0J%3N>=HKKA$7+"$R0IRLEY<8EA4/`A"
MT'!I*C5Q2ZPBTIR/X$5-(^%31_(W)6GBY&G9R$T(Y6;#PG%-A\9S"V5>>,)I
M2$R+G7F*K=PB$&TV="6+^!@XZ%:%#50A'1T00`6"Q[<I/D$@F[@BC!"Z1?U9
MQT$:NH3IZ'&6?;XD<GFLTR_HI$UCQ2L8@91'%37&'NWLKR[\&-B*^*2Z4$1%
MEQQ))UEFDL<)!>,!16)F!#R`MPA0H"@%\($%]#8@4#AU?N*$6NA(_],6:\;,
M2=@1AUA==+VR(HQG!</7!@N&/Q+E1),&FYZOQ-JGK?7$<Y!QX3(XT5">Z2]C
M9+&!N"H@AHTB<V7B\@`SFYF!*E`G@7JDES8<8D]])4\C2>4807EQNE:XPR!B
MB1-Z;)`6F)AJ0@Y))UZ8EC!T8L@3!:J1C<!A,^D-*3>$040_M?;/UNV09IED
MX.@V:[00DK0PH?%3\@`3G6T*P[A^-<5'+5H%=70``"(0`/"D.,48\C55SS6<
M_N(CBZ[FZ$W'>VFD;/72&WF#03S1J3OB0TV:QFJ>^S.?YR0J&ITR3G9Y\H>'
M;KF63%QK+`:RIWC@(3-BG@RRZG!-![1*WO^N)K`@:?PDB$NILS3BE3@=(5AX
M!*8QN`3-20[KXY2<.AFPU2M#;633OKX!8O0:;CXP1L@P;NLB?H%V)O5[2`!P
M(-XE03:*&?!`&F+0FE"MHPK0C.:SIA(M!I8%B7#B(T0N,36UGC5?UJ&*)#*#
M@;1XS%8P62$*B:J1N-SDOINEBEY:#`K+X81_G`%4%OV9P]:M60LHY!%\VEO6
M0Z47,33DGF7;8D)>*4:[=0C(10&8L@IXVH#DY5L7`C(]?6`WO>MEKUQ5O%+Y
M>LQ13F%.V]BCL9LPIT$6FIV<W%$)V)9GIE3:V#N?HPK/">:@(83:?C6RO-.I
M(HS$Q%L`/!T`*4[_-HJAZJ@&6N(ER<2%MZQ$;9'7A.8^_\6W?FXV=`:1P;G@
MB$<9!,DD=%82BZ0II?/JQV;R!1%F'9&_3KIEMV+Q(P_-NJ<B"EFV8`8/(\%@
MHQ%@$A2KBNTI,S("&;!R!KHP!@EH63)`#2.9(-8,.VO"&8.E]9DK4Q<[Y=?-
MT55!G,OWB>@0%D2"L;E)."0/9.%+UB;Y!CSL)#\:&F*XJRJNJ91!CIQ(=!S'
MAH00%7IJ2142TA(E!YP>NAR/)4(8T0D(R0`H20ITN@),FB+)%,G.R#S:K^M5
MG)5BRI=GTT1^307X1M!<+Q(Z1'^RZ@O.F#63=D--X"DES30&'IB?]14J_Z]S
M4BPJQN.=_Q!FBEU9RF"`MXY.UMJ>9R<H'H`\1<DUCVFJ-TKY$;9LR`70*M4%
MFNO=91Y_]GE)6U'H0M1XAKQ%W[SMN6QE:I]Q"!PTHXB6UAL&+%FY+T/U2\`3
M8M`!,2PSPP<,@`?W1MG/8]P&"_2+<E8\EPZ5W!G!P5!=YCDU2"@C-&)Q$,+;
MO`&TW=TWB:>M-F.5L_^V9/QQ4AFN`A\$-SHM41A(-RG%96B+]QL&E5IAIF8N
MD71WAS;J!3E"LCBU$!HSH0BCH&F9I@X%0`%F1X)FQP0!)%EY0S+MH$A`4AEO
MAWB6`0F:16OM$GN+1S'R4RW4\"+\Y38XPC#B0?]C>H0S8#2#[:8H7$1IXO`Q
MIH)'$@0_IO)W,+47(1-&"50#XI)VZG`R*Z@.H;8W+!@#LE%L)O$N*T</[C-3
M98-:UR$^W:0B&.(U^W.#G$,)M4!Z^%*')O(+:;)#O?`1T8)$]J(57O=U,M=<
M6U9IXY-OQ^`5&E``8B``Z!(#20(#)F,R'L1,W&=M4I4!RG,+S9(=?_$*.E,G
MEO)WS0`2T0(+WQ-@;&02MD-_TI*(MM,PC7`-N1=#@@@C$4)!KA<G,QAXP=92
M0")H"*5T3DA(>92+F2`FRW`<,6*!NE$5-[%%L:`%=S9=?=2!U*@C8K<!$1=`
M)!A`YBA``<0DY-4%0:'_`2,2<V^7:G.86L+X+OM%7X-1+:VP(2UT*;F(%8/$
M,YDD=7SR,0MQ#3;8B`BI?`2&1RD2*1SQ.N7A1]`7@#"S`<>4-^I`@AW`>=JV
M-_\C:IZ'`3]!$Z+A('$(0?[PC[>@!3\E*PZA$C0HC1XA>FQ$<`^A4Z*P.(&%
M6O+B#PU"$RXY.FU"'"!U"YA2*NI%&`4#E-D@"T]C&59XAH3`6@7@D4:2,AHE
M0";C3)_W/U*T`:&2`0$`BDPE5.DD/:EUDO&GE@1I*1FQ%VTB@"MT$$(4"V>R
M0UH`$]>%'8OS%O)$%2<D3_L%.=MDAKOB+(BD9SAA&4<W:,15*"6U>.W"BW1!
M_V?$]3%3]VU#V!`JI!EJMH,>V&?1(9);&``F>(Y$L5'&5&W:)ANCQBO4^%S[
ME!X%R!:.(8P7`V2((A)X5PA1B%:Y"!+NYYMXQRMT@2&2`4,1H9L:,B>6,1%B
M%FB&Q`IG$6>,()'0<PB"$S"8HU@"I)%7%5Y7J3(@>9Y3M!]\TTP<5P,#,G1/
M8W"FA4I.97[M8@LV-PF7HE;QPB>%Z"J!J`\Z\@^,ACD886+]F93B,YP;`94;
M:!9.H4_!Y83']8/$T'.."7:?,`9C,'U#T7DQ\!K`4P%+0E49D'$9]WG9]C\7
MAW%=L`DJ4G@.H7--8W)SE(K^64KW!@JV@0E\Z0U$<O\-0V,6OR0:O)`TS%`@
MQ"`F-+J3`M$YO38*==<M]K>C.'-;D)ETA5)UAK-#23H0TG%7U4AUT/%_=R&;
M4-E0H(E>LWE+\Z9I8W<D3&),JFE]YZB.VC8JHP*#,9AWP@@_TT`D8R0C$;HM
M@II''Q,A1L-'TR`X_\<KN=@E,T54X>&,&;1W,15C=V5<N/0+B>)S]`&HBH$9
M:-)=Y.4:%2```&!]U8<N($E>*]@%LCI9Z=(7'<*7\-=>.#*(('4<9]53U/2G
M&\.8UZ`+P6%Y^4`S%!17PSHB*VE>9QA0R/69A_`74P>(TTA@MJ$%+EF#KH(!
M^]:9JE`D&(:J8B`&!$``P"/_0'@SEBJZHKR#<5'THC"C`P>R33J#8BG$"SBJ
M)FYQIK0AJ,BF8,XP'V<"$SL88,+(1S.*#?Y@<V"QKS%!,9!SB%N#K=?4%B22
MI0JXI82#C=9Z;M*Q#1<[F=5"*KQF,1NC:?*1%;;2I3Y34?\SCC#`E11@3$S@
M6$M"IYGH3"S(CD?9ILD8J+[74A]SJ`KU"Z304K:B@V/DF1A1@()XK2>+M&CV
M68NBJ#7Q.8%Y6(,5?X]7%=5I"3`5)%ZW3[+'",0D121C`2)*%.>ZKI_2B6`I
M:NF@D0(R!GD2)3\W!`ZZ0E$[AR2R/6OI'<\6=FMB2D6V'&MI/IJ5"Z,S"],*
MD/4`_RMZEEK9&:2Y(B<4JUI+MS4'BD+#$1GV$!4:X`'L6C*,Y5BK*TGAJ:)@
M.98G>J+--%41`'[P$'X)<Z:[(!T@<4HC1!ZTL`W=$:$Q8IM3X1A5T%KRTU>Z
MYU,<L4T3E)S].6PGA+03>K%;P14D1Q_)N*6&!ETV04W[^0D>F!BOEF;U<2IA
M1SG1L;24^5J]I&DBJ"2J68(1\'!T*EZ9F(ZP6@69A@%&]UQ@1Q6V\2B5<$M+
MVR?)@8$3Z&J4.9\"BC1Q1R0,,0U`14=$A7*J!JU2N7-M`:YG:\`X):4Z*$J/
MT3IET48_FPXI`SP^\!IB8(X1$`)CQWUTF\,;)QDK3"OA`/\M!&HECEL=Q?H1
M5H)K!#%=&].@RIIB-"%O@M@=U+LG%%1@6+$AG',^5D(/L!,:"'F+7G=JR^6D
MZSMCPM`%9)FJ(YB_8@``,%`H&Q``JHJ)Z9AQ.`PJS#2[D\5(Y!1^C7.#PFM"
MIS5G=!$O`:$YO'&7*:PKR1<^]-<2Q_B$Q-AXM*`@@FC$*A4A:LE'PN@93Y%4
MJ*@-LO&]77-+?F4JU=5NT'F^K'(V4^</+55@#@H<`D$,A_!&`&&:QJ0D*&B"
MU:<RZ9B.'6DRYHBG>!P0&X`-,8A%#!')W+E#AVI.;.&Y\`="B`D1IN&9+^5T
MR29$D>,SP$@B<V05I@5&;@K"EVG_%;9!PJ3Z)=5E31P(,^G0KGK3'Q70RV:7
M47@30.G"@NCYE2"9<3L%)2N2LB9DJ?A&CR7F+SU4/@[ZE/&D"?3H0,_&-'R1
M07>U.#FI3I0*,=JA#:_SR9`39XKB)P(G"\E'(Z'1$N[P`#8091X@QR*`KDP`
M`S#P`H4RNS!PKDH020,$J^^:;7D\53'P!.$'#WH44,)6Q)]@HX"99^,3#E/7
M5%XJL+U@)AD@J(ML.:%!E!C*C8GV$FY#&F-QA+<LM`-G+.TUREID`&<2O@)W
M,R44*RC%RNA[*`O+."N[(P!1L)861D:2!O\3``^'@@7`!(8=/!V``TMB=B_<
M.ZV9CIVG_S<;4`>C5@U]JDN)2*47Z!2$@R^(%VM16J#VQKWR8HVTAFL;6`MW
M="I@:U(!,S.Q3#'5&5@8L`$6]:C"!"[\\7`P8-@D&G$9Q001(``B4':1U,__
M_)5=0$SKB11J]&'`PM`MQU9RT6]I.;HQ=6[^,M%LE:P\R2$V\0^6<"G"8=&T
M@EOM%;EJ-K#T,740NL`.?#;W\8$8D*@NP6TD$@,QO0X44`$B<`$]799?\`4I
MX`$>8.`R30`WRZZ>2+M!35D('@.7M4#Y$PSN],Z*FT(/FV>I`W`(#(N8\1)H
MD0&*]X1*"'8>39!+O'.CD1,8\I=.1U^SN=TUA4*YK45TXT&JXO]7N'4^4(T,
MB-<9R-L27;R@;7'(<+$!I$+C+1*B`D`!&WG8'<`$<S""`63<61Y`3&`R-7N5
MX\*:0U&S<YLWEMT%B(*^DA+29F%_GWM+0*"-?0(97#$XIK*T,"5L46P9D2=$
MF;$_?^?%@H`_W($\#Z,T"*-JG-0*1><(ZUPQ^[`!&<`8-5=)+<([1&'<3=`!
M!!`\/B``'Z`R%_`!6^DIRAV[*MK<_IPWNQT.1SA^IL&<>E:^<Q&+\["RHXL@
MCA`<\7#(YL<GH\,C4)DT^B+KHA&F#.N=VYV\"EPFU\G`L#8*(V#`)BD,ZO+2
MVI<WKJ'I3=#I$5#@!YX"7W`"&5``%S#_PZUI;;.;HK0:KRNS`48=)3!S%=4%
MET$GN3_SC,@>N(IB'`[VR5+:9B;.&6SA<O0B*RR.3L3QXN-W*?Y)WUND*R:W
MZQ&A-=7L`2F0PGXZ,Y=3E(Y)8&A]$#OIS;UBI7NM:;%L&\M@)'.``Q=``(B]
M412`V"@8210@!HR=SS/=X.,"S)A(S%PYV:$2%);5U1_[\>HU<)1W@!3:](D:
MKLD6>6&#?`A)6D;\4/E]EZUH4'(>G>4\("3T3C"25!@Q2_0RWH?1$PW1J-PS
MZ2;>'%ZQ&MSWZ2(@`IU.`.$U\SB@K@*`V%$>!6X;`>J"ZN\J:BOZHGI8;PT%
M-.<U?IRC(.OV_\0C2U;V%JP%8JS(E4Z7&Q"##F&YL[MW,1RQM2'7B`^*G&R+
M5W2WN;7;>#"VP!\FDVU6Q01-(`(XP`/A!0,>E`%?0`13,`4MD`([+5Z2%/NR
M^ZXIN@Z[3]1/(`&,X#*S$A=B<F_M]3-XH6G$B6(J)7!2WRT''!UN)HP*FC@^
M/`Q<-LY3N\%+?,E.Y\GS@^N/4/%6MQXMD0(IH&9=G9/-*4&B"`@&*H.$A80&
M@H=/&$\&BXA`D4]`!D`8E)5`51M5&!@V"8BBE9\V,4PB%TT"K$P%KQ0=.`04
M<QT%MP5B'0&ON!4!O;V^!3`%$3$:,<EU554&0]&&*J+3U()#I-"5C?^)UM.9
M0-TJ0RI/-I:8VXZ1-I>BSI=`-NOFGHR)V0;HD92AH98Z93(0ZI(->I:@V:C2
MCEZ";/,07:+&:!*B)T^R8?!&3M.&#?+\U;"A3$,(910$X,`A@`F!E050"1!!
MJP`.)A0HO(K01=FRGT"7:>A9LF>7!``A'3QX">G`>4`*-AV"U-*E;`=%065Z
M[UTTJ`/W>:5J-6K8>?S<W6-(M5):>@8P,!P5$-0^A]P00107B5RY0:2`9,,(
MJ1%&<BHB00-H:ABR"!%Z$4AEA`$.$2(Z>,CPY<N4SU\\%)@CX%@`&`&"JLX`
MN76$#*P];(`6C6HTMYZ6MO/4Z6"DWG*=S>W_=T_QJ$GG@%"[G;Q*@`U8;4SJ
M1^DV=72AH%DMOH^2IX"4^'4UR`_1-\""Z`HOQ?"\H5$#GVS&6+V@\"H(O5Y+
M;_Y;-7)Q->()--1H,5$T`X8CUT;1(%656M+5H`$3.#2!&0&NX$0!$P?4Q$0%
M'P@PS(C$%#",B<6@ED$R0C7SC#[O]1<C-8]0(XZ,[AW"CD5Z.8*1?MO,(Y=@
MW2U$WG^+6-*--.'`-0J$4)$5B1:17)5..]6%]4EZYZ###5;*$?*06"'-,Y0&
M9\8000<BK(2#&`(TT00!`F!8YX:7S41!!`)$<))J0*W(HE!H:I#``UE!A!]8
M2ODF2E8`]8.=6`3%_\404@N6MU<_!*6C%U1H=6K<D$-HT@FG#U:YS99D+765
M6((-\8A6]&%32%B5..,=)0_H$TE5&D10C(F0!=-+!:PT,0!F'UQ0@`<I1!MM
M9RG`($8%**(&Z#*P=0L;9+!Y@(P!8XS1('6?A$=/IHL*"5PGIR;@CCMLT<67
M>5PJAH%LHLA%GPJA0"2/E]D\M!T_53*%CI=HY?8=IQQ9(Z-6#J>;XRB`W;@(
MO]TALE`\"8,58\0Z>L.-..@\`:"2`%LU:4`,ZD-*11C5T(4/%US0)@&OL!)3
M:;@44$%F.KV"K3`!W"*LB2<2"U05S711#WHXOC<@C>-<`T[$HDS7C;WXH/]G
MZI:_P@S5->4L@D]_X3"Z:BE>02)/4]V!JHYB$5E74=X6%;(I6E44VD47(:C9
M@1@BL"(&XB+(25-*(KADIP@%6(!+#!+ZM)J@0`E>%6U8HNJ6HX&%HY1V[Y05
MBEI8:D6=W)B\HXWI=4F4KCM$N@7Q4UZZI14Z`F.SSX]<^PA/)Q91]4\"D6B0
M1C'8^F)L`#G%9&&;!R3^[!?2IM!9`!5<B]IIJ:'YD[>P!=HM9,\\T&O;U%7Y
MB:X+XQ?<)?<LG#\]UK73"&*.D$XC;"`;P^0O/9LJ#W]V$Y+ZH6,N69$+ZXSS
M'ZW=RH+[$=+\G`2?#J9G5%60330FD1MG(.Q46_+_3P<!0PA/G4,B_(D+_B@1
MD='U#BT"Q,@3NK",I`E`9S@I`&8*$`LA4BYHP\+%B6!P-&(88T3(\$D7FF$#
MF7EPA8YX%043<<45VH@ZU``0[CRA,H$M2B#].I5T`#2(?O#(/%=21S2,-"^"
M0,15&X&?)>!2PTFL3!)*THBMMH&4D0AN<(,+5HHZT`%DB>$`LVC"`9K`!,<]
MC@`'*(U..H`Y\VTN!BORY%"2D8`Q#.1O=/$-)H34.]AAY3NCHR%:%+,ZA"D%
MEK];)2Q9)[=T.64K_)L9)E9'-]S9CC]>8@35;+01<6!@`U5\B(.0PD/PP8F1
MR!+`T5P#.1$,P$TB@$$$_[K7&2)X8`Z+"X"P*A#%9;@&?=QZ#2@AHX$AF"M^
M_:,CV2JV($O]1F%H^2()_S,\<<BJ@/-Z`AIAMSM(-$1W>]2$+8V4J5)08FL>
M?`_`2'$0_'31@UEQQ#XV$Z3[I$L3W.$B1S)Z*RW\:"/7H!(7)5BI=/CJ(%W*
MX0Z5$1G(%&`5013`'(@A`C&\@@DP\-DK2(2:837-%_+\R>#P<YN/'H=![+@H
MVZRZU:QJ]2+H(",D2-&)N.T#A2K;SR($B"^(.DDJO,P.<<C&,"'1D$I)J2I&
MU*(=;-2FD(4:"B)[HB;(J"DEBUL)`2RT"DJJA&<S$8`8F&`!"E0@!HD,2OI`
M&?_*HI2DEK5IVSKDI\M@]HM_IA(,>"(U2]=AJ50)0H14>AF5U69B7G=;"CH2
M@TNY.<E3E,H8RM1!('^>U2'3Y.$Z)5NG.33A,AUH36&%I1(>&`$'D"P-M+P7
M+2)D(`!BP$'T&IF:Z;X&?=]R#;B>$2F"(`6V94T7W.*;,':%A$SBX%$YO*H7
M^6Q`;>\(*7%DZEJHR+4KNE%0_EI;/);N!SZ`XZ!5\ZN8;$!+E\]D"%1`5BF5
M>A@^@)G.6;%JE?]I1!VXBXK`'-"%&KAXIVH25VL"P(26'+4`*JG`AHYJ#&T2
M@Y'!0!$OC)6BI8K+G9AU!E?Q9:`/YK%D2R;HS+XVF$;_E(4@*AB28O9C))8=
MARE9$L16WE&53W!'9F;KCI1.:AQZ/'@>29+97W>*)L*=I%!J(E0,+(`*S/A9
M3I=A`H62Q00V]8E/,$B3^N*9@<#B^1FC:,OK%E.65>[6M6U;6*B^V%K&`!>X
MGM;CPEJIP=P1Q]+$A5@H%J&RL%#D1V%"SX)N5(E*D82ZJ5""KE6!&6`8=KJG
M$0,/>$"%R\#I!=-*@0?LD('G50``1DT:,-R)7M:X1L:O>8T&OC9-YD&)*0R)
MARI/I2LV_^8>_PL2_I;DWW.<2F"@\A*7J43+-(('5-_1%=[JP54H0SA47HRA
M2-4FBFBECK1CHVH%/\I"WE*"_]5;ZI@RTR/3A(`%(W6H@PU<;`/"=LN=01:J
MH(TF@NCAXEJPP`4%DI8MH0V9R,9X@3&BNJ*,K^W!'IQ(8-!#M2BKE#YY_+>_
MJ"&>U^K%!B!AM5X&TY7<Z6Y``)E;NNSH,7T3K$D0<](?43H8VM!9L'=V9Q3Q
M[,[#U>E"+VG<]2ZCDP\DSA7`\.3Y!&7M9!#6?!GH0KE^=:BZU5M2NM1EI^A&
MT[AHH::`IQBG8!NK&NY1(6BT:=3EX3K206SQ,AN01KXFPRU?PYF<"-)O8F!-
MS#36S[10K]@CTX$!?---X@V`M(A`A"^$*WS1C4`%.*FF:D?``^K\?;9=\]]#
M*<_;=O\5BSM`4L<Q,D3+<\7`"-;6M1F*HE3\4ELC-')`"-OR^E9AR`OC0J_>
M3-KG)OMH#4'\YH?SPS`I^._:PGJ?A4;Y$!317R*T[SHN.D#S;H%(&$%8G)4!
M:(`&ZQ-D'[)[ON`*,8$+`I`+$-A4O:`T2P4#3Y1$&'@,ZY,!PO$$8])!P6,C
M,H5SZ'=%H[8.680\!,=]QG$;"S()II5%!B)A<Z5:TB%#$9=Y54!")N8(6F`@
M$=<W\$$OZ.!B\I)GB*0Y/94,@044?$(3.\,$JL!8?48!-T`G;+<F!3`H!2@H
MTD5V4C0&S!,5J?):S',DT7%#N2$1'E40R!51QG1;;%@ERN'_,MYQ*L?T%:KD
M):M#;ZLR'1>U7^GQ?Z?U))IV%COH8E$0`366,W)R/8FS)^KU:S/V$I!D!*ZG
M7=U%>RE0>R\``#1Q`S?P`TR`#%]H;9$1?(\!+NQS*`Z"0S3$%?.C8;28*?20
M'-L1<39488,P!/OR7]T0A![33U6%+I@08O3A42\$(5LRA_YV@ATT?AC35H_P
M"-P7C`'D4!]S#]78;QDT0&'#?:,P)$PV?XAT$,&R<J_!"5.P/K\W#(T4@<3@
M,X*V23_C1+=0-"D29*_`2,40?-^29"^2'FCC.Q<Q#M*X9.=`?5E$?S#5+P81
M0T:RC5=5@YAP1_%#1K-V(YF'/U@E_U!BU3=:@QM'J%QVAV>KB(H_\80@%UDS
MD0HSP1)]1@`84@"+U866%0"9A3ZNT9*@-"AZ5X8.D@G&J#N)<A>S2$.PY"FS
MI)'!45JT=&5.^3`VU7F8`&ZR$S_JI@X\=Q'SAU5WX1M>0FHD07KA$R>.LQ*E
MX0.5*%WFY0-S\`&3A%UP@AHI,`5$H&QYF0(O$%Y-D!/:A`SH!1D8B(J5""VS
M\0#9<19X!&8H%9F=D(8CMA`)HY%;)!$<4X[Z(SL>DWQ<1!SB*!'?!C$]MY`>
M1(U7A#<"`8/!2(Y&J2L"AWY),CIA0R-P\1WRMH8V4`==,(!J<B(1H`$;T"TI
M`!G`YPO(PO^`KP`G];@+#PB0)0(]3>4+&XB!ZK0BK+$!75`%7:`/.C!36"5B
M)HB:&",K1V*1W2AP)[5T(R:#2%(<_N!0,Y.+N,AYZ`DA;95%`T(8_"%-6(*2
MCA:<ZJ0:@N43CQ$`K#`9S5))%?)#.M,A*9$]MP`#G&0SW`*/3>B$+@F+V.$4
MNGE#"59KI0-;&T%,$DEI5BF5*M9FU6$508):4%<J)G1YF+!]M?9@)0.`GHE#
MMU,=LE(%:B(T"[I8*U%R>V(!;RE=ZD4!3?`!1]HF1I4"&=")1/".NF!4/J`+
MT:6AD;%-Q:)>'L`O9>@/2.$;]C,W:5J1OM&0N!@>H3.?Y;B9@-'_D9;'2M6@
M%+1V%PJ%8"(3C>;9-1+&-@FA@]N7&#80?SX24B3D4;,990'F)4_P?SAZ:KJS
M#70D'6?9&A1@H=D)&](2CR?"2-J4$QW@"K?`!-?TC\@B/4H4D$%3@;?`2*@A
M3ZRA`0LA-=>79>-I'.49J,>!%CH4.V5U4820)$E9=1LA;^KV?8]B*MJ17Y>@
M0]N04V+5(Q&6%R'H%.?`0REI7@4**"Z)BI7%"BH1.9/1!*JP6!)*)VW2)TG#
M$WBGBN0C%/9Z=WUGIA)%%7(A*JU39ED26[/%4=K1"52Q$!0S=09388'A%+Y#
M$2TJ$/*B<Y)`&#"BHP^6)$1'9AKD&P[R_P2*-`<58`L=$),B,`<4X)9+NK*0
MX:1T:2$'```PL%V>.*89X`%IF0M*LR*N(0S(PHK@$AL>$`,(41\^BA_U@[1=
M(1&_\7QE8BH*A"\"(D+%)80>-4M0$7%B(PGP(4&YD6+&^JO`JIH0-JT,4IN"
M(!\9P`BOY%!7)K8>E%^6PC_H"5,4<16O-&H:=P[!@IBC41K!<%Y5&BUC.@Q%
MTZHZL2$H1ZNGB@L2*#0F!SWJ%&1,A(&H<63T5`5KVR,U0@J<!ZQ=A)OTDA$R
M]",XM0YJTU!]RFI4@X>I9D)3IWAA!F<2!*1*T2YF*DW[0!1+N":Y4%[;PJ&:
MLPQ\ECB,HS//Q?\2%D(G+6%HD+%[F(6@Q<*<B"E579`!&P"+@$<<EW)+J4,P
M+C,SMA,[^M,.LBDP;1@7\_D=:<@PKV)N\A-T2>*?5]1S["M#%+,4!&$*D6&A
MOX!.;'D,2LJR+.L#%(!)JI`G,/`"T$)[8YJ7'O`"SQ9=<GD,\;2*X`,,@>N*
MR#D?#]$J/KHN9]11=F@I\ID6""9T&S,;(?:UDY(;;C,87`L?``:_H,M59)NB
M2E<._60.T,*VL-E+((;#A[<=J/,$Q&@C[J`=C\FWJ]<+@N9C`MD]RA9DP\!$
M$G@XV")H6OR`N&`,$HB!TIDMT5,!OM:*'PB6U4I@-\R0965E0>=,08?_.IJB
M#[/FD!UK''8U-@MT7V!5F7+$44]9E"0A.,H`/MK$"UZX+2[Y$VMBKBLQ)Z;7
M.#.)(2Q1LKX`A:VQ>Q6``[S7.1*"61Z*%W=<11K)2[`U:@D32\+DAJ602GAH
M:R>%.V79%-!*5F=F#GR1;BPU"D&XE'`VEF=Y&@Y88WX&N`2<S*<AF)?A9XDC
M>U/`/;1WI=5R+0'@`T@%M#"'(L?`P<7"+XP9/_'VM5$I'N4GG_+0&_9W)8Y`
MM4#@4DUVJ9E*P\!U?>[0J+/SJ&TLJ*F91]<JOH-`I?3KC<JS5OK\C?QI:=]!
M@H+@;;HU:A@1+&*G$W/@$FE)+*TA+>)R&DP#_X$16&BH.JLH]PI)%;D=T%2S
M.CZ5RT388HD\T0P"\D&']Y7[O)K(4Y'6D3+*=`W:EX./@D)RI$$1-]0$C2\<
MB:FYPA"MY(*XXQ0==TC!8J%F/&W!VY(#"H6&UB:4%(F95).&=AG'@&-!`1E1
M+`.'-G9#@:%'H3M2D7A[\4P,`J,TFD=+C)5-"<-@P1@9-B9+/->U)#=)75LP
M3#JP17!8XV$EF0Z8$G0=Q1J^L"&3@0-0RD[)S++!*325`SEK.:6=Z)<>,`4>
M<`>[=Y.U.F.1T='/@FT]^QS=$#]CLB@2I(?\\"YVB%+Z%->?T&3^Q7U44JGR
MM5";XI"9T)!=@DN`VO_&U/AY--3:ZY9%B$"EBYJ#GB(PG^M%:G4@9$(@,/K3
M^'$.3LQ-K1$3<S`9T>:*V[71L>K1I^J`DL7%CCN!Q7#2S`G&M9HTC;1[MU"@
M-YMW5/0H<US3$],C]_P;TW=]6;3="4M!V1`/#;D8OL5+PN298K:T'6,5!J(<
MLD5^P_W4@Z5(+*TT5=TY)2%W/P$YX=4FC7,!,B"%B2,GQAQ=EM6%CDRDF)$+
MJ`C5C1:+D()UE"9N"(=;[;`J>AB^@?$JEG(JI)4K11NP#Z.?2LFP`):05]-%
M!W&F.:1<_H@+R>MVIUC9+#LB&YP2RGL9/+-=4Z!L-<M$N\!ZW1Q\26/%P:#_
MVL42`)N!$!YC`.'LC!HV-VIA9K.X(`M&EC/L7^I+C'J1AM_16W<AW*QV-J8#
MX%U$MHI1UV[X-6I#I5*1;GM45=B-,;]:@L6X#4(XG^6W%.;ENQ;@R%NJ/4OU
M>V,ZIM,KQF)LQNO=WB`M62<]J]BR@;2*Q26R>U)=J^&2`1GW(K$%Z?N)J4'G
M,%I5#KM87/R9K$=ND:AS;EDISAC^-E9)$2-P>)[I;;M[2'86`Y`+XB'.R&@2
M`1:*BBG!"A<`I39Y&1=0(2+P`4V`DP>PJG'G3DS$"L!0#'#YA'GG/@;&UPN#
M.HG>"10A$.!1"0"A9#3*7J62#K8\V"?5AJFE'E8B_YOCFY%%OJ+)WF%[A!0*
M59S?`L4O09>S0`$#[.65*#36#+2.B`.\]JXS.[C33*4XNPO!`)"6F)W`]^JK
M#7QT3K1C]0#JV[%-SAOSLZS/($&6V3'T`Q<']5\&8""\W#`,O\0-$W1U:MS(
MCL._I3&XM'GIH1:;X9K*KG.ELQ_'W3I?9$Q0H4,=%SB'W(H14-$^Q:F^T$C=
MC)PS1M*Y4&.)#-*.2_BG:J&XOE1(E.L58`SEWDA*<UZ;L0G='?9=E1Y7D[IN
MQ#9[=>P)[20:P8(S2%'+J@Y^7*U5(H02026VY!2&5&<M9C,\-2PW?N[!NR94
MO0R0(P`',$F+E;Q&BB$N$?]9;CEMD5$TF+S!PB>\RP`*90J@DB+W1C@SS737
M?;@=Q#5JCG(P57*U0VZ5XA&[99&#Z$M"9=(C[H6I!]$3K`%R$(CBJ6<!]-_R
M+B\TO>;W>.^(,P$(30(X(A4!$1X>*40>+RDI`145`A4%,)41,3$9$9F=G8F?
M`:.)`1X9-@FJ!C9`KD`8&*TVLU6QMD!/3["Q&+BM!KQ5538&*@9#3Z>Z&%H&
MST.LLKW/K+@80,;5P;'.V]_@QL?AY.753\7'L@:[[-C&T:[<[*?/ZME`K;!/
M0T,J3[:JJ1AH#I8W54"&(9-&RX:N+C$B!.AP2"*%`A0Z=>A4X%"!#I)@5$34
M:93_R0(H/PH0T*'E1S$L!3#YV(%F2Q@P0-9$V?)DRPHM:Q[B=*A*A@P+_9E;
M6F[<ME@+H0;3)>];+PQ/M+FC%NT90`RLLE6S,0Q6%;'5L#W!YM3`5;#!LM'*
M!R3!@QH:\G;96P-O1(F=-&G01+BP8<&((UPJ$"'OX!@6.GP0(0*'Y29-/DQN
M@H,``9D%5OJP4,#0J$ZD*6:*Z&%HX;PQ-*R2AS!7E0T8$@0KR\N5C5B^;YU]
MA@'WL]_!#"1PY2OW<ENR?K_"QEQX;K?$B!=3[K87OWA7Y>UZISNY*ANL3PV6
M6(")`,H5,EJP\*F^?<#V*72H3*```1P;$58?$SA<P(0(_P>(44D`,#B2@B)3
M9!")&&(PUH$`(YU67RDF:8A(`"D8($%88>D##"_-T7)<*\,TQUP^T`5T3#++
M8/4-$%K0Y=LS"1&3S3'J-/,.4]L,U!:12Z%S#CI@=065"M%P-<0CVQG#RT)D
M(1/-6F@1%`Y!KV033R[HT*++0W]%8D@$%Z%T2``1G:92!2(APF%*>*;$1`4$
M=##3A7X&"E-.*`'U$4\P?%2))2D!=<F"]65@5!5(5OK-.`1)Y998Q^@R%32=
M>O?-6EJLLPU96*FX*3=E%<E+J?:$>E4PVYWXD%Y].69?;(\=YNMA$5R(44<9
M:-#%8Q%,0@@.'S1!`&6$B/`L#O]-''C`'`(4RIAAQ@[&R2>:=`);##:,\4!8
M0Y0W3':LT`*<6*@2!QUU9C79&W?-O0.+;\!8`U>^[P+''7)I40,E-UE]*LTS
MJNAFPV`!E+91)Q=UH"!*]V6L\2<%B%%(>RLQ<8BOR0I`0!.4B9"M)8Y,0<0C
M*;Q0@1@423Q2*':VUB$IGWB0295A\J@/P"_VZ,M9^QHP#*I7$N?!!NF<^FXU
M^<S5ZE/462J.EUJ7HV0NQ#49)51;DFW`(V0?4VI=0_2(S#A@VR-WD5K1I5PR
M2^M2`SKK!=9Q1X=NZXE$HX1&24<[IY2H)8N[%W)[-3$1*"5!74AG2BX="A+B
M-TDBE"C_&70A:3]==ST!7%<2=`Q=GFZSED-8'1QD/M`<APN_R/0HW=S="2RW
MN\,54]ZQ@QG;1:Z[\OKKKX&%2X')!?AP(9RQ040Q@90=(()[)U/+Q`6=/0MM
M!1()$$$(40CVV%%'D5128\778%=<I-\&UF^U8N-//L!)IV\LQ=A7E,1BM-[@
MXT0-P8:[ML.+`)[(=_PS55>TL1;NT,8N0(A!Q"+0L6Q53``*HI[&_K*\<.U'
M##,Q'$9,LIK"3$0`%Q``R@0@DA<T:!&->`0,0.@H28S$3CL+X@]/4:[DL$TY
M#?1%T7KQBZ']9AK448M;GL8[621M@DOK1;_V-22G&(EK13)2_^F\U@JUG,DA
M%>224_:!@11DH(+;6!LLNO,$**D@:5L#(Z:"H86AY>U,UFN>!F$"N)']A2@F
MV8\(8$"X4;Q`<1'K0./V1`E#A89F+@&43B2)DY`T2B@3D80H02D1#QAK`U68
MX!B;\@P'8&`"8].*W)C41?!08Y;OXL=8KD$I6C%G=[@L51>/018?N4(57:@/
MK]9SD0!80!-1T$#Z2FB89\:I)1FA`!.8D)$,$"8O\_'!>RH3K6=I3X;2P@P3
M_H.A9!7@FW':$(<(!S]-V.`!#UA.F&SQF[.49U^P"*`2@Y$N@)QE;&*)SC1L
M499TT2ILK$++;HBA&RMR8TA;J=*H@/^6C02@ISXYV68'/M,!"EC`,1'YEC)_
ME1<./FYF):6`3!DUE*,0YGG4(L`%8LC)&SZ("$3@X,RRQ2"1G"(#.A/BSC:$
M"GTJ1S<.F]<L%,A/'UF-&$I,&@`Q\+2NK`XK[9!:BY`!E;7<$AQ?O-07C[1*
MKPB4+=P8`5IL1)`GUJ,[6A$F$`:"`;DJQ:P"(=(M4'FF)]1A`]_R9K@"0*&2
MUB=B`=A`#%J#DAT2E7",P@G@)+D3GJQD)Y]MB7L`0*>:;$YS+I&$XG("%)#<
MH4Z?Z()1;*#*58I1;K%(V%HF($NK^&XA9GT2U8!CHZB@,F`'Q$9NN:8%+E71
M1V4:3&M:LIK_1F8"I8YY3'9+R$$_9>10%/"!):AGK(C$(#0I^P`.W).RG7+&
M0$PX``X.!Y3KQA.(IM#0:6"C`0/@TZ.RB%+>"!A0J>"/=-(PE5FL-%:SX&(;
M^T+.'=<1CR<.Z140'8L5)=H/NU6X"FYLJ24BP`D?7K=;)&Q>"WT5@/>L#(3]
M:5-I:-:1%6NBQ1?X@1(N`)\`V/`%0'T91R@DDD,-):DFX5`0>T8NW:1K-C"Z
MW_UBI,!BD*6?T7D1$ZE(NE+M(FH\PHHOBM$V+4K8BVQMJZ70$21Q=$=,;ZY=
M++H:9VT(5Z]V%JXY.E4%#81``WM#AU'8IXGVE4\`<^"F3"FPP3A%_S(E,BU<
M91EYK(A=(E%!$42?*L>22W1:DC#5["5J8BA#,:BU,-60(H:!"J_:UDMM5H<#
M!"N+A!D)1>^`VU8U>ILJ"%JC!J'K.;`R1U?G%B^?>)X(FH"GD55!MGW.;K2S
MB]+")(MF,\7(3"5'"?(>*R(%:,(!4)93S.#@`":;[TO&R1C)M3`1#VI-(DI1
M$CAUX<]=,,`8EM,*W024&6A!$0/UE:,P[_7-*`I;+ZIR47D@E']A0TN5@"D-
M#%L0N.RHPC<U$($7G*(%"E@"4E<,FT\HUE?2C`C*^L,$"BE:<I]!V;+G$%X;
M;\`#%<#,M(AZPY>]P!$>V"%E$LU-4""9%/]!K'$GD(J*?"8@'E0)$_Y2!`PK
M4MDWKF"H+ZAX'.5VR0!K<X@TLE(O3JE5S9;R$IMC'>:P[:XKRM@`.IB1,.UP
MXXE984;LRO%T[/0Y"M'<RR:.L@$T;&+I'`G9-KF9.,;5.&*.[T@,CH<7!H&$
MM2-=R20$Q9),5F+4-P$)4%K+DLV*WG-*+PIBZX[V/.L2*[SM+3C6@@ZT1"-'
M]S+B5@](BW5AU.#%K<;:*%P[&WS;A)01A*'4MQ?B49O:L3&,X;@)7IDZ;B4L
M(2]Z/$(MSAQ@W`0X@`Q4IK)GH9#'C*%`):R=LWGKS&>!V4M>@#:7:$P=P@HD
MX,+Q#X1T,:WAM`+_0!)''62&(@P'6/\`%PN39P&%1'?##C:`6+R"5(KP!1MP
M`B>P!`K`=-@%&S:U/!%P(-5"`7.@,MS$;2B#&9@A`A<04X'A39+58IT!/H34
M$3"C""DP!2G0,2I3,8S1,_FE5#Q#8HB0`4#P`&U#8`[#(F<Q9CI2%KP11;)0
M%ERU`6TS%Q0V#L%5=Z\#(P?%.V[6>DS!-6MW4:YS2PW8#T_@1L5E$'+F.WAG
M5EFQ5M405>MR7AB1"3;%/GSX+9&`:-A"<X5C::`D:8SC3,?#03$P!AK`$Z4U
M.9\E.3#!:=F2$Z*':3_1$C2#:9;@.:+$,T4A*;K4-6`49G6$5Y824`P7_V:_
MU7!65"L;L`$6)WRY96L#$6%DM@H/@U(%4!GD9`C,UWS/MUT"<F/O45(?H6CM
M\1D4@GTT1#W'D@FDD8(B(`/5PAG+=@$H,QFA\0$K,0>A`2>>X'[NQT+@(G_'
M@T%61#KC@5$&R(H2A5=M4Q;'H!!C,C5=!W$`Z&::,G<9%B6ST%'I`FW%(UV*
MD`$;\`5?<`(N<`(ML`$A=GSC4D+HA8S8<H*?D3(%@AD\IC*?4VC1UT$@Y#%B
M``.GH(-!!C,P8((NX2%'IU3P1Q0QH&_)D1SI@B)+8R95<S33\$M$8P/U0!>J
M(A;!I8`"IE#I4(IB.(9D:`-K)##J(%<',V;:@/\V;Z,"2@0WV=%AOZ"`MS46
MQ;07(4@9S[@:1^%&[),"):$H/)0GB5(1D.=XC1$"YS4S!:`!?H"'A@(#W#:)
ME1,4>]):+?%9B8)YI?$H"R)*HB02<"DI,>!KLC>&@<4+IZ@I1+(ZS%%WMM0,
M-\)$"EA,2!./52-V8J0C#I$`>)%=I.$QOJ@@+60\\M<KR@,LD]`?[5$)UI>1
MVHA]!.`YJS$NP4((XK8].M61,N0]Z*0]*$%#)K<SY0B7F5`#>V$#-2`T1\00
MP&!_`FAP6",T>E4O"[&/7?=$N;,.8!)6IO@,L$(Z_%(73_`7XL)QII`!"KF0
M&'B?+=`"1X%BU18#:6#_&!'`3LN):"C!!.1F&>2DC=HX0Y]#8HHE5-AG&8:`
M@XL0,XJ`<^]1DHMQ,T+HG.WC`4UFDQ,T9LVQ&[N!#=D113$R':O6$/%(>W-4
M.V85$$.@9TNY2DKB6UI!>Q<U)&RX'<V`1Q"8=RHBI.$0EM%X(3)'<WH8`6B9
M`6X$?X4#$I-HB9\C:3@A$H#&<9,@F"%0`QR4$X12&LZ8*($Y$UEZ.8KY$YYH
M.!012HIY.8W9:^&Y2OO`=I>IA<HUA\/6"@5'-2U"@,50'%ZW40[Q(UVA3[20
MFB+FC`C";-35!<8GC!/)/#R(C$!A?>/D7B;C&7XR"=O"*Y_0`=%"&=I8C>,V
M_T,KMW,7(08_U"'SUB'UT2W&D@K^AJ@1YH[[=W?<&2]^=Z+X9U'Y2#8!-3MT
MXUQN069CX@JB0U.,X6-'E0+U200*>9\C<'/%\C#+Y)_61JK;@UZ*=C+D]'T(
MRH(JZ%XT-C(/RD&4,2TJ8U2+8`<PHY8%````(!*;8PHE\7-"E%0;$@"H0%#I
M,B;%Q#]91PQ4"!8X&1U9404O("D/-D&D$C?#MA8/UC0WNDJF<H:VUJ-Y9R,I
ML`$0J$0),%!@:5&KN%$80#PQH$W;Y!E-`"F?X$;S6F^0QT,MR1Z3)A*35P,Q
M8%F9&!]]P2"E`10BU:6<Y3F<-GJ9:!.J!4*+$Q1Q^O^F]!0#QM%6^])FM769
M[""'U1`/6J!73E$<U<%`J$)QUNEP#6,#WN1\4:!L@K!.(J!>/A`!X`AHL4F,
MAV$!+28MV[02&.$>@M`$/+:;GN$9E+0F`I().+5L\H49`U`@VO@?WH,@Z@82
MX-)(L.IC%>$SM&JK^=0*`U%F%J9_#1&`+V(-P^$65]L;4!)!63-A^&.*I,([
M:J.`IN)O3P`1IV:;0O$(]?D%+M"0P>N07P"B\L<KTP1N8@`@VD093"!>XBI?
MEE&][46XRR9SF+`A$E$!*K-3E5$AIT`$=@!4\(9S%Q.8J<>O'2JKB1`#1]@/
MNE@=U6%0MX!UJ&)0#\551AC_$,$Z1[I!3&#U&[N0,+^7L5JSL5RC*7=$H[WC
M1F/#IU3I%0%AI*Y3!T>S'I)3H-LD"(BS=`]2LS:K?J25>A^Q.(=07HK2$ILF
M2A'@!R%@"9MD"2#$$H)I.8,I"9WGEXI2"9?G.1&CF'>P*&]2``B)2DJ1=G2$
MIV/4CG7W5:4R<&5TOT_!3_W2%1%4%\@4=-(8!6,I!MC"@I[Q?05@`?H!/WE;
MJ>$2@HJ'N`6J@H2[H)I&`#]PN)IG2,A"`>*6&0=P`<4)/LYB&7_['IVA&.;S
M6$&X9!*B/,;2,'RD)73A(K121OKW/U(X"^F0$$UR=Y)<<<3:BF#T!-ZP(PZS
M`9@U_TZ4(!+`.ZU`5:T8F)\V-2ZZ@E[5DGD$\+(Z5;VZ7*ZGRH(=.5_9US.C
M.KF<`2"F$&2,X'&0L$,X0#-SL"`F\7,OL#/\RBA,]01(>).XTR[UXB(VTAQ+
M,T<P<@K38+9"$H]TA+MBL@_HC,!+X0#^&PZ<28O]USM<)H]E!Y#S4!YU*&C/
MIG'LL4W+.,A%=S,W**5R(DF(8VFJU1B5MWF2,U*;]A,QX`>-B'E6.K46@TFD
M5EJ30#DX'!2I+!$@00EW,,17"K"(15M[QC6S,T!+.2O!2EQ@@954"&>J6S5U
MB)W9H`&1T!%MXJTR(6X'0``4<`$?H)QG3*EZ(9LQT'*+<O\RX2I#.U75"]JI
MAVO'A]-"W]*+<ZL]!T`%34`%;$`MRW8@V<)./J!^'<`:]`2K_@H8KV&K->H,
M7(DT%W;.5,.K%44IVHD/N>5O48@Z4,0C8>C27X4EK2`Z&\012F`9%6(*;L3*
MQ7N?1G%BNB(`D_&W8L!R[K'+H.W+5MV1Y*0R>>BD]1%^?NR+DN`!*:G,4%H!
MS<P3JI%?TAQ$BX,Q2T<NV1P7P+`*^3(O_%),`AC)&P"PP.`_A3JV"W=P/.(-
MJ.C.1#(!\*R`X;`VP]6`RO!&I!.D4(%KP3`"T$TUDRI_'#0*,K9H!@H:#%(1
M(1QOHC"(<9FE-89L-N&I09'5?5+_T3_[*)7ST4K[62SA'@HBM9WW$Y13X)9X
M"0I2`2A]&J/@1E"S9P(1)`D3MJRG9K3'P&#W1/Z+:W:C<%/CR''Q;7_H)W,P
M4M!2+0ARR^1V`$Q`&A4P><ZWK=TK$Q<Q$[EYKJ.-&5BMWRL10KLB/8-`&3(P
M@_(%/B=SY.MT3C)17_'=2$I6$9*7%VD@LGTW),4D+[FS+^S"#94<<`+3-)HL
M8'7ABLY-#EXR),=BRJ<1&QRD!()`8S88O-1:G_?ID)<]RRPX$RN!N.MTH*!=
MO48PVJ1-3LU<$]U4'W`K")6!(8O@,H]PD!.2RF]92HXDS?SZ2(4#6Q'0!4@8
M)C@]44<#_^9&$Q"QX%$(^[!A88`,]U6M6+$0M;5@Z,ZN9-W@@+'_,`*;;)69
M8C8V,`*S5KOF$8""QQZ)PFB9,U,$0',\<3,7BM")(Z:)\ND^JQ\#CM_Y?;@C
MU0%X&2RG%Q3-6$F=1PD$7DE4VEH,3FILVA$6(PD4(K/3?!2]A%:7LL31O933
M(9H\F;J:K%7O\$2_/1L/DVQ%#AK_,7X4$'[=9Z!%31^5`)N.(9:2\%TUX0-K
M;:`+VN,JJ-]9C7TT,Q+.4P#"F=0<N5/A\P'P1;CG5E(K,3C]6CB9,!'5%0'"
M8W]5HXI7DV!#`AQF/CL&&W$]:18#J--+`2:SH`$JE;EL'!19>O^0"GGGKHR?
M@\9Q'O-B,K%.GH'H/`#:1F`$.%#HHYTRB+YL-4&$]8%>TC*WS";9+Q-OC\`@
M`(`#CO*6':+I#<+II]81(@'J<5&'M^I@U*#)WDQLM[!U1O@Z``,.X4$WZ@#=
M[V)VT@T.IX/K@95A;48/*1!\@'51XS'>DYR\<8D2V58`SQRX)S@3^@5_'Y(X
M.H$Q@!8")5,!,!<HE:/?(\4$7PKN2EO2FH=JDTAZHT?N)<VT@,(8H7$'S6AJ
M)7$*Y/(EC+]WEGFC7&3=W8R/N/9;4V>K^=`W)D0A*/2\XR;^X^8#3*!>(\BS
M>@$1X/:#[9$1YG\R<=R1[J6"/R[1G@'_\B4I2*<!"`('33@'`S@7%P<R%TR#
M!"($3!<X'10%`@4Q$0&<`9^?'AZ?$3$Q`04%G1$V!@9##P8854!#LANT&$"N
MLD!`&,"M!K[`Q,7#P*Y`557"51L8-KJ\TL`83[R\*MDJ*@F^7:>=FQZEIA&I
M`A4PZQXI&5_Q\E\G]?8M51D>`A<%3`(=F!2@P(1`$Q$'#N#@@6.`0QP+C1@1
M(2*118H3(6K$T:1#@0@@0Z(3@T,`(1$"!,#P\"6%2W<N`U0`($95APJ@/KV`
M`>.%3U0P/*8J`"/"DS'*:B7@Y:M:M"?5F%DCYHO9KPT>,MBH6F56%6R\H`+3
M`C9;ME^O9'4%_Z)E@H%M9N/*G4N75[*ZP[1H.:OK258;3S"D_:5K66`,;ETM
MM=&EL89-!>8(%4BA\B=VJ@K<%,#D$HQ.H4#FO,QSSN<876K$Z`"P0\`.DI@$
ME.V:@&W;-RG4\"/S9@7705/^=EU!S&^`%8176)Z\0]#DOXO_)GI3C+H[=SRN
M(E4%+C=M!K1<<W47KWFYVXI-0V;-JR^F7:TJ&V9CJWT-CTW%>(PNI8`Y_@B`
M@PA-<$;`!TU$0,%!,H@`4@41:-`%?IQ\9`HJ$5A``6P&7:#$!115=$$3)#9Q
M&VZU$6`2B=9U,,XFI6!"D2(-"GB`"#]$(L('C31Q0$H$:*9*2*.)@O_A.<6=
MEL!2!GQ37RW+=%6-+^G9\$P5KQ"VBU?D32,-,5T-(U5]6]G557E/E!774EV@
M8R%(^IF21@0I!:6*._#,\P41)[C@0CU?C%"%!Y$P`:"&<]A&R480.70(#E1,
M-*-%(%($48B7`K1*2!F,1.`%1@R(TSLN$>'2.P&((89`KHVV$PP%^$0=K$(&
MD,%1MK@RQ)+T`?&E`5LM`\TLT4Q#+#-6!K"!KUZ=*9@K3Q`V'EW;B/>*E5O=
MY=UYW,Y57ES;)M,->QYL8,!A;U4+S&%@V3*+8YO``.!0`]&K"BJH$)72)3=]
MYHF1H!#%$ZQIA*!:`<,1P.%MKC%!6P<__&#_6T&LZ=9%`-4-QYJJPMVTV6;^
M':>.:ZP!A'#)%:0"G:HXI8)*RMWA%=@NLCS;[<U@'8:!%H21)Y7-=A5+<Y9;
M/1%.G/J5TE_*!`F(PP<B^$`!1`(00,$-@U"`#@S[Q3`DC/IMZ-^'!28R:8DF
M,DRR;4HT<4%*UA45$HP4"((0U`:12!$A!TAB$D(BJ)())Z*%,@HH(&W88@1C
M//!-8>S1K-[0&.!2F);24F47-,BL19\N0$LCI5/"Q&6+!@'`:DY^^^%W"@R=
M"0R3GD3X^2<]+8RP00`BX*!)$108U#NC//#@4/%4\""1B"":;2E$H5[ZMG:<
M=HH)(DT,P$,F`:00_X^IHJ3@P0O%E434O3KYQ,XZJ;#VV2<Q/+%4`HXOY>NO
MPP![IK-`Z"Q5,S;(BK20Q2QH10MH9ME6S<CD%,3<[(%Q^19ZE#$M90QJ`[:H
MP@@$DY["7,,[5YH0.AJ6"H<-9$,"N5?[/!(0S3"!)^@3C;U2$:$:1&%#&E-8
M0=3F,-I$C`!*4!AL!,`X#6@&.M'Q3\<VMIGDM&8Y'9..^Z3SB0ZH2E5W^`11
M*I"=F-%E71V$H!C/!;HPL:<]0SMCF1(P!%L`H0;A*$4<+="ZU\V0"27)D--P
M0`$?($0=J2@*AES7-8PI40EM&Y';$H&VM*$H16B#6\K*021T?&`CO7.;#/\&
M`2(5-0(2(M`:PD`3@5$`#'$@*8!U/I*`,2QE&M_`Q6"*-0UI`:,9G1-,E-+H
M'C'1@HU:@ARPVO,4M&C#&PFP000PLY\)F0(_57#=)>JUDE/-HW9^@H`]<+$!
M&."``!FR0`$H,3R-%*]XD)*(1"XB(DSA('H#"I')1(&G370`(@3@P1&,H`X8
MI(`(``U?!C*P(/.E;C0!V,DZ@O(9]+T@`!IHXP-V-83['2-_47*/KWZQOVLL
M(RO(LDHTI'5`-8''+>&BA:_.M,&WC/&!$L0+,!(#K')!Q1B8<Z`RZM.83<C&
MA/X8BFR&HD58P0H5KLE$^]X'FO.Y3`,U"($/.A#_1.*0[*H<PNJ)@G@;`<3`
M#S$(SG*((X`6";&L3DR.<<8JG8$Y<6,*8TY9D_H1*_XF`[4P77AT\4H'O/2!
MVYB`5P03F%;H;#TN'0O/FL2K&F@`3OF1T(3XDSJ7@41%DA$(12A@`0)`Y``%
ML,!T-/%,#8A3B;8A4?,H52(@V>8':[.-`!!9H)!]1"0@L>*`C,`#!JCH`WW+
M6T(R(0A`:@:W"%6:(84"52;M@EEE<J,UH$*+BFHP3!P%BWPR)XW#OD(%MAS:
M8:`K)L$L:4DVV!U/(M28R4XHFJZ3"5$#,#L]V8,>7VC!&C90G-#&P`=,.,AG
M!\#;Y&DD1&\;D8)!%"HJ_U`AG>I,'@\N$"3#9>`4%1"!&/0FJNY-@0AV`"@1
MII"!5!G'.9TX7$)?@+"4(144.TG!'AX`!S:J($UL2:,L`N.L-`4#68495`8&
MZ\%;2NF!,[N?E9C1E5S]]3PQK<L$'.#`;;@$EV2D!3)T7(,$.#8"<YA##U,X
ME#G@1+Z5'<HTA:0R%[LL7YV`JM=.I%78DDQB6CW1B52B`;`V<:P"H(@2A3,R
M)PKG#B=>QUM9HZ([I(QD`OA`)JSHF@)HQ2RV^)(OM.``FC[9/-MXPL^"X=+#
MJHDP/-L%KQZ+K]:U%S_Q'5)E[JD0)EC`1PX3<^\Z8(&I7J(4=(1,<DZD6DHQ
MLO^V52-`Q&#;U4$KT4750P<>$<$#**1D0$`,XH``E)(=0>C7I/#$*B[LIJM&
MR`;GE48K-EIJ:VQ`&#P.QKJFZS\L$ZM++JW9NJ!EC&-\:4E`<-W6V-O>@N-'
MA&P>2@0RX!(]Q6,*]8``!%J0`79PMM>3,$2D>(O.2VF8)F]+)*B&Y^"-&\'!
MQ3-"1V[;B4YA3`R?4HA*NB=B$4\A!>0#``!<!`H8W,$GR]%,2F;%$QG3F$E3
M=L![#.AC78CG&L2:1;;ZYP[1$2-:_]/RS9;!T?K,`A?J_K1YHBQ3#C[ARF5)
M1F!,>BYG!N`_/10JJV*7,D\,I=(N6V%FCHHO#8PA!B/_4QM6KQJQP2],SRJI
MP1@BL!SKR!4E(:L.<J"('/^T2(KKN$-KB$.3QHNA9##(@!E4,(%Q29T]GA:[
MS-IC)9NEY^D(9,M4EJ2:]14`JG"4K'M1UPFB7*()'Z!`$1R1$`+XX$"?7V$'
MPAD##0G=/\5F+;*3K>P4J2@E)!ITW46"+Q\U!)X@8L`W"=2A@GQ3:G6_DRC@
M9($(2&TH\HISE[=LOV^EMRO84')A+8@EM9Q)&/>&;Z%F)2T5%L7P"^BV4>EU
M88^1.@0W60<73?!269BQ<"W1</-@#_70`@Y0<3A!1\>7$(EP3IAD-L?F-L]S
M8"'2.[QU")I"7SF!,)?4.S>B_RK=<RKBLPJJ)`:?\1M,0"`%P1D'(0G95R=I
MT#A[4%'W`P3>\00.4`?[QQ:B$PVX\`N^L`S=,SK]%A]:=S-1%R92%X"JYRT(
M=!Z"15COT%TULX;9L!B/I0H4$&8.<PD"01E"0BNW=7<I!"M"H1E"`1PTY%B8
M$%MW-G@_I&>(N&<%8#`RH0YI96C*P3&.F!(E(TG$P46.EAU'U'A<I"H`@$A<
M]`)U,`&EIP+'H"5CB!?;T#-J,179<%B[X!W14"8&T":4&`$UD(L3DAJ[V`4V
MP&J5P5EX%!L!UC<`!A%04QDF@UN7`'W1)R)*H'UYAGUM$XU`PARW53CH<!`3
MUCN1</\!FV00!@$U#D,%)O(?++<=(.$#"A)FZ3`'G=`%7B8,2R<>\/8,I`,M
MTZ(SS'(-^7=DTD!!'-0E^Q87QE05&P!K8`-K&@!?#<F0KJ,9MM<]%Q@/'E!-
M]'`"^24H*4!#IA`\$'%.#.%Q!$(BZE0I\*2"EB(1&O&"HX$)`!!/EU)-I^(!
M'S$GRQ$<B6`$''`#"W`#'-"3"Q"4-U"4-T`!07`%M'>%L1AJ3DAEK?`-LO<S
MS6"%Z64K!UA&MX1&6Q<?EE,?0%8ZJ9@-9(<7@N57[T!&ZV(M<I$/,O$^/S5F
M'G$)%2`02#5#F1%(%(!4,^<Q"N<'-0`#GP<;R]8PLE%XLH'_B-9';/OB!R&P
M/H;&&H*F1%!$>?Z1;4(D>7CH&[\AB9>2)"-`BBKPA$^P#6M0AF.90&S8BM9@
M%L1D%DP91ZJD$A'0&+GGBXRQBXY%"G1X-U'C1R)0$`7Q`6+`6?02$NTG-OS`
M3A71!(A4-6.E5=CGG&U#?5<U)'"B(`7@62*@!(=@&WO3!,4HGA0P(@B10LN5
M+\_'0NH0"NA6'P:`%/"9%\34#,R0,[1X%V)X8QM@+FH9-/DV.:XP+DF1%E)W
M-,WT&+#V:A!)(>S3+R_@/?&`<^W@/1K8`G60`2P6`,T7/`FQ$"39G*`2E!RP
M<1VGDL]C*36!.'"&,!`!*L,%*UGA_Q(1D`8;L$Q`<@$@4`)!N0`(\*-;L`5`
M&J0($*1&&J1(L`LZH"MFX(1Z,33?$%)8LG:MAP%9L67+L)7$I&-XL25,]FY5
MVH6IB6]C!`Q7:@!A$ABI=RXV$`.=PA-:%"`5P"_^(!1QBI<)MY?M$TC.@8=?
M%0/+\5IVYAH2(S&)>*AL(UM$Y`<:@#*1J&&15QPA4U:M,5M<I2*60!"8&40?
M@DA>P`,*DT4.0'JS\`3N@A@*-*9,(1[8L'8U,S-F<1CBD49-00YO)P++QXN.
MX8L%UU.=4#>2X%E-T'Z","!]5'SU8ED9HIVL02D(ADBWH3&Q-9U%^$C$D8V0
M41F%H`B#</\0W$IA'&$H!'`#;N,P%P!S.+!S)',!`*`PT7@O-;1TO#*?:,HY
M:/HS:;<+@$&09.F*;(@N`EF0KKENC5$?FU!'T&1PCL&0D/$)R_$"[C"A+N$3
M+*&!@3(HJM.ABZ(\S*-@$N&C0RD1Y\22\>1.5).I`1-TJ2,&'S!A`W`$&H83
M`Y4!<Y)0&38`)<"C/EJD1]JS/GND2(`$<%!C:?($=;`S?,%D7@<$5&8-0J:O
M1C85J`A!'!4?@E$Y_:>J9"I&@I45/N9C?A471MLI1!(`E8$P=$=4>%E4>^J'
M]()5#*4*,5`#%D"8L"49<[!LAXBH>@:M!I$27Q4!=O56Q>%XS''_18<F!MD1
MJ"1"`!R``I`;N9([N9#+`3]``1JP%.*Q%X11BEK+#0"++AW4F@.JEA?5)+6X
M`>=``36!&@7[B[K'&)*%#JDC`)5!87%8$#?21\!7"$S@`Q4`C\BIG1UR$8F`
M2%5E>++52)>:F="Q*>&F2N\$HR9R`.2($F)`$T+G!-S;O=[[O=R[`N(;`V:P
M*Q,%+&GQ)$"@.\:"?P*K;G<!L/II,S/%'OWZ%`89++IY"A'2.KIG<`UZ"G\8
M*Q%KD3SA`2W0`AN@@;HS/A:B(4KP3A.A2!\"*DU0I`C``1PGDJ&R@B%B',EZ
MMMCH$QT@`MK3<3Q(7^)3'"+`6RBP``MP_Z1`^J,T7,,VS+-&FJ3Y6+KM497`
M0&52@A5@RE&W-'5+)T8#!#K!<(6J6I;GX1=#EB94%K:Q6@<9>F$P`@H40"MV
M4E1DIK:P,H<"HT*L03)&=502$@%JLQP1\[@H<!N&RK>*0F$$\'E0Q7B4J58H
M(5?J@%:%"R1*0+F"/,B0>P-%$`(&`P1P0!BEV0VI.J8%B;3W*\GMYHJ[8C0:
M\(L!($ZEL*"_6`4%VZMOJ"`W@1`)\;N"X#"N`7RV!KS9N*Q-LS<6X;?6.JV-
MY$@DPQS4PXP%8,)-8`2,\(,E@:D@<@?@V[TKX+W)[`3BB\QO@`9R8`9Z,%%I
M8J!2TG7Y=T#C<?^JU1`TWP*KC%Q>DZQC;@0$X9#)7M/)!]>K$`B1;<)FS@&Q
M#8=S/8&!][`$6/$U"G(!`U"2V;=(%P"R)4HBQE/0RP,B')$R,P0<<<IB%6`$
MQP,1-,$R&78`5,`!.RO#"U`$06`!%A`$(6`!-^`#05`$'QT$"."C/QNTM-@-
M2><`#H`-\/F%9IH!K?@,4W$77-HM1'QZ1,QN3[S3<N'$YG%V*5`%,%U!KED%
M=:`!Y%:V=XB'ZBEK0C)-`].'>:DQ\*<Z4`6LG!DQD6NY>\NW;7..N!H#8V!$
MDSB)5\0<G;E6UN&<A&RY1OD#37"Y/OD#E+L`)"VT6K"O0S`!>["FJ1G_OV3'
ME7`A+5'9=KYH1$J3'[S*4^P,:YT@3I#Z-`50!`=RRL<G`YDP35HC$I4Q"9_B
M(8BT;)EY52I2(F6=-E<U6N&&+S3D"(EP(P=A'?CT`TIPS.+;V]_KV\T<OF[`
M!^4[!$[8#4]0A<G4D`$*.FD'=68W`B,00?0[+>*BEGJQ%VT(+%U0!5TS)`S)
MH`T*7PB7&<LQH]Z3`NRP$@NL@2>@`.HU#A&`1XJT82LRHC]0HAS@`S=`!27`
M`SDKLD8P(G:80E9D,EK$8JF03PQP(^FJ<P!@PCG+`3B,I'Y@`4R`B[DX!HM7
M%+FX&WZ@QA3PLTC:#4FP!WN0!$*0!"R^BEXG_]U1)T!1TGJ9(]0PQ97$TC,[
M/31$#&6H>3/O,%U?Q-3G3+8QB#X2F0J@;2_Y\D)X^+9^*3`P-+<A\`\<P@1@
M7;D2T[R':A+@V;IP%%;#0:EDU2+.\<?0*L@D&I2=(34!]KL^(#7Y[<:1NP`?
MG<BN(-ACZAUG^!8`*Q>;6QX=U#.V$,KPT\FXF9OL#('\RWASFLJ:6@C&YPB%
MT`0^("2\W*QN@[S*-JC2N2)E#22^46D(A1FD<'RK-2!E]0%0L-O'?,PD`[[+
M'+XK\`9=8`9-2GI);1_=K(]"/KJ&'8O\ZNNM6AZVI-VHJS_/H+IDB[`+VZ`-
MZB9`40`P\0X7*;/QH/^!2T!Q.[')[A=@%0$WBK1._KW?_0T"(P+1D4)A12G&
M5@0`_82GYC<@.G<I.+"C*GVD('WAG!4"ZXP.$>#O4:`!(<U908#2%8ZD<'`N
M3E@'+([BT9)15O%10S986I)J8QA,ZE:UM'@6O*`%/39V/]XM*;`!HNLM1.Y,
M^@`:.CA#EX'5]@+S=L(OE$@=1#6W&@`#`/%:B1HQM-RWT;B\JS*WX?`R<*-A
M)[89:^5$B$3GD`O#ACH'_@$@?`D#E7'I8T4B3H\"/A`"<"`%;N%D8\J*?5X7
MMF12S*)JHI;)`/],H:RPT$XX@AL@?W3I?4,0_W`C[1<0N,6LWLKIU3=XLE7_
MC7X;>0.Q':D#0YM"RJK>.V*`O,SLV]X[>,%K&CQ1:;0.W&\@!WM@!AN4'FL1
MSJ/;+OH6R<_R"VA?O^SBS93,;J"LNOQA#J6EH-!.^Z>@Y)YQ@]YSD3P1H>[=
M`@I0<9_AT0!VVV7U-JHELAM7`E1P`R(]`%0PKD9Y`_[@^.PCY0-#+P*@<ZJB
M3B^,PS\:!(1C"L%V"10`(W1D_L1/1ZC01T.:P_51!PZ`XGO@XE/X)58Z9%SH
M=2,/"`:"@X2%AH0854!`B1L;51A/AP9:&)9`3Y&3@Y:;GH-/*1N?@IEU754:
M71H1`1X!!0&P'06QL+6XL;4PN@5,M+B\$04=%17`_\"X&GXQ%03/SS\$/])*
M2L_6UP39!`(7(@(1(36L!<858@``8@+MQQT"8O("VTHH]_<</S<WT@0=W02\
M(]8AF;D.,`@TF<8!'PH*06HL(D7QT`1!6K24LG3QDZ6/@U088&2C9(($-JIT
MB1$@@BH-JDIVF;D*ILV;$2*P!'9!A@`+/G"($'&!0@$<.`H8I24K9TZC!$0T
M$<#M7\&K_JAF:\<582RGL(S9DM52:0`!..3A\*+$B=NW;W/)94*7;@%>LPK`
M?;L"C9PZ3R1A&(%A@@Y&&`RH4('8AB4;@CY"DE0I$B;%A3(E-J`92"G-&#R7
M]+P(2)48,%GJU!"C=>N;-O]3L6;-LI8/"A5@I-C])4,`&+E3M&CQY02$$TNJ
MI,B=$VB!>%(O-)G^[8(1'B6R&_E!X4<3[A3XA6]RX("`7##2JU=?J\,=`#B:
M7"C!80&"+5L0(/!A@:4L"T!%8(%1!0!%04ZU4.##;?S!TM)M]^6''Q)(E+3'
MA7LPAD%)A)&$@0<I)`+)1QM69"(AFCU1$@:..!):(4!49H!C!CB`@0.>='*B
M(1Z,LIA(GJ1T6A=/Q/"*++6TU$I[<N'R2Y*S_,)$>[SX<M4N[`7010T1M`,-
M0-"$R8TUVTQWG@8UU+#3.?+(PZ8`!<4CE``_V.,0!\\(,`=P5Q5D3)]@^DG+
M'(3_SC'-`@VAP($%-<"1QXXFVJC12)=49$DEGA$"A`V;`G&2#;2A1DY,-LQ4
M:DTUV;1**RQ50!<.`E#`A$(R#$`!!3@<(!03N-'BU%,`<46/58!F98U677WE
ME#D"C4564RS%(X8U>SEQU7KIU<7$#W05NN==YP"SUQMRF)')!!-HL89BF@FB
M`FB/@/+1I(A),@EB&VT666@EE322IPF8AAHK+;DV,&P(&QQ`!07X@)`K*?26
MPF\P]'A"<2=D/$(5'@AC`8("2-7$4!=\(P(/`Z"<LA'?W4`!@.$1,(`,./`:
M#+;J(03#"S#<(0(55*"P`'[XA<`2&BO%$$40/MS@@P8`_Z)&00<^!/%Q:Q'P
MVII?<L30`41$3TBA8A?:Z)@-G:7D00950,)I:9">>';;FSJV01J09+HO9"(E
MHAF.D^@8-V=K*[;8)REM$$,5I_CV;``Q#"/7K5:B1SDOR70P!R[%B,'P7075
M$D$-72P<9C>G9Z.Z$M(5.$XYP`F$#CMP%B-L.T,ID>@]U$"3&W"_7RD+\.G5
M<LPO5]YZP^X6A`#'X*1PQ)G@G]A;F>`BE<9I`@:D@JJJJW0ADRJIRK:2DKXP
M,=3(O`XU7L@X?%V,LCG=(BP![P`*S>KM,*5D!$9!!\,>][@E4:5:+R`(H!;(
M0&`8@QY*X8M;R-6%.DQ`0Y"A1/\G1)()PI0((R3ZS"?P-3U]S<@25>#4]DZ2
M`'*@)G(Z<0W";'*P@44.!E\S2GIV$[&.Y<8#&,O8"5J0BELX158"F(Y\2O8-
M'%S'"-992#^XT[0F4.$"!)@2@7B6,YVMAV<5N,`1A!:A+5P!"18H0`S\D"8_
M^,%A/JA!",;Q1@)08!QT[-(=V9@FKX$M;%N@D&?V8*/'9&I#0-A``-BF"$;H
M#7J>.)R('L&O*J2!DJ0A862J$!CJ%<*3.WI"X8`TB8N\"Q6*T\`3NM`*`AID
M+K8`72XZ,"6O*&5J\!`#+](3.AC$8`P:@`<TN&(H;*B.`!<8@!)\$`(V1H!/
ML_/<.=[_\<!YM*-D#EF0=^R(H&G^"7+/%(B2*-"_/@4@#<.PTSTH4`/N0?(0
MTBMD11YY/<`-HC03`17I6C,3V/23)JFZ2>0BQP3<E8<)%B#``4IFQR;@@`!*
M`<Y7QLDL=H1+?\;<"E/`8@[/C05*9.E%`"C@EA7`Y04O:*!*^^2+,-FE`R4M
M*1K,\"Y!="$Q?<-I(JNP24$@!B3SU%&[2M&V$66*A2CA)PQM.,/7T"8UD2O(
MK8H1`!XN+#<O2($0A;B!\]%/5B,C"A.'8H3KB(``-YA5%F]``!S(@`#\(1"X
M<H;#+Z(4.%1H@GWP4X0@S-$""%T%:D+@L.;%P`)]I8`=0Q`%_Q^@1H]!*`)_
MHF`!&%`@"D703QF1L(@D%/)%BC%-VT"THDJ]<Q,=V=<&,L"OQ.4M1J"EU$<<
MT$D3<L*VH4Q!!DZ4B2JL5@.@:B62'D<0I>`"27>!05D*@D,JX=!/QP"=+7^I
M@0H(9%C3R&@V+A"K(/B!L%.S;CO":M$[W(&7Q9BF`!RRS(_!HP(4:,US9-<_
MG0RC'?&-ENRZ40%PGD4)/UC`/180!"3`P3,JF$`2]C"XH0XU;A,@D214,(1_
MP0U4_8R!8%6EJJ*J!!4VR4`!6L$P"I#'9<C,E0!\T%81/'1J`H!!_1#T"V%A
M='_'^AH`E12`]"H7N7<Y[N-68%*XC/_X5QQ=Z;5V<25B/!<N*W"#&1R@`$[=
MB%V6^"P*.7E;H%(DPIIX`MTH!0FZ(34!0T#):5A3L*<F+`,O')CB(G`,'4)L
M-RCEV0N^L`&,%:<%(U#D5SL@!K&*`(H7P`%WLP@0NG1`!+J*U8)DI2`FS`%Y
M.-O9"ZS;!`[H!S_[\4$,!10#H\1W0`(B4`08E$9?`3#54Q)U<YKFM,W:@+88
MR,@%]Y6(19+HD:>-GF\IN:(J>#"VC!B!O5(4VT'0"'JAV*W<6)0!MA4)R#P>
MWG$)TMP@YR7(!]&9[8[!2_9H8`Q=\M*LKC$=;`RE`U%P8Q`H<`$O.(.6'7`H
M.`1RA]\]5[W_#F%"#(O1@1@^YQC.@)-]S0'?UER5FA6PK^E>)N"'."]325`!
M@R$U5$9,"GI:'L00AH!/3XG/A2\1U4U`/$,VC]A^'QA90S]0\.>01P2B]MR!
M_M>><E[E=/5P=01\U>-CA+2Y['&6+(KLA!7(8F!$`BC!FG1+7.P\%TNR.@6(
MW'0T>#8T$[#1$]XUF,0PHFV.L1>O<1L22@P"S!HQ36(ND3>3<`_-#TAJ!M@<
M0QHZU<VLR8`C1$P+N>IF`[I-P:8#T.<^7^P+@!:QQP`X!]PIV@L\6,BL%N(+
M,7S@`S'.17CBVJUK%6-G/2LT`8:6'P0,Z$`Y$74:E0)`!1F%+K=1_XH/GD0Y
M!?E"][<"H.X_7;1,<$H+NS:^:7KDF(D$VT29:%'>#"`BZGW$7B@4C&V?W6#=
MAC)QU2:2?XXTO"I!*;E)(D9N.$<+@@?C*JXB2&XZH"4N>6E_7"D90MW(BJF1
MJ2#;D$Q2(3OKT2?.X!`H4'`Y85T1)U_N<%W]!3("`#FE)CO!,H$22`%%8`$5
MQTR9\B/H<B)@EB^I!3U9IB,C9V%`4`/]@BI)TT\PT38M!Q-IT!1T)@8.]0%%
M<113T02OT@25%GK_0R`$!R@UYB9']A3M\0_.0@Q8@A>RX`$>P'1QX1)=,$<`
M-1,Q0'7!$&1+T61R`5-\(0=[@`'KP@BT!?\:LB5A768)DO!@A]`9@H!VC=$O
MGL%"0Y!W-C`PK;`:+P1GLT%#@5=M&3!TA9=<:\,;'L`S/=("?;8&PQ%Y=S&$
M"C$41*$$=/$,=($6!R`"`Y1^L.![='$KEF8H3``<;K)Z]Z$??O4:(9`U+G$U
MKT@U40!`%C!OYW%8+U.!:G18MV@!N1@%2A,""+!7^*$B"(8NUY,):Y-V%Q&"
MST<*O85)DJ%VS`89G4`BFG!;D!1M<=,(@K=*?8A<0.9DNY!^YM<*?%*$??(+
MT<4$?Y(>HU,#SZ$0"W$[=V0":D(,R$-+LU)O7C```S"`Y%97S[4-^,`!2A`K
M.1$/_25?M,,58A#_"U/##I`S(+<3#[:`B@@E6?C`*%)0"@9P027H$9LAA\'F
MAH)381/!@J>R82\8&[+1<I'SD`4E*^8A*R[V`3C@,G-R'@5%?S9((`RH/U-!
M?[\R4ND%#"'E9$EG"Z]`A=9"?R\!52FWC@N$<.VWE.T!?\?0=!,D!^>R2<H&
M&BK$AOO2-I$00CFB"2SR$8L0&HZ$5'F8`"L!$T]G0W!V,*$2`]66$Y'CA.D!
M,1GP!8:YB$!DF)`7B424`DER1&AQ5DR05@+`*QV``SPYD>084MTRF0M2BM+@
MD`7A::"V`/'F1F[4):-#1R%``2)P1W,D1P4@`DPP1[8YFTS@5W@$C`40_P6V
MZ0?%R'I;$`(3(1+7DQ@VT(R24)+1*&Q%M9;Z\@2$P0D=LDG0R8W0YGT<!XY5
M(`<$\RP21W6A(YBZT&U=:4OP`"<*I!Z_%`(P0#M3(0\P<&[`1#$,:%Q,H`1>
ML)\HXP47<`U;F3.[<PT"(6L,2('S=0[BI([M0(%G05\-6C]B@5@LQCM!``<'
MYAGH`HV>$'8.<!$H>5HY)8=I9F$RD6$Q0`ZKP6$W,9.I`0L`]#4%L%!,<`&O
M\IHLUD0C5E`O1U'`<Q7)@F2S4&>40Y%3Z6^U\`)D(97,Y0$IYQ0:MA+HIRWG
MR`LZQ%RW0$O)A4-P\09UL`>9H@5T,P1"<DAHV?]!VO@1S(D(K^4(A)!V$X%4
M>5<%>Z<:-B1#H4*(?@F8-9DE+P`BBKD;O_&G001HJ\4S2K)[ZND+EZ8^'W``
M`/!*LH!2LP"`3'`;EL8$B`(G_\@!1+,@:*(!OAD":618%N";#A.+`C)O=K2!
MI$9.:O0Q`C)TO2@@E$4!QAA(@F`NRS@C/?)V:]J<D]!;:FE]D&``0Z`"?H,(
MT+D9H,1;VLEQ=4"G&=`%74-`95$\YV<07A0Z7E$\E)-+P;-DU!4RN!-Q-3`&
M^P@\T15`V`"0^ZD-C"9N!)"06<0<.4%P!B<0?2)C'\-P#NI-M!1#5Q4`_1$!
M!)`H"Z`!<.,NP?IV0B7_/<)Z(W`I"!4V&BP($S#Y=S/H9K41HW,`:;K2,.21
MB<]1,_F:A/7#9-!5>$+Z7$J')/U:/)0:`$R*I>03*FBR$L^U4I@S3=+5KP4!
MEDXP4Q[W$6=YK&VH=FF*EJ3$"8^P*6HI+XO`*08@IP:02GUH,%S;&H6(9`9G
M2T$6,:*0`9OF.7\:,1G3`@K`,5:Z(+FGI;X@`CQY'G)!%DK*,U=!**5'`?I!
M#%9$FOE1!#%D:C`C($XX($=64)=*:0ZCGI26-6(`4:8V#'5F(&6T!?G"$1-0
M8;\J""7XL-`CNM4H+T"5=J9["97RK-`7K5\&C6*V6MW9!8Z#;<@UGJ$#"W6U
M_Y&]9'[0)18X%(\%<&XQ4&CAD*[K>@[F-SLYM`W(Y)_UH`3,A4,_@`_2X!4#
M9W0Z,5]%*&/==!X"<A8(5P%[`A;&\#\P0`WWX`-(D`>90E.B"V8782/V)*S4
M%T(I^#8C\3VH(5@<FS`&(SD`=![TA@,OTU:Y`H1,`"OMX&0\AB#@$EU\^C&_
M(1;8&@`OX!;36R7/PG4:S%+]FX7GHV1-UK/&DS_L")91ECA:H`/4MP'.NHV@
ML8WWJXW7<PB(X5L8(!)*.SU/4+5WR$*)A#4%$\`&4XBQX!I]2&*Q\#!K4VTI
MD!YYMC-?L`9KNP0;T#'`)U<G"RMRH:23FD`5S(Y^<O\>Q1@5]1$A^F$!3YP@
MJW8KNX=[E*98^.6$Y'16[6&9$"0KQI5%!W(K%E!&FT(D=0!:0R!*&_"T(VF_
M(RFZ]ZLW'9<(RD:U^_+#;-E]TE81&]H1L2MXJ$!^0<91Y@<ZO_,[PW.()^Q`
M\5`[2ZE<Z?I,RS`&K&20QL`+#*A+Q,"IUO"?V^`%\ZH7^<`/3.D4,-#`8*%#
M6H0^QEP_2,+!2V)=2!E[/E!Q1>`HN\JAA`"B\22QSU>2EV"U,V(#W+,(JY2S
M&@9X`E5#KW%#(T8++'8`M#1S<$4!A8842N&R3>$@D\BG@7F?%URI@)(D'A`!
M1%9D@J(Y4^(2H-*_+-&S2E;_JP%[4<0BADTG/L:6+B("!!7FAANAEM9XK/B2
M(LR*"8&F"9I4"3X5IRRTAWS'M1&PEU@C.N.H)/.3'A0@"XGW"NJ154$T1"-@
MMGAQ*S?=`0#0B9^#"WF6U+N`PNG9+!Q@!``@`'L5(4$0`2^`&E$3!8H5`54]
M62867PP2`PN,4+>!N&<%,X[E`R+0`0=[J@ZC1F%3(8_QC(KQ(8F<S8X\.)L<
M@B4H(X.P,3O\+AMCC8"&&5HPG=37PW'CC2;"UYA1!ZO%-BMQ)$)VMS*;##`+
M;NU!;DHI+?,7+C+F1LC;T/[&K[,C%L\A!@4A'=G%4*%#4@.FN"WQ+`RG+%@C
MU,(U_U^6%4.18Q2S?=/,$LVMP8'KI`4'9@![@,UOIQG:7!CV6Y*(01)WV"D)
M4,XP&8B"Z)?KS-L[(;-H@11%<0.@-S6_(!0O0PQ@`;9"6E#J><%WM97"TQ)O
M4-#6PDN$@F]JM!(Z,<LDG%[#^XHNH0$/-P<%P2U/5E(Q8`;4-P*$T2^2X`"%
MC'V)P-&<P:QO*#@3_E.5TBY]`QD!HP4`DP!Y%RK\#&?<'3FP$`^SK1,]-LH5
MDP%DBU)KT]-K2Z?['!;IL*A)DM1*C96VXR;P4#*%EJMG]$PI*D=L1,_,9)LA
M<!00P>1,<`"YR>1'00"C.D=JW0$Q8)LU8`&YH0$A$->5$O^"*N``/0(D&\K(
MC;S)G]1L;$GATT,8%WY]<M>-KDL*?,W)OA5^UZ;/WG:.7K%^3`:%#+>4ZQ<G
M_1.\\1@!8S`&I%V0S&M=M$,[#-,_UX04KPE`U8L"/U`$M2@+P!U1S3)B2GPK
MY3CJ+=$?M7'3<C4_]`-`#<$!42`1"I9@A8`N#L;-P@K=6X:LG0(*X3,;*)=R
MM,$JK+`D".*]\/`<G7@KN3(44X(4=@$EK:3>L@`/_@-2>,M%O'1++8$&!$W?
M7*@4JC!0K#3N5!<`8!XY,"$YN7`#<E'0$2`'ASP"+1!W699@UE>QM\[1(\AL
M.+7@B2%/D9%!FW*U5YMW&^`2$3#_T%BCIZZ!Q"(@!BMN7Q)U7+I5F(I)XT+4
MF+D1%NM`Z`6@I"//XW?5L^@`#MWP#=,A!CA`F@B@F\.PY:WA5ZEJ-?PQ;R)0
M`(0K:F)-FX2K($4PFVP-0&E=F8=[6"./!C%`?$B`2!.0W!=DYG>]YFJ>YH8@
M=J:K?7`^5&PH&6S7NIG\NEC/&=2Z`:OD.+G`8P;)L@,12[TKKNTG7OD3C]=>
M]^\@`%%M._3E.4-:U)$67QK@`_G`'SX`;K>0R\-<>[^''N*4S]>NI:!>`/]P
MT[-="_VPOK1^0;:^R"4TOW#^W-X,P\VW0A,A9N7.T#4T&UNH$TLQD<G>"@+'
M@[(R*]+N_P--\`%T&RL%`9Y"BGZQI.V3FA[DMO9H@`94F`QTH:WQ=3Z/);;H
M'@OM'N`]=HK94A?%TW1$-E-F&9>10'8RC)8H(K'5=T+VU$&`,QAC1T+2O3UJ
M@C7<78@P#2RZH"0.!R<4`(6)N/%!!`@0)X,G(U4!=V)B=S`!C@$%!8\OE)64
M,)@P'15B``("(A=-33@X``0+"%L(/A8Q$1$6%I$4L`44/DP"'10%3+>@%[X$
M3!2D`DQ,Q!0".$V_M!T"!+<4`1D!/ZI;6T#>$WL3$RH.'ALJ!@;B$^GM[N_P
M\>_K[BH3&!A/3^E/&U7[!IY4J9*/7Y41!M#A*YAN(09Y$-\]2?^1(2(\>N+X
M8=B0(<._+A$@19(4,E*'D9`JP!B)J4-+ERX+5!!0X58!:6)H=MA9H<*FFBMO
M]N0)0`Q/GY!V%H#!"<"'#QTBO(K@8P&*!122]?1Y*T"OFB%#[I1&<R4D&#1A
MA?1)=I>C7KMJA63:80X!%%>#)%"'KMTZ!QC8`<;@P.^ZPXC969RG6",^&QBJ
M`#&0H+(!;S:J:-`0(T87SC$V@^8<,D!.F06D1F@4(1*3`P>:B"@FFT+6#F)P
M$(!5,T!IM6<Q21(9Z=&DI9J"WBS@^<T*)\]_;ITN`$;HD*$#3)_Y:2O-F34W
MA^1<8-IW[M/8/G?R1HZ9)/<PV+B,;]__D_J.\:=3/#@=D`T;R,>08O<@I,(3
M(SQ$WV0&1&;#@T`\`$0&G:G564<49J!6:ZD%X`$L&JY64R28O$#1%RBB2(@@
M@WQ1R`8OB-&;<<998LE+FRB2TP4B$-#$`$4IP<$"W"#@6PP6M!)!,@7XX$,U
M!$R3%32@S*8,$S?(ALR5S%RP93(42/,+!3?XEDTJW"`QV6'DF-,7/8O%>1$\
M3P`&4$,#*1C90_K<1Q!`D=VY$$%RRC-1118E1F`[#M1114?_:.`!<2.9=-)*
MFIPDB5":2O>34C=]HM-T8\'TZ28"B.&E2SW5@IQ,G1@5P"N^6765+CV)6LU7
M,%C3FDZBGM3+_T]>00)L=R/IPHMMVODT$UXH^%"#/>RL&1!AXMQ'F#N**EKH
M?GX%VN!`5<R7CF5`//'99J%UT5EHHX%&P0<B4+#2NZOYYHLRI1#@`P$X"-`$
M`6$>,(=-Q3D""W&/5%H`)30BE\E)1[[RW`HK\"3JQI]8!]*L&@3`\<C??5*`
M>`&09U[)`D=9DW/0H;$'M?A,!I@#^P"AG[;Z->80/E4$R"T[!^*G[60Z/_B@
M?-Y0UD6&CN"+(2Q(:J+6U+9TVH@'&:28XA13N,#B"2Z.L$$`+]!(HXV1O*!)
MKJF*(8((3?!(]R=-:%,DO+E8H`$LKC!#01$^X%($!;-98!L%%KQ&0/^2MS2N
MFY.X**Z;++$03D`',011!`+;J(E8F^?LE]&WA3:F3IWY`,1SS3H+6M_K=^J<
M#Z&HNW/H8H?%<[J[%';Q]%ELF9D45S=M(E10MFW"TT[=:24JJ3EZ^E.5(NS2
MDR.:!`##'>`/QV$`MB[`!%M1[M(I\J'Z-'VI/?D224\P$)"^2S#,L4NE0\W$
M`5X+Z((ZQM$T;>UC,*H;8+=Z)Z?3J0,?6L`303`PF<I8Q@`VV,QGVA4OSHC&
M!P%;SKMB().W^"`"H"A&E$C1A%[@8&YBD`12&C8<1S@,)304#EU.&(,40`)C
MSQG*42I`@!](@SD?R\ZHID,`MASE9']+&0G_/V$_[]C/?@5`0P2>@P8S["$)
MUU+0!.J@(`,VQ"'[<*`6S/:0H"G(='X9P0B><*`$328SD@$"A""4`-"$Q`,7
MPA"%.-,3$$V-0A%0WE(<X8$4>(T(8!/;V+[0@CIL8%(?4ILC+#&2#HRB"9^0
M6_9RD[U45>`&V]C"%<8P!C_\*P8UJ$$(_!`"Q%$@!+C$)1,^P(0H!"&7!)!!
M$WX9!5U^0``6R&4M`Y9,7-8@`F(@0!1HB01N<`,(>]#"FDCW)@?F[EMU<D!A
M-#)'@Y2S(0D"%`;..2X]O?&;NS.,-^$$QP$FQ)(<\4P4D7.2DMPD*-RCGU"X
M(L0.,`$WR,.)C*3C_RPG"E$``)A;*4^R%4W4<#@%N(`2\,(!(XZEB3H9BQ-+
ME3SGL64[F2II04^JDE(QX0?_XT`4@"".OFA+,/A(X`(3D[K&`(9!/]/99(8P
M!,O88%V@$5YG1#-"%/*B8A6R6B\*5LI>?,!?!;#?W`HPBPJDQ#<+,PX.Q<J2
MX@#'AM"!CDN@L92=_.(DGHG!K+H0@$L=U*#)R"L3,I&ROT5@,W7-J\3RVH$`
M=`$-SWF#%^%S'VTZQC&N^QFXZAB@/\F''XLRP&`*XP`[XA%"0!C(@PQ0`PT@
M$JHQZ(@&W.4(S@BR(PLK['*6X@&O?8$(*R+;(%K`VTNJK1*;9(DT1#&*C?^)
MP!,S$8-UK+D%7&H`E[F(JP5\20%_!<%)TRT`#K@Z50L0X`"/RPKCF!`P)Q5#
M<3UR4N02R019V`9TU]R#M4@GSV^B;@+BO--]Y`BH!#$J3Y!M!]`*@@_[\H,B
M0Z.G[^;A)XY0J`JO(-'$8K(4$CF/)?&;W[%Z\E;PG%01^)NPQCJ!`QZ]4`0R
M8@W:AK.3_^&E)LX[:#(T-="#^L(G=P65O2IZ$I<JSS8RX<I*-C'CE^)%6C05
M1V?+J)]O-F:!_$A(@PH<GW$"1FGG,JIFV+7:>+TBJE$9(84B?(NQR(9>MAE`
MCY[!C`,PP;PH\8"</>2!M`&7K!([4FO&U($[I-7_"7@=RUU74I.X@JRNI1)I
MHI4BGK_*5=&++K0&+N:&+^:70>GH3Q@9I`4TMD-;0=N`N7):S_W@HS`Z,\2`
M,2-:(.PEM;222FHCT)'.U%DJKQ6D/^/<-12YP`4J(H2P%3`%3>(957A#L7ER
MDBL81&`^S'U%Y2P0BR4E0[VV\9$`II0,$;R0&,1@@@@.$+`KW>`"!^C1#<`$
M"F0LCDR[0&6:T/&$<=#7=-XT,$2T-<XPZL,A_?X9P#]M60KBSK[QQ'>^YP$N
MS<XQ,K`U="8P9<.Z#N5M.WE))T,*/>TAFZ4QF3C\2.SM4N`@AJ6IX?<JX&(4
MV`3',XX*+)A2$R`+\7R\_[`%35)C#?`<12[,`(M8!#`'M_X`@#5(!SD*K%E2
M&_C)/*W'E-W9;P/JC#(6Q*!H/%A:>$F%79B0]85FO9K4&/1)Z;:-;$I1C`[0
MJT=A*NP?)^4AM-V9AO\\D@6\9YN90.=B#"VH\@R='?@U="O24-YJ8<$9[=B%
MB(C?"G,F#9TW).%FZI#(0L[H#LG>QT\+L4].%[Y9`W2:7'B<S$#T:(,$V*#6
MJ<$7K2ODFUSKNJXD&@[7?$V$%`E[14OPH;%MB)-D#XP`(/[)R<9`U&@OCMJU
M^-<RL@(,NMW`1]W^@&Y&08QQZX8`%R!&$PX0?F40C`!T:_N;J\N+;6A@')GG
MIO_"];V8R/3;`7]*R#I'$,%,XP[T/F5'EV$(!P=/""9/"\<8F;9.^F!)&N(1
M[B(Q%",2%W8\(^43;\,6F.!S2Q$WYX&!$Y<IUX,#'T!N(N!5I2%6/W$#`!0+
MY4$3(!5FB403LS(+&R,-%2`5LY`3C!,!S-`=W$$!2"(R`A![$>!S1'07*,`!
M(9``*I`$I&9&^L8.O:-@4K9D"^@`"50?>H1U1&4`7;`![.(9[A(:\%(#=`4R
M[((UD-`:%6`;WI97S+!=L\`CY-=W'3)\:V-ALI:"YW,P0(0Q@>=0A<9:GJ$=
MB>8:,B92)P,2?Q4RVQ%Y\1,:;^`$T%$'^95Y]N1O8?3_:0*7#P5F1H-Q)]PR
MBA/@)^4B6GMD`TUC6B'2AX84%@^H:[0V<Y>"*2:"(D30>R[R>X2P!%-`=W8'
M,6VE")]`-RN4$ZR2@S50&4/P`,SE+A80!!I``14PC84S7;9T.$W2.&XV"^<5
M3/XB7O\B3$YR`XQ#`0<@`*U@&YK3`=/E"D%@31J`,_%7#J6C0`E$?[H#&/YU
M+0<!*`?7:?]8(`]!;WM"&09`$`68.PFGC_O(8.@T.S;`$;36!57`(701%(DX
M4!NW<S+Q"1T7%[#";(D6@BWA'20H`GD8,3%!/D?6&2\(>;L@:VB1@YWQ@]Z!
MDS:X;17B8>`1`.XU$USU"CC(_Q,$X&)Z,0$)P@ZAQX\\E8";-V7V"`]<6$$)
M\(49-(9*!2^>40.O,(:I56N=`0G#H@LFAU57M0E9D3WIJ&*3D#9J0Q)@51)"
MF4B:$@`7\P:)-%(B-8F&&`+-XBPT)C\'192-MAGE(4226(@PLP)UL`<7X4";
MIVEA%!GEPG1G=$!,-T_^*'J822ZLYPVN9@"F-16RMR&U2(L;XCVRE0F[=UM>
MXXLGP%LI()<0DQ+&&$K'>'+G$0%=8$$)\`#0:$U^<)S'R0S-%`*R1`';%02_
M%`)!P`0R0``QX$O0V00YT`1%`)W020`Y<`'3^$M!0`$R()ZY5`.(@TRXU`4A
M8$U(H/\?\J>/_&@H"1)Z]9&?#&%Z^FE`BO$ZH/@0FFF`B*)P$3DT"^A?19,!
M*<`U$'86SJ,<)94I&#A0RG&4R"8=[S,6*+F!N2(CFY(:)7$),)`V*>`#,3E%
M)U63,T>#.2F2N?*&.E>$%0*$D@<+/\@<KP"41.1B,X4!"E`84DA_B%%J`S25
MVF(8X&([3\!'6;<N2[5![R*68D:69-8:R]($,O!FXN9M,:2.`=,I-:2'US!"
M"N.#D;`P,;"7?>F7S@-7C9<=C'D2=\5219B8&O""331$DM<<%Q.9?:&)5LED
M^TDN>4**"X%3#W&*F_A`!8&*>4(H0I4`8_`$KD@U%7(ULPC_6ZJY,)A0<0%P
M(K+9BX2@(BTP`BE0HL:A"4"XFSSB<060!C4P!@E000\P!-&H`<542_"H`4DR
MC11P`8-C&SY0!.357K[`.-\57C^`"XY3.,50.'!'?51A1+(@"180.O&A&!A@
M#@A8G_$`H(2B$`31?PWRCP3Y1@:))^DT9?KVD$4*$9F%A0;!H(#$6O-#,2FW
M"4'!%"%U<<_C5FU!4;$R'1VZ@2C7&F8Q%YM0"1XP!750!"FZF#2Y;;[!"5XE
MD\RV,211'C$TA!O#'1B5*D6I'2/3!'AA`9VFA:,(K@S4<*NC:99)3U3X&*R8
M97N!D:/Q&5\'&N^2:Q5BE([`"XU3_YW)V@$!HW8GAP-1L1-Z^"&#A#)FD@Q@
ME3)C@`:5UY<^EG'W$D5E*8("&RPD17N!XW,QYU:_T!F5>(F!*JCSP'1[PB!Y
MDI!O2QB:9H7QL0^0$:GE,IH&4%0V<"$].Q6KB34;D@$?XH:2$!0OL'N[R(NE
M"B`<@1K$@80;FST&Y1/`V8R7,9Q9B:O6)&T]6`O5M3FV,2:R\0S8)VXEZ",#
M\P,X(`.QX2/$$+O.D`SBEVX$<P.WH`MWP`3PA00JH#/YU:T;\*W@&@^G1K?C
M<B=K](_[9:[I:A!O-*`.>8`&&A'[N&2NPQ$?H@$9V5899RD5&&3K(Y*H,A,Y
M`J)A4K`5=?^PSD8>C5!7F%(!#KL!3S`$07!DK@`#.=$=G^`K&#LK)+2Q9"&B
M'JNC.@DW")PJ,.`*1_B!]O,_/M!_")2\5EB*<*N9$;D.7#@?PEE:6W=44YJI
MMO>*)2$6D2!1+.D#H#0E."%S=*E)7Z=4P%%A<N$9":`'6`L=B&90-S02J@%6
MO=!6&#BP)&4I-C$602S$$;"VD&D/?K%O^/$S#S*W`.%3^U<8+^L.W!L0A@HT
M=X253X,A9G@UM,:IG0H+DW)#)7HBN]B++M("&_`%'N"_*<:8Z)$J)_@V)T.I
M"5`#K4><GVM-"!`#A3.Z3B(FV48;SK!N`R-NY&8_D1R[L]LC3(#_;I@\,.61
M?C?P`\6`<Q0`7^^G1_=Y"!G030F8O*S3LDTF</QIKNL4>K;S1@2Q4_$J$0?8
M+08*99UU3J_7H'\5OBD9<@-%/Q?GH2^7*BSC/AP#@B&8@U(K%A>'-@$P!03A
M`"JPO]&BL82IN9V!%F$F5Z,R%JH19`2,0H>7L6M!HSNZ1%CR/Q:0$!><8+A\
MSWY1)U)V:F?4;PQ$(/^Y-%@)N/[`=>[R=5\&:Z^EFI#@""I17>16#,TP-P1#
M7M4Q'+1B'#7<=<!A%@K3!6,@`1+`PY;88Q268XFV5QS)"Q:*$RL*$]-S8R."
MTHMFB9:(!O5&'_MY$?BQ1I9%$)#!=#1U_QF=ABTO>SKXY5\"80,",4'FXJ2/
M\H"IN<8;(F>M62F/T&LM@B(`X@&<T`E%X6T]AK[MME<J$0.5T8RUVGH6-`0&
M$(U(0HW,$`%!0!464`3:Q5V&XS@^:!L6H*5-<(ZX0`!L8`3MV(YHEB3%BCAB
M$`%1$`-H$`3P%044U+S=BB@YK8GWO-E='!_MM)_T.LN:.<OLRA``R-GANLO>
M`I$[U72!D0Z/(F<9H`%HX#T;Z+0E<6%"84JGHC'.(BH+A1LZ$F(2DP%HH"$-
M4U%9_0]--P$2V\WD3)C]%,XT.)32;80A:81'G'%#3)2JP:\[,0?QC`)%$!!-
MB8"<C<L(.G67F?_%WD)/D/$$79AU&R$:7<#19EBEK&D+J9&FVH4#R8`,`#,'
M3_)"RC@K*7@DJR6E);$U'Q(:LRH!#W"U:I4\'!F),=H_LA6A9.%08QT]0682
M<#,]G^!GT+$!F$B0N!.12:H%<TM@"]%_4.8[BF$(2;H@.N-8>N1J"0!A(2*X
M5*V:B;LPBV0<M>4U==R@,!!1.-8!<W-7!P4*"W4PST:KI,GC/+X73\!<L50#
M?J">`A`!RA0"!;"E08"=40">CU,$1>!+X"D"\=CFX(D#/A`%;5Z>.4#G9_Y+
M%&`$8M!,<A`"G[,%]8@/Y50%C21&Z;WH"H9?RWO+Z(0[_FBN`D&H&"#_XP.6
MWJF-*+S,VC..0`=2!0U*$<<M,4RQN*A",4LQ%*MNC!\'-UPAW`"``T?\J4.<
M232G$FG#-76@`NA0(,^]`$2NQ'7Y@B)*',)!$F[H%F'%,&H1DG*W,!Q2#?),
MO.[-Z*C=>?_XE+V\VE,FWUBY%T%CWSS[B/K-FMB`4;X@`L)48KTP&\V#*S/!
M&B2Q=9E:86`UV\V(E12>,6T5%'M,,M\A<Q&3,&?:%LB0/"0RXAQCXBM0!60D
M1Z>WTU8)U)BI3@.G0/.G@%C8D/1A+CO^`*;YBE--U7)V\F;BT6<1JAD`(#Z$
M":94#3C82<S&5QJ0`!)0JZ[&BA9$FOJ0JW>>_Q73A5V'PY**@X[>Z"]R2``,
MT$)<\EW">GT5_0$M5%W%0`%*L&U/TB3!BW_ETJ2'D`*X,]0!@>WXG,^PC"!/
M"4&,LB?Z4,_QD:C9KLN<OMIS[^B!<2"^Q35:)#&(IRG]4U$F(9*#O[',W''&
MZ"RI@;B-@-Q,<0<C\@(>40=UH`\.-P)%\#]8`8N]H-$A#E4)GMQ%B%H-'1(V
M-R-B9_J%(\^=!M!FW^D*1MJNG4:N/^.<YPU%51FAM74V_+-CF<:T"%L-(PW>
MEFZ_X`Q8Q`P&!5%&H5QB1WN?FK@:$$N5<;.46HG^/KXA*?#3HQ*/N.#D+CSN
MJ0%H(2J_D%`!?X.6^/_P9.000:V%[9`NC+H1_S#+EC]U"\$@V9++A@$(#A@C
M&`88&$\&!D"*BEI:BD`V!@DV&1D1`1DQG!&>GZ`1'J.C`1Z9`:D!!04O'BD9
M*3``8A45,`44%`45`AVL'6("N+<176,/"8S*C)3*-C9/-EL(6ULQNA06$13<
M!`0=NDRL%R)-3-],3"(?!]_O.#(?3007!$PX;.[H]TT?.`0HC!,HXLX/!-60
M.*ABX$D5&Q@"I*A2!<.$BQ,,8-S(L:/'CHT437AR2-"A0XI.HDQYB*3*0BPQ
MF/SH,62C)[!$UM1(DV/(DP94/,G@P=2E53!@V.H0(!.%#KTJ%%`JP%:OJAW_
M8'00@'4K5V%5>XD1!L/3JE1%IV9]X6J#M"IU#DW0@D%+$10H;A2(P"D&MZ:K
M"@10*E4P7[^L5+'B57AOI[.9%D-=?!AQ`%T<4/B`I$)GS\\@>5[4.`BF(`>)
M>'KV&1K#I"?+$E320#N&AAI=_![&Q/N2[]\9!E]6QT0`#A'W!!`0(4*7&!'"
M*D`]4,%3WP@%?IV*D,9&@F0)%C4;\\;)BE]0<67GRI4`^_=5R_:=3[\OC/?C
M;`&["I_K'2?F=>%2:2\Q,@$0&1ER4D4-M:2(`R,X8`@A(CV1H$8V:>3`12:9
MA(A-0#SB#!",Y/;))C%@$HHGI9A"2HN"!884*U;A_Z)85M+QXLM4,`2@00(2
M2,!,([*1N(@-%4UCS1;<Y-*D+NVQ(@`3%%QP@`CHT+-..]]H&<\!])C#Q`7_
M]$-``00<1R4X%-Q0U0W5;*'0(4E6(=$&51"2$6A\?I3A2(,(PF!*+50!"2,.
M;#""(B11E-H$)V4D5Y\9-I23:#YA^MFC$T#X81U$-87)8&K=LDH'7O6X7E=;
M@?6>+:_"2DLMJ<2(5%*">;!!%QA4E`BD+6`0XETH++#7)S+.J-0OAIFU6*TT
M2K4**-DMMIA^T]Z("P6966#@:GWRV0B@A"02Z;BC>?0K1B*E%$U=E`R10&Y]
M==&%!IZ@&,$E^:JX+[\1X/^"':H$'(!#$^=0P!64(E30#045X%!!4WX%]HEM
M-7RG3`)#++*(&>4Y@=XM^[7G7G^VE+4B*BM2Q94Z^F4':W^^=&">'&:4MHA<
M+FV8(%W"]OJA28PZ6)J?-K$[DH<41M(,O`\`4<43->AF'2?^?O*BBZ0H)M@X
M`500G7JJ>%WM8CW&4,,#;,L6B3/A00--11@LN45N%@2A@<(11.&##Q8440`.
M3%B@"^!,N.-#-A80(,,%?Q].0`[-+0[X#6PT9\'?15``701%6!!#$$LB`2G=
M56SP"MUZ'AANN!C&KJ%*@YZK8+E"'0))3*E-*FZ&.&4`+KN:]I0TA(N:444*
MH_#_A5U2A*$J7?10<<5LJS6+[:HP'13WG#!B`&#K8.H9QI`A%24XP@8G$4M!
M4\]3)6VMTJ42F?0IQUA`568%++WUBM'/)WA1/3$0X`=X*8)J7O>ZFYP+*`OL
MR1,FJ)J02,,&)`("QX;@D-K$P%ZZL8W55L8\#XSJ,F@RSC]P$(XF$&XK!/!!
M#'R@/<=@QS"<T(!WQB`;9G#,`5H``LC,,S+U0`55'7C'-Z37@3F4A390U$`.
MHTB;_;$'9E(1R!&1B#]4W<P,C]B=7!1DD900`B*(")0!@&8@HZ6/-(20T(46
MV#N52$@\D=`"!N4F1191K!/;$04IS,*UHM1J%U`"P([*_X:*5&2E;&4YA@38
MUK&0R(L2!D"2:X!`$KO5P`^@]`/?0D!*4A9`!DP(@BI#$`3'$<`"48B"*IN0
M`QSDK0BJ)$`#>."#(.`R"#?(P0`HH,H@A(`"Q[$`*;L0@M*-)"ZI4UT&>D4W
M80V/@:'92+MZ1J`/%2V-*DD-&?<$*8M@<S3!NR8V&T).`WBJ(:'2!!H&DQ6H
MY$@P]^$>K*S"E7MJ3SK=\PISQ@(``$#K!4E!2P;.QY(-$6@$6@@"7A8`F*4(
M@"SO6X4OWI>)J%SE%_2;F"JB\A[![&(RJ$B/5PB0&11$H2&1.*<$Q3F3<GYH
M)!NQD+ITJLV;1`,(PNKA$VJS"?\-F"@#??S7RIJ7B5\(9`YC,EA`FG``[G4C
M`AT0`5>.-94_=J&')))-#30X!$$(,61%S`4KLL'6MCII97"]SQ69<,^U[L*N
M&070"NJ@@HLTPR3FDLM"5,*()Y3+G8<]R02/)K0QCH91&LK(@$K2B&9([2%2
MVX2*C((U%KVH:X4TI"H\P9ACL2R`,1*8#9#1-H^1:`B7%`\&\!04(-@M!!HP
MI@9XD3<+B"X*GBM`$2QG@<01X$F-8T`3='$/"A"``<T1R`U\D+CHJF-Q"(L<
M!7P0)R0D(42S35T`-H"D$9@7)NJ4*=(`91&A-6.-@S($^\1I6&^R5[TCN11^
MC><IDH3_RH0QH*=6;%&KZC5&++[@S\P*$PQ7%31\3.&1*W15AYXU8K`E04D(
M$&@L*:'J#KU@ELR8M8NJT+6?J$I*S*)UXA`3!U764BD!E-!2%&B@,RH(XGX?
MJQ%Q1LJF.R:>`S/HC"Y4H8\?[`)O4J144*BH>1Z8"BN8X(,"B.!@)V,"_'C$
MQ='RY3;?289X@%"#&AB@8PY(PA`!%(`C;DL79;N,6TLF'03_KS!+8=92WEPV
M.`=@!8#>:U]#,A>()*)1%0&:3DDC$_;R+I,4.02))*TTCWBH-)VY"44>8H,4
M;:"/J>@+)CY+:M'&^4;'LE\C$Y.K#82Y;1E,!&QAVQ"@JD01_S4H@C40@$@+
MI&)Q[:$2<5QH#R7&0[GUH`</&,``(R",'@?01['O8:6#J>,&-Q";`!:`D"T\
M80]:R(.@5)>"-.)ICGRR4&<HR$">7!HE(8IT)-3(:'-NQ'?G3&?Q@CP:P"X/
M+9P@WX!Q9!6`MHID!>QGR=XC@EG58BVN6.@3.E8:"0DETJ>Y2`AN@!<"S&$.
M`.4G%Z>'Q)"')<]+R1&,D5BSDMM3>EKY1DLY$(*^'@A!_+;)T6QJH7VO,R22
MP*"1AB`U*>;P7E?KS5*AK`KFBL!@6BV`#Z!E%AC#SS8V*+-L8$VB,@,!S4\P
M`QH`Y(3`6.OL:+?6.)B`*K:SAXOA$/^(>G21]KJO0*]/&+1H]+B2V;+/0;$C
M281R]R%J+B)UKM%=^@[$3I#8="4L01)Y#9"Z*M2@TYFHC&=+;<@6G?I9A(PS
M*_CBG1XF@Q%#[UC'I`'!DH0@"KN^`0RTL8K%N8=*:-*+"\^QG'ODPQV['Q,#
M!O`-,5U`!L1G`L**@P.`H.D'NS#@`I;T[4=T"@,M6)U*M``;1."<)C:9X#HY
M-)/2``UH@]4)8#N";VSJF]\[\5`54)$!-&0">C42C(Y.WD]8U>):^O05S_$5
M\S,1>5<AY80:+]%H$U`#/H`7YP!R63%@]P`,6$%R`85$XQ`M2T%7<%=7(;9R
MM]!V"%0L9C;_`7NP"/"G")U1&A:B6)6&7Y4B-QET>4;'"?:"+R@",$QU"DSE
M+-R`#E=F#]9R-5C%%/MB5%E7"90`'N'!2=`0%$_@`&8@!W<':#P"/7"WA7#'
M=B7W=ERT'S"6'1^89UQ$=F_P*ZLA"2^Q`?-%3AFA`AW2*4TC-!51>71C:ZC'
M4SWU>#)!1JX!#1G$"+@1*E_F%UOC(J=V:I%1*UX39S&PA`E@9FZ301QS9AV#
M1H!G6"/`2DM2!+81!$_16Z`C.")0`)NS7<4E`P*P.*K8!&P`.<0U.3RP7:K(
M!#*``]K`.<AT`1:@`8$3)UM@`'N`$1)B)PO%/@U!"$+#*2"1:8)P_Q'K0BD8
M,8491C>)@#SV51)PB!'MQT#O!W^MD23!83^(D13VM!>K`"N_X'9C$1;,<E%U
M=E';LT@F5&$JD(\+=`CEXA(68B%`D`9X`7T$5$^H<E6EI59;9$]7!3%9I`MF
MB%*9L%7=$``>2()XX0,GF"#B:$9EY((<THTR:!,0(0E3,P8V4!M\`4+[PF2"
M!&4K<Q:[L`Y7HG`!<!V0$0.6QT.#V$.5R(:3`%15>(7G47`S$RM&R1_]=Q5U
MU@O[<4]0\0U)"7=DAP;KEH\;T0QNF`CK@PA9J5."$"'NU'>I@T&;QB`Z(Y+I
M$E@+B!+*("SR`H7S9XZ`Y'F+R$@G!"V)H?\8'O`0;H-)S"`)&J0(F1A.(:$`
M+:`!S;0D8V`"-5`E$5!*-1`"!?`!J61,K\<$.?!*1?!+DR,">2-+K=0``]!+
MN!0%P80#O;1*%'`E%B`'BVD-2$",&X(A#O`*O;(HZ$,GZ%4\(C$($9(N#<01
MUP@3P'E'`W)-W_@ZX2B.'2%XO9("JK`)I#)PJR*/P!`=*R>/7D&/8<$5-A(!
M4[-N?+@G(Q`L_OA80*`!"Y`7%K`_X,".A[$_$V,648$J7'&3`;8POA4!'@4K
MVH`-6^4\7E$!,I=`-4`\SOE`>L(HJ-&1(.)>8T!YM.$)1M5'FO62/^@O-](]
M['`<(M`!,J0;=/G_55R72;$1'K)5!9,6=N6!A5FH%=VC#ES(A<1!HS0ZAB_'
M"C!`HQ_W<6UWAC>3@M/H5YSDAB.@B67$>.YD(8!%1HB6)'ZW@-?4<XM%)]6$
M0>*AI2K::461=()TEW$&"F4C9?HG&$A59AFS"'%#(EKZ7JP'>"GA`'6@`;"W
M:Z-S3,<%C-I@BJC(.,9%7??@`P73!#YP`TT`?8ES`6U"#VUR,+O07!30!`+@
M"7#270:0!$EP$9U1![@Y60\Q6TU3/!.T$!&"$OO%:`X@"-S7$KW3H/NVG.'2
MG,Y9C2Q1!QL@G:HF<`4W@1Y%CP9W454A@+V:&!X0`W40%`VQJJO:3IZR_Q(4
M="0K4"SO*95UU@'SF9^<`#'94Q7ZJ3`"0`&=\)_Z(3K^*0`V5*`LA1<W$`((
M\B!!)A(>\H(MH98Y!R(408-/<"]^81M(ER^;MR\::D*-A!UB@`-7$@Z$]`E&
M18G@T0@0,0FRH8^7!0TRL0=H$&@C9Q4@9W!):93LL4\%5P#%P1[1\@W]=W+2
M81Y.$`%F(!3E&1.55P@_U@R=LB?UBJ44@2=T@B>1!H,=<4>H,2%N2#=OLS/>
MT3&28(BB9I>+V&2-E`HV8C]@AGH:5`ERPZ6-\!+BI"!)(`1'MB0(L`#BNCB>
M,`<5*!#C0%580@!>(@/ND&P$,``R(`/(<0'0IO\/]'![5(4#`G`#8-,!'"",
MC%",G9(2NI*-YQDTT31?%=1C82D3W)BJ"<B/WF2-?^ASLMHG^E:>M7H3=5`%
M\72L`S,5(98*3R&L8ZAM_!0^W&-/-I(!7:"L<6AIDF5>J<%N&&0!&7D#2R2C
MU<$)C*&?_NFQ]?F>^C&N9B@5GS`9HF,!]^%Q/]!2&@D$0KM?/5=O<+2DC_6Y
M">)><_,$"3!42,:2`BM(L'!"IZ`OG6!%8J"P%"`P7[:$BJ`QRQ"Q6JJLEV6Y
M0V"%1/2QMD```)R4*#.RW3DE^^<>'2O`5F$S@(8&+XM3%[&I:Z02(U`[K4-.
MJ9%^\N6SU%0(B.<K0+O_$^@334VC`B32@E^GM$IFCGUD:G$&8*'P>:80B9,8
M"4]X)!#!HG^II#I'"`J@`#:`!(LYMMU@M@*Q4<Y%)<;1!"2K)2(`M]]@#S=P
M?'%K#\('$,IW)LN!'$]1%A0P?;()!)KZ('EWF\+3(*=*31N0`<H(4]\DN6DT
M`N4I?N`X""01+%L;G)^QN>EV*9Y;J^C4*\'Q`J+R/%VT'MK&<OKTCDN)*Z[P
M$.CB>'XR$HQ"$<!4+#>@!/SG,*2U50''?U5A&%94`#&P#4L)0*DPH'YQ%=^`
M%QQ0!"12C:_C,\98FQ-2"`DHR,_YO748B)%@="N95+ZQ,OI25`&F@<]",0U;
M_R1O\X29N$>,D&G[>YYJ-G9WAS]&Z1YEB)_?"1]&>9W2<6+O\0XUHE<K@`9U
MP)$3?'T@7`@NX9'7!%C4%&E%>X<\VQ+U2A,+PK,055G*6@@J`%L.48X1H))W
M>1CY4C%Q9LBR6V;2@$F4`%1S$XA:NB#P',<R\5TD<J<(4`1=X)\^$`7;D#?(
M)%R64P2X^$JS^#B1`SB3HXN;$SBX*-.^Y3>?0PUCC()[,,N)X*D;$!-"@T9M
M[+A%(Y9J?!*VO#3NUR$E$;E\XL>@T;F\#!*LISH!X-#!@7]B00L(9@O<\Q5>
MG7]M`0W.F"D^-QJY0Q'`!<M2.:SHVA0-AHK[^<UQC?\=%V7*?I&RX!D9%X6M
M?@%#ZZH99O9]=JQ>'GFE?UC5%1(3\R:(S5`%G7#0]-*2+IEYG>6O^,(C/"J_
M6)<Q#_O,9(4D<I-W?662%=$"5&B%=R<RVAP55+(R\5MPX+Q/)<,L'1O`YER?
M@.8$;U`'<0$)-^O.R3F6A;?/'B'"F^:S"P54>')>=K0G&])S"UA-<W1A&0%;
M0%`QAZ$!FR4C3O9DXU,`'J!#&2,)1)))<V.Q&+1)AKFU=5$2'`T$L;D%C]F*
M(3"9DTD!ELE*QA0$3,`&`I`WQ?29H9E+#:":01!+J$DYJVE,52(&/F`W2$#&
MFNK3!@#4#S((>`A4;NR&I@'_08K0E9'K3A-@<]BTJDI=<7TBU9L"R%6]4Z+K
M`6RA"5L]8-HS%@15"S/SCBF3'A)1!?HXR=K$;CNQ6(1`$6G0GBC``1X7GTB(
MUQ/3"=93<%OFE,K;E,SK"0+D%]$[O7@1`Q$TDMO+EK7)V(\E-(Y@38(I'BJ9
M9%8SV7_T94:%=*>REX?1!9089D4RB,L@-7LD$[5I:]@W`FH6,F3'HR3["Y1M
M+X[>1V0HHUW8/72G%;EP4C=*'(*!!AD+(&ZP!X*G!7'H*>AW(5K0H$*SU!OA
M(1!RECLK+!0!5-7$@&ENF!B]JHO65S(!6_,23[;AW5@5/O5Y(@N;%IK@'64F
M'C\9_[$5P0B"^+/>U"`GP<<DLA!WN@5!0%V!XP,1X%N3^J=4\IX`$0%L1V5I
MLESHL"97(A#?(!!^RUQ4XKLQ9#<(8K@8?IM!;=QNR#Z7%4T,`C0C@>0O\<\8
M(E.KRHP4<4=1;6_Y!N,QGBD.D0*&''$1@%"$$18/]IT^7G"XT!;1FEXW9SR@
MB@$:\(!-?@]S`&.'$393'F`1"=@N+Q59;G#$BU)>?D`MM0"3((T[ML?'3>MH
MGA*#0C2*`-F2(,P7RMT5,]G^^NC)/.PKV;4:\Y-!AWIRHQ(90>A5T`)UD`2=
MGNAMQW:F[.CW0AL@1(8UBD1/>3V3SG81X`9O<(5R4/229O_<<0$O<"SMC<+P
MU2A'^GR6O<*S#`($S)C!_<:,DL8(TQY'XH>5D"`O#L$R(H15./`!8@`_OF%(
MC72LXFMF4:@,$RTWG.;>]1SM@-@ZWV4#@J`!NX80VT6H'B<.N>!"6)+N6V*9
M270/[#`/[J'[<'L.ZK`_5Q(0-\!MI4/&]HX@V:@KHB$(^RZEFW82PHT^=-P@
MU00)A]W4R*/P"X]?5/WP2G/)NBHJ'@"\8:&=[#$6(7<+/9(!D[`:S>H1LPQ^
MD'+!+4`(P-A2/W`#3@0(!041A`$"`H.$@@4='8(!A145B1&+!3"/A1T"'801
M`104'"@H108&21-/$Q-)J:RPL;+_LQ,8(QBKM@ZS!K2^O[.KO;88PQC%IZ=`
M-D!`3UT:,1D9,=`Q$1:>GQ$Q&M[?US".W-U/8P\&3\T&">U#"<W+QT`&0!@V
M5<<8#D\&QT\8-K1PT"6"DX-.&DDZ5*":MQ@0NT7K(*FB18M,&$ERI/$BQ4YO
M5CA9@>;)KF6W_@'$0.\4K%,`J]QR20NF/@Q5-E39B;,*O9O')O3:56N?OGKT
MBN+$U4NH"A4&;$@%DD##IP#4%(GY("``)$(>O'J%$2"&C00UF,6C&I494'O'
M<N[<@,S8L1$.TCU)H@6#D#H8D&S9@@#!`A\6F!!@$FI.`0H$<`B@P*1)Q@L?
M#BAN0N#&_P49!Q9?$'!#P`$13"K/H2Q"`),;/Q`,WH*$7I(]$^*I,N#`PP::
MJ@).T[EL9SZFP>DFP]#"Z$Q@T%GQWF=`Q02BT(-&__4D10:8VZ$_615>:+H-
M8B%E"-"(H@`Q8@1(@G^H8@<89%-4&0_\.M&FL*Q5DWDX;5"'`U5H$(4/I/Q`
MP2-?52))`9#$D,U5Z7WR4800!4`AANQ5T,%7%E)`"@4A])+$>*RX4IYTK#B@
M3RY!]?=B><(LQ8H^YM5SRE3I=`%1!A$\=$T!]0T"433=0%1)A1ITD<`Y/B)%
M3SML2;545"S!=50MXPFDA9`KB)10>XTTU$45UWP590PP;(0FFO\B"J(01W,R
M@9\C91[DAAE)K'$/$%KH9,-*6O223"_.&`->3>/UQ5)`^1@W:3X.W$(44<3(
M6(PZRQV7UZ)/G;)32U9YX$$$8050`0Z=!+`JJQEN<%8"S+2EC*G,G'J,`87.
M=1PRQ-C2SRHK:C'"7PX(-IAA$71AP;114"!"`5%8@%@1!82F+06($2!#$]."
M:X&X%R#F`V(%R)!N$=12<(-L@R5%2S^]_3:44/CLE(%/^E2AQ6[^Q%6%/WCA
M).-S-\:R+X#;:=<P*]U]E\[$LK"(8W5/K"=6!B^(N-%[\-$GLHB88-6/C4TE
M0QXK0$1W2D\..+"!!DA$L<")7H%8P(3_/3L)BE@4_EQGA1WV[*&=1W/CPR@+
M1('$P'MHW`J.YEU7(S$O9XT=QC4AC$%P>&6=#%12_<@FD45&0X$`'\B``Q.$
M--GD54MV44,"0]0S1-](L9,`._48W,RO*QVS"P9U1+7!"#9HT.>9[4U231="
MYBTD11==)!\3FQS"2>4>=8#0"GSLH8*R71!J*2ZZ27=Q+RN;Q-UX2_74;S_$
MU%(%/QIG>E,R+0%["XLNNRP5,PD\855Z'B)22,]A>1##$WO7,)XZQ=MCPYI:
M3FJP<8D7B\'`TIE1AQ9K")$*$,X6%H,<(83@1P@4X%!`_?PSP08!,0A"$8(0
M@@[DX`(6$&`0_X)`@!S@P`<*#`(%9"`"""XP!!:@%VWVX**8X89BO/%-RV!B
M@Y[PQ!9:B-ET1L`[G,S$2RALV/;`5A0:5NQ1-`1;.M;S@K&(83ZB>P\`XB.B
M^Y`E`TSACRQ&:!Y/K>PE+HF)/OA1AQ881P-%N`$*.+"`4(1"$#"0SV,@,:U*
M0`@3&GD,)3XAB"\*8@Z3"$4V?K#%(M0&?;&PVH`H-JJ"C:T6M\CABX8Q$S^.
M2G:+JI(UB-0-"W0``!^(I!B4])"Z,5(J-8@'.Q[0CJ@TPP8&`%S!7G<P/QZC
M+Z4\H1O,=!#.<:)M4<(<YJRR$-$1((CUJ4"<Y(.?"@A`";G<R.G08/\&\LA(
M)O;023_L1<->C*`Y3SA./EK"-7_8JAY/Z$M*-C6+FF&'/^F0RA-*"(2_=0QZ
M`7@!A61%*P]DX%984@OSXL&34P%AFAN@2T[BTHP3GD\9A$K8/L;3C-G0BQ`6
MJ!8!*&"!!S&4`A>X@0]2`RXFX(``$UT,:R8#&<8$0`P=\`%D8J-!)"#!%;B!
MF'0P(,*:T20=Q\CG<=+A3.6D8P3YH*G-?J>CK`DR8G_$V`TO]M/M=&VE'N@A
MTWQYAUH6\6@IV,`3H*+'E\!B%S,;P?&(RI^>1/-WO-F)5D>@A1I8@!0H^,%K
MO(BD#G@Q`@_JR#H]1!%P40"N2W4$!;SBRP+_K&NBI/!!")IQ+Y7>;F;:Z9TJ
MBNH+?A"26(H3!B(7M0QZ,*EN$A)`:]QJ@5A>@QL[T=O@E@'*=IC6'H=+I,%F
M9).;C&!FQS&#&PXB$L[5*0)1>,B;/!"GA1#@M[<,HHBX\8EI!`"X%C$=0MX@
MAZJMC%)WN46B#'NC4>D(A0!QB=B$PI/BW.2J%/N%\K1TK"?\K0H8>H%Z>];.
M#722</T\2U3J406I$&<>2Y&+KRHEUG70HR\*$!XVQQF"*!B4$6Z55RA$QX0?
M<.`&3!#!`4+SVQ]$Y@`X:,(/VB."(XC@AWIM0@DXH$':`&$/*%X185_"TM\<
M52@`T6H^^//54R(J_QE:D`E0$D4PQOY"8A,;ZHM]G#%9N+0*2;5$;RE"Q#U1
M2#E4I6XL'!`SI5`JBL?JB3UF7(4Z(*H9(6`0*3C@(*_\C"R0H(`O?0F?!,-5
M$E]AS^B2))8X^94".T/!#4*023Q6MV8$VBK75#'D'&*'4X6<XM<FFXRTV2`B
MVEA:`3)2)&M$(`,:L,'>$L#)J3#/M%PJ(2@790.=Z&XY^GAF,7`"$`?4`0T(
M.4A3^VJ!$%PC!B&(0.A\B<M>=R`&-8A!60J2RSO<P71F6H$<`/7<6XS@<8#$
MA2"QZJGO)C+:Z@A(7*98':M*5BA0+!\]T`;*<WKE!2F;WK\$QXZ65%89)?^L
M)\#NH6VY;/F>^E1./"1%C,`)+P2S(<P"NNA0'Q"`,Z%PQ`V:<`0JP$;#$)4!
M%5+#F1M$QC**80P'2!SPVDP`Q;CA7I6%TF*5$J5\S3Z>+5*2C$RQT(D\*C21
M:P@V!W@'AS,/1C=5<$[\@-&7C8"/+H^H@97IY1=`P.H$M)GJ&>_F"<^62\"8
M4K-XU`!_:/W!#7Z.9E#X<@YP9,@B@"8(28CCEG4J>QQ'H><@U*#/#:L9>;(J
M[4XMVL?<C#;=7RR,1/9M'9EKDR4>1(Z(1`F3G(;'6IA'ZIL<"Z;'L>DJ$J<3
MF(X'+V9X`VT/<HE)U#H&%,"UKN=$>C0UQ-;<*$C_:L2!B5@KVPPJ6-'23_E,
MLLY^'X:^JO!8VP]5+*Q+T)V'3WU_=S[>9-35,4!]G^&Q='YE51J8TN!VM0YX
MWY._6XZWL+9M0E-/DU"IAEU2'*"`>SCK60@HPMLH$`1M)90"`.C`MWQ0!"8<
M@5P-18S]T^5^]1_!"#Y0&!WG<1R$&P*"5/IR+_T&$RU@4SDV8[R33REW%XEB
M.SD7"T`6=S='5!>8,4?%#T/0'4O&9">C2QZP'U"1#+[W"P,S'5/G#SMQ+#F1
M3_H4$WDQ=VNA`6*F9WN",O=Q"7,``W"47!]Q"8Y0.<%E=K[T`PY&"@L0!,V@
M!0,S0P$R<MV$53`E:('D_Q\=""/5M(`ZUR.+,@3-@"M"LPDHHR01H3?:DRN*
MAR6?-&HMD3A:0&/*IT\YY1(KQQ,KD4TX(0>:5R9]<A\18&L!T%D1`#JE5WH-
M\3S=$`#BT`B"2%O-Y2/1-@$J-Q.2P@^Y!PM`D1>$1G?QED_(8&13%`Q`P12+
M@A.@U`6M(BNKD@%=<`YC<%IK03B.$U/TMF7&81R]$E,ZL5_.,"R)4EE/H``*
M(`1+H`#P<WZ#82T!@#G\<P,RP`0243\%P!5-H@$AP`1<46NYI0$4``(<-QLF
MU0RWP4'OLV((.!2`YHF%='DZ!EO(L#`M<`L_T1PI\4^+U8496%T;*',S5U6$
MIO\"=>`JHK,1^'%$I:A$T%%E0`&!-Z4/,K43^$`7*@%"GI0`6-<@J=$!!%`1
MXJ!+[<%Z'<$Y"!:)%.$8D\:$:/6$F40HTJ%'[-A-O1=C?Q1SQG2!UI53>D==
M<T=9\+4,F?,)%2!TB=`--C`&8^!)]?!I@S,5O[**PV,3/&%J,%8P4<=:.58'
M@,A*3F!L19(&@V`5[]%K:/E#W5`)W5``\2$`!+!Y*_`GUG$X>"$\J[`P>6%W
M-/2.65B5*D@IO3@V,.%-*Z<I>51M*H%CN%!"IG(5[B15YY!X5L)XHV5"TX03
M^%8@]S!-^D47]\02]:0XN5$<>.$^2=`,)A5PAD$!1>#_`X]A`05P`8/`"+4I
M`IWP,XPQFQC547BV`"5F8BV28J59D_X@0B9Q:(.V$OMX%W71*<JR<F/C6D'E
MC]6I@19C3')'A8RU/7PW51OP`F(@`@#`"1.R;EQ(:-OA@M$UE>DP@W(QBL'H
M$U:8#GD!!!B$5F1F811%`2`Y)XG@GYSP&/Y91$ZV+B:"5CZ@`5$8(WE4A;Y@
M$I.G6(/VCM=!9("&D[@3C\4'18GT(X=R64L3B]T@?=/WE&XX6J3EGC#E>'27
M$_=8%X5C:L;R21A@!G(`:R-A)BE0!W!2)!\5'V+0!$V@!$9ZI!?0!$*WEHWH
MEDIP.F4R!4E@';G1*5H%8R:A_U6+$UEQ=VB[@#O'@1=Z,3,5*87Y`&Y:HP]6
MI(I6]@\](BFC=BCI(`T;T#J)%T^WV$E><E_UU7W#,C[>)S[YE!))ET+7AP')
MB&+7(17.2!@(P`'`5#0/HEFX.6F"(`(X(`($,&E;IUD$`)P!MP4VH([IV$$'
MV(X7&B.]`WG-`5O01*;[`5MY"'72-#;>R9T_]8\O8G/9&2/>!#P=*E2X2C''
MD@%;<0!#5`$OD`$."0M6$ZPK<4SG\P]Z\6PT:)&"*55`689F14=CYB#J<DMT
M$GHQX`.;,`C9L&85L1KKDF<H(%@R"5X72A3-P'?701XNM#A;F'<6BC&'YHGW
MB#O4RO^%O_IB'ZH\&C`-GI`&W2!:T]=)GD85@P,/0+$HY7,,*F`LT#43M<,3
M./5/)E$'7JEY(W$0;^`&PA8M$5`1O7:DPE4DGQ`E`7`'L382:""RKY!C1H$+
MDY<+B,EM]QH>%IJASN2<JD@,49=M9]JB<3%63,%O4]E[%1N"I35.G\9)\,`,
M4\$WRC!U^`6,]J:9V;H?N1.,H%EE_'8+M^$B.*$@H6H8`Q<*&M4!33`9!3"W
MK?$@&K8`-P"<P8D$>X%2KO`*`N(B>RE"LL`UO(-3K;I=P9$39/67@:9C7$IH
M%EA4NEH>O/HHOPJL/N:=_4JL3Q``$A9_)WATFGM5BA,0(P#_8ZSVGCGQ+_UR
MK;VGGA.P`UC:##50!.Z*`@N04#YPE">S4!8`>KX$`T["LL#5M_II`3:@!0[P
M"L#@#,F9F"OC<N&'IC.7=U)$([C'1^5!*GTC%1%!#77*%DC!-UGK#$`"4-FK
M**;T*;^R%!^[BI%7!;@+"R/@E6B0;"OP!F\0`&@@![HV=$,X!\`%=F"G2[)X
M#6C0OSMZ$!$P!35SIL+C*5\Z0R:A.-O%&WD79-3).\/RL2*\:F1E0LX)M=0Q
M%!5+:IH6.*!&6KE"/"\8F@4R%]PWG\.23-LW33NR;2;A"M5V"S;0J(5A&`^6
M+0PE0=Z2?^K7!'X;JJ)J`"%7JM>Q_Q8Q$[U)X%+Y`AQX27):Y9QA#&[FDVH5
MJ`J:4BQE`R#!.C&9*[0!Z:O>-!YM+$/;T[G.NL'KH1\P835"_`O>E*9Q01?]
MP'2XD%]F.PU@11Y515#T@)\^X*V^NRX6MA@(3+P-!4<PP+")N!A,R'9CY@-1
MP`S!D)=Y-*Q0Q#4.T`+-D9YX!U[&\*6=\C*7*S,?2@]K`A%=8``/P$F?="75
MMZ+(5SC;MEB/E8FF4JLTI7SY\&R+=@]/T+_^ZP0GJWFVE9"_)1_V@09=$!*3
M0UO$)*T\$;VD&;02JC4SX7*@:&C\H)A`439?N$^N0[:''(SZ@#YT=TJ)%&_E
MA"M445EI,_]]*N`E+U0XQA&HF&DI\7;#OJ(3NS=-8UHLKH`4.2.`Z!><"\!%
M;VO1LQ$$=U2XA(;%SM`*KW"<^E(SND!3+E0,*K!3QU(+`1L<S7&?4D0/4.=L
M6Q5>C/7&V[&Y1-6Y=(QW=-RY[^A2A#*'MVJ[5[@I&GNF2&O"ASP7&Y`!,F73
MC*Q'Z2"%N`L'0"!!H+Q%&_<#E^Q7E3`'B)`&TU+)7_VN1?"\U`J]*S*LWBFO
M9/P<S%$VH?O*PY"'LSQE=<P+9T.&4K$FO'Q:\I0K?^,/"[THT;:O9%,L.<4<
ME$N8,&@+&[`$=<`*4B@I7?#`(0&E(J$$3960M70(QM8!``R693+_P-W6%Q=9
M!4E0?M];U,:DI6'%0E=8'DDW>;\'N:OJ*<>S3SV!4U(D%])E3$9K="#*BA"[
M/.T+$V%:#-?QGO,Y=?LDW/GPVJ2X%/A@16&,Q;F#`>FX!S*B(`8FQ:S)T>@]
M&./!09M=K]LCTDE'TJA:;=:%4WE8OSORL7L9QEG&'$SQU';'B3M]G0#9J_XQ
MQ[7\4T1-U`YZ"C)R<DE-"X#&GCLQ*CDF>5N"(,]&U;'JRL!35557#]$0R6AU
MXF$]<#>P<1+E`[W;(`RUR['G*?5JN5USQ[KW'PA"F#VU*7_]9V3L=*N:,3^^
M1,E@3M3+;HM'3J+D)4M+Q^&7E]X;QJO&_WW4>A/&013%:!QRD*/?7+-@'N9?
M_K_+1MXKP\-B]:L.FIXH+:873.#5>R/4&Q,TR$*TT\Z4RXL!\]I2AQ0XJ<]]
M3&\L\6GXL#SN]I[.V7<!0Z/2U,.7(BPG5"GV_,A:L-#_L-GQY@U1$`4`AWZ>
M;E"A6C_GJ!O2*]^ZT:^'^QN_=Z]0]\YBBB]4[J(;^LZ'[)QS[&,\'1T^K9T*
M7N1"V^#)F=<12I"^FJ8Q\3M=E5-@"E8]0=6?DI??1(7Y2S&GI`4E/G`GKI]K
MG>V^NP!%T`6*,[B><BB@>\HW_JND*46ZEW.!C&TX:2/-=.1C>@JCQ0XK(:>-
MUQ,LH1<XJ2DTAO^TRIYJ^SB1QQ`E0;%OS"&R.>H&GQWF#B_F)[MLUA'B#\B9
M<MR/":ZJN/?F/BZT5;:=`:$3A$Q\>TV?AO(/]53=_]6>?22P\_"4]*!]W9,X
M6OKOMT!*@,I?,=6+A_J9/J'9J#0C4I@'DH*MWF!2!;;>4HP$-6`&BOK>(+=T
MQ1D/M;PI)HV3G"(3H`A=+'+7&WJ/HP(0]PACPIU5QW/.!=Z7<9S@V^GK/0W4
MO!W([>[*0NM:4J13)W0+=7"7-XP+7R.]A@HL0B'N*?%]-K`@L+'MV?Y@X)(&
M::`!>[.9NU`S(IO!,8,^W$G@;4XLK<P;=,U8[SC+U337,F3DIV!.H%3_67I:
M0O>`[S\1?A#.&X5/F,`3QCG10F)S%/_0+S/2#RW-RAC@#1R4HP$@$I,(VCO:
M)RL0`6@@I7L`+"G4%*X&&*.IYFRNX[J@%')']\#P3?R`R/FZ_5(4?*P?\J6&
MD?E@R%'K1S-&P_45;\A'\ZVK*(ES*O@`J!N03#FO#]<'"%55&X)56@Z(&",8
MC`X3#D]/#B,*E8X."AA:0#8:&#9`H:*CH8A:IQ,324F/CJFOCZJKK`ZACP88
M'AD852T8!H\C&R-/!KB^D4^\&[_*O!BIRB-5OP9/TQC%!MB0$Y*PX.'BX8V(
MYHCCX0XI&4^QDN>0\?/T]?:1J?'YZ.G@KL$8_QP\*S;0FB)!`0$JDS;"@0%^
MJ4YM"O5DUH01#7D9"M4I2I0@08J(M&!A),DB09`@L<$(%,MA6O;5"8AO0DQO
MR?*Y>\2(IJ)LP"#JZT=OWZ5\/Q,M*@;OG+IYKW+",F9LB#66GQ(DL&'#@`UJ
MC(J%,J"EYZ)NP18M=0<,(P9"/;,YFR:)$:YA/2,Y6C/,Q@8%J\S(D>/FC>$5
M*]X@-LSXC1LW:.346:+`P2E;B$;4F;2(UUE$[B"V\L;Y5]Q+]=*A<\;(;4]'
M#W\NZTEMT""XM*MT#INL-2,M5+T6XDJ<K%F@09\]"\7(-N[FBC80`DM]>A66
MU`0J^BS+09U*@&<E6?^4K[+X)'M6.1!O$U5WT?O.(\+\4%?<UFKONU.FF[/`
M1=9(<Q]O=9W5U#^PV*-@(@$MN"`[>K7BX(045KC@:*"EHH@RPT3R4`O,>/-(
M?\8XT$(+#FG8`C'6H&/./O!(XDLCSTR#"#7&$%2%)`TY,X$U94'G&TX.9"?)
M@:^8PY0BE_QDE(50-DF--^4\&>6+X`1G@%6\$/<)$`EX=9HQ^6#D5I+X&;E3
M=,\9LYUKS1"2GX>3Z/96%3FZN<R.@NB%U@08S,@,,'HY6<Y/!I*&H(O_)>3?
M@0J^$J"`3.+2&36L::1<(9SNJ)QT`.9H$S7D`4'5IM5@19U<9"(:4%FAV#;_
MR`A`?"H(7((`(2M<ER+4YS?:)15-*S\!H<4BFU@3%#^H79E:';H()",S3/4"
MH(:ZN;DB(S_B@NDQ*SJ@`D\].DMA.>9""*RY[+8[CPK70(,-D\K9%91NDM@)
M8"2!-H-:DO0$2DQ=+6#*8T-(V:@A1@XY,XQ`=PWL+<)0Z02,DP*Z>^%H@*[%
M)+/NAJ.E0<3E:H"IN(SYB(#8Y..-6\*`=O$&OB#$KV]NW:R?-?K"Q=3"N,I%
MSK:$/!%3HUJLN`^]`XLCVG;R-!+:A`\1I-92L5U*B$!V8@!$9]/A5D6M8>_H
MH:6>.02$CG$9[!=80*6(*'G&U$J-=)L6$K2NM5G7_YI`N-5DUF>0[,<@<,]H
M]Z_&S^IR34/"^!MY@('ZXN8(OHCH0-$\?5QF@XS7@ZZSZC8;^ND6MNTU?]F]
MC)QGG_W4&Z;[6*EDD3U&TDLU13+CT$.8_SY)N%3BZR;>Q=1)DRM8_B@@OP:B
MKL\_/UW,G>WF9DG5$UUQ0@A+*!OD6X8\*I+Y3D&>.>E;BQ3MH6R_#G@6H-F\
ME1?ERTP3ZD[YV&E;_>01QK6TD*F$`(Q12&D$H&A'(6W(9BF:^PF(`H(0^'6*
M&KK:4R%,(R#=Q$0;6N@:OS"EMVQTJS2*.-J/:E1!L$CG?W$)VP:PTYQ;[2A'
MRO#%9YKB)ZZ9JC6%<(CTG/_R"`]L(%\H&HBP)I87)G5+4PVJ%+$<-41SC.Y*
MI9-0%:O8BJ"<Y2TM8,HU#&:B0?%K@A?;78X2AZ5[_,<5&3N.GV1S'!S2:T#'
M<5GSGL<UT&$O9/SHESMDMRC&:2]E8H&BUY25,C-!0W-JH5;A)C$^HQ6C8&_9
M0,.H!#8`-M),D&A$!8GQCO]]BW\:ZHF<VK:([#BB+OCY1QN=0DF!(*-"@]P-
M%55$L^;HLF\;[(FNF#&(\1WG*!V#CK+VE#]1Z8]AK;#;=LJ"#6'<JH8:9$9+
MGK$KN5"J03U\I3ERQ3=>(.,;6C1D$3?0(C@Y*6LFA.(:OZ@1\L!C?ENT(NA(
MUX[_=>4SGP#A&N:J89"SZ"\L:6R(\AJR1FH<8D'%2`LD#+*[4.:,)[O+Y>NF
M83E+@>6BIE,*4/HESI">CEQ1Q)H_0C<L\17.+O4"QL7>!,Z%F>^143/3P$SS
MPF%HR&K1R4:/%.D,#I&J:8#"%1E=)K421N>C)NQ-?BKVI(M<+7E%>1*EEO*G
M8'!*F]4LVW(NV*<:,2*,*^O8;@B8HPUDX*`XVLY!?N$BF!&0?M.0U2<TTLTG
M5&<V2H1;/)"$CA"2*ANZ,=C44#<!:+$S>8(`G-DB]KM,-D-&*.+)B7Z!4N;]
M\XI1RN(_1\NPP%8#KRU;(M?ZPQ]_R8:6^JC::X%1S$*%_TL>D?M1&;-!P-T>
M[ZC0(*(5#02U6&!(>BI2Z#.<ET]\"(BBIK);9W[4VP?B%&W82!Y`!B*-GH9(
M'LZ`83/DNIL;@16<VV#&00D;EDR^\#BR2T:C"%<[HRAG?UG5HG6)*"'6W:>5
MUN$$,.]4*P!CQ&#%8T2(V,(0Z;!MH)V)T`,_^"/;"$.;7KM3%3)0&SZ)=:^"
MT"EH8E0/:63'5Y)$KB,<VZ(;70V`9QJC-P^"H]+(#9JC95"[1)MCZ0$O(`)\
M(N>`AR-OG>]#FFQ1,5_QVG0.UA7Q;6TR\56FI50SJO$"<D84.I3.O5*0A!TB
MME)JPM2<[F`-:P3*"BP[("0,E/\OXDQV1<2R^F%J!%_0)ASO,@RP1$.NV]&9
M;LYR.7/>TA$TP0B'AH$WB@X)'XV2FNTTY+M$934>=`0O3YH5&]]D\C9><Z$-
MA:0W,SYX?N0BE<WXS(UAP0Z";M(-WC9E'81@YS8P[)N>%17.>`1)2-(!E3Q.
MJB''/>02\](I?J;+R2@6EY.,RC$&-L,N'O?XI*4-HJ4$R!1J1N*9`8D-ICB#
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M@'@?%#3N5,ETHK1`^Y0V<:\'T,>7AG_GF-O+5ZCL894&1SS?P!?PY`QJ3A-0
MB-/F,$1E%IIY2ZA\__8O9B5%<T1R.N9LQBCE4KAD7V)J"=K[:XRB$^$K4%'S
MT#I^7I@K;I9-FK,J9F#Y/AJ@/Y(_>&FTN6<>U4AS?YBCIH[>_^#F_`U"2D'^
MM<U7R@;'Q6;/`([]^L>Y#SR5'H1BT$Q+Y'M<![?S,T)RQSCP,$&D84T.1`@K
M%%24LV!(-@)X9SDK]#`5<AKZM'?]@0X;8BG;8GJ^L1/\E6])<7Y;=":-$F=;
M%!HYHSC'90ZFYQ9KDW`,@TZT@37)@S<5%$\8=W8"X0T@@CE)UAO-02UAL7=+
MP0M&E39T=A:C%'L<,C[=P!`0A$IMM!W]<4#XX"H-<D#IAF@R9#=?,748I!'O
ME1O8)&$5=S9L`E4WXQH1I#^@1QNUIBG=)(=-QT8.DD"\D`&X`A=*@P['QBX_
M$G]"(5"`%D9_F!US(T3U%H!MMV-PQ_]UC&@AQ+(BH3%7-G%AFL!Y<=4+WY)4
M#`4[?0<7%:)60&%5U0,UL'%E"Y04^:9%3.8Q](5<$H)1T(`VLS1$@S<EBB-?
M4'$L5P4HR.9(SL,RI\0^RT`M@Y<?5,(Z_[,R<_$<E9AW0K4B*E=9/G$<D^-7
M:K@R"Y4-(!-M]V=`BO)Z\J:%4%%7%S8OY2<(7.%"A!`TS%1D#B$PA%0,07(;
M;&,6`_=OY;9&<"$V"F9#?E4_[R@G:D%V$T(:/",=>GB$H.-^[R>(BS(BHL8[
M)!4,!<,\PL*(_>>(`!B)(<,0D_1,G4&)7O1B`]449A)OOA0H"'F'"512&3F/
M)AD,13,SW'?_:?&5;]_(4LP2.ZAFCBSE9>7CC8%W#@>3%]U`A`^I':U40[H3
M;&?WAW($>>EX?0M4<V_H%H-F&@C!AF@C#4J!$9ES$3.R?\?4DRY"4S?QBDX8
M?"B7&0"&33($;`5):K=B:J38&6SE&?4D%XR7%_`0%US%%#0'%K?&?%#U:;P"
M%E"B%Q>V0;.2#!!I#T+IAQ(I,GX9/.%U3I:(5PDA@J/5D=7VB"#9+D9Q6Q&(
MD$EU1.U$,VGV,"C8(?P2<:YTCK2D6V>B?T"648AF)]X"7"4B7"&X7$MYE.H4
M+".$E9"H,5Z5(@H3;47Q.,MU;'MI0KI%8W#A+;P27(=P+!W(,P%1_W.+ETO:
ME"W2DC=;Q0V9$1`]85.YI3PA^%(B]HWV=5`WX7W@U&M#$8S6M7ZXEC>XQI*,
MN6`,D3:S4QMR@2^9Y`L%IX_+(U+JITIW^2G,,&N$<R5$-J!5.!,E99D7`G]&
M9)VP<"0R)AO;4I)GUPJM!I*D^78?>9K9,YC8D!RM$RBTR3.T4SDS=H$DIXN7
MUD95%DK)-"]5Z)10$U]`0)R?,6=J>5(EV"A8)7F`&3VS^&35$F(T$5%O@C!T
M@A'(4R^^]"+@&6@&$%?/@1:,-P@$U`Q<J4EB.5^+UR/DD5P7:5UZP2-=.8B&
M,Y;(4A;Z\G);USF[D8\%21W@IW[N"&K/L/]M?HD3<S5R-30-L@F9"H>.J`*@
MII0F<N)"*RJ)@[4K8X,HMPFB`F&9(OI81WD(#]$U%:6!#-59?Y1C+_I_,`<E
MS1EW59>0GO4(X5*+TU`6,Q(NUG,I':@7_6$6MT1\LC2(-K64/*HC(_!!D_`P
M3")?>?JL?31L3\HN!R)OPB*:4>)X<68C]1=<@:=%WP`LX-8L75HXA8=[^+*&
MK5,W,),1]3-!'W,TLY*-$:4_JU<D5@-*/P&>P#A?#BJ?:W%/"8N<I+&<A'DF
M=\6K\HD<BP9J?;(K&,:,N`<=@Y:P"7A@V;%,Y&DPV[$M"^<JS!&$H^9\8+IE
M&9J0ZLHA8*JL9%G_+B8H3E#S=4[A6,A7%+)33`^(KA<IHQ[*+EX7)=J`0'#)
M/%;(#SS[#\!PI<+%++>5"`08,8=PB9O5/S>$1!F!(RMH7.DF(0PS'R1E-YQ#
M7@JE'JJP&O*VFUN$%('Z8_N'FI:!3NU!9,B&(KCI9$@2.<N!"OW2'\PAF7K(
M'*&`-Q@Q`4MZB0='=L>"%^>V6ICCH.SJ@YI`'O/UE/]A$QK9''50#(*+++80
M)%O76IOJ)UQ'?$!D(+TQ="V4E\$D:H5`*7*2.5,KISM1*\V19[H7L=4`/;YT
M&62!-XR[J+WD&MT:)5]D)J-K84S!+(:9HELJ?[D`=V:F'62G1`H%>3):_X%(
MJ[T)B4/#^2.S2'PNTPJ4*9U($@LYBVF(H)H7P4`GPE`Y9$;1&I7ZX8K<`D>Y
M>H$V-5=F52>#F`1R,Z]V"%`"9!O:"J7#2S\K1';U%P_G"QM.%@V.Q@MN)B4(
M<0J"L`D!:BQE(97X4A8J<K*UX!JKQAJ1:93_86%38E.U,:VH^R(:YPTMU"#Y
MB4L<>T-YRZN$N:4)5TPA%&P5JKS6P35NI8<(DYTA-[V`>F!%\VDU*S[W9R3`
M039^TUH?%K.YNJM"!"*CZUY?(#3IA*/$$"C#%B/9RY^S)#"K-<,V%KXZ-KYP
MC)1QM@$IX`$ID%E)E0*"3#&7P,>Z@+\CD`%]K/])7>0`7R#(*>!3)*I5M^.C
M&7-T^#`"?DQ!W>M+K),!&6"(/8FNA<-KXZ)C=#LH:@LYWUL[26`-=)<(COFS
MH?-0]Q<L9XM<L(QJFY,!H_LXS.,.=:!0+_,PIPP;)N*&8)%9KX0-MT)*;\%A
MV24;>G@0((P7+M0"Y$C%"'EBN,>M_]-+(1N$[GFWGM%1N]>L$W(SSD'!H#NK
MPU6-'GA0-70;P5:[>94!`?`"'A``NB`(^GS(TWL0*1``%[H+GLPZ?:R'VU(,
M5;#0RG0J;]IWZS<;_`'&&C-(OZH(H*R'9O-[PV-GT+$NRI"T*"<AD>5O^J>K
M`0A:4&+2)78@&[#/'L#_SQB@`G70Q_S\5I<`#!M0TT!=!2I0!4!M1'6P,MOP
M`OP,U"W`OGZ2#`\QN@9Q(K^<0R-GD@X`RC837NY9!76P`4J=`HK8+087("V6
MIU"=S*@Q.7<!5=R*(`+C#@-UBSXI67%])W-[IAY@U$_0`D7]5EP6#2/0Q]J\
M.4#]Q[?STWOMQZ$\S)NQ$S-QC#QU'2S[+1C`88*4`4;$&KW@T+3"")KM`=H\
M#>)9/0;'CK,2(//E.Q^#&BPS*.0H-5#R>M''+9>):52(4R-D)Y"`:\'&8=K(
M(063`4K=SV$]".Q`?KU0,&[%"#6=NWKF5S7-8>[S!&`-`P9]&JJDH&)(3&/8
M_TN,=0X#)7VW4LTTH5LD4B1D-U#]YC@;8T7)BI`J)ZXM?;<6`M/3Z2(I\`*^
MO-_LU`+\/`Q'C2'3G0LO<$3[+=KG!!M5P,\GDN!UT`)?,+IUT-BBYU9__`1?
MO=`;4`<&P,?L$,HM(,@MD`1/4,WEG=RVE`W[#0,O4-B)+!TM\-4T0TR*',G9
MX%:CS=!<QH&[E\&T&$JE*IT:0U&*V9+VW2[7L-_\K>$>``,I,`5*S<C\\-`O
M``,;H`(C\`(!H,A0WBS$'0`Z_<\"A,`SWM=Z6#0M]&%!.!W6G0)"?0W!9AHC
M]>0OD`*Z$Q`3I*\$J8=U4$')LUD[7`^11%<W&*'G,O\W74-U"K)LYUT@\ZW>
MWF5*I?;3`2`(3"X=FXP!?;S8U`WG8,W/D=SI]@$M_*TIDL#D=Y[C[*`+(.['
M7[W81D34'K`CBJQ)=,TX/H@W9)/F63B?PP,YMUG2[6`A>MJEWVO'=VPN^`UX
M_JT"&0`#ODS<?CS(0>'D!ZX"*2#M=1``4+[7288(25`'_/P$./W<8"W6,ZV'
M0%W<HWOCS_T$3[[7Q3WOFE'N54#38JZ,W>['_+T*Q!W6FKS4TB'(-9T"%7[G
M)W[@N.,*@#KHV+.3:\?2[M+=Y]E*Q.!C@ZW34W`--3T%T.(!G^H(@TWO[`36
MM9[NWA@)Q-T."?_'?3SAFBW_"(L=`%W^YZ1N1(:\V*1."(H<1@_MZ?<3ZE/^
M%I!L1'T,T8H-[C^=`L3`QWUV7O%;)]RP58CN(%P)0'+E("[GKHN>+QWV5=I4
MS2]4TSMRW>R@U(-0[PKOW^3.WVFNR/N\"_N-YSG4UWNMV7B>TTK-WT1?ZQO6
MXDC/WT1]X$T!SZ"Z8LR-V7GI,V`&]DEA(Z#QQO1]#A/7\+D,&LKNTO=-OA>2
MU5Q>T%C.][HPW<.X\&(^W84/ROR\(Z!![AY0!^?.WR$_V)=NZM+!Y=%KR$W^
MY%.P^JN?[@L/^'/E".D.X!Y0$5(>R0V![J/;`HJLU-/FX/Y]K@2!&S$;9VRT
MP$2N_^O_Z-VR-B.,-0&:[58O`/()W_='%`^:#2(';@U,OM>%[0HM3[K\7`=?
M0/O]7`=2#@@>&1XO'E5/&QL9+R\9&P$P'BF,*1XP*74I,!EUA!E3*1E5&*-/
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M!^Z@^<I94]TX;\E&!%/\;*KKM=2PS8,WJHHHUM->,YWP3]`D#UPSD"24XN2P
M%B11T:K36)*G8=L*9C!0E='>5E]:V5X.L<Y`22\").)G%F,+CZG.7^8X2J:G
MSKQ(QH,8;T,E0L"GT.KXN6<B=.&$1HXPI(!S$CKRB+/4.3:M-0V#.JW4#3H(
M;A,;A:W)%@\IM-&6"#XC>$?>(P;_P>6*0)Z8LDD5?R$'G">9"%3%!`8$5`@C
M4TA7UR,8J<#7;\SAUXA0NNEVCRPT\8)/:]/,HU-124;8&%=%$ECEE:^A@V4N
M&>0&E3D/M:(/?]MEX(`M&QCPQ$87Z>,/0-3415(B0!IP'C]5Y55%)P&,T!%&
MAZ7`X@N"I850+VW]644+SE#'6R%7$9?$!ILD,9$'`4BSD$$DCLF(!U_02&`R
MOE2HDE&+5J%%3]Y`=Z672U&8"#**)%(%@;!N24U`9#&2`7(O[/F7EN?EU1!P
MI[#U@FH6)EO19X`Q0LMV@D*T:0K_!+`1IG6HQY8@Q$'TA`H.,,KA(C=ZQ)\T
M&*1"*T"=_\TC9)K;.,G+(2Q-2)I0J4'3FFG%,(A,-4(M&N%*R,CV[X31I%-O
M.#:5@H$HL\U6EXB1O())0+)\2AQ@,!P$XY^;<K)5MWNBZX@F'HR0REX=O5"'
M9.%I9LC$Q^H#EJY+<3,33;4Y,XT[\2!H4X4A=D(ESTPW#<W!54KU9;FM^.H6
M0OCA\D4C$]C2"G!N!42<@J#A]6DA3VH%PPL8O-7*MH;\0PLA7\3(526_`F16
M`/#@U\HR/9T"5F]^<CT!G\O$"!ZA=>'';#7F'@,,K$K*Y@`0J+T*FU+E!#.;
M/!\ZLX[3L"DF-R9W.@*95A[@LH%B\/VI"-K!!'/1+,"IJ5\D!__I9\A%'-NB
M[:%[?VO+)3&'$E-[9-7"D.H>2#-H<?']?HEWKT3O3C<TS:I4PA8*8U2""T?'
M#M34$!U..2T9_0PW12GSE/@YA1,/YO#8.NO`9Y*%WZ\<P90BOH:?B8EG(&1Q
M!'[&HHKLI$E)>*L-O`*@BB?`!1.\&,O7:H&!3L`@5*0CR@2Z,0];P<-AW5`&
M@5*E(*/T1#%2"Z$,LX0^W<20<\08`2HV()C</"0#7VA!.?R4N"^$XA#4*9<B
MOJ":T&#F$SP<`?Q`]AEW)`)F0JM5(@33@E_5XR`3ZQ(B9F6;4&2%?8S2APJZ
M]@5A,'&$8Z3&"+[PA0_-+%IF&L<ZCF+_'&(T0S$-.^&_JC0YSE$C&)$C8RFH
ML2H9UJ427)D8`3,0C$I$QBV(R%V[-JB671&P%FN!2R-@1@NJ<6(0!-S(51+1
MBG=(0CH&A)0RVJ,=-=E"@8;`'G#D\1M,J8(7OGH?E+#QNM=P8WS'L-(PCM$J
MIPRR&N?(2?A6TX*<'(P4@(S'$[10GUY$*1NRD,6M?"&+,&YG6A\*VB%*R*A#
M).,9BME`'3NXSBWR$!BB(85W>$B:L.B"&3,<"H=,:!PEMDU?[YL`$7N"G"X%
M]*%-T1*6;C@5;@!T+9T;$,"((13XK81&[)/CVXHQC90X<1IN>>&MW/*66ZF)
MF<@0U3.WX<?:_ZF#8,504[T(`3A7L2\=QJ`I-/[S.2<5`TO\$ZC\TE%"VK@D
M-C-DS2@<9B#S+:PN2!$?A:RA)@I)L:,CR$LX&#4K`R"#>^ETBS>V6!MV*6(4
MC))?PN0I-)_)0Q2TNI5*TXD!&^#,(&<%QCMY$0Z6A-0:ZSA:3!D3L9DV!4+"
M9!6&3G)"THQ`"SCA4/ZJ8(.BX0,>W9!'AU")J5I4K&W4"6V"U"18Q<"CFC[K
M$/B@DS#%@$:G#DC"/S!Q48A>@U9"@PYMGI3,!WF5(A3,E6^7J]4M4=2PATS*
M85V%$@505R7*1<EA<UA'C6(WIVOI5V[&A\QP`$.Z/;DI;9_ZT?$"\?^Z*,F7
MDFS%(6P>53>K691CAV$4`$FC'E_(WS,P@-E@-))TI``---97#M9&-TZIK88*
MR/5==X@JI5\(``;W]U5^(0@9N-5LHVS`C=FPJB@->]W`6(N9VB!QF4>3F&>L
M26!CV&1_N[EO/M_)V`05";+68$U276M9<9R#0T26AU%,Z$YUFG"'^GL=:\U:
MDU*,T!C*$#)H:^2(A'5CF4LM'W^+&5_F6J@F@ZR0P&(C38H@0Q#A,S-S)7JE
MYUHCNRDM<U(0ZYKM9M2[4'$),N0'G78F+*DA9=^J:JR%15]WS]`)S9]5\I*>
M+(JO]H@'?*?"(!6NA%$442$VO4$D!S0:TEO_&A].]#J!1N.4TA\%]&EP\I][
M#5>O<LRR>5'BIVI&`WY:T*$SHH&_1MOKO^;#1W#=P0YZ**FM.5E-8GKA,!H>
M>M3IR"ZL1X6AS6$SV^^`V&2/W*%U^D)_HP%N";TLFW2.PM7N4V9_HZ$%6J6X
M%P=^H7]I2]WIRIE`Z\OU39)1V`<9J!S=NN5^_RU#.D?-H7WF%WO]38Y)6S>Z
M7Z[I1_>L1TJOJG8$!TT]<+'0WNIXVS1R":0G4)DR[\;6L[+!K&AR5/:FE]<1
MRJ%.O'JP;<YF?RQ$=52U84$I"@BQZ-T-0$/:FFH:>4-.<EA04\/C5M=DR1@`
M`J^[#(]ZMZUR;5Y'_Y(6">-[L.N@LM+)4Y[M#8J??!VC)FI67;X@K_Z+FJ82
MC=-MJU52X8;9\R"K4]O]H:P?PT_>'`VTA:8%XW:;?94S';L8VK"%;UK.>2^0
MIUES9CX*8ZR->,>C&1Y"AQ?)SDJQH'U:4<':V?2F?D0ZKZ]">Z[H,?8I\7?'
MRYR:8$_5DM!A^>U7[@!47$6(?.:(9S*P!&$DP>W+_*QH=\A@89S:]=0]?A+<
M(5&=)`$U0,"<%GMA`QN`X]_8J`,BZX@4H3^X&BT_ZD:V"DVA]2N'XC8R?Z-Q
M\(#Q\)U:D`COT&4J]FM^\FU6XB>.(`K0-%<Q$5P44BKBT&L%@FQ,D75`X/\A
M^%`'<X0+%P)4?/8-VA`^:]8D]?,-`S8:DA<GR1`ZTM,>WB03YQ:#@Y<DRN`S
MEK9O\;5D9"8Q%!)PI/=^UU!MH_8TFB8^<O6#SQ`4/*9>0<@TIF=#$-<40[1`
M`)%G5#$4C`$6TW4G7]-&5(%>8)%$/A4,.T-=SZ`FAA8+*:`:T\"%N+5[M?,G
M%Z%@.>4RE,!Z#J`"$P&'7O(^`Q4T`;$!)O5EWN8.LJ`S'`@S54`=S#$*^/.`
M9A>%`75DW8`[M-,Y?J9G$S!A(V0-7N,_0L1]*X4R;E$.QN5E`&56<G5;L>5:
M"]$R!O`Y?D(:QP!7#A.*@K`8XS`0TE((@N$OHH7_=A&#1-MC02GP!7>W%D!0
M#X'G#`Z0'5,`1R1$&E.F4_%V(4LU7H*D9N%0()R7&QRRAJ`S#UTF6B5$4"*F
M8MS`&*1!=GW'*#IA5MU8;4_(9_33&EAF7NY050_"0S]!@=,@"5,%A/?8-)3H
M&JBW$E8$C)C!%<H7"D)D%:C@1>52>P1C(J\S?[(`#:#D,L;71HC@"&^D"*LT
M)I'B%:;0"J&@?/HP1U?!"6\A"T:4`:H14M8B">I'#K)3%^=7!Z"P2I<(1*%`
M*Z@@"0OH/SSD"-N@"(H13BUI"IP@%C&Y$?9!>S'!=?E#;68V/FKR&\X#'$-T
M?LRPB!PXC]SW.NHW#BP3_TXALBC?V%3?H`]5P4,&4CFL0E;F]44<U$4'858[
MA'AD15`2M17QPC\CM`@:ADKT8AL4XU3J:"_4(3M/HV"C8%:)X`BW8A\CD`2/
MN$4&8EG9A$+4U(JB`4A>R4RO55CC`#10MUGT=8O*UE?QD(X!IB:-]S3O](?G
M\(W5!!H=B"#KX'YR!GF$AA-'<4SFY8Y.1TUIV!C8<BMM=Y`(64.OL9`J415;
M,7*-DAF_D0QY."1>,PN$.`QO00G'%R.:<4IKPQ!3$".^LEM38"@+)"@DPGIV
M@S4?DSR,T$;$4!6$L!^_DGT&,7)[41"AX!%FD2[5<C;B,9\6T1O7T3)_\@HB
MT_\Z@X(ITR(<<Q,)DA@+6\1<1P8:"]H"U%$5P^`UVI%)55,<DD%`_ED,G9%E
M9X).P'@?Q$$1!,1*&A84O<&2C%(UN=0*ET@6&M8+KT`)I/&;I^!+:`8:C3$M
M7R0-5\EZ+-*CA>!-1KI+B^"A8Y$F:+))"]1%P#$IA8`IP/$01IJE@(2&1_%K
MLC%O>I5,[RAHE#<^)!0-_P%TZJ9(/T-0:F5-.1%:!M>F=QI/NT:<I$=_#*6"
M^H6*/$%UT8"*+-(E:U=8U,DS"3D5V'EG47H0&I05Q$$B\%`(SQ(M+T(+M>,C
MZ%D+22!*=&$`W=$=J9`R%D$(4P`LM<`FE.!%6_$GW]+_+:;*'ZZ22?X#$=9@
M*+\A,HU`G@O:,:T#/(JR"+A@"N+1$=-!*5TB.)@R#^$!K171)?SA;IE)<Q#E
MG.O0)H[)"2:B')@`$1QZ-XWP)X\S`>A26N#`DE<8+HR`#I_B/(W@(AS1GC'A
M"8H0I'K!(QS3+K0@''R#3?#`H<U:"P@RBWF1F5<Q"@)$'[_AK,3Q&X4C"#JT
M'($1I9\`C(LP!6:Z.*(0+F0A$T%F=\*0*D66@_VE7['Q#89*0J%#;:*%;N6&
M;DI692-X$M%D'&@%(".8J=9056!6K4.%J0Q5K??@@9[S"-,1;H-F>4P;4=:I
MD%/(%-/P,G*C"O6).K1@!N61_PDPH&%7,8W.9Q?J!Q8J$"V-8`;2,8N1$".7
M!):2`*J8LK>9$*"8\*NT,`1/0!8<01=F@0EP="B/T#S6H`D;TQ"U8(6"LC>E
M>B*<H!Y+0*U[`*"MH"UR$3)#P!\(L;G>"BB7\"U-54)=)J(.0TS`>#S:HA]S
MPQT&(:L)\;$.*:-9FDYPL3954+>$4`>\FZLK6@7^\QO@<"PI,`5BHYF,^1?`
M@ZMFL`A<<6.CF[O44QMS(AQK`ST,\3N-4"-E8:H80!:;.S-V\2?;<+QF,`E3
MH!^G-"V6D*!#V@CO0R"N91/5**D#]HW4ID*"M6#]`AM-!33J9@^\T*<,7#G'
M,)RB,?]5T;$K6S1H4M*UF1=X%J)J#V(P`S8^L<$HR:6SHM&U6+*I4-&I`](1
MXA$CG.!+>V&5B5)*]-$M+5`9CV(0X*!^<N,1TD$M?*LFW:'#:S)`";$HDZ`M
M6Z$>PFH>='$>GU$['M2RXWM(T<@/TYM`4ZJY:VN_)5,14[`6&H.\V"K#@[$G
M)B$[BBD+D2"(B?!&RV4J+E0'_$`U%&H1M5(1P=&[S2H+CX-')09/K/`1NA`M
M//1*0X#'C?"V*/DI&P`*`7H=A)(BN/L\:DQ"6P,<V1/!GM`WS>JA?9R_0#FO
M[)NZ>($17WDC7]`X,F,`J0`1(^L5IU`>L\,WN;$:=N<YLU3_7Y^7#2B<@."`
MJ8+E)&24,.DH?1JX)*PA>$:+8EMU5@GBP:I'-IG:*@,\2SO'FOJ&P/.S0JNP
MO?)`<AZHPKK!PDT!9[HQ"(\AEG+S-7XB"8_R&2X#HZX7Q/Q@(B;,"?KQSB%B
M25V%H\#QHY(0I"V*AUGQ&UE:+J6T6\'G`!!ZIG/"@B22%Q14$3V*+-\JK>6+
M$4EP`I0P,S%#&30CI!.:""3A'7/2+B0!"<61/YK)M3P3/ZVA7T;L*XH9(J,*
M1'X<+67<&8HPH/#3Q#,6I5_C)H^,-E2,O%I!"Z#P*XH`"K=ZLC*#$"W@.\>#
M+:'\%\R68;3`$.(!2*20/1R:-Q34_T7W^ZX.T1GXT3<:QD60@!'"X`D:T1E=
M@3,S?*9"_(%MIEGV,Z?%>(0`5\Q,`B6(BF8++(,@6E1S!0Y!A(-Q:L`78DW]
M!7".I:BE1X0&TB2$5MA/2X2OPPT$>2NE^;7H'"NHW<)FHAO=0D<\Y-1TU5T<
MD3ADAGB.<#"(Q$/_<2;(=T_2ZH$EIU#R-$]*]!\*);U1I'K(ZR=?,`410D03
M`9#L@TA3$$3W`#68*0N@M-WAQ-T4XPC>,9A@,1$G4+]UD`2=G-X3H!_16S?>
M44>,$F#^(1.,,@N6:H[0Z%LHV'?5,)\;A)+WP43V@0N#0(CW#*35$(IQ?4L!
M!*IGZ@'3F/\)-LER9$H<6<U)*@IGF5`+`X0?8Q(4@X`OB8%*BTD2PLP+1TD2
MIK7A9N+@:#*+]\%!WP$V5VPIN3`WK5-\K1,FHC`(V+)Z`8HOI^EI"_9A$B,_
M1V'D>6HNUF`P0@:-;^6G6^FG`[6GV19-2ZMOGD8J1J9"FEV)G9U"O2!<'CC`
M9$9P`U;?[$*0";C?J4U#SM7:QK3+PY=HKN=ZS\>%E)91FN@@R)KGN5=3O35I
MVJ5=&F?HLO<3V94P\BA31B-.M;D1\+"3Q6`I/!SH-0IQ#>.;[.4G]Y&EH55"
M]BA#(ZJ;U<!]]%>6E[T:_/;!/QQGCUCI2G)'26,H6:4EAR5/6=;_+5D5.K2%
M>/#`0=S`$<KV$4*!>(G064+37P,E"MZ1$U7`?B?13G/$%44G9$IB7HC#<@H`
M$"'"/=4D>%]DCJ&^2_[B[$51/P#BOX,&#D2W$TJ^,`5BB^N>CDZE@7*I[Y%3
M6!$8(0^"34[K'TBQFT\HP./H[U*;&ISW3B6<96\F1C8=YT6BSDS!SD7"<5K<
M;\,'75J8Q.TG:]"G*\3Y3"0TC."F[+;"["YH6)71`LK(75+T;?'^FP#WMM"-
M3=U0;X3M-)156#S1YQL/'><59_AX9JV!*FH%:H?T2&VH;3=ULZ6@4Y`%%K^F
M/R>A5HKT6Q8S/UY^:)@I@=M@16,%C19E_[,=Q`V9,7M//XM@Y,"*IPC^LTL&
M<X0:4AOIP$RZ1N]+VG-(UIQK,>V)5U\5@U?=,YMZ_SH&<PU\-##$H.98EC;_
MYCG=W.6&5L(98M@E+"7R@NT(3/$5O]KK3.<\4]VO)_27)VOQ17$7YTPM0=-T
MMQ*M[Q3Q<'XX8700])@RYTTWZ?%A&&0$#.?R2%N+DEL^4FN%&E"H,FA;3O)N
MMT=4VT\I412NT5]CCH3.;L"VD3^2CP'S-/#U[52/?Q2TH2;L3FH(92OV""%A
ML1%>(E$;$L'HL,S,;)?&4?<-@]FD`@\L"`@8556"(PZ'3X*#&R,8AQ,.BAD;
MBHI5&QN7A(.+F?^9&((8F"V?AY&@(RV&IZ:1+2V'(X21JZVVM[BYNI"#=:08
M3P:BE*;#CJZ,AZ"8QQBD'AM/#JFUNM;7V-G:K2/5VZT>&=^XD+NWY>7CII#I
MY[F@Q[GLZO(.$Y"IH%4MCA/&PIV699HT(EBD=MD*%;KDJ$456<"D8>CFH$ZW
M$8R:4:1WK9"L5_'.(;2%D%TZ=/><P1(&LAPHDO9&%C.%L=&L8@Y)P8KT,-,O
M?Q@F5"$(\M$33:^J*#LT:)B#)XU$;2*4B-"PFS0OAFPUP4`B2E+!;L*DJ=*E
M5U\*QAJD:J*C4%*I/9%H5NG3J@_W!8T4Z1-#2V29,;PT4.RT3%6^$+O_2ZW;
M2V4O_27C^=$;QV\3+-JTJQ?G*WXJW_95%95TN$2.+ZM>;6WCY7"LL<F$5&=U
MR6M:@#K0$EF+ED<R28X\N6Y"/DO\C',"%A93AC23JFAYPGLK+D?2>"X#YF#?
M/@<`&\V=1LK05PQ`@,2RO!JBOU=<R5T+_@X^95.Y=Q^JOONW__[[[;974TUQ
M1]XH51DBBBK\Z-==!OS89X\#@C&23B@CI$4+9:)@`)!`H=AR42JZ'(>)%A@)
M$AAB4Q%&BE7[C-B(*XUT$^-3-'&R2G;>#?($4.\-$A6,GF2@SS(!48+7*!OP
M,YX@#LUXRV/.K/)+3;&-4\<LLMRHC"JQO"(E_XUA@HE!.%4NE>6:E[E&3QVP
ML2GGG'1JDX\##KFB"I=4873)).6I$X];PTQWR"_V'-4D(H=Q-T%YTO"RBG7C
M*!1FG:WM1$V=EF!%(8N3C7;GA&5U)M$GF-C3#(-B!54E1-,H9<Q#MDR4BE+9
MT=260U:%LD$&A`'3U*_!7N71+"%>U&`Q;"UFBG=@IC113CM)AA%9!1*RXI$8
M3.)4AU5-Y*DN*J4H5:^48IKGILHTV<RB-,%[2#*0>)#"F)CF6R)[V\`ICKX`
M!ZS:>PUM@".>R1CP:9B8-,FOG:!Q8E>8;R45$GS&?3;H0^E^,VIJ`E]*)J:=
M3BCF(DI!\E:3#,W3@O^W34J$)Z\9+27*M?!(U"4AW4B#+:T7BFF9,_LD`Y<G
MK:K8\'+85H(!BHYT@R@BBHAI2XPM\1CAQ+$$5L5150#1W";Z(.:7/A+/0A\W
MS$AE#)4!5[(IE,NVI6NTTXR@@"GV/AQRG6ZJX^_?A!?^CE6I+#O:4SLS1XIB
M'6,SHIF#,/M0@X0J@W74=G-X627K14[GG6FNS9HE-2I(&,<V.[SL7(DQ4C-E
M#4]Z"BF45*[,B-_%*LM%K=BJ54Q?DC;DZMDJ7:K9R]$X+6G!/\3N[L:'1`VM
MN<JR-(&=D'6D)J5N$AV^DK<E?NV%O_I[6\(KONGD\;00P+^&`QRXEG'6KW__
MR#>K=%_%EXL:LC[C-VLH9%%>61`KL(2/4"',$)#0"62:PI&/%9!.&"L=P`H1
M*#U1JQE]Z08E(#&7#%$B&>$ZB^[>A331*$)[S.%9C7:2H]_=`B(';&&!MJ4T
MLQ&C2LC9BZH<4@B^'(I:$Z+%GIRE)YP=#5C,,!<S)G&4%GREA2[!1IK<11CO
MB6Y.1#N,D\3(-AIBA(:'@8;I]M>>"UIC<&R,(\G:DBJ*M8(9B+A$+8I8*7B<
M\2V56=6D8K1'"JJD+1-(!!$KM1%;?5%.CHF@&]?D##P6D6BP*D8FCC.7<BGB
M*4HZ([+Z@;-,%.-WB3O49FP5/!MUCEEE0UXT;N:U_V5,HI8*064S0$&:/)U2
M:HHCCXJL1QH8:0MI-4);P^`B)+*4!X1:+$^@?@5#(PIL<E)B%RHF0XUX2"U_
M<H3D)',!QW":,S9N01CF4J$D4Q!1&D7SD,X>HPWA<8Z74:L&1&A5I70X!DR<
M5.0X*88/-,9M5&`2V,H841D<-2:8-4G1>;K3B&3T;$&C:A<_,&$[CYA2$$R1
MH8@NYXUPX8XPW3DAL#1Q%%LZ1R!3R:CS$OHEJ>'K5<%4B9`ZV;VR0(18OSB:
M3S)B2H^I8GM7<:"^'@,2&06O+?]$HP+`9*]SBE,UY;2J5AG9B%WQ(Q\9)9JX
MA'G*1YYR48G\HZKDI4Y!'O_LC!/RTU[\EQ"0D>AOK!Q9P%2V3PE&+W%"'(W$
MF&K3H_&*=&A#*:,4T39<O3"G,@H)5!IVMAYN\GA_`A4CA.2FY]&4%PRZZ<E"
M@M.W!&4$T8EBC0*S49Y15DAZ%-0HOF"DJ]!T@X)\GC=GAR5=&6($X5CC5K-Q
MOV]D=;C(W==$X+7<A#($)Z4@*RV*2ZZB*.P7J+'84Q8$R`XNKFL64B1H.D*Z
MEOPMDFDBG'V&XJYUD*>;NT6+K`"9EW?Z26HW"05AS,,LLLB"&V+:BK+&U$..
M':6BGH"1B@:16N9%I94$%-%GN-9$S&E.:LW@S;408Q/MM="CGH!%-^G!3LH*
M`EC_9J5D3>%Z#([&2U73@B!PIR#<Y.X+J^"TL8XI5DFLX%&,Q_B*&8M2TW&$
M]:L<`YDPCT.KW0%3'UW"YS5()].`-?*V5DXHE'1$S(^`<!@NA@>("\),2X$4
MH^/2B1X3N9[IY1-X\"0$HH:%-+(E-7<-#M8I)*.Q=4`IE0"^U9?W-,;M"BFH
MTF-2TE9D$WA\CF4<56$L4JRFSSU4A#)2\O2`2[\=&WF@MSBNIY%[)S%9R)T-
MBA)-G7'/(P\TO5&SY,S*V(\PQJM!5X1RQQP9.L*5%X+\RV"#"*2X]GGC7#^D
M[[5H`4CXSN(LL"*EP^IXC,;8I=HCTDR2H[(B3RBS:</<_U8B/`C97A(32K7J
M937*%3&;,&E/7:7LBW#8'HZ&&3%$%AT\:M-&J4VFDNZ[+:='K0[J:D/4!+=J
M-Q$%1,U9[;V>69:KOZ'`2&CA)\BH!G8E,SM;JZBKY),PMBD=&R)CC'^I^62<
M4[FQX;4BT9&9KA=G]#NC6:4\F62*V0CLF.]DSY7XI<58EF:6+Y"BMDK2!#7E
M,C.9ZK1WU)O67)D2X58(;495:YA7580[?I0E-HGCJ"/.XMU,&50URB)&!$,U
MO5CD..%3!K4M$`YW.1XG4&O7N+-^/)I5.2NO]70@JX'H2U7&N)_/^FJ[#6C7
M,=6X/:J0I*\WHLTC`B_03B>-VO\O3$TQVRI*A$J<#:D&Z7^'KLG\;I:[J(08
M;Q'(AU'F!%)9C;5U0PNB7M]);LM=>5'Z=RQ%RXGT2&Z+O?$%B%R4,T?YG8LS
M7K[XZA`:F/+==K=WNNZMD7LKZ([]_?US^$W/$U\CMJ=!P0>G>\2R-20CG;@^
M/#3NY&A*\*937A90+P4EOFJDKB=?VV=3[<!N]$0C3N<Z'74M0O(2KY(7G',K
MJ8$7"$A/H1$XB8-QFO,S"[$M^0`^W@(1J,4(A4<9@/54@-8,TG-;A_1*2C-A
M_R1OR^5HT'<9$X`B7N0<C,!\$,90I&%\IJ``/`@QAM!UM>!7(O)VW7=#VF<*
MW'>$AE/_+FO!<*_T&0WB9@34@+]D5N\Q)M-S%I[A=WN4$2MT'>Q294N5<NJG
M+\-3?8_Q$5H6)EY&@EAB@BUT"N(B0BU`,"^47^XF/7#89`Y56*BQ".8#4U$$
M&BNR'!OF8E03);H3<085&GFB@&*"91?A/1RC:#;",0.(3KQQ,D63`011?/9T
M$=+#@S[X@]HP54'(=D16A-?'A"*2A(>PA+!X7FR5&/U`1O%G(`S7%\[B70]G
M0%T8$VE"-&#R(S/#2UOC"OH03+=0%/"'<C1WAOF25Z.2+M2`9>KC>8>4;(=A
M@U1"#9:D.LOQ'J)"@5$R`OPF#=?#,WNR"0C614UQ*Y25$3]E_V*Z<2O:R"!H
MY%F4&%IJDHV7,W2CX('4.`[&QX.H$&_=$QV#8E=7IS<]>(H^Z``5>0L7J4J8
M]D"51A-&6(MYLQH?"9*$`WC"Y`^+`$%5H23#X!J`%4L5\W`UEDZ@I1<LH11B
MLX*NXD0&9T?)&#>_(750(2'5Z!G;I52Z4(7[T8DC&''_1C.*R!?BV"J\H8/;
MT5PILF?A%TS2LP]0U6Q#@3+#I'0H-BS1X7HQ1%*\X5OYD`ZJZ'05R'/L9!>W
MXB*+<E=H^#B``@J@N`$:XH9GI6ZM0)$9B0T*X#I-PE:'8(H>\`4DB80B^8J/
M:3@@4RZF='&P0!W3TAGTUD2(PRO/4_\I`E=4A_%@+6EQYO)*N-!X^D=QYH<Y
M!TE)YK<*U6<-\W@3@2@U,U%)"]=B"29A8C=&W>08"N(ZGC(M#A.0E[-)IG5G
MWU./R]$]RS1X22%:3=DU-L4VV6E$`KE;R`1OUW1T7X`V?4D1C6$EZO9_BTF1
M1L4J9V>1/=B8D\D-LG@((SF?"I5R(*(REL2;\9)?035VR="*VT!72O1FIL17
MB%,CA("*3R5Q]2D;4](9MK941@EQ!3J/H(%M3?D6LJ<D4.&5FJ`F)]4EG?1"
M'^$*7=F&I4D1+E%S&5%M2T-$7<)H^K4B(=22B_02V6AZX><-3A5HK!,OH]!+
ML2DGSM"7/J3_=7;57J*W*859F'$G>AB@`-S(F(Z)GR&I&O>II5:V"FO77>WE
M/%U#?S&J$*I9H,58)F:"2-.U<`4TAA&*&>\Q0M&XB2I64[$F=Z&A%VO(C\T`
M3\ND2/8':X<"*J!P*F/!(;5W-0`II,O2C:MD;[D#%M#Y>BX2%3S**EU69>=I
M3>=)3(\36CUIF(1YJA?I"!;Q*TJJ+8IA)AFW.Q;5`J<XF`Y:(GI2I=Q8I1Z9
MI19YJZ:*JL+*GF@8H5WJI64X`OZ0JR;RA8K'?WJZ=>XEFOK47GP&&4&5IK%X
M#-J*I)-&5M%H39@RAD=Z'3.EJ4T$$3*C9HA!6&7W*8N0J*C1>K^E_WC;B6J`
M!AF%E8)W5S0?U@G%XBY^B3Z2V!-;@7/>((5`6CVGI+"]!*RI.*R$:9&-4`>K
M:H.=H&45"%4$-%6JD)&UF@T*T`U6BG6>QX,#MY[T(+$L"[%94JK8<*S(FI=S
M90P:!1FC(*,T]#9$20_<JH6ZUUP5DSJ10ZXN2TDE!IO.F)>P:3L49WF+0B7%
M=`RRASM?F`)-DF^KXRX2(5YM\T.3F!R^Q3ZZHG4!IJ+7@CMCJ1C!D@Q=9("H
MP"HX6!.^L&Z3J""J\E"001ZD,;2\NIBVVK*"2Y&/81%=E[7_]Z3L]+$>RTXD
M.[$B.[@>23]2&K&#>ZK%&IDSNS_I=40RVO]Q1*96N=JS@O)+],ERYM:YS9=-
M[UDGS`"%K4LR5S:GGH6W-54@9J)U'IH*BM%V+_(BHA$K$J2Q:MM*&#8H]0B-
MHV&U/7>I`712'$6<FS2:QD.BB;FP9SNV[A,247JYEWM#\C89(]L")T";&U"^
MBZD33PJYP2J1PSJYZUFYP>J](3NN]:D`*9`"T[JY>"5PN](0&B=B"N:G!'HZ
M2L9="[60<<>ML<LF_C"7CS6G!3<I2\L1<1N"[Z43IB5]#\=>*I$=4TF@`!=E
MVT5`6.>&G=,CCOM464L,-:<87]L-#29U+:EDZ9JP0F,+@KE`(\*]N&"*]-NR
M@8N<62N1&ZLWJ5#_JV<D?7JS-T$LK!.Y-TG0`G$"N:B:"T^<Q<0J.1&:`?<R
M`4?+OW12LE)224;3N2,<:\83<@;<(/D'F&?H31#:FM'W6@!7DI17KD8FA;52
M8KG:C;!`M:/`.N;I.M8S;<6FL'*<G;"2C3O["CE+(##<NT1T%H-L$Y"<L\$#
M@I0H>K&8O6[X?#\<OUK\Q%1:)CZHL"-K4ZO,*DC<Q%I,RA0[Q1XP!=Z+Q:6<
MQ782H1O0F/@@QGCEN<^R&#;;+HQ00I;:P/T&8'^FNJM)>6S,)MMD@ZA4P/F2
M.,:GQ]&'1$O1`D;W9,8<*-CQ,K_I#/-2Q/3D)V?QISFQ;CVJ.'J$"9J1_Q.K
MIWKKK!=^B3LGI"T0\BL[4;(*^Z`CYENALC?`!+,8F<N""TQVHP`G<`*T:I%B
MXL378@@C^\VOX(./J]#LB;\IX,0<'=+?R\6LD0+0`,SU8Y*P0B#\E8QB18;B
M5`N`E:+%0%IRJE!%0UL.ILVGDU"B+"<QT@NW\U51N0R0K*HZYQ,84+?G^&!]
MAUV_--`+Z3TX4@?#8,*$L*H"H;9ZL3H08A:SQ6%ETG;LMK`_?9X2_`U7?)&G
M&)=6ZK$9[;%+X+XZH7D%&=<BG9$94,NDG-=^C;DDW1Y>[)C(B-+26!&U(4HE
M]$XK^0E$AH-RX@L[\02^4`5;PB\6>]FU4;=T7/]/%$,L=Z:.!R5C/*TE1Q1/
M;7G5Q\DRN+;4X`-OB<V/W5`;6S8*:H))-$79D687/U('E`H]F0%FS@1\&'BC
M.L10KI/9F^V58%(;4/&I]%EU4<S6J)IIUGW=UWVJ!_U;V`S7<;T$GV&X)ORQ
MI%`'(NU.)OT%Y@W2?]W>WEO:NJ``7V`O&P#9AFT_YK'9JJ`P*15D8C41=3`>
MA=T*29`$,F@/!M[<ELW4]^!>`*ZNY!$?=%(5#M%8SK02V8$0!8Y.&U&W#5XG
M*T?5BM(\<]%)FT05TJ`HE"`FFQU9=9!(QN@M2Y$@J9%6)],6BF35@ODC/@-I
M:./;_^H(S/`K5UFD+;#_V<4#//RVJO>:P?"=)5>\F)E-#?QV+15YF$?.;QZ[
M'LLGT;)=RCT(WE.0WDZ\!.Y]YI?[Y+KP*RD`BE\`P_48YW(^YW1>YW9^YWB>
MYWJNYSI-64K*YDH*BH*^YX0>YWHYZ']>CU^0OX/.JG!>Z(1.6Z#8YK]B+R:-
MM9`.Z9+N'*^:Z80NZ)3.JH(^ZG[>YHF^`8SNQ;?4EZ.^ZI/@Q:8>YZ3.YIA@
MZJ[N'),0ZKB>O[:NZKS.Z*R*ZFV>ZGU)[/6HZJ?>ZK<T!<P^ZE_`[-`>[=(^
M[<SNZ7[YYMC^[-.NZKN>`M'>YLS^[+`^!7[)[5,PZ8P.[M2^[NP.ZVU.J["<
M_\O8/>\;?>9JWAI3\.:C_NO\WN_^_N\`'_`"/_`$7_`&_^ONWN_[[N_VXNX)
M?_`!C^X*[^X>T/"PCNSY:^FFGK^T!?'\?O$/C_"F7O$9;^D:S^LA[_$"+_$L
MK_(`G_(3/^P(GP&+;M(DC_)>?//A`/,R7_(HG^K^3O,)K_$2;_`5?_+V<O0W
M_^M*W^N7+O(IS_,U[_)43_`GK_)+S_15__)?`-%ECN9@/[CW;KEA7_9F'^7%
MY\F'8G0Z:[-_;0T4.0(07=/PL"V9*F9;',7<"+@JFTYYTXE%RK93(](O\=9E
MLJ>_2OB@H)#5IKYOKB!J_'[+Q<D*.+#`^PI678&;8/^(R*VI1#RFO*2[%1$F
M/='"7K=9F*A'B3$);/MZ-JA=:>LP%KVQ/EUBLK_*]:[%2[#[O-_[OE_=)*N^
M<RV$&/&JW0#>T5O\LH\6.FCD+;#[K^#[TB_]9U_]@COV]ZU5)*LK*R.T;&1\
M+C'-1,=W3]N#][,Q)QYOB-O9!>K3V$]B`*5UQHMA-C.)@>7-1!>I1V4CP@((
M&RTC(X,.APXC&X*&#AB)7QN$(PX3B(,8+8PCCXF+GU55+1BA59^+G*&*@HL8
MA9PM@YB'"HFQL;6UMK&$B+Z_P,$*P\3%QL?(PPX*A8/#A8(CS+>3FH+#2YJ&
M"M8MS-"W+4O)Y`I+Y^7IZNO_[.WNC<'Q\O/T]?;W^/GZ^_;?M1BD1,7*-(J?
M07N6'%G+D*$*!D&D6NP#B,A5,TK`,E59->+)PT4##];K9`MC(9(B\[TZ-")2
MLT.=)JUTY"B:)%]5OJ38()#DJA:A'HW8.&@F04*B.+F2Q13F(4W0'%;<D.$3
M4*`/&U)UZ/"C*9[:OFYR%#.<KD3->"$Z2\^=VV+2+M;*%HZN,W#:8DF2-HT1
MTW`GO)EK=ZXPNK>($RM.!B^EX\>0(TN.5^L510=0FZ&<;-!2IE.E6FG:3`]@
MITR$M#F%^=4A3XT124?VV4C1B(2<XQ%D*8O035_5"M)4I+?3DR<MJJZJ0I,@
M4$&._S8Z+PC4T5!1CZIC3BW<>KC3T+XP)75J$_GRHTR9B@31^K1)_WA36TP_
MG=UQYGCE/Q&X*+7PT:06338;3#%(-B=,$9AA##98F#D.1LA@?132UUAN&&:H
M88;?\`9+=QOB\X\VUY%2E3:7310+6I,`]TE5`(%T6H@E>4@C<+4)]THO-)5T
MDB\/R9)B%55]!212K3Q1B$+<%010<!A9)],OKV`5D6]`#54(>^+%U@)[T6#U
M%8J/+%64-+3(I-\RNE1(80LG7)-?-,R<(-X2U<B)8%R%3&%@7WKR)XZ$A!9J
MZ*%N)CK,A3<VZNBCOW##R4TK0DK9/T))0E6,5FU0)C\6I?]&R4QU4/5%D5VU
M`EZ*DUE6(UDT:O:JAS==5N5O9/DE$2(;[&3*KL/IM4%T&$R0R4?`/F4-):X\
M-260X22U$69[1:))!D-Y.B8JJH!TJHRFY7437]ULL$1;BI;C(']QAO/E.'#B
M9Q><XFC##(*"FC48O1(2<^B_``>,7[KI,&KIP0A/-LQ''R8L#"*6:/-:KXRP
MFL]1+6%4!V8.*8(J>3&:%J)%,!FL88>S7C((KAY6>II?&'E$U2)?*(4(-#P1
M8MI/(/*,DID7VI:7CIJ`N9<I'G\"2RB??%$STM.AF4LST="B#,'(`+Q@OO6:
M=0Z<"])[R]>"+F%G?X."C8W`;+?_#3#6!4?I\-QTIY26R9"QU2-ILCGPE8G/
MX5W:16E%^=DB,'YT8K*<T6:2X(VWF/*1O*!4Y2@D!3F3WXB+9[@K(`4%T*_4
ME)SEYLO<3251[85K])76@*)*[.+Q<HLD*S+S33@8P:TNP+&8;6!A_!G6@H)I
ME_WU%R<0S_R@^+HM_?34'U8AY'5GKWTPH>JMX<X90:O4(`+!G(_>F`Q4AV6/
M;'`JJJ)4U1Z&9\V$>JR-J"7/CMT=%=)PC/!4=#;"D-3\(C,0$86//(4:A5P%
M6`!QEU.<,S]/?,E3DO@(S7CRFE!<D$1"R\"9I'0W0OC./O\R1W^XUA^R@>T<
MQ4,'G/Q4_R_EF2V&U<NA#@V5*.QM[X?;4P:D[@<MWCG"):TX'UL,`95#U$$U
M&H315S+PA:Y@B#:[(N*&&CBY8*B)62UK1)G\\HB@)&<O<J.66*3BP.6<QG:<
MJ,CECD0X\N!L:3G9H&^8Q@I))&45(-F826#VC!.N;7IC8]>"Z%(\L-$+0HY4
M9/#PU;P=6O*2/$R,#X'(R4YNZ!70Z1$BD$:<&.D%1/V0HW]"4CA7;&01IF`(
MC$0IF?K51A*XH1$7]5>/RXEL%_\;(RL<\,3V21$CF1J$TU!2/I9=Y$*VVU59
M[G85+`$2ENH!))@<<COQH.(933*A[@R)2!?.4!SY\1/9%&28!/]5<@E^:EX-
M;8C)>MK3>F[9I"?WR<^4?$9`R"Q3[(AB&9T=9!I+R<[*F)5!1<22(9'(7(;L
MIT_($(<E+*,E,*()*\Q\!U;$@8I#9.82EYV'*F!D24DM1PT,"-%_$@'/[18:
MG?*@PBON`X5&/&8-@DZC-^"LSST=!#;E@6UX12W,#"N95!C&$'I#C:I4'V2,
MBO;SJE@M368P,:U.)(<AK]F-8[X!C8J@"*.I8-J)@#31D'"Q;YQYR:S@NIJB
M9)`B2Q$5D*P2"X]T8W.QNZE`(3*:(L+'K+T1F?\"1),\6N,CF9#?B?)$,[U@
MZ7;B%*=BILJ@HK*+G8)Z:O1"*\_FL2O_;8:"@&HYR]JV'<.J68UM;)\Q"MO(
M)SM4A&5`4$/7>GP#=+CBK4)NJE8!=C0W%$TCC?*7T=[>[)2*G4Z9,J4I`:K"
M<X:`;$B9<U'_?6H7J(N:8MW%+.`Z311\W"`J<%8>O%C+&?YPQ\"*T=IV\B>>
MQ*.A\Z;PM2DPCZEG^QI4(Z3:U=;WP)DL!FQERV!^%A05SQ5%3DNQ'E<99$=#
M`5U*,?$*J!6.+=YSC.1LVRBRHO6@36*IJ'P2P)BF1Q#H_=7&-.'!__F2+&:Z
M7RM]`9457185(K46+&VG'"`_ASW*"2H*$=R@`=]0D94\[:#\RU_AG0`"^;WR
M.0S<H`)[F<M,_PZSA!;<X#)K#R.\X%^46B(_GM1A/2!!$S]L\T^8+(+'\RNL
M0.6\C,>P.(MD/DAR1>P?9++H0D%R7XPHL2S1Q#02?\.17GM4);D!K6=,*:%F
MW->-@036*N#(Z7KY\A8Q$U61_XTAJJ&,Y25`@%U?CK6L9^WE?\G:U#H,M)EW
M[3",&9>+BO@6>H,-85^$&":L4B##,)I!C.JH:K2H%&1H`Q$N-FHF31QK<%1<
M%*<`"'0UL0I!(@AJ*HV0TM4P=%Z7A&YBW^))*S,:-'C*:=(U383$V2RN&03E
M_SIOA?'$\JMA3>N"&_S@!=\W]73-ZX9#"H')@G!$6D&D#>HC10^)H/]_:C*I
M\E*K2?"0JV,<=SCE?C)')C^([3R%&YR)L2;;Q(!?=Q*1CL7.*![2\7]@0E:7
M\0;4>#WCS#@2NR(_1[WMS9K"_Q6O?D?Y"\@3'O.<RA^$6_WJ6"_PTO]U@I0[
M_.O92S/NF)7II8C%5!F]6%&2PFREE+)DC'@*KIIQ;!$]=Y",VR*VX5%W?:29
M<<3!^4^26%.>9+,5-P[617`T0@5X-=,WFP2TE^*^]PXE%D:3,.8C@41&S/>0
M6R]4OA2I("B;7AP#O_*KL\[ZUB,\].WT.MAG?S!?CRH<WB%[+$&RFHN]!"HD
M<5\<,>"2-S(75]SPQF/DJL7<_,-^:8?,RLW__2R5<M"X?D-B%;&SBU`B5G\"
M/9/<HCFCD!KB(IPFT<R<AI>FP8P0GP<][)^L2*<.7$%4-FV"2D]U+:_>]0`8
M@`FW;UU'>P8(*2`V;A=E'83W&4*!>0W1>RKQ=VSG'9CC+M/U=RTE'WUG#Z[2
M?&WU.%$B1/[T>+S$$MP14#E%8P[@$8D@6;6U*X6V&B5$:4:$6!B&@J>4%K@3
M0$UC6;136?8"?_-7&%>W95?F3OO7/!#@)PJ"98HD@%(XA5:'8`5X@%@(*:$2
M>(83$K=31C0C>WWW3-F%%<]5;;*"%N_F"5VH7!TH:1Z"$F]X$$_"(]FV%G.H
M$EA"?0-!$6>'?4]$_T4N\2-;R",/F(;RP4L:)RO@)"SF84$?U'G$MH(@H1];
M!X#%\W\)\FKQM(0"YTZJ576N)FNF5XJF2(6H>&M#=859V(H*HS>V-U=&M!*%
MH`K.!0P/QD9G-5S(I!IP-T@L,PNTT!9W5QD,IP^3=H+?TPW<1C1)@PG458G=
M,4<V6#K?UQ@_I1\40342%Q?N-V\75'E#<R"L%8"F>([GZ"=$4'7W=P(N@([P
M&(_R&(]6-X^J]WI=%FM<)WNNV(^")G=[>&*_>`DU@VQ]F`_15#EW(S*%A1<P
M458>U43A(DW$:"-=]$DWD7S\*!G_)&THJ!F+1GQCIQ"L<TK7:&C@51"/8_^-
M=3B+V2A\A_:-/^$T0D@-]66.]@B/4[".GU5Z.?F30'F*"&>/J=AJAL**_IB4
MYX.+``D.<"=&:;B+>76+IO-NO&,F03=VW%$6I:,6A\AG#Q-M@`:6(S,+)):'
M(Q=-*14<S-&'E7AYU/58J@1^.<<C4O(?,K5X:A)G+XE=RB0>3B,LY'B3F!B4
MI=B)"4($ZYAZAMF81#F4\UB4^ZB4E&EW7K07'(8[$H$=S>)1FF%;>^92OD5Y
MO3@_J_!&K2.5Q889!9E,CQ!BMC1(*!DB%Z61R'8CA^AS)3$:/T(5F(<Y<F>2
M-FA`E^$_:YD7)K&(P$<)R4<BXN(NB^!??#680X7_DXX9E(QYG=I9BBYP==M)
M<`#8($A9F>09EFOA41J&41%U"#W!;$YRASO2@8Z'E:;#+#]A?&17,18(;Q+W
M4?/`?&*$EB@62B3&)E3I3\JR$GA50ETA84KC57OQ3<`Q:<]EC6HH?CL3)O"U
M.X*I'Q+#)2NS%U-5E!#@`B9ZHBB:HBIZCCSYG2YZCBH:HS(ZHR2JBK%7GCAJ
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M^F6%>JC2:FZ09T%F)5AIB"QH5BMFTGO>`Q<FE'MMUQPV)G$8L#[C`B5L0@M8
MA%:Y(*"@DE<<&"G.MQ:BR1:RVAT:26.[01S<EV&!5QN)V!@EQ`PN14V%]!E0
MX0\\>";"<B=H@PX!DXHYV:Q0)J-?=H\E>J+\8:*#NK$H&H\>*Y0EJD@>.[+@
MB?^RK!9K'GL+\,BQ?:JR'XMUXSFM.2IVO\$1G<`-.7M3SO:4<<0D_4`,:\(B
M:K:@:]H(,R9^RNAX4X-R\&H0,<$3"1JU!B%$;:(+^*D6NB`@GG(2EQ9!V6$^
M($5&D6=$S8*PA[:#/:<K[N*R[\0V%&N/,1JS'!NR[)*B[,B8%FNG?&JB7D:W
MS>I9,6N*>&MZKE>S-JN479MFUI1N6LND80)&&#.#IO.:\@`7^L,,Q?9VPU4K
M"SAC&II&6`N@AIH2)"@KOM@HMJ)\Q[6;\&`1<>IVF*5`(<5[0;>#WN:XS<*A
MCIN-^A$7MR.-(X`O3F9K<RN/,AJS7O:.I8BGGU6*^D'_@C"A!5;#%W:1CC[Y
MD]"+CMV;MWYJN#"+N*VGN(M+F84C=P3*2\QHK4\YM6"4;W5G#!9V%.Z)FF7"
M$9*JH%KK.`)IM2*B"V0RI6P"P!/!L]=0$201J4X4;"8Y1F#Z)`*QAJYC+0'U
M3'RR#.25.M0D$Z&F*VDA/<5J>LPZOB0;N.CH2.,`,0:@`BZL`S`<PS+\`$,P
M!"Y\PRI@`!.PP[FD8'![F-A98(#;O,LKOC([L_5XNN>+A7VQ9N(1;;_!*<!8
M7A\Q%:!K+^?YGXS*/TU!%F`[N>L6H*_9M>N+3`:,+LKP=ME6#"$BP)@9M([7
M(QP5>:H*4KQP4UP,C<"U065B_XSS\;3S,0GS(@XFQ(."\#7C(,+/^F7,NIWL
MD6:/L,,MK`(RK`,/\`>87,DQ_`"<W,F>_,D)8,DZ<,,&4,HZO,-I0DUZ$0GL
M4GDG+,0I:@56X+Q&3,LKRWI3H,1+;(!8FJJPP!TLX8`/X1L7C#D]J%"\](:+
MIX9=DF.#U6P_,6]'LA9Z^7+TLS#T>99:VL;Z8V%:J\$KTQ@]]AK?]\0GT;!M
M%&R>PQ*0"%^W9S[P][:%_(/3@XIV6\(F+(].TT+$<`@34,HJ$,H)$,J:7-`R
M_`<SW,EG<`:?W-"?7,FAC,,N7,JXT7,_;">I5L(OF\\S^\I-J,N[['#;G'SL
M*C&C`O\=SWR!F"-,E<([FU-WH@E>VQC%<AENF+I>DE!W5UH2.WO-.P.U!7S&
MY[.Y/Y6`.[J+D+B:21U!G*#**FD-$17'/!O(`RL8PKN#E"4(B]0V5'C/C:S/
MSV.A$W##FOP`!GW6,8S):KW6;(W)9U#)G(S0<*W6E_P'G%S0!&W*N.%2:Y.=
M%VO+=NO1'IW+(<VXV[P+?S:UM74(PN=53\R`QD5TSI#%PJ"U,C%-GJEG%A0J
M7GD:MI1%.?VZ%S;26+2MO4/9)\=G!^M6/=U]HZ`,X6"NPU52[XEY4>P;%OR1
MO,.P,R43!.+2FH`VQRLAM*:Q!2:X44C$1QR/\^'/`/W":!W_W6DMUY7<UIFL
MU@O]UC!LW=BMW98<UV;]W7'-T.(=WIL\RCE\R@F!#;%P6G'B-,SCD]][G81=
MV#E*5KUC6PNYJ0(4S15:$[(0?6C\'@^YAIY+$*,[C,L0TW2W"Y%"O1>7J+@(
M'1HIU")QI?B*X5G<D;61&M;R70_Q7F(TN\VQ@M`(O.Z,XGS1)#C-"%N=6K.&
MQ(ZYO"A\>NCDSV--UM*]XP:=R=/-UMG-W4(^Y&O=R9ELWN5]UP\@`9Y<R11=
MT4U2=>[HUXY9W_9=GN&W9I@YE>&'(@LHJV\<TP$,;T&KIHH]M9K)G#M[KZ8[
MQL8@$G'<9[:05XLBX(Y"=RGR'F=1_YR7([SGP=K`=9HL'7CJB]7@1$@F1%Z-
M")W"/=Q;9AC%O;<U_I.`C8XBK@P\#-W13=!EC>2:?-W5W=8PG-VD7NJF7NH/
ML-"?C.JI3NH._>KA?=<)C=X4O1;*:N573IZTE2.AI+#3Q6EVYGTM\;6U`J_$
M@*MHJG'5EC[PQ7-8=(AX^.9P7C^G`-J[8N&HNR8DQZX+'.#$_$1DR](006<8
MN+!_Q0F.AQ>XL)>;4+S%N\I^<2@&%NF2/M_H>+>5+DEII@O__-P2K>G1[<D2
M(`&G?M!K_>F5?`8LL/`,W_`.__"G'O'9W>JD/O`6/_`3']=P#>N=/`030+C;
MB>NY3IGW:O^6!!XD*Q(NM4(BR:2@IFHU0E2_&"A=),87`-&X:$)B.ROM_+#-
MIPEA,P'ACA*YD[WM"Q[3:IGR0-8ZR!*G$RDL;E<X.G/2_X$F\BP3)G[(A%*/
M)JNW='N.5QG)IFS*`UWV9G_V9B_P%O_P#\_DG"[*9\W0G3S08U#W=4_W%]\#
M>K_W;-_W?K_P,Q#X@0_X@\_0?W`&UFWP=MW)*C`"?"KR(X^H5I-0:4)&F\,P
M&KAR*96'R%"A8/18EKH2"V.7G*M\.A_M_7RU,4]&)@UBV+X/<9Y\K]D[::;@
M66YXU.&#C_,B(H1C.!,)O1HU4E/Z)$(,+N>PE0@2A0*9ROJ.N'#_%OT^]F./
M]F6O]A+P]PU_\4R^Y!+P]C)L`$``!`:0`.(OT.1O`QJ0!NJ__NJO`1H0!>X?
M_UW0!390`_9O_T!@_]1O]W4/"#V"/2PSAH>(ABQG9W^.CSHZCX\/.@^7#PXM
M)YR=GI^@H2=3(PZFIZBIJJNLK:ZOL+&RL[2UMK>M"J8*O",M+:88#B,;&PX8
M&,3`R!@MQ:6:Q2V^I<C!M+S9UL._(\+-&]Z^O]V[NML*XR/ITZ;>#MGQNKCP
MO1M?Q1M5&/<M\[ST`IY2L&T<P6W)I@D;>(Z<LW#<'+9S4"7<AA1?%#(CAF_:
MNA$@)7[DY8P<2)`*?DEKL429KPT.E\B4_PEA)H2;.'-R@B"JI\].+FH*&6IJ
MP@0#2),BU9&@:5-,#R1(E<"BJM6K+*8.FCJF:]>F-<+:&&L#0Q4-:&UHB%`@
M0``/$2*D2$,W@MN[`>+:O:NWK]^^=`,+#APEBH80"08-4M-#S:%%#R9)GOSG
MP9D'!EI\.>'BI^=.I`2*=J4+8+U<_^8QE*=Z%T-SJUNKDMTZ'FK:K'&Q-CU[
M'K)Q`YU5<Y9Q(;%PPH13._8-@^Q4\NH!Y#V.6;-IW7P)>V=:E\%AX7JEWAW+
M=C9X#[]DV'`=.,,DM\^/3I7,>[%_IZ@Y;T/PF"EG%2&GW77E-%/1>N4<\Y!*
MZQCW$DS^#),2.?_AC-"2A1*M1,X2O]1$4TTYA8C39Z*X8.*))GJRA`)".&"4
M4C`BE0!5525BXV-92?7`&$XY%=838W4AI`8;I)%!!G%Y$``,<U0@P!P1Q%"`
M"#B(($`%<\!00`$P=-GEEF"&*>:89(J)UYD1I(%6""&$Y68-3AD`A`%-16+G
MG79"E=D&G?#4IXB?A3;?:$(D(80";:S!WT*F#>7H4*K5(:D#\`UD76^FU(&*
M?-8I^J@":X0J7QN)6L?,&J9>>EH;EG8:J@-#&>KH*JF2QMQ&T^@"7T4@5?B+
M:L*5]!TKI)ZB*3P#D=:+1LG`I$XPI966T#O$1+M;;J_(PVI_Z:U718#_*CFG
MVZ"L*(,?/-3(A^R$#R'3CC*_"'./-_D@)VQ)Y:0#GDGIA)1/=B1!N-DF)[`T
MT\$B)NRGGZ%`D")0*)IHA14G,@S,44AID904'"<UXXTVLM"#5%\E4`,0-8QU
M%I%%'IE!"A[$+'/,;KT`@Y-BB"""!5%0(,;/3V99YM!$<^FEET4/?29></45
M0PR#I;$!6FB=19?+6-=;;Z#0D$L/B_"!BNBMKD$GFS5$;2K;.\RMHMJECP:S
MD"FDIGJJW=:H&X]SR(2Z!JR/MN@V,[:Y?9"IOLQ31X#0I+2!`A-P@X\ZSCT'
M#ZFLLF+Y:L^VUPTSNZRS2Z[#H#1N+,D<YTP&__M((XVXMVQ.[H2-!U.==/\\
MV$(SU8S3S3T8U.&Z2KM'9)+HCA__$;[.AN1+1@3_<C#""N\48D\W/=S9)Q%O
MSXDN1V$<HXP2S$`""8F(//*."0!IP\HM'ZG7S/2[13/-`=C<I``Z\^PST'.8
M0](&2,"D:4E,1TL@TK:TP##=!4Q+HY_,4D#!"E+095/X@GJZYC5Z),$TM9(;
M!OP6*BV$:@>A>I2L`N<H59&J.[Q(VSR28*A*X>V&J*J5[,P!PEG@QFVGL(YW
M?H4NX;A#&D?\0A66@RQ5:`I1F8..YJ)5#W50XW.W*DV\XL4.MODP.K,QQV]@
M4@5O520%$.).;\#8P?_R)&@ZZ8)-,%0"/8A09!KW>`:!5E<\=/D.&*73G4>6
M12&/<(A/G)#>]&RBL!&1Z`2`LE[V3N2)BXU/*4XIWPQZ\!6QH&4#,3A2!25(
MRE)*L&8%V%__>B8"``JP@+",I2S#]"4"ON"6N,RE+G$909D%@(-MK,7>;HB!
ML6CAF,@T(0EAU<16(,YO:I.A*0I5*+G1!G<`R1S?DI6MZ/B-5*\Z1N'4A@UV
M1(@D'NF&.O6QG+DY$5;%.D44I\B;8ZC.>6U#EN^*X8Y<'8Z8Z*@G=-;!BVT\
MI!AG7`]RD'%-'@83%J;)%^SBB#M[;D"A,+%='O7(NXL^(W0A(4>_S*D\=D#_
MJ!O)VX3!%OFA1CX2%`S[A$XX`9'PS4E.0$AF,O;1!;08"4D1,*62WB+4HOHR
M?ZETDLY\P$I7SO*I4(WJF)9&U:I&\)</M<7>O*&RBRHT:H(11PF/"=;!'$D?
M?0O52Z#A*-7$+9^M:*M`OT9"O]EMC;&(IW,25\1G:.J>Q(`&05<!'R%@#G,0
MG2MXT@@[WTCC.,X31D$!BHP79JMK[UC<D<R"T87";E.QR2IJ3E$@Y#WK-$?,
M8T;\`]F2(",?'8E7Z%3BK'3H8D&#])=#3KHAEC9RIB_UC$P\D<<6?*M>HARE
M49?+7/S5#ZD54*H(?!"#_PD@:%+-KG8)Z!8S6?6[_W@!IFB5!2HM%%,M;*G`
MS]:KL_6NMP(9*`LSU%(``>0L9SIKI7L%`(,(5.&8&,A`S#)0"DB1#5FH,N\J
M6)BV0=EMG(`3W!K'.3;K$/$_7QC!7S6#G=U9`WGR"9L#VF`JQ<;B6?JJXO`6
MR[9XPB*>_>K:=!:2NA$$*$"N@X8[QTL/Y/TJ'8P2*6H)5(SU;">=Q'O)$I]!
MQ'X5\B.Z1>E)5'<"Z!6,I8R,9'`#-84N9W`*+K,@S)I+YC(+%971%4`3IEM=
MH&%WNW".<P'!2U4EB9?'0%R#"8NI@0#@X`,RR(&@!TWH0>,@OETHBP9ZVH1!
M-^#1CR9TH&6`@P)4`0@;\/_`+3U@#**D"IS01`6#9[4+2.WP%2%<,*EI!0\#
MMPH9%0%D*8RHG';T!XC,1%0.08<-L[V&&UICST>3X>)7Z#6PQP*(-<Q2KV7T
M8UZ\QK-`II,@<9FS<@013K/2^(MC5(&V#RF%ZGY,R))(*")\\HB%'E2P1"J`
M0UA>0L*V#(H->+G+8J:@F??-;Z.B^;IK9JK/KHNE5\H9S@<\N`/I;%6"7NOA
M$(^XQ']33`^(0`8B@,%SB3HS]HQ0K2,8LRGS4@`QR.```?C64#G]C2J0A2SS
ME2]E;2=971QJ/!!'Q;%4,6I7;,.AS'FY6?;!#-J&-#?SK+D(7RY?;.I-.E$<
M)T?_[J'$,K)'MB/T87Y@`I.Y)<-=SRB&O.KU#H;J[5P-Q:;3)<YV*D9D//OJ
MIT:$E0]OC/&BT#L).+(##0K5=EDKF;(S"M;;1=ZDI2W=D,$\<>_&YUO?_8Z\
MY(M:LYM)E[K6+;C"-Z]PAG_7X6T/O>AM\_4T"$`&<TC#?Y.)3""X/J?'G``*
M=T#[5#SA"09X@HN,8H,:="$&'?@`#OP;U+>P)^1/M5\*C(P!W3/DYLIF:&RR
M(3AU3?-3$-;YSIEYBDR+*0)HO?M:><@:LU<8&6EPX`M2`/KH="=4F"O<"#(R
M@@QD&,>O.\;?1LW"K??*66W##W6'?U,F3JQ1.\Q14-GW_VNCUX!#9&OS<'3+
MH0[$,6SN\#+$$T@K9EL3DD90=E"^0@Z$AV4X,5R'MP20A(*@T7@O(V:3]X(P
MR%R5ITILEGD!Q'DXN'F>9S^_Y(`^R';ZAP$!('QI8`-T80%0,QA/LX1/@S4N
MPX10F(1I$`4U`'PY``,:4$;KH6=5``.`)@-LP`8,(`,R`&@?\(5DF(8G=P1'
M<`!4T`0$0`'@9P-/@&W2<2G6-C;QT"+0%T.F!A#?E"AK@"VLD`$F]X4?D''^
M519,-A'D1Q#:\!LYU&<B@(AG"`-5L';NERCG<6NJ4W<;U75"U'8*XBR_HQ"F
M4`4:=%;_]PUKT'X`,5@%I5:H,O]B_%$VOO:#H8<>I&,:JK,=7:<)L>5A[J)!
M9+<1$!(>I1%2`!-2Z281BF1XUW-X5?8%+@AY,9B-VKA<,WAY;28&5W*#G%=+
M`Z1`Y)B#"^=YL*B+['@06E`%%9`#3*`6<W``.'"/59*/.H./]YA?5$(E!W``
M'V"/_YA?]S@'BQ8!'R`&,0`$UJ!G-M`!@D8#%-D`A98#D):1#4`#&MD`#(`#
M%0!^-:=L(&$=*(%8YT%#*W0M&U&`V&9]I_`$&2`"%RD#8A``6<A.=C1](F0J
MIO<!%WF%C)(;NP$ZH%,2%]4ZQ=`1S6%^$D<1%9)1(>4-+>"$W](ZQ/AP#&%W
MJ0,ZZC+_6*?1CD!(._+Q/,OP.?A"(?02#JJXE++&C.'Q@0XA;NN`E/27;O$&
M*(<W!2*WC7[YE_Z6/TSBC39H<`=W-.5HCHK90#I(9^LHEC[H#1,P`@*0`Q0P
M%G.``SS``_AHC_Q()?R(`T8P``/``!1)`UQ0`CR@FJ0Y``=9A`IY`!%@7FJ%
M`5TP!SEPFC3`!IX9D#@0D`S``$<@G,')!1RIFQ99:1H@<TLW%J8B*KPA#]9!
M%D``<ZF"<ZU13&D@`A9)D6$P:`=0`$7X+>B@-KYA=P[P/A%`D[G)!J<I:',P
ME#`9B;?7?+?"#V:$?QYG#;J'`:SWG\A4$?MP)%RY3V=%G@@E_W8[!G3GD2I:
M8$W2@5J028KM80[JY%I[YR[$0VM:0Y?L4A+9X(PP<2$.<$@:1#PDJ&4%,P6`
MV:(N2DK=R#\U"#2:)V>+>:,XBJ.=MR6..:%BB0P[4`65>9DV4(]>$)#VF*3W
MF*0'P`!->@"M:9H4R0:J6:6D:8\("01I\&>S*0R3B)NGR05-X`-_4:844`!,
MT`0#8)RH20,Y\`%SD`%U&$1?=Y77.1W6-W1%(AA/$W[39X<$883<F9MMNILY
M<``"X%]Y@QN3-3=2<@!@>)QLZJ8(^8AE`Q!/0)[[L$3,D$?$D`'A1G&W0I[$
M=%Q5L#A+Y(B?ZC+ZX%4*]0WB11[>1O]TI%J2YQ"!YNFCUP(/,'$.SY`.^)`<
MHI@0OW"BJ4-;S^`-V5!((8JLN1(2)UH2*2HBOY!(+/JBV.JB,;I4WQB.AIE=
M.1JNXJI`C6E5!?"8NKJ+([`#E&F999&9%\`#5,(#`S":G(D#5%"O`[":`^`%
M_7H`A#8`(C``5`"E^$@`RQD!7.J0J`(D&@`#@?9H;)"E_NF?E**2M+<#YF5C
M$9"98<`%QID#,H")R\8/2_(E*4!T0C1D%\46<Z!FH-F/X-@!;8%&I1`VH%(L
M!26HCZ:;4QIH(I!R3]1@TH&>P^`!8@"4.6"<7``"NID#E>ITI@,0&6`T7A(`
M[$&>(-AUYL7_#"E@-$P0MF([MF/;%L97@.#!JE40`9:G)1M0AU\W?67)%@S4
M`1I71AYP)-]&8,/PB.GZ<-GQ+O]R.R997-7@+(9K@"\A4H04>(=$>*8HC0E3
MK3#!HF_!<=F:N2^XK3,*CC7Z5.,:NJ++F#AX)@7@#W_K@WTKI.Z*`16@F4E*
MFO1ZI?F:KZM9`@,`I0S`!H/&``-P!*5YI8B:L`,9`?5Q#ET``R![F@*@`5W[
M#H&C3<W'#R\P`*C)!;P[?&71MQL@!H/V`996!YUH=^:5!DM2B4$9E)0F``7@
M7_<)0ABPGCV+FE1`!6[*!M\I`@40`XS25M"'`=69?NPYD2+`!!>P_Y$T\)T(
M61]-Y#L'407!%V@BRP8X@+5$5UQBEPHC4`"!%@9AX*;I.VB!=@"M!`-OD0:_
MH1(98!8%(,(BD`%]RTWUL"A:8`,;$``#3&D%L,*9E@)YX</&8"VI6W[4DD??
MD!W]X'489A'`0($=(2`?P5LCM4\B2'@GP"$KE675PPE?,%28J[E@S&^5EV;<
M6IA0-;IH/+KHB!>G.\0..(A)P+H4D`P5`*4E\)OT2J\@RP9<(,(2O+3N&89L
MT`"\FP-L,+L#T+Q:$`%.&@&E1A!5P`0^6P&96!J#>'T,1D,M4`$;^;%N6@!=
MH'NW)0:H:9%,T`41=G/($`4^T`1@Z,&"1O^&`]F;$9N1-,`#X@E@SM%6\6L$
M&7D$[=L$?.RT'DD`**P%;<!"!%'#:4``,H#`;YJH&\#)&PF?^S`"_,$B==`"
MVUP<&)`&UNN>#1"R`J!ZS9)D\R`X&%``/6N<%NEH&2EHD$:H7$`%-Z`FR7`3
M)U`,<X#`#7``*&QS>IAL)50%%O`#3CMH8N`!5:![58!&'L"CQ@`;;MRHUN%1
M&KH0(!J6?V00@14-X88N)(52Y78/[9;%>2DB0=$)77P_8?S2^S;&2H4#F$>C
M`91PY\A`":?3:3RZ3*!`8DNN:_Q`J%O1H0?'<FQ>K[N:O_F[]!J&ABIH86C(
M.;"[NQF&A"S5HTG_FHK,R++YR&8!`Y-<R?\KQ/%0"A/`R`C,D7.P#_I2!:3,
M!18)RJUV*-,;`:XLP@=0`6W1-&F2!G$1`'/0!`<0AAX<!B)``<L9/(9R#A'@
MRY#&`!%@A$QP`&&`U0V@OQH`!&$9J!LP)8,VR)6V`>\C`#UKS8S"B]L<=A7P
ML5*-D8>*D\[@1Z(S3<'0PAO)!0,@0#LM-#<S!R)0V(Z&<5A;HA"@&1G0S^Z,
M`QN@!0)M+?"`?C"``[DI:/H;`S90!W6Y?#[L`2D`2+F:NGB(Q!DE6?M";;9V
MBA^M&2?EH=6*4L\*;M$8;RV5$RO-Q;X$T_I-9C(MHS4-C@$D-+'4TP0>_Z[H
MR*/=5=1&S79(/:1:,`)U/`!W?`!Y7`*\F]6\6\B"YLZZF>$R8`2SV]6-#-8C
M``,3:9&4+"N(4F*@1D):`,X(+-<"P!XY!-<5F0-T;6IF$0'>2]4'P`01D(7^
M":`8H`&`7=F''0;A681U,"N]G)$,$``UK`$%@`.%S+M'P`0Q$#HYE`%U;,B#
MS`87$`%=4)VL6\U0FXD^MB+"\2T1<`"E/`!-P`"#5L[\M`ONI,ZXO9M-@,+>
M<)5JHH5&3@'U*,@6&;25O,\;``/0S-S.[2B%I6OO&`'.C)$-(`.)NM@,I0PX
M5ML@H8D^&K>=HT%V5]OF1I;+BAUU!PZ\50K]0O]XSQH24P#K]$T]*LTP+:TD
M^[WK@;DD9-RY02/@B5G@Q)ZC0QT`;;S@;=?@EOG@2^V:^CJ:%YZ;V`N&8+Z[
MAGS5?4R&FTFO%>"\7NW(K480)3Z1@I;B<D4X,*16BSP`N2W7;;UG12X"-T[7
MZ$(1."S5-KF(76N2)6D=59#O'DP#X:D!3\`+'[3(D/UHLHD,F9K<`)N;X]P$
MB\AG.*SA;PH#*`RW9^ZF--#6UO!C>O0^$DF1J+>>$\D`/O!M2^`:C7+;&,F[
M8J`!<W.5..9RZNF][FG(`I`!3^0,C,Z1.>#H+!(KI\$/H!W+5"">SCF20*;N
M[J#L>6-$'9T,YP8O=O3_Z='P(.(`C72YN,H!]M5:ZUILW[B>W[R>]J747:I$
MT]U:<#B-0`4>X.88X'9_]S==[*0K5<BNX,H.<<Q.`284X;CKN[Y;`O)LR,,9
MG,$I`PQ@G#LOAH[/`/0*!5`PXXL\XN,^#"9.:.BNXTX9HD-.`0RPUC)0`/XY
MB1=`D8*&^J'SS3TN:.4L7Z\X92`1*J>"*C80`97YL6P@`I,M'0J?D5\M.D_P
MV0<POV&@G%V0!I4M:+",`Q3P7PS<\1L)\MS`YI.CG33Y:!4<`W/0P0U``/JP
M(LIZ'GH>\SD@`D%L3I"E#`"\^R(P\$./M>*VZ!N9G,W]*:8`"%HC*7,?;#DY
M_S("$1HV&(\8"@X*E".0E)23DIB<G9Z?H)P.&"T;(Y,M+8^IIPXCK2U?II(.
MKIL;+2,;7RVNN:6IK`JOI1O&J<?!+4O,S<[-$-'2T2<N$"?87Q[;`=O>W^#A
MXN/DY>;GZ.G<`05S`@(B.#XQ!2)B[W-S,`4%,/[\_@(*'$@01KZ#"!,J7,@P
M7\&'$/_Q`SBQHL6+!5J$VLBQX\8U"I)4$9"#@J`*.'CP$#'`R``>`]BPH<&@
MA!$>-XVXY%&""Q<V7&SBU'ES0`4-6M(P.!"AE@(A"A[!0-2`!HT*530I6-.F
MC9"O8#/5&;M!0%6K#42DT;)F#88G&D14150`0RVW5?_FY&AP"$<$+6RYMJE5
MJ\XH#",D?54P04L$'`VXR,@A((93!8[E-JAZP$-B(9,01Q`@@P:7,&$8_+C1
M1*;,1(NJL,7DH$J%O30VS\DZ(I<"5J4P:)@C(TR#'!725/$@U^J`"%6@6@*9
MZ>NH`GL1B='@H$XP7;D,+^$5M0J%TE;9),>%H4J!S<=Q;-#R5/JC&`%P')(A
M`T>!-$`\(L@IHE#25B>$>:0@1ZRX@DM4#FI4B22Q]#()8:[XDHHLB.'2&RX-
MON(`,!N<,,4RP#RCHC/32(.--=B<H`TWZM1HXXTXYNA!`.QT4`$\\M!CCP`5
M.`101$CZT]"23#:4Y),"823_)482+FCEE0:&-%))B%5P0`DE#'``3#S)5!47
M`Z29)DP#,""350R0^=(!:0J`5`1+-44)5(A-A=95654R`E?UA>5`$D]@D$$!
M##00!@UA?%!`H!#&-5<.=46"@0V/14:###!4@=B!M"1A'6(A@=4&9E4P(8.9
M!P2P"681:+894UIXM9@#-L3`Q`%<0$H#4+D=QX9_&CPRZ*&@V;87?+MAX*$Q
MDJRQ0141'!`&%SG$&D,=,>AUEIU)9$*=8J!A@-UQ.6Q71V_(>*A`'=><D`L0
M,3071@Y^@>@>?/QN$,E3#FB!K0`'(-)M;,JVE9A6M"BP:B985JP)*J9HF%A4
M'>8R_TEO)\PZS,.9P-M"!@(+`TPPDKSRH2S*+*'`BL^TZ.*++L0XXXXZ]NSS
MSS7R6$`'[\0S#P5BW".`0_M`B623"'4@]=145\V0TT].J?5$55;L]4:)B402
M!5VF5`(.!]S$`P,_\14G3FN^U%.P0:ETTP5LVNE8GIKP.0(,9UDUAP8!:H$!
M8*,09I<C76@0@!@?3(;(`05LX("A56A&EZB6:%`!&V>)$(,C;:T*5EB8G`X5
MKVG8VJ[EE&2V&9Q_K7%Z5#8L)X8,@:/%0&R&I_Z5V&@=MUL5P<C2\@9ID(2:
M#'.DD4$+RQUP%E.)NS+"Q*>NBXB=I"1FS(<@"[&$O4!H8/\6I&S($($-NOR[
M60YJ0<)K%,0]2S\%HEYV[M<`9)!&-,0Q35'"0R/*F"<2)*A=P"P7D0!/+!+S
MBM_`;!<26L(R:+8$FU$C1B[(&3:FP+-N`.V$*$1A`%Y0@!\!Z6@`4!J1!J(/
M@LQA:@;)1P6*Y)`.P&"'0&0(#Z&6CZDQ#6L#88(2";*U*74M@%`<AI;&=I*4
M#`!M`SC"`'ZR%S8P0$UJ`A,#_E03+;8$!W6Z$]_V%)6_]2YZ:8BC'.68@0Q(
M+P+M0)C"%N8!V5QN5U40P_PP):I'I$$,5K%*94C'/=5QPI&84=]9Z)<!3<CN
M+`SX2R1.9XGVI*`"DT$-#;KU'V7_;:Q0Q"M>!4P!KU:VP'$)<PYT=E''.<QD
ME*M$%256=3E)J"L[[4J#*8HQ`D&4X@1U,)4&JZ`!`IRE?>_[31I@<(CC'"`-
M-@C0<@3``$2PX0#10PIAH((@#$71:ZCP6"LAQHF5^>83EZE$,8Y1!0*M#$0.
MPD4REC$S#G;0@S&JA@A-Q+,4&G0<*4AA"A;*T(2"8X4_%(`81"`""E@`:4F[
M1PT)LL.`;!2((`VI2$=*TI(B9(<W[$!"E$0UK%E$(DU\XCF_%K8MD6T$*.$)
M#E[EQ3>EIYLR>54.N)6#1-*D?7%2D][PA#TV]JEW#*"H5..A$Q$8`0?Q>-7L
MN`"""\PA_P#*R56AR*(Y0D+B,4;M0"$'QLY5;<R1EG#/+;OE`;O02C-P\H'A
M_F@=PB1A`_50V`4HT`C#M:5OUE%?(HTW3'46(UR'"`,;!H>\DVV@4[F)E0TX
M)C%T7>=9:5&.+L8'F-$FTP'C89Y9LN,^("B`>=0$';^PV:L"X&!8B:CH6K0P
MB=O!4V0S[8A32G&*=;*S9,!84"<Q:-F')1`9PWA0+$"4"IGYTX/UPEF,2'A0
MH#7TNPSU!GC#$=Z?O>`%$;T'!6(0`8F8<!P\BF]\,8)$B,RAI/C-[TAUN-%]
M]",@3>1:<*%84RKBU&P[E8F;?.*:;N:@?8?X"5!^@EL9,$`G,/]9ZAJ?4A[`
M)7);>Y3<'D?\8!J`P`A,B$`4DO4(OG9G`V6=%"0"\(%G!L`1`]M$'3"QJD?L
M*2R6L`&-T2*#%]BEF+6:'4WT&@F^SBH)Z8N`&'!0@?<%:%##N,SJ1E*\'(2J
M0J$9[6,0P84#I*`]IOB"'9EP"$0TP3*7T<IGJY*6*$@K%^.#A#*,4876`8PI
M'?J757+0A#@&0``?>-8!8`"=`0F/G`,&(,;L.4!;_#83QP6%LF"6@2^XC!+*
MB$7(2$3=#=8,&@`%X4"YV]T<@?>[XA@O0E_-T#K:VABXKH*NC9&!%`1@'Q&(
M`7L]D`*4%5(+0$@V$'!<A0W4L=:VCK;_K1?Z[(9&(`(+O?9"@R;?;GL[ON<]
M$A(#S`^91MI*!>823ND4IC9/IIJN4=AKN`6?03X8!U;4<%,YW!X8?!C$"IN,
MO4%;;Q-3000"*$`$TF`7<MK%4NR2,6(*@)X&R,`#H_"$82#!<7:N`<FWS0T;
M.G#D2](N>+WLA!`ZF0$/;,`PIWS%CF=5&P$L-@=ST*=O7-%G4)*9`*:H0[/Y
MG*U$Y(`!`:A%CF7F2^PD4G3-CFN>7[R+#=B`4T=@%QL$($SV!`!@1O`!$R"#
M"`8,5C9M^1\#,7&)<POW-QMH&7'C^5N2*9<4LJ@Z;4SV!5Y4R&3!.(&*((!J
MFP5TH`1MM:ME_[V-AL::UIWN.ZY!Y#(!3<``F$]``G2@@P088`*HW8"O/:`!
M#42@&RG`A18N;P#.ZP#SH!]!KQM/[5M/WO:3S[WN<Z_KWO=^!+ZO)_"%/_S>
M[S[WT][V?P$,4R>ZW6OI-LF!!Q`FH;H)M`^6-YEQ@Y9#M(]-`]"WGCCL"C\E
M$IPT+,@.*7J`R5CE40<00``L%QKAE)4):YT*:BR.\1RSG>,-XPEN`01HE1O(
M85<F1Q,1X&-R9FD<,T[U@6D51!M<9E2YY""O\`@TYDU48`&OI0I1UVRD\2@T
M(`9?0'>9\$N#)@(1D#'$("_O4@JBD@8$L!?<XA?-=@*?U45<0`6\`_\487`!
MHX,8V],)+09ISV<EI;`)#7(Q;W=*&W%DR!`+LK`QQ/!`GC8R@(<-IM9!A3<-
M`250VU50BD<.KT9[M$9M:M9IN/8=G607&#(!H">'K/=YF-=ZKI>'!B!6SK8-
MC7-Z'C`]:[!ZER<%.B`%4O!YHT!+>=>&\7)\;9A[;N@RE%B)KY!V;0$8FJB)
M=-B)GOB)F@@$59`!OR814>)\27@ET=<E[-9^!\``1_`:?,$%#%"+ME@3;C(3
M0&&+:9-O:K1OJ_,WB)`;-,!US=9L&E!9J6!\&Q`#:8!'`@`"1I4#'P`#EM,&
MQ10%%S!(^`<)4]$VG3$6&],56^$6'(>)F.#_,D_P&#XQ+`(0*!B09->S@$VV
M2Y=@&(BE.J`Q"FJG6&<1!J%2"[K`"[5Q&\/X`U$@!#*R5KH6``D3+`.0='*V
M.BIX"&J1"J"F#(=23*^0!A7``(\B68-C`]Y!/=AQ2P-``%3PCR+01TZ1<FUP
M"4B8BATQ=Q\8,3@9"IH`A5'X(1LB"R=`,E687)]V3*G`A=#PA3<#0@%%0O%5
MAK/V7=&F>]0S`G4`@+SE`)^XE;"WE868AWDH!1/0%:60`>^C`;Z6`IZV!CL@
MAX9XB(GX>:3@B*%6E_'""I;H,A]GB0Z#B7ZY`X#)EH`YF(0)F!-0F'38EIV8
M;#:P`:6X?/Z%BC1I_R5"T`)C\P@YU1(O\1)'<'TUH38XP1,\X1-#)10Z<0%J
M@Q5:D`(;YC?F)SA9`8`8,IM*UVP>P$W;@AH#D'.&HP4:L(WS@W\?\YH7YV/G
MPG$3^`F#@@%`D`$X$"Q\\8[O$H^VT@`,4%?U6`G^IW*>T`J8L`0U5RPY$`:K
M1"&YEBWO]P%]A&?78DIIT`2>$@;OZ&.<T![K8I$:\`3*N%Q5\`2YDP:'-D:#
MU@09@`')I$&`16<YP`//N#O;`@(XP`2$TUN[HBR3Z1'P(G<2DFGPQ*%@$UV_
MH$^ST`(GPC+]U`PMP(4QPB+9M92'UY0E!)4-Q8:3]QVR&8=>F:,Z^HEW^/^6
M8"F6#M`&99D"-F!Z`:"6@]*6!H"(<`E["427=FF7>9F7?DF)?IEVA9FE.ZJC
M!A`@&8!>$?%2YG:AH5"98Y,[7D)]/#`F+\$`I5$5205&7P22J$&+X*<F\3<?
M*?`!^T8)_694@*(5VPD*AZ(H'2"@Z1$`A^.;VVB`^%<)%)=(%T<Z#F.@XOAH
ME+!C@_)QCA%R#X85W4&=]99)#/A_6$*?M5`6XGD5C;4$[9$&<_"/`C`]IM`>
MJ0`)51``1V`:D;*`0>H5N.,>WD0_$5!'VU!'<>10`=`!(L`VB70$<]""+;`8
MN@`X\S,`RI$!,/`!VV(:3>"K0-9)/'FA<K9.&>K_H0,V(A*R`25Z#!K4A2L2
MAH+WKBF*#2ZJ:F/8:L4F>=]!"[.YI0`;L%RZI&#)>8J(C<Z6`;G3<DBJE5_9
MI(HX6G7I,E&:"U,ZI5>:L8*Y`QA"F`*;HSNP!AZ0)!4!`V-*II^0!);9`&2#
M`3FU$CCA!5Y0`LY:-VJB$IHI5#+0$J&I$U[``ZK)FGW:88"Z2H(ZJ)KF`'Z&
M%I3!<,(A2,%9!9@P9,&2`S?69!/CIZ,RKKOT<9QR`.DA`W5Q&/*X&:2:G9QU
MJI*0!$K;!(E45+LQ`@3I``0(ME;!%!BT,3("GH8D`-Y'&3&P20XGK.-I&BN!
M-OB&-@>`-C*0:.P"&P&0_P%#5VGR<QS/874;``-V&Q^3\@1]4RX=T7;GAC$:
MZIV3J:Z_`#-3L`'ORG3^%(8;E`K1D*+9%88AE*\'E7K.A:-R6`L?^[O`BWD^
MJH>@MP.Z4$=%RK">YK`$"[&QMT^3.+$7.[T:>Z6#V;&#";Q;J05?BB0E>[(H
MVPDJ:Q8WE:9'@$5I0F&F\44WJR8.5G9J<T4X*P!ZNF%^*HP6"#O:J2`C,`&>
M$SCTX[0:`+7'(9R2X`%@"YTP8*%&N+6@T`9>.V2CU!EV\0AE:YWT*#+TJ8J'
ML@2Z8'.#1@.A\ANYH)]Z08S@\R`CPH6QHRZ)Q@9A$"MV-;C84530B0B24V^>
M8O\L!]`$_\%G$=)TL],MRG$MCKF2[=,?E3/#IA*Z&YRNK^6"34BF!/0RU,5T
M)[HB]1I0-5.[MKMJK;:\ODN'M$F;VGO&7-F\8*F(._`;=50#&L"PIJ"8S8N(
M3BJQH4:)RC"]U%N]?PF8V)N]:$R'(S"RW@L0X!N^43%%+,N*6;13DR%4\N8F
M_,$?$/9@[;.XFHQO&38?3#5^?%(%KPDHY3*3'K$#-K`ND,(O"RAT@N2H65$+
MSEE4N;%*3[!+J$.)NE0H?BK*Z,$O*4`@EV2V&7RT%;,QN5"!HR3"@2*##HD;
M#$!8:+9K5>`=UU(%-M`\,#Q*A4:AS:+*/E$"5+"X:!3_1MU$@I23+,7@2\Z6
MS.\Q%]>D!7QV,"`))P0`'0.S&(_4P$@+1;Z@0$W(M>>&S-)UE/8B4Z\+N]`@
MKX<'QKG;"F5,&)_HL(-<T<);L*]7O!:4`?HIQ_U;B&]IQQ'K3A9;B9/(QWSI
MQUAZO82!F!4]`1B0`B2+R(H<A1@@-BQ;152`$P[V;J^1?:ZQ'TG,'P<0#_&`
M;S^KFI_<-QV&&U6!%:5LRAO1%>H".J;!RG:1.0HZ*811%MS7DG:E*]2*G)AJ
M2&+P8'R12[%SP6>KP?W,$1B@01[\GF]+`[OQ,;)'$F_"`$PP7Q/!(^C%0NQP
MUF];%Z<S9Z9!!11P>M=F`=?F_P,4P`0#L']BRQM<V"$E0CT!H#_7=(S'J`&,
MLEB4DQ5-S)WU^<3G-&D1T@H"'6D3"!XDW+K6Q0R4X$_GLUWV>J\-C;LI=(*@
MIY5E_-+"S:-J3+P.T,:QD`$U,(J!N`%K((=+&M)Q&7LG;8EXB=)4JM)9&L@>
M.\C<"YD/0=,UK6F,+'THH::G81I&13>F<1KN+5FGX45RPB;Q]XN@W$93H3]0
MC3H*4@O_:Q7<4C^U(0),.RD3X\+/`CVR\6.Y+).HLRD48#U[$2M:,<P87*I:
M>\S\E->K:K0QB0$.V:W#TGZ6+&]MYDW%(>(-(`9I0*&?E4B%1@H0]`C-1HIC
MA`C^`?\[*5H,<RFLF_%-*&,*QD#C$=`:='8`3,!PZ&JJ`V:N4PQ<27A*&)E<
MGM`,61RO\OI!#"V&(_30+<VQ6VG&PXW&%UVP;+S1HMAR*//<$X"(TBV6U'W=
MV'VQ:6>E*KVQ+%T+6:J8:/P$@#73)CO>H/`*.-VR:5H"7L`VM.@3C!XLZJW>
MNG@:7Y030R$FJ^08!]"GEB",174<H,IA"S2;HA"/D/&VR?$(,,:T^#<8"O`$
M&7#65*$6-D`?^BAG/Y8)O5*#N%49%<[6Q<SD5K+"K*"J@[1*$+0!MY&;H[1'
M.LPN]6;#1$8!A@$6(^!TW)PLO9&!JV`,!5`"V8<#UKAI<1?_":7PSA,<S*.E
M=(8T!];S/"(0`+)!A+31"<F))1RZA!HCD':'LBJ303-3V[1MV[<=AF`HK[?;
MY=WP7CYS@GK.L1P;T10]YF1>W*YWL+VA9LE;;"W`YM'->2(=YR4]YW1>YYMZ
MYWC.TGO.Y\`+!'].LH$NZ-UY"B/1R"[[`24`!3S1F32;2+38F;5X!#3+-C4!
M)EHTIV&2Z;D4`6*B)_;!Z0:8<UKQ/QLA!+F.'KDA`_!>3*F^[(]Z(>H2R</"
M!$.(`?I(3K[%G*#MZ-\4`%W`1L-,$]CIUJ=Z\3I8@7.1<WSF`=RJFTU``'ZO
M!$K@]X+?]X)/`(3/`PK:!)8#%G7@_W3?DQ5?8>6U_4H%T'XX7``L5B)+`!6E
M`#C9<4W@<0IL*S$.`%@X4+@-<`32C*K'U=IO-S*8$"+R`O,8HQ$8^>]5+O!A
M.`4GH.4&#\9/Z3/=0'^$>=Q[+O'"7>9K+(<A>S(*&\?%5DS0S:1PF8@@+_+8
MO9<E;_(I[_#'#[)>6?K+UU\#T0^)'+XB4@7P6;YCP@,_2P5ILJM6`?0[O=,\
M8/\O800[O9ED`@@\.#@555H1!P<1#@I"0B,8(S`Y.30--'-5#AB;&&L*H*&B
M#HP*&0(RE5QL.1=I&%I:&Q<T-)1,5:$.=6FH;%PT1W-I-IREC:*C-AL%.`UL
M-#(P,74*;?]""H<B#=PT#!X8&`K'X<GFYPH82RTG(U4"M;9AF1L;O91A7$QI
M&AII%C'X]?,GL%^:-,S8-.`2YD.`7*`P%*AD2XR&4NM:C`#EH$65&!UDR&!U
MH,`K#.PR5BG`K4&.`QE::-SHB".&#0'$`*/!Y@B,5\7$;41']-R(HZ$V,FJQ
M882#$3*=%IU*E>I0!3);8-V@=8FY)6##BA5[HNR4LF4AG/B"]@0$""[BHIWB
M(8!=#WCSZMW+-V\`#QM([1@L>+#A'1,2*U[,N+'CQY`A&S`@18?ERSH,)-ZQ
MAND&&U4R>(BY)C'ERCJDJ-;\%.K,H[!CRYZ]IO;LH[5SZ]Z]YK#_;U(.?!M^
MC)AQ\0TO8"B',6>Y\^5:JTJ?3G1CD@U-&E!`V0''``:)#AP9<`1:K9Y'Q(\O
M07Z`^P$'VL>'?T"`(42*&-7$4&52I4O#\%?%@%7<YMD&*00``PYLA&&)2R)$
M`$LL&XA0RRU5B&-3!A7(0,,J,EQ`00P9`E=3&Z1,X$`5&T0@``.4<#/'9W74
ME$T$1K3D#3CBD*,A=>DXL$0[[SR80P,5;#!@`*E0<L!#_"G)(B20W+1!)!K)
ME$83'W*1@PAID)+.1/$TH4$Y1S$%B0(;;9!!`0=`X](<,80S)%<K=</&!RD@
M)8HCV#A@0PQ,'-"-#&)X<&:!5P&)SD9*_[DVCFM2.6KI5!M%-617R8SEZ5AF
ML676%*2V599<9M5U5U^LMNI!"X(!%YQO*CH0V:VXYMK89*AAEMEF6VT`1&BC
MC5#:!)1=IIH4B;7VVFW0QJ8;;FO(QMNUO0EGV*Q::.M8<8L=EYQR<S3WG'/1
M7:IN=0Y<E]UV(W27R"#T'C!2#C(P0"\.!WC'PP&"[-MOO?55`40&!WRP2"/8
M1.)?/"+,4<!R3)C[W!P5"""&"!_DP$:3^(HA8235:F"A+3G@\F,Z&)S""BOX
M-A%`!`@-*""+,410P!P,4O)2@-78>$B.+7U3CH^62K7$"!O`8PDE28(VA\]L
M"-!4/552R@A4]?^DRXR'M<A0@%02'<E-$U%$DA171RU5#YPMR<#$9QWAR=(E
M>V;PXS'(C'-3`")XG`H.!<00U,I`#B6F+EM-BO7BZT8N2E0*<*6`5Z%\JCE9
M:'TA*A%GM87J"739]9>KJ.>5`JRR%K9MZ[K&+CMCO/J:FF83[!#LL&FD\,4(
M6B2FFK*J-1LM;,_>9AMMTF*[F[:'90L]N)LU)JYSY9Y+;KJ2=^]4$E40D'(D
M%7QPQ`>#))QP*B)]D(C[\*L?WOOT)VSU(?HN<@V;#E,2SS-4>YK/!M@2E^"+
M%3(0@4DX88V2G0Q##`Q%.`B%`Y^YY`@X$$$3"-"<BA&@"2*PUP!E(`#_*$7"
M`8"Z$=&X8;0>21!QTE$**+94"P-&#1$MP8&$1G""IJP!`TD@E5?J0,1Z$#$)
M=6C1-H#!!AQDH!-W.UO:/C$IIC4E*570`!-D<`E\=:!.'?$(2RKQDBOIH@W)
M:(T6JN"B5"!P&$$9!S8<I91C/.5QE=,(*?S4O<0E0U(R`8LH-D?(=:SE<T0`
MG>A<,!=5G2YUJ%M=ZPJCF$G.[I*QJYVOI(`[W7EF6`AJ2O`F,#S+K,9XQZ-4
M*JU5+58ZKS;3&TQN8@FNP2@&,==C3KDL=C'N]7%=-*E#`1(8F`@$H`"F2Z8R
ME\E,TZG*`Q2@@(0V,`D!A`D95)I$/,Y#$0<]_ZB`X.0&&_0E@`)$0!,HW(_)
M:IBR$HD"$D\(#<\8P`8YM<1C]=SF)61P``5>$2F`:AB."LB`D8WCA4D;!R.:
M]DTDV4,`1ZH%`=*@A<N=8"8RZ:%66LF52"AI`U.KA9<*D"&)%-`B:[B&$!@1
M1K#LD6EIF`,#:!"&AE3@%5R#P3UQ8,:#)F4VX=A`!0;P($2=LT!RG..EAJ*F
MI>BQ-;],6J,"F97+#;*087E+6-82NBDD,I%I&5WI5@5)5_5IDK.JE255A,FV
M/D:3F.$DL#[)H@PT13&E3(U<5;3*J*P2-JTTUK1>"<M8SI*6FZEE[A*#''+M
M4GO,\654$RJ$)R`B!_\P:($-GF`#&\1B$T]XPH2T$([2UB$<I(U%:4F[B5AT
MH0;%",`!<E``&_A($OCD`@AL\0LN^'85]0QN<,=C!`+<0)I1Z$(Q&%83!ZR3
M)VQ0&=^.TJ,JI($"/Z`",,)YB5J`8`!&8$($8M"%)#BB-@R3X$"/]!(>^91E
MZBI%%2IP'E;,2+8>H\$!*'`F%*ZC:XX3+-?J<:41X(@&(.!"`T2@-QM,I)XY
M$,,&K(&-)<QQ'4LS%DS3P(0<U!1?,VI#"]*@4TK(@*=[/&AI2VLL-()B"04H
MP<M.3-*AI#!QE&JJ%:7"Q\DN54T9L>J+L0H6=IP`+*0;%:F(D`*PGD"LCBS_
M:R2=LE:UPHZM;LVR8N"JK$YVIAZ@"<V5\-JK4_(UE5GY*VT(RYOH24^6A8UE
M8F^YV`DT5I>//=<<).MC2ZTH`#CX0`DM<)!"%]H"%H@`S3)$Y=(:^M&'3O0<
M$@8#O2&.:2G(M*8WS>E.IR`#=E52E<+1J%"T(`.;OF)1-F'%%.`E`.."00&0
MZ8%/*RD<D$/'J3G=E%Q[#].JR\`(1%/K6MNU!9&`Q`9^IR&FS*0.GLF*FS1=
MZRO=9-,Q(4J1L^815./%U8!A"K%JG>D6H(@Z0I@VMGM,G:P1^`O_9%N??[D$
MRP62R)Z"@)'+XKE^?V$*GLOTO]L"<"F759)H3;BM_[3,\,4D*Z[%FX!'X3TL
M1HV2E*4TLP.F=;RL^#5:;&:S8>(,O5D))['%L24S'/O8/$=VWI%SP!.882\9
MN$\]1\@Y`QCP@9Z+(041_*%0;PZ>^<TO%1^H0)U(K0N^)5RA"I>54>IH5:F_
M=]63).**<3W)Z2RN#HNC8N1@8ZLP.B79>G1-1TG-MJ-PY:)UL**S+<Q2,0$'
M%"M%D:^3X5>T1R4<+,J2Y:S.IJHX0E9ZAZI4K7BUINP8YK^T-U?PG6]]SR7@
M_P;X%WPG*E*1RN"01'C4@=/PTF^Y5\1+3+*O9``,``%W9$:-F3G#<6AY_.-K
M#ODKVP!G6KKN,"B?\\KQO/]+E^\9\NMR@"P"4(%`WSP\\.OY!WX.]HA@(`8"
MD+[VM]^O$I)WQ:"HQBC$M'486I\Z=BQ%J:L2&[!WHK2C<%3K?(P45LN$U%S;
M<=^Q)!-[]U\C`#9^H+`17C%'=T<4SD9E3`-O9^<F_>=X"B6`5*%43<=NT^%1
M7($UT89\O\0.H"`3ET-Y6:550W)(OJ-Y_G86I4(7KP9ZK")ZH[=PIM=P#[=)
M$T!:$Y(`$E`#"?``J6$:IV%*>T5[N1$MMX=[RJ-[V,)[;5`;O#<]OS<<N6-+
M4VAG$T-\Q6<QQ\>!EK(&G6`/BA:&8AB&M:8)/Q4:$>`!8[B&&4!>H+$F10$M
M4Q?_&UQX#BQ&A\"$.?$75;"!);W&)IXA%2WP!3,!B/`&'(.8@1IA#CW&-]*1
M9@/85"Q2!0F8;.:P=^>`#5=Q@'YV(`0&@(18AY*3$EC1%2((%F^!%FI!.IO7
M;Y[G5:3"%G3Q`G7A@GT!@Z,W@Z57@W%U@UI@``\@`2PP`V,@C"S@@YH1A'KE
M9;4W&T>8/$FHA+O!>[GQA+%D<E*8C8@Q?%F8A=LCBE5!1*&0&^57CB13C6V0
MCC8!"^:X8D^14NH(CNC@B&,'*?%%C\CW%(&X-92S@&S#C^ER>U=W#I##B?,(
MB(M("@<"@'^(C^C&$7U$8*`&@`S)9_+(?O9V9*>(BJMH_RH`QWFO"#HKZ`$O
M0%:VJ#JL$X,RJ(M9QHN7D8PZ.`,R.0,](`$RR0)GH`.OEW%#V(S.>(2K)(W7
MTH2'Y7N4%'Q5.'Q8Z(U;>)%5\0D:@7]701MLDE+6@$;4A1M]R$=^(G:2LW[R
M%U6$YV>8V&=\8SE0P35,\3M^96J*J``7]6)`XI`"F!%>L5"$^'@RQ!%ER8$9
M40\3^8!557A.21T@:)<;F8JJ>'E?())+1G`D:9(G66LI&8,LR7`N:4H&H(/#
M.),]D``L$)HXF0":-'L^*1O2EF9!*93.8XW7F%9(J7)7N)3%]W*%B0[JZ&+3
M`1O)H)L*D%)6"23B-UDV8G@4&/]S="D=?3EO8F(YIN8YK),58K*67,$4$DB!
MQXEN%=:/U1D5CE@*R3D5Q9D,0N";NG8@=@45H58/!P66MZEK<5D6&[D$;U&?
M]JD67N68H=-()?E(DTF9*IDBE]F2J-=E.A":,R":8P`$QHB3MR-[/5F$1OA_
M2`@MK-F:K@F%5#B%*;>-5]B-M6F;[SD5OB8$@O2!`\B;>"<$2&2/G\`WV)"=
M"E5]`YF)2A6>1:&'@Q0*:$1%#GD,G:&CG2(=>EB`[484BT./X#F8F;(!2[`4
M90$K6Y$EDF6!?\1^-.$(2^-LTC9AN]EC,BJ7CGB753&(3&%7=94!\`:"(PHD
M]O8%\UG_G_39D7.1GZ72.;,HF5+FGPBW`P%Z90.:*Y-A.YFA`V>0H*(I`0E@
M`PEP!H[JJ#I`2LM82:>)FJJYFD5XH=-(2[3"H8GE`"M7?!4`HN5BD6V:#.(7
M4,7)".77"$A$1!UAHWT3@7<)=FC2E\=))34J'6B$1NHG8+O*)D/AE2,@I(R#
MI%)%F'%(%1B(?UPJ;0.6?^?@E<?9!C96%-7"7`.X;&]YB1`)D8$5"C92"C]B
MK)@"D4U*8(#I.:IVJNQ7BA85I_=I*G.A2*'R;Y$YF7S*.G[ZIZ07J()J`(0Z
M`0<JFHZJJ(SJJ'\`J9)J9BJR/-#RB9=JH0(F6)KZ/-J2H1L*_WR$$:KE4@&C
MVHTB>JKB2)#'D$);HZM/`0HN!G8C$(\\VG2Y]E)9HZ*^)B9;Z9YVJ*+I^*(C
M$'<"9GY$1%V_*7;JQ[)/,;0IZ@`N-A25<HEV)*Q961V<4'^$^:01X7;(YA3^
MR&/<RB*W5@[(`']V*+9;PSC450Y*)2#JJJOCIR%^DK8ER[+62FJ6"(WP):R,
MF"D,Z"9<D9?NNINEV`*&E)CV2:^(2SJ*E*?ZJA=]ZJ__"K"W,JBV0[!G@)./
M^@`)4`5PH`-_\+DYV;![];`0&QN"B807BZ$]6XV#D8Z^P;J=RK%^R@PABS&U
M6YM-2;)$-)RZT#;IE`S&D&+J2`KB0/][/)J.!=F>NN".$92\_/-^4SN/OML:
M7N%BK1%WGE`ERAI^&#"T@J6W+BNLG4"SYX:BA<>)=L<WI^6.5%NU[J>WUM>L
M6[-LT3$"\"8@&'`X>,<R8JN;K":V\9>VX3"N*S:)X6!N+RHK<'MV*_:^+[1B
MU/4$L,HT9[<1:K,V##E@[*H5RQFX28$54;H6IHAOBIFX=UJO*IBO)[FOL0*Y
M*RFY;R6PE6NH"OL'.I``PP($EO&Y-HPLD]HL/NEQTD(M(B<<J<NIP(>4O6&%
M(0NR($NJINJNNS!N>'$"K!H.J)9JI[4BJ%92'B5LUK<!Y)9IPD8*")("$4!M
M97P4GA,I/[O_"<16;>QR6F)L;5IIK9^VOD<!:BJ:#G60:8R&%'L,=,GF=I\6
M"9S0`KX#"0H);A[P.TBAR/_D%"P";L(&EIL0&IE6AM6W$5^0`012R6LL>=VF
MAF'X::2`(AJ0:8&!J@@2`1/F%`AB:54B&C'0")2<`6)8,P#,Q2E08`+L#VE<
M;J#P0_RA:*",6AJ`S.H:`UXZ%'[XB1W!KO`6K!Y\#AYW2"-,9"5\N&7A9&VQ
MN"ILBRP<'"[\PC"\*S(<5UH@!35L&3AL,+W2PZ<QNAM7J3,AH1:[>\*1CO[L
MNMKBA$V(Q)WJJ1.PQ!YKN[=;?%'<INZ0`LLQ:R^0`7[#'QT@!K(&_P,O8&W\
MD1,PP-',%QB04`4>70`O4`"O0@H9\`+)(0;E!`.`P0G4-#:[0$2*#`,5@$S(
M1-$K^U/(`P,`4`#`G!M?4`$B4U)"-3:SD0)&3<AQFQQV['8O(`#"]C<50,@M
MHQRS5@"K8\'4]`):<10DG=.S]BKFYPZG4`&PAM,IL+X*D`*)4EHN8D(#!H"`
MDT$B(`)B`-8HA`$1H-<IP#?A$`%B@`,>8*UU$```0-6(3$V$`"N0D`$\(P(7
M<`%Z70$2\J)_+```X`%4$E0!(`!Y+0:D'0`#>,PBD$'@(`O-AP-4C2!VT=4,
MY(^!J';R=LV/.'E8P1:&JQ;>?`)$8"K!'?\JC+O"CLNOYYS.D4&Y[&P`[WS#
MP]+.ET'/RP)[]ZS/U!(+RBVYQS$Q'^O$"UVJ'@RS[E``&$TB8-L"K<0?`@`#
M)=4V@%<`Z$-2Q=`,>N,.*_%S!,*;4'%](I`D-J-L8E`!/TM$)(W1EC:)?2RU
MD`#7&B,A<5<M+0,`TR<ARS#@5!(;,$#:[EW(W6O441T.<-WA.6%")`T`&=`%
M-_$:-U$!F?44?AW450`:[?I'+2,"[FT#&0``[LW(+:`Q:7`P()N>!]RW+5)!
MF&U,8)P./M!>*\L(=6!9'>,!.]"]P^1$_,'>$188X=`+#2!>/M`,7Q(`GQ#E
M$0``,A``HY8!"W+_`#FM*BE@?5T0`":6"3;@`1^0"F!2!1`-TX[W%/#VR0R)
MEAQ<K-:,VU-J41?5V_,*W*?RS?8*<,5-SL?=PI"[W3%L.U+PBX]JP]"=(>OL
M@\%3W93:C+6ASIC.DEKP)KH$WN&=N]?<,AAM,*AUA^SMWHP2&Q)13@(0`9UE
MWI;&'^9-##9SP>.P`1C=66G9XAU0!:=5!QDPX`;CQ9;X4Z4U7Q7`(15P$7T8
M[3#0`3>U#`(P![(1&F)@%P+@U-0%`_91R%3B`2*#?4F2Y1@`:.?4!:+5[>V]
MM0Z0`@#P1?G+=.:`Q6)`W]%.4I;H[?FM-_50(%W3\!$P"#[0#QG"LAC0_^0Z
M9(F08`,1T'-4GK\3@0-+QQ\5D`--(-(W`5$%H`&P]=<1IA7Y>^9IOF(!X#XK
MWP4:T`4#`BG"_B6#$`$:L"#9%R&A<1<3%@F;!VKI.8BA:+*(_A7.MMN++H+W
M^=L>:1:D(^GC[(+E3!BM<Q@"*J!SENK(LL[*PNEG\+GP'-VAK@.C[K#7#;$<
MEZF[0<2I*XVQ\&:R0DLCT.<?^]T@VM#R*'8_"VAZ,R!*OW3`\PXB8!>T6&!K
M8`/L'@,PT`01T`4%@.*LNA(\?DP!H#=VA.P=@";IH`$@6P75<N<'``X9;J6C
ME@814@.RM0BML089T/B],`<:$`5*T`%8"0E!+_\`4:`!L]X%?<CNP+P1+L;N
M&'/?&D9-_SU>*FXL*0\#5")B@%-":1#(/08),2`")50`X&\X5X$!'M#>`L#Z
MC$>):L+Q."`#35``3%``H,_D_"0A6F"Q?OT!WP`(;1@:!0TX:1@*;1MS.48;
M:VL8&P(Y!5556H0R.%])&!@1.#D!=0H*&Q4-`E]::0$%%`$M#FT.57,-<P(R
M%!8X(@4,!Q$8:QG(&R.3*<@9+54;&]$MI];7V-G:V]S=W2,.(RW@(QLGU4LG
MYPI+[>[O[Q#R\_(G$$L04U_JZE-3_"?T[9OBX44`#QX"'$3(L*%#AP=3;'!`
MT1;%BSLR:M3"4<N$"1K_0WX<"9*DR9,C=WSD^%'E20,&=,B<J6."@3]G_OR1
MF0!()BDT:QJ00I3DCDB13K6(U&;-B!%50$$=X?2I5:>1GB+=RK6K5Z\=.ZYI
M0_8B19$?UW@<X0$&C#EP*\"=2W=.-6]X\^I5X,!:G1$O`&0`M:%M!1B#1VBI
M(D",P@(!HHYH8P.&``UI!(AX)5C!,@P%<,!0&"##B&L.-HCI`$K!&@6#!%2H
M(@E#`&(8K%H]==HS[&55`@1[=:!`G7!4,X@($`I'`0U-8+3AC2&-"`$1(C3.
M\.0I*!ABINT^)43#!1'%$KE>MB%"`0'8M4XZ7"4<["H9`E1PO"%W;VO+Q'"=
M_T*[1);;$K"!YEPF3[4@S08MC(.!#:+D@(,8UWE`RR<^R$",#:!4%<H!'WAP
MBPV%'-(7*G.PT00D[%7RG`::%,#)%`Y,6&$I?%&RR@8VI#$'%19FX(`0M\#0
M0`$%?$!``0<P$0$#'S`G21V3/)C,@U\\>-=>8(8)YE.>.=A".NK`HZ::]+29
MCC\`G4`$$0#Y\P]!!B&DT$-\\KG01!4Y,(%9(&6T$DMA)=K1!(NBA!),(\$$
MJ4<OQ1244#CIQ)-/6@!%DTTZ%)725M<@54X:J*;ZX*JL:MGJJ[#&BJH&F8S5
M1D9F.:#12&I-P)9;<\E5%UU?BFDLF`[4X0$`'DP83?\&EFV@!7`"P*"!#5%)
MM0,&EG5!H0AS@!<#=06(D4$7752QS'^I`<#::4[=<L=LDE"(`W/^@9,-@KG-
M!RX,!5PWD589`,`<(4T$0``,"@BQ!"@!X%`M#!7<JZY5X&5+D35"=%&!`/W]
M]QFV&8A1P1?>40)#?4_E:(,-&\#`K'_98!"#&)?8H$$'8J2P,6Q`>(!#!"!Z
M%PV$5($2P0<?%)!&!!EL0!X&'0[]!`9/Y!C5C@X\T043.6RV8BHY7+!!&P&*
M8<FU058B!@2PV4N**;?D@H,'-G21AHT'I'#<)+F4AL,!(@R=Q@<'!`!ALN)\
MT4PR4&60PA==%GOLY<?>)0[_A.V<\,5=:X;>9IN>V\./G7?:V4]!"^W9Y^L.
M?<'718-29)0#6@CJD:(CL>2HHQT]\000'$TX(4PL&1"II4'9=$9..^G0TT_-
MQR1J2UO!&\E1&P3@UO<P,,%$!W.(+SY<3(0?OOD=A-_!^_"_/RS\<Y$?[EMP
M*1Z21FOLG]):A@F6L(9E%\P9D!M/.0XEQ."!J(`H`.$)!P88`P-O204#?>&6
M&+*E'0"8*X.@$4,,A'<U,C6L71TXSGH44`63T88]^XG,<<BT(G;PQC,0E`@F
M(K`<<BS"8,`)#0XJ<(HE."`#U9I&-,"3&*A81C+C86$'0'8@`"T#6_M)S"2J
M18YP_VS`6P80Q0L2\1]K8$`Y!7!6P'SV&L]@8%G%H,IK&E0-[RSM`T0#46ZJ
M034/%2`"*6B&=V)0@1Q4(`4QX"$;5G:*)%1!%6:#31U*E@,FQ.`58I"!"#P@
MA`3MR!2P28$(9&"P-$2A23@8C"`RTX#(5$`&,JC`TW!0I7*T`$LMZ%(SJN`@
M:41M'`<,9N:0%J%S((@=H6,3Z?KQ#P@P$W6H.QWK]+00V%DS`[.SW4=T-1+<
M:4%X+P,"$%X&B@EBXIP/2I4ZL\/.A)#F,4P:S0:09Q*87$HHS].4]#CEJ9F`
MZGH@(95K(A$.#X@!!PA-J$('=X#!)50$A4-H0R6*4(@N-/^B%8VH12LJT4UB
M0"-DV1Y:"N6K`,ZA`B@E(%PL)TS,]26!DP3/:!0BFY!-4```@`QD,@#*.CQQ
M!-B*V`?O\P+1P.(@4K-&:L0`@]XX!145Z("$0)&!_8S&G=A<43M.D1J4.G""
M'Y,=5;Y@L`D&Z94P.*8"#)H"4(!H60'X3!5DQJ0`O$!#I\#2?NI31`6TH"V/
M86H+_%.RIO8K!0!3"$J;B(VG*,<QL$AB(A"T#*%Y`)33P893FE,E3)A0"'6@
M`"P!0%H`P*`_&.B"*#[@P<%58#!]20+91""U9*F&$Q@:G!B*T4E0>&"4`3C2
M?0(@`*;AX`*C$$$,^L7*N`K1:4+_DT%<*0>.7F[@EY*37,A:RMV\F*E,)SAF
M,D5'C]/YHQ[1#`@1_F'>:;K3FO#-*NT$Q<UN;B"0$"$-D_;KE@X("Z4?@X^`
M&R.&`AO8P")@8*>41Q)[7LIYT-L4]3YE/2DP.*!("6DDM+"!P``#HB`.L8A%
M0#B(GN?#($;Q>4;,8H@6^`)-@&@!1K`_7.TJ)2IYXV'B`N!@$:N[!WSI".I`
MY,*\X'LO2(%N@G.8[YG&&@GIUP1?\(*)_"8%37;+"[[0E[MTV`-D:F/W-.24
M<:3&>VZIP)9OJ%8%?.&N1GOCFD\1,R5#!0.(]4##V%&0D*GKRZ<I*/A@X($3
ML",<"OD/_X):@-@F>T`9$AJS"=^<YBU+I8R>*4<!OE>`1^<&0'A^`4]/,9T:
MDOJ(;FFBR*`%O@K$-3<Y,HQL%-<:WGA@#@6XBP-:\`(``\P#&:A/)V&3@2/[
MK).2P(_W4DKH_D2B>W-(00ORD^0JI(%BC^ZE.,KARV8X3AF?!K*X;^A7SOEU
M'44<+WF=^4SSPBD@<&+W%_#4NFK"ER'VEB^AZOL1':/TP``/N($%?.`!&_S@
M.*L"I!K,O$])(9_1FUZGJA<J"X_J*QP&CQ@$$.,1PX<N%1#QQC4C!KA@Z#IO
M<3&&#JSR@8N@"8V9L:[X_9*63,#?/$YI7'X\[@.VS#_24-<,C?]VSFV+;+!6
M\4\=COD4)?(2F-<P.JGS*HY\66777BH3QVQH0]T\9:N\N=B2JR`$A_G5.U>/
M$&^@@HD(02C=5@'=5I?`[<'2K$%1A(HTUH5I4&-B[Y?F"V_&8<+,UHSMV;H&
MDJ*!B;^<R3Z?$0<FI/*E<&`"-=`X9SFKF"#/DGH-@[5!'<Y9]%,XI0H:D,8$
MIT&87RH%:;:\;]3`W?>>"[-!ZUB"--"1[C.I.Q[U>":<4I?>?LP[!7EZ[[T;
MDF]PY&I0+E%>%<KU;Y3*!L#8SWZ`M6]]V5P?^]Y?F85]9Y.&^_/A$=[GA/U9
MX0L?Q51;R?C(5]QQB`J`"9O&-05.^G'_@%G&U1$`'@+0:<15+;M0<O$T%_#1
M/@30@#A#"[33$H:"$CB7?2=5%Q7`4K8G)J=A0K!A19]13J;&59E&%218,^7D
M&U$712NH%4F70-W09FI%)NZ05RN(`:8`=MY`=Z>1@CNH@R"8%1YX#?Y!,]M`
M)IO'@DJU%R/86"+X,Z;71A21+]F0%-C0%`FB%5$'"C4T'9]A1NK1,,B6)0[R
M.4JW=T54.4VW`=]&#LNP@<+T)1&R:+MG#;^W)J/3#^WF3`)1)^OE#\AG$*3Q
M.H,(.Z:1*_2E$I"R`07`?5<5`1Y0`"<U:`B!4J6Q:6DV4YNV:16@4R=U"35!
M*1_A8-4#<1)F_P/])!,V0106AST8%S,C5S@"T(":<1U,TAAS``N2.!INP22Y
M^$Z0H1\5$`'"J!")!1EN$5D")G,7T13]$Q+:U&\>H'/:AX$:"(?'HALMJ(11
M-U`(Y'5#R(TE*$<="([&4H/L`$IK-V1<EQ?FB!?H"(+:J`W@6'OC^([=8'@<
M.(_98'CB:(6?)X1AUE@>F%GV*(:=M'?6M2Y%5EN[!VZ]U"7EB(W<E4MTB#38
M<(?`MTSMI@Y$,&\`,2?[<`*!^$Z$Z#JOHV\[<!83."@=YHC9T3JC`8EVA0Q4
M)A'>DP)MX0$ZF0('P23$&"YS\`)5(`6,PG#W!&'Z-#TV\&!#013N]_\5:C%7
MWH<AY5.+(N!J^I%8OQA93'54R>@]D'$8QMB)U'=4L$`QWC>`SG<1'*$K-T82
M%5B-('>-%'E``GF0>^%UV3"$?:F%+:4FVP"$0`8/V^@-XMA8(-B-XY:8`.(-
M`&D-2%&"F%-V#N,PZN!VXV`FO2$.FKDY<<>9?GF78"*';Y=+Z):1&MD.HQ-\
M`0%O_K!>=0)-)5F(?H*2?:*2$;A-MZ`?_L4D*`4#Q$AH.ND!Q,@0DM,,/*D0
M&5`0"#$:S5"<NSB455`3]61^JF@`IJA^35D]K!B5&#=7&U=@U?(>)Z>5P2B6
M"N%?LV:,`O`^7]F)O:B59'D0[M$8LT@`;%G_8RL9ER3!%MS78W5)FG#81@;$
MC:.IF.)FF*JI#829;H,YF._0@BVEEWI9H?:8H)`ID`9DF9@97KFD.6Q81W3V
M.9G&AF[(;>M"H&)R%]_E(.L@#C*XFOC0FJX9F^QE.G1B?%_`.B;9)[8)$0BA
MF]%8.\&19NMY&"D`B<W)DQ%P&,"6$#QY5\SWG$D6-8CU/=1IG4CIE-O)E#3Q
M`$+QG1?G%4DRGO:W"RXF`(IEB>]D?:ZF4P3VE9V6C%<5``$X4_H!'[0X8_P)
MERYA$@`:H`,4%W;)HN)VH=_0EWBAJ#$HF!#:9NDFJ1.*#0XC@]<@7LC$H#UW
MD$.FH1Q(;@1)D*!*_X^F%XY'6$9]AR![MSF$)P[G4`W($2$-\B!DXJJ.BJC9
M\%VH\'9^1:DT:J/S('Q^>#KSYJ-!RGS)BF]#FDTKB1'==*1A23&(X0P\:9S)
MB`QH1FAZPA"!U*22@XE:A@%<NCQ)J9WI!Z8S(:83`!106:8&VA1)0G`7HE$;
M!YRSEA#[!1_(Z#T"9I8_F9[>@V8$^Q[+2&,AH1;^^9_32*C6J*L4>:%D,FP0
M.ZF<2G?`V@XFM"9V:'86NZG)U*`6BR"<&B8D>PWJR`UM5*KC6"J1*8]C8D4K
M^)>J&HY=PDM(LWMJEPYF5B80<IK*H!L86;'>M;,GX*MJIYJK*:PWJCJP&?]-
M4U";KO-.5&MO^+801'H6Y=>;F;@?AP&)HX$,.ND6P)8?W\.3R=F<WUI-[M$^
M,$"4Y3J*V(E/Z>H30!"F->&NK9@1`D46MB">`I9@)V=_.J5?F+A?P+E_)M,8
MHR&)*,5?"`@PNW"+![L_Y.<H@QJ@#TNTQD*QW-!)$CL"97>$W?4.+!@Z7X>Q
M2LN#(ZN#2^"Y&DNRR72ZF@JRD)H7ZBBI"O`7?6="*QNZ'M@5BL>/9($-=5"\
MNXN/F4:JO0&ZX\%MT2"1J_<Y1N179H@<;*@,GK%[NN$@G.L-1UL-,.JBM4>C
M-3HZ^*`.?`A-.3HG<"*U]5:UN%EOS8H1A&(3'R'_K=D'`V-;MLL9`#VYK64;
M$<U)I0GQ`L0(/Y%Q8>;JI75;!7>[KGE;<499*%OAMZ5&E02W<4UP`1Y\?XA+
M,0%F/ORW"P.F@`*&PA<(']W'K\[W.Q38L)H[H-];PX&INS_(L;8;.G88LH8I
MF.:[PSI,H*7*CP,UF7\Y)IY*C^%H0J"Y*GQG#B2K#K"W.4%;#I^S&[9DP^2&
MQ>)K#E^B5K(;K*VIOOS`;K(Y!3OJD;))DE1&3?*+F\S:K3S9EO8;J!.@O]@G
MG-G5K<5I$.)Z$`2;$(E5$,>H90KW*.?ZI7:+MZMH80R6$<YH*WY[IO!!GAS7
M!)H,<Y<\G@='<`AG<)@<_\H#%E?/V!1:\*<VYV^$2HV'RL6P/&[F.\NT?(>Q
M?,O!!$PJ&B&\7,6]1*NB24>:^5U648><J\5L.,7AM2]SIY%,>\;EQ6YR,B?\
M0,W.%(APO'Q]HF2U\*R`&JA5T!:#UHN/`3XO(*[PTU_Q$S_@\S[?$QFA6$^+
M_,`13!,P\:X2B,%(<13R)V#Z^<D`_<\`?7W\Q\+81T!,8,()E\I:L&$NT9*K
M+,,.*Q<9B,L6?2R5VKJUO-$<S<,9W5<7'=*=^9!7/`(222:YI+VX6LPG[<6W
M"GLU;,7GEIJ9VLQW^,SJ6UZF,\USLL:K\\;N9+7:C!#<?"NY8B@4$<[CO-1,
MW?_4O?C4_B>N1)D`##R*\[R4C1P4]]R*A8+!(<7/L.C/A2I`!ZU2)Z5S!*2E
M`".N^_4Q"[T##;T]-A?#K9Q2%/W*(9W7/=S1?-W7'*W7(?W+O\P7*7W%J)#%
MVYO%M;HX6&RBQ9Q4%=N!W(LFM;O70KQN99S3PVH/:-S31.`"S%005+JL0UW4
MWBPHW<2UB+O:K'VX=K5?YUP`!B&(>Z(0Q$B,C4B4"]=@5QUQ62T38KK5[K<#
M?ONL2-'/LD$^`\1]&%C7=/D6RTT74U1@EY#*(X7'<BG1FGO7@-W=#NK7X!W>
MJ^G=L(S2E=/+XY"S0;N]$,++#N)U[QVBG'FB>`V'7GS_"FD"H?MRV7@HK-"L
MTR'9TR<`VOX@VMD\U`YAVO<;K>H)C*MMN'7UVHAKDK4MR(0\&ABPVY'2VQ)6
MSSH0W$\YW,6M86MP<Q"T<10=8`.]X@`-<*!\R:)L,LU2*,^:$H["RA-]4O5-
MWJ0IWC[^XT`>CSQN>RB=O754AJ_*O:?QRXNM+U9,>**YO3O><R&Z.<N,3,P\
MQK^'TYP-X-7,QCL:M4!-VMJLX(@($UR;6.>LB_RUVD[-:9NXU"CE`4"@X5;M
MP%@-P8X<XCA6W%&X!@X`!%@6<)\\RAL\<@?GW/L+/CN%`30^*#`LC<Y]@14]
MY#4<Y)B>Z1UMZ?:]Y",JV2V=_[TO#7NYA-AK6(*?WG0FBJA+\**9J=]*R]_*
M9*/_O=EQ4LUIC,U!C>`)#@Y&?>8&$&M(9LYO7NQOKCAV?N>EF*X&H.<SL1./
M+.)D0=R*\'YYK)-Q+-2!U)/;WNW.\.VQ$NZL)X$PS,`XOMTZSNG?J^GLWN[C
MK>Z-.7C!7.4D+;3:^Y"O"IIU%[01.>45N>I@;(<2:KY<#N"@'>`N(.!BGB=D
MOGQF3BB0<D3OU?!$W>T6_^T8#^[3``0]@=J\C><1U^P>#NU#L=N2/.W$?2L;
M)DYN!2*)@MIA<2B(B(BY4TZYXY:X8PRZXQ%F(<D:P9(+>W/:S=R&"N\]/L1[
M[>Y*[__C65ZR1G\YMZJ9@V>KUEO21EZK^8[D+!VTJTZ:+;`.XYL7M%SPKGGK
MN.Z^"R_(V;ZLN"EM,W?:>)PC5A>"FU?WH'#SSQ?I>E]^'"X]">#L,D'RD-SG
M(*7/NK%Y4IGXBK_XE(S!_.G-_K,KF>NP<^'O3X\Y/+RZ2[_Y?=WT'WWYV9AI
MO;1V\KWD$LD;J8[%5USJY%#J$=+U1+YV(WIN20N/LTSVTFSVZ@#:?X@G#+_V
M<JQ\1`T._=GST#CSN^GQ>[_\Y3ZW,/&E?S_R8VKRQ%WXDIR7Q:P;7:']V:,5
M7"%'BA]233'^7OWXAK(K>#;IE0_Z&\CY[O_^(<O^QN+$#=+_TKAJ72H]V&92
MQ:X*"`H;&RTMA`J(B8J+C(V.B(:$&U\M"BU?)TN/C$N=GI^@GQ"CI*4GIZ2G
MJJNL1*=3'B\O`1X!MK>XMQZ[O+:\'ADC#@X[.\/#Q<D[$\S-SL_0T=+3TP8&
M.MC9.M9G9W]_V`D&54#:X!,&4M;-Q6W)[N]K:Y&#7X/W@X7ZA83[_O[]_OD;
MT4:>P8-M$B9LEVQ"0PP98%282+%BA3D8YU3:Q+&CQX\@0XI4$*JDR9,H4ZI<
MR;*ERY>>1LJ<27/DB)N)1EBRIP`GO4HC!MV\F8_0"$,MA#D(>N\HI9HAZ=D3
MUN*4)I)7-\%<4JHK!%6I6(EU<<+5_PE8LFCE6NOK5RU:O#(H(&;L&%UE=AT6
MH\:WKU]KVK)Q\P9.ASARYG2@4V>`W0YXRI09'#KBH.7+:W!BSEQY'^7+"@MN
M5AAYF5YC$2VJSJ@1JNO7L#EMG0W3J^W;N'.7HLW[9.S?P!=1[JG3P:4-.`7Q
MG'M\V,U+0)TF[6G(7J3@C9;P(_3ER\U3&SMYW)H;["BQZ,F>13OK+5M<;FOM
M@OL%65V[=^_GC^SPF6EH^`WCUS.`!;:-`=U\$\XXY61SSC7K,,-0:<7LMQ>%
M%(:V4&B;&:0A9.TD!-I"RCBSC`,;2*1:1:QMA-V+,,K6VXPGZ6;CC;?1J&-6
M,?8HTU`Y[?]DU%"'(#45D90L=4]23!7RE(^6G&"/4)$4@HAXX]6&FWE?H;>*
M"UU.P9Y:[\'G%EQP;3!,0@'B95<RQS@3H(`#ULE,@8$-IJ!A#"8&6(1Z@0BG
M`Q)2@R%#'R:JZ(09AG;H?_UID>**+&;D(I28PK;CII[@Z.FGG/*6Z:@=#9=<
ME3I9LIU3R!&YY%'X\`,4(JF^>$EW^03U))99OE0>*N=YJ8H+Q+X22WMEFOD+
MFKNHZ0";;>IWC+1SQODHI':B<XV!Z218V&$-8@/.GXU)^!B%`M(IS:$DAJBH
MH(>:6YJ%>T&C16J43M0BJ?S.%"IMGP8L,&[_LM3OP8[4JBIRM![_UY-QW=$J
MI#"Z>@?=E3#ZU%T**>`35'@?D7>;6&$)>T*QJJ205K)K]?*6?,Y&5NW,U69K
M\YW;YHD@80LBYN"!C#EV;;TF#MWN.XL.?:'2?$V:[T4857`IPE0[4K#(.`JD
MM4`#DW*U2E6'S<@E)V!\<<5/ZLJD4)-,'5M6&TV90<?5+?E)1[/9YF7)PA*K
MW@DJS\)RR_+Y0HN:\-*L>%XW9YNS-MWRS*?/V#P`-*!*-U2TT:6]"R]_IS%-
MC=/YSG&1U&*GKLC7HG3M^NN@LLZKZF%#5RM2N$]%:U'(7??B584X94\&&11"
M_"0;@,(1P%[M':S)?J>\\N!FD@GSLS(O_ZY]XXX;N(T4WO8<K@Z66Q.TO**C
M?RV\[PZM_J-]D4ZIZ::[33O"LG,%^_[\$RS[_:EC"I!N!10"[FXJ%_.13HZS
M@0Q(@GC=F4(E0F$UYG7%>5V"'LH`-SWJM<5ZA\.>F[2G..[9Z7&"`9_DP*6-
M\J4#<YDC6@S9ES3X"<V&HU-1Z4YG/P#R*W_](T553$;$('KM?SZLVE(PH0@I
M;4171MF)DUJ%*2CFXPLIL,=33)(="YH"/7SS4O1.$3@/5N]E(104"1=GPCJA
M$!N1VQ,+L^'"\X4NAG=\E.<^Y+[-46A`\EL1_5"71*J%RH@C(V(1$>F5?Q72
MD"09A")R)XE^]/_C*3=Q@+]XM+I$,"DH632$`Y'GHI)T,6_-`^/S^K;!,IKQ
M@VCT`.*RM\:9M7%`;_Q>^"8WOCK",(;`=-<>CX8A_Q03D#J<'P\?B3_>,#*5
MBHSF(I]Y1-HP\V`M6`+$7`2K$Q1I$B>0%<;\9:6$P2HI#)P$KL)IB:M04$98
M^R+)5BG&5G;0@_.)Y2Q'6,LYW?(OWHOCM_I$Q\N5*X_!-%JBA$G,/_H1='X)
MY&J6><W?`+%KTLRH1C?*BM?EKZ*V"J>5M',(1+0M@5?BY"-XM8^L7.4Y4YJ2
M\*JSD6Q^+9$<9<48.2BX5^K"<!ZHS^<JU$]__E,:N=330"E'/H/>L(__"&77
M8X;94(B^3W,13:8@*0I2U^2O))]2Y05SNE$<G<!37WUG5X'C)&X20CN%`(](
M8J(JDX83$YIX*5'HUAU8$4*DXF$=3LEZ"K_]S94^S85\A'JHHAKUJ-!(J@$>
ML$*"5LZI5SUF9C$$HF%>"QI+*U%6GW:Z^JW5JQ<=&`;E25BR#I9+-OKH:7]S
MSE0=115.*EM(Z*J(#8BT._J@C#JGXC&X8DEV>FMM87>*V,3^-*@B1)=C\0/9
M:$B6LG*T;%/-]TNH1K51RO`L#K^+K6DXX`M:G:AI9TN3U*I6N?"-+[!BBT3V
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M-(:[X8UP>+J%H`XU:-E%ZA';T,SF3?/3UIQK5W-JP82UC6$C'>UYOU:59]5-
MP=K=7D^>8E>\/24GX5HWH@Q)G1S#Q]PV(,&\OIK)1-Q@8<?"7"@G=K$*J"I1
MJYSM.VT[0=[N,G<[+.X2(PT>5-5XO="=:G7OT'2ZO7-:.P4!_<EXWCBG]ZS3
M@W-/S??6,[\;OU=Z7*PXFZ7[6%U1@,L<7$VQ@8,@,+-3BMR!%2OG6)>VQ:DW
M'[@$->/PL`\MURC:;.=2"BKLMF&^_3.TVQ&8[WM?RA>:4/3QI4)I-MVZ*Q#_
M<S8'W6MRAD#6<;YS#=K;K+!M9-`#/O1%^/GH2-='.[=9%0(NP3KLG,04-B#U
M4-K4S9Y"V>"S[F!JOVP77P`[42]-=JQJ^NQI_Q;;Q:4#MW?W7*8NC=SGKJ&$
MCK=HJM;[#OM^X\6/#)&CUWGA5_$ZYI\'Z#-OO,#AJ3S'DU02E(AK=T2*%#X7
M>]G9_WS!]C?&Y!/^R0]^9==YD7H2B9V?)"S[Z[V'=F[+GJG@L#W)WW%NT#6*
M]RKG>^N"9A(A?,I$?"TV<UN2;QC%<^;G@.9W?F0%)M!T5A;X<[L1?=('$B;1
M0U*B'<O6"3,%5U]0/$N`/%A$"7DE?LXD,(G7%7]S_S(16''I9T;KAWJJ5Q>L
M%W^N=V6P9W\A-S[YAW:W9VW'%&(`:(1U)VH$>#I[AX#V]54+B($!4T\S>(58
M*''3Q%IB91M?M8&+MCPE<2E'426WPDYEN&/\P'3#I8*0UX)52(6/)H-76'I1
M=GI?YW[T4E3RYX/T%WM!F!CZ]U1*J'M1Y0Z\YWO%9&+`EW>K!H7L!7I<&'KS
M9H59>(G)EU'$,E;"HF\V-G2,1WV>D$U7XB399P_75U/;]Q0?Z%<J*`HH(6,O
MF$%?DH5V>'%XV'YAMX?]U(<6]H,@MW;X5WM$N'^,$FIZ-'>*^'N.$7R/F&N2
M2$]A%4TSJ%,[-2R8&(,1M_^)<SA/7BA;TO=XUA<*I*@J^H`\5R$E_>`4#G05
M)=@/?!9.HUAS)B&+5*B-=(B%M^A3-YB'N[B#VN.+U06,:K=EPSB(ZE.(_D=N
M*;>,FC5NSOB$T(A<-L>)<BAKVUB'&?DW.9<>'"5XM$ACT!<J&_A.+9$(!%<5
M3A<EVV=3QZ$/W?&*O897^E,C]LB`7)B/^BAI=^AU_@@M$U9+`@E99Z<#6C9[
M.I!_UG![<`=BX06`G),^$)EW!D@1>@=S$[EDU813\*:).\E@$1A-(>F-7JAX
M)%F2!L-%@O!;_>!-W!<0VB$E;ME6!(<*\?1>SE<*D9:-Z$=M;8&#S\(F5+9Q
M`<G_B'YH(&B'7?<GA+6WE,883$[YE$FH<85X=TW(&E4)-7,`B;,U?KO!9%TI
M31JY?`RVA3>R;VAI,*LS'94''>?(=-XW06>H#W)I4V`16"LQ8V0I>-?(ESQY
M<7_Y=8'9!A9B'T)IF+_XAXH9B&WGF`^%1Z=V<F3FD&`V@,''&JN!$9QY6IY9
M:WF9"KR)CQN9B1HEGCFUE^;9B<'B:'7&*6#X$DHF19>0`IE0"#/YFJ^HDD42
MDYG0"5U"CQ7)/W1&"M>HDSLY;388G*DWG,5)%\>):@.IG)UVD,X9F=3Y?^US
MH29BG529$=FYF5GY;J$)6]B8GJP4EJ2I2/2FA1\YDCOR_YXN@9)QF7V7%'Y5
MHE\!P0]W)4%GT9^]=I&Z.:#FF8WJ@:#XI*!SH1`-2IB+TX.'&1B)*3D/@)1*
MN93/>:%(F*&101HE!Z%X5X#862G:&:*;`FT8%'$0:(MB002N("93D*(IRIYF
MZ9ZIN1(RJI]M`PD%U@E28J/,%FP19)LTR15`FC7_8&LL:J`'NG6#@X?"J:2#
M>6TSXZ3)B9A2L)SD0Z6-::46BJ5;.IV?RD=EQJ%@ZJ%7R1K;N5;=B9$=14_1
M0Z18QZ9L2GK6.'II6HUD):<9>);A&*/!!AZ6QY)?$&P$!)/68:P(=A:8T)__
M"6.0QI&UZ)M&RG5(RJ"1^J`=Y_]QEHJI4TJAG&IRGLI0HAJJO><^7GJ9V'FJ
M&9&J(+6JK`H6FZA(;CJO]+H>8B(6`E$%58`!-M"O3_"O_^J8`#NP!%NP`.NO
M3V`#"=NO#%L'&/"P55`'=3!$8MFJ<[HI,*J:OQI7OG6*W*$/?':*<BF/A2`F
M*KD*G?*FNCJ-$WA^L'I8C,HRCKJ@7/I^@])ZV8H.]#=9A&$Y!ADN"J(.MM>I
MABAW8E9#TEFNIF8H$Q"142.F(,J=;Z@CN2&G0P2>!!H]F/`%4Q"3N((/A*"O
M8ML%"EL#9GNV"3`&:KNV8V`";FL"91"W:C"W=$NW<7NW=_NV;XNW9;"W?-NW
M>ZNW;CO_!C9PKS(H@["F;[O*JUVE4E/+1:/8I_L`3MED>7RZ?9<[K/[9I_TI
ME_HC)2IKGP1GIKOI%>KQLAU)%JXPK8UJ.)6F`!-2+4PZJ6-70C:32]N`76?P
M`)8#!",`M$.(=A,@!43K>@(R-%H@KE0U55IJ56?6M).2F589->P*0`[W;+=A
MM?/%@$X6MOKZL&1K`VC+MFIK`CUPON@KN&^+OCWPM^ZKOF][!7XPO_1;O_9[
MO_3[MO5[M@Q7JQ588XM+IZESDJ+($KEEG]5!LMOG:YBK`)SK"0\\DX/*M6=%
M<]YIL5.(NH2GNK_)CZXKG+@GNY(:+?!',S>#NSPK1YKJ=L3;_PQ:\,):H"YW
MQ(2/DKS,FXCF5K1,BR(I)J9\UYF/.R-5*T3;JY=@<@IUD`#LF[YZB[]^$`)0
M',52',5^<`7RZ\18?+]3/,5GV\7TZ\7U&\51T`55\*8Z=3(6B9,UAIH#O'CQ
M6+EM1;$T.42GN*P5_*-FS+D7:+@!FI/J:;H;I,&5R,&L*[,?3+.[&"T\6,*V
M=+OT1S[<5CFS%[1N!P2-`<-:X,(QG&DW=*7[,9F(V+Q#"5K0V\/3BY52RVB-
M1L07B)-C]`1K6[]C4`-0'`2V?,NXG,NZ;,M;W,M;3,M2W,7";+;V2[YC@,5B
MK`%=,`7X>+IA5*BC<#6JX\;$RFO&JO_`<\RYVF<5O=:URRK!RTK!+UB>M+I<
M@GQU9='!ZG?(29K(^#&[(LS(->/(EOH'W.:SGK9EV'`&6];/_OS/_@P$`@W#
M=G=';Z*\H.PH.MP7)R)1*D:]0*S*V<O*>?DWFU<#8Z`!0:#1O+S+'NW+(,W%
MPSS2PMP%76"V)IW2*KW2&M#2&I`&:6`!,FT!(1`$,=`%&Z"%')FH].5(;>S&
ME<MKG="2)!&3+HFY$ES!7]'`?9K'2@VGT7K.)Y/.A9PL:/2ZPRFI\#PG5+8]
MC@-[]MP-XK-EO'L&/>"V<SL#:KW6;#T#<^NV"2#00/#"IY%'!XU[-YS0#74S
M/*QF$)W*[MK_%=IKL7\S"#7@!RT]Q2N]V"K-L#8@MI`=V9*MKV!;V99]#S"=
MV9J=V1F@V1$0`!00VC=``5!,TS'0F^8LGLWZC3Z]2=3\+Y:G#Q)$-GWZJYBK
MQQ7,N;3XI@`ZA^_JE>=,%H0<LU;-SEE];5M-PC?+1E^=`/7<:2<]!CU`MUB`
M!21PW=A-`M6=W=I=W6H`N#5@`YALPV/'?PB=A`Z5+7TMO?KRUZH:Q+TQQ*-`
ML5Q2V!MPV"T=!3&PW_I-//[]WX=V#UX[X`1>X!QSX`B>`O&Q+`70X`X.`Q`.
M`QXJ`!,A``(@`A?0!%30!$40`AU>!<U\NHDZB]',QL#VVC/"@K;=_[G_QFRK
MD$U]>MN84'-?X<WA/`7T^!6^?2,F6JN"/-6K2]QE<M6/JH?O/,)'+L^/Y48&
MX-Q0*@7?L"=3:@)J,`/<C07?70;5O>76?>7>_=TF$->8')3AE;0)72&C3`WK
MS=X>6KWW(]&-)IJG,`A=D-$:8`&V$`%ZON=\GN=\KN?NX1X!X.`-S@2&;NAS
M0`"*3@`6+@!-H`07$.F2[@647NE>,`"8GNF8#@6<SND,P`!0\`&B_@$,P`8,
M4`(EX`,A$`7*3`2!+.*^3>(6C+'C6'VUCN*<0K$0S+6"JKGA5-N9N[D+3,%A
M,99JG+65*)K!+195/>2*)1=939S3\BB8%O\@M]ODB`D'1DD^#R`!5<[=UUW=
M?:OEV-WEVEWN6QZW;QO7XKT&F8S71_LA:["\R&!"#A`1$OZTI[RNG1G87D'?
MT#/G&V`#=FX!!9`1'=`!%:#P'0`#"D_A%BX"$B_Q.(`#$U_Q&'\``\`#F>[I
MG0X%G\X`(##R'S_R)G_R(``%)A\&)L_I+0\%81#R7``"7,`%JAX$8TQQA?7,
M&+RKU40C!>RXN'XU9[CB*LF?<>6Y,;X*9KQ][WH;':GLRPZS-7BD\`'MI"'M
M-MO5U2[#N(3M4&J4W<`":N#E7(X%<<OEYQ[NV9WN?&L"X?WN";6\UM8X!]6T
M^*[OFHF9;DX[<)[_O=2(,AM0YRUM`00@`A;/\4;``R7``Y&^^(P/`C0P\RA?
M^99_^9@O\I6/ZB6`^2C_\:@^\C=0TS%@`\,RU;!N[-_I\R4^]*X?*D?OHW(Y
M[-]\*][\;V(2SG8\H#`H@2H:W,*M"E\@Y.\AZ+2`]1MRUT'9]5[_%V\$!]K^
M`-/=]FZOY>)N_=N=_>8>[FB?MV6@!G`_YDB3.727WMQC/L)[[V`*M:C:[]@;
MY[^O'H,_!K9L^)CN!:B^^"!@!`0`"$H@)80E((>(B8J'A8V+C(V$`Y.4`Y&7
MC5X@4#P#/#R%'"$A15U++B>H)ZNJ+JZKL+&K$+2UM$NXM;B[O+V^O\#!_\+#
MQ,7&Q\2QN"=?S2?+SDNK7RE?)Q#37U,GV[2SMMBRJ:[DY>:JXN+GZ^SMY+!?
M+R\!]/7V]_<>^1D*#FW_.]HX&.A@A\&#"'<07,BPH<.%$R)*G$A1H@$#.C)J
MA`/'@`DU)$*2P(*EC,DR)%.J)#ER)1:1+4^:,&'2!!`M6B8D--B&Y\Z#_X+V
M/%AQXL6C1XM>-&I`HH,4,&#,F5.A:H6I6+&>4,"UJ]>O8,.*'4NV++*SX-)"
M:)%.W2MN7<:$"%+DQP4E2HP80:&7PXT?(#Z5X/$(4:%/B!%7JH08DV-,B@A%
M3G0AB)]2TE+%0O>V[36UNW2='4VZM.G3QL(]6__2(IJT9M:>,;.V!)NS*=W"
MJ77'&YUG5KV#GXL5;QZ^X_CTV?/`SQ]`@01_(GQ(O?K`HM@M8M28,8&!!"!#
MICSI4N5(D>5?QJQ99F:9,4!L&-"R8PU0Z?@14D1Z48>*__\E55%3V6$`E514
M69555EN5Y>"#$$:(FC!J@</6;ZST\<H4<<U5Q`U>X,6#7H(--H@AA@36"60G
M7E+8BS`B`@4(7-1H(XT@#,`%#24PP(4A`Q3A1Q`:*``<+)UA^%E:H=TRX9-0
M1GF::*LQ<PTNK<7FC#,GL#6%EMNDH]8XP@VG))EE]J89//(@YV8]RL'97%`!
M+92?0M;ER5!VV?7'G0[_"8"'7DDFN<0>2BR)EYY*[<GT$7PW_10=G@5)9Y04
M4O@'X*8!(L4G109-@($'44UEU54+3M5@A*RVRJJ4O51HRX48NJ"A"[AU&$00
M-S!@A!>?>&+$)UYX<<&OQP;;(P@,I!CCL\\R(*VP%QRKU[5&4-$$`1<<T403
M1C1AB`5^A!"#`VZADF1;%38)`:SPQBNON[F\F]DV+5P(FVQ<9J,EN^"DD^:9
M:*;ISIK3M/FFFW'2PUP_=$(WT)UZ5GS=IP-NQYV@Z)V$*$GM77$%38D.^M*B
MA,K4@QH)V(!30G9.3*E^$6&:*7<`!JJ#I]B%JA.H.XA**H*GIJJJJT@G/1:\
M_[+:0G`Z4U11PUQ!4``%`3_\D)=>%Q!`@!)>@YW7BM!"Z^RS/_)0[;8W4$#!
M#4RT3<`--WS[@]<_-,$`!5>$$(4-&VQCZZW#N8)-+;`T;<N\C#=N&CCUUB8+
M-%]<^&4LN&4>9KKO<&[PYZ"7<P(1"1NW\)O*>9""`D(%)+',DEJL)\86282I
M1@E\9++'((M\Q<?JG=>2>HNV1Y/'9;3\LD&P^ZQ3T!%=)(4*?VHDQ5(2W4DS
M]-D';6"I"5:5*@P5K.;X^:,I[O22X'3^2FRK2%U#%$'X``+8!`P+2@G5CG@M
M*&6#D8VX$,!#$-!_%_@6$YA`@&TQH6M-$`$$M]4$-O_<H&]1"($&K&$K*V@(
M2><(V#?4A[X2FI`7ZH-'E:S$#<VM8ANX>9IG0D=#T*6"=,Q0V.D8YK#5M>X?
MD\*/[!J"']H1:`*W`]08PJ,HY)7$=R8X64J&1Q(UL"0]:C">>TR2Q1K@A#X'
M`>,7<1(]C>$.4-[!WO.`TCI+%254WR.:^,97OA/:D4+J\P;[;.$^W\2O!C78
ME05&U`1K70!8>O'"C`H8P!JAK490D($,#H`#$8@`!S@0PR4Q:4E.BJ&0(BCD
M`6[@!S]$00,;3$4?/,B9$*YOC[*ZHRSGE4=87$XVL]G&$KZDC1;*<(8U#*9P
M;EBZ':*NAZR+F,0H-D0[N9'_=C7K3@)Z,`.3$<IW??L=\*[(392!;"9;)%0"
M;@+&H!EDC!,PP,VJUZF)X(=.17RC]PYDJCD:S7RSG&4>]5BA/B)I%1NHP9""
M8(%C-2%K6<.+0A4)@C!`H02.O-$`"7@(*$!!6AC-J$4M*BU)+`8Q1KB`&,0@
M@`ITP*0P*(!*4ZI2E=*#`E-9(`%\X(<K!"$&51!<'VY5L'*($);MRJ=0H51+
M>-!&&E.H!C3"M+E?>DZ84"T<#HMC3!X&0'7)?,XR\]-,9_X$FK;KSAFJ.<7>
M^6X+0=C"[[QIJ/1HT3U5+`,<EL>]Z*VS>M=S)QN'DA^]UE6OHJ)G^(PF%7P.
M]83[_]3-;M[RCG>TP`;SHTL3*BD``5Q@DYC$P0<^<(#-'N"SE,QL9BUIR9&6
M]%17B0I+Y3$/#[CVM2F(K6QE"YO:UC8-&TB#;M-`CPBXS0<A,($&8J"!#:B2
MI^WXZ3X/RUS0^"*QKPP'E[#Q)1C&!H=.?6I4M_L*%TQ5AU7-!S)_N%4A=K5Y
M"0%K.J7)Q.&5X0I;V$(1$("`(JAUFVYU8DG&\U::6+$,:K#)%[FWG0<8&&='
M3$@;[U21OP(VCO5$559*95CFHB^Q(VP?8[M+CBG88*!%8,*V4)N@#G2`I07(
M1P16S.(6IR`#,(ZQC&5L6]O.=K:OS?%K`[#2E8JOLDR(@O\)S%7<XW)X'<H%
M*N0L+-2@HA"ZL7#:+6T#&]Q@]S/9!0YWM]S=[YHNO,L9KS*#*)WSHI=FT,1(
MH%8FQ??&-PCTC3,"[LM6Y,&U4#4!IWNB:)(>)."+-:.>#@S\`/\<<8VN`XCV
MT*Q>"`]V011F,F+WF6$^,K:G'*J!!G9%@0)00,>Q51UL9TQJ&;^XQ2MVK3U:
MJE(FF/BD%:BLK"U;K6(!BP>VWB@4.,N`#\C@`Q?%*`]\8`)3%G<*@SNR*Q$W
M"R4O3M+ZA"ZE$R?EIMZ&"%?68W:YS&UBYO#+8':8F+5*YMB=-YYIOL@93C82
MF])W`?".-WWI[,U&H62+'M.SO@'_7!,@W.1F!V[G!(1"<$7'+KWJG8BC%03I
MPD*[A-.N=.=Z>JM,:V`4/G!;CJ]ZCQ3S6!X%4"WY3B6`D9J\DZ(5;6<[N]G-
M2O+EDK1H0V4NHXHR:P`6=2@EID6!8I\R<,EN!9)?2>VF/=R.THYXL['L0FZ\
M$&&JR3*WN^WE<",'J__(:E#.S,QS.P]C%YDF>FP:[[++^[X?VZ:C[CTR.YM@
M9/KFLTG&N3&!\Z3@VD/TUQ,>6/`Q?,(./SHM,1QE6JQK'3OM0]2F5DH?,$$`
M^%/H7;Y6K4,.((`9S;RT.%I`R0S"D09D1,TM48(!,.`(`[B@36,`])V6*>JR
M6*[@897T_Z2S2QS87D7NLPS,J6\9AU,(`+BM?E6L.J?@0*S4HLVL?`=C)U`<
M(\$5$&#VZB,@!&WG'7^-YS&1'0^<4-QWH_R,.S5.H/G:*X@#G+)^OD=/X8+]
M.U8B/?MX0;GP$#C\.1*_>('ZP0=B<``#H#^W%E(\H&N,E("&X2*-L#\+.!B$
M(1B)(1D$X`=#QGK(9BO!D0JPAW^*4W^E47NVQWO85H)-Q7NRX'M<5G6GPUI?
MIFK%MSK.D6A"P75E9F:,UB??T0/B409P5GUFAP!(D'WLD3)ZUGUMIV?A=X1:
M%"C78WX*L6@YZ'Y&`7]^)V&`-P<5!H(3<G]%IW_F4'%2$P(UY?\#EZ0VPC(8
M%V`79%,8CO$(CK$8DZ!K&P6!A+`BI"<8@R!`*!!<?A,XJK2!+M"!19='7(@,
M(BAM*#@ZV':"6L8.9Z*"OU=,5J<P\H!U6D=P-FAN736%2O$=U=1NU`>$92>$
M<$<3;W<\6D2$(8.*,X%-<>>*,^%O3=$44HAP5%@[52@1CD85#4=_ATA4A/>%
M?B0ZYA`U74"&)F`!2O`M^5,M7*,UP3((P2*'BW$V#_@8VN@L81!Z$X4($45`
M7-"--,`#03!D40"(@L@*G@%=P?@+B1B/O(<XN\>.&Z@DDLA=I(,;X$5\R'1\
MR+>).\%\GI@Q8R`291`"/D"*I>A]2GC_BF_G?6^5A*\(B[$(3OXV`3G1,T0!
M=IYB,R`9DIAR:.EDA0AB-'.@6EKXCL*H=$L"AD+G"E.P`<D87$&@!#A0(BB2
M(Q!5>A#8"0-P`!<%!8LAE(TT4105&3+'!;@V(A<0+`?``P=`!0?P+5290"%E
M"190;,>6@?MG#O\$,.[(DO42CT6%@H-(=)\3B?D85?LX!?TH?"X8E\*7#SZ4
MB36(?ER%@QWY*3LH$B90!`P);QRP`$7@?7`'18DID4H(?MCDD!=I`D[X*2)9
MF959,R%I.R`I/65DDBB9DBJYA62)%L,X0C#YB#-9DT.F!&$0+M`X(FJC!%WS
M-5NCAPIXF^`8_U)=DS4RM4`B)C<B,#=8TP0'T'-7,%Q`AWA@R8YBF5BC:98N
MZ52&)SK:!8ELV9;"M(]458G&<8FKPQ7(EWRW2)!]R2=_&1+3-Y@<4)A!D)@5
M.3*G*)']]9X6&9E.:)F8DHOJ93.Z&!&].#ZA.9JHX86F68Q])),T.0I]\P-7
MDS64YP5&(#9W<Q=\`4`X\@AT2'.*D*$<NE&Y:5`$P`1NXYL4(``+5$A>$YQ-
M(`,7=(')^974B3#BD'3/"9TIA(*U@`ZDXQME0C#8"57:Z0$O`(/%IV-&>J2N
MU1P*EI?CR9=[5Q1:<)Y8H)"DN)[KN0#M.9'P"9'9%XLUY3NE=)%:]/]O^4F%
MZ,1W(/E^$J$%@O6+`2J@I%&:^-=8U'D.J<EX?D`!`W`LR6($DJ`_*/)0V(B;
M,I(B9Y.A#+`))!)2WP*-A<2G=_&H30`%/V"!YK(!QG6/,JIMSC:6@F>C:9$O
MHDHKL5<A*<BI:'("F.J(,61+FI,Y+?2JLBJKL8"IMGJKN(JK55`%+;"KOOJK
MN[H!P#JL58"K,7"LR)JLR!H%S-JLSJJLQZH!7=`%THI*58`!:Y"7SR&0E"([
MY=DG8D<"/@B$5FJE6`J9KYBNX/=]<?>8I0217JH%>2`%^EFOTB,@T,.F(K>O
M_`H#H@FGL2*"8DFG!_H.46,#9)BG`Q@NDI?_0+*9(ES``(M$J`KX4(D:&`1H
M!#A0+(/A!3C7"<4R+$;``$H07#40`QE@7#T5DYMA.*AJHTP&JHHSJOG2G&FQ
M83SJ>JB`J=K0`DM0!T`;M$([`L0JM$9[M$:+`76``=/:!<0ZK-+:M%U@`S8@
MM59+K:B4M5J[M=&ZM1K@K,\*K45@`61;MA80`V;K`Q:@`5J0K5OG#_8!1'MY
M;I^2$Q=QD.(:!-57KN:J5MID/(CYD.RJ;^YZBO/9'GDPK_1:KU3('P0"/4_1
MKY+KKP!+#(DXL,H6DP9;!3:@`8W'L`[*+95W`1"["0J8E)%AJ(.ZAR<""<W2
M(Q1%0(9:<Q!E!$%0_P9^@+*QX0J$`T*=00[,5HB)>#XR"YU/(RL'VK)6@`I?
MD`$1$``1(*V`-+W46[V`-`HA<+W8N[U2JT%;.PI;"[;B.[[->JSEFZQDBVIF
MN[[KBVHLY@/P&[_Q2P'PNV(9YS;X:P%5T+;96B=PZSIZ.1TX6+?1\P#59`)P
M-E_OQK=7JE:J&#)+&)$/3+B/281'B(IPH+B,R[@$0J\7$;F3RZ__6KEE.8(S
M.IWJ4J=@>;`7=P4%]0G'0I2<1ZB%$".>EPC86,.0@`@7JR**D)1,603O%049
ML+L:V%V/J&7!6VDBZ#C%JXCSN%BMY$>$\P4\-@<4$`7^-S79:[W6N[U@'/_&
MX*NU47"L13"V[)O&%F"_^-O&\BN_;1S']#N_<ES'<_S&]_M;$9#'^3NU;NN_
M;1"W`C&WG4C`Z20H/MB>:#6*#+P`:"<3$9RN;D>?4)1O^"97&HP=B[O!%9&9
M_/G!&1#"(DS">%1[F)O"!;LAG-O"0:`WXL@%@@H%H'>;JVL8MHP(:D.ZSG+#
M!L0C%!6A2D`8K0N.)4!L)A`%+\9!ZY#$9++$PDNCC?/$<NI4!V./+:N!)Y`!
M+U`!!$`!EE%*Y2+&XCS.8;PKYKPKYZO&9XN^ZHRLZERV++9;\KQ;ZPRMX^NU
M6CL*1:"V?JRM@AS`!T&0!'P1*B`!,Z`&<^%N9<?_M^=Z$ED4D?":BI/LF/*)
M/,@#!T"0IA/!GYR\T8MK,YR93@8`PJ*L6B-,PI<K)BA<,(^HRIV+?4%``!>+
M(B4@<X-Q>8Q4`M=2RV=CJ$;P-<,RNXGP"3GB":"@%W?(RS7"-\(5`1G0TCQZ
MH,[\S)XZ>-)\H[QGG4=2C$3082_0`5C\S>#\KGHVUA88=V:=UFKM!U[<UF[]
MUM.[O5P\"I`%2-,JSE=[M53+N9V+2J<T"E'`SS;@MLD7R/Y+R,WD?!-AM_^1
M`"R`T$605O-%F`S=GMI4$A"]9TP(8`%&N#5UR4X$8&<`!_2*GV7:T4CDP8ZK
MV@X0RB5MTJ0<#"E]POF7_[E0#5!8.V0_`'JSS#]?(\POTL.,$%)^BKI#G1<@
M0"(ZC=R#L;ISPZ=X47DA%<R/0$I-G;(92#@X&Y-3W:F&&,U7C=6+Z#DR:F00
M,`4%8&(%$`/^%Z8]\-X],`;R/=_T3=_0Y]9``$A4N]\8T-_]_;3!FJL"?JNE
M5N`%/ELU9ELSE@+*0;\6D'%K:P,8X,^';5YTRR=V.P'4\P`(75_Q]6X+4-DB
M@V<0[2C@1"A8\-"$"TX631X`Q@*DG=KXB=J8F2G>4;4UD``90:]L&G*O3;FD
M#*H84MN^&]4KG-M^<`,U8@BR*\P1&M2\O(<)E,M&("S80KJ1T00W0`!J\RT*
M9?\$R7T!."V[-/+3GX`_6',!G,`#LVRZ/^"'3IV<VHTP!-O=5-W$J1'>)CS>
M^&@F2.)ZW!``ZAT#"3L&)TM<PP6MQUK@MBIC&V#@D"Y;I79CE%[IEF[I2)KI
M.D8/K%8`\$N_&N`R%/XZ`#W`Y]=^%&&W!B!H9Q`""X``=`'B(6ZNEDWBE9QG
M,Y%%*-'9%`S:-?%?:J`&I&W:FTSCI=TR&;#>8_``B]OC/P[D*&VCM:*Y4[R<
MPMH%45!*%#`8-\`!&,L!7\,!UB*;PBR[A/`7L1DVT'@7%_`(>\H#OB(VQ^(C
M3"ZQB[11DO0!`D``D$<`(D`)OV)ZE``%E5%L$>`!N,'_N\;8LB"$JJ6JYTP"
MCQ`O*WR>@MN]S)O!4\&7WNO=!34@WUV@#YJ.I)7N6J$V\@U3#_,PERP?PJCU
M\B1767=@<I5E<C8_4@"0\SJ_\YPD`DQ@`?3[-P`Y$(9-ZC'CI!%Q,4J11'"0
M!C>``/`59PO-GB/N*/*IV2Z^XA+LT/P612D>[!E,[/E9[)2IT9W\A$`0`^L=
M*/0A!<[^XR<=C$+^&Q=?Y.9`.E70!3'0>#I]`TK`!1$:-MSR/\N"(\V2E4;`
MFTK@L0P@`PP0!A%+<SV"42$BNC@@@).@L3M'E`ED6;/F^0K$!"+P64$I`UY0
M!,46`PB?W0L/0@U/B'<^\;*?_Q85CX]V;XS%J/$\U@'KG;!^H`&<7@#Z8!P%
MT"8ZQ%K"%W(^%A4O/VLW__S0__P[G_,XK_.E)0(\GW*B-?W<O_W3GW(S%?02
M/NK4T:T7KO1*`2AP@`04P`%0_UZR/NL-;6<5_7U<?Y$5G>+D,1+!#@@)4H.$
MA892$XF*BXR&C(F%0`9`734)!EH34EHI,)Z?H*$P)TNEIJ>HJ:JKK*VNJQ"Q
MLK.TM;,GN+FZN"XNO+V]N<'`P+A573%^?A8\7$8@($9*31?5)0Q<7`PR7`,\
MV#('#`<'.`3G2A=>.#@\U0,,`U!0`P,7YP1*2@("3?[W!9AX&<!NWH4.!1(6
MZ-"A`O\_,7,B6&`B@MR!#P-\F#`1Q4.&$[WZ]"GF2U@PD+)VJ;3%LJ7+ES!C
MRE1)LZ;-F[^(D2PI3*2O*0$6,K$00ID?#05@5*B0M$+#I:(\0>T@0,S2"E8=
MBMG*M:L($5VWB@!`MNS8LF3/HEV;%L#7MVY%L)O+CJU=LCCPTL5Q44`$"CZB
MV,#0IG`;!PYVK-EQ&+%CQSL>2YY,&?&.1(@?+3*@(P$2'QPX+"ARY<H6!*@7
MJ!9-NHSKUR9*FX#M>K9K-;4WZHY]Q789++A?8P&NQ@0<`X>2*U]>Z%'R!)8N
M(=?!*:KU4:^R:]_._93,ESA!EM1I4CRQ$U..Q2@:Y$*#$CS_XE](EVZN"`)-
M^-8;4.X^.@(.\2,@!100,!<\`Q!P`X$)-22@`!18$`$3>QT4@`48%G#55C"D
M$04%%94CS@V]:1#!1R#Y-(PN.IV'TW<PQBBC2^'5:&--+19CWBXNC/23!P$-
M590R(5`4EH!A)<D5`&(\^)"24"[)9%AH<0776GME^95];X%%5I1@/A21#S[$
MT`5AAAVF&&.5)=;FFY1-D)EFB1C@F04<&"$:`EML$401J2T0V@((7$%;&;R]
MIBBBMR&Z6V^\S88;<(H.IP9N<`#!W*:<(K*((7E(T5ET@@S"25+7A4)*=ZRV
MVNJ,M81W$GF_F%?,%!MTH4$()H30_P0#!##!!#X$4,7/03X4R%<Y[`1+(($,
M!2A`!Q;$0$$3'Y"3K1(W1!!##!$86Y483*21!H5TB8`0@P[>494`!4SX%@X,
MY/"#'[V>.$6*/OK"DZTDU0CKP`3'>N/!/-*:<(XG[<BB3^@!*:P/0_H10@$'
M-&D5#/IT7,U656[EY+A(@FDR5R-?I?)2#+7<`0P*Q5Q``#33/'/--7N@\\XZ
M1^#SST!'4("$99ZI0!N,J;E88Y1%!N?3DM&92`)`I/%#:'OZ&>AJH17Z6F^N
ME;;HH;CM%MM&LI6!VZ6P#4=<IIW&O9PFR>D`QP81:#"&=)ND@&JJGZSJZN"$
MLU)P++*.Y_^B>`#_E.MZO1(@`T(^![64`%H5\"V(<WWPP;3>QF"!AEB)["T%
M8M!U@!),4!"44I<W64$`'LP!EER>$U#`#_H`R`_,!7CP5P$44'0`&P2$<$4-
M^O*K<./_OGCX]#(B;/U-#+NHXXH/CX0+D#!$I(%1(02`.50O@/+"^NR_$`#[
M-'OP?ONT\VS_SBGDK__^_/>?P?\`#*``!TA``>8O:#[;603DA[.:5>!G%C!:
MFA*SM#8Y#6H8=(#4#*`!)EP`:X1"#0)4(RBL<<!K88.4V+#P&THY2@TL1%MO
M9),VMBEJ-L-1VP/DQL-#T`U44K!!`"[@`S\D0`M:Z-O?`(>=PF7_YSN#*]@)
M$(>38>0(>B79EZXT8`(_,$$&\/*6SY8BACMLA5HQ*$!%V'$1=1'O!@Z2W5+B
M%8`*S$$`;+P`$Q@B@#N040PP2*#/?!`!V_$E6#?`A\8>:*Y&?N@".&##!8*@
MC!AD8%\,R\D5PT.]3L+H>J!42?9&N2+%^0@7?@M?WHQ2`W#]3'@,K%\*\!?`
M+]@R`_G#9?]V.4O[]?)^/&N?,-=WG9494UHE4U*7U#(O"'9A,$@K3&*29L$=
M6/.:%\S@9!YA``Y>RX1[&B'73(C",L@&;2V$(0M?&,/2S/"=M@D.;7*HAC/`
MH8?X1(1R)J$!HO@!"$CL&Q-!(3@GFH)@_]OQ)$RL2$H736%?(#E!':JP'C]0
M@`&`W&.QM"*`.7@T7@7P*!YQ\`$<,.$'/T"!$ASRE8@(SUP12(/Y>``%$<SA
M!BE%`0'X(0(*-/*G:N1+$SK`A(7\#G-B%)W/"B`&$<B`!Q:H9`8V\`L5-90D
M"LTJ3&[TG:M&3Y->75PFIY"!`!"5`N,SBK4H\!>VV@Q5"@%>4I;XB:>H["&W
MZ])>[E(6=GC.(H!EH^=*FJ6]W@5D7_K2D43V+K_\3`-`P,`(DL:T:38-F]?4
M9F48H04@:``TX!0-"4L(S@48*H6VV8@Z85@V'!8'4I%RIVL;I5JWF0`)APB5
M(WZ8S^0@)P]P"/\N'/*0AVXZ8`KI&V@3#7K0@254JRQAJ%=Q\=!?+*$*$0A"
M"'PP`(@,2Z6E(]?/TA#3-'"N'`3XP0V<`""6$L!#/R7O'+P`!1P(X*1.X%U1
M@P4TFE'`=A6Y!T(*`+H(_+$",&CJ5IIP@!(4\2B7!&M8B0'="M."JS*9KB@G
MK+"QEI6H!=!`#8P2@:\\1$!8$5!"KL*//XK,F'Q<YE?\L4RQ@.5((\NQCG>L
M8Y2-*TE30FQ3X^4S#0QFLH9YC#4OB]EL:M8QC/"L#Y@06M&.L[2G-2?8V`F<
M'#)J.+J!9Z34%IS@X#"']RP$<7W(V][F%@Y(B#,2@BL%`S@@`\D=:$'_F6OA
MK.+B)=*]:BX@Z@(BM`"[%@B"#WB`@PZL5PGGX&D!&KF!1D8@/YZ;5@'@Z)0"
M72!"9$H6@0@`2?LZQ:@4L!9*+R""\,EE7B)82@`RD)!O$5@N\9H##D3`#QQP
M@0)$^A\F.=PB\$RQS[`Z6(8UO#!B\\3#`8`!0D1L%`OPA==-^LH9&4*S#LSA
M93"3]E6BY5%AX0/%+!9`I'?<U+=H3,;S8D>\"TOO=,&[J?*6BWU,*J&\#69I
MTH2,DRW3Y($_F1%(2,,-JFQETI9V"[_1<FI-H$ZWU::%88[4F-5&YABV\#<F
M0`XAUNP(-S,'SE%`S1;F3-SJ*'>Y?$8V]70!_VA_35B4AD9T$"S@A0.<E;V:
MOF\$XA?M@%"#'=,:,%-BX`-UYV<.!-YU-2")N4`*38P=((`71.`S`7R`U_D!
M`%)-!"\"5T4$\8(!6/AQ`"[<`%\U$#86&_J+6;C`8'^6>4M"F7=:;+)&SAZE
M25J$'J!(NP!1&+$RK)VM<ER`IUEA"A-*1C(!O875<KG(8'?=I6KHNS]?P3R\
M1S_U)O3#'ZA'/8]7WP]^-`$_GG_+4`AI9`P`O+)+GDS!#:[916CA0R8<K?`=
M#D*(YW#+B*JXI5X#0T>Y4X5;7EOS-Y)#+)A`S0$MN<F3`]PHW*`$'(A"G+60
M!Y<K=\_=T;M":5+SN?]GDD6].'0$?%"$(ES@<P.F2JH+](-U0+TB(C`?7O`!
M6>$SZP,N#2$7J08#N[85D+0Q&[`!2A%M2W$!8A``$2``:\=J]B4&(/5N3G%J
M3&!'=R0"-)`\761)PT9L+!(+P'!A*Z%^M\!WMO!W\!=X835X`?-0'@`#PE)1
MRA`$3A4/.-`$W\9K=_1M1+5N.W4.YH8?J2<"5$`7C^=ZIB<`TU`-ZM:$3C@L
MQ.(R+>.%J4<-4S=U\$9O@#4/4+`-1\``[I!>33``;=@$%D!(@F$#:^``229P
M3(993[9-BH`!H!5\PT="H44H5W!\BX(%)$`";N-ETQ=;\*0HK,5.OZ$&.C#_
M<DFT?7$#7"%``2AP`T$P?N67!@EQ?DL@$ZH@@YW$?BX1:((V>">`73Y@`45`
M`)\S.^`R,]92`10A`F6B:T6(1U_G%-X"`W>P$$V2'TP0+F+W$$R".3037O=%
M`3(S+.G`:YBS$&1X#UY(+.G@!5S0!)0$82OH;+S@@B@Q@YRT?GSGBG9'$S@X
MC\^V25,@,4*B#%?@*SG``%0P`$:@;O<Q+#=P`^;6>J>7>JQF!*%G!`XY%U1`
M!3RP'Q19`@=0#Q8QD$\H+"YS4B=%`"+```QP!!=)D?L1'RCID"II!!?P#V4X
MAOCP`^E%`/]X!!=0A][R3(3!)DIF<+OWAU$3B#YP_S6E58A&62B*Z!HLQ(B.
MZ(A=AG$R)(F^<1OKI)0LI`8/``3$57Z<&#=V`P<A$`7B-URA<BIT%15)00JJ
MF`JL.#TUT7XLJ$FS.']%$`1,<`"F5P#_`Q4.T0%-@'8&QEAB4`Z8XSH=(#+W
M8)"MLQ!&A4>\=FI4T6[IU3+X$(Z[5A5+X3%>0%-JV)E0X`SEJ`$1-H]U-Q[L
M*#V>]([P*`M?Y7[T2$HZ2`Q$$#$!02U#LH\$D`-L``\,T)+^(0+#<I&`91%_
M-9PG.9'U$!_)B9+QH9)?X9#>B%+I)2S429T_\)'$DEXH)9/GL)TH59`X=9W@
M&9[>N9TXA5,L>0%&()$W2?](9@)-/,F'NE=P0/D8OA<%R>)P1GF4QF=.5OD;
MC1B@;J-.&2>58^-E'Z<&$J"5)-=F75DWP35GPZ4%W?0$>#90:=F6&IH2J\F:
M+@B+L4@,Z?$7B48!]M!103$N8%%4,6.-#D(.ZM8Z5#%UV8D.Z:`.4#`?^9"%
M`4@O;)`M\2"20HJ7_G!''56"$"$`Y/"<)<`%)1!5?M`%HTF:Q7::N2!SJKEA
MSQ.;KYF#$G8"LXD>?L,$<^!/1,($.<";4,`#3<"2/]`$.)5ZW,F=W?F$W5F>
MZN6=!:E>!<D$?6J>7BB>)X52?BJ3W[FGYDFGTJF=BYI>!@F%^.`/W?EZ^%&0
M1B#_#@=0B]Y2>]$D&;OWJ?2I35&F`6E@B^(40OLI?%N0B)7B-@':B(^80[P!
M3[)UB?])?>O4`PFPE0_:*2(G!;Q:9P9@H>ESEJ&0H1NJH6\97;,2ER**707@
M`XIF#SOE"4BB;M[&#\4"DE^1+5LBD)RW+.(P#O(`#6H(:5XP'Y`FD_[PIA/)
M`PYY#<!BBV(9!1I`JC$5!>="8Q<P`%P``E`:=P_UFK:"=S2';%EZ/5V*CA)6
M:-0UIAT0`2&@>'YP`VG*`-`P`$T`K[R#4M.@#Q10D"'KIR);/'Y*LN49GG>Z
MLHVJG?G@J"_KLI+:G=/0G?@!:>E%'Y6)L]>)'S$YL]A(_PWIQ0X$$2$QQ:D#
M!ZI*FUFBN@A```0V$`)($`0BM#6IBH@(&JNO&JOM!'U1^7%J(ZL1IS:"0'*]
MRAR_:@@5BEPO8*QRA:S)RHK+ZG?:XZP]X@O02G\^X`5>H`2[U@2]DP]>``(R
M(`-J"`*>.0`F9J0>93N42@7Q`*\E<`T\$!CF<J_WF@8>$`4A8`$$X)#4,``E
M``($4`0A4`3ZBB%3=@/)8@0,,`\#`0*_!G<Q4%WT.'@P&(.WX(X)BR->VFQ=
MRJ4.^U`0*[$42P$Y<`T9&X<)<@\_H)(7$)Z)E)W?Z++$4KTMNZ[$XK$\Z[,S
MZ;TV"[@X6[/!$K,MZZ?9^::HA_^=ZHEYY6"T%H"T\[FTH-I[BZ!!DS"U(H2J
M5TLHQ@<VC_BJ3OF(B').9S-F65N5EJ(&"4"69^MFPXIGIV@=<75L<5MA&$:W
M($I*IR0>WD-1!%($%G`!4.`%IM>="X)3D'921E#"*+"94!`-/E6O]6I>$2"6
M-V`$[G`!/'`-`T`!^DI>/U,\!,($<BBZT#"Y):##SCFS^`$-YCJY;L<KK62[
MI-F"5GH3W]&["(.#OKNPBM,BLTF\"]$!%'.\,B"2&:L$HDMJ3?"\\B&]AHH/
MV$NGT[F]=NRR/"N3W1N3=/IZB[JNW#DL@4JHVZD@Q7.GAFJH'UD-^7$1!S`4
M$E%[>CC_O_3[DTVK"-8T`0:`!!8@?%:[GT@I'$PIP%Q;P&!SP&*CE&66P/7D
MP-SWP)RB!1)LK#(S"A=L81EL=QO,P2WB/2VP5D60!A?`!DV0!E6P`56`N3"U
M*^?2DM1`4R#``T`<!1A2AV0B+#C%`R#@#5"<Q-MP`-PP`$K``2KUN?^JQ"!P
M#3)P#TT0D?*!#^VKGDKP#%R`@D=17:Y)=PE#1:%DL`EK@\+[N\!+L.[W4+2V
M1Q0PL=66QA@KDFTZ`&]Z`3_0K]Y@D'GJLAGMA.3YG8N*IW=<HXPJG1Z]O>9&
M5-7I:"&[(`0B:L\2:LE2BS`=:KQ3'R*0'P2`DX*A!95QR?6;_\F)L,EW<@.C
M%<K\Z67#(<"PZJK`L1L%_+7I])]6J08]`,NY)<M2<$\ZT$UIJP6F.,&@(#-P
MF\M^9B,UV+!7U2_`,!)3$,P$8@%10``,<,RD^E-#EQ`1<`/T@L3K_`U'0`5'
M$-B!#7;XX;K_^LT9RU/>D*Y*P#OJR9(=8P370`5$,<(M.1\+0FJ05L]M"@V3
MU$4:L`&$QH(Z`G_^#$H`G:57=,6)`\8-"Q)$@-`!H-#4MGC;\+H@T)NNFP\4
MW:8.V:<=[='2N:>,VM'C"9[/DMS*/=,R78O8C"&`<<VJ*].@5MV@YMP6$,+9
MW=R>!FG4\)<"@"'>8@,\75D$Y].AFO]!C'`9$W`GP[>_5]N?+:34`\R(3;T1
M$>>U4TV5Z[3`5@U$#YQF7-W5M`;6GR#6N$S6,<+%%AR/^\PP:AT2+M#6&A"R
MB78#T+"94/R&_L"F%Y#$VL``DROBKW<!)0"0E,H[7N"0\/J7W,P`3'"O3$"&
M8L"G-YL.TN`%UW``K&O$D*:>YT`-C?TK&)OA1>`'8]`%HHW6L.DP6,S@4"Z/
M7BSE8+Q)A`<,^U)6"X%6BG<%17`\0FH/%P`L]5R0Y0L8U`W3V$PFJENU@.+F
M(B3=(HPA<ZZZMEB'URS":9[=!-)6PR,AQ),L$O'6>$XF!9DL+`T8-[#B]\##
MZDF'$K+3E>S_J>B=WAC$"(BA!7#F`T0-RJ<JREF6U$H=P&"&WS'TM0-JE4OI
MWV8+X&>K`YG(U9K`R9-0X&>)X`VNX%NURZ=]L!]:C\06X7=+X<4CK13PF;W=
MP^ZPPHX]=2PIV4[Z`Z;K`VU:#8VMPKR]GA+YF4V0+-4NJ1XKOC0UNMTLDFT(
M`O-!SSC>DLWPS0ZF#$J^@DP>>+N`.*EM$UM\(_P,Y:X][]05%-/6Y5$P`/TH
MKT;P*Y`V``MRLA3P)_4G0F^.&CZ```]?M1)O\0@P\:&6\8"1\:'6\2T-T]%-
M)J(S\A+!Z;;XUB//!,U-)F@>TVQ.[=(@D^[@#N(=`S8064]3Z4VF_]Z8X0":
M#@3X^=Z?SI^GE=2E7-],:7VUQ?0:=XF4PK66<@:MKF8\!.M8G_5_<`9<?P:P
M3@C=I$]20*QQ%=:WG.NZSJ&HW54-,]`-)>Q9A%TL'P040`X^@`2W&(`M^0,$
M0A_=V*_:H`2*SI(SZP_ZH`[DOL[DG@U+K*,S.77</+F(G<2)/_F(/;M^4,4B
M^N`<INN$Y_:MJ9H/-?H%30PB8571,TI$`/"(=YM"V(_^R@#2P``)WSK!HEZ*
MMK\8KQH6S_L(0-0>GQH2/_'!CP`6</'(+T(?#VHKX/+-OP"L^P8+X@/-GRQ.
M0"8K\`8?7XLMC>8;*^T4<`&06[EU&`,UH/_S.Y][?FC)O+=9<J)!$7JZ(]3[
MPC<H)$3Q[C3?6UO?C0@(929E6(4FAR97B(2%C(6/6&HF<'E2EI>8.IJ;.@\/
M9Z"A+*.DI:02.IA2J0:6#ADO!;(%,+6SMP4G$+N\O;Z_P,'"P[TGQL?(R<JZ
MQ+PNSR['T2?0U=;7SWW/QM4G7U413#Y!/C@R3$4434873>T$!$KP%SPE#/;V
M7/<,-#Q-2C]^*+F@1(D1+R5`@"C!4"$(+@H92GP(@D?$A`XS9L3H<.+#&WY,
M^(DQI1LU;"A36F/6K*7+8-BDQ9RF\MJRFS=5]MFYTZ3,F%,"%.A0($8(/WZN
M!+F08Q\#'DH&-"'_,.`'!0),?MR(X@.!UP5>NR(0Z[6L6;%D?:CU86&LV"(6
MUK8=>W8M!0H^*-S`2V&%CQL_V.[-R_?&6K5W#5NXL9=O$W\W"%"A<F0`A;@Q
MN@#!X*"SY\^>=XCN++HT:-*E=YQ>[7G"A,X3I,!!@F3+%J^VOR[8S;OW;@1;
MK@C'0J*X\>*02&`1Y`A1HD60HC^2!`<.)QU_LH?:;FH[*`G;/7%*D$#5*BFM
MI$R`-:L6#%RW6+YLAK.^_?LX7W:#QJTF2FTT\?=-#'L%88$(30W```,#$$2/
M$07%4T\)$($P@((/031`0@TMI-&'(&K$T4(C9AABAERDR`4!(8BD04G\_YWD
MWXS;N##?C?--@Q-*W/#D8T\T!IG2CRO]5&100Q5U5%(A--&4/4\UT2`!/%@5
M$!,WP.757!9$L"599GE5!%IB+<"66A'X8&8:A^$UIEH(X!477GE98,%=;+VA
MEF%1Z-6EG`6P%9=:"]!IJ%J/-?$#`1<8,0`/ET60AF:<L?:9:0ZDIMIIFEJZ
MFFL.N&;`;$&4E1L"OJ7*&W#"74'<<<8EM]P@CPARB'"'."(=)&IX!TIV?UPG
M[+#$7F<>*Y:L%TM[[\$GBWPX!H/?M-3F]TM-,@8H9#;;9'O"%%7$H%<112@1
MQH(0E<".11X.\!`/%\1K1#T5.I3BB1V5&&*'%/_QFU"Z)GX(Q4--!!&2!AG(
MF.VV*?4'3;0XQK2,?SW^:/'%&`,Y)(#6^.B3PT6>$$&2%BQY10@$/+F@5#P8
M024!@/V`I99?A8DJ6&;]%B=8<*+:5<]WA1466C6[A9B=*^#UAE]_^2#N97DA
M1N>9>$9]V`_PSD,/I'"EH8$-E7J:Z6AC8PI:IV)_!JJHLT61,\ZJIHI`$<%=
M40:LQT7'7*V(M*K(KM*ID0`<EJ1BWN&7<'+XL(MCHNPMMCB;"\3"5&OYY=#N
MTO#"(`L)8.?@:C!N$`0P,/!&(BIDQ#_Q7,"A1PWIF_J)`-M;PH2Q8R21$>P4
M],]`ZA9Q<,+\,4SQ3Y3_"T/CPLM38\7ST$<??<868X/Q-1IW:Z1)4XQ,5,E(
M7>''#RHSV*@1/WBAQ`U9,69G66;:#*;-0M-?/P)SV3\T86HEW7]>3EC!&^ZR
M-$-5[4Y_6<"=#$.G&SCJ""6H#(5^`!<+?"ULGL(4VLZ6FK2I[34[B(T.9E.$
MFZW*A'$S5=U>!:M"J$$-M7*$K1*!*UH!;CJ3*%PFBL4XQ/FP<(9;Q>/:([EG
MO>0FO\"<$J=UK?H4R7@N^-S"OK`!T3'!`J0+@T).IY%ZJ6M>\ZJ'A_*%+XG(
M3B,0*DA`6L<1+O"."V'@4,O:49""7.!"/D`*POK#/"B&K!K)`X;$DC&DD!'2
M_X\TNIBVLL$Q'74N1MVC!1,B<!1%^($)Y6N0%WA`@-7I12LW>)_^1JD_M=AI
M4*8\S)G@)"BKR0E/%F#:7:(0@5!&X)6AO-.<JG87.OW`"%0HP85XP`,&$*""
M7]."!S7804XUTX.AFH!H8B,;.`2AA+Y!H:K*0K<@V*V%RED.(]10!EWUK8:Z
MNN$D4A'$5?!0<3^,IR82-\0BQN>(2\RG/IN8DR<:3XK6F,(&ND`!<02!"2`X
M'1=GQZZ(B%%%(&H9.PC2.B/\2U\)2:,\%F408LIC?0XDT>TD&D8O>.$A>?1#
M%S(PA3XB4F(/"Z0O!HF,_S1R1\7KHQ-UM#&>\+0:C?]TI,2FT#T*U(*221')
M#3+9J`%T\@*,@5DH2W@6+LVO:*BR&04B$!>NYL6K/DC39;IT&%3*Q0<%B,";
MTH"7--PRK*\<ZUBC9E:V4&!K%WH4&YJ`3!LH,VW,--NEGNE!UT@SA*."PQ60
MH)O?Q$UG90E"$$)PM[S%\+*/.*<B#G'#1Y!`<.V,IVA'F[@@ZJ">]C2B2_3)
M6B7:9&(OQ=XTB,"M:`PT'..@@.D&-B(&>(B8O(-7'2V"$6+V:R&\BY?O#,(0
MX0YD7LV]77"G:U%.!B0@`VD403XJ1BAX04$W.$H-6.K2V)I$)93CD3+^\PPB
M'&,#&_C"%TX`W_K:=P,9R*__?O.;@OZFP`/]U:]]=ZJ]\M)$I]]J00MN"8,.
M!,!D?J"`#&2PH06YPZF-8HQ6Q%$$G&7UPR"&W]S*<E52DM(NEZ%`6B.P@@AX
M8`4K2$,`6AP`Q:CXEE#+BYE<^1?M,BJ8#3!"!:-@@\U`,S2$1;*F-E58PTIA
M<"8HE393:#]OLE`YX2PG(;0,B1G2,%>==2%Y&D=:=\)SAZK81.&TD`&AI'86
MF9-6:^=<K=>NU[Q`G2TCI]&%&#"!`ND(`Q<6JI![J&Z[=50""EKV40((9$0D
M#2/OA'D!>`CD?+S3J!$<TK*$4/2ZK8O7=BET+@7EX`<&JP%)#(SG15HCO33=
MWFNG_Y#?+^C7OQ[(M0<"$(!8N&<.%:B``,1`[&*+00`5F`,,7L!K_V;@"RW%
M"5'+RPV=$K4%X2IH!R@0@AHDQ0\^8(`,),*`"S.*!QIF'Z!-S.YVV\_#^[O+
MG0H0@#>\(0(L;C&+4WRF`MB):E/KY64<Z*@[#H`+0;8`7(ALY".7C6P<7/*1
M#1L;\B"APX_M#2DIB^5PQE#+Y>0;#85CJS!'8G`^#&V:YXDX8ZT\B&SN]9ME
M,875TOGF][%)D.Z<2&T!:4!_'M-30FU1!E0("IG.=,OJX;)%7;>CO*OC!1;R
MJ.!6^NE-^$?4YX&A1T'A*1HUR$1[IP0>7$@$[8!JJE?=:O^5R+KMQFLIDCH0
M;&$;6P0BP`$.#G"`#^C][WP/O.`''W@`$+L"'7@/KP/@@0BD(+]$;:E[W0Z4
M*6!;7$.A@`:\+3X+#$`&$%Q0O)SZF'3_6<KN#M-5YRHH.:'R,FR:FIWD=,LY
M48TPL[?K"HH0`2>\P:QR:E-<'I-V>O1#X1:(09$QN!J(/YS)@Y4X-`UK`!7H
M(`%(L$#&W6WE79$3Y"'GF]]LE4[IS,`$0`""D\O\3C6WG.52B/FRWESS).+\
M_DO<.<]GI`V'^71`L@`7+7-=D7$^YU-'%M5<$X)HCG9I[A`A4X<N>>4/4Q$/
M&]4HOV,$"\(@8+11UQ40C-%+9:7_<$4P67Y0`QHP7W"W.;#E1RWH'^XU!1X@
M!GI'>!]`>#@8>'F55WMG@Q_P@T!X@S@@`F(0;#"0`M%V`D1`6SPR:^"2;07`
M!`6P>=]F`4;`!I6Q(*M3`@4Q`%@B,T&7,S8#;[I1AF81?*LD*/^FAG*QAG>2
M8N+PAOS#/WMQ)[XWA["$)WCR2TM7#VS``SX`%\K7<!D4?<ZG9!N4-M1G?2/$
M5E3F;DA`'+S2"#,4?ELV<G;S'.7G<5C0`T"@!=,D*F5F9CRT."RG`_(W<P50
M?[Z`?ZZ8<S/23U#4?S+R?U44A0IW1P3@#O'`.HR21KM((H\B3!4(#\9X;NRP
M#N*6`SEP_P#$M%U@&((A*'"F1(*3%0+8B!3:N(W<N(W=]B(PLH+1$(LNJ'_*
MT`(I4`%^MTF"]W<[.('$M(,+4@(#LUL+DE#T"`7ZN(_ZN($3)@,Y\`$O('=*
MR(3-(U!5T&<C\QY14$E7$`47P`8,8@^KPP`$416`P01A2&+N1E6CE#]>LB4?
MB6+S%@!Q$0`1L#1LX3_R-C)I@F*%LB=Z^!@'1P,-P`8T8!F">$&`98C0AXA)
MYBE:8%B,"`<:H"9R8Q;D0C\>UGVU\D+EE"O@%Y5],PB)4'[)H0:?6!H4UY6C
M"$0N5UJ&@XIM-G^IE82OF);V88Z'A$C&P(1]8`7:0$56I'!4PO]11/=<RG4!
M1B=H#\&%'TB`E@9*6B&"IZ1PDG6-V+@DW=B8CNF8XO.-1+6$XOA(L68YS7,3
M`2`&`!`O7@!,?V=V[SA,HKF!^K"!J(F:$%5HZ"(#J#EA8N`!T\9JL[8!":D!
M"PD#1I$42M$$$KDA;M0$%DD5,!.-'IEZHX078=$6/;,6-S`W:N(5%(`_:%)[
M<S)[%J"243!`UWDGOW=*>J%*P==)5&!T;,`%-,``66(!7@,V@,5DB0B4@B4V
M0^D:C'@&2%`J8`%9<Y.8UQ0F_!F)7<8(S#&56N8<5FDWG44",P`'H!A"AB4:
M6E"?7>D:\A268#F6J3AS:*F6'KI_V/+_@E#TEMD@ERY`EP45B%2Q419H$`!!
M@-,H>_[IGXM9HS9ZHSB:HS8:$MJ(H&7P0D!*0WYP%%TPF0;9=M)@8/F4F<C@
M7B>PF6@G:DEW$$I'3*)Y(:_YCVS@FJEIFBKRI2JR@0`PD+,I),:`D%V`F[30
M`>`C'"BSI16V.FY$``=0G!J9)6?!D3<SAF98%FC8%FXR*((:%V[AAK6T2]<Y
M0';%%TP30'2%&(MZ&#=`#^>I#RE"0>S)DV(36(>(&M+G011:E(KUGY%E&Z::
MF&\#;]XTE90(?E)I*XIPH#8$.#.0``]:H5TYH;JJJ[A*3:5U'D"4`!I:EF\F
M%!UZ##;WH3DG_Z+B:#S?`BZU!#58<D!V4H*)6:/>>!0Z>J,&DH9V,EDTNJV+
M60,F0$X("J3H*@E(@8TU8`,M$([-&HOXL8+?`@-X)VKXFJ\7(`)&D'<X,"\'
MT*4+,F%=FB*I*0-<X)H(F[`#*P`9L`'P2B-3(%^VF:8C$X5()1(A@$D7$K#^
MP`Y4H@04`(;H<!9D&)VI)Q;OTS-NJ'!T@3^OAQ<CLU4!<!E"D6*!\E6WU&(^
ML`)ON`"A]!=\X0,_T"AL()%<()$$8"<QH`%`8`,.%[6#U606R@G501M82QN*
MX*:215795!9V`W+B9*"+0)4@!V;1P8GH1Z&]BJM+EAJ]:@`49P!T>_\)Z\%K
MQ;J*RZ`?3.J*\=IJ9QIM2[`8EU%!Y!(%DB6N-CJCC-NX-^`%Z]`.6E&"BGNC
MY.H<KHJ@(J&-8Y``+4`-/L6"M,DPTT*O7]`!49JO8J"O^XIW:"<"`7L$IBFP
MM%N[&T@#(A`!\15%Q:,21#"Q5%0%&H";[S%)1W$(&YL#^B@#?O</BB("33"R
M&HD.QXF<]D,T]_,S@1@GVML69A)+^'87CD<!]U:S,7!+7+55,="S:9`&/JMC
MD$I73!`O#'``1^":1]`$3+MY4"NU_CN?IT%QI'@=W@%#6"`2I+H;%'!""+"J
M7/;`9XLK6Y:YL[HK90`'<ANA<-NV'*S!TZ3_*5WI`%\@<_:$M\<:9S#1M_CW
MM[%U$TM`(*$4!%%@C8E[H]P8`HV;PS0:!.H@``+0`1KI;Y-5`]BHF#O*C8<0
M$H/PH^:*N9*`"&/P!!`[!93)PJ)+8(![NJF+KULL:J[[N@%KNV(LQF%P``60
M,$=*FTL(;54@O!=KO$I<`Q1P`#7X`2(@`$T@`@2`=ADI,RYKO6%!A@CPG&XQ
M%M-9R*;D,S[#)8+Z5>O[>W<!%X:";S!&R?\6?+*G#ELS&8ZBOW;"O_[[OYT*
M&@)<+-XQ`[&B%/#SM0T<MN%GP:U"H):X-S>D!H2#'A3WMAO<P;W*E=)D6"),
MPI*S>'J[M]=RF;)H_\7*[*S*L`0:P#XE$P)%L"28R\3H&@E#JL/:K`$QT+23
M-;P:T&T\VJ.8VP-ET`/H;,Y0:<WK+*LF$`+@W+3P-9M'NLSV7"094`%='"_[
MS,]1*@(#(+M<.L8$;9HR(``I4)"]ZW;>\(1J.A0^<!1C8`(UX`.NVW<'X+I[
M+`+L<UU_7#0>IC-P<S]YB@!<Y14A^;)L<3]6A4MP)35Q,1A;E6\X-BCA:0%6
M01@W<&%9DRAV$@%$UK^A['``3,I.9LJA(`%JD#=^X)&L7`1(L,18V0@T--7D
M!S@,F@!`0+=<K1ZYK,M@W;:^3''![&;#;,)(-%/(/+KWW-8A:@P0H`%#0?])
M(1`#-4#!MR(<VDC$,QK.-5H#@,V-8^`'$WT(8]`#)I#.Z#P&C-W8Y`'8[6H#
M-M`%1^%EB="-D,VN2-$%+H:$T19Y1J)(;@VXZ?BZ^=K/HN8.%T`%`3O0!3W&
M"L$%(N`!($.;QL#&7<#9LK!M&L"C-1`!<Q#<PCT'T\NO'1T0/N`V@9QZ^:,_
MS,D6<"$71C,6:>`6$8"2;XAO:%)CN8=`W8UB:V$F\J;)9E=I4G(!@C*(0QVU
M1?U!54LLX=$#+23-C05O)>C*G775%DS+@(-^=9L>O.RV8QW@AK4!>'O6:,VL
M33C:#-["W=(%`=`!$=#-=OV8C;FYY&P"A6W8B*#_C0D`V2`.V+F=IAH`7Q2N
M7S&0!MVLXD'@;4/JXH[I'#WP0F,0`P&P;``&;1MPIMER/=A0SPWN=J6]KZ?-
MNJDM+PKRVJ\=VV8<L:/K#=^0VS&PVYHWSE%0LY*2!F1U%TV``QJ&W,J=LE_"
MIW0Q)G]:)T:3R*:$;S%P)Y)2G:'T-&\8%X'2R-6X8V?"**N]+AD=B,E7`T"P
MWD0]RNXM0O`="@\@W[!2!DW=IZ;4D":P'&$FMOO]RM)A`ND13UR]Z9F>P1.0
MZ9?0U9CPWT!@X,0,'XMGK,D<(VT9Y*Z.2`JY>8#=X9NEN5*)X2<HV;D-SKS>
MZ[X>SQ1^F!3>S7Y-S3Z:_ZY`JMCFW.$AL)#,Y@$L!=HGD3&&].H,7=IYK+KZ
MFG7<'J5)KN0$[1`'33P+/8[60%O?\@U/T&>[/867:P)1$(4J%H5,``_SZ^6`
M`1@4@'KOQC-^"A9W4C]YL9S92])ED3]G58=UXB>$V[-;5<DL]ITK8!A%P!AV
M4;3G(P+$A`/)_>>$*.B;2NBM<=2'#@J)CC<D4`;TO3]A%0$9L'D_NBO(\7&O
M3*!+##AE,&8^Q.F@SG[F\=\&8.JG/@NIKNH*KN#6_NI!A1)U`-D]BMBVKKE#
M&@547_563_7@S*Y$O)B\'@-1T,U8#^,(.N/HK`8S,`-`>O9HG_9LC\[.X8TQ
MX/\!+S#W`>#9T094'O-'2:]>0][%JYNO6=<.JDT/L@ONJ0FF"0L1X@8`";T?
MY<X]+?`$-F#C21(%E^L'49#'@>^O+B,E?Z855M%A(@:@\C/FJK<E5C4W<['2
M*KWZN$<88A47@9$.4',9!92=4F-`X\D[."#X=T0!,VSY3_`$(+],(@\;T33`
MG!`>$H#*Q7'VZGI-A]'9CS=0"6#`TL&)F"7IK0HX@E,>7_F5H56WEA#TJ8X+
M16_T((I3>]_^YWZD2PA?O-XBN+XDV3BDE9O_?^WBN0((:H(S6#.":C.&@UB'
MB8>/CSTFDR9^?B&8-7XU&A$!,#`!'AE34R<N)U,NJZS_K:LG)T2NL[2UMK>X
MK"<I`F(7(A?!P2+`PL+`3<)&`PPR`T?-#-`Y;-4R,@PYVFS77-@E`P-&7@,@
M(#(X'J>OL+JV1%,M9C4Q`04P!3%^E28A349-`@8DH.0'`08_*!!@DC`*@H=I
M'DI$8&&B101%+EY,XP.!CS06?(BD$*&(#PHC(X0DZ<G"2I4L4<8XN=(E!0H6
M(HCT<<.'R9TX+?PP8H3'0`(\;D2Q$*-&#2`8'$B=2K7JU#9MK&J=NJ/K5@<3
M)D@-*T6'V;-GS[`X\^>!A!DD2,P8DZ"N'C]!0GK8F\*.'7A+GB3`0A@+"<)Q
M$Q<F7*8,8\>,332&7%A-`@.8_Z64U<RYL^?/H#GK"*W9P(8`J.T56%T@=>H"
MIF#);M=J72YVLVW?WLV[M^_?M5T0R;"A2Y<:8WK,*',%4PA+EYY#GTX=^J3I
ME"1/GBRH\2%&D,)#<B0>4IGLEIQKLL0IAJ<7+T21*C4KEBPB1$[I!LZ_]PD/
M8H@0D#&_%$.@@<$L$XT,U#2##0/A\$!4$TH00,`/-]R`D@\N%6%2"<VD8YML
M[MABRA,VU'-//GY<T6((2@!DX84_8(A40@LQ08%#&CU4T0(7`1D2D!.)Y%%'
M)W$8TDY*BN022![EU"1**VTXTDTB!1`!!3?H!)1/-UE`Y0W!\&#,`4P4P=1Q
M4'WU%?]6;EK5U0Y?A376!&6AA=89?/YQQ@-PD6`"!E$9,`0G$?#5EU]]P%/%
M!B%<L=ABATVZ76.%;3<I83U<1MJGH'8VFJB=F>8::ZNYAAILN9%8(F^M[M??
MK+36J@LL\&2@@0;'):>(BU=HQX]DCW@7'GF#?$=8=]V5H086W)7GW;*+?*=(
M>#V<1TETNV*RZZ[N?0)#?!ZD,%\IK=JJ;BZP`"B&$LD80PR!PQ`S;U'0,*`O
M`3<PH:&3%A01A'/3!3M)8_T8$:(ZMXYX"SQUI*A:`1;L8T)S!`S@18T<8WB#
M$AK^P(2_&4FT`)%$(I#R0SX(V=%$2_J@$D4Z8501116IZ63_1%%^Z<,*.*VP
MPDDHK>!$`"=I>=,;6UI@])5<BL3$!5X<,,`!^C)`@$LQA/!45'%:!6?87'FU
ME9U@X:GGGFOY^8`:<B70P@AM++'$%"GPY9<==.R==P$W%'$%99LNAJECE"&,
M^*2=&C"J9FN'"NKCD)=ZVJFIJFI/;.F^XINLZX8N^BSXE9Z?;*64LL&WW>[S
MK+*,3#M>>7"#]VSLSC9[.WB%&\9[I=)>JFUV+H:P5`2>W+0:!05T4($``E10
M`3X%E&MN*5_$-OKVNJ1003%&R(O@,?86P\,SS%Q0A,4';_=([]"&H/`'(C;\
M*BT0V]#):C!$4,,D+OK!`'A@H0H9_\1C&F(($_*1LY!0I",Z\Q'+7N9`(^',
M)2HQB4J4%!*5=+"#,5@2\L2$O)NXAR7(<P\'56@!-"P)2U"3&1.4<`&L,8`+
M#&!#$Y3DM3:1C2IC^^&<ZB26M.5I;3I0"UO^I)P9U*`%"H``$?9"Q;_LS2\>
M>($8#D`%`O@@"$@8'*;@!ZW)9,J,E+*,XT03.<F11D]YXHRI,-<:S;$J5JBX
M#1ZYQ\?1E:X4\(!%ZE3'JRY\"Q-^<!8C*E.L9\7%=M1ZG>S>1ZU%;BH\VZ&$
M\-RW26U=(@I;8LW(.L":YT&O`AT`!?7D,Q_\L*(/?;15NP0@`H(<:'SULE>9
MPL$,'@1!D?_P2XPP*Q6_"QR!?@$8D6Y`5YLEZ"\"_//?/EQT`Q[PP`M>N&91
M+J"A!(J,"2,L0LT<**6=N,2<*G323\QIDIN@,$DBT0E*O'03Y$4@`RE`7@8R
M8,]]VI,D.9%G!&8BLS#1Y*`T/,`1\I4#(RA)`U_[(1"S(M$AGJV(9$&B693H
MMB;68`,0<$'>KFA%OVGQ&D>@0A-Z,K!(7>&E,)7,&3N9N&5=9E1F<:-.-3JJ
M.;ZFCG;D7&[RR*[.Q?*HLTJ%*0:9NGT2\C@U<`XB@Y4[VS'KD97)*A8N9H+7
M%0MAV;E.=:1*5O;EKA&$4(3MKA."&#`/57`=V<C@"H-4MF84@)3_11_VBM19
M3<$#T+O!#^)5+WH5:%Z[M!J$?CFI84YJ=X<H0P@NP`!DJD(6M/%<*V"IBRD$
MI@O0O(<T+^8'"IS/FB`88`EXD)`,]:M&+^N1;!\2A-BR;$L44!I)"A"3W7)H
M2S+S4G`CP#0/O&$%!>#G"I2&O-6(I#448(('F@9-"KRAGMA-*#9PR`8>4$!-
M$/6A1!T01+)95"MHRZA&^;3$!S1Q#/:Y8M[*A9\4I"``8I`!%TJPT`%<P&-6
MXJ!/!O;22VEGC-!:5J<X`P?*Z?2-/"V+3S475#PRTQ6QNG!?-VP+03)UG_8U
MEZZ,PQY-2%43Q!)$),U#TTV&-:R7J(YU_UZ<G;,B@C#74H,GHRHFN"J/MR21
M67"Y%H,8[*H+-K!!"]:Q5\YR^',96!X3"%L@P\[+0.>#T`"#8`(RTNX\Y_%'
M,PX0@,NB8IFNX.LK3F2#T/;O.3"E0%&L.<!E&*&U&1K9#VP[6XV4#&8ZN6<(
M[ZD3I@34@\B360B'&P&@!4!H`<@`I'G+-(#*+`,B0<.@>7LE'SA!A@2X``ZD
M@4,N#."[%@@OV,9;WK"=URKI5=MZ^W0&'71U!CUH00J((%]%F<L#%?B`#,SQ
M#"X*Y`)-($"R_?4##@R$I6+4EJ8>8XC'-?C!GT%B`C0JX<M1.*CU21>)[B.+
MV^BUR>A.MY-SH?_N=C?9%:Z4#7XRO$?\F6[-&ZC"KJ)09/?8,P)1&(,:*E%B
M)*@GD8BX%IB-)1ZK?I7AW6G?9#1)8P`:[&!6]>0FC!="IA0Y"B>VQ$O#"O'S
MU.!14R!"'ZQ0&Z7&IMS;@_DJTFT%EE?!!IR@0`>"<>S#E@^766;``7!0A*X&
MKY/9$?,'R+R!E)_.5>QZ`CU6TP$?/`>`%IBS->E,0,%RZ9O?]0D"4'*DC%#)
M2$MZX`35=':?6"``YP1*W,44%*+]UI\#]7<*8Y`!#,:`:?8L,G"#<G:7#!8'
M.%QH,YBPE"A$E-6M=M.<Z'31.QUQ;>SEDPX2@(@>V`"??K.O%>U;@0/_=`.'
MTC@"+Z\V`"H@^Q_AZ*^$*!`"`![XC#;=MFA`<Y;)>2;"9C&-![YM1YFSHV'K
M&.J3TZSF=<_\8:6CMZM`9[I[IZ(XS@E"$/@M^('6O@R2<)$E#'[P%"^+=V0L
MS&%HY]6!5_S]-#9P6"^NR19/?/[B#\$&-A"+=[.#J:6#5'N%'[!D<SC7!6(R
M-;J42X:E#%=S`$-7!/;78I0`(P>P=`&P`5_@2D]G?/!6;E*G(AU`>Y9P,19P
M`69"%"IH!/S26F`7$F;W,F+G)`+V$![",@%3)4PB3QR")6$B)CW((43#%)Z`
M/%I2#UJ"&KBE6_:`$UN"6RLQ$AP2:B+`!8G7_PP_H"91T`7B]4-805&N-GE$
M9'D\E7FU!@>.-`8;L&M]LRA^000IH$4?(&QL@'I9LU`+9354(`)4\(!6,P#\
M902!$T9<A6"580*Z5SF>L6TY]2D.!GR7L0'#1WRGXH&9Q4<NESK&ARO1!W5G
MEF'0%V^76"O7=QQDM7T?IP%>4P:&,#SBYQ1>4X+`Y#N[DWZ,1$F+H6,T%5GR
M=QTI)A[.DDD6)WXE%E5D=8P:T'0NL'(LUW*SP4>;>`K5-P5X%T),L(#DTX`)
MPDM"5W0O1H'",@D6B(&F,'-JQALX)X*TAV)74`3_4$!*$(\7T()?QQ"!TV?X
M"#,O$6C\1!(S$5!ID/\&>A<#QU-.6`(T,T$2`3!/K9$H6E*$_A9=G690/_`+
M^B4-S4``6A@"74@V7RA$8EAY1E2&[/4'F^=(:M`%*D=2=F!?^'6!6%.'67,-
M-)F'X0"!.`F!L7<$1D![PT@XC)$`0+`9H_$X;91M1<E3:%$6D3B)E+@JT:AA
MN>!*+<=4TI>)5YF5N_&,ZI(*-^<48.D<K6,"/:!B)!!Q7!4=ZU%C*_8=*O98
M[!>75E4)QA@"VK=]10!RZ#%6Q]B7?BE5T%$#7:",?4`&S8A\HQASTM<"&I`!
MH*"*%/!SQ8!8RA`^VQ@.$.*-WS@\!R:,_:`$`T".3':.NU$'G&`/.@)1P7+_
M!4%``.&S@D7!+ZXE,ACR9QJQ,@^!F[E),[]E`?PV0LBC)EJ2!L!)>(R6:/[(
M(?[6?8)F3UQ#=TQB)6+2!*,&!8HG`UN3ER&09.-%7I&W%9-'>>B%4;*&1&;X
M!YP''EVP:R2%'\`VAS(0D]Y`DS69DPIU!#B)AZKW#$D1!(-S,=&V&"8`!PE0
M.90#1[_7B$JYE,$GB4_I&C+'E;"2?+20&U]PH1B:H1JZH1BZ3Q[JH2$6HBE'
M&S"7;I^H+K!T`BT`55X3ENIA=(&"50AS"0.S'JLI&89@BW!YB[P(5O.7'FKB
M$D(ZI$6`"7=YI$;:E]0!F-415F-@`X1)!F2P?*V`_UFJ\Z$@ACS2,S!RA@-&
M0)F2*0)$X8"\Q`-%-W(UUHM[>0E*<($X4&:CB6ZE^00:,#&.9S$AX)H4`B_P
M8B&N%5TB4P#(LQ26YG:%&G<4<1%%`$/&"4\H85TKL0("55UY]V\#15W(<UPD
M<5P%)80J,31T%ZH4\`O0<)U-$#!1`%$VT)T?:5XA.9YD.&M]@IZWDY+L&7K`
MA@/7H"]<P`8Y9`VI]X=7@X?VJ5"\=`0EL#6)-#P(-G!P,)39!CF-*"J]MZ#5
MJ@/"]Z"I$:&I<)6?B#J9R%13\`4@%J+F.E]4M!>H`1_L"A^J]*[P"@KP42[H
M<HGS)I6^D:+YAG-@V:^`V?]5AB%,X$%P[`$=!L-B:DI:,I8>?WFD=QD%2"I5
M+?67!+.P"QM3]V<"G-!TI[!RB7E4F)4*6?2NSR,&8A`]`E``F.`#<T8%*H@#
MDKF"VWA#XG"F%C<=V1<$'A)WS"-8S(!,_&<;_G<;56!(H94/*-8/0[&G-!0,
MLNE-_N(2$^0C)6-!$D01MHDS2>(E.M$3[20E`0,P&'1.S56VH05-2M.0#.F$
M\H0321(U%D`F(L`,&"D#(N`#49"J-6`#J^:1WZD5X3F&(RFK;(&>/6`8:E`#
MMVH'Y9*K'Y`UO<H-W(`-^+EZ"H52Q6HUJG<^/'D#_KE)RS*@T,I[TRJMUVJM
M>9+_K=H:`#!';]DSKJ_;H?@4HNF:KNW*&O&J2AVPN[S+N]+SN\`;O,([/>/"
M%]E#HJ/#65-0'/WJ%#B;"0@W3'&A8]H1'258"11[B@Z[O=P;L0V+I!9+'3"%
MIA+G/HQT'I<`+L1A"B'[L;$$"QE0`3@`@3A0OW,(LR*0LN=D$!82+T90OP#\
MORHXL^!P:MJW%"^4(?Q+0]G$2U"@+]\P9OG@5*GC&_FV/ZO1%'CZ`UX`FT3Q
MM("*(?D8)!A!@S@1D(F"/`')3Q$0D"C,017!(3]!MO\4`"<T74>X%_9D+O9$
MG#`$%%0RJG.;>LW@4'FKJGT;-JT:AJ]6%;%V>7J2>7]@_[B%80)5$`M^85\P
MH*L'8(5>+`.^2JPW:36FA[F9JX<\H(=9&&UH!"U7D(A(>:!P9*TYU:!.^:#E
MACH@2KOJZAKMFKN`#`/#^[N]6\B^BTJ&[#R##+S%6R[S`8H5>AMJ5@I%V[SK
M\;P6XTC#I(L:"[U^L!0>$LJBG+>D?)?9^Y<R9J0'G+=!T")<]7[10BG2N\G4
M^TE%YJ'B:A\<5@H``L#V`L#S"[/(1B,,P3$%E`PB4+];1Q3G,T`#P`8`@8(Y
MZ2`/DC5"IY/A``7'>@`$P#_C\@(>H#VW<<%':P%)ZP?5%(\5,B/\PB4AW!.W
M*1$=<3(F0\+MY)QN)62$QUMMN_\ACRH3S.EQ^!PNW>=6%)!.-_&U!R5JS%`"
M(`(A>&MD>YO$<?*%8,C$1"06ZF6>)4G%X)$`#O!7]B6'VV6%O,H&^)F3PWJY
M9IRY$<(#5("L>X8$MR>@C-A[OQ?'IKN@J>N@JYO'@I0W]D`]J`(*O!O(\9K(
M3``#3,"[HY3(4&W(TE/(,]*[C(P:'O"ZTI=').J!R\A9UY=O4%6PU&&,F1RC
MT[LMB!0=I]S6TL'6:^W*\*<=;ZE^LWS7TANP6-4L;*4!_O:AJ2.TSK<]J8!?
M8D!E+PO,@*@O`X1LZTPCM$D0`J$P$.+0UCS-C!T.#EW`JZ?9JN?05S.'HBT`
M'J"!NU'_!?IVM*-U,10@#@DRP!@2VR+3`1YT).RT$R/L$>[D`V\`Q"E1A,3Y
MD!&`!D4X0B>Q)2L@)DX`-"BAJ8TV-&'2VR(!-+C%$SA!`3@P0'>H+Q00!!*]
MJA2]%19]T7'2Q%01%AH]`8ZS7FM1N&^C?BQ@`WB316)`AUYLTL1:K`M%D])P
MQC@9#MG=>DW@DVU,&(BXWD@9QW1\K<)WQY3X=+#0`OJ6$[@+5Z(D5Q@^!QH^
M!TZ-X4_=NTQ=5U"]X1R>R!L.O.P\!XM<`?-Z/>(Z2/,V;[C@8<O[E6!9'?V:
MR7J]?CH&+,3(E\<8OO17?[.H?CN.UT@^RX40EX+0`Y)P'>UA_V2[@MI5T`+E
MN(S!0=A38-@]1S[$T,PIG34/+'0XD&P64B.NA12K=]EK+G3ZJ9^;#0[\%>?,
M<(%+=P!SD`8;0)7"40NHW9BL$0%7=S$^P`/J#"_"\`/Q6(\_$#`2<3-%(A%5
M2T&VO;/SY$%#FNF9[A,_(9P_981)>*G"?:G*V;;1>78HR`/;S0`[(M%`X`#A
M+=Y+C-$7E=[KS=&SFIZ(,09I@$\!(+^[R@`@X,77_.80B(=WF-+^C9,X<#XJ
M=0,A@#A`B8AU80";L7L)NN`,+HD.3GP0/@55('51]9O,(U=QY>'H_N$=4.*\
MN^'K3N+P3N)3_>X:/KP","/0D^_Z'O\]%2`&=T"\\"$*UO/(X*H?M8`ZJ;-_
ME7SC9<WPQ'(8PN1^<[V916[727[Q>`T_[.?D')\=8T`78#D&9/GDE,#Q8_`$
M5MZQ]C,ZJ5``)BL``A'ST),,13%`=,9Z9SRF`W(UUMSS#@P%*MW9@.C0>!CG
MJ\5Z=AL!&]#GN"#A79`!JB'H%G,%%N`%CRV/33`4/2E8L-5G1-(D(L$1O\4A
M#J'"$9`"(32<*90D4>@S`/UO&=!]'YHW]S1\1HCV+V0!UR6=:LX`1`\-@4.0
M7-B1;F+1(&DVXYG>4,PVA4NKE1$"H>`!,```PN;W-Q2L]JF?T8#YRQ[T`Y#=
M%T![F^(8EB'_E'"LB-2J[76,K=Q.B>GZ=#4N&/X:!<%=`!INX>F>^[L[5T;M
M[KNKXL);XH,\!_'*&JJ2KL@C8A^Z?RTP-R,P`H0R%59>K\ODB30NX?S:O`TO
MBYJ\U[5XY!@?_AE_?G')\>;?`Q__\75Q&37P!.Z?9#;0!1A`Y1*>;^&>`"R0
M"/J__ST`"$]34RZ%+B<G4R>&C(V.CXXG&3!B8DV730*:FI@71D8\5#@X/*4#
M!P>CIP,\!S(R#`.G!P.C(IZR`U"[4+J\O\"LK*`#G\0,'TP9D(XM55T9`04%
M$2%^)B9719\7W=X7/T8#%#<_3$P4/@@(/NKL/D4(%.OT]?;T[104_Q$1Z?H^
M%O[IXU=@'S]^!F-8B*"0@H6`!GT@Y!<@0+^(`0OXH+!"WXIV2F0Q&'GDB(P?
M1:)$"5'#!@8',&/*G-FFYLR;,G?HQ!ES@D\'/J7H&$J4Z)FC?Y(F4(.E:9DH
M`CIT$(/#E0PN;!B41"6+"I53)E_!*GE$%JJS:-.FPB'":Q,?5YK*E:O&!)P$
M.@Q(V<NWK]"B@`,3_6M@@P</%3WPR\`XQH8-52(3073B"^0G-3+7\.,G<P@-
M:2),@\%DFNEI3*16J#!'JFO7JUFS[M"Z`Q,8IPM4K'BP-^/'CS5$'HX!@XWC
M-H`H7P[$@'/G/R<`U:(%ID\%B1117G2(<O^D[%,@=]'<F;-YSIDY8V-*HKW[
M]_#CRY\/?RY=IEC4J"E3ID</;/Z9,,:`"6C6D@U=)#A<%1NTT,(@$$8((2(1
M.HA!`CW,H.$,^FDXQH.,4,@=,R22.$4*E%B"B0"5B"%`)]^((",.7O!@BXR?
MX##`2+DT0<"/0#;!PXX@@+!++EYX\8T22A#PPY,$&*&D)]V``H4K(GA@"!%$
M,.-,%S%(HYLUV)@01#=-`DE`$S\(2<X/Y5`0SSKN/+2.!??D60]$"[5CP486
MQ,#/0A9$T5L$&BS6ST41K+!"0$YL1,$;;PS4&T`*M7.#/NEL])$/!/3"0`E:
M,<`&`86NU-)+/.'_9%.K,^T$JT^T3O"78$<A]<=2<CTUAP`BI"(D`Z\<@=:-
M7UGUBE;&;J76LZ.,XA45!!01EWU-U=7<4'SIX)=@X`)&F&&)I1!#9%T@AYP&
MDR5B61V8&4B>9QHL)"8,N)UVZ&Z)*790!FD$#-QC"PXWP@C%):SPPL4=[/`(
M54!<<,$#5^S@"`XH\$4*7VS'72*(&-+'R%M"*!YYYZ5L'C9E8$'?R^UA2U=^
M^NW'W\TX\Z>??YT=AT$5/X_@X-`M>.QQ(2,GK7322/=A!=.(0&8#AAQJV$,"
M#X[H+B$E=MU(ER=6H.**FW#21)4RSDBC%S)><+;;31A!+`.TB`"C)THV__DD
MG)O^X^<;%E#Z1A$4*.'-+1>(P,,N=,/0I0M<,G/",V%*$X`&UUQA)I7?@$*`
M$CQL"N</<N)#)S[J`$1GZ@"U`P\"A/(30Q$2/<20ZT7\^:=#?[J^+T.'QB"H
M[,._$4$&,;@NT1N`?F3!#4..6D));#21J@:KPGK3J]K#M(/VM=)Z:V"Y'O4`
MKTV928`75;%Y02C'CF*$5U4=$)96M)!E[+-JL26"_^`(0LNP10(U)``OW/++
M7L+%0&\-I3"'"<!ACL>8#*3@@A?TP..^$!X;R.N#Z,F,!@05`'SAJP`>B,%X
M/JB9`ZK+)0E;4,6`4T$+8O"&.,SA!6L8L!YF8/^&%5/`"%(@00X.XF-''%$D
MIF#$DVW&/%>(HLK\H#G]R.P^-=-/SK:XQ2SB!UL:4D,-8I"!+YC1C%SBDM%"
MMH@1]<$%2VL:R9QFA:>]L1!,_.%X3-"#,=2@#E.8C"$0P4&O&;(08$N!V#!Q
MB;*]Z!*),T+:$->-ML$-DJO842UNY`T".*0(N2O"X$`IN%(*S@<_.!S<:D2W
M`X@A!8AXW.,:,3DP540WF"M3")H`A5*`8D@E4$(3!H`.`MP`'>K8@CSH-`]Y
ML(Z9L'N(G^(Q$-YL1%((R0=`]+&[;>Y#>/ZR"`DI0A%JB"8`%$!A/]JAD3=T
MQ`+OO`$K27($-ES@>MG_ZYY,VJ!/[W4O?+8*5_G.\(`QJ($$6#"!'XIP`2BP
MQ4GO^Q\J_#>*M)2$)&<Y0BOYEQ;_I<TK%+@6`6=PO@0JL('A&M=A5LK2EB)F
M"B1SP08PP,*::N8S)"S`"0,0@QH,:`P2&,/YQM#'"%@D`A'DEU)-<TO=\,NE
M+MTA8U)0P1X*C(9`W,`(M)"&`I0F`&9$F@LD1-8)@8PR+3#.9K`QQ929H`Q:
MY*)<=69%^\",/C7(@':ZPT0S1LB(-<3@2G%8PQ]NP*PA8\3(ZEC'.#(BC9$[
M)(G>:!@6-3(3E;B$BR!)R<1-4I*7Q`0.>%2"`4S)"-^XP*1,R=K6/N\"7C"<
M_R<^,:0=,8`):=@`'*U`AC<>L1#B$91IHJ`>$^RR!+ZD[0":-`#2F:,#!7C(
MG/1$W3RUXZA'-6H*C8I4AH2&'ST\2.OVL0(G\,-1W'V#-`[US=T5)`+MN,A#
M?N`%(]!B5#O"`06"$`7L`2$F0H#5]_J9$UG-2GP"94&N'B`!#9G)`C]`A0A^
M%*R*GH4M]5/+*Z`5K0S30A:EZ+",O%(M$URQ@`?LE@Y4@%+!(-"!>3%,2Y6Z
MFY?&=*8VS;$(1VA4G>H&45U(P$^).H8(Y&L:8LI-;G;C5*6V%*DIB``&"\N8
M'L[PA[^I&%>!)0(!>.`+8EWC=M+X,0J%9P,V4$];5?_&,IS5U:YWC7-\9E"#
MQX"'B3ID:45>P.<^^]G/$CS,#?6JG<2*;&E6@*-D%RW6RJKH12Q2T6;/UME)
MB@"TC+Q$L.@FBRFE%AP^:*VH!1>0D-0H%[F@Q0&:$($-G(".OE4$<)^1J.$6
MUP\$8`4/C#$D'PW`F,^5TW2K2^P%W$DB$0B4\!BBD&4S6W;@#8A$?+=.A?3F
M#<-C"!H$93SA[8Z;T@:4#U!@HQ*45I,44(E_GP"3`+=JP`3VGH%;12N]"'2@
M#59#$&Z0:QG@0-/0HL+_Z@<+_N%`X)*,%BI"C&H;16O$5'@+$@:(+37TP%L+
M-`"+6PR8%ZMTQC268`!@>D?_'.N8A>;)3!=X+`W<B!-[1#;R"96\9,N%'#&!
M]M=!/)#!*==P`X;-Z@9R^YBMID$,J!"#!UP-QSLRNCMH]N`8UNS6,LCYZEB?
M00^@D0*7.IFEA]IY4OGUYS[WB^>$_BWDGL[V1GO`LIG`K*0?F;@86?H6C'3;
M!48;"UIX.DE)4L(-1CWJ4J/:+&GY``Q<302G%>($D15/HL04@ULSH12[IBT/
MP,$#3YX#3O580.H<$H5KZJZ;#^F=._Q$*-K!UT_7#+7Q."(13GTSV]`.`$`&
MQ5U[&76UE.*F#S0"*`J(8[1'*"W=TMW?&@"!W=V#=[QU(GV>U'M\@!GH&210
MEP($_TL&![B%$8Q5E0TC+EBH*%8J+FPW2"8NP]&J+2LZ[+^O4.$'03"QS#CT
M`!AKG.,I]4`REG,A)W(D!UPT=7(V=1XBE%/3H!@J-$9'1G.GT50A9U2\$784
M1%6,,06,81D;D`(-DE57]1A:L`$",`I*MP$=$U-/1P2*\#-=,`;9$$57X%8*
M]598MX-Q5A<:8$&"ED%@5T'"4X1&:(2]L5(A5P`O,`U\%FA456AG]5AM5R*4
M]7:/)G>:17>=E5IMDW<`%PL[<@"8QPJ`]P/*DX8=<0,K<`-NR`10\CX@UG#U
MDP.OM`@Q%5DR-1P]%EUKI5#0DUR_9`0_P`."]WDWX`[4M?]ZQ[8.N<,.>,(.
MMN<[X)8.ZU0$ZS0HO7,0O/%CZ;0;_3`-\+4/_R!MZ90/^K`ISQ-B):%\MY42
M_F4#_51]^D1]_^03]@8NVM<#:J`!37`6:3-1Y7<`J'4V."`6J>!PMN`V:W(V
M1N!A#H=Y`G=W_S,`$0<7_%%Q:G`&W#(4&P>`@2$4"0!!B*&$7V=C)9>`"JAC
M?E`@F1$#%%`!95,`(T2!3)5D_**!_("*^G!+8H)V-L0Q*?`"/-=2(CAT)?@S
M<Q`M!5!&A[8T$.F",74"2U`'&]`%&5(&9:(R461B//B1]%$7-:`!PD&2)'F$
M,6"2";*2++F2)HF$^L@O2D:0%Z3_'86&2+.D:-^A1%8H4UAX69&VA9SU:8>#
M=YEFC)QFC5;Q`4SI"E[@)#_P(TS2#4G"`TG28;I@6D/R":(@<%4Q$HHG:Y`P
M!<,1#:+XAWY@?(*(>>%P`<>4&DSP.L0VEXZ(B8>Q$!Z(5%5F.Q:0._L(7AMQ
M/`=!1"MP/,;#78+">JWC`VDP)YLRBOP@>LEC7\>8?`-@$M72?$`@B[5X$]3W
MF:!IBP>&B]A7%-K'`B9``6O!%L`XC.UW`<KB;]W0E9?T?F>Q8:O)%G:7-M+B
M%3>0?S<S%_L!!W``8^`(+N)(CGIVCB-W8^JXCNPH9"'@`Q4V"@*0!E%@CTV5
M3D>&+ZE!_PT^T`%F4TD#UV$-F0$>``,OD`)3D)X$"6@>@&7`T0*0@0'>]S\P
MD`&0MW:2]3%+X`!U0)]=,`/MH1_88(,VJ(,@N:#OD1\F4`,MF2`F29(K"9T0
MNG(G681A)Y.C@2]/R#$LF$3[Z5BTQ).3Y9-P!VF9U0235G=$Z5FAQ4B;AE]T
M(R.N)#8'$`N\H`L,\`OSUV&I@`N;-S^29%^Q\`%*9VB-$!Z1$0WK]8=7X`/B
MD'F_Q`.I9`1O6`YR60_J$`_&Q@[T<`.KLP[ST#O29`%!(&VG!RA_,HJ=PBD`
MD7K3E#MX`DJG@P"T4P_QX`.)R"?D\!`7@%P@8&Z7*0--D!)14/\#3\"9G?EN
MH2F:]%9O#%0^#W`&/1`""_EP0/H*.%!)5L%IJ"51>)<XJ!`6N+F:1DF>O'EP
M5&`$;W$%9:`Y]J$&<``$I7F<19&<,K:<3Q5!!RA3SVFA.C:=U<D6%J`!VED`
M`C`'<R`VRRHVE2`"%9!..)`#UMH`V-H`UIH#,O`!_L93&?`",!``&70'[_F$
MAZ%7930P50`$$3`C`@!+8):3(6(T9'4"#\(8&$F@!:J1V5`F+<.@`EM`==$9
M+!0"+)$@+71`0]:P"6"PFH&A(Z00"[&A3:53)O0"Y$IHWJ$T52@R*)J%0<FB
M7/BB,'J4D)2C(\$&!\`$1C4'`1`:!##_$D9R)+)@;KVP2?0W8KM&!;N&"[OP
M`3CP`J[&-4L*&57@I-0`I18PI;S&`R602CB0I<@$#Z;W26H:IV::>G_"3&F8
M#XDH*6([MF_ZI71Y#XKX.I7H.GU9B#PPJ&)8/:GB?(P:;[,X;SA1*[F(*PMV
M!@GPKAB6"C."/PN7?A,5?J0J8<]H/V*!C,=2C"_BHJOJ%?-S`R&04!XY%R8`
M!,6)J\BI`^.XJ^;8J^@X:\*ZCJ7WBQU&`;5&@7-P`,LZ!S\R!Z4AGB(@!FOR
M`=MZK=O*!F*!`QT@#;&Q&I4PKD[&,6<4=%S5!"H(5D9T1(,0D%VGA&4G<O$Y
M@QSB,C&C1>PQ_[`"RR'_@1Y"UHX?Q+`_%50-F[[NJ'(OZ6R'@G,7:T+JR7,3
M0J\?BT=O!VDJ.C9TYZ(FB[*7P'=C6``!4Q%I`(\B8)DBH173TTHX(`"K,0?H
M%W^">&H'\`$"T&J!E),P.`7.4#EC<@W8L`V[EERE\`-*<`!N.#KI<+9S::<+
M('H^$,/M('JT(Z;7)(EHJWKML#K71#O&UL,Q?`^I1Z?3%(B$.@`E(`/WQ%\L
M`7W3=[>C*:GWEBL2$`,"L!8#)PH>5JH3U:HC5C]L,0!B,1)BL3\7=@$_(@#^
M:VE$>HW\D;E-44!V\6*>&QCC6`73JX0X-V._2I:GJX"E1P"T$"VL:_]D]BC&
M#P<L8NP*;&"M;/#(#4`#-."[K_`!7<8B99,)K&%"\@@#\5E&(&B"4.$_!6!G
M)P!T7<=G\MO*K6QV*60#!J4&_.J]M@P?%M='Z3L&!]3+#2L!P`S,#U!0#GM`
M!B*A$YL![PN_%XNQ'KJQ1GN_C#`%`<`)UKRB9D-I)ML-`-P$P<(&I"(#%1`!
M:1``%:`;3)#`ML4C5)`_,G`$;]%#%%!AR<@-F+<X%XP##;D!>CA6BO#!B!'"
MFK,Y]67"5JH$#+#"<>+"]##$H6=L<R)Z]@#1>T(/D;@GL.<0K)<.JB</%PT[
M]<#1XG8#R5:(.)#$I&($:*HJ4&RWLYBW`(7_BY-:/C6PD!/%LQS%"F`\8FJ3
MHV=LJOWC(VMB241Y<)YP`W%!<7*!8G9\QT4QCLHANM;KQS$%R(&L8Z7'!(5<
M%?2(R$J63A<@`]P*?K:PR=U`"J'`E7I7)>1)42<]/6$1%B)`P%8&'%J@`9FJ
MSS_D@14!`\,;&R;DS$C6+XCB4[2\(;><V%:CR[LL9+O\V+T<V35@``>B(`Q2
M04@UNDRF9'ZMGD54:&GTL=1L6=?\:(^DS=O<S7M7%JYP`&<=?C)B$B7QSJO6
M!%2P%4<@`HQYP!'PB__3JE4J)>AWP?'*>&]T1VA%+K@DPF8B)(/X2Y^CPN7@
MALWDI:?CI8OI.B*M_SR1&(F@-"==.EU]&4V-R`X4S=##%HDW0'P"`1`WX+.7
M218,P`-H&@1/[-+X+1,Q3<6ZF"M%)L:W<&FM`"TVDC8PVA:Q^<X7!7[',F%,
M0``P"C>GS;RN:@0$($#9:!\S(`$(9`!./1B@^P!98`-Z5HY4?4=6?=4V57HW
MH".C\`%S$`5=17/IE(*P790`]V\R,B2;APO6R,TO(@+$(M8Y0,DTD*TY\,@R
M@%M6!H(C8`,%4!4X,`<1)*Y^O1JN?(_^F!C'HP&RS(N'K2&)#3,;4N8;$N:Y
MS-A#%MF-G0!#,`2][!S+H2Z6'1F/44'32W9\9H\=ZJ$\9T3[686C;0FEW?](
MI^V_+]K-WLPC(Y$6=#/;:.$VMVTL=`.SH>C;.E(,RG@+9]$X^MET3G<(#])C
ME\/<(0`ZP3TD/]*R%'`.58LGIM?#VL3#&1VG]S!=/9RG"`!?.GRG/=S0$PWL
MH6?1>PH0=*H[4:"6LJ`_`^`#06#?BIK?+KW?X>/A57P&&B``3:F;B3,+_5,*
ME"M),Y+@L,`L:+P637`.P*)WF2``:ZQI$7<!5.`#2""KPCD#+%!2'_[4"=!@
M),['.:>$?UP%*IYCB3+/FX3!!\SGA`Q^8A')EFRMJW8.S>@D:\*,KLX$O_C(
MN]OQUBH#<T#.`?.!D`$$`3!P`J!36-[*%%B`:'?_&425(67NO69>\S9?YOZ1
M\\',RY%]0,_Q\T\0]$(O]'50!S]#,1536'NLY_8X<Z;1V>/*GD7C1HEF2+X5
M`)4`:5K8[IW0A9^FZ,/T`?<5"U!;)*65HT<"!:55`E!@)*W``!;&%4-"C+QY
MN\-MAQ&`"$SS.-E!1--0>66"!&Y;I4/2)`?@>1W@2;F#*6QJIMQ4>ONPM>DP
M70X][`CPI6E+Q(K9*5\K[)>/MEK[;7_B!;L`U_BU7QK`$M$N[01&[7H[J2S`
M`C50``UNFQSU89A74:;:N/1T[@^E[IG<2$`2Y/\SFZA")O>>[\;YX2S6[S/P
M[Q$$5:4[5@1?\#45`G]R_P&;%'Z(DF2Y<4P,D.2[FZW9R@#GQQ6D8*J03.0>
M?\E,R93`>SQI4$$@"`1I,'#2ZLI.7X$T!@@>@AXI*1D;=4\)8ST],X\DD9*3
MDH^6EYB9,XV<G9X28P\/8PD)!J=`-3:KJQBN&%6QLK(MM1NWMQFZN[RZA8,>
M`<(!!<7&Q\4PRL;*RB^"4R<N+GU]5M/8V=K4+E\!8F)-`@+BX$WBY.<7(A?M
M[N\7Y^?I\DTB!P<#`PP@(`P,)4KL.P#%BY%]`$L45.)%Q@$<'S[@.\"CXD$<
M$`^($($CG\,"T:Q4(T)D&I$34U(0*Q##CPF7?GY8-&)Q0),?`PA08,+S1I$B
M%O]\"`U*P8(%"CZ"^HA!-*E0H4@12)U*M:I4"T6N6GT*U`?5(ERMBD7@`VE3
M"D5]*.%1`L21M_LH!`D1HD:-)P[RZMW+MZ_?OQ,""QX\V(".PX@3GV&1(`)'
M?!@C#W@[L;+ERC(R.SS`(/._MT<FXF!'@"<!=.,(J";'<2.["U28^"@2X@J6
MVUC4L'AP6$KBW\"#)S:0X$$58`&`(9]2;=J4*G:C2Y].O;KT$$8O/,0H(H*&
ME<@*W&#"H(%Y!A6I7##"_IVZ`6S8_&.@+_+&>/,J-'O!_X4P0BE\8<@M:6Q@
M0QH<C=8!#,<P&%XQPPPC2"$4?A%-"Q@`L4@C:JBAR27_'EK2X8B>E`C*&"@N
M4DHIJ`#A(BNOS*+!C+C@\L6-4U@XQ8X\[MC+CQD8$F0*$40P2(3$]/?"@\TX
M6$"3`:1`1#5]D-''-EAR\\4+X(Q#CA+FH"//??#`(\X\X]1S`10RZ'.$#&S`
M)9`^!\1SP0#Y0#&`%TIH!]E!^O!`$Q4BE';:'`4PP0,7(!P@1@I36"&2"])0
MBI)*Q+3TDA]7W,##`.S5=,$/."BQ$Q,W_&"44V91<(-12"45E`41F!7!4+=Z
M=1564R65E52ZDB76`E016Q6Q2I$U6UE/&75K!&G0>JL%4:1!@`C[@`;?#7/5
M===?X(8++F'D"F:8<#J<<48:_P)$A@,/..")#P.A3:2/O)?AHYE#1W3VF64\
MD&::EZFMEJ!&(E!!A1$",%%4;5B0H$8/O$EA,;H8`V<*!AND@)QR1T[!C0O/
M66?RR==%2T`^`V!4@`81/%@,$P?D(`,.:3:QFFGNZ-Q!!?HM4\!_@Q02`:0D
M)4U$CX7<N,LM&&C0+D8=R/P@DLE-6(@N%FX0BPT&H-B))B5^@N(H*Z9M@(M/
M`,%**[/,4B,N0`(I9-V]3&$WA;\<*4P!_5D=7I,P/`-II=H@OLT)6XJ1CI>.
MSZ-FF:[=5P\Y])S#@PST'?!69A-Q?O,Z\MY;$9X,&+'>Z?#B'$$4$03@71KD
M,?!0`/\B4W,E-BAE\'<$-;CT$@4E6%23$3(UL=,/I76UJEG-HF5!#&6M*BM2
M70';JU04C"6L]U(9.]4"XH=OOK!9*>5\]3XTX29<FS-1A`;>XB7N_>&6J_\$
MYPK'6`$(VTB\)D(9>]T+7P0$3;\XMT`&L@PR(F@"3YA``,P53``)ZH@`<6`$
MG3G,!R$H@VX2T)N,F?`W!M@`R+*VPI+LKF0HBZ%UTA`!)@2$3C#00`8<!)X;
M%`-H%7@!#'#@C\S@H`,=N$!Y:-"``Q2`"&2P@Q2G:(<I48E*9,AB%D>2-`#=
M[18C&,$0X54!P84':X,X6B]N404,/,$`0WB`'K)`QSI*0`+_HGC`$/8XA`3L
M\11K:YO;;!"C6=2B!7-+)-X6R<@,Z"UO>^.;QP01(<#QQXQ,:D:4,J"X$U1*
M<43XP@DRP"4!*`%-!*N'*IOP#C*MDF"FO!-]$&(["'+$(1UAV;W@,@!!K4Z#
MH_&.!H(1@QA00`01^8``."DR25VC)*/\7?!,,+S45>2:@KJ!>D[%$Z.LBB@1
ML-Y1KE<4I33E)]I+9[#`URNAG(\JZV2G5&Y``;#$Z@9)P<FG]*0/&1#``O2S
MB_WP1U"][*]<I_#-;WBC@S^<(0H="4<3,)(O?!SP7I:9CT8_IQE\5`2"#3/-
MY51C#_M4#@<7*`T3"@"\W>C@8J4X_^$)4P@,(P4#9,%PH7.@(\.>2B<&-0Q(
M"3I2@6(*S@..G$(!<$"#'+#A`Q40``#(P8:F0G5*4B1)%:NAQ:YZ-8N3(L+6
MUK@!#!1`!/`2`":-@36BJ9&L7JM#(D[!QS\:X`E/>)LKXI;(OM;HD8T,[(\D
M:0A)#I9"N^#;"L&S5IE!*06>C&QDMR%*4G;)@JE<I699B9]7>JE/"-$7`812
M@#E`BP(7<`B>!M".@\R'(NRA2<M&<P`!4"`"<Q##'.8@@,K@X`46<H$5K,0[
MWQ$#>,(S@0_0@TV+W*`=R[O!:(T"EAN\2B@_J=ZLFM*4I^@J6+\RBCQ[%17O
M>24K\8QG$?^@%RM9/=<(;2D!O=C0!`O,Q2YN<\`$^+)?P11T+P=%J$(/\X?$
M_$%J(A```=91T7PA<"(:G0]'95"O7G9D-"&EX$A/XQIXN$;!I7D9"5]ZF)C*
M-&,T50[15*Q3DO'4ISZ%&04&$)"(&M5J4=J1!T20@QX+H`,0$4$2<]"`'%0`
MBL[4HJ2ZZLPF.QD"+A@K+[Y05L?`2PPP:*N6M3RANM6HC:Z0:QWB%@N_UJB1
M@!6LFGM!6,.V^<U].U)C'5NX)CTC&BB)!I9.0DH!B$$)C\NL*KVTV4*+XY1&
MZ,Q$3)N&-+`T#5%@PF;HH[I/_<-TIZO/A4<#D4DS``H'@"JD=+?_.TI-X7<A
M2*X%H(!-+USS!]"5[@]^X!18X=.<TG)6.'T03EC)ZKM3"0H"RCNLJG@7O<9>
M@/6B1T^T.)LGB5*-M)G'R@&`X)HEN(`/@G!?MVE!"P$65X#'S;_^`0<(.V[8
MM7))0'HUV#+]VBAE0&/17O+@(2F=8`7EH6!RK`,_[C#":'1&@-VFH107TX$I
M3HQB%:J8A1'(0*/3T&(8PKBG,/,!?$OPD.Y\!\>._(('!-#C`\!``,D4`1,N
MT&,Q$,'),(]YS"$`@90`J:SL&HT(LKSEGDL(0(LT\]S67+<>$;V1?$LLG)/.
M"TD621`V'<:<K<8@_NP'4CS*$DI><`?'_\'RZV#/F:$UJYW-/*0`C2[&K5;&
M&5U>U',LDV\O]S&`#^"R[?N``A0^\*C<-6<:*`D&2U--31,4@0=><+7B#?*#
M/KGJ!ZF:#:Z',DZBP*J<0V&6L(>]/66-5RK9=0H^?4!/'\PZNJ<AJ9UX<`'6
MK^,<?6J'$F;-O#[9@R/:YG9=7.2B<1N4W,`WE[D1\X`$I"&J/&G"=BK3&7I7
M]"T1II?S11.OUD5P#OH>=#K:P=D-1E`U<ZA`!(!00H6/F.'"2;$@"C2CM_'>
M!A5_\<5CF/$+'`%/&/%.`)R$C!=,`0(GD`(5X&,5`!$`8'<7P`0B(`,`\'(P
M)P0RYTQ",($3:/\%"J```7AS(Q`%<Z!S'>!S()@U4G9T)%B">--F0[)T8T58
MOA!GP?`W3](,0!1V0+0@0D-U#&)GA!`-)+$-1&!9?Q9V0DAH8[=9'2$1^'`!
MNV4/Y$`%\Y(/ET8G_T!A\?9I>O=IG?$!ML,Y"J%W?.<!>D8E@#<%@A<`A.<2
M0>!J-(%XB8<\!.`%U@5YM.9-F4=Y[:4K:,$J7K$`P1(L%C!>WN4JJ$(`D"=M
MJ;=@.E,PTD9!/`%B2O"(D!B)D;@.]X`/(N`#4=!M+F(`Y)87P?>)IZ`"!$9\
M-E```H!]4[,1$+8OG"-]GA-AGO$9TP<9&%$1W)%A&L9O9](.KD%1EDC_<+P5
M`#;0&PIU?N@''.H7`0;R-E6@`1O0:!$0?_/74UU`*TUP?Y`1`#"#*$R2`6L`
M`2D``SE@<BCW`0````<@`Z>(`P"0`DL@!!<8C_$(CVU`@?*H`&W0!O+8`D*2
M!KM`9<U(,QQ1`2$(@EIC@@BI="SH"RFH@B-X6!12)!(I=<D``T`45>"0D7Z6
MD1N1D1[ID5Y2`7/0#)GD(%>W(YZ$#5>R-!Y0`5XWA#"9.47(2CC0BI<VA7;G
M:1NE450X'U#`!7JB=Q?52\6#)V(`AM)0:J;V@F:87$%`$VN(3:K!`]9%B+2&
M76#Q%-@S3LZ#:Y7'+`@@;%!!3W$X:X9X.>>P_XC,0WM,\`,39)9*(&VG9"?N
MPFD=.0Y=\C,5@$1\R5(ST@4U<`K\TXF?"(H&((JCJ'`1D!H8Y"ZAPXJ:,860
MV8H*5"^TB`-48(L)AGW9IXOJ($"701H%5T8:0(R^88S'.!P.!W6Z8%,L-C(6
M-XTGTP4JTSEGMXV.E0)KL`8;\`+J6([GB(Z9<8I'N00.H(_W*(]+<$B(5"-?
MT((>4"13=@NEJ!$X4P!,69!HY$5WDY!'AU@*:5B1Q#<2Z9I,N21/@D1``SD;
M^9$:&9,$<UF0XSA`,Y+\-SC.$`".I#B6D@(O$%7P.80SJ8LU21_R93O_(!&<
M@W<1=G^3<01"-2=#>?]`;,$#>R<&`;`!_&EJF**-R14"!Q&5H1*71D!/M+<L
MOV862E$611$S]'0,2+12AT@`'%!!JP%BJL$\JM$!.\H$/"IM!!-!XW`?"89!
M(N!U!,"7*P4A2!([%LE#13(,$1`#?PE(@2&8A9FE^G,*J*D#,<!;/'H!CHD/
M;S*99AJ9TE=`ESD:-*$1*M69DM-][%89&Z$:3#"2!T=B)9::P4%33X=3RB$R
MN_,%\B>;)@,[-&,[&%%4:7"?S!`!870<(N"2'X`18J!S"08#8E``7M.,SSAQ
M3P>#=\I;O:@O'V!:$<<+U!D`MXB=VLEE12.>"?F00W)832=E1E.>$LF4S##_
M!^J)E^XIGR\9H#AZH\3Z=7OIJ!7I#$B9DF.X?S#`E^MYK)DE=IMU)WK7#R"@
M=T)9;Q,ZE!+ZK1/*=QEZ`BZT.YYD7"_SH00P``M3$>L!*@1@!#K1E@ZC%`YS
M*C,C;6AB#UZ'I'OIEAU@KP/KHSRJH[;'6:UE!)5SI)>%1+NU4DJ2-4%""&L4
M"[I`0\=53!K0!1[KL34P!C4`LD/`B>4&2":KI5EZ"@:6+D"06W%Y>X]!IA-F
MD_,!F1MU&=Q1JFXZ07=JK:P$FI?1,@E6&B,9`20T8%W*I^H'J($Z,H1JJ#$$
M.S>0CMLA`#'0J(Z5H2.@0IG:E\6`?;XJ`,H`H&(@_[2AMB]L`"<]UK8VXV/2
MV0MI8`,1P!V;2DFONIU:PW2+M'3AJ9!L%I%'0R1^LQ(R&%7KZ9X.^Z_`.JQ@
M-ZTAV0$A20`54$'4BJQ`I*S)P!^$$%G0-`7_N9=\:8,_`TN."Y_]*@_8"@5=
M*)3B^KJO^RGCBJ$:.@U_EZY_$P7L>G^?PCHZPP/*,VL\L1,"T%GQ0`[3YK,&
M.[H_0P"0V'T<`0#<,7`70#!)"FW((`SEN1(!X!\LE`%5$`,94$PQ\#4V(!TH
MX@=^,`;4M+[I&QTAH`%4^D8H6[\JN[+#ERY28TJGQ+.>TT"QR)/[\AFN:!F8
MNA'W5B=O^K,RN0YS6AE$J_]@=PH#$6`82LNGR%@%+NBTN`.UA2JUU"%C-7EA
M8O`ZFML@O"4`HGN1"F:V->.V,`S#-,`&YD$#-!`&,-P=T"*W&(`@K9%ER)&W
M*[:W?%NK"[F0@Y4!1^.:%)F>,SB?9WNV1]J>CG.Z*@QVNS4.%SF2/_,S3SHT
MI15^%PFYEPM+0%,UF60X._*Y7'<'%XE$R\`3TAJ@X8!9JB1+0^FML/NM%36N
M(E"NI'8EZ?J"FM*^-Z`Z@*)W]'H#$N0JSB:(XR&\AL@!'/"(LK<>1I!X7F`F
M!%=PNX4H$ZLDG$L(V2FE$C=Q43`C].,M(:N^KJR^=@'+=!$"W,9M0$&'UE,$
M41#_!360`$!0O\"<LO<;S/6K,8[Q9^>`MO];I@%\LP.L0#I[P-@R`!&DO+QU
MQP[<QQAFM*9%?A>,P<-1!>;IM-#@P2!\,AH0%")P!!?6'5'P)(Z%`SWV`4?*
MLQB13&E+9.:QS_S,SS/<5#8C$3O[QXT6)+N0!E60<Z-!D!RLG<KAD!!=GMFY
MK!8)-,%ZT5_'N`0#H"FLPAWPR3!``1#"<T#$4C&3#"REQ/LW@V/\Q&6\T<I:
M.)P+67D6`"Z)N4IZ#`8+H'X&DZN$QQAE0'L\U'!')P=DCKB3E&(XR,(0`S50
M>%>`6A>@R8J74G8JETKP&O<A!A=@Q2HLDA/$5@$@TDS*_Z31:5-/EZKCJ\HS
M0A?5\<IV,<OQ&P5%$`-1P!3>E,M'85]"P6T4D(G;Y@<_X<JD0,S$''R&3<P*
M]QM`<%;L$+0S2[/,;+/.[$!#.UO2S`/JL<`,K":1;1GZP`X2O%O"J*<Z@)C@
MK'`&(,[D?-9*+*C3$+7G;!TAD`;MP\[;$0!1L'\RPP3R;#.=9C.9T6,R`,,U
MS$3^;,/*/<,-L+;J>`S)44;^:-`9NP$:T($+S4(XY=`X!=%.%Z4K\<07_9Z7
M.ZWK64:\)9(W""%3&@,18B06:=+$$-^"%X/GW=(OK<5XJ<(\=`Q"--,[T@(V
M_;AC#+;&(,>F.ZQBHKH/^F!N-__4;\<RF6;4]V*._J?4S<'4`>#4A><':O&(
M5)UXCU$Y7G?&?.D@$TM)G&M)S^!%6I.J5-K6;AW+?A`\->[*-2#7&E#+/]'C
M/^%-/E[+L^P'V&$!ZFOD)D#+)E`&G/(2)H`%)G`%'5(&/;`BB6V_A7'E6JX"
M^?L`",9!D-T1M00:`QQ]$N9@[M*P(L"P'C1!I>MO0?O`$$S-WS>J`5`%QKBT
MQV@*&JRKC1;C`647L-T-'SS;T4$]!(#;+@,[W!@>"L@&`1W0<%+<Q-VV7+#<
M,QP?;,`%G!YA7+"V3@14<:L?J7HWC58%%'"+VDW.!NFT;P9TA#O?&/F1\>G5
M8QR29US_MD`S-#\#@Q1\TBD=`QZP#!()5&4K.S$(@S$8@T)3T62<WU\-TSRT
M$DJR@P)^NBW=TDCDZ&^>)D)*A'<"H0<DU!".:7H\[N,.`/YGNTL]2M$I.T_=
MOA9`>Y!HE=&&QD/S'[(3.Q#"'RQD"'%;)!S[ER![,O$[([O,%`A/US]13+N\
MX]U"%Z_,*5=0>$M>!AC?(;EQ!5*.!1B?&R*D!KDQ(B3?",6G<"K`Y5J^\BQ_
MF"F/VCH@"A%PJ0>@.KUH=S3;&6AJYK44S0-=.>T@P7)<N@K[V9>]$6V>91N0
MYZE=8@9@`\TXX^I+31FO!A(SZ+)MZ-01!3[`!(J.`W-0+8VN_],%T'K@AWT4
M(`!MLD#^P@^<KK;Q`9F;S@7$+60\+54"4.H'C=!URQ%WV]J%"ZN`JH+!8)'P
M:8B([]+TV=,JS*F^XQ\IH$(OT#'O'G'#_@P9$`Q")-,.DKE-4I'"0)+P7`"W
M#NT$KL4,TKU+`H.0?VI>;<;9GNO((-(,_'7A'J[E#F&V$RBNUUH6RD]N=P``
M`!+4("D9[NZQ`SP6'P1HL0).\/Q.L`)OP!1(]',62[Z'$`L>R\HU/AW=+]?@
M'[^US&TU9*,K!4*OS/$6WP@9CQLD_R&/<!LB/_(B5`867_'M^\JD4`HO#P@J
M@BH&A8:'B(D&$XR*CH,ZD3H)"0$B./\'1B*;ES(R!T>A#)Z>#*:GIT<'JZP'
M.*^OG!><34T$!$RY'1T5`DT7P)>MJZ&K`P,X(K:Y,`4;"9*3T=/4U9()#Q(L
M,VIJ6%@DX>'?WVI$+GU]+E-5->[O\/'R\_)1$12KL`)I,<T%_P"9%*@5PT*$
M"&FBX%MEB@L7!@YIL)F8HZ+%'&PNROC`L>.!CAS%1$B1(H-)DQNJI+F4K,!!
M#S!CRHP9H*;-FS=GRB3),\7!`#`JB!$CH*B`"DB3*EV:=,X<I`+$B!!0(&HR
M`3`BQ/#PSX/)GP4"A!6+M!F,LP6"5E!;-NC9MS#FG%7*"VI1NT;SZMUK%._=
MO&O'OGAA<W#_`*Y"^2I63(!7AUP"_S&)JE>$L6.8C_'@D1FSD0NV?C"Y<8."
M:1\^*/Q0<D&)E\Z;C[TJD.'$"73I7-B>\C-"C3$F@H>P@/JT#PM%-`2)$2-(
M$`TAHKOS0[VZ]>KPHFN/7CU$C>O!@_O1D/J@!0M!3'13TZ/'^FXSXJ_'HD;^
M^_;MP^L//L8//7=`N&,`)00F,$2!"0RHH",,%D)(@XBH,`TE!6!RP"4L#7`$
M`Z"$XN&&'WYH2C'YP`++)L"DV(0`MT#&Q!P$^#*+")P=,,J'K`S`0S*VS!%9
M&M!<8\V00S[0PPSBD*.DDN:DH\X4&]CPWY14OF,/!53HB(D($6@`_]"7D@D@
M0DV2525##F&D&08-;++9P)MO7B2G#```,%0O%>SR#P45C,G32295H8&8./#`
M1$DIZ!3!3#@U:I-..\E$00%/'<74I9@BY=13O1`UAY@B$'4464B%]4];9VU:
M@5.KQG547)>RFM1BM-9JJV)E_5.386*9*I2HO=!ZR[`$]'(+B\/F60`O>UEV
MV0`E?%C",:`U<0-JYV6;FFDW_.#M!0-X<8$1.GJQV;D#K`)#;5^<HXYN)TSA
MTT$A4"?>=M?EJ^^^UUUQQ7[!E5'&>^NY5_`,)GP'7'CXF8!?#^$M'/%U[U`7
MCQ\)^#'&QF,D``00!@PA\H&4B$S)`P\@J/\R@A!&*$@B@SP8B8/1_'%&`G/D
M<XF./(#"@(?#A"CBSZJDRX,11E`1"XJU-,VBCP7D`J,`,^)PC(VHJ%(B#J`)
M`'4!0$8B!9%D5V-D?4NF70X13JX3995PTW/E!0<@\TJ7:8$9]8M'?'```!QY
MXA$F&>70)@UPONDFG#0P@-58`1QT$',1B%'`GX!NH`$,E_!004D9)`JI3HXV
M.KI,`73`Z:IU9>IZ4[+VM51:<ZT%5U"[M+XZ5*L&J]>LMP8O_%[`Y[HK83>E
MQ3OP>PUKU+&R+[6+7DTXJV-G`S`P[0"?&:&$MS\0D**)PQQ`A66?O++U4"]\
M8=LY+L0?K[R20_?_';_Y`AR>P"8(/##!WE#;DN+#C6X\;`P]X%C'WA$"#42A
M(`<Q#4!BT(4:F&`,5**.`CF&GXZ%;&0D0YD(1SC"E16H92@TQ-AT,#9*&"`2
M*4M`#7*6C`M8S6HVDH'6@H:*$>$(,\D0@=(X(0)@U`)9N!"(U&2T"1QBC10[
M/-&*OA8!((BM;%B\QI%F(,`E-2DW4))2W,;X#@U$P`=-J!LLN@04O4%&!!^P
MTU".TH$O,0$'%3F<'A?W)BZ4H`,U40OM`J"!&FA@+3`A2>8P$(!D&$$`H,O`
MZ1A5.M.-#BA+4=7K-BDKIZ1*=66QW5J88BG?_45VPTNE*FEE%S&4Y7BP_P3(
M7(;B2E,2ZY8Q"E:GCE*4QL3(%[6P#(=@PQF>(:V8Z3K%1SC2"K]QS8:P6!$N
M_K&H%$SA??&+WS7I=Y!"6@=@#PLG?@`8P+2-HXOT64_":M#`!TJN5[`J"A%9
M\0%2?"``71C##,90P7=L<(,71&`X"43"@AHTAB9T80H+P4(I./2A#HV&0G7P
M`!NDX1Z6P<$Q"X6)(WRB%1XBFM!(I)GS:0)%*I)FBUS$A!A5+5T^\V$K.*H,
MKT6FBE?,(A83<"02H),<96!;;K[P-C*240-I\`$3U(B)`IAQ#GK;6U3RU(R<
M:"4&3#@3FO2H.,3!R8\!H)P'(I"!&&@@GSVHP?]9QJK(DVP``Q%XQ2,CL(&3
MD`0FBSI=)1T%DYIX(``OB(LF-TE8I1QEL(5E7E]0^3M3KO*QJ0P,Y/@:`7BR
MQ;"LG*I+)F6:7Q;E%YBX'O:NAHP2T6)%-BW`:2S`G-9&(0H.9,X&-C"%:][&
M!?#336WEU5<-*-!A!F-/.(7[,`(6L)SD])_`NO&_]Y0A!!W@Q"M`4D]2:%5.
M%;%N`6H0GW]R4*#B%&?'#DI>$JHL$@72@2)T>HT34D(#<\BH,>HV#$]H+110
M%-HP=$2%\Q&QB$X;%DNE%J,F6FA#(P(%*TQ41!8Q85(1L$%.V3LD2FSQI]\(
M:MN(*D:CQBT$2;T!4S__``,-9$`N;OP45<32@:J>Q3<U\,$!\LC5!O"Q`6Q@
M`#XQ6`,94H)C@Q(`6R.9@31@8"6%$H$'-A"#NIID7I/<JY0QF=@J._8NODML
MK:X,V2Y'5G95+=U8#_*5OU[6=7<8"@QB\!UVAJ`(N8A1,)<)4X9PB!4B6*EI
M(G">&,!6.],1CW7<T84JT':WV4PT;G<;ND7Y-H$;"^\_16:`)SRAQSSNGW(W
M33`EB4,<,ZB!`%R!"1QTY+K6#9P]G6EJ&/!42A*00'AGW1[B]L"@L<ZUKLN+
M4$J@U]>2>&&%?YW0`24`OC)@`"Q8<6=6>*)\T(8V#_I[4EG40L`#AHR<64*,
M_PTENWP,!@TN*!`Y";.0PD2R,)(PC`4-#[6H'HY;4O%1V@_,@3E?L^.+[JV!
M&$RNM5UH3PSP6)'$&;P!!4>X`"A@D//\9%),Z,`%8."!M@)*4`*PVI@TH('9
MVO4E>IVRHPI@Y4OQ!4]+60SO*./EEKN<,<_32QUU-?)2+=G0&0!*[3#U%@\4
M\GXF"(%I)-A2EFQ"FKE0K0\B\&?O7`P[%9M'%SI.V_BEPPJYP<V[=.M62]O`
M`6!W``8P,(*RCZ`%+9BM;7;#:*WXH1O?^+3<YTYW/RSK'[N0"PPZ\%E"N>*_
MH2(*47Q;A;%FH(()D#4!PTNP^/1``BC3M>0GGVOR$O_H&I`@4LPVSWELV*``
M'U#V*V;Q"A[\-XC+CG;Y!D!M%%G;P=F&S-1(?^!1?'L8X5[&GC$P87130]U)
M0J>[U<'A>(]QWDP]@`#,ZI2H4NK>-3"#]'^SL03T)ZYQL@@;K!O%5[AR%W`Q
M54T.@KF+P[?4!8A!%0SM\=")[I(B;Q3)2XY95BH65X#A\LOW/SR__,65584\
M./$"`F`G+[`!=6`#.)<H@>46</$"7F$2'.=-)N`'Y9$M!D$!QX$>TN$?_%(E
MT=$%%22"4V<2M84.5I""6]<'6+=UNU5;:;<![E-;7_`%-$B#-C@%1$`$\U-;
M&:`5)D!W0CB$X2!J%R(58@#_59`#%I]"2WI!%!'0,7E5$F9E`XFW1<9U7.\Q
M`X]'>5[HA08%;),0,YK'>6:H`I00`2*0`S9B/K604DU3+:=7>IM!/OE`!9H0
M#*>U4K'W(@4F#,Q&"N!V(J#A(^3F`570>[YW#2AC,/\C?$+U)/!F?%1R)2)@
M-P<@$EZBA'9$*99#.9(C.10``QG'7[.`6JN2;X\"*3V1!D5F<1=7!17R"AUP
M>.LW6TYV5^]'2?%G$\I32LM#6,*C?_Q7C,:8%[24C$D(`X`E@(6!%#>'`99F
M:54@28`5$R4!)=68`55@`P*%,!;`#"X1!8"&/_1`@FZF'1/(<5/'<2=Q32R8
M@E:0_VA]0`9DT();MW;QHFC\F&@[B%M$,`7N%P-!2(0&^6E^T`%R)`9V$GA&
M44>1`Q11,4>)$85C8&(G(5MG17VUEH4$5!]<J&LL())?2'D%)0V8)PA#0H:1
MH)(M*2$)8`-SP$RF\'?5TC0X^89Z6$0[J32FQ9-$=&VQMS=^Z`N`R`I`,XBQ
M(&X/5A,:(%&^APVQ-I(LT![]82_]HP;GY%/M%HENTV&4."5S0VH7TB44P(G-
MD'23P4O$LRD^,AI@0FXW$8J0(CD^T1-$YE880`$L40&'UP48P'Y.YGZ0THN[
M0B9!`8PHQSPF%SS$>(R0V65SA&6M@A9AP2N-LE89,%LML/]^&+`!?26`%?=D
M,)$!A81`,^`'%`!*4&4!$U@OTT$/(4B"ZUB;Z^AO=FF"MN&//'@"+.@D6R<_
M:Z=HPTF<^G@"7_!D!'F0S$D"8U``RAB=#$D4S%A9)&<I8A``&V-BS*$!@K*.
M(N@.'.0>'NEX(LD"Z%F28$A"*#F&:%B&$H)>0@*3:N@W6*,*07231_19.1F'
M.\E@0,DT?"@9D4%@,2(5%I)#(/516U-#NN>44*E3)Z,-VS`#Z&F5^5,&Y#`.
MP_>585DE9H1&,J`^.$!(/@`UEAD946.9S@<0-P`04X97H3BCH9B7H1,E:J@T
M`M`E7:"`Z\=^=L6+O3@6RI,ID7G_I)`IG=%I*7I'<P>1!E":!KB8$E4P=EJ`
M`2F`F8]R&-SHF4\0,E6@<SL'`X01$V7%CC40`W4Q*EJ1!M#A=.D8`K1YFZU5
M66P6IUT0`WCR*LQ8<=9TG">(=?VX@X3:C[=UG"<0.NZGG`79G$38`P'@A,@X
MF;2T%I%S$&D1`S*T**9Y5B3XJ?U4,1L3'!WI>%6)GA6:GB2IGI!G7KZ6`/%9
M#4$2#7!@#2$@`.EC(]Z&GT>'DXN!D\%@!``Z(P`VH&`29]#31-W&H'AF8(3X
MH(04H3NE#<95E0\34!=D,=^AE4#EE6'TH52B`<1!``Q06CA08A&`HFD)&?_@
M#RWJ?&(V_TEC5J,VF@)I8`-1D'$XD)T:8`/^:@.!":1/MHLB9Q@O4`"$03N-
MB:0,NTJ3.9&`T:1CD4B;.5L_.G8V``1:H`438``0];$.57ADBA.)5`5U\*4A
M@S)5X!:V\Q9K,1AE2E:4TZYY<JE:89M35Z=@T:Y[AQ1IT&9PJJ?26180.)HO
M.#_Z:(.`.I@\(1,P&UBC]`)E55:-ZJA"V`.5PW*;=`>6ZA4!UP-;X15FQ8XD
MZ*_TD#$:$VGMP86IVK:H2I5O^X4%)8:_AR!P<+=WBP0<E[$$(F,,^C.F\&Q!
MA%+]:12_$*S.JE$\:41\J*($^DNW4#T)2B):DPP$$$S_=0$.9O\:`;`!TDHV
MB5>ABQ=._!%0_L%.?F`"X-"5;?.MX/H?(*94)7(`%5`0S8<6`[:NCONNDY43
MIR,Y;#42L'@21G9^.```3O6O_EIH@AFD-"%E,*LW:@$8#5N]>R%XHA*Q:.%7
M3PJEFN.9&+"QC0"RY%N^$`4$&1!8SE@3*;`!*)NR#U`%#7@[;S&_(XM7916*
MK;61_>:I9G0J4'$':9:,,!`%_E&;:EH41/$KR?@J85&:&8"#>"DZ9,*S:TI+
M=<*0=0(`Z]):56NU<V<"$:`6=[))9]&Y0Z`'8_`$@M*=$_BI9@LW:8L?Y?FV
M-HRJZVE>%48@>8L$2/!:J:%:"'%13?#_"1X54X';;"<B"RF"N"QA(OEI1$C'
MKOJF8L@BN4CI;*X`&N'S"_^%=)SKN4("NJ&+GA8Z3@843AMSN@T4`JI+`E\D
MB6#YNO$0NQ30,Z0F!G[F26]!H+O+NV!B2?(ZHSQ!5H"2`5^0!H)2`!?"P12D
MO,M[BTS[O)7TM-%+LX]IO2^GC)39I(?!5MZ;$E:ZL5H`!.9[RJALOCJ@!3FW
MOH>Q`2/@``Y""6%JR0>+L'QEIA54F_W$3Z<9DQY@OV>&%`$0`CW@!R'P6F<5
M`_/'R0JLC$E!I@V8%-))1'5R"0``>)O`D&O6;\L)PD)H`LS,%I39%LA35ETP
M!&-@!I(DMIK3_Z/N8`.@*L]Q@S&15IX62J$W/)*3%X;6$$-`8`/$41S=\@,<
M<-"12P7EJB&J@&`@``6F`!(+!L44G:"F)<72]):Q=RS9NPD@%447,"R@M31=
M,VZ3D@:?*ZME3,-KJX7PD1_]X0YM[`=E8`+>.HET'`_S1@6K@"%,]R*WDV\L
M^JZ]$L@D.SHT2GZ&#"C>*W07@@,=\,C^^C&1++`^0<F.8LNW7*2:O,EMZ0\V
MRP\<%[X;^S&F+`5Y@-;FFP=LW=:I_-;E"P<8$,PP^\DEL0$M4'9:,"!82F3"
MFYN''"@&8$@O7$$(Y`Y'DD`8>1)YM2NTHP'M(4/]=$BB(JF?I:1#L?\)*[8L
M#'F\V:S-VCPC:F96?O;!X"P.(MQ&D=.=H4I]8Z`'L&T&79"^24$8=-6C5KA`
M\2S/N#U&:HN%U;K/)NFJLRI10/"_3&#0!_T#-W#0SFT$)<`%(#``.H24V@,%
MV?-L'Z%ZW*TS-XDL?8BL+*>LUOU1RD``/S`+,P5@FWO2*?U[%-H>%PK<C>=X
M">0?#00=R#P%N.$"1-7:.=UA]H!&'X`)!>X#:1``J^(B&DT[?TS4(C>O-&H2
M_'#(KFBQ<.4*`+"CN!W0-O`$_QJ8[4>P`S@8O%LI7;T82@IF546QN#@"I!SC
M<#WCJ=Q0#V76`!NP/[H!43K$JEVTI8D!!G#_I6-W=K`L=F0WI3+(F7D]`F,G
MY`^0I_M;2,!%GA;J,2".`6FW6TWK`2.`#8BP`4(AP)A-2UQK.V%QLSV*OA6P
MP41$2Z`M%8'7S<S1`Z=-=SW`<:[='EF`05+R!"+8;];(%F_!I1,H)=9GE3+$
MCC$\1C-LY:/;A</]`.U%Z1*5`"'@`\WMW`>]`)[>+1R0-%FB8#O4;=TF4B.5
MZJ7^=ZCU-"SEQ[NP;:`!3>F2E!<B`+F@KPFJ44:P#$WI#+/Z4!-"4/E1:^1D
M'UH(,?A=0?X1`_P-1AL`X'3<82%*`/;I"A20!AY@4]D&R%&U5XJ2U,)KHVY5
M!4"0!C9D)Q'0VS5@_VE4#;!63<$W<<GOFIB97(P/"XS;>QC=B^%D3<II3>,"
M[U!F'>-7*LD\#J5W-1/B'J5^UF]`(9I>86R+X`!$7G9%?G9-;G9KX``=:VS9
M8`-C.X$UL$6HFL\N]`0.H/&[$9`9\.7J=0@;\`)T89GC)SFME?/=:58)(.8+
MJ8R<D(R!1\"D#=EW/G=JP&-YBA*%MA6!9!:9TJ>;R7%5(()B)$/PT.@?=C&D
M:C#QH:J2)T+H9>GM%06:SND<X.EJOP`<`"[7T]T?K>HA@NH@C41)Y")^7`&7
M*[E%9`0U@B-;C`N7FWJO@(<AG0LV\0S0$%%U^V,,$UP`)!_&Q1[9.AW;^?_L
MDBCM.2W39T0`KI`/3'!1W#Y@LN2NO%M),9%7I],3B\K4LW7N&5<GA%0#?SZ-
M[NZO(DZ:?548"0O(_G=R]SZI#5Q*^UZ:4OI6I>RQ`T_CUV#6[QZPL^6*5UW!
M\'KS3/=G@18PZQ$?<+PYS.A77O$$(E0@A,`(8C<">*T`ZJ\`'O_Q(/\`0("Q
M4RV582\V%:_Q:+=VW:A0A@`(-C$1A#&&AAJ)AX:$C104!9$1-ALP`&*8F9J;
MFR(B!3%=&ET])%BG)*FJJZRM)#TQ!3"S%;4O`1$9&1$>'KPO,+7"%;,O'AD;
M5<I5B8E=738UTM()/6/3-5W9VMA=(<W@B2$U?B;_/3/H+"P2$@_N[^\J.O-P
M2%$4-POZ^CX(14%%?/R@,N#`@8(&$RI<>."(PX<0(T)DP.!(0A%-"&@DP*0C
MDP(?07;L4$%`DPLX#N`P0H5'08@&10CH*$`$CIL&;U(Q<H$CDP`!"FQ(8&">
ME'E($RA5.B;!&',]U$B5.H/JC%-8T*%3T\.$B3%/P8[I,L5%GSXNIFS@AJVM
MV[=PIX6PX(/)AX0X"*2)(&!.QSF`/<*(1+BP8<-`$RM.W*NQ8P\ITDC>H&&#
MY2H8,&C9K$6'!B8B,`708,,&D"=/#*@V<+HTABH;=*5HK/C%X=LP2`K8S;NW
M[]Z:?`N;50"HK\DC,FL!_Z):BG/GS9]+GTZ]NG,@R[&_5K9!\FP/`6Q'FD5^
M<'&@C6)$T1`BA)]RYJ:B<T6?A(D(,!BGV&#@G=('0RRE@@H&3*`%!B,DF.`:
M&#C@P`2KJ09AA`8HI<-2JP$!A`.9(9A@%1]"HV%I-H"SB`46-!)!`)`0UH%N
M!.Q&0`5B=%!9!3@`H...EW#"B2<%C#)**:;49V0J,]@7`3&R#!;,8(L9Y\$P
MQ,#P@C'(),-,.,]TR8U2<;W5WC<:+**>,]*,T4,/ZJS#SCM##)A`/1;<D`\"
M06RQ11!!(''%%2'<0-!"=S%DJ$2(1L2`#!6I),(%`FCD44>%>:2;`!>@I%)+
M+O\UY%!.&3%!0!,VX:02#E0\RM%Y`0Q5X3RJ67@A4TR9,)4:6LV')!:W2E7&
MFE!]E0!99J&E%EMA)JML##X4D)-!%T@V1P5_S5$>893>IFV4OC0BF60:*%.:
MAD`L-<8#\R3@SAGL_G$&$`',0=)H-92&6FH1/@&$#:_%EL%WX`$EWF'ED5>2
M&`*4]!O"NV62L+61H!?999IQ-H%U&$N11\;2L<89@K!UMU<O0(U7,&&X$&*!
M>E&T1XY74:F!RI$TMS)##%`&`!E_\"R5`%)(Q2DAAR.LL=F#S$DXP82Q$A4A
MN21Z&4Z9C*CX2(N6;L2;$IDJH<1)F38AM@@$Q+`!CCK_WJ0V0VJ+<(F.8@1I
M0Q5=)*"&D5CE7:3>/5!]""'HK5BR+0&49\N5QV2Y)3A>/B.-']/X(=;D8GEE
M`GS8M!=%#'LM@J93:Z[9CCOU(+`/`EM<4<85?DJ%!`4B&%JHH0LE:OL1BUIT
MP*,9^>01MI/&:%*F*:'*0Z>?.NH3`:6:JA-&!,QQ'B@^_^<..SX_94(9\N6J
M"J^]<A7Z^-=H4-99:4V!K++LMS5.%!%04'Q,$>#<%WF`Y:^_M>:AK'.WWVH&
MB6J@(3A4SV<$K%>)-)``=CGP@>_"CRSH)8U[48@U^^).;``FL,(4[(,T\E'"
M:@&Q_T5@,IC)3G0XQD+JY`$[_Q\+F<AF$QY@E`<PYJ%`RE:VGG&\QRO<PU7-
MADA$$H0@8KY`1G_@X9]Y^.<=.I"'TC:3F:19,$,C*HV)_J:B^&&-"20IB49V
M\[5,F?$"3>#:!3QA1B.XT8TV*5LE>B0&3^!D=CFY27!`L8P:F.`JKLB;(`=)
M`C74P$1^XZ(NPJ.S&&0@`+4H!BX0T8SUN>\]C_O*>^`SAA]>S@_`"M;E-K>7
M+J:'/=1X``M,@`0?Z`,!J+O"*<I@*Q*4P0*QBQWM=IF0VR6J43>!GN]^)Q*/
M"&]X-CD(09"G.YEP9%3-2\FI<`"]D`!%`]=C!_9JX!2E^"$!E@LB.K)"SE.$
MCRNW"O_=5PYY/K0007WMBV?FWA>_7![@`R*H7P'$4`'^$8<QO2!$`!,QK@(>
M$`X(U1`2D/"-S:4H?I%@PAQV(X(*:,!=['H`!($@P?R0!C45O*!J,@@;V9#L
M2H3YX,F"T4_B%`>`EBG:9C;6PII.AS,'@LVWTD";)L&`?RA+SWI0Z<D@8J&(
MJ<`*4HOHAZ#H+`5*9&+/U#6KGR4E*1[#P&GJU:5F+*(1/KC:(V[0D1]L1"->
M^YI)P&9&-5[@C7#E2:;B"L>\F.T%=\AK+1KFB;ZJ+4>:N$,%=):!*OC1%'I#
M["`7>]0RA,!,*$*1BD*QC5%D(Q;YF:1E'X=)L*PI&S6XAGO_+O<RTI:V!J/]
M85=LM=I/UB`(47BH#U;TB)2=4`,,A24L4Z<ZJ43E%180@PQ4PA"$\-(@OD34
M<(,)J6%FJY@2%9[8WIJ0@@R@(#)HYO+6V+P\HBI43*BM!IHB#5'`[X3<W"00
MJ5+.H^;MG.D$UEAB4!:SI&4MT9"G/-NC@?@)8'8B&`WGP$50#5$#@0G`1C,V
M-X@5$08PO+&CVCX@@P]8V""%^@`.T@!!"3R0H^89332>4`.1/HU?)?W725.J
MTH(%(`V6J=AR;$ICZ&B'.VE0,7A\2A["4&"V/'09?&PEE:,N]<A(KL]]_@?5
M*BQ1JNC2`1.E#$6@*<4`58C!0[WX_T51$:`#QQ2`UZ9[QK>6.5->\`)=C:!F
M-J-QND;@P1O3;`1/5"`#+?"`E:[$YSZ_``]XR*N@Q<`C,<`@`\\P`6*3RMA&
M-S8(D35$9`&G6:+6(`I1*`*FV[-)^/AAM*@%I35"VQ7U?M(KD+.<-+:7ZLM=
M`=7P^56I0Q"%L%[-,(_P01'^@80R&%DKMHR`"&97J(<<5R')C4A"4M7<21$S
M>#%B:S(5<MT#9'=W3>A(C"1L*F56,[R0P$50"I`_`02IT^L]!2`5JP9:<@]\
MX(OOJ+M`WV*EY030T"_['(?:_M8%(V(30`2`\(#_M,.!$DA`F21#B*O]A:*F
MHO`'<I"#"O]36`8YL/!=<(!'O.2$PP_TL`/A@!\H:2"D)L8BBOU%LO"PN,6S
M2($-C%+C%FYF#99A."]*QN,<SO9,/HRU5)),]*+3#!9,+NR3H<ST*COQ`0GW
M0`?*NI&T>NV,?<WZFM-,9S=R_>MMINL9X=IU3P@@!1#P`)_!P/:VNQW0<,\K
MCP#P@F=HP`1Z<_1[]68"2$<61;.=K"AB,(ZY7,T'*/I'IC4-:<0C`=V=A%D9
M4MV#3YNCU9\&I1I,D%I/>WI[F[^<YE(4UDCX`-.QM9,/@C#:J,R@##$0PX5[
MJ>QC>\IV%-$=7GCGW&?_)=K<+15R#84#\$+3)GXUR`"H@$:?/`+_)!V8EOZ8
M8`%T@UYF,TMJN]TMLR+'>RIK@EP-ZHV^*>`[O_H.$[_;T_"01#\#JF0'"R!X
M!@T(8&W6ED&%]7^7_FO<_\1%7#>A8=-T3]1T$PR@82"'<`]$<O]T<C6`+RDW
M4AED&3H6,":C4BT5`%6@`S4W'1K2+SG&"SN&/SGT8_43`^SA2:!G9$;W@C!X
M)$C7"TVV=$W'=$!#94!0`&+#5FXT5W"5=7\59\<C9VP&=FN6A#QP`3]&%P3`
M`S?19FL$`&>7=H#F=EB8A7\&=W#G`4^0"(I&2(JU=]['*_816X=@`46@'OR%
M2JCE'B'`!!PPAW3(`3]PAS]@)WKH`[W&_U#OH3VL!DJ3YT>BYQ6A9BM7X$=J
MD&J35PZ-2$OO,16T)'KP$P7E$"@\D%T#8`39=@.(1P%*,'O()1&V=WN(DCNZ
M@RK4U'R]5RG:ME;<Q1(O\2G&M3O+@RG-XU<ZT7P=X7#1-2D1X!Y%Y7VL8$Y3
M,4CP90V2$P'M=%_YEGYQT25RP0@>E`$)(`'S1W\L8`/#ED?39&'4)'P:EA+\
M)`;45``=@`,(@P,54``5,'5B1`#2=!<1T&$/E``E5QP0*($3B$%S8X$IL'/C
M1@LD)"\D,2TPD`8:0E/5D0<.F0><H5-I\!T\UV,HN#)C(G13$8,<V9$UHP8:
MD'0\<X,WF(/N`/\$,+`2;L0I;U2$1<@2Q\,I+OF225B3<$4`[G$%?G`#`T!-
M=#:%`I`!$(!77%B45WB%8(`'+^!V5Y(!=9`(OF9D2D5(6(%]\<9Y4<!Z8_(-
MXW!()P<YFG,#/U"'35"'=;@`^.`#?P(YGG<YMC*(Y6!YI&4YY2`5/Z0&.AF(
M7M%;5Y"5<8EJ1*8!(J!_"L$H1W`\4,``!U$1`X`HI8A[^I<\J,)[K0@\<Z`1
MTY5U+@$3"E%\M\AMC[)&NPA>ON@[!$`!06!JUS<S[W6,4PE?7'%Y!=",:F%8
MT+@-C?,,-L`6M`8_U=A`],<N+%`#`C!-X>@)<>..[H@)5=(!,+`BLQ#_`040
M8`%0(P%@;BDS!RD!CA]0CR%WC_E(04G3CZM1&MRA8T%A,%3BG`<Y<`DP':K!
M+Y512AZ@+<5Q0IOF!Z_V;A[9G_Y91"!I0E%%DE4F57^0+@^P@S@`A0M*!0XJ
MD]<U`"5P725@A#R@9EYP/&HVD\=CDW"%`S_@:3>@-D=89S@0E"=`E($V=SHB
M=W*'!VQ'!S+*=A[`#'Y09&.X6(BE%;[R29_6,B_S:3[T.`P5`D5``6,YEF:Y
MI/NP`$7P:IQFB*;&EJ<VB67PB%=:EU:*EWX01([%!`8Q$P5@`4%P!>C0`SZ@
M?\ME$PY1`A.J?`?0*(YI>[B7>P?A*&@4*<[V_US&M!LGP6W7A3N-HA`R\8JD
MDHN9TCR\"&X4,"EF)0#59SE`9%2MV2N"Y"OG)&M!(`"T.06VJ6^YZ26EX3C/
ML#G2F5+6R`[!R0)`4)S%4R,=4!,"$!2S6C(P@##G00S6V3_%X20KT@'F>&$?
M$``Z\)T.E``9\(#2P!PE1IX&\`2N45(TE)XLI3"\(0P%D`8AXQVF-%F;1@Y#
MQI__.:[D.D0S4`/&D0O\H4W:U'1/!P\'.@\2H*`QR0,M01`1&J$3*J&;.&=?
M1X0=&E<N&5=J0P#Z^1[R<Q-S9A,"!P$I$`!L!PR"-K$3"P!W``8R.J-@D`*&
M=0XR,X8?6Y7M1F23*/]Z?N0'*TA:7WE(PFBD%+"D')`/,,L!^Z!KY8!:Y#`-
MC]=I>3FI[?8>5VH"^[F?4@$H0EH$!$"8A%E\/E`&]F$7UK9Q(@"A#4$1BEF*
MM)-<!V&OO`->>SHIE^FGW/57+V&G%V%\N)B+?F6OB_IC!7!6H\($(>"6/NN:
MYW2IF%J&OE)Y%'`!S?A.GZHLH3JX)+*;ST"-$7-HUQB<9\`""=`!!'BB05$!
M`%`!X&&YB9&2<0,>`VBYIYH85:(P':!+%!8`<#!_&'6/::"LTF``S4J>4)-B
MTRH+T](P"-,$";,;N!!0]=-#/K1>25*NPCN\2'6NZ5I80,"N;^*N!OH'?W#_
MC0KJKVQ6A/E:H0,``A7J$F_T5P,KL"_Y=6K#!._1'O)#A'!%!4T0`2,P!5/0
M!T3POD1@!W;P&'Z&L5@X!6806E5QJ4%T*Y!H#B;@1UW1'I<7I8?4!6#A#?H9
M!/APAS/[`_MPEOSPI.+W,N`*:W3IB';9I8](MX!B`:+2!"DA`VQ`30$H`S@0
M`E@0`DW``"7`!0S`!L8I34<P7%B[2[ZD3#OQ9I+RM2-1N\@D?`?1F(+*F-0$
M7F$;?*4R;:C2MLU2$VQT`9$JJ?T+FXNU?65H3MS3=Z-27RZ0/H&[;X,KJE%C
M=X/PFXS;N(_[`0"@1[(@>[.Z3_D1,+4@"_M$CK)P_PD"@`F[4T?%LYT<5P"G
M>P:I>ZRK:W)N$2%.0R'DLB__B)Z1<"F9@)R8$"0OXWK!2[R:O,E(50/@D40;
M0'#*.SI2]:Y5=J#S6@`X\'4OJ;UP-8<=^I)_M:`T:;X#"W8W8;"0*#^U;`0G
M&@$MH`O"G`%H4,SL:\SLR[Y$D+$9"P9)8`#1$#-%-K+AM'UNV0.-&'X$7'DG
M]Q6B`*Z'5&MW$L$SRZ3\$`08W(@9O#U5FJ4<++19.A>@D7^$N1#&)0,W,!<N
M01$#L*:EXJ`-<</&5CN)HGS+QQ-BT\,^+%%A^Z=V5(L.8;5X:IHQHL3XAZ>D
MV2S"EQ=S*ZG7!YLA*[)9;/^,W.,'/J`$!$`$7_R^YE<%Z"=/8ZP-8^(X97*J
MA)$!0X"-JYH`!1"YH9%,AA8)$S4\,8)_:\.=TW02'%>`!5`#V4A_";"Z$P2!
MTW!`B_PT6?3(-&0;/W4PNF@03*!HG#S69,U4*P(9R/`$4#?*I3QE5.9$[Z+*
M;L2@-\$#)4`%31K!V4O7K<RA?FV$<,4#.(EJ(WJA08@#2I`+_Z427'=&*!T]
M,6`#RV%!#N(`"J``+6`98U`50J0&(7`%UOR6X13`Y=`5JQ;`J'0-A">T0>`#
M=Z(GNF4Z,[L`$KP`"/#9>=F('*R?W&.E5QIZ5SIY\CR8#%`0@VH0A+E\/+![
M*1'_T6IJ$=<%A3=LBLF&.][U*#+B%PL=7:/BT`[J$H%Z;34,*A2=F4(H33$!
M*1Y!`19``8ZR.T5@.:_VT?[[VU9I"I8JE<:(!29@`1NATB[`TB?@TND7TUO9
M'H-GTY&`TSH=G`D0`(42CG\E8?>D<0883`PC#+$J`+':C@5P?PEA83``!.O@
MX#@SU=A@U5>-18X\-])*,K1;$H<ZCP+@!V5]XSA.'TN&UAN@UJ-\!FT-#T\'
MU_0*A8^29A)J!+:]Y+3-`7<=9W4=L'_-H6NVA#^&#R+,=6]D$Q=P0A40IS(`
M`F(.`E!0YB`0!CF``X0P,<A@`_@R`BTP`I:1`%O1?77)_RMNN7D_!(E!&J4H
MZT,:T#)7T-K]H"=;H%N'WN3E3+.G\]G;D\V0Z&DX.R:8MFMU(<(D/%S8M1#Z
M5]RI8@2->:>ZHZ;UW)/H3:?5G3QXL8JXJ]`^?)G",[8+JJ^XHSNIV%R8"3;G
M?>J[TQ.4@G@^('SBNY?[6<4]VH*H8(PCC5@R4P8,G(<W`.`"3N#M$]-><N`A
MD."&P>!/#4$/3H"G\G\8IG$#N#NYJ^$OLE=[;!-U=''C>``%0.*,&]5.0D'<
MI.(B!34D(KLPWM7KOM3#%01WD^,$C^,[KJX^_N,9A8-O/0]Q/>M&OLH\``)X
M;3JOM``H4`)R-5<;.N543E?'@_]&%Y"AJYRAVXO8)S0'NE2$9=[R4'``%T!N
M_+1/EFL9-J\+,4"(/Y1YML+?-[IY.:EJ0<H>HK>"J,5Z`5$$APY+I\/TBGZ6
M<YC71?#.7C$#?M#>8P5&8`8V(TSJ-GRGB\+I2SM7"4$1R$WJT-V3TTW=M[,0
MX9C0T>-LT`48TB6:Z%U[G6E&CY)UN[X0JO+K6E83."#%>ZF1_KN7[V9D^=UH
M)GT#5R/M[S3@+ZU^UMXEV/X-9UP8W+ZJ9Q`![[Z=[_Y_XWAAW+8VX<@P?2$O
M$9,R#-3MJEOO5*WB*TZ!+;YR)K5CY.;5*D%A%C#P!?_[G'SP:;W6H^QA)5EE
M#U^$:G/_/!K/Y#3KY!J/1E?W5A[_\2#O!6]U$R,OY3>1V&F`(P8QO=%]/#TI
M$SB`PF)P3P)`D"14`!$@68A'%XAWHY>3)(`":ZK)E>`,'T@`"$%1144("X<<
MB8J+BX@<AY`^14AE:B8F,QHB!P<R'P<?H0<,##*F#)RH`S@#HYROJ:8R!T87
M%T:<IKFR,@Q'!P.ML,/$PT?'R,>DI+^<."(734T$!$S6U]A,<P0"TDT7(C@X
ML,J^P0?-S^#B[.WA[,XXM=5,%!&#3"(B3'YE5WY^3)2II*9@P4M7!&(AP1#+
MP()8%C:,J`:+FC)!*/C8Z(.("Q=$B$PY4<5&B"XH4]98R;)&_\J7,%.&F$DS
MA(88$0KHU)DA@0069X(*/0,T@J=02#^8RG%4G`@Q`@14@*'37H0(:6)HV&H#
MB-<$8!,\D$"6[-"S9Q*DH0HC@`:68>."-4"WK@&O0&SHM5&ERH8-&3*DB.`A
M0(`",.;,$?`4QP<*91A*GDRYLN7+F#-KWLRYL^?/F<O$".`A0H8-3\:676WV
MS(/7L&._UJ'C`1`F.'CPJ&7K`@\&("YP0*'(2(D2O&\96:Z[N?/GNI=+E\Y#
M'CLCXIR+NW!5`*<!NH,-6.[%B!(".Q5;F]-A3@7%B@G\^''#6@$*^"D4&5AF
MX;^*5X1PB0D!$5@#0`(A$4)")H001/\1/B0""2,44@@))#=8`-!-&E"@%#"@
M</+!,K/`(@LINHS2##JEZ%)+$R*T0DHGO/0"C##%Y*CC*T<P$P\T30A`3S;9
M;!/5-^L8TR,S)0R`S`$\Z#-..U2RT\HJNUU0S7WW1$&!"$WL1V"!!!4TD`G_
M"%110Q=5$I%D$5D441DA6."#!7AV]%%((Y5T4DPOK0133802BI)-..W$DT]"
M`=6H!&GH\Y144^D4P%5II+&5!GL!$=<#9[065%E#O38J6F>II5-;;]4@EUQV
MU8777ACT]5=@*:3@06&K=M!!5/I08`)HQ!9K[+'()@LG"6J,YD$*I]F@&FNA
MMB;;M;39AEO_=-%\8UP)32QRPP]&C&<$#\$TYX47T+4;W73G5G?NE-E18>]V
MIG6@1!/G"C/>!4H$C)X/$?BP4WX%&$9!`4Q0\X-]&BWL`T%S]F>)'Q694(,)
M%U\R$$`)T;G1A9#\4.')"RARR`T4X'E8``)\>$XJRQPCRS#G+$E.BR[:$@Z-
M/1[!RQ$S[_A=T3KBZ!20U!#I-#?=@/..DC4?I_,!S]!;93OBZ0;FEBU'$84/
M3=S0#\AJFHD0@OU)9-%#;Y(0Y]Q8^%$$GGCK"9)())G4DDN`OC13X%W4=.A-
M.2G:DP2-HI6`!B&T%!=9+(B*ZE#97J[YY:HBYM9*K\85*UVSZM6%_ZV`X:HK
MKPQK$Y48PBHK^^RTU\[90FIH0!JT&TC+FJBB_G'M;+7=EMN[S(TW#373\`LE
MN\]EYRYT\,Y[P794VDO%=CZD@=\/OJ4")<!*`$Q`!>A3,Z0VVZBO?@?X^4!!
M/298!!%%E\C]3T0$>FP"$@(12`@V4H0@!&%!5W@0`GQP@Y,U(F6/6,`-6+:P
M`+R@`C@XQCD8,")T"*U$'H0%*X3F"UB4HD>F4%X3QI&B#YKB%S@RFGAB^(JN
M4:$Y^K#%\IR6#?5%35+C0$>)DN&+$BA#!NG0VM;$T;4H38,)7(I!%"S`A"*@
M*00!(<B9_@&RR$S&(6Z2B-SHYI`ZX2U/'O\!R0FF,(4J%"XF+1$<X6+RI\(A
M3E$%2`&C+E>YGSAJ<ZCZ`R`'>1;&E2H-BFI5Z,(R.@,\P2M[L4&M;J6Z71FF
M5Q40@!@*,"S;>?*3H$16[G:5J]Y-BW)$&94AA3*\;-F`"5":'@_6!;U7'"]Z
MLG07<Y"WM>:(PPOV$(`M9KD;'HPO8`%K0@7NDY_\7"4G47$?`?!S#0KX@2(&
M,4B<\E>W+%XBBP/Y1\CF5@8T7:$(XS*9`TDFP1OHY`479*$OED'/7B#CA49#
M!HIL-(!H7&``):I1"9VQ(RK-T);9P<'V1,";(#6-A]=0GS2D)@YR)",9K3A&
M,=@QM8I^!QA>>R+_ERQ0A`AHZ`I("$@VO^D'FEQ!C,R"F]OB-$:+V.V,:-S3
M&MOX1IBP9(Y`K2.B$K>3%!A@E:@R%2&7RE1"/@"1.U'D(N=B%R`\,B^T\DOJ
M!+.Z2R*F/9KD9"C'2M:R?A%W&B!,!%)@2M:PX*VJ+"2V='`&&W0@EL\Y!Q2@
M("*L06-=T+EE+J?GCASV9ATXN``%`B""\BRG6X^]130$4``IBDV*6H%<"&)0
M`&E6XP8/#0%_LDE:B%@B;1<Q;9OX@Y`K,"B!#'3@`]M9`'B^0`#RI*=N=8O$
M%>7HB/@\`)A@Q`D7GD*C6-/1$JE4G:49`1K=4A]$K2'1;T@IB#QB!A'/_[$*
M*DDJ2-?%[I5""C:3XBD(`,FB05CJH`/6#TZC%2,9^6=&G.J-"#MU(Z!H`M3`
M&0XE=U2449&*%J4V]<`(9B54=2+5J<;*JI#<"^H"PU5+7A(&'<CD)CMIU@Y[
M6'8T54,(U`HMW_V.6D.1P%SK>M=V&<$+MD#F>:A1/NAI1["#15>6NB6-&2^/
M>=M9;!/.@TSF'=86E+5`%&+`Y":_I:44X,:,UV>-_:R6/V4Z"#C+T(-R#NC+
M8/[RF4)0A`6H4[8<F$_";.N=3NSVS37S[6]YEH[A7N`5O/!1<HG!#MTL5U+/
MA6YTI3M=:G3#NE;R8#FTF\1G2$,`<X#B3JRAX?^?P0(\/(@&V,X8A`-=8:5C
M<E`1HB!:.+5I31.96T7HA-.\I1&_;-0O'>O8WT'Q%\")$O!1-P?7!/NZJ4]-
MI*NF2E597362$ZYD82X,`_2)@1\?CK:T/3-3BM2`,,_*@(E/3*H4MY+%>&U.
M+:9,`!G;HCR!Q7$NT_6B^4CSQP2X'@Z`R5CR"8P`2/*&-*!HE6=:0"M^N+:4
MW<<$"C)A8C'ULL>TZ`?WAGE`6([XF?B#A7-2X,RR?5AMX2D&FL'YS<DP6LV&
MH>E-C*)%RR"H+;&6F^4^0U)'UJ&0",U#0T]42NAB$3-*H><!2$D$8"/8ORUP
ME85U@!N6_@YY^<UI/US_H4SE;*FH"_C2AHQ6#7"BVYI,`*%6V^G5^:VUV&52
MJ``7==>`?.L?^:CVM?\Z[0_@;%2'3>P''UO"6J5PKBQ\&,0T6PP=\,.T!T_X
MRVC]VJ3Q@+9/>>*A"&]XIK+!',+MRTS;(E[AP5)@<^P<=O/XYH953I`](()9
MFJ=;ANUQTW22C0+X8"818,*05?_9^ECSZF<2\YC`G'N!/(2T7DZO@^Q$@0:B
MF0-,L.T+Q/`)X("`1"?:[47E;,*!BK!YY=)YRH>QQ.V]G*&"CKG,'PI1F]_\
MADY:TLY]E"Y)499@SXQ_P1;6,,9P/TOEM5,$T)OE;[;W@/T@&?$E7UIG$75R
M_R>M=E\BP5-C)W:%T@5FIQ,1@':\UG9M]W882!1Q)VS$5FRD<W=ZD6P5MFQ]
M!P-_5P&"5W@JJ(*J=FVD5`5``'EE`7G7(CQU50&4YV<SA&FZP2ZLL'F<]QR/
M!43,Y4N)%4PZ5#X^`PV"-F35P`U(`@W3Y`.RUQOZYCX_H&0`Z'0+YV7E)'%@
M."``X2"#0'P3-"XWL!'C@F;)9UO,-PH@\'S[=`K2=U$Z,B/%8&?9IW[6%P]^
MIE"2$HBA)W[20'-.8R03!0[HEWYQ]B28]G("<'!X\DR&48GXP3"+<6<BA']0
MA(!W(B`541`]8"#MA44<1@(41QGSI0;GA(`)"':QUO^`#EAV:85'$XA4;I>!
M;Y>+0\$"&SAW'9@`=A=A(9AWRN95?E<!8E`!-;""SEAXUG85&U`%!C`$#Q`6
M-`@;M3$\-F@#.(A+Z.8<Q[$;F(=+0?@N1MA+Z-)=.&`/%7!OWA"(Y$$^^`8.
MO;$O\J&$RY%#L^>$V,`R=U)`6%0@_B.&+65`=T-\K.<KOB)-\P&0*X-QB[!F
M'-=\7,`%T$>'NC5].F(CKX`*K_`U32`>?,A][6`O@AAZ*:E#A4AE10(UTJ`/
MZ$=$C`9#/("2D&8/1&<P.V&"/MD>B\$8V(4U3K0EKA@$3Q>*IR5U!@2*5@<W
M9T5&K.9U.?41+K!&+=!3A4/_:ULY.(2R*6"Y%;1(5#HQ8'_4:[J8EGST`!JP
M$VX1C*.#%UA5C)0T@LNV*LTF%2$P`\_8E[=#4Y41-PVA&3:E`56``9Y"%J\R
M5]OX`+2QC8_Y`#;@'<6T-48P4<\1CK*T@YQ)!<S!1%NC=$#2!!W0'44&>@PE
M'?2(;T-V;S_`FN6#'4SC,-?PF@17<!I!4E%@0%.T$?@Q04Q@F]+$!+[2,`\C
M'[8)D(8P01+Y`PE3&,LW(L"Q6[T`9R'7D2"Y45KR#52@?2#T(RFYDKT1B-TR
M<]-E)#\T-3IW44KC%$W`;U:!B>Z125%1GS"2=#_R1+E)4AM3)J,8</_7#Q+Q
MA8!9_U-DY`=VDB<<L:!I9)5$``%U4"@26A-A6:$6NBD1T'=E>52YR(MJJ8N^
MN`&*$@-P^6"E8P-U,$E;M7<6AI=!N9=^&:-CQ&4*)X9J4FWS1499IP;".`$&
MH`-DT0-".@:O\IA&^IAB8:2260$?D%A2,U'?\)[YL(/-P9G@P8.$Y5&7)@[F
M(1\=8`W[B2<4T`W)Y"W308Y6F(AIBB0^\R+DAIS"Z5ER*J>V.1]VZFYSBIP$
MD(8C8WR)H&:)YP',!P5<\'S1AY$@]R1SIF=\!@U"0EP;]0R!!G[AJ9+0]6CD
MEPT,"9,4-90DI`Q$TPHOUP21UC#0`$4-`Y/>,)Y:RG)3HO^?&V$!_&<09W*0
MNRD@;G.C!"@GV&0"0;"@P.J;;#02PYJ5$_J5-'&AR@J6&:IK/X$6'OJA&?@`
M(KH3)-J!<7FB&*"B>K<Z=^EW0:D!?"FC'29?9M)[Z36&`%H#-'$@NJI-"U&`
M6J<&$F``/JH#"6`#`2&D0TI5<H&O87&D#]`%WM&E\U%PU,4\-])Y5+I+Z1(>
M-S)#[KE#^WE`9$@(A$!T\[.JEW<NNX0\R]%R+2<=\L`<CZ5O\):G*NM9<;JR
M[G,>/Z`1/D`R$_2<A<%\]:21UJFH<X9<&R62,%)1A56IX3F>J3=SI:JI1V=S
M4J.>^L1SOO4,6\($]G<`%U"?46/_M-=EDN/P-?6`@*!(JP0B:KLIH`Q13A4!
M4V1D$`@:K,!*`;G"HHK7E<=J$\FZK,O:K&?WK&<1K=+Z:[[8EM9:HG8!@I+$
MK<KVK2;H'@(0!5A'KF;EA6N3KC-AL1)J0%MX"=F$HTH9)P91K_>J%@3S%B;0
M`VK0KZ1C`+#RHTBJ`07[IC^@!.\P#EB:>=!!I=QR'@4'D`A("*;H/P=Y-[ZY
ML3#2&Q];/6?:9[GQ7/*0FI%U6"WILM+[LON"LOHVGAY;-AIQ(104J#A+(A]'
M3SR[(SY+#*L07?<IB.*WOH<%<SI$#4FKJ3Z4ODD7-/H$0HZ&'O-#`)OP"8[6
MM(+(1+F`_U#N60VY.:OK12`/(I#OQ2RZ&I5C9":_ZK;#2P%4@9<%$`&:-:%X
MV\%AJ;<;RK>]^+?26CF"JQ,D2J1U9VS$*$DB*+?(F!B9Y+B02RS8=&4*41D7
MDZ[IQ:[LZB`T@;DQ4`1,1L1;2)!IX[F=BTT](`$),`$3H`-`X`%"4@_W@$5"
M>KH],`8U()=U01M2(`6/XQVKP!SHIG0]"#T/BVDP9@ORP;LD54!-22B8^R`'
M]"!Y4GP)>R2(U;'(FQS&"\CL:[TI.[WN0\ALZL?44:54V@3T,;,<@6V[\KTH
MLI'3=YU&D\E^U3Q-R[Z>;+0L:9X]1`#M<VB!B%U+@@Q*`R9SP/],469RL$"T
MZHDS'`6KI,8Q*Q6\18!%:X(%EU"@!DH1-B4_S53,^=$!>%0`%L#!'MS,&*JA
M><2AT$K"'UHY53"B8R`!*KQ(=+$2$!9)+FR,=EF)>)E),?"X-1R8H;A%/,Q%
M8VB*!2$9:N!-4E>YF$L(,8`W3/9O318#ELL2,P$Y623,O$H13?S$6I``4YRJ
M45$!\*/!^ZK%"JT77D$76@`$!J`!'6=,K\#(5IHE2A"S&B''`\G#08S'=D+,
MUA"GK<FFI_P.#$6.?SP=A,BQER=^;SJG*'MDB[S(MVNEF#8`32+4`^#(/H``
MDRC)E*RSESR^FJQHU(<U/&:/GUS5+/G_8Z-L:(>&6*C,:`/U#)%(,`9#M=@5
M1"^W-$!$0]]1R^_9,@N299;`KI@;$`-ZHU&IQ+Z<$<9LS/4A:3NQS!+JS((-
MPGD$!"+<.-2LEA)PS5$U!ORJS2JLNG/!$B>J%[4BSH*Q*R18S@)@`>@,N5@6
M0.Y<SX2R$O8<.5EDNO-<(%]Y64TF-@:TP96[9$1\67AS%<L\+#DJB@BMNA%`
M#UJ]>A00`[_;KUUL`UIPT1K-<CW(&P)#'_%#4A;K=*/-E,++0/5AF]=KU2S9
MM+_$+C.MFIZ<B/F&R(3,TV?ZTT"]WE3ZL.'!`SM4`)I->M(9?0Q@1$T=U59J
M41]47/@[U>K+_]U4/7[J$VERNJK8(1X\8H=^%8G]1@';L$)#B37>QPY4X+2*
M*K)2F(91H%ZT>I!-:;;^T#91F;8.88#$O-?-5!_)#-BT*-@>3-@I8-@=FMB*
MS=@,YM@]P`)"JLV,9``M\03''4F779>9S7><'0&?7:XWC&JJ6`8@P\-21]I?
MJ0%+)D6HC2!C"Q"",!.F;1-B0VHVH0%"G,\1T$PI?HE09`&=E*,S,`/"B-$)
M$'L)ZSZ'5L7#'0(ZOL43#00:4&YV2D&2,-T,,B!<U%YF^)H!HQRS5![KLH_A
M91VU$`Y>T%B/+B7)`3WA_;R#'*5JBM[IO8[<E7GL7>JE+M//<0';4_\!NT-Z
MU6G?^$T..[+?U?="*%1GJYJ:@!9^XN>^@[:R?!P.,73)JR"%&3R)/K`8]QE$
MR(4T\$`C-P,,QR.%;IV4N5R*=,T0FJNVV.2Y#H%.Q:?BO\GBS*03+DZA,.[!
M.`'-'D#CT(J6-NYK9('CE97-_,H",]!'8"&7<@G.IZ-5J3,8FDW.R2@`$>!%
MGQ2OY_IE4LXQ<6,F(=-2`/'#)SW$&-MD>,)DK?(W!U(#6W$@?C`&`:<!:2!_
M"IH?V`"%UF5I3'"*!BJ*#S`!&&T#=!Y1+XNR#D[<?L"O!A+BU/UEARYJ9@A:
MBWX!CDX>XO;HZ[(UCD5+3O_''>M84._)XAW_R)@W0Z1NZEJ_]=,3:*II791U
M%8S56[T5L1IT4#K2+DB3WYP0)=VR#N+IR:/I4'-ZYS=7UKF0G<"P/6UM4D57
M`(PA*3>4<VU_0\7`D?%POFFXRZBE997[UKBC$+NJQ*L6`N'.,F>8^6?HG%7Q
MU\R<[LNZ[HK2[H<=%&H7[V\W[]C,KSO>=F6Q[W/I[R(H&-A&\(B120>O+-C4
M>^Q5TI1;$^HE-Q>3$*0=!!:?D'%,"%$0EE)4H5/$SQU.(&/`Q1I`=`4C/P7P
M*T)94:(0J=`F-R]_NC-0KU[1!35?Y]6EIE&!S/]FBJSU#Y4KO+^IZ$CR8DZO
M]%(_T\UU'=(!"%Z"_X.#1EY&B$87%XF&C8^01CR3E`.6EYB9FIN<G)2?H)-&
M5)&*BZ=-J4T"'0&N(C(,1S)'1P>7M9@'N[R]MYR^M<+"O#@B%TV+1B+,(L;-
MS!?-I\BJ`@38V=@"W*I-SC@#O@?A.%35!$Q,!3X1/A0P%6(X]")4D^*[G_G!
MQ+OT])I0L!#$CXDR:K"H66C"3XB'!M60P'(0BT42&"UJM)A0C8DB-T**%/FC
MI$D"!5*J+!#CH4N7&F+*G$FSILV8,2($6.D!B`069X(*!2JTJ-&C2),J78I4
M@H:5,<;TD-"C!PL6,Z[.R"I!0H($!H#8&&L#0Y4N5:ILV)"A;8H('CRXFO^;
M,EZ%`"8PZMT[\>)>+'HI&O1#N+#AEWYJU'@9(DB4("$(FSCH,;*)Q@\7AX@2
MHTB1*`\A!]$`,V>$"!926SC]C@*%"'X\3O83Y70$UQ0$'/C`F_<_8\@(_&!R
M@X(/"T5,+%Q>IGGSJ@_"`M$00)UU;02\-5&B"I4`)@-!![%`X<8/`HP*#>*!
MZ)"@3^T/E4(4"O[\^?(EU>_$O[]_3Y3<%XDRIE"SR'9*)-B$-AVL4P`.L3!`
MRRZX'*'++>-T@@\_PPQS0"WD').*--`PDTB)!Z;"#3?8$="-`-Y(@X,^])#S
M3'#8,)&=``504,`<,,[XSX;\#,`#%53PPXLP$]K_&`X!QX4P&4(*J=%#0RY5
M1$(9R@'&UT8:J5%&"!0P8=*9+6:W4DH!M,18"#?%*>=,M>VDD@<V_'0444SU
MZ>>?24E0!51C4%6555E=I>A573T`EE@VI*766FZED$)<<=%5``QSW)577U4V
M-]F4$@7&$6%7)$98"(K5D-B;CL4@JZP6Q*"!JX7--EECN*XZ7FI11%%$K*JY
M4X`Z/1X[QS;<S!$"<Y=9T)IK3"R8S7#%&9?:L)!%9I!SX#HW60_1C:5!!-;I
MB)UVU21##3.I9,>((_K!EU^]H`B82'WV/<+O?O\%+#`F_XJB[RF(&*BP=@EB
M-QRR3.#`P,1-5@C,+_Q5_\)AA[;,(L,!I(RX3(DFCAR--<PR^R*[SA0#T,GI
MR-LR#M^Y*(8SOAW`0SA*ZHPD#_UX;,LM/!,PD)0(=23FJI9Y.1E@7IH:ID(F
M6)!F-MHEXR!4;\[I=9QU\I0GGX"6;7;9@D*5@*%5+>KVHA(X^JA9DU:*J5R:
MPA`/!7YP><7?A@5^A7)Z+3>E0XQIX!AGLZI6:PR,1T':FYFQ&G@-44CKP^:<
MEW===M#,^,$!,I2.P[,9+;V99T6H]ED0L+MDV-^#C\KEJ+B/VL,8!MC010S5
MJ8,=C`S'>($2IY1,GR()0\+OO@7[6W`H`U=O_273LR>@PMRCDK6U#O]@GOC9
MEO\I\<0@8I++?SCPVSZ1^7@H-,C(D&C,B217PV*+*W9CO!$O<P:\<J2C"]3H
M'R)8!8F6A+%QF(,*0EI2+4KW,8Q1H0DWL``2J,21*[W*#U<H`]0X&#5052DA
M9?###1;TO>]=8&LI.5KBOD9#FNA$;'HZFPYWJ)2TJ20&:S.45MY&1$;%[2M`
MP(!9V)*!2V'*%779FZL@4AC-,`:$E)'(F*2$.,UH('.R"I;D))<XQD%N5K*R
MC05"4!43C,$AM5E-:]#3,@I&J'2W(,7QAD.!9YU03+E+%:IH5[O<&7)4A<S=
M[@R`@7,=2UW9::&[#I2@%(V(0(V@1/OH41_H90]@_L'_6"=$.3#X8:]?^H+$
MPB29H(9=[4PE&4E(7%,<SOG@!CP80`E*,#2,I4]#1]H90`"")$YJ[!*]\$<T
M2+2,[J'L:LQBUR*8`9P#I4-X%T`@BKYQP%F,PQ?#C."'/%9!(QWI`C>(0@C#
M!$C$100CS='(ESBR'(H4(5Z2S!H,4[+&E]3PGS*YX9WR)`$>&O2@01G4#Q-0
M*"$FJH@0/>*C@*"%)3*Q+:>12P1<I1C$,09VH(E,(1<B&<Q4<3-AG!R<OABL
M&*PF`+:Q30!<TR,*:$`-,Y!-#7)BG)XVX6-&L@0/<"0^XQR'6R$((4+"!:Y#
M.O6I)DAD[GC7!4<RH0/8R*>[_Z+1R@-A4A#T.5(QB?E)?O%GEVA-*UJO%[!_
MI9(:I3"0-UJI!&C"TB2R'`EN<&/+S9$GET;BA?J&IHE)(.FPB$VL8DW9LW\D
M[QC<>R8T742\[C`39L0YEC1V<0P8R0@'BQ`GB+X)SI;M@DEXO(5AC=#'BM"3
M2^XTP0BA%A@3,H<B%$B@5K5C'96\1@-=@,E#`/JUL`TTAT@A&T*7*Y2N8(!0
MA9K*3R!*W:L4Y0$ZR&X"=&"`[@*!HEJH:!6LV)C%B9%QI&F5JKYE@L6X:@QO
MQ-QJ4(,<86D.-S?XG/^0(0(!%$$B'&E($/I:'M=P;ENQHR*J#`+5!COXP66H
M"GQK$/^!8V4U1I=LES0SC*\`10*4_5&KB$><5NN5-5]O[9[W1J0*5Z;IKGF5
MY5YG;."^.NX'Q]0$A4YI6,2*];"3>*"/[P'8"Q4#LJM4T?Z@>8T+KV)$`KR`
M`"H`GC*AAQ<)C*3]#DC:+@_`&/>P1"\JF,<D7<`"$5F(0F#KDG620$PEE-H?
MU7"%W&YGMZKH;0PC8"N8Q&2EQ(U33NR4$CP5M"ADLRYS%WT&YQ(Z*E+I2E>J
M2]VB_"&[F,YTIJ40J3\[)DY^)LT7;>6J4<$W`370@+1F_+E)2D)]LIB%$2Q0
MAKY,I`RIHIR"04C(7DOUP<`VI'.60VQB]Z`&%BC`A;VJ8@/_B0C*)P;%?TB,
MUB,P0*W7BUXJ$]%L9Q:/KN'#:XQC3.,:]]7&CO,,!9J`B)_E6*CU4:R\D92(
M>R#"'$$NLF"I@&1+6F/)DW7R5@>X#A\Q00`B0*`WF%',G76Y%V(6[,X.*\Z)
M[3A)32A""-7,$*9)*2%8B"=?)@+R8M/9!QK&<P=6OK7C]'FX@`[T308MM@<8
M)='*9;1!':V2",`WTI*F-!&-<FE-&UV[-G")9A3C$L[4JJ6TDN-K0E"&&5S)
MC3NUC6L(4'$[ELY"IA!.+:E>3S$U-=AH3[OMAJUF>8Z\2CWP@P9\,(=+]KO;
MU+![AQG;B1%?@MK8)EBTM;?M`C6[_SO%8UA=6W2F<9?[\>>.O%\=MRW6M>X'
M"-L7D0'BOL/B3V'0>%?H>%:,`F4MX$R^A@`6T:P>O>-831#=`42TV5YL4IP/
M!Z>0<[F+#TB(`3L>`!.2*D*E-22V(Q3AV^E);"Y98)(I=V$Z&F0=U_#YY3&7
M>4UH/E";(QK1.=?Y#GF^J0@P%+Z2#KK0%47THQ_=`']V"4CM.ZUIE4D=6&5"
M$/*24X_0IG/F4TWQ0@"SI"W(D6#?(BYJMX!.Q53-46Q@$H&A<GR(DSD44'>1
M95G^MF+3)`+29@F`%X(EP%;P-CTIAG??0U?<`3[:`&/C5H"/5VZ2-X.31WF5
MQSH^$$D9)O\"B-`,G&0.CS`-_J:!+D0BX"`D]:!AJ*<-<_`YV-&$-=4.[W!P
M$51-,])+OX%[N><RB"4DOD=!MC``5.`#2-`E'<%F$%%K;R9"<981<R8;(<`$
M";1B+70!!(!5U.<@KX$:?:9]@B90;&(#WA<4BD:(X2=^.B0!SU47D/85Z%<5
MD[9^1U%T[I=I0!!&JK$YN*$NW"`CO[$;,D``^Q<U5!,"K>,9!X9@W>(MO(9(
M#/B*#@@N)K<1<C:!A=$8K?,.^24\&4:'O=@]F40D:L4Q1R"":U5*G51X"'-X
M60-NC.>">16#?*6)1D6#UGB--7B#(($U&E@B]4`RD/5O_N,-3;;_#=WA@[T@
M(HR7+NRH#LLR!_`(CS!D'*C!&F6"<$?&#$"36BZSA5U&#Q2G)&!X!$U@`1MW
M0K,!$83S9@DQ<FYH;+?C!Q20@=*'5=/7(`4P%Z=A*WXX<X"8D5TPB&=0B"-Y
MB(AH-HJX*9L2%;OCB`V5?M-5:99&B968708P*SZ@#JL'#J1E#$F(3OOGAAR!
M:R`4.+-#2*\82'_S5`Y83Q+H);1H0A,H2.65BYZS;,MT,M#';)E7+T2F;^-4
MC+QD;>C#,8"7,=DS'YC$;:LTA`@2<-!(;M(XC=A8EW:9BJZ#@S]@+44H>MOT
M3/W3/_PC3:8%6BSX,.V8+LN"#?+8(_5X_QM[>!L69D!'!D`?0F;^Z(\`20I<
M1CI?=P0_L']48CA8TC2@XI!"R1Q75S7)`'V(%R,Q<X<KAY$4`%,;V9$VP7V!
M^`"'5I+@=Y((E9(PL)(]8'42]G,P&9-%1'0TZ7Y2P%VJ1AX#`%0'`'Q&PF\B
M@BT&."P1L68+L50*J':W`V%<TI1M%X&HZ9`G)"I4&02MLVKYE0TK>$G-2)]P
M%5;O9@G#,#%E*9:UP)]G"2`GIDJ1E60MMH1Q*6-S29=WV:`.FHTWZ)XKM"X#
MJ#):M3\`AWK]`V7(,!QW=1XMDBZN%U.T`IFX\2.@(U@X\&J9V:(N<R3+P&42
M0@M'<`-($R81:?\9:@AR;2B4"M$#$38J18`>6TF?W7&'V<!RR/(:CS,YN!D3
MG/&1`8`!#T`4.4>2P)F(-A!%,5"<6V$ENX-^O)E^R]E^-6F)&B`K/G`>Q`&#
MQW&`"%@8M1.+X9*4!R$JLMAVZ;FGJ?F=XRE('F65\4D`"C))>.8N(O.!P."?
MQ%@+`=I6:3D@WB9)K_2A+U@^TOB@FKJID6>#EE<$:\J"%;J$2E:.+K*$J&<F
M+1A+,,A7?-A2&^E2IV%P'5`!,&):.H,/%/*/+IHA]0`0XF!MLS``/J!48>)!
MN0(U/(J:4<,0N!.'<YAW=&B'V-%;!F8!DJ,!!N%%_Q0L,Y%&A):155#_I89X
M<UGJ)SI`=,UE`SNA-QM5%3BU%5<R!E_Q`&,:B6\SD]AUIMDE%J'A&*NX:[W6
M@.0YG@Z6I\O*IZ;"'*(R&53YK^^Y:K2D+L83CG-E/`KC28-%EOS9G\-@C,CH
M5G'5;<4S6;!TJ0L*>9RZLBSKJ9^Z0MZ`JC([LW;5ID;E.B#UGBZ%1J9Q?;/*
M!+:*<-3$"SO36/]@>^&DF57X,@`Q3C1P`1J7-+:HHV"BL(5CL#5@9R2;#"V"
MD37%I*!A`CG57MD'4."Z$@$PKE:J7"9YKD;!FT'Q!W\0%!*PI<,YG'PF)3T0
MKPLA8?5ZKS^A?F_+K]J5`.+R:W8J;`:[=GD:_Y5NR*P:T;"WB(NI08WY!:)9
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MU@7`=1L`,.`@5\6^!&$0>XM3?=N27Y$`#APW#1S!7U'!!]NX?I&>0\G!H9&+
MO0NB\SG#DL2!\U(@>^>YN[#"LLS"(@BI,7R"JVO#-XS#*<O#OOS+/2R\MX0M
M2_RF30S%NE;$1ER[P@O%SAS%3BPL3G<:CU/%A(9-A<E)N<=E,X)'+=-82';_
MCF0\M`-P!&?6-VUG)138-U#C=GM:0K(Q&4'`;IJKOMIPQW@<`5%PP#-``E;G
M$%YS7F@$R"(YR(1\%.<"4S60%?]+M^S:6X_,<NP0R2:`P`D,IC^'R0V\T6?Z
MG!*<`)Y\ITS5QO,$2`G9&!^\BP)GPM4PG^RRRET)/;J`/F,YRS9];<=8/=HF
MJ?-"D:FP>*O:>-$(N^8&S$8]NT3-H+:4B9/7Q,/[S%`=U5(]U;##.E4]+&(D
MJ[;!LSM1JXO)3;\19ENL>]2+1TE[9!OXO,_@#/HIBNOT6A2XD.YLM84S*B'0
M`8;7;'9,'#+(9]KJI1ZQ&/,+==:,MN/*OP=]%.U%_T;*`12*S*Y->!T=@,KI
MT"-K%!$)?-%7(C>7O%V:)@6@#=HZX-%P`-*?'(OG2=>%<W6^8I7J<!XBG'<9
M]M,NW9?WJ;%_MTN8<-.\W;$N?+K/DPB%D#"JK`IVQ:HHFZE'O=RTF]2PVZEY
M><Q4/=U3;=50_*G8S3K(42Q;S6>G\2/C:%IBF%B\!TY`,V9FO4FV%\Y0=H0^
M>%@VZEJV*!E0&<JJ[<^L?0-YK6)[C:E[M3EYJQQ]"]`WD=4#':YI6]#FFMB(
MUA#CT@-QZ]`!D(<6*9^KT&0WX`-%$!D(L17^G-DLT"CV^MD>'=K95=J'A,$\
M.M>J725K/!Y3&,*MR6*9V__2W%&H>(>?N;T):+7":>7C(5A8.596(^N+QEVI
M)RL2SLW<3,ZISHU?R2V#>)ENV4W=5O[$V9WEVGV#R;N\,54`'2"T0TL.UTEO
MHR!:3B)8GFD+3?L;8MR!V?O>%T`!9<B&\^UFIWG?XUN>$KG?SA2BZN#?TX@:
M45`#%=U&@ET39G3@`YR1&@"W#(Y0O(D!P>.$*QTO57;9`N[A7UILAQ*FI];9
M##7)Y]FC"CN!#NLKJ>$Y.F+"LUWCWG/"TI,)/][;LDSK(YAM(GLPLMUB0!W4
MNZSD1-WDQ#Z#3TYCEYKLR?[?YT;E6O[44@WM5_WL66Z#Z5;-\S53M7FB6(RT
MX<3_@_:@A5_&#S-*"U^&A-_H5<X@3`%$(@1@D%TRE%$E&6I(TJ<^GA%`PI&U
MCDNJLGYMZ'T[!JE&$[-2OX/6Z`&P`9`>Z4OQ!]XGMV=@KQ$?\0]`Z>RH#76(
M#D:CX9:Q$/V<GIEM<J72XG!-@:&1TL+#'6YYJ*[F/*94;:([NKSM=R18@J$@
MPRKFZTB.W,*NW,7^\S1X[,H^]$0_U$K]ILZNY5!-[4S_J=;NJ=A^&C.U)C\2
M>UE8(W'>F<5`[F!X[E4HQM0T<;ED#O7P`S[0O2343O0NE'J^%R8=`UN9\WO=
M[P56;GDK%0->58K.Z"J1\$/@OPS?)QOM*`U,Z7GHNX?:_V3@X0.28^@"'J\?
MCYJ1_Q>HOL;EE3D2BW_94%EU>+$YCI_"R$ND:^M`GM.ZCDI%3I&_?BU)[G@T
M!O2P'WG'/F-%7_0?>OM"K:!%#:%-W_O4[CI/'_R5YU+9OA(030!'.$Q7;[W_
MP/5?Y_6.I1W/6[0VL@OO#AF4L1&PA46EPN+W'7+R3`!^OC"K3T"!KOOM6^@5
MK<ZI5O"+?O!]OP%K$_C7-?CV;Z^8K-$5/^'I`@@$@DU*38:'ADJ%B!<730($
M3!0^%E%!(7Y^)B9E:IZ>,S.?:ILFF2&H0446%CX4%#=,@H6+AHV-B82(NKNW
M1K^_/,(\`\4#!P,ERD?,S`S/T/]')<W.T-;*V-C&V]S#WM\\P.+CO[>XNXJ"
MZC_L[#?O\.^O\_,^]O?X^?K[_/W^_P`#NJ)'L"#!>`@3*DS8KJ'#AQ`CME-(
M3Q^KBQ:*:-S(L:/'CQHQBAQ)LN3%""@#%.C0@8G+ETP$B!"!HV;-`P=LXL#)
M,R?/8CB/R!@J@\$1G2*:J",@H,E,F\=RUFSB(P22$";48-FZM8PI366PD.`J
MEH39LVC3IL5"RD0()D;,R36W:RG,N_(,1K"@05,H-6-J:(A!N##A"`%@%"@`
MX\6&!!(BGYE,N;+ERY@S4W[`N?/DSJ`Y)Q@]^@'I!!HBW"50:U<O1N<:I7-Y
MXQ6EC$7_@N@.H7O5P'?L9KD>3GSX7''"N&T[<,2:\^?0LDF?7D*Y]0'@AI$;
M-_<6(B5+ESY,:'"2P//HTZOG5[[]JX7PX]_X$4^B?8CA\Z^#2-ZVQ9(@!0B2
M2026=!LK*"&V6`4,5C#'@R\1<,%3-_&$0U0XX<!#A<C@Q`!111V!TP!)12(+
M4T[I%!4.25&`"299<>6)5YEP(A99:N6H(UN;U$!!7-W)A4YX=[T4SV(%T!-!
M#%BI(4H/-80PF&$Q(*888XY!)IEF7%86VI=@@DF:::>51EH--701P2L1YE*<
M<8XHHD1WAP@@IWY-R#8GG6_F&>0%P"1WW0#41-,,=(@ZI\V@_\9D]\UVY0B)
MSIWAC0>?0>MEJNFF][CGGGR@`G??J/?I9^JI^SG4GWGY%,C*1@5ZY*I)][1B
MCZT#+=;!'!4(X*LZ+SE%84\6ZL1A5"`6Q4"&):K3%$T[`863"!<P$<45?F#2
MB8Q8>'7%%5F9A:.X9>FH%H^F^`#DG^=\9U>1>.6E9!0U9"6*"8)1B5@'BS7V
M6&02="EPF&&6]N48G$76P\*?W)M)#7X(UHI+@Q`GJ9^.V!(;NW-I?($B[1Y"
MER.-;"=H,=25D.C*STB3<G7;P%R,H(YJ!VF0KH%7J:7QE,?IST"KYRD]H8)*
MZM'MH*KTTDR+YPY"%;4ZZ]2O=D0UKO^XVC//8DS,P92O8`M"L;`<6C@3A3N-
MB%.R(0Y`!4TSV0)MVF8W88$?5Z"2E2<REN%MN&-Q==96YN[HE0D6K,MNSOFQ
M`R\3"2TV#U\F].!)#]D:9J5BC65@`,":21!:9`27/KKH8Z2>^L(,AQ**66H<
MGFT0%K!)P)L=8PQ;QAB/S&?O&<MEA';#Q"S=<\T9I3++R#/S\J`U9[<=78>D
MTWA#\?D<]/;<:SVT047'A_3X/S1M?GARUI*^G(F8JJJ\K.)S]47][#6_K:V,
MM#77'7Q=)R1+21'=BF4$$100;3P92G.&\@RW48%9:+-)3T10`$QDJTEDT4KL
M-M$)<I7K1H3_*QQ:NK6)(@"*8[QSEWY^\+AW&`E)DZ!7Y>Z5KRJIA',O\!SI
M$@::,YBN=``+HL)81T0B;L)R&RS%*4)0!!_$8A#4<XUW1):[7J#08^881_&4
MDPWF*0HZ+L.&\Y3!*.LX"E+BF"(B5OB^516D>W#<WM#"5S3RC>I\>#15^OK4
M)^NE"AY1JU6!]F&0)!'$!_9SU:U$HI%<1<A7O7M$>%)$K`RQ:"83>DH"9<`<
M!7(2!U2PR=F,E;::",`"2)@=!F4T([^%Q8/D"EP(13B6'FPB"$T`$O"BJ,+K
ML9`)#7F<2Y(4@;[8RY8AJ-)*6-(!&&0@`0@S&)D2,,W3J*Z(V,QF_RBRJ<2(
M12D5OGD/,%GC)TP&+X587!P546B.;W`#&\K+1O*\>(V4E5$YT0L'&M<U')VE
MBF<]PU0<!_JS.=(1/G9L2!X7JI_UL8^/5F1G]9Q&'_C)CQ7Y\!0,"_`2CC(!
MAOY99/XR8I(B6*)V,)D#V/)T-D?\2A`"N,!.RG8`'IQME'03"H@.8)2:DE*"
M':H)!8/P3:+NC2QL<:4:!A="PHV+EB1H2P@(H$MU]A)5$2D2#/GBAQX\R0]1
MB(#D`E#,:()IB*P;A9-<Q]:VJH%UFQC#PZ04A2A8(`*.'"<Y<7$!+T0JD]3"
MV3K5N,L)`<.`!C0"%;:XG*`T0QGT3-3+R/]XSVU(;Y]5),3.VNC&0Z*'0`25
MXZ<."H^$)HVAYG.H(B:U6HA&E%W[_*MW_#D1^!4D>P0QY-:$^5'=AM1^*+%'
M(DT:A!A0X"5>@Z2P;OJ(L,64IE*Y*;1ZHL`/=9(!;IO;`*5U`+NA(@26T`3?
M6!D[K3"U+$X5'%2CZC<__*"J?V(<:L56I$DPJ:LTA-@1O<HP)*IU%&W]R^5*
M80HT\::X&'4%UT[T6G86,(WL[`YRO,$-QU;#.?-\1A=7]KQ[1B^VBB-9R/Q)
MT8I21'L",5!HX6A0TLZ'?/.=KVI;X]I(%A90(,:LI/Z8$)>PD$CP0A)(!\*F
M.:040L.4G'L0:;__ND;!!Q""Z2%&V=+F0B)/`[00%0X(U*#(X!C+6N`!J!#*
M2N*$!],J0!3H:H$@^&%;&1S%!YL*PEG2DBV8NT&(!3ND&"^E)1^U;[V0:+G7
MF<70KOOO6PF<B0OJQE84\*BSTMF(P':G%KX`1LD@_*?$!NIDU_&0<T*480U/
MX[&3E0ZC\NF-Z?V.$"0N\=.@)E#U4&W%F?H>+$)E6H7ZF6G6>^B,6]LG%&H:
MQSE.-G="ABHJULE46@VI*[IFY`=Y[6L5:(F007I(E%C@,"?R7SGGALE##$($
M9H[NW"HI`BJ(R!DB`F66SUP3`E@`O%7BRQ7@'&=/G!>]=2[7G1?](XE._^K7
MZ^@?H"E0S*XNC,!>_40/_+:)1J="%1@59_G4L8@@K3;"![0T%H?'@RU'R@A^
M)?F&-%3A"RL*LF`<8ZHG>QV:M5K'A/U.K".RD#?:^GXBH02N_:'K]]1Q?`AO
M:/IFX5!TU'BP(%=V;(4!*9O)EF/2S3HZE?+G818DW`"$*=BRG620;MN0>Q$K
MV'P5/)S>-&."D"FQ1"05G5@(&1.B1G-$%,JT'6,`\A8!$RIQU[U@A=]Q%KAZ
MTVMG6BY:70;O<]+#TQ*&QR`*,<#()5*1>4C'0J_DA'7'+T9I2D?8L,BYY]SG
MZ?*7OTSF'8;>&7.<V5C_<]:TKK4_@*[BD1PHP?^_SQK0=!T^.^9QZ>C3V?J>
M+L73'T?JT"<'J_4)8>DS%BDX-5:YS0VL849(RH:H6-@(P)(B]6_L%7`)2@JP
M]IBVG=S;?P0EO6Q)4EK($#_AJ0R.4B&DX.`"!8!(B,1PAZ<52+45YG5>'J1>
MZQ55MI0X$A5%DY='IT5L<,)\L+$[0:)%Q&`=8I0\\!19SY%J-<=8TQ<,U'=U
M.1=^LF9BN:=[_<![0/<?^T`_FM)B1W<T?N9'>X2!N'-ZT1>$)(>"5$=U*L=J
MKC8\E84=H+18X"!*(B=)2M,4+D6%O!-VM\-+D"`)KG`[D.0=$Z)]529_Z,83
M']`30C5=&1()`Z134E'_?RS"(@1@2*Y0%39R@$\E2[(D<`TX%GZ#2WN6.R'#
M@A.8?(Q#8\4QB$\G8408:B-B#,SA/"[7>H@R<Y15@JV6@B9CA.2P@NUS>Y?2
M'C$H@Z0H=!<E/T%3=$8#8PC7@P_E@PT&6T(XBY\V?;:(1HL%%+*W(63FA-]0
M=V^W=>W7%+L04]M'C&$(A;A@(M/F)\"C76D8?TY!+$,!AQQR`01P#/'629R4
M(<(@5'(H":\0@`6(APRHATC5AX/SATH0B$+"2]RW@['VBK!8;,^G1:$F+48A
M@AA6:D8!>QZXBS<7??#H1RW8<YX%$*2XD"K6/9YR4*12B*QA@;#H?+1XD=9G
M_XL:>5G(D8L_84;?V(M]]U/1&(R958QA2"TL!5V`%S<"P(5,("R5)EUH>$EG
M,V746(UP:#9K\X9$06^B%(Y;8X>(=X`CQ'AY"%7=4@93Y8Z^,V*?*&--9T7$
M@8B,`#P9:1V/."@\08F(@FJPEPU+:%D<N6R!.!QL!%"U`0N!]`\,^9;S(S3?
MPVMW%&/!MGP5"76,B)%\J8E'N)&`^6&IAR'(`)(K1V8D>4EBF'4M-3(J*4`S
M02QGB!,?4)EG*%21D(74`G\T42PV:4YAN%,_F1.=>7=!05W5F#8;<C:1,`^2
M4([FJ'A(>8Y*&3M^H&?.QSOKPW2[F7R\29$4Z8G-M_^)%*8<A6(->I><AG(H
M_2@B8]DH&NEJI%<]4;E9+HB0]<`/!"(@(0&7"WD>.+B*]I%TPX:7%I.;?1F8
MZKF>['F"P4`L`IE/B4F2C/D4@=69:6.9E2F9R?*9%`)X769)6F<+!S":!<I)
M;C-O:_-):*:3&?(V,_&2XS@'+L()!FB.1QEP27EG9>`'!>=\K/6;E+(4_F2>
MO$!LQC:8@R)&T/&!_M@\S&!F9?1A5A=;\%B=UEE;+PB#4C,2W/FC&-&=WAET
MX!F>"\&*J95\Y6F5O'!C650.?+E/[3FE5$JE@=(3V-&!SPF)Z59)\XE]I=FE
M;TB9/[F?Q,)RZ9:&0M5V99;_-OM7=\?PICWY?W(WFFEX`1(::10*FQBJ@'W:
M@"3D`Y8688DPHDNC6O:(;"H'G<I1F"@C'5Z)G/X8EI?H834#?:\&:^ZCEK;5
MEO]Q$3\:JJ+*$4,J?.SQD#D8D:@U;&XR*1KX)U%*A,JVD1E9I;8*F%?ZB*#&
MI6):2<:@H%*!(7%(FMI5?W4'A0B4+`?P`6^*'?H'(LOBH,3*=1+2;@W:C7'!
M`Q_2C3R1,66H0#EA4]22I[)0H6$1F[*IH;3)H8@36$YZH[9'HB0*)YGV:5L:
MB6'$G"S3'/:T:OD4A"=9%[Z$>VLIBJ,8I*.:L*$*(*MP->C1'J15*G99GJZU
ME[$J_Z6WFK&VNJ5DR6KXI*45UJOIQETB6Q,`:K(`>K+&4@S_%PDN]`-Y<J!%
MP1P?TC)="0W)$J,MR3OMUDDQ2F9HUE,9X@AEN*`C8E-X&FA=8ZX7"G!VMGCI
MJ(X\4@1Y\JZDQSZT@(CW2(3%N:(R\TZG%D;P1!V6"K)96I:=>$7Q&(^"P!_8
MF9"?BK`!HAMTVQL*>[<-&Y<!@:ITJ:H3.Y45"ZL76W4:6[@:R['0Z;'=8+:\
M*K*..[)C"17"Z@C==SLB$+3+^8]TMT!L\X_@.F9HIE-TYZP.2@58EB%&RRPO
MR35[>H<,V'A0NZ$#5P91("%6&W4<R+@5Q@W)V;N6J&J&.?][*(AS'(.6F\I9
M!>MSN^>C'5&WSON\JH"WTCLK>\NW\H%T?VNBB0J$&&FXWON]V8&XB5LSN3B6
MCVN^,KJ$DML3=%<ACYDGBW5=.M6-\YLLSS`4;)"_;(`,K-<<'C*:22%W$J23
M0X$#+_E1Y7IX4;LCL]EXM5D&06"[L*JH0#)ANEM&RZ"ORWEAJ/:U,PH.`,MG
M.1.O!"`1@&2PR\M(S0N]+!R]TCN]@U2]X'.]2/-KB%JHB9B;];H=*9=CX/O#
M0`P.XKNXX%"^Z"NR1PR?0ZR-#DHWV$$R5*"-,DL4V\HV5DRST;"M]_N3`0Q*
M!?1`!<J-.!`)'B4`-Z#`LNNG1BG_M;'S%B)FL5Q[P<8S'2^JN6+KP1\+PGY)
MO&HK>0.KHYT:/]I)$A[1PH9<MR]\MXKT#\37M^.Y4!2[O189JT%<R;NZQ)B<
MR5V;Q&*:R9E<DSS50`X$M'_WK`RTQ2"BOU3\'-!:Q0=`,F=30&UX`"(PAQ[5
M!$P0!*[KP!FZA^M:F[?YQG-168O"NX8R#9):J>,KF#<3>2$ZD;;'J<GKJ7'+
MO"M\R-C,PHEL-8O,R$;*$'5Y6DVSI#<<BPYV<B#6PU-GR8KKR>[\SIA,88Y:
M6><+SXZXE7\7H/AL88]H8:SLN2!RG%6\?\P@`RV;)^+0LS]ANDH[![4<!/NV
MP#DB.'BH_X[BH@8>"H;#'+)W;(FR-S-HV\Q6Q5J&FJ,L%%#*>[`,6\C9W-+8
M_!$NS)W=W`^C971'ZK<,5<ZPYB9:.\G'1L&#"\3Q*<?V7-1&C4]1C,_<I96.
MB\F/J\0DBZ7<\$#URW=DAL7-4\7*":U'0"A'4,OE<P%]QV5':P1D'&D$8,#7
M@GB%0]%KS,970`$:+1<,4!W3P;$@+-(G1*C])'I8I9;4/,@EQ=(N7=B&W<+<
M#%H`,5J._,CC/)7T>)[<.[AHQ,Z.<M28G=F:+,3SS*5+W*6-^M2=W+B^6BQ1
ML4!6_0M1S+D!+0-L\&6E1M!%40Q'P`,F(A/14G+$4!-4@(TNP?\F`H`#35`$
MX'*A(O2Z$MV`I.`#<\U7>$S$PFNCSEP]66N0+4BP*5W-A'S-A]W=WFVW&A'3
M0DJDWLS8-XW3>`0>>$F15&EZ3QK4EKV1FCW?]+VEE)6)E[RE^4V84$W:HMW9
M0]P3SX`,Z_)`KOW:U96_6&T-LQT./(#+LH#;%09*(G#`O>70+&(!X'*NZ,7`
M<Y;&(D0*%C#7(A/=>HTSBEB5).Q+)P:W/;K2A,W"WW5@WUWC="L@M$+3C8Q0
M.KBJ/8C#YZF7'$/9<1S?[5S?2)[D0[W?SWG!H!VR__V13BW@`[ZSE<;$LDW0
M\X2_7^8=)L(4G<D-0D6M+H';..`#>,/_X>+"P!D*XN;2+2/.5^T"U#^=J?V$
M?'_MMB@=V"+EHZ#*$=W]738^Z`'2D(1DWO`!3.@]SCJW"#_>?#J\:41>B_&M
MY)9^Z9LMQ&2)N(P5U5*-Z??<E72'$Z8+13MAOS@+(N%`9DWP2Y;K=]+"(DKA
M*UXC!IWI(A&=7F_>YK]\W&5@`54;17LMPL6QXM>]H]DIV-L-TX8\X\[N[(-.
MZ*1*$D3WS<#Q$CT.R188V:\ZY'$AA'M,N$8.ZN1>[NX<OI!XMGC=Z4]N[HU*
M#&8F(MCX8_,GZD3QVD$AW&U2M+SZ?TT!"2HU(0=PQKD.XNGJYH9#M<+L;&]B
M[+>'/6Z4PH/-_]TR_NP6?_$7][R"'NV(+"ODK0\[+CXUG-[F^>CTFJ(7.9"6
M[>XLW_+VK.E<ZDY<F<<GT^XN#]+PGI.O+`E/%$!^HECA`#>MWB:P[I'(D!2&
M8&3$>``$`-$<WNOG4M%]R!81O/"V0*UIJ>=[GNPUN.QSV\(8'_9BO_&[D?$U
M/B`YGE$0"RJ*7I<YC;7L#>F1+CRTJ$^5?O-XG_?Q+//<Q?=,#=U::O-Z[^G[
M*7@N!"_!\6/^_N5-H9HFMUAC3KDQ0;1V(U[)_>92#ZAJ4/4VEB=M*\V=JNQR
MR^R'//:F?_H77_:'G=AIK_;E(1_8'A$^'O>2/?>2OF=_%83C/OCDWO^OO#_$
MZ$Z8%";'4H[S6S3:^NWW[ES\.W&9:5/A2T&,N\`$/L`$);+O:;-E)?,V+'(+
MF;F9(N`#2+#+?(CYF5^;4V7U>7*=V2U(*LR=I8_Z\C__T%[84>#QOG>JUEM:
M/@8(/X*#A`2&AXB)BH9*C4I-D)&2D1>5EI>8F9=&G)V>GZ"A1CRDI::GJ*FJ
MJ@.MKJ^PL;*SM+6VM[8ENKN\O;Z_P+._PL#%QL>\N`.K!P>MSLNDKM+*K:>Q
MS=G9TZO=L,W5RMK:."(BEN47YLTX303J!$SR3`1-(CC-1T<#5/TX.%3.-1$@
MS]Z]&R%,E,'"$`L)$@X?2IPHL:'%B!0S5E3_$^)=O4E-+E"@X*.D21\64JI<
M6:2E2Y=!8LJ<*3.$S9LX<^K<R;.G3YPT@P9YZ7*ET9-(?8Q<RI3IC:=0H\HC
M1'61U4..LH+<.DF3UZ^81(D=VZF;V;-FPZE=RY8MLK?(9`V3"[?N6V6F1I4"
M-P!:*6YK36$;QS<:VE1MQ1$^4.Y?.7,#F^#3UF2>O#GV\C$XX@P'*8`"XS$1
M$!+'CR!7%C:$B%%CQ8L,7;MF&.+'A8]=4:HD2E2H[Y_`@PO?6=.WS"A1B!Y-
M:K*I\Z51HS\5-(_JH*N+LCKBRCWD)4A@PU\@2[[\I\/HTR=>SWZ]W?>]Z,:/
M!;_^7%MY]3[;YIA:_[3`?PTV#BSI(=:>+(L-@(\,,CQV@0"&7#"9"*+-4\\]
MV>C#63,\!%1)9:.5UH0%J;4&D6P3P18;BA319AMNDEQ@P4O&Q32<3G[<J.-/
M-0:1W$M&J<2<4L^-=(-3TMU@V53678<=(MIMUYUWXE59I7E8ZE5@6@=VF9A]
M8(8IYIADQG5+?M+HDTU__EU3#2JO++;-*SQ8LZ5_[>&PGS9],<C8/[?1`PF$
M3!1@H3W]45$G.1Y>`")IYE!!08DMLOC:19:FB(4?+VYU01%![2CJJ,35^&-+
M05HP))%%0I=D=$LRT60A3R;RR)0@6:G))YMDZ<F=P*KGI5IU55/FL<@FJ_^L
M+[B@.<`1FVWHF*)UVBD87G"Z(N><=/+@V2K_]$/%MW@F5FU?FAW`PP$,R/!G
M.>Y85L"\]%SHV#)[@F/.@_((8(X(5""DD(F9L@9;P:QQZJBG09#JL*@T(7=J
M4:FJFE2K2+[*A)),,NEDK=EIA2MXNH;G*Y;!HC?LRK44B\NR,,<L\WO-EL))
MG>UNQHZWU')S[2R%L0(T8=T"I`I`XOKS[<H':`@.#]`>X5@S[AQ)00%/T>/O
M9-"T0H41YPBD3KP7PA/$P`AK>G#!#OG!Q,*YAI"C'W373??#P_6(G'*I#HGQ
M<TDN.>L/(&,EY<@EFVQ$KYPP?K*6*:O,\N2YN'S_R\R89ZYY"363<O,`[<H@
M;;AM9HM@UX:9HN?I`W)C="I)?^U/N>V5H,\RG->YS]0?,-9$`20920"&O0.T
MN#L_;`S5#Z01-)HE(_JQ4-J7KEVPV]Q=@/>.0DV,:M_,_?VJ5,IS[#&MA1,0
MY>&(E_SX^[]&GC+E]!.S^?WXYV\7+:<L7@D/#(C6`<:%-&D([1M\\IGI\K6-
M.9&"@*=`6NP<<Z\YH0XP-8O3,KC&CLJ0I"04((``1A@/X)$D`BB,0'.T%@]_
M"80""5D1]524MDW=('O;*U7$)E:QE/@-8^.#5:P&ES[#16ED5$J<)1XGOR;2
MKGY>TI\4ITA%F,D"%<<;_T\)!#@M`QH(@=PBD)O0Q;JG'2UV2C,'!>.40)_)
M@EP%K)8V-I0-"C%A)+I)20RBH($^]C$&,4`AD0QE"$&I@R!1,($:")8I&B+,
MACB$6%`D!J0>_E!\@8O5^=!71/8A,5=*_`K\G.A$*$ZNBJA,I2II%HN\\.!X
MD#""[9IQCP`=$(P7M-88AY8@:Z'1'R+HQ#W6V$8%VK(4_0BF$<2U*#GAX$'Q
MP&,>5X+"D<S+4)<Q!*0>Y`,_+))ZU9-A(_UP0ZY<H&$\F>3>*KF<B_W-2+`R
MGR:;5$1%K*\['TIB/O4)%OB1AY0%,J5`[;?*@AJTH%?T7.,61H`;$$`?:ER:
M+O\#!*!=TF);=OIE0/[%T8B&\8UL0AHG_G6)8(ZKF13LZ$`.H<DE8?,0WFD"
M0LH`3K6MAFWD[(XZ^58QI+PS8QJSS.`$4<^K;,>3H`SE>/PY%H"N8J`"/:A4
MITI58R3TE0N%Q&E\8`09C`M@I;-H.!98"XQ&(UQ)(VDE.DK!MOZ#6]\2*=CV
M!3=*1)2C;OT'1U<Z!WK,H9#7E$<]/O2#*$ROI@_!%$[+R94>^C!\/QU?2X=:
M5/4=D3NW:I]2*\%443CU9U"%:E5'2]JI7O435<L1!=;%F)X9LUI/U%8N)QI;
MV?;2,$C3ZSDR$<Q(4?`OG2D%6N>J5DD8@A+JZ*A'W^7_H$&14#3T,B1!@G!8
MQ%J/19#DSJK>&43!#96H147J)[.WV:5RMK-D.4QHN\0Y*);VO?"MXE5?";TF
M_*`(5P@!$XX`03%>J[;HFNT7;V%6X>KV*Y%*VC^\%2[?;G2WFH"$(L"#5[<.
M\S&[7:EHS%</`G13G#55K*6RRQ7N!G6RUJDL5IH@LBF55W'H;6JPUGN@^-KX
MQCC>GW_I6]>9%H$']^!'G89,K6L`N##=$NN>V%A@!M/5*Q4V!W'_-=(G1UC"
MA3P$:9+[KY1RU!(BB`2A8@5#-2`V(Q99;'=.W%*A<E+%C1AO5U[LN!A[=L8T
MKEV.]\SG/@=#EYV`FR&*H(8K_Q#`7?CJT#**#-J*-MJV;=Q69QQ#4BN7=%_(
M3:Y72%9?+"MBRVNU<(:Y')IYD,0"(5#-F6W:2!)OI<UNKHJ*H11G.?.3SN>U
M<WGFEV?W^/G7P,ZQ`@,="4/X@*9!N(`SLD$*#I'5T;&];8`Q2NG>?L6XI4D'
M)O"93T0(5IND\4[8+*W<VS04U8I<)".MNVXT8X\[](2S=FQM3EPO4==9<FJO
M?1WL?ON[JL-N7+&;X`,3D,`$/O`,%?IR!"^B);22'I!CP!9A")&,I$ET,?2>
MNR1$A#NI7%:'HPA`@2A(3PTH;_>959[8CG1GUHQHL<:A9^][X_L\`-TWC?_-
M\YZO,O_@L(R$!0Q.`DXYHTXR&,#-`CI0OD3\799VAP@-4M=<<7K;SF5I2ST>
M[I)VF@D6\(-"4/[-52-6#5'X"(R*7;CU9197-;\YSINH\[;X7(H!S'O>[\[W
M,@%=T`08ND/48`$1Y&"`G.G'G6C\=&CH-L/:9/O4/;5IYW)<D]<DY-37BO&J
MH3HU*"^#JLT.SC)88.!;N2>]YQQ*N?]S\?N^CUOZCC^]ZYWVN+?/WR&A!$-8
M@*8/N0(%H,7:U`F+9;0[%Z2IO;#G)L]"B?CXM2,S$`A52![SDJ:1M";N<T2S
M""&X@D+*8(+RJSO-I+>4"2C@CO;3N^8PCO%G'^U>RUTN]WC_M[W^]\___O<?
M_S>V>Q(V(L`'$?J5(0JB<(QV%BM#+O[A@!6T&$?@)XSA*"-D?;!6+Q\W9R#Q
M7!5B0CX0`2NA%)IG"#]``180!&(W?N1G?BF'?MAE`CEB$W[`<A/A!^S789YR
M:_"W5+KV6757.0#89_Y7A$9HA$-86JUD,_[C:;^76!!1!$9P>,XP"A*D@+$S
M8&PQ#D#F-=42.TW(6?W0%ZT`+7ZR47552/-P`YF'34SP5R)T@5."@=BW%"BQ
M1\B1$BJ$$N"W@N4G>N4W=F1W?@[1$&I`?BMX!3E2!!:#$@6(73@H=6MW=3T8
M%O@&A$%("TE(A$?8B9X80)LX6DNH_U#=YGMF=B('1P'N$D"><84=@D9:6`U$
M<R_\("[^PU`$\#$1\A^$H6W&I88FU!31I8$;*`ET6"C!B!)1$`0:<!-T(WZ!
MJ!#1*'K4^((8P1!J8`(A,!3LI"I/.$XY>%P@%W<_.']*EHFN$(I[]HGLB(3J
M:%H[EE62:`&G.!$=X2X[HU%)HV0?-0NM^!G?\C70<P@_\!1%@A(^X%!4T`R<
MT`RBLR9ZU7P$T%>%(C[?-GE9=WW71`$BR$<T"(W3.(W46`;GIRDHIXU1T%/?
M.&(A<$,P-8Y*='/FR(#H2%#O"%_MF)/\=Y-2-8I858H$4`2M@8U!T`3;\(K,
MA`H+*"`79?\-7_,)P21A=W1JH!("2'`WVXA.<I,C0>`#]*`.1D`.?P*1F$:'
MR7@23/%M%WB,\H)'%K",-.@'(!F-@2AZZN8:)^D'W,B(([B2V!4$/]![XC@)
MM[@KK@<YL%>3]<.3O["3JJ23D'E[C(E0\=B$DBB4FD("IH<#^*@@^ZB4BF<Z
M2(8-7L,)`EDUI]8P=#-^%I&-(UF7Y:>7%D`!7SE,8TD.E%:*\F"0@"-/+16,
M5!D%-G&5<JF(=:.(XD>2($81V9A?W>B(!5,&@(D(6W&8<U=*BLEOR0`+D]D+
MCIE*D1F>W?ESE0F4F%D1$K%^9*10Z85,H:E\!*(H_0!+#>4#H++_@JK1FJ$W
MDOQYB(`8B'K)B+3Y#K;)&+UX8'!SC*^"-4^1?4P1@F^)3L3I!Q/ZC&.WG!,Q
M`X<H@R'`EWWYB"AB>HE0G4PUD]Z0G5\RGG7QG:@4GI&IHJGDD_)X".>96"OB
M!X=V=%B%,@]49`E%!2-7D/89?OEIB&3'GZ])ER9@G,<Y@QTZFTI"H!RT&-,B
M$)ZVAE:#,24Q(\+)$\<Y?F4G&QI*?LZ9$AX*G9EB>I(XB4U0HOJ&HO0#HROJ
MHG1:IW;ZB7)J1:,XH[T7!&@6&UA0!!<@`Y[#6<ID'A1%#3]9-3[0,!?*&D>*
MI)+:@M%X!4SJC%@9$P)*`3=`.!<R+GQ2_VU6JF%8VA1(L1MPJ1,U8*'*:8-8
ML*&*&`1!@J;JYP-K.IB0L*-,]*9P&@YY.C-W&JS"2J>_JBRG99D=YJ<M@A$(
MMRZO!&&Z<C-)<S,EP`/V=0.-&GZG"!N#V*W>&JE(6JF6:C=U`Q2HPBI3L7;6
MIW7*\Z!;:A1%@!PV@A-?*H@V"!$GJ8@=ZJ'>"**R(7R".:*1H*OM::+PV:OW
M5ZS+,JP,V[!XJK#'<JS[Y`XA\*<W2`&M<`&D$)._\I07<(*.>HW8^*TD6[(D
MFZ1*JJ27>A.:RI?,$22\\1+RJI68ZH=VB:$PJ*'9R*&5U##W6G04$+#4.;`&
M>WP(JPP0N[`.N_^T3*M_2>MW>RJ/]E6QV-41RU"8[N,_C?,#GU==^FFR8!NV
M@\B?*5NV@3BN=H,WY"J7?]BJ[:8BK[JS,LB(?(D:_BH;Y"2T+YFK17NP1ZMG
M3WLL33NX31NX8W*L02=3?H`B@!H$#\4#G18CF9!QR$,!9[.L%_&M*%NV(RFV
MWKJY9INRECJZI%NZICN7;:N<)=EJ1@J(5R"K?!D"/_L0^J6WN-JW?ONWVFFX
M8D*XOMNPO!LF\T5LD'`#1&<B)J(&4G@`0(FK,04>DO@#/A`"V\JMZC:V2NJ'
ML5DW9MNYGKN?DQJ^W1N^=DEV,!AB##$#<4M^>XEJU..XM@LCN*N[2,O_+/01
MO&/RN_H;K/BK>S)JF4U``<>[K%!X<+:*K.+HO,56D-B::C8*M^M+J6N+E5ZZ
MMBGKO=^;P=]+DN9[4^G7$&7PI"E!M0A3!%<A"?-+OPD['Z_PM/O[PC#\?_VK
M8\,K<"%Q;*QAL:@(L+?XBP*+/$<RO290B`:3N>L+H&D+%#V"(W;#N=7HN?HY
MLG$[B*]JI.:[NNG'G'[@LB3<2!80O_(K.2I,.3/<F#%\QH1;QOY;"_W3PQ9`
MQ#J,BGY@`3]@#]`+(R^9BT%\-BMBB$8,ON6WLBSK(S%KIBZQC#1;L\]HJ:$[
M?CU0OF`KQ1",H5F<6%?`Q6E3!CZ0BU9!M.HU_\9DK,:\@,:DS+2B#!]GDA_0
M@YG+*4X180*`.8"4X&D$B:VH`:BM^<?^^9\RF,19Z2.$_#WPRAN(G,AQ.<&K
M.;Z0[*UP6\DL<LDSXKX(H\F<O`B>_'"@?$JGK`NEW,T,N\TTS#^J7`D$$`3G
M:Z,YG")^X`.>2I#@98)"FA"70L6Y/,6`O*1,ZJ0LNTZ.-<SQZB,S.Z\],<&C
M*Y(8C,7.K!&P[$/@=P4%LW[8<<TTF<TK`\Y;Y,T8;:<6#1>IS(260`"RZ\&7
M4L`8<<DW-`C+0PA'4@1$9Z-7/,E63(V52JY*S,\S$J\QF].'+#'%+-#T2JZ,
M3)<<3(@)[1H+[4/2;/\IY!31D&!\)TK1PV+1&3W5+KK1=X$?X_RQ#BW2#US`
M+1($G3H^!5D$-?C`1CS)9OVJ9'NV^:S$W=,2/.T].BTQH?+3R2S4]#R[9P;-
M'MK%*,(I3-T$3OU44!W5X$S5B*V35FTF;)S5/V!P-S647*W.14`!@I`DC4HI
M15S%A"AB:M.MX7JVR,PC/6(<\LK$VEN7]%S4&K'%T3S"!5,;@3W8MU38@'O*
MB9W;#[O8Q=#1I%@)CVTP7IW.59N0TH&"1!H1F6N-UX6YW!K!,AW(XI?/:ZM#
M\TH3@ZS(;-NV?YC7K)T1<VP4?BT;'3';M6W;%7W8NKW>1<C;VSE6^;$X1D#_
M`9VM$93<(C+8E0:YI>`WQ&D-TQX,X"HRMN(KKM2MS\%A-T'-@D/MV=\M$2'P
MVBFQN"/FN-@19[2-WG'JWKW+WCG)X6+"%FTLWS[@2&KS2)>,%.`GV0+NX$4L
M&P%NO>1+E^-ZN@1MT!WLX@^NF;"+U!3.(H17*X^0X1JNS2!N'Q[^X4>^QO#M
MT97PQB9NUIELJ?N*&G_:XB(-TXR+Y5:\RY,JU$B:U_>]XR3`UROQXR%J`4(N
MV.==Y#6VY/61Y.T(Y_4AXO%M!$U@SE'^&M957<X-X/\-P:S=XH1XO<U-YK,1
MX4'RX^V&<&M.Y&YNV'1N%W+.CI/.2FK1QN,!TLT<_\?8->8VQ>69V[F3C>B;
M#>JF_J^R&B2R.]P4@8./WN:1OKN7?@R5OMNUSMA-3HH\\`,UV.DG/F(SI-:D
MCN7AV]GGG.K*GJ9/RI>,V*AW6Q'262\7SN:Q..NTGNO`<.N>J.U7G>FJW.M7
M(.B8.^C$[K:B/K*3FN-ZO>RFOL44\^Q%$.T/L<XA%.O7CNUVY^VVSNU'R._O
MS1Y_L:,\8+Q['NS.[,?(GNX0#*[%CNKNSMH++<Q(3>\DH.9M9^W/IN\[!_`>
MWV?#,F2>PP,44*2HWNZLR_`J;Q'DB^X('_%FMRG=J"KS#N-T_,X1#>D<WVL?
MW_/"YB4B?S/T?>C*KMRH*/_<@;[R:0V^__GPR0[ST]R^_&J?](X%-]_..2_K
M.S]0/M_U\17RT7`S)4[TR]['+"?JIR[@H>?EU`CL4#]B\,Y3]EF/:*;F.'_"
M.K_UZ^7U?$]:8#_R/""49/_V(VW?@&[XG:[RA)\IL,P;(UBC=9^+6(_W6J_W
M]=?WF']0?_]*KZ3G.A[Q?PCQ:=_5-93NB_](^\I3-/^V=C_YG9SWEL_UF3_[
MY-DE0=_YIW[Z6)"5X2=^85KZ*_?T:7WZ(1J@J@_;-B_Y(*/QYQC[BTG[T!\S
M-!;T`Z`]N7_ZJ=\2JBE^*E?J"8WRBZ^-.?WX#IW\NMC)A.W\]!O]["][4!7T
M)=#_!(L[^,O^NC';,/EIL<)/_&4/"%=!182%A1:(/A8A6"2.CY!8/@0_!):7
MF)A-/)R=G0.@H:*CI*6FIZBIJJNLK:ZI);&RL[2UMK>XN;J[O+V^O\#!PL/$
MQ<;'QZ_*ICP#G$8E!'XD6-76D-C9VMO<W2:#A$'B1>)^5V5EC=39U=3MW=CJ
M\//T]?;<6'[@AH>(%D4ARL"31"F3P4N;/'E:QK"APX<0E2&;2+&BQ8L8,VK<
M:#&BLF:=2ORXXLZ:O'LHZ979)PZ<N!`FTI7L=G)>S90X<]HS$8*?(43D_,BD
M.:G208,)%7+RR+2ITZ>E.$J=2K6JU:M8?T%5I;#$#1,E_Z_I'!NO9Z%Q9T/X
M6;OVRI68\6XZPJ)&+-F[>/%=,4O('\"W9>H.+'H4J=)/6Q,K7JPJJ^/'D"-+
MGAR+<:F%)2B`-?DN[U@_/LD-:DFZ)<R3<DF4\:/61&K/L'6N#A%B'TQJ0XD6
M+*SI\%++P(-OI4R\N/'CR'$)#[5P@`^!G%_'GG<EG*'2^T2'\^,:'L\@`:?C
M["Q^;AD3Z&.:I$?0*&]+294NGT^_8?+[^//KWTB_^?.PY)57CPGAD%;@6:45
MR)TZ-:D!6A!@"6@/7=():-=@N[U'0'R^=8A8?2`NM]^())9H8F4ACK(4#T5$
M=Z&$\*QTUHS7C6/@=@*Y\X@@0?_X42&,Y@D&)%D$:8B0ATA^F.*2BIWHY)-0
M1L8D<R`%X6*`0VJCAEEHD5,C=MB%<`5J/?6898SJ_7CF-D4:N6&224XI)U11
MUFGGG1C-N901C%RY)CYE=ID=F-AMYUHU@I"38WGHJ(1>;O5@`5>695"0X7L<
MPBG?G)QZA.>GH(;JBY[---&GBW]R`UIH_!#J$EK@L3::CQ:NU1U-Z*B1DJ0+
M#GG%#9?REJFFS75JK'VB)JMLLJ1&,Z:?J6I#X'6LBN:JH`5&.*&:CZQV:WE8
MH,,M64'\8*Z;33BSZ;'LHK(L+@S$*^^\]-9K[[WXYJOOOOSVZ^^_``>\[[L9
MB5)",R(^^8C.P@POK,;##U_)&<04UR7QQ=\4`52U''<,X<4NLM868-'-)"[(
9$FOS#H,HM\Q97-7X8:FP3=3<A!)-!`(`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>f39432orf3943217.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432orf3943217.gif
M1TE&.#EA40+K`.8``,;&QLK*RLC(R,#`P*:FIKJZNJZNKDU-3;Z^OKR\O$A(
M2+:VMD1$1*NKJ[.SLZ2DI+*RLK"PL(R,C*FIJ:*BHJJJJJ"@H+BXN`("`I24
ME(Z.CH2$A):6EIV=G9R<G)&1D9*2DHF)B9B8F$%!09J:FG9V=G1T=(*"@H:&
MAGIZ>HB(B'!P<",C(X"`@'AX>&YN;GU]?6MK:W)R<GY^?F9F9FEI:6AH:#T]
M/6)B8F1D9#DY.5]?7UU=75M;6UE961L;&S4U-5A86%145#`P,%)24E965BPL
M+!$1$5!04"DI*?[^_OW]_?S\_/O[^_KZ^OGY^?CX^/?W]_;V]O7U]?3T]//S
M\_+R\O#P\/'Q\>_O[^[N[NWM[>KJZNOKZ^GIZ>+BXN3DY.?GY^;FYNSL[.#@
MX./CX]O;V^CHZ-C8V-_?W^'AX</#P]/3T]S<W.7EY=;6UMW=W=34U-#0T,7%
MQ<[.SM[>WM?7U]'1T=G9V<3$Q,W-S<S,S,+"PM75U<_/S____R'Y!```````
M+`````!1`NL```?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=C4I3
M6H)>%1,4#P\=)3$Q,&U_2@L/%&:";GMO:DU*GKV^O\#!PL/$Q<;'R,G%2E)9
M8E]D>'=1@FE^=F&"2U964=Y14N%22X)/WN1_4%UI9GAT`7=T<7B\2EM83KS*
M^_S]_O\``PH<^,^)'3X7!+"ITV6+%2KH?BUI`D5*/3AR!%#[HR4BP8\@0XH<
M2;*D229MV+SZPV3,E"9+]/53@DX)G`![V-B!<X:*3)-`@PH=2K3HQR5<S@A"
M":9*T"=:R)AY)Z`.%*-8LVK=RK6KH"9GS-S9$\`,E:XTMTP99>8*$Z]P_^/*
MG4M7TQ(M=P0$8*/F;-T_83)F^TNXL.'#1:_^Z4+'RD]C2L9L2:9$'Q@[8M8B
MWLRYLV=@3MH$6-GO28`'!O1L3.8D39P``<B\_4R[MNW;@I0X$;2ESF/*;0R`
M,:.E2P4X3_I%80-!@);DN*-+G\Z5"9@U=G[S0WKUC9<_3O`,H#-['Q,Q=/)\
MI\Z^O7N"3+"\22!'L3\G:`0T(60%.BPR!I2Q&T!*8.'7>P@FJ&`O2Z"11P!I
M^.?/%;@XM8@3=P`@X79U!""`1PN&*.*(BH0AP!U<V-=/$V\]@<5OE1G"1!9O
M-;'?3%-XP0L3&Y+HXX\(?K':/VHDP(4B7V2A2/\7`XBAG3)8K*''@$!6:>5G
M2V31AQ@#,7%&``!H<2,B:!R9"!-;!/!%0$M4`<<:>%AXY9QTUF4%`F@,I(4<
M"ZA17B)H=/')4@%-$0`?9E!9YZ*,#J5$%>0PH>),8>@A0!B**A(H)&;XP<63
MR$Q1QQQV:-;HJ:A^)$4<?O38CQ-U#-`'B(ML^H@2:"#@QY#]4*'''E*D*NRP
M_,3!@1FN]L.$%9DV8BLD3G`1`1N@(A/%G\1FJZTG2UA@`@7!!L0$&V58\FPD
M3XCW1K/\5,KKMO#&ZX@2?0BQ`1BT\N.&`6E,&LFYDD31!@%C!-0$%P0(*N_"
M#!L"A1DBI*!'M<I,X:__)&9,=@D4["K7\,<-2R&&'@?ZHT06>5RAB1((W/''
M$GZT0$\E40SP8D!6H$$QR#Q7284<5\@)4!-J(""`T)4T.(`?`=2@P`P%E/!"
M'CL;8@4'0<!`1T!/V#&`4CV'36<9`##-1D"/`@#`%V-:TL0;:LH!`PXA\)'%
M%02\H('&C4`AP`LM4$##"FS'9#(<?(21K]B,+SA%%'+`T7:[`@R@,B9-6/0R
M`C;($$<Y`,SA!@`L*-`(%1#@<(*9?YA1@PL=Z,$Z/TX`($"RC><>71-XQ($.
M$U=4+8P4="!`QN23*!'%'&@PD48*)2P0[E)X*,#"#R@LTH09*[0PQX9/0,`*
M_P%[0"'\+[`B@(7N[$OWA!H+L.&$$UF</PP67&IR!0)<?)$!$GG`EB`*\(,C
ME,`*B[``!M8`*B6XX`@#6``:IK>/*?2I?1CTC!*@4(<\L&$M3YC#&^S7BPV^
M06&8`,5NGL`%"<3@`4I*1!\V,+4JF$,?T0J3$AZ``QE\0`S8>EL*4!"$/D0!
M#G-@0Q1(V(DK^(&)&8QB8N"P@``,H@L+0"$_P+``.6B""FTH@!BZ0`(D+,`0
M7$!``#8$AAW@``$+L,H92$`$(OC@`@2HP!0><(`'K&<):="``O+P!PW4@B5F
M6(`;I,A(88GA`FTX4!0*$`8H>N(*):O$N!R`ABH\@/\!#QC,()Q``"(<X0<E
M6,\@H"`'%]!@`310``?2H(0VJ(`%(!!$&!Y`A`=4H00[6("%)'!(053A<OZ(
M`/(:R4RAQ"@*<E*"%Q!@JF00S0X=DP04X)"'.+CA`C8(`1C^A(4%X``(!WC!
M#A@`!!&\P2-U*`$05."&,-3!"TUX0@TR,`@F?*$%+(``V`1!S$,HP0]EN!@Q
MR!``9#;SH29A`Q^0IX:)[D,)8C``&QR3"3,4X`U66,`!)##00<Q!"#<8@@?$
ML(00TB`)#$B!RIQ0`'MQ(0V".$,$TC`'#)R@$&>X@2$*>@A?)6!QP[A"22'*
MU(\\`0!]F,)/E-`AA0JC"6+_T,L6D-J(*A0`!SN0@!S.L(`4G,`.*G+"`E8P
MA`.H``^*ND(%<,``!:"`!CN`PQB<(*DK0`$%!3R"!@HA!@8,M9@RTHSYFLI8
MV\3(":Y2`ANX"HPG"``!^;.$Z\PH@AJ4P`4K*(`ATI`!'0QA!P-XTA9J\`,@
M&"`,7MJ@%=8@@1&P``,ZR,'Z!B&&$1RV$6"X0PR/H00M(+"QR$4&%9"86;1]
M80T#T((`(U$')`BA"`1XP@-,$`/Y$8)X*="!`E+0AXXQX0([6($%_-`$*D#A
M"GAHP`J.H(,4[&$"1E"!```PSC_T]K>,4$(7]OL%2U;"JV!(KH*%L00U#"``
MNSU$_Q@R28PH&$L#B[R$$CB`@1O@`0TGP`$!)K4%%!S@!S28P#(%0884O"`%
M5+"".M+`!3<@801#"`(!]$&`!U@'`8+Z;R&(&N`Q9$`"?JCF,-)0@.,N^,F;
M:`(8!K"'=PU""6DT,"6HVB<RN*%R$8Z$$I[08`88`0-(J`\AEA`&#]P`"`H`
M@$*5D(82\(`/78/"5;3PA1``X;8_`,#T(E"!I?"B##H`L"*6L`4$Y"$,`R!#
M`I1HC#%`P,E0SG3RT@"```P7$9#C6S&VEQPR*,4+LWO$%-@@@"G\D@$=4+(6
M/"`$%AS@!C#HF!8DX(,45,%E2J#"'>K0@A$D(0@;B`$[5__@Q3\8H-"$@,,/
MXB`T(B-""P#@@Z"N,`#PL`$!U"J&&[K-LR5@@0M,"X`=ME"%;&JZ$U/@@QQP
M5P@M1X()9:A#(8)&B.54\U'!*X03X&``-53!`$DH`*]"JH,W&^`A(4C"!0[T
MJ`X,80":"_8?I@`!F`)!>B\30P^&H`,<<`$"T!Y$&!3004(8$A'*$X`P]1&%
M8J)D`GB8;B_Z4`![5^D)#I#!"39``@M8@`0::($,**#*=W>"";N92".6H'-?
M,.D.%$2$&I*X&RYD(`<^V,!NGR!1-LQZ!R#(Y!4B$(0AL*`%:"".$K@1`APT
M``I/X``-0)`&.XP!#)]*`P%PD`3_!7@@U9)E*P-T0()"N,&W@]""$EY^"#WP
M`:>+P((<"I!J7R@A)SXG$4;3^P4H,.&807."%-SP/PZHP:I.OW<7$*!O1S`!
M#1D.ACZ:8&5$+`$*5D@`$3QP!2P8H)=,;L,6UB"$O?TD"@`@P@V,<(0A*(``
M6MB-$IC`A3*4@`5#(`%L_X`%9E%(`3HP@@BV\"0GT.$`1_@`82%OBP74X'-K
M%@1$#'H(/<."LIC`!`B`6-G2!`_``UY$!B20`BT@`1^P`2<@`K4`!0M0`BNP
M`)\6>Y/0!4D&";FR8IN@!*,#@G]P#X<0`"-@`GLP;X+P!BL`!!]``#*``F<P
M50N0`[9V_R]?L`$C<`.O%&R9$0%$@`-FL$%@P3$)@`-&8%=+E0@M@`,`,"9"
M-@A4L`(HT`;D``5T``>*(`5VH`A5`"$`:`E1`'N-D@4?8`)RD`82L`,$,`!F
M$`9<(!H/4`-K,`H)$`(KP"]FJ(&$X`16\!9,,(94B``9V`EWH38UJ`AIT(1_
M(`)'L`-\$`=\T`92X`1:\`8;D`0J4#"K%#.+EP)TX!=4P`<F<`,,H`()$``I
MD`(-A04JLP1M,``F0'(P(`=*A@A.8`8T@`2MZ`?!,H5_$%(T$`!R$`!]P`>=
MI`C<I@A-X`6R,@RAER!ML`,>L`0&(`0.,%T!@`-S\`<!0`0'L/\!>0`!*1`#
M#I"+?D@(3/`&<$AOH+8`HO`+3.(<C:`&33<(6Y`!"@`$1&`"!<`'?:`88?`!
M-&``4A4`.S`$0R`!7V@(]+(!1X`!&Z`&?P`&3F`X?$!X/W`"!*@(<?`",;`'
MV]<'+A`#>O!X7V$!..`!Y3)W:^``95!UY,<'C7`CA#@)5?`&P[($`D`#$4`%
M$O`"'YD."(`##J`$`S`$*_`!%5`")K``#B`!%T@&[J9I3W`&:R`'.C()?8`'
M.0D)YL8&`_`%-$D(^`AJ>L`#/S`$,C`'=Y`'8)`<44`'+O8"(Z``-G`!O0<%
M=Q`#-'`!70`&<%`'#+$&3N.#/@`#;S#_)DY`!FS`?OV4!@\0`PTPCX)@!1Z0
M!!R@`&&X`JZX>@-`#4S@!:.A"%A`;I^0!G(@F9W@!'S@4(SR!`;0`YX"`S.0
MCX+@!!U`!'8`!FA``RP0!"[0!U00`#Y0`Q/@!ZX$`N&VCF$``.I3"4]0`'TX
M"5VS`/CW"&E9;TR@#Q>``4G``B+`!@4``/4#"P,P`AC@`8K0!A\0=K!``'6@
M!FRF`4.`3BNP?0;@`QGP'5A01D40`WE`#5I``3RP`89@?#QP!".@`R<0!`&@
M!%JI<*!V"*D)"?3B`&]`89@`!GJ`*F:P`1)`!@`0`P70(TW0!C+P`A(@`Q)`
M`!Z``R/0:R\@_P*_0@`P@`(&0``2$)5P<)9-Y02C$P=C(*1G4@".F`E.$`;7
M60C=J0U9X`=](`5XL`$E<`$(4`(W8%<!('FK-`<;L`%X1@A0P`8M$#U8`(M_
M(`7I0@36@TII0`54D!QFT``E<(X>8`?'V88;L`($P%+]Y`46@%)"0`$-X(I*
M!9<=D0@!X`=:1'ZJ^0A/T`9)9`5AR0A(0R=_&0)1$`&2B`ASL`([L`,DT`67
M^`12T`8H``,;$`(Q(`$%P$7=0P&L:`(=@(69M@4"D`69:@A>``"=\`1F\*1:
MITI4X(YQ:`$OY(E10`$X,`1(0`%<$@8*0P6#)P*T]`=<P`$U4`%IP/\E3+`?
M7/``0F!]XTD$%5`%>"`H9!:L8T`15&`'#S`",_`%'K$$!1`#UH<"XS1F7N`'
M"*`XVF,'<_`3&3H)3K`'<$*"/+,`2*`'35`#*Z";@F!.-O`"9(`(7+`&*4`$
M(B`!LI0%=4`!(Y`"YHD#0<"3R;5]L!!Z4/"KBF`&!B`YEM"=5*0&O*D`#9"/
M2[``1W`$0,``'S!@UBD(%B0$$L"/&?`%7S`%8,,$()`$IB687<`!0JL`$(!,
M9E`+`1"3(_`!%ED(;#`"ML4!9(`.33``7W,^V)*PE"`J$\"%FC`&1>DC4Y`!
M,>`&=R`#)!!F5`@#/(`#&G`62^`&QXB,FK'_07;0JAMPDA]P`5<P`3'0`@0`
M`#```Q:`!TRE!&4P!Q(K$EI0!?8&!F+P!GS`!F[P`#N0`5W@$5D0`3X@K2?`
M`40`!#M`"_Y1(!1P`R\`!WA`!5&0!@.#!&TE`DZR%%\@`?!7!`8B.8E":V?U
M)Z;!5D+0`G'P)TB!I(?0L2=$2!N#F9@0!0C@B562!C20`5,P`$@P`-/E!KY[
M``%`#G0@!#2@`T?@`R&@`"X031W+`T+0`2AP`P@@,!R0BF8``31``W>+01CE
MFID0&9K0!4FY,A6@`6H@!0*@`,CK$9)U``PP!!F086=@`$"`3A/@7R[#&P[0
M1UQ0,Z8%!!D@2H2@_P<_4`-XP`V\,``WX)'8<@8X0`0LD+\WP@1KT%R5,`5J
M0`&Y]`=9P`'F.PG+(;Z4<`8`(+/140`\8`!+@`(X0,-7M@`\0`/WIP1A,`,E
M,`<PD`()H`$F0`($L`(P8``:LWUF@`(FH'0YD`$`4`6#!P,3P`<N``,$T,!A
MHP1@D'N=H!(:Y@9Y(&B9T`1(M``-(`$],`-;U6\+(`,L,`(;P`4>S`4B<`!Y
MB0(I0`!H!0M>9P1#\`-$T`)C0"M,D`)&P)<&L00G$`,]X#M_R`>;.`0C<`=]
M8``T(`$#<'E87`A;P"<7H`H](`(T@`*I-0D!(`$HD`#V5KX_H@03X`/R8_\#
M+2";N=$`--`#*2`H=H`#&8`&."`"*B-9'?`"$S``$D`#%'`@*$$!-1`#>$P#
M;$`%%Y`"/-`!<J!WA\<^5;`&`1"IFM`$#I#,;0H`:_"ZF;`_>N`%[$P$&Z`'
M'F$&Q<:4`J!S3%``$UD")'``*8``&=8@-(`!$F`J2T!I?_`$"C`$)A`'NS@#
M(W`!F.;$G3D$.``!.#4%2P`&!'`##Q#!?3``:)`%%J``--``60`%@K,!O8<(
M63`#,>`!P%0NEE`%DQHB9[`"&S`%#K`#!9`O9&`#.,`##;`$4Q`!-2`'2D`$
M!TL(L5`#5P`!!$`!*:`"#H"978/&,+`*&4`'6!#_`32P`190`*U8`0G6,TZ@
M!K9#NK[`!.KX"6`P!SJD"4_0!R&5`AM`#TOP7&\@!7-0`@UW5HM#2@IP!#*0
MGEA``38`J'5`#11*E07P!=!\DB<P65Z@`3J``480`U%8"'>@`F]6`@2`!E3@
M!5U@!R*`!AF0!"-@K(G@!E]0!QF08DLT!7H``%S@!72UL8Q`!G=5P(@4`R70
M`.)-"6RPI.[1!OQL!0,03-K1!CW@1F>T83O`!N89`R=0`)J!C3T0`"2PV"8@
M`@]P`BFP`*;"!'F@`:NP`B80`GB`-R:PAPM`0Q``N/)2!0+`!V4`T;\0!7>`
M`".4"5%P(U[0`C1``']R_P4+$`-`D`0IEG6$4`?S=0`3@"UL``.MFP>2J01\
MH``'L`)[4-H?P`,C9@4T,`0P0,6>%`1&(`0?T!%A4`8#0``!4``'D`1]A,6/
M\A9*4``VD`)%2`AM<`)",`)(8-Z)L`04P,]>K8\$P`,U``%VH..,\`5/M"!-
M@``^$`!5<`([D"]0X`!"$`,F4"Y?L`,?X`4B&<<U$`1(P`%;"@-LT+KDH*\U
M@`)K(`*23@>F4KU#U^A"K049P``@```LV0)KL*G$$JRC*0Q,<-6+H`5@7`E6
M$`#J8P>6O`=%U0)!BP)7+0<2@`$L8,A7@.1V\`0AU`(;H,B"0`$,\`,-\!A;
M8/\`Z'<#(O`$CD$%9#.A?P``U3<SDL`$82!!59`ZR'X(7S"1(W`VBB`&1R`!
M5J4$$8`!$[``H`T)?G.([.$$:<@3A.LJ3@`"-!`$(1`\>^#D`7"0Y"`%`P`"
M.5`"'/``;$`#HM5O+F`"6&8!,V`""*`YZ;`&:;@"*T`#LT2HT.,`#X`"*]``
M8S"-"E*?)CYU>-#KSCA9G9!O7H`",4``(#X(FHD#'W#SAJ,-6W`"-``!*5@"
M:R!`2]"X-BX!`<`##)!RAC"B1```.#1X)(>C7B!57G"Y9A`L,9'`>A-P`M\&
MT`@X2PYSM(@#>_`$-/&'3?$'`T`$,)J>A4";)=!+GZW_*U=)"'Y@[>P!!B8@
M`5FPGE9D"$4-U3P@6E"``#=@!DP`!),_"#\K`UA`!D=Y`699#@XP`GN``#W0
M`Q"`!R6`!`;@!HXY`4BP`0/L`G%@!6`@`S<PMQ]P`+20^#]B;D@L#%'@`)#P
M!0:0)YD@!9_R!V.`[0:0*5O@!SWM!";;`0"0,O8@`B/0WS$P<$'PW^A0U"++
M!U^@`-1W!`=0`G3@+TR@!B#``AOP!%`0`$+`RA@`"$,D9TQ3=!=K.!UA?V5=
M?W]2%B,-64J0F)F03%E2?U%X,3AXFDYP9D^:43Y%`0AU3T]L/$9">A<-2Q!&
M#5>7GP5(-D\!%)!*<`Y?OYK-_TM+S='2T]35UM?8V7]*`3P35Q0K;]%+#D$\
M)@%_5R4E86L(.S(!4)=/(2\!*1L204@X)0:`F5&BS8D29+H0P&=@@HD8:Z+\
MDB+@0XP5+F)T.%/F@8P<$QI(H.%`"C-M*%.J7,F2FI0Y`+RT5%E&'38E7ZS,
MA-3D#A\S4S+$>"`FDQ(I$&Y@$%)!9R8Q%&A\<%`B1@@]8*!8*0+E#[$3--!T
M24%C@I,_;F9XN%&$30@D!II@4K(EQ0L#=#P,X'$#"(<`"PY@N-$B08<<2H_H
M@.#I$Y<V^EY0.!M-R1@^`;+T`<CGY)(T*Y*PB($&&B8F>UR\<""BB`\)7P"D
M&-(!DO^5##LH3"D00P(;2'F,89I2YN3.X\B38ZM"8,27,1>E51%Q@`8,+'_0
M$'E0IH<,%$)6""$R04`*"7N($("TY`,Z'`H@?`DB'%.6(!"4<#$!EPRS)A2\
MM@(#*-`QQ1<I,(5'"@I,@(=<RD4HX81*7,)$5Q-6`P`3U3@A1AW)/4&&`V9L
ML<`(&5"&B14(C`"$`D+H,,0(`&`WUQ@,L"!"$TYP`2$.C4%B!A`_K)&)&QE<
M$8<-D,!Q40!XO&$!`Q>408`)&+!P0`E7K(@#$"-@\,,-,7@!@P(8,````&B\
M8>$5&MQ00!9&:1%``5>8X8(0:FC"1!HPL*```P<PD,0)Q67_XD0#+-P`00!2
MU//$`NME$L(/+Q2%R1SU&76&&AQ.PT27&99JZEPQP)`%'4(T$&0F2\0@@Q`6
MU)-`#W,84,0`D&Q1P`8[A&#!`GF\X(<F5*P@`20#T$!*)G3LT$<$.*P`00,I
MQ,!&J']@,<`&/;Q@0@T=7)'&!#'L,$`%,_`P@&FGQBMO,V,`0.J\FDAATS1E
M+!!`%<<I\48!;TS1``XA@%%*`3P`<8,$9?Q!A@1]]5"`7$\8@`,'8%3AAA0+
M.$!'`R.H"$D''&CBQ@=7R!'#7'/(8(01*53!`0\<?,#"#WXPP\8`88C1@!$T
ML$&9&A(`H0,1$%!!QB=@F($&"CLL_P!)%GSDX<87,L20P!2::+&!$$D(@4`4
M411``PM"A/#T'UOT(,0`,CFQP`)LZ*%(V!ZDH4EPTE`AQP)43&/%`L;AJ[@V
M2L0A`P%>+!##!2;SQ$8/->P`P!-5',:&&CODH4D9,W20!1X3\##'V^LTL`,;
M$Y3@`@U!A`#`&%HXL"L')03P+0P/3`##"@,L<W4<(M#@@@PX4(!&&`6X4,($
M:Z#@0@)?0+CX]L<ML04=,7&[_2G2--'%'`%LH;U*5!0@0P8-L%'&&B:HT,>K
M^J9PPP@EQ!&D%'@P`0-N8`(#F&`#;XC"'YH0!2_XP0`L8,$0UO<'`EA`92S3
M`P_$IP4A%/_@!`<0AQ.:P`8-Q&`!6H#$%:9PB2:D(869B`(;5C`"PA1`"V%@
M`L"F@``%F.`!?$@#'#J``P.<@1DX,8`";G``"+C!-$O@@A(5H``+<*`&%+C#
M+_13@!&P``,>")L%6`><3OE)?=N`%R:B``"`<>^-UDA`$0HP!A68@!'1Z$`0
MBE`"+OS!"S1`@1<&L``:J(!U36A''%:P@1,$@0@K0($=K$"#%%PA!AMP0QI(
MX`(%$,$%-4@!%Y2EP&VH003S4`,(3&`"O]D'`B?``0YV8(*NB.`'7=C"!&P0
M!`G(`8[`1`D7UB2&Q"T.`'C4Q!G6,(<N&#,;3$B`#TX`@1(0X07_-C#!+S4!
M`!/T)07'BH83V`"$(^#`#I_1`A/`$`<$X$`I.C#"`$Q&@-H<B65E\($*DOD'
M$[3@"`:`PQKZ@`DW$($!":`@-63S@R/D@*!M:$(8GD"%@_%@!3&@0.$R\002
M'*!LNI&&%$[P@Q]8`(9.`%$`8J"`)!P!"$20"2:T,,:_F5&D<W#CC6P4S)[^
MD00T:(,=9/`!G6;""QD0@A`R0*<"O"`"`UA!!B00`QKLH`4%*``,.@`!&T#`
M"M]#00UJ@((0+(`.-&@`V/ZPA/,A80YML`(!>."%DP0@=&UP@`4;B0`P0$,)
M66!#"E9@%P,000,H@$$%#D/%JI5!C3[M_VF/`!``,%2.>T[0`YTR,88`S,$+
MJ6C)#(4P@2I4@0)5Y<-&>4*'%NPO!0!8K2:@D`!'$N`*3NB8&9S0@24.8043
M6`$0V```,V#A$@^P9T%9MH0S-*`$!#`#)%;0@?V9``'$C0,>`,"&`&S`!07@
M:35VLX,;#"$?;]B"%-;PA0D``5%(5`@/1G"`#(A!?'/IB`)*4`8[4*$)69C"
M'$AP@R,0@0,D8,`&]"``-W"(IF3\0QX><(TEA($/<N`"$I\967Q-804U>`(`
MA&"U:&@!!K/D`!.8T(`@A,P'#M@&&U!@@Q58]0$%V($`-%$'!O#J#QU`@6P%
MQH,T((`"'P@""O\2T*4ES`$_[K0+=!WP`A=L!!-0V$`&4G"`!IC@!:$UV#N3
M\((&]*G#P61"`!(`APY3P7^:($`%0CL3!1@A#TM80`JV`UDNB,!%0B``AJ*!
M!@GLH`$K5D,5"K>'##``"#B8@%R4@`,G4"$`>0!;<E4&@GMMX04Y((`35I"%
M"1QA"#?(P!I@D((V'$,/08"!&3BL"@OH``,'D(`7EC"`&MA`IIAPP@!*P`(&
MM'(:3^#-"]APW#^``0M/&,`!?K"EB/TA`A-0@AL*\(4_0%@3G,J&$PCP`/RB
MF7M-:!;=,F""-T`6&$2P`0T>VX46A.`,U;3V,>"P`SN(@0XC`8`?(2'_A@^8
M``T=N$@,>O"7+IPAX7F`P0;8D(?9S5("(4C!'C30`C2P]3(G0`$;')`"%2#`
M#7^P@A&HL``;#`"_4"C#!`K%OP(<\=SX>L8VKJ!08"[!"<9Q`!C6@`<ZHP2P
M?ZC`SH!0@TPS@PEX.($"@!"#?TD#"G<8R0*NH`8I/$$+NYG!#5S*@#ZHJ`:>
M4`(4..2!E!VITYEHPAD>4`,6X*`%`0B`$(Y`;0*@80UC@`0Q#@B`05.#"EPH
M``YT<`0&>(`,Z]/"`O@R`@K4P9A+\$+J4)"&P*?A"DR(`P$8P/@C:.!>`ZC4
M$KJR!1&`*!.`LX86V("`-M!AT$LHPUIQ+B\G_T!@!PD0PP9BX!15B"`(`-$)
M&&C`@2_XH0,F@,!F_T`%%[2@#RMX00QXP(,95*`+9:CR%FBP@?FU``<]V,'P
M7("@$YCF"7DX?P?X,`41]$"VGPC"`,@P`!&LX`0%8`$9%03Z%@UR]0)&\%L&
M4("\-R%8X`>&UX"9$&-05WS:8`5O``#=(@1^44HK\@!!D(`_$`#/E`4A0`,$
M\`7P,@5RP`%)D`1!\`)$,`0]8`$;90,>"`D2@`-G\';W,A=X``,OUP5T,``D
MT`,_8`0<$`>O=PP&8`,2\"S28&$#<`5+4`#FI(&:$``P``1`8`0V8(%&D0`K
M4`(+$`9CL$4#X$4_4/\#./!H)R`'9S$`$Z`)7E`"!B!;X48-4(`'!<`&35`%
M=S!H2O!9$G@J3O`!/;`%9W``)/!NW;*##-`!GE``1$`':Z``P+(#XL$!6/`&
M1+```P`$=C`%83``0J!^/$`$`X`&0(``E,$$8@`!2"``97`%(2`!QB$'/=`'
M6K`'M@8YO]`&06``"#")"9(!,U(")V!4TQ`%;8`"0Z`T&J""AZ@<=6!SM(9S
M>Z`*9P!94/!N2P`'"P`'5O``"C`G)^$$%W`#YF4`8G`'+%`"=94)4X".#Y`%
M2\`$480%5U`!(S!`#K`%@-4`0/!H%Q,#K_('#P`"4%)0<!<X`G!#2Z`$TS'_
M!$LD`JD0!@JD!%.P`#W@`5L0#5&0`'.`!62035]@,IGG`CJ@`TAP!UY0`0H0
M`97S!JGR!CRG!&>1!6*P`C>@`RE@!CR"!RM@!#I``UM`AYJ0!1ZP!FN@(GM8
M&6X``6Q02E&@!B:S!\!VC1%2!SD@`2S&`W<@#6@`:CQ0`'^0B#00!QF0`W53
M/33P`BL@`W2X`].W#06@`'&P#370`";C!`X0`V8``8@5`R@@`(6C!`1``Q.V
M`RH``S1P`$(@`0Y``3VP`!+P`CWX!W0P!$*P,2G1!1E``S-C`@X0>%ZY$J%B
M;FC&!'4@7M(0!7[`!PKS!V-`1"90`*'R!'8P`'<P_P8-8`,@H)K#L0`X8`0C
M\`%6<`6I@!0750=+8`44@`,:X`52`'67T`4>T%!$(`(#5U`<<`!VQP!&5T'*
MQ011@"0_.!QQ,`!J8!Q10`!!P#8B\`5\L`=A)A09$)[U,@!<P`95\2Z:H`8P
M<`"U``!6P`2Z5P82L`(&D$("^@(#4`5-,`904`5;8`<Q\(4KP)N9P`0#8`,Z
M,`)(8$;?M@E/(``WM0U<,`!S$('-8`81MIH[D08WH)@?4`.NU`P0,`(R$`2^
M0`7!4@4GD`&[]P=,$`8CP`1-\`0N@`*&QP0FL`-6P`$C8!<,X`!-H`1+@`*$
MN0]F,'HF8`..MP,O4`8HD/\",L$$8V``#'`"$V``6=`"%I!V<3`"."`$VY02
M2B!#+Z`##&`$&7!S-GH-3A``=+":6">C5X<%3(``.D``@44#->`%8A`!?1`%
M>6`$$@!#F+`$?,``(_`#&*`#*A!:??D'51``@P($$I`%5>`$$O$'4.`!!\D"
M'X`%D`A8&C`$0U`YFP8)43`'#=",)%D%D+@-5.``1F!>6Z=&5;``0R`";$0X
M4V`#"L`&YRD%,P"L&``$+!"CQR`&5C`&'P!3!Y!`3["@4]`$5X`"?'<`J#";
M<(`FR@4)*=HM$2`"==@,:I>#T\`%W7:H.W$%'(`#I_`"(."H6]`"1=`#&D`G
MK!+_`60``!M0`G-`9WW``P10`#;@`CAP`#BP`1"`!1KT`&:P`R10!@;0`D$@
M!#)@%W]1`Q;P"U$``</C+T[P`BFPD%VPKF=`!@30`A[@!12P`T)@`GG)$FE0
MF@Y3`A#@J`:[#KX3GZOI!/[1#&WF#'S0?7N0!K]0`6`R``G`C,8)"4Z``#Q0
M;)Q7`#UP:AF@,$J@!UI0`31P`F%P!72B!%[P!BV6!`J@`8]@#62`!`'@3)A0
M3]QT``M@(T^08=2P!;OW<$+``D5@`%4P!6C0&%H0&BU`!AO@<OA%!AF@`$.@
M+F:``JBK``T@!I11`"7``XC3+5BK!RGP@C0P`.<9#5+P_P$:<`<>N*]>D51M
M8!IU8`<<Y@1C(#YCL*I5NQ)24`(O,`:L8@#20`;C<@`$$`5,0``^$``&@`1[
MQHGJ8@4`@`24PI=*0@$D:P)%4`1Y<`$*L#G$J@<B\`)T@`=ND+GKHP00P`-1
ML`6B*P1Y0`67H`1HT`,)``$*\`(^T`'_%`0^(`)-VQ)1Q`<UL#0*X`#Z&+VV
M>B=A<%F':$PEI@E/$`,L<)T!```2\01EP`?3=@$YR`1L\`(,,`0M$`>3-@;N
M-0(*L`!64`!"X`-WL*1N9,,(^`,F8`;+ZB=<("A!8`%5<`F,&VRCAP8(\`;\
M1P94"PEV$)Z0D`8AH)P]0`=P@/\`:<`AGR@"&+`#MWD,4T``!S`"1F``([D-
M<E`#0%`=?+`%#S`"'0`'A?,$RW`%=%RB!B";TR`%&H`!.&`#<"`7^ZH?/I`!
M<>``1`AXU%`%;&!X@@C"*H&*!0`%'V`#-;H-$"`*-"!=7M`"*``'C-054+``
MX!))&X`'$J`!FJ`$$L`#.K$$!S`'TLH!*B`&&K`!,O`=<I`*3D`001@#)(!B
M1(`#)V``(!`#`!`#*=`56!`#/]`#,3`'&:($;6`!/("1+K``"RF!2J`%`&"(
MHMP,)VP4<6":"K`"'Y`UA>L$:R`#,!`QT724(S`#78O"%%`$?.<":N`%B[E`
MOS<8&W#_9M<@H"9P+',<+/-I3TM@`5+Q"+!I`'G0SIH@%M'@!A)P`$,0!"=`
M``)P!QM%!886`:QWNC^``P0`B7+0A4>`!`^00E+P-F&08'9G`$^L">>X,5T!
M*"\@`%U04W^@)P$!"5"0!Q!`!D?MR8:W!`0US]C0!`Z0`WP@!A)@`@>M*!8@
MSB4`!@P:26$P`QH`JG"3`3A@!5A@!C4@Q/#B!3'P`6]``AJP`B;P`7<P!=[3
M`B4``#"``@2P`=SW`B>``!E;0BE0%%V``!K``S&@`230!RC0`2/I!'3``TA0
M`XMJ*HWCT4`@!"\P)ZZ)9ESP$SWGE=,9#?5L%&K0`2QP!".`_S?<Q4)_\`4$
M\`(<,`,(:@(+(+"8T`2\B`1-\P=90`5>X`1J<`*[#:QK8%1,T`7-:Q1E0$24
M>AIHP"`9\`!0(`<K8')4(`9VT!558`8"D+;-8-+1(&![]P,EP`9[\%ER(06*
MG0(BL`.D^@%P\-I9$`%"J;S8\01>\`4.P`,ZL-LN,,F9(`5AT&R8(`5Z8`(:
MISU-`)`A\`!IT'HQ8`%G(`5LP`A,X`4`$`<<IM6P,@Y>;0U?T`(UDP>'YIIJ
MD`-%L`-J^0<-T`-Z$`<)@`,B$$Z0`))\0`&AQ%*]@0!6T``'0`<00`,```84
M``-%0`0E0%47H#9\@`D^W.4&P`93X/\#'G`22I``0>`&9C``+*L&30`L/)`!
MRFTJ?N`>@IL"`_#%<*2LV^#5*&[;TA!:59`"/Y`$#$`!VZ59D##'"L`",28-
MA5@#/0`!:D`%C[5`<M`"Y;0"<Y`%6&!-(M`5!K%P*S!K?\#4<8%!0A"NX9$"
M9_`$=3``W&H4+02):"#&I\$>;"`:++";<9`'=G`,:I`"1W``>6QB&L``'.`%
M63`&2L)`%$`$+.`#((`%=B/8>L"J#K`#HD``.C$%!L!(_+0-?/`"NRT$-'!"
M4U`%>8``O+Y%B0/CH2KC,SX-7X!)4F``/0``B5.W+X`#/K``3/"[B<UN&X`#
M06`#,-`'8T#_+=Y%F*>(`LCG3R7P!J6)!Y>0>1"P`2$P4-I1EARU`3#0!&K`
M!C)@`G%0Q0L$L@4@`CD``T(@-PQ``P7?NR;6`"!``'60I"K1!'U@`3LP!#X@
M`X_[VHMC!7?@![-ML%(`O9EPVTM@"'8@=R$0`P0``J1*`P6`!G+]!1^``P.`
MX3P!!B!`76D@=RJD!BJ@`#\`!"?;5EY@!7/PH!*@`R`0!BSZ`AN`+D<+*U90
M`3UP`PS@?SZ04UB3/B4(`&=`0?1]&D,7!5*``/I<`3&`D2'@!U*X0`L026Y@
M,D?!!X'$SEX`!5A`!5(P`.]T!"6`!QS2!%80!AN0`X%=`@@0!FS0_P)E-K,O
M%W=]<`)(``0FD`%U;@91\)MF0+5*4`9[8!*98._L@>_YK@E+H`<Z$*,:L`-R
M':IY$$(C$'A@4`*M!@,2H!-CL/`K0$5%$`8[H&*<59F0@`4W@'*9<`49D`&^
MX@!M`P@#6W]_61\T9AP,.#LK(S8+=Q8[>B8IA&(*1S0\<X2?H*%@/#\E%@<E
M<UBAK*%47$ZA2PY$!T-($W5*K;R]OK^$`VB[P,7&Q\B$4G>M"Z!3:`MI7AX'
M#L1C*PI)+P%13%Q2RC0]"%!_2UX<2!Y=?TU*64]H)3\Z0S\_*7%C5D_O5.YT
M>'/NCQ0+-VA,<54@B!$&*=P1&A,`0A5@3?\0T"%&"(W$/TRZY$$0!4")'6@(
M+2E09,20!E[^6-E"[,(($694SMDQHDP5>4N4<`F`X\@/%C^$0+"SA$J7)TZ4
M2(A#I4F;/V]HZ"@02@D9#DET,/!$"`J9"'2*U3%`!105-@55ODE&MZ[=4%@\
MQ&C#ID2&*ZR4C#F!PX:$*4[DY*@@!D>#N$K"S("!A0N$'6RR$%NB9P<$/1M`
MT(AAP4P5*&9J9%A08T*#%#QXQ%A=`D0`$R*N*`%38,,.%QDLR(EA8.&4!4@.
MI`A3['B0`GTZM,@P@4,)$F3:^KJ2P>\+"V'B_HGB1P2/&T4V(-"RY"Y=)E06
MHG-/OSXK*@.:$;+_8F>-F2\6T$``&*`HH48*1HU`0P%LS`$'(4ZPH8$)#H3P
M0@=?L&&'$E4X@48+1MR`A`%I!,`#"S>,,,`49T!A!1A=E%&&%A&LT$%.H%R1
MP'DWX?&)%70$($9[Q2P1E1)1-/&'1^]HD<<>:@A@P@8`_/.)%&PD8500*O2Q
M!P#R5='`"BTXL,()#=2Q1!]W--&%`$(,<40+>7SQ@`(L)&%!D%-`,<456)0!
MQ0,GP)!`%*`\`08*"@SQ0@3:+?$%`GV(8PP33*`CA1)OB2>8?:"&ZH4$,:BA
M1PX>Q,(*&2GT@(,#4RQA``X"?!%`$`.,0203`RA0``0RI&!#$#`,P`44_PL0
M,<`%/110@`D[<`("!3)$L$`."2C!1!8%I$!#!@0$@`</!%CYAQ)7;+`!%W`\
M<`,`5E2100Y"J+`*,$QH8`0,:BSQA!L5O)"!`12LH$$`\K%21@@2I)$%&QRL
M8$$<JI8%!@%!%,%`"04,&6HO5;S!Q[T?EUP7?LU$H<8:;)RQ@`D?E*'D)UCD
ML<,--]3PP@@W9"``CLJ8F(0';%`AA152Y&%!40QP0$:F\2RPPST&F''&'P$L
M,44!+K1`A[E_3"$'#"G"X`?87;A1,3),L'''%GB,<84<?(CQA@8QS&$%*$O4
M\8$""ARPP0$W!&'`&WL3$M(#.B!A1Q0!/"$%%O]RF)`$`T$@0,4N3I0!0Q(_
M!.&&%5KD!(<>%#`@`4V?"#6!$`H0,4$6F4*H1A9$)C/%'&1DT8=XYYHL/#)H
M*$``$QSPD`9'H`C@PPL\`$`(#B6$$4,/!QRPP@XM;)%O#6$(48(7O.&@P`HX
M*`=&"B]D83L!.3P@)`$T:-%5$!3\<<8`0[1@_R<.X($:6H`#%+#@"$-0P`L.
MX(?:_0(*.?@`'AR0`QL\Z`]08$,&1N"!/&3@`!3('2'ZH(`&A*(+`X"!#P:P
MMO'HX0-&4``2-F"'X1DD`!<``_!LR,-60$$.S"-$"`I@!LCI0`1E"&(!D'"#
M(7``#$:Z@PQ8H"`W_`'_#E9\QQU<H(,\_,$)!#C`#Y*0@3,$\0]Y2,(^GE`&
M+DP!(1MXP\P^088>W.`'1WC`S#+X/_<L@0L`D(`(`,"%*-B@',#CP@P.P`(B
M!*`M7HB`$1)8@7>P@1A9<(`"-/"&)V@!1#]`@A^T`PHL?*X!3<A"$Z10AQ8@
MP0&)^P03'L``'?Q@!%G\PQ7F4A\IM*$!'4!4#X?9"R9,@`8``,,&8-!'OA$@
M!CE8P1>8X(<5B"``+R!`%[PP@`W$(`8F6,$&UD`#BQ!""5NX@P(F(`8J\`$'
M7P@%&V*P`#-`H`,^Z```+&6&&4A@;"6001(.((0/#$`/((@!'TBCA2G`H0A)
M_UE!`(JA!#\000<C4P(*9]`"`Y!A/'#@@`DTT(`/E(`#=(!"%!Z``SJT\%Q6
MN(,*8-"!/H`M"F7P``^0H``7%$!7H(K'&]8`!V$2\ZB)NH.E0(&`!0@J`T>0
M`!MF]H0$Q.`&J("#>*JP@!@P0`%2U4,`SA`4*T"`!CX0`@:&,`,R@(T04S`!
M!ZOPA3_.`08Y$$#"T-$'%=R``318`!]2H!X[```/#G3/%?Q`@@Y`0`(+Z@+S
MZD`!!>B@!PZ(B2S-``(B+*(#*#"`'1:RA#:((`<T,,H.+C"&5O2!`2$@0QRX
M8`4_$$`(!/@"\[0`@1[HH`@Q*``(<F`!--PA#Q>I3_\3R."``BRA#(#1Y2"0
MRL,J:,`%7V@##RBPUT]0`;5"L$"F]'"``JBA!P/('1/LT(('G",$*]BK$@"@
M`#;TI04QP$$!K(2'("R@`$*8@$Z#4((@/*``!S!`'ZSQ!":DP0!!X%)[Q5`$
M/F1*"B3H@0)"$%U@#.```:!#"@Y0KG>TP0.C48,R"M`"S*YA!CT80?>`$88&
MT``'>V#%%09P@B$<@`<2:"U]GA"``<!ACM2E;A/,X+X_`.`"/RKR'&@0PPU$
MR!%)V$`=$ILH%!SA"$10`1C\P(?$/:$`0,``'1PH!3#4+@P8N`%EG*`%!?1`
M#TC^@QHV@"<<R$$*@%%"`&;_4(0+#GD/"!"#%2R0A!6L(116J"P0$AS+KI1!
M2PJP`!%>X``X$$.91XA!<@FQ!2'_00)'4``?HA`%37K`U(1X`@+L"`01A($)
M_N*"!X30@CS;10H)D$-R'2`$/OS!#!]-LO#:L`(5=&$!Z!7A)_)@@VBMH0E5
M.$09MK:#/!@5"O0+@`=,``-.A&`-6=""!F@0!P[88`T06($-BL`#$&C`!@'(
M0`P>U(0M3"`%.,B`","P!L?E;@E=Z,$"KA"&.N"``'50PPEX$(0)O)476E@!
M&<F`)#!XH`8<T,,WKK"&$FS``02"`AA"8((6'.`!2_W%$JH0APV8X`$R:QUJ
M1&`^_P7,``(=IDL<VA`592M["6"``P)<D(*KR7(+`0#``Z9V%`64P`\OC74!
M8+"".7Q`""D:2![HL(6@8`$",0#!%[8P)ARD8`%58`("=M`H1B"W0&80@0YN
M@-XZ_&$+4HCZ.Z-J'S;`@;(UZ,`6S#*`.#QA#&$<0GBOP.5/I$$#1]#!`ZR`
M\`?T(`4&``.BEHS?`5PA`!+800XD<!4JF$`!0%#`#B3@!21C80TX&(+JOM"$
M*T@!#WS0@B*.(`;Z[&()5N"($_"0`H.EP>@EBP,24)D!&J2D%6O@@1"$D.,J
M--\.$G`!"B0``T,YH0H=,`$`:E`">Z:^"#5`7PO8`(,23/\7"PC8``U"X`&_
MO8`+H0`%+&!L62`""G!MG_`$$Y`#8"`!)F`"$K`!1-`#-+`#"%!Y7;$$6K`!
M$G!7::=99Y`!X10Y7]0MWS%=#J`#)N0+46`'>6``%R``;M`$2U!S*Q`"!%(@
M>.`!+Q`B)>``.]0+37!QT$==7O$".!`!OG8N=1``!:`!+%!"T@8*:L!R!L`I
M2E`'&2`$0$!/>+`&<J`J8)`!"E`#+G`'2E``*_`"<?`':7`#2:`!;T4%!+`#
M0T`$&<`&JN(&`[``&H`$+#`$">`>>[0`--`"2?0)<^,;0W`#;36%BE,`#/`#
M,`"`H-`&,!`$()`'F@4%`R`$T9+_`4T0!B1`&E'@!`T0.@#00G4@5T#@:&Y"
M!4]P!PM@`-K0:-V%#%-`!Z/&"LAR`"]0?$5('U!P`C%`!I5C`97V"5O@34"F
M2@-03@7P`GFP!6S0`BD@`1I0`C$@`F:RBBJ!0D;`!ET@!1F@`KVH!-EW!GDP
M`2ZP`R)P![&P!'D0`PWP3AN0`S]`!#Q``@7`!RV``@C``Q>0!5U``"R@`V$F
MC+S0.6T@`3Q@!$?P`7VP!%=`!R^0`A2@!DK`2AFP`A\``$V02A>P`B5@DF;$
M"U>P`/67`0D0`&M@`,L4`A=`9W+@`B7P`"K6.E-@!QF``W\E`06PC`%(!PC0
M9,-(75"P_P<G4`)L$'.MP`1:$`!FL"FML`0`0$`9(`98H`3_D`9S4`)?E@1(
M8`&&]P=/8``ED`)FX$#S``,U<`,/0#(@H08D`'N.P61>>0$4L`!'LP%'T!.0
MB"\N>`9L9TUN<$9S\&5"L&6\`'DZ@`$:$`9G]`YC4`-#L`#_8`<<4`,$,`4<
M<045H!5"8`9KTP3=DD`EH`9/H`1I,`9TT`!KX`7DA0$%`)7'H`1BD`==^0M1
M\`8Q4`(`@(%)^0OI@HAHL`,98%2EE%\[8`&QT!`+8#/.0`A-X`=KZ0;N4P0A
MP#Q*@``Z``8``%HE$`)L4#MZ0`0+,`$[``,N$`0CT&PXM`,-8/\B!,`A$-`"
M0;`#,F`*?9`#"!!K6T@$+1!TS1`$"@`#8[`&+O`#-X`"K14%<]"?%-!:N_$!
MED`Q,L$")V")K?`$D`4`6T``*"`"'+`!$``P-(`"1((`S<<!7!!$<2`!N<<`
M+9``1"@3E5*<U+4%*O!PH%F9K*"!O+`%(H`;>],%9[`W48`$(_`#.+`!*<``
M0%`#`R`&)F`XE>D$M@@#1J4$!D`#+``$,.`&3U`%31$`>7`'7R`?'[`",#!1
M=/$$`C`&"/"`.<8+4$`"2"`"O0@*`X`#-+`".M`">U"9J)E[-'`&!$`$*Z!9
M"K,"/,`'<_0%*,``+"`#%!!/3D`%:`#_`&SP>%O`!54@`3+``;A)4520=8'Q
M!UA``*H!J3SZ"W*@%**I`&)P1DP`8"M``TET!0Z8!5\P`K`$"E"``C50!Q;`
M`09@C`2`!DU@!;WJ!BG0`GJ0`3:P`CV0`PZ@`C0@!M5Z#F[2`33@`A*@C(V*
ME"#A!8Y$!6X@`2E0!G_P!3?&`&OF"UN0`2S``,-Y3E=P`4F``3H0`7M#!0G@
M`S.P!JVE*#!`GQN0`8-)"!D@`4W@`$A0`5H@!5,P!A$@!-SU&MJA!%@P`.V9
M!\TT'GX@`T2@`#=``F;P#W0UJTF&!B(P`B0!$GHP7<:@!'-P!\+D!*A&L!S2
M!$P0!AZ@`R,@_P0)<`X(=P('H`-?M@(9(*^LL%XJP`(F5`40(`0Z$+!)8`!2
MX`1G0`<%4`$Q\`93P`1>N01,8`8F0`,!(*1\HP69T@1YT')0!`I1<`<,61;0
M%H\`,`9,D)8X,`/0Z@`3``=<EP=QP54\H`%4,`/Y@`$;,P!_2@A88`!Q8D9I
M$`()A`$8D`%X4`5-(!#YUP%QH`1*X`2QD`4(H``;(%G`T()9<PQC\'QE,7<$
MT"\RRPL7H"Q,L`(F8*#G1``^4`0F0"!X\`(G@`<MX`*,(`.6^P=B``,A$``]
M$`(.<`(S@`(G8`(E8`,B@`8!)TQA8`'U]P`.P`4F@`)OI0=#4`=.$/\&@OH&
MN3,8+6`'*5!N#+`",N`J^_8+5K`#/[`#:5&U"[`"H40!L1`%`W"2,$H(*W</
M$$"4*I$$B$(#;/`'8$`'<D`38Q!<39`"*YB``V`"%V*@@O8!2``$0F`"'8``
MO-2[/;0%/#A(/+`"!B`&`2"KQ1`%#=(>3.``0#`$."!:`P"1+'``%O`1GQ`'
M*?`#"-`!08`#3JP_\`4!"4```!`#82$!"Q`"1F$#!1`&!9`#1R"P+B"26O`/
M9Z`%:Y"1R<8+60``5<)L);``W@D'DGL##?!67H"M&H``:KD##)PI$T``Z.``
M,2`#A_L")N`C?Z`"KT<##*H`#Q`*3)``-'#_`G(@`6:@`4+``CYP3R<R`C%@
M!GN0`40`NDD``G9P!5W`!(#!!9Q``3DZ0HT7A+RP!&FPD^>T!0Q@!!R0B[,J
M!270`TWP!3>P`)`85RM`!"B@!$OP!C>0`&0P`@``!7.@`$7`$RJ@`Q4``0R@
M"^<2!0V0:5'P>#O@![)@!@JP!&&0!BB`!&^P.>C0!@>P`&\0."R``4(0!'30
M!6!`!!00``=`J8M&N3Z0`L2I$FCP`T:0`\8,"E90`1AP!!H`11T)`4`@`3KT
M!QD0`!N0!`\0!GG&!$:`:SE``DDA4AC``B3@AR*-`JV@!.!F!"F09TK0!`,0
ML'?H`+A#P\,C!?PC_XJ$L`"@"[H*``%FD'RYJ3A.<`6I=01.BB<$P)Q=8:T@
MT0`Z@`!<,`;4``07L`4"\`$8,`(L8`+,00AFD&9R@@$_T`DZH`,LH`%=(,D6
M^01[\`,QP`4BI`13``!`%P8TP``<"0K@$`()F2<W``1_%@I3@`(9/21/<`5*
M,@(VK1)X,`)'\`(Y2`@:T`9RD`')5P:C@09@8`5?(`16_`8%8`0_P+(74#M-
M0`&SG=&690`:D`0WH`!H4`5*``>)H[\Z(`"D9)T78[_)(`7PXCL1@`.@.R<$
MH'F\7(1F(#%7$$#YX5H4V&U(D@$[\`9U>'T@$0<KL`("X`55<`-SK!(9T/\#
M2B``<T``_I22?S`!/7`']W8"+K!3*8`"`\`!/2``$X`#$Y6YB[0#)5`#]?T"
M>D!J*4`$0M`!$0L2O3T$$1`7`3`!#H"&@6$`^N@#?!`+3S``*1`$4C`5KEHP
M-@`!(E0"^;,"H,L".*"/.T`$/T"I,V`!OB`%`A(*4:`'`H`&J,=(/'`"`""W
M1&T7`!`"L/8'=/`#2^W*/5`":Y"JO,`%`V`&&00#/P`$DPD,$I"G?\`%&N`#
M(Y`$,!`&((`#D(4!1+#!BD,'`%`&>B"6[;P?AIC6$B",6N`^4E``.S`#_Y,%
M<S`'8.`&Y88`4,D%*.`2,9``KZ`!+L$#>DP(:G#_$@MW+F^P`&V@!0?``:&@
M!CK`"J`<!R*0.*@I`R,`!#K`!GY``R6@`D,@TQUV!F#X8$:0!")@/UYQ`FNN
M``[08(3@!EC@!AN``RQT+F9P4*S:"TIP!K2$)U5^!-4I!AZ`NSSJ!`'@*WG!
M`.J:@`N@/3$@#EC0<@Y\`'H`-E.P`C/`!1W``30@!`80!JVY!85^!FX'`T5@
M`020H'FP`C$0!C6P`4JR?#C``R&0`0TP!3/@`\G-!&#``&#P!&(08%J@!&@0
M!#6@`XGH"TU0!"Q`M:4+!`R0T0Q`D%T@;;L!F#\0JE0@`SF@!"'`#"I1!HQB
M`-/T!U00!![@;WCT`P>`_P%((`1@8@$FH-6@P*5&$`*?L'P+X&;G5`4(1J4\
M4``MW^0\I`?_7.55O@'7'0J)40!;\'B]"0PJ8.:$0!1[()8:<`Y*(`<\T`)J
M@PY40"1+(`5<5K$,<$<?`-A!D2D.?$0#@`!>(`8:P`",&PIA0`%),`(*,`"V
M9P*Q]QR,L@=[PP1;,`Q[D/)'``*A(`8,P`H:8`8:1)=,``(?$``.:@:[<`4B
M(`0+<"^L]@E0`#Q*D'%UC0,+D!)JNP1+X`8Z4`.MY@<7[D,T#O9+/8!<?VH]
M``=@L`-0WPI9(-Y"L`&#0.@1(`?I30.'Z.A_8`?$<0$',`$7L`%<ZW8?<,0`
M(/\$#=`>6&`!U0H!(K``=;`#$\`*%``(1%9.5R\P:4M_BFTT#78K+30\*Y(X
M*52*F9J94!\M8)DB"AM&#"E%+"Q!*'&;BE8/)B\C(E8+27.N8P\E*PM_9QDK
M'VEL'1P&`64$.#!3KIE2,2D+'YE;:4[037PJ#$E"(&:)T.7FY^CIZNN97T,8
M\/$81Q#DZU=["&3L!0<#VHM`$#&RQLZ`+DK^+%EP8T<8=EDH"`'W0<L44`'\
M6.E!!,4,&A2>;.KBX0"+(@TPN5(")\:1(0VJ-"DCI0P4/20.),%PPX;(3&)&
MN))@9HP+&`\S&3@Q!$4:`7&@*$JSX@8!=DO8P)@GQ(__(B\>8F`X$.4*.TU-
M%,B3!Z3.V;=P-WE)@:*-@!<&K*P<`R-&$0]5G"R@8:"`C0(#,M"PL:*$!QP=
M*-`(H`C+'1$[9$28(X?&@"::P,0@\*2+'1H9X$A)V&0.C@80<C"F44/#&RYW
M<%@P0&,!F@(Q6(SHH:$+.B5NCFY1-.:#`AXLA(AHH(+##2-#1FP0H"5A)B59
M!KPHD8(!#3;0E)R!T&+%@"\!*&QPL:&#!ADR.`R0"FT)FA02;(''"6$P\8=W
MYDRA1P9(,'!`"WY@84]<%%9HH1)]C+`6!B-4`5<38>SAQQ@(FO/$&B;`T$<4
M?YBA@0]#!#'!'7G0H048`R1`_T`,#X0QH3E.N,C`#0?,L<<87'SA1``G`*$!
M&:`IHH05`_1`9`9M&+A2&`OTL`$;47"!!11LF$&!$3HH(`$.2?#`!QQ0)!34
M4&8H(08).!@@AB(-S#`"$B8(<`<?;FPA1P(+S&#"'2JE8T4#0AQQ@P9A_<#"
M"WI8",>&&.A@AH6@HD,&#Q1D`4$0>90#0`XUU*"'$E-\T,,7$_CP12914&"#
M?M@<`(HF2K00@Q-Q4+""GIIT@`,:)*1P0@@?O'""`6J(<(`=.[;Q!QLAK("#
M)3C$84`,:"BBA@D,"-&`.GH$8<!/5AQP0!`_\,B!!A!\8``!"AAA*0\3<%&B
M(F[`$/\$`P0,O$D:,+S0`1Y*/!&&&6JL=@X3>?@`@2)ZZ'"'ENLXT0`.0"1A
M`P%FA:KRRN=HH:$\2,"A\#IE#(#>.GKL,$,;;7R@1@E'M!G!&Q1DP.(?6W!`
M@P4IJR-&"-\48<`?5Z0@!`U-*^*$`2^PP,`&RY4#A0,[[)"R&V>,H84!#+#@
M9<HPZ!`"`@AX..<F1&6"A0IX7>'``FP<\0,0$JPA0@=E:"F'#290QLX`#!R!
M01([_`*JRVO%8!S++%-1``]KA''?%S_^044#0?00@K9FP)"!%@04D65H.%#0
MA@$4X%#"`&$XP00<*V000`D;;+!##SQ\H$<?)Z`@@`P?@%'_!@(GS/"!"!D\
ML$4)+8R121-U6``#&6*0<4``$B800P\VL`&0.500L$(`B4`QP`$O$#'$!@9D
M(,(#&WC`_RCPK'X-00$AT,,5?N2%`LB`&F&(DBN8``8#S&`#`S@#R,Q1A0ZL
MP`P`L0,,XJ*$+00`:@H(@@K8@(69<>Z%<5'#RS"0@@*L@`-L^,E;G,`%13RA
M=*ZP10Q,H(`5G*``)!A2#R1`-S2P:`EM$$$,(O"K=$2!#2?0P1`8\`()H$&"
M2L#"`$QP@Q%(X`W\<446$+`"!N!A#%3``Q2RX(8)($$'1V!!`3RD"`B0(`]A
MV()(P'`#.FD"BA\H01`LX8$%X,!2_SO0@`ZI!@`8;&>2YQ##!$JP@"JX4!U+
MP,,#:`""'\1C!8V"H866\`$A=$$-,9!`.;S``0;LP`1Z$4`.1-"'>^T@!08X
M@R+`$#P$"*$],H@!$6)``69,``!YD@H<2O`")!3A+W@0P@5*A(8#7$4A"KC`
MT<QU`@K<80,AL-H&2E*#$F@A'5GX``]NI9`.W``%0&``!R*P`0)4P`4..,$&
M&I"!!?#O`3=@P0^2P,EWNH(.,EC!`\0`Q$Q`,P8-\)XYO+"!&+BA#?N@F@I`
MI88,!"$)1FA!`IZARI;"90ETH`$&6!`V$@2!`VJPD!WZ@$ES<$`!"P!(%U9P
M``P((0!TR/]I)LKP@A@,@*7E4`(7V%`%)FC@!TBXPR:4P(84&`$(1[!&.9R0
MAQ3L8$5:JD-X;/"2`VP1"1;0RQ\,4(%-]($%8YA0WEQ1!B2L``Y-4,,`##:$
M'WB@#*YX@!`\0(9/_N$);?A4J+KP`!R<@`I,D,$\-H`%EU9H"7;@`0'.4(`=
M`.!]F5C"&VKP@B*L(0I;\,`*YF`!$^AA`!_8`0YRH((.[*``(("!MJ1*!PGL
M@`,%,`,?</"Q[ZC!75D@`PE*$(<L>&<*.PJ``0!$`@FL@`!]<$,!"".!$K#A
M#1<XP`\.L(,(2`$=36"#PSS$$A/(BP6ULT`*(,`!"U#@`Q5H@0C_"-#/_E(`
M!1M(`@N2,`(4O,&3P%)#`<B#@`B.E0P16`$&2826`+S``FR80QU4H@4AF&&#
M<"'N!A2P3`[0@8^>C;$YS(`&",S!.TJX@@-1T(>*HD,*@H7Q.90P,/#10`<,
MR,$>E^"%9S"A#B&(@0.RX`J)`<`/;EC#"E`0@!)5(0`UN,$0G#J'%KP@`$*F
M$@Y<```K1$$)8&!"%%PS`@:T8`].&`,$D$`D"HB!KIL`@P[\<#-%[!4:5%!#
M`M#PWD?IH(P<:,.$IK"`$C@8&E:(PP!H8J$GU"$#,5C`YAY[`@A(4,;L4,(`
M*C>&V/5X@@D(P@IB4*<LG&`%:`#!"G(:_S$[;$`('8"`&`:S)TU8(0@4H`(:
M++`""%A7$5)0C!V"FX(#>*D`6;C"!YBKM#?0P00E4`$*3#"#%0`@`QN@IQV"
MH``DK`'%T+@`#1`@$B6T`0E$&`$+FNV!#!B@!"((>`/T10$50&`&&<@`,K)7
M@G[]0`<;*$`:%;$$*J`H!1TX@PN78*H23"ME2XB`$`@0`*HB2`M&,($'9F>A
M*[Y@`#L"P07>B^J::ZT>/U)"%YAM`6&FV`D)48*/SR&%`,3@!D#@<@#F0(9$
M/($--&C!C:7$A3VL@0MRD$`-!!"GU)(A!`H8P@%@0`<21:$`2$B!6_ZP!VH.
M``YG2,.>EI"&#?\,X08T2$#7%0(&#>AO,1381%"8\!/0''H39)A#`-Z<"2:(
M`01!&((0)I"U)7RASA./0AO6P`:+52@,H/X`%\@Q!:G\T.9G<<`!XM`$&L2@
MLZY8@@78+0+C,((`4@#W.!51!5Q8X0(3.,`&J*P(*EB%"T(HP0%TYP,)7&$*
MJKN"`CQP!3`L8`<C:#@#1,"%'6R`/TP(@P%P4(`P3,$`2`#(`GB0NB\X5A$;
MJ(',%#&`I-]`"#A@PP<RX`$.0"`%$_``O^4!'M`!&0`!*]``O.$`#_``%J`!
M$C`/!T0:$T0&%5!$85,.36`&'9`$-``#0O`#$@`'$*8)6\`"#3``,2#_!'@`
M*DI@`@#`!70``!V`!!2(>C)6#.8P!@9P`!I@(590``(3%TR@!R]P0"7P!5L`
M,DT@!R50`[>R!@/`!5H0`SO`!U"E"$S@)SMQ!!*P!-=U!FZ``/M&`SU@`!ZR
M!.0`!3&@`RQP/C2W55]``BQP!"`@>$*1"7$P!R>@+="0!E;@0EU@`/GD3=[1
M@P<P`FGD!4.3A7'Q!!R@`Q'@!IO@`(Z(@^>P!2E@`D^P!T(``?#V!W"``@=0
M!`^0"`9@`PX``!:0`3L@`1&0,FNP`P.@+!E@`C'``\)'`"30`WP@<@'`!$Z`
M`+)``R50`@XP`$@@!_8`!7>@`P'P!$S0`#&@_U&9,``T,`<#X`$$H`$I\`$A
MT`.HL7NSM`(JH!)7`'8MD`0,8`'LT0$=X`$-L`%^Y&\S$'#<*`$$)0$3<`(2
M\`$:X``?$`$RH!9'0#C[L552D`?>1P#$EQY`8`<%T`%"0(G0D`4\`&H20``I
MX`(>(%EO,50IT`(]P`(Q<`*MZ`(:D`?DB(DLXP0#(%?ID04D0`,D(&1G(04`
ML`9M<&H_QA\+03(CH`%XP`1>@%A_P`0&,`(W@`"?UAN.^`49@'1G^``C,`1&
MX#-+\`2=]04X<`,5\$Y-\`96,`5OP`'ZQ@`.X).QQP5(`#::<#=20@8[4"I2
M4@;%-E:;HP1CL&(>*/\"1W@`)]!#.K<&`H!:<9$&%O`"(K!W0$$_+ID.9"")
M4N`!2!!2KH`&0I`"0!`'2Q`%(8`#8U`!,2``$X!_I+@!#:<&/K`!/;0$75`E
M*S`!#B`&%4`#8(`@3-`&[I$(6[9!3T``06!]([`#,7``#\!2"+`#>&`",M`'
M!M`#,6`$1#4`[_<'96`$"Q`E7J``V'<I*$``P68"%[`F^B<"%C`=-7`!DK$&
M),`!D;$`-@`!>U8`&D``%D`?$J@`$0!O2T`&#7`#,""3FR`445`%&M!#T*`%
MLH0%`M`"!P`!?)"+:[<.9F`$O+$`68`#6%`&':``&L`'']"4D0E#4]"2KL#_
M!14`!`YPG>4P!7$``01Z#F3@!9H@!710!-D!`UO@!P:`"4[0!7X0*10PHTW0
M`$"@`T"0!["7!0[P`P?D8$[@`@<@!U2P!-J@!$[0!">0!#J@`P"`D^>P`B\1
M`@`AEXI0!D*```M`!UB0``$PHYMP!0,`+&[P`))S!!X@!EJB!%)`!2YJ#E;@
M'!I:#EG04R7*"0:0`WT`!AN0`@JZ"5!@4XSC(62``Q(P!@_467XZ6#10``@@
M!3#``:C%$B,P`%K`!AMP1._3!<ZB!R>PB9*@`0M@!><"`VA`'FZP!R<0`PJP
M1,>8!RL@`O2U`$9P`#[0!N_7!*[86'_0!)`SG4``_TP@T`$$5@T/4`$ET`$H
M0`$3@"\2``(&``,=$`+<"`+5(`(1`$PA(`(&\`'`H5X_8$9S,'$'D@7CQ3\I
MXP1L@`>%]`=.(`&1N@E9D`068!Q+4`<<4`+WV0(;8`%P@`Y0H`$YP"4Z("]'
M,`%-5P4-,)(6(`$PH`$`$*B)JC*PH@$UH#TD5`5S,`=I\'YJ8*.;(`5DHP-(
M(`$5``$!H*!1L``OT`*2]@==\%,Q0@&."![*LF`TT`%?@`=?4)9.X&LZT0.X
MMPY8T``KH`%EL`4/\`(DP`5AD(=_@`8;8`,+P`1/!@$%D$K0($9[80$]I@1J
M4">A@@<?D+(E6+)G`0(\4/\'6L`#&\"6?X`%&<`#<$5E<G``!=`$/L`!;)L%
M/P`&42`''$`$!A"'<!"A;]`#,."=N)@`3/`%,>`!>C!R74`'UM(#*>!Z!H`'
M2$`"A9<&'=`#""`'5L`#'``:2N`!-"`$*^!00V8"*1"QBM`!0+`"\PH"%;`!
M$Y!.>S`#)$`!'-``+6``()`""+!_!$`!`>8`(N`"!?`!'?``_@8#!C`!)K``
M$F"M)2`$\S`".9``T!`%`J`!/=``5^`'<6`%>1BP`ZL)`7``'!`.-@IG"V!6
M"^`!-M`"_YL)`5L"(>!]&]!:1V`$F+H/4U"_14`![!$#(ZNW+;<.2U`&OP:Z
M)!3_!@$P`$,7L[-D`"S`(1[P!6NP!E'"!<*9`0B``X_V`7FY$AW``C)``6_0
M!U`P)E"P?DDP!$<0>"L!#7A`!"U0+IE04@S`-DGI`:2"!="*"9I7`&EP#FZ;
M(`"0!Z-&(585!-R'#HA:LGT0!!ZP!`_0`VPP,W<A!+3[K"A0`V+@`!P0"2&P
M!B+Q!.LG!\:CFC%``SC0`@1&+A*0`\;1!)56`S0PD@+@0199?,L%=%(`@4*F
M!`VP`[%U`C8@!"&P23O0&Z%X2'+@+IG0!CW@`S9@!*,A`A+@`"#03"50`1I`
M`1VP`0L0`A9``##P`!)``B1`JQ+@7R[0`1\0S"@P`!OP_P$-<`(5$`(DT(H7
MH$P_\`,,<`(",#!/<`4C$P,&D`4*H#4)Z@K1A@,LH@0+L`+#[%!DX%THL$F*
M3$\*(0<\L`/S.2%94`$KH``ZX!AN,06RA0(>T"T20`>I#,+G$``@J0YCH`$O
MX`'`^Q91L,(R6PY<:RE(\`!["`#=\0=0P#9>R+::,-$X\`%ZT5E-D`5:D&!'
MH``64`53,,`@X&038`-%$`-W`!I;8XQE3-(.0*97B0(X0`!-H`4",``;K1`H
MJC=U:@Y-$-7L8`?"LI;IL``^Y]!_(``[\`"P0`-]4`X"<,@]L`=-D(XQH`8[
M+0(G$`0]K0((8`%%``"*8@=_X/^D&X`#)O`!'_`&S*;7F6`%RM(&4N`$#-`!
M38`@4E!P4O``)W`",A!Q@*J4/#`'Q^@!QI,$/\`#-+`QZ+`$`3!YWN$&WJD`
M/V`"!.`!*+``)Y"/ZDL`(A`"$2`!S00"Q-P!(L`_&C!@]:P"_I4"$8`"%M``
M&C`!*<"-!J<!'6```7T$1W``(=!<2O`%`N`A@]@P/[`:3I#.FO`$%#`O&Q``
MVB`%!L4C5J"&>T`"+5#/&[`"I<($`-`#/;`"A+U574":!\``)M`!6@";!$`>
M#Q`M*F`&@NO5T``%!6#5Y3`',-";%>(%<M!3+`PL9_`&6\H'E``#3$D#-=)T
M=QD)!1#_AP[,D$3@!U0`55M3`PJ6`I31!DN(@)PDO`BP!Y1@`0'0`B6PML!2
M!Q+0+V9X!!K@F6B``'APB5*R!Q2U"6&,%GXPU'%!!200`R2@5.@PAB0K8U"P
M(XT5`QM@XIE`!1)`!"_P`6I8N@2P!30@2Y7QSBE``?NQ`Q?P4#HP!E7PQ!F@
M55-,`QX0`,X2`SY@DWW@!'40!!J0!CR`.!>P`BO``SP0`C2P`7?0`_)K.B)@
M!$A@`U*N1K=&<U#0`$GP`@R&#"%POB4``1D`C["H`@H(@.++B[!M`0[@`K?M
M`10``@A@K@M@OK_]@-`L`0;@`A.@<!0P-SMP`X*SF2+`!BAF_P62<0)\T`)E
M3`8N,!P%``9YG`%Z8"!-0#9'I!=*\`8CZ0$6(`0CP%X=(*9\-;M"L#^B-K@2
M8)/;90(3T.0*#L8.;@YG@`+DG.#'X04#T,-_<.&/I6@:4=0H4&Q04.9`P`,E
M+E4L-0627LZ*$`4C0P,C-N9>D``\\!)YM#MF,`5Q:$-F$`9^X`1GQP(VD-^9
M4%P,%@.%9@5OX,7OQP0!L`8E\N2#NP<)T-4DA`8,8@``+ZE\(.8E.W[&L5V(
M^@4G@`,^,`&K40`X``!/\`(9(.8`0`1@8!DQ@`)VH$-Y@`,+```N<`(T,!XH
M0`=/L%P1\#D00`8&$`)$0`3'B`,7P/\&2``!`'$%":`!R,@'6H`PB=`$C2P$
M%9$.7U`"`NM#)Z``)3`$1/#<,#`!K6@`]RD!$G`!);"])-``&QD"I_ZP%"`"
M%?`!!)`!M=P"#S`!TLR/O5P`,-!,'C`!""T",X#Y_D7J\W`#$L!RFE`&!F`"
M+``!<:($:7`P._`&3)`(;9`!,G`"=-#8M@`#.?``&<UV),`#Z6Z#::0$:,L$
M"K,$;FT"(Q`$UR\&,T$`/$Y0)H`"73!T^4XA3I``&T`#<=#0YP`%*@$(2G]_
M:EY_2EEK`&=R*RX%2X.#3@D_/SHE`7!Y>)%*:"<X`0`F+AU>5'U*2F(!"D`_
M+PD#*RP_.`#_7X-M5G%-?79P)B\-49*'6QH*0S005(-*<`4!S\?6UE:"@G]8
M`X--:`EFU=?EY4P+-!QAYN9R;.WQ\O/Q33!V?TX,NM=O03Q`Y/RQTL$&&3\#
M8/!8HR52$S9"%CPX$*.'"08\`*B9($0.!")DE*3)0>-$#R0]\&3HL>58&0T[
MFOSAPN-.)$E.$`AY`@!!BQT%_)B(L6/!MG9.`!!Q(.G,#APP?M#@(\+$``T;
M#*B8(,'`A`-S4$AHT+6%`0@O"GC8\(##!1@$(NR`($+"A`\!9&3(0Z.`!10=
M/N39(($/#0(=7BA@88`("R,_8LBY<O/8EQY!)BQX)6/)&Q@2V$@9_Q3`!XT+
M9R)E$7%#A)DH;1340()&TA0[?R5LR+`F#)-K2O2LH"'D!@DT4I:@P6&B@`$D
M*020HT>]NO4ITZW_"4-D11LGVB4]29`FRA<N5P(LH-)&A1!XQY:`@3%$B`X%
M"I+,8(.FI:0R2!S!`Q144/&;'W3L\,,1/MPAB1)\,)`?!VF$(9,82[C1`1)&
M6:,%`3<P@,0#OTG2Q!U':6>&'EI<D0<493C0QX,/ICB/$ER46-T8!83GHW52
MG"!(%C:,8<T3!-```PXAN?'"!G"HP!8*!QR00PAR@(##`!O`H(L8#9@01`DB
MB&!'"#"P(\D7)J2P1110C!``%-LH<08,)?]TD8$$)3S91Q1+1)'!"P'@,"4/
M1K!0Q`D"R?,$"#3$$<D2`8Q@@PXZF+!`!APT\($!&8@`P0P-B``"!%U)``(!
M&S1`0@8$A$``!QI44$(#%(C`:@6$&9`"`1:00``*;6E@``H65*!!DD7L4,("
M&K05@PY'Z""$!F0\<8T9#XR``0Q@-)`#!`M(0,,$OBW11P<FJ!#'$TI0$8$$
M"@A1Q`9N0/-%#!L0T$`%?A1`0@DPW"&%C4KTX<$*1/A@`P1C.,%&!BE(0,$&
M)7#@ADP_=FR=&@-`T?$3`Y1BA[;A37%''@8X(``85<20P@4B2\)$&"H<,$11
M3RPQ0`E`,)!"'TW_=`'&30.DL((>=URAA@L*Z)!#`2@_"*`.%'C!!!E,W/$!
M#19H<0PB(@@!&0YA",($'&)[/,@7`120P0!L5#')`PIXX,0`1`AAAA(2$($#
M?&X?XP4".A:N^!]3O&",$SW,<0P6*L@`QPY[*$$'#A38\<('V6P1P`8]O"`!
M`7C`H,$5#[JQ&195#%!$`79+$@8.&9AA`04KQ`""`%TT`<<*']!A@@=Y2%##
M#CU(L,`,)^2Q@@54*`%&#"QT!X:-UBCA10@MN"'($Q`H@+T.,"RP@0<4?/``
MK!VHX$`&'1"0P0,:-/!7`QK`2L)=!+B8I^['`:Z0H`$GF,">*L`!5-%O_P4-
M\(`&.C#!%+BO!`_PP/UT8X0AA$@"<IB"-;86@144P0@`L,(?JG`'#;S@`7&`
M@A/4X``<2``!8]!"!D9`!!!T81!,6$,-%F"&$[0`!#&@P!W,@``9G(`/9[C&
M$\`P`1S@8`>',4,5OM``XB'F,&P0X>+&^(T^]"%QX1'#`FI`@CIPS#I,N$*I
MU,`$!/P`!7`HT1+`=(`;*,``XAO$$K00@1[@QP)F"(`<QK`$)6C!`#&00`84
M8(0#+"!?W;N`#RA0!Y7]@0X&6$$&VJ`C1R*`!CI@``@H\"0`>.$.`ZB=VYP@
M!@M,(`LZBL`02C"$"P`!"2/8`18PM8,9C<T)3/]8PA0J0QTGY*$-9%Q<%8[P
M`4&480<2&(T=>F"`*$3!!G]X0!#:P(8##``\Q^!`$*3@!C;@(`6&D(0#>B"'
M"_1-""^H`0A:4@`A!&`B?+C#`W(PIA?8BPT%8(`>)#$&`Y1@`PB(@Q\4.@D<
MQ.`&$!B-//H)@1)=`0<]2($.BB`"!88R@H_@0`8J<,`6>&`"+]@4!PCPJ1)D
MP`.:ZH`(VI>`%E#``#0P@`4X\(`-0.`$((C`"RJ0P0Z@H`4W@`$"3#'4":``
M`B;80`%40``)I.``1^B;"C0Z-C@\``<Z(((9!C$%"&S`!P\0Q!+H0($1("$&
M0AA`B:0@@ABP80%(@(#_(*#@$QJLH0EX\$`05J"&<IRH`T(X@`UV0``E+,$/
M&<!!""X``AY00(S1+!P3"H`/MRGA`B=(0\=Z<8$]["`)(TB!&*;0@0,D00$0
M`*TUHN"`1!V@!&=0#^O^(`4'*.`'(<C",6KV!RA0RP1PR(<%%/``?N`$`D)(
MPA`L0(9!Z&$/&O`!`!:WA6ED1PDK2($9_`"'"]"2`7L8PAZXH`0YN"$+`<#"
M`21$`R`TH&KTB`,<N!?:\$1A!S:8`'WAX-4.U*`"2V!$"IS%AC48X$H#V$(D
MIA"!$B!``BN``0V*T#P`I($`S;&`"0)@AP64``<Y>,$,'L&GZ/[A"60HP`I:
M_Q`',J1!`6M($>52<(8!3(`'(0C`&E(0@RVA\1I6,,`+#NO=%^"`"$"(`0%>
M18$,*!`%7/'``U!`TPI8(`43.($'@D6!:'G`+I(D@`@J<#\*G"`"(="5"`P0
M`@L\0`40R``(+/"!%!`!!A1HP00XL&80&.`#]3O!K#PPK!``80@Z&,$$``S$
M.AC@!D;H00'*P`0L^($#);``&JH``!WT(`>=&`080E`"-X"!!@BPQA5:\`(L
MH*$/;UB`"R20!RY<(PII,,#R<%"""9C!"F;HL`0TF`)5Z[;`X9%"'@+IL26,
M@=/:64(8XM8!'S#@!D#@80;H6`XEE`&F&6A`<81@@?\^".`.6A!$&!Y0@PRX
M@0EH^$`,9H"`91I``><VH@3N\$9NY.%2"DC!`,30ABIH(0!56$,2#H!.MVE!
M"^!V`@]84"\[*$$*.^!!!5B`!"($H`<4*``.SH"!#,!V`T.H376D\&1L:R<*
M&I@""C@GPBT,((H!L`'!3)"#$<P@`RM``@]<P`$V#$,`-)"`3."0)`:L(`0J
M8'`*E"N)`*0`!6=P`AF$$$^<O.`$;?4`#%I``BQ(P@0M``#N1/#5'V"``:.<
MAQ1D$`-R?)H&1M!!""+0+P*D+P0>>'28)Y`"/'O``2%H``J(VH+YG4X"#D#!
M3E?`AYM:-0(GD$`%3`"!H9+_Q0"[<4`)'-`6V",P`XQ7X$LE\``)A``!64$!
M"X[P`SJT8PHXP$`+(MG8/VR!`BX801"0L#I)O"$'!'#"'180!!6H5A(A,($>
M4E""$L@``7L[P0NJ?PTI)$`"^RT!"A*@3/7)P`($.,$*O.%S'UD!`3_4?];A
M!@&0`!UP`S\@`6UW#54P`3&0`5&T!&5@`44P!#C0`&8```%@#-Q``$1`!"\`
M`58``"U``P'`#2]P!$*@<\<0`"N`;CQ@!DO0!%/P!`(P`&N``Z"&`CU''5K`
M!@2&$T&``U4P`C#@!!G``GT`-U"`!"%`4@O``V*``4LP`B30!T9P@@*XA<Z'
M`C?6_P8$L`(B$`"C<05`T`%:H`$RT`%*0P`(P"4]H`$?4`!>(&IOY&T2@`-8
MP`4$$`1LP(&#@`;G(@<4H%@X`$,UJ`>4%0`QT`$0P&16Q@%R00$..`!-L`1D
M<`!&,`(;<&W7P`1LL`,34`U3$`('\%I!<#JG$@(9X``M$$&GDP$&((<&<#HZ
M10%)]0$?8%44,"L/\"E[`GL6(`(S=3HBL`$.L!OMHWXSH`$P,`$3Y`$SE7D=
M0"JA4HAD,0$/$`./I@-)0`,W``;FL"\V-P5BX``RT`()T`5I(`/U$@$:!04+
M@`-T$`<E(`$?`&,],'OCIP$%\`(&\'$3$P,1P`7A$@,A(/\`9'<,46`'!(!@
M6&0`O-`&[$)I&E`"%?`=7'@C63``*M0QZ3"*;'`",8`&2[``)[`!=6`=3M`%
M`#`':M!PQ]`%%7``*(`&-0,%9W`%'+`@0$`$$<`&?0`%F/@`/.`!1C((4<`&
MR[<#*2`'@'AC=``TYM,T?P`'8S`'!7`&4.``CT&&/Z($<;`&W&8.3$`#+:`$
M,I`"(L`"`+`$>)`&2K`#&Q`$(A"%;D"%(^`!;&`$>T`/8/"6&QD>9T`#X"0)
MJ_$",."1'&`Z:```*Z`!1Q696"<">\0&/0`!@*@$#O`">U``,.`"!T`#&A``
MO_$&%[@`1&!+*U`#"J!9I,,'FD3_94U0`"E@`A^``@`P`#W07<YW`C00!`00
ME><``3S`!Y*P!25`!#;P`SU@`1ZP%2KP`+NB`K`2`KJW`'#Q`1*`9X\6>:VB
M`1+0`<@(`AQ@`#``*B%05`;``:`W`P3@`1/V`Q8PC"[&`2#`%HJV)PO0`J%B
M%RA@`&\V`"I`<BL`!&M@#GQ!`4K``@.@+4[@8C20<J(F"5>@6&E0*"(@"&;P
M`3:``S20`A0@!SE0`2F2B1,P"%@``3G0`A=`G(/`DRN``TAP/)*2AI'I5BL@
M`<8TF.V0!@L@2]HQ!2RP`XS!``QP`#U@!>CF`W^I'4XP!C(I"7Y0`C%P`7_0
M28S#$RTP_P0,@`.N:00E``!8X``'8`)V=PU0X`$'D`$+6`<9P`!`L"5PH@1,
M,``%0`"JE053``#\@B(^$@U!:`T;<`-SH`,]J0,?`'P*@`!)T`$*T`(G,$YZ
M20)WD`1:&`]@<`%IZJ/TP`040`-X=@U4$`<2\`(4,`!^@#$$L`!L2%02X'1.
M68+$P0$(```HL`%YT`+X\@4%$`-$L`/I10.XN@%J$@7A@CMRX`5F4`1OD")>
M4`(40`8(X`$[D`$(D`XT(`-M,*AOHP(HX)M_0`!"T`,CH`.2=@*=@@(-P`$<
MT`'GJ0&K)&DBD`$4,!8?L%-LP0$6$!B+=IX^U0&4%J`?((OK`_^=7=55/!`#
M2#"C.6`!O#<#)C!F%$`"'E`!8T$"7"4!%ML#0\`#^*0FV$`"*Z"%++`!TQ,`
M9X`W/#`#7;`-;_`Y5&`8;V`-8X`#&F`%;,`!/H``&#((5,`!--`'*M8J9@`'
M#1`#'"``9`4-4U`'??6A*8"!6?`&0BL"185FI.2IW:,%G:H=95,`#0`'%?`%
M<C`$:<`"*#`'2E``T-8&81`"1*`#&X"H4_H@==`'2?D'`(`!(6`&,G$%4#`%
M`X!*(Y`!:,`$4Z0,(Y`$1W``*M`&S/4@M<0"$N`$32`'(0!J&)`$'M`&6G`&
M=[`[(A`!NN`$D2`%!="P"^")U[`$5W#_!V6@'5>@`B,@`5>@`",P`B50!2DP
M`B*@!3W``+["!B4`.'?@!22P@.9P!D+*M>T`.#B@!U`@`>W`!0*'`GY0!^H'
M`GOP`"D@/R'``!)0!\E(`Z9A`AJ0!BD0`K(D!0MP``2`DQ?``WL["$_``VB8
M``:@67Q0,[XK`VN0`R=@`B#*`@P0!"F`2?%0!B6A(PV@`S7``CH0;YD7*V[5
M`0]P`K7H+RT0`1I00.R*`A10`9FW`1I``2'`9_>#`J'':#,P`+QW++6X+#,`
M`2KE`.DI`?Z9`A"@`D'@`R/P`2$0PC5@/QQ0`"ML`4)P!"5P`QV0'8/`!1L@
M`P'X!TGP!%L`_QE$<``^``+'L`8]L`!/$``5\`($T'9+T`(E8'4P8`)"(`0B
MV@5<<)M94`,RH`9KP,8<0,<48`(E,`!-:SLBL`(\L%BY\P=@@`+I"`$?$)EE
MP$S0^R/9];AKU006$`1Q@`'#!P=)H`<A@`(!<`0T\`J\)([M\`1V@`#^(0='
MP`PG&%PG<`-#$`.Y=@P/40(_P``4$`0U0#B2\(\?3`%<$*=&L`,@\`*@A@0B
M$`?JXRU'L`-K\!MNH`9XX`8$@`,S@`?Q()8#$`<P2@^2+`F18`4X`$V3['-0
M<(^C`73R,`5FL`+F1`9S`*8!<`<P$!$Z1BAD0)=2X`0G4`)9P$QZ,/\$;S`Q
M5)(#?(`%3"`21K``<!`$];FP-A`$!:`'0M```X`$`;`$3F`&/P`$0&`!X3PV
M"24`Z.0$+\``/8`!0N``:38`H2PW!B!I"Q`#`,`!*@`JPF@`+H``B;9H$``#
M%E``LT<6!*`"!6`*")!@%`2Q"P!V>R`#HG(Z(6";,#`')>`!#<`I)T""9WH#
M3";'K_4#)X"IW*,$9J``%L`Q37`!#'`&*?`"/&`#0C`'',,$!A`$<$`'/-`"
M*]`#*^`#)Q`'<=`#(K#1""`%5[`'*2`$?8(#!F`'.H``->,]":`#,R(%:)#/
M!3`&"%.J)U`$2_("?T,%?O`"-E`'`+`#.T#_!ZZ[D3[SD=5Q`R,@!@I``^/Z
M`P``!7RP!28PP0&0JY5"!TZE!3I06O&`N8?`!&?`2S]0!#5PKC@`!Y-[#$[@
M`#NP0@1P``;0!5@P!6Q`!'CD:2P0-`I0`"*T!&9P`TD`!#K``D,P!!D0!/'=
M`F/P!4[P!#*Q!00P`BV@-=:P!%^P`)*+;4`GLM:1!5_@K>G\!"(0`C<1!=9+
M#V4@`?S"!G2`)Q2@!WQ"PC/P`D"0`!8``B5``S40&H)@E&T0`C@@MC!`!`Q0
M`RAP`CL@!WT8!S'ZB#5`&(3(`VW#!C10$7EPM\=@!2&P`M\W"!TP`CS``)H2
MC/L*9BNLPL?R`&W6_P`@4`'#`GOPFC_1D@$K+`$<$.'00@#YMP"`\8NSV`$3
MT`(8^P$>P,%R7@'5M@'N$Z`JP`$.\"E>=0+4,@(W<``ZC@5?L`55$P$Q0`?;
MP`0;8((\8%&1KN.#X`:`G051:!1-X`<:$`,TL`*:D@<+80T`P`/\1R8=]P=-
M``!"$`<#@+5;P`4HL`(G<`=/M@1WD`$E<``Z8`$J]`9"X"!_(``E($KWZZ-F
M0#/6$0,B\`<J@%M)8`%_<`5KE<TL0`?$K0!L$)U9H`,L.`]:(`!ML`1[$`-#
M$,T1<-W7P`8Q(`E:0#I(@!]Z$`!]L@-'X+G^\0=G``!W\*OWCH9_$`4%</]<
M1-`!8#`%7S`%7/`$;R`"-1#@0$0&`T`'@VP=:,#H!?8%@IS.\E`'.E`U%'X=
M>L`#"N`'7'!P*0`&:L`#2$`'QI4$]O4!-\!T79P"8\``',"!3A`&@4-$52`'
M-+"0@U`%D@0%5C`!+C<%;\``AFEL'8_,UYT"1_!W=Q"9`^`^*2`1-&`&MYD\
MK**-Q,H!*5``(A`F%V``/!``%,"N)$##`W``!AB@$E``8!,`.]``!4!FMIIZ
M=K`#%E"+$#L'+@`#`0`V@>8!**`'*N`#=X0)'$@%<*`'SRH%&C`$#-?06T`#
M#U``0P#'06`"S`4&#-`!2V`!,2"DL*L`9"P%C7G_!CK2!.%U]+R[`FR]3$Q`
M+U]`.FU0`;Q[!9`O!`PP)P@S!6O``#^`!`2@`P70!+$.*%;0`$/P`./,A5?0
M-M3Q!D"`!D"@`2.%`'T0(:/<E@V0`AL``"-P!R*``MVNW#?B!'L0`5J@=J]!
M#W+0[@]R!0<0``8`6V4`"$U,`3TK7$I_?V11B$UB6(F14@A&0$,-8TQ,?Y!1
M`D<5408"4)&FIZB)2U8G!WFIL+&I80-.LK>XN;<+!*91)XBZB4QF)R49>`@E
M)@UL&C`M#S`N%'`$"G)E?RT@2Z9*;T(!=186.!EFD6<K*!4T(2D["BP*01Y2
MN'D*"ZE3)T0L6#`PH8&`_X0+(D!`B);A@X$9$#IH,+"!`@<-$TXTX)!AP@82
M$E10?.!!PP(4#3)L*-#"@`45!C-XV.!`@P4"*%%XL!#"P08"#3[X)&'P0H@;
M.DPH</`D%9D8*MJTB1-G`P,8#XP((=+C@K<_2@CL8&/%#X<8!2`E6I<A@(P4
M*8CL@-'`2I\8&=#LD!`&P88>"FBXH)&A#PX.7Z$,*%&"BI(R'VB@L)-J28P8
M$;HX4;%C!D$M?\1L*+%)F.G3N%`H:-'&1`\?*:2$4&"BR8$@*E[XL1`F0((H
M'[B@OA(@#YE@N,P<<$#%E`D223H`".`E49,"1%Z`$<;$PPX,1T244>*EC'<,
M,__*5$$=R0P,&A&:L+\E10^`K_/S"R-`PU23%0"PMX07!O30`AMX:$`$!6^L
M$<,*#E!P0`T_C`&`1#NTL(=C3`PPPAQK^%"!!@KL@$0*;`2``P%BW<%)'AB,
M,$0!MMP2AP(WU$#'>J<T$08)!]SP`PL\+%""!`B$0`!&'+@@0`@]:4#!1!2D
MD,<'&T``P@,A1$!`"0649,`)$\!0000T%)"!!`9D8``*#R@3`04AM+G`"20X
MX,($#VCPP`=Y;,!!`3&P``0.-[P!BP`*)%!:%`W<<(<5%F!PPPVDJ*%&&1*L
MT,4`/J"P@PTO[#`!%V;P8$$!XECAQ@0[U+""$$%4((#_#P@T]4<39A!@!!MP
MG%&"!34FHL0:0F#AAAQ>@)$`#3FPT9PI"VSPA!LK:)#%'UY\$`,B3K30@'[D
M?J$&?K(TH85\3T@QA7Q.:*%$%T/4H00CQB*"'&I;")!'%OO"0HP).Z2AJPPG
M"/0`&'D`,,44`4!`@!`2R)N+$EELD(0"0&CP!@M##'%`&/,Q(<8,0:1%+BQ-
M`#`'NBO'C$H'1P1@RAP]V#R?$@&48`,%9$!0@@L%^($"#!)\8,((-P3`P0Q"
M("'#!B:L0,8)-%R1"!<&F'"B!'2<D$)S2ER0`PX%Y[(`$C?`808**VQ@AGP]
M\I$"`S_\@$0)'S2@`@0B?!#!_PP/-#3!1"!H``$,/+DI^`>";U"X!`ZHX$`&
M*K!$P)H32$!2"QYED$$(%9#>@0H5M.!!!B!43L`$/`Q!@Q`Q"(>*$A+0H$TB
M7M"0@A)+&,`##S)8`=84`#`@`14?'/"`&6AT+<0.*<"P1P,OI/$-JR3_T0,%
MI27B!`0,N!'!:"^$($!33!"0PQX9X""!"<QL\<8))GB@?2(J@!#`#@V@&UA.
M@(!$D`$&Q9*9,)8@@#64@EQ82`%H8A$`/B10&&&8SK1P\885O$``?WB!&T0P
M!!8<H`-U*$`!ZI`(*S0`!Q]02RZXH*`CQ"@%`6*/$M30`@AM4(&)Z,(%U`#$
M(IH"`O\FH($<:J0$.93@!'6(PGRD```-O,`#<;C`!EZ0@`$\H`0@$$$(9+``
M/53`!35H@`.^\*4OG`(`1&"#%L*``QB`P0H(\$$=T8"+)X@%`"APXQ+8\(`7
MI,`,/#)%%0!P%"#\8`0XH(A01)(!$<QD`2'@0)LF\($.?.`$!@!!WPKB@0Y\
M"0(2R``J";`!"WC$)1)`90<RH($*R,`"'&#3!QZ``B6EP``/8(`1:C""#6PA
M%6/XP`J("!8[F(`"6JB"!'RP`Q1,JPE^X`$!FL`!UHPA#&4PPQHVP`((O($-
M+;#`%IP0#"EDH`1>((`QXC8'*BQA"KD+6PP:H`$A\"`')TC_0`MJ\(8,R$`;
MDU"F`Z;`AK-P('HKZ(`/!`"S<2;"#C;`AQ%U$04YK$&&^8%"P$YAAA7,0`VZ
M,HT3Q%`*)8P4%6,H0`TDH``0T``$$KC!"'9``CR<H@T<P,$%L/!25"Q!#S%@
M``)`RATN<(`&%7#C1O\0!3XP<ZHQ6X)C'+``,BA`?72+P@*"$%"FJC0"9`7`
M%U;0@P[@H0`^`"4,</```N@@#'7(0P96``&`)<(-..@)$GSP`A\,00>0%$$N
MJ+!%*4@!!5<%RQYZ4(,%C"$55."`#T9@0Q@H\R03X(`((!`#`DB#`"`XG`@*
M,"P"I*`!(.!G"`*P`@)08`,34"4(_P+:`A0X(`:'<TD)[,:!!H3@`6QZP$HT
MQH(2C*``+W4##S90FB<,@`@)",T*B."#`D0B+$&H`Q;4P(,(D$&`92B!!N:@
M`R"4H!XI>``<WF""&<!!"!M`PPD\R(`5/,`%&V@##$LSA0_4,0,%L,(+8!"^
M1-!A!&BX0AJR,($CX*`$.#"K$EJPAD28@`A2Q&HNOE"`,!05B`$@`@KJ`#-A
MG`$/*97%$AZ@@Q),$`PP4,`1#N#`4RBX!P/0:"RB8(=$LD<,'5!`!6*\T26$
M6,3DDH)!E#`'&"CA"36)P0*^`*\`[-4"=9C"?!;9J0D(H`(S*$$>$&`!OL6/
M!R:PP0/BL?^#%7R`#0;8YP=@``<ED$$"/V"`$`K0X,K(`0<LX$,6I-"".,#L
M"6R@@`E08`:B^G@`$AA"$HX0F,Y1@`"[Y(!%8(*"#!BD<`3H``H,\`$+-``%
M!K$`G0P0@@]HR2(>($`+0*U**7V``\A-2=]*0(_IZ6&D34B`#P)`MRN`(`9M
M@((#;-"#%W0X$6"`4AN0J`$:X,!W`@@#'>AJ`!L$0`P#^,`.HD:$?:Y!`1+P
MPQO*\`4'M*`'"Q"`&V@P+E,XX0([:$(9[/"@`%QA$TZ@PPHFX($2D*`'!^`,
M`;9U"B;HX05,D((#@E`"(4-9%E<`P!U^.-4NY%D"=;A@+J)`ACS_;"<7`K2.
M'X+`@AO$(``>?T(<)*!FDH,E"@W"PP-/PP0R>"`&#[#=1I50!:U]?&5<&(W6
MNL"`="3B"2E`@@780#<H>(`!+?"#F.=#A18@@0-R`"R^W6``BA&J!P90PQU>
M4`*SIP`,,=B`?)0P`!Q\F.(ROFX!T!"$%5R`YQ`(0XOY?H`7%,#IIYC"!A1@
M!`Q@0`,S*0"P35V`';@$!@L0@4$\4``:=*#-"_!`!'IYZ`DTP`0&(,HSYA`#
M$DQ@X1F(0`9:P%H0%.``/W!-#U3^AR=8``F0!^P,J#J!`^1@!T+^P@Y4,(8,
M^,`-?[A""/S>`R(H``T/4(#Q(C&%%<C`_UA'N`/PKO"&``C`!$"`@`-*GX,M
M!Z,"2)!#\X?W`B/$P`"]HE0;D`)>4`!!(#P#``MY@`0```4J@`-A(`$>]W2Q
MH`<(,'X?=PWZ,Q^VX%+SD08X,`(_@`)W`#-F\`,:<`I+``<+T`<G=@MA\``'
MH`$ON#)*``87\'(4R!Y-<`<XT`$A-D@Y0`J1<`4+T`(Q<`%A(!]5L`<:L")B
M\&2G805Y(`%:=CTP8`)SX$79P@$;X`()D`$[0`5B``8TP`%M``84,#P9H'2I
M4`534`4H\`,2``=/P`1IX%H]\`-$4`*656A1$`</$`,A8`=6$#!8,``SD`0_
M<`0C`%PMT`$4D/\!%2!J$I`E$D`!#2`!%2!Z))`""Y`"%,!JR/4`(K`!;:)*
MF2@3%N`";\(!G/0F"J`#*W`#!C!VIK`$=2`#$G!,?S`(.%``3Q`&;,4#%)`8
M:Z,'4&`#(K!!2C`&!J`#5+`%`-`#<Z`%7W&#9_@%B2,#.*`"=I`%3>`&)K`!
M`4`8Y\,"/R`$(4`H,Q``,=`"8K`$7<`'$A`$)I`!%M`&:?0%[[0!,0`'MX,%
M,%`"9@`'/?``61`&(3"!.Y@*6U`'3(951L@W:%!H',4&9#!T*D4'&P`$(T`#
M;.`$3*`%$]`#27`"D1`%:8``>&!DPO`$<+`!$`)X6&4%;V!6#YD+3.#_`$(P
M`!QI<8<!`*6Q!%=P!R%06V;@#5.`!AQ@`AP0`,2'"TI`!79@A0\P`,KP$P#@
M6H("`T!``Q*``RE@`C$P!-SE`Q;@D-^E!AO@+>\H`B\@`@#0!$XP!A?0`&HP
M`RS0`A%@8J?@!&I@`"Z@`0C@BZ9@!7<P`PQP!$?``BFP`1(`:KG5`0V`6Q^0
M`9O8.1ZP`#!@`!Q@:VXB.F-"`3/!21`@6AEA`9YD$$8@.PR0!S$W#`&0`QV@
M45@P5GM@<280!#M`A+N2`32`!ZAR@&>0C0HG`@D``S#P`D60`A?P!4P``#)@
M`"%"``!P`CN0`STP`PV0`AZ0`#&P9$R`!7J0_P(X4&H&0`<'8`-ZP`9M\`5B
M4`9B*`9MX`!$X`!P40,;<%FH``<G@`)I\#\+4`K$B`<UN(-*P`0N]00)NC)+
M<`8B0`,6@'VGH000$P!@,)6I(`5T8P470`,,,`(>T`"UJ#Q2-09SL`=6T&*X
ML`1J0`+`!08/FA],X`U+X*([B0LAD`->\%).L)PCL`#%,B`00`,\H#-_H`5S
M,`/[P*&XD`4%\`(*$`!D0`!!``-D$``?$`0;X`$F(`,MH`-&0`(M<`!R,)NG
M@``'4``!L`$'8`%/4`4#8!4TLBLM8`)ML`=&,`(K@(&^T`<9(`0RX)^YN`4.
ML`..>00WL!(XL``6X/^='^"9&8``*1`!(X$"$+`!*(``MY0`DVEK']`"`.`"
M(E`37`(!'U`"1T`#![`#D64*%,``>%`:3D`#-0`:$+`#/%`";1`)6K`"''`%
M(M`#,7``*\`#*>!&$-`#>D4#:``&`Y`"-H<#@0$`',`#OPH6;@`!"P8`[2<$
M<:""+/$'=K$",#`&4W`%8G`&=B4!.;`"*H`!+&!]!<"69B`$#>`$,NA3B1`&
M2'``,4`9.QH+2@``.?1T6M!V$B`@6+`'2J@+:-`%O@``16!Y0P`"9H`<7*"3
MN2`%*7``$$"Q'X<`$U2PIG$'P@J3IW`O=;!7)""5QH(%`+`!,M`!9)`(4F#_
M!R@@`R+@!Q.I"U3`!A(@`QXP!PD0F1'`!@X0`A*0`C$03@/X!2=V!1GP`B7X
M!TY@'B\@`0"@!2_[`AJ@7F*P!CC0``BI`Y)S!JC@!%Y@HNWHAG^@58O)64<P
M!#`0`B(06IMC2C-@$)33$1*PM[_T:R6!6J:V:[FT.17P`41@!"\P`BW`EF+0
M`BW@BTU$`Q-`!8_%G1)@:4O`!SM0#2D0`EE@!0&@`3%0`R60`B7PIC`P?A@:
M!SO``6%0!6U`!'UP"B![=[P06`F@%D[0*05%=S%``T2P`1&P!]X1`2_``6[`
M`400!`H``=Z@!60@!EH@!4O@`37`!CBV`389@06X_P(G(%4H&YAH0`<8.54#
M0@`Q(`)L>QI+D`4"$`!J4(-V(+?F2@`N8`>"\`6&RAYFD`'_MP4ZJD!4T`<%
M\`4)G+ZH0`?Y^<"G(*7OE8"1`*,-4'B[&T2>V@-RT+ZY0(\7L`(X$`!X(`)(
MH`%:,`9(L`%W$`04P):F4`,@P+)80`<Y!@!*0+/LZP$'0`990`,;@`5\L(XP
M@)BF``5$*P0?X',1NG&+R@"YMP(#@!.7TP`M$`(+T`,.$`$:\0$3T`(2,``O
MT`&@=0)(=`)Y4`,B4XL(P)'`*@0/H%%\)P1^\`=9H``XP&/(00`,4`=7<``&
M($!+``8@8`/K80`^P%1XH/\`?'`&*2`V/%#'_WH`'M`'/"")/3`"KL$!:S`"
M&=`%1?`!4\`$9U``/"`$*-!*Y(4`3!`#/%<"71`,5'`&=?`&`\``.C``#:`#
MH7`*#(D/49``.V"A$.QO%&Q$8=``(T`LJ($Q?C``-HD*$RL+58``>@"HIB$&
M,-`5W#Q5;K``(YG,N=`%'"`$;K#,+?L$:+!%;I6-4Y``)O"9)J8$4&`&:=8!
M2SD?4:`'6=@!`O``)HP`\+@&":P$>[`<(JRU97`#&3`>8)`"&D`%?+`"PH@`
M0R`$&J`#1U`"$R`&`=,$5D``+[`!"5#-^`P`U.J81O`!,]`!$Q!;2B)/!;`!
MJ37_FI+HBB$@.;&D)!-``T!P`#T0!%2+"E0``4&P!U_!!<+IP`:P`SL0`_F[
M%H9D!6HP!THE0T[@`#60!Q8@`3`0`T)P`@NP3D=Z!P10!`,P`(,Q/*I#`U?,
M`WZ0HU0``$B8`0\0`'9``W,@0%79`C-@!69``38``3P@`3M``$$+`#3@`5Z0
M9`00!IM0!7:0AF+0D)%P`2?`LN;\!7[@5Q^W!%C``2M0`=UC&DIP!;B8"FC`
MOZ9`!5G`SBW+!I%!`%50H_FA!&X``'P@4N:,"U)0`B_0VJA!#!I@`A+@K[2)
M`C_CBTO0!E:(`M4Q'TW@D3'0`1.&!3C`!K>@!"M0,VIJ_PIFP`(Z\`*B0@)7
M,``[X%T&<+>FI`$\D`08L"+AK,<34`):)H6JL`<A8+=)`0(5H+QTTK06T!`0
M\$L&P6H4``*D8P(/T`$\P`)"H``Y(`:P\`$^L+&)L`4O8`+KL:M"4`(8G@AU
M$%%=H`$R0-8TX(=6(`4GB0`2\`)F,``>,#LQ4)9!<`>YLZU5P`>J^Z5QL`<\
MH`>!"=)_(`5KD`,(L$&AV]Y0FP(8$!U%$K1LP`.%'#_[<W5E@`9P$(%2$`=]
MH`9F4`,='-R1``5V,`!VT-!%I`1]``,\,`!!FPN$K:;7?`I0\`9UG@M3X!T9
M<+(B)@5L(`!'C>:QL`078`-_'?\S2B`%=#`#*2`"+*0*5%#">[(MLTO<^D/;
M+:ODDUP!RGT'XYT(:4`$.-`"+O`!O]TCUO<#;U`%<X`'<%`",*`%::!C*?!D
M3X`'/7JWM87,D=`$7=!FF3.!2R`%!;`T1_`#0'`")V`!J[.)F[,!_%1)$G`X
MJ=8""R`!26!S2C;>;(!T=@P!/C```F<".)"0=%,%_`$``P!<[@)(,6"L*P`"
MBU$!3$1%56H%3F``*U#-7W"VO6(!._`!`,`CQ*@";``#*Z#?/M`#7.P'QF``
M.```:N#P+4`#/XH*5D"39;'8_&T*8#"Y32`%8L`&),H&;.#ET\*@R>P$7S``
M9$&!`S+_/Q8@M\SQW5LP`!P>"7F>"%G@!VM0R[<0!:*M"@$`-PLP!;I-+F=@
M](@>"TTP`#T``484NB>PR>B;Y-\I`Q,08E&0!RW0M0-,=`/0`CR@%2#`W$N,
M!!A`!''3NBT@`.T$Q)SU!DV@!&9P\$K0!A/>L*E0%3ZP:97EV5O0`56S!L:=
MY!<``SK0B*NA$:_5.9O:`2)P`O_U`'3R^#=`&T0P`"XJ?2!@JP;P/G\P\$$P
MY\@A`D*`!WHQ`:;`!*77`5H3`[5Q"G2`!&:0!A[``>C-;(GP!3(<`&4=`CV`
M!/QYOS2@`6`06$TP!0.``NMN`F3L!S2P97`!`S*@DU2P`BG0__,\,`$O2`>Y
MGPAWP`+HW@7AI!9AP`9W`'DH>Y1KT&<V+P`NL`)Y;$!'``@G4G^$A8:$5&=*
MAFA=A$IO`W10AY6$%CV.A%D9-!QNEJ&BHX5294^DJ:JKJUHM/56+K+-_3@D[
M)0!8A4I8#0<?<DZ$4`$[+7Q9M+Q.#3@*+$4%8(M+"$`"61H]-`PR#R4[!@4\
M2#U[72\\)@=H4`9'266RH4QF-C0823`#595+8TH0F8!GR2$E[WJ,.')$R(`8
M*!)L:)"!``<8`4ID6/`"0X\@.ZY8FF)`!RA"6TJ8N/(DP@$:+ZP4^A(DPY,M
M%%:@:5*H&0X_(F3`$'*`@ADG4`CT2/\3(D@`#C8$TJ#0H<@6#D3\*;E2`0>,
M%#/4^!E2AYZ2*",L0/FR00*"("!T##!XB`F"`PBJ/,#QA9`42I7@C*A3R`L-
M%FQ"*6%"5\R``'V^C-E"Y0F]9;.6M+D`!K-G)5MJT%B`)0<&#$-.IF+2I\X3
M/&.:J'%`ABZI*2M.MV!2A\,!!TP\TUIB9X$7X<B%I[&AX7+R44O6;(CA05FI
M"2Y6&$#U)\J`%#$XC!$N9<$&!D:$<,"S@(4-+H2\/##!X(")%!]4X#B"0LL?
M)6`0\`43*1SA0QNK+('&##NP@($)!E!AR1@9K+""'#P=$H4#,P#!P@]%;/`!
M!3`8`$(&#FS_0`$'#!Q1PP@M9'C(%"[$,`@A=10A@A-3:,"#$!ML40@:.T#@
M1@@KU%#$"RT,(`46$M@0P`H2M&&`!CL<D$,*.<1@1@HGG(%2`S"L\,$#95#P
M0E^&M'&``%M1P(,?PQ`R10,T#"####Q@<,,).,AA21,.[-"/#"9$00@3"\QE
MB!(%"`%`(78@069BJBAA11AUF&&'''OH<=0CSXW21!C.E3H*$PF4<,!IIQ&!
MQBI8W#$`!`-(<F,J5Y@`ZP\QT."!D*JFX@08P16KK"5+Q('$'K8M&\H25'2@
M@`9O`/;'$FELH(`!9/#4"P4C>*#&KL-AX=L!21RQP`4*E,"&A$VX_Y&"`CS$
M,(,!73S`0`9U3+$$&3=@4(*,E9S5A1AD?.%&%T]$`0`2K^H`L**'R&8#$7ET
M$>U_5V0`Q`U'#/'"&BYP8!X%)#`P1`M'%)`J@"]04*<2!BC`AA)<P'2``:44
M,`099`0A@A1=M"!$"S0(<:T:0AA`5YP,E%'%$B9D$.T2:B@`@!AF4+!#`ELL
MHD07-&1`Q@H'["!#$$$8UX4).0B`!`)GP!##!S18=T@5*M`0A1H'3##U!`8@
MD.P?4#300Q^$+$&``F9`D<+.J:ZB!%U.!)#K+HQ3`<7'SZ$1P!6+2VM(%+#"
MRL(=I(?B1`$#I$Y*%2.TC@$0(JENR$T%I/_A^_!_8$$"#AOLL/?7L?L>100M
MK&`!=YM08$()`V0H!00PO&``NK10`8$+2.B0@P<%;)#R&(N,80`*V"OZ?`HJ
M&<%"`:-<(8$,$GC@/PGP(\$7E+"&%.Q@"$>@@0%D4HDO9.`%\AJ)`4R0A"3\
MH`<:R,`$3'#!&!Q`>)5@PAQZ`(%2B"`%"!K`1V(0AT(\008QL$(!=A``0UC!
M`#A8@#]T,`&$*:$!2!C#4TKP@@_8018(<`@.X=<#(9A``G2H``\ND(<>.*!X
M$SA!$`ZP@0U,P`$TP$,?:J`"$V@@%'W``0FR0($>U!!'=$"!#@NAA?N`C@HE
M<$%?V``#+J0!!7/_*-5BZ'(&.?C!D'%H0QFFD#E:@*$/XR'>?S:@N].P8`&D
M:,("]&"(/O"AD86@PZMT%S-0/B<+`)@#&_PA26EAH04E*`,8A&#)(=R`"%XL
M@!_"0`7;*<L*`^`;;3*T!"Z8QP1X"\X6`A""'!@`#-2C118"<((A*$`(&G!`
MA3SP!BHHX0P):`$RW;"$+.QA"#H`0)TJ\00`T(`$:P``'Q:P`-HAP`,Q,$`4
MGG`'#@"!"#'8@0?"$,U:6,D%&PA`)`NQA"WP`09#\)`/@I`$(?"@!+.J!!4J
MD(,]<(<+].M"%"X@!"*D0`V/`,,+2"`&)I1`//1X1PP"T``0I(`&)@C`_QF6
M@`4+K(`-&DC!`E+``QSL0`)[,$`,^/`!+SG!#>DK@@Q.(($U5(`&='H$%P`P
MA`"0X0TI<,``:I"\"##0$)V+P03D4X(]/"(`!$#`%Z90B#J8X`-T_<,74@`"
M(65A!A%@@A4BD((-\*%LQ>)1%KK`A2^\X0YZ*,L?GE"%RBQC"<%I0AG&H"UE
MF0$(E;3D`A#F0C2$P`5F,`088+`!/Y#V$6P`;6B!$(9E*4$*9Q```,B0!5.V
MTC,7V(',"K&`(806`S\P`@Q:*04'E(`&#UCG'\KP@!7D@).$T$(%2F"#"11T
M%EDP@`M8<`,3D"!]-9!`)+5`@13@X`(9L$!>0_\Q@1ULP0PQ:,$$0N4`"9!0
M"AMH`6"@```-L.`(.+!B9Q>%!P[<IX65X`)VC&N@"80"#$'0@(P`P(`"\,:]
M`[G1$B[@QC><H`02R$`)2O`&KE&)#S@@`!X:D((B*.\%/LA`'XA``%9RX0%<
M(L`"RK`"#["RKB,X0Q.HL`$9M,$V75!!"Q)``V^Y*'IB"`4*8I"&.O3@`QG2
M0@=((`'5*($#.,A#(>ZRAD6P800$>)0=2.""$F"WE5HP`QZH\8<IL,$,7/"E
M8K:`!@$(`(2);8,&Z%/)(TA`0H9```Y*0(=0S*$%-*Q$`XX06AW$``1^*]48
MUA"`-QSYM\L:``T*$*W_)M`A=\=M`:K'L``)C*8-&6+"%R``I@)P81%G0,`'
M7`"!-`AZ-5U`0`L8H``<B(``(B@!`>Q@A26<P0$R^$$$$!N*%"3@#Q*@P!:V
MX(:'86%*!9B"">1`CRH`(`,'^`$-<%"!+TBW%G!H[P;F0*Q",($+=Z`='"Q!
MP!<0@(%/>``-`+`$.-0`!T$H`&"N0``:Z&$/-1-`4$*``AB<(#P/(4!CYH""
M&A0@`%G@00,Z*X4"Z(`+9@C`"U#@AUALRPPT($!&2I"D'*!`#V!X0PE4H-0(
M#``'UPN+)<Z`@@TXA@8-\+$#3D`!9!&""QV@-"&BD($8"&H)$+#!`K[;A#00
M_R`%$AB`%YJG+,P2H@EBJ(,=_$"'.."A#EO`PK'_8X4RL$%46X"";V?QA"\D
M8`(X:-=ICK`!12WA#1PH`02T`$HL7``_=D#%%$[P@U\E(><)@(,WGT.MO$HA
M#/-%M;0R("9+0"$WE?P!2E7_!S=(8&]RL(T2``!+#[2^]AM8`;:^RPH\J*`'
M0-#!!PHP@1BD``&#L`,.:."""2ST$"M0QL)Y_@$4C`#J'MC`$AH``5]6`0$V
M(&\05G"'F:E:!@WXO;%F&$B_J%@-2K@`$79``]6,P00KP`0.<`!X4`A60``Q
MT`!D0`55D`23<@@9@`-6(`<($`,2L`":\`<$(`1L@/\))1`#/<!%\4<`1!``
M"Z``-80&#[0#%Z5`%.`#7?`&^?4"'1`*QF`!3O``.5!I_Q$&#]`"(B`C7+`"
M)9!76.`"+9!E4,`W&34*`V`A%-`&@Z<Z9S$&;7!(K"0&:1`&&',(3Y`&`[`'
M9L!VR+$$7T`!!X!`%%`&MN8!>^>%>Q$":L`!R`4$/D``_K$L4'`'<X!HM/>'
M+D0"2:`[1"``8T"&TK($6E``IP4!8D!,9#!!:?=K2N`%"%!G`S!`F/%O!>`"
M!Z``._``$<`!-6``*>(%9D``+[`!=)"'A7`F3+`!G)8$&Y`"+&`$"F`$(*`$
M(L!JH7`%`8`#-[!B1>``\W#_"%!@!OC$`:MD2EL0`B9PC$Q@!R^0`5.`!2)`
M,12@"4L``#Q@`%?0!C@0`-'B!2J0`690``7``2NP`6Q0-F40`A(@!R9P`H2%
M`R^P`QP@`!D``P)0`B%P!DY0!@6@10C%`7$``K$D"TS@!A'``&;P!0C0`W?0
M`2\``S0@`*\5!<V'`%[0`DY'#`EP`AS`!Z#S!PA0`PZ@*$UP!PJD*'"0-:$V
M"DZ0!I*X!EJ`B)(D"U;`!64`.E[0!W!P!EM@!5,`!5;06[4@!E@@>,K2"P40
M!#U@`-S&"F<``3LP`@]@!E$PA:JP!%.@!?#Q!TW0!5+@E8`X/'A@!*Y#`3CE
M`&/Y_X=RL`+400:'8``^(`-460AXD`,[4'7"P01L8`)"``0,,`%KX'T*<$=*
M80()X#<`$`0#(`;[H0\]<&4I``;X50:DT`$[\`<6H`,[@`,9``>^Y`0$@`,M
M@`"05@EJ0`,AL$X#0`2C!08AH``]H#7$L``[X`=F8`$1.!IFL`AAD$>J=@(&
ME`$1N"\T<`)T4&02L@0+L`)[0@,2``8FP`$(LP0?L`)D"05```&IYP5!!0`A
MD`))P`)[$P.$40E:@!5:0`8X``(9`@7!E0+D^`@1T`/?1@B1P@>$$`=!\`!H
MR5`+8`,I\`#REY:6\&]FL`<(```!<`=FT`:_U@1[L`9O0/]\PG%#+R`>R$$%
M'H`#%-":PK$$59`&:)`'"9!:#/JBE7`%)<!I&Z`$3T`&#4`E:Z"4JF=M`_`"
M)^``8L`YN_8"$@``68!98?`=*3``8:"3#2H&";`"0H`$0G`"-."*?R`%>-`!
M*Y`!?F`%2D`&*U8`"-``&B`!(=```A``%L`#["8*;J`"1,`#,,`!9\`&SM<"
M/+``G:$A:/``,2`"`7!63!`!&6D02J`%,``#:=`$?,`#\]8&R?*1)P`'!&`#
M%]"!.[`#0I`"QW,!$T!I2M`+<F`!.]``>)`&6]`#:Y`Z5O``!R`%;U``,9`!
MS<@X!7`R8!0#)8`#1.`!>^`&<V#_`Q;P`25@!A$`),*7>H]`C1TP!1T@)=4@
M!AD@`Q506X0`5B'@']]4`AL`"E/P`2^`(,)1=MBV`0B0DS`J"DOP!%.0E$H9
M!6Q`!W6P!$X@H68`!EIP;ZF@!&F@<!/`)LEAA@:0`P]@KH3'!75`!P$0!V"0
M!5$`I>V*:DU``$G&4#VUB@O0A:H'!0,`2P00ETI`!0YPD0:05U`P!RX``QZ0
M99AAHR'+`,G'`7V0.DM@!22P`BBP!E+0!!#0CAE``@U@$<BJ`6=E"6AS`ESP
M`RB`!0,@!!'P!!Z@`,$B`3!K"`WEI1N0`$T@!1-0!'$@"W4``RH`,1,`$BO0
MF@ZG`=6"_P-P4`WD>50.L*1"(`:7X00[<$9U0*8:,`<80[4[T`<5D@(KL`,Y
M$`)\X`9HUH%"8`9/$``M@`-"@#PED#XRT`4.8`/347[_(&EK,`424`)V4`AJ
M$!04X(IP0)J`\08KP`'^<04S,`-V^1RW9:LA0``S6;'0<05A$!P;T@$:H`$@
M8`#O^(:%0`4M<`)#^I1<<`(HH`I.H`6@DP4"\`9C@+R\^Z+.2@QX(#)F!8@&
M>P,MH*V$\`1V8`$W0)^$X`1?,#DOT`4%BE9I8`$*H`#F\$:&,`5FL`(C``%-
MP`1=('=V$`=H``8>:PEWH`!K\`1,Y@0?<`!M<`4M^P5HH`,;(/\$.1"7AB`%
M<:`".G``*W!D91`UE(4"/,``%=":"S`"M:,F)LHX)M!C:T``(5*[C*,16W``
M1:``)@`!(2`$$!`&=78&02`!6"`%:E"U)H`"-&`!9>"KK:E9'%`$9&`%'0`#
M3E!&2H/#AM`$#Q`$<A`&:3,(3N``DM,#"-"%"*`#:)`L9H`$#L`39U`X"_8<
MFA0".A`"2;N]JL`$4*`%9?`&"/``(M`!>+,MHL`$6O!:JK($O9,P=%$'!2``
M6NK'F#P+4D"N,U``??Q;2G"R,4``UR=F5>8`=1(%">!\$9"!R]`$#>`J2;`#
MN%H)6R`!B0L`'&H)3B`V;S0%.]#$4$#_!SD@`E$``3P@`%>0`SWP`A_*P860
M!BEP9!80!$<4`(09-P9H`2]@!FSP`1+``RWP`.W9!CP``A,95#&@``R0`AZ@
M%!Z``#S@`*6:`/0C`A5B`'K0`Q%P"%*`0?C6`PL0+6CP`AXP`2W0`C\P!#/P
M`F=K"5Y0`BE`!0$0-4K@;A&X!',@`#T1`B^0M1S``RZZ`$&P!D^)!S/@(E*P
M!`:P`S!0`9&<R;2`%$I0!VN``'D@)F?P!;S4!/,[TU=P!IV"!GT0*GMP'#*=
MU,(!!7"0`D``'(#(!&40FHUG"%!@!RC```90)Z<B`AA\:C/M!E[-;"^`*890
M!7C@OPV\&A=Y_U98\`,&`+0,D'LQ$`-!/00>9@`WD`$*T`*7O`4B0`E*@`0I
M<(@#$`3KO'9;UP,F(`4&<``!L`9.,Q3(DP1MT`$'H`@HZ@<KT`,/L`!N$``'
M(%F1XP8M0`*$P`<*\$F&L`!$8`9K@$XE``-/K2@!,`1Z(`&..@`\Q,""A@<'
M``%+H`%!,)8)8`0F4`.,40A=D)LWP@0'(`$BL01)@M2"A`<*L'BM69,$``0;
M$--*/0N`/`Q1$`9L$``(8*8+``!^4`;)P@1.X,B\T`1.D"Q1$`<7YP].<-YO
M4)15\!<_'=X"7@A5D`%DE0?:*RU/P!'CG'IAX`&K>`&`\00.X*L.`/_>FEP!
M,8`$0R`]`_<HY!D#^U8/^TP!AT`%$F`%=98%<L`#J>L!/H`'3&8"9%`%#T<#
M-&!]A#`&''#5.V`X5'`"!\`#'T`/`!`U44"$O4,<$E`##9``4B`!.[!@7(`$
M$LX&(A`#8U<(6?`59O`5)Q`"&X!B?@`&T0,')_`"9Q`%!,`T0F"D)C!&'+`%
M%B#B-G!G7VP!-,`&82#B\$$%<6,$/)<L2Z!"5^2?WV@08R0")YD<8R`!L(9<
M@E()0"L#$#;@I;($2,FN4=`&<9`M_Z&99C#JHU[`$+L(3W`&5B#?F-[JG@$0
M"P`#.P``/OV'4@``_D4`3DD(73!4-(``M6[_!=(QE5WI&<(>`D-`!$)@+K8C
M!A$0#G@@79`B!`5P;U-@`VIT;G%#!010`]UD`C*`!6YP`,:<!T<0`PB;!6/@
M`0L,'&$P`T[C`"+6`$[Q!QIP`N!M!3[`!U80![[A`91'"&Z@5F3``QM`N310
M`P,P!6XP`RH@!_H8!@+0`3R``EDL?'``FT=6!0*``RIPQ1_``5'0`N"Q`EY<
M".H"MV#``R1`5U#`!QA0`$!`/\'!TCG08MMRY`G`!$K0!CTP/:2G!2C0>:V#
M`J`$!7?LZDJ_]$RO&&&P`3G``9/^AUKP`$CP`7P@75^@`37``6\@"U.0FB&@
M!PD\"U1@`<^@`RM0_P#R>PAJP%TA``<#"?4+2@A6<$GOR0-EL#8MH`1H,)5*
M,`=#D`"+,`7CDP(NT`,I\`,*,`AY0`-!8`.EBQ*Z[04`0``24`0A,``2P@1'
M/@$+$"(`F`-%<`(&\``]<`$/4`2)H00/\0)"$`,K``%4QH.+`@$WP$`%4`-F
M30AL4"04\`$F4#(;4`,4T+VUAP.QB9>5E@43</D8@``W``,HL`1B,%7$,@4H
MD`-U@JH*>Z(-T">5A`0!WO3F?_ZNO@1FP`$I``-LP.K#TP45<`(K,`#%OBUO
M0`%UA@>5"@@$*2L(4DI_B(F*BXMA!"5#!S$>7DN*36U&/"HI"@Z6C%,H4/\F
M+F-L/`]5`#<1EF09*R=D37]<$!([,2%P2P8X.#9?B$IG-AM8%#@$&3L,,246
M'D5K'31Q?U)Z(CDY*!)L$2]TBE(`/`Y130P93H>(2Q-%6@$I(AXE*7A/3`,,
M%R%,S/'`H@6-!TX8_0&``\*3$"O\_&$"XL@<`Q@0W.A01LPN+(BN[%!QY<^3
M?&@4JESY!\H1##!C8F`QAJ7-FSASZMS)LZ?/GT"#"AU*E)$2/SUR#'#SKFA.
M,BF(3$A3BYB>`S4N=$ETAH80`F2"@IEQX(`.%'ZH*)IQY5"#`J`63<$1Q,"?
M+SKR,/DSI<(($&^>(`H@:<`62V,T]/"P0<$.#DW_"2_`$F,%*"H%A)1XX(#)
MBA2,Q-QH\\3-B0YJFE:18.++AQ@ID!QP4&9)E0\OW+C8D:8#D0P3B.Q8(<1-
MD`Q-)B"AL$.-PB8.D,1)4^+$%"5?<!#!$,#!D0`/IB`8D0<1DS4'"B!Z@^-#
MW*$47LH\,L"I_?OX\^O?S[\_2R5W:+!""V9`T91_?RA1!@4IP%`(*$KLD8$+
M(=0AV%T6F)`"'57\M(0:!)@PQ`@U4(#%7C!X@4@%<"E4QA$D"':%!RZT$``4
M2U#A``HF3)`%$TM(^(($:!@(@`Y(!%'`.U&\ML<?(7``4B+%$-$&&`"4$,,"
M5EBBA!HQ0##'"B'(@,,*_R[,<04>,7R`0`T5D+'`!T$H`%L,(+"!PP-J_8'%
M`BB<`$`<5O30@!8OS+`""FDH!,8&)8BA)P$&IA$#"]OML0`06#R100QP'"*%
M`2\(\$<3<^RPP%Y.1;&!3!@04!6"M-9JZZVXYFI3``J8(,`6!])JAPT[1"#&
M@?ZDL$9;B-2Q@Q`('`N4'"LH`(0.%IBQ`A>(3-`B(U>P<$,&;$2!B!PTT'"!
M%X=XL0&V;23$1!YV-B!$#0R(D<@7,ZB@!1Q^/$`$`674\@0`(PQ`P`$;"/&"
M$$@88,8`0P"0F1Y_9%$"#RX@H<`("0!P@$2)4$&!`ELXX00.!AS(A!](S,''
M`O\:``&$!3L0\%XB9AP`PA($**"B%&%,H,`/VP4@`!5@R``:(EG`$,,A4(B@
MP(7V!8"##C$1H>O78(<M]M@\/2&'"#%D8(8[MBYAQB,GL&&@>0&(@$,&:0B&
MG04OE("'(3XM4<<$,>B@P!$/7+$$BSO[F4,"4A000@T$=,$$$W)08,()@2F1
MQ0(;F`#!%4Q000,#/)P@A7F37@'1!!+P`!L,#1CTA@LGJ&A%`!_@8((''I21
M`0QN**(%`3CH,0441A0`.")2J+""%A6D$`,.*,QAR!,/Y'!!V@8P<$,(0<S1
M>!,$\"!'%2^T0,823CQ`P,DL!($!%U,$L,,$M2@1``__!*""$L:P`PE,R2E/
M:(`-`J"$%F!``6$AFP0G2,$*(D@*9IB`"S[`!RO<B@EE6(`)0E"`,R0B"F^8
MP`I`$(`.-8$,$7#!!OC`A6#EI`EB@,`*#J"`AFC@6\3H@PF,8(`O,`$+=Q#!
M"BRPAR@X00T1*`$(%M"%)8Q!`"=`0@8VP(,<$$`+Q(A`#/CPA11(0`Q+V`(`
M/F`#&'#``'"(00>R0"4K+.`&5!@#&%8P`14EPET2B,,]5E"##2R%"60X`0K8
MD((3#.!302!""`P@@0TX(`8/((,%8N""$O3!AE?H0`G,<(<4<(".=+#`!BP0
MM!^D(`55@$`/]B`8*!1@!1"(_P(3!+#$/CEE-2YHE"TRH`=66?"8R$RF,G/R
MA#F`@`$AZ-"ME!`'"C#`!5M0Q!/V(`%)LJH)9B#!#DI0O)\HH0TG`\(-A)"`
MIK`A"`,(`\YBP`9$6&$`&SB`!0YQ%`_XP`5::`,/=L""'?0@)>:A00K*@`8B
M%`!KB#`#$LY@!>JL@`[&U`,1Z&"``^#@`#FH00I2LP8A%"`"2.!#&A!@`SO%
M0`@'6,`>;C"'"XF'3@[0PQL.\`4Q],!J'0`C([(C@ECV8`Z':,((&&:!!C`@
M"5^(`@]6L#I$I"!2$YD`#>Z`'S#H8`*^7*98QTI6L48!#QY8(@"F<*L7&L`$
M/P06(O^B@`8"K$`$`3#7$\H010TDP(\]>4(8Q"@$!M"``'WPP`%6$``I."$,
M#D@!"AP0!MO(P1H6T(/*P-"`&RA`!C2071L2@8<2B,`+?;C`"C:`@#,<(@H#
M\$$!*+#:%-0@!QM8@!P(0(,!X`,`81"`EG"P@TXBX`$E,!4BN,`&J=GA"U,P
MZ7NH$($#M&$!&?@!#&B@`AJD@Q%/R`/+M/`I,"P!"B<P`!"0$`(+&"`#<?!#
M"1I`1R501P)MZ4((4L`N^S`A`C@80$+*2N`"&UB"3X``"H*P`&FV;0X?Z($$
MZ%BR`K0@9Q>"0@!0@`,/U.0G3O"#"$8P!`8@[@+=O,#JF-#_!P[@@!>(J$)D
M:0`!)I`@!V<20CL2L8<1(&`))Z"!!6300Q-D```IP$$9%&HN$)F@"!*0``G"
M,(,9F"L1:=``#+[0!"VP0)A4VAP3&A""%KA``GA(Q`ER$(<@>*`"+#B`!&A0
M3X5((`=UX$(/0K`7,9#A"!^XP0%4D*TH7,"DB;@`$1:`"#L4P0(.+HH2,C#*
M`UOZTIBNE1*@H(8,V*`#>;V5$]Q0@1IH8``.GH(=8N$!/T#!)&+@[9$/R),F
M>,$!//C8"PBP!@[4P`-TX(<7"F`"%$1`151@0P8**H0=V````XZ"!FA0!CCD
M8(Y,R$(>#-(@")0!"`NX\A^6D(4,_Q`A"E9X`PT*4))$T.$%$`#`-W*`!$&-
MX2@K(,`>=N"!/5P5!SY(;PD^0``AZ,$,G"@!21222!"X(0$T-A`8<B"`(X2`
M`0<@`!NR\`%J6X(*'I"!',Z[`!L@8%9$40(9AL363+O\Y3!W"GEI`(/RX&H*
M#:!YC14!!Q"\``5ZN,P$3&`"`(B[)Z-*P0U^<-@X:*`$+0#`(1*\@A(08$HL
M&`$/<$"R;)3`!&08`PX:<*`F&"`&7FA"'71@``HC`@`U6,``7KD"&K2@`:_>
MPS(,0(,%S*$%.!""#\R(`PH@8`<)N!`;3B"#$Y"@``C@`1C4K8(7>(#6B0##
MBS_'@_(P8?\+%U!``#`@@6=PP0LM2,$[N(""&DS)`SRP`W[8D+.6Q_SVN,_]
M391`!32@K0-W0#F"G@##NVF/&%18=0Q($(=70^$+'=C%&L*Z$R>``0+.`$()
M*L`'$IA`!`!X0A.Z4(`7;*`%)HBLODXE`!P4P`T#F(`//F`81$!!JWP000EF
M\`*#<B`!<2`!)0``9?8&9T!L*[`",6`"+;`'(:`!ZY=&?@!7<*`%6=`#?G`@
M6N!B;[``)6`$*4`#&Q`#="!\I\);?5`&+;`!66!?-P`!#G```'`$&K``8U``
M-9!X"1(`-L`_?V`&,I`!D484Y28#:=`XNI>$2IA[V*$!(Q0`N3+_!B&7`@4P
M8(B`!A(@"[*'"%OP`2(U`!#%$U/P`"^@`RS`1P$(=38'!3=@`G7@``]0"TQ0
M`$4P`%-@6R:``PQ`!"@P``@7`W+@`B8P!>>Q73Y``S/`*%7F=D[0``U1!DXP
M'ENA"%`@9$]@``V0`RW`)="S`35P!SO`>$<@!!M``V:@$$J@`37`!=HB`N8"
M!1F``0VP`$0@`#_0`%+@`$$``/#@`#L`A7^@-2*`'TJP`2L0!DN8C,J8A%-`
M!R;@`VO@0;?R!'@@`4)0`6,`(52`+CW`!WT"!6F03Q#@6C_1!%FF`PR@`S#`
M!O6@`!HP!`10`QA`''LP!2>``UF0!D"`_P!/L`16P`<[0`0N0&-X<``.D0A,
M8`5!)@5+($I:<"!VT`,!@`8?T`$H(`0>U@1*T`?I@0<L8``(T&R=D`%T0`0=
MX`!#\`6($CL?\&JAD0,<8`XW@`!,L%=9(HMTR`9[4`4;TX)_0`6EZ!Q-``%"
M0`<V%!1+4`9#@!#+V)1.&7-VP'@2\$FX`@<?L%IK$!=*P`8;(`,;T`;\Y`64
ME@+U`11<4`$[``1#8`\#10!;T@(^T`,?DP)78`<\T'6(\`0G(`)=A@`*8(>*
MD`<Q,``%4`(KT`,X(`$V%UL.@#,+4`$PD`/#,0,P@`,)\``[\`9S%0`A0`,H
MP`%^T`$O8$L2UO\0QJ0(^O,`3P`".#`,6K`",E``*8`!$;``'E`%;(!)K%(&
M+Z`!J\-Z,=!N]E$!/#`'I_F4R)F<!+8$7M``._`":/`\M.(Y`V`"@TD%<5$&
MN)8"T7D(6!``*\`#>^"3/:$$5:`')Z``&?`&4Z``"1`%)Q`'!J``AC-?.V``
M5E`53N`!0L!-1"!X!K4&65`%%H`#9D`!-N`';%!Z*T`L*[`#<!`+W)(-??`!
M/``!`:`%9D`$PZ`(HA`#6&"70=`!/.`!01``C?,$FX(&57!5':(&"\`",9``
M)8`!!E`D;T`$GX`(=+`##H`(!*0")B@431(#8*F<2)JD904@+?`"&0#_!KBB
M!'"@`3$0-XM0#R8``FB$"&H0`B\0G\>I$_9%`CB0`@G0`BV@`VOPDPY0`@KP
MIDG``"4P`'+P8@&0`Q[`!+"U`3M@)S/P`;RY`0ZV!1-0`A-@!TO`15:("%_@
M4%50`!`0`ZS%*IJ'`MCW`4*``:5@`M07$K"A!`.``Q.`"%U@F$D0`X5Y!&V0
M!2+``\[Q!T[``32@F?^U`QAS'V1``Q^PJ$K:J[YJ05&P!W9#`J3Q07'`6R$0
M!\\#!7I``C'``5%U*FKP`%[)!E5PE+M7!P\P`RGP`"?P`A3P!5!P!@C0,(4%
M!$&@`000`"]0`+.R.T+P`7"`<RE00U12!CLP_P`AI`$X0"#7L01Q\`(5X`=X
MVCM5-P,%D`=!V`&VJ@:?80(39A1U4`(><`9\T!"'<`'(LP)&$'<B$`%C<%43
MZ@4",EI1@#QEZ13@)`2J^:LN^[(5Y`1Y$`(Q(`)NIVD5^@(J`&;C%@`M4+-"
M]0=HP&$HH)E`@0<B``,;,`$GD`(=@(Q;0`$N(`1!8`(6$#M^,"M+0`$P8)4M
ML$,Y(`+.\003L`,(4*`7T`$I<`"RLP%2(P`2@`-U@`A:T``IX`(98`%X0"9-
M8#<A@`-/`EX&D*]E<%72^`<21@,E``0UP`9,D``\D+)HT`,4D!![Y)OW`04;
M@`.`!;.>^[E@`P4#P/\!,4`!<!"&_K$$`4!;'\"B3`(`&5`#&:`&K\@&:AL"
M=W"M@5-7*:`"%!`")=`!;1`%98``:\L#<JD`+A``8^`%*%`"?B`!,#`'"6`"
M24(#&C!M`B"KH\4$8+``*1`$(C`!9*!#IZ@(;;`##Q`&?0`$9O1S,@",BT`%
M#(L&9!`#*G!T-G!G)8`$(F!'-`",2[``-$"3?\`&5ANF0K$%+7`"<`"Z$!S!
MNL($K1H"">"2MU(`9W(H36$%!M`#+3``5]8$O)0"!K!^/\$'QV`!'?!B`U`2
M:6`]1=`#!\`"B-@!?=`#'Z`(87`"-F``>J`$,3`#0Z4#<H`%PLHR$_H'88#_
MOQ_\`BQP!#R0`B:`A$V#`DI0`#U@<XH0`Q)@`R>0!EH0`CZP?DW0#*?(!(,;
MN$ZA!&;@`P0@P7(\Q[5R4WQ4)-BJ'T^PNB_P`7UPN%30:R8@O*O3!&R`7"1Y
MN+76!Q/0`B%``EG8``62!@GP`D%`7!Q@!B<``MF4"$\P`#2`!WQ0.R4:!QVR
M!'30=P60-BB0%%Z\!@CP`JJ4`G"P!C8P`S)`=HQ`PCFP`&=``O&;"%L0Q']@
M`QH0`7WP!C8@`FRE!'8``Q(`1EWJ`G-K'U,0`3NPIG2\S=R\'U&@`D*`5PK<
M'TI@`$+0`H6@"&.`J1H0:@E"`0PS`#?+$TM0`')&_S-!P`%T,`5-H`<Q$`,\
MQ`-'@`/1^`=54`$*(`=T8@`K@`,*<`,J<`$-,`)T``$^0`[^(P,R4`,]0$].
MV@06T`,,BY>),`4.<`-WP`7;Y6!9,``VMP*KD@`]D+)L4`0>L%PTA[I"804A
MD`/"V<U`'=1#89YY0`#S7"M/P`8>T"9X8'M9`&$K$">OF%@KX`%L($`^8<@J
M)`$>T)D&4`=2D`:7Q`-!8(8Z8%L2\`8OT`$>M`1B@``K(!40,`8D<`(FE`BH
MO&AF0`<_0`(-8D9EH!!=\$I=,`?>94Q7H`(+@`"'<`9A4-<(%044$`-XH`1+
M$`$Y``!(&!1D8`*)(]2@'?_:-M$$53$%87`(5D0%_5A]&DD%6#!@3J"[BJ`$
M;,,23P`B3BK"Q"`%=?!T(G`'"?$$7L`W$E``0Z@337`+-O`!%O`!IG4C6E"=
M+T`$.N`#!C`&0A`!$+4$`P`$G'8!;BN@F5<"$F`-(7`$/V`"*Z`!6+T(<2`#
MB>,``8QR`1`FZQ<&,%`"_<5Q)E`3($T#`I#'0#$QO"K:!B[:&9`!?[`'0)`$
M*:#&1@`$\HL32L`!"-`!0S`$*X`(`U`"06L>P)<34K`'660!&*P$6\"#?TD,
M4Z`'*L``%J#(/`$%<L"?'#``**``!1`%X.@!CB$#0<`",.Y+>4`$<>`;(+`#
M-T#_`X6'!?:\RBG@Y`>@`4(@`$C(!D00C:U73HE`&1M`!B#Q!C?@`"Z)KQS0
M(5N`.T=]X&S>YD1!`1A0`DK`?P3``FP`!!D@!#BP!5Q@&'WP26)0!@&`!7KP
M!>]0!BM@!B_E`*]*!6)`!66P!N?[!Q90`INM$$_D`30``FM@>U``!]M%`F]@
M";9&`;++!P6>$TP0:U[\`"HP"0'P>05``S:0`T#``D.``@60"W&``B[0!DPP
M!0#@`I<,QGFP`_0%O*SQ!C:T!1Y`!&F0JR%@>XC@!'C@``$@0`20F5,W``RV
M%SW*`4/JYN1>[CLQ`4%0`G^P!5,0!SK`*VMK/2R``4GP_P-'8`'U?@1)@-YR
MD"`3``-.H`,_P`"@,.L<8.\_(%1<``3'?1-(G`(,X``'T@7B)01L``I2$``:
MP';CCA/;J`$*H)@2<`-9.05F(`+/8`.C>`%7D&^+V@0]YK@>>>S<``)5M0A7
M0(JB>P-^L#-;0`!.,`=QH)<FL,0J$`2G_0<=50<'0K;8<$X`T.\\T05.D$%#
MR`32M`074.!A0.WF_O7*N`17E0BY-@4F$,46$`2S]`/G,`-'T`(<,`1V``01
MT!+MX00WX-`[L!<&P(=```8*8!<)H@-<59Y.``N]N0<8/`5]L`&6]P8)\5AH
M(P$G5XYN,'0J,`$:X`+`%@5G,/\!*;`#.6`#&3`"*1``PHD`-$`!D'("&#`$
M,T`##1"F2I``[C<%'+`"/'LJ=-`!-_T$:$`#$G`A9``#&4!'6:`")B#C6U`X
M0-`!:(`!0,```LX(#C`#,S@"0O!A!OT#$@`],2#C?T`MU0_VYO]RG=0M+&#<
M-R``^31_>-$%*^#V`[``(S`%-V`74P`$<0P(;D]6.F-_!D0;(TXX!'^/.@B/
MDY25EH]*:1,R)F^5=Q\K)V=*CV(9)2MT2Y>MEFX6+24$&2DE9G]G#RD[.#L_
M.C5S4@LO%*)8$",MPI=-%SM^6!(V8I5+;Q\1;7]L1`91CUPX*E-_8S`F799[
M.GL:2`/_1EY656@$$U^W6`$6`P(@W$R:(<&`""DC]$SZ@$'"HR4"KN`AH*'*
M(R9"U+C:R+&CQX\@0XH<2;*DR9,H4ZI<R?*1BQ)_*ARA\X<,@R@(1@3YH`8(
MEQ<PC@QP,&+*#0-_HO3PT,0%%B\WLOR)D&A1HTDW`JAD4N<%C0:D)C61@V,%
M`BT/P:2@,:$,DY)+TH2P42%!J@5>F'#90`-&#B`LA&Q`(.2"@!XF4)CX<FG+
MAAU;^B#Q4&I2EB\-)BQ@\N2#CW!_E%RX\49)$ST*#%2N=&6%@B$$)&#`@`/!
MD1M'CN@X>F3$D1\_<&"ZP>9/E0^%'N'Y,6+#HRY'*/1F$>/M_Q\+)EIJW\Z]
MN_?OX,.+)^G"!)-?07#442`$"(T@$M(D.?-B!H8!$&Y4.?J'B8@34"1Q@`XG
M/&+``2<L$@0%'J@A!1#KL"1'!BML4`<KCS2QAPHO:&!(:'AH\$(+?IR$A@@P
M;."`!B6$@,8?:E"P@1!'),'##49LL`$!*X1`Q25E\!#"$P4HL`:&CSS1@0<2
M!#`%%ANT4,8D(O0@T!\$]'`'DI5\(400"G```0P$L-!`$E[$4((20%@PPA(W
M/%""`DDJ@,4?;FQP`QY)I?""CH]L$1T+:#C@@T5_#)##:N,UZNBCD$8JZ:2M
MI`&'$@7H*`(67[S`015ZE/'$'4R88?\'`E9<X8<2`USQ"!LO7-'%"R)@N(4=
M8/"A1!M=`%#%`$(TL9T3>RA00P!78*B$$P[<\`(;YBC!1``]"-$JHR$QT8</
M+P1P01`Q"&#%$D[480`+=#CAA!X,+'")$@@HL,<4&01;"11LM+!!!G&LET%E
M7JP`PUM62&""JZY`H,,5"0`AQEM$H#`"%C'`\$>;"C1Q`P0E'/`(%0=`,<43
M?RB@P1][S(;!#7?\(2@%(X3AP`Z(!K`#EY3FK//.//?L<TI2E%#`1TMLT,!W
M>FP0PP9@K$8%`GX^L,5%:$A0@@9VG-2'!!4Z$(()(K31Q`,X/,P!#;A8,L4#
M*_3!10DG2$7_B1(.&$`!'W%`@`0`POZ!!P\BE")&#BK\N-$"291!@+,H=*$#
M`0M7?'$'&1]E`IW]C7!&!BTTH<`#4ECA00LC\&#-&$=8<(/,/%@AQ1\7V/#S
M[+37;OOMCEYA>$=*:&'==Q#I8`,;B":IN@1FO![:&@>4$(`5)\5!!`X!0,`#
M$B5$,44(*!0_2;DTK`"J#NY2HD43#N``PQ142(!#95$XD$08?RP!`!#%=51%
M"1C\8```L^E!'I!@A10X1P$5V`$3D%``%`CG$4BX0!2.@`$%9(&!CP@!"!Z1
M!188H`A<*$`)!O@'%5``=RA,H0I7R,*0A($/4\!9>)K@AU!HX`R__Y,"`F#P
M`@^,H3)Z<!\(\/`[D2RA#R`PP0;(\!8J6(`&)$A#%:1P!3N(8`4N6,,3,D`#
M,JRF"7#80`1"0"HOT$`$AL/""TS@A/YDP`97\H@3`*`1)9Q!#E-H0A64((4?
M68$)/\)"$T0VB1"48`E>"$`XMM#&/T`!"I/H0A.HL"PI,&$,6#C`G5K(R4YZ
M\I,[PX((2F``./2M44YXPP1H(($[0(^#?B"!#1K0!G-`(0X$\-0>]D@2;1F@
M1WO`@A3H0(`-E$`&,D@!`020A3I(``5IF-L>,K4!/4QA#SR80#AVU0(+K$,,
M(8`!&!Y%!Q#L;B0"X``HU\G.=KJS)5Q8P/\*>*`:2$D!(#O(P"8_EBD<5``T
M3```"(3DA9,$X`,Q2`$:BO@(,L1@!Q`@&26H@((%%$`J&\`!8_J#@!P,X!%Q
M\,$#L#4>)I`4)"9]ITI7RM*65L(+")!`"AR0!H:&!PIRD),(7#D)+>B!`R:8
M`!JDH(0HR($`)LB`KTH"A3<8X`0PR,`$#&"`#IQ@1TRT!!8\4(<H@$$"*DA#
M*;#0@1CT08\SFP-H5J*$`/#)I7"-JUSG6A([H`(%:)!A>*Q@`!.4P`+>XT(&
M8F""/%@G"A!(00HH8-.04.$.<X#```*PSW=IX0EG`%QEPE"A-D;!+\IKB09B
MT#*ZFO:TJ*7K$KK_D(`6P,`!;CCE>*K0!Q+$0`1QV-T6`A`"&1C`#)YE`P%H
MT($]A/8[5%@`#P#01B7L(081B((2^B`#`J"%)4K`0PHD<-W4>O>[X&TG`%:P
M`A&0(5);0`$-4)"'4RKA"S"(P0?DT,@I@"`'(4``)+T3A1#X($).0``#/KH$
M-@3!`MN!@Q`RT-CP.OC!$)X=$]Q0`!><`"\-[HX2KA`'#I3@`=":Q!@$$((4
M&,`.K+@F!V)@`3J8HR5*8(,-*'#=+LP@!6500A9$\`(TR#8E5"BK'3(<X2(;
M^<B.<L(:<)`"J45*#"U@)1M^IP0SR(!68GV$%S1``PVD:R5+V$,/D-+0_Q5H
MP!QC.($+7LR2*:"@!FE#LISG3&?P,*$,$!C"!E[YJ"NP80<'D,,IEY`%`!R`
M!QM50A7N4(,(JJ0!(XC#),XP@@*PH@D]:(!$69(%(73@N'4.M:A';1(G0(`3
M$ZCL>.*R@1=(H`^-K!\;3%`##22Z#A^@P0;D4)(NF``&AHO"`PZ`"R<4B0_;
MN8`/AD;J9CO[V1V1P@`^D`,"4!)2<&A`#5[PA5-&@0TDV$$(Q,"*]QJ@!"40
M=$C2\`)]/D(**<C!.)=0KSB<U"1+,,`.`J!7:/O[WZ2NP@1>0$I0CP</)>AR
M'5;CA#FDP`0/N-)TK:8!,_1[$D3:01XFX8=OM/^1##;(P'Y9`H<5M."<`$^Y
MRD7=A0:4X`4&>,*]O4,L"FT@+Y.(0@%"T.X?AH8-7-R`&5):"3Z&``=W*,42
MZ+"#"(@#!Q(@\DB4X`4<?,![*\^ZUN5\A5QN@`\_%H\2XE`"$X!@G&)!P`IF
M4($(H4RQ&I@``N(@AP%0X`0T.-+'E'8&1U*`V-IA@@=Z<-ZM&_[P1Y89#$J`
M@&L[2@IZT,`*/O"%6%-A`"AX`0'&P`HF%*H#&>!`!D0@=\,I(0PVV``7_F`%
M9A2>)5&0P+,03_O:0[@.*1`"`;X@=>X\P0%("`&R**&D`V3`#P8O^@!VL`!A
ME0$'&=BT2G9%.-M;__K_W\7#`UJ0`@%@X>+=D4(>-)#4-(P\"PN(;P/*0(5-
M*^$)/CW!#`*PK`'08`$S)XD3$K`#`X`?^P`8@.]D!SA``P;`!;VW'4^P."@@
M!WSV!U?P`<TC`@,P!P"0`!R@`#PP!Z7P!!2@`*^W$E#@`2/P@`)X@BCX3G%Q
M;BFP2_G''5,``.IE`6<0:T]`!@$P``50`),5!DKW?"$P-2WQ!2L@`2.7@DB8
MA*#$!&"0`%WC<XZ"!79@`2O@`7>0?'/#!S)@`7*S$M/R`H"EA&(XAI[$!&]`
M`D*0`@C39P.0`@HP`6Q6"6:0"G3P@B+Q!/JF%62XAWRH0DQ8`#F@`6O0A8U2
M_P5Q``(RH`$/X```4#TD<&,+H&HD$0:GI`4;L`)A\']]N(F<2"E+<`<<0`0?
M((GBX01IL`<)@`"J&`!AD1)V,`)(\`AOD&E'V(FV>(LZ<X._A`((0(B1\@1K
M=1)3H`"S`7,U4`!AAXO*N(R/H@5()33)"!Y%]0=?D`(#$(<DT0$J@P&$PHS>
M^(V0T@1B@`)(T`%=H(DK@05=UA]AT`(,T``X-Q(#L(VS@6#@>(_X"!Y>0`$U
MX`)Y@(Y:$P0$X#U:<$5"DX"3P`9#0(_]0P$`F8\0&9$>`05D@`,*``%68(<C
MT00$P`!N0%+O5P8MH`,&D"P=007$R)!'H`(/*9$N^?^2EO`%904#=_!C3P``
M)O@15X`"+J`1''$&)$!P^.<*3'`"#*E[M0B32KF4'($%=)`#0C`'OO,(";`R
M;N<12P`&09`!L=814'`'*G``"\`%.*,$!/`#VZ@#`9"43-F6;FD);2!Y,S!T
M:(D!0U!/'F$`/L`W)%&0)9`""'!*=E"70W`"!?66B)F8EL`$;=``*8`$V_@#
M'X!R:D,!,:`'+5ET9V``,X`#?+`%8L`#_=,!GJ"8IGF:CW`&.L"0@-<*6K`#
M'!",*'$&%I`".L`"ZH::NIF82Z`!%,20.G`!V.($?Z9-@?<%FW`"!3`&T;B;
MS@F159"2#%F/L;8$%(`$I>F1'7*0`N45@L_YG?E(0PL@`C0P!'6I,D>``[PV
M!AMP`G`@'DM@!A%0`BU0`)0)GO@)CJN%`">@`#CR`RRP`#@0`I$2`"_P4?F9
MH!+I!%L@!R4P`@.`D-NQ!-*GH!8*CE3``>JAD1?:H1>J!40@`;[HH21:HDRP
>!CG@`,U9HBR:H`NP;"T:HQXJ!2UP`CDIHXD9"``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>f39432orf3943222.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432orf3943222.gif
M1TE&.#EA_@$B`<08`,#`P("`@$!`0"@H*%%14?#P\-#0T*"@H````.#@X&!@
M8'!P<'EY>9"0D+"PL%!04#`P,!`0$"`@(!04%#P\/`H*"AX>'J*BHO___P``
M`````````````````````````"'Y!`$``!@`+`````#^`2(!``7_(":.9&F>
M:*JN;.N^<"S/=&W?>*[O?.__O,3((,0D#"5`0404'8'0J'1*K5JOV*PVZI"(
M&@V%P:``CQ2.1P$L)INW\+A\3J_;[W4`1/3`%!0*2WU&"Q@.!WU_@1B#>(Z/
MD)&2DY0^`B*7&`*9F0`!&)Z<G",%`*:5J*FJJZRM/9F)@().A8>QBXTC`*Z\
MO;Z_P(Z9;&-E#1@'&&AJQ&['2<'1TM/4U3)(3$5/&)^@2QA-1MC0UN7FY^C4
MXS"[Z>[O\/'`[?+U]O?X<O3Y_/W^_S7V`1Q(L.`_@083*EQH#B'#AQ`CKG(H
ML:+%BW,H8MS(L>,/C1Y#BASI`B3)DRA)_YI,R;*EQ94N8\HT"'.FS9OX:N+<
MR1.=SIY`@P;[*;2H455$CRI=ZB@ITZ=0MSB-2K5JE*E6LVK%@76KUZ\EP8H=
MJZ,KV;-@S:)=FU4MV[=0W<*=>U0NW;M`[>+=>U,OW[\N_0(>?%(PX<,>#2->
M?%$QX\<0'4.>G%`RY<L`+6/>G$\SY\_R/(,>G4XTZ=/63*->'4TUZ]>]7,.>
M/9&V;8*R;^OF44K$@0;?C`38M289,N`F<N^&G&#0@4W&D6V"T.>!`#48)&Q:
M]P*`@$\.&A@HQ.=/@@4&&C@(/S[Y\O<QGH_29$)!@M^&#'BZL7_0(`.?`-"`
M?_Z18HIR\"V6"?\2!62BRR<//`>>`@(\,\-^\^T7"B;SD8!@@H<YZ(``W&%7
M(08+.`"``RA&%\-^"P@QR!_(I$%(C(RX!^*.*F12A@EDB&"?(>HM$1X-^Q7P
M@`*[%-+``@J`HH`:2C*I(X]8EG!)`A`$X"6*7SQCP'<"%#!B``(4H8.%[&3I
MYA!^'+@+-@D$5\HWO?407)MO]NG+AWX&:@.@@A;ZHJ$)RO<`BP:X"$XRW(%)
M!Z&(CC6<'P\HH:8(!0CAX`B?QD%II6!=:@23GZ!IG2<'1'#`<P\4$BH<HY+J
ME:F:>))`E`D(@"$R(NPQJU2V[F;JKI[LE^LGEP2@0`!>#*M%K<5F=:G_DJ9`
M:*:OS&*P1P+1YE'M;8HR"ND##9"8S`('G/DJ>1F-NZ.O;TQ"K;Q@)1``BY7<
MBV^A_OX;:,`",P4``IO68,">5!!<L%*`B"F.$:`(D8`0!40JP@)L-OSP:PUR
MB0F3`I`<P`+H18G?"0(@X'(W4SC\L5`',"F!ITN4"<Z*E^SQ0,(D9,SP53.O
M]IVSLF+BAP`'>(=!`XBDT,5U0`,A<]$\-<=IN/09D&D#$'0J@:,D^'IT%5=C
MC9-^(QQ0@''&Z>J`$'ND@*8$$(B6MMI4+0`S"@X$H+'5?"<(D@%Y"_@WT87/
MAAX,"T2PB:]H-[[1@4-?`PGE,"R\L!5[6PY$_Z8H7L=P`Y^,R30)$GBYN@WP
MXL'Y"U/_7+GH\H!M2BU_(\[L$G4K'>S;7R0`P&]+>,)B`N'-'8`0R11WQ^PN
MF/VEQ[C#,]ZEWT$P#K;@Q9J+@\/M008`$H0G1J8!-`!`!&DP*:PF#OQ8!_4M
MW)WW[=FGHV0!PVF0XLZ@GU2Y3V?"XX;R%I`MI07N`<-)U2XNP2T_#$X+^&M!
MX"[H@]#U#P>JPQOJ$CB=L64"5P[Z%H5`T0VF!:`4$50@?4A4".;9(8,K4-WK
M8O9!>'`O`(N2%`L-`<%/M0Y-QOG.$.D'00KMAWOT>18.MS#%%'S'%%7[2`_?
M42<1*($)I-`&=S!W!O^,%0$)3UB8Q9:`!&Q\[H9$.<!P`)#%#F[Q(BB;1A51
ML`#M[%`*'KRC2_9X`BM=(9""9`DAZ^-'LA$ND0`!(#P660+]8)%_D.Q'`]+W
M#DHR`663<Z06,^D/ID4)15#C6+M*IA](=6P5GK2@)>F(25+>(TA>R)4NH]2@
M`NPA1;V()3@2-T+LV1(??12`J^C#S#`LX!+VD58JA!FYR>GMF/FHF]>8>8GV
M-,@0"HA=*X0)CBP@$IL\<`"\)/!-^BB)3$B(0!U10<X#N`P!BX/".=&Y!275
M0P#\`AT_'T*B>GCIDB[X&P`X=J.-X8@<`V7-,Z'3@EU]J@^""X2`W$<CB$;_
MM!_Y1$4IY$32DIHT<X?@H`D<I"$T<2B!(]WG1X&``%<`H`(#R*E.=\K3GE8`
M(4"\CDY8&B"7:J)#NIBI/VK:"@`,X`)0C:I4ITK5`2#$>B%%P46Y0892@$$)
MI_204OO!5%8XE:IH3:M53>"`"$3@9B\@3Q\6>HSSD`=E0)/I6'E0UHD\-:V`
MC>I:39`G&8AR!7K=JP[ZBI2_!A:P@VT;1L7).,7:@[&I..MC(2N0".R"2P$%
MI&7O@5E4:':S:(TL.,B753O>\8LDN-@(MB$"+]EVGM,H;;\<B]JIJC8[PVD5
M;G>06,8T"$WC<)8"D@'$/'I1#Z;(G#5T2XG3]E:J_[\]3\E,4UR)'(\$:>A&
M_+ZA.LE)LPKM"1RH^,#,T#(3'`]X`!(`(09#L/*H`J`L*JAK+]Y>%ZJ_)19B
M"M`Z4J@A/+U4UGIU8<8WWBE."-7!)N2Y8`D`(+X0<%0F?%D`#LM3:[S<<$%;
MP5])6/>_%PCPM!:S*)@IBVE@()N(@=@T"3R3CM]9E+X"`+\=:"U(OIF.T]XK
M/&4-9Q3.]-%A*5'B2)SXORI.J4`/LR\%"_"9:**KEKY@G+P5XG\%[,;U=.#-
M1D0O$$AE9J\P`2Y,>?,2?NM%DR'QY.L&.*BD,^9@)`>!L<UV7ZI,H/#V%2QE
M96I1(ZR9#YXI7_H@HJ#/V?]?V20;H>Q89V'602("-J'?2LSY$77N;8"Q6LO!
M:*A.OF)2KQ:J82?0BX'I0P/J```(`\"/EI$XKR\^W13_0ADA;7WK<,O"&.-5
MS`CN<P*A2Q"=!*@'%.QJ!_+<9UN9=1H8O,9#J%&KXL+J>3<*ADJV[[#MS08X
MB(=,4*<<40CYY-</:'HH.L9MAW(_-L`*,.^2>=!=TC1K'P`%1R[G;5-?VQDA
MLQQV#OH]DG4GW`E7^S<IPOK&<]`[#P87-<(G]\I'C@9#U491$?<=AV9!`#KA
M=L?%)Y5Q;B,$7?F])FE^-813=O01$G="6`67CI5GI.7F1LBSNM3:'C!<)"#W
MDK/_]Y9S3.QBR`1O*M#OC9"W/4?A7#D-AC"'*Y7&H=WK`&!^I4L-G^MCZH$-
ML!P/6NK-T)P)-A]X+Q8QW8*C&+L(63L$W*M/K7>+!(`(@/>`H8"PU5WJ=Q>L
M1@)`<F*3QN&$/;HR).#U<=H]\2E&R$1[_.W1UB<"E;>)O=..<%.$?N&>7P&/
M3Q^3T7/6!!.=7.=/,V9KM(KU+7&]6H$JOZ;-GC2UMSWH4^'NR1G_^,C?#IW1
M_GHML2C.OQ]-\(6/>S@$@`(,R+[VM\_][EN`8+I/+;`E1^'H@V;ZPF_\'`)`
M`,QG?OGN5[&^L)YUV*#?]@A0?QS8'W_P,W_W)?`LT`)7_^;W&?>7&LLD"?R'
M>2K&<OU'`HB3'9Y0=/PV&P=H#;:F?UJP@(G7@#_W@$,``0E04_;#0_9'@=60
M@9'`@7?G@6<'@F>`3WI`=D9G@2B8@@GH""R(8BXH*O\G?I-B@_9@:V%U!SOX
M:_#'@)0B>2AQ@>=`A#K8?DJ8A!VXA$)X#UQ2A'1PA`='A2WX<GPG6B>8#[ZD
MA7+`A1KGA3PH=/K6=L!W@^=0AG:`ABZGADA820="?X-RA60(`6:X!708=';8
MA95T<@M`@Q4XAOW@2X9WAE)8A8.8AB6P*/G5<:/T&DX(#XR(B%,0B%07B748
M@`M`'1JXAXKH#W_0B(#XB%\(BO^"6`(%\$R6>(FLD8GR4'B<"`6>2'JN^(FP
M2"%PB'JG"!"XN(HPJ&T_6%5"UWLUP$!20B5+@A!,2`7>1B3?$#AJ$GM_1`FV
M6`_%F`6[V'R]=HQ"\GREV#:4TP=V)2-7`A$20@('D")]4#-Z4`*XD@K=:%"Y
MZ`/A"("@EHR^Q88MLPDT`$5'!5,'4A'I\3<G-":ED#"FHCJRDFG2$2NE`P$1
M8'W!6`XFU9$=J8?YPXIKV(N\B(=R4I"[0"#LY5&1\3=B($`2$$ZA8BJ&QWAI
MH@SW$2PC,'B`N)'3U5-`&903X),A28[U!I!X!P27@A[JP1Z4-8TQ\S=_$%]M
MAB+K8"K_G6!4$?0LN;1<^T>49>=^!`"6JB>2=SB.4_@1&`,UOH$<+/D0RH($
MXO%-\O4_)("52)`I`/5-W^(%)W.&9"D-"""6@6DW9DF(:`F))7`?-;./]2<1
MC;(Q?K``C?8'^',`V!"+050AC>8NQ:>1_#"8F#>6_'B8DIB8K3B)7=`^;G@3
MN@:8H4F8I6F4&&>4$9(^A<DG07&.5Y"/Y2":B4>:/="/0/B/1CDF]0.22,*'
MI"6;PVF:H8B:(YD$CNEXB@0*?G0)E@E!D^";T^6</$"<RDB2XC@"D1,AU6F*
MUQEN:,`'83B'N8EMX+D#XAF0Y.F/L+@`+G-MB;B>3`(`>8F/__'Y"\!Y=\(9
MGM#YBM)YEN:)`.AI=MTQ2*!P-,GPFO`9FZ,YH/:8H+ZXH(BI"^GYF"EQ">&&
M0/4":E`9`P6*8@=*GQQ:DAYZFD/`<:T9$B3Z-VEP/#J3`,,7%2OZ7RVJ`_69
ME,:9EB0`<\Y8@!V1#,8&@5`3')L4HC/QH]<5I#DPI(IWG\4)>(+GG0&Q%-_(
M%%3:6U:*`U@*8/YGE%9WDTJ*$]>!!2US3W(ZIW1Z3Q9*H/,II"]:GN2&E%FZ
MF*]"=R:H%')H!0+``)C'`'>Z:WEZI7N*G\AHFZLYBS7(%`40`93Z"HB:>(K:
M<XUJIH^ZI9%JI"-PF^K5ICNA@E1PJ/^)NJAR]JDW<*;O5Z2*"8$`-22HNA/O
M4WTSP*J<ZJJ\,*:H5::Q&JKC2:NI25C*N9Q1<7M3X*MWUZGS!JLV(*L]2"M^
MBJ8F,"`/8&$U6A2C**4P`*TH)JT61ZTU8*UI2JI*@P`IUW=5$:8_0*[_9:[F
M(*R;1:S5:JSVB:S3>9<QR2[?:A1^&`7T>EWV^IOH6I#\2J0Q&IT>\F"Y"A2^
MQ)\W<+"]E;#?F:&SR:Y'29OC46`3:P/M%#2YQ&CB:@ZJ:@F;&JW`Z@KX^ECZ
MFJX-^Z</JZ"3*0%NE:G]&05CDI$!Z`4+90@:.@VV]IX7V[+E^K(DMK`SH*Y:
M>JQ>A`#1Q%W_AEH"ZL$)@L>KZ>"LFMJJGLJQSTF;#LBN]1,!5+NL,F`:GQ(D
MVDDO14L-PO6UOQJVP1FWM56SVNJO#`I>)2B&JPJ/$U9!1$80\HH#&(M:&EL-
M,1M8,\NP9/N!'KMB59`)F+E@.8:T_F`=/)"XF[6X82FV"!JY+SBYYF0%=!(<
MXP!;"E&H.>"YCP6ZN>6T,@"U?/NAM#(6!*:AL!M8LBN8M!L#MGNS'2HJ9+&R
M-M"[@/6[T="X@/6X3ZNWLTJ\,&J\0%!\%FL1!N"NB*NT]<JTK."\:06]M2N]
MURH5V3J]UJM/>/L/7EL#RIM6S!L,XHM6Y"N\YKNNM;J^5M,-[Z0&_VCRIJH3
M"/*!`%S[#M"2LIK@O0@+OJM0OU1UOS`PO*.ZO[E[%=U@);3&>,C0-$*0I`S%
M$(<[K@R<L0ZL"A`\51+\`A3<IZ0[9>Q+0I>B/$6T"XH&$6]*`_&+5O,KGZ+K
MHB^,K4$\LFLK9L>`.G\I!F6"+?48$:X;`SM,53V,IS^LIT,\+>E[OH,*!)'Y
M!2=R,D'D-4P"2LKW$)?*FU$\55/,J%7LJ%=L3EELA1N8HEN`O-53PHI[PJF0
MPE*UP@F5OU';K_H@%6IK$&V%>VDL56O\JFT,JF^,!>$GM?S[%G/[`HD<58L<
MK,$[P8!\NS)ZP5&)7ZLS(O>5&%",QY^KQ__[M<DLW,G4RZ<"%LJ?TBML%#QP
MZ9&XG(>@@LJQJ\J>QLI__,B'%,=!V##,@CGM@A$($)3,O%-#N<M@.ZV-7*S"
M##K$'"_&K`FW=8\2P<=1=:"7#%69#+/`7)2F*[D6_`/J5272B#9_)P*GFAW=
M#)[A?`'CW+33O*_5C#;7K$_/@B+L^);]6[A,<V&\V9RB6\_W'+[ES`(M_+'G
M3%Q_YR`Q-06(8&R.8B8\-\\)S<N^Z\M,UM!EN<\-T\\Q7"`"S0/;>\`)X<U0
M!<X>O;P@/0DN?0%^;,[I7)L171;@(1Y/&04\>M`+4=,P'<WGFL\T2](Q8])`
MT*3(TXYZ`@'9J\S_]!S3\CO3DD#4[?O0.IW3ISLZ6#T06@W-=2O-=]NQ7HW.
MR3K).Q"N+3'6F&#5/!S6D`#7H[O30HS71-P"[YL2=JW0=/T(=@W$>HW%2MVS
M9.99,?'7<BW%@>T(@VW%A0W'ATU<>I*#;UW51GVO(JT"7%VV:9UN._#$F=W1
MFZVP2`VYDPW)3!W+.5!X-L'8I[VQ9SVVJSW,E6V=9LI.L:W997W4M7W7H>V#
MN2V,.'#(-R';O\W9J1V]Q?T1K4VY-W"T.*'<+FNW!KK5KES!:PW*-4!@/'L2
MUKVTV,VBVOW<'13=7VT#!;L3X_V]Y0VDYWW;UHS>ZDD#L,T3[]W`\5VE__,]
MW'D-X'L]`@T0`0J\$?MMPOU-IO_=W1`MX%O\(CVJW[Y]W6:=W6CMX%VMX>L=
M`W9<W15.WA=NWAG^K]QMXM[]`K[4OAP=W("]X,/:X"C^X!P.R;WZAR!NVLN-
MVL%-V!!.V?1-BRXPPNX=XO`]XO)=XGU+XS,NW2Y0R4*1X'D,X_DJXTN^X4W>
MX2QP,"P]$E*>RE0NLU:.NTQ^Y5JN`D&M%%_>RV'NN&/^R65.YDZN`A6[%&O^
MT6W^O&\.L2X<Y*[%`O$EID;.WTCNWTHNYZ!=XZ*]`G]PX.(]Z`I>Z`Q^Z'".
MY69NXV1QYS*=Y^.[YSC;YS]>66*AZ5?-Z?;KZ?_%"^J*+E#)U^JM+M0<0>IS
M;>H1C.K5J^I9;N,(T'V\WNL4P.(,(>N.3>LJ;.NP;.F(KNN='>N0/N62'N.4
MSN=Q7NFG&]F]K>,6#MP8;MNACMM^7H/6/J7-#N;/7N71_NG3+NTK%NXR(>QJ
M_-AXP.[Z_.V`I-[*WMQ^/>YL7NYB?NZIGN[HON[+CN#ZCN?\[N;^?NL`_^\"
MC^\HX>Z*#.]W(.])3>]78>_I1O&E[>*-_>[$WL?&#JFX?ND9/_!4C>TBKNTD
MSNVK'N`M[S$:SQ(0C\D2;P<Q7[[VS6\8+U`W__`%O^D'K^<)?^R)GNLE[_"/
MCO)'KO))SO)&3]P63VS_/9_T'#_;C&OR)O#9:OWTE3/U)#'SXESS=>#UP1SU
M5K/S78_U%@'V]BSV=$#V./WRAFWV,%`UNP#W(<'V"_W`:G^7VSWRR>X#;S,L
M=]_W+;[M"VSUH=OCDMWM]4WW+5`*GS)2[H,`!'#YF)_YFK_Y`_"?N?SYH!_Z
MHC_ZI%_ZIF\*EK_YJJ_ZG7\@$$`!JQ_[F$\!B7/ZMG_[IY_ZLA_[K8_[):4`
M`[#[LC\![N/[QE]2#3`!PA_[Q,^ZSWH"<A']NGW?_#']7VK<U8_]V2^BU'_]
MW._]WP\%A&_]S!K^%V+9V@_^W5_^VV_^:TO^YY_^[-_^4C`LCLXI.G#_?I#_
M_Z,-`I@XDJ59%J>ZBBG[DBX,RS-;VRN>FSL?_W1!E6]8-`Z3AB2SZ7Q"H](I
MM6J]8K/:+;?K_8+#XC&Y;#ZCT^HUN^U^P^/9PE%NKR;N^KTIS^?YZ3D$*"R5
M``#\*38!!&`<8#@F%2R40"YB45J2)2PH)))(8F(T$.Z(WET&'#0L%`P&@([.
MOE`&)`@D/*P.$6(4!+@*R-)&^1H$W.:.00*S(K?20B(N\#8T//PE%`84(#H>
M$!>/CR@`1V)4HO(X(ALDK),[.38X&)R3&>1V-Z0H%`,PI\Z``PS_]@3,X^@;
M!D3R'AH,L`]=/!N.O"T8!!&*HP0.%,`C`RH9J105^?^4,AF)(+H]"I(U:@B@
MU*>-#QTM"'D21L=J,\79_.%HD*N<8QPL6(`,0R=?LP0DTYE.8M"J5J]BS:IU
M*]>N7K^R\18(K#8`=7(`,$2V%H"Q9]+:3&"6EH%/O%A<6IOF0*Q"+_*>**#`
MP8%*>,'6;03XQ.(K@@D;7M%8#M^`:E5,5B,*W"-2`>RMRL6WX(+,>K=L-K#D
M`+)NK`X(*%#*`*M`!_S<A@2I%&@`PT:G,WUS!.?=GY'!3@"\=)7;(G)WYAU\
M6*,&P>-LAJ2ZM>Q8^UPW<%MF,T69"P`4O`4)Y^DQFQT&4-V@D4GGR6J(8K@0
MP/GTRM%%=A5YCNS77R3_L5?_17XQ%9A.>;<%Z,9F^\G'GP@D*=?-&MV\HLZ!
ML9R72%\D[=1>%I48T`A\]<PG23+)\%6"`XGP=<XM(,(7$(E:<8@41?#PE^-+
M!%HQXR/=$`BDAXY`=:,<*#:R'XLQ13(DE6H()M$_+X&D`#;AI-.4AR:"45<`
M$(0WY(LD8?!`)Z7%$\P#L7&YS9>)S%?-F%AE*<"6A-CY`)@YZ=F2@@O,"8Q$
M@88T'TWXP&$FFDC9M:8(#PS"#1QGD;D&IS9\JE>H7HRJ2*F=HIJJJJNRVJJK
MK\*:23#W!&`=,-;!$FL7N2)3T"!+#&)=+;-Z1D>M(OQ'%C!*W?K+L7R52,6R
M2Z34_ZP!U8AG!Z^?8?!KM]S*T<]4W@Q"[E!`Z:I@MQ8ZZ6&$)XB;D5GWH3?5
M6O%V@UZ^&GT1[XR*DNO0(N>J$Y*'PJT1Y84N_F)4NEI0$I**+35P$`P*1^)B
M?-%FA3&;$IGRA<<:*^"7J3DM%$LD_($KQTOH=/?+?`]<]K`5`-",#F'IT>$@
M#"^+2Y)L$"RZULL7E2*S"`)S`;1)2!.G",Y+#'5`>@"L9P<K:1%V2]>Z('*J
MS3P\$#:(Z=!WGL62S??.*@Y\?>%:6Q/$ET=V#^9*%W3#8_77J\RG2-GS6GB>
M(Y^\VX9<<+TC0N.(S#7VS6$WE((WR*+;!R)+)&!(X\BNM2CX$I]_'CD7HC/E
@N1^?_P%Y"G-=_HOIDM->N^VWXYZ[[KOSWKOO$(4``#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>f39432orf3943219.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432orf3943219.gif
M1TE&.#EAA@(C`^9_`/;V]G!P<&9F9FEI:1`0$.KJZO+R\EE96=S<W.SL[/3T
M]%!04````&UM;>;FYC`P,`L+"U5554E)2?CX^-+2TB`@(#\_/]G9V=C8V,K*
MRDU-3;*RLK:VMN3DY,;&QM34U(J*BCDY.>CHZ$5%1:BHJ+2TM*:FIL+"PM;6
MULS,S.+BXA86%KJZNB8F)BDI*:RLK+BXN):6EJJJJJ2DI/KZ^IF9F34U-924
ME,C(R'IZ>I*2DIR<G+R\O**BHL3$Q"TM+8*"@AD9&79V=IJ:FG)R<HV-C7Q\
M?(6%A6QL;(>'AUQ<7!T='7AX>'1T=(B(B&-C8TQ,3%)24D)"0C(R,BPL+#P\
M/!L;&R,C(X"`@,#`P$!`0*"@H/#P\&!@8.#@X-#0T+"PL._O[Y"0D%]?7Y^?
MG[^_OW]_?]_?W\_/SX^/CZ^OK_[^_OS\_-[>WOW]_:ZNKN'AX9Z>GL[.SGY^
M?HZ.CN[N[H&!@5Y>7I&1D6%A8<'!P;Z^OK&QL='1T?_______R'Y!`$``'\`
M+`````"&`B,#``?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH:*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PH9?"UI@CER+6UZ(
M7EN;65F)7&+0P]C9VMO<W=M?#%T!!,B,#XM:TX=96IM86(E=%6+>]?;W^/GZ
MEUKT?UOG&#%`I\X0.W?P$*7;Q["APX<0>W$9.,A?``9:E`7`0N`!EXOMM'3I
M\@>DLH6#+E;XPDX+`VA<7*XLR='C'RU8P@G:0F#FNY@,9N[L^.5+!0+0O@2H
M<"VBTZ=0HTIM=+#0E@I@1-Y\D&7>%@;PP'ZYFI4DRG_DQ'!E(`9+A9+I_[HL
MV-J57C@P#+YX2?OVG=HL8D@*ZMK%2X4`7[UD80"FV=3'D"-+ME>5T`)H>V\B
M>_>'(@-EE_]D/MOE&I@L`0=F:995\Q_.GV]FV;)`VH,O[[#<%DTHG5%!7<2@
MGDR\N/'CMBH/0CEP(6Q!%)G+7EZPZD`N\C!.?RX[)X/O67Y6"%I.4+JJ[Y0C
M7\^^O7M-%`7=ENX\+'3SZIH71*FX7><_<H&Q14C3<)<.9X,@"$87!/0FC7_I
M^??>A!16:.$@"_B318,!D`30=O;]5Y*'YYS5H6@$6.<:%@2^%F(Z8+SUQP)>
MO+,%/!,Y.%$S6*EWX8]`!BG58N(00,]>#S`&XO\?'8F(I))G(4D`%BK61$"+
M!D[S0`45M//.7EH<YF!)/9WCHY!HIJDF9<8T5:,ZS/PAC9SP)"0:E3LY)DB-
MF%V3D!ABU/A/,W,F%&<U8B@S)Y]6.;9%HJ(UM>:DE%9JZ:689JHI9,]HHDPC
MBA:TZ:BDEJK-F9,$M`@8\&PAJ:FPQBIK+:A*$I\B",ZJZZZ\?D*C(#3RQ$``
M<AZ3$*M`$4N(L,KRA!1(-PD2P!<E,8"444RYBM9,-QY%;:_@ABLN</08-=$6
M8!#`DA:9S;C%2*@U=6ZZ>K&5KAA@B0@C5F(0X(46!V+AQ4M+O4;.`G.-J_#"
ML-+V1V!<E,/503/YVZ/_&`G_$;%\LPF618[ZKC9-CISY)=A*6!!;*\,LMXPF
M%PTN@$Q6X!T4@!A?G//==Q+^03,#X=DI8G0%)CE0R;GAQ]G*+C?M](1<$<#%
M7L*=UTY68A![ZR!4LQ/TGD/C!]`6X+CH(H(!%_OTVFQ3R&([P\'\('0+/0!-
M%LK*>8[<,0JRDF=>R)VRG$?7B47?`W.Q=,]M-^ZX9.#0`_,#!*18U0(-^HP1
MT(-,7KF67+;39)@/3(P1`0/U>R,\6Q)`[.*/QR[[5`(+@EL6IW4J9U/AB?K'
M[:=I#*BB.&(Q%FL"!UJ--"-;,]@TNL\N_?345V_]]=AGK_WVW'?O_?>T?"L:
M__/DE^\[^.BGCXUB@+W31>UWVLBU^?0/$C0636VQ$1;"K:;^_P`<1!?.\HG]
M;:1_>DH%2]IGP/($<'L!`!C`7/6J2$QK$Q=$!(O$]QXP%083^MO(^7X1@!+"
M[X'3$TENOE8)`O)CA+^;TH5*TY4`?&H17`#,`1U2HYO!$(4N(R""O,!!12@&
M/WH9!$L(D4,FBNIC^/F=[RH#14%,;3V&V4D%A,8U5IG0?T_Q@A=%>$,@LDR(
MK?H.2:X#I8)\A0$>`9BUFM&%[YB)<L/2&^J(Q84DJ4LV%X$C(7C61VM1"V"9
M0TYIK*B;:^#-A\;)8<IN9D:&J1!I3&J,NLXCPULAQ?]=6IA+/_82N`I((R^+
M(1Q+4C<7AZ4C+S/2DUJ^((:,!$"4-F1/'ZVX(&/\\#@W1%<9*SDK+3Q`@BX:
M#DWV![#*Y,R*2R*4*56DH@6\+R>R(8#,"G&08VA,/^[!GPCW!+`$3DB2`7`@
M,6&%1O0<#F']RIK]>E:?:EEK;O]1D3&1>9[Q5$!/[/"#%LK@!S\P0*`$+:A"
M%\K0ACKTH1"-J$0G2M&)EB$`9/!#&!X0AH:6P0)CZ&A%1TK2DIKTI"8-`Q;0
M@-*6NO2E,/7#.BW1SH!L!&;IT&9YE+F:^ACED/A4C7^:4XZ3^.\+.+&?!?Q@
M`35H]*`62&A,ITK5DYXA#0'_&(,:1.H',YCAH61X@!FX6M6RFI6J82!#"<E`
MUK.Z]:T.G6D+1<49<NR%6ENZ207*2(Z8#*A`5-KK8H*JMO_4,H=O2<=,,J14
M/Z3!`F&X)5.E"M?*PA0-)4P#2QL:A@JT=:%FJ$!&+4O:TCX4#6880QK.8-K6
MQE2NE$#C/]0('`ZI:B=V7)(?>S34PE[':,A(QQMM,IBE;M1:+(VJ:Y<;436L
M];,,]6I$PQ!:RC+WNF:]ZA@"L%GL>O>AL)W$%\KH!<<0D6O4.F\ACO@[9917
M8Q\K+Q>^-3+ZVL\QXQU?(;C0W3*(%`W0_6YIS[#5D7)4HF<8@W*ORX'N"ABF
M:4W#_X,G+-/P1H3"WL6L=4=*AJ]:%*2L;>T'1E"Z",`!PU0U0XA1W%H+VV)C
MU'D$=PC!8M>F80QL=>D#5BQ1-51@K*45@1'0L(4RE"$$6`!`C5VJW30$>,E5
M=7$M<C4=1RS-$%#.<D/),`:2DN''K2UR0<GP@Q-H&:4`/K-;I4P)YMW)C7@2
MA#7>^P](S3<\7,#.!Z/X)OOAKR*KD]/OO"`&9&C4#&5(LYI;BH;M\CBF%7BT
M1*G[@-&6E0(1<*I"M[#0R)IXT2=5JZ1!;5(V3P(C`0`3.<CDDFF,XRCP6$KI
MY,2E+BTF7_AYTLQ.%^M:VR=,K?9#ZPBP85)/EPP+R+%9U?_0Y9(F>,$Q_<``
MGM!63C/T#!+(@0*,/=(SI%;3W"ZIJ6U%+<X\\P'-V$AG>`0/J<WH-%(;F-FH
M<Z(/(<9G[8C-%O^3U/>5H0)^.`,#BAWNA9ZAA`2GJ@5&/=$S6&#A+ZT#"+!0
M;&M[%-H%[_$8@)SQB8X[$M$YIDMLIQ8J08A*5PJ3R>]#Y71()U*^/#F_`2O=
MR7;<HQMG>%G+T.R3EN$!(47I&X1@`(AR0.=I4,.);Q[1!`=`YS?_."2B<\U8
M8^0!*T_F%M-3):&Y/#^:$[D[9^ZBFF.\X\BV=&G/7E(R-\$!)/V`$HX@42-+
MM`=I6#K3'QJ&&R<\XU)_!$5"X[/_SFA$8#)ZWV\&W74'A68T,V-7XG\-6"X7
MM`)_!_49,N_6C\+4#%8PPK8G2H0H0+V@=I=H`@X`@KU+M,.N5VC@'4$1LK"(
M2=:0X6&^`H_#@&%BO<7"K\2&%:U8\_?M\'TG021PM0X\XV'@O&79GM(`K"`&
M$X!H&18@?3^\H/O,[G[LF3[[1L1')=3Z2@5&$L,*+``>1LDC-64819/$T'5O
MP=;[R/X./Y"!`1;P`.*'8=3U=`*&!DL54PE&`$5``PO%!C'@`FHW45O@8!-E
M!G,@`^/W4`DV@>%6?IK`7L'1"F408A5@@6IV<*?76F,P@'5G`15P`065`#80
M`$_V4!9'_U(9<`>CMX$,Q7/@]H$@B`D#4T(,8$ZH0`8$8`8+`'`^N%P.5U8^
M1@1#L``KZ%`Y2%*KUP-/V%!7"&5#F`E941NNT%4@!FI8!64X5E5L8`*4TP`%
M<%)*UE)DX`(DT(5>Z(%G%H;>P&U<YH*N=09.&%,L,`>L15U+<`1S.%)H@((D
M15TAD`)XN%!_2&I\V`VD!H1JMH8OE04CP`/7-@808`1%5U$\`(A>N``-,(D+
M=6-?*&"7R`V+EF`>IF8;Y5)L(`91X(@!9P$C0`$590*HZ%#;-XS&5H`W.&&Q
MN`UJ9@8V:&QFH(<4Q0)/$(0/]7,'@`$4:(P.E08:D`&L6%!GD/]L6K:,VJ!E
M/,>+6K91R=A0+)`#6>!E%7``7A!18E95D74`7Q".?L!LZ@B+YH@-?H`&RH9A
MJM5Q-5=19L`!)T5=*T`$"8"#W!A1<,>/R%AC`2F0/@9TULB/<-59[3@!.]""
M+A59!$`$6#B1$H4`<<"/F_=6.Q,4_]A0M@-4L?5+&L1%&=D(!?4``SD&AS&3
M<'4&[0AJ9C``$L4"52"-)C6.-A"/"W6/;V4&$0".'GE6`V=D8^"3(Q5%^34)
M+M0(5+:3/.D'"]!=S/9CKSA5SEB4H'8%",!W`L!Q5/51W[AI*CE183`&>5"1
MK&@&'?E2!Z50@^EM4M5A4E4&9K`:#Y#_*/G59X-6:(9P(\UP#)(I/+4S7[@Q
M-<;C(H_B9X[A9F0I"&-6BP655@OP`$YF66C`?3Y(!DK04`G@BF_E8R/0!WX@
ME94U`3%P`R(0CLSFEA0UF'Y0!@00<`1@`03@5.-@`<^G!@#8$>"1#KJF5ZU&
M"..@!?X";+"T)92#6%N2FM_I%D=!+.FBG<V`:J-)FAK%E9R5!@^0;,+9E/-)
M:A6``@IE`#D0`GDY46E``&.0!/U940[P!"#@@),8650%@`_'`%\E76C@DSOF
M!P'P518@87BS$.E0;R4"#_LW"+!T./TF,`%A.GG&.5SA%J+Q&0LA3["TGG^@
M4%;8=&;`D5<Y_U5D<``%10$N(&&F15T$(`!LT%K490-^>:,HY:#C,%H!V*`%
MA0;P^56#&45?=Q_U-!CT!%B#P1&$U1T)\4H`<TPB`J,*108^*E&850%C()03
MI0:FB8<5P`-S4`/U.54U8`$NL`$*]0%'ZE8']Z9=>`9L&E&#"9\%!5)>]547
M$8!26E!4ZC56JJ58.B:<03EATJ5I(QM@(3];0Y8*=0;N25',]@`&6'UG.HD&
MH`06,*3,Q0$V(`4Q8`%54`("4`%6``2+^%;;9P+9-XD)>5+$*5IF.5I.Q0`=
M5:%^0`"L14L:F@6/UR!7^CLRL@60FAXEBJGA<3*D!%]CNIX+=6"/B/]LJOF*
MC3:H':<`,<"?%B"#KE4`4&"#"78"5<``$*`'D04!2="K9L4&-[`"$7`$4Z"G
MD[A]=5I0Q/EE_E<!;KI4!)`&2OA5"E8&.($3,3$;Q6<6DNHWZ61*/D4..8&M
M.0$&!3-`SAHB9*I0#HM2?1>?!0E6S\B*8>`"'E8&58"@S,4&=.`Z:54!&H`!
M#E<!`EM5+$`%464&$!``0B`%!0MJ87"6P+I0PJH2+/5_:MIE8>"<&8$OD&I_
MT2JM>51/=31!*M(=\C`30)$1W3J:!K<`+^5M:AJ8%,J4&Q@&9&4!#$E:&T!9
M%*"JW45=5*`#`/!O1M"G+94`9O`#EC:.%O#_!@<YB0%PJI8%H[[`4.#Z4FFZ
MI@IUM>9:<`8``B]`C%-@62AP`+58``.@L`X564'0DD\``<"(BVGP8Y_U;Q'0
M`T9@`C;K@\ZUM*4FN;S`4!A55:,:`&H`6:SX!B$`MTSU!F]U`4]`;07%!B``
M9DVW`"VP`C_`C2S@`F,`=6D0!'.`!D<0M#[8:&O94K[[NPO5:&<EGJO5A9%%
MEPYU!BYP5F$``C.@4&R0!BL0=!)%`D$P!BO`%BC%`E(@@!0562N`!0(P`A\`
MOTY;6>F["PT5JE3E5&GU`!;0LC?G`!I0JA(U!EQ856\0!:7H!Q_@`M3'4`B@
MPB90!3]6`56@`B0U_P$:0`!R.[\6L`0](`4'<,(;J%42/,&YT%#$6UE7Y7[*
M"VH[,`+B=P8_0%480+HB50!F0`4YG+D6(`$RBP!W``>Q>P0125$+L`3GJU"M
M.Y!`0+Y(ZE)D4$1$/`LX-U71%U&8!70#VEH&G,4-Q8DOY8PAQ@9%L(3U2097
M0`1U@`82@`4.$%I%H*\090%FT`)'`,03I92IJ5`I``)GW,8+]7/#%,>RX%"#
M6)+=*ZI;R5V+Y@$V(+_=5LHI502N65`PX`(SVI!F<`5$IP95L`48`)0FP%!P
M0+[&)<`M.5$?(`68QU2=5J&\"V5-^\P-A0:>)<JWX%"8ZU((6,BI^;Y+UO_(
M('Q2`4!W)S4$+6!I!HS`;2O`.]!5/R`#"!@$.\`&#G``05`!4O"Z"3B0%C`%
M/@!1"3`.9[K/"H4&(Q``8QQ[K2G-6LQ2UFP+#N5<?[RT&;S!#%U6?/`$N8I2
M"1`$/5A184#%!44#.8##$P4`1Z`%A.M1#Q`%";"7`A"X%3`"*X`$??>?-0``
M!)VP8V#)?K`!1UNW8"4%5AE[>WG1&^RH#TT+#V7!S'55\;G$II5@S,N60#!2
M`$";!<4!5_"R$64"0?!P5F`'D`Q6#UD'1H8`45`!1VL$#!E92[`$G#7)[;RC
M4@!Q#+73G=:6XT>W,+5QLK?4<NQ0$7R``8#'U^7_`$3@U3$5!DN0T!#%!CM0
M!-T%`R&`UQ&5`9?]`A)0`3U@!D%PH)-F!BMP`Q%0`5`@`]05!#E0BH+(@6,P
M!22`!*CK4'H=B@CMR6#5<Q4FV+$`5H`Z4:BEJZF\N2_5R$;0R1<H!!*U`7,0
MEP5U`5"PS!*5`=,M`P*`PS\G!7S0A&S<4`!P!TOH!Q[@`:PE!"W``7:``0YP
MVPKU;\P=R115!E(@!'40>XGF<Y7;V[[]"GSGU&@:`*2E!DWHS7#%`;E;5F$0
M!"OM!R<P!0)>4`A`!"L`N0XE`D]``"```CI;I@0@`3&`SV8&WG2P!*?,`Q8P
M`68&!W)04"`@!+#<4!8`_]T/Y=X.Q65QP*HWI[DE1<UMU=^__5"W3%&81:1D
M$(`<K(!'7%EI`*@0&`'=Q0'<VXYE8`-CP`(/)VF(N`%I8`5'`,EP$`4MT'H*
M5=4O<+=^0`(20)PUW@819>,/]0).$(=,Q^,@;0$H".2P`%%F6E%%_M3P28XQ
M5<_^:UD<!0!)<(=D,`>26%`8(`%X/E&:;0$P(`]_-XY5L`%+H:<`D`,M$`)^
M4`!TX`$*@``E4%`?<`1RP`.T#00`OE`6X.;R75(`0`1(`-D%=[5NF=0TJ>=E
MR(&OSE!_GF&'+<0H!0!```5Y/%%D4`564*,$,,)^<`$"<`52[0<.<`<5,`0@
ML/\$%GZ-^,P!`1@$8_7/2%``6"`'&3`%'N`'<[`#=G`E.7`%Q_GFLE[C*%4&
M4W`#.I[KA0Y1@!U7OMX*$;7?#H6`&,9SI+H!>G?2C\7'524#2\``*V`&(Q`"
M%6`!/M`$%3]10K8$.<#A_TY1:0`!5K``$>`'6=!EB'$&`#`#'N``;``$VA0'
M$&`#GO?F-&[;+J59=3[R#&5YX#7PK!!1*0M11UUC!,X`4,"N32=6%SU28:`!
M#S`%!S!P'G"'$,``IYR4`%H&5Q#I)14&$O``-N`'>4#>=ZBC"H4`*3`%#Z`&
M\C`.`0#G3'7O/`]3!4#G!8?PUVCP"T7T10]1XXCT"Q#_]6Z%FE20`TZ_4`!@
M!`>@W,=N!Q``!"EP!61``GHP[0>PP@M5SQ9``D)`!=<.WG,``737[IJO4'"'
M!WT@!#">`S<@NQHU!FQNVSLOXS$%`&,@!OUN;,.^OIX548*_"A(%^`65S6<&
MU0]0!-"-TBYPZJYE!@1``ALG`WTP`05`X5DL`@U`!=R^!,$]40`<``YPARR0
M_0ZX`UJ`!&@_^Q'P?T-^J!(UXV].53O@`O-<<!<%"'Z"@F$6:(.(B'^+C(V.
MCY"1DI.4E9:7F)F:FYR=GI^@D8FC`62C?F2'IZNLK:ZOJV<!%50Y#P$'(5NP
MO+QF#`0M9WX7-BMF8:XT21!F_SU78\.]@F`A#V=W?M(B1HDL##9[5P]EIQ:N
M%FVMY].K;#%3"V95+.WV][QDIH,6^ZVA``,*'$BPH,&#!UVA&8.OH4->A18$
M4R*'A8.'O108<4%@P9,5`E8LD,:*QH8*"VX\L%"N78H0%39X\),`2`=!.C`8
M,7`D@X8*#Q8PH))@%3M6Z=8]9+.C2AH_9K2-T8``HU5[+?V,B?H*H=>O8,.*
M'9O0U8.K:!T".!--4)H'#)Z@T*8@[:@4!TRAL6!#`KE7#K0\@"&$@+]I-0B,
M\$."AZ`/TM+,*`#E"(,65P@0>+'@"@5SZ*HB=5@@RIAD?H`,*C,B"1N[L%F1
M80B+K/_MV[ASZR;X*H":06&RQAXN2(8A1&6VA"&SP,6(%KM@>P$"YK6?.D`(
M/'4UX8@5$!N6,(@`IQT)*F,N\(!,!TD3$C>TQ9"0HT4$$R$LG"%3(<"+!T]\
MALA11HEF%#YLB!&%*H*`D`@9]!!'7!D/H-;5;AAFJ.&&N+U2!FU^+&"AA':Q
MH,%VR$6GS5L,3$$"6@KD,(!U?M2P0@`CGD(#"?T]L\`;1)!!@``%P))!?@,$
M((`?+GCPA1\`]-%'$5]8%L(.$%2051AF7''##@0@490@!)JCSFCVQ`#%;XDX
MF`B7&GQ`8EIH]-<+AWCFJ>>>G,!2@2`!,#CG512,@.,IR8W_(DL%5P!A(#Y&
M_"7("5/H]\H&5UC`@10/<````'`H$(49!(!``RMP=,%`#EZD84"1:-#P!@XQ
M?"!`%0M4$$-(*")RQ@)4'&$$`3>\5N8H2:'92Q@!<#6*FXJ.T>N@^!2"ACZ\
M\*GMMMSJ"<L8:)0Q+;4.(6&$H(EXX-@J:`0`#A:CE'&%$A.TLM\@",`DW"H.
M2%$!!P(0`(4?/100@!]E7.!'"A9<L<$I`31S!@!1^!$&'SM\-H,?#DR@!`$-
M"+'"::U0^`,+#;]P;"(6/(IL+Q/$0`9)SY9\!A[DXM,/H.BNTNW/0`<M%BQJ
M')PS1C)HP"8K9>P;;P40N!!`"A8+_]'";"YP,(H">R2BPQ7.LA(S%6:<%`4%
M1_A1@@-7^,'!$2]FT$,%1`[B00C""#)!``8`P`$26=2H!`LAK,"#!<?!PA\(
M/$`=FE*OL#$$$.6U$O8J)\PQT]&\;(7(8:P(+?KHI'_"RUF<XX.&/+`T#4L:
M59@QPA(B#;(7%`K[$:,$=0RBQ@,DNW+2&"=HL>H*$'@Q2)%^8'#P"T58@,02
M('APP`\-:""!@T+$L+P@"$AA@QI+M+`T1&94<$,58B+E,B(D$/`*&E$X?<KE
MK!#10(ZI/PCB-*4+H``'^`A8_*IG_6N%`P:0!YJ5S`00L4$0M/"6*T!0$&IH
MP0)>((&E4?\J<:V@@!0L8()<J6$!-MB!!D""`9OXH0,5RUT&$)`#Y%U!`>7X
MP*DH,),=("`-#BA,$6J(OUZ<P0)4",$5<C`FEKW/#]6P@(I.T2YD^,*("R"#
M`1*8"`KQKS8$#*,8A>8A,Y"AB%Q,1`$&(`7[,6V*K/A`?LA@@3LXX`R".@D!
MF+!%.$2@`N=;Q0?\M0,B$,!99:A`"#00`AO,0`6G*M(+!$$#$#!``Q!DPP<>
MY@><I2`'?C``$YI!AY$Y\!Z)M``#5E`L)R9"#OKR0P!&L#E?&6$'IVQ%VJ91
M!A#088M<K-,749'+08SQF,CDDRO"L`"+H2Z-J_!`!4#7.CBN0BC_]?"#&J@P
M24$H0`+18,L*B'",82)"#(<DP<CXEX8A_0!J-7#`"D10ERPLX0$7"$.1"K"`
M$_@A#7)P6P9`0``)$,`&+$$+&1C@&R0RCTQG$L0<-.,K"W3A5(*8`1-HU`MH
M3:,.9TN@M5C!S'\D\Z0HW8TK`B6(D4!S%,RRHCT\T$UTZ,`"2JB<&7"T@P,(
MIPP6"$%$5\&"*HQA`R-$("%F,0,SM*`(#G@#$I3``"9@0&V"*(IC[C8!"02A
M`D4(@&'0@@$)6$H09+C%F)+%HP-`X9FKD<(&6)`7?%"S%P(@PD-SMK-6J&%<
MQDRI8`<;EI(YBPR`3>`:E5#,M"QN"$,J_](1*C""BXR"#"L0`C`3(4(+O"``
M5P@DNX+*@C%4H`':J<,%Y(0`!,2!#@/S0PP,4)@TV*&<5[G``;0$TRX5*QU'
MH@(4EG!78A"@`AM+'1I&H-F<>>X5P1L%8:=+7=ZPXG]G@"L7V4`'+;BQ%ZXS
MX!A:H(-A32$'8:!!#&X`@-ZNX`B;3<``"$`'((#-G*=00P4T`($`=``93&C0
M":!:%S_$X49B<(%+K6*`)JP@L8+X%17V:X40$.!0HZ#M",X0AC&,X*KV0.,T
MU!"".%!K-A#YGR*JR^(6]VD59MA7A=+XCBG("2-ET!IX'["$/'2F!J\I@`6.
MT-Y$_&H%<4A`#O\(8(0CF-(>F*("B`%`@T,,0`$OP,,)^O"3"LC`!EF2`(@=
M8H`AK%,9(("`!::0J6)RP`7"66YQ+6<5+HF(1%[L11I$ZP<7^_G/E(@%_M(P
MYT'Q$\,XMF8K6+"`Q.2`!0^00)&X%`++=A$N"TC!6[_+"A$@`0)E,,.3&O#0
M-@AA`ODT;1DXDH,W=,`(#.#D*1R0`UF?`@,K4:JOJF`!&"B!MZ>0!1K_6N0K
M7D78Q!%F.Z(;6$`[^]FK8':$FYFZ2FJ@L:A4=+"E18@G+"$&(*#>J<XP!_:>
M(@TK((`.[%'))9A!:P60ZAF$`*7V<B`!56B!&0Z,HP#`P"((6,`#2I#_B`DD
MP0J[E8*`$)$`(H06,'>@@@S"G5@5$$$`^/4#"HRP<%>(&!^L&0)L1MH.-.#O
MV2@'-*(2.^.<J5=2:4F4*S+0!0P#P`@/;HX)9F$J/Q0@"2:&:0"0/(WAX:&F
M7KBQ'Q!0#R2,C`-!.&L&1""((B`LTG/QPTD.$`8'X""1>;BQ`6X`ME<L8PFU
MAL8PMQ`!78^B!O1^Q<<;0@8!^!,M?;5'`!R8\KZW&#2K*$7..!`"'<-&YJR(
MPP8P"H`;!`'#%)(`REJ@XX7D\HA3X,.E0N""0V0@!SYX`PW"0/`S^6`*(1C"
M`1@`@@SL8&-#>(T(]$#O'@A)``\(P2$FT`93_QR!5`&P45M:L:,*C.%K(+S*
MA_B,B+F_5"O.)ZF*_4[]Z5[VNPNA%@J@(.V8:QMAPM'#$LZ*"'1#@0,5D+3%
M`A#24>C7!I7+L`0J@`0":&T''*"!`<"P0#\,`(8,L`-490&_D#91H`)"T$PI
M0`)%X@%G<"(UH!H[\`)95Q42P``)Y0IRD"DD,'_,QP*+X1!D``5OP`K1YQ!T
M]1`HYA`QMF+5]X(GI2AF,2<T4`0+X'96@7B(D`$#X"QA8#7,MWX54`)F(&[:
M``5`4&S-UP+>DP@R\`-$D`"M5Q08`$I:YP?E\017,``_,`5C\#L1L`,,4`5)
MD`$G("!T<!,9T`$JX/\'-%`Q3R!??I`!!T`$T_0*$V`$5#`$9/`#:$1;`H!M
MO4`"1Z!TS3<G99!"(-=R#M$K,/B(R*1W06@5:!`!A886.L@Q8Q`\`#`'^A8Y
M[C(",#`&#B,(9;``]M-A4Q!TF"(,?;,P&5`D".`#++`D>C`%4D`""P!"F)4#
M4'<`%_`"5P4`,N`'=M`#X%,.S;0D.<``,E42,>!NSS!\H]`#`L!I]J``0A``
MO7.(@Y(&`N`#)5<!&7</D'B.8805*H86+-`LY:A\*A(&1P`%#$("0=!]B<`&
M-^`"8Z!.!44"%B`!+;%3V90(>X&+#Y!-1W`!`F`"*(",'%`""/`"G'(#2P#_
M2$('`51@!Q``!%"@`#5!#"\2(D]2%6:V8*UP$@M0`B/D1C.`!;ES>%,0`S1R
M@E?!`48@CK#@`)T7&^CXDP'4?._X)W:!`-PGB':1*!,``C_@0?F!C7[``E1@
M`6]@0E`Q3G20?E?580IW"OQQ!5408`,@""]@`$[``F?0`0=``#$`!%;PC(IB
M`160!%3``$K@`&WH!\I3=7Z@`T$`<ZP@0@\0`W]47#X0#G.2!C9`DU!Q-#2`
M!`=@::L``%-PB?8@#4"9F:(#'$8#73C8#C%@`U!Y>%O@`%,@4P8P?Y;)!K^V
M`PUP#(C082M0`V:P`NOF!V@@!5;76P0`2A'@("#`_P83\`(R``%L!`'46#(0
MX(QED)<SD`%^(`&Z@UH0-@@>HQTUX(Q?I(TH22+,$@)<DCK;5%.G$`$VV0O4
MIIGJ^3.#8`9(B4&=^1"$8YG#40;L0Q(SX`)P>0IL@`</8`;G@8][(0&C.'""
M0`%F0)Z#P!93T`47P0%L``)3,`4>$`4P!P!DT'&(0`%58`,DT`9\$`9;=`'E
M<`$Z(#7E>!(!<`*X4@%`T$2K@8J<\RL64"^(L`.CB1$[E4M"L(Y600;EL)Y"
MJBV#X*.LH%WW<`%/H`/O"!L3@`-G(`%8T%XO$`+=253\R`-0D'Q>>05$\`98
M]T(9H`0(1"$6\`$O<`!!$/\"06`%AV&/IC4`>_4!"[`"+%``%9H#0M`$?O`&
M)_!!2)D"([0I$&!U!T`JK>0'/G``U2DA=?`!:K"8KQ$'7F@!46"(PY$!2/!_
MB-`#C&@7##&DHIHGP#$--]@0"$`$4?">L;$!4V!99$`"U@"5&?!6S'&'L,`E
M04`$=*`8#'`%,=`%`Z"A:$4`$+``0-`,%G(DQ\$E%4`'8R(%#&`"2*`!9<`"
M!N`%",`#*3!_4#E(%?`"A@0"(B`"'U`$12``0;"'"X!H.1,S"U!@9C``E:(*
M0A(!>0D;#K!Z5$`'4IH,'K`"37H/:G`&HWJP&F)7YPD<3=`".3IR\H`:(M`%
M8^7_"FV@`<1"1`,K"!=`.Q<6!OHE`34@!5_$):N4=0L#!1CI*V-`+&Q@`3>@
M&(%C!`<P!@X0!(?T"@D@5@U0!`1@`;N5!1E`!*CF<TH``2W0-3/Z`RCB`(7Y
M)F8``7.@A!@!`,F*#/PA#U*@!E?PF1B!L&"K&]6"I*^``E'0J!*2!M3((_MY
M"NAG!BASI;`@0AA(,V9`!3U78$86D/[4`_HY3!3R!`,0`O'S+TB0`C$`/"EJ
M5"<@K3Q4`QX0!@F0`:+B`QI0!4JPED]$'%R":#7PG\-$HU1C%2=@`2C))0]0
M!!5@`3=!(F'[NK;Q3_<@MZQP`5T0!QN;%GR0@7.8'TC)_P)FM0<:`)B\D`!(
MP``K^R:DN`$<`"Z(L@+0@)1DL`0A0`4M\`940`51P*6GT%D\@`0Q`9U+L@$)
MD`1^L`=&,`-?X`%9,@(/^Q!U<`,H22FTFPA$P``X\!#["FR)@``0,)LQ`$02
M`KL$'!:R<`]D`"^P<`0;UC^NBB)M<`?\RPI&&1-,L`+TF0@)X+,YVPI[,0(;
ML`!Q-PA'0KRMP"4$\`#IEKRL(%\5L`-+5C&"@`'K]@5A$`0-@`=1T`,<.0`]
M``%>NQ3PL#1R$`$F/`J#%!3OFP@`8`=6`&%(,`84H@$9T)94BQ8!4,!:?!!I
MP*I&1@4>\H7]\P&&(K%/H!VO0/];[Z6Q[:"/!,``^.B5Z5<#,NH'10`!&6QD
M-J"=KK"S5]!DZ08#-F`#!0`'4!`&88``0"`!AW`#(S,`:N;%#;$'L3,(^UJQ
MK6`P]$4$02#)@V"U-V).B8L:F!4%6/`#Q0@;8``&6]S*`F&DL/``0Y4('/")
MJ6,`3R`%#`)9[KH*?3`DZD1^O?`!=<F]RU2;1I`&%0"0%2`%`=4.>``!\N,*
M+T``8R`#5``!:J`&10),])8#S7Q5^1(,$SP<"`!.%B(&RCH_5=4#*R`!GCPI
MXX=M92"PL1FU0F`&36(7?]`%KOS/G_`%>3P*:;`#I]!P3Y"[:+$!0,`@*'``
MQ@QC5@#_:GY@!",)"PG`!`]0`020O_8``%2U?A!0`&E@!4E@HZ_`HB.Q,I:L
M!)X5``]P`!CU`D4"`S/@1[]!`\46!A%`>1+"%&G`("=@5JS*+$M@!4U3!4H[
M#7*)J:-`IC"U>FX8`V)PQ0WQ!P'`!0"]U9K0R]/P*XE@`#H0`4N,%O,&G8+@
M`!(\B;&P`"$`G6D`!:/+"OH(-CNP!%-,K*P``'1`-@^@`_5B`1H``A<P"[9V
M"BI@Q"W!TL9+`#M`=D80'("2!!V@`$<0`T/P!`J@&B!0FE*```EP1#^PU&E1
MA7OI!XE=S@9D`0IG9Z<-"RQ1`1$P9FE<'V9P%`4`!&7M,U^P_P5<_=N6T`4/
MP8@U8`,#;1<[A1IGM[!=I$ART&$:\,SY*)4+("<9,,U"(J>O0`)+T!86,`:L
M=`Z_0P<78`$_<-AI/0=!T"O'XL9&$`/9#$H7X$^26P`.P`</(`044#%/\0$9
M4((\\`2R%#&KBA8Q]<GJC;9^M5^0(0$-$'^(8!)V4&SLT$Y$T(VML`5G5B9J
MZ]$.L0C^#-PB#@E@\'V\('B-V[:#LK-M1$D@8`7)N0I4YPKM1"1HH`5U,PA[
M0`57,`=2(`@W<!0H_**K(`<6`',6$`%TH$J#0`9SP`'Z)05*U\3]E2,$PA0*
M%@<_P``U2P!)E@!XT`'%_0,_G@&8&_\#^H0$:E,7HRL"*E";K/(07A`%"P;*
M7IV/>P5C%Y8`JY8#>NLV+?#=03"20CYT-X#AB9`%",4@Q\(L51#$/H/57C#B
ME,X(6?T0]`,$,4XN&/`$#^4`O`:5%V!0AD=2`6`%6J,&53`3;#`'#"`$.\`%
MEEPFOW(%TBT(`(!:H$.`I?(#B3`$Z$4JIH``")5+N)TK/(`%AJ%?&E`"1WX`
M+]`'L8/(J'7D#'!&:(WK?!,?LC0"]M<0/#``*$WL$;VA(V`XK]!A5U`/::`%
M54$#LV`*8[`%00`%7D#K2(2IN(RK_,`N6B!R^+`(O5WIE9[%#O$.#`#I=@&R
M,^X'>4@%EDG_6U<0`&,0D$X=EV\=!D7P`A40!`5``G/`!Q1``D"PBXA"-\Q#
M`F_)/^?080P0+6K081?Y7>?`76"U`Q7PC$[5`'@3!%)P!D9`!E9@!!O@`H.#
M.!W'!AT``"4X!SO2`/&PN:R`1ZW+,?7!UC0!O@&PBU$`X:/5VD,0`U"8`#!P
M`S0P!R"`6=.<"/H5A8*P`_K&\GXEQ>:X"%E,\"(^\`V1!5I`!K[!.3L[?)6T
MSJZP`\=`!U.P`CE0`B@QR_E5`4HPE6?0!FF@`/60`7(2!RS]3TL@!%9:3$?!
MTF00`<Z^N>T%L_UQ'G(;!JNW!",0!$=@`PN`!%,9:F!E`1`@`$B`_P&T5O64
M;_E^<`-TX_6QH`0R!0!8$`3.-P%?8P3";P5`$`/V(9FKP!]Y,`ZB`0`Z<`$9
M4!1`0+:"T"4YX(6@+W=*,-?98O=:C?>_+0:3?@\L:D5E\./D4@<@T.*"H))(
M&0<H`0@D-A9E80$K,4TK.09^CH^0;1H5A0E^,VQOD'X6FYMA#S.>D)V.%@ZC
M?F%J2S*>"4`$%BT6>PN4J3(_9A80(!5#`P1DCV%C$`M&%1I-"46JEIB:JF:+
MC:E>`R-GCR1+8]RICFPW*V-O#Q9HQDLU0E9V`.)^'R,M,T=]?@A^%%]H<$S-
M"U-A6JI2\_R<Z;(`34)(?R*"`1.QHL6+&/\S:MS(L:/'CR!#BAQ)LJ3)DRA3
M_@D0\:$G-&G".2)0QZ7->6QB7"'F:(.4!V4>^ICR(,Z!"CP=G;$0Y,:8%4>N
M03HC8$4:1QU\^&'QB&>!%@DM>)B'D$P0.ZA&63@ADYRY,V0(A"!P=12:'#'"
M.")3`0(#,WHWH;'@HL8(`G38^,FZM:O2IST\*<CA(J@C$B$(/=Q#Q4*1*!74
M0!J\A,Z8)3'D;<)P8!@'2";\),C@B,.,*V'YB4/XL`R0(P5<6F2ILKCQX\B3
M*U_.W/A-/R\66(:D9,/SZX\*#`@0>,(1*TGG%4$:9P7@46I:""EC`8KNVB[&
M1%8`*8"?`B\2?"'_\H-`V+&[3;7`%">HU08:"Y3@P!-`%1/`$B1X`D`-P'T2
MTSQJ_`!%%Q8H$9PC]N&G7QROF?'``3*Q5I<?`!C10GBI)&#B#CI<848J9+A@
M!`</1.`%)!LL849L5[&AVCX@^!'##!7X1]9[:EU'00XI/&31%LUEJ>667';I
MY7$VZ:'%BINH\01V+B$0!1$(S*&!3!M4P-U#.ZP0P`93+"!3*F:T<,0-ZAF`
M`12>%9"$'P,X$D$8EH2100X56!`"6&0!>-`F05;@XR86\).`"PQ$,,I2(<CQ
MB`Q5H("F(V&840$=$2R!Q`*,JI+!#K%%X$`31I"QR`<'"!"8'R18<1Y._S?8
M^`(58PP[2JM4X!%#$',`T(<4%IC*@0-V^`%'DB2\<($?'EAA01>X/4D6FC54
M4:4X7\8K[[STUIO<0W!$,*<XE*XZBA=1K$#&#PQ(<,T&@^R9R@E36,#!`0VZ
M9,P*8N0!P0JB52F/`!TX0`0.KMPQEPTY!.'D;I9&20H$0$R+1%J<(,`!`6:<
M888$&(Q21@5WO`#%C?X^<L88#`PA!`1WA%Q&"A+X<<$'%/#@AP-+,(#$-22X
MH.=#+%"Q`!D+:.;2T$L,H00$E-2\3P+R`#""'T\H(,`!$$CQA!45A-7&NFB>
ML8``\-HK^."$%^XEEBV)T\$`$CB4D'1!0V)`#O_FH0&&!",\5804N"3DP20D
M*#$,=B=`0/,98,@`N!]L\.&'"3MX8(0`2QA!=PL%\*96RI[H;H$0"RRQ@QD0
MQ!.S!8O\>(8474#Y2!H$'/!AY(ZPM\(!"[3`P3-%!#>N`1GP<(8:.2S05`@1
MS[.'!`_T`!J,+KUA>AI2^U&#'P'LX`@.'_@1PME.(`(#+)``W?7.>9P*6AD4
M]@C#.?"!$(Q@2(CS!W&\P`6B<0D9<D`]/Z1@!0MP!0<RD(!<T<PE1*#+"R"P
MK^?X`(0B)&%LIG:C,-"`!1`8`QI<8`$R/,`%#_@/WQZAA@I$@4<_\(`%EG"!
M3CT@`\<0A1_*T`+]/>+_!AU0Q1@(8)T.[H4`3Z!"!:8PO0&("0!=8(,"KJ*!
MT26$#4@8Q@P@<*SG;&`%6M`"&M5XE03P1`H9>`$#`A`#"%B@B$3)S1"#MH$"
M060X$HRD)"<YKR\@KH*>0$`7@&:3,%`A<G`(6PTFEP(<R&,./VC60W@PA3&4
M8`068.!#$$"H45+)E'Z@C2.^T`<1P%)U/\B@'^(BQ`!]P@Q4,`$9X#$S`JQ`
M`PP0`A\LL`#=I"$**"C#`;CRB,%HP%1>;%4%MF<R&CC@"'[@0`=,`()=+:&%
MXN!`"P+PAA!L[3H?^`DZU<E.!^@2G"F(@`7L,(+.^0%ZBC0F]7*@!!$TT")8
M_Z"D1"=*T>-LX0L5\40&EC##YU0S:&9@0`R*P`8#E*`?V'+</$Z`K8<9]"8&
M$,(5$G6#DIYT:NA\`0DN<!2SF:=WQ;S4J!9`A2V8@0`/`$($7I2&1<R@!0+@
M1AD(0`!=EJD"`I@>]?SF`A($`*N+^@`,#KJ$6'*M,V580/INDH"OJN$$!PB#
M6/UP@H!`!P<.N$(%M@`$*Y!)(.I2*/4*^="*@"$+%4VL8A?+$<1F=!-E`(%M
MKD.&OUXG`""XQ09R0($!A.8A#HA`!4B`!;]BQP!',,\`]K8#-N1@`K1I'8MR
M0``CU.`*X%`9RA;IB3(\0`HM@-2QC!&$&50#"@O`0O\:1M"$(T'"#$L`@58C
MMS,HL,`"%8`!`I)PE.F(HPVW(`'EX/>0.A"A=HY(P`!H@(`2(*`&<`A.!Z!@
M!2:<%YZ/,""G$$B*#EY``@&PCR,NX@4Q,/;`"$9P;Y/D!S4(\R%G""*:$*"!
M+2X@!BLP71U3P:T@"`$(.7263<I#``ET00ZB>.\-!J`$KC0@#E=80!I<0(`E
M6#6!E>+M*.)RS]%4H04M>$H$@F(`&J1B:`0`@6*HEP$;6+@)%6@!72#,!*CD
M@(4B?HA;M'"#(Q3A`2SH00(,(`<)@&`.`J##$I30@R8]`)Q`)<O>!#OA`TB!
M&YS$"$83S.<^4W+!7?F!5ES_\H`LOW$'>0A*JQA`@-PF1`_F*,,@5'J3,$3@
M`1N@0!C*T``.K("T^^A``B@@@1(3H`(,F`'T;J#;@_`.QZN2PP.^^@0UA&`*
M,BG#N'IK`2DXU%\QC:HJ`@`!*Z@R(3,;0PH:)LN$)&`$5WC;?7(6!`\H(0HD
MF`$`,A"$T2JA`D'@P%'O%^?=S%FHJ]I`91XAAL+Z^=WPEB"@BV$&73TD#>05
M!PN`8-=^*$%L\X!#%"Q``B-`8%(O>$Y,"1``.(3@``>8`"HXH`($Q$`*'CCJ
M$-(@I##XS08<"``5X@!K5^O8)@40P+[Z%`4R!$HA3R""H0<FA.G:9`8@&%8&
M)*"._X=<@%!J$$(%I#"%L;*5".!1PA,*@`<H5$$%%S"G'HB%!"O$H`5"\L-@
MJK"',80@0OT-++JO@X(H<-(16W!WO-?.]B]EP;&)@T1D/7&&`SP!9D.U"857
ME(`XYAL2#@A`$&+0UR84H`,70&H67%(>)*1`!*RF`!O@8``[,,``9>B!Z##;
M@AY/L0)*X(`%IF`I_9+BU6&_#A*@H+`S2&#PU8A!(\H0@:AXHE5)-K)-6""%
M^OE!!$_X;$+.\(1[4"X-D"_#%6QPXU2XA0'CV@,&4M`#&G2`!E6J``B`\!<G
M5.#8CBBB`&0@J7=Q(J%C[R04GI#EM`^8P&V/O_R1<UB+>/_"`SI(11FJ<`3G
M;J+0#Q$!$1`.$W`#-&-HD```=D!'-;`$!(`'!1``24`#M:8I/Y(*8-`P/B`"
M-``"&"`$2/`%'I`%"F`J4W`%$-`#%K!6D)`&5G`',5`!![`WII=?J)=?UX$@
MW@4;[!$"T;$"4I0`(.!^F^`W5_`:"2$"(;`O!0`"'9<0DV,>6[`"(X`!'?B!
M2*`,2H!WF[`#7H,&KD,;;\`'$3B!9U($!``!+X`M._@(T#4`OY!5YR=G)X<A
M.I0*'841]3=_?-B'(Q%1]@=9;=B"/S!UG@!B%0!GJ:!2+T``GI<*>K`$"_`"
MZ=``:L`")F`"*G`HCF!P2C`!FP#_!S8P=%/D`3?``V60*#N``XY0`!(P3@_@
M1N)@"!!P`T?U;T'5:@E!`4?0;-43%'QQ`"3P`"&@`HYP`5'`7[[E`OTSBS(Q
M`XWFBX_@:6,`8Q"`!F5@BJBHBC!@!E:0*)MP`0\@4G[`!ZJR!6]PB9G8`4G@
M`"NH!GKU=ZRR1;;(<#5H"N>FB_.@`V0@C7EV$6_GAP(YD!M!07'W"&4PB)!@
M"''U"!A`36I@!51@!/Z7`1UU'PRBD)"@`DKP`!R`!1!P!0X@!/VS`RF@!E(@
M`?<C!$8P!C_@>QBF!'Z@="EP`C()!S'P`F^P!)NT!%<0!W*"@"]A`1'@`423
MB^4V#P5P_P1XX'^]91FML@(]P!=ST`A#(W.CP'$@H'O=X'M3<P``]UU@&700
MT``T:9/>DI,[V049,"``P@:_0`8((`27``(C,)(EF0(DT`(,4`4R8"Q""5D=
M@@,+P`#HIX^C@`%&T$7S\(\6P06`2)"229"1>9#5PTW#IQ<7<`>=4P%MX(T]
M(`\4)F"R00<58%D2@@5!D`;%L@(O("FN@``#8`#6@0:6T`<%`@(6$`4[,`4N
M\`5MH'M;P`?<L`,H0`<J(`,,,`8G`$O2F`I%I`0"0'J[-0HQU2_B0`9WN$K>
M]7$L<`@D-T50,(B&4`$;8&0>,`+/T(HYL`3RZ`@Q)3!U8@5%0/\%$G`!PUF<
MQZD"`$`!CM"1!Z`#4!4&'4`$!F!79?`!L3D`.S!(6*`US[EC6'4`(6!^!Q0C
M7_409H!??*)V$5&9DQFB\P>B\_80!J`(9!(`K^$W%7`$]T0.#!>8+.(-`3`$
M$&H&5R`$#;`$=[`'2G%324(!0.`'/@`!5>`X8)!%?J``._`!0U`]L$0"KZB1
M+N&-P&4!S6<*KX9:+0`83ND(--`#8_!@";$%;>A;$O":-@`@:3`&F#D5LQ!@
M@=&!!PB%&&8&.F`.:'!41(`'*T`$3?JD?E`')1`<+*`_-V!(9Z!527$&)""D
M56`!-?`#+/@<XD1?4."?%[H)YF4C)?#_I:H``F-`I9O@F)`DHJ@J?P:)27+'
M8`FQ!W8B8F&@%P9`!RLH!?[9-6:5$-Y@`6"P@M-A#`R0`\J`!!<P!PEG`CX:
M`WAP%.6@`#IP`HX$`"(P=7*``:_X!`-@%1W$#GYQ!UPH%IM0'O<T!3E0$Y#`
M`7:0`3*Z"5N`@-!S!R10`2%`&X8P!8/V".=T"SCC!QL08Q%*KC(P"-/A-RM0
M!-70!(OG!T8``G"@`$9``859`G0)`D/@`+CJ4/*0C5I0`3*0![(8-$;(``P@
MAZ0`)6ZA2FKP`#L`BI`0!R!`:2Y!;GZ0$2":JCCK9R0*6:[:F`S0`$NV"13@
M`D`#/0\@?`,Q_PD?.65#20501``GL#=@0``&``4$H`0F0`,[4`?<8`/T$06Q
M@0`!4%MB8`[M:A,3(%IDT"H00(2<8"EA\!,GXPAIT`*Z1`,"@(37X;:W1VQ\
M<%1TJ1`6P(G^2@49=%054*FW]Q,;,+;DY5L6D`+((WDTD`!<P`:,AHMT"0<9
MD#,;T`!^,`9@(`P2H`,Q&DY0$!J&0``W90KOD0`/4`5SVRHMD!8)$`&J@AU$
M:+,YV[OOMK.0@`%ZVYAX$``MD'#%0`3"LI`/X@KB```[0+0T&I@#,P!Q='<[
MH`>M=`9<H087,`%#FJ2+00(;4`5C<`.P)+.,](1*80%KJJ5^8`!,4/\!>=!*
M?3L`1:`!I"H.CC0/I,("8S`%79169K)AQG`%C&F=WI<&Y;%AGL`7>5`#0:`!
M1E`$',`L88``;7`"1O8,(*``;*`_>/!])V`N$7H3T7MV6P=.%K`W"4`$5W``
M\T1W2@`$1!`%)SP*AEBS&'&SOOO#B06\Q7"V:-`C>K""61!3&J"^[6L!7S`*
MWC`&>Y`9)RQ..;`#2*4937`#)\`#4)(&7_`&L%1/5T"FC/0#CU@]H.>.'E`>
MF!.6Z=HP`8"NV#&K+K$S=R!ZS.<`2C`&3-"_HV$!$M",XVHG'&`#:?PLU1`!
MVWH%OGH-%,`$"!"MD/`%#_``?_-2D1/%AB;_?KF#`,DB*3WG"3DQ>FD`JA#F
MH7_0!4#<RHLEQ+]X$[XR`";`:'C0&T.GJ1Z4&3W`F?M;A!)0-4%$!V<'GX[P
M`6-+!PU``$)PMBY!`3]!JBY(`$'0`B&`%*GP`1)P'FHP!3$0M#>1D#?AC3F`
M!PP``6"W;_T&"?!X`#GC"$-A`3+`/K\\%5.`-AK0`1HP=3D0&9"@`!@@`,#P
M!`S@!%ZTRW#L"="U`DOP`%.`M)OPFG61!@]@QE6JRC[LRAH=005V$;W%MPD1
M!E.PG$FP`DJPSGQ"``/``ZD;#"=T'0``8H"1<'#@`2I@`&B0!Z;R!'70`,/J
M!.;`%&`7-,@<LAS6_QI"(`5T!*^/R`LY_`@O4,^.(`(KP`!/D`-6(`"HX'H'
MH*0+60U$P`*C2`)WP+0*=V7<$0-^P`.WF0+<@`5SX(I7NP`YA%T)O"I?(-#O
MJ1"W,``A\%//(J?,FP/.[(88O=&(+4D!&8BM^AQF,`=+80,IL$5>F0K"*@&L
M`'XW<0)>LR<C0`)JH`)AD!_T((D20`LK:@(5P'X+0P5/(!6>L`%8MDIV<D>)
MO!60$]BH*0YF6FFCNG5E\!0`TLV#.#0,H`0\$*O8P0(M``5QD+NG$@(`D'`7
M@`7?8+P6`#@T(`,5,``(R`(KT`"H/`-_(:-L\`+FT8B:_0AL`#;--C1L,__.
MAYW8]/U`7.`%'LVS-K$!N>T'.7#<TY2,#S$8#.#/SQ%:#1*>CM`'%W@5LOD`
M,9!"Q)`D'<"*3<4(&QD!@]0G5@0)T+RK*]4P'@`Q"JD'4;#;F^`#K>42O?T0
M`-"F,O$$$/`$)$"4J!`&,@`$%PA9XSB\-N$W!,>*Z829-``&:/=+VZK6CB"\
M?D`$5``$SM4&0.>-0_T(&6!/$=HUTA$V"AD#F/T087`$R*NA\UW?9AY!)2H.
M)"``2?%S0%$-<Z#:$8#2Z(%5-I<*"F@%;^,`,^``*;`#FD!N8<`#AR$!!F@&
M(C`LH.P'.1<%Q<4BJID&:(`%.!`#W\83%)`'FCS_"J%5$*7U=R^0!H4-!SG@
MO//0XL][`T@P'?E$"-Z8!#7P@J@0PCT+"7%!!'0,A55&#(N>)"H``GIPH&"0
M<A#P`,N<`QB0<%IE!&<0!4N@"=<9N&%0RS\`=F6FN)L@">TC!"\B#C>`XJ/`
M`;?]7&5^YN9>.&D.Q83<!D\@,,5P&FD@!(N`RJSB*@%PYX\0TRM``!>`"@F`
M!C.@/Q&``$V0`VPP`(/45`SP21UP(UOP`N]2('G[`#^P`E;`%2!``@K@`'S`
M`1!@`P)@UN*P*T&0!"#&H2SB+ZV"\H^`ZJD0`[_F!RB@MD(S!A70`U<&Y5K7
MWU^]`D"0ZYXP.1"P*`\?__%^H-58D`(L$`00H`PD"P)\@`%S`#>.H`$%X.]Q
ML((0\`,I4/!$N@-M`+E/8-2C@@0K<`.4X\".0.\A'0"(WICE?NYR[R5<D-^-
MG0II\&!'L-1#N01B&@07>61;5.60<`)EQ0-$H/1^$`$LX`%!I,%2[\A10`4,
M$`0[4`%0T`%OHP0MLM8'X`=Y``(J0`(<4`@>!`7'Z`<]L)SMFJAC$"0@7JHV
M4-BC,@:?F`HN_]649@1U*IA7\`:W`"`Y8N`"L@)W_0C)O0`7L/F=SP.?'_HJ
ML/H$8`*@@A3TZK("X`4(D/A2P_@>L`)G`/F6T0"J8GDL#PE)P$)O`$*RE+;W
MZ/\2:-``@3L*IEH1&3WW^+\<L#Q%M0X(?GYQ%F6"?A@6"V>'C8=J+4(<%E%P
MCI=^919*!8UA1BXY-!PQ)VE^2!,QC``)3Q4].A5I80$M'&9!"VQ1?@)^/B1^
M`WX3;'X>*6%^'WT^`0L6:)B."%$6'`T5AI@H$6;4X>%P=CO'CEO<C0!`4(R"
M&55C[]1D5G8<#TH.?F%F$1TPE:D0($$C%4A<&%+!P4^O7\%0%7CR@,4=`F3"
MC'EPA,"#&WZVC"IU*M4J/P#ZS0B8@$0("_3"79!0J,L#=8[*:"`CKJ<C-#G>
M8`(GZ(_1HTB3*EW*M*G3IU"C2IU*M:K5JUBS:MUJ%$O_TDME0#CR(>64(`0'
MMOD4$:&""SHQ5N0PX)/,D@$%`-BQ8J8`.`1<:.0Y1)>-C14K=$`(L$P0&@M0
MJ$AP(?8-"\)^BGQ`\H*""3\<;DBHH,:G@X0D@%@Q>ZD`"#.-?<H6Y&7`Y4;I
M',FP4%K0!RDW32^HL,2$$RM`4IX9P]I1F@HYZAC(L2)-#T%04OCIX\>R(`!F
MEDQY$@3V(4TC]"QH0<0/8,&8_3R1<\!`!!6O<%([D[8$=9Z8I#`'+;,52$(4
M%#A"E!]<->C@@Q!&*.&$%#KH%5)@B27(!0<P)H@!0E3G4P$-+`$""`0LL$0,
M9JPP1TKB^$/`$DHT]D$&?H``_Z,?0@1Q0Q!0@'$%3)BH4<$(A$!QVPU2-#",
M(&\88$<)`RQAGCAZ\47"$F/$Y@D(>-!5X)C^:/#%(;D)PL$""R80`$:F'1!$
M#*I9`$L`2Z0Q0282Z'A)+8@AL<P%A]3@!P]]I,2&`"F2L,(BF)!1000]/!"!
M''X*TJ,?'8B!C!P+$-`<-08P45T<*WAX"3EOG#/F;&<L@-<A"U9HZZVXYJKK
MKA9^E9-8#BA!I!\&Q*5J.#2@&(`)5T"J20@O+!"$,#W%ZL(,)&QA`(Q;M%',
M'@]8(`0!I/74HA`C,.`!2K3RM,4$(#`P3T\`;,F<"])0$X,-T[SJ[QF*>!&2
M(11(T?^E('4`0<"5X;`#`1-Q<,G(0%)L8.<&@J1!!;6.`/S`!C,8TDLG?HC@
M!`<N5&&"!,&%XP\$34C!P`7=%G-(!F,4$("\7F)B`*IC_#BL(PKD$$),_LY6
MA@VSUJI4%KQ&+?745%<]%1>^-A+6"U3TY@<%*^1;[9`93*%6(V2DF(\$/0M4
MP109?"9(#$.4,-H.#2P\FP,$,'!#05T<L@`7(5%1B$]G+,%;J%X[$H86#"?]
M:AG7I@."%/WZD<&C2&-RP1(+>'!%RX>D0<`3)%2PP#*UC*%`D178@#$`.9`<
M@Q00D$"`J+.A`8%:='L`@@^"J&#!D)G+%'89(Q"@WR$\N`#_H.3^DG%%"DXG
M=:'5W'?O_?>V@G7%@GZHP0#'?MSFB`BOR`!"GM3X,VT:<HDI3AI!2$"#'S0T
MD`,#"RB""PYVE@'L@!HSH((9B*"#"R#A"WDP@Q(0D`,@+&%Z#9O#G&8@'@A4
M85W.F1?UJ)>&!_Q@>@E`PMG$X8"T<&`O&/1$`"H`!C-0(3E^J(,3TO"Z2YCA
M"CI@@P<ZD"P(V"`-5CC6!P2`OD;$H`5$Z1\%TK`%,A1!"DKX0>/B)X06S"`&
M%;""#2[EN`!$;H1D,D(%#K&4`(#OC7",HQR?,A0)X$@09EB`%>B0DAD\P!')
M6D(.4G>L_2P@!!L(0!!FX)-:5*`&_S^JP!:BD3D056<!4SA!(TK@@B"<`0&B
MP=@'2I`"#X1@86US!`#L888:+"$*+."!`UI`@`/P@PTQT,#ST%@@"F1`(U'@
M0@)R,`N?9"D)/>!+*AL!,"V<8`Q+$(H:/A`%N3D.FG0`PA6T$`4(#,U-&+%`
M".XH"$>-0`(>>($?=J"#!1`K`QTYXR4,``(HDF$%05#G!YX``0%THFA*Z!PO
M9\."*DQO*=N;HT(7RM!<00U#F%A.%QB1!BUL0$5T\.0A:!"'*XS!!"T8FD_*
M\`!HB5.=U;(``U90@0I@<`>I:LQ`-$`\/U@``ET`P0>*$`(UR&$$1`@!%2#5
MDRTM``QVBO]#$<9P'T$(``(#L$$,!SJ;`@R`&&?I2"$Q`0`Z+"$`<5"=0*FA
MABM(H0=7\`@$@,`$"?`!$X]A0!"HL,()W`"5@C#2';1CTR"`H`UU\,$!"@"%
M,;3A32(4!]!(8`,+(*&G/R5"%,*SD5U2U2=H$(.7EK*%AGKVLZ#E2D+_((XR
M:*$+(I"4!LS`@`?<D0-#JL%HMBB;"[2``0*H007&Z1,C$8"<815IQFKI``L4
M@0'11(`7PO`"'CR`=.&00Q4>H(,N8,0!%]B``E``@.LL804N6*NK+CO2$*CC
M#88;:R->H+@-2&&%!<I`W\H5*TG^HAX5((`E_,"&&W#.AZ<K@`7_I&"!%H2@
M"IU`P0Z&9-E&>*"Q()```-VS7'5F`0`96(`-"%`$\LXF(-0(K8A'3&*J@.&A
M1JG+"'YI!@@H`8EVL.$08O`#\AG("DU8&15D8(86Q$`V9O@!"`K0!/B6D0I*
M6(&/*V`$!YB`#L6DUW/20`*^<$</<AAF$P"P$RA<0`E&8`!?/2R3!:!PAK3]
M$RA(`.51S0:F>#U/!?+`CS%[P@P?*8``H'O-$`B`,D]\``#:D(0+^@1$#R##
M#J#8`SEP@7`F*``0%J"$!?``8`P@<T]@((&QEOC3H`YU%L``T9[X0PE+74`5
M8+"``*"5@&/*0`@\*8-U`2P$+!B##:P9_PX5+$%OB+,`%:9`(R4P@`%;Q<26
M`L"#$*R@#`FP`PMJ8`(.F$`$2#""P/9@A06,H<$>IL``5,4&'8S/F$!0H`R^
MNDQQG&`*\AHK$H&0`0DT41`IL`+O1FJ!$5#A"G8X``$@(,]+H,H,')@"%1A!
M!@6\0`\[&,(&#J"#&G@`91O1-#5X<``W-R+4(`\Y:!-:H'AFX@$$P!>XJ?$%
M`51@!GP@@P]<$(("P.&]=X"!.,EI\!7`6C9&VC`!A(L)65M@`QI@0!E*4%$*
M@``!Y9/!`@[@YRA4H`D!6(%Z+YM"*;R##22@PL^I8:\36(#H/LE`%%J[\EHL
M00=,J-$A^DN`9/^+0U(H3]'6!<&"*2Q`!EJP``G`\%8A<`8'.9C!`6*^`P@P
M``1Y6*/&F6F$(K2[*$GIK,@WSWFKN?$HLTE!$-!0!C6480)DF.J(!,"`'`P"
M`==F@P@$P9/P/`$$%;B#MQSA!`AH,FE)][@CY&`G&3#J#MN!1P?$LH$0!,`0
M0(``%N9`\,L/M+]34,<>#+=R/^SA[#UX;YI[$BP&P`E6=M(!<Q@Q!@*@(&EA
M2%?W<6"#!Y#@#BX-"0(PT,,2',$"9A`':,$`=#`&*V!CFF8`:6`.LJ$4G]=Y
M$!B!N/*`I.43$U`N@N```G`=K[(#!"``.Z`"<W`(1<`/)B`61\`$WD3_`*]!
M`%A%*Q:P`DGP*A,P''QV"8QB!AZH*B5P"!10!@<P!=/0`7@05VCG86\P!0M2
M@_GG$WK``'DP`,#V*C?@>`77$T8B!22%!!8`388R)EXP&I(G#DH@*D90?8UP
M`IU`6%`@@H[Q``S0:9-W"$Z@$`6B%*,E@7JXAZ)5:N(P!@@(`@-@?8<@!S2!
M!BJ@3ACC"T4@`@I0!`"``+NE`4)0`19P`'N@:R#D!V90!H\!!;O7$_TU/F%P
M!PW&`2$P!GOP$@-``B+P`PY@/T00`%G`'2ED""^0;DTV>05P!"C%7S?P`%<(
M.Q"@`GYP`',Q&QXP!390`3Z6-!^@4K3W6R35_U0^$4C@8`'B@%X!P`$VH`5)
M@`(=0`4TL`4\0"@S<`1?H(A.503ODP0[0F9AH`0(V!-)\06:QX?ZN(]6L05?
M`'H]L0/N%%%FUA-ZQ@`']`3J=`;:80`&``>=8`-I]0`YL&^2T@4DH`_OUXFT
M%PGV@PDL(';O8(H!\A(LX'(CF`%ZP`$&P`%(X`<!,`8_)A1^8(PXD@$C```M
M8`5'L"<>-@0O<@@A251DTF,[8`!E(`%;0'X'H'0<P``:$02\UA,<<A,6(`#\
M`(!*D`)D$`1!B0EL@``;X%&-H8V8L(P6X`%*\`!+\`(7!P!'T`&7(2[[M)`X
M8@!<`)%A<$H@,%Y49?\&`;!WF)!Y_\B/AGF83H&/`!D.)'5Y99`#,>"3'5-+
M&=`)```#*.$`.^`%:2`$!H`$!R@&B^$E_F`B0T``=R``ZN`/]7,)&:`!AW,(
M)-D(>E8!(*`P!*`#"E`T?C`#K[,#LT@!'^`'7H`!>!`#(R`(GN('*'`&Y+*(
MO,0&63`&7M,&&G"#8[(<*Q`'?I`&(<!(E^``T9<&OND'?^0'C\%;XE`'1"`B
M-E4$+OA'`-,%&-`B=A"/4')L-E`#PVE3X9D6)!``$+`"&/!^)#`!)B`'BQ(`
M0E``$W"9F;F9G>D'/V8M#3%012,!W1=B2$&!B/FA(/J`XH`#HR<;X@F=YV'_
M`:<C`'(P`U#'(R3``R&Q`EH``H:3/,PT!A60!/^C']K)G8)P!E%P?HTPFWY`
M(H)4D02@!$+@8DWPHD53!0<@`E"P`G[G`SKPHLAP"$SP`B50!8B$1BSP#8TA
MI$0:#@7P>Z7U`#;@`;6@GL40?5O9"&9)>[G'<X2A`S%U"!;@`C&`!)DF"")P
M`S=P`2K",1@P6V&@!CH*`<-!*!FH!%;`!-''`$]@!P1`!'?P`G(@!R?0!8M@
M`/Q$!5F@*3%Z"&<P>WY``OFC/I(3/:IWATB1AR!:J_LHHM1``UTS)F;0`/QP
M"&BP!+C``#.0`0;P!NTQ`$HP!1``1ABXIEJ@F@)A_REPP`%H>`FSZ0%<4@8$
MA@;+40$LP%J?@093P!,(,`6*0"XN(``SX`,[\`02L*K-D38!@)\%L@,@<0C6
M.HR'8`+')@IU00!'8`"QL@QG\!(XZI]W1@`'U`@8D%Z.4`BJ<Y[`&E`#@94R
M<(`]<P:20@!6(`8OX'-H\!)G$"M0]``0@#$L$!P8$"YCT'Y=D*RN%U!5\%8]
M(`RF@P7[XR^UP*\-V*&V&K2&B0584X&8,&[^@@90<`0[H@E1H`&']$M)\`5=
M1`8"`$5CDC8-EC9$B:UE(`)W\``R,`!:I#6;$`%60`4$\`4)T`4M8`)/]($A
M4@,9D"!X@)YOX*`H(`0?$/\&8423!:(&R5-O1]@(<O`20T"/2T`".^LR+<*=
M#A``7<,/>$`'?G`$*&``=9JC;>H'"4`$5Y!F9FDZ?V)&86`Z!Z!>VJ@&'K$"
M5<``=RMG+O`"+K`$0?`!">`"5E`$&X9K`CH$%$`7(!%I?K`!)\`/=M",%SH;
M!H`%@3E02#%J0CN]?/@%A4D-.["YKZ(&6O!6AY`V2B`#.%4$+1``1Q`$8P=D
MX,:1F(`!=7`'6K`$0X![!0<$#``!0Q`N4&0#Z!L&FJ`!`H!):HH$8.`#(A`&
M++`,"G!(/X"BX<`"$C`];3`<W:>!%3"V0R<!++`>RQL.UF(%!Z`!$V`(%Z!)
M"@#_`@U`!8SY`%)P;M10I]H+K$L;`EKJ"!^@N0"J&F9@!C%X`'AP)K[``'M4
M`1(P/J_+&"2E!$"P`A`@`XYP`B),PB<`,!:`F3XQ`R!`B++:%45+O5ZLAP'B
M`EKLN!*@JOU@!@0P!3G@`C?P$ALZ%#\6#NS;"!0P'."%!,R26(U0-#V%QG3P
M`UB`L&A3`0>PEE*@2;\D"$#0")=!4E*0(-3``B-P):7BGN*@9QP&G^9Q3[E%
MQ!@@#NS5)0:@!W-C36C0!S'L"`_P?N$`PS)*#;/4L(V0`5I0`2NP!$R@`UP2
M&XL:`"BGHCN0=3'P,>@:$Z:S`*ES!:PQRJ5\""00AY"*_PE;H`713%5`^\78
M'(&7X`$ND+!)<P9FQ$RA\CNQVCM$;,4^A!.8#`Z/`0'.0W9'4*I!N@`,\*QW
M!@%4QP`1@`5[X@!9\)*&4AH&T`&F,P#]B:I0^P[3X7/6ERP$@`0Q@"\QX0\,
M(`28>@?5+`@;T%('``9A(`)RDP*T.`,3X``Y8`4]80$U?`EU.A`+(,\LC0`9
MD8$7<0J:,*#>/`$Z@`=DH*,$8`/'9F2"4`L$,`(Y``$N4`,?32TBG04D[0`P
M@,9$`&(W8P-VAT9'P04>FLU<'6HL7<Y)4P8+\(N90""\E`8FTKBTH@YED(I>
M4E9$8!"-X`5'P(`_<7FQ4G]-V?\>')`$.+(!DN8';=!A)A`"-*2O"Z`.%P`%
M8B,.]&$!)RG4\YR6,P2=`&`$5$`&`T`.7T`!/[`N33!D&,`!H#N&+[S2$:L@
M0.27-H4`X&P$7%-(9."1CI`!3("B9Y`&H;(`.L#*EP`P$F`#"P`!;^#9H"W:
M'K!3?J`$8^`"%VH`,Z#'Y'448$!J77W=)<8%8F"T>!0`FD8&5=#!5*7+P^'`
M'/E3C:W:.B`(&2J8:WH%59A)1R`P%"`"G3`!4"`?7,"%6M`#5<`:8=!%XT>;
M+N<^\-,3`W$'+-!O*9!`$J`$J+`#P1L#*6`0&-``=&<&6Q`$*8W:=.H(N#<&
M5."JK8W_#$M0`0,@F8?`FD#J`"_;;FB0!A;0;7APT'*F`25P4SU@X4Z2"4<Z
M#`BP,W$#`AGM84=1F-B=Y"+F1HV@!JG,=60F`02@P1;P`,O;B3T``6#=#V/0
M`G9@7E1E.E)P!)/R8W/0L"B@'1K@"P7@`I.2(--1`?4(2+AG!'1P!5>-"?1#
M!!%POV<@!PWA)`E`%Q\@![.7!2@+IG:2TJ&("=JKHI1B`1*P!WS:!@I3&F10
M,01IU5#@S=10!KX<!"\&R7BT!$E@`A6@`?R@`C#``4]P""7B`BG2Z!JGY+9.
M8@%`.(Y1`6.,1GQ+54HP`$M,!#W@R9Q8!F80.RA*RF!A`9ET_UFUP`!`,`#(
MY@%#(`A*D"#&R`(G,0`NYG-[QP;O,P8U@"^>[FX>408L<*$%0!=S@``#$`,7
MD`/P!@(JY0+%U>'B\.A$$"(Y<`,5$`6,H-)5KL%G'*9@45)X*AN];,L'$`-G
MHA'(=M1)4`-ET`%+*6LV``)04`'NS4NW'O*@A8]#_0#G[F%E`-\#!3`K<`("
M2@8MD@1F0`*1("E1`",!$`)R'0:I:Z=/H.)HQ/)@,`;-2H(AH:9-X`(,$)OB
M(`+XH@9I,>`-0^UDL`5([P('`).^`:A-8`3EL1SNK.^M_!,6L`0XP[`M$@,6
ML`<$$`-I\P3[$RL'`"-GD-_3*`34P_^Q[;<"1'`!CQ$$-@#4E^$%:4$&XS+G
MFF84*";RC!]'`N,'!3F'EZ#;I#Y"`T$$"RX!)[`"];QV#]`#-D0ML7(#-7``
MR<.:<4Q5`]$`1$``4?#JGUPR>&\`#7`%6\X_,@8"+H#XXE!E9@!"(H#W?J``
MY_`$/?`""Q,'`$0/:&#:CN[A?%HDD>#D4<`!\]64@C=#%ZH3)D`$2##167?[
M/1'CP[$`Z3("&1D!Y>$$+2#=DF\46]WX\M\]G#@&DA\.+V`&E4]"*P`(0CTK
M"S<V%F=E%E(;"S\;?GYD03&1EI%G"P]9EYV>GYYF!%$D+4H(D60(`RMF8:"6
M-"`$9B8N8V?_L+!R%A8I>`ZI""`&9I8"/Q8@$0]EGA:Z?A9MNM"@9A5S,00!
M(%4+B0]0+!95,!.SSI]G%C89T?"19686#!!'4B$C%NKQ_O%_LFSY0["@P8,(
M$RI<R+"APX<0(TJ<2+&BQ8L8,QY4\^"?1X]%!A3X^"E,@!4N7%10<XE,!20D
M'DBA4&:+&2TG/I5Y$"$G25!AHBRI82;('``"*H"#Q^'*`A(2^)&DH('`C$A>
M7OD!(<2!@!,'6%5HTF`%&5#68%E`I597F#%!EDBIT$_2BB9\(!#(84Q7F0I*
M4/PLJ48"`P8K\'P8S-C/GP!<-$J>3+FRY<N8,U?V0D!KX\]^U$S1_P':#YH%
M?3N%$46D"`$IE=XN\/&)#($(7DJ3"9'&@HL0(2`T@P=#PH,:4"J<_5A@`(&U
M`YKD.9+#``4Z$L#XX1!AQ9,6$!:LJ($VVMIJ\,HL2%.R"H,E0%:TR!TM#8$[
MP3X[.%)%S1DR8U1@A1)B+%8:/'^(H=F"##;HX(,05L;%`P&@<2!H9@20RX7K
M+'#%"0$P\$8D:%A`!QN>F$0`#XTA<,`.6JG!``'+Z4)##C26P,``GOT#PQ(N
MA.$"#I:(@$$.?;S@@@D\,!#5(14\\<8#"R3PC'G4M#48`$0LH,@#'D@!`0?P
MO+5"723Y\(0,GIR1Q@($/$#&AAQV$N&=>/_FJ>>>E'4AQEMU-F:2$",%>LE.
M51!A@184I**!E6U:$`(G'QEP1(U^Q+%"`#V"LD$%`9A@P0(Q+"$$I/%\T0X+
MU+`P`0D^D'&!$$_XD8$,(53!AQ)T^;':%3&X1$0=EZ2%%EOED32!&E#T\]<#
M;U@@`0;PE!C%.Q\YD`.9T:#1&X5J='H@G^26:^ZY=XK1Q1]^<&HH8Z>E@>J[
M9C`0P`L5Y-%H-']%`(<_!L0P@H61>#`%(DR%8`$+$D!`@C$P*$%`&BCJ4D!2
M'851@@R"\9&`"@9P<,89$5P1PDGL79+)`V"8L<(-%1O[R7E:>G2&#2EW\L0*
M@EQ!Q`7PJ%$!?O[_."#$`73Z4T8`#SQ@!IJ?H2OUU%17'5$6#T3F1QF8ODO2
M;@2_>P(9`1!P@VL#S`M*&BOD4"@L0M:(P@&]1H.!!!6\0819%TSH1PITX+&`
M"RR`4D`.%9CA@!%<^'&!`"EL)T`D0N2P0AXACB&N/`],,8,%+$MC'K(S>P1`
M&NY^<H.9.[A,A`'PF&&%$_!X0`74'H6A1@!*I1'V8`%8+?SPQ)OK105>$!1)
M1UXSMEKJ@9;A##M7[#`&`5N4.08$=$3CF<2IZ;)W&D!`\(,(GKBXG14/&&@)
M"000H($?6)"GV@M;]`#!"@TL8<'OH+!-!%A0@2E48'3HB8<!GD"":/2E_T13
MB,$85E"":,#A!PPH$X?^$Z`%S(DD)BF>"$=(PLQ,*`L%B<086-(\QISA!D=X
MVX6D9XF_#(`'%M#`OG1A+=(9(`DON`0/IJ`Y>&S@"F/PP`@8@`00^$$/?7!"
M!_S0`0D8X%]^2,,2BH"B`BB!'VBP4A]R@H<+X"$2(``#%"R@!B&LY!^KR9M]
MU-:):>@B!/'@P!.HY<!+J,%G+[#``8#VB1A4(`TV`(4#`D`;KWE+$RO<W"?,
M<(826O*2F)2(GPR2"IFUD"2GJT'%#E0&;EDB#16@`PDJ()*@M4`(N9&!#?KA
M@07\#QX?B(K>"&"J*RQA``J(A`QKA(;OY($*<__BEA,I`(1(L"$!!A!""P1`
MA!:$[Q_L>$`>KJ"#":`E2Y[XPC>B<88`7!,6YS1#"VI`!I\1RQ*:"@`';+"`
M3P`!"DEKX3Q`%P`6PF(,CD'(%[20R8(:5(1;6!<G?44`W'W2(VH(0>%(F3W5
M7.\&1D@E'4.Q@BH<P1(.H)L_87$!(EPA#N/;6@4D\`8(V(`(6QF"`WY``?0!
MP`\L$(4K$C"'()I@#WZ(@0EJ@`8$K&`%#T!"$'#1F+^,0`KCF1DX+4&57KW3
M$Q]H`/1BMXX`%<%EE3"8!3B@A.%TH@PK?"@H=O<`"Y@!@))P1D+$4($O'/2N
M>#W7%[)V$$L$`*!J=9[_&1XPT<_4!!0EHD(-+CI*3W@`"G\-`@D```0KN"(:
M==B;&9RP@B*>D@!!&$(%0@"&#S3P!'?P`Q&,X)0<1$(.?J!&+2<@`1A\8`!!
M6,`+%.90DAQ!+YWSB27L:(GF,"!G`8C`#OV0@"-<Y2-.!(4B/`>G"L3@#A/S
MQ`NB<,[`J@9`5/*="B.1$"U@`0L%\4(6(O,'];+W#U]`85[G2]^,<*&N"#EE
M`'KK77B<80L!H(%A*[I6P`22"C*TA!!NN;5ZC""?G_!!9S=P,+CZJFPE,`,$
MYK`#V%&@`%,8C@(H<`141B(`P@P#Z")@`^5<B`(K0)A+GG!5XOKA#00X``'.
M_SJ%E)U@`<$D271A89L&6.`%$-BJ'P"P`,_VU[]DT(0%-!10@TQH0@0!PV$(
MX`4MSRAY73C,`_ZP2<[4UR#JS8*:O\`%NU[$"\F;#)P9\@4W,XC-"\$S1.8L
MWXFP+"&6<!-@G_R3#@#!`XWI`!]U@0T\[.`'A+($&*(PTE2T#7:@P$`$+*"W
M*U0Z4A,;0P@X((LEV.&C?BB"#^B0@/PTR@`Y@``3C`"!RY9&!6ZLRZ\J(0U4
M4*`<`EA"UU(!A0C8FB1]*%.]$'8)`(A!"?PE-"C&\*T`@,$@`/[#`Y*G!06)
M80O=3M`6...%^V8!#`3=P@+.7!`L'.8P6L@"02]R7O_*U%LA[E8H@^*]$'Y#
MI-X,H$@`@@=H2ZP0PM+V1QJ8^I.1Q>,,8W#!PR9V`BET-Q*K6<%S+Y%9&MW@
M"L>.AM`$``8")-D!$P`J3$EP!`Y\@00@6,`,5A"$#81@*:4Q`!-6D+-.K"P+
M%LA`L*L0A)!;(@$#>((99C*8:.M"!A88=L+KTX\LH+<@7;AV``:BB2U$INOL
M35X6*K!>!G!AD^S^P[T)(F^,K%TC;S^(%J[M('^7M\\.B7M$Q+``+3Q`"^;%
M@IH]8_2IPS$`&B"=TIQ>PW*XA@$-).<")!N)"=R@%2!8`L,]8A@+\"`'A/1#
M`6)@@"!F``4L@(`%BK`$!NS_X$+QE*0E>&#R((3`!<SNQ`2P(`5UG$$*K?S(
MQ;N5@S3(WO`IJJ<E$$*`=Z_;"UJ8$1B@+_W';!F%<\=OVM_>=K7/_0_C!C\*
MU6P0+)A7[0'HP@(B<_;SJQW=`WF_%N+_A05T(3+G;?_5V5Z!+GBA_O<7$&"P
M`''F?0%8?]^G=@.U!?47/&JF?I'!;P#X7G\@@?;'7N87@%Q@?P&`7NBU!0-(
M<`.%!>''$%QP;N?5"VWU`-1&0\CG$6@P`K7B$640>?Z@`"T&!630-(4%"SL1
M`B!`"#UP,(S7"1>`-UR#!0E0!*(W197`(AD0`A5``F%&!"XC!)@&"@B0A:`P
M`X=@_V&=P`&XAP12Z%"9,&P[T8/Q,'R@H`)F$$0O^`^4=`D'@35JE@4!ESQ>
M$`!:H(=\^`7XQ6_J0@!I1Q#<1U!8`"H$D`5=,!`$L&Z-V&X$@`4/(`98P`T4
M\@=]=XD#P0!:$"+)XXF@R`7<T'=JAP5=\`"42'?@%R=90`!=`'AJ!RKLM063
MN`#!`XN@^`>BR``+P(F7V'<$%6^D&`"F6!#$"(NR2%>4N"Y:8'^3R(L56`&<
M2(JQR`!XYQ"7<!H`$@`J.&5F0`9E`(9QJ`9C4(1;0V#5@@NK,2;V`02-M38Y
M!@0T0A(T@`6M4'GYX3BF%PDW0`L<$`0!D`$C<08$T`+N<_\)]\@`5)"0E_`6
M;Q0-!4`$%2`#E]ASEW`QA7=*@[:&-*A\<>@/Y60G!A$`"D(0"P`&F\1W*[D`
M8W>"V`A?!#!OV_=NV-AV9*=V?N)_#U`!?X`\!;$)[66)ZX)N9(9_Z,4`R2.4
M2JEMYZ90VW9>X?9_!A%OX/8'I.@%J%A^Z_8'TT=P_,8`=C5_ITB)6,EE\::2
M!+%MR"@0!)658C!^6D"*!'%^`4>6'6B4I)B-#=$)QC`/AU(&:6`&8P`ZO6`&
M9J`&98!PTF8&`Z!XTJ6.L``'YJ05`/`$#$D"`=`"'!"/*1(B-T`2'-`"4F`$
M.$!J!1!$,F0$7K@P(?``[&$_88#_0^(0>GY0`DB4`D]0`42@-CM@3?`@"XG3
M%$H6"0G0`$K`F)T`!TF08-?@#[4D=2'I$0>A?0G2!5_0?`109]II5P\P(Q5`
M=]18B#IYAR=(4`$7$%JP5P.HE(18$.EIB.C5=ES`=]&8GF%9EU9GDU:'!6+`
M`-1(@?%V;P.Z?_`U(_[77N87D_B)0N=%H/*VG^_69P6JG^#7!140;_,&<!7H
MH`]JH1$!"E3F%M*#F+94`:."F-)S?%YS!D]P`)!Y5I+I"0XP!T9`)R2P!)RR
M$U"`0X3C7Y*"+;@4%6@``B2@``[`!P4P!WXP@QH0A4?68D+@!Q&``$W@6CZP
M`]00(DU@_P`>$!7W$CFJ%03#DBDML'FPT!1C4`-$"@L;0(Z?``!V`%-]U"U&
ML#K3&34&@7=MAI7K11`GR%Z!.F<_:6?L=HC2J)Y_P`WF9XP&$9^GJ*A^AP6_
MF*CYV:&H:)[UQHBP6)7]J9]QMX<54`&D^(M,::$/>G4::G5=8)YM":&).'`:
M*I_2R&^I"J(0`10=:3-EH`:(^8UC8`9I0$-HP(71HP1%8*R',J.=P`("%@EO
M@'M)PS9"X!)08)O250%0(*2?<(2@\B\8,#F.8PE/T`$4$#^T`@$,D`<1X`<(
MT`8?P$)SZ`!PH&%!(`5-"@`-@%.:8P%()171``.]@!P1V0EL0/\I@V&._,6&
MD6!*>=H8$K(%/DF>B)J36]EW`!9N!9&3*KFIZ$D079"4%MJ@5YD@6GE>8D>3
M'7J56?EV8$!WV#AO.=F@9?F6!,`%5CEO8E"`.7N6T(="X$:*7R>RMHH%>KF(
M$@$+G_89:,`UA`DZAX%[!V`&<;"/!Q(&1``).L&L?M`'7@)26E"P#QD`$)`$
M+O,$WN1`L`@*1D``1A`&#G`!N7`!^)-(D<`#`K`C0@"@#+`!#W`%'&`E;/`!
MB.8'2>`'"_!19X`!N2$!3>H'*)`30>!BT0``>$,&1I"/GX`!/X!BGV$&$2`8
MDP0+,X!S#^L/;_4)E8&'\4<0K3M?B!K_JTCK;EGPGX::B(FX!1[[D_;'`"+;
MH9:Z7K"(H:<H!JJHBIYJC;+X=ME)J7UH+]&'0C3[H,HXC,+;!<3;ELI+4*E8
M-L/XB?<)O/FGC#$9HIU`!G`:/8)I!K9T!;C7!49`!QQ`D(T1`]?J"8>UG!&0
M.@"P`U3`L.P@`1X0<0ZKJ[-T"1Q@`6/0`!^`!"]``2:P'21``3T0":DW!CO0
MIF2P!#E`0$$``P=@``<P`5PPI2E0P7X`!9&3;&]0.)JRD9VP`4M0"S:`II;`
M!G@`!>G[#P!P`\T9"I\@!U"`D:=+3A>W(-U'7UOPNE]`<.9'=P/59BIKB.>W
MQ/`5/`/5B.@U_V\!,)8$T<7PM0`+8%=6;'X&^AAV-8'@][I>J04!"&[G=6U<
M3,:ZFWX!",;U-\8EF<87B)5B/(!8B;W?5H%HO,;P95YV]Q"?B7QAT*N_:@$$
M@*+&Y@1\X`/."0HDTZ7+VFQ8(`$XJGDLZ@<\0`77<P?1,BW5$J1W0P"U,@#0
M:@!VX`$?(&`7T`8'8`%I$`5BNQI+<`,2L`1YT`%O<`0B8""A1QX\T`<`X`-3
M8+IIV@(+P#``:[`D@`5BRB%<0@?/&@G7=#'%6<2ZL`"21!!U-A#UV;I6U[K?
M1JA;(`;L%U]8$!G&:ZCD6<]Y=\8.`H(^F[2>,&AHL,/>E0ADD"&]@/\8WR`$
M1V`")Q"C+B@/%04`=%`%_<`+#*8+6&,!?!`!H+("3-`#5P"C05,!#'"XW'P6
M6\`&`,`M&`#)>2`4&\D.KL<[,>`#4^0',^`,42!ZD0`#06!6NG`W#[`%)B6=
M+"`$#EDG9#`"+U`QJ=$<&@#0X&P):+"TY%6!?Z=M/1D\6J8%T5@V%=#5%=`T
M`3&J&<J+GFC/:'W/>(*'83O%VN@):4`GXAS5)+*^A?F=!&`#$A``=K`#9?`!
M;,`%5W%8,O`#.4,!&"J=E^`%&@T$EM,79D('5ZBLJB$[1B`"T=0HW10`"L`"
M20`!2$`'%6##^%L!4O"=0(`!4V0`D0,`3(#_``X@,8IM"25%`'C0!`RPD0B@
M`4[F-:M!!85C##1`!P]`U73]$W6I(/1)JEO7QKR8/.-YLYH(!J_(!5X0<$F<
MUMJ-$.2WUB1($26QC0P+SHT\#^QK`2*M%U1P!TP@`4K@&4Y`"RS*!D70"C4`
M`;UM&OZZ`1/42+H`<0QY`4S8`3<``B,``2/@`0PPS=WB)%L4`/NZ!2SB!P:P
M!4D6RC5@+R>P`E80HT$U`NA8&IGP!#D@`C8PWL=-G>*;H5R-0EZ@;K-ZBJ\(
M>-38?=CMUMN=XY84#VE@W"G>)KUJ`1!P,"Z5#PR0`V60`4'V"7OP`V.@!U%0
MT9Z@!J_$!Q9PO_SR_P`C(`,M0`)V4%8S,`!6@"DD8`,!0$?&-04PP`$%@``I
MT`<JD`8#4%:Y!PL?L`\L,`!4D`8]&9K;.`:SW3PR``%=H)P_W@D^7M6V&GA8
MT&4,\'<Q?EYC]Z!J-F\WKN.8CDG^,->'_@]E$`++@09CP#L,<`4/<`!MH@D]
M@`0M$.B^HDXWH`-W0=GG:P55,`!ZT0+R;0D4/0]7`#.6,`MI@`+.4`1CH`1^
MX`(ID`%TXW3AFC=$D-L90`0B4$O#@0%*`,,M--Q?V^G5XKFZ8*'JPG8X>VWH
M=CP@BP6`2,[J9>F*FNGP/D*8K&L@Z>UK*`6%HP9!8`(N4QV7``>L$`-ST/\*
MH1QH$R39*^`$M&X)J^$DOD@G7E&P$$<%P%X/$6`V%U#!P61UE@4/F<5S-;`I
M'4`#$]`!"C`YD$P%-F#H+:0"$V[O;E'OL&"AU[W$I&I_8'#5H+(%OON3UK8)
M-C[6]!SO1#\UL`#N\H#B,.\K8V`#.%`B2Y`$$S0#````L68&,;!4+/\)/6`%
M##`%)"`><>!?<+(!`M8<NWY63;,'%F`J#-#>?L`%.O`$^!W*,=!91=`"55`K
M.SLY',`"#O`""X`C$7!3WL4"E[ST_;SU`>5OMH@],LD-/IF=2H%>@&@O[QYP
M]X7C1=_YY'+TH1#B]HX&$5`)5"X$)3`JHZ('927_^LQE4FI@`CUI!)_2F^DQ
M-#9'VBU1`0=0!5&@!PN`C1=@!5(."A^P:3Q`D64P#'YP`@7@`EL3%63@`QZ0
M!PS@^HQ!`TGPWHI?'XF^?!&A7B![DIY?_B2DM%"C^]T_Y5'P`JO1`EL0`3=@
M.:[N"6R@`R`7"2(`!CT`"&8K.VD50@9^B8J+?E\5%F6,DHEA9@0V*RL+#"UJ
MDXQU1%=J.BL,!7!2"0`3?@H(1F)($Q$,#PN1G[J[NFQT&KF\PL/$Q<1E`<5_
MR\S-SG]>#`$!#%[/U]C9VMO<W=[?X.'BX^3EYN=_NF')C&%C8<;Q\O/#E0%A
M9V,,$&;P\34MQF2(D6@+_P(,"LXLF+(AP*!/!000(!-/X9(5!/KQJG/CBAD0
M*\8D$)&(HAP$0/((@`-B0X4Q/:A8\$>/&`P[>FKJW&DLS`)CS;)HV09&RX(L
MS1B@6\JTJ=.G4*-*?;:+'2,T5GEJW3KI3)D>#M"<D9=E"@$EB0!X\0,@S(D"
MB5XPL$'"PA0.DA80P#%OPJ:QO&J$[#'%0H\9<'G,\`-$1(X09`#X$<#@CI0*
MP;A*PB#$A^;/6WW2'!9TJ#BE4U.K7LVZM6MGN]*@Z0JZ]E8:=!K$HV6%S)`7
M(#P4@``@.%X_=2Y3.Z"FPA0$BRRD(2!!<C$^%18\X'7A@84=$2IXPB(`X9-$
M$?\$:/%3!`\"";6DV%X$0(,%P//S%PLPVQ@7,6)P(5066'"QC!=8!`B-%V"(
M\0>!!E:#Q1?+_+=%A5]L8<UK'';HX8=3[7)&&OJ5N!4/$N#'2T<'5%'?"QYP
M`,`1';#@AP4%F'!)#U6,$0`5?)C1`D&)6.#'.A5L,(P#2CP0B9&?U)%#!63$
M<,48//AA@`%PP*5!$T(8"80?&>C!@0(<0&&!!'+,5P8P)L:YBQF>Q/-`!0\\
MD$4%?"X`#0%W#H5%G@0$P.=0#.!)@#5Y5A#`@WA>".*DE%9J*3:\C"&BG)Q^
M8L\%NY3QP!AGB)$("GZ0,($)<K!!T!Q!C*$&`1;T=X;_71N,,44/-RIRZP@>
MZ`(`$%:06.0D;-RP`IVCG@&``SMXD880?L1`QA@()%""`@KDX,<,"OAA8QD5
M1+"69E\$8$:G["JB!D7QD&O@`EL0P$4T?X#1Q1]<*#5HOO;V^P<#%W81@%#\
M5B`@`9<V[/##K_&BT2=C]-=NNV=L@84#DZ#!P'E^!)L($R_((0=<%$CQ0`@2
M4"E)<P=P8%<%C#0G`0:,3'#$$O=$)\D>M\R@,@&\^B$$"5GZ0485-?AQ@0]B
MJ-`#=(HHT$0"Z@8QAW4[(0#%.Q>'+8\96#"#\,`5@D'-'UB4?;92J`F%105:
M:$%`%F=#K/?>?)O#"QKP3B*:_]CMTE"#&%PG4H8$%MA0A09^'('$(A<,0$`1
M`60T&B-F6/%$$@1,(@@1=23BTGV20)G("2$\T$,$!%00P@X6+'&`'S6\0,(#
M2$BQ0QX,$'`#&XIT(!DB;/0Q&11+V)&X/#6,8#'AU$M<]C)O_YF=OVZ;!C?V
M6F`1?MM>Y-WW^>BG#QLO64GB3O7LDB'](F<0<``1%5!A0`$P%#!!"AI@@!D>
M<"45>6H,*Z"9X,9P!1(,`#.?@!(;0$"`-/"`'_"P1`V:\P0/F&$,:$&"`)5`
M!!>,(`_),`,%#-``CB6B#4;P0!!L0+5XH&$,@8.??M`PO7BD85]LVX+WV/8H
M@;7M0?]#K,8?MM`%,0`Q"P(RC?JF2$6]"4-3N]B<#DNTC@-T0!'NF(()A&0!
M,/B`!558``>>X"1CH$&!GW@CM71AI!>T(`!@N(6*W!&"*3%``'Z@0!HW$($'
M!.$`+ZB`#1*@`!`T(`%8\`,7N."'%]"`!&IH00Z>MXL+@&!B6\Q/&&92DS,0
MK%Y%6892Q*"G3;"M>ZH<V`+`4`$-G5)AYJNB+G?Y(6&<08NA%-L9).`\1:"A
M<3*HPA3R4`$I(&$B\U!=!&O(B!U0P`+>T4,A,[,((1"``"\8`Z!>D#F*N",(
M.3!"!6Z0`N4EP@LG\,-Q_)`$,P0!"YQD1`)`L)A@ZL<=P#3_1KT(L(7L<>$!
MTEC4$;/'`"Q(8QD#O5`N>4G1BJ:&*W7R9XG4`(7,-.<*29#"#31'CP4`(9]%
M:H,D:K`$<4(@#0U8@;$DX0,;]*,Y57A`#DAJ3`O\X``'@$`4V(`SY/B!#G[P
M0@TPX($<K&`))/B$`9I@`T1H=#X`Y8E%M\I57G(%*U<UD1D"(+(C68(!J"OE
M&"J0!!I,P@(J5<0)IM#&2C#`"M14!`*P4()%5((`"S"@NRH0!3I8@0I5<*L$
MX(`S$:#@!7CPPP&*<(40@*&:+<AA6#\S2L'.HZN@#>WYAG$&STH"*P'=;&@$
MD`.:G*&'-2&7$EP8':K5`00NHY\%_[1``4;$H0%Y)48E'H"%'1#@"'!`0@9>
MX(<!["$%1LI`"C(P@!7,P:U>`$$:4JO:G51L*Z(-KW@O58_VZ>*8W.WN3M#`
M'-`\@0`@L$(Q%6$!Z,1@60$EUP#@X@,IS)0>^:#"$<P``25D@41`8$,1X+(6
M`-3@``PH0Q%V8%7U:F:4L*W)>#?,80X1`XO#0*^%+6R!$52@!P0^0BMNA`")
M?$`8TX&"$M);C#)88`$O6``5()<(%PK`!P]8@02:9-H1U^28&=9PAY?,Y*@0
M(PU%ED0^:&SD>9PA"DK2R@)&$(,'2*$'"T@2BRT0@.99AP*/7(0#%+`.X1%O
M*V0@P`J<X/\"*.PA!_)!@016(`4@/(+*528&&J"IF28;^M#G(,89,EJ/[P9:
M,PJ)`DI[8@D=Q%D),,C.`YP``6#4#E1*NP)?*JD$M_KAF"X`M5;L&H/I#(`-
M%`@".*L`P4=K9=":U0JB=\UK;V"U5K;6##*8RQ.%5&$#9EC"#);`@!$<@$]V
M($$+A`"/2HPA`NNJV17VRQ6%6$`)+;O"#K10@?\&NR9D"$"4E=SK=KN;&?H)
M`*//O1,*F('8.Q&5%#A0@1CLH`7]6`=4[;DUW'%S$6:H`!W>K!51D?N;8*.W
M3LB0[=J\^^+M+I&Z);X5$E0AR?&(,P%:JJ)CAB"<4-W"P>DW!A?_#(\KP`,V
MQVLRAHI;'.,X/[0QS#MS3IU!"P-8=1I6[H?F6$`'%H"O,&Q,!1OMQ`<'B'C/
MY>&.-/"<*SG/.I-WOA-`3_T39<!%B31H*`%,6A%DJ$`3&!X/5ZGXZ_-P1[KU
MH_6Z;]@8:IAW3QP-]WFD(0(I^*<X=V#/J/*B$N5F^S#*,(#@]KT>:/@)W>U.
M^=#VY.K"E??CXQZ`)X!\*TZP0`C>L(`?&%Y$"W"!TX5Q@II[??/LJKSLN1H/
MS!<#RK"71^1SK1D.G"'M`I#!RC*P]`=$01@9(%7NA2MU$\W^^10-^>>7/Q\U
MC"$&IOY,&2)AUP%04`"TG81@0O>)!`2>__J"KE@8>&\;Z+N_BA4QMTZFC_Y%
M<"`'YQ=V,!02`A:4^?2+@`!C8`%O0`6?H`<+4%;UIPMJ<`^=)2?O%X'I(P\@
MQA-F8',+N`LOD`,DP15@P$VBT@5Z('K$EPBA,!%6@H%'\@2@E(&90G^%)H$R
MN#=CLVYN%%@NR`MA!P)G)U`9%F?!5P%=D`'*8@:LI'R,0`8XF(,=LPC\T2DS
M&(4/HWOL1P_K('],N`AD\`#8QQ-;H`Z9`P(4M``S4!C<!`!8X`)$QX07J`A/
M"(52&(>5,@^V1P_6]WKHYP`:T($U\84B8@%7$`2PDVL7\`-8F(619S$XU"YR
MV(@@0H>UX0YZE_^%B@``0U"%PU`ZQ=>"?@`'#2``>)A[8T439(")^>&(J.AA
M\K!]MG&'E`AVLY1];@2#DJ``1B`!M(A^D9<9I1@VJ?B+K!%,5?>*GT`&-M!7
M\;*&NB`#1Y"+Z#>*6GB(<0*,U!@B_J0&-IB#ZQ`"KZ=RQH``1-!;Q+@(8==#
MUD<XU9B.3S&.5:80IK@(WD@,T,B.1Q(`6.B,[:>.^H@.-2&-GR$K]$B.4I!E
MO!"/NP``UZ*,3"@65[6/#ED.-5&'FJ&$V>B":7",!:F0+W`$\\2.J?5+\/.0
M(AD._5B1JS:)XQ@&0#`'134)!ND^9_!%`9D/[#=*H9B/(YF3VU!*_AC_D'&R
M!04G"2^I"`70!<U'C/804%D5DCK9E)AR9!BSB#X9,B-`D(HPE'Y@`A*@D-H8
M94>)CDX9ELWP:#;&E2Y8"1'`AW[PDADP`N^8@2BI6F(YE^E@:PDYE:4%C[F0
M`A+0,_1XEX%&EV*Y$R8Y'X#IDPX``F&@<B+0!6G%CH>Y"W$)EH+9E#LAD7$2
MF>R820U`!#]@EO6GF;KPAL%4F4ZY$WFG0THXF=K8AG\Y!J#I!U+I3Z9IF3JQ
M#J&$CU,)>]86FTKSEKY8FSG)$YAY,=NUFTQX!AMG#+T85L(YG#M!!KH9)\I)
MFLB9>S=9$CU9/<\YDL6VG6*S?M?)FVD`FW98_X$-V9T/J17H&5:X-YXSAPS3
MF0A@U5WJN9X66)CA69YDD)WP23UAX)^+4)_V>9_[>&M^:&%9,`V^^9^$8WW+
M.7^2IUX&6J',\"BZQ`5;,`T;8J'9D"Y=``9-`44>6J+I@Z&\Y`5.)`8=6J+I
M$@!;8"`F.J.&!@8B:E$,XJ(!L``*XA231*-`RC=($5H!,"'=F2$R^A1<H`4M
M&J1.FHY>L*%-JI,:&@`4HAI=<*5/NJ4/F05BH*4/*08'PQI&RJ5F2BE)NF$J
M.@T:0HTJ>CUG&J>&!D1-]@5B"J-3&H%V.@U?*J=^VF0LRFM[.J;N1R!L"J8<
M<J-_NJBMH:(YAP5;@/^H&.<%10H&:?HA6R`IC+JIJH&B&)<A`2"C/WIH7X`%
MTR"IE;(%#L*IK!J6I3H-"4*BH%4^D&HVE]HP^M*JNDJ7M%JD12H&0YH^>-,V
ML`JL>0HQZ;*KREJ;Y<,,&E.I'R(@60`&<*HQ6``&LEI%R;JLW+H4FEJ-8D"L
M;6.JX]HVP8HW>".J>!.NY4JNY+,,7X"NH?4%?M*M]FH.-FJ:Z"JKTGJL2[:D
MMWJO`NL-GCJP>\,%71"P!KNPV%"P#-LP"*NP#SNQ$(6J%`LB7N"O%_NP"+*Q
M'ONQ$$.G(-LA&CNR"QNH)OL:5IJR'YLA+-L:7?"M+TNQ#CNS3Y&I-NNQH9K_
MLU(AL3PKL/GZLT([M`1+M.B0!25KM-R:M.B`($S[##[KM.)`(.%0%'`J#C[;
M##Z+L^(@M0VSK4H;MMZ0!0P0K-_@"-I`MF;K#0X5#M]4L]VP!?6Z#7*K#74S
M#FK[M7`KMGSK#'D;#FV;#7\+#LT*#@U5#G?+#8F+#8L+#H-+*?3:MQ,KLU"A
MME^@!?52`12"!03P4']`#9KK"`P@16S3N8]"MET0.Q2RI*-[+UI`(3"Z1/0R
M%$*T!:V[1*,[#1>:*!<247]PN;#[*-/P`$`T4*&J!;?K!0BEN<;;#*!+(5KP
M`,B+H=3P4-/0!01##?N"NH!B(+Y[N9Q;JJ8;%0`K_[D/B[)2H;9D6R@,T`71
ML`#86U#2(+VB*T7O&[_KJ[U_8#><.Q0$-3!#T04+T+8.=0L$$PT&+$6@*[\+
ML`EX4[;[.Q3(>[A+]+:<>\%_D+IS4TMOZZP))<$,H!W5``;2L`F7*PT5,+K(
M&Z_!H[U<`%AZ(2`,,,/W2S!*FK#FR[&KFKYE2[874C=D&ZH4T@45D"\,P`6!
MBSW2P`44XL,1'`T.(@;5L``'D\)_\`#AZB]*U%!2;`UTDQ1ED[K+0`!=D+=W
MB[SWP@QW*X2?^P#[6P%(:R"-2\0/(J+D]B!E&Z5&+!1N[%#ET\,VG+JVZP7]
M@JW2\,="?,-9F\/+NK=+H?^^$%PW+SS#^V(WT5NV2<POG=N^>(P40`S!:BL&
MX:,79%NJ6JQ*;8,:C7NXB?O)GBS!I!O!`T,W5NQ0B?+*S="X=YNW@S+#0B$H
M2@')2.%0#E4W#96WD\S)3;&D3\O(NKK#42',LDRI*2Q$%3"N"((:S$#-!&/&
M6I"WEAO"8M#`#$/`J-%0@;O*9=/*WQS)L.P,=SNZXPI1FU#$NCP4A"S+:NM0
M7>!0O\PVP0S(P]Q0Z(P%#SRDW$RYY9"ESMS002'0$9P%"Q`AIFHO6>"^F2S1
M%.W-_2*\J/%-=@I8`#W2`W.M#/"EHPO&GWO$_6+0#&"I7]RXLBR]?R"FG^L@
M;=O_N)F3P0RSRV4;O;C[SVT+R8\2O20,14<!SA-=TDRQL@[]U-)<-]&`)X!<
M`;%3T[:PS8F"4`<MR]0PO<N@%[][TB,=N(>+4+%#NH?K!;%CU80</%;]SLV@
M%_UL"YR,O9;\!W1M-G9=U$.AMMB+4#\-S)V\O@A5(-^4PG^,%%/-U4OA!1;[
MU)+KM%*+LQ*M!3=:%`NPN@T<%`N`V="`!=;`M>(#IUD@*:+](&YS/08=VI=+
MNJW]NPU\I44!!CC+M<P`OFRC!3B,Q+QM(+K-#$6!PSCKM`B[V09MV65#V1-"
MQ?#ZV2+JM9>MJ)+-M]/Z;GL"16PLAXM<W=SJR$V6PKXL_X=;0-W>O;#@S61O
MNK8RJ*KG3;&1RK>Y^MX3V[%BV\STO:LBF]_\S:CH*[1?@-_]W:IV2K3E.^`3
MF]X@&[$(3K/=O;$,WN`3>]TYR\P2?K$*?K$,?>$4"\TLZ]0<'N(F"N(B7N(&
M&K,FGN+WB=LJ?K(";J_FW>(#ZZ@R7N.5N=\VGN,ZN;,;6ZHZ_K"C2K%@:[-(
M(:WRRB_A>JQ,_+L/S@WLK:1@^@5-_N.\%+D_&]`S/,,)HRBHBC#?S!3:G+ZD
M^^7A@.-4SC?Y?.5(Y`Q=`$18,+>E4443=1JH"-EGWIW!',M'7"%P_KD\2KOE
MLZ`3+3Y7*CXW>JV8RR]=$#[+P/_:H,TV18':O]T,]`K:44KHR["CHMP,&C*M
M`NR]$HVA;8HWMGNU<6CFW;KD1)OG0>'&V#`HAB+!!%(HTMO`13PHG(L4N5L-
M74!<#R"B_N(H=P/`U!"E!/#FGDK&Q9X%,'SK#Q#KN3SK`4"\^ULHU[R_PVRJ
M*>V(&<ZI%K[J>)SE!AW+S?``FROK;PXIL?0`UI"K2J0G6N`@=JX4<,PV^_+N
M!%*OBDJIR_#->\(O2F'NNQWM6+`OJ:0%IVO/V8XVJ!C?`[OAX)X%>H(WY4/N
MS!`WZ`Y+:)/E*:W*7IHH!;+QX,/PW_P%P>.^S8`@R(LW233R:DP@L$3F2O'E
M1Q3FW&W_ZM\=V3;+ZLSPPL[;H1B/[0N51.A*(1[_(*E[[PR/,$=/S45<(8`U
M*"P?2T'_\D./[;%$\V5C\W*(ZKI*XA$?RWIR('N^#&._Z=]\]6A3[X[J\:G-
M]']0[P5/\M-ZH]I\-G"</6<_YC"_YHPN\?LKHOW,\*CXW\J*XF++\\Y*4'GD
MJ7,S-QF_YFCS^+5$]ZR$ZY,O[+K>[UGP!<?^V5H=`"N?/93/]U=/;H82QL]^
M[9[KB`7.K2RNM$,QY(W>N3C<#&^^H9^;(1>RK:91VOV>Z>=^/;__Z*:QLL.=
MID+4-F#@^XU.+YYJI3B;K/$^P'P.HQ>RZ:G8[6<:^W>./F0N_Y(\KJON7>-2
MKNK8\`4Z[Q09"P[AWZ4QSJCS7>/^;O&-KLSEP`6/\OJO#@A8?X-_782'AUM>
MB(R-CH^0D9*3E)66D0&7FIN<G9Z?H)9;H:2EIJ>HJ:JA6EE96H]:8*"O?UB"
MC[>'#*N]OK^2F<##Q,7&Q\C)RLN)BUM9?ZY_8%JXK;586EU<A%D575Y<70M?
M?UY;75E;7PL!X@O<[+*%%=FMT]6#7`M=`;A_6Q@(8K>-F<&#Y0XJ7,BPH<.'
M#[N,(K"@T#,"6!X(NJ9E"\9VA#P^^*)%&P$N60@$>%6/@)8`#PP1Z,?`RP.7
M%2I<S+B1'T9"`1AHX3*S),2C2),J3?_E!=;2IU`?B@'WH,*?"EX"C.)BE2.6
MBM,.M?)R\D]';X.TB+%EZ%76M*Y@Z=+ZARO1M/_^\-H"B^BBJ(`#"X8HCMO@
MPXA[?7D`9D%-`F892.;%\0N#F7_AUK*%9?,]7;6\9&,0EW/DR9MU$>*E^E[B
MUUP,OYX=JC#MV[@WJ<P6H*):5]`XF@N04VQISIZA@1Y*,6-I7;^!.U4]B+4U
M:+D#>UF;O3NEV-[#BQ^TH&,`M85P9>((9I9>XV2YG77Z6="KS16>"^JBGBBW
M!7GMU1<!F8V7E"$&)JC@@KAA09H8#)23TGF&5/:14W"991)*]"EGGQ9>,'`>
M:2EMX=R$VFC_&,!/J[E3%(:T?0$<8.XP&%Z!-N8(&$E<D$0(-04%\,47F0`I
MVQ]"UC5..40.DN06HS3)URVS]./%`J,8J6078HQ"B!BP$'3D8-LM4($VMW2A
MQ0/58(?4%^[I>%N2<M9IYYV?9+'``V+@2`@78'1100!^XFEH*1(=JN@QYT"B
MB"1C?F=)7I!0BHAH;D*UCVN3\)7.HJ!ZTF6HI/K29"R9-G*E)BM9PLLDKSI2
MP0.I*N5-G);H.4^IO#KJ9:_`#L.I(YM9,JPDL4:2+"/++K7%`V-^,=6:U$H4
MJ1>"_JJ0I<$>M`5WW8;;29/5,(!@0"5E<2HL'HGXQTU:88$1+ETD_\2%%@Q4
M\(5(0U8@E'P.(MB%0+S<FV\Y`1!7",$`$>`N4$(A^2]`\B;$4!<%Z8/%-^L@
MDH48,=7*Q<981)J,,.)ZBV#*+.<*B[E@1$@6&$$=QPL!8F3Q`+8Z;0P&677%
M"O+'Z7QCTTI\ZM5%S/O2BB^2K8QCU@+J.'USSCN')-`6%0!I2]<-[8/RR`]L
M8?(AKW#+Q;/@&-1QR\J<"O?<D=3"@'SJ()C?9KPP(`87BV`CC+[4$))1.8O<
MXZ4_>N&=:(C1+%+X/(_W_3>.O&!I#F18H*P0%V43\D4%X$JB\R$H6>QIK<5P
MX3G=P\@-^^P>OPQ7:S;_`:&Y')J&9.?_</^5[RSWL..P(*^VXEK!@D9\S_*Z
M2Y9Q=69A9QU#H[O)E\62/"M;2A21;IBNN!JS,NVF@H7^^M'87CWN?`^R'>G8
MX`(&FZD&"MD]@V;!>/+WH=XXP,"7ZAGP/>80`^EV<<#K*>19%@/9V1HQ#MD$
MI(#8PLA?>*8M8O2)?;TH&0C79S?-6(4+)+)*%G@!K=_5;S56"8D@4&C`NYD%
M>;<S1,S,,HML&!`+.F0A-QBW&B09XEF^(X07"O4+"1("8Y78Q_G`0(!R8&AD
M,[$7R2;(E-*-\(M@S)/[[E&5G&2!*`]P#)+.1"#+^.,?>SH$6;0PJ#^8B20Y
M^0D`R?*`!["&`#?_@<4]^.C'-6J!0`SD(P-Z2"D]#:I\O<"884#'+4>`KH,Q
M\T<+_\0UUZPM)DQ,Q>O"2,I23J)1N'@4%W+VJ"^4+)58^`N4I.&DUXG&2Z()
M!Q;6,8I4+B*7N!!#GP3Q*'/$$I8XP@6F!D%+1M"L`@OXH"KNA;+%=!`2HW//
MQVZ!!6%.95;2'`1?=!(2+5`-&#4R)2?NI<YV:D)?MRG3(T]ADU^-CGN1N-\7
ML/4`K0!'#'LBE+3.I*TL"$J$T2C/-4^A#G=J@AP.C2@BN.&*<S#@`?+K)4`6
MP<5&X((;Q:1$2!O!C49)XIE8"F4E[AF2D53">QM;Z""`!`V6F$V)@FJ;_SFZ
M4+:.>F*4$G4$G8(:T57-LA6&:1(OA`2&2L9B&AMA':H>L2K92:),_91J][1@
ML6SX](G@X(=/R;=3C,@&BY^JRQ9%251)X+.MZBQ6L1@X".I,*JK&TNI<-T&S
M-(XT$DX<!!2_TXY+6H*#P\%,(LX4)Z[IM!1@T"I<)]NKH,#3(Y<%617Q-0JU
MF$N<#LL$O([*V3\H%4E<T\D"`B>,)OG(+&89G4Y>`L@C:<,001F*65;4PM$1
M8!3P<JV_@!H)K+8*$H.M2](H4<]L;F)D]8C-QM+*3#K>%!_GI*PJ5*K=.WD$
M#"`+T184)J]`D4X,D+DH&'2"PBU0\0O9NL4*M?]2DQ)V)%U<^IT^.$>:Q>BE
M*<JC%3E7@X5]=2U%=/3:H`+"P5I\0V>0K$1?4SK1?`R")#)M1/;6^U9+?+)M
MG<05?,W*3#5EN+N;@!**296H:4QE$/H"8C0P^IX(`00>[J%5_=!2B)S9KA6Z
MV$)%:$4(?95'F)FXWCSL:D/-`:TCFQN=8'W</B_$<)^@V,Z:6F7-;L!3I"/Q
M'B.D=1XT_2P2?#FG3>6X(IWR\[HKYL2WXAPJ3N%N.=1[52VH(1G]I*8S/\Z"
M+E!(PR=R+0`8&X62/417Z"WOS[6X#XQ*`2B>?AD@6:.$!"6)"+9]2PR1%?2:
M3AP-$Y<ZNG]28':ABU#_.5,6'72N,W9$<QT\U[BZ9/&QGZ<#Z/<`&1?]A!$Z
M2$/'12PZB0ATM/4@#0M)RP\5$`2*;BF!L2N]3F<B!!D9B!-+8VJ$BV\&G*`(
ME8@^_LJQW'W$^8)JU5@;"M&;6Z\Y[F;KOHV"/Z<CBI]K<I724$;0N""9'/OX
MKA@>F\E..B)&4\07%"ZB:Y$>"K_S6XJ,3#*YD*J&8<O]ERZ,P0\@]P,9C%87
MD)'[$:R6;A;11L>_S=2<DG5$JR7:;G?CB8\_J8I*3!._?-TD'(`D``'4)2+Y
MYF16[?/UQWYKVD4BPB5701`OT,L71A=Q<WXDWIF<OB*DN[$6O"T+*9(+.B]"
M_Z*Y^4%$!>NB!3.$_.UEL(!KV!9S=`/D3)G*X,D-"N65DCJ,[+`YJ6ZICU%%
M`QHF15XN+]R9R`+D&5DXQ\=*JE%%K!(:A.XT-)Y1UY*K(W"9^L<R`2(M[;G\
M\28U4;J_HQ'1,6:E^HKVG_@AOP>0X>VX]P,:7L_,\D3X$-0X)U]"]R=YU4M^
M/(5SW8+:E*\*/EC-(H60Q8-A+W?8$=L+K#Z(?Q4TY#[WFI-CMNJ6_(2*CY-X
MUQBJZ6R;YQNJ24-]JM;$DN)1"`E*#OI])U1,BNM3@J7BM$F38'&<)CI@4V1E
M\'TA%P868#\ET6TI=W8P<3E=H$&)8%TA07(HUG[NA_\GM?!7'G4(,G9UEP`=
MP.$%_M<)S00*D"%GF88D\%`)DO02B*!/%Z8N/'-[N7<&Q#<.82!RWU`.'Z92
M9!-+HJ%8W5"!"$4-QR)'#A5.'7@G<X6";D5K#'1&W<`]5'AA5C@L**%$'?:%
MW?!56*@/V%&&8B@Z?Q%]`SAM4A1%&E%/G;9)76`!9C`&92,:%6`&/PAR:)!V
MXO!Q<"=WV+$Z:&8TJP1->9=3?V%0W'<(Q!6%DC@8M=`*7^`P:O)#.!000A$@
M^()1H",9F3`:3L>)^?!K.A-:IN4P;'((EWA1W#`P?90[NL``C@$M.N-'(X)1
MK]A")7$932$9FD!VCQ@)U@3_@&#%#6(3<F<P@>?P`&-0!F;@4J"C@SLX!E^F
M*Z3V"HK#)MJ"5K,V@4?R-I-8CH=1B7I2,JU8'^]11601(']310UG&5\S,K#@
MCC^!BA&R0G;D#D9!"-'48Y>X-B3B%-?#.[\1(9?X-_D1D/EE3C=D&3$W4<ME
M6@<X"?>T/:@#$LIEC0LXC;'45"ZW&&J@@"&'!C`2;MA4?C8UC@2E,7&H#Y&X
M/B=GCG:"CC940.P8(31&1-1C0.&P0\OA7_J%B@;Y!V51.(0P+VK2.3!&BXJ'
M#Z>3;"F1)H+$:&SH"-4W4Y?6/3NC?>9`?*.3@"8Y<@42`"5IDGX0!F,P2A%(
M53!1_S(C-G,M*4XDMVXCU&(V>9-7J6=7:1K$5E<!`A<&XS`\ISR"^3Z]=FM)
MMQHE\1+P<Y2U6%WQ4SU"41+K@965X`VJ(X"2X%489Y&S5@'>IY9AX%(_8GLF
M>9I>,CH6\&UV^5@D97)+1!RR.9?C4Q*K%4:&MY=\63U)^9>U2)0^294`96R'
M29Q1)5]'&9R[,$EB(`PZ)IG(PPV-49FM8$-UH8D(Y)6948"3($FM5VX6,SIG
M8)K$!R98`EU\B'N[YQ[/<IYA0`:@]'+9]0AL\P7015V)I5/P58SKHW^^N2#H
M"!)&H7'UT(Y@P!6#^3X5X2"'B90+FJ!&23V%]8_D,8KU0O\@*^0*)P$A@.F/
M5$:5("%C.^E3YS%)'#D)9==EAQ!8,@(HT$B6[GF`'A<&S1B'7#,&Y^D'9?!E
M6&`!?1AR9&`!V<5WVY@N=[<KA9=^_<@GSC>@4EH,Z/B*1A$S,[&)DF%A/SD6
MK$AO'P(06[J<B\D+O0@CKXA(`P-(T*"+!_F)O4.5:9HXC.8OD"`.*[-Q&%DV
MR"A8!7$O"S"-X*`G%I"6(*<&\`0Z:?!V89`&_>0%U&`!<M=Q@OA]93`&T\9/
MI^<(B$4-`]929>,.1;AZO4*J4RH>/6):RB@C3K%/2Q0-\K-$!8(=^FD.T*"?
MKYJJYB"KJKI$NHIX**B4?U*&JGK_#U\(K.^!';]Z8<I8AK6:JUJEI]FSF;&'
MFOI@839AC46:#CDHC;UE`1[Y=O0Y/8/P`(NJEGYPGVH5DU3%$RAQ4$?R"BIA
M&'8'-S5WJAXX:<N`,SIC=HW0A"2H"HO16-;JG5XU<*U9`30:<F6@4*O43?%`
MFNB:!GFQ&.CJ!V;@%"A1AO5J22`##CQ3D^90`2K1B$J:,O>*KU*HK\K0+N0Z
M58Z0E:'`F5_BF9@P%*$)@/=3FM]W!IB*"%K`LPIXFN4#$^'Z=F.`(*-C!F:@
M@=Q8=]IP1L9G,>XPM1=6?MT2>,S`3=PD:/4G*:&P>,0@#B"".H^GLLL@9G[J
M?'A:=IW&_U4S]0!#JH!GT()`L0`+ZYY]=S]I]#,PT9X+.)[/PK-J8*2TBK6/
M0%:=!`V.MS9.FA506JK3M@R3,1D0J@D8BG(`NPD=6@P0@IKW$APLB[;H%(-L
M-Y,4N0Y]9S@"&)WH^H="*`:WX`6$>K2P.P@@\X,^JQ/;T4_GN7M>DKNY=ZG$
M![F;JBKCM[C:0D7!PQ.FRB`<N`RN,(N")K.Q,+IH0QJD@!)1&@J7RTS:F[FD
M"PQXJD0`^@@#VZ>%L#*^FA%I,+<AIP;4^`!F4`:%2S7\1`9]2)\)X7&X%P9-
M6S+C!+>%4*D]NZ)D([*,D'+HE1>@@Y>.E8(Y$KT&\8\.DEM#=/\PJ(,ONF44
MHZ/!\N(N?N12EH4PB,8`X_59$@-/)"$O&EG"&SPQ!J-;?$$<,WPD-_S!&#+"
M),$F#P/#XWL*TMJ5=5.M!4))%Y9&>V(V&1$`/0IR]!D/#V"H/HJ'3%P!8U`>
MRO@295E'D!@`%YL&ZM-2QX=R/G,O+603\`!=)>&-3VLH]_*\P&#!%^48SR`B
MK6@X&)&/L-!'\K):MC@PSW)1KH3')X$OQ'&9^XC'S88:I!$0*P(C%1@4&[''
M<C&F>YP7AR0O7.4O.TS(^+(G]<7(06P*`UM.$EQNKC.YIB66$NL'.2K`,^JS
M!>$-0LN,,!$E?U&-%QM#3W2N)NFHR@C_)FGUQB@7.CQUB89@$Z5CO`;UJ7("
M40U!Q\8&1%81,[+Q#4BR<.RR"/@C(JG:N=#4=,-G"Z/\S--P-_-%NZ0A*-&`
M*]J\#B&R%A`B&HMD9;A%8_-&SS7QO=$0OBK4SM>LG:7\"1Q6LU$Z#MBR;@`8
MG__KJ(3B/^'GT*NIKN-UL4EKAE)+O_`+<AFM7.][J7V'6)9$*RO"=.H+DYWA
MKCH2?PM!Q]61#2[A1VZ2+W1$&6&R``[#'-+SS]`@$#%M%!#:H8>T)B2BO43-
MLD`-OC5%&I=KTW;*U#[MSYUK%$0]T]I;T)Z@MNL;16)5D0'X%T':T41ZD2-+
MUF_WAT<,C;>\_X`6(`SW<X=Y"#(\ZM:M-<5OY[,]Y6TS)SH`(DL$C)]!2)L,
M`@:IG`PPK1?94`^SZYC<I"%$03JMF!7^<L<_C0L"(=2\0-2,'4N=F]3F<"1`
M+2%([=2OTHG4\=FFG;VBZ]-TQ$URK-6'L';*Y50+S*>\9SC3%@`&K(!J\#IV
MB-8^"J282;M:8`%YRYH!V(<`7`_GH`5CH`;RZR6V_'W-_5&$#;3[HCLVF[CI
MDI_:E=@"L2+OFAFM&)T:LD*S@'<Q*!"=2W`QPXWF[-/D;5#LW-3^`QD5>`AI
M=!7PX"Y!,=_O`@OHK0\`SAK)4M6-G-_E+=N:\(9)_'<&&%E$C'%!B_^N49Q`
MN[1*OIM[]$FI/SBN^R0H.OB'V'&C'FXT`"=+<HNN%ATR26A$>.E6R6?,;27>
MG9$O!.#+YNQ'%0(BE^')(3(K_75161`S-\'-\]VA*T2R`8W?*Z2+(GA17"<4
M[G*Y#N+CD&CEHY@LEN$T"][D.^[@ES#$AQVW38/#8&U:YI2W(3>-$4L&WBK+
MT?CFN@4Z;C>(LB`:#R!W0M@.:ED&N0UCPNV'6,%,D9=02$4K#-H)Q@M?T'P;
M(-@0_.>UML"XYH1/V5`0*D8-*ZWH[G$>DJ,-(#4*7KMXP8<XW8;JI(X(V?`/
MK\Y,L-[J(FAAEBYMYS`*K"[-9(Z1:1>`9X[_::YCNA%NEQ:@XG48KA^]LPOH
MJ(.Z`'9H`0B2K72+C?BD!4>;>V;@11VN@#\JA/UD!M*.>&:R#N=;YCPA:+!)
M&W/6Z^[N"3985ZP<"=46FC3+W7U8N&/!4_I[!@VXW-^WK?N4Z!;9UKA7!I.F
ML.B:M,,,L<\R!FV=X:-CJ`TK"WQ*Q)\0P=F-&+#&$/L@S1\_)E-23AWTF$PJ
M?=@K/R=O#!U60._^4@(8FG=:6,7X+)2:>VA@Q:MD3NZ!XB;YHXBP`%1LW<3'
MO211J-9->Z9E`6E0!B,WJ,=MJ"DZ#:_\=FH@CZ@YD2[3"N!]&`**V))!8WYD
MB]DK&;,0,Y+!/97K_W059[T0,N/HQ++^_/+(E3%NRUP77[1WSL5T&P`6<"0`
M=;'R6X.VA]8\&+Q[&#(YR*BN++3W&WF",HW"\"P=7:2N-+GD2`J.^`PG2SOS
MO$)#(M"S70&`:D=`KBU`;64\/E%NDCIR)(2L0_"'H--V*S^&$0ZVFFY#XHKX
MM(48NH)H\SW!KK)B(SJKZU;Y<=!_DERJZ>*9HC-N+JXM9(_KN3%F\,2&WK^5
M6O$+:OWV>X`4??!XN*`$#P9"FGO"')JNPQ0\)0:0+N$*$=O#T+E^PV#7+A>0
M40_$&M.X"P@,7@0!?V`,7UH/#PP/?U\$#`R%#`N16)&%6`Q_7(P,8'^BHO\,
M70Q9HHH$"ZH+6Y*@7Z!_`02C?Z:3HKE=I):3FPQ:GI*.FW^;I@1>7)&EM]#1
MTM/4U=;7V-G:V]S=W9Y;HUD57]I;#U_G7+?@HU\/?O'R\_%CO8]86%Y970]D
M]/6ZK/.4QL^9,0_$<-E28<R9>&0LE..B)0#`@Q6V>-F2SXLH+`_"`)QWYH''
M46+&B)QGSY,8:86\8>."I0*6+R"QK)/)DYL7+3V#6LO"0".#?`PNW=)2`1>G
MI$EWDL(BBB@_H)C^:&$@QM27?ED6/*V0)=*6K<@XB0'UH.FH0UXJQ-SZ``O=
MFEW&`;6I=8&[HZ8V<ET;+BF8!P3&9=Q"`,RF+,?_DJT5LQ9,@`HGA6K>S+FS
M9YE?R(XZE_F:F`=<NBR0^NA!J%LUS:RD%\9"S'-JU%C0DL5+@`=I5H99<.^=
MFGEAS-3=I^C!L#]>_(V,EQSUK2P6IL]#8QWV`S,/P]1-%$Z:F-*?_S#L\N5T
M`/3I9:9F'9\G`0(5CFY:P$CJVD]_)!6`+J,<5=4IKVC5BR)_6,6%%UZ(%2!5
M#$;&"7_0L=9%4QNF8HM6'S(3&E!=`%442@QP\>`?"[A5@5^Z'*,%4(_0=(J%
MZ^A72CGU]>CCCT!&<PZ/M#R731==1!B3..2(\IL%#VRQT`,.(1>EDPO,AL88
M&='T0`#*E3<.&M.148%`_^Q44(9V\DAT2US_:$>&28\TIY!Z#44Y#I'1>/'2
MCV!HL4`6Y^05I#;S'>H-&`0P@A07AZ`R"EU/%>+<+08V>(H7IYPXHZ99A`;+
MA%IAQ8F,-$)3`0%,"5)J*C0R)@E0KQ"5V3&3TOBI@:AVLI4DD)W*R82#2.*7
MHL@FJRPVI^V4VCTS::'3E;>HTTD78\1SAG(ZG37&FF6(EEJV%W';8&^BG#/;
M=&/\*<H7%JP+4&TQ>9%/;R#)!I!RZQQ&9G7ZA)8.G=5`^^-56V0QXVO+LJ,%
M?`U/`V&`8"1HU77(.,+7IP521<NP#P3VJE45N':,@9]:.#+#LL#"U:NO<KI`
M(O]`<5&*6Q]QLA%%COSQ`(Q4]=H%`5M$JC*I"VW%9\1,-UT?DLXFI$UT6X0F
MZ2BJ#00<;7,F>=7,G6RM71@!&/P'`?("Q-W2IX$WDGAB5D!&&5Q*>5J5`:4;
M$CUD-/I%`$96$P!]/GK13]4;EA<QV$Y7P^HF$`*6XEE_$'8F+A4PNF2`T@YX
MSV4]?VI5)10]1:&I::5%$<YK[?0SS*)S-0B-;6U.E&."K/6%+"_QRLF,JW,Q
M8+"I3U@3I*<TKOSR05&TY#L,7R/P87QR0=R[%L0Y4D0>C[*`]MJ-T?TN8Y`Y
M7;@\/IG00@T])`\:HJFWM[9FV)3T&&98X+%J:9OQ,)+_V4A'LFAB$WO9;UD!
M6!KS1C&@9[!($IK0620(4(Z6+0-3L.C.(>8"%*O\*C\V.UWJCE&LEXEB$0Q,
M$<<^U0Q)E,Q)L[C%)_Q"C$;D*&B<,(6T7`B*HQV%*,58H!"':`VJ,4F!U#A+
M>[HCBG8\H@+F8].PL*:OZ83!'J(P7$688X'C\(U.!*&.<MZCL"[Z84[IB]>\
MNL:%+Z`+%^2B1TNDIHW-(6L]`TL2LA)(Q&A09A1<^"-T)(43(D%F:5E(Y-6@
M$\/==2(+*A*#E"")+D?N8Y!9Q(+B&D0D+D#2D8_@D;UZ(ZE7T">0=^H$97:"
MKDO2)!1;4$AO+GG)!GG$7JGL_Z,NAVBUT3#Q&B!Y%FM"PS`L6(1-<'L7%F#9
MOGG1,33'B4A>#"<W>?AO'?`"'T1"]@7?5&0GV&+3&5/5H.S0)B'0XX8=DQ6H
M09W%4$#JPB9WZ:.OI&B(64`A/??)SQXID8&KT0;4*@(-ZCEL`6L:"1JT4![5
MJ.$R.FEG0OVPT/*<PWWQH!M#"0BEF(0FB@`I@VV@(89CLHD,QV*@&>-1T3UU
M`PS16Q;"PJ*%F'Y&DOT4BO48YXX%M$@7)1T-0Z.!1&D4U4GKG(8D7D.YG#KU
MJ=QH5A.OEPU/Z(-:OAQ(/T*6R'YH$WX3J8@\PF`FKW7!`FFH'X]`DC:#("04
MF3D,1O^M^"&4+&"N``%<O]JR`#!0<V[DL-8WDJHLPT7I*QF)ST:@RI-?]6P4
M^9'$1%@EBD-(5H;CHT9=JL&Q:[RQ>(P-K6BQ!BTG8N,=58L?:;46IS*PPJ^_
M"<X9T1$V;<9#-X/:"!C`&4<KXNPC9A!G195YGC).E"7W4)=;,_(3DP0@H#(Y
M26J<PTUE$5`?-='):)G&*3$0A4B\JY6H:,0*3FTR4YZ4RCYVDBE`0A)6GG0O
MG[PP$4D=X[WO6AJ/0K7=_C;-JN[(G#8$]D]`+L"C:J('1C1B%RV@*33'#2EM
MQ;$`<<X6&M9;J=J:)#\UE)6^7ATK';&UKN2P*D)F`TT%XJ?_,-XL"X^%@IA_
M?70Q$ZIR'S<J&8UL@M]42$(?$_1(,"CXJ^Y!(BD>84HD''%D753B$IE("R.L
MT\!"$&4K99%$BF?,Y1ZA]BT<Q@9II#H*(QKB`2!%CEI5E69GSK<"LIT.OZ"C
M!2CE=D-D6!<:R3<;D?+&-U\*4R<./*\YSE,F>VJQI*AY:)ZX\:@%%12A'+S(
M;GS!IEV6!E&,DEE:V&*W'(,*`:3R"MYL:!R]6$59-"F,J[6(40OBBE?`(B$&
MD,4L:)&,['2$8_Q4YC(R]N]Z,[T9@655&W9Y%C1Z*;^VSJ,,Y/Q#@L=&+<AH
MTDL!P*L?L/A$\VE42K$1R9RM9]+M_]3-D^CRA&W%(P9B:H8QZDU<%G^C79Z,
M8P%8X(^4L#'3UWKC;\3&QGWRDUE9="_4A"#05,ZFB:;8>M^D&@4A'I$*1S@(
M0K6FD#&$M0[GM"Y`"7M9,B#=WU=(HM':F*),>),/Y@UIM0(5B+2@\?)4:)L>
M8*U*J/ZJT/B=HPQE^(U"SE$^ZN@O75I(\T'6=Y:9UY9-!W&7(7K+4M>`(<P]
M>>Y[H&&ON@PD)\&N!FD`F5W"2<.PB$OL@%,:\&HPRE%I>BS,='&IC@7(91]+
M"BK:&W%8@4I4DB!5RH0%JV#\^&(E9'N7FX&*LI@]&RKW!LL[';%D3Y6PTG#)
MEV]!YJI\Y__F?E!#DSP!)E8P^#NS4<.$GSN;ZI!1$;\ISVF<G1RL^\R+;`J`
MNYA!I2BB3[`]L1Y37)%YL*?K3&&/AEZCP3X]7N.Z!JRW-7;;]FM,+(9.&O52
M=BQ"NY="D>^J!=`P196JC>P4)<.=X%&WB77,Z#&)Q+&DDH:(@"N,@>7`Y3H@
M!(:70`:;?O(:PP(9I?$%``@=MX0%DC)Y#:))3`-`3815TG-8M@<U@S8C4L(0
M>",/<X)-V2,/2Z<1[E$&XQ9.VQ,RS'`U`:`2XD0&F24V5G1@>F,!9W(6%E`&
M'6B!S4,MC.%\0H)\53$CE99Y$)A$DI8-,(:"U2<4CR,(B=!-MC;_(SS",1NB
M.>07/.55`2]Q*4<A%8K0#`O209VR&FB!,NS'%09'%.W6&!=S/)$2<(.P2(/0
M%EBQ"(2P8D#1'+/`"8RB!1<D"GTE;;V@>[/3&%IA;5>FA<OB$@$VA-2P)S77
M1$X'87Y0>SIA7/404!\U+_4340[X=&SB6JKB;!SH)@U(*"M615;24%ER6Q;@
M"JN@))KA;B@1*"ZF:4+X+H=##8S(;Z:'A))V%H.RA#S10+U@%28'+'[W")+P
MAZ)`<):%,K`0"@3W%K!0#K&C,#P40J]B(8QP09\P:A<#1(U0?:\@%_W2"S:3
M,88P:NLH*/(3((=8.4MB3%SP0NC0<N]P_XCY@`7J2'D_LGGR0W+58A+!]";4
M<G5I]F%?L0@><U$G)7>X4!#B-`9V=!C9-AUI8!VI\3T(\0!G0'08!3^A,"X`
MH0:E8%H]`6MFUY`HAS#SMC[+YAH^D3B/!PTTE3"_*(G)1XRB($BI04J*M!.@
MU(#Z=1,-J#@<04A(*0X*F%^/%$F3Y$D>84FHL%Y-&4CZ$)69E$MP*`:K,A"6
M<2I4<7_R6%.D((_"H`BIHC#:>);.@1:3=PC$ERPN]9._9`UZ583OPF'*-1*X
MQ1KY1(HL]5O(<(-CPVWC`"7=0B41UA*@6(F=N!&"H@9I,'K2<4ZIY8C=0!K&
MUR="9W9HUT2?>?^7WU!VV,!HC,8B!.F3&":1K@F'F:$%YX$?$M)R9OD[DO(4
MQO.)4Y$3>=@%_<B/Y<<(T?8C8[<+:#(34$-'0I4^K9A[T0,&%@!ZA<DC''$3
M8?&!FJDWX;&19+0`9C0<'O4`N#</#'EM87.>A5DQ$Q84.H@G/L@.(+%US(>:
M\MEY\A%C,Y%=]I*2L4F:TA.@2]@5H]"/A;".N$DCOQ,.<2&/%Q1?N=(5,U>7
MH3!YEA1Y/K)\OH)YS'=80\5Y3%0!%B9Z)Y%(9U9T`#$G)Z$:9:`;?^95*\$=
MY1$`:H2>7*5%:-D@4!2*!(,])TD.^BD?,A@-+<8>TE`H2#0ESB<H-]G_F90V
M$^<0)?SIDU>':00:H.8%'61Q&F%!E@W"H%J1.0XFCR42%N.#"9"1&'CB&'EH
M;8>1!6`)2#W)$\J611)H#=!C;+?`E[B`F&5B'?`2`!#%1<<U;EH07"!X;C5!
MJ!QF@B/A9UQ7`=9)'9@!#?FR$CFXG,$7,EYG5/*&B[<H)"%#59Y!4U@*#5T`
M.'GQ3IPI;#[UI%GJFLFHCHQ0"_92EF):$:R2([XB#*P!%T210DW"@`,29G&1
MJIVJ.'S*;X'UHV'C,7Z"E#Q'#\^%33T*$<CW5ZYU#]%A6P9A+BAZ0A3))L-8
M9FC&)C3ZDX(2#H%$)?;P$QXZ8.+B'A`CG)_:_R>ABF%JIUC[:AYB\EJH2FQ@
MJ:RS&J!4R0VC&B0`UAGIA'2MJ3?"$SBM41Z'008P>I696HG<=@YMYF>](0;+
MU)=MAASM<AWFQ";^(PZ]X8>`BG.C=V!AL"U>=X_OD:>6-I`T5UV<QPSV>G;X
M^40&2PWM`3@S,B.ZIT#713A;,$^J^:^C]1/0=;!4&Q0+>RCQ&1171R1#*C@+
M8#AFPZ=_N5SN>AI04AYLI1UH4*025[)6$E,V"JYY`QV!M@C9AF<XZA'JAAP;
MF1'-*A,ETA;]>AT+4V;N4BB.R*1>L+6G&3()@Y-;T`_V"4A5JAY21Y\V@1/Y
M&EH%6[6>&Q1\I"S)V?\3P.>GU6`]`N&<>M.B+*A@W$(?6$!UD:IXB4J*)2%[
MBW!GP%%BSS1M?@"R!F0&0?<<T+1ADQ:Q1'4>!$5`#T<XJXD+..EO25HRLFH>
M."L-@<*I0M6J6\8.2OJS3R6UU?NYY"M$X_"JV)`UD@B0F7=8>6IYUB.[:F8V
M"Z"H<C)ACL%,&_@^C\J""^8E;C-<9]9F_\L1Y;&)7[1$XYND@G(BU9(?!"!]
M9&<3VIM%4(L+%9R^G/HW1^L<\B055^>(86&(8D9I2II3G5N^*IQ3T7&Y5<6V
M`BD]F6.:RHDUY:H=:6`VJ5%-([&1`Z$%WT)OD"(H$[5GY.:Z]G,6%:`%V#G_
M/R.Q+8KGQ/+@PZ:+;`]POM.@C1$,'^SSM<5W0(^@>-F@>V4F*-3G#J=1;]'!
MF<_K60*;B[LDOBL\Q_UTIXB"57\[?>@`?&$C=81*F&.@B3,RC`2DBMOFK9E9
MB1MI5M^!$*QE17,R3UL0G6IKF#9Z7/&Z68`K3^\Y#?94"A#C'.>*8>N!2Y:6
M*G&!OF1VCS>YM*F9.&TL1%Y*Q[3<3UWKR:H5B=>@#M=Z"YN'$QG83+1!51"Y
M8)U`=$!W=$\481!A`>RQ#X3DN]H1>25%F*HW$:S:5?Y`+S&\#59URV=7"SL"
M#596(B@7**N"O!_!,*-LA*/1/?;"?)5[NMGU-YO;_SCRNL"UO,]-P[C6$(F6
M=R1)XJ=W>1ID<)E)(E$BAK8W2C\'M`6$^AK^XJ.E@04W_#;XUD3Q9VN&S($<
MN35;$B414A1Y/&!14L760!.1,*HP9<%18G:ZIX39$#B/Y4G]:'Z3DAD]DRC3
MX*I2RDV?V32SS,]$O4O=3%),A-*9=V`J*3^LFWJ[H<T'39-P!,F:7&850)@&
M<:E8O;^KV)>$BAAEH(%S!9F4"(*_\:SJ[,MDX70RP1#"\!J;`WV8B@KMA+[>
M0R06IPC+E$B80`!Z])2I<"W52U-XO;VH.)_)DL]%W=BZ1&[3H(.].!,4"+?/
M<<1J@Q`B>!YA8[_:\4O1P?_,VQ$_#191=19A).F=U+'(BUMG:M"ME96N?",1
M`=V95WR]+[45&4%YI7R@5P.3U2"R6*,(+])N#5(791$E#S,*%E>G>#JT%%93
MBJ8L0^W8UDU$'"J)SQ.BIT46_MQ$$+BWVG$&"R!U62"_]*`<1!5B)TE;1TQ6
M*-B0<2)Z:]70I9@7."'88SO%J*'4P,0;ME=FX*<-_/!P6<PQ@EUFA_-XK)Q%
MC:)[79%^@L)[T,(/BR+&190X+GDHC'W='CY$-6=F3X2\0\+'IO4`HBU'4N<)
M7HU<651G/W.5L34;'1B9S9Q;O_$SO!6*%A!360T0<^3"V_`SG0QF/^-3@'W8
M"G[_'Q+L*QZ3X)C;Y+&]$S]Q)LZ19+V`8L["U=Y<=]QP7?;LE>E1W1]>YLR#
M6LTZNJ;1WU/;&M$#@Q@=$[:8T*=]3AZ#P'1S)=BF!L2!K>PI#QJU-`MPT3W\
M@AM8&S?!W3)QD-$P-(2"'[S!$%=+S_<A%0()Y3^HV$[]%C\U-$.C:H"$&,[=
MB,>)**?!'D';&1UNYJR^//<89ME]#4@BB]?!88\&P&F33+2@1B`KWU5G44FG
M8*%I""/;;>+$Y]"@!2EN39>=#T,'Q&5`HS3L#57,,X%$-%D`.!F!SBA74!Y1
MRLU:%H=]US@)QN^B2)7&$$3##2]7ZNS.5;W-&63>ZO0N_]2EJB+^C6'2TM2"
M=59FH-GONH'P(RF0RE)U`VA0PB.S9T5KMA1N*V(,<Y5G);?<%AIS`Y[[@!@#
M,^KM2WG1L1I#`]'V90G+M"%2[LN*$R@$<+A?HN0-8LXT=R9GG+PAXYO90&;N
MW@V*1NY!L>KU_O,-`X%3*N020X&5ULN8;1!"["V6B9F$3C]4S4"M*R>9Q1!R
M2U$")C\(,4W]$&>5J,D*B:/\P<'Z;%2*[@Z`31'+<!X5P]G1D>0;,KG*AY/F
M?*V8GN%=XLMVL<0!D`^L\#,9V.V1S:DY[PV,!MS>,.]`O_B'TK"MH5IZ2@X&
M96#W(-Y\^R7TI9Y>P)UC4U<GI/_51NP8^?<;'8T^'W&CKE53`/RB/"C%\>`_
M8!L4):T>1//QAJ,0@013_:<BGN,8@(U$@Z.O)W+WSY?J+/M9ENO-!+44G]%U
M-['@V^#SC#_]`8E5>S+91JC`[$`MQ2LG7(X,3R]'%TDEH.?#81,`:J#9JO0E
M[E/C5:U@YY:=/,(_0)ZZ@B]FT'J@C0$)-04(8G]_8@M>?UYB6V")7%L56F"/
M6EF#EE]<EII_7%@5#Y6;HJ.<CUV'I)9;7:FC7@];HEJMM+1<8@\!7YY8F;6X
MH;7"P\3%QL?(R<K+S,W.SYM?%5^J#[Y<75V^H[C8VIK28(->%6A^Y^CI?F$/
MU)<59F'_ZNCL@G]?#Q8/IUM:8V7JQGR3!O#<F0`/>OW9DN_!@DQ<'IB91\],
M!52#P"R85P^?N&58M&S3U&7:%@);OH"1E$5<%C%8!F4)($YEOPI;;L8:YF@?
MQF/]N@03]25`,6GN-LV"-HJA4*<_-WG1$F`DTZM8LVK=RK6K5X88`SS<U&U4
M-BY4-X%I9XG<&8KT8`WJMV"+HPICWJ9#HV4G0W-^R%@0FF6!!37K%AC]LQ9P
MNC!I<D7]\X`,W'0+AI*SC([OEBS3EGD;%=&:&)0!JC)6Y`5,%B];L%3BDCJ3
MI`4$L&BLH'!8T*'&"D<BNMBWEJ1*O?[)HH72;U'`E$N?3KVZ__7KPD)>RT8*
M-/*(6%[MK.;K2Q8NS/]11%/A8Y<Q8<Z82<@%C)8%!=F[PR4O79D%?7G117,?
M,=0?7&0\(-4#!\(ED$Q88/&%@)6%H1]#5AD3D3W1[(--;BDQ)M0@`8A1R6>+
MA`@&38-@T04#0G5!@"X9=@?@1\@(B-,E"Q13%BE+*:?C9S>.0U6-V"6IY)),
M-FD6*X-$--XH^.Q4I33`G<6)/Q:=DD47%G!V3AFA193&8Y%YV44^QPWRWF5G
MC&&-)F!8T.!Z%8C"D!EZJ<-.3`L]H(8:%D32R2=>B(7D,%52.6-IMRQR2WU;
MB)&)%W4-(H8DD[:D&EH$+``&%@2T.?_,D,H<VHM(Q'#72I#2>8%%0E^4A!!P
M3N:JZZZ\,K7A.SBFPL4"72#5SW>*C5,9.F44^MJ:9)0Q7R9?A(G@8%9I,=%E
MYP0P5)U]4J0&6X0T9^E">#GFQQER_?'>@7%6,""F4"KC75,,I.20&-]@8^DM
M*X'Q+[\0=2&&%[=\L<C`!#R`"R2X"LO+HK9`)0QXM<`ZW2VYW,<;Q;V&+/+(
MO3::46C#:,'`2W.VU:XTZIZ#AIQVP70NS-SZD49Q@SR0L\YS.K)%:_<5I$Z"
MOKP;QGSA+:?%87Z02<VP`7`DD)3,@#4*J5E\46HC"[=XRCTY@:%P?6+8(X:W
M9"^B<*`,I*W_Q8X\69S,<ZF83,L#?5TG1@73<!S`9"07;OCAU-T[5\O9]15J
M-!6$\A><`6BL1<P</1#L'[.F<2<Z#]X#3QH69/:EM:"/9>;1\E(CH!9C1R1F
M7&*$PXRBHF!C4KXKUK329R[!)!.+*DFR$B*I982%72V!!N("%9SKVSX1D]*)
M)L)M/@A2*5-H5ZQ'OE)-L8B7;_[YT&CMYEC#G$55NX&ZL];GZIR1IR8!6&#T
M/&BTNY9#=IE5`,(5!@L`:G)C&D.`UI0&-1!K>ZB;1[-,98D%S$YFL``#RI(Q
MFMP]P!JDPH*).%$;QN2D-:^)S6Q*:+R68"(V[@A`TT3UHBZ`049-_QL&<R@A
MC`4@9QPE&5J4//'#5QU"52!K1G0&<3]+[+!ZZ(NB%*>(.TXDBR<.:Q1:C/(C
M0FR$6_KAA!BH8AXP7=`/820$@]9%LYZ,P1SL\LL:ZR>G@ZEP>^7(&1EZ1!(^
M^<<DC$,&UH@B+]TIS'@J&M$?2G2B+*2(&C?\B`C%`;R<4&,F%<C$VDHU*@*,
M[51!;(4N4K'#YO1%8[28&_G0]<FK?.%(ENB"4;(0H7.A:HJXS&7Y.L@)^-7B
ME2G9X"(+N0E/Q(,B"9K:`])P!D)1@D*>.T<RW30&/UDD/,+AH;O@<YFE\=$2
ME\L9.\;CCD?D)3#6T)(R/#**+#SJ@Y'4E/^D+"4)6V8*8$.SE"-5@ZE8X/,+
M^B36I4H2O4E`412RH@]1BH@]0(&S&+-X8D;N<]!C>"(86PS46G`Q.$3,JC>Z
M#*E(G31(T544>X#\SGW:@19]&(HAYT1'9*@EJ'3$*X`/&`.`($*5RY"A`CSC
M7#7U^$U-00TN_=L)0J#7-.8X!%-!/88&&;J%?.$#%)9*1+\,Q@6`K61@4,+&
MT&X!&X&50G4T.8\UPD8(P(E0"[ZT!4<)1TJ'#@*5KVI+*)<SH"DE`Q^J458L
MNC"6I3AE:A^EZT@7RUBML#,CY!(&6&8U$O&(;EELW!%=U%"&JRTGC_.03T+N
M@0K9_:R)+0H`_=#_@31.A*0N.B+#G<*X1=:V[BQQ!4H@+1$``IAG1KMPS=ER
M8@\7'4)A;K.+P-3&-N2:+18"`]0-9W%(%"WG`3/:`O2D)]E],+2==OT#7E.A
ML80JQ'M)),5%P1$:5XD7>\V1G+P4V]CZVA<94[5$%VM1.5[BT1W2D,ACKHD>
M+`1`CJL]1Q@RHXDM#)5;H4-/)3@:+M#U:YELA(6LX-$?P2CSC&JP:N280=@,
M8:,=516A/7IWC]\=CY;2I0EZ7"R.1"UF5,QSC?$8DY;E+,\++1$0C%:1&_IN
M`C2@J`4MDT,,O'(L=A,[2BY&<JS/9J%K[XW&FG8BT?MZ^<O$P%`LOW$Q_]QR
M:"ZF8LA;QL!->B1H<Q5(L,PNH@FTO!$N!;RQ1!!B*9@:;<&+J=;LEO:Q1UB@
M4-2JP/[FO)+("O*!'K1&`!BPDBL+;(6JD<30S`8;"9%((2TTFR,\O<BFT;@J
M*PH%(Q?2R;Z0JI6MJ-0MNQ/>\0)I.$V!G7QAG8KU:J*+HW(1X+XG%3Y3:\M@
M3K:R2<*^C&*Q=GW[=<NV8"?6SA$=#MR$1!(LM18UQTM/0\QCVF4@!3,-R(8A
MP[BL!-IY_)3,VWL`YM0PC?T>HZ3LU49):M6T%$D"DHI<-8K^+2));HH0-CD8
M7W>BB!X=K)Z7$I6F_E90B,6Z7N:MT9(U8>M1//]@UD<N$H\93`K`6H4[B0#0
M!^^S*5Q(?!-(1)[#TKOLFJ./:B[S:RL\PCV2U$N\BRY#@V@;&S#<):;I:.TV
MY2&8S,1VSJ%XE[OG*RM2JSEG)?KU@ZWM#9J7?,2B<&<O/I@VV]A0C(MH!,3O
M<<]-Y1,]6^!GV_^=58*):&`!J_M6'\";,>;V'E$57%0V_E#?A#7*"`UB)KX4
M;4W,ZH=HZ<6:%-X6[<*B5CC)D"F.B'B;>QZ7)<42,;RCOBB-EKU(/]K'$2&1
MSF;>/OA!1W][>2;_*!"GA9K:`K8N0<UM@@!R1J,VHU02,>ET*E$UQEJH*F)M
MN!V@B.`7\>URBY:8]1;_6QVK':^O78BD%6QF]>(A$O$9M5=*4]@]\':W4918
M>]>)M9[>2.["ZR%^#!&*O\?IP7'Y]K1"51L&4I8`>[MF9)]W@"4#=@M!0;6`
M(=K!?SLQ+)\0'O:A/^I@!JR",^;V,5\B$8,1;V=D$'+R0UH0@D?S0^^!.9U1
M)G!E`9EG3(IA6<M@;V[B6V+G(M2B&UUC%\0E-L=5-F^S7)K27$`(7<+#&,23
M(BVQ'$?(8L6S"#6F,C%29%]05*047S[&9+101:)`@*2P>:XE+X[V7Z7W?U`!
MAB&':UZ(@&PX,LNG7[LE2H;@7O\%@M(T7[6R+&$0.@C$.J>`'JB@@7"B,8J6
M_S,19C-`]C2+AD[CAUF$)B$H(7K+0(>6,"PH!B/',RKV$'<N06-,&&-&9WU0
MZ%$WMCSU86DC1!N+$1N;ED*R04*99DFN(2NE$AL$X%O$H",RI(6ID`VO``L:
MUU>D0("`-5\-U@ZS5PR_L8::<$N,IW-M&(U*(F9N\G.V(%`.LPGJ`QHQ,T&O
M43E:L(G7)BZH]0<+(&[=U"Z`6(5'Y2>05BUI4`;OY@5/=P[3(CHQ$P:]Y4@,
M>&_9Z$$BT5LVH5SF(3!3(T.V<4*<!D.?EI`Z]D*CY"[]ADB8<$.*L$@C-'`J
MPB*<DY$O\0GA:'&G\E';T''N4BR!PPN$0R'<A3T$P/\`JZAKG*,%`F*-Q?!$
MSY@[489>TMB3V*%.[I)\UG-Y<?6`@5)AG2$G/Z%=P<<>:K%M2-4NQE0ZSU(!
MLA47[*8NWKAA<K**\C8/XP)0<2AET.@UVK``#L,V$GD(_J8B/D0B(U0["W,(
M&A$*DT0(K5$IBW=VA+`(A%`?"V!/#,<I^A0;$>=/(<%WE?)!T&@]<Y5EI.$P
M;Z@*QJB3"?$3^!`>QK8<T*,-_[@,0\*3=?:8,>>3IND5TC>`5KAS[:$X8Z9?
MU<8M:6!76?``2)ETY%((0B$X%99&;Y)`P&A,93`N!6*;ZR$G->$+\S,/,T6)
M4B5,`T@`EH)=YG<N\10IC$#_3X;)=O[D=HVP3P/5G73'!5HU4/^200+357;G
M+P@CE^GI"`"",)63&_81/5[G%.,E)=1X9%C8%,;X>)7X4?A0.[[W#.85@)KW
M?CU1?Z?9H,V`#YM`9\(P5?O92V?&`#^31E>6B!;H;D&S>V<P,W(!4X#A85NR
M+39E;+&10[,B9_;S$UUP1@(Q%>%U##2X$)'H29AB=-67$H*@5=.GGM8G"-A7
M,$.3"&5%I(5P*=_79SDA-B;B7&<CA(1`/E)JA-*%&U.80\+096W1%R6V<\C6
M3MBUFB2"$JX)#8*'AO"E37CCH'"Z#`Q8*_+'A??0>'-AE3ZU>J\0`/-1+)@W
M.YYE_UKH<!#T41@K=RF811&$-A+5DJ&9U(R*J&`6H`M_5PQ`21*^!0:>]*2<
M,S8`]1G#=7Z?^H/)M1IJ\XI2*@Y4ZH1*&#R`,A.^8SPUMHN,88K-,XJ8TJFO
M9H!Z13=8XEY4LY(((8"<HSE[]0X*,Y;;`Q.*\6/&L'GV,7R7,*;9$Z?8:@SB
M\VN-N0EG08F*4YOZ,#3&="<8F&B.,4&,($"$$F@UQ1&1(8!<T&Z780'(L1G<
M,DU3\4&G$*C]]UU85*-6]'$G@2)0Z!(B-!<L(HHO=H1%=XJ:5@DV-A>*<(HM
MD8K)8T*MV&F8EI`IL9`2(@@R1)<L(6JG$0E_0W+"D"BY$/\Y\.,1AT4:CYF9
M;4&2@9(H[*,G^U!^5U8(O.&K3A1?':AS+/L]()>M2`M>Q:0],)<L!J.-JW>4
MZW!-"H,7>L&'7TE'F<>0GZ6"Z9!UES".'&%`XQ`A1E>N\W"/!'$.A)(9G.I(
M8V@,P.0*?/,A*R)="OD%"E,[)`1J)Y02L!&17:`09>-($.D.@\N6%%D?`>>1
MCU1P+>*1.WM)7;`3RR,.=J28#(&GMC`KO#&`&^2E4`L]1<0Q\>F<\6:LE<BF
MPI"'0[.9=19EI9FTM#L\1R:4IA<+VK4)R9@_=S*/&D%VZ)=@WA2AP<<.F[,6
M`T01<203%<!9-`,;.=4GH=,8ZE#_!A^T"\RJ0]"Y/9XD@;+F"*LTLH3@2`)#
MEV^Y2)^!EPMC&^E[N7BY=E_R$8J`N91R,W*!3]^YG558*6DSGHG`3UP%,'.C
M&W-#;)(U7Q4*1'3#?^"(*UUWJ8K34B[H5\RXLEMVH'IBC()7N[0+&J(0MW@4
M"C19B>[UFQ31+%98"$VI(!R7>NK0/Q^!$..Z@.JQ@I)S;8\(&_=A!F0;*)_3
MG#89K6-Y$M-)DY<[*9*@$(4A#MAI?@K1OV(D"?LK=]3W?'IGGNJ9=\X75I7;
MGDD*>&B5$F3%5MIU1/R2&U^2&U['')26"AG7(N0R:QMB.TT1M?C`&:(E@#E)
M#$C$NFBF_T@QZ\'8F@7Y`CE%Q!!)$20EA6$YH[*$H%KY2BZQT6=%(T%E\IM[
MC!Z&H0:002YB03_S:!ZH$`!ME@YL]BN3F+._1@!FXTEK,PZB(J0^ZE%0(B!V
MD0A#ZEK?@,M>H#"PX:DX>`\Z.*J6"ZHY(2K*E39#6`E7NAK2-2+5Y4A,>&,R
M(A2]2@RN^XJY@PMK4J,!6)N+T+TDPBKXZ"=I\A.BZ1OS);HR(7+N3,@^B4D_
ME)G;L%^&H'\X4A@_@X'C<&6'<DP>"A&[)X_M;$9<1WOH[!.)`DO8P'N]MPD,
M<"<%)"&<JR$])@HRHC#`-30Y<<RFVC5&]]&I9:IFPZH720BJ6O^X*+UB24BK
M/G9`P\&P-18ARI-CYENKBT%+&ULILP$]*%L!D$P+B?*2N%9,?*-(,+?1"TQ\
M]=(/7HM.?C6[$TI1KIMX='.T\AR-M"2)`0I47P)O,J$YT-G)EX&U9E"LL&&U
MJ'QAL].VSR(1.Z5_)A@8/ZQ?5:-'&K,G_=$_9)!&?_5W:&$:*+$VE>!(!^MC
MJ<JJ+9$3AVW3"Z$;$.O8R'-C.6&QEP:+&9&WG58KM.&W#YE0,61J)5N1`>=I
M;4D-5=47_="/_^<)#-#`-,N91[TX71>9XU%N8.1D=J-#-\*RQAK'<;S57!T3
MKZ"Z.#::?;8R<NQ=]4@[PVM;Q5*!G'7_1=*`CK:G.>@!8/3*J`R@%A80U7Z`
M.VNA#^&!"V-`;V@P+D#;'>3\"@^!0R&2*'CKT7I;*5,SN)GPT;`Q(7&'N(2[
M"(;K"&J9N*SV2(RK:H[;%Y!$<B+4-<=13X?0Q"WBE]II3_0[3^AQP*32WGE*
M`+P!H,V8?V(!5257H(-PCCE#=,NCC3*9BXHG0%'1P9T@&<3-AH0W*PA,)0ZS
MI*!!6$/EC0$M#YY!39_CC;O`S=S(+>R"'%B`HGC6+D!V'LS1CO2`M?+PR8.#
M&_K#RKI%.&8YV+K\&0<COC&D<.YIG?FLOA.6I.[K#O![X6;GQ/6KQ'K)G;S\
M=N#)&#OR3W7'_T\ELL5D3I[K:3#M"08,,"MGUEV4`.(,>BBP@V\H5<^7C$SV
MVDMF("WWYT0BQQ,3,\@-5IF`?./*1GAAJ+JB4TYLT0\WG%D\V!"ZE]=P<0:!
M:;SBY&AH$7OK$6U[@A"#\]SU8.1'PP`?!SNWX^5S@1+PK5V(I>%+O'@2]\3:
M&<5SI^=Q=YB"#GU`BG]7O,O8MTAB!<8Y(1+PR:2`NWUJD\_D]QKTQ,Q5JD':
MX,K%0%D-`TD4Y4'!5#W4V%+>U8$7-%.B@XYA,(\CWL`7`Q7QW&7Q3.I>9NJ4
MR6L&M@VU&:MF;1`6L3D6]#-@:PEZ>AGL(4G\"F0(O1<HPQ_65BR'XO^G^;M[
M%'$UG_EH0GD:K]P.@K`+@3;+8_X2M@Q$0Z,PC8V8JE$4/>_1PCP0Q<R#16_2
M4QJ.S7RGI]JJ1%BRGY@1Q$-C8A<1)NFM4.+"3B2,>-1HWU5%:QLUA<((".$Y
M>P@E&J2";7NO-AMFSIVLU?HR8\KP7A9YJ<",I7DH._'<9Z`Q&0]A_0(3."70
M?Y3?0^5,<1U-"8(*4G>]SB)A1[2HM*,W.7*I3!V)K*$2P2Q)'85<(BTT#/?Y
M0(C2#/>*B!TPM[J)"^MOL$KU+I$:NAH`D5HIRG5EE#VQJ]'3&!N+DQ9,0SR4
M'()7+/D(8EDCPU(OUFM38Y!Y8Z0%!R2VU[O_6QT\>O$UW'H%C#+7DG8_4J\P
MN+1PK5%B-\*=6"_3-;ISE>X8:%:IZ><]O0E-J$D9G-_&4[+.O+7.Z?S3%VD*
M"'^"@X2%@U\57X9_7`\/7&($8@%;@EA867]@8%N<F5F4@F)88)I9G%N?EX);
MI%Q@IUNI?UX!6(*HKU^G8HI<MKBR7F!?7JV^MEQ=6\M9D5];`8I_75A>?YVI
M6U^O79E_MHK9G(I@`>8$NP2WBXM?6I6##%W7AEQ:CUU=7(N-\=@/PO@92'!@
M&#.)"'T)6+#A0#05^"W:4H%>NW9>NE38`NE!@'J#N&"I@(6?R`?6+JI<R;*E
MRY<P8\J<2;/FH0I9_[*P6YEQ(Z$M6KP)ZOB1D9@*#ZYU66!F@18P(BN8$6CP
M03PP%=`0#$.FHC$M8\R,6<!O(1F'`\\$>/!MT(*S:`N:$5,H@`6X?B!">V1S
MRX-IA1;NZ\(@RS;#VVA58R5L&S0LOJKQD[7%6+%HTR1CZV286[1OU:Z-$^/E
MU8)I`<1DZM6)M":D6;1@0?F'-"<Q_+(L^(:E4^U76W#36E"J-B=(7AQ!8_"/
M)2+`@K3$EEYHJ1<M`=HA*@YN#-6X?M+L_+.P#'@_91+6UK*@^9_I;5O6>H#;
MK]!"]NM1M&BSO___``8HX$Q^*:+32U&5-`A\@]@WC5\5+$#0&6/X1-$89?^H
M@1,K##FDA@6G[?(-(EJ==X86A;QUGA]C[*.)%D%YD=$#::215`!DV12`%A(%
M1D``C>3CFFJIX,8%,_6D=@UK8`@'QFF"4+*:,4U.!J5(G4`"G)-=E`))EKAQ
MHN`7[1G%B1=BC+*%4\4L8^8VN*$))"VI<0&))W&*X:(R8CCR2SHO^072("B2
MU\4#7B[PD57M@/$7(01\%Y<:CQX)V8QX%40&7\IXIQ9]/1K**(*S6:/;4X8`
M=1\8[,4WX*NPQBJKK'U*="!,1S[`GV(^"3)=<;%98)Y!")4$QB5)+B"I0^FE
MJ,:*88S*11:E'4K&LGZ$H:@E#'VX&Q<5:)%1%S;_<;$`N1,QM]`":?+SI"^]
M015F*[D19U0G:$Y++WEEWED9789E-QQ4_GY!%YKH9L01)*<TR0@6"2]#YE)B
M.`Q)CK4X5AEEEE@$32K0O)+F%P0,]JA+.X9*:$A:($7`-NJERM=/4IT1UZ9E
M/6"&&DY5MM94!.%H$HT%'>31H/,)%ZA7/;GW'HS?9-$%/+-6;?756%^D3X^W
MRJ1J6UZ4*E'3@GQA[59=A;KFBNA54$@64F'[T*A^X0A/5$!7%4\78S14Q@(5
M^6-3<DY;0D`6)--3<9'D82&PU%!!8Q@GM#A>-B5>0/-Q)2*Y^`7FT!@C2\=E
M58PX1[+0]0?$UWQ,#%1-_\8SB36N?U%*DZJ;DPDTGI3B##OFE&)[%Y($J?)%
MRJ!KR#MEPX.(85I`1\C693]@`:@7VES06&5E->$85J'I45/H?G'7S;J&FN#Q
M*L&W?B%D*V85^UG7;__],.GS]G@R,3A4J?5X7]($$H8*#"H+#Q@6^DRR`$=8
MPR]CT!Y!]"**#E$(>Q7`4%<R<0\S."1:O:@`=V;RO'9H9#FCF)/!*F,[T17'
M<:V3!>*@PK'5%04QL+A=;RR!B??(8A,Z5%TT?+>)3OAN%*P@A2E0D8E:""PX
M'($%8IH8`(&A8AC4"@X'JQB);90,0?1I5$+@9KN_U*H?VV*%%K1B-%-I05C9
M.O\7AR2XE6+I:QHD6I%X)N(5F$CM;G[A'YT*]3"2T`]_B$SD_2!FB*[5)'ZL
MZ",C\O,PE(Q*)];`%%J$1IX'P*4K]``*A@:RJ7KP;5EM'`:R&.%)AZ#!*EB1
M7DR`(LLH100+/X*%)D*QNAX6T1/OX>4H;A>+Q'Q.B!73!2H440O@R4(7O$"&
M@JZX#6-`AA&:^6%GCB0-080&&Y[81C>^$0YP9L-LZ0##.EZRD,)A@P#2$52M
M]->/4=6F0P0!Y1?,!J-X8,$"<B.(C0JQ1F@AZB*LV@U,9E29V4@/7*F2I"(G
M2E&K+601CAR<V!8$M08%Y1O[$9\:/B2=^>0M#"WRE??_"N*MG#3P`3FZ1P#.
MLRGH8"%3`TG/7@[9$BSPZ"($`,,)Q?#,P\B"F8O9S,;V>0QL*H@REC%&-\'Q
M5,Z0YDA=R$Q*B-2D:[PK2K,@36O<!:75^<8VP<E-ERQQUBV5Q5Y?PH<Q7O82
M,IJ0+"3+!SUDHYT->=,[<2F#!0@I"@FM"")U68`"74FUU5D/):'ZHSO;<1),
MV)-P[5#5H"K*V<[V1Z&-%&2Y^E047TWM'Z<J#JL(\*R'@(\CI#5#&`%"QX*4
M80SB*D0K5S0&U94M;OG,1XYHDKR55&!'@?/FD`SC##LA*4I799)PUH2,5"!G
MK-BX4KRT=!MWK?5+8,B7F-[*_[G%Y2M@_/!"OQ9G,"[(*;U=,!*1G$$+/36"
M1\2K969G5@ASD2MY,FWG?@&C*+:!EA4+J&U#2BD*9.GF?`VA(#7ZEBT;E580
MD'3)45A5B5BN)#9S\JR(1_P2MV%4M/YQT"`8NF*-<.0]78"P'SYUBYS40PP`
MU2/_'J#@AJ0TN\L@BEH6H%Z!$7>V*B$9*0"'!2==B:CR`HZ"=,-!**/)A^P@
MDY?,"[!H8)@X=EH<?<,6,8Z@J6%TZ1R&EY&YC8VN<V4AQ>E$YT^/R5!R\S!7
M4E["27N,BCZ$>TX[SN@K"[#-1B;)2:[&4**&F.&GC3!#A@9++6M1I::L].""
M=16?]_^YA'!3VQ69L+/9>Y::Q*A.-6$)`0I9^:^0"H(U?*U"E3"DIA`$8)M.
M,4PM!([R@VGDVQG0\%I(Y-F>)!3AIXF'">*=HQ)?L!R,(Z<-RI'Y<BS<!L?@
MW+ALTYETY#&=[8XT.AO&L!/CCEV#=_=#VVDB3;@XAP\YL8GWK`(;MBC>`W[:
MDN*ZPZ^@>%Z!3.@B0MBEM6AI46ZD(MN/!&NQ/TY.IHB]D:B,Y:<2!X]@E3<4
M2O8[(H7PL*I4A@B>IOKD%%TU(4`N*[/9,U?\.5(?$R20^!9B)#C5U)ZI80$S
M@,BE%D!XMAC5P:(A9",EM`D^8MUO7'K#Z?L,[P^C=$,9GN+_2$2U1-4YHT-_
M]A"']3:'[)280QG:FQVM("83Z?3$9TJQ25MT9F6(88Q>=#%Q8'2GHPY5"2^$
M*]K\)81,!\&JC_;D6D5+HU^^LZFL'IY265YI0\X@VUL4`\.2!P\!,AL4_=8E
M/GX)E8=9K7*4FYZB#*"?M&>5M!ZI&!>MFJ0C%@#[5H5-9\MZM$FP0Y#;PN/P
M8=!0$W=;$(ALXF0UP4+J27MJRE+D*4?9$"S.&<SBI.EVMCLJ>6Z-C62^3OO-
M9`SJ=M&DR%1UJ5(U_V0X(T[,>#,EXQ"G4,EYS4X\()V28*>R)\*7^1S*WX:`
M69:08W]S-R,!--$2#SB"+8)54J/P_R`%!1[:,D*3`"T6H#JB<T`=I1(]Y$W#
MI1`&5!TC='HDF$@,8&2&4"964UD@\6J2I4;5P&-Y42&P]0`1-!`_U@@Y=T'_
M0FKDD7D#H2$&$W@SH0^$9!^NLA)`8144<5SB9QF/H7[&\2\R\ES4H"`5`PM7
M987QM22\XV1)$E94XF33$"^U,0QII0G?!67<E89DLH1H0E<N,7J&0#V#L#5(
M%A@QPS>35VQ^<3T<Q(?@<08+P#\5$%`3@GS8)&.3-RI842,5`1T91E#78"XH
M^#8<9R@EN(F)U$^498=6$U(MUBOR\V(/AG"4!UE`80$D\5N+U1`'80$$U6C!
M!6#E0ANKEO]:?@0X%=,R%O$+T?6%DY%5C"`EUU4EV04O8.)6:KAE^#(O8[)>
M9X(;Z#4<Y44.!Z,G:[8P\T4:,*4,@.(2H=</V"%XLO$.[D1+0T$T:'$0I"@(
M3'%HF8A[X"%A:P%3E>9)DB)AB]=[E$8(M\=THI`=@J,2#V`()L:)"IDU/()L
MA=`GD_4JK]9Z_V-(O((786`COH5YM-B.(3@(.$*+8W$=ER@3`O8'I<=0)@>0
MS"94Z\`.5'8OX=5E6097[`4PDU`V8(8F>%(YY4,)7"`YJ/`P`O,YWK9M$!-G
ML!`R-<0ZY-$*)7,/.]<22\$^R4%[AV`5@K8(A.8%C-B.#)`B:;#_(BEC%+UA
M##:H8)@F4VE!@WAC,V1@`:BA+`Y!(>_(@AP2E'ZE$JO&!6&YD(!I-2AB+A_8
M7X>B-!;%=R$!0`W21P'Y'0GI*W0I@42W(]X0+&J@+8L2D2VQE2B)/",AD"LA
M$B4C-25C;8RT?=FV.0_C.6?90E-G0Z6SE#14;C#TE.@&.UG72Y^@34'$"O(V
M.49T=EOP,E>YDD.11LLC0F+S'()"<(2`!6/)6P+C!8BC#/J8<.5C`6E0!G:4
M4`J$:*R$4Y1G2$`1%"8AB'%!(26Y'UOC*)Y'"`?Y$W\9F/8)*X3D***YF!9Y
M-2K9F+M2>%5V-#]&'N+@$3T&$<,WE@58_QD+H"Y[21//N3)**%$L(7-/@4O2
M<750I'77`':9(':6H!J:0&^S(**U07;%I`IHIZ++1"=HYW;DUPO%*'?#@$[$
M\$4N49`R,PV0@!2?PV_]11L*@:!Q`4*B(!6XQ1$'*$%(^H.T"$K6&6,^YSD5
M\(IHXY!=,)WGD0:9N([9,8XL(52"YPCW>:8#0EA$T7S88*&SXFDO<F`N%P\4
M00"M8X/@4Q\V2(N4H@AY]#T/@!/J:!,CH3*EAU$;*([X(`L5X!/?9TPV5QO)
M9%2)D1$Q.GZG<$W*<'Y1Y7Z_4%73YQE390NB06]7]554E5_%R9D@F(05%"JS
M,2[:84\^)1N+UO^1K[0W@#5C>2IS&*(&C>47'1F$(%(,B%,]PSIYJ[:EB.@'
MG,0JCA``"%0)H+@24TD-8G"H:+JM,4&$`$&,C1)[6".*IM58=`(J3],R)6(T
M#O=&:H`&X@D4P]JGA%832P$C(Z2M[N!BNU@!1*4%/\(/7.9>S"`175@;S&4D
M7#@DPJ@)1`9667",TZ5=8(*&7.*,428FR?$(D3""*@&?T#D]^Y"'(.BC6N!!
M&:DKUOE&PT)!EOA!E6>=JW1/S5H&\SD(6"!T[3@JUAFQ!X@M*(4N=A@`AS-X
M+K%ZU$`N^LJM3+L2]]9(B=I(IY4U"04V_/H_*-$Z9Q-<CH<%[#(9^%3_B_14
M$XV`@5>[(QZK$@&)G&NV#FL"3]45L6*%C%^%)1F;AD*%L>*U+UKV)E<6,%^V
M9=A87V469D=!%OGU$O5JCNL@$65[DCV*8<1'2A;@#3,R6+XPN0[1%0=D6.>!
M6"!X@VBAH)%D!FM1$MFS%417CAQ2#`[)@83D;TO;M+2["*\[BI/UGU?S@A7)
M=*(X'VGP'8*UD<F!+2UR'2C&3@ZY/DW#MD:ALB\1-J5)&$FE&Z7`DXP3;8_3
M)4$9?Y53E$`IE&^6E*K99M_&;0:SE*ACFUT2E?C@O-6Z8O/3)UT"#W:U"#XE
M$7_*+&Q2"%=J8/%1'C15*1J1M>#9$$(X@+5F_V'#P!YJL"E]9T^UDG14J3QE
M2Z&UF\$7>KLKME']$)K.VQ^0!',MV%$TEU-8.0@ZXZ06(`T<7%?PY*HD/#7]
MJ:CWT6]'D:'PY!LBH4)$E3E2YQNR&6ZT26X*N'4YI`D[Q)L^Q'5*+$3!.0Z<
MP!S'N:.LNYS00;0[%;(`D:PL-1[@TF-;D49H<BD:D7/AT7^[):52L\8SHYXZ
MYPW1EA*>N34#UV](MA#YJL%\/)K8P5-XV0\>MX(@W""Z`AAS&DGQ%3V&\K40
MA`9GH)4Q$Q/ZD12Z.!&L2Q$/6U<]`Q-^01]'`4LARDN7$*(F.LICAWTOJA/(
M!#O95ZG`H%305'XURO\8Q(,X.BH?'#RH'%(+A1D2>:@%S3IC!T4+$>LHOP:+
MEU0!9$!2U/*S!/%C^YM3E#8?R=4(7(H6-CM"2L0(?+6X26:N]XO!?5S.AG`4
MK$JNF'S#54/"'$4=&':Z[H*O?J$&Y=EA!""HBH@@^(`=0MJ\*M$(.P+/RS8_
M==4R:1*H];$+X)=4E'$DY*>IV=08ES&J6+@)SE`:7+A5DW.J1'9"6\`<^N>J
MC@6KXC*V@6&N'(+&#Y$0RM!S*GN*Q>=7_=B6%0=!/H=V#^#%Q+;/FIMP&^DH
M,L(H*+T2GBFFA#"[YIS!<-H.K]9(3I&VL?(U+?9RLU$49E,!/5<&&9+/_GK_
M$B&<E="FF()7R,LS*@OQCA<:FFP:@"VI!2>X)`GK7+_8A9#0L&M2B<8XMQ.K
MC/)BL=Z%L<A!`(^`2R2-R?JU%-`+8!Q\O[]@>(<2O)N6N7@1E[MQ>&70%7.)
M+>59$CGQ(&&+%F3`/P2`I3Z&+K5Z+H'*#7PECE/99P15PTL]V^Z<9&2]"),X
M*Y=\KHAYGB]F.Y=`"J;TI2[AF;RM,NJL"<C7)X"7$DNS*RPAO5U"&)7"AO.2
M.T(!7E<F)CHIN/_B0]5IDSUY;89"O\HPR2L!SNN(=NQ!']NQ7_6P$`RZI"=A
M!MJ#,YVDL^A!WZ.@()UR'AF9PH)PB(>E'M:9.3&&_\9(V@@*LK&NRZH@R6_^
M=1$HDMRSO=14K;9K@9C]9=96,\(>+CX>`3+`O)&>O,]8Z]R$%WNST2-CFQQN
M^F%1.YJ'&PWPM+W49J(^B6W=6TRM&6='.;Z>(VZU"0L!ZR<O4=2'H-*(T`GH
M'>&VDGD7I*?7,R=PX\6\NJR:UJ4"WJ8L[0>8!@X]]W.8\AVY2A[F.L%/_HD6
M_,*?R2')>^$:O-N4Y>']Q7Q8L[8`.BC3@DM%J=(PT>(5"MTP5A$LLQ,7#!0'
MUIE7Z]I:,`I(43%4EQNFPZ'E5D4?ZIM*['6]:42HW&"W(U3JDCY6C&+&349(
M+7ACZQ<]UD:#D%,R".`5T/\0`;"K<;&`>>$4"Y"9T*QS!*2>/7TM!YC9WI,>
MC:8/?B"L;%,57`H1K47A=2&D<K[4N1U1A/X3AXPU:[KB!S;A/QB?*J'D%_'4
M\&-/[ST4$>+F`>C!+1$;&Q%]1%4.\B:IJJQ]K,P*WO?*2,4.1(6IM+RI1(O+
M)7D1D(L?A8'MRO#+Z^A;_S3,%O`-`Y$&%%:/#]!::&`&U](5HELT8T!A$&$>
M=IGQ:8F#@!4M.[@6P4L&9F#?8![KT>)!LC7,$T1\E-)HT(X?WCKM?:SG'RNN
MB$K0H9CMDOD4CD*GUPI&)MZ9<H3%AHS(!T61.TJ_;0T_;[T.EI&IOO"U4X@F
M5<C_'YJ1A<V%50;+L*TQ(\L!X;^E7SY5M>!`9,H9&,7<2;KVD6$@$+*5-WZS
M4CY'!FL1`&?P(7#$[*04Z\02-W%Y/9KV2E_NCI(2*7-S%AV_[#DE>9LB*3>/
M'TJM\TV[[>TSM1C1Z%8SD:5L"=+.3H`.$RKH48`AZ+BP$<%]ND?CR1\5O4XG
MZD1VU]CU7+]@77QM)7Z-'-W5C$;1)X\0\(&"XMZD/+H1.(V-WD:*/M>0'!9P
M/==B872T*=H3^<'%:#V=!IL"%SXG-UQQ7),'A!^TTP6Q`&,)$6CP\I+?\M_1
M\<MR^=5QV)K/QZ]W$;J[[I`%"'^"@X2%AH>(@EY=%5N&_UD+B9)_7@0!DY)>
M%5J-@F(/7()<75V$8A4/6EM969]=7V(,75F8A%E=JK6BIPM;6`0/M%QB6V!>
M8G]@OH)?"V"48LJP?ZV7?\W/Q\JME%BO%5VC%5^Z?UB@AUP/R(/J6U\5M(=;
MZ->X8E[T8V5^_?YF6D+!0]/O3(`'9L*0>3`&C4$+8?R$0>BO8AD+%LJ<(9/F
M3+\Q8RJ*]/>`GS\T$$=6G$A&8@",(!\\.(.RI4J5`19$E+@@@,I$6A!YB52N
MJ-&C2),J7<JT5A8M6N0EXH*E`I90Z<X%\-)4EY>#5P=A>98TYX.P1>$MR.+E
MG)92HM81ZO*@4Z&GEB!I(>N5KO\8K+7H:1%S2@O1+P&V</FR2IDCJ@$$8MGB
MY8NQ+<7^0!88+8ME,`RNR@2,B12B+P\<#4(-!LP#<H=R8J571B$X+Y`LJ/$W
M!BX]@BO3/`APILP8"VGZH7E@\^:9![O]E7EPL^+"G33]+!SC<>3RELN3^U%#
M`"*:"L"K^PL#TM_SYATF^`-*OZO]^_CSZU>ZR.[4+;<E`F`77.UG"%5G<97%
M`P4>-=8PPS4XR19:?%&A*%+!PQ<74(V32'^8$=`(:9,@B(6$DSS5R"=6J1;`
M5LDHTQHM8`1`%A9BT"@C&#0FY@D66##P#CCEJ,/.(\!(!<8XGY`HR@)P_4'/
M3OU<%%7_?V-4P,Z4U9%1073^$)!>=0LTUP]#W:ED1DIAP%1!0F18L$]%YQ%4
M!GJ\A;10FNI)Q-Q)%9BT1@$V9#`?(D$A:N"BC#;J*%)?G>5D(13.DLA343TJ
MR(!>N':B410&2,\KDWSBA1;64/K::JG4D\DO6U7U:3F<EK,(`6,M@.L[U`3`
M#F%@</&.8^0L@H4GF`G[119@8($8`<OB6HZ%JAE"3V5T808**9.Z,T@78U!)
MYQC!4#-(`.'VJ<8"(OU9W41F]*,&1L1=E-%([?EIDT)HEK&`!62<(9Q'U_4S
M47)KBJO>>6`N!-P:#M00@0>''OB`4(EJJO'&'.]G(HJ/++!7_R)?9*LQIEG4
M6DL7!"S0*52TH(P(*5X\0$"U8KD*CV&3(@)A`%TL$&`Y8,!LZR^S="'+,5SD
M$XX@7?SU1S0\_B4L@5#C,_6"KVTAY+0>QA;0()6XC.II%9#%14]]GE%!(5J8
MU.4#P*%1AD-9DJ&P']_U,[!V#*&!1MX&4\1WH"/%N8!&:Z81T1@Z*0<P>R'U
MZ8\:>/K]`)4)T''"`C)43.FQA^#2\>FHIYZ4RA\R@G,AD4K]:,FIR3Q53U(:
MQHK))?NGV5GPL"5K**-$*>4FQA<UZK*I2.64R;I058$SOT0U3#Y@2+W%`N0,
M4\PP7"@C-1A=T`-*`-#2RF`ZIK734__-KP^R)&Q3^]3G0H58.*=*!8>QP`)F
M^)<:PF"&-U&I3A^IG'0PHH8SF.$!%JB`3=1`M^KXRW[*85>5T',PR_FC8`G<
MR00`<`0B9&$,!1!=.RHP*4RI[H4PC.$CC"8)Z:'E0.>8E:-B=XO4I,.'@^@A
M9?S2M(,DIBJ8N9`H1B67<]4E?D;!5-I<5Y1%I*9G\]@$,2K0"6VLPA'5$,0M
M@L48&;V#`.&@"_TP$8"Q60QG[@@>(NA!&M28"5]/6U`$7Y&;.X(D(BQQ3]YL
MLX\U$:1-\5+)&;($)GEMKD\360F>]M0W#_H!<CM!9$5F$(`4"`$,%ZB(Q?A"
M"'B<2H:H3&7_ZF@'14((ZP%8F^/0'&5#Q*P#,%\@`"G)=A!\#(\:T3@&`2:5
M&5'0)6WV`=&I<(5%'%JEF7?AQ!;$P(FG?6$RE;E,,;$0F6N(X1=_&4WTVF<(
MU$`O>!1:XUR>1@T@"<^`(O&?->C1'2NQA2YZ.P/;^`:=D1#0@&HP@][TU38"
MB,0,XJD.`A_2$PM`,`QW&I-ZY.D>=_FA``;`@A(Z8(*1%,);Y?10QE1)TI(V
M*G;07%XBBK86C0WHF@FBQREB^=%/;&5`M%@$*:XXE0<(39U-:4L%H#4JD$F"
M=9@H&:[(A\8;84%'Q5A%,A*SA9OE,GDU;.(C/!2I@\#"5:[$W::@_V.<*^JC
M.Q-1#1924I%%-B(,:6#@!B4J$B\=-*'5&0,&#4:N.UZN@IC;C4$(H*>96#*0
MRLF<'V@P`!/L8```,(!'R0;$0K@&-B,UJ68W>Q\;0M-VA[A%+C3%TI0-%384
M:ND\WL*L-O9"%+_,'SC`BI^?Y=*GSL-$:6V%OJ2AD5?&VE2RWJ$%:(%!6KI`
M32OI2(AS%,]GE047E0PBJ=0&`)E_`%=U'&C8DSQRHA40R70&JA)-\M.A&:&N
MXZSS2.%D\D\YV=M-SB,WA_E#!#+`PA$D0(*;K"8>\W!59CE+X`*O;I9"H6*"
M>?HHT:Z"A@Y&1(2S2%/S+0":)/,%D("4(_\G`>@U0BS*A&LA/>JUK!5<&`;6
M1B&&!3"HJJT,;=@,$332T$P+I`NI/-:FP.`,IVE2>0!>;Q*`1J*$3][IIQ_B
M6J9_F@')[YEK00;Y0.*P)W)_5`YT*&?)\52P'P^DD@%",(87D,`$-%C#3Z2T
M*AJSDQ)$,;"<YUR4W;Y*4CZ+[0ZS%6)*9&M2*#U$:0N3JK0PH@M/904K?*&%
M6T8S*L=U=%\8')A-8,;2PTC&--41$)8!54"T?=+%VH$JY<ZQS>KPZT'C+(CO
M5B=A5:H-YAJBDHA*!"0TZ2LANT/??H#0/0^$T[^28UX_1!2Q'G1OGOPQ@3XX
M80Q/.(`!UD#MGS3_Z4!B_5:,Z<SM;HL1%]O6C$V-NBD$,ZJ6O22>K(R*(!@]
M8J?A/L2I1E9#`'6SE$J+3`[)G95GED-%#Q;28GR!QK6M3Q>R^>$W)04_>'QZ
M:JXJD^7T2BEXJJ0W6@[``[EC+[D!#I!"7DD!GWP1"&;N)?*5B'`\GH:$7F<Y
MC>Q3EOV4R'Z8P`8>$``8,-`G<A("?OD;M;>'3G2R_7E"YB9$I7*[J%>^8M_E
MIJFJ+"5;IF,B"P`.(A9$9IBG*CWK/T]W5:6.":1.0JE/95DO"!!.-V+BN8?0
MT"[JDK(VNYDT.4'R2J`T5H<Z`D#<68E<#I<>Q6DD;V6(+S]5K9T*I*LB_^BR
M7!IJKIUTQ1=S=+U)FS!8$V9S(0!*>`$5X."&=UD@QZ4$NR)F7/36>]NS*:)A
M:$6V2T8M766@O8O(JK6@ATO"0H`9E3$442-_4Z*RKCP'78J6*:+ICK?@J-%@
M8%4DY!/BLDJOD'/3<38,;<HP'B^<6E/BP&>RE!_+44V<Z&H<@`E,H(G-?$4F
M+Q("Z+VNCRR#&?:?)3E]W))1%G_^L`9%(`0R``0U0`%JYAS,$6#JA!J^YWH2
M6&!.QV_,`#WRIF`-1GNVPTH+]A<LA!1VQRUY5@\<XGN<<EOQ9@O@5B345`$,
M\!81&'2U-U:DT20^]W.5942PI"!=`##>11;:M?\2"T$@HL4]GN!J([%(>^4'
M%7!_@A=SLP:%*+=D9#4O!-`2F&1)O>9KW>4'#B`'(8`$&C`'=;`P>&((UY9Z
M,SB!;LA92S<)@=9O-W12KN.!E``6W7(.(6@4)3,(VY-40@<)L;<)<U@+5J08
MC#(_,\,`]Y9=X:!5L@4;:X-!BI-3=&$&U]4](7<3<5)H4]-C\V4!(I$3\L<W
M0`@X#I40\[(X*Y$O^7(X`[0`HJ@>Z^</5=@/7E`%,2`!`F`"`&"+7U8()*AT
M!_>&R-AM>E&#R9<@/E-4FE)+1"1N$1):3V04Q#`(+F,+BE8(DS$(H59.V7);
M.O1V>H8?S(5MD;$\.$;_+7.D1*DV$L:1"US`"L1C4=7Q-H2@<?=C`8<45R2'
M$>%'>)H#2%["<7WE!\]!;(;C96B`;)+W75SF#W50!%(@!E/``S2@'F%6,1R"
M>H*`!6Z7C"1)9R!2=DD'B+#4AO8!(4]G%06B4K9P(CF$8<@R"`$!(:@")-?E
M:%F08UZ'B.@3"6:'=&3'%#4F;\@7`$+B<(BPAO`PD((D=&+4A!<7)5_@!0B2
M$"JA;`N)!JUX>!+T0=TU<Y=C`8OS$+J!BLWQ<HAC2;'807Z@9B@@`0U0!4P0
M!_*15Z*H"-8'=R49F-P&>Y)@9Z$E>XZR/+@'%7SQDW/G;K\7)6)P7;(0+"&9
M_QHV@QE'0BI%XER?@)AE]WQ,L398Q0RJYW#7,C-1H@FG:##Z2&JN6%YGP0P,
ML7MP-1Q\DF5=6"5]57XYP2;[5&O'(1(+D!Y_1$&MN1(64'.5Y`<34`!=$`(#
M$`73]BZ=*$I.Z4J2*)C<*6<_8X'4T(()YCN-@C)V=I*.^76<F0BH)A.$(9(R
M,1D)PC*`097_9@G?9GTILGM*`5+68G=L=DTCV0ZS"8@:9)VJH6$^B(_\E*!?
MMDA"QB_[<!'V@YR*=!`MH1&%PW@541(5(7$4]6M]TIRVIF9K``)'D`<'\`)R
ML#"I*!+T\(#ZV9TT6F`RV3J4!CLUJ2D@,F$E!I)B!/^:I62"-E--GK%]`$(_
M0)(4#-`.I'!T?4&>M2!'A_`)/7B9.G4:E549YH`0\G4>\@`N9="*.740ZW4>
ML/$)"D-`"%$<^V<2(NI/Q6D1U"%SE:-_"(41?V*6(ZI8U[$&'-`!?N`%(2``
M41``I:=0BE41#T0B6,>2-1JIJI1[=-@SW\FC.<1*Z@:DJZ&!JM(@]"`T(FFE
M5SI62:$T<<$.G\=,G6E\N@6@ZQ0*+`4E1H(VE*@%<I(@-L4GF,.)>%56CW$.
M/@4;TM4E7T(G2J@2YX%DU\5X%'5)BZ-_7%0;%F"5<Y,>\34H#]`'8"@%3W`#
M'R",]P<2_PF>DGJN)'621LG_;R\5C39U3<^4GA^2;N6$9\2W84$I"@EG%*09
M%')'FY=VE/]1JJ#6+3CF2EIB:@[HE_LB'#<5.+<I$"_:5KU$8]8J$O2W'EY:
M'1;J!P^$$0$3;.(22'().`[!H!PID;3HG&<`!%=``7Z``#_P`FR@'KDH>/%2
M"/N*KCQK8&UAKP(BFM;8?(_"*0`R&"0&=<E7`0$0@;:T@F_T!ZJ@1,DP8VIG
M=4%+=7>GE#A#+8^*""*)%5&9.!8P"Z(5%@,Q4:]%"/;7)\H&5P)UFX&'?SN1
M+Q`:,,(1>+W6G.ZUFQ.G0(&T!@,P!]?5H@;0`QNI>;%()ZGHI*79LY"K69<J
M"<M(_S(8Z"CF*;3K:@CDDPI`TAI`XF)=P(Q)A5U0`1AK"''U*)ZZ4+FD!HJK
MH4MLF)JE$R6N<8H46@A/"$D/L$NHL3_XDB[G00:)%Z%Q`KQ95K(&,W(;\2]S
M:FLA9%\>5+(,TP\HP`!&T`058"B\JVH(U`]Q`;61.[XR5)2PXZFP0Z^SPV>L
M&WM$ZTJLX$YLL12,*`@C58R0B!7JX&**&*6.`'2KE5JT<"T[JYU'XAHIYQZ9
MM;'S-5K,!R.YT4C/VK$2467%\2]K8C^=YXECV:&95*U6F,`BL<'C@2=G4``I
MP`!V<%T4LS!*AG]\<@W81;XT7&"4ZDQUV(SER"BQHZE3>O^Y^I&.]AL7.:8.
M.>:.A)FT7(2UVQ>>J9"E<3=:(3EDWN$APX`CQX`F59RFAE6$F"A!85!)<>J%
MW%$<O+:H-\$`(E$!$1%EB]NGA?=($R`%&)#"0!``2^`#(K&`4C82-]L/]5O#
M@DQ@>#BP`AMUYMJ2F7J.\RII^)&4A."OE>6.8F2UO9"2$L:ID.A*W#*CU,!Z
MFO&#C$=!G&@&95"$^:`%P+L0Q"J*_C(RPP!^'Q$Y%A1>C,JA&RHO^U=E'+2<
M7;8G>1(&:P``8M`"%_`%*DP$%:#'GIBLMU:+"V&3@SS-,'2([ZBU,_2^C6*T
MF/Q12ML4E7@(>S%C7SM6!0*8QZ7_6BD"I$9LP*QQ:N>,J[!T3Q'*7@*!CW%B
MMAA,+L2C!9375EG"%WYSH!Q;I^XA)_+7>1,1`*?L4'03@!X$:SQA/V"`!DS@
M`@CP`0Q`N%?@`7P,>;0L>%0,$M),S2:M.A_COE@;GE+L**5EF)N[%/X)-ZXB
MQ/OJGY4X8ID<=&"G7(&LLVXTML9&>UMY!NQA36A<);2'&SN&LB)Q!@0P"(XD
ME62Y$R^QG,4A5W2")]5;D-]K.1.ID']2``C0!1Z0`RV``1>`O<J<!1_-$[7(
M3S%'42==UP1FOC^'OGF=HXSB8#I-N4*:7*H'-X!1C(!)R<=7+<C,UUK'AJST
MJ$+,R;;[_V6"-"+;@[1L!H4%`:!80,7XDBK`X2]KB2^1(Y<'>09N91/V1<'M
M(;U@?9V]%@958`)CX`-&D-9MP`"::`,\)WBJ!KT::Q-V/=R;!=/RMJ.5RJ/C
M"*5G!\2O&H&)PB&IXI_9*<,9<D6,W$XJV2`UPR"0_%%:Q27E54!K!`\B?#@2
MLB#DY4^G5VX.-2=WFTGY0L)5(I!LZG@1H6PTY['./%\6);U,:0)YX`&WC0)P
M@+US$$I;'7->J#"[2=P0;E)_?2#C)B#=G!\V)%0Y+!3J6RKA&,G7,,DS'*,J
M23^!3`\(EIYANX\NPW=QU[OG$M*>B'J:@,MH^GV#(51/]M1`)/_>HKT;_Z1Q
M[O+5(YPE8^(O.]$W;ZP>P.U>;L`#""`!#-`#3^`!0$`%?=`!$%`$#O#1%`S2
M"O/E$3[FZ<K<I[:>G*NYVPP.C)%T\.#-SI@(^`L4Y9P,=I>Z>*XS7V-GCNES
MQ3/3ML!Z_5T1O:H9OI"5!\&5^%<@TL6F)P)X9QRFCS>5`U4&&FJRZM)C9%`Y
M=0(OO^QJ[>$&?$``'J`!#$`&2)`!0/`#7^``8\`%="NGM:C?*D3FMOY"22QA
M@2U&M*<QI27`VRU+1RG=NM!HH.HJ/H>_<^YG(^+7!\&_X4NE_TDBKK'C_(,.
MJ&$&:C`&JO`S:0(0]_C/7L)'C19!W1/_G/Y40$AF`9JM94`>4.UW$((SL7VB
M>!+ARVM@!`-``#ZP``RP`PV0`4?P`!E``XD;S/Z$LGP*OK?>\.5[X?;@R<PN
MODWAU[07V8=)M*@Q8$!1V.P4SJ+0?:LGL)YU*S>3A\/1N]@7&Q=&FPYU%8`G
M49`C$(H%H7^A#P$$%S7#>%:B3DY=BN'G)1R*0.<1`&1P71@1QDFMN`H496Z@
M`%8@``20!1'``$,0\'90!0@PE^N![H`RUR"\9@X_]B\4AYG0X=[LJG:8&JC!
M`$<R";"T":E@(>40W2*/TS,*[!2FE1)258P1CJ0)B%KPCSWX%/=RU&.E=XZ^
M&)YAFLE)!JSV_P=L;*<&0P;:7L$6]T'^B.D)!#CM[MN`0A!K<`0%$`0"``$L
M4/4U$``><`0IP..JAGFP7QUD7_LOY+I3\<T?!8V/0A4,4`$:#DT#QO&*`L`R
M3$JCP-@LW4J&24?+'KZ#H*9U5;;W!!7C)\+X$\G)V2:O0P_6'D_[A!*F3#B[
M5I`A7#@(PU:6T]4FNP89@`$2X``K,`"H?P`,4`,-X`&"NM52"0AD#V%^A85H
M%6B&BX9_CH^0D9*3E)66EYB9FIN<G9Z?H*&BHYA>715;F%L575Z56UI=6:29
M75VK75];#ZV56I*_FEI?%5^/7@1@DUQ8%5A<DZ8/6]"265W370M>6O\!E,3*
MCEUCC(ME"UK5CF(+Y>6(D6(6:NZ%9]/K%18/`5ZK8XH,A7E`YE`B@68JF"&D
MQL*^`(7&D#MD@4P8B?7<J3E8R,R@-6M"<)`@8L4`"!P.,*CQ(@$C,A8",I)(
M:!%,F?5HZ=S)LZ?/GT"#]F3F3!VE+%JTS#J:=.E/+K8>@=&R(`LL69."0=**
M*:DQ2%.K4L+E2A)1+&4C?6'0"M\D,,4>:3&3T9#81UL6G*DKJ*R8+EB^F*I@
MD1&BK^,,"<J%U$(9/V4JT/,C:"^C,&0JC+%L*`#$0I'1#$Q3]^4@0QC]\/CR
M@P.4`B91WF%`8@VC-*<O+_B\R&/-ND*#"Q__3KRX\:!<=O6R=$U+*DJ#G_/D
MXA92\RU9T(63"TP3%P+/)EVK'FFJTK&LTOZAOH68TTB[U'UY4-H/;FA>LF1)
M_@"@.S/IK#=7&0TI1=1"A<!D#!?=E%.&!5J`<<88%OCGAV]\T;?(`@%5A@9!
M]:&V0$VC^4'#%Q;`\``'491TTAM/"`"`;:A-Q,@]!<UD8VG']>CCCT`&*91R
M[T6##3708?%`>+2P5XDT[9TB'5>.4&F)%DJB%4T`#XAAU"-?',G4>>[M\I4D
MMGS)98[NC-&%(W"9X5$KC4T6T9M_>`&B(1.B\L<J#@5('9OE3*BA8NV4AHAA
MF@5@01BAA>A'&+L9_X)&17ZLX40#(DT!1@0)K(`$!"]DX`:-DUI`USL5/+;(
M0*N&*.2LM-9JZZU(G6?)65\^PH48_*CWR1?.87*6%\T\8Z65E53@""YG0L+,
MDL(ZX@677DX2IA8/?`%LK^OM]DAVL7AQ[0-I_):J-W_F1ID%50V6AAI+.D(,
M3GPFA,5ZU7C1:GT/X-009^Y4YL=&^RQ`+SD&AS@0FX@H`D`&`B`1`@LV@'%`
MJ`VT<`%(ENYI&KX?$EK?K2BGK/+*/46G2GJO\!(M)\3,?`FTNU0@++.3B,&N
M([D6B1<K-J^G9#^2Q!?5,M7MLE=#54T;P%[W/!?`B`Z.X=RO@3T;<%V42O_W
M1W:EA6'!9V>D808:#SKVWVEF/'H(`Z1=K6Y=B+A*V0-GN,&!$TD,,$`5,-BP
M@1()+!$''(SB6PAN=T<L:2,L5V[YY9A'@NR2X()%E=#C-M5)S9^$954L3O$<
MR=6]NBR>Z),H=Z8MW.RK;05..:IN&6/@`\L##\P"U8Z%+F#[(Q7<76CPJQ.D
M_*33@$980XZAT3NAJ:7FQX=J7$1\7?3*I+L?:^51Q``"7&QX'@Y88,#(;8YQ
M=\.3^Y'Y_?CG3^NOP5Y"KMB:DY(FIE*T38P'.]KY@^H<`94%]$\2R"J*D?PD
M'@)@J1MZ`B!>NL7`Q+CC#%S:CB,60)K2I`%/CWC_`(+J<1A'<.D!"P##@0B&
MB%GLC3-](@,(^2$(NI1(>J(167T$02*,K`$#6V#`$XJ`A/2Q(`1\>((#WM<;
M=PE$5>6(V_-.IK\N>O&+P9'=)5RWI2YUSFMGY(0TQ!"F"BQ@5VX1HUF44ZT\
M9<DHU.F"&`C0GKCT[`'5H$X),Q(&`D2"A*5AW7K$@`4O_8-@">(@%RKEASZE
MXI$'X^`?QG<CCYCA#&I(@R(>IIA!<&]R-"E$B=P`@P/T@`%C`$$#+,:!$+R!
M!V[0T0>%&)'O30Z,P`RF,$41M$OPBA+3TE+2`#F=+'TA6;V:CPC'EI1IXN5S
MRP!6+Z19)DVBJ0OJ\%E]_P*`POU,:X6O<I.]+)"&,GBD'U-Q6R2A,:C+Z(L+
MY`*G.'R)D$2!AC=VBY3#SA:R'+TA``>8`0.4L*G!@4$"*$`5]`:Y",F]"EWU
M*\<P-\K1CGY#3+NBXRM@]@ARIE$4..-%6KY``'U"4(#BZ4*Q8A>+8IA)2>!B
MT,_LI9`M^D&=[>*2@8`U-8&XY5XVD5F85&@!?1)#;Y<1!`"[$*N,D,&?E20,
MI1AFQ;K@R!"12D`-:M``)9A@H4EH@``L\(("&`93Y1`$R7B94?MY]*YX'>:Y
MLF6)JX`.:*);FE""YE<SB=0LT#22&9?)/ZB@4'/5R0(YJ0&LS5RF2^O(C?5\
MU_\?`L61;^YXD%+R\Q6D>I5*`9!?7;1XH0<D;`$,*,@8L!:BO)7R#&M(0`K&
M4`.$GE4)("!G!#[`"($R`D/FX$A=%Y'7YCK7B\FLHW42^-$*/*`X2T4@`Z3C
MUV4<-A+1+>D"'$N=XZG%C^TJ`QKN"8LQN`H-,_7@(G;XC"Q@09E8D%M&SN`L
M2&#!9.48R'/R,PM,E@,CWJM)``C0O07PLV`QZ0S67E`%'XQA!PA])7`#P(0Z
M2)1^B]#>;9>KT>>:^,28(\L880K>+AWII#O9:QNE\[^Q8#-VK+@&.+%$+`T^
M:Q@EU>^D%I,?!^YC00VJ1QC2H+/IU@<>D""&9=U1PV?_*81+6`@#U/16HA\>
M+!&DE!3D5(D1&B"``53`@0!V0(0(O#(/(,`!`!C!R8M2M!!V(W&)4<SG/J.L
MF);8')/6XY9C#B>9SY1@GEX<TYE:`Q49)-T?`RG?E\!K9G0]L`CU9*>"/<`5
M4`%>/QH#U2]_);\DPLUF>$<0013D4FPBHFTEI3U2KL$$6$!S!@:P`R$L@`1*
MW(!$O4=EN`I$Q'JFG)^7S>P@7<>81#47>:R\G.%`2YME,70`I]&K!:Q"%Y^F
MA&`%69HR4"EYI0$J/K-@KE,4YKC,U%..%I.%I<Z;F7^HM&(J5(:TI6$O%OWI
MB,(G*;/%ZI1K8($8<L``%^`@_P`]"(`&7L"`'@P[TP%79::3W>R.>_PX4#KI
M*OA8"=,5A["\<(J*$>L,]2CI"V#`-WBQY-\[MVFG?XCYE"]S-IX&(&ZR.-!O
M@&I:L&KG7+R@)T8S4H8'=-H,DZ$41(@HJ9*!]2`.```1TL"$AN^Z!U>0P`G(
MP(:*.MW3D$1$IY/-W(^[_>W(2>PW4`&[1OL8*-D%=,[K#A^8X?0/%0#7?``8
M\U*G$T^`*@HL%@!5`<-)N><HUC_B9CM8.,X>8T"O(S8>8HJJ02^D3&5ME4MU
M/5BA`P&X`<-=D($\F&`$!SA5<B]?YT)LY/)LMRO<=\][G:S<.IHDXTL7.QP9
MLSB[E/^8"BN`AG.>GBDOLK!W@#'[!V#5)#-TZ@*F(K.472C/4*GX`KN]YM,$
MF1?PAM=E&.(&K]ZU2NJ3DZN("'%F!C@@`'A8?0J4,`,0$(_JEX%L>U-^'-=[
M!GB`H&!R:*0Y=X1,R2)=/I%,]L4YUH(M7U)>XW)^[?(5PW,&U@-I7+)"\/4<
M^G8P\,)N`1`+7Y%G2F8&;P0)Z(8W?I0?[99I7;9T]Y`(7R4IR+55?C`!<9`!
M#,``(D`$16`$#-`"<A`!"#`!%1!BM&5G!Z9:N9<3"'B%6)@)Y`(&\8%,T392
MU28<N)`%7V@TU&(OQ2(&!A)X_A4@A$919Z`O7E!9`1`7.L7_=%H3"5CP8(@"
M'^BR10KB0JH"(2CXAP6U/6?W.*;T+[1F(V&V`R$@A$0H!&*`A"W0!S%@&^XU
M*0Y&98DH$)14A5:8A:18BII#``P@!JH@,Y6@=\*!<KDP-%T`%U^@4W7X*R@D
M6/,!8$.6=/K!0)QG",SS"%@0`.4G"/0D4T&G))]T&\PT/'R2>=1P-&60&8I@
M7#0A?PZS=-LC&7Z@`&$0`E.`!D/H`$00`V;0<`90=@=CC)EF7!K'BZ*H;*98
MCUF8)G+7BGRG%B`U'#.6*UO@"ED`/-*6"EB`#9LSD*K(4[AG"&9@7@-9'T`U
M-K/`C)"$9^/U![L(&5IS29IA&6ZB_W0`%H>*=U][T3!F`Q%C5EO&1G`8``0\
M((YKP0`=T`!#,`<K<`(250&,:!J1TY/SZ`[V.)17.&[?!1TL!D$62!SG$AA8
M@`ZWD"=^A`7UUB4#&6Z.0``7>5G35(?RF)+VP@]8QA\6,BE`E07*54F]XR79
M\0#.$)9K]RJ940V%$(-?)7I/1GJG80`NT``8\P`4,(1PL&9%@`*,H`8,Y@XL
M6$H-&92Z1Y20Z78,HH%_@CICU(#+D"40.!1EZ`A8(!U4N1YUF`4F-PY;>0@S
MQ246`&G,J"Z.EW,<L63!4B?T\AQ.XP[K5R^0X"^-"3U?40B(E#<&%W^@U4LU
MH0)6@`1/9/\#'S"$;2``9^!6294&=^:#SDB`01F9VNEQ3M**U%4)_(,TZ!&&
M8<2*>7*&H6DM,H4=1Q(6AM="#+(JZ]=RE05PN$-^<95RR)*>M><.%O`>Q%!^
MCL<%*5@AO1,3.Q@BK,6)O.$'';`$`<`"5<"<0X@`>"!1/R4_`W%1`(:7CCF*
MVQFB*-:=*T9!?66>KZ,KPP%HN(`5NWDD7X`M8(`-L19N\A95Z9$75($84>@@
M%B`V\U$?D2$L<+%S9J<,@Y<@!+"(O7ELCLA+#K`$`P`#53`%]:<"LJ=*H:A9
MWO@J!/6A/"*B8OI<[L$)VC8F?Z61_2@<KN.*#/2`62)9_(`.T/#_5!G1$.>7
M6O5Q0I'`#Z>Y-V6AFJC`!>Z97,:`EL;02^_2I!HW2+.V"%$J`!RP#P@``3.0
MI94D1&E0$`0W7\$(IH4PIJ**5Y+6"?Q!GB]EHDI)?&S:@,*W0:U`%O46EKU9
M2(>4?DE%3_?E2/WA.`!"3W.A2O=D;V6`&Z[0A7\PG,CU9"+3J1+E`!6`!!LP
M`BZ0`!0`,@91:FBP``!H*6D)JB`ZJN(*3*4*"MT5:)B)6&=X:%\H:+WB5X"&
M!39W(VY!6J9@;#.1D;M8K"I5)ZB!)S?Z$NFQG]FB2!H)(@+(=,JUD@[*!>P8
MI4B@!A(P`ABJC8Q``%2X;XP*JN/:L<"4_Y&TL(70IE)@N)D](4;\@ZI;F%T,
M(D^LTGT*T3L!2:._<1%X@I8X`1.R,!B9MY!V6@]X&F5:<2^P0IQ#E[%^0`(R
M4@A1&@`O<`0B<)T!M@!=ZI!=!:[AZK%:RVRO&CLIIX\J^HJP<ZXO"H)+<@V$
M<9B:I`TUL4-B$$%KTW2V>;60@0ZSX!3S4:N&Y"MQ8296)RDLF)*+L`8ID`%`
MD$M^(`)+(`0P0`.Z-'UDP#LAQH=8VW9;>[G-=J;B\9V2,&/%T::<^Z;TR0\3
MB"#W$2[?DYO]L`6VL!3]>2/]18Q5M4NI<"VQD())P05%5S;:DZ!^``!;X`)E
MP`,34`@%\`,=@/^IP\DJKJ(A15NYLH*YI)!K0ZBJ7X04HT"H"I2F>&$)]P4)
M#)`)J8"]0'*J)MNUQS"63.FJ4G*!T48D:M@-(IDAZD$VY1:[#*0%+LLHLQ!S
M2(H%+=4N?WI9$`.4:R`$+L`':A`!Q?N-""!1OFL(G?I3:`!KT"LITCN]LD"&
M!`!CEZ.[H_"]M>@_"_2]CQ"^F!"^Y"LD9.N`BF86G1D<X0EJ^0BKXL=WGP@9
M#0J<[Q&P]8",+F1=N3`8)D,OQH"LU*&*6)`.5?>)%EL(U,$"))`!+$`CV&H0
ME]>M!T.U&WO!&1S"QQ,\7Z`+B_0<7%,66Y">2U&+NAN08Z-,X_*+R++_%,C"
M5W-L+[J`MUSP*V9\J/IQQI%@7S1&E8[E!;6HQX`,+,9PQ^N0QN;%`,AB#",\
M-F#"`/JA%$S"R,<ALB%%LF.!HF+XM7]"4M;1%*Y3`9P1!FEILT!S7P'))>E2
M#BD(K*LB6F``MX1PNMI0#3V6;W@2(K=G"`QK"#BP`$8P`C!@`%9L$Q%V8#UJ
M'UIYP;_TQ:%@PG\0/-SR"\!3`=Z@!16@!88$P.!L#"BL%&@Y#6!@002@'@R`
M0>HL0TL*0WGRS@KT`-RB#%S``-11`03@#=C;SBGXS7L+)^T,'CE7T`$PA$L\
MD/BLSV[Y`!T\A%J`#."L#'7(DX]L7>OL&1H9_[M:,(1HR9-O1-')\"/H"Q^6
MB:8G5TUP<F-E&Y!9,A6;^',7-;=JX$[48I'_:BV\9$G)D10!``VZ6`Q)_`A#
MY"X)ZP<OL`0"T`8R,`$8:A]7:YV]X1`#+,V62\V><)#Z`<`*I(K8RP6!!\G5
MQPWCJPSEK!][>QX^`[[&(,+!TU_>`-=?_0?%N'=PD2?Z_,_D[`IO6U*I,!5U
M+5G?B\G>,!5ZLGF7;-?[,A]_H,^`]\BIT`4!,)#5]U@JW,%>$+YT7;XUO+D1
M\B1)&1QMNJ85V"5SR`MY`=%'*H@UBQNKJQD>X;/?BA`5($*,M$&&3![I1EO+
MRP@3H`(AH`$%P`$\$/_5"1MFDVL?\XK5>Z;5G4"]#'#;VVO7WPS.`\G-KK!@
M+IK6Y-O.V0R^56+/'XT,BY7-'UW=CAT`C&0[YOP+*.R6XGD,.OK8_K4O2K'>
M"VE?!+#8Z&W)P6#-]DU-?[#.WB;>WUW/28'"09(<I(R4UKN;Z2K#B;57%ZB9
M5\$+!%&-=EB"D=0*XE<6,=>;\`4)>0$-LXRHD4!(H1C!A;`&QDT$!V`"&S!G
M%S6[!K%V/W0&6.7<60O=F2#@U;W$]X46IH"*^]$,#+`OWAT,2^[*XJU`@/&]
MV<$`'1P+15[=!:XGS^3>BXW"1V[)4L$`Y#W@GHG?L[#.'`31WNS?4TZ5`?[_
MR(#U!]ZVS@CNY%*>Y;6R>-QK-"\,7C$L%.9KAG`LB]+@'.VM=,T-5E2B!;C*
M)_C0Y0?YS6^R"]6B9"*3<8M@`#O@`!DPO`I@&)D6S!6%KW3KX_0(Y)H@Y&Q]
ML\DA#E@@0Y4YX,%#OG:.3U%^X#FGO=21'<^A#+H"&,[R%XY0#/_\++`N%\H@
MV';N+84]"\(^-M=US8NMZ[?<7X`!OL=:Z50;"2J,Y];^9^AP=[YRE'X8B\1Q
MKM!B#0]@R634!8N.&CA'#,U(9?>Y"V!`FN"LBK,\"?:N-S=1#QB0`R@P`6\0
M`XY;4;4]@(US7/*(ZH^IZD%^?N>QV5NP"DD\D%M`_TXZ5N"-U-_D*U/9(>>C
M#`9+_!U@D,[^<-M+K.6XH-<;[RS'?LUBH/&/L`"S:,_YIA18\I3<4&#+QU(F
M;\F(N@HF_PO<G,Z/'$-^LMDO>,+YCN=&W_(I$W(WD](IVN<\P<ENF@U;`TU@
ML+\'!K`.%"P&5DK&D"9A20V")0GE,,'+.KAGD`,A8```4`9T\&%?(\O/#&*'
M0+G.+?&<P.K=1P`D1PP,X`T,TL[0D$0B3[Z+[X:.P.`)W;>&;S73;0RZDL_A
ML`4$$!<SC_@[Q5+]["R1CT_@<1Z<+P[@30W?O$F9W]&L\,BY]C/4=_,`/ODN
M%/LKH[G6$+HO_;DPY3HF#/\E_J#:V@=@`T';KK(8-RQ/]S%)Y434T[;B276T
M[@`2&^`">F`#7+`&`&#C'3'5`ACWBW`H$,\(@K_^G&#G'?5[$$[N[DH<Q[0Y
M7`)>T+1XK&N(VP,(6EM_?UL/:'Z)B6466EE?70\/`5Q<#X.$AEQ?#V"$GZ"$
MBGYC8V&)80]FHXIK:SQV(UY*$ZRD8[9^J62VI;F*`6J_P\3%QJ'(R<K+S,W.
MS]#1TM/+7E^?7E[4?UR/VM*;?U]9Y%G?7EAB7,A<8EC?VZ%?E=?Q]J%>D=#9
M]_WQ8%H69&G&!4L%+.N2M9L$SQ]!0UVT<2'P("*R+14B9EF@Q=VD`!7J&3J5
MZ\S_F`<-%V#Z$V!!MY#.4%D(H`C-`UZC7/D!0&($BQ$&`+!*E2:736&C4JTB
MIH:FL:=0B3F<2K6JU6E8""3$@H7:1`9=NB[#LN5:O2Q:_FAAP)9!URP4*SQ(
M2(A+!;D$ZC7;,G"9([3/NMCC$H#9%RU?^"XC_(?KU<?(LG01]#!CPU`0^T+&
MK*5+V$*=-7_:$CK?)3!9$@8P52R-6$)=!G'Q7&CN,S]G;M:L@(@5@#8B#M2(
M\H'$&E9H+.!D588W<MW&'D2=3CW1YNO8LT/#XI:0XVE9'C1^G6P@0C&$`#L*
M50%31U"T&R]XMMXON;3.&-@#[*Q^^;3?:7>5:5O0I0QI_P(M@Y86G@@H1@4,
MIL=1@Z!LQ&!!!R5$@#%DH/1'%ER)\8`6E_S1A4O0H%%!&8IT>`8K:["PPQ<@
M%*&'$@6X@9QSMG1(TFZ]&;-`D-45.8R`2":)'19::#4>-Y.)A05`F'RQ0!?K
M=-&>8U9B6=`ZD/PA!FKII>7?A^*E1QX#"7$QGSA7KI,%&">^%%$ZZ`$DUE]I
MS;;`-5YLT45?6W3GIUZ$`/1GHIW-UAXY?P0*I19O678H?%L&4*=W$2HYF$$(
M-2,99<KDTYYV#WQA*B:K&ABIEH-@%-&#9/S(2H=9+H":016`X:9@T!@2I!D6
MV'H<&U%P($841G"@PG&CN)A+2_^V^M$AD<604921W.;BZ;?@]L,5I4]RE-4@
M#&@1``->3#196@\0$`!7$[5D9E<!?1A`7^J)AD5AY:4)BKM:`"AO15M0]`58
M?,E[D%KWJ;5``%K!M2\AZYK9F9.$?"'O`A5\R$!+"\0[[UMIF4O`%@FG&A#%
M=)F<50"3-/9`5J*%*XVLER%#H*O8@`HT50%B&*K1KB*M*!@&F5'M&%ZJ^PD8
M(5FRDC,B_N@+C'[0$($01V@AP!RUC$)LM;IL/4H:#Z!-3"K=QCV*SG37W0Q7
M<!74%99/LOO'`UF0Q@T!7@#&%9V$H`37@V9]<9:9;>D78"C\@2+X1.@(!A#$
M?_C]61;_(?-I%\9\A0R*?EXX2>J'Z'7.DEC[`HBRB>LXYLCH+*UDN.;P:H.X
MW=,HFC,[0BO#!40]^_-%!4GSG(EEH2P40.&3L5S!&"^&,3$W)68RU_(4.D,;
M*@]LFQ,"?MP@00Y':#"#'#HEHG92Y?>"2W46O"AWW,#WW[_M7.E*.Q9`@*[H
M!V+?X=-XN-.6@:PE?)]0CQC*\:3_(".!()K=>@Y8'_WP*0N1PT+E"*$?_DPN
M"S3SH&8,-[L!%A!B(&S+:UCXH;1$#C_^B\:HKG8@Z!TH-%4!W#(0U!?A7:0B
MJHJ$&+90LE,MKR]N<@D84@4-+I#K#WY(SG)&<888R$`.8[`#_PC&<`0V*((H
M1GD`4LYH@:54)PU;W%^1<DC'<#G&8OBZV0(,2`A'8)"%6!@4.6KGM\B8231@
M>!.4/C$14$P/@W<\I.LXY[H/`HX<A<,A"6OHG1D2H`MB4&$$9<=)$F%ACS"\
MI#E&^23`,*`<B*JC,W[6#",JPT(0C(<8`,8,"V%",MVK4,$*9)``Z`4FZ"B1
M)O813!5A2Q$)P$,7"J`!!)RA!T))A$WBN`@>*2(WW(S*&18@QV[)\IQ(2N`+
M#_@9#@:N3X1CH>#$U"Z*`(MRDF0DQPP!"B%&BDV7(UPD.<?.2L%0"ZE;!VI&
MZ+J$JF4ECO&"?CYC%\,51G`%A9A#R?]4IE:FI0(#\4+KT/D,HR6O0M6K!JSN
MX07;/(.67J"9.O`!D@6X(Q(%(P")5`(;OCUC>7HQA/Y&H:,+D.``#QA`"EP!
M+3\TYYG6>L!0M>E-([6MG$8BJ58W\QT0=J4"5^J..PF6%A:Z2TLL68!$>]:O
M4$0"#`D+7\*V,,7"D-6C$I-H>AR&KX@5C&*9#,7(U+(QNB3,("645VA6=M@1
M_0&L7>A.0+SP5\)%<&4#!=6IMAHL'ZKT$D/C1O&H<::2%J\@-^N92"=S,W9L
M+UA4Y%2UW``#"DS`"#6(`!%@$+]$2,L6`2C6K2P`5>H$`ZMSY*QRI\*R3\1&
M')W9`KXP9I;_.(GCHH.PTI^LJ(UT(.,+A3%F]"+[PE!D!2P)Z=(ZF@O>&AYF
M:E<T9GMG$Z'V@D(,?3I1+`/`(+7^`2!\ZT)X!5*8P\0&9?.8#`0%S%Z`,8D\
MRZUEP887O=&R`WG2V*4]G%>(C,02%&=J*0^9@067SD8PMLC``.*PA1S$X`XT
MZ*T?@HNV,,PO$6QS6W70<#_D3B?"0`ZRD(=,9%!`(IA#].Q%@#A+E]K#E@L:
M'C\_\<1HQ(=[K<O)#F(P`":`8`0<2$!3T]9C^IE/$3>.6P5\3)TBNUE4X'$<
M.Q#%#PK_-+0$^;#/3LJ,<&C'SV^N2DP?,%-FV+(\$VI&:?>3TE=M_Y8E6C!L
M;)UAB9%R8B6CV$`-,A``([B``V:D7SBU.)0V(G<,Q66SMP+-ZM-)8RV3,20H
M''-`TMI95)J,7F$F!PV&)D,Q_?!UJ_N!VG>(JM')6)4R-"SH2!0H4@8A$2]K
M@V=YK`YTB!I%`,P@@"84X<S:5*-1JHH;Z&"U*:J&RK#7+0TV"=N\$)[&HOU!
M0_#D.AGS9G?=./S90A,O0Z!H:;4_!7!E5(#/`P-)4#T$BE8H00,.P,(7W##F
MI^;BMT!2]9K3?0Q]+Y<<+2D(8AK#*"S-2:V7*I0(`92);,CF2O,B>6.N^*$&
M)6;F?/-C0L1@#>M:J5.$D-245F>B3&UJYO\0O!1@Z"NE1H$N(I<*%&F^0"5&
MB85E$9&-@LU[128U"$__I;F^HTP04)WT>!7Y1KZIPN]9@W89D'AT6H&FB`]\
MV@UUT%&TKFJ+L]WJ$.E>P%0YOFJ/<W9F(UH`R%P'0I(5TXJ%S9@K^^C7*ZVS
M,04D=,=,!\H'E5@PCN!I0C_VT3URC)/I6A<\9':P7=^,`*)Y6<521BG&%G!B
M+3M,8>&B^!&I'BXEQA>EU/-ZO62EQ.ZH`,4&PC#@M];PXG"V,]K.F8E-^SJ'
M9N2#]KA0$$6B"^$[L3(4`8``L&#,B:!6+M*<8XYKB_!2@?Y63_DAT^E'/S%_
MG6`<2ID2VI#R:-'_2&K!1T(D4I]@62$Q0:64!6(@&$ST.RC!`->0&JSD-_[$
M28$4=G_C._>$.P'`%VG!-P'T)I[@"/S7,"2D#8[P@=P0.H,0@$["47\34@]B
M'H+A-RR(._(W:/YV2Q,V1#HU8INQ0\G&-`$$!A\F8LLP"CA``T.19KI0/ZQ0
M"CI63G`#?[\@?_,W.ZXC2IW$27V#>@#H"/A!:Y/D5EO@!:8C*!"B42%S8)&S
M$0R`9)-'21@X.S<402&T=&)`0!+'`)^D@A$S'OSA3FO1%IR#%L)6:Y-4AX?(
M%EK(2,&'<-&'9)]@@LXV<%1!2QEV@<G0"GIW1N8V"J26%#.!A7[`=Z@X_S>1
MB$X#U85V^(IFZ(CW84)\Q(BCH1*"44S\Q3DA<7"!5`[KM0`,H#O_9X<TY$JP
M%$&J%%BFA$HQ=1<'U4F%2'D=04'KH8CW=H:->(S7""FM.!I*EFPR11=]*(D%
MEQT8(EX/<3,#1WX[LD:D2&[@M(IPM(JL$([G](KW9R("=!!=<8*,9T/K`%(P
MN`ZHI!\@]5\=2`"ZPCF"LQZ:(A[SQ'/`$B"TR$H#M9`&&'0Q&#$%!08-HD(G
M6(T0\QDLD8@(Y20L2`@+22<+F8$9E9+Z.$IK5Q>3J(9`0WW7P40(0X%UP8`@
M$RHQD0BAZ`=J0&Z^)54[PB*KB`;DA(^*4)-UQ/^/C*=88;$GA360CZ5X!JDQ
M%,-'FG4U\9(EDZ!3G`,&\C(XGA$RBH<S%4AYER5=LS.6(*8N\51ZD25QMV<F
M:E4P73![FP1#6*F2A`58GS"6Q01[C5B85$EETK<7=S%2R)!]V<&`3%(P!4,6
ME!@*%Z>*9B-<>Y=JZ28=4FD=C^D_#=9':E%RQX,)E]*:[7486R!?=N492]2:
M,P=AM5D7BI=(+%$/(P<GBT)?X=->^,&.L/&!V>5@8C<IGC";T=45`"8GB'$I
M]I6<UU"=P7E=T,EU3=<@.,2=J8D--$.4R@`0/WA+R,99O;``;I-F/G*:,R:/
MJUB>^)F?^IE#J#4]"L'_/)4HA$&7B>YY1@M09J((;K=0A817!@B*BOL9H1(Z
MH4DB*['TD.9):*&%-%HEBEN01A^:%!-#GZ-@FE))H2B:HBHZ%63W7XHT,).8
M9!9!4E7V73`Q,);X+5V@9RO:HS[ZHW2S*@`JHWQFF?XS17IF"+%4HW0#!M<'
MI%`:I5**'6KHCKBV=D280\MT04Z6*)-&-Y8PI6(ZIF3J#XDD/908=P+Z*F]G
M-YXQ-%<V&EU:-_Y5IG9ZIW@:/4-:&SO:#(.&GA5V$)UY'6[RI-P3;V^:0V)`
MF7G:J(X*I1@J3#<I6@Q!I-^BA-]EB85:1U[PHH_ZJ:`ZH<!9*BNU%TBT#.IY
M_VN/P:1&=J.,E*/],Z>A.JNTJH]V,7#)!*C_L79'MJ95H:2_]J7BL)#[Z*NU
M>JS(RFHV544BXI_,H&RE4HZ;(2)#4V*N@J0T>D_)NJW<ZF:;,PT0P:-!8Z4*
M$:-6$:?PH:W>HXEV$V_=^J[P2E*6,*B[JJK<T*Q\QI/Q8$7NRJ_(D*CQ&K`"
M6Z8!P*C4`*W,$*X*LI[V@*GXH*E7,K`2.[%0^FX':V$^R*N120W8E@Q`%3VP
M&@_C,$B"I@WS(`UR1K$JN[)>P7!3L1`SJE)R1U,:&@V$@5"_-IQ4UBM5\8AY
M031]%0W<H:XL6[1&&PH%"QF9X:?!MZ$EIIRE4F("2O^MH4`UXAH/]8&N]\!K
M])%+1_NU+&NQ+)IH?8:OJ!H)>U0.Y."D#\!3RJ"U6]JS_))?7;>HLW9%>N*;
M`M85:3@GF_(K,OAT/<<W)T>O8'NXGSJOVH&P0W2J<&>$`21">.:O;H4B5Y&U
M7:$RZ/)<WI%Y$\17$A.8?85XH-<9W9$)%`$7[](8RL>NB/NZC9JT2,*AO50P
M7KL-EQ8]$0L9/ILEM6-`#5&`#5@I`D@N?L0[$[$.8N<(`94YL/N\R"JVFX%V
M,4NJ,\NQKEH7(3L5WW@B]^J'W,B-'62+"(0RY'N)&41Y7`N][)NGBALNI#$H
M3)N.-DLSEP$^V.$?'J1'?.3_:NA+0N3K1^9;AN0AP.KKKNV;P&0JNW2#2^WH
MK)2&$09KM=E1'ZDS2>W$'@-!)Y_#/$Z"2@9\D`,(8N\T..B`P`J<PA4K,';#
MN`=2,B)D/'1"KI8CJX_1&5Q1$5VYE^$[EA;S,)4UNAIDN@6<&I]4,!6DPDH<
MI79QM>!"NXOAI"2BF04S(C&<#$>7'?RUF6`RG;IYMV*1MU`"2H-@3*OY*_E'
M77#"-\VUQ&[\HVE,1]1KN%6TNQ[W!7MBK&^\QS[*"5L5O_9JL]LK9/PP,!11
MEM1PLGR\R.4IK.CDP/>`OY[R!08;#91,8O&&#CT8#9/*R)[,;NM+4JVR#27F
MQ%R%_\+.$,I?*+>?W,I:Z,="9E+1@!&H[!"*`BB8\`X_Z'7>09M6`C"W3%GK
M(<9H3!Y,PC=,U\N"\,L?(ADHLA[JY<K2W&HI.V1H9U/BBD*5>AT>TQ(A4XC+
MLR7*QYBIQP"F5Q8?\XN/DGGX8GFO<5C;H[F=HR[F?"Y9P1&'5"\<,<W\O+*!
M@E/J,BXD`GX"PH";5(V.$9,W>`V4@3>M(SE=D8,>W$>O07__13M]P]"#$$#B
M@3F.`(%TW,\B';TDZRG:['^;9(9BR#EWE$)/\HBO1,!4!H@6X4+]NQZ1:XT@
M$H<CW=,^33F?%$I@"-'=.$DX+4)!3=3?.(B3$XVAP[]&;?\>`:33P5C2/WW5
M(AU1)20>>I70-AC5"Q201(V2E/#!KR&2FY11[K1`\&1%)4Q/6!W7_'Q8%8`Z
M(T.,-@,BX\Q\<LD5="TYEU2804QE?;G#8M777''$^?Q):"77CNW*_)5(VC!U
M:=&I&]TIVED(9=Q?V<!3W'EBN0E??&-@TJ6;XL4R_Y*HXJ5=IOS8+!LYV?NR
MMSL6*Z<\5^L?7##;XG`-N`B[JNS:[?M*Y*`/5O';R8`WVRAOJNH?O[U!*2HI
M'&L>A1#2SS#5P.W&C'A`Z*`9T@5%(G2R[<`J@8(>)W8.VF`-W'`-X4V-9446
M\G!SZQTI$J$J-;L%A580BE@7GG'_WE<<=!K*+A)7%Z%=GM*K#&8(M5,AW->-
MW9<5*3I%`)Y`,6LQ$`]0`03`F)*@?*P;+R+$%F*A86@%G!F^:RL'0EI0`90Y
MQ7]CX21>0PR$0G*1)I)``,0:0^]`$0Q`(2\^A_&2.!5NJ.%8X,?=OX_1VPNN
MP.E2,-W!)>+A(?,".O\4,;?*)*"1Q.&QXH0Q07W"/,B=@04!8GD2,A*E-POX
M!Q^,&ES]2HD9T0[(PALT$%_9@JX[=DJ.">NR,H5@$#_K,1G!1[:Y%K)A,M.6
M,(,U@&`!&VYAY$<>W/^"YVHQ(FO1,2)BW7X$(4V2OO66UF2HUSF506@!!N;,
M0T=]P`L(_Q<%`Y![HAFVTQ>,Z-P(9.F,F9H@E'S_U2MB0`"8ETCS@>(J5TGD
MP`#N@.L*UH9U48QJR=O@)X&&@!:*ONC0>T`BTD=9&='I<C.01"E<<<)W"&),
M,B^2@^WO@-RUD2XD7$$A?$B@$T#I&XM!*[Y\C4#@3MVM=N4--1!<(#F%@19J
M"!M\]!=IHI"3C4.YG3C,I[R2,0AZY>PJ7&NGXK:>P":O(R@NR8#`DAJ99<P!
M01IIT8#IH3=H(6<)+Y<<_UAX3)V'M#P=\\\3O^9_('JX_K_N-/)`^9@F66*0
M&$GDJT+5>$`C!!!L\>Z;/I@*C^3BV&%,DQ8$L$0%)%&U^4I,C_\19&XX=?HA
M!01\_V0]'L\@@/,@Y<[T("$F((7$E&(7`3!%YE",H:3J:H41`,;M]TYY3[^G
M5%F-AE`61*V-7ZCS^-&/8.C@6@[T^1V^0__LH'`JZP(3A9(1#ECM`Y$P>#Y0
M5E_LZ$(H%[[1M7WXB%(?"0,3EI#T&_]*RU/H"<.P5I\Q!I+V:^WX>@Q]")WO
M=V]#VM!:>K])E!%KZ='1Y*R^FM/L@[_(JT3RUUV-)DX`K\\2<='O@Z@?H!XO
M`D\1%P[XJ2,)O-_[>PS/I@/<T!W&[\!SD`+=+`,I?.MRWI$H8Z))>#PGTCW=
MT(8.U'^XDSKP)-89"-?)\<`=E8P9?>__#_#_"=,/"'^"?UA8@X>(B8J+C(V.
MCY"1D15??PL!DIF:FYR=GI^@H:*CI*6FIYU:68Z%HE]<J'\,8+"-65I_MZ2M
MAZN1O+'!AUM>C[6E`0P,%<6;QXI>6\+3U-76U]C9VG]>6+ZJW%ABL%QB6%Y<
M75W%W;ZO8F!_6V*#\^1?Q*_ATH?=_.7\O'@9)X_@H"\,5@$4)-"@F`=?;F7!
M4JL=HG?QYC$4QR7=NH9<LGBIQ*V214%BM@#;)BH`249@#)VJX&M33%NX6.K<
MR;.GSY^/O!#00B">*J$/*N#2HI1`%F7G"#R8]4?+`RT,`CP@8"A`A0</<GW=
M<E1J!4P,S6)*_TH`$Y:O7KR"/825P1^V;N$*4J:J@M\%W(86I7LUZ]:H255!
M??O`"P/'Q2J`$4HTGE>_,H&B6DG*;B?.B'1I'DVZM.G3OPQ]":L*3)<_7.P^
M_B.F6]?76UAC"H`+#"X"L!:`R4)`D"HL@+GD))1<"Y@*W!AP02X(N*5X@^P^
MCSX=\"!=Q+DX)J0Z["`MNWL[?QV;//.]?]1AP=5JM2Q8%3*C;N3R"V\&TFQ!
M0%9?^+6%2@1\D5-_`70!(!8,O/9',EK`$@`64G%!X3`$$"!-@1[^X1]66Q18
MP8$8?@&B-*+MY^*+,,8XC55:8%650F`D<]=9Q;0"CBPWNB?14$QYD_^3*C_2
M51,OQQE"7(WY'6(7DQ/I!UY.=M%HXWFKM*(+%SE.:0@O=CGF5%57824::#+>
M^)0YQ1$@1A8/W'*<9$"ZR8`88E30!1@)YI:%.FAF44%*#&3F&#S`G;7%8V]B
MZ$6-$^'I**3+M:GIIIQV2E<7A1A25@4+E-G%@%4&"20X7O85:A:B(5D3EX-0
MZ65^A<PJIG&I?H>+:%F"NA*K3FHA%*F[DBG(`N9I(:R1@K`IHRITPK>G>.YA
M@99GU$)WWXV@PEJ<<^YY)L@6$L+J;1=SFI<L)@4*PFZ+GM9K[[VC+<"/41-A
MTAX_SUHBC5!!MAJOB%[$FH6^\@["<'QB2$C_27W>?M$,?!$+,K&5OV(IL"#8
M\2JD%MK"EJQ,93)PYL.3K:O?IM1Z+(8R74PW)LJ\`LMK7<H4;(BY[@FR)K1`
MMM)JM$3CJ_323%NSA63SW?C0PG8]T*Y*"T0CF;,^YX++66#4J?#3.2Y'-F^.
M;>%5T&#7*65T:D.WDJ$1>4QVU+2V.G6IS-D&WR51W_UU`("^K&G,\''3ISDW
M)XYXGK(J6>XAO"2<4ZX>&UTLTO0V[?GGH'N2#"4W<C%5``2,5$%6N7`U(0,5
M=JU+@:PK_#KI@XQ>B8"D\T([6MF=2T#O^G&AE,ZWOR1[A:>G3ERH>X7'Q9FZ
MB^@7J/4^7K6%T).)_XY3R*O2(&Q+=?GS(=O]0=-LDNFLN<F1#9=IZ/37;__]
M^(^F_81-#>0ADU\1F\=NA!37$>L/4CE$4I0RH>&%16=B^)],4/<5K^7O@AC,
MH"*XH#R!2$(?GA`))T"H#0\*@H--(T8THG6N<\!F3K`Z(1;P(1!^R(08^SA7
M,6(XD4.4PR#VX(8-7PBKF@1QA1I,HA+M1R]I#6,52=H$B3@116RTXC6=6Z(6
MM\C%+DXCBX^H(B>DDXI9;<,N8/2B&M?(QB2F@UR$@.,,M5"B2WAM/I6`533P
M&"UGA<1/T2B&;VX(!COZL`L+V%VBT$>R$W:AD;!YI%'$8,B#+(!<;Y3)?/]J
M%LE&9@$[.)1',;:PBB)FX5%&XF,;5\G*5G[.*BEZ"^I6`;MD+`!#I!S*J6Q&
MG`4L`#I]PL(#NB`@B%"K+5$J4HC.XRS@;$AH7'F`(2Z)2S2E2)DA0V`7DN&%
M+DCS`6`0$'(P04T/'8R,\9$&`0!#S$)0J)?,<J4\YTE/&4T/%L.A"2%>PX!*
MT)$\X:F*2KP!G?;,R8+@4`7V#"70"2G*.O\$6@"D8;SXP*(0]_R#_*1QH4'$
M96?T&`EU-&I1]SC//+191U+4YS<T%A1H]8RI3&?*$GIY1A?<,M_0,)<X=#$P
MH1*!SP&%=KGSG4<9/2O'`KA"KZ%N1$TSRP\'5;;_CA<NU1#L*ID@5E/(QQ2G
M%6@<($W'2M:RGL*F1(6<3HO*TZ*=A3=!BMRJS.<KI.7).#"$HC1OV52ZGG"=
MPBSEJ5X3%[]8\Y;RN&0VVS*?```&K!:\JUDG2]G*0D(H%GI:E_@ILEQ!-"9$
MR](JR!+703D).D[%;$.!AKT)Y0E4JIVH4T5#$Q?>`@S8D8V\#!&;!SSCDFK3
M`CT@BSS+&O>XQZT1ZKIQEC/E%*#KW&5;[>)-U"TE:\?TBJC\:IQFP@)HQ.'-
M:TCE(%&A)W6IS0I4OSE#KEQ2?0LHKR!62KF$S*P28`U`<9'+W_[2](W8F0]V
M%K2[$ETHD?(PL'%@X\M"_WK-/Y48I"!<DN!#(K@JB/`-)Q74SDY:IL##(!D6
MXC$?F6@8%AQ62;0D=)`**>A<TA"#%ORS8/_:^,8X7B(X<\SC'ONXA!<S!0H_
M090?&_G(2-Z%X4:11DG,,,E0CK*46;%D431YREC.<I2_$-]:;-++C=06(I_A
MFPM_61Y<#D`Z%G#16[`(%VM6GI;G3.<<3\^QN`CF,`D133AI!7B."8!6:).?
M/2L3/7M>QBQUH85+6*?.D(XT<ETSWX&4$A=N&P@67N.;[U0`G[2Y=%6&BT5<
M4&73MZCHA/@AZ5:[>JP00NIHN\!`H!WMA*M;@"]\6KZ1Y4DBBD%JE5]-[&*O
M$?_5L)K.6TU-N<T-HAQ38:Z@>WVTF\I*;"(TMK:W[472TF92H_W:*EQSZW#L
M+-S+DT67]&LLZPR'V_".MP:GIP[H5'<HA,C/B<J-0$$#Y][4WAP#'K#HI9PW
MR/).N,(_QV4$<Z'!WBEQA6EL28=#?$(@IO$LR$5C`"_\XR"?+$Q#3O*2DW7D
M)D^YRETY[)6[_.4PC[G,9T[SFMO\YCC/N<YWSO.>^_SG0`^ZT(=.]*(;_>A(
M3[K2E\[TICO]Z5"/NM2G3O6J6_WJ6,^ZUK?.]:Y[_>M@#[O8QT[VLIO][&A/
MN]K7SO:VN_WM<(\[*DQI2CES*F$Q'`7>LQVC@5P2/6;_S$01$1ZCD"1;[O-$
MJN*5T99G:"K6*.]$,O@BHT<MG@%L'B-4"A^RIR@C\(AGX^47[]M.09X4JT.J
MXT]C^='/+Q+"AE&!,N/YA(3>E:-?_.MC='I1.$;QV3S-]'*O#%9+(O8NLCSM
M97W[5B)5*36:BN*-7_D:[9X3K5<&\%#3^A-]4OH#WP3R]S-^!=7([LWWXO@C
M^7PNEDKQWMJ/@U1V#.,A5?R;=]'ZTR_/_5L"J>@G>*#W'7GG"`GS#"$1@(P0
M$0JH"`.R#$A%>(F0,(O`=R<$*PVH"74Q/Y`'>GJD",@7$:OW;`7H"%D@9R*X
M@(>7"/ZW"(8W@OR'/_[W>XLT_Q]<<P@RUFCG8GUBH0RX<PB3AU3;5Q4UL@4/
MAWP"XH/*0Q8UDF&IMPS!MP@(`15(17W=14=@X(/1P(/2)Q/*H7C+I%'6]PQV
M8BR+4!?QMU7.XD*4\X"P(V?"-BE"F`@:HGAJ%F)-""C*`!'D,X>(D(1(%3L3
MQC/0)R+6ISSIH'B<%(,8U(*I!Q@SHPS/('T1!X"+ESJ','^+MWW"QC/*$$Z7
M>#&]=RZC9X6)$(F/\8@@J'U/.!U(A8K^`G[`MU5(E4V35QR+H(E9\PB:B%0)
M(B7:YX;Y-PBRN(?U]7FD9SJ;.`RCAU*>>'^U5Q/*F(R,>$$MN('1\7G`""#1
M\GR7!_\\M7=Y%^.+E_>$=E@K]Y<6H_=HC("&\<%XJPB!/D@(WEA\]#AZ\9=Z
M^E$7+)8(V1<A43@(6>AZV[B.QWAYF0%YPNB#HU<+PU>*QC%ZN<!\$Y9[+5>-
M3=."O:>/WQ&!W8A4NJ:)RS%_[<,S(0-_N"6,=0)YRS&*FN@-[[<GCH!4G`:`
M+'AYCS5ZE9!ZK=&*\D)YV6&/+KB0*A,`A)=Z'A(V-KD7SX=;3^@+#UD42DE_
M'ZE]@[)X\`!^NU:%61"$:/$?/MB$T<@02`5.@(B+&&D_&IF.\]>2\UB5WJ$^
MZ2B75)&-B\24RM`,D/=I\S67H_B`<<F3ME"+)C.,0;F'X33_7(H'DW99"ZVW
ME3TC-![)"/_HB_1P$*](EL.H>"0QD#(I#Q0YA=QXCQ%RF)_IF3(Q?\`CF(>Y
M?-I(&TOYF&FIEH:)CI'IF4=5FE49,II(@I>)EYD1B!VI?;9I+KTGFB'C%>C!
M'ZK7E[!SDWEYD/W(#:<TG+97F-<9:VFX")69F2C1G/-U%:Q6EL^&?.^'4E5!
M,U59$SQS#.-W2A>#C:UIG;YPGN79:`,XFTNSEI$9&Z])F%5Y#*.("-TP?GXX
MD4))FL4),I,I"=*'4D$(G>A)F@%I211Y%_E7%T.X"-V4>\TP>=L)G9R8?]*W
M?;%V.>"9GLNPC4O&!8"8*>])D=(W_YWZ>3_\:2[21P^B*:!SJ:#]($R+%YS#
M.)95N:`^*@G^R3H,^HF(()P'Z8%>L7@U,7G>\8`5ND$/L8PJ>GWSV:6!&"KS
M`8]'NJ4LZD.4I'ME*IG_69LU2IMWB0@D:9N0:(Q&6J0G%(1!VJ4(>IU'VGL#
M"@F>F7M#N']_R@W/>*&>5QP[N@E>$)/-`I2,L'[(1WSI.*#R"9R#$$$$J:=$
MVH)M&CK7"*F)^G]*:J>FBJ>89Z!#>J&CZ*<]"@F]V(Q-6IN%*HM#<:&RH`Q?
M$(D3F@@1L60\$Y'/V0B2FG^4&IF6"JFY>I>!.G"LB:EJ>IV>^JF?XW]).J+]
M9*4'N:UV>?\BW[69J_J:?5JIK_H(YNBA:5JGI,@7\4"DPGJFI:H(D&=WO7>I
MBU"L=TF3=%=$IDJF78J4+F2O,;JF;TJM]>-_K9=-[_>G`]I[K3>.X/JF[MJJ
MZ>BN7(8%1@@-QYJ@R_HR?QJGT3HKD4AKXJH(M6<X$3JFZ#)B>MJQSDFCW"JL
M,+IY-,AJ`ANNUVFO@O9D!LLT^_<%#XB6WRF/'-BCKAJ9=BFD$LNJ?IF.-/B;
MD">!J!B%-)FN_>JOH%FR4_B$CI"D[`@;#V@>K?<2[@BMT`JR\G(A))&LPXJI
M[OJL+ANR/ZDRVPBS/>LI7QHJ,5FP(I*G,>NC';@LJKJTXDJQ2)O_>GQ)ER$J
MN)*8"'4AM(3ZJH]+#D^)",+(I;DY<-@QE4I*@]Y!@RR&KS?DG;6'%FP[LXMT
MLD/;MLL*CA39>I?9>J9XMYVRL5^K,9R)"`V;CI[)%9X8NCB[)$V+M)`G33Q3
M90^X>_/:LF/Z.GOX%M,'IXKWFS"QL?$)DM`KKJ+[5S2).I-YNF6:I%G1BVD8
MM,@!*Q3YD%GAO51)N_ARK+^8")HHM/W:>^I;CR@UL'QJN.9B?Y=WN[3(IGVK
M#+\9N4@;K?!'G,RXE(ZPM]]X"**)IBT[?I"W>"P&OEUZJ#XIK++FKJCHM^Y[
M+Y0Z8]P)DHFPNTC[CW4RF?HKO,3;HT![_XD!&+@."*D&/'*Q>B%OZ5&^&`E?
M.'HT6IFE-\&&&:L#QZ,'?+-W&<.^6+/U(*7N^HX6',)*`Z9@6B*-()K4*S30
M\QU=##*KXSKDP;.OXE&A<C%50GM?S!"G0E42V$).-%`)F2NAL<:U,B!X8AL4
M8;G*$)>0L`5+Y8-=,(!4LPQ[W&S>@,AF1!8^>,A<O!(#97QEK(8T`PL#E4U]
MHC)9H\<(EQM[.+M4C#^>^<;]E:2@',I3A[8\]K"H?`I^\,JP',NR/,NT7,NV
M?,NXG,NZO,N\S,O"MZ=VBURPX`6(V\JNW,O(G,S*O,S,W,Q^<!K/>*7'5<'Q
M:LRBX,S8G,W:O/_-MWP:O=BK_I5]F&C-I,#-YGS.Z(S,I[&7&6A<M1>&Y'S-
MZ3S/]%S/IV$;&=MCY2`.I!S/G%#/`%W/:[`&M#S0%V`&",T!NNS/81?0#DW/
M!`W+`^T&'""$$=W-#/UU#[W1VSS0M.P&;E`"%IW+&:W1''W2SCS0%^T':^`&
M:U#1VK?2M5S27L?,!.W1KRS3L^S1-RW+*BW1/LW1:\`&&7`$2'#42#T``S`&
M3S```G``1\T$&$W36V?3/]W3MJS26KW26NW26XW3#^T&-4"42+4$8>#2[P<!
M4TW56;?+8)W3+/W3N?S5L?S5/*W5&[T&"!`$E%H!=0#2:;W6;'UU;JW_TWM@
M!&;``C0PUW8MT6OP`7.`!6D``'2=UR)-J4MP`0[@`%#`>((]V%67RQ,@`@A0
MVJ:-``#P!,HP!@"`RVO0`5L0`R9`V3M=`\H``050`#L0`V00!CI]R[^]TUGM
M!R:`5'/0!@B`W*8]`T@U`&>``"KPV:`]=;7<TFY``0<``9<'`6`@`,J0![0=
MUQ/]TS.@W4$@`G2]!D-PVPG``[>-!A=]TS@]WGC]RBZ=TU?]VU[-W`P``6)0
MURT-TUDAUS,]W81=RQ-``^>*5!#P!MX=(;3MU2I]WVM``N;M`#?M!A*]WOU=
M`.ZM,E]0W^+M!Q(NUQ'=TB@.U!.0`08@T2"]_P;%W=\Z4-<N+>`!0."T;.`'
M+MP`@%1(T`9GX`5`#@<`\.!=T-KW+=XMS=(&@`(4@`%L0-`EO@:VW=\)```4
M\.03$.4Y[=5*GM\G+N&P[-(D$`,X$`<;\,I>X-0"(`5(%0("$.=Q_@1/?0!*
MH`11$.=$(-TZ_G35[0<]K@Q,L-6O_.#@W089D`$=$.5KD``ID`%]0`,&@`89
M0`$TH-(&``-D4`,<0`>W70`*\.AH0-E#_0$RL`-D``-MH`)P@`%>$.H9(`<`
M0`,(L`$RX`$3P-)UL`<D``9GP`4[<`0@T`0ZL-AZL+%E[0!AP`4:X-FVW.>A
M7=TT@%0Y(-\>;>0`H/\$$``!!Z#2`@(!*Y``+[`"$-`"!3#0)-`"8,C>)T``
M$!`$%,`&*A#(2+4"]DX`!W`"V[X")A`%#P@!&B`'-=`"VLT`*S``"'`$=P`"
M."`':Q".Q_II`QW8SP[MU$W+)"`!$H!4+G`'=W[G+.`'V/Y^4*#258[;%LX`
MY^T&18!4+1`!%L#@"5`&[PT`TN<"0$`$_ZX%=K`'BU<!(T".$*`%*Z`,*[`!
M(%``2$`"";`&)X#LRI#9'=`!G:TR?&[Q2U?+9G"L0"#R-`,`)&_RGVX"%XX`
M!9_T;@``2,#>--_?7P#3$'`!;L`&.P"`-/#TMPT$!3`!55"6/@``_$T`:5#_
M!`B`!R_PREB>Y2VO#$*0Y8Z?Y3NP[1#P!%F.`5>/]4E7RS'@%PP>!)X?!"NP
M!5[/`.`=]@-]\@60\D'@`'@0]4T_T#'`]N\=XQ#0`2[]`DCE\'C/`',P`0-=
M]580[V[0]@10``A@!AYPXBSM!B1PVWC@TR\]TKB,^5%WRQ.`5(,^XJ-_Y.^G
M`1.-^JJ/`*J->9<^T!P.`3-_VU_@`("Y`2;@`LIP!77@]+>=`2J]\0P@`1%]
M[!T."&M^@X-KAFLR#`P0-X1^AQR*#`&"@HZ7?YF:FYR=GI^@H:*CI*6FIZBI
MJJNLK:ZOL+&RL[2UMJ:7EQ.20KE^`HI=``N*$FYN_P`!BA`%)!`,06T#BE4`
MAS7+"67+:&LFSY**%G)N:R?+.(02BB.$6<L%EH0&'"4<0`0$04T<_?[WDBCY
MPG2KH,&#"!,J7,BPH<.'$$\-'+1+4:]<P!@((\8@!(`V2B0Q<P;-P0M)+Q2P
MN6`AV[9%<FC(F<+@BA0)2%X`>&0.G;IBA'($,!/!B[Q!>B1=,0#@`LUP4!F`
M.#HPHM6K6+-JW<JUJU>)$RLRN'@IHS`DDK0$84``'LD@#@"T7!1"PPJ1VI9]
MF=&60(P>6\AL,5'&P)JDB](-6L>@G1\U:L8L*).&ZCM%5VCX\?(TJJ(5"*CZ
M^DJZM.G3J%.K?CC1#P!>OO^>*!H#X`0X:D3@?2NY!LV5<!!"P-NC%ZWG149H
M((;@P1+C$8;*E+%`X$P9JB]KLMELX_@B/-M;#UI-OKSY\^C39QUHB,V,&D.^
M/'*T)D.-&AEHK,%P!$D.'@H@L$,-)DR@0@]#D#"!'VZ$088`8PB1`0(Q[*!@
M`7'4T$,=`!RAB!56+&'%;3@4,,006]11R1Y#U)"%(6J48<8899!AB",B'*$C
M$E7T^(2.0`(9`P9LE".>'^HEJ>223#;I9&N6'')4E(7P9$@Y;-QH9"5KE+-&
MEL?P]$@YY;#0%A)U<!%&&&C<Q0`/QU1"B!N$&!*&&6B<848;-\YY)0G+Z"#:
M?'W6BN?DH8@FJNBB#+5&IY1TUBFEEI-V.>4A5DJ9)8/S/*#(``ZPP04'PM54
MQZ.36FEE&7L42I\AB7P'I:M5,6KKK;CFJJLFLZ::BYSR!%O(C5P..VR4AM`@
MFTCA5("#:*BJ.I^DU*[QQC(Q'*GMKMQVZ^VWJ6DK[KCD6BD"$B.*U((07PQ:
M[J\.D$#""RJ\.QJX^.:K[[X'V>OOOW6&\85T)R!@#<!0(GPOOPPW[/##H"@L
G\<045TP0Q!AGK+&W%G?L\<?;;BSRR"0_"?+)*']<\LHLMYQ:(``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>f39432orf3943220.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432orf3943220.gif
M1TE&.#EA^`+>`^8``+72Y24T8X]4,W:(K2A$A"(N6/>QD:UP35!4:,W/U?W^
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M2%A<7IJ^VB@I;P@G3D9`@"E,=#LO<PLJ.BE+B2I,BRQ.CBE/CB'Y!```````
M+`````#X`MX#``?_@`41@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH:*CI*6FIY*"#ZNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PL/$Q<;'R,G*R\S-
MSL^Z@]#3U-76U]C9VMO<W=[?X.&WTN+EYN?HZ>KK[.WN[\CD\//T]?;W^/GZ
M^]3R_/\``PH<2+"@P6'^#BI<R+"APX<0GR6,2+&BQ8L8,^:;J+&CQX\@0XH,
MQG&DR9,H4ZI<6'*ERY<P8\KTUG*FS9LX<^H<%V&GSY]`@\:L*;2HT:-("1)-
MRK2ITZ?FED*=2K6JU7@]KVK=RK5KM*Q>PXH=>U4JV;-HT\HTJ[:MV[<=_]G"
MG4NWKD&Y=O/JW3L/+]^_@`/3!"NXL.'#W/PB7LS898K'D"-'MJ>XL>7+'PO8
M>,.YLV?./"@3QDRZ],D?%#0D6,VZ=0(6$5+0JVRZMFV#3!(HV,V[]^X*!63W
M'7V[N'&'3+[LA@&#=W/>P(7#HWV\NO5W3(8H``)CS&XW;KK_CCV;^/7SZ.]E
MWRY>@1LHS,=+?T<]O?W[VI(O?ZZ@^?/HY>$GX(#I_*!=?\^%U]]OP05(X(,0
M=K,>=PGZUQ^`PT6HX8;53-A>>/$I@.%TYG%HXHG#&,B>=^Z%QV(%Y&6(XHPT
M`J,?@LXM*&*#,M;HXX^VW!BB>[V-2%^)0";IX_]C0K((7GPPP#B?._4I:25=
MDF6IY99</O:#;CCZ]ML<74(6%9)7ILG7'`\\5L`/&]0@IYQ;S&GGG7CF.2<(
M+%3@YY^`^LE"G7=N86@-AF[!1#E5JNDH5W-$&ND/=%1`00)>S#"#%5YTZNFG
MH(8J:J80_)""(G-$L$4";H2J::<SN-$`F^$T^NBM546:@AP@4.`%$6[L!H0;
M0(AI[+'(EIH"F8\]H(5D-7B!;&^SBF,KKN!$*I.DM!8W!Q,5:+!=L=L!2^ZT
MZ!JKK*2OR!8MLB%66RN:V*[#[;WWFJ1MOK<]M@$%0!`1:[H$IZOL*E.V^<"[
MOOD7;[??7%OO-?A6#''_1A;C6]P/:11+!!&\@0=>P23OMFXL[DJ;KKS@2#SQ
M6Q=?QS$10!3;'7_$CERRP:;2PC"Z+$=,[\M$5Z5&#2!O-\,8S`U)[,X\)^S*
MSV(&NUO0@Q5=SVA:K#+T1W?<T;5A,;>2P@_*]=;TVDU#C>[!"9/YP!8J`UWV
M-BYK/4W>$86-V-VKS$%WPVPSQ[3;TZX;,ZU4YT@MX-GP/=77/DF-TAU_WQUI
M`0R<ZUSA8S!=^.BDCZZXW($S^V[HK(?>---8=R.YWLJD&K@KND+^4`3<LM)L
M8]K&,@?:T\+@QL=`B%[Z\J,K\(6IO$/,9LH(KJU\<[$G1KE;VZ<4P0:$SDF'
M_YURZ/X0$S7T4`,=[+,_IQR6[Q4\+'-L("Y_O1U/<\V>(^Y;`C^X`+/:);BZ
M]:9FC[-6]XZRP*.DH``5(((&--"I"<(J`5LPGT-8(#!->?!CJLF@!M?10(+,
M[P&88\4<$"`N8X&G6#.PX`1G2,,:VO"&%*3`!C97@`*H00T][.'1$A!#'%*0
M"-G#6PF#,KN8I$`-%1B7CF#@,1"@[AA+Y$8%K.8;&()@62-$1Q8%<L(4MFD.
M(+C?D%JD``U48`-P1(`<YTC'.MKQCANH%`724`(*E."/?OQC&EB``#@:<@.%
M-&0A?\"H,?K$D11AUR\DZ3L(]B=GPH)A#<*("T@^AO];LOE=,U@0+"ZZQSM>
MJ,&RO!8;X6@L?HEA11/S(;@6$FXW"=ADF7:Y)16ABP',VF4C:<<+<L@F>I(2
M92\N]L`H-D=GO"'")K'XBP*\X0<_8((VF8!-;/)H&2Q@T;F>DTKA2&,.<M!F
M-K?)36^R(H4G3$L$&D>A^&B@!LG0C\W65J1O'HF8P:"5I'SX`SD8]*`(3>A!
M"X#0@LJMF0B"YFYF,$UOK!`"7_C"$(8``8Y"``(4P(`SPBDL,973%05H`$8U
MNM&-9K0$"+A8/+4RML71DY\:R"`R]%FX(L6(1)0!""1[,=2](6P.:F#"%EC`
M@#^6@`90C:I4H^K4JCJ5!3W_6Y8SC6=*!5"4D]'@10-F@"PDCE2<)E7E`[+R
MQ"@B*Z=R.R=8E5'47<S2%[UKQ=$,R![^P!66MH@G\>K9-NC\])];$^HUZNH,
MWCT@J2!(PQ`TD#3_]>8+;UB65B/:U:_2=1<IV,(,:@8L!=%,`PT`K#!(NIVT
M'A-A:F#!/C_7QHJJ<*[)8&PN[KI,?CV@@,;R:P9=F;'B^E:?82HE@U1[)H#N
M0EM'`UC^7`>UY]3L>9J=PU8EZE7;:H--:"3K#*!0O>.A%K>Z8&W_%'!2KZ&S
M`O5LD3VGV:W@F?$J%5/AX,0D7+D95Y(6<P5R0Z3<'3%WF,[%A:[DT``P/1,*
M\,$?_[I&-P8@?&$#IX(H<[CK66Y("@1D;9X7DE@,];HV=>\]5G-R*3W[=B6O
M^I66A'OSUV,@UVHCLYJ1J*3;6T5*#BQ0V1C@0]N"D<YY&.:=)3?<6>]F0U<@
M9EJ$FP:$$:\2G&CU37LE)0?XA@E']ZRO).^KE3&O8J\Z,E:-C:&BTEZ2BU'R
M)X\3K.`YU$!<R>,G&TE6N&)]@0E@7#)72]I=]+)R&+H2+>N@T((6P``*FDJM
MH6]A8BVKE1!M)2Q.Z?M;,S^E6XZ%A=]^^ZXUTEBGJ]""JE6-PK"-NM6NCG78
MQO8E!1!!=%"`9I34P&J@TOD670:9&[S3-)$ASKK.RZIV.?]+Z`YO@UEC[8_R
MH%#A&:1VE%GN37M_F^DOSY=,`G5Q54KBZE5L08W'@NLJ9,WN=KN;%<0+7829
M-K(XH[!'OY[%M[0S!@4]FJMN&*UE@0"!S+8I`MNU&KF<_=TVC16!)FW`60FM
M;;7>3@X#6"]O:MP32J(E*^=.,V\@7-M)RR+>8UB:Z$*G@#'LN!V\?4J/8[E"
MW;!N/\&:`0TJP(*>^_SG0`]ZGQH@!U8(6F<+=S)1BRH&!CC]Z6EX.@-BBFV*
M\V;;JRC`%J3.]9V_@59RU4I/A)/=5P!WQB1/Y17-MJ5V:8EX1"BLVBH0S#(A
M.-_Z1H!N#+>?8GD!#>#]+XHEY8__HRM\HDK71@2"R'C&S_P5E:YXPAH?Q!\"
M<7$F'\CC8Y&5CM]K$-S:+W]7C`8U@/&_J)?4!I3SL=:[GF8,"([@[VZ-S;LB
MY@*Q_7/U'M&:W=P+=#"T,M>:\&8G7AMV!\;7(G]UB[NB66::3$_,.%.[ZO[0
M$HFY-`I0J#RA(0U6F#&.O,``/9G__'=J0,\#!:@^#0K]/0"!#6A?C>MC7WZ\
MIS*%O#,#-`PU*X)&)*U5:&MU"YG7"F!'9FL%,55""+=W,<RW&UB'8JZ`.9&2
M%:-6??J&#=KG@*^@6]*@!6^0`0!@09\R0ZLQ`Z;F'.0U`ZM!0:,2@S+H!6WP
M=0JU4')0_P-$-(-CT`"=)S148E>P(#&X)PQ2480("&,(DW]0TAP>TP-UEBH7
MXS<:]DR$)DULDA522$EAPX6UL(7S@SF%($N$AR]9A$S/=V6MP%IJTQS;%G@P
MUH4>5X!>LU8>V&G,HH&M4&X?2`ZC@6D7*$L18$9H8H:BMFZ=%SU).#^$`7JR
MP!'QE`*\9V3(TE6692S8]1AC8S8+PU?'`AL*I#U[0X3V]XC=<X>/B`T7&(E,
M^!S\`050.(1]Z(CO-&H!>'BV9EN@-#VII@5C1GU[*%=YI6I@Y(?(I"N:-7RM
M@(J"B(S+LGAR4`#.*!QL2%M8=XP0PVJ$)TMF1PC$^$F?YUAF8O^'@ZB`?8@P
MTI&.]V>'OC..DQ$XTB`-?!@X6C)`*I0ZB@@68[B'M_5\"'`@EQB0Z()==0@+
MHA<RWV$UH#@O2D0O\C!&?H&$7Z%\/$$+?_B'7\B,;=**R]%:1!"+MJ"1Z]8F
MMWB%%350X1@!:H!4<O-J#)B(93@(*[F2=,@[*IDQ"7&'QGA&Z80`-0`"ZM=S
M<+`%",`$Y?,8U;@?['5IGI>2-[DO/3%V!<DFK/8FB/230-D`6@D"(%"4Y1-,
MWR@9\$@>'2<(+!F(['A_QX1-5UD#B_0#IO<8?BB(;0)&/4E'&^!09@)>T3,(
MOW-,8#>(_0@6D@B0;2AW`HDX0V`J<TC_*P=Y2PK@@Z$8.2*)%=!0BI6)17=5
M",S$D0M2++#82351A0)(+EBXC`B@E:JYFEHY?V8'"]S'FJP)`D5'?6\@FZSY
M!K,PAI^$/A4``0E`03/0>C/@!0DP!`P``AOP`'#`(FVXE*_E-;>)FUJY!8S$
MC<<D#;*A!C]0`RQ0`D,0G)GB0:^2`!3``"S0`QN@3>N)39OQ!G.$*`V``&!A
M`ZJ9E:Q9`YV7A]W9``Q``>$Y00GP!1#```VP`4?Y@'7Y+=[YGZV14>=YH`7@
M+&18@-:$`&\0`#\ECZGCCX99/8B9F&Z#7;X%7H^Y((4EF0S)@?M8"Q#9@8UE
M*T.3F71Y>SQ!_P@G)(E[)R:@"9(N2B^DB8NGB3`%P`(:0)[DZ07J-I*_!0L_
M4`(=A*3#67!UZ(MT(Z4>A%H%N8Q:^``%@``L``&4I7%:-@1P0`&6&!_;UA,%
M,`"_\BJ>,IQEH'3)A$Y@>BFCY3DA&G#&V5)#D%$9]8(P"`1IP$BJ]H^OXD&P
M,@,E4'1Y"*9B.IS'4F4)4`(UT"!1*8UV&J:_4ED'5&4%B@"FEY81@``#T`"(
M(@);`#\5V*%F\X\-8RP0-V',4ZO-<SKL$GHR1F'DHJ(M4XJ<AXIH\J*7>7TT
M&E;!NCT3\34XJC&_E7_'$IKC4`M!:I+=\D0<)'+1M`6/$39=BIVH,?\M"8!A
M[)@"#0`RH=,_UA:=-KHL&\`""9`TRB-M\9%KTS5C:NI\L0%%XLII;%<_%3`$
M(&,XOM<Z1+:"!9,&HYH"&P`FQP(!1_DM#?`%GOIFPT9=VY$`1"<;W+(!%1"O
MSM%OK,-WP@(!-6!ZY(``!EI(-E`#!EITMP-/[3*)`<DV(FHRC%2BYN:)^7,U
M!ZB9>,.EN?60R]"B6/&0?".LCX>-^,*$Q@(%P5=,Q%&M`SBD'<<"P\ED(/(Q
MW%J`WVHVX9IG:W1A8/=;YPH$PQEWY`4#`G-MLO!$->`KO.$ZMJIGS_F&7NIE
M:[1BFQ0\XFAG%%!9K?,ZC'8]-MM%G_,<:5#_`%W#L+J1/$M#+`&C`!2PDG96
M`M*B:4?&/ZAE>FS"!"`P!&2E`!!FN#9;+$`P!/C$"C9@H.#3`%N`2`R@4UEX
MB!OIL`2#L"`J?I:UF,48"XWC&U9#8I2I0,-*0LOHHK+8$,&#+X[;<@366C,0
MM9-4AR59M2>)K7$W)/%!!%U+&#%S-A2P'WHVKA`36@-[NNN:O+[S`^$"+.1K
MMPA"<M4S+1/894I9OV&6*H3Q`_!J-?QD//"+(]V!:[I+NJ:TN`C3L-!+9$SC
M'94++GM'M\P18<%BL\<#!"RV0C2@,M9S,R#:10276:?2`(5JJAO`)W*P=8Q9
M$F,'J[0JOP,H;8=S_[,$F9,["R^\0;PL2G^WMT08:83$0;06^8$5R8VY-;3Z
M:#'/RV1$DG/!QTMM%VIL6GS8*U#:N[O=^T5T>#O@.KY:O&([9#:BI<43E41G
MPP"C!1ZF&Z(LR+O--Q\05;]ML[_&I`8@D``UXS#^@71*^BL()#`U'#)04+&\
ML;BAQ,!L`Q_>,00]$$'?,;*%!2(VNS]O5`,0@&/,,5X)TA\1AKA>``(D*0)P
M8&=3IW[UPP"ZV:2W-0AW,'9O\`44TK,M\AX0IKO\TV^U+#*\+#)UJP"EXK6"
M2:$YS,O\X8H\O%C`R@P-I'W%6AY@\0:'@BC3'&0X4DHC,P,L<$C<W,W=_/\&
M-D#%CV7%IIF]:C``Z4M;1,#%X(L[XAN__&&^9!QB(>Q5LQ*^0`8RP/)O_J'+
M[B$P%E19`4=>R()U<\R]?(N6&SD$W''+_?PT--B5/@D"#```I&7(#>R<ASRA
M;:+(A24>,P`!*G@SP];)(=-3+/<%:4"Q(1,KIGDN`R.\ME8"IM*F<'`!F%P"
M)GL!3*#*K'R/V/D&`HNP[R'#!T0SR'.SP,Q(Y@%RGF@UAP,#R5Q[RQR24OL5
MMJ>/6GW$0INL2=S5Q_!`#::D-80IH!DZX&&O[N%2@-K6;LU2;0T!/KB-AF>M
M]-BFZ:R4Z\RN/]UI[US/N#3&OE/&SS0DZXN=:@#_!QHP+.[1-CKC!D-0`5T9
M1S4`!VW@!<96T,Y'DFZ%T&TD0MT"1>CJT"UG-2;[`\GT`-W)`(M-,Z.7`!4`
M![(-!WURL@OLL'P,'\=S,V.0-!J<!EP)`A];OPO"<@)3,T_"&QJ<G-[9P9;8
M<A66`)D5`2)`=S4`4RPP*RH[?S+5+D)-IE-TP*X]PR+Z/!?0CFQWHL;"`C]K
M#!)9Q,6$U72UU>NXFQ>)),?J"Q>I#+&%T<N!:VEM(>"=+D00>[='SKMAM5Z*
MSL%E:SK5SK?UU\<BSV9$V(W-'];6O+%A9^)"!%/V3`/S!?.)VAP;/3^P!30P
MNIH])9;T5J#-"@@@RT5-_V3'LQNJ"VYH.3P5H.*Q^@4]\$."L'@3FBK/FY`!
M/F0>SC0?TT9O!)>3(@(\.VPZX^&:LAL:,'5?R9UNQ5\5I@$(\!C7+4<LH`:I
MR03JQ]%)"`MB``$!$S"O%RLBRUW*[3'(PS]V?N<7_7IN_GH0P`0:\T.2PD*V
MQC^M1^B1V=[%\-XQ:M^8"4G'FM_$X$C,V!-J$&W&<FMKD]EJ75VV%GMJ6-=7
MS(YX/7H.KM!]K2WABBP4CC`6KB#"DN%W:`,0,"X09L'!0@0EL`$TJ:##0P//
M'<<H-0`J5G+S,P"4M;W/L>0)(*K/>('BR#$:YS$,<)T*\UN\\[RH2RZ&$RLE
M[?]5-(``7VD[#V`#8.Q"KF@U5UX#Y=.DRU(#/$Z^8W!/;<)@LZOK1S,`JBSN
M6M@MMNB3YL<^/6"D_1,?->,%%=`#ZH-^"H\GPNUT?N+P3U<!#%`!;JGPKKFB
MOSJC3>W"-JK?PYJ(7$V.Q\N^YV`(*+8LV9JX5(3!%_QH&AW#Q09,GX[@N<@F
MK[S@XZW.(@3A'9KJ$S[&?J,%(+8@3X*ZZRKN.&]K!DR_-.#G@IA"F)8".FB_
M%G?S;;I>WQ8\!5`";1X?2EXS%:`&-1H]RT('N/T<O:W!JYMJ%D@F#8M`3Q/"
M*<=>+!#N_!N5(F!UA]D?0P`"J.VU:W4V>CQ.:R/OJP#_9"OKG0,04TCOJK#F
M^(L8*8)..).[P8@^/-JA/VZ.W,'BZ<)#\D!XF:+YH\E;$_N]=/9=H\HKB*;?
MB%4MM7XX/?U]F+W-\J_SZZ/'-D1`=S]]O=$T35;/X+?DO:;>8JI=[L:RZFW2
MZEQ49=?6+3&^'25]^PHP!%]^]SD9&ZB!^^UE]5O^G&'&RK$LMLT1.DA-!V)O
MQ)W&,466<LXO]N4(3XX+]Z54P%2T&U]`F[^[APT`"`H*0(*%@E!0,`I$;0AJ
M*0\1D@^1*0400(J",)R*&C64$7,%"`TL+%L_<Y&1$92MKW>NE'.UK[</M7,(
M&@IN;H8P1$0*&ENZN,G*RZ\__PF^AM$P%060S-?8V=K:D]O,LZ'@K;/BV=W;
MDNG>X=_JX:[GL,OE\O6OD^ZAR>+\M_GC]-:Q`XB+W#EP:AH0(Z2@TQ@@8\9P
M$O3+#:>'T3(6ZJ1I484Y*<`5J-`0&#!#1$"LFE1@`+&.*(^QHF7K3J15/RAH
M+)1@PZI7*;;,"%8(R(P&]U*H(5D(6"="QB)8:_>@`(,Q.Q5XJ0%)W<A-&C^M
MI%3C&2>+#6$`T_##VBQ9K&JI81%,42<B%1X]N&.35HH-9GVY0701JQ<&;W[Z
MN[4%BB"&:6&,<0-$@P@>BN6Y*E!"6B>M7&^-*E"@G+M_N'39>J6KAA<%$2$;
M$AN)K_]M2K;YQMK7]Q63(8,D-YVH@-K4?0*3*R\8</F\?/&<[T/-C1YU@N^D
M7X.^>!WU=."B>P,?'7SW5P4:R#8$!*+$IL`P9LU(7!`1!H]$DE0+#:5*6"V]
MI!$1,H&S6B@XZ016-#UE%M10&QER5#AS_`"<9XH000,3Z$3"P$D:;=452TS!
M5(A86LQ20R\MJ&71+X(DT!8[NK4RQUST(>(+-<G4\E<"$U7$T1A>&-?5/;C4
MX-@@FW"D``0-5#../YMU1I\B(J(C26;BY8*,:+6X!MMZ)X+22F^X[=6A;Q<*
M)UA#@ABGW9S2=9G<=>8-],US7>9ICYW*X'G:==59!\]!X4W_=T]XWT&7Z'A^
M+AH//JXD5(8&"62J::9$0.3BFP]Y(>JHI)9JJ@8:#%#.5_R!:-]_LP0(9T8$
MCN7*@5L^D--&)C:HSX-$%3*AC0B\AF$Q!<Z3"SX5N!I-EEZ5&%8-8SV`P#,M
MN@BC`CVI(<J9BSZ@!@,:340$"P7,E`Y(@`7Y"T=>L-#6B/6HN"1DGR50PR,A
M^2F))59Z!MI4A$;:I6II>CF'F.WM9$QV>KY37IZ_;8+5FYKP&"B2$-,Y)Z#>
M@1RR01*;UIQ`B)[\L:33&3IIN'H2.G([C6Z7RP\((+!!SCQO`(=99U4$#%XU
M%&WTT4CW@'0-;\"#WGXF19/22INY_S2KU,ENJ=@D*>S:)(,(."A4L((,>RL(
M.VDR!!,IS-$<I9$TFQ6T)"X8#6VSO($M?]`0,@,+M4PLR@9?,"D-LOJ,PRZ0
MBFR;UA=,N#THQTH^1HA%$Z7Q"-7J`AAP70-3J3)R+4>0FRAAOK;>9P\#Y"]Y
MZZXB>3<5-W0QC!FG&R@YHH_NL3F^;P<[S%1*2MZ4L`S/\GF1[@X[/Y-"__SN
M'>N#:,?7(]^\H1`_K_SQ-/.^C&I_`2<<C)-IA4;P"JN&NGXE]5<($=3J4P`+
M`M*:->JL<.VUDSP)6S>`%2%A(8457RF7($H@A[8=BE$#J<#%0A0:TVU&6AG!
M&R7D0`%/G?\$&`W[@D\<F)T4R&$`0VF/"BFB@"\@H'>+<Y?%8$`!.<RN>#.I
M'`Q4B#E%Y,46V:M2N;`4&M%)K'?$H\0><&,;U"W,6'692.LDIIK9P4X7X/E)
M[=R$NSBE*T^3<]WOZL2^TCE*/-+SGF:Z83*3'=%UKW,9<WH'/N:@IF8Q\][T
MCL<][>GQCP^T8_=(9HL47`LV6-'1269`A\Q<XT`XK`K4Y%>V^B'0:B:R3[)H
M`C==*2B3W!(@U\96P+(=<(-I2,OABE,`]TU/'A*<6P6?9K?9U,]TD6B`%R3#
MD/<0@@@E")O;.#<'.32@%\&9"!"&5H$?&,]'[6I<U!110RM"\!7_.FQ80Q+!
M2N1IKRJ?XU7HU$'..P[*B7/(31.=N"(,27$+HLGB%;.(Q751@@F%4^6;"L$C
M0#Z0G%H:8R119K#FP4R-`_F'S+#CS^7!D7EL5)X=^\BQQ!'DG-BKXQSAZ$]&
M&:QX?#S>+IX1$1A`P54SZ,%$KVA-)R)PDLZ:P2VKEC^L56M9;*2$UP26@+#!
M8@ZDK.51W*93G=0'+&X`'#(0VHU8[@1:M+R:+7]R!Y!<"P8S&,9@,M0>(E#`
M$=:`Q!R84`$-`*%3D1D$,?15SW/\2(8F`0($;!C1B&63(7S[R$RF="B`#1$T
M;WSE7@$BN5JHDR]:6Q@R><6Z`J4Q9=FC_P4^O[9/+W(T.^`36<3&""C3T!&A
M%JV7>2@5T=+:Z9R@E>CKC/=*A;HV>BQ3K?18>TT_QM%X):OMGYX'%VN1]#./
M44!*?_+8D)[#%JQJG-3^<\F:QN0X-R'JLBJD$VV"C9ACLPM*D3(+&T!`GQ$Z
MUY>^Y[0(.)6"]))D+4]4()N8D`5>."L1>NA+(@R!`0VH0<Y`4`$(&`MS$8G(
MT-#5+_*LPI",JRPAYBK=RY+%,3#9%H^V9I!_<>:O6PGL:E/35E>@B29A6FQD
M&DLU/7(4D),E@D2$9HA^WK:.&G6H0#<[,\$*DK4.!J-!<6SBZJGVLPP]66H]
M.N2"T/9M0<;M2O\WS-<*'Y82AP1N0_S6R-!BYW3_6$5RY?=+2U)"5J"LU5Z_
M=:A:,$%!._'5)(`Z%.U*Z)0/L(%13:0((%3`AL3-K#A8,$%QTNW+&+Q;>RG1
MM31TB@A0"/!3'D.$&8AJ!K(QJ4.P<A\.J<L\"#ZJ(1C<T`=4KB@OLNQ!>7?A
M*P'VQ-R9SD\*BYU1B&)%^!H2LDK<4>>!!S"+"!IL.N)BU&9TQPO]V.@6VEK8
M8@?5T;-Q\B!KW)5:U+3)UNT?-UI0DIFQH#)6]I$=53(JY0;*SY#J#H5;Y2JZ
MDJHVZ4MTMAQ3YGX9DP/:'YEC=^;Y])2XE,AN_`QXBUUE4A,,P/,-ES?_B_.*
M4Z9'`O1Z!6&,52!6*@_80`G0&IDQS&`,%)=&#P$(S#=,M\*BR'0FV\/I[=EK
M(\OLSX0=F2@YA/-K6?JLS")0FF^9^^:[Z`69AC'KM@ETLIE0+@L5P`#=8=:<
MP]/LC$7&;9EC#XFYU:B>VQAM;>N89#:>&!U]7-H;]TG'#HUCC'/K36CC\#:'
M%#>59<?VFR=#W;A@=S1F(!/TP%M_@9/%:LJLAK)4UA#WQH6^^6;*?J=2TQ.A
M0%NL&'97&/QK,JU'`D'9\+W(0FL2'XH;9I`(2>_0#?.%#3>;9%+'`"$!S>Q*
MX$#N6TT/0JYTQ>.GX80YRY8'22['<!&W;2?9_Y$C<#@/4P+D.XSB#^/T6U!#
M2W.515N#IV)2]L7%BFY$DT]]QMA@>F2C?D1F\S[:W[>V\VP]2$41K]JF_35R
MQL[DNMKVC5LO>Z+`SHZTPV3<1*##LVF\??4&:>YU]V[.-3_'X#:]%3BTT'<0
M\"YIYE.,T6;[5GBO(`?[01]8T5-'LGV3P&>F%GGG,'EA(1.ZL24ID`(VP`!>
M8!(<41_`)324001>``')IWJ#91Y1-BMU!GL#MU&SMX*V!SWAX%>F%G/AIPRK
M-PH(4#1T<#0]@`8]T`,(T`,-P`!IP`!6>(586`'Y10=<V(5>R(5*^(5>N#0U
M\#,C!@T29G1K)#B`A/]]RU`:!+5D!&=MS"9U'75]U.-\H]4G.-0H)I9JX7-M
MY2=:XG-LM'5B@L@Q:2<-OT0'A[)1#V4/_B=TPN)N57%WRX6`L]!@0`4<1@%*
MW.(3@@>!A"=<<#8'($`FMJ,5Z'(>2B8W`O-GZB55[.5PNH$,%0("0]!#H^<0
MG7!213$#$,`"D1,2NI-L#X!@<*().<A@PO-@C$4<+N9(XR"$L;A[=]@CR/`&
M&:`!634#X)A5C=8I&L``/Z`&Z)B.:E``<J!\9!5?C1:.X>@%\NAHXFA\\2B/
M7I``"R$9VP(C4-"*+D-UT^:&R0"'RN**."9_U2-_8C>'[!<0;81$$@5U=LC_
M5/VW6WTT=8_8,F3'=:RGD>A418L8#&OG37EHB)/(98M@B6J`B?YQ4](5`3;`
M`F8%$9T7?2*$7:2X78E3+%<R;D/P0D:$'1,P!/]&1".R&70A;@PG@@\G"K?"
M!#20@H2@"4)R$93A!E[P!110`36@"AV39^KP(\O8)"0G!S<F#ST(0!6PB6$D
M%06``[KG%O2'DIP$$F]0!D3@>@US'WH!8JHQ%\0P'X:9%5TE$>_1%%K1`(&D
M9$JVAV4T)Z01,1/YD1K6D!@U44491I<&?Y!Y4>7D;+]VF4W7>(+3F>XW6[)U
M1IF9;;GB6^#%2\*U/@QE?DDF=[-"/^(`9@/2``B(_R#B@@`,L!!N@!71%R.B
MV`WZYCBF2!.Z\EW[U`F0AA<-%"[UU#9O``&N-Q%TPY2UI`EX8Q.Q20I5>1:%
MX`440`-M0`$4T`8E8(6H@`!B"5UG5)8WR#><`'N<Z0Z?]AG2Z#0WE%-S69>1
MF#+/82U#H&(C=VC4MWI.)`IR@#^':5V'21'M45*",`8ZPBVPDGY0UWW!]CN5
M68,@YWWA@EH[AI<7^5&!R'WL<(?<=I^*LIII)$9&%GYCAZ.)<Y=2QR?@$&4K
MB!$R56$P"G_,`A8346<?L"^79T(5`"$<H4*`F0L(4B$U<"%8`2/.R1/+Z5X@
M`(%<Y@7`B0P)T0O'N8)9U?^8RJ<%-3*2"$`!M><9E0$*G',_0:<)VL16>^4V
M:L`$+,`XQ$$$PV@#!1``-F`#/,`#`>`*)6B7!K%J>>)>@)&G)[&?<P6DV`1A
MZ/EZQ:$&8W8K4EDEJP,-&89LB]$7$'HK&^")>=H1OU1T;8.`#_<`%.@L%WJA
MF<2AG$<,:T.:(2J:2D<G)6J(5W>D*@IL55=1:Z@R'$ED4==C&75L012CKZ5;
M2]:B%FF'@]0/'GD+0KJD1%H#_W2D[S>+=F$7@U"DZC`'NN04P'56+@02RR('
M-5`"K[%#%Z$(HW==M4$)#2"F(&(493I,NF(E3A$1@@$,1?(#XJ`+<K`!985(
M25G_IT`$GN!5)IQ#"6]0`?Q8"!>C`26P`:T$7:QA3^^P&HQW"[C6"9>Z0YE*
M?M`8&2!$"#_T/%L#3@+#L&82B5?&2>W:JJ\'0$QR']7P+9;7#118F+G:M$-D
M<8W6B@L)FH0XHAY3K%<W6\N&H*B6?3!F;"O:FEHKHYP)DM=CHS=*M=%ZK:K9
M20G5=<SZ="-UAK294H$DK;9U0:0'7'1G8%N0@F?H"XV6!O3Y`S90`PR`3";5
M,&D*BH''G/FS72`A.631"Z''8CPW`Q30`&\@!S0G!SA3`5]`#"55L5Y0@`#2
ME)1'+91+"FD`(8QV5N;H2MWP)<S15I`T"RW;J9AJ0S+K_VE+XK)UQDK+ERBE
MQE@\>X@=`Q>K-Q-"2S9%*ZNK4:NV6@%,Z[386W%68%\.J)G5IKP&B1['2&3%
M%9)YVVD.MH:E*:W<BFP5F;60=:YL^)#75I`YEK5Y=*VR-;=I!1O`,%Q-1K;5
M.'D^*%QUMR5^%[C\001?4`(E``$?*QF2<6CTZ'HQXE.0BX,=\3='"&B=LI45
MX0L7)P@Q2`,54`%I0`$?.[31]QFGJXE5H;K3\B4(,'&2<3%G!01>``=5-)(0
M.CNX2'.ED;N4L+OZJ0C.V(;`N[<MUDIOBT4Z&XU8`D^T]K4"2KFZ>R%ILPBR
M>@N(9:5+.V(K.,9D7,;N%"HLX/^[H"E;ZK=TT/%%CP52OM:MM8:(S^9^:UMU
MHYG'8HNL>.R9W49:!J6LX`>^GMFB)L>_P+7`/?!/=;RUXE(B!4QWCG1F5^DD
MG`",[(&3+7)6$""Z@1M`V)4_3L+!HT"O.C5QB[!,O\"I%JQ6:#5?Z</$+TQ4
M>NN4W,*Z6F:]GJ),*@0!($"&-;`%9+@%QJQ?",`$YZ@+0XP+RNBR7U-R/[K$
M8IP[D-1M!2K%6E&`Q:NUJ]=;SSM$PM#%X:!NQ62]U5S&ZDS&&**P%!`Y9%F'
MC^*0;OS&5J:_W)JL!0F_/*;'+R:V,@J_[UO(UB-V0Y:-2+I'AXQ^^#NW4J8)
M1&";YYO_SW53S20L@JP1L`IL4N`H&>`H$9*V",&T`:G$H='WN+>R!<0`KY\Q
M5#-Y*S5LG"#-$2?ULB858()``5\P&38]Q1>+KJ`C%C[B7>Y1QD:A`5Z`U*B2
MU*."*DXM*JB2*4-``2Q`GZUDN\FXB$LZ$=+LHCHTQE[48+6[+%&\MSZ]JE:\
MB9(#%^63L2-FM`139N<\T^M<UV!M@0_Q!=3B<^358]]+8\KQ/4;'1T"&DI+Y
MK(<-K8089`-=9&MKR,;EK>K;;7+(T%FGK5\KH@2IV%&VF'4KT8D=4L=&P#-=
M-HX5<I9,631=&/51CFWA-2"](&J6TBN]<8I@RAM;"QO0!B_Q_XLYV=.EW5-P
MP-,VK<.L:T&S"!\3P59#_5V-EI.^F+U/M;EXAK3)B&L]E!98T=6;60.]S1$G
M00U8K%!E+<;;#,7Y"P^JNM;_(K2+K-VR*R6B4PL4J)C2/1_$L2U`\`4J46!]
M#:+(:&7.P52#_=^NB:.;V=C05H=TO.`>E="D1=E;"[=UE>"6;:0*'>$2_M^H
MN;Y;=T@*RVC$P$AWZ\CR3$L9.K!G)8*UBP`08)R7P])'I9Y1DHQ>HXH-`@^U
MH-*P3'M&`3C=TS82*V)'-:3I8U\J`0>XNI\B<D,M`1DA'".Z;$+%.0Q!XS@F
ML2UTYA".41$YS'#R`E`_TE5XA7%/$O][+\;COJ"G:*4QGED:V9P1A-#D;$M8
MS)<.*;"=;HU(9Y47QX%%K;04`WC?H+,(E.$%P02J/$K9>QA_<SPRXD$:^RS`
M$ZZB,N?7#8782IS'&Z[IY&O@.KI:H9W62AS0^"R;UD4(?D.NE0[0YI%`<F[`
M)>8E:K`!#+#"L3:H"=`&#5",N5!OAG-=$>`MHD!*%JK#W&5L!5`#:;#"6>&=
MP^@3<]`LJE@9*G%#<D`N61$5JO$&:8!,+$81SK+(*_C;_"$,(RXO.)75SR`;
M*@0$-<2CH[4%JAX-#$%]''6Q//!RGOHPUA3JQZ/G.Z'J@#FK-Z<4%$KH%TH$
M";"YOH[(F^[_OBI9*&A4<W\XQW^=K)!YV&0WZI@NR)<^Z5P[6IK]\18>O^X+
MX(]NZB=Z#S4,`10``4,@\Q!0\U\``:PNP,>:'@EP\S4?\U\0]%]E\7GR`S70
M7PD`N(PV`QKPR<G\)7-@`P-0\S(_!%9O\R70-!&P1+FP!3+O\S9_\Q20?*Y5
M&FUCK_VE`9UBH8N@`4/``HDQN0T`]E9_]1#0!JR^%YO1`!#P!74_\S;?"%<]
M"S_`]RFHY2WLLB[XC]G-T1<H3-T@<50_^51_9^6*HR[N\W]O\U%23EHCE54A
M`G]O]S5?`GEOV!UU>0_P!FW@U)N"*0D`^^:H!G)0^[9_^Q(;^["__RF\W_M.
MO?N]W_-?N05,4`T.9$$HS]@=[_D5":3L1_2=%MF>?W3H:^K"6L=M>/'H*_'R
M^\CZC+\(+?$L;V,%\`9O\`,;D/X;P`3K;_XUE_+%!AXX\P;JK\SJ_P:M),C#
M3@EJ``AO-0T5%0P,%2P--4P%<X\1D1$/$39O&YB9&TR8!9%[E'-RFC^<&V^H
M`922DJL1CX\%3%L5)1`00T.W-"Q;3&HI*;$_IY>:F&\_#P]W=Y%SQ,>HR`64
MRP^/:AL@-%XP"C#A"N/DX]_EZ.!0X>QC,V-`0"S5K6I,3,:F/S]O-IZL`",M
MBU#`V#%.R5P-%#BGU1P;QS+M>Z-J(4!7`?\!.ILDI\:6&B!#@@0!<@NA0RA1
M%C+42Z3+ES!CAD3P"Q:D2'<P7K28,:-%GCNO"=4I<.@U@CUW*IT$M)5"5DV+
M$IV4%./4I#VO!M0Y]:A/JUFM7HU*%6I1LUB=?DT;MJI0+==L/DA!-NW0K7.'
M!J/;D"%4HZ_4J'DTEZZG@9X@82-<F*X:J:\>[0TVIW`HHD^?(>;'Q(8-)G(B
M[!UX#>XRFW/H#FSVC'#E8`^TF%[H*L6%.2`2A!L3#HB&!,`U_`9.G+B&&3.^
MP6C1`@HX=D`4E&#R4ZCJQM6WMKHN5_5?27V1+NX^NGIFMCE;I[X.>_V<&AK2
MH=.P)77CR7$GHY;_+`S6=:^5B8665Q=5]9U;!(9E%"7_V&6>6@5"**&!;+$5
MU8-G.;C4@4PII!563?$D((=U:5?AB1-V*)"*D<U10(,;:BBA12^*IE-X';H2
MX&FP<"@>CGVM`@93$<@AAUPS$K51*Z]8!QLV0H5G$6H=;K0D*SMBYLQ<T(`P
M!!&[C:%``G"$])%,)K%0`01>C#$&%&ZT,PX$U(7W3X`PXA7C0E2BJ!F6`4[X
M85+IJ;>@3?`]Q\YN1"A`7RR39!E4CYKQ&*15.&;(I#5$,NFGITZ5*!5@>;:E
MJ5NA>HJ9AY^&V-5YJ*9(88XFK@A9A:+6FFN2?HIX878R=FKA*@EF!16._P0F
M<5A<&C73#$8WJ77-E2\ZPNI%F5YKJZA$P?(/6,\T^]=&R[Q!`Q'Q`$$$NAJP
M`(Q>>MDWAQIO5.!%/&ZL`P,\"D#P1I`1"EO66K*&EY.VD8:[U%&[#KQM)`6$
MMB!!C\"WZ,5B:E!#M`@6>R)0K@[X\:I<#9HCJ;8:*^NMP+*(ZZYBF0PBL3&B
M2%O-INJ9LJ]C@>K3@2,&:U>2L/H8JWD7ICIL@J\&A2524MZLM,.A=J4TSP2?
MBE2GRVQ`03Q@0@%%=!7\T!]M'H[W"!T)D+-H=!0PX2)CX`:-<\*CINRTRERG
M_7)`WT)6V7M>@&...(9K3-K(/FNMJL<_"RM4K?^.V[S@-34*_.G4O\I\Z^>:
M0]XK@2$/K37368,HJ(B@-KRZW7KGS#17>'&+UM2:YSXS["#GBC"M'3M(;,G@
M_O4A+!N4X(8"RRNPC@)#4)<BQQ2K`4+AS4.G0!I'.L+8[9M:CO7NFP?UH>C@
M!7I:#87+E_@6I,E</.@QN^XR\+&CW_'ER]1(5O'VJYK.<N<Z_35N6YX;5HI,
M!KFQ:*5HL:L<D>KV0%S-2'P#-!K?0"<H\+5N5:VBW>ZL]L'?$;!I+TK-#TJ`
M+C&9@WD-R%3M`#('KS'/#<MCQS@J<"09SBQRDH-@^>87OP.:3U<BFD,/VB>?
M;SR*4T`<6`"]PD`C:C#_:1X\&?]>%$`$RL^`"**<!!DG1MU9*(PS+*.F?#6K
M@)G(50G\X>GBB,8"_L^"9:0C\986PBN6+&>5`4%\@"`F'(Z#"#5(P=;*2!<$
ML%!=V1.'QFQR-ZH%JUA-*]_].`C&R!QKB>Y[7V4V1T6099",<L3=Z/B'.7IH
M$G\17*,8>Z?`5]XO1'T46A8U.,&81?&5L+,9B6CYL9QM,E:H#!T(@=BRR>GR
MEYDAYLJ.Y2(&Q(,W,!`;.=QU':4DH2AJ<&1TB)"],32O!&8C3"5'9SPWKLYR
M5)N=_8A%N"9*LCX^-!TG\UC+!_Z1EU]A9?]*%4N]=3)U"+5=.W>YT"'>;GRV
M_UQCVNSV/Q&>4'7&W%`7`5J_=0I0=J;LE<\PE$HW`E!J&;WE,E8(A(O!:7D)
MJ($<GF2-MQCF#7"``+K0%:?=C".FJ6'*E9(YP,5Y$([('![Y]L:*;VVIGNA8
ME*/P^4OP=9)D&"V+0ALJ/(%FSJ,%.M\\L9K5:9:U=&9]:(DJJ,^0JM*,"J(9
M4]\:4+3U#*Q^7!G,.'A**V[0D@=%(S)Y^0"6*N!-BW)#/+Y0`03\8%EY>8!@
M?E`#%E!@!@H`P@ST=8Y#PJ&'?>MK8.$JJRG^KH'HB13[#.<V'3Y*AG;LJAHC
M:$"DODR@#_BJ1-M(RD&=C[>2(V5?C_FWV;).F&E<:/]=BCC&Y`[V=$?[B28S
M>2HZQI*-(RTF0DL+3*M&H`*-(@)GP]$\(B2@!`QH``C.5`,0L(`!%$@`9@_[
M#G:X`5T*F`$#S,8*<@T7C)C\)U.M&\]E?JR>B%-4QJC:0;]&]*\/JZHSCTNY
M!>F6=/YTI^[&FM8]$9BKTR6L6N&Y5!"7%)>SY2U:.:='";=L@RCV\(,-?%;>
M)=0J6XA/3R_6V7&X809>\()PO-"H<F1SO/CU0MDX]JSADM:=$*5K1F,,4&.M
MML?@<).C8A@U$QY5P%5.G>><6=`1MC)_'^;C@_'HY"<[U[J8B6*:;YN_-3/4
MDK:D,%[/V#H-E]G/;L[EGV?_S+<'R($!C7(#-GGLG%`>CL?G(,(0&L#?Q$B"
M-7Z>GYU'O&E]1@X;B7*T!AKPBJS->;N=)NQRB7=F.0/:I!U&VUN[N%$5>[=5
MMP9I`K%KT&"6U*1Q?K4#C59`'U&4A"F6)G!AC,3?6I%`<V!"!>)SV/%>3%%8
M=FFCQU2!#0RF1PO!-*ZG7-4/+I"!Z%[=EB)0`P@4Y]T)T``$:M!&/=>[P;G>
M,(3YVM":#G2Z8EUVKCU6:[!^V**;UM:+!SUH7C=7I*HLN)<=K'!3^_;@50QQ
M=4_=$U$T(`'1(0<0<,CCYS0/''$RY"$30(,:>"\QETIQ;P\H\3L[N,\969(<
M$("`_PWP_.>9X/D/NOMK=O:ZW+T='H;_?=24AEGF:V9KH#VMZ4Y+5\IX9J;`
MKTM@W_+9H#:G];['C70[GY3C63Q,`1!0@3+,MQR+[BP,0HX.('@!`HU5!H-2
M7=RQWQGA4$=ZH>85H/UD(^NU=/K6^5YBB0X4[2:.*.2!6?"Q#]OJDY_CJP[.
M>$&_6N-E__K3'=KY8Q6D`?%]NZ/+082[,Z`&_I"B>#+OZ=%'/?.%BH!@U$,I
MG`QUQE@L?>>1IMO14S?A$!,^S5M<>X:KCJ"2:!"'9?2MRJ?EJ]-O\]0[K/C%
M-U[T`J=]I`KP`P2```ZU&`*\B0.!-%1`O321V#)^WZGB\_]]%=*/8V`S-UK?
M-21S#=$C@=-]PH-<RB=Y\<,@`Y@W-[<L%>9K0P1X1(=!9!=V71=L`16!4$=K
M-#97!EAO&X6!MN*`&OAYHY5O#N-6UQ<`EB`&+B@&J.""_I!_<;2`%@AG@(<8
M5"%VGD=B**B"955G6%>!*4AY*F)_]R=^!"B$!SB!0^.`T/=<I><['&=]$->$
M;.9\?A<ZR7>%"<<SS?2%B9=G2HB%WF>&J6:%T75A&(=JC*>$9>B#4Q&%RW9'
MH&=[MW>&6YB&S(=\37AU-Y=4N_5*-HB'R$6'9J>'1@=H:FB('YB%9"@02%B"
M_"=U9D&"?2=\8'9_#08C>Q>$`D/_>](W?!!3?3:'AD9GBL*7?Q62)YB8>/:V
M.32(;T3X<(&'?RB(%:^89T17?998BXB';'989<AVA9,8486(@`!1B<J'B)O&
M?]Q7/I`5C7[BC,_XBHWHAM=8A'RGB@#W@>+G/Q.7A[;HAUZ8$=[8>>+8C&B8
MCN$X@M"W:UBX7*A8CW%8CP=H?U9XC_BXB/VX9M8H7)!(>G]HAE/T>01IA/\(
M.#9(9GCF.]^7B#4C@E%8-'L5?<QF/'NW>5WH@9&W(0&IC0PI.T?4?+KD<.5(
M;!)(5!Z9D`6F:J5X=`HRAL:T1YY&4-Q2=9A7=*8V5]05DA_)(?'X99!(4/YS
MAX"SBEIH_TL-"7XB66XY29,E6(^ZA8EW)85-M91%IX-[)HL[TY.!]X@4`HU/
M&7ZY^&39Z))H=Y5:"8R@R!8#>!B[)#_+2#5LN)"*B)=+67D-PY=BZ982J97B
MQX]O^(T*28IM&8EJ)'%Q"(B.^)=Z29C2^!T<)Y<JDV8K:79$D8R0)U:QJ%V!
MR(LTAY"PAHUIF'PZF8J(QXE':74@J)=>J8-I"67YN#-0%'6\4IG!2&B7&%S*
M"",%$`!`&9J:F)EY.)PN&9%=29K#MY*7IWUY"9@9Y'5OB91[Z)2P&9V@J7S[
M*(&_4F/I5I"G!$#;J12NB)R1*9G9*7FA%YE2V126Z9K2R9OE>?]`0*F>YWB`
M3X&3_KB>61>>S'F*V4F7D*F+`;":A(B757B6`=J>84F<VIF42>@I5LF'BS2%
MG_B81;61&2>0[NF:^FB0]'F+O?B@PA22NJF`#^F$N86>#3JBYLB3!3J8_EFC
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MFW<XG*`JJW%ZJ;Q)K!<ZCYXSE/BXJN+)JXS'GS7:,"Y*J8<IK0#IHF-*KC5*
MEL5WJY':$U%XC%NCHJ-Z(E"XI(CHIS^*FOH*3_`J'AT)E\")D,B90/5J07$I
MK"A2+;I(),Y8*OCGB58CK@E+A]1JJ6@1D+_*JI^RKO_JIK#*KM%JL8!:I.T)
MKT?)L:E*$`5[?>?Y8'(YB?U:>X2*?3THL2J;:@'[L(G)$]X:L\.Z(MBG1P0K
MD2\;L(9)%3#K_[,)BV?,B(Q(:YD*:UIU6JU*BXPT>Z<O6Q95N[$-HK`IJ34K
M"ZM9J:)H.K*R.7L,J:S/52VE$K/82J\8!;40ZHE)\557FJY^9;0(NHS(B9[F
MNK=-18=DRY1PNYR+I!5V.ZS6:+0U6+&6"J5Q"ZV$"[@BRZ7/R*T=:YY%:C^"
M&Y,=.8?_X+5Q6PUQ9K,Q>Q1Z2[)5R4<VRW3ZZK,@ZZY9>K/41[*V"YR(Z`H-
M&WU0ZXR(@:](*[M_TZ^)>ZL5J;MM$:+F.KN)R[NUE+IERTXV*XE%Z[Q\IK?(
M&[WDT[SU][36:SKHF:$\>;5="[QC:;YH6[[/"[0%HKZJ:2#N2[L=:_\RT+NY
MGDN-6RNV=>NX&AN]L0NP0BJCE;N_@4NWU[>LMDNOB^N*`DN(?WN[!UN-"]RN
M@^:V$;RP"5RW?&MG=MNV&ZNXZZ2T^<NR[JJIMSO`YUJMWYNVNG.>W(NE9+G!
MI3C"\EO"NIN_HMMI53F)L4O#39O`.:S"5#N<00RP=PNR;)NLSF=_$XQT.=RY
M-6S$]^K"3BRZ"VRJN"NA),QFJPO`$LS`+!N201R0ZVC$&8RF47JR'NO%5T'%
M@:N+5AF.IEFX7BS!9\S"U?C&9QRUF=N_<(R^6MS'>-R,-)RLI`NL][O%B"S(
M,NS`"JS$B2R[@'S`9FQ)1EF_VGN*%[R_#TS_QG&\M*L9M5H:R'`,M(M;P!`"
MQ7I\QWK3KX-[B!79R(H[P?)(NP_,JD6\QB>:.:<,PA/K,*JLLA8\;L>XF0(9
MNJ#\L[49Q<)+N:A<FSY;R+R,HA"'S&64O\:K(<OK"=%,L9><M7GZP^!\B4DL
MQ"3[13.\I94(I2)\GSIKOSK<Q5T(LM[YL%FL80MQQ=>+B>-,H5Y+O!G"P_:<
MNY\+H/);L5&9SO-<@`HLST0YE[P;OQ`]P6),S+G<C1W\,Z(\O%:\R:29SQE=
MA%X+G^_JO>HHT8;*R"-+P#"*H'?ILNMXR[?SQ'TJTP$<R3>*TQ\M,R\\HEU,
MF#;=RO>\R"3,E1@]_\GENL+QC-*3"<Q#/;<NJI/'!\KXN:N:*+D[JJ,M/85$
MO=6/BHK_2\G5J:3M.*`I:[!(K<MJ?2+"6<J/NU`#.Y+.?*%M_-2:LKRF#,D?
M8M?'#,8QF:%H=[)^FJAEIL;0F<S3^]8?_,K3R,ALJ=.32L%WS<%94]'.*Z^.
M6BNC6,A;R-<CF%4MJ]C\IEU9S+EPM</!>X1&F;R87*#_^K<]0\VU2Z%Y?;1K
MS<$D*-@H3'I![<?+S,PS^MICZ]HT'-;-+,@9Z]`]6*I,#5SY[,^LO-O_^=KW
M6H>,+9HFXMDLN<(A&B$U,L+\.]:HFI\J?=S8?(\E_6>W3+$YO4M=BZRERO^.
M8TG*=8S5VZK(G9R,O>W+)>S,/<W2J/+>6/C?&@S<Y'S98IU2^RU+-RN^">ZI
MS5V=8`'>S3R'"-ZMT:W([2O@N+G!!!K7Q!N?]VG@[2W:OIW,I(JT;5W>&@NZ
M.NVTXAOA#I71@^+*':G<\?R]LWNAP:F.__C21XW`DUO6<]W418[!=@R0NMRW
M"\G97,N=+X[1)Z[,]GFY.'O;W;KC4D[?7JGB>?S*-QW*V^S!:XRRDHSB&9[+
MZ2V-U<WB?[Q]1E[@27W"4:[4TNVA;>ODORS9=Q[&=,SF[`WF2<[23J[G<OW,
M0O[@"JUI(]P73,SA/(XBPKG?IKO@_5V&D([A?YW_C[X+TVH[Y(;^R'UZX4KN
MO^8\YYQ>9I"7V!]<VS%\TF9HV8Y<F!E>KD!9QN=[OY3^P!8NU^%K<S+>JW(>
MUW0<ZL-^Z]NWVFM*Q*%+[+3=R,@N0GE>YTD)KIE.N;MKYW+>WR9]ZK"VUM<^
MZE0MZ@=]Y]<:S!B1V#N\XGZ]2)0ZQ>Q]X_R+VMQ^ZGD>TE.NX6N.Z_`LS-9;
MXT@>T:O<KA@;R:VIMZS.M]J-[YE[P^X+\-MN\/L.O/<>X03^YJ1>[^3>OUO[
MQ)-\C,4WQDS;[S#,\-#^Q0//O:\NQ"+OTIP<N.Q>WQ$=[R3^XA?=T0[\S<%>
M[MK.W=Y\YFC<\W=\\_1N_]Z(KO`#?^BRK/#-_O,+3?07/_15:[*07LZ#3/4`
M/C`>K^@"G\EAOO30WN:#C/1ION-)&_4#;,\`'N(=>]$'G>UI"WTKKM$F795S
M?Z9SC[M3O+!D:_?AO?9'7\D96KP*^/?LN^EVN^+9"\D\?O>XIK[R2A".3]_%
M*_G='IP'JO1(3N/";-/BV,$A3_,-WN-GSK.J&\$.S<=]'JEG/^C+*)Q&+?EI
MG<B0W_@VZ/9:>_G/++3NWNR!'^;56\/!2:56']Y6G[G_W;`[K/="+\E[_[N&
M+-FE3;`QW.[@K:YQN?/6.\9DWN!?+.(>[N^KK^:KO/)_C+[:S<FA7_[&/\P#
MU?^W[Q[V\/_\N37Y)([[NL[L"9_^+P\($0\1$04%A(B&B8>"B(Z/C(:,A(J.
MDHN/F9J7FH6<G04!D9.?DZ"6F8J#E9Z?E*:OL:FCB["=E):VI+NNH*:LLIZ-
ME<"^K[JDN:>$@\*XL\'%RH*KMYBRK-*0R9"B@IR]S\S!A=#8DL"VF[#9H]K2
MO^;IX<OBP[OWULRKO-OYB?H@H?(735N]7JJ$\5-GS!HQ=^@"QB/HS-D\1`L!
MROM%[UJJ6NLX,B3WT*.KCK>X53PYLN#`E?-:EKO6#F0NF2_3W;29<MI,<2P-
MNHSFLY5#CB8A[NR94V5$GNL\_GS(3BA,DTO)126:5.3_4:8PD7ZU5_-848E%
M^T']R+-DJW8RQ4Y5:]:A3[=U*]+D5?92I57>!,9:*)?66G^$\<6*.?:MXIF,
M-?%K]#8IKF9/MSHV;/$0X*JY$DO-&[$90<)2#UWZW!C=8[PH]6;NF[4A:;JU
M&#VH]J\R2:.4`J><)*K4P,B[,4X^5M;B/:L)76M\%MFV=*Y_"P7&[/EJ\]3"
MIT=GJ;$4].[75V):?A;@=U\!J.E3*3M3DOL%DMB&_#C"??NAM`1,$N_-$H`W
MIDG4GSJ9F=,63MJA-U%6Q>A7'H(!W99A@/+EAXB%VS#RGU:O8*A972<9R!"!
M(%KF2(N*Q!927O[-<A%%X%A5_V*''=I"H(@>DF,AAYW<9V1;X^B%WW:IZ#?B
M4)L$)TIR\!0VDCOS`86E1,+)=9>7B81W8X8AR@@<F988.6*+_+7$YHOX9;-.
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MM&^D+OUL2,BR`BG2'*-+8Z\9QTP5IH^@/%^CDWC:M("ZY>:BL-BV_%MKA5;<
M"L,_/2E@2%OZ^]]_7AL-I3YYDS@;?2`CT^7+2L=ELU&CZCV7R:@*-3&.3EMM
M=)6^J@Q/E%SCJQ18P68K,C(/4YOQ63]&A.BP6X_EL%TB`9SZZ#`3ZZ^^YB1H
MKH*''<UTEMGZA:5YPQ0=XGY.U:8>T:+CC&+,E.D%W+I7\<[_^9<R=ZW5HFGC
M7(RXPP^F/%P,TJ43CH.^7NS2-\:&4%5>9J-?<DS'6*:&LG"G,+/C9\)PP@QV
M'S)EI=D=R8#WM0V1CV;;"U_$$N<YYV7O1(`;$[!JPSRI%`=3?P/=I8K5N'2Q
MSW-!R5SO`(:C<C'001WA#8V@]QS2.((]TJ$2,EX3)=3\K(71ZU'*0.,?N63$
M:2$4DM)&5I?]O>YRQOO)_BKE(K@)8PX=,<5D?GB^V>FO%%%K7E@P4A<96JP`
M<W`B$DVV.*Z53575H<>ZC,@*-H;(C;P)H]#&)T&\U$*,9;N>^#IG%1G638H#
MK-(9HZ8.%M;/6=DX4`$WR$@N/B\M_S*C'`S-Z$@%S@2&EI)?\"@!AD6"Q':@
M<9W`_D2]AKUH6/MP#"&,J!W%U>YK3YF20FSW@%]%`(]1\@LH.BF>>SAI'+HD
M!_PZ5YEUQ>9FK!#-<1"6RK_PBWVT:TIVT$@LSZBP7E',D?465HX/&I`LNO`?
M*,?UE00)LC_`O!]T@@-+8U#I2[#<TR6?N)I6XF)_`*06)FF""AMNPYR(P%!"
M@+G)`O`2>800:/_>:0CX(:Q?L_H(#P_!2G96]%DHZ^-*XG.S3"@3,@LD!N$8
M`0;P"<*)/NO3@0:A2(4,4'NZ606(`B`'B[G4>42DD&:,-(EJ@`:*6<0<(<!0
M4@!"#!50E/_:D&!ANU5^DI.WS.$,`=6G`FT1&N]L1)?(B8L\5J^J?P0K"1M"
M0$@^-&N\L-!RNM,0(U$)0[_\T,RLV4.,E4.F!/7$'-8JK$ZQ***F^1A3+]E4
M6$TM=,GQ%)74](@ZY>=]XJ#B+?&9*7=%U!XLK9Y#HQJ+J2UG$'$J`&O>ES?\
M^,2N`&W&R^ZS&]#V0Q&0HESSLN,?1=5(K2!UE7)<L5<KE@=3D@+MJQ)DPV;<
M(2,`19%\"NLJ7E5(;G^"A=SL<T-$QHZ'"*6:&=6)W1.2D2#%Z9_:J@HT;G@F
M!0_8@Q;6ZUIJH/>N^P#M`U*PWCNL5PN[>2\BM+`'];9V'/QX`'__[ZN%.H%H
M-P2^;RU]9%_\\@;!][W3?-'[W^.NM[_J=;`C^JL%"H,R+Q9V<(?QJX@4O/<I
MK1V$:5+<O!2S&%003N\>-C'?`JOWQ+OQT&[VT.#;K,;!"$Y.D%N+W_C6]TY:
M,.J!Z+2'UEKX`7@;)C,ZW`P$<_B^E!!P@F^\XAUWN,E%SI,UU5``-42UQ@T.
M<W+2#.1XW8G-4$[@"Q^@!C5XT7KOZZ^67;LRRF28O_"K,7'3JP4CSC>]=\AP
MEPEM8RHWX@%O3C1[I\C>T/QW,)!NL(`#25N":-.!U2$+T+`Y'CD'2Y3S4Y`W
M:(L2@PP453^(]0\"<(7XS#@)!ZIUDW-L_X-:"S@)5\C/%:X0:S(?*`#]!?9]
M?E#F`ES!!@4H\)3W<(4W6!O:?]8"L&M=9T.H0<_CB(^V;5!L_$+V"DFHLQJ(
M_8,ZZUH+SJXUP6(=`#44&-?L5O>WU]M#94!9V48R=@'Z&XIAV]D9M3Q0NZ<<
M;QYHV=FQ#E"9DXQK43#[V]\VL<]RC6XRQU3`:OB!M=^`[@B$F1Q[`/8;Q/`&
M9/-W#P$*P*P#Q..*WV?85\AX"D)1JOZJP08K?\/`.1SR'UR!&H-@=[237&M9
MSUK<M(ZXL(M3[_ONX0=`MW;.36[.2:1`#340P0`P(-J$T_KF5_!OO--=<6^_
M?#?K#OK1.ZR*CO]>H0$B:(`-^&V-.R1!Y&]`@`V2H-Z4+HZ^2<CZ&WJ=X:('
M6[ZU;/>L!?%UH+/<!O7>0PKV0&N#%QUL]*7V?=1-[X-'H-Z33Y#,95[V':O\
MVL%N,@?1%DV<[NO4$*H)ASI*:F+F%!3(6A4\A;H>EXI6#0W(0`EP@(,2+/\-
M_!7#`)P_`.BO-P`#R``.]OX&'"A_^<QG@/-QT(#^UH#YS7=^"3*0@0E4N@#2
MST`=YJ]]$8C!WEKH/OC'/X`&W)_"N'8':H`!Z=<`]G9<#S`!ZM=\Z-=\&5!^
M>W!^ZC>!&8`!`H9]$TA]#?`&]M94C-!]#>A\[-<`\]5]&3``>Q=G^I'_?]/'
M`&_06GM`@"4P``%P`7N0?.`G?B6``!>`?.G'?PU0`TMG<MC'?LRW?@,@6M3P
M!B)0`O-7!QG``!B0@OE`9S]0`]E7!V50!S.(`=]6`^.W?.M7`_1U?N@'A"]8
M"+MQ!U=P?D_(A0,@!NJ%`$CX`_BU<PVP?ABP!Q=@`PR@?$>X?'66?8!XA`[(
M`#9P`5IP!02HA?1'?@6@7PBG!0B0`0"0`6^@>3^0?2$X`#]P`7.P!=KW@]2W
M=_P5`%@H?X]8`TVF8Y*!?&4``)Y(7Y3U##:``0SPA">(`-\&"N]3`&_0`-Y'
M?S,HAYNH?09XAQA8`@T0;6K`A*H(A3.8B6_P_X<+>(3*)P+V9H:!R(`(H%XV
MD'XH2%^)9@/9-XV-]P99J(L#@``ZE%VN]%7[A#FO,1)KU26>-#O;XTK^TE(E
MDVK_TS``4TL,\`$:````\`$`4`<U<`$7@``)^0$?,`!JX)`%4`(*^08/&8L(
M&9$="0`,T%\8X)$?"0`8<%]7,``>N841F0%[=P$UL)(1^0%U@`#T10B)]@89
M()$TF8@%=@<CJ9`(*9$=.9%\V``\^9$2V0!:<`$!@)$(R9$260?-B%ZR4@-U
M0)1%:90/"0!$4`?61RM:(`99"0`;H(C\!0<:\`$9\(E[(`(S&94-N0<#0)2Q
MF)0NJ'DI<`4X,)1#"?\!GYAD-6")"CE_"0D`3%ED$6&.AVF8$ID!WP8"9<"3
M1-D`#@D"APD`+"F1$`!]@W`'ZMB8=1"1%`F3C_D#Z*4%:J"27/D#ECB390"9
M:K"3F:F4=?");U`"'3E_=UD'>X<G+Z0%/\``&E`&#>F0-J";)%D"G[B:0JF4
M9:"1%[")=[F0+6F'CG4(0#9EJWF0)(A>*/4?`2`"DTF5#5">-NF!27"!#9"5
MA3E_$CD`_567-"F=#Q"4`,"#*8"5[SF:2[D'")"5=ZF5"5D"%1F3S_F<&."0
M;^"1)ZF(R!>1T=EA`^B>6ZB%\:EY-J0^F?-59N-"9V,\&<04V020T<,)!T+_
M"N$5(ENU%](!#('QC%B(D%3)@0Z)`%)IG$VI!@4)`)_X`PT``E@XFB#9`$9Z
MG#%YB4$*`DS:`($9@X=9`G30;L&XD(D(DPCY@`@PI/%I;S@)I9JID`V9`O9U
M!7G7`'`PFF7``$PJ`CQX`4AYB7!0`TP*`AOHD`'0EP!0`C40=ADPF67@A2GP
M2?Q9!OT7A'8JG3C*EH'Y"OE'FV=Y7PV`D`Q0D=-9`Q5`HQM8D3>(D#C`I'!0
M`G?)`*C9@V\`A@C)IYG(H*_Y@&]PA;JYH.\5'ZHQJ0K)`%,:C%OXHPC0G@H)
M![SHD$E:`B"PI2J9D"*@7BDG`E/9CB*GDCAPH`D)_YD7`'*L*9\V>*H,4*`@
MD(E[8*<UD(=9"@=VFHS,^@%26F=7.']NR50W.)FEZ9!JL*7;NJ<(L*HI$*</
MV*='RJGXR0`U\*Q;6)%\-V>$T)0_``$?@`.?&$9PQ)<?8)P.29\-0%\>US7Y
M!Y75MP<AUY[8^@,:RX=Y^JM\Z)H*67WJ.@!4V8-'FGRIV@`8$(0I@*5R:J?E
M*IT_P)$`@`,U>`$0&XO1R:!EZ8DI:Z@:*B6ZTUV:@A3-PG/G@`VAXQZ*Q!IB
MQAG-L@TI&E!S)0D7I!V.DAZFHQ+^F`T\(%HS2[/4ZI`;:9V7V)PX$+'2J;8F
M"P!QJ[8(R@!GJ[9R6Y:5JO^W%[`!+/"),#F9:4N7TQJ)*K::"TFDI7F'9ZL&
M;UL'9^FW01FM?JNV!5"O;]J#QPJ6BKA@UL2?:7NY$,FH%Y`"265R.KF0GTA?
M6C"I>VJI#DD'J2J[^2J1<*"V<X`!9;"6<%"19PL'"FF9:JNX]:FWR*>?8<0(
M^<>WLCN=3JJV&T"D@BNLL1B2#KD'RHF]^:>I?"B]7MB5Z$JPJLF:<#`'I^N0
M09F[EPNG"#D`>=N#[LF^Q<N+@ZH(<*-MD2NXZ'6VQSH`>JL%('"R[7L!J_L!
M%?"\-F"`\HH``^!].#``-:`&861BG0H`-5!H454`/!``ZWD%M`D"$RN1QVEF
MGV#_7[!+MWXK<NAKF@N9B;9JH#>:D+>YPF\0OWNPK1]PG&J;`D&)O>V;LWZ)
MI$3ZPL)*P]7KD#]@D]6J/;0R(V>2M>V1+Q"50\>63GW6%"ARQ0#Y::>GM;]"
M2N1!1#D2QAS286@KNUI0`['(A0AIF7OPMBJLMR`KD4E\F9[ZO'E;`PJ)B>T[
M!V?+QFPINTA)DVJ`NH)@`SM)E1CIN29F8O(:N9.KMJ\KD9;;P\7;HYL[G7WY
M`7!0>`#Q`&1INNU;NFUYNN4P!X]*DU=PNO0%NS*LMK0;NSU<R/1K@ZS)G.E[
M`11+QX3YR0YYMI",NJP0E))[N9`LM`F9Q$$)P&I[K#C`_X<WJ)"Z[+<MC*`R
M3*'FB[YG:ZO$>[FPZ\Q[2\UW',Q)I1O-RY4.Z[_OJ[??JI#)VKX(>LS6/+/(
M5\01:9,.:\!969IAXL&J::MM^0992:K!?+]@M(:OVY$,[+>/J[&Y*:9VFY"!
M^KSM&\<)R<,3_0%]&\0T^L8V6)"&Z;D7@)F:&;[(/$YRI4&K0\9ILSX0X1IB
M$ADP+9#Y8E:&83\)]3)A>Q31\AE4VPL=EJ1I6X;OBP"2S*,9Z9"`/)T8^0'2
M"<E@"I(#P`!679IO>:N6.@?J!HJ!3+AN.9Q+^0#5BE[-/,V(Z9`/4,$]N,B3
M^\B5O)`,4-56W8P6*<>;#*<2*?_#H4'0MVJD+,`"T?N067G*U2!@?ET'K6QB
M6L"LM#RS^TG-P(M>A0R_>KNH09N]=8F8>0N1"!G5@`S9)\8,SKFPD_W(HLW/
MRTS)(PF2;NG7:<VY!,S43;W1V8RZYGO0"_T!WXS:%XRMQ;O9"SF#-;`!6\T<
MZ06[;PHW-4:?SFS!<5H'<("F<,`"/$B7DAW,\Z6W`ET#U@8"?'JZA_!U=7G*
MYUPJ)J>XFKF%(*"NKVK"/97.-,H`#8``/_"]9TO0BYN0'6W`"DNC_6??9QO:
M/=C)QXFZ)N;95&W5]&VI&Y"J*HN)#7J"HTG2^IVE_3>EVNTRD2`V8<((6X43
M/P0/R%+_XCH11`@1&"'^-_X##`D'XCR]XBMS+%OB._Y8#EK0VG4PV6N<D"`0
M@?RMCDL-BNCKF@D9U3O&NS,ID1H``14)N2=;L@TP`%0^W8(KR(8ZY:TJN!2*
MU^++UV"DRC\@R>;,7W$ZE!))!*=\`07@Y;N<I#O>Q*M!EFAND`KYIH)\RJ/]
MJ`NYV.L%R^3[`'R\LQ4)R&IPKMA*7P9,FU%MN)P]T:S[N:C+W`MVL*4-Q(.Z
M2I/.SQ*9B(RMX_V7?650!I>LU`#`OO,%18*@B-A,L(/*FL1KP7#)VY`=1@*&
MUHD>1O+]G&NZ`4?;"NFUV8*+3_S%F@S@D!=VYI1)!!4PLYM=_YJ/3&3&V]\<
MJW$F5\F>"[J4(9S'FI#8&J"R^`-^E-Z^6N=E\+N[K-Y3^:8S^P"VZI<+R<"V
M7N`93=M&O>2<*;@_\+Y"+GX`T*V++)VP2)0\^8`5*65M`J*64UWED3IE'!RM
M,WSX$TFJT;4"I$K+`^,4'U`6WX^\,+8Q315@&N<=MI\):9FS&;'B![>GFU^K
M.\>('*&:&>J'BKZFCJT;,)D\60:3FZ1USM'\:V+Z?<IU7`8\R`_"V9?TS##)
M79B'.@`5T-YXJJ<97&B;!^?`.TO@OJ=S70%S?>5@W?*>P.>*?;I_7KMH*>@*
M:;EPA^A\J.@ZN=06>ZP5B^SS')B[<?]1S)L$SOWVK+3/?OT!GKY>K;WDAEJ]
MILZ^#JL(Z]7JBKASL*[6Q7[R,^NPMQZGV-H,ZU6-1'J0>XWWVE%34%[#)I94
MB7:LQUZM9N[T=`VPI_OL?*AA@G#V[XL!K_J]*9;C$GV_"+('X9BJBTP'8)>0
M"2S><E`IX@9VN5B2LLC-ZZ7(0EGWZ"6O-<``.GN8Y8?(7V?@3$T-<,X`<!#^
MTVVI0DR1#;J6MUG')-V#U8_/44YAT^&/*=JBFZ&B^\A.QT#_#]+QB00($8(!
M!84%@H:(A1&)@X2"D(N,DI.-AI>+F`&/BI"3GXR<H*.,E7LU```9:A=:*0\U
M90!P%Q=O=:G_N6^M#P\I-AD?`+LI<Q$/:@T`'PQ[M<^U>PW"):P_#0TXRV4;
MM36X97!P&<L#SJTI6G"I=0UO#>0`YA=SA0\_.!]UW?3'TL(,6$%[%D`;``07
M4J3[Q\Q9BD^^Q-3YD.%'K11[YJ3PMJQB0BV0M+R)=Z65%BW*`.!@=?)4JE4F
MU8CX\&'>QE-E]%F,-D!8@XWIWN0\6`NDH`>+'D"Z(Y/FRH2>)CVPA0N`C8]:
M,+P$`4<6`!'G+JCI":!9PGK'(IQ$19'5Q@(#EOV\\$#+GK@?&CA[8"S"GF3"
MYBD]%DW-FQHB<`FKH1!2`#G(\M5Q:^S0R;AEB]J=-NM<L9N</;Z"_U3WPH\!
MLF@"_*&EUX,[=S`L/EM)J3)F:O`!9+"LQEY$CS9>V//C\("J^T:WXEQGYRM?
MT8IC8."U8C&U:K1]J%%+:2]4\@0.-+ULI9H2-,VI"59F%[2_AZFS^Z%0*250
MF`YUJJ0_48%-^B'BB23Y11)@*9T40DB`]U&227\.0G@)@`8.V,@D`2CBGX68
M[(??@1H*&-4@AJCADBHLI</6/!>0I4LKQ_P2S#`)'?)`$K<Q,-XS""Q3!T+/
MO-&1>PA,!%-*`.@5TXRYI"+,9'0)HL45P=3AGG?2I&+60&\9!.1PM]`$0BT5
MIE#D!]7L>`%;,/%25PHC">/>23.IQ))=X/^E>=)8Z86E&YKBW>63%JV8%L\\
M1JE1P!ND%9`$GCX"N8<O$?!@(U6I6*105N4XDU(=W"5T"DW-P3B'%FI<H886
M;(HWEER;8B2"7,YHT1=3*2'*5R'CG9D7F0H6$)E.M?15UQ[YR*/9/TFJR18`
MH>[AUST"J8%``PPHEM=42K6F%;1GS5%/AGS.4LL/)>1"D4721F`,&$KQ(-XS
M($0:I8HYI9E0"@7\,.]P*95!WRM:)*%=J(-%H%5-80WT0[[.P"$,0FI,U%Y"
M)@[T:J90(8B?*,#U5Z&&EXBXWW\@6A()ARA#.#+*41'(((,+4FCR@"!70N*(
M_RW(W\OW>1AT*/__J6$B>#"=Q&JGY\8C9\>_3$3C0X>HL;"^>_PEW`\S,K"3
M+1WMU*I8O'U0AJ2Q"(,##G64D.YLKYQ*I3Y7JL5L">QFG36ANH%*J+7:>73!
M@,?DZ5POKJRY#-[#&6VT%NCZ)%QV3-MU8II[;"8,'*P0A]IBA&Y4KI+1W`9J
MYX8-T$!=`IX4)P!X._,7!@.P-M4MJ;C7"GCSJ%&VE4$.57NM:M30`"MA_GC.
M&^A],"9=F]'*BR!_Y5IK+V\,X!LTYWV@`<(]8\<`L?S.X=I=J0Q05-:R*8L.
M-,#0Y/7>Q0_`2J"G+5,!*XRDD`P`/TH(7S[!IW6=*UU,\U\!^O*0!M1N_R!A
M$HT_>H0FY_#+@?2!1MI*E8X4&*PW13G*M^P7C3T0S#032=,/:H``9_Q`:MU(
M`08;]@VSL0(I(R(9:4(QLIAM@A,7BE#*9I9#!0$Q0I'(&1)Y!B"7K<Q`#0K0
M)F(6+,<0T3X>XEG0%D&(:_$&`&5H``)V0D$69>E%#XF`C)9!#+3LX5MU@`,(
M&B`.=]PD;6BJP0^NX2.Q+4X@7*.)1]!7$W\9[31J^PWDJN0><9UD&OI0'3;@
M,(`-N!`]*L%&!123`2#QI3(V8M-.C**6->6D#`R8I`,1L)%Z`5",",`+C<`$
M`LRTHP:[8%8&&L`5<OCD'-:"1RI*($9`OBT<-?\P7C`:`!5)1(\:#4@F:@0F
MDAI@1AYZY`AN:H&[L@CDC+"+IC7M)):>Z`,$AWE;J<1BO+=E``0(4$,:-<<P
MDX@D%7#`97'PPC@MW*$`EE(+2E*!$%O91YG"R``+6<(9]:'C.</!P%"(*4TP
MLD)U_AJ.Q#X`!V<(PG\]X:!])/&LX45NF&_8"%J.\H">[!(!;RC.^.0QAXZY
MQ(#TZ,4T=OF&-]@``9A44CJFY$OP?<='JH,#-MS!MWS]"X5FXT=/B.E3&]0@
MJ!YED(62T""6<6B*2IFBT(0VLZ$9T8H]?%`/=49%4=@,B5U%*Q1-YA\0O0R*
M0W044L8G#">!ZP(4G$O_+7RWC*E]-'X?:*,@_K<,U=`D2<)Y8S`>6X>J,$YQ
M;7D&'LTCM2_5@H(74TH*`GFV[OB"(8YM[%S0Y:349L`]S^G$`Q"0$Y&2AE6I
M<:P&:C)8O&B@M>T@%%U<U%API6`=K7WL+L432+,Y26!!>IMJ`*`!4#7S$<Y(
M1FY;FZ;;J.M7F"5A+9`D7IE,5K?B9=YC@1LJTPS%KV6X2K?4(#%Y7.\!;X#`
M=+55@BO=06<BF0A8H#*'./65)A#824,=,M*I6&TBCG4**V::`;>%#2M[L,%$
M;`)*R\`E)_HH`2XJO(T:R!,I`;J-,+RR&M,B8V&B$=8#,+#;%8.X)@)Y4T%`
M_W@=I;`EPM[#0"TV\,?QD)8?*@9C<<6;,)G9U4%9M(2$;F8A+>;U$/DI65I)
M$2(J9MFN7F[0$<6<1*UZF4-G+@"J&E`"!@S@S0Q@@'O>L#8@;2I[)7A@,31R
M!1&L35/B\K&;!Q!G-\>9E0D!$YLA`($Z9&``Z!0(GL4K%A`4VJ>$/MY%-G*-
M0X_F@C@8P%7H8KX(U"#4`\#!H%6-Z&08>M#1_)I"ZI$(_*8:#@40H(!L7>@X
M$QH'7W)U!AC]Z#=X)@6G[G6HKW(*7_LZUL*M10&P->@!E$`$;CE7+3-0V1+`
MX0TL.0;,_O8.$3L:!^[X[-K>3&@&`"E[.*A!30?KP/]E/V,/>*YL!E+Y-=-D
M(P-E:!L<?A"6L;1YT&[.]5`+D.SMM089-8!#"1H=<`:`X'#_K83_QN<1D-0C
M&]5.)4L:'CI:2PE,`^#VN=-MBY1#H`QE(*9S]L294%$M*74I``9PP.TR['*/
MU!Y`2F]^C!5*O-&,UIY`'N*:-\19T\;PQ0]J:6Y'5\#$%T$<CN+<1F%%():]
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M,;Z@$([C+PVC%'=@'W)0`!O!%E!W*K)7%$!Q$98C'+1F".&7?D:C>^2W?^(Q
M5/@6#&V"8I0068<T+['W)BBF1A<!@M/G';U@-,G7#R[8./LW?95A-UFC4J70
M$K"'$35(>C6(%KZ`*L@P$-&'@-`06T&D17CG57]'-%UF=QWB=U.H94\F1(*7
MA:*P_T6+5S*(QW<JDU9F10F#@7[D=WWK9PSS1G[B8AD#\7D?I2;%$FB)HR;4
MAWY[:(?%)RXWN&GUL(&CL0C1MB,:H88#H30F>'R'&%N3<"IV:(&*N&E[5HGO
MYX</]TD[0GVEH8<CE0F<AXF9.!YL^`R!]HEW.%2@6("5Z(FDF$8QPGK'P!>D
MV!K&D'$%T(!J$3EEP!V7V(FG>!$_4Q=Y.(F@J`5PX1,7D8$[Y('(.!J>H(KC
MX1H)PX>#83Z'R"5]81FHMWEJ08JEV(S&\HC#R"77@2!.9H87$GF"5X:'QX4>
M\V5+-`I7.'@D@WA@-E<M,T1Z1W<$(H55N&NQ5WF?9XP%*?\'J?APG]<7=M$:
M>]:`1VB,0T5]#>D:0%%R=(B0MQ=U\F>1[A*'1_B'@(@XN'@)KKB'N*@1>!@K
MZ2!0_`$BVOAPG["#KEA\ST$U*JDTMG*0;[*'O3!KE1>`K0$)GT=]=O$9GR=C
MX5<?A4@@&=(+B;B''3F5/>E(MN>3M5B5YD.5];%KU]=!#=F0GJ@T=5>`M6@?
MXB(<L*@4YG,'20!$)A(Y5C)K'.F)KD&2/],7X6A[0NDNU-=_O<`(RJ`!XM5A
M*W,L36F+'?22:7$4LWAZ>^8:BU`?N)>!=?$FDKF4^G$LQ;!`@'@4KH"+%CF3
MKO!)*S6*`8@XW]B0X;,SG<!548C_CU"9(61EC^U(=R?C,[A)"KG)91[S5C+C
MF_ZQ(&%H=R<#AF&X15%1#X!8CEC4C8\9AVAX#"8WC2S%"-29%(\I"(#8"%))
M&JX!F>(6`-0)"9]Y?(.)">.9G=J9FNU9"EA4CVD)$?99B]9Y((,YF/G9@)9A
M4(P0GH?`EX,Q&(;PG<>@!BQY(;[`G[U`C]W9E;NR0`LDC=.X@._9G,XYH-Z1
MBHC9GFX9FHM0:M03>#MD(\7(GSDDFY/0>P@@`@P@;Q;J&GU!H)\@"38I@]DH
MG]XA)?QI`R*`4=/#,_B9%J')4@E3(?;`E\]9(=&9@9TYGI<YA@%"A_:@HJCI
M+MDYH&RU_Y[3V)[;N8[NJ(_W:(]?*(]]5R"/)V4TLYR*]V1DB*:1!U!1)#11
M:8]*6E;,B9UUYS(&&J4Q6:2$(UMTE4/XV3.`.C2]2:1\.H8[1)Y7^JA\=W>4
MN8^6:JA2F*1%)*B8^J@E$Y]/Q'AV%8J0^9N,BJ=1\:=4)*DVHJE(Y*JU-I#)
MF99LF9F[-B)-!H9IT:K<^:A>BA0>F(ZK>JOTN5:J&C.$8Z*.IZ)1M(6[>JB=
M*JN`IZD?(S)DY2!-=)QT!64`&439:H9K^H]7B*AU2E>V67B$LW@V,X_^N%:Z
M.66S.JCNNJ>-MWC#"IR^J7?*:I]R^J[`<:?TJ:B3JHZ/H*SM2O]EN=D?8'4S
M8+:>S2JO8K6M5=:I^KA61#2QP/F$4;9W6]:%7>@@2?"8WTBMF^H(3G2?BSI7
M&U@CVKJG3HJ<>7>J!HJQ6!BS&GMX8?8R!1NMN'EENPEY[2BPDYH)9\J.-#NF
M_XBJX&IE.'-$')NTW'F/=06TUIJR":NP)QN0876Q:4JT61M$E'"F8J8?$3N<
M[&JQ08ME8L6F]]JL-/.O7ZNMR>FM9.NTNMFM6$B%>KN.8@JV\BBJA,=#:-NR
M9KNL0?F5`QL!0&2W'X*W.E2`:WF=A7>P/7L@BUNU2R2W4HNUMZF.]2BUM@FX
M"<*UQQFVG+NH\+JM?NNX`:DS@9>K;[O_MQ>+HFCJJ/]1A7TK1+9KG.&ZIGEW
MM6R;CP\"5T'[K8ZK,WY+I>0ZIL,[D,/KIEB6O&R*N<5K"1%[HS$KO-!K",+I
MN_PHO5CK1**JNVD+H2(BAKK[KEKXM\/IL&5*--%[LU/+,L";NE+FO,V;1+R[
MOGCGMF3:,HD'-,@9DRECG-S[N_F;L_T;9?`:M++:C][[(>T*MKS)NF/6OV9E
MFQ0ROS#CK;S[577K,O-KIM&;K@$04(IKMYI@I_];12E\L@0<ML:K(6]UN=B[
MN<KKPNO*C[CKJ!@"1#QPKCX[MGGU0__ZK,AKMEFVJP<LK@H[N0K[P5#TA4*,
M5Z%KN3F\K@O[_[R,MZL_!(8U?,76"H_P>V7VVR'H6V;)N[8CG+\RK)P`%;K=
MZ[E9.\,3`I5ZJD/8*L6E@*B.<%<Q'+Z]>L<F>S+A:A\S7`D+6[8B7+AJ&C.6
MLL0?(\9P2[_TR+<7'`I*-*Z/_""4K,G^V[Q@:\%!O+V*=[;CJ[^F'"*9V\!?
M'&9\.[L)_,H8+,D_N[>TW+N!NA^9;$1FK*?`+,9U*[8%TLFG"Y6E;,EOJL2]
M;,2U3,#\V,O)C,':NW?2##*7C,.R&\6AS,6#"L"W"QR1C&;9["$^8[T[/+5?
MIJ0VK,G8[,:;"QR/E\N0W,ZUG!_".;9)J[U9=KU-C,M#_&7$W*;[O/_.R)O/
MV!K%CYG-$T+,7KC)!OT?*#RF$;O#&\S%?IR/CL$))^QU?0RA/>/0<I7"5A:_
MFO#.?XO2V;RN]UC#!;S2`SV%Z<S0(:W&!*VW_"PA)RS$_UO(RMS//!VKC#?1
M@8S/"'W3KWG/$T+4^KBXY\K*Q9S45+JV$`W3`LEX$%W4]#P@T]S!,OT(Y!J\
M65B]?PS*Y8S(I^N%(8R^9+W+C(#"6#UE+GS$H(PSQVS`;ZJ_(:.N=QV_`YS1
M%0S0<*O..PO88"VN<(W7)MVT`TS2XS+,)KV[G"M%<LS-Q5S8+AT58/6:$=V.
MF1T)05S)G:W/[[K!H;VUG*S/`.P)'5W65&C_ON8WV6EA,Q>-UVZ]S99KP^8+
MGB^\ST2#UF;-UNK*TSY4MXJ0K:>LUN?;SOTHL,T=O8J]UW4-S=0,TD9MV:N<
MQ!Q,RX\<PV8]N6!]U*N,QLT\9BU<5[T\VF0ZI^K\,QGMWM0<R'/*T@:<KM.+
MQK79IN![RFQ=R7M-O/D-O^[-TCBLA1L,UD"]S)'`5>N[Q&)(W\H+Q6J*SH(\
MWAW,MG/]OA/NX.CKTNLMJN?<WJO=W<:LSM<MO,I<U`*=R56&U3\DQ\*LQ>.L
MLQS-W>;MXA5,(#S``[/]XL;-'S4\X^9<XTV$VUHXS83:T8CLS)P]X7;,VN?Z
MQ;+\SRG\S@_-FS>^_\?+*:Z$D-D-33.!C=0OKL$('L"(@.2W[,[AC>`3LM'^
M3-D*&\3,?<!1;.6X;./+;-F0D`1\SN5X3C)?6,HMZU8OOM'YZ-1B2]<AS>*@
MN\ETK>8;K>#?K;,H.N:*SKU/W=%R&\94K7CT;>=)#2"T+<QQ_.AHQ=9%+M4"
MC>;`C.G';.(2;;.\:0BA[=K0+-'8K,RIKM+^L>-<V]N*O.9^M]1%^[V^#+4E
M'`I(+F5L[L>-Y]U^3*J^.^IYW=``2[ZN[L1^_=9,;;/'#NS:K2"U3ISX7.OC
MV\_CKKHGG=;WJ[A!'+*,`._3+E:M[;NX3KI3&\8Y+=&6<JSN_>WUVM3IGO^^
M/\S-**[LQ2[A!R[2"/_K`OWJ#N[K/=SL"Y^GWOS?TRW?=^[CG1OPDIS0W#V[
M`RW6393/A=?M4JO*&;U$SARH*5T($C^YR%[B>[WL?^?Q&Z[&.]W#..W==EHS
M2JS0H\N_>QWRNYGE+Q_2VQ[@1?WSRXOAXGW#GKX)\-[G@@ONSZU52P[P1+3R
MD>W*1L2X>)S30%,S*BP);W7P:ZS"-=[JK6SV7UO0S]VM2M_Q(R^FKUW;A+[E
M&OVOR/VYV'S@5>O.D3TR.PSL;OSW#6[J@EM73:O8%[OS=KTS]U'RVISQ>XN[
MHEZF]FSOPVW0D_R.C0[Y-`Z%^-&TNVWP8^UX2K__V$/.UZ/[^+;,]-I>O(+.
MYU;/YW#.V(,7UO&,^3*_QQ?]\FG6NH3_\;L_^=AK()!?N(=_WUZL^'V;,S7,
ML(7.WE-HA1T"W(JLMK-9N6'(Y'/LR`1_W&5[P31/W94P[N.?[1*^G`L?MZ/<
M]U_NTTZV^+?M_DTNZ1(,"`4%$801@@4!`8.&BH2'CH./D(6'BY"(C8P!DY>2
MAHN5@H6?B:"9GYVBG)^2E0$\IINHK+2KE:.NL;:-JK.LO8>OLDF)21%)R*F6
MK;>7I8X\LK.AR]6>P=&%B92@H=S=O<ZRF*#?UZK>XM+/S,V^Z>*+S]/PY^&"
MPI2\RXK-[>'?"+&+!,R=_[M?MZ@%3&7.&C6"[8PAFVAIHK&&JI`)2H*HFS98
M'7]=5/;PG+ED#R,\.&91%+Y^$).!D2.GP$1(Q7#UXU@)C$UBX"!I!,>3Y"":
M,-$YY&6(9L:)LI*F`XAO$$=&K:2&HB@J600PI9(90S0VPIQ#+2'B(W23+<]6
MC$Z^C:!H*"6O=`ERXS@2*+5QQ,8R@^EVKE&60]%=Y"K'+%B+<M\&0'9JED:L
M;A&!,?K0JR2N'M&R?3E9\,:;(2<1<]0OTX-@"8-E\O2K(4:7"FLA=#BJ-^Z7
M>@MQ/-7Q'O%YF"[Y1GYPZNS9-EFR+%T8+\)C&PNKI+MII2,YT+.SMB1PV\IM
M0O\);>YX\5#-4<CN)#O[GN6@LY/O%)H#?C*DS;[9LUE@VI#GEED1(+7('-<U
M1=-[!<"BG3[1<5>`4PQ:-!(C8+SV"D0JS<$@6#X=:(AZ:*'CU(0UC>33:=B1
M)0A_-?T4$":+;2B?(#4Q&%U!;5VHR$I`L6:,?BNEEIM^&HT4$CG*J;32B@^@
MYM`B_26Q!UT\`$@6?#R)Z%02=^C'329V'0-=;TE0B5@!8(@X1TZ")(E(>M\-
M\@"1C=CYV5!R`!AD?J/L*2*.27@G2(G8$>;G>)#J1!QM!CT7%"[_&-@;*9%\
M2&E!]@#S(6N95(99@^90V.EOO:$GDI/NQ+>GF7N^5L#_`RG4.J>FPK4EY:DG
M:B%L!'MHX5U>N&JAWT%W[.%LL1X6L$<*>R#Y2:*YRFE3LRNMY*RP?O+3%9G0
MBL*@2F7>8>PM*>1ZHDK.XOJ`&MU`MZ$HQBKKWKG;EKFG%EL2$FVMA*BK10J?
M[$EMF5(:6\B>N*P8WQVX1J"&O.<2LL<#RAIR[(5H4?S`EKJ,_(#!^3K\*[$B
M'QM!F<X*Q`.\L^2G[,$`JZ%2<39NG&ZSPCILITI:G+4(Q^OJ>7++'(?[S<95
M'H+?RTA76RO(Q$X++H)*5RMPL0$#&^.>S\9\B;]$*RJE&OZN)&+#`G.\,2JS
MEEGDR/*1JF6WX#YP+IG&$MSR_V6UCAQPDN$M!PXPNFD2)6VZ';3IXQ&":$MS
MG_HS#GE*$J;,;?18PQ"FG-OPA@U7I)ZZ#39L5P#KJ-^ZIQJPRRY=`+`'H`5V
MGYBN>@"IJW&PK8A<<7IPAKQQNNJLR[-Z`'//D83J9@FB[AX!O(%`#36\<47,
MGOAEU>I7N$X)ZU<$L&<DM;.%?NH__+")RO3@$H'J5PAVZ"#-)O'&!!,0PQM^
ML#X][8%V$\#`!&P@K8Y=(7[>@]T5]$07]$%L*ZNS0?Q0=P4;S&$E',0?`XNE
M!9<<*0FULQ4A>(`ZX.%O=05`F`0Y.`AZO4]XHL@>`QTAI>F]00PU0(`-+H:X
M1>@'=__H<V'Z?J!!G>7.;XOHH`UX<#4.LBX1/(@&50H@Q?)A110L%.$/&I.@
MY26B@\?;DPMA]P,8NDX:(GN=]KKW`S7,K4YWN((%Q#`!!+RA.Q$(8P8M((?U
MP0YUB)SB=H#'NB3LKGJ^H\4>IB<&!;YA9MY!XB%M`+Q;&>,\-A##]KQ'P=B(
MBU2@"E4_."&*1W5B<@%23N(>D9O=<`,:ZPA*IC!R2\?5(B6Y24PX;#"`#)0@
M`\@T9AU*\(8+[`$!.$`F#L1PL#NHH9@XL('#+E(#8Y9@`#:8FR&NT(!DFG,`
M-;B52M10S@R(0'T(4HD-HEF"$N`@FMF\P`/:B8,!?&]/Q*S_PP!^@+`Y:"$`
M&&!`!LH```#4(0/H5*=P3%B`"3#@F`QXP[JV\X9H9@`'"`A<`43P43$4ZPK8
M-"<.&H``VRFI&S\H)C(Q(+Q)Y+$&Q61H&>K`@!K\@!`I4`,"BEF'G2ZS`070
M0DSK><QS_D`+:N@F1&.(D"N0U)S*Q`%!V5G/9-:3`1@()RF(955DEJ`&%KL5
M.Q]JUJ8BLPXUT,(;DHG/.M!4"\249@.@%@$,?'0"'US$&TA:U#+LM*<$G,7(
M,.#6>V)U`&JX9C1IBK#[D?2L%?.K,;&:`;02#"4UB*8(:GJ(*C7@H8XU9@T^
M*%5SE@`"S'0F!CSJ5M5>;!4!&.I"_P%@6(C6@&.$B"H.ZE!8GM8@LN6L)PZ:
M6H,]7``!6.VJ.W$UTF6N5`VY>D!',X#4L\QKL#B`0$,?VH`W.`N:T2T!7)\5
M@!HP@+@ZA:@8+F@OP]0#<ZN2Q^8L]Y8-P?))`SF34K)2BH+@1"MJ,<5@#))*
MG@&G7HHI,"54<H4,?*"A'\@P`"[<S`O4H`P9_L``8@@P!G`883D<0(@!T(!A
M&2.F&B[JAC]0A@9$X&!S4/$'&(#=\]S*!AG`\(4!D`$;.%/'%\:`<^5JX0P0
M=`XI",``0'SAG<ZXR/3S##$&@&$64U=C-=AP0QE`T`NH`0<7KL$%+I`$"U^X
M#C-V*%(?.?\-]+Q!S!\HP0\NP)]&D)/*O&4H$2"@T1*>5LQ6YK"9W2SD#.O9
MF0UP-$']](`KE$##>/Y`'?:\!RY7F;<:QL$;DJ2E/4R@#AIF0%(CH>,98SK#
M&'@NG+O\@;U>X`=N_D`&.LS.)!MT7G[5\$ZI#(&0'DL6#7!UHS^@@1+8\=(:
MV&NNM&#I"[<8TBMVM08P@#0B):JO&\8!=EE1)1$,6<QPO4`*(CWD$--X`\X4
M09S=#8"X?BP2&)@U<8N:87$+ZP<B`'2B-[V'9(NYH?5.@8<;C?`=*UP-)MYP
M'1"PY@>$><<QW!-T-ZR!1$?;N0B8=[NOS4X0.Q2^%QY`Q1Q,&6G_P$,JO021
M-\BQ.%B2+A;(^V6E)*P<`&M%YZMD!<]#!YM@]'PJ+9=&P@IP:0#@@'L-:``&
MCKOF-\RZH4IV)@,:VDRC[6&N76:`<X\Q+Q4#X*QO.&V_]QQ4>8O8N=&*[!O<
MV]`,^%$-SH0#PL^^YPM4.,]XIQ8&Q'Q6"#9@IT9&<87J=`4<-)S'[E))R!%>
MAN::.>)J-G/3&;"]<HJY`79<E\MK:/:&EJ&9*DQ"OC/<V1]LH`;BI;@6$(!J
M7=.Q!B4`0#/5$.2S@Z`&46<IW@ONZ,`WY<8_R+W3N5<#$#3@MT?><&>UYVD6
M1P!ALW-[ANO03*@*M0&_W[I#X=#\!NQ9_PUSGS4Z?^#<Y'=Y`,XE?N45_O7:
MPS5^/^AFO;=6X+2#'PZSUE/`1W%[X'@```(7`#!0A68LMF9[@`%O]GR_AP$-
MD'BDEBCL%&X]Q@IY-%0(5UZ!9W`E\'S@]WS#EVRZ1H)1AP%[MCN@<`=@!P`#
M%5D_T`"P-7P?=F%H-W=!1G'H-V6\U0`;@'<+UU#D!P*_5P/P=GGG-E#.%'(B
MAG=XA68T)H0_\`8F-@`*!X5U\'S`!WQ&=@%6=V%P4$=7*`("53$!412<P@^>
M\PX$L28Z!SF3TPZ<,CEO,6#`,F"7(C93X1*3\DJ1LP@:TA8$4A634$(6!@"Q
MMF:.N&:S=W6ZUO],G:9H*%9P#:5\IZ=/-]9K```'SG4!(+!ASK9F:N!V\,=G
MG1(!D+9A#*!PD*AW>P=9MX9JI2B&;D:+COAU&%``ZI81VZ`%879R#A57V16)
M>[=K6G=A%*=Y:>:(&:AI(?5(GE!IJ$9<#05ZD?<&F]=W:Y9_Y^=ICP:-/K5H
M#=6,C^B`*%B**?`(0<6`F9>.T?=VIJA\JJ9/(S-7FC9KUP8UL#B&XYB.O/=N
MD'AKR@=GZ78!D59YIFAV`6F*W7,P"#,.%_-PN?<!F0>+!=A0\;B,#9B`$"B#
M1)B.BB<PT8@#<%<]@Z`%8CA>WK@'PZB+Z8B)M2:/:Z9X*SEYROB(3*3_<,EW
M85K%D^6X9K2G:=[H82"6`2,ID%RV=[9F=3(8?^S&?;!H9MU#E!LFD^D(@7G6
M88YXA;\H.K91,X'H"U\4):-C<W`X"J.R*3RC#:6R7Y/0"Z?@*B^W#[AQ2W0I
M#5[Q,VWS,L9`,OM`"`>UB*#G+)$%BY&H:T&V8\YE=AU&"#\`CQ'7``DX,FH`
M!]:FCFD6B@^`BF.G%PF(@@SPB%J@F6RE:6HVD.*F;BBX:3;)DOHT+D,2`1$'
M`DTI=D$E+`C`4`^5E<YB=LVH!DV'CHN68?"G,NRQ)R&)3G"FC+,S>)KFE8[X
MC[47C[#8+N;(8H@96:&H!>N(=\235&=V82#0_YW8Y8">-@"[:(\/<`'P(H(@
M@&I.=IFX4G6V>)2P.)``L(0^J7P#\)Q[!H$).8;U9I/5Z2$\))L0MV$=Z4P&
M"'IJ4$?<:)Z0&))Z]BR)F8#O`B_2*7:<^#?O>6<.-9(/.&;#IYWJF)78%5F)
MV2YV(CR3)U#L5Y60F(,,29)5N0$@5@=+^6$.95XN:D<-J8/7V$P_`)Q,&)7R
M"(M0F*%#ZHA3:7Y01I+O,'H$ADHZQT.^-(>F4H?5L"D2$B#W@`EQ>2FIP1P)
MU@GL,`^[T2FG,#%^*2SIDE9"]S!_YU`#P``,L%S0)VNU5@.S9EY-28E[(JA$
M]@-TT%#PEUV9J8-3%_^@3)J`IZBD38$OT?B*ZI8K7%8&O]=0XK8')M::UX2B
MINB=W_DV-J(24+EI;Y"4>T8T8L!0`U"A`(``E7BK]?B,T"B.PG-OWV9VS65V
ML>8N[-::E]DNL`BDNG>3(E*5O#=>?'I/3[>B@#>;(#-)!LA3?'I,<36/J?A,
MLZ9F"#-)P@IQTGB9*J%P8UB??/:LM[:(Z)@"[C=Q9K=7-:"::W9QL,EG=O0L
M-VDA2O.>Q.F@CB@L9R:M?5I/)H>`(%EE)<"G%P5Z@>,(B7*B]%@+''-GFC:2
M^S1>`]```["G68>)#F5/.*!0VN@RM_*J"/=1Z_>=[#:.*5"EF[J%U_BC"!?_
ML2G[365V3:H9:0#`8VJ`:JF(:[R:@!+II`QU=A';IT%9A+RU3#$+B:="2XAX
M8("X)L!1'E<B.6QBA[TQIF/Y16W9EGP(<Z02=*B0"&=J%#!';<$WMW0;?+_U
M&F-*)DB[;$!0`418E.<YBCL64USG3`=C;@VX!T>JM$";:2GGC96:L1$B"_-"
MF@K7+I5ZJZ)J;5BH:[[8H)_H7.S$`",;LNRGJEYQHC*X9JBFJT&U![/*G720
M89S7E,WXDP=ZLX=GE-CJ(P601_2Y9^S6J)7+J$LF)V:Q9@;GHYLJ)R)R`06P
MB!K@;B*VHF=G?!=R8P&@?-1+!.$JBW4`!PW``.(%_P`BL&0K<077*+PI!RT"
M(U?!JV[.2Z_R>K-`UK$<.W&#EY"#=[U660&E:W[MP@AC*@CMJ'R9)R\)RU#T
M]H$WVG`A1@1ZEBL7LQ%[@H*I^!KO\2]B(''>^+$0_`%`4(HFZVHBK)3P>1\G
M$HV81F1EB&T[%GC.^ZSMDH/,FX!%2+TG!E4FMFE%6X5CF(J].9TWZ3"WHG!`
MVKT?T'=`FVU$1E/8>@T%9@UN*P\%#*=5,15:!!";,AQ].`I;;!-9K`\P@6#D
M,0[98"&X5!DE41)SF<;!.(;GIL,A5@)4!1..%+TZ.+=P@`!$.(9PX(PRN(C=
M=\`TUF&:R6(L"56)+%`BJ_]\L:5/&)R2E5"\#J=NQ0L`=-"2FA9-1/:YXI>*
MKZIAO&LG3B*<:P:$`\"2D36KU;L'N5<&QW2.NYJ[!M5I22F>V8L8'^I<'.NN
MF4N+10-%UP>>+HF/8E(3[;B((SBW2TB3['A\2@7)P0<'`X``<V!F30G!GTB$
MT6F\8BB@^F0T#R`&\5NS<D)M%E8&%/>LN%:B>R!O9S=<"8FH*`QQ1'!A-#:-
M)!%E"+QF9O&.F5C-DOJ1P@BRP8=.>&<TK?2QCOF+*Z(2_,IVN2*T`E6Z#-``
MV6RR&2"^43<`((!W]'!`.)5K")>*I"F>VJ(GK`5B9<!VPM*_,DBW1%BJ`+!G
MPPC_47#&GA?`HT2<7711$QP#I(X<=7``!R/)52"F`92W5Z\1*1&B1;?1QI`R
MN5[+&E*MECS1'ER\0DE1Q8OCAKAT<Z'PU6F,"FGZ''WR"S#W=7O*IR-;`14@
ML0`\LJ`',8$T/\1IH=6YJ?`K8@JW`9+8K`G8FPTE`MMSD1D0`)QIOJ%(N#&L
M3Z")S!WA+):[J:6:HT+[LKX(S7BG!LZW=;JV9]'RO@:*3@B@7J.-CT/,TZ.\
M=YFWU[E[,'L=V5"$#WO0>'6'``C@=NQLBL?:=V[#($/=M)'9(P4@/);&D4UJ
M+-+)CE-R*Y/)U]6)N4W)75/&J_DRF77W>P6M9B54)T7I_V3H?"Z5MLY=!V7O
M?-/'B7#UO+Y\!GR2^MMTQ@COD0(\\,\((P=G$:&/*-N6F8#Y^@'(NJEK=A9C
MRIS@/)YU,HRP62M<28O*JITTF8KIF#2$X8#HAU/E"YL#7I_N\C8GD@)#7`>^
MF"LI@*C]^H@/9W:<5GJ,RI)[FWE&(R;7-\0%[JSO:8I72'?2]U0D(0R+4RII
M#"5P*Q5N"J:+U]6&D$5U4<6\1"I:"I?Z)1MM+,4UIZ5&;C%#VN61)2('U&-%
MI+V+^*!%7)1PD,WKMG<`$(:9R>9[EZ./^I'*6W><-MG9\@D`8W`,P)(#W*F9
MM[>9&'A<:)P75Y_1@@P7W&5[I_^OA:VDN8IPPUF<U?D&$)!F?6,AX@H`7\!;
M;([4`BYQWUI0KZ,[8%=K"O<NG&20Q2B/<A.>SNHQ/X!Y3=IVP(FN>69D!R.U
M<!Z5[:@GX\UV/G)C?\=]\DN_#=5WS-KJ\9ID/-ET"4S&@T"O%TFN_"$(!MB1
MFVO0($"[V<SB-5L<1".=&;S2-\:%@0=LX/R(N!*Y/,WB?H,?[U%',SF,S9JD
MF&Z?>4TLX=RQF'S0_FZ30/O256=RX(SK/-:[<C!$P@AB.7[@<T#O__V:+<@S
M8/T;4LP+0W>V9:P(26%S&4&'E.#D7>L,?`@E-(?R;2K5#S8I76NF+Q]@WXZ@
MKKX6QY#_1X89?U\.9<*(:FG^C27`U`T5AC:@?!!U3^]U\&9GX;/.HJT8A4;<
M"`>4F],"HRJ6HRF^=[?XDUWIB*/\X#Z2"`_`W41&K>IEJBG`L4R_B+0LR,T%
M51TE?5)(*I$ESW60!F;_!1\``7TWW6=G7GX350,@!MHL<4+Z&NZ%I$$&5Q,^
M+P=#?*-]0#Q"G@QXGF9V0%5:JO3H?HEJW6_&L\N%D&]0LV;Q`$/\:+\^&>K,
M6Q37+G@5RTR\S0G9:>-E><[XVQRZ&Q%?[?*;W`60[?_==`&^!]T^M,/GHOO3
M%.KS`!]J1VK@%,DMT1Z\J2"LB\YK9JCXJQC#+\^`4QLP\YP,_YO;SDP;,TDX
M]?:RYE"D/=1VKJ%J`&5!%7$=5G!"SZ0IL`4;5@:4=4`(``@,#7,7-64?)3\7
M>W.-A&H-`XH7E!<8`!\9BEH%`06?`:$%$1&=GI^CI9^EHJRMIJ2OH9ZDJ*2W
MM;01K;B]L)VKN:*I2;J[`<*SM3RZJ+"E/,S(M\$%S*.F`=>NN=@1<RDI6@^D
M#RD7X5KJ6L>CQ1$_)1\`=1DE]QDX-HL(=1]PYQ;5`*`!0)D-E$`<2E3IPH9#
M$!3M&3"O#H,!#.I@*O.&TD0`].S=JU-"S9X&)332*R%I48-Y-2JIH0BR)"4M
M;_P9'%`#P0!,==ZH(R>'1X$]&`Y1F/^$+N>'.C$=8F*@IA*"0_,Z7OB1H2(.
M'!E``LB`$-T#9WO>A"VSY>8%-17F-=A#*2?(,BP'E*"G-5[%$G`:X`#944W7
ME25PE,@PH.I)L?8B9T#P%L??>XNI+OKY@0'="V_*U*S*%69#-?(`#*#[0(V:
M?H@VJ2GPFD'*FB40T%7[H0Q3WB"C;NTZ#T>--PVZED%PCIRJ6#SFQ,-40UVY
M`(,!@/#X-O7V12`N9QB?H88::G("W$G2`"1)S/;>[*FQ^"[+CO,_?&A,:<XG
M<VJ(`!1F)4"0P1LIG`5*`0]@4!`.#=100W)R!?2#3G7@,(!>?*7%0%A/W4?7
M0.X16$<#6KS_15-9;S&@GVJ?S30//0-$<LA<%UPUCTA@0;59;PR`(.$`.D5%
M#2C*0+--+=5LDPTSP@AC2BKMX&(+DU3VDD24I5@YY99,;IF$,\XDJ<TTJI!Y
MC#:I7)GF*4C"^4HPO3QGCG,/D`,,*FH\4-J,8CVU3XZ'\!?.#PQ@`@!":KCX
MSV>4&/:!!MNE`(=^+X*420V??33CBT^9=%B@=4AT*0#"#:=?!E5%B@&(%2F*
MPR9I1I"$HW!`VMT\`U"RP52MJJ@H96^-BND\#"!(20ISL)+$'0-E$BPE+\7F
M40W^`*K?K#>],5BF0%U1+*:8S,C08]HJ&I,:EH&JJ6^;3?59"NW)_Z4&':LR
MY9)^)11P@3I[Z!B16;/5.P^F.)8&P"8N*=I`0"F\,0!6](@%`7,7G$6+,WZ6
MH,$'U;'S@!8_6$;I35J@)I='U1Z+\![L.+->O6)I&I06&+C\%+$UZ*=9(ZND
M+.#!\WR,JG7/17!)S9JJQE0*V"JJJ;3HE@O3B%+7O%^*,@*@U;].=4;((AM\
M^^D\&(Q(L:+Z-=`PTQOA>!8UPY2YY)1IDID-*J%LN:?>>&,I>)VXC&G,D<,,
M_@PO93HS^)IGMEE-*F?6X@HVJ[C9.)6CZ$D+FWD6(-A7#)2N6$LX#5`>(7/D
M*?%%BLS$TB0IHH,!`\;M,9^&N.-P40.3G/\S!WU?%?]58Y!HJ!CN_&DA&`/$
MGJ-&#;@W4-4Z:OS00$8&,=:`#:RMTNP5(GRUP3D08Z"7".!(#.'U39TNU%O;
MFWX1"/(MZQPK$<R7F-L9J]T/]-(2]"$G`V4H`TF`!ZD4_*`&.*B#`C,@@OQ!
MHG2F4Y[U^&$\#'ZE,*/S7>D&H*$?:&$^'[)>0)*'@PHBP!Z<:@AH2#@`'F2,
M'!(#S`\2I`J?'&]#N:.?[ZHBCJWH!7KA6"'U5$(2$2"@5?QC!8-28`.]X*`C
M,=M%^9)UD[,\CUC32XP'B\<<3K0B3V+`'0;5.``;:`$!)5BCAK3BK?==P#],
M"L#M-G01V\PQ'';_TH(-U!=!T5C$/,L"AP.3D\`,?>]?$.3C\>A8/`]6+T4-
M8LPFS+$[XX!C;`_,B&@R$*%6O0&#&#$>&'V"P.X-('\9ZY(4;S&+P`&#2="9
M1N-J-29BU&UCDZ,3X?*8)2P%HY=MVA@O:&F46*@IE\-89B=H*<U0=,-QJJCE
M,PV'#38Q*&6ZDV'&`G+"/81C#J[)DTD"LHAPWC!/Z#-G)2"E*W0XPB2ZTU7M
M/`*IV@%,GGD:F3K^-911>,0UKG&G66Z9)]T%JQ'IV.<B$OHO@?*3G0F5:"68
ME<QO[@&?Z/OG.0:JA8`XE*++2N)!4<K/AGR&I.VLYR+\><*65N*?\P+'_TWH
MV<!TA+.D/&SH9Q3$H(3V<Y\/^&@7SZ%09IGC)@@U24,4]+C^N9,=Y4@JS&X8
MCH#2!69[T.I-D1JX<4AUG@/]5Z=TM\^/?J81W1C95F6XU?V5`Z<(W><X'C"V
MMR!4G_G<Z4;!NM::5M2=SB%H)2!JTK_2]:Q7E>A'';O3<60N2V>2DS'HE"0N
M_8U.4RH3FMPT3"EY"9O`$-,T;7799.HR<8BS`3(^<3=@\DURN+V2:+O9S"KM
MHDT1**DX4YH@=J9@%4^%F$29=8NGIG2XBVV$'.0`,79"5X;P3&EST5$)JIK#
MN@WAH10?<(=],@NN(]MH$9=EV0)(U!'@52\/%_\4@3R1-*"<<.]&OUO?X9[7
M$0^`+CETZM\DQE>^UZ5$0"'6B)$=V)[@((=Y^4H*XVH,&0]&QS@"<J?ZLM,1
MW\APQJK1C/I.6!7.30=^]=??!&.U5HI,<'B-VXC]ADX7`8:N.'SQ38WNM[YY
MZBMV(>9?`D-7'<;]QAS,"]%F12"^YPRQCM$1CB,/)6^<VQLK>AM,S9$83F`R
M;2>X+,S2'J.WV63<+6>9-#(UPQ.;W>WEZ+OFSV).;UAVLYPHITOD?O><COBD
MDOGJII$9^KOD2!`J`LK?)QL8T$`K0.OX&NCD,C9!`6W=4`B="G.4U#ETNE-$
M[7J,"-S!Q./`I4`9G:?_^B;-T/]M75>[.FF^'<ZJJ<;2@D']75E#>@YR"!KZ
MSDOI24\:T:WV]9^+BVF^?K>BC`9RJSOG87$@F;FX;'9S\0MJ/POTVL[Y=#G^
M,XY(2SK0BH1HS&R="VD'69;?R&JKW<UJ1B,YU]?\A"*3N&QB`YC"()XT__`4
M46L']+2=^^XZ7DP-1QMXU\;>=Z43!(Y-XVFOI&C=EH)L;A,_.M#?*/:CF;OO
M/P/Y35G>Y8)T2V(UW9:TW9@SS$L+##2OO!M@NF4OO<0XV+Y)F6]^K3#Q9NN4
MGR(6NHC<Y1#>.B<K&:Z8HQOGLDIUP4T[%<8VIG]&`?5S._G?=M+3<UK7)7W'
M_YS3M2[F:H\4C'DW5W$,0CN`MW[NHN/25B>WIN4"&@Q9;]T1!9ANL"4-\&:!
M&+FJ./R@*8S<9EWIX+<@.V@1#V3`!S[+76(\DQR?'@:%O4L"]X\GR,YV8SZ]
MS<WP<WUM<>>X@[I.C1>?V`MW=+B"'L1I:CHJH.[JG9]6X(0CT]5#;@MRC#[K
M^H[TUZ>-"TYGW$Z@?W[BS:UZ)?_>\4H6'\C)_=MG2/'+;8(2F_.8>IT7CFY!
MGWII#9>$9M[62@'(>=!]D?XLPQE-;$)ZTH=N6]1J64F4(WYK=B1L-WE19WP"
M2`MZ0B6>TSFWU&EY]@F=UTV90PNV5V?/!#C8$`VU,/]=\:9WMU`,8?8WU)`$
M.^<Y0O>!%B@X=*<YGF""N"`+G(,FKD8FTU5\N-1R-9AZVP9],U<KKI8>R\`#
M-9APCF>`K`<G9F<-/`@=DF8E9.9ENP<T^;<+O;5,,;=R,WATN>!^-_@-`XAT
MN<5U>49VC!-LI"""](=;;79;0#-XUS1^JO8<XH-ESW=+_I&`P#5VE\=0W89X
MP.!X;_:$0&:`(/A]5%*%3$@Y:J=WMQ5F:5@`858Y5AAG-"<*1K$W5#(FD6@,
MW$1,6!)G<))O?Z-,,WAGU01GKG5_L]5:I8>(.?=_H75TK*=;M-!+RU0,V)0W
M2MB$0/A^Q)0EI3AX-^@F)CC_A@5X3'+&>KYGB[44BLJX.0^X=K;H?9(HB9P8
M@L=HBC''9H83?R.XBV[F<AA8@3[W65+B.*LEA9<#@[:"3"VG-WHG35V6<D@H
M@1(X>,88B]Z7)MGH"O>'#29H@G&&#1-HCYQ3C`?949$HB?KGCFDVB-](CL%`
MBX%7>P")663B-ZN@9E]6D"[H<BF8A8]H9LBD33](?YEX#;"%"L=89C)GCOXW
MBGFV)',"C*=0D,ODB-'03::H.2+HC@39-V+2-Z5@`^YWDVP&C.\XD&!RC&G(
M#$49?ZR%B[@%DM4(@*50%(PXD&/H6E?2C%5(E$XYD&FH3<:T6<J4E$HH)D+9
M"659_PQDF89.J0U@8I>V0I3@V)1F69>I)R=.$DTY"7[&A%IK.0UCJ828(PIQ
MZ92#8R9`1U]YEHP,:85RL`Q"UYB.R5K8Z)!Y>9?B=R9%Z7]\DY8(28E[PI=J
MV)A\:91(MR6H28MR<DUJ291G.0WMAYOS^()PJ7\L1Y-UUI-B6"OEB(6PUPP)
M>&N%@R2T)5M(.)&$(Y=J9I%U4YG,:7>A]7/A-YBF5XEQ(I.KZ)9]0Y9R*7^:
MQ9N2>7-Y"8Z:>9M^*9YHB(@^F9[.:&M`-R8<>0I^,PM<^)+I:`J:Z9:ZB'Z&
M"98H1Y=Q:9O2R9X(*I[@.`L!&I?O.)[`5*&]"'06J8Z1D_^5&<F<V:2!JS"4
MF^F88Z99X#F9,3F?'3IFDC.@$CJ4MKF>4_F@C&F'6OB?B=AGI?B"GQFA>2F5
M0OF6CEB++&>8C/F41BFBV%B6#`JC!.J,R;",H[A+9F9+LL"%L)<-MA(-'JFB
MPT2?OUDWW'!W:M:-SV2%UW"*8BB==_:+_-F%TI!,2+J?`MB9?TEB7-J7^,F7
MV2"BZRDE5/F-U<1GHQ";%$A^(:H-F1BB.T=TPMF>"[J*H*4+O22=,:>&$[J7
MZZF?9_F42!JH@6J6`"J4$!I,W3@G9IJ:V<2EIDJ<@<F&>,9:HNFI,+BCDMAS
MJ(BG::HX&_.J^/D)+\F%V=!S5*G_<S?9IM^9#(?S@/WG<C`HHG7)JI]ZEJTG
M16[9>IY9HI/J2^X0F_O944&'EK_UF(-8H"D9A\R:H5GZC.UW-[6HG+`7I6D9
MF+YHC9D#BC%'B6S&"YWU@,K:>DJG"N)IGJ[V@N$8HYJE6IQ(D)\ZI_"GBDVY
MI53IIM,ZG.]XG?X8.%`Y?M;4+&49BJ8(G4OW#J8U2[BUI[^ZB,(@H.[9D,N9
M6OLILKK5EQZ)LN^'3,50IPXIE]34)A!9F,ZT=`+[K/@7J#-+I78S@URR)KGP
ME)S)<MVXKRG7LR$HBSD9A=TZ@FKYL@HJ6IX%@DGBHO*WI'D)"C87F5_;9S\W
MK_NWM-:X_ZR!<XGF2*!"^[2IQ0JRU9U8:F;*VK-:MHYB.J9U%KA6N(&MV%HM
MZI$1N&4;N$L2*KC.R*,LFJ+99#ECZENQ^@(\,)7;2`S`FJA!RH]<B)>3BXW?
MES1#&JY)=X6*6:C`Y(1F&KA,&`%@P)5:B(Y+F7ZT&)JMBY\?BZNJ2;/(()V-
M&0!@();$0*HQ:@V#YTW.D+*>2ZD\*H(N"0U"AZR7591/Z9FXN+O-"R?Z"#BG
M2W1PF8W6T$S5";IE.;BCI8KA-Y\:*I+)ZY1(0K2ZE*;CJ*%H:&>!>Z7=5)C6
M68W5,$QRV:W+>K6]!8_I:@,46)E\*Z__&B?YYK^%";&JP*IQDO]T\1<X.YF3
M6!IX<8H*G<>79;MED:F)7:B8<]*KB&D,Z4LGFKNYW6NTQ6I-?EJV5.J=K.B9
M5[J5[IK!DO-+S^@L[;"!7.;!.XF_%UFNCCI:HK59:>K!W(J--:S!OCNBI?J-
M8RNX(&BG!IMS&*RMZ4B4ST"\'II+!6RE?,:Y#2F^2I(>^MB3HG<*MLN\F],W
MH*7$V1F4`[G!25**5BH-HA``!ZF/B4FK,#JQ:Z*++-K`^6BV7SG"*?S$AUJZ
M]+@@\+J&2!=\H<"J_UG#>Y*AQ<1CB&I_SWB^V`N_+HR_4A<`2&G$'?4+46RA
M'VRV20DE=G:=LH#!K<REN92O19>>7/K_P9U\A6PICU(\A.DYR-M0.9H8S%V<
M6>77R??[DR::N[+[)(A9I^T66NP+G,.*MLQZG<')GU<9F]P8RGLVR47JRM7L
MR%?+G2;L@M0,R\[D9K-\EBRYA='@?L(YSIHXNJP<BDORS]RXH;MLP6]BT&PI
MAK-X6;Q,T/Z<E)6<S[Y9FXJZS;-5H>3,.?O\P!1<)W+YJ,!@6\AD%.E+<U9*
MC]HTF&ILO6?LRLX)EBB)M!6(OJ'9SZ;LOH)I6S#MS><;S90<S-"`#4@I9CQ@
M`PPL2\RY9\"8.;,<?C-=ROP[B(P+TR;\EZU+U+^0?\]@#4@YS1VMGM9`SK*@
MU!BM@8FC9\D\_V;N:LY:"%OSR+N\M:MIIM:CRUNS)9QH.LTJ_)UJXLZ86:AH
M;70F2HZ?D],;6-@%B)(HV6Y'N<V4$]9;N-4H7-9+IXA)38//##A6O8A:JB3"
MVM)[!KP%<-2%"QUQNGX`NIZCC"4#ZLWCZ@R"'+?!]\Q#;'>5J,S=<)XMS=?#
MRF?WRV7?-\B""=S_AYI\W:&D[=:'.\2NC--'#-C?*=-!S*]Y6[?07'2*NH45
MZ20__-#J[,OIV(7VC*/19,M.+*P,7=E`S#>;#;*OM;I&1]UP1MX`>9BY])52
M/`N>K'^]>LM.',PKE]&QC'^AF=TIRI^GL-FYI=^[K9U3<IZO'*5Z_?_+Z`?7
MH>S@%H[A^IK+NARPP>WAXF?A->W6X/K=_EQ^`?U+/?G:ID6\T1FB!/Z)SB!;
M.PQO#QO.P#G$$9Y9-\U;AOM^(ZY_OOG=>SW1+^SCZ(RG&BW:NBR9N_#*VEJ1
MV<W0JFBAB9B<0:S8\XS,4(RA6_XYV2W-%UJ;T+S?4TZ$4RZ[/JZRLAW9L5#F
M@DG)OMFA@VV]T%2=XNK-?>[542S(&=ISB_K8*BO8;=[9+:G<J\SFT6W$*BS/
M51["O(W*/WVEHRV`=AW41^GH+(GI]4?.^SVY&M[`J[S1_7O4)2K::)F=JCWD
MX2=^_^R<A+N&UUBC(@VL.$S,G#DFF6C.MQW_W&_^?[P(F/#KS?\=SMY-VHE]
MM:B@TX`*DLR^PP'MG(/M)@P.F$ALM@@<@`'9V!@JQ0%-WDSXYQY:Y8Z-P//]
MYM3^XSVMWM1D[KI,KX!=SW,VVM3>U4*<P?'>DE)J[/<>L`S>9;^-Q%]>S]5=
M?Z\0F+\>PMT=P6-LW-INUOQJW#MM:RQ)[[1EDW`M=43WC`4_SSA*H`E=[X!Y
MQ-7YH7X>Z&T]S-6ZXZX=@CS6K8+\CZXX3>5.6F`>MRC\H5I9HJUPRDB2X(*<
MC/\\S(<]X9J^VC[/Z6>F\26]VD$].;K`UQE]PJR(G#B>6UCMW'""O]L.#90M
M=:2`Y90(Z@D8T4FX_[IPG9CV[MQJZIU>G^3];?;Q*,;*WN)(`J=J>>%;YO#^
MRZ]%?ZK-C/2JG,Q]_65J?MHAO.KA;,RY;3<LS.P^"=U4/K66SH1AO)LQK?9)
M>,N;7]J,X^!</[M9S<+VJ=Q3W?1C&=:H7]R\>S@%O*GG=UJ5B.M$W)LG[&5+
M;G]OO9A(_.A=OUMC5N$^OR89?/1:/HOQO71CG=%=W]+PK>#?7$M*I[)WO>$*
M[H@#;\M"3G[%'=94*^S>KY4J'TWX';GH;\S"+8_)'JYV@\OD[M3%/]W*BOX;
MC<N?-0P<#@@1!0$%!8(!A(.(`3P\`1$1C(^"BH6(@SPV/(:'A)"*B8J.D/^2
MGX.6B8R-G(J?EY:8HY$VDZBVC)JLB*ZOH(Z&I92OH0&YD(>ZEY>9DY*ZA:>*
MFK6>G<J6C9^_O-#0Q9O'E[R$RJN"YM[DV(W4A<*IY.C;WK"@U4FGI`%)QQ'\
M_?CV)6$G[M@@?[LB+1)FB1LR5J9`<:)DJ%6D7[8DTAN'BU-!<<%NA4*F;5,!
M9A4]Y;M8S5XWDM9.TNKDL=E,4XL:TCSW*V2UA,5JI8.UDZ6J=OJ`F7N7LV*^
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M]TTRGW(ZQO(BC-;TD]Y#:`$X#'3YY4CD5QA.]U!IXQ$#UGB&B<,;@0!)5T`2
MO,'WFS^%\+9EER..E0D/_PX!-Y1^,.463GVMF69,!)D@"8^="J)2)T]X$D51
M1$_IR=A@0/+XC%L$>G,:G3<=^&"@?;VS&">+AHC*6(@FBLE-075E:*%-<5-I
M;/5=ZM58B7#4J(,U$54/7ZDIQJDL19IJ47;I5-HH=K)E&N692E$C[$MF96A-
M+@\4H,F;<8478D''@@.7/JB9-9D]$:DBK:4T9>54GO%(RPXPH#F;:FW)J,+)
MI*0<RMF`T%I5X)5?"OE;;9=\N5E.C`C9R6*S8<E1<I[F%=RWT`8HI2WZ&3IP
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M>D+C:$=7Y`KMPKOJG'_.I&K"&B3QX'.O?B*;?.'D?-+*^W0[TH-GZ"PM0+X)
M9^=H5SXUX^CM'*1X4^W(,27-);@>WWA;\TN]W&C+R-W_OGN,OV2&O>'$BR4Q
MTE[":#4/:;7*5U8AWIE(Q!Q<1<ITLTB%[(0DNB3-[#TE@0Z'YH:J_V3#*ZUJ
MSH"&\['YO*YW.T)/S@S20%IAJ7'3^0_M^,1#&*JO?::;UO)DD:8<:L]B[.@A
M\?#4&Q+*1#6L(.+N1M:^14V#%Y_8G0R#F,0,LHE93&L=!;^!Q7XTKT>Z4\RP
M_-(@*=T,,9W*(+D@@L#LJ&D\CN!'503!/\4MHH]@^@Y\LFB@8B!'A5J36Y`*
M-CL@WBB'2JN)V0@XG<B4!U"PBHN"%.8LFG$/>*E:4D9NM9+O^!&-2%/;"'W&
M-@ZI)1VK#)\'5V:J-SIQBS2Z_]/T'H&OIM$L0JW897FV]XRPN*E"X-KDS/)A
M2YX12'=&6Y.CW&BP\.D2D@3K9>X>"926!,>1C=0(>9A%,C]*CCI08^3>!D@V
MVP`2$E?*(R+X$:MP($<K'*S&F3;)3\>H<(ZH$@H^V3,CJ!7I?I3\GR#8U9ZZ
M?>V<TZR:M'+Q*GA)[8+5`%B!*BE&L#RS%@7M4&]\IDW8=?%I8@FB#(_&0$19
M:Y+0_`CYQ!DPY#&E,ZF8U0.S`AYT"28S)*KD19=H38_,BF7J\)48+T-&%(H2
M2I\,Y8(86"Z>>M.:-MG6L*S:MH\"HRRL\A.V8#8D(=K./=!DH?$DNILF<HEP
MJ_`0)?_P<:&)ZNA*DO1H+_^!&WS\XZ]ZVT5`EK,9';HE0>FK'M**HJZUQ>>Q
M+"J*</(S5IEQU'B1"][7?G*>%.6,?9-SEM7HDR.2,DYS.--B+G$J+)Y.KZN:
MA5<46?32ZT#0M&E]EVU+V,M,?:4[UT%J:S<;2:CBL'#H>21F9V;,:_7%&;:\
MB$EPE[Q453&FW$,LG!!V+OB$\HW,Y2>T^!>0PT*OGOKCY0V;5A#9]4FY9=TA
M/,.4M7/YS[.5[,_6V*:H'6J,<QWRX%&*>Y:6_BF,_GF.?)@*-9\.9I!3%-XU
MOQD\"+]6B^YP;E:L!B20=+.JP(0F9B;C7G,1RT54:MB,'IC_4*QV173[A>R`
M!7.(-$D&@A\R["6MQU36]5?##1N;14GVRU$^C9=Y9=*&V-BK0GX8-^/*IAL-
M5$IW&N0WY;4*<P%X,87D3V;#4&W3,`1/C7'Y'U']%C:B)]D2XU@YPTOAJ::H
MS>DL*V?"Q//#KG)G$VL#I])#KGJQDYX.%>6F,&HH&PFKT/"X-,.\9%?RRKC+
M+*;Q%4N!LI2)9\?I[*6XO0M4G3%-&'.%D!L=3<2GY1QJF#Y7@R`MU5C80\)A
MN!=VT0WH'-6(:@]1IHS;Y+68*>T\`5FBST(&-5E-$4M"T'.#@<8G;_X*D,#^
M%9^T:6*.YA0-+KWBG6;4"CU#-.P,_]^:E1>!HI]VZ.C-0F^A)C%SU61=4NBR
MZK/25&AU?V*9*'-OW;^ER'/UFR#UG$R$7)S$:3IY&Z4A>M:K,W$]:F53935C
M6T'S).P2#HFX,CQIT'Y-==`47TD69FVQ!2G)L[U=2./7E#L)QHU/O,;J1A$<
MWV#8S@#*Y$O/AGQ^$74=?3U0.DUT4.2A.1A)")#Y6HH?^#C,"2/8/4Y\*4!Y
M*T5@!0)7%+]T2_E#I">BSDUOG4J`6(-?)ZSV0F;2BMO!-4_<5:SJ$@]T'65+
MH>CL3EO\O)J"GW:CW+M<MQH*O*32+1O+UOQ5'?$+G_TM9UFWL<>4P;3@1RM5
M+':Z2?A$/O_H)"ZUX($;7(CG1JM4RQ$QPHH[M+?SH)Z7>*,#CR_^G.>TD5?T
M50KGG^1JWGNP*BUK6#9&T4O>7VCV%IK?HPJ!TXCG\!SL/*4WY_S0E2D]R<E@
M`9BEKG(DB4)$Z7[9HAG3Z-<R6^-7ZO`3LZ,8EYK/_Y#G%CZN0COS3N>81FLV
M=7%BB!2Q?R%>*+%YV"14W^)YVJ,KI<))(X4?"%-_,#8:[0-,^K,JO\=X'\%^
MR'`7*C=H%`9+.18W@(%SX'<DVS%<OR43XJ)?;I1]*!A5#+5B%_,H1L)=,X)Q
M,TA=(B=5L-$?$%@EQS1\Z2(/,Z5X-R9_6`)UUU8JU)8C_9$?^3+_3_<"35''
M5V@$$22C03B7+WCC;<&U#S>5=^$Q423X<U>$:`KC-F08+!4!,`\E5,Y1"M-2
M%8;44^IG6^0VA[1B`8=D-$8H/&U(@BL(=!^3=^3&*+STA(NQ'L.7A@T&?F#5
MAV?SA0N#B+,@+GTH-O&F5VQ$?\*3B7?82]W4<9PR*#)!B#F8>L&T*)D&,#KT
M(_R")$=%"HOX2TX34RMW9S?81?M"B0$S;TKDBK#U8Q[V52OW=G/BAY18%VSE
M1;,P#5`7?5P"'5UB=6#7?N=#+N5U??MFC7<S?7,E=MDX'6@6)@$%&).`5W(H
MA\#"$3="(V<(691W$QOHB'(B>I,#=&WG_XCVD`FFN$Q[1T1&\B*XL"N30X0H
MZ%'?H5'1Y!6)."AAN%H%B63M$XFHQ(]WL2LZJ&^\R(""Q)`)AD-=U"U_N"AA
M(T!J)X0*`Y)]1QAQM!FW5PY`UX\I@7Z,B"(14HL-64<F*4BPZ(_I0A64%QMV
MXQFB`'>ATA:*07+*J##M.&KV@X_V"!B-@GQ^YAO+I9`--G:1`UA7=U=<DGP3
MV!-5Z0]3R(^Y8S]V:).)^","II;=-5.G,6!'EH&VE33]UF^=%7S1\4%JQ'B/
M<8N,!A*C)4<(%)B"*2):)2!Q11O6H7CF@7<&1%$YYR/-95\%Q9AEB#JW1V0!
MV%O2M68!F)C%$?]ET&6,J"E'X),H'M>2J*E&97=0=ZD-,Y%MCSEW4$4;M!EI
M2$>0G'@B@"E1=7=L>ZE2<!E%>5EWC_26<5>3L*:,8`=U5F<EVB8D*S.!6S)/
M26:.\$0<H_!6\Y5@)!EEGW"6:6B6:75_>@)K@%F9#@E>4,:>FP.!&L@::MF>
M@N0@$8*-ME8.>-@(#.0=7M.?[1F5'9@U-`6+-+)PJP.?QVF;&H07,`>3L\%V
M\GD4T--/D1%EXV(;&)H8;B.$/C*B'CJ`(C&,1L&9;+4IVY(@J,9R?O.?#`5=
MD;2A/<&AC($@%R>@_6.@8F-O'&:4F#,,R"$>*&9^ZG5[_=,4IHE8Z]G_?^49
M2'#R3E%U,UE&=NZ$93BQ/V;9-TO#9`3QA&4FD5;2)<%#BT?W.C2J%;&Q3P3#
M**IAFOWI?OEG%^9S/2K8H7`I%<H"BI^HA=ZE7>;W"8L82:B#?M-PHX*Z*G[Z
MD$FJDYL#&RIWD_I4BII`<,$U(_KG61,D74UZ)WNWJ9=TF-IRGX%9@ILZ:Z')
M$J:)?B-H$ZBH%T,)H/'FJG>!C-\5H$KA"(VYI]OBAFND+"18J&21J<@X(@L2
M@Y=ZH<I)J+1`8.Q2JLI`F3W8@=_UB56SB#XH+DCZ%V&)3`)CG<*I-7H$AEOW
M"&%9+Z+@/#U'7,Z667<R;N0Y:2G*IIMY-IO(_X?4X)*/IRV[ZEM$:@%,"8<!
MPE`4U8C'9@&.]X<Z^HP`FU/T2+#VH%%]^K"Q(+!R%JD`RIY^*`H"JV"Y*2?"
M"9VR0F!K^AF,%TW8P)`'>1W`(FPB6@P8:T%E,X!QY*%U)VDM:Y\X9Y#7L"D0
M65\+F8O;E1OZ:F/:-8"5PH#^&*R-%0OFD',="[2:IY(O2SE">!$L>7KP`*#-
MV(C?<6TLV"-T`V?4(X5H:Y1Y`Y[I19TQAE**<"7%(S%ME48%6']@&V"!R;+=
M(Y^]6!\A9$AH8F+^VI3D(CQV80,*NQ'Y)7A""DEDN7+&]C:4X9:X\:Q/>23!
MF88NMV:".ZJVMIC+N?\@L#%3)S:R.SA0\3F15.:?\+<5&TJ5AQL:@AI_@1*F
MJ)=?05I[3[*WZ/=O']JO_V473<M(*>L+<<B8MXI_GA:D6+<[WB&,[=1XT%FU
MGL&W0U&YL!)B$N91TL=*W!ANELE"P200K-&=9BF6DOI''S9L8812Z3INV,F,
M^0<XDQ5_#W:;4*0B/)96C4"LP>.<%;%1^%>G^EM&4NL-KFHJEWC`:,5M\(._
M+.H=#N*2R1BI3N*I,?EG:#H>G/*E1^F"W/,>3O%9(*PMSWIW1.I`/#1^4!&3
M]+9PIZ:Y)3&0(WR)K(EZ2M:A`5R_@;.%5;2L,I:MB6(,CX><&PM:1%P_'HC_
M%K0JPGCFM<!%DKH@Q-PKG-^HCR>,L]S";'2S#/472]G9%]?WK?N&LSB2/(K4
M-RHHO^;X5JQAA1ZH$-OGI:EW+*8X*B)U#\_R-1HU$$XJ?3RX#W5VE)9!L1[&
MB2?!72*8D8Y:KHW13.Y4&Q3+BJ:82VXAR,Y&R:6(5.CDQD:#&G5(BW.,5R86
M6+*#"VMHPI35QT-X9S?;33K7QP,"E)>8:&\K(`OT&<[*1)CI6]R@N+`:8&PZ
M=HVF7+$0B1V&?W@5RAOHCU!W&G(+DW7[A8?5$0MUR6#HPG5Y-P$A"](\7A-!
M3\\FJ1`Q6&PL;L`!6+U'P=<A9N/L;4T[QO&+GG\4_Y;))K]_%%!R#!NB"+@=
M*\BPI951*(5Q&[?=Z(ZN"PI>Z%*"E5L_&;:G[,ICPDFIN\U]B\X"C2@":C=U
M+%33:&4(&ZGX7-&=Y:5N&YMCS+AIJ\^>$[OB=J7:F=(T#:,H<\\M+=#]K'TV
MC&$I5\W^2J+UT=`(O77#^*.-L7TU+4GG86W,Y+828=0*C8>;;-")("98RH6(
MY%/O2C?DG'@JHQ_GJE9=&DV\\:SZE\@5W=55F,W>RT=TI5*<Y8&?-"8N@<_B
MMI39*:%8EG,AO<]F[=>O0QE*N*XN#8;GJ]=DDM0AC0[QX8739Z9[_9T%(=!,
MD]5H&[4S>@\CVHV8O<U1:_\.>!5U"K$_$(W3>HIZT?<:?_UM\428V[IXMZ&?
M81%82_P-B_>MP@'97!<V[@=4+$':49U@6R?/F-IK-(L1FDS(2KL_S3R->'LC
MK5TRAYJ.RJ,HX"#5:T?=:B2_2BC9?C7)`?+-Z$J'WZD>SF;4WAQUFR?9W&>5
M-6@0K@#=%"BN_J%'E^K.LWS5\R6O5"D4*#U]EZ$WD`-UZ^@<O#TFB+C7UZ';
MP2#9YM16U"IK^)Q'1NW22)R=!36-")%'"6TT?*4)>G12BV-#0",,7D+"SPC*
M+5*N`NAX1IQ$S0QVDJ#/4BE3C$$FB]>=HF4EXOG;),YU/"37SP4P^,`.(Z[@
M"U7_'X/TXTB>&2..V'TSW4N8CVQ9((*@6C5NUOY@Y.)AICR.Y%)=4IE1W9"=
MOC-NSG_MX8=`"_)LS.G(X"[^KF:Z%6?=?QJ>CD$EW5^F"L8-./B3)9[!B/@S
M;77>U6!B0"(6`'QXHV';"=/(G9`^$(M!/M.HR5):M]8X4G^$O&(Y6C[9N-Q0
MX>!(Y$>:2\5S(L159IU9XY40W@+!YW<=X'>9TKX2S1Z3SJ$8MW^-Z_-'R+U(
M4]7,V[I%R_Y9QV:*UY5M(Y;7K]L'RN<KI;2,6&<^Z;,>QX<-#])GX%4-V&QA
MU_.$QA1RS$U![&"W>_O0Z9%-L,2EOB<H5K3L6^YPZ,Y&_Z-!2=QU'I8(^WA_
M]>H8E#=3S>MA0EXVLN[1&:.A9);&<>C7.!`"6ZWMF"?7..#[)',3FGFUP.W!
MTK9;<M_A@<CQFB_KNLGV`)[WS`S)KC=H%2&:C-[/V)8_&FLB7_)NO-ANK>O"
M15PF!U0\'^Y@N-U#Z$;D?>0\T.O-_+PB-^^=+LVKL'U"*Y0I_>;D_<D@;M8I
M'\X^J.WB>>'/+K4LQS"VG875/-G'IDL+L:[)P*,(+=BFS<P`8N`8\M<=WPA1
MOM)Z@^D-:6UJ2O?Y!=2OV_&P'2Q.7]/H"_#)<]8?#!YO=>DUWAMM[0O/*NDT
MIWUDAQ)-^[GD.$#JGI^:K/%%X?]7]HS3B3GSQ\S#4>@E]TV7YUZ7NH-B<XZX
ME$]==-GI)7_9J:O/R^WJ=3Z#WYS"8XK1:2C(YM[A'A,FZ7W1,TWY^^D_<*Z%
M6HDO&(Z$'1],K"W1W(O:ZCSEJA[3\3'>EIG>RF_ZA*RVEJ7Z4OJ^GO>A<0S6
MFUR-2,C3JSG3)ZWE"DDUZU_,J\_DEJO\WP8(`3P\`84!!8B%24D%AH>.B8X1
M$8X!21&,$06+G(V'C(**C82(B)R+AJ2%!9BLK)JA-C:'FI>,I9.5FZV%-H2#
MOH.#D)JFDZ"?AIM)JZ&%A+:KF(*OB\67GI;9BK#`G].'D8FDS,T\F]L!DZ.$
MM-VNBLS_T)2TRJ.2E,+N]\CCZ@7DE)6#5&[8)T^LRB$:YB\;*V>64`D:A,M0
MOT:^+H6Z"''9LV&W#,$*%VJ3,F4C+19DB$S;*G8/"8W$YNS51%^?!FI\.6@G
M.FD`VY'\1>IG1(0E%2*C^8RD(%FT3"8;.FO@.'@6(QE<YFGGHZ+VPCI"!8R<
MIJ)(06[,YY+@QZ(CC9H,Z#294)>_N`&,RK,JPFPM5X'B@7,70GI#G4I5%]B5
MJ5N+#EN=J#A3RY[E;.&2!VS6NDZ(P*&,;`BGK+)W+:U[C+!EI]+ZHO&P19%3
M*V.W1`,M%(&'!74SSY[+-4_AI)32DE`,X!D<4^`BXV(*+)@W_W,>ZS:.LKE;
M6\*.;)G)P@IO^+3A@&]YH@A.TWC1N?:1.A^1>LQP&26J#G6L>\YM8/WSGCQM
MV31?>J40(P\CLFC&373*T6+<)9@(E5!1[+%U7W81(5;--I%!4X`-O\7'6%?T
M\>+.0,E)P]P_HS!5'E;A<!@=-;W90"&**(9WUD'(M",5*X3MYV)Q%LW$526#
M;5)D?Z+<.$]7I6QC"C7*-7?886QQ&)E7\;2RHT>S*4D6<(2Y@IR(W(AYUFDX
M80,9)[KLZ`AAPN3YR#>VT1EEA]8`%(R60`TSG2V@H</B0>Q=-UA$S?`6%%:1
MI0.*9R]:HM))<Y6I822[577=8A)MZ?_+=P^V<XY&F)XJV4LY&9I/H'=IM"IS
MG@&TI$#W$,=8)?7,PHZFU3G5DHD_64B)J"!E!I@[;>YEE&#+0BKLEN$TXH]H
M5RJ;1*X,E>00K#)IJ-N)KI;$ZU1G<H@51<N<2B"WNFSH(7)1@>N78']%-0A]
MSR5GZ(M2E=I:216>2-EC109E;#^%JJ84<L?T5"VHI8J4))?`+F/--:VEYV<O
M55$'#3<[GG?:4L>$MJC'Z>!)5&77'!,2DQ2&*$MA`U4H$R,?6]-GG8.%VZQ"
M_#@<<%.O#)N*D/V:(^QYH,J'TU?S&?<B(PW'U9%6!C4%M"?AB3><<K<F!4LP
M>`68BCGH`;O_UBA73_0SRF!-J4B]XS0[MT7BCDJ?E=GA";=B"\F4%('W\/O1
MG>4*=!)[DXVVK$&<33LD1N:-JY(\5Z]WT%`8HI>.-.?I,VQ+=(?S)+XJL2,D
M96?.E1AI<F,%E:8L/0LO0^?R%Z*0G&5+[CGW&%702SESU4]*.5?<65LXQ_.*
M:,*X`M)QZ>RBGR.S/-X5-J$5LR34AMWY"%1T=KY,RZSI4HRF)`HHK+/FW$E;
M^,D-]*2@!6)1V.(6MH1D`R0C\H6OND([_F"$?S3"U3^*Q)&GO0T5N\L6.Z`R
M"3Q1!VM[LLEI1E.::PE.718DQE/:$8T28L=LFX,(L%0FE.?L["$-_Z)'));7
ME&F,,!PM(5&9<`6/JFTD,\)124H,=[G[(`4B\Y"@8'!'F%9Y!FGJ2][:(+A$
M"]@`AR94S$;X\Z8:8F]`%,Q,)4IWH=U5*11X`B/UU#4[[*Q-60=\CP3CPD!@
MT:1N'EM-^D;7IH_9#1J+RHKU.)2:?ZSE90[2Q75Z<8XC0D:0QV'&)4TD.0XZ
M;#6GN!+D#B2W/<TP0N[Y8K6X-D+N9#&1VEO?K?+#'`N0XX,6S,99'N)%'`[1
M`K:4$(#R5HE=+DM8$W$%,.4ENE+NR5;VFV"^O-BA`P(K-4["3\G8D\#P?<^9
M*!E%A;8I(1*%SRAA<^8BHL@L]`B1-[`#I_]S`#@)3_J&A3<#I^1<EY$$3I":
MBKJF.@^6J_<`!*"U@(0,JS><ZW000]0DI/H2B1>3V)*5_PQF>4IYEP2UZH5I
MZN#NEG:2A?DKFO/*$L^.,QU3H$@GG\FG('`WPWB,K2EVB=M4QD)3R1ED.>7:
M!?RN9[-,^E%VQ2S&H4"EJMZI+Q?RBJ.-%BJ4*@*G>+=@R`-5<SKU/86#]C$;
M"-U%F;<]8SPR388)935,9U)3(D*"*KB""KE2[DQ"<+06.5[75KM6!3$H<=0Q
MN;I&;-[$.V_3WK4H.%5P0L6EWJ(@`",(3JNZS(P8X:?$]"D4]CWJ2`')2#QQ
M>M93X6L=D@5>\6K_\CA<F0<\F<7@V?3Y-+2N4RCC),E?FYE.\+DJFX72USXB
MY<PJ5J-2+O5/\YZ3#W\83QVB6-HIPODX9AR7:/X+X4P_IHFB8F(=W'/&E!CB
MP4K9#)<DA`0ZRBLX4]PSE;ZL[J(H-"H8&O**3UKA1XSX'5K*BQ/_^]_NH"8_
M\:ARDF-+[3:OUI-AX2*!K)J-,48EJ%493J$+D^L$_<(J4>7GPHUBFERQP5BH
M-M15(&83\0P<DULVL8F<<[#XQH'?J45X?5]T&KSD]R9M-"P3$C1;&7'Z/70`
MD)7((TM!#\Q@5:@WMR)%'CH\V2#.S3BI69IEMGI\3%_.#)8])@LB+R%@_\]8
ME6DS].&O/)D(OU!PDAE63W)'5RZETC=8V!Q);V"$+V,()R80M!-/*V9*_?7I
M%&.+3.'X@:_':L;(:^1QQSYK-+"@6!56E:U5@O>5?:'X?IE>;;D(E%@*_SB.
M7W7*7:`D/O%Y,'E?O54ZI]5:"MNZ,!+LVU@XC6/Z(6]K!I9P6<URNH6D*UVU
MR;6HH=5;!SML=:[U\4^_TTC.#`:9XZ&;E%OK2K,V\+&W=M5J^=3(UMU6ECC>
M=@$;6U>,8I1S&`J?62Y354RK`MR&,_:ZN^JTV$X65YZN53>NF;T*<^UD^29(
M)R:$DMM89F\6$(,8O(FJ\7VP%#DKK&E5E!6/W?]OTHA&M$L+9RQZ95!1R.EJ
M/;;20I,8=&>X5HNJ1"O%UP1KR6P[=^/*FT`6#GR=;CX-PH>^0E.<7#\&CD@5
MV6?2F>O(/1H=F9-R!7!LB^IIJ_H60#W2E]D8V-%O+J'$S`E$B0!=Z3O#-#+K
M.HV(HLK''PZ&VGD'FRM%-))3][IKD4TL"Z[S[M"SKVOOTMNG0">#T'3Y$(5N
MK;KL\9BW'-]3,)AV65;M=;ZY%I0H#UVAW]NKKXNVS5V.*9EA^]=^3SH\>^6H
MK\>IOG>:VL(0)9)>9?(4T]B$#<2``0R(P>LA(A;7U?LE]0R;KDSBSM45%/*0
M-VTM6</2N.').BS^2:O_HBG:&E_OV84Z"9AEZM7T4YW*7RU4$."_4.0*SW1/
M0C$5I]%-ZB#'/G\FK*S/>.O`?;7]*X*UE,H1<4]G)?A7&K94?HNB%FG7-(AD
M-['G?U27.[7T6I'30"1326E$6GMC3JZT&/WG=1GH3"N3(OG02'%484:T$4MG
M&"'66U(E52J7:C+2*0^H(X(7:<P@@!DG$WMQ3?)B:T=52\U!($%B2H3Q&S"4
M<N"C?THS?E6$"E[44W*C-WPQ'[=G2/0C!A,P`6)P%-9'$UM1)2[59G4#*PH'
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MV"Y99D#T]"UV&(#>(&(8B8+<DX$"%X!E:"A$6&'`(?]2C/%3FW579Q4/FU)_
M:O9-5X4G&;0]:Q%DV1&/**18GD@[1)AT&?=7?N1#92%60Z)AUR-88\07<&()
M>0%5A_=7N+AGNW9,*Y-A/J5Y@]4XJ`-P/_5Q-OE8+9-L-70*YE1OL<(H]U,Q
MI2=\/D23&38IJ60>BZ!';)*5/4E*Y%@?2=1G"94:VZ,T;B)R>928E$(-==)2
M52*)RG@U00,L@38G:YA'Y0A=6J5:B]&+@($+\Y=3OQ)^?M0/_C-FI163'U8/
M>S-<CB1?&P2!LC9'?$%'3!,DGN5!GX)=@LE6-_%QF>AXPO2&'<6;_70:H`([
MK)9(+;1"$?80VG`9W/&7M:'_G"?64`WX-HN&+R/S@GZ9&`BC2ZM%;S_8((P#
M6/Z11/YA58,%#LZU&SRH*GO8FO%I'):"=/T&*F3'(*B'C,1WB>M26IQG(M]$
M;;CY'/`99+]HAS,!29#Q2<"8%(\A<NM$,JZ`*#I$EH@T5![3,0_8(<$S(F@Q
MF9M96IBV44GT&!;)G")#1>CS(CX32S:Z*;622$Y657T72T<I0T"#@_C'@]L%
M(`+:+&U%B^IE/3)$G<Y`8@RF="<C46N2CV2D<FB3?(IDC"]#<A.Y4+[R0<$C
MA9&VFS^II?+CH8GQB>,H<!T33[;SHS;I9&>2F#*$</(C$@(D42U">'3'4YE!
M:F[8_T,F@Z=CX1`)*$T%FEC:AD3"$XT%=J?G*$EZ,:4`=JA5`C##IA<N$W*7
M(UAB&*B]13YR-J:Y97B05BN9HAZ:Z8["T&2(B!>L:E3@AS/>XX!T9I#2]$:S
M)SXA06"J0T2?4CBS0V3%IE\Q!C#)PI9B0P^X%2&8>&"Q4U;ZT0[Q$88F]7]C
MYF!BI1<75#Q;)0[W*)ADE%UBUFEUD1#=^B-7JHOM)WMCQAE#E)S%HW>5MJ;'
M03NG0X]3$6_S6A_K<39%@C)^-'L_5@ZKL5]+)#$.0XJ:93O/ASED^2Y8XH`F
M:4D!FU/D.CE5E4/R\'R4P:XVA7_RVF;_NBLH27Q`PPL!AO\3YH-Q0-,)AL.#
M]F@=99@^H"&HS7-FZX(YR^(QK(JA=/-#XEB?4N8]OQH^];.R'DB?KE,F+?D3
M800UW[0_LW1@!U([JTF0"G*"@J,4'L%WXPA;7NNR%@I-U?HS.GLI)X9?6;=`
M3N,O>2%";=M"(H>6/'4/\W`YVI>ABI8YSDI=JL-Y6R4<B+:0#6LD216*<6)Q
M^_.G:BL^&H:4'[M4^34,&WLWOL$[^S)F`]D-Q).Q=&)/5Z0='7::/M=OQ!%T
MW/D?GY2E;VA6IVNR";(B30A;I&4+]0=[(I(L`BH0R.4Q[X6"9C<V\:.TR`,&
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MK(][*FC?QV2&;,+=P\=(`BMH!82IH!6+&GW$O'A3FLDL\18MHE8>]FNW*<=3
M=!N0K#C4-)!CPG%2-"5S=@CY]L5O%[U*_(&X03`H^L5V\UAI=U>?6PMA3$Q/
M(ZB<6'KD,)D9>T"-LKWN4A#-&RZATZ52E,)H5WC([`^-@A/S-D4%&)`0";L`
MED&Q"KKVUG?KA\,SJXQXEHSSR1:3`TC*"F>M-K>(830,;3P-F/]."`26^N"9
M^W9$N%H3*T%31)K2&W6ZU#NX\R4[5A@X+H@U?C,6^I4<XV-EC-H1:QMME4K-
M+`TW_6LA5L:2"//0RD@\B15LP'L@+DC-#J34C%D[=P1"?/$]J,8;K-HX;H3-
M#U;*/154,\LS;$L^Y`RZIV*6K=2]&,>R^6C6*4DP6?IHZ=Q@]9P//[2.!Z=O
MI);$;$QZ<06*(-$P>CD1MM+23$T:FIMW>)P4K75MUW+*`-)/XK*,!:1M!#:G
MOG:.!Z>3EV*9TM-W"Y-9,'%NQ,QXKD&$3?>GB6,Q.<+3N2UC>+H86L74;X=T
M>T1'JQ(4+#2T/[W0L0S4T)74&NF^#)3_6JX3FVT9:P[=S%O%.(SM%L3(FIAF
MRVMG%^9])#^4++2!/#\F"D\BKUL6O(_R(W&KI],2K`?A4O9;&*$1JOMY,\23
M'3]DAKA2*7+6AC\4WC3'5I-YJ&K3@[V(V3"=+<9K9**$,-#JFWMQKB:F?F",
MJ^.2'][=ICJE04_C1.W5GEB5/!<^9IU5XAE*;0,X1EE<:,KVDY%C6BV95D,B
MK"/.P(0:+@FZ*)YD?9RHN=6Y<S&)/#G4.(RFE[@MW/3,/O=2KN_-*P%+%X6[
M2E?A,[':AGK<W0YQ+^+QY=JR6C9,Y9S-U7A+X9&</*$W.3.)R=X!-N9=YK[;
M)`#C'`1^(!:>_UQ&ZT@+GC72ZV.,,:%9DFM*M==HSFHLP7&[6PENY-_]S8R^
ML(!8Z7!0;-Z@A#:6Q65)'*JS*JAMU'DYAB._V!#2L1+E\M[(UE#U2(1_QDEH
MG5]^;+0%`^5M^@S1T$\-(].WXN&S#M)IR;FSR8CR-R_@X',.97\+::$UND!>
M_B`*1,G';A4,LW[L&#:9_F\6\Q>UN\*ZL8SOX6B`@T].0H$2DQ=XAH!H@[9T
M9B"$%;*8(%P@LN&H+>W<QLU__-6JT#<MICVKED!$(MHVF0RV@UK.6TS6?C$Z
M$18^VB4+:^$&?B:T".CIEK_]6^?)<NF=8[P'S,`C\<9^O7(=BSXQ^__6GM>X
MHD#.`D77S+UCG4GQ?5*'$(%:P81UZ\7#[#TUVR$Z%3S@JA,SZ$JF?K.]29V(
MBNT<R],^`Q[;U``&K>>;35R=*K7%#1$XOX5"V2DH@9DW`&^2"2C(0G_:6,.V
MCI$_XR5W+_`6D?`"6&5)4V@\3^\W[:0I5S!;>/K3`U:3#>$P4G^_:C1[\OH[
M+*02/'`%BZP?&BR7*XD6AM]K63^W-#9`S_RP)MIM0%_YD49M;5;T$-./-:,H
M+&XH,.M:O40?JK*),$N&&>:],AI=15B/!MP75R.1R(4KZ==S>7*;+]OZ-$@3
MP@VKC!B\V6%\+PW))%(BE"QALT9$G_1`1U/_0KUD?R#=L70W3K-0&Z*Q,CW'
M-4\;KD6ZT>U#"##JM:1@$.P#/-_L()W!WJDOY[_=B!HT#$($A5[=L+\>6O(&
M"`%)204!/#PV%C81$3R*21&&`9.4B#R3AP4128F7DP6@AH@6/(.(-J&7+Y^&
M-H*3D)&*G@&:A9<V-CP%20&Y`9&7MYBTEY"<KI*#P0%7-E>$`8JINP75CKN2
MMJ>4@[V7W(._S-^ONL20UKJ'M=&'W)'CUMF5Y]:U$06YM+:5BN:NHE6B=$[;
M)D28!`T2E<A5/%>\8/7"I.O6I4W[*.$CU&^AI'SL&($"U4M7IWRB-+8S1C*B
M+U?">''D6"A9.X$)_T="DM0-)3M+"=G)#&5AP@0QM4318A5PI%.='@5IXEAI
MZ2]"0F723%7KECV!GMAA379HH<.7H"Q%M/!/ID9<V=@E9%8SH*]=21S-$K2)
MYUV+27<%XR'+`K"_A2OZE%MQWL!A\2R8125+3+*I584IU9A/U\/#Y_)9L*RP
M4,IW55,.`U,@B^&Z$1O"ZEO,V-VY>15B*QF0DV5A"^4*CRDQDSY2@Z[PE;8W
M'4_4\\("F\?+4=)<MFR0)OGMI_*\X.;ZJDZJ,T1K;($/;!5X:5J\TJIA!_E;
M\+#-@$5I,J3)$66$])%2&C&H=:=16G9-\Y)4I_0VT3M"I=1-.;T\DE=%>?^E
MIY!(W&VCGC'Y/)7:,,!I)A$AP174U4@AFC8A3@<.$E&!L2Q(8&I=B2,&4I'`
M(M%;*SXEY%`M,<32*4NMZ`TH/CTGU"8&I@,4;\#T&)Z$C/W#R&9=_557E1:%
M5=LAZ1WCERFYF$4<,6RBYDMZ6T)G&D*@_$+2>N$)QY9"J\BYH'DKJI20DXDH
M)&@T=KX))I=N^F.82'[%=M:>5$DH:"L:AL+3EHD*!99*8D[223]^7H4>7HN]
MM=0H&VTFXU7(!-FHF^#DXE!T+%T(38:E5"J77^\T--)/L*ASC9:##=>F;"AM
M!M)YELC8'3B_$F29F1!*B2%:(_EE:5C_Q!*BC`?_7902AT[]*-V$)BZI44;&
M;`42/VZQ"=5I01)S%D*9&>K),$QN0M='0S)"TU:GQ7LA14T)Z8Z8GCX,8H8V
MF"+@)XT@I\^D,,DU[:*/&)M46B%?]5*MO?[*RT-JWM)?>1&,>C*$[WD":9HE
M58-/`&+TVHDX`A9853_SV=AMR/[5>8[0T.VTYY<8)YWQ-4O_JU2\"U;XVLY[
MRO+?Q=4^^5D!<F2TW#C2[-K)H)D1_:BBA>R']C3HV43<.W<^W<J_@'J-8+4W
M\G5ARKI$TUEY&]?Y3WCWS<8)*7^'4DC72;`E*4&K3BPS0M$`39@T%=<%85=N
M#@OYX'%CA7C7MZ6$XDPR_V4R+YA."62*&(;QY!'`.!T"+W#I\C,3VS2QF6-^
M&'+2Y:Q5^B*5)LW:=E'!FPR)I3?@U>/05M3L+:$WW\,(U-Y_$])IN#6Y1]N-
M.5,4E]T9?8RQBY<6;BR:5#=V]2?=YW1*=8T97T-T5I!_Y4<X&.*&.E#QN,(M
MS&/K&YWW+L3`\2&I/:4S1:A<M:`O44QG$/*$C"Q!JT3]`@RBZ(4SSC&62DPE
M>]^RBPE1L4`"_J17@*%5A&;(,.*L@W]<<9UJ-M85.UWP8V7Q2#':EK4F-H0C
MC2H-8Z17#!G:Q%:Z68=8[A,VB*"N@R?S5Y!X`1G7C4LGIAF$!3`P`1:2T4<L
M2?_-^)0!1<;):$0Z`9*TC)="Y6F*6DW13U_:HY(A/65)[AC(3G8(DT^@"$>2
M$`MM"O+(Z14*([/0S%4@]+/(7&9V5`*)(DQ&I],X\'%/JLETY&$KD[D2%_,Y
MSGFX8C[#B&,?%5$-4/Z'24FZ[)8^:V4IP/B,5E0,:/:@!B9WA:2"F(TQ#/2-
M36B#EY-DS"1A*=S,M$3!F*2/9()YR3Z\$H!57,$3X_B@(]GU"*]A$77J$!4-
MZZ88BY`'/IUHS#ZFI4!U7&P_8OD3<Q3X%_:PBF0%B5TI'K(?MM@*@,<D(:P:
M)(QY-90RXG1E,G[!'HN10F'\*<QT'+I#=&XT(/%@2;?_IH>()9$1C67AP00P
MP$;*Q.D5<4R2[%)(31%"*H/-BE'_^!*=67[CH?=YJ8$TPKT.361X.07&PA`5
M*H%IPT4>N>.;%,8YD3E&6+SI!WN4<XL=;<@ZMR2+J+14`,OY1(OFP-U%!D.-
M;,!$2Z";RNARZ8B>#<LA8)"@)"Z)EAZ]"Q63&,TQ(3,M$L%I8Z5P$;5N,1J\
MI&]+SH!8F8CX"GQAPJS@V^DSR02YXQ`F+^>D2"BT<\R<A6@=+DH$W7XVD:MY
MQ3):Z88X<:H7GR'.6SR1;97`DQU[@"MTV.@IQ+1C`:?<C4X_F<;4-!7)8+JU
M20>QGS'G<X5K,>,GL<%=\P(:_[91?,TN;*,(I8(ZEMI@T6M1`9SK-(C3YQG2
M)9R8*0:0\CI#!">(6%NGMU0:'+G$+5D5':3*=H)%%M7->`?S+(H<1I60T&48
M]`T.J!8*,(#EH\*^"]2',"&@P2B$*N^1*O^T`Y\3Q2)62VUJ2)]:$C%J$$$R
MO!2I2/<+8:6T20MD1/5N"*KI`.4*NRK'C`01+<FB!FL@X@9K4905,*VI0P=N
M1"D>\(#8MD49`&OBK.8J9(R<0S81T<0#HO'@=.G18$(^3;B@9"8FV\G).;%G
M2HU9@#47(A8KM=_HTLR5;EV'@:JAA.A2A9]X[$PC75OS))K$'@7[#F^.N1P/
MQ%N=A?_"T&0)$PN%CNJ[TEY5&TTFD'LPX8Z*`"A[W;'%D"I5"^V`=L+&D5XA
M']:.VX@POEA38L3D%RA,M6-&9_XD=R1X2"P/2CI+;J&)`4PM)9;FC:Z:W>SN
M.161D+5%SIO#`R+@C!]<XR78DU$:O=$7LEHC+3<IB7+:T1?P"5JZ]O[<:^0B
M2BT2JUS0<\05-K8(?4A5.(%2Q'=<RA4P!)84K(D%0EASB#X)KD'[(&%_\)&/
M[Y0YR[V&7K=27"`,>VTZD9O()I2C!BZ#[A<12H(:.+[GCWMFW;50@TAL1:Q!
MJ$'GXLIK(0Y"MTP8)*6[Z2Y2]B!-3J'WEF](DYY[)#DUI-C_T0RV2W;"&9>Y
M)H&LC'G#&SS4T$=]^$_6"4`6`@`&3EGF=^J25*^RWME!(8KG^Z-?3=KI]*2H
MQ%<;[$U6[ELN8RJLT/[-C\-V.(L.5?=Y_#SV@PQ85\XE4G0XQ""!*4P_<]BR
M?=D#Y4K7&DV>.-Y5&IX='P$]@0$P8``-$,.6!M'E&@P`!S@8@`U28%KLO:$!
MKA>![*$T;AM@P/4,$,$N+"LJ#(A`!`V@:1LCT&7]'6KE9U$.YU1RDN,8RH'-
M$(0-<```!AQ&PQ]YD*W>@('HO^&GTWE,I6HKJN>Q0S9OPF@S:M"`_C=`!!@0
M`5KP>_\7?>U7<&I@?"+P>@V``'A!_S&+Y"^HT7<+<043(`(XP``8<`5NAV@V
M,%,#$((88`/C1F\1(`8-V!5T=@7'QP`:"!K290/^YW]BT&?QD%J+%"\D1%3J
MU5P14`,04`*[%P`#``$-T'*4L'"]4`!B4`(X('N.P0@RV'\#`(!B,'`;@0BQ
M84>#T7;X`3[LAP"+\`!$J`$EP`-D>&)542.WXB8.AT*B(EZ8Q%N\E4I]9"E<
M(1LE84M"%$*8$4<)H6[(=AB4,WB$]U4.,A2HIBK'YDCRLUYSHC*#-$1_9&!@
M,6CV<A<1DW=-U1*=9U+U91I-88A@42:C1@B+\6NZTX>61!@V(`)U4`894`<`
MD`%B``GC]O\&#``````!95`";Y`"Y#`(&%`"LI@!LE@#!;`'^5`#&0``91"+
M#$""<28(8D!^`!"+O%@""/!S:@82T,-NR\!ENR-DR[!RT%!O>W`''#%NL7`'
M`0!\&%``.L>,YE@CX#!P/S``O%@'&+`'>Q!24$)]D2".!O-B7#9(J6=1DT:$
MT-B/1[@'#<"+95`&O`@`;Z`%:N",T%B1T(@`6L!H1Z*#V50:KVB1LP@`W#AN
M'B8&SYB-'U!^PQ<)[%<"Y1<`PO@*-6"3L@@``]!G%@$)+@F-VE@'`_!^U+=F
M@!8PZ28NR[`0C(`!,?D#%Z`&&?`!(O!SC#!NYA@`#R`&'U`&((G_/9N``;08
MC6=YE&[19UP&%=_X8O,F"`^0`N[X@V5@?BF@D350`0T`E`2YE5VF'`/Y`.QX
M$%529AH&-1$"B&RB07C34T($+T`2&&Q":<7B8,I@(R$AB,V6/J?`<*9P'8TR
M:['Q4:X3)BH5)HXS>91W(URD&>C$+AW5B2^U8?LTF]IPFC>Q6D$C:M6CFC<!
M9J)6%F]4"!/Y`7#P`V]PE0/P`WDY?A_`C3\PG=[("#P`#39PE0PPG0/P`1EP
M!1J)`%=9`C4PG6^@!B%Y=A&PG-%9`[97!M[9C7N@#G`)$=@1D-?RE%?P!COR
M!@$`D,B0!'>@G.=)EZRE!@"Y!]BA!0R:_X!B]P8<V&6Q^0`_<)4?\`$#@*!,
MXCPAL@<)B%%3L9\[@@H`V0S/<#.4\0NYV`!UX)WE>0%[T)UE``?NZ9YJ<`'B
M&98-('8#4`8UH`4%0%8=I$H_-26F40-EH`')B0`0@*$M%R>[\(H,4`,(``<:
MH`$#L`<IL`<UT**\F*&\9XTM"HQJ,)T)"1*U@``MF@'NR8\8^@`:^0.VYA#C
MY@P<6)!,EPMB5S$>NI'0^`9560(?T`![H`5TZ0O\R8%WD`)O$)8@>8])@`$`
M@*%O@``,$),UH'/7(797D)`!R9]BX)^S9Q91]Y]JT)T9<)X(6J8_H*5:,)^V
MYI4E:`/^V65BI_\5Q=>?5Z!S!&=GK+")3:.)4,:*GI=C,T%!71*(\P<E6P5.
M;CEKI`8KH``&&L8;'B-CR/8(6*);RT,CPN9-D0@BU;5DE7=#G-EL?T=1AH`<
M-69B\M(M',5B;"8Q*K5%=$(A?R:%W0D`&W`!%]``'U`'5"F1T+@!>^"O_MIE
M4@@-2/H!"."O;V"1-5"5`)NJ`(FP='D/P,"><'"P>T`'3<H`"(H!N8>3#U`#
MN3>=#8`#_8<#=3"E20"0NEB1LB@"-O"J*#L`QU<'&;"!.PD!3UBH>W!\&)`"
M,(H``X",97"4T;-0"-"/M?@&]E@`#:"!_'>$^SBEMH<!93H`9YD!4^K_H0U0
M`D?(>RLK`EX)(`#Y`Y>:H?ZZ!R+@G52)L#!ZJ3YZL%4Y=O.Y4'_2(^)"5YW1
M"Z@ZMW#@G06@!5WV)C+W`PA:E5>)`Q[[!JY'BP/P`!>P']U9`G.+L%S9"`,G
M!I1[L&H@J"*+HRGYBPW0JFI`L@-0`\<GM>*IC1FPHPA:`]!(E:,[J`?[E0P0
MBT:9D0/HJ!>@!>PX"%S*BQ-[`1&+G%H:`+8'`=!XE(5*M<\8C3`+D%=@>[XK
M`BQHD2HYI6JP`7```C>J!3\@`LCXLIF:`C^PLOW'`!`PNZW*="1KD4O[!M57
M'L@`'[F")GXW.@7V:W5#'ACE1;&C/U?RK-S!_V*]-$;0*E'5<$C^Q2O$>5^.
M05`7!$2=ER^#5CVJ!CVW04N&IJY"4BQ+\BNMQ!L<E0FU)2V(A&JR%5D[\RN?
MTD*C-QN@<`4#H`%ET*_*RXN`>JH!VW]\F9$Y^0EJ`+`?`*@74*&#ZKBU2(6I
MZZ\F]@#9R;S^J@:%6P94V0`:@)$7$`$X\`$X\'-VFP'(&)TV`*/..``@X+4^
M6;N3RK-?BP//2,8WN@>76@(':P-->I?&*`([]@!)W)[/2*AU:K?PF0'3>96T
M2,8I8`,,.+;9*+4`*[!-3(N"O'->F0)J,,99^K8`6P8@8)ZXJYTWBK$9"V_+
ML`</8(^NG)"R5A9$*/^W_EH#/.R<9/@D<YG%)8"EEIN7%-J=<'"C7,:>Y`E\
MJ6NH+.D*>Z"F`-``;RNH)7"C.TF%%IF5$AF3WON/7=H`(``'M(@#!7`!N,S%
M@8JA!ZNF==``.PD`D/O#/3R\ZFB[`/"P.#JITJR\%4FCNZBY37Q[T;>+=SNT
M\&F4/"L&#2N+1UG(U7RY_&B4-ED'->"A^UH')="B8@FC&%"1;CP`9%N"Q')J
M<X>OSS%>)3<0@.,8=S2LAZ<5V'-#",=P$KS"#JPI4(,/M?.;D400U_$/)\*)
M],IQ!B)"J[4\D">*>">($_%2C1-&QK1;[_$"30D^D_9!J;1@U!$E;F8B]#C_
MD='\<V#]L)\<EB5@DP&;D0^`5EK0L,VYD;0HS6I`BSQ[QSAP!3!J#5G09U<<
MRC!ZG("ZO!/[`TDJS3$:G6_0OC'YL%J0!/.[C[5(E?9\A,CLGR(`Q'7[`0SP
MU]ZIJE0:`7-0"*SQ`%=@DQ5=N&4LC%=PJ4;ISGOP`V,*!PV8`G/`N`#9L(,M
ML?(L!B%9?:C`>Z",MP1+D5_:Q$TJ`EK@KRE`EP\@;D24O315H]+-?^>9:04@
MJ0!`OD*,SKN\'[5@N<<+`0A`VW.PW$+LMKG8HAC]R#CP`X@;##'[!BU:`3]G
MNX-JM#^WMKM8QN8<DPS0?T$\OT*,R72@`9B<NX;=_[;K;)&!_:?#^U0;:9%'
M^<XE@-=:$+=N"]L?,+&OC:#/W**$^@.D:P,)6`/_";#`"*=[4+@/;<\5_0-C
M7,:'70<(\`,-*]>":K&O[9PB\3_&,B>7%Z[=*FJ)AE<XHPVY$<#E5-78$WX5
MLCVFXM1W8B,F/*_&L#8:+!54!L`BXQ_')N3<`1[7"N8T@3/_XE+;=1DX36]1
MX15`D7&Y4'0NEF[767=%1G_%HEN&.,)B\0!O(*C96`)7"<:YNYT?VZ(9"J3X
MP'3'68LO.;%J8)&&KJ9.JNAR$`&1?)4=>P%;"M@PVITB:[L`K<?(Z:\_`(T3
M^ZJ_YX)K2I4($+"X>ZEP`/^Q##Z\E[K9<[WA"!O++#)NDDK@V0B2GMR=;FOJ
M+<K$"&OC(3C&#CN\P3V1#RW2E]!E;9O*VWR7_O>PA/W$P^NA978;'?W%%WF1
M&A"3&1H)<6/%8ZP!%)#1`7NC`N,3!;"E#0L"_CH'H4W(Q&[,>R#?R%G?O(@!
M#)JOZ^FE[NZD62RYK@>?+0[K=*L&"`!\7NOP3XO.N6OO&IX!`P`'Y*?K/Q"6
M06P:]-BP#QF=<ROBWKGLDSKK36Q[(`V?]FZ[98#LR=W?)3`';\OB-XKBJ6R[
MF`RPH6R53WS8*@G.5$F7SU)%D54Z3B8W<*5@@5%`MJ+D]/5K3`YKR`HU1.(2
MWM/_#1(,BHI6.RT-%&^$1;HY/GLTFOUC0#G#.\6S7?3BU!4V*$'32JVD2$S>
M1YLY14W#6&J!$FYV%S[WVF_LSJR-NX(Z`&\[N!?0EL"@D6\`!S3*CX3>HB*P
M^"8?D-!CQ9J.MUH<EG/K\S6PB_M,ZBQ_ZAL=X4M;M2IYHZ^.R:2^S\L[M[=>
ME1:)SPFK<_G`"#H<D[EGDSYIN4+<`$9K[$M,MW_^BY)_^_XJJ6QJC,DKH4D1
M"6-<NI]NRS!ZL#\0L@?[JEK9+*#P>ULPW=-]GBU"?0GXQN.;X^B)N.-V$10*
MB]'L^:"@D?N^I5I@`R#NRU@)"'M:!4D1A6]U'V4E#`,U_VH7%WL-964,#24`
M.)`U'W4_D1=J()67#`"?%QL`9:![)1\-%S]E'R4###@#`Z`_K`BB`3P\$7LU
M```5((DED+,9MKB-`\`_`Z@-E!\U%\>MH:$@MLY[<!\9D`T?#,['J>H,>Z+0
M#?+6M<@E;Q<I$0$%!0+8L/$O@,$`27@0)"1L&(\`$0HHM&#C80%_PR`F+#B0
M1T"%"`4B3"+LRL,D*%.B?)$R(\J,PBH>?!B14,"&`P_^2P(0($J!PV3V[/F/
M4,*'&2\:BFF!Q\N'!A5:Y#D3*DJ`#6%2_2@3*M&J4(4=Y&D3:\.8`[M:H#B0
MXLR1*E.*??HOHEB%%:=^+*C5Y__0KR0#/-"RI_`/6`,@J1DP3A3C9K,0(+"A
M1IZD/8L!H!.%6#&#=6H&7;SX!AH<><8@?$@<24VF#*A`B?H,)](/11N>Q8K4
M:7.G5&H^R[J`H%;N"Y\9<(YE6<T/-0]J%BC-JH[U6I`7?S@=ZD>B?9$F-?Z1
M00.P9YH!0-;R0"+`RC9PK':F1ET&V:'V?"Z#`/6/&C;X`U`$-3V0PH$()OA`
M>W]%<*!AB,FCQ7\U$//`#Y1D4(-E>T17C':L"4+>:O:8%AJ!_ZB!R'R5@7,8
M<\:HQ\DYD!BF6@.<Q*8**Z[`(HL:)DHBBCVL[#-(10LB@`P=QGP``!R*P0)E
M>"V"P./_<MP4!P`WX14F#COAV3?C9A=8>=\%\,@#Y&ZB./=&`XDP<&!`HTEU
MT5$WA>3026()Y!9/+@6FD50H5O333WO&I>A1(_%PQ4@"V7`14&3=Y%!%>Y7%
MTTL5Y?37IWLZ9=1'>!'$Z9X[Y=D755D95"E.0GW5*J0.&?175$A!)5-':;FU
M%UQQ44K20@$5(A%;F%)%4Q(R$5CLIX38Y=$5-=3P`QVP0("?DK'\8*4&7#;`
MB@V%O5'#!G0,H`%_X1T#0`/>EK&E%J(-6)HGV<"R#BA:1"(N`-NEP$]PJ]FF
MR#[>;?>#-1]H2YPBH`1'1&W$`0Q*"I^5P)N3<&R`P``X,FB0_SIUO%'8*!^`
M*PEC8`K\1BWGI;`'8]JJ<<PVD6@AKI/#+1C!,*0-4`L$\!*FCL,7+!@)`M``
M`#(FX'JH5'0&1I*"%@+SLR"#HP5PQ1L(;%`#+&>N_`$.!:3PQBF>.-+``&_0
M:P,&#4!3!P9O*&9.'>?"L2XP*;0G:01B)#*<U>QIB>,/&<]8AV+.U0+'PHP]
M3MRZ$?OHKR)T//=Q+RD#LT<!%:FA!K?<E/,!FYV48>WI`^1FWW,UU`+";/B:
M"W<W#;^NACF0)<P+`JH-((\Z):A)CV,X[K%!\8';51=0#`%-$DP(162#!0A)
M=3V?`^WE3[(-=5T2L(L>U9)3*IT5P/]:!>%:Z_4(#740K^Q#2VJMV=,_DZGO
MR\E.6%6KG@2F@"3!"E+$L)!7224IFYK5510(%9I$JB.E>HM/T@<3B]C%)CR@
M"$ATLA,(4J52H++(%4Z!#`U`X#S]R@PKD,$:-/$H<%9J(01JT"]Z60,`ZV(%
MCI)&J@C$!QE(+`,O^!&!!UQ@10`X3@H*<(KAO$$#``!&?32@B`S400-G0@#$
M<-<`@6D)%`](3FNN,4,`8`!%_XC/.BPSBUH,8`XSFP\_U`:S/6JA=LB```20
MP:59)"(5T0%(^*[`1B`^20TI.-K%!(09!&3"28%\0^`DXI&:--%G:B!01$8I
M'=*=H@P:T(#_/OHUBT'RL!NHE%<2>6B,#,@2&138QQ[>()\VUH.)MHK`&P;Y
M2_8$[D+7J$0=:H&#.3S,80LJ@+I0X45/0$))#G,-F^Z!Q4$"H!>_2($:B%(`
M0-[.,8K@QN^`6`9O5@,6+K0EF]Z0B1E"`&%-RP`"M@@FFT$@B*J\F+A8XQH-
M_(B-$)`7#GX0/8DL)%+LZU.K;.(GF<A/3R?Q'K,:*%&DH&]1PF#)"X;!DF`A
MZZ&SLL@P-D71F#S$4*]*%4A6:A1<S24A7>G(!+-B$9^`I7XAR4M'_@*HO(S$
M@/RKGT_O$A:W!&4A23%*^H;54T,<$"U1:5:D"A$8O[!J4R,$2`UV_T&-RA2&
M7IAY4R/Z(XD4_&`+.+K:&W;1`&L)C%Y.5!%=]\F>Z(10,.7$0+5J@(`?6(8]
M!=#"FB"3@CF4LP'@J0^\6C-6>%'(F1AZA"@0`%F!V6RR*>`L>#;[M@%@`)(_
M(P:&&F"#G(FB!@U`P-4X"XHY0.<'=*LM'D\'!T><KFBMB9,\VE/`QU8+!)U]
M8ETAT9[WI<VM8P69M08CH#[U1)0W@99"(M*`1L36&9%X`P`<E@(>9$.PU1*L
M*VQPWL%.]P%[^,_;OGL!Q!:$='2+6T,+,!@,@6QAU1(8AD[[@#D$SK^0I1`D
M%"P)T8;BL[O`FV>SP=!0:@^_D[5-`S"P3_]);*"[(.OP+-Y6V#>!)[X($,$`
M1(``)SZQMW!S:UV;\Z9=:+:^)O8L9V4[B[%>0K-72ZU+8P*ICIR%@C80`_?&
M]]"IZ(H@4;%516\ZU>N5%"0@30NF+GH0@-`T56CQ:$1V6CVIU`4CJ$+)^-R2
MEIWP=(`'A(E4Q;(]I)3E*YXBBZ"&'$%%OB4A%!D604!BERK'Q2?2"I5!X$<7
M^Q7E)X8Z5E/^@=8]9(T]302(@>@5"L4ZL;$&QC0='V#A"&"MOJS$:T22TD1P
MY*>)SC+G'N80D:KQ@U[]0E!]L^9J7A=88(UU<>#F8.N<H177P*R+I;6V:4AV
MVC(ID,-S3JT%QS;_$=G/QIHW$(!K(RXY(*&Q6H)"T=@"R$$B$.%T8<#!(.TU
M9=6=))VG:E*^BPR&W)L6UR\/!%]76\VQS@9']`;#:7H%F2B2,E#@L(81>Y-Z
MW0)7D"@'LVQR9RUP%S]0SCI$QUOCFFL9:>*E;8WQ_%S<P+P&!WM.?;5<)TC7
MD5#X,5EYS'LC;C`M-WFG^R&,23'P(MNS`:#6`F5$70I\4.X@0?Q!D8O\U<MB
M$,.CTE?2A$R=63RH>EQT):JC_X-/)QD53BKH9JX2(LT;?/.FKA=T128=542!
MNZOV-Y!A%>568KF)7.2W4KF<A%'[&R&FZ&1HE<1]?A<\NEG(4K^KEDHF_X6X
M]H'PBNY/+@C8@3/='(@]2IP?DTX$VIKG!P$T3@KFXF@-I5)L<(HSF=OA/I.\
M;</=5ZRU7/3$WCRMFTAL36,-TZ1.M2C'=_JK)1(ZH$;KYLT]#(6W1P[IGOS*
M-\EZ`(!I=)ST2C%L;SJ9)S*88B%XAVSOUU!5\*EU+DI6+M)705BZ)P-8*+.+
M\?+-.ZL`SA2WAP@.WQ[J_8,.1V]A\4FLQ&R7QW/_,!@+0G/!IGO$)GH+8CK(
M9X"7%QTBX2PBUU<'"&J>-VSC%&Y^I(&UQP^V96#XAB`>\DDH&'H?%P'0\7M4
M<U<+^'U\IVC#P&AL!WD0=2IU@6Y[8E$5%'0?%?\L)S%2?[<H4'5^+H%NF>)3
M3Q5E*$06:68K!Q1I%`5EGN)02&$JAU=<'#$10A<0D`<M0'5W>9)5V2,250%4
M9*<^-I$^4I42EF)FHY%^0M@^C\93YC=`2F%Y/U,1]P=[J\9?S46(HV069FAY
M@B,I8@@1+/B!2P%E=-,?6E!*#4)KH!<=XS1Q'Q1-"6B)`V*)!`>`U+-_`B$'
MSN(1B,4#<@!]!I%IK,@#8+`UG9=(-@!;FG0!J>5E%-%$/"&!FR@=9A@I2C$@
M5/,SOA)"4-44>!$6>V)OGF2!`?$&N1B--;%\GQ(!]G==V&6(<M!3-@&(Q.41
MQT*.G#@4G^10CC@UM/C_C?Q%)Y[(C>EX78D40L3@#_^P>Q\$:PE8B==EC,,7
MD`."6*%H(-;XBHDT&MPX(%/3B?ZHD.[F$>_#/<>2%_S#/Y-29YRR=%+8=`&@
M9-TC0L-P=1S$/D>A=<$"0,TX%OZC%SEH*'G'D-^SA&Z69B0QDUM8"!,9*,H"
M=V4V95AA5"B$%7Y!5%'6)S`)$@:D)TQY%877/HI64QD!AH_V$Q3TA$?&$'<G
M2F_V%0A7%*7G93TU47TXAUX1D]EU+`'P@(518/"6B!$!?6EI%@JD?D`C+>OX
M*Z$H*R'19=E7ESHY5&?(B@$`!L;BE00"'1+B4.>F45[C09D23*12;Z2(%U_G
M_RDKR15&98;96``O.`@]%P&M>&X4U!.C22=W8BM>N8/$Z&5))T+%.)?.,BOF
MTS7Q!IE#-9MT.9LV!99W%YH?<7CFHYK%J)HH!)R2J92F5YNH&8C$.9EBF%/+
MZ!9!961SIX=<IH4&D7Y4^1(DJ1*!XBAP@9(XY9H3,`'$\A1[(1="I9)WAR@6
MZ9<\]1.)-A>_LCT4Z80V&90W*"ED@4%SYV@,\2F.9YT.,1I0.3]/J1(OX#Y0
M@68_X51<Z)3N@Q;-PG9>P9]@,)$0(6\`NI)*IWY".!0AQZ$HD19)$2DZL35E
MF61>H2RD&3Y%951NEU5;&&]U1A.(Z'8!@E,H&IT4)/\,37$G5^!4!<`2!Z$]
M2T=JU-43S<@5+K5Z#`2.G"2&[_:'/ZJB?!=HP\(6.BH6*,)`NBF,9O:-E\*(
M$C&E9W93;8>,7HJ&4+I5$9H7)-HH@<9D4761!P$_!"('1B:5=NJ?%[1E=D)D
M?M*AEKFF?2<05Q"46L:?O9D3!**,>2<M&3DX`=1F0Z83$P$I1&<5ID<2;C$^
M4YIT0`@5?`IH5Z`H)/44Y,F@&;4]YVDJB,(7\=.,7T:E8HAX/;F$O5I5S,)F
M0H&A6F%T=X@5(@FJ2_4KQYD5?X)E8[8^Y[.@#'H6@`=X6J@KCS:9#<$3D(<1
M;09"I:>E606;)MJ;,(&?'J'_+)!R!8\B/S:0!1RQ=,TI/6W!0%=1;Q#%4X(I
MJ8&W*^HZ/6>9J!<TI"JZ%.9'$D7Z<P@K9<7%G^:6?I.9HDDF!NOJK4AW?B@J
MJA8+*+F"/1;`0';94RO)J>189U<9%8+V)X*"I)IJ$F!XHH/WC'VB$"+;BIRT
M$H[RKEEA4>%*0F860B!I=(9I=<Z80:0SI+^J*T07/S?UF#:5%KS(B&_FLR!)
M*V[F*4`QHI0:>!T4LA3)=O63J%)QA\I8JZA2$B8!%ZTZ4M^I*`WZ9!8P`6)P
M5$16I6\&M$HUL4IE=,)P0C@596^8M*=JHXO*E)2:0!#U0,]YA;1J0(J4K&%G
M0#BY_RAQF#[E0S^-IJ5OAU%C>X0_`2L#1#W+>;:]F@4'*K/5>8,_1S^$X*XH
M<05UY[&H\J4].!"/DF06@*0I:A%M1W?Q:0@YX:TBFV1-)I$2U11H.Y7+$E5U
M]@*Z*P<*^[F\&&_,-PQF2HXENA8O=;69JY0AE)^&NK-8RX.ZRQ?:BRD\\`:#
MPQ6U4GKB:0A%2A#&&Q)7H`(N*Y'<^Q/N^D`4"Y8Y@9_GYJ="-[V"YIO^ZV17
MM[@X&%(&'*QLF,`C6P!@H(P309'"$ABBJH.&.[`JQ2M#:X2-XA1^0H[9RC_?
M$U0BQ+U!69TV2D#8.9E=&I(%[,!)X*Y#6*U1P18=>X9-*?\2UK.&?J%H"<J3
M/FI"_C.\829G$104?X)D-6B&.%5`QCED;3=!7CM5!+JK$&2?$*2<->L42HFM
MHQ*58DLJ#'&'",L]VXF%64MT%OG%,#6B54C"0(APR-*54'A!9H@73^%1V1-T
M`D2'C#)T]/IU2\8H:"G(`/MW8$JX>4FZ'71WNFMDE@EIB)JJ[LLI4+B1(C1V
M7SBU/>A00O>'N=(2<*R$0>5F^RL7R=@5;,L6DS:%,UMG]Z>,9W>C[/FF*EIF
M&VG"/GJ9-H6L7AJ5W;K!/77`N]JM9]<K@T;(6%;"QM+&:VB?`J%D@UQT*CK#
MT7+`=A<8):6=/>L43-9X0\EX3#O_K#>9=RNEQQ;QMTM;%`C[L%P<=GYK4QP+
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M+#R%DMM<_\)*RIGZ`Q29^1=8IH0Z.D)CF;:-IW9@%9_V@W;I2G183&=-]Q5(
MNV<=Q'5$-L^(_,S7N;.@JRAI2<V8N723/;R#RQ2M:UVE75R%K(XR[#XPJ79F
M:68IA;ZA*\2B?=/_0W;X3"FDJ]QA)D`"'79YVKEHC60E&[1]YST.^LYR/<)>
M%V87*&^(>GY\0:-U;*!`V"@/-<CO3,0V:IU"*"P:Y1(E2L3`>[2"6]QGT;M!
MP=8]F\WN7=W4/9,-5,]*;-]!!3X$;99V>Z:GNH6VRI2]J78=S#XE2ROWW8;?
M8Q(H&:?;;=ED6+86=2OM?'0TL6K,F.'O["K1[;YZP7>_:9F7[/_@C.83EZ*R
MZ'S@0(A!IHJN%VF36BQED=+36%6K[MLU`]*E/VB]93;06*:.)[HL694L#\11
MS*V9V]ET2KV4.H76\6W'GOTGUEH].J733%VV>PU`?&K<"B2844EW[/.GX?O6
M).3;+G6$S#NC0?5S=@[3)-LI$>7A*'NP&Y4]X*J#03YF6VLJ;2:J*VTG@F)D
M*3QX@5[?=*Z\33BC(\YJ1^$0OSSFVDNE0DK.LV*70MG+)0S4>?BG&#H6E=X]
M!CII7;T^6!X4\&F=LPZ40&&WG'Y`)CY53YZX^E.4+J7$D)MW*KJ$8D[*!]YE
MI\XGH2M4O]F5J1F^38:&->VD&813"8K_HG.1?A`%U#);Y4:,N?\3=$,:='1!
M57L;[0)$UEMQY8+NY8:BU\9R/4J+V2BUK\:2N%><Y?3=9$(9G84JI`5\MN#:
MEQ49[+1ZU80>$&P>*&^]/U28MR<MLDP'0#)JI^LZSI.2MQK/V!KIAD"E@[RB
M$5P6H08KJ8_>/DI<MDJ%V7_7YYC>=8>\V!/.Q/X[/?M[KM0>G85]E]GNR(W>
M\H36S<,[Q591TJ:R9J*BD5I.48RFX_SI/5A_=DJKE`0B:.0(RH[:XA-)TV1.
M/5;E4L_==PL]9=(LAP2J)_C#57JVGA8\EF9A074FU%<Y%9#VL%X_Y#[?LU/&
M>)VBUD4'Y"@J_]>)"E4/OA>"?-OPSA1N/:AW>[!+L91*-].5@I,V7NPL;70X
M33[7+BB$'&?O6[AI/-<*JMY_S[Q[3#[,7/1WDK:%']Y,>7A+G]8\R?.2CZV"
MQH-TO9F#[[,2Z=*-C>[&FJ%Z2';+_).:J<V\[_#,#?M%]=Y:,<X46O1)/K+H
MFQ<`C3U+#*<C?606ZK29/?TSH<PI_%,U1=K+;?LCO:O-C'CI#0@%`0$\/#8V
M/(.%282)!8R#@TF%A0%)EYB9@I2%B(V#!:&BHI$V%I0!CY>DE8:'B9BBC*B&
MITF"EXV+C+>&J+>AC9ZX$9^<J0&FM3:@!9S,@H2OEJ&NILR&@X?,TO_0@@41
MC-L6-IGFYM^^%F*(RZZ.R=ZAFKZWUYW4NHZ;S+/,$<6H^1($;5*[?HK:I?)G
M*0"Y`,4L6+!4K]$M?<BD5;J8#*+#B>)`5D24Z]4^78@>$6PHD8>XE,D2?9J%
MZA'&53$OK>,1KN6FAHLVU:3Y"E,C0>O*)3&%#.;&>+XB..LD$Q+)`M<>*2,H
M\RDEDE9_)4QE@UTH9333$BUH<*8VETO)7:I8R>T[>'<;?G)FRQE):=H0FERH
MT9-42G,?1N!A*]Y8FC&#:70T5^FU5(SA9MMKL)U-J"=W,2ZW^*&X1)6$\K@"
M]YS1;(PD-CQ$;10I0K()U98T2QLY6,!PY1K_C?OD39R#+ZH^^<A74-KQKF6*
MV?%68D\7$UU#N_FA0YZ\YM4BI]3UI1=&H^>6>.BWP'[1YI5RR372YF.6#-(?
M*!54L5;[M<-#,%3!TAQVQ"74%2+8Q31,86!I0YA[[U#$#2P8'4@585=!E9!@
MOEBH4"^_I7::36@EX]U7&%XXH%\,5A4908W5,J`QR%0"UCL/`D;CA;3YA5J.
MG*#(#&V0&%(9=*[8AX\_01*$#3P^JMB55S4)TT]G^-@$FX>!N40=-)/E=]>`
MPR'49#=`F029@:,]*513WFUCGYTE(>8/55ZJR611W5`6$VOHF3?7/G&&.4IP
MPJQ(#21.1O=H*O&1_T@AAL>H\A)L'#D'#TUZ\G.D&!.!(Q2@37GB22OC*/3A
M7H_\QZ"`^9U3:$F'L",->T5!)@LD_+SXY:H'P0?8H0L!PXA\.W9B@Y?L"3K0
M3&@M!DV3IR')5XD+I>972$IE(R2!J"C2$E@G^J6@(O`T&",FC'%[T55,RB9D
M8$"%6,TZITB"K[K=D.A1@YPX$N^(0E73E;TY.;9<?A\IU%^0U#FLVTOYUK.M
M0GVB2)%ID3E663W@5C5G?5")D^IL(\;&+8HMRH1DPQ0#N"]Y$8K[B96G^>:1
M+J!$/(ROCO%\[$!<)7*K>3K7-<U,MCD8+GWR!?.*)Y1R)-E7(+&;J7Q?(?_C
M9;FW%1F+>G;^UZ1PN$G(%'7G3J2;BE,&[:QVOQ@*C#LJ\MJN//+E2&0SW6R'
MIH]M`5/;;9&@9*&Y:.IG3TJGY9G?V$VC)E$2AU&VT4MI-M0G=DNYQ(.N&D*6
M9W8R^7L04)&85KF0`!&79SA$>L6-;,.A2?+:D\C($$Q8\\YN4Q#3)FOK82)2
M#-;:SDBR8YWK%>S%L/&NUL48`S2CDR$J,DA+WLMH,E-C`ZNEDR[#9=<_UB;?
M.NN%S&EEGP,/>%A!<_.F#[)T&X[K#N>09SV/3*`BG7E>L)IN\0])2V&+UP[Q
MD^"H9!*_`0LI)#,9L2A#@9>@%>&V8;+E&*<1.WG_F+[&!B02HF89=G(.;3)3
MF-:MAC4!N-725G$Z;FSG:2+#Q6VF4AE*):\](&%($4>QN'G`RUD+84IL@"0L
M,;4++_\0DHDR4YI23:LN?WN/^RJ4F`$E*#+!$Q_&5G<JSS4&4,3K2HZ,M24'
M`2<S(1$3Y39SQ/<<\7,%I)$5K]2Z.5T''%#94A+D$A?,I.1Y<M0(S-($03P6
M@#W'2V,DJN$-BT!)1A2,RXV",C<#Y61[+F1).;#2+[LTCI-*.:5^2'F(7C`)
M+T.RI0$C`\F!N`PBHU'=W"`1&_V)+%"#V*$YKG"%.69-BPX1`\2><2T,F2,Z
M49+,UO@T%6?U*Q=>HTSO_[`&-K+AHE']T@H[D!00=I$D3G4B!#OBU20HTE-C
M.6(-<)*@S)A88QLUJ^/B0,&JK`4-H%CS)6PD8YT+EC-*T:'FEI2$P1OUJF+)
M>5Z)OK*C?H1/.I/[T$D`BAH2<E)!.CD%(N^3-[J%R*2E$1/O;*<N_71H&:68
M!L!(AJ>V:.E%NTHHUGK#IN[=RQ>='(U""D$.#4F))1.IGC4^QR-G=8B*JC0B
ML?#ICF=@ZE4'E%_AC.C2DM:%6B+YC>58Q)%[?`A$^/HE`#VE%[<BDUU[\HTQ
M_Z1(0S705\3$H$1(-4<6D05#E/H1TIA((%H!!(,,^N;(4D,8_)3S%P]]B+A,
M0?]84X&J29$EH3^WTR\=]>L>&/I,(7!HGH^DHB53?4Q\F%A8(X(-H&4:&>>B
MT5#>[.E+*'FC+1+GJ8*Q+$:5'<>++M,SW53H0:@UY5?8$4+3U(-59C731CG4
MJH^5JI0<#5MU!31&IIH%LA9ZH56/53BN,HBP@A7@9$P"R&CE[+VKO`Q?!EFP
MH1VL+M7`#7SI251:D/>(L\I'=P5KQM8)Z,'"@BTWQ@E?UZ*,FB^TFF;_X4Z0
M^61GV'T+G:8$3E<8CV'0V2IN8HG01[7VKVWAX(%,4:./6I0^9+TG<&QCPLNY
M;%4MFD9OCZ$XC#3#I@\1E2'@BXL*G>ZTY,F@YA#Z0L?_E$6E_@(*,_>)B;)@
M``/KM)/X(-K$:,`N&"\HP`L"Q:H:"104\Q*JG:)1,`-7&2DWZFPP,3A/?VTT
MH<]@&5*B2ARDD$I:U%304/ZR#K(D^71]SE-X1?PE<O1$##<Z\:%3$8Z[W+*D
M3<DTIG]I:--PTJMLVAD%/R+3+?%+D1VQQKI>P0]'/^N8_*K*+)U<9\@$L&A]
MX\:I#U)28OM#G99Y(ZGX9]6G32,UL"G+LQJISE,`U9\;,L9&HDU=5M(GUX3!
MIH$/W):(]`,M6%DV??3&S'R1=5FEI"(8'V>;3F@VL8(`0V/%XJ29">-)UKG)
M9>O7G\(U513_/2:1GRP@]L3S_V`9]&&+)?&K`%RA9;FPP`2^#.:,Y$Y0CT#/
M9WRKS6YRZK^_"$A@5\P)3&9'0);Z6!TY2JR#Y+HD[ID%PV2#.U;YT#W)$,-Y
M41*NK<1K4JLJ$7W+,FH-P8G6K&;=7=W*&+,$I$*#ENEPM>C"I2\[36+Y<$MX
M(<,'/S@IG.O@;+Z;E#YI9^D^%#I<N**\^]%-%5JJ.=<(N[\1W4^4'$*FK`6\
MRL()II5HD;2<2\HO,V%=4G%1RIR*:Q+.EDI*3\E*NB7O&"<3J_'$?$&A0G[R
M9FKB&\:0N%<PLP]RH>\JI%CSW7:C#Q-=N2Z0\I0L4,)EI,J%%$C,[Y0`7$"E
MT_AI__\4<R(NWAI^.E_-=/:[-,3`<0M<).`8,KUK(I'FSY!K*$LA;`][JQ<2
M86/!"4RLA9F;'VF?I:ET$VU[X=79`AJTT)<!#9[^28TK>_>5IZ-U6C<KF+)"
MKC5%D7`=EI!_T8(/O*==<D-/S?!D9&$6+H4G$65$8V=W-R-SMB9K7`(+Q<!W
MK):`ZT<J[T>`^3(,4K$3X!(>]P-IF!%Q9")DR+"!RM`XK+8M>C5X_[17C)2#
M_B)W$>%%#T%"4"(/TF$EE[.#T;2`$I9B<Q8;F-:"U`5O2>$S68=UBO,::K)/
M+Z!OH2![Z45&/L4_@Z!/6`83.%%[M1(\^C(FF,1;;L@*M,+_"O8F>:J1-A&S
M,TAA./%WA,6&2:NE?9D@>J)W?ZZR*A,P`=(4'^&`0S?TAN<@'\OR)I40#M-P
M?.7'"YOB:<9"5X<"16'B&S]WBD5'7QF!:F!"0W3C&\/%(Z3C:0MR(75RBS-#
M7\SS0M!3+]"0?YSXB<.@16NR?S-5)\N64QN".<_&?CFX)E?@<OH''(D4(M@B
M,A)X?!9U-3,76Y)25!0H6(*ABO2SB-Z!C2O"?C]H1,4E4G%U=.+(,F_G+W7V
M*G>5&^,AC]CB:\WX%]#A(?DX)U)A$TYU+)@0AF)X%(FD0-"S$)@G11V!=\'"
M/*=".MO"5(7W612WA_NP%DG6;RX"_XL-(D^Y4EH()4+7H'2U0HF("`Z49(/G
MF`^&P!HX5"@ZM`ICR&D8LQ<:,8*8!D'S@'D=1(TNY':#YA$.9Y(MM`QIEQ3F
MPV$N&$TX4XHR1%T1L4ZM430NR$JB58PVQV)]MDW5!1Y7]FR>0AO^IQ4E`D[$
M\WME:7;%MF2N=FA/1Q_2%D++UHL+LF11%4T($P^/@';B*(5QR5SAQR"<!IB'
M"0Y,1QY3UCP5=GM88HJ<\Y82)V_&(YD0$5:"!4PX8XO%PE1)='MUA"3^-Y@M
MM"YM-PE"1SJ`L1@DR"OC:%95%V$OHCB_`Q^9((8_@157LT_5L1$3B20FDB0P
MEWM<>!%.Z?\6J82;7S-!IJ8/`=4.C<8L[/!J-.="WC25>I.(JA!]("-LFY1(
MAG@>!UEBHE,TV:")*0$CH`8L:P)&TA4M6F4P_VABM@"/H`%&ZZ`K(R-S-/<;
M/*AD']6:$#$N7/(A/J&?9UE2K8E]#E9SQ]<^1)%M3(<0.;$Q"HIE4=F@:6B@
MT4`QRK=DNL*$20@D0O==QY1_UF`:[A<\JBA@2<2<?&6@03=M/VA:G>5K;&9O
MN7%ED_51-\>9&=BBY]9MHP4]*<H;E,6BW?6*NV:-&B=-2?(W$HHZ1[<<_3AA
MDN,CFL)/HD<@@?$TZ1.1"=0)O<%$=$6/V?8>G)AZ&/>`>,A1CK?_)O#2@!]I
M8BE:6AB)6N?7'GUE*^CA6S_&3;M'5U\J>M.A#Z?F2+[CEAZU(7LR+QF1>X!:
M6`<"A:M49Q?E+N-0HHBAGA6&85>T=KFB9TVE,GQ!)C+D00[V&UF82>)"@<-)
M:WNB6+%J$?="8VV2?'LY7GP9:D6T8@.S=#9$+QE4?\3I47G:==HG+NC%=/GC
M,7&QAJ$I5'J401\&&Y6&:4YW-__)<K=G2*J&964'2-N&,X?V5,VUK;0)1CMR
M+G*W1@TCF&4'1(M'K%TJ+KQUGG-"4A"#5]6A$?8Q&QZWIFT"1#D%L%RY&24V
M&#E6+M8H6JL0$M;%BXVIBLUVGTG!6JZ!_QZ#FF4(]7MP5A@0HS=NJ'`XAJUQ
M5HR:P:78)T)<<6K(E@MYA5$<(IN#)TGAET1YM),&TK.."45<D1A)I(E]`3T.
MEI<QDGG7HCW-$8219+3W($(.<YHHXI^WU'ZD\ID>]+0@,3KK(IQ*15(ZTU2P
M>7D>J!_<LZJ`.H]J04_"`8^;D3,Z2V1NX1-L"21XM0E,6RSN)DC!L"G64F5S
MT9J#\25/,7;GM*R&2W@XTR4\B78J86'4P:^I5GFC9!POIAU`1TP7`UY->CS[
M]A0B-3^S]$X_)SM5FB6?I6N7P4??QWZPE12D=23%AEI:PGR>V%I]]$]:,W^"
M@(@Y9!0:^8I",O\R)P5.P>4G8L*.],5#[3DM0%97K+HV4L)TF?9[.D..LQ-;
M5E,(#WJ8REN'2I2!\T*B%O5H->A#8\0-H)&`E"!WIHA2NW90+-8EH)*%Z?9=
M?Y$71I(JMMHH_AF.>)1ZP"&B8K:_6!J9L-"JN#)(.D43H'=T:N-N7M$UOZDX
MB)"%<F4QAI6IGXAH%3RJ@_06:7=RDMHH$T`F]A(B%=4EXR(D0W6G;*=2ZL)0
ME7@:<JD7TW0\82,EJA."ZD>G.)$7`6<2259B-=%8KG*GR:@^(%BWO/*9EPHW
MI\`4AE`-6T:-Q7L>;"-WOFFU:G>(BCH=V$5CQ6:_)..)?0-?T`$L,)+_38K;
MBP,S$;G9Q-@D9K&[)97DOM$WC(97)UL50E^XPL;V6<XFA65D2P2K9'83FO5K
MJP?L<[-!%5U66CX17?9I11*W@C=5>:>(PA%TH,]8BT4Q8\XR7@2;+IFQ-E)C
M0\E7O](3K]E5C=Q%BL55JD_5O9@<P<;HOA\#5*KK>&YA>+-)H^EED#*4#T8A
M'9XW*:`K<I"3()"2%OL)2A2QB^4"=D.#*T&"'!LER]1AAZ[BQ&-GJ1!53X<F
MRE7;;%-)(/HD"8@X'1FW<1.AB]>"7+6BJ&OFA63QMO(7/G&8@*PY3V3D/[%U
MJX`15R%J@Y*:O?[X;"A&)F]%)-CQ$\7H'H8)_T%)&&I8HV@>Y8MW0HU,&4[3
MA,E%FLX%+6N8AR4?1='?U,9C=:9S)&1*98JGAAP8R+!$)R(RT1*/$[-YBBU[
M"+]"R%SALR3CR#$__1(_)RRNN=#&E801*C.YF)6!DD`8.E6;,C[#53'*N(*X
M]Z6BDG08RKQ@^LQ9C,,Z.+#CS`O!24@4V5Y9D[H&O2L7BVJX*5H/-9)6;1TE
MDX^Z<0^Z,D/+=HZ,H$^$<I#^HA4;-P)@YCYP5\/GD8CT"#V8%$#ZH2%D98(Y
MN!.-TSO`]457@4]1I"8S\8E,:ETS976#4!K5)&2;0CJG2;M]93MV?=:4P:NL
M:0&()#M1^RQ"*9.2VO^S$`&D824+A29NA06M07>#UEJI*]I3[A@,0M<08AQC
MB9F9"SQ?9A*;HQFV4?1=LS>*]<6AWNHPF0"12*4F&02!V6H9_'.^AG6B$S)J
M]\-*SJP1^#TZQB*8_!L5EY@BAE4;GIBUIUAR_4I,<0)1S&LPW`*]XN/<$XA<
M.!F_D))(YW@9M31R9(0YW@*2P%D+^DV75N5PYP=#G])!M_+%\4!]DOV("825
M!AUR:Y9FKVL*$R`W9KM'\&%FJ>T;R4@X2$RP0#,V$1MG4^W7CG,3B4>O?GTJ
M6W<FD03#/?/1"5O'G%J#5-*D@]$<4&05B'!Q(J0O&"/1N/0.QDDK?#3B!&/_
M4KR=$7`7JAE=);@EO4*6O?V572G\OS9R)U,8O_AQC?Z-RTQ-1^25;:G1:?`+
MO@]XTWW^+]=30S+IY.LX$]!-T!6BJ'A7*(1@YK102*$`!M=D(RM49$ZSEGC8
M,_*7TN1$Y@[;YGL9;$&;LJXWDNX$2`;WBW1)G>L4WU9R5KW#?#N4$SR`SV\M
ME5A&J+E`+N[$M.IJKF]6*Y9TH<+Y4YA:RAE1:R@<+/`KIY(4`(0U/D4G,P6(
MKLNX7Q1Z@#;V<K'^0V)D:.7@6B)6RPIKQ)7CET48*30:SN9;H/6>&ZK&JF+V
M5IX3)'>Y7_>>BS9H>!PB4YBF5_;3-`</(:XSRFR+_XTC32OIBS05LV<)\B>>
MG,K32&<R`\>:O,_\A:$U'5=`"EE`:_"_<,;FN4;A:._48)/^L&$OHA(H[U*$
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MW^#$TA8E-GO$+`((-F(V`3R"@S86%C8\A8P%!0&2DI&&/)6/A3R&B3:>C4F.
M`:&&DY.AHXZ@G)L!D8F*A*X!GTE)5[*=DIZ2EK.;O(ZPC+_$JH6+O;*^FIRS
MPZV0M4F?PLJ-S)O:J8:*T:^7U,2>R\3,M.27M+'$!:'$[XVZZ(WHW-7OT/>-
M!3R+2=U<^5/7#AVO5_I0\0(X+MDQ5:32*8O%#Z%`<]5HU;-$BM5%11;X'8LG
MK)[_L58OFC%*TH_=2H:@-.XR=O(1S)6:AJ4217(=-IKU5,8,\*)H45OV0EWY
M&2SHI*(\EBY\!$D2*G^>%)TRY4U0R)?<M/&[^HD0TGP91S&T,,B6)6WPJK("
M5558P5YBM_H3@VA0`4]_%WF#Y`YN2%LL"UW!)=8MHQ>(]S'VB+BR3&T4D8D!
MZ9`C4DF0>4)$BGES-)CN$O'X;,H5JL*,%HKBL3FQYU)N'3Z\AOORYGT(8WI*
M$L'>UMB9C&EU',XS.N(,9XT:6,IB`*V5_O6S::]X,+7T-J6V(`D[S(CAKI-'
MK[?;ZO#+MQ/:OOH=>4C^I(-+-*F4>O`'#51`<<GDTTAH_P8YQ`MMZRDEG`T#
M4A-2:L:HQ=A*+_C'%@\18/+,)1&<UU-B-DC%`V2U"'*)AR1UJ%I5%>)E222:
M7-<63*G`(\XHUDWR22NHV)*26B],@XLK?]VX#26.X')8(4C2^,PBJK7F(Y5L
M%2C7CVJ10F4]MG$"EC*,8(=,;/5LB0]XP+1#%C;@(=6)5YXLA4Z6:=(H)BBD
MQ;9(80<BEF%42]D9D9V0"1E*,@N&E*!@Y#5#I%%RVL"<HO:!-!]/&2YU5!)#
M0N:.509&(Z!ZJP$9'90S(2D@0S^R-!"!ZWG6U(>NFI63F[2]-YA&^%4(CEK^
MD3F?A):JEXM9Q?JX*6X('030/_^H1O(G?:RN$T!Q`LI'3BK45BF3M>_EN!XR
MZFCT26A_TN*7/?UDD064P8:C`@E7O!#!"U(5=&,B5X!Z+V0O<'%%52PMA"VH
MBRVF`K@!4X,`$W+T<V"1LA#UPKTJA*:C(2J$3'!MU.!!B!Q`BA*`'!7/:%$E
M>>4SRCRR52@K5<Y$E%%5HW;)F%)7$-6?<I&B]RU`08U:V")8[>2T3_X4J!`^
M?1[MFE#@V?73=)NUHR8C?*:T6%0G"LJ)H9790@Q?B8@A"CGIH*+*-'W&4F.B
MB&$5E5F@$HJH96(]PHE+WM!#E)"?.KCDI[NXU&HO08.*=]JD[FK*G$SI&N"$
MJ/ZRT;?_-':RC4<J<V)??<W`=>PZ:(I9S'03(IOC1JS(224OHLM::X&"$.+=
MLM5$FXZ8-\-^F%?%,!7[F3]&K0XS!^GRBJ-PCP(5._($[TO4KGB%6$8>X4?1
MX"$-N5A*WMPBM4P->TI4U.0P0=G&OD;*2E4LYX]RE,J6!;;U*C`)'M0Q&&R5
MI&?8:U-06N&3:6V*%@%["YA&%22EX.1G+!D5G7X#,[`Q4%6(L1:6G)(U9!%B
M(#*25J48>+7J4:(CS+@)+'BD$&=4;F^1B\Q<2)6V"PW#`D';'I>D(\$HP2\=
MD_-8H>H#JIS\[3-O81:>VG9"0B2.4D4ATZ0J)3IKD"*'B4I<_VO$)`NU>8)M
M"1O$3+"A.C3]XG:R^!T5;<$62^U(%7,YB$%L:!\JSDR-QX@B<C)&QHP)`XW4
M^`U)"ED]M7D#-QWQ(S(LX)AED#%GR-K$84)$/F8I$H6"!!M5Z+202M91("0S
M3HD6L\J0%8-IGPA6%KR"#3P,D#X\""#8+$""`.:R*"KP1@"%QJTS;HH_`NOE
MH`K!A&8ZLYD(V((T>X"`#5C3F7)`WJ(.L[&'T:-Y!=&%M`9GFFV^IQK^*\MJ
MIN?!24!";M_CIF=HE!M%^`56XZ!=E^1DFG.80F>_*0EEI-1(JVB-1YA8D]H&
M`8Q-K!!,3<0AGU"!"[1)KC*T(<2<'O\9EF]ES8/":5.!4B(DH:FFI`0+0$4A
MBA1':>1T_X&DH+!X.)6&+5%[(L:&*@%&HX`F)4"*FD/0XL)T\"("`F)0+_X!
M$+ZX-!Y9P8@'<=*NY6`E85F"AUT\RHJ,K(0V;G-@*IP:N?U4+Z>^NTZR=LJ]
MID[`I=<HZE1-8D<+3&"M]]F+U&[BD1_%L@"*H",@EQ,`I_(-GQZM:"\L%#$+
M[*"QL3N$CE2*B^$5DA_\0>J["N<NTR`I?\Z\Y@80\(9V_@5"!4``&U:K`Q94
MH`(RH,$:9KL&&>A`!R>0`0O8T`-G$N)>^%+!%3I6I+R2K$J)!*3.R.%2RV)C
M/;T[W3O8%I3_#)["D>\Y$FM,T:8<>96-!B43TUAHBH0V$A:^"(7.6'B5)3%)
M=:E02"RD,8ZCR6UOJ@(JH28J.;R5`G<C;(U$N*M.%O:.&)\:$D,2!9J2-NQB
ML^"<=KH*RXC-]"@I2:E1?`HWDV1F78SKTGZ!01';@2U3SSU,//;D"$?M):P&
M6HCS)ID>OTX5(VCD#69K42UNJ8XIS^4+ZNYD1YVX"T*+_-:>#"'D]BZI=JCJ
MDT%$">`LV:9ZIPW&AC+(R%UQ0@QW5>^4)5'9@*G'PHNY1<-"AB]97($O>4!<
MR(2;BHK:Q\(U&EWSF(Q:EC%AM%L`00-<RX)";X&T/R",')CPAAJP_T`)M+V!
MI(-`Z4HKX=)*"$)M==#;9@*Q*%?@)8,9D<U5*K"SZ_$63CJQ*#62Z"=BB6*6
M]AD9(9U4'*@;4G]T'#R93#9!N7#*?=VH$4V6TQTD`AU+8)BQ#J8%$YJ,5(L]
M^IDR\U`38SO<A7%:IJTR[;W#D\XWD]$21F0[;0@JJ;;[9@@[]6<C3RJ//.1!
MR6UO&''J5NF7^.DG!&^X<BN%&W<Z;!6EK@.NB<R%BS<:#/_EZ).$;5PN`*F:
M;IB%X-P*J%J=UCN)ST3@URC0)*=T0MA-/%)U=-U!6YI7K1B4EDV]CVHPYT"%
MV2A5WUY%DVEFFBZVB6]*1=^GA>2\?HAA@/]R^,$;EKYT"$VB80-RT7S^4EK]
M_7EB/_CS!I[)=6?VP+4RF.T-:%M;W>J`MSWH`1MT(-L@H.#ME$:!`2H=A+F;
M00D.<(`2[GZ"LV_]#:OAEZB/0HO2AB(/U(/CJB62&HKKIG$XWYW`25BYDW9J
MR.J%C<E=N)U=,-$NX7+:FX)!U#KV[)OJN/(Y@G.74D$Y,ZQIMZ?,AM]U]Y=2
M2M4R(G3EK+0TKG#;JWT821H*O(GQ;'2=CFSDIF4[WO[>@M(AP=>[%ROZ]&I^
ML[%(0+[<AEK\CQ-7N(*,>JRNVECAZ/]].5ALK.%YE&8*^M)6#Z)J\H\CH,BS
MT?@=WGOOST.IB13_*?K09<LE$3XW&/F75<92.Q;4/G[C*3Q@2WY637_V=87&
M`B#0`UMG`TQ76APH!M)T:"'8``T@32#06H6&@BEX@2BX6FS``C(0=FM`=Y2&
M:92V!IB6:2BP`'+G=G)G`$`8A$!8!&:0=T;H`">`!+PU,>W&9KVD&59$`L?3
M-9]34'-3#:X#/S0V+=]6(__$,"H6:EFC:Q'Q<6L"+"]50^[Q#N)F1DTS;'"T
M"K=#0NIT-5YV0P.&1T;6)]L@?24R%AL6B%`Q"..53\U2@*E@=%_!-%?!2I&3
M86D3?6G3;NYQ#=>F-64CB!J68817(C-!&D^2<A<#B<%G<;R'/>;R'DUF_R.;
ML7#I%%5CU364$!BJ*`8<HG^%<X`:15AU]!(BLE.X>!CP8RW]]G#?ICMKY6I>
M83?*<B9,5F_7\59WH1QMH7^LQCI;I4C1&!)\LG&`U19)(AC)4B5DM!P!J"/!
ME"_%Y68@@0<4LVA"H':X=0)'F'=]MP(^H`-(<`+\&(,YF&ET9P8T.)!!\(\&
M>6EFD)`*Z0$>8`9%$(1%$)%`^'9O-Y%R]Y!#&)%F,`4>X``Y\)$<\)%(H(1"
MT$Q580$FP(P`DQ)&Y5)@50O3PS7D@503T(J)AW[H!3OEXEW9%32:R'PS,X?8
MAQ%#TQ!X$5ZHYTZ/\@P:%1N):#$>95"6$`RCPO]BB9%P>Z)!M<-@9793FF@4
M&<4H[W%JK$%PWE:-^P`D*45[9Z%NH98^UU%=P_8_7_EOUI-%3:$KO0$+W"@+
MW-:300D@.>DA2R55AY`JVBAP./96)&>&J@.,<*E`4<0VE#`CL)(]6=$6,^9E
M"R((;[5":P0\P+=EJ-<HE*E!&2,Z)`82Y6&+[==P3I4\$X$<W3!8KKE&P-!B
M'&0Q,:&2GO`&[L@$:@>#,Q@$9M"1]9@#_*AW.9B0=!>1T!F1!!F0"6F#-7AW
M"0F="3D%4X"1&8F1%"EW%2F$!J"=Q^F1(,D!'#"2;!"//:`-5R"%+N<5D#$X
M#95<,&9#DLE<\ZEQ.87_F2L1'#+S?%ET$>61&5(9;`NH2DAIEO?`?<ZC1S*B
M&X#24)53$F,$*<K@>9801L+@;HA3EQG2->:XH/>UGWBU)D#%2F534\J7,9]A
M"V_V);^VH`4JHO=F#QFBEX?1><7FB;E1'\[Q(+IP*:H44'GT/U[$.H<@C$P%
MF^5`93A!#]/%"+$I(E4B/5/683(S26?D:@/!'"-7*F7QHB;!4#90DTRYH0%H
MAMQG.$>F5_73/=23F%*:E\;8-IR#8#\:G'XFCR>0:1#)D(1:J(0:G8A*GHJJ
MJ(BJD8WJD(\JD4(HD11ID4+X@Q"9D'F7GAQP``?@`P+@`SZ@@113"/BR%)S0
M_S&+@GXO-HZZXA!U1*82T1,^P3KC$7B>H8G$HE%=8TCQT!-9*#@/=%`$EIO.
MH%>'=85\`FVJ8J)DD16<DT=E@Q1=J6TX>CWV="X[P25RLRM-X3B59VZ!DD7^
M8")MJ11,LU.6<8=$HC&!V$3L)AK16A,\4FR1TVXR4J"VDS,/89GYIQ:]0RZC
M@8MHJCW-I8U]M%@\,5WBV&'BDXS#V@G$*`H:U(H%&Z![J8WL9$8#2R<NH4>`
MT:;(5@B`Y!^E])**4%G?>G'*97*CP"@5TJ2]Z@D/PY+SP01BX$P(``(5L`8W
M4'?E"9V$RIV(2K30N:CD.9Y(&[2-VK00>;23^I"5:O\`%RFUF#J$16B$.:">
MG;H"`A"J*\!;3``)1@&71+E4A#AY`$N-[Y$8Z>,+LL$Z:%4.DR*(S]J+5@(L
M_J%`;+@CH4-L11DC<!.KD>%"]0I?;)*'L_,6+H:*3:08V69\UUH*L!040#5@
MB>$(2"J:89-])Y)A![<)2X%1-(%(.\%^/_65I.$D0&2D>^DH5\9*9FM]`B88
MJ'-226$/?_4?Y79B:$&921"KI\64F/2&X1$4Y`!F+&M',Q(>(+LIL'2ZFT"9
M1X95J%5Q5$$/PH,ZEF!7E!2.,X,39-1"FI.'7U:-VH2[G?ERY;LFW8M_B=D(
MB]9,/8!;,N"#DSJ$1ANUDJK_J%,;GDJ[M-_9J$'0OU1[M4%[P.%I`%-0=PL,
MA!QYA%N[M0?PM0)`!0=P=KWE#AM#`NLTE0_4#6HJ(>>R.19:+R:77E)B5<!8
M2G5I++((3SR13FEB",.RH`3F>^=HOK-:E'WXK$/!&S[L1SKT8#S$B2(J2'ST
M/LCA-/!CH8X)KRIE;LQ2*%J1'Y5B+E%)K%^HJYD"ETSE"Q,[1B42FU/\N=H&
M;*[1-!!1J\81QDVY3G)[C7;S*GNY+-Y%?\X;+LG`$2UQ3F?[<[<K2M12QU8E
MOG0;FJCE;0+X;2;<I<4ROGT$B\VX<3AR#,@T90OD0<L!"P^S&)"P:!OP=6L`
MP(L:_Y'=29Z2&L`*#,"NC,!(&YU!6&F7BL!'&\!%,`5!.)Y$F)PAR0%4\+54
M0`4K<%MLL`&-P#',P4"E=W&.?"XBMW#-H;A(TD`SYASN&H@25Z1R8QV*=[L$
MD<??028IXRR#H<2Z<C-N=**^5Q++L'EQTS<KU6`ABJ-L3)OM84-FR(S$JR-`
MLU)1H6^+\&#X"A,D%J4Q\A2JVVZB,V#-V\Y/ER6%XBDY.B?']!(U([AV$RT?
M)'`(D7@NJ56A6TF]9I9Q`W,C88;B+!*#XZJ-4B">052]YS7C&[HTID7))G+J
MQ'Q..6;PPQZ])V'RA\,#EK)NL0%;P`)M<`.M/+54&[2IC/^TK/S*5/W*N[RT
M=/>#%2FIMVS+E'J16;NIG!K,&`S,&7QV;^`P]>D)\B,=.G&9!^VR>:QB9MG-
M0Q-_#8+$=ML_#6(*+(ES^.P8;%K3@<LWQL)91^2+W5?-6R42F*B40I4]RM`P
M=7NM8&D6S,I[B-5=ZL&(MK"]X;H70=,0Y#%C.$)4NU0/NJHQ'T6B_:8[0EH^
MA,<FC[1EJ/`"Y795H')KVB56H)(;S.(G_8&*`P)6OW<)QBL0,.U"B'4L^:=-
MWF@5_Q=NK,<G:1I6M.0.9N*R,<;2/6S<7$A`]Z%>3:-J4CE>Q,(77&.+8UQP
MNE&'H-U2)J`OA?4&%,,$;!!V-\#_@Q2Y`/[]WY4*M5*-J55=X`8NP$VMRE^M
MRE$]A,B9`YNJGCD0S!?LJ0=`S$AP=@@@!P#1,--HNT*2!WF@`JTV'[<V"9Z-
M%8LA-!?:4O^B2,5W?5G$DEC">P2VS3;3<,J3-(W=,UWU.`IX',3&1<9`K3T<
MU"%=)SIBV8)8+"2=-/ATC(F]D\*@&YDB$<#P&RA4)3[%NG\8`&"0NN^J:U'#
M%PPUAQQ!62RN,4W$&.M`O5P1&SD4INKSN2LZK3*Q5;NJN`WM)["V)548M\SU
M+'VNGP7A#.R$V4F9'5U!<&'J+.#BE,^J52T]E4[Z0+(QAU=&)?<`2Z($:X(9
M83R0!0-$_ZZB=#7QR05<0`(VT$RCK`-*4-7_[=]3"YX(;,H&GNL%+L!.';6Q
MW)W].P6;Z@`>(`4<8.Q40`8^8.$7CN&<1C$`TTM5LTI"LABJCJH!83C0]D49
M02FWC:YU,C8K7L_:S""5F+<-@40$!5X.)V:2K">G3M*2%+C5Q3I`U"6*42?9
M;!!C0U6#@#9,WN2`Q)/+I\8R1,U[<A:%9:5N4VSCDX='@16Q&BJJ2U+HP#:?
M<#N#P2^'I6`65!^2]5>LH%T0(7AH3*X'$J8[&BNA"29LO&7<`P[H8TF8M*7[
M`(4B=$+ALLG3P#QZZ>_U`\CED9JWTW].H7NRX'+WG)I#U-AR;?]E$N(KSDSP
MVT=L*[H+.?MG+."S`#SK_4WK4QW`NN[*_#WVL.R_K)R1OR[+#"S64B`%6TOA
M&&SAQ+P"Q7S,S50GY"J4Z#H*,RH-?A$8='HBZ##/VASJMP!QZW%OG#B]?4EY
MN]":2DH6'(KPLRIF%7<<'TOH_@0KB+*KHAMXICX-LI>M.Q'P@<C&W"5_S#>S
M&%WTW=K$1N,X%5?;?(-33K(9CYC-_X;RF7D)'MN%9#,YK)T-!GA.7V$#*=6Z
M48]2Y+H8R;#RNN$2W0C3H_FMPO_IDZQ'IN.EW9`^%KW2V]3$[+0T?7PTX=]'
MA0Q'Q`LN_>1S9IGP!V<UB*Y7'M?8:#'_(9=D%AL#"!97`4ER3$P];#(W"R@H
M!I"."Y..DHV/D)&.FI6=GI.7E:">I)69IP:8FJB01:Z1J$5310:NKE,>#CD<
M'+M4`@)4!QP'!RM4*\DZ.FP]3'(\`2\J%C;6-M%)`=8\VC9B%CP\-A;AWM?=
M/%?DV`'2+_`O[DG>YMOEZ>6#TDGQ\NK?;`08%\W=O('7+(@1:-!@NWO8'A)"
MR,V@MFW6+#1TQZ.<N8[1Q%4,4$";.((OZ'&LU@Y>OX'KKF33=J5<1H'RWOG;
MR3->QY$&?TJ$2&YAPW'H-B845VW;0G;HEA(D1.^%M9J"K%'E:3!G0FSCQ(!C
M1Q(A(7E54\+L_W:/1P&,%-<).OL37DT;*KF2&_0"J5:3'O^Z^SMN9;N*[$R"
M%3?89KN24Q%&^Q8.+L2@[`H6K99M8-,"!,?ADTR1I&ANWL:B[MMTX$ER&MN"
M;DWQ8<>QV=ZV_@DQY,-RA-3)%5<`=K4K*N!1TZ@-$1L6:TH]LG1I%*;KTK.#
MHD1]>_;OJE*%/_5J4R9;YV7E<J`KAZ]@O(H92Y;L`!(=0H0\`YW%<6>M;S'6
M$6=(-=9-$NM<I9,_!Y'#0U\V#(*43.+(-)$[$,+FVT8JL>-1019MPY9C#&%V
MS49"#8511ME`A=2!BJ'C#T"H:2-/@A8V:).$5PS23T]`SOB48,$E5?^@<0)=
M=`Z!_UD#CDC1*%349`)E1I!*/3JX34P+QJ/32F,Y)5:8;SFHEDKOH$1:@!%)
M^5=?,O7C()HIY:36@TD(1]MAX"01('!Y8N,G;_6XA1F4@PG$`SAE%8A1-[,E
MF<2<\Z3(EE:+,I=G-0449TX]5%74F6.A*BH66Y%=J0T^G49F8F62W68H;Y&J
MA(]BL^J&'*S<8'5%/)_Q\`8;)T0G2BB=C.(=>,RBL%THSR[;;">9F,<*+>*1
M]\IYN+#7'@>_4-$+,2L8XX,/]14C1#.'5"9ED1J!9D,6<I19V6PAH3I<G3VM
M:D]3]=A00`2/'G32NR)N]&<UMU[4X&0LE1C_HU;NL'EB21:WXRAEL$Z$E$T7
M!A"3CRD%JB`_<,KU*3E=!MG3BW,Z_%5KL)TXC\G&12/O-V*\>(]"+%$YH&<1
MCIPD05HQB*'#`S)5CEB<)1H-O_!(<P]'0_E;%%Z`S?HIABZ+G)2GZ3!:6FD%
M%5AFDK6U,VDXL\4VTE0@"B;8:8R!MI!NE16XJ:(3V>WVHY]FNFK/)@<7#F.;
MAD-PC;7I_-/AOC'DLT.2<E/2/3)Y60T]%N21'(1N(0*"$JE$0DFTSW:'[+2?
M+,NZM-.>,IZUIF0R2RVOJ,?>+L2$&Q]]*Z!;WPK`K,`,`F_42Y;(&LG#C3CT
M3'5.X#WV>"%/A=*$_Y-7&H^&]5*!;A0X2Y^97QAE%).$,]N*1V0HYA69+%K#
MXP?F,8YX&I1@2VKAQO2"PAB7!8DQUQ@<18`V/@&ZK4.!^0O[&*65"88#4QX9
M"#BRXB.39(DA=LK)^#[V%(`5#"T7\5*O5'0XAAU-$-+#AEI:EI-^".<O+?0+
M-CY7L.>1!5<Z'-60VK2RO@$*9-<+(@31\3&&:(DW/[L46`0(J9\E4$-8"PG-
M@,.F?%'**8LCXM'"%SYSR`MB/1K="WR5/16HH#"&Z`$+:!"$9#5B=M*BG79>
MYSH\L@YVMF.%*G+'.UK8XA;=<@^XJ"",^##R7/1AI`#((``?+(,-"&#"2?_&
M00+DL$91HVE:]0XC(X>)L&J4(M([C".6LEQ1@B4Z"CX<]!;S)5`L#)%94E3B
M%Q!-S)>>B=C@2*B1Z5W#1VG*DH7N],$72G%J!N0)<5;4L<&HAI;%N8E2GG03
MOWB$,PG\YA3!&,P(S<2#Z$CA1=XBA@FX!6@D*A38=H(AZ%43<^_J):A$:)&7
MS`-"40N<DQ;2PD09:$`181M":^1-@B:!@9%ZE(9H!<9TGN,;$[``/2AC&D$$
MJHF.RA,N0?*JC&ZT3V3#F4U$TXT(9.HT'7*222?%J$U5KF89(4G<<IJ3!)E@
M!R10C@DL((<XZJ".T^GC[.SX'63ET8]0M0ZSJG7_'6UEJQ78J@4N/#"%*;!'
M"CDX`"-YL8MB4`&2\IDD)<MU'S:@`0%E*<?H2$""MD6,-A^"(9IX.1%`P<5.
M51D0+ANCI8<\Y`6UO$T8V=*0394P29N#BJ`4$[&)=&I%L6S,6/Y&-(3]+$L/
MNI--[!'`H/'#IH6B9S09%\2@.$9\#13(VF`FJP"X:2%'<E+07O0DH.')2S!Y
M7L@6A0$,#&FE#BS(C_IE$H,$B",ZW*%1WF:U+F61)M^4'&=<2%B_38ZCEQ%I
M1K%12YQBZHI-2<RBQ$`(CFH#:N3=V16#"3'"ND-*JV+;!)Z"*O1.T9@%^0@N
MW\N<`+2SIB,D2XI\*##;_Q+4MG`S<$:1@R&D74,%%#E$#W1@+#L^*P0@#D'K
M2,''V$DUJBBNG7C"DU5:F$(6Y,%%5[VJ2$8VDAAB/2NZBN$#,E!RQY=LQL$L
MX$8WPH-E--5H`11B*'CRQ90W^^O5_%DGB=H#*H/9$(IJYJC&1HJCM<3L3`Q3
MF*-H4RD929]C!GL1K`#*2[Z:&CH#ZB4UK6-J-'P9B/"6CO`]"44$NN^((L)-
MZ?(LH:>YIDB^&0XOU?F#93&(!3`@`A$8]T&,0\B=\^R/EU3-8PGTC?YJ\J!Y
MQJ,>@E"';_M:V2B6TT]PL=)*13-8PAHVE&Q^$4OO!Q:%&,4P%$/H?=,W/>02
MJ/\H>[.UY6XEJPY!++U<ML%^V1;JE;2&@=?K3;05,@$;Y$2'XSL$$]B@`QD@
M]5B3"+&Z0ZQ'2S3UJ2B.ZE173)[TO'@*Z9'%C'41//GXV\;($*M:=UP,^KQU
M`\_HB`F"2@_M7>8R@M64PZ)\*P@?J"M5&T2DP*T;@UYV@941E)<=S#/&1JYB
MUJ9-;,<L9H+H9H._+A)L?L6T75KM?]"41]7446HM<7HG9<Y8`D_::A,Y4.9C
M:>6`@&;,-+^K@F+8!\9=\H__N=8"$ZATMQ?$D4&0.H1*>T=U&VC"@-CS+//T
M'X%&*RG,9JZ5(H55:C3ZT%]+2=A$J1NC/"5WFN*%Y"W_G*A(?IADDDS4?929
MS*E(CA4G)C!4IXH[B,@)>)(C5#/I%-.(DGW?/_/,FN@3E`Z+6M0-]&`+(*C`
M&A@!K>VL^_7M=E:)91_OVJ^..]\))"MXERTSX!L%AYQQ+LHZ#!S[.\<"]W$P
M"DX\'8#`&47]AB<[E&PFORWTYP2L5:[\M;07IC@3V&_46L60>V6,9I&FBH,W
M2)M>AJAF]ZQVI4(]RD6W,Y<@_Y5/)@3-KO<HYXY&.O(43?``$FCR,V9C3*/A
M3^`V)^NU&5#G)%72)EMS7I)B)VDG48ZW#1.``0T&-L)!):86)%LV>(WR$XK%
M#US'.>,@$X1'327B3<5&,V:3_T_P127S!1A7M&A.5(,]`WK6\#>/!R\\Z!>@
MIWBQ<8.=E7G1-46CP4"4QS'M)4R3)13<A45;`T:*]R1":`W/8`B(P`(RL'JM
MXWJOMVXC1F*XAVZV5WNT-WO6`@OU5DBI4`2^AU6(M!Z[<`2\$!_'9U9J]6/E
M0CS*T`P(ITFPH0*'@Q?K%1*XY$0=I"1M(3W=QW73)`88,`+&)5MEHD5[]A4;
M$F:4"#5HPT2R%#3:,#$/U#9CIB$EIWX)03*)8DY4X4'_9VI+HQ@WUV@$B((A
M$T$VLQ3I9RD.=&CL@PU0,QI@@4M,-CEI`5Q?4ANCL3:=LEP0`FDI!"1B%T#_
M!6IE,_\D4P<3%/)!MZ@U>V(/`^9@'^)JX;1WBS)>;=<WM09/37%Y"P4HZ\42
MH%9^/J@_.-50!=9.^F@8BP@ZR=AKBR-,D2=AJ)@XMM5MJ;%!H#1+WX1@6,<2
MAX``8G@#K*>&9ZAN2T4**R8=;5B2DB`=N_<(+=8[O6,&V')(1;`>#M"'-/F'
MR:=\D$2(Q6-)S`!]^1@T5A).L*(/ZN<O/3=9#3$CLB5M^[5?.D,:[=.$!H5F
M9P9A0U@IZ#,1HY04A+!3"N098R(_TGAQ1%,1+A%<`*0T57,CYF`5,K1:'T(/
M6G,%?V9T0Q%$9L<^3V,4K-1TC(:4N,@A2\*%&/%Q/B$(ZQ#_(GDV$%830T+3
M/<7Q)#ZS<V46(0:%)4SG/E#4--0T8.LE4%3D%-.FF9/%98E&4)\9*."$00(9
M:<&63PR3CHOG=HN!=1EU(:AA>?<CFXB#$.@3&UCW))"A9D;A%_/8)RN"<V*"
M`%O0``S0!D,`8LBR8J#PD2(6DDF%'219DK;G;M2R>ZFS+>BA;Z[@DGCH._Q6
MDV;U;U1`23A)/,QG/,ICB-=`BN243:&V:$WA%6V)9`[C:<K1:PL!6XX"*WCI
M1,IE:R98=Y*))I9R(=&%(6P2-37WCNSEE4CD02SQ9.YP%XFY7.$H=F9"&@:T
M=$$8:ZOFH&DVC$()3J.E&N54:&"$_VW9^&G`)0^=<HPV4T_EU#E@,X)$DPV;
M.1?0PS4LLR7"834=L0\4(T(7!2B-(P_`(3()")0#J380%IO+YD0A]V?1%5".
MLE`'-C[MA4&QT4M<63!6-*;9%AK@U81VPT/X\([_PAQ'XE?_\WC]\'_-P00;
M@`#/(0,T,`0)X`77R4<?]I%X9!ZX4PIW5(;<B9TB&8>Q`)-:-0OH44BRX"W`
MTX=FQ4B?"@RB6DDZF9/*P`QLP"Z'(#\!=2*-XS0;N*<DH$89>`XU,1:\*&F@
MA&GY:2$DI784JD.^%B(+935;63_THTK&*9PD)UP9,A*C-&N(!8TVJG.3.(EJ
MZ1/AY*IT*?\(1+I*63%YFI41QX6K0\0QJPF!)!-VT5@6F-AM9O<C&"8V=V%=
M.E=GBS5E2]JA(F<F<%(A$F*9GH%G#B%,5%$7:^11ZMB*=I=0#>%K)))*_\*%
MFX-?C^(J'(-;9^9SX'41X,4R6+H9C_6:/5A@1'=?5=(Q/`.,NP$P'`4&JU13
MUJ`"5Y`'5]`I<H``J;<("\!NL?>&/7N&BTJI(^FHUA$M0.N&V7%5<PB3^C9C
MMP"36_4[G8IC`"=)P.`#DU1)\KF374L?]M&3XI8D4>$V+V`!)C!X]"<RL]H3
MC841MXH/0"<HECDA,I28MB5U]E09<IF/6`9L)5*`*A-:J@@_G57_G`+D:[F$
M,XS1$.R0(R0()"#AF-LS3PAT&W]W%\?1$E8C6<Z59'V)N1E+@2.5N-KT:3S:
M%0:!B2+0`.('0!B6/4G#(*=4@*]I%-?8<)]2$[]23]S@6]@EKN6$0U!T9X[I
M<G$3/W,#&_?W<A90$K1D9;`8+V*6/P/V4+<)$1-CH)3B'Z`)-?V`;3X4,1='
M&%_A2LB6)!#E<ZTEI07F(6YA"%M0`3>0`&@8>Y$J5>`)'MZ!M)&:>ZD3"^?Y
MM*[@`5QE"UVE;S))D\8'<*+J`[^0M?1Q+J:JDP>P##V92>2G#Z<&&#_8B/9B
M9&MIH]M;EV+WH0CY?T<&2@WA9B"TIXK+_UDIHKHDY&UHX79;MC6P]H"OF*P'
MX1HK]7/::+NAQ27_I!.-JS]Y*Z41$B'\-%]_`H$1*R5,QPW)F*]W89FHB[HJ
M*`8-T`"5MHEF>8TL<Z^UZ[LX:'V\\4D;U98H(QP'5CEC1UBM@2#ED!*\&[S'
M&VPN<G4UTUT%&AMP$:;5-EM_;)5$0Z:VM8&S2&PN=&W(Y4Q28QDPB!DV87=K
M9SD44VS(D03+P1D%$(8WX`6&>JBX5V+YZPG@6;1J"(<FN;1,FV^R@$@)W"T>
M<`L'W%4+K)XY%L'`@+5<6SP/K).$B`0G<`)BNZI.O!,!8T6(\J/FT\8,,Q?T
MI+#3O&G2\RL=L?^+)\/-"',_##-YWB2NYVMFFQ%IMR&9&B.,!)04M$N`GZ8F
M6A*`$.(.W&03/P+.4G<C1K)=`ZJE#XA+C+)TUS01_\,7(9H3K-NZ\-K$,M2"
M_LJN=T)*OF6$T',%,(S1-N)I'9%1QZ$]_$0XN30TG-46CAO$BTPQ.KC)-%BG
M^/?'C1-0OEFG]6A]!1.MG*$U$H$DB5+3A:-RAXP1"[A`?Z=->.<JX"P-*D`"
M-E%43``=T8FTLD=[KN.S*:;*JXR2K`P[4@T>JZRI,R9C8<T>F&K`7#6UZ>FI
MO7RU6(LNYS*JQ`RVQ8`$='T?.M`#"/<#9^%H'GMMN"6*(?VPW\070/?_$=F%
M9Y.[S7^C5[NX=L`)7QAW&C`D0GG:&0N$8)?-''OAN>T\0.\<319!.FRI?Z=D
M8>3*7C9RC?5JK5`QITT,-;AZ03#W-%4RVR%RT!L10AV!`6`L`NX46T7##>SZ
MMIL,#AH+#BDQ)]M'<]`<3#*!7Q-W&CM]QS8E#74A,P#32TT2--`KLPNI<B(U
M1FD*;@;Y@R7G+\.%CX%1-Y5%=/G0,WP3:=O'*W\,O:'6W8B3>,.F?@.!!XVV
MU"1@#8;`!H-Z8JWG1R"9J*;\.I6Z+9R0+=@".R8FX5\=?+I\UKI,UKYCUGJH
M2&K-UC:FM5P[JJ1*/*;*?/9AS&V%!AN@UZEK_S46"U&UQ,4/BZL@=*]BTQCZ
MZ$\4,XYR@=`=2BI!BFQL84,>$DLTTCXR!U%D%Q%`R$/0=6;#G91<P2"DEEJE
M#3(+R[F4>!=K*=0RRKRQ+=G5`%^G+1&J&<2G%$P3`,9;9\E2<F<@:C[^MYL]
M`\X`46H<C('@.@A[F5D_4W;`\4FLW6BVPC9"KN-W\THL0AI;&3^J@L/6!HJ'
M84(FO5#41BHK_4K/=A!3&DSMU]YIWDTUG224^"``+A-RL`'08;]=K535>;]!
M*^L,/L`.?BWEL0GC,9*V(U7SMLK!A^%;9<!D[57><NSNX>%^".(4G+5:VP$E
M3H@G+M=U3=<]N0%/V?\53-U)V7,YH47E]X"K^V"C6V)/#^%/GP,2HU5@;'D<
M&\%T6A[3WQKDKNI:66CO#"8.D!UF1]ZN@3V"VCBBFW84OR99XE,]QU$9-\QT
MA?:`MY6R*WMW$?N)2CP0:@$<TN:!BIG.9K,]_/0/YK0.89EFY&`"O4F4@?U)
MUJ2Q=5.5XZM__]%HEB'9:4/R]BY2Q:F,_Z+)[6U%MN'7?\=D#T<8+L3>/Y3(
M)&?/(4<SFAS4DI4V?JU1%C?TX?-!&AG508M'TCD[L@Y[:QB'M#R>6<4[NQ/+
M7\T)N4-(`;SVNS?+ZC$+%T[L#B#WWM+ARFZUH`IP;UU)<$V(YO*UZ>)O=9W_
MS$45Y+^B`D.E.+`2TC'D)H>%@0F)BO=*4D=.&R"OY34NF5,J3HTI-D"!\.=L
M=%'COKK5=ER6@6)'Y]K8F,O-ECFW*-VX=-1LW1F1(S-MYK?$?K,FT!*94.[^
M$@"AC]J*$UVF$\@FTR'4PG4K%T;A)D\C-_<DHM2<):E&,23B,:W!NV,GN%8W
MO'&%??$#A'@.ZHZ'TLYOZH1BFEJ.4(:]L8H6_N7$:\^6W6FF&1%4L,OFVB##
M_EH$"#:";PUM"2TAB8H+C`N*(8Z)C9./DY8+*)F9!IR=1453H:*C4Y^F'AZE
MG:NLK:R?KJTHL::EH*B?4Z@>#CD.J`[!OL`YQ3D<_\@'RLL'5,[./CX"TP(^
M*]?8*P<KT=G9S,M(XCIL/1M,3#PV/`$J)`0D*B\J%A;K`?CY^%?U]0&"[%[D
M>Y&$AP5U8NRQ&QC@B@U\]019N!)`(#X;$:_P2)(/HZ"$`0IBM.>QHD`>#NU1
MY(C/($:0^=2-7!C2H!@Q#TO^BTA3G\^?0($*Y,=#(,:`_W#ZBZGR($NC]NQQ
M/!C@YDN9/'A8M6H!I\%Z";O>VRGH(4NR]FKZ$_D07Y(70_OA=,BNZ#R34+/:
MT!CQXP1[-ZG6ZYDO21)^;?FI/2B1)+LD!70"Q&LQYF29DY/8"'R/HTN(5#>'
M'MUVY.0`71,"])R6K$T+%_^I?LT7L?5FU6UC&SZ:5/:]DFPC<GRI>J'+`II#
M)V3'>V1+A3805!@RHP4B1H^R:\=>"=(E1IIFO:JE:Y?Y4:<\2)'BH<@J]Z]B
M&3`%2[Y\^J!NI2K/*]@O_\7\9TPQR1Q0H#+.3$.%--0(X(TWW7#C#3@4ZD`.
M&N;(<=%>[N01SQ4@5O16/BD-]L]#<!7V`D8.>5613R`6E!!B"T$5D4G/.7:4
MC&*`.-8+,CF46P!9R04;<L%)Q5$!+G4%&UEEC174E%0"I4Y1#>T56V`+&78E
M/U=4IDY496$F5T[K;/;11[")Y:24'@D2DD4N[25319\]121B`$5)DT4GV<E/
M5(S_W136<JBU!A28%3'ZUI6WE1723D\>E2*.^*185Y3W?'9;`,AY-)R26L$V
M:EVQ];5A5C?5)"I9K#WYE7&@F;@3JV(\EN=G1'8UZ66_OF2#9SG!U.NPD5$U
ME5,%*5H`:H-L08,74"`B"7>)6&===HU4,DDFF(3G"G[ZF6>N+J&@LAY[MI"+
M7RONPC>?O/;A)XJY`/X"3"^^"$/@,<@$S,$R"0JP(#714+',@]5<8\TW%"ZL
MC84ZH($`.DR`VI`%>1#T`HAPI2BD6,/9-5"S4?6(:4?LB'5:7/5HA&6O_6R4
M:*\W4:0/B#'[)!/)^#!)Z)!U2E3:<O<`6EF53/^$D@JQ_U%T!6>=[3,146+N
ME=J=MSG)M6H1X?927\8U%:9`'(UL@@4$Y9GIQA/)V6M*-5K&%VQ3K^/D5CW:
M=/9/0*XU:&%3!8;3K_X(C6)E(3=^$DF3J<GC0WEZE)5:9MWJI9\A;6;S33P(
M;:I+E]-L\XXH#[8;3AR!?NR&ZV2U;$<'(7?BC2@_Z_I7D)54^F#/'H7<5S8P
MT<.TUFJGB+;;>KL(>.%%+YXGY('"W[KKJF>N>MBG$B^YU']/WWOU<4(N*NGV
M%XP4P^S++X`"QT_P,\]$J+#$VEPSS8/7+!SQ-M>@6#F8((<"/,LA.JN'"@*"
MDK),1#-#RM2*P`:;2YG$(&,B"?]#1A(B?8S$5CB3R-H(,JI!;80E/P,)"C^8
M.9I=1B$V.5S39B@4@<`%@U#A65]JUY&]T.5%O5J;6$[T&IZ4A2LX45.B.&4<
M%FEI9ZDIC5-"1BE)T<F!-;HA=$C3#R=ML85.`\AL`%6X?DC1+!@$XD`<%Z@H
M_4IL+.Q<6ISC&M#HQ8UEY)1D2',1%=[J*ZH+7E^BU)HTWJDWIRN-:=X(.0>.
M+BVSZHW&_&$0`CC$>#3P3K:RQ3SF>2L2DMC$)CHQ/?/9BS_<PYXJ5RD%9&2/
M%.*+I;M,"9]XH=(_`&H?+@=$H(`9XT`(HI\S(H8-97##0?PSIC;^U[\#4`Q#
M!#2@:%+_8Q$?D:12;8$:4^(F%9_`A45O\LD'=38I0*[C+*@)#%_.:"<)IO!)
MP0(AD1K3)>)U31]+HR'3J+C`@T!%3N84IP\G$K)2"8MKJ2'3.UVV'#.IKEET
MTX=-&J.SQFU,(FK,$HTPU<`Q%45-M?'*#YGVE96X4RZYRF!;/F/!E;VH:+F1
M2&`,8X&_Q(9RCC0:[<Q($YG*\%.1.5R==GA.S7"&AW4*#$1@<J4[F@:CH^IB
MYCZHPD\EAW)#TVFL+,`%$O#`>&M``;9"0"UM0>&LS;M$*`T0!/O,BQ3I4Q<K
MY[JN(]B5`^Q!'WJL)XI:D"L4?C7%O-SS/?/X1PK_81\N<PDP_X!QH%\`6P8P
MFS%,<!1S&Q%Z$/XHM$QE4@P$/<B8:'+VED%!!Z=_"A3H>*/&P*4,GLN*V\PN
MNB,/?B17*#,-1<3T6HG2\RQ8413.BJ.0F.ASAI>*R^FZ&2>JD(BG@=L+WYQJ
MN%S)Z3:<:15HXC0LUQ9W3R,C+4?DH<U(YD.;@Q)$>7.DEU3)U*,CHI)`[$$0
M<=;F(*^)VAHE&%T\#1)Q#L0J4:=B`]T=#CA:*8ZK<AK"(CVIFZ`SJE.J\A<E
M+?&#S#'B1GQG%1G)2@P5[BGD8.(U7BVEPPGF001X,(&_<($B&Y#!$-3JA>9I
MZWG0$VNX@M#6\)UR%-NC*UWM2N3UG/\+R'!-,F!ST=?QV7(7P9"K>@+D+U[Z
M\K&0C=]DZ==9B`%0F5[^LF4?YED+L6`+"'B#WBIH6JRB]D4W'-LA5V8:/S8J
M(P&QT6E:PJFT&#6)%?VGDR0J5=_JU"WS3(T<442DX^Y3:;'!TD1H9SD@VK-,
M(S%4(U]C%;0<*BJ+:0P:L4C$=-X(GYIR[LI*I!%"7^$M2_G@8'2248;@`VHI
M"I09MW0XQ`!1(+B&F341M0\.ZL5$MWD,M!R<TS%-0(90^LT04]S#(AVX9IMI
M\;#2MNM$.66BFTM3IT4C;FWSF6PA3/>HTDUNA#P;-G+HP0V\0PGE74(3I!3/
M7Y.\/;FR4LO_KFPED8O<[WOM`JY'ABOX^)J>5/""/=@S1I4'Y,L!]0+@%'H&
M9YLIYOXUD^.<[0:85T`Q<IP#'3SP:D3DD4:`-$X%6GOP2GT2-MP^MV;UA9L_
M;)BD!!9+-87Q-'YS=.ISTWI4%)7C;@'74D<#+E$;`=F+/)*6RAS1*W,\%*83
MRE.J%^<T3Y7;F!9)*<B9C(KMP$L8^U%.C-QYZ:3#[YZ]:=&?A%W2.9L:/&NM
M%Q`):9&Q];.IEYHK?7A-D@;%\(ET\F?F*+B/#V[HFWABIMPDN"W3AGS+0#+1
M2&VH9IUKE82K)AK'"R:)80E`O&\0+DO0^SOX'A=]^&T>(:\'X%H>_[@SCI"]
M?A<\KGI5^%[1U=>#>Z`8$>?EQ'G)?-S_[_D24V;'H8]9:S`C&Q9B0SEZ@`"S
M;^@B%3V6Y-)H7%.+QH/]V*U%GMH3E)CP;9-O#=)KNO<,JEK0.L-2G%KM=K+`
M>;].QS1$P0\V1"0--!@Y9WZGQ0^'@A(UEVR0\E^\,79N-$_)=BP_4W6,PT9I
MYUL]`RU68RKE1(%SAVK\9!F-]"*FU2(5]#:9,BO&QAM;918?,TB.I!PX:&V(
MPD(`\2SV9$1&E!!EA#/%Q5UK88#<97^;%WF1YQ44R!,YPCF5=H'GETZ(0@]@
M!1[?80G2<Q^S9W"U9WNM%#\#5X9V]0Q'@/]7>>5[;'@>2K8+N;`?!J<O[/-8
MZ\%\_;)\%(<,>"@P$3,PS_=Q$--9$2,.F"6(V/=,"'`.!20T14$")%!?3M45
M41>)<%$0%4$<M`9(&I%S@`1/<?%!_Q<I8S=_0N@632)<</-$"^$1(,)`.U<2
M-E1W`3@E<#$HT':+A#(0@(0T`&$DW$4<-Q)W:5)IQ$,F+4$U<A-MN"9!.$*+
M0Q%S:Z$"("(/Z,2#I1,4%M1&&I$9.W)Y(5*`>'(4.V0B\S41@N=K58%;6O%L
MB$(\%&@5G_,7WDA?J/$7SY(:<%2.HC@5]#@6AS1$__!ND`.$)*%"">88SX%Y
MA_-G8=$8UR01SV;_$B:``#T@`UOX+=%#/N5S2OTFAF/(`68XDD?P#&3@#&K8
M>VW(AF^("ZAD6(=E#.R#?!:7+_QB95C6?)-%?0"T3!.R#=1GB-'P,/Q3<F@`
M37(@!SB4<BG29P\6)IB"BVCB0I/V-K(6?L=(&#)5*1$Y:!P1>'\2)&*W(>I8
M&57'(FN43[4X)5-#;)Z!&";2)(8#&QB4D%;1)Y]V&3#U0@69$]=$;(DV&,WX
M:_-@,CCB?JE!$0:Q$DN3BCV!=OBT1AXU3ZWH9PF)0';Q./?0&A^($&M#3LXQ
M004)%JQS>=M%><)X0I4#=+U8FAT6;9S98B(XA34CET+5:=$F)_SP;LJF_SH8
MUIITB9LYM0[N(`9;,!U;*#VE)$M\M0L@&9(B29)$)DS.0`8GF8:KQ(9&MI(%
MUV^+Q3YWZ%@`XR^+A8?'\$M[N)-_.#`<YW&$R$P'(`Y(P`V954R):"'0Q`2)
M(0\?4R8N$3@S,Q0L>!&I,A$]85K^=$%=%"9GP2<Z<7GRB&B%AG[?A3B^MHUC
MY!':U'1K.264J&HWI1`BFA!'58SZZ!4`@41[%XP*P194!TD)U7Z$P@/:)"*T
MDUH=H4Z28A@[LQ<E")E!@1D6>%-18T)RXUIU01/9^(DU84(K,J*%IU*FL2F_
M,1,@!D]R4Q+DEFCB5DB^TQ<@%J5K03J>%W8S0?^D]A2FF\*5Q6(;]_5=>T0`
M*B`&/<`"K*>1&^EC2D8*80B2R""=NB=,UFF=5)"&*0F2_L:=,`EE>'A[`$>>
MC(6>YME+ZDDA.^F374:(^;-,ADB?]7F(`30.VF<.^IE-?J<1,/=1>T>-/*,R
M`-5%+7%G.%=0<01%7XI5FA9TM1J%<L(1WX2.+>A-'G&.K>:"'?IT(?B!`"86
M:;0WOLAI8`.1$=IH>SEA#M1IG2<WQ,)3^/2)2`%_3=&0#(&@AEDE0!([;HHB
MPPHKS>*7=K0QY&25Z8>*5:F.@R:A0G5:O?EIU\2F2R6"D/=]M,9U1E-($[8U
MF"A)?R1X7H0;;->N?23_!CZS@XRA*!:P`T9``&*0A8T@+N/QA7MJ+G.%>]%I
MAM1)/P(PJ(-:J`'WG*K$AE%V6+@TD[]$LGP8(,20DSDIJ35[(!C'#(!(3)EJ
M6>&`!,HPGPQ"E"O0,/9)<MD'`B"``$HY$9`H#R1@`5!#2:IG`23`@!:P&P7K
M3R-"KH=)*$\B,G%C>0R%`1)+KZ!G&8>V4SM'=_YE%JQ5:\?Z$R6"@.@7K9@Q
MET4B7:3I49$B)V:Y9I,Y)H$!>E0'1N/DC*5'%#7J:Z\103J7-$SS*#)%.5#W
M.HFR=-'U&CJS48;6,SED-8K97+J";->D;#)E4X.7%#9PCKQ2.#83D;_B;DRX
M_Y"K`WHH4Q?WM5-*I1D3V2RM6(PGU+G>NE-^L`-O(`=,@)$YMIS[MJ?`)V1D
M*)TGFR`JJ[*%BITNFYU0MBXSJTH]:[.&RH?$,*GH>9-^:"`5-S#O&XB/9;1'
M^WSV*P['U"`-,W+WN7WFD#G^D`54811W,QCQ%T%,*D%@4G3G"(4Y2J)`ESJL
MLTUH*:^.H99KI(Z+B;=Y"R-I,J^9TC5WV:51U">D66(W.'-H@;Q)@1-JRF=D
M)[<H`BE(XURSH7/%%54&6B4U&D("&6NMP2BY1C,U):;QJFNV$C@ZHQ/#"$-+
MD8$/(4AG0H1CAZ:=8BOW%3I0$L0D)D59,288&)BJ]O^B,-I08N>F#@:\<>M`
M!&`/QB.]'4N]Y,&G;4A7N4>2)YNRT]"]WON]6!:^MO>=-&NS`5.&?/@?D:J3
M.FFS\!LP@7@`OA`.01M]^6NT]%D-U+"I2ON_Y8``-J"4ZU``.]=/EN,FBRLE
M.MQ^N[HGZ=<3F?:0*%QT9)Q_!5JL`IBE58<I&KR6(/.)BL2`)(HF!E%A?_$9
MBQNMN[&+C59%(7RM[Q:K73PI(=@GTFB@&F&O5\.MND4800J\8&&V*T5?3YI%
M%B$C]&A&Z.1=@G?!IT9K5;08(.1(__IS!78K%.I<78047<256:?/H!C/%F@B
M@N0[PD(DPJEJ"$%LW`H[``'_O75Z`^`"'A_+9&#XD?\&<-I+G7WLQWYL,"SK
M2^`IR,P'GN<K,("Z>VD(68M59?'3AS=KR)5,M,40R?_3J=60M)[ZDY<5G^30
M`Z0*O0_A#B3`!2;B-5&$3VTFHQQD0:V<FT:SN"`:;7CRP#U,0QEJ+&K7RTY7
MK,>H-<4R-F*TE49T6\+"HRT<JT^J-P=UQ)*R36-$(EJ#=15[$/RP-IA3;+)6
M:?I$5;!A`[`+'$3Q(H/9$#E#85]K@'$FB@M)I$B:#TP"$R\:.LM":X#=MLD&
ML1YD++`Z2>CV9Z%7>#>CI$P58#LE/"^\$:;9N3'1*J)3=!@D/'(@'?/6>J/D
M8WSU_Y+.B<<HG=(<G;(>[=$@K3`O;;[LFYXP?<B`6I)H^%@W^=PQJ7S'+=/S
MVPR/-=/79TP4(I\'P"`Y'0W[4Y\@-P[D\,D7\P]7X`YA7,\/2W15"3-+_'E5
MQQ+-=5.&@B@K5(&5*0BMQM6$22F9:"Q`FK<.D<\HJC<2;#1)@,H2<6Q);7@'
MH2BLT1A@<Y?"-2N"ERH/V4`<!#3VP)]9TC7R9*Y6:.&#M'.,<FMI9Q3KD!)7
MVLPT4Y:L!<][-AOMNF<OVK<%BU/*8CKY6#,\VKB2.*6F#<]1K'@AJFID4^2V
MPBO>!J>,T1;0RP)#L`AYJJ<7+89YK,=[#-S!/:@-0C_*\/_2O>18U(V^T[F]
MPI23[W.3R$>S>7C<E&K(\U.IVGWGS,#=/M`!W^W=F45FEX7)`F0.BX@.27GH
M@'W,=\+.,AH5#'IS"-B4$3Z;V*54*+AG>3$9`XYJ/K,4#NS?7=V"\Z5I>-G/
M%2L(]+A:.?%L#WJ:$13+FVLTJHSA+43"**I2#@AJ*_ZDFC9;YBHD87J02H$[
M+'(I*E"C>>+6J'-ID^*D[R>OBR'#I^%0-`%)*(:0!UL[RQNB9@&QE]<ZA;='
MTDY?!2V+I`-N-Y-.PP)UD:U0-V6X!<`$5,XM5SY8%KW;O*W<7+Z]'?W1?,R_
MPWT_9S[P9'@`9ZCF*,NR_@$,[F/_GGK(OC']L\U@($2;W3VYW4+9`7P.WM,P
ME.!-E!&B3$@@0*,:6H:.#HH6X_O<./87K\`<JW?T775QWPI)@7^R$\_.H28H
MF;$X="YUK%.S=(8MP0W$@B?<KYK62#-*:'$;L:*VD'N66^U\6T`(UNJ`UZA6
MZ7NG-!J,RA$N!GC@16?T?\>N14VL6TO19@J*)2GN,SD>;0O1SVK[8=?&NJ>6
ME40(VR_DA&<J:["CQ?V,.)4BCU-J?[*B>%*Z.#;`!K6]/(APY1Z)[ZJ4O<N-
M\-30O?Q[/]L[Y@3_I]17J`BOY@;#>PL/9>O#2C;IYN89\5H6B!]WYST-#H8H
M`!K?(!Z/_S`[S3^=Q=U06P,UD&;T-`\DL`,B?&[*6BL&JBF3;5_8RH^OGK8>
M;(OY-#A,7#<?;-CDW,#O=N!C,VARTK`Z]?(O.*&Y-38AP<,9_N0M\Q`-2R8C
M\_58HDU=E$12`FS/N'ZD>405]LX$!0@O`8.$@Q86`2\V%E<!/!8V/(N0DSPO
M+U>0B8^-A8Z#CX>@AX<\CA9B8H<V`4FGB$F+-I,6IJ(!-JH\KJNUAJFKA+*.
MB[:0IL6OIH^3K+C`L[NOB9F1DU>AR*D\!0&]K"\\)JK1H%MK"0L+(2WM[0LH
M!BCQ!O5%]U/Y'OM2_?[]'`(&/$*PH,&"5!(J7$A%@,.'$!U2.?\0\,"!%1@Q
M6A3(T>(!AB!#BAP94N(1#CD<J-SG0:5+!RQ?RG29(V7-FP%Q<JSHL>?%C!97
M_`RJT2(2)!Z/7A30H6D'`3Y\0(Q*U4?&JUB-(M'!@H4.-FQZ(-B```$3'F]4
M^2(4*IB@09D.75&12!`M9VQ)!<.%"I*FMY+\(KKDJ3`ANI?>#L(D2A$CPY`C
M&ZY6BYFD":IT'9ND=I;G7&J/@;KKJ=3C4*?$F%@[BI2I0JM218J=6<QL:[J2
M#<JEEY0-NHD<J5!!&/@BV9<QI[+M:E&C%\!?!Z@&]Q;?2,`T[=8^3#*/UVU]
M9;,Q`5:L6ZB]V1;F[/LKW:5X;&M^:UC_@4J&$'TZU6R[)%U),`9.)E>\D(1\
M%A"G0A;BF<(@'A`Z8P$)*I"P`R(\R/$#`C*HLPX[[4`!10OPT%.//?E,P=(_
M_NS$P4$P$D020Q%%5=112/E$D4!$134551$)0,:01!(9Y$,*(=F0DB>EM%)+
M3[($I4PUS723`S?AE(.+.G)`E(Y8%76`4F#ZX)1#9T+E4%56416F4#WE>)0.
M7X4EA!`;J-**(-^Y1IR!T^5!PJ!_;D>*)^&9HJ=ZY`SB2GC82":I)W:)D@2!
MDV;JR17DR,:7?+:E<LI_MO52"V]]24?,+-810XE<U>F%:"^J>H-*J=8<%QJK
MW^F2C5S:M16)_R."#$?88H]HIA8PG3`"7'"$A%/?8X4D>\BBIQ1HZUR&`;K8
M=+64DD@N-L3B*6^_6-.*K:]UE^AN>H+&"C/^2;),*;R(Y@VKSI![H&P'-H;I
M%=JB(@V^UXF+R6J"H,*$'')L4,$0ZH0`8@M0P"!B"R&8>"(^*O+#HA0[Q8C0
MC"COB&..'F$EU4-`PFSC"@E%5.3-1D:4I`!)*M2D2U)*.=/0*]&4998"U=21
M3SSI^%-61CF-U`IF-H7FF4_)7-6;3B>%(YU@]2`6$V0SX9DIQ+TRX9^7!";N
M?K(40UA?UXI1VBJ1:IHIGW+'I;>F5\PB!F;1,`-:JK+<BOALG:DJ2?]_GSB6
M*E^"!=[):+X5<@7AF#U.ZJUGT])K>8$/V[9>TET"')^E@%:J*HUD4YQBK?47
M3B&NKW>=H9*Z!ZYKPD##ZE[#D-L**NT%(_HHV0W/W6:+]K5N,J]*1[=GI'3B
MW#0O2-^<#8UX)L85201H@0FK1<+$!CVP,;'%\+LC/\?PV',/R"N.+)#)!J$\
MDD<\:EE59*8U-E$!(VXZ(%.:@K,&#@E)'PG)23@@A2AY($5!FU+0@#8E)QUM
M2RC12=,V,L*6<:UK2IG:`A=H-186<&8GU-'7Z$3#L(EE`V^P00$"Q)A#4(AM
M"0,'YN*#.]DT8QF?R=O?]I:>22Q14MCH"VC_'&$;'I2'/&*@%ZK(49EF>`9W
MV,/+O]1"L%N82E6T6$M;LG,J1M`MB[_2#.G6`J@TOD9UT3G?+K!(FE`\)P##
M,8S;A,B6QR$G<Y2KU2#HXKO?E0)0I/"4-\K3BF&4SC?9R$_U"!%)2C)J-]%8
M1=R<2!\N2H<SE$R"!3#3"NJ$!UBU*!]O,C&^Q,0E%7A@0@]8<(,AI.,&\_@0
M_(89@OH9X'XI"ID'1D:R_?'O9"3IFD<2@D"IO&Q--F(3FZ[R,JM0;85"<N#-
M)&*1(X`$)16$23+O5X1]W"^#4QI:2SYXM)TPK81$@=I%9,BRI3@E32ZLT=;>
M1-`O&>4$6PF;67Z@_Z'$.4-!AAM67ERC&+?IR3*?,1WMGABMR/TN$:MX%D<U
M1PM@Y,8OM<G5X0ZITK<-$1+EXXMLI%>7N+C4;?$Q37D6]SER6`,2VZ";)6A'
MF;44*BZQT\M/>9`)Z0PGD(!<G0HBD393!$PPE``&-5Q:"!7TR1DV]05]E)J:
M-DH($;F8@#;T(Y\K@B>-.?6I)E`#*E:@ZT`3N.)@KG,<_53B<?D9A&P*@*#R
M;6X">1!48ACQGRVPH`)K6,,-@J"$RBHA"`:H&#$]9,PBZ$.9S`0(1YYI$&F2
MT"('I)HUM>DFFK56FU,1@!!@5LV,^&!)'1B2!'!&SH$D9(+I=,`ZV9D/=O^^
M<Q]$*QH]5:(T>P*0)]0D*)SV^;2H]60%+/RG=ELHT&V&R;0465F=Q%(6LS&A
MJWY\#'!4H)=.%"MNBWHE'4<JF;?X[3H\$*EA]#N9*IJT/(_KJQ';J+B]O(<U
ME$N&93BE54$TC%:$N*I2:7,M6V"G/*RT#!N/09@[$B@^?T(J)M93#%Z`KQ9O
M"62Q"G$L/@6'K(PBL78$&3A330Y>?ND3,#ZW+E$B[R[_R6NY##4+(O/X>TQ%
M7F"JF%8`;X=7,IT7\@Q$5R7+BU5Y7<9W;+"^]K%`!FNP;&6#$`04?&A^%O/0
M/.RGC_PQTT4O.@B<*Q)`D-","K>-+FMCALT]NTG_*D_Q9LN")$XR\`S.49J"
M9XV+3$43%YXOZ>`'L01"YW:$(06M+E!\`B?L;O?3W.WS0/4)WC&)]RMB>QC$
MY,`@\.6A0,5J2WX5$Q=99,-:^J)O9(X5JR<K\HE-%=^R;H/%6WUUBW:K*.JJ
M96-8U+553!T>&G7%+UHJ[C-UD^(L`K<:1^27OXZ4:"CLJ@NV&,*N")Y=K$U!
M.V&9;I6V.=ROO7V-WB0/DX;H'!5UQXN+ILI:\J:<OD"U1TEJ(XOJ.=6`%^7%
M78PQ?)),S7JDQV#!B0$/>M`#'K;0`Q!\.;)D)G,PSXPQ=\!/'?/P&#ZDQ,Q*
MS_GESD6M2-[$IH=D#2I6_]'!44[`<YY;U@$'6&%4QA3T?T+$@5`AX94NZ&A&
M&[?IC<[@DUY2)4J+$.81C"Y&4EL4H'3]NIUFB@0D`&JC'^G/WA33IJ5)IC&-
MMVP0.D2AU#9K![-7,*T8=]UVL5%='X;7L4(&8_U>NI\NQZ<E#4U@+)[K`R^#
M;WW=(U8;$YRB+@->F6GCY_2*5K40;C,2!61D$G5?FC;2UKE0E7[YY)ZY814\
MOC%V1U^#U/:6(S_#,%]H-C.Y56)H</J!=S1X(VU#*37RST#XOQ4G^-<_"JZS
M4=XAQ9"'Z0Q.#%O(/ANZ`N8;W&`=G`W_,-N1YA*=J!YD-H/ZS3`%,R`SGE:G
MI__\Y[P13NL9AGZ>V<[%K`09]/P$E55T3&$52.``)R`$G^802`<G(;02Q>5T
M]W-,$'@/&U0TD39/],01+I=UF/8T&N%U'SA=8E)T8U=VH18DW51;4#."7>(E
M7Q,6/4`VD9`8K@()"D(7=]<=FS!@U#)[?O=4D_%(P]!WZ_540*@YE%1D*U4+
M$U<;E-`GO6%NOW)Y$D=@4+@7[0)A-7A]HL0J3E@-CS`!QW$;EK!(X$8(824N
MLK,?:L-51RAZE')K;T,O;74H^V$*2-4,E-`)KS0]HE!7@H49KM%7_+((K$1%
M5P0^H^`,P-<P@NAC3-9):P%\B[`N@&4MO[`KB3<X&"#_`@W0`([5?=\7?IR5
M<J2X`),5<F16#RGG,>=W3&V&7$3#<BX70M#5,@M1<ZRU`DC`<TAP%3O'<S+@
M?_Z'4,9X`D&')E&!!$IP@*"F@`WD`QM1)>P'=4[WBA.X<A6H7!Y43[;((PHA
M<PEQ$6FW::0V%$&1728($3?W0C`4@M/E-#RQ<PG%!F;1#6TC.M"A(*_2'JZR
M8YDD&48XD`1)D%V%AF8T8Y!1D$:X.4\H;->B4B9519H05HZS;*``#:AP.;9B
MAZ_A&Y$08'VAD8QS;:]2-^20.E$E&;>$<)RB'QT55J%GAHC!>IKS2$U%'\,"
M*H*A*G$Q'.*R/6J#+31U.#56_S<VH`C;T(;!T%9.MCO[]E/70DF`J'<@N4I/
M:1ET%QZJX%5ZL0.I,`&YI$LZL`8CAW*LN&:JN(KR8``B1XHG5R*MB#\5Z`'J
MUW[KMTR4EC3-!7;>M(L9H7,^5UD(M14X\G^(F9A%YQ0^`(#.F(#0.$X301$I
MX7[W\#&,AHT3J$Q21Q-&@S0Y<6GCR($UPS57$10FA(YF,G9D9X(`)6HX]Y?E
MJ'9KUQ,!\35H$(-G(0EX0`F)\%0D@$BU4Y3'H))=Q9#(.9""E%-<=9S)^9+Q
M!@DV)61Q@Y+>(SF/M!AI5#NZ<CF5XI&+J&V1E%*&`PR=4PP\*2I\\BQ0!0JE
M`0T,YO^>JA,>2;E10,@Z?_&2235D3O0I?J0;")(?X,&'IO)B>B(M.N9LL;<*
M'VDW8P14^M9$T(-P"6='6Q9+`'=]S?=DHN.56?!M1_@=&:)+8)9RQ^26E#5F
M:RER9WDQQ!27)NI9,7&!%V1<Z@=_6.(E/>)=1H%`0A&,8N:+P5B8O;@5-&2D
MO<ASB]D4/L",2E`UD!E.8_=`U'0`E7F9KXB9V?A^4+(/G"F+W`B:*"&:TY2+
M`F":YMAIIVD1J\F:K>F:6B,SU=0F64%J);0"8+,!3)!+MW<)344=WB9PP],:
M\Q95R7FHB!&H']4]J_%KB+HY*65K@DA)K;,LL01)J.-BAH/_=[B`&?=5>6X$
MDZTQ4PH7J;B1;<>0509V&.UI&%($;U0(2(G2=XO4&KX1%WB8D/T2+)K@'*CA
M&+'#;-D3`-V02;D'J^N2<(*%5K50`-T`;^(9E-H!.KCC26:$%]"J>'I$%PP2
M2+[C587@K`4`!@$`,62S2V`69I:UEM[7KFLPC#*@!&9&<IM5BB;B6<FD04RW
M3BEB!DI`:4>A6KLHF$'ZBSJ7I(FY,E-C(UM!%73B`T(P,X#&F$A09CJ`@)`I
M%62P6U2*9U3``3"!I5EJ/Y@I@8_&$HKVI2TA-!DH0CH"$F<J72"83VOJ::S9
M%&^ZCMTU:G4J:*56CT)0-G+0#8`T_R%J^)$]J0P",F^(BJC?DE^]UI&-1)/(
MR6`%%GVW@G@EJ8BN@'MO0V61Y%>W2GD'EB`NEK4G%8;7$B[A\CI^P0IT\Q?%
M\H9W@QN">$?0D61?RX:U^CNYJCL2FI2JA&#,0$O=]E&;HE2,!*C]:4><1*$P
MA@O'8:WE)@N5`CF?XK5X@4KI0PM&&*Y$.PCBZJQ@4+IRP&4]X%@5,(QKH(J1
M%5G#>`(T-+L`6&;"5$PH9Z(FVV88E$$8E*]8,C4""[$1FW,(.V:$B9@(2Z1;
M,;S$*XTZ0#5"035W4KW;)8UE]IC;Y1#8M;$<:V@OLP(@*[(C6[Y:RIF]"T_(
M91/L&T+-I?^CD[D0$40S,ENG(`@G;5J")>B:[1A;L5F_-.LT&`$V/?`&&4*H
M<Y6%=DBHO\.1K-JTR>E4P/&2OJ9ZAUICEKIXO$&)J<I%8F0KE?`6CK%CQ4,:
MGY"&;)$[5VF=IR)@PH.UU&*0\FD!&(`!Y4(>8E@.>6NT"!89!//#G,$*N,H?
MO,-BM]0Y`M*W3,E(AR(MNUHNXW9KS#!E[S&&906%N,<?6%RVWW&4YV,"WS$<
M84P(XPH&M$JZY$H,"-``+$`#[1H$KUN,LPL6:%#'/8`&=`*O2C"*<JFEC?99
M^*J^5+(E1'&P25HG=-*+\+K(1.J+)F1;:><C.,>+OQ@458&QVB7_C9>EO=JU
M)F+WO0KX%`?@`)99!.9[RN>K3"KK@!W$7!\$CA,AOQ<Q$;95OS)+CCA[L_Q[
M@CO;6FOJ@?:W:6%A%J\0G.T!A;S2;K<PQ)X`P<GI;8#7D4\F4H^*DL*35;51
M8S",8+W!D938*'FG5.SV8,!S#/_%*H$SD3G&&<V#D*10A"%Z&2(P`IEW1@+7
MP^:&D,9P?<-S5KOJG>[95M$9+&^5J=,@S=VC'=)"41WY&-+2&;_`>W.UJMN9
M":M!"EE`(5D@P^L%!N-Z+,Z:K*#P'QCPB0QPTC1``Q4`-C8$@ST@!&+3/F"A
M`P#8NBSJBO80!%O*F:Y<$_V4%(,9<LTX_YC\]W_-.Z?:I%J0O$W16TV3'!6=
MO`(`*`,K\(Q'!\HLM`(YX`'DB\KF2US)Q-,P`::?>74?(8[QZS*V[($$536Z
MG+-1:G,_XLL`_,BGN0)@$;1,X$-I,P@,(DJQNDC+W)PXZ,P,*<&T)RZ?"J*%
M/9"<8G'+X1E'R4;L]DI4&(5,"3O1TH<3M;;.<WC]6&QIBT7`)U+BC$<J=BF#
MDU=Y);:4D$:LH)R%(8>9%X9V`Y4+;!C`I[;N^5)X<5].%`[=!JZ*T*CD;"D-
MS0J\@,0V,`Z[(`YL=0KH8P%9D-%7,"@_]%1VL-W;?2QV\%0O$+K5,MEA6=*?
MV``@4`,U$-/LW?_>:,`&>2R*I7@BF(7*(--F/7TE*K$R0;VB*1JD0MJ\^3?@
M6R.-!S"[WS3)WW0F4AT$3H`$U_2::#*EAL849"#*(>O5(TL/IFRRC/:ER94E
M.?J^`<$0'V$5!X1G:JV"D#R]+I/+N@RG-M>.WB6]-9NF`4R.83$+)*`ZKG(V
M$FPL=V<HBF38SER&_8F%1KB/C@V2)A6JEY%Y-PGEWV(J4`:M/9@PP6(HJ9#.
MC#=3AL=&DST!J\&';?@;^^CCF<L;IP14NT*USP(8J8H*Y[D<KWU6K(%&T-/:
MO;UX;U-Z`R<70Y5)D#)$MW<7%BIW3V4O4'N&B2&N`5"Z1.N5C&!3A\?_VC6,
M`7FEWF51%AM`%I\N-G7L<:M+`Y(U!"^J9O2PBKIK/T5PHV6=)2?@`)=%9F(6
M<O1MZY9%I,Y+X'LVO$HM%-&K`S[`!@GNRREX`BAP`Q!^35?#CEC]3UK-U1VN
MX2?BBA`8BRI"-/(GIF4ZOQD1L[7,XBQ>CC[2`6ZZRRT4:C'SZ]\%)B*(I_9X
M7E'U.$\HHJQJ2P)C@V,,YT9>D#XI=WQQ.1=<G8<G&TC%1@$-2V6X*M:V5=U\
MAXG#S4\>&-9R2&X4J1V</:K2S8GQG96D.T5T>`VOG%#%":'`A19W.+$-/".]
M2'>%PXBDAVR5Y#WH'MOC1YK4@]J&.89WDA62_]UU0:QE/`AV\"W1$M*8L]J9
MWO1-GU>:GE>I\`94_P.?O@%H``(>)P.F?@,)X`4;8W(GU^JL*$P+8`#Z$%R5
ME=\JH7[^_?;J]Z^%J5K6VQ35^UH#Q;-AXLMWKP/D^)?X"Q52K0XGX.P!A2;C
MY$*CK&C6GI9KYL?W#77QM+X9Z+X",8Z8%NZU);&SR?DM;K,W"]=EQQ1'4OIK
M\N[455T'=0)LL`'NP5ZPPRW[=?*-@1_.^>\%64B!MZBR:BR&.AW@TPP3B<[)
M<@W"ZC>*H2L8(@IAI438(_(QYL%K=,U?[E_1)Y2"D(9I`QU!*2H'HCFI,`Y9
ME&)'"*YT&+:V/;G*Q_]5KS%5\1'$^)%&G3#$!M9ZP)\]E](+2=4;60@(62H!
M*CP6/`$!/"J,@R\!8)&1B90!+Y>)5S:;-F]B8A,3&`TBI0T8J!BAJI]O;S97
MFIPV/3HR-#>Y0R$A+;Z_P+P+"RC%*`8&02B]+;R\*!X.T0Y*0=9%9DK49F9%
MR,C6X=QF4]$Y.0<'*SX^`AWO\/#L\ROU\S[U^?KY]P(^0AW\Y6.C`\F)$TC4
MK5"X`IT`?TB"W-#QT%V\=Q4%D-FX\2$\`2LX>/#VK:3);\=.%EG)<HI+EBNG
M2?-@+H<#!^=RYN3`\P`5*CY_"J6"#Q]1@?L6\L.WCFD[INO>29@Z]:)5C`'_
M,VK=BG2?PG0,U1U`XN"$#C9,Y,BQ8<%"'A*,,%4BU,C2%3$6$K6]@HA2H[^`
M`PNN>XF'X41L+:AXT5:Q)4)^&070Q&-6VT\6/L6RP+>Q!1N5#'FFE(0'YL97
M*%WQW#>1Z+:@#6W"_&G39QNTQ5C&FYGW(46>KPQ"5#FXWKP!,O]6Y#KQZ>5U
M_<I>?5DW6U!X/^&=W'91ZT0JJ%O"'1MV8MO+Q2?_/'>N\M3KE1ONC3IP(DPO
M"NB7^P),`4C[S15>++.!(DH#")Z2"BH3:-<*)_`%D$02D\G"PBZ^A##,`KPT
MTZ$PQ%BCQ(@D(;-,"%_<L,8-&HXXA3?%G%12.#"9_X%3#CW]U`X\0@@A@(_^
MW$-//F`EM520Z[@3Y%/L(#&B#`B!)>5"2#3EI`P4;15/11QU9%%%!^0PDHQD
MEND-3&@6X1)-;-[DYHTWZ81C4.D,5:</5-2C3E?Z,`05.TOILR-55WV4459<
M)0J5D5(V6B0;/3#!!%LDP+78)2](!MX@E:A'76N#A2JJIH548H,)OR7&PR.#
M:)I);`&0AYN#G"!F'"6O=:<(==>)\9UGRRF2&+#H:6?>9_3A55RO%C3H&G"H
M&588L9L@HNJSCPP++&?MN;;7L+79$(J#RK)E0U^<>JMK9:!1:.ZLR/:EGKFX
MAM8<<8V)@2JQPOUEAQV82O\B,!B8J%!`97WQ$(LFO872H!BC)*C@N-J]LDDL
MB4S8'KN9L7"B,QH*@T(X(QYTD#8.=(.,F@:,[,3+-S1C#0K#&*/2%".B'.><
M0@EY3Z!&ZE#0E/WX[,-8#*V@0U/^G!"$$@<AD5`Z7B'1I`Q8MJ/5E@]U289'
MB/K`@0,EEFEV26FNZ<&::M_4YIMRYG@`!T%103<[0M&]`DA)^>G4HGW:(Y4$
MA2+Z9:**&MFGHWL&R0:DDUYQR:699MKM?2^(=AQTHW;^%R&@4G)M8H7PU5ZU
MML*FG'*A`8LN=;"M!EIRIT587&/GBIZO=<B2^VYOM-YNK&'R>I:[NO1EHBNN
MVJ;_>MDAZ1[677>RP4ON;<O72TA;C-!K*O#;"=N6K;-??GH6L6:AOOK?$6S)
MP)$\DL@DJO6:G8.KI'*@"`W44`,"K;`8+.9"(=<T@@0$\`S$9$`S#8TL9U$S
MR,E&-+.4K,PEX8#9%V8`!6+0S(,&4!--=L8!J2&!)R5D'*.D-A86@H6%3<&'
M.IXB!"8UZ2#G2`B5HM2.%3@@"":+FM"\,L,5'$0'6CN4X332);!E)"1C.IL4
M5P83EY2#36MR$YNF<8X;G:,G<Z.;4.KT$Y#P9&]%`912[,$/Q1'-'80J%.(4
M]<0VVE&%(*':67J`B,G%!5.N^H[R?O,IR&S*<Z,Z3'L*_PD[]C!'6.6+E>JJ
MLQQ\/>]9K\&,A`SA&VXQ)Y/(P1>M9I$;9'V&-A/@S"'@!9L^9LYUS#,6M!!1
MB$'0ISN/4-BP$D:\Z9E`<@P[C7;.!9MN.4(%W4F,]C@Y/$DBQWO$JR4C%I$N
MR5S"#G,1&";@5X!(E&X^UC&0P\8I"@SXKP8/TQ^$%M8MXO%`?6U!(`'FR;XL
M3*`"4$/(U$QX`@IN"&0U^X85O6&-7"0`"E!PX#7*$2<4@K&%2,BA"2=*40E&
M,(9_ZI$/R%*EI=!#"0:P40X0HB<8XL-I4).:$(4F-3VM8P4&0>(<N<21K!CJ
M(53(P11*8HP83?$;:++B%;<8C?\1S@0G;MI)3U!HIZ`(`"@^`=1#C/2G-;*Q
M2$R!8U7DN)4D9F0>#UF4&E^JIRFM`*I@.0L3#DFYR>$*7;@:GS/3Q59$=LXU
MB"CDZL+GG4UH#S7/(=X@]](Z65(G/*Q1A"6+*;U1KA)\QZ+D)VZG+1M4<W5Y
ML=Q=>*>LP#02.:YI9&KZJ$M5<LMZV7EL)"NAJ=<<CWG508^N5!5-[W"*4Y?P
M#_PDD5N"R4\_!="8^/#'BG*2<YP/@@6\SJ5(A1'H7%D`5J5X4"FXO-40/1#"
MXW1P`ADHHX$=RA"(CJ$F*])DI\6X`8<T9(`1>1%'#HTO3[IX$WT&\;[V/<$*
M>O0.']'_PR`4=`!%#S"/`XPH&V71(1*6I@^#+/@?/A`:0@I2I31&F*3^F"D3
MR8"H)0K@`&1#24\M^-/R"E5M:R.JVZ;1IB^"D2=-+>-/[(&/L":%;TW9APRI
MYA2/$*YP6BD:.RIB-!J/M:Q%JA/5%API.2BV$8"4C"+G(IX7'+:6=;5KJ$#7
M%PN@:CJR9,XFIKFJ%PP+%HE539H1\QQE[<HXI9+=;&^3F]W<[SRH;4PO4<.6
MP7J25[V"3V`,L0/'L+:1@C3-(?;"2=AH1G:/'/0BH*78N/9.=9.=)63H.C#]
M1.#3$>BF;B4!W&Z&=F&V^00Y]2<*BHG!%;.PW937%]W&F&!?_UFP%&#`<Y]*
M%.`':)#!#1+@A18@5+P@TQ`Q+FA>+'Z0&-J(KU+E*R=I<.--$7QPCX2@`VMT
M%*--"L(PDJ$$?A[$2B1#B#X7[-*C(6';4^'VR\RR-"%QMTH9GFE-M821HSE`
MQ",F\=E,/%"ABK"H6UPQ"5]<MZ$<Q1]$`:M3[)ACLN:Q2/NP")"_*G&P+BF)
M1;$QC1?"N!>:I<G1I%Q=IDQEN;*%FJ32LN<,R4S0X*8W$8(%E#_Y&<.LAC??
MR=7LS+6[H*?96I,D>G5XDYC5/*Q<BTYELWS5'`6NRWBB001]CL<J3ADB-9IB
ME6B;.SY%:SV<>^GYI%<^3<KA55VJJO]L-DM=`%#;_>Z@3H)^0L.)ZKA"._E#
M;L4Z$6N,3081%)J/`O=E@5SK>M>8"YA<`J"?#<B`@P@]-H@V9+,@F)BH'I""
M`Z90#"5\T29O2BJ.<B)ZHR+U)CKT60VYJP2:/:UD%<:'$C@4HI1:U&H;M899
MV%$0[JX;4#Z8R@]^(($-Z.`&7W`"O>U]D`,0V>-:V?>AFNB#')0HX#:3(L%?
M=/`4CS#AJ9\VW<#B<*%4I(Q(2E+()ZYC*NDP*3NZB)+":C0+][\??*,U3#$E
MC;)@;"`$:^47F)(IPT%+[6%E+L<]=,&`,C<JH.,:>/$NV($7V=(ON-*`Q*$M
M$?)*N`-IM,/_:-^C9XIU.\VR:+H!6>;"3)AA&;/B9CQW2\@!.YJD",_A2=$A
M36$'.L"2&A!(2,O#*^-#'EWW9*T22*T175E0&89$"?[A:7AWA7>W=YD`"OHC
M3L>%7*[P!K<!(>:3>%E@`]'E,+[!7#'W.90@:@6P@'*A'SS``EZ@`%"0(<3`
M>;D0?@3')E(0B($H#7!B?EN$8D;E8F`Q-@[``8JC`[OG0,40#D!$8,&G;+VG
M;B;T4@BQ;3UB"VL`)>>&#T(P%1MPBG10`=`7?6;Q4C+43]8G<EY%4QSV-8GR
M-2!&$N#G4P-712\R5*"78JFW,_"U5'3B<!5Q5E,%%0+Q%%=55B5U_W\OA556
M<7W]QT9,HT;:R(PXA60D]XU'HP,;D!9.5F:`Q%H/R!VAQ#UQ48%WI0B,D!G+
M92"U$2O"01?1\1V(]BPZ*`:I$4RFU#IK%BL.8AZZL8&ZD75U)CNF\8+!0CN=
M-#O4`0IY(1K-<X_1L82L%8^^$8^9]2GR4R&KH7BKLBGPN&52Q@,'`US^@85W
M5X6A1G>)5X.B8`H(8D[GY#]/EX&PL##LU$Z&`4_;@CNX@0KH)!AO6(7_`0GQ
M,WG_,0%ML'D>M"&<YU/E!8B"*(A>M`UF0(DM,4(.%10RY"3'P`U!8",=%7S-
MT%/IEA#X$`1K*2(CXF`M-7M"\SAL@`8ZL/\B3B"*2.0#!R@$&_`#&P`":4`!
M7Y`B,I![@-)/.2"`]L`5-66+B",V(;:+`B<C:?*'H#<3")=^Q4@W+S84(G<4
MT[@W&/6,WT@EZ$!$"@$V'_%_1V9D?S.;>],5&*<4[#`66R`&:6$8E[(8U417
ME<8=H(%,T-.$[FB!P&$"!8D;4F<=_>(JQ`DM*E@\O6%S":DMQ+$Y$HB!#Y-*
MOP,\1+ETY<(;#EF29Z8M;-9)OY$KBL$JO$87AY2"SV-)K7$82&AH=.$=,!<7
M5"@P5HB%P/5ID2!J_D$AP>2%JR`"`S``_%,#./D_8=B3$=(MIJ..7G9KM[8^
MA0"<E?`&(E`&`%#_!@P0'0'J6Y)@"0O8".HS`3B0`#5C#%3)>52$B%F9E7#2
ME<K0"S>@,_#E*`GA).HE,C2#`N4&82?`>^NU`")R?#Y0>^4F-`?03_V43^O`
M;6=QE]JU!D,0?4)#?$=$!S]`!W#@!!"0(HJI`S74F$'@`+<)@-G71#,5$MV`
MF68#$U147@<G5`B'?JJW$V&4#F(D8T/1#D2AFT:FFE1#<CDP-6)A5DEB*/\G
M*'^BC2+'#U,5.&N$#QR0`RRP!9("G']$5V[8<NOH&,LI*L5I9;S1(/8S3,SY
MH7)70)MU*_%!/=B)2YGD6`6"'9Q0&75&/;"T'?#9<\"B+_D)2XU`3>#Q_Y_I
MLCN@44B=\EG"T1E81WD(JA^1X))WIW=)$`$38JN<@#\.@T[Y@P&FX#_&XI,*
M(T@2(I\J0`*W!BQG&$UO-X6QT@`,``$:0`'(\1^\A2F1(1C$(P8E$`+AUS(C
M!E17N44Y*@6?6A:U5PP+X`L+D$_])")))25!$`)Y*`S6X*3EUA0RL%[CI;%2
M(Z83)C2@F`LJHE\P)8YH0`=,L`%P@)@I(GT'2!`G4+-H``<RX`0W,`0)D`!K
M8#5MB@].H@1H%%:(TP$<QA480610Q+!XJIF;V1(O47Z="3<Z$98PUG[N5Q1`
M05:,0G)2\E`O-#70.&19@7S;J#CX9YL"$1;MEO\.4J-6<J`"7,`%<D%+%NB1
MJ4.<JSH8H@-XXBE,EH5(A"!WQ8&>J?0LN?J>UCD]EV8LV$.>">EH3U>1QW$=
MHFMFZ'F?IC$!A999>Z:"TM&<@H!EB>N>L],:GU5=)%""E!<!8."MH+:[61A<
MNY)J!K(@.8E.[*JXJ%"A.N=6WK-IC%`I\SI/'XJBYK.`^F$#"``"7P`!>``&
MB?`OC<`70>EXNN:4/-``:X`V,-)3:--L68E"@7@.D<@A>4BR0;"82O`,*5$$
MCK@0*.`&"66D3Z-/X4:R!^%=4+(&*?4/QD=O(``"J@A]N8`E,(4$>3F8J5@"
M.HNT;*JE:!"T1'L#,+/_!B?`#AK5)-7`IK-(M56[-39E8]X'<`%')EN[$@-5
M!.<%C&V2B.HW-PW7?D]UFH`#C7J[?I^*#G,S-3SA0KDI@%55<72K8_0P0Q?G
M%4B6#F>!!Y8`N*8Z<XRD*T!XN$@)D;0R=6/FN)?+&3^'"-CQ&;@E&H6DG_EB
M2H80G<A2(#@HO!19:?!Y'4B7+Q,0&YK[G@H#+)9`NYYQ6RN8+,J",']!`N3K
MK$GIN[R;A;"EN.6T()J,KA5S&WDP@RR'C\B42NYD&+=K`8]'O?^1'W#(K0,3
M*]B;!@FP!8KPNO-D`H4&%Z[4HM-T"#PP`3*@BR;"OC>J-N]+;<O`(AAK#2WB
M_R0B\PT.D`XY<+$>XB%(ZGLOE0-FL&Y((`,KD@!]^6Y:>A8/C`80C)A#$+-(
M5*4Z4+-T<,Z(Z05>L`9(](DN.[18XK+]YR1!8#4:IG$L[!%$EHLR/,,JL;5=
MRS8Z;%0UH7XH],-"059&L3=Y0E:.`D81M7XNM,2/:E8S-,113"1)DR1\,E58
M=321FE8Z(*I)L&M:1I`?V1T?FF5BO!@GF)W+95=X!2[A<P7UVDH),TGZ"(..
M=F=$5V<:Z!MXI7@*9'-+]SP,(Q^6QKK6N1GP81AXECR5\"^/@*`':J"CQKO!
M]1_L0ER:S&JNY@G&<C'P>B]!:0'S!,D4Z9^ND6LV#?\9\O,">N?5\'--V)0%
M>"`&",``&C``I+.<AV$###1%#QNQ\L4!I(<":S#9(O*Q3R-N>O@T.`$6XJ90
M)#.786I$)7-$.N`$Q";",H`&W%8!%:`#='"*AJFS$\RF=VG.%3"T,*O.3:%=
M+HN7:/`S]E8-P#='6M/"6Y,HN8B9"VL2-<RU)Z9B8.MB\45&[8<G$:>,@=(H
M+_:I)71"1CQ?2*PWJYDT>,LHN>E1NWF;JPD5!6@6"/`#]U&J:'Q8\0$J-8V4
MA7P_JZ0;6G88D=L@5Y`$=T%,B65)ZD$<BGM*YW(]DP2#US''CT%-QC-;L)H9
ML*H7OH'(ET2"=V%*IM-TQ//_6MU*R5<HH+M+XJ$&26*(O/K3A0$T"Q8JOHE0
M:@6$U:<L79:2'":`/IQB:O<A:KGUXZ,V"6``OL_;!$V@`EG@G!,P`!K``"II
M0`3`H280UW]!L&]E`]T60FIR)B=A7H[-$T>`0CD@EUA3,A)1#2$``PK@!B%P
M`QR;`V?E-$^C4MXE$3<P?2M0#4H`)>U<VHF9IDZ`!DS0`S3@!'"`BG"0!DZ`
MF`GP!3(0F`1!$%B#-:Q]EP1QE_^@79G.!D."4;0WW,1].%J2;QZ!B_^6$EG+
MW,W-IP\;C%RD5*$)T1$'%(!"!7R3J(0*%G-RQ/"5$]+<14A\#B7W%9(:.!AW
MTDD2_YE5O#B-<A:#&8=01H'O^,6*42JB7-,7"-/UF!R-B\9=UB!"K:%N?(/1
M$M7BOAVR(NX-8I'``^"Z`CN"M@BK\7.V\>`6GH%PIZO6B1>`AAG4<8^MX<H"
M`VISX)*2D.+LHL<,.DZJT"`"-$"7,ZYU)UPK6&NH<LJ&0!PHB@C^P90'JI3>
M"PGS,_+>NPBT9KLY3I`-4`8E8#%ML0,3T`5=$`,$8$U9!LG,Q08@Q>4WX[['
M?`1"/^:?FC-8(WS\K.8(I0#S?.=)NE%7*@-]WD\LD@#Y_#@G$(I8\L%G>K2)
M20$-L`$UP``,`-MP4`%ID*9?D``44`$@@`;9M5V8_L';!O\H^HP/+LM@[=:F
MH;["`@VU+6PX[S!D7G4T'E#0RZV^S9W0"_TV@2K=.4*V.D)_(KU^88(.OIX3
M."$UFC_L2%QR:GO>B^.-1++L6@.-(AVI]0#M?=2.=H6=H2L<77??DB%EQ&(:
MWSYS_KU7DZMFN(-)0XAI96Q*!6E*X&.#R-D8MQ4>C,<6SG*Z:[A8/3?5]2J^
MAQ&2`U/),1D!<W#PGT;6%HX*"J(_Z/ITL!:LVIHQ>[W7>0>\Q%-K;;$^)$!-
M>3`*(A"JN8,)X[I;NP4(=G9@@V!9$Q-9%A99C3P\*@&2DBH\%F(V-64)%0P#
M6Q97)CL[!"0JJ*DDJZ>HDP5,)P;_!D6U4[5%4[H>NQY2O\`<1\/#'#D.)S(R
M:PLH2"LG2C)*-]75RDHG)P<^/CHG2-\W:^()"3<T+#T(+&TT%6AH.C(WYE\)
M$`UO;PT-"'1PTI0H06'@)P0]&FSIL:&'D(<0(W;KM@*)Q0,6D1S8N((C1&](
M9.@0TJ%D20$"3J+T@;(#RI0O4W9@N3*F@`-%#*#8R7.6SY\^<0G-:>N6KBD>
MDBI=ZL&!4P<YHN;@L)$#52I4-F+=2H7B"A\KJ*P8N[&LL1P'.#B5^M2BU*A5
M<VB,JA$CU8X8ZW(<RW<O7KYD5PB8V#%PWP-D$5=$PF9#@!>07Z2:3)DR#TE7
M%DFR9.%R_^7/H$.[FG3EL@TQJ&V(IKR9AXU%/*Z@%A/J,N9%N#<'X+R(=N90
M8B9<$L[Y](39%E[;.#V;M@U)DG&;L``Y`*I%KX=;V!V\-VX>+W@GWUWI4:4L
M`0JH+Q"AO7LP\-W+G\\^POH"R_?5P("A@8C_(C3`7PW'H;;/<C;8ED02ZRW(
MH(/W%4!)*CR0T$@6K+`FB0D#E*&!!@P@($D!\*D'1F3PE0B&A"M*,L@D$X@@
M1FR7J2=)=F+L,`%__30`1P(S)$"$!A#(*`8&7701`Q^K4!;9))6HP`0;:P11
MU%!%)07,+\(00\PQ2BBQQ@T+W'#"-T&(=*8.%<C@A!,W!)$--_\6Z?#-FC+<
M\\470Z2!@`T-E$$!"'2``(>;]R3P18@;[K@%"P.PL,46-2#PQB-XX+'0!DPP
M\1`;*[#!A@Y?320$&]&`D]&J&OD@T3<CF22K2R_11&M+M)Y$4S<Q^9!#3CKQ
MA`)0Q,Z"Y95%(<744D^]-9555I55%E>"^2`68&11%=>SQ[`%E3%KP5751E*9
MI5A&TOJ5F+J*<<3K7X4EAFU6VK#!!"62K?:9=;]%@ATDD4RH[\"3%&R)<ZM9
M5]YMG05@@PEB3!?*;I>)M]TCNUT",6[+]49;:LI=0MMQKB5GP7'837C%;Z&D
M(AD)'L>,HW>[O9:%;3:F&-]\\^W,<WO_ZB4Q"0_!^3?`T0R44$&/&-0@QH$K
M3[+@?0\"?9_""4]6\&,OI%C`%0TP4`80$(C(GM?PO6`=#XK<?/($`8`1@!VC
M[<C#UQ_SAP&`(XR@MPA)0Z"!%3,``001"3"`08X[6("*VM"))D<L5N)R5"]:
M;MFEET=0<00'T4BSQAHR/*.#$D&<*<0&:,!1CSD+!(&$-W9JHP,(.CB1@!=[
M?I$&!A;4@$,)#1A:01H4])Y&`\F14`4!662*AQ[4VR&'''IDD7VF/8@Z:ITZ
M9+0"1'>RRJH.KD8$*TFSFE0K2[?*Y)*N*_'ZT@$.Y"3L3L42>VPNEPN@4I3U
M%*@X*RK02J!6_[8B`&H!Y@!H(9=4SA*5<!VC6<\R!E7>8A%M840NZ5+,`]FE
MKE+!ZS`B#`M&3J".YPQ,0]99VW1,LX@7VA`T-#R-:D1#"8QEAX:X^4X,`\"R
MY-B&.R.;P!5>XQJ4I6812VP.;9*3G2#NT#-!=-PD7B"RWB#B$>+)PG/28R*?
M_>R,*W+/@VJVCS<@R`9OJ$$#!I"!.I;`$PVH@1L/-"()!>V,$6A1#Z,$FJV5
MR$$,,M'4DJ""'3&`"$,P6]HHP8I5M.T1.[*`C0K6'S'40`0#`.4`>B0@O?5G
M``R`@#F\,`,8P,!P&FB`PZ;#BD94LA70D<3DJ!0$,QCE*$K9$I>LPO^YSE%!
M+6'2!CA(=3J1H$$(\:A`HKS@A1OH8%3*T$$\V*2[(>$##F+@SAP9D+029.".
MHXR8":K0!1,$8'*=PD,/\!!//%Q(#SV@@9TLXH!P($$;C#G5/%3USVRP:GSJ
MLX@/VC>KP>#J)>T;S$0FNA+\Z606/>E?4(9B+&`>!1<#3$H!*WA`:*6+*P((
M"U:P98RZL,59%L0@M";8K;=H"PGBDA:VUC7"%);*!R14#%C2@I%K]H`)<F`;
MP/2U-53\YC']2@76;J@O2,@F.#L,#21(`QN'=;6(GF$8%,&(&]1<HC-5+)!P
MLL,<[?SP8%-<:A$=Y]2SQJQB.$M1>^8P!_?_]!60\F'/@R2T'-1,8#\"TN,^
M$%`#.`P`!QF`0!DR,(#%/0=C`4C"<W@&GZ96!K-;1)&*P`#8^;R@:%Y(``CP
MP(@+-4*J6RL`#_A3V.#L")7]&*6/2,E;5#(@#:I,@!6@``,H>($(1"@!`G8T
M`1,PZ6:N>)+"()$%)G0O3+RX7#"%24QB<"4K2`B3,F0`T#NQX9EH`$$:A)M:
M+PR!!:*J``4J``)#(0](&BA#!1#`MN1,P#^D=)H;%=$$=DX`#PCI'@L6O&"%
MV#-Z+*#!F585OHQ<\U0LL!,S-:SA<$1$"/M<*$-E!5&5R$]7$TWQ8`[@@9_P
M3Z.TJ(6QB`+``&HW_[M,&:E-HS6M[V9E*QQ)RU2$?$$#7O`M(TW@3,/EE)O2
M)80[C3*\NK$1BOAT+RLNBX9[<#WS$*RI1-0,%VNH-:H.[#+#R6IHN-JPLQ8L
MBU=0F'7@G)RK+N(X.F1.<,QJLN3,!L\8LUB4,B8Q+2X1KPDBHU__ZIX'.)JO
M?/U9`1:$&0198!]B8.Q^3%F#2C%VG(_-``Y""3PPCDAH7Y30VE`!QH!MK6!3
MFW02`%F?GB4!<M;Y;P,2`(0*,"'1Z2&CT+PZFTX#3D#'66S81@F'9@_`L0$B
M)2C)60(]>8&X+:#F#"!0`]@\3M63R9#6)J>#-6!.F,'HKC&_VY%HD*YTS__P
MP3_/FUX6Z,X*YB#2%CC%#G)6H`(TD&P"VG`0/%1!>O3L%!,2KO#L9:$)_ZT`
M.$*G3&5LP9YX:)-%M)&#-=E)5$?M`7PY)8$?L.Y.&I;(J$ZP`I.0H7TO+_&M
MVI?BFJ_8#!C%Z+"*A8N-UO@6EM/%SY6E%!U/T*0GQ<JTTB45G%:0R1:\8%,0
MJ.0C5]#)%X%RE/U2%A.ZZX1_L3)>_JD#3LEAJCP$,Q%G&`#<.#429M:7VF(S
M`3474@5"/.L1'P'G(181$[^1C7"ZHQSCS*9CKODS;?:>14@`K#.E(6.MY?.`
M.3BZ\I=_0'L<;9]$#EM")7O#D?A3(`.)7M.=[O3_8?=SM'[(<0`UB'QZ".$:
M,.YMK0ER]:MGK[/2_JRS`N--(P,T!""P0`ZJ)N)K$/&W:"O$]0C(=.K'"0?>
M\G9`>QM`"2#PA>%"`0HM",'NVN"8SI#`%!>JI`HB\P)!Z%(./8C&4]`]3'6O
M>ROM%A-Y-5R1$Z"7FPF@`3.06BSP!M<C!S:P!;Y%3BR01VYD,XV@!]=C75O0
M(PNV!8G0"%M``Z23$1.6#.F0"!DG<01E._]T)D>%`%N``&K0@FKP`V@@`T-P
M`_N7/D+0#=]P`"X'<RKA/K@B*Q,A42HV&!R`<SOW8C"V41^5"\=R8\Q20!B4
M03QV`$IG+MK2+4Y79$]G_V1/808&1$'@\H4FQ4$AY%-2UG4HM%,ZY15BD1?7
MM`%G]T*OAEF_43'3$7<WA#&8(!J9$1M0Y%4-8QNEP1ML]PBEX3&GL1UGA1Q&
M9%;-@58FXT1C5#/8D6BN=A][97F8]VB,]E=_E7R[,33Y(7JIUS2>A@"HF(JF
M]XBV)1R2<"06(#06(#&CT%RA$"-BD'RX5B(DXGN!U'LDDB*0@0HPPP@`PS4%
M(`8!\@4*D`:=IC=,,R"IAP#],4>P=XIOP%C52$J<IE9&$S@SX`8S$`+D""1>
MT`#,505&4`E;E#;#J`I<8`+TU#U(X`#T)P4)Y%T^=BTG,#I5D@VJH@P9UB;W
M%O\D);`%RR<<>(`(R*$]U*,'IE",CP)P'(@-:Y`.,\(##=`&Y"47J])Q)U`!
M%X<'(%`!%U82J'(G"W943+!O+6AR&P`"%+`[YW`";/`1WJ`$2)`29-"3L_)R
MN>(^#!6$-6<_%8%S.9>$0"$4,?8_3M@4#@"51J=D2&<62(>%WF)`.M:%WV)U
M6J@M%-1T98B&V)(N\$*6B7$1@%&%104"CB&'NF=J@'@=9(:'JQ%HRQ$:F6$"
MTY%HV=$:@P@>;5=H"Y-X'X,)L'$R(X.8F*!G:T5%7<1$?<B.DM=HFK>)F8=&
M]F$C)=,<#PA';71ZFF8IH=E&;_0*5J,V$A(C&/!&8/3_FBH`BZ^@'KXH'SHC
MC%/E")'0-2NR'M41`!B0`0SP!4"0."P0($T3?:)W6-O8(P,``JB8>ON!6#S2
M--!H2OX1('#``FF@`5!P#@D0`EZ@`%X``DPT&@*C`N(&=Y%P@$*P`F]1?YMS
M?SX&%OWHCV=2*O-``S)``]4P!'T"!UM@5EE@`EE@/6R#!\$Q*0RJ)#L@!EN0
M2OZX!F$2)C1``PBID6V@#4Z13!N'!))273T``DR@!A(@`1V`*J,CD`CY!BMH
M<FA`!P`!)U^06DXP$A]Q.CMY$B,6E#TZ$[QB<T;Y*TI9I#XG%$_9%%"IA51W
M%@ID%L]"+E#A=%$8E5!GI5/A_Y4%!)91J!=EN'5FN1=H619U\14H`63AH$UC
MM%1Y:!L/HT4P<P5V654TI#64<%6O,2.`:!NL5AG%^(?$-AQFE7@><WB).7B-
M^494A#.9R(F.E@*9=WEJA$CM06G*)WURE)REN:FBQXC+42.25C/GQP?3(08*
M\0-,L`$;($?0V3&KD%F)9$:EQ8O3Y0A;M2)>XYMK8P%Y0`*F6@%#8`Y#4@%P
M``*EB`%G<`9Z4P/U!0+]L*R=A@!A4U\LX*RZU2,BX#?)RA^@U``L``=?\)W7
M9@7#=8YGUP@$`#VM8*>>I0**@&#=\PW/4DS#L(]*%Q+OM@9K,A9LTI_IH!`#
M"D:-T/\$3?`(&X!-RY"O,M`#C8`'+#`$02`G`'F"VK!?\,<"Y*41X7,F&"L#
M%<`"T^-),MHZ((`&P!HD3K`TK,6J:*"J)EL-7_`Z%>`0$,$&8=)R/^JC/0H6
MNU*4M9(#.@$L1JI10P%TEK,L(H5!#D"5&@2E1X>56QEU3!J61=9D4FI!9ED8
M.M538RFF[2*F@C$8ZR(7]I)4D,$%K.9E-J09;?>'D)`O<PIW<MJVD[%5OP$R
M?':,Y0$:?'D)'>-GC^BW<,6(6?0O-4*;D?H`*;"XC,MY9S1ILD5%G^H:HXB*
MF$J:F_I&"0*J$5!Y5D,Q000Q8A"1)O!?`\$`;1"L&@`$0W#_5(\@&?71>[;I
M-053'KFWF[2)JU!"C/\B>S:``0Q``1`PO(23!L0*`J:(K!C`G,Y:?7.D#W\F
M1SA`;>3$``$B`HN#&GEP!7G0O?^52A5P`T$RKJN$H<T5D;J7GL38)*,Q@3U0
M84B00/9*!6<J%G:2L+&S3!IV7B'W*'ED6(C0!__%@4%0)>,0)]EP<='#`!`;
M!"@@)R)!L7"``'+`#C?9`>33GV\B`R"KH`T@H_4UHFDP!*QD!>^%![_+`/05
MHP&1/'R"#VZ9JM`4@[+#/CK;@SDK4?4SA"P!5$3J8CLW8S`F8S$V8T&7%+Z$
MM%"Q%E9!=5(X4]XB%U%A!DL*A08D_U('Q*1#MH7EHE-=5T+RLBY;RW5F"19B
M'`Y'=79<@+;EP:8#TR]A1E=Q&QID-EV9T1P)<C(-8QF5(1FB4%8F,T6/6$5\
M-D7CL1Y^57ESP+B0&JD\8R.0ZS"@N2--\S2:NZF,A;F?>;B;IWF;N1N-,(M\
MV;>.4#!7$)P`\`'(Y4V\]@4UP`1\^@*V";DVDK9*=42T^<F[NPJ6`&PZ\P(V
M,@'!.[P40`$:D%Q+8ZP$PGR=]F\5<$<5T`8L\(S5*`*CADH`0LG/80/-E0>D
MP%PB``'(TUX#6`T)0`-ZJIX$X*?LZHYK4UW6U3VB`A@I-A9=T4!=L0+?L`9.
ML`8A8"8C,?\JHB)0$7:1'BLI"+`(&S@.$ANQ$:L-(>JP-U"AV;!_X[5?/*`I
M-#O#+#"3Y^"Q#.H/A<(IZG4/Y)HX8B`'8O"<=-`Z%4"CY@`!`X``"F==:'`"
M-<Q0$/6#$44_M?)31$D1/^P305S$0PPL0ENT9K#45+PL2_PM3MHM38Q`2&9D
M.;#4:V'%4('%80F%6^S5"#26A@'&8IRU09:U*+01:`S+I_".9A;'ZQ=5A#2G
M<IH*KS$:*G#'#-DQ/[09%$+''R,<E2A%A856B<:Y?,7(BMW(GAQ8E&L;E(L@
MGD0@_5')H?DTH3F*IUD`BOMH[@%Z%K,(-R,)O;D>UD$".X`#'_#_`1_R(;UC
M!:X,RY0@>08#FWU4'R2RNQ4BVK8!!@ZBRQ42&T?R6`-Q1ZE4!@R01]%G6YL6
M-O,%`6V`NLDM(&?`?-B[(ZB!`?NP."=SW=V[`XNS!>?DT;L#!3>@.Q!P<;/H
M!WZPK@4#&8)$'NJ\"`PW@37+!EY!SQ,Q*BPP.KI#@QZ'L6,"H#/HCQS,!-G3
M``7NT`4,D#J@#AIHDC?Y$&R2#&]2`37@&@WPTB)1LG!``5X0?NC0``LY`,2*
M!IX"!TZ@)\)5`AG)K/95W&E``S@@`G47``IW<F;"/CO=XSWZ$#R*8D5I/_@C
MM$/[$T2<Y%BB"TOMU"0UU23U4E$>=4W^_]16G@-<7=5/W<1):V0>M+4CI(9=
M^[5A[G5?'`YL0-,`X]8WA!EWJ`(;`UMSG`IUS!M[%LB&K+=S71EMQY!X5D6=
M<1F667F+K=B:2!_J0;E+]`8[TFF<6IJ3K<FF&6>UYME^E'QLXUH80R*Y'%B3
MYC"H<04D,`$9P-J]<^KFT`"_-HN-$QNE/"([$]\":QZD35HF(B&1L#*E$<IN
M$R.H=#2C9(J4\C0`?$H,$&%#0`-#0`$1Q@!'90-KK)[\H9A'DMTBPQP!L",`
M$EF)0L)0,`1.$*PVS@A-\IN@82%;1=J0\PCOR@2I6-.=\F'>PP;(G@#A1SHZ
MT`,]L`;7%CL\(?\GRJ0#&,@"X;D`!A\[^@HK;#!/68``(!`1(RJ#J44!RX,(
M)EZL)6NR%&`%+=`")KP%BB`"<""C.@`'\K4G]C``I5`)$-HCP\Y:6:">)(`@
MUO6P-[!0/&X3-RPK0#X_*D$88^$5*P&?4Q`41[Z4_X.D2TUT23MU49Z56OET
M;^$!7EA!3J^54Q?549@648G%-J5U\7+69?VEAH$75^:U!V`G7`8):\P%DN'&
M"?,">QD*<CWG3K6'E=!6>(NHCJ.VH3%W(H,:=Q,`B:RXA=ZXDHK(]D$QEQSI
MB/6_EXW9F&V:R]%'$:")F<D=B&`"FXLSG2YIG1D<V3<`$X#:&3`DO6/_#OGF
M!13@-,'13@$3C$#3&F+4^98?`0PR-*]Y"BMSN(G^7P`"[-+(G*;$'UMP;,`*
M<-),`R'"!!;`QE>`"-0^H!":@`T@^K_+(UN``YN`;\&*L@"Z!>DA\S&_9J^F
M"N='`!)S3P=X@)VB[_"_#H\"XM<6`AQL+_L^`^$7.Q<%"$HG2"<R6UE;;3<R
M2#IL;#HRA2<Z('@\-2PZD3(L<!5#7EX)%`,38B(5%2`;/V@5%`E6LV4865D3
M#35H<$X4$,`0)2(375TF*CP\-C993$QZ>K<6%B;4S`@@0S=H0M[?`N'BX1WE
MYAW?Y4+FY.$^[_`K\#XK'$4&!O?X^_S]_D7W_P`*'%C$C)DI"#U,*3+%@0</
M#ASDR!%Q(L6(%3%2-&/1@4&)%T%6O#B1@\F)($UR"`FQ9,D#,&.NF'F`9LV8
M-W'JE#G3)L^?-5<08K.!"8\77+B\2,9#A=.G4*%>4?'BQ94=.ZX$H&9A:M2O
M8,.JL"#&!H\`-L10$U.6VH13U)0U%?N4QQ4+-@+P*!#AP8,4@`,+#NPW0H'#
M`1`K8V;C#5L$-2(C>/,&<@T$F"-3%O.F,67&9Q-'&.VW=(HY<PKHS=(L2S4Q
M)K+P'4V;-N(`:)FQQ="@M^\!P+N0V(%#@X8$LHP?3^`%`@)FQ?@DQJV7J3(5
MU,&`F:T]`/9D)&Y=#__P8G:2)*J530#.'HX(X`W>BQ#1`,,IMM=J,&B0B`4+
M&CWXAP`3-BSU0A+4\?=&`Y.QL`4##$R``0Z]G<)?<41`D<`--XSBQ`T)1#@!
M5CO$UA1Y+^!6%74\W$+"BS`^9<>,,ZK0Q"UXY*CC,TS((0<36S1`@P:B>'$#
M#31LP08--R@1Q`(H1!F$((7(T(,="+#`A@1<,B'$?QS*4`$+"%BP11I.R*`F
M'"!4@-R;%5S20!IPH&$G"&E0\(4L,Y31A8NY?)(&`_1ML<4$%F11A3$39&$'
M#WKHJ.,$>+R%%S-OU("D$%Y^LTX'[9!SCCK>E",`.Z>:*DX\\O@@P`HYZ./_
MSZRSRIH/00!-81!"9BA4!$0.8>20&2`]-))&'Z'4*T@4=21212I9]%(.QFH4
M;0X[]134MC!INQ.WVJ[0;;?B]B0N3B><P`83Y"7%!5-T@84;#]8XQ0,U7L6K
M[UU<R4466V6)\19^\^Z;C`4\D#;8PG/8=MC#RWB&66:155SQ9)1EO%EGH.$V
M6VD@-YQ>%LK,*]=LM=6F&FXV6"!A;QC$+'-\]%7<`'`C$+##`&4`8!QR7U#P
M"RF333"""!CL0`W)V1UF6`%@F'S=4^1M-]MA*<I%PKUIX?!!&<!!R``.`\P7
M,\#,4)/'%6D-P!\+/?0``A,U-+#!90&P;99J#3"0_R4("%"PG]\(X-#&`#6L
MQT(;&@"AX1"A&!E*&UM0\R)VU.FKXHK>J>":"02$3D"BMY#LHX^KN9Q)Y#,<
MV0;<%<BPR28G*"%[(6,BX(R2:&Q2@0XLQ/+%#4Y4<.@6%82I`R]IO"D+Y6+T
M#3@(GY0`3`(:0##`"#$8T00)+A^*!^G1)*H"`8LB^D8/D/CW"`@L--##&TS@
MT7(-`S#0`X^>"A&._Z(ZAS<ZA8Y/!;`#9!C'.WJR0`Z8`1^VHI4$!7*KA>"*
M(0J90K4VV!*/$$M8'?R@!ULB+91(9"70.DE).'``#CA`@QJ1EDIT$BZ:^,0G
M-#Q7#8-2PW/EA!`GV%]3E/\"+WV!A5_8J88%C*BO:ER!;7I!BZ72`C"U%,R(
MX$O87P8#LM&L;#I>5(UCZM8;BUD,,QK+&&/,DAB4@:PPAJ&.7N02&C"DS#9/
MRUO:!"8A#+R';$BSSUMFQIO\92`#(@!=`\KP,Z!!;@C'B9\(1M`%I7E,.T];
M&1U+YC'N0(U%K=D:U7"SA3(0H0QBXT\-`+:9@0FL1'B)WA:RM`$0,*!-:6A`
M[BQ3@S?\H&\(J``#MC`$R@T3`0Q`Y18RT;<$`&$,7H"<*&XPA`0,X`VX.9\%
M2*`";D9%CBGJG%-((+HL$.`64)$C>%Q##=%-0`0E\,(,9@`#X@V!3'"@4S>\
MP8;_=,E@#:HX!!-T&3LG%`\6"?B"0M.PA;2XZ09U:I,3]L0<*T2(+&7L6PE*
M@`,&#(`%O=Q!%Y;P!P(D(PO2D)2.MDD`$^2B`;23Q.S$M+\WC,^E^=L"CSK5
M/W&8BE2<VL`ZA.`#58%*`&1`U:KF`2L*2C!***@50/9Q05QI$(;)\@A&#$(1
M8(4P(@9)5@FMU:P<L'`E+VFA0X#E$AGFD('E\F%.WHI#'IJKKC@AA`YZ8`.J
MV&LN3(P*O9:H`B0&%BS5.`N_EJ$6M;BLL0B;6KR68I\"`"8U*`LC;>;P@#E<
M-@`"BUE\W-;+#:11C6P[B]/ZLD7"/"".RKB%652[VCOF__$*E:F!S';+FYJ1
M$6:"K&)HWS,`'.!@!-C!@"FM((M9($<#1$@`'!"@EJE<02[BD<LEH89)Q##E
M15.CCM/`L")EB`"ZQZ$`"'I@QAH$21?X42(/Q(`X!$"``128`2DHD(8*P*$!
M(*@!"'0!&594X'4)&`((D-0#&@R!`:OP#P,:!\UM,$>AT1R`?4Q@#6]ZK"KA
MA$J,2A::`&A'+BVC!H=#=SD5U&@'\$S`#+P`!2M4DP9U*\$JNK&!'LB@FE\P
M*#%JD`H9."$-(&C3GA2:``@TX`IBP.\JJ)>G/6D``!3`0%.4X;(18$!\>,B"
M'.1"@"4L(08FL`$>>K`%$+R/!?\@V():K#$!50P""7C6`2'4Q(8!Y<@$T1LF
M'J*AAV<(U5.B2M4`GS'44@G`5>1(8%*5NBHJY&`*$LPT56E558`HY"$%D8A'
M/-!54FLU6&`-JQE"7<*0F)4D9UWA25!M$;36&B8F.0`5=$@/;GT+*'2]*UYC
MHM<>Z&&.V3QL5*Y0+ZM00]E0<6**TK(6A('V/E8$K+Y>8((16*`O!3#47E@+
MLH4]P`9^]$U\=.'+'_R`,6WD2[D!4QHOSG&3G;1M'O62ED'>;&QE@UE]9'89
MW6+@,I2Y%#.>J,=,O6<"><,`!(@P"RO,\^)`\`)(MQ!<M3`-/=HYC':B-D=F
MG`@[(7__F'?G,CJ$-:!Q1-!`?R',@@$(DP$E*(.3!:;B@3&`!@R80<R/(PP*
M5`#`%4OR93:P@0.S(,%LD,$-EI2`"M!`F$B:`1!@,`,+$\$+7SA.`Q"6#*>(
MDRZ<DV.+V,D5UFA[*4]I@MQ-@($!#$$!4("!%WR!X[[MF.EHH$%"WX2#"60J
MG\6C\I(5"@$1[$`,-5`%"RJ0AA(([0ME*$$#Q,"'*OC!F]@==#180\XF&&$'
M7P[2Y&6G`U483T?(@X.>@8CG=*G+SS>M^Q8&C=*=>@K21Q7`-QA=P'70`])(
M/6`YR)!`<5"!`YC6]`0CR(^J+D2#`,%(J%$-PJU^)*S/&DE;_T_8PI6H!(4Q
M;+59?UT3>@A;KCB!?[;>[RV=%((-EY`LM*DVV"36"]K5@#E;T5AE@1;_$A=G
MIR_#80/@U@`XL`7RMC"GX5FGP0/O-'`'=QDV\#"UT5KTUEEA=&\EEEDI4P#+
M8`$9$UH3H%OT41^],1\8&#/8)EPVH!5R=!Z(<1@M(S".)7%$<'%C``-C``1`
MH``*0`/Q@0%B8(,CMQUJ%UN<I'(B%TYSE%V=(UX3,'&D\`E#``&_H%#51`0`
M``+OEA?HYC=I\'4_F%!!E@;]Q28!1@<(0`>2@0!;`&=MH'$_I@,TH'%.T`9(
M\G1;UW44$`JD,`1EP`)X40W64#KI)/]'"5@ZDIA=^C=.Y,1BW&0!(\``=^<&
M"F`%,D`#%.`@#,`":$`'=,`+PB,+7E!X9\@`;`('<!`+V)-@#+`#3F$#60(A
MQF5SI(4`)E`%,1`#QZ`,>(``;,8&AF(H878CT?,[FT`(>58(#I(CNB1[,44)
ML\,&^S,^9($_#=",XL$CAT94XR!\B]8_1'4`R"<.S)=4[\A\2"6/]B!]TS=5
M5-5IN`(1'I!]U8(1'O!!JI9JHI9^XV=6YW=^KJ9^",E",9%K[.A^PL9^YL)^
MY#*1.Y$NZV(4[[)_Z=1_8_%L1N0=]](53O%$/)AB_4(-R&9$2P$Z!=!9$Y`!
M$"B!"Q,!\S7_,"@8`'U!&#Z9`ET4`4X8;TZ#&BD#2F-T,\9%*+XA6F6D6_6Q
M2IS!&$_T1/!V'H:!(";3,GUD'[.%&V_``$1(!&-0EF[P3#"@`&G@7M4U6^*Q
M-5%H1P]C-2((EV=1%060!*.1!"GB.??"`EA&`;+H!6Y033,V"EY`!"702VI!
M`"(@#,Y4)-M`)[)XBG28=$@W,1OP=&KB!9W)`FM03$;G3%PW!(4X"D/P!5Y0
M!L10(B;@82L"%C`2'DP#B23I.8QH#03@36;G'190=VU`!)ZX=TX0(GW#`JC(
M"Q6P>%:@`1DP`A+"`A"F"E6&'$.PEB^B,P)C*/;!&6]P7=<E.H*D_WHLH":J
M`'2[EP65$CN#$(UYM@G5B`=WN$_\-#NSLS\I!GGS,0$VT@2[J0R%]@WMB(Y"
M4!3?P`;>X`-(<`#GV*#A$(_O*``'\$"W8@!1Q0]18H\0U&D6Q!`8U(^_@A`:
MX4$>!'ZC5I#,PI`)>7["TI`E-$,/Z9"NHD/R4)'S-VS!5I%X!A/%QI$>^8C,
MMD0OH$3ZTA3,EA7><1>[4194%%GA91?;UDTJT(`B(`<V21@1,(!X$9-7:I0J
M8T<I`T?V!DID\3(PV!O`40%N$V!F-!E\Q*1LY#$J\T7)L$;YB0$CX&43D#"J
MD18,0`1`0`2"*IQ%:(2"Z3:NE"A[H9<A-_^4:\<,;H<;F&08W3$OLUDZ/-``
M;S($<"!/D%-1\@0$$%`#+8.G&/`%"A!="=`"S+4(,M!?=/`#:O`#=W,S;J-*
MF+$%"=`)N_ITH)D`C!.&,!!=TC0*>X(#8I!-O&DOW=1BO4D==B!.+Y(4F!@6
ML;6(8@"<,V"$1K(&3N`@_G$GL0,BR"$*`[`#)",&TDD#>?(+%-`&1X<`?A`%
M5:`THY<%)C`I;*$CK($\T#A[,052.;(%-$`)@U`[VD@)239H<2.K:C"K&Q`)
M:Z`F(/4&>;`61&8*)"!W<N<YO<=3X^`IY8B@0K`")\"@`^J@\QB/`E"/^W"A
M^`!54*6AUB<0%N3_*U?%CUO5$`%)HF"%H@Q9:RMJ$@7IHFY5?@X9$S,J$^XW
M5Q9YD4_+0SN*:XW0`SS0D3_:FR5YDB))%W?!829YI#RG%E1T%MIE%]HFFT^A
MESB)*!&`&G![&H&1I:)!;AX(E($Q!TT(IH9!6WQQ&">8K7Y$'Z+5@H1K,[J`
M<`EGIYS!`^CQ,#@(2CLP(MM$`N!9E4JZ&V;C%AA0`5H'J(*Z=0H0A%\P)C40
M&MPUE"8C6R4SJ7-Y=CP0'N/Q`MUQ%KJ:8#>@#:-0KA?G!110`P4@!S=3`PF@
M`,@!!1K"(5_`7!70"N[VL+7T"?ZU3'8X!#+`!A.K`[O:A]4DK-!$3432_X4`
M4`(8H&*@(SKFLSFW`17FA(G+&A6TR79@2Q8B@`,0L*T*8"1'PA\_!X<5,%'.
M0P'\218NTP"3-R;\,2`$D@4=NPQK9B@&+&'[02GJ^1\R99\!.[":\`B/H&>;
M8)Z6$"D(X+#N1@>@D&")]YUK\4X5L*<<VP0V<@O\`T#_\PTCZPTFBP2NDK(.
M&J',YP,NZP\SJZ'YV*$$L6H>^J'\R(^>!BPF^A`D$;3F-[2VEA(O&J-)JVOA
MX$.M4G]1BZ-O-2X\B@3KDFQ004?*MK5#:@WY\A5;P<9<@2]LL8,J1G;*1C++
MP!=SP`-X``:<!;<4>!K(QEI/`[>&(0>-(0=S(/^I8&`'$!,]O009;/%;:.I1
M+0A<B<,6;W$*-?A$A345XN4TY\&74607;,.Y$X"Y-I`'LXD753DAQY47`0`"
MC:-?P*`!,S`&1O@%238@:[<8)G<B(?<T=-DYFU1B39@Y7/`BQ*2_/Z9?%/5U
M1%*ZSY`\%?!U7S!/&P(',C`+B8>*L3JK5$8\((`&/08Y.K`&:Z`#0X`D1I)@
M">`&,*!W-Q`+Q_$%````&H85V_04?7G&:4L7TR`Z+6<!E:+),C,"^3-A"@`#
M\'Q/?9,!_45Y>O(%P+`?L/$6KFG0*N4,")`C55"O6\#-DF![M1,$LF-L>,``
M)9TN&(P$:K(%D;(%L>K_;K3:)B0])F'F4C9`JZB()U8VOG!`JFP1C'V#`:W!
ML;/I.<@8LD+0`P7J#>R#H#Z0+LC'PRK[H"U+?18*LQB:CQ#4#_AX*P$Q$/GP
M:0^A02`J0JLF0B+Q:E9\0M$RM"%!M$*+:Q`)$U3@#C2Z0&#L:SD:?\.&9P@J
M!^YB%5!8B?OR?US1QLQZ,/A"P$[Q+XEZDM`F10SX``'0QYPEE)Z%&@4@!O;#
MDX5!19#A&SB0`3@@`O"&%HZ1"Q!"'\!!7&YS<+S1E)'AG2BX@TL8`*/\VZ.L
M%P0,I9]<E;RMR:>P-F>!()C#-IF2.+?]%BP``0G%7WHR`VXPG$=W*([%1G-)
M_Y?8-1Z=E,QF;!US41YBD%_4)`-M,`,V]EQ>8'$:L`H]4`&(N2?ZY00@(`2]
MT%]HL@ITP'39D$\)1=\-=D]K<`/IO`9/1Z[QS*VF68OX/*I/U"+_-YN@EP5.
M`7=/@>$O(AYGG*WS838R*"$04KP:$L\)4!_$!2%MT`8EL!]RYEC]K`QB8(<1
M[!_^<2@<-B%!)@G26`A*8%"[AP>3A\&=L'IB(M/R&:L;D(JJF%#%XR!9D*V1
M4<YT``).D)K8`P`/R!5&/0RDH]27<PO("&GOX`T]]@A0[0-$10A7C=59'0Y!
M/%49BJ%W;H]E/54#<;,8M!"@UBO&TH]N;4(HT6H..?_%"@EKL):T,T0%NK;7
M`K!K=O5H\A?&@$TN43O&E,`I'&YV:*QL2.1L81L6%J`T2C05:]&=UE98RH8;
MZU$#$9`"?.S'H\%9IU$`;Y$%I/U:!>"`)9`!/>.%PE`"UR1%*]@;<``AL@@'
MMPJ#D2$S$T!='-/)#`>Y>_G;WJ$7=S$PF`N>U<8,>9,+J8P85\#*T7.KF5EW
M;C,`)<!XV$.8T21/%3#"<D"4Z0%8)C/>(9<YYBV`4(,U3R$&-$`$84(#[EU-
MY6IQ&O=S+"`*V^`A<"`$:&!0GQ`+@AE@`88`O#!15^<@@A>*"<"'-\`"GXJ8
M:1E-A:@!7%X&F[?)$_":,1+_+QB>3C-R=C!6-JS.21.0VL6K=_).*),4,\NX
MC)>P@R,":'>H"J$XL320)@WP!BV"`1DP/!/;GA_L"^&(".9LTT+`!OZ!)$ON
M&FV&!FU2`;W3(?HE.%LP7]++"J_P(4RF`92C!RI6!50_`&)P"V3N%#C2`U?-
MP>6I+D3E#0=P`O+@#H\V#_"0U3\<*](WQ-+'Y_C8YPSAYQCT?1^D*\+RUF6%
MD`B)M'AM0@Z@0FF5:[E&!:KO?':U`H_VM/175Y?^+;5'"3V@%5G[%?VWQB89
M%N!C#?@"98.$*/Y^V1(G`I8U7S'Y6O7F,A9@8@TS&@&03#HWX24P*![52T2F
M;K:J_VXQH[AEQ#&HJQJCG$>AL6Q6R97WT=C*<%T>\[!7,"&FX!A\M!X]<_W[
M0488P)3O#@A?"5X)@S=.@Q5,3#P68A:0-CR3`95@EP69E0$JG3R=FP%@!6!)
MEP&3/"2K)!851$,),A5>,T.W0QHS1%X@-$,LL11?7C<5(!MP5C=I3L0::7`L
M#`T;&V@5@A`0##1>-!6R,K*Q@[D*"C,)$`D:A5X:U%N/%I.=]_B=)/F;]ZMX
M>"RP(C%!!`9)J2IUFH"CQ!!TZKRXR2#"H(V+3!!L8<&BP9:/&+I,F-"@31L:
M-&2L62-#AA,9+&I8L(&!`04G-UB>.*%#AXQF#2QDF5#CA_\:-3^N5:!QXU":
M!F)(@D`#YQ@=.,.L6%G7`*`(!BQ`@*AZ0U"A!`S>-+)@H@J&##C$9,G2I,E`
M%4VRX.GA0X"`#CY\J@RBA(T0'T*$K#BQHJ]?`3XB2Y[\N/+C%3F*&-C,N;,!
M%*`W@T;AV4`1S:<WIS9]NK7K*5.*3/%@QH,#,V8<W+9M6W>.'`Y^!__-H7CQ
M`\</(.<@7'?QWSF.,^>@7#D5*@+(^+W>>(5WR-7#A_=.OOR*\>?%JP^/9"<;
M!#SD?,IW;S[]^Y6N[+#0B2U_%5?@8X\*_D'B"`883&#!%978=]^#H$R0P0`%
MI,"#&`%$,,<#'$9@PP0FJ'!)!"3_/A```P!\00$$7T!`01HP,C``''"(T,"-
M.#:`(`*25*)&$F(D:,,F!9"820&H7&&#(R88>,4J`%ZAI!AB7!25CE<DD40!
M4O)@`P(U("`F"`S(:.,C06901@D.)9#&6`/4T,``TQ3B#@2QW)#`&`K0`$)'
M]/08P)%(*I3*)T022DJA`F;A("H-$)+`#2QX`<4MDR:PRPPL5#"$#K$0(PL<
M:&P03@5P#`(/`S7\&=,&(%"P"SPG>;$&"[*P$((,-W@QA*\)P``#$0G$`H\&
M\'"#@!QX*)@%"03L`Z$*+^3#"@$$S&4?#Q,,,,%:!EH0+4-M#.&&`E!XX84"
M$%34@$8-_["`$DH5+,7`%@&),8"+*RGAKQ(GM!36!!^R`(=8:`@A6`5.-,Q"
M/40A0`<:.H#@4P)6M&"%$P,@V``<'R.#1AK#%&)%&2+@D04&<8)0`8Q?Q!PS
MJU?PD`4D)DS`0`83S%77/JO0U<1>.O35@<)K-$68#H<AI@-/CODUV=2166:9
M#YEQIEEIG(W&]=>=I>::;+#)1EMNM3E`&V^Z#><V<<;%39URSPD7'7/0S9V<
M==AI=QT5Y?7E@WKIH6>>=]4AOM[B2#2N0ZF,9*$"%Y1S49^#TZK`R15-]M>Y
MM?-=`8GH5(YD`2J89TY?`!8,,$``*41PNH8=\K!#B"-&P.$#//\P4(B*%%!0
M@O`93.@QCAA4&<`;R1>I801!BJ'E]%M62P*XI8]$)95YY"'Z!&)<<>05+(M@
MPY8!8#!"30"44>_!9);90`UOO-%`&650L*<M%4P3IPAT`H`[AH"G!,3L5TZH
MP<Y$(`8>5&))0J%$*"Y!04THA!^54!08JM4)&VP!6;'000+<4*Q,S6`&;J!`
M!2@U"%XXH5ZE"D>I*$`$8K$*3`PX1JIJ.`,(G*18N%J##G:UAA;H*18P&`.Q
M8H&L=Q""!4S```-MD#E6/&@3=O!'*T30KJB8`%L$4($#6[>-&2@`!E"`@@+B
MT:ER-24$(<A)2]9``3AL02,X&`).%K#_`*7QI&(@^!8>&H"&'QCR!PJC`4YN
M,H!'2&4L/8%#&F*AL2_@``,6P$`)&``'.M1`DB7#&,HD1P(I`I!-,AJ`CL)'
M@KQ`8@<Z`T!0A`8E$@@-#UM@6@=VR09>W2`(06!:8H302Z95AFKDD8S5CLF!
MK8%M-*0!FS2W-C:RF6UM9YN-;FP#'=\`)V]RBTYU\`:=<GYS;^'!SF.XDTR_
M%$XYBEO/X0KWSL6)!PD'0((.V-`#)DAN<I7S1.H@%*``<.X__I$6@.@3KJB<
M#G524MT5>0!`&Z1@#@[<D.X"L`,_4(M$)$(%3?3WA1+`*'@0*('K#J(D1X#O
M#4.*7B9*\2&"_]D@?*$0HX&V%Q7PH6D'.^A>00YB2!N\H08V:@#!+#`"&T%`
M`RE5T<'@`!:.Q`D#9=``$6"0`">0"BLEN)'K])<`%?ZBK"N\`1I*D@$&B$!!
M$ISI*$:QB4/9YP45)`48ZNHH%02-!UM(`+&\`"H2YDE3NY"%+-3EPI^4*E45
M0,,0B*".L.(P&G`H@5EH4*9;!.,&(F1),<H:+!BX`5CJ(D0MH$"#'HA@"Y+H
MJU\'HE!JO8`3]&F%0%9!``LP@`@,$`HIY[(*"X@@`Q18UQG5F(#^_2(G25L`
M"@`F`R4X(0T5^`@+TN`2EK!`!D&0P4[$LH5&-``9=&!#3UBP!DT9D/\:$Z@)
M_(1`%0H,01!;P<&W]-5),C5#9@8LP5O#J!\$(8@>DW@2`>H"B9$P0`,#$,K/
M6ID7!N=2"!+8I1!\"4RF]4`(3.B!#)@6M<?XX'#*7*8[L_;,T$ASFJ@96]F*
M0)O9>.#&--[F<(`3'+SY6#KBI)LYOVDWXZA'G28&W'<Z((!ZVE,\Y7GR>AIW
MSWTR00Z=J)SEQ"C1^_A'<P<-$(2`2@(J.7!`8NXR/BI1DS>DP$(\T&@$"-`%
M$@3@!;J3G<>>6M;@M:@"\QM2`>80`2TM+[[)<RB##-I0\(U.=!>YJ?(2'%^8
MQC>^KAL`FW!4`SFITL#V0RY6:EA'ERT%`F7_"-,PO"J$0Z)A&`(>0$,&00$:
M))<0@B!"!<2$`"F.H(&+*A1NO>2H#.IUKK?EQ(#NL8ED!T`,$`!"(=A[VCS=
M8%->&(>>:N&%+[RD5&A`A'L)&-96C64J51E>F>25`/:"=@@L.0N>B*``('1;
M$+50U0S6P`8:L*!9$PA(MOQ!K7YHD;9S$=``B%""-T""`":(>+2,BR?EPB"U
MX*#!&BKPM!.L`9CB;8D3VH"O3B7,U0W+2?^Z8MRPN(P&<-`!(J"P%0H$16=@
M$1E6[FLG')C`#BL[;V;9!)<RO74"(^@"'VK&BKDX/0O8XH,1C-"DD0P`9?RQ
MRS[JPO4L7#C#1SN!_]*"<((>]#,C_4O882HSS\943<4"H`*+G?F9:+[XQ=24
M336M>>.^\X:;W8P.<<ZYG""3LSG>[/'<TKG,Z_1%.R>6,N&<#&4H4UXY[=%!
M/S^A94^HF3X\^)Q_4L<#!HG.$?48Z.<]\8*:("`"*0B`#?*L@AB$2!0DLH'K
MN`@$8GTA%D.HQ@^8,`="(ZFE03KP&\!G`R5!,"H(<G2B"B*&3*BA`/;K6)`,
M,@`99<`=)F4`"#XY(P!B"`0LDAEV:?0R5`,`&26``#(,":L*#*,,JM3T"6]`
M@1OD8JLGI`B:D'R.YB@.9`D4A`F:(""(4@EXE5<7]&P00"RRL`;I`GR]PO]#
M3N`KL8!"7M`PD84-(_0-+T,-0M=)R?`RFW0,--!NOZ`#31$,A3`$LH(.]]9"
MJP4%-\`&)]$#'A%!]E%;5J0ZMF0!#0!5\R!QT:(Y*M``%8<.7#4(;5`F3O`X
M:$`Q'B=>27,#$+`%;[!=&T!_:``"SC`$AU`!1R<"J/(^+J,G&&,%7Q`48E`F
M('`556%?&*,!^+<#!.`E)`%`G^93$E8%77`&9V`"66`#S?(1C+@%$[`#1D``
MMP-+(H`#LS1;>%%A>3$!+"`$NW0T,/A+9&=VC&`#(L`"'S9,4A,9*$8U4P,>
M#D!W71,:T&1W=Z<UIQ$;U>0!L>%WO7%C.Y8WOW'_`-]$-],A9-W4&\'A'.AT
M`-=A8E9#!I!W'NEQ>95G3_$D>9BG3ST@"5E6'ZN7#U\&($TB+6F&#Q8`5^'X
M(#SP`MU2`WEF`Q42`%6P`YH#!A%0`',(`3@P@4!@;^V0`#2``#^@$55R$1:0
M!U1B8)V&:#R%D(_P!E0BCT=2`S@@`IT6)G*"/%*T;C91+R^"*F/8`/:7`0WP
M`^AG0!5`!T9A*C3(#AH`!V_@*5,Q%B0#(_=%#3MS0B\D`_IS0K50`B"``-MC
M(`Y$*'2%.G:E.0@X"A9T00*%*#;P6X3`$C.@6I-2"T2@@X3P*_16##<@`W2@
M%/PW50=3+V(QEA5@4FFP_VZXLA0)T&_MYG_"H%SJ,`@S``0SD$:7H@-KT`9L
MT!%RH!>(6%O3,A#9$C1S$5A#(!-0ARU0H@(84$#GPE5Z,B'R<@Q72%\Z`)=V
M\F\B4`)T0`>^\")I8!;,T#$D,3S10!7.<!9CH`$L,!+QL@4N@U(L,@0J-0%=
M,`([,!<`T23"I0=.UP154`5+T`48\!&N,F(ZT"DL,`]L80*4:(F(B(E-D"U-
M8`0$P0)L\(D*,W8G@`8(\`8W<R-OL`BIB$S>X8KN.3BQJ#6B48O05!JR*#9[
M1TVS`1N^V#;>5$[343?&:'C=U#:!9V35\3<F5F+2*#7T9(W:*'F-@T_JD7F;
M5_]ZY[B.]W!08%:.4;*AG7`%5;)0&LH/^H(!!?``'E(D)A`#63`H$1``.H,_
M&M![1#`&)U1#S04"-S(//%4Z!J8C"9(]-J`&^2A["/(&#%(`$E("-;`O*\@J
MUB`G#%`"!\,`$-`,944C[%<"654""``">C1_]`<'>"((&K!K+/`%:U@O:S@S
M#;`S&N`&A\!$6J%&P:<61QD*_7`H-E!L1X()>W4Y]N&`H6`'!L4`'U"5)W!"
M9W$#NG"C^&8L;D!"7R`#+2ES3L`"8S@5)#.6$Y,&)4`#HPH!_B:0WO!=V;8&
M>B20RD4$[N`%]%:I4*`.*@$,*,$$N(0'#?@@T!(MAGG_.37P*RP7<5^TA!-0
M+B-T1IE2!M30EC0R%:0Y20.4`/H5FC;IIIKU.U^0`9AT/Q10DR_CAGE9!D'A
M)0@P)Q50I6#A$0JB`CO0FR[*`WJ@!P#Q$0!1`X]PG%1'DBS0$SO1$RT!$TE(
MG4AWD2;0!-BIG0MF`MX)GJ$8!&9P`N^A,B305&(@!XO`!,/4-.]I'JYX`/'9
M&?19GV$CB[@X8WMG!OS9G\`X9.$D3G)#3OZY8XHG'L^XH(_1H`YZ`%$6H4#+
M'A.Z'@%[H:JWCAQ*()_C5_6Q#XY0HOAA7`V0HA'@*!\B.?@8`$ZX20GPCT0`
M!#AJ1@H`"X"&(ZJT/0@)0<TG_R4U53\_8`-(]2[U8U1?\3'44`%92BI3JFG<
M(">"M3'(<`UIL`U9-00]0`=Z=(54L7ZGB::LT@#-97^:"0)I0`@,($7?IP!#
MT!)MH"E6P%RPY2600"4SD1#&5D$&)T8#L@ES=0H-\@DD<`4#H`N3(@.6\JB"
M15F9XG^"14)=54@_@`TR`#]C,0SH)4EE`@Y`5"S>X&^^\@L;V%[H`)"R2@2T
M>I4JT6XRT`8]\!%RP#K"!33!"B$WTRPTQ`)B<*R1J0)B4`*%<"[I@#$`$%8D
M@RK2&BL!N2(0<"-WFP858W]G\050U0`F@`$X\"8N<U+MH(?>,A?-%R0C$7`J
M0YRJ@/\MA`@^N+0%;-`_S]D_C@@B#@L./:%/.H`$2C!BWHD`?$"=\6HC?#A;
MK9287-`$#JL#X,D&22.QA8$`*B.9WI(*&;$!(;:>KMB>R71BC0&+I5&R+G9W
M>Z<:8\.+-N:+W*1X=W,WR1&SB!>,/9:@?X-DEB&-VN&@YA&T9IQ/$TJA[!&P
M",`(1QN.K"-ZGY-F-@,@X0.U_&`#<6H#')*.[UHD!8`![6,P"5!OO9<N*%1M
MP=,&VR"4/\`@26!0SI<E,JHC<U(-"$!5#5`_8<(R89)2Q0L!+W,P<9I5YAHK
M=;0!1_$#=-"X[H4,.,%^,,)^3=$.#"`F+J)(=5A?E34G3T7_!*#5F7L"!7SB
M!='I:)#``T@I;#:#$*8[*!N$"1>T;*G`E()\6@EP`N8B*7H"E%U55K<@$>%<
MA0DSFF-8%2\#(V+A!%G*64[8;K'``B<AID/`%-IF+A`1J37D!FG4`O$&$_S&
M$0"1/`G'#P<'F5#B=&]``QH0%.("<=$2+7-8+&*K`.JB`4(IN0=SA7`0,^WP
M!>TS/QQ!(Q0C`V91"/.+`3>#`-/`)O'G0VV``QVS`X2(`2'R"9/@"'BP),<Z
M=3G3`&R@7C[!$RY!L"K#B?42,"UQ`NW!$R#P'GP05#1M(Q,01JQ0%\\RPQ:@
M7C?,%#JL`SPL.071!:EP4Y*0$40L_QGM.34@&QDB2W=,;'=-;)_5!,6N<6-3
MW)\\]AQU@Z#+0;,\%HS%Z,4Y&XUB;&)&K#@0>L;;.+2,0[&;UPD<I*$1A0J0
MX#D"L:%B-IW_@<=,V0`E(`;%9P(C,`&:,V@6P`YK6,CH,`9N8+T*4&VW4`8`
MD`$@8$@PI23U$Q55TBT=HVGSPZ,@4YZ=-B<3@``EH`$MLGYK*3P4H`$?()OV
M!P?6,(9N:E\:X`Z1Q13I##^9]06\>\O(72PK><Y?$)OM<EQE0$(-DPMC,`8P
MD`[H*VC)9E?V?92+(LW#AM/,=F=)B5N";&^$M0;8;`7V-0--)`/UC(=WN0S&
M@`9C:0U5P?_1,(((W+`-\@P,_K<%Z]H#Y=(&85DLYG(N"+X+-62]:126F^N7
M@3F0\84'B.JKZTL?P.D-4#$!?<`'?`"LK1`,OW)&4:C<2T$!8=$#8Y@&!H2F
M&B!+3\I))>T$N;#`-B<4%H`'-3`-93(C'D$E!#!U57`&(X"(!#`2Y7,C(G`&
M?9"=!%`3,J!/WM$33U,OT=DLA(0&0:U>SOF<'*'"4ET%5&W5JX#5)*#5ZO47
M1R-BHA@$J`@0\-HQGB`NEF,!ZID8;%W$W;'6Q*@9<>UB)DO7>=<:*<N+?E>S
M/"9XIN[7U,$<-?N?PD$=@..,.<NS.ROKD*'6BLW8]X1/NI[&:CS_93+`!CT\
M.7A<V9P3(F+4)!E*(*_4V5`["34A!B3"FQ9@!W90`'+@.X`&%M$6VV.01NAP
M6C[$(J*LD2R)V_13/V\P`-Y:$^-7`1FP20<#)J<(%@I4!ED*O,D@,UIES+B2
M!N=\D]ME%FG*TJ),@Z12O"4$#.5IP*(\%NM:!M%]22.P+R0T"_ISH_`-!!40
M)E2R`U32)%3$E(K"*%'9WW)%"B_`07.!K!/H!;LB`[5J#D-PE=AK#+1@+#-P
MJ>NGMQM`FA,C20*<I6E@:TO1!BP0/&1"Y/;%(F3U*Y5*!%IA!5IUH\*BX32`
MP][96ELPD!DA!L`Z4:K0=#=C`2P`87C0_R0\/KK[\N/HD)4".<KBB@@>C>`E
MD"`=62].@-WM8SQ`%0,QX`>EXZ,'V7R_:@)=P)P<40&S\%W^AB]ZH885L!-_
M!.?KA2^XQ)*KO`$<\5T"@P`DP`=YL`,QT%1=8-431F%YL1&>>#0;9H;`5'8J
MDP5\8!&6#320D)YF)P0?-AEN=\2LF,2#XP&BP4?2M>E@0W>@CHNX@4W`:*!$
M!K,SBQSEY)]P0QRPKJ#9,<:S3NN.@<34N-AGO.M4ECCWQ!-LL`$#LF6'`E`"
M)5&A5P]QO"#X<'JGQQ]*N8X.)`;Z50"V`P@$*G9V<@T:$'`,#`T00$0*;C`P
M"E!6"1`990`4#?\L#'`_HC]O-35O/PB+"!@5<'!I);(5%0,-#"5#3C4X$`UT
M&QMT(!40"0D:5EX5;$,4KZX@('`47U\:RTQ;$"4L<&AHTU\)0T,,;P4!`6(B
M`W`5N#@XC#$C.&5N"2>P$!]`8V-@W&"Q10P>"S9X!"A0($D2,"\"\+!AH:(-
M%1@7,F0(I@`8=2HFDL"(D0</%>IL,)CA)802&3-F)/`RY(:7F#/6W)"A@YQ-
M+PF<N'H'1]H[5Q72:-!`BT(%&HLHI('PI0(%;N.R?F'9PHT;(L>0$?DWQLT0
M%FO6L%DC8ZT.%D.V,&&#!Z5"%4U(DB"1I>+>)EFRA.2!(0,#/(CQ5*G_8L*$
MF`DB(`S1X$:!@B%K@-*H4**"41E.CGWQ0L27"1)\,`R0=94;`Q$8)NS`0MO%
M2!YXMFR9L*7&E@8%+9AH@H<%#9XZD.A8?D+&&AI;$#>`PV:YC@HR3N@XH9V@
M'CP8$*C9HT84"!I?=/&L08`/GQTQ5(\01*!)D[TD[`<NSD9(APY"L""9$]RQ
M@0`>31`@@@@V!&"#"2=9L$-%%HAA`Q-,]*"A$#ZLX,.''GXHXHA4Y%"$`0:@
ML``*-Z#@(HHPQBCCC`84<2*,-A9AAAD>].ACCPX$F<.01.;@0`X<)'G`D!P<
ML.211`8)99)4'D#%E50((``99&CI)9=@<NFE_Y8=KF"FF4ZFJ>::!R#!YIMI
M(B&GFBNHJ:1R;&S`Q$E<<#&822KT65(6)Y%DZ*$\F&"!215:<$5(&%44845_
M'FKII2&M@T,##YH@2`!@(%".5;X@4,)8DTSBAA=?0.#J)FG4P$(9<)0W2BEO
M;%##(J8PX$0:18%`QS"R&./%#34,0&LXL$@UU3%6S$!##[X2!0X:Q5B#20,(
M;`%'9\'>LE4"L3):D1BF(*`N`F^P2\(9.-1!!!0W."&+!D#(Y`4%(""@ASHF
MV9"%#2.A]*="ZG34D3H2`7KI"R@QK`()%@R`30LWZ.#%JD`-09H7--UPU@T)
MD#S$.,[2DD92OZ:11O\U3KU<#`7HN8J)JU-]\3(-$,P+A5<R(:,!$6Z,P=)9
M--RPEEIKL-`,"SVP,($=/%C0UWV&$EJH"EDD6-$$&4`P`1X3>$H``8'9L,TQ
ME2E`#DL4X&++.TY<DT`9B`P@6Q=G=(%!`X`#IYO5%>VP@Q]_^#%!#9ZPP`(M
M#$#5P`16;\$`+=Q9EYP,-U#``F(8@!`,$S]L\#AV,M`2G0E;;%">,&A0$VW)
M,H#@AQ^&[Z":""9,;!]^^F7!GW\`ZC#@"4BPT0.")(P@@@4!2/K@A!2:A.$&
M/7`XXO;<^[#D%"BB$$00-)9O_HPY%C$%CS_^*"61',!/9?PY'!`_E$.^CV3_
ME59BJ2687PJ3F,8D@#*9J4-LFA.<%IA`!<K)36EJ4INT8R`^E010??+38#!U
MJ48IY$$64,&C5"`I<X50(AQ,(4HLL*`)R(8$+XA``!B0@,<E@`(($(/%_J$`
M&$"!)A2@0`8T\0$(U``$$*#`#VQ%"@28HA@0`,$VOO`-!(A"#1N``]YF,`9D
M-0(.&XA=4J1"`6C-H`((>%PX0``.8HQ#`PD`HPWD\(-=70X>N(``(W(HAL:0
M8"&`Y$&[:I##,X@@`_-:P\HJ4(9\S>0+#>C!8UPH!DD%X`5@Z`A#)&8HAS%,
M(YE\`<0&12B,7*$!"9@!QGK",59I@"4=2X`,:*`+_V<$D2I?:!E2:)&4IKC&
M56THPRUET0;(P>%QCO"A5XA@!2L0`2='&X(.9#`$-M#2FC+H03&;T8#<3"`P
M'-S+V="&$#$P0`-;J)H%Q-D8,:QM"#/H(4O<@(@2X&```V!`&X90!@BT81$L
MB$T7NA"#'>`A"TS`0P]TPU#=8``#!%4-+VDA@UG2@&8-,,@MP(&=:5:T.:#Y
MG`5,H2=1;``$+^O<RAK@J2U8D1C0*&,SC\6"&/#A=GV8P#TG\)?[]!0PQ=&!
M?X0@!!VTX09KR-SR[N,\,:BS:I443L$2PH0W8$@(&^)>`;EW``?<"$8H`*N+
MQEJ^L)ZO1CE:7_M\A+\B[?^/?D.R7UN-)*2WILE_6P)@7LD@@3#]STMG.F"=
MUJ1`!AK620],;)L(F[D\;<U0&KR@"@\%0H4(9U$AJ=`53G(%"DTVA0&X0CLP
M$`,3@*H`("A#!6I`@1D,@"(-*,,8@#")'][0G@/`P0<2T"\&#`$-:L`B(:<!
MAYYI``XU2"(=2A>,(U8``$LI&0A80`$T_&`8Q%B95IB21F!)0W1T..<'/E`"
M!$A$'6\`7&]THZXWV&"SXD3)%=Y`W]_@<0#MR,`,Z'71$@``"#29204DN:A/
M7E*4$@F,@D\BRE!&)"(@N92!&8:!5+8@`3H8@AM@.8YG`M%S3^%,+%P6Q$5.
M="C_BDBBRBYWN<<YCA:GL\I,(D&T?,V`"$O9V`TJ<)8,3[.:L]1F6X:`1A8@
M0`YR"(P%SO:[@G7R"C:P6`,L@`<3[*`Q5GY,"=Y6B9\!00-ED,>"%M'B!M3`
M(`0PP6(8@Y@M.,XX%7@<#5@PN2K;(PT5S8Z<FN.$N&W!`G\;%AHTQ`;LH"X-
M(A!#%B;0`#:*$18):*;.1#`!`FQA`"Q8V30J0#(K1'<`?6@/'TR@4QQ@H*<$
M^"EQ&B!4``G!FIAIC@Z62@(,)+IJ?1%#5$F0P9%<P4(!8(*Z-`2.[HFH@!SP
M@/G&RFP:F?6LZ9O"6CU05[?N+P?4CBM<Z5IM)=WU2O\3_R"7)-!7<7=)`('U
MT&`)>]AV)[:P;Y*3#MBPI[NHX`6"$N%G#Z4.#Y)04>?JHTFNT%E*[1LC>S&4
MK3&P`QYD$@']=#.K:E``PE!@#`HH"TLPP0!;Q%8##=A``RB@@^"2(A7?&L<,
M&*"*-(B"#BPH@:NH4@UKL&!78/RN-"J`#&M`P,B,>QP<`#>`#````!G(:(44
MU2`>;&0B[R5X'G8P4,C@(ER+L&<#1E`"#;CM!MPP!@UH,).0VX`B`?=+1@)`
M"#M$."-P-PG#1(E@@!6J+X`N`Q&`@I8-@^P8.*F7*\8.CQ%/]"A#X>4[&$#G
M:;``!)Z8+@.F.V=:%B,!-/`"$/\JDZ^EO-(K-%A+6YH&E[>HA09,FQ8-&I#0
M@SY6+_BAF`7R4)A$+YD$:2:U"P<@&2]$`@9C*2(.,H`!,;1+7>I%S`0&ROQ;
MC/WY%=7)G+^)!Q'@`'4?50YHG-"&+2S:S*,((PM`4Z\TL!S0C49I5=0?+2M\
M06^6G@>*TZ"MI?@BU>TQ7-%%@.I4V\<^%N!F_4%4L+8&2*`=RR,(D#$!:#=)
MCA(H&<0%!)`'(J1KQJ<N&T!4QN8#Z.95*<)L9@6"9P5M:25M[C-7\L,!#C`%
M1T(E2,)M;N5M3@)NX29`Y&9N8B(B(8(F#;18/NAN:J)8"U0G\M8#&%(H^49P
M!V<IEQ7_(5A&28["*(T10DOH9"JP`R/0!:8%!EG@7R*P!11`!"[7$6)0`D#P
M"+8U!"70<;#1=14@<@P`7'-P13]07,Z0`.?P.,&`4L9P%5]``4-P0S5@`RS0
M!K"0!F@01EWW3"4@`IPR$>:$`PN"7XYX9@@1&`I1`&='$6+P-PU@:R.``6>@
M.W4``"OS"I"'1PUP2`EP&3)0%`P``;24+Q6@&RXT`964$`V6#@FF8+=!$IBD
M29M$$CR@8,9X$CPP`1``2[/42M!R"7](1L)4`A10`BX#8[SD#8I@?D/7:)Z@
M"'%63`+B.&=1`5Y@'`G`<X_`$G`T-#-0#J<7>L>A`P.!%FS`_P)*DS1K40'%
ML07_$@!X81_C=#;XL5DV\%!E8SC+UP6A:&O[%$^2P$6E,7P88`-OX&:/PW@9
M.0!=8#B6@V<5=1PRH`0W$`1.,'W5!PIQQ@9L<(!(H!,WT`8-D`5B`#B"MFFA
M<0D4()-_(P+$0"[34#>1Y@4:T`88D(R@,`PDIBWCQ0!B8!^-@8N'Q'^XER#W
M\7^`L07,0%2OYELWH%0'E04[`!N-,DDC%(%<P`=<\`+OD@<6@2%7I3W<LP(<
M<"(@^")D-8+FDSYIU2-%`"3YTX),DB0Y(&V#&3_WXP%%@IAJ0H,!!"8WB(-;
M=6P%5"<\B%AN`D$0=%@/%"?P9EAX@O\`2*A!#K.$).$@?41"NF8!N$@A!2<<
MO6.:AD(`,=`%6:`.#0``#&!K>-,`'E$`%L``9S@O0&1^\C`=IJ@KDZ<&<[A$
M/U`!?Y@&"=`&"$`,X``+N01IQE(!;Q``;\![NFD*+*`)95`"9[8%"6$#R=(`
M]$5?!*<1#"$AG;@@@2,"BR!F$Y`'-<D)T'"*[U`"^)0!7K<OJ:,),^%[YGEV
MFV424-<PQ4AE!?:;F001#/.@6;`7@*(.+[!))J&)*P$R%04%00-X&F`-/B=S
MU=@9V$@+FT$4Z5<+9E8,4`07;2`@-``"Z<@"3$$#&E!&SX0->W>'<:8T]CA+
M;+`3^,B29T'_36LQ+8R74)64'_9Q*210-1.0A0,5&[+!=!/``&7@>ST$!;/U
M!4-D"X5(#FVP&4_A3\57D^!2`7U&`4CE!'FV>BDI.J3S`VA048'8*@-0(>U@
M%+Q41C/@?C_W4")0-_R"+=40%C,@-A,1J-0``6703QD`H!B0!WO1&#M0DV&&
M?P.)E22@E0.(53QV`TKP$LMC`4U@`HZH:XY122-D*"00FR80`YI:I28A!TR`
M/=FC@2/251]XER(8/GFIEWQI@M)65T)"/U3B`-GV5H39;56")30H;N06F6%2
M;EWR(06D)99YF6V2F9OI;N7:F4%8KFN"@!MP8"61$!@16:;9*913_R&5I`*<
M"'"*(IMZ\0<Q$`,D4`!B,$2Q(0(EZCH=08B:MWDR$3<,<)RY"0'JX@K.&5S)
M=4-E1)U95!16X03A()W7``$]H!%1E@$#P#B`@P&GX"`84!&C]0.A90,6:'Q7
MH(FP$5L08`O?A7A#]T00D!1IT&>+)'.[J2Q`X#9"40)EH![[@@!,0"'&MYKO
MV3`;D0X*P:`\P!=:$S&9Y!%OEP6.P0-RP`+/)"T:\T,@<Q-AD3*7\PJ`4Q2O
M<!3$,'E'5(TN=4[Z5$.205TW``+.0*/45`XSL7%>$'IG\30ZH!;.T:1HX31G
M47J<TP.SQ`2\44J&(I"YQZE75A%*6!*_YO^EE!&FE&`.PY>F24,.:U`!W'$#
M-\`(GG!'?>8J.]$<X3@`.A2'P8`]<$!+(/,%9<``$Z`:`Z!S[U!&-V$%/X<8
M(D`!K[AIC0H47F"4A&("PKL(^/6)^3F0G,IH`%`'`(NY3/9_$U`!.N`#1!4U
M-9&J;?$&2Z8@(E`#PD$YLVHHE,*:6,`'!5.,PK,N"+`AKP8B.3"L*D*L>'FL
MY6,C.&(C4[#`;/4^S0H_V!:M\V,DB\D_UEJ#VYJMW*K!9-`!6S4FEHE`:**9
MZOHF9S*NA`5OGQE!\H8&#0(QB>)4$R.O")=")#!"K&D"G?48(?1K]:HH\ZM"
MCX5[_^H'(U%T#7#_92+PNS\0`1W!`ZBD``Q[0V3FNF7`6ZI0`<XI"JR51*["
M`C90`+(2BQ5PG1``1Q"P!7*P$1&@0Q79()^DB1E5&"<+.*;@B>U`::O(#JH5
MM\'R#K&@1XP#`=?(1AM0A\#4#CVC`!GSDS<DG35DB0$7O`_U4&='(12BJQ$#
M*EUK=Q:*'\7(&TS``C/P"&O`2B+J=T1Y0]$P=,1%#(-'"S5:##>W#6F<7@D@
M"YBW3T\Q!#20IL:Q&1<EN#1A'&O0`S=@N&T1>D7*-&VQ$\WP%M6$%@LUDWAG
M-@29%Z=)$IB,9:0&ND>;*F8ARS]+4:R;9T[@!-P`.(R'BAN01F.7`+GT_[LZ
ME`%PFP9M0&)J6P89`!NK`2S`0`R`F$HT(0*!T:7(12KC@`S\C%^D13&39!`'
MD1"XUQX$4`4*B0%UD`'?2P!&$&KUT01&T`03X#@?0E1P,01*4"`'<A\M)!P[
M0(&=A)KG,@'XFS45TIK&!Y<:T@,MJ00"3,#%>CY?%6T,#"0.C((P**W6-C\S
MZ)C8JL%2G:T#Q(&`)5@G[)F'E=4I/"<D_(-LLAP]L`&0B`<"!S%6>'")HL,6
M03GJA,F;I=;Z%B@NL`1G4%IBL%-*G'0<D0XU\`52O&%!@4<=-P#0A5R7\P/D
M81XO4T9I@``,H9Y>6A33`6-J/*$5]XF`%%H$]_]'-D!TAH&*C.,.<)!/'H<`
MH@4LO=3*5K$40W!$06%=X0>=Y!"@E(&D6U:H0[E:+M23^"2)UK<I,EM)"*,P
MG,2@>W&,H")*!2`'>,``;E;*1)`Q&J8`L'0,Y9`&0@</BC!GDD%#-$-D/+=:
M6]`&,BDK0V#>-\3+%5!,FV%-<_8<M$0#3G`#Z&M-:H%4UG2/TYR/H_?,0U8=
M]FT<RJ=HEX)W8+N]8G!EJ49"AS0TE@$#(2`3C!<YM+`<VV=1,N`J@".3AVQ2
MA:AA,S`.1?NSQ;N&4S$T5@``99!HC>`9S/(R@4@:&F#0Q;B*N35$\N>(`M4%
M3Q`#!,`HRC<V9HUE%[W_-QAP3P#KT490!>-D!".]`R9]TB!`,@:H'2V=!;8&
MOW[420&C:V9=:892<#O@UHHB!WJ04/U+5"<0!$)-K"CR508<(T9M@@VL/VY%
MK=N&/Q8\)N8VU5,]0`0$(NK&U2B\U7"B6%XMA`TT;^PR-K!)JPFW;XDB'*L)
MJ_I*A4O(`TJ(;W5]!F=PI0-0R:J!`UM0`$[\$6+@")L'!3H##_.P&D.3!B"0
MV(N=7A!P=&F,ZKRN&NRYB7('!FX'G+9P=C^@G@L2&V*``,5U3]8(#';L1)`7
M<RSWV0P0"]\`#.%%C7B3`*;@#(XV#22F`6?1``+J-C+P../03)ZVAO>$3PL"
M_QNXR`XX4`,&9HP+=A+JL!&9]'85@>;%5`'Q!`081@/Y0`Y)XQ0TPP*8QW,7
MI0&TA'D(CWDT-&>?H)&QZ$^RR&..,\MM`-\]0#-/,_+2M+CZV#31?*3W>'K.
MC,Q.HS3-H"&?(P<(@7:8O"@W?P45G6J`9G3Q-`DS002=('1PH#GD2TMEE`"`
M\[,(,`Q)P0`#+<]DNB"7>HH"?0Q>8`4?4`:C;N[<@E)]]D9+T<]ETUD,J:6M
M>799X-%18->Q40J>$&=O!AQ79F6ZTP5*3IM+$`5&8#90WN2/$R(^W0:T@X`(
MLFBC[ED7)'>LJ6N4`RF953@[L*E5FAAFC2%LH`0@N/\B!"PC<$[G=;Y64J+4
M^6-M42(_3^WG40WHVDI`DWE`A,YN[19OZ+KHA^XDEREO!F+6BV)E\YO60OP8
MCN_X%0'$):'6CP(Q7/#I9^`\O[T@\U`#$3`'%+KJ4AP)Y*)/EQJ+S^0YEX,`
M[VP*MP"@6]#$',$#L`&?F\1V=E``73H`W=(`HF!]HQZ\XV\*&:#:)1!RU0D(
M(!49964-3"P0:2`;/VIS""6%&I0-"#0W(&AP%104:11>7@PL&1]`-S(5#%]>
M,V-6:14##1-B%C8V/#P!O6\,)5MBMUG%*KT!!05@S&`!*CPVQB34!+9R-&TT
M,PI`7BPR4&M#0RP40SIM;2S_&A05[31>G@EM0^U#VNM;6PVD^PP0*FACL8Y%
M.8-L"/:@0:/'$!D.6;!!Q^(&&QD6&;)9(W$-&QT66:Q9.'(-Q!L2A_38T@:/
M'%L68N:R,&P"AILB:NV(4<4/'P(8,@`@H@`&C`0)B$```:=$!1!0T0BJ,&1&
M`DH#1+2IT`-$&G+SD"(UA`%'F31PF';ZDL"*%:4BQ$QH0`M.FB^>/,FJ,6$$
MAAU-FF0A08!$%@MX+!0C8"2*GQT81,!AP:*"#!DG+JOZN\-6ERXX!G0QTN6)
M$0(F"#`V8L1$@PHZ?*SHP89&@AM!E.CH@4?PA`$8+.2YHJ(XCRR[;`RS,&'"
MKBS0_VC2G)!'!6$561*;,&&!!Y,>.H*@&$^^_'@#Z-&;5X\B/?HB\.%/F>^A
MOGT'^!WDV,]_?_[^`.;`@8`''$#%@0(D2,:"#)(AP8,01OC@@@E6*(`//ERX
M0H8)RK;""@>`6."())9H8H%(I#BBB@<@@6*)(J*(Q&Y,,!&3!2:(04)QUO'H
MXX\]%A>37,W=8D-,5US!"P]`-@G-+L5Q\<<22XPP@@@X9``!`*'AP$`-!43`
MC`IBE`#$&&ZX8843;4``00DE)`#$#!109@D"?(F1QQO#V+!,,E?<9$,2!00@
M!@8(O/&&#0&\04$;-?13PP8UP%$#`AN\40,#`)2```(#5/^01@DLU$`''791
MX*8&:3#10`(5-$*'5'``)%8"#(!`PQ><R/)))S.X04,#.&C@S0UN?D$$#`HD
M``<=PES1"P\QF6`+GYPV(`:C`=CA+1@O(+/+N$P>T\L+Z`80&1X$Q0,#%#/0
M4($7,L13P0W?T%!.&R@-08-!;5"0``1#R$.!O*1\2M<^#32PQ4(-;3512FRP
M<4,/(I&TD0P;Z6`Q94-<U-"_/:SA<4@A9TR##$)P%)%#6^#1``9RW=2`"`,,
M@$-H#&2`PP06_$0-"1/@,%11"HA"A+,5!)06'%+=V]877VB0P0`,5+")*J)6
MW98&5@VP!0-E0-VK$VRYE0`+.W3_9T%D(L3M<)$6$%;%$D],@,=AS?&S#PNT
M[%2%-5A7P,()B&=V604-=!%#<\WA'$,?(RSA@FJJ&>'":5O0L*''/5"%FQ(G
M\&9"%F(`E\=P3#ZWBUS"[6#"DT<.8[NT2`J7!Q_4\"`'$QN9)WQ[Z97GG@'$
MNQ=?$?--85]]^$$?8'X>Z.=?@!QP4.`*5'`H0(,+2B@^A!0*T$$''7*X884>
M?ACCB26RN&**+LK88OWPQT\C<]S%M*.3`#0.#^1RJ%O<HCA)"B"0QE4<$N!M
M"3D3@5`*40<&>*D!86)&`"R`@S.Y00%0^`($R@`!!E!``T08PQ<,MX5<7"$)
M,+R"<L20_X5NJ0`##>`3`AHU@`SDD$\8*`$$+M6&7(D*!#_X@<)*``!#(*`I
MBVB$&O:``$^T`@@40,`6$H"6M'2B`G!0%B4T\"4X4(`3$/@$',(X@W@12P,@
MY"*PT&2%I\0-`Y"S!7=D:`,1`*"%`7A.,?Q7KF0T0QF%LLZ."C"!-FR!#>M(
MP+MF<`.JJ,(+-UB#%U:&DFRPX%^U80@^:%"GR@B"`5M@00/PP`26;.%W`H%8
M#[0QL8DD)"066<-(+E,RD%&F(9992$HHIH.1?%((]>K!#?[E+Q:4P$L[8T#.
M:'$I30'#.9AK3=$@D``W&&4&HEA*`]RA"330`00,0(K:K-8`%O_`00><J$`%
MG'`5L6B@!#/K!UI$A3:V(`65$^@"T(K1O\,H)@N!84UC)K`/?KR&%`0IH;8(
M4`4<4N8RB4N<#FH1`X$VYV8QB,$9%)K-S1%@;+$!'0MN0SJ(X&%O>*#%+90D
M2&HU9P<DR`,!H'&D'-F.45>@R;96QX6B'@-X,@@"\H9'GN(UU3W$BX\!EL>\
M(MC'>=6#WG]R0+WJZ6>K^^$`$K07(N^!ST'C&Q^%SH<^#&5(-MYKG_ORA[_[
MQ8]^*$(<7N\ZHKFFB`4@J,FVMO,_`%+#1TKB(P$M(#OB*-!'0[..8ZT3`RMA
M*4M4PTO.&,<$940@`$7S`A`^"`,OC`7_`H28`1`>PCANR:$`T9CA%0K5A1&(
MH0%(5`,(2@""&EP*3R+`@`UJ4((TI`$"EOH4#AE`CB%\B0$TH$,2?[`!5'%3
M`TBA``A>]12[R&(37W`+)2J`@`:D<8U@Y$35-%`&@'R`")24%P54"P0%#&$6
M(@`:"7@QK>B(8&`@:*$QT(4N1!8J.3<J*AXF<`8;X*$-'JO3#=P`A8/1((WW
MTL9#/OG)?U7&C(9;APYH4#&/?!)C,F""'1K)`B9D000INQA&2@81DRD39+=,
M2$/60.(-D_C$\J1Q;3S&D8I\<@T58$B2&4**`;```<OI#G\MT,/\-J<*56@"
M`40``0UXDUD)_QB"LQJPCAJ4TQQBL8(H@H$!!D!M$Z!`2MH`(`+5,&<`;7BF
MSW:6E1$XKK8CR,-QK"67+6AQ9B9P01C"P"Y2Z.#1B;O,RE@P@1@TK`92T8%E
M9$"9$\!S"\WQ:&0<E^7-L09SJID`"W2`AH\D1,PR>#0:$+"W+>?7!L1AX"V:
MDR03M.Y&MZ`)[J*\K<G&!`$B4>I2A\>>\S3[>.]Y#_/FPSPS/,\,^/%/?LR`
M;0=P.]O](6M9.736\(4OK1-BZ_DNY%8,64BN<S61_$ZT5_HAX03VWFM?X]TB
M3_?@!S9(35!-L*/#_DA)0"*!8VT*M'(]]N%8>()E=08!JE$@9TY!0/^8"I`'
M#`P`C@H(N1M,6X8,U&$HWN!T7-[P@]<R81B+RD5?AH$#.%0W+1N@U*>VNW(A
MNH,..?]!`S+`7"(0`5)4\6*OY%DPL:CR5T-8(532:86VE($%_`!(%WM5M4YA
M+0&J-2U2B!)R&N`I.,^(B4TPT`4QF``#9:#`!ICP6F6$ZQG'N5%,QA6`%ZA`
M#GC(R24@4DJPWY<!;7!")[3A#@Z;XY>:KD#GN,*Q6>H8Q3W0PX-;G(4MI.SS
M)%D(5U`R,814))06(S&):Y,0CLF`(PRIU\H\_,M/MH$-J\`#/]Z`1X*CIB>_
MR4!P8H)0+0^]##,P2K.JQKB$S4H08DZ`*+S_H`$<S`QGZ"6E/Q/07@R$M*,B
M8$'<K(2!,YA`IR:H@@E$BD>&YD0$61,(`S"`!1>X8`+0K4!&,ZJ9";BF`4"7
M<W2@`ZL&#JH0,S?U&<&U`U6@.21%`(&1'931:AZC`]RT!IFA`[26!5LV`!.@
M"T]")KOF:SB2)$,R4U>P+1L$--+!*$Q"`MSQ!EN05,LF/$[E;$\%;=)&545@
M;3YH;?D1A-_F;=T6;OMF5F=%/N@F`0NB;A;";G'E(1C";_&3/_=3/_F6A745
M(O*&.#JP`=32-D&%4P`T64U"`D)EA@^G0'P@<5>")14G0@Q`-J@4)E=P!F?P
M7R$7<M[`?1D@%$01_R^`TP"3,EV^M2AO0!<8$`#$!4:R8"F1LEUPT`#XA``$
M8W/3]0,@4'&N0`044`.)T%VB`D85T`IM804V-XK?Q11I@!0H5`(U@`<\E`$E
M@#5M0`@D1`LX('W>0`Y?P`TA-P3;-0`CD$<PX8(3($0(4",&M1T$@!S(T`O*
MX`S/\'=Z@&>AMPX](##W]4DAM@YMP#&@I`_H,&*IU!"4L1`>LWH0H0=Z,(=X
MH`<3@`ZVI`,J\7H]P$LF,1$<XQ$6DQ`>00,!21E%-GO:\"_R@GLL$#ILX!`5
MDS(,@#'!H#,BD'X]00TC@`,B(#L3@&55$`,2E!3,TBPW`"N@^"SG9!<E>?\5
M&N`%$%`+U@)_)=`F90```U-"P?49CM,_1-(<B?%26,8:9Q`J[E09L?9ZRR0,
M?>!QFO`1!BA/JD"`$P`4.:0&5OD#J`(*3G"`>&`".[`#`D6,.W`:IG9J$-@$
M@:<U:.`QD,12NK&!33`"'L@+")0C0F4!0867.'(CP\8#*6A`W8%K?KD=%O`&
M"*`#2E"#-JB8.:B#/!@?SL-MW.9504B$VV8]_"%NW(.$#;*$$M`!Y-.$Z/-N
MZY,^&\(A'K(][U-7[V,_5TAO6]@B72@#(,`$RM$V?-E`D:5`0W-`:ZA(0&*&
M?)"'(F`E`$$U)<0I^&0CE=9Q95!?(3<#^%`"TE3_`G#D!FL``CW$"%#A6X9F
M`XDH-C:`3J#P%+U5`Q4`)QD@,#;G"6BP`9N@BF!W%;P"8G;Q%.?4BFYA!5]@
M"93X%&BP"7;ABH:0'#8P%W+3,`Y3`X=B%L:B`<TE6B$W9K4@+=-R)#>R!;L(
M`AO()`'`#(4B+EF`H190&)VA!PV0,B.19+-4)X;S28)P>RS*HB0C,2%A3`NY
M,@O1D"3FC@JA>>502PGP:A@S$@Q1,B3&$1]C$.#`8PS!$(Y7$.B(CCDJ>05Q
M7ZN`,T,0-\$5&#Q"`B-P-1/0&:EA'6V&?"/I!6(V+"R0*U'C!&*V7F7@@>D7
M`Y%A07,H398P#";@$WRP_QV%1AF"N@JU,#@$,`)9XTZ/]FB7`:?#8A.$B``]
M(`1"D!"4L96J,)5G@`%O<)7Y.9\W0`$PN1-A.0`[P`>:4Y:J$1AI&:"@8QLW
MH`2Q1FN%,93.\0Q78)?2$53!AB-[)$-(0J8QP2/`NATF8`/?(0-3Q9A,93PZ
MN(,["!\_:&V4N6W=!E8"(FX(4B%)N(1H)9KK1II16)INY3X?DC^M^9KV=E>Q
M26\9^)U9L$<T41U?6EA.XI<J,*R_:7`-E&OE0@*559QY6'%N0IT`X`ZV0PT8
M``'0>13RDA5T89T*<`.;``!P@)50L0J0N"D-`0*J4@%`YPA8239@4T<;H"_O
M)/\(%*!X^MD6"=!;;G9.`;I&<?(6K%)-6Y`3\000````$."!-4,WNA!;BJ(<
M`]!E"D`$HM"2T#D$L\87U6(MH68+$\!E&R`'_(4,T&`8,M$ZQ=$+8O!D+%%B
M&#,R(S-,MF0012I+X;@1'5$QZ`@1I"!,>B`'/YH%VD!CRM20%F&/^9A+*)%)
M&,$0/,9CT,5A/3"W^G![(%`0J)1D;:I*$N4PK](`TN$C!-`%6#(`LU.BJD$T
M9.,%:8H4CI2SH<(`3A"';G(UC>,X(94CD).S,2,7@+:I=,$`FJ$93K!,I<)8
MH>*J.I`X2"`#2K`&110YD]((WR%/7[&R-(`!F9M#U:7_%@)S"AKP!?/GE3&P
M!#&@,QC`!^"K4`JE96\'H`V9N$,0J[K!&Q;0!+\A7+L@'4/B-OVSEWB9KS=R
M4Y.E<,.0!ZG!`WIPF$&@;..Q`,VZ'M"V/,I#59))K97YP-AFA*KI/=_3F9Y)
M/NHVFA7R(>/*/F]EKB&2KNF*5UJXKN@:(RE"@&C`!`%``CNP+6)`AE_*FT)B
M`]"PAORZ7P+$(WP@E\7)922$%V130@@`@AV7`63GL("3$PU#`:LE%6>11-,[
M`-1)LTL!`@E``=*5B0B0!I1@<8)``SD7>:)R%V[A!5_`H6`T*P&Z736K%#7P
M`\HP7*&2,WE*3<L!C0<&GGBB_Z!TT65`H+0#DQ3UY05ID17M=XR[$``V`'=P
M0&O^<U"+'(W/@'>_XP_K8#&TL:)M('HWQ@9KD[87HS([]K:U`1Y4*DQTMP40
MP`9RD`7)I*-*>A!KHR^OYR].RFF35I"75QF=\R];T0`TD*>IQ``.8VC_P@0O
MM05E\$H\L)M@Z7$X\!=7%@-^@']EX`4A!P.4!`&.)!<ZHR4%2PNU<%.L00W*
M@4/PQSCP5YSD!W^XNSB6L;M#\+.VX&0]\'P$&&NZ)`/J`&JT@`#/]TEBAL9.
M0`,;.1=0$4]K8;,),,U\X`=^(%)8,@(2;7^IJE#JQY2MU@,],`#D,,`N5:([
M$%RX9O^_0V+#-$&8QPHE\ML<W?&E_<,=T)`%WZ$$RK94!KR8SGH\"ARM\='`
M6N4`0QT]W):9(T(%W,.MX'/!$I+!3\C!4.ANZ:,A&P+",)+56%C"\R:;JGFN
M][.H/7`<L',%>5`W,_QPPZJ&AE58U$(<]MK#.N,7XBR'A<``&E<`7)`'9U`"
MHLLL=&)!Y(Q#2,&A)D0':D!=250#5%P&2LMJE;0!B7U*)I19>($&Z'DJ`+I&
MK8@4'V`(D3(`:>%;="$4[#4`4$8D,!=SN(9KO1!PD(-#A+A==$'%7M)E1F=/
M,[`LAKQ=PH5WM=.3(M`.PL`++P`&(7H<Q4`8)>K"7<!*0:;_HS0``B63$!10
MMDBJ3"=!,6G;R=*=HW"+W:I`=V(``3K`!#SP,1@A$MIP`YEDO-JPW@)AW:@W
M$%+:IL:,>-*$=?^R#[K'`#04#5F!')VGD;-36"0@4%26`?G5-H>5!UP&1^\"
M!4BQI5MP$\U1`_R`,RPH!CK9!;8[`*!P`TY@7.<PS>G7!3ICE)@1O)<!"@#@
M@3E3B$FD*U1!#@-#,UC#V:E0BFUA%<YE"VVJ>).Q%M)'"<*7!U@0!7]P!F$Z
M`$&9JF4Y.+^!6X8F!C`V!$H@JZ;3!'U0G+XJ;`,D96,J'>5B4VW3&=V!<##(
M'7K20+Z#,3=P@TSUK'8^5?`A;0T,_X340]1#"%::R9D,XM020@90G3ZH*=5/
MF"`<C-4DTIH@4E<E+&]=G5<IXFG"D`LSA2/_8Z^&Y3].XNG[]3_40IC&T4!#
M.0!X:!9N4D)E0`\:U\)\S0`:H'QND,5MH)$Y0XEK@VQI@-B)+;*4R(DY>K$_
M@`:B4ER@D%D,\`-,0`NS@FEN;)->4`;6)Q>1LL0ZXR59(0S^QQT!D`16J08;
M)`:^50,W@>%#=S7G&=IS:!<`P`UMU$1>D$*&3`<-8XPV(5"[%A"VB0MZ=R.%
M44C/@`$+*0B8QVGJR,HE5AO>'3$=(1%]ZQ$LJO`DMA#[,*7+R!+#T@`R@`_\
ML@:/XDE0:O^C.,:D).]<CDL*#D,0JX0'OW`(N_`;6\`+%H`S&%`,TMP`"`X9
M.;(S$W`%'$@`/[$#1YL44``%1T$.^>5VFAXIP$"Y.6$EM249J^`)C7H#(D2G
M99$U\G)1\\P0&@`!6T"="$!=E-(`:8`OU,=]P)$U7I$`3L`)%,`6,U!U#*`W
M6B$+S*OUX34&'X`#9U`86$`:88H#,6`"42#EJOH;`W`IB<%E#_%H;$"KAQH7
MU6(!*I""W6$MQNI8S^#Y_,-3UF&L;1,E*I`+&]`Y05`$-;C3S';GS\K`DOG`
M'C`%UXJ9!&(@W:,@W;J$H!F:36@^&MQN<$7!%L+![6.%VP,_]2;_/R9,Z?=V
M`J5"=P=J`@-'K_>*X/[CZ0UT<,;&'5ZI^5!"`GDX`G@X`(50L"=$]EBK`GS]
M<4ASZ]H0&CK#";`B,WA]E<(.""44:0D5""QP&QL@('".:5^1$`T!`5L##34U
M"#4#$``:90T3$S86/&(#(C5BI&\V-CR5`2HJ/&\3FV(8#2(B`PP-8K`-926.
M()H@#<`5)64:1%Y?#`P:,V,*%'`#`QBD8A:P*E<VNQ006UL3%GE9I[(O8/.5
ML@43-&PU-#TZ:ST5^,E@@:`-"S8WV%1H`Y`?C7QK#M[0P68-&Q;\6+#H08.%
MD(%;VNB0,80!BP%M;K3)T(;&0I<4-#*L_T"!(S\*+H=H'/+09`4(&M691(#'
M1H,V6^3(X?%+#`\>$[HYG2`"!PX\6:@.&$%"!0D".WQ-P#`@@X@)7;K$\,/'
MA`@("8B,@0(C`84A(EJ1PE`UPZ`*--N,,F&";(-&%9PH7HR.P80M#.`LZ\%D
M`XN`7A(,(9*@`0,*AQLX@D,(FP8(97`P`QSIT9<$":S(9A`.<@72%"A$BFVE
MS`@^!+C\,7(&0X8Z79I4,>*BN9'G39K$Z$84#PD,;8;(T'&"#5$"3;H,8&?"
MPA4>%G98L$#*@@D>MN#;(&5B1[@K5U38,)''O85:`(HAQAN'*&'`@2B@L,`"
M"3;HX($0-@CAA/\0%F'AA468H:$'9GC@H0,>3.'`B`[D,&(.'*1X`!54""``
M&3#&V$$'$M1HXXT2D$&CC3IVH*,`,[HH@`]$^K#""D7Z(*2+21IYY`H'1"GE
ME$=*B00245YY999:6KGEE%-JB80.("#`1%;L7)''#GD`2$Y7M9``9RWK73&G
MFW>Z>46=>Y:7!0]9U++#"".<<<8`=90!`00EE*#!$"`LI4(>AVJ@P*5N).!$
M-=T$PX(&%&R`0`5HJ*'&#Z9N`(<@=['`!`(-T+$!'8TTD@8$7VB0@1@%%,`#
M69CPU2D+6SQE`@F[;%$#JFH$4(X-/P30JP6$,H,#)IKP`DPP"'#"``3_MU60
M1F0->%8"`\]HX$9FZ,P@UQA.H+',!.>9T@H&(V#`"UQ;X,%#`4D4`$8!M`"Z
MWGJM\,"$#&QPQ$9%/;#`$`LR%%1!10>U<='$_SS4@T$.LY&/#OG0L(8_;:3D
M1,H95--1`R%MU!$;D$J\$T8&T5!21RQ0$,P6$;>!@`UXB!&,+#Q`AH$%`5A0
ME0BP8,``#ACP@`>^`_C[3GE>J>#6M=7BP,`WQW9U'0YE$*$`#`IDI@$#6_#E
M"PO/4"`#8#<,44$#PI80KA-##+&&#(33-,D6-,!!QP^,J^I$`C-D1H0&%7Q;
M02.C/8Z-%0EH@,,$#900R=^O=1[Y`'QD88)G_^B6D0`$%)1P+08F$,`'%G[\
MT04&)0`P`@'/->?"<T9$5T53ZX6'0P(W*''R=^&)L+1Y/.QY,'UZI@?.P?+5
MEQX\9N<AH!AX]"!#$.@;D."""SY(H?L4'H@AAAJ:,<44'G:H(8DEEH@B!U%B
MD8MT%*,8X>B`!X31C#H`)`86B4E&2M*2AJ0D)SWI`%4"$P;#A"4Q<>E+&O12
M"+FS$3R8\#[BRX]7G@(G.;EI/6Z*H5?R1(*#^:>&Y7F*"K!`J#/$0`2)PA5.
M-.,J^%!J``"XE`+6=8/8,:`;HM'`%[IU.519L0;BR@U2Y/`#1G""$2#XR6L`
MT(!>%2`"/&#&-P;T"O][6*`+A5$-+-[PAE9LH5P8"`>^I)8!.!PF&340#1P`
M$XP:T`TP@)$,"-#EMV]Y88E>6%0T%``O>:GB&]\@Q?;$\),MF,("-;0A*$GP
M%*O!#`\:X0A%+,*&B3G$(1O1V,=Z@)"(W<`F(AO(X&1P`QJT80TFHP$.7.(2
M5AR%#4RP0$M`T(;+M8$!"S&)3I[8`(FIXS$&88(>\``9!,@A`'CHQ@304Y7Q
M0*6<%LB*OL;)`P*\(PM9J$37WB2WLZ1B`.$@C!]R-P(<0."1EYJ&!DJ@K'+5
MP%8W<`(-9$"#&WR!`I@8@-\J<#>*+E0&BGE-)OR&!EHY@B9>F`'GK."%<5'_
MX#8@D%=BOF"%%LQ@!AH8`'LL)RXGZ*9S&CC-`)ZPA#SD@1>_$`'?)B`@/)B@
M"FN)PA_&P@``B(``P!O><\`3'0+\8@=0-4(,EG<#])40/%V0GGE4$`![6:`5
M]P$0#TPPOH/E!Q7JZ4\IO>)3^YPB"VQ00OH:Q"`&24A]#OIK_.17!,):2$,6
MFH+^S,"_')CH?U(2X(L*B,#*XLA'/5H@!97D0"<1:8)*&M*31@NE$())3%CZ
M(`BC5-H#K#9,)SB!#BB#'@&MYUAQ8J$,50##W>9V3E=@ZY[44XO]F"!0*N##
M$P@5A1%D``!#^`($")$`&B``/ER83AF4Z(89#,&)_U!L@`82L(DTP,%4C;/5
M763:JS?\(A/+&``.6K:%,THK`E?0E[0`-HLK!"`/(RAG("^GB3NR3A4-$$?E
M$(-21L"!`K"I@&7T!H+%H6H#SFC4MQ+@!BB4A`%E\$(VO'`;50PC%O#AK0G&
M4H$$P`T#.ZB%+,@Z#S`$X%]R8`$#(E8!53KL8VP`04U8L`8A4(P)'0F93EB@
M$YV9+&4M<0E&--+C5`Z$!W)H@$[.Q`)P/9-U00E)`Q`P`3PT@`9OD$,6\/#$
M-P`*`V(3@QT@@P,1O.,75./MO9`;PUFHX$\`(D%]=G"&`(O@"A.8G0A&L`,^
M/*<+:-,`$"XU@]>4(+X51O^#2A6#T8SBLRH@4`3CT*`SR+DK`<0J@7G#^!<(
MN^NE;_/,=#--D]=880Q$*`,&!"VU`3BC#`"H0P8@T#(,G,$79Y`3#L]:YC6W
M(BTQB/98RB("X`#/"%"E*E1',)YK5V$`S$.?#'I@5.5(3X5-LZUM>0L?]]2G
M"^$0T)[$4)X<`BH+IN"/3_VK,'\$(4)^#:S`!3M8"ET(L1G:D`<:^U@`!K!%
MDZ6L92>N0`DL,$@/9-*1/CM!C2/)@E!JK6E=VR62H[9+K7VMEZXT6R:88P+'
M\EZ@\T2G__AVA;6PDUN_!Z!\_X<$3UAT%,[PW.A"0&<:8`A\2!"6#+A!B=Y-
MP[C_NO&+G"8C#2!0PQY^L($:#+($B]K"?0N``"AJ`@$#ND(!Y$"P`N07`U=(
M0A)ND:T)^+2<Y5*<J#1QT')U`P,V>,-H&GS0+';.NI]*A"+HX/5O`<!O;>`P
M%!*@*,AE0P&)J,'2YHV6`.<+`W!I0"P"$#""!0"';"TS$Q!'RXR,VR0]L$@/
M:E(1(9"L(2*#R4,>TA+"8>1B`Q'9PV2P!1V+K`(60&5+MI"%+8"&!3#3"-J9
MP.8&Z.$=#9`C5.;;`*M5Y7-V$)8(L))Z$P"HK+609YSD1("CQF`"!&#Z+U0A
M@B[4$(@9V,H.YK2#;ZGK4F,`.4`!#+%"!P:(!A6@$3>0_U`NE@H9L"RS`@(2
MDP!>P#FO46>JADCAHALA)1NQ]AF2,4AI<%->,#D9,`(FT`060!93<RW!\@UX
MX`)+X'G',A;Z(CWJ,%1=<`9I,1;9)P)]0#SQ!U5-D&UDT07>)@)#T#PG,&[E
M9@2+1CU7T`KND29/T2>$L3UG16_Y9',&0QB$T2;QP03F\V\(,G!HF"`%-UCT
M4S\=LG#\<R(J\G`#5$`P,G&6)2,7AW&?120?%UJ@U22DE4$CYT$GAUHKAR4B
M!T)(<`(;\0;NH1[#-2<DH$(O9'.^I4.V0!B@=##EH4*J(P9V<FPC@`5G@`,`
M4`:1D!U>@!0\T`0DP$-.IT10\/\%4L<I#)`!'T`Y((!U%Q9(P-`H+&`!8!`!
M28!&ZO`#9M0K`:`42O$KPD!'-Q9(?)-)9<$+EQ:!",`X!`("J+@K;R`NDK$!
MC/,#=,``(W@-0]`#(*`=FO9U?D,!H`(';7`-4.`%93!L,\`V,%`!@51G>T0?
MY;$+L%,#^0:&A`%5)/`G8C!F/^9Z0I"`/E8";*`#$[$0`4%,&#$0/*,Q"L%C
M`+$W!B$R+H,1-&!".M8&6<-ZU*<'GH$':C8!U>`O3M,R$Z`"B99_=R86[["%
MR.5G,K9T6=!^A+$#.^`'"(E4,3`H5O$-ZD$5:#,`^[<#T58%X@$!_T=)D(-J
MS,`"%6;_@+2R$[!!!!0@!B+01[9R+I`@&["1`((A44YP&X/D!*4C&S"%@5@7
M1HN"*V-4`JHP`C$`'(4Q`LOQ!WP@)RNV!$M0:+^@#B+H$@%A$M48`UTP*`U@
M%GT0'47X%515A.+Q.\2CA#>P'0QC0M$18/^!'NTA;SKD;OYQ5O[%'EU8"W^2
M!>/#'USP`EQ0B:]2$85UAFDH<&MH<//CAOL3AR4RARP"<7:8(WB8AYG%0)I5
M01*T)(`804DRB(080E]RB![T0::56B2G`W!0`UI3'K<U5O-TB3,T<S+6%=:S
M'I)(#@)B`S?V221`BEB`!:BHB@_U3Y-@`U[!0SB@-IBB*6D@_SOS!0!`0`27
MDX";D"UX5`-,(##'&`"/\0-S$`$%8`J?Q'90(0R!]`8_\`:9L`%T!#H94`('
M%1F#I'<(@!C/I0$-\`8C&&J-$Z,CF"M>`"E"E@;O*"[0)(^%0`,46!?5\$^7
M]P5^Y`UB8!^:M#L!=AO7)`:D-&.T4`F^XI5()C,7,6X!(3(140*[QU`)2`,Z
MH&,]`$UH8!*M)#,:`3<V8Q);4`&8T``10P/LP#H-D!7!8`-J=A0-@!5;@`-M
M(`*\54XW61CZ$B@V]">R0`MX(B?N5F_NH9!RDF*UT`>526C?P&U;T9!F80(!
M%IA@\199"0,B-@/!4`V'88"+X$NPD?\K$,`7QX`&<(`N(P@;'CA0^Q(3C8!1
M#F67F0$W\Q>,L@--F#`!?!`#GN<'3)<6TDH*ZI`6(Y`6(@!-@&&F&$4#T"14
M:5$89RD"51`=V$:$FDD`TR$"T`&%<+$&3<@&Y=8$J*EG$V`?A/%6:]6%\7E;
M5*A6]B(@N,4%7G%69"@#!@*<P8D@PSDA\W-P;@B'C:6<DM6<=_B<E:59'2=:
M30*(0M*QI.6'(G=:W=DEWZE:)J=R6#(2!!$+[&$"\:EL,11*\9%;\($?[18.
M4*$>U;-6,(<?]6(!A38"41`&(N`Z@8,.H0`'^4$"Q#$`DG8I]Q@[&;"B:7,I
M,<$"['`?LU#_/0'P`B\@=U11CB6:K35`1W1$%@)R#%U7GN7X!B"`E5\``CQV
M.:+61:P2%Q7`!!4`*>R(&X#Q.`D0"<%``^8U+E0&"1'691HP!E;P&NY"!).6
M`'2[#/A"*(0B/43U%%IJ>O6`,,,0`)[1$+_W$KM'3!TQ,_G`$:T'$&W`:A+3
MJMXZ`,7'`,N@#I@P>H6Z-'Q!.[_"?4U3%I_S*U.#J"3@!T89?S<W<YQ)`'U0
M!=`+O;4#3\L;:)3Y%8)VEADP`23@7'QC3A;0?J%SM90V`VX`%.B2";!JD10X
MN%\``)B@@50V!+QJ!3`5#&=Y#(-$`0[%4CGU3$BQ:'[0!82B%EB5_U7!$W32
MXW4)2%$C<0,1$3?8*@*#%%LRT(2[I`-V>JU_4&CY-P%5E6W@057'4VU9-0)P
MT3P,\P8F\&AY@3#LL!\V5ZD[D!]`*P:5*9_J&5SJP3750R?'L@./<0)FJ#[L
ML[`-:P`78E@0&[$D\C\.MR+,25D]@K$W,B,ULH<=P'$0U+%`TG$BNW%%HIVE
MY9WBR4%FC(AHS`8H^J0$8`[A0'.\E9HI1DK%E1^OB9[HZ8G#0`ZUX`<C\`18
MX`(C@+3?)8]E4`$V8"=&L`3@-FEK,P.#6P9U4`<`\`&3M@W$(@O':'HV\`T!
M8&.[D`O+H@9E-P!G6T>],#2\\W7^R`F:`/\'6#D#-'!F%``"9/L#-?`9N4++
M3,!DBD0::2`NKY$KG6$9)S5(XD+,A[=A8R#)XQ4-0``$7L`S53IZ]?`4`8M6
M3PH.5!%]+0%E4088/),1-&`9/<8S0/&FOJ01)T6G$MDOGE$#@&(4^'1CA?K"
MZ?04<&86IA!4X[2%8B!#ZA=HV5:41ED[\2?'?38+M#`G5MD6.R"NWK`#`U`&
M#"`]]_)^(M`&_\2/D4,$0Y"KQU`#LH*`]$N!5J`!9#1@#1P0]+L;D30*^L)(
M8!<)TL4HV0H!\O547T$8>O%N:J&8,TC!5+90%;`&$$P#TD/`0J5I(T$X4JT#
M&IS1:N'!.("$12C_PD48'7WP"WYPPAFPA$VH`PB@T.+!#K)9#ER3'CWL0N3@
MUD9I'C!T!7;UB7MB"_ZQ`_#&!'D5(>L3<&@XG!;BL!G2Q(S%<"G"`<LI61%W
MAQ=KQ9>UATO"A]2YL9LU6MDYB(EXB"2KQN#)G6/2`QO``X+VK[X%0RXDLW&=
MQ^^1;_1V"F<%#[5``&<@R"[P!$@K7?+X-@@`2D80!6]AH#```Y/#TL`V22--
M+*^PR'",MK&P"[M0`A:F"6^P"714+D.S!:IV4F`$C#]Q#4#1$HLS*[F:I&UY
MRSW#"%(GEX3`.:&P!2;**!\E=73YO_[GN,,,"9*K-C-``099#[#P<NL4_S>9
M1%0VR`SRQ1*+@A.7X942>3&LVTIA1`-UZJT&$3-!<13]@I(-(`?7)V8\8`<6
M(%_%PA09D-7']6=-`#K2`Q^JXTYV\&<SSKP'0P#N1I72J[R^Y=!=&ZE`K@+Q
MUP<DP*D[N&CZPC=AA1KC017<JP)P%F*7HJI;63F7=H"D$3BV%@K2(P(H)8*E
MTSGP"W.$0196X8*71`K4UI0"0HT:44T9C0$QH%2'<AM4)M6$0P'Y1\"8`)9H
M\'LRL$L44&<3$`.%UI0CS-5$2`#<%@-.:P1=P`!+J`1W\]O@$1;3PP[H<0K!
MQ84J9,.<:%?XX6[T]HE^K&+L<0;O088Z$`0HH/\^1BS8@QT_&&+8;GA8B7TB
M4"S%RRDD=EC%DCW9&NLBT^D#,T(D#!2(?BBR$,39JI7&9CQR&G0ELD5;LFES
M<`T@O35#P/6:0FP>>`QSVKQBIQ`G,;`$1:O;4L3;G5,"2V,[/T0!,[`V;-,V
M`)"*P*8VA5`N=W2G&@TM]S(,(E`""+`!VFWP8P8K\[P%JBAA9!LZ\D@$G!$0
MMRPOJS)16)E30X`&:^H(3K!JI+$;`(`#ZU`#`Z]J[7U3$!`,SR!2A_L%D@O)
M0Y`)`C(6FE3S-7^#OU"U\R4VYS)E$DA+&Q'A&M&1&%E\+P,T0_$&JR<T((Y*
M#/`&X'29^`05N0@U::3_"F0>';F%B6Z2!4UP7%`U:!,MQ!.]'O`$]DW0XS]>
M2KE,MJ!$JE5``&$E7U1SFSOP#*,@/3\-9U@YY9D1.83TE:PVJVUI%KS0`("1
M!C85YJDA/9=K*)IT\Z9``I?);=?B"[[&`-[*`!Y=`BQP!E'@K'^DS'@.&,2F
M+YA0\(US&4X0`@[U.B+@0X5VC8F>;55UF@.`A,^A70D0!(3SV\43%B,P/OCQ
MB6"HL_C1VGM=P[PED&.E0M=#.[;`!`<K(0HBZTC,A@]KG,<IAQ3KV+^.Q<%^
MQ91-[)T56LCN0%V\[!'4Q:/UV=#NG>%IQM6^`<DD#C>W[2X$"%<D/!:%A28F
M_Q8V*BH\B!:$B(D\*B1_2TMA2QD:7U]#$`D:$`UB)G]G(R4S"C`P"C-#&1DX
M)65$"AHL(`P5<`PE)1DE#1L_"`T-;V\-<'"^#2`@#=`5#`D-6PD5&]T((,YI
M7QJBV\`@:,[2<.*B7FW=+&F^ZQ44`!JC-3PV`388P!@(%#B@`88&MC00H?`,
M`A$@0!YZ85!*C(4L60(4""!&!`,<LVCA*)A,1`T$`U@@DT9C5TL:#+94L,:`
M18,V++9LP;.%P1LF/-X,&,`C``\,;1K8R#*!088&A$1D8""&HP@1$XIF242"
M@`D2*@($8,2(A`5).TSLV!&CBEM$!`@TP<B(AUVC=O_Y7;%KH^^/OX#_JE'S
M8_#@OV)(F!@P@D"7$2.N[A"#`<..";,F3!!Q>83F`1D2`%$`*\$,+Q585&A0
M`UP:"@EBBX(@(@^?/#M`9X``8=A(@UV"QXABA(2@"94-8A"Q/(.(!@,$JIXY
M4X8,)S>^,,#0100<.N#345]SHP*$,@:?%OZ[`03L%E]N]!9Q)D8J$3A$F&@2
MEX`1N?S)U<4`&/AG1`P#E)&`#"?(T(,%1C2QPU5B6*3"%1:=]<A>>RF62"*"
M6)"A&)I9P.$55QA28EDVX($'"TH8@,*,*"Q`XXTXTFC`CCSN6,2/0/YHQI!$
M$NF``SEPP,$!!RQ)!14"1"G_`!E44BE!!QU(H.6566[9Y99@:HGEF%)V((`/
M:*:Y@@]8GADEFF>FZ<.:;Z*YPITK,*DG$GSVZ>>?@.HIJ*!],HG$`7SJH`,;
M/=A@5Q8D<,$%68P4<B$)F%9RR*:-3,+#%2J(^$BH:6'*!R9AA($#``E\,H0H
M0PQ@2A_V,:`!::YX00%!^(E&1`4@T%!"#73,Q```PVY00P,4(2!"&DY\U\U?
MO"2D`0@(0%`!'6B`8%X)SWS1JA<:]`(L.W"T!D<)GN3#P$DU1#<`.-:4@`\`
MLHIH$65;G(0``F_T19E396A`P4P4>/'0:1,A8)0-^HK!+"T#/#=!A3:\(<8;
M.M4@_]"R%="`$PN]L)`3"P-LT<._,0'%@\=BR"&'&-%598%4#$R0!08XY(?1
M8QA`\FA18HE5"0&8\K`5(FO%X+33DI@`(*5U-9)77GWY%5AAAG6]]7H3%'(5
M'\'UX<=:^.&`P02V/+?V"%T0<'-H;I#FAA>GS</``,Y4\%H"K`*N]@Y=G''?
M55<9)(8-)`IG'W+0"43#Y!"T\1&!T45#;W76W0#X`-T-4,.T[54@PQ!>B`L`
M<^H=TUH%7U@!@Q4W4)#!`!/4E\I(.S3QGW\`RD5`#"(TYI\?(D`PQ`DZR+!3
M?U<9$H`%%YM0H8DH7IB6B!:0=<5E.X@X@0DH@GH6]6%3*O\B'CVPL(:,,N*X
M@(TXQM]CCT$"6>3^'AR90Y),4M*3H!2E*I$A2U@"TY?$E$`O?6E,9&H3FLPD
M)RE)24YPFI,/XF0G/`T*48`*H9\^2$(^[4E/BD*"#M[`ERPP0E)DL12FC-.(
M\YW%0H182_<^98+QQ3!L)#`"JL*0($^XBAQ4L0T6SC```(P&!E!(``TJ4+'(
M#4$!%&@?!$#P@PW0H085*`$#I`&[-,3K"W`PAF!^@`;8R:8"6RA!&L#C-SBX
M1ERFT<"YUK$.=HA+'P'CP00&,!*2"42,!!+#9<9WA0#((2\1JPQ^(/"!!%#@
M;PO#&REJH!G-4&86RNB+6.QB`>C_;`$@'XD)LTRFDYH`C`G,0H#,F)`2)OB#
M9R*`!,\(E"+\8"54GG0A(\8R3&+R!6)K:=H$NL"6M$AMAE2CU-6.R8^O=<UK
M7[/F#THT@@&0;01\P)0)I(*#L-D*!PU`S@@0T1U;X,(-=SM-2P8"$MZ4`0*(
M-`AD#!>#/IRE,@?120,0!QD1I$0UDZ.!#-9``0@TE")#V0*W0*"#F33("1A-
M@-JB,SHOT@$.3GB5%V)3+H`4`XP($Y<59I"`W@R`GV?``"WB]KNX-.&F_"&>
M"/A@H!&$Q@D-`@$>A!<9BQ2%1(C`X5XTM*'L$<*3FS*1BC`@AK)4(@_6PP,;
M9!`$'N5H_W[UF]']#``DL@II?T4ZDEJ3I"0G#=""58(@!+W$0`@>4*YX;1.9
MTF3!.E50@QC$4YX&)<(1&@J$AR*AH49HPL4B`00;X,L,)Z4I"X"E+(Y(A`V%
M]HA"["54DS"$!?R#B2B$000*@L`1$T`5"_!AB2*HPT-<D0`G!*,@(M@""[PP
M!`34H`T56,]?$/`,=A'A"S5@P1?0`)CVA.,+EQQ""60"AQ]X"P3<\J,5K&`P
MF\S$CM)H1@D2\`$`L*`OA2#106K`7H`%K)&"P%0>,E:A&AS$H"7`P4<R\`'4
M^.T+>!,7$8:PA4#>A689P(#`*+,VGCFG)RG;`@*V(`(\,($);__8FPT*P(.>
M-``/!9A`SZ!B`4+BSBHBZ`(DSI>1HA&34DTPBP76HIG@L*4+,4@+TC)%%DI0
M[5-9RR;7N'88P6!3R%^;P`@L@`%OQ@!NA.O"<@@T2'R1""LF\(Q,3:,`>$)A
M!C/0EGX-NK>A%&1?$XC!'_S@M`F`S&]I$%GE"(3C$=1$&CHX@9ZM(X,;:&`(
MR6@6>#:`!H3R=@@:4)M4[!@R)[Q&(3.(3P*>$AWJS,0)%%`I.6X'TS.`Q'C]
M$9Y<%',5/QCA/UT(S0T:Q`(\[(<`D0G:],*&B$\5)47;2P0CRC=CM:0/0Z8H
MA&9,T(CXYN'8X6,"&V*THZ^"-4=C+8+_C_2'5B.I%4EM=5(%I42EO([)@=\&
MMUP%$,$V71!.%OSKG0(KV,%^L+"-1>R?"!5">JL0LDS(0O>D60CC@"5%F@41
M4TU`2O+%T!2Z[HH0GY`)U`)`M4-`M`:&Y5HL+$$JLU6`%^0#`088-!D1[U<O
M-G`8PA"77:VJP1:6^Y>/,B`<%(CY$!C@V^](([OL\%4"B)$,Z%0L.@QH*`30
MB9QAVZ"1/]A(UJ[`N&4:+C*L47DSHH-(8&C`"YC&XR6_L!`$..J&)&(`;3K9
MR0HAIT+/R0N%\2`S,0AD`M-+'@[$T.&>B8`0R\$`L:?W%1*X^.^4R()7V!(#
MLJ]%$G&16A.B_UF7JY5/R-<LLF&0O+5N6+Z+@.D(]0:PEH+FIPM%[T@9<@89
M$Z2"!#*%@`9&TV4PSWPD%R/1!"C\89Y@`#*X?\XSH`6MB,\\G55X%G44I><&
M70=U+.!9,;JX@?;1X`9W\\('$BP57U!``S>`5@*\,`8K;)_Z()G'I?^HD$33
MYVE,K$,#%-Z?FXZ:``:-@8&Z@(,$W"#/*I&:8Q@#L6&#Z%.D<GB84CYFD1;;
M8R)/-3[(@3V4<!8D@!M@(0=,H`-!(&W.]FPW,E8\4@1F("34EE;7QE9*PB1K
MLD%PY6WA5E=A(F[C1FYF0FX<A&X8="8E&(/M=B<E5%B.E5B*%2@[B/\$S(,M
M^29,F>)9@W`A(&(*/C9CX=.`P<8(-F`]%E()I\)P8>!3`.`)H'!U;5`#9X$*
M/O4!0/`*+3`$PI(?`M$`L,$:?K,!>T`8[+$N:3!>$I8&D.5;S0!S#9443&`#
MSO`OZE(!G``$K%405&4#6S`4SY$,_>)U$),U1?,#&K,L)5$0$X`VX,)>FN@M
M!&%U1%`[PA)S-V`%N0!'6]!)%L`,^8%>=J$"=C!*40$5!6`##8!.&<$S:D,(
M`]`&N(-W:P,6/'!983%,,00QZ25[G71XB8`1E#`61H,TE`*+U01YUT1DE/<U
MEI>-VJA&DIA+--,%?N!YG'%LB=``]U0\.Q#_CC$P3AD`&[C096Y`!*PU$A5"
M&0,U`*E1`6,&>F<`'9IC.M=Q`YA6.>DT`&G@#'"`!FC0/"S@!/;'=0S@4P,0
M'F2$.G<#.&4P%.!2`:TR?@FP7=R5,SPC1VD`+9DF"D1`!&50/&>0CCN0?CL5
M:L$38[`&.KYC!/0W!#=@'17P('*!($$C>^%S(J*B%MU#@!IB"B@B6CUT=L66
M(H6`&WGP`HW`!#W`54%P@?-#/V*E@1X8)%.`5B$(0(-")U'2`=V&@N&6@@N$
M@F5REG[E5QB$;G+9;CD(;X7R;CIH*#F06$!X`FP0670Q@%,(<"9B/>%3%^=S
M(3.F2)!0*;IV-$OP_P1/$`:>!@!EX`FAX`6D\(5+,`(XL'JO$$4PD1^94P)>
MP`(;L"YT`(?#90]_HQ31X$7L!0[L$'.L]08<!D::$SF[`0$#@`"A]P;V%3!+
M)Q8%D)SH4QGLI1-;<(\CMCA-P1#@(`WKX!1[$YH*4![VT"JQL5(J@0?\<'3_
M,!**0'=V4$RWI%]P1S/`:0$!T!0$8A=%IPA%413%5!:80@""MQ;<T6!K4SU"
M\W<$^C".<C742&35>(V!L8T.JHV`\08BL#C%0S;!,0(MN1S,@5KH,5J0T0?=
M@0.A\(ZDH7%M,`N+"!H=%S+*XQS^R3?)\`S7@5'6X9"X8Y#810<_P`1H,/\Y
M0W`:,P`$)>!3)>`+,R$/J$,$(P4``("&[/(%!PD')[E2,X`>:H$?<G223(H/
MM+$<(]`TW=2DO0,\."5J/(,!-XD@$+"32N`@H]4$P3<"9A<VH,)T-X0(PKA4
M4>-C*7(QU.,9^)DB%G$95T!9/,`$"+!L09"5-[*56YF!T?:50!*6^S.62U*6
M&V2"9%`F:MDE"Q0F#=2IYK9!+RB7<2*7'>1!/8B7/$A8];8GC<4G)\`";'!A
MK6@6Z6,6`D<^Y\,A3+EB4\@X'T(`7!`%E!D&",*DG["9@&8*6!`%3.1$I`$%
MND(!)6!FS$($#-`>%,!%$<HLP8!/68$,_F*=`U#_`N>Q.@$`!@5P#$.A')5Q
M,?V0=U=1`S;P`_ZP#,N`,?_`'-$!`II(B<^P-\R!$`SQ#/3P#';'+`DP!I9$
M`Z'@"4X`8"IQ,60'$$_!8/!)3$;A4^C$#WD'GSQP/48A32^VGP1PB82S3,L$
M>GHW/A?1BD;S=QN!%W8A!W^Q#-E$&$4F7`S:7`\:M$'[%\QA`V,3'(F7&[10
M&1FPDH3SI3O@&0.0:21*&C.P*]=J$`T@#DY0HYA6`L_A$3,A1Z;3M==!`PY9
M3@,``=]!!]9)`S_*,%4J%45J1[OW*C/0?1JPDH/D4"59DJKUD3/P`2LI?\A#
M==9*L,Q!.$-1'T\F`@"0_P%=X#LVY7[\00(#,@(W^0?)LR!(`$>NQA\40B+[
MMI2/D)@7$B+.=)1UBCZR9Q%+A68F0I6@]08(H`-KT%6-ZJA<V97X,ZE`X@'"
MZP$@Z#]D>:DK\"3KUE<N**J?RB6A*JJ<FFXRF*ES:9>*]8,\.&\DZ&[RII=^
MR3P]L`&.0BH6H:OI16R:,H4)^)@\<!F.`I67:`)<X`*4&0?$4P99Z"HCQ0+.
M"JVH]40PL'$4,!+OR@!$4`+?L$6N25Q^TU!PL&$_0(D`"P+GNAM@^P81``9@
MH`97P!PFXF*-%`"[=#O+\"\(<!#),!2WAQ6#-"_6&</F409/X3$'BUW&0`?!
M</\[^`$`7W9)[3`N":P3,.LH'>$<<:=@'&L5:U,4$'-913.,F%4(!K@VP<$=
M11<^>&H!Z4D6Z5DT>3%*`8!DTQ)Y#"JT:)S&#OH7!G$%R_%-?<>.Y<0V&D`@
M7XJY73!.YU&U"K`0,\$:"."V,UJCL)$4,K$:#8`&7L0"-+`&K\)U$-`=V@(.
MP>`WIC$#2FH%*REV!Z.0[!!QIC$&&B"Y)E"+\Y`&H<"DHA"YBG@&<;$#`+4V
M.X`T>4`KA(0!3G,0=2"YE%NY_4$"""("I^8"1C`";?`%0.4\H0M_+FQP-?0(
MG@*,9Z%#N\9#%N&4AS`B$^`HBZ`"N,$'%L`^+*"[-<+_NX^J(UV9/QU8!%,P
MO,0[)->&)"*X),E[)U1@@LQ[EL[;EG)55_I<JB[85W0YT&HB6-GKJK'*O0>`
M@X1UE["J`R`0,"J0!9.A(8<PE(V@2(G)0V%#2DB%@,B4!UQ@!/?[!R.@OZZ"
M.JPU/G\0!1?G$*TPP#>`2`?\`1"P+!"`!H=!G+^`KELD!QW\`\P"P\T0#0C`
M`P4`!G;PBF+0!5=0`$DP/9-Q,7G09"@*L`BP`;[5&BM\RU?0%,U`#Q7\#`D@
MCPV```PP!)!%.B"`KLA",F7@!E?[:!^Y741``PB0;UDC(@T`G`$C!B.@=]!H
M57<A%DM-E?QP>)?Q-MQQH9H1_S[=\YAB3!:P>*#3^+.8C7EJO-F</2T_<!!?
M+0)^\!B%$]@:NC;'PGE\P`?V404[('9EX`6L!P50<%QI\'+$$AZFP\@"^2HY
M,0\(P'QTP`*>XP4C906KL[9&6I(5X)`?2:U0L)+)0YUWJU*#BP-QLQF'=!Z]
M(4<$\KC%XP=Q$0.-W06N'0/!@1\8BMZX.+F_4Z8[EAO";`3$/`(4H),R0`.E
M\&J1X:>\9CT;,@@%=WB4`"J$4(\ETDBN2SV0@!'ZAAM88`)98)4GT&SF?,YB
MI2/J[`%%X,["&\_&>ZEZDKQ/DL]]M<\/Y+PF3KUPR5<QF*K>>]![Z:KV!JM]
M,H*(,O\37F<7/=19`J?%&4)P,91KA_!_D4!:#&>L&;"_$9</TW4*41`%JO".
MLY-]`[$W%$"(R5`"(#`8MDL-Z/H4&P8&$1`!M&BO1X<B/]`/'!8JE;$X5Y`$
MS%"PK%&+SO$QRH(M6LU>"%$&P876+X?#?X$&<L1UVHH`+,"VW0("J"Q'9?`!
MQ+"+1``%-P`3L`&2L0`"\>I)1XP55+5+74`U,QL`N(H(RP09P1$<C^T5<A/&
M8NQB');9LM[9M%[KV0@8-2`"-K`93@,9A*0?]7@S36K%+6D"5JUZN``#]B>/
M1IJCX`$")G,ZKU(N6V`YZ,`.,E`!-V#<WEDNYVJM1MIGL;/_75X0W4,Q%=*`
MRH%K!40PRI_W!R;0'5<!4/.[`Q;W!`:58I0Q%"5SI!/#'+U.2.YM(`'2'WU@
M4%5P:D;@:3H)A#J``$/5!`,2-'L1"9)@(F7!5&D!*JE[/L,FJ.D%516O-*6B
M:WJ@;&M`(Q>.X;X;)$3BX2!NO&PE*'CR)BN0SRA85Y^*XBU(0?CL\_@<]-@;
MXX>EO;!Z]/1F;WS"5K(JOBX#V499%N`#%@58NDQ(/@>N5(BP<$^@Y%F8`/<D
M"A2P!6+P!RY@K`.0[%#T!<&@7\"0`,H.!QX!!P"CPG#`PD_-P6#`$7`W!Q$P
MBT=7(6+AQLQA7X7Q!G^XYU+Z+B13_P/H0@>^E>ZF,00]L`4.A09,$!CN`1MX
MTP;(P+;T@LK"\@4V#1T9@#<RH`-3JP%Y.P8P$`(ZX*=W00(&M0_/68MJPYC"
M&!9,5CR@YVMA,UJ[WP2O^.H<)A:R?L;9F-7+C\*V_OQ#:PP;,``BDF)_\!@&
M%93QBEH)-FPJH&23))K*?@,L93*!#A[990][FP\TT!/H]`P4T+6CN%T?F0`Y
M`3O4V=S9@>F<"0@##0.$`QD`9749$!`,&%TB`T]11D9=(S$Q$U5-?#%+3Z%/
MD0T-+!4T,B=.3C(R3A0#CS$C`S@CE;D$NP1&3021794N9SAE0R?)&WB<D`T6
M5R0$)CLF%O\6/%=7*E?4U!8DVMS?$QAB/`'=$V(6Y>?<*A8F\R99/#97`28B
M12C^"P`#!O3GSX!!@T423IEBQHP'APXB2HR8HV)%#@<R9ERQPH</CCX$B!S9
MH:1)DQ)2JERYLD/*DS!CEAQ)DJ;-D1\/<-RI<2,2)!I_"@T*-.//GD5['D@J
MM.E/'3V8!+C&@QJ/>"1(5%/!M=T.$N#B[;"@XIZ8==!49#7R9,23,$L.??E2
M!D("+T,:B.GC(LJ9`1H4P(`!)4&)PPQP0"`"PTH%$2QJU,`P`<&;R_@*%``#
MAD>Y*YHCV!#1X(T8,5=L3!!Q6M"/#340_'CSXT<-!HVV-*A0(4W_!1"Q$0PX
MG&!&`A!;VJ2ATX,.'3B^&0SQDB`!!!8#(,`!P9MWFA(0-&@7@4.#FQLT#A$9
M`V6,@@1L;,AO-V$'!A$BWGC&3WE"`Q%=D,"5'5F(D`%K-J@00`!<,<@#.@P&
M`&$`<O!0VX489JCAAJ]MX"$"((;H7(@DDNCAB2BFJ.**++;HX6NO#<`.@'^,
MT$4F]ADR0!<89)`!!B3,LX.-Q901V&#&>:$!`RR4\)MDSE4P1`(:#&'D=0PP
M``<<W3EQ5W7%E2'"%@R4D<:6O<V5@!5$6)=!`^6,(`(#A8B``09;B#%/+0.,
ML`0?&`Q`6BG_"3K"H3'\Q4`#((!PRBJL_\A``P0X`'B)(;CL4DDOTOA"0"W"
M&$&,,4/(H(0,RYC01`SX01.D/&.5I<T5\GBS33BT5G.6&/)I<]8$P)Z&&JW?
M7*.@#?>T<T(0!`DD$$$H'(100M0V!-%$$UG$`48:[=111S>))!-,+)4DP;CC
MVC13N.R.Y"U/2BDU%%'Q&C5OO4X!I2\2;/0P'PD\U`KP@_,$3,\U`H)ES37R
MG$865P2`,DD4.``P%P!V?9``"V+P$85?`P`@&&$)4$`!!#X"0`00,]``60W(
M:E;`/9?E`T8`Y5A&FQH(5/J&#:<%BH$-#3``7`5P(+!!B`U0H`$`+#30!@5P
M;%";&C\T4(+31/]XP0("#%#0*'<04-#;EPGD1:9OOO56`05?B`='`S@D\)X,
MNR4PQMX*M"##G5L$:\)J!R)[9SD&9C!"%ERIT*.,"T8N8382+LCAY9AW>"*(
M2XOHW.<@@DXB'9QOKK2+J*?.XFLB3&"!"",0T$6`#TZ@HPEB&-/`G;-/0,($
MBB7`V&#4+5GTD['50(,&8%(Y!`MS=L>;E]5]064;@S+@9`4E6%^=!N(9<V#K
M@P,[01>N9X''#F<<VI:=&)C"0-O@E0`[!F?<AT$-(&S)I2LTX(UU8'>I.HC`
M")K*!0)]T00,W*(245C"`(ZABA/T``^JV@%^\F"#:LPC+;CZ8#6V<:O_;]A'
M#!*:#SO*80*S6,.#L;H'K:XA!C;(`%HH<-8"<!BM@U`K(0ZY%K8H<A&E>"LD
M[1(7NLQUKI@T<8DT65<':I)$D7SD7?6B%U*8DA2BW,N+^7H*&RP#CJQ\`QX6
MV$$UH$&LL%1%C1;`!]!<)R`N1"$440A#R"X&@2]01T8DP()?1%`&!8S,.`#`
M&`3*X`4@$*$-V`&!#0*@&1Z8YC(HQ!EE:E`"$&!-,I:QP1MJ@!_+[*8!:3@3
M<&I@"NYI8`:\@4`%K.:AYZ0I`=:C`0@FU3\T;:E[X!//%M[``EE"AP*^H0``
M/@"`QU1L!C=@`70T``2^08$&YD#6@E1@.UD$_TX^IUE-GRS`H`)E``$RF]P]
M,L?.#9EN=)^+ISQ'5*(/G>Z=JLMG/FM3"AO(279=X(.01H`#'*`O`V*JCS6D
M,8)%#&$&@X%!VC0`20;\!@UT0`,<*&`%ZUG!"EX0V_'0E`:[?$\#91B`^3"`
MFY.5H2X^JA0ARU!0#&3!`F>YSYBVL(41G.$,3UC"$B(!@HQ60`:\H<')*`4G
M_$BF45PZ*@T"N+PR-.!&@4II%7;A`@7VPA==Z!,$APJ!4B5C"PC8:A7DQ(YJ
MQ.H*V<B5K1HGUQT$BP<O"!@[RL>KU)R%&F.YBGSTBCLFL&$-`/F'LWCHPQ].
MX2$>\,`0)7*1;?4$)/_@JJ(`EKC$E[@$BB91U[J2>$4L9K&+]M*BO+X(QC#J
MH%]ES(H\$@:6^EPE'O5AXQ7L:H)\\.`LL>("%O`8!A$``)>*9!X#?&>$04+`
MD#!0@!MF`+XR()2:1&A$!1I0`YYV%P,Z>T,[[$1,"-0`-N=%[R@)M8$&!!`.
M='C1!BJ@G"\0`9;%K``:T$`VLZ7!>GX4&W2XI,K^@:<X&J`!6K56`NVQ#0(`
M0*D@LC.#D(('NVY0`!0H$+AP`HN@`T#`:M81+)R:0$#Q(,0/(A"`VESF,NV\
MG(L0,,]XUJ#&\JSGBDJGSQZOSFK_N<)]_'`).=UO=\`:@`&%I,;9&0("7AC_
M3&&&D-U3_":C7+H!+M=D!0V48'?1Z\V!@PF``\5@=O<A!'Y(0YD=Y"$&BXB$
M+!`W@"Q5@`$T8(`(?@H*$6QGOSJ`PPG^1X,I.2(2L3D1"%QQ@R'<P+YB0C,A
M<1"#!.JB$DVPW0'[$@4##6$-KD!.I3^ETEJ5,1H*\X9NP0)#&F)#'O)P71M_
M6Y^Q9&4;-FB8-?2``!;<0+&+A59CB["0QT8VLI,E8A$OF]EPA;:S*'%BN3@[
M1761%B?OXD@6\<7%H-@+M4=92KXXL"\=Z""V`IIMPF`=#6]8@RNLAD:MJB$@
M/H1B"6$8P7'I4E8O>*$-6R!!<\_0@`Q`UY!$>!K*_S(0F#8QJ0*G:'"#02`;
M&R"`-&(@)@M`T(#M`*?.'(>#]GH]A*I="#;<LXL&O'`F9$*5-[_TZ`PH@(#;
M(,WCT&&$\"`@2?DX$`(-UIZ/2B`+@D)@!BWCCGV)X(8,;VQ,:"&!&"8X@%S?
M!P>RV"97?HN#!JBA`!8_48=B//86A8YT:)?,C7%,.A&5*$0^CKL^8;2%`5QA
M-9F0DRU$8((\U(J019^=&DG0H_!$MS`WF$%>LE14[OQWRW=):7U8M35&?.&X
M9:``G0AXHWGDM!SK^)4Q8$<*J*;RJ+#(P(XNU0#^-NH4.C@!`"DZ"`;(YD)T
MD`$%T&8%`*S^$C[JPE<WI?^+)FA0!#&(X%`SX.A0;T'X3:@%6L`15X,!-F'1
M2*.0'I9&M`P.&_>@Q@3$WT(V6O\:-LA"%A!0@2#H<"`%F99"%H)L!QR;L@ZP
MB+:8W>R;4-LE+/%$TB:`4*1$[>(1V)9M.K$".K%M6_1M31$OX19&JX4$9)$5
M\'9&LB4D)Q8DL<(-:;1&N?(5!-`^;S$"1O)2?>1O$-``)O`'6+`$&%`"0``$
M@J$`>$$!1"<=*Z,!2$,#\/4V)5`&G;0!;W!Q(49,-^<<5L-^AV$7$$`'(%!R
M&\!?T.$DC^='UQ%`O00"_/4VWI-@/#4`O]%+=Z9,X,,`;T`K9S$(@D(HDG$:
M!%7_`EXP!D[@2BO#,E`P!#7P,P^2#:]3%ULP%8$B"[F"#0$@!AE0`6H@!PC0
M`%9S<K718W#W=O!$!U#"=O1DB7`G=Y[H(C!2`P.`4\CG!X=R!G9B'[!C.S2%
M`=5``!:0!<!0!X8G&-3A!@F@/8O2/VD`-\Q#)1J``ZZ(9@R0`8>!&'`0&V*`
M`9A0!9G0=SI5"-HS)V)2"SB0C%A6`;&G>PF04I?BA<RQ`=P!!S*0`#?@-"V8
M&&^`-:^Q2\7A!>>8`+XW.\"G.)8V?+O@!Y%P!J"P?.9H;APW`GS0!&%E#J>F
M#0U#;R24:A\D#E41++)V%0$#+&OT02I@`_1@#0]"`@%@_P,](`/OEU@$(2WS
M1W^2=7_YIW_:PBT;D1$A\1'.QED!Z%D#&&V@-5HW@8!6E&T,Z"T.J&T3&&Y&
MX8#Z<EH_44:-HQ8?Q`,`TWW<!T<"H@X[<%N#8P($0`M/$`<]@E)]%!YXP0([
MP`=8@`7%0$V&A(MID"6E\#9$0`1I``*I9#50=1C)Z"@M"#940P=7HP;B.&8)
ML!W:(8YI<(=;\GA4D@:LM'&-8H5@:`4S`'!X<!J[85':@P.+T`@-@`#"$D?R
M`4XD1AFHR`"!43(TD`;"HP!(MS'=93YV57!?EB<3<"AW0@@80$X6D`%I\`,%
M\`:1.(F<2&._&9R>(T]K%T\T-O]/EOB)ROEC/R`<>@(@?#`[8$$`#E0I]N$C
M_:$)$\`J&;![AJ1A,P`$N9@E%M6+)O4%C$!T/O4$9X!F@+,%=Y)3AS*?_%%[
M;;`U0S`$-``>=D(G->!Z:()Z7E(&A[(H*((&W*-EN.0%+3@GLJ%1Y.@ECME1
M\C@`[7,)#&!`?C!\"H1`?1`);N$6!F*.KA`U(N`'JR(+2`F(''AK<$4/@;4-
M90$KP*);95$^KJ-7[%`K&ED67``PAH58.Q1L\2=_Q\80DI4M*:E_EL5_5X1$
MHG42-#F3-$DNG*5$,5%%'L&3"M@M1(E:#KA%0KE%L964"D,6`2,PJ?:!0<(.
MVN`-GN#_%G%0EACS!5/RE6)``"Y`EB%C@VX@47FV*(2R&,O!`A1`!VJ`-1M`
M!UIS9R4``+;'`%^`!B?'/SEG,K*D-2"P`5S2>+UA4F40&47#*&/#)8^:<"R@
M'[E6`RQ`)_]!*&@U'V61#?A@&O$C9X50-PI0*J69`"RC-RW3`'E"%4*F>CG5
M'[%94"*`#5F``Q2@FQBR-)B8B9OX=IUCK?9TB<Y1G*)SB=BZG.`J7\U9:H<2
MG6<`,+^S=]<I)H_0!?2V`Y9I-R/C!D!`4>1IF2B#&,)Z)_SX,9IP%KJQ9G."
M=;#C4Z77/TG%"EKF>W4W`!FU7U^("C?@)1I@)TX"H)_J;UN6_U+DP2B]X0I.
MX%%64!V^=Z&U0%.5UJ&Z\"DRU2<C:HYK0`/8,0%-4`5V(@X@""N]%0XWJD8*
M*:/S-A8XJWT^&T?$L@ZX<V)E00)<\*,\@`>^-A#/4J338FS&ABU,R@&5Q9(+
M>$0Q*:5/1*73]G\%2%H>45I<VBT,N&UCJK9KZQ00.)1(@6Y)J0(?E!5,"5@=
M.%M<T0T'DS"FF)5_D4B7=Z<)4`%BL!:K408U"`4P$%)Y1@C<Q0!$<*A-XTDI
M<#4_P!U;@S$U("6R`1M<8JIE`QX,P*I)`XX:Q3UQXV6924H#@'..:CT<IIG!
M(@:A)$>#-9'H4P[<Q3^E0`B6*;P`(/^>C79YF><$(%4!3/`@N893#@0YUW`%
M?O=Y]I`%V;$!!5"I:M>]U=J).X8BG)ACW2J<X!NNX,HZM7DH`'5F=Q()\(,#
M=5";5NEW!``\=I%A@X%P^4H:<@)F8S*1[M,6\=-QVM,&VK-(7S8!(.,D6])+
MLO<*<8,#=<<`\:5HJ$`!(1`"2C(`:U.87X!,4$8$%`H`78<#)7!Z1[5[P`@^
M!O13ET)3-*NRFT*0!"M3=C$$K0!Q*M4$'SH"#S-#IB8.'JA]MP)7/*J13-EN
M:K0P>I(@]*$GMY(53=L$6<!K+""U\-=#C55L2(JU69L#V\*UV0:E4<I$342E
M:"P3*G&34D3_1>%RMJ5U11NA;<P6IEXJ;FVK6D$1%G4+;VE$%MG'6_`&1WU;
M/BC&!8$[IX1D,8A0'+GH.R3@"0T``38X!H^+'G129_^A`5_`<3+[`YE[-4Y8
M4N8E-;(AA1U'NDM5&EL0&8OJ>A40'D````V`++^59F18"',3&S:`!]#``W*@
M&:E!'ZS$'Y01*$9S8Y)1>X+*`,5+'4A5-DHU`Y6+'(&S4H:PK%9G)^>0#3R@
M?I6,`'/@F]WKO6UWOJKSFZ+SO>9K(NC[B:^Q.T(F`GPP).1Q"^:S#DK6.N<#
M+)I@#&5`!",3741`A`RP!7F0!P`[JEL`OP6+'Z1JJA0P!-:3J8E2_V<PA[!'
M-;'H.`@9@`:+BF5.,!TM`%+!2!YG8II?X!OA@73@XWN!`G2IE$J[MW()5V9[
M]E/W@9U-0,.8U@4%90N"`F4)(`,Z`'&.L`OX@1I@04-*NW4BM+/10"Q_BV+:
M=T:YYC`XA19JD15,^Z,`(P<]<`,;G$-;/&S$5FQ"I&PKV:1NVQ$Z:8";!;9I
M/)-@6Y-72A)25&T'R*4^B<=B*K=9Q(`3V,<H]L<]^S"LUEMB06]]:U=A00*+
M3%860Q</Y662[`DS2-"&!$UI*;RD<5S(`7$_4,X7<AO(]*BQ<;H>\E04O4AJ
M^%NEP#\<QP+&D$@,D$D2(@;_80["(A\4PO\@-'0:(#(9\=.JJH<!UN!`)>!Q
MI5H!&4`G%=.61YT&B30='Y4`PKJCQR("C0`L@;+<Z)!^66`'6P`!6Q`!W(O.
M:-=VRUDBZ>S.[\QC\1QWM7$?W'2B^$R;[7`X$R2,@F>5P/!2!!U1"D`$0Z`]
M2*;,=D8#;;#<:G0?I,J+Y^@$YW@#)3`"A<@H(MT#+.`*:?-0W)U?O<0E7N(%
M(QLW$%!GOF$]*^T]'_4!\YL'!H(#YME'$=:6-(5U/O53!B(F/RTJ*ENSEGGD
MV<$\:W`"`:1GJE(+8]$P>A+$AWA&VA`./'J!":-J;C21XX=3['`5&%A'>,L$
M%9``(4"D\E>25YO_+2HYQF2L;>!BQE%DURBAQG9N+F1;UZ%5UU4$V($MV%[$
MM@^8+WZLV+(EM"3T0589)">6#?%`#[L`5'$@@Q`V%V7PCA``)`)G'PSP`=]9
M&/>)=8)"2!J0F;VQ`>PX&[MQC.9E`UM05%+H<=Q#`771`)14`+[MJH2"9.S0
M.'D@)^9PY1QTA)-$`H=2-`-PSAT'<[L3*`Y\A6>2<@=B"-24`$X`'@"0GTXS
M!#WP*[=;<`P01^WPVP4\`><]`2VXO9/8O<"1G.`*3V=7WSIVWYY8&Z*X6\A'
M"^[JKH%2*8N+`WE*`'Y'#3/%=(Z+<+DXW=EC,JWP"A3@,O\A9[TQF!3P__"M
M,"46RP`8Y1QH4$Q?0%U?T&409TQ(,SUK,@-=]@$_HC4`AC0LG/)$D`'"QRJ6
MN0C5Q0@'TDT[C8H9\`$#H$!=I4`UJV09H`C&D#8W$`1K<&<#P`D$90ZZ`D($
M\T)?P;/$LD8HEN@>Q-AF\2NHH7U@?9%A[;1;0`-I/K4]]$-K?6Q)2EEO#M=U
MO!$O2>=\GM=WWL8M@<8O08#_)RZ:M9.`;L=X#)1@^FT5Z!1T"V\`HQ:F!NE:
M,7XH-E>T4A]9T059*8-RL4C%H7@-D!4$P#Z``5V/JX-ZMF8#70'LYP2(FMIS
MLC5$1QL(\&=SPXL7PP"3A`Z[21H_TYGIH"=F5/\+=@(G*Q4H>F$[!*<E:E>J
MIIH!74<W%O7`\04'A]%U!@+J-R!FVXY+RXMDU>"[.-`&KI-3^&$(PGC>8D`!
M+"`'W#NMP=&)]_2)\GZ<Z6R^]JZ<IV,;H[@/`04((SLJ65D8.#@B%A@0&1A=
MCQ-=,2,9$#,*,#`*;D`:#`PX#34U<&E.3C*J3A1M`R(B`PQI:7`@+#*X0S<)
M7@-;);4@IA5P%`E$'PE67FT,$&D5(,,5%%_+R0`#.QB6M*@40QI>,T0:&2)=
M!-RRH!4-#1@3\P,X`V?X(AD?`P1&_P`#5M&7H4X&'&42)+@1Y(:,4%6:')(W
M88>%*U=4J"!A88>)'1;_2614T=&$21(;49(`:=*"2HX6Q,B<(`9CQQTD<F;A
MP:4GB2Q,6"P82A2%40,&BBB=PM2#4Z<.HD;-0;4JAZL'LAY8P37K"A\"?(@5
M$)9LA[-HSTJ0H':MV[9KX;J-F[:NW0YFR>K=RU>L7ZZ``6OMJG7KBL('D"#1
MJG@QXJR*(3=N[#)GSI27+5LPX5+C9A,J=U2\J.*C2Q,QGCQ9LF0`@`1#%'K1
M4&:`F)QY8H@H`P1(IF8,!@B'589(FAH52FQ0\V/#!A`5TI2`4&(+CP`_$`PH
MU@#6*Q$8+"1)$N!%``L3KA0H$."*C8Y=)I@0$PM\`P0;:F#`T'TX>`L-2`/'
M_X`-3-,`'`P@\T4\U*&QP0\0;@#'=!`(EX$&1'Q!`04E:#".%<RP\`8>//"@
M`@]BC("#(_.(1A,&PG5APWF@V``AA`B0HB,"//+HW(]`!BGDD,[U:.212!I)
MI)!*+NGDDT#B]Z!V8E@@P@A_C!`#`29U48\($W3CR`XQF$0`"1,@Y(5OF4"A
M@!<TA-(`'734,(PJ,H`S!`-;B%#"?70XAT8:X2B$X9\E4&`+H4X0V@L17E@Q
M`PT-X$#=-'!4<XT51!`!@`@@B8`#*!`H]$49J*(S`BQ/8(&%:/N%.0$>>-!C
MSPCXJ*B-"4T$9(0++@!$4*IE>`';#:G(0,,$$F70@/\8\UR$T7L@>639%1Q]
M9%%GV)+P44N6;6122SQLAE)).7'Q$P\V9,3#!!4,0=0"1J&05!%3>#"%4OCB
MZX%44U5%%5:#';;55CX`!M9>=\DUU\,0LR7Q6PU7S-?%9/F5<&"!#68888\U
M)IECCY6<V&)(5&;9RI=IY"UG+K^\694=?<:9!03XH1IKNR5P30(:?````PA8
MML,($(SA&PS`"1?<`(?>0K0:&]!I"H6*!*`U#PC`T<`;-H1=8@#KK<<#2%<D
M44`$-F``WJKRB-J="`@T1PJ/I#0`RA99#),I"'3@UW4)%7P!*8-$YZAW-&GX
M_(JERDC#0FR12EH!`EMLT47_%SN<'8L-Y1(@*\T6\'!%%B*T4?>-^>E8PY%0
MQCZDE+0G"7OL2<H.I90_2MD<F%?`XL<(Q,-2/'AB8F!"%1_%T`72KQ&A@`)0
M)%`.!14P``<:-01>RH#AB-/&%@TX6S5TT0$-FS@0,-`&!=%4('\:O'@!J8>4
M/B--=$Y\L6FGM>G"JT90CPP$HP)7DD<?_G`&`@Y@"02H`O'@-@'R=2<1(WA"
M%)[@F@'PRE?`"I81NE&',@"@5#.`C0Q.H(HU=*$)$\B`;6)2I7+%Y%LD*-%&
M/F.MC7A&)O.Q@`JP)2YMJ0Q<+R.!N@K1+I]L@09#J==1EN(!?N'+#&;X%\`$
MEH.K_W"@,(0YS%<4=K&&18PM'3CC7-"RQHJY\2P8TXM8.":8@WW,8(B9C,GV
M:#*5L6QE&MFA1V+VK8Q<P005,8FU^/"$#"ZA9T.(#0`\U(8:I"M+&2#"TJS0
M/G=4(`,S`,(7O,:"&N0''K$8CABTIC4PB*$&5XA`!-9SGE6RAP?/F\`;WE``
M-;P!%J^K`?D8(((:",=.MBA2CAA0AD^(@0408$&@?J`&YL"!.L@@`@-J(!T0
MH`$$:8``_"C@(6*N*'(@8("'9@"%=@Z!!5O`0T?D80,"UN`-DAB`##&P-??P
MH`$0J,&-[.:ZV^GNH,JTG4)[M"3>(=1)#*6=<YH3CRNLJO\*SQ,5#KK`!VCM
M0`S,',`$)_$1A&!H>C/@A7$:L!T0W(T.U+B!L30``7A`0$!I&`(J>F&L9=34
M3]"07P7ZMPPOS.8<LI"AWJQA*`^A0S@C6`(68N"V$52P"R;@DO.>MRJ1ABD6
M#&`!"Q@0IWJ(%%<$+`,.JA"0$`+K'UW`00E/V`O8)&L--\!`$W:0`0:(004V
MD(D%8O*9EY2K)9P1"48.*0:/2$LD+\,A27("$I68A`N$L$`3,?N&"D01!?2R
M%[[V944/9%&+7!R8%[_X&#'.$2P+XXM=U$A;B*61+F]T8QPS]I>O;$PP=0P9
MR?A(7,CX\8_A<IEI7%:S$QUR6XG_)0$!&KF:W6@@-@F`@(<@L(6-<($/9\"!
M%98V@R&4``<E8$"'>J.!"EAP"W?;)49X$($Y@$%M)L#`#QX@RP#L,B8SNH*L
M)M"`Y?S@=;O<I=X&0(H!'$@8@?(;!0!`A(!6(`%P:,X&$$"-4JV/3].9AOP&
M5`V%E"`6$"!"`F;1AN(`01,*H``"F#"V1;@M$3/1YP`F4"Z99"$`6R@#")@3
M(=>]KDD/U=U"';IDAR9Y=TW"SXW<Q@.W3:(+#1R!'V+0G1$<HC8[.%-F>B8]
M&%3/>A08:PEL\3J8IN%GV&7!A&QABD;QHA<@&D-``7K33!'*?]B@S9]@E%0(
M&#J]P9&'_P-%<`8^F&!5F:,(!D:P.5P]TL&DR!0+*D"#-L0)`AALX`!`W86V
MNC58,6#`7%'EH87@%:\BX%(&'$&`(4*K2F(`34YXP!&6'-=FUN((ML85W<QX
MRR(D,8$+?C+8*_1$!4$)K123PA32YNM?J.7B:KW86C'Z%K:QU<M=:DON-N;V
MC1F[F,:X,D<Z@LPPQ95,O!5S7$!B)F;K$.(0-S/8('I+W])=@B,K<5U3>6@(
M($@)'V(`M>G!((6&AL`U.@4$XPCS/C]8SWC(4QX[V"$`1[-E`?;PA@%@P`;X
M#%,\;*`W.KD40KM$`#3+P`"6CGB:S*&%-8A0ABV`8`@5@*F?B_^1!@_YKPT!
M2@,XE>[G8W@A#6[3+@3@P`*]A9*="D"X,#$@!M,1$!TSR@*!WR8<#&3!#A,H
M`QR(W)PZN=V@3\:=0J-DN[@?-'=2?E`-1"#@=#B/#WDP`1_TD8@)Z&,;!.@#
MF38W@(1@`J6]^$+V%.5-JSE!(5:XQB?&6HQ,R0^[F$_`4V=-=&OXSPICX/FL
MXX'6"<I#GO!I9"JUM*I85'T`;4C$?G(E@@)-`P0ZT`&>*M"(5^Q'GQDHM1&B
M`*PPA"&$1MA!XTU8!G$8RR%KP.L`!KLBY5T$/32I$LL4&9*4,-:QUY+923"3
MF<KF!`L$V,E[?,+R&TA[BM5^BOX#IMK_;2.!M043&.DV%@*`%P4X;A-3;K1U
M;KD51^OF6^[6,1TS;Y'A%5V!1XE1;\EU;X%4$D-T!9LQ&C6#$AM!`(^T&N&E
M`0KA,T&3`"R@,KKQ!0[W<!H````P`TJC2<9A0340`+)4`(MU!:QD>"IG`VI0
M`#F"`"B'`&[S+&]P(.E4`3KB-PPP!%Y04\\``@-5)]'A/[11=4`G=)F2*=;@
M(9_`8;1@"]"A<]8#`;&P#QK`(=6@23.P"5[@7A.`'B?7-@94`V(`"?OA-@=A
M=G:`!S?U`W(0(4G8/4AF=[*#)+,#=XXH=U'6'-DA`C)Q)91@`MUR!O4@")60
M`92V.57@$8SP_P6/IP#E!1L-P`(TL#UH\$V%@WE64(,F)P+:XV=$92B<!!YA
M,@`ED"C^,XQ?($/,9`_;0`)]X#QAT@5B4"L35#Q>I3@D1@,0X`S(TWMVXC?R
M,WP0H%;@T07Z4`8C\`_,YP+.!WU^,'VHTDPJB'UXQ0`6T`2-%QZ^%BV8<1,G
MD4,Y,3.2A1(\@%BZQGZ9L5S_5B+.ID0\T`-K$`+31FW7IG]0$3#;YD7#98$"
M&!8$R#`(F!8*>$8,B&X':(`:J3'M%H'>AH'%58%\E#+(96\MHUPX83H!N2W!
M1H(D$`57PAI0XS->J((5('XK@30SJ`#)\`&]T1M&Z00@0#[P-1,T`?\V[V%X
MX2$+&_`&K_,#;X``NU0#K?@ZFU8,OE,#)4`#-)``;N""-$`!@/--Q&`,*Y@`
ME.(,#1`-WH0@AF:&#%!!TP$'=!`@T8%"90`+#$!A-\5,FC0&;O`F+-`#>"`'
M579R8I`!9?`L>0B"'S$"#3`!64`2.)`&B'@CBQ@X##6)2M:(0>(C$%4[JNF(
MK;EA$_5+>7@E?6!5B-1`L>!EA#<!!"!FO=D-7^`%BZF*D9<]K_A-M]`X*^@A
MVL!2#-!YI_`S0*,!.(`/E58/B#`JQA<W!Z%/(]`'7`4+L,`"KT`\3R!J`P`X
M=/!-P5<!,G`,#'!\(N!2R.F>,G`#-R`.`)#_"&"B#Y]BCNCH?,_W?(-70B8T
M22HX!'B%GS0@!J@#``VP$HD$1$*4+=]2H;RFCXF5$IMA$?OXDIYQ$EQ``%72
M+I9A`T$Q!/9R%/?2%!(YD?WG?V#D;F3!%;+E1FCDD1\)DB%Y%P>X6^N&,"@9
M;XQQD8F11QH(DR2(&5RB6?R&+BGA,EBPDU'0D\,8-!JP+"Y!`'^``12P-)M0
M<1]`!.7@&T!``9D##Z%@5O>T2X;7`(&5GEX)!Z0``I@V#&W``@A0#7#P(-6D
M!@CP#.%@+)O69R)6#,375!6P`=D3('06'110*E?HA#6@7J``"A2`*NWC-J/V
M"<@!`6L"!&-@E#10_W5Y&)F'``'\A")N$QZ+50A9P``4P`2)6&1O5YJFR22I
MB7>XZF2[RIJOF60(0)H2]2"_A`$D``OY13Q0%8B2T'T[L#G2B@$E\`4:,)PI
M!#040%9J2(;7H'FT<5:X.`NL\#,V*$/12#SR$(CR,%AB4#ZO@*Z:F4K;$:DE
M(%+YT'N_-PTZ<`)$EUWQ8`^FM`%,(',T<&?C``#H`":5\"E_L'P!*J`$6@FH
M\AJMMA#X>0-H^J#;]Q'S@!$R`8*^IC(;P1*<T2TY\2WKQS(QHQGK1U@XJ5D,
M&00&8"](8441^112$:-7\7_#Q3$;\UHW.I)U86ZWM:.VU:-VL5N\=9)UQ/\Q
M']-:>21<CY&D+]DR_=BA@W63QN8".U.EKS&,"?`!7C`$6["E?-`%);`TTV,.
M--4&R-`;"="4T@!0!B1#IO0#Y"-0,N<W=!(X>B-GC;.HU?`@&V:G\G,,E/-I
M`E)YZ>1A,Z`!++`!+)`!+!"+U!!.S81A-@`&)3(!^C0JEXIIGF@I&7(,VI64
MTG,#((`'?5(Z^V$IEGD(,K1*&`&KHX8`M4I0=Q.LKKFK&U::M].K3@:)D.B:
M=!)1$_4#%;4J!.`\*K(-W(`!HH$0)D=I,1!F)M!XR(!2US`#%6*732>V'K)C
MR^B)LV8)AM97QH,K5?"^??`1^U%[_`$/V(@()L?_([\'!ZNPK?L1"W5*#6)%
M`TY``T-0F=WP-1#"!'3``G>F(=:J*I!@O7ZP?%$0!1(;!E'0!]T``";D(9""
ML?BYL1B@5GF(2)?9H1[1$A^8+2OL$HM5DRU1.E>+DSFQ#C_4&4-D`Y2[!D%0
M+S?K+_OG`%)@%17)DG<$@=\F1V`!1T1[@!/#1DC+HSFJM$[,6[R%DNR&@<'E
M%9"!&"I9M34,HIB!2-`%<%V[!*NADPGADY-4MEM@`]+%!SO``!_`"9R0`!Q2
M<[CG!8RY!6VP=AM0(*.V3?G!`FP)R$SII]7T`Q-2`D!#-(CL(,A!.&2H$#-P
MAWH#BRX'J=8:A_>!`,XI_S^S4`+45P(@(`8Q,`_A!S9O8`%YT"Y7P`=?ER&0
M:CT5AV8]0*L68%7E@HOAP1E5-0_\,0$GT@`]-P>LT[NXFJM$$F70K)K!6G>H
M*:S#RCN^P[Q\YS8QX#PNL@,:16ER)0)YT)M<PCR--P2/YP;V`QP'A""1^C,U
MB`Z3=CSP$`_P@&L30#R5YF7\0:]5B#W;JC=_$L!WB:BF?(OI.0WXP0:XP`N:
M!QZBX!Q"]V:2,@/^H[":"+IJ%0-^P!H7_%91L`08E0$VB*69G`"HD)]#T`!B
MUPCR@1.$52XMTCG=0A(F*T0@2%F.51F\-L8K8QJ'!1J8=05,T`,R($6B)<1/
M(?\%16P57;1:2*S%?H'%)'EN4VQ;:X1;2ML7??%;[A:`7'PRB_%N1QHR5EO#
M+8L>(6$ZR.4":JQ!E;""IS(.+6T#*2%]&@`#BPD%0%<!P]$`7SH#C0D*U)0=
M'`8*K0BJ\"1.!@8A@6,,AC8$X^.*=/`#:-"MFO*M=%H,@8*<T`')&:*%Z\%R
M*X)HH(!I")!K626$O10`@47,&"!J%S($IC`$UEIQU^J"6\"9*5(E1(@M8C"_
M7X<#9L<#6[`@<T!D^4&LONO,P!K="26)O3-W=M<CQ`HD$+)W?0<26(42>4!X
M9K<;)B>MFP.ZKS$#;K#>T^,%VQH-##!KFDH=J7TE9P#_TG[`#5X&-YSJ'ZG4
MK>!#`3O%EGH33'Y#=;@@`VD``"4`(P4M)0UPL`JAL2L&(_?A>=$)(K5(&SA`
M//DP:X\0`P#1F^98TC7X`1_@(<:RTK#!`K12`HZ0!RIQ0R&8AY`ELD;4C^+2
MTSX-U"M3$AF1!1^A1">"U$5ALTSM`4YMQ-S6LU.-DJ]5U5>=6UFM1G!AQ23)
MM$,JUBI9@6%L,B[IXRP;,^]1.A@!62QC!*RQ&D]P(:;23&4+I]X%S@#`UYP`
M=.39>_!0!C,@A9Q&!XU,37LJJT!3`1/@::+)C8FR(36U!7JZ`6A`)P<R5-::
M77RL/?NJ-Q`P2=MD`W@`+2IW_V0R`39">`5<,A\3P)7ZT1_8:2'D<`Q?H%W7
MI<XNB`#@$0#YQ:E@`HBL'+UF)W9I)@?,S8C4[<R_VF3%OE"N.:RD&2BPJ7>*
M`,XQ`)ZZE@<JTN&&IU8AO@-]8`0DP`C%P0G#203FQ<?9B8RC`"V;T\T[<`;_
MW`Z@,!WW&HX.M*^'RFFLN`4,X%+=LYX#C%TT)8AS\DV;Q@L@`L$+VWO1<0I,
MI>$?4`=G=0:&MR+I$!"]V2M&\+PX4(-8J@$I=`-XI1`,0"O,A*SJ(A)_Z!&^
M=@7EPA)MW2W$-E@O(>8`65@X;0*8Q34R,"]35`10L>11O6T'X.072=7LMI%F
M`4<X6O_E#X/E/LJT)0FU7&[64ULR()/65QM(&U$B)0(Z*+LR7!`%<?`$81!>
MK^$S"5&V+#`C&^$'NV'G3.,$@.T=#5`",[!-D]S(C9Q.P2AY>."*$3(,PR`=
MXD0!."`&+*>>,#7I3O<%?Z)RL@#8H3#Y#H8`\\`\I;,V[.&NX5?/_!$<!;+J
M8"52=?\!,R#WF2).<SBW3##</&8!>``CF#A8-F"R@L4#68`'<2+LBGADU6SL
MNDIWRLXDUAV\#X7=PAN;LT]I!/`(7%5[X$%X.&'.1L`'X(X)[-T)&I!>KW!E
MOR@"O>TVXDGW!S(+_*.QA3?QS]EYF.*>UOA.^@X'#@4"UFC_<#^5GFA`?$-P
M"LL`""U67PDE&"(X#!5I%$Z$5I`:&C@-9R-=$X@`&5T$1I^@1@0$50,``!H?
M&EXS"4,W";$T>%D#91@D7%PJ-F(373L\5R86)!8[R#LF)"17*B0FRB;$S,\\
MS-C9VB0J/,_3%ED6)GQ</'@R(0OK"R@&!D4>'@Y2.3D<^/GX!P=(_OP`#ZP8
M.!#@0!\'$0I8R'"A#P$=(DJ4**&BQ8L8,VJL.+&CQX\-0SILB'"%0((H4P9<
MR?(DP0/%MLF<R8R'39M7KLR,LB1.F"4,`,3Z4B:!EP0,W@10H8+/B`QC%"B`
M,6,(C0%8&31(HX%"C09MT*A1\Z/L_P\0#"B4@,"`R98*"#8@J`$"SB(*";Y0
M:,`C0`TX:.C4;0"'`8186K=8$//FC0@1#3!@F,#XC0T>67#:N&*C\=P&H`<P
M$#%93`,<%4#46`V"<(4!CS-HF$$AS2(`$"AH`$)[BPT+DVV*>5S,UP`<(BP$
MX)Q%'(,V3,B6G8N@NO4-V+-KW\Z]NW?M<;=;'S^>._GSV:]_[WX^/!WL/]XT
MF$`"0Z=#B`9@FC#!!(8,&5S211<Q5+$#!A`,X84;"K@1%1`:,,``#ACDL<,(
MCXE6P83(C>#A"*"!4%<%%<C@A!,40)"!")DH0B(<(E;`@B-##!'A%B4,4`,=
M/`H&BQ4)0/\`01DB8-A`!80XD<87D$"BR@`QG(%#"7:EP8A1K,Q0Q@`-C'#&
M@`V8<DL3H1A!YB@FB'#*;%ZPX@HLLM#20!D-Y,(%"6*(8<($.V`S#3+1F*`3
M-\/L,(ZAV-A$DTR\7,&%A<2HD`<?1F2!3@CJK.,./%/,4\\]^N3#CS^D\F.2
M2J:N4)(/JSKT4$@>;23KK!A%),%$''VDJT@"O.I02L"BZI))+:4*4$R+)DN"
M-SQ8X"RC7$3QA$]/X%"&!@"4450K%"`0P%(DG%%"5##``$4";>"@KE9P:##$
M:@S`\8-T/R``!R-IE%`"$TPT\!X"=,`A,"-??%$"`@44$,!;%0C_G)4B(-A@
M0W\FY#F!#0DOQYD-W]H!7&@-K+8:8:+E&!D&`U"0FL`"$Y9&!EB5\`41$`X!
M@0:$X&P%#:!=-L$(D@T0X'Y")Z?"8F)D8<,`;2!`[P8[DK?>U%2S9UY[Y8&'
M=75:5ZTUC]71$1Y\/T1&PH`$_()?%VLC2&2!%A#0!)XE%,4@%%`H0`126)V1
M"0YUE-#PO67`/""&6-E5(@TRT'!BW0RT"%A@<BV2@!4USM#&%HK0@89=<+!P
M@Q6"Y$7D(6D-DF\LEUM!!``C\.&'"((S0D&-1LV@P8JP?2B"*1HTX,DG<I,I
M"@%JHD*$)#,<=<,-0P2Y!1X8;)G'G7SD_VF".,H8PY\TR!XZS3+/*%O--A8X
MJ@(!%5N@`A=_F(`'"YBRLVD1\=!C3ZC[\,-!J0))U4L$F)"$L.I5$5G(1VC%
MP(SHZH$0[`"O>M6KD@0K6,-"2;$"@@1DF>^#,^$"%I[PA"B,P%HXJY&--``!
M$/3E&3'`@0;&4*YS0:`$B>!2`P#@!3:(@0$RV(!9H+8(?6GE,JN!&LON18$O
M`(`!<IA#`,`0@.&(0`R+2=\5`E``X$P`91C`6`#B(QD,@`8!-@!C`ZA$!Y'1
M17$28D$#).0:@;6&`6MA`2+*0#,GD$@W&D@`!7:&@"U@H"_A2!,.)F"3M`'M
MB["90'-$``$Z//]M->CQFB;9P[5,ADUL4OO.UL:V28"!C6O9*8MD2/`+`NR@
M$WSH0PP&4`<*30`'`&B`"?H0#6#<<EM3@8$"("0AK1`&#FMA``M84(';W8`!
M62%1"6I#@Q(H@@9#P$L;#I$!?_7H<TZPP@R^<!@('*("?XG7O:)GA3',@`A$
MZL(`A)0&&9B($*W[0`8P8`0^Q$`$&1"2M@"4`77!)D,#P)`,-2`"$Q@O%*,@
MP`BT588V:8`(SJO1%X;`@BQ,(`,,$`/[*B92I@`J&K\P@0IR<K1`@8,;()S)
M-;!!`#[`5`Q;8$$"ZM<.%+@C'E((:JA:4BIB:?`D!E$505BE*@$T58+_$-'5
M13K0P*I:Q%81E,@$27+`"WI56!L,B`=C2M9<N("$3\"0;#9:(TEPE&//V,$`
M9DA#*'B!`L4<S0ZAH`,QX""(/\".8.["%F\5((UU5-R&&J"4C%7Q8A%(PE)6
MFH<KF`8#$MJ"&*RS&C.&"38#\(T(*H`&$86H-<A$3`]8H#(0T,$L"*C`8:!I
M+2(HX`8H2D`@9]!.#8"`"5],FBM',``,6(`_7PQ:03&0F2VT\)(U\.0FIWN=
M4682.Z1,SRBGBUU3JB>5-<"%"3HQ7@(PHP_YF8`%3*$?M@U(&?/\P@S*!8.H
MT&9"%6A`C-)``QE5X'DWV`OGXB4B'A4F+;'`_U8#$.':>S4,25;P`LZ"A($1
M".Y%:8`3)&8P@PQ,@``8F!*)4(1/"4\"`U^R!%96_!B@/88T&/(2RK(EO.&!
M8A2B<-NUVH115\0">@S`0Q4R4`**Y<E]S3@&GZ+1O96*SP3F+:M,;C)3$O#!
MILU"@$YYVE-X>""H4A@J44U%YH`4)*FG6FJOFAK5J,;*JG"N558[,L$#6K"K
M7P5K6/LQ5BE_4!=+2"MI9+A1'P<R*9/E@YJ`0$,8W!6:$\(*`!0@@QJ@IBP;
M:",(FBFD!DP1#&``#I>BRQAG<7$IR_&%#2*0,![X0@P88,P<H7G&P(I,1)L>
MC<0&`*,TP$&_=/GC;O_>I=,*"#'3=5G27;$B&P4D`+=XR=T8O%"!-_#@BT7B
MY@!V0)D\B$$9/V-19B8``7F9I5Y8DPMWURV7=+<;E>^V[G4U.9Y3JAL^"##N
M>,<Q@ACX(0;8)LV,!P#E46"#DA#P`A1J2(09E"!,6L&UXEA`@V=O=#*)0`"F
M-P`"F7T!MX2`S`#J@I<TL(`!NFVG..G4@-P,[$2/B,0`\F#E$V8@14,J@Y#2
M520//2$&?4B;P(&&LM%TX1)/^)(MN@GE3[B`>)Y(6P:R)8F+'J5-(8#>+*H`
M.`Q,`XN#NL(QN-TG:)0=&>.(<OG\G`U%88,/Q.C,EC/59:#60\Q[!@@2DFK_
M9J,NU<X/@:J;.Q+G6=E*SK>:LT=(4D'`6]"KP^I[F?7>9[8G"]"(.X.88A&]
MH]!`#(F>*!#*I0`OW$!=!I4A#)R`L@K0X0UT(0P><_2&`H`:#`6`];P25H!F
M74&R`0@7!MY@EBH^QHQ!0\X<6<":&DQG-170N69'"R.R=;P$2P)"`D0$@94U
MLS:&\0($F*T!2NO`+@EXYPS.M<P:]-Y]5YA`0G/BK`I/H++AR(P8!/<#.<`V
MNNB17>PV->WQ;MT%;_+F;J5D'6TD-O<F1&_@=1(U#462'T0W&4\Q`!,0`P/2
M@2)0!@HB3#``)!KP<`/P<+@F(C!2`;$@88/&`'&Q_VEW,11.``O%A144H#)V
M<1BST7`S``&DH2_ZE08P]P@:\#9G$"6(H"\XQ"5;L`7\$0-+L`11<#R9\&(+
MU@9MD%!>DE::)R0B4`7#\W3'(PH[@$O7TCP-AR5>L%%M,`%-8`M>AT5N-W9[
MHEXYP63*$#?5L':61P)9D`UWL@-B8`-,``([17<^Y65"I0]YMW<K<2J1Z'=_
M=T`)Q!`+5'AQIG@/%!*.AV>J\G@%@4%GQA(=](<@]#Y+D'FF``"$T'F"Y"U,
M41\0``13H0!5H2^)`#@?,`8W`!HLH!J@(1F486T)8P=V<#20%0$1$`#C,`U,
M<6TL,A<;0!:KT1BPMT8,4/\#G#,P<%`#R$88$$`$1`"#A@$"@546`9,&0O(%
M@21'$)`&*L@`:4"/-_,%$U('Y?<%3A`]-,-HCL9\#8!%XP!)MG1T.``SRL$#
M-I`9%H!';W!)#`A*#SB``XA*G:0>"3AO55-O8+,=\3$?]0%E'H(((X!2_?%1
M`2(9P*`,_U$&,R`5CO8%XC<A,`,":)"3I85@.4,A(L`"&X`&*6(;T987NL4`
M*),!ME$!*-)$&B!.5E`&2/E%Q92#.3=0./`A(_`$2Q`#9D1T$X`'>/`+4DB%
M+K`$7?`5HD&4>8%7,*9T.A>&8TB&P^,'N*0\%[4W+?@*%+`%3:`F#>4LSL`,
MTF#_*,>0/JR$`=+0AWYH><T1B-S`!:Y4B%LP!%RVB':7#T?`#U30F6%5BL0R
MB::"$*8R$H*'B82GB9N(55FU59X8BJLBBGGV$D<%$ZCX0<]@0L1U!A_HBGE!
MDX)4`^`2+AE@6\)T+FIA3;CT`>,4(@A@&=^B,`&0!`GS`@'``P=2>QD#:^HE
M!GF0!YEP,4<2%ZM1%HU1`X9!`]S(3`VC';EV,T!``PA@&&@0E(51&[+UFTC!
M`FW@:[91%_=""/@X(0D`!%808'C1<#0T!O(I'V4D&;A$<-SV.U<$:\:5&93D
M-$.$26'321;9D?!V-1D9HN)A7=PUD1292C\@&18`#`0P_R`<.*&P(1D`@@$&
M)PZLA`.'88M4H5M?`!D@A9.>LVFZE1<W8#"'`!BR]6!,PCI`HH$`Y7TD-ANM
M\'!$=QP$U82P$1E=L`1A$`8NX`+&<`C#N`44^B%3""*@<216$F`H@D,]UP4`
M!81BZ'1T^0E_8`M%H0JSP3I'42-^.5$#H!R"Z4K*H`QYJ">'PB?8,(NH6#[-
MP0RZ\`QB@`=;<`.7^5-?!BI'T*F=Z9DM49L!))H"P2JE24$C,7@4,554I9JR
MLJJM26=U!IL',9NC2(K$4GFWN0W/,$)/D%"4Y)L%LPI#L`7>P`P34`(?8(L-
M4A6YH2\`L*P)H$-X\"W,J#`KM?]%D@5K8E">9($!-8"-^58D>,("*P@C.Z(:
M<-`&L<`"6]`&%(".YX:>;3`$[MB7+%!NI;4(2WDS3ZD!<-%,MB$P%;`6UQ(A
M$S)I7T`B:9``1#`&-*0`0\!8#'D9`9`''S@`#<EM0',:,,-(=C`G->!_F`:`
M6?.AZQ%*7=-NW:5=&ZFRI71*#C@V*XH+:(,VS2!7'^M7=<`B'4@@(28DQEEZ
M>1$91.9:I74O0Q%(01(9++,A!,,ZL6`([/,[_-I$NH4M$(`#6-%B'H(?]F$H
MT2"%41`%8?H'!V*U&^*.XU<DE@!LT248<&!/,E`!-+`E'M(%FF<XGA"F9`@*
MLZ-S_JK_6T=A%*Y0K$W0!66``Q;0+(>2#%K4#'?X)WW2F'\8C<:@#4>#4Q20
MJ5[F`)QZ`$?PJ510+*%YN@;1#Z-:JJ>R$+`9>)EX5:WJJ@S$B;+**@R!NXVG
M9K)Y9AC$0;JZJ]G`%'Q`0BTV=05CK[/Q5N4S`0Q0?F[`(&Y0N``2K<N37YIE
M`9O1"X68$_17&M`D1-0('_)!&L=EK@WC@!SW1P[+`,Y%`:^%;`)C&$99!LM$
M`4IJ1P&:8%_`?"Q0!O@[(FOACOJD+GPT`T>:?@\K3&[`49KE"_RA;6HS&0:I
M@0%@!\X%`B1K:P`(2M^%LMZAD0:(@*0T-B][LBD;%][UP4+$_Z(P>G3F-0R(
MP"(_M"7VT0550`YR);1ND#>L`QMM4`)(6Q=.X*2Z$R`38!?[A;4)1B0[P`=Y
M("6Y$5`J0F0YU#M<N018<"%E]$4+AG14:`G@ZAI,B:#U6('?V,%U,2,W4*^3
MD+?_I"XC8*=ABF-&\`=/(22GX(Y7UR8UT@`>M;43P!EVV#TP!0W(M0S1$+Q_
M")EWP@W:6P-MX+GQX`&<.KJD6[HL852C8HHYL,E&96=/)4&PBRNT6WBV>XE;
M)<JBC*N_.RJ,++S+LCZ^<T)[7##IAQ3N\PSR5P;#Q""X*&$`<C.J0`.M@0$Y
M!1JD81EOX`N280/HB9,B$A>"(38@(/\:3Z@D("!$\W(6C'`S1+`70:R"BK.#
M_,M\`^MK(X*UDO!PT+>4^9(B%,6U.NH%"J`7"0JQ;@`$$VM(Q!C!I)$G`LTG
MW-8??2$&%,`"&PPUT85)#2B`(%RBH?1=).JRX9&`7H.B*1H>/Q!>>R(@_68)
M)9E0\E<'VU9P3(9P,Q"]]WR4(B`ATGPO<,(DNJ,?58`!,!(FTX1/DK`B9W`&
M24=<H/48)_-B6\F541`E)0D:SP%2(O#3O,DEJI&T)5*WS:05(H"NV5$#,@(+
MT;,['I*$Q)65?4#'H!`%?]`%&:!S9;`F?>P%-2(">&`"`,)(A2PHS6`,3,8?
MRV!VNRS+#*G_N8TK!C30`IB2*3\U!:"+#YB<R:%*9GLW$/_0#Y!(J@_1*A!!
M06]VRG!&>*WIFDR%N[WKRD=UBK*<+$ZQE0IU"D.1?E[0!J!'`GV0";XL%5/1
M"NF2D*GP`?'Z.YNF,E@1KHVQ8!.P,,$((VT$,$H,!T,2,D/@!,?&<0,CH'!-
M<>56%Q*W)$]I!1`0KHO@6F_$"&W]`71B;3:``$)CQ5.2")$!4!5U6S20S^ZD
M.RQ@&3?A/4`S#K"F+LEQG39A!_O'`.>&;M6Q(Z<$T1%]@%E#T2%:@!M);Z8D
M,N]Q;_4R`LI0)$='7"L";NJ%(!22MS`ZI[LA%83@!>Y[<C!2)4U4_S"0``$C
MT`2N-$?#+"2Q4%`]E\5_P`<O^DC)9=1;N00_+1E'\D>YP1;M+=6!@0"EQ085
MT`9*0DZ_LXU#!`)XX3Q-!(0>\D\%-0)_X+=A:@154+9&$$-E4`?:HCPM^*<L
M,-?6$D;?9@)YL`R#0@(G]2>"H@+3P`V6:WD-J0V-BP>%?=A=9@"*#2H<D,F:
M/'F4W7>E,MFC4MFE^HFHF9J<;56I#!)<Y7BVJD&E:)NG31-90`!I14(GU-:<
M-P3-T]WKXP=?E`',J@!0,`1M`$VBL=8?,`1L<()"U!HU(!J,%8%<8@,L(#C;
M7!9C$5O-)`E`283O\3G6%*`Z,[&%@6L\LO]I,G,Y)=@`6R"#7U%$0W(*%.+,
M6["F(F,=;[`#(NYL"J);,S!M#KLYE/%%AX,5%!QBR)$^XY`%'B,A3+#0H&3@
M'HS@"7Y=&+G@)\R1!-@C/:+"Y#L9$F7AOO-AR?5%*C(9RF!P0:L!P-R";7!R
M@O-R*UZD.)"$\\ZU$B(:[LH?76JVQR-T1/W2J%<D@@:NK$&P=9LO)9`A(>-:
MV`$"%!<][D@DB`".@84&2Y)^@^`$;5U<_090`=+E7UJV41#F3Y>GA9.0U])C
M7M`"KA!D!&`+%8H,>?`,2%;GQ;#(W[`#YK7G?M;GV7`9#VG8];.(A+[8^(#H
M9L9!D+CWD]WW167_$*\2VI-NRI5>59>^*R/QB1<DFP1D$K$LRW$3`T?]JW4@
M%`D`@FT"`5L`#7`78K9UVU:A0R(72&S0`!D``F.!';WNSFO4-,7&S6,!>P6;
MO!70`XOP'INF@ODI7Q`P%\$H6"-R)=P=1C90+R>X+OI"9%J!7/Q1B'T1`-S;
M62=T,^J>3?)%%5Y`!&UP,GQ]#`!U2,=P""@6)@UE![4`'?1"'7-AX`:?X%I3
M@/%V\/*6T1W:H10>@38+#)=``'$."%T#&0,8&!D9&`0$)GTQ,2,X&65$;@HS
M7EX9#1@,)0P,&1"C9640)0,CJB-=&!,3#2*&$Q9B$X]+2T9^KS6Q`P,,_Z00
M#`TC(@,UR@AT:"!P%4YI%&4#R"QT=!L_&RQM0PD)7PEE(L@U&\_37U]6,^(`
M&H4CD)(#,6%A<4M1449&+OZ)J(-C`(XZ`(AD"@%%'(,)!$0`&"!&S`X3)%20
M(,'#Q`X+)DQ8V`CRXL8=.S)JW,BRI<N7)+ALY&$C2Q:7*BQ4",$SQ`(4*`P8
MF.(@!X>C5)(J/<"TZ8$5!Y`@83H528X<4YM*W?H4:M2G`@3X6.'#1U@?'=*J
M[2"AK=NW<./*G3MWK=V[>#N$W5NVK]\5@`'W#0R5<.`#(V$J7LR8)8^1D$8\
M.2,B`P``X89D@B`BY,8)#+PH4`"C(0T&(AHTV/^"H8X7'35*R/@Q1PV3'V\:
M,*A0`G,--$/@_."63C4#"A1*0&@#@@6+#>EJ('A6@0*[!!!`;`%6@\XS:-,2
M$&'PA@?-W-94<W)5WH:%+!8LV)C_!@$&<RP,&BPC.@&%(>"\`\YX",1'DWLF
MB%".!3N\8@@&!PU@@ATJB-`&`FH,QXUT""B3#0(@(@#=!B*.:.*)**:(8H@B
M@C@BBS#&*&.(*[JHHHDQDM@B=+AAT`4)772Q@RHD7'%%#(.(4%$)Y009)#UG
M#$)))6X0,4,B$U2&R)8X%&3(&6<L$<,??&R41P/6C*">.5W$T,42QZ0&`@@-
M@%`!#3100\Q]#"@#0C;_SK!`@SA#E($:#GUF0P<<3FCF10(W?#$1FG.F@=TZ
M"5AA10*7#7#&$S%$2=`984011S__N!`0`2,0@LPDF7C!$*0T;)%%%X96A-$5
M+'GDZTL>$:"19XT5*Q-'\]W44DXL].034`84,84'1G%PA%+8.I455UI9A556
M5W$+E55@C47666C=1=>Z[+;;5E[PXK77O'[5^]=A71F&6+'\\FL3"7^H\D04
MK6H@3CA>S%#-!'E\QD(""KA1FG]>(G,&#EZPT(D3&]0V7(8#I`%!*0WTT(9P
MW'P'QS3)M<%`#XN*2,=T<,`A3#A?I*$,,@-48#,H)5```04-O&*T&!;P$$``
M_U>X9T$>[DWP()KJJ=:S05U"H`$,[Q@<#@4RW#`&!5LX^.!]9>#@R@0H>70,
M!A:H$``&$/20X7`;<.CAS#.7>./?@.-(HXTSV@A=X8:?F/C?(/8]>(D_&`(D
M*UV,T(=%E5OSRD$B/%*%'S'PL<,`H\Q@I1M`N%%-G.:(L(H(72SB0CZJ+M(@
MF@P$$S0$&<`>)#(U_UD#"#I4(`,-X)`M0@E_:I-W!<>%PVD)N,^YLA-.W)#`
M#%9\H8$\&`1301HEI"%RIC.\8XHLDU%61P:DFAI%&*FN>@@.(T@9:PL-W=#&
M%A;H0@9*0(N;7&%8%T%)2WC0*Y%LY%?]@LFQ#J0LEO\PRUD_"8JTJ'64:V&+
M"E[IUE:DTJVK?"M<49G*N%3HE7/M!5YP88N[9LBN>-E0+_,2BUETR!>R&.:'
MATE,!(?H$INH(&`CX,?%-`"`<23`"PUA0!<2LP,10,P24+!"<E`C`OP-0`,R
MJ$$TZ'`WO,$A:$QB``(8`(=MY(TZZSC%%N3P`]6`B$[08-+W^O0&&TQ`#%O(
M77I4HPPQB,0F\@D`#YIF"T.@21:S6%X%YD1).&`-!Q#X0OH2,`3D$,H+8Q@"
M"[:PA8K$QP(0HHA[=N`CAEV!!RK(@@HFP!PZXNU#>V/&X@+'R\.UB$4Z\N6,
M!#=,%>W2F(W[T"]Y5`,,D&#_2$_*GS4,P8H))(EMCP!3E#)``2)$+&*J\Y0V
M=W`&L[FB<F>(03_\<(:J`6-ER($`#F`7O@$$CPXU@,,)HC&.&4#@/AD`P8CH
MT`#D?4\<9=@$,NQT&6EHSPN:4I@L!D&#"HS/.OT<@Q72)H)/@6D@=1A!%'+!
MCW^8E``"G*>4-!`K3-R`:'BHPD$F8`,2*,M7"EP)L'8@+!*$1(A$=$E-8&*#
M9O5D`3\I@E(Y:*T/)L4I3,%*"JM"0F^94*HII`I36OB4'88E+5]52PQI2%:Z
MV.5=-\1A#OG"E[&8"XCZ`FI0ATB`F/!!8$N($F:DIP$B)*`$&!##1OPP`@@`
M`09N_\CB%[8(C&,`H`0(:``%0%#&'X@1.2*C`1.VT("!U@R>DF*`#0I0`#&D
MYK,6+0$BU&@!87U$#(&5SWR,=(6E!<`&C<2`,H9')V1\`@0UL$7(X$"=SX8B
M`YCDCU]O``Z#;2H<(&""TTH2/B79HC+S'.W25&`'/)2@`C:PY0\ZE$P9]?*\
MB(.1,(&97K^9EY>$8T9WG.>\O,'-!/2`1!?QEX<\["`&5324,9QTABJ*8@:C
MB1@1-,``:CJR9RRP7@G:4(@)5$XU<QH>:F4@`PJT01:@:`!Q010-2YF."&50
M$_.:8:<T.&%[;MB4!C;1@/%YCP+\?&+Z-"&"";0*`N9S`O\%I$<$(DS$'![M
M0F6J@0M_&&$11FA"$V1:`G/@H`P:P$0FH,!<%N"A"3-U3TT]@I*4Z!0G/N7I
M`TURYKDNI@$A:,%14:#4(C#5@Q^$ZE2O$E6I6J4H5J7*MDC8U:VV50!@74M9
M%]VNM+@EK6I=*[KZ(A:X!L9<^W+S7%60AV,\04P2:2*`Q*.!_PF6!'V`$!$0
M.['E(,H:$H'`\":KH91Y(CG4LP$>&H`.-'SVC!#H5`!(6UH1%"/#RJ!I`1@$
M)%EH%[<5>848W',?/H$`1,/[A45]IAH<I*%FX[.HS48A"2PKA*_L8(<7*D!*
M'P5):IJK2#U'$&TQ9,$.64!4%L3_2UYF.`Z8Y^UE>^,+\($7DT0"3V8V#O<B
M#)@`I4:H`N6$Q$K754$B:KL('Q[1AU8-&0BC48@&J@R,`<1"&!6MV310X2,U
M62_"XV-!=1HECRW\5CH;H(.EVO$H)KJ.`<"M#@6P]X6$I4\#^---&0"`8TRE
MSTIJ@P0BE#.*+XR"=QW-GV3.H.1)#,`/?W#RDPD0Y2DGJ8M8UC(4AW"#"GQY
M`'6@Z7L8T;9B(1`CS\2("MJL:9?`6<X^^4FTIB6%#CJ5"GHV2E:C<L)PF1!<
M.1!A5PP=EG,E6M&,SGQ<'`UIM4@ZAY1^*UE$;QBY]MWN&Z',UA4D:@!]CS.G
MYD,7<.!-_RQBQV7`,,=EME`#"J",&]XQG]#@\`8YR`$!Q(5&S6Z-BC<48&E@
M"(#4;&">I=%$::](T`!H6I\.K<GDL7`%=S(\)Q'SYA2<\,0DT8`&$8'`$_)4
MC@:`\(YQ>$$#5L@$$6I5H)H6J8HC@`>X)36K8!`B8`$!D`7'@0?\QB'*I%X!
MAU[II2,0^%X4.$PT$C@*QS<,YT88P%-=T`<H%0,;@5+`X$QTLPD6]B0Q(`)#
MDP!NX`9C,`/?`UA98G+#<R<54"<BQ@`%T0H8]B?I4`+80RA$H#:@T!W.P"C@
MT`(]!S[`P`)!8U%.T$_<,Q&M@`,```$6A2E6,(/E0!FI<!\E9_\.E!,#<#)/
MJD`9$?(')O4/9!=E`M$[D9!VL=(_;M<$`]$`"!(2;(9Z$!02=<5WIT<"?\<3
M2*5!'B`%A7<$>(8M(<1X5$456/%X.0!H6^$`#C!H6]44.T1I.*0NFC>*:-5Y
MGO=YAV8N]P)$IE>(BK%W,0$G`M,JHA8.+%4-2',2`U!["M`0RP$*7/0%'\!K
MM,8--$,^5E<#SV<'`5`#P9`:JJ%;"#!:T6<'/%`1PQ8!S^<>MH!;&*`;(K`,
M)*(,WX@FP<"'8G!L/D-)/2B,":`QF-1&Q.%K:2`I):`<"#8#0^`]!I-EF$`#
M",`$M6!A/I9[#V(TX3-/",@#+``!""#_7GF#;?^6@1$(7XCS(A1Y@1-8(W[#
M./[6-_7%(Y$#$6UB!$'"$M:4"B9`-^5@"(_0!7S`DO.76%[@/1#`"<B@6]XA
M<Q$&#17`.TH&=#R2#O^A&4/0!@F@-CVC#-4A?`G0`F-P?^!3&>7C,_68`%E6
M9``@`G^`).]SCR,C*9?1.^&3`2,0!BZ`!4,R<7S@"&SH.JSP*@/P!V07$&,7
M9570!*V2"G#W1'=(*Q.@EW5`$;7@*[#(+PC44Q#DBBUQB(&G00[`B$UU>)%(
M:'RV9U>%B7^&582V5:/G%_,BBA(@0Z2X:*:X%JAX%CKD5811%I>V`JW(F(K!
M!5BP"F=P"`;C_T3?8RAK@Q(BH`$14QI>T$GW*$@),4DT@#(=`@WPQP!BL(P1
M,#<8T$=*LS2U%0!VP(RP)0;#]GQ2<Y#65`R4`ATS8XR^X`DL`")L1%SU]7[6
M83H/03I_H@X4X&+B00$W4PF+-03?$U'OP`+KT05L4Y8/$1]Y$!(6\0H\D)T-
M``%SI"$YAVT'5Y&`TUX8J3CNE2,W`G`>J2A\TY'#40.Q8V$HQ0H8H`IF:`BB
MT`"M10"0$`.'$`\QZ%?\60U=!'3SY6N3-&3@D&++`P?-P`(N5H6/<I1#H#;+
MLQOF<R?@8`50,`8:4`UH4P+@81U8201`\`'PTX*M@P,E@"BYDQJN4/\9`Q`'
MIT(``9,F(W"B<`F7<3D(]Y`J;RB'!'`_^6,9++5E7D`!M=($*24&>&!(>&=!
M@/@1&F$2LLD2#;``@)>(T1*9C7AXB)=X4L$!6U&)5Z&)@):I6+5X7?%6H)D7
MH^EHI6F:IVD7J2D6\T(8E488L9FH+L$%+O`$:W@&&<!$!X.5>V)A:]H`5T23
MQ%F<EK%_=L("RE`UT?@&PQ8`8+!L$Q``<Z"-UI<TW*4"8M``8O`&;_`#:F`#
MAH``VAI9S?=^RD!<W=$A[P<!Y$",:8`&M;8!#5`"US%R$\`"7P"DT"!D,E"/
M&D`,ZEID-U"%?94^4*``7M``TTA]*O`8#3#_0#0%6]-46WO'75MPDQ"I2](Q
MD1U)H1*XL<$D.!AI@1CJL2.K<+IT(N,%-SL0._BU7R-P$6PS.IQQHEU`&4%R
M90F0.N]``8^"L%T$7,W@##96DU&:&E2*!A6P/0'KESV7"'3#=%TX9.@S!BC6
M8PJ2`<*'$)CQ/9O`AF?`!U@`"Y`D)!:0)5TB`F9:!28H2/F!"+`F&6]*"#$`
M$*L"95&&4LAU#%>6IU"TIVW0``3@!Y(0;662$QM!B(3:$L'R0`Z4J(O:J()G
M9Y+YB-FB+2@T0IBJB9=8B47!F9WY0ZZY`H@6+Z5:JFQQJJF*+I;VJK#:$ERP
M!+3J.EJ(&>#P1$/0_V!L$R>&%9SZB!SWV!L?0`2^%V$=$ESR4;86D`2DI4A2
M8P$1\+S2!S>GE`6P4`.Y40/#`2*U5@,,T`;/82??T1TDDD?B,0/I*33:T`P^
M:2G/=9,#X'L^Z9,"2PQ#5F3[V5=%5K!><&VV8#19@ER!9;9J4ULV<6\3``$#
M(%X_@$OXI*$<JX&%LUX9&K(2C$P0'"+X]"$H^P8J*P(7@:(]E@=2(Z`#(*5M
MX@="8@(#@!F5<&X&8ZR#0%S.P'Z6@C/D8`W?!0)I,`32(+7YUU=..S)*&A[X
M-P-9RAEH@BB_BP@%<8)5A#^HTK)CVW5J^&FM@`QU4C,RT$G`*`*T6CG8U?\%
M<BIE<=@$+BH)JK"WCP)%,X`<G4$`@Q!<@ZIIBYMFK!M4CRMGCBJY'42Y3Z45
MFRL5WW*I17$"F_EX(Y15@-$4Y^)68#6ZHEFZI8FZJ5MYEV8N=YRH#!03\_,$
M\\1Z\_H.J+`>NE-[$S,$HR!_P?L%+,`&"1L`T'N-8E"=`0!;$]!':M"MJJ&M
M;R`USN:,P%4G)I(;6)8=!54!V/LQ/Z##\LI2%8``-)`=.HH<XY,IKT=*YF,^
MX+8.3'0<FK%@R$$)"C`&8X!8-*`:I20296L-T\8@;^/+$Y`%`>!=)?`#!0"A
M\X5/')*1#\R1!I>!&UMP_M:1A'/!)NLBD+,!#I?_(%T@<3O0!WR0!Q""/UDR
M$18!=H^0)::0LT!09`!2#/'(?NP'!Q30GU9@,*@@/MLF`TYDBT30.\M3!N6#
M*=_3T=4`#//$2IQP!FLZ`7A0METT`)_F#PE2$-#8O3+-"9.A&T"7#<1S)S1P
M//A)JVO:168IIP30!/\@94W`!Y(@NTNWQHF%'!)"`@K"HA74=X&H9H=[>GF,
MB(K8B([H5'IF%5/A>-^BB2>PUY>HN9?J9YWZJ:!G%J(JR:1XJJB9NCXT&+#9
MNHIA'ALAJV'P!(106$TTK]B!&FO:)6F`8*/A!CT'`$OW`7VE`2S0`]8[6L]W
M(-1G'F(P`A/@C#60(?6!_QNXX0L]Q@.1)6+L"1U64P;T!Z!<"*%+6(_7<<["
M0%SB5C-6JJN\IQR3!$>9Q$1@Z05^E2<)D3I04"4O4QXT$1_5]4>OT`KW<;86
M(`<*2`'%A\\SLUL0V,_^_,\%34P:29'S[9$8_(`Y-Y0.9P&PXR8IP2L7HS82
M+=,^`B9MPDK+,015<G\`4@+;`0%`.M(5T%R:LF`-%J_?-CY5*#W;@W2NT`FB
MD$F<(MJFD#LP/0(F`!_DU$IX8+:I,-1+<!_0R-S$:0U/T`ELA`8L5CPR@#W9
MPP!4K61H7#]R6':+D"3Y4PK.%8-D704D,`)E@-:,"4&(ZHI_UZAQ;2U^C'@<
M`/]5X6+7F]O7>ZVI5R7(@]RIK6DOD%S8AEU#FX?8CYR:]A(8F2R;_L<%44"K
MN1=LUX&54<I%D7"/GCT:'4T$'Y#HW_,!,T`#HR0U9:-;O#R`AF`#NH$.R@`=
MF1Y9[%P#:5`!:+`-&A*ORF'=._K,R[D;O-$.X0#A\;I\Q&4G5EJ#JP$'`[3-
MS?P!CX5)7@`$>RHT?64)3JX=98.07B)M"&H(LH"`64`Z"'#/>'.NN<2A\!VR
M\KTX%6B!][VA,*+??L/!'\$*;A(Z#:)DFI."'^@'?#!V&%`&`.(&F*`!_.F@
M#8`#<+"$3"H]5K!@.'!RGWY1WB.5_>H[9'B/;?"E\[3_&F;+IB\[)*UC-8C0
M4>D4)?TN(L4M#4[`.VN:.T";#?D*(."``U3M8U_MAK6CU4@>$;VS30#04FX0
ML`_!*M7P'K+Y*P=*+&X=9W.V07)]>'5]B=[B+69^B6:`B8ALUR/$0H91+VT>
MR6].0W*.JJH)>JSHV(J1&+1)U:I@&>SP/7V5`*A1"(-0`L#Y3?2WFZ-=9!#@
M')SE@Y_0`&^P`=JZ&GU$2,@V'>L(!\NQ!2!PK[6&3SH\,N+A!"!0GZH1Z]!@
M'2?-8&\0&SN8Q>>GKA\PY?*1&UZJ6@/$.\BU'_B[6)H$!*E3">]8-DCCV@8A
MO;5@"--V?3R0!0VJC!"*2_/U_][5[DOU;:'6;CB/,\$6V>T?NM\\X@HD8&%N
MDL:I0-Z;LPF/@(8`1C<`8B4T*+4`:D]P9*774;6].@!!8QWQP$1E0!"MHPIG
M<Y#1%M3(,$\TCF$-26YI,@B3Y-300`-.L*^2(KL#(")XD^^>+_*J``A=&`,9
M`S$$+D8$BP1-C",9(F<B&1I>"5XS;D,T#!,$764,%EDDIJ>HJ:JI*B0F.R:F
MK[&KM;4-(2TANPLH15-24AQ'1U3&QU0'R@=(2#D.#LX..=34)R<.9DK3U=/-
MSTC*SN$KY3X^Y@+JZAWM[AT2\?+S]/7V]_CW[_O\_0(=ZGRL6X>NG,$5%FPI
M7%CK2O]"$EQ</!$Q8L2@,E^^:-@X(T&%`0,&E6!0!HB"DQTAC&0``8`&(!!8
M,&#QHP:#"A5*P*FQ84,#%@ALB&#0`,2/'QN.PKE9XD,"$#4H5-A`!PT(.%C3
M?$F08`8%$&D87&U`IP:<"A02;-0PH,86!C@:-#C+H`2$,AH`E,!@0HR8"2)`
MBI#;`,,$,1<U$"$RA`($Q4`Z>AE2PX8-"Q;\8L`!@8'A084F!)##@X<=.UL@
M-"@@Y^@/.G00U*@!&X'MVSUSZ][-N[?NV\"#"]\M',%OW!N0^R8>O&QM!+![
M_I@P@<2.+C&Z=!&!PQ"!/#OR3,!19H#V,S'\$!##8`B$&3/_B&B@,$0#`^X5
ML%9(0Y]K@@\`F)<=!MR582`$".(@PH(5C=!%%7WD(0:#&&#PTP`,9(##"-P1
M!8)M(*!1P0U.I%&"A@/@4$)^6%U5`0WTW:#6`-P-\,91&X#@A$8:J$3!AAQ6
M2`@.9Q!@A"**-+(("5UTQUT=&LS@129N)-`)!DU4D4$)8I3"T)<DM#*++#N$
M">8MN>P20B]%>"`,,<4@D\PRS$B3@S-F6%--#DIH0PTTWC`#33AU'K#",BN@
M(Y``Y[`#T#[Y1"KII/;T8^D^CJX#$$'G&(3.0V>&FLH5-I@2T40-#@!``ENM
ME<!](8DP$@0FP:"`%Q0P<!\<&-(*_\$6:&V@!E5TY%3!;`U0P,(;+,$AK!K0
M_@"675NQT$,:%<`&0G[;:L45$118!4=M=.A7`H^_XF$#`D/=5%<&=ZDD`@:"
M4.>7#:3^1=T.DU2RV!<44/"%%T1(Z84&+%2H,'4#0)!!`YK1.$%FAV5A!QXQ
MR=':4=#)1EMLP2TG\LC)%6>R;<<5U]/)QI&\<G//V4:'='\18,*#V<6`P2&`
MS=MD&2+X<20C8@S@GF*+8:)!!0UP=E,:3@C,ZD:15$31@AC2V,"\._![1H,C
MG&&A8`LR0$$;;9004@-;P@$"'2"P`(<,3I1(01EQR5I!B#.#P``-0["JT88@
MO4$5'/P-W/]11AF$/2^!&HYP))*+.$(`"3'@H"&\`,Q@Q91N>)%&&A@<J?D$
M7HIJBY@F6,`ZJ*J3@(LN:[+IYC#$R&G,`1S4V<P)=SZS)Z!F:#,-H'<V,Z@X
MAAZ*:**,-CH0/Y16;WT]\$APZ:6.NC,0I^=\&GOL/)0*$1>H5C1`&:RJM58)
M6Q,X:ZVWYMH='(4-0,076\#Q5;1(J0%(!E`"#90``0VC@VLV4`,0@`4"`1O"
MWM+@++@Y\"S>"IP3K+(WJESE+`+;2`5L4#X;V.1^@I$+`MY@`9N]P@)7<`AB
M%H0U0I2!"`I(P!"VXH7(=(4(%<"`&%K'@P#P0`0.P\!E9E@A',3_Q087:\,`
M-+9`D$&G!L-QF19S(YR8J8R++$,.;EKFLBYB$3<S2PIB3'"S*G1A!":X@BD@
MD0&^B*`\,<AC'KLP`18,X0:*F=*4["-`!-%G*ZRB0%AH1)&*=`$6!+J:)&E(
M$9#@;RYP8$$:;A"P+Y0@,%O"22994`$=R,`_'VB#_,B21CBT80B!XV0"'C88
M!("%`IS\@A6LH`&N-.YK%6I:XR;7!,M9C@15P$$=G)@!`!#!"EUQPPQDD`81
M'*EA&,@"%\:GD#&Y8@>7BQT!9L<+V[TI3KI;1C-^%[S@'2\'V#">,Z@Q3VD0
MJAET8H:A.@6][E'O>@"]GCOBL;WM?2\@_^$3'S=#%<-3<&$)(WC"$R;QF*FM
M!0(T(E!W2H!#D\Q@"&F#E5RXP@802.4'>U###Z"%@/T(C`((V,(!D5(NK"#.
M,8YA`1[FTA-M8;"BHD`6T[""(175`0!U$`%U#/,7,;S!,F]XP[UL\!<,5$0N
M(-B"7`88F+J4X0-`F(\.(?"%--"@*Q5`@+Z6VK!(5&@".SC,('"@1#!D05=,
MV%@`KT@;X&SQKR\#CA59!L8PGDR+,(--;)(CG3=@`)S8N5EU3`&8D$P(;R/(
MHQ_X$`L,("B04UJ,:AH`$ETQ8("6G0`&OD8A"U7@M*]M`X+N\YD!L,BFB+M!
M1C10A@K9A5M8//_+62]JU;@@``TWE9$7H)D`(JAF$+:-6MUT:07/60$"(XA"
MV+ZF3!$L`DE#8X011+!,0FC@`[W4A!N<<)\J-(&\&.#!0A72-5IXDR';W"8)
M+,""%M!N`0LP0)O.205T[HX#'-B3@N')C0:;@1O)>P8WPF'/0AWD((ORYT`#
MRF%*;;B@EOK'I@:24(3,5U0/X8)V)?H$2&@@(US92&="HMH&,.`E)B%"`BC0
MB0$V``)>*"FV5JK2E6X`+0'[%0(84`.DY,A%_&E,'>T@!K(@Y8,Y>0P`'G:9
MV6#HM%R=UP38:`("7*$`!0A``&R@6K%92"X*&P`%9]/`GY!25W7XP#/_TW(#
M!-'@!O&A`)P-LP/$G/8P)L@"&S%C@HD5,0!#P8->&<C7D`'VKXD-8V$-^T62
M-><VBVW941X+BC)K1Q!6I:&%((`#<!Z)#[#V[%T*IM[)T&@$A=;7&\7,H1HN
M"),X<2DL9SR4$F"+!M@*]E8T`@`AUN5#*V,!O+AREX>-8``LT"17;J#<@YVW
M#85Q(@-&YP09[1(^UWU"%)8PT6N7I\Q'2L30FF"$]VH(!P``T*K4>X/3=J$)
M9ZC#"$B0!=B=V!06\.8+2X-P4Q0\Q5R(.,(K0+M=H$#`M\N=,01PC`-48Y["
MZP:@MH&-!GL#Y'?R^/*4<6$,3^^?V>NPS/,Q_]!V:*^@F3IH^$Q\<#"E&`L5
MD>@(\)V15B6@#;IJ`'@P<&,BF*1*%"A!=YS(-@WHH`?[$99K:H+D$I2A`7A@
M`4]Z@EP,"NP+HP`##T`@@BU@F3,```!=)Y89&UCH,'[)@][S<(4`J(`'N?Z+
M;"Q$P],VX#`3J(O;YB(7N;U6F?FVPE;J<PDO0($Q6(1AF`*0>!&(@:H3Z+5H
M[&!$%02@`0><M,QF8^E+(U:P7C09<XS#Z<".[--83*.HIP/9,NVZ.R.P%YLS
M4,=38^<Z\'H/E0Y6'I#X90);H^20*%*AP!3E@CBA`01@N650EH`"3F!:`W`"
MY/]H0*FZ2B-RO=61P/\!;1(5<((&K%`B&25@EQNAZV:V1.ZT6&(,.D8D1@!1
M7[,^./`)\38YC5!OD``298!4^^8&"B!!Y@%PD4!PJ=-SIQ!7L6`!L``J#X$9
M$"=Q/&`!%*<FO8!Q!)9.">9.R/,G@#(-\>1.$08-)\`,PH,HZ/`\+J<I_3!S
M0+AA\F!S\P!B_D!BYV!P&K@0I\)B9Z`J@J,1.Z8K`Z!:@0$`0/!TDQ%U*1(7
M##`#0,$"%$`'`/0&-O9])=`&6\`#,=53+>)2K-(``0`&`>!8ED08</9478`'
M68`!6S`!-H!F5R`A$K(#5Z`")D`@!!(2=/9FI'5:\R(K#*`?R:8K)3`2&?#_
M51UQ`]KW8IB@8S4@51,@"(*0(H8QBC4B&BJ0!5E@>A.@AJI7::WG>K<'>[*W
M')RF''Z%BX(%:K27&S\@!N"41P20'1R":Z^P5)DH`M@1`WT0"R:P/LKG!6[@
M!O)!(]VQ59HS`'+!$IB5:@-P%CC!'V:%("U11VPSB6^3(XX!`5P1=U48&`VT
M'Z.S%;LT)0D@"2+@+5*Q(URQ2P`2$IM1!E'720D0=[Q%(V>P;MNU/AG0!49B
M!"XPD9/#@`K"'1K"/M280Z_U;SM0"!BXA*GP0OLU)G*$<)AA*A&W33R`!PQ0
M<2E8!,$`)^G$._0D8=4`/-?P@MD0#3B)DQ068>1P_RB$LD_FD&$B!BE`N)0Q
MIP]&R`\'Q2A**)*V@#Y.J"J>&&-E,!*1N""THH7N@70@86/3M`%P``%DJ%(,
MM!3\(6@V``8V4!@?!`(8XG4`P`!B4`!@@&9"$8J681E]EV:&80$T`E55A8>%
M<6T84`,XL!-EX4!8=18C82&ZPB)O@P!G"4$I`@%@]5$T4`+MHPE>0!2GN`.8
ML07=(08EN`-O%7KS4D1B`&YZ]0.K-U@H0XME5'N\D8N'I1R[V8O041NZ$8P3
MT`3900#7X0>;Q0?<,7><@0%\8`1\\`<[D$?2&!].9XUL$4D-@"RZ8E-I<!>?
MU%5F@RV2J7T)T!('2`GC`O\;(A(XF<`J=PE]X5@!.U1_NC1(0!,#2*1(Y$96
M]V<%1-!;T)4BQ.<P3G1K2S`)74"`_?*01D*1\G8D``=\S5D'F""!5J`K(]`$
M?.!$>7`95)D0K=`U#V&BJC""+(D'-`"3%P<,4J!Q<F*3PZ-@#@`\,9@-#X8$
M/0F#ZT1/V)!RA<)RZ?!R2JD]2\F433F$V?.4WO,]/C"55+D*#Q51$W5'6>D^
MA5`8-9(!.*0`H=,8/48C7W@#=/!C9$A3W7(N&5`#<U@`569X61..(/`&`5``
MIA<`?Q&(:%8:5_!YG!=Z<?$&MD&HB-F%2C0(%X05<I%)658"LY$!%#`N"X0X
MLP7_+R^A8T/@$E%B,'5J&3P00Q:``<2'`18PBE:E47151!90`BPPFZ!FF[>)
MFR+#F[,:,K9*1KZ9,C+C,:PWG&_P"3$P`@3@!UU@`@PW=)YG`^MC'HZ$'<Q9
M!D`F)1VA%@K2'5!1%N/'(J-SB8>'(0Z41B#P?5M1;<7U(2("?N66";QD0(B!
M`^J*+5(CH#.@`77T!Y!05E`C-><%("+`GQL25X17&.B!!5B@713AH,T)D1(Y
MD?*6",;I1!S"3)@P`PI`!)TP`E7`!REB`B(ZI:<P"Z^3"BI*`E35HBAX<1EG
M8!W7@@OF@GVR#<338/#T<3@H@]2@3BQ')T6:E.]P<TN:_Z0`)81%&'-..F($
M(:4@BPHJ%E$+>D<`L&SN@U'5AXU?"@,?Q6.F14`=81404`,J56=9AE%V:@=)
MD`03`C&?9P&@JF9^IP+4$8AJ$`$\4%6+Z5@T-!<*1"Q4@44"1%=V^$%81!7T
MJ!%?5P,0D`9)<3CCN!6]@H4)(`/:]QCP`1]BIUH-8B&:HU2190'BL2`8T'=9
M@`,,P`1;1ZC!*:NT6HNYVKJ:YAN?%IR#*VK!:C,C`&O800"<-0EBUJSIP0=+
MH@(8(*V8@(\:\3`8T@!H@`;:4@&D!#!V,2_I1W9G$3B)="(5<EK;PDETHUS5
MRB7C`0'!YBWW-P-`\`&>`%$&"O\OTDI\D0,8&Q(%4?`'?7!M%F$8,7`&K#4"
M"NM$#%N1$>H"'BJQ0Z<Y7$&-8Y`K(E`%!#!T@*BT\Q5.'FB:9$(+#:>2^W6R
M+CI@N*,[1T"C+RMA.IJCT%"S[90#RB#"0NIQ19E/!N&S/RBT,LRD17NTWP/!
M4]H*$!$%3[`$83`)1Y41@2-C1(&J@_`!)Z$`F_B9XD8!EX`&-5`"()`<C%>7
M#(``::8"!1`!;,:G:&9$)*1F*L"?$U`^/U``CL54L\$=#6"&SH*94TPL<),U
M8K`%&<`T2;%2TF)L%)`7W;DB/7%+^9$&,[(^SO0%I)2)\`$%UJ@LAM$Z)#0A
MGD$**G#_JJ;)MC9@>CS``&VP`;&H6+:YNK7JNJ0<J[/:&[';JXR5%(ZU"%T`
MO&_4:[(,?86P`WW`!WZ@1W?DC@5S"6G!)4Q7`<O+O,CUO%_0$E68O-4[!-^W
M7/[Q=1-`"/Y9`3+@O?6J`3C@%_B&+5%CCU:0A0"@=/8["5D#9X@&"?%K!/0[
M=(RT(!;J(!7!71L2D0K8L-<$)$Z$`[U$C3"@P-4!":$K7TL;LF-6R5V#"J`B
M<190MVVPP2LK)T?0.R[[)WOR8"6GPC7Z#3?(H^]$*#G(@XEB#MX3PS,LPT1(
M4$?;#@.!PTL;$4NP!`Q)'E_`/FIQ"?`S`9RU`R*`8PH`!0EP_P-I@XDN806'
MYX<+XQ=^80$!8`<J\'>G:@,1T*=^\7!]MP/!5V4(<!2A^`-1]09_6QER40,L
MP$IKN1]V\;5;4`;.XAIP@S@9@2">=Q,Y4B)N@Q;_40B8.@.<V!)$,`:VX@8T
M@``B.$2(@2'401V4,`!BX+9-;0=(A`!ZA;JI.XNBS!PE4\J^V#+!^;JH7!R*
M]8MY#%>@<`C#RATC<,M=DP>D6@(.HAW$V`69^!)3(GG'7!@W$2)HT`/(U1^L
M(@I;,!18D1;@-P3+M4L)\'67);YT4V[%NQ@?D,W1#"_L*ZWFN!>5]01A8`11
ML!T6P4>-QLY.ZP)\,`E$@4GG$A;=T?\%7S.L*4*L\2:A"FC:3^A$[&.Q$_@1
MGP#;(G"2`[V!L%#!)"#0Y[--;(L`%.!?O.`+;D*3R(!@#FZC,&AR@'("]=23
M%(X$%XWA]%1/('T0(@;#/XND)=UA)XW2-OSAZL#2(!MQ/+QN9T`>`$#346)`
MAK$()C`"M'(24+"%)Y*)+@&&?W@O7^RV141Z@"=$=XIF;S`O%(/8B=H6-="=
M-Q)5"$!:&0`'")0?3784*M4`_-$29;`%:0T"*B4BYDG(+_8%BCT4VS*I9O<%
MSXUZ&9`),@`"J&>Q?ST$=MX`%7&*IB@&F#$(GO>G$Z,"=O!C6Q"+D[V+E?V;
MEXW97?39G,W_J[$JG+LGC*``D3ES!CLPW@OR1J5:9HQ``.'[!8OAURG!C>.&
MVU5AGX,TTY^$(8-,;O^X2U90'MP!`.*[KXA$,#W2SEN3H%KCAW]AVG$@;_S)
M2%N@JLS8P]H%$HMY05"#$Y$3SQ-+K-]ESPH("2+P!%VHD2;A$2%!`,DT`"I^
M<"7ZWR3@!ZUSP?I5X`?^7PH>HS)J#!&-8-T@<C"H!"17PL#S#<5#X?&4)\^P
MH^O$LSNX3TFI81\VXD*;TN]PP_W-M*F@8A*UH(9<!D-<K^`&3KI+JE>[XT-0
M!L0')8HQ`&+N5`$0U6O6MJ0WJG*E=;+1U<&Z(*J)`8LZ&X_YB`2Y_P4-8Q30
MHI8V9HZ_8A-&00?\`0?(!9IK@9>;,1)N\U,'B=<W-`-.P"OO`0.V<BLL(.:8
MH6998&.A6\EVNQE5:.AI_:I;5^F4W>@O\^BD#/>I&WM9]!MRWS$H0T;$68P0
M>1U]<#E^D-API3F9I4?9T20(8K%C,`93^*U?H5A@X1_X]S"DQ:W\X1]:22,$
M%#"=A$AJ(0ID`Y'&IQT3@`?P.P!/$`?S^P?;X6-P8!=;^@3#2G70816FY`0R
M\'@-HK_<L<`16I$*"-L#,`E.]!@:((%>\%H80.[=H7D3[]_V56:KP+8U,`0(
MOB8JR.#'<.\N6\)\<CPY>M'`(SPVR*-!$/\$!-^C!\^#RI!A*@WB35KB#A]0
M(9[2F7+N!Z=?J,##/0P(2R)U`!`)APD:90T6)`1\73A$"I0P;C.*&1EE"3,,
M6ULU"#4U;Z1OJ&]B$R,3-B(#&QNB/[,(I@TB6V(-%14@&S\_:C]P:240&E];
M(A0;Q!L@<"`-:8D092*\<`C&<-]IAHF+%A8B)<`U<`P,$``:``,X)1I`5E]E
M&D0P_%!>+#4FK,(P`<,`"#@(=IE@8N"``1-XV,$#@8$<.<)^(-A(I^/&C[)"
MBAQ)LB3)C1L^JES)\J/'E@@ZO@2Y\J2LF#`YROKQ9@*!'5U^CO!#HN@9$2)B
M^!E09L"9+EUB5#'_0:!!F61$9LQ(0"'#@`8,TH"@@P9$!0J($FG(@)1!"7`4
MT&HX!&_`CCX[#$+`MC<#CH<-<B6-T27/CA%(133`T&!`!@8CSIS9<09Q`U(@
MI#FAD"8-`Q%'_XKJ**W"C1L4KH*.''I`4".P8\=N$N-O97G)$DPB4H%!`P)-
M'#,D4+2X\>/(DRLO2IR$B1TFBN[8T>BX#1M;AK1H$2+$`@-%I$@Y0IZ*^?,'
M.'#(D<.!>_=FVIMQ<*)]CA/N[SN8?P))_1QF!.B`?@,B@01[2!R@X((K^""`
M#RL((*&$'51HX8472J#AAAQVZ.&'((8(HH4;8FCBB18*4-UR++:8'!=%_ZWX
MQQ-/+!'%"!D`\$5:BC!"`A]\_#&`%Y10X@81F6SR#@1;!*8..R4,4,--N8R0
MQQMP-$!'9G2,\DT-()S#`AXL0`#',VJD&4T:<7VQS!9IT%'+-R#4P()<APS`
M"P/?3`-'!6SNJ$$)8@2@@ABP-%:")GSY)D\"0$!!03L:C`&#`C#,0$,N&'0J
M$`9[86!"%EG\5,XJ%DB$1PDEZ(&1,*.D-!-*)M5JZT@HY5022UWFY*M*-K74
M*P*R[M03`29T84*R,<0@61=(C="%8R)$1\"URUIE"!%CC*$!!1"4$-@O:/P9
M3EI6K(64/)T%JL%<\&0@;67K)H;4+A;D<90(7?^,,$*GL"@66#L(B8"!9"+X
M1H<L9<'AA!.`4I!0HB@Q@08--`R!2#:5/1$:#J_))AL!5>"``XVXS;5;;R)4
MT80(&6`@1G0NUMQB<\[MP(=T.^!<U'79;><="@9,(1YY1YQWGGKK.:#$@/M!
M_=[3)^`WH'ST6?W>@/45>,"!.22XX`$K-`AAA!.B:**(;+?M]MMJQVWABC;7
MC1P7,)*PHA%+V!C%&3FFY84BVCP7E0@:%)EI`A7)0X@B6Y@%#!RLEO!+,,R,
M(`:6%4P3T@\U\'F0!@R0Z4R:M60&@C40:-P`G,!(4V<U.R:20`,VB,%`!6C0
MH0Z@ALPU@`V&7H&!6W__/32`8JS@D`$$0'A1`5,:S``#%%!HBB\/`03`0PW(
M8%`.*P.,8$'W*DB41040X)%1+5/*5-.M]->:*TR[_JI_2_FO-),L"PN&#7R2
M+*K$`#$XX)=D8D``'`T``U")X`0:L!=(N4$!&DB#7VH`%C^=I79?L`(1LC&!
M'4S@''MQ!P#*<)6_B,!?'EO(<SI%D('`(H&)"<QE,%.!(>PE2K!X#`C*DAD6
MR.!A#_M"S$2`@QH(0Q8@T%@"AA`7MDCF"0<TV0@(8`3@B"PVCI'60TIPB$FX
M@0:?B4$31@`R"T#';G`T#LZF0P(56&!9-/L9=A+`G:$9P`-2X`#2E$:%(S`-
M_T#S<9J`X!,@)?0G/UJKVB+?8Y^P*8@]8U-0V59`-@=12&X9:EN%WD9*4H(R
M;G2+(QSS5HZBN&`)80C#WW`PER%HS`M<T89S_"4"2%$""ESY3"Z<EP\0("`-
M%2`&*:KQEE$T0%QO<`LPAH&Z=92``E\HP033\(QBT``.ZD!+(JS`@AZD`9P-
MR$PO`I6`+^!`##RP0>B,N4YP'8("#5C%0B9`BENL`@&KT)<\*$`$Z3GF"UZX
M7@AFT(8:B&$5!>D4`S*PF$Y1ZWQ9L(`*[!"`,DW@5?#;@/R`5;^2XHI8^TLI
M1X8U4EV=U'^]ZE)*/B>&:T6%``=$RAE^!)4^-*`../^05@R@0Y4)X&!;,_#'
M$`JAJ,Y%K'8)2%<)%((!6#!@'@P80%8)<H8:Q2$*45A"#/[`QJ]4U61^`<T!
M`8,9:1Q1!NR#0%MVUSDT](`%%<C8+2'`P28^D7([\H(7O@`NIW0U!DP,*A]@
MTX0O&N%E&8"*5?,Q"2!0@`4M:P(&$N+&-ZKRLS]ZXQU[5AR@\;$["R`:()&6
MM/.01SWLV5J`#)#(^;3GD0XPD'NJYH`BQ"=J5_M/@@RD(.*2;9-H@]"$!'!*
M49;RN6XCD01.62$!Y!&T<:1;6&,9!1'H"`)0I0`<WA``$OAK!-`#@@*`28,*
MZ!`I./C`F<+R@Q1`HQOG[$W_`BJP`1J4(!A/)$T:OD`#"K1A%`R8DEG@L*4T
M.$%07\AGPKBQ@7(9`YLK%`'W>&"!QF25'>Q8GLQ,T*RI!*``*!X@*6C8@.=I
MP`OG!)<^!.N&!+!@,1-8R$.9.`$+B,$")Y39";5A!SM0<`L%R(A(.4)2DSHY
M)2J%R;!\Q5*93)E8_6.R_$1*4S'0)@9&<-90@938+F#`+SYQ!+),8-2]Z(,(
M1+CG8K1Z562P\"H(6=YYG[`0QN@0`PZM:F(0(S"G_FDO%"B!;PQBN3Y](V)Q
MN0H&=J#5!O2NPA_\PFD89U$%L\F6"?""%>[Q!<CXZS9>\8-C9\/&$2QA!+CI
MQ`6'_Y`+,,=@>8V8SG6Q6S<_0.=4I-6;#5AP6N^`9[7E(>1ZU+.U_2S2MOAY
MFH$,U![W*"%`V+8M>Q`T[6X?=Y,.\H&X)21N4(X(NNB.[BBG2]T.6)?7\(Z!
MC6(Y@C*X:8J'&()O?NRL,Y0`"$#@1P+6P([$'`4`%6`""YR`!M0-XP=@048"
M&*!P!F0$#9V31AI.`X$V;.$-+*A3QLV%S00`(,&K^,I&I.$6;)9AJIUE,V-D
M!M$=Y$$%Y;U6$PA@@RO\('<&^8KR-%&&#X2++@EX,!`2T`,F>$\%5["!.3@+
M40S\RS$XB$@`M@"!!B0Y(U>FU9-/FN7[1?GL,!V6253BD?^1!C`8JB"9K;N0
M*N<PL5IB.*K!SAN56Z^P'G">8M>K*@]-&#Z!$)1,W^(0!B.8D(E9G8?S@&CU
M":ONT4XXS8X88!#.^.+R9WG7!VA]:RF)U"S8'/44=\2OKS3@P3?(?*C3E8"F
M-*L5504J`UVPZB9$0@1/@+5C0GW!V[G&"$L90'6>LVMXWPP+O_:QSK@03Q9X
MH8_?*0(@!=G:UE)AV3GPK=.NG<CW\-:18-OV"<@?!-IB.VSVZ;;8QH;<LHW[
M0<R-6[KWSW]VM[L#S>=\=N,'3Q`%]&8(.Z(QRE`"(C`!=40".\``D\`/7G`#
M_I55Y5-O-+`!U0`"#J=,;L$F&PC_`@P0#-%@3'20:65P8#;0&)<A4N`0/!"`
M`3W'`R?T$.Q@,B$V8GAT/B@6`+GS4'F0!R1@&%(1`XQ!"ARD/`_!1#E"!!#`
M`L<0%TZ@&[>#``5A9A;%%A/0A0QA`D#V0F*0!0$@!AG``C\`4O@S=B:5$S$U
M*SC!=E$&94PF=B^U4E:&$\924WW`0(3A!\C"!_O2A9L@`KI&%020!=Z5#S-@
M!5!@!8/S&<MS!IU2408C!B9D=>>%%(%!9P3#0I]A=0-@.7CU:(`R!()B%^A%
M+@SS08S#0DX!"YFQ<3?0.J$F6#,```U`:3@0%DBT(Z.6+O'@!U40&="B"2'C
M6+3Q%XCQ_Q`9$%7%!P?\8@1_``LSPS,!>"T">!QY\!P_QF:J=AW6QQVI=6SC
MD6S)MA[R\32-A&V45&T'4B#KL7[M%P2U52#;MFWS)S;UUR#D]DGNMF[2U7\$
M:4K_5R$!N(TUPP<U$DM/D!M?($5<P0@J`'5Y,``?$'"9,@1M4`+)\T(00`$(
M`"=P\'`9`0+7=$T;B``5L#"CD!D#,(7XP`(V\#TO.`OFTB@(T%D%H4,K-@&H
M8`,521Q9<`7=4P`!\`8S)VC_T@5YD54[I(2=F#";8'2`,F"',`->H"D!45,6
M<!T-D$"N,#XRTW-?R3U9@`,58`-R0`P:X9+\PX:WHC]6%G9HI_\_(8%E=(B'
M=1A`/,&'#`0)_I*!+[00CK&+T[$#5=`L(E`&:`$#EK(50P`12#&$!;$%5148
ML+`\+]2,Z@0'`R"%?*$)RX-5;C$->%4!MJ,!.``4&0`,&]$#<"!.BK`7#-`O
M`^`PD&A@0_`NH38#93`".P`SEN-@-R`H5C`#']`4?O`WDO4\([!JL;$4"=2,
M.$!\"B`]+V0$?`!K7XB-"KD<Q`$C#8&)=]$'/E8!U[<`Y6@TY]A]26-('@`U
MV5:?VN8>8,,!7^-L06"/4I./`+J/FH1<GI0V^E<B!9F@"%HB`DE="1F>+$(`
M-!)+2Y`C.I)O7P`!$#%:PUD/_<`X;2#_B:#QC#U0`YUADC@9#MC``#8`<>#4
M$1P$*->4H37P@QS$&#@X>5]1$-+28]QS8E%W!3XFE,X!AA9P"F_@3`]A,F;%
M"@Q0)]0`I7_B%\Z#%1IP='/A)M+S`SS0I:="07*U"K"60(5B*#BG`C'Y!FT9
M8'O)$G)I/[]2ES1!97#H/W$Y4S?!=O(30%@F##459EV$FPD!)";`!WD`,QDH
M5%*!`5?Q!0H0*;BD;\Q@5F#Q&(K!`D?%A908&(X6%L?`*N#2`!,PBITS)1L`
M!Q`P8/>0`/+R!$\:#16P&<<I0N\R*&86%C>0=.X2C*RZ4V?V&#/Z!>_P`<M9
M/E'P2L^9#=+9_P1-("1!M2\X``!><$%GM#Q5T)T)`8$THVL0JAPPXF-=:`)<
MP`=B4`,RL!VI133N.4B%9!Y'D`/S*1_8=FWV*"#5Y@#ZN2"(E&WO&(]ADW[&
ME4G)53;+E7\GHB'KIJ`%V0$,RK`(>TKOUJUVTU44R@``L$+Y9IL-V"^,408:
M"0->``%H%#`C0`_&!"C!$!._PR8LU``\4`#J(">ST`#6M**%PCT#E$.7`6AB
MT',F4`4]\Z-(Z6,/51`E)$,&(0)*J(0L%AA.FB598DP@$!=YYF)0^`W85#M>
M0`,UT"GG51#.4SA#5I:H(A'-@``@M61QZ*9O6G92YJ8UD79Z.F4MA?]E8A<3
M5;9E>OD#8O!8?O`'.!5!RX(8K2`"&JH41*AF$Y!"63$#-<8XN<!6$=<YZ_`\
M+B0/8>%Y;@$H>-9UP_FD"_,#=&`-AV`%X,(63S``0S1@7_`PI?LN,Z!-D0`!
ML2<#6!E566$%&3`=3O@\*91";`%!-K($71`:32&=CV4$3!09\)4/U$H!RP-F
MD8`!.;,#X"FQQI&X0,80),`%8K`%:T".1*-]1X..KU5)SM:._KEM5Y,#EY0#
MY,>O^4%M!0*P\_<U"1(A$$(V!9LB!LNP":NP`NRP_@=*$8N]$=J]%"M+C8FQ
M@J=HXF,!584C'^L%DZ(\+U0"7@`,%5`"77+_>9WA!`@A!BG6*4JJ58N"`PTP
M*G=T1SW;I5)W!3+<I8&;46+@<SS1M:20*#37&#7@.S_\DM1`.0PP07PR%@"V
M`>$``.*2`260#^+%`%_P+EFA`$,``OB"<QQV=Q8@I'D!,&0J$:"R!6G[AG4(
M$FU[AVC<IG#+QBXQMWEXI_?3=G4I4R+!$WQ``'X`B(31'$95!Q!Q9EF7F(1A
M9GWAN&[@!A2`1@$A`M-`&H#R:,>`$`@T`)_G.[Y`#XPC5X@E)5MR88:@>G4Q
M+9G,&6R2E<JI`0/PLTR1J@XFK.\`9P`@`F0%?!^3508S5!-P0*ZV!`B#`X"<
MQ[U'`,N[+Z/CN%;,_P(#X(=!513,=[W8BS/E\!Q\P`46L`4W(+Y%LWWL^EKJ
M**_VF1_;IAZ79`9*T)_R&W_^*G_Y*[!FTTGDIC8/:TH"C&[_=\`(S")<T"^P
M%`44A+$K=!6<UP@1A0,:F9TA&F)(40(S4)(L4`(H!29_<KHB8`,1@)1BD+0Z
MI$,"80&D0APG%@$7?04_1K0UU84Y*PJHX$S+Y"F\("7JQ$/L`"XEP`P0T)*G
MEY.*,(J4D@"=47);J<@(4).GDG)BJ4\$<4)_`4]VL+@-D+9PS+9IG)?SDZ=K
M:-5NB(<OT:94W:9T+!-X"G=]T`1[3`+]0C,FL+QY8%1L88Q04043L`D0D/]4
M6K'(;=")GHP&>OTGYH(,1;Q99Q(2X).A(1FJQ0C3UL`9J=>(5A`/TQ*2R`0H
MM3,#1+!TOU$%AIMH67MGA;#,RQL;7^PIR-*%,.3+:^455#$RLF%>S]J,R3"M
M"K!?MQEF"50<SPR!GH4</O-9XUD<6>`<?L`'UWP#W6%L'L#-Y@M;\N%;]2G.
M`T+.^QD@Z#Q)^EAM_SIMQQ6P]K=)R^5N`(DA"[JP"DK`TN6@^5PS@O`$8>`"
M9W:Q%\L)+]>`U.$<`\`MEV+!:(2!CI%!/T""*<NIH[A!5\`#-OQ0/2MU7WD=
MAF*FZ6.4*,8#J_!0C-&%.R8E?3H*I4`*7_'2F8'_`,*@!AO`/H+2=0U``;RS
M.HG`&1"PG*#YQ!D$)NR#B['-`IA)0UUX=P+Q:\[<A:EB!V*@H3SP/KGB.W8Y
M=GKIMG@I$K2"MWJJU7:\MDN>4F'-$T31AS@U`D.U$/WR+[^*`7E\+8FHB&60
M`0G5`E``:NZE5772.P@@#7!``\I0$07Q%A4VFR%I.X2]S`:1N1!#NEZ0/82#
MV87@"^RD`1\`9Q10`X>Q+L[C%TUH,";@0$O@`KQ'S`_D+]!245U%(TCH&,O<
M6+'!1:'>!58TF,\(VQHP/5W0!U6P/,9QV]RJV^%9#BI``G^P`WB`S<7]'8`4
M2(/T6NDQ(&;`W.F<'_J9_Z_RT9]!('ZQQ6WYF"#K(3;$Q4F=Q$EF4Z#C5EW@
M/9`,6L^EE+`-JC8&^Z#G71PW`DMAL%DKA`^<,"@8\*,J0,P>J@`S,`3Y?55'
M]2TI(3`;75%`60X>_;(1H`87'0`)?AT\H`*_'0`35`I)FJ3+E`OY)`:J*PO]
MU.:Y&>!Z<A!3\D0Q@:KM5'M?40)BL3JI*MGP<%40L`F7Q0!H4=G=D@#<,(8_
M:@,&$<%NA!3BTSW>8P<6,"E9(.1R6-5.9H=4/:?[`Z?^\\,P&L=R+"Q3!F7&
M`HA6'NF)!1H0M`,4SQ811!A7=Q4)Q0^$===[,@U#U.9YI3$9.E6C.@T5,,5W
M+O]8Z<*:4)$C)AXQLZ<54(@!5?%#>W%O9?`.%,4*H'$MA-$I9\`0%H`'FU4^
MDVX$T)<P`G,0%?%"FRX9GJY&1D#I7T0`I!Y4O(0#"'5!1+!5K`X+UFO;=(3;
MY`Y:/M-*).`"?<`+Q1T"ZEJ^Y>'-U6:?DV3L"L(!\%$$]:IM`!J@8'._9?-M
MX'9_W2TW'A+`!.SM'#*0X6[>Y<XB#*G>87`&T6IO=Y8`XF*61<&H15)C"7U5
MFZ`,(/"]-=2SY="E`9`$+U"1/%\`:5(``X0!JD`0U0$(%@T,(!N&&V^&"#4B
M##4(A!L("#\_:I`E)64`.&(-$`V&:!5I%140&@FJ#(/_)7"E("`53E\:&@P,
M&1D?MW`50T`S5C,)+&]B$\G)(C@#&,D8.#@B%@$V%CQV/`PX>)65DI,(=.+B
MA^?HZ>J'D^0(X>63Z>7SYN-T^'0UC_?Q]/#Q\KE[-\[0CS=]"/2)08!`EQ$#
M!DP@86+'#A,BZ@SH<J:+Q0G1`)3Q`J/%&"L)AC#`,*!$!1!HT"``44*5S0PB
M&E7PY<1)&B<)K`A-H"'#"`P9$J1Y1>'&EP0SHA(!M4-$1!RZ,I1@$+'!L@%/
M7!@96V7$B#-GEDD[NR0*EC,Y]\$!P0#"C:T#1#QY@I89CAA&7`C&,K:)D88Q
M=(DP:W6(%S<*B*3)6<4(Q(DD_TBH(&'11.:*GC.+)D%@M.G3J$N/MD"""Q<2
M8EB$:!%B`0H#4Z1(.<*;"F\.P',X<&#&C!+CQ8<KSY'C@','18)$+Z[$`7/A
MPZ]G/X"$.1+GX,&O6.%\O(_SZ`4(Z,"^?7L)["7(GT]??OSZ^//KWP__OOT.
M_[DGX("AH6;@@0@F2((1>X411@P#B`2!A!!DX$PR79@P`00*P`"#`AI`D(DT
MNI21``AB;&'#%05$4,`U`<08@`HTJF##!#6\4<D;-32P3P,-8("-&"(TD`]!
M^]!!5S$UN$2))6JH\0,<)4!@)0X3;(&#C[)00`$IM:CRA0@3L$!!&DO)D@8%
MM6BPE?\N'T```@)P`$/$#%`00<$66V#PC!@6L(3#"!98L`,&(F"PPP1FF6"'
M'"QD,,$W/\"3I#_KU),I0/[\4\\[Y\03CD!'=OJ/.$>26BH=!OU@`F(-==%%
M#`Q5-<T$(N"TPQ\--811&1D,`0,4,+B1``2.-+`5"/C4``<%MA"E01D#0&3*
M3F#:)%11BV%5`IIL/N5%5-3FE.BAY@8Y@0E96,#,"&&X4$45)G1AKI\#0%#&
M2A/$L`1$D<P$`AP]H3G-&6?%,`)678P5[U@0\Z$05A'E-(!CD.EI%6!=X-#%
M9JI1=%%FG2EH\F@A9\9::[!5$,++"QA01&X<\':$;\!QP-S_<,4EE]QR'"`A
M=`YF&!!$$-1EMW-V.@_W'1+6?<?=TU*3=\!X6)^W@GKJ#0@@?V"'+79^_O7W
MM==H=R!`@2>W[3:#3T3QH`B;3"@A!2N)L8-9.S``A`*`$W%L!M)@!<$'<-QH
MP^(VO`&2&(OGL8-J8@S@2*AS(@*D&)XPB\\&E<A2`05EW%(##13048G`SJ(B
MX18(B,"L*7#P])05(7I%=PFQ^#)Z`A]\D`$#)>``0`);H4*$&QY",<06@/*@
M`@\W#F`AYQAVP=+U,3:0P1:4_B#.I9AN&BJHFIIJCOGHJ'\//N[3TXZJ2:8*
MJJL2^Y&0K*)-8#VA9UA+1SHR@@F(_Z%";9B!`H*!K`'4``-;00,=T/"*IP0%
M=V40P:$B4KLU?<$*7E`%,382@QWDJPQ6^D(94-@&KC!#!+*:UPBT9Q8,O7`)
M82"+O8I4I!I4(`%XR\NLK`<'?*`A%K*X@1,H8"&$C6!O6!F!$:(0!;%`[#"&
M>:%5(@*!QRQP"`/PF!'\-P*0C:8B.R#915+FMM289F6O$0,#7E8;F=&L-SC3
MV<YZYC,S*,<Z>B3.T8[V,^M<YSI-R\'0HB8TJ86G/%@SCWG6D[:RC>V2F,2/
M@,QFMDJNK8V@-!D7EA"W,/AA!'4`@+X``(`O4,`9@`*)"2I`A`X!+D2$PPH.
MVB"9-^!!#/\L&4#M?+2(!Z;Q"I5C5C^<58C8X0`#<H3#DZ*DA@U0R4I#:(,L
MG!"3@;U$%JA(@"H;@(`&S&4G`_.@!G!'@0;PJ24,(,42O]"F$E@N`P#00#M/
M,:[FW<"=$]">GW!EH2XDPP0(-0&B1&""&&$`%`&@%*IJ4*KUK0-]GV)'_$RE
M#GG``WZHJFA`!D*0]PED'Y<Z$NA,P`<2\(%7LGH5`?:V&)#H8E8Q\(-"R50E
M&GAA@408`@3:4*1X=K,"):#G!37`B1$THA2C@X!CO#`N-V$@!AR!2.&:D1,,
M.?4)_^J+57*"@0;@H`XXP>$?8F"5(FZ@!K&8A0Q&]TP($8(</5#_$AQD<(,A
MB',C3QB!PJ)(Q8==L2%&>!=$\M+%&4`F`<QH6#1$H)G3H/$S.Y!8*-VXFM:X
M1@PTH&/,BN`!W?3F-TWC61%Z=ISE:*<X@R2D(0V9,T7J49'=P2T2./!(YWPG
MDI$\#R4KZ9[_9/*X_!F0<8G;GD]N]KFB:8AF_`#6,/RA"_A<I2K*4((&`,H$
M,3#!`!0X!C>,09]<"2,.2O`!"ARC2`VXU@",](9C)*-Q1I+$.>`0SU.4P;O?
MHH24PD$3H0IU8-P<Q4XHF(8PJ7*^9OJFFBA`E!!6`'(\>,,`*)`)+W%X*PU@
M1BK+4($:L``"1"`"%*)2C"T<U`06L`%+_ZAQ!0MH:%W38U<`"B"&##0@HM\H
MAT`\Q;XBRV^C'E5$DN<WD"&'],GC$#+]4.H.?;SC!V)H*0'^8`2%.74Q9CE*
M-/["ASY(S"&Y@D`:$K!`8[40`PBP7%P]J%2A9-!/@Z"`E2`@+56\TEQG\0A-
M,6#0*NS@(>8R%P>!U*,,U&$K>G$J#BH@07P,3`9.D$$:*H2!*D1$=4RHU"GZ
M*E0(`/8L"S-*#*IH12,TH0D$&,L(<`(7QH[+#6[00`,V4I:\'`@T:F0;=-F8
M&=>0``%MH$T=26O:FQVAMJI=;<_^J!PS%,%HL4V.=G+`6YUUVSN-'!IO#Z`S
MJ@$WN#X8+G._EO])2R+W/L6=S[J;ZUSHVCLS?-@+%3LFDN,])7<V"("&,*(!
M("RO!3>@`0M"G!/C06`1%`!!I4#0(P9(LU*[YEPD*D%-!)"B2AF4(PUJ`#HT
ML``FSTJ`!6/1!HK"Q)MLLL6^:K`%9;G"%PS8-"N+@H'%(6.A1PFQNHB$%0!X
M`0(4ML6=E`H")F2!!]2S`##S@KV%/?,*,>)!`.Q@@>'90`[?"`>5RU=D]I4/
MR9WB5$A%*JKY2?FDJKJ')'Y@`S&0IC*];L89+'(1\1K%B04D`%(`D`$-M#D!
M-*!!D,)8NUG0\]],9<`9:#78K&1EOG[*R0B6H-,\>`+S0+**-*JUV-K_61H$
M-B<%5QD_S$M7H`U#&,*T&F!"$82=8!=TI3TWOY<GA%$$D[_B6&(]%NP"?ZSX
MU`"NO<""E?1A"59!$&@*5;+3$#M!A>J5:%YC@2T,@3:VP4VS;0:<:B/-VGPT
M)&QO<WY"^O&0S'$.<WB;6_KG5K?S[RTDT\TUM;&G:YO4'\G%;LAU2<45'_/V
M?_5V;\-V!G$3!1#"2B9B$Z"`#3:F`A-0!D#P-RW@!"RP<!C0%YNP#TX`!U%2
M*1LP""RP!<_R<!M2`980=BE8`AS63C8P""BW$WI%83:Q@JSP.3ZT)M("`5M0
M`"^R!<2S%<2C"SC`"@;4+SN0!U?0/W[R#+A2_W1`,`2C\P6.,16UP`(TIPS0
MD!<&M"@1,0$VE@S5D`7K]75A-PEC!U)E9S[R@'9(IG9,!E(C)61YJ`_UHRKY
M,'=8UA"5X1!',0%\<"B$YC\^9A%^8"]=X"[<509$``0PX`5]Y0Q6D7,T:$$K
M!"Q@9A9GD'G3X%2*`A*`9A9EU15`DH3%`T,+8W%(Y#NH@R:FABNL0''O``*:
MQF>Q!T:X$@ITD@9.\4$MH'+`PGM[X1<P=$6"$1BN%@-Z!Q',D$]`X`8S0`,5
MT``$X`(080*;@1IY@$;4-S('HGT(DGW2)1KMP@;?9QLH,#/C]QLYX`'((1WH
M]S/"81Q!@`+N=VWOI_\=XZ9'X*%'00-_C<0=^E<>7-.0:@.`:%.`$KD?RI6`
M[2%L#!A*!$!*5!2!JF037V!/T&1C%I"!&Z@`'?B!7C&*V/4!Y%0"3K`!<R`E
ME5`#EN,ZT`,!%0`ZD@`3=/`L7V`E(G`C+(`/<W%$3$&!(("$LNA-0LA4)8``
MBW,,"Y5YF`<Y-990>?`&4H<,NQ818)D!E*B3%"9[0)0`1%`"-8"&%O!T/(`1
M(B`&*F!C#Z$]OV<"V6`]8E``;PB'%*4/Y*!1<]@^=FB'>,ADII(J('525-8L
M*/67K/(D8D``KP9K:*$:8Z9!N:)!.3539((4=0$9,#`#-]`&W@47AO.)%9+_
M%Z$(5E'`!PK5#`QG,:S)&,+4`*CW@<2#"UJ1$[IP+7,!!RQP"A8T`+%9"*)0
M`3<`%9CH!!`P*$7RDWXU!!3@&"T00H2W>6B!FCC1!7[@C-#8!'XPC7F!`Z53
M2V[0!BP@`I6Q,!.P&2MC6191CAB9&;UR?:MA`=IG;%F`!RR0`"T`C\RV&S9S
M!,(Q!<5Q;44@;=1&';%U-`MJ!MQV2..6?^0&?X9T'8T4-`NY`OS7D!"Y;F%#
M@!-I'_1AD>X!D?69D2:C&@00`ZX9!0U0-Q84DGF!`?62$Q!@<"B9<#3`FHLQ
M`!H@`F\P.B!P@N"09WJF(L+DAP.C)(ZG0@S`.3YR_P@_N29\I@%?P`!,\`:[
MA@M@F@D54@*?.5"`$G`W\B<Q9B@/459%@@'[@`%P<!7-D`&HH*5[=B8_1`1<
M>@V%@E",J$%B"!*_9P%V8`?>,P%\"0[^`)CH@U%E5YB2ZCYL1U*`2"J/Z9B9
M6A"@,XB5Z1!GT%(D`"'.$"AU,"AA9BA.9:=E()HS(%2L\&5;9#%DL@/;&68(
M`R3J12)V.@T8\"^64SN]4P$TT&''<A;KA4Z2$%\-IG()@"4LP2Q)Y!0),"XJ
M5Q1'(4RCXV'5:@6"DYU+L)W,@!,C$`7@61A]$$8(DQ<#<)Z0`0$L,`"`\00>
M0R.D82#`QAGFN%GJ6!K&9O\#>,``7E`;MS&@!<H!#N`!"%HT1J./Q&%MT3%(
M?/1^]\=M`_EMBH0=&>H=&MI;60.B_9>`(UJB%(FB:+.B+)H@(?,'KOD'&)!*
M4D6!\Y4HN,(,E>@A7B!4%A(1$`$``^"EKH"DE<(4>M8`/,""AJ`/*/<3]`0*
M#]2D$_=Q^00`#+`%`<`#G-,C\"5TSU`H^BE=/$!W;]`G>,:USS`(/@)7O7-/
MQ'.G2W%->I9BH-`GR7`11'(]A9('>4!]T:,"=C`!&8`!B[HZ?2@J@ZED[G-1
MD[I1))6'?^B'CQFY%!5E!O$&KV(87886?H)H!81*6-('>S,"%0%!&<!+S`,%
M.?O_3-JS`S^'9V"F>9JW6$#RE;FP0JMI%5J1!B[1>+^C`5[P!1B`!2U!<DE+
MG%JJ9X."*.94`KY[`]2Z3D+!`""!`U#U$\OINRGFL[MRJP.@$>5ZKE;$#!@@
MJWRF0`HP!+O6,/0Z`I55&M>7K]7W7.BH,EO0!@,;?E-06C7S&U*PL&80!`UK
M'-7VOP:`;>[G1[156\!!;N16;O*G-/`W?XX4'I,$LB$;;^Y&LN]FL@.R@"E[
M,NMH!$O0%E%P!MGU>`E`+0O%*(/P`1MXB=ED3Q&!*`!0`CP2M#3Y`SX4+J!@
M`S-Q#J,`+E_`"9`S=7#0(Y8C#9D@`@@`.0&`#2\BA7K+_SF`\L0:(BNC&+ES
M:CD,0+,LX0KFM!.U0SS<527Y="::D`I:6@L,()50!W57`)IB4&,[-`%:%P":
MP77=!62$6TQL=[B(>YB0BKB+JSYZZ+A_*+F*+'>@8P.7>Q@*8SV#(BOK@A2!
MNW<FT"AYD"L)U"''2`%8$KI6.;.XVPQG,;["A$05$$^HHR]E`)U(1SLQ40I`
M,0-$X`4B(+P,P"H41`JELTZJ8!2X,@`54`MG<KU"00SL:4)J-@ML4F$IED&Q
M%JZCV*Y&8:Z"\8R!(18+LQCFDA1>-`3KV04NL`2^9D:_9A'!-FSKF!DVX'WW
M>QNE1:"\T;\12L#GYT<]`\`%7/_`^8S`%NIM#>P<XW8`V+$T&1IN'8H>Z?&0
MZJ9<QB5O(TJBF`1O'"P@'OS!"J)](HQ#4;`#^%0&*&QJ;HJ*0OHWEYAP+I0H
M,_IP30*#-#D3SLQAY`17-0`.LD"#I..S-F"$R&0506*F;]#3=9<%52`&.S8C
MR$3%(.$G1P$7%D=1&Z!7C<<50)()IE`*M<,49:P)1*!/OLQG7E(,3,#4RV`A
M=;LP&X%U^NFW-K`E-B!1?MD.AGNXZQ,_YV.82';(4P:9FMJ84OTYC?S(!'!*
M8^49`X===<`8$R!XHBL"5N)8PY*S$.#-B58"&;`3NU8E]D2;OE`*:U(*-+!*
M..`'H"G_U1N`!K]H$\\*?0X$E&K&9]5JRQ#P1")`@Q#@$T[@5U8P!D3P`0`@
M`C/5KIVH5)^($X!!17QQ!M;<!524S59D11U#>DY5$U[P-\4`0^6<%WD0C@ER
M6?J*LBTJ71;8``E0&Z,US^0G!0NZH/P\L?P<6P&<?HADD-Q1H1GK6JZ%D.#A
M2.?VH2%*7!H\T1=-7.*MT:>AG\4VPAV)`],R!%P(JU[1M;@"`"]L!11``UT,
MU)]0!H_@$E'2DY_-)@,02R%&<LZRRKI@3Q,0`&"0U($R`3:0!#(2`&R=##4D
M!L>0M2C5%1/@>;<]%[$`)%M=`78J`C5`/"_!*I6`!ILF(K5+_P1?X",58"*\
M@#NLX!7K4B@U"R@4,5#H(B10%Q%QW9>+X'9I=SY&5LAH=\AT/5)]_9>*[-?A
M8!`V,#F&4=@S%%XD$$PSA!4XBB@[$"BKB@,)8(F76*P-H%!`L@6HEW,[T7Q/
MSJXY!PM*4@I)5Q0Q@`%M($U3#0)IX%=H:1,X4,U,<0-H(BXSX`786A5B>28>
M%!2^301E@`%^L$76DPEX\::T,L*D%*Z2W##8#-W2W0Q[4=U$`1D:4`&+X0)1
M8!5\X-V<)3*O0NT)CI_6)QH6\`8L<+^VP6S[^VP>L*`R`\#M5QS^;.[_^\\!
M.7_>5M`&36VSM1P5RZ%3<S57`UP^,/])%CG@FF31!9XV&8W@".*OHX1#+O`'
M$2+2QV(EK*"FP(1BM42:&CZKD*T!<V)Q(0Y7KU`EE<TBR*2\L]OH.1(C-6*$
M3PPYC-.538UG_(`(/3*L<.`C&(`+OH-..`=R);YA150).RA.;W(X-5P7)J(!
M4:%/+(`'4)<%[5*S@XY&.&X]&J0"`<`,;\#'E@*9ZM,^D3JI;IZ8;KZ8??C7
M%#7GF\JIE3"9>=X'@B4:8Z8HW4LF"O5$;-J$;#;9JQR7RILDWO393^X5P<HJ
MA@`"%+#;05DAVF-Q5TJ=-.!7PD`41E'S>BI/XN(&7YT!72!XK^XE%J0*TZ*)
M@_*(01?4Z\+_!S#JZV"%FJ4^157D(-E<?-)P[+=-%!.?!B$F&!`1`Z_1HI<U
M4_NZT:9!WMM>`?$L,^K-&_4X!==V-`T[2/[\O_XHL=,VH=QVH?'WP`BLWX8T
M-(H4'E5C-1ZZ[Y'TT)7D[__N'P$O\`=.\"A3;%&`\'Q`-ZV4$@X_PXH8#1HP
M\4.@C6`)"`,,91IP;P-P&QLU#7!P##@X(F(!E0$V$PU;-C\V-CPV5Y5-!"J5
M!39B8F^LK!BO$V*,((J+CG`@#2P,#`T8`R45<'2*/W0,)1!E90R,)2!T(&D)
M"10E7Q\9R"4:`+T5)0D:,U9$$#5B&%VPOP,8._`F\CL8(A@FIA@X_V\!/_X;
M"`+6H$,PH,&#"&HI7,BP%L*'$`M"?"@Q(!V#=`9:),BQAL>!!#]Z#"F28[$?
M8@@T,4*`SYDN?`@0B#%"1)<)`P!(&K&CRX@)?F+@R*`!"`PH7FX,88"A`:*/
M=-"PF`IA2`((#<0(0K.!#IPTR:A]H0`APT\6%2HX^>)$[9<$,V9X28!C708(
MPF2LI3;#C0(-`V+X$1'I+@0(;7`P&##@)^$1+HRPC.'+YRL,9\XLB;*D\QG"
M.)Y$&1VF=.G11J(,"/VD)@Y"1!00H=%`1.0S`[IP(4&`A._?P&7R-@&O=W$2
M)GK_%NY;IO+E,BW80$`C1`@4*`P4\2!%RO^1(QQR."AB('L0`]J#G$>OGKWZ
M(F;BFW&0HSZ'`P?"T\<OGG[]^/[5)Z!X.2"!'Q(YW+<"?OBMX(,/*T2X@@`=
M5&CAA1A6*(&&$G3HX8<@;OAA!R.2:.&&&::HXHH5"F`"<##&*..,-,K('!=_
M+!%&9"-``,`77Y21P!<EE."."1/$,D!1"KB1@!.\+#9`!H0P\(8(N.0B0@,@
M7&9!)2J84DDJG'CBB04\J)`%/BJHPLH&K;#"B"]B-,!`EG"DI>=7$)2`@1@,
M4,#5#VKX0T<%%"S#S!8B/.,5!=6DD08V$$"2P0<)P%%#!1`00<088Q`QA)9B
M6("F!2*X8X%O2$[_D(=O:9(0P`09U%"`'/\8!-)%`3F44$(-!;O01,06:RQ%
MO"+`44=0D232LR/5$)`_*9'"DD\UB3!"/2-T(4(9[C1&7+==K%9&;##,,$0;
M+,@R0`70<`1"!314-00$(DP@`@,@@,"-!A0,X8475HA3Q@AUE@%!&FE-FH`5
M,X2:@`A&T!KI6E]H,`X10)1A4ZK;BI"J/1C$8L$.(T@211B2$5"NMMM.*<D9
MG#W1V0BKC1"%"SR;=IIDJSW1FKGCP.`&!;6QC%L7S=7X'`'QJ$`"/%2;L&K3
MS3$''0'2]4!!"`M@5\04W7'P77A3E(>=>^NY9X!ZZLGGP-P)<G!??G7K_U>W
M>``62&!_=-?G'X,'1.B#`!).2"&+*8KH>(B01_YXAXPSOGB*`F3^8HV<=\ZY
M<[YQ882./&;PXQ!E`'!5+['$8D,#&B@@NQ=0\B+(,@"44*=`"(A1IG1@2FU*
M`9>LPHKOJO!`PJFOO.'/#XMX!`(<1M:PRRT@:&0G`SZ6D56@=/PS?9Y?S*!Q
M"4X%DZ<P7U&0<:7):&S-$$-H0`3$HK*050$\F"H&8?G:@;YP,(`)B"(`PC,!
M5@*`*W_H"B0'`0BP&#)!8?GJ6!C,H$4.LBQFC<2#T(**1C:`$A-8RP@^64UN
MB+,#$V```C@0@[ZZ0``3^,$((J!2;!2@KC8P9?\+#*@`&C8"`DA1XU[V2-7T
M($6!2<W%"A`#P"1$H($RI,4)>X$BQS0P@HKAX#!@A$`=RI*!#/@"9"Q!4@/(
MU84JX*$!!+39$HQ0A2XTHC8-L!,`,D#`;HT@,SC#@<YZMJ/21$8R.;09S@8`
M`0UX`08*&$)MHF"$&&BK-\^)42:'TT+?"+!J-M):U@C@B08,`6QBXXYWSN8`
MM:VM"$$H`GG>%@0SP$T)M92;?^R6(+P=X&\)XMM\"H0$!\AGF`*BCX$.L$P'
M1:A!A\N<-!=WN<:A2'+8+%'EMEFY:6[.<^`,)V]NY`(=A2$*9RC!CY1QE4IA
MX$LNE"$$@$!/*]P@2KS_J"(`(%"/&M@@``6(0"6N<$`$^D8%/'`3*WX0$%8D
M217I$$%"HI*+6SRB+'E,PS!(^#P$(*H,%,C`)!J0!C2@88D,FY3&-%`"CR`C
MB-.K0!H@\#Y+G>L9#:A``NYG!2=5H`86@$4LVC$!XM1#!#NP@`QW0`(56"`#
M`[!!`QEJD5T]I"&]LB`%-3B19!VK(LI:5K0^&)*,A#!:%R&A&$Q(QTJ.X*TP
MF0!<7^@Q)+TU*#3!`3=DYP8O+$5:^X)&5]!0@?HYLAN22!5:9"JI+Q3L840`
M3$V6P3`GN(\O0&#I&9X@LJ8P9@"=/<,$!`@R2K)$7R+K%@98<!B;="$&^NK%
M_T5J``*T-+$$4'WK'P,I`DKR[+<\DXP11F"6..`LAPGP`A04D(`U+L$%?G@K
M)CNG-7B8*AXL_.;68.2<5##`"Z@T`-E6^9T<3`$%87ME+,F3R_/D4I>[Y*7=
MPI,#9`K3OL:4VX#JLTP&28B9#5*<`![T(`I54YHG.M$UL<DARG'SP2R:IHO$
M26'J/H<+7#"G"V+`@!\%Z5X4Z`4E@JJ*$G`,"%!(0!O*6*2KI&X=#>`!#P(`
MAE2\(117X`%!"8J3!CC/'V^HP8W?,(%7,((%_7)$]KR2%A]!8`L-:`,<"%4H
MLU;@+641P1M^$8TT\"(MEZ4&#3SR17C%U&$?\$8)R/_R@334M@U>(`(48``#
M+]!@"S690"7Z)[()J`!JZSC#+R2!)A4H!DT=30A9KZK51BN"J\CB%4>,)1%)
MFW4@S7+6KIX5UH3\X`ULK0(!HAL#Y^00!W\J`;A$8-08N'H)@H@=G;W0AI^^
MCC8$00,<G$"-AUE!`S@X`Q8&P+`\6?8M0]JI%$O6@+M<`]EBJ91N14V`*L3`
M9IS9610>,YK.Q*`I<*B-H(?`%@:(X"4-*(&;0P("'9P`BQ0(\66*K,+GNF!'
MP'7!SLX@2.,VA@')A4)?[?'</W2!AIX3)7*29#6J?9*[X]P-="PP@3;,`&SB
M5>5WP.,!5ZX-/=J!3WS*4\O_N,TM<,',&]\29$R1*S._]A4<?Y'0WYH;2$+1
M=%"!,U1-$W&HP2&ZD(>$CB((7RAS%KJ<A*FIW0H[/3C3]<W*=C28,GP!`/1;
M!E3?:0$3](\!L3'*#!*@=2I1"0`EPT"0,;"%MOOS"JDHE8Y_40/H*6).TJK!
M`'P,1'AQ5`UJ.%0:EO'D+62@`L":Q;PRU@T&](Y+7Q&&3)$M/U\PL@2.8$`:
M+IMF7N`64V2AAA?&`,D9.(%1&.A?D@;XCIL<G-Z28-.^Q,"#YTF0K%ZM8+"R
M:D&NYK[38?T]0@J2K`Y>>E?'/[Y'$+#\\(%Z):(VP0AB\)N7)?6+M1G!BYP3
M@]7(_[K.%&"7WOD5E3P9T=?9P,P`*"",-%C6U]0`]@1B(,`I*>,P&2B!N4$[
M@B<8@11]$!2ZM0XXPT<CX`=1$`/>@@AH0%N,0`%.`!8BE0G!``)HD!'M)@,W
M`"1?P$^OT`6X04!GD&^&I&^5)`E+4!,X4P;*U5?NT`62L01GP`<6%B.MPD))
M<A-%A37"(7'C9`%O-`10@''C93;@(05I@QU*6![H(7*VA!UP`R`GER!(P$O!
MY`%TTW+PI5_V@2#TP0$TMTS]13@,$DT%AG0MTG,8XF`D`CD9XH81AH:8<W02
MU@%RZ`--]W1ZN$E&8!I_,`)U("2]MD]'PC5P-P`SH`"0!/\#5<1'0U%&`#``
M0>81.846FN(\;X``L<`#3:$LO8(`\X((R3``;P0!4P9X_^`5AT$6WU,!&S`O
MPN`5:Z$!"0``;:`),F51;B$.8\<""&`#>=!L^;=F8E0'?)0J0_$!&B`,W&,_
M'$,$3E`;2F4/JI`J7&<JID(`$]`%.]`$3:`"^D`)ML<L%2%!NK=[YPAIP%<L
M%>%5E59\QJ=\'_0LFB8M'&4#*R$9)I`9`I0D<_5%[Z`M$_`22^`MW!,QX$<#
MON@4#1`-:G$#O0877B!232%3\>8^]D.+&@`!C=%_0O-6(@,S!Z=;Y/($@L:0
MFJ!W15(")/,+=W*!)Z4+DF)94B3_5^3'46BP>5\P!-8@2$M@DI\1"5TD7/DF
M&=TW`)O5?]^B`6/@!C/``'@6@T]`?4X#.LLA0/(0"^E0,J.E7<K!!7G@'*:R
M`2R0`.%5A';C`;)4'@L0-FR)`N\U2_`!2TIP<G03AH(#<PZ`2^]U3/,QA0-R
MEV%(<V18.!*R='7(.&P8="K"AI:S<RV"(6BX=&G(='IXF<L!(WPP=2Y`7#]R
M1&4`5:5R,KX#.T#@%T1`)*"5*JOA#6]@)R34+R#`"R!`*`A@#T$U`!>X`8!7
M*+.Y>94B!EM@BAPU/?UR94/B,:^3".,S/9M'#0"P*%NP?G>2)V#Q%AJ0#?ZD
M5`/T69_E_PLX44:T"&8`\`&110T4P`(38`.O$`#]4Q-=X#]-<0]B(CSZ@`']
MD(H7L2P&88Z.!A!;Y7O[&8]=96GP&(]GE:"<QE'^8`.\(5PI)`D@F!G>4@<,
M,%KK,']5('T,D`$(F0`T0!L(H`\B$%-.`)'QUS$!1`_<`R0`H#%]8FX8T'^=
MX0)YD`<HHRVO4!.,`3.?L24@@``]<)Q!5`'>J1@L8%&+516--``NU`RV!P=6
M,1<A!EJ;E1F@,0)_0)3`900N\`>,D92<50=P(7!0.0)5D!I3^3E1]QLLU(^M
M4S)8R5UYL!LRD073H5,8MQU28#8<@(3HH81*V);F$1]R*7)*D/^7_N&%<R,?
M2J`$MM27QV27@+FH_`5@9!@AB)F8BKE@(&)T/,>I/;>I22>'$X:9EZD<JLJ9
M_*8Z"9!UH@E0,F0#-9``],1<%0">9Q`RN?.:YP!X=[<O#<`(!&0!#0`!M8F*
MT$,'+$`6^H<'>'`GRI)3PR`-CD5V#%`G%6`2\W)LW5`K,G8E1;(-8;1UZL"-
M.P!1Z>`+7)DRII.:;\$]H)=<[9()";4MQY6#`(0/5V`!O=$F9I2?AC);TI(L
M_NEHYVB.Q#)I&!&/PL=\F69\$*N@%/L1"/`\A=()*I"/,[%(!X@%?N`'VI@!
M=9`OHC8<EC04'%-G]P*5@]8PEP4DY^/_1R#)FJ`%6D75$UWPDYXQHZM9&Y%`
M0.>*&WLG/6G!"W#``D*I#Y(@6!L`!R%Z+Z:#`T7F>-!#6`$39V-7%HU!H04H
M`C>4IK]U&I%!&)JA6QE0I@K0!G(5`VI*E30B'*KJ&R<##T6FE:L7#UE#`A@V
M3G@*`C<`7@N@'=UQ-DA('DN(7H1*2V8@2X;ZEX`3(,;4J'X9-W[YEY0:("F7
M`PQ"F,QT<P1VAM-$A];DJ8X#JI%)NI*I=`A6F8=S='F(JN(TM[Q!.AN&`ZY*
M#<N`:F@B5S;P!A`@.[@*`ELP?V=`#V7TFH>G!A?P/*^I>53"`)Q8!K1@*!8X
M+S2E?Q/``WFT_PC"D&0.TX$LX`RX0%L-XR.-1PF@4`^V(PB@12<R5&JF8@-*
MA0!.L9HB,Q3VTT1X86(`,Q=`A9OV8`,[(#),=3+;@B0B0T-.Q9("2U40R[`1
MA+!8Q8Y@%7P22Q%DM6@<5(\*FE8G\3PB_`/*0P`LX0<OT04V-#(S6D8J>'"N
MIH",X06RTT/MDIL90!8OND_YQW]"HX`Q8`(1E4<DHX(D*3)YE$>.H!A2(C*K
M(7GKDQ;)X",9<+P$=+'+>F49,P2J1I$B`!!NH13PUX$O^!(%&!A<>F_G)!DI
M@P$I^%9IZP5`H`#\U"TQ6&I5R1S,@8.P8"I)0C5[V[<$D`4\\`85X/\%+4"$
M9<-QLB2HBNN6ZW6YF"N%_2')C7NYE#N%4V@@]"4@-M=,B2.ZT52J:MB&J&O*
MW329=3BZI&RJFB.[>\B#*\,S6"`"`)"[T6E&^$`/TE$"<ZP`=E8!YI8M7?!%
MS(<#:;`!*9"Q!>!110)5F/`,BN`5T"`-[H-1Z]J?\])86.9/-;`O4N)Y9)%E
M.?C'L4!D[!H+."IHKV`/'\$HC!$)C$$40&`-+O8%[E<--5`/$25CJ)6S<'IJ
M&%`*/,`8M3>.$7S!_RDL%GR@&]%!D296FQ:QRE>.(3S"&%TH5_"@1H#"3$4"
M?)!#N6'+&5!D,-P'?3`3D5`48^!7/K0%$17_M)'`"_:P`S'0&3M22;`%&JLA
MT^=FQHR1Q(X@S&#A(ZB60^QC4C%%`5541?FR=Q/5/HXU=AGC,?7@")L'@6\!
M104#+J\UDC)S!FF<TY)1S"+PQL3U!31L#FL$@Z-#0SZH25;)&\#1CW)JMZ-%
MNQAVIQ:P!4*8R"@P-HLL!;.$'6UYV.81R7(CA5+8J([+7G'CA/,QR9I\E\Q$
M7S0'A@=2((:Y(`Z"F*1\RJ)MA](439LZ8*Z,8$L7N["<<%A#`OI&RR-@=3L9
M)&6`/O]$`C=A`P.P0^I2`O(<"?50!@&<!G2@K,:`*"$U`-)1HH-U@5X!G+?M
M"TY1=PSEG!!0BZ[)_S\4QYI._+Y_TG7)00([=@5#G,1(_`J",*R8-M3F1AB=
M4@T48)WA,';FI@H%A%J,@:Y6\RHY.@&^$0"IP@FV)Q!6-<&\M]`2=,$1P>`%
MBGP>#.$*@=$4/L*]V9MR$``DT`<L@1S<^!N[:D"TXC$M9`)\$+)U1$!E``2A
M,A?XLHVNAM?U4#*9T1JZU120)\R:=QAUL!.$H7^2PC["C)$?0+4Y5+W^@`8T
M8!7R/8%`"@=O,0191`U6X#TF(`)-)%/'YFOF0^)1\`0'ET-U,)3`1=:C@X(V
M_AI%408XX`MB74XP$=<0)]?-\4GT,`$GPXVK(@]:XS^'G,AA(TN%RP$=-_^H
M"P`VZ?4VL@0?C:J%NC1RZ-&X["')E2US_=&%S$1,GHNIB?/9J'U@<CC:VW3:
MIFU@ITU-I\[:K?TYKQW;+H`%L_V9J!.:#?`)084!KR/'LE$-P$U`C2$"6&$#
M6_`,ROJ*P%DIZ[D%(*$(L*B3D7AC>C<``W%F9,$,M.>>:!)WI2)#KM.O)N!J
M()BNJU<;\0Q:?X(!BR&;NJA_K0D$"<`^U]!(`\,`GR"--2$&-;$#[DD"Z1"?
M&_T;`0!'%E``!:XL!]Z?C]9["?YHP"?!Z_CP#8Y[)%$0$U[A%B_"O4DH_J`&
MQ,,#,^&VR/%'W`*2]Y`3/OY:KC88C4)/J4D#;9[_'*/6$]GBG8TA1_0VK$EF
MD=;0XTZL;DT$![K&,$R=G1G0%"WU#X0%D1I0,(=10#4!!Q0P%UBTU5P-`7B.
MY3/I/HX%,6/P`1Z3!UC0&=YB.A23;\$5@P3TDW\T`*E#!$9R;ET$YWP@Y\$1
M2L#1*JLW#_/02<UA*M1Q<8O+IW9S7H9]Z*@4^(Z[E\84Z8XK'[)DN;;TN'_9
MV('C'YK+(.(AAF,88#@WRFFHNBRB342G(IGSNJ3:(J8=VFD((:B^`JJ^ZC,R
MU[Z1&L%U!J;#@6"4WT4V`L(>.[+!DS3@G?7`D;1*`2"@K-%]S4PA"]`@/N"0
M#-$98Y50)]^9Q"7S3PBD_P(F<`7$XYZIH)5;.5=;\BR-P!A2XA3:<+3%9I$B
M]1J><B^'\9EO40&O.0`R-`E:X0[P4"Z2``AB`2HD)#P!$SAB!3^-/W0("#4U
M=)"1EP@;FIN;F!N8H*&8E9:1I:)TDY2DF9R.K["QL&JO<G(%`0$\/#:]%C%=
M77T$629G(SAU(C%\$R)=`P`B$\%^!"0$1B,#$$0S"4,4$`,872,B(@,X&0QP
M#0,,&3@B9SL8`P-P<!45:?[^)2#@&&&"&QPZ&WYL@#,$`H4O$`2*P""BQD(G
M0YPX^6*EHP8-#";<JW#CB\:2"6:,Z0AA`@$,$2F(*P,`@(8/1,H,6!(ES)*?
MR/]T_C'BHJC1HD:BX`-Z#H=3=`,FC#"2],D.+EP*%;JVE8!7KUVU%MHQ@6R7
M'19(F"A+UD0A"S;PL!C2(D0(%`:*>/`@A4..(B@6"!Z\`(5A`XB+F''@P$P1
MQ&;,(`[B6'%DRY$;+];,.$>.SIX_@^;``0D2OPYR'%C-NO6!%;!]^!!`N[:`
M#KASY[ZM6[>$W[US2^A-NX-MW`)DW[;-O+AQY\97O)Y=V\<*MV*S:]_.O7OV
MK]][NC`2HP2`+^@CRINX8\0(&S42*%!`Y`L-!@/2D1,!@0'\$B"HH<8&=(``
M1QI.R#2`!6)L,4`#FM0`!P,E9`"!3F_DDHL-&#10PQ7_N%PA8@"X8!/##F*D
MJ***%(DPP@06W#,`"#706$,#^E1`(0X=EH`#`Q4<U`@()5#`P#80:`!$`FDT
M`$*25GCAQ1`/3L##"!A8H-\(.YA@PC8BY&&!"5V2H$(B&`3PRB63D')**Y_`
MZ4DGHICBIINHC'(GG)K($HN`@`8JBX:Y[,(+'B)AH*B+75311!-&!!/#.5WP
M$8.B0455115^_/%'%$MLD\$,I'H1$0,8`-/`JBS@4$*0#510(0[YZ9<&!6GH
MDT8_7Y210`9<#E""19J@4<$7'VD`41L3B8#C0S<X<4,"'5GQ44@3,$"!1AI]
MD8`&WEA!1`83.%,A30F4H2X$_R4P\$P73\2QQ!/S#I"!"'P0=9115*4#U#&U
MMKC#&51%\40,6(G%%39?-;P=`3M$'+%;9%E`U@[7F,`@`U[855A>?/4EA0&#
MV16"8(8=IAACD1F`5Q!!3%8$S)%MYEC-+&\FFF>H,99:#J7Y9=II2+!FVFJP
MO1:;<LFM,)MQU#$7W-14!\<;<K7!QIMUU<W&='--K["<;3Y@Y]W9:'L'GL(Q
M1%'4#@R<EQZ[[K:XR!L0`*$`$%_L"M5^993P7X"/H`%"/^(,6T`!-DRP:@/H
MH+-JEKBH8/F&8EC`@XA7C)GB!,=@4`,";Y0NR23OX-,`1>WF&.0^_3@!00:*
M9@!@*_]T&`O!%_?:J^00++!``WI>S&!J#;O<DZ((9&5I`<2*.H-/ECR8@$,#
M/*P929NL@*+))=_7B0J>EKPYIRM^R@+H#X+&<@LNNO`P)HKEGC-"%XM.(_$.
M59A0!3`QR`958I",:8@``!"(G*2&<@9X*.D;:<#/!";5`#2DPD#\F%"%[B4&
M#.`'!&A(R`8J(!,(T*`-]^I".B)QN),DP`M62$"Z]E."?\A`6C*TP@R(`(`!
MB,$$#"C#MF0RA(\0X0,?2*#T@H$.!LS#1>4*QA/B)2^#B6`>^=+74:CB@C.(
M`"A3=-$9`#;&*%0E!MI96,/6N,:MF"!C%R-3N:AA@BS88`O_$.C8QXHP!;YP
M0`J`*9G'"J.RR"C!##%SF0%BII@B8,9F.//99GSVL\],,C28+-H!CC8TUSB-
M-M816W*B)C:L7:UJJ,0:<4`)-JUES95,6]IQFF.VM-GREFL3BQ_<Y@(^1$-N
M$6G7JJ81@#G8H`1$F`^3*H`/?*2C#!D0`P(8``*%U$B#[&K`&Q87`<9!#@$V
M@$LO;%`H`C3!<KBPP8H8E*BR]*%#"&C$&TX'`@.IXT$B`)(^0*@)$""(`NE:
M70D`5*-C]0V@94`'#I3DA1/N[@M>\$8"&H"`+8A@"V+`TA7N\:(NS%&%M)J`
M(;*`#Q[(P1&?V(`J5F&^.8EO%`AH_VDH-I&^FJHO?1KRA1@^>@X7*4I19]E?
MEX)!U"[$H`I4,8)7C'#%`9"E#!`H1PR4NI4)J$,#7M!``L21@0:H$`X@J`2!
M]'&@"XVC@PR`D$+0``<GR#`<][G?-@STD&U-JWA:5:((A,@/!'F+6CN41L2X
M$9$A#$%=4)W=1-0Q@C[TSZH#P!(&1$+4)_2D)T^XH@C\H,4M4B54])KB$B([
M1?MU80DN,-@9%K85K;#QM0YC6,76DJ@SQ``N6Z#+R1(3,@=,(3"&6<`@4Y:7
MS"`2+Y.)6<V6F[-)4I*2GGGN<T7SLZ&59I.M*9K39`,;IT$M:JD,;RI!&37G
MD)>\H5P!<O^HXTK;Q"9KM;RE?-4&ENSX`;6]W"LPZ381&%D@`#9@`!'TUE!F
MWC,=%JK!&]QQHP:PH%8/>D,2-+0X^;V!G+I0)SD)<4X2B.'"'S:=.FL@.C'L
M0`05H)&!]IDC"OD0`Z\*(?MH@89;>:L,'I(5'-A:5Q*FJXD)`((&<M4`9.X0
M"#-(0PVV@`=$B(!!ZL@2`2Q@@3SXSZ.%L%PZ+'#21L1II968:9SDQ*>7GJ]/
M-DVS+&P@!T+I@@14WJE(>HJ.<@1C`EXBD\3*=88N]-FHUOA*$PC`V:3^P1Y8
MR@".8\#H&'QJ"0W$`0"DY`6(E``#[4DQ*<9:@38D-BK0:$#N*@#_CH?(L-+C
M"`8#&)"&&B+H6RJQ%NVT!-78_34!'P#"N,:8GW-02!Z]#H87,["3)1S5JD_L
MT*I=-`*>\,2+\YCJOI!2L!%8=EY/R`^H,CN",Z#6")#FPW=<"]O7,@QB75H+
M6LH%C`F\(;=U60!B^B@%*4S!9804+LH.DQ@S'#((_(8999:;&<V8@;J27$QH
M&B-=GV'2,YS4)&NZVUVD=:TVX@WO*7?#2MZ8-Y3<I?@KQ<8TY8`<OO--.7W;
M2((_X/<E=0!``B`2D>O!Z`H3$$0#E(1D"AB85OA(1@-P/KK1E4Z<&-9%%@ZQ
M.!M<V.FERYP-KF`FQ\73RP22Q#X>!(U<_^W3(@C81SS85;L!).01]80#0+6J
MDW>4`'9@/9"W`#"/$I2!"`D($@VZ000-&`\./^`!'BR*`3%<D4?/DQY!#D&(
M+*@``XK(GI=-P;TW<8)/*:73F=7,>5@8:A>%"J><6\3LGDYVCA(C:J.->J(W
MQI8`7H*].4;@!RQ0Y1H$<`9-(GN_+A&`#WVX(@"0#(XOE*`!SJ!F)2Q(APH,
M86ZH4J&3#.I7:F6UAQ%C``1V57W`6N$#Y/J2HLOP_&\!0%UTY_4`SM"'M8`I
M>E4X\3RL'05+;:-6#MY="?#1;7I-:BF=Y5E1X![;EFTB$`=QD%GO,AZA(FX*
M0V[EEDMO1`(7(_\2Y9(BT8,`+)``=8%<4U!OCY$R);-OB)$74W`9P#49B$1P
MD31)QH4SHN%<J>%P$.<7'&`T.2!Q%"<=2B,;/@@VT+%Q&6=*T,%QHI1>3M-=
MM$%QRM%=UL%=Z'4=*C>%W,%&),`'^-5%&:!5-)=-__4"^',%\4$$9#@$!M9,
M3J0,C?-?BX,+5'8(@T`(9E(]%O`#;X`'I1-U<X1G(P`AFI`[*Q8K,M$`<I$K
M"#%C/U`#%#([V((/E*"(_4%"R:(3-V([$)!B^V!J&D`.VD<$7D`!-"`..U0\
M1$`!DX,!6Q`C^4$K9V%5]Y(%`9`%A9`%=@`35H)2EL`]WL,)O-B+Z-/_><!H
M*+E@.6-"#8OB3,[B+)-%%M00147E9XT6:(_R*%2Q*4HU*<]``%VP#B*`!7EP
M>WEP#8G00Q/0!TKE)7T@?W<'0Q\Q#E+1#LQ7($X00]:B`>,0.;'"?1PA0S)$
M=XI2`LMT*VZE5>*RB=00.132!NWB+JL3`]F&`T\0!I^5#CZE0O8"D5,$*NE`
M471`5@G2:D?B'D9U?UU`%/H2!OQB!']`@/.R!.F`@`H(#)\U`@[H6A`8@:SE
M1G-4>`QB#QU"`S/0`A]C`'WD`2X37()$2"7H2(^!;\A%&33#@L_U@BU(204'
M&@\G<9V4-$JS@^]U7N!E2E53A$2X2ECS2>E%_TIBXX19,QTGQQQE@Y-R.9=T
M"1X$P!/C04#*\@6&!551H3D:$P!B``$X@7<T\&#-A`_$UCB+T(9OD',V8"A9
M,)D\8%579X>14#HDMCKW(&J&4T_UU%<R)`)XH'UHL#X$0B1E\`4^5P-BL"H=
MR0]]I8DX]@8-8#M@=3C5]P&7Q@W%XP0T(F#>H&M?P`(8=0AB0`Z&ER6R:`]X
MID(O0@!G0CN2UPCE$V9BU@F]Z">T`(RQ((P:<@6BERCN$3GNX1[+&#&K-WO/
MV"@!5`A\X!5^8%1>$0/H,`)>(0)U@`,B%0/V(@*XIU3Q20@'Q",B&0,\\0<@
MY0V59B0-8`-P<Q"5</\XWL(11Y1`7=``^F1K'>$MUC(0%&$A,H$>W_(M'Z`,
MY\E^.]4AT4-ER&9M/-$,^O$@6U`"]D@KW6:?M!)6!:(KN#)07G4_H<)80\%%
MTV8$3S`"VQ8J.+`$81"39V!&2V!4-]D5=<DPA;`6T9-S,;(%<]&!>,%''A""
M@2%<)T,8Q+5(B)$R*4,SCR1)<&IP+GB5-],96!D:0>,:GK2#Y55>S_$<0LAQ
M&T>61+B$I20`LF2H7QDVVZ6$S1&7=1FIDNHP=XF7#71^SV=8_8%\;Y@$%K!0
M1#`&7G`#^)&8R(`#>5`N3B<)HG-A;Y`B5#:9L7)V$0)6DO`."I8.^D`'C4#_
M"YDX0Q/``A0`!YO`8@"I5120BCC"5EY7`1M!HGFW9`&!B<YJ:E8P!`JE`5#@
M!(9#`43@!F[@#5^P!>%D`<X@`N'D+)FS`XQV!O=`;"*E`M8S=-HS9N#CBV?G
MG6IV!8>P.<.8I7,F6::'`7UV(A$C*8PV>U/T!'WF!WP0!9^"H$:P*2)I*4VU
M`R00`QF@#(4`>?R9!;GG(I/Y%>WG/P<$+/=3!=G0!!F+#WVW56W0!J`&)#5@
M.&U5H3I$!!!`B!C@#_O@0EYP:@FU`UC`!R.@:.A!<Q2P?^<9D7$0!O$Y*=86
M#.\Z`,'`$SL0*R`4/&@@`U_`#_LW63C@<_N$06D0_Q$1P3SPDJ3JL%E)9:3\
MDEE18##UXJ0*V&=+D!3T::5<09<DD`?G]CP,\E.%1Q9;0`-V05P"=Y1)21A*
MN;AL6DB+P5P,QS(YTW"0I#,.YQ=`$QK9=8-<R82C=!R`FAQ!F'$8)ZA`J*@@
MEU[NQ99OR1S7,:FT&ZG8,"]SVT#J@AZ&);/(%TX3T`L,8$1X)Q!`%UFN@H&3
ML&J.F(>O*@:\X"2?0`F?<"!PP`(9D`$U8`,B0`'5%"@;<#CBX(X:"@+ANP]A
M14+(HE51X4&ODR,;(4,:D%!BP"'K,%`EM"ZH@@P```-,0@%E`"YNH&L@L07E
M4"Y4)@+9.PV-%C'.@`'$H/\"%I`?-O`*VOF+^FI33M<+H*<AF\.,`7N>]\,6
MZ,BNPM9GYVE4T-@IGE)[Z8B-S),'VW@O?+`#`U`&.("Q)P8L)`"R%"%24X8!
M+R+$*BPI!3I!`40`?=`'?-!`T8!56]4?Y9(/-NNLMP8N"<![%+)J(\J/'X$#
M8]1M/04/^($.]1#&H74&(D&1D]4`KD(K4F61![$!G]D/P;,.Y?`C%800'=EJ
M:$ML1@44]S15;[LOX-9L!D,OB'RWWD85P="W:^.W?'L-%H,_BK(%7GH#0[E(
M`)=O)F,R:'H8B;2FA/0RCT1PTI49EC2#,KAPG<&YL)Q=VL6#(O<UYG5>N_$T
MND'_J*I;J!^'-(TJ'5J3EM7!A&D)&ZY7N\H<@=C@<F$0!5YT(17:$*AB`07`
M`X5W!;^T0PFP?U#A(NN0(OE`Q^XP`!5`479X(WA@`TXB5KTZ0@,%30_:O6C@
M9352(VD@0U)<`P-0`S]P.&EWMA\A0ZCBQKEBMB7@+5\,O;)X#S\"#P_M(<ZP
M4#`0`OH``2^$=]["`)FC.;%X?SPBBQE;#UJA`H['`U=4P8BH$/F:P9RW"Y-)
M9>8*5&O<7ZB79U["KM3`>JK':!'CL,`P1NV:#B.0!V>0##ELU,DP`#4L(QB;
M!R<F`OU3!=!)$4*,8`/!*;[7!0N,#H`V0.D``:1B'_@A_P9YH+6Z:6KR"W[/
M<"GVLBXTL2XE4'K^1Q:0(U=42Y'X^#A;4$\B,%#,1"L(-B.@"3MI<!\;BVGX
MD!"TL`'Y#`[]P8JG%2I-1<A)9<BAXFR*;%E)ZB(2BZ1=`,GU)<GF9C$[@#\(
MT`!MD``H,,HN<S+!-4B.6\J1>Y3\EA>.M%RYW7!6.8/2Y<H/1QK7I:>ML5U^
M2KI,L\NZ+)94D[J]_!PBMX06AZC3,7+![(36D<S+O-TL!VYA$`98,`(0(#?>
MLJF"8`$C\%][E4=$<`,LP)E8`@VT$V`EP#YVN!!OASH^9`,L4`&,+2`*X4]T
M@ST>Q*,&$E9$(D.!@P&V2:P(L?\0_I`D,D0!&"#!M[E_JU8D%P)-[V)4$6/6
M><"BD_4&[8$#9>`&7@`"<Y$27K`K7\L$YFJ,0QP5)A`,C&4"/""'6A9-KP#@
M+NT(X*D+A2(_+GK5Z"G$R_A#.Q"?EB(I[<EH59".P,?$5'T.=G:1!*O`.E'#
M"IS#-0PF3-P'*N2,8-)KZ;#44"$/,3!HL%?CBC9_;_0H).`'ZE`&,<2:%-!5
M5O5V!R(.%6H3/339T.843N%,DV4.]-(3?G`I>@T53I0?^+.1(!!3A],/*58!
M$J'`KP('.A":MP)5YX=IZ#!Y<."AWR`3`^%GD'9X9Y!%`3@>`WAMBMQLE#T"
M#OE9E7+_;F"AS#:I%OC3`S20`'?!IF8J;X%QIK--VY%[VT'`E*<<2="5<)C[
M,Y44&D2CITFC24E87KC<`<JQ2K?,RZJTR\TANDTSW2>'A%Y)':&DW=S][H7@
MW>.!`1EP'D.@X',-(^UA`P5`[TE2BN^]I?;05=P+`72P!S[.SZL&3>0J+(R-
M=O64!I;VH%:%$.A+SA*?``!0`IALSJM@MNN;=QAF`1KZ(P^&'PS&KHL>`WY`
M`B*2JBTR.=D&`5``!='2!MZJ`47RB0:\C)IS!<@`12=&#AI3,2J`S1!0`VH2
M";WZXS\0/[L@>CMUGN6"*84'J\\C1^W)>BHKGRSO!YSB18RB_T(;NPS0`$V8
MUD#WXB7V.0#,0`#8.'OE^13WMY]C?"^DU]:-1M621@X80P";LNA.L85:U1!=
MA5;X>R'GA[;NDJ)C-##Y<<!\9FTBW(>0\S<XT`8_,A';T`ZY"3LEX`1G2XX*
M/,?6>;;ITBXIY"QO8"P44'[B$D._0@_>-N@T>=F&K`VRGJ2TSFVW#FY=T/)M
M1+O<<=H3P`9#X`6#4:8>@Q<H(-N.N^Q(R:;%A<IR*H.]'5V5>W`[@TDW>`"D
M4=S6`<S1;<L7-^Y!Z-Q6<TJ(VE[M/\Q\JJBBRY75W?ZKX>[OOMUI@87/#`@N
M,3@`95]?9649`V(!%A-B!6(9$!I`0_\5%0,B&)P3.`PV-0QP:A<_/VH_("44
M$"5;/`T,=!L;:'`@N$Z'$`,(8@TU&[5T(!5I%(<`#&]OLPP5<)D,)1`0924@
M8E4[.Q/@8F\U#1C@-E=Y,5WLYC4U&`T#\_,C`Q`S4$Y.;339<!1F5'ACH:#!
M"2-PX)A@P\(.=A-$;-J11<6$,@U0_=B02J/'CSP"\!AYQ4;#@F+`85B)8<0(
MEA-V%#2QPP3-">QBK.L2H\J2*D:,$"!@Y(]./SOL#1BQ`P..,CA&Q!"1H<Z`
M'3$P#,#1A687$2(FK)38283+>76BCJ!:1\17$3@&9#7GEL##GG_\\+%)P,0`
M``,P\(S!AT__'SYP2VA(\&4(!1P-',+%D:$R91R<6G99LB1*%"Q-%4IDH+#>
MB#-G)#8`P1H.G&IMTF3`##>:M-85*"1(H$$#`X0X:J`2@J;"%R]>-$"@4&9`
ME[7'*`RY<2.!%2N[$V00P7G)F8091O`)&M2%>?-&7+B,LN1)^Q&<GYA=%W1)
MEQTDANK/K[^___\D!,@%%T,AQ<<$,B00P@(,HK!`"`LN@(*#$$;(8(,39J@A
M"@88,*$!181HQHAF.&"B`V844>*)+#J0PXLGKNAB#C.^^"(2!QS``1(<Y'C`
M"BOD".200/K@@P`"'(FDD4HBZ:23'439@0!25FDEE%$*4*231:YP_V21/GC)
M99!=&DFDF&>N8,)_;+;IYIMP#F5!?DN$$88@?QWRQ34E,.)(4SR(44(9EB10
M0@D9,+!58%M98,,T/Z2`BBJL+,=`+#7`@<`MNA"3FS(0,-#`!`W`00<J=,"1
MC)X8!5"`!9TPH*BLBHI03@T3Z(1?`+Q>$0Q,8KGTW`#"O$,./4L-D($&^CB1
MP"N9?#%#&EMLL5(7YH`#ED,C3'!&%Q-L)8()*JA@P7:3?J3N%;V:=%!9+KFT
MDC?>3%!0O3BQ,UA/!#31!`%]``544$/U,<(B9TQ51QDB/*0L#F?TT=12]-IS
M;43SS";1`&6TU<4\S3WW4F`1J60"3B>/0/\N?X4-9=,.5#601X`T]Z7LLE_P
ME@!4+9F%[4JDAF7!<YS%N];&6Y4!``25B8":/:2X)C4RK@!0`CC5@%#+1B#0
M,$0"-[C"0$L#U)"JLSDG@!QVOHD%2B84W/`%=M?UE@$&6'@60T)M_4'>>>>E
M]\0(GKDGG^$NQ7!&%$9$\40,`?;'7YR2"TA@'W[$0(!%:SQX(8,08OB@A9]O
M.*&$'`;1(8A%K)ZBC"BJR&(.'-#H8NVSVVZBC2_VF"./.`JIXP%AINEDDTL^
MN2205&;9_)3/7_G\DDQN:6221Q:?/9%<_HA\\5VN2?GXY+]9$`F>F>>'"``L
MC<TKQ(+35$'W?`'_A!?+E5`:)UN)\6@:&U"#*C8"!VN\H@$-:0`=%DB,:20#
M5`B,"`-`L`$$@``.`T!4(OP4@+Z0H"G9`I<)+'"%*]B$)B8PB3,0T`EDE0,2
M&"`%:VK`FF/(*AXXT(`"6K`&&E1`:3I+0`4@88-R\2HB&!##2TA`$PN@D`3E
M(D$,)\`#.?Q@)"+A01:T:(&4J*0L9NE$MU#(@SE]4%_YNL\.@-*O?PEE+WS(
MSUJD8H3Q#(5].(A!'LZP%9GQ82J!R<,WP`*O38BF`90!``ZT@L@ZC.`K03L9
M!FP@EJ%UH0K@0H@)($D"/M"K7A"1AQ@$N8,SK&0MBP)`;_"W"#'P@2EV_U%)
M`\`R2[`8C98-R`0R6D$!"BP"+)5)0QJD\1ID,.8#$$A87#2R`1"D80A>P,XU
MPO.Q4GW!#0EP0G5V4S<&X.$3%!"F,G*F@1G,0`,?R,`97!"&*.R-$!F(P=\`
MAYXEP"<,3W#/`-QCS].<80E!Z<(9(K>?R8V/!`,:$`%T,D(+;.%S%ZJ0Z$@G
M.@QM:'4&"$*(.D2BCIIH1">Z40Y`:CO>H:A$O/L=CSC`4A\!27@_LAZ3KG>\
M(T%/2S]J'I:@9Z4IW;2F8KH>DXXW))RZE$A*`E^2AA0F\97OJ5`]WQ^BX(*B
M-$!I$$#$*T0EABM$A(3W2``1O$`!_2EJ$Q')P/\$?M```.Y!%9YJQ348(88M
MF(TCJ4I#*W*6@1H4H``VD`<Q-S$/3MB`5RK8"Z\62TIZX<2491$&`B8KCWF4
M@`&>H(HT=.F:"@QJ'CG<H0Q8\,,R]#(9#2#(3+R1D,PXD9";*Y=L"1"S-YBD
M(1.PUE@*2\ALU:0F0_EC3F)`K_S@1P61,X()=-*O+B@$`WL90%O\T(<^$(`/
M"]W*0`7IDF\@!"P2.1H.TG(T;(QL40BA2TQ&(`8Q8,`F24192QZ2DLR$Q5PU
MN8G(OD(;9!5V*PQ096/:<%DQ).4EG:`,84F#F6\E91.EJ@"M&-!+5P0&`[-Q
MS:D0D`RO'2(\?!0!URK_<(VOU4T#``B+"`X5-R<HPSKFQ,X`G,B`,CCAF8?H
MC0:(0`3`K),]>_M+!KHP3WH:P9YURN<2EE(TI_W3!5%XCG4C%T>#QBD_>4AH
MYD9H`S$,('01E>CG*"JA"V4(=1C-:!!2)**.DJA%N],=29&`!!BAE$<Y"!Y+
M?7>`X+U42$C%'O*F--0GA0EY2.IIE0RMO$9K*7O@8UZ08NHE,QE/2V=R*E0W
M3;GS8>%.+N`#A@%PB#)L-3)>%8$-"M``"(AU!J&J%5I%4`<,J*$&;E4#,8Z1
MC`.^@50-0,!&R.'9:_ABU7^5!"&=<5L>_#4+`--C"4MH8'"(Q59)#(:H:`B"
M_W>`H`&Y/-0`ME"-S>J"#L6Q<"?*0`0H+(`"-*!$SG*6!G`+YCXT2<A"+*#O
M$5@`N313019VD,%%E$,>M`'6"5^FD^%6P0\FH*Y^^-(7=IB@DW"YBA2K@H$`
M.44$>?@C:O##1PPH#EM@P0PJ,\"PM3PE,&;9BK:"=;(N$`!<6>@6K"9@@H9I
M4BPG:R\GFB(&%4CR6]\"U\3H83133D:5JMQ9">AB*QI6(`-IZ"RB2@"'<HC`
M-L(4I@_;,`17_P;#(K#%1M#@A,4P1G].&T&P0:";+T@GFE;PP@P`T(`^4*45
M^_B:=:`P!BO,0`0W9P`V$K&,1)B:`:>I$WL^-ILS%/\9<(T;P1/PZ1Z7-!DU
M78#RX&+0!YIAU\IQBN.`L#)"/-A@"VT`\^AD/V:(.LBB:,X0B$:D(C=[E$:R
MTQV,9E0[&AG?1L1G:?!\%%.7@B][CA8T]93GO)Y&O]%")>J8*OTEIE9/IL<;
MDZ8Y3?XVG<\(H#X0(7K!IP'8RP)Y"``8)I"!+^R8`IH@+/_JT(`"X+HCZ*8J
MO10J;U```?`&\0!NF[`QMA()`:`"KA(`-L!L`3!M7>1$P?(2XN`,X[`2E?5"
M7X<;Q"0-BN<+P0`!:0`"S$0':7`(F"5='P`#-Y`)RY(`,X`<:6!;%2%;/$!P
MC+`60-,4CW1Q4$0"CZ!;[77_,C&!+X.!$U50!4[E+__R1`0P1Q=W,(M$`GE`
M%2#'1/:P`SR`7%\A2%01%7SP%I3!"7`!%>)U-YT@1DG1!;`B$UT@!B:@,@0'
M#OZV$E?P$B:``04!B(_09>#0%200$Y@#<4,1<'Y!,EZQ$J@!%U3Q`;M!`8I2
M`[!B*YN2*IF@=4S#/U&C-<WD0[KA:G?S"0W`*17@8L=Q3E]@%=\Q#\D@3FIS
M'5:@`7?S2I108:ZF`7HW`U8``8*Q"5I1&5M%C.;@$IMG'_SE')>''E"F>>S1
M>?#A'6;Q+8TS>CO@!YN6'VL2(-Y@`EE@`4R``"R@(!8B9A$%.F1F4:;3(6OV
M.B?%_WL@Y2+R6%*\HSNW4WPT@E)Y5F=YQGP"Z27>EU0T%7U2,CTZ=7U48F@%
MN50VM525%F@2*28U=9!+-7[EMY'Z<3[LA!X3$&#L5U:!81`6$`""XFJPYE_$
M(ET#(`H,$$`;8'6'<@T-$``1\%<V4!88``SM)086$!+(-1(%D).4!)3BX%[F
ML)0B0$&HL&NK@7"0H151DPM:4P-4@PT,$`QE4`&UD&[[8'\0`$S,<@,LP``9
ML!O(X04E@`"/$!-P*1'@4)(J(1K'I0)-8!,S\3+ZPA/W,0%0*#YX20"8I#D$
M$"Z!1`(<,P`FX%4R!XXN00"1,T:%V#`PHP@88!<2P7)J*/^)Z35?"%$3E[0.
M6<`.5<AS3)$'[A<,>9`2`0`.OD)"D.!502D8F\,?4@AP>V$"F$0RWJ`K,O&'
M<;$LRY$&U3`J7Y>*MG`+G54U&%$%`T`+'&$+<*`G7Y`&<8$!!*=`QI%-O*`V
MYZ1(SX$#RY$)JV(=8P`$'U`"1(9AIG8-2A-UIA9S`[`$!/`'PV(6C_2;RHA/
M/#$9(T`>Z8%Y0;$>[6%/(N`>WR$5`'5D3)$YW%@^DQ,@$M-0>-`#(+`&7D![
MLE<A"T)[9F8Z'-(A'-)F;W92+$)2(;4[M?-F_ZB/_TAGR@=3E)8F,T53/Y5H
MB\:0T;.0,U54C)8E-\H]%8D\6^+_D&K"D4K:'^?#!782%`1':N]#D@SA"%V0
M!6)`GC88*O0@:XM@`PA0-A;D&M&I**EE@"J0;(]PDDE0@24A6R3``W;``[?%
M@37@#/!@#F)0`P-@*K:`!JQ1*F=9&0V@;7"`!ASQE``!GQFP!0V0`15P0960
M`,)T'!#0``D!`%#@!3[$`-)B3D"0``U@+4M($UM1%B#$6ISP;^7R+SAQ;W[Y
MA-C%!WDP0DPT7]<EB?C1!94Q`AZ'&9)YB`W#`P$R%2IQ8)*X%CM``$ZA<3V'
M2LGXJM^@G2)D#DFA+2ESAAB0!^]U!6%!28Z20B>#6UTT`5D`#CP@%L'Z'T;0
M!\3%FU_Q_UN:!FT81I[*87<6)A:BLD"UT$S3``&JI`$#4`5?9S;II@R+L2>S
MP11?YUDW0(MK8P6`\1`ED`#AY&+5H0%6D)X:P!7/\749T`804`<9H#\0QD?A
M`6I&P$=+\4@BHXQQX!W\%17/6%6"0S@'>CC>D3B=X:"$(3'<B'IP$B">9%T%
M@0<LT`;HV(ZSYZ$0%:(7%02JTR$F6H\@]7L?!2.]TX_^.'PN@B.UXSM^-CP$
MZ7U'"B58@K8\JJ,)R6C+@VC*<VA(`J02V22%AJ1)NJ1+VJ1/*A2M!I^FM@A5
M"BLF$5:AF@9E>E9;@0..,@'P,*J3Q8%74`!@@)<06)2`!90%4?]&DHE<(B$6
M;Z`1XU`#"'`L(N"HT7!!KH&H:$!:;5`((B`&(D`!*OB4-J0,[9,!X%8"D8H,
MF^4LC&%(93`&0E0!.)``,(`<,_`%"&`#6=`K`:)O(M!%A(0?`1*&4-0$Y=(7
MG4L"51`#?D`"?H<9$[!QX5&KM#9C5R!%81&&I:DR!.!$+_$5CP1,BX1*S1$1
MD'-S*F,N+S$T]J*=2I02W>(2Z840UY8'W-J:$R!(7?4-Y7I&;SDT53`T\&4!
MI=D5?%`%!!!R0R&%V?LQ/-<73Q@#@(E)"I$!E,@8KL`"718-9D,'F](U$#`$
MB3"65:`5KA$05H"PO2&Q#),'(U`'`!#_=JZ@-GIWBSC@22+92^1D';=X-_8@
M`E@`;+BDG9LD&D\0!W82!4KQ$FY#&X0#>O80%7T@H`1J!(,3'_G$'0CJ-)SA
MH%T0(,MEO9(3)^$8OUC*`&H3`BW@M!#EH6`6(;>'.AJ"446@456[(HL<(S*2
MCR-5(P!Y(P?0.SG"9T<5)CGE`T)BD-.7/)^\/&*2)1:):4`%I,4CRH4&I-PC
MM]''/`*@D7I+?OG1!$8P,,S*<C4\39#!<W$*!CP@`@!+!!K0)W&!+)0Q`2AI
M`U7T5V[**VBZ.0;(`ZC`@?[S!NU5$`T!%IMB"Q84E13V&Z,0J5LC0!O``JL"
M&.X%&;N6!J_0_X+6H1RC&@UZE0L"F#:$E0%$D`#10&%N-P,)``<]L`765A-4
M.0%7H!7/!451%'`?!`XFD*X*H3)^,;&'2!D=QT3;,A+\9B\U@41DX1+DZ7XI
MAP.#5!9*-,=&IYW$6DEBH91(U`E!0RH,`0FP$I0QP:T!',`&31,8<*Z9"0[G
M&L`F8`<>1#,U0Q3]X5QN07H2IQ]^<#.]L1M?TP;FD$%:4POF.`37L1N^T$*N
MH4TRX"QYMQN+$;M7Q;O)(#>\,0-$``0:T#`LJ\O8,!MQP0D)49]01EQD`31I
MM4_N$06I<1NY@*&9(!IGH&1EW#!%5AXW^P2.PQD)ZCAKD3``Y<5,D?\?$F.]
M!E40`/)!R[JY8L`"0R#(@,R.$O6A"W)FAHQF'H("(5*U1?!1ON<B,3+;+>*U
M+_([-G+)+360DT:09M+)U&,F=NO)HCS*4U+*24)49.*V<RLDJIS<*X`]<5NW
M2"++LPQ562:930`4574&3Y%50U`94Y="8!`!<V`'!T,H'T`!]``6]'`W*'D%
M8#`'<U``Z9`'A\4KQ*H"7G6GHHL`H5NZ>=H)JU%#W=8`I.5J;3`!;W!9PB9`
MP[:HU_`;X:(UKU$"PP3/O-$&6^!ET')!M"AC9?P!'R`J!?0!,^`&"C`#-``"
M(5X0)828!*QOY0NGSV&N?C&6^($!(ZLRL(+_&418,L2:KF%A;2XAB1];&6,A
MB3`]+G?(+4/CJU[8<9L4%EJ!X*3B@2E1#N;@*PR1$@/7<>P@18`XA$QQAS;1
M%3@QU`!<$4W`'T%1785QQOH1+B,`A59F!#"S"!#P`8O12S2P!1;0`-J```O4
M`#0`Q<B1`&U0#M&)#&DPUB&`';NQSX'QJ*]``W%#3A]`S"502]R1&N`U'P:M
M$)O73O@I$9Z05IB1$Q\3#8@*`CJ@`Q5``YZ.,(J]*$16'N@QH"Y@3XO#3V:!
M3Y4=`T\0%-\!7$SD#4DM)YZ]B.I@F./X!B!P`QO:`G\,(=V.VJFMVJTMHAQ2
MHKW7>[[G4;.CHB&%_WPNXB.6#-QDHLG<]WS3E\H\"CU%U;9QVR1TZV@O5=W:
M@Z31=VCX[@/:O=WE,S,!\MWI<9B$L,OFW0`FX"KJ/7^)1`1#H'^GKKN!PLQX
MX`Q$9%O:'(860"R)^@/??*<U8"MB02RYL#4_P*>>JAU))"N)RHF2FK`E4`.R
M:S;#U%G`*Y8BT/+9L!J[E%6]@1E;T3X,P`(E\`6AK@!NX`5IT`-O,!(!\@BD
M$4;IQ=#EL@.4X:M^P3`71ULF/9FQJ\#/*A9Z2!7A039M(80245]_.$EBP0-)
M1`),P6\GXW,1D>2=L*=>%[LO#0E*Z45S:,%WB!4V)V4NL4D\UQ6;Y!5O>?^N
M/&$33WC&0K&(_?+!8K_G#T==Y'%=>:T8=J?KA7[H$[1`Q^!J:FDW5PVIR*!-
MUF'6ZPD?S[%XC+%X?"+?\/$'0R&$CZ02XO)/2^"N"`YNDU6&F\`.0PP!D0JH
MT^`U90<5_]1Y#X,!P![L537LTLA/!CHXI['L1O`<.R`QDND-0<L?0ML'F>\H
M=<4`T/3'W6[:@@SNJ&/('P((!BB#@P9FAT6)AXN'#HL.D)`YDI$..3E(EY('
MG`<Y')P<H`<KI:0^I:BIJCX"`J6N*P(='0*MM*ZSM+6HKKBYN3ZMP<.VPKDK
MQ;')P,?`SZ6RS28$U=;7V-G:V]S;>20$)$U51B[_!#L#`!!#0QD9)0,8%B]@
M$6`3.!``1!HE#`,#1`@<@6.`#3$3$#0`.*`!`AMOWH@1DX6'B08U-FC46*-"
MA08,,HBP88$!@QH_U*C\40-."0@42H@0`Y(.'1!PX(``D>9+@I]#&DP84`%.
M4:-I*/A,H"$#!C%O7/I+4R+#N@001(P06*)?A1(ERF@@,L,+!1!;)DR(X2>/
MF`$B=Q#`@"&+"A(J\EH8@`/#%8M:+?`@84%$EQUK,<03B$$@CCH#)FQUAT%R
M8WF5\SRU($^,WPDB.&,P(:)R/`Q])WA^ZO;IF\J>)UA0/=O$CM$3Y'7I0F`W
MGR==_(R(T65$E:TF=A-0_YNEBXGD%F[;M4VMR38CV/LLQR&B2I4^1JHU&=^[
M8-<$7X:TR4J3`0@T.-,,^9G`BX8/6177*4%5:7VF'Y0A0@Q++!&#"`.$1,$_
MI]&U58%/1.%'%P@V0)<(.&2`PPAG$-A80W34`(*(%9C$P(8QC+!?3N^!0(,3
MZ$%01@8C+/'$$F?`U1=VY;C@`H_813'""%$4N,2#43PQY!E+8*>D7#O$8$(>
M?.S@1SC@$&`!"5QRF4<,?=B&!QY;L#"$%RVT$(*:(;2YP)MMQAD"G&XN@,*;
MA!0BB)Y%F)'(GWTR8@8DC512R:"7))J))$AT<HDHGW1B"BG)H'(**\$\8XPN
MN?_L8@LSGFK:#"S+%.,#*;,L(TTPJS;S3"W`4-/-K+36FDT>>833A!_E&,%'
M.A"L`T$).&QH00`1V"-&!F4``,0,;?RCE58C:#C1`!F!M!"V;_R`0%I93-``
M'1N0FY(:':6A#P-O6(!#"72DM`&+<"AU`P0#O%'#`!H5M5.]]&%EX0`45(`3
M4OYI`$`#-O#`PQLBN&,B#B8UL,,27/4#4@G[>#%$>B#@(5A>*ES1``X-1"?"
M!#R03/(.(^R@0A99I#@1!CL(!-=B`]0!P0@4\B6""71)-@'1T4V01Q<37)'9
M"`C-U!A-*UL(VH5^!7#%T7F9,,$..W1!0F[)=6$!TR;_C'#T"+:-P,>$?RS1
MA1$CW%@CA;9A0`)B8T_0VW-JWR6>=01@Q\?AXE6C@@D%F<#E-3P&/<!8&D"0
M!@T-\+`%`P;#D883/GWQQ5@?]!6E"'64(2,`&FA0ANH!#7GC'V`K5AK0B#5&
M[9`C-.![#34H5!4\TQ8+1PUTP&=43"50("#1*&_T`PCSH4>52$_<>`:&-(+G
MHX]`^CADD1"*$*&2P\4019(#DL!'##MP&:5<7G;991Y@$X#'!%LTT`:::0J@
MFMZT`#G5B4YVNE,"![%`%!C``'^"8)\40:A'.`)1DS!4HC:8J`-DPH./ND0G
M*#5"87!B%<ZH!3,^=0M>W$)5_SX(E:B0$0U,N4(5P(B&II3AJEW@`E2RLI40
MAWBK7(D#.S_*@PA>%RP(O`-E8N`!&*9H`P8TBRPE\!T&SC`"NKA#-1F`@TH0
MH"^`!&]?#5"!&!@`APV<2PT_H$.]G)@O'B0(>6@PRHC@``$-)*`,?1$#'!"P
M`1`DKP*?\XD?&2`&&]2``?SQ2!J2XA,`.,5K:J$+!LB(`8S4X&O;XPL`_%$&
M"D``"%_PW!!J0!(+$"!,:2M(;N3A,A588TB2`9IC:+05')2!`9+1V==6EIO9
M3(`$A]',<T:#@1'DH8N%P1I=-/.4W.0ND\<:F]AL>9BS`:YM93O;VG;`![<)
MQPC$*?\GD6ITH-J1P&M]ZXW?=E.%:CRG&N$11Y?&8YUW\J4+?>!#'\`3GG#P
M`4$,8-T7*$"#-@Q`#%O(``40%CJF$`$``]K!'U!3!ZNH3D,-V>*-XA"%/]`.
M-:<9$E\*PJ&M-,"0&Q!1#5B0!H\0:Y='^5=28O3+VYSD!T!%0`42,`-^Q"0#
M`ZC;$[:7H0'U"'Q/I1N1R/<$\]EH2#$@$/O.P*4^[,!QYX"?_<8*#K7@`:(T
MJ(\``VA``Q*P@'@B8)X6^,`@).*!$Z0@(BQH*$M(0A.6V&"CD""*41Q`%".<
M%"BB@4)A%(-4L,`%#E4EBU_,\(:,G>PR<IB*4;505+A0867_.Q!$(IIVB'S0
M%1+-,0(F-E%#*[.`;`/`@XB5@0A><$]E=G`&M<#E*25PP@\N`$=O&<5S^,H"
M'DI0`3<"-8\X,67!Q!``WVT`#1XQ)`@JT,<_H@R-R).C1T#'E#)@(``!L`$&
M0N(/BKT+'I51R]>.I;4K>,9W#6BI"!):AI<@D@A?J``%O,""+50&?B:8#4".
M9A>\E%4@7?@0('5'F:L%A`1T29MLY,$93&+8;+NM3#-G@YFO8>`PLD'(#HPY
MFQ5W(09YJ8+9[L*TYASM,$1+#@9ZPQN</7.98W/;D,KYXHSN.#E[\YM:;%D=
M%8Q''/S$!G:\,Q?#I)8`UC%"/PF`_R%?^O$+ZP#F!*S(GY>$SB>`Y%WVAO2A
M@*S,-F>XD9$BO"W\)L@D`^C0"`#R'N6Q@`8%XZY34,-<.*!!(_4:@@86JJ$(
M8^NZ<*!!]68P`_3484/98RID8O#4'ZW6"%Q<`E6MJB01=$C41SI#.`A@&[F<
MXZMDS1*K5=.#H::I36MM:YS>*E<%,C!/#GR@!`$5*$$-ZE#'!FQ@(0&I2&6"
M`Y%:P6%)<=C%2JJQCC65,XXA6F>P4!D\O*$J:O@I5IEJA=Y.AF6!L6Y?T**T
MIXUW-W)5#1(8(0K?PP"S(`!F)T+1`EEX3G69I0$OI($%`3E#,W.#LC<0#`US
M2,&YYF5*?/^1A'/DNHG!HBNZ-C!,7(34KE',#.8&1(UB#8"#B63TNLBT.G=;
M`!Y=@/>&*US!:TQ3#4)JT!A(%DLKHH0``V#R$L[Y!`1,`'B69H.@NEB@"EF%
M7[6<`IJ(/;2+4[/`"*(S@K'YA2Z<.5II(CP;$,M&+0AYCFQ:[347R]9L2`Z;
M"G;3M<-8)\+).2;:1G.;Y6!@:1N^66XBD^$A"<<YSDG.<\P6-@L(CE;\))P*
M<M8%@?(!2`7=LP@@\('*4<"A8M!ZAIK81`;XCG<%B@(66E,0@;B>6DNED"=%
ME),2^;QX#)ADYQ"9,`B8A@'FNBZ,O%!I"KBCBP/0B1-N4+T$6*'_TM[ET%+W
M?.DS=)I'WTMUD6ZDE:N:FD#W'M(W","'5F_)-GWH$C8`;H,M5.!,:V7KK@MX
MP+<2(H%XRI.P'4CL8A<[$L=6*)K`03G`"9-0@-#V*-0V0HF5#)WU"NCF6)>U
M*3,$*C,T;N&&6:WR#-[6#,,`*YKB0P(`;_)6@MC`!UEB2U'0*S'`+*(3+!G`
M`!A@`P4`!EX3`!C0+!HP`Q20!K#5=/@@`B9S%FIP`1-7+S%A$#Q@7<FC$X5$
M20L5&:#1`,[5$6#!;U^0`1-0``7@<!IR(B=",?]P-%GU55<0`%P8`+&1&_*%
M2YJ'`<!3`R#!%TD5$%8!%AYA>A7@1R#P_P9J$25^X#4($C//D6``1QHK,V)T
MX31=H`)/00+&D39>,X.YH5ZRP68S&!U7@!A)TXE>LXDL$P,3,'<FD`6CT00C
M0`#'H0*Y\3C%X1W%81MZ-T^+AS]_-W/X91)M\$L!X1DB,"&\<1C-00V)]V+6
M@!W6P$_B<!>$8T\$$`,!8267=WGA@1U=`!!B$2SI40*5\7JQHWG5$`-Q)F<X
MTDD,`1!A:%4Q@!HZL1,'TQ\SLC(8PCF&=ET5(`,W(#I9J#8#P`(V@5T4\!->
M0!8)H`Z[(0(E(`-.L)`W4!_/9P4*$QDQ`!Q[Y@[6]SV>AI%"$B%&LA5A<"1:
MH55"XDQ9\D[S]?]..Y!^LO8<%F`#"&`F7J!K;85`!#0G]X=_^4<(^S=L?A(H
M?7)!A-)7B6()F:`H2+`)GE"`#"@IDB(,TB8+-H0IW79#.^19J3)9P_"`%*@J
MF8)9RO!#+P1:(CB")EB6V8""]58X/O*,OO2"_A89+?,<!3`!&0``'T`$EE,L
M`1$0*+4U:2!&<P!4+%$!3F!*.#`!`:`0;E0N\$&8A;E0)J<8+$!(-Y$@S*(Z
MH8%>:NA2%J))3Z$U),`%)(`K-@`1?H@@YU@:L@$2.@$\_T*'S=0`S')P.`$6
M_U$":2$&":876T%+)$,"66`!LM@%8F`'N>$T6S<DE)<S#G(0$W`0H8?_$&@G
MG`D&-M'A8H[3!3:`9!,@-DR#8?'#-FFS-SO&3<;QC,[!B6@G8A:R$`CB#\S"
M.A8U`Y5C(0-2'/*$3(XS&HM33^(!95%F#>`Q4"9@!-1P'&[SGX7#(P0Q`!PC
M%GX$`2:GG#B7-X;13&JF)/CE.PA"F,'"'2HU%0?W4A5``Q#P$\]3+6TDF"`0
MD%Z0`)\G$Q0B`GET`R_J$UZ0HTP!`<XA`A0@`PIY`PUI!0])GY&1),5A6R)P
M?9TVDD8"DD6R%1QR!NLS)&"U:F"S`]_0!_!S9<)I`4SPDO\3DS))?W,R?W`2
M5_FWI@ED`$$@"!*$"'DU*'YR;$(Y@`2H**%`_T(G-&V3$@TG=`S;]H`V1"KL
MID*/12F:4BFMH%D0N$*CPBE?N6ZA)4-D:9:8B@W@X`+X1@!^,`!EX)8:TA<M
MHP(!,`?N4@=$]07$TGJJ62P'P3D_$)@_\(2%Z40FAP"&Q**(5)@!F09O4``\
M0!,L``?GR"`FEQ=XH0(\T)(3(9T3T2Z\=08*!X?`@P"*P2`%T9E$D1-&<120
M)!(`\1)@81+!$B,4\!``)ULJPQU*DRM?10VR%0ZVM&<(T:.)*`]_*!O1$9VA
M]S6W08QOQP-\\S6L*)QZ`S/&A$S'-!I(XQF"$2['%'`OU@6=Z3L,02PA81)@
M00&MPQ0Y2@1`4)\-`/]UJ4@<R!0#&#:*MB0.D&,$`<4CB0-E7-($%#)0!,6I
M*_B,`<$`K5-*QM<`R0$TP200VP*;3#*C&`$"*3=>%&!*(J$8;8!(%1`\?]90
M["`@5;!>(%"K>20?.3H#5O`%`C)XA/D30BJ01*H.>C,"$'`##.D31%I4%S4`
M.X`%!4(A=3D`?Q!5G>8"0_*D>U8@6V%J$0)J(A`_:2F<^1-67R5;-/.2`Z8F
MM^969HJF:6I_OZ9`=N*F=H57B`!!/4FGAG"G&118!_@)T&9M)R1MBR5ME,)8
M6BENM*N!,02!(=@!FO64Q$"5&$@,.-1NJ8*[[A8J/C26[Y:IREMO).`"86#_
M#GT`JC'B1&!Q7E,4`:CJ2V7PHFD`$--2&1EB`WG@$2E1JW*4%*8D@V(@AQE1
MJPU0(J9$M@R#AFK8`(PQ$6AG`P$@.(0A6VM(%^O;F=1Z&P,P(@B``'*8$PGB
M#Q9"C_YB$SQ1`G5@M`,@(Z;7`&9&'P7VA_&*(2YGB(4XG?@[$S:@&KF!O[)U
M-+4!'5YC`XAA8YP1>F(3-GL3/U]#`.(IGHW('&K189RQ`\')AKFA,_X`2541
M@WAH$HC4//1!?,_7.AK```/2!W,C8R205=I4B(=#C04U.#7;C*QF`JB(`V?@
M![R">4T`C:*D.NOP2]W)&(U1%<EG$K`%-`WJ$46!_TB7PV\`4`9",0!M8&CQ
ML@%#Q0X+U087*@(9P0+V,A]>0*2M,P!5,&:/N9!?8`5$);;XP1MGH*K:N!1,
MX3HHLCYR@R%E,``K^#VK]3U*0HY/,`!V(Q!GT`5-LCU<M;@H>26LM@.AIUPO
MV9``5+GS)R>\5LPVR4!VTFM!L,QO*KI_(BA`>;I_E4$$V"C5MI0->"FRRRF&
M2I4NQ&VH\(%4"8&-VEE3R2J0*H&=PBK#:X''^\[PG+S+J[S-&P;/>U!E,+U/
M9+WU,`<!D`Y$I0%I\'JE@1H9(`974*SR0GOHBR\\4`!7((<8L2TF\@\(4`#,
MR@.TA1!Y8'/X\ZR(L1O%8?^M9,1S-5`F(848^_52.>$[1A$2EO04#@H'YE*K
M+1HLTQ(Q^+(0!/<L7E`!""`R#L,#ZE40.-.=N8&)(O8&:MA(*W,%LY$TK#B*
M-<9A=9$<K(@9P7@.79`%81,NSJ$VWA0N06Q,JU%UYD@QZ.@.P5)QP=*Q20$3
M6"@ZSC>WZ-$4AM$;L,C5!)`%57!/R1AYA.,K`^4K5R8>!+%C^.1IUL@0^L`Z
M_1498H`@6W#`GO.7+/`5[I!4>R9)AH8&GR-I3(%1H$$#A]:$^>B06#$`3./2
M%#`$"^G(D*P!`^`U0_<%OGK)`TD61%`"[X,@^<#&_B8MJ)>WW","J0Q5&.D"
M&./_RK`,DJ9&R^BD%;)V#6]S)28)%9LS!'$B?S)9?\7<:VP:;'A55Q%D;,DV
M"78ZE);0;$KI"8CE**_;NC7$NZ*U0K!""^',S<7`"RCDE32T@;;@@3RTW[W@
M0IZ2X/$,SR0XSR58S_;,!QB@#TWT+C(H1?40`7:P1/5A<-YH(8^!T$:1$C>!
M%/PFH060+([DGI\$AQ-!7W=1$040`"V&/[WE(-2:21@@F'$D(B#``B=2&@N!
MQ^THAR4B%F6P!251`B!`F7`@`P)&MGN)D(#4LP!`:41`!`P0U/ZKFP0A$FK!
M-(BA<PA1&191.]2E`EO'&8NC-VJA7@DF#RTL&66WPG#'_QO=V1LP9IW5).0-
MD2`+;"+ERGM*`6;]9NAR+=>B$Y!$.K>8'(_!"";I&3-WH7[XA'G(Z,50)A[7
M.`)^T`=5L#[XMCX'`A`0<%$]Z!%;@`?[U>3_Z!%`WCR`E!ML1"Y,4*L],03#
M4A55`WP4!]O`#)%-<1@-,$E.8.P.V>@:,#0F,``_4>C.-P-N0!804`/0F#Z]
MY&8B(&I16B,&0B%-E=R,C42(RY%%DE1)LA5QUB0'XDS7X$I<\CXQP`<6$,`,
MP-VW)LRZ5I/AG<S%K'\/I"?#)KH.\),"")2HFR@<0%@=E)2&98`YX("<T`JP
MZY251<X9""I3^0LV)"HZ!(*QD/^5C1J6V_99G++@*"_/#AYOU6UO/;(<&=!O
MPV+4^IOA!:!O$.H$;N:]&%('$Y`$'1$\3<LY%2,&,[Z_SME(I?D7#8->=\&L
MI0F=SXJ_L.$6(N`0Y;(3*=<`+%`5P+1>18$&-4T'%;`>\FL#(!$\/)$`-Z"0
M3-$75Y\A3[%>8V$%1.`&%)`6:I%@P=E)$_`&)#'ULI5@]]0$-%,1B[-U/,`;
MG%'O9W=V"79V,=-X7Q,NLB5BB5@:1BLM_N"@";(@S9.'8#%)/5%QA4GZ-97'
M-M6#/8')C?[H`K)CQ*'7/%:()D!00)(X6-8$FXY/XF$"L_SI?R#J,ILC7@83
M3YM%DVW_>F@@]H54`7^FZPF``PA1`C2=/'_FHEC!Z[2>$X!&`>3EQ,.N1*4D
M20U9UW8/`&P#&B%!>L'2!OX`/`"Q!#_R!Z5.+5TPCAQB([,,""(X&0,Q1H<N
M+H=&B49+(B-+DH\B44\CD&>&,2(B>21\?`2C!"0$.Q-B;P@L%`E>(2$MLRVQ
MMK<+N;J["R@HO+^^P@9!!L'$144&!F8.9D7-S@[3U#G6UAQ(2!P<UQP'W=\'
MX^0'*P(KXS[HYNL"[CXKZS[N`N_R]AT=Z.?Z^O;T[*&K!S#?.WCXW@E<2%#@
MOWSZ)$CP-]%?1(D4.^P@Q;&CQX\@0XH<9804"1*+FNS`40;"_Q`($#+@$&&A
M0`$P$2),P%$'@`8*`T0,&-II0(8&!7A@:""B@5,,8DR8R*,B@!T5*E[8M"'&
M@@VO7+U>(:'BR@0$/]+^V$"'#H(:#5@TP("!`9R[+$#4@#N``00`&2:8P,&`
MCEJV:"HD2/!%`PLQ(ACLA9,F384*%'R6:!`4!P2G`TIHF*'!BQL*&WCPP*J:
MZX2]-=YL0#`!3Q:LN'&?'-5EPFK!6;J8L-#%PH0)62;L2#Y\A.#B)L386(J!
MA?42%"A`8%"B1(42EL$SH%"9O/;*:2!08%"A\N4*=^&`B/^^,GCL7Q:_\J)A
M,8`!&)"P0Q<$=-&%"J?X88))39#0Q/^#'!T2TH--&-%'%7WTP<@BA\0P`$O]
M,08!#AA8,()=:+1%1V+X98?#!!X.T$`%7\R0``0:6.$%?PDP,$$7`\!4F1,W
M#.'%#"U8H4$&72@%``!#YJ?D!T1HX",&`XP00Q="!=5)%SN8L!,.(\011A1_
M<#+34T8Q,-<23SRQQ`B#X'#&(HDHPD@4BG0RR9P#G'$))!AT4445(PRP`PEY
M<,&%"X_R,1P>"+`APPT+V$++++=TR@LPON0BC*C+_$),J2@04TPR9K0*S31*
M4#/--=Z,8XT#UMB:0SGER!./.>:LD!!`OM(3D$#F+%300_LH*^PYR@IT[$'1
M2ENM``]!U`'_1MM6=)%$%6&TT4CDEFLN*2Z8A-(B.PQ01GXO94!(33:!48`%
M/)6AP1<,#$644!F($$`2?%C0E6H\7*%P50'@]D(``5SQQL2J<`65P08W4,,&
M:6U0`P@@PX%9!G39!3+':OQ00U\4?$&R"7W1L<$&(%1&60+]6<$`!I'-6,)=
M[7W1&`1""5*&FPW`,82-IE&`@!C'88!)EQ]F4`$=7V5QVTFF<"15%A9410*8
MS!%GP8#&(2<8`1A,8-Q7)6<`01D_IT?>79:Y1P%X$'0'`7J7B5R!7O/-!\>,
M\#'`0!I[=P>>=F7HMY@&E"=01I:GC$#`CRKP8(J#34184D<44MB1_X5]^(%A
M2:-3Z(<@=1#AA7Z?B4$G'&BDN`$::>@G-,E`RDCC%T[@:,7D,Y"X$]WM$9F?
M%U980023)&"001GO"OT%`-@?35=051S"QQDCC'")<.UF,(*@41CA!R8:@Z"Q
M:&7,=`:<Y->)@8:,--)_(GZ:!)T$]81._.A0B9J`HQ;(!4E9@`FLH,$00I"I
M36VJ4['XU*=^(:I0]0)5IUJ&`:"A#&BTZH31D!6N:)4#<>1@5N-`0@MY18YG
M/2M8!#&6/815#WJTHR'^8,@\GG4M:F5K'PUIB$/^L0Z+4(1;W0+71*0XKG-9
M\8H14A<BC&`"$?CD)3'!P0!J`H8RWLLH9?_X0`)*\"$Q%HTP-DB"":Y@DP($
MX"L*@U@`5A.Q5*CE!PA`P,2>1I<)+*4&=-B+_.;#`K]PKVW>V8`:)KF6&F!&
M/22R``8JD#L0M.<R+4N`DACP%N[`!PTB2X/0N-<)@#5@%7!(P!BLT`(8)"`-
M#,"!&/W5%)YE`$IM.\Z"1%&*W.@F"S$8@0EX<!SB#*=$8A+0HGJS.8,%J0P^
MT<#?WL.>]C#./"4PI<CBHY<:'&XREU&<XBRCN`HH3F2+FUOD\B.Y_D`@*%)1
M9A6$(SH+C8X`I3,=`3@D(5(4M$&C6\0?,(&#T1S)"T2SP4[@H*(>P($"I=F1
M!LH`":$TKSR22\#_].;"D[PY3Y1CJ)*=,#&"!G`GG(H#T'&"UX4HA&]\03F#
MU"(CD_O)*9DB``''/@8""'R@;X&:4_YT.8+P'2(,85!$GER`B3-$01)TBD0!
M17`&0QDA41AP%*1<(`H+X&$++%C#!#ME00QF4(-P]6`OAB%"504A",I@Q@E5
M&*MJS&J&X'BA`Y"@*W)\(QWJX.$]H"40Q>Y#6-@ZR+0BVT0D!H2'\8`L$AF[
MK&99EK+XV(<3@ZBM)WI+BJ@%5Q6QR%ISC<X")]E0242@KY?L38QB*$`$YF`O
M$HC@>A_X0`;Z192@?.@-][(!#VQ@@S?40#I7R$-7;-`YR-3@!RD#I%XV_[`*
MIAA21B#;6%I`P)TAM`0J;.386N[B25%^@0(-R`("&D`'\K(`;S<0&LY(68,2
M`&!PGJQ,?C0`@'X!S$U^&<T,QF"C-/!R!(5,A28SH`$1"#,+)S%FUP@@E0YC
MY3@JZ$T6,#"<+I`@FLV,&@Z>]"0192<[CJN,7=C+7I#-Z'`N[>;BN@F?PXU3
M9#XKP=Q@`@%Z+D:-A!!!F`QE@1C$`$.D>!#7(.21@D:Y="3!$T&-D,P!`$!V
M7AB"FR3*'IFA@04TP-E^-FIA#.#`.\VCIY2(0*(NG*@.[\V/?@D<L$ZL#Q6&
M=,I<-@(D,DGB$&+@F<9*1KF`W>\,@F``"-J"AO_Y?`$(`(A))-;G9IF(P!"(
MF&J>JGI5.,T$3IWH:OBZ,)/8CL(K;T#S$'(1BUK4FA9NI>`NA"'77>N"UZDJ
M1K#OBE=6[94:QV8A8&^UJP,@`5?`(JRPDI6.<R@V']5>B#S\$8_*-BL@#W$'
M9.^!K<<RMED0L183FUC:T3H1M=]*+15;2V\KFB"V434"'T0`@00,(5YB[$(`
M=AN!`JC@MQ0^*G%;B8D,(.!>8F"%C`#TAN9"S6U7$$,#$#"SCIMS/@R8EYOA
MH-[LTJ$","G!BRP@([;<^&-.$.5B&"`&<P(-:*H\'LXJ\-P&"!D\=ML>`.K@
M)08\*0-"3L""9YD&IQ#_*I@[F"XS[]D5V))"*NK""EEP8X+>J.`XP2&T!<2T
MN0E(-#)STY[0*.`$\/18/NQ-&M#2*<[X^.LN<K\Q'&#*1NZ$G(VJ9,SDU,C&
M$2QY`J$K!5DV;`(N&O3*35!!XK?,H<<#%$*<<!<1A':#]6QA"^S)'0MD$/,0
M*5T#`^B"]>#LA)A;X4D:^`!'_1"%&-2%R.$D3%/*9[XP+&$C)N"9GQE*"#E%
M(0PQ<,K&9E,#!L0^)@-8PAF,`A\0Y$YD%.`/]@9PB:X.H`Y$[P(B\BWJ`HZ@
MU$\("JJY6J@^G$&,HBC)5]!Z`UW?H@50N&"N?PWL7LNU_R!4!,1V5ZYR;,[0
M_RI_12N$U0VX0EC.MBN(-0Y$Q`[6!BU-Y`/)HBQ,M&VB]5FDQ0^-U0\@B&X&
M$2U'Y%GNEH+Q)F_RMEKU]H(@<6\H$08=,@+7\V]](T88P`,XD1,!0"?^101'
M,Q2\1SX9L`4!H'%L40%R(2-OD!;S!16O$4B&@5T_X$G^!0`X`#5'@5UJ0#,@
MPP+YT08E4").`4B7`3(THA\:4`);X'/>,7>!ER-EL`5BL1,I)R\J%Q128Q0$
MICA_002RDP`L4`-T,2XDD$<1DX0E<!3"I'BWL1JXD06CL""5N"!?IS8[8!S#
M(1@_PA5&`1/9H3V6\7:"XT[IE$YP,!3*IWQ\$12*\_]F;?0A#"`4H($E8I1@
MEI,``$!X##`"PF$@"V("&&("&6)EHQ!0B<=A_+,('O$@'!(^&K)0(B`:BT$!
M-$!*>-`70$,#3F!D&E`E@9(HHEAD.!-[&T4F=O8$9Z!33`$)$"85=@8)E^`<
MPC<72U$"94!TZR,HD2%4,U-?&'4C99`!2^`ADC9INY,&_[8OX90EY0,D^YAZ
MXQ=5HO8(D3`)0Q$G8`6,^Z1+FV@!%H``("!!M*8I^)=_N.8IH-)_'C0J<P5L
MQA!LRQ`$)Z0,**1"*V0-V^"`'`!#,21M$CB!%`B""K$L1QE$X*8M3$DL"%%N
MZ!!9"_&!Z48/)ZB"[L:"4A3_;RX(@UYY=:5@!#08!:K'$D/P!2.B@SR8$Q'P
M`IWV99<C`FW3CD;8``&P$PCPA3+#&1NG,K4(-2(@7I,T22<'8R\B!BVWA+@#
M!PR0']@C`HDF`C-3`Y46-+3S2@BP=W#6'D*F+U9R'*"Y%)^')7()FD+!`-C4
MB$A7!C,``3S'%1NA`HPG%083&1<CB2J`81OF$5N'%<'1!<GA-LK!B<&7:'W!
M'HRC/4[@'C(64P/@8TZ!8W`0&_,%($M!&$:A2SCPCG"A,?C8%$+A&3Z!EMC3
M'S(!C&-G*%6`=1PA9<OX3R31G@&59?Y$>=2(`X/H!-GX7-7X'M^X&`,F7!@0
M`U$P_P'7U!+=PT9.82#&USZ($A3ELU-%PWM+(525U``XDI:00'WQ`30R\`56
MT!AU<`8&2DH!R0)&\@H)L!X0"8SN$GYXHB=3%060\"="83Z)$I$?N7(CR0)M
MX&\G*0LIV5:XT)+#`&PQ>:2I`FQWM0RND@RO<H"RPD+:8%C3X(#;`"R)E8%&
M.6X:V`'Q`)4:6)7E9EFAM41H.I5()*9IBBW>,EIOJI5R.A%=^95V>A(N<%4D
MZB[_1C<&5A-L60`K40?A6#M1L0.(&@-B)%$X4`$_L`=ID3))@W*7HTF2885@
MZ$G:$4YFMP77Y4D\1P=[IST%A@'--VDDF4HX0CDT!S'34?\G@R`3,C$78K`E
M2_`')!``!9!QG4`7=,$EU0@!(B,C.'(W",`S!M(%,1`FI=`:UK,S8L";O6E,
M6L=A3D8`*M!U8^<V8#(=3"$CE-$RZK$WBQ,?<#&=RL>*_2)H?+&=2]$4$X"/
M#7`<\\H4BL8S'R((V40!;4`Y[X)TD&`"")*,5$:,&-('`\4@\VE0J%-YEI=E
MU$AA&O!O:&EA-CA<W)$?F89-EQ,G[#B/@N`E4LB@<,*.9\`931$7^C@B6:)Z
M(B`?B,06GC0T%$`($S`")4`#I[0[0T`D5G`#FE9H[T$!__8*I,$8,^%G(E`'
M]=-4_6.1HA9`6)4E^5.+AM(%BB/_2%M``QR4*;>VDOMGI'2%*J/B"V0;##1I
MDV:P*GN%@,S60K0B#@?P0LWF;$+9#M=&+6%Z+1Y($"BHID>9;B5XE>@6;M[6
M;EEI$7,JIQIAIX[;$23@`F%P"3M`6XQ!-T0!J&PY&,`EK'.A'$[V.F,D!MSQ
M`Q>0,I.$`-^A'@,@!AJW?*+:8RB'EFYH`WL!2(DT']^A/;73?#^#<^GA$QPE
M!CQ@,,)GJEB"CUV1!WS@!Y(0=6^0:`V@2_Z")1^R&>Z$FBOZ!6GP7&#2K+A)
M`F-'6V4H!AE6%1K&81W688J'O@-R8B:F'$K1%^'D.&['A#.B%S+"E_G*'8TD
M1F(T%TZA_PJ)UC:?*Y<\8TAM%C4W"B)MB)HM$1,!HR4&>RB'HB&0UR`.TD_U
MR2'*6"&49P3DXV6S<R.;P0.5>SW8PV)T(T;E\P1Q$`51X`??U:)TP5*7<`FF
M"AOS`0%5,I&8L#B7P0+P`4J40QH#<+,EH`-",#.)4;0ANC?.\5ME,(I?<);1
M,SL:4`<,1\7J$SZ)`+53A0E_DE7$5YHEN@4E.00<]+7ZYU9BRVLB9+;&T$$@
M),<UN;90VK;-H(!T>PWCT`UUBUC3]D/#(FZ<58)C*I4H2%IKZD1+](%4*<E!
MA)7?LH*+"V]U^K@P&+F6,`)]T`"18UYL%!1B$`!E-`=SD`4?@O\C4$*]K00D
M-,=R);`!>X"Z:J"ZV>%@JJ`QNS,?*4(9,(&6`[`7],4Q-),&0E9D!7G*B99+
MA!&+ND0(;:.L?I`'>:`PT84!9P`U<TD^ZP,_L,&8"V<4U],=M8@=JE0!%0<C
MDF(".]`'?-`'"Y(<.``'RI4;'\$UTZIU)]%U.Y"M)H:HB*F'ZE0!1+&N"MT9
MX=G0^TL8GLH9-6`#\[5H4!%,&+`#4C,@,=!UD)8H/?$3E"I/EZ,<ZED%`$6P
M6$:?R+C2)-&,#DN?D#8`X>AO-:MDY-,ENQ3`A1(G<6`FM:=3'S(4=5*+_?@(
M,K(7*P('3C!+O$@F0&@9\I$8-)!F_7'_.5+3J+I[`Y,#/;S(41/P6ZQW`_DE
M2M&C31W5<`5Y?GDBQJ.65%B5M*%!-"+P>6A&`VN`*;_@QF]<I/SGDJ4RDZDB
MV/TG;'),;%!J0@G(DS+$D]Q06!%(;1*86=("+<-"I@XAN,SBR(*KII3<R):L
MN.`BVIF<R9O,R?5&`H]R"7R``?UF.:5L8:B,$W.@`N;\`3_1!M0;%%Q2`A-P
M!0U``71`22E3,T5&`2]R!::Z%BNBNXQ39)MAB(EI3M]!`?KR&1;01Y$I:$^1
M"GE@C.%S$@J3!S?+2[UZ!EB`!9$!LR&SBDE+&/^A,0C@%S4"`340UI]&F^=;
M%3`C&<J1TJ.P_]\:QC4$0,\FH0+O:P(,U1=(%W+]TB^Z%!D3-Q>EV39PP3,(
M)AG.E=3=>:QFEPK!ER@B8&<CX`?*.C6$*GM^$<'0]PGM*3H6_$\?3&4#U<%6
MMM*+4$#N,K$$R21=<`:("FB&!&$_XK%R0N*^ZE)96#\M2HOL$1\?>CQ+TC;<
M8:$_0`<RL!AAU@9M`"`GDE]2<B,JRA^H9TA/G@9$4M;1HR3J(WQTLH\B4`5M
M+6J)D'YRL@11\'ZGJ8^=8-<_F@"]X+46!+9^G:0R.<=CZY*^8-C#4`PCA$)N
MZPW;P-A8F@-(4,CMP`YXRU@)D<A!=&X=^+=E2H)0R6ZC#KAEJBU0%/\1IA6G
M6QE%I3UOJ.VXJNT"E]`'$Y`!BU&0!N8;9903!Y<!=8#;+&I<G^9S&*`"UH,&
ME`1(X=HR1[$*XK5>Y5%D_V$#=Y2\2:-.L4H36N<;Q:L:ME,BKOL)`](;="'M
M<!%3A#&O.S!]LDL?#EZ-J`E3VBM2%%`#FF1BG;,:)Q$Z8B(W\YK=U"J;7;.^
M4E'PLKDE)R;6`".K$%X4U)%H;A./M`H@+O46H:J[^%L#;R&<73&A\U@^4<!2
MOT0$"?`=+*YR&5W!%KP@)1%0_PXZRUCC\(EEK+-EB3`G.!LBY+H1,\P'&OV.
M5$./<6)G&N,6<'%).9@E"(<=%=``GD1Z_9'_:<XQ`%<CLVE0UC;R$B3R?BOZ
MG]DQ!(NA)/^!"J&1G+Z#,X)(,CP#82S!Q3$0QF*,".F7D=)WG`S0!D-@'6BE
M5KO`UWW]5G\-@'DU#'EUMG1%QW1L;,T0Z8[-D\Y&#I9.0[Y2;>MPR/#@V1V@
M68VL$/IPN(/[R*%>N*-56MSBIMSRZO*&R;%^VK/.6K4^)\N*`[N^'7S(@S@!
M!LK.$Y1#`4P(GB/>``%S!?T%`I,TF<^.W!<-`APGLZO[%V6``;J5%&$=%'MA
MX1/=,`VRB:H1,04<-;X*)O$JWSQ\.`.0!CIX(N]Q%\'<B#-!&*GI%"60'T0`
M`2`@48;78:$`"$8$_R19)@,E-18V64U-!(^0@RJ3E)0DCI$[)CPD(F49`PPX
M`PTB#1,-&#4-"!@B8A,88B,C.R(BKF)B+'`5)6DEOPS#%7`@-1C)8B0C(EU=
M,5VW(U%/`R,X91\)#"5E$.`EH!@3,555!(V1ZX)&@I"-\?($[O7V[_8QS1E`
M7@DW%#)@V'&&EBM1#$*U@3!*Q(@NS1J`@-.+09HT%,"!VH$A0PDX:#8@`$$A
MP1`-%"H,P""-02\*7[[<N)'`R@P-&@3&$-$F#<TO,&M:L?(!P(`=.P8``%K3
MR]`91#Z4N78+UX`Z=09T,>(B3!@78%UP=;'$X9(G3\X,H,&6!@06+&BL6?]`
MEVZ(NRWRZFUQMV^(NG51"!X\V("!(D4,"#Z<^+!BPI!1&%9\V(QE,PXR8\[!
M&<D!)#DX'!A-6C3I%2L.K/`A(/4*`:U?=^@`N_9LV+-IK\Z-^[8`W[EI_Z;-
M>WCPX\B)!Y=P>[8$YAV>2Y\^W3GUZ]BE[UC'O;OW[^##0\I#@HN+*"/.)$V0
MX%O":Q;`@)D#AL2$`1G*)*``IY2(`<Z(`(H*8C``@AH_(%`#"!5@!-0`%@2`
M0`,-+%A1,!24T(`-=G1H1P`6Q!*A!22^8<,5?<000S(33"#&&V^(@<$6R-PB
MBQ@U\`+"1!11Q$(%%`#`0(LEN-3##TC^``<$9>#_T,`P3`ZP2@DU`:$!`S5.
M8$(6650R218#0("+)NF08*:7EI#P2!^1-&(F"9,8H@$`&3"`BXRR8)#*2A.(
M$,L()B1CP@@36)#,``EXH0%0%%#@Q$60&I,*H8,.!`U!Z46Q!`XBX%#'G`Q`
M```X$)2`PPAF$F!"%28\8D\?L+8YCSJNWN/.(_-`XLYYS91`A`9>>$%!&PV8
M`)$J(P%3005.9%B'DZX,T&`:%/E2`9-E3!4+#BP@L`$=(#C!G@9$)%"D"/ID
M4$<&$`#E1$Q#X53'""Z,4$))7SCQ+GLM$*6!"#MT$>87Y!+AQ0S^#,&I@*#@
M(N"S6W45%EAC16$66F6U_]$&`S2TP08+"80@F%TMS+!77GZ%$.Q?@1$VF6&2
M,?8RS(Y!-MEB,U^F\V8Y((&$:9R=1IIJHZ$V&FL^O`8;:L/5UIMQND'=6W+%
M(0<UU=`AE_5QU5%GG72Y92<V==N)9_;9:$="GGE&=''&3NRY-P"`8H`1000!
MJ&"!@/I1P$(I<SLDX``V%'C@#W2LT@U,)6`00`0%V(!!**10*%$--A1@API9
M\!!``5>T:$/A+[8X0C)ZLI*D@I93?B@#Q2QK#(,.7JF+1V@@N<%$:8@Z%0XX
M9`!`D3A`H,$,8VC`P@\V=&$"YS:H^8@)JXI@U#)HJI"JJJUR;T'VVJO)1Q<9
M?/^@@9@--,1``X=DPP`L(79!`$&QZ((#`!\0<=-^%SUZ48-P6`6%R.$0/SPC
M8&<X@Z8XA1\`"(D!WP!'0/RT@RK$8`GF0`>NFF`F>="J5N_0E0=U92NN&*$@
M`\")%X90`19@P`)=J-`;?K"[937(63@8B`@8P`(0A&0#-6B428HT@`D(S"7,
MBLD-AI"`&5A!`]S8P0CJ("2,-`I>3SP?!@B`@3(LJEE!$<H'()",48S@$!GP
M"`\;L(46X6",#I%B\$[%%:\8(0I1J,=Y+O8$]*RA#320`0WB$K*ZA*`%4(`!
M%/:2LKX`QF4SBZ1A$$.SQ$1&DI/<F64RTS.?D29HJ$G_3=%.(TH?1(TV26O:
M;%B3'!^8,CA7$TYRGD,UK&$-.K3\&BV]%AVPZ7)L8BM;VH9)3.]P@1Z:*@L$
M$O"%,K0A<#LH0`1X@`<]!&`$^0'`5/XS-P!UJ@0(>,,`X""2B51@&-UH``_`
M4(`73$)&8M">"2QPA2L$X)Z-F$0`K@`+$X7S#1.J$(G81X<-?,M"%/(%!4[1
M*6,4]`<(@@-,F(0#^V&I!G"@R:.^D```P&$`P1N>+!KP!2`H@`@40,8UD-*]
M1YQI`J!PD06VU,$W-:%+:`(/'U0U`/-E(!7L*H$$$W"\!+"@!B:0HJ9&$*(P
M>6$,8X`"%)A)@30,0UKGI%;B_P:8#&BHJ`^T4%$,`-3`X:5!FTR$0)T&PH=Z
M<%!Z]6BK/=81#^Z4,(3QV-4)=T@$*X0#`D7L@D/I4%`T+"M4#LQ`+3H%`H.B
M@05I2)0_JKH2:7CD74,`2**<:`4OO*\C97`4!682$Z+B)`,3X(.]LE5:?WVC
M!-P4P1G^X(=S1(-%6W@2N6!++[6L:P3NL&,4JF"$*OP!"Q8;`<;"@($U#&$-
M)U!"$`"#%T2>C"\I>V1A7H:8[LZL,8T)0A`$$X3';/=EXK5,$3"3&0=TD@,Y
M&`U\.;":I*G&:/<MVF\$P,I3!D<VR.EO+7NSM>@HQSIA2\[5MI;+7@*S.@Y^
M<#"+2?_A"@^B'G@<P3*'$-J$B"!"5YCGAS"0#6V^IYMS"Q[F4@>@_JBB!C5X
MPSWSIH("%`!$)'+1Z$;'B2Y=`0%)8@(3@(B`"<V-''/;$8]VQ((!I"$F'^X(
M.9-$0Q`\N9D"$<-_P`6DE#R9/2I)8QD8<*@$*&`,;A@"C'%!@,Y5XDT34.LI
M6M4$\&5A>]SIH)>8`8"<G`*"3&(F41%&+-.A901B&("B-&`%J":@`@R:'470
MF88*+*A"78U&%_Y`BS^HZ!8-/%^H(JBQ`2R#'GZH;??Z<"MXQ.,2F(C$/>CJ
M"%N!)0K2P,%-8I(1"%5!!`$D+!UZ$!>A:L1/(BA!#^'@(/;_U(0]8MH)!*K:
M*`HPD=%#X88;%R7:F!!L!E8"V!E3G($V9&`4;&P1B7'@(E>8`J38`H=^OL"I
M)[C`MV5`EQ&\\A4,1^$,#EEN%^:R!NE2]Y!Y6>3)_`*8!=B,N]V->&(FWAB8
MQ6R[.#-`>LT0A$TZ`#,<"#E\Y2N:4+H&OTECFF^:)N!5QK(#+5?P;WQI8-PT
M^&NV=`YQ&BSAGOO\.<*TL-#-1@(]NH!\"6`2!#P\@3S,<SX%F$`VBE("%(-T
M%$ZR`1Y<Y*(KV$`1)/I<WN`TXQC9P.RD(Y$)^-F`#:@!08@#086>))`^#6`B
M(='=DY9IE!#A8,H;>-*R2D+4,K`1_Z0,&N2/OGPE_.!@3J,(4[F$M8$`M$CM
M+9T>^2IZ!15LSA*8,`&;7*I/-$D/$EWX5`;\A!]V09$]P0+L0`J2%J7LIR8(
MJ\`&?H"&QG[+G#>$-!QPD0Q]C,`/">3#IP$DO/,!J0Q#&`*IG!$#/"[!#]V+
MAPIR)>M;U=75W;^K$<J"`R\0H5P9,G45G'R,&O3^6AS]0JG\A`&7\`XFWJZ)
M!O)=!0U#P(K65EKDH@%',58.U"C+]'H=50*G\Q_DT"(M@@<2B`=;$"T`$BK.
M-A1$H`!6(GW@<`U+0!9\@P-;P6\3$P6<=@UH$05A,`$R$`(WL`8HP#+5=5UZ
MX4C:=5Z,T?]=9L"#X"5>Y74S0@@S#E=>Z848[&49[Q4:0[,:H71?*1=*_34U
M_&4U4`,=+S=+NT1S$(9@4X-@O10V6?-S9`A,03=T:.@=Y3$61A`#]P,!TN=A
M`W$%!3`']+$#GN)`5==-P,,I3C)38O`X$:`&(*(+-N`Y^T0"`5`X,[0Z_X0,
MY"`C-;![0*1D%<$N#;`W$)!W;Z<&@<<`U<8`>&`(#4!85E95:;`O^]<`8M``
MI5)IO=!L&J`APS`J,?8&%6`POP('"-`,7:`).R4)DW`%M^`B\T1K<)(]=R8]
MU`,);X*'YX-L:60\2==$,T`!ZV,"`*</#F01SY8&>6=8N8,@@0?_*1_A"Y-B
M+"/0!V[C:?J08GTF)!2`$TG')`VP`W]`#T;@)B!D*[06:R140J[2!/>P!-B@
M`58R+B4P`>N7!L?0>\Q&$_$"`#FT0[S@$U?D;$0%`.@R`E[D*&#4+N0"!!S9
M?V?$+J1R;I5S*'[B(K"06RPP#*5&(2PPCV?F%#"0DV-@!4,`$W0R`$_P%0:9
M'ZL7!6#A%6%A!%CP'P^Q!"PX`4I`%RA@2`@G53:(@RVS71*G,SZ821SW,C$S
M&>(UE1K7<4B8A)L1<DS8A*XD2JL!&SZ@7U4#',?1-#/7'+4DAKC$A0Q&2S:W
MEV*(<Q%6AH0Y'6>8AHCY"#NE)B:T`PR@_TVO!2!,)4T1(!\6@!]E\).@!E+7
M`"`6``N>8P.+V")B\'6*P`.HB0H(\'9(@@!;X"VK<"<2H60U4%`;``="E2VF
MYHJYHSL[@IO>]CXV(`*3V`LVY!/C4@9;P`2N"`'5<A$P@1-O@0/>@`BH0`%`
MD)U>4`&M4`M[1@(60`#W@0N%8@+)"#Z7T!WGF29]H!2KAPK32%4)<'Y+IT,B
M@`5*P4/+]`45`"X^!`=.H'M(@B`@\`L9$BH+0SU=D")GD"+1@'5>)"14`D6D
M@@%%QP?#Q2JB1URME@X>!)#=]X]W13'2``&_PDQC-@%9D&P!A`81R5$UD3Q#
ML@6A`"0WT"PP.O\N'-D%)+84^E):?584.001ZI$,J;`%;:0+,M(I#C,,)<!1
M&GB-Q[`%%>`%4A4L5E`R5L!,4$J1U/`5Z)$-4Q$#1\EO[N`'`-(%3MD56Q"5
M!Y=P5GF#6"F5D#1)/,B52-@8ER%>93DS?+H816"6ZY6$[L49:UDTJ,$:;KE?
M<:D:QD&%=VF%!E9+?9E+OM2%8/.7O'2IA=FIV7&8B9F&.\4%N^("?.`)$=0P
MDUF9\J$"F*E-WK299\0`)J(+-4"<R'"+,2(&%L`#6;`%C:4[Y2013\)N-O`D
M;0=1;[<[5@1;%&@@_KDL$U$23T1&D@,"=`!`@Q=_[<$*-/H-E=8-HN+_0&("
M;\,3/##A!?W``C%"#DBQ`WZP`V*5:Q-P!9[S9J?7)F_B)1RT#FKB"?4I=1D0
M)`!0$N#V:#4R$*'0`)'%GW3@HC?T!1\!`D#FB<!)!*.R>GY"`-#`CGW@!P\*
M/!%J$02C`=*G`3D4`WZ0H:XV0NQ0#Q[ZH0%)#S'K""0J($`P`XRB(7C`HN:T
M+T,`I2C;(@)2`OKB(`)()V>`#O>1+?K1'BIY"BI2!3O`!Y]IJS#Y(S94`GUF
M,."F`&>VI?Z3HS-1MKR6$:<E`D'I%>B!F238%69J!"F8'DX9!G&``6Y*,GH1
MIR@SIP\'<44P!9K4@SUXENK5IQIG&'RJ<8;+_UXY\'&AT1E-F*A+,QI-0[E2
M4S4%9JECV+G+P9?8H4MZ"6&>6KIF&*JHZU)%%Q8$X`FCHE9V4@N".`<1H`)\
MXT"1!VJG<@BE"6.[TQ^F$$X_\`:BPP-;L'O>,J"WV0W:M`4\\"0U`%%5-JW,
M!%N%PP!T\`,@0`.09F4Y*GL-4`+%8$[-1E3@=(CBE"W!(`X>,0J3$SS.J2#7
M0@0Y2P%REZ8J4EM5P"9((0978`$[P)`M=2;HJ88$3`(80%'D$#Q<FW0GD;.6
MY@H)9`I+\@7@N#NW^0564"[KTP`4L2"]<UK>-`$<VP7CXP<,VH>?`@`7T6?^
ML$Q#4BOI0$*L-E>MEO\K=]4=]T`Q^[`-9]L`>/`D_=$@^\(>!/,!BM4GTP:2
M.:H!11%8SS"K"4$A22H&>%`%SP`1NKL01`4!W;LD'\!9P8(P5'4#I74#,J`#
MQKDLD$(!V<(`M+`$_-:V^<%N$D,Q;3@WT%"W=YNW57F5./BWW]5=4^`!.O-Q
MES&HA)L8'6>$0*BXZG7(CXL9/A,TI.2HE0M@K<$:7UB7DQJ8G\R7DWIS8O-+
M8%C*IIO*VI&ZJ<N87,%%PE,&\L=TLPL&+X`-F4F1Q$<+M`!2"'"L%0!1W[([
M=[<!;Y!;>&"\D[A[G:B]O8.-6V`#][',#")\^/(%[[,+(!!WYA1&LY@GQ5/_
M:>?$`-FD31\V4X$R#=&2"A,0,*TW%7L'`%9259@V$`;,`R1B`>OY9K)"".`3
M/H]`/I]P"O@A5*-R$O3+G0X!$11R+P[Y>VH``N<W`P!@:340*HVU)!G!*;Y(
M`%A,`"H+TK9P"U0T/*%"C\9347S0!Q9D#J)7PZ%J0L7%H?7PCJ9EP0RP!<\J
MOOT#HS$Q)UH!LGP3:$;<!IS"$ED,@4BZU$AJ.>R3'QQ5,.>W0I56$E#$*'"8
M$D3\/]+ZF\]I55.,U"P8!UZ!#:*"6G*;5.>0:R-P07S<`%-9@SFY<%A9IW8:
M<87L`7KM<8.;R$`(A&9`&4&P7H;;7CSC2?AE<G#I_QJ7^TH)IG,V][D%YF"!
M"9A[&;J#.9BA.S::K<JGR\JAZLJ"0#[:-,L`,@&"6)EV0&*Y3&:ZT,Y8@`4D
MA@%7$+YT<`%[P)H(,#?D7%%@(J`(XI_,-FWK\W5MM[QP\+!`XFT_=:O]25@N
M*HL$F#F6%RI+%SQII)(L\1`QD`>=ES=21"@L`7`A50>962HS\&A"Q0(5.`'Q
MVHS).&-CQR7=\<^@-ST#C(=T8A73."I>!&Z61GTC\-3%$!+9>IM4A24%\`,L
MX)QT(%'G=-0/X=%;H2(>K5HD?=XG?=5$8'C0P++@IX_N4,,A5+,$V8\PNX_S
M4--G-)])YQ8X@*00Y&7[PO]1^%,'&/`':]T,W43%","K\FI!L;`%.Z0Q3&02
MZ[,@#$`NS+3!"0.21YX2Q\!EL6-#/6(,%E(MPT"<8A#`.Z`FFE+6PB,5Z&("
ML,"CG=+6U<>"7B$""U"#@'P761F6.VBX>JW7#F#(AKTS'X<8?]UQ'"<9B:S(
M[O5QA7K)]P5@*3=SS/&%/+=SG3O9E"VZ$?9+GGWII@NJH&UA9@*S;@B92W?:
M*G`WJIUHK6VD`X$4]]$`M9T!<*`&%X`@<Z`&=,<0$V"\I4B)``2@,0%8)A*L
MO?=^2$MO*C6QU7((N0P!&\(#JC(YW@0@J.._(.T.6$`"]10B_]$IT`X\P],^
M);#_*$^F`17P!B2RSU\""=1#/?MJ>OE*5]EC")^P$IW"+J];)6E`Y$@QX!`T
MON#RH_('6T#V`Z[8GU;69.[[#'R`Q<45`VWH!]@0:A9L/+]B/&3$!WR@XZQ"
M#W)UPQ]:5S;LH>P@%B%4JFWK1>!P$FV@TUO`).SB13CQ#:"@(M!P#DFE"TR-
MI*;`/D)56O0+55;`GW`@`^^RI3+!:_Z3!C0P+&G00S"V(\<)*;`#(*G@;I9C
M([Q*(C:@`N/'@OL``.9"#C!&HZ-0?4Z)1^?!`&\.I]?EMSHH<8*+YYGA`>TU
M]XB\287;@V5I&4:(&81KZ(9:J)XQ2HC*2F20-*R42Y'Z_^B,?MF/3;I>TS68
M'OFIK.F;7F&D^LJ&4-JAC@MT>#>6.0"Y7'7!0Q7()@(\(`:_\`-S,*`"+U1U
M4@,%(`;8*MSOAZ-C5@.R/XDTE*TX&A2$(SE.&J[8'1`K$3"_.$\GPD^1*`L`
M#!%I,>"J@"/L`SS,IR[BFT;=8`Q,!`>FJ8;V/0EX%@GF#O[I^0BVX!Z'8M#?
M4!,P0`.Y90)V)SS%4"T:#`3F4B0U4&02Y9`3`0@L`R4X&#LQ?GU+?'TQ!#$Q
M70,B.&4`7VDE&C,:$%X:`UVB73%5)@0$3:JKJ*T$1K"QL:^NKBXNL`0F)K)&
M72(9&D-?"0E##%MB#6T9.#@9;?\,#343.R9\554Q$Q@-(@-M$&40)0,-W0QE
M&I]61$16"5].%6E?\DYI%?3Z<'#Z:?G@@$!#!T2_?_I8P&DPC9H8#"(:3)@(
M<0(/&V*V-!C1)4R8)R)^01#68`L(%@QPA,02I:6+*'Y&M`G1H@44&#!JZ@S!
M,\2"GRB"!C5`U$"1HT6FF/'`U$$.!TZ?0IWJP(P9J&:*6"UB($@0JV:^8M4*
M-<=3LSDX'#BP@NT!M2L$R"5#1D!<`1TD2.C0`:_>OWSU\LTK^&_AO80!&]Z[
MN+'CQY`C2YY,.?*.6I@S:][,N7-F$D9N&>$CHDR9+V7*B<!@H4"$"&#`!!`!
M`0``<B7_,DR:M&/$@"LV&#CY,4?-CQ\(&I2``(%!C0(6&M`I.-!@&@H4OC3'
M,*'!@!H_-ABL0`&"/0H8>`0P@0$#`P:31$0\)\8"'UA\"%P)`%Q9Q$GG8#!"
M#&<,4(%`T]$!!P,E2.-,!N0PL)"!%'@Q`P7GD)(?`22HX.&''I*0!0FM-$'"
MB2>"J"()37Q&8FG;88##<J:9IP$,%&RQA043##!`;0<.5`$Q,T!P70D@U``"
M"`D6)(@SK$'RB!]\G-&(*/)58EL)%&A`A`9?<#+`(=F@TJ*99[XR2XFKJ.)*
M+['@8D0ML9P!3#%XPM.&"!/U.8&.$XC!37OR#7#=#0D0`80"_PI804$%UD%0
MS##$W(,/`S2T00,(.J)AD$`'(=0/DTJ"4!(&6P0JQJH6M&H!)1C@80$>W4VS
M104T.('#`$\\,<((530@*88@5-#&GEU$$88+851AA`D])F#333!`45-///T$
ME%!%(974%%,PY4%94J$EU5160:755EI]!=95[Y9%KEILM;666G+-U9</<A'&
MEU^&!8988HWY2S!C`5>F\,(,-RS999Y%+/'$FG&AI@L$C%#'):E-,H(%8+@6
M6P`80`A`&3B\MYL(O0T@!@\L.+%!<>'54`&7Y;F<$1T;(+"!@@!EET`9#5C`
M@S(#F*K/>PPZ9X$*39BP0P`V6&!#'O\[J%I?'GXLL40,.YQ1`P)DUR`"@PVN
MMD,>,AZHC]LEQ"U?;@"4,"&$"7CAQ1`UV-#ABBBJ0H(%)EB0A8H@GJC9B4T@
MK@(&9=2ATC?/U&9>`C!\41*/@S"7!AQHH`&'$_8`]`62#8"@Q@47&%=L2@-@
M8$(DCS@R8!6B^(B#;9UT2807Q6C`P`X[9&,*+[V@V::;J.32F6ASG@*+:%WX
M1HP5V,^0``1M?(=`=P,PT(8S\(6?`0`::%!,.\`70\%UX^3S-CWYI('/_&B0
M_6D_#.3#T/];J,$;;$#`JKFJ@%93SQ7<LP4;O`$!/6`!#29(`QG(H`+R$<$(
MEF`$#$CJ!A/_'-^`_*`LCV1C`B(8`K5J8BUL96M;W"**M\(E+JJ8ZX9.P<I5
MJ@(OL+@K73S<8;DX@(2UU,M>;,%+O^JB+\'TA6"#<6)D\B*PA`'F8`[+HA:W
M:!B(4>R+8-R,$4@DBS.<#S6Z&<`(3!``D87,/;4I0_E69B<<U"``#9#9',)3
MD*`Q9P`3F<8&!BFZZY0G`1E`0`%"%AWXI(XA[4'`%:#6!-R1(`"85,$?SL`=
M;ISA#",X`Q;.P)`:#!(!-8`#0')3B![9C3SS,`AV=$,)!C`G`_#I'P7REH!D
M>+$5C'-<XA27"A:AR'&L<`4&ZH`R#0Y@1I8C!@R\4(&B]0A"[X-4_R&=@!V`
M0*H"-6"=<13TI-7,K@L$$`4?.**+&!3*-+U+0/KR1@0(<&0)9:H%\S"3O#=E
M)C1RV@7R8A&#$=#&2S/`WA<HD-#WE4`=C)H!)OQ1`F(4XP8WL,<-*'"#(6"'
M2]I<TI(:H)`C,:`""DF2DO[WOQK41U`3.$7C5&`''MA4/9BT`R;;:`/EL.`D
M%;"@$RQX@J*R8`LC>,(2PF"$"3#@"R"L9DRK4,(P1`$2+!A""W"2DYU@2UL+
M$`H*BF(4I-!P*C?D@%K-P@&T4`5=[PH+6'2(5JG0RX@KR*N]!$"&OO#U7U7<
M"\"D2-@I3@:+7$RL8BOSRS`Z]K%-D$4,2O]P">WXB$\!>`T8Y@"&'FG);I>=
M!$0*@<<T;&"<UL'.Z3!0-8B``)44S0`K62L;3-J`&Q,8H`6N`!P;\"`+)JA>
MH-XPP#S4X'\^XDX>V+:0D2[)'S<[60/$(((2'`@-&S@.'6X9.Q_5I@3G^-$F
M8#`#%DS$!"GZD!U6Y`H3H>AO@&/<\E9QHAB<#Y??8(#);#0&+["@;SN@1-P^
M)Q"#+`D@!Z$`'-2@!D\9Q#OFP("@N.,-#"274#ZR!)@DE3[L$2$#,37"\OS9
MF3:I"4YP:EXOHO`K''A)?0E`E!LXD3Y%`6%OC[J./8RD#V[B0\?O\P<<QD:=
M\52@?_"9SS3ZM*K_)A,0.*TZW$XQ*0<;,.'*5R8;V7I0@1LX@09K"',0E$!F
M)7A%!A+Q0VB,$).(2%AZ45A"2ZKPIP&HD*O6\NH+M15#&9JU*75MJUH'O58<
M4B6N<\VA$)]BAAS<"Z\^T&M<Z**O)T)QL(2%XF(WS>E.=_&QH`;CAEH4"S\P
MH++-F<0$,OL:SIK@F<P$K8\<28D&\``#%<CN!CRU("XU1PP%*``/4.@CAA1[
M-2IX`8@P:8'ZD,`%?,@#M/HD(`R8,KLUZT?XI"$H'X5JI/T;"0`:<(419*`"
M=#C.KN%`@9,5`M9E,,<@-*``G)2W:O%-48=(!%]DRI=-Z551$_RPN^9X_T._
MS+3'BUF``$%1XAG6!=T@LTN'"CC!'_*HCD%\!"`1'/<]<6/0^T[ZS`%H.![R
M](*'(<`=4QBA#_<Q0IGF--]]GK@7D15Q9&^.XCB#1!T:L((]JA5C"@Q!;PEX
M7QIH,*P@U2"5;S/DYUC`@FF@DB$'B;#6++`#"[P713B=LGHN@@<$:(3J5->!
MVM6.A!.4F<Q>,0"WO+(&9)B@"A[).U,!&H:OT?E/-,!<5W72@J^"=2C=FJ&X
MQA5H0A,:+6TURUNWDFC)U]4J]TK+`:C@@TCG=2Y,)(-@J_C$@B%V,:?WM.I7
M_YC&AOKUGB$U+/HP`%0G.3TBF\,<+#"`#&2@#O^@3<FNLC0`&[@'!!N`.LAQ
MF9[8!-OX#4```0=XA4L&0`4I"@`/KO`&,5PA#V+H_M,ES/74Z1J52H*#^5H9
MOGY@]P=J0("OA]8`MEG7.O;`QQ<TD`&#4@("N!0^7S`&,P`%8^`<$Q`#`G4*
M_:8B;"(X7]>`C),*:9(*!&!RNH$.OJ<=(S$#1(`D$B8CT$0!V*5KQX$&GV-D
M3`("3F!=[T$>#2(IVH$/)4!@WP`,Z),^Z:-R'@@*$Y`-SE-S-_>`-8=B*98+
ML;`$OO(C'P`F5C`#7B`/_R`__N!-D#(=3V<J%-4@`U!UI50V%,$=WL<#*F!3
M*I`%64"&U[=]!(1E3`#_03W0`VS``D$U06&V!C)05$7U=EYQ`RCP$S11$]AC
M!?R'`:&A=SXG"F"S"W_"`FTP`PH`!7FF9X<G5F3E+4500U'!5FIE1)Y(1&V%
M!&YU+HBVB3=T`F:Q%D_!`7<1:6S!+W315X(A%ZB7>I)ABZR7BZOG>K#7BZZP
M(624"Z6Q8\/'6B(3`7.0!93P>VD$.QGT'LUF#OEU6?)AC'8@9040`-WG6^&G
M'A^2(LUV'#]0`-SW0,=U#MP@`C]E*JEC*N8#`"#V*@P``L=A'#]0`SH6#RXS
M`3A`8/7P*-D!CP*"@])`4E\`!`4(!"60#$9#AL*$?>W5@(@C7V?B7OU&`*71
M_PS>\`S8Q&%$0`%C$XVRQ1P%EFX3MR33X0\$,22?<QT`43_8\6,MJ`_/1`GH
M\P%-F#X)Y05E(`(64('1,U"R4'-I8H1K0B>R@`5*.`(0$0SQ8`\Q1F#\\#;]
M(!!9^#_?$&%/%WX#5$!?YR&8I!XU]5M5(RAGAU)LD)9IJ78G0%1M269["'=Q
M!XB!R%5C,`:*`@`#$`/,DG<M`0DQ(`9X4'9;X(@)``612'@N!$.(=XG?0D/C
M8BZ$9D14\(EOD1:1YU9!Q$,Y((HWE`-%540'D(IQT0$^@%=X$8NS>#"!M3"X
MJ(NPN6F\Z(NT:28G1@"0$P\=LQJM`1LC(R,9,`YSI/\[NE,X8=APJT)<-K!(
M6=`$V*B-8H`1T2F=NT4"MP8>#*8&;T`'*[4@L6-A!R(0"'`<-K,<\-A`U85\
M/P`T01,\)5`#[O$H0J9*V:$!1+.,$#`-U;4)5@`%,Y`&TA>!J!!P#_DA%@F!
M,R5P_R8L&FEAN6$>'`8$7S`V`J0<<0,!%$`#UZ5K`S%(*@D'"]4/5O@/V2$/
MYP$0SF!0&C9/"8`]]BD"=P<)?I`(?7`*[35B1ND\K6"$?=`'*_:7U?,C>+)0
M\O."*K,0Y_!T2MH>8G@%V_<TRR9V-\4$5I9E/4!2:$=!++!V;*>'<>D50>"'
M&!44"Q"(+:`WGZ`^M]$,H9#_#?CT<GS@*EG`!#U0++LT`UREF(875I8H0V65
MB8MGBI.Y%E10F4:D%J)XF3@$1&4ABF5!1&9Q`DC0%O3"+WUA+Z6IFG[%FK'9
MJ9[*,+-9F["7'\&(,1ZDF[3T,6X$&]=T,@R0E<]$2S@P`1CA6YF5C38`'#C5
MG"H0`%E@-,=19;K%I#%E`=8FCLFW)"B5!LW1?2GS?@QVC[:$&PU@?-+P7*4C
M-/+TGCLP``LU#_[`3?O7DQ#1>RDS"1"04&,``PD@$5U@#0PHD1\RH!,HK\,T
M@>V%FQ""`^'UH%\P!'FC`!HP9--0+#68'4-`A:'3#RF)<0GP39GPDB5J40OE
M@LG5_P"FD8,ZF#XL5SRTH#S[E&*8T28YVD])Z#5+P!'4)0[,T2`5P''FL&1:
MDZN\13@$X'69!);75X9E^2<:L05Q&+1IB79;R@)YR'9M%Y=F8&9!`(@[`55A
M"K!#X%%,$V'<80VN@(998&405)@TH%4W07C7LJ=\VIA^=A2!&A6.1YF%6JB;
M9T1(@*ALI9E742Z.:A9%)(HGX!9KL0*6:A=Y9:ET045X\9J?>KB(JQ>A*JJ@
MQ@>D>C$$8$:W40:T!*-@\!J^V:W!B3(PZPRKH4;-UI#9V'U<V2H.F07M`7_B
M2#9O<%SR$4CM2`<^\S.8\J\,@`!X\![991R\5@_;@R&W)?\"RGID[U&B\C2K
M%Y@``4$/I"-/>@D1IY8!'E<#%$`$8X"0U%0?AW,XPN1>Q?20[V5B%AF^33`!
MP2F]#LH<*&<%!$@!5/<>+ZEC\B`_\_,V]@"Q$3M@7!(WY1$A\*$2&F.>ZT"(
M10*CJ&"CLW"4).8F)8MB)G9B7M,27[,-6#D?Q%H?-,M;O2IVVF<#'8Q`$X:E
M1S9!%;!V:JD#2)#"*1R72B`#<HE1>((G2`<!%,0`:*<C6S"8@ZD'/*P'<J`'
M.@Q!;*!V%M117B").U%X+N03?&:VB7<49T4NF-F)F]>V5*!7;GL`<:O%:7&W
M:'4"C\J)HIG"]=*W^2(`GI>:HN?_1(:;N&[<J8O+N(]%JJ`1&@2P`P4'@/$Q
M`:Z!N6#0K3@0:QSW<")0(#Z9G&(P?A+V0-]C-"I@K."!K`6A$247C4F3;MFY
M`=-:#CO2`.C6,\4B$/6@I@RP*B(0*O[``+ODGA.`FYY##W&S?^E3")00;\<E
M7HH"#RQ0'P+E"L=4H%#C(@GJ(1`H7Q/P4!EP#O^W?W@R!@+;(%P2O_*K=%$G
MKA``.@NB#]9U9/H@6P\*@"HC6KB4#ANKES%U"*10"KS0/#?*<T:93"`[8LWC
M$GN'.ZJ"G,O%*C<U9=FH?1=ACCBLI$]WEO6+4ES:I5YJ9F7J$T.`4=@QM4.@
M*4Q3=3I2_Q(3@`<]+`<:W<-8)L1T"&8WL-!BJ\0T\54O)%9C159G"\6`!GF#
M:L4P?<652<9OD<+F0BYUY6A:[(E^BYIGS"^I&3"M^<9$C;AQ+,>/U2&O@`M]
M<&HLN\>LIEDDX"._)T?4N"L%4GP/038,\0T8X#.M*V%'@P$3)X[W>&3MA@,$
ME#*[&Q[*"J'.P0.IY*%!,CK%0`P9D"J])Y7T("GR!`IBH`(]Q4RRY7L0(EN%
M;%#/P#24A9#;FBK%:J\&JD\LH@H3&3@MXEZ-HPHF$+VQ4\LM"CQ/Z`5*!Q#]
M4X/2+,W800X"P<VI_+(JDQ+A'!&K48VR94LP)KW5`*]S8IMO8O^4($N!\NS;
M"T@\AT`@,;`LN9`U31:=DQ0`&BT'!1#=%R&=W$!2N')202)22T*')Z`#;>F6
MX6U!8891&`6P[1/1)\4"&<0=.HP'6=##/+S1<N"&<J@#1FM!31N(2US2_+W$
ME=AG3_QGC*>V@UK%/E"HG7?%*\#@GK@6GGFW=ZMY#]ZWG=<6?ILO^U*X4#34
M1?WAL7G42!U&2KUF?&!R._:J(1'5L$$"WQ"<`"`-[6%0H>0C&#&/QE$VIVQ*
MQ\5:RL`SIY6=%>=KI<P#)#5QGGP0`(M(18,`<)!=O$8/JUP,W]$C99!-_\!A
MG<!:7F<"OC$?\@%)>5!0/Z*7J:0)%\+_;B6``&;X6QP2@96-?9B-V:P0O@I:
MV1=X&]]I2U]@!7H##YBP2B^)VC4X/R<UZ`U2M>]QKI<5($S:28-"&];5)<K+
M&B0B4,9C/'Y@/',2"_(LA!6("L3C)TS69`F("S'1'EN```.DG--G=C@<ZPPA
M"%17OT2+=D%E03+@!.?=T!M%09D2#>7#WB61PSH<W_$=W<J.97$XAT9+`^>]
MT#RA9TM,TOW=Q`(^X$FAB2Y-Q5;,+VTK%YZ75Q4NBGGK%$C0J*+)MQ8^[D#]
M+QR^Q@/3QB!>[XHEXB-.,7R@.$;`5!AY&MJAXEW``Y>K62KPXJ;!`)UT!CN`
M!>XT`,25`6GP_P-[D,G>H7[ET&S2`'_&L6NBTTT5(`8!<%SAH4J@`P)I,`S;
M$SNIA'P_4RS,JG!E<$<!(`8#4`RX@3/D8%YB<`A_P`<J4+,/01&'0#FZT0#/
MH`X75Q[)L`O$8Z.2S2*4+=F4A*\6*`*WH?#ND0%]#H5#VDW:_38@QS3PP3^Y
M43[&-LC=@`%GL-M9HRK$,P(A-PCHPP*G$*.`60I5H&:P0)1$B2(';-QO7^K$
M]0;U:!S:F`=S<@;.,",_Q=7>(`*X,D'6I1#M6)5P0(<79$$%+0.YX@3BN@[J
M0\,H=2IG(`JF0`!:FP5VT/JN;P?+3J=#:[1AZK0CW1/63NW]O6=EF__2B7>V
MX,+M:UO%5IPOA?K3Y(Y76DS&GBD5Z\Z*=M&W?AMIG6>I@\'AB1%%]K[]NHCO
M^2XQ=-SO<R(LDPO`K-''(R,)E2!'_\/V#"\)?3,`(%GQ'+\!-_-'T=@`V(8&
M^@`((!447Q`E-0%B#3\_((YP%4X07U]E`Q,8#"6/%14E$`"A)1,!*CP3##@,
M`P,B(@T--6\6)D:V)%=7-F(3K#@X(EU=(@,99749FAI#:0D)#6([!-,JU=;5
M)-E-!$U-)-?@*MXDW=OCW>`C`&49KS@0"58S7@E>0#-?:6D,JP-P#:P&\.,W
M`&"K!A@2)GR%X16O"3LB3IBHL.$`'!=QE"C_XX5!E8\?39B8-JV<R9/94I*@
M%6VBRXEBWMBPP4B-34:,-B"H@:'!A&DC,H#Z0(]"!18#]77J!*>ITTYIH-*@
M,(0"C:M8:;39VN87/Q8-MHC!0S9+%FMVTJ:5PY8M$R8]>K!AP4+&FALW%H38
MR[>OW[^`^RX83+@PBL.'#2A67*1QXRD>(DMVD",'A\L<#AR@PKFS@,^?5X#^
M[&.%Z0.G-:M&4IFRZ@.9!:Q`;=J'`-N@.^C>O5N";PFZ?PL?3KRX\>/(DRM?
MSKRY<^+22$J?3KVZ]>O8J_.9MCV;D3`NFF#(D*!2NQ$C3!2($`','#"]<)0I
M4R(5,%==_(C`$``#_P40>^SQPTUP4&!(`S;PL$4-&]"!!@MPT`%"&A000L$`
M8BA"QP8<3E@A(84T<(48Q1@R$`[&L"."&";L()(%,&9AP0X39&@!#P14$4,7
M,=`XP1N\-(`#`!I8,H((\F4@$#\04.!$>370,HU(61"04A/A9"D..26-HZ4W
MVY"`P7PX^#0`!!I804\"&K0)P3X#M>+**\00,T!#(M08D8MBN-++)9@DA-Z@
MKQSI2I*LT%?%26!VH])9V4Q#BT0OP10333CAI,8/'-)1`R=+\=/`-!C@0$$"
M"A!!A`8T=,)`!?K$&E532\$:*U5>$)$`!#2\2A=8"DU@@5E9Z*&''6P=J_\6
MLG+H\18><M%EUPU#)!`888'MU<*V?^G%5V'@+H""N(@AMMABCD$F660.4(99
M9IMQ-MJ\G^E&6FWXOJ89$OPB0=MLHI5FFFCU=B``;[P1U\%S##?L\,,01QQ=
M=A17;+%VVQ'`!Q^1NN`"`1.44)Z*Z*G'GGM@F'`1!$VFHB0Q(_"Q7P`APZ'&
M')O^0,<@+`]@00$[;8"&(R"@`0>%E$"P8B\1-@B))$-0,DHI?6K"0`-UPH(!
MBR94T0<?-@0@M@H3O*+U!#&D[0<&!=6`P-L-4-`F`Q9E4$(Q]5&8P`P:L+`%
M!C&T:,(W6JJ@TN'DH`-.XH9?6<X$&0``3$,0S##_@Q7.1)V`4?]H75%""&&-
MR0A[[N"'"7T6Q,#+!V6-D$+$_'(G!BPO:A*7TZ%.Z4L9ON$[IIDR\H9.GX)`
M*U2RZL,/'"-E,L0,8ZB9@!.UIN$$54VZ&BL#:92@BD89)(-0C3!:@(TI<C#;
MEEM,"!$7&VSH4!<-=PWA;;9[%8;__H(99FZYB3F7`1Q3!'5-IEV6P4R\/$,O
M,I#!7J-9@6WR-9O5]&M@`R/-;0AV,(35RS@+BY@(1TC"$C)G8A=+H0JMLS'N
M<(P$!/`8`<3```!4`@(#*%D`3M8>E;VC#!#@!T:.E)Y7\("&%5##'C8EH4%(
M#0,V0``(Z$#%#0A"'R""_\`$;/"&!C``#L:#RB<,@8$K&,X$%HBB3,20$#'D
M(1<P]%H,:I2A70B)94K"`!;R8`)B-``2$!+$%P!0@IX4@QU7&\`GK'"/`2``
M(C(B@#7,TCC$$4Y+EB1'.+`$.0T$D7+.P$L;!L("$-2@!BZ)2!XB$HT=-.0,
M1SK#&7;4A0EL`4D""6(J"N(*K9TR(F=(""9X`8H8;&-*(FG1'+L0S#9>"G@W
MP0GQ'/%'2"!O(-R+%5/`"(<!=*$*$\"!!F"`.7HXH9202,,7O#`/^L1I`'1Y
M'1W%<",>V%,M<A!;`-K"!++T8`MS8<$)E!"$@HZK6WK1GU\4^BW^76LP`!2@
M1/\9DZYUM8LR";S,`N5%+P$X$(+VDJ!L1`,PS<PF!_ZBC0]*@QO0^,!>"#/8
MP8!CPIK:]*8U1>$*=\I3Z:3$""XP`@%$L(Y"%&0$$U`!&)8ZAPADX2(9J$,0
M63&GK;6"B_RXB12/=KTOE,`G&)ABIZY8H4'BP`8%*(`-,N&].<$"J5<(0#;0
MJ,\`7`$3\^1%#*+PAPG$`@$<LN(DYO-53+!"$!0H004@82"E$2-R98(#`Q*+
MJAE4H`<8R,]'IG')PCG*45<J'#8BQ4D(?."3+$B&G!HP`@RX)$-NS(-L5YDA
M0V+D(ON!""8`$KX29."V^SE#1%Z4C6N<0@PUR(`&ML;_"[85I">PB(7;WA`\
M3DT3!-4,U4#J,Y"E-,41;N,0(VH0#)#AX`-`T(`S-)`/?GQ"`^N`P.2$,1$3
MX&%8W[AG``JP/CF\10@`AI\.D"`#)1`T"(CQUF``<[^',C0$"W8HA!?L/Q1,
M5*($-*`''"`%*51&@1NEPF@<2&(2RQ2"&YP@!BOXKY6NM&"YB6EO?!,<G-KX
MQCA.CDY[RN,5>L<6!!C!?"AQM09T@01@:`][>(`D'-2A#G)R14'^-!.!,`(!
MU:00(1B``#M6P)1A+$%B?\L?L17@%*++T!N+>X55UI*>]+0`&^W4MAT803]@
M))HC*`0/#7`YG&G(\X;04($$_P!1R@,@;"<^X04W*.`&;)C`$YX0`RN)MARA
M_1)H+=F-(V;@M%_%&E(C@H6-\:%%+D(U,$<`D-49(QEYU*U?F^P*U^Y`ML4E
M`0\:ATQ%B``.7]#``$[Y*:=(]HO@)7;QGN(J;,+I54YI@"G#NX%,1?,'713!
M#DB@,@VL:AU`Q,B<<@L1*W76#M<(``^:]9;WQ8\U#B#HN<KU8`GG+UP4SM_^
M\%UA"Y^K"!=.%V3:U>$/*[`S'/U,B1?NP(,]L(,O'BE+*RA!D8YF-QWL3<*$
M4^,<>_SC-MYQCT=>L6QXS`@D&$$=AGRU\J)LJ?VYR),90.=6.%<F`ZA`M8OM
M"9;A$/^M`>AB0+!&U4OPH!36L"LOW!@3/JYR(EU`*G5Q@H!$&^)N&.A#%U[E
M":4P%DU$H``"3*`1$`36:'+S9$$N,I\O%D@#7FAT`M!@`5A6VMR<+:YHK3$.
MDGP6'"91`=E/*]\MI+)TNW-),)$4OI6SK#YYS!`::3$1&-DSUY+*$$6$68,&
MO/<+7_Y4L;5,`:4TN[O8[*Y33$D'P-;$)K"/IN]V<DJ`8(`;!&`;05YA>!CI
M(D'5"(`=D`[X_-H@6C(H<$$7`T``1KC!$N8WN/2-/W#1.Z+_;LP`MU_1#7/8
MX`='^(@97N+=/!#C+K6-BV<SP986S&`(HW''00CR^MO_82+_)[G^I9,Q*W'!
M%D)U!BGB52RP'WSP<F!0`/$Q<P%Q$6MW"38@$%3D%)H@%(7$`PFH5F4##7(&
M6Q:`;BI`22H0`+N``&^``,(4*+30$P@@35CV"5]@:`-`(SG7"6*U`846;%X`
M`5NP`\5`*T[P!5%#`:&02%#%#WJC`3.@``D`!Q.`'EW0!R/16>%P.)6D#9IF
M$@2`<A8P`!]0!JL`#:,S**T5*)\3.[=5$*^S'Q9P!<5U>;I6/BW27)^#`:=D
M@F]0`\W`7HJ%/"!2(250`LJ#3=X%1C5019H2>["'$R=X2J!3AUNSA=N`.G64
M(*505V.C;M?`!9S(!00`(PBP!2RP_P8%%00"9(K.-WW49V_W)GVK2'WA$E'F
M@F$$5(N-(1F5D5'AQT`*1WX+%W_P)U.C(3#J9QLP%5/`$1PS!D(A='_.^(S(
MD7_[MW\9\T(`2``Q(!^3T`:M,`)]D&1+U1XD@B+(X`L.&!!EY%Q+P@]2!D7"
M-X(%0((V(F<V(()5<A:HDRD;`!#[(3HF`!!P,#3?E4Y?0`0?P``1H5@;@A,U
MP`"%X`Q?D"<BT"0)H"J;<ST`D`!T$SOLL`\EX&V6XP45@#;2X%F9=&FXPPTH
M\0U7(`(:\`'#MA!SLEH\$2R5,@&3EP79$$EF<4PBX2.06`-B\#9OXSM&N0$U
M4`$QR"9?D/]8@?B4@:@\B_5=U/9ZBGAM)_@VQ%81EF(#'=B&/!!XIE!764(L
M,#(2,>0"X$$`>""*,A`$!>08S'<8X?(MSP=]#B5]SV>7^-9\%C:+%&6+4S`%
M9C`%!<0N&(491Z`:O-B+Y->,'Y4PO!%C'2`PI/%2QYB,(31_-%8<R[@<S0B-
MHFE3TCB-)+<=&_,-30!D?6!U1L5:._`"/`0&78@BX6..&<$*9;16T45L"%!'
M8V,-ZW%$<D8^Y<,#WT`"$]""BU@#`K$D6R,DLP)&&P)L>T,$6B0&@H@&#@("
MW"-F,3@W90-$E$`)UG,JA(2&0(1%F5,M<"`&,-0U4W@X37`6GG7_#I8$>%Z2
M!PU0!AIP'T6'$0CAB+])3SJ97R,H-O9T!6<)=5T`B7:X$W;H.QRBE<3V"$BC
M7F\B*[629PQ2;5>)E5FI;*=D*1[H>V:T:R2P`UF`=&FA`B^0H/:$G)&"3`20
M3&BY,5A@`0@P%V\9EP"G&*F(+0ME;PREET<*47Y9+O.&+K980!K&+KFHF`B7
M<(ZY<!)`!L,1?YHI8[*!F>]78S/&F32E,*&9')]9IJ.YIOAGFFY*$JC9!ZH)
M9`20:)0`AB(P`C$@FTH&!BUIFU#VG%`U)[D`(Y;(`VF4"V.3!5@2@D=W=%RT
M$X%"/A/@-E1'3;`"`64@`A8P'FF`!M66_Q,Y&(,0L#6#P)X:4'J$$`\:4`$F
M,"8;6B'60PF[0G0B8($5,@GAF0880"-I4P665C@P-!V?Y0U9HA(DD0UYH`CB
MQA`*L70(``<9@"#V=`VZ`".:1Z(U"0O*II4(("%3A%W8E5W-)F:$\";&QA0@
M`%BANHB,2)0D:J(Q49QBD`MNF"6EL`,6``8Q&J/%)2-2`J<;(Z<DT$+(A$8]
MH`,#!9?:)Z3C0BX/>Y>LV#](RF\3!K%^*4`-.T!/&J63`7X<4*56ZHO(,:8R
M%E(=-%,;EZ9;RC!G:K+-^+*_<:9L6K,2L`.FEK,ZN[,\V[,^^[,]JS'5:&YT
M*@)#AJ<C<`8J</\R,#<"OW";-9=#1_(-;;A?ZI9&NT!/9G06G<J<-]%Y/`$0
MT-`3G5,T&P("3?D%'X`#;)0!.L<IQJ-E2UFJ%M``E.`DE.`$L^H,33@B:**J
M^M!5GL1:;`=$8L8FY9$`)8``,*)W5SBL>9<2^CFL]!FYB=.H'1AG]GITBH`!
M)4`$#)"U=/@Y=VB4.Y%L=PA8-<!L1[,]W,,/4QF[)0`''<(`/;.NWJIL$R&4
M\Y2Y,S$3/'`%1V<!2(6)+Q"<U9`%$9$2?)`V(Y%,J"FT.MJ)02429!&*`S4%
MICB7^':Q=JDM#$:Q>IE@%4LN\Q9`Z&*80<JQ@VF8&G91"/0N(99PY)?_I5I:
MLO(G?S&5<<K8<2RKIIY)?QP'LPOSO_]KLZ.)LT"[P`S<P`OL4R0`9$8PD7=Z
M'F?``^S1'F#0'T];!\#0@%([@RI0/K"U-78$#<)[5PW0@M*TNK"@"0B2"6#D
M>IP"![NBJ0R0(=S#3=UCKDM9!@A2`]DS"*775>$Y`'D`.1^P.;<2@T0``'GJ
M9`#@MH.P*[FZN+30-9ME;E2HG]U0'>/0Q>)0#NE&?-5@`W\"`4```6'[.HX(
M$W@(K\4F7<7S1]FT/=X%7@NI$V\S(1%"!W#P"7?3.=PJKUB;1I#*(D>G3VD5
MCQ,1CR-8K=R&EC>:HSO@O#<:M'S@`IQX<O8%_RUL4&!R:0!T2:03=F\3>['\
M5LKT5K'H*Z0:"Z6&J1CMZP&#N2X;EHO@-[_CQW!9"IK)J+\G*Z:A2:8`/+,%
M3+/!C,P:-\S^Z[^@J<PW9LP>I\`.?,W8W,#)2@)!90NT8T,D<P8DD,%+!09=
M\+1`9(Y(DJ<SV&:5VGD&(0ODM1_UB@GL*EY65`&V"P`#L%9E$JH2`@DTD#08
M8@$3J;<4$A5I<`.4T"8X4*GP@$74@S29,RJ=JEQ>!8,)L`XEP,X:\2JG4AX-
M_0PND4QBW)/'1!V*PW>-FB4M70T\X)78"A.E$CFI2DW2IJVG]`C_$+N+Q0K:
M,YU%PYU5%*HNJ!,-8/\W<6(VPM0[,V&OPHN)8@,C^U4`QQN/`?`"(M$XM#`I
MY38EJ-DC(M%_TJNS'G/6:`0M.O"CZ_NPJHS*<%U]XXNQ2UK*Y$(83,H83IIA
MD3$%`Z0NMVQ1\2N_5=K+OMP<FYF_P\QQ+<L<RNB9Q.S,S=R_SZPP`RS-)<29
MF)UCUIS-GOW9/&MRMM`$.S`D\X%#2?LS3`L?3[L.JT5$2'(&5Y`)"*`&M"<0
ML0`0.`!%/;&0`[(I$R)F9?#0O1`+A-8DL1*#7[#;LYT!45$A>AN$B0L`&^F?
MR`T5IP)?#/`3*Y$)J@!/KR"4;\`VL2,R,[`J$%D(6R#3?/<H9J&2*[UWH@7_
M0UY-$29*$PC``&50'D:AS]!F;,>C"0JM3:SP#\1&!]55H9[R*;!`57:8U$IB
M<[!51[E0K8Q<SDOU`B^PP8N<!<F4:O(I'2W2!=(PUM/@!VDC#3"4,4*ELP"(
M!2Y0:G(FBJ3(O=W;BM^+4-)7USP>L>0+F(_QI(<I!;9\F(*-0"![&>)GV`Y$
M0OVKOXX-S,?<I5VZV,+,I<O,L@<,V2Y+S??7`9T-VF+^V5;2S4W0A?.1S@UP
M!NH!CDMET,7@VJ^3$#$P`G<RVQ```C?1(?X@K9O*1@Q0`[_-*:L[1G?#"[]&
M>E'A1(70#JY4`M%=>EA$JQF``3!"5!R].O.Q#M,J_P8$X")RAK6_.Q-L)"=@
M1P3TT"0@@B&\H$Q\(%2$8Y_R+:P,6IR8<(<QX3O5Q2D[LY3\77K.ECRPRTV+
MM2$@>FV$SN`&H<Z]Q%RN]2(6D`V[-H(;GH$8#@;78)^3;`(/.A&I-B4D80([
M$@,<PP=^P#%]D.(YRN)&D+,B_LER81?,IXJJK)?B&XL]GN_-!U&Q/)CI4E&5
M8<OO2QF)F4"+N5'S<M@XY>66W=AFNJ7.+`22N9DRQLS"S,P,#_'/D?$Y]K)A
M/N8@[[,NU$*>"(`&709W2G.D$P!N#@8VP'AM9W/"M`/H<04(X-P;L$0#\@.!
MO!%_O@4#8';5%JU0X7,Y;/\##8`F32GI2),T^Y%H3"PKJTK=]7I$(N!;:6C@
M758*V8"U0%(#6P`0;=5:_4D$0(#J;<(FWM8&8@$150#KLYZ@UN"&<O@0K]4[
MNSY[#'X\>A,/^>"ZV^0(&W+/GH+@^BA%L-!-('P0KG6B-A!7WT"6"8KAD(P-
MD[(G:-0B+B$,)#XXU,$'.\`C(V%J!:LVE6P".=ON[DX2%G"]=8%@Y$OOK5B^
M_5;7%R9`&4O*_K;74/H8[0L9"63+B(E1(,O+H$&R-F;,\]?,^7OQSQQ3`!;]
M*RO9U(^,B-TPR\^F'Q_RW&]J`MM"A@.`)-"?-B0Y>3H!&/AR6<!XQJ`1S1HS
M9R#_`EQT)F@035:T.@?2^M5$18(`"!45:11?7Q`--C6&:8U.%(\W7PDE&#LB
M$%9?%(V%"1H:&0TF)CL[8J@VJCP!K5<V;V(3&#4-@R44`!\?&FD-(Q,-&D`S
M7E9>7@F&E`@\/`1\!$TJU-74K0'5)!;<J+(3$ZAOXS_EYC\;&W0U(`UP@O"#
MC0QI$`"@%()P<"`U-0AOSI7;@,`?"'X']U48P(#!`!$B,&#HXLT""1(J>%1K
M]:)C@1<!.K[0MLV4A1TF3H*;T*7+#FXJP7698,H$`1-\^-@L%6,'@8O0^/0Q
MU8>/!5(X<RI=RL>(43QX>K!8$P0%B@58LX;8FG7!UA!8_Z^&%=LUJ]6S:*T:
M6,NVK5NV:5$8"/*VB%V[4_(6F>*AKP<I.3@(]NO!08[#@A,?H<*XL8#'9")+
MEBRALN7+F#-KUMRA`V?/E3MWMBP:=&G1I$]W?NS#A^K7L&.KWLR9MNW0H"6,
MOLV[=^\=3(,+'TZ\N'&F!((JO6BD.0D,]KX`*"$"&`\P$<!H#X!A`(X,94HT
M?`AQQQD1>6P,@`!"C1IT("J4*`&A1"(+#5C0H0.BD2!"AV3`P!8#))#&._(\
M8L@7`^QP11X-0*`!!`TQ(%X%#=1@PQ7.K!*`*F)@T$`##)4X(AQI3)(`!%]H
M```$<$R4!P8:$)'`C4-\D6.+7_]L8<-1/VU$#0]9P&2"-^!X,TY``KV!0$$@
M)!1/!172TT@:#.@C7T,05``"&G2DLX$_2Q8T(D-94@G'B"/6X`TJ%O!P448:
M40-22"*-E(T*%_5)@BD[L+022H*RY!()*4TPPD0C=($4*3=%$T,,?BAE$P%^
M3-H'"3H]:EQ*44V%%E9?:?456%U9-59<8K'ZUEIW%?%J6VD98$9=>AF0UZZ%
M]0588CDXT)=A@27&P0&-,?:8`),UZ]NSF^6&V6ZZE5:M;*H)H>VVW';K[;;8
MRO:LM=7V=EIJTT*KKFT=`'?<N_#&^RY&1KC@`@$QX%"&(10\U`4)$00<<`$[
M##!`!M/_+?30""+$<)X85S2007OOU8`B(1!0B(`-(ZJ3QHLE-))Q&3BX.4!X
M\'0"0!D48J"*#02<!XPW-O!0#@^P/.F/+0T-X<4,,VCPA1,5[).B,A3,9R$#
M<(A0Q7-E`&'%,1HD8$R-"6S!@P5X9%&D!3_&(L:39"\I$#H$K2,EE59>.4^%
M^C30SS_I[*<.E5%FV(["!O=ML`@-8)`D"<D%:8T*'.5Y.$FDU/3H#C.!8XK@
MI;04`TW@[-1%HX*B%"E./%6:%#29NI2<4C=YR@476&#AE!%<2T476::>"A:J
M"["JNZNSQNK[K&K!JI=:001AQA1K\468`PY(81@'BQW!@12`_R%V[`'()@M9
MLY%)0,:ZX--&;;C8;MO#D][DH?XX9".PW[>G=8L:^+&9>RYNZ(9O;FWMRNO_
M__[#B+WNE2\`&`("#\$`";`3,#`4@`\B\,Z+%`81$9SA#`.`6(3:\X.#5,`)
M:7!"QG"0(1%XZ6*WH``%(%"&`;SA"F(0008V@:7YE&``#1!#S8C4IRL$X!7C
MJ,6(6)"E*#&@#!.2D-`.P8G_J#!I:;@%`G]A!!),``)`&`/0B$"$&5BA1AI@
MP09B,8$M2$0B_OC'V7Z@LW8@"!YMPQ(]X%8TA-!M`^5PCSG&Z*0*4,AO#,`!
M>3)4@W"\;(=[LI-(''B-D?#I(I=*SO].:-*%&"#E)SRI)$I,T))`N:0G-Z&)
M)SM)@!U<;B<VB8%+DI(33/6D4J=KI:=RP@47-"<:>-B"J,1BNU[B+G>ZHY5<
MXM*[6.U*+[*:%5OVXH%D%L%X4[@+7YA'/>HQ+S"+H<(!./`\P6`O6<IB%O>^
MYSW]F1,WN2'?:[:%!C3TX'RQL$`>^.`"H[S)20BHV[>$,#]S8@M_T_IG:J1U
M3FKI)C/I=!<`%\K0X/RD7O?RP\D.F$`",!`[!2``1/35I094,"+=F0!W,@"'
M#:!H$""L1PL!(K$,A*QH`&)A"33$@RM8,8(Y7$4!`N`,KN%A`CLC$0,H@,0/
M?"&*481#"<K_P+(G(E6%)2A:E!+"D`S4`0<8$(,)+B(&!E3M1LA8!M`HL*8(
MXI"03TI'078&AP&P36E9<EM#]&%'.N03CVMD7U!IT9T,X)`6;GJ3&%C!"FP$
MH``[=>3AY.2G4@`*.*DS@2HA9\E'2792-$$*.,[0*,>10I4N:<D$;!*HT=[$
ME)N,!C1,$0/5(N=1T&B=4XQB@2W0X`9EZ64+3F66LRCSMW7QW3'[@DR[*).9
MS;2+&8(@*V82JYJ'L5YCMIF8;SIF>^,\9_C4&:YOO?-\`,$#-PHG%,M"!2IC
M(]L&#*H_[HYF-K.YUD`)&E#[C8^^\^M?0_?;T*U"U"DBV-<A&!`1_Q,4`#L(
M)@'##M91\D2$1!B(&(7\B-1&T`<1/"@`QQ!&(0LEC0$9LH%A"\"#L3&)C378
MPA8\*@(CKK`,]U!&?2ILH0O!PV@0^#`(".+&0`I2<&)X9,$$;+4$W.`&"?#B
M4>$X)3A6Z<ERO#$__'%7O)Z#?6OUQQG],0N)H&(6.D0D-L!6@`@@=CN)?"3A
M4@>HQEEN)JBL'&L[A9-1.NJTI=V<)2!5RI9HT@03L.1-*BGG2/&!<*;LB6MS
M<DO8$L`(?^A#2BS0`QH,055>.54+-KU;K@`S>+#"2W'OLDS?2?.8>2&,!XI[
MW+\DURYT*<*PGA?=Z"J&"@+09G6SMRQQ<O]/N[XQC6?(MT]O]8`.X.V!V"H"
M6Q/TH0JR1`K7O`$5,3'AVDR`EGOC*]#=O&:^]V-7/\=]/_WR]]S^VRH![&4$
M`D3H@`3&@`GLH)UZJX"S,BQ#T?P601)R#,;U,5H:+ERR5FRM`0W)T),"(@?$
M&AQL;Q"B.^JQB2PA!`XKS#$4_^.?*1\$!/M)B'^H1$@6)S`<%K`IH@/\U:H9
MP@M$T,2"GDCSD;,M372-4@W"9&4]EN,-!%FK&<](BW"(X0VK^%&<1GQ@!R+X
M&JVH1A,B6S@V]V2RK.U)322)6E-:5K*5--UI1:NH$7B.<"P![58!O4G(D9*5
M?$!MI9!C+SKCY);_!.!&#2J`V]R1ZBM>L%UOVR+J5!,7U8A/O*H7S^K>N=K4
MTVQ>L8Q%>5SG&GO6]<&RQMD]8'\&?^HL=K>0C3Y4X,$F3.F#I+]>+^44);*D
M."]4TKH!?@Y[V[BO7[C`W4_QU>]:L%$HNH?_J:TVH5[MQL`,64A"#%1!!?7>
MSN9&H*\T`-)"96#`.%C`U(:4P*5*2\1.#_NA)_U`CV):*RT*,@`;\F@3\?`P
MEK!4QUN(IP%C3..30(`FA_RU!N,`5*G`#5&G%-#Q53F2`%9`!%)S(T(#56XC
M9?LP-W>U1C\71&DD$8$#9$<'-C5S6..'6$T7?20(!B.Q9K#W=9'4.#T!_W:L
MY3F0`CDO""F.U4D^P68SX7:!YA.!8@J!)CD\(6@QT"C)H5")!DO*D1-UURF,
MUF[=P`)]]W<AL&F]]&FAMA?#]1?4LWA<V(5>N&K19%RO,@75%(;)4QB21WEJ
MR`&6EVO@M'G.TGF>%U"A5VSNM!_?139PP@VD$`T#Q&Y.476&)ASDE1.6)0ZT
M)R9B(GKRDWON=1FP08?`YXBB(7S$=XD.91/'UQP$,`$E\`4P9A^6`'US4&\!
M,(34AS+]1U03(D8(D!\L,");0#<_4%@?`C8\$'&SF!\UEB4X5!!*E33S<2`2
MN`]K,E5YPQ!4@D,86`,BXE&!\P]A)F))\$/8D/\$)&8>9U`I&*`O99``.3(#
M,``T,X`T\Y!S_6!7Z6"!/U`F:>2,16=TX^`A3">"29`$]98=+[`=UI`%T!!+
M.S!WAAAGEX(472=:F\1UES,I!5E*DS(I-^AF+L$2P`$Y,M%F+GA:5_=G23$4
M.U`4K92$2Z@^C'83%B`&4-@5OE0JN5-J6>@7U123,ND\S,,\7UB3.`F&I.86
M>R$%T[,K!B!K->F3:WAKN!89CW%=OC89<Y@NDQ@;^Y2'[8,`8B![CM84S1$&
M6OF'[3:0?=@ZK<,I6-D<S?&'ED(*@J6(ZO`^\$-LW()[D/A[3TF)IV&)F'B7
MT9`2QV=+!"`&W@@`HN#_$M>1'?5&``R#`X!));@P!.#(F$-0`370<^[Q'DZ2
M8BM&2"B""Y]P"%]0`FM"(KC01/K@0?N0(6J%`.;P!OSG$"/B9>*P;$@'@O<X
MFTD@,`,3`"&"`6<0`WTP`?IB0%_@!6.@1<:0`&1UC+1X#C[7CA'WCFED=&+@
M@3YTC=@H@B(H,$VG.-0`%"H(DI82'*"#$T$1@RU(2IY#65NGD):S24C12109
M@Q-A2J9U$Y,U:);09RA!`GY02<91+SDQ3]%@!*#"`HRYDBSI6X7G*S.YH#)9
M:SD@DS49+#B9D]%DACRIA5*P:GB!AK]B+-(#/4>0/4<I&;VVE$S9E*`'E=SR
M_UVSJ(>F=WJ7)(A+85E-01RS-!QD698#!);"D1*"E5Y5E@Y"4'N,2)>\1XF,
M6&QVB9>7F#I-P&XW<3(PAE4F46;19Y@15`<N!0$.J`R,Z06/N6-X5)D@0$3C
MT0``L7<JU`E1=&/(.%7[L0X6XXL,(*8+!R5M`A#SN"$!0)O84&:V.9NN\`HA
M8E86%"@3935$,)QC8`7*D`;I:&4#<9K.*8U'AW0B1IWV>(^VV4#W"`;6X">%
MHX(W^BD]RH(],1-%J'4M^#B30FB/XW9:!X-NMTJ>HY&5LTH\$9"3(I!PIQ3^
MR0<`:HBU10,)8*!F$93"11@,&I-%J8;112S1.J'"4O^AT00KPO,7@I&A=H&&
MW:081Q"NX#2BDX%=E(&B1UH:QM8#:K4%5"E>1_$H59"C9#FC-/HN2-$'A4BO
MMY03K?.'`"N@C\(->'"I9-,#2:HM=+FPZIJP^X0&2\JDQ&<3)#!`[19@3(4#
M$Y`'9^`RA*D="K91"/-5R6`(2C8$Q_D.%Z9"FP`"[@,"#%`?66)Q\5%'^#>I
M>/0>/U`+#@:`8E!(7S8!+S2;B,6I`E.;MHE8-84SJO`&P<`F$-$F@C,!,M0B
MQ&`%7G0C7^`E5#:5[Y@D;\`-+\,*U;FIG0H&2=`1VM$1VD!>JT>J7\=?L`0Y
M?B"#<F9*=I=H$`E[HT0HFP3_#J#E$S':9RX1*((FJ]%P'+,UHUP#A;XT%LRE
M/+UB>$3YK#[ID^+ZH<]::QS@H!,:369@!LTUNGQ1N<EE!M0T>2`ZKHY!&9PG
MAYY'!N6SHN!5E04K;9<"K!!E+ZS3.O8*MY!RJE?)%'$+=_^:HZB3=_&*EMXP
ME?ET5TG*L+"1L`@+7J77O#H3L1*+;A1KL8;)0B0##A`A!E:Z'><100CS"<J`
M9%-C"%530QE3'X(0,@I11W/##OMQC"."FF@S$&O5`.[Z)!NB"E=PCZTPFX%J
M9@[W(ZB@?H$UC\V91NTP(NT@.!)3(U_4OBVB`9[))O]`)DM"CP50MM<9,/BX
M2(JE_V86,*HT.$M]:'<TVJ\+]1.N9`HV>#GL&82Z:I`^"&>00PH[R%JF0PI^
MX&8Q4(3@,&C\F83QDA*V)7AA,1?&(RPZ>1>^XJ'9U!CAJKE9O,5;O+D.*J&K
M1ERF)FO4,Q@;>DT>RKKA=*[>([O.0C_Y(QO=DH=6&:.JUX0`R[L\>I9(`:-?
MQ\0PC!3@"<CWJA1<N;BJ][:'J"13Z;!OB7L/JRUT(`3'%J=/<CY:!;>HH+W;
MRU_=NY4$T`4(DP$1(0*"-`$%,`>EJ!T%@P/?\8U:FP!08`5(1@0:D`_&6#0U
M@`;OX!]T<('G5PX(`*?^,*;7FPJ'A9W8B+01<(^(I<`\]?\R>O6,!A.+"N>.
M;E2_5((#9M>-NW`/N)PQ"0``)'1TJO`A8M"GT6R=T=Q`^Z@X0/$3*.B5AYRX
MT(!*,UQUQ4'#,EBKE=5VKRIVJ.I)/I%9%%D3?#!9?0AVJ$2?E21*E!(OIY-W
M*#D$J`(6<B$\QV.A05FZE6N4VI-KQL*Z6TQ=E!?&$HJZ#M#1HFO%VOJ3:6P]
MT/.&O1;';WRBZW)?<]D!*ZJ'4`%;.LH'?\`48`F6\Y2CR0&2P&L3WDF\31W5
M)E`%5,T'?6S50L$4](H%X)D')G!>#9Q/<0K)"1NGFOPF0:V"30B69FD*GXR7
M.%%+6AD&49I]&#`"?U,#/,#*]?;_RK`LRQH`-%Y@LD20#UZBB/"A$"4U$.<P
M)A/\#P!A#H5EG0(S!P_0J236M*B08FZR)'J55CK##O?+#B>RR[@``1I+)!(#
M`"O#,@X!.%M@`;*I8;+=J=AY8&RK9D"A$P$)=WU0Q(-[$XNL%,/]UDIAMV\G
MD7MKD#E(D7@F.:V*$O49=ZW*9SLP`F;G2H+V+A5=K(&7K,P5:E<(TI2GN6SX
MAF1P>=[$QHR!>9@'+)Z+AGT1NK%RQ9V[:L=3&#2=325JKK`+;-ZFHN;3`Z9G
M),Z&E0/T+DG=;I+DG:3:Q%+=U%A]'(`(:4]M=V!]=.K%<W4SUF/M77AH5U,9
MMN)ER)9U_^$!FQ-N;=R7&-<N,-=5U&48$$$)AP!R$'VO;#":R47(`%8W``>^
M#`+G]QX;$!]P0&47"`OX%)L@F+2`>ME.CEBOD#.6.<$4_`]+0A"B[4&C^:;U
MVPDLA$!X8`=V4&(S+@);@'0-Y\YE-@=;$P#1MU,D,<\Y\;:%*+S<>Z.$K!/'
M`9(.>5FTJDH0F9>Y*M$\N)YPECIC9\."V\*(2]V0-1P-;0(,+@8-@-$AX%O!
M-2S.^JS'8M/+HDW6Q<;NC=*=6VL3Z@'TG<:5V])FH-_6PVLW_;ISF%_3.^``
M04\6N[M<V12/-ELIJ-9:O83G=A-&L)4)[L=Q)LA"D<?PLJ/`_O\H09T3?E#M
MC_*CT0D32\WK[+;'`S378=`IR:'41>C)+`Y`+AX%81`%?T`"5W`%EU`=W@%B
M;W!8VF$"?R,"-28A@LT(+LL.>%7,;>6R!<$D&_+N/J0&#[#PEKWPF+W`(/*:
M35N9H=VUE>KE\N`0"-)6%<)O647FB-,*-C!8K!PP)=^I/+!5V[G"RYNOWCD4
MP#VCX'G/R<O/=PF2K]=*/=B#F?20?%#$](DY*%$3;F=*=]:0^-)),;\3#'E9
M*C[12\'LS>&C%7"LJX*@I1M=9UR4F,>ZFK<]E\?>TX4]T'H8J4[?H?OJS0,L
MJGY-TF5YKXO3VA7@V8+K""!>P7%+9.G_NZF7QXQ,\TQ:%!;[/_^X%-4ND,3!
M;K\+^)SL*>-.EHK?A-S^XEC@\D51W"M^[L1'`'^P!$L0!5&`$7Z`W3MP4P;C
M,O@(!EF`R@;S'?-A#\H`0EP;.`&!9>/P[JH`J+9M\@I,8DQ+Y999"^XJJ5K.
M#L;(#V"B-GFSRQD`O@+R$"IF1BCW@4WGSF"0\C8@,-K))ZKE>II_[CB_R*15
MN)<3=BA!9_()D8[EU7X6D(DK''9K^(/^\SU1%*CU_K%T=U,/%3T`"&L+@X0+
M*`9%'E*+C(L<CY"0!Y-4!U275#X^`IQDGF0"*Y,KEYR8IY,<DP>/.:ZO#@YF
ML[0>L:I4'!ZV_PZNCY94`I_#Q)\2Q\C)RLO*'<X2SM'10D(]/0AB8B;;)GS>
MW^#AXN/DY>;GZ.GJZ^SM[NX[.^_S].1^?GQ&2U%12W]\9T;LN$)BQP0,`P9@
MN!*A@`H1&3+@P!$Q`X02:1A4`%&CQILW-@JH&5G`1D@U$6R(X3&GY8.7#QKR
ML($`P<>;-VLBZ-B1SH:?.CLV:``"!!PX%9+":0`G(8.G#)Q&%;$%FXT`!0I$
MV,JUJU<P/.+9X,&#!(&S]=*J7<NGC]L^!/ATV]%E@HDN&&+$\$-@6]\870Q.
M.!O8Q(0N@.7)+9?X;%S$BN/RT0MW<HQNWL[V^6;$B`D+>-@(&A1BT/^A1(H:
M,8H4Z91K39V("?`A"I@IUY58K8+T"I8L6F9BY<"52TJL7JJ`42GF20(Q9M"C
M2YLN38@/--:P:>.&F:WW[^##BV<7;[SY;R8V_UG"?LF(,WYV7(YWY<J$!B(P
M!(CPL(S$A"(,,-$`(B#P`P]810#32P6(88%6*4T@1@0IO"33&SN!,%0-/_W@
M(5`\%<41'37186(-&A[%`@,EE`%`!E,U@,&,&'AD4D@0;M62@A9Z%0$8`:@@
M9%GQ<.?'6VZ=IZ1W<>W05Q>!T5687-O(I]<.)A04@T$C1(G/8O8DQH<?>GT)
M#IDQ\$&"'XAYLYED^73VF1@LW(!"(8=,D5K_:JM%<L2?1^!V"6S",`=**)3<
MYMHJC++6FP-*!'><+\`<(<4N#OR"2:'/1>?I,L]`0UT'G#A#3379X;'-9DNV
MZNJKL'I37JQ,$M#%"".PARL))`0T@04!!&O#0<#R@`&,#8PPP'L!#K#%#UEI
M]4"%+Z70H!A9I50#`@&HX2&&-84(`HDDEL@3BD8=5=100P7XE%,)L;"%&"9E
MRU5+^"[XP(Y;@?'""T*JP&M?53K)S:RT)LR.'R:<)=@$$TB)EGQ18MF78%`&
MQ@Y@@'71<%SW@-,F'_+M@,^;WG1F!`$6(%`G(:?IR:=JD``:J*"9<,*IH:2.
MHC-NM5&Q0FV.NG+<_]&4!I,+IL0%P^FG4#,SZG0"G&K--6*HNDT^?V"A\-=@
MAUT.PF*S@_(9(N3ZAUXD\-!%?A9<8<,5!22!8``V8"""1QC@D':S"(PTQ[0I
M%%YA!`%L,6^XVWZTP4[BBHC&B9$;54$:%%Q4`8$;=F2320AFE>_@"RHX1U=@
M`!FDD&81\)8WV]Q3I&-\H%7V[=[@0T#)4L93F)57-KS-80:U"7+M;9G#,5_D
M$(`F7VBRREEG+&\A`YY%3*']S'UR`"C..NMLZ##.B%)*^`)<,K30EZ2"A"H<
M/-I+#L(-9TGZ'`A'7&S-10UU!\>8&JE,=:IJ9$-K5>A#9[#`0*_A[H$0-/\/
MV2*8CAB\IVM[4<$5ND"@'<R$;EM)0MX2(H8KC"`#N!J0@3S$P@WDI`8;TM"(
MSM61HASEAG!8%[N:)96G-,!&/+"7CD:G+]2E[E\JR$(6S,*=V!U)>N:@75N@
M2,%77>QW$-N2E&(P`2T*SP2]@U+#OF&[<C2)>;`#4V;0)*LMF2E.M;/`%F@`
M,T1LCWLU^QYNT+<SGD4#43D+GP^$-DA-$*U1O'E4TDS1&PZ<;QC^^]2HR%"=
M`EX-`5I;53Y<P,G.5/&3H)S'!$,)CKB<Y1]FZ0,)P*`"$XQ`!!.(%H_4\(8!
MU*$,-2C`&7"`JP$\)2D5H``%2O!+=K%+1,A,9HK_DI(&C"3%F#*:D1A`0A:M
M#`Y?I'M)OKAR1"2R[BS<J,(VJB#./J3G37`*Q_%(&383Z`6,=ME=E*`4/.YP
M#$I8RHQDTOD-E)VI=I(9(V;8Z#R](&^3GI$C'0UAQUW,S$^!^M,>Q3<^\DW'
M!XE"GR8V:DA&K>)]11N.(X,!B@.\`A?\(T,DI3/):5CM&MHQ@2=5QLE.3I&=
M.,WI-T:I4S5Q@00"`VJT>/"9',&D00*:@!HL@"MW0>`+&B""`HB0@"%0H`(Y
M5&:ZCD(4IK"@`E"!"E40,!:R8,6:^#(<-GO4+W_9876\:MT4S6F"!"+I=3T-
MI4'B43+A\>XP=N'.81`C_\;N4"D\\JD=F12S2;G(41"GR1X>\R@H]%7T$\Z@
M)'5JLPD^;G0VM5F%*'B3G).BE!,K0(+]2@')E4I-@!UX:0_F)8;$>C(SWG"@
MFZB8U][BCJ?L9!4!@!JP%^0(##E2T%8*@#>(B0&P&&``!!)`A#',H*H4H$$:
M<F@BRP$3K$J!YE!L`I($[6M?AE/K6ML:K("9Q0(6&*.;[G$RZ;&*M[Z%X.ZT
M^,YNV'-+D!'>8*.TI;C@]SMEBLN5PO%8AF9/3XW(X\U.$;[+6E2`&#W`"OCH
M65'49F@'`.E'*64;3ICTM,9P;3.H4\!38:<'&W@N8M83A7^0HXGYS?'M@!M*
MM_^@A0`J0*)6DGNOF-A+##/ZE4I*H`$KC,$*"?@"!=(`S*S"@450&<"&R`LZ
M>U4+FVN-25O]!3"!T:Z)JWKB376L4\SP-S!H`:-<^GH&C[DS8_,I</+.X\XT
MN8Z+W?C#'SZSA38X&,*.>(0>76/9BG;`$["-!F=U]D=AZ(PV(`8QHT#LBE4X
MS1,KB-_]GJ;B9+"X@`B@0T<@IJK![D6+><C#F,")9C;;6F$\!B4ZCT2"%T3@
M7V#P45>8FY5AB>&L*6$`$68`Y2A?%:PX8(`(V%65SP4Q1]E,;^%<PDW5L6Y@
M990+P]!\S@/?6FQ)(D=?2P8F_W)#BWB6TC:VU(V[FCO_+6SJ`O0@A@^O*=3!
MN^B>1">:4N9D-M+2R/"&!9!9S)**$X9<P48W/30D(&$4"X>T234<FU*;FH`N
MM@8=G/M<B-4%GECBZQ?);=ASN_P\N0[E6>X!Y(:H(-@1R&9#\)8-DU@`6Z?;
M2@`:H`$@:$#*6-60C*9Y%;2V1-OI+=V/F.M>6N>.OE@'!V:V]G)=\_:*6C19
M/_U",))%["XCX"*<Z=*P)R)I/,Z#$EP,LI>566`"%;!3$1+A@$0K&GSBZ^.%
M-8OP#F"TLPV'M#1F\UG::'AHF@CQXS/NC`QO(L4K/34U+EF3"9QA!WD@P5T*
M:X$=8"!B$,-2K;O.>B7%'*=9__)U@G)N."//)%AGG4-6@HU49-DH6-:L%M35
MRE;DEAG<+!=''XZD)'O?N_7J2'<X^FPE)\FE+^*<&,/H@B4\-^R=?;&WDMYY
M=\2LS`1B`,$:$&$&6TC!3X!O=#$0?JK8"L$9H4"\-!S^<(T.#?*.-WF7)VD<
MAWG^HWFH4A/98'+Q1!>7L0UY4#P1HW+<D&ZW!7T8J!:O5T7FE!G;H`([!P9/
M9SA:(&8QD3K+E3HJ.!-R,$3"EU9@UA*I8P=5)T5GPAWNH#(J$PZO@U?CX'S2
MEX'N$(2RPE?<MW5DUX'=T!<0<QA<%%@:LRIW=1Y_$0-X@`=6PC!BT`,R$`22
MDBF*=O\$!S!A%,9'!A=I+59_AJ=_T0`-A#=`<&A(M+$)CO=_`PA`H;!A!A@U
M+D4-;,`&V9$U=:4738AZH!=K>H$%?T!.5<!%JH<9G<%)0CB)HL18.K494/2!
M29`MA*-M)XB"*HB"M#<'4$>*@\--04(660!??C%7RP=%S]<J20*$L4A*]\9/
M/+A;X$"$ZT9O>Y8>FL%U5'(7:6)0=&$FSK=G]7!@\1%/?K`$,=`'/\<&,J`$
MR"%AN$$H%28,4_.&E51`&V4=L"$-`30UI0):$E<UZ/A9H6)XZ1@J!V@J/8`J
MBC,O[X8858)/7,<QJL0'^*1R;K*+E#B0Z["!$61?=,47*I#_!`RI(*68+=>4
M<_I21"'T`G`E5["C2;9&BV_G6VAQ8'#A.H:U?/M$=T98;SR(D-)S,AJ36`96
MBVR1)(;1!9N!!?P@C7C``M4H4DWS&MH8/OU'?VG(43[08N0H*N4X->P(6NSX
M:"H%#9#7AIXR*D*P+0NH;Y[4,1&C8'#&E?@H3RVY%RE)D&2)#@8)0;Q5)5D2
M9$EP+_S2B9ZX%67F7N!&:[,3%Q58EASX@[&(B62'&:P"1E="/&4'#V*Y)0$)
MD]]A3H?1!US@`M!H`GC0`RQP`I:I*?''890V'6G8F9UI?Z.2E`($E(Q7*D<)
M#9IP?P`TE7TX6_.2>FB!)H(1'T72_T;5YX#5-S*NJ)>\*0YG"4K^-3M"!2$P
M47O]DA7!P@.KB&;T!83*V)L49&XA$V[]Y!9D-R:U8TZX23PMIP[XT&=CLA>N
MHYCAL0U0@@5<@`61.9ELH`-(<`(7EYF:J5&>69_4\!/X20W3(9JPM9F$LI_(
MP'CP"!T@EX!;<'H6,QF%@7[T%`]<Z21@N0.8V#&,U9'0V9N_^4`6FI%^T39W
M$RW,I9RK&%]-5"0FP'SW0)X7&ER\A23<<#$&97;\I7KO<#*(*1]\082O<C"(
M@04NT`];\G,UT)XZH`/_)W%$28>-EZ2:@`8O=C50JA-2.J4(\!-74W]JV)\,
MUW_B(Y70,/\;6[IBST!`J5)R8D`";=$[3*B/^=B54G)08E*=.KJB`YFAN..#
M`#6,8/2(++=Z=`I]Z,1N*=F!<V9R6W(E[T1&Z6&8WA"CSWD>1'@PB?BCT.@'
M))`'8H``5_.'?\BD0L"IG\JI\QBE4YH-!P1?>&"JW)&J5S@!BJ.IUF"E&W"?
M/U&?7$IIFH4,#X>&FW<-$F(8@=6H>G$ELPE0#HBH"QJ>B+F+>/JG=6J)EQB$
MW;$96\,-X\:G8Z2BT:>,.HJ)Y#"%TC>GW)INWCJ)&YH['`.MO]BF6T0QZMH.
M9Z$7?Y8FR".NBRFM__4'+K`>2R")IIJIL`JE`CNP,*43VG"%?2K_4]R@3[0&
MK!+B7*`A!EL@(1^1J;$ZJRW664!)2<AP*%3Y4M@@F/JHK!)Z9R<'3HUALC$0
MFV6B?,WJK)-HI[<SA8_*E[M%5]*9.V83D/VDBP?%L\RW9CS+K%`4M&ZB&<SW
MDF!CM$*[%O@5KXA!H<AC)N!T&+@2,1D3A3V[,+43EOC`%^.Y)'A:HEVD6.S!
M28&)?O^:#=JQMFZ['>1F;T80#CK8%@?3162B;[9";VLZ`3H!I4.Y"5X*<O8G
M6XKS*WG@!V<`'R`#&&?`!WD`1B?[%V($M?HV1NS&3^<*LT(HLQIJ7RY[LZXH
MKDVBL_I$#H*F3IE!L_N$G<JXJ.GV8ZY[_R2Q^49Y.IV']36X^[+A$7>!T3%P
M9K>.`488@"LC@`&^$[PCR;7^V`TQ2KOV>AZW5240\WWF5U.>1*T+JZ?;FS)S
M.[<T.SU&8&,-5+X<N@/[8)/L$04,Y`)8H!>#!JP3FZD;<*59BH!"\#@Z48AV
M,1E+@`5S:QDQ<`;1B');(R6_TQA5**&<ZZR>>Z?:N@[+AUMG(IU;%S*K@I<,
MG*=D!";W@!D@$SL9R3`A,R9?HCL@HY()(W8O&<'G`$Y?@IME<F<0>GV&4;PT
MDGI[5:^@2QYI<A>*P7S1.QZ;$<#<4')5XD;FQP<VIH,7.`Y.K*).',!I]`<$
M_+[P\0T=LS)K@_^/Z`<Q4PJE^,D$3*"_-N&V@B$?!!P#?S"WLMD'4M)%!N.N
M)$.A!WPE03O$#9R!#SRSO(MO7Y+"HLNS<48P)[HU>&EU;W2BXS:,&3DF'T-V
M'[P8#$,R59*C/B:2"I.B@RP>^7@9(YNW$)J/KV07)C<")B</>FP.&L,F)[RY
M8IL/'.JP.U!Z6:NWG%%3+K`8L*P.LJ:,._@6"YNW`%97B%$%YM</4>!);/*K
M_WJ%T!S-F=2=`%&,9]#&;L$Q!*.F\_:5_@@E8-L[1KO*>]QZ?5PVY/P.P0G.
MU8D>TF,"D6LQVWO(#5NM\N9N+`<8?UG/:NF/::<9V:F[7Y+.[$#/\L3_5^DJ
M/(DQ%WAQO!&#9#-2%_%`T.+`)IM!%]_@=BZ\C+O81#J,3P<Q`>5`5TTDS#W8
ME[Q+;M5;B%B215%`KVW1L@E;TJSBQ`R$)AW3J&R:QK$SK`^(FPH=&.%*T>5\
M;N?\-5)(175[TLZYM0`U/&GS,7W1L%1R%B0P`:ALR,(XO'C9,#N0-EKM&%.]
M.[A"H_5,,.#T-B,`%T*,U/>UT>=PP)"!CPZ(N11Z&$DF&'J#H`0#UXGE3A7:
MRZXBS-S!T_S+=20]TSB(I_:&@^/`<JD7TC_W7`2<T0;UD<C#0./00)VD,HJ(
M!230!W--8/`$6-97?;0YK.&<8$0+UT6=7T>M_S!;0X1++7[H4*)Z,QCP%&!^
M)=%YH-;T5AZB=QF[<P9=1-Q?+0)Z&KD4^B1I\E>C#!B!%6MZTP7.DZ-?0ZZN
M70[L6F=^<<]R(=U0TH2&8;P8\!G".`]]<*-B2;2Q@I`I`PX[0,#Q4&>+2\!I
M6X&V+0X--*C6V;W3EY=^\`=H8BM=4*B!-3Q3TA;_@(O>\`?20]4A.7<//2.U
M++FHO+"`\9VC)P_CEK*C2]2OS6:Q34'9N]_FP!T$,`%P4Q!O(P(P'E@6!.,B
M<"L`(A!=HB:W$AAZ0^,>LP.X4J(OGC;Q@`$>T^,P+A!W0>.H''I?/0)/%+8)
MH]T2C(GF]M\R/-Z6R_^G"(QZQ7NU@65@]+!\EZ&@WYHPPNC$:Q,#[RO2%G3?
MC.78Z&"^K9W8-U:!X]O&1H`8LDEO>!!?J:??M3A.-$W2)&?DGW'/;2J6\M8D
M"UUOR3CB!%GB.M;8+YK;HE?:+"X"V_!*=0$E/9YZ47W5^2$8SP7CM07C#6.=
M>UT\\1#5@/5*&&`!>WWJ(]`P5:`L$Y#IJUYN+B=/E_%.N(F/@$8PB9%ZM[)@
M;$&;@OFN%$0F]AW928:/9K/=+FM.22(E\9$7F%%]'&U&=4R(6Q+HW6PR^/25
M!>6+DOZGE)YCELX-K\2G>-U!+'[KW,#BY_WJMWYW<`,Q,X+J3[[JYM3C)U?_
M>D0.7_7^&0%R>@@A`JKW-A,0N87N6RNY4Y`1IULT9U^YIUVTX_AD[;!S=MQ7
MLP>IQGAQ>@?QZ9#!/+8[M"[/%N0&/",?/6)N'K))3^XF)F")F.EN,NZV[A?:
M[N[NHK`#Y)Q>):_45")PZKL>7P8_Z^AW\/AN`D@>XT`^`KM%O#2>[P=O]+]B
M`@&B]$IN*["$R(+.9C&<&+W##3@ON0O:S5DK=MX!Q/)T,I\TP>AZ\@B:\OAD
MNN*0NDX]][66;_"DVC\;'BL);QYS15&H[8X>&)6<NT#/FT*?7^]N]*J7\$SE
M\/C.*Y_1^09_ZZ1^>EJ6#7KSZISN/.847W2Q\`&/__DD&N-JZ1>Y7:WE]L>D
MU+IJ3ZS![?:N+J\$0T]Z]AU'N*P@;_,9??*H7#PX;\(O[.!K06ZR,MI^AIW0
M3_SS-!^_"V\6`^PT^LB33_G.7I;V1G-47_:&$=7)C?JH!S$PGG*RKRPSHA`&
M/P"IGOK?R9T(@;Q$#@@8(B,[A28C(A@F)A.&!!@#$P2+BWV6EWR9FIN<G9Z?
MH*&BFGZ9.UTQ.S&IBUU=.R:3,:X3)B2GL)2S.Y.COINK)GXQ?`2_Q\C(?GY]
MIA,8$UTCKZXQB\;-R=J?E-W7IS'1I7S+V=N@YINJA:ZOB[-=M<:J,7[&FI3G
M^OO\_?[_`)$5"DBPX*]+R_\F34@4:P(B$1`)Y9'VL(L)08-V8(0HXM5#CH5&
MC,A4BA''C#M&8$@Y@*,BC2=73H+(:Q&?2Y8,ZO24$YR)72;XF/`Y="BJH*=<
M=9M%+*`?5\.ZV-M)L`\S9^U0%6*U+M2P<55QDLS4!Y>FG#>K?O+I2BB?I$&%
M[>J$B:K=NWCS\ANHMZ\^L900V1J*`9JA1=$,DV"$P2)C:(T(/(-<ZZ>UJX@+
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M(;-,X.<S,`I#DH7@[+@-EDK2D]1W9:4"UI1Z1BKI3DE.&ER$Y.S`3):<XBA*
MIYQN4@H!JO!DZ2=6C8,F.TI]<U1QUMRW"SL65L(40/3$__)44WE.:E4?Q;$C
MTC36,#AA*F;E9-6I_30*VRO-.7HBL]16NT^EUMZU3(.@=@LEHJ#>Y&F$8YX%
M);,$8`H7A4`A!5NQR5'RHZ9P&1-54^<F4^=;J#13;K6I_+F#0\-V84R-'MY6
M#TF]9AM*-E85,EN-ACIL\<6:8(LQ/W_\@>=5O^HEWC[D>NPIQC[&VPJ)L2Q:
M6[P'0V6G19K$<`9W^MBT72F%8FJM5H4-/+!(C:QR'[^OO+GEQL=L9S.03$<=
MM<92;^,Q60V+G.\Q?SPW<K;,&!/;*1-PU4Z'[=HF[ZU1005?<S?WLR8X/*_R
M7\7IJ9C4&2HU0K`T:?)[FVUX;_\\:EJ#VEWUXA=3S3C7.=(U2N&:=(P.Y;\8
M@0V8UJ+UHV/)D>B=34EYIV@N/CHZUY/.[5-4NHJWSJSFY/#K$#3Q$#P-+*P&
M]:YWCZ,J;G=^D%![\,A+ZGCRH%C>R;9;\W$U,AU/3U?TF4O?=9386YK-TQU*
MPTN"CB&E,CQPSOQ=4GW8^]LYP"9$:K\SWBFI$49DDC]F&$PSV@YG:(<U4M*%
M8@SE#&=@%>8<]@>P7&5XRV*>!(VTO`E:,'EHB=8.LK$=UP0P0O-K2NF4X[M7
MS0LYQ)#1H4P!E?K%X![P$9>4@C/#C%%$)(TI&^^J@:QXQ*9L0LG'!8=(1/-4
ML(A(Q-C_=7;VEF*$+@;-D0HIO(,L5@@C6!+STZ)*M3E^;"<3MR+'5"#%&B*9
M`SY)$8D/8Q&.6&6E(232RA632,<Z4NH[=LSCQ:[#NCM9Y7WU^T[;-$6^#?VD
M'7;"@#6`=Q.?Z:-U;_)9#?WR+;"THF\2@X=;"`@+-F5G?0_4HRA'Z8LCDO*4
M10IE5)C!,_O1S0_T.@K2@#04N`1K-XT,I38N08]FA'%3D^Q+)>,7E':4S3-O
MF@T)D=G#8A5B@:B,YA!-*<UJEG%;9-E%JK;#(MB,`Q?K4-3:PJ'#,)Y%ER+*
M!MW>HCA$J0<3%8)-)F&QJUF,PR@[5%@NK,E//5*SGP`M2`8=_[D+55FH.T!R
M39KP"2>DI<)^X(%.?<K20O1Q3TOER8DL+#(?H@A.C(%4:.^F$[F`FC1X_SRI
M2O4A23PICH52$5L+2_$F#[D#:<H45=:0P4%_M3`I$_U:1BV1KE;928<>JLG$
MA#2OI'!KI5"M6DJC2M7)K2:"W1%2(^U6.EH*SBAF8I4\QS*\9I%$G3_M%PR?
MA$Z1U2="55`9OW:HJ"`"18":FI4K_%6.JOHU6U/]JV`?IDIO#NHWW)37V6RJ
M3U6EPWD29>?"P!$CQ&7T)E4`7L)"HS2AX**A70IBRO"%U<&:-DR!/:UJR\HP
M;9+%;?4CD5`LA,;DO!13:(%L0"A+@/]('HZ&6"O&KAH**_-)!2G*[.0LUH1%
M:`G7D:N-[GA2*]W3UH5%K5V8AO!XJT.6R%X0JYYN_Q&Q5#2#LL>S;%]@.946
MU?)=K$(;*DSWJH2%<Q7M"UEU]^L7ZO+WK^R)BJ;L@2:[#4,5G)UO'*$(ICZ(
M=WL`45=%:[13JO14IM]\W[Q,X5X-*?85>3#**FK$VO^:^(XG3G%X-L'6SBX*
MIB3$*2/U2Y8'6X\@%NTL#<UASE.,8$,O1BAMBG-/1'IV0G%3;XJ7?!X\,GFP
M5PTE5KGYS=B=;;8*[F1=?F7C&S?+2NML48K^`YL]D;,1/BJ)PII)0F7.RD_O
MNADTGTSGM3C_N<[651$(L]I7-%5C45"9"S9)P0P;SYFP@W8JTDH!W1.UM1^K
M^MY-::2IF\S"L]LU+DT%",8_X_G3Y_`OJ$T:,GMY!ZUGZ(QGDH9?2SPJ121!
MH"]OAJD'#O30HM"DI9/C/BE:Q:*Q5=6575@S0([ZV*,0-;+YZ:!EM+-1\G!S
M/3"J'LJ28%<]%2.<J,V/*-Z**096ZZYO52@RO:B`,^).;);-[E`HN]W,GJ+]
M_(!FVWZ(K:B]D]+,L:U-$>1>E#8N%`^KG-]E&$B#K++1E`QO=K^[X=%TD+?K
M,R^M;*K1&<WPM-]$8QI'F**K""#%6VCI:<2PQUV(F_&J40XT5:=[_Q!_\L-C
MKL?P0,EI/DT:;7()O7<>+HS'&KB]'DTR7VKE0P4N-F(M_B2\"HZ#[XL0S&F>
MXIE3O8X29TYL>*@=5W.PPL+$R<X.>>Z&]C4@R[K7"/LC%R!I2*MI_M'`R?&^
MJ5]]R5:_.Q)3=<X';L?>O-!VY<"NM0BV"!P>%D8G!4KWHW>A?4VWGW,8+;YQ
M`-+E0]>[PS?HK<Y[_O.@#[WH1T_ZTIO^]*C/(([:=FIQV3KUL)<T+:)!C<L\
M,_4,0VA.8UL/6%(X9B1V,8Q`]*G8&__XR$^^\I?/_-+?OOG0C[[TIT]]V%\I
M/'XW;"YE6/W.9X(6$SO;/G$/4M@Y/CE.6_]X/0JJ<W6WD.]6[;[\YT__^ML_
M.L^_O_[WS__^GXSX$65JFH(0P.1_XK$J:,8W_E,LUE=^C;=4E$=A=)=`F]86
M,A53\!=_!KB!'-B!_I=_'AB"(CB"H;<>#&,.KG9VER!>!CA+N1,-:A0/RD%^
M&>A"D:1H0M84Z!.!4W%V&DB"0!B$0DAZ(#B$1GB$'(@._5:`$+."U:-_/4(+
M07,*J=8%T,!]I8<U_28AVC%?WA&!6R%@AQ53Z<)M/(&$:)B&:%B$:MB&;AA]
M8M)OU]$Q3DB']]<C?D(1A@$H9H*%J+>$JZ(AH[(J+)1DC9<:5X%QU_.&C-B(
M_,>&CAB)DDAZ>(+_@JHA29;`@G>()Q)3&/V3:A,00/'P'WZ((YW25Y@0(=ZE
M2>8G1;$E;\20*L)`=(LXB;9XB\H'B;BXB[P(>CU7BAR8$)^S._TS`=JF*IS0
M,=4!,IE(A[AE1GIE#8"'2P#D:RU7#KV8C=J8?+JXC=[XC4<(4MZ6%;0'"Y=6
M.\O2!U7@,>R%33BAB9?H!U=S+X<T0&2W,"[$+>"XC_PH>MW8CP`9D/S7;\,(
M"[3'<F+$5UV33'?3C'88CU(7B$8%%S!5#.DHD!B9D3CQCQK9D1Z)?*Q4#QME
M3(LP&KP6D8TG3]P"CQ#)05MG$62C'$650L#XD3:IC1QYDSJYDYZWA(U4_R>T
M((-9X766,`L)A%XU^37P)V"J$`VUD"FP)8^_PI-4>8LY6958F96IPE>69!0K
M07O#`D6<-R&OL3!,2$8,<W%W)45$)D/+T#5:&9=M>)5R69<>22YX*2M:`99A
M693TPT.*<Y;1X7?R>#S@AG#SU4B9:'-VV9A!2)>.&9G\:#E]IHKM,`U.*0V-
M,5\#R'KH,Y52.9C_X8P&U87MP&CAL3V2N9HA")FL^9J\R()RR$(X=!P4`3BD
MB'@*UGO_$9J<TG/<=)H)"9O$R8&N69S(V8@VUG.-X@HJ,3!^4C"Q0C<BMC.J
M(IA2@HI+A4=PF9S>:7_'^9WB>82&AHVI,@NU&?\2`G1`QR4,(O$NN-6=X&*>
MW.1@F2"?XYF?T1>>^MF?(=AE6G@5SX!#*4>2G[,R7(>/#M8I7?.+%_>6_AFA
MS,>?$EJA^P>@VJ91?"F*S80<M/%V"[.@OZF,SYBA26FA*/IY%)JB+%I]74:B
MV"@QFNF4\].>*:$(0B&1#`8JF-)`K*0B^-FB0NHM*SJD1JI\+^JCJ5(%.Z1&
M.X1^+^:A(S9MU^B0#3H.2KI]-Q&D1]JE^,=Y7AJF\\=*<I@N@YA7NRDXI"**
M,>5L-6)OO5<(9/J$6\DI#RFF>%H68)JG?-I\9+J$*5B4M^5;.^AL-^,^M%8C
M`[$M=,JE??JH&[FGD#K_J;`'B-##7BDY#H*(4V,H191&6;-8#EU#IY1:JGIJ
MJJAJ>I::@B'I*+"T=2,F1:U4#[NY*',Q@P5XIZG:IT6ZJZ:ZJB&S2N9FEJ?)
M:.A35#\&ABT"/;Z*JKW:K)-JJ>YX@X+(>MM2K87Z%+O#<N8)K9/ZK-[:IX!*
MD-[DIN?F5!'R+`KFBEVUF]T:KKPJJ?`ZKZR*EVZZ0;-:@=KAIO7P.8(4*+`*
M,N]*KT8*K@3KI2W7F:NBJ07::;(Z2$+6;^C#6&_BJ`<KI`9[L48:-LTQ8((F
M..SWL$P!%4A9.E34?BQGL1J+HAF[LBU:@&W#:`*V#*4CLX*VJ2G9>-J!0O*(
M_YTN6Z$M^[,I>JG".2/38$-G8+-'VXJ,]B,1&"L.U;.^*;0L*Z]4^ZO;LE3]
MBE>Q8:Q9X7LDYF<U$DE1>Y\0>K46&K1HZY^7&AL:HK,B^R$T`C4O1B.]1V0]
M*H\JN[;>J;9\FY\)R4XZ]WC,D*U/8ZS3T%>A]7V)NRV(56AON;=_6YQ^.[GB
MR:B%>S/E"B.O>C9@*Z=B:ZX,VR_*V$"D:KGY6;FHFYS5$YKVY`>:2V**9K<\
M8QN(9XCPP(Z2N[I]:[6\*Z:ENY6Q@4!QVK#(*A7E@'Y@ZXI,\0?VLKN_2[F^
M&[U>*I^;@D`E$A4BQR7#1X7Z!A7,P#X$8+I32[WCJ?^ZYEN<;FDSMOL[ARM&
MAVD;(1EUC)J^^HF^]MN8<-D)E99RL2I"73(J`)2T-^%CO7>(8N2CT)N_D8F_
M#"R73_@QL54BP0:5[V-1?P0D#E:Z)_K`DJD*21K"(CS")%S")GS"*)S"*KS"
M+-S"+OS",!S#,AS#\>AFCC=@`.>N,);`=3K#/OS#0!S$0CS$1%S$1JS"JW#$
M2KS$3-S$3OS$4&S$E^B7#T5AG]NYM":Z_1;%7-S%7OS%8!S&79;$8ES&9GS&
M:)S&1;S!XK4J;;*\QOI!?MFFTZ;&=GS'>)S'4$S&>MS'?OS'@`S%I9!R\36W
MP_!!/'B,>AO(C-S(CNS'?/S_R)(\R92,QVS<QHOLHTXU0FU#/X/$5JQ4R:(\
MRJ1LQ)%<RJB<RJKLPY?LHY';,0/A5+KF8ZY88-O$J*N<R[J\R^)URKS\R\"\
MRU:*RZ1IKO)[4%&[JL&\S,S<R+[<S-`<S9.LMYE\C+_SM0XKLX`HS=S<S67\
MS$!LJ6(LSD5,SMXLR-OLR']ZK\!FE,1@NJU[SO)LQN:<RN#\P_7LQ?D<Q/L\
MST?<SWYLJ;;Q)KF;P/Y\T&4,T*)\SSZLT$_LT#(,T0B-S^G<R-):8/#P03PW
MT1S=Q1(MR0P]PQ^]Q"/MPB7=T29=T8Q\T8>,"B-P!AX#SYF,TC3]SRJ-RB$=
MT3?M_]$['<X]7=,B_=-]S-)4&$#*88>O#-1*+<0GS<@Y'<--7<Y"'=1+N-3\
M/-5Z3,Q%N4'VI&U6_=5#'-6`_-0P+*U@;-9$?-%@K=-B/<Y:_152V=9K/=</
MIM:J;&`LG==ZO==\W==^_=>`'=B"/=B$7=B&?=B(G=B*S==)NLBWO-B0'=F2
M/=F47=F6?=F&_:*4C=>8W=F>_=F@'=JB/=J@;<*D?=JHG=JJO=J3K=F3S=FL
M'=NR/=NT7=ND;=JVG=NZO=N\7=BN+=FPW=O"/=S$7=RGC=O&G=S*O=RB_=N1
M'=S,'=W2/=W4/=,B7-W8G=W:;=?+^=J\N=W@'=[BW=S(/?_>YGW>O.W<D`W=
MZ-W>[OW>>GW"\#W?]$W>W0W<WUW?^KW?YEW"XET]40!+H$O--"NGKEP.6)#@
M"N[*57#15=#@C'W@E_T'6-"Z#W[A$`Z($D/,6.#7&6[.TGW?^,W?)%[B)E[=
M'1,%4>`"`H[#!+[A+-@Q"C[C?H#AVU)+-?[@$8[)EDWA%H[A'[X,#2XQ`R;C
M'9[7#I;C/7WB>\W>3/[D4![EGLW@%Y[)'5[E25W5))SC6$[8=3WA/*[E,)K.
M"1[?8W[34BZM3I[F;-[F;A[8)&KCU5/F6"[B22U>*AX%/JKC%<WE0)[/F/WE
M6]QE@+[D8G[F;^YL^9WHC-[HCG[_YR`.X3LPXQ7>NBT^8*T,HQ`^YS,NX;K-
MZ93>Z5<ZZ"2<X.K=Z&O^Z*J^ZB8NZ*3>CI,NZHA^YY9>XZ\\XU%PY.E=X:%N
MY*)^Z"S,ZJG.ZL1>[.]-X:9^Z41.L[!DZEB@YY8.Y'RNX2Z.YPFNXKUNZ@\6
MY+1.V;ZN[3:6ZY6^Y^OX[>`>PL8^[,:^[NR^W76-.MT`+#;!9:2:/MT@*MIF
M"#F>Z>9.Z8+^X79^V#C\[3"*Y]!.HH60XN(^[I@<TP?.[3T>\)GMZL^]Z.U^
M\1B/W7\0!4:@R5[I"HWAB5:H2'U@!#5.49Z8\B(_`9;`I-#I;%:QZ:,:Z@GN
M`A6.[5?*_S"G#M!:WHXS;03J*.V$+N`4CNVFGN2`"/32[NW^K=@[G]CJGO%2
M/_6]S?%_\$*'@`,9``%<W_5<GP%UD`$BL$&Y@`$X4`=UP/5HG_9U4`89@`,B
M4`LI`1&$2^3+/O1?KK`VENR'K8Q%7M</'B<8CC^8G/#BWL94*L"+\.=,O^5.
M/_0C3O62/_G#W;I"(0(`0`0:4`9E\`6>_P6<#P!N+P)B,#!B(`8-D`$```"?
M[_FB7P8`\`$:P`!^,@`X,`#'<1BG?_KZ01_P$2=$7@\/MN"([?>+K.(-5`6,
M(`83(`9X4/HFT.`Q@/R:[.-A'B<FP/O8'_U5O=CEW?>07_&4/__^Y&_;;[$#
M>8`!94`$)=``6_#^\/_^GE@+>*#\%B`&GAC_\%\8`P`(&AH#&"(XA#L3(@V,
MC8Z/#1B2$V*5>7D[.WY^,7^>6*!8?YNDI::GFYZJHZE_45&>?B:*CEMB%CM5
M?:^JJ:*QG%5\F2:SCB(88B:9K:RHS]"DJ]/4T=;/U,#7VZ@Q,=S@X>+CY.7F
MY^CIZNOL[>[O\/'NPSMB.!\96Q/[^A-;_?NZ2!*(@1_`??PH,2`"84LA$1-,
M8(`@J*+%BQH2)/@"H0V#`0UVY"G&IX\?5:%$<<N639HK6)M,-("@46.;!A,T
MG>3%JD\O/U6"[C!A02(.00D$X<"P3.?_3W8L6[9C*8_3MZI8LVK=RK6KUZ]@
MPV:M(FM"F0\-:C`H`X$MA+<0.+XMXW:N1KIPZ98I4:-&&0T-FEJPT```$"`*
M$BN&P1B&XL<*@!`!@$.$2'HH76AV9FK4*CY\C(`>/7K524^\9(D9,.,Q$`@0
M2[[45BHHV:$[1&0@PCCQZV3,3KK@?-KTRJA4BY^:M@UY<=KGO(F=3KVZ]>O8
MLVM'-TH7@2Y_^U(@HL&*^1GH9YA?KT']#,1`QA!9/X,(D3(-$%#0P,($GV*$
M`4#$84!D5-.!![:'6&0?E$&("29]H@H?RWE"5DS%9*)A3L048T(IL_5A@A@L
M>*&8&PH0D0`#_TQ1^)QIMBV#P0`"CF'C&)*U,0$NK<!BFH9.20.-B$T-]:$L
MQ1#IH8N;D/54<"YETZ&'IIBDTVFID.,-<EQVZ:54QWTIYIADEFGFF6BFJ>::
M;+;IIG%AOBEGE^#$8@1X`&RAGQ6">)&`%X#Z&>B@7M0WQ@R$EE=&,AGP=]I0
M#21`(!`#3-#%I9AB>L9#C1(Q!F-$9(`!`49$@<4.&#2"02:B8.%"J568@(<8
M_S3`0@4,Y)IK!2PT\`\>>!3S3:DN@&*""":ZT5AB##4@!AZVN>*J"[S$*D8#
M0Q"A`&,S0,$8$#J:(.$?FK@:QA]=V*I#KUVXT$<5KCACDA%!30#)O?^^_H-`
MAB;8%D488?B1*B-,!752*-2J,@&P6SRR3T'[?&.2B\0U$]66<Z999\8<=^SQ
MQR"'+'*9<8Z<\4KS3O!%GF*TP:<&?FI$Z,R&(AJH1E8L*D:C+/0A2JR1$DB$
M"*0:8?311A/PGP43T/AI8H/X800H&&0`@"`#^'<P3,5LP4(;0[0WH-!$(#I$
M&X@4([4+89C*![*-(3IV@0PLW*\?45!KJA$B-IW`M@I`D<`0RL(`[@1\_.&J
M)^5JYL<`?P*J`0XQO!NO'YIH8@10(B25D>2>(Z71$!"4@`PET%;!M@MG9/!G
M`I7V"V]*473B!QY;B$!1`@`X.,(((@0OP@C_E?O1Q_&H>(FQR5QNS/SST$<O
M_?0<ETR]QLV-8H19>2+0!J(PPPQHV?799[Y];MCHAAM0()I`SHSRY_,H,DD:
M&1$-6(!\E?W&0-0$#-"`8H"0`<3U@0\C*,."<&`\XY&E&$W[B[8D@Y&Y2:8,
M#'!6OUZ"A;=IH#$K:H,&"*0!!MA"=J\PG@5H%4`">:$-+*"!MPRGH\0MCEQX
M<Q4&R@`9``1F!XISAN;H)0)M*<!&AQF0?29%0@SB!`^-2Z!B2A"1H'SB5.\*
MRA9:*!D`L&@'70C>`,9XAC_$8`<E25Z7EG<]Z$2CC7",HQSG:#+KT?%+QY$:
M]_3DLCY%KC[K(]``_X&0OC&L#P;N:U#\>J:2^BUH:&+8Q/&.IXHLGM$"$QD@
M!%:U`\(H$`9C&,`W8B0&W8VP0&7(``."UP@1#(`!5OM`$AT4D>(00`0?=$P"
M_L$``2D1`I4JRC<@.(!LS;)28I#AMVHH(<SYH8,3P($2QT8$*HIK.*P`8G>*
M>!@-4"!7.`@G.#.0@;\(;441R841$J@L(#!@*$'IPS>,Q+0!0,`+72R!!F?Q
M.U<2CQXF42.7V-A&Y]WQH`A-J$+!9(V%XC%[>BP#R_H(,YF]YS!N,!\A`ZD^
M]B529SP+HBR"=C\1B.$;*<'"*V`A%`),H`W;PM$FAT(823%&E%F<!>2.6?\0
M``%H,"ML0"_'5L()$,`G1KBE!CX%@UUFH900D"5B2FB+H="*!B9*S`Q@8P(7
MQ$"9-(Q(,S7Q!T<6:#_=-"D?PJ"29\;B6$9,0`-F50P"9"@1A6@#/AW#'V7$
M:H>,&<,[-6&;H!0#`PRP0A)ALZ-E#,,;$?M#&J_4F35V0HX&=:AF-\M9YMFQ
MLV[$AO;VV+*7":I0&$V/:HE02/*!#WX[XX](S2H9$6QPI?]J&[4D28(N0,`W
M0+!F,;`%!,;@8`<$&`H><+E89PVF*3&(5:R(PC01*+";`U"&\8R`2Q#.M2@-
M.`J!/@`!9UUK-[XI(5-.L@,:-.9PXA+I4+97@@G_4J`&]3U,`?E@*L]4$JY0
MRY^'3'")*4V@!#-X6D/J"EA0OC,/0#'L+'27X,DL11E'2B-)?+(_T0[TLG',
M+&A'3.(2G^FSH,WC]B3*1_"=]CUEFUFATF<S+UC!"XI:)"CH%S0WU%9V``LR
MP#0#BDO@,C(*F$'6/!2IQ,!@`%A8!NX@0*`O:#!6$2YLC([:71L-8;U&ZRYC
MY-JO8JQ&4O!)``L8\#??J#DB/G'!#A@P0S>$:ZP[:,(6VJP!$1`FJS-H0!^*
M-8THR$($8PAP)3!WO#0BB584>%I?3="$!H=R!WW(1:PPV4)0`K.*!G/C'WR2
MI0I]>(XB-K&J5\WJIS24_]4J)JW+K/"Z/Y7/?0<JE*=PK9$<QY8%.Q[IWQ"#
MOZ+T032@0?8!1U)*!=YODP38!`$:P,-M0=FJ`P!T!<20"^/IY'A5B.Z%_,"'
M":3!4X>J&P'^P-U<*B`!!=NT(NYY&`442C%>T&<Q@F($.=,95.%ZIDJ,M)#$
M0/NE*%*`CGY!25<<.M$*``PNG!2O[JBF1,RB(A\(L,/BNC,3_C,&1;I)@Y#L
MVXJ>L%+R/(P<@EXOU:V.N<PWB^+.QIK%I?V<H-!7XT'5;%`X`RE_=@RTOZ$H
MT,K(A9DK(09^"!7-0)A!!AH@-5APO-H*&`"Y:`6!A`]A"R:(@1%6X9.HF&#/
M@/_[\KK;#3AXW\VP+$3S8Q)0@0GD87/P&C4`9P"J`D8[B)FP`-J3/`!-R"2K
M7A`!N2/L"7H="^*`2:XNQKY2OF$.#T$[C,8)<`9G?[S,B#TE>5D`:ML<3!2D
M/DGV3HW9FL_\];`/\>I5??.)EL?6Z,EH1E6[VD.EA];O$SH+@ECTQK2``F-\
MI:XJ@"L&M($FK1$<,-?+BSQT/#$,'%&3$],&L%?AAEV:10;PW0"E<?<#BO$A
MA"P4*SQ,@`40,"(1AF#2/$SKK7OO>RU5<48Q%/PW[S(BOY48!90)*!<%L8)H
M`39QBJ,9/$$NN#,$251`6,`%G;<@#'`+\S8V5E`"&`#_+,M@,*<1"A7S:JPG
M>[,7>RJX@B^7@B56>WPD.6/#+#Z&(O4V*1V%2'X"6R$U',47-S/P`1_`>[F7
M<(&3`$Z`$X,1&IY@?<X&`]DW`16`3XB1@1"2-U\2%`.@&$KF'^<'..HG<'\P
M796``4>Q(F#'!Z#`5C]3!?D'`T00<*!`)$U6((4W=E5@`=D&-28E.SMQ0`H8
M<?G3;0@#$U&&><-631/@*A>8&!6``%N4``/B31"Q;Y1U1<$F@M>@/"`&1S#'
M@J`8BA_C>C0'42O6/12E1$F441;$BO%A2,KR48OT!\,A;(UA.$L$&;JX+7[R
M39%@`F/G!R30<3<U%'M'(-E5_P53\PMD5W9D5P4#4%PP``4,X(5B]F[K18)"
MD2&+$!&)HQEL.(;AQ@!\!X?A$@,JD5PEX!B_41+TP@<3X7&;5!1.`@MO8T02
MUVW2,C5F)`MXL(>$!T1&T(C!50'&1`1?,`!@UR^9<R6*0X(E^$:6A6JD*(H6
M>9'8LXFP9HI[Y#TWI@'V41^1(1GG4S9+I#Y0T#XXQH-#5XOUTQA04#HX4`+D
M5`(V>9,9T!;MH1CD,74-A$D\5(RS0([WDUWDMF/4,$G[PP=5(`+EZ`;O%!K7
MN$L?DA+=H0EVE0<4@AH/V1,Q0([Z%W9O-0()X!A$4'@1X@DF,``"9(<8AC?%
M<H\+J/]I7)ER_X$M[%@&WF<$Q.@&2>%"VV8!T7(J#GE%H261)^B)%8F1C-F8
M=.*")(8R$=4]%/"1-@8H/B89,C8#A=1SOL8SH2!L"K`^,T!Z$>,-9P1R#],`
M(E`"7N`8D5$&EI&'6S`$BI&!34>.2612FQ`&P]%P4L%N3AE8U1AFN=14@?%,
M038<E3-V`),W>`@4I.`S<U:.H5)+H,`',9!MC`$!9U`L.Q$&\-AU`[))RQ!G
M'51$`:8")D`JFO&>Q1(#NC-#7D!Z_<)Q$-`8$$`!@$8!SD(`5?`*YU*8S!$.
MG$B1D.F8"KJ@#&HFIV@++B,H-<%:47<S%K5K,6,>@B!T(K#_.']E=*.9/\F&
M;*0Q&A#4.:`D'^5%%#MTFQ%QC+452?_B`JA@>M/9E%;P*5#9GN?7&V069Z:B
M$L>6-[K%?N.F.-7I&_OE(C)1!MJB9#OP"YM@:#N0;0-2FK@@+66EGA%'>EO0
M!0CQ,#-B-;QQ*#2``,%2!5?7&PQ0`Q4@B9(!.V*%!><2):YF,6GB<M7C#A@Y
M%0W*4.KPIW$D"@/)8G@P:Y&3%`EV*!;Z)U:08+@&?!J@ERW39^R'B(HQ!@V0
M!VP5#9,T#&P)2HA4-UEP?5DG$OXW-T9I!`!C&T#RJ@8(C:V19-6H-,RE2P7#
MCZ7@$S[")48P9T9$0!.@&56`.S1@_X/FJ0FDEFD2$7\H`@&(DQIPE42#`Q<4
M<*U#,`0)D&"1H0$08)^R(Q%8AYLS085>0`,+R8PI5PJO^B)HHJ<GPZ<7Z:>"
M"B?K4*]M1*B=-U'FL:TV8SZ(TG.%\BE0@&.W]R>4*D)PX*&8ZALBP*G8U!)!
M]`?X*:H*`*T6D$`+`F7_P1H$@@.15`6^63'?H`W%R@!(Y@59`X@CE!ANIXRT
MP:M>\JL%%QD9L`-L4ZS;-PAB8`-$`1H$0``6\%2A&G$/&R\).""&LR"[Z&0)
MD`&$P&VQ>G7%I0`96!1F*'_E)09;Z0F)HWJFMB;P.B?OT*=0@:]WF@YH^W+;
MLS(0VJ_E,_]-2T1(&D5(X)-K":L!"\M6L3)XD4$T`)-2H;!2T^)2)1!3"O!E
M0"F-UT9;^1!NBA.D0:I2K_">4=`'+Z48<G54'K0@9#8[6+"K%>>KP*JD,<`V
MF/M_:O8/&$`0K5L0N=-FKS$!4YJTH#(X0X`7;P&26N4$&+!"VG4:?/E)[I03
M$,1FQ":G:G@23.BN;S*V<E*V\WJV:RNO:QL])N%2;KLG-V9!Z/8T&S4V&34H
MM.8%>=NA(UL_/&E;1@.?[SDMQ0(*!+`%,*48\]A@4&AX+S4V<D6/W[>&[_F<
MN14&]8,CBL@W'J2Y@>$3*N4,=4FZ-1LJI^L"9H5(=T$7`-`[>E'_!I)X1##@
M!1FH:4W)&S`P"/XP"?O0`&V@+6.0`+;%;>*2-SI$O.\48<DU$TD$PAB@E1%V
M>H7H)M#[)M)KD?2*MM9[O<^3O2J#BC?F!>:#(H7T-(_!&"H).@@+H7TV9&5%
M4BG"OOWFOL5"9--24\!50$#9&`/@!W:U&E183;?0+Z'@F^#HFY7K`A-``Z_8
M9Y@&&D>&(C\:N0Z,E!`L?QD@=EAP8`2R+"/)1(*T+8:3`*571(PA<45A9H.Q
M!526(K0DF*HS9-?W<=UA+5M``[/*$"+`!R00+0\)OT#<B1XSQ*)8Q/AZQ$A<
M1VJ,`5>C)_R)8^B!6E3\J/2Q'N81,P9B_[Y8W*&.XTB^(6"%-4FNBFE*@P'C
ML;2#(!(M>E.C]E=4AEV4$$FH@#QYP`6Y`6@X,`$,[$&]`0!,P<"Q<"%B\JOG
MQH[A(A-MZ05P`1?DE,\Y"0$9\'RES`)O`!3<1<(2)SM5T"'41B!J)@8`RJHN
M0+6)43=XPPO$A&:3$3M^Z,.]*K:NW#&P'(JR7*^T7,LB@SE7!P`UX#T5A6.V
M9B/`AR`X`]-)<;ZN$KKJFQANL$\#MM,>L@,C@&`I2@048'=.Z&1:!Q2RPI;4
M2GIOB20=(A*Y46U`,`0BZC93R10-V,YXBAPT2\)V-@$D,&?P865-YQ`0$Z:3
M@`"1`IOWM5V27/_"1&/05E(/U,:_(L!OIG)UMZD,+Q$%2Y?0]C$Y3&'0F-C*
M)3W2+!C2@HK8)/W*6+E#*-TR1!`HXD--%F&P?2(Y%G$?$)IXQN,--PT#5E`!
M_U#:IEW:ML(`-&%$FKS`XKI`6)!3,$H>^H0ZP'+;LU(#X24@D;&BZ)G`CJ'.
M\45HTGDP,[L#%?`T7TW&*6*%/<W3Q,`TY+@^7K!M>3#"D]P`_Q$:8\<W!WU>
MGV*'[5D2'#<$;$H):K@9Y')8NW$86^5<(7A`:<DF0>PF'PV*BOVGC-W8'4,A
M+G46*;W"@C`#?3)!1/`!&"$^"<[98G!/=VT;'"<IRM+"0_`%7R#3O0;_DC=(
MVX.]<:;*0$P9;A,6?]3J$:LD/*]4`A1!5#>A7="I5+ZQ*(DCPQ;GO"Q!LXYA
M2&U0"0N!(HMBT-8`*;(+K1`F`A_`&.J,"1("$[*0!S-Q4;+)P^7]-+@I''MS
MT$.!6!:-3OYKIVI2WVURWXE-O4:<W_S=,?ZS`_%G4BQ0`C20!B60*S30!G1>
M`C-IYS;)`',>YS9)`S3``#8Y`+HM"($1(]OG&DT+&:#D!4-0VQ_2"?#H;`IP
M7"%.AEJNX239R^@Q(+YA!<!T0O#R"J)AY+X!`",0PYFXU5%!LX^A(PT@0,T-
MC!N]"CR!@`0@!B4`'Q^0-20@`@L"&$H.OU&P_SGD=BWQ%QD`$#MZG1@T0`GP
M$K\JP6Y&0")P*AFB4GH4Q]&';>:QQ^T+NM]GGC&5LY8-XBP(<.[HCNZ5$*;[
M4`EO@`!B`._QC@#O_@;XQ1"E9P(C0!$*GN`8,3@4$.=IX5?C-@*-@C4-M`GT
M4(8#8#5BX[T$7@8TP`*V4`D[,#6I85T5`0$C\$RF`A/N_"5&\)7A(]AL"3.;
M9#2\T%\HL6/#7@77\A>"H'&XM*$C(!MY$[]C=T;:Q^\:``"6\1V-@F-U$\/0
M7AQ1$.\-</`_GP$C4%C/V]%[ZNVO1_6.">[A3K:S<!1[\1',MWRX\B#_04RY
M,D:Z\A&O1!%;NPR;,/_R`^,(;P\)DG#624>7](,JD=``7=`,/H)&RS`!;^]*
MR;<(=-\4M)@P??/VJ^(S$!GR>&0O!+,JDM`P6[`#0V:5+0\*+S\,<Q\)QCCW
M!0$:*J7YA&HE?Z4JJ[(YBN\?>L-6Y!)=>6,M@!\)&$`\G"#MAATR8KZ"5M^8
M6)_U;0(+WV!]1Z&*)'G\U4PA_R$"AL'(DG$8^+!/0#3L6#`2U%4,6LG3VH\;
M.]`)8[?>RT`EOC#ZV)1I1K+34P)=03'C>Q.`1,%T_2*@O^#X7S+V6JDXF0:"
M=-HV$`D(?GY_A%A8A'Y\?'\$>3N/529YBB8F?7U_6"Z&6%%_ESN$?)65ET;_
M1J,F.R9&+F&O88)553$Q?WQ5JWF3?(:>FH>$PL/$Q<6UQLG*R\."SL_0T=+.
MS-76U]C9R=/<W8/:X.'BX]O>YM#DZ>KK[.U_4:=^)F\U#0PE]VDE)?K[.".9
M/O'!,&"?P8/X1&`04^D1%EAA_D0B4,7/)DX8#1'RY*GBNRA1L*RB%<./D3Z#
M.,$".6N6HF*7_@B26,5(IY"'6C84(V96%%@Y9VJ+XH?`NS`N8DPPX><A4D.R
M6@H5=M.%Q!@M^VAJ6243QHX57V'ITS)3&)!&JF""&`9+2:EN_QA!.]?%1:#L
MD+G;R[>OW[^``PL>3+BPX70AC<C<U7#"TD<[)CR*_Q$*)Y\^D!])7J7*Q*A'
MWP9UE>F5D&).A82!S`02I$9"*/WL,.F"[&69KW'Y07G(UZ'0HM[)-)G:)69(
M-GTANB6\4Z%@IYKYL>4BRB9YLW]&F=TTF,S1G38)?QY].%8_JP]Y*CD<T0[V
MOSSYJ=CZH?,_E'<O:E936'+O[8FCUV$$6G/.@=]<<V"!V2S(X(,0NN.@@0B>
M@TU&&MEUR&F;X*(6>O9]HM5%=I%8'4[5[3;+=#^I5]%%L"7XW"LA"7-)2M:Y
M,%]#6*'4!Q\EC9@C3IDHAE(>?VQ"%BW=52?2;/>]YM6&K!&)VB">>`;268?4
M@MY/?N`!Y4/B]6?()I[PYO_4*Q*%`B!IBNUV'&1O#C)31F@%M-]R?.PP"VB7
MH$0:-<-5.)TM$2:*B*'=-&BAHLI,".FDE)9C#C:,>K,76DO.@I$@LQGS32V8
M=#)?)*$D1PA]-L8F(T;"0(/).Q4%2IIJOUBEVBVH$`+?*9#U85-U,GF&17FS
M#M)+(?])EPA*C_`Q5S"Y#.+*?'Z>2=1\,YTH$VB^A"1;J-/)Q0>WF,B&;1^3
M$'+B;XO\,LRLPG2UVF6SN)KJ=`EF*LB`E1+H[S2.7AJPLYH>K#"EDC(S,,'D
MS'0C>N=&8LEIO[UGIY>+_&MG)N_%4,ESW\JXF[HQ9;1HK;LA4M%,Y2U1WUBQ
M!7C_:U,L<6:O(2>1>XN@,]TVE2?+S8=2+LB()\^YZ,6RHK:S_:D55*J$BE&P
M^+%WX\O.T`+91_)^`\\I1G@LRWP?W8+O,U02.C#`"P_V<#0%)[QPPW'G+?"C
M%,[]##C/<+>;*C%$05E#GNW7!RFGSK:DNFJ9D"5G8BP"U>%R3=>0X_0&]-V?
M@E.C"+TWM7+(*N^U%,./G6.QHQA^IO1M*62!:O2XB<0J2,>'DE)U4^Z!EN0?
M?J;VAPD,H3Z3/)7,(M<AJ8"NRBR>39\OM&+#(TJ<B_ZX"@$FN%3DZ"Y=]@TJ
MBP3Y-J)Z"^;WWYCRK3#>[=<?&/V6OB^CP]%0,EGQ\G!,_V2Z\(T^+84LA]-)
MR"0C+1,XQC$QZ((M##B;RRRN:N_9`4J"]+D_B8QI+VG*N?`3$.L<PH$C65&?
M0H$>ER%O>KU`R0-71P!!]`$K3+IA!`D8FTLP33,"5(3K#@>:IJ@K;#R9@!@<
MTY+(I/`T?7C@GS9#F<A(IHF9^9%<%(,?Q]F0#[MPC`1KA0G(A$\S&DR6(O3B
M+[C9CR_ZFTK?[#8_^;WQCGW!GZCBN+]E0$,S(AC``'`P@"X08'$$(>0`1-`%
MM4P@D$LQ01<4XJ<JC$"0@A1!23`0R$$*<@0QX,,C1W`)23PRD(0$Y>B<\0@'
MBD`$$P`?*2XY`DGX802:I`EF&O\P``PT)!*CC!=^7BD&"XCAE5WXQ"0SV07(
M<%*"JW@D,\\C$Y2(TI.OG,!E8H#+"5A@![BT!9:@MP,1,(`!.,"!"'9`@($(
M<BDOP\(9!+D%$\1`!/_PTPX(4LA9/!*=Z52(&/)0B7]B(#8.Y&4Z,P!+SG1A
M``R`I0,A.H`)5&$"(U#ES3+E1CRR@X]U:U3<].C1DHJ#I,3@8Q\CQ4I)XB`#
MBWPE!C183@BH4P2@-`(!,``!``R`G2.`*3NK,(`ZQ'0$NY%F!LJP2%#N-`,,
M*-LU,W!3A93DCZL0`0#*T`!2/&(``,@`!AR13@)2;P(]90!#+&H"#,!4$2>)
M`0ZX:@'_M_XT*0.`*3)1551?JB*O,>V")8YV.)[BP!X0$,&/_"`"AK:5JF?X
MQ#L,(<HR$$$#7["I(0G0@*WZ<D5Y&(%G[8F##S"`G2;0:AU\28`N0(`(886`
M!@`@`M@Y$`(?&`!*)#F`,FP5`A!@0#-'(8(/$(&KJ35N&410!7QJ\C;IXBC[
M3/K1.(:4&WE#*76W6PWMZLZZ%$+=(^:*`0N8UY@36%P#N/H&V_+AJ0!(K`5$
M8%3.,*`.WN2)($Q@WKP:<D=H'0`E1,!4_FZ.<\Q;8CKQ$<DJB*&W92B!-_>A
MQ%4\&`(#@$!Y)?/8`>2!+#]R*PXPP(`,3(`$?.@"5<OKB,/U_]:O$Z!J?BLA
M,9&U%0(LL$$-@CL)!^(``KP4JQ"=@X7*FK8&-=B,"3I;AAI,3Q(8`(`&MF"!
M"3#`M!9`7@,T4`8,@`^M1&`!'B90`M@V``]C?JT(]CN`#V@`EF+`P$Q7@0<&
M$&$&7AA`G8&@@3?CP9S/%4BA#-51[H8#I/$SV-WL:.A&=Y?1+`7OHSDC2:;R
M!`,-:,!,98.!,L!TD;/I<&\UG5A2]%:1&"!$*_.*`:9)$L.7V4%>=^"(5C)E
M.A7A3%X;0%\1D$(,Z&R`3<DLX276%<-N5>LW]PG3%I<D#VZUZ5A9UUB8SAE\
M+VX(/F':`$#MKA*=AFD)(#""/*RNK?\,L&E7+8<14>(6`FF(:"NCW.3I^0':
MLZ4RF;&L"A%PV<L['8(&Q&R!+20@S&A&JQ5$8`02Q,"R#+!`#>[12S\!6P,4
M2`"0(9!9/V\!`\ED6G0956A')_I]UX78HA5M\I;G3Z1S1'EX=1'E`1@3L25`
M;6=+\$I0RL.N$PBH8RO1VT7VTE>KZ*N')`E3:,VZUAB412O)O%RPGG86P"Y!
M/9B*@V(7T]\1S8"&EVW77=R0$;+VJ6<>@1).OK266<YV0P@R;E\_0AB/Z'0)
M[%&"G^[.`NME@`E(4"J,W/:R9<!P8;=:@RS3H@\8Z#.5Q5!:P5>BN%TVP4XA
MX`4QX\'@,_#_/%KSW/`)0/P-6\B`F_UN92]4H`U>@,`0*D`#(MA\B<1Q&\FG
MZ_*4#\SW=!LII'OO<N\N2M+5V&`B8FQB8V+@I=I,+9"O0-`*VK6N<UVNKL5J
M7A.XAP`O)D!)7CV`LO6AUXPYUWM<MHH&U.'3&:A#+1V8[L;G-<)*1-Y<%\D`
MM:NB['E00_M%8%U5$D!R;U?0:3B`6G+W"&%D4]RQ$:O`4R)@`V_@7P?8832&
M&J)@>AK```^$'TL&``#0`$M419WV`2P09[(U`*2`>;XD2E\0>F*P!:7U!2:8
M9K87!7U26D"&`,*66Y,P`6T0>BPP`S-``5O``$`0<;##.X.V>\0'_SC(]V@L
M=S#&-X4FE84JA0T=$TJW1%6:U@`EL(#$508,(&<@UP=/97.I18*^%G=,I88A
M018FH'0J(F**P`=G\%(*,0(@ESLE05.LYGQ"10"RQGU!%U;Y%U3KI`HO%0/@
MHV(C)F<A1P`$R!29P$UR1E\_A6VKU1"`B&E]IT&98!>[P5-IV`#I%`-&,'[/
MMTZ"P(''XX$V-PFNTU8`\`%0I4ZT%G0?@(8EH`$:IFW_)BVN10004`$E0((#
M4$Q5]EH#4&30E@%<%F]EH`$>YFXST``&9WO`1@2G%3M!,G)2J(4GYS?`AP["
M=X7H:')<B&C7$">)X`</E4Z$U%7@\WSX6/](M_!0784\YC1_)C`"^*A.UD$3
MEW0&UG11BU0VRX=/BI137;0;]Q2'?R51X%11E?!0Z^0GE[0#)P%M_Z!Y]YA.
M`S`"+H"(E^1+IG%/^*A)U$,0@F5/$JE.DF$M2B)*Z,0`[U0QB%1QQ+$1WS$!
M@[1N?Q`+;?52&="4FF0$$S5NUK8YSU=1:U008J=.-8DZ^*22^_5(/V93O;0(
M1CEBQ]1+QZ1.*Q(TWT5HO/>.D29S"C)\DY*%</E&\5B%RT`TP_%>D8$!C@$[
MX_)`$R!!H!(9U+-$?F)15@28$Y"0H,,==E@#8D!.801R$\`>,3(?M9`+J+,9
MLU!%B5`+CE,+N,#_+D_2$@\$F"(YF*O@#$:P`UT`F'EP*N-22;30!0^D"CBS
M&K+A&%N@1"H"*@(D"%PT'OXD0#L`)KE`F)EY*L@S`8"I>2BD&6?`'1?U0!I$
M`&F!%8@H&2`Q'^8%G)&T"*I081@T&<C2,5HD77?)/W9IA>Y8*0CRGO9Y1S.Q
M`^^UAT"3"`303DRC'_RB'^=R'GO83IXC$/3R+(HC&WLH+4RSF8D0H!.J+HH@
M.GLB%T"C1?@QH0_J#!=*#3_RGX3'':M#H8KPGX3"$7TY"HL5&@8X0BG%+?[#
M/@^ZA_0XH;MPH=RQ2C3ZH()"&OPI#..G>0\*&Z.CGR"4H<T0E]Q0<MFE_U)Y
MJ3]1*H_519?%T(7W.2D<T1K#T*4.DZ6%P@Q$\S>0MCSJP)?'=WP08R?`X0PL
MF@Q>JJ9.N@T;X:7$L!I92@W/H*?%$`QT"C9X2I1WF@[F`*7M**5T!)]4FJB-
MV@[U.9=ZN:5X9)=:*B%6>J6+RJ@P5T?=@*@KIZB=RJGJZ*ARJ:F;ZJ2E2JE;
MB*5[.JF&FJGK8*FNFBB'^I;U(ZKS^7*KZJFP.@Z1&G.]RJJ56JL(<ZJH.JRS
M:JQM.:H!<ZLEI:NIRJMS4Z6_>E)3BJS$BI?,RJ;:J@Z7"JG=&H789:K1`*J^
M*JW!)ZS5:J[M*J[=&J[;RJV[2JT/`T>R"J[C&O^?>_.IN-H^ZEJN['JO[DJP
M\%JOK_JH\TJOTVJOO[<7\KJL")NPSDJ?WH"N6!BPTI".RFJQ^1HQV=JQ"VNM
M%:NJ[WJPWQJK$SNC*QLAT.I1&KNQDJJP&?NQP!JR)SNR`+NO-GNSUXJM+=NL
M`INNTH"QSQJS[#BP#QNJ-*NO\=JS.GNT0>NM(@NR/WMH/#NU#/*RQ8JTA**T
M_D*R*>NS4QNQ4<NT0RN?8TNV:PNT#;M'6EL@7(N?7ONU:ENUD"*E$(NS!GNV
M8JMR8)LI^'JU5*BU_'H8<\NP7LNQ.2NUA+N.27NWC>NW-?NV%(NW;MNV6&NX
MXRJW%_NO>E.W=DNJD\O_,%"[N9;+LDU+N8Y;L@X;MIAZNH6;NL>:MJU;M%<E
MLRBKN7\ANBOUNO`3N[0KM*4+MZL+O,$KN;X+N,JKKO>YO(S+O(5!JW&[#%XB
MO2K[N'DDNM&[KKN+O2;;MZ0KOG[$M\OKO<TKK<_KN]V+OM.;M<-K#=>KN\F*
MN8#!OC/KNFQKN^6KO6:+O*/;O^>KOY>KL>O+O?E+P+T+OPJ,#?/KOME[O'*#
MP($;P$X;O^1:O`5,ON%+O^,[P,F;OKIZP'7;OI%K&-2+P<SPP"=\P1+L/A0L
MPA8<P?S;P;!;P89BPB$LP"#LP1^LOO8)O0E<PS#,N=6K#"R\PS1LOPM<PD/L
M_\,N3,3&R[M4J\&J&[\]W,#$&[`DO+A/#,43;,0J;+VY"\%6J[V#Z\4X_+MG
MK,55S,$`7"$Z/,-3G,5*;,,C',3XN\9L?#\,+,7:D,1TG+E4O+U.O,9I[,89
M#,=U;,6U"\B/;,=]O,'.J\<Q_,,M3!@IK,@K7,:9W,:%G,@Q.\>3C+J*_+^-
MS,B4;,:I;,>0*ZI=C+2D7,I^L<F0[,">?,?[R\2U?,D\?,O:8,N.O,5+*\.#
M?,62+$?&K+>6?,C+3,N&C,&'FPR"K,Q1S,O1+,M?_,F@#+YQ'*S/;+ZLO,H]
M_,J*&LNCO,W<[,=BS,ED#,RS#,Z(Z\MX?,RF#,^+7/_,F,PHLQS/]%S/Y]S,
M:OS,6_O'W@P.U0S-_MRYPJO-B+RW[8S-J$S.NDS1`VS.S/R>0LS'!1W1!QW(
MN6S/P3S1[#S0^VS-UPS&WRS.@JO.%8W,R8S1)%U\>TS0GNO1*HW0H`O1#(W"
MQB?'-OV]'TVL\OS+^'S3+\RJ0-VO1RRQ32T81@O02QW._[S2:"R[+3?3Q+S.
M>7O57IW,+WV_TVS47.S2*'T,.VW64WW2YRO36/W&-ZS1;SW6[YO4,*W/;+W1
M3#W&5&W76QW669/2>"W5>MW7H?S6CJ;5<,W5BH+8C@W6@-W+/9W7<VVL46W5
M90O9(OW7L+S0[LQ=BIW/C&UPJU]]V)I]UF'\U(1=V2U[V:T<UY1=U:^=QVI-
MU]'*VGP]SW[-V6L=V\ZLVZJ-V87L73%P!K5PW,B=W,J]W,S=W,[]W-`=W=(]
JW=1=W=9]W=B=W=J]W=S=W=[]W>`=WN(]WN1=WN9]WNB=WNIMW6<0"``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>f39432ore3943201.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432ore3943201.gif
M1TE&.#EA,@`P`,0``(."@L'`P"8D);&PL184%<'!P:*AH61B8U134W-R<I*1
MDL'`P34S-._O[]#0T.#?WW1R<Y.2DK*QL?#O[Y*2DD5$1$5#1(."@____P<%
M!@```````````````````````"'Y!```````+``````R`#````7_8%.,HR1%
MT76E:NN^9"S+$V9C2Z;O?.__P."NDA,:C\C,I9AL.I7,IU2XG%J#U:N6E]UN
MN]XK.#P=DY_F<S.M1EX,[3(\CJ;L#@&#@*`()#($`P,`?0<'``9_``$*/`((
M``@\#'\$"9(Z*CP#<QD/%CH`?QD8H!D"`1D6&#^E/*DZ"(V9!SP6#3H"&+,#
MIJ4,M02JK#X8`J\`%L+"F1<]`0`9@\2PI)#1.JNMICH$D`$/HTK./`@.`G"]
M"K4ZI0(,&?#:.\P!QSN8J@X[FHX/#J`2/&C`C)0I`JGFG<+4X&"@>PRJ]>,!
M`-<I#',L&,`(8)&>`!@2)+`PX(`E#+TL_P1@@`!!@`"]^$&@@X8<S203;Q[)
MJ9.*31T)"!U@8`'`O:([BEHX9@&3)406#I@2@,?/O68^%NU08&HC/!T&3-W2
M\7+'(!T-,"5HR.]GJ%0(B!XS=*!3LFP#VK$[!4HC#P=YL?8P<,[!UPP*"!"P
MF`'``0$)V!UPI<H"J(Z;)+K-8"`5@*\'!@BP\"D4J$#9,&`BF=?"++*!QV6M
MIN-<+EAW,]BKW4E!-%3,!#S(QU,!!K8Z!F"`1Q5#))3"!C`"-$@CM&S0.A>4
M'8?`'A]7N6SN^8,G^?+CSXM7[Y,]EO3NS;L7/+^'_/D7\M67N=_^S/YM`<@/
0'-R<DIL05-5BF0,8(0``.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>f39432ore3943202.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432ore3943202.gif
M1TE&.#EA!@$]`.8``/KZ^I*.BZ*>FJFFI`P*"H2"@IF5D[6PKKVZN)63D<C&
MQXF%@O+Q\+6SLCHW-J6AGKRXMK^\NGEU=/;V]961CKFULG%M;()^?)V8E='/
MSDQ)2</`OK&MJ:RHI>[M[!42$E5249V:F>;DXVQI:8V(A:>CH45#0U%-3=73
MT2TI*7YZ>79Q;M31SV!=6\'`P(>!?<7"P:VJJ;&OK>OIZ(J(B,S*R%E55,O(
MQF9B86QH9N3BX75R<7QX==G7U1X:&N/AX+BVM4A%1,[,R@\,#5Y:6-K9V&EE
M9-S:V1@5%8Z*B,K(R&-@7UU85D`]/"`='-;4TM_=W-W;VH^-C2DE).WLZ\G%
MP>+@WN?EX^#>W3`M+"4B(L[-S.CGYNCGY:&;E["KI]+1T-;5U$U(1L?%Q<?$
MP:JHI_#O[NSKZ=O9UJ^MK0H'"/3T\P@&![2OJE)03S8R,2,?'Q,/$/CX]_/S
M\BHG*+NWLQL7%QP8&/'P\$E'1UI75Z^KJ"PH)[BSL`<%!O___R'Y!```````
M+``````&`3T```?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E8XL`@=;!D49.I:@
MH:*CI*6FIY0P%0-U*%5U0JBRL[2UMK>0%6T#"`<<'!"XPL/$Q<:++!$1=1!@
M-6?'T=+3U*$0'!5"0G449-7?X.'A57T(?3`0+)_B[.WNM74=!E\5)1RQ[_GZ
M^Y,D,!01GG#H\V7"'P``!LE)R*^A0UL,8)1I(8$&CB0T,FK<*&&'A#=@#$5Q
M,L7!FQ0ILCCA\;"ERU%SE@SQXX<`&S4$/L09HL9/'#4?:/HDX&>(P4(SAO#$
M&><#@1$OHTJ%A$4+S9E^>@JE272KUW6$>FCU:F&JV;.&`#3IZK6M6Z%'_PG)
M^<"F;0ZT>,\*N?FV;ULJAD1@]7HWKV&7>$#@],N89MQ!'H;4)7RXLL,D)]R.
M%:JUIV>MAW3,5$,Z#LW"EE._L[#`[>2M;)#XN=G3)E$HAJ#T9&-S,FI2``9$
M4$!<!)=]$"SD&+%#3PL9JE'IV=%VA(H%&[-KEU`GV0T6>R)T>)#&A?GS14Z=
M43JDJ0,*^W@4[1J'1O13-L1X53-#T@,,"\1#01L;"#/#8C6Y(<4^"GCE@WV#
M0+&%(!DH$,9]DM@0A%<$F"%)"4GT`4$??010@3!4;$8`A*9H`$<*<&CAQ!T-
M5))`6P80DH4?<,#AU!`80C)!$%EL-@0#DG000/\)"QP@P``<2`+&"BDX8>44
M3OC`AQ8I-*'%!U;Z(($@<_PD%`$)H**?4#<%0TD#/GBUX"!9=$74%$$^8D83
M#FRF!C218+"'%R4(0`&A:SR"@!M#$$!`>XZJL9-3<3B*!`%(+"&(!VS5%(*:
M;15(209M?3J(!CGM2``<>3H"P`DDF,99?Y&@D$0`&$0`P0,</*8($'?D-!,!
M.Y%FK!JOU64$F8/YD44`J!`QVYFB3@(&CH2<X&@.-3G1:B,`Z''!?K1"TD<'
MV)`!@0`G.K(A;SX5-1.\2!0[Q`>-%C9'LS:H$.U\6-50211MI7GJ$$@X0),=
MWS9BQ`4J>B#)!A0D@(+_%Q%X4>TB.JC1*!M!??#&%"3#X0,23B!A1THF.+"#
M(!/(:IH-)*`2@`DG$'&"&QK@,PD7;<TI"`TK9'`%!CR\T/`@:_QPQ150//VT
M$7"HJ,,9'IAQ1117;#'&>2Z``;8+.I!!A0BXB3`!#VFH(($$">`@`0:%]`#I
M%#3E$0D`2-3U4Q,YZA-&6W0OS0@,?&U64UL$X$14>Y(VRQ5-"A@BQQV<%>7'
M"86DZ&A3!&@:2;"?9V%J/C,$;?CA-SU*U.MO.;I53TMQ]5H&AYB0>4\@%"+:
M!\#O9(,D=I3FAP\&?V,%"BCT$`9#<Q`.B@X91(!``RA@,8D(?TS@JQE"R`#$
M__@H*()%&36D(44,Y5."0E].-"8_[H8HW)8;A70AZ4Y%X4"\[01(PB``\`/F
M%4$'6Z#?(;@@G`K(8`P-8,@?A*",#33@`08HUR%84((B.8HW#C``&)[0E@$0
M(@D%2(,!:%"``OAJ$#6@@0,<Q18U9$$"!C"``')8@!&<`'BX^8,;@`>'.-2K
M<H(HP@[@0).QI&!C?Y!#`UK0$QS88'%92,,DWB>_+KH%B84H@%MZ1P@/5(HI
M?M``\1I%%!\L2Q!0L,IL<-*"1`A@6M.ZPB"XU1,S`0$1-S!!;+*RN.-5ZE)>
M>0`A=&=(/WC+$`/`VU8@5YNW#,$'<3B*$7PR$]-4SO\,1&C/3'Q0%Z+TQ%^"
MZ$,69)8#-W!F"/X3!`ML\(81Z#$17'1+I[S8%C`20HQM42,A=!`'WL2A4OB+
MA!UF0Y0L).\**:")4_Q01T30@"N>*1>W&C4MZ!C"`HT:#5%,TQ4V<',KR1.B
M-&F"A&]J17+D9`P!)/:'%O02!G2P$U=D5TH!_$$^\?2#"ERYE3CH\0H[L(`-
M"D`$1>22<;RDB:RV$A)#B!$KKQ/F(%#@J`]@C@UDA(0=E.(ZH4%S<GX(J2$:
M0)/)?."6?S!`6]HUB#E(JV\2K<EN"MF6`A#BBFQI)R$DL)^B:"`(8H!#HY`U
M.VRNPWY;<4"]:D+#HK#A-03_>`,(KL+,*5R`H&S"7QDH`(("7*``%3W$^RI5
M*:P,`0Z[#,I6](F@,RGA$$W`HVGBH`$##(`"!BB!!(HY!#N8I@DP4``*PJ`$
M&"`@`RA00!E"$(+V"0*N-/&!'00HB),NC@`:-80+]@/3$+3%FX.0#QY]$H<\
M%$`*29"`!MZR@&QAJBM`&H00%,<&!\A`#MYC00X4YP<3#,"O!DC4'_+:%J80
MP`$+:$`9-N25P7@L"&7X00]HH+AVRB`$.P-"$@2&B"-DP01O,$$3FG"")L!!
M`HIK`@C4:X,EV."^%GB;!7"@AQRTX+Y%@($9/"""&O1@`Q?(P0(H4()"A0`"
M^T38_Q"F$$X?-*Y(7.FDHYA8HT$P42A30(UGA1+:0I2A+3!-PFD)$8.:R)4F
M)O"E(,:P2S_X=!",%$IN!6&!96ZE"<<IA`%VZ8,Y&(*Z^_'!$"Y0B"_MAUAO
M.-T?&E3=/^A@!1:(@AAB&0D:6`#%DHA`T@+0@S:\H'"'X(U2[H"O#0<%"7>P
M@P\^4"],&5&4'18$'W@BT>%U-IJ+BP/G$'%BK\"4REM!P""P`.@SO2$1JMW*
MC04Q6\UEA9Y_D*M2:!*!0TR@QC+.=(W]0(<@$Z+2L(E#`'R%:!T+(@Q$",(%
M\#`)&D1:*#!]!`LZ4`<+6.$!&RA!(JYB&N#9@0UVN"T!XO_$EHG61-&#6.9/
M8L/D/W<JF8<H=&;]<.A0#4*,8XF#$UXXB"+T=)$\5<,ZCD!<*R`BQT*!5B'6
M-,D18#I;;1G"'PT1O2J+0@4J`',DT'"!#GAAL7U0)"*6VIXX\$$G=*:S$8/G
M,8\UCI2^A`.\B(+*/T"S*Z11:2%,:^A!J-@K;OJ#[N3*FXZ'YMRG6C96,OEJ
MGM)$@80`0/R\<@"+MD7>AT`5;'J.B'R/0@*WIDFN'7'E"JR@`PC8@`'('=,T
M'``!:4@"\.[EA#AD@08!H,`")%"`!10@"0DX[@-,_0?,=H5%)ZU+74I,B`8,
MJX_E"L!<_;#O/\BFCX_RV2&N`'/_0>CN41(=Q`1VY)4+2'`0,7B-4(+XRUXF
M`MXU`90A&&!T4=#`!KM<>B-T0((JO,``'.B`/QMQA3@H.2<$P/8C)"F9#U3;
MXRG@9J/H/@@7.'N>@VCU;,@KEIE@Q02,*!BZ+;WC/X2`J6>2@@3QT(%S7D4,
MAQB!Y1&1!\DWWQ`V_WXE:'`"Q8F^$2HHP0,$T(,Z2%D1GY:4RF(O"1-\KB=P
M;W11!GV(T<X5,(+P`/MQ`X+0`6V!?/#7%K6%8_N!:7B0`LYF&G```AJ@`9C#
M(>-V","T%:$V"!LR&`2@>>#G;Z'@94(A*^?'"`$``P(``0D@(HX0,X_"'@@(
M"1KP3GZ0_W]S1!,B1P@N`'(X`5-Z5U!N<@"[1`>+D#IR0@C4]6(]0`@W8'U;
M\0&D(3N+\P;:<P@@(#D=*`B9,5<B6`B=%PH+(`#X0E)Q(`03X`'>HP-S,`,>
MX`%P"%QQ*#$L4`4&\``U0"("L'J,$!D^87$U^`@.8'Q$H8-;P7M_L`9?-DDP
M-0#>]@=]H#@$X&Z)H(1;(31_T'UCP1^%T`!RQ"%-9!,U80/I@0@@L$M=J'(<
M$H:$,(:/\`0/<`,W(`,PL`%[(`1S``/6@P!`0#%^%0,RD`100@)[T(<"H'HE
M0`((@`.J-Q!>(`1]T`:.8#<W<4Q^H#>1X`2T@W^#,&(TP7M<8/]/G0)\@G!R
M\.(''<8`<4(6BD!"7C%IF\@&*2`;60$6BJ<'370F;.($(_"$BK"!0M%IW->*
MPV8DDL`#*_`%),`#2V``&'"*A<`#%W`H%U`'1,",`H`!&%`!20`&(=```K``
M3[`"&!``7E`#!D!T?_@H'L,&@B8)2A8O.3@(87"!)&8(.D`'3<$7N#8(`N@5
M)N2%OV<'^$@(5M!U\;A\%Z@&]R8(%.!C;.`$<L,#$J`"-6")C""0E'-Y^Q$%
MP^9]'[(")-`"`2``4;``65@(&T`#,<`!/'``%Y`Q(;``-H"2`["1''`!7R``
M""`!?0"18-D(6%!*0C&(CI`%Z5B3?Z;_.1=6"".P&)/1.%E1+HVX%4/I?))7
M$V]@9"/'1+LDC]WWA5F1:Q00BD-@`C]0"?;D%:M(FJ.!<X4@.>+'"!M``EZ0
M`(&%`CE`D(5P`,0H!&48`QNP`B7``Q%@`Q@C`!;P`$S``0)0`A@@!`3R>(H`
M`+"C%(C9"'Q`F35Q>S/P!A@E*3N@`"YP`:K"$WSQ&C!%5$(Y0)N$4L1B`1AP
M7"J@F!NW%3L0%[J#!%C!!H,Y`4S`4UI@G9&P!&V19X:`>6KP!,-F:44A"1<0
M("I``A+P`@O``H<0`"_@!3R`-"\@`#SP'"$P`GO0`20P`"3P`F?9ARQ(>8W`
M$Z^C!MO)"&NQ_Q@?P")_0`0L5Q-(H`4S,4U^8`=0]9,\5D*$4`0I@'AGPE8N
M24AMH0(2Y$HS>8^",`"*\P%+L`,\H`+[A0,M``)Z``+_90$6$`&>20C,M15C
MD`BHUD0P\*`(0@!4EP@;8`%M0`%[&0`=@"2&P)!I4`<J<`$36@"LL0`YP`%`
M4`(18`!><`&"\I9=``E',!E:P7^/H'^,*0@R8'/L=$PS`63^MQ4P10)(2@A<
M,`658H6%%$X?8`'.9F.$D`<H-02T(@5(0%R31!JS@W@IX)MZAE5\EPA;M3BD
MH:&(("NV49N+8``DD`0&D``)X*5M:@@'$`()0`$X0`8DL``=,``+D/\$$+`!
M+]`!&#`&7^`+;5`'DL`I/*6(BC`%,TIVA7`C?!:K!-!A98"&,U&J')*9A+`"
M+U8IA40`0/8^Q"(4\J@M*5"L?M`^6.`$CQ-15\$&-/4'A4@LDQ$#;KH?LOF*
M`<4&1Q`)%1`!>P`@`_!7:4H(%(`K4+``8P"1,S`>-T`"';`!"!`!9)`!#3"8
MDE`$O%$7,P&OB?!A-!$"+B<(6R`&(.@'3#``:2J`PT(4_IHR#C`%6@"PA$`%
M2;"F7-$",)`0#'`")\`$)\`<`+L`3"`$7*`S(!`75*`"Q2.LDF$L$.H5=(!I
M#6``>RL#,=``*UL(*#`<Q*$`=Y4(1:``7'#_!580!EH)"G.C$PTW!-4J#$I`
M'`G$`#X;"0S`!5@``($["%0@!#"06+3&N9$@!`J0!D`@>*/``5I!`$[`,N>5
M!1J@!VY@`KG*(77*#R-P<HUC$ZNX.NT```E@CWZ0`D9S'%PP`1H4`46:%0`8
M%2N@`MY)$RY`O`XAD&P0IXO@GD(A5%+QH3Y)$Y6KO?D`!(LI>XA`!DIYF&;!
M`_&Y%8>+OOE`FC01!(H@!P&`DUFA!N0E%05`<EL1P/;;#A.P%H,1!\^A`W%A
M!C=PFDQ:%!_`95)Q`7T"<@][P/FP2>4X!'S0!'HP`GH@5<$[.Q;`/69Q`:%T
MC3-1OQS,#C5`!YMI4H5T510]80<*=Q804`<G4(%N`*9I%</L@`)!`1298R8O
M61,P*0%^2L10C`L3(`--,!:29ZDM``2G&\5<C`L`@`4N0`$C,,9DK`(Q@`5L
'U\60$`@`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>f39432ore3943217.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432ore3943217.gif
M1TE&.#EA2P`O`/<``/S\_",C(_[^_OW]_0T-#0$!`1$1$0H*"@X.#F]O;_O[
M^Y.3D_KZ^OGY^5Y>7@\/#PL+"PD)"2HJ*G=W=VYN;G9V=EE961L;&Q(2$GAX
M>,'!P5=75S,S,R@H*"0D)`,#`S(R,B4E)2LK*RPL+!D9&04%!0("`J2DI!`0
M$,3$Q'%Q<?CX^#`P,-75U?7U];R\O"`@(!<7%Q04%"DI*?/S\YB8F%965KV]
MO>[N[JRLK`P,#!,3$V!@8%!04/3T]$U-361D9%Q<7,S,S-+2TA@8&!X>'O#P
M\)65E:*BHI^?G]O;V]/3TW1T=*JJJJFIJ6-C8^OKZU5554)"0D]/3T-#0U-3
M4QP<'#L[.S@X.!\?'WEY>00$!.+BXIF9F0@(".CHZ'5U==G9V;Z^ONSL[(Z.
MCM'1T:.CHZ>GIYJ:FI>7E]W=W:&AH8N+BP8&!AH:&E145$A(2"\O+S$Q,8B(
MB(^/CT!`0+6UM2XN+D='1SX^/F9F9O?W]T1$1!45%>#@X#HZ.IZ>GN3DY+^_
MO\K*RL+"PM34U'IZ>H2$A&)B8GM[>[BXN&EI:4E)24Y.3D5%12TM+30T-/'Q
M\:6EI28F)MK:VC8V-O;V]B(B(M?7UVMK:]S<W-C8V$%!09&1D2<G)ST]/8&!
M@>?GYW-S<\[.SJ:FINGIZ5A86)24E+.SLYN;FY:6E@<'!U)24DI*2I"0D*ZN
MKH"`@!T='5%14>'AX5M;6X:&ACP\/-#0T-_?WX6%A?+R\K*RLC4U->/CX\_/
MSTM+2SDY.>7EY>;FYKJZNG]_?Z"@H"$A(6UM;;>WM\?'QVAH:+2TM$9&1HJ*
MBLO+RV%A83\_/\;&QEI:6HV-C>WM[>KJZIR<G$Q,3'!P<&IJ:M;6UJ^OK\G)
MR:NKJX>'A^_O[XR,C'Q\?)*2DL/#P\#`P&QL;,7%Q8*"@JVMK;&QL8.#@\C(
MR#<W-[:VMM[>WJBHJ)V=G6=G9[N[NW)R<GU]?8F)B5]?7[FYN186%EU=77Y^
M?K"PL&5E9<W-S0```/___R'Y!```````+`````!+`"\```C_`/\)'$BPH,&#
M"!,J7,BPH<.'$"-*G$AQXAH&A02*\?7OA(N*("L&665@TAD'!PX@^*`#@<L'
M1?B8FU/)1@@@?G@8B-4!A`$$,43T&?%&@XL&`PZ*DH%!!I4KD*9L<,.*6*\5
M#G&Q\O=`#S!_""Y8N4"6!(H(_K1HF()6Q(E)!7:0('M!AH$':./"R<4ED`^"
MM*[X&SP8`M,''S[\R4&M(0!_$&HQ\4>GH`\DTOR)$YC/WX@366*(H3'0')(%
MM`@3AD"J8#?5_K(->S4-!6%$#5?X(Z`EB#]7!2.]H,,GG4`+GD\4*3+."(!_
M`):\0$6'2HG!.R"K*$.0E+\"V.D(_TFQS<*6P<PV,73GSP"/1_[6,$0N(@D1
M$+,0#G`EPU^`+0CX$T(-'_USAC\8Y.$%"WX0=`UA&^RQ4`I<67"'/TG,YP\(
M*4@@@1(*(4."/R58$:`_J?QS0S'^7)#)#@=H0)`B)ES1QR,@*I2,/[$XL0&&
M&HJP3PB<0#%A!_ZL<@<!_OS@@A!KM%?'%B@00M`@)C#3AP$<*42(/S'DXH@_
M2##TXP45%`%,(`PM,Q@1&\SP0`H&^O-!")?,@`E!J8#E3Q1^/)<0.OZ@X``+
M_H0C0$%E.&+'0!3X,T,J5MRA"4,"G'!``6PHX\\UD3@Q&`PLL,#%0(K\\9T_
M9@"P:$*B&O_P!`?^U)`406;XX\!?__CVV05QJ-&0`*#XXX$6(IB@1@Z#&8/%
M%D`$804)!(#GSSP-,*1!>T^`X$\6#M10#"!KU`"-/["\:HH_5DS#BP3"+@0`
M#8,4(,(2/=0JR6`'&``;81>(T=`-A2(2Q[^$]3&,0#0@%T`35!Q@94.W'(#!
M`N>F("J):+EA#`IMJ.9`*0R=T!X;X/!ARQ65]/!($5)4<<-`0Z!A)P=R$+"+
M0[<0<``L5/@CR,8AY-&&(#CDD(L)_K2!UA^X+"2(/S*<,4H7M1QBR#+\\+'`
M,&0X,Y`"@Y'0@0B].*1$$7+(HVHB2`P6PR4Q#F2(/SI8@$63D2C_M$ZA/$B`
M,&%L#&3$=X[\X$5K#2F1!0N*"%;&:_[(1838`S7BCR/'^)N!A`@=:(`#%P[N
M#QJ&XUT+-OX\@15#2Q`0`R!Y^,,%LP)^@L$]!-WR@3\=C+!A8P@=@:`^4^CZ
MR@)-Y'`$&D_X8T^!AWLQ02;^@*+`0D.TL(0_,+PBA3^!$(H@$0&L0Q`#<_C#
M@2H!3#)&0G%[<$(E_G1BD`^[I+#]/X>#`"RRD3^&?$,(/P(#,9B4!._XXP`0
M0,#$!K`G2L0"`6S(0PE"D9`F^*,(<Q`>/!AR.`1X8Q%D:D@:"J`##23"'XT(
MQ#L&4P"FF4$@`VC!/\+@"7\PH0[^R,]!_P`P0PPL`A+^``1#=$&B!!P#7:\Z
M2%+"@)P?S(%)AQ#`Q@BS,QP*X`8F@`$;XE``(1K$#Q[TP`O>X`\5""HAP1B,
M(R(E"87D8`B,\,<5TG$N+.2'1;LA@C].0!`N"*X5$WB`,8R$$()=(AIZ\`<%
M+($0`"1E8U%P@#_JF!!-^@,.X/!6!%Y0"@!@KP">8(<_VD$0#[9!%'QH(R41
MDJL`]`.%3=#/$OY2AL$\0P6;3(@0]F:`%ZB2"*?X1S44@`C(5.$.^!#"0#3Q
M"7_$P080\,<0%#(*?[BA"_F:PQC&`(5R0@$'H6C&%+9)!W]X(0&1?%1!%$".
M9HS(3@&Z@CP%$O^.RIF"!$5(&PXT`$3PP<`?>3@50LI`AD(%`3XP@`,<\$!1
M/#!""B7XP!*H`01_1,`&^?K!!$8ZT@IL0)"JJ0,HTD803;:A#^!YPR(8<<_"
M\$`8"O&6/TAP!C>8;C!U:`(<9O`F6_R4,#OPQA<,(@MK_30.A,B60I``AD2@
MP@5H8$(&MIH!0QQ#`C\X!"OL@`K52"-HA-E""2+@!<(PHP*#0$@J*I`!8KA"
M&B/@@%XY@(4GD"%>#&$``P0B@!4(M@$-8(`E@H$#`'Q#``S81`M:$`8<;"(9
MDVV!$I2@"4U,%A-CD"I"&-"`[>E"&%](;2B^P"M,#>"U_W@5;$-B$`'_*$"P
M@E6`;@'`VS<21``#L*UO#5((&^`A"))(@AG(0`L'=,$,@"`7&E2ABC0<80'8
MK2X:NG!=["[@"*?P[@*ZT(4TQ$,65:C"&][0@PVD-PI1Z$$C&O$#.(3U&1NH
M!Q`J$`W1%D0,6."$%DQ1B2ID@`D5`,(35("-((#@$UAX``QF,`,0P$`&!=A"
M%F;0@0Y(P!,BZ'`'[F""`\CAP%I5!R_\\8L,4*`<1CW`-5CQ""DH@Q%!40$8
M*K!4A:CA#7'0`U8&,`$@".00BPC#/WB`#('X`A2_6$46<D"0-<15(%#(`B2"
M,`J!K$`,EW"?+AI0B!6+P!J"ZH0A?O$,.T0Q_R$,:,6W()&A6^!E`$9(7A[^
MP8ERS`L\MC`%!!PPRU=XIF__2$,$(E``&(SC'UWPAP00I047!(,6!3B`/Y;Q
MCP:X`0$6H$(V%*H0`)S#'W(X0D9H$(!8",`'46B/(68`AD[[XP][H($'6H$#
M@<A9!QGZ!PX\(0.F2>$?Y_C`#<(0@QB,80\O,($,VD"G%7C!`V#0@S8&\N;:
M=L(?C)!0`R;A#P`HP0:J2<,-R.&/"?SC!08X`'>68"T>#(164JB!C.;P@6UZ
M@#+_V,9@`B`L!7A+>&1PB#NXH0Y_Z*$!E+`"^<00!0GDPE^C.((6@.<_%DRB
M03PH`")X@0%K"`114?_[QQ"0,XU_!.``W/B'(@;S`%8J0`X]H($@FK'MA:Q`
M"C$(@!MV(0!<7,`?SMB$`4)`B6A`0`@VP`0PK<")$E!@`,F(0"-HH($'F.`%
M_R#J<P!@!$I,X0""&^$89$&8#@A#`!C`@#)L((<N(02X`+@!(DX1B@'@X`M`
MX,$*N/")&CQG"+H@F0OL0`\'6*,:_W`!*I1<#3(H(A(#>`$R%##;4KC"!CG@
M/`.$4`M!:$,#/A#`-L1QBAH,H@'=)@@;,%`""$0`@@>(P'7\P8(*)`#!=*V`
M%BHP4E'H.!$;P(8%B)^(3$B``-!'`/2G_P`=>($`TL<^!!Z`@@<08`HZV,)<
M!U:!`!T8(",'$<($)+`!43B`"CV(`@="$`(/!,#^`<B__O6/?_L#(P`C4`<>
MP`$+E@`&2`$(2`$&>(`(N(`+2`&R$`(2@`?Q``20(".TE8$:N($<V($>^($*
$$1``.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>f39432ore3943218.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432ore3943218.gif
M1TE&.#EAL0`D`/<``$!`0+^_OW]_?^?GYP0$!/W]_1<7%_[^_AL;&\7%Q0X.
M#M+2TAH:&O;V]A`0$`,#`PH*"L+"POKZ^N7EY1D9&<W-S04%!0@("+.SLR,C
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M`='1T82$A**BHHR,C(&!@=_?WPP,#(6%A=W=W3@X.%]?7PD)"7Y^?BXN+L3$
MQ-O;VX.#@_/S\\#`P-K:VLK*RLG)R>'AX3\_/T='1ZBHJ,C(R/7U]49&1B`@
M(+"PL(^/C\[.SHJ*BGAX>+FYN3,S,QT=':^OKVYN;G=W=W5U=6AH:,/#PU!0
M4.SL[#X^/D)"0C`P,"(B(C8V-F)B8A@8&!P<'#0T-)V=G<S,S&!@8"$A(=34
MU`\/#RDI*3<W-XV-C4]/3RLK*YJ:FIN;FU=75WM[>T-#0V5E9:ZNKF]O;];6
MUH:&AI>7E_GY^5%14=?7UX"`@&MK:T%!045%134U-0<'!R0D)`8&!M#0T%U=
M75-34UA86"TM+:6EI;*RLEI:6IZ>GJ2DI(B(B'9V=B4E)<_/SZ.CHW-S<TA(
M2#(R,IB8F%145$Q,3&EI:;2TM"PL+*RLK)*2DJVMK7Q\?%E9641$1'1T=!\?
M']C8V)"0D"8F)J&AH9^?GV1D9%Y>7@("`FIJ:GIZ>KJZNBHJ*F=G9TU-34Y.
M3FQL;*>GIUM;6Y.3DTI*2I24E'U]?9&1D2@H*&%A8::FIF-C8[&QL7%Q<;BX
MN*NKJTE)20```/___P```"'Y!```````+`````"Q`"0```C_`/T)'$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQHT>/'DX(1,+EHTF%>P8>D%$(B<``
M94[*G%B-005_"*+%.%D.@,^?0(/^]/3H$*4WE("2RO'36@!]F-BIX$,HP#`^
MY/HY(M*/UX8`8,/.F4F68`,J<]K@>N'E2+\X'SU$ZD>WKMV[>//JW<O7[CT)
M96=JD6$'EY("J+ZYV47*8P,4?2-+GMQ7A\C`)MG02_&GWQ1_F/H%X]"P6+,1
M'AIJ,4&YM>O)PC";I/4BD9TI_2XQH%M,81`T8E3TV^!P`(+7D=WY0,[W@1?9
M'OU,V->OPX]+=D4<#%+5#-U?`:(4_S_.?.^B'N7U$G`)76,)%C3D%,+1#XJ9
M,/U4&$HM,($_,!5(0`%=H]0A!$3&2=;(&3#XLHT2LUS1#SJQI&)%/Q`PDT4$
M<V63``V!N%"7-)L8<,T7MO`@&0'^M9=1`3/X\XT+*Z#2CP_H]3"0!S\8$0,$
M:PR13C_1E"!1@GT9<`(SSAQ@2#]-D-+/"R;`0=\(@S@P#61G./*!'JS4)08C
MH_@C@`-&6!`9BRYR9$\_HTS`!%V?D$"0=Q&@\D`_"*`AGD0_@!"9$_ZHT@\-
MO_3#!`G]"%*).G[T(T`V_;2R!`'"$.#",I34A0,"5NC1SP=#[+)FBVTR=,`?
M"C5!!WT@6/_2CP(8##1%!%1\H((1NO3S3$5(\O7"`F](JN(23?3C2BX=R'#!
M!*GT,P039("!WUW%H)#%!,>U$L>IJ394``10T++%)$04Q(,+B=*EP#3^M&#D
M$H(`P0E=E(1@4;![93+`"/W`0D,_3QC1CRU'M-/%`T;\`(LDF)`!@Q>&(%.7
M"PNHHH(_CUS0"Q3@ALL0./W<XD\-_=1`T!BLS0H`(@+EHL0K7>BB"1-PI+'#
M1?SN-<LD_52R3C\:B--/#H00(<VLM:21AB#].!!!")#1Y0(F!BAPWP7-K(BJ
MR`J=T8\W_L#23R<$L2",-2SXD_$63TQYC@[]/#!$1CVGIW=?;(+_S9"48/BS
MB2[+^%.!!C'YT\0"*_A`31`PS/I"/X]H-(8">V<>LM\+W=!/.@T`0$`=DF3P
MP2G^=-"!+)`\8(`>&]3-R$8#?&!*"&$)0`)8141RBSQ@&9/#+0"X88`I;@`@
MAQRB*"%*,HIP4QX$FC!@/049,/#`UYPCM$,'_9PC@P$/(#$#"F0,`@@%5N#A
M!0$*?!%($1RM`((<$W'0@$"RR)*:!S%801#,<8I'J.,(V>`!&GH0BV$0`QH!
MP($AP,*&+RQ"#`.8@`8GD((G6(![W3L("\C0CV8D(`L0"($-^I$)&Q0!#@90
M!OCZX8>.<"`4#*A"0@:0"[*YJ`$Q<$4__UI@D4X$`!3^H,(8DD`'@8@@`*DI
M@0CNH`P[^",`0/!'$$(@AC$41`9$,$(`M."/$DBA%VT8!@'Z<8@B]*,/40B3
M`=JPM%`XH!\\&``+)J`&%DBA``.!!")2XH]%8(,..YM#)ZK0`!9P(`4#X0`$
M.J"0!9@@#6W:00F@<:,@4`0(%^@''$A0#@CT(QM5T`9=K-`-6IB2`)5`F3G\
M$8^Z'8$@!<@`&3[0CT#X(QH4,(4C_!&Y?C@A&/T8!RCHI@GLT(49#;"!`1@P
M"4%0X`[^``+00*`"9&'.`3X`GPIRP`<#""(#A1#("AR@`R"TPA\2*(`(JE&'
M`$B@!"U(IQ[`,O\6@>RA%DF0PLX6$(`Y2,(?;<!#&0)`1'](`2QY\,<`GAB`
M$!2@"F"Q(D%BAPY/3@0(+NC!`YQ1K%&4@1W]N$8`<F`",Y"0+H$``<SH`X=&
M'&`@.U"`#KI@C@O,X1/]2,,"!!(+NAS"%/V@0"'Z8!<4I"9N+G@"(?IA`W](
M:1E50$,_.G476PP@$;M`#WM><0$^4"$"\"S`+.KB!!E<`@5XL(L&2I`'X23U
M#6!88S^L(((WA$)-_4B`)`84-2IL()1T.44.Z-*!D@PD=K^BR![6P$(VH$<.
M>5"`+FY:S#WU8PDA>,%.CK%7-MQ4(`7`3P7$QH-*6(`/V!3(P"!P!>'_A"$-
M@NI')/``SVKT8PVFP(]VT-&/+OAC$/T043^NH(,[9D`-VN"%!<)@)']P0`&:
MB-%`5L&G+.!B`:$01Q1`]@%>]$,:?,"0*2M1!`4D@RZX*%92<S,&NP@`8`2`
MP`/N6!<C^`,2@/!'W&!0D3W,J@L'*$4_5`$("05@`O4@`%`=<`XAS*$?Y:C`
MP(A1AM/ZXP"!Z(<H0K$&)"2"`0T5B!KLN@AG]`,$@HK&`=1P``E$"@"U[$<Q
M4@`T7X`":O0P)C;!AXP*.(``%R`'&@3"`0>`@#0#Z90%7N`+Y"K!DA;P0BUR
MPUUC".-&6ZC%>_LAAZ'A0`JY(("I1@&P'#Q)_QMC4`9IZ](#0`HD=LRPLT2:
M@``?,B$3&0B'#;*`A4Q@`0T5"$8D!/('3:QA%?,P``A\<)D/>\(*6<B`2T#6
M#RG@U`9KM,1NZ&*`5_CC!P)I0Q:6BP6Z:&``OC#`&A"0#Q+LXA0ID$`CDJH,
M-T#A'5BHH3]60`$X]((@1=B$)NAB@0?HH@Y8L``>[G4#E!TB`OU0@BU>>J.A
M@<,?*J(+*RK0#VH<HA_`$,B6'3#KFPPD;B8XT$2X4&E):($#J0G"(.K@V"0.
M)`83`.0*M-!O@AQ@?_Y@01ZZ89#0V.4#Z91``TX`"BUTP08#V`(^6L"!`11@
M"-`0B0<\#9C_MH`*,_^8@#^J8.<!8.$#;1/(#&X!/;KH``'4$`'Y%A`Y;!BL
M'VJ:A(+KDHMQ].,;J;B`(C"`H0R@&V4`$$CDG&`%2WCTSOU@@+PE`@H`;*(=
M(\!%$X#P`R)R80:(T``P8*&&:[3!"V(X01XZH08K@@$#>,>`%X8@AADL``,V
M:$$(4+&);9QA&P6P0R+L\AE_]($"%+B``0#@`T\D(!TV@`<$/F$)1>B@`U>`
M!PF<((I4N$$1!LC!&2J@,H&X'.8#:8#3Z=*($S!@%4/HAR4D<"];Q&`6+Q!%
MT.Y@%QX(0*X',-J+C>&6)0A$!BWKAYT>F_6M1T0&[V`$(A:@AQG,@`XM:$#_
M`B#!"&S48!IT^,,*BC"$*CS##X10&1B.,`4-<`(#(V##`+[0APT<HPAX%P&(
M<`<[HP71<@5$L!/^$`%=<@IQX`K$H`0`<`@8D`-,$`O5(`#7$`?(P`2,@`/;
M,`5?8`B.,`7'``9B`&4N9P(J-Q!)``,!T"*+H`<-$`YH`PB+(`,-,`*,\`C]
M@`S^``[8$`<WD`(`0PY3T`K5M0PU8%PD,`+3=VI?T`COM%'5%RX!9A$_X``:
M$!@#D#6$%!%)0&=Z-A#S0#`8H0%7V";=<!EET$0&(0$!0`L#$06H-FP!$`-M
M(`4I`!8EEP1_(@G:D1%:P$M=.!%)D(@>5A"FAA%._Q`UUB<;(7`!.K`%_H`"
M-.(/U@``*-`$H/%&`_%G)7$OB;`_G-0/9N`/P]`/UB`0L,`+\((1#;`$,'4#
M`G"+N"@`-^`*[F"+N:B+1!",=?"+MW@#1T",R(B+<4`#-Q`';(`&\F`&[?(%
M92@;=&``1",X4!`%!X!,Z.8/:_4)-.`/(2!N_A`._7`!6:0(=,$/_B!$!,`J
MJT8(&Z$.FG./>5$/(I,&<L`)_H`#L2`08\`&?>`2"\!=Q.`/)(`"GC".[N=N
MJJ0`@^`/M.`(2L`JJG!+&P$(C0``;^`)0?$(S3`.K```I0``D<`#)DD\I;`$
M/N$&U&`"5S![_5`\B0`%W%7@$[-G`;Q``);P`'`P)6KB#(^8D^P@"V"#E`R1
M!SNC$"E@#*@00@T1!6H`!"D`"1'@;C=EB?Z0`A$0`0L@`F5`!;WP"A&`!PL0
..`8`4`5PIE6YI$`$!`#L_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
